<SEC-DOCUMENT>0001410578-25-001470.txt : 20250721
<SEC-HEADER>0001410578-25-001470.hdr.sgml : 20250721
<ACCEPTANCE-DATETIME>20250721061215
ACCESSION NUMBER:		0001410578-25-001470
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		154
FILED AS OF DATE:		20250721
DATE AS OF CHANGE:		20250721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Carisma Therapeutics Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-288792
		FILM NUMBER:		251135627

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 401
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		2674916422

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 401
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sesen Bio, Inc.
		DATE OF NAME CHANGE:	20180516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>tmb-20250331xs4.htm
<DESCRIPTION>S-4
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.0.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 7/21/2025 3:59:42 AM -->
<!-- iXBRL Library version: 1.0.9292.28120 -->
<!-- iXBRL Service Job ID: adc50d26-b381-4aa8-9444-70d13d74ddf5 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:carm="http://carismatx.com/20250331" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>CARISMA THERAPEUTICS&#160;INC.</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" xs:nil="true" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_ltVNbYivXkekjiw03dKW4A"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" xs:nil="true" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_M3CYe3Zv_E6bgld5te8Zvw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" xs:nil="true" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_sU_Vuv9WSUmKRxDVcXLfLA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" xs:nil="true" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_1E9j0k2uV0iCfG9MW9TNAw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_WPLQ41LZf0eyECdOSYT34w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_XLxbnzFrpUm-24ijgeqr1g">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="dei:AmendmentFlag" id="Tc_KLusxZL3ikSEZWZMgx-krw_1_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="dei:EntityCentralIndexKey" id="Tc_J-aQsiQ57kCsHnQKoa7Xag_2_1">0001485003</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_EC4pGizMUEmwsFpD3vArGA">41750109</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_1t_Gb32An0ig-gvOCgjziA">40609915</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_c0xoT3reKkCaOeL1zPSHLQ" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_fhlu0P8GC0OSYzMKRGa6pg">http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_IC7n65_vc0OYd91beSu5RA" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_qKYmVxKGPEGEDMmZP0kvsg">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_m_pObOvhDEicQLnUh4byOw" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_w59cdNVWLU6d09CxPojcvA">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_2mhPn7jIZ0e-ZbcpUrxB9g" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_sktIWaH1v0C3Alvvbznotw">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_2mhPn7jIZ0e-ZbcpUrxB9g" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_wSmhQcT4p0uaTZTD8dNi8A">P4Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_UuJUKdscKU2BamT-vknOlA">41788096</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_YsbYHRwR2UyuINXyqElSpg">41750109</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_O60app-ziUOiQI-0SFDxHQ" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_Y6YvLEfyKUG_kk0uMc5sKQ">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_O60app-ziUOiQI-0SFDxHQ" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_DGF8BxLO20aH0nuzKXhnJA">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_BqAFVKxD_0eZh52zf-_cHA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_RR1pBUqe5UemOm2ln3QA2w">P4Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tmb-20250331.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_94R-tIsNFka2JCxWnjX7Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_carm_StateJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_F3DomWzyU0mk1y1R2qHVZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:StateJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wF0j2cynSUuqz6R2wHJFsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yJlKgp-b0a9kywLP5wfMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NBJH3utECkSeITbgKbOBjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KOBMN_pRd0CpuuBgDONMeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KyGaWAjqJkmBWbexZMF-jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lu-cSSufUEqWCNoTK34t1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JA8S9njYW0u1srOBy-b4Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_djTn0QuJAUyMxSDTnffWJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9V4P9b_imUeKWRIMprh3ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p0MZ0Mf-7Uu7LB1ZZP5Iyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CiZKxNIbvEyRs27cGTE1kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mWoZC8JK0EyoFq85L59bzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_4dq94_1obkuQkmJaNiEQBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_W2GgALqdeUG9d8eSxLoY-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Gi-5K4vpZ0SQCZsnJh6q1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rddcZYrYF0aGvo9ie5UZTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_CashPreservationPlan2025Member_feBnUr3Dfkm1-xoc5Tr1Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_RevisedOperatingPlanMember_8xDVoP31YEeXATz_aXlYog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:RevisedOperatingPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_b0EJK8W8H06cy_5zpLWtsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_KcFLfiniXEG_gOlYI1LmVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_0LrR7jztQ0mtgFQjdW7yZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_bhT6DCaLkEussR-MSi5DIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_XarV9JooQUGFgqT3MKU-nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0Ff2XJct5EKaCIPhtjMWRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pbvS30z8A0CePGJ6mxV3wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rXpt9Tr8wEWedRsbme4_rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_EbpMHxZ2vk61tk33Oa6FYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__FKxuQApK0mFwWZqpuOrwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_nnJFjCrHlUqpNk-U5M1Zug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_pc5coAuKZUS70I6GNo3axA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_O60app-ziUOiQI-0SFDxHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandSeventeenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_BqAFVKxD_0eZh52zf-_cHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_2mhPn7jIZ0e-ZbcpUrxB9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandSeventeenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_h2U2al8QUkCz4difeEQiVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_12_31_2023_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_61_8Uvl5hUOnb8pf--nrlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_OiQ4pvFuv0SzT93oHU7Tbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_PW5Xs3_AFk2m4nSwFHd7Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_KzPkm9W5EE24UqG-d_OiTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_6dVwitkd0UeHb10KsXjOdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2024_To_9_30_2024_Zs5TM9E90UOa54MlGv6RJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_Ffe941lEKUCa5q4ysfJI4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_OptionRightCollaborationRevenuesMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_NbiVSknF-U-gNgbz4Ymr5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:OptionRightCollaborationRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2024_To_6_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_vCHDp2Flj0-8HoO2F7_1lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_OptionRightCollaborationRevenuesMember_SRYjOrMSy0aaO5SPhrCxDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:OptionRightCollaborationRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_MilestonesMember_FUdbCZoQDk2Dag7HM2RG6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:MilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_gNQIWKQL-kC9gvHVRwSeLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_oh2OTmiJvkKgA0D-o9Y6Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_IC7n65_vc0OYd91beSu5RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_c0xoT3reKkCaOeL1zPSHLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QPK_k69qc0WEZlJvXGRPPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_lGhVgDEdm0KquD87r_9DVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ATt2SkLHckWBYPbLkkt-Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_e9iO1ErRnUC87OlaTyfKaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_TTkLQHgTUUWOQaI1eLingg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_m_pObOvhDEicQLnUh4byOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_M2tlaUEGPU-AJlzF8cCTTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember_6a9BvHfS2069NVgEd9BlgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_q6mQUCRJFESSS-dSvTvrAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_SbAUMjqBzk-GzWMJw0e0Qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember_IuSFljhV5ECw_6wtTyDvMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_QBP2ErMrOUK4Ayldn4JM8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_MqoxSix-Y02bOPp5O0niiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_V1MVYY5yOk6TrVp02Gj08A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_GuIsy6UvbEOGPaKsDXeA4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_1_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QZ72PuDG7USaQrTyk9GuVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_26_2024_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_eohhy-W8CE6cTQBIagwUsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_vJj0iOym_06oJXQKAC1aOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qPQeNLve40WJSXsRyUdx0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_carm_Pre2018Member_dstQjZ_6a0e4qC0YXpJpZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">carm:Pre2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_carm_Post2017Member_f3GDnlkCKkiBu7MDgLhD9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">carm:Post2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_f1OJ6DnIk0WtNUSppxvYrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_carm_StateJurisdictionMember_efJJVuhcvkquKiB45VCQ1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:StateJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_carm_LocalJurisdictionMember_3b4Lne7Dpk26SoUxioVhCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:LocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_o52ygJ2qtUW_8MtdyoucDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-EXk6InjekuA8cdEMBjBkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_V0Pkqzz_AEyhjqolIkoUug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dkWHVbHbIEmBDtxSTvwOZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_26_2024_To_6_26_2024_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_pGYfhVmGEUO0Q3irnyGzOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-26</xbrli:startDate><xbrli:endDate>2024-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_mc__W33L60eUsMJuatMfaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableMember_2St9M_1mr0e3gTe3DEn6vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_Xj-_M61yuk6R7alr9CUi3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_mVjyQyWkQ0ysng36Cpz6dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QKEF25OlKUyFEjDTw-T6ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_Zc2Vn1pdQEyg-izKUAgkWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_oADG9dBYzE6u3XG_uLzZiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_AtWenqGmtUa8z3-Kd3hvvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcPCJIcIO0eFOPtvCF5mqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVEm6mt950Ss-dIhOM6psw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fkuPLbunBkio3h13YwQKEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sizU-8d-HkiGAXLhA7EliQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_6_2023__sMm62IFwUO3DNhZ5LDZlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_5_2023_xtoCxfMB7kSash1MJ5CA_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NHpG9u0K8kSnQJhkduVBWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qni1eLtrpEqVTUS5DP3Q5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C2na3yFo8kSa8lpEjLIVYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_P-hP9vpSB0SObx9s8SRr_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RNeFS6gXN0O81arpfa3vew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_FPiLpPUNo06fNsnw6eJy3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_i3-WcXRxi0W0jzEpmZkO4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_7_2023_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_us-gaap_BusinessAcquisitionAxis_carm_CarismaTherapeuticsIncLegacyStockholdersMember_pAj3UmfAuUCFRdiN77L70Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:CarismaTherapeuticsIncLegacyStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_o9XCCXxBxk-Bcr0qGS2Bcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_0bTbe1UO4Eu2oXU8xcRc4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_zK5vgRHDUkuO_I7i5iruOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_4gn5Hkv1tkSIJa1ZsZNSzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SxDIMm3BHU201oGx7GMaZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_-bxZ8-y2T0-7QhFzHLqqMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_GdlsibT2VkyP132eYkVPyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_s7tqgkjRX0S1t8FSmRyS6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_jY5QK3zjDki_xjht9LRM1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_weRP70dN20KmCCCCJPZOwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Nd0oPvzMG06tOEVwN21Lsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R3R2qv2BVEOZuSzVu7JMsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_carm_SesenBioIncMember_wbOBDpL9fE2NWwfHImRktA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CtxCArF56kS82xK5cMVGuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giltrRhLwk2uYDDpgJGllg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3bekv5USnUGc01h2wLoVyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_5_pFMaKe_E6No8FPBreF8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_pDUA6rIWwk-29qcuwaw0qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_17_2023_x6SGs_0tqUWE9Nmq-r1zlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_12_2023_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_D_fnvKHBKEejhcN9RD39EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_12_2023_2Ua3tacy0kqoCl2kZhnnpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_9oZWrGbwu0CzsSwa4YaYUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_UFBhEQ0DHUmjWP1OKnrZfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2024_To_9_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_CC5mai144UKxgWO0ed8BXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_CVCA_jIaNUSvPGLAL1iRDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_XRurAXNE0EKR2OlnCsvD0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_xyxFVBcDT0CVZTmDOmX-AQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_nQIYGPxOV02W0fAFKZQdvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_C2cp3L2L3EiZlfTKfZNEqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_8qNgXN0bH0eJkf5RqlBsfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_S3eeHUCF80-ErdmPj3uyZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_CsDzke0V0UKpQy6JppgEbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">carm:ReportingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">carm:ReportingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">carm:ReportingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">carm:ReportingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_ECKpLj9RxkeJ2fOMI7xCfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_R70NvuCqk0WTJXiSPZpa9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_H-d_HedKTkqWEw-yuQFN0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_BvRnm7gZx0yPcQ6vufXWdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_baLeGNcD3EigtjEBIXS6dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_Tu1FMTWJ-EKur2Ehg_NuIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_8sZcvCnSPkeitKoqY5sunw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_TrTvMEg3XUmfyU3iMfTZ3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_c-DL08jYk0mOjzSXLvRWJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_3NLofzzltkKOh4rmrr_2tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_9VloD_2BKUaBco__8m0cCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ"><xbrli:measure>carm:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_stockholder_xwrsA79JVk6r5Olbumrfaw"><xbrli:measure>carm:stockholder</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_product_3mVjd4sUPUK6dqSqJB3SiQ"><xbrli:measure>carm:product</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_ieOgHbuNO0uMDAyeDWsL6Q"><xbrli:measure>carm:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee_8zftLesBXkivzIcTQ6E96w"><xbrli:measure>carm:employee</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:10.35pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2e2d8050_7627_4b94_8b57_1282591f7468"></a><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#231f20;font-weight:bold;">As filed with the Securities and Exchange Commission on July&#160;21, 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 3pt 0pt;"><b style="color:#231f20;font-weight:bold;">Registration No.&#160;333-</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="color:#231f20;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-size:12pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#231f20;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="dei:DocumentType" id="Narr_XGoNSfJdwECecumJTYRVmA"><b style="color:#231f20;font-weight:bold;">S-4</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">REGISTRATION STATEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">UNDER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">THE SECURITIES ACT OF 1933</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="dei:EntityRegistrantName" id="Narr_Cc9ftLfcw0-A7w-7Ea_dRA"><b style="color:#231f20;font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="color:#231f20;">(Exact Name of Registrant as Specified in Its Charter)</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Delaware</b></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2834</b></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">26-2025616</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="color:#231f20;">(State or Other Jurisdiction of</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="color:#231f20;">(Primary Standard Industrial</span></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="color:#231f20;">(I.R.S. Employer</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Incorporation or Organization)</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Classification Code Number)</span></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Identification Number)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">3675 Market Street, Suite&#160;401</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Philadelphia, PA 19104</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">(267) 491-6422</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="color:#231f20;">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Steven Kelly</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">President and Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Carisma Therapeutics&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">3675 Market Street, Suite&#160;401</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Philadelphia, PA 19104</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">(267) 491-6422</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="color:#231f20;">(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Copies to:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:57.55%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:42.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:57.55%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Brian A. Johnson,&#160;Esq.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Christoper D. Barnstable-Brown,&#160;Esq.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Mark Nylen,&#160;Esq.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Wilmer Cutler Pickering Hale and Dorr LLP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">7 World Trade Center</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">250 Greenwich Street</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">New York, New York 10007</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;white-space:pre-wrap;"> (212) 230-8800</b></p></td><td style="vertical-align:top;width:42.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rachael M. Bushey,&#160;Esq.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jennifer L. Porter,&#160;Esq.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Laura Umbrecht Gulick,&#160;Esq.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Goodwin Procter LLP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3025 John F. Kennedy Boulevard</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">8th Floor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Philadelphia, PA 19104</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(445) 207-7800 </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">Approximate date of commencement of proposed sale of the securities to the public: As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">If the securities being registered on this Form&#160;are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box </span><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">If this Form&#160;is filed to register additional securities for an offering pursuant to Rule&#160;462(b)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </span><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">If this Form&#160;is a post-effective amendment filed pursuant to Rule&#160;462(d)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </span><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_6f0fe50f_19a6_4e9c_acbb_a219383c0419"></a><a id="Tc_wkU4qyN01k-rWuSfIyji7Q_1_0"></a><a id="Tc_LqSuK2K-CEy6W-hM75eRIw_1_1"></a><a id="Tc_yg--yt91oUO2UranQO12nA_1_3"></a><a id="Tc_zjKNUvyUjky73kL4Arcqhw_1_4"></a><a id="Tc_fAcIJDF3p0qxWHhmRVecVw_2_1"></a><a id="Tc_UIlYCQyj0kezVXw8zQasGA_2_3"></a><a id="Tc_Sw_JQbjLPkuSCYB8Gze_xA_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:24.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:24.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Large accelerated filer</p></td><td style="vertical-align:bottom;width:23.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:24.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:bottom;width:23.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="dei:EntityFilerCategory" id="Tc_NSl-twNIXECY_rhK0HgckQ_2_0"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:23.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:bottom;width:23.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="dei:EntitySmallBusiness" id="Tc_u8U1sP5ZBU-rYixW0AjtCg_2_4"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:24.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:23.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="dei:EntityEmergingGrowthCompany" id="Tc_E3ZX2TP7XkiCWasOH6vIjw_3_4"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act. </span><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">If applicable, place an X in the box to designate the appropriate rule&#160;provision relied upon in conducting this transaction:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">Exchange Act Rule&#160;13e-4(i)&#160;(Cross-Border Issuer Tender Offer) </span><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">Exchange Act Rule&#160;14d-1(d)&#160;(Cross-Border Third-Party Tender Offer) </span><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine</b><b style="font-size:8pt;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:621pt;left:0pt;position:absolute;top:29.79pt;width:28.5pt;z-index:251658240;"><div style="height:620.45pt;left:0pt;padding-bottom:0.55pt;position:relative;top:0pt;width:28.35pt;"><div style="height:620.45pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:28.35pt;"><div style="left:0pt;max-height:100%;position:relative;text-indent:0pt;top:0pt;transform:rotate(180.1deg);width:28.35pt;writing-mode:vertical-rl;-ms-writing-mode:tb-rl;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;width:100%;margin:0pt;"><b style="color:#ff0000;font-weight:bold;">The information in this proxy statement/prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></p></div></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:680.79pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e32564d9_c4eb_4867_9814_60b25c7f053e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 36pt;"><b style="color:#ff0000;font-weight:bold;">SUBJECT TO COMPLETION, DATED JULY&#160;21, 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">PROPOSED MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">YOUR VOTE IS VERY IMPORTANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">To the Stockholders of Carisma Therapeutics&#160;Inc. and OrthoCellix,&#160;Inc.,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">Carisma Therapeutics&#160;Inc., a Delaware corporation (&#8220;Carisma&#8221;), Azalea Merger Sub,&#160;Inc., a Delaware corporation and a wholly owned subsidiary of Carisma (&#8220;Merger Sub&#8221;), Ocugen,&#160;Inc. (&#8220;Ocugen&#8221;), a Delaware corporation and OrthoCellix,&#160;Inc., a Delaware corporation and wholly owned subsidiary of Ocugen (&#8220;OrthoCellix&#8221;) entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) on June&#160;22, 2025, pursuant to which, among other matters, Merger Sub will merge with and into OrthoCellix, with OrthoCellix surviving as a wholly owned subsidiary of Carisma and the surviving corporation of the merger (the &#8220;Merger&#8221;). In connection with the Merger, Carisma will change its corporate name to &#8220;OrthoCellix,&#160;Inc.&#8221; Carisma following the Merger is referred to herein as the &#8220;Combined Company.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">At the effective time of the Merger (the &#8220;Effective Time&#8221;), each share of common stock, par value $0.00001 per share, of OrthoCellix (&#8220;OrthoCellix common stock&#8221;), issued and outstanding (other than other than shares of OrthoCellix common stock (a)&#160;held as treasury stock, (b)&#160;owned, directly or indirectly, by Carisma or Merger Sub immediately prior to the Effective Time or (c)&#160;as to which appraisal rights have been properly exercised in accordance with Delaware law) will be converted into and become exchangeable for the right to receive a number of shares of common stock, par value $0.001 per share, of Carisma, calculated by reference to the exchange ratio described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Merger Consideration and Exchange Ratio</i>&#8221; beginning on page&#160;180 of the accompanying proxy statement/prospectus, referred to herein as the &#8220;Exchange Ratio.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">In addition, (a)&#160;Carisma intends to enter into securities purchase agreements (&#8220;subscription agreements&#8221;) with certain investors, pursuant to which Carisma will sell, and such investors will purchase, in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act, as amended (the &#8220;Securities Act&#8221;), and Rule 506 of Regulation D promulgated thereunder, shares of Carisma common stock at a purchase price per share equal to the Aggregate Valuation (as defined below) divided by the Post-Closing Carisma Shares (as defined below), immediately following the Effective Time of the Merger (such transaction, the &#8220;Investor Investment&#8221;) and (b)&#160;on or before August&#160;1, 2025, Ocugen will enter into a securities purchase agreement with Carisma, pursuant to which Ocugen will commit to purchase, immediately following the Effective Time, shares of Carisma&#8217;s common stock for aggregate gross proceeds equal to not less than $5.0 million (the &#8220;Guarantor Investment&#8221;, and together with the Investor Investment, the &#8220;Concurrent Financing&#8221;). Carisma also intends to enter into a registration rights agreement with the investors that will participate in the anticipated Concurrent Financing (&#8220;Registration Rights Agreement&#8221;) at the closing of the anticipated Concurrent Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration of the resale of certain shares of Carisma common stock that are held by the investors participating in the anticipated Concurrent Financing from time to time on Form&#160;S-1 or Form&#160;S-3. The closing of the anticipated Concurrent Financing is conditioned upon the satisfaction or waiver of each of the conditions to the closing of the Merger, as well as certain other conditions. The anticipated Concurrent Financing is more fully described in the section titled <i style="font-style:italic;">&#8220;Agreements Related to the Merger&#8212;Anticipated Subscription Agreements and Registration Rights Agreement&#8221;</i> beginning on page&#160;202 of the accompanying proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">Each share of Carisma common stock that is issued and outstanding at the Effective Time will remain issued and outstanding and such shares will be unaffected by the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">Based on Carisma&#8217;s and OrthoCellix&#8217;s capitalization as of June&#160;22, 2025, and taking into account Carisma&#8217;s current cash position, each share of OrthoCellix common stock is currently estimated to be entitled to receive approximately 327,677.6433 shares of Carisma&#8217;s common stock. This estimated Exchange Ratio does not give effect to the contemplated Carisma reverse stock split (which is more fully described below) and is subject to adjustment based on Carisma&#8217;s estimated Net Cash (as defined herein) at the closing of the Merger as described in more detail, including other adjustments, in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Merger Consideration and Exchange Ratio</i>&#8221; beginning on page&#160;180 of the accompanying proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_31f4d2ee_e317_4e89_879b_ef649fd993a0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Immediately after the Merger and the anticipated Concurrent Financing, Carisma securityholders as of immediately prior to the Merger are expected to own approximately&#160;10.0% of the outstanding shares of the Combined Company on a fully-diluted basis, OrthoCellix&#8217;s sole stockholder, Ocugen (but excluding for this purpose any shares purchased by Ocugen in the anticipated Concurrent Financing), is expected to own approximately 73.3% of the outstanding shares of the Combined Company on a fully-diluted basis, and the investors in the anticipated Concurrent Financing (including for this purpose shares purchased in the Concurrent Financing by Ocugen) would own approximately 16.7% of the outstanding shares of the Combined Company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Carisma&#8217;s Net Cash as of the closing of the Merger being approximately $0 and the anticipated Concurrent Financing amount of $25.0 million (the &#8220;Concurrent Financing Amount&#8221;). Under certain circumstances, as described below, the ownership&#160;percentages may be adjusted upward or downward based on the level of Carisma&#8217;s Net Cash at the closing of the Merger and the actual Concurrent Financing Amount at the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">After the completion of the Merger, Ocugen will continue to control a majority of the voting power for the election of directors of the Combined Company, owning approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % of the outstanding shares of the Combined Company&#8217;s common stock). As a result, the Combined Company will be a &#8220;controlled company&#8221; within the meaning of the rules&#160;of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) and may elect not to comply with certain corporate governance standards. While the Combined Company does not presently intend to rely on these exemptions, the Combined Company may opt to utilize these exemptions in the future as long as it remains a controlled company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Shares of Carisma common stock are currently listed on the Nasdaq Capital Market under the symbol &#8220;CARM.&#8221; Carisma is not currently in compliance with the Nasdaq Capital Market listing requirements. Carisma intends to file an initial listing application for the Combined Company with the Nasdaq Capital Market. After completion of the Merger, Carisma will be renamed &#8220;OrthoCellix,&#160;Inc.&#8221; and it is expected that the common stock of the Combined Company will trade on Nasdaq under the symbol &#8220;OCLX.&#8221; It is a condition of the consummation of the Merger that Carisma obtains approval of the listing of the Combined Company on Nasdaq, but there can be no assurance such listing condition will be met or that Carisma will obtain such approval from Nasdaq. If such listing condition is not met or if such approval is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties. However, in the event that the shares of Carisma common stock to be issued in the Merger are not approved for listing on Nasdaq, it is possible that Carisma and OrthoCellix may mutually agree to waive the applicable condition and nonetheless proceed with completing the Merger. If such condition is waived, Carisma will not recirculate an updated proxy statement/prospectus, nor will it solicit a new vote of stockholders prior to proceeding with the Merger. If Carisma proceeds with the Merger in these circumstances, the Combined Company&#8217;s stock may not be listed on Nasdaq. Accordingly, you are advised that Carisma stockholders will not have certainty regarding the listing of the Combined Company&#8217;s shares at the time you are asked to vote at the Carisma Special Meeting (as defined below). On July&#160;18, 2025, the last trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of Carisma common stock was $0.3922 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Carisma&#8217;s stockholders are cordially invited to attend the special meeting of Carisma&#8217;s stockholders. Carisma is holding its special meeting of stockholders in lieu of an annual meeting of stockholders (the &#8220;Carisma Special Meeting&#8221;), on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a.m., Eastern Time, unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the Merger and other matters. The Carisma Special Meeting will be held via the Internet at https://meetnow.global/MMLQXXY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At the Carisma Special Meeting, Carisma will ask its stockholders to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve, pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d), the issuance of shares of common stock of Carisma to (i) Ocugen,&#160;the sole stockholder of OrthoCellix, pursuant to the terms of the Merger Agreement among Ocugen, Carisma, OrthoCellix and Merger Sub, dated as of June&#160;22, 2025, a copy of which is attached as </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Annex A</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to the accompanying proxy statement/prospectus and (ii)&#160;investors in the anticipated Concurrent Financing, pursuant to the terms of the subscription agreements, the form of which is filed as </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Annex I</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to this registration statement, which will (a)&#160;represent more than 20.0% of the shares of Carisma common stock outstanding immediately prior to the Merger and (b)&#160;result in a change of control in Carisma&#160;(the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal No.&#160;1&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve the OrthoCellix,&#160;Inc. 2025 Stock Option and Incentive Plan, which will become effective as of and contingent on the completion of the Merger&#160;(the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal No.&#160;2&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To elect three Class&#160;II directors, Steven Kelly, Briggs Morrison, M.D. and Sanford Zweifach, to Carisma&#8217;s board of directors and to hold office until Carisma&#8217;s 2028 annual meeting of stockholders and until their respective successor has been duly elected and qualified, or until their earlier death, resignation or removal; provided that if the Merger is consummated, the election of these directors will only have an effect until the completion of the Merger because the composition of Carisma&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal No.&#160;3&#8221;);</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To ratify the appointment of KPMG LLP as Carisma&#8217;s independent registered public accounting firm for the fiscal&#160;year ending December&#160;31, 2025 (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal No.&#160;4&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve, on an advisory basis, named executive officer compensation (the &#8220;Say on Pay Proposal&#8221; or Proposal No.&#160;5&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve, on an advisory basis, certain compensation arrangements for Carisma&#8217;s named executive officers that are based on or otherwise relate to the Merger (the &#8220;Merger Compensation Proposal&#8221; or &#8220;Proposal No.&#160;6&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve an adjournment of the Carisma Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No.&#160;1 (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal No.&#160;7&#8221;); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">8.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To transact such other business as may properly come before the stockholders at the Carisma Special Meeting or any adjournment or postponement thereof.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Carisma is also scheduled to hold a separate special meeting of Carisma stockholders on August&#160;5, 2025 (the &#8220;reverse stock split special meeting&#8221;) to approve an amendment to Carisma&#8217;s certificate of incorporation to effect a reverse stock split of Carisma&#8217;s issued and outstanding common stock at a ratio of not less than 1-for-10 and not greater than 1-for-50, with the exact ratio within such range to be determined at the discretion of Carisma&#8217;s board of directors, without further approval or authorization of Carisma&#8217;s stockholders (the &#8220;reverse stock split&#8221;). For additional information on the reverse stock split special meeting, see Carisma&#8217;s definitive proxy statement for the Special Meeting of Stockholders filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July&#160;7, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As described in the accompanying proxy statement/prospectus, certain executive officers and directors of Carisma who in the aggregate owned approximately 0.03% of the outstanding shares of Carisma as of June&#160;22, 2025, and Ocugen, the sole stockholder of OrthoCellix, are parties to stockholder support agreements with Carisma and OrthoCellix, respectively, whereby such stockholders have agreed to vote in favor of the approval of the transactions contemplated therein, including, with respect to OrthoCellix common stockholders, adoption of the Merger Agreement and approval of the Merger and, with respect to such Carisma&#8217;s stockholders, Proposal No.&#160;1, subject to the terms of the support agreements. Following the effectiveness of the registration statement on Form&#160;S-4 of which the accompanying proxy statement/prospectus is a part and pursuant to the Merger Agreement, OrthoCellix common stockholders holding a sufficient number of shares of OrthoCellix capital stock to adopt the Merger Agreement and approve the Merger and related transactions will be asked to execute written consents providing for such adoption and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">After careful consideration, each of the Carisma and OrthoCellix boards of directors have approved the Merger Agreement and have determined that it is advisable to consummate the Merger. Carisma&#8217;s board of directors has approved the proposals described in the accompanying proxy statement/prospectus and unanimously recommends that its stockholders vote &#8220;FOR&#8221; the proposals described in the accompanying proxy statement/ prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">More information about Carisma, OrthoCellix, the Merger Agreement and transactions contemplated thereby and the foregoing proposals is contained in the accompanying proxy statement/prospectus. Carisma urges you to read the accompanying proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE&#160;</b><span style="font-weight:bold;">26</span><b style="font-weight:bold;"> OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Carisma and OrthoCellix are excited about the opportunities the Merger brings to Carisma&#8217;s and OrthoCellix&#8217;s stockholders and thank you for your consideration and continued support. Sincerely,</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Steven Kelly</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Carisma Therapeutics Inc.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy statement/ prospectus. Any representation to the contrary is a criminal offense.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">The accompanying proxy statement/prospectus is dated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, and is first being mailed to Carisma&#8217;s stockholders on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_7887a65e_e1e2_4c6b_9370_73da610383e9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3675 Market Street,&#160;Suite&#160;401</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Philadelphia, PA 19104</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(267)&#160;491-6422</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS IN LIEU OF ANNUAL MEETING OF STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the stockholders of Carisma Therapeutics&#160;Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTICE IS HEREBY GIVEN</b> that a special meeting in lieu of the annual meeting of stockholders (the &#8220;Carisma Special Meeting&#8221;), will be held on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a.m., Eastern Time, unless postponed or adjourned to a later date. The Carisma Special Meeting will be held via the Internet by virtual audio web conference at https://meetnow.global/MMLQXXY. You will be able to attend and participate in the Carisma Special Meeting virtually where you will be able to listen to the meeting live, submit questions and vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Carisma Special Meeting will be held for the following purposes:</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve, pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d), the issuance of shares of common stock of Carisma Therapeutics&#160;Inc. (&#8220;Carisma&#8221;) to (i) Ocugen, Inc. (&#8220;Ocugen&#8221;),&#160;the sole stockholder of OrthoCellix,&#160;Inc. (&#8220;OrthoCellix&#8221;), pursuant to the terms of the Agreement and Plan of Merger among Ocugen, Carisma, OrthoCellix and Azalea Merger Sub,&#160;Inc. (&#8220;Merger Sub&#8221;), dated as of June&#160;22, 2025, a copy of which is attached as </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Annex A</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to the accompanying proxy statement/prospectus, which is referred to in this notice as the &#8220;Merger Agreement&#8221;; and (ii)&#160;investors in the anticipated Concurrent Financing, pursuant to the terms of the subscription agreements, the form of which is filed as </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Annex I</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to this registration statement, which will (a)&#160;represent more than 20.0% of the shares of Carisma common stock outstanding immediately prior to the Merger (as defined herein) and (b)&#160;result in a change of control in Carisma (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal No.&#160;1&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve the OrthoCellix,&#160;Inc. 2025 Stock Option and Incentive Plan, which will become effective as of and contingent on the completion of the Merger&#160; (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal No.&#160;2&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To elect three Class&#160;II directors, Steven Kelly, Briggs Morrison, M.D. and Sanford Zweifach, to Carisma&#8217;s board of directors and to hold office until Carisma&#8217;s 2028 annual meeting of stockholders and until their respective successor has been duly elected and qualified, or until their earlier death, resignation or removal; provided that if the Merger is consummated, the election of these directors will only have an effect until the completion of the Merger because the composition of Carisma&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal No.&#160;3&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To ratify the appointment of KPMG LLP as Carisma&#8217;s independent registered public accounting firm for the fiscal&#160;year ending December&#160;31, 2025 (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal No.&#160;4&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve, on an advisory basis, named executive officer compensation (the &#8220;Say on Pay Proposal&#8221; or Proposal No.&#160;5&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve, on an advisory basis, certain compensation arrangements for Carisma&#8217;s named executive officers that are based on or otherwise relate to the Merger (the &#8220;Merger Compensation Proposal&#8221; or &#8220;Proposal No.&#160;6&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve an adjournment of the Carisma Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No.&#160;1 (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal No.&#160;7&#8221;); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">8.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To transact such other business as may properly come before the stockholders at the Carisma Special Meeting or any adjournment or postponement thereof.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Record Date:</b> Carisma&#8217;s board of directors has fixed&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 as the record date for the determination of stockholders entitled to notice of, and to vote at, the Carisma Special Meeting and any adjournment or postponement thereof. Only holders of record of shares of Carisma common stock at the close of business on the record date are entitled to notice of, and to vote at, the Carisma Special Meeting. At the close of business on the record date, Carisma had&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock outstanding and entitled to vote.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Your vote is important. The affirmative vote of a majority of the votes properly cast at the Carisma Special Meeting, assuming a quorum is present, is required for approval of Proposal Nos. 1, 2, 4, 5, 6 and 7. With respect to Proposal No.&#160;3, the directors are elected by a plurality of the votes properly cast at the Carisma Special Meeting, and the three nominees for director receiving the highest number of affirmative votes will be elected. Approval of Proposal No.&#160;1 is a condition to the completion of the Merger. Therefore, the Merger cannot be consummated without the approval of Proposal No.&#160;1.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Even if you plan to virtually attend the Carisma Special Meeting, Carisma requests that you sign and return the enclosed proxy or vote by mail, telephone or online to ensure that your shares will be represented at the Carisma Special Meeting if you are unable to attend. You may change or revoke your proxy at any time before it is voted at the Carisma Special Meeting.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA&#8217;S BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, IN THE BEST INTERESTS OF, AND ADVISABLE TO CARISMA AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. CARISMA&#8217;S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT CARISMA&#8217;S STOCKHOLDERS VOTE &#8220;FOR&#8221; EACH SUCH PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#8217; Meeting &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to Be Held on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a.m., Eastern Time </b>via the Internet by virtual audio web conference at https://meetnow.global/MMLQXXY<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The proxy statement/prospectus and annual report to stockholders in connection with the Carisma Special Meeting are available at https://meetnow.global/MMLQXXY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">By Order of Carisma&#8217;s Board of Directors,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Kelly </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">President, Chief Executive Officer and Director</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,2025</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_90685432_21a4_4bf3_942f_8f60abde68ce"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXPLANATORY NOTE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The issuances of all shares of Carisma common stock in exchange for each share of OrthoCellix common stock is intended to be covered by this registration statement on Form&#160;S-4 of which this proxy statement/prospectus is a part.</p><a id="_6268419d_d68f_4c79_924d_2bc7b71e406c"></a><a id="REFERENCESTOADDITIONALINFORMATION_155662"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REFERENCES TO ADDITIONAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This proxy statement/prospectus incorporates important business and financial information about Carisma Therapeutics&#160;Inc. that is not included in or delivered with this document. <b style="font-weight:bold;">You may obtain this information without charge through the SEC website (</b><span style="font-style:italic;font-weight:bold;">www.sec.gov</span><b style="font-weight:bold;">) or upon your written or oral request by contacting the Secretary of Carisma Therapeutics&#160;Inc., 3675 Market Street, Suite&#160;401, Philadelphia, Pennsylvania 19104 Attention: Corporate Secretary or by calling (267) 491-6422.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">To ensure timely delivery of these documents, any request should be made no later than&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, which is five business&#160;days prior to the date of the Carisma Special Meeting, in order to receive them before the Carisma Special Meeting.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For additional details about where you can find information about Carisma, please see the section titled &#8220;<i style="font-style:italic;">Where You Can Find More Information</i>&#8221; beginning on page&#160;372 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_41e12f9c_18a7_4926_9009_3d309abd9d8f"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REFERENCESTOADDITIONALINFORMATION_155662"><span style="font-style:normal;font-weight:normal;">References To Additional Information</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">i</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#QUESTIONSANDANSWERS_721333"><span style="font-style:normal;font-weight:normal;">Questions and Answers</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PROSPECTUSSUMMARY_346096"><span style="font-style:normal;font-weight:normal;">Prospectus Summary</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#RISKFACTORS_41144"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#MARKETPRICEANDDIVIDENDINFORMATION_507649"><span style="font-style:normal;font-weight:normal;">Market Price and Dividend Information</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">139</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"><span style="font-style:normal;font-weight:normal;">Cautionary Note Regarding Forward-Looking Statements</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">140</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#THEMERGER_885693"><span style="font-style:normal;font-weight:normal;">The Merger</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">143</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#THEMERGERAGREEMENT_125403"><span style="font-style:normal;font-weight:normal;">The Merger Agreement</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">180</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AGREEMENTSRELATEDTOTHEMERGER_629264"><span style="font-style:normal;font-weight:normal;">Agreements Related to the Merger</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">197</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CARISMAEXECUTIVEOFFICERSDIRECTORSANDCORP"><span style="font-style:normal;font-weight:normal;">Carisma Executive Officers, Directors and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">203</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CARISMAEXECUTIVECOMPENSATION_762390"><span style="font-style:normal;font-weight:normal;">Carisma Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">211</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CARISMADIRECTORCOMPENSATION_587305"><span style="font-style:normal;font-weight:normal;">Carisma Director Compensation</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">226</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CARISMAEQUITYCOMPENSATIONPLANINFORMATION"><span style="font-style:normal;font-weight:normal;">Carisma Equity Compensation Plan Information</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">228</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ORTHOCELLIXEXECUTIVECOMPENSATION_580384"><span style="font-style:normal;font-weight:normal;">OrthoCellix Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">229</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ORTHOCELLIXDIRECTORCOMPENSATION_959481"><span style="font-style:normal;font-weight:normal;">OrthoCellix Director Compensation</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">230</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#MATTERSBEINGSUBMITTEDTOAVOTEOFCARISMASST"><span style="font-style:normal;font-weight:normal;">Matters Being Submitted to a Vote of Carisma&#8217;s Stockholders</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">231</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PROPOSALNO1THENASDAQSTOCKISSUANCEPROPOSA"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 1 - THE NASDAQ STOCK ISSUANCE PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">231</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PROPOSALNO2THESTOCKPLANPROPOSAL_172991"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 2 - THE STOCK PLAN PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">233</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PROPOSALNO3THEDIRECTORELECTIONPROPOSAL_9"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 3 - THE DIRECTOR ELECTION PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">240</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PROPOSALNO4THEAUDITORRATIFICATIONPROPOSA"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 4 - THE AUDITOR RATIFICATION PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">244</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PROPOSALNO5THESAYONPAYPROPOSAL_214682"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 5 - THE SAY ON PAY PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">247</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PROPOSALNO6THEMERGERCOMPENSATIONPROPOSAL"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 6 - THE MERGER COMPENSATION PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">248</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PROPOSALNO7THEADJOURNMENTPROPOSAL_760612"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 7 - THE ADJOURNMENT PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">249</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CARISMASBUSINESS_106114"><span style="font-style:normal;font-weight:normal;">Carisma&#8217;s Business</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">250</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ORTHOCELLIXSBUSINESS_195125"><span style="font-style:normal;font-weight:normal;">OrthoCellix&#8217;s Business</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">284</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CARISMAMANAGEMENTSDISCUSSIONANDANALYSISO"><span style="font-style:normal;font-weight:normal;">Carisma Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">310</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#QUANTITATIVEANDQUALITATIVEDISCLOSURESABO"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About the Market Risk of Carisma</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">325</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ORTHOCELLIXMANAGEMENTSDISCUSSIONANDANALY"><span style="font-style:normal;font-weight:normal;">OrthoCellix Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">326</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#MANAGEMENTFOLLOWINGTHEMERGER_235287"><span style="font-style:normal;font-weight:normal;">Management Following the Merger</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">336</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CERTAINRELATIONSHIPSANDRELATEDPARTYTRANS"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Party Transactions of the Combined Company</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">340</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#UNAUDITEDPROFORMACONDENSEDCOMBINEDFINANC"><span style="font-style:normal;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">344</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOUNAUDITEDPROFORMACONDENSEDCOMBINE"><span style="font-style:normal;font-weight:normal;">Notes to Unaudited Pro Forma Condensed Combined Financial Information</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">349</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#DESCRIPTIONOFCARISMACAPITALSTOCK_276019"><span style="font-style:normal;font-weight:normal;">Description of Carisma Capital Stock</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">356</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#COMPARISONOFRIGHTSOFHOLDERSOFCARISMACAPI"><span style="font-style:normal;font-weight:normal;">Comparison of Rights of Holders of Carisma Capital Stock and OrthoCellix Capital Stock</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">359</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PRINCIPALSTOCKHOLDERSOFCARISMA_390058"><span style="font-style:normal;font-weight:normal;">Principal Stockholders of Carisma</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">365</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PRINCIPALSTOCKHOLDERSOFORTHOCELLIX_13066"><span style="font-style:normal;font-weight:normal;">Principal Stockholder of OrthoCellix</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">367</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PRINCIPALSTOCKHOLDERSOFTHECOMBINEDCOMPAN"><span style="font-style:normal;font-weight:normal;">Principal Stockholders of the Combined Company</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">368</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#LEGALMATTERS_608613"><span style="font-style:normal;font-weight:normal;">Legal Matters</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">370</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EXPERTS_777361"><span style="font-style:normal;font-weight:normal;">Experts</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">371</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#WHEREYOUCANFINDMOREINFORMATION_997838"><span style="font-style:normal;font-weight:normal;">Where You Can Find More Information</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">372</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OTHERMATTERS_595745"><span style="font-style:normal;font-weight:normal;">Other Matters</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">373</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#INDEXTOCONSOLIDATEDFINANCIALSTATEMENTS_7"><span style="font-style:normal;font-weight:normal;">Index to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexA_512168"><span style="font-style:normal;font-weight:normal;">Annex A: Agreement and Plan of Merger</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexB_435155"><span style="font-style:normal;font-weight:normal;">Annex B: Opinion of Lucid</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">B-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexC_214320"><span style="font-style:normal;font-weight:normal;">Annex C: Form of Carisma Support Agreement</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">C-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexD_774422"><span style="font-style:normal;font-weight:normal;">Annex D: Form of OrthoCellix Support Agreement</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">D-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexE_617142"><span style="font-style:normal;font-weight:normal;">Annex E: Form of Lock-Up Agreement</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">E-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexF_507394"><span style="font-style:normal;font-weight:normal;">Annex F: Form of Carisma CVR Agreement</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXG_45134"><span style="font-style:normal;font-weight:normal;">Annex G: Delaware Appraisal Rights for OrthoCellix Common Stockholders</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">G-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXH_560042"><span style="font-style:normal;font-weight:normal;">Annex H: Form of OrthoCellix, Inc. 2025 Stock Option and Incentive Plan*</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">H-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXI_835065"><span style="font-style:normal;font-weight:normal;">Annex I: Form of Subscription Agreement*</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">I-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXJ_764894"><span style="font-style:normal;font-weight:normal;">Annex J: Form of Registration Rights Agreement*</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">J-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXK_360403"><span style="font-style:normal;font-weight:normal;">Annex K: Form of Proxy Card</span></a></p></td><td style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">K-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_364617"><span style="font-style:normal;font-weight:normal;">PART II INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS</span></a></p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">II-1</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To be filed by amendment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6475b815_b4b2_426d_a6dd_1b9a0beb8b45"></a><a id="QUESTIONSANDANSWERS_721333"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">QUESTIONS AND ANSWERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Carisma is also scheduled to hold a separate special meeting of Carisma stockholders on August&#160;5, 2025 (the &#8220;reverse stock split special meeting&#8221;) to approve an amendment to Carisma&#8217;s certificate of incorporation to effect a reverse stock split of Carisma&#8217;s issued and outstanding common stock at a ratio of not less than 1-for-10 and not greater than 1-for-50, with the exact ratio within such range to be determined at the discretion of Carisma&#8217;s board of directors, without further approval or authorization of Carisma&#8217;s stockholders (the &#8220;reverse stock split&#8221;). For additional information on the reverse stock split special meeting, see Carisma&#8217;s definitive proxy statement for the Special Meeting of Stockholders filed with the SEC on July&#160;7, 2025 Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the contemplated reverse stock split described in Carisma&#8217;s definitive proxy statement filed with the SEC on July&#160;7, 2025.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following section provides answers to frequently asked questions about the Carisma Special Meeting, the Merger, the anticipated Concurrent Financing and the proposals to be voted on at the Carisma Special Meeting. This section, however, provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross-referenced sections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What is the Merger?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: On June&#160;22, 2025, Carisma, Merger Sub, OrthoCellix and Ocugen entered into the Merger Agreement, a copy of which is attached to this proxy statement/prospectus as <i style="font-style:italic;">Annex A</i>. The Merger Agreement contains the terms and conditions of the proposed Merger. Pursuant to the Merger Agreement, Merger Sub will merge with and into OrthoCellix, with OrthoCellix continuing as a wholly owned subsidiary of Carisma and the surviving corporation of the Merger. This entire transaction is referred to in this proxy statement/prospectus as the &#8220;Merger.&#8221; In connection with the Merger, Carisma will change its corporate name to &#8220;OrthoCellix,&#160;Inc.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What will OrthoCellix&#8217;s securityholder receive in the Merger?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: At the Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, each share of OrthoCellix common stock issued and outstanding immediately prior to the Effective Time (other than any held as treasury stock,&#160;owned, directly or indirectly, by Carisma or Merger Sub immediately prior to the Effective Time or&#160;as to which appraisal rights have been properly exercised in accordance with Delaware law) shall be converted into and become exchangeable for the right to receive, a number of shares of Carisma common stock equal to the Exchange Ratio (described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8201;-&#8201;Merger Consideration and Exchange Ratio</i>&#8221; beginning on page&#160;180 of this proxy statement/prospectus).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">For a more complete description of the treatment of OrthoCellix securities in the Merger, please see the sections titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8201;-&#8201;Merger Consideration and Exchange Ratio</i>&#8221; beginning on page&#160;180 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What will Carisma securityholders receive in the Merger?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Each share of Carisma common stock that is issued and outstanding at the Effective Time of the Merger will remain issued and outstanding and such shares will be unaffected by the Merger. Immediately after the Merger and the anticipated Concurrent Financing, Carisma securityholders as of immediately prior to the Merger are expected to own approximately 10.0% of the outstanding shares of the Combined Company on a fully-diluted basis, and Ocugen, the sole stockholder of OrthoCellix, along with the other investors in the anticipated Concurrent Financing are expected to own approximately 90.0% of the outstanding shares of the Combined Company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Carisma&#8217;s Net Cash as of the closing of the Merger being approximately $0 and the anticipated Concurrent Financing Amount of $25.0 million. The anticipated Concurrent Financing is more fully described in the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger &#8212;</i> <i style="font-style:italic;">Anticipated Subscription Agreements and Registration Rights Agreement</i>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 13.5pt;">In addition, each option to purchase shares of Carisma&#8217;s common stock that is outstanding immediately prior to the Effective Time, whether vested or unvested, will survive the closing and remain outstanding in accordance with its terms. For a more complete description of the treatment of Carisma securities in the Merger, please see the sections titled &#8220;<i style="font-style:italic;">Market Price and Dividend Information</i>&#8221; and &#8220;<i style="font-style:italic;">The Merger Agreement&#8201;-&#8201;Merger Consideration and Exchange Ratio</i>&#8221; beginning on pages&#160;139 and 180, respectively, of this proxy statement/prospectus.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: Why are the two companies proposing to merge?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Carisma and OrthoCellix believe that combining the two companies will result in a company focused on developing NeoCart&#174; as an autologous cartilage implant technology utilizing patient cells to repair articular cartilage defects of the knee. If the Merger is completed, the business of OrthoCellix will continue as the business of the Combined Company. For a more complete description of the reasons for the Merger, please see the sections titled &#8220;<i style="font-style:italic;">The Merger&#8201;-&#8201;Carisma&#8217;s Reasons for the Merger</i>&#8221; and &#8220;<i style="font-style:italic;">The Merger&#160;- OrthoCellix&#8217;s Reasons for the Merger</i>&#8221; beginning on pages&#160;149 and 151, respectively, of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What will happen to Carisma if, for any reason, the Merger with OrthoCellix does not close?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Carisma has invested significant time and incurred, and expects to continue to incur, significant expenses related to the proposed Merger with OrthoCellix. Carisma&#8217;s future operations are highly dependent on the success of the Merger. In the event the Merger does not close, Carisma will have a limited ability to continue its current operations. Although Carisma&#8217;s board of directors may elect, among other things, to attempt to identify and complete another strategic transaction if the Merger with OrthoCellix does not close, Carisma&#8217;s board of directors may instead commence bankruptcy or take steps necessary to liquidate or dissolve Carisma&#8217;s business and assets. If Carisma decides to dissolve and liquidate its assets, Carisma would be required to pay all of its outstanding contractual obligations, and to set aside certain reserves for potential future claims, and there can be no assurance as to the amount of and the timing of such liquidation and distribution of available cash left to distribute to stockholders after paying the obligations of Carisma and setting aside funds for reserves. Accordingly, holders of Carisma common stock could lose all or a significant portion of their investment in the event of a liquidation, dissolution or winding up of the company. A liquidation would be a lengthy and uncertain process with no assurance of any value ever being returned to Carisma&#8217;s stockholders. For more information about the risks related to not consummating the Merger, please see the section titled &#8220;<i style="font-style:italic;">Risk Factors&#160;&#8212; Risks Related to Carisma&#160;- Risks Related to Our Evaluation of the Merger and Strategic Alternatives&#8221; </i>on page&#160;30 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: Why am I receiving this proxy statement/prospectus?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: You are receiving this proxy statement/prospectus because you have been identified as a stockholder of Carisma as of the applicable record date, and you are entitled to vote to approve the matters set forth herein. This document serves as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a proxy statement of Carisma used to solicit proxies for the Carisma Special Meeting to vote on the matters set forth herein; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a prospectus of Carisma used to offer shares of Carisma common stock issued in exchange for shares of OrthoCellix common stock in the Merger.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What is the Concurrent Financing?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Carisma is expected to enter into the subscription agreements with certain investors, pursuant to which Carisma will sell, and such investors will purchase, shares of Carisma common stock at a purchase price per share equal to the Aggregate Valuation divided by the Post-Closing Carisma Shares (each as defined below), for an aggregate purchase price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million. Carisma and the investors participating in the anticipated Concurrent Financing will enter into the registration rights agreement at the closing of the Concurrent Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Carisma common stock that are held by the investors participating in the Concurrent Financing from time to time pursuant to Rule&#160;415 under the Securities Act. The closing of the Concurrent Financing is conditioned upon the satisfaction or waiver of the conditions set forth in the subscription agreements and of each of the conditions to the closing of the Merger. Further, as part of the anticipated Concurrent Financing, on or before August&#160;1, 2025, Ocugen shall enter into a securities purchase agreement committing to purchase not less than $5.0 million of shares of Carisma common stock, with terms and conditions of such securities purchase agreement to be substantially similar to the terms of the subscription agreements to be entered into by other investors participating in the anticipated Concurrent Financing. Immediately after the Merger and the anticipated Concurrent Financing, Carisma securityholders as of immediately prior to the Merger are expected to own approximately 10.0% of the outstanding shares of the Combined Company on a fully-diluted basis, and the sole stockholder of OrthoCellix along with the other investors in the anticipated Concurrent Financing are expected to own approximately 90.0% of the outstanding shares of the Combined Company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Carisma&#8217;s Net Cash as of the closing of the Merger being approximately $0 and the anticipated Concurrent Financing Amount of $25.0 million.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What proposals will be voted on at the Carisma Special Meeting in connection with the Merger?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Pursuant to the terms of the Merger Agreement, the following proposal must be approved by the requisite stockholder vote at the Carisma Special Meeting in order for the Merger to close:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve, pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d), the issuance of shares of common stock of Carisma to (i)&#160;the sole stockholder of OrthoCellix pursuant to the terms of the Merger Agreement, and (ii)&#160;investors in the anticipated Concurrent Financing, pursuant to the terms of the subscription agreements, which will (a)&#160;represent more than 20.0% of the shares of Carisma common stock outstanding immediately prior to the Merger; and (b)&#160;result in the change of control of Carisma (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal No.&#160;1&#8221;).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">Approval of Proposal No.&#160;1 is a condition to completion of the Merger. The issuance of Carisma common stock in connection with the Merger and the anticipated Concurrent Financing and the change of control resulting from the Merger and the anticipated Concurrent Financing will not take place unless Proposal No.&#160;1 is approved by Carisma stockholders and the Merger is consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">In addition to the requirement of obtaining Carisma stockholder approval, the closing of the Merger Agreement is subject to the satisfaction or waiver of each of the other closing conditions set forth in the Merger Agreement. For a more complete description of the closing conditions under the Merger Agreement, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8201;-&#8201;Conditions to the Completion of the Merger</i>&#8221; beginning on page&#160;183 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What proposals are to be voted on at the Carisma Special Meeting, other than the Nasdaq Stock Issuance Proposal?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: At the Carisma Special Meeting, the holders of Carisma common stock will also be asked to vote on the following proposals:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve the OrthoCellix,&#160;Inc. 2025 Stock Option and Incentive Plan, which will become effective as of and contingent on the completion of the Merger&#160;(the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal No.&#160;2&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To elect three Class&#160;II directors, Steven Kelly, Briggs Morrison, M.D. and Sanford Zweifach, to Carisma&#8217;s board of directors and to hold office until Carisma&#8217;s 2028 annual meeting of stockholders and until their respective successor has been duly elected and qualified, or until their earlier death, resignation or removal; provided that if the Merger is consummated, the election of these directors will only have an effect until the completion of the Merger because the composition of Carisma&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal No.&#160;3&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To ratify the appointment of KPMG LLP as Carisma&#8217;s independent registered public accounting firm for the fiscal&#160;year ending December&#160;31, 2025 (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal No.&#160;4&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve, on an advisory basis, named executive officer compensation (the &#8220;Say on Pay Proposal&#8221; or Proposal No.&#160;5&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve, on an advisory basis, certain compensation arrangements for Carisma&#8217;s named executive officers that are based on or otherwise relate to the Merger (the &#8220;Merger Compensation Proposal&#8221; or &#8220;Proposal No.&#160;6&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To approve an adjournment of the Carisma Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No.&#160;1 (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal No.&#160;7&#8221;); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To transact such other business as may properly come before the stockholders at the Carisma Special Meeting or any adjournment or postponement thereof.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The approvals of Proposal Nos. 2, 3, 4, 5, 6 and 7 are <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</b> conditions to the closing of the Merger. Proposal No.&#160;2 is conditioned on the consummation of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Carisma does not expect any other matter to be brought before the Carisma Special Meeting.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What constitutes a quorum at the Carisma Special Meeting?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: A quorum is needed to hold a valid stockholder meeting. A quorum will be present if the holders of at least a majority in voting power of the shares of Carisma common stock issued and outstanding and entitled to vote on the record date are present at the Carisma Special Meeting either &#8220;in person&#8221; virtually or as represented by proxy. For purposes of establishing a quorum, abstentions and broker non-votes, if any, are counted as present or represented. If a quorum is not present, Carisma expects to adjourn the Carisma Special Meeting until Carisma obtains a quorum. Shares present virtually during the Carisma Special Meeting will be considered shares of Carisma common stock present in person at the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What stockholder votes are required to approve the proposals at the Carisma Special Meeting?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: The affirmative vote of a majority of votes properly cast at the Carisma Special Meeting, assuming a quorum is present, is required for approval of Proposal Nos. 1, 2, 4, 5, 6, and 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 13.5pt;">If you vote to ABSTAIN on Proposal Nos. 1, 2, 4, 5, 6 or 7, your shares will not be voted FOR or AGAINST such proposal and will also not be counted as votes cast or shares voting on such proposal. As a result, abstentions and broker non-votes, if any, will have no effect on Proposal Nos. 1, 2, 4, 5, 6, and 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 13.5pt;">With respect to Proposal No.&#160;3 (the Director Election Proposal), a nominee will be elected as a director if the nominee receives a plurality of the votes cast by stockholders entitled to vote at the Carisma Special Meeting. Broker non-votes will have no effect on the voting on Proposal 3. Votes that are withheld will not be included in the vote tally for the election of directors and will not affect the vote results. You may vote FOR all nominees; vote FOR a particular nominee and WITHHOLD your vote from the other nominees; or WITHHOLD your vote from all nominees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: Why is Carisma seeking stockholder approval to issue shares of Carisma common stock to the sole stockholder of OrthoCellix in the Merger?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Because the Carisma common stock is listed on Nasdaq, Carisma is subject to the Nasdaq rules. Nasdaq Listing Rule&#160;5635(a)&#160;requires stockholder approval with respect to the issuance of Carisma common stock when, among other instances, (i)&#160;the shares to be issued are being issued in connection with the acquisition of the stock or assets of another company and are equal to 20.0% or more of the outstanding shares of Carisma common stock before the issuance and (ii)&#160;any director, officer or &#8220;Substantial Shareholder&#8221; (as defined by Nasdaq Listing Rule&#160;5635(e)(3)) of such company has a five&#160;percent or greater interest (or such persons collectively have a 10.0% or greater interest), directly or indirectly, in the company to be acquired or in the consideration to be paid in the transaction and the issuance of common stock could result in an increase in outstanding common shares or voting power of five&#160;percent or more. Nasdaq Listing Rule&#160;5635(b)&#160;also requires stockholder approval when any issuance or potential issuance will result in a &#8220;change of control&#8221; of the issuer. Although Nasdaq has not adopted any rule&#160;on what constitutes a &#8220;change of control&#8221; for purposes of Rule&#160;5635(b), Nasdaq has previously indicated that the acquisition of, or right to acquire, by a single investor or affiliated investor group, as little as 20.0% of the common stock (or securities convertible into or exercisable for common stock) or voting power of an issuer could constitute a change of control. Nasdaq will consider all facts and circumstances concerning a transaction, including whether there are any other relationships or agreements between the company and the investor or group. Nasdaq Listing Rule&#160;5635(d)&#160;also requires stockholder approval for a transaction other than a public offering involving the sale, issuance or potential issuance by an issuer of common equity securities (or securities convertible into or exercisable for common equity securities) at a price that is less than market value of the stock if the number of equity securities to be issued is or may equal to 20.0% or more of the common stock, or 20.0% or more of the voting power, outstanding before the issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 13.5pt;">The potential issuance of the shares of Carisma common stock in the Merger and the anticipated Concurrent Financing exceeds 20.0% or more of the outstanding shares of Carisma common stock before the issuance. Immediately after the Merger and the anticipated Concurrent Financing, Carisma securityholders as of immediately prior to the Merger are expected to own approximately 10.0% of the outstanding shares of the Combined Company on a fully-diluted basis, and the sole stockholder of OrthoCellix along with the other investors in the anticipated Concurrent Financing are expected to own approximately 90.0% of the outstanding shares of the Combined Company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Carisma&#8217;s Net Cash as of the closing of the Merger being approximately $0 and the anticipated Concurrent Financing Amount of $25.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 13.5pt;">Accordingly, Carisma is seeking stockholder approval of such issuances under the Nasdaq Listing Rules&#160;5635(a), (b)&#160;and (d).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: Will the common stock of the Combined Company trade on an exchange?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Shares of Carisma common stock are currently listed on the Nasdaq Capital Market under the symbol &#8220;CARM.&#8221; Carisma intends to file an initial listing application for the common stock of the Combined Company with Nasdaq. After completion of the Merger, Carisma will be renamed &#8220;OrthoCellix,&#160;Inc.&#8221; and it is expected that the common stock of the Combined Company will trade on the Nasdaq Capital Market under the symbol &#8220;OCLX.&#8221; It is a condition to the consummation of the Merger that Carisma will receive confirmation from Nasdaq that the Combined Company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that Carisma will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties; however, if such condition is waived, Carisma will not recirculate an updated proxy statement/prospectus, nor will it solicit a new vote of stockholders prior to proceeding with the Merger. Accordingly, you are advised that Carisma stockholders will not have certainty regarding the listing of the Combined Company&#8217;s shares at the time you are asked to vote at the Carisma Special Meeting. For more information, please see the section entitled &#8220;<i style="font-style:italic;">Risk Factors&#8201;-&#8201; Risks Related to the Merger</i>&#8221;&#8201;&#8212;&#8201; &#8220;<i style="font-style:italic;">Carisma and OrthoCellix may mutually agree to waive the condition to the Merger requiring approval for listing on Nasdaq, and </i><i style="font-style:italic;">if such condition is waived, the Combined Company&#8217;s stock may not be listed on Nasdaq following completion of the Merger</i>&#8221; on page&#160;27 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 13.5pt;">On July&#160;18, 2025, the last trading day before the date of this proxy statement/prospectus, the closing sale price of Carisma common stock was $0.3922 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: Who will be the directors of the Combined Company following the Merger?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Immediately following the Merger, the Combined Company&#8217;s board of directors will be composed of six members, five of whom have been designated by OrthoCellix and one of whom will be designated by Carisma. Effective as of the Effective Time, Steven Kelly will be designated by Carisma&#8217;s board of directors to continue his service as a member of the board of directors of the Combined Company and Carisma&#8217;s board of directors will appoint the following OrthoCellix designees: David Anderson, Michael Shine, Karthik Musunuri,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, to the board of directors of the Combined Company and concurrently therewith, all of Carisma&#8217;s other current directors will resign from their positions as directors of Carisma&#8217;s board of directors.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; is expected to be appointed as Chair of the board of directors of the Combined Company. The staggered structure of the Carisma board of directors will remain in place for the Combined Company following the completion of the Merger. For additional information, please see the section titled &#8220;<i style="font-style:italic;">Management Following the Merger</i>&#8221; beginning on page&#160;336 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: Who will be the executive officers of the Combined Company immediately following the Merger?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Immediately following the Merger, Steven Kelly, Carisma&#8217;s President and Chief Executive Officer, is expected to serve as the President and Chief Executive Officer of the Combined Company and Natalie McAndrew, Carisma&#8217;s Vice President of Finance (Carisma&#8217;s principal financial officer and principal accounting officer) is expected to serve as the Vice President of Finance (Principal Financial Officer and Principal Accounting Officer) of the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: As a Carisma stockholder, how does Carisma&#8217;s board of directors recommend that I vote?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Carisma&#8217;s board of directors, in consultation with financial and legal advisors and management, evaluated the terms of the Merger Agreement and the related transactions contemplated thereby and: (i)&#160;determined that the transactions contemplated by the Merger Agreement are fair to, advisable and in the best interests of Carisma and its stockholders; (ii)&#160;approved and declared advisable the Merger Agreement and the related transactions, including the issuance of shares of Carisma common stock in connection with the Merger and in the anticipated Concurrent Financing; and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in the Merger Agreement, that the holders of Carisma common stock vote &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the Nasdaq Stock Issuance Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors also unanimously recommends that Carisma&#8217;s stockholders vote:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; the Stock Plan Proposal;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; each of the director nominees named in the Director Election Proposal;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; the Auditor Ratification Proposal;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; the Say on Pay Proposal;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; the Merger Compensation Proposal; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; the Adjournment Proposal.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What risks should I consider in deciding whether to vote in favor of the Merger?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: You should carefully review the section titled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page&#160;26 of this proxy statement/prospectus and the documents incorporated by reference herein, which set forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the Combined Company&#8217;s business will be subject, and risks and uncertainties to which each of Carisma and OrthoCellix, as independent companies, are subject.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: When do you expect the Merger to be consummated?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: The Merger is anticipated to close early in the fourth quarter of 2025, but the exact timing cannot be predicted. For more information, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8201;&#8212;&#8201;Conditions to the Completion of the Merger</i>&#8221; beginning on page&#160;183 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What do I need to do now?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Carisma urges you to read this proxy statement/prospectus carefully, including the annexes and the documents incorporated by reference herein, and to consider how the Merger affects you.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: How do I register to attend the Carisma Special Meeting virtually on the Internet?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: If you are a registered stockholder (i.e., you hold your shares through Carisma&#8217;s transfer agent, Computershare Trust Company, N.A.), you do not need to register to attend the Carisma Special Meeting virtually on the Internet. Please follow the instructions on the notice or proxy card that you received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">If you hold your shares through an intermediary, such as a bank, broker or other nominee, you must register in advance to attend the Carisma Special Meeting virtually on the Internet. To register to attend the Carisma Special Meeting online you must submit proof of your proxy power (legal proxy) reflecting your Carisma holdings along with your name and email address to Computershare Trust Company, N.A. Requests for registration must be labeled as &#8220;Legal Proxy&#8221; and be received no later than&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Eastern Time, on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025. You will receive confirmation of your registration by email after Carisma receives your registration materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">Requests for registration should be directed to Carisma at the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><b style="font-weight:bold;">By email:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">Forward the email from your broker, or attach an image of your legal proxy, to legalproxy@computershare.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><b style="font-weight:bold;">By mail:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Computershare</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Carisma Therapeutics&#160;Inc. Legal Proxy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">P.O.&#160;Box 43001</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">Providence, RI 02940-3001</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What if I have trouble accessing the Carisma Special Meeting virtually?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: The virtual meeting platform is fully supported across browsers and devices running the most up-to-date version of applicable software and plugins. Internet Explorer is not a supported browser. Participants should ensure that they have a strong WiFi connection wherever they intend to participate in the meeting. Carisma encourages you to access the meeting prior to the start time. Technical assistance will be available one hour prior to and during the Carisma Special Meeting by dialing&#160;1-888-724-2416.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: Why is the Carisma Special Meeting a virtual, online meeting?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Carisma believes that hosting a virtual meeting will facilitate stockholder attendance and participation at the Carisma Special Meeting by enabling stockholders to participate remotely from any location around the world. Carisma&#8217;s virtual meeting will be governed by Carisma&#8217;s Rules&#160;of Conduct and Procedures, which will be posted on the virtual meeting platform in advance of the Carisma Special Meeting and will be available for review before and during the Carisma Special Meeting. Carisma has designed the virtual Carisma Special Meeting to provide the same rights and opportunities to stockholders to participate as stockholders would have at an in-person meeting, including the right to vote and ask questions through the virtual meeting platform. There will not be a physical meeting location, and stockholders will not be able to attend the Carisma Special Meeting in person at a physical location.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: How do I vote?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: <b style="font-weight:bold;">If you are the stockholder of record of your shares</b>, you can vote your shares by proxy prior to the Carisma Special Meeting or online during the Carisma Special Meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">If you choose to vote by proxy&#160;<b style="font-weight:bold;">prior to the Carisma Special Meeting</b>, you may do so by telephone, via the Internet or by mail as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">By Telephone</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;You may transmit your proxy over the phone prior to the Carisma Special Meeting by calling 1-800-652-VOTE and following the instructions provided on the proxy card. You will need to have your proxy card in hand when you call.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Via the Internet</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;You may transmit your proxy via the Internet prior to the Carisma Special Meeting by following the instructions provided in the proxy card. You will need to have your proxy card in hand when you access the website. The website for voting is available at&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">www.investorvote.com/CARM</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">By Mail</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160; You can vote by mailing your proxy card as described in the proxy materials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;"><b style="font-weight:bold;">If your shares are held in &#8220;street name,&#8221;</b>&#160;in order to attend the meeting and vote your shares electronically during the Carisma Special Meeting, you must register prior to the deadline of&#8199;&#8199;&#8199;&#8199;&#8199;, 2025 at &#8199;&#8199;&#8199;&#8199;&#8199;p.m. Eastern Time. See &#8220;<i style="font-style:italic;">How do I register to attend the Carisma Special Meeting virtually on the Internet?</i>&#8221; You may vote your shares online while virtually attending the Carisma Special Meeting by following the instructions found on your proxy card and/or voting instruction form and subsequent instructions that will be delivered to you via email following your registration. If you vote by proxy prior to the Carisma Special Meeting and choose to attend the Carisma Special Meeting online, there is no need to vote again during the Carisma Special Meeting unless you wish to change your vote. If your shares are held in &#8220;street name,&#8221; you must demonstrate proof of beneficial ownership to virtually attend the Carisma Special Meeting and must obtain a legal proxy from your bank, broker or other nominee to vote at the Carisma Special Meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;"><b style="font-weight:bold;">If your shares are held in &#8220;street name,&#8221;</b>&#160;your bank, broker or other nominee is required to vote the shares it holds on your behalf according to your instructions. The proxy materials, as well as voting and revocation instructions, should have been forwarded to you by the bank, broker or other nominee that holds your shares. In order to vote your shares, you will need to follow the instructions that your bank, broker or other nominee provides you. The voting deadlines and availability of telephone and Internet voting for beneficial owners of shares held in &#8220;street name&#8221; will depend on the voting processes of the bank, broker or other nominee that holds your shares. Therefore, Carisma urges you to carefully review and follow the voting instruction form and any other materials that you receive from that organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;"><b style="font-weight:bold;">Even if you plan to attend the Carisma Special Meeting online, Carisma urges you to vote your shares by proxy in advance of the Carisma Special Meeting so that if you should become unable to attend the Carisma Special Meeting your shares will be voted as directed by you.</b></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What if I sign and return a proxy card or otherwise vote but do not indicate specific choices?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: <i style="font-style:italic;">Registered Stockholder: Shares Registered in Your Name</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">If your shares are registered directly in your name, your shares will not be voted if you do not submit a proxy over the Internet, by telephone or by returning your proxy by mail prior to the Carisma Special Meeting, or attend and vote online at the virtual Carisma Special Meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">The shares represented by each signed and returned proxy will be voted at the Carisma Special Meeting by the persons named as proxies in the proxy card in accordance with the instructions indicated on the proxy card. However, if you are the registered stockholder and sign and return your proxy card without giving specific instructions, the persons named as proxies in the proxy card will vote your shares in accordance with the recommendations of the Carisma board of directors. Your shares will be counted toward the quorum requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;"><i style="font-style:italic;">Beneficial Owner: Shares Registered in the Name of a Bank, Broker, Fiduciary, Custodian or Other Nominee</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">If you are the beneficial owner and do not direct your bank, broker, fiduciary, custodian or other nominee how to vote your shares, your broker, fiduciary or custodian will only be able to vote your shares with respect to proposals considered to be &#8220;routine&#8221; or &#8220;discretionary.&#8221; Your broker, fiduciary or custodian is not entitled to vote your shares with respect to &#8220;non-routine&#8221; or &#8220;non-discretionary&#8221; proposals, resulting in a &#8220;broker non-vote&#8221; with respect to such proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">The Auditor Ratification Proposal is a matter on which banks, brokers, fiduciaries, custodians or other nominees are expected to have discretionary voting authority under applicable stock exchange rules. If your shares are held by a bank, broker, fiduciary, custodian or other nominee and you do not timely provide voting instructions with respect to your shares, Carisma expects that your bank, broker or other nominee will have the authority to vote your shares on the Auditor Ratification Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">Carisma encourages you to timely provide voting instructions to your banks, brokers, fiduciaries, custodians or other nominees. This ensures that your shares will be voted at the Carisma Special Meeting according to your instructions. You should receive directions from your bank, broker, fiduciary, custodian or other nominee about how to submit your voting instructions to them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: Who counts the votes?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Computershare has been engaged as Carisma&#8217;s independent agent to tabulate stockholder votes, which Carisma refers to as the inspector of election. If you are a stockholder of record, your executed proxy card is returned directly to the inspector of election for tabulation. If you hold your shares through a broker, your broker returns one proxy card to the inspector or election on behalf of all its clients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: How can I find out the voting results?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Final voting results will be published in a Current Report on Form&#160;8-K to be filed with the SEC within four business&#160;days after the Carisma Special Meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: Can I revoke my proxy and can I change my vote?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: If you are a stockholder of record, you may revoke your proxy before the vote is taken at the Carisma Special Meeting:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by submitting a new proxy with a later date before the applicable deadline, either signed and returned by mail or transmitted using the telephone or Internet voting procedures described in the &#8220;How do I vote?&#8221; section above, in each case, prior to the Carisma Special Meeting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by voting online at the Carisma Special Meeting using the procedures described in the &#8220;How do I vote?&#8221; section above; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by filing a written revocation with Carisma&#8217;s Corporate Secretary prior to the Carisma Special Meeting.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">If your shares are held in &#8220;street name,&#8221; you may submit new voting instructions by contacting your bank, broker or other nominee holding your shares. You may also vote online during the Carisma Special Meeting, which will have the effect of revoking any </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">previously submitted voting instructions, if you obtain a legal proxy from the organization that holds your shares and follow the procedures described in the &#8220;How do I vote?&#8221; section above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 14.4pt;">Your virtual attendance at the Carisma Special Meeting, without voting online during the Carisma Special Meeting, will not revoke your proxy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: Who is soliciting proxies and paying for this proxy solicitation?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Carisma and OrthoCellix will share equally the cost of printing and filing of this proxy statement/prospectus and the proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of Carisma common stock for the forwarding of solicitation materials to the beneficial owners of Carisma common stock. Carisma will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out-of-pocket expenses they incur in connection with the forwarding of solicitation materials. Carisma has retained MacKenzie Partners,&#160;Inc. to assist in soliciting proxies using the means referred to above. Carisma will pay the fees of MacKenzie Partners,&#160;Inc., which Carisma expects to be approximately $15,000, plus reimbursement for certain out-of-pocket expenses. In addition to solicitation by mail, the directors, officers, employees and agents of Carisma may solicit proxies from Carisma&#8217;s stockholders by personal interview, telephone, email, fax or otherwise without additional compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What are the material U.S. federal income tax considerations of the Merger to U.S. Holders of Carisma common stock?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: Carisma stockholders will not sell, exchange or dispose of any shares of Carisma common stock as a result of the Merger. Thus, there will be no U.S. federal income tax considerations to Carisma stockholders as a result of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: What are the material U.S. federal income tax considerations of the receipt of the CVRs (as defined below) to Carisma stockholders?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: The U.S. federal income tax treatment of Carisma stockholders&#8217; receipt of the CVRs is unclear. Carisma will report the issuance of the CVRs to Carisma stockholders as a distribution of property with respect to Carisma common stock. Assuming such treatment, each Carisma stockholder will be treated as receiving a distribution in an amount equal to the fair market value of the CVRs issued to such Carisma stockholder on the date of the issuance. This distribution should be treated first as a taxable dividend to the extent of the Carisma stockholder&#8217;s pro rata share of Carisma&#8217;s current or accumulated earnings and profits for the&#160;year of issuance (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Carisma stockholder&#8217;s basis in its Carisma common stock, and finally as capital gain from the sale or exchange of Carisma common stock with respect to any remaining value. Carisma has no accumulated earnings and profits and expects to have no current earnings and profits for the relevant taxable&#160;year. Thus, Carisma expects this distribution to be treated as a non-dividend distribution for U.S. federal income tax purposes. See the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Carisma Contingent Value Rights Agreement&#8212;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</i>&#8221; beginning on page&#160;197 of this proxy statement/prospectus for a more complete description of the material U.S. federal income tax consequences of the receipt of CVRs to Carisma stockholders, including possible alternative treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Q: Who can help answer my questions?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.4pt;text-indent:-14.4pt;margin:0pt 0pt 12pt 0pt;">A: If you are a Carisma stockholder and would like additional copies of this proxy statement/prospectus without charge or if you have questions about the Merger or the other Proposals, including the procedures for voting your shares, you should contact Carisma&#8217;s proxy solicitor at the following address, telephone number or email address:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MacKenzie Partners,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7 Penn Plaza</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">New York, New York 10001</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">800-322-2885</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">proxy@mackenziepartners.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_357db8c3_9e35_4cd0_a57c_df0d7fe77477"></a><a id="PROSPECTUSSUMMARY_346096"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROSPECTUS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the Carisma Special Meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy statement/ prospectus, and the documents incorporated by reference therein. For more information, please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page&#160;</i>372<i style="font-style:italic;"> of this proxy statement/prospectus. Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the contemplated reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Companies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Carisma Therapeutics&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3675 Market Street, Suite&#160;401</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, PA, 19104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(267) 491-6422</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma is a biotechnology company that was previously focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;and December&#160;2024, Carisma&#8217;s board of directors approved revised operating plans to reduce&#160;monthly operating expenses, conserve cash, and refocus its efforts on strategic priorities (the &#8220;2024 revised operating plans&#8221;). As part of the 2024 revised operating plans, in March&#160;2024 Carisma elected to cease further development of its first lead product candidate, CT-0508. In December&#160;2024 as part of the 2024 revised operating plans, Carisma elected to cease further development of its then lead product candidate, CT-0525, following an assessment of the competitive landscape in anti-human epidermal growth factor receptor 2 (&#8220;HER2&#8221;) treatments and the impact of recently approved therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of the cash preservation plan approved by Carisma&#8217;s board of directors on March&#160;25, 2025, Carisma reduced its operations to those necessary to identify and explore, a range of strategic alternatives to maximize value and prepare to wind down its business. Carisma currently has no intention of resuming historical research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix,&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11 Great Valley Parkway</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Malvern, PA 19355</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(484) 328-4701</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix is a biotechnology company focused on discovering, developing, and commercializing new regenerative cell therapies that improve health and offer hope for patients across the globe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s initial product candidate is a Phase 3-ready regenerative cell therapy platform technology, NeoCart (autologous chondrocyte-derived neocartilage), which combines breakthroughs in bioengineering and cell processing to enhance the autologous cartilage repair process and is being developed for the repair of knee cartilage injuries in adults. Knee injury increases the risk of developing Osteoarthritis (&#8220;OA&#8221;). Approximately 27.0 million people in the United States are diagnosed each&#160;year with knee OA&#8211;a large portion due to cartilage damage. It is estimated that more than 50.0% of patients with knee OA ultimately undergo total joint replacement. The average medical cost of knee OA management in the United States is $140,300 per person. Based on recent market research statistics and the current reimbursed cost of autologous-chondrocyte implantations (&#8220;ACI&#8221;), we believe the addressable market for NeoCart is approximately $3.0 billion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">NeoCart is a three-dimensional tissue-engineered disc of new cartilage that is manufactured by growing the patient&#8217;s own chondrocytes, the cells responsible for maintaining cartilage health. Current surgical and nonsurgical treatment options for knee cartilage injuries in adults are limited in their efficacy and durability. In prior Phase 2 and Phase 3 clinical studies, NeoCart has shown potential to accelerate healing, reduce pain, and provide regenerative native-like cartilage strength with durable benefits post transplantation. NeoCart was shown to be generally well-tolerated and demonstrated greater clinical efficacy than microfracture surgery at two years after treatment. Based on this demonstrated clinical benefit, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designation to NeoCart for the repair of full-thickness lesions of knee </p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">cartilage injuries in adults. Additionally, OrthoCellix, vis-&#224;-vis Ocugen, has aligned with the FDA on the confirmatory Phase 3 trial design where chondroplasty will be used as a control group. Ocugen has completed renovating an existing facility into a good manufacturing practice (&#8220;GMP&#8221;) facility in accordance with the FDA&#8217;s regulations in support of NeoCart manufacturing for personalized Phase 3 trial material, and OrthoCellix plans to engage Ocugen for the manufacture of the substances for NeoCart and the final product of NeoCart for clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix is a direct, wholly owned subsidiary of Ocugen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Azalea Merger Sub,&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3675 Market Street, Suite&#160;401</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, PA, 19104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(267) 491-6422</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Merger Sub is a direct, wholly owned subsidiary of Carisma and was formed solely for the purpose of carrying out the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Merger </b>(see page&#160;143)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the satisfaction or waiver of the closing conditions set forth in the Merger Agreement, at the closing of the Merger, Merger Sub will merge with and into OrthoCellix, with OrthoCellix surviving as a wholly owned subsidiary of Carisma and the surviving corporation of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Carisma&#8217;s Reasons for the Merger </b>(see page&#160;149)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the course of its evaluation of the Merger Agreement and the transactions contemplated by the Merger Agreement, Carisma&#8217;s board of directors held numerous meetings, consulted with Carisma&#8217;s management, Carisma&#8217;s consultants and advisors and outside legal counsel and reviewed and assessed a significant amount of information. In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, Carisma&#8217;s board of directors considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the financial condition and prospects of Carisma and the risks associated with continuing to operate Carisma on a stand-alone basis, particularly in light of Carisma&#8217;s March&#160;2025 decision to preserve its existing cash resources and reduce its operations to those necessary to identify and explore a range of strategic alternatives to prepare to wind down its business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that Carisma&#8217;s board of directors undertook a comprehensive and thorough process of reviewing and analyzing potential strategic alternatives and merger partner candidates and Carisma&#8217;s board of directors&#8217; view that no alternatives to the Merger (including remaining a standalone company, a liquidation and dissolution of Carisma and the distribution of any available cash, and alternative strategic transactions) were reasonably likely to create greater value to Carisma&#8217;s stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that Carisma&#8217;s board of directors undertook to additionally seek value of its remaining assets, including CT-2401, CT-1119, Carisma&#8217;s macrophage and monocyte engineering platform and our CAR-M platform and sought to realize value for the potential milestone and royalty payments under Carisma&#8217;s Moderna collaboration agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; conclusion that the Merger would provide Carisma&#8217;s existing stockholders an opportunity to participate in the potential growth of the Combined Company following the Merger, which will focus on OrthoCellix&#8217;s lead asset;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; belief, after thorough review of strategic alternatives and discussions with Carisma&#8217;s management and outside legal counsel, that the Merger is more favorable to Carisma&#8217;s stockholders than the potential value that might have resulted from other strategic alternatives available to Carisma, including a liquidation and dissolution of Carisma and the distribution of any available cash;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; belief that the $15.0 million enterprise value ascribed to Carisma would provide the existing Carisma stockholders significant value for Carisma&#8217;s public listing, and afford the Carisma stockholders an opportunity to participate in the potential growth of the Combined Company following the Merger at the negotiated exchange ratio;</span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; belief, after a thorough review of strategic alternatives, such as attempting to further advance the development of its internal programs, entering into a licensing, sale or other strategic agreement related to certain assets sufficient to fund operations, combining with other potential strategic transaction candidates, and discussions with Carisma management and legal counsel, that the Merger is more favorable to Carisma stockholders than the potential value that might have resulted from other strategic alternatives available to Carisma;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; belief that, as a result of arm&#8217;s length negotiations with OrthoCellix, Carisma and its representatives negotiated the highest exchange ratio to which OrthoCellix was willing to agree and that the other terms of the Merger Agreement include the most favorable terms to Carisma in the aggregate to which OrthoCellix was willing to agree;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; consideration of the expected cash balances of the Combined Company as of the closing of the Merger resulting from the expected gross proceeds of approximately $25.0 million from the anticipated Concurrent Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; consideration that Ocugen, as OrthoCellix&#8217;s sole stockholder, committed to participate in an amount of at least $5.0 million in the anticipated Concurrent Financing; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; view that the Combined Company will be led by an experienced board of directors and senior management team.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the course of its deliberations, Carisma&#8217;s board of directors and also considered a variety of risks and other countervailing factors related to entering into the Merger, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the $750,000 termination fee payable by Carisma upon the occurrence of certain events and the potential effect of such termination fee in deterring other potential acquirors from proposing an alternative acquisition that may be more advantageous of Carisma&#8217;s stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the substantial expenses to be incurred by Carisma in connection with the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prohibition on Carisma to solicit alternative acquisition proposals during the pendency of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible volatility of the trading price of Carisma common stock resulting from the announcement, pendency or completion of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the Merger might not be consummated in a timely manner or at all and the potential effect of the public announcement of the Merger or the failure to complete the Merger on the reputation of Carisma; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the various other risks associated with the Combined Company and the proposed transaction, including those described in the sections titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk Factors</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Cautionary Note&#160;Regarding Forward-Looking Statements</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; beginning on pages&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">26</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">140</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, respectively, of this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing information and factors considered by Carisma&#8217;s board of directors are not intended to be exhaustive but are believed to be a summary of material factors considered by Carisma&#8217;s board of directors. Carisma&#8217;s board of directors conducted an overall analysis of the these factors and other factors, including thorough discussions with, and questioning of, Carisma management and outside legal counsel, and considered the factors overall to be favorable to, and to support, its determination. For additional information, please see the section titled <span style="font-family:'TimesNewRoman';">&#8220;</span><i style="font-style:italic;">The Merger&#160;</i><i style="font-family:'TimesNewRoman';font-style:italic;">&#8212;</i><i style="font-style:italic;"> Carisma</i><i style="font-family:'TimesNewRoman';font-style:italic;">&#8217;</i><i style="font-style:italic;">s Reasons for the Merger</i><span style="font-family:'TimesNewRoman';">&#8221;</span> beginning on page&#160;149 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OrthoCellix&#8217;s Reasons for the Merger </b>(see page&#160;151)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the course of reaching its decision to approve the Merger, each of Ocugen&#8217;s and OrthoCellix&#8217;s board of directors considered a wide variety of factors. Ultimately, each of Ocugen&#8217;s and OrthoCellix&#8217;s board of directors concluded that a merger with Carisma, together with the additional financing from the anticipated Concurrent Financing, was the best option to generate capital resources to support the advancement of OrthoCellix&#8217;s pipeline and fund the Combined Company.</p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional factors each of Ocugen&#8217;s and OrthoCellix&#8217;s board of directors considered included the following (which factors are not necessarily presented in any order of relative importance):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of NeoCart and potentially provide OrthoCellix with a greater opportunity to advance the NeoCart platform as an independent public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the anticipated Concurrent Financing will generate capital resources to fund the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits from increased public market awareness of OrthoCellix and NeoCart and the ability to dedicate financial, management and other resources to the NeoCart platform as part of an independent public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical and current information concerning OrthoCellix&#8217;s business, including its readiness to initiate an FDA-endorsed Phase 3 clinical trial for NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the competitive nature of the industry in which OrthoCellix intends to operate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s board of directors&#8217; fiduciary duties to the sole stockholder of OrthoCellix;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s board of directors&#8217; belief that no alternatives to the Merger, together with the additional financing from the anticipated Concurrent Financing, were reasonably likely to create a better path to commercial viability for NeoCart, after considering the various other alternative transactions with respect to the development of NeoCart including additional financing and other strategic options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s board of directors&#8217; expectation that the Merger, together with the additional financing from the anticipated Concurrent Financing, would be a higher probability and more cost-effective means to access capital than other options considered, including an initial public offering;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected operations, management structure and operating plans of the Combined Company (including the ability to support the Combined Company&#8217;s current and planned preclinical studies and planned clinical trials);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the business, history, operations, financial resources, assets, technology and credibility of Carisma;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of appraisal rights under the Delaware General Corporation Law (the &#8220;DGCL&#8221;) to holders of OrthoCellix capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of OrthoCellix capital stock as determined by the Delaware Court of Chancery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and conditions of the Merger Agreement, including the following:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the determination that the expected relative&#160;percentage ownership of Carisma stockholders and OrthoCellix&#8217;s sole stockholder in the Combined Company was appropriate, based on OrthoCellix&#8217;s board of directors&#8217; judgment and assessment of the approximate valuations of Carisma and OrthoCellix (including the value of the amount of proceeds from the anticipated Concurrent Financing);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expectation that the Merger will be treated as a tax-deferred exchange described in Section&#160;351(a)&#160;of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and/or as a reorganization for U.S. federal income tax purposes, with the result that OrthoCellix&#8217;s sole stockholder will generally not recognize taxable gain or loss for U.S. federal income tax purposes with respect to the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the limited number and nature of the conditions of the obligation of Carisma to consummate the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rights of OrthoCellix under the Merger Agreement to consider certain unsolicited acquisition proposals under certain circumstances should OrthoCellix receive a superior offer;</span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the conclusion of OrthoCellix&#8217;s board of directors that the potential termination fees and/or expense reimbursement payable by Carisma or OrthoCellix to the other party, and the circumstances when such fee may be payable, were reasonable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the fact that shares of Carisma&#8217;s common stock to be issued in the anticipated Concurrent Financing to OrthoCellix&#8217;s sole stockholder and other investors will be registered on Form S-1 and Form S-3;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the support agreements, pursuant to which certain directors, officers and stockholders of OrthoCellix and Carisma, respectively, have agreed, solely in their capacity as stockholders of OrthoCellix and Carisma, respectively, to vote all of their shares of OrthoCellix capital stock or Carisma common stock in favor of the adoption or approval, respectively, of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to obtain a Nasdaq listing and the change of the Combined Company&#8217;s name to OrthoCellix,&#160;Inc. prior to or upon the closing of the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the likelihood that the Merger will be consummated on a timely basis.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that the Merger might not be completed and the potential adverse effect of the public announcement of the Merger on the reputation of OrthoCellix and the ability of OrthoCellix to obtain financing in the future in the event the Merger is not completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that the anticipated Concurrent Financing might not be completed or completed in accordance with the terms of the subscription agreements and the potential adverse effect of the public announcement of the anticipated Concurrent Financing on the reputation of OrthoCellix and the ability of OrthoCellix to obtain financing in the future in the event the anticipated Concurrent Financing is not completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Exchange Ratio used to establish the number of shares of Carisma&#8217;s common stock to be issued to the sole stockholder of OrthoCellix and other anticipated investors in the anticipated Concurrent Financing in the Merger is fixed, except for adjustments due to Carisma&#8217;s Net Cash balances, the amount of proceeds from the anticipated Concurrent Financing and outstanding capital stock at the closing of the Merger, and thus the relative&#160;percentage ownership of Carisma stockholders and OrthoCellix&#8217;s sole stockholder in the Combined Company immediately following the completion of the Merger is similarly fixed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential reduction of Carisma&#8217;s Net Cash prior to the closing of the Merger or the potential failure of Carisma to satisfy the minimum threshold level of Net Cash required for the closing of the Merger to occur;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that Carisma could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the Merger might not be consummated in a timely manner or at all, for a variety of reasons, such as the failure of Carisma to obtain the required stockholder vote or the failure of OrthoCellix to close the anticipated Concurrent Financing, and the potential adverse effect on the reputation of OrthoCellix and the ability of OrthoCellix to obtain financing in the future in the event the Merger is not completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in connection with completing the Merger, the time and effort of OrthoCellix senior management required to complete the Merger, the related disruptions or potential disruptions to OrthoCellix&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with OrthoCellix, and related administrative challenges associated with combining the companies;</span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the additional expenses and obligations to which OrthoCellix&#8217;s business will be subject to following the Merger that OrthoCellix is a newly formed entity and as such, has not previously been subject to the operational challenges of being an operating business as well as additional considerations with respect to the operation of a newly formed entity as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the fact that the representations and warranties in the Merger Agreement do not survive the closing of the Merger and the potential risk of liabilities that may arise after the closing of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that future sales of common stock by existing Carisma stockholders may cause the price of Carisma common stock to fall, thus reducing the potential value of Carisma common stock received by OrthoCellix&#8217;s sole stockholder following the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">various other risks associated with the Combined Company and the Merger, including the risks described in the section titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk Factors</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; beginning on page&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">26</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of Carisma&#8217;s Directors and Executive Officers in the Merger </b>(see page&#160;166)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In considering the recommendation of Carisma&#8217;s board of directors with respect to issuing shares of Carisma&#8217;s common stock as contemplated by the Merger Agreement and the other matters to be acted upon by Carisma&#8217;s stockholders at the Carisma Special Meeting, Carisma&#8217;s stockholders should be aware that certain members of the board of directors and certain executive officers of Carisma have interests in the Merger that may be different from, or in addition to, the interests of Carisma&#8217;s stockholders. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Steven Kelly, Carisma&#8217;s President and Chief Executive Officer, is expected to serve as the President and Chief Executive Officer of the Combined Company and Natalie McAndrew, Carisma&#8217;s Vice President of Finance (Carisma&#8217;s principal financial officer and principal accounting officer) is expected to serve as the Vice President of Finance (Principal Financial Officer and Principal Accounting Officer) of the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Steven Kelly, a member of Carisma&#8217;s board of directors, will continue to serve as a director of the Combined Company, and following the closing of the Merger, will be eligible to be compensated as a non-employee director of the Combined Company pursuant to its non-employee director compensation policy in effect following the Effective Time of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the Merger Agreement, Carisma&#8217;s directors and executive officers are entitled to continued indemnification, expense advancements and insurance coverage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In connection with the Merger, all unvested Carisma options held by Carisma&#8217;s non-employee directors will vest in full upon the closing of the Merger in accordance with Carisma&#8217;s non-employee director compensation policy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Certain executive officers are eligible to receive severance benefits pursuant to their respective employment agreements with Carisma.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These interests are discussed in more detail in the section titled <i style="font-style:italic;">&#8220;The Merger&#8212;Interests of Carisma&#8217;s Directors and Executive Officers in the Merger</i>&#8221; beginning on page&#160;166 of this proxy statement/prospectus. The Carisma board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend, that Carisma&#8217;s stockholders approve the proposals to be presented for consideration at the Carisma Special Meeting as contemplated by this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of OrthoCellix&#8217;s Directors and Executive Officers in the Merger </b>(see page&#160;170)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In considering the recommendation of OrthoCellix&#8217;s board of directors with respect to approving the Merger, stockholders should be aware that OrthoCellix&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the </p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">interests of OrthoCellix common stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One of OrthoCellix&#8217;s directors is expected to become a director of the Combined Company upon completion of the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s directors and officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that OrthoCellix&#8217;s sole stockholder approves the Merger as contemplated by this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion of Carisma&#8217;s Financial Advisor </b>(see page&#160;154)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma retained Lucid Capital Markets, LLC (&#8220;Lucid&#8221;) to render an opinion to Carisma&#8217;s board of directors as to the fairness of the Exchange Ratio, from a financial point of view, to the holders of common stock of Carisma in connection with the Merger and the other transactions contemplated by the Merger Agreement. On June&#160;22, 2025, at the request of Carisma&#8217;s board of directors, Lucid rendered its oral opinion, subsequently confirmed in writing, to Carisma&#8217;s board of directors, that the exchange ratio was fair, from a financial point of view, to the holders of common stock of Carisma as of such date and based upon the various assumptions, qualifications and limitations set forth therein (the &#8220;Lucid Opinion&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The full text of the Lucid Opinion, dated June&#160;22, 2025, is attached as </b><span style="font-style:italic;font-weight:bold;">Annex B</span><b style="font-weight:bold;"> to this proxy statement/prospectus and is incorporated herein by reference. Carisma encourages its stockholders to read the Lucid Opinion in its entirety for the assumptions made, procedures followed, other matters considered and limits of the review by Lucid. The summary of the Lucid Opinion set forth herein is qualified by reference to the full text of the Lucid Opinion. The Lucid Opinion is intended for the benefit and use by Carisma&#8217;s board of directors (in its capacity as such) in its consideration of the financial terms of the merger. The Lucid Opinion does not constitute a recommendation to Carisma&#8217;s board of directors of whether to approve the Merger or to any Carisma stockholder or other person as to how to vote or act with respect to the proposed merger or any other matter.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The full text of the written opinion of Lucid should be read carefully in its entirety for a description of the assumptions made and limitations upon the review undertaken by Lucid in preparing its opinion.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview of the Merger Agreement and Agreements Related to the Merger Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Merger Consideration and Adjustment </span>(see page&#160;172)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, each then-outstanding share of OrthoCellix common stock (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of Carisma common stock equal to the Exchange Ratio (described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8201;-&#8201;Merger Consideration and Exchange Ratio</i>&#8221; beginning on page&#160;180 of this proxy statement/prospectus).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No fractional shares of Carisma common stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. For purposes of calculating the merger consideration issuable to the holder of OrthoCellix common stock, the number of shares of Carisma common stock to be issued shall be rounded down to the nearest whole number (without any consideration payable for such fractional shares).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Carisma Common Stock and Carisma Options </span>(see page&#160;183)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each share of Carisma common stock issued and outstanding at the time of the Merger will remain issued and outstanding, and will be unaffected by the Merger. In addition, each option to purchase shares of Carisma common stock that is outstanding immediately prior to the Effective Time, whether vested or unvested, will survive the closing of the Merger and remain outstanding in accordance with its terms. The number of shares of Carisma common stock underlying such options and the exercise prices for such stock options will be appropriately adjusted to reflect the contemplated reverse stock split.</p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conditions to the Completion of the Merger </span>(see page&#160;183)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To complete the Merger, Carisma&#8217;s stockholders must approve Proposal No.&#160;1 and the sole stockholder of OrthoCellix must adopt the Merger Agreement and approve the Merger and the related transactions contemplated by the Merger Agreement. Additionally, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">No Solicitation </span>(see page&#160;186)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains non-solicitation provisions prohibiting Carisma and OrthoCellix from soliciting a competing transaction, except as it relates to the anticipated Concurrent Financing and any Parent Legacy Transaction (as such term is defined in the Merger Agreement). Each of Carisma and OrthoCellix have agreed that, subject to certain exceptions, Carisma and OrthoCellix and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize any of the directors, officers, employees, investment bankers, financial advisors, attorneys, accountants or other advisors, agents or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any Acquisition Proposal (as defined below) or Acquisition Inquiry (as defined below);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">furnish any non-public information with respect to it to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">engage in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to certain exceptions set forth in the Merger Agreement, approve, endorse or recommend any Acquisition Proposal;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">execute or enter into any letter of intent or any contract contemplating or otherwise relating to any Acquisition Transaction (as defined below);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">take any action that would reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicly propose to do any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Board Recommendation Change </span>(see page&#160;188)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Neither Carisma&#8217;s board of directors nor OrthoCellix&#8217;s board of directors may change its recommendation in favor of the Merger, except that prior to receipt by such party of its stockholder approval, such party&#8217;s board of directors may effect a change in recommendation as a result of a material development or change in circumstances (&#8220;Intervening Event&#8221;), or with respect to a superior offer that did not result from a material breach of the Merger Agreement if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such party&#8217;s board of directors shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to effect such change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such party has provided at least four business&#160;days&#8217; prior written notice to the other party that it intends to effect a change in recommendation, and during such period has, and has caused its lead financial advisor and outside legal counsel to, negotiate with the other party in good faith to make such adjustments to the terms and conditions so that the acquisition proposal ceases to constitute a superior offer; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if, after the other party shall have delivered to such party an irrevocable written offer to alter the terms or conditions of the Merger Agreement during the four-business day period referred to above, such party&#8217;s board of directors shall have determined in good faith (based on the advice of its outside legal counsel), that the failure to effect a change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of any material amendment to any superior offer, the party considering the superior offer would be required to provide the other party with notice of such material amendment and there would be a new two-business day period following such notification during which the parties would be obligated to comply again with the requirements described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the case of an Intervening Event, the party suffering such event shall promptly notify the other party before effecting a change in recommendation. The written notice is required to state the material facts and circumstances related to the applicable Intervening Event and that such party&#8217;s board of directors intends to make a change in its recommendation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement </span>(see page&#160;194)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Either Carisma or OrthoCellix may terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination Fee </span>(see page&#160;196)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger Agreement is terminated under certain circumstances, Carisma could be required to pay OrthoCellix a termination fee of $500,000 or OrthoCellix could be required to pay Carisma a termination fee of $750,000. In addition, under certain circumstances, OrthoCellix could be required to reimburse Carisma for reasonable out-of-pocket expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby, up to a maximum of $500,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Support Agreements </span>(see page&#160;197)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ocugen (solely in its capacity as the sole stockholder of OrthoCellix) entered into a support agreement with Carisma and OrthoCellix to vote all of its shares of OrthoCellix&#8217;s capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby (the &#8220;OrthoCellix Support Agreement&#8221;). Certain executive officers and directors of Carisma holding approximately 0.03% of the outstanding shares of Carisma common stock have entered into support agreements with Carisma and OrthoCellix to vote all of their shares of Carisma common stock in favor of Proposal No.&#160;1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lock-Up Agreements </span>(see page&#160;197)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently and in connection with the execution of the Merger Agreement, Ocugen, the sole stockholder of OrthoCellix, has entered into a lock-up agreement (the &#8220;Lock-Up Agreement&#8221;) pursuant to which, Ocugen has agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Carisma&#8217;s common stock or any securities convertible into or exercisable or exchangeable for Carisma common stock, currently or thereafter owned, until 180&#160;days following the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anticipated Subscription Agreement and Registration Rights Agreement </span>(see page&#160;202)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma intends to enter into subscription agreements with certain investors, pursuant to which Carisma will sell, and such investors will purchase, in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder, shares of Carisma common stock at a purchase price per share equal to the Aggregate Valuation (as defined below) divided by the Post-Closing Carisma Shares (as defined below), immediately following the Effective Time and on or before August&#160;1, 2025, Ocugen will enter into a securities purchase agreement with Carisma, pursuant to which Ocugen will commit to purchase, immediately following the Effective Time, shares of Carisma&#8217;s common stock for aggregate gross proceeds equal to not less than $5.0 million. Carisma also intends to enter into a registration rights agreement with the investors that will participate in the anticipated Concurrent Financing at the closing of the anticipated Concurrent Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration of the resale of certain shares of Carisma common stock that are held by the investors participating in the anticipated Concurrent Financing from time to time on Form&#160;S-1 or Form&#160;S-3. The closing of the anticipated Concurrent Financing is conditioned upon the satisfaction or waiver of each of the conditions to the closing of the Merger as well as certain other conditions.</p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Asset Contribution Agreement between OrthoCellix and Ocugen</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2025, OrthoCellix entered into an asset contribution agreement with Ocugen pursuant to which Ocugen agreed to contribute to OrthoCellix, and OrthoCellix agreed to acquire from Ocugen, all of its rights, title and interest in and to, and obligations and liabilities associated with, NeoCart. As consideration, OrthoCellix granted Ocugen 1,000 shares of OrthoCellix&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management Following the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the name, age as of July&#160;21, 2025 and position of each of the individuals who are expected to serve as executive officers and directors of the Combined Company following completion of the Merger:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td></tr><tr><td style="vertical-align:bottom;width:30%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Executive Officers</span></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Kelly</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">60</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:top;width:30%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Natalie McAndrew</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">51</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vice President of Finance (principal financial officer and principal accounting officer)</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Non-Employee Directors</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Karthik Musunuri</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Shine, MBA</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">61</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Anderson</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">72</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Carisma Contingent Value Rights Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At or prior to the Effective Time, Carisma is expected to enter into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with a designated rights agent (the &#8220;Rights Agent&#8221;) pursuant to which pre-Merger Carisma common stockholders, subject to the terms and conditions set forth in the CVR Agreement, will receive one contingent value right (each, a &#8220;CVR&#8221;) for each outstanding share of Carisma common stock held by such stockholder on such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each CVR will represent the contractual right to receive a contingent cash payment equal to (i)&#160;the Net Proceeds (as defined in the CVR Agreement) received by Carisma to the extent such payment related to the disposition of any Carisma Legacy Assets (as defined below) during the period beginning on the execution date of the Merger Agreement and ending on the second anniversary of the closing of the Merger, if any, plus (ii)&#160;the Net Proceeds received by Carisma to the extent such payment related to any royalties, milestones or other payments received by Carisma following the closing of the Merger under certain of Carisma&#8217;s existing agreements, including its collaboration and license agreement with ModernaTX,&#160;Inc. (&#8220;Moderna&#8221;), in each case subject to adjustment based on the terms and conditions set forth in the CVR Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The contingent payments under the CVR Agreement, if they become payable, will become payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. There can be no assurance that any holders of CVRs will receive any payments with respect thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The right to the contingent payments contemplated by the CVR Agreement is a contractual right only and will not be transferable, except in the limited circumstances specified in the CVR Agreement. The CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Carisma or any of its affiliates. No interest will accrue on any amounts payable in respect of the CVRs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Risk Factors </b>(see page&#160;26)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Both Carisma and OrthoCellix are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility that the Merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to the Merger</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Exchange Ratio will not be adjusted based on the market price of Carisma common stock as the Exchange Ratio depends, among other things, on the Carisma Net Cash at the closing of the Merger and not the market price of Carisma </span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common stock, so the Merger Consideration at the closing of the Merger may have a greater or lesser value than at the time the Merger Agreement was signed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The issuance of Carisma common stock to OrthoCellix&#8217;s sole stockholder pursuant to the Merger Agreement and to investors in the anticipated Concurrent Financing and the resulting change in control from the Merger must be approved by Carisma stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by OrthoCellix&#8217;s sole stockholder. Failure to obtain these approvals would prevent the closing of the Merger.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Failure to complete the Merger may result in either Carisma or OrthoCellix paying a termination fee to the other party, and could harm the common stock price of Carisma and future business and operations of each company.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the conditions to the Merger are not satisfied or waived, the Merger may not occur.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma and OrthoCellix may mutually agree to waive the condition to the Merger requiring approval for listing on Nasdaq, and if such condition is waived, the Combined Company&#8217;s stock may not be listed on Nasdaq following completion of the Merger.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma and OrthoCellix may mutually agree to complete the Merger even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If Carisma and OrthoCellix complete the Merger, the Combined Company will need to raise additional capital by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the Combined Company&#8217;s stockholders or restrict the Combined Company&#8217;s operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma stockholders and OrthoCellix&#8217;s sole stockholder may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the issuance of shares of common stock in the anticipated Concurrent Financing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the Merger is not completed, Carisma&#8217;s stock price may decline significantly.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma stockholders and OrthoCellix&#8217;s sole stockholder will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, the Combined Company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the pendency of the Merger, Carisma and OrthoCellix may not be able to enter into a business combination with another party on more favorable terms because of restrictions in the Merger Agreement, which could adversely affect their respective business prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Because the lack of a public market for OrthoCellix&#8217;s capital stock makes it difficult to evaluate the fair market value of OrthoCellix&#8217;s capital stock, the value of the Carisma common stock to be issued to OrthoCellix&#8217;s sole stockholder may be more or less than the fair market value of OrthoCellix&#8217;s capital stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lawsuits may be filed against Carisma, OrthoCellix, or any of the members of their respective boards of directors arising out of the Merger, which may delay or prevent the closing of the Merger.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma is substantially dependent on Carisma&#8217;s remaining employees to facilitate the consummation of the Merger.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Carisma</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma may not be successful in consummating the Merger or identifying and consummating any other strategic alternatives.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If Carisma neither successfully consummates the Merger nor identifies another strategic alternative or, if such other strategic alternative is identified, consummate such a transaction, it is highly unlikely that there will be cash available for distribution to Carisma&#8217;s stockholders.</span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the Merger is not consummated and Carisma does consummate another strategic alternative, the amount of cash available for distribution to Carisma&#8217;s stockholders, if any, will depend heavily on the proceeds derived from the other strategic transaction, the timing of any distribution to stockholders, whether as a dividend or through a liquidation and dissolution of Carisma&#8217;s business, as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If Carisma does not successfully consummate the Merger, Carisma&#8217;s board of directors may elect to commence bankruptcy or liquidation and dissolution proceedings, and such proceedings may delay Carisma&#8217;s potential wind down timeframe, increase Carisma&#8217;s costs, and decrease the cash, if any, that may be available for stockholders.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma may experience difficulties, delays or unexpected costs and not achieve anticipated benefits and savings from its cash preservation plan, and such plan may adversely affect Carisma&#8217;s ability to consummate the Merger or other strategic transaction that enhances stockholder value.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma will be substantially dependent on its remaining employees and consultants, along with any other advisors and consultants it may engage, to facilitate the consummation of the Merger or other strategic alternative.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if Carisma is successful in completing the Merger, Carisma may be exposed to other operational and financial risks.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma may become involved in litigation, including securities class action litigation, that could divert management&#8217;s attention and harm Carisma&#8217;s business, and insurance coverage may not be sufficient to cover all costs and damages.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma has incurred significant losses since its inception. Carisma has very limited cash resources remaining and a very short operating runway before it depletes its cash resources. Carisma expects to continue to incur significant expenses and operating losses while Carisma continues to consummate the Merger.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the Merger is not completed, any future resumption of Carisma&#8217;s historical research and development activities would depend on completing a strategic transaction that would support Carisma&#8217;s prior operating plans or otherwise obtaining significant additional funding. Significant additional financing may not be available to Carisma on acceptable terms, or at all.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s independent registered public accounting firm has included an explanatory paragraph relating to Carisma&#8217;s ability to continue as a going concern in its report on Carisma&#8217;s audited consolidated financial statements included in this proxy statement/prospectus.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma has never generated revenue from product sales and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s limited operating history and its cash preservation plan may make it difficult for you to evaluate the success of Carisma&#8217;s business to date and to assess Carisma&#8217;s future viability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market price of Carisma&#8217;s common stock is volatile, and the market price of Carisma&#8217;s common stock may drop in the future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma does not currently meet the requirements for continued listing on the Nasdaq Capital Market. If Carisma fails to meet the requirements for continued listing on the Nasdaq Capital Market, trading in its common stock could be suspended and Carisma&#8217;s common stock delisted from Nasdaq, which would have a negative effect on the price of Carisma&#8217;s common stock and Carisma&#8217;s ability to raise additional capital.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The contemplated reverse stock split may not increase Carisma&#8217;s stock price over the long-term.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to OrthoCellix</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix is a Phase 3 biotechnology company with a limited operating history on which to assess its business; and has no products approved for commercial sale, which may make it difficult for you to evaluate its current business and likelihood of success and viability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if the Merger and the anticipated Concurrent Financing are successful, OrthoCellix may require substantial additional capital to finance its operations in the future, which raises substantial doubt about its ability to continue as a going concern. If OrthoCellix is unable to raise such capital when needed, or on acceptable terms, OrthoCellix may be forced to delay, reduce and/or eliminate one or more of its development programs or future commercialization efforts.</span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix expects to incur losses for the foreseeable future, at least until conclusion of the Phase 3 pivotal trial of NeoCart and may not be able to achieve or sustain profitability in the future. OrthoCellix has no products approved for sale, has not generated any revenue from its product candidate and any future product candidates and may never generate revenue or become profitable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even though NeoCart received RMAT Designation, this designation may not lead to a faster development or regulatory review or approval process and will not by itself increase the likelihood that NeoCart will receive marketing approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If OrthoCellix is not able to obtain, or if there are delays in obtaining required regulatory approvals for NeoCart, OrthoCellix will not be able to commercialize NeoCart as expected, and OrthoCellix&#8217;s ability to generate revenue will be materially impaired.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If OrthoCellix experiences delays or difficulties in the enrollment of patients in clinical trials, OrthoCellix&#8217;s completion of clinical trials and receipt of necessary regulatory approvals could be delayed or prevented.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix is heavily dependent on the success of NeoCart, its only product candidate to date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Data from preclinical studies and early-stage clinical trials and &#8220;top-line,&#8221; initial or preliminary data from OrthoCellix&#8217;s clinical trials may not be predictive of success in later clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Failure to obtain marketing approval in international jurisdictions would prevent NeoCart from being marketed abroad.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix will need to obtain FDA approval of the name, NeoCart, and any failure or delay associated with such approval may adversely affect OrthoCellix&#8217;s business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Geopolitical events and conditions could adversely affect OrthoCellix&#8217;s business, financial condition and operating results.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix has never commercialized a product and will need to build and scale its business for potential commercialization of NeoCart, including building its compliance, medical affairs and commercial organizations, which, if it is not able to do so successfully could negatively impact its business, including the potential for a successful commercialization of NeoCart.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix faces significant competition from other pharmaceutical and biotechnology companies, academic institutions, government agencies, and other research organizations. OrthoCellix&#8217;s operating results will suffer if OrthoCellix fails to compete effectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As an organization, OrthoCellix has limited experience in the development, manufacturing, distribution, or commercialization of a biological product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix expects to rely on third parties to conduct, supervise, and monitor a Phase 3 clinical trial that OrthoCellix may initiate for NeoCart, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of the clinical trial or failing to comply with regulatory requirements.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix is substantially dependent on Ocugen for the manufacturing of NeoCart and support of general and administrative functions of the NeoCart program. If Ocugen fails to produce NeoCart pursuant to the terms of contractual arrangements with OrthoCellix or fails to comply with stringent regulations applicable to biotechnology manufacturers, OrthoCellix may face delays in the development and commercialization of, or be unable to meet demand for, NeoCart, if approved, and may lose potential revenues.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix or OrthoCellix&#8217;s third-party manufacturers may also encounter shortages in the materials necessary to produce NeoCart in the quantities needed for a Phase 3 clinical trial or, if NeoCart is approved, in sufficient quantities for commercialization.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The number of available, qualified third-party manufacturers is limited, and if OrthoCellix is compelled to locate an alternative manufacturing partner, NeoCart&#8217;s activities and commercialization could be delayed and additional expense would be incurred.</span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix is subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect OrthoCellix&#8217;s operating results and business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As with all patent prosecution, there is no guarantee of obtaining and maintaining patent protection for NeoCart. In addition, there is no guarantee that the scope of the patent protection obtained is sufficiently broad or enforceable, to prevent OrthoCellix&#8217;s competitors from developing and commercializing technology and products similar or identical to NeoCart. Furthermore, OrthoCellix&#8217;s ability to successfully commercialize NeoCart may be impaired due to circumstances that may be out of OrthoCellix&#8217;s control.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If OrthoCellix is not able to obtain patent term extension for NeoCart in the United States under the The Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Act&#8221;), and in foreign countries under similar legislation, OrthoCellix&#8217;s business may be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Third parties may initiate legal proceedings alleging that NeoCart infringes, misappropriate, or otherwise violates their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of OrthoCellix&#8217;s business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If OrthoCellix fails to comply with OrthoCellix&#8217;s obligations in OrthoCellix&#8217;s license with Purpose, OrthoCellix could lose rights that are important to OrthoCellix&#8217;s business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix may not be able to protect OrthoCellix&#8217;s intellectual property and proprietary rights related to NeoCart throughout the world.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Intellectual property litigation or other legal proceedings relating to intellectual property could cause OrthoCellix to spend substantial resources and distract OrthoCellix&#8217;s personnel from their normal responsibilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If OrthoCellix is unable to protect the confidentiality of OrthoCellix&#8217;s trade secrets, OrthoCellix&#8217;s business and competitive position would be harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Healthcare legislative or regulatory reform measures may have a negative impact on OrthoCellix&#8217;s business and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of OrthoCellix&#8217;s product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix faces risks related to OrthoCellix&#8217;s collection and use of data, which could result in investigations, inquiries, litigation, fines, legislative and regulatory action, and negative press about OrthoCellix&#8217;s privacy and data protection practices.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix is subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws, and other laws governing OrthoCellix&#8217;s operations. If OrthoCellix fails to comply with these laws, OrthoCellix could be subject to civil or criminal penalties, other remedial measures and legal expenses, or be precluded from developing, manufacturing, and selling certain products outside the United States, which could adversely affect OrthoCellix&#8217;s business, results of operations, and financial condition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The use of new and evolving technologies, such as artificial intelligence, in OrthoCellix&#8217;s business may result in spending material resources and presents risks and challenges that can impact OrthoCellix&#8217;s business including by posing security and other risks to OrthoCellix&#8217;s confidential and/or proprietary information, including personal information, and as a result OrthoCellix may be exposed to reputational harm and liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s independent registered public accounting firm has included an explanatory paragraph relating to OrthoCellix&#8217;s ability to continue as a going concern in its report on the combined financial statements of the NeoCart Business of Ocugen included in this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:10pt;"></div></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to the Combined Company</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Following the Merger, the Combined Company may be unable to integrate successfully the businesses of Carisma and OrthoCellix and realize the anticipated benefits of the Merger.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If any of the events described in &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risks Related to Carisma</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risks Related to OrthoCellix</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; occur, those events could cause potential benefits of the Merger not to be realized.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market price of the Combined Company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the assets subject to the CVR Agreement are not disposed of in a timely manner, the Combined Company may have to incur time and resources to wind down or dispose of such assets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our stockholders may not receive any payment on the CVR and the CVR may expire valueless.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company may incur losses for the foreseeable future and may never achieve profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Conflicts of interest may arise between the Combined Company and Ocugen.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the Combined Company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The unaudited pro forma condensed combined financial information for Carisma and OrthoCellix included in this proxy statement/prospectus are preliminary, and the Combined Company&#8217;s actual financial position and operations after the Merger may differ materially from the unaudited pro forma financial information included in this proxy statement/prospectus.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma and OrthoCellix do not anticipate that the Combined Company will pay any cash dividends in the foreseeable future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Future sales of shares by existing stockholders could cause the Combined Company&#8217;s stock price to decline.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">After completion of the Merger, the Combined Company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the Combined Company&#8217;s stockholders for approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the Combined Company, its business or its market, its stock price and trading volume could decline.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company will have broad discretion in the use of the cash and cash equivalents of the Combined Company and the proceeds from the anticipated Concurrent Financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Being a Controlled Company</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Following the Merger, the Combined Company will be a controlled company within the meaning of the Nasdaq Listing Rules&#160;and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. The stockholders of the Combined Company may not have the same protection afforded to stockholders of companies that are subject to such governance requirements.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">These risks and other risks are discussed in greater detail under the section titled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page&#160;26 of this proxy statement/prospectus. Carisma and OrthoCellix both encourage you to read and consider all of these risks carefully.</p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Regulatory Approvals </b>(see page&#160;174)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each of Carisma and OrthoCellix will use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of the Merger Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted by such party to any governmental authority with respect to the transactions contemplated by the Merger Agreement, if any, and to submit promptly any additional information requested by any such governmental authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Nasdaq Stock Market Listing </b>(see page&#160;176)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Shares of Carisma common stock are currently listed on the Nasdaq Capital Market under the symbol &#8220;CARM.&#8221; Carisma is not currently in compliance with the Nasdaq Capital Market listing requirements. Carisma intends to file an initial listing application for the Combined Company common stock with Nasdaq. If such application is accepted, Carisma anticipates that the common stock of the Combined Company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;OCLX.&#8221; It is a condition to the consummation of the Merger that Carisma obtains approval of the listing of the Combined Company on Nasdaq, but there can be no assurance such listing condition will be met or that Carisma will obtain such approval from Nasdaq. If such listing condition is not met or if such approval is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties. However, in the event that the shares of Carisma common stock to be issued in the Merger are not approved for listing on Nasdaq, it is possible that Carisma and OrthoCellix may mutually agree to waive the applicable condition and nonetheless proceed with completing the Merger. If such condition is waived, Carisma will not recirculate an updated proxy statement/prospectus, nor will it solicit a new vote of stockholders prior to proceeding with the Merger. If Carisma proceeds with the Merger in these circumstances, the Combined Company&#8217;s stock may not be listed on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Anticipated Accounting Treatment </b>(see page&#160;176)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Merger is expected to be accounted for as a reverse recapitalization in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Under this method of accounting, OrthoCellix will be considered the accounting acquirer for financial reporting purposes. This determination was primarily based on the expectations that, immediately following the Merger: (i) OrthoCellix&#8217;s sole stockholder will own a substantial majority of the voting rights of the Combined Company and (ii) OrthoCellix will designate a majority of the initial members of the board of directors of the Combined Company. For accounting purposes, the Merger will be treated as the equivalent of OrthoCellix issuing stock to acquire the net assets of Carisma, which are expected to primarily consist of nominal non-operating assets and liabilities. Following the closing of the Merger, the net assets of Carisma will be recorded at fair value, which is expected to approximate their carrying value, with no goodwill or other intangible assets recorded in the financial statements of OrthoCellix and the reported operating results prior to the Merger will be those of OrthoCellix. See the &#8220;<i style="font-style:italic;">Unaudited Pro Forma Condensed Combined Financial Information</i>&#8221; on page&#160;344 of this proxy statement/prospectus for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights </b>(see page&#160;177)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Holders of Carisma common stock are not entitled to appraisal rights in connection with the Merger under Delaware law. Holders of OrthoCellix capital stock may be entitled to appraisal rights in connection with the Merger under Delaware law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Comparison of Rights of Holders of Carisma Capital Stock and OrthoCellix Capital Stock </b>(see page&#160;359)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Carisma and OrthoCellix are each incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the DGCL. If the Merger is completed, OrthoCellix common stockholders will become Carisma common stockholders, and their rights will be governed by the DGCL, the by-laws of Carisma and the certificate of incorporation of Carisma. The rights of Carisma common stockholders contained in Carisma&#8217;s certificate of incorporation and by-laws differ from the rights of OrthoCellix common stockholders under OrthoCellix&#8217;s certificate of incorporation and OrthoCellix&#8217;s by-laws, as more fully described under the section titled &#8220;<i style="font-style:italic;">Comparison of Rights of Holders of Carisma Capital Stock and OrthoCellix Capital Stock</i>&#8221; beginning on page&#160;359 of this proxy statement/prospectus.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5c21ea66_7dee_4d1f_b151_867db4fa92ea"></a><a id="RISKFACTORS_41144"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Combined Company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained or incorporated by reference in this proxy statement/prospectus, you should carefully consider the material risks described below before deciding how to vote your shares of Carisma common stock. You should also read and consider the other information in this proxy statement/prospectus and additional information about Carisma set forth in its Annual Report on Form&#160;10-K for the fiscal&#160;year ended December&#160;31, 2024, as amended by Amendment No.&#160;1 to Form&#160;10-K, which are filed with the SEC, as updated by its Quarterly Reports on Form&#160;10-Q. Please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page&#160;</i>372<i style="font-style:italic;"> of this proxy statement/prospectus for further information.</i></p><a id="RisksRelatedtotheMerger_508566"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Exchange Ratio will not be adjusted based on the market price of Carisma common stock as the Exchange Ratio depends, among other things, on the Carisma Net Cash at the closing of the Merger and not the market price of Carisma common stock, so the Merger Consideration at the closing of the Merger may have a greater or lesser value than at the time the Merger Agreement was signed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Effective Time, as described in the Merger Agreement, outstanding shares of OrthoCellix capital stock will be converted into shares of Carisma common stock. Based on Carisma&#8217;s and OrthoCellix&#8217;s capitalization as of June&#160;22, 2025, the Exchange Ratio before giving effect to the contemplated Carisma reverse stock split is estimated to be equal to approximately&#160;327,677.6433&#160;shares of Carisma common stock for each share of OrthoCellix common stock. Immediately after the Merger and the anticipated Concurrent Financing, the sole stockholder of OrthoCellix and the other investors in the anticipated Concurrent Financing are expected to own approximately 90.0% of the aggregate number of shares of Carisma common stock on a fully-diluted basis and Carisma securityholders immediately before the Merger are expected to own approximately 10.0% of the aggregate number of shares of Carisma common stock on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Carisma&#8217;s Net Cash as of the closing of the Merger being approximately $0 and an anticipated Concurrent Financing Amount of $25.0 million. In the event Carisma&#8217;s Net Cash is below $0 or the size of the anticipated Concurrent Financing is less than the anticipated Concurrent Financing Amount, the Exchange Ratio will be adjusted and the number of shares therefore issued to OrthoCellix&#8217;s sole stockholder prior to the closing of the Merger will be adjusted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any changes in the market price of Carisma common stock before the completion of the Merger will not affect the Exchange Ratio or the number of shares OrthoCellix&#8217;s sole stockholder will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the completion of the Merger, the market price of Carisma common stock increases from the market price on the date of the Merger Agreement, then OrthoCellix&#8217;s sole stockholder could receive Merger Consideration with substantially more value for its shares of OrthoCellix capital stock than the parties had negotiated when they established the Exchange Ratio. Similarly, if before the completion of the Merger the market price of Carisma common stock declines from the market price on the date of the Merger Agreement, then OrthoCellix&#8217;s sole stockholder could receive Merger consideration with substantially lower value than the parties negotiated when they established the Exchange Ratio. The Merger Agreement does not include a price-based termination right.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The issuance of Carisma common stock to OrthoCellix&#8217;s sole stockholder pursuant to the Merger Agreement and to investors in the anticipated Concurrent Financing and the resulting change in control from the Merger must be approved by Carisma stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by OrthoCellix&#8217;s sole stockholder. Failure to obtain these approvals would prevent the closing of the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before the Merger can be completed, Carisma stockholders must approve, among other things, the issuance of Carisma common stock to OrthoCellix&#8217;s sole stockholder pursuant to the Merger Agreement and to investors in the anticipated Concurrent Financing and the resulting change in control from the Merger, and OrthoCellix&#8217;s sole stockholder must adopt the Merger Agreement and approve the Merger and the related transactions. Failure to obtain the required stockholder approvals may result in a material delay in, or the abandonment of, the Merger. Any delay in completing the Merger may materially adversely affect the timing and benefits that are expected to be achieved from the Merger.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to complete the Merger may result in either Carisma or OrthoCellix paying a termination fee to the other party, and could harm the common stock price of Carisma and future business and operations of each company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger is not completed, Carisma and OrthoCellix are subject to the following risks:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if the Merger Agreement is terminated under specified circumstances, Carisma could be required to pay OrthoCellix a termination fee of $500,000, or OrthoCellix could be required to pay Carisma a termination fee of $750,000 and in certain circumstances, reimbursement of up to $500,000 for Carisma&#8217;s reasonable out-of-pocket expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price of Carisma common stock may decline and could fluctuate significantly; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial costs related to the Merger may be incurred by either party, such as financial advisor, legal and accounting fees, a majority of which must be paid even if the Merger is not completed.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger Agreement is terminated and the board of directors of Carisma or OrthoCellix determines to seek another business combination, there can be no assurance that either Carisma or OrthoCellix will be able to find another third party to transact a business combination with, yielding comparable or greater benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the conditions to the Merger are not satisfied or waived, the Merger may not occur.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if the Merger is approved by the sole stockholder of OrthoCellix and Proposal No.&#160;1 as described in this proxy statement/prospectus is approved by the Carisma stockholders, specified conditions must be satisfied or, to the extent permitted by applicable law, waived to complete the Merger. These conditions are set forth in the Merger Agreement and each material condition to the completion of the Merger is described in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8201;&#8212;&#8201;Conditions to the Completion of the Merger</i>&#8221; beginning on page&#160;183 of this proxy statement/prospectus. Carisma and OrthoCellix cannot assure you that all of the conditions to the consummation of the Merger will be satisfied or waived, including the need for Ocugen to obtain consent from Avenue Capital Management II,&#160;L.P., Avenue Venture Opportunities Fund II,&#160;L.P., as a lender, and Avenue Venture Opportunities Fund,&#160;L.P. (collectively, &#8220;Avenue Capital&#8221;) pursuant to its Loan and Security Agreement with Avenue Capital. If the conditions are not satisfied or waived, the Merger may not occur or the closing may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is a condition of the consummation of the merger that the Combined Company&#8217;s stock is approved for listing on Nasdaq. There can be no assurance such listing condition will be met and, at the time you are asked to vote on the Merger, you will have no assurance that the common stock of the Combined Company will be listed on Nasdaq following the completion of the Merger. Further, Carisma is not currently in compliance with the listing requirements of the Nasdaq Capital Market. There can be no assurance that Carisma will not be delisted from Nasdaq prior to the closing of the Merger. For risks related to Carisma&#8217;s noncompliance with the Nasdaq listing standards, see the section titled &#8220;<i style="font-style:italic;">Risks Related to Carisma&#160;- We do not currently meet the requirements for continued listing on the Nasdaq Capital Market. If we fail to meet the requirements for continued listing on the Nasdaq Capital Market, trading in our common stock could be suspended and our common stock delisted from Nasdaq, which would have a negative effect on the price of our common stock and our ability to raise additional capital</i>.&#8221;</p><a id="CarismaandOrthoCellixmaymutuallyagreetow"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Carisma and OrthoCellix may mutually agree to waive the condition to the Merger requiring approval for listing on Nasdaq, and if</span><span style="font-style:italic;font-weight:bold;"> such condition is waived, the Combined Company&#8217;s stock may not be listed on Nasdaq following completion of the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement, Carisma agreed to reasonably cooperate to seek approval of the listing of the Combined Company on Nasdaq and to prepare and submit to Nasdaq a notification form for the listing of shares of Carisma common stock to be issued in connection with the contemplated transactions. Additionally, under the Merger Agreement, each of Carisma&#8217;s and OrthoCellix&#8217;s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties of various conditions, including that the shares of Carisma common stock to be issued in the Merger have been approved for listing on Nasdaq as of the closing of the Merger. In the event that the shares of Carisma common stock to be issued in the Merger are not approved for listing on Nasdaq, it is possible that Carisma and OrthoCellix may mutually agree to waive the applicable condition and nonetheless proceed with completing the Merger. If such condition is waived, Carisma will not recirculate an updated proxy statement/prospectus, nor will it solicit a new vote of stockholders prior to proceeding with the Merger. If Carisma proceeds with the Merger in these circumstances, the Combined Company&#8217;s stock may not be listed on Nasdaq.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Combined Company&#8217;s stock is not listed on Nasdaq following completion of the Merger, trading of the shares could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities, such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of the common stock of the Combined Company; decreases in institutional and other investor demand for the shares, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute trades in the common stock of the Combined Company. Also, it may be difficult for the Combined Company to raise additional capital if the Combined Company&#8217;s common stock is not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of the common stock of the Combined Company and could have a material adverse effect on the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Carisma and OrthoCellix may mutually agree to complete the Merger even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, neither Carisma nor OrthoCellix is obligated to complete the Merger if there is a material adverse effect affecting the other party between June&#160;22, 2025, the date of the Merger Agreement, and the closing of the Merger. However, certain types of events and/or causes are excluded from the concept of a &#8220;material adverse effect.&#8221; Such exclusions include, but are not limited to, changes or conditions generally affecting the industries in which the parties operate, or the economy or the financial, debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general. Therefore, if any of these events were to occur and adversely affect Carisma or OrthoCellix, the other party would still be obligated to consummate the closing notwithstanding such material adverse effects. If any such adverse effects occur and Carisma and OrthoCellix consummates the closing, the stock price of the Combined Company may suffer. This, in turn, may reduce the value of the Merger to the stockholders of Carisma, OrthoCellix or both. For a more complete discussion of what constitutes a &#8220;material adverse effect&#8221; on Carisma or OrthoCellix, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Representations and Warranties</i>&#8221; beginning on page&#160;185 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Carisma and OrthoCellix complete the Merger, the Combined Company will need to raise additional capital by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the Combined Company&#8217;s stockholders or restrict the Combined Company&#8217;s operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional financing may not be available to the Combined Company when it is needed or may not be available on favorable terms. To the extent that the Combined Company raises additional capital by issuing equity securities, such financing will cause additional dilution to all securityholders of the Combined Company, including Carisma&#8217;s pre-Merger securityholders and OrthoCellix&#8217;s former securityholders. It is also possible that the terms of any new equity securities may have preferences over the Combined Company&#8217;s common stock. Any debt financing the Combined Company enters into may involve covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the Combined Company&#8217;s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the Combined Company raises additional funds through licensing arrangements, it may be necessary to grant licenses on terms that are not favorable to the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Carisma stockholders and OrthoCellix&#8217;s sole stockholder may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the issuance of shares of common stock in the anticipated Concurrent Financing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Combined Company is unable to realize the full strategic and financial benefits currently anticipated from the Merger, Carisma stockholders and OrthoCellix&#8217;s sole stockholder will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the Combined Company is able to realize only part of the strategic and financial benefits currently anticipated from the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Merger is not completed, Carisma&#8217;s stock price may decline significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The market price of Carisma common stock is subject to significant fluctuations. Market prices for securities of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of Carisma common stock will likely be volatile based on whether stockholders and other anticipated investors believe that Carisma can complete the Merger or otherwise raise additional capital to support Carisma&#8217;s operations if the Merger is not consummated and another strategic transaction cannot be identified, negotiated and consummated in a timely manner, if at all. The volatility of the market price </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of Carisma common stock is exacerbated by low trading volume. Additional factors that may cause the market price of Carisma common stock to fluctuate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the entry into, or termination of, key agreements, including commercial partner agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by commercial partners or competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the loss of key employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future sales of its common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general and industry-specific economic conditions that may affect its research and development expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure to meet industry analyst expectations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">period-to-period fluctuations in financial results.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of Carisma common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Carisma&#8217;s stockholders and OrthoCellix&#8217;s sole stockholder will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, the Combined Company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the completion of the Merger, the current stockholders of Carisma and the sole stockholder of OrthoCellix will generally own a smaller&#160;percentage of the Combined Company than their ownership of their respective companies prior to the Merger. Immediately after the Merger and the anticipated Concurrent Financing, Carisma securityholders as of immediately prior to the Merger are expected to own approximately 10.0% of the outstanding shares of the Combined Company on a fully-diluted basis, and the sole stockholder of OrthoCellix along with other anticipated investors in the anticipated Concurrent Financing are expected to own approximately 90.0% of the outstanding shares of the Combined Company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Carisma&#8217;s Net Cash as of the closing of the Merger being approximately $0 and an anticipated Concurrent Financing Amount of $25.0 million. After the closing of the Merger, OrthoCellix will be a Controlled Company. For more information, please see the section entitled &#8220;<i style="font-style:italic;">Risk Factors&#8201;-&#8201; Risks Related to the Controlled Company.</i>&#8221;&#8201;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">During the pendency of the Merger, Carisma and OrthoCellix may not be able to enter into a business combination with another party on more favorable terms because of restrictions in the Merger Agreement, which could adversely affect their respective business prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Covenants in the Merger Agreement impede the ability of Carisma and OrthoCellix to make acquisitions during the pendency of the Merger, subject to specified exceptions. As a result, if the Merger is not completed, the parties may be at a disadvantage to their competitors during that period. In addition, while the Merger Agreement is in effect, each party is generally prohibited from soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any acquisition proposal or acquisition inquiry or taking any action that could reasonably be expected to lead to certain transactions involving a third party, including a merger, sale of assets or other business combination, subject to specified exceptions. Any such transactions could be favorable to such party&#8217;s stockholders, but the parties may be unable to pursue them. For more information, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8201;-&#8201;No Solicitation</i>&#8221; beginning on page&#160;186 of this proxy statement/prospectus.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The terms of the Merger Agreement prohibit each of Carisma and OrthoCellix from soliciting competing proposals or cooperating with persons making unsolicited takeover proposals, except in limited circumstances as described in further detail in the sections titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8201;-&#8201;No Solicitation</i>&#8221; beginning on page&#160;186 of this proxy statement/prospectus. In addition, if Carisma terminates the Merger Agreement under specified circumstances, Carisma could be required to pay OrthoCellix a termination fee of $500,000, or OrthoCellix could be required to pay Carisma a termination fee of $750,000. In certain circumstances, OrthoCellix may also be required to pay a reimbursement of up to $500,000 for Carisma&#8217;s reasonable out-of-pocket expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby. This termination fee may discourage third parties from submitting competing proposals to Carisma, OrthoCellix or their respective stockholders, and may cause the Carisma or OrthoCellix board of directors to be less inclined to recommend a competing proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because the lack of a public market for OrthoCellix&#8217;s capital stock makes it difficult to evaluate the fair market value of OrthoCellix&#8217;s capital stock, the value of the Carisma common stock to be issued to OrthoCellix&#8217;s sole stockholder may be more or less than the fair market value of OrthoCellix&#8217;s capital stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The outstanding capital stock of OrthoCellix is privately held and is not traded in any public market. The lack of a public market makes it difficult to determine the fair market value of OrthoCellix&#8217;s capital stock. Because the&#160;percentage of Carisma equity to be issued to OrthoCellix&#8217;s sole stockholder was determined based on negotiations between the parties, it is possible that the value of the Carisma common stock to be issued to OrthoCellix&#8217;s sole stockholder will be more or less than the fair market value of OrthoCellix&#8217;s capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lawsuits may be filed against Carisma, OrthoCellix, or any of the members of their respective boards of directors arising out of the Merger, which may delay or prevent the closing of the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against Carisma, the Carisma board of directors, OrthoCellix, the OrthoCellix board of directors and others in connection with the transactions contemplated by the Merger Agreement. The outcome of litigation is uncertain, and Carisma or OrthoCellix may not be successful in defending against any such future claims. Lawsuits that may be filed against Carisma, the Carisma board of directors, OrthoCellix, or the OrthoCellix board of directors could delay or prevent the Merger, divert the attention of Carisma&#8217;s or OrthoCellix&#8217;s management and employees from their day-to-day business and otherwise adversely affect Carisma and OrthoCellix financially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Carisma is substantially dependent on Carisma&#8217;s remaining employees to facilitate the consummation of the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June&#160;30, 2025, Carisma had only two full-time employees. Carisma&#8217;s ability to successfully complete the Merger depends in large part on Carisma&#8217;s ability to retain certain remaining personnel. Despite Carisma&#8217;s efforts to retain these employees, one or more employees may terminate their employment with Carisma on short notice. The loss of the service of certain employees could potentially harm Carisma&#8217;s ability to consummate the Merger, as well as fulfill Carisma&#8217;s reporting obligations as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Carisma</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">As used in this section, references to &#8220;the&#8221; &#8220;Company, &#8220;Carisma,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Carisma Therapeutics&#160;Inc. (formerly Sesen Bio,&#160;Inc.) and its consolidated subsidiaries.</i></p><a id="RisksRelatedtoOurEvaluationoftheMergeran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Evaluation of the Merger and Strategic Alternatives</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in consummating the Merger or identifying and consummating any other strategic alternatives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of our cash preservation plan approved by our board of directors on March&#160;25, 2025 to preserve our existing cash resources following reduction in workforce, we reduced our operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down our business. After a comprehensive review of strategic alternatives, on June&#160;22, 2025, we entered into the Merger Agreement for the proposed Merger. If the Merger is completed, the business of OrthoCellix will continue as the business of the Combined Company. Prior to the completion of the Merger, we will seek to enter into a series of transactions with certain third parties to monetize certain legacy assets, in accordance with the limitations and requirements set forth in the Merger Agreement.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s future operations are highly dependent on the success of the Merger. Although we intend to consummate the Merger, there is no assurance that we will be able to successfully consummate the Merger on a timely basis, or at all, and there can be no assurance that the Merger will enhance stockholder value or deliver anticipated benefits. The process of completing the Merger is costly, time-consuming and complex, and the consummation of the Merger is subject to certain closing conditions, including, among other things, approval by Carisma&#8217;s stockholders of certain of the voting proposals contained in the proxy statement/prospectus. We cannot predict with certainty whether or when any of the required closing conditions will be satisfied or if another uncertainty may arise and cannot assure you that the proposed Merger will be successfully consummated. We believe that our current cash and cash equivalents are sufficient to sustain our operating expenses and capital expenditure requirements into the fall of 2025, and as such, we only have a short period of time to consummate the Merger or other strategic alternative before we deplete our resources. We also may not be successful in pursuing and consummating any asset monetization transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, we are not currently in compliance with the listing criteria for the Nasdaq Capital Market, which may impact our ability to consummate the Merger. The Nasdaq Hearings Panel (the &#8220;Panel&#8221;) has granted us an exception to, and an extension of time to comply with, the Nasdaq listing standards. The extension of time is subject to our demonstrating compliance with Nasdaq Listing Rule&#160;5550(a)(2)&#160;by evidencing a closing bid price of $1.00 or more per share for a minimum of 10 consecutive trading sessions, completing a strategic transaction and otherwise demonstrating compliance with all initial listing requirements for the Nasdaq Capital Market, in each case on or before October&#160;7, 2025 (the &#8220;Nasdaq Compliance Date&#8221;). The Panel does not have discretion to grant continued listing for noncompliance with Nasdaq listing standards beyond the Nasdaq Compliance Date. There can be no assurance that we will be able to satisfy the requirements or conditions for continued listing within the period of time granted by the Panel. Further, consummation of the Merger is subject to certain closing conditions, including, among other things, Nasdaq&#8217;s approval of the listing of the shares of our common stock to be issued in connection with the Merger. There can be no assurance that we will be able to satisfy the initial listing requirements for the Combined Company in connection with the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger is not completed, this may cause reputational harm with stockholders and the value of our securities may be adversely impacted. In addition, speculation regarding the completion of the Merger and perceived uncertainties related to our future could cause our stock price to fluctuate significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If, for any reason, the Merger does not close, our board of directors may elect to, among other things, attempt to identify and complete another strategic transaction like the Merger, attempt to sell or otherwise dispose of our remaining assets or dissolve and liquidate our assets. Any of these alternatives would be costly and time-consuming, and we might not have enough time or resources remaining to identify, evaluate and complete another strategic transaction before the Nasdaq Compliance Date. Further, we may face substantial competition for attractive counterparties for any proposed strategic transactions. For example, there may be many other biotechnology and pharmaceutical companies that halt development of their programs and instead choose to pursue strategic transactions like the ones we have been exploring in connection with our strategic review process. These companies may possess greater financial and managerial resources than we do, and they may have more attractive product candidates, intellectual property or other assets. As a result, these other companies may prove to be more attractive than us to counterparties pursuing strategic transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we neither successfully consummate the Merger nor identify another strategic alternative or, if such other strategic alternative is identified, consummate such a transaction, it is highly unlikely that there will be cash available for distribution to our stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we believe that our current cash and cash equivalents are sufficient to sustain our operating expenses and capital expenditure requirements into the fall of 2025, we do not expect that our cash and cash equivalents will support our operations for more than one&#160;year following the date of our consolidated financial statements included in this proxy statement/prospectus. Our available cash resources continue to decrease as we incur fees and expenses in connection with the consummation of the Merger. If the Merger Agreement is terminated under certain circumstances, we may be required to pay OrthoCellix a termination fee of $500,000. Even if a termination fee is not payable in connection with a termination of the Merger Agreement, we will have incurred significant fees and expenses, which must be paid whether or not the Merger is completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If, for any reason, the Merger does not close, our board of directors may elect to, among other things, attempt to identify and complete another strategic transaction like the Merger, attempt to sell or otherwise dispose of our remaining assets or dissolve and liquidate our assets. Any of these alternatives would be costly and time-consuming and our cash resources would continue to decrease as we evaluate other strategic alternatives and prepare for the potential wind down, liquidation or dissolution of our operations. If the Merger does not close, we might not have enough time or resources remaining to identify, evaluate and complete another strategic transaction before the Nasdaq Compliance Date.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Merger will result in a successfully consummated transaction, and if we do not successfully identify another strategic alternative, or such other strategic alternative is not consummated, it is highly unlikely that there will be cash available for distribution to our stockholders. Accordingly, holders of our common stock and other securities would lose all of their investment in the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Merger is not consummated and we do consummate another strategic alternative, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the proceeds derived from the other strategic transaction, the timing of any distribution to stockholders, whether as a dividend or through a liquidation and dissolution of our business, as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger is not consummated and we do consummate another strategic alternative, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the proceeds derived from the other strategic transaction, the timing of any distribution to stockholders, whether as a dividend or through a liquidation and dissolution of our business, as well as the amount of cash that will need to be reserved for commitments and contingent liabilities. Our available cash resources continue to decrease in connection with the consummation of the Merger, and if not completed, as we prepare for the potential wind down, liquidation or dissolution activities. We cannot assure our stockholders of any recovery, or any specific level of recovery, on their claims and interests if we were to determine to pay a dividend or seek a liquidation or dissolution in connection with a strategic transaction. Our estimates of these amounts may be inaccurate. Accordingly, holders of our common stock and other securities could lose all or a significant portion of their investment in the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not successfully consummate the Merger, our board of directors may elect to commence bankruptcy or liquidation and dissolution proceedings, and such proceedings may delay our potential wind down timeframe, increase our costs, and decrease the cash, if any, that may be available for stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger is not completed, our board of directors may decide that it is in the best interests of our stockholders to commence bankruptcy or liquidation and dissolution proceedings. In that event, the amount of cash available for distribution to our stockholders would depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of our cash resources continues to decrease as we continue our wind down activities and incur fees and expenses related to the Merger. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution of the company, we would be required under Delaware law to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations. In addition, we may be subject to litigation or other claims related to a liquidation and dissolution of the company. If a liquidation and dissolution were pursued, our board of directors, in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, our stockholders could lose all or a significant portion of their investment in the event of a liquidation and dissolution of the company. Accordingly, holders of our common stock could lose all or a significant portion of their investment in the event of a liquidation, dissolution or winding up of the company. A liquidation would be a lengthy and uncertain process with no assurance of any value ever being returned to our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may experience difficulties, delays or unexpected costs and not achieve anticipated benefits and savings from our cash preservation plan, and such plan may adversely affect our ability to consummate the Merger or other strategic transaction that enhances stockholder value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of our cash preservation plan, our board of directors determined to terminate all of our employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. We expect to incur approximately $3.8 million in expenses in connection with the reduction in workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. We also expect to pay the majority of related reduction in workforce amounts by the end of this&#160;year. We may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, this reduction in workforce.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While we have retained employees we deemed necessary to pursue strategic alternatives, including consummating the Merger, and prepare for a potential wind down, liquidation or dissolution of our operations, the reduction in workforce resulted in the loss of a number of long-term employees, the loss of institutional knowledge and expertise, and the reallocation of certain job responsibilities, all of which could negatively affect operational efficiencies and increase our operating expenses such that we may not fully realize anticipated savings from a potential wind down and complete the Merger on terms that are favorable to us, or at all.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will be substantially dependent on our remaining employees and consultants, along with any other advisors and consultants we may engage, to facilitate the consummation of the Merger or other strategic alternative.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with our cash preservation plan, we have terminated all but two of our employees as of June&#160;30, 2025. Our ability to successfully consummate the Merger or identify and consummate any other strategic alternative depends in large part on our ability to retain our remaining employees and consultants along with any other advisors and consultants we may engage. One or more may terminate their engagement with us on short notice. It is also possible that we will determine to undertake future reductions in workforce. The loss of the services of any of these individuals could potentially harm our ability to consummate the Merger, identify, evaluate and pursue other strategic alternatives as well as engage in potential wind down activities or fulfill our continuing reporting obligations as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we are successful in completing the Merger, we may be exposed to other operational and financial risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although there can be no assurance that the Merger will be completed, the negotiation and consummation of the Merger will require significant time on the part of our management. The negotiation and consummation of the Merger may also require more time or greater cash resources than we anticipate and may expose us to other operational and financial risks, including increased near-term and long-term expenditures; exposure to unknown liabilities; higher than expected acquisition or integration costs; incurrence of substantial debt or dilutive issuances of equity securities to fund future operations; write-downs of assets or goodwill or incurrence of non-recurring, impairment or other charges; increased amortization expenses; and possibility of future litigation. Any of the foregoing risks could have a material adverse effect on our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in litigation, including securities class action litigation, that could divert management&#8217;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the past, litigation, including securities class action litigation, has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, or the announcement of negative events, such as negative regulatory decisions or a determination to wind down operations. These events may also result in investigations by the SEC. We may be exposed to such litigation or investigation even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management&#8217;s attention and resources, which could adversely affect our cash resources and our ability to consummate a potential strategic transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses since our inception. We have very limited cash resources remaining and a very short operating runway before we deplete our cash resources. We expect to continue to incur significant expenses and operating losses while we continue to consummate the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have incurred significant operating losses. Our net losses were $60.5 million and $86.9 million for the&#160;years ended December&#160;31, 2024 and 2023, respectively, and $9.3 million and $19.0 million for the three&#160;months ended March&#160;31, 2025 and 2024, respectively. We expect to continue to incur significant expenses and operating losses while we carry out the consummation of the Merger, operate as a public company and continue to wind down our historical operations, including the payment one-time employee termination benefits to terminated employees. We may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, our reduction in workforce or the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;31, 2025, we had cash and cash equivalents of $7.7 million and an accumulated deficit of $314.8 million. Although we believe that our current cash and cash equivalents are sufficient to sustain our operating expenses and capital expenditures requirements into the fall of 2025, we do not expect that our cash and cash equivalents will support our operations for more than one&#160;year following the date of our consolidated financial statements included in this proxy statement/prospectus. As a result of these conditions, substantial doubt exists about our ability to continue as a going concern. We have based this estimate on assumptions that may prove to be wrong. In addition, changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. As a result, we could deplete our capital resources sooner than we currently expect, including before we are able to consummate the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">To date, we have not yet commercialized any products or generated any revenue from product sales and have financed our operations primarily with proceeds from sales of our preferred stock, proceeds from our collaboration with Moderna, research tax credits, convertible debt financing and completion of the business combination in accordance with the terms of the Agreement and </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Plan of Merger and Reorganization, dated as of September&#160;20, 2022 (the &#8220;Sesen Bio Merger Agreement&#8221;), pursuant to which Seahawk Merger Sub,&#160;Inc., our wholly-owned subsidiary merged with and into CTx Operations,&#160;Inc. (formerly CARISMA Therapeutics&#160;Inc.) (&#8220;Legacy Carisma&#8221;), with Legacy Carisma continuing as our wholly owned subsidiary and the surviving corporation of the merger (the &#8220;Sesen Bio Merger&#8221;) and related financing. Because Moderna nominated all 12 oncology research targets under the collaboration agreement as of February&#160;2025, we will no longer be conducting any additional research activities under the collaboration agreement and we will not be receiving any further payments from Moderna for research and development services under the collaboration agreement. Significant additional financing may not be available to us on acceptable terms, or at all, and may be impacted by the economic climate and market conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have historically devoted substantially all of our financial resources and efforts to pursuing discovery, research and early clinical development of our product candidates. As part of our cash preservation plan, we determined to pause all of our research and development activities. If the Merger is completed, the business of OrthoCellix will continue as the business of the Combined Company. Prior to the closing of Merger, we will also seek to enter into a series of transactions with certain third parties to monetize certain of our legacy assets in accordance with the limitations and requirements set forth in the Merger Agreement. As such, we currently have no intention of resuming our historical research and development activities. If the Merger is not completed, any future resumption of our historical research and development activities would significantly depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding. We expect that it would be difficult to secure such additional significant financing in a timely manner, on favorable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Merger is not completed, any future resumption of our historical research and development activities would significantly depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding. Significant additional financing may not be available to us on acceptable terms, or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger is not completed, any future resumption of our historical research and development activities would significantly depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding. We expect that it would be difficult to secure such additional significant financing in a timely manner, on favorable terms or at all. We would only have a short period of time to consummate another strategic alternative before we deplete our cash resources. Any future resumption of our historical activities would also depend on the terms of any transactions we may enter with certain third parties to monetize certain of our legacy assets. We may not be successful in pursuing and consummating any asset monetization transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that we are able to raise additional capital through the public or private sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing and preferred equity financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our operations and ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments, declaring dividends or other operating restrictions that could adversely impact our ability to conduct business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are able to raise funds through&#160;a strategic collaboration or partnership with one or more parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, discovery programs or product candidates, grant licenses on terms that may not be favorable to us or grant rights to develop and market product candidates that we would otherwise prefer to develop and market on our own, any of which may have a material adverse effect on our business, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we were able to resume any of our historical research and development activities, our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, costs and results of pre-clinical testing of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, costs and results of clinical trials of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of and development requirements for additional indications for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our collaborations with Moderna or others;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to scale up our manufacturing processes and capabilities to support clinical trials of the product candidates we are developing and may develop in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential changes in the regulatory environment and enforcement rules;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the payment of license fees and other costs of our technology license arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain acceptance of any approved products by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount and timing of revenue, if any, received from commercial sales of any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential changes in pharmaceutical pricing and reimbursement infrastructure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of raw materials for use in production of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we in-license or acquire additional technologies or product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited consolidated financial statements included in this proxy statement/prospectus.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The report from our independent registered public accounting firm for the&#160;year ended December&#160;31, 2024 includes an explanatory paragraph stating that our recurring losses raise substantial doubt about our ability to continue as a going concern. In connection with our cash preservation plan, we expect to continue to incur significant expenses and operating losses while we carry out the consummation of the Merger, operate as a public company and continue to wind down our historical operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, and it is likely that investors will lose all or a part of their investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have never generated revenue from product sales and may never achieve or maintain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to pausing research and development activities, we were in the early stages of development of our product candidates. If we were to resume our historical research and development activities, we expect that it will be a number of&#160;years, if ever, before we have a product candidate ready for commercialization. To become and remain profitable, we must succeed in completing development of, obtaining marketing approval for and eventually commercializing, one or more products that generate significant revenue. The ability to achieve this success would require us to be effective in a range of challenging activities, including completing pre-clinical testing and clinical development, timely filing and receiving acceptance of our Investigational New Drug (&#8220;IND&#8221;) applications in order to commence clinical trials, initiating, enrolling patients in and completing clinical development of our product candidates, scaling up our manufacturing processes and capabilities to support clinical trials, obtaining marketing approval for our product candidates, manufacturing, marketing and selling any products for which we may obtain marketing approval and maintaining a continued acceptable safety profile of our products following approval. We may never succeed in these activities and, even if we do, we may never generate revenues that are significant enough to achieve profitability.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if we were to achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our discovery and product development efforts, diversify our pipeline of product candidates or even continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our limited operating history and our cash preservation plan may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We were formed as Carma Therapeutics LLC, a Pennsylvania limited liability company, in April&#160;2016 and converted to a Delaware corporation in May&#160;2017 under the name CARISMA Therapeutics&#160;Inc. In connection with the merger consummated in March&#160;2023, CARISMA Therapeutics&#160;Inc. merged with and into a wholly-owned subsidiary of Sesen Bio and was renamed &#8220;CTx Operations,&#160;Inc.&#8221; Sesen Bio&#8217;s name was changed to &#8220;Carisma Therapeutics&#160;Inc.&#8221;. Following the completion of the Sesen Bio Merger, the business conducted by the public company became primarily the business conducted by us. We are a biotechnology company with a limited operating history. Cell therapy product development is a highly speculative undertaking and involves a substantial degree of risk. Our operations historically have been limited to organizing and staffing our company, business planning, capital raising, establishing and maintaining our intellectual property portfolio, building our pipeline of product candidates, conducting drug discovery activities, undertaking pre-clinical studies, manufacturing process development studies, conducting early-stage clinical trials, and providing general and administrative support for these operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with our cash preservation plan, we reduced our operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down our business. We currently have no intention of resuming our historical research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our prospects must be considered in light the foregoing and in light of the uncertainties, risks, expenses and difficulties frequently encountered by companies in their early stages of operations. Prior to pausing our research and development activities, we had not yet demonstrated our ability to successfully develop any product candidate, obtain marketing approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown obstacles. If we were to resume our historical research and clinical activities, we will need to transition at some point from a company with a discovery and pre-clinical focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect our financial condition and operating results to fluctuate significantly from quarter to quarter and&#160;year to&#160;year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in tax law may adversely affect us or our investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The rules&#160;dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent&#160;years, many such changes have been made and changes are likely to continue to occur in the future. It cannot be predicted whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law. Prospective investors should consult their tax advisors regarding the potential consequences of changes in tax law on our business and on the ownership and disposition of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use our net operating losses and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have had a history of cumulative losses and anticipate that we will continue to incur significant losses in the foreseeable future. As a result, we do not know whether or when we will generate taxable income necessary to utilize our pre-change net operating losses (&#8220;NOLs&#8221;) or research and development tax credit carryforwards.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, under Section&#160;382 of the Code and corresponding provisions of state law, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50&#160;percentage point change (by value) in equity ownership by certain stockholders over a three-year period, is subject to limitations on its ability to utilize pre-change NOLs and research and development tax credit carryforwards to offset future taxable income. We have not conducted a study to assess whether any such ownership changes have occurred. We may have experienced such ownership changes in the past and may experience such ownership changes in the future (which may be outside our control), including as a result of the Merger. As a result, if and to the extent we earn net taxable income, our ability to use our pre-change NOLs and research and development tax credit carryforwards to offset such taxable income may be subject to limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">***</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">We currently have no intention of resuming historical research and development activities, and the following are risks primarily relating to our prior operations and historical activities, unless otherwise noted.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Historical Discovery Programs and Research and Development of Our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cell therapy is a rapidly evolving area of science, and the approach we have taken to discover and develop product candidates by utilizing genetically modified macrophages and monocytes is novel and may never lead to approved or marketable products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cell therapy has yet to be broadly applied to solid tumors, inflammatory disease, fibrotic disease or neurodegeneration. The discovery, research and development of engineered macrophages and monocytes to treat disease is an emerging field and our CAR-M platform, which is the first CAR-M to be evaluated in a human clinical trial, is a relatively new technology. Our future success depends on the successful development of this novel therapeutic approach. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. As such, there may be adverse effects or limited favorable results from treatment with any of our product candidates that we cannot predict at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success also depends on our successful application of our proprietary macrophage engineering platform in the combination setting and to other indications by reprogramming the target specificity of our CAR-M cell product and developing product candidates against a plethora of tumor associated antigens, including in therapeutic areas beyond oncology. However, our macrophage engineering platform may not allow us to generate new INDs to expand our pipeline on our anticipated timeline or in a cost-efficient manner or at all, which could cause the potential value of our business to decline and materially harm our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of macrophage engineering platform will result in the development and marketing approval of any products. Any development problems we experience in the future related to our macrophage engineering platform or any of our discovery programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our clinical trials or pre-clinical studies or commercializing any product candidates we may develop on a timely or profitable basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are early in our development efforts. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are early in our development efforts. Prior to pausing research and development activities as part of our cash preservation plan, we were focusing our development efforts on CT-2401, our product candidate in development for liver fibrosis, and CT-1119, our product candidate in development for mesothelin-positive solid tumors. We have not initiated clinical development of either CT-2401 or CT-1119. We had planned to conduct pre-clinical development of CT-2401 sufficient to enable a regulatory submission to initiate a clinical trial. We had also planned to initiate a Phase 1 clinical trial of CT-1119, a mesothelin-targeted CAR-Monocyte, in combination with tislelizumab, an anti-PD-1 antibody, in adult patients with mesothelin-positive solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to generate revenues from product sales, which we do not expect will occur for a number of&#160;years, if ever, will depend heavily on the successful development, marketing approval and eventual commercialization of our product candidates, which may never occur. The success of our product candidates will depend on many factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully completing pre-clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely filing and receiving clearance of IND applications to commence clinical trials;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully initiating, enrolling patients in and completing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scaling up manufacturing processes and capabilities to support clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">applying for and receiving marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining intellectual property protection and regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making arrangements with third-party manufacturers, or establishing commercial manufacturing capabilities, for both clinical and commercial supplies of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, enforcing, defending and protecting our rights in our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not infringing, misappropriating or otherwise violating others&#8217; intellectual property or proprietary rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of our products following receipt of any marketing approvals.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which would materially harm our business. As a company, we have limited experience in clinical development. Any predictions about the future success or viability of our product candidates we are developing or may develop in the future may not be as accurate as they could be if we had a longer history of conducting clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Drug development involves a lengthy and expensive process, with an uncertain outcome. The results of pre-clinical studies and early clinical trials may not be predictive of future results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The risk of failure for our product candidates is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of a product candidate, we must complete pre-clinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Clinical trials may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. Even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Before we can commence clinical trials for a product candidate, we must complete extensive pre-clinical testing and studies, manufacturing process development studies, and analytical development studies that support our planned INDs and other applications to regulatory authorities in the United States or similar applications in other jurisdictions. We cannot be certain of the timely completion or outcome of our pre-clinical testing and studies and cannot predict if the outcome of our pre-clinical testing and studies will ultimately support the further development of our product candidates or whether regulatory authorities will accept our proposed clinical programs. As a result, we may not be able to submit applications to initiate clinical development of product candidates on the timelines we expect, if at all, and the submission of these applications may not result in regulatory authorities allowing clinical trials to begin. Furthermore, product candidates are subject to continued pre-clinical safety studies, which may be conducted concurrently with </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical testing is expensive, difficult to design and implement, can take many&#160;years to complete and is uncertain as to the outcome. We cannot guarantee that any of our clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, among other things, flaws in study design, dose selection issues, placebo effects, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure of any of our product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other product candidates or cause regulatory authorities to require additional testing before approving any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize any product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or institutional review boards (&#8220;IRBs&#8221;), may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators may determine that the planned design of our clinical trials is flawed or inadequate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to establish clinical endpoints that applicable regulatory authorities consider clinically meaningful, or, if we seek accelerated approval, biomarker efficacy endpoints that applicable regulatory authorities consider likely to predict clinical benefit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pre-clinical testing may produce results based on which we may decide, or regulators may require us, to conduct additional pre-clinical studies before we proceed with certain clinical trials, limit the scope of our clinical trials, halt clinical trials or abandon product development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate (including because of a decrease in the pool of available patients) or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may decide, or regulators or IRBs may require us, to suspend or terminate clinical trials of our product candidates for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or IRBs may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our clinical investigators, regulators or IRBs to suspend or terminate the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators may withdraw their approval of a product or impose restrictions on its distribution; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from any health epidemics, pandemics or other contagious outbreaks may result in adverse effects on our business and operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, if there are safety concerns or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur unplanned costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be delayed in obtaining marketing approval for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not obtain marketing approval at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval in some countries and not in others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be subject to additional post-marketing testing requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have the product removed from the market after obtaining marketing approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product development costs will also increase if we experience delays in pre-clinical studies or clinical trials or in obtaining marketing or other regulatory approvals. We do not know whether any of our pre-clinical studies or clinical trials will begin timely, will need to be restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our clinical trials, including to add additional patients or arms, which could result in increased costs and expenses or delays. Significant pre-clinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. For example, in December&#160;2022, with the passage of the Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;) Congress required sponsors to develop and submit a diversity action plan (&#8220;DAP&#8221;) for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, DAPs must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In June&#160;2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs. Unlike most guidance documents issued by the FDA, the DAP guidance when finalized will have the force of law because FDORA specifically dictates that the form and manner for submission of DAPs are specified in FDA guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Similarly, the regulatory landscape related to clinical trials in the European Union recently evolved. The EU Clinical Trials Regulation (the &#8220;EU-CTR&#8221;) which was adopted in April&#160;2014 and repeals the EU Clinical Trials Directive, became applicable on January&#160;31, 2022. While the Clinical Trials Directive required a separate Clinical Trial Application (the &#8220;CTA&#8221;) to be submitted in </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">each member state, to both the competent national health authority and an independent ethics committee, the EU-CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The EU-CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. If we are not able to adapt to these and other changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, cancer therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for second-line or third-line use. When cancer is detected early enough, first-line therapy, usually hormone therapy, surgery, radiation therapy, chemotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. For any of our products that prove to be sufficiently beneficial, we would expect to seek approval potentially as a first-line therapy, but any product candidates we develop, even if approved, may not be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may conduct clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may conduct one or more clinical trials with one or more trial sites that are located outside the United States. The acceptance by the FDA or other regulatory authorities of study data from clinical trials conducted outside their jurisdiction may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the U.S. population and U.S. medical practice; (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant good clinical practices (&#8220;GCP&#8221;) regulations; and (iii)&#160;the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Conducting clinical trials outside the U.S. also exposes us to additional risks, including risks associated with:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional foreign regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign exchange fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with foreign manufacturing, customs, shipment and storage requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cultural differences in medical practice and clinical research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diminished protection of intellectual property in some countries; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The results of early-stage clinical trials and pre-clinical studies may not be predictive of future results. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and preliminary or interim results of a clinical trial do not necessarily predict final results. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. In particular, the small number of patients in our early clinical trials may make the results of these trials less predictive of the outcome of later clinical trials. Our product candidates may also fail to show the desired safety and efficacy in clinical development despite positive results in pre-clinical studies or having successfully advanced through initial clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Our clinical trials may not ultimately be successful or support further clinical development of any of our product candidates and we cannot assure you that any clinical trials that we may conduct will demonstrate consistent or adequate efficacy and safety to support marketing approval. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in late-stage clinical trials even after achieving promising results in pre-clinical testing and earlier-stage clinical trials, and we cannot be certain that we will not face similar setbacks. Any such setbacks in our clinical development could materially harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may announce or publish interim or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. Preliminary or interim results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could be material and could significantly harm our reputation and business prospects and may cause the trading price of our common stock to fluctuate significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we experience delays or difficulties in the enrollment of patients in our clinical trials for any of our product candidates, our receipt of necessary marketing approvals could be delayed or prevented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Identifying and qualifying patients to participate in our clinical trials of any of our product candidates in the future is critical to our success. Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients who remain in the trial until its conclusion. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. We cannot predict how successful we will be at enrolling subjects in future clinical trials. Patient enrollment is affected by a variety of other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the eligibility criteria for the trial in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perceived risks and benefits of the product candidate under trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirements of the trial protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of existing treatments for the indications for which we are conducting clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to identify specific patient populations based on specific genetic mutations or other factors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient referral practices of physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient consents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity and availability of clinical trial sites for prospective patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the conduct of clinical trials by competitors for product candidates that treat the same indications or address the same patient populations as our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost to, or lack of adequate compensation for, prospective patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of any health epidemics, pandemics or other contagious outbreaks.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our inability to locate and enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary marketing approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which could cause the value of our business to decline and limit our ability to obtain additional financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If serious adverse events, undesirable side effects or unexpected characteristics are identified during the development of any of our product candidates, we may need to abandon or limit our further clinical development of those product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of our product candidate are associated with serious adverse events or undesirable side effects in clinical trials or have characteristics that are unexpected in clinical trials or pre-clinical testing, we may need to abandon development of such product candidate or limit development to more narrow uses or subpopulations in which the serious adverse events, undesirable side effects or unexpected characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In pharmaceutical development, many compounds that initially show promise in early-stage or clinical testing are later found to cause side effects that delay or prevent further development of the compound or decrease the size of the patient population for whom the compound could ultimately be prescribed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, if results of our clinical trials reveal undesirable side effects, we, regulatory authorities or the IRBs at the institutions in which our studies are conducted could suspend or terminate our clinical trials, regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications or we could be forced to materially modify the design of our clinical trials. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we elect or are forced to suspend or terminate any clinical trial of our product candidates, the commercial prospects of such product candidate will be harmed, and our ability to generate revenues from sales of such product candidate will be delayed or eliminated. Any of these occurrences could materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical trials will be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">receives marketing approval, and we, or others, later discover that they are less effective than previously believed, or cause undesirable side effects, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal or limitation by regulatory authorities of approvals of such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seizure of the product by regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing of the product or the manufacturing process for any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirement by regulatory authorities of additional warnings on the label;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirement that we implement a risk evaluation and mitigation strategy or create a medication guide outlining the risks of such side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities of such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product may become less competitive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of regulatory investigations and government enforcement actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of legal action against us to hold us liable for harm caused to patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">harm to our reputation and resulting harm to physician or patient acceptance of our products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we have historically focused on discovery programs and product candidates that we identify for specific indications. As a result, we have and may in the future forego or delay the pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. For example, in 2024, we determined to cease further development of CT-0525 and CT-0508 to refocus our efforts on other strategic priorities at the time. In the future we may further curtail, pause, delay or cease development of other product candidates at any stage of pre-clinical or clinical development based on a variety of factors, including our judgments regarding costs or timing of further development, probability of success of pre-clinical and clinical development, regulatory requirements, competitive landscapes, commercial potential, relative benefits and costs compared to other product candidates in our portfolio, and our overall strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our resource allocation decisions in the future may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Spending on discovery and product development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Failure to allocate resources or capitalize on strategies in a successful manner will have an adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the closing of the Merger, we will seek to enter into a series of transactions with certain third parties to monetize certain legacy assets in accordance with the limitations and requirements set forth in the Merger Agreement.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may evaluate certain of our product candidates in combination with other drugs. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs, revoke their approval of such drugs, or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to evaluate in combination with our product candidates, we may be unable to obtain approval of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may evaluate certain of our product candidates in combination with other drugs. For example, prior to pausing research and development activities, we planned to initiate a Phase 1 clinical trial of CT-1119, in combination with tislelizumab, in adult patients with mesothelin-positive solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not developed or obtained marketing approval for, nor have we manufactured or sold, any approved drug that we may study in combination with our product candidates. If the FDA or similar regulatory authorities outside of the United States revokes their approval of any drug or drugs in combination with which we determine to develop any of our product candidates, we will not be able to market such product candidates in combination with such revoked drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If safety or efficacy issues arise with any of these drugs, we could experience significant regulatory delays, and the FDA or similar regulatory authorities outside of the United States may require us to redesign or terminate the applicable clinical trials. If the drugs we use are replaced as the standard of care for the indications we choose for our product candidates, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. In addition, if manufacturing or other issues result in a shortage of supply of the drugs with which we determine to combine with any of our product candidates, we may not be able to initiate or complete clinical development of such product candidates on a desired timeline or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if any of our product candidates were to receive marketing approval or be commercialized for use in combination with other existing drugs, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the drugs used in combination with our product candidates or that safety, efficacy, manufacturing or supply issues could arise with these existing drugs. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our other product candidates for use in combination with other drugs for cancer or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in our efforts to identify or discover additional potential product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A key element of our strategy is to apply our macrophage engineering platform to address a broad array of indications and targets to generate next-generation therapeutics, including programs for indications outside of liver fibrosis and oncology. The discovery efforts that we are conducting may not be successful in identifying product candidates that are useful in treating cancer or other diseases. Our discovery engine may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval or achieve market acceptance; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may not be effective in treating their targeted diseases.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Discovery programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. If we are unable to identify additional suitable product candidates for pre-clinical and clinical development, it will limit our potential to obtain revenues from sale of products in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adverse public perception of genetic medicine, and gene therapy in particular, may negatively impact regulatory approval of, or demand for, our potential products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene therapy is unsafe, unethical, or immoral, and, consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">their patients being willing to receive, treatments that involve the use of product candidates that we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">***</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">We currently have no intention of resuming our historical research and development activities, and the following are risks primarily relating to our prior operations and historical activities, unless otherwise noted.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Commercialization of Our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of our product candidates, if approved, may be smaller than we estimate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of our product candidates receives marketing approval, we may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current cancer treatments, such as chemotherapy and radiation therapy, are well established in the medical community and doctors may continue to rely on these and similar treatments. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenues from product sales and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages of our product candidates compared to the advantages and relative risks of alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of sales and marketing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to offer our products, if approved, for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which the product is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment in relation to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party coverage and adequate reimbursement, and patients&#8217; willingness to pay out of pocket for required co-payments or in the absence of third-party coverage or adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product labeling or product insert requirements of the FDA, the European Medical Agency (the &#8220;EMA&#8221;) or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">support from patient advocacy groups; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any restrictions on the use of our products, if approved, together with other medications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our assessment of the potential market opportunity for our product candidates is based on industry and market data that we obtained from industry publications, research, surveys and studies conducted by third parties and our analysis of these data, research, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Our estimates of the potential market opportunities for our product candidates include a number of key assumptions based on our industry knowledge, industry publications and third-party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for any of our product candidates may be smaller than we expect, and as a result our revenues from product sales may be limited and it may be more difficult for us to achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our product candidates if and when they are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not have a sales or marketing infrastructure and have no experience as a company in the sale, marketing or distribution of biopharmaceutical products. To achieve commercial success for any product for which we may obtain marketing approval, we will need to establish a sales, marketing and distribution organization, either ourselves or through collaborations or other arrangements with third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently expect that we would build our own focused, specialized sales and marketing organization to support the commercialization in the United States of product candidates for which we receive marketing approval and that can be commercialized with such capabilities. There are risks involved with us establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In general, the cost of establishing and maintaining a sales and marketing organization may exceed the cost-effectiveness of doing so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Factors that may inhibit our efforts to commercialize our products on our own include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit, train and retain adequate numbers of effective sales, marketing, market access, distribution, customer service, medical affairs and other support personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to equip sales personnel with effective materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to effectively manage a geographically dispersed sales and marketing team;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating an independent commercialization organization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third parties to perform these services, our revenues from product sales and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are acceptable to us. We </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, thus rendering our products non-competitive, obsolete or reducing the size of the market for our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biopharmaceutical industry, and in particular the cell therapy field and the liver fibrosis fields, is characterized by intense investment and competition aimed at rapidly advancing new technologies. Our platform and therapeutic product candidates are expected to face substantial competition from multiple technologies, marketed products and numerous other therapies being developed by third parties that use protein degradation, antibody therapy, inhibitory nucleic acid, gene editing or gene therapy development platforms and from companies focused on more traditional therapeutic modalities, such as small molecule inhibitors. The competition is likely to come from multiple sources, including biopharmaceutical companies, academic research institutions, governmental agencies and private research institutions that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The competition is likely to come from multiple sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies and public and private research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are aware of a number of companies generally pursuing the development of myeloid cell therapies, including, among others Myeloid Therapeutics, Shoreline Biosciences, Inceptor Bio, Thunder Bio, Resolution Therapeutics, CellOrigin, and others. We are also facing competition from companies pursuing autologous T cell therapies, allogeneic T cell therapies, NK and other cell therapies, direct <i style="font-style:italic;">in vivo</i> reprogrammed cell therapies, liver fibrosis therapies and other macrophage-targeted oncology therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we are aware of a number of companies either marketing or pursuing the development of liver fibrosis/metabolic associated liver disease (&#8220;MASH&#8221;) therapies, including Madrigal, Akero, 89bio, Boston Bio, Resolution Therapeutics, and major pharmaceutical companies developing incretin therapies such as Eli Lilly, NovoNordisk, and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our development programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other marketing approval for their products more rapidly than we may obtain approval for our products, including as a result of our decision to pause research and development activities, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming&#160;years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Technology in the biopharmaceutical industry has undergone rapid and significant change, and we expect that it will continue to do so. Any products or processes that we develop may become obsolete or uneconomical before we recover any expenses incurred in connection with their development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have pursued and, if we were to resume our historical research and development activities, may in the future pursue the in-license or acquisition of rights to complementary technologies and product candidates on an opportunistic basis. However, we may be unable to in-license or acquire any additional technologies or product candidates from third parties. The acquisition and licensing of technologies and product candidates is a competitive area, and a number of more established companies also have similar strategies to in-license or acquire technologies and product candidates that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in-license or acquire the relevant technology or product candidate on terms that would allow us to make an appropriate return on our investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we may obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. The availability of coverage and adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products, including our product candidates. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, government authorities and third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers its costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules&#160;and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules&#160;and regulations are likely.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that our product candidates, even if they are approved for sale in the United States, in the European Union or in other countries, will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, or that coverage and an adequate level of reimbursement will be available or that third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our product candidates profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of clinical trial and product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. While we currently have no products that have been approved for commercial sale, the use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidates or products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">termination of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of marketing approval, recall, restriction on the approval or a &#8220;black box&#8221; warning or contraindication for an approved drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend any related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced resources of our management to pursue our business strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distraction of management&#8217;s attention from our primary business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any products that we may develop.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently hold $10.0 million in product liability insurance coverage in the aggregate, with a per incident limit of $10.0 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage if we initiate and expand our clinical trials or commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">***</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">We currently have no intention of resuming our historical research and development activities. The following are risks primarily relating to our prior operations and historical activities, except for the risks relating to our ongoing collaboration with Moderna or as other otherwise noted below.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Dependence on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have relied, and if we resume our historical research and development activities expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay our ability to seek or obtain marketing approval for or commercialize our product candidates or otherwise harm our business. If we are not able to maintain these third-party relationships or if these arrangements are terminated, we may have to alter our development and commercialization plans and our business could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We historically relied on, and if we resume our historical research and development activities expect to continue to rely on third-party clinical research organizations, in addition to other third parties such as research collaboratives, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials. We currently have no plans to independently conduct any clinical trials of our product candidates. These Contract Research Organizations (&#8220;CROs&#8221;) and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. These third-party arrangements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, our product development activities might be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our reliance on these third parties for discovery and product development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities in Europe and other jurisdictions have similar requirements. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We are also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize our product candidates. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned, and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit to the FDA. Any such delay or rejection could prevent us from commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding more CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays can occur, which could materially impact our ability to meet our desired clinical development timelines. Although we plan to carefully manage our relationships with our CROs, investigators and other third parties, we may nonetheless encounter challenges or delays in the future, which could have a material and adverse impact on our business, financial condition and prospects.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have relied on, and if we resume our historical research and development activities expect to continue to rely on third-party CMOs for the manufacture of both drug substance and finished drug product of our product candidates for pre-clinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We have relied on, and if we resume our historical research and development activities, expect to continue to rely, on third-party CMOs for both drug substance and finished drug product, as well as for commercial manufacture if any of our product candidates receive marketing approval. We have relied on these third parties for the manufacture of plasmid and viral vectors, patient leukapheresis material logistics, as well as packaging, labeling, sterilization, storage, distribution and other production logistics. We continue to rely on these third parties for storage, distribution and other logistics of manufactured plasmid and viral vectors. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on the third party for regulatory compliance and quality assurance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach of the manufacturing agreement by the third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential failure to manufacture our product candidate or product according to our specifications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential failure to manufacture our product candidate or product according to our schedule or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We or our third-party manufacturers may encounter shortages in the raw materials or active pharmaceutical ingredients necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or active pharmaceutical ingredients, including shortages caused by the purchase of such raw materials or active pharmaceutical ingredients by our competitors or others. Our or our third-party manufacturers&#8217; failure to obtain the raw materials or active pharmaceutical ingredients necessary to manufacture sufficient quantities of our product candidates may have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our third-party manufacturers are subject to inspection and approval by regulatory authorities before we can commence the manufacture and sale of any of our product candidates, and thereafter subject to ongoing inspection from time to time. Third-party manufacturers may not be able to comply with current good manufacturing practices (&#8220;cGMP&#8221;) regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If any of our contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement or be unable to reach agreement with an alternative manufacturer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have relied, and may in the future, rely on single-source suppliers for certain materials and components used in the manufacturing of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have relied, and may in the future, rely on single-source suppliers for certain materials and components used in the manufacturing of our product candidates. There are, for certain of these materials and components, few, if any, alternative sources of supply and there is limited need for multiple suppliers at this stage of our business. We cannot ensure that these suppliers will remain in business, have sufficient capacity or supply to meet our needs, be able to supply materials to us at costs that are acceptable to us, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of certain materials and components exposes us to several risks, including disruptions in supply, price increases or late deliveries. This supplier may be unable or unwilling to meet our future demands for our clinical trials. Establishing additional or replacement suppliers for these materials and components could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from these single-source suppliers could lead to supply delays or interruptions which would materially adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect to depend on collaborations with third parties for the research, development and commercialization of certain of our product candidates, including our collaboration agreement with Moderna. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may depend on collaborations with third parties for the research, development and commercialization of certain of our product candidates. For example, we entered into a strategic collaboration with Moderna in January&#160;2022 focused on the development of <i style="font-style:italic;">in vivo</i> CAR-M therapeutics. In collaboration with Moderna, we have established a Messenger RNA/lipid nanoparticle (&#8220;mRNA/LNP&#8221;) <i style="font-style:italic;">in vivo</i> CAR-M platform for research targets, which enables an off-the-shelf approach wherein the patient&#8217;s own myeloid cells are engineered directly within their body via the administration of a LNP encapsulating macrophage reprogramming mRNA CAR constructs, removing the requirement for <i style="font-style:italic;">ex vivo</i> cell manufacturing entirely. In June&#160;2024, we announced the nomination of the first development candidate under the collaboration with Moderna. The development candidate targets Glypican-3 (&#8220;GPC3&#8221;). In February&#160;2025, Moderna nominated 10 additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February&#160;2025, Moderna has nominated all 12 oncology research targets under the collaboration for which we have the potential to receive future milestones and royalties. We will not conduct any additional research activities under the collaboration agreement and we will not be receiving any further payments from Moderna for research and development services under the collaboration agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Moderna collaboration agreement, assuming Moderna develops and commercializes 12 products, each directed to a different development target, we are eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. We are also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. We cannot be certain that Moderna will take the steps to achieve any of these development, regulatory and commercial milestones, all of which are outside of our control. Therefore, we may not be entitled to receive from Moderna any remaining milestone payments or any royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the completion of the Merger, we will seek to enter into a series of transactions with certain third parties to monetize certain legacy assets, in accordance with the limitations and requirements set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Collaborators for collaboration arrangements may include large and mid-size pharmaceutical companies and biotechnology companies, among others. We cannot provide any commitment that we will enter into any collaboration. Any such arrangements with third parties will likely limit our control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into and we cannot be certain that they provide any value for our company or our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Collaborations involving our discovery programs or any product candidates we may develop, including our collaboration with Moderna pose the following risks to us:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations; for example, our collaboration with Moderna is managed by a JSC, which is comprised of </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">representatives from the Company and Moderna, with Moderna having final decision-making authority, subject to specified limitations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development of our product candidates or may elect not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition or business combination, that divert resources or create competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of any product candidates that achieve marketing approval or may elect not to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition or business combination, that may divert resources or create competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates on a discretionary basis; for example, data, results and know-how generated in the performance of the Moderna collaboration is deemed the confidential information of Moderna, which we may not disclose except under limited circumstances;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator may seek to renegotiate or terminate their relationship with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve marketing approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; for example, Moderna has the first right to prosecute, enforce or defend certain patent rights under its agreement with us, and although we may have the right to assume the prosecution, enforcement or defense of such patent rights if Moderna does not, our ability to do so may be compromised by Moderna&#8217;s actions;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates; for example, Moderna has the right to terminate its agreement with us for convenience in its entirety or with respect to a specific product or target on 90&#160;days&#8217; prior notice, in connection with a material breach of the agreement by us that remains uncured for a specified period of time or in the event of specified insolvency events involving us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If a present or future collaborator of ours was to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any collaborations that we enter into do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, or receive it in the timeframe in which we expect to receive it, the development of our product candidates could be delayed, and we may need additional resources to develop our product candidates. All of the risks relating to product development, marketing approval and commercialization described herein also apply to the activities of our collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may in the future decide to collaborate with biopharmaceutical companies for the development and potential commercialization of any product candidates we may develop. These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are not able to establish or maintain additional collaborations, on commercially reasonable terms, we may have to alter our development and commercialization plans, and our business could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We face significant competition in attracting appropriate collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, the terms of any existing collaboration agreements, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate, document and execute. In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any collaboration we may enter into may limit our ability to enter into future agreements on particular terms or covering similar target indications with other potential collaborators.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms or at all, we may have to curtail the development of a product candidate, reduce or delay our development program or one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market and generate revenue from product sales, which could have an adverse effect on our business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have a number of academic collaborations to supplement our internal discovery and product development programs. If any such collaborator decides to discontinue or devote less resources to such research, our discovery programs could be diminished.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our discovery engine is supplemented by academic collaborations to expand our platform, which we rely upon to advance our development and commercialization plans for our product candidates. For example, in August&#160;2020, we entered into a scientific research and licensing agreement with Nathaniel R. Landau, Ph.D. and NYU Langone Health through which we obtained exclusive rights to develop their Vpx lentiviral vector globally for all indications. In addition, we, from time to time, may enter into academic research collaborations to explore the development of new technologies and indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While these academic institutions have contractual obligations to us, they are independent entities and are not under our control or the control of our officers or directors. Our research and licensing agreements with academic collaborators generally provide academic collaborators with license maintenance fees, development and regulatory milestone payments, royalties on net sales of products and a portion of sublicense income that we receive. Upon the scheduled expiration of any academic collaboration, we may not be able to renew the related agreement, or any renewal could be on terms less favorable to us than those contained in the existing agreement. Furthermore, either we or the academic institution generally may terminate the sponsored research agreement for convenience following a specified notice period. If any of these academic institutions decides to not renew or to terminate the related agreement or decides to devote fewer resources to such activities, our discovery efforts would be diminished, while our royalty obligations, if any, would continue unmodified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any acquisitions or in-license transactions that we complete could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have licensed four patent families from the University of Pennsylvania (&#8220;Penn&#8221;) and one patent family from NYU and may enter into transactions to in-license or acquire other businesses, intellectual property, technologies, product candidates or products. If we determine to pursue a particular transaction, we may not be able to complete the transaction on favorable terms, or at all. Any in-licenses or acquisitions we complete may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an in-license or acquisition or issue our common stock or other equity securities to the stockholders of the target company, which would reduce the&#160;percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and nondisruptive manner. In-license and acquisition transactions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of additional future in-licenses or acquisitions or the effect that any such transactions might have on our operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;<i style="font-style:italic;">Risks Related to the Merger</i>&#8221; on page&#160;26 and &#8220;<i style="font-style:italic;">Risks Related to Our Evaluation of the Merger and Strategic Alternatives</i>&#8221; on page&#160;30 for risks related to the Merger and our pursuant of strategic alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The FDA, EMA, or other comparable foreign regulatory authorities could require the clearance or approval of a companion diagnostic device as a condition of approval for any product candidate that requires or would commercially benefit from such tests. Failure to successfully validate, develop and obtain regulatory clearance or approval for companion diagnostics on a timely basis or at all could harm our product development strategy and we may not realize the commercial potential of any such product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If safe and effective use of any of our other product candidates depends on an <i style="font-style:italic;">in vitro</i> diagnostic, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product candidates. The process of obtaining or creating such diagnostic is time consuming and costly. Companion diagnostics, which provide information that is essential for the safe and effective use of a corresponding therapeutic product, are subject to regulation by the FDA, EMA and other comparable foreign regulatory authorities as medical devices and require separate regulatory approval from therapeutic approval prior to commercialization. The FDA previously has required <i style="font-style:italic;">in vitro</i> companion diagnostics intended to select the patients who will respond to a product candidate to obtain pre-market approval (&#8220;PMA&#8221;) simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of pre-clinical and clinical data and the submission and review by the FDA, can take several&#160;years or longer. It involves a rigorous pre-market review during which the sponsor must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse event reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Given our limited experience in developing and commercializing diagnostics, we do not plan to develop companion diagnostics internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in developing and obtaining approval for these companion diagnostics. We may not be able to enter into arrangements with a provider to develop a companion diagnostic for use in connection with a registrational trial for our product candidates or for commercialization of our product candidates, or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates. We and our future collaborators may encounter difficulties in developing and obtaining approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our collaborators to develop or obtain regulatory approval of the companion diagnostics could delay or prevent approval of our product candidates. In addition, we, our collaborators or third parties may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics by physicians.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any companion diagnostic collaborator or third party with whom we contract may decide not to commercialize or to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our product candidates, or our relationship with such collaborator or third party may otherwise terminate. We may not be able to enter into arrangements with another provider to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">***</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">We currently have no intention of resuming our historical research and development activities, and the following are risks primarily relating to our prior operations and historical activities, unless otherwise noted.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected and we may not be able to compete effectively in our market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success depends in part on our ability to obtain, maintain and enforce protection of the intellectual property we may own solely and jointly with others or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technologies and product candidates that are important to our business and by in-licensing intellectual property related to such technologies and product candidates. If we are unable to obtain, maintain or enforce patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Moreover, the patent applications we own, co-own or license may fail to result in issued patents in the United States or in other foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce and defend the patents, covering technology that we license from third parties. Therefore, these in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with the best interests of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent&#160;years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Moreover, our owned or in-licensed pending and future patent applications may not result in patents being issued which protect our technology and product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value or narrow the scope of our patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, we or our licensors may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office (&#8220;USPTO&#8221;) or become involved in opposition, derivation, revocation, reexamination, <i style="font-style:italic;">inter partes</i> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our owned or licensed patent estate includes patent applications, many of which are at an early-stage of prosecution. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned or in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to our inventorship, scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial costs and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect our competitive position with respect to our current or future product candidates for an adequate amount of time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but there is no assurance that any such extensions will be obtained, and the life of a patent, and the protection it affords, is limited. Even if patents covering our </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">current or future product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, patent term can also be adjusted due to delays that occur during examination of patent applications, which may extend the term of a patent beyond 20&#160;years. There is a risk that we may take action that reduces any accrued patent term adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is necessary to pay certain maintenance fees, also referred to as annuities or renewal fees in some countries, throughout the lifetime of a patent at regular intervals. Failure to pay these fees can cause a granted patent to prematurely expire, without an opportunity for revival. There is a risk that we may be unable to maintain patent protection for certain patents in all markets due to finite availability of resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidate(s), which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, we may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, if we fail to comply with our obligations under any license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in us having to negotiate new or restated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the United States, the term of a patent that covers an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Hatch-Waxman Act, as compensation for the loss of a patent term during the FDA regulatory review process for a drug product subject to the provisions of the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five&#160;years, but patent extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates. There is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions could be for a shorter period than we anticipate. We may not be granted </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes in either the patent laws or interpretation of patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the maintenance, enforcement or defense of our owned or in-licensed issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The federal government retains certain rights in inventions created using its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights&#8221;. March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. We collaborate with a number of universities with respect to certain of our research and development. We cannot be sure that any co-developed intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own or in-license technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Although we or our licensors are not currently involved in any intellectual property litigation, we may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Competitors and other third parties may infringe, misappropriate or otherwise violate our or our licensor&#8217;s issued patents, the patents of our licensors or other intellectual property. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s product. To counter infringement or misappropriation, we or our licensors may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive and time-consuming and can distract our management and scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for&#160;years before they are concluded. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us, alleging that we infringe, misappropriate or otherwise violate their intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including novelty, non-obviousness, enablement, or written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, <i style="font-style:italic;">inter partes</i> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. The outcome following </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">legal assertions of invalidity and unenforceability is unpredictable. Similarly, if we or our licensors assert trademark infringement claims, a court may determine that the marks we or our licensors have asserted are invalid or unenforceable, or that the party against whom we or our licensors have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks, which could materially harm our business and negatively affect our position in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated, held unenforceable or interpreted narrowly, could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent, and could limit our or our licensor&#8217;s ability to assert those patents against those parties, or other competitors, and curtail or preclude our ability to exclude third parties from developing and commercializing similar or competitive products. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents do not cover such technology. Even if we establish infringement, a court may not order the third party to stop using the technology at issue and instead award only monetary damages to us, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to us from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management, technical personnel and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources in one or more aspects, or for other reasons. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of a third party to commercialize our own technology or products, in which case we would be required to obtain a license from such third party. A license to such intellectual property may not be available or may not be available on commercially reasonable terms, which could have a material adverse effect on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than us, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. We may not be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the biopharmaceutical industry. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, <i style="font-style:italic;">inter partes</i> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions, such as opposition proceedings before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biopharmaceutical industry expands and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The legal threshold for initiating litigation or contested proceedings is low, so even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. Even if we diligently search third-party patents for potential infringement by our products or product candidates, we may not successfully find patents our products or product candidates may infringe. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third-party intellectual property is invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations or methods, such as methods of manufacture or methods for treatment, related to the discovery, use or manufacture of the product candidates that we may identify or related to our technologies. Because patent applications can take many&#160;years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that we may identify may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or that we have incorrectly concluded are invalid or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may identify, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we are able to obtain a license, we could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right, we could be forced to indemnify our customers or collaborators. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">our business operations, which could materially harm our business. In addition, we may be forced to redesign our product candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While we seek to protect the trademarks and trade names we use in the United States and in other countries, we may be unsuccessful in obtaining registrations or otherwise protecting these trademarks and trade names, which we need to build name recognition in our markets of interest and among potential partners or customers. We rely on both registration and common law protection for our trademarks. Our registered or unregistered trademarks or trade names may be challenged, infringed, diluted or declared generic, or determined to be infringing on other marks. At times, competitors may adopt trademarks and trade names similar to ours, or our collaborators may fail to use our trade names or trademarks, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks. If we are unable to protect our rights to trademarks and trade names, we may be prevented from using such marks and names unless we enter into appropriate royalty, license or coexistence agreements, which may not be available or may not be available on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Effective trademark protection may not be available or may not be sought in every country in which our products are made available. Any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may license our trademarks and trade names to third parties, such as distributors and collaborators. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of or failure to use our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, know-how, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules&#160;of, the relevant patent agency. With respect to our patents, we rely on an annuity service, outside firms and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our obligations in our current and future intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are party to a number of license and research agreements. Some of these agreements provide us with the intellectual property rights required for the development of our product candidates, including the license agreement with Penn. These licenses and research agreements and similar agreements in the future may impose diligence, development and commercialization timelines, and milestone payment, royalty, insurance and other obligations on us. If we fail to comply with such obligations, the parties to these agreements may decide to terminate the agreements or require us to grant them certain rights, in which we may not be able to develop, manufacture, or market any products without the rights granted to us by these agreements and may face other penalties. Any such occurrences could adversely affect the value of any product candidate being developed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a variety of purposes, we will likely enter into additional licensing and funding arrangements with third parties that may impose similar obligations on us. Termination of these agreements or reduction or elimination of our rights under these agreements may result in us having to negotiate new or restated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations and prospects. While we still face all of the risks described herein with respect to such agreements, we cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the above risks, intellectual property rights that our licenses in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the payment obligations with respect to licensed technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on our licensors to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. Licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce our licensed and sublicensed intellectual property effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications of our in-licenses. If other third parties have ownership rights to patents or patent applications of our in-licenses, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, including of their current or former employers or claims asserting we have misappropriated their intellectual property, or is claiming ownership of what we regard as our own intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of our employees, consultants and contractors have been previously employed at universities or other biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We may have also entered into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. To the extent we become involved in litigation that may require discovery of our trade secrets, know-how and other proprietary technology, we will seek to secure protective orders from the court that bind the parties with access to the discovered information. Despite these efforts, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. In addition, we cannot be certain that proprietary technical information and related confidential documents that we have shared with our collaborators and/or submitted to governmental agencies, including regulatory agencies for evaluation and supervision of pharmaceutical products, will be kept confidential. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering our inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our owned or in-licensed pending patent applications or those we may own or in-license in the future will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">claims of issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research, development, testing or commercialization activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Supreme Court, other federal courts, Congress, the USPTO or similar foreign authorities may change the standards of patentability and any such changes could narrow or invalidate, or change the scope of, our or our licensors&#8217; patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own or license expire;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may harm our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If approved, our product candidates that are licensed and regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;) was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the &#8220;ACA&#8221;) to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, a reference biological product is granted 12&#160;years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four&#160;years after the date of first licensure of the reference product In addition, the licensure of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as its biologics license application (&#8220;BLA&#8221;) does not reply on the reference product, sponsor&#8217;s data or submit the application as a biosimilar application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that any of the product candidates we develop as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing. Nonetheless, the approval of a biosimilar to our product candidates would have a material adverse impact on our business due to increased competition and pricing pressure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November&#160;2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April&#160;26, 2023. On April&#160;10, 2024, the European Parliament adopted a position on the proposal requesting several amendments to the package. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may, however, have a significant impact on the pharmaceutical industry and our business in the long term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">***</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">We currently have no intention of resuming our historical research and development activities, and the following are risks primarily relating to our prior operations and historical activities, unless otherwise noted.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Regulatory Approval and Other Legal Compliance Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The regulatory approval process of the FDA is lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The time required to obtain approval by the FDA is unpredictable but typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained marketing approval for any product candidate, and it is possible that none of our existing product candidates, or any product candidates we may seek to develop in the future will ever obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates could fail to receive marketing approval for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for our proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical trials may not meet the level of statistical significance required by the FDA for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may disagree with our interpretation of data from pre-clinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA or other submission or to obtain marketing approval in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in us failing to obtain marketing approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. The FDA has substantial discretion in the approval process and determining when or whether marketing approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA. Risks similar to those outlined above exist with regard to regulatory authorities outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we complete the necessary pre-clinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by the EMA and other regulatory authorities outside of the United States. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party clinical research organizations or other third-party consultants or vendors to assist us in this process. Securing marketing approval requires the submission of extensive pre-clinical and clinical data and supporting information, including </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">manufacturing information, to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude us from obtaining marketing approval or prevent or limit commercial use. New cancer drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have relapsed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many&#160;years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional pre-clinical, clinical or other studies. In addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, under the Pediatric Research Equity Act of 2003 (&#8220;PREA&#8221;), a BLA or supplement to a BLA for certain biological products must contain data to assess the safety and effectiveness of the biological product in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless the sponsor receives a deferral or waiver from the FDA. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The applicable legislation in the European Union also requires sponsors to either conduct clinical trials in a pediatric population in accordance with a Pediatric Investigation Plan approved by the Pediatric Committee of the EMA or to obtain a waiver or deferral from the conduct of these studies by this Committee. For any of our product candidates for which we are seeking regulatory approval in the United States or the European Union, we cannot guarantee that we will be able to obtain a waiver or alternatively complete any required studies and other requirements in a timely manner, or at all, which could result in associated reputational harm and subject us to enforcement action, invalidation of the marketing application, and/or financial penalties. Our collaborators are also subject to similar requirements outside of the United States and the European Union and thus the attendant risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we could be adversely affected by several significant administrative law cases decided by the U.S. Supreme Court in 2024. In <i style="font-style:italic;">Loper Bright Enterprises v. Raimondo</i>, for example, the court overruled <i style="font-style:italic;">Chevron U.S.A.,&#160;Inc. v. Natural Resources Defense Council,&#160;Inc</i>., which for 40&#160;years required federal courts to defer to permissible agency interpretations of statutes that are silent or ambiguous on a particular topic. The U.S. Supreme Court stripped federal agencies of this presumptive deference and held that courts must exercise their independent judgment when deciding whether an agency such as the FDA acted within its statutory authority under the Administrative Procedure Act (the &#8220;APA&#8221;). Additionally, in <i style="font-style:italic;">Corner Post,&#160;Inc. v. Board of Governors of the Federal Reserve System</i>, the court held that actions to challenge a federal regulation under the APA can be initiated within six&#160;years of the date of injury to the plaintiff, rather than the date the rule&#160;is finalized. The decision appears to give prospective plaintiffs a personal statute of limitations to challenge longstanding agency regulations. Another decision,<i style="font-style:italic;"> Securities and Exchange Commission v. Jarkesy,</i> overturned regulatory agencies&#8217; ability to impose civil penalties in administrative proceedings. These decisions could introduce additional uncertainty into the regulatory process and may result in additional legal challenges to actions taken by federal regulatory agencies, including the FDA and Centers for Medicare&#160;&amp; Medicaid Services (the &#8220;CMS&#8221;), that we rely on. In addition to potential changes to regulations as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays and other impacts, any of which could adversely impact our business and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Finally, our ability to develop and market new drug products may be impacted if litigation challenging the FDA&#8217;s approval of another company&#8217;s drug continues. In April&#160;2023, the U.S. District Court for the Northern District of Texas invalidated the approval by the FDA of mifepristone, a drug product which was originally approved in 2000 and whose distribution is governed by various measures adopted under a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;). The Court of Appeals for the Fifth Circuit declined to order the removal of mifepristone from the market but did hold that plaintiffs were likely to prevail in their claim that changes allowing for expanded access of mifepristone, which the FDA authorized in 2016 and 2021, were arbitrary and capricious. In June&#160;2024, the Supreme Court reversed and remanded that decision after unanimously finding that the plaintiffs did not have standing to bring this legal action against the FDA. In October&#160;2024, the Attorneys General of three states filed an amended complaint in the district court in Texas challenging FDA&#8217;s actions. In January&#160;2025, the district court agreed to allow these states to file an amended complaint and continue to pursue this challenge. Depending on the outcome of this litigation, if it continues, our ability to develop </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">new drug product candidates and to maintain approval of existing drug products is at risk and could be delayed, undermined or subject to protracted litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to market and sell our products in the European Union and many other foreign jurisdictions, we and our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. The failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any jurisdiction, which would materially impair our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we could face heightened risks with respect to obtaining marketing authorization in the United Kingdom as a result of the withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. The United Kingdom is no longer part of the European Single Market and EU Customs Union. As of January&#160;1, 2025, the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) is responsible for approving all medicinal products destined for the United Kingdom market (i.e., Great Britian and Northern Ireland). At the same time, a new international recognition procedure (&#8220;IRP&#8221;) will apply, which intends to facilitate approval of pharmaceutical products in the UK. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators (&#8220;RRs&#8221;). The RRs notably include EMA and regulators in the EU/European Economic Area (&#8220;EEA&#8221;) member states for approvals in the EU centralized procedure and mutual recognition procedure as well as the FDA (for product approvals granted in the U.S. However, the concrete functioning of the IRP is currently unclear. Any delay in obtaining, or an inability to obtain, any marketing authorizations may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inadequate funding for the FDA, the SEC and other government agencies, including from government shutdowns, funding shortages, personnel losses, regulatory reform or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the FDA have fluctuated in recent&#160;years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, disruptions may result from events similar to the COVID-19 pandemic. During the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. In the event of a similar public health emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended. Regulatory authorities outside the United States facing similar circumstances may adopt similar </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is also substantial uncertainty as to how measures being implemented by the new Trump Administration across the government will impact the FDA, CMS and other federal agencies with jurisdiction over our activities. For example, since taking office, President Trump has issued a number of executive orders, which could have a significant impact on the manner in which the FDA conducts its operations and engages in regulatory and oversight activities. Further, while the FDA&#8217;s review of BLAs and other applications is funded through the user fee program established under Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), the Trump Administration has indicated that it will be reviewing that program and its implementation. If these or other orders or executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. In addition, the loss of FDA personnel could lead to further disruptions and delays in FDA review and oversight of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, if a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulatory requirements governing gene therapy products are periodically updated and may continue to change in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has established the Office of Tissues and Advanced Therapies (the &#8220;OTAT&#8221;) within the Center for Biologics Evaluation and Research (the &#8220;CBER&#8221;) to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review. In September&#160;2022, the FDA announced retitling of the OTAT to the Office of Therapeutic Products (the &#8220;OTP&#8221;) and elevation of the OTP to a &#8220;Super Office&#8221; to meet its growing cell and gene therapy workload and new commitments under the Prescription Drug User Fee Act agreement for fiscal&#160;years 2023 to 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from the U.S. National Institutes of Health (&#8220;NIH&#8221;) also are potentially subject to review by the Office of Biotechnology Activities&#8217; Recombinant DNA Advisory Committee (the &#8220;RDAC&#8221;); however, the NIH announced that the RDAC will only publicly review clinical trials if the trials cannot be evaluated by standard oversight bodies and pose unusual risks. Although the FDA decides whether individual gene therapy protocols may proceed, the RDAC public review process, if undertaken, can delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and details and approved its initiation. Conversely, the FDA can put an IND on a clinical hold even if the RDAC has provided a favorable review or an exemption from in-depth, public review. If we were to engage a NIH-funded institution to conduct a clinical trial, that institution&#8217;s Institutional Biosafety Committee as well as our IRB would need to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has issued various guidance documents regarding gene therapies, including a draft guidance from November&#160;2024 addressing various questions and final guidance documents released in January&#160;2020 relating to chemistry, manufacturing and controls (&#8220;CMC&#8221;), information for gene therapy INDs, gene therapies for rare diseases and gene therapies for retinal disorders. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, we believe that our compliance with them is likely necessary to gain approval for any gene therapy product candidate that we may develop. The guidance documents provide additional factors that the FDA will consider at each of the above stages of development and relate to, among other things, the proper pre-clinical assessment of gene therapies; the CMC information that should be included in an IND; the proper design of tests to measure product potency in support of an IND or BLA; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five&#160;years of annual examinations followed by 10&#160;years of annual queries, either in person or by questionnaire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, for a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with good tissue practices (&#8220;GTP&#8221;). These standards are found in FDA regulations and guidance that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products (&#8220;HCT/Ps&#8221;), which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finally, ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional regulations or prohibiting the processes that we may use. Federal and state agencies, congressional committees and foreign governments have expressed their intentions to further regulate biotechnology. More restrictive regulations or claims that our product candidates are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As we advance our product candidates through clinical development, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product for which we obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with any such product following approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any product for which we obtain marketing approval, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such product, among other things, will be subject to ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market any product for an indication that is not approved, we may be subject to warnings or enforcement action for off-label marketing. Violation of the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) and other statutes, including the False Claims Act (the &#8220;FCA&#8221;), relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown adverse events or other problems with any product for which we may obtain marketing approval and its manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on such product, manufacturers or manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the product from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on coverage by third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar restrictions apply to the approval of our products in the EU. The holder of a marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules, which can impose post-authorization studies and additional monitoring obligations; the manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory; and the marketing and promotion of authorized drugs, which are strictly regulated in the European Union and are also subject to EU Member State laws. The failure to comply with these and other EU requirements can also lead to significant penalties and sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any regulatory approval to market our products will be limited by indication. If we fail to comply or are found to be in violation of FDA regulations restricting the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA, EMA, MHRA and other government agencies. In September&#160;2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a drug product. Physicians may nevertheless prescribe our products off-label to their patients in a manner that is inconsistent with the approved label. We intend to implement compliance and training programs designed to ensure that our sales and marketing practices comply with applicable regulations. Notwithstanding these programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our products for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable regulations regarding the promotion of products for unapproved uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the regulatory restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading, and non-promotional scientific communications concerning their products in certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will also need to carefully navigate the FDA&#8217;s various regulations, guidance and policies, along with recently enacted legislation, to ensure compliance with restrictions governing promotion of our products. In September&#160;2021, the FDA published final regulations which describe the types of evidence that the Agency will consider in determining the intended use of a drug or biologic. Moreover, with passage of the Pre-Approval Information Exchange Act in December&#160;2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patient access upon product approval. In addition, in January&#160;2025, the FDA published final guidance outlining its policies governing the distribution of scientific information to healthcare providers about unapproved uses of approved products. The final guidance calls for such communications to be truthful, non-misleading and scientifically sound and to include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use of the approved product. If a company engages in such communications consistent with the guidance&#8217;s recommendations, the FDA indicated that it will not treat such communications as evidence of unlawful promotion of a new intended use for the approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In recent&#160;years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the HHS, the FDA, the Federal Trade Commission (the &#8220;FTC&#8221;) and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">asserting antitrust violations, violations of the FDCA, the FCA, the Prescription Drug Marketing Act and anti-kickback laws and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations originate as &#8220;<i style="font-style:italic;">qui tam</i>&#8221; actions under the FCA. Under the FCA, any individual can bring a claim on behalf of the government alleging that a person or entity has presented a false claim or caused a false claim to be submitted to the government for payment. The person bringing a <i style="font-style:italic;">qui tam</i> suit is entitled to a share of any recovery or settlement. <i style="font-style:italic;">Qui tam</i> suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a <i style="font-style:italic;">qui tam</i> suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a <i style="font-style:italic;">qui tam</i> suit and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations in the United States, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may seek certain designations for one or more of our product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six&#160;months, rather than the standard review period of 10&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These designations are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualifies for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may seek PRIME Designation in the European Union for our product candidates, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the EU, we may seek PRIME designation for some of our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA&#8217;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the European Union or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the European Union and where the sponsor intends to apply for an initial </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. The benefits of a PRIME designation include the appointment of a rapporteur under the EMA&#8217;s Committee for Human Medicinal Products to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables a sponsor to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#8217;s grant of a marketing authorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We, or our collaborators, may seek approval from the FDA or comparable foreign regulatory authorities to use accelerated development pathways for our product candidates. If we, or our collaborators, are not able to use such pathways, we, or they, may be required to conduct additional clinical trials beyond those that are contemplated, which would increase the expense of obtaining, and delay the receipt of, necessary marketing approvals, if we, or they, receive them at all. In addition, even if an accelerated approval pathway is available to us, or our collaborators, it may not lead to expedited approval of our product candidates, or approval at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the FDCA and implementing regulations, the FDA may grant accelerated approval to a product candidate to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies, upon a determination that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage but is a clinically important improvement from a patient and public health perspective. Prior to seeking such accelerated approval, we, or our collaborators, will continue to seek feedback from the FDA or comparable foreign regulatory agencies and otherwise evaluate our, or their, ability to seek and receive such accelerated approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that we will satisfy all FDA requirements, including new provisions that govern accelerated approval. For example, with passage of the FDORA in December&#160;2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to: require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to the FDA every six&#160;months (until the study is completed; and use expedited procedures to withdraw accelerated approval of a BLA if certain conditions are met, including where a required confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product is not shown to be safe or effective under the conditions of use. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence, including with respect to &#8220;conditions specified by the Secretary.&#8221; The new procedures include the provision of due notice and an explanation for a proposed withdrawal, and opportunities for a meeting with the Commissioner or the Commissioner&#8217;s designee and a written appeal, among other things. We will need to fully comply with these and other requirements in connection with the development and approval of any product candidate that qualifies for accelerated approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval. The FDA indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to support accelerated approvals of oncology therapeutics. Subsequently, in December&#160;2024 and January&#160;2025, the FDA issued additional draft guidance relating to accelerated approval. These guidances describe FDA&#8217;s views on what it means to conduct a confirmatory trial with due diligence and how the agency plans to interpret whether such a study needs to be underway at the time of approval. While these guidances are currently only in draft form and will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to seek accelerated approval for any product candidates.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Union, a &#8220;conditional&#8221; marketing authorization may be granted in cases where all the required safety and efficacy data are not yet available. A conditional marketing authorization is subject to conditions to be fulfilled for generating missing data or ensuring increased safety measures. A conditional marketing authorization is valid for one&#160;year and has to be renewed annually until fulfillment of all relevant conditions. Once the applicable pending studies are provided, a conditional marketing authorization can become a &#8220;standard&#8221; marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will cease to be renewed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the FDA or comparable foreign regulatory agencies will agree with our, or our collaborators&#8217;, surrogate endpoints or intermediate clinical endpoints in any of our, or their, clinical trials, or that we, or our collaborators, will decide to pursue or submit any additional application for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that, after feedback from the FDA or comparable foreign regulatory agencies, we, or our collaborators, will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval. Furthermore, for any submission of an application for accelerated approval or application under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted for filing or that any expedited development, review or approval will be granted on a timely basis, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time period until commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to obtain orphan drug exclusivity for any product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable period is seven&#160;years in the United States and 10&#160;years in the European Union. The exclusivity period in the European Union can be reduced to six&#160;years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order for the FDA to grant orphan drug exclusivity to one of our products, the FDA must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA and comparable foreign regulatory authorities such as the EMA can subsequently approve the same product for the same condition if the FDA or such other authorities conclude that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2017, the Congress passed the FDA Reauthorization Act (&#8220;FDARA&#8221;). The FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. Under omnibus legislation signed by former President Trump in December&#160;2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of the FDARA in 2017, but have not yet been approved or licensed by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11th Circuit in September&#160;2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; Although there have been legislative proposals to overrule&#160;this </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">decision, they have not been enacted into law. On January&#160;23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. However, on February&#160;14, 2025, a federal district court in Washington, D.C. fully embraced the reasoning of the court decision in another decision challenging the scope of orphan drug exclusivity. The implications of this decision, and its impact on the FDA&#8217;s implementation of the Orphan Drug Act, are unclear at this point.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not know if, when, or how the FDA or Congress may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, to obtain orphan drug designation in the EU, we would need to demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition. There is no assurance that we would be able to meet that standard for any of our product candidates. Further, if we do obtain orphan drug designation for a product candidate in the EU, we will not be able to maintain that designation if we are not able to show, to the satisfaction of the EU regulatory authorities, that the product candidate is of significant benefit to patients over available commercial products for the indication in the European Union and any additional products that are ahead of our product candidate in clinical development for the indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are required by the FDA, EMA or comparable regulatory authority to obtain clearance or approval of a companion diagnostic test in connection with approval of any of our product candidates or a group of therapeutic products, and we do not obtain or we face delays in obtaining clearance or approval of a diagnostic test, we may not be able to commercialize the product candidate and our ability to generate revenue may be materially impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are required by the FDA, EMA or a comparable regulatory authority to obtain clearance or approval of a companion diagnostic test in connection with approval of any of our product candidates, such companion diagnostic test would be used during our more advanced phase clinical trials as well as in connection with the commercialization of our product candidates. To be successful in developing and commercializing product candidates in combination with these companion diagnostics, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to ensuring the safe and effective use of a novel therapeutic product or new indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared. In certain circumstances (for example, when a therapeutic product is intended to treat a serious or life-threatening condition for which no satisfactory available therapy exists or when the labelling of an approved product needs to be revised to address a serious safety issue), however, the FDA may approve a therapeutic product without the prior or contemporaneous marketing authorization of a companion diagnostic. In this case, approval of a companion diagnostic may be a post-marketing requirement or commitment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Co-development of companion diagnostics and therapeutic products is critical to the advancement of precision medicine. Whether initiated at the outset of development or at a later point, co-development should generally be conducted in a way that will facilitate obtaining contemporaneous marketing authorizations for the therapeutic product and the associated companion diagnostic. If a companion diagnostic is required to identify patients who are most likely to benefit from receiving the product, to be at increased risk for serious adverse events as a result of treatment with a particular therapeutic product, or to monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness, then the FDA has required marketing approval of all companion diagnostic tests essential for the safe and effective use of a therapeutic product for cancer therapies. Various foreign regulatory authorities also regulate <i style="font-style:italic;">in vitro</i> companion diagnostics as medical devices and, under those regulatory frameworks, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any future diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization in those countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genomic alteration or mutation alteration that the companion diagnostic was developed to detect. If the FDA, EMA or a comparable regulatory authority requires clearance or approval of a companion diagnostic for any of our product candidates, whether before, concurrently with approval, or post-approval of the product candidate, we, and/or future collaborators, may encounter difficulties in developing and obtaining clearance or approval for these companion diagnostics. The process of obtaining or creating such companion diagnostics is time consuming and costly. The FDA previously has required <i style="font-style:italic;">in vitro</i> companion diagnostics intended to select the patients who will respond to a product candidate to obtain PMA, simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of pre-clinical and clinical data and the submission </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and review by the FDA, can take several&#160;years or longer. It involves a rigorous pre-market review during which the sponsor must prepare and provide FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse event reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is possible that an <i style="font-style:italic;">in vitro</i> companion diagnostic device could be subject to FDA enforcement discretion from compliance with the FDCA if it meets the definition of a Laboratory Developed Test (&#8220;LDT&#8221;). However, FDA issued a final rule&#160;in April&#160;2024 to end enforcement discretion for LDTs and actively regulate such products as medical devices. Under this final rule, LDTs are required to come into compliance with FDA&#8217;s medical device regulatory requirements in a staged approach over the course of four&#160;years. The implementation of this LDT final rule&#160;could potentially be affected by the Executive Order, Regulatory Freeze Pending Review, issued by President Trump on January&#160;20, 2025 and/or the anticipated change in leadership at FDA under the new administration. Further, while the final regulation is set to take effect on May&#160;6, 2025, a number of parties have challenged the legality of the LDT regulation in a federal district court. That court held a hearing on this matter on February&#160;19, 2025, and is expected to issue a ruling soon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any delay or failure by us or third-party collaborators to develop or obtain regulatory clearance or approval of a companion diagnostic could delay or prevent approval or continued marketing of our related product candidates. Further, in April&#160;2020, the FDA issued new guidance on developing and labeling companion diagnostics for a specific group of oncology therapeutic products, including recommendations to support a broader labeling claim rather than individual therapeutic products. We will continue to evaluate the impact of this guidance on our companion diagnostic development and strategy. This guidance and future issuances from the FDA, EMA and other regulatory authorities may impact our development of a companion diagnostic for our product candidates and could result in delays in regulatory clearance or approval or a change in the determination for whether or not a companion diagnostic is still required for our product candidates. We may be required to conduct additional studies to support a broader claim or more narrowed claim for a subset population. Also, to the extent other approved diagnostics are able to broaden their labeling claims to include any of our future approved product candidates covered indications, we may no longer need to continue our companion diagnostic development plans or we may need to alter those companion diagnostic development strategies, which could adversely impact our ability to generate revenue from the sale of our companion diagnostic test.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we may rely on third parties for the design, development and manufacture of companion diagnostic tests for our product candidates. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining clearance or approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory clearance or approval processes. Moreover, even if data from pre-clinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory clearance or approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our product candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected, our product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of our product candidates that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the co-development or commercialization of our companion diagnostic and therapeutic product candidates.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to civil, criminal and administrative sanctions, contractual damages, reputational harm and diminished future profits and earnings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any drugs for which we obtain marketing approval. Our future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable state and federal fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. These include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Anti-Kickback Statute&#160;- </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchasing, ordering, leasing, arranging for, or recommending the purchasing, ordering, or leasing of, any good or service for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">FCA&#160;-</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> the federal civil and criminal false claims laws, including the civil FCA, and Civil Monetary Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, false or fraudulent claims for payment or knowingly making, using or causing to made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;)&#160;-</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> the federal HIPAA, which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters, and apply regardless of the payor (e.g., public or private);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">HIPAA and Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;)-</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> HIPAA, as amended by HITECH, and their implementing regulations, which impose obligations on HIPAA covered entities and their business associates, including mandatory contractual terms and required implementation of administrative, physical and technical safeguards to maintain the privacy and security of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Transparency Requirements&#160;-</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> the federal physician transparency requirements known as the Physician Payments Sunshine Act, under the ACA, as amended by the Health Care Education Reconciliation Act, which requires manufacturers of drugs, medical devices, biological and medical supplies covered by Medicare, Medicaid, or State Children&#8217;s Health Insurance Program to report annually to the CMS, within the HHS information related to payments and other transfers of value made by that entity to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Analogous State, Local and Foreign Laws&#160;-</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> analogous state, local and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader than similar federal laws, can apply to claims involving healthcare items or services regardless of payor, and are enforced by many different federal and state agencies as well as through private actions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, as well as tracking and reporting of transfers of value by pharmaceutical manufacturers to physicians and healthcare organizations, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and/or administrative penalties, damages, fines, individual imprisonment, disgorgement, exclusion </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Current and future legislation may increase the difficulty and cost for us and any of our collaborators to obtain marketing approval of and commercialize product candidates and affect the prices we, or any of our collaborators, may obtain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, impact pricing and reimbursement and affect our ability, or the ability of any of our collaborators, to profitably sell or commercialize any product candidates for which we, or any of our collaborators, obtain marketing approval. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by legislative initiatives. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any of our collaborators, may receive for any FDA approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the &#8220;MMA&#8221;) changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for prescription drugs purchased through a pharmacy by the elderly and disabled and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this statute provides authority for limiting the number of drugs that will be covered in any therapeutic class, subject to certain exceptions. Cost reduction initiatives and other provisions of this statute could decrease the coverage and price that we receive for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2010, then-President Obama signed into law the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August&#160;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to two&#160;percent per fiscal&#160;year, which went into effect in April&#160;2013 and will remain in effect through 2031 under the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. Under current legislation, the actual reductions in Medicare payments may vary up to four&#160;percent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Consolidated Appropriations Act (the &#8220;Appropriations Act&#8221;) which was signed into law by President Biden in December&#160;2022, made several changes to sequestration of the Medicare program. Section&#160;1001 of the Appropriations Act delays the four&#160;percent Statutory Pay-As-You-Go Act of 2010 sequester for two&#160;years, through the end of calendar&#160;year 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the four&#160;percent cut to the Medicare program would have taken effect in January&#160;2023. The Appropriation Act&#8217;s health care offset title includes Section&#160;4163, which extends the two&#160;percent Budget Control Act of 2011 Medicare sequester for six&#160;months into fiscal&#160;year 2032 and lowers the payment reduction&#160;percentages in fiscal&#160;years 2030 and 2031.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Further, with passage of the Inflation Reduction Act (the &#8220;IRA&#8221;) Congress extended the expansion of the Affordable Care Act premium tax credits through 2025. Those subsidies were originally extended through 2022 under the American Rescue Plan Act of </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2021. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since enactment of the ACA, there have been and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;), Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, in June&#160;2021, the U.S. Supreme Court dismissed a lawsuit challenging the constitutionality of the ACA after finding that the plaintiffs do not have standing to bring the litigation. Shortly after taking office in January&#160;2025, President Trump revoked numerous executive orders issued by President Biden, including at least two executive orders which where were designed to further implement the ACA. We anticipate similar efforts to undermine the ACA, and the accompanying uncertainty, for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, the recent election of President Trump, coupled with a consolidation of party control of both chambers of the U.S. Congress, has led to new legislative and regulatory initiatives in the United States and the roll-back of many initiatives of the previous presidential administration, which may impact our business in unpredictable ways. Market uncertainty and volatility have been magnified and may intensify due to the statements and actions of the new U.S. presidential administration and resulting uncertainties regarding actual and potential shifts in U.S. and foreign, trade, economic and other policies, including with respect to treaties and tariffs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EU, on December&#160;13, 2021, Regulation No 2021/2282 on Health Technology Assessment (&#8220;HTA&#8221;) amending Directive 2011/24/EU, was adopted. While the Regulation entered into force in January&#160;2022, it will only begin to apply from January&#160;2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the products concerned. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products as well as certain high-risk medical devices, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to scrutiny and considerable legislative and executive actions that could impact the prices we obtain for our drug products, if and when approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States and foreign jurisdictions. There have been several U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, in October&#160;2020, the HHS and the FDA published a final rule&#160;allowing states and other entities to develop a Section&#160;804 Importation Program (&#8220;SIP&#8221;) to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America (&#8220;PhRMA&#8221;) but the case was dismissed by a federal district court in February&#160;2023 after the court found that PhRMA did not have standing to sue the HHS. Several states have passed laws allowing for the importation of drugs from Canada and a few states have passed legislation establishing workgroups to examine the impact of the state importation program. Several states have submitted Section 804 Importation Program (&#8220; SIP&#8221;) </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">proposals to the FDA. On January&#160;5, 2024, the FDA approved Florida&#8217;s plan for Canadian drug importation. That state now has authority to import certain drugs from Canada for a period of two&#160;years once certain conditions are met. Florida will first need to submit a pre-import request for each drug selected for importation, which must be approved by the FDA. Florida will also need to relabel the drugs and perform quality testing of the products to meet FDA standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, on November&#160;20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule&#160;also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed, and recent legislation imposed a moratorium on implementation of the rule&#160;until January&#160;1, 2026. The IRA further delayed implementation of this rule&#160;to January&#160;1, 2032.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The IRA has implications for Medicare Part&#160;D, which is a program available to individuals who are entitled to Medicare Part&#160;A or enrolled in Medicare Part&#160;B to give them the option of paying a&#160;monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare beginning in 2026, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part&#160;B and Medicare Part&#160;D to penalize price increases that outpace inflation; and replaces the Part&#160;D coverage gap discount program with a new discounting program beginning in 2025. The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part&#160;B and Part&#160;D. CMS may negotiate prices for 10 high-cost drugs paid for by Medicare Part&#160;D starting in 2026, followed by 15 Part&#160;D drugs in 2027, 15 Part&#160;B or Part&#160;D drugs in 2028, and 20 Part&#160;B or Part&#160;D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least 9&#160;years and biologics that have been licensed for 13&#160;years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023. On August&#160;15, 2024, HHS published the results of the first Medicare drug price negotiations for 10 selected drugs that treat a range of conditions. The prices of these 10 drugs will become effective January&#160;1, 2026. In January&#160;2025, CMS announced the selection of up to 15 additional drugs covered by Part&#160;D for the second cycle of negotiations. This second cycle of negotiations with participating drug companies will occur during 2025, and any negotiated prices for this second set of drugs will be effective starting January&#160;1, 2027. CMS issued a public statement on January&#160;29, 2025, declaring that lowering the cost of prescription drugs is a top priority of the new administration and CMS is committed to considering opportunities to bring greater transparency in the negotiation program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. In addition, the IRA established inflation rebate programs under Medicare Part&#160;B and Part&#160;D. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part&#160;D whose price increases exceed inflation. On December&#160;9, 2024, with issuance of its 2025 Physician Fee Schedule final regulation, CMS finalized its rules&#160;governing the IRA inflation rebate programs. The new law also caps Medicare out-of-pocket drug costs at an estimated $24,000 a&#160;year beginning in 2025. In addition, the IRA potentially raises legal risks with respect to individuals participating in a Medicare Part&#160;D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual coverage limit before they reached the higher threshold, or &#8220;catastrophic period&#8221; of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100.0% of the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and price caps on annual out-of-pocket expenses, each of which could have potential pricing and reporting implications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On June&#160;6, 2023, Merck&#160;&amp; Co. filed a lawsuit against the HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce and certain, also filed lawsuits in various courts </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with similar constitutional claims against the HHS and CMS.&#160;HHS has generally won the substantive disputes in these cases, and various federal district court judges have expressed skepticism regarding the merits of the legal arguments being pursued by the pharmaceutical industry. Certain of these cases are now on appeal and, on October&#160;30, 2024, the Court of Appeals for the Third Circuit heard oral argument in three of these cases. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. This is increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In other countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we, or our collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our drug to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations are subject to anti-corruption laws, including the Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;) the U.K. Bribery Act 2010 (the &#8220;Bribery Act&#8221;), and other anti-corruption laws that apply in countries where we do business and may do business in the future. The FCPA, the Bribery Act, and these other laws generally prohibit us, our officers and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA or Bribery Act violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA, the Bribery Act, or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States, United Kingdom, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations (collectively, the &#8220;Trade Control Laws&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act, or other legal requirements, including Trade Control Laws. If we are not in compliance with the FCPA, the Bribery Act, and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have a material adverse impact on our business, financial condition, results of operations and liquidity. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Likewise, any investigation of any potential violations of the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FCPA, the Bribery Act, other anti-corruption laws or Trade Control Laws by the United States, the United Kingdom or other authorities could also have an adverse impact on our reputation, business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February&#160;10, 2025, President Trump issued an executive order directing the Attorney General to review the guidelines and policies governing FCPA investigations and enforcement actions. Per the executive order, this review will result in new DOJ FCPA guidelines intended to enhance American economic competitiveness and to safeguard national security interests. During the 180-day review period, any new FCPA investigations and enforcement actions are to be suspended absent authorization from the Attorney General, and all existing FCPA investigations and enforcement actions will be reviewed. Additionally, after the Attorney General issues revised guidelines, the executive order directs the Attorney General to assess whether &#8220;remedial measures&#8221; related to past FCPA actions are warranted. We will need to carefully monitor the implementation of this order.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, the European Union and the United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in an enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future. In recent&#160;months, the Office of Civil Rights at HHS (&#8220;OCR&#8221;) has been especially active in enforcing the HIPAA rules. Additionally, OCR is looking to amend the HIPAA Security Rule, which (if and when finalized) could create additional compliance obligations and risk for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. The HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to potential enforcement by the HHS, we are also potentially subject to privacy enforcement from the FTC. The FTC has been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be &#8220;unfair&#8221; under Section&#160;5 of 15 U.S.C &#167; 45(a)&#160;(the &#8220;FTC Act&#8221;), as well as the types of activities it views to trigger the Health Breach Notification Rule&#160;(which the FTC also has the authority to enforce). The agency is also in the process of developing rules&#160;related to commercial surveillance and data security that may impact our business. We will need to account for the FTC&#8217;s evolving rules&#160;and guidance for proper privacy and data security practices in order to mitigate our risk for a potential enforcement action, which may be costly. If we are subject to a potential FTC enforcement action, we may be subject to a settlement order that requires us to adhere to very specific privacy and data security practices, which may impact our business. We may also be required to pay fines as part of a settlement (depending on the nature of the alleged violations). If we violate any consent order that we reach with the FTC, we may be subject to additional fines and compliance requirements. Finally, both the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FTC and HHS&#8217;s enforcement priorities (as well as those of other federal regulators) may be impacted by the change in administration and new leadership. These shifts in enforcement priorities may also impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are also increased restrictions at the federal level relating to transferring sensitive data outside of the United States to certain foreign countries. For example, in 2024, Congress passed H.B. 815, which included the Protecting Americans&#8217; Data from Foreign Adversaries Act of 2024. This law creates certain restrictions for entities that disclose sensitive data (including potential health data) to countries such as China. Failure to comply with these rules&#160;can lead to a potential FTC enforcement action. Additionally, the DOJ recently finalized a rule&#160;implementing Executive Order 14117, which creates similar restrictions related to the transfer of sensitive U.S. data to countries such as China. These data transfer restrictions (and others that may pass in the future) may create operational challenges and legal risks for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">States are also active in creating specific rules&#160;relating to the processing of personal information. In 2018, California passed into law the California Consumer Privacy Act (the &#8220;CCPA&#8221;), which took effect on January&#160;1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the EU General Data Protection Regulation 2016/679 (&#8220;EU GDPR&#8221;) and the EU GDPR as incorporated into the laws of the United Kingdom (&#8220;UK GDPR,&#8221; together with the EU GDPR, &#8220;GDPR&#8221;) including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November&#160;2020, California voters passed a ballot initiative for the CPRA, which will significantly expand the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. Most CPRA provisions took effect on January&#160;1, 2023, though the obligations apply to any personal information collected after January&#160;1, 2022. These provisions may apply to some of our business activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to California, a number of states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime over the next few&#160;years. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering or have already passed comprehensive privacy laws during the 2025 legislative sessions. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Health My Data Act in 2023 which specifically regulated health information that is not otherwise regulated by the HIPAA rules, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation in 2025. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Plaintiffs&#8217; lawyers in the United States are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act. The rise in these types of lawsuits creates potential risk for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, laws in all 50 states require businesses to provide notice to customers whose personal information has been disclosed as a result of a data breach. These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, states have been frequently amending existing laws, requiring attention to changing regulatory requirements. We also may be contractually required to notify affected individuals or other counterparties of a security breach, incident, or compromise. Although we may have contractual protections with our vendors, any actual or perceived security breach, incident, or compromise could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data security and in responding to any such actual or perceived breach, incident, or compromise. Any contractual protections we may have from our vendors may not be sufficient to adequately protect us from any such liabilities and losses, and we may be unable to enforce any such contractual protections. In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA and the processing of personal data that takes place in the EEA, is regulated by the GDPR, which went into effect in May&#160;2018 and which imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to &#163;20.0 million or up to four&#160;percent of the total worldwide annual turnover of the preceding financial&#160;year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GDPR places restrictions on the cross-border transfer of personal data from the European Union to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the European Union to other countries. In July&#160;2020, the Court of Justice of the EU (the &#8220;CJEU&#8221;) invalidated the European Union-United States Privacy Shield (&#8220;Privacy Shield&#8221;) one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States. While we are not self-certified under the Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the United States, generally, and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the CJEU decision, in October&#160;2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The European Union initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December&#160;2022, and the European Commission adopted the adequacy decision in July&#160;2023. The adequacy decision permits U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the European Union to the United States. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the standard contractual clauses and other data transfer mechanisms. The uncertainty around this issue has the potential to impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;23, 2016, the electorate in the United Kingdom. voted in favor of leaving the European Union, commonly referred to as Brexit. As with other issues related to Brexit, there are open questions about how personal data will be protected in the United Kingdom. and whether personal information can transfer from the European Union to the United Kingdom. Following the withdrawal of the United Kingdom from the European Union, the UK Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. While the Data Protection Act of 2018 in the United Kingdom that &#8220;implements&#8221; and complements the GDPR has achieved Royal Assent on May&#160;23, 2018 and is now effective in the United Kingdom, it is unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under the GDPR, although these transfers currently are permitted by an adequacy decision from the European Commission. The United Kingdom government has already determined that it considers all European Union 27 and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom. to the EU/EEA remain unaffected. In addition, a recent decision from the European Commission appears to deem the United Kingdom. as being &#8220;essentially adequate&#8221; for purposes of data transfer from the European Union to the United Kingdom., although this decision may be re-evaluated in the future. The United Kingdom. and the United States. have also agreed to a U.S.-UK &#8220;Data Bridge,&#8221; which functions similarly to the EU-U.S. Data Privacy Framework and provides an additional legal mechanism for companies to transfer data from the United Kingdom to the United States. In addition to the United Kingdom., Switzerland is also in the process of approving an adequacy decision in relation to the Swiss-U.S. Data Privacy Framework (which would function similarly to the EU-U.S. Data Privacy Framework and the U.S.-UK Data Bridge in relation to data transfers from Switzerland to the United States). Any changes or updates to these developments have the potential to impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules&#160;may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our employees, independent contractors, consultants, collaborators and vendors engage in misconduct or other improper activities, including non-compliance with regulatory standards and/or requirements and insider trading, we could sustain significant liability and harm to our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, consultants, collaborators and vendors. Misconduct by these partners could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state laws, and requirements of foreign jurisdictions, including the GDPR. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter employee or third-party misconduct, and the precautions that we take to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we or any third-party manufacturer we engage now or in the future fails to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could significantly harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We and third-party manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Although we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We maintain general liability insurance as well as workers&#8217; compensation insurance to cover costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Employee Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our internal computer systems, or those of our collaborators, vendors, suppliers, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our internal computer systems and those of any of our collaborators, vendors, suppliers, contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or email fraud to cause payments or information to be transmitted to an unintended recipient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we experience any material system failure, accident, cyber-attack or security that causes interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, independent contractors, including principal investigators, consultants and vendors and any third parties we may engage in connection with discovery programs, research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, including principal investigators, consultants and vendors and any other third parties we engage. Misconduct by these parties could include intentional, reckless or negligent conduct or unauthorized activities that include failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide complete and accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state data privacy, security, fraud and other healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report complete financial information or data accurately or disclose unauthorized activities to us. Misconduct by employees and other third parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the EU Data Protection Directive. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Risks Related to the Ownership of Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price of our common stock is volatile, and the market price of our common stock may drop in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The market price of our common stock has been and could be subject to significant fluctuations. Some of the factors that may cause the market price of our common stock to fluctuate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully consummate the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully implement our cash preservation plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our determination to pause research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to conduct an orderly wind down of our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if we were to resume our historical research and development activities, results of clinical trials and pre-clinical studies of our product candidates, or those of our collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical trials and pre-clinical studies of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed financial and development projections we may provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed the financial and development projections of the investment community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of qualified scientific and management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or stockholder litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general market or macroeconomic conditions or market conditions in the biopharmaceutical sector;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of securities by us or our stockholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if we fail to raise an adequate amount of capital to fund our operations and continued development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements with respect to compliance with the Nasdaq listing requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse publicity relating to product candidates, including with respect to other products in such markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of technological innovations or new therapies that compete with our products and services; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">period-to-period fluctuations in our financial results.</span></td></tr></table><div style="margin-top:10pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The price of our shares of common stock may experience increased volatility as we provide updates regarding our cash preservation plan, the Merger and the wind down of our historical operations. For additional discussion of the risks related to our evaluation of strategic alternatives and the wind down of our operations, see &#8220;<i style="font-style:italic;">Risk Factors&#160;- Risks Related to Our Evaluation of the Merger and Strategic Alternatives</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased stockholder activism if we experience a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We incur significant legal, accounting and other expenses as a public company that we did not incur as a private company, including costs associated with public company reporting obligations under the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Some of our management team has not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that we comply with all of these requirements. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules&#160;and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not currently meet the requirements for continued listing on the Nasdaq Capital Market. If we fail to meet the requirements for continued listing on the Nasdaq Capital Market, trading in our common stock could be suspended and our common stock delisted from Nasdaq, which would have a negative effect on the price of our common stock and our ability to raise additional capital.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our common stock is currently listed on the Nasdaq Capital Market. We are currently not in compliance with the Nasdaq Capital Market listing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;10, 2024, we received written notice from the Nasdaq Listing Qualifications Department, indicating that we no longer satisfied Nasdaq Listing Rule&#160;5450(b)(2)(A), which required us to maintain a minimum market value of listed securities of $50.0 million (the &#8220;MVLS Rule&#8221;) for continued listing on the Nasdaq Global Market. In accordance with the Nasdaq Listing Rule&#160;5810(c)(3)&#160;(the &#8220;Grace Period Rule&#8221;) Nasdaq granted us 180 calendar&#160;days, or until April&#160;8, 2025, to regain compliance with the MVLS Rule. We did not regain compliance with the MVLS Rule&#160;by April&#160;8, 2025, and accordingly, on April&#160;10, 2025, Nasdaq notified us that our securities were subject to delisting from Nasdaq unless we timely requested a hearing before the Panel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also, on April&#160;10, 2025, Nasdaq notified us that we no longer satisfied Nasdaq Listing Rule&#160;5450(b)(2)(C), which required us to maintain a minimum market value of publicly held shares of $15.0 million (the &#8220;MVPHS Rule&#8221;) for continued listing on the Nasdaq Global Market. In accordance with the Grace Period Rule, Nasdaq provided us 180 calendar&#160;days, or until October&#160;7, 2025, to regain compliance with the MVPHS Rule. Additionally, on January&#160;6, 2025, Nasdaq notified us that we no longer satisfied Nasdaq Listing Rule&#160;5450(a)(1), which required us to maintain a minimum bid price of $1.00 per share (the &#8220;Bid Price Rule&#8221;) for continued listing on the Nasdaq Global Market. In accordance with the Grace Period Rule, Nasdaq provided us 180 calendar&#160;days, or until July&#160;7, 2025, to regain compliance with the Bid Price Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Following a timely request for a hearing, we presented to the Panel our plan to achieve compliance with applicable Nasdaq listing criteria and requested an extension of time to do so. As previously disclosed, on June&#160;10, 2025, Nasdaq notified us that the Panel determined to grant our request for an exception to, and an extension of time to comply with, Nasdaq listing standards. As part of this determination, the Panel directed that our listing be transferred to the Nasdaq Capital Market, effective as of the open of business on June&#160;12, 2025, and specified additional conditions for our listing on the Nasdaq Capital Market. The extension of time is subject to us </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">demonstrating compliance with Nasdaq Listing Rule&#160;5550(a)(2)&#160;by evidencing a closing bid price of $1.00 or more per share for a minimum of 10 consecutive trading sessions (the &#8220;Capital Market Minimum Bid Price&#8221;) completing a strategic transaction and otherwise demonstrating compliance with all initial listing requirements for the Nasdaq Capital Market, in each case on or before the Nasdaq Compliance Date. The extension of time is further subject to us meeting an interim milestone for a strategic transaction in connection with our ongoing strategic process. The Panel has the right to reconsider its determination based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make continued listing of our securities inadvisable or unwarranted. The Panel does not have discretion to grant continued listing for noncompliance with Nasdaq listing standards beyond the Nasdaq Compliance Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are scheduled to hold a separate special meeting of our stockholders on August&#160;5, 2025 to approve an amendment to our certificate of incorporation to effect a reverse stock split of our common stock, at a ratio of not less than 1-for-10 and not greater than 1-for-50, with the ratio within such range to be determined at the discretion of our board of directors, without further approval or authorization of our stockholders. One of the purposes of the contemplated reverse stock split is to increase the per-share market price of our common stock so as to demonstrate compliance with the Capital Market Minimum Bid Price and help us avoid delisting of our common stock from Nasdaq, subject to compliance with other continued listing rules. Another purpose of the contemplated reverse stock split is to help us meet the minimum closing price requirement for filing an initial listing application in connection with the closing of the Merger. It cannot be assured, however, that the contemplated reverse stock split will accomplish these objectives at all or for any meaningful period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot assure you that we will not be delisted from Nasdaq. The delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and would also make it more difficult for our stockholders to sell or purchase our common stock when they wish to do so. If delisted, we will likely trade on the OTC Markets system, which could make it more difficult to dispose of, or obtain accurate quotations for the price of, our common stock, and may lead to a reduction in coverage by securities analysts and the news media, which could cause the price of our common stock to decline further.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The contemplated reverse stock split may not increase our stock price over the long-term.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">One of the purposes of the contemplated reverse stock split is to increase the per-share market price of our common stock so as to demonstrate compliance with the Capital Market Minimum Bid Price and help us avoid delisting of our common stock from Nasdaq, subject to compliance with other continued listing rules. Another purpose of the contemplated reverse stock split is to help us meet the minimum closing price requirement for filing an initial listing application in connection with the closing of the Merger. It cannot be assured, however, that the contemplated reverse stock split will accomplish these objectives at all or for any meaningful period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While it is expected that the reduction in the number of outstanding shares of our common stock will proportionally increase the per-share market price of our common stock, it cannot be assured that the contemplated reverse stock split will increase the per-share market price of our common stock by a multiple of the contemplated reverse stock split ratio, or result in any permanent or sustained increase in the per-share market price of our common stock, which is dependent upon many factors, including business and financial performance, general economic, market and industry conditions and prospects for future success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The contemplated reverse stock split may decrease the liquidity of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The liquidity of our common stock may be negatively impacted by the contemplated reverse stock split, given the reduced number of shares that would be outstanding after the reverse stock split, particularly if the per-share market price does not increase as a result of the reverse stock split. For instance, if the reverse stock split is implemented, it may result in some stockholders owning &#8220;odd lots&#8221; (less than 100 shares) of common stock. Odd lot shares may be more difficult to sell, and brokerage commissions and other costs of transactions in odd lots may be higher than the costs of transactions in &#8220;round lots&#8221; of even multiples of 100 shares. If we effect the reverse stock split, the resulting per-share price may nevertheless fail to attract institutional investors and may not satisfy the investing guidelines of such investors and, consequently, the trading liquidity of our common stock may not improve. Accordingly, the reverse stock split may not increase marketability of our common stock.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If a significant portion of our total outstanding shares are sold into the market, the market price of our common stock could drop significantly, even if our business is doing well.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Certain of our stockholders have rights, subject to specified conditions, under our resale registration statement on Form&#160;S-3 registering 3,730,608 shares of our common stock under which they may sell their shares of common stock in the public market, so long as the resale registration statement on Form&#160;S-3 remains effective. We have also filed registrations statement registering all shares of common stock that we may issue under our equity compensation plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, we are also party to the Sale Agreement with Jefferies, as sales agent, pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $100.0 million from time to time through Jefferies under an &#8220;at-the-market offering&#8221; program (&#8220;ATM&#8221;). The number of shares that are sold by Jefferies after we request that sales be made will fluctuate based on the market price of our common stock during the sales period and limits we set with Jefferies. Therefore, it is not possible to predict the number of shares that will ultimately be issued by us, if any, pursuant to the sales agreement. As of March&#160;31, 2025, we have sold 1,362,917 shares of our common stock under the ATM for net proceeds of $3.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If at some point we are no longer a &#8220;smaller reporting company&#8221; or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will be subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as defined in Item&#160;10(f)(1)&#160;of Regulation S-K, we may take advantage of certain exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2022 and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. If at some point we are no longer qualified as a smaller reporting company or otherwise no longer qualify for these exemptions, we will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If we are not able to comply with the requirements in a timely manner or at all, our financial condition or the market price of our common stock may be harmed. For example, if we or our independent auditor identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, then we could face additional costs to remedy those deficiencies, the market price of our stock could decline or we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our executive officers, directors and principal stockholders may have the ability to significantly influence all matters submitted to our stockholders for approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June&#160;30, 2025, our executive officers, directors and principal stockholders, in the aggregate, beneficially owned 38.72% of our outstanding shares of common stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of the Company on terms that other stockholders may desire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have broad discretion in the use of our cash and cash equivalents and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have broad discretion over the use of our cash and cash equivalents and have adopted a cash preservation plan. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. Our failure to apply these resources effectively could compromise our ability to pursue our growth strategy and we may not be able to yield a significant return, if any, on our investment of these net proceeds. You do not have the opportunity to influence our decisions on how to use our cash resources.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Risks Related to OrthoCellix</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Risks Related to OrthoCellix&#8217;s Limited Operating History, Financial Position and Capital Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix is a Phase 3 biotechnology company with a limited operating history on which to assess its business; and has no products approved for commercial sale, which may make it difficult for you to evaluate its current business and likelihood of success and viability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">OrthoCellix is a wholly owned subsidiary of Ocugen and is a Phase 3 clinical stage biotechnology company with limited operating history. Since its inception in February&#160;2025, it has incurred operating losses with no corresponding revenue and has utilized substantially all of its resources. While OrthoCellix has an FDA endorsed Phase 3 registration enabling clinical trial design, OrthoCellix has not yet initiated the pivotal trial and has not yet demonstrated an ability to obtain regulatory approvals, manufacture a clinical or commercial-scale product or arrange for a third party to do so on its behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about OrthoCellix&#8217;s future success or viability may not be as accurate as they could be if OrthoCellix had a longer operating history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, as OrthoCellix&#8217;s business grows, it may encounter unforeseen expenses, restrictions, difficulties, complications, delays and other known and unknown factors. OrthoCellix will need to transition at some point from a company with a focus on supporting clinical trials and eventually transition to supporting commercial activities. OrthoCellix may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if the Merger and the anticipated Concurrent Financing are successful, OrthoCellix will require substantial additional capital to finance its operations in the future, which raises substantial doubt about its ability to continue as a going concern. If OrthoCellix is unable to raise such capital when needed, or on acceptable terms, OrthoCellix may be forced to delay, reduce and/or eliminate one or more of its development programs or future commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Developing biotechnology products is a very long, time-consuming, expensive and uncertain process that takes&#160;years to complete. OrthoCellix expects its expenses to increase in connection with its ongoing activities, particularly as OrthoCellix conducts the planned Phase 3 pivotal clinical trial and seeks regulatory approval for NeoCart. OrthoCellix may elect to advance future programs and product candidates, which will require additional financing. Even if one or more of the programs that OrthoCellix develops is approved for commercial sale, OrthoCellix may incur significant costs associated with sales, marketing, manufacturing and distribution activities to launch any such product, if OrthoCellix elects to commercialize on its own. OrthoCellix&#8217;s expenses could increase beyond expectations if it is required by the FDA or other regulatory agencies to perform other clinical trials in addition to the planned NeoCart Phase 3 clinical trial. Because the outcome of OrthoCellix&#8217;s planned Phase 3 clinical trial is not guaranteed, it cannot reasonably estimate the actual amount of funding that will be necessary to commercialize NeoCart. OrthoCellix&#8217;s future capital requirements depend on many factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, and results of the Phase 3 NeoCart trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining, defending and enforcing OrthoCellix&#8217;s intellectual property and proprietary rights, and defending intellectual property-related claims, including claims of infringement, misappropriation or other violations of third-party intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of the regulatory review of OrthoCellix&#8217;s product candidates and obtaining the requisite regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of OrthoCellix&#8217;s future commercialization activities, either by itself or in collaboration with others, including product sales, marketing, manufacturing, and distribution for any product candidate for which OrthoCellix receives regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of product candidates for which OrthoCellix receives regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of OrthoCellix&#8217;s future collaborations and any future license agreements OrthoCellix enters into;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s ability to establish and maintain collaborations on favorable terms, if at all;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which OrthoCellix acquires or in-licenses products, intellectual property and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operational, financial and management information systems and associated personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, OrthoCellix will require substantial additional funding to continue its operations. As of March&#160;31, 2025, OrthoCellix had no cash. Even if the Merger and the anticipated Concurrent Financing are successful, OrthoCellix will still need to raise additional capital to continue to fund its operations in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix has concluded there is substantial doubt about its ability to continue as a going concern for at least 12 months from the issuance date of OrthoCellix&#8217;s combined financial statements for the three months ended March 31, 2025. In light of these concerns, OrthoCellix&#8217;s independent registered public accounting firm included in its opinion on the financial statements as of and for the years ending December 31, 2024 and 2023 an explanatory paragraph expressing substantial doubt about the NeoCart Business of Ocugen&#8217;s ability to continue as a going concern beyond 12 months from the date its combined financial statements were issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix may be required to seek additional funds sooner than planned through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, and adequate additional financing may not be available to it on acceptable terms, or at all. Such financing may dilute OrthoCellix&#8217;s sole stockholder or the failure to obtain such financing may restrict its operating activities. Any additional fundraising efforts may divert OrthoCellix&#8217;s management from their day-to-day activities, which may adversely affect its business. To the extent that OrthoCellix raises additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences and anti-dilution protections that adversely affect your rights as a stockholder. Debt financing may result in the imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect OrthoCellix&#8217;s business. If OrthoCellix raises additional funds through upfront payments or milestone payments pursuant to current or future collaborations with third parties, OrthoCellix may have to relinquish valuable rights to its product candidates, or grant licenses on terms that are not favorable to it. OrthoCellix&#8217;s ability to raise additional capital may be adversely impacted by global macroeconomic conditions and volatility in the credit and financial markets in the United States and worldwide. OrthoCellix&#8217;s failure to raise capital as and when needed or on acceptable terms would have a negative impact on its financial condition and its ability to pursue its business strategy, and OrthoCellix may have to delay, reduce the scope of, suspend or eliminate one or more of its product candidates, clinical trials or future commercialization efforts or cease its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix expects to incur losses for the foreseeable future, at least until conclusion of the Phase 3 pivotal trial of NeoCart and may not be able to achieve or sustain profitability in the future. OrthoCellix has no products approved for sale, has not generated any revenue from its product candidate and any future product candidates and may never generate revenue or become profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Investment in biotechnology product development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant risks that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. OrthoCellix expects to incur losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. OrthoCellix does not expect to generate product revenue unless or until it successfully completes its planned Phase 3 NeoCart clinical trial and obtains regulatory approval of, and then successfully commercializes its lead product candidate. OrthoCellix may not succeed in these activities and, even if it does, may not generate revenues that are significant or large enough to achieve profitability. If OrthoCellix is unable to raise sufficient additional capital to advance a product candidate to commercialization or generate sufficient revenue through the sale of any approved products, OrthoCellix may be unable to continue operations without additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NeoCart Business of Ocugen generated net losses of&#8201;$1,026 and $2,081 for the years ended December 31, 2024 and 2023, respectively. The NeoCart Business of Ocugen expects to continue to incur significant expenses for the foreseeable future. OrthoCellix&#8217;s operating expenses and net losses may fluctuate significantly from quarter to quarter and&#160;year to&#160;year. OrthoCellix anticipates that its expenses will increase substantially if and as it:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advances its existing and future product candidates through preclinical and clinical development, including potential expansion into additional indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks to identify additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains, expands, enforces, defends and protects its intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks, obtains and maintains regulatory and regulatory approvals for its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks to identify, establish and maintain additional collaborations and license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ultimately establishes a sales, marketing and distribution infrastructure to commercialize any drug products for which OrthoCellix may obtain regulatory approval, either by itself or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">generates revenue from commercial sales of product candidates for which OrthoCellix receives regulatory approval, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hires additional personnel including research and development, clinical and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adds operational, financial and management information systems and personnel, including personnel to support its product development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquires or in-licenses products, intellectual property and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishes clinical and commercial-scale cGMP capabilities through a third-party or its own manufacturing facility; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operates as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, OrthoCellix&#8217;s expenses will increase if, among other things, it is required by the FDA or other regulatory authorities to perform clinical trials or studies in addition to, or different than, those that OrthoCellix currently anticipates, there are any delays in completing its clinical trials or the development of any of its product candidates, or there are any third-party challenges to OrthoCellix&#8217;s intellectual property or OrthoCellix needs to defend against any intellectual property-related claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if OrthoCellix obtains regulatory approval for, and is successful in commercializing, one or more of its product candidates, OrthoCellix expects to incur substantial additional research and development and other expenditures to develop and market additional product candidates and/or to expand the approved indications of any marketed product. OrthoCellix may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect its business. The size of OrthoCellix&#8217;s future net losses will depend, in part, on the rate of future growth of its expenses and its ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s failure to become profitable would decrease OrthoCellix&#8217;s value and could impair its ability to raise capital, maintain its research and development efforts, expand its business and/or continue its operations. A decline in OrthoCellix&#8217;s value of could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to OrthoCellix&#8217;s Development of NeoCart</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix is substantially dependent on the success of NeoCart.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s future success is substantially dependent on its ability to timely obtain regulatory approval for, and then successfully commercialize, NeoCart, as its lead product candidate. NeoCart will require additional clinical development, evaluation of clinical and manufacturing activities, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before OrthoCellix generates any revenues from product sales. OrthoCellix is not permitted to market or promote NeoCart before it receives regulatory approval from the FDA and comparable foreign regulatory authorities, and OrthoCellix may never receive such regulatory approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The success of NeoCart will depend on a variety of factors. OrthoCellix does not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to OrthoCellix&#8217;s intellectual property rights, potential threats from the intellectual property rights of third parties and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. Accordingly, OrthoCellix cannot assure you that OrthoCellix will ever be able to generate revenue through the sale NeoCart, even if approved. If OrthoCellix is not successful in obtaining regulatory approval and commercializing NeoCart, or is significantly delayed in doing so, OrthoCellix&#8217;s business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even though NeoCart received RMAT Designation, this designation may not lead to a faster development or regulatory review or approval process and will not by itself increase the likelihood that NeoCart will receive marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2022, the FDA granted RMAT designation to NeoCart for the repair of full-thickness lesions of the knee cartilage in adults. The RMAT designation was created to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure a serious condition. The receipt of RMAT designation, or any other product designation may not result in a faster development process, review, or approval compared to product candidates considered for approval under conventional FDA procedures and does not assure ultimate marketing approval by the FDA. In addition, the FDA may later decide that NeoCart may no longer meet the designation conditions, in which case any granted designations may be revoked.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If OrthoCellix is not able to obtain, or if there are delays in obtaining required regulatory approvals for NeoCart, OrthoCellix will not be able to commercialize NeoCart as expected, and OrthoCellix&#8217;s ability to generate revenue will be materially impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The research, testing, manufacturing, labeling, approval, selling, marketing, and distribution of pharmaceutical products are subject to extensive regulations by the FDA and other regulatory authorities, which regulations differ from country to country. The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many&#160;years following the commencement of clinical trials. The outcome of the approval process is inherently uncertain and depends upon numerous factors, including the substantial discretion of the regulatory authorities. This is especially true for rare and/or complicated diseases. Failure can occur at any time during the clinical trial process. OrthoCellix cannot predict if or when OrthoCellix might receive regulatory approval for NeoCart. Any delay in OrthoCellix obtaining or OrthoCellix&#8217;s failure to obtain required approvals </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">could materially adversely affect their ability to generate revenue from NeoCart, which could result in harm to OrthoCellix&#8217;s financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Securing marketing approval requires the submission of extensive clinical data and supporting information to regulatory authorities which establish NeoCart&#8217;s safety and efficacy to repair of knee cartilage injuries in adults. OrthoCellix may be unable to execute a Phase 3 clinical trial to support marketing approval. Securing marketing approval also requires the submission of information about NeoCart&#8217;s manufacturing process to, and inspection of, manufacturing facilities and clinical trial sites by the regulatory authorities. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that OrthoCellix&#8217;s data is insufficient for approval and require additional preclinical, clinical, or other studies. The FDA or other similar regulatory authorities may determine that NeoCart is not effective or only moderately effective (e.g., studies may not produce the necessary result on all study endpoints), that OrthoCellix&#8217;s studies failed to reach the necessary level of statistical significance, or that NeoCart has undesirable or unintended side effects, toxicities, or other characteristics that preclude OrthoCellix from obtaining marketing approval or prevent or limit commercial use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent OrthoCellix&#8217;s ability to receive marketing approval or commercialize OrthoCellix&#8217;s product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators, including the FDA and the NIH, or IRBs may not authorize OrthoCellix or OrthoCellix&#8217;s investigators to commence or continue a clinical trial, conduct a clinical trial at a prospective trial site, or amend trial protocols, or may require that OrthoCellix modify or amend OrthoCellix&#8217;s clinical trial protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of OrthoCellix&#8217;s product candidates may be larger than OrthoCellix anticipates, enrollment in these clinical trials may be slower than OrthoCellix anticipates, or participants may drop out of these clinical trials, or be lost to follow-up at a higher rate than OrthoCellix anticipates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s third-party contractors may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to OrthoCellix in a timely manner, or at all, or OrthoCellix may be required to engage in additional clinical trial site monitoring;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities or IRBs may require the suspension or termination of clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks, undesirable side effects, or other unexpected characteristics (alone or in combination with other products) of the product candidate, or due to findings of undesirable effects caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in marketing approval policies or regulations, or changes in or the enactment of additional statutes or regulations, during the development period rendering OrthoCellix&#8217;s data insufficient to obtain marketing approval and requiring OrthoCellix to conduct additional studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of OrthoCellix&#8217;s product candidates may be greater than OrthoCellix anticipates or OrthoCellix may have insufficient funds for a clinical trial or to pay the substantial user fees required by the FDA upon the filing of a marketing application;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of OrthoCellix&#8217;s product candidates or other materials necessary to conduct clinical trials of OrthoCellix&#8217;s product candidates may be insufficient or inadequate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix may have delays in adding new investigators or clinical trial sites, or OrthoCellix may experience a withdrawal of clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients that enroll in OrthoCellix&#8217;s studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the study, increase the needed enrollment size for the study, or extend the study&#8217;s duration;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with OrthoCellix&#8217;s study design, including endpoints, or OrthoCellix&#8217;s interpretation of data from preclinical studies and clinical trials or find that a product candidate&#8217;s benefits do not outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may not accept data from studies with clinical trial sites in foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with OrthoCellix&#8217;s intended indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or OrthoCellix&#8217;s contract manufacturer&#8217;s manufacturing facility for clinical and future commercial supplies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of OrthoCellix&#8217;s product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a marketing application, or other comparable submissions in foreign jurisdictions, or to obtain regulatory approval in the United States or elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may take longer than OrthoCellix anticipates to make a decision on OrthoCellix&#8217;s product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix may not be able to demonstrate that a product candidate provides an advantage over current standards of care or current or future competitive therapies in development.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant delays relating to any clinical trials also could shorten any periods during which OrthoCellix may have the exclusive right to commercialize OrthoCellix&#8217;s product candidates, if approved, or allow OrthoCellix&#8217;s competitors to bring products to market before OrthoCellix does. This may prevent OrthoCellix from receiving marketing approvals and impair OrthoCellix&#8217;s ability to successfully commercialize OrthoCellix&#8217;s product candidates, if approved, and may harm OrthoCellix&#8217;s business and results of operations. In addition, many of the factors that cause, or lead to, delays in clinical trials may ultimately lead to the denial of marketing approval of any of OrthoCellix&#8217;s product candidates. If any of this occurs, OrthoCellix&#8217;s business, financial condition, results of operations, and prospects will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The failure to comply with FDA and comparable foreign regulatory requirements may, either before or after product approval, if any, subject OrthoCellix to administrative or judicially imposed sanctions, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on OrthoCellix&#8217;s ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on OrthoCellix&#8217;s products, manufacturers, or manufacturing process</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters, Form&#160;483s, or untitled letters alleging violations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">civil and criminal penalties</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of regulatory approvals</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizures, detentions, or import bans</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">voluntary or mandatory product recalls and publicity requirements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">total or partial suspension of production</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of restrictions on operations, including costly new manufacturing requirements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending marketing applications or supplements to approved marketing applications.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if OrthoCellix were to obtain regulatory approval of a product candidate, the FDA or comparable foreign regulatory authorities may grant approval for fewer or more limited indications, populations, or uses than OrthoCellix requests, may require significant safety warnings, including black box warnings, contraindications, and precautions, may grant approval contingent on the performance of costly post-marketing clinical trials, surveillance, restrictions on use or other requirements, including a REMS to monitor the safety or efficacy of the product, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of these scenarios could compromise the commercial prospects for OrthoCellix&#8217;s product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If OrthoCellix experiences delays or difficulties in the enrollment of patients in clinical trials, OrthoCellix&#8217;s completion of clinical trials and receipt of necessary regulatory approvals could be delayed or prevented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Identifying and qualifying patients to participate in clinical trials of OrthoCellix&#8217;s product candidates is critical to OrthoCellix&#8217;s success. The timing of OrthoCellix&#8217;s clinical trials depends on the speed at which OrthoCellix can recruit patients to participate in testing OrthoCellix&#8217;s product candidates. Once initiated, OrthoCellix&#8217;s ongoing clinical trials could be discontinued early if they experience slow enrollment, and OrthoCellix may also experience similar difficulties in future clinical trials. If patients are unwilling to participate in OrthoCellix&#8217;s clinical trials because of negative publicity from adverse events related to NeoCart, or in the industry more broadly, in the clinical trials for related third party product candidates, or for other reasons, including competitive clinical trials for similar patient populations, the timeline for recruiting patients, conducting studies, and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing OrthoCellix&#8217;s product development, delays in testing the effectiveness of OrthoCellix&#8217;s product candidates, or termination of the clinical trials altogether.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix or OrthoCellix&#8217;s clinical trial sites may not be able to identify, recruit, and enroll a sufficient number of patients, or those with the required or desired characteristics in a clinical trial, to complete OrthoCellix&#8217;s clinical trials in a timely manner. Patient enrollment is affected by other factors including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and nature of the patient population (for instance, OrthoCellix is pursuing clinical trials for certain orphan indications, for which the size of the patient population is limited);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the existence of current treatments for the indications for which OrthoCellix is conducting clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the eligibility criteria for and design of the clinical trial in question, including factors such as frequency of required assessments, length of the study, and ongoing monitoring requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perceived risks and benefits of the product candidate, including the potential advantages or disadvantages of the product candidate being studied in relation to other available therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition in recruiting and enrolling patients in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient referral practices of physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of publicity created by clinical trial sites regarding the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients&#8217; ability to comply with the specific instructions related to the trial protocol, proper documentation, and use of the product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an inability to obtain or maintain patients&#8217; informed consents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that enrolled patients will drop out before completion or not return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to compensate patients for their time and effort; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity and availability of clinical trial sites for prospective patients.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix may not be able to initiate or continue conducting clinical trials for OrthoCellix&#8217;s product candidates if OrthoCellix is unable to locate and enroll a sufficient number of eligible patients to participate in these clinical trials as required by the FDA or similar regulatory authorities outside the United States. OrthoCellix&#8217;s inability to enroll a sufficient number of patients for OrthoCellix&#8217;s clinical trials would result in significant delays and could require OrthoCellix to abandon one or more clinical trials altogether. In particular, there may be low or slow enrollment, and the studies may enroll subjects that do not meet the inclusion criteria, requiring the erroneously enrolled subjects to be excluded and the trial population to be increased. Moreover, patients in OrthoCellix&#8217;s clinical trials, especially patients in OrthoCellix&#8217;s control groups, may be at risk for dropping out of OrthoCellix&#8217;s studies if they are not experiencing relief of their disease. A significant number of withdrawn patients would compromise the quality of a study&#8217;s data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Enrollment difficulties or delays in OrthoCellix&#8217;s clinical trials may result in increased development costs for OrthoCellix&#8217;s product candidates, or the inability to complete development of OrthoCellix&#8217;s product candidates, which would cause OrthoCellix&#8217;s value to decline, limit OrthoCellix&#8217;s ability to obtain additional financing, and materially impair OrthoCellix&#8217;s ability to generate revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix is heavily dependent on the success of NeoCart, its only product candidate to date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix currently has no products that are approved for commercial sale and may never be able to develop marketable products. OrthoCellix expects that a substantial portion of its efforts and expenditures over the next several&#160;years will be devoted to development of NeoCart, which is currently its only product candidate. Accordingly, its business currently depends heavily on the successful development, regulatory approval, and commercialization of NeoCart. OrthoCellix can provide no assurance that NeoCart will receive regulatory approval or be successfully commercialized even if OrthoCellix receives regulatory approval. If OrthoCellix were required to discontinue development of NeoCart or if NeoCart does not receive regulatory approval or fails to achieve significant market acceptance, OrthoCellix would be delayed by many&#160;years in its ability to achieve profitability, if ever.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The research, testing, manufacturing, safety, efficacy, recordkeeping, labeling, approval, licensure, sale, marketing, advertising, promotion and distribution of NeoCart is, and will remain, subject to comprehensive regulation by the FDA and foreign regulatory authorities. Failure to obtain regulatory approval for NeoCart in the United States, Europe and other major markets around the world will prevent OrthoCellix from commercializing and marketing NeoCart in such jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if OrthoCellix were to successfully obtain approval from the FDA and foreign regulatory authorities for NeoCart, any approval might contain significant limitations related to use, including limitations on the type of injury NeoCart is approved to treat, as well as restrictions for specified age groups, warnings, precautions or contraindications, or REMS.&#160;Any such limitations or restrictions could similarly impact any supplemental marketing approvals OrthoCellix may obtain for NeoCart. Furthermore, even if OrthoCellix obtains regulatory approval for NeoCart, it will still need to develop a commercial infrastructure or develop relationships with collaborators to commercialize, establish a commercially viable pricing structure and obtain coverage and adequate reimbursement from third-party payors, including government healthcare programs. If OrthoCellix, or any future collaborators, are unable to successfully commercialize NeoCart, it may not be able to generate sufficient revenue to continue its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data from preclinical studies and early-stage clinical trials and &#8220;top-line,&#8221; initial or preliminary data from OrthoCellix&#8217;s clinical trials may not be predictive of success in later clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The results of preclinical studies, preliminary study results, and early-stage clinical trials of OrthoCellix&#8217;s product candidates may not be predictive of the results of later-stage clinical trials or the ultimately completed Phase 3 registration enabling clinical trial. Preliminary and final results from such studies may not be representative of study results that are found in larger, controlled, blinded, and more long-term studies. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies have suffered significant setbacks in advanced clinical trials, notwithstanding promising results in earlier clinical trials. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols, and the rate of dropout among clinical trial participants.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, from time to time, OrthoCellix may publish interim, &#8220;top-line,&#8221; initial, or preliminary data from OrthoCellix&#8217;s clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data becomes available. Preliminary, initial, or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data previously published. As a result, interim, &#8220;top-line,&#8221; initial, and preliminary data should be viewed with caution until the final data are available. Adverse changes between preliminary, initial, &#8220;top-line&#8221; or interim data and final data could significantly harm OrthoCellix&#8217;s business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The FDA may determine that our product candidates have undesirable side effects that could delay or prevent their regulatory approval or commercialization. If such side effects are identified during the development of our product candidates, we may need to abandon our development of such product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Undesirable side effects caused by our product candidates could cause us, IRBs, and other reviewing entities or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. For example, if concerns are raised regarding the safety NeoCart as a result of undesirable side effects identified during preclinical or clinical testing, the FDA may order us to cease further development or issue a letter requesting additional data or information prior to making a final decision regarding whether or not to approve the product candidate. FDA requests for additional data or information can result in substantial delays in the approval of a new product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Undesirable side effects caused by any unexpected characteristics of NeoCart (alone or in combination with other products) could also result in denial of regulatory approval by the FDA or other comparable foreign authorities for any or all targeted indications or the inclusion of unfavorable information in our product labeling, such as limitations on the indicated uses or populations for which the products may be marketed or distributed, or a label with significant safety warnings. A label without statements necessary or desirable for successful commercialization may result in requirements for costly post-marketing testing and surveillance, or other requirements, including REMS, to monitor the safety or efficacy of a product. These could prevent us from commercializing and generating revenues from the sale of NeoCart, even if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many product candidates that initially showed promise in clinical or earlier stage testing have later been found to cause side effects that prevented further development of the candidate. In addition, adverse events which had initially been considered unrelated to the study treatment may later be found to be caused by the study treatment. If NeoCart or any other product candidates we may develop are associated with SAEs, undesirable side effects, or have properties that are unexpected, we may need to abandon development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective. The therapeutic-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. We may also be held liable for harm caused to patients and our reputation may suffer. Any of these occurrences may significantly harm our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to obtain marketing approval in international jurisdictions would prevent NeoCart from being marketed abroad.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to market and sell NeoCart in jurisdictions outside the United States, OrthoCellix must obtain separate marketing approvals in international jurisdictions and comply with numerous and varying regulatory requirements. The approval procedures vary among countries and the time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. The clinical trials of NeoCart done to gain FDA approval may not be sufficient to support an application for marketing approval outside the United States. Seeking foreign regulatory approval could result in difficulties and costs for OrthoCellix and require additional preclinical studies or clinical trials which could be costly and time consuming.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NeoCart is not approved for sale in any jurisdiction, including in international markets, and OrthoCellix does not have experience in obtaining regulatory approval in international markets. OrthoCellix, or any current or eventual collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not guarantee approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not guarantee approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, the failure to obtain approval in one jurisdiction may compromise OrthoCellix&#8217;s ability to obtain approval elsewhere. OrthoCellix may not be able to file for marketing approvals and may not receive necessary approvals to commercialize NeoCart in any market.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix may be subject to fines, penalties, injunctions, or other enforcement actions if OrthoCellix is determined to be promoting the use of OrthoCellix&#8217;s products, if approved, for unapproved or &#8220;off-label&#8221; uses, resulting in damage to OrthoCellix&#8217;s reputation and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix must comply with requirements concerning advertising and promotion for any product candidates for which OrthoCellix obtains marketing approval. Promotional communications with respect to therapeutics are subject to a variety of legal and regulatory restrictions and continuing scrutiny from the FDA, Department of Justice, HHS&#8217; Office of Inspector General, state attorneys general, members of Congress, and the public. When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory approval is limited to those specific uses and indications for which a product is approved. OrthoCellix may not market or promote them for other indications and uses, referred to as off-label uses. OrthoCellix further must be able to sufficiently substantiate any claims that OrthoCellix makes for OrthoCellix&#8217;s products, if approved, including claims comparing OrthoCellix&#8217;s products to other companies&#8217; products and must abide by the FDA&#8217;s strict requirements regarding the content of promotion and advertising. While physicians may choose to prescribe products for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical studies and approved by the regulatory authorities, OrthoCellix is prohibited from marketing and promoting the products for indications and uses that are not specifically approved by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If OrthoCellix is found to have impermissibly promoted any of OrthoCellix&#8217;s product candidates, OrthoCellix may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations regarding product promotion, particularly those prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted a product may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified promotional conduct is changed or curtailed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, engaging in the impermissible promotion of approved products for off-label uses can also subject OrthoCellix to false claims and other litigation under federal and state statutes, including fraud and abuse and consumer protection laws. Such litigation can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict the manner in which OrthoCellix promotes or distributes therapeutic products and do business through, for example, corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, suspension and debarment from government contracts, and refusal of orders under existing government contracts. These false claims statutes include the federal civil FCA, which allows any individual to bring a lawsuit against a company on behalf of the federal government (&#8220;qui tam&#8221; action) alleging submission of false or fraudulent claims, or causing others to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government decides to intervene and prevails in the lawsuit, the individual will share in the proceeds from any fines or settlement funds. If the government declines to intervene, the individual may pursue the case alone. These FCA lawsuits against sponsors of drugs and biologics have increased significantly in volume and breadth in recent&#160;years, leading to several substantial civil and criminal settlements, up to $3.0 billion, pertaining to certain sales practices and promoting off-label uses. In addition, FCA lawsuits may expose sponsors to follow-on claims by private payors based on fraudulent marketing practices. This growth in litigation has increased the risk that companies will have to defend a false claim action, and pay settlements fines or restitution, as well as criminal and civil penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state healthcare programs. If OrthoCellix does not lawfully promote OrthoCellix&#8217;s approved products, if any, OrthoCellix may become subject to such litigation and, if OrthoCellix does not successfully defend against such actions, those actions may have a material adverse effect on OrthoCellix&#8217;s business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the distribution of product samples to physicians must further comply with the requirements of the United States PDMA, and the promotion of biologic and pharmaceutical products are subject to additional FDA requirements and restrictions on promotional statements. If the FDA determines that OrthoCellix&#8217;s promotional activities violate OrthoCellix&#8217;s regulations and policies pertaining to product promotion, it could request that OrthoCellix modifies OrthoCellix&#8217;s promotional materials or subject OrthoCellix to regulatory or other enforcement actions, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, requests for recalls, payment of civil fines, disgorgement of money, imposition of operating restrictions, injunctions or criminal prosecution, and other enforcement actions. These regulatory and enforcement actions could significantly harm OrthoCellix&#8217;s business, financial condition, results of operations, and prospects.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if NeoCart receives regulatory approval, OrthoCellix will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If OrthoCellix obtains marketing approval for NeoCart, OrthoCellix will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities, including requirements related to the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising, marketing, and promotional activities for NeoCart. These requirements further include submissions of safety and other post-marketing information, including manufacturing deviations and reports, registration and listing requirements, the payment of annual fees, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, for any clinical trials that OrthoCellix conduct post-approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if marketing approval of NeoCart is granted, the approval may be subject to limitations on the indicated uses and populations for which NeoCart may be marketed or to the conditions of approval, including significant safety warnings, such as contraindications and precautions that are not desirable for successful commercialization. NeoCart may also be subject to a REMS that render it not commercially viable or other post-market requirements, such as Phase 4 studies, or restrictions. If the FDA or comparable foreign regulatory authorities become aware of new safety information after the approval of NeoCart, they may, among other actions, withdraw approval, establish REMS, impose significant restrictions on NeoCart&#8217;s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix and any of OrthoCellix&#8217;s collaborators, including Ocugen and any future contract manufacturers, could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMP and other FDA regulatory requirements. Application holders must further notify the FDA, and depending on the nature of the change, obtain FDA pre-approval for product and manufacturing changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown adverse events or that NeoCart is less effective than previously thought or other problems with NeoCart, manufacturers, or manufacturing processes, or failure to comply with regulatory requirements both before and after approval, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on manufacturing, distribution, or marketing of NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">modifications to promotional pieces;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issuance of corrective information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or other clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical holds or termination of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to establish or modify a REMS, or a comparable foreign authority may require that OrthoCellix establish or modify a similar strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability for harm caused to patients or subjects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reputational harm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning, untitled, Form&#160;FDA 483s, or cyber letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension of marketing or withdrawal or recall of NeoCart from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings or other safety information about NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that OrthoCellix submits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution, or disgorgement of profits or revenues;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seizure or detention of NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA debarment, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from federal healthcare programs, consent decrees, or corporate integrity agreements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties, including imprisonment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent OrthoCellix from achieving or maintaining market acceptance of NeoCart, if approved, or could substantially increase the costs and expenses of developing and commercializing of NeoCart, which in turn could delay or prevent OrthoCellix from generating significant revenues from its sale. Any of these events could further have other material and adverse effects on OrthoCellix&#8217;s operations and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of NeoCart, limit the marketability of NeoCart, or impose additional regulatory obligations on OrthoCellix. Changes in medical practice and standard of care may also impact the marketability of NeoCart, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix will need to obtain FDA approval of the name, NeoCart, and any failure or delay associated with such approval may adversely affect OrthoCellix&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The name, NeoCart, has not been evaluated or cleared by the FDA. The name, NeoCart, will require approval from the FDA. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. The FDA may also object to a product name if it believes the name inappropriately implies medical claims or contributes to an overstatement of efficacy. If the FDA objects to the name, NeoCart, OrthoCellix may be required to adopt an alternative name. If OrthoCellix adopts an alternative name, OrthoCellix would lose the benefit of any existing trademark applications for NeoCart and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe upon the existing rights of third-parties, and be acceptable to the FDA. OrthoCellix may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit OrthoCellix&#8217;s ability to commercialize NeoCart, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Geopolitical events and conditions could adversely affect OrthoCellix&#8217;s business, financial condition and operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes in U.S. government and other nations&#8217; administrations and their associated shifts in policy and priorities could also impact OrthoCellix&#8217;s operations and market conditions. OrthoCellix&#8217;s business is highly sensitive to geopolitical issues, including foreign policy actions taken by governments such as tariffs, sanctions, embargoes, export and import controls, and other trade restrictions, which can affect the demand for, and OrthoCellix&#8217;s ability to sell, OrthoCellix&#8217;s products and services, cause disruptions to OrthoCellix&#8217;s supply chain, and, ultimately, could adversely affect OrthoCellix&#8217;s business. Global conflicts, including Russia&#8217;s invasion of Ukraine, conflicts in the Middle East, and heightened tensions in the Pacific region, have significantly elevated global geopolitical tensions and security concerns. Economic sanctions, export controls, and other trade restrictions, for instance those that the U.S. Government and other nations implemented against Russia in light of its invasion of Ukraine or those relating to the conflict in the Middle East, could directly and indirectly result in the disruption of OrthoCellix&#8217;s business and supply chain. Although OrthoCellix does not have any clinical trial sites or operations in the currently affected regions, if the current conflict expands further into the region or continues, resulting heightened economic sanctions from the United States and the international community, in addition to environmental regulations, could limit OrthoCellix&#8217;s ability to procure or use certain materials or manufacturing slots for the products needed for OrthoCellix&#8217;s clinical trials, which could lead to delays in these trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">However, portions of OrthoCellix&#8217;s clinical trials are planned to be conducted outside of the United States, and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make those clinical trials more costly to operate. Significant political, trade, or regulatory developments in the jurisdictions in which OrthoCellix sells OrthoCellix&#8217;s products, if approved, such as those stemming from the change in U.S. federal administration, are difficult to predict and may have a material adverse effect on OrthoCellix. Similarly, changes in U.S. federal policy that affect the geopolitical landscape could give rise to circumstances outside OrthoCellix&#8217;s control that could have negative impacts on OrthoCellix&#8217;s business operations. For example, on February&#160;1, 2025, the U.S. imposed a 25.0% tariff on imports from Canada and Mexico, which were subsequently suspended for a period of one&#160;month, and </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">a 10.0% additional tariff on imports from China. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. Any changes in political, trade, regulatory, and economic conditions, including U.S. trade policies, could have a material adverse effect on OrthoCellix&#8217;s financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in funding for, or disruptions to the staffing and operations of the FDA, the SEC and other government agencies, including from government shut downs could hinder their ability to hire and retain key leadership and other personnel, prevent NeoCart from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of OrthoCellix&#8217;s business may rely, which could negatively impact OrthoCellix&#8217;s business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Currently, federal agencies in the U.S. are operating under a continuing resolution that is set to expire on September&#160;30, 2025. Without appropriation of additional funding to federal agencies, OrthoCellix&#8217;s business operations related to NeoCart&#8217;s development could be impacted. The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. In addition, government funding of the SEC and other government agencies on which OrthoCellix&#8217;s operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other agencies, including substantial leadership departures, personnel cuts, and policy changes, may also slow the time necessary for product candidates, such as NeoCart, to be reviewed and/or approved by necessary government agencies, which would adversely affect OrthoCellix&#8217;s business. A prolonged government shutdown or significant leadership, personnel, and/or policy changes, or other substantial modification in agency activities could significantly impact the ability of the FDA to timely review and process OrthoCellix&#8217;s regulatory submissions related to NeoCart, or other disruptions could have a material adverse effect on OrthoCellix&#8217;s business. Further, future government shutdowns could impact OrthoCellix&#8217;s ability to access the public markets and obtain necessary capital in order to properly capitalize and continue OrthoCellix&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The U.S. Congress, the Trump Administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect OrthoCellix&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2017, the U.S. Congress and the Trump Administration made substantial changes to U.S. policies, which included comprehensive corporate and individual tax reform. In addition, the Trump Administration called for significant changes to U.S. trade, healthcare, immigration and government regulatory policy. With the transition to the Biden Administration in early 2021, changes to U. S. policy occurred and since the start of the Trump Administration in 2025, U.S. policy changes have been implemented at a rapid pace and additional changes are likely. Changes to U.S. policy implemented by the U.S. Congress, the Trump Administration or any new administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. Although OrthoCellix cannot predict the impact, if any, of these changes to OrthoCellix&#8217;s business, they could adversely affect OrthoCellix&#8217;s business. Until OrthoCellix knows what policy changes are made, whether those policy changes are challenged and subsequently upheld by the court system and how those changes impact OrthoCellix&#8217;s business and the business of OrthoCellix&#8217;s competitors over the long term, OrthoCellix will not know if, overall, OrthoCellix will benefit from them or be negatively affected by them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to OrthoCellix&#8217;s Commercialization of NeoCart</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix has never commercialized a product and will need to build and scale its business for potential commercialization of NeoCart, including building its compliance, medical affairs and commercial organizations, which, if it is not able to do so successfully could negatively impact its business, including the potential for a successful commercialization of NeoCart.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">OrthoCellix has no prior sales or distribution experience and limited capabilities for marketing and market access. OrthoCellix expects to invest significant financial and management resources over time to establish compliance, medical affairs and commercial organizations for the marketing, sales and distribution of NeoCart, if approved, and other capabilities and infrastructure to support commercial operations. If OrthoCellix is unable to establish these commercial capabilities and infrastructure in a timely manner or to enter into agreements with third parties to market, sell, and/or distribute NeoCart if approved, it may be unable to complete a successful commercial launch. To the extent we enter into agreements with third parties, the revenue we receive may depend upon the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">efforts of such third parties, over which it may have limited or no control, and its revenue from product sales may be lower than if we had commercialized the products itself. OrthoCellix also faces competition in its search for third parties to assist it with the distribution, sales and marketing of its products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If NeoCart receives approval and does not achieve broad market acceptance, the revenues that OrthoCellix generates from its sales will be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if NeoCart is approved by the appropriate regulatory authorities for marketing and sale, it may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. OrthoCellix has never commercialized a product candidate for any indication, and efforts to educate the medical community and third-party payors on the benefits of NeoCart may require significant resources and may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Market acceptance of NeoCart by the medical community, patients, and third-party payors will depend on a number of factors, some of which are beyond OrthoCellix&#8217;s control. If NeoCart, if approved, does not gain an adequate level of market acceptance, it may not generate significant revenue for OrthoCellix or become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The degree of market acceptance of NeoCart will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy of NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of adverse events associated with NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which NeoCart is approved and the approved claims that OrthoCellix may make for NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings contained in NeoCart&#8217;s FDA-approved labeling, including potential limitations or warnings for NeoCart that may be more restrictive than other competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the standard of care for the for the repair of knee cartilage injuries in adults could reduce the marketing impact of any claims that OrthoCellix could make following FDA approval, if obtained;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the relative convenience and ease of administration of NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost of treatment versus economic and clinical benefit in relation to alternative treatments or therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party formulary coverage and adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payors, and by government healthcare programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price concessions required by third party payors to obtain coverage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent and strength of OrthoCellix&#8217;s manufacturing, marketing, and distribution of NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution and use restrictions imposed by the FDA with respect to NeoCart or to which OrthoCellix agrees as part of a REMS or voluntary risk management plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse publicity about NeoCart or favorable publicity about competitive products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product liability claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the market opportunities for NeoCart are smaller than OrthoCellix believes, OrthoCellix&#8217;s revenue may be adversely affected, and OrthoCellix&#8217;s business may suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The potential market opportunities for NeoCart is difficult to precisely estimate. OrthoCellix&#8217;s estimate of the potential market opportunities are predicated on many assumptions, which may include industry knowledge and publications, third-party research reports, and other surveys, some of which OrthoCellix may have commissioned. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">not guarantee the accuracy or completeness of such information. While OrthoCellix believes these industry publications and third-party research, surveys, and studies are reliable, OrthoCellix has not independently verified such data. In addition, while OrthoCellix believes that OrthoCellix&#8217;s internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of OrthoCellix&#8217;s management, are inherently uncertain, and the reasonableness of these assumptions has not been assessed by an independent source. If any assumptions prove to be inaccurate, the actual markets for NeoCart could be smaller than OrthoCellix&#8217;s estimates of the potential market opportunities, and as a result, revenue from NeoCart, if approved, may be limited, and it may be more difficult for OrthoCellix to achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If OrthoCellix obtains approval to commercialize NeoCart outside of the United States, a variety of risks associated with international operations could materially adversely affect OrthoCellix&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If NeoCart is approved for commercialization, OrthoCellix may enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. OrthoCellix expects that it will be subjected to additional risks related to conducting marketing and sales activities in international jurisdictions and entering into international business relationships, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">different regulatory requirements for approval of drugs and biologics in foreign countries</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">challenges enforcing OrthoCellix&#8217;s contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the need to seek additional patent approvals, licenses to patents held by third parties, and/or face claims of infringing third-party patent rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tariffs (including tariffs that have been or may in the future be imposed by the United States or other countries), trade protection measures, import or export licensing requirements, trade embargoes, sanctions (including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury), other trade barriers (including further legislation or actions taken by the United States or other countries that restrict trade), and protectionist or retaliatory measures taken by the United States or other countries</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation or political instability in particular foreign economies and markets</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties staffing and managing foreign operations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">workforce uncertainty in countries where labor unrest is more common than in the United States</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential liability under the FCPA, the U.K. Bribery Act 2010 (the &#8220;Bribery Act&#8221;), or other comparable foreign regulations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including pandemics or other outbreaks of infectious disease, earthquakes, typhoons, floods, and fires.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These and other risks associated with international operations may materially adversely affect OrthoCellix&#8217;s ability to attain or maintain profitable operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If OrthoCellix is unable to establish effective marketing and sales capabilities or enter into agreements with third parties to market and sell NeoCart, if approved, OrthoCellix may be unable to generate product revenues related to NeoCart.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">OrthoCellix does not currently have a commercial infrastructure for the marketing, sale, and distribution of biotechnology products. If approved, in order to commercialize NeoCart, OrthoCellix must build OrthoCellix&#8217;s marketing, sales, and distribution </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">capabilities or make arrangements with third parties to perform these services. If OrthoCellix does not establish sales, marketing, and distribution capabilities successfully, either alone or in collaboration with third parties, OrthoCellix will not be successful in commercializing NeoCart for which OrthoCellix will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to regulatory approval of NeoCart, OrthoCellix may build a commercial team of specialty sales and marketing representatives in support of NeoCart that OrthoCellix develops in the United States or other foreign countries, if approved, as well as distribution capabilities. There are risks involved with OrthoCellix establishing OrthoCellix&#8217;s own sales, marketing, and distribution capabilities. Recruiting and training a sales force is expensive and time-consuming, particularly to the extent that OrthoCellix seeks to commercialize NeoCart, if approved, for repairing knee cartilage injuries in adults. OrthoCellix will be competing with many companies that currently have extensive and well-funded marketing and sales operations to recruit, hire, train, and retain marketing and sales personnel. Further, OrthoCellix may underestimate the size of the sales force required for a successful product launch and may need to expand OrthoCellix&#8217;s sales force earlier and at a higher cost than OrthoCellix anticipates. If the commercial launch of NeoCart, if approved, for which OrthoCellix recruits a sales force and establish marketing capabilities is delayed or does not occur for any reason, OrthoCellix would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and OrthoCellix&#8217;s investment would be lost if OrthoCellix cannot retain or reposition OrthoCellix&#8217;s sales and marketing personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix may also or alternatively decide to collaborate with a third-party or contract sales organization to commercialize NeoCart, in which event, OrthoCellix&#8217;s ability to generate product revenues related to NeoCart may be limited. OrthoCellix&#8217;s product revenues and profitability, if any, under any third-party collaboration, distribution, or other marketing arrangements are likely to be lower than if OrthoCellix were to market, sell, and distribute NeoCart, if approved, entirely themselves. OrthoCellix may not be successful in entering into arrangements with third parties to sell, market, and distribute NeoCart, if approved, or may be unable to do so on terms that are favorable to OrthoCellix. In addition, OrthoCellix would have less control over the sales efforts of any other third parties involved in OrthoCellix&#8217;s commercialization efforts and any of them may fail to devote the necessary resources and attention to sell and market NeoCart, if approved, effectively. OrthoCellix could also be held liable if such third parties failed to comply with applicable legal or regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event OrthoCellix is unable to develop a team of marketing and sales representatives or to establish an effective third-party contractual relationship for such services, OrthoCellix may not be able to commercialize NeoCart, if approved, which would limit OrthoCellix&#8217;s ability to generate product revenues related to NeoCart. Even if OrthoCellix is able to effectively hire a sales force and develop a marketing and sales infrastructure, OrthoCellix&#8217;s sales force and marketing teams may not be successful in commercializing NeoCart, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix faces significant competition from other pharmaceutical and biotechnology companies, academic institutions, government agencies, and other research organizations. OrthoCellix&#8217;s operating results will suffer if OrthoCellix fails to compete effectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biotechnology industry is characterized by rapidly advancing technologies as well as a strong emphasis on intellectual property leading to a highly competitive environment for the development and commercialization of regenerative medicines. OrthoCellix faces competition with respect to OrthoCellix&#8217;s current product candidates and will face competition with respect to any product candidates that OrthoCellix may seek to develop or commercialize in the future. OrthoCellix faces competition from many different sources, including from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regenerative medicine sector is characterized by innovative science, rapidly advancing technologies, and a strong emphasis on proprietary products. The competitive landscape in the field of articular cartilage repair in the United States is emerging and has stimulated a substantial amount of interest from companies developing tissue repair solutions. Products that may compete with NeoCart include Vericel Corporation&#8217;s collagen membrane (&#8220;MACI&#8221;), the only FDA-approved ACI product in the United States, and Aesculap Biologics, LLC&#8217;s NOVOCART 3D, which is currently in their Phase 3 clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">OrthoCellix&#8217;s commercial opportunities could be reduced or eliminated if OrthoCellix&#8217;s competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than NeoCart, if approved. OrthoCellix competitors also may obtain FDA or other regulatory approval for their products more rapidly than OrthoCellix may obtain approval for NeoCart, which could result in OrthoCellix&#8217;s competitors establishing a strong market position before OrthoCellix is able to enter the market. They may obtain patent protection or other intellectual property rights that allow them </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to develop and commercialize their products before OrthoCellix and could limit OrthoCellix&#8217;s ability to develop or commercialize NeoCart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, OrthoCellix&#8217;s ability to compete may be affected in many cases by insurers or other third-party payors&#8217; coverage decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of the companies against which OrthoCellix is competing against or which OrthoCellix may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than OrthoCellix. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of OrthoCellix&#8217;s competitors. Early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with OrthoCellix in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for NeoCart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If third-party payors do not reimburse patients for NeoCart, if approved, or if reimbursement levels are set too low for OrthoCellix to sell NeoCart at a profit, OrthoCellix&#8217;s ability to successfully commercialize NeoCart, if approved, and OrthoCellix&#8217;s results of operations will be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s ability to successfully commercialize NeoCart, if approved, will depend in part on the extent to which coverage and adequate reimbursement for NeoCart will be available in a timely manner from third-party payors, including governmental healthcare programs such as Medicare and Medicaid, commercial health insurers, and managed care organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, determine which medications and surgeries they will cover and establish reimbursement levels. Reimbursement decisions by particular third-party payors depend upon a number of factors, including each third-party payor&#8217;s determination that use of a product is:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a covered benefit under its health plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">appropriate and medically necessary for the specific condition or disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost effective; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">neither experimental nor investigational.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Obtaining coverage and reimbursement approval for NeoCart from government authorities or other third-party payors may be a time consuming and costly process that could require OrthoCellix to provide supporting scientific, clinical, and cost-effectiveness data, including expensive pharmacoeconomic studies beyond the data required to obtain marketing approval, for the use of NeoCart to each government authority or other third-party payor. OrthoCellix may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third-party payors may deny reimbursement for NeoCart if they determine that it was not used in accordance with cost-effective diagnosis methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse for procedures and devices deemed to be experimental. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for repairing knee cartilage injuries in adults.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please see the section titled &#8220;<i style="font-style:italic;">OrthoCellix&#8217;s Business&#8201;&#8212;&#8201;Government Regulation and Product Approval&#160;&#8212; Coverage and Reimbursement</i>&#8221; beginning on page&#160;303 of this proxy statement/prospectus for a more detailed description of the third-party payor coverage and reimbursement concerns that may affect OrthoCellix&#8217;s ability to operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">As an organization, OrthoCellix has limited experience in the development, manufacturing, distribution, or commercialization of a biological product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">OrthoCellix has limited experience in the development of product candidates and have never undertaken the manufacturing, distribution, or commercialization, and OrthoCellix may be unable to obtain regulatory authorization or approval. Additionally, development of an effective product candidate depends on the success of OrthoCellix&#8217;s and OrthoCellix&#8217;s partner&#8217;s manufacturing </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">capabilities, which OrthoCellix will initially be reliant upon Ocugen for. In addition, the development and manufacture of NeoCart may prove to be particularly complex. Further, OrthoCellix may be unable to effectively create a supply chain for NeoCart that will adequately support demand. OrthoCellix may also face challenges with sourcing a sufficient amount of raw materials to support the demand for NeoCart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to OrthoCellix&#8217;s Dependence on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix expects to rely on third parties to conduct, supervise, and monitor a Phase 3 clinical trial OrthoCellix may initiate for NeoCart, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of the clinical trial or failing to comply with regulatory requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix expects to rely on third parties, such as CMOs, clinical data management organizations, medical and scientific institutions, and clinical and preclinical investigators, and others to conduct, supervise, and monitor a Phase 3 clinical trial for NeoCart. OrthoCellix may have to negotiate budgets and contracts with such third parties, and if OrthoCellix is unsuccessful or if the negotiations take longer than anticipated, this could result in delays to NeoCart&#8217;s development timeline and increased costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While OrthoCellix expects to have agreements governing the activities of such third parties, OrthoCellix will have limited influence and control over their actual performance and activities. Third-party service providers are not OrthoCellix&#8217;s employees, and except for remedies available to OrthoCellix under agreements with such third parties, OrthoCellix cannot control whether or not they devote sufficient time and resources to the Phase 3 clinical trial. Nevertheless, OrthoCellix will be responsible for ensuring that each of the clinical trial is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards, and OrthoCellix&#8217;s reliance on third parties will not relieve OrthoCellix of OrthoCellix&#8217;s regulatory responsibilities. For example, OrthoCellix will remain responsible for ensuring that the Phase 3 clinical trial is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and comparable foreign regulatory authorities require OrthoCellix to comply with GCPs for conducting, recording, and reporting the results of the clinical trial to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. The FDA enforces these GCPs through periodic inspections of trial sponsors, principal investigators, clinical trial sites, and IRBs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require OrthoCellix to repeat a clinical trial, which would delay the regulatory approval process for NeoCart. Moreover, OrthoCellix&#8217;s business may be implicated if any of these third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If these third parties upon which OrthoCellix depends do not successfully carry out their contractual duties, meet expected deadlines, conduct the clinical trial in accordance with regulatory requirements or OrthoCellix&#8217;s stated protocols, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to OrthoCellix&#8217;s protocols, regulatory requirements, or for other reasons:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix, OrthoCellix&#8217;s CMOs, or other third-party collaborators may be subject to regulatory enforcement or other legal actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data generated in a clinical trial may be deemed unreliable and a clinical trial may need to be repeated, extended, delayed, or terminated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix may need to identify new CMOs with which to partner for the supply of NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix may not be able to obtain, or may be delayed in obtaining, marketing approvals for NeoCart; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix may not be able to, or may be delayed in OrthoCellix&#8217;s efforts to, successfully commercialize NeoCart, if approved.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that a Phase 3 clinical trial will comply with the applicable regulatory requirements. To the extent OrthoCellix is unable to successfully identify and manage the performance of third-party service providers in the future, OrthoCellix&#8217;s business may be materially and adversely affected. As a result, OrthoCellix&#8217;s results of operations and the commercial prospects for NeoCart would be harmed, OrthoCellix&#8217;s costs could increase, and OrthoCellix&#8217;s ability to generate revenues from NeoCart could be delayed.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s reliance on third parties for a future Phase 3 clinical trial for NeoCart would entail additional risks. OrthoCellix&#8217;s third-party service providers may have relationships with other entities, some of which may be OrthoCellix&#8217;s competitors, for whom they may also be conducting clinical trials or other therapeutic development activities that could harm OrthoCellix&#8217;s competitive position. In addition, OrthoCellix will be required to report certain financial interests of OrthoCellix&#8217;s third-party investigators if these relationships exceed certain financial thresholds or meet other criteria. The FDA or comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted by investigators who may have conflicts of interest. Lastly, OrthoCellix would be required to register certain clinical trials and post the results of certain completed clinical trials on a government-sponsored database, <i style="font-style:italic;">clinicaltrials.gov</i>, within specified timeframes. Failure to do so can result in enforcement actions and adverse publicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Agreements with third parties conducting or otherwise assisting with NeoCart&#8217;s clinical study might terminate for a variety of reasons, including a failure to perform by the third parties. If any of OrthoCellix&#8217;s relationships with these third parties terminate, OrthoCellix may not be able to enter into arrangements with alternative providers or do so on commercially reasonable terms. Switching or adding additional third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, if OrthoCellix needs to enter into alternative arrangements, it could delay NeoCart&#8217;s development and adversely affect OrthoCellix&#8217;s business. Though OrthoCellix intends to carefully manage OrthoCellix&#8217;s relationships with third parties, there can be no assurance that OrthoCellix will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on OrthoCellix&#8217;s business, financial condition, prospects, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix will also rely on other third parties to store and distribute NeoCart for the Phase 3 clinical trial. Any performance failure on the part of OrthoCellix&#8217;s distributors could delay development, marketing approval, or commercialization of NeoCart, if approved, producing additional losses and depriving OrthoCellix of potential revenue derived from NeoCart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix is substantially dependent on Ocugen for the manufacturing of NeoCart and support of general and administrative functions of the NeoCart program. If Ocugen fails to produce NeoCart pursuant to the terms of contractual arrangements with OrthoCellix or fails to comply with stringent regulations applicable to biotechnology manufacturers, OrthoCellix may face delays in the development and commercialization of, or be unable to meet demand for, NeoCart, if approved, and may lose potential revenues.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix is expected to enter into a transition services agreement with Ocugen (&#8220;TSA&#8221;) pursuant to which Ocugen will provide, or cause its affiliates to provide, OrthoCellix with certain services to help facilitate an orderly transition of the NeoCart program. See &#8220;<i style="font-style:italic;">OrthoCellix Manufacturing Agreement</i>&#8221; and &#8220;<i style="font-style:italic;">Agreements Related to the Merger </i>&#8212; <i style="font-style:italic;">OrthoCellix Transition Services Agreement</i>&#8221; on page&#160;202 for more information on the terms of the TSA. OrthoCellix is also expected to enter a Manufacturing and Supply Agreement with Ocugen (the &#8220;OrthoCellix Manufacturing Agreement&#8221;) for the manufacturing of NeoCart. Ocugen completed renovating an existing facility into a cGMP facility to support clinical study and initial commercial launch in support of NeoCart manufacturing for Phase 3 clinical trial material. This facility is needed to generate a patient-specific NeoCart implant from chondrocytes derived from a knee biopsy. See &#8220;<i style="font-style:italic;">Agreements Related to the Merger</i> &#8212; <i style="font-style:italic;">OrthoCellix Manufacturing Agreement</i>&#8221; on page&#160;202 for more information on the terms of the OrthoCellix Manufacturing Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix will rely on Ocugen and may rely on other third-party CMOs to manufacture some of NeoCart&#8217;s supplies and may rely on third-parties for future Phase 3 clinical trial supplies and, if approved, will rely on Ocugen and other third-party CMOs to manufacture NeoCart. There can be no assurance that OrthoCellix&#8217;s clinical development, and, if approved, commercial product supplies for NeoCart will not be limited or interrupted, including as a result of impacts of current macroeconomic and geopolitical events, increasing rates of inflation, rising interest rates, or that OrthoCellix&#8217;s product supplies will be of satisfactory quality or continue to be available at acceptable prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As with the third parties on which OrthoCellix relies or expects to rely on for its Phase 3 clinical trial or possible future clinical trials for NeoCart, OrthoCellix has agreements governing the activities of Ocugen as a manufacturer but has limited influence and control over Ocugen&#8217;s actual performance and activities. Ocugen employees are not OrthoCellix&#8217;s employees, and except for remedies available to OrthoCellix under OrthoCellix&#8217;s agreements with Ocugen, OrthoCellix cannot control whether or not Ocugen devotes sufficient time and resources to OrthoCellix&#8217;s manufacturing requirements. If Ocugen does not successfully carry out its contractual duties, meet expected deadlines or manufacture NeoCart in accordance with regulatory requirements, and if there are disagreements between OrthoCellix and Ocugen, clinical development or marketing approval of NeoCart could be delayed.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The manufacture of biotechnology products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of therapeutics often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, and compliance with strictly enforced federal, state, and foreign regulations. If Ocugen were to encounter any of these difficulties and were unable to perform as agreed, OrthoCellix&#8217;s ability to provide NeoCart to patients in OrthoCellix&#8217;s Phase 3 clinical trial and for commercial use, if approved, would be jeopardized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, any manufacturers of NeoCart must comply with cGMP requirements enforced by the FDA that are applicable to both finished products and their active components used for both clinical and commercial supply. The FDA enforces these requirements through its facilities inspection program. Ocugen must be approved by the FDA pursuant to inspections that will be conducted after OrthoCellix submits OrthoCellix&#8217;s marketing applications to the agency. Ocugen will also be subject to continuing FDA and other regulatory authority inspections should OrthoCellix receive marketing approval. Further, OrthoCellix, in cooperation with OrthoCellix&#8217;s CMOs, must supply all necessary CMC documentation to the FDA in support of a marketing application on a timely basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The cGMP requirements include quality control, quality assurance, and the maintenance of records and documentation. Ocugen may be unable to comply with OrthoCellix&#8217;s specifications, cGMP requirements, and with other FDA, state, and foreign regulatory requirements. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be detectable in final product testing. If Ocugen or future CMOs cannot successfully manufacture material that conforms to OrthoCellix&#8217;s specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure or maintain regulatory approval for their manufacturing facilities. Any such deviations may also require remedial measures that may be costly and/or time-consuming for OrthoCellix or a third party to implement and that may include the temporary or permanent suspension of the Phase 3 clinical trial, once started, or commercial sales or the temporary or permanent closure of a facility. Any resulting delays in NeoCart&#8217;s compliance with the applicable regulatory requirements may result in delays to clinical trials, and NeoCart&#8217;s approval and commercialization. It may also require that OrthoCellix conduct additional studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While OrthoCellix is ultimately responsible for the manufacture of NeoCart, other than through OrthoCellix&#8217;s contractual arrangements, OrthoCellix has little control over OrthoCellix&#8217;s manufacturers&#8217; compliance with these regulations and standards. A failure to comply with the applicable regulatory requirements may result in regulatory enforcement actions against OrthoCellix&#8217;s manufacturers or OrthoCellix, including fines and civil and criminal penalties, including imprisonment, suspension or restrictions of production, injunctions, delays, withdrawal or denial of NeoCart&#8217;s approval, clinical holds or termination of clinical studies, warning or untitled letters, Form&#160;483s, regulatory authority communications warning the public about safety issues with the product, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the civil FCA, corporate integrity agreements, or consent decrees. Depending on the severity of any potential regulatory action, OrthoCellix&#8217;s clinical or commercial supply could be interrupted or limited, which could have a material adverse effect on OrthoCellix&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any problems or delays OrthoCellix experience in preparing for commercial-scale manufacturing of NeoCart, including manufacturing validation, may result in a delay in FDA approval or commercial launch, if approved, of NeoCart or may impair OrthoCellix&#8217;s ability to manufacture commercial quantities or such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of commercialization of NeoCart and could adversely affect OrthoCellix&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If OrthoCellix needs to identify and retain alternative CMOs for any reason, the technical skills required to manufacture NeoCart may be unique or proprietary to Ocugen and OrthoCellix may have difficulty, or there may be contractual restrictions prohibiting OrthoCellix from, transferring such skills to a back-up or alternate supplier, or OrthoCellix may be unable to transfer such skills at all. In addition, if OrthoCellix is required to change CMOs for any reason, OrthoCellix will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. OrthoCellix will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce NeoCart according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect OrthoCellix&#8217;s ability to develop NeoCart or commercialize it in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of NeoCart that such CMO owns independently. This would increase OrthoCellix&#8217;s reliance on such CMO or require OrthoCellix to obtain a license from such CMO in order to have another CMO manufacture NeoCart.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix or OrthoCellix&#8217;s third-party manufacturers may also encounter shortages in the materials necessary to produce NeoCart in the quantities needed for a Phase 3 clinical trial or, if NeoCart is approved, in sufficient quantities for commercialization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s Phase 3 clinical trial will require a patient-specific NeoCart implant from chondrocytes derived from a knee biopsy. OrthoCellix, Ocugen, or future third-party manufacturers may also encounter shortages in the raw materials, therapeutic substances, or active pharmaceutical ingredients necessary to produce NeoCart in the quantities needed for the clinical trial or, if NeoCart is approved, in sufficient quantities for commercialization or to meet an increase in demand. Such shortages may occur for a variety of reasons, including capacity constraints, delays or disruptions in the market, and shortages caused by the purchase of such materials by OrthoCellix&#8217;s competitors or others. OrthoCellix, Ocugen, or future third-party manufacturers&#8217; failure to obtain the raw materials, therapeutic substances, or active pharmaceutical ingredients necessary to manufacture sufficient quantities of NeoCart may cause the manufacturers to fail to deliver the required commercial quantities of NeoCart on a timely basis and at commercially reasonable prices. If such failure occurs, OrthoCellix would likely be unable to meet the demand for NeoCart, if approved, and OrthoCellix would lose potential revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The number of available, qualified third-party manufacturers is limited, and if OrthoCellix is compelled to locate an alternative manufacturing partner, NeoCart&#8217;s activities and commercialization could be delayed and additional expense would be incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are a limited number of manufacturers that operate under cGMP regulations, that are both capable of manufacturing for OrthoCellix and willing to do so, and therefore NeoCart may compete with other products and product candidates for access to manufacturing facilities. Moreover, because NeoCart must be manufactured under sterile conditions, the number of manufacturers who can meet this requirement is even more limited. Initially, Ocugen will be the exclusive manufacturer of NeoCart. If Ocugen, or the third parties that OrthoCellix engages in the future to manufacture NeoCart, if approved, or components thereof, for commercial sale or for Phase 3 clinical trial materials OrthoCellix expects to initiate in the future, should cease to continue to do so for any reason (including the termination of OrthoCellix&#8217;s agreements with such manufacturers, which can occur for a variety of reasons, or the bankruptcy of such manufacturers), it would be difficult to obtain a suitable alternative manufacturer. OrthoCellix would likely experience delays in obtaining sufficient quantities of NeoCart for OrthoCellix to meet commercial demand or to advance OrthoCellix&#8217;s clinical trials while OrthoCellix identifies and qualifies replacement suppliers. Any change in OrthoCellix&#8217;s manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the FDA or a comparable foreign regulatory authority inspects the facilities for the manufacture of NeoCart and finds that they are not in compliance with cGMP regulations now or in the future, OrthoCellix may need to find alternative manufacturing facilities. Any new manufacturers would need to either obtain or develop the necessary manufacturing know-how, and obtain the necessary equipment and materials, which may take substantial time and investment. OrthoCellix must also receive FDA approval for the use of any new manufacturers for commercial supply. Any such developments would significantly impact OrthoCellix&#8217;s ability to develop, obtain, and maintain regulatory authorization or approval for or market NeoCart, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The number of available third-party facilities may also be further limited by natural disasters, such as pandemics, floods, fire, or such facilities could face manufacturing issues, such as contamination or regulatory findings following a regulatory inspection of such facility. In such instances, an appropriate replacement third-party relationship may not be readily available to OrthoCellix or on acceptable terms, which would cause additional delays and increased expense and may have a material adverse effect on OrthoCellix&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix faces potential product liability exposure, and if successful claims are brought against OrthoCellix, OrthoCellix may incur substantial liability for NeoCart and may have to limit OrthoCellix&#8217;s commercialization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The use of NeoCart in clinical trials and the future sale of NeoCart, if OrthoCellix obtains regulatory approval, exposes OrthoCellix to the risk of product liability claims. Product liability claims might be brought against OrthoCellix by consumers, healthcare providers, pharmaceutical or biotechnology companies, or others selling or otherwise coming into contact with NeoCart. For example, OrthoCellix may be sued if NeoCart causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, or a breach of warranties. Claims could also be asserted under state consumer protection acts. If OrthoCellix cannot successfully defend itself against these claims, OrthoCellix will </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">incur substantial liabilities or be required to limit development or commercialization of NeoCart. Even successful defense would require significant financial and management resources. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue from decreased demand for NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of OrthoCellix&#8217;s business reputation or financial stability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exhaustion of any available insurance and OrthoCellix&#8217;s capital resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease in OrthoCellix&#8217;s stock price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations and enforcement actions by regulators; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls, withdrawals, revocation of approvals, or labeling, marketing, or promotional restrictions.</span></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">OrthoCellix may need to obtain and increase OrthoCellix&#8217;s insurance coverage as OrthoCellix continues to conduct OrthoCellix&#8217;s clinical trials. OrthoCellix will need to further increase OrthoCellix&#8217;s insurance coverage if OrthoCellix commences commercialization of NeoCart, if approved. Insurance coverage is increasingly expensive. OrthoCellix may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. On occasion, large judgments have been awarded in class action lawsuits based on therapeutics that had unanticipated side effects. OrthoCellix&#8217;s insurance policies also have various exclusions, and OrthoCellix may be subject to a product liability claim for which OrthoCellix has no coverage. A successful product liability claim or series of claims brought against OrthoCellix and, if judgments exceed OrthoCellix&#8217;s insurance coverage, could decrease OrthoCellix&#8217;s cash and adversely affect OrthoCellix&#8217;s business and OrthoCellix&#8217;s prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix may seek to collaborate with third parties for the development or commercialization of OrthoCellix&#8217;s product candidates. OrthoCellix may not be successful in establishing or maintaining collaborative relationships, any of which could adversely affect OrthoCellix&#8217;s ability to develop and commercialize OrthoCellix&#8217;s product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">In the future, OrthoCellix may seek to enter into additional collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization of other product candidates. OrthoCellix may utilize a variety of types of collaboration, distribution, and other marketing arrangements with third parties to develop and commercialize OrthoCellix&#8217;s product candidates, both inside and outside the United States. In particular, OrthoCellix may enter into arrangements with third parties to perform certain services in the United States or other countries if OrthoCellix does not establish OrthoCellix&#8217;s own sales, marketing, and distribution capabilities in such countries, or if OrthoCellix determines that such third-party arrangements are otherwise beneficial. OrthoCellix may also consider potential collaborative partnership opportunities for sales, marketing, distribution, development, or licensing or broader collaboration arrangements, including with mid-size and large pharmaceutical companies, regional and national pharmaceutical companies, and biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The success of OrthoCellix&#8217;s current and future collaboration arrangements will depend heavily on the efforts and activities of OrthoCellix&#8217;s collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to collaboration arrangements. Accordingly, with respect to any such arrangements with any third parties, OrthoCellix will likely have limited control over the amount and timing of resources that OrthoCellix&#8217;s collaborators dedicate to the development or commercialization of OrthoCellix&#8217;s product candidates. OrthoCellix&#8217;s ability to generate revenues from these arrangements will depend in part on OrthoCellix&#8217;s collaborator&#8217;s abilities and efforts to successfully perform the functions assigned to them in these arrangements.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercialization of the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Moreover, collaborations with pharmaceutical companies and other third parties are often terminated or allowed to expire. Any such termination or expiration would adversely affect OrthoCellix financially and could harm OrthoCellix&#8217;s business reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s current and future collaborations may pose a number of additional risks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development of product candidates and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could fail to make timely regulatory submissions for a product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable regulatory requirements, which could subject them or OrthoCellix to regulatory enforcement actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with OrthoCellix&#8217;s product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than OrthoCellix&#8217;s;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates discovered in collaboration with OrthoCellix may be viewed by OrthoCellix&#8217;s collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of OrthoCellix&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more of OrthoCellix&#8217;s product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product candidate or product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation, or the preferred course of development, might cause delays or termination of the research, development, or commercialization of product candidates, might lead to additional responsibilities for OrthoCellix with respect to product candidates, or might result in litigation or arbitration, any of which would be time consuming and expensive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend OrthoCellix&#8217;s intellectual property rights or may use OrthoCellix&#8217;s proprietary information in such a way as to invite litigation that could jeopardize or invalidate OrthoCellix&#8217;s intellectual property or proprietary information or expose OrthoCellix to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties or fail to maintain intellectual property rights which they license to OrthoCellix, which may expose OrthoCellix to litigation and potential liability; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated for the convenience of the collaborator and, if terminated, OrthoCellix could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Collaboration agreements may not lead to development or commercialization of OrthoCellix&#8217;s product candidates in the most efficient manner, or at all. If any collaborations do not result in the successful development and commercialization of OrthoCellix&#8217;s product candidates or if one of OrthoCellix&#8217;s collaborators subsequently terminates OrthoCellix&#8217;s agreement with OrthoCellix, OrthoCellix may not receive any future research funding, milestone, or royalty payments under the collaboration, as applicable. If OrthoCellix does not receive the funding OrthoCellix expects under the agreements, OrthoCellix&#8217;s development of OrthoCellix&#8217;s </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product candidates could be delayed, and OrthoCellix may need additional resources to develop OrthoCellix&#8217;s product candidates and OrthoCellix&#8217;s product platform. All of the risks relating to product development, regulatory approval, and commercialization described in this report also apply to the activities of OrthoCellix&#8217;s collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, if any collaborator of OrthoCellix&#8217;s is involved in a business combination, the collaborator might de-emphasize or terminate development or commercialization of any product candidate licensed to them by OrthoCellix. If one of OrthoCellix&#8217;s collaborators terminates its agreement with OrthoCellix, OrthoCellix may find it more difficult to attract new collaborators and OrthoCellix&#8217;s reputation in the business and financial communities could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to OrthoCellix&#8217;s Business and Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">In order to successfully implement its plans and strategies, OrthoCellix will need to grow the size of its organization and it may experience difficulties in managing this growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix expects to experience significant growth in the number of its employees and the scope of its operations, particularly in the areas of preclinical and clinical drug development, technical operations, clinical operations and regulatory affairs. To manage its anticipated future growth, OrthoCellix must continue to implement and improve its managerial, operational and financial personnel and systems, expand its facilities and continue to recruit and train additional qualified personnel. Due to OrthoCellix&#8217;s limited financial resources and the limited experience of its management team working together in managing a company with such anticipated growth, OrthoCellix may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix will be highly dependent on its key personnel and anticipates hiring new key personnel. If OrthoCellix is not successful in attracting and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon its ability to attract and retain highly qualified managerial, scientific and medical personnel. OrthoCellix will be highly dependent on its managerial, scientific and medical personnel, including its Chief Executive Officer and other key members of its leadership team. Although OrthoCellix intends to enter into employment agreements with its future executive officers, each of them will be able to terminate their employment with OrthoCellix at any time. OrthoCellix does not maintain &#8220;key person&#8221; insurance for any of its officers, and in the future, may not maintain &#8220;key person&#8221; insurance for any of its executives or employees. The loss of the services of OrthoCellix&#8217;s executive officers or other key employees could in the future impede the achievement of its research, development and commercialization objectives and seriously harm its ability to successfully implement its business strategy. Furthermore, replacing executive officers and key personnel may be difficult and may take an extended period of time. If OrthoCellix does not succeed in attracting and retaining qualified personnel, it could materially adversely affect OrthoCellix&#8217;s business, financial condition and results of operations. OrthoCellix could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in OrthoCellix&#8217;s employee recruitment and retention efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix&#8217;s future growth may depend, in part, on its ability to operate in foreign markets, where OrthoCellix would be subject to additional regulatory burdens and other risks and uncertainties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s future growth may depend, in part, on its ability to develop and commercialize its product candidates, if approved, in foreign markets for which OrthoCellix may rely on collaboration with third parties. OrthoCellix is not permitted to market or promote any of its product candidates before OrthoCellix receives regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of its product candidates. To obtain separate regulatory approval in many other countries, OrthoCellix must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of OrthoCellix&#8217;s product candidates, if approved, and OrthoCellix cannot predict success in these jurisdictions. If OrthoCellix fails to comply with the regulatory requirements in international markets and receive applicable regulatory approvals, OrthoCellix&#8217;s target market will be reduced and its ability to realize the full market potential of its product candidates will be harmed and its business will be adversely affected. Moreover, even if OrthoCellix obtains approval of its product candidates and ultimately commercializes its product candidates in foreign markets, OrthoCellix would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix&#8217;s employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix is exposed to the risk that its employees, independent contractors, consultants, commercial collaborators, principal investigators, clinical research organizations, CMOs, suppliers and vendors acting for or on OrthoCellix&#8217;s behalf may engage in misconduct or other improper activities. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to OrthoCellix that violates FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare laws and regulations, and laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to OrthoCellix&#8217;s reputation. OrthoCellix will adopt a code of conduct, which will become effective as of the closing of the Merger, but it is not always possible to identify and deter misconduct by these parties and the precautions OrthoCellix takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting OrthoCellix from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix is subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect OrthoCellix&#8217;s operating results and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix, and third parties who OrthoCellix works with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. In addition, OrthoCellix is or may become subject to the terms of contractual obligations related to privacy, data protection, and data security. OrthoCellix&#8217;s obligations may also change or expand as its business grows. The actual or perceived failure by OrthoCellix or third parties related to OrthoCellix to comply with such laws, regulations and obligations could increase OrthoCellix&#8217;s compliance and operational costs, expose OrthoCellix to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on OrthoCellix&#8217;s business, financial condition, and results of operations. Please see the section titled &#8220;<i style="font-style:italic;">OrthoCellix&#8217;s Business&#8201;&#8212;&#8201;Government Regulation and Product Approval&#160;&#8212; Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations</i>&#8221; beginning on page&#160;301 of this proxy statement/prospectus for a more detailed description of the laws that may affect OrthoCellix&#8217;s ability to operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If OrthoCellix fails to comply with environmental, health and safety laws and regulations, it could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of OrthoCellix&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. OrthoCellix&#8217;s operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, OrthoCellix may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair OrthoCellix&#8217;s research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The rules&#160;governing U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect OrthoCellix&#8217;s sole stockholder or OrthoCellix. OrthoCellix assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where OrthoCellix has operations to determine the potential effect on OrthoCellix&#8217;s business and any assumptions it has made about OrthoCellix&#8217;s future taxable income. OrthoCellix cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on OrthoCellix&#8217;s business if they were to be enacted. For example, the United States enacted the Inflation </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Reduction Act of 2022, which implements, among other changes, a one&#160;percent excise tax on certain stock buybacks, and on July 4, 2025, the One Big Beautiful Bill Act was signed into law and made significant changes to U.S. federal income tax law. Such changes, among others, may adversely affect OrthoCellix&#8217;s effective tax rate, results of operation and general business condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix may acquire businesses, product candidates or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that OrthoCellix believes will complement or augment its existing business. If OrthoCellix acquires businesses with promising markets or technologies, it may not be able to realize the benefit of acquiring such businesses if OrthoCellix is unable to successfully integrate them with its existing operations and company culture. OrthoCellix may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent OrthoCellix from realizing their expected benefits or enhancing OrthoCellix&#8217;s business. There is no assurance that, following any such acquisition, OrthoCellix will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on OrthoCellix&#8217;s business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to OrthoCellix&#8217;s Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">As with all patent prosecution, there is no guarantee of obtaining and maintaining patent protection for NeoCart. In addition, there is no guarantee that the scope of the patent protection obtained is sufficiently broad or enforceable, to prevent OrthoCellix&#8217;s competitors from developing and commercializing technology and products similar or identical to NeoCart. Furthermore, OrthoCellix&#8217;s ability to successfully commercialize NeoCart may be impaired due to circumstances that may be out of OrthoCellix&#8217;s control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s success depends in large part on OrthoCellix&#8217;s ability to obtain and maintain patent protection in the United States and other countries, with respect to OrthoCellix&#8217;s proprietary technology related to NeoCart. As of July 21, 2025, OrthoCellix has 17 issued United States patents, four pending United States patent applications, 20 issued or registered foreign patents, and eight pending foreign patent applications related to NeoCart. Its issued or registered patents and pending patent applications include those licensed from Purpose Co., Ltd. (&#8220;Purpose&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is expensive and time-consuming, and OrthoCellix may not have filed, maintained, or prosecuted and OrthoCellix may not be able to file, maintain, and prosecute all necessary or desirable patents or patent applications at a reasonable cost or in a timely manner. In some cases, OrthoCellix may not be able to or it may be difficult to timely identify patentable aspects of OrthoCellix&#8217;s research and development output to obtain patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions, and has in recent&#160;years been the subject of much litigation. As a result, the further issuance, scope, validity, enforceability, and commercial value of OrthoCellix&#8217;s patent rights are uncertain. OrthoCellix&#8217;s pending and future patent applications related to NeoCart may fail to result in issued patents in the United States or in other foreign countries which may impact protection of NeoCart, or which may effectively prevent others from commercializing it. In addition, the laws of foreign countries may not protect OrthoCellix&#8217;s rights to the same extent as the laws of the United States, and the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, unlike patent law in the United States, European patent law precludes the patentability of methods of treatment of the human body and imposes substantial restrictions on the scope of claims it will grant. In addition, unlike the United States the European Patent Office typically limits the claims to those commensurate in scope with specifically disclosed embodiments. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after the earliest priority date, or in some cases not at all. Therefore, OrthoCellix cannot be certain whether OrthoCellix or OrthoCellix&#8217;s licensors were the first to make the inventions claimed in OrthoCellix&#8217;s owned or licensed patents or pending patent applications, or that OrthoCellix or OrthoCellix&#8217;s licensors were the first to file for patent protection of such inventions. Databases for patents and publications, and methods for searching them, are inherently limited so OrthoCellix may not know the full scope of all issued and pending patent applications. As a result, the issuance, scope, validity, enforceability, and commercial value of OrthoCellix&#8217;s patent rights related to NeoCart are uncertain. OrthoCellix&#8217;s pending and future patent applications may not result in patents being issued, thereby limited protection of NeoCart, in whole or in part, or allowing a third party to commercialize competitive technologies or products. In particular, during prosecution of any patent application, the issuance of any patents based on the application may depend upon OrthoCellix&#8217;s ability to generate additional preclinical or clinical data that support the patentability of OrthoCellix&#8217;s proposed claims. OrthoCellix may not be able to generate sufficient additional data on a timely basis, or at all. </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of OrthoCellix&#8217;s patents or narrow the scope of OrthoCellix&#8217;s patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if OrthoCellix&#8217;s owned and licensed patent applications issue as patents, they may not issue in a form that will provide OrthoCellix with any commercially meaningful protection for NeoCart, prevent competitors from competing with OrthoCellix, or otherwise provide OrthoCellix with any competitive advantage. OrthoCellix&#8217;s competitors may be able to circumvent OrthoCellix&#8217;s owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. In addition, in order to practice OrthoCellix&#8217;s owned or licensed patents, OrthoCellix may need to license additional patents to commercialize NeoCart in certain territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The issuance of a patent is not conclusive as to OrthoCellix&#8217;s inventorship, ownership, scope, validity, or enforceability of NeoCart, and OrthoCellix&#8217;s owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit OrthoCellix&#8217;s ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of NeoCart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of OrthoCellix&#8217;s patent applications relating to NeoCart and the enforcement or defense of OrthoCellix&#8217;s issued patents relating to NeoCart.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act includes a number of significant changes to the United States patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The USPTO developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, became effective in 2013. The first to file provisions limit the rights of an inventor to patent an invention if the inventor is not the first to file an application for patenting that invention. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of OrthoCellix&#8217;s four pending United States patent applications and eight pending foreign patent applications related to NeoCart and the enforcement or defense of OrthoCellix&#8217;s 17 issued United States patents and 20 issued or registered foreign patents related to NeoCart, which could have a material adverse effect on OrthoCellix&#8217;s business, financial condition, results of operations, and prospects. For example, the Leahy-Smith Act created a new administrative tribunal known as the Patent Trial and Appeals Board (&#8220;PTAB&#8221;), that provides a venue for any third parties to challenge the validity of patents at a cost that is significantly lower than district court litigation and on timelines that are much faster. Although it is not clear what, if any, long term impact the PTAB proceedings will have on the operation of OrthoCellix&#8217;s business, the outcome of patent challenge proceedings before the PTAB since its inception in 2013 have resulted in the invalidation of many United States patents. The availability of the PTAB as a lower-cost, faster, and potentially more potent tribunal for challenging patents could therefore increase the likelihood that OrthoCellix&#8217;s own patents will be challenged, thereby increasing the uncertainties and costs of maintaining, defending, and enforcing them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If OrthoCellix is not able to obtain patent term extension for NeoCart in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, OrthoCellix&#8217;s business may be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration, and specifics of FDA marketing approval of NeoCart, one of the United States patents covering NeoCart or the use thereof may be eligible for up to five&#160;years of patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product to account for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval and only those claims covering such approved drug product, a method for using it, or a method for manufacturing it may be extended. Patent term extension also may be available in certain foreign countries upon regulatory approval of NeoCart. Nevertheless, OrthoCellix may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than OrthoCellix requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If OrthoCellix is unable to obtain patent term extension or restoration, or the term of any such extension is less than OrthoCellix requests, the period during which OrthoCellix will have the right to exclusively market NeoCart will be shortened. In such cases, OrthoCellix&#8217;s competitors will likely obtain approval of competing products, including NOVOCART 3D, sooner than OrthoCellix might have anticipated, which may have a negative impact on OrthoCellix&#8217;s revenue.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, for OrthoCellix&#8217;s licensed patents, OrthoCellix does not have the right to control prosecution, including filing with the USPTO, a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of OrthoCellix&#8217;s licensed patents is eligible for patent term extension under the Hatch-Waxman Act, OrthoCellix may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix may become involved in lawsuits to protect or enforce the 2021 issued or registered foreign patents, and eight pending foreign patent applications related to NeoCart, which could be expensive, time-consuming, and unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NeoCart&#8217;s competitors, including Vericel Corporation&#8217;s MACI and Aesculap Biologics, LLC&#8217;s NOVOCART 3D, and other third parties may infringe, misappropriate, or otherwise violate OrthoCellix&#8217;s rights to owned and licensed patents or other intellectual property related to NeoCart. As a result, to discourage, prevent, or counter infringement, misappropriation, or unauthorized use, OrthoCellix may be required to file infringement or misappropriation claims or other intellectual property related proceedings, which can be expensive and time-consuming. Any claims OrthoCellix asserts against perceived infringers could provoke such parties to assert counterclaims against OrthoCellix alleging that OrthoCellix infringed their patents or that OrthoCellix&#8217;s asserted patents are invalid. In addition, in a patent infringement or other intellectual property related proceeding, a court may decide that a patent of OrthoCellix&#8217;s is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that OrthoCellix&#8217;s patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of OrthoCellix&#8217;s patents at risk of being invalidated, held unenforceable, or interpreted narrowly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in other contested proceedings such as opposition, derivation, reexamination, inter partes review, post-grant review, or interference proceedings in the United States or elsewhere, challenging OrthoCellix&#8217;s patent rights or the patent rights of others. An adverse determination in any such submission, proceeding, or litigation could invalidate or reduce the scope of OrthoCellix&#8217;s patent rights, allow third parties to commercialize OrthoCellix&#8217;s technology or NeoCart and compete directly with OrthoCellix, without payment to OrthoCellix, or result in OrthoCellix&#8217;s inability to manufacture or commercialize NeoCart without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by OrthoCellix&#8217;s intellectual property is threatened, it could dissuade companies from collaborating with OrthoCellix to license, develop, or commercialize NeoCart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that NeoCart infringes, misappropriates, or otherwise violates their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of OrthoCellix&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Part&#160;of OrthoCellix&#8217;s commercial success depends upon OrthoCellix&#8217;s ability to develop, manufacture, market, and sell NeoCart and use OrthoCellix&#8217;s proprietary technologies without infringing or otherwise violating the intellectual property and other proprietary rights of third parties. There is a considerable amount of intellectual property litigation in the biotechnology and pharmaceutical industries. OrthoCellix may become party to, or threatened with, claims by a third party for use, misappropriation, or infringement of their intellectual property rights regarding NeoCart&#8217;s technology. Claims of use, misappropriation, or infringement of intellectual property rights may arise from competitors or even from entities that may have patents but do not use or practice their patent. OrthoCellix&#8217;s own patent portfolio may have no deterrent effect on entities that do not use of practice their own patent. Moreover, OrthoCellix may become party to future adversarial proceedings or litigation regarding the 17 issued United States patents, four pending United States patent applications, 20 issued or registered foreign patents, and eight pending foreign patent applications related to NeoCart, or the patents of third parties. Such proceedings could also include contested post-grant proceedings such as oppositions, inter partes review, reexamination, interference, or derivation proceedings before the USPTO or foreign patent offices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The legal threshold for initiating litigation or contested proceedings is low, so even lawsuits or proceedings with a low probability of success might be initiated by a third party, which will require significant resources from OrthoCellix to defend. Litigation and contested proceedings can be expensive and time-consuming, and OrthoCellix&#8217;s adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than OrthoCellix does. The risks of being involved in such litigation and proceedings may increase as NeoCart nears commercialization and as OrthoCellix gains the greater visibility associated with being a public company. Third parties may assert infringement claims against OrthoCellix based on NeoCart&#8217;s existing patents or patents that may be granted in the future. OrthoCellix may not be aware of all such intellectual property rights potentially relating to NeoCart and their uses. Thus, OrthoCellix does not know with certainty that NeoCart does not and will not infringe or otherwise violate any third party&#8217;s intellectual property.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If NeoCart is found to infringe or otherwise violate a third party&#8217;s intellectual property rights, OrthoCellix could be required to obtain a license from such third party to continue developing and marketing NeoCart. However, OrthoCellix may not be able to obtain any required license on commercially reasonable terms or at all. Even if OrthoCellix is able to obtain a license, it could be non-exclusive, thereby giving OrthoCellix&#8217;s competitors access to the same technologies licensed to OrthoCellix and could require OrthoCellix to make substantial licensing and royalty payments. OrthoCellix could be forced, including by court order, to cease commercializing or practicing the infringing technology or product. In addition, OrthoCellix could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if OrthoCellix is found to have willfully infringed a patent, and could be forced to indemnify OrthoCellix&#8217;s customers or collaborators. A finding of infringement could also result in an injunction that prevents OrthoCellix from commercializing NeoCart or forces OrthoCellix to cease some of OrthoCellix&#8217;s business operations related to NeoCart, which could materially harm OrthoCellix&#8217;s business. In addition, OrthoCellix may be forced to redesign NeoCart, seek new regulatory approvals, and indemnify third parties pursuant to contractual agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection for NeoCart depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and OrthoCellix&#8217;s patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance, renewal, and annuity fees on any issued patent must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of OrthoCellix&#8217;s 17 issued United States patents, four pending United States patent applications, 21 issued or registered foreign patents, and eight pending foreign patent applications related to NeoCart. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If OrthoCellix, Purpose, or other future licensors fail to maintain the patents and patent applications covering NeoCart, it would have a material adverse effect on OrthoCellix&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If OrthoCellix fails to comply with OrthoCellix&#8217;s obligations in OrthoCellix&#8217;s license with Purpose, OrthoCellix could lose rights that are important to OrthoCellix&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s agreements, including the Purpose Agreement (as defined herein) under which OrthoCellix licenses certain of OrthoCellix&#8217;s patent rights and a significant portion of the technology for NeoCart imposes royalty and other financial and performance obligations. OrthoCellix may also enter into additional licensing and funding arrangements with third parties that may impose diligence, development, and commercialization timelines and milestone payment, royalty, insurance, and other obligations. If OrthoCellix fails to comply with OrthoCellix&#8217;s obligations under the Purpose Agreement or future license and collaboration agreements, OrthoCellix&#8217;s counterparties may have the right to terminate these agreements, in which event OrthoCellix might not be able to develop, manufacture, or market any product that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could diminish the value of NeoCart. Termination of these agreements or reduction or elimination of OrthoCellix&#8217;s rights under these agreements may result in OrthoCellix having to negotiate new or reinstated agreements with less favorable terms or cause OrthoCellix to lose OrthoCellix&#8217;s rights under these agreements, including OrthoCellix&#8217;s rights to important intellectual property or technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the Purpose Agreement is complex, and as with any agreements certain provisions in such agreement may be susceptible to different interpretations by the parties. The resolution of any contract interpretation disagreement that may arise could narrow what OrthoCellix believes to be the scope of OrthoCellix&#8217;s rights to the relevant intellectual property and technology or increase what OrthoCellix believes to be OrthoCellix&#8217;s financial or other obligations under the Purpose Agreement, either of which could have a material adverse effect on OrthoCellix&#8217;s business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that OrthoCellix has licensed prevent or impair OrthoCellix&#8217;s ability to maintain the Purpose Agreement on commercially acceptable terms, OrthoCellix may be unable to successfully develop and commercialize NeoCart, which could have a material adverse effect on OrthoCellix&#8217;s business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix may not be able to protect OrthoCellix&#8217;s intellectual property and proprietary rights related to NeoCart throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Filing additional patents or prosecuting and defending OrthoCellix&#8217;s current patents in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect OrthoCellix&#8217;s rights to the same extent as the laws of the United States. Consequently, OrthoCellix may not be able to prevent third parties from practicing regenerative cell therapy in all </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">countries outside the United States, or from selling or importing products made using OrthoCellix&#8217;s regenerative cell therapy technology in and into the United States or other jurisdictions. Competitors may use OrthoCellix&#8217;s regenerative cell therapy technology in jurisdictions where OrthoCellix has not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where OrthoCellix has patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with NeoCart, and OrthoCellix&#8217;s NeoCart patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for OrthoCellix to stop the infringement of OrthoCellix&#8217;s NeoCart patents or marketing of competing products in violation of OrthoCellix&#8217;s intellectual property and proprietary rights generally. Proceedings to enforce OrthoCellix&#8217;s intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert OrthoCellix&#8217;s efforts, resources, and attention from other aspects of OrthoCellix&#8217;s business, could put OrthoCellix&#8217;s patents at risk of being invalidated or interpreted narrowly, could put OrthoCellix&#8217;s patent applications at risk of not being issued, or could provoke third parties to assert claims against OrthoCellix. OrthoCellix may not prevail in any lawsuits that OrthoCellix initiates, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, OrthoCellix&#8217;s efforts to enforce OrthoCellix&#8217;s intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that OrthoCellix develops or licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If OrthoCellix or Purpose are forced to grant a license to third parties with respect to any patents relevant to OrthoCellix&#8217;s business, OrthoCellix&#8217;s competitive position may be impaired, and OrthoCellix&#8217;s business, financial condition, results of operations, and prospects may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property litigation or other legal proceedings relating to intellectual property could cause OrthoCellix to spend substantial resources and distract OrthoCellix&#8217;s personnel from their normal responsibilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if resolved in OrthoCellix&#8217;s favor, litigation or other legal proceedings relating to intellectual property claims may cause OrthoCellix to divert significant resources or incur significant expenses and could distract OrthoCellix&#8217;s technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of OrthoCellix&#8217;s common stock. Such litigation or proceedings could substantially increase OrthoCellix&#8217;s operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. OrthoCellix may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of OrthoCellix&#8217;s competitors may be able to sustain the costs and resources of such litigation or proceedings more effectively than OrthoCellix because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on OrthoCellix&#8217;s ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If OrthoCellix is unable to protect the confidentiality of OrthoCellix&#8217;s trade secrets, OrthoCellix&#8217;s business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to seeking patents for OrthoCellix&#8217;s technology and product candidates, OrthoCellix also relies on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain OrthoCellix&#8217;s competitive position. OrthoCellix seeks to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as OrthoCellix&#8217;s employees, corporate collaborators, outside scientific collaborators, CMOs, consultants, advisors, and other third parties. OrthoCellix also enters into confidentiality and invention or patent assignment agreements with OrthoCellix&#8217;s employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose OrthoCellix&#8217;s proprietary information, including OrthoCellix&#8217;s trade secrets, and OrthoCellix may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, many jurisdictions, both foreign and domestic, are less willing or unwilling to protect trade secrets. Moreover, if any of OrthoCellix&#8217;s trade secrets were to be lawfully obtained or independently developed by a competitor, OrthoCellix would have no right </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to prevent them from using or disclosing such information to compete with OrthoCellix. If any of OrthoCellix&#8217;s trade secrets were to be legally obtained by or independently developed by a competitor, OrthoCellix&#8217;s competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Legal and Compliance Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If OrthoCellix fails to maintain proper and effective internal control over financial reporting, OrthoCellix&#8217;s ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in OrthoCellix&#8217;s financial reporting, and the trading price of OrthoCellix&#8217;s common stock may decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section&#160;404 of Sarbanes-Oxley, OrthoCellix&#8217;s management is required to report upon the effectiveness of OrthoCellix&#8217;s internal control over financial reporting. This assessment includes disclosure of any material weaknesses identified by OrthoCellix&#8217;s management in internal control over financial reporting. The rules&#160;governing the standards that must be met for management to assess OrthoCellix&#8217;s internal control over financial reporting are complex and require significant documentation, testing, and possible remediation. If OrthoCellix is unable to conclude that OrthoCellix&#8217;s internal control over financial reporting is effective, investors may lose confidence in OrthoCellix&#8217;s financial reporting and the trading price of OrthoCellix&#8217;s common stock may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix continues to implement measures designed to improve OrthoCellix&#8217;s internal controls over financial reporting. Failure to implement and maintain effective internal control over financial reporting or a material weakness in OrthoCellix&#8217;s internal control over financial reporting could result in an increased probability of fraud, litigation from OrthoCellix&#8217;s shareholder, reduction in OrthoCellix&#8217;s ability to obtain financing, and require additional expenditures to remediate. Additionally, if OrthoCellix is unable to conclude that OrthoCellix&#8217;s internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of OrthoCellix&#8217;s financial reports, the market price of OrthoCellix&#8217;s common stock could decline, and OrthoCellix could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in OrthoCellix&#8217;s internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict OrthoCellix&#8217;s future access to the capital markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix may in the future be subject to securities litigation, which is expensive and could divert management attention.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix may become subject to additional securities class action lawsuits in the future. This risk is especially relevant for OrthoCellix because life sciences companies have experienced significant stock price volatility in recent&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The cost of defending against these types of claims against OrthoCellix or the ultimate resolution of such claims, whether by settlement or adverse court decision, may divert management&#8217;s attention and harm OrthoCellix&#8217;s business. Further, potential claimants may be encouraged to bring lawsuits based on a settlement from OrthoCellix or adverse court decisions against OrthoCellix. OrthoCellix cannot currently assess the likely outcome of such lawsuits, but the commencement and/or resolution of such lawsuits (particularly if the outcome were negative), could have a material adverse effect on OrthoCellix&#8217;s reputation, results of operations, financial condition, and cash flows. They could also cause a decline in the market price of OrthoCellix&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If OrthoCellix fails to comply with federal and state healthcare laws, including fraud, abuse, and health and other information privacy and security laws, OrthoCellix could face substantial penalties and OrthoCellix&#8217;s business, financial condition, results of operations, and prospects could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a biotechnology company, OrthoCellix is subject to many federal and state healthcare laws, such as the federal Anti-Kickback Statute, the federal civil and criminal FCA, the civil monetary penalties statute, the Medicaid Drug Rebate (&#8220;MDR&#8221;) statute and other price reporting requirements, the Veterans Healthcare Administration, HIPAA, the FCPA, the ACA, and similar state laws. OrthoCellix may also be subject to laws regarding transparency (such as the Physician Payments Sunshine Act) and patient privacy laws. Even though OrthoCellix does not and will not control referrals of healthcare services or bills directly to Medicare, Medicaid, or other third-party payors, certain federal and state healthcare laws, and regulations pertaining to fraud and abuse, reimbursement programs, government procurement, and patients&#8217; rights are and will be applicable to OrthoCellix&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">It is possible that governmental authorities will conclude that OrthoCellix&#8217;s business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud, abuse, or other healthcare laws and regulations. If OrthoCellix&#8217;s operations are found to be in violation of any federal or state healthcare law, or any other governmental laws or regulations that applies to OrthoCellix, OrthoCellix may be subject to penalties, including civil, criminal, and administrative penalties, damages, fines, imprisonment, disgorgement, suspension and debarment from government contracts, and refusal of orders under existing government </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">contracts, exclusion from participation in the United States federal or state health care programs, corporate integrity agreements, and the curtailment or restructuring of OrthoCellix&#8217;s operations, any of which could materially adversely affect OrthoCellix&#8217;s ability to operate OrthoCellix&#8217;s business and OrthoCellix&#8217;s financial results. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security, reimbursement, and fraud laws may prove costly. Any action against OrthoCellix for the violation of these laws, even if OrthoCellix successfully defends against it, could cause OrthoCellix to incur significant legal expenses and divert OrthoCellix management&#8217;s attention from the operation of OrthoCellix&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please see the section titled &#8220;<i style="font-style:italic;">OrthoCellix&#8217;s Business&#8201;&#8212;&#8201;Government Regulation and Product Approval&#160;&#8212; Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations</i>&#8221; beginning on page&#160;301 of this proxy statement/prospectus for a more detailed description of the laws that may affect OrthoCellix&#8217;s ability to operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare legislative or regulatory reform measures may have a negative impact on OrthoCellix&#8217;s business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The United States government, state legislatures, and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription products. In recent&#160;years, Congress has considered reductions in Medicare reimbursement levels for products administered by physicians.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ACA substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacts the pharmaceutical industry. The ACA was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. There have been significant ongoing administrative, executive, and legislative efforts to modify or eliminate the ACA. The ACA has also been subject to challenges in the courts. Further, other legislative changes have been proposed and adopted since the passage of the ACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional changes to and under the ACA remain possible, but it is unknown what form any such changes or any law proposed to replace or revise the ACA would take, and how or whether it may affect OrthoCellix&#8217;s business in the future. OrthoCellix expects that changes to the ACA, the Medicare and Medicaid programs, changes allowing the federal government to directly negotiate prices and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing, or other legislation in individual states, could have a material adverse effect on the healthcare industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix expects that additional federal, state, and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement, and reduced demand for OrthoCellix&#8217;s products, once approved, or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please see the section titled &#8220;<i style="font-style:italic;">OrthoCellix&#8217;s Business&#8201;&#8212;&#8201;Government Regulation and Product Approval&#160;&#8212; Healthcare Reform Measures</i>&#8221; beginning on page&#160;304 of this proxy statement/prospectus for a more detailed description of the laws that may affect OrthoCellix&#8217;s ability to operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix&#8217;s internal computer systems or those of OrthoCellix&#8217;s development collaborators, third-party CMOs, or other contractors or consultants may fail or suffer cybersecurity incidents, data breaches, or other disruptions, which could result in a material disruption of OrthoCellix&#8217;s product development programs and cause OrthoCellix&#8217;s business and operations to suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">OrthoCellix&#8217;s internal computer systems and those of OrthoCellix&#8217;s CMOs and other contractors and consultants are vulnerable to cybersecurity incidents or data breaches and damage from computer viruses, unauthorized access, ransomware, social engineering attacks (including phishing attacks), natural disasters, terrorism, war, and telecommunication and electrical failures. While OrthoCellix has not experienced any material system failure, accident, or cybersecurity incident or data breach to date, OrthoCellix, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">like other companies in its industry, have experienced, and may in the future continue to experience, threats and cybersecurity incidents relating to OrthoCellix&#8217;s and OrthoCellix&#8217;s third-party vendors&#8217; information systems. If a material event were to occur and cause interruptions in OrthoCellix&#8217;s operations, it could result in a material disruption of OrthoCellix&#8217;s business operations and product candidate development and, if any of OrthoCellix&#8217;s product candidates are approved, commercialization programs. Likewise, OrthoCellix intends to rely on third parties to manufacture OrthoCellix&#8217;s product candidates and conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on OrthoCellix&#8217;s business and operations. To the extent that any disruption or cybersecurity incident or other data breach were to result in a loss of, or damage to, OrthoCellix&#8217;s data or applications, or inappropriate disclosure of confidential or proprietary information, OrthoCellix could incur liability, the further development and commercialization of OrthoCellix&#8217;s product candidates could be delayed, and OrthoCellix&#8217;s reputation could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, OrthoCellix&#8217;s business processes personal data, including some data related to health. When conducting clinical trials, OrthoCellix faces risks associated with collecting trial participants&#8217; data, especially health data, in a manner consistent with applicable laws and regulations. OrthoCellix also faces risks inherent in handling large volumes of data and in protecting the security of such data. OrthoCellix could be subject to attacks on OrthoCellix&#8217;s systems by outside parties or fraudulent or inappropriate behavior by OrthoCellix&#8217;s service providers or employees. Third parties may also gain access to OrthoCellix&#8217;s systems using stolen or inferred credentials, computer malware, viruses, spamming, phishing attacks, or other means, and may use such access to obtain personal data. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, OrthoCellix may be unable to anticipate these techniques or implement adequate preventative measures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any failure by OrthoCellix or OrthoCellix&#8217;s service providers, collaborators, consultants, contractors or partners to detect, prevent, respond to or mitigate data breaches or cybersecurity incidents, compromises, or improper access to, use of, or inappropriate disclosure of any of this information or other confidential or sensitive information, including patients&#8217; personal data, or the perception that any such failure has occurred, could result in claims, litigation, regulatory investigations and other proceedings, significant liability under state, federal and international law, and other financial, legal or reputational harm to OrthoCellix, including class action lawsuits from affected individuals. Further, such failures or perceived failures could result in liability and a material disruption of OrthoCellix&#8217;s development programs and OrthoCellix&#8217;s business operations, which could lead to significant delays or setbacks in OrthoCellix&#8217;s research, delays to commercialization of OrthoCellix&#8217;s product candidates, lost revenues or other adverse consequences, any of which could have a material adverse effect on OrthoCellix&#8217;s business, results of operations, financial condition, prospects and cashflow. For example, the loss or alteration of clinical trial data from future clinical trials could result in delays in OrthoCellix&#8217;s regulatory approval efforts and significantly increase OrthoCellix&#8217;s costs to recover or reproduce the data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cybersecurity incidents or data breaches could subject OrthoCellix to individual or consumer class action litigation and governmental investigations and proceedings by federal, state, and local regulatory entities in the United States and by international regulatory entities, resulting in exposure to material civil and/or criminal liability. Additionally, applicable laws and regulations relating to privacy, data protection or cybersecurity, external contractual commitments and internal privacy and security policies may require OrthoCellix to notify relevant stakeholders if there has been a cybersecurity incident or data breach, including affected individuals, business partners and regulators. Such disclosures are costly, and the disclosures or any actual or alleged failure to comply with such requirements could lead to a materially adverse impact on the business, including negative publicity, a loss of confidence in OrthoCellix&#8217;s services or security measures by OrthoCellix&#8217;s business partners or breach of contract claims. There can be no assurance that the limitations of liability in OrthoCellix&#8217;s contracts would be enforceable or adequate or would otherwise protect OrthoCellix from liabilities or damages if OrthoCellix fails to comply with applicable data protection laws, privacy policies or other data protection obligations related to information cybersecurity incidents, compromises, or security breaches. Further, although OrthoCellix intends to obtain cyber liability insurance, this insurance may not provide adequate coverage against potential liabilities related to any cybersecurity incident or data breach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of OrthoCellix&#8217;s product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The United States Supreme Court&#8217;s June&#160;2024 decision in&#160;<i style="font-style:italic;">Loper Bright Enterprises v. Raimondo</i>&#160;overturned the longstanding&#160;<i style="font-style:italic;">Chevron</i>&#160;doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The&#160;<i style="font-style:italic;">Loper</i>&#160;decision could result in additional legal challenges to regulations and guidance issued by federal agencies, including the FDA, on which OrthoCellix relies. Any such legal challenges, if successful, could have a material impact on OrthoCellix&#8217;s business. Additionally, the&#160;<i style="font-style:italic;">Loper</i>&#160;decision may result in increased regulatory uncertainty, inconsistent judicial interpretations, and other impacts to the agency rulemaking process, any of which could adversely impact OrthoCellix&#8217;s business and </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">operations. OrthoCellix cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action or as a result of legal challenges, either in the United States or abroad. If OrthoCellix is slow or unable to adapt to changes in existing requirements or adoption of new requirements or policies, or if OrthoCellix is not able to maintain regulatory compliance, OrthoCellix&#8217;s business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix&#8217;s future employees, independent contractors, consultants, commercial partners, principal investigators, or CMOs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on OrthoCellix&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix is exposed to the risk of employee fraud or other misconduct. Misconduct by future employees, independent contractors, consultants, commercial partners, manufacturers, investigators, or CMOs could include intentional, reckless, negligent, or unintentional failures to (i)&#160;comply with FDA regulations or other similar regulatory requirements, (ii)&#160;comply with manufacturing standards, including cGMP requirements, (iii)&#160;comply with applicable fraud and abuse laws, (iv)&#160;comply with federal and state data privacy, security, fraud and abuse, and other healthcare laws and regulations in the United States and abroad, (v)&#160;provide accurate information to the FDA, (vi)&#160;properly calculate pricing information required by federal programs, (vii)&#160;comply with federal procurement rules&#160;or contract terms, (viii)&#160;report financial information or data accurately, or (ix)&#160;disclose unauthorized activities to OrthoCellix. This misconduct could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to OrthoCellix&#8217;s reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is not always possible to identify and deter this type of misconduct, and the precautions OrthoCellix takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting OrthoCellix from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any such actions are instituted against OrthoCellix, and OrthoCellix is not successful in defending itself or asserting its rights, those actions could have a significant impact on OrthoCellix&#8217;s business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if OrthoCellix becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of OrthoCellix&#8217;s operations, any of which could adversely affect OrthoCellix&#8217;s ability to operate OrthoCellix&#8217;s business and OrthoCellix&#8217;s results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix faces risks related to OrthoCellix&#8217;s collection and use of data, which could result in investigations, inquiries, litigation, fines, legislative and regulatory action, and negative press about OrthoCellix&#8217;s privacy and data protection practices.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As OrthoCellix&#8217;s operations and business grow, OrthoCellix may become subject to or be affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities, including various domestic and international privacy and security regulations. The legislative and regulatory landscape for privacy and data protection continues to evolve. In the United States, at the federal level, failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a)&#160;of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Through executive and legislative action, the federal government has also taken steps to restrict data transactions involving certain sensitive data categories&#160;- including health data, genetic data, and biospecimens&#160;- with persons affiliated with China, Russia, and other countries of concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, certain U.S. states have adopted privacy and security laws and regulations that may be more stringent than applicable federal law. For example, the CCPA, which took effect on January&#160;1, 2020, established a comprehensive privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules&#160;on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. The California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), effective January&#160;1, 2023, expanded the CCPA&#8217;s requirements, including expanding consumers&#8217; rights with respect to certain sensitive personal information, broadening the application of the CCPA to personal information of business representatives and employees and establishing a new regulatory agency to implement and enforce the law. While clinical trial data and information governed by HIPAA are currently </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">exempt from the current version of the CCPA, other personal information may be applicable and possible changes to the CCPA may broaden its scope.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar laws have been passed in numerous other states. Other states have proposed new privacy laws which, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make OrthoCellix&#8217;s compliance obligations more complex and costly and may increase the likelihood that OrthoCellix may be subject to enforcement actions or otherwise incur liability for noncompliance. There are also states that are specifically regulating health information. For example, Washington&#8217;s My Health My Data Act (&#8220;WMHMDA&#8221;), which went into effect March&#160;31, 2024, regulates the collection and sharing of health information. WMHMDA also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data. In addition, other states have proposed and/or passed legislation that regulates the privacy and/or security of certain specific types of information. For example, a small number of states have passed laws that regulate biometric data specifically. These various privacy and security laws may impact OrthoCellix&#8217;s business activities, including OrthoCellix&#8217;s identification of research subjects, relationships with business partners and ultimately the marketing and distribution of OrthoCellix&#8217;s products. State laws are changing rapidly and there have been discussions in the United States Congress of a new comprehensive federal data privacy law to which OrthoCellix may likely become subject, if enacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix may also in the future be subject to data protection laws and regulations of other jurisdictions, such as the GDPR. The GDPR in the EU and the UK, which have been incorporated into their respective laws, impose stringent requirements on the processing of health and other sensitive data. These requirements encompass: (i)&#160;providing information to individuals regarding data processing activities; (ii)&#160;ensuring a legal basis or condition applies to the processing of personal data and, where applicable, obtaining consent from individuals to whom the data processing relates; (iii)&#160;responding to data subject requests; (iv)&#160;imposing requirements to notify the competent national data protection authorities and data subjects of personal data breaches; (v)&#160;implementing safeguards in connection with the security and confidentiality of the personal data; (vi)&#160;accountability requirements; and (vii)&#160;taking certain measures when engaging third-party processors. In the event that OrthoCellix is subject to or affected by privacy and data protection laws, including the CCPA, CPRA, or GDPR and other domestic or international privacy and data protection laws, OrthoCellix may expend significant resources to comply with such laws, and any liability from failure to comply with the requirements of these laws could adversely affect OrthoCellix&#8217;s financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants and legal advisors, which are likely to increase over time. In addition, such requirements may require OrthoCellix to modify OrthoCellix&#8217;s data processing practices and policies, utilize management&#8217;s time and/or divert resources from other initiatives and projects. Any failure or perceived failure by OrthoCellix to comply with any applicable federal, state or foreign laws and regulations relating to data privacy and security could result in damage to OrthoCellix&#8217;s reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would subject OrthoCellix to significant fines, sanctions, awards, injunctions, penalties or judgments. Any of the foregoing could have a material adverse effect on OrthoCellix&#8217;s business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix is subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws, and other laws governing OrthoCellix&#8217;s operations. If OrthoCellix fails to comply with these laws, OrthoCellix could be subject to civil or criminal penalties, other remedial measures and legal expenses, or be precluded from developing, manufacturing, and selling certain products outside the United States, which could adversely affect OrthoCellix&#8217;s business, results of operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If OrthoCellix expands its operations outside of the United States, OrthoCellix must dedicate additional resources to comply with anti-corruption laws, including the Bribery Act, the FCPA, and other anti-corruption laws that apply to countries where OrthoCellix does business and may do business in the future. The Bribery Act, FCPA, and these other laws generally prohibit OrthoCellix, OrthoCellix&#8217;s officers, and OrthoCellix&#8217;s employees and intermediaries from bribing, being bribed, or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Compliance with the FCPA, in particular, is expensive and difficult, particularly in countries in which corruption is a recognized problem. The FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and OrthoCellix may participate in collaborations and relationships with third parties whose actions could potentially subject OrthoCellix to liability under the Bribery Act, FCPA, or local anti-corruption laws. OrthoCellix is also subject to other laws and regulations governing OrthoCellix&#8217;s international operations, including the Trade Control Laws. In addition, various laws, regulations, and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-United States nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If OrthoCellix expands its presence outside of the United States, it will require OrthoCellix to dedicate additional resources to comply with these laws, and these laws may preclude OrthoCellix from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit OrthoCellix&#8217;s growth potential and increase OrthoCellix&#8217;s development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If OrthoCellix is not in compliance with the Bribery Act, the FCPA, and other anti-corruption laws or Trade Control Laws, OrthoCellix may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on OrthoCellix&#8217;s business, financial condition, results of operations, and liquidity. The SEC also may suspend or bar issuers from trading securities on the United States exchanges for violations of the FCPA&#8217;s accounting provisions. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control Laws by U.K., the United States, or other authorities could also have an adverse impact on OrthoCellix&#8217;s reputation, OrthoCellix&#8217;s business, results of operations, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The use of new and evolving technologies, such as artificial intelligence, in OrthoCellix&#8217;s business may result in spending material resources and presents risks and challenges that can impact OrthoCellix&#8217;s business including by posing security and other risks to OrthoCellix&#8217;s confidential and/or proprietary information, including personal information, and as a result OrthoCellix may be exposed to reputational harm and liability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix may use and integrate artificial intelligence into OrthoCellix&#8217;s business processes, and this innovation presents risks and challenges that could affect its adoption, and therefore OrthoCellix&#8217;s business. If OrthoCellix enables or offers solutions that draw controversy due to perceived or actual negative societal impact, OrthoCellix may experience brand or reputational harm, competitive harm or legal liability. The use of certain artificial intelligence technology can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement. Additionally, OrthoCellix expects to see increasing government and supranational regulation related to artificial intelligence use and ethics, which may also significantly increase the burden and cost of research, development and compliance in this area. For example, the EU&#8217;s Artificial Intelligence Act (&#8220;AI Act&#8221;)&#160;- the world&#8217;s first comprehensive AI law&#160;- which entered into force on August&#160;1, 2024 and most provisions of which will become effective on August&#160;2, 2026. This legislation imposes significant obligations on providers and deployers of high-risk artificial intelligence systems, and encourages providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems. If OrthoCellix develops or uses AI systems that are governed by the AI Act, it may necessitate ensuring higher standards of data quality, transparency, and human oversight, as well as adhering to specific and potentially burdensome and costly ethical, accountability, and administrative requirements. Furthermore, in the U.S., a number of states have proposed and passed laws regulating various uses of AI, and federal regulators have issued guidance affecting the use of AI in regulated sectors.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The rapid evolution of artificial intelligence will require the application of significant resources to design, develop, test and maintain OrthoCellix&#8217;s products and services to help ensure that artificial intelligence is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. OrthoCellix&#8217;s vendors may in turn incorporate artificial intelligence tools into their offerings, and the providers of these artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage OrthoCellix&#8217;s reputation, result in the loss of valuable property and information, cause OrthoCellix to breach applicable laws and regulations, and adversely impact OrthoCellix&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Social media is increasingly being used to communicate about OrthoCellix&#8217;s research, product candidates, and the diseases those product candidates and investigational medicines are being developed to treat. Social media practices in the biotechnology industry and the FDA&#8217;s regulation of social media continues to evolve. This evolution creates uncertainty and risk of noncompliance with regulations applicable to OrthoCellix&#8217;s business, resulting in potential regulatory actions against OrthoCellix. For example, OrthoCellix&#8217;s employees or agents may use social media channels to inadvertently provide inaccurate or misleading information about OrthoCellix&#8217;s product candidates. If regulators become aware of such disclosures, they may take administrative or enforcement action against OrthoCellix. There is also a risk that third parties will use social media to disseminate inaccurate or misleading information about OrthoCellix or OrthoCellix&#8217;s product candidates. If this occurs, OrthoCellix may not be able to adequately defend OrthoCellix&#8217;s business or the public&#8217;s perception of OrthoCellix or OrthoCellix&#8217;s product candidates, particularly given restrictions on what OrthoCellix may say about OrthoCellix&#8217;s product candidates prior to FDA approval. If any of these events were to occur or OrthoCellix otherwise fail to comply with applicable regulations, OrthoCellix could incur liability, face regulatory actions, or incur other harm to OrthoCellix&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Evolving expectations around corporate responsibility practices, specifically related to environmental, social and governance (&#8220;ESG&#8221;) matters, may expose OrthoCellix to reputational and other risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Investors, stockholders, customers, suppliers and other third parties are increasingly focusing on ESG and corporate social responsibility endeavors and reporting. Certain institutional investors, investment funds, other influential investors, customers, suppliers and other third parties are also increasingly focused on ESG practices. Companies that do not adapt to or comply with the evolving investor or stakeholder expectations and standards, or which are perceived to have not responded appropriately, may suffer from reputational damage and result in the business, financial condition, and/or stock price of a company being materially and adversely affected. Further, this increased focus on ESG issues may result in new regulations and/or third party requirements that could adversely impact OrthoCellix&#8217;s business, or certain shareholders reducing or eliminating their holdings of OrthoCellix&#8217;s stock. Additionally, an allegation or perception that OrthoCellix has not taken sufficient action in these areas could negatively harm OrthoCellix&#8217;s reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix expects to be a &#8220;smaller reporting company&#8221; as defined in the Exchange Act, and has elected and expects to elect to take advantage of certain of the scaled disclosures available to smaller reporting companies, including reduced disclosure obligations regarding executive compensation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix expects be a &#8220;smaller reporting company&#8221; as defined in the Exchange Act and has elected and expects to elect to take advantage of certain of the scaled disclosures available to smaller reporting companies, including, among other things, providing only two&#160;years of audited financial statements. OrthoCellix will remain a smaller reporting company if (1)&#160;the market value of OrthoCellix&#8217;s common stock held by non-affiliates is less than $250.0 million as of the last business day of the second fiscal quarter, or (2)&#160;OrthoCellix&#8217;s annual revenues in OrthoCellix&#8217;s most recent fiscal&#160;year completed before the last business day of OrthoCellix&#8217;s second fiscal quarter are less than $100.0 million and the market value of OrthoCellix&#8217;s common stock held by non-affiliates is less than $700.0 million as of the last business day of the second fiscal quarter.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Combined Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Following the Merger, the Combined Company may be unable to integrate successfully the businesses of Carisma and OrthoCellix and realize the anticipated benefits of the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger involves the combination of two companies which currently operate as independent companies. Following the Merger, the Combined Company will be required to devote significant management attention and resources to integrating its business practices and operations. The Combined Company may fail to realize some or all of the anticipated benefits of the merger, including the benefits anticipated in the Financial Forecasts described under &#8220;<i style="font-style:italic;">The Merger-Certain Unaudited Prospective Financial Information</i>,&#8221; if the integration process takes longer than expected or is more costly than expected. Potential difficulties the Combined Company may encounter in the integration process include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to successfully combine the businesses of Carisma and OrthoCellix in a manner that permits the Combined Company to achieve the anticipated benefits from the Merger, which would result in the anticipated benefits of the Merger not being realized partly or wholly in the time frame currently anticipated or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">creation of uniform standards, controls, procedures, policies and information systems; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential unknown liabilities and unforeseen increased expenses, delays or regulatory conditions associated with the Merger.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any of the events described in &#8220;Risks Related to Carisma&#8221; or &#8220;Risks Related to OrthoCellix&#8221; occur, those events could cause potential benefits of the Merger not to be realized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following completion of the Merger, the Combined Company will be susceptible to many of the risks described in the sections herein entitled &#8220;<i style="font-style:italic;">Risks Related to Carisma</i>&#8221; and &#8220;<i style="font-style:italic;">Risks Related to OrthoCellix.</i>&#8221; To the extent any of the events in the risks described in those sections occur, the potential benefits of the Merger may not be realized and the results of operations and financial condition of the Combined Company could be adversely affected in a material way. This could cause the market price of the Combined Company&#8217;s common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price of the Combined Company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The market price of the Combined Company&#8217;s common stock following the Merger could be subject to significant fluctuations. Some of the factors that may cause the market price of the Combined Company&#8217;s common stock to fluctuate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical trials and preclinical studies of the Combined Company&#8217;s product candidates, or those of the Combined Company&#8217;s competitors or the Combined Company&#8217;s existing or future collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed financial and development projections the Combined Company may provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed the financial and development projections of the investment community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if the Combined Company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the Combined Company or its competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actions taken by regulatory agencies with respect to the Combined Company&#8217;s product candidates, clinical studies, manufacturing process or sales and marketing terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and the Combined Company&#8217;s ability to obtain patent protection for its technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or stockholder litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if securities or industry analysts do not publish research or reports about the Combined Company&#8217;s business, or if they issue adverse or misleading opinions regarding its business and stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of securities by the Combined Company or its securityholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if the Combined Company fails to raise an adequate amount of capital to fund its operations or continued development of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of the Combined Company&#8217;s common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of technological innovations or new therapies that compete with the products and services of the Combined Company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">period-to-period fluctuations in the Combined Company&#8217;s financial results.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the Combined Company&#8217;s common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect the Combined Company&#8217;s business and the value of its common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if the Combined Company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the Combined Company&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on its operating results, financial condition and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the assets subject to the CVR Agreement are not disposed of in a timely manner, the Combined Company may have to incur time and resources to wind down or dispose of such assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, Carisma intends to declare a dividend to each person who as of immediately prior to the Effective Time of the Merger was a stockholder of record of Carisma of the right to receive one non-transferable CVR for each then outstanding share of Carisma common stock, each representing the non-transferable contractual right to receive certain contingent payments from the Combined Company upon the occurrence of certain events within agreed time periods. See the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger-Contingent Value Rights Agreement</i>&#8221; beginning on page&#160;197 of this proxy statement/prospectus. Pursuant to the terms of the CVR Agreement, if the Combined Company is unable to sell the assets subject to the CVR Agreement prior to the two-year anniversary of the Closing Date (as defined in the Merger Agreement), the Combined Company will be responsible for any wind-down costs associated with the termination of such assets within the parameters contained in the CVR Agreement. Further, pursuant to the terms of the CVR Agreement, the holders of Carisma common stock prior to the closing, rather than the holders of the Combined Company&#8217;s common stock, are the primary recipients of any net proceeds of the disposition of the assets subject to the CVR Agreement. Absent such CVR Agreement, the Combined Company may have allocated such funds, time and resources to its core programs and the foregoing could be a distraction to the Combined Company&#8217;s management and employees. As a result, the Combined Company&#8217;s operations and financial condition may be adversely affected.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our stockholders may not receive any payment on the CVR and the CVR may expire valueless.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At or prior to the Effective Time, Carisma will enter into a the CVR Agreement with a rights agent pursuant to which pre-Merger Carisma common stockholders, subject to the terms and conditions set forth in the CVR Agreement will receive one CVR for each outstanding share of Carisma common stock held by such stockholder on such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance any payments will be made with respect to the CVRs. The CVRs will not be transferable, except in the limited circumstances specified in the CVR Agreement, will not have any voting or dividend rights, and will not represent any equity or ownership interest in OrthoCellix, the Combined Company or any constituent party to the Merger Agreement. Accordingly, the right of any of our stockholders to receive any future payment on or derive any value from the CVRs will be contingent solely upon the occurrence of certain events, as outlined in the CVR Agreement, and if no such events are achieved for any reason within the time periods specified in the CVR Agreement, no payments will be made under the CVRs, and the CVRs will expire valueless.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The U.S. federal income tax treatment of the CVRs is unclear, and there can be no assurance that the Internal Revenue Service would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The U.S. federal income tax treatment of the CVRs is unclear. There is no legal authority directly addressing the U.S. federal income tax treatment of the receipt of, and payments on, the CVRs, and there can be no assurance that the IRS would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs. As discussed in the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Carisma Contingent Value Rights Agreement&#8212;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</i>,&#8221; Carisma will treat the issuance of the CVRs as a distribution of property with respect to its stock. However, there is no authority directly addressing whether contingent value rights with characteristics similar to the CVRs should be treated as a distribution of property with respect to the corporation&#8217;s stock, a distribution of equity, a &#8220;debt instrument&#8221; or an &#8220;open transaction&#8221; for U.S. federal income tax purposes. In addition, although Carisma will estimate the value of the CVRs for purposes of reporting the distribution on Form&#160;1099-DIV to Carisma stockholders, the value of the CVRs is uncertain, and the IRS or a court could determine that the value of the CVRs at the time of issuance was higher. In such case, the Carisma stockholders could be treated as having additional income or gain upon receipt of the CVRs as described further in the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Carisma Contingent Value Rights Agreement&#8212;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</i>&#8221; beginning on page&#160;197 of this proxy statement/prospectus. Further, notwithstanding Carisma&#8217;s position that the receipt of CVRs and the contemplated reverse stock split are appropriately treated as separate transactions, it is possible that the IRS or a court could determine that the Carisma stockholders&#8217; receipt of the CVRs and the proposed reverse stock split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to Carisma&#8217;s position, which could result in adverse U.S. federal income tax consequences to holders of the CVRs. The tax consequences of such alternative treatments are described below under the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Carisma Contingent Value Rights Agreement&#8212;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</i>,&#8221; beginning on page&#160;197 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company may incur losses for the foreseeable future and may never achieve profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company may never become profitable, even if it is able to complete clinical development for one or more product candidates and eventually commercialize such product candidates. The Combined Company will need to successfully complete significant research, development, testing and regulatory compliance activities that, together with projected general and administrative expenses, is expected to result in substantial increased operating losses for at least the next several&#160;years. Even if the Combined Company does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conflicts of interest may arise between the Combined Company and Ocugen.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ocugen is currently the sole stockholder of OrthoCellix and following the Merger and the anticipated Concurrent Financing (including Ocugen&#8217;s purchase of $5.0 million of common stock in the Concurrent Financing) is expected to beneficially own&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the Combined Company&#8217;s common stock (based on the number of shares of Carisma&#8217;s common stock outstanding as of June&#160;30, 2025).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">One of the Combined Company&#8217;s non-employee directors, Michael Shine, was affiliated with Ocugen as he was formerly an employee. The remaining members of the Combined Company&#8217;s board of directors are not affiliated with Ocugen. The Combined Company&#8217;s relationship with Ocugen and OrthoCellix&#8217;s non-employee director may create, or may create the appearance of, conflicts </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of interest when the Combined Company is faced with decisions that could have different implications for Ocugen than the decisions have for the Combined Company. For example, such conflicts may arise in connection with the manufacturing agreement, selection of additional targets, the negotiation of the terms of any future license agreements, the allocation of resources and expenses, the enforcement or defense of intellectual property rights, the pursuit of strategic partnerships or transactions, or the resolution of any disputes that may arise between the Combined Company and Ocugen. These potential conflicts of interest may make it more difficult for the Combined Company to favorably advance the Combined Company&#8217;s business interests and may adversely affect the Combined Company&#8217;s competitive position, business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Combined Company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s ability to compete in the highly competitive pharmaceuticals industry depends on its ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. The Combined Company will be highly dependent on its management and scientific personnel. The loss of the services of any of these individuals could impede, delay, or prevent the successful development of the Combined Company&#8217;s product pipeline, completion of its planned clinical trials, commercialization of its product candidates or in-licensing or acquisition of new assets and could impact negatively its ability to implement successfully its business plan. If the Combined Company loses the services of any of these individuals, it might not be able to find suitable replacements on a timely basis or at all, and its business could be harmed as a result. The Combined Company might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company will require substantial additional funds to conduct the costly and time-consuming clinical efficacy trials necessary to pursue regulatory approval of each potential product candidate and to continue the development of NeoCart and the Combined Company&#8217;s future product candidates. The Combined Company&#8217;s future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain and could, for example, through the sale of common stock or securities convertible or exchangeable into common stock, significantly dilute the Combined Company&#8217;s stockholders&#8217; ownership interests or inhibit the Combined Company&#8217;s ability to achieve its business objectives. If the Combined Company raises additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely the rights of its common stockholders. In addition, any debt financing may subject the Combined Company to fixed payment obligations and covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Combined Company raises additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, the Combined Company may have to relinquish certain valuable intellectual property or other rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to it. Even if the Combined Company were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to the Combined Company or its stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company will incur significant legal, accounting and other expenses as a public company that OrthoCellix did not incur as a private company, including costs associated with public company reporting obligations under the Exchange Act. These executive officers and other personnel of the Combined Company will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that the Combined Company complies with all of these requirements. Any changes the Combined Company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules&#160;and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for the Combined Company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Upon completion of the Merger, failure by the Combined Company to comply with the initial listing standards of Nasdaq will prevent its stock from being listed on Nasdaq.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon completion of the Merger, Carisma, under the new name &#8220;OrthoCellix,&#160;Inc.,&#8221; will be required to meet the initial listing requirements to maintain the listing and continued trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements. Pursuant to the Merger Agreement, Carisma and OrthoCellix agreed to reasonably cooperate to seek approval of the listing of the shares of Carisma common stock being issued in the Merger on Nasdaq at or prior to the Effective Time of the Merger. Based on information currently available to Carisma, Carisma anticipates that its stock will be unable to meet the $4.00 minimum bid price initial listing requirement at the closing, unless prior to the closing, it effects a reverse stock split. Carisma is scheduled to hold a separate special meeting of Carisma stockholders on August&#160;5, 2025 to approve an amendment to Carisma&#8217;s certificate of incorporation to effect a reverse stock split of Carisma&#8217;s issued and outstanding common stock at a ratio of no less than 1-for-10 and no greater than 1-for-50, with the ratio within such range to be determined at the discretion of Carisma&#8217;s board of directors, without further approval or authorization of Carisma&#8217;s stockholders. There can be no assurance that Carisma&#8217;s stockholders will approve the reverse stock split, or that if approved, that Carisma&#8217;s stock after the reverse stock split will meet the $4.00 minimum bid price initial listing requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, often a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split. Following the Merger, if the Combined Company is unable to satisfy Nasdaq listing requirements, Nasdaq may notify the Combined Company that its shares of common stock will not be listed on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon a potential delisting from Nasdaq, if the common stock of the Combined Company is not then eligible for quotation on another market or exchange, trading of the shares could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of the common stock of the Combined Company; decreases in institutional and other investor demand for the shares, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute trades in the common stock of the Combined Company. Also, it may be difficult for the Combined Company to raise additional capital if the Combined Company&#8217;s common stock is not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of the common stock of the Combined Company and could have a material adverse effect on the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Once the Combined Company is no longer a smaller reporting company or otherwise no longer qualifies for applicable exemptions, the Combined Company will be subject to additional laws and regulations affecting public companies that will increase the Combined Company&#8217;s costs and the demands on management and could harm the Combined Company&#8217;s operating results and cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company will be subject to the reporting requirements of the Exchange Act, which requires, among other things, that the Combined Company file with the SEC, annual, quarterly and current reports with respect to the Combined Company&#8217;s business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule&#160;12b-2 under the Exchange Act, in at least the near term, the Combined Company may take advantage of exemptions from disclosure requirements and reduced disclosure obligations regarding executive compensation in this proxy statement/prospectus and in the Combined Company&#8217;s periodic reports and proxy statements. In addition, if the Combined Company is a smaller reporting company with less than $100.0 million in annual revenue, it would not be required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act. Once the Combined Company is no longer a smaller reporting company or otherwise no longer qualifies for these exemptions, the Combined Company will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If the Combined Company is not able to comply with the requirements in a timely manner or at all, the Combined Company&#8217;s financial condition or the market price of the Combined Company&#8217;s common stock may be harmed. For example, if the Combined Company or its independent auditor identifies deficiencies in the Combined Company&#8217;s internal control over financial reporting that are deemed to be material weaknesses the Combined Company could face additional costs to remedy those deficiencies, the market price of the Combined Company&#8217;s stock could decline or the Combined Company could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Combined Company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provided the Combined Company continues to be listed on Nasdaq, the Combined Company will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules&#160;and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that the Combined Company maintain effective disclosure controls and procedures and internal control over financial reporting. The Combined Company must perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form&#160;10-K filing for that&#160;year, as required by Section&#160;404 of the Sarbanes-Oxley Act. As a private company, OrthoCellix has not been required to document and test its internal controls over financial reporting nor has its management been required to certify the effectiveness of its internal controls and its auditors have not been required to opine on the effectiveness of its internal control over financial reporting. Following the Merger, the Combined Company will be required to incur substantial professional fees and internal costs to expand its accounting and finance functions and expend significant management efforts. The Combined Company may experience difficulty in meeting these reporting requirements in a timely manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company may discover weaknesses in its system of internal financial and accounting controls and procedures that could result in a material misstatement of its financial statements. The Combined Company&#8217;s internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Combined Company is not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act, or if it is unable to maintain proper and effective internal controls, the Combined Company may not be able to produce timely and accurate financial statements. If that were to happen, the market price of its common stock could decline and it could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The unaudited pro forma condensed combined financial information for Carisma and OrthoCellix included in this proxy statement/prospectus are preliminary, and the Combined Company&#8217;s actual financial position and operations after the Merger may differ materially from the unaudited pro forma financial information included in this proxy statement/prospectus.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma financial information for Carisma and OrthoCellix included in this proxy statement/prospectus are presented for illustrative purposes only and is not necessarily indicative of the Combined Company&#8217;s actual financial condition or results of operations of future periods, or the financial condition or results of operations that would have been realized had the entities been combined during the period presented. The Combined Company&#8217;s actual results and financial position after the Merger may differ materially and adversely from the unaudited pro forma financial information included in this proxy statement/prospectus. The Exchange Ratio reflected in this proxy statement/prospectus is preliminary. The final Exchange Ratio could differ from the preliminary Exchange Ratio used to prepare the pro forma adjustments. For more information, please see the section titled &#8220;<i style="font-style:italic;">Unaudited Pro Forma Condensed Combined Financial Information</i>&#8221; beginning on page&#160;344 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Carisma and OrthoCellix do not anticipate that the Combined Company will pay any cash dividends in the foreseeable future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The current expectation is that the Combined Company will retain its future earnings, if any, to fund the growth of the Combined Company&#8217;s business as opposed to paying dividends. As a result, capital appreciation, if any, of the common stock of the Combined Company will be your sole source of gain, if any, for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">An active trading market for the Combined Company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Merger, there had been no public market for shares of OrthoCellix capital stock. An active trading market for the Combined Company&#8217;s shares of common stock may never develop or be sustained. If an active market for the Combined Company&#8217;s common stock does not develop or is not sustained, it may be difficult for the Combined Company&#8217;s stockholders to sell their shares at an attractive price or at all.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future sales of shares by existing stockholders could cause the Combined Company&#8217;s stock price to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">If existing securityholders of Carisma and OrthoCellix sell, or indicate an intention to sell, substantial amounts of the Combined Company&#8217;s common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, the trading price of the common stock of the Combined Company could decline. Based on shares outstanding as of June&#160;30, 2025, after giving effect to the estimated Exchange Ratio, the shares of Carisma&#8217;s common stock to be issued in the anticipated Concurrent Financing and shares expected to be issued upon completion of the Merger and prior to giving effect to the contemplated reverse stock split, the Combined Company is expected to have outstanding a total of approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock immediately following the completion of the Merger. Of the shares of common stock, approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares will become available for sale in the public market beginning 180&#160;days after the closing of the Merger as a result of the expiration of lock-up agreements between Carisma and OrthoCellix on the one hand and certain securityholders of Carisma and OrthoCellix on the other hand (and without giving effect to any restrictions on resale under securities laws). All other outstanding shares of common stock, other than shares held by affiliates of the Combined Company and shares of Carisma common stock to be issued in the anticipated Concurrent Financing, will be freely tradable, without restriction, in the public market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">After completion of the Merger, the Combined Company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the Combined Company&#8217;s stockholders for approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Upon the completion of the Merger, and giving effect to the issuance of the shares of OrthoCellix common stock prior to the closing of the Merger pursuant to the anticipated Concurrent Financing, it is anticipated that the Combined Company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the Combined Company&#8217;s outstanding shares of common stock (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, Carisma&#8217;s Net Cash as of closing being approximately $0 and the anticipated Concurrent Financing Amount of $25.0 million. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the Combined Company&#8217;s stockholders for approval, as well as the Combined Company&#8217;s management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of the Combined Company&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of the Combined Company on terms that other stockholders may desire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the Combined Company, its business or its market, its stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The trading market for the Combined Company&#8217;s common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect to not provide research coverage of the Combined Company&#8217;s common stock after the completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the Combined Company will not have any control over the analysts or the content and opinions included in their reports. The price of the Combined Company&#8217;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the Combined Company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company will have broad discretion in the use of the cash and cash equivalents of the Combined Company and the proceeds from the anticipated Concurrent Financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The Combined Company will have broad discretion over the use of the cash and cash equivalents of the Combined Company and the proceeds from the anticipated Concurrent Financing. You may not agree with the Combined Company&#8217;s decisions, and its use of the proceeds may not yield any return on your investment. The Combined Company&#8217;s failure to apply these resources effectively could compromise its ability to pursue its growth strategy and the Combined Company might not be able to yield a significant return, if any, on its investment of these net proceeds. You will not have the opportunity to influence its decisions on how to use the Combined Company&#8217;s cash resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company&#8217;s ability to use NOL carryforwards and other tax attributes may be limited, including as a result of the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed above, Carisma has incurred losses during its history, and the Combined Company does not expect to become profitable in the near future and may never achieve profitability. As of December&#160;31, 2024, Carisma had federal, state and local NOL carryforwards of approximately $374.7 million, $280.3 million and $65.1 million, respectively. Carisma had approximately $12.6 million and $0.8 million of federal and state research and development credits, respectively, that may be used to offset future taxable </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">income. Under current law, Carisma&#8217;s U.S. federal NOLs of $120.0 million incurred in tax&#160;years before 2018 begin to expire in 2043, if not utilized. In addition, under current law, Carisma&#8217;s U.S. federal NOLs of $254.7 million incurred in tax&#160;years beginning after 2017 may be carried forward indefinitely, but the deductibility of such NOL carryforwards is limited to 80.0% of taxable income. It is uncertain if and to what extent various states will conform to federal law. In addition, under Sections 382 and 383 of the Code, U.S. federal NOL carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership change&#8221; pursuant to Section&#160;382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least five&#160;percent of a company&#8217;s stock increase their ownership by more than 50&#160;percentage points over their lowest ownership&#160;percentage within a rolling three-year period. The Combined Company&#8217;s ability to utilize its NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed above, in connection with the Merger or other transactions. Similar rules&#160;may apply under state tax laws. If the Combined Company earns taxable income, such limitations could result in increased future income tax liability to the Combined Company, and the Combined Company&#8217;s future cash flows could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unfavorable global economic conditions could adversely affect the Combined Company&#8217;s business, financial condition, results of operations or cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The Combined Company&#8217;s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to the Combined Company&#8217;s business, including, weakened demand for the Combined Company&#8217;s product candidates and the Combined Company&#8217;s ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain the Combined Company&#8217;s suppliers, possibly resulting in supply disruption, or cause the Combined Company&#8217;s customers to delay making payments for its services. Any of the foregoing could harm the Combined Company&#8217;s business and the Combined Company cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Risks Related to Being a Controlled Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Following the Merger, the Combined Company will be a controlled company within the meaning of the Nasdaq Listing Rules&#160;and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. The stockholders of the Combined Company may not have the same protection afforded to stockholders of companies that are subject to such governance requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">After the Merger, Ocugen will continue to control a majority of the voting power of the outstanding shares of the Combined Company&#8217;s common stock. As a result, the Combined Company will be a &#8220;controlled company&#8221; within the meaning of the corporate governance standards of Nasdaq. Under these corporate governance standards, a company of which more than 50.0% of the voting power for the election of directors is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements. For example, controlled companies:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are not required to have a board that is composed of a majority of &#8220;independent directors&#8221; as defined under the Nasdaq listing rules;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are not required to have a compensation committee that is composed entirely of independent directors or have a written charter addressing the committee&#8217;s purpose and responsibilities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are not required to have director nominations be made, or recommended to the full board of directors, by its independent directors or by a nominating and corporate governance committee that is composed entirely of independent directors, and to adopt a written charter or a board resolution addressing the nominations process.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">While it is expected that the Combined Company does not initially intend to rely on these exemptions, the Combined Company may opt to utilize these exemptions in the future as long as it remains a controlled company. Accordingly, the Combined Company&#8217;s common stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Combined Company ceases to be a &#8220;controlled company&#8221; in the future, it will be required to comply with the Nasdaq Listing Rules, which may require replacing a number of its directors and may require development of certain other governance-related policies and practices. These and any other actions necessary to achieve compliance with such rules&#160;may increase the Combined Company&#8217;s legal and administrative costs, will make some activities more difficult, time-consuming, and costly and may also place additional strain on the Combined Company&#8217;s personnel, systems and resources.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_035145d7_9953_47f1_a9ff_6f17463ea74c"></a><a id="MARKETPRICEANDDIVIDENDINFORMATION_507649"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MARKET PRICE AND DIVIDEND INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s common stock is currently listed on the Nasdaq Capital Market under the symbol &#8220;CARM&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The closing price of Carisma&#8217;s common stock on June&#160;20, 2025, the last day of trading prior to the announcement of the Merger, as reported on the Nasdaq Capital Market, was $0.441 per share. The closing price of Carisma&#8217;s common stock on July&#160;18, 2025 as reported on the Nasdaq Capital Market, was $0.3922 per share. OrthoCellix is a private company and OrthoCellix shares are not publicly traded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the market price of Carisma&#8217;s common stock is subject to fluctuation, the market value of the shares of the Carisma common stock that OrthoCellix&#8217;s sole stockholder will be entitled to receive in the Merger may increase or decrease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming approval of the Nasdaq Stock Issuance Proposal (Proposal No.&#160;1) by Carisma&#8217;s stockholders at Carisma&#8217;s Special Meeting and successful application for initial listing with Nasdaq, following the consummation of the Merger, Carisma&#8217;s common stock is expected to trade on the Nasdaq Capital Market under Carisma&#8217;s new name, &#8220;OrthoCellix,&#160;Inc.&#8221;, and new trading symbol &#8220;OCLX&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, the record date for Carisma&#8217;s Special Meeting, there were approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;registered holders of record of Carisma&#8217;s common stock. This number does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name. As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, OrthoCellix had one holder of record of OrthoCellix&#8217;s common stock. For detailed information regarding the beneficial ownership of certain Carisma and OrthoCellix stockholders, see the sections of this proxy statement/prospectus titled &#8220;<i style="font-style:italic;">Principal Stockholders of Carisma</i>&#8221; and &#8220;<i style="font-style:italic;">Principal Stockholder of OrthoCellix</i>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma has never declared or paid any cash dividends on its common stock and does not anticipate paying cash dividends on Carisma&#8217;s common stock for the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Merger will be at the discretion of the Combined Company&#8217;s then-current board of directors and will depend upon a number of factors, including the Combined Company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors that the then-current board of directors deems relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix has never paid or declared any cash dividends on its capital stock. If the Merger does not occur, OrthoCellix does not anticipate paying any cash dividends on its capital stock in the foreseeable future, and OrthoCellix intends to retain all available funds and any future earnings to fund the development and expansion of its business. Any future determination to pay dividends will be at the discretion of the OrthoCellix board of directors and will depend upon a number of factors, including its results of operations, financial condition, future prospects, contractual restrictions, and restrictions imposed by applicable laws and other factors that the OrthoCellix board of directors deems relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6dfbbdaf_56d1_4173_a5a8_eb302187d42f"></a><a id="CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CAUTIONARY NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This proxy statement/prospectus contains &#8220;forward-looking statements&#8221; (including within the meaning of Section&#160;21E of the Exchange Act and Section&#160;27A of the Securities Act) concerning, among other things, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the structure, timing and completion of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the likelihood of the satisfaction of certain conditions to the completion of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected effects, perceived benefits or opportunities of the Merger and the anticipated Concurrent Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Combined Company&#8217;s anticipated listing on Nasdaq after the closing of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations regarding the structure, timing and completion of the anticipated Concurrent Financing, including investment amounts from investors, timing of the closing of the anticipated Concurrent Financing, expected proceeds, expectations regarding the use of proceeds, and impact on ownership structure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations regarding the ownership structure of the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations regarding the CVRs to be granted to Carisma stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected executive officers and directors of the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expectations regarding the anticipated Concurrent Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each company&#8217;s and the Combined Company&#8217;s expected cash position at the closing and cash runway of the Combined Company following the Merger and anticipated Concurrent Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the future operations of the Combined Company, including research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature, strategy and focus of the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development and commercial potential and potential benefits of any product candidates of the Combined Company, including expectations around market exclusivity and intellectual property protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">anticipated clinical drug development activities and related timelines, including the expected timing for announcement of data and other clinical results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations regarding or plans for discovery, preclinical studies, clinical trials and research and development programs, in particular with respect to OrthoCellix&#8217;s NeoCart&#174; technology, and any developments or results in connection therewith, including the target product profile of NeoCart&#174;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the anticipated timing of the commencement of and results from those studies and trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sufficiency of post-transaction resources to support the advancement of OrthoCellix&#8217;s pipeline through certain milestones and the time period over which OrthoCellix&#8217;s post-transaction capital resources will be sufficient to fund its anticipated operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome of any legal proceedings that may be instituted against Carisma, OrthoCellix or any of their respective directors or officers related to the Merger Agreement or the transactions contemplated thereby;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of OrthoCellix and the Combined Company to protect their intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expectations of the Combined Company&#8217;s financial performance;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential paths of the companies if the Merger is not consummated; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the anticipated structure, timing and benefits of the contemplated reverse stock split.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These forward-looking statements should not be relied upon as predictions of future events as Carisma and OrthoCellix cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. In some cases, you can identify forward-looking statements by the use of forward-looking terminology including &#8220;could, &#8221; &#8220;would,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;targets,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;pro forma,&#8221; &#8220;estimates,&#8221; or &#8220;anticipates&#8221; or the negative of these terms and phrases or other variations of these words and phrases or comparable terminology but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The events and circumstances reflected in forward-looking statements may not be achieved or occur and actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the conditions to the closing of the Merger or the anticipated Concurrent Financing are not satisfied;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure to timely obtain stockholder approval for the merger from both Carisma&#8217;s stockholders and OrthoCellix&#8217;s sole stockholder, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainties as to the timing of the consummation of the Merger and the anticipated Concurrent Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to Carisma&#8217;s continued listing on Nasdaq until the closing of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to Carisma&#8217;s and OrthoCellix&#8217;s ability to manage their operating expenses and their expenses associated with the Merger pending the closing of the Merger, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the Combined Company upon closing and other events and unanticipated spending and costs that could reduce the Combined Company&#8217;s cash resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the Merger Agreement may be terminated in circumstances that require Carisma or OrthoCellix to pay a termination fee;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that as a result of adjustments to the Exchange Ratio, Carisma stockholders and OrthoCellix&#8217;s sole stockholder could own more or less of the Combined Company than is currently anticipated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to the market price of Carisma&#8217;s common stock relative to the value suggested by the Exchange Ratio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected costs, charges or expenses resulting from the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive responses to the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that Carisma CVR holders may never receive any proceeds pursuant to the CVR Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of the Combined Company to recognize the anticipated benefits that may be derived from the Merger, including the commercial or market opportunity, including estimates of the number of patients who suffer from the diseases it is targeting may be lower than expected, of the product candidates of the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the uncertainties associated with OrthoCellix&#8217;s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s reliance on the manufacture of product candidates for clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s plans regarding, and its ability to maintain, obtain and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize its programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to the inability of the Combined Company to obtain sufficient additional capital to continue to advance these product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to obtain, maintain, and protect intellectual property rights related to product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulatory requirements and government incentives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">legislative, regulatory, political and economic developments beyond the parties&#8217; control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks associated with the possible failure to realize, or that it may take longer to realize than expected, certain anticipated benefits of the Merger, including with respect to future financial and operating results; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk of involvement in litigation, including securities class action litigation, that could divert the attention of the management of Carisma or the Combined Company, harm the Combined Company&#8217;s business and may not be sufficient for insurance coverage to cover all costs and damages.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing risks should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere. Carisma and OrthoCellix can give no assurance that the conditions to the merger will be satisfied. For further discussion of the factors that may cause Carisma, OrthoCellix or the Combined Company&#8217;s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, or for a discussion of risks associated with the ability of Carisma or OrthoCellix to complete the merger and the effect of the merger on the business of Carisma, OrthoCellix and the Combined Company, see the section entitled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page&#160;26 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of operations of Carisma, OrthoCellix or the Combined Company could differ materially from the forward-looking statements. All forward-looking statements in this proxy statement/prospectus are current only as of the date of this proxy statement/prospectus. Carisma and OrthoCellix do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made, the occurrence of unanticipated events or any new information that becomes available in the future, except as required by law</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9ca80ea5_8e8d_43b4_91a7_c77e9487621a"></a><a id="THEMERGER_885693"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This section and the section titled &#8220;The Merger Agreement&#8221; beginning on page&#160;</i><span style="font-style:italic;">180</span><i style="font-style:italic;"> of this proxy statement/ prospectus describe the material aspects of the Merger and the Merger Agreement. While Carisma and OrthoCellix believe that this description covers the material terms of the Merger and the Merger Agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement/ prospectus for a more complete understanding of the Merger and the Merger Agreement and the other documents to which you are referred in this proxy statement/prospectus. Please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page&#160;</i>372<i style="font-style:italic;"> of this proxy statement/prospectus.</i></p><a id="BackgroundoftheTransaction_154149"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Background of the Transaction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to March 2025, Carisma was a clinical-stage cell therapy company focused on using its proprietary cell therapy platform to develop transformative immunotherapies to treat cancer and other serious diseases. During this period, and in furtherance of this strategy, the Carisma board of directors and Carisma&#8217;s management would, from time to time, review and discuss Carisma&#8217;s business, financial condition, operations and strategic priorities and consider various strategic business initiatives intended to strengthen Carisma&#8217;s business and enhance enterprise value. In particular, these discussions included the exploration of strategic relationships, collaborations and partnering opportunities with respect to the advancement and development of its clinical programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October 2024, Carisma received written notice from the Nasdaq Listing Qualifications Department indicating that Carisma no longer satisfied Nasdaq Listing Rule 5450(b)(2)(A), which requires Carisma to maintain a minimum market value of listed securities of $50.0 million for continued listing on the Nasdaq Global Market. In accordance with Nasdaq Listing Rule 5810(c)(3), Nasdaq provided Carisma 180 calendar days, or until April 8, 2025, to regain compliance with the minimum market value rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2024, after consideration of Carisma&#8217;s current cash runway and operating plan, the Carisma board of directors approved a revised operating plan, which included a reduction in Carisma&#8217;s workforce. In connection with the revised operating plan, Carisma elected to cease further development of Carisma&#8217;s lead product candidate, CT-0525, based on the Carisma board of directors&#8217; evaluation of the competitive landscape in anti-HER2 treatments, including the impact of recently approved anti-HER2 therapies on HER2 antigen loss/downregulation and the effects on the future development strategy of any anti-HER2 product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 10, 2025, the Carisma board of directors held a meeting by videoconference at which representatives of Wilmer Cutler Pickering Hale and Dorr LLP (&#8220;WilmerHale&#8221;), Carisma&#8217;s outside counsel, were present. The Carisma board of directors and Carisma management discussed, among other things, Carisma&#8217;s efforts to engage in strategic business development and partnering activities and fundraising efforts, including in light of overall market conditions, particularly for biotechnology companies with similarly staged programs. Further, the Carisma board of directors and management discussed the status of discussions with Carisma&#8217;s lead partner, Moderna, regarding Carisma&#8217;s existing collaboration agreement with Moderna. The Carisma board of directors and Carisma management then discussed potential scenarios in the event that Carisma was unable to consummate a financing or strategic partnership or otherwise was unable to extend its cash runway, particularly in light of the possibility of being delisted from Nasdaq, including a potential need to wind down the regular business operations of the company. The Carisma board of directors directed Carisma management to pursue and effect any necessary arrangements under Carisma&#8217;s collaboration with Moderna to preserve the potential for future milestone and royalty payments, and to explore possible strategic or other financing alternatives for further discussion at a subsequent board meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From February 12, 2025 through March 18, 2025, Carisma management engaged in preliminary discussions with multiple potential strategic counterparties, including Party A, a privately held clinical stage biopharmaceutical company, and Party B, a privately held biotechnology company which discussed with Carisma a potential merger transaction with one of Party B&#8217;s subsidiaries. During this time, and as previously disclosed, Carisma management also concluded discussions with Moderna. As a result of those discussions, Moderna nominated additional oncology research targets, such that Moderna had then nominated all oncology research targets under the collaboration agreement for which Carisma had the potential to receive future milestones and royalty payments. In addition, because Carisma would not be conducting any additional research activities under the collaboration agreement, Carisma would not receive any further research funding from Moderna. Moderna also agreed to terminate the <i style="font-style:italic;">in-vivo</i> oncology field exclusivity, which allowed Carisma to pursue <i style="font-style:italic;">in vivo</i> CAR-M programs, outside of the nominated oncology targets and product polypeptides.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 18, 2025, the Carisma board of directors held a meeting by videoconference at which representatives of WilmerHale were present. The Carisma board of directors and management discussed, among other things, the status of strategic and financing discussions to date, Carisma&#8217;s cash runway, and a potential wind down of the company&#8217;s regular business operations, particularly if </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Carisma was unable to identify an attractive alternative strategic transaction. In particular, the Carisma board of directors and management reviewed discussions to date with Party A as well as its scientific and business profile, with Carisma management noting that a non-binding letter of intent from Party A had not yet been received but was anticipated. Carisma management then reviewed with the Carisma board of directors the company&#8217;s cash runway and estimates of costs and expenses through the remainder of 2025, noting that Carisma management anticipated that the company had operating cash runway into September 2025. The Carisma board of directors and management also discussed the sale or other monetization of the company&#8217;s clinical and other assets, including of its CT-1119 and other intellectual property and other assets, both in connection with a wind down of the company and a potential strategic transaction.  Carisma management then presented to the Carisma board of directors a revised operating plan to preserve the company&#8217;s cash, pursuant to which, among other actions, Carisma would cease all further research and development activities, pursue an orderly wind down of its regular business operations while exploring a range of strategic alternatives with the goal of maximizing enterprise value for Carisma and its stakeholders, and implement a reduction of substantially all of Carisma&#8217;s workforce.  Following discussion, the Carisma board of directors directed Carisma management to further refine the operating plan and to circulate it following the meeting for final approval. The Carisma board of directors also determined that, once approved, Carisma should publicly announce the revised operating plan and that Carisma was exploring strategic alternatives.  The Carisma board of directors directed Carisma management to continue engaging in discussions with strategic counterparties and to in parallel preserve cash and prepare for a potential wind down of its regular business operations of the company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On March 25, 2025, the Carisma board of directors approved by written consent the final operating plan to preserve cash resources.  As of March 31, 2025, Carisma had approximately $7.7 million of cash and cash equivalents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From March 19, 2025 through April 1, 2025, Carisma management engaged in preliminary discussions with various potential strategic counterparties, including Party A and Party B. During this period, Carisma management engaged, and through the date hereof continues to engage, in discussions with various counterparties regarding potential sales, licenses or other monetizations of its existing assets and intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On April 1, 2025, Party A submitted a non-binding term sheet proposing to effect a reverse merger with Carisma under various scenarios, including either a transaction with Party A itself (in which case the value of Party A would be $695.0 million) or with ones of its subsidiaries (in which case the value of the subsidiary would be $80.0 million), in each case valuing Carisma at its market value based on a trailing 5-day volume weighted average price determined prior to signing of a transaction agreement.  The proposal also specified that Carisma&#8217;s net cash at closing must be greater than $0.0. Based on the estimated market value of Carisma as of April 1, 2025 under the methodology set forth in Party A&#8217;s non-binding term sheet, Party A&#8217;s proposal reflected an implied ownership of approximately 1.5% (with Party A itself) or 12.1% (with the subsidiary of Party A).  The term sheet also contemplated a concurrent financing of approximately $50.0 million into the combined company as a condition to the closing of the transaction, and further stated that if the investors in a concurrent financing required a lower valuation of the combined company as a condition to investing, then the relative ownership percentages of Party A (or its subsidiary) and Carisma would remain constant and the valuations of each of Carisma and Party A would be proportionately lowered.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 2, 2025, representatives of Carisma management and Party B held a call to discuss the structure of a potential merger transaction between Carisma and a subsidiary of Party B to create a combined company focused on certain of Party B&#8217;s clinical assets, as well as to discuss preliminary due diligence matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 4, 2025, representatives of Carisma met by videoconference with representatives of Party A to discuss Party A&#8217;s proposal, including: the valuations ascribed to Party A and to its subsidiary; Party A&#8217;s proposal to value Carisma based on its pre-transaction announcement trading price; structural and intellectual property related considerations related to the post-closing relationship between Party A and the combined company; the anticipated timing to consummate a transaction; and matters related to the proposed concurrent financing, including Party A&#8217;s ability to arrange a financing under current market conditions, the proposal to make such financing a condition to the closing of the transaction, and the proposal to reduce Carisma&#8217;s valuation based on investor feedback with respect to Party A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on April 4, 2025, representatives of Carisma were introduced to representatives of Ocugen by Ocugen&#8217;s financial advisor, Chardan Capital Markets LLC (&#8220;Chardan&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 7, 2025, Ocugen and Carisma executed a confidentiality agreement, and later that day representatives of Carisma management and Ocugen met by videoconference to discuss a potential transaction, during which representatives of Ocugen indicated that they would propose a transaction in which Carisma engaged in a merger transaction with a subsidiary of Ocugen, known as OrthoCellix, which was focused on developing its NeoCart assets.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On April 10, 2025, Ocugen sent a preliminary non-binding indication of interest proposing a stock-for-stock merger between Carisma and OrthoCellix. Under Ocugen&#8217;s proposal, the proposed post-closing (but pre-concurrent financing) ownership of the combined company would be 90.0% by pre-closing stockholders of OrthoCellix (contemplated to solely consist of Ocugen) and 10.0% by pre-closing equityholders of Carisma, reflecting implied valuations of $135.0 million for OrthoCellix and $15.0 million for Carisma, subject to adjustment based on Carisma&#8217;s net cash(based on a net cash target of $0.0) and the valuation ascribed by investors in a concurrent financing, which was contemplated to be $30.0 million. The proposal also contemplated that the board of the combined company would be entirely composed of directors selected by OrthoCellix.  The non-binding indication of interest also proposed a mutual 45 day exclusivity period. From April 10, 2025 to April 25, 2025, representatives of Carisma engaged in due diligence discussions between Carisma, Ocugen and Chardan, regarding both OrthoCellix&#8217;s assets and programs as well as Carisma&#8217;s legacy assets and liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on April 10, 2025, as Carisma had not regained compliance with Nasdaq&#8217;s minimum market value rule by April 8, 2025, Nasdaq notified Carisma that its securities were subject to delisting from Nasdaq unless Carisma timely requested a hearing before the Panel, which it did.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 11, 2025, representatives of Carisma and Party B met by videoconference for a due diligence call regarding the applicable Party B subsidiary&#8217;s technology and clinical assets, as well as regarding Carisma&#8217;s legacy assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 15, 2025, representatives of Party A sent an email to Steven Kelly, President and Chief Executive Officer of Carisma, clarifying that the focus of the proposed transaction between Party A and Carisma would be between Carisma and its subsidiary, not with Party A itself, and further expressing flexibility regarding the relative valuations of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 18, 2025, Party B sent to Carisma a non-binding letter proposal regarding a stock-for-stock merger between Carisma and one of Party B&#8217;s subsidiaries, in which Party B would own 80.0% of the combined company and pre-closing Carisma equityholders would own 20.0% of the combined company, reflecting an indicative value of Carisma of $8.0 million and Party B&#8217;s subsidiary of $32.0 million. The proposal letter also contemplated that Carisma would have a minimum of $3.0 million of net cash at closing, that there would be a concurrent financing of at least $10.0 million and that the transaction would close &#8220;no later than July 31, 2025.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On April 25, 2025, Mr. Kelly and representatives of Party A met by videoconference to discuss Party A&#8217;s proposal including, among other things, the relative valuations of Carisma and Party A&#8217;s subsidiary, Party A&#8217;s clinical pipeline and programs, and the likelihood of arranging a concurrent financing under existing market conditions.  Representatives of Party A orally updated their proposal to state that legacy Carisma equityholders would own approximately 20% of the combined company, before giving effect to any concurrent financing, and that Party A would contribute $10.0 million to the combined company while also conditioning the transaction on raising an incremental $50.0 for a concurrent financing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Later on April 25, 2025, the Carisma board of directors held a meeting by videoconference at which representatives of WilmerHale were present. At the meeting, the Carisma board of directors and Carisma management reviewed and discussed the strategic alternatives being evaluated, including the proposals from Party A, Party B and OrthoCellix/Ocugen, as well as a comparison of the relative benefits and challenges of each proposal with respect to their respective assets, clinical programs, transaction structures and terms. Carisma management also reviewed with the Carisma board of directors the status of discussions regarding the potential sale of legacy assets and intellectual property of Carisma. The Carisma board of directors and Carisma management also reviewed the status of discussions with Nasdaq, including that Carisma was scheduled for a hearing with Nasdaq regarding existing listing deficiencies on May 22, 2025, and that an adverse decision following the hearing could result in an immediate delisting of Carisma (in which case none of the potential transactions with Party A, Party B or OrthoCellix/Ocugen would be feasible) and a positive decision would nonetheless likely require Carisma to consummate any transaction, as well as to complete intermediate steps, following a timetable specified by Nasdaq. Further, the Carisma board of directors and Carisma management discussed the potential timing and scope of responsibility for the engagement of a potential financial advisor to Carisma in connection with its strategic process and/or a potential wind down of Carisma, including the challenges of identifying an appropriate financial advisor given Carisma&#8217;s limited resources and the fees a financial advisor would require as well as the challenge of identifying a financial advisor with the appropriate set of skills and experience given the variety of potential alternatives for Carisma.  Following discussion, the Carisma board of directors directed Carisma management to continue discussions with Party A, Party B and OrthoCellix/Ocugen, including regarding clarifying the certainty of each proposal and ability to consummate a transaction on the timeline required by Carisma&#8217;s cash runway and anticipated Nasdaq timing requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From April 25, 2025 to May 5, 2025, representatives of Carisma management continued to engage in discussions with each of Party A, Party B and OrthoCellix/Ocugen regarding improving their proposals and anticipated ability to efficiently close a transaction.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On May 5, 2025, the Carisma board of directors held a meeting by videoconference at which representatives of WilmerHale were present. At the meeting, Carisma management reviewed with the Carisma directors the status of discussions with each of Party A, Party B and OrthoCellix/Ocugen, including that: (i) Party A indicated that while a completed concurrent financing must remain a condition to closing it could not commit to any specific committed investors or timetable, that there remained questions regarding the proposed post-closing relationship and intellectual property ownership between Party A and the combined company, and that for these and other reasons Party A indicated it would be unlikely to consummate a transaction on the timelines required by Carisma&#8217;s cash runway and anticipated to be required by Nasdaq; (ii) Party B had proposed a lower valuation of Carisma compared to the other proposals received, its proposal required external funding which was not yet committed, and its ability to consummate a transaction on the required timeline was unclear; and (iii) OrthoCellix/Ocugen was amenable to revisions to its non-binding proposal, including regarding the relative valuations ascribed to each party as well as being open to expense reimbursement if definitive agreements were not executed by a specified time, and further that OrthoCellix/Ocugen had retained Chardan to assist with the financing, and OrthoCellix/Ocugen had indicated a willingness to efficiently pursue a transaction pursuant to the necessary timelines. The Carisma board of directors and management further discussed Carisma&#8217;s limited cash and employee resources, as well as the need to finalize the terms of any transaction in the event of a positive decision from Nasdaq. The Carisma board of directors also discussed that, given the time pressures facing Carisma coupled with its limited personnel and other resources, a transaction committee of the Carisma board of directors (the &#8220;Transaction Committee&#8221;) created for convenience (and not because of any conflicts of interest) could help facilitate an efficient process. Following discussion, the Carisma board of directors approved the constitution of a Transaction Committee, composed of Sanford Zweifach, Sohanya Cheng and Marella Thorell, to advise and consult with Carisma management on Carisma&#8217;s strategic process and evaluation and negotiation of potential transactions prior to formal approval of the full board. Members of the Transaction Committee did not receive any additional fees for their service on the committee. Throughout the Transaction Committee&#8217;s evaluation of a potential strategic transaction, in addition to formal meetings the Transaction Committee members were in regular informal discussions with Carisma management regarding the strategic process and alternatives under evaluation.  Later in the meeting, the Carisma board of directors and Carisma management revisited the potential timing and scope of responsibility for the engagement of a potential financial advisor to Carisma in connection with its strategic process and/or a potential wind down, including in light of the challenges previously discussed, and Carisma management observed to the Carisma board of directors that several potential financial advisors had declined an engagement or had requested fees that would potentially jeopardize Carisma&#8217;s ability to satisfy any net cash closing condition. Carisma management and the Carisma board of directors determined to continue to evaluate the appropriate financial advisor and the timing of retaining any such advisor. The Carisma board of directors then directed Carisma management to, in consultation with the Transaction Committee, focus on identifying opportunities to monetize legacy Carisma assets and intellectual property and to prioritize discussions with OrthoCellix/Ocugen on an expedited timeline, including to finalize a non-binding letter of intent prior to Carisma&#8217;s hearing with Nasdaq given the likelihood that, absent an executed non-binding letter of intent, Nasdaq was likely to make an adverse determination at Carisma&#8217;s upcoming hearing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 14, 2025, representatives of Carisma and representatives of Ocugen and Chardan met by videoconference for a due diligence call regarding OrthoCellix&#8217;s assets, structure, and development plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On May 15, 2025 and on May 20, 2025, the Transaction Committee held meetings at which Mr. Kelly was present, to discuss the status of discussions and negotiations regarding a potential reverse merger transaction and asset monetization transactions, including the status of discussions with Ocugen (including its request for exclusivity), the likelihood of identifying additional potential counterparties &#8212; in particular in light of the advice from Carisma&#8217;s Nasdaq consultant that absent a signed non-binding letter of intent Nasdaq was unlikely to grant Carisma an extension at the company&#8217;s May 22, 2025 hearing&#8212;and the likely adverse consequences if Nasdaq made an adverse determination following the hearing.  Following discussion of these considerations, the Transaction Committee directed Carisma management to pursue improving terms with Ocugen and to prioritize signing a non-binding letter of intent prior to Carisma&#8217;s hearing with Nasdaq.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 20, 2025, Ocugen and Carisma executed a non-binding letter of intent with respect to a proposed stock-for-stock reverse merger transaction between Carisma and OrthoCellix, reflecting: (i) a valuation of Carisma of $15.0 million (subject to adjustment based on Carisma&#8217;s net cash being greater or lesser than $0) and $135.0 million for OrthoCellix, reflecting indicative ownership percentages of 90.0% for Ocugen and 10.0% for pre-closing Carisma equityholders (without giving effect to the contemplated concurrent financing); (ii) that the combined company&#8217;s board of directors would be composed of six directors, with five selected by OrthoCellix and one by Carisma; (iii) that Carisma would be permitted to engage in transactions to monetize legacy assets, and prior to closing Carisma would issue to its pre-closing stockholders a contingent value rights agreement entitling the holders to net proceeds of certain legacy assets of Carisma and net proceeds received by the combined company under certain existing agreements; (iv) expense reimbursement of Carisma&#8217;s transaction expenses if Ocugen determined not to proceed with a transaction or definitive documentation for the transaction were not otherwise executed on or prior to July 31, 2025; and (v) 30 day mutual exclusivity, subject to extension.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 22, 2025, representatives of Carisma, Carisma&#8217;s Nasdaq consultant and representatives of Ocugen attended Nasdaq&#8217;s delisting hearing for Carisma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 29, 2025, the Transaction Committee held a meeting at which Mr. Kelly was present, to discuss the status of discussions and negotiations regarding the potential reverse merger transaction with OrthoCellix as well as the status of Carisma&#8217;s asset monetization transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 30, 2025, representatives of Goodwin Procter LLP (&#8220;Goodwin&#8221;), counsel to OrthoCellix/Ocugen, sent to representatives of WilmerHale a first draft of the Merger Agreement, including the following terms: (i) a valuation of Carisma of $15.0 million (subject to adjustment based on Carisma&#8217;s net cash being greater or lesser than $0.0) and $135.0 million for OrthoCellix (assuming the binding commitment of the concurrent financing); (ii) that Carisma would be permitted to engage in transactions to monetize legacy assets, and prior to closing Carisma would issue to its pre-closing stockholders a contingent value rights agreement entitling the holders to net proceeds of certain legacy assets of Carisma and net proceeds received by the combined company under certain existing agreements; (iii) a termination fee in favor of OrthoCellix if Carisma were to terminate the Merger Agreement in order to enter into a Subsequent Transaction (as defined in the Merger Agreement); (iv) a termination fee in favor of Carisma if the Merger Agreement were terminated under certain circumstances; and (v) a proposed definition of Net Cash, including the specification of certain items which would be deemed to reduce the amount of Carisma&#8217;s net cash at closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 7, 2025, representatives of WilmerHale sent to representatives of Goodwin a revised draft of the Merger Agreement, including the following terms: (i) a valuation of $110.0 million for OrthoCellix, subject to further clarity on the timing and amount of the concurrent financing, (ii) certain changes to the definition of Net Cash, (iii) removal of the split of certain fees; and (iv) inclusion of a guaranty by Ocugen of certain obligations of OrthoCellix under the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 10, 2025, Nasdaq notified Carisma that the Panel determined to grant Carisma&#8217;s request for an exception to, and an extension of time to comply with, applicable Nasdaq listing standards. As part of this determination, the Panel directed that Carisma&#8217;s listing be transferred to the Nasdaq Capital Market, effective as of the open of business on June 12, 2025, and specified additional conditions for Carisma&#8217;s listing on the Nasdaq Capital Market. The extension of time is subject to Carisma demonstrating compliance with Nasdaq Listing Rule 5550(a)(2) by evidencing a closing bid price of $1.00 or more per share for a minimum of 10 consecutive trading sessions, completing a strategic transaction and otherwise demonstrating compliance with all initial listing requirements for the Nasdaq Capital Market, in each case on or before October 7, 2025. The extension of time is further subject to an interim milestone related to Carisma&#8217;s timely filing of this proxy statement/prospectus. The Panel reserved the right to reconsider its determination based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make continued listing of Carisma&#8217;s securities inadvisable or unwarranted. The Panel observed to Carisma that it does not have discretion to grant continued listing for noncompliance with Nasdaq listing standards beyond October 7, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 11, 2025, Goodwin and WilmerHale held a call to discuss the status of documents, negotiations, and the anticipated concurrent financing. During the call, representatives of Goodwin informed representatives of WilmerHale that OrthoCellix was unlikely to obtain binding commitments from investors in the anticipated concurrent financing contemporaneously with execution of the Merger Agreement and would pursue obtaining such binding commitments prior to closing. Goodwin further noted that OrthoCellix would remove any closing condition in favor of OrthoCellix regarding consummation of a concurrent financing from the draft Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On June 12, 2025, the Transaction Committee held a meeting at which Mr. Kelly was present to discuss the status of discussions and negotiations regarding the potential reverse merger transaction with OrthoCellix, the results of the Nasdaq hearing, and the status of Carisma&#8217;s asset monetization transactions. Carisma management reviewed with the Transaction Committee the status of discussions, including the likely timeline to sign definitive documentation. Mr. Kelly also informed the Transaction Committee that Ocugen/OrthoCellix had indicated that it was unlikely to be in position to deliver binding commitments from investors in the anticipated financing concurrently with execution of the Merger Agreement and would pursue such binding commitments prior to closing of the Merger. The Transaction Committee and Mr. Kelly discussed the risks and implications, including of transacting with a counterparty that was potentially insufficiently funded at the closing, and determined to require that the Merger Agreement reflect that OrthoCellix/Ocugen must obtain a minimum level of executed investor commitments by a specified time and, if that has not occurred, Carisma would have the ability to terminate the Merger Agreement and receive expense reimbursement. Further, Carisma management reviewed with the Transaction Committee the discussions with potential financial advisors to date, including the financial advisors that had either declined any engagement or who had requested fees that could potentially jeopardize Carisma&#8217;s ability to satisfy any net cash closing condition. The Transaction Committee and Carisma management then discussed the engagement of Lucid to provide a fairness opinion to the Carisma board of directors in the context of the proposed transaction with OrthoCellix. </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Carisma management noted Lucid&#8217;s qualifications, professional reputation and experience, including that Lucid has been engaged by other companies to render financial opinions in connection with mergers, acquisitions, and for other purposes. Based on these factors, the Transaction Committee authorized the engagement of Lucid to provide a fairness opinion in connection with the reverse merger with OrthoCellix. Such engagement letter was entered into between Carisma and Lucid, effective June 13, 2025. Following the execution of the engagement letter with Lucid, the Carisma board of directors was provided a customary relationship disclosure letter made available by Lucid, indicating that Lucid had not been engaged by Ocugen or OrthoCellix during the two-year period prior to such disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">From June 12, 2025 through June 22, 2025, representatives of WilmerHale, at the direction of Carisma management and the Carisma board of directors (including the Transaction Committee), and Goodwin exchanged drafts and participated in discussions regarding the terms of the Merger Agreement and related documents.  The items negotiated with respect to the Merger Agreement and related documents included, among other things: the representations and warranties to be made by the parties; the calculation of the exchange ratio, including a downward adjustment to OrthoCellix&#8217;s valuation based on the amount by which the amount of the concurrent financing is less than $25.0 million; a commitment by Ocugen to execute a binding commitment to invest a minimum of $5.0 million as part of the concurrent financing; the restrictions on the conduct of the parties&#8217; businesses until completion of the transaction; the definition of material adverse effect; the conditions to completion of the Merger; the determination of Carisma&#8217;s net cash balance at closing and the level of net cash required as a condition to closing; the timing of filing of the proxy statement/prospectus; the timing for OrthoCellix/Ocugen to obtain executed commitments from investors in the anticipated concurrent financing and the consequences for the failure to do so, including termination and expense reimbursement; the timing for delivery of OrthoCellix financial statements required for inclusion in the proxy statement/prospectus; the terms of Ocugen&#8217;s guarantee of OrthoCellix&#8217;s obligations under the Merger Agreement; the terms of the CVR Agreement and other ancillary agreements; and the remedies available to each party under the Merger Agreement, including the triggers and values of the termination fees and expense reimbursement payable to each of the parties and the outside date for the proposed transaction.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On June 17, 2025, the Carisma board of directors held a meeting by videoconference at which representatives of WilmerHale were present. At the meeting, Carisma management reviewed with the Carisma board of directors an overview of the background and business of OrthoCellix as well as due diligence findings to date, including with respect to the management team of OrthoCellix, the technology underlying the NeoCart program, the status and plans for clinical development and regulatory submission for NeoCart, the planned ongoing services arrangements between OrthoCellix and Ocugen following closing of the reverse merger, the NeoCart market opportunity, a timeline and key anticipated milestones for the NeoCart program, an investor overview for OrthoCellix and a historical statement of profit and loss for OrthoCellix. Mr. Kelly and the Transaction Committee also reviewed with the Carisma board of directors the engagement of Lucid to deliver a fairness opinion with respect to an OrthoCellix transaction.  Mr. Kelly then reviewed the status of discussions and negotiations with OrthoCellix/Ocugen, including, among other things, regarding the proposed equity ownership split of the combined company, net cash closing requirements for Carisma at closing, provisions to allow Carisma to pursue asset sale transactions in parallel with the pendency of the reverse merger, the CVR Agreement, matters related to the proposed concurrent financing, and the composition of the combined company board, including that one director of the combined company would be selected by Carisma. In particular, the Carisma board of directors and management discussed the risks that OrthoCellix would be unable to obtain sufficient binding commitments with respect to the Concurrent Financing prior to the closing of the transaction, the risk that the transaction with OrthoCellix would not be completed on the timeline prescribed by Nasdaq (including due to factors outside of Carisma&#8217;s control), the risk that Carisma would be unable to sufficiently monetize its legacy assets and its ability to satisfy the net cash closing condition would be jeopardized, and, further, the risk that, should the transaction not be completed on the timing contemplated or at all, Carisma&#8217;s ability to effect an orderly wind down could be adversely impacted.  Mr. Kelly then summarized the strategic alternatives considered other than a transaction with OrthoCellix, including the relative challenges of other reverse merger transactions previously discussed with the Carisma board of directors and the potential benefits and upside of the OrthoCellix transaction to Carisma stakeholders in comparison to a wind down of the company&#8217;s regular business operations and a subsequent dissolution of Carisma.  Following discussion, the Board authorized and directed management of Carisma to finalize negotiations for the OrthoCellix transaction in anticipation of a subsequent board meeting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 19, 2025, Mr. Kelly provided to the Transaction Committee certain financial forecasts with respect to OrthoCellix which were based on forecasted financial information provided by Ocugen and as further adjusted by Carisma management, which the Transaction Committee reviewed and approved for use by Lucid for purposes of rendering its fairness opinion. For a detailed discussion of such forecasted financial information, please see the heading titled &#8220;<i style="font-style:italic;">The Merger&#8212; Certain Unaudited Prospective Financial Information</i>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On June 22, 2025, the Carisma board of directors held a meeting at which members of Carisma, representatives of Lucid, and representatives of WilmerHale were present. During the meeting, representatives of WilmerHale reviewed the fiduciary duties of the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Carisma board of directors in connection with the proposed transaction with OrthoCellix, as well as the terms of the Merger Agreement, CVR Agreement and other ancillary agreements, and Mr. Kelly reminded the Carisma board of directors of Carisma&#8217;s evaluation of strategic alternatives, including the potential alternative transactions the Carisma board of directors considered as well as its discussion of a potential wind down of the company. Representatives of Lucid then made a financial presentation to the Carisma board of directors and, at the request of the Carisma board of directors, Lucid rendered to the Carisma board of directors its oral opinion, which was subsequently confirmed by delivery of a written opinion dated June 22, 2025, that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review undertaken by Lucid in preparing its opinion, the Exchange Ratio proposed to be paid by Carisma pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to Carisma. For a detailed discussion of Lucid&#8217;s fairness opinion, please see heading titled &#8220;<i style="font-style:italic;">The Merger&#8201;&#8212;&#8201;Opinion of Carisma&#8217;s Financial Advisor</i>&#8221; beginning on page 154 of this proxy statement/prospectus. The Carisma board of directors then discussed various considerations with respect to the proposed transaction, including those risks discussed in previous meetings and as summarized under &#8220;<i style="font-style:italic;">The Merger &#8212; Carisma&#8217;s Reasons for the Merger</i><span style="white-space:pre-wrap;">&#8221;. The Carisma board of directors and Carisma management discussed these and other considerations in comparison with proceeding with a wind down of the company&#8217;s regular business operations and a subsequent dissolution of the company and concluded that, based a review of the proposed OrthoCellix transaction and the terms of the Merger Agreement and other agreements, the fairness opinion rendered by Lucid, and discussions among the Carisma board of directors at prior meetings, pursuing the OrthoCellix transaction on the terms set forth in the Merger Agreement and related agreements was the preferred strategy.  Following such discussion, the Carisma board of directors: (i) determined that the transactions contemplated by the Merger Agreement are fair to, advisable and in the best interests of Carisma and its stockholders, (ii) approved and declared advisable the Merger Agreement and the transactions contemplated by the Merger Agreement, including the issuance of shares of Carisma common stock to the stockholders of OrthoCellix pursuant to the Merger Agreement, the support agreement and the constructive issuance, and (iii) determined to recommend, upon the terms and subject to the conditions set forth in the Merger Agreement, that the stockholders of Carisma vote to authorize the issuance proposal and the other Carisma stockholder proposals.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later on June 22, 2025, the parties executed the Merger Agreement and the other applicable transaction documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On the morning of June 23, 2025, prior to the opening of trading on Nasdaq, Carisma and Ocugen issued a joint press release announcing entry into the Merger Agreement. Carisma also filed a current report on Form 8-K with the SEC announcing, among other things, the execution of the Merger Agreement.</p><a id="CarismasReasonsfortheMerger_45554"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Carisma&#8217;s Reasons for the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the course of its evaluation of the Merger Agreement and the transactions contemplated by the Merger Agreement, Carisma&#8217;s board of directors held numerous meetings, consulted with Carisma&#8217;s management, Carisma&#8217;s consultants and advisors and outside legal counsel and reviewed and assessed a significant amount of information. In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, Carisma&#8217;s board of directors considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the financial condition and prospects of Carisma and the risks associated with continuing to operate Carisma on a stand-alone basis, particularly in light of Carisma&#8217;s March&#160;2025 decision to preserve its existing cash resources and reduce its operations to those necessary to identify and explore a range of strategic alternatives to prepare to wind down its business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that Carisma&#8217;s board of directors undertook a comprehensive and thorough process of reviewing and analyzing potential strategic alternatives and merger partner candidates and Carisma&#8217;s board of directors&#8217; view that no alternatives to the Merger (including remaining a standalone company, a liquidation and dissolution of Carisma and the distribution of any available cash, and alternative strategic transactions) were reasonably likely to create greater value to Carisma&#8217;s stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that Carisma&#8217;s board of directors undertook to additionally seek value of its remaining assets, including CT-2401, CT-1119, Carisma&#8217;s macrophage and monocyte engineering platform and its CAR-M platform and sought to realize value for the potential milestone and royalty payments under Carisma&#8217;s Moderna collaboration agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; conclusion that the Merger would provide Carisma&#8217;s existing stockholders an opportunity to participate in the potential growth of the Combined Company following the Merger, which will focus on OrthoCellix&#8217;s lead asset;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; belief, after thorough review of strategic alternatives and discussions with Carisma&#8217;s management and outside legal counsel, that the Merger is more favorable to Carisma&#8217;s stockholders than the potential value that might have resulted from other strategic alternatives available to Carisma, including a liquidation and dissolution of Carisma and the distribution of any available cash;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; belief that the $15.0 million enterprise value ascribed to Carisma would provide the existing Carisma stockholders significant value for Carisma&#8217;s public listing, and afford the Carisma stockholders an opportunity to participate in the potential growth of the Combined Company following the Merger at the negotiated exchange ratio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; belief, after a thorough review of strategic alternatives, such as attempting to further advance the development of its internal programs, entering into a licensing, sale or other strategic agreement related to certain assets sufficient to fund operations, combining with other potential strategic transaction candidates, and discussions with Carisma management and legal counsel, that the Merger is more favorable to Carisma stockholders than the potential value that might have resulted from other strategic alternatives available to Carisma;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; belief that, as a result of arm&#8217;s length negotiations with OrthoCellix, Carisma and its representatives negotiated the highest exchange ratio to which OrthoCellix was willing to agree and that the other terms of the Merger Agreement include the most favorable terms to Carisma in the aggregate to which OrthoCellix was willing to agree;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; consideration of the expected cash balances of the Combined Company as of the closing of the Merger resulting from the expected gross proceeds of approximately $25.0 million from the anticipated Concurrent Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; consideration that Ocugen, the sole stockholder of OrthoCellix, committed to participate in an amount of at least $5.0 million in the anticipated Concurrent Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s board of directors&#8217; view that the Combined Company will be led by an experienced board of directors and senior management team;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the current financial market conditions and historical market prices, volatility and trading information with respect to Carisma common stock; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the opinion of Lucid, rendered orally to Carisma&#8217;s board of directors on June&#160;22, 2025 (and subsequently confirmed in writing by delivery of Lucid&#8217;s written opinion) that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review undertaken by Lucid in preparing its opinion, the Exchange Ratio proposed to be paid by Carisma pursuant to the terms of the Merger Agreement was fair, from a financial point of view, as of June&#160;22, 2025, to the holders of Carisma common stock, as more fully described below in the section titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Merger&#8212;Opinion of Carisma&#8217;s Financial Advisor</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; beginning on page&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">154</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors also reviewed the terms of the Merger Agreement and related transaction documents, including those described below, and concluded that the terms of the Merger Agreement and related transaction documents, in the aggregate, were reasonable under the circumstances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the calculation of the Exchange Ratio, closing Net Cash and the estimated number of shares of Carisma common stock to be issued in the Merger, including that the valuation of Carisma under the Merger Agreement would be reduced to the extent that Carisma&#8217;s closing Net Cash is less than $0, which would result in a decrease in the ownership of the pre-Merger Carisma stockholders in the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and nature of the conditions to Carisma&#8217;s and OrthoCellix&#8217;s respective obligations to complete the Merger and the likelihood that the Merger will be completed on a timely basis, as more fully described below in the caption &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Merger Agreement &#8212; Conditions to the Completion of the Merger</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; beginning on page&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">183</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the respective rights of, and limitations on, Carisma and OrthoCellix under the Merger Agreement to consider and engage in discussions regarding unsolicited acquisition proposals under certain circumstances, and the limitations on the board of </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">directors of each party to change its recommendation in favor of the Merger, as more fully described below under the caption &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Merger Agreement &#8212; No Solicitation</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; beginning on page&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">186</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential termination fee of $750,000 (plus reimbursement of expenses up to $500,000), which would become payable by OrthoCellix to Carisma, or the potential termination fee of $500,000, which would become payable by Carisma to OrthoCellix, if the Merger Agreement is terminated in certain circumstances, as more fully described below under the captions &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Merger Agreement &#8212; Termination</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Merger Agreement&#160;-Termination Fee </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">beginning on pages&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">194</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">196</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, respectively, of this proxy statement/prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lock-up agreements, pursuant to which Ocugen, as OrthoCellix&#8217;s sole stockholder, has entered into and, subject to certain exceptions, agreed not to transfer its shares of the Combined Company common stock during the period of 180&#160;days following the completion of the Merger, as more fully described below under the caption &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Agreements Related to the Merger &#8212; Support Agreements and Lock-Up Agreement</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; beginning on page&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">197</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the support agreements, pursuant to which certain stockholders of OrthoCellix and Carisma, respectively, have agreed, solely in their capacities as stockholders, to vote their shares of OrthoCellix common stock or Carisma common stock, respectively, in favor of the proposals submitted to them in connection with the Merger, as more fully described in &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Agreements Related to the Merger &#8212; Support Agreements and Lock-Up Agreement</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; beginning on page&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">197</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the course of its deliberations, Carisma&#8217;s board of directors and also considered a variety of risks and other countervailing factors related to entering into the Merger, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the $750,000 termination fee payable by Carisma upon the occurrence of certain events and the potential effect of such termination fee in deterring other potential acquirors from proposing an alternative acquisition that may be more advantageous of Carisma&#8217;s stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the substantial expenses to be incurred by Carisma in connection with the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prohibition on Carisma to solicit alternative acquisition proposals during the pendency of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible volatility of the trading price of Carisma common stock resulting from the announcement, pendency or completion of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the Merger might not be consummated in a timely manner or at all and the potential effect of the public announcement of the Merger or the failure to complete the Merger on the reputation of Carisma; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the various other risks associated with the Combined Company and the proposed transaction, including those described in the sections titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk Factors</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Cautionary Note&#160;Regarding Forward-Looking Statements</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; beginning on pages&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">26</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">140</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, respectively, of this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing information and factors considered by Carisma&#8217;s board of directors are not intended to be exhaustive but are believed to include all of the material factors considered by Carisma&#8217;s board of directors. In view of the wide variety of factors considered in connection with its evaluation of the Merger and the complexity of these matters, Carisma&#8217;s board of directors did not find it useful to attempt, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of Carisma&#8217;s board of directors may have given different weight to different factors. Carisma&#8217;s board of directors conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, Carisma management and outside legal counsel, and considered the factors overall to be favorable to, and to support, its determination.</p><a id="OrthoCellixsReasonsfortheMerger_138485"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OrthoCellix&#8217;s Reasons for the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the course of reaching its decision to approve the Merger, each of Ocugen&#8217;s and OrthoCellix&#8217;s board of directors considered a wide variety of factors. Ultimately, each of Ocugen&#8217;s and OrthoCellix&#8217;s board of directors concluded that a merger with Carisma, together with the additional financing from the anticipated Concurrent Financing, was the best option to generate capital resources to support the advancement of OrthoCellix&#8217;s pipeline and fund the Combined Company.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional factors each of Ocugen&#8217;s and OrthoCellix&#8217;s board of directors considered included the following (which factors are not necessarily presented in any order of relative importance):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of NeoCart and potentially provide OrthoCellix with a greater opportunity to advance the NeoCart platform as an independent public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the anticipated Concurrent Financing will generate capital resources to fund the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits from increased public market awareness of OrthoCellix and NeoCart and the ability to dedicate financial, management and other resources to the NeoCart platform as part of an independent public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical and current information concerning OrthoCellix&#8217;s business, including its readiness to initiate an FDA-endorsed Phase 3 clinical trial for NeoCart;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the competitive nature of the industry in which OrthoCellix intends to operate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s board of directors&#8217; fiduciary duties to OrthoCellix&#8217;s sole stockholder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s board of directors&#8217; belief that no alternatives to the Merger, together with the additional financing from the anticipated Concurrent Financing, were reasonably likely to create a better path to commercial viability for NeoCart, after considering the various other alternative transactions with respect to the development of NeoCart including additional financing and other strategic options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s board of directors&#8217; expectation that the Merger, together with the additional financing from the anticipated Concurrent Financing, would be a higher probability and more cost-effective means to access capital than other options considered, including an initial public offering;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected operations, management structure and operating plans of the Combined Company (including the ability to support the Combined Company&#8217;s current and planned preclinical studies and planned clinical trials);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the business, history, operations, financial resources, assets, technology and credibility of Carisma;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of appraisal rights under the DGCL to holders of OrthoCellix capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of OrthoCellix capital stock as determined by the Delaware Court of Chancery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and conditions of the Merger Agreement, including the following:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the determination that the expected relative&#160;percentage ownership of Carisma stockholders and OrthoCellix&#8217;s sole stockholder in the Combined Company was appropriate, based on OrthoCellix&#8217;s board of directors&#8217; judgment and assessment of the approximate valuations of Carisma and OrthoCellix (including the value of the amount of proceeds from the anticipated Concurrent Financing);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expectation that the Merger will be treated as a tax-deferred exchange described in Section&#160;351(a)&#160;of the Code or as a reorganization for U.S. federal income tax purposes, with the result that OrthoCellix&#8217;s sole stockholder will generally not recognize taxable gain or loss for U.S. federal income tax purposes with respect to the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the limited number and nature of the conditions of the obligation of Carisma to consummate the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rights of OrthoCellix under the Merger Agreement to consider certain unsolicited acquisition proposals under certain circumstances should OrthoCellix receive a superior offer;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the conclusion of OrthoCellix&#8217;s board of directors that the potential termination fees and/or expense reimbursement payable by Carisma or OrthoCellix to the other party, and the circumstances when such fee may be payable, were reasonable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the fact that shares of Carisma&#8217;s common stock to be issued in the anticipated Concurrent Financing to OrthoCellix&#8217;s sole stockholder and other investors will be registered on Form S-1 or Form S-3;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the support agreements, pursuant to which certain directors, officers and stockholders of OrthoCellix and Carisma, respectively, have agreed, solely in their capacity as stockholders of OrthoCellix and Carisma, respectively, to vote all of their shares of OrthoCellix capital stock or Carisma common stock in favor of the adoption or approval, respectively, of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to obtain a Nasdaq listing and the change of the Combined Company&#8217;s name to &#8220;OrthoCellix,&#160;Inc.&#8221; prior to or upon the closing of the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the likelihood that the Merger will be consummated on a timely basis.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that the Merger might not be completed and the potential adverse effect of the public announcement of the Merger on the reputation of OrthoCellix and the ability of OrthoCellix to obtain financing in the future in the event the Merger is not completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that the anticipated Concurrent Financing might not be completed or completed in accordance with the terms of the subscription agreements and the potential adverse effect of the public announcement of the anticipated Concurrent Financing on the reputation of OrthoCellix and the ability of OrthoCellix to obtain financing in the future in the event the anticipated Concurrent Financing is not completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Exchange Ratio used to establish the number of shares of Carisma&#8217;s common stock to be issued to the sole stockholder of OrthoCellix and other anticipated investors in the anticipated Concurrent Financing in the Merger is fixed, except for adjustments due to Carisma&#8217;s Net Cash balances, the amount of proceeds from the anticipated Concurrent Financing and outstanding capital stock at the closing of the Merger, and thus the relative&#160;percentage ownership of Carisma stockholders and OrthoCellix&#8217;s sole stockholder in the Combined Company immediately following the completion of the Merger is similarly fixed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential reduction of Carisma&#8217;s Net Cash prior to the closing of the Merger or the potential failure of Carisma to satisfy the minimum threshold level of Net Cash required for the closing of the Merger to occur;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that Carisma could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the Merger might not be consummated in a timely manner or at all, for a variety of reasons, such as the failure of Carisma to obtain the required stockholder vote or the failure of OrthoCellix to close the anticipated Concurrent Financing, and the potential adverse effect on the reputation of OrthoCellix and the ability of OrthoCellix to obtain financing in the future in the event the Merger is not completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in connection with completing the Merger, the time and effort of OrthoCellix senior management required to complete the Merger, the related disruptions or potential disruptions to OrthoCellix&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with OrthoCellix, and related administrative challenges associated with combining the companies;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the additional expenses and obligations to which OrthoCellix&#8217;s business will be subject to following the Merger that OrthoCellix is a newly formed entity and as such, has not previously been subject to the operational challenges of being an operating business as well as additional considerations with respect to the operation of a newly formed entity as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the fact that the representations and warranties in the Merger Agreement do not survive the closing of the Merger and the potential risk of liabilities that may arise post-closing of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that future sales of common stock by existing Carisma stockholders may cause the price of Carisma common stock to fall, thus reducing the potential value of Carisma common stock received by OrthoCellix&#8217;s sole stockholder following the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">various other risks associated with the Combined Company and the Merger, including the risks described in the section titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk Factors</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; beginning on page&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">26</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing information is not intended to be exhaustive, but is believed to include a summary of all of the material factors considered by OrthoCellix&#8217;s board of directors in its consideration of the Merger Agreement, the anticipated Concurrent Financing, and the transactions contemplated thereby. After conducting an overall analysis of these and other factors, including thorough discussions with, and questioning of, OrthoCellix&#8217;s senior management and legal counsel, OrthoCellix&#8217;s board of directors concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. Based on this overall analysis of the factors described above, OrthoCellix&#8217;s board of directors unanimously approved the Merger Agreement, the Merger, the anticipated Concurrent Financing and the other transactions contemplated by the Merger Agreement.</p><a id="OpinionofCarismasFinancialAdvisor_687326"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion of Carisma&#8217;s Financial Advisor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to an engagement letter dated June&#160;13, 2025 (the &#8220;Engagement Letter&#8221;), Carisma retained Lucid to render an opinion to Carisma&#8217;s board of directors as to the fairness of the exchange ratio, from a financial point of view, to the holders of common stock of Carisma.&#160;On June&#160;22, 2025, at the request of Carisma&#8217;s board of directors, Lucid rendered its oral opinion, subsequently confirmed in writing, to Carisma&#8217;s board of directors, that the exchange ratio was fair, from a financial point of view, to the holders of common stock of Carisma as of such date and based upon the various assumptions, qualifications and limitations set forth therein (the &#8220;Lucid Opinion&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The full text of the Lucid Opinion is attached as </b><span style="font-style:italic;font-weight:bold;">Annex&#160;B</span><b style="font-weight:bold;"> to this proxy statement/prospectus and is incorporated herein by reference. Carisma encourages its stockholders to read the Lucid Opinion in its entirety for the assumptions made, procedures followed, other matters considered and limits of the review by Lucid. The summary of the Lucid Opinion set forth herein is qualified by reference to the full text of the Lucid Opinion. The Lucid Opinion is intended for the benefit and use by Carisma&#8217;s board of directors (in its capacity as such) in its consideration of the financial terms of the Merger. The Lucid Opinion does not constitute a recommendation to Carisma&#8217;s board of directors of whether to approve the merger or to any Carisma stockholder or other person as to how to vote or act with respect to the proposed merger or any other matter.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Lucid Opinion, Lucid took into account an assessment of general economic, market and financial conditions as well as its experience in connection with similar transactions and securities valuations generally and, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed a draft of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain publicly available financial and other information for each of Carisma and OrthoCellix;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Discussed with certain members of the management of Carisma the historical and current business operations, financial condition and prospects of Carisma and OrthoCellix;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain operating results of OrthoCellix as compared to operating results and the reported price and trading histories of certain publicly traded companies that Lucid deemed relevant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed the financial projections of OrthoCellix prepared by management of OrthoCellix and adjusted by Carisma&#8217;s management;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain financial terms of the Merger Agreement as compared to the publicly available financial terms of certain selected business combinations that Lucid deemed relevant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain financial terms of completed initial public offerings for certain companies that Lucid deemed relevant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as Lucid deemed relevant for the purposes of the Lucid Opinion.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In conducting Lucid&#8217;s review and arriving at the Lucid Opinion, Lucid, with the consent of Carisma&#8217;s board of directors, relied upon the assumption that all information provided to Lucid by Carisma and OrthoCellix was accurate and complete in all material respects. To the extent that the information reviewed by Lucid includes estimates and forecasts of future performance prepared by or reviewed with management of OrthoCellix and Carisma, Lucid assumed, with the consent of Carisma&#8217;s board of directors, that such estimates and forecasts have been reasonably prepared in good faith on a basis reflecting the best currently available estimates and judgments of the management of OrthoCellix and Carisma. Lucid expressed no opinion with respect to such estimates and forecasts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, for purposes of its analysis and the Lucid Opinion, Lucid assumed, with the consent of Carisma&#8217;s board of directors, that (i)&#160;the Concurrent Financing Amount would be $25.0 million and would occur simultaneously with the closing of the merger, (ii)&#160;Net Cash would be $0.0, (iii)&#160;the exchange ratio would be 327,677.6433, and (iv)&#160;immediately upon the closing of the merger and including the shares of Carisma common stock issuable in the Concurrent Financing, the holders of OrthoCellix common stock would in the aggregate hold approximately 73.3% of the fully-diluted shares of Carisma&#8217;s common stock (excluding certain options and excluding for this purpose any shares purchase by Ocugen in the Concurrent Financing).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid expressly disclaimed any undertaking or obligation to advise any person of any change in any fact or matter affecting the Lucid Opinion of which Lucid has become aware after the date of the Lucid Opinion. Lucid assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of Carisma or OrthoCellix since the date of the last financial statements made available to Lucid. Lucid did not obtain any independent evaluations, valuations or appraisals of the assets or liabilities of Carisma or OrthoCellix, nor was Lucid furnished with such materials. In addition, Lucid did not evaluated the solvency or fair value of Carisma or OrthoCellix under any state or federal laws relating to bankruptcy, insolvency or similar matters. The Lucid Opinion does not address any legal, tax or accounting matters related to the merger, as to which Lucid assumed that Carisma and Carisma&#8217;s board of directors received such advice from legal, regulatory, tax and accounting advisors as each determined appropriate. The Lucid Opinion addresses only the fairness from a financial point of view of the exchange ratio to the holders of common stock of Carisma. Lucid expressed no view as to any other aspect or implication of the Merger or any other agreement or arrangement entered into in connection with the Merger. The Lucid Opinion was necessarily based upon economic and market conditions and other circumstances as they existed and could be evaluated by Lucid on the date of the Lucid Opinion. It should be understood that although subsequent developments may affect the Lucid Opinion, Lucid does not have any obligation to update, revise or reaffirm the Lucid Opinion and Lucid expressly disclaimed any responsibility to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid did not consider any potential legislative or regulatory changes currently being considered or recently enacted by the United States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the SEC, the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of rendering the Lucid Opinion, Lucid assumed with the consent of Carisma&#8217;s board of directors, that except as would not be in any way meaningful to our analysis: (i)&#160;the final form of the Merger Agreement would not differ from the draft Merger Agreement that Lucid reviewed on June 21, 2025; (ii)&#160;the representations and warranties of each party contained in the Merger Agreement were true and correct; (iii)&#160;each party would perform all of the covenants and agreements required to be performed by such party under the Merger Agreement; and (iv)&#160;the transactions contemplated by the Merger Agreement would be consummated in accordance with the terms of the Merger Agreement, without any waiver or amendment of any term or condition thereof. Lucid also assumed that all governmental, regulatory and other consents and approvals contemplated by the Merger Agreement or otherwise required for the transactions contemplated by the Merger Agreement would be obtained and that in the course of obtaining any of those consents no restrictions would be imposed or waivers made that would have an adverse effect on Carisma, OrthoCellix or the contemplated benefits of the Merger. Lucid assumed that the Merger would be consummated in a manner that complied with the applicable provisions of the Securities Act, the Exchange&#160;Act&#160;and all other applicable federal and state statutes, rules&#160;and regulations.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement provides that Carisma may engage in a Parent Legacy Transaction or Asset Dispositions with respect to the Parent Legacy Assets. Any net proceeds from such transactions would increase Net Cash. Lucid has, with the consent of Carisma&#8217;s board of directors, assumed that no Asset Dispositions or Parent Legacy Transaction would occur prior to the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement also provides that prior to the Effective Time, Carisma will distribute to holders of Carisma&#8217;s common stock the right to receive a CVR representing the right to receive contingent payments upon the occurrence of certain events set forth in and subject to and in accordance with the terms and conditions of, a Contingent Value Rights Agreement. With the consent of Carisma&#8217;s board of directors, Lucid did not assign any value to the CVRs due to the speculative nature of any assumptions that would be necessary for Lucid to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Lucid Opinion does not address Carisma&#8217;s underlying business decision to proceed with the merger or the relative merits of the merger compared to other alternatives available to Carisma. Lucid expressed no opinion as to the prices or ranges of prices at which shares or the securities of any person, including Carisma, would trade at any time, including following the announcement or consummation of the merger or as to the potential effects of volatility in the credit, financial, and stock markets on Carisma, OrthoCellix or the transactions contemplated by the Merger Agreement. Lucid was not been requested to opine as to, and the Lucid Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the merger, or any class of such persons, relative to the compensation to be paid to the existing Carisma stockholders in connection with the merger or with respect to the fairness of any such compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Lucid Opinion may not be published or otherwise used or referred to, nor shall any public reference to Lucid be made, without Lucid&#8217;s prior written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Principal Financial Analyses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the principal financial analyses performed by Lucid to arrive at the Lucid Opinion. Some of the summaries of financial analyses include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data set forth in the tables without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the financial analyses. Lucid performed certain procedures, including each of the financial analyses described below and reviewed with Carisma&#8217;s board of directors the assumptions on which such analyses were based and other factors, including the historical and projected financial results of Carisma and OrthoCellix.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transaction Overview as of the Date of the Lucid Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based upon the exchange ratio of 327,677.6433 at the time of the signing of the Merger Agreement, Lucid estimated that at the closing, and after giving effect to the anticipated $25.0 million Concurrent Financing: (a)&#160;OrthoCellix&#8217;s sole stockholder, Ocugen, as of immediately prior to the Merger (but excluding for this purpose any shares purchased by Ocugen in the Concurrent Financing) would own approximately 73.3% of the fully-diluted&#160;shares of Carisma Common Stock (excluding certain Carisma options) at the closing of the merger, (b)&#160;the Carisma equity holders as of immediately prior to the merger would own approximately 10.0% of the fully-diluted&#160;shares of Carisma Common Stock (excluding certain Carisma options) at the closing of the merger, and (c) the investors in the Concurrent Financing (including for this purpose shares purchased in the Concurrent Financing by Ocugen) would own approximately 16.7% of the fully-diluted shares of Carisma Common Stock at the closing of the merger, in each case, subject to adjustment of the exchange ratio as set forth in the Merger Agreement and described herein. The assumed value of Carisma ($15.0 million) is subject to adjustment by the amount by which Net Cash is above or below $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement provides that the parties will use commercially reasonable efforts to enter into subscription agreements with one or more investors designated by OrthoCellix to subscribe for and purchase a number of shares of Carisma common stock representing an aggregate commitment (inclusive of the Guarantor Investment) at least equal to $25.0 million (the &#8220;Concurrent Financing Amount&#8221;). Prior to the closing of the Merger, as part of the Concurrent Financing, Ocugen, the sole stockholder of OrthoCellix, will enter into a securities purchase agreement committing to purchase a number of shares of Carisma common stock equal to not less than $5.0 million.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix Valuation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the purpose of the Lucid Opinion, Lucid utilized a valuation of $135.0 million for OrthoCellix, comprised of the negotiated equity value of $110.0 million for OrthoCellix plus the expected $25.0 million of total proceeds contemplated by the Concurrent Financing Amount. The assumed valuation of OrthoCellix is subject to a reduction by the amount, if any, by which the Concurrent Financing Amount is less than $25.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Analysis of Selected Initial Public Offering Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid reviewed certain publicly available information for the initial public offerings (&#8220;IPOs&#8221;) of nine clinical-stage cell therapy and biologics focused companies that completed an IPO since 2015 and whose lead product at the time of IPO was in clinical-stage of development. Lucid focused its analysis on companies developing clinical-stage cell-therapy, stem-cell and hospital-administered biologic products in non-oncology indications. Although the companies referred to below were used for comparison purposes, none of these companies are directly comparable to OrthoCellix. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. These companies, which are referred to as the &#8220;Selected Precedent IPO Companies,&#8221; were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AlloVir,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Artiva Biotherapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Coya Therapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Kyverna Therapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Talaris Therapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Longeveron&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cabaletta Bio,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cue Biopharma,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Seres Therapeutics,&#160;Inc.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The total enterprise value at IPO is defined as the pre-money equity value plus indebtedness, liquidation value of preferred stock and non-controlling interest, minus cash and cash equivalents at the time of its IPO. The Selected Precedent IPO Companies had total enterprise values between $36.3&#160;million and $694.9&#160;million. Lucid derived a median total enterprise value of $163.8&#160;million for the Selected Precedent IPO Companies. Using the 25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile and the 75<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for OrthoCellix, which was approximately $81.5&#160;million to $445.2&#160;million. This compares to the OrthoCellix equity valuation of $110.0&#160;million as set forth in the Merger Agreement.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Precedent IPO Companies</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:29.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Filing Date</b></p></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:29.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuer</b></p></td><td style="vertical-align:bottom;width:2.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Enterprise</b><br/><b style="font-weight:bold;">Value&#160;($M)</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">7/18/2024</p></td><td style="vertical-align:bottom;width:3.13%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Artiva Biotherapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">81.5</p></td></tr><tr><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2/7/2024</p></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Kyverna Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">530.6</p></td></tr><tr><td style="vertical-align:bottom;width:48.96%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">12/28/2022</p></td><td style="vertical-align:bottom;width:3.13%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Coya Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">36.3</p></td></tr><tr><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5/6/2021</p></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Talaris Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">391.4</p></td></tr><tr><td style="vertical-align:bottom;width:48.96%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2/12/2021</p></td><td style="vertical-align:bottom;width:3.13%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Longeveron&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">163.8</p></td></tr><tr><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">7/30/2020</p></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">AlloVir,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">694.9</p></td></tr><tr><td style="vertical-align:bottom;width:48.96%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10/25/2019</p></td><td style="vertical-align:bottom;width:3.13%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cabaletta Bio,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">113.2</p></td></tr><tr><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">1/2/2018</p></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cue Biopharma,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">81.4</p></td></tr><tr><td style="vertical-align:bottom;width:48.96%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">6/25/2015</p></td><td style="vertical-align:bottom;width:3.13%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Seres Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">445.2</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Analysis of Selected Publicly Traded Cell Therapy and Biologics Companies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on its experience and professional judgment and using financial screening sources and databases to find companies that share similar business characteristics to OrthoCellix within the biopharmaceutical industry, Lucid analyzed selected financial data of 23 publicly traded companies (referred to as the &#8220;Selected Publicly Traded Cell Therapy and Biologics Companies&#8221;). Each of the Selected Publicly Traded Cell Therapy and Biologics Companies had a lead candidate in clinical development and focused on cell therapy, stem-cells or hospital-administered biologic products in non-oncology indications. Although the companies referred to below were used for comparison purposes, none of those companies is directly comparable to OrthoCellix. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. The total enterprise values are based on closing stock prices on June&#160;20, 2025. The Selected Publicly Traded Cell Therapy and Biologics Companies were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Armata Pharmaceuticals,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Artiva Biotherapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BioCardia,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Brainstorm Cell Therapeutics Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cabaletta Bio,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Capricor Therapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cartesian Therapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Celldex Therapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Century Therapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Coya Therapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Creative Medical Technology Holdings,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fate Therapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FibroBiologics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Forte Biosciences,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jasper Therapeutics,&#160;Inc.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Kyverna Therapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lineage Cell Therapeutics,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Longeveron&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Omeros Corporation</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pluri&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ProKidney Corp.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Sana Biotechnology,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Seres Therapeutics,&#160;Inc.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Selected Publicly Traded Cell Therapy and Biologics Companies had implied total enterprise values between negative $113.5&#160;million and $1.1&#160;billion. Lucid derived a median implied total enterprise value of $40.9&#160;million for the Selected Publicly Traded Cell Therapy and Biologics Companies. Using the 25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile and the 75<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for OrthoCellix, which was approximately $0.2&#160;million to $181.4&#160;million. This compares to the OrthoCellix equity valuation of $110.0&#160;million as set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Publicly Traded Companies</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:82.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Company Name</b></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Enterprise</b><br/><b style="font-weight:bold;">Value&#160;($M)</b></p></td></tr><tr><td style="vertical-align:middle;width:82.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">ProKidney Corp.</p></td><td style="vertical-align:bottom;width:1.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,128.9</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Celldex Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">691.2</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Sana Biotechnology,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">575.3</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Omeros Corporation</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">480.2</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Capricor Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">234.0</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Armata Pharmaceuticals,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">192.8</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Lineage Cell Therapeutics</p></td><td style="vertical-align:bottom;width:1.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">169.9</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Seres Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">95.3</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Cartesian Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">86.9</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Coya Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">56.5</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Forte Biosciences,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">50.7</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Pluri&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">40.9</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Jasper Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31.2</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">FibroBiologics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25.7</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">BioCardia,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.9</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Brainstorm Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.8</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Longeveron&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.0</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Creative Medical Technology Holdings,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(4.6)</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Fate Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(20.7)</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Century Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(62.3)</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Kyverna Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(103.0)</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Cabaletta Bio,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(107.5)</p></td></tr><tr><td style="vertical-align:middle;width:82.22%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Artiva Biotherapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(113.5)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Analysis of Selected Publicly Traded Biomaterials Companies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Based on its experience and professional judgment and using financial screening sources and databases to find companies that share similar business characteristics to OrthoCellix within the biopharmaceutical industry, Lucid analyzed selected financial data of seven publicly traded companies (referred to as the &#8220;Selected Publicly Traded Biomaterials Companies&#8221;). Each of the Selected Publicly Traded Biomaterials Companies were focused on biomaterials and had a lead candidate in clinical development or had recently begun generating revenue. Although the companies referred to below were used for comparison purposes, none of those companies is directly comparable to OrthoCellix. Accordingly, an analysis of the results of such a comparison is not purely </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. The total enterprise values are based on closing stock prices on June&#160;20, 2025. The Selected Publicly Traded Biomaterials Companies were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Abeona Therapeutics&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Anteris Technologies Global Corp.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BioRestorative Therapies,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CellSeed&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Humacyte,&#160;Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Orthocell Limited</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Sernova Bio</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Selected Publicly Traded Biomaterials Companies had implied total enterprise values between $2.8&#160;million and $378.0 million. Lucid derived a median implied total enterprise value of $109.8&#160;million for the Selected Publicly Traded Biomaterials Companies. Using the 25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile and the 75<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for OrthoCellix, which was approximately $66.0&#160;million to $204.4&#160;million. This compares to the OrthoCellix equity valuation of $110.0&#160;million as set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Publicly Traded Companies</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:82.26%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Company Name</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Enterprise</b><br/><b style="font-weight:bold;">Value&#160;($M)</b></p></td></tr><tr><td style="vertical-align:middle;width:82.26%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Humacyte,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">378.0</p></td></tr><tr><td style="vertical-align:middle;width:82.26%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Abeona Therapeutics&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">241.1</p></td></tr><tr><td style="vertical-align:middle;width:82.26%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Orthocell Limited</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">167.6</p></td></tr><tr><td style="vertical-align:middle;width:82.26%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">CellSeed&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">109.8</p></td></tr><tr><td style="vertical-align:middle;width:82.26%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Anteris Technologies Global Corp.</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">91.7</p></td></tr><tr><td style="vertical-align:middle;width:82.26%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Sernova Bio</p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">40.3</p></td></tr><tr><td style="vertical-align:middle;width:82.26%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">BioRestorative Therapies,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.8</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Precedent Cell Therapy and Biologics M&amp;A Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of the seven most recent qualifying merger transactions of companies in the biopharmaceutical industry, which had a lead candidate in clinical development and focused on cell therapy, stem-cells or hospital-administered biologic products in non-oncology indications (referred to as the &#8220;Selected Precedent Cell Therapy and Biologics M&amp;A Transactions&#8221;). Although the precedent transactions referred to below were used for comparison purposes, none of the target companies is directly comparable to OrthoCellix. Accordingly, an analysis of the results of such a comparison is not purely mathematical, but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the companies involved and other factors that could affect the merger value of such companies and OrthoCellix to which they are being compared. Lucid reviewed the total enterprise values of the target companies. These transactions, including the date each was closed, were as follows below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Selected Precedent Cell Therapy and Biologics M&amp;A Transactions had total implied enterprise values between $9.9&#160;million and $970.0&#160;million, excluding any contingent milestone payments. Lucid derived a median total enterprise value of $295.0&#160;million for the Selected Precedent Cell Therapy and Biologics M&amp;A Transactions. Using the 25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile and the 75<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile of the implied total enterprise values, Lucid then calculated a range of implied total enterprise values for OrthoCellix, which was approximately $38.1&#160;million to $526.3&#160;million. This compares to the OrthoCellix equity valuation of $110.0&#160;million as set forth in the Merger Agreement.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Precedent Cell Therapy and Biologics M&amp;A Transactions</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.1898117%;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:31.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:28.93%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:16.14%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Closed Date</b></p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:31.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Target</b></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:28.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Acquirer</b></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Implied&#160;Enterprise</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Value&#160;($M)</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">2/22/2024</p></td><td style="vertical-align:bottom;width:1.88%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.31%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Gracell Biotechnologies&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.76%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:28.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">AstraZeneca PLC</p></td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;width:16.14%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">970.0</p></td></tr><tr><td style="vertical-align:bottom;width:15.8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">7/11/2022</p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ViaCyte,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:28.93%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Vertex Pharmaceuticals Incorporated</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.14%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">295.0</p></td></tr><tr><td style="vertical-align:bottom;width:15.8%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">10/19/2020</p></td><td style="vertical-align:bottom;width:1.88%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Koligo Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.76%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:28.93%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Orgenesis&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.14%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12.8</p></td></tr><tr><td style="vertical-align:bottom;width:15.8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">12/16/2019</p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Fibrocell Science&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:28.93%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Castle Creek Biosciences,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.14%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">63.3</p></td></tr><tr><td style="vertical-align:bottom;width:15.8%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">10/16/2018</p></td><td style="vertical-align:bottom;width:1.88%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Regenerative Medical Technology Group&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.76%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:28.93%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Predictive Technology Group,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.14%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.9</p></td></tr><tr><td style="vertical-align:bottom;width:15.8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">1/5/2018</p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">TiGenix NV</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:28.93%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Takeda Pharmaceutical Company Limited</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.14%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">673.6</p></td></tr><tr><td style="vertical-align:bottom;width:15.8%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">2/10/2016</p></td><td style="vertical-align:bottom;width:1.88%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Ocata Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.76%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:28.93%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Astellas US Holding,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.14%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">379.0</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Precedent Biomaterials M&amp;A Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of the eight most recent qualifying merger transactions of companies in the biomaterials industry, which had a lead candidate focused on biomaterials and were in clinical development or recently begun generating revenue (referred to as the &#8220;Selected Precedent Biomaterials M&amp;A Transactions&#8221;). Although the precedent transactions referred to below were used for comparison purposes, none of the target companies is directly comparable to OrthoCellix. Accordingly, an analysis of the results of such a comparison is not purely mathematical, but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the companies involved and other factors that could affect the merger value of such companies and OrthoCellix to which they are being compared. Lucid reviewed the total enterprise values of the target companies. These transactions, including the date each was closed, were as follows below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Selected Precedent Biomaterials M&amp;A Transactions had total implied enterprise values between $15.0&#160;million and $1.2&#160;billion. Lucid derived a median total enterprise value of $60.1&#160;million for the Selected Precedent Biomaterials M&amp;A Transactions. Using the 25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile and the 75<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile of the implied total enterprise values, Lucid then calculated a range of implied total enterprise values for OrthoCellix, which was approximately $42.0&#160;million to $102.5&#160;million. This compares to the OrthoCellix equity valuation of $110.0&#160;million as set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Precedent Biomaterials M&amp;A Transactions</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:22.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:20%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Closed Date</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Target</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Acquirer</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Implied&#160;Enterprise</b><span style="text-decoration-line:none;"><br/></span><b style="font-weight:bold;">Value&#160;($M)</b></p></td></tr><tr><td style="vertical-align:middle;width:22.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">12/2/2024</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Tantti Laboratory&#160;Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Repligen Corporation</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:20%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">55.1</p></td></tr><tr><td style="vertical-align:middle;width:22.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">9/18/2023</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Elutia&#160;Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Berkeley Biologics LLC</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15.0</p></td></tr><tr><td style="vertical-align:middle;width:22.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">9/5/2023</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Conformis,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Restor3D,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18.0</p></td></tr><tr><td style="vertical-align:middle;width:22.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">8/31/2023</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Kerecis LLC</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Coloplast A/S</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,200.0</p></td></tr><tr><td style="vertical-align:middle;width:22.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">8/9/2023</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Axolotl Biologix,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Carmell Therapeutics Corporation</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">65.0</p></td></tr><tr><td style="vertical-align:middle;width:22.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">2/14/2023</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Embody,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Zimmer Biomet Holdings,&#160;Inc. </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">155.0</p></td></tr><tr><td style="vertical-align:middle;width:22.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">8/9/2022</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Biorez,&#160;Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">CONMED Corporation</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">85.0</p></td></tr><tr><td style="vertical-align:middle;width:22.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">4/4/2022</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">CartiHeal&#160;Ltd. </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Bioventus&#160;Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">50.0</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Discounted Cash Flow Analysis</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid estimated a range of total enterprise values for OrthoCellix based upon the present value of OrthoCellix&#8217;s estimated after-tax unlevered free cash flows as shown in the Projections. Lucid then reviewed and analyzed the revenue and expense projections for OrthoCellix contained in the Projections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In performing this discounted cash flow analysis, Lucid utilized discount rates ranging from 13.6% to 17.6%, which were selected based on the capital asset pricing model and the estimated weighted average cost of capital of the Selected Publicly Traded Cell Therapy and Biologics Companies which was 15.6%. Given that the Projections only extend through 2033, Lucid calculated a terminal value to determine the estimated value of the NeoCart program after 2033. Lucid calculated a terminal value based on the perpetuity growth model assuming a standard growth rate of three&#160;percent as confirmed by the Carisma management team.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Using the range of discount rates of 13.6% to 17.6%, Lucid then added the terminal value to the net present cash flows of OrthoCellix&#8217;s cash flows to calculate a range of implied total equity values for OrthoCellix, which was $326.0 million to $588.1 million. This compares to the OrthoCellix equity valuation of $110.0&#160;million as set forth in the Merger Agreement.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Carisma Valuation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Analysis of Precedent Reverse Merger Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of life sciences reverse merger transactions commencing in January&#160;2018 (referred to as the &#8220;Selected Precedent Reverse Merger Transactions&#8221;). Lucid reviewed the total premium to cash delivered to each target, along with other quantitative metrics. These transactions, including the date each was closed, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Precedent Reverse Merger Transactions</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Closed Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Surviving&#160;Company</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Public&#160;Company</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value&#160;Delivered</b><br/><b style="font-weight:bold;">for&#160;Public</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Vehicle</b><br/><b style="font-weight:bold;">Net&#160;of&#160;Cash</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($mm&#8217;s)</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6/16/2025</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Crescent Biopharma, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">GlycoMimetics (Nasdaq: GLYC)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4/28/2025</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Jade Biosciences, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Aerovate Therapeutics (Nasdaq: AVTE)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4/15/2025</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Tvardi Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cara Therapeutics (Nasdaq: CARA)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12/13/2024</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Palvella Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pieris Pharmaceuticals (Nasdaq: PIRS)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10/17/2024</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">TuHURA Biosciences, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Kintara Therapeutics (Nasdaq: KTRA)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10/9/2024</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Wex Pharmaceuticals Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Virios Therapeutics (Nasdaq: VIRI)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/3/2024</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Oruka Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ARCA Biopharma (Nasdaq: ABIO)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">8/12/24</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Firefly Neurosciences, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WaveDancer (Nasdaq: WAVD)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6/20/24</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Tetonic Therapeutics</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">AVROBIO (Nasdaq: AVRO)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4/1/2024</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Tawsfynydd Therapeutics</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Onconova Therapeutics (Nasdaq: ONTX)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3/26/2024</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Serina Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">AgeX Therapeutics (Nasdaq: AGE)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3/25/2024</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Q32 Bio Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Homology Medicines (Nasdaq: FIXX)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3/21/2024</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">LENZ Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Graphite Bio (Nasdaq: GRPH)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3/14/2024</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ImmunogenX, LLC</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">First Wave BioPharma (FWBI)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12/27/2023</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cyclo Therapeutics (Nasdaq: CYTH)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Applied Molecular Transport (Nasdaq: AMTI)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12/18/2023</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Neurogene Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Neoleukin Therapeutics (Nasdaq: NLTX)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">11/13/2023</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cartesian Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Selecta Biosciences (Nasdaq: RNAC)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">11/3/2023</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Korro Bio, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Frequency Therapeutics (Nasdaq: FREQ)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10/31/2023</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lung Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Aileron Therapeutics (Nasdaq: ALRN)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10/16/2023</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Notable Labs, Ltd.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vascular Biogenics Ltd. (Nasdaq: VBLT)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/11/2023</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Dianthus Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Magenta Therapeutics (Nasdaq: MGTA)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">8/16/2023</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">EIP Pharma (CervoMed)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Diffusion Pharmaceuticals (Nasdaq: DFFN)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6/29/2023</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">TeraImmune Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Baudax Bio (Nasdaq: BXRX)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6/22/2023</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Spyre Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Aeglea BioTherapeutics (Nasdaq: AGLE)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6/1/2023</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Elicio Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Angion Biomedica (Nasdaq: ANGN)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4/22/2023</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">GRI Bio, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vallon Pharmaceuticals (Nasdaq: VLON)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">29</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3/20/2023</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">CalciMedica, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Graybug Vision (Nasdaq: GRAY)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3/7/2023</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Carisma Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Sesen Bio (Nasdaq: SESN)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2/23/2023</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Enliven Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Imara (Nasdaq: IMRA)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1/9/2023</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Catheter Precision, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Ra Medical Systems (NYSE: RMED)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12/29/2022</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Disc Medicine, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Gemini Therapeutics (Nasdaq: GMTX)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12/27/2022</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">GNI Group (Gyre Therapeutics)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Catalyst Biosciences (Nasdaq: CBIO)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12/19/2022</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Kineta, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Yumanity Therapeutics (Nasdaq: YMTX)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">11/8/2022</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ARS Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Silverback Therapeutics (Nasdaq: SBTX)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/28/2022</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Aceragen, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Idera Pharmaceuticals (Nasdaq: IDRA)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/15/2022</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lisata Therapeutics (Cend)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Caladrius Biosciences (Nasdaq: CLBS)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">7/5/2022</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Syros Pharmaceuticals (Nasdaq: SYRS)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Tyme Technologies (Nasdaq: TYME)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">5/16/2022</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Aprea Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Atrin Pharmaceuticals (NasdaqGS: APRE)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10/24/2021</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Quoin Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cellect Biotechnology Ltd. (Nasdaq: APOP)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">8/26/2021</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Aadi Bioscience, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">8/3/2021</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Decoy Biosystems, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indaptus Therapeutics (Intec) (Nasdaq: INDP)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6/28/2021</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Tempest Therapeutics Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Millendo Therapeutics, Inc. (Nasdaq: MLND)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6/15/2021</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ReShape Lifesciences Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Obalon Therapeutics, Inc. (Nasdaq: OBLN)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4/27/2021</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Leading BioSciences, Inc. (Palisade)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Seneca Biopharma, Inc. (Nasdaq: SNCA)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4/16/2021</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MyMD Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Akers Biosciences, Inc. (Nasdaq: AKER)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3/31/2021</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">StemoniX Inc. (Vyant Bio)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cancer Genetics, Inc. (Nasdaq: CGIX)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3/16/2021</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ChemomAb Ltd.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Anchiano Therapeutics Ltd. (Nasdaq: ANCN)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2/24/2021</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Viracta Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Sunesis Pharmaceuticals (Nasdaq: SNSS)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1/28/2021</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Quellis Biosciences, Inc. (Astria)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Catabasis Pharmaceuticals (Nasdaq: CATB)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12/22/2020</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Yumanity Therapeutics Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Proteostasis Therapeutics (Nasdaq: PTI)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">34</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12/1/2020</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Petros Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Neurotrope, Inc. (NasdaqCM: NTRP)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Closed Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Surviving&#160;Company</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Public&#160;Company</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value&#160;Delivered</b><br/><b style="font-weight:bold;">for&#160;Public</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Vehicle</b><br/><b style="font-weight:bold;">Net&#160;of&#160;Cash</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($mm&#8217;s)</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">11/23/2020</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">F-star Therapeutics, Limited</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Spring Bank Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">11/5/2020</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Ocuphire Pharma, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Rexahn Pharmaceuticals (Nasdaq: REXN)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10/27/2020</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Viridian Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Miragen Therapeutics, Inc. (NasdaqCM: MGEN)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/15/2020</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Adicet Bio, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">resTORbio, Inc. (NasdaqGS: TORC)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/14/2020</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Anelixis Therapeutics (Eledon)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Novus Therapeutics, Inc. (NasdaqCM: NVUS)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">7/6/2020</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Kiq Bio (Cogent)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Unum Therapeutics, Inc. (Nasdaq: UMRX)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6/15/2020</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Forte Biosciences, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Tocagen Inc. (NasdaqGS: TOCA)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">5/28/2020</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Larimar Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Zafgen, Inc. (NasdaqGS: ZFGN)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">5/26/2020</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Histogen, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Conatus Pharmaceuticals (Nasdaq: CNAT)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">5/18/2020</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Timber Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">BioPharmX Corporation (AMEX: BPMX)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4/1/2020</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Curetis NV (Euronext: CURE)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">OpGen, Inc. (NasdaqCM: OPGN)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1/9/2020</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Protara Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Proteon Therapeutics, Inc. (NASDAQ: PRTO)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12/30/2019</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">NeuroBo Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Gemphire Therapeutics Inc. (NASDAQ: GEMP)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">11/7/2019</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Venus Concept Ltd.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Restoration Robotics, Inc. (NASDAQ: HAIR)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/27/2019</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Ocugen, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Histogenics Corporation (NASDAQ: HSGX)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">NA</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">8/31/2019</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Brickell Biotech, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vical Incorporated (NASDAQ: VICL)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">7/31/2019</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ESSA Pharma (NASDAQ: EPIX)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Realm Therapeutics plc (NASDAQ: RLM)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">7/22/2019</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Salarius Pharmaceuticals, LLC</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Flex Pharma, Inc. (NASDAQ: FLKS)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">7/15/2019</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">NeuBase Therapeutics</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Ohr Pharmaceutical (NASDAQ: OHRP)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6/10/2019</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Oncternal Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">GTx, Inc. (NASDAQ: GTXI)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6/9/2019</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Edesa Biotech Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stellar Biotechnologies, Inc. (NASDAQ: SBOT)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">5/9/2019</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armata Pharmaceuticals (f.k.a C3J)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Ampliphi Biosciences (NYSE: APHB)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">5/6/2019</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Adynxx, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Alliqua BioMedical, Inc. (NASDAQ: ALQA)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4/23/2019</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Mereo BioPharma (AIM: MPH)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Oncomed Pharmaceuticals (NASDAQ: OMED)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4/12/2019</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Immunic AG</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vital Therapies, Inc. (NASDAQ: VTL)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3/26/2019</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Enlivex Therapeutics Ltd.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Bioblast Pharma Ltd. (NASDAQ: ORPN)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3/18/2019</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PDS Biotechnology Corporation</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Edge Therapeutics, Inc. (NASDAQ: EDGE)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3/13/2019</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">X4 Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Arsanis, Inc. (NASDAQ: ASNS)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">29</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1/24/2019</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Seelos Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Apricus Biosciences, Inc. (NASDAQ: APRI)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12/7/2018</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Millendo Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">OvaScience, Inc. (NASDAQ: OVAS)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10/12/2018</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Aravive Biologics, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Versartis, Inc. (NASDAQ: VSAR)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2/13/2018</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vaxart, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Aviragen Therapeutics, Inc. (NASDAQ: AVIR)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1/30/2018</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Innovate Biopharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Monster Digital, Inc. (NASDAQ: MSDI)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:18%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1/17/2018</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Evofem Biosciences, Inc.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Neothetics, Inc. (NASDAQ: NEOT)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">29</p></td></tr><tr><td style="vertical-align:bottom;width:18%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1/4/2018</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Rocket Pharmaceuticals, Ltd</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Inotek Pharmaceuticals Corp (NASDAQ: ITEK)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid reviewed the value delivered for the public vehicle (net of cash) from the Selected Precedent Reverse Merger Transactions, which ranged from $0 to $44.0&#160;million. Lucid derived the median for the value delivered for the public vehicle (net of cash) to be $11.0 million. This compares to the Carisma equity valuation of $15.0&#160;million as set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summary set forth above does not purport to be a complete description of all the analyses performed by Lucid. The preparation of a fairness opinion involves various determinations as to the most appropriate and relevant methods of financial analysis and the application of these methods to the particular circumstances. Therefore, such an opinion is not readily susceptible to partial analysis or summary description. Lucid did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Accordingly, notwithstanding the separate factors summarized above, Lucid believes, and advised Carisma&#8217;s board of directors, that its analyses must be considered as a whole. Selecting portions of its analyses and the factors considered by it without considering all analyses and factors could create an incomplete view of the process underlying the Lucid Opinion. In performing its analyses, Lucid made numerous assumptions with respect to industry performance, business and economic conditions and other matters, many of which are beyond the control of Carisma and OrthoCellix. These analyses performed by Lucid are not necessarily indicative of actual values or future results, which may be significantly more or less favorable than suggested by such analyses. In addition, analyses relating to the value of businesses do not purport to be appraisals or to reflect the prices at which businesses or securities may actually be sold. Accordingly, such analyses and estimates are inherently subject to uncertainty, being based upon numerous factors or events beyond the control of the parties or their respective advisors. None of Carisma, OrthoCellix, Lucid or any other person assumes responsibility if future results are materially different from those projected. The analyses supplied by Lucid and the Lucid Opinion were among several factors taken into consideration by Carisma&#8217;s board of directors in making its decision to enter into the Merger Agreement and should not be considered as determinative of such a decision.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid was selected by Carisma&#8217;s board of directors to render an opinion to Carisma&#8217;s board of directors because Lucid is a nationally recognized investment banking firm and as part of its investment banking business, Lucid is regularly engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Engagement Letter, Lucid received an upfront fee of $50,000 upon the signing of the Engagement Letter and an additional fee of $125,000 upon delivery of the Lucid Opinion. Additionally, Carisma has agreed to reimburse Lucid for its&#160;out-of-pocket expenses and has agreed to indemnify Lucid against certain liabilities, including liabilities under the federal securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the two&#160;years preceding the date of the Lucid Opinion, Lucid did not have a relationship with Carisma or its affiliates and did not receive any fees from Carisma or any of its affiliates. In the two&#160;years preceding the date of the Lucid Opinion, Lucid did not have a relationship with OrthoCellix or any of its affiliates, including Ocugen, and did not receive any fees from OrthoCellix or any of its affiliates, including Ocugen. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to Carisma, OrthoCellix, Ocugen and/or their respective affiliates and would expect to receive fees for the rendering of these services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, Lucid or certain of its affiliates, as well as investment funds in which Lucid or its affiliates may have financial interests, may acquire, hold or sell long or short positions, or trade or otherwise effect transactions in debt, equity, and other securities and financial instruments (including bank loans and other obligations) of, or investments in, Carisma, OrthoCellix, Ocugen or any other party that may be involved in the merger and/or their respective affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consistent with applicable legal and regulatory requirements, Lucid has adopted policies and procedures to establish and maintain the independence of its research department and personnel. As a result, Lucid&#8217;s research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to Carisma and the proposed merger that may differ from the views of Lucid&#8217;s investment banking personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Lucid Opinion was reviewed and approved by a fairness opinion committee of Lucid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain Unaudited Prospective Financial Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">The following information in this section does not give effect to the contemplated reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma does not, as a matter of course, publicly disclose long-term forecasts or projections as to future performance, earnings or other results due to the inherent unpredictability and subjectivity of the underlying assumptions, estimates and projections. However, as described in &#8220;<i style="font-style:italic;">The Merger&#160;- Background of the Transaction</i>,&#8221; in connection with its evaluation of the merger, the Carisma board of directors considered certain unaudited, non-public financial projections with respect to OrthoCellix as developed by OrthoCellix management, which were adjusted and revised by Carisma management as described below. On June&#160;16, 2025, Carisma management received a revenue model regarding OrthoCellix&#8217;s business and lead asset from OrthoCellix. Carisma management evaluated this information and applied Carisma management&#8217;s judgment (as well as the considerations and assumptions described below) to develop its view regarding the revenue projections and resulting free cash flows of OrthoCellix for each of the fiscal&#160;years ending December&#160;31, 2025 through December&#160;31, 2033. Carisma management assessed the revenue potential of OrthoCellix&#8217;s lead asset, effective tax rate, market penetration, costs of goods sold and other factors described below in order to prepare the financial forecast for each of the fiscal&#160;years ending December&#160;31, 2025 through 2033. Carisma management further applied certain probabilities of success, as determined by Carisma management, for OrthoCellix&#8217;s lead asset to reflect Carisma&#8217;s probability-adjusted outlook of OrthoCellix&#8217;s present value of free cash flows (the &#8220;Carisma Adjusted OrthoCellix Projections&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carisma Adjusted OrthoCellix Projections were provided to and considered by the Carisma board of directors in connection with its evaluation of the transactions contemplated by the Merger Agreement and Carisma&#8217;s other strategic alternatives. The Carisma board of directors directed Lucid Capital Markets to use the Carisma Adjusted OrthoCellix Projections as described below in its financial analyses and for purposes of its fairness opinion (as summarized above under the section titled &#8220;<i style="font-style:italic;">The Merger</i>&#8212;<i style="font-style:italic;">Opinion of Carisma&#8217;s Financial Advisor</i>&#8221;). The Carisma Adjusted OrthoCellix Projections were the only financial projections relied upon by Lucid Capital Markets in rendering its fairness opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The summaries of the Carisma Adjusted OrthoCellix Projections are not being included in this proxy statement/prospectus to influence any stockholder&#8217;s decision whether to vote for the Nasdaq Stock Issuance Proposal or for any other related purpose. The summaries of the Carisma Adjusted OrthoCellix Projections are being included in this proxy statement/prospectus because the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Carisma Adjusted OrthoCellix Projections were provided to the Carisma board of directors to evaluate strategic alternatives considered by the Carisma board of directors, including the transactions contemplated by the Merger Agreement, and to Lucid Capital Markets. The Carisma Adjusted OrthoCellix Projections may differ from publicized analyst estimates and forecasts and, in each instance, do not take into account any events or circumstances after the date they were prepared, including the announcement of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of the Carisma Adjusted OrthoCellix Projections, although presented with numerical specificity, are necessarily based on numerous variables, estimates and assumptions that are inherently uncertain, and many of which are beyond Carisma&#8217;s control. Because the Carisma Adjusted OrthoCellix Projections span multiple&#160;years, by their nature they will become subject to greater uncertainty with each successive&#160;year and are unlikely to anticipate each circumstance that will have an effect on the Combined Company&#8217;s business and its results of operations. Each of the Carisma Adjusted OrthoCellix Projections was prepared by Carisma management based on certain estimates and assumptions with respect to general business, economic, competitive, regulatory, reimbursement and other market and financial conditions and other future events, all of which are difficult to predict and many of which are beyond Carisma&#8217;s control. Although Carisma believes its assumptions about OrthoCellix to be reasonable, all financial projections are inherently uncertain, and Carisma expects that differences will exist between actual and projected results. As a result, there can be no assurance that any of the Carisma forecasts accurately reflect future trends or, in the case of the Carisma Adjusted OrthoCellix Projections, accurately estimate the future market for OrthoCellix&#8217;s lead asset. There also can be no assurance that OrthoCellix&#8217;s competitors will not commercialize products that are more effective or more successfully marketed and sold than any product that OrthoCellix may market or commercialize. The Carisma Adjusted OrthoCellix Projections are subject to many risks and uncertainties, and you are urged to review the section titled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page&#160;26 of this proxy statement/prospectus for a description of risk factors relating to the Merger and OrthoCellix&#8217;s business. You should also read the section titled &#8220;<i style="font-style:italic;">Cautionary Note&#160;Regarding Forward-Looking Statements</i>&#8221; beginning on page&#160;140 of this proxy statement/prospectus for additional information regarding the risks inherent in forward-looking information such as the Carisma Adjusted OrthoCellix Projections. The Carisma Adjusted OrthoCellix Projections were not reviewed or approved by OrthoCellix&#8217;s management, its board of directors or its advisors. In addition, the Carisma Adjusted OrthoCellix Projections will be affected by OrthoCellix&#8217;s ability to achieve strategic goals, objectives and targets over the applicable period. Accordingly, there can be no assurance that any of the Carisma Adjusted OrthoCellix Projections will be realized, and actual results may vary materially from those shown.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carisma Adjusted OrthoCellix Projections were not prepared with a view toward public disclosure, nor were they prepared with a view toward complying with GAAP, the published guidelines of the SEC regarding projections or the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information. Each of the Carisma Adjusted OrthoCellix Projections were developed solely using the information available to Carisma management at the time they were created and reflect assumptions as to certain business decisions that are subject to change. None of Carisma, OrthoCellix nor any of their respective affiliates, advisors, officers, directors or representatives has made or makes any representation or warranty to any Carisma or OrthoCellix stockholder regarding the ultimate performance of Carisma or OrthoCellix compared to the information contained in any of the Carisma Adjusted OrthoCellix Projections, the likelihood that the Carisma Adjusted OrthoCellix Projections will be achieved consistent with any of the Carisma Adjusted OrthoCellix Projections or at all, the marketability or market penetration of OrthoCellix&#8217;s lead asset, or the overall future performance of Carisma or OrthoCellix.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carisma Adjusted OrthoCellix Projections included herein have been prepared by, and are the responsibility of, Carisma&#8217;s management. Neither PricewaterhouseCoopers LLP, nor any other independent accountant has audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the Carisma Adjusted OrthoCellix Projections and, accordingly, neither PricewaterhouseCoopers LLP, nor any other independent accountant expresses an opinion or any other form of assurance with respect thereto. The PricewaterhouseCoopers LLP report included in this proxy statement/prospectus relates to the NeoCart Business of Ocugen&#8217;s previously issued financial statements. It does not extend to the prospective financial information and should not be read to do so. The report of KPMG LLP included in this proxy statement/prospectus that relates to Carisma&#8217;s historical audited financial statements does not extend to the unaudited prospective financial information and should not be read to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of the measures included in the Carisma Adjusted OrthoCellix Projections, including unlevered free cash flow, are financial measures that are not calculated in accordance with GAAP. Such non-GAAP financial measures should not be viewed as a substitute for GAAP financial measures and may be different from non-GAAP financial measures used by other companies. Furthermore, there are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation. Accordingly, non-GAAP financial measures should be considered together with, and not as an alternative to, financial measures prepared in accordance with GAAP. Unlevered free cash flow should not be considered as an alternative to operating income or net income, prepared in accordance with GAAP, as a measure of operating performance.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial measures provided to a financial advisor are excluded from the definition of non-GAAP financial measures and, therefore, are not subject to SEC rules&#160;regarding disclosures of non-GAAP financial measures, which would otherwise require a reconciliation of a non-GAAP financial measure to the most directly comparable GAAP financial measure. Reconciliations of non-GAAP financial measures were not relied upon by Lucid Capital Markets for purposes of its financial analysis as described in the section titled &#8220;<i style="font-style:italic;">The Merger</i>&#8212;<i style="font-style:italic;">Opinion of Carisma&#8217;s Financial Advisor</i>&#8221; or by the Carisma board of directors in connection with their consideration of the merger. Accordingly, Carisma has not provided a reconciliation of the non-GAAP financial measures included in the Carisma Adjusted OrthoCellix Projections to the relevant GAAP financial measures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma undertakes no obligation to update or otherwise revise or reconcile any of the Carisma Adjusted OrthoCellix Projections to reflect circumstances existing after the date such Carisma Adjusted OrthoCellix Projections were generated or to reflect the occurrence of future events. None of Carisma, or, to the knowledge of Carisma, OrthoCellix, intends to make publicly available any update or other revisions to any of the Carisma Adjusted OrthoCellix Projections, except as otherwise required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Carisma Adjusted OrthoCellix Projections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Set forth below is a summary of the Carisma Adjusted OrthoCellix Projections, which are select projected financial information for OrthoCellix for fiscal&#160;years 2025 through 2033 based on information as prepared by Carisma management in connection with Carisma&#8217;s evaluation of the Merger. The Carisma Adjusted OrthoCellix Projections were probability-adjusted downward by Carisma&#8217;s management by 53.6% to reflect a probability of success for a Phase 3 biologic company similar to OrthoCellix&#8217;s lead asset, which adjustment was determined by Carisma management&#8217;s judgment and experience and with reference to the Biotechnology Innovation Organization&#8217;s &#8220;Clinical Development Success Rates and Contributing Factors in 2011-2020&#8221; report published in 2021 for the likelihood of a Phase 3 biologic company to reach FDA approval. The Carisma Adjusted OrthoCellix Projections also included, among other things, the following key assumptions as to which there can be no assurance: assumptions related to peak market share and revenue relating to OrthoCellix&#8217;s lead asset; OrthoCellix&#8217;s lead asset becoming commercially available in 2028; growth in unit pricing assumptions; Costs of goods sold estimates and assumptions; Research and development expenses decreasing as a&#160;percentage of revenue during the period covered by the Carisma Adjusted OrthoCellix Projections; EU expenses being assumed to be 65.0% of the projected U.S. expenses beginning in 2028 after the commercial launch; U.S. Marketing and Promotional Expenses beginning in commercial&#160;year 1 (2028) decreasing as a&#160;percentage of revenue during the period covered by the Carisma Adjusted OrthoCellix Projections; EU expenses assumed to be 70.0% of the projected U.S. expenses beginning in 2028; and an assumed corporate tax rate of 21.0% beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carisma Adjusted OrthoCellix Projections for the applicable periods are summarized below (in millions):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:28%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2027</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2028</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2029</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2030</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2031</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2032</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2033</b></p></td></tr><tr><td style="vertical-align:top;width:28%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">45.5</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">111.9</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">204.9</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">330.5</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">495.5</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">707.0</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating Income</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(15.3)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(11.9)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8.0)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(51.6)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(10.4)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">42.0</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">118.0</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">225.2</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">372.4</p></td></tr><tr><td style="vertical-align:top;width:28%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Unlevered Free Cash Flow<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(15.3)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(11.9)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8.0)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(51.6)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(10.4)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">33.2</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">93.2</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">177.9</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">294.2</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Risk Adjusted Free Cash Flow<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(15.3)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(11.9)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8.0)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(27.6)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(5.6)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17.8</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">50.0</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">95.3</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">157.7</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unlevered free cash flow is a non-GAAP financial measure defined as operating income, less taxes, less change in net working capital.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FCF or free cash flow is a non-GAAP financial measure defined as cash flow from operations minus capital expenditures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In light of the foregoing factors and the uncertainties inherent in each of the Carisma Adjusted OrthoCellix Projections, stockholders are cautioned not to place undue reliance on the Carisma Adjusted OrthoCellix Projections.</p><a id="InterestsofCarismasDirectorsandExecutive"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of Carisma&#8217;s Directors and Executive Officers in the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following information and all other information contained in this proxy statement/prospectus does not give effect to the contemplated reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In considering the recommendation of Carisma&#8217;s board of directors with respect to issuing shares of Carisma&#8217;s common stock as contemplated by the Merger Agreement and the other matters to be acted upon by Carisma&#8217;s stockholders at the Carisma Special Meeting, Carisma&#8217;s stockholders should be aware that certain members of the board of directors and certain executive officers of </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">166</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Carisma have interests in the Merger that may be different from, or in addition to, the interests of Carisma&#8217;s stockholders. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of Carisma&#8217;s board of directors and OrthoCellix&#8217;s board of directors were aware of these potential conflicts of interest and considered them, among other matters, in reaching their respective decisions to approve the Merger Agreement and the Merger, and to recommend, as applicable, that Carisma&#8217;s stockholders approve the proposals to be presented for consideration at the Carisma Special Meeting as contemplated by this proxy statement/prospectus, and that OrthoCellix&#8217;s sole stockholder signs and returns the written consent as contemplated by this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purpose of this discussion, Carisma&#8217;s executive officers are Steven Kelly, President and Chief Executive Officer, Michael Klichinsky, Chief Scientific Officer, and Natalie McAndrew, Vice President of Finance. Carima&#8217;s non-employee directors are Sohanya Cheng, John Hohneker, Briggs Morrison, David Scadden, Marella Thorell and Sanford Zweifach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ownership Interests</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June&#160;30, 2025, Carisma&#8217;s directors and current executive officers owned, in the aggregate, 1.19%&#160;percent of the shares of Carisma&#8217;s common stock, which for purposes of this subsection excludes Carisma&#8217;s common stock issuable upon exercise of options held by such individual.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of a majority in voting power of the votes cast by the holders of Carisma&#8217;s common stock present or represented by proxy at the Carisma Special Meeting and entitled to vote on the matter is required for approval of Proposal Nos. 1, 2, 4, 5, 6 and 7. With respect to Proposal No.&#160;3, the directors are elected by a plurality of the votes properly cast at the Carisma Special Meeting, and the three nominees for director receiving the highest number of affirmative votes will be elected. As of June&#160;30, 2025, certain executive officers and directors of Carisma who in the aggregate owned approximately 0.03% of the outstanding shares of Carisma&#8217;s common stock have each entered into a support agreement in connection with the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See the section entitled &#8220;<i style="font-style:italic;">Principal Stockholders of Carisma</i>&#8221; on page&#160;365&#160;of this proxy statement/prospectus for a description of the beneficial ownership of Carisma&#8217;s directors and officers. For a more detailed discussion of the support agreements with certain of Carisma&#8217;s executive officers and directors, please see the section entitled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Support Agreements and Lock-Up Agreement</i>&#8221; beginning on page&#160;197 of this proxy statement/prospectus.</p><a id="EffectoftheMergeronCarismasOptions_80542"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Effect of the Merger on Carisma&#8217;s Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June&#160;30, 2025, Carisma&#8217;s directors and executive officers owned, in the aggregate, unvested options for 1,715,430 shares of Carisma&#8217;s common stock and vested options for 2,521,227 shares of Carisma&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All outstanding and unexercised options granted pursuant to the 2017 Stock Incentive Plan, the 2014 Amended and Restated Stock Incentive Plan or as an inducement grant under Nasdaq Listing Rule&#160;5635(c)(4)&#160;will remain in effect pursuant to their terms and will be unaffected by the Merger (other than with respect to the acceleration of vesting in connection with the Merger described below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table presents certain information concerning the outstanding options held by Carisma&#8217;s current directors and executive officers as of June&#160;30, 2025, without giving effect to any acceleration of vesting provided for in connection with the Merger. All of the options in the table below were out-of-the-money as of June&#160;30, 2025, on which date the closing price per share of Carisma&#8217;s common stock was $0.3920, except for the 56,982 vested options held by Dr.&#160;Klichinsky, which have an exercise price per </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">167</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">share of $0.11. The number of shares of Carisma&#8217;s common stock underlying such options will be adjusted appropriately to reflect the contemplated reverse stock split.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><br/><b style="font-weight:bold;">Shares</b><br/><b style="font-weight:bold;">Underlying</b><br/><b style="font-weight:bold;">Vested</b><br/><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><br/><b style="font-weight:bold;">Average</b><br/><b style="font-weight:bold;">Exercise</b><br/><b style="font-weight:bold;">Price&#160;of</b><br/><b style="font-weight:bold;">Vested</b><br/><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><br/><b style="font-weight:bold;">Shares</b><br/><b style="font-weight:bold;">Underlying</b><br/><b style="font-weight:bold;">Unvested</b><br/><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><br/><b style="font-weight:bold;">Average</b><br/><b style="font-weight:bold;">Exercise</b><br/><b style="font-weight:bold;">Price&#160;of</b><br/><b style="font-weight:bold;">Unvested</b><br/><b style="font-weight:bold;">Options</b></p></td></tr><tr><td style="vertical-align:bottom;width:42%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Executive Officers</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Steven Kelly</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,611,473</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.03</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,093,292</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.80</p></td></tr><tr><td style="vertical-align:bottom;width:42%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Klichinsky, Pharm.D.,&#160;PhD</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">489,924</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.58</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">469,598</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.63</p></td></tr><tr><td style="vertical-align:bottom;width:42%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Natalie McAndrew</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:42%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Non-Employee Directors</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sohanya Cheng</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,600</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.97</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30,100</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.97</p></td></tr><tr><td style="vertical-align:bottom;width:42%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">John Hohneker, M.D.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">34,400</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.60</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23,650</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.09</p></td></tr><tr><td style="vertical-align:bottom;width:42%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Briggs Morrison, M.D.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">142,649</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.13</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,900</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.25</p></td></tr><tr><td style="vertical-align:bottom;width:42%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">David Scadden, M.D.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,825</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.67</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,875</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.67</p></td></tr><tr><td style="vertical-align:bottom;width:42%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Marella Thorell</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,825</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.67</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,875</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.67</p></td></tr><tr><td style="vertical-align:bottom;width:42%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sanford Zweifach</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">210,531</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.15</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">32,140</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.78</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Management Positions Following the Merger</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Steven Kelly, Carisma&#8217;s President and Chief Executive Officer, is expected to serve as the President and Chief Executive Officer of the Combined Company and Natalie McAndrew, Carisma&#8217;s Vice President of Finance (Carisma&#8217;s principal financial officer and principal accounting officer) is expected to serve as the Vice President of Finance (Principal Financial Officer and Principal Accounting Officer) of the Combined Company. Each executive officer of the Combined Company will serve at the discretion of the Combined Company&#8217;s board of directors and hold office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Director Positions Following the Merger</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Steven Kelly, a member of the Carisma board of directors, is expected to remain a member of the board of directors of the Combined Company and will receive compensation to be paid to directors of the Combined Company. For a description of Carisma&#8217;s current non-employee director compensation policy and the amounts paid to Carisma&#8217;s non-employee directors in 2024, see the section entitled &#8220;<i style="font-style:italic;">Carisma Director Compensation</i>&#8221; beginning on page&#160;226 of this proxy statement/prospectus. Following the closing of the Merger, Steven Kelly will be eligible to be compensated as a non-employee director of the Combined Company pursuant to the non-employee director compensation policy in effect following the Effective Time of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Merger Agreement, effective immediately prior to the Effective Time of the Merger, all other then-current Carisma directors will resign. All unvested Carisma options held by such non-employee directors will vest in full upon the closing of the Merger.</p><a id="TerminationofExistingCarismaExecutiveOff"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination of Certain Existing Carisma Executive Officers Following the Merger and Related Severance Payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effective as of March&#160;7, 2023, Carisma entered into employment agreements with each of Steven Kelly, Carisma&#8217;s President and Chief Executive Officer and Michael Klichinsky, Carisma&#8217;s Chief Scientific Officer. Pursuant to the terms of the Merger Agreement, effective immediately prior to the Effective Time, Carisma will terminate the employment of Dr. Klichinsky.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Mr.&#160;Kelly&#8217;s employment agreement provides that if his employment is terminated either (i)&#160;by Carisma without Cause or (ii)&#160;by him with Good Reason (each as defined in the employment agreement), in either case within the period beginning three&#160;months before and ending 12&#160;months after a Change in Control (as defined in the employment agreement) (the &#8220;Change in Control Period&#8221;), then Mr.&#160;Kelly will be entitled to receive, subject to his execution and non-revocation of a release of claims in favor of Carisma and compliance with all post-employment obligations under law or any restrictive covenant agreement with Carisma, (a)&#160;a lump sum payment of (x)&#160;18&#160;months of base salary and (y)&#160;an amount equal to 150.0% of his target bonus for the&#160;year of termination (or, if higher, his target bonus immediately prior to the Change in Control), (b)&#160;a lump sum payment equal to 100.0% of his target bonus for the&#160;year of termination (or, if higher, based on the target bonus immediately prior to the Change in Control) pro-rated based on the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">168</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">number of&#160;days he was employed during the calendar&#160;year in which his termination occurs, (c)&#160;COBRA health continuation for up to 18&#160;months and (d)&#160;100.0% acceleration of all outstanding and unvested stock-based awards subject to time-based vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Klichinsky&#8217;s employment agreement provides that if his employment is terminated either (i)&#160;by Carisma without Cause or (ii)&#160;by him with Good Reason (each as defined in the employment agreement), in either case, within the Change in Control Period, then Dr.&#160;Klichinsky will be entitled to receive, subject to his execution and non-revocation of a release of claims in favor of Carisma and compliance with all post-employment obligations under law or any restrictive covenant agreement with Carisma, (a)&#160;a lump sum payment of (x)&#160;12&#160;months of base salary and (y)&#160;an amount equal to 100.0% of his target bonus for the&#160;year of termination (or, if higher, his target bonus immediately prior to the Change in Control), (b)&#160;a lump sum payment equal to 100.0% of his target bonus for the&#160;year of termination (or, if higher, based on the target bonus immediately prior to the Change in Control) pro-rated based on the number of&#160;days he was employed during the calendar&#160;year in which his termination occurs, (c)&#160;COBRA health continuation for up to 12&#160;months and (d)&#160;100.0% acceleration of all outstanding and unvested stock-based awards subject to time-based vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Natalie McAndrew, Carisma&#8217;s Vice President of Finance, is not entitled to any severance payments. For a more detailed description of the employment agreements of Carisma&#8217;s NEOs, see the section entitled &#8220;<i style="font-style:italic;">Carisma Executive Compensation&#8201;&#8212;&#8201;Employment Agreements with Named Executive Officers</i>&#8221; beginning on page&#160;215 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dr. Klichinsky will be entitled to the benefits afforded to him under his employment agreement in the event of his termination without Cause within the Change in Control Period. Although it is expected that Mr. Kelly will serve as the President and Chief Executive Officer of the Combined Company, if his employment is terminated without Cause or by him with Good Reason within the Change in Control Period, he would be entitled to the benefits provided for him under his employment agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Taxation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of Mr.&#160;Kelly&#8217;s and Dr.&#160;Klichinsky&#8217;s employment agreements contain a Section&#160;280G limited cutback, in which Mr.&#160;Kelly and Dr.&#160;Klichinsky are each entitled to receive the greater of (i)&#160;the best net after-tax amount of any payments that are subject to the excise tax imposed by Section&#160;4999 of the Code, calculated in a manner consistent with Section&#160;280G of the Code, and (ii)&#160;the amount of parachute payments he would be entitled to receive if they were reduced to an amount equal to one dollar less than the amount at which Mr.&#160;Kelly or Dr.&#160;Klichinsky, respectively, becomes subject to excise tax imposed by Section&#160;4999 of the Code.</p><a id="GoldenParachuteCompensation_141725"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Golden Parachute Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This section sets forth the information required by Item&#160;402(t)&#160;of Regulation&#160;S-K regarding the compensation that is based on or otherwise relates to the Merger and that is payable or may become payable to Carisma&#8217;s NEOs. This compensation is referred to as &#8220;golden parachute&#8221; compensation by the applicable SEC disclosure rules. For purposes of calculating these amounts, Carisma has assumed:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effective time occurred on June&#160;30, 2025;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the employment of the NEO will be terminated on such date in a manner that entitles the NEO to receive the severance payments and benefits under the terms of the employment agreement with the NEO (as described above). The employment of the NEO is expected to be terminated effective immediately prior to the closing of the Merger within the Change in Control Period; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the NEO does not enter into a new agreement or otherwise becomes legally entitled to, prior to the effective time, additional compensation or benefits.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The amounts set forth in the table are estimates based on multiple assumptions that may or may not actually occur, including assumptions described below and elsewhere in this proxy statement/prospectus and in the footnotes to the table. Furthermore, the amounts set forth in the table do not reflect any reductions in payments or benefits that could result from the operation of Sections&#160;280G and 4999 of the Code modified cutback provision that is in the employment agreements of Carisma&#8217;s NEOs, as described above. As a result, the actual amounts, if any, that Carisma&#8217;s NEOs will receive, may materially differ from the amounts set forth in the table.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For a narrative description of the terms and conditions applicable to the payments quantified in the table below, see the section entitled &#8220;<i style="font-style:italic;">The Merger&#8201;&#8212;&#8201;Interests of Carisma Directors and Executive Officers in the Merger&#8201;&#8212;&#8201;Termination of Certain Existing </i></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">169</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Carisma Executive Officers Following the Merger and Related Severance Payments</i>&#8221; beginning on page&#160;168&#160;of this proxy statement/prospectus.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash</b><br/><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b><br/><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Health</b><br/><b style="font-weight:bold;">Benefits</b><br/><b style="font-weight:bold;">Continuation</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b><br/><b style="font-weight:bold;">($)</b></p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Kelly</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,622,400</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">67,621</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,690,021</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><i style="font-style:italic;">President &amp; Chief Executive Officer</i></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard Morris</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Former Chief Financial Officer<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Klichinsky</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">790,400</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,937</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">817,337</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><i style="font-style:italic;">Current Chief Scientific Officer</i></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The amounts listed in this column represent (i)&#160;cash severance amounts payable to the NEO pursuant to his employment agreement equal to 18&#160;months of base salary continuation for Mr.&#160;Kelly and 12&#160;months of base salary continuation for Dr.&#160;Klichinsky ($936,000 for Mr.&#160;Kelly and $494,000 for Dr.&#160;Klichinsky), which amounts are payable to the executive officer in a lump sum payment following the executive&#8217;s termination of employment; (ii)&#160;a cash severance amount payable to each of Mr.&#160;Kelly and Dr.&#160;Klichinsky equal to 150.0% for Mr.&#160;Kelly and 100.0% for Dr.&#160;Klichinsky of each such officer&#8217;s target bonus payment for calendar&#160;year 2025 ($514,800 for Mr.&#160;Kelly and $197,600 for Dr.&#160;Klichinsky), payable in a lump sum payment following each such officer&#8217;s termination of employment and (iii)&#160;a cash severance amount payable to each of Mr.&#160;Kelly and Dr.&#160;Klichinsky equal to 100.0% of each such officer&#8217;s target bonus payment for calendar&#160;year 2025 pro-rated based on the number of&#160;days such officer was employed during the calendar&#160;year 2025 ($171,600 for Mr.&#160;Kelly and $98,800 for Dr.&#160;Klichinsky), payable in a lump sum following each such officer&#8217;s termination of employment. The cash severance payments are double-trigger benefits in that they will be paid only if the executive officer experiences a qualifying termination of employment in connection with the Merger within the Change in Control Period.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The amounts listed in this column represent the value of the full acceleration of vesting of in-the-money unvested stock options held by the NEOs. There are no unvested in-the-money stock options held by the NEOs as of June&#160;30, 2025, and as such, no amounts are included in this column. The value in the table is based on the extent to which $0.4186 (which represents the average closing market price per share of Carisma&#8217;s common stock on the Nasdaq Capital Market over the first five business&#160;days following the first public announcement on June&#160;23, 2025 of the entry into the Merger Agreement) exceeds the exercise price of unvested options. The acceleration is a double-trigger benefit in that it will only occur if the executive experiences a qualifying termination of employment in connection with the Merger within the Change in Control Period.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The amounts listed in this column represent the value of continued health benefits payments in lieu of COBRA to be provided to the NEOs pursuant to their respective employment agreements for a period of up to 18&#160;months for Mr.&#160;Kelly and up to 12&#160;months for Dr.&#160;Klichinsky. This is a double-trigger benefit in that it will be provided only if the executive officer experiences a qualifying termination of employment in connection with the Merger within the Change in Control Period.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mr.&#160;Morris ceased providing services to Carisma on December&#160;31, 2024. For a description of the severance paid to Mr.&#160;Morris in connection with his termination without Cause, see &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Carisma Executive Compensation</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Indemnification and Insurance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a discussion of the indemnification and insurance provisions related to Carisma&#8217;s directors and executive officers under the Merger Agreement, see the section entitled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Indemnification of Officers and Directors</i>&#8221; beginning on page&#160;190 of this proxy statement/prospectus.</p><a id="InterestsofOrthoCellixsDirectorsandExecu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of OrthoCellix&#8217;s Directors and Executive Officers in the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In considering the recommendation of OrthoCellix&#8217;s board of directors with respect to approving the Merger, stockholders should be aware that OrthoCellix&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of OrthoCellix common stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">170</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the OrthoCellix common stockholders approve the Merger as contemplated by this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ownership Interests</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a wholly owned subsidiary of Ocugen, as of June&#160;30, 2025, OrthoCellix&#8217;s current non-employee directors and executive officers do not beneficially own any shares of OrthoCellix capital stock. For a more detailed discussion of the support agreements, please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8201;&#8212;&#8201;Support Agreements and Lock-Up Agreement</i>&#8221; beginning on page&#160;197 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shankar Musunuri, a director of OrthoCellix, is Chairman of the board of directors, Chief Executive Officer&#160;&amp; Co-founder of Ocugen and Michael Shine, a director of OrthoCellix, was Senior Vice President, Commercial of Ocugen until June&#160;30, 2025. At the Effective Time of the Merger, the Combined Company&#8217;s board of directors will be fixed at six members, consisting of one member designated by Carisma and five members designated by OrthoCellix. Shankar Musunuri is expected to resign from his position as a director of OrthoCellix, effective immediately prior to the Effective Time of the Merger. Michael Shine is expected to continue on the board of directors of the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Limitations of Liability, Indemnification and Insurance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the indemnification obligations required by the certificate of incorporation and by-laws of OrthoCellix, OrthoCellix has entered into indemnification agreements with each of its directors and officers. These agreements provide for the indemnification of OrthoCellix&#8217;s directors and executive officers for reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were agents of OrthoCellix. OrthoCellix believes that the certificate of incorporation provisions, by-laws provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a discussion of the indemnification and insurance provisions related to the OrthoCellix directors and officers under the Merger Agreement, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement &#8212; Indemnification of Officers and Directors</i>&#8221; beginning on page 190 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management Following the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carisma board of directors currently consists of seven members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with the terms of Carisma&#8217;s certificate of incorporation, its board of directors is divided into three classes (Class I, Class II and Class III), with members of each class serving staggered three-year terms. The members of the classes are divided as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class I directors are currently John Hohneker, M.D. and Sohanya Cheng, and their term expires at the annual meeting of stockholders to be held in 2027;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class II directors are Steven Kelly, Briggs Morrison, M.D. and Sanford Zweifach, and their term expires at the Carisma Special Meeting; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class III directors are David Scadden, M.D. and Marella Thorell, and their term expires at the annual meeting of stockholders to be held in 2026.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the completion of the Merger, the business and affairs of the Combined Company will be managed under the direction of the Combined Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s board of directors will initially be fixed at six members, consisting of five board members designated by OrthoCellix and one board member designated by Carisma. Karthik Musunuri, Michael Shine, David Anderson,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;will be nominated by OrthoCellix and Steven Kelly will be nominated by Carisma. The staggered structure of the current Carisma board of directors will remain in place for the Combined Company following the completion of the Merger.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">171</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each executive officer of the Combined Company will serve at the discretion of the Combined Company&#8217;s board of directors and hold office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of the proposed Combined Company&#8217;s directors or executive officers. Although Karthik Musunuri, who is expected to serve on the board of directors of the Combined Company, is the son of Shankar Musunuri, a current member of the board of directors of OrthoCellix, Shankar Musunuri is expected to resign from his position as a director of OrthoCellix effective as of the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of Carisma&#8217;s current directors are expected to resign from their positions as directors of Carisma effective as of the closing of the Merger, except for Steven Kelly, who is expected to continue on the board of directors of the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the name, age as of July&#160;21, 2025 and position of each of the individuals who are expected to serve as executive officers and directors of the Combined Company following completion of the Merger:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:2.33%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:47.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td></tr><tr><td style="vertical-align:top;width:41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Executive Officers</span></p></td><td style="vertical-align:bottom;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Kelly</p></td><td style="vertical-align:bottom;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">60</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:top;width:41%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Natalie McAndrew</p></td><td style="vertical-align:top;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.65%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">51</p></td><td style="vertical-align:top;width:2.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vice President of Finance (principal financial officer and principal</p></td></tr><tr><td style="vertical-align:top;width:41%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Non-Employee Directors</span></p></td><td style="vertical-align:bottom;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Karthik Musunuri</p></td><td style="vertical-align:bottom;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:41%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Shine, MBA</p></td><td style="vertical-align:bottom;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">61</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director </p></td></tr><tr><td style="vertical-align:top;width:41%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">David Anderson</p></td><td style="vertical-align:bottom;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">72</p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:41%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:41%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.33%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Form&#160;of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with the DGCL, at the Effective Time, Merger Sub will merge with and into OrthoCellix, with OrthoCellix continuing as a wholly owned subsidiary of Carisma and the surviving corporation of the Merger.</p><a id="MergerConsiderationandAdjustment_864866"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Merger Consideration and Adjustment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, each then-outstanding share of OrthoCellix common stock (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of Carisma common stock equal to the Exchange Ratio (described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8201;-&#8201;Exchange Ratio</i>&#8221; beginning on page&#160;181 of this proxy statement/prospectus).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No fractional shares of Carisma common stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. For purposes of calculating the Merger Consideration (as defined in the Merger Agreement) issuable to the holder of OrthoCellix common stock, the number of shares of Carisma common stock to be issued shall be rounded down to the nearest whole number (without any consideration payable for such fractional shares).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Determination of Carisma&#8217;s Net Cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Merger Agreement, Carisma&#8217;s &#8220;Net Cash&#8221; means the sum (without duplication) of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s unrestricted cash, cash equivalents and short-term marketable securities and the cash consideration attributable to the sale of Carisma Legacy Assets (as defined herein), solely to the extent not received by Carisma as of the Effective Time and solely to the extent Carisma and OrthoCellix mutually agree will be received within 90&#160;days following the closing of the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">solely to the extent Carisma and OrthoCellix mutually agree such funds will be available to and usable by Carisma within 90&#160;days of the Closing Date (as defined in the Merger Agreement), certain prepaid expenses and deposits, credits and refunds.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">172</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">minus</i> the sum (without duplication) of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s short-term and long-term liabilities (including any outstanding liabilities with respect to certain Carisma&#8217;s obligations) (including all accounts payable and indebtedness), including lease termination costs, all actual costs and expenses (and reasonably projected costs and expenses as mutually agreed between Carisma and OrthoCellix, acting in good faith) relating to the winding down of the Carisma Legacy business and any related prepayment penalties and premiums and any unpaid Transaction Expenses (including any costs, fees or other liabilities, including taxes, related to the premiums, commissions and other fees payable in connection with obtaining Carisma&#8217;s D&amp;O tail policy (as described in the Merger Agreement));</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any and all change in control payments, severance payments, in each case, payable to Carisma&#8217;s employees, and any employer-side payroll or similar taxes owed in connection with the foregoing or in connection with the exercise of Carisma options and vesting and settlement of each award of restricted stock unit (&#8220;RSU&#8221;) awards with respect to shares of Carisma common stock issued pursuant to the 2014 Plan (as defined below), the 2017 Plan (as defined below) and 2014 ESPP or otherwise (&#8220;Carisma Restricted Stock Unit Awards&#8221;), in each case to the extent payable in connection with the consummation of the transactions contemplated by the Merger Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">50.0% of the mutually agreed estimated settlement amounts for any transaction litigation existing as of the closing of the Merger.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No less than five business&#160;days prior to the anticipated date for the Carisma Special Meeting, (i)&#160;Carisma will deliver to OrthoCellix a certificate signed by an officer of Carisma setting forth a schedule (&#8220;Carisma Net Cash Schedule&#8221;) and the date of delivery of the Carisma Net Cash Schedule, setting forth, in reasonable detail, Carisma&#8217;s good faith estimated calculation of its Net Cash as of the close of business on the anticipated closing of the Merger, prepared and certified by Carisma&#8217;s chief financial officer (or if there is no chief financial officer, the principal financial and accounting officer). Carisma shall make available to OrthoCellix (electronically to the greatest extent possible), as reasonably requested by OrthoCellix, the work papers and back-up materials (including all relevant invoices and similar evidence of outstanding obligations) used or useful in preparing the Carisma Net Cash Schedule and, if reasonably requested by OrthoCellix, Carisma&#8217;s internal finance personnel, accountants and counsel at reasonable times and upon reasonable notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If OrthoCellix disputes the Carisma Net Cash Schedule, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed-upon determination of Net Cash. If the parties are unable to negotiate an agreed-upon determination of the disputed items or component thereof within three&#160;days after the delivery of the dispute notice, any remaining disagreements will be referred to an independent auditor of recognized national standing mutually agreed upon by Carisma and OrthoCellix. The determination of the amount of Net Cash made by such auditor shall be final and binding on Carisma and OrthoCellix.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s Net Cash balance is subject to numerous factors, some of which are outside of Carisma&#8217;s control. The actual amount of Net Cash will depend significantly on the timing of the closing of the Merger. In addition, the closing of the Merger could be delayed if Carisma and OrthoCellix are not able to agree upon the amount of Carisma&#8217;s Net Cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Procedures for Exchanging Company Stock Certificates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On or prior to the closing of the Merger, Carisma will select an exchange agent mutually agreed upon by Carisma and OrthoCellix and, immediately prior to the Effective Time, Carisma will deposit with the exchange agent evidence of book-entry shares representing the shares of Carisma common stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of OrthoCellix common stock (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As soon as reasonably practicable after the Effective Time and in any event not later than the third business day following the closing of the Merger, Carisma and OrthoCellix shall cause the exchange agent to mail to each holder of record of a certificate that immediately prior to the Effective Time represented outstanding shares of OrthoCellix common stock (collectively, the &#8220;Certificates&#8221;) and to each holder of record of uncertificated shares of OrthoCellix common stock represented by book entry (&#8220;Book-Entry Shares&#8221;) that were converted into the right to receive the Merger Consideration (together with any dividends or other distributions payable pursuant to the terms of the Merger Agreement), (i)&#160;a form of letter of transmittal and (ii)&#160;instructions for use in effecting the surrender of any such Certificates and identifying such Book-Entry Shares in exchange for the Merger Consideration (together with any dividends or other distributions payable pursuant to the terms of the Merger Agreement).</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">173</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon surrender of a Certificate and identification of the Book-Entry Shares, as applicable, to the Exchange Agent, together with such letter of transmittal, duly completed and validly executed in accordance with the instructions thereto, and such other documents as the Exchange Agent may reasonably require, the holder of such Certificate or Book-Entry Share shall be entitled to receive in exchange for the shares of OrthoCellix common stock formerly represented by such Certificate or Book-Entry Share (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) (i)&#160;that number of whole shares of Carisma common stock (after taking into account all shares of OrthoCellix common stock then held by such holder under all Certificates so surrendered and Book-Entry Shares so identified) to which such holder of OrthoCellix common stock shall have become entitled pursuant to the terms of the Merger Agreement (which shall be in uncertificated book-entry form unless a physical certificate is requested), and (ii)&#160;any dividends or other distributions payable pursuant to terms of the Merger Agreement, and any Certificate so surrendered, together with any Book-Entry Shares, shall forthwith be cancelled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">HOLDERS OF ORTHOCELLIX COMMON STOCK SHOULD NOT SEND IN THEIR ORTHOCELLIX STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF ORTHOCELLIX STOCK CERTIFICATES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Effective Time of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two business&#160;days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the OrthoCellix common stockholders and the approval by the Carisma&#8217;s stockholders of the issuance of Carisma common stock and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger. The Merger will become effective upon the filing of a certificate of Merger (the &#8220;Certificate of Merger&#8221;), with the Secretary of State of the State of Delaware or at such later time as is agreed by Carisma and OrthoCellix and specified in the Certificate of Merger. Neither Carisma nor OrthoCellix can predict the exact timing of the consummation of the Merger.</p><a id="RegulatoryApprovals_750098"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Regulatory Approvals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, Carisma must comply with applicable federal and state securities laws and the rules&#160;and regulations of Nasdaq in connection with the issuance of shares of Carisma common stock, to OrthoCellix&#8217;s sole stockholder in connection with the transactions contemplated by the Merger Agreement and the filing of this proxy statement/prospectus with the SEC. Carisma and OrthoCellix do not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Tax Considerations of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion is a summary of U.S. federal income tax considerations to U.S. Holders (as defined below) of OrthoCellix common stock of the Merger. The discussion does not purport to be a complete analysis of all potential tax considerations. The considerations of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws, are not discussed. This discussion is based on the Code, Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. OrthoCellix has not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax considerations of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion is limited to a U.S. Holder that holds OrthoCellix common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax considerations relevant to a U.S. Holder&#8217;s particular circumstances, including, without limitation. the effect of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules&#160;under Section&#160;451(b)&#160;of the Code. In addition, it does not address considerations relevant to U.S. Holders subject to special rules, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. expatriates and former citizens or long-term residents of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders whose functional currency is not the U.S. dollar;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">174</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons holding OrthoCellix common stock as part of a hedge, straddle or other risk-reduction strategy or as part of a conversion transaction or other integrated investment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">banks, insurance companies and other financial institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">real estate investment trusts or regulated investment companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brokers, dealers or traders in securities or other persons that elect to use a mark-to-market method of accounting for their holdings in OrthoCellix common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partnerships or other entities or arrangements classified as partnerships, passthroughs, or disregarded entities for U.S. federal income tax purposes (and investors therein), S corporations or other passthrough entities (including hybrid entities);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-exempt organizations or governmental organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons deemed to sell OrthoCellix common stock under the constructive sale provisions of the Code;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons who hold or receive OrthoCellix common stock pursuant to the exercise of any employee stock option or otherwise as compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-qualified retirement plans; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons that own, or have owned, actually or constructively, more than five&#160;percent of OrthoCellix common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds OrthoCellix common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, a partnership holding OrthoCellix common stock and each partner in such partnership is urged to consult its tax advisor regarding the U.S. federal income tax considerations to it of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">This discussion is for informational purposes only and is not tax advice. Each prospective investor is urged to consult its tax advisor with respect to the application of the U.S. federal income tax laws to its particular situation as well as any tax considerations of the Merger arising under U.S. federal estate or gift tax laws, the laws of any state, local or non-U.S. taxing jurisdiction or any applicable income tax treaty.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purpose of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of OrthoCellix common stock that, for U.S. federal income tax purposes, is or is treated as any of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual who is a citizen or resident of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a trust that: (i)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code); or (ii)&#160;has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Each of OrthoCellix and Carisma intends that the Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code and/or as a tax-deferred exchange described in Section&#160;351(a)&#160;of the Code. Assuming the Merger so qualifies, a U.S. Holder will not recognize gain or loss upon the exchange of its OrthoCellix common stock for Carisma common stock. A U.S. Holder will have the same aggregate basis in its Carisma common stock after the Merger as such U.S. Holder had in the corresponding OrthoCellix common stock immediately prior to the Merger. A U.S. Holder&#8217;s holding period in the Carisma common stock immediately following the Merger will include such U.S. Holder&#8217;s holding period in the corresponding OrthoCellix common stock immediately prior to the Merger. If a U.S. Holder holds different blocks of OrthoCellix common stock (generally, OrthoCellix </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">175</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">common stock acquired on different dates or at different prices), such U.S. Holder is urged to consult its tax advisor with respect to the determination of the tax bases and/or holding periods of the shares of Carisma common stock received in the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger does not qualify either as a tax-deferred exchange described in Section&#160;351(a)&#160;of the Code or as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code, then each U.S. Holder would recognize gain or loss on the exchange of OrthoCellix common stock for Carisma common stock in the Merger equal to the difference between (x)&#160;the fair market value of the shares of Carisma common stock received in exchange for the OrthoCellix common stock and (y)&#160;such U.S. Holder&#8217;s adjusted tax basis in the shares of OrthoCellix common stock surrendered. The remainder of this discussion assumes that the Merger will qualify either as a tax-deferred exchange described in Section&#160;351(a)&#160;of the Code or as a tax-free &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each U.S. Holder is urged to consult its tax advisor regarding the U.S. federal income tax considerations of the Merger in light of its personal circumstances and the considerations to them under state, local and non-U.S. tax laws and other federal tax laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Information Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each U.S. Holder who receives Carisma common stock in the Merger is required to retain permanent records pertaining to the Merger and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property, and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S. Holder who owned immediately before the Merger at least one&#160;percent (by vote or value) of the total outstanding stock of OrthoCellix is required to attach a statement to its tax return for the&#160;year in which the Merger is consummated that contains the information listed in Treasury Regulation Section&#160;1.368-3(b). Such statement must include the U.S. Holder&#8217;s tax basis in such U.S. Holder&#8217;s OrthoCellix common stock surrendered in the Merger, the fair market value of such OrthoCellix common stock, the date of the Merger, and the name and employer identification number of each of OrthoCellix and Carisma. Each U.S. Holder is urged to consult with its tax advisor to comply with these rules.</p><a id="NasdaqStockMarketListing_340825"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nasdaq Stock Market Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares of Carisma common stock are currently listed on the Nasdaq Capital Market under the symbol &#8220;CARM.&#8221; Carisma has agreed to use commercially reasonable efforts to (a)&#160;maintain its listing on Nasdaq until the Effective Time and to obtain approval of the listing of the Combined Company on Nasdaq; (b)&#160;to the extent required by the rules&#160;and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Carisma common stock to be issued in connection with the Merger and transactions contemplated thereunder, and to cause such shares to be approved for listing (subject to official notice of issuance); (c)&#160;prepare and timely submit to Nasdaq a notification form for the proposed reverse stock split (if required) and to submit a copy of the amendment to Carisma&#8217;s certificate of incorporation effecting the proposed reverse stock split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the closing of the Merger; and (d)&#160;to the extent required by Nasdaq Marketplace Rule&#160;5110, assist OrthoCellix in preparing and filing an initial listing application for the Carisma common stock issued to OrthoCellix common stockholders (the &#8220;Nasdaq Listing Application&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, under the Merger Agreement, each of Carisma&#8217;s and OrthoCellix&#8217;s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the closing of the Merger, of various conditions, including that the Nasdaq Listing Application shall have been approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Nasdaq Listing Application is approved, Carisma anticipates that the common stock of the Combined Company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;OCLX.&#8221; In order for the Nasdaq Listing Application to be accepted, among other requirements, the Combined Company must maintain a bid price of $4.00 or higher for a certain period of time following the contemplated reverse stock split.</p><a id="AnticipatedAccountingTreatment_789486"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anticipated Accounting Treatment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Merger is expected to be accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, OrthoCellix will be considered the accounting acquirer for financial reporting purposes. This determination was primarily based on the expectations that, immediately following the Merger: (i)&#160;OrthoCellix&#8217;s sole stockholder will own a substantial majority of the voting rights of the Combined Company and (ii)&#160;OrthoCellix will designate a majority of the initial members of the board of directors of the Combined Company. For accounting purposes, the Merger will be treated as the equivalent of OrthoCellix issuing </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">176</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">stock to acquire the net assets of Carisma, which are expected to primarily consist of nominal non-operating assets and liabilities. Following the closing of the Merger, the net assets of Carisma will be recorded at fair value, which is expected to approximate their carrying value, with no goodwill or other intangible assets recorded in the financial statements of OrthoCellix and the reported operating results prior to the Merger will be those of OrthoCellix. Please see the section titled &#8220;<i style="font-style:italic;">Unaudited Pro Forma Condensed Combined Financial Information</i>&#8221; beginning on page&#160;344 of this proxy statement/prospectus for additional information.</p><a id="AppraisalRightsandDissentersRights_86951"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of Carisma common stock are not entitled to appraisal rights in connection with the Merger under Delaware law. Holders of OrthoCellix capital stock are entitled to appraisal rights in connection with the Merger under Delaware law. The discussion below is not a complete summary regarding OrthoCellix&#8217;s sole stockholder&#8217;s appraisal rights under Delaware law and is qualified in its entirety by reference to the text of the relevant provisions of Delaware law, which are attached as <i style="font-style:italic;">Annex G </i>in this proxy statement/prospectus. Stockholders intending to exercise appraisal rights should carefully review <i style="font-style:italic;">Annex G</i>. Failure to follow precisely any of the statutory procedures set forth in <i style="font-style:italic;">Annex G </i>may result in a termination or waiver of these rights. This summary does not constitute legal or other advice, nor does it constitute a recommendation that OrthoCellix common stockholders exercise their appraisal rights under Delaware law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Section&#160;262, where a Merger is adopted by stockholders by written consent in lieu of a meeting of stockholders pursuant to Section&#160;228 of the DGCL, either the constituent corporation before the effective date of such Merger or the surviving corporation, within 10&#160;days after the effective date of such Merger, must notify each stockholder of the constituent corporation entitled to appraisal rights of the approval of such Merger, the effective date of such Merger and that appraisal rights are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger is completed, within 10&#160;days after the effective date of the Merger, OrthoCellix will notify its stockholders that the Merger has been approved, the effective date of the Merger and that appraisal rights are available to any stockholder who has not approved the Merger. Holders of shares of OrthoCellix capital stock who desire to exercise their appraisal rights must deliver a written demand for appraisal to OrthoCellix within 20&#160;days after the date of mailing of that notice, and that stockholder must not have delivered a written consent approving the Merger. A demand for appraisal must reasonably inform OrthoCellix of the identity of the stockholder and that such stockholder intends thereby to demand appraisal of the shares of OrthoCellix capital stock held by such stockholder. Failure to deliver a written consent approving the Merger will not in and of itself constitute a written demand for appraisal satisfying the requirements of Section&#160;262. All demands for appraisal should be addressed to c/o OrthoCellix,&#160;Inc., 11 Great Valley Parkway, Malvern, PA 19355, and should be executed by, or on behalf of, the record holder of shares of OrthoCellix capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ALL DEMANDS MUST BE RECEIVED BY ORTHOCELLIX WITHIN 20&#160;DAYS AFTER THE DATE ORTHOCELLIX MAILS A NOTICE TO ITS STOCKHOLDERS NOTIFYING THEM THAT THE MERGER HAS BEEN APPROVED, THE EFFECTIVE DATE OF THE MERGER AND THAT APPRAISAL RIGHTS ARE AVAILABLE TO ANY STOCKHOLDER WHO HAS NOT APPROVED THE MERGER.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you fail to deliver a written demand for appraisal within the time period specified above, you will be entitled to receive the Merger Consideration for your shares of OrthoCellix capital stock as provided for in the Merger Agreement, but you will have no appraisal rights with respect to your shares of OrthoCellix capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To be effective, a demand for appraisal by a holder of shares of OrthoCellix capital stock must be made by, or in the name of, the registered stockholder, fully and correctly, as the stockholder&#8217;s name appears on the stockholder&#8217;s stock certificate(s). Beneficial owners who do not also hold the shares of record may not directly make appraisal demands to OrthoCellix. The beneficial owner must, in these cases, have the registered owner, such as a broker, bank or other custodian, submit the required demand in respect of those shares. If shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of a demand for appraisal should be made by or for the fiduciary; and if the shares are owned of record by more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal for a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact that, in executing the demand, he or she is acting as agent for the record owner. A record owner, such as a broker, who holds shares as a custodian for others, may exercise the record owner&#8217;s right of appraisal with respect to the shares held for one or more beneficial owners, while not exercising this right for other beneficial owners. In that case, the written demand should state the number of shares as to which appraisal is sought. Where no number of shares is expressly mentioned, the demand will be presumed to cover all shares held in the name of the record owner. In addition, the stockholder must continuously hold the shares of record from the date of making the demand through the effective time.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">177</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you hold your shares of OrthoCellix capital stock in a brokerage account or in other custodian form and you wish to exercise appraisal rights, you should consult with your bank, broker or other custodian to determine the appropriate procedures for the making of a demand for appraisal by the custodian.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At any time within 60&#160;days after the effective time, any stockholder who has demanded an appraisal, but has neither commenced an appraisal proceeding or joined an appraisal proceeding as a named party, has the right to withdraw such stockholder&#8217;s demand and accept the terms of the Merger by delivering a written withdrawal to OrthoCellix. If, following a demand for appraisal, you have withdrawn your demand for appraisal in accordance with Section&#160;262, you will have the right to receive the Merger consideration for your shares of OrthoCellix capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Within 120&#160;days after the effective date of the Merger, any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 will, upon written request to the surviving corporation, be entitled to receive a written statement setting forth the aggregate number of shares not voted in favor of the Merger Agreement and with respect to which demands for appraisal rights have been received and the aggregate number of holders of these shares. This written statement will be mailed to the requesting stockholder within 10&#160;days after the stockholder&#8217;s written request is received by the surviving corporation or within 10&#160;days after expiration of the period for delivery of demands for appraisal, whichever is later. Within 120&#160;days after the effective date of the Merger, either the surviving corporation or any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares held by all such stockholders. Upon the filing of the petition by a stockholder, service of a copy of the petition must be made upon the surviving corporation. The surviving corporation has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting stockholders, and Carisma, which is expected to be the surviving corporation, has no present intent to file a petition in the Delaware Court of Chancery. Accordingly, the failure of a stockholder to file a petition within the period specified could nullify the stockholder&#8217;s previously written demand for appraisal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a petition for appraisal is duly filed by a stockholder and a copy of the petition is delivered to the surviving corporation, the surviving corporation will then be obligated, within 20&#160;days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list containing the names and addresses of all stockholders who have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the surviving corporation. After notice to dissenting stockholders who demanded appraisal of their shares, the Delaware Court of Chancery is empowered to conduct a hearing upon the petition, and to determine those stockholders who have complied with Section&#160;262 and who have become entitled to the appraisal rights provided thereby. The Delaware Court of Chancery may require the stockholders who have demanded appraisal for their shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with that direction, the Delaware Court of Chancery may dismiss the proceedings as to that stockholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After determination of the stockholders entitled to appraisal of their shares, the Delaware Court of Chancery will appraise the &#8220;fair value&#8221; of the shares owned by those stockholders. This value will be exclusive of any element of value arising from the accomplishment or expectation of the Merger, but may include a fair rate of interest, if any, upon the amount determined to be the fair value. When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding, if the Delaware Court of Chancery so determines, to the stockholders entitled to receive the same, upon surrender by the holders of the certificates representing those shares. At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter only upon the sum of (i)&#160;the difference, if any, between the amount so paid and the fair value of the shares subject to appraisal as determined by the Delaware Court of Chancery and (ii)&#160;interest theretofore accrued, unless paid at that time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In determining fair value and, if applicable, a fair rate of interest, the Delaware Court of Chancery is required to take into account all relevant factors. In <i style="font-style:italic;">Weinberger v. UOP,&#160;Inc.</i>, the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#8220;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered, and that &#8220;fair price obviously requires consideration of all relevant factors involving the value of a company.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section&#160;262 provides that fair value is to be &#8220;exclusive of any element of value arising from the accomplishment or expectation of the merger.&#8221; <i style="font-style:italic;">In Cede&#160;&amp; Co. v. Technicolor,&#160;Inc.</i>, the Delaware Supreme Court stated that this exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In Weinberger, the Delaware Supreme Court construed Section&#160;262 to mean that &#8220;elements of future </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">178</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should be aware that the fair value of your shares as determined under Section&#160;262 could be more than, the same as, or less than the value that you are entitled to receive under the terms of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs of the appraisal proceeding may be imposed upon the surviving corporation and the stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court deems equitable in the circumstances. Upon the application of a stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys&#8217; fees and the fees and expenses of experts, to be charged pro rata against the value of all shares entitled to appraisal. In the absence of such a determination of assessment, each party bears its own expenses. Any stockholder who had demanded appraisal rights will not, after the effective time, be entitled to vote shares subject to that demand for any purpose or to receive payments of dividends or any other distribution with respect to those shares, other than with respect to payment as of a record date prior to the effective time; however, if no petition for appraisal is filed within 120&#160;days after the effective time, or if the stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the Merger within 60&#160;days after the effective time, then the right of that stockholder to appraisal will cease and that stockholder will be entitled to receive the Merger consideration for shares of his or her OrthoCellix capital stock pursuant to the Merger Agreement. Any withdrawal of a demand for appraisal made more than 60&#160;days after the effective time may only be made with the written approval of the surviving corporation. No appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Failure to follow the steps required by Section&#160;262 for perfecting appraisal rights may result in the loss of appraisal rights. In view of the complexity of Section&#160;262, stockholders who may wish to dissent from the Merger and pursue appraisal rights should consult their legal advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">179</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_fcc7c29b_0f07_4091_a877_3d011cc63f42"></a><a id="THEMERGERAGREEMENT_125403"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE MERGER AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached as Annex A to this proxy statement/prospectus and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual information about Carisma, Merger Sub, OrthoCellix or Ocugen. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Merger Agreement contains representations and warranties that Carisma and Merger Sub, on the one hand, and OrthoCellix and Ocugen, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if such statements prove to be incorrect. In addition, the assertions made in the representations and warranties are qualified by the information in confidential disclosure schedules exchanged by the parties in connection with the signing of the Merger Agreement. While Carisma and OrthoCellix do not believe that these disclosure schedules contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Carisma, OrthoCellix, or the Merger Sub, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between Carisma and Merger Sub on one hand and OrthoCellix and Ocugen on the other hand, and are modified by the disclosure schedules.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Structure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the terms and conditions in the Merger Agreement, at the effective time, Merger Sub will be merged with and into OrthoCellix with OrthoCellix surviving as a wholly owned subsidiary of Carisma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Substantially concurrently with the completion of the Merger, Carisma will be renamed &#8220;OrthoCellix,&#160;Inc.&#8221; and expects to trade on Nasdaq under the symbol &#8220;OCLX.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Effective Time</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two business&#160;days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the approval by Carisma&#8217;s stockholders of the issuance of Carisma common stock in the Merger and the change of control resulting from the Merger and effecting such other changes as are mutually agreeable to Carisma and OrthoCellix. The Merger will become effective upon the filing of the Certificate of Merger or at such later date as is agreed by Carisma and OrthoCellix and specified in the Certificate of Merger. Neither Carisma nor OrthoCellix can predict the exact timing of the consummation of the Merger.</p><a id="MergerConsiderationandExchangeRatio_4174"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Merger Consideration and Exchange Ratio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Merger Consideration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Effective Time, each share of OrthoCellix common stock issued and outstanding immediately prior to the Effective Time (other than any Excluded Shares or Dissenting Shares (each as defined in the Merger Agreement)) shall be converted into and become exchangeable for the right to receive, a number of shares of Carisma common stock equal to the Exchange Ratio as described in more detail below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No fractional shares of Carisma common stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. For purposes of calculating the Merger Consideration (as defined in the Merger Agreement) issuable to the holder of OrthoCellix common stock, the number of shares of Carisma common stock to be issued shall be rounded down to the nearest whole number (without any consideration payable for such fractional shares).</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">180</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="ExchangeRatio_898766"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exchange Ratio</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Exchange Ratio formula is derived based upon (a)&#160;an initial OrthoCellix valuation of $135.0 million and is subject to certain adjustments, including based upon the anticipated Concurrent Financing Amount and (b)&#160;an initial Carisma valuation of $15.0 million and is subject to certain adjustments, including based upon Carisma Net Cash. The Exchange Ratio is calculated using a formula intended to allocate to Carisma stockholders (on a fully-diluted basis), a&#160;percentage of the Combined Company based on Carisma&#8217;s and OrthoCellix&#8217;s capitalization as of June&#160;22, 2025. The Exchange Ratio was estimated to be equal to approximately 327,677.6433 shares of Carisma common stock for each share of OrthoCellix&#8217;s common stock, subject to a dollar-to-dollar adjustment to the extent that (a)&#160;Carisma&#8217;s Net Cash immediately prior to the closing of the Merger is less than or greater than $0 and/or (b)&#160;the anticipated Concurrent Financing Amount at the closing of the Merger is less than $25.0 million (and as a result, Carisma stockholders could own more or less of the Combined Company).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately after the Merger and the anticipated Concurrent Financing, based on the Exchange Ratio, it is expected that (a)&#160;the Carisma securityholders immediately before the Merger will own approximately 10.0% of the aggregate number of shares of the Combined Company&#8217;s common stock on a fully diluted basis, and (b)&#160;OrthoCellix&#8217;s sole stockholder and investors in the anticipated Concurrent Financing immediately before the Merger will own approximately 90.0% of the aggregate number of shares of the Combined Company&#8217;s common stock on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Carisma&#8217;s Net Cash as of the closing of the Merger being approximately $0 and the anticipated Concurrent Financing Amount of $25.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The &#8220;Exchange Ratio&#8221; means the following ratio (rounded to four decimal places): the quotient obtained by dividing (a)&#160;the OrthoCellix Merger Shares by (b)&#160;the OrthoCellix Outstanding Shares. For the purposes of calculating the Exchange Ratio:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Aggregate Valuation&#8221; means the sum of (a)&#160;the OrthoCellix Valuation, plus (b)&#160;the Carisma Valuation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Carisma Allocation&#160;Percentage&#8221; means the quotient (rounded to two decimal places) determined by dividing (a)&#160;the Carisma Valuation by (b)&#160;the Aggregate Valuation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Carisma Outstanding Shares&#8221; means (a)&#160;the total number of shares of Carisma Capital Stock outstanding immediately prior to the effective time (after giving effect to the Nasdaq Reverse Stock Split), assuming the exercise, conversion or exchange of all options, warrants, conversion rights, exchange rights or any other rights to receive shares of Carisma Capital Stock which exist immediately prior to the effective time, (ii)&#160;without duplication of any amounts set forth in the foregoing clause (i), the exercise of Carisma options outstanding as of immediately prior to the effective time and (iii)&#160;without duplication of any amounts set forth in the foregoing clauses (i)&#160;and (ii), the settlement in shares of Carisma common stock of Carisma Restricted Stock Unit Awards outstanding as of immediately prior to the effective time. For the avoidance of doubt, Carisma options with an exercise price greater than $2.00 per share (before giving effect to the Nasdaq Reverse Stock Split) and warrants to purchase shares of Carisma Capital Stock issued by Carisma, shall not be included in the total number of shares of Carisma Capital Stock for purposes of determining the Carisma Outstanding Shares.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Carisma Valuation&#8221; means (a)&#160;$15,000,000, minus (b)&#160;the amount by which Net Cash is less than $0 (if any) and plus (c)&#160; the amount by which Net Cash is more than $0 (if any).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Carisma Value Per Share&#8221; equals the Carisma Valuation divided by the number of Carisma Outstanding Shares (rounded to four decimal places).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Concurrent Financing Shares&#8221; means the number of shares of Carisma common stock issued to investors in respect of the first $25,000,000 of Carisma common stock purchased as part of the anticipated Concurrent Financing (or, if the aggregate amount of the anticipated Concurrent Financing is less than $25,000,000, such number of shares of Carisma common stock issued to investors as part of the anticipated Concurrent Financing).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OrthoCellix Allocation&#160;Percentage&#8221; means the quotient (rounded to two decimal places) determined by dividing (a)&#160;the OrthoCellix Valuation by (b)&#160;the Aggregate Valuation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OrthoCellix Merger Shares&#8221; means (a)&#160;the product determined by multiplying (x)&#160;the Post-Closing Carisma Shares by (y)&#160;the OrthoCellix Allocation&#160;Percentage minus (b)&#160;the anticipated Concurrent Financing Shares.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">181</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OrthoCellix Outstanding Shares&#8221; means the total number of shares of OrthoCellix Common Stock outstanding immediately prior to the effective time, expressed on a fully diluted and as-converted-to-OrthoCellix Common Stock basis assuming, without limitation or duplication the rights or commitments to receive shares of OrthoCellix Common Stock (or securities convertible or exercisable into shares of OrthoCellix Common Stock), whether conditional or unconditional, that are outstanding as of immediately prior to the effective time.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OrthoCellix Valuation&#8221; means (a)&#160;$135,000,000 minus (b)&#160;the amount, if any, by which the Concurrent Financing Amount is less than $25,000,000.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Post-Closing Carisma Shares&#8221; means the quotient determined by dividing (i)&#160;the Carisma Outstanding Shares by (ii)&#160;the Carisma Allocation&#160;Percentage. For the avoidance of doubt, the Post-Closing Carisma Shares shall include the Concurrent Financing Shares but shall exclude any shares issued as part of the anticipated Concurrent Financing in excess of the Concurrent Financing Shares.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Determination of Carisma&#8217;s Net Cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Merger Agreement, Carisma&#8217;s &#8220;Net Cash&#8221; means the sum (without duplication) of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s unrestricted cash, cash equivalents and short-term marketable securities and the cash consideration attributable to the sale of Carisma Legacy Assets, solely to the extent not received by Carisma as of the Effective Time and solely to the extent Carisma and OrthoCellix mutually agree will be received within 90&#160;days following the closing of the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">solely to the extent Carisma and OrthoCellix mutually agree such funds will be available to and usable by Carisma within 90&#160;days of the closing of the Merger, certain prepaid expenses and deposits, credits and refunds.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">minus</i> the sum (without duplication) of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s short-term and long-term liabilities (including any outstanding liabilities with respect to certain Carisma&#8217;s obligations) (including all accounts payable and indebtedness), including lease termination costs, all actual costs and expenses (and reasonably projected costs and expenses as mutually agreed between Carisma and OrthoCellix, acting in good faith) relating to the winding down of the Carisma Legacy business and any related prepayment penalties and premiums and any unpaid Transaction Expenses (including any costs, fees or other liabilities, including taxes, related to the premiums, commissions and other fees payable in connection with obtaining Carisma&#8217;s D&amp;O tail policy);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any and all change in control payments, severance payments, in each case, payable to Carisma&#8217;s employees, and any employer-side payroll or similar taxes owed in connection with the foregoing or in connection with the exercise of Carisma options and vesting and settlement of Carisma Restricted Stock Unit Awards, in each case to the extent payable in connection with the consummation of the transactions contemplated by the Merger Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">50.0% of the mutually agreed estimated settlement amounts for any transaction litigation existing as of the closing of the Merger.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No less than five business&#160;days prior to the anticipated date for the Carisma Special Meeting, (i)&#160;Carisma will deliver to OrthoCellix a Carisma Net Cash Schedule and the date of delivery of the Carisma Net Cash Schedule, setting forth, in reasonable detail, Carisma&#8217;s good faith estimated calculation of its Net Cash as of the close of business on the anticipated closing of the Merger, prepared and certified by Carisma&#8217;s chief financial officer (or if there is no chief financial officer, the principal financial and accounting officer). Carisma shall make available to OrthoCellix (electronically to the greatest extent possible), as reasonably requested by OrthoCellix, the work papers and back-up materials (including all relevant invoices and similar evidence of outstanding obligations) used or useful in preparing the Carisma Net Cash Schedule and, if reasonably requested by OrthoCellix, Carisma&#8217;s internal finance personnel, accountants and counsel at reasonable times and upon reasonable notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If OrthoCellix disputes the Carisma Net Cash Schedule, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed-upon determination of Net Cash. If the parties are unable to negotiate an agreed-upon determination of the disputed items or component thereof within three&#160;days after the delivery of the dispute notice, any remaining disagreements will be referred to an independent auditor of recognized national standing mutually agreed upon by Carisma and OrthoCellix. The determination of the amount of Net Cash made by such auditor shall be final and binding on Carisma and OrthoCellix.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">182</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s Net Cash balance is subject to numerous factors, some of which are outside of Carisma&#8217;s control. The actual amount of Net Cash will depend significantly on the timing of the closing of the Merger. In addition, the closing of the Merger could be delayed if Carisma and OrthoCellix are not able to agree upon the amount of Carisma&#8217;s Net Cash.</p><a id="CommonStockandCarismaOptions_3597"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-style:normal;font-weight:bold;">Carisma&#8217;s</b><b style="color:#231f20;font-style:normal;font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="color:#231f20;font-style:normal;font-weight:bold;">Common</b><b style="color:#231f20;font-style:normal;font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="color:#231f20;font-style:normal;font-weight:bold;">Stock</b><b style="color:#231f20;font-style:normal;font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="color:#231f20;font-style:normal;font-weight:bold;">and</b><b style="color:#231f20;font-style:normal;font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="color:#231f20;font-style:normal;font-weight:bold;">Carisma</b><b style="color:#231f20;font-style:normal;font-weight:bold;letter-spacing:-0.4pt;"> </b><b style="color:#231f20;font-style:normal;font-weight:bold;letter-spacing:-0.1pt;">Options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-indent:19.95pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">All outstanding and unexercised Carisma options granted pursuant to the 2017 Stock Incentive Plan, the 2014 Amended and Restated Stock Incentive Plan or as an inducement grant under Nasdaq Listing Rule</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">5635(c)(4)</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">will</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">remain</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">outstanding</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">accordance</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">their</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">terms</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">will</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">unaffected</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">by</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">Merger (other</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">than</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">respect</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-0.1pt;"> any </span><span style="color:#231f20;">acceleration</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.9pt;"> </span><span style="color:#231f20;">vesting</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">connection</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">Merger</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">as</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">described in the section entitled &#8220;</span><i style="color:#231f20;font-style:italic;">The Merger &#8212; Interests of Carisma&#8217;s Directors and Executive Officers in the Merger &#8212; Effect of the Merger on Carisma&#8217;s Options</i><span style="color:#231f20;">&#8221;</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">on page </span><span style="color:#231f20;">167</span><span style="color:#231f20;"> of</span><span style="color:#231f20;letter-spacing:1.05pt;"> </span><span style="color:#231f20;">this proxy statement/ prospectus). The</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">number</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.55pt;"> </span><span style="color:#231f20;">shares</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.55pt;"> </span><span style="color:#231f20;">Carisma</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">common</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">stock</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">underlying</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">such</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">options</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">exercise</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">prices</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">such stock options will be appropriately adjusted to reflect the contemplated reverse stock split.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2025 Stock Option and Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Effective Time, the Carisma board of directors will adopt the 2025 Stock Option and Incentive Plan, subject to the closing and effective as of the Effective Time, and will include provisions in the registration statement for the stockholders of Carisma to approve the 2025 Stock Option and Incentive Plan. Subject to the approval of the 2025 Stock Option and Incentive Plan by the stockholders of Carisma prior to the Effective Time, Carisma will file with the SEC, promptly after the Effective Time and at OrthoCellix&#8217;s expense, a registration statement on Form&#160;S-8 (or any successor form), if available for use by Carisma, relating to the shares of Carisma common stock issuable with respect to the 2025 Stock Option and Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The form of the 2025 Stock Option and Incentive Plan is attached to this proxy statement/prospectus as <i style="font-style:italic;">Annex H</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Regulatory Approvals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Neither Carisma nor OrthoCellix is required to make any filings or to obtain approvals or clearances from any antitrust regulatory authorities in the United States or other countries to consummate the Merger. In the United States, Carisma and OrthoCellix must comply with applicable federal and state securities laws and the Nasdaq rules&#160;in connection with the issuance of shares of Carisma common stock in the Merger, including the filing with the SEC of this proxy statement/prospectus and the required stockholder approval for the resulting &#8220;change of control&#8221; of Carisma under the Nasdaq rules.</p><a id="ConditionstotheCompletionoftheMerger_898"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Conditions to the Completion of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each party&#8217;s obligation to complete the Merger is subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the closing, of various conditions, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the registration statement of which this proxy statement/prospectus forms a part will have become effective in accordance with the provisions of the&#160;Securities Act&#160;and will not be subject to any stop order or proceeding seeking a stop order with respect to the registration statement that has not been withdrawn;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there must not have been issued, and remain in effect, any temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement by any court of competent jurisdiction or other governmental authority of competent jurisdiction, and no law, statute, rule, regulation, ruling or decree will be in effect which has the effect of making the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement illegal;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the holders of a majority of the votes properly cast for and against by the holders of Carisma common stock must have approved the issuance of Carisma common stock in the Merger, (collectively, &#8220;Carisma Stockholder Approval&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s sole stockholder must have adopted and approved, among other items, the Merger and the other transactions contemplated by the Merger Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Lock-Up Agreements will have continued to be in full force and effect as of immediately following the Effective Time;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">183</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amendment to Carisma&#8217;s certificate of incorporation shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments as are necessary to consummate the transactions contemplated by the Merger Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Nasdaq must have approved the listing of additional shares of Carisma common stock, including the shares to be issued in connection with the Merger.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, OrthoCellix&#8217;s obligation to complete the Merger is subject to the satisfaction or waiver by that party of the following additional conditions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the representations and warranties of Carisma and Merger Sub regarding certain matters including matters related to organization, capitalization, subsidiaries, authority and anti-takeover statutes must be true and correct except in de minimis respects on and as of the closing of the Merger except, in each case, (1)&#160;in respect of Carisma&#8217;s capitalization for such inaccuracies which are de minimis, individually or in the aggregate or (2)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties must be true and correct, subject to the qualifications as set forth in the preceding clause (1), as of such particular date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the remaining representations and warranties of Carisma and Merger Sub must be true and correct in all respects on the date of the Merger Agreement and on the closing of the Merger with the same force and effect as if made on the date on which the Merger is to be completed except where the failure to be so true and correct would not reasonably be expected to have a material adverse effect or, if such representations and warranties address matters as of a particular date, then as of that particular date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma must have performed or complied with in all material respects all of Carisma&#8217;s agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the effective time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">since the date of the Merger Agreement, no event, change, circumstance, occurrence, effect or state of facts that (1)&#160;is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial condition, or results of operations of Carisma and its subsidiaries, taken as a whole, or (2)&#160;materially impairs the ability of Carisma or Merger Sub to consummate the Merger or any of the other contemplated transactions must have occurred (&#8220;Carisma material adverse effect&#8221;); </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided, however</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, that in the case of clause (1)&#160;only, Carisma material adverse effect shall not include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (a)&#160;changes or conditions generally affecting the industries in which Carisma and its subsidiaries operate, or the economy or the financial, debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (b)&#160;the outbreak or escalation of war or acts of terrorism or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak (including the COVID-19 virus) or any worsening of the foregoing, or any declaration of martial law, quarantine or similar directive, policy or guidance or law or other action by any governmental entity in response thereto, (c)&#160;changes in law or GAAP, or the interpretation or enforcement thereof, (d)&#160;the public announcement or pendency of the Merger Agreement, or (e)&#160;any specific action taken (or omitted to be taken) by Carisma at or with the express written consent of OrthoCellix; provided, that, with respect to clauses (a), (b)&#160;and (c), the impact of such event, change, circumstance, occurrence, effect or state of facts is not disproportionately adverse to Carisma and its subsidiaries, as compared to other participants in the industries in which Carisma and its subsidiaries operate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma must have Net Cash of at least&#160;-$1,000,000; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma must have delivered (1)&#160;a certificate executed by an executive officer of Carisma confirming certain sections of the Merger Agreement have been duly satisfied and (2)&#160;written resignations in forms reasonably satisfactory to OrthoCellix, dated as of the closing of the Merger and effective as of the closing of the Merger executed by the officers and directors of Carisma who are not to continue as officers or directors of Carisma.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the obligation of Carisma and Merger Sub to complete the Merger is further subject to the satisfaction or waiver of the following conditions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the representations and warranties of OrthoCellix regarding certain matters, including matters related to organization, capitalization, authority and financial advisors in the Merger Agreement must be true and correct except in de minimis </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">184</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">respects on the date of the Merger Agreement and on the closing of the Merger except, in each case (1)&#160;in respect of OrthoCellix&#8217;s capitalization for such inaccuracies which are de minimis, individually or in the aggregate, (2)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (1), as of such particular date), or (3)&#160;variances arising solely due to the transactions contemplated under the subscription agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the remaining representations and warranties of OrthoCellix regarding certain matters, including matters related to organization, authority, vote required, certain capitalization and financial advisors in the Merger Agreement must be true and correct in all respects on the date of the Merger Agreement and on the closing of the Merger with the same force and effect as if made on the date on which the Merger is to be completed except where the failure to be so true and correct would not reasonably be expected to have a material adverse effect or, if such representations and warranties address matters as of a particular date, then as of that particular date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix must have performed or complied with in all material respects all of its agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the Effective Time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">since the date of the Merger Agreement, no event, change, circumstance, occurrence, effect or state of facts that (1)&#160;is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial condition, or results of operations of OrthoCellix, taken as a whole, or (2)&#160;materially impairs the ability of OrthoCellix to consummate the Merger or any of the other contemplated transactions must have occurred; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided, however,</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> that in the case of clause (1)&#160;only, material adverse effect shall not include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (a)&#160;changes or conditions generally affecting the industries in which OrthoCellix operates, or the economy or the financial, debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (b)&#160;the outbreak or escalation of war or acts of terrorism or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak or any worsening of the foregoing, or any declaration of martial law, quarantine or similar directive, policy or guidance or law or other action by any governmental entity in response thereto, (c)&#160;changes in law or GAAP, or the interpretation or enforcement thereof or (d)&#160;the public announcement or pendency of the Merger Agreement; provided, that, with respect to clauses (a), (b)&#160;and (c), the impact of such event, change, circumstance, occurrence, effect or state of facts is not disproportionately adverse to OrthoCellix as compared to other participants in the industries in which OrthoCellix operates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix must have delivered a certificate executed by a duly authorized officer of OrthoCellix confirming certain sections of the Merger Agreement have been duly satisfied.</span></td></tr></table><div style="margin-top:12pt;"><a id="RepresentationsandWarranties_411199"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Representations and Warranties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains customary representations and warranties of Carisma and OrthoCellix for a transaction of this type relating to, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">corporate organization and power, and similar corporate matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">capitalization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authority to enter into the Merger Agreement and the related agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">non-contravention; votes required;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the absence of undisclosed liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the absence of material changes or events;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">185</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with laws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">health care regulatory matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee and labor matters and benefit plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">environmental matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material contracts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">insurance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">real property and leaseholds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">transactions with affiliates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">anti-corruption and sanctions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any brokerage or finder&#8217;s fee or other fee or commission in connection with the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with respect to Carisma, the fairness opinion from Lucid.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The representations and warranties are, in many respects, qualified by materiality and knowledge, and will not survive the Merger, but their accuracy forms the basis of one of the conditions to the obligations of Carisma and OrthoCellix to complete the Merger.</p><a id="NoSolicitation_857529"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">No Solicitation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each party has agreed that (except as it related to the anticipated Concurrent Financing and any Parent Legacy Transaction), during the period commencing on the date of the Merger Agreement and ending on the earlier of the consummation of the Merger or the termination of the Merger Agreement, neither it nor any of its subsidiaries will, nor will it or any of its subsidiaries authorize any of its representatives to, directly or indirectly:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">furnish any nonpublic information regarding such party to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approve, endorse or recommend any Acquisition Proposal;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">take any action that would reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; or</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">186</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicly propose to do any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An &#8220;Acquisition Inquiry&#8221; means, with respect to a party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by OrthoCellix, on the one hand, or Carisma, on the other hand, to the other party) that would reasonably be expected to lead to an Acquisition Proposal, other than the anticipated Concurrent Financing, or a Parent Legacy Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An &#8220;Acquisition Proposal&#8221; means, with respect to either party hereto, any proposal or offer (whether written or oral) from any person (other than the other party or any of its representatives) contemplating or otherwise relating to an Acquisition Transaction (other than in connection with the anticipated Concurrent Financing, or a Parent Legacy Transaction).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An &#8220;Acquisition Transaction&#8221; means any transaction or series of related transactions (other than the anticipated Concurrent Financing or any Parent Legacy Transaction) involving: (a)&#160;any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i)&#160;in which a party is a constituent entity, (ii)&#160;in which a person or &#8220;group&#8221; (as defined in the Exchange Act and the rules&#160;promulgated thereunder) of persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20.0% of the outstanding securities of any class of voting securities of a party or any of its subsidiaries or (iii)&#160;in which a party or any of its subsidiaries issues securities representing more than 20.0% of the outstanding securities of any class of voting securities of such party or any of its subsidiaries or (b)&#160;any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20.0% or more of the consolidated book value of the fair market value of the assets of a party and its subsidiaries taken as a whole.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A &#8220;Parent Legacy Transaction&#8221; means the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) and/or winding down of, and/or the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or other disposition of any Carisma Legacy Assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Carisma Legacy Assets&#8221; means all assets, technology and intellectual property of Carisma, as they existed at any time prior to the date of the Merger Agreement, relating to Carisma&#8217;s research and development programs, as conducted and proposed to be conducted, including its CT-0525, CT-0508, CT-1119 and its engineered macrophage, and <i style="font-style:italic;">in vivo</i> mRNA/LNP CAR-M programs and its partnership with Moderna, including, for purposes of clarity, the tangible and intangible assets of Carisma relating thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, prior to the approval of the Merger Agreement by Carisma stockholders, Carisma may furnish&#160;non-public&#160;information regarding Carisma and its subsidiaries to, and enter into discussions or negotiations with, any person in response to a bona fide written Acquisition Proposal by such person which the Carisma board of directors determines in good faith, after consultation with its financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (a)&#160;such Acquisition Proposal was not obtained or made as a direct or indirect result of any breach of the Merger Agreement, (b)&#160;Carisma concludes in good faith, after consulting with outside counsel, that the failure to take such action would reasonably be expected to be inconsistent with Carisma&#8217;s board of director&#8217;s fiduciary duties under applicable law, (c)&#160;at least two business&#160;days prior to initially furnishing any such nonpublic information to, or entering into discussions with, such person, Carisma gives OrthoCellix written notice of the identity of such person and of such party&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such person, (d)&#160;Carisma receives from such person an executed acceptable confidentiality agreement and (e)&#160;at least two business&#160;days prior to furnishing any such nonpublic information to such person, such party furnishes such nonpublic information to OrthoCellix (to the extent such information has not been previously furnished by such party to the other party).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A &#8220;Superior Offer&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20.0% in the definition of Acquisition Transaction being treated as references to 50.0% for these purposes) that: (i)&#160;was not obtained or made as a direct or indirect result of a breach of (or in violation of) the Merger Agreement, and (ii)&#160;is on terms and conditions that the Carisma board of directors or the OrthoCellix board of directors, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other party to the Merger Agreement to amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Carisma&#8217;s stockholders or OrthoCellix&#8217;s sole stockholder, as applicable, than the terms of the transactions contemplated by the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Merger Agreement also provides that each party will promptly (and in no event later than one business day after such party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other of such Acquisition Proposal or any Acquisition </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">187</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inquiry (including the identity of the person making or submitting such Acquisition Proposal or Acquisition Inquiry and the terms thereof). Each party will also keep the other party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</p><a id="BoardRecommendationChange_295647"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Recommendation Change</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Merger Agreement, subject to certain exceptions described below, Carisma agreed that (i)&#160;Carisma&#8217;s board of directors shall recommend that the holders of Carisma common stock vote to approve the Carisma Stockholder Proposals and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in the Merger Agreement, (ii)&#160;the proxy statement shall include a statement to the effect that the Carisma board of directors recommends that Carisma stockholders vote to approve the Carisma Stockholder Proposal (the &#8220;Carisma Board Recommendation&#8221;) and (iii)&#160;the Carisma Board Recommendation shall not be withheld, amended, withdrawn or modified (and the Carisma board of directors shall not publicly propose to withhold, amend, withdraw or modify the Carisma Board Recommendation) in a manner adverse to OrthoCellix, and no resolution by the Carisma board of directors or any committee thereof to withdraw or modify the Carisma Board Recommendation in a manner adverse to OrthoCellix or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (iii), collectively, a &#8220;Carisma Board Adverse Recommendation Change&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, notwithstanding the foregoing, at any time prior to the approval of the proposals to be considered at the Carisma special meeting by the necessary vote of Carisma stockholders, if (a)&#160;Carisma receives a bona fide written Superior Offer or (b)&#160;a Carisma Intervening Event (as defined below) will have occurred, Carisma&#8217;s board of directors may make a Carisma Board Adverse Recommendation Change if, but only if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the case of a Superior Offer:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Carisma board of directors determines in good faith, after consulting with outside legal counsel, that the failure to withhold, amend, withdraw or modify such recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma has, and has caused its financial advisors and outside legal counsel to, during the Carisma Notice Period (as defined below), negotiate with OrthoCellix in good faith to make such adjustments to the terms and conditions of the Merger Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer (to the extent OrthoCellix desires to negotiate);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if after OrthoCellix shall have delivered to Carisma an irrevocable written offer to alter the terms or conditions of the Merger Agreement during the Carisma Notice Period, the Carisma board of directors shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Carisma Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement);</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">provided that OrthoCellix receives written notice from Carisma confirming that the Carisma board of directors has determined to change its recommendation at least four business&#160;days in advance of the Carisma Board Adverse Recommendation Change (the &#8220;Carisma Notice Period&#8221;) and during any Carisma Notice Period, Carisma and OrthoCellix will negotiate in good faith so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and the Carisma board shall not make a Carisma Board Adverse Recommendation Change prior to the end of such Carisma Notice Period (it being understood that there may be multiple extensions per the terms of the Merger Agreement);</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the case of a Carisma Intervening Event:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma promptly notifies OrthoCellix, in writing, within the Carisma Notice Period before making a Carisma Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Carisma Intervening Event and that the Carisma board of directors intends to make a Carisma Board Adverse Recommendation Change.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">A &#8220;Carisma Intervening Event&#8221; means a material development or change in circumstances that was not known to, or reasonably foreseeable by, the Carisma board of directors prior to the date of the Merger Agreement (other than any such event, development or </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">188</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">change to the extent related to (A)&#160;any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof or (B)&#160;the fact, in and of itself, that Carisma meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of Carisma that occurs or arises after the date of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Merger Agreement, subject to certain exceptions described below, OrthoCellix agreed that (i)&#160;OrthoCellix board shall recommend that OrthoCellix&#8217;s sole stockholder vote to adopt and approve the Merger Agreement and the contemplated transactions and shall use commercially reasonable efforts to solicit such approval within the time set forth in the Merger Agreement (the &#8220;OrthoCellix Board Recommendation&#8221;) and (ii)&#160;the OrthoCellix Board Recommendation shall not be withdrawn or modified (and the OrthoCellix board shall not publicly propose to withdraw or modify the OrthoCellix Board Recommendation) in a manner adverse to Carisma, and no resolution by the OrthoCellix board or any committee thereof to withdraw or modify the OrthoCellix Board Recommendation in a manner adverse to Carisma or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the &#8220;OrthoCellix Board Adverse Recommendation Change&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, notwithstanding the foregoing, at any time prior to the approval of the Merger Agreement by the necessary vote of OrthoCellix&#8217;s sole stockholder, if (a)&#160;OrthoCellix receives a bona fide written acquisition proposal, OrthoCellix board may make an OrthoCellix Board Adverse Recommendation Change if, but only if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the case of a Superior Offer:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the OrthoCellix board determines in good faith, after consulting with outside legal counsel, that the failure to withhold, amend, withdraw or modify such recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix has, and has caused its financial advisors and outside legal counsel to, during the OrthoCellix Notice Period, negotiate with Carisma in good faith to make such adjustments to the terms and conditions of the Merger Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer (to the extent Carisma desires to negotiate); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if after Carisma shall have delivered to OrthoCellix an irrevocable written offer to alter the terms or conditions of the Merger Agreement during the OrthoCellix Notice Period, the OrthoCellix board shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the OrthoCellix Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement);</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">provided that Carisma receives written notice from OrthoCellix confirming that the OrthoCellix board has determined to change its recommendation at least four business&#160;days in advance of the OrthoCellix Board Adverse Recommendation Change (the &#8220;OrthoCellix Notice Period&#8221;) and during any OrthoCellix Notice Period, Carisma and OrthoCellix will negotiate in good faith so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and the OrthoCellix board shall not make an OrthoCellix Board Adverse Recommendation Change prior to the end of such OrthoCellix Notice Period (it being understood that there may be multiple extensions per the terms of the Merger Agreement);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Meeting of Carisma&#8217;s Stockholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma is obligated under the Merger Agreement to call, give notice of and hold the Carisma special meeting to consider and obtain the Carisma Stockholder Approval and thereby approve the Contemplated Transactions and the amendment to Carisma&#8217;s certificate of incorporation and, if deemed necessary by Carisma, any Parent Legacy Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carisma special meeting will be held as promptly as practicable after this registration statement, of which this proxy statement/prospectus forms a part, is declared effective under the&#160;Securities Act, and in any event no later than forty-five&#160;days after the effective date of the registration statement. Carisma has agreed to take reasonable measures to ensure that all proxies solicited in connection with the Carisma special meeting are solicited in compliance with all applicable law. Carisma&#8217;s obligation to call, give notice of and hold the Carisma special meeting will not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or Acquisition Proposal, or by any withdrawal or modification of the Carisma Board Recommendation or any Carisma Board Adverse Recommendation Change.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">189</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OrthoCellix Stockholder Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contemplates that promptly after this registration statement is declared effective under the&#160;Securities Act, and in any event no later than one business day thereafter, OrthoCellix will solicit for approval the OrthoCellix stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Directors and Officers Following the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma and OrthoCellix will take all necessary action so that immediately after the Effective Time, the Combined Company will have a six-member board of directors, with one director designated by Carisma and five directors designated by OrthoCellix. Karthik Musunuri, Michael Shine, David Anderson,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;have initially been designated by OrthoCellix and Steven Kelly has initially been designated by Carisma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Steven Kelly, Carisma's President and Chief Executive Officer, is expected to serve as the President and Chief Executive Officer of the Combined Company and Natalie McAndrew, Carisma's Vice President of Finance (Carisma's principal financial officer and principal accounting officer) is expected to serve as the Vice President of Finance (Principal Financial Officer and Principal Accounting Officer) of the Combined Company.</p><a id="IndemnificationofOfficersandDirectors_77"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Indemnification of Officers and Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, each of Carisma and the Combined Company agreed to indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a director or officer of Carisma or OrthoCellix, respectively (referred to as the &#8220;D&amp;O Indemnified Parties&#8221;), against all demands, claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Carisma or of OrthoCellix, whether asserted or claimed prior to, at or after the Effective Time, in each case, to the fullest extent permitted under the DGCL. Each D&amp;O Indemnified Party will be entitled to advancement of fees, costs and expenses incurred in the defense of any such demand, claim, action, suit, proceeding or investigation from each of Carisma and the Combined Company, jointly and severally, upon receipt by Carisma or the Combined Company from the D&amp;O Indemnified Party of a request therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provisions of Carisma&#8217;s certificate of incorporation and by-laws with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Carisma that are presently set forth in Carisma&#8217;s certificate of incorporation and by-laws will not be amended, modified or repealed for a period of six&#160;years from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of Carisma, unless such modification is required by applicable law. The organizational documents of the Combined Company will contain, and Carisma will cause the Combined Company&#8217;s organizational documents to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in Carisma&#8217;s certificate of incorporation and by-laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From and after the Effective Time, (a)&#160;the Combined Company will fulfill and honor in all respects the obligations of OrthoCellix to its D&amp;O Indemnified Parties as of immediately prior to the closing pursuant to any indemnification provisions under OrthoCellix&#8217;s organizational documents and pursuant to any indemnification agreements between OrthoCellix and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time and (b)&#160;Carisma will fulfill and honor in all respects the obligations of Carisma to its D&amp;O Indemnified Parties as of immediately prior to the closing of the Merger pursuant to any indemnification provisions under Carisma&#8217;s organizational documents and pursuant to any indemnification agreements between Carisma and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From and after the Effective Time, Carisma will maintain directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the closing of the Merger, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Carisma. In addition, Carisma will purchase, prior to the Effective Time, a&#160;six-year&#160;prepaid &#8220;D&amp;O tail policy&#8221; for the&#160;non-cancellable&#160;extension of the directors&#8217; and officers&#8217; liability coverage of Carisma&#8217;s existing directors&#8217; and officers&#8217; insurance policies for a claims reporting or discovery period of at least six&#160;years from and after the Effective Time with respect to any claim related to any period of time at or prior to the Effective Time with terms, conditions, exclusions, retentions and limits of liability that are no less favorable than the coverage provided under Carisma&#8217;s existing policies as of the date of the Merger Agreement with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">190</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">any matter claimed against a director or officer of Carisma by reason of him or her serving in such capacity that existed or occurred at or prior to the Effective Time (including in connection with the Merger Agreement or the contemplated transactions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provisions of this section are intended to be in addition to the rights otherwise available to the current and former officers and directors of Carisma and OrthoCellix by law, charter, statute, by-law or agreement, and will operate for the benefit of, and will be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their representatives. In the event Carisma or the Combined Company or any of their respective successors or assigns (i)&#160;consolidates or amalgamates with or merges into any other person and will not be the continuing or Combined Company or entity of such consolidation or Merger or (ii)&#160;transfers all or substantially all of its properties and assets to any person, then, and in each such case, proper provision will be made so that the successors and assigns of Carisma or the Combined Company, as the case may be, will succeed to such indemnification obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Covenants; Conduct of Business Pending the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma has agreed that, except as expressly contemplated or permitted by the Merger Agreement, the subscription agreement or any Parent Legacy Transaction or the Carisma disclosure schedule, as required by applicable law, in connection the winding down of Carisma&#8217;s prior research and development activities or unless OrthoCellix otherwise consents in writing (not to be unreasonably withheld, delayed or conditioned), during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the termination of the Merger Agreement and the Effective Time (the&#160;&#8220;Pre-Closing&#160;Period&#8221;), Carisma will use commercially reasonable efforts to conduct its business and operations in the ordinary course of business and in material compliance with all applicable law and the requirements of all Carisma material contracts and continue to pay material outstanding accounts payable and other material current liabilities when due and payable. Carisma has also agreed that, subject to certain limited exceptions, without the consent of OrthoCellix (not to be unreasonably withheld, delayed or conditioned), it will not, during the&#160;Pre-Closing&#160;Period:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities except with certain exceptions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (a)&#160;any capital stock or other security, (b)&#160;any option, warrant or right to acquire any capital stock or any other security or (c)&#160;any instrument convertible into or exchangeable for any capital stock or other security;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">except as required to give effect to anything in contemplation of the closing of the Merger, amend any of its organizational documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the contemplated transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">form any subsidiary or acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lend money to any person, incur or guarantee any indebtedness for borrowed money, guarantee any debt securities or others or other than the incurrence or payment of transaction expenses, make any capital expenditure or commitment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other than as expressly required by applicable law or the terms of any employee plan in effect as of the date of the Merger Agreement: (a)&#160;adopt, establish or enter into any employee plan, including, for the avoidance of doubt, any equity award plans, (b)&#160;cause or permit any employee plan to be amended other than as required by law or in order to make amendments for the purposes of Section&#160;409A of the Code, (c)&#160;pay any bonus or make any profit-sharing or similar payment to (except with respect to obligations in place on the date of the Merger Agreement pursuant to any employee plan), or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its employees, directors or consultants, (d)&#160;increase the severance or change of control benefits offered to any current or new employees, directors or consultants, or (e)&#160;hire or terminate (other than for cause, or absent such a definition of cause, for conduct that Carisma or such subsidiary determines in good faith constitutes material misconduct) any officer, employee or consultant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into any transaction outside the ordinary course;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">191</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its material assets or properties, or grant any lien with respect to such assets or properties (other than the disposition of Carisma Legacy Assets);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make, change or revoke any material tax election; file any amended income or other material tax return; settle or compromise any material tax claim; waive or extend any statute of limitations in respect of a period within which an assessment or reassessment of material taxes may be issued (other than any extension pursuant to an extension to file any tax return); enter into any &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar law) with any governmental entity; surrender any material claim for refund; or adopt or change any material accounting method in respect of taxes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">waive, settle or compromise any pending or threatened action against Carisma or any of its subsidiaries, other than waivers, settlements or agreements (a)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (b)&#160;that do not impose any material restrictions on the operations or businesses of Carisma or its subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Carisma or any of its subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or fail to repay when due, any obligation, including accounts payable and accrued expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">forgive any loans to any person, including its employees, officers, directors or affiliates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, assign, transfer, license, sublicense or otherwise dispose of any intellectual property of Carisma;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terminate or modify in any respect, or fail to exercise renewal rights with respect to, any material insurance policy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into, amend, terminate, or waive any option or right under, any material contract or contract that would be deemed to be a material contract if entered into on or prior to the date of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other than the incurrence or payment of any transaction expenses, make any expenditures, incur any liabilities or discharge or satisfy any obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into any agreement to purchase or sell any interest in real property, grant any security interest in any real property, enter into any lease, sublease, license or other occupancy agreement with respect to any real property or alter, amend, modify, exercise any extension or expansion right under or violate or terminate any of the terms of any real property leases of Carisma;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other than as expressly required by law or GAAP, take any action to change accounting policies or procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)&#160;change pricing or royalties or other payments set or charged by Carisma or any of subsidiaries to its customers or licensees or (b)&#160;agree to change pricing or royalties or other payments set or charged by persons who have licensed intellectual property to Carisma or any of its subsidiaries; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agree, resolve or commit to do any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, notwithstanding any provision in the Merger Agreement to the contrary, Carisma may engage in a Parent Legacy Transaction,&#160;<i style="font-style:italic;">provided, however</i>, that any such Parent Legacy Transaction will require the prior written consent of OrthoCellix to the extent any Parent Legacy Transaction would result in any monetary or other material obligations of Carisma or otherwise or which could cause Carisma to incur any material liability that could extend beyond the closing of the Merger or contemplates that any consideration paid in respect thereof is in anything other than immediately available cash, or otherwise interferes with or delays in any manner the ability of Carisma to perform its obligations under the Merger Agreement or timely consummate the transactions contemplated thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">OrthoCellix has agreed that, except as expressly contemplated or permitted by the Merger Agreement or the OrthoCellix disclosure schedule, as required by applicable law, or unless Carisma otherwise consents in writing (not to be unreasonably withheld, delayed or conditioned), during the&#160;Pre-Closing&#160;Period, OrthoCellix will, and will cause its subsidiaries to, use commercially reasonable efforts to conduct its business and operations in the ordinary course of business and in material compliance with all </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">192</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">applicable law. OrthoCellix has also agreed that, subject to certain limited exceptions, without the consent of Carisma (not to be unreasonably withheld, conditioned or delayed), it will not, during the Pre-Closing Period:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except for shares of OrthoCellix common stock from terminated employees, directors or consultants of OrthoCellix);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of any of the foregoing actions: (a)&#160;any capital stock or other security, (b)&#160;any option, warrant or right to acquire any capital stock or any other security or (c)&#160;any instrument convertible into or exchangeable for any capital stock or other security;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amend any of its organizational documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the contemplated transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">form any subsidiary or acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lend money to any person, incur or guarantee any indebtedness for borrowed money, or guarantee any debt securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any lien with respect to such assets or properties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">waive, settle or compromise any pending or threatened action against OrthoCellix, other than waivers, settlements or agreements (a)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (b)&#160;that do not impose any material restrictions on the operations or businesses of OrthoCellix, taken as a whole, or any equitable relief on, or the admission of wrongdoing by OrthoCellix;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or fail to repay when due any material obligation, including accounts payable and accrued expenses, other than in the ordinary course;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make, change or revoke any material tax election; file any amended income or other material tax return; settle or compromise any material tax claim; waive or extend any statute of limitations in respect of a period within which an assessment or reassessment of material taxes may be issued (other than any extension pursuant to an extension to file any tax return); enter into any &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar law) with any governmental entity; surrender any material claim for refund; or adopt or change any material accounting method in respect of taxes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, assign, transfer, license, sublicense or otherwise dispose of any intellectual property of OrthoCellix; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agree, resolve or commit to do any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the parties have agreed to use commercially reasonable efforts to enter into subscription agreements with one or more investors designated by OrthoCellix to subscribe for and purchase a number of shares of Carisma common stock representing an aggregate commitment (inclusive of Ocugen&#8217;s commitment to purchase not less than $5.0 million of shares of Carisma common stock, substantially contemporaneously with the closing of the Merger, as further described below) at least equal to the anticipated Concurrent Financing Amount and to satisfy the conditions to the anticipated Concurrent Financing as set forth in the applicable subscription agreement; provided, that the form, terms and conditions of each subscription agreement shall be in a form reasonably acceptable to each of OrthoCellix and Carisma. OrthoCellix shall provide Carisma at least five business&#160;days&#8217; written notice prior to the execution of each subscription agreement, which such execution shall be subject to the prior consent of Carisma (such consent not to be unreasonably withheld, conditioned or delayed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, on or before August&#160;1, 2025, Ocugen shall enter into a securities purchase agreement committing to purchase not less than $5.0 million of shares of Carisma common stock, with terms and conditions of such securities purchase agreement to be substantially similar to the terms of the subscription agreements to be entered into by other anticipated investors of the anticipated Concurrent Financing.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">193</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OrthoCellix Audited Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As promptly as reasonably practicable following the date of the Merger Agreement (but in any event by July&#160;9, 2025), OrthoCellix will furnish to Carisma (i)&#160;audited financial statements for each of its fiscal&#160;years required to be included in this registration statement (the &#8220;OrthoCellix Audited Financial Statements&#8221;) and (ii)&#160;unaudited interim financial statements for each interim period completed prior to the closing of the Merger that would be required to be included in this registration statement or any periodic report due prior to the closing of the Merger if OrthoCellix were subject to the periodic reporting requirements under the Securities Act or the Exchange Act (the &#8220;OrthoCellix Interim Financial Statements&#8221;), which will be prepared in accordance with GAAP as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto and except, in the case of any unaudited financial statements, to normal&#160;year-end audit adjustments) and on that basis will present fairly, in all material respects, the financial position and the results of operations, changes in stockholders&#8217; equity, and cash flows of OrthoCellix as of the dates of and for the periods referred to in the OrthoCellix Audited Financial Statements or the OrthoCellix Interim Financial Statements, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Except as set forth in the Merger Agreement, all fees and expenses incurred in connection with the Merger Agreement and the contemplated transactions will be paid by the party incurring such expense, whether or not the Merger is consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Commercially Reasonable Efforts</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each of Carisma and OrthoCellix has agreed to use commercially reasonable efforts to consummate the contemplated transactions. Each party will (i)&#160;promptly make all filings and other submissions and give all notices required to be made and given by such party in connection with the contemplated transactions, (ii)&#160;use commercially reasonable efforts to obtain each consent (if any) required to be obtained by such party in connection with the contemplated transactions or for any such contract to remain in full force and effect, (iii)&#160;use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the contemplated transactions and (iv)&#160;use commercially reasonable efforts to satisfy the conditions precedent to the consummation of the Merger Agreement described in further detail in the section of this registration statement titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Conditions to the Completion of the Merger</i>.&#8221;</p><a id="Termination_263528"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Termination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Merger Agreement may be terminated prior to the Effective Time:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by mutual written consent of Carisma and OrthoCellix;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by either Carisma or OrthoCellix if the Merger is not consummated by December&#160;23, 2025 (the &#8220;End Date&#8221;);&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">however</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, that the Merger Agreement may not be terminated pursuant to this paragraph if Carisma&#8217;s, Merger Sub&#8217;s or OrthoCellix&#8217;s action or failure to act has been a principal cause of the failure of the Merger to occur on or before the End Date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by either Carisma or OrthoCellix if a court of competent jurisdiction or other governmental authority issues a final and nonappealable order, or takes any other action that permanently restrains, enjoins or otherwise prohibits the contemplated transactions;&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">however</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, that the Merger Agreement may not be terminated pursuant to this paragraph if Carisma&#8217;s, Merger Sub&#8217;s or OrthoCellix&#8217;s breach of the Merger Agreement is a principal cause of such Governmental Entity issuing any such order or taking such action;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Carisma or OrthoCellix if the OrthoCellix Stockholder Approval has not been obtained within two business&#160;days of the registration statement of which this proxy statement/prospectus forms a part becoming effective;&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">however</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, that once the OrthoCellix Stockholder Approval has been obtained, neither Carisma nor OrthoCellix may terminate the Merger Agreement pursuant to this paragraph and the right to terminate the Merger Agreement under this paragraph will not be available to a party if such party&#8217;s breach of the Merger Agreement is a principal cause of the failure of the OrthoCellix Stockholder Approval to have been obtained on or before such second business day;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by either Carisma or OrthoCellix if the Carisma special meeting (including any adjournments and postponements thereof) is held and completed and Carisma&#8217;s stockholders shall have taken a final vote on the Carisma Stockholder Proposal and (ii)&#160;the </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">194</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma Stockholder Approval shall not have been obtained at the Carisma special meeting (or any adjournment or postponement thereof); </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided, however</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, that the right to terminate the Merger Agreement under this paragraph will not be available to a party if such party&#8217;s breach of the Merger Agreement is a principal cause of the failure of the Carisma Stockholder Approval to have been obtained at the Carisma special meeting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by OrthoCellix (prior to Carisma obtaining the Carisma Stockholder Approval) if any of the following circumstances (each of the following, referred to as an &#8220;Carisma Triggering Event&#8221;) occurs: (a)&#160;upon any change in the Carisma Board Recommendation or if the Carisma board of directors approves, endorses or recommends any acquisition proposal, (b)&#160;if Carisma enters into any contract relating to any acquisition proposal (other than an acceptable confidentiality agreement) or (c)&#160;upon Carisma&#8217;s willful and material breach of its non-solicitation covenants contained in the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Carisma (prior to OrthoCellix obtaining the OrthoCellix Stockholder Approval) if any of the following circumstances (each of the following, referred to as an &#8220;OrthoCellix Triggering Event&#8221;) occurs: (a)&#160;Carisma fails to include in the proxy statement the Carisma Board Recommendation, (b)&#160;the Carisma board of directors or any committee thereof makes a Carisma Board Adverse Recommendation Change or approves, endorses or recommends any Acquisition Proposal, (c)&#160;Carisma enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement permitted under the Merger Agreement as defined therein), (d)&#160;a tender offer or exchange offer for outstanding shares of Carisma common stock is commenced, and the Carisma board of directors (or any committee thereof) recommends that the stockholders of Carisma tender their shares in such tender or exchange offer or, within 10 business&#160;days after the commencement of such tender offer or exchange offer, the Carisma board of directors fails to recommend against acceptance of such offer, (e)&#160;Carisma fails to issue a press release confirming the Carisma Board Recommendation within 10 business&#160;days following OrthoCellix&#8217;s written request to Carisma to issue such press release in response to any other publicly announced Acquisition Proposal with respect to Carisma or (f)&#160;Carisma materially and willfully breaches its non-solicitation obligations under the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by OrthoCellix (prior to Carisma obtaining the Carisma Stockholder Approval) if any of the following circumstances (each of the following, referred to as an &#8220;Carisma Triggering Event&#8221;) occurs: (a)&#160;the OrthoCellix board publicly approves, endorses or recommends any Acquisition Proposal, (b)&#160;OrthoCellix enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement under the Merger Agreement as defined therein) or (c)&#160;OrthoCellix materially and willfully breaches its non-solicitation obligations under the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by OrthoCellix, upon a breach of any representation, warranty, covenant or agreement set forth in the Merger Agreement by Carisma or Merger Sub or if any representation or warranty of Carisma or Merger Sub becomes inaccurate, in either case, such that the closing conditions would not be satisfied as of the time of such breach or as of the time such representation or warranty will have become inaccurate; provided that OrthoCellix is not then in material breach of any representation, warranty, covenant or agreement under the Merger Agreement;&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">further</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, that if such inaccuracy in Carisma&#8217;s or Merger Sub&#8217;s representations and warranties or breach by Carisma or Merger Sub is curable by Carisma or Merger Sub, then the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy until the earlier of (a)&#160;the expiration of a&#160;30-day&#160;period commencing upon delivery of written notice from OrthoCellix to Carisma or Merger Sub of such breach or inaccuracy and its intention to terminate or (b)&#160;Carisma or Merger Sub (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from OrthoCellix to Carisma or Merger Sub of such breach or inaccuracy and its intention to terminate (it being understood that the Merger Agreement will not terminate as a result of such particular breach or inaccuracy if such breach by Carisma or Merger Sub is cured prior to such termination becoming effective);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Carisma, upon a breach of any representation, warranty, covenant or agreement set forth in the Merger Agreement by OrthoCellix or if any representation or warranty of OrthoCellix becomes inaccurate, in either case, such that the closing conditions would not be satisfied as of the time of such breach or as of the time such representation or warranty will have become inaccurate; provided that Carisma is not then in material breach of any representation, warranty, covenant or agreement under the Merger Agreement;&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">further</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, that if such inaccuracy OrthoCellix&#8217;s representations and warranties or breach by OrthoCellix is curable by OrthoCellix then the Merger Agreement will not as a result of such particular breach or inaccuracy until the earlier of (i)&#160;the expiration of a&#160;30-day&#160;period commencing upon delivery of written notice from Carisma to OrthoCellix of such breach or inaccuracy and its intention to terminate or (ii)&#160;OrthoCellix ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from OrthoCellix to Carisma or Merger Subs of such breach or inaccuracy and its intention to terminate (it being understood that the Merger </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">195</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Agreement will not terminate as a result of such particular breach or inaccuracy if such breach by OrthoCellix is cured prior to such termination becoming effective);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Carisma (at any time prior to obtaining the Carisma Stockholder Approval) and following compliance with all of the requirements set forth in this paragraph, concurrently with Carisma&#8217;s entering into a definitive agreement for a Superior Offer (a &#8220;Permitted Alternative Agreement&#8221;) and after having paid to OrthoCellix the OrthoCellix Termination Fee; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided, however</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, that Carisma shall not enter into any Permitted Alternative Agreement unless: (i)&#160;OrthoCellix has received written notice from Carisma of Carisma&#8217;s intention to enter into such Permitted Alternative Agreement at least four business&#160;days in advance, (ii)&#160;Carisma shall have complied in all material respects with its obligations under the Merger Agreement, and (iii)&#160;the Carisma board of directors shall have determined in good faith, after consultation with its outside legal counsel, that the failure to enter into such Permitted Alternative Agreement would reasonably be expected to be inconsistent with its fiduciary obligations under applicable law; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Carisma, if OrthoCellix otherwise fails to secure the Concurrent Financing Amount such that as of September&#160;15, 2025, Carisma has not received, or at any time ceases to have, aggregate commitments equal to or in excess of the Concurrent Financing Amount.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The party desiring to terminate the Merger Agreement will give the other party written notice of such termination, specifying the provisions of the Merger Agreement pursuant to which such termination is made and the basis therefor described in reasonable detail.</p><a id="TerminationFee_487209"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Termination Fee</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Carisma must pay OrthoCellix a termination fee of $500,000 (&#8220;OrthoCellix Termination Fee&#8221;) if the Merger Agreement is terminated:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Carisma or OrthoCellix for failure to obtain the Carisma Stockholder Approval or by OrthoCellix for Carisma&#8217;s breach of its representations and warranties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at any time after the date of the Merger Agreement and prior to the Carisma special meeting an Acquisition Proposal with respect to Carisma shall have been publicly announced, disclosed or otherwise communicated to the Carisma board of directors (and shall not have been withdrawn); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">within 12&#160;months after the date of such termination, Carisma enters into a definitive agreement with respect to a Subsequent Transaction with respect to Carisma or consummates a Subsequent Transaction with respect to Carisma.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">&#8220;Subsequent Transaction&#8221; means any Acquisition Transaction (with all references to 20.0% in the definition of Acquisition Transaction being treated as references to 50.0% for these purposes).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">If the Merger Agreement is terminated (a)&#160;by Carisma or OrthoCellix because the Merger is not consummated by the End Date or because a Carisma Triggering Event has occurred or (b)&#160;by Carisma to enter into a definitive agreement for a Superior Offer, then Carisma shall pay to OrthoCellix, the OrthoCellix Termination Fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">OrthoCellix must pay Carisma a termination fee of $750,000 (&#8220;Carisma Termination Fee&#8221;) if the Merger Agreement is terminated:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Carisma or OrthoCellix for failure to obtain OrthoCellix Stockholder Approval or by Carisma pursuant to OrthoCellix&#8217;s breach of its representations and warranties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at any time after the date of the Merger Agreement and prior to obtaining the OrthoCellix Stockholder Approval, an Acquisition Proposal with respect to OrthoCellix shall have been publicly announced, disclosed or otherwise communicated to the OrthoCellix board (and shall not have been withdrawn); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">within six&#160;months after the date of such termination, OrthoCellix enters into a definitive agreement with respect to a Subsequent Transaction with respect to OrthoCellix or consummates a Subsequent Transaction with respect to OrthoCellix.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">If the Merger Agreement is terminated by Carisma or OrthoCellix because the Merger is not consummated by the End Date or because an OrthoCellix Triggering Event has occurred or by Carisma for OrthoCellix&#8217;s failure to secure the Concurrent Financing Amount, then OrthoCellix shall pay to Carisma, the Carisma Termination Fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, if the Merger Agreement is terminated by Carisma or OrthoCellix for failure to obtain the OrthoCellix Stockholder Approval or for OrthoCellix&#8217;s failure to secure the Concurrent Financing Amount, then OrthoCellix shall reimburse Carisma for all </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">196</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">reasonable out-of-pocket expenses incurred by Carisma in connection with the Merger Agreement and the transactions contemplated thereby, up to a maximum of $500,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Amendment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The Merger Agreement may be amended modified or supplemented by the parties, except that after the Merger Agreement has been adopted and approved by a party&#8217;s stockholders, no amendment which by law requires further approval by the stockholders of that party will be made without such further stockholder approval.</p><a id="_7a7329da_1e07_410d_91c9_866dc7510c45"></a><a id="AGREEMENTSRELATEDTOTHEMERGER_629264"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">AGREEMENTS RELATED TO THE MERGER</b></p><a id="SupportAgreementsandLockUpAgreement_5038"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Support Agreements and Lock-Up Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Concurrently and in connection with the execution of the Merger Agreement, (a)&#160;Ocugen, the sole stockholder of OrthoCellix (and solely in its capacity as the sole stockholder of OrthoCellix) entered into the OrthoCellix Support Agreement and (b)&#160;certain executive officers and directors of Carisma have entered into support agreements with Carisma and OrthoCellix to vote all of their shares of Carisma common stock in favor of Proposal No.&#160;1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Concurrently and in connection with the execution of the Merger Agreement, Ocugen, the sole stockholder of OrthoCellix, entered into the Lock-Up Agreement pursuant to which, and subject to specified exceptions, they have agreed not to transfer their shares of Carisma common stock for the 180-day period following the closing of the Merger.</p><a id="CarismaContingentValueRightsAgreement_20"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Carisma Contingent Value Rights Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Terms of the Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">At or prior to the Effective Time, Carisma is expected to enter into the CVR Agreement with the Rights Agent pursuant to which pre-Merger Carisma common stockholders, subject to the terms and conditions set forth in the CVR Agreement will receive one CVR for each outstanding share of Carisma common stock held by such stockholder on such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Each CVR will represent the contractual right to receive a contingent cash payment equal to (i)&#160;the Net Proceeds (as defined in the CVR Agreement) received by Carisma to the extent such payment related to the disposition of any Carisma Legacy Asset during the period beginning on the execution date of the Merger Agreement and ending on the second anniversary of the closing of the Merger, if any, plus (ii)&#160;the Net Proceeds received by Carisma to the extent such payment related to any royalties, milestones or other payments received by Carisma following the closing of the Merger under certain of Carisma&#8217;s existing agreements, including its collaboration and license agreement with Moderna, in each case subject to adjustment based on the terms and conditions set forth in the CVR Agreement.</p><a id="MaterialUSFederalIncomeTaxConsequence_56"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following discussion is a summary of the material U.S. federal income tax consequences of the receipt of CVRs to Carisma stockholders who receive CVRs with respect to Carisma common stock, but this discussion does not purport to be a complete analysis of all potential tax consequences that may be relevant to a Carisma stockholder. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Carisma stockholder. Carisma has not sought and does not intend to seek any opinions of counsel or rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a position contrary to that discussed below regarding the tax consequences of the receipt of CVRs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">This discussion is limited to Carisma stockholders that hold Carisma common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences that may be relevant to a Carisma stockholder&#8217;s particular circumstances, including the impact of the alternative minimum tax or the Medicare contribution tax on net investment income or the rules&#160;related to &#8220;qualified small business stock&#8221; within the meaning of Section&#160;1202 of the Code. In addition, it does not address consequences relevant to Carisma stockholders subject to special rules, including, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. expatriates and former citizens or long-term residents of the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma U.S. holders whose functional currency is not the U.S. dollar;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">197</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons holding Carisma common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">banks, insurance companies, and other financial institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">real estate investment trusts or regulated investment companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brokers, dealers or traders in securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">S corporations, partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-exempt organizations or governmental organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons subject to special tax accounting rules as a result of any item of gross income with respect to Carisma common stock being taken into account in an &#8220;applicable financial statement&#8221; (as defined in the Code);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons deemed to sell Carisma common stock under the constructive sale provisions of the Code;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons who hold or received Carisma common stock pursuant to the exercise of any employee stock option or otherwise as compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-qualified retirement plans.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">If an entity treated as a partnership for U.S. federal income tax purposes holds Carisma common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding Carisma common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">IT IS RECOMMENDED THAT CARISMA STOCKHOLDERS CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE RECEIPT OF CVRs ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">For purposes of this discussion, a &#8220;Carisma U.S. holder&#8221; is a beneficial owner of Carisma common stock that, for U.S. federal income tax purposes, is or is treated as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual who is a citizen or resident of the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation created or organized under the laws of the U.S., any state thereof, or the District of Columbia;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a trust that: (i) is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section 7701(a)(30) of the Code); or (ii) has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">For purposes of this discussion, a &#8220;Carisma non-U.S. holder&#8221; means a beneficial owner of Carisma common stock that is neither a Carisma U.S. holder nor a partnership (or other entity treated as a partnership) for U.S. federal income tax purposes.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">198</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Alternative Treatment of the Receipt of CVRs and the Proposed Reverse Stock Split as a Single Recapitalization</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Carisma will treat the proposed reverse stock split as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E)&#160;of the Code that is separate from Carisma&#8217;s distribution of the CVRs. Notwithstanding that Carisma will report the receipt of CVRs and the proposed reverse stock split as separate transactions, it is possible that the IRS or a court could determine that the receipt of the CVRs and the proposed reverse stock split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes. In such case, the tax consequences of the receipt of CVRs would differ from those described below and would depend in part on many of the same considerations described below, including whether the CVRs should be treated as property, equity or debt instruments or should be subject to the &#8220;open transaction&#8221; doctrine. In general, if the CVRs are treated as property and are not subject to the &#8220;open transaction&#8221; doctrine, and the receipt of the CVRs and the proposed reverse stock split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes, then a Carisma stockholder should recognize gain (but not loss) equal to the lesser of (i)&#160;the fair market value of the CVRs received and (ii)&#160;the excess (if any) of (A)&#160;the sum of (1)&#160;the fair market value of the CVRs received and (2)&#160;the fair market value of the Carisma shares received in the proposed reverse stock split (including any cash received in lieu of a fractional share) over (B)&#160;the Carisma stockholder&#8217;s adjusted tax basis in the Carisma common stock surrendered in the proposed reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The remainder of this discussion assumes that the distribution of the CVRs to Carisma stockholders will be treated for U.S. federal income tax purposes as a transaction that is separate and distinct from the proposed reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Receipt of CVRs by Carisma U.S. Holders</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">There is substantial uncertainty as to the tax treatment of the CVRs. Specifically, there is no authority directly addressing whether contingent value rights with characteristics similar to the CVRs should be treated as a distribution of property with respect to Carisma common stock, a distribution of equity, a &#8220;debt instrument&#8221; or an &#8220;open transaction&#8221; for U.S. federal income tax purposes, and such determinations are inherently factual in nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">As a result, it is not possible to express a definitive conclusion as to the U.S. federal income tax treatment of receipt of the CVRs or receipt of any payment pursuant to the CVRs. Based on the specific characteristics of the CVRs, Carisma intends the issuance of the CVRs to be treated, and will treat such issuance, as a distribution of property with respect to its stock. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to any description of the intended tax consequences summarized below. No opinion of counsel or ruling has been or will be sought from the IRS regarding the tax treatment of the CVRs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Treatment as Distribution of Property.</i>&#160;As discussed above, Carisma will report the issuance of the CVRs as a distribution of property with respect to its stock. Assuming such treatment is respected by the IRS, each Carisma U.S. holder should be treated as receiving a distribution in an amount equal to the fair market value of the CVRs issued to such Carisma U.S. holder on the date of the issuance. This distribution should be treated first as a taxable dividend to the extent of the Carisma U.S. holder&#8217;s pro rata share of Carisma&#8217;s current or accumulated earnings and profits for the&#160;year of issuance (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Carisma U.S. holder&#8217;s basis in its Carisma common stock, and finally as capital gain from the sale or exchange of Carisma common stock with respect to any remaining value. Carisma has no accumulated earnings and profits and expects to have no current earnings and profits for the relevant taxable&#160;year. Thus, Carisma expects the distribution of the CVRs to be treated as a non-dividend distribution for U.S. federal income tax purposes. Carisma U.S. holders will receive a Form&#160;1099-DIV notifying them of the portion of the CVR value that is treated as a non-dividend distribution (or a dividend to the extent of Carisma&#8217;s earnings and profits) for U.S. federal income tax purposes. Although Carisma will estimate the value of the CVRs for purposes of reporting on Form&#160;1099-DIV to Carisma U.S. holders, the value of the CVRs is uncertain and the IRS or a court could determine that the value of the CVRs at the time of issuance was higher. In such case, the Carisma U.S. holders could be treated as having additional income or gain upon receipt of the CVRs as described above. A Carisma U.S. holder&#8217;s initial tax basis in such holder&#8217;s CVRs should equal the fair market value of such CVRs on the date of their issuance. The holding period of such CVRs should begin on the day after the date of issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future payments received by a Carisma U.S. holder with respect to a CVR would likely be treated as a non-taxable return of such Carisma U.S. holder&#8217;s adjusted tax basis in the CVR to the extent thereof, and payment in excess of such amount would likely be treated as ordinary income. However, the treatment of future payments, if any, pursuant to the CVRs is uncertain and alternative treatments are possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">199</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Treatment as Equity.&#160;</i>It is possible that the issuance of the CVRs could be treated as a distribution of equity for U.S. federal income tax purposes, in which case Carisma U.S. holders should not recognize gain or loss as a result of the issuance of the CVRs. Each Carisma U.S. holder&#8217;s tax basis in such holder&#8217;s Carisma common stock would be allocated between such holder&#8217;s Carisma common stock and such holder&#8217;s CVRs based on the fair market value of the CVRs on the date of their issuance and the fair market value of such holder&#8217;s Carisma common stock. The holding period of such CVRs should include the Carisma U.S. holder&#8217;s holding period of such holder&#8217;s Carisma common stock. Future payments, if any, on a CVR received by a Carisma U.S. holder should be treated as a dividend to the extent of the Carisma U.S. holder&#8217;s pro rata share of Carisma&#8217;s current or accumulated earnings and profits at the time of such payment (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Carisma U.S. holder&#8217;s basis in the CVR, and finally as capital gain from the sale or exchange of the CVR with respect to any remaining amount. As discussed above, Carisma will not report the issuance of the CVRs as a distribution of equity for U.S. federal income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Treatment as Debt Instrument.</i>&#160;It is also possible that the CVRs could be treated as one or more &#8220;debt instruments.&#8221; If the CVRs are treated as one or more &#8220;debt instruments,&#8221; then payments received with respect to the CVRs would likely be treated as payments in retirement of a &#8220;debt instrument,&#8221; except to the extent of interest imputed under the Code. If this tax treatment were to apply, interest generally would be imputed under complex rules. In such a case, a Carisma U.S. holder would be required to include any such interest in income on an annual basis, whether or not currently paid. As discussed above, Carisma will not report the issuance of the CVRs as a distribution of a &#8220;debt instrument&#8221; for U.S. federal income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Treatment as &#8220;Open Transaction.&#8221;</i>&#160;It is also possible that the issuance of the CVRs could be treated as subject to the &#8220;open transaction&#8221; doctrine if the value of the CVRs at closing cannot be &#8220;reasonably ascertained.&#8221; If the receipt of CVRs were treated as an &#8220;open transaction&#8221; for U.S. federal income tax purposes, each Carisma U.S. holder should not immediately take the CVRs into account in determining whether such holder must recognize income or gain, if any, on the receipt of the CVRs and such holder would not take any tax basis in the CVRs. Rather, the Carisma U.S. holder&#8217;s U.S. federal income tax consequences would be determined at the time future payments, if any, with respect to the CVRs are received or deemed received in accordance with the Carisma U.S. holder&#8217;s regular method of accounting based on whether, as discussed above, the CVRs are treated as a distribution of property or of debt or equity. As discussed above, Carisma will not report the issuance of the CVRs as an open transaction for U.S. federal income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Receipt of CVRs by Carisma Non-U.S. Holders</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provided that the issuance of the CVRs is treated as a distribution of property with respect to Carisma common stock, each Carisma non-U.S. holder should be treated as receiving a distribution in an amount equal to the fair market value of the CVRs issued to such Carisma non-U.S. holder on the date of the issuance. This distribution should be treated first as a taxable dividend to the extent of the Carisma non-U.S. holder&#8217;s pro rata share of Carisma&#8217;s current or accumulated earnings and profits for the&#160;year of issuance (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Carisma non-U.S. holder&#8217;s basis in its Carisma common stock, and finally as capital gain from the sale or exchange of Carisma common stock with respect to any remaining amount. Carisma has no accumulated earnings and profits and expects to have no current earnings and profits for the relevant taxable&#160;year. Thus, Carisma expects the distribution of the CVRs to be treated as a non-dividend distribution for U.S. federal income tax purposes. However, if Carisma cannot determine at the time of the distribution of the CVRs whether or not the amount of such distribution will exceed current and accumulated earnings and profits, Carisma or the applicable withholding agent may withhold (potentially by utilizing other property of such Carisma non-U.S. holder held in an account with the applicable withholding agent) at the rate applicable to dividends, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividend payments to a Carisma non-U.S. holder will generally be subject to withholding at a 30.0% rate. If a Carisma non-U.S. holder is eligible for a lower treaty rate, withholding will be at such lower treaty rate only if such Carisma non-U.S. holder provides a valid IRS Form&#160;W-8BEN or Form&#160;W-8BEN-E (or applicable successor form) certifying such Carisma non-U.S. holder&#8217;s qualification for the reduced rate. If a Carisma non-U.S. holder holds the stock through a financial institution or other intermediary, the Carisma non-U.S. holder will be required to provide appropriate documentation to the intermediary, which then will be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. Carisma non-U.S. holders who do not timely provide the applicable withholding agent with the required certification, but who qualify for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">200</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the discussions below regarding FATCA (as defined below) and backup withholding, if the issuance of the CVRs is effectively connected with a Carisma non-U.S. holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Carisma non-U.S. holder maintains a permanent establishment in the United States to which the distribution of the CVRs is attributable), the Carisma non-U.S. holder will be exempt from U.S. federal withholding tax and the distribution of the CVRs generally will be subject to U.S. federal income tax on a net income basis in the same manner as if such Carisma non-U.S. holder were a U.S. holder. To claim the exemption, the Carisma non-U.S. holder must furnish to the applicable withholding agent a valid IRS Form&#160;W-8ECI (or applicable successor form), certifying that the distribution is effectively connected with the Carisma non-U.S. holder&#8217;s conduct of a trade or business within the United States. A Carisma non-U.S. holder that is a corporation also may be subject to a branch profits tax at a rate of 30.0% (or such lower rate specified by an applicable income tax treaty) on all or a portion of its effectively connected earnings and profits for the taxable&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future payments, if any, to a Carisma non-U.S. holder with respect to a CVR may also be subject to withholding at a 30.0% rate unless the holder establishes a reduced treaty rate or that such income is exempt from withholding because it is effectively connected with the holder&#8217;s conduct of a trade or business within the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the provisions of the Code commonly referred to as the Foreign Account Tax Compliance Act (&#8220;FATCA&#8221;) the issuance of the CVRs and future payments, if any, to a Carisma non-U.S. holder with respect to the CVRs may be subject to withholding at a rate of 30.0% if the Carisma non-U.S. holder fails to satisfy prescribed certification requirements. In general, no such withholding will be required with respect to a Carisma non-U.S. holder that timely provides certifications that establish an exemption from FATCA withholding on a valid IRS Form&#160;W-8. If withholding under FATCA is required, Carisma non-U.S. holders not otherwise subject to withholding (or that otherwise would be entitled to a reduced rate of withholding) may be required to seek a refund or credit from the IRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any withholding required by Carisma or other applicable withholding agents may be satisfied by Carisma or such agent by withholding a portion of the issued CVRs, from future payments, if any, on the CVRs, or from other property of the Carisma non-U.S. holder held in an account with the applicable withholding agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that the issuance of the CVRs is treated as capital gain from the sale or exchange of Carisma common stock, such gain generally will not be subject to U.S. federal income tax unless (i)&#160;such gain is effectively connected with the conduct by a Carisma non-U.S. holder of a trade or business in the United States (and, if an income tax treaty applies, the gain is generally attributable to a U.S. permanent establishment maintained by such Carisma non-U.S. holder), (ii)&#160;in the case of gain realized by a Carisma non-U.S. holder that is an individual, such Carisma non-U.S. holder is present in the United States for 183&#160;days or more in the taxable&#160;year of the sale and certain other conditions are met or (iii)&#160;Carisma is or has been a United States real property holding corporation, (&#8220;USRPHC&#8221;) for U.S. federal income tax purposes and, if the shares are &#8220;regularly traded on an established securities market,&#8221; such Carisma non-U.S. holder owned, directly or indirectly, at any time during the five-year period ending on the date of the distribution, more than five&#160;percent of the shares of Carisma common stock and such Carisma non-U.S. holder is not eligible for any treaty exemption. Carisma believes it is not, and has not been, a USRPHC for U.S. federal income tax purposes. In addition, although not free from doubt, Carisma believes that Carisma common shares currently should be considered to be regularly traded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A Carisma non-U.S. holder should consult its tax advisor regarding its entitlement to benefits and the various rules&#160;under applicable tax treaties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">Information Reporting and Backup Withholding</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">In general, the issuance of the CVRs to Carisma U.S. holders will be reported to the IRS unless the holder is an exempt recipient. Backup withholding, currently at a rate of 24.0%, may apply unless the Carisma U.S. holder (1)&#160;is an exempt recipient or (2)&#160;provides a certificate (generally on an IRS Form&#160;W-9) containing the Carisma U.S. holder&#8217;s name, address, correct federal taxpayer identification number and statement that the Carisma U.S. holder is a U.S. person and is not subject to backup withholding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">201</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A Carisma non-U.S. holder will not be subject to backup withholding with respect to the issuance of the CVRs, provided the Carisma non-U.S. holder certifies its non-U.S. status, such as by providing a valid IRS Form&#160;W-8BEN, Form&#160;W-8BEN-E, or Form&#160;W-8ECI, or otherwise establishes an exemption. However, information returns will be filed with the IRS in connection with the issuance of the CVRs, regardless of whether any tax was actually withheld. Copies of these information returns may also be made available under the provisions of a specific treaty or agreement to the tax authorities of the country in which the Carisma non-U.S. holder resides or is established.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules&#160;may be allowed as a refund or credit against a holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PLEASE CONSULT YOUR TAX ADVISOR WITH RESPECT TO THE PROPER CHARACTERIZATION OF THE RECEIPT OF THE CVRs.</b></p><a id="AnticipatedSubscriptionAgreementsandRegi"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anticipated Subscription Agreements and Registration Rights Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma intends to enter into subscription agreements with certain investors, pursuant to which Carisma will sell, and such investors will purchase, shares of Carisma common stock at a purchase price per share equal to the Aggregate Valuation divided by the Post-Closing Carisma Shares, immediately following the Effective Time and&#160;on or before August&#160;1, 2025, Ocugen will enter into a securities purchase agreement with Carisma, pursuant to which Ocugen will commit to purchase, immediately following the Effective Time, shares of Carisma&#8217;s common stock for aggregate gross proceeds equal to not less than $5.0 million. Carisma also intends to enter into a registration rights agreement with the investors that participate in the anticipated Concurrent Financing at the closing of the anticipated Concurrent Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration of the resale of certain shares of Carisma common stock that are held by the investors participating in the anticipated Concurrent Financing from time to time on Form&#160;S-1 or Form&#160;S-3. The closing of the anticipated Concurrent Financing is conditioned upon the satisfaction or waiver of each of the conditions to the closing of the Merger as well as certain other conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Asset Contribution Agreement between OrthoCellix and Ocugen</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2025, OrthoCellix entered into an asset contribution agreement with Ocugen pursuant to which Ocugen agreed to contribute to OrthoCellix, and OrthoCellix agreed to acquire from Ocugen, all of its rights, title and interest in and to, and obligations and liabilities associated with, NeoCart. As consideration, OrthoCellix granted Ocugen 1,000 shares of OrthoCellix&#8217;s common stock.</p><a id="OrthoCellixTransitionServicesAgreement_9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OrthoCellix Transition Services Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ocugen and OrthoCellix will enter into the&#160;TSA pursuant to which Ocugen will provide, or cause its affiliates to provide, OrthoCellix with certain services to help facilitate an orderly transition of the NeoCart program, including the provision of assistance with respect to clinical operations, regulatory affairs, research and development, finance and accounting, information technology and human resources. The&#160;TSA&#160;will specify the fees payable for these services, which will be provided&#160;at varied hourly rates, which OrthoCellix anticipates will be in excess of $120,000 per annum.&#160;The&#160;TSA&#160;terminates on the end date of the last service provided under it, unless otherwise terminated earlier by either party under certain circumstances set forth in the TSA, including in the event of an uncured material breach by the other party or in the event of insolvency of the other party.</p><a id="OrthoCellixManufacturingAgreement_968374"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OrthoCellix Manufacturing Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ocugen and OrthoCellix will enter into the OrthoCellix Manufacturing Agreement pursuant to which Ocugen will continue to manufacture and supply NeoCart to OrthoCellix until completion or cessation of the Phase 3 clinical trial, unless extended by the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fee that Ocugen charges OrthoCellix for the provision of such manufacturing and supply services is based on its fully loaded cost of performance determined in accordance with Ocugen&#8217;s then current accounting standards included plus a reasonable arm&#8217;s length mark-up. In the event the parties mutually agree to modify the work plan under the OrthoCellix Manufacturing Agreement to increase Ocugen&#8217;s performance thereunder, the parties will negotiate in good faith, including to reflect any adjustments necessary to account for such increased costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">202</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9b32735e_f746_4eb2_a541_c53eddfa8b7a"></a><a id="CARISMAEXECUTIVEOFFICERSDIRECTORSANDCORP"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA EXECUTIVE OFFICERS, DIRECTORS AND CORPORATE GOVERNANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the name, age and position of each of Carisma&#8217;s executive officers and directors as of June&#160;30, 2025. There are no family relationships among any of Carisma&#8217;s executive officers or directors.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:14.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:35.89%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Kelly</p></td><td style="vertical-align:bottom;width:2.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">60</p></td><td style="vertical-align:bottom;width:3%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director, President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Natalie McAndrew</p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">51</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.89%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vice President of Finance</p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Klichinsky, Pharm. D., Ph.D.</p></td><td style="vertical-align:bottom;width:2.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">35</p></td><td style="vertical-align:bottom;width:3%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.89%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Scientific Officer</p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sanford Zweifach <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;(2)&#160;(3)</sup></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">69</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.89%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chair</p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sohanya Cheng <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;(2)</sup></p></td><td style="vertical-align:bottom;width:2.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">42</p></td><td style="vertical-align:bottom;width:3%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.89%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John Hohneker, M.D. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)&#160;(4)</sup></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">65</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.89%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Briggs Morrison, M.D. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;(3)&#160;(4)</sup></p></td><td style="vertical-align:bottom;width:2.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">66</p></td><td style="vertical-align:bottom;width:3%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.89%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Scadden, M.D. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">72</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.89%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marella Thorell <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">58</p></td><td style="vertical-align:bottom;width:3%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.89%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the compensation committee</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the audit committee</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the nominating and corporate governance committee</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the science committee</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Natalie McAndrew </span>has served as Carisma&#8217;s Vice President of Finance since January&#160;2025. Ms.&#160;McAndrew is a Senior Director with Danforth, an advisory firm focused on providing financial strategy to life science organizations and has served in that capacity since December&#160;2024. She previously served as a Director with Danforth from August&#160;2021 until January&#160;2024. Prior to rejoining Danforth in December&#160;2024, Ms.&#160;McAndrew was the VP, Finance of Apertura Gene Therapy, a gene therapy company, from February&#160;2024 through October&#160;2024. Through Danforth, Ms.&#160;McAndrew served as the interim Chief Financial Officer of Baudax Bio,&#160;Inc., a biotechnology company, from October&#160;2023 to January&#160;2024. Prior to her initial employment with Danforth, Ms.&#160;McAndrew was the VP, Corporate Controller of Tmunity Therapeutics,&#160;Inc., a biotechnology company, from January&#160;2021 to July&#160;2021. Ms.&#160;McAndrew previously served as Head of Accounting Operations at Spark Therapeutics,&#160;Inc., a biotechnology company, from March&#160;2015 until January&#160;2021. Prior to this, Ms.&#160;McAndrew served as Corporate Controller for over eight&#160;years in other privately held and public companies at various life cycle stages, managing finance, accounting, and other corporate operational functions. Ms.&#160;McAndrew is a certified public accountant and received a B.S. in Accounting from King&#8217;s College.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Michael Klichinsky, Pharm.D., Ph.D.</span> has served as Carisma&#8217;s Chief Scientific Officer since the closing of the Sesen Bio Merger. He previously served as Legacy Carisma&#8217;s Chief Scientific Officer since April&#160;2022. He co-founded Legacy Carisma in 2016 and served as Vice President of Discovery of Legacy Carisma from October&#160;2018 to April&#160;2021 and as Senior Vice President of Research of Legacy Carisma from April&#160;2021 to April&#160;2022. Dr.&#160;Klichinsky received a Doctor of Pharmacy from the University of Sciences in Philadelphia and a Ph.D. in Pharmacology from the University of Pennsylvania.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please see Proposal No.&#160;3 for the biographical information about the directors, including Steven Kelly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Director Nomination Process</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s nominating and corporate governance committee is responsible for identifying individuals qualified to serve as directors, consistent with criteria approved by Carisma&#8217;s board of directors, and recommending the persons to be nominated for election as directors, except where Carisma is legally required by contract, law or otherwise to provide third parties with the right to nominate director candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The process followed by Carisma&#8217;s nominating and corporate governance committee to identify and evaluate director candidates includes requests to board members and others for recommendations, meetings from time to time to evaluate biographical information and background material relating to potential candidates and interviews of selected candidates by members of the committee and Carisma&#8217;s board of directors. While there are no specific minimum qualifications for a committee-recommended nominee to </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">203</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors, the qualifications, qualities and skills that Carisma&#8217;s nominating and corporate governance committee believes must be met by a committee-recommended nominee for a position on Carisma&#8217;s board of directors are as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nominees should have a reputation for integrity, honesty and adherence to high ethical standards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nominees should have demonstrated business acumen, experience and ability to exercise sound judgments in matters that relate to Carisma&#8217;s current and long-term objectives and should be willing and able to contribute positively to Carisma&#8217;s decision-making process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nominees should have a commitment to understand Carisma and Carisma&#8217;s industry and to regularly attend and participate in meetings of Carisma&#8217;s board of directors and its committees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nominees should have the interest and ability to understand the sometimes-conflicting interests of Carisma&#8217;s various constituencies, which include stockholders, employees, customers, governmental&#160;units, creditors and the general public, and to act in the interests of all stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nominees should not have, nor appear to have, a conflict of interest that would impair the nominee&#8217;s ability to represent the interests of all of Carisma&#8217;s stockholders and to fulfill the responsibilities of a director; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the value of diversity on the board of directors will be considered. Nominees should represent a diverse array of personal and professional characteristics, including, for example, academic background, professional experience in the United States or internationally and/or expertise in a particular discipline or field. Nominees will not be discriminated against on the basis of gender, race, ethnicity, national origin, sex, sexual orientation, sexual identity, religion, disability or any other basis proscribed by law.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The nominating and corporate governance committee may use a third-party search firm in those situations where particular qualifications are required or where existing contacts are not sufficient to identify an appropriate candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stockholders may recommend individuals to the nominating and corporate governance committee for consideration as potential director candidates. Any such proposals should be submitted to Carisma&#8217;s corporate secretary at Carisma&#8217;s principal executive offices and should include appropriate biographical and background material to allow the nominating and corporate governance committee to properly evaluate the potential director candidate and the number of shares of Carisma&#8217;s stock beneficially owned by the stockholder proposing the candidate. The specific requirements for the information that is required to be provided for such recommendations to be considered for an annual meeting are specified in Carisma&#8217;s by-laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming that biographical and background material has been provided on a timely basis, any recommendations received from stockholders will be evaluated in the same manner as potential nominees proposed by the nominating and corporate governance committee. If Carisma&#8217;s board of directors decides to nominate a stockholder-recommended candidate and recommends his or her election, then his or her name will be included on Carisma&#8217;s proxy card for the next annual meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Determination of Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Applicable Nasdaq rules&#160;require a majority of a listed company&#8217;s board of directors to be comprised of independent directors within one&#160;year of listing. In addition, Nasdaq rules&#160;require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and corporate governance committees be independent. Audit committee members must also satisfy the independence criteria set forth in Rule&#160;10A-3 under the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule&#160;10C-1 under the Exchange Act. Under applicable Nasdaq rules, a director will only qualify as an &#8220;independent director&#8221; if, among other things, in the opinion of the listed company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule&#160;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of Rule&#160;10C-1, the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">204</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(i)&#160;the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director; and (ii)&#160;whether the director is affiliated with Carisma or any of its subsidiaries or affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors has determined that each of its directors, with the exception of Mr.&#160;Kelly, is an &#8220;independent director&#8221; as defined under applicable Nasdaq rules, including, in the case of all the members of Carisma&#8217;s audit committee, the independence criteria set forth in Rule&#160;10A-3 under the Exchange Act, and in the case of all the members of Carisma&#8217;s compensation committee, the independence criteria set forth in Rule&#160;10C-1 under the Exchange Act. Carisma&#8217;s board of directors had determined that Chidozie Ugwumba, who resigned from Carisma&#8217;s board of directors in April&#160;2024, Regina Hodits and Bj&#246;rn Odlander, who resigned from Carisma&#8217;s board of directors in June&#160;2024, and Michael Torok, who resigned from Carisma&#8217;s board of directors in October&#160;2024, were each an &#8220;independent director&#8221; as defined under the applicable Nasdaq rules. In making such determinations, Carisma&#8217;s board of directors considered the relationships that each such non-employee director has with Carisma and all other facts and circumstances that Carisma&#8217;s board of directors deemed relevant in determining his or her independence, including the beneficial ownership of Carisma&#8217;s capital stock by each non-employee director. Mr.&#160;Kelly is not an independent director under these rules&#160;because he serves as Carisma&#8217;s President and Chief Executive Officer. There are no family relationships among any of Carisma&#8217;s directors or executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Committees of Carisma&#8217;s Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors has an established audit committee, compensation committee, nominating and corporate governance committee and science committee, each of which operates pursuant to a charter adopted by Carisma&#8217;s board of directors, and each such committee reviews its respective charter at least annually. Carisma has posted a current copy of the charter for each of the audit committee, compensation committee, nominating and corporate governance committee and science committee on the &#8220;Governance&#8221; section of the &#8220;For Investors&#8221; section of Carisma&#8217;s website, which is located at www.carismatx.com. Carisma&#8217;s board of directors also appoints from time-to-time ad hoc committees to address specific matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Audit Committee and Audit Committee Financial Expert</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The members of Carisma&#8217;s audit committee are currently Marella Thorell, Sohanya Cheng and Sanford Zweifach. Marella Thorell serves as chair of the audit committee. Michael Torok previously served as the chair of the audit committee from the closing of the Sesen Bio Merger through his resignation, effective October&#160;31, 2024. Regina Hodits served as a member of the audit committee from the closing of the Sesen Bio Merger through her resignation, effective June&#160;30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2024, Carisma&#8217;s audit committee met six times. Carisma&#8217;s audit committee&#8217;s responsibilities include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">appointing, approving the compensation of, and assessing the independence of, Carisma&#8217;s independent registered public accounting firm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing the work of Carisma&#8217;s independent registered public accounting firm, including through the receipt and consideration of reports from that firm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and discussing with management and Carisma&#8217;s independent registered public accounting firm Carisma&#8217;s annual and quarterly financial statements and related disclosures (including any interim financial statements to be included in Carisma&#8217;s periodic disclosures filed with the SEC) and Carisma&#8217;s earnings press releases;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monitoring Carisma&#8217;s internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing Carisma&#8217;s internal audit function;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">working with Carisma&#8217;s executive officers to evaluate and define the goals of Carisma&#8217;s ethics and compliance programs, evaluate the adequacy of Carisma&#8217;s internal controls over compliance and develop proposals for improving Carisma&#8217;s internal controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing Carisma&#8217;s risk assessment and risk management policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing procedures for the receipt and retention of accounting related complaints and concerns;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">205</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">meeting independently with Carisma&#8217;s internal audit advisor, if applicable, and the independent registered public accounting firm and management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving or ratifying any related person transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparing the audit committee report required by SEC rules; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conducting an annual self-evaluation of the committee&#8217;s performance.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All audit and non-audit services, other than de minimis non-audit services, to be provided to Carisma by Carisma&#8217;s independent registered public accounting firm must be approved in advance by Carisma&#8217;s audit committee. Carisma&#8217;s board of directors has determined that Marella Thorell is an &#8220;audit committee financial expert&#8221; and independent director as defined in applicable Nasdaq and SEC rules&#160;and that each of the members of Carisma&#8217;s audit committee possesses the financial sophistication required for audit committee members under Nasdaq rules. Carisma believes that the composition of Carisma&#8217;s audit committee meets the requirements for independence under current Nasdaq and SEC rules&#160;and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Compensation Committee</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The members of Carisma&#8217;s compensation committee are currently Briggs Morrison, M.D., Sohanya Cheng and Sanford Zweifach. Dr.&#160;Morrison serves as chair of the compensation committee. During 2024, Carisma&#8217;s compensation committee met four times. Carisma&#8217;s compensation committee&#8217;s responsibilities include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving, or making recommendations to Carisma&#8217;s board of directors with respect to, the compensation of the chief executive officer and other executive officers, taking into consideration the executive officer&#8217;s performance as it relates to both legal compliance and compliance with Carisma&#8217;s internal policies and procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving termination benefits and separation pay to executive officers, taking into consideration the circumstances surrounding the particular executive officer&#8217;s departure and performance as it relates to both legal compliance and compliance with Carisma&#8217;s internal policies and procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing an evaluation of Carisma&#8217;s senior executives, including the establishment of corporate goals and objectives applicable to the chief executive officer and other executive officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving, or making recommendations to Carisma&#8217;s board of directors with respect to, the terms of any binding offer letters, employment agreements, termination agreements or arrangements, change-in-control agreements, severance agreements, indemnification agreements or other material compensatory agreements with the chief executive officer or the other executive officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and making recommendations to Carisma&#8217;s board of directors with respect to incentive-compensation and equity-based plans that are subject to approval by Carisma&#8217;s board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing and administering Carisma&#8217;s stock option, stock incentive, employee stock purchase and other equity-based plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retaining the services, following the determination of independence under applicable Nasdaq and Exchange Act rules, of Carisma&#8217;s compensation consultant, as well as overseeing and considering the recommendations of the compensation consultant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and making recommendations to Carisma&#8217;s board of directors with respect to director compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing, if deemed advisable by Carisma&#8217;s board of directors, and monitoring compliance with, stock ownership guidelines for the chief executive officer, directors and other executive officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and discussing annually with management the compensation disclosure required by SEC rules;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparing the compensation committee report required by SEC rules; and</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">206</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conducting an annual self-assessment of the committee and its charter.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under its charter, the compensation committee may form, and delegate authority to, subcommittees, consisting of non-employee directors, as it deems appropriate. During 2024, the compensation committee did not form or delegate authority to such subcommittees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, under its charter, the compensation committee may delegate to one or more executive officers the power to grant options or other stock awards pursuant to the Carisma Therapeutics&#160;Inc. Amended and Restated 2014 Stock Incentive Plan (the &#8220;2014 Plan&#8221;), to employees who are not directors or executive officers of Carisma. During 2024, the compensation committee delegated to the chief executive officer authority to grant stock options under the 2014 Plan to employees who are not directors, officers or employees at the vice president level or above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma believes that the composition of its compensation committee meets the requirements for independence under current Nasdaq and SEC rules&#160;and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Nominating and Corporate Governance Committee</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The members of Carisma&#8217;s nominating and corporate governance committee are currently John Hohneker, M.D., Briggs Morrison, M.D. and Sanford Zweifach. Dr.&#160;Hohneker serves as chair of the nominating and corporate governance committee. Bj&#246;rn Odlander, M.D., Ph.D. previously served as the chair of the nominating and corporate governance committee from the closing of the Sesen Bio Merger through his resignation, effective October&#160;31, 2024. During 2024, Carisma&#8217;s nominating and corporate governance committee met two times. Carisma&#8217;s nominating and corporate governance committee&#8217;s responsibilities include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying individuals qualified to become members of Carisma&#8217;s board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recommending to Carisma&#8217;s board of directors the persons to be nominated for election as directors and to each of the board of director&#8217;s committees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and making recommendations to Carisma&#8217;s board of directors with respect to board leadership structure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and making recommendations to Carisma&#8217;s board of directors with respect to management planning;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and recommending to Carisma&#8217;s board of directors the corporate governance guidelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing an annual evaluation of Carisma&#8217;s board of directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conducting an annual self-assessment of the committee and its charter.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma believes that the composition of its nominating and corporate governance committee meets the requirements for independence under current Nasdaq and SEC rules&#160;and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Science Committee</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The members of Carisma&#8217;s science committee are currently David Scadden, M.D., Briggs Morrison, M.D. and John Hohneker, M.D. Dr.&#160;Scadden serves as chair of the science committee. Regina Hodits served as a member of the science committee from the closing of the Sesen Bio Merger through her resignation, effective June&#160;30, 2024. During 2024, Carisma&#8217;s science committee met three times. Carisma&#8217;s science committee&#8217;s responsibilities include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and advising on the overall strategy, direction and effectiveness of Carisma&#8217;s research and development (&#8220;R&amp;D&#8221;) initiatives, programs and related investments, and on Carisma&#8217;s progress in achieving Carisma&#8217;s long-term strategic R&amp;D goals and objectives, including pre-clinical studies and clinical trial design;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and advising on opportunities and risks associated with Carisma&#8217;s R&amp;D initiatives, programs and related investments;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">207</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and advising on Carisma&#8217;s significant medical affairs strategies and initiatives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and advising on trends and innovation in R&amp;D to enhance Carisma&#8217;s R&amp;D capabilities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conducting a periodic self-assessment of the science committee and its charter.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board of Directors Meetings and Attendance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors recognizes the importance of director attendance at board and committee meetings. The full board of directors met seven times during 2024. During 2024, each member of the board of directors attended in person or participated in 75.0% or more of the aggregate of (i)&#160;the total number of meetings held by the board of directors (during the period that such person served as a director) and (ii)&#160;the total number of meetings held by all committees of the board of directors on which such person served (during the periods that such person served).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Director Attendance at Annual Meeting of Stockholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s corporate governance guidelines provide that directors are responsible for attending the annual meeting of stockholders. Four of seven then-serving directors attended Carisma&#8217;s 2024 annual meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Business Conduct and Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma has adopted a written code of business conduct and ethics that applies to Carisma&#8217;s directors, officers and employees, including Carisma&#8217;s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Carisma has posted a current copy of the code on the &#8220;Governance&#8221; section of the &#8220;For Investors&#8221; section of Carisma&#8217;s website, which is located at www.carismatx.com. In addition, Carisma intends to post on its website all disclosures that are required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate Governance Guidelines</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors has adopted corporate governance guidelines to assist the board of directors in the exercise of its duties and responsibilities and to serve the best interests of Carisma and Carisma&#8217;s stockholders. These guidelines provide that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the principal responsibility of Carisma&#8217;s board of directors is to oversee Carisma&#8217;s management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a majority of the members of the board of directors must be independent directors, unless otherwise permitted by Nasdaq rules;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the independent directors meet in executive session semi-annually;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">directors have full and free access to management and, as necessary, independent advisors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new directors participate in an orientation program and all directors are expected to participate in continuing director education on an ongoing basis; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carisma&#8217;s nominating and corporate governance committee will oversee an annual self-evaluation of the board of directors to determine whether it and its committees are functioning effectively.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A copy of the corporate governance guidelines is available on the &#8220;Governance&#8221; section of the &#8220;For Investors&#8221; section of Carisma&#8217;s website, which is located at www.carismatx.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Leadership</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Sanford Zweifach serves as Chair of Carisma&#8217;s board of directors. Carisma&#8217;s board of directors has determined that the roles of Chair of the board and Chief Executive Officer should be bifurcated at this time. Carisma&#8217;s board of directors believes that separating </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">208</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the Chair and Chief Executive Officer positions allows the Chief Executive Officer to focus on Carisma&#8217;s operations instead of board administration, encourages objective oversight, and is the appropriate leadership structure for Carisma at this time. Additionally, Carisma&#8217;s board of directors believes this leadership structure is particularly appropriate for Carisma given Mr.&#160;Zweifach&#8217;s extensive experience in the biopharmaceutical industry and service on the boards of other public and private biopharmaceutical companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Chair of Carisma&#8217;s board of directors and an independent director, Mr.&#160;Zweifach&#8217;s responsibilities include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">chairing meetings of the independent directors in executive session;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">meeting with any director who is not adequately performing such director&#8217;s duties as a member of Carisma&#8217;s board of directors or any committee;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilitating communications between other members of Carisma&#8217;s board of directors and Carisma&#8217;s Chief Executive Officer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monitoring, with the assistance of Carisma&#8217;s legal advisors, communications from stockholders and other interested parties and providing copies or summaries to the other directors as he or she considers appropriate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">working with Carisma&#8217;s Chief Executive Officer in the preparation of the agenda for each board meeting and in determining the need for special meetings of Carisma&#8217;s board of directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise consulting with Carisma&#8217;s Chief Executive Officer on matters relating to corporate governance and board performance.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors believes its administration of its risk oversight function has not affected its leadership structure. Carisma&#8217;s board of directors believes that Carisma currently has an appropriate leadership structure for Carisma, which demonstrates Carisma&#8217;s commitment to good corporate governance. Carisma&#8217;s nominating and corporate governance committee evaluates Carisma&#8217;s board leadership structure from time to time and may recommend further alterations of this structure in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risk is inherent with every business and how well a business manages risk can ultimately determine its success. Carisma faces a number of risks, including those described under &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; in this proxy statement/prospectus. Carisma&#8217;s board of directors is actively involved in oversight of risks that could affect Carisma. Carisma&#8217;s board of directors oversees Carisma&#8217;s risk management processes directly and through its committees. Carisma&#8217;s management is responsible for risk management on a day-to-day basis and Carisma&#8217;s board of directors and its committees oversee the risk management activities of management. Carisma&#8217;s board of directors satisfies this responsibility through full reports by each committee chair regarding the committee&#8217;s considerations and actions, as well as through regular reports directly from officers responsible for oversight of particular risks within Carisma. Carisma&#8217;s audit committee oversees risk management activities related to financial controls and legal and compliance risks. Oversight by the audit committee includes direct communication with Carisma&#8217;s independent registered public accounting firm. Carisma&#8217;s compensation committee oversees risk management activities relating to Carisma&#8217;s compensation policies and practices and assesses whether any of Carisma&#8217;s compensation policies or programs has the potential to encourage excessive risk-taking. Oversight by the compensation committee includes direct communication with Carisma&#8217;s independent compensation consultants. Carisma&#8217;s nominating and corporate governance committee oversees risk management activities relating to board and committee composition, management succession planning and corporate sustainability efforts, including the impact of environmental and social issues. Carisma&#8217;s research and development committee assists the board&#8217;s oversight of Carisma&#8217;s research and development activities. In addition, members of Carisma&#8217;s senior management team attend Carisma&#8217;s quarterly board meetings and are available to address any questions or concerns raised by the board of directors on major risk exposures, the potential impact of such risks, risk management and any other matters. Carisma&#8217;s board of directors believes that full and open communication between management and the board of directors is essential for effective risk management and oversight.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">209</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Communication with Carisma&#8217;s Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any interested party with concerns about Carisma may report such concerns to the board of directors, or the chairman of Carisma&#8217;s board of directors, or otherwise the chair of the nominating and corporate governance committee, by submitting a written communication to the attention of such director at the following address:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Carisma Therapeutics&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3675 Market Street, Suite&#160;401</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Philadelphia, Pennsylvania 19104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Attention: Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You may submit your concern anonymously or confidentially by mail. You may also indicate whether you are a stockholder, customer, supplier, or other interested party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A copy of any such written communication may also be forwarded to Carisma&#8217;s legal counsel and a copy of such communication may be retained for a reasonable period of time. The director(s)&#160;may discuss the matter with Carisma&#8217;s legal counsel, with independent advisors, with non-management directors, or with Carisma&#8217;s management, or may take other action or no action as the director determines in good faith, using reasonable judgment, and discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Communications may be forwarded to all directors if they relate to important substantive matters and include suggestions or comments that may be important for the directors to know. In general, communications relating to corporate governance and long-term corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances, and matters as to which Carisma tends to receive repetitive or duplicative communications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The audit committee oversees the procedures for the receipt, retention, and treatment of complaints received by Carisma regarding accounting, internal accounting controls, or auditing matters, and the confidential, anonymous submission by Carisma&#8217;s employees of concerns regarding questionable accounting or auditing matters. Concerns regarding questionable accounting or auditing matters or complaints regarding accounting, internal accounting controls or auditing matters may be confidentially, and anonymously if they wish, submitted in writing online at&#160;<span style="font-style:italic;font-weight:bold;">www.whistleblowerservices.com/carm</span>&#160;or to Carisma&#8217;s principal executive officer or principal financial officer at 3675 Market Street, Suite&#160;401, Philadelphia, Pennsylvania 19104 or via the toll-free telephone number 866-822-6485.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Insider Trading Policy; Anti-Hedging and Pledging</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma has adopted an insider trading policy governing the purchase, sale and/or other dispositions of Carisma&#8217;s securities by Carisma&#8217;s directors, officers, employees and other covered persons. Carisma believes the insider trading policy is reasonably designed to promote compliance with insider trading laws, rules&#160;and regulations, and Nasdaq listing standards. A copy of Carisma&#8217;s insider trading policy is filed as Exhibit&#160;19.1 to Carisma&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2024. Carisma also does not engage in transactions in Carisma&#8217;s securities while in possession of material nonpublic information concerning Carisma or its securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s insider trading policy, among other things, expressly prohibits Carisma&#8217;s directors, officers, employees and other covered persons from engaging in any short sales, including short sales &#8220;against the box&#8221;, any purchases or sales of puts, calls or other derivative securities, or any purchases of financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds) that hedge or offset, or are designed to hedge or offset, any decrease in the market value of Carisma&#8217;s securities. In addition, Carisma&#8217;s insider trading policy expressly prohibits such persons from purchasing Carisma&#8217;s securities on margin, borrowing against Carisma&#8217;s securities held in a margin account, or pledging Carisma&#8217;s securities as collateral for a loan, with an exception in extraordinary situations for pledges of Carisma&#8217;s securities as collateral for a loan (other than a margin loan) only after certain prerequisites are met and only with the preapproval of Carisma&#8217;s principal financial officer or general counsel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">210</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b8b8f6ac_76e1_4d23_96bf_a4c7314216e8"></a><a id="CARISMAEXECUTIVECOMPENSATION_762390"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA EXECUTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following information and all other information contained in this proxy statement/prospectus does not give effect to the contemplated reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Executive Compensation Processes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s executive compensation program is administered by the compensation committee of Carisma&#8217;s board of directors, subject to the oversight and approval of Carisma&#8217;s board of directors. Carisma&#8217;s compensation committee reviews Carisma&#8217;s executive compensation practices on an annual basis and based on this review approves, or, as appropriate, makes recommendations to Carisma&#8217;s board of directors for approval of, Carisma&#8217;s executive compensation program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In designing Carisma&#8217;s executive compensation program, Carisma&#8217;s compensation committee considers compensation data from comparable publicly traded companies in the biotechnology and the biopharmaceutical industry (based on, among other things, industry market capitalization, headcount and location) provided by Carisma&#8217;s independent compensation consultant, Pearl Meyer&#160;&amp; Partners LLC (&#8220;Pearl Meyer&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2024, Carisma&#8217;s compensation committee retained Pearl Meyer to advise the compensation committee on Carisma&#8217;s compensation program for executive officers, which includes base salaries, annual performance-based cash bonuses, annual equity incentive awards and severance arrangements. The compensation committee established a peer group. The compensation consultants made recommendations with respect to the amount and form of executive officer. Although Carisma&#8217;s compensation committee considers the advice and guidance of the compensation consultants as to Carisma&#8217;s executive compensation program, Carisma&#8217;s compensation committee ultimately makes its own decisions about these matters. In the future, Carisma expects that its compensation committee will continue to engage independent compensation consultants to provide additional guidance on Carisma&#8217;s executive compensation programs and to conduct further competitive benchmarking against a peer group of publicly traded companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s compensation committee reviewed information regarding the independence and potential conflicts of interest of Pearl Meyer, taking into account, among other things, the factors set forth in the Nasdaq listing standards. Based on such review, Carisma&#8217;s compensation committee concluded that the engagement of Pearl Meyer did not raise any conflict of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Named Executive Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Set forth below is information regarding the compensation of each of Carisma&#8217;s named executive officers for the&#160;years ended December&#160;31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s named executive officers for the&#160;year ended December&#160;31, 2024 are (i)&#160;Steven Kelly, Carisma&#8217;s current President and Chief Executive Officer, (ii)&#160;Richard Morris, Carisma&#8217;s former Chief Financial Officer, and (iii)&#160;Michael Klichinsky, Carisma&#8217;s current Chief Scientific Officer (together, the &#8220;Carisma NEOs&#8221;).</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">211</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information regarding compensation awarded to, earned by or paid to each of the Carisma NEOs for the&#160;years ended December&#160;31, 2024 and 2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name and Principal Position</b></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Salary</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Bonus</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Awards</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-equity</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">incentive&#160;plan</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">compensation</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">All</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">other</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">compensation</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total($)</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Steven Kelly</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2024</p></td><td style="vertical-align:bottom;width:2.88%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">600,000</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">247,500</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">855,300</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,250</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,720,050</p></td></tr><tr><td style="vertical-align:bottom;width:18.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><i style="font-style:italic;">Current President&#160;&amp;</i><i style="font-style:italic;"><br/></i><i style="font-style:italic;">Chief Executive Officer</i></p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2023</p></td><td style="vertical-align:bottom;width:2.88%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.25%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">460,833</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">301,840</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,717,517</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,235</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,504,425</p></td></tr><tr><td style="vertical-align:bottom;width:18.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Richard Morris<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2024</p></td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">486,000</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">656,606</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">697,650</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,840,256</p></td></tr><tr><td style="vertical-align:bottom;width:18.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><i style="font-style:italic;">Former Chief Financial Officer</i></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2023</p></td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">384,302</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">183,064</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,077,948</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,487</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,662,801</p></td></tr><tr><td style="vertical-align:bottom;width:18.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Klichinsky,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Pharm.D., Ph.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2024</p></td><td style="vertical-align:bottom;width:2.88%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.25%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">463,000</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">138,900</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">363,580</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,250</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">982,730</p></td></tr><tr><td style="vertical-align:bottom;width:18.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><i style="font-style:italic;">Current Chief Scientific Officer</i></p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2023</p></td><td style="vertical-align:bottom;width:2.88%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.25%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">345,625</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">164,640</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,077,948</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,164</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,603,377</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The amounts in the &#8220;Bonus&#8221; column reflect the amount of compensation earned by the Carisma NEOs under the applicable annual bonus program during each fiscal&#160;year. See &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Bonus Compensation</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; below for additional information.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The amounts reported in the &#8220;Option Awards&#8221; column reflect the grant date fair value of options awarded during the&#160;year ended December&#160;31, 2024, computed in accordance with the provisions of Financial Accounting Standards Board Accounting Standard Codification (&#8220;FASB ASC Topic 718&#8221;), and for Mr.&#160;Morris also includes $293,026 of incremental fair value related to options that were modified in December&#160;2024, computed as of the modification date in accordance with FASB ASC Topic 718. Assumptions used in the calculation of these amounts are included in Note&#160;10 to Carisma&#8217;s audited financial statements included in this proxy statement/prospectus. These amounts reflect the accounting cost for these stock options and do not reflect the actual economic value that may be realized by each Carisma NEO upon the vesting of the stock options, the exercise of the stock options or the sale of Carisma&#8217;s common stock underlying such stock options. For more information about the modification of Mr.&#160;Morris&#8217; option grants, &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Employment Agreements with Named Executive Officers&#160;&#8212; Agreement with Richard Morris</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; below.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For Mr.&#160;Kelly and Dr.&#160;Klichinsky this amount represents 401(k)&#160;matching contributions. For Mr.&#160;Morris, this amount includes 401(k)&#160;matching contributions of $17,250 and separation payments pursuant to the Morris Employment Agreement (as defined below) of $680,400 during the&#160;year ended December&#160;31, 2024. The separation payments are described in more detail under &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Employment Agreements with Named Executive Officers&#160;&#8212; Agreement with Richard Morris</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; below.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mr.&#160;Morris ceased providing services to Carisma on December&#160;31, 2024 in connection with Carisma&#8217;s previously announced reduction in force.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mr.&#160;Kelly commenced services as President&#160;&amp; Chief Executive Officer of Carisma on March&#160;7, 2023. The amounts for 2023 reflect the compensation paid to Mr.&#160;Kelly as President and Chief Executive Officer of Carisma after the closing of the Sesen Bio Merger.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mr.&#160;Morris commenced services as Chief Financial Officer of Carisma on March&#160;7, 2023. The amounts for 2023 reflect the compensation paid to Mr.&#160;Morris as Chief Financial Officer of Carisma after the closing of the Sesen Bio Merger.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr.&#160;Klichinsky commenced services as Chief Scientific Officer of Carisma on March&#160;7, 2023. The amounts for 2023 reflect the compensation paid to Dr.&#160;Klichinsky as Chief Scientific Officer of Carisma after the closing of the Sesen Bio Merger.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Narrative Disclosure to Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Base Salaries</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma uses base compensation, or salaries, to recognize the experience, skills, knowledge and responsibilities required of Carisma&#8217;s executive officers.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">212</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2024, Carisma paid Mr.&#160;Kelly, Mr.&#160;Morris and Dr.&#160;Klichinsky an annual base compensation of $600,000, $486,000 and $463,000, respectively. As of January&#160;1, 2025, Mr.&#160;Kelly&#8217;s and Dr.&#160;Klichinsky&#8217;s annual base compensation was increased to $624,000 and $494,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From March&#160;7, 2023, after the completion of the Sesen Bio Merger, to December&#160;31, 2023, Mr.&#160;Kelly&#8217;s, Mr.&#160;Morris&#8217; and Dr.&#160;Klichinsky&#8217;s annual base compensation was increased to $560,000, $467,000 and $420,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From January&#160;1, 2023 through March&#160;7, 2023, Legacy Carisma paid Mr.&#160;Kelly, Mr.&#160;Morris and Dr.&#160;Klichinsky an annual base compensation of $440,000, $400,000 and $340,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Bonus Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors may, in its discretion, approve and award bonuses to Carisma&#8217;s executive officers from time to time. Performance-based bonuses are calculated as a&#160;percentage of base compensation or salary and are designed to motivate Carisma&#8217;s executive officers to achieve annual goals based on Carisma&#8217;s strategic, financial and operating performance objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2024, Mr.&#160;Kelly&#8217;s, Mr.&#160;Morris&#8217; and Dr.&#160;Klichinsky&#8217;s target annual bonus was equal to 55.0%, 40.0% and 40.0% of his base salary, respectively. Taking into account Carisma&#8217;s achievement of 75.0% of its targeted 2024 corporate performance goals as determined by Carisma&#8217;s board of directors, Mr.&#160;Kelly&#8217;s and Dr.&#160;Klichinsky&#8217;s 2024 bonus compensation was $247,500 and $138,900, respectively. Mr.&#160;Morris was terminated on December&#160;31, 2024 as part of a reduction in force. Per the terms of his employment agreement, he received a bonus of $194,400 based on 100.0% of his annual target, which is included in &#8220;All Other Compensation&#8221; in the Summary Compensation Table above and is described under &#8220;<i style="font-style:italic;">Employment Agreements with Named Executive Officers&#160;&#8212; Agreement with Richard Morris</i>&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2023, Mr.&#160;Kelly&#8217;s, Mr.&#160;Morris&#8217; and Dr.&#160;Klichinsky&#8217;s target annual bonus was equal to 55.0%, 40.0% and 40.0% of his base salary, respectively. Taking into account Carisma&#8217;s achievement of 98.0% of its targeted 2023 corporate performance goals as determined by Carisma&#8217;s board of directors, Mr.&#160;Kelly&#8217;s, Mr.&#160;Morris&#8217; and Dr.&#160;Klichinsky&#8217;s 2023 bonus compensation was $301,840, $183,064 and $164,640, respectively. In addition, the Legacy Carisma board of directors awarded special bonuses of $50,000, $30,000 and $10,000, respectively, to Mr.&#160;Kelly, Mr.&#160;Morris and Dr.&#160;Klichinsky in recognition of their valuable and extensive contribution in connection with the Sesen Bio Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Performance-based bonuses, which are calculated as a&#160;percentage of base compensation or salary, are designed to motivate Carisma&#8217;s executive officers to achieve annual goals based on Carisma&#8217;s strategic, financial and operating performance objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Incentives</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although Carisma does not have a formal policy with respect to the grant of equity incentive awards to Carisma&#8217;s executive officers, Carisma believes that equity grants provide its executives with a strong link to Carisma&#8217;s long-term performance, create an ownership culture and help to align the interests of Carisma&#8217;s executive officers and Carisma&#8217;s stockholders. Accordingly, Carisma uses stock options to compensate Carisma&#8217;s executive officers in the form of initial grants in connection with the commencement of employment and also at various other times, based on performance. In addition, Carisma believes that equity grants vesting over a four-year period promote executive retention because this feature incentivizes executive officers to remain in Carisma&#8217;s employment during the vesting period. Prior to completion of the Sesen Bio Merger, all Carisma options were granted pursuant to the CARISMA Therapeutics&#160;Inc. 2017 Stock Incentive Plan the (&#8220;2017 Plan&#8221;). Upon completion of the Sesen Bio Merger, the 2017 Plan was assumed by Carisma. Option awards issued to Carisma&#8217;s executives during the 2023 fiscal&#160;year were granted pursuant to the 2014 Plan which Carisma adopted on March&#160;7, 2023. See &#8220;<i style="font-style:italic;">2014 Plan</i>&#8221; below for additional information. Prior to the exercise of an option under the 2014 Plan, the holder has no rights as a stockholder with respect to the shares subject to such option, including no voting rights and no right to receive dividends or dividend equivalents. Carisma has historically granted stock options with exercise prices equal to the fair market value of Carisma&#8217;s common stock on the date of grant as determined by Carisma&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2025, Carisma granted option awards with respect to 500,000 and 221,000 shares of Carisma&#8217;s common stock to Mr.&#160;Kelly and Dr.&#160;Klichinsky, respectively. The shares underlying these option awards vest over four&#160;years in equal&#160;monthly installments, subject to continued service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In June&#160;2024, Carisma granted an option award with respect to 125,000 shares of Carisma&#8217;s common stock to Mr.&#160;Kelly and option awards with respect to 85,000 shares of Carisma&#8217;s common stock to each of Mr.&#160;Morris and Dr.&#160;Klichinsky. The shares </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">213</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">underlying these option awards vest over two&#160;years, with 50.0% of the shares vesting on June&#160;17, 2025 and the remaining 50.0% of the shares vesting on June&#160;17, 2026, subject to continued service. In connection with Mr.&#160;Morris&#8217; termination which became effective December&#160;31, 2024, Carisma&#8217;s board of directors approved the acceleration of the first 50.0% installment of the special retention option to purchase 85,000 shares of Carisma&#8217;s common stock granted to Mr.&#160;Morris with an effective grant date of June&#160;17, 2024, which would have vested in June&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2024, Carisma granted an option award with respect to 438,000 shares of Carisma&#8217;s common stock to Mr.&#160;Kelly and option awards with respect to 170,500 shares of Carisma&#8217;s common stock to each of Mr.&#160;Morris and Dr.&#160;Klichinsky. The shares underlying these option awards vest over four&#160;years in equal&#160;monthly installments, subject to continued service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2023, Carisma granted an option award with respect to 600,000 shares to Mr.&#160;Kelly and option awards with respect to 238,000 shares of Carisma&#8217;s common stock to each of Mr.&#160;Morris and Dr.&#160;Klichinsky. The shares underlying these option awards vest over four&#160;years, with 25.0% of the shares vesting on June&#160;6, 2024 and the remaining 75.0% of the shares vesting over the next three&#160;years thereafter in equal&#160;monthly installments until June&#160;6, 2027, subject to continued service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Outstanding Equity Awards at December&#160;31, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information regarding all outstanding equity awards held by each of the Carisma NEOs as of December&#160;31, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;securities</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">underlying&#160;unexercised</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">options&#160;(#)&#160;exercisable</b></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;securities</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">underlying&#160;unexercised</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">options&#160;(#)&#160;unexercisable</b></p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">exercise</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">expiration</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">date</b></p></td></tr><tr><td style="vertical-align:top;width:31.97%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Steven Kelly</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">625,797</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.63</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9/18/2028</p></td></tr><tr><td style="vertical-align:bottom;width:31.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">381,304</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">34,664</p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.46</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3/31/2031</p></td></tr><tr><td style="vertical-align:bottom;width:31.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">225,000</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">375,000</p></td><td style="vertical-align:bottom;width:2.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.25</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6/6/2033</p></td></tr><tr><td style="vertical-align:bottom;width:31.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100,375</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">337,625</p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.10</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1/31/2034</p></td></tr><tr><td style="vertical-align:bottom;width:31.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">125,000</p></td><td style="vertical-align:bottom;width:2.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.03</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6/17/2034</p></td></tr><tr><td style="vertical-align:top;width:31.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Richard Morris</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">289,718</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.46</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/31/2025</p></td></tr><tr><td style="vertical-align:bottom;width:31.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">89,248</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.25</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/31/2025</p></td></tr><tr><td style="vertical-align:bottom;width:31.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">39,073</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.10</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/31/2025</p></td></tr><tr><td style="vertical-align:bottom;width:31.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">42,500</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.03</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/31/2025</p></td></tr><tr><td style="vertical-align:top;width:31.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Klichinsky, Pharm.D., Ph.D.</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">56,982</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.11</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11/01/2027</p></td></tr><tr><td style="vertical-align:bottom;width:31.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">75,976</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;width:2.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.63</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10/21/2028</p></td></tr><tr><td style="vertical-align:bottom;width:31.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">102,704</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9,360</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(10)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.46</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3/31/2031</p></td></tr><tr><td style="vertical-align:bottom;width:31.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">89,248</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">148,752</p></td><td style="vertical-align:top;width:2.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(11)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.25</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6/6/2033</p></td></tr><tr><td style="vertical-align:bottom;width:31.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">39,073</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">131,427</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(12)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.10</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1/31/2034</p></td></tr><tr><td style="vertical-align:bottom;width:31.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">85,000</p></td><td style="vertical-align:top;width:2.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(13)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.03</p></td><td style="vertical-align:bottom;width:1.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6/17/2034</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option award is fully vested.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option award vests over four&#160;years, with 25.0% of the shares vested on April&#160;1, 2022 and 2.0833% of the original number of shares vested thereafter in equal&#160;monthly installments through April&#160;1, 2025, subject to continued service.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option award vests over four&#160;years, with 25.0% of the shares vested on June&#160;6, 2023 and 2.0833% of the original number of shares vested thereafter in equal&#160;monthly installments through June&#160;6, 2027, subject to continued service.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option award vests over four&#160;years with 2.0833% of the original number of shares vested thereafter in equal&#160;monthly installments through January&#160;31, 2028, subject to continued service.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option award vests over two&#160;years, with 50.0% of the shares vesting on June&#160;17, 2025 and 50.0% of the remaining shares vesting on June&#160;17, 2026, subject to continued service.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option award ceased to vest upon Mr.&#160;Morris&#8217; termination on December&#160;31, 2024.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">214</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In connection with Mr.&#160;Morris&#8217; termination which became effective December&#160;31, 2024, Carisma&#8217;s board of directors approved the acceleration of the first 50.0% installment of the special retention option to purchase 85,000 shares of common stock granted to Mr.&#160;Morris with an effective grant date of June&#160;17, 2024, which would have vested in June&#160;2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option award is fully vested.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(9)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option award is fully vested.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(10)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option award vests over four&#160;years, with 25.0% of the shares vested on April&#160;1, 2022 and 2.0833% of the original number of shares vested thereafter in equal&#160;monthly installments through April&#160;1, 2025, subject to continued service.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(11)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option award vests over four&#160;years, with 25.0% of the shares vested on June&#160;6, 2023 and 2.0833% of the original number of shares vested thereafter in equal&#160;monthly installments through June&#160;6, 2028, subject to continued service.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(12)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option award vests over four&#160;years with 2.0833% of the original number of shares vested thereafter in equal&#160;monthly installments through January&#160;31, 2028, subject to continued service.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(13)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option award vests over two&#160;years, with 50.0% of the shares vesting on June&#160;17, 2025 and 50.0% of the remaining shares vesting on June&#160;17, 2026, subject to continued service.</span></td></tr></table><div style="margin-top:12pt;"><a id="EmploymentAgreementswithNamedExecutiveOf"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employment Agreements with Named Executive Officers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effective as of the effective time of the Sesen Bio Merger, Carisma&#8217;s board of directors appointed Steven Kelly as Carisma&#8217;s President and Chief Executive Officer, Richard Morris as Carisma&#8217;s Chief Financial Officer and Michael Klichinsky, Pharm.D., Ph.D. as Carisma&#8217;s Chief Scientific Officer, each to serve at the discretion of Carisma&#8217;s board of directors. Carisma entered into written employment agreements with each of the Carisma NEOs. These agreements set forth the terms of the executive officer&#8217;s compensation, including base salary, annual discretionary bonus eligibility and severance benefits, among other matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agreement with Steven Kelly</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma entered into an employment agreement with Mr.&#160;Kelly (the &#8220;Kelly Employment Agreement&#8221;), effective as of March&#160;7, 2023, pursuant to which Mr.&#160;Kelly serves as Carisma&#8217;s President and Chief Executive Officer. The Kelly Employment Agreement provides for Mr.&#160;Kelly&#8217;s at-will employment and an annual base salary of $560,000, an annual bonus with a target amount equal to 55.0% of his base salary, as well as his ability to participate in Carisma&#8217;s employee benefit plans generally on the same basis as other similarly-situated employees. In November&#160;2023, the Carisma&#8217;s compensation committee approved an increase in Mr.&#160;Kelly&#8217;s annual salary from $560,000 to $600,000, effective January&#160;1, 2024. In December&#160;2024, Carisma&#8217;s compensation committee approved an increase in Mr.&#160;Kelly&#8217;s annual salary from $600,000 to $624,000, effective January&#160;1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Kelly Employment Agreement also provides that if his employment is terminated either (i)&#160;by Carisma without Cause or (ii)&#160;by him with Good Reason (each as defined in the Kelly Employment Agreement), in either case within the Change in Control Period, then Mr.&#160;Kelly will be entitled to receive, subject to his execution and non-revocation of a release of claims in favor of Carisma and compliance with all post-employment obligations under law or any restrictive covenant agreement with Carisma, (a)&#160;a lump sum payment of (x)&#160;eighteen&#160;months of base salary and (y)&#160;an amount equal to 150.0% of his target bonus for the&#160;year of termination (or, if higher, his target bonus immediately prior to the Change in Control), (b)&#160;a lump sum payment equal to 100.0% of his target bonus for the&#160;year of termination (or, if higher, based on the target bonus immediately prior to the Change in Control) pro-rated based on the number of&#160;days he was employed during the calendar&#160;year in which his termination occurs, (c)&#160;COBRA health continuation for up to eighteen&#160;months and (d)&#160;100.0% acceleration of all outstanding and unvested stock-based awards subject to time-based vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Kelly Employment Agreement also provides that if his employment is terminated either (i)&#160;by Carisma without Cause or (ii)&#160;by him with Good Reason, in either case outside the Change in Control Period, then Mr.&#160;Kelly will be entitled to receive, subject to his execution and non-revocation of a release of claims in favor of Carisma and compliance with all post-employment obligations under law or any restrictive covenant agreement with Carisma, (a)&#160;12&#160;months of base salary payable over a period of 12&#160;months following such termination, (b)&#160;a lump sum payment equal to 100.0% of his target bonus for the&#160;year of termination, pro-rated based on the number of&#160;days he was employed during the calendar&#160;year in which his termination occurs, and (c)&#160;COBRA health continuation for up to 12&#160;months. The Kelly Employment Agreement contains a Section&#160;280G limited cutback, in which Mr.&#160;Kelly is entitled to </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">215</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">receive the greater of (a)&#160;the best net after-tax amount of any payments that are subject to the excise tax imposed by Section&#160;4999 of the Code, calculated in a manner consistent with Section&#160;280G of the Code, and (b)&#160;the amount of parachute payments he would be entitled to receive if they were reduced to an amount equal to one dollar less than the amount at which Mr.&#160;Kelly becomes subject to excise tax imposed by Section&#160;4999 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agreement with Richard Morris</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma entered into an employment agreement with Mr.&#160;Morris (the &#8220;Morris Employment Agreement&#8221;), effective as of March&#160;7, 2023, pursuant to which Mr.&#160;Morris serves as Carisma&#8217;s Chief Financial Officer. The Morris Employment Agreement provided for Mr.&#160;Morris&#8217; at-will employment and an annual base salary of $467,000, an annual bonus with a target amount equal to 40.0% of his base salary, as well as his ability to participate in Carisma&#8217;s employee benefit plans generally on the same basis as other similarly-situated employees. In November&#160;2023, Carisma&#8217;s compensation committee approved an increase in Mr.&#160;Morris&#8217; annual salary from $467,000 to $486,000, effective January&#160;1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Morris Employment Agreement also provided that if his employment was terminated either (i)&#160;by Carisma without Cause or (ii)&#160;by him with Good Reason (each as defined in the Morris Employment Agreement), in either case within Change in Control Period, then Mr.&#160;Morris would be entitled to receive, subject to his execution and non-revocation of a release of claims in favor of Carisma and compliance with all post-employment obligations under law or any restrictive covenant agreement with Carisma, (a)&#160;a lump sum payment of (x)&#160;12&#160;months of base salary and (y)&#160;an amount equal to 100.0% of his target bonus for the&#160;year of termination (or, if higher, his target bonus immediately prior to the Change in Control), (b)&#160;a lump sum payment equal to 100.0% of his target bonus for the&#160;year of termination (or, if higher, based on the target bonus immediately prior to the Change in Control) pro-rated based on the number of&#160;days he was employed during the calendar&#160;year in which his termination occurs, (c)&#160;COBRA health continuation for up to 12&#160;months and (d)&#160;100.0% acceleration of all outstanding and unvested stock-based awards subject to time-based vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Morris Employment Agreement also provided that if his employment was terminated either (i)&#160;by Carisma without Cause or (ii)&#160;by him with Good Reason, in either case outside the Change in Control Period, then Mr.&#160;Morris would be entitled to receive, subject to his execution and non-revocation of a release of claims in favor of Carisma and compliance with all post-employment obligations under law or any restrictive covenant agreement with Carisma, (a)&#160;12&#160;months of base salary payable over a period of 12&#160;months following such termination, (b)&#160;a lump sum payment equal to 100.0% of his target bonus for the&#160;year of termination, pro-rated based on the number of&#160;days he was employed during the calendar&#160;year in which his termination occurs, and (c)&#160;COBRA health continuation for up to 12&#160;months. The Morris Employment Agreement contained a Section&#160;280G limited cutback, in which Mr.&#160;Morris was entitled to receive the greater of (a)&#160;the best net after-tax amount of any payments that are subject to the excise tax imposed by Section&#160;4999 of the Code, calculated in a manner consistent with Section&#160;280G of the Code, and (b)&#160;the amount of parachute payments he would be entitled to receive if they were reduced to an amount equal to one dollar less than the amount at which Mr.&#160;Morris becomes subject to excise tax imposed by Section&#160;4999 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December&#160;7, 2024, as part of the reduction in workforce, Carisma notified Mr.&#160;Morris that his employment with Carisma would terminate without Cause effective December&#160;31, 2024. Under the Morris Employment Agreement and based on his termination without Cause, Mr.&#160;Morris received, subject to his execution and non-revocation of a release of claims in favor of Carisma and compliance with all post-employment obligations under law or any restrictive covenant agreement with Carisma, (1)&#160;12&#160;months of base salary, which Carisma paid in a lump sum rather than over time, (2)&#160;a lump sum payment equal to 100.0% of his target bonus for the&#160;year of termination based on his departure date of December&#160;31, 2024, and (3)&#160;COBRA health continuation for up to 12&#160;months. In addition, Carisma&#8217;s board of directors approved the acceleration of the first 50.0% installment of the special retention option to purchase 85,000 shares of Carisma&#8217;s common stock granted to Mr.&#160;Morris with an effective grant date of June&#160;17, 2024, which would have vested in June&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agreement with Michael Klichinsky</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma entered into an employment agreement with Dr.&#160;Klichinsky (the &#8220;Klichinsky Employment Agreement&#8221;), effective as of March&#160;7, 2023, pursuant to which Dr.&#160;Klichinsky serves as Carisma&#8217;s Chief Scientific Officer. The Klichinsky Employment Agreement provides for Dr.&#160;Klichinsky&#8217;s at-will employment and an annual base salary of $420,000, an annual bonus with a target amount equal to 40.0% of his base salary, as well as his ability to participate in Carisma&#8217;s employee benefit plans generally on the same basis as other similarly-situated employees. In November&#160;2023, Carisma&#8217;s compensation committee approved an increase in Dr.&#160;Klichinsky&#8217;s annual salary, from $420,000 to $463,000, effective January&#160;1, 2024. In December&#160;2024, Carisma&#8217;s compensation committee approved an increase in Dr.&#160;Klichinsky&#8217;s annual salary, from $463,000 to $494,000, effective January&#160;1, 2025.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">216</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Klichinsky Employment Agreement also provides that if his employment is terminated either (i)&#160;by Carisma without Cause or (ii)&#160;by him with Good Reason (each as defined in the Klichinsky Employment Agreement), in either case within the Change in Control Period, then Dr.&#160;Klichinsky will be entitled to receive, subject to his execution and non-revocation of a release of claims in favor of Carisma and compliance with all post-employment obligations under law or any restrictive covenant agreement with Carisma, (a)&#160;a lump sum payment of (x)&#160;12&#160;months of base salary and (y)&#160;an amount equal to 100.0% of his target bonus for the&#160;year of termination (or, if higher, his target bonus immediately prior to the Change in Control), (b)&#160;a lump sum payment equal to 100.0% of his target bonus for the&#160;year of termination (or, if higher, based on the target bonus immediately prior to the Change in Control) pro-rated based on the number of&#160;days he was employed during the calendar&#160;year in which his termination occurs, (c)&#160;COBRA health continuation for up to 12&#160;months and (d)&#160;100.0% acceleration of all outstanding and unvested stock-based awards subject to time-based vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Klichinsky Employment Agreement also provides that if his employment is terminated either (i)&#160;by Carisma without Cause or (ii)&#160;by him with Good Reason, in either case outside the Change in Control Period, then Dr.&#160;Klichinsky will be entitled to receive, subject to his execution and non-revocation of a release of claims in favor of Carisma and compliance with all post-employment obligations under law or any restrictive covenant agreement with Carisma, (a)&#160;12&#160;months of base salary payable over a period of 12&#160;months following such termination, (b)&#160;a lump sum payment equal to 100.0% of his target bonus for the&#160;year of termination, pro-rated based on the number of&#160;days he was employed during the calendar&#160;year in which his termination occurs, and (c)&#160;COBRA health continuation for up to 12&#160;months. The Klichinsky Employment Agreement contains a Section&#160;280G limited cutback, in which Dr.&#160;Klichinsky is entitled to receive the greater of (a)&#160;the best net after-tax amount of any payments that are subject to the excise tax imposed by Section&#160;4999 of the Code, calculated in a manner consistent with Section&#160;280G of the Code, and (b)&#160;the amount of parachute payments he would be entitled to receive if they were reduced to an amount equal to $1.00 less than the amount at which Dr.&#160;Klichinsky becomes subject to excise tax imposed by Section&#160;4999 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Invention, Non-Disclosure, Non-Competition and Non-Solicitation Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of Carisma&#8217;s executive officers has entered into standard forms of agreements with respect to proprietary and confidential information, developments, non-competition, and non-solicitation. Under these agreements, each Carisma executive officer agreed to protect Carisma&#8217;s confidential and proprietary information during and after the executive officer&#8217;s employment with Carisma, not to compete with Carisma during his or her employment and for a period generally lasting for one&#160;year after the termination of his or her employment, and not to solicit Carisma&#8217;s employees, consultants, clients or customers during his or her employment and for a period generally lasting for one&#160;year after the termination of his or her employment. In addition, under these agreements, each Carisma executive officer agreed that Carisma owns all developments and inventions that are developed by such executive officer within the scope of and during the period of his or her employment with Carisma that are related to Carisma&#8217;s business or research and development conducted or planned to be conducted by Carisma at the time such development is created. Each Carisma executive officer also agreed to provide Carisma with a non-exclusive, royalty-free, perpetual license to use any prior inventions that such executive officer incorporates into inventions assigned to Carisma under these agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pay Versus Performance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables and related disclosures provide information about (i)&#160;the &#8220;total compensation&#8221; of Carisma&#8217;s principal executive officer as of December&#160;31, 2024, (the &#8220;PEO&#8221;) and the other Carisma and Former Sesen Bio named executive officers (the &#8220;Other NEOs&#8221;), as presented in the &#8220;<i style="font-style:italic;">Executive Compensation&#8212;Summary Compensation Table</i>&#8221; section of this proxy statement/prospectus (the &#8220;SCT Amounts&#8221;), (ii)&#160;the &#8220;compensation actually paid&#8221; to the PEO and the Other NEOs, as calculated pursuant to the SEC&#8217;s pay-versus-performance rules&#160;(the &#8220;CAP Amounts&#8221;), (iii)&#160;certain financial performance measures, and (iv)&#160;the relationship of the CAP Amounts to those financial performance measures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">This disclosure has been prepared in accordance with Item&#160;402(v)&#160;of Regulation S-K under the Exchange Act and does not necessarily reflect value actually realized by the executives or how Carisma&#8217;s compensation committee evaluated compensation decisions in light of company or individual performance. For discussion of how Carisma&#8217;s executive compensation program embodied a pay-for-performance philosophy that supported its business strategy and aligned the interests of Carisma&#8217;s executives with </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">217</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s stockholders, and how Carisma&#8217;s Compensation Committee continues to do so, please review the &#8220;<i style="font-style:italic;">Carisma Executive Compensation</i>&#8221; section of this proxy statement/prospectus.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:13.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.41%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year </b><br/><b style="font-weight:bold;">(a)</b></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Summary</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Compensation</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Table&#160;Total</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">for First&#160;PEO&#160;</b><br/><b style="font-weight:bold;">(b)&#160;</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Summary</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Compensation</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Table&#160;Total&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">for&#160;Second</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">PEO&#160;</b><br/><b style="font-weight:bold;">(c)&#160;</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Actually&#160;Paid</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">to&#160;First&#160;PEO&#160;</b><br/><b style="font-weight:bold;">(d)&#160;</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Actually&#160;Paid</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">to&#160;Second</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">PEO&#160;</b><br/><b style="font-weight:bold;">(e)&#160;</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Summary</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Compensation</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Table&#160;Total</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">for&#160;Non-PEO</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Named</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Executive</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Officers</b><br/><b style="font-weight:bold;">(f)&#160;</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Compensation</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Actually&#160;Paid</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">to&#160;Non-PEO</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Named</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Executive</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Officers</b><br/><b style="font-weight:bold;">(g)&#160;</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)(2)(3)</sup></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Initial&#160;Fixed</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">$100</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Investment</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Based&#160;on</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Total</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Shareholder</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Return</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(h)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Income</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Loss)</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(in&#160;millions)</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(i)</b></p></td></tr><tr><td style="vertical-align:top;width:13.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,720,050</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(16,464)</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,229,703</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">517,462</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:7.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.04</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:7.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(60.48)</p></td></tr><tr><td style="vertical-align:top;width:13.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,132,710</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,504,425</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,732,750</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,060,686</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,434,814</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,038,297</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">42.28</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.41%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(86.88)</p></td></tr><tr><td style="vertical-align:top;width:13.75%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,394,282</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,091,226</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">789,060</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.32%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">791,728</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:7.02%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">74.79</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.41%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(19.88)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The PEO was Thomas R. Cannell, D.V.M., former President and Chief Executive of Sesen Bio for all of 2022. Dr.&#160;Cannell served as the PEO in 2023 as well, until March&#160;8, 2023, at which point Steven Kelly became PEO.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table describes the adjustments, each of which is required by SEC rules, to calculate the CAP Amounts from the SCT Amounts of the PEO (column (b)) and the Other NEOs (column (f)). The SCT Amounts and the CAP Amounts do not reflect the actual amount of compensation earned by or paid to named executive officers during the applicable&#160;years, but rather are amounts determined in accordance with Item&#160;402 of Regulation S-K under the Exchange Act.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;width:2.03%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:7.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Second</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">PEO</b></p></td><td style="vertical-align:bottom;width:1.68%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:8.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">NEOs*</b></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Second</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">PEO</b></p></td><td style="vertical-align:bottom;width:1.66%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">First</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">PEO</b></p></td><td style="vertical-align:bottom;width:1.66%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:7.7%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">NEOs*</b></p></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PEO</b></p></td><td style="vertical-align:bottom;width:1.66%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">NEOs*</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">SCT Amounts</b></p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1,720,050</b></p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1,229,703</b></p></td><td style="vertical-align:bottom;width:2.35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">3,504,425</b></p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">3,132,710</b></p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1,434,814</b></p></td><td style="vertical-align:bottom;width:2.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1,394,282</b></p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">789,060</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Adjustments for stock and option awards**</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Aggregate value for stock awards and option awards included in SCT for the covered fiscal&#160;year</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.94%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(855,300)</p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.48%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(328,303)</p></td><td style="vertical-align:bottom;width:2.35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(2,717,517)</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(538,974)</p></td><td style="vertical-align:bottom;width:2.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(813,719)</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(394,154)</p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fair value at&#160;year end of awards granted during the covered fiscal&#160;year that were outstanding and unvested at the covered fiscal&#160;year end</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">139,774</p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">32,125</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,327,508</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">263,289</p></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">739,689</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">358,294</p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Year-over-year change in fair value at covered fiscal&#160;year end of awards granted in any prior fiscal&#160;year that were outstanding and unvested at the covered fiscal&#160;year end</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.94%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(773,891)</p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.48%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(153,330)</p></td><td style="vertical-align:bottom;width:2.35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(44,958)</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(13,204)</p></td><td style="vertical-align:bottom;width:2.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(300,005)</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30,460</p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Vesting date fair value of awards granted and vested during the covered fiscal&#160;year</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">102,336</p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">45,476</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change as of the vesting date (from the end of the prior fiscal&#160;year) in fair value of awards granted in any prior fiscal&#160;year for which vesting conditions were satisfied during the covered fiscal&#160;year</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.94%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(349,433)</p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.48%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(139,200)</p></td><td style="vertical-align:bottom;width:2.35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(8,772)</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(399,961)</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(107,628)</p></td><td style="vertical-align:bottom;width:2.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;">70,979    </span></p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,067</p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fair value at end of prior fiscal&#160;year of awards granted in any prior fiscal&#160;year that failed to meet the applicable vesting conditions during the covered fiscal&#160;year</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(169,010)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dividends or other earnings paid on stock or option awards in the covered fiscal&#160;year prior to vesting if not otherwise included in the total compensation for the covered fiscal&#160;year</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.94%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.48%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">CAP Amounts (as calculated)</b></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(16,464)</b></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">517,462</b></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2,060,686</b></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2,732,750</b></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1,038,297</b></p></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1,091,226</b></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">791,728</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Amounts presented are averages for the entire group of the Other NEOs in each respective&#160;year. The Other NEOs were Monica Forbes for 2022-2023 in the table, Mark Sullivan for 2022 and 2023, and Richard Morris and Michael Klichinsky for 2023 and 2024.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The valuation assumptions for stock option awards included in Compensation Actually Paid are: (i)&#160;the expected life of each stock option, which is determined using the &#8220;simplified method&#8221; and which takes into account the average of the remaining vesting period and remaining term as of the vest or fiscal&#160;year end date; (ii)&#160;the exercise price and the asset price, which are based on the closing price of Carisma&#8217;s common stock traded on Nasdaq on the vest and fiscal&#160;year end date, respectively; (iii)&#160;the risk-free rate, which is based on the Treasury Constant Maturity rate closest to the remaining expected life as of the vest or fiscal&#160;year end date; (iv)&#160;historical volatility, which is based on the daily price history for Carisma&#8217;s common stock for each expected life period </p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">218</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:210pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">prior to each vest or fiscal&#160;year end date; and (v)&#160;the annual dividend yield, which for Carisma was zero as Carisma does not pay dividends.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Amounts presented are averages for the entire group of the Other NEOs in each respective&#160;year. The Other NEOs were Monica Forbes for 2022-2023 in the table, Mark Sullivan for 2022 and 2023, and Richard Morris and Michael Klichinsky for 2023 and 2024.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(4)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Assumes $100 was invested for the period starting December&#160;31, 2021, through the end of the listed&#160;year in Carisma&#8217;s common stock. Historical stock performance is not necessarily indicative of future stock performance.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Relationship Between CAP Amounts and Performance Measures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following charts show graphically the relationships over the past three&#160;years of the CAP Amounts for the PEO and the Other NEOs as compared to Carisma&#8217;s (i)&#160;cumulative total shareholder return and (ii)&#160;net income (loss).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"><img src="tmb-20250331xs4015.jpg" alt="Graphic" style="display:inline-block;height:191.6pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:473.95pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"><img src="tmb-20250331xs4016.jpg" alt="Graphic" style="display:inline-block;height:209.75pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:492.1pt;"/></span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">219</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Carisma&#8217;s Existing Stock Option and Other Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2014 Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2014 Plan was adopted by Carisma&#8217;s board of directors on January&#160;17, 2023, approved by Carisma&#8217;s stockholders on March&#160;2, 2023, and amended and restated to reflect Carisma&#8217;s name change and the reverse stock split approved by Carisma&#8217;s stockholders on March&#160;7, 2023. The material terms of the 2014 Plan are summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Types of Awards; Shares Available for Awards; Share Counting Rules</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2014 Plan provides for the grant of incentive stock options intended to qualify under Section&#160;422 of the Code, nonstatutory stock options, stock appreciation rights (&#8220;SARs&#8221;), restricted stock, RSUs, and other stock-based awards (collectively, the &#8220;awards&#8221;). Subject to adjustment in the event of stock splits, stock dividends and other similar events, awards may be made under the 2014 Plan for up to the sum of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6,852,232 shares of Carisma&#8217;s common stock; plus</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of shares of Carisma&#8217;s common stock as is equal to the sum of (x)&#160;the number of shares of Carisma&#8217;s common stock reserved for issuance under the prior plan that remained available for grant under the prior plan immediately prior to Carisma&#8217;s initial public offering and (y)&#160;the number of shares of Carisma&#8217;s common stock subject to outstanding awards, which outstanding awards expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by Carisma at their original issuance price pursuant to a contractual repurchase right; plus</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an annual increase, to be added on the first day of each fiscal&#160;year during the term of the 2014 Plan, beginning with the fiscal&#160;year ended December&#160;31, 2024, equal to the lesser of (i)&#160;four&#160;percent of the number of shares of Carisma&#8217;s common stock outstanding on the first day of such fiscal&#160;year and (ii)&#160;the number of shares of Carisma&#8217;s common stock determined by Carisma&#8217;s board of directors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Up to 20,556,696 of the shares of Carisma&#8217;s common stock available for issuance under the 2014 Plan may be issued as incentive stock options under the 2014 Plan, subject to adjustment under the terms of the 2014 Plan. Shares of Carisma&#8217;s common stock issued under the 2014 Plan may consist in whole or in part of authorized but unissued shares or treasury shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of counting the number of shares available for the grant of awards under the 2014 Plan, all shares of Carisma&#8217;s common stock covered by SARs will be counted against the number of shares available for the grant of awards. However, SARs that may be settled only in cash will not be so counted. In addition, if Carisma grants a SAR in tandem with an option for the same number of shares of Carisma&#8217;s common stock and which provides that only one such award may be exercised (&#8220;tandem SAR&#8221;), only the shares covered by the option, and not the shares covered by the tandem SAR, will be so counted, and the expiration of one in connection with the other&#8217;s exercise will not restore shares to the 2014 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares covered by awards under the 2014 Plan that expire or are terminated, surrendered, or cancelled without having been fully exercised or are forfeited in whole or in part (including as the result of shares subject to such award being repurchased by Carisma at the original issuance price pursuant to a contractual repurchase right) or that result in any shares not being issued (including as a result of a SAR that was settleable either in cash or in stock actually being settled in cash) will again be available for the grant of awards under the 2014 Plan (subject, in the case of incentive stock options, to any limitations under the Code). In the case of the exercise of a SAR, the number of shares counted against the shares available for the grant of awards under the 2014 Plan will be the full number of shares subject to the SAR multiplied by the&#160;percentage of the SAR actually exercised, regardless of the number of shares actually used to settle the SAR upon exercise, and the shares covered by a tandem SAR will not again become available for grant upon the expiration or termination of the tandem SAR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares of Carisma&#8217;s common stock that are delivered (by actual delivery, attestation, or net exercise) to Carisma by a participant to purchase shares of Carisma&#8217;s common stock upon exercise of an award or to satisfy tax withholding obligations (including shares retained from the award creating the tax obligation) will be added back to the number of shares available for the future grant of awards under the 2014 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with a merger or consolidation of an entity with Carisma or Carisma&#8217;s acquisition of property or stock of an entity, Carisma&#8217;s board of directors may grant awards under the 2014 Plan in substitution for any options or other stock or stock-based </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">220</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">awards granted by such entity or an affiliate thereof on such terms as Carisma&#8217;s board of directors determines appropriate in the circumstances, notwithstanding any limitation on awards contained in the 2014 Plan. No such substitute awards shall count against the overall share limit, except as required by reason of Section&#160;422 and related provisions of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Descriptions of Awards Options</i>. A participant who is awarded an option receives the right to purchase a specified number of shares of Carisma&#8217;s common stock at a specified exercise price and subject to the other terms and conditions that are specified in connection with the award agreement. An option that is not intended to be an &#8220;incentive stock option&#8221; is a &#8220;nonstatutory stock option.&#8221; Options may not be granted at an exercise price that is less than 100.0% of the fair market value of Carisma&#8217;s common stock on the date of grant. If Carisma&#8217;s board of directors approves the grant of an option with an exercise price to be determined on a future date, the exercise price may not be less than 100.0% of the fair market value of Carisma&#8217;s common stock on that future date. Under present law, incentive stock options may not be granted at an exercise price less than 110.0% of the fair market value in the case of stock options granted to participants who hold more than 10.0% of the total combined voting power of all classes of Carisma&#8217;s stock or any of Carisma&#8217;s subsidiaries. Under the terms of the 2014 Plan, options may not be granted for a term in excess of 10&#160;years (and, under present law, five&#160;years in the case of incentive stock options granted to participants who hold greater than 10.0% of the total combined voting power of all classes of Carisma&#8217;s stock or any of Carisma&#8217;s subsidiaries).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2014 Plan permits participants to pay the exercise price of options using one or more of the following manners of payment: (i)&#160;payment by cash or by check, (ii)&#160;except as may otherwise be provided in the applicable award agreement or approved by Carisma&#8217;s board of directors, in connection with a &#8220;cashless exercise&#8221; through a broker, (iii)&#160;to the extent provided in the applicable award agreement or approved by Carisma&#8217;s board of directors, and subject to certain conditions, by delivery to Carisma (either by actual delivery or attestation) of shares of Carisma&#8217;s common stock owned by the participant valued at their fair market value, (iv)&#160;to the extent provided in an applicable nonstatutory stock option award agreement or approved by Carisma&#8217;s board of directors, by delivery of a notice of &#8220;net exercise&#8221; as a result of which Carisma will retain a number of shares of Carisma&#8217;s common stock otherwise issuable pursuant to the stock option equal to the aggregate exercise price for the portion of the option being exercised divided by the fair market value of Carisma&#8217;s common stock on the date of exercise, (v)&#160;to the extent permitted by applicable law and provided for in the applicable award agreement or approved by Carisma&#8217;s board of directors, by any other lawful means as Carisma&#8217;s board of directors may determine, or (vi)&#160;by any combination of these forms of payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock Appreciation Rights</i>. A participant who is awarded a SAR receives, upon exercise, a number of shares of Carisma&#8217;s common stock, or cash (or a combination of shares of Carisma&#8217;s common stock and cash) determined by reference to appreciation, from and after the date of grant, in the fair market value of a share of Carisma&#8217;s common stock over the measurement price. The 2014 Plan provides that the measurement price of a SAR may not be less than 100.0% of the fair market value of Carisma&#8217;s common stock on the date the SAR is granted (<i style="font-style:italic;">provided, however</i>, that if Carisma&#8217;s board of directors approves the grant of a SAR effective as of a future date, the measurement price will not be less than 100.0% of the fair market value on such future date) and that SARs may not be granted with a term in excess of 10&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Limitation on Repricing of Options or SARs</i>. With respect to options and SARs, unless such action is approved by Carisma&#8217;s stockholders or otherwise permitted under the terms of the 2014 Plan in connection with certain changes in capitalization and reorganization events, Carisma may not (1)&#160;amend any outstanding option or SAR granted under the 2014 Plan to provide an exercise price or measurement price per share that is lower than the then-current exercise price or measurement price per share of such outstanding option or SAR, (2)&#160;cancel any outstanding option or SAR (whether or not granted under the 2014 Plan) and grant in substitution for such awards new awards under the 2014 Plan (other than certain substitute awards issued in connection with a merger or consolidation of an entity with Carisma or an acquisition by Carisma, described above) covering the same or a different number of shares of Carisma&#8217;s common stock and having an exercise price or measurement price per share lower than the then-current exercise price or measurement price per share of the canceled option or SAR, (3)&#160;cancel in exchange for a cash payment any outstanding option or SAR with an exercise price or measurement price per share above the then-current fair market value of Carisma&#8217;s common stock, or (4)&#160;take any other action under the 2014 Plan that constitutes a &#8220;repricing&#8221; within the meaning of the rules&#160;of Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock Awards</i>. A participant who is granted an award of restricted stock is entitled to acquire shares of Carisma&#8217;s common stock, subject to Carisma&#8217;s right to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) in the event that the conditions specified in the applicable award are not satisfied prior to the end of the applicable restriction period established for such award. Unless otherwise provided in the applicable award agreement, any dividends (whether paid in cash, stock or property) declared and paid by Carisma with respect to shares of restricted stock will be paid to the participant only if and when such shares become free from the restrictions on transferability and forfeitability that apply to such shares.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">221</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock Unit Awards</i>. A participant who is granted a RSU award is entitled to receive shares of Carisma&#8217;s common stock, or cash equal to the fair market value of such shares or a combination of cash and shares, to be delivered at the time such award vests or on a deferred basis pursuant to the terms and conditions established by Carisma&#8217;s board of directors. Carisma&#8217;s board of directors may provide that settlement of RSUs will be deferred, on a mandatory basis or at the election of the participant, in a manner that complies with Section&#160;409A of the Code. A participant has no voting rights with respect to any RSU. A RSU award agreement may provide the applicable participant with the right to receive an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of Carisma&#8217;s common stock. Any such dividend equivalents may be settled in cash and/or shares of Carisma&#8217;s common stock and may be subject to the same restrictions on transfer and forfeitability as the RSUs with respect to which such dividend equivalents are awarded, in each case to the extent provided in the applicable award agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other Stock-Based Awards. Under the 2014 Plan, Carisma&#8217;s board of directors may grant other awards of shares of Carisma&#8217;s common stock, and other awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Carisma&#8217;s common stock or other property, having such terms and conditions as Carisma&#8217;s board of directors may determine. Carisma refers to these types of awards as other stock-based awards. Other stock-based awards may be available as a form of payment in settlement of other awards granted under the 2014 Plan or as payment in lieu of compensation to which a participant is otherwise entitled. Other stock-based awards may be paid in shares of Carisma&#8217;s common stock or in cash, as Carisma&#8217;s board of directors may determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Eligibility to Receive Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of Carisma&#8217;s employees, officers, directors, consultants or advisors are eligible to participate in the 2014 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Transferability of Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Awards may not be sold, assigned, transferred, pledged or otherwise encumbered by a participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an incentive stock option, pursuant to a qualified domestic relations order. During the life of the participant, awards are exercisable only by the participant. However, Carisma&#8217;s board of directors may permit or provide in an award for the gratuitous transfer of the award by the participant to or for the benefit of any immediate family member, family trust or other entity established for the benefit of the participant and/or an immediate family member thereof if Carisma would be eligible to use a Form&#160;S-8 under the Securities Act, for the registration of the sale of Carisma&#8217;s common stock subject to such award to the proposed transferee. Further, Carisma is not required to recognize any such permitted transfer until such time as the permitted transferee has, as a condition to the transfer, delivered to Carisma a written instrument in form and substance satisfactory to Carisma confirming that such transferee will be bound by all of the terms and conditions of the award. None of the restrictions described in this paragraph prohibit a transfer from the participant to Carisma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">No Rights as a Stockholder</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the provisions of the applicable award, no participant or designated beneficiary will have any rights as a stockholder with respect to any shares of Carisma&#8217;s common stock to be distributed with respect to an award granted under the 2014 Plan until becoming a record holder of such shares of Carisma&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Term</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2014 Plan will terminate automatically on March&#160;6, 2033 (but any awards previously granted under the 2014 Plan may extend beyond such date) unless it is earlier terminated by Carisma&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2017 Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Legacy Carisma board of directors adopted, and the Legacy Carisma stockholders approved, the 2017 Plan in September&#160;2017. The 2017 Plan was amended on June&#160;22, 2018, December&#160;21, 2020, November&#160;9, 2021 and April&#160;7, 2022 to increase the number of shares of Legacy Carisma&#8217;s common stock available for issuance under the 2017 Plan. At the effective time of the Sesen Bio Merger, Carisma assumed the 2017 Plan and each Legacy Carisma option in accordance with the terms of the 2017 Plan and the applicable stock option agreements evidencing by which such Legacy Carisma options. The material terms of the 2017 Plan are summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The 2017 Plan provided for the grant of incentive stock options, nonstatutory stock options, SARs, restricted stock, RSUs and other stock-based awards. Legacy Carisma&#8217;s employees, officers, directors, as well as its consultants and advisors, were eligible to </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">222</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">receive awards under the 2017 Plan. Incentive stock options, however, were only granted to Legacy Carisma employees. As of the closing of the Sesen Bio Merger, no further awards will be granted pursuant to the 2017 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2017 Plan Administration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the 2017 Plan, Carisma&#8217;s board of directors (or a committee delegated by Carisma&#8217;s board of directors) administers the 2017 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Transferability of Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2017 Plan prohibits awards from being sold, assigned, transferred, pledged, hypothecated or otherwise encumbered by the person to whom such awards are granted, either voluntarily or by operation of law, and, during the life of a participant in the 2017 Plan, awards are exercisable only by the participant, except that certain awards may be transferred to family members through gifts or domestic relations orders or to an executor or guardian upon the death or disability of the participant. Carisma is not required to recognize any such permitted transfer until such time as a permitted transferee delivers to Carisma a written instrument, as a condition to such transfer, in form and substance satisfactory to Carisma confirming that such transferee shall be bound by all of the terms and conditions of the applicable award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Effect of Certain Changes in Capitalization</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the occurrence of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Carisma&#8217;s common stock other than an ordinary cash dividend, under the terms of the 2017 Plan, Carisma is required to equitably adjust (or make substitute awards, if applicable), in the manner determined by Carisma&#8217;s board of directors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and class of securities available under the 2017 Plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and class of securities and exercise price per share of each outstanding option;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the share and per-share provisions and the measurement price of each outstanding SARs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of shares subject to and the repurchase price per share subject to each outstanding award of restricted stock; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the share and per-share related provisions and the purchase price, if any, of each outstanding RSU award and each outstanding other stock-based award.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Effect of Certain Corporate Transactions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the occurrence of a merger or other reorganization event (as defined in the 2017 Plan), Carisma&#8217;s board of directors may, on such terms as Carisma&#8217;s board of directors determines (except to the extent specifically provided otherwise in an applicable award agreement or other agreement between the participant and Carisma), take any one or more of the following actions pursuant to the 2017 Plan as to all or any (or any portion of) outstanding awards, other than awards of restricted stock:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that outstanding awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon written notice to a participant, provide that all of the participant&#8217;s unexercised and/or unvested awards will terminate immediately prior to the consummation of the reorganization event unless exercised by the participant (to the extent then exercisable) within a specified period following the date of the notice;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that outstanding awards will become exercisable, realizable or deliverable, or restrictions applicable to an award will lapse, in whole or in part, prior to or upon such reorganization event;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event of a reorganization event pursuant to which holders of shares of Carisma&#8217;s common stock will receive a cash payment for each share surrendered in the reorganization event, make or provide for a cash payment to participants with </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">223</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">respect to each award held by a participant equal to (1)&#160;the number of shares of Carisma&#8217;s common stock subject to the vested portion of the award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such reorganization event) multiplied by (2)&#160;the excess, if any, (A)&#160;of the cash payment for each share of Carisma&#8217;s common stock surrendered in the reorganization event, over (B)&#160;the exercise, measurement or purchase price of such award and any applicable tax withholdings, in exchange for the termination of such award; and/or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that, in connection with Carisma&#8217;s liquidation or dissolution, awards will convert into the right to receive liquidation proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors is not obligated under the 2017 Plan to treat all awards, all awards held by a participant, or all awards of the same type, identically.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the occurrence of a reorganization event other than Carisma&#8217;s liquidation or dissolution, Carisma&#8217;s repurchase and other rights with respect to outstanding awards of restricted stock will continue for the benefit of the succeeding company and will, unless the Carisma board of directors determines otherwise, apply to the cash, securities, or other property which the Carisma&#8217;s common stock was converted into or exchanged for pursuant to the reorganization event in the same manner and to the same extent as they applied to the shares of Carisma&#8217;s common stock subject to the restricted stock award. However, Carisma&#8217;s board of directors may provide for the termination or deemed satisfaction of such repurchase or other rights under the restricted stock award agreement or in any other agreement between a participant and Carisma, either initially or by amendment, or provide for forfeiture of such restricted stock if issued at no cost. Upon Carisma&#8217;s liquidation or dissolution, except to the extent specifically provided to the contrary in the restricted stock award agreement or any other agreement between the participant and Carisma, all restrictions and conditions on all restricted stock awards then outstanding will automatically be deemed terminated or satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the provisions of the 2017 Plan described above related to reorganization events, except to the extent specifically provided to the contrary in the applicable award agreement or in any other agreement between a participant and Carisma:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each stock option granted under the 2017 Plan will be immediately exercisable in full if, on or prior to the first anniversary of the date of the consummation of the change in control event (as defined in the 2017 Plan), the participant&#8217;s employment with Carisma or the acquiring or succeeding corporation is terminated for good reason (as defined in the 2017 Plan) by the participant or is terminated without cause (as defined in the 2017 Plan) by Carisma or the acquiring or succeeding corporation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each award of restricted stock or RSUs will immediately become free from all conditions or restrictions if, on or prior to the first anniversary of the date of the consummation of the change in control event, the participant&#8217;s employment with Carisma or the acquiring or succeeding corporation is terminated for good reason by the participant or is terminated without cause by Carisma or the acquiring or succeeding corporation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors may specify in an award agreement at the time of the grant the effect of a change in control event on any SAR or other stock-based award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acceleration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At any time, Carisma&#8217;s board of directors may provide that any award under the 2017 Plan will become immediately exercisable in whole or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amendment of Plan and Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Carisma&#8217;s board of directors may amend, suspend, or terminate the 2017 Plan or any portion thereof at any time, however if approval of Carisma&#8217;s stockholders as to any modification or amendment is required under the Code, with respect to incentive stock options, Carisma&#8217;s board of directors may not effect such modification or amendment without such approval. Carisma&#8217;s board of directors may amend, modify or terminate any outstanding award, however the participant&#8217;s consent to such action is required unless Carisma&#8217;s board of directors determines that the action, taking into account any related action, does not materially and adversely affect the participant&#8217;s rights under the 2017 Plan or the change is otherwise permitted by the 2017 Plan. Furthermore, Carisma&#8217;s board of directors may amend any outstanding award granted under the 2017 Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such award or, without stockholder approval, cancel any outstanding award and grant in </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">224</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">substitution therefor new awards under the 2017 Plan covering the same or a different number of shares of Carisma&#8217;s common stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Termination</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2017 Plan terminates on or after the date that is 10&#160;years following the earlier of (i)&#160;the date on which the 2017 Plan was adopted by Carisma&#8217;s board of directors or (ii)&#160;the date the 2017 Plan was approved by the Carisma stockholders, but all awards previously granted may extend beyond such date. Carisma does not expect to grant any new awards under the 2017 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">401(k)&#160;Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma maintains a defined contribution employee retirement plan for Carisma employees, including Carisma&#8217;s executive officers. The plan is intended to qualify as a tax-qualified 401(k)&#160;plan so that contributions to the 401(k)&#160;plan, and income earned on such contributions, are not taxable to participants until withdrawn or distributed from the 401(k)&#160;plan (except in the case of contributions under the 401(k)&#160;plan designated as Roth contributions). Under the 401(k)&#160;plan, each employee is fully vested in his or her deferred salary contributions and Carisma&#8217;s discretionary match. Employee contributions are held and invested by the plan&#8217;s trustee as directed by participants. The 401(k)&#160;plan provides Carisma with the discretion to match employee contributions. Effective May&#160;1, 2022, Carisma implemented a matching policy under which Carisma matches 100.0% of an employee&#8217;s contributions to the 401(k)&#160;plan, up to a maximum of five&#160;percent of the employee&#8217;s base salary and bonus paid during the&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Policies and Practices Related to the Grant of Equity Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma grants stock options to Carisma employees and directors on an annual basis. Carisma may also grant stock options to individuals upon hire or promotion or for retention purposes. Carisma currently does not grant SARs or similar option-like instruments. During the last fiscal&#160;year, neither Carisma&#8217;s board of directors nor the compensation committee took material nonpublic information into account when determining the timing or terms of stock options, nor did Carisma time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Summary of Dodd-Frank Compensation Recovery Policy or &#8220;Clawback&#8221; Policy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma adopted the Dodd-Frank Compensation Recovery Policy (the &#8220;Clawback Policy&#8221;), effective October&#160;2, 2023. The Clawback Policy complies with Nasdaq and SEC rules&#160;and regulations and generally provides for the recovery of erroneously awarded compensation (as defined in the Clawback Policy) received by current and former Carisma executive officers (as defined in Rule&#160;16a-1(f)&#160;under the Exchange Act) in the event of a required accounting restatement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">225</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_95ed83c4_3e94_4853_83ba_38778f3feedf"></a><a id="CARISMADIRECTORCOMPENSATION_587305"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CARISMA DIRECTOR COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The following information and all other information contained in this proxy statement/prospectus does not give effect to the contemplated reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Director Compensation Processes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Carisma&#8217;s director compensation program is administered by Carisma&#8217;s board of directors based on recommendations by Carisma&#8217;s compensation committee. Carisma&#8217;s compensation committee periodically reviews Carisma&#8217;s director compensation program and makes recommendations to Carisma&#8217;s board of directors with respect thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In designing Carisma&#8217;s director compensation program, Carisma&#8217;s compensation committee considers compensation data from comparable publicly traded companies in the biotechnology and the biopharmaceutical industry (based on, among other things, industry market capitalization, headcount and location) provided by Carisma&#8217;s independent compensation consultant, Pearl Meyer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During 2024, Carisma&#8217;s compensation committee retained Pearl Meyer to advise the compensation committee on Carisma&#8217;s director compensation program, which includes board and committee fee retainers and equity awards. The compensation committee established a peer group. The compensation consultants made recommendations with respect to the amount and form of director compensation. Although Carisma&#8217;s compensation committee considers the advice and guidance of the compensation consultants as to Carisma&#8217;s director compensation program, Carisma&#8217;s compensation committee ultimately makes its own decisions about these matters. In the future, Carisma expects that its compensation committee will continue to engage independent compensation consultants to provide additional guidance on Carisma&#8217;s director compensation programs and to conduct further competitive benchmarking against a peer group of publicly traded companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Director Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table sets forth the total compensation paid by Carisma to each person who served as a non-employee member of Carisma&#8217;s board of directors during the&#160;year ended December&#160;31, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees&#160;Earned&#160;or</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Paid&#160;in&#160;Cash&#160;($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option&#160;Awards</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)(3)</sup></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">All&#160;Other</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Compensation&#160;($)</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;($)</b></p></td></tr><tr><td style="vertical-align:top;width:28%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sohanya Cheng</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,917</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,375</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">39,292</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Regina Hodits, Ph.D. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:28%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">John Hohneker, M.D.</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">38,750</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">85,527</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">124,277</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Briggs Morrison, M.D.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">57,000</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,227</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">76,227</p></td></tr><tr><td style="vertical-align:top;width:28%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Bj&#246;rn Odlander, M.D., Ph.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (5)</sup></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">David Scadden, M.D.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,000</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">53,975</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">78,975</p></td></tr><tr><td style="vertical-align:top;width:28%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Marella Thorell</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">27,500</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">53,975</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">81,475</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Torok <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">39,583</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,227</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">58,810</p></td></tr><tr><td style="vertical-align:top;width:28%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Chidozie Ugwumba <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,750</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,750</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sanford Zweifach</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">124,000</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,227</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">143,227</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amounts represent cash compensation for services rendered as a director during 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The amounts reported in the &#8220;Option Awards&#8221; column reflect the grant date fair value of options awarded during the&#160;year computed in accordance with the provisions of FASB ASC Topic 718. Assumptions used in the calculation of these amounts are included in Note&#160;10 to Carisma&#8217;s audited financial statements included in this proxy statement/prospectus. These amounts reflect the accounting cost for these stock options and do not reflect the actual economic value that may be realized by non-employee directors upon the vesting of the stock options, the exercise of the stock options or the sale of Carisma&#8217;s common stock underlying such stock options. On the date of the first board meeting held following Carisma&#8217;s 2024 annual meeting of stockholders, 19,350 stock options were granted to each Carisma director in office on June&#160;26, 2024, fully vesting on the one-year anniversary of the grant date, subject to continued service through the applicable vesting date. In connection with their initial appointments to Carisma&#8217;s board of directors during 2024, Ms.&#160;Cheng, Dr.&#160;Hohneker, Dr.&#160;Scadden and Ms.&#160;Thorell were each granted 38,700 stock options.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">226</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table shows the number of outstanding stock options held by Carisma&#8217;s directors as of December&#160;31, 2024:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:71.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:25.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock&#160;Options&#160;Outstanding&#160;(#)</b></p></td></tr><tr><td style="vertical-align:top;width:71.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sohanya Cheng</p></td><td style="vertical-align:bottom;width:2.88%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.24%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">38,700</p></td></tr><tr><td style="vertical-align:top;width:71.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">John Hohneker, M.D.</p></td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">58,050</p></td></tr><tr><td style="vertical-align:top;width:71.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Briggs Morrison, M.D.</p></td><td style="vertical-align:bottom;width:2.88%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.24%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">155,549</p></td></tr><tr><td style="vertical-align:top;width:71.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">David Scadden, M.D.</p></td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">38,700</p></td></tr><tr><td style="vertical-align:top;width:71.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Marella Thorell</p></td><td style="vertical-align:bottom;width:2.88%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.24%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">38,700</p></td></tr><tr><td style="vertical-align:top;width:71.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sanford Zweifach</p></td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">242,671</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr.&#160;Hodits resigned from Carisma&#8217;s board of directors effective June&#160;30, 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr.&#160;Odlander resigned from Carisma&#8217;s board of directors effective June&#160;30, 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mr.&#160;Torok resigned from Carisma&#8217;s board of directors effective October&#160;31, 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mr.&#160;Ugwumba resigned from Carisma&#8217;s board of directors effective April&#160;1, 2024.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Steven Kelly, Carisma&#8217;s President and Chief Executive Officer, received no compensation for his service as a director, and, consequently, is not included in the above table. The compensation received by Mr.&#160;Kelly during the&#160;year ended December&#160;31, 2024 is presented in &#8220;Carisma Executive Compensation&#8212;Summary Compensation Table&#8221; above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Director Compensation and Narrative Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In April&#160;2023, following the closing of the Sesen Bio Merger, Carisma adopted a director compensation policy. Under Carisma&#8217;s director compensation policy, Carisma pays its non-employee directors a cash retainer for service on Carisma&#8217;s board of directors and for service on each committee on which the director is a member, and the chair of Carisma&#8217;s board of directors and of each committee receive additional retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment is prorated for any portion of such quarter that the director is not serving on Carisma&#8217;s board of directors or on such committee. The fees paid to non-employee directors for service on Carisma&#8217;s board of directors and for service on each committee of Carisma&#8217;s board of directors on which the director is a member are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:18.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Member&#160;Annual&#160;Fee</b></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chair&#160;Incremental&#160;Annual&#160;Fee</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Board of Directors</p></td><td style="vertical-align:bottom;width:2.19%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">40,000</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:18.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">67,500</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Audit Committee</p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,500</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:18.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,500</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Compensation Committee</p></td><td style="vertical-align:bottom;width:2.19%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:18.25%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Nominating and Corporate Governance Committee</p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:18.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Science Committee</p></td><td style="vertical-align:bottom;width:2.19%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12.7%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:18.25%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Carisma&#8217;s director compensation policy provides that Carisma will reimburse Carisma&#8217;s non-employee directors for reasonable out-of-pocket business expenses incurred in connection with attending meetings of Carisma&#8217;s board of directors and any committee of Carisma&#8217;s board of directors on which they serve. Non-employee directors will also be reimbursed for reasonable out of-of-pocket business expenses authorized by Carisma&#8217;s board of directors or a committee of Carisma&#8217;s board of directors that are incurred in connection with attendance at various conferences or meetings with Carisma&#8217;s management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In addition, each non-employee director of Carisma has received, upon his or her initial election or appointment to Carisma&#8217;s board of directors, an option to purchase 38,700 shares of Carisma&#8217;s common stock under the 2014 Plan (the &#8220;Initial Option&#8221;). Each of these Initial Options will vest as to 2.7778% of the shares of Carisma&#8217;s common stock underlying such option at the end of each successive one-month period following the date of grant until the third anniversary of the date of grant, subject to the non-employee director&#8217;s continued service as a director. Further, on the date of the first board meeting held after each annual meeting of stockholders, each non-employee director received an option to purchase 19,350 shares of Carisma&#8217;s common stock under the 2014 Plan (the &#8220;Annual Option&#8221;). Each of these Annual Options will vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director&#8217;s continued service as a director. All options issued to Carisma&#8217;s non-employee directors under Carisma&#8217;s director compensation policy will be issued at exercise prices equal to the fair market value of Carisma&#8217;s common stock on the date of grant and will become exercisable in full upon specified change in control events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Effective January&#160;1, 2025, Carisma&#8217;s board of directors approved the following modifications to Carisma&#8217;s director compensation policy: (i)&#160;the Initial Option award was increased to 60,000 shares of Carisma&#8217;s common stock and (ii)&#160;the Annual Option award was increased to 30,000 shares of Carisma&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">227</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1c6a91ce_cc86_4163_a3f0_d9841f278060"></a><a id="CARISMAEQUITYCOMPENSATIONPLANINFORMATION"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA EQUITY COMPENSATION PLAN INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following information and all other information contained in this proxy statement/prospectus does not give effect to the contemplated reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table provides information about the securities authorized for issuance under Carisma&#8217;s equity compensation plans as of December&#160;31, 2024. As of December&#160;31, 2024, Carisma had three equity compensation plans approved by security holders, which include the 2017 Plan, the 2014 Plan, and the Carisma Therapeutics&#160;Inc. 2014 Employee Stock Purchase Plan (&#8220;2014 ESPP&#8221;).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.013893127%;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:21.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Plan category</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;securities&#160;to</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">be&#160;issued&#160;upon&#160;exercise</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">of&#160;outstanding&#160;options,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">warrants&#160;and&#160;rights</b></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-average</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">exercise&#160;price&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">outstanding&#160;options,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">warrants&#160;and&#160;rights</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;securities</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">remaining&#160;available&#160;for&#160;future</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">issuance&#160;under&#160;equity</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">compensation&#160;plans&#160;(excluding</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">securities&#160;reflected&#160;in&#160;column&#160;(a))</b></p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.98%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.96%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(a)</b></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.52%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(b)</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:21.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(c)</b></p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Equity compensation plans approved by security holders</p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.96%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7,746,991</p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:13.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.81</p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5,020,720 </p></td><td colspan="2" style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.98%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Equity compensation plans not approved by security holders</p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:13.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td colspan="2" style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.98%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.96%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,746,991</p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:13.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.81</p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,020,720</p></td><td colspan="2" style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 7,746,991 shares to be issued upon exercise of outstanding stock options under the 2014 Plan and the 2017 Plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;4,781,159 shares that remained available for future issuance under the 2014 Plan, which shares may be issued pursuant to stock options, SARs, restricted stock, RSUs and other stock-based awards and (ii)&#160;239,561 shares that remained available for future issuance under the 2014 ESPP.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2014 Plan has an evergreen provision that allows for an annual increase in the number of shares available for issuance thereunder to be added on the first day of each fiscal&#160;year during the term of the plan beginning with the fiscal&#160;year ended December&#160;31, 2024, in an amount equal to the lesser of (a)&#160;four&#160;percent of the total number of shares of Carisma&#8217;s common stock outstanding on the first day of the applicable fiscal&#160;year and (b)&#160;the number of shares Carisma&#8217;s common stock determined by Carisma&#8217;s board of directors. On January&#160;1, 2025, 1,670,004 additional shares were reserved for issuance under the 2014 Plan pursuant to this evergreen provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">228</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_310a056a_457b_4c33_aa6f_457f8c6d1450"></a><a id="ORTHOCELLIXEXECUTIVECOMPENSATION_580384"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ORTHOCELLIX EXECUTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Executive Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because OrthoCellix was formed on February 28, 2025, there were no named executive officers and it did not pay any compensation to any executive officers for the year ended December 31, 2024. OrthoCellix may reimburse its officers for any out of pocket expenses that they incur on OrthoCellix&#8217;s behalf. OrthoCellix has not yet entered into employment agreements with executive officers. If OrthoCellix does enter into employment agreements with executive officers, they will be assumed by the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock Option and Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma plans to adopt, subject to stockholder approval, the 2025 Stock Option and Incentive Plan, which will become effective as of and contingent on the completion of the Merger. For a detailed description of these requirements and the terms of the 2025 Stock Option and Incentive Plan, see &#8220;<i style="font-style:italic;">Proposal No.&#160;2&#8212; Stock Plan Proposal</i>.&#8221; The Combined Company expects to grant to certain directors and executive officers, including the individuals who will be the Combined Company&#8217;s named executive officers, equity awards following the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">229</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9505cffb_091e_4916_9b5a_168cbb671fa1"></a><a id="ORTHOCELLIXDIRECTORCOMPENSATION_959481"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ORTHOCELLIX DIRECTOR COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Non-Employee Director Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that the Combined Company&#8217;s board of directors will adopt a director compensation policy for its non-employee directors in connection with or following the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because OrthoCellix was formed on February 28, 2025, it did not have any directors or pay any compensation to non-employee directors with respect to service on its board of directors, during the year ended December 31, 2024. OrthoCellix&#8217;s current directors are Shankar Musunuri and Michael Shine. OrthoCellix currently does not provide any compensation to its current directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Historical information concerning the compensation paid to or earned by directors of Carisma or Ocugen may not be directly relevant to or indicative of the compensation that any such directors will receive (as applicable) as directors of the Combined Company following the Merger, but is available in Carisma&#8217;s and Ocugen&#8217;s previous annual definitive proxy statements filed with the SEC. Disclosure of the compensation that Carisma&#8217;s non-employee directors received during the&#160;year ended December&#160;31, 2024 is included in this proxy statement/prospectus under the heading &#8220;Carisma Director Compensation&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock Option and Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma plans to adopt, subject to stockholder approval, the 2025 Stock Option and Incentive Plan, which will become effective as of and contingent on the completion of the Merger. For a detailed description of these requirements and the terms of the 2025 Stock Option and Incentive Plan, see &#8220;<i style="font-style:italic;">Proposal No.&#160;2&#8212; Stock Plan Proposal</i>.&#8221; The Combined Company expects to grant to certain directors and executive officers, including the individuals who will be the Combined Company&#8217;s named executive officers, equity awards following the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">230</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3df57c9f_fb0a_456a_b129_fca5f1a84408"></a><a id="MATTERSBEINGSUBMITTEDTOAVOTEOFCARISMASST"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MATTERS BEING SUBMITTED TO A VOTE OF CARISMA&#8217;S STOCKHOLDERS</b></p><a id="PROPOSALNO1THENASDAQSTOCKISSUANCEPROPOSA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;1&#160;- THE NASDAQ STOCK ISSUANCE PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Carisma Special Meeting, Carisma&#8217;s stockholders will be asked to approve, pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d), the issuance of shares of Carisma common stock (i)&#160;to the sole stockholder of OrthoCellix pursuant to the Merger Agreement, and (ii)&#160;certain investors in the anticipated Concurrent Financing, pursuant to the terms of the subscription agreements, which will (a)&#160;represent more than 20.0% of the shares of Carisma common stock outstanding immediately prior to the Merger; and (b)&#160;result in the change of control of Carisma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately after the Merger and the anticipated Concurrent Financing, based on the Exchange Ratio, Carisma securityholders as of immediately prior to the Merger are expected to own approximately 10.0% of the outstanding shares of the Combined Company on a fully-diluted basis, and Ocugen, the sole stockholder of OrthoCellix, along with the other investors in the anticipated Concurrent Financing are expected to own approximately 90.0% of the outstanding shares of the Combined Company on a fully-diluted basis, subject to certain assumptions, including Carisma&#8217;s Net Cash as of the closing of the Merger being approximately $0 and the anticipated Concurrent Financing Amount of $25.0 million. Under certain circumstances, the ownership&#160;percentages may be adjusted upward or downward based on the level of Carisma&#8217;s Net Cash at the closing of the Merger and the actual Concurrent Financing Amount at the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The terms of, reasons for and other aspects of the Merger Agreement, the Merger and the issuance of Carisma common stock in the Merger are described in detail in the section of this proxy statement/ prospectus titled &#8220;<i style="font-style:italic;">The Merger Agreement</i>.&#8221; A copy of the Merger Agreement is attached as <i style="font-style:italic;">Annex A </i>to this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reasons for the Proposal</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Nasdaq Listing Rule&#160;5635(a)(1), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common stock, among other things, in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued is in excess of 20.0% of the number of shares of common stock then outstanding. The potential issuance of the shares of Carisma common stock in the Merger and in the anticipated Concurrent Financing exceeds the 20.0% threshold under the Nasdaq Listing Rules&#160;and is expected to represent approximately 90.0% of Carisma&#8217;s common stock on a fully diluted basis immediately following the Merger and the anticipated Concurrent Financing. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(a)(1), Carisma must obtain the approval of Carisma&#8217;s stockholders for the issuance of these shares of common stock in the Merger and in the anticipated Concurrent Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Nasdaq Listing Rule&#160;5635(b), a company listed on Nasdaq is required to obtain stockholder approval prior to an issuance of stock that will result in a &#8220;change of control&#8221; of the listed company. Although Nasdaq has not adopted any rule&#160;on what constitutes a &#8220;change of control&#8221; for purposes of Rule&#160;5635(b), Nasdaq has previously indicated that the acquisition of, or right to acquire, by a single investor or affiliated investor group, as little as 20.0% of the common stock (or securities convertible into or exercisable for common stock) or voting power of an issuer could constitute a change of control. It is expected that Nasdaq will determine that the Merger constitutes a &#8220;change of control&#8221; of the listed company. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(b), Carisma must obtain the approval of Carisma&#8217;s stockholders of the change of control resulting from the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under Nasdaq Listing Rule&#160;5635(d)(2), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of securities in connection with a transaction (or a series of related transactions) other than a public offering involving the sale, issuance or potential issuance of common stock (or securities convertible into or exercisable for common stock) equal to 20.0% or more of the common stock or 20.0% or more of the voting power outstanding before the issuance at a price that is less than the lower of (i)&#160;the Nasdaq Official Closing Price (as reflected on Nasdaq.com) immediately preceding the signing of the binding agreement; or (ii)&#160;the average Nasdaq Official Closing Price of the common stock (as reflected on Nasdaq.com) for the five trading&#160;days immediately preceding the signing of the binding agreement (the &#8220;Nasdaq minimum price&#8221;). As described above, the potential issuance of the shares of Carisma common stock in the anticipated Concurrent Financing is expected to exceed the 20.0% threshold under the Nasdaq Listing Rules&#160;and the shares may be issued at less than the Nasdaq minimum price. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(d)(2), Carisma must obtain the approval of Carisma&#8217;s stockholders for the issuance of these shares of common stock in the anticipated Concurrent Financing. <span style="color:#212529;">For more information regarding the anticipated Concurrent Financing, see the section titled &#8220;</span><i style="color:#212529;font-style:italic;">Agreements Related to the Merger&#8212;Anticipated Subscription Agreements and </i></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">231</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="color:#212529;font-style:italic;">Registration Rights Agreement</i><span style="color:#212529;">&#8221; beginning on page&#160;</span><span style="color:#212529;">202</span><span style="color:#212529;"> of this proxy statement/prospectus. </span>A copy of the subscription agreement is attached as <i style="font-style:italic;">Annex I </i>to this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is conditioned upon the approval of the Nasdaq Stock Issuance Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected. The closing of the anticipated Concurrent Financing is conditioned upon the satisfaction or waiver of each of the conditions to the closing of the Merger as well as certain other conditions. Therefore, the anticipated Concurrent Financing cannot be consummated without the approval of the Nasdaq Stock Issuance Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain Carisma&#8217;s executive officers and directors have agreed to vote any shares of Carisma common stock owned by them in favor of the Nasdaq Stock Issuance Proposal. Please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Support Agreements and Lock-Up Agreement</i>&#8221; beginning on page&#160;197 of this proxy statement/prospectus for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the approval of the Nasdaq Stock Issuance Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE NASDAQ STOCK ISSUANCE PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">232</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_305e911e_e1b1_465c_bb5d_846a23046b8d"></a><a id="PROPOSALNO2THESTOCKPLANPROPOSAL_172991"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;2&#160;- THE STOCK PLAN PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma is asking its stockholders to approve the OrthoCellix,&#160;Inc. 2025 Stock Option and Incentive Plan (the &#8220;2025 Stock Plan&#8221;). On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, Carisma&#8217;s board of directors adopted the 2025 Stock Plan, subject to the approval from Carisma&#8217;s stockholders. If approved, the 2025 Stock Plan will become effective as of the closing of the Merger. If the 2025 Stock Plan is approved by stockholders and the Merger is consummated, no further awards will be issued under the 2014 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors believes that the Combined Company must offer a competitive equity incentive program if it is to successfully attract and retain the best possible candidates for positions of substantial responsibility within the Combined Company. Carisma&#8217;s board of directors expects that the 2025 Stock Plan will be an important factor in attracting, retaining and rewarding high caliber employees who are essential to the Combined Company&#8217;s success and providing incentives to these individuals to promote the success of the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of the 2025 Stock Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary description of the 2025 Stock Plan, as proposed to be adopted by Carisma in connection with the Merger. This summary is not a complete statement of the 2025 Stock Plan and is qualified in its entirety by reference to the complete text of the 2025 Stock Plan, a copy of which is attached hereto as <i style="font-style:italic;">Annex H</i> to the proxy statement/prospectus. Carisma&#8217;s stockholders should refer to the 2025 Stock Plan for more complete and detailed information about the terms and conditions of the 2025 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of the 2025 Stock Plan is to provide a means whereby the Combined Company can align the long-term financial interests of its employees, consultants, advisors and directors with the financial interests of its stockholders. In addition, Carisma&#8217;s board of directors believes that the ability to grant options and other equity-based awards will help the Combined Company to attract, retain and motivate employees, consultants, and directors and encourages them to devote their best efforts to the Combined Company&#8217;s business and financial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Approval of the 2025 Stock Plan by Carisma&#8217;s stockholders is required, among other things, in order to: (i)&#160;comply with Nasdaq rules&#160;requiring stockholder approval of equity compensation plans and (ii)&#160;allow the grant of incentive stock options to participants in the 2025 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If this Stock Plan Proposal is approved by Carisma&#8217;s stockholders, the 2025 Stock Plan will become effective as of the date of the closing of the Merger. Approval of the 2025 Stock Plan by Carisma&#8217;s stockholders will allow the Combined Company to grant stock options, RSU awards and other awards at levels determined appropriate by its board of directors or its compensation committee (the &#8220;Compensation Committee&#8221;) following the closing of the Merger. The 2025 Stock Plan will also allow the Combined Company to utilize a broad array of equity incentives and performance-based cash incentives in order to secure and retain the services of its employees, directors, advisors and consultants, and to provide long-term incentives that align the interests of its employees, directors, advisors and consultants with the interests of its stockholders following the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s employee equity compensation program, as implemented under the 2025 Stock Plan, will allow the Combined Company to remain competitive with comparable companies in its industry by giving it the resources to attract and retain talented individuals to achieve its business objectives and build stockholder value. Approval of the 2025 Stock Plan will provide the Combined Company with the flexibility it needs to use equity compensation and other incentive awards to attract, retain and motivate talented employees, directors, advisors and consultants who are important to the Combined Company&#8217;s long-term growth and success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is anticipated that the Carisma board of directors will approve the award of RSUs and stock options to executive officers and members of senior management of the Combined Company under the 2025 Stock Plan, subject to stockholder approval of the 2025 Stock Plan. These awards will be shown in the table entitled &#8220;New Plan Benefits&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of Material Features of the 2025 Stock Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The material features of the 2025 Stock Plan include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the maximum number of shares of common stock that may be issued under the 2025 Stock Plan is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares (the &#8220;Initial Limit&#8221;), plus on January&#160;1, 2026 and on each January&#160;1 thereafter, the number of shares of common stock reserved and </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">233</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">available for issuance under the 2025 Stock Plan shall be cumulatively increased by&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;percent of the number of shares of common stock issued and outstanding on the immediately preceding December&#160;31, or such lesser number of shares as approved by the Compensation Committee (the &#8220;administrator&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the award of stock options (both incentive and non-qualified options), SARs, restricted stock, RSUs, unrestricted stock awards, cash-based awards, and dividend equivalent rights is permitted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the aggregate value of all awards awarded under the 2025 Stock Plan and all other cash compensation paid by us to any non-employee director for service as a non-employee director in any calendar&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">year may not exceed $             , provided however that in the first calendar&#160;year in which an individual becomes a non-employee director, such aggregate value may not exceed $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any material amendment to the 2025 Stock Plan is subject to approval by the Combined Company&#8217;s stockholders; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the term of the 2025 Stock Plan will expire on the tenth anniversary of the closing of the Merger.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Information Regarding Equity Incentive Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is critical to the Combined Company&#8217;s long-term success that the interests of its employees, directors and consultants are tied to its success as &#8220;owners&#8221; of the business. Approval of the 2025 Stock Plan will allow the Combined Company to grant stock options and other awards at levels it determines to be appropriate in order to attract new employees, directors, advisors and consultants, retain existing employees, directors, advisors and consultants and to provide incentives for such persons to exert maximum efforts for the Combined Company&#8217;s success and ultimately increase stockholder value. The 2025 Stock Plan allows the Combined Company to utilize a broad array of equity incentives with flexibility in designing equity incentives, including stock option grants, SARs, restricted stock awards, RSU awards, unrestricted stock awards and dividend equivalent rights to offer competitive equity compensation packages in order to retain and motivate the talent necessary for the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Carisma&#8217;s request to approve the 2025 Stock Plan is approved by Carisma&#8217;s stockholders, the Combined Company will initially have shares, subject to adjustment for specified changes in the Combined Company&#8217;s capitalization, available for grant under the 2025 Stock Plan as of the effective time of the closing of the Merger. This pool size is necessary to provide sufficient reserved shares for a level of grants that will attract, retain, and motivate employees and other participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, there were stock options to acquire&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of common stock outstanding under the 2014 Stock Plan, with a weighted average exercise price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and a weighted average remaining term of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;years. Other than the foregoing, no awards were outstanding under our equity compensation plans as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of common stock available for awards under our equity compensation plans and no awards are expected to be granted between &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the 2025 Stock Plan is not approved by Carisma&#8217;s stockholders, the 2025 Stock Plan will not become effective and the 2014 Stock Plan will continue to be used by the Combined Company following the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Description of the 2025 Stock Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2025 Stock Plan was adopted by the Carisma board of directors on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 and will become effective, subject to stockholder approval, on the date of the closing of the Merger. The 2025 Stock Plan allows us to make equity-based incentive awards to our officers, employees, directors, advisors and consultants. Carisma&#8217;s board of directors anticipates that providing such persons with a direct stake in the Combined Company will assure a closer alignment of the interests of such individuals with those of the Combined Company and its stockholders, thereby stimulating their efforts on the Combined Company&#8217;s behalf and strengthening their desire to remain with the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have initially reserved&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of common stock for the issuance of awards under our 2025 Stock Plan plus on January&#160;1, 2026 and on each January&#160;1 thereafter, the number of shares of common stock reserved and available for issuance under the 2025 Stock Plan shall be cumulatively increased by&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % of the number of shares of common stock issued and outstanding on the immediately preceding December&#160;31, or such lesser number of shares as approved by the administrator. This limit is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">234</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The shares we issue under our 2025 Stock Plan will be authorized but unissued shares or shares that we reacquire. The shares of common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) under our 2025 Stock Plan will be added back to the shares available for issuance under our 2025 Stock Plan. Awards that may be settled solely in cash will not be counted against the share reserve, nor will they reduce the shares of common stock authorized for grant to a grantee in any calendar&#160;year. The maximum aggregate number of shares of common stock that may be issued upon exercise of incentive stock options under the 2025 Stock Plan shall not exceed the Initial Limit, cumulatively increased on January&#160;1, 2026 and on each January&#160;1 thereafter by the lesser of the Annual Increase for such&#160;year or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of common stock, subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. Based upon a price per share of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, the maximum aggregate market value of the common stock that could potentially be issued under the 2025 Stock Plan as of the closing of the Merger is $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. Shares issued in connection with awards granted in substitution for equity awards of an acquired company (&#8220;Substitute Awards&#8221;) will not reduce the share reserve under the 2025 Stock Plan. However, shares underlying such Substitute Awards that are settled in cash, forfeited or otherwise terminated without issuance will not be added back to the share reserve.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The grant date fair value of all awards made under our 2025 Stock Plan and all other cash compensation paid by us to any non-employee director in any calendar&#160;year for service as a non-employee director shall not exceed $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;; <i style="font-style:italic;">provided, however</i>, that such amount shall be $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; for the calendar&#160;year in which the applicable non-employee director is initially elected or appointed to the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2025 Stock Plan will be administered by the administrator. The administrator has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of the 2025 Stock Plan. The administrator may delegate to a committee consisting of one or more officers the authority to grant awards to employees who are not subject to the reporting and other provisions of Section&#160;16 of the Exchange Act and not members of the delegated committee, subject to certain limitations and guidelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Persons eligible to participate in our 2025 Stock Plan will be those full or part-time officers, employees, non-employee directors, advisors, and consultants of the Combined Company and its Affiliates, as defined in the 2025 Stock Plan, as selected from time to time by the administrator in its discretion. As of June&#160;30, 2025, following the closing of the Merger, approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; employees, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; non-employee directors and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; advisors and consultants of the Combined Company will be eligible to participate in the 2025 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our 2025 Stock Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&#160;422 of the Code and options that do not so qualify. Options granted under the 2025 Stock Plan will be non-qualified options if they fail to qualify as incentive stock options or exceed the annual limit on incentive stock options. Incentive stock options may only be granted to employees of the Combined Company and its subsidiaries. Non-qualified options may be granted to any persons eligible to awards under the 2025 Stock Plan. The exercise price of each option will be determined by the administrator but may not be less than 100.0% of the fair market value of the common stock on the date of grant or, in the case of an incentive stock option granted to a 10.0% stockholder, 110.0% of such share&#8217;s fair market value. However, options may be granted with an exercise price per share that is less than 100.0% of the fair market value on the date of grant (i)&#160;pursuant to a transaction described in, and in a manner consistent with, Section&#160;424(a)&#160;of the Code, (ii)&#160;to individuals who are not subject to U.S. income tax on the date of grant or (iii)&#160;if the option is otherwise exempt from or compliant with Section&#160;409A. The term of each option will be fixed by the administrator and may not exceed 10&#160;years from the date of grant or, in the case of an incentive stock option granted to a 10.0% stockholder, five&#160;years. The administrator will determine at what time or times each option may be exercised, and may, at any time, accelerate the vesting of such options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of options, the option exercise price must be paid in full either in cash, by certified or bank check or other instrument acceptable to the administrator or by delivery (or attestation to the ownership) of shares of common stock, valued at their fair market value on the date of exercise, that are not then subject to restrictions under any Combined Company plan. Subject to applicable law, the exercise price may also be delivered by a broker pursuant to irrevocable instructions to the broker from the optionee. In addition, the administrator may permit non-qualified options to be exercised using a &#8220;net exercise&#8221; arrangement that reduces the number of shares issued to the optionee by the largest whole number of shares with fair market value that does not exceed the aggregate exercise price.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">235</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The administrator may award SARs subject to such conditions and restrictions as it may determine. SARs entitle the recipient to cash or shares of common stock equal to the value of the appreciation in our stock price over the exercise price. The exercise price may not be less than 100.0% of the fair market value of our common stock on the date of grant. The term of each SAR will be fixed by the administrator and may not exceed 10&#160;years from the date of grant. The administrator will determine at what time or times each SAR may be exercised. Notwithstanding the foregoing, SARs may be granted with an exercise price per share that is less than 100.0% of the fair market value on the date of grant (i)&#160;pursuant to a transaction described in, and in a manner consistent with, Section&#160;424(a)&#160;of the Code, (ii)&#160;to individuals who are not subject to U.S. income tax on the date of grant or (iii)&#160;if the SAR is otherwise exempt from or compliant with Section&#160;409A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The administrator may award restricted shares of common stock and RSUs to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain vesting conditions and/or continued employment with us through a specified vesting period. The administrator may also grant shares of common stock that are free from any restrictions under our 2025 Stock Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. The administrator may grant dividend equivalent rights to participants that entitle the recipient to receive credits for dividends that would be paid if the recipient had held a specified number of shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The administrator may grant cash bonuses under the 2025 Stock Plan to participants, subject to the achievement of certain vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2025 Stock Plan provides that upon the effectiveness of a &#8220;sale event,&#8221; as defined in the 2025 Stock Plan, an acquirer or successor entity may assume, continue or substitute outstanding awards under our 2025 Stock Plan. To the extent that awards granted under the 2025 Stock Plan are not assumed or continued or substituted by the successor entity, upon the effective time of the sale event, the 2025 Stock Plan and such awards shall terminate. In such case, except as may be otherwise provided in the relevant award agreement, all awards with time-based vesting conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the sale event, and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a sale event in the administrator&#8217;s discretion or to the extent specified in the relevant award certificate. In the event of such termination, the Combined Company may make or provide for payment, in cash or in kind, to participants holding options and SARs equal to the difference between the value of the per share consideration to be received by stockholders in the sale event and the exercise price of the options or SARs (provided that, in the case of an option or SAR with an exercise price equal to or greater than the value of the per share consideration to be received by stockholders in the sale event, such option or SAR shall be cancelled for no consideration). The Combined Company shall also have the option to make or provide for a payment, in cash or in kind, to grantees holding other awards in an amount equal to the value of the per share consideration to be received by stockholders in the sale event multiplied by the number of vested shares under such award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise determined by the administrator, awards under the 2025 Stock Plan are not transferable other than by will or the laws of descent and distribution and may be exercised during a participant&#8217;s lifetime only by the participant. The administrator may permit non-qualified stock options to be transferred by gift to certain permitted transferees, subject to such terms and conditions as the administrator may establish.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2025 Stock Plan requires appropriate or proportionate adjustments to be made to the number of shares reserved for issuance under the 2025 Stock Plan, including the maximum number of shares that may be issued in the form of incentive stock options; the number and kind of shares subject to outstanding awards under the 2025 Stock Plan; and the applicable purchase or repurchase price of outstanding awards under the 2025 Stock Plan, in the event of certain corporate transactions or changes in capitalization, such as stock splits, stock dividends, recapitalizations, reorganizations, or similar events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Participants are responsible for any applicable federal, state, local, or foreign tax withholding obligations in connection with awards under the 2025 Stock Plan. The Combined Company and its affiliates have, to the extent permitted by law, the right to deduct any such taxes from any payment of any kind otherwise due to the participant or to satisfy any applicable withholding obligations by any other method of withholding that the Combined Company and its affiliates deem appropriate. The administrator may require that such tax withholding obligations be satisfied by withholding shares of common stock otherwise deliverable under the award, by payment in cash or check, or through other arrangements, including a sale of shares issued upon vesting or exercise of an award to cover the required withholding.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">236</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To facilitate the granting of awards to individuals residing or working outside of the United States, the administrator may establish sub-plans or modify the terms and procedures applicable to such awards as necessary or appropriate to comply with foreign laws, accommodate local practices, or obtain more favorable tax treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Awards under the 2025 Stock Plan will be subject to the Combined Company&#8217;s clawback or recoupment policy as in effect from time to time, and to any clawback or similar requirements imposed by applicable law or stock exchange listing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s board of directors may amend or discontinue the 2025 Stock Plan and the administrator may amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may materially and adversely affect rights under an award without the holder&#8217;s consent. Certain amendments to the 2025 Stock Plan require the approval of Combined Company stockholders. The administrator of the 2025 Stock Plan is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options and SARS or effect the repricing of such awards through cancellation and re-grants without stockholder consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No awards may be granted under the 2025 Stock Plan after the date that is 10&#160;years from the effective date of the 2025 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Form&#160;S-8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the consummation of the Merger, when permitted by SEC rules, we intend to file with the SEC a registration statement on Form&#160;S-8 covering the common stock issuable under the 2025 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Tax Consequences</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the principal U.S. federal income tax consequences of certain transactions under the 2025 Stock Plan, which, subject to approval by Carisma common stockholders, will not become effective until the date of the closing of the Merger. This summary is not intended to be exhaustive and does not discuss the income tax laws of any local, state or foreign jurisdiction in which a participant may reside and/or provide services. The information is based upon current federal income tax rules&#160;and therefore is subject to change when those rules&#160;change. Because the tax consequences to any participant may depend on such participant&#8217;s particular situation, each participant should consult the participant&#8217;s tax adviser regarding the federal, state, local and other tax consequences of the grant or exercise of an award or the disposition of stock acquired the 2025 Stock Plan. The 2025 Stock Plan is not qualified under the provisions of Section&#160;401(a)&#160;of the Code and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Incentive Stock Options.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No taxable income is generally realized by the optionee upon the grant or exercise of an incentive stock option. If shares of common stock issued to an optionee pursuant to the exercise of an incentive stock option are sold or transferred after two&#160;years from the date of grant and after one&#160;year from the date of exercise, then generally (i)&#160;upon sale of such shares, any amount realized in excess of the option exercise price (the amount paid for the shares) will be taxed to the optionee as a long-term capital gain, and any loss sustained will be a long-term capital loss, and (ii)&#160;the Combined Company will not be entitled to any deduction for federal income tax purposes; provided that such incentive stock option otherwise meets all of the technical requirements of an incentive stock option. The exercise of an incentive stock option will give rise to an item of tax preference that may result in alternative minimum tax liability for the optionee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If shares of common stock acquired upon the exercise of an incentive stock option are disposed of prior to the expiration of the two-year and one-year holding periods described above (a &#8220;disqualifying disposition&#8221;), generally (i)&#160;the optionee will realize ordinary income in the&#160;year of disposition in an amount equal to the excess (if any) of the fair market value of the shares of common stock at exercise (or, if less, the amount realized on a sale of such shares of common stock) over the exercise price thereof, and (ii)&#160;the Combined Company will be entitled to deduct such amount. Special rules&#160;will apply where all or a portion of the exercise price of the incentive stock option is paid by tendering shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If an incentive stock option is exercised at a time when it no longer qualifies for the tax treatment described above, the option is treated as a non-qualified option. Generally, an incentive stock option will not be eligible for the tax treatment described above if it is exercised more than three&#160;months following termination of employment (or one&#160;year in the case of termination of employment by reason of disability). In the case of termination of employment by reason of death, the three-month rule&#160;does not apply.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">237</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Non-Qualified Options.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No income is generally realized by the optionee at the time a non-qualified option is granted. Generally (i)&#160;at exercise, ordinary income is realized by the optionee in an amount equal to the difference between the option exercise price and the fair market value of the shares of common stock on the date of exercise, and we receive a tax deduction for the same amount, and (ii)&#160;at disposition, appreciation or depreciation after the date of exercise is treated as either short-term or long-term capital gain or loss depending on how long the shares of common stock have been held. Special rules&#160;will apply where all or a portion of the exercise price of the non-qualified option is paid by tendering shares of common stock. Upon exercise, the optionee will also be subject to Social Security taxes on the excess of the fair market value over the exercise price of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Awards.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Participants typically are subject to income tax and recognize such tax at the time that an award is exercised, vests or becomes non-forfeitable, unless the award provides for deferred settlement. The Combined Company generally will be entitled to a tax deduction in connection with other awards under the 2025 Stock Plan in an amount equal to the ordinary income realized by the participant at the time the participant recognizes such income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Parachute Payments.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The vesting of any portion of an award that is accelerated due to the occurrence of a change in control (such as a sale event) may cause all or a portion of the payments with respect to such accelerated awards to be treated as &#8220;parachute payments&#8221; as defined in the Code. Any such parachute payments may be non-deductible to the Combined Company, in whole or in part, and may subject the recipient to a non-deductible 20.0% federal excise tax on all or a portion of such payment (in addition to other taxes ordinarily payable).</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">238</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">New Plan Benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">No grants have been made under the 2025 Stock Plan, however; it is anticipated that certain executive officers and members of senior management of the Combined Company may be granted stock options and RSU awards under the 2025 Stock Plan in connection with the Merger, effective as of and contingent upon the closing of the Merger. The following table summarizes the stock option awards and RSUs that are anticipated to be granted in connection with the Merger to each executive officer, each director, the executive officers as a group, other employees as a group, and the non-employee directors as a group of the Combined Company. The value of the awards granted under the 2025 Stock Plan will depend on a number of factors, including the fair market value of common stock on future dates, the exercise decisions made by grantees and the extent to which any applicable performance vesting criteria are achieved. All other future awards to directors, executive officers, employees and consultants under the 2025 Stock Plan are not presently determinable at the date of this proxy statement/prospectus and have not been included in the table below because participation and the types of awards that may be granted under the 2025 Stock Plan are subject to the discretion of the administrator.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:26.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name and Position</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Dollar&#160;Value&#160;($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Subject&#160;to&#160;Stock</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:26.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Subject&#160;to&#160;RSUs</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Steven Kelly<i style="font-style:italic;"><br/></i><i style="font-style:italic;">President and Chief Executive Officer</i></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Natalie McAndrew<br/><i style="font-style:italic;">Vice President of Finance</i></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Karthik Musunuri <br/><i style="font-style:italic;">Director</i></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.4%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Shine, MBA<br/><i style="font-style:italic;">Director</i></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">David Anderson<i style="font-style:italic;"><br/></i><i style="font-style:italic;">Director</i></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.4%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/></i><i style="font-style:italic;">Director</i></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/></i><i style="font-style:italic;">Director</i></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.4%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All executive officers, as a group</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.99%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All directors who are not executive officers, as a group</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.4%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All employees who are not executive officers, as a group</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:11.7pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span><span style="display:inline-block;width:6.3pt;"></span><span style="white-space:pre-wrap;">Amount represents the estimated value of shares subject to RSU awards, based upon a price per share of common stock of $  . In accordance with SEC rules, no dollar value has been estimated with respect to stock option awards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Equity Compensation Plan Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">For more information regarding Carisma&#8217;s existing equity plans, please see the section titled &#8220;<i style="font-style:italic;">Carisma Equity Compensation Plan Information</i>&#8221; contained elsewhere in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Resolution to be Voted Upon</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">The full text of the resolution to be passed is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">&#8220;RESOLVED, that the OrthoCellix,&#160;Inc. 2025 Stock Option and Incentive Plan, in the form attached as <i style="font-style:italic;">Annex H</i> to the proxy statement/prospectus in respect of the Carisma Special Meeting, to be approved and adopted in all respects with effect from the closing of the Merger and transactions contemplated by the Merger Agreement.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">If Proposal No.&#160;1 is not approved, the Stock Plan Proposal will not be presented at the Carisma Special Meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Recommendation of the Carisma Board with Respect to the Stock Plan Proposal</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">CARISMA&#8217;s BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE CARISMA STOCKHOLDERS VOTE &#8220;FOR&#8221; THE STOCK PLAN PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">239</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_464f460e_bff0_4708_aac7_72c7df9b8b86"></a><a id="PROPOSALNO3THEDIRECTORELECTIONPROPOSAL_9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;3&#160;- THE DIRECTOR ELECTION PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors currently consists of seven members. In accordance with the terms of Carisma&#8217;s certificate of incorporation, Carisma&#8217;s board of directors is divided into three classes (Class&#160;I, Class&#160;II and Class&#160;III), with members of each class serving staggered three-year terms. The members of the classes are divided as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;I directors are currently John Hohneker, M.D. and Sohanya Cheng, and their term expires at the annual meeting of stockholders to be held in 2027;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;II directors are Steven Kelly, Briggs Morrison, M.D. and Sanford Zweifach, and their term expires at the Carisma Special Meeting; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;III directors are Marella Thorell and David Scadden, M.D., and their term expires at the annual meeting of stockholders to be held in 2026.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the&#160;year in which their term expires. As further discussed below, Mr.&#160;Kelly, Dr.&#160;Morrison and Mr.&#160;Zweifach will be standing for re-election at the Carisma Special Meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s certificate of incorporation provides that the authorized number of directors may be changed only by resolution of Carisma&#8217;s board of directors. Carisma&#8217;s certificate of incorporation also provides that Carisma&#8217;s directors may be removed only for cause and only by the affirmative vote of the holders of at least 75.0% of the votes that all Carisma stockholders would be entitled to cast in an annual election of directors, and that any vacancy on Carisma&#8217;s board of directors, including a vacancy resulting from an enlargement of Carisma&#8217;s board of directors, may be filled only by vote of a majority of Carisma&#8217;s directors then in office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors, upon the recommendation of the nominating and corporate governance committee, has nominated Steven Kelly, Briggs Morrison, M.D. and Sanford Zweifach for election as Class&#160;II directors at the Carisma Special Meeting. Mr.&#160;Kelly, Dr.&#160;Morrison and Mr.&#160;Zweifach are presently directors. Each of Mr.&#160;Kelly, Dr.&#160;Morrison and Mr.&#160;Zweifach have indicated a willingness to serve as a director, if elected. If no contrary indication is made, proxies are to be voted for Mr.&#160;Kelly, Dr.&#160;Morrison and Mr.&#160;Zweifach, or in the event that Mr.&#160;Kelly, Dr.&#160;Morrison or Mr.&#160;Zweifach is not a candidate or is unable to serve as a director at the time of the election (which is not currently expected), for any nominee who is designated by Carisma&#8217;s board of directors to fill the vacancy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s stockholders should understand, however, that if the Merger is consummated, the effect of the approval of the director nominees named in this Proposal No.&#160;3 will be limited because the composition of the Carisma board of directors will be reconstituted upon completion of the Merger in accordance with the Merger Agreement. At the Effective Time of the Merger, the Combined Company&#8217;s board of directors will be fixed at six members, consisting of one member designated by Carisma and five members designated by OrthoCellix. All of Carisma&#8217;s current directors, other than Steven Kelly, are expected to resign from their positions as directors of Carisma, effective immediately prior to the Effective Time of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is <b style="font-weight:bold;">not</b> conditioned upon the approval of this Proposal No.&#160;3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma has no formal policy regarding board diversity, but Carisma&#8217;s Corporate Governance Guidelines provide that the value of diversity should be considered and that the background and qualifications of the members of Carisma&#8217;s board of directors considered as a group should provide a significant breadth of experience, knowledge and ability to assist Carisma&#8217;s board of directors in fulfilling its responsibilities. Carisma&#8217;s priority in selection of board members is identification of members who will further the interests of Carisma&#8217;s stockholders through their established records of professional accomplishment, the ability to contribute positively to the collaborative culture among Carisma&#8217;s board members, knowledge of Carisma&#8217;s business, understanding of the competitive landscape in which Carisma operates and adherence to high ethical standards. Certain individual qualifications and skills of Carisma&#8217;s directors that contribute to Carisma&#8217;s board of directors&#8217; effectiveness as a whole are described in the following paragraphs.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">240</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nominees for Election as Class&#160;II Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Biographical information as of the date of this proxy statement/prospectus, including principal occupation and business experience during the last five&#160;years, for Carisma&#8217;s nominees for election as Class&#160;II directors at Carisma&#8217;s Special Meeting is set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Steven Kelly</span>, age 60, has served as Carisma&#8217;s President and Chief Executive Officer and a member of Carisma&#8217;s board of directors since the closing of the Sesen Bio Merger. He previously served as President and Chief Executive Officer of Legacy Carisma and as a member of the Legacy Carisma board of directors since February&#160;2018. Prior to joining Legacy Carisma, Mr.&#160;Kelly served as Chief Executive Officer of Pinteon Therapeutics,&#160;Inc., a biotechnology company, from April&#160;2014 to July&#160;2015 and as the Chief Executive Officer of Theracrine,&#160;Inc., a biopharmaceutical company, from June&#160;2011 to August&#160;2012. Mr.&#160;Kelly currently serves on the board of directors of Artelo Biosciences,&#160;Inc. (Nasdaq: ARTL), a public clinical-stage biopharmaceutical company. Mr.&#160;Kelly received a B.S. from the University of Oregon and a M.B.A. from Cornell University. Carisma&#8217;s board of directors believes Mr.&#160;Kelly is qualified to serve as a member of Carisma&#8217;s board of directors because of his extensive knowledge of Carisma based on his current role as its President and Chief Executive Officer, as well as his significant biopharmaceutical industry and management experience.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Briggs Morrison, M.D.</span>, age 66, has served as a member of Carisma&#8217;s board of directors since the closing of the Sesen Bio Merger. He previously served as a member of the Legacy Carisma board of directors since July&#160;2020. Dr.&#160;Morrison is currently the Chief Executive Officer and a member of the board of directors at Crossbow Therapeutics, a position he has held since February&#160;2022. He is also an executive partner at MPM Capital LLC, a healthcare-focused venture capital firm, a position he has held since June&#160;2015. He previously served as President, Head of Research and Development of Syndax Pharmaceuticals,&#160;Inc. (Nasdaq: SNDX) (&#8220;Syndax&#8221;), a public commercial-stage biopharmaceutical company, from February&#160;2022 to March&#160;2023, and as Syndax&#8217;s Chief Executive Officer from June&#160;2015 to February&#160;2022. Prior to joining Syndax, Dr.&#160;Morrison served as Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca plc (&#8220;AstraZeneca&#8221;), from January&#160;2012 to June&#160;2015, leading the company&#8217;s global, late-stage development organization and serving as a member of the AstraZeneca senior executive team. In addition, Dr.&#160;Morrison currently serves on the boards of directors of Syndax, Repare Therapeutics&#160;Inc. (Nasdaq: RPTX), a public clinical-stage precision oncology company, Arvinas,&#160;Inc. (Nasdaq: ARVN), a public clinical-stage biotechnology company, and Werewolf Therapeutics,&#160;Inc. (Nasdaq: HOWL), a public clinical-stage biopharmaceutical company, as well as on the boards of directors of several private companies. Dr.&#160;Morrison received a B.S. in biology from Georgetown University and a M.D. from the University of Connecticut Medical School. Carisma&#8217;s board of directors believes Dr.&#160;Morrison is qualified to serve as a member of Carisma&#8217;s board of directors due to his extensive executive leadership experience, medical background and training, and extensive service on the boards of other public and private biopharmaceutical companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sanford Zweifach</span>, age 69, has served as Chair of Carisma&#8217;s board of directors since the closing of the Sesen Bio Merger. He previously served as a member and Chair of the Legacy Carisma board of directors since November&#160;2021. Mr.&#160;Zweifach has served as the Founder and President of Pelican Consulting Group, a biotechnology consulting firm, since December&#160;2019. Prior to Pelican Consulting Group, Mr.&#160;Zweifach founded and served as Chief Executive Officer of Nuvelution Pharma,&#160;Inc., a pharmaceutical company, from June&#160;2015 to November&#160;2019. Mr.&#160;Zweifach currently serves on the boards of directors of Essa Pharma&#160;Inc. (Nasdaq: EPIX), a public clinical-stage pharmaceutical company, and Compugen&#160;Ltd. (Nasdaq: CGEN), a public clinical-stage drug discovery and development company. Mr.&#160;Zweifach received a B.A. in Biology from University of California San Diego and a M.S. in Human Physiology from University of California Davis. Carisma&#8217;s board of directors believes Mr.&#160;Zweifach is qualified to serve as Chair of Carisma&#8217;s board of directors because of his extensive experience in the biopharmaceutical industry and service on the boards of other public and private biopharmaceutical companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Carisma&#8217;s board of directors unanimously recommends the stockholders vote &#8220;FOR&#8221; the election of Steven Kelly, Briggs Morrison, M.D. and Sanford Zweifach as Class&#160;II directors for a three-year term ending at the annual meeting of stockholders to be held in 2028</b><span style="text-transform:uppercase;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Directors Continuing in Office</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Biographical information as of the date of this proxy statement/prospectus, including principal occupation and business experience during the last five&#160;years, for Carisma&#8217;s directors continuing in office after the Carisma Special Meeting is set forth below.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">241</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class&#160;I Directors (Term Expires at 2027 Annual Meeting of Stockholders)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">John Hohneker, M.D.</span>, age 65, has served as a member of Carisma&#8217;s board of directors since April&#160;2024. Dr.&#160;Hohneker most recently served as President and Chief Executive Officer of Anokion SA, a Swiss biotechnology company, from January&#160;2018 to February&#160;2021. Prior to Anokion SA, he led Research and Development at Forma Therapeutics (&#8220;Forma&#8221;), a biotechnology company, from August&#160;2015 to January&#160;2018. Prior to Forma, Dr.&#160;Hohneker held various leadership roles during his 14&#160;years at Novartis AG, from 2001 to 2015, where he most recently served as Senior Vice President and Global Head of Development, Immunology and Dermatology. Dr.&#160;Hohneker also currently serves on the board of directors for Curis,&#160;Inc. (Nasdaq: CRIS), a publicly traded clinical-stage biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, ArriVent BioPharma,&#160;Inc. (Nasdaq: AVBP), a publicly traded clinical-stage biotechnology company focused on developing new medicines for cancer, Artios LTD, a private clinical-stage biotechnology company focused on DNA repair mechanisms and Trishula Therapeutics, a private clinical-stage biotechnology company targeting cancer immunotherapy. Previously, he served on the boards of directors of Evelo Biosciences (Nasdaq: EVLO), a public clinical-stage biotechnology company, from January&#160;2021 to July&#160;2023 and Humanigen (Nasdaq: HGEN), a public clinical-stage biotechnology company, from October&#160;2021 to July&#160;2023. Dr.&#160;Hohneker received a B.S. in chemistry from Gettysburg College and a M.D. from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School. He completed his internal medicine internship and residency and medical oncology fellowship at the University of North Carolina Chapel Hill. Carisma&#8217;s board of directors believes Dr.&#160;Hohneker is qualified to serve as a member of Carisma&#8217;s board of directors due to his extensive executive leadership experience, medical background and training, and extensive service on the boards of other public and private biopharmaceutical companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sohanya Cheng</span>, age 42, has served as a member of Carisma&#8217;s board of directors since October&#160;2024. Ms.&#160;Cheng currently serves as the EVP, Chief Commercial Officer, and Head of Business Development at Karyopharm Therapeutics&#160;Inc. (Nasdaq: KPTI) (&#8220;Karyopharm&#8221;), a public pharmaceutical company, since December&#160;2021 and was previously the SVP, Sales and Commercial Operations from June&#160;2021 to December&#160;2021. Prior to joining Karyopharm, Ms.&#160;Cheng was Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals,&#160;Inc. (Nasdaq: ARWR) (&#8220;Arrowhead&#8221;), a public pharmaceutical company, from August&#160;2020 to December&#160;2020. Prior to her role at Arrowhead, Ms.&#160;Cheng spent 11&#160;years at Amgen, a public biotechnology company, where she held a variety of sales and marketing leadership roles supporting the commercialization of key oncology brands, including as Executive Director, Head of National Sales Force&#160;&amp; Oncology Contracting Strategy from 2019 to August&#160;2020, Executive Director, Head of Marketing&#160;&amp; Sales for their multiple myeloma business from 2018 to 2019, and Chief of Staff to General Manager and Strategy&#160;&amp; Operations Director for their oncology business from 2017 to 2018. Ms.&#160;Cheng holds a MBA from the MIT Sloan School of Management and both a BSc and MA from the University of Cambridge, UK. Carisma&#8217;s board of directors believes Ms.&#160;Cheng is qualified to serve as a member of Carisma&#8217;s board of directors due to her extensive executive leadership experience at biopharmaceutical companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class&#160;III Directors (Term Expires at 2026 Annual Meeting of Stockholders)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">David Scadden, M.D.</span>, age 72, has served as a member of Carisma&#8217;s board of directors since June&#160;2024. Dr.&#160;Scadden is the Gerald and Darlene Jordan Professor of Medicine and Professor of Stem Cell and Regenerative Biology at Harvard University, a position he has held since 2006. Since 1995, Dr.&#160;Scadden has practiced at the Massachusetts General Hospital, where he founded and directs the Center for Regenerative Medicine and directed the Hematologic Malignancies Center of the MGH Cancer Center for 10&#160;years. Dr.&#160;Scadden co-founded and co-directs the Harvard Stem Cell Institute and is Chairman emeritus and Professor of the Harvard University Department of Stem Cell and Regenerative Biology. He is a member of the National Academy of Medicine and the American Academy of Arts and Sciences and a Fellow of the American College of Physicians and the American Academy for the Advancement of Science. He is a former member of the Board of External Experts for the National Heart, Lung and Blood Institute, the Board of Scientific Counselors for the National Cancer Institute and Board of Directors of the International Society for Stem Cell Research. Dr.&#160;Scadden is a scientific founder of Fate Therapeutics,&#160;Inc. (Nasdaq: FATE), and Dianthus Therapeutics,&#160;Inc. (Nasdaq: DNTH), and currently serves on the board of directors of Agios Pharmaceuticals,&#160;Inc. (Nasdaq: AGIO), a public biotechnology company, since May&#160;2017 and Editas Medicine,&#160;Inc. (Nasdaq: EDIT), a public clinical-stage biopharmaceutical company, since February&#160;2019. Previously, he served on the board of directors of Magenta Therapeutics,&#160;Inc., a public biotechnology company where he was a scientific founder, from November&#160;2016 until its acquisition in September&#160;2023. He also serves as a member of the board of directors of private biotechnology companies Lightning Biotherapeutics and Sonata Therapeutics. Dr.&#160;Scadden holds a B.A. in English from Bucknell University and a M.D. from Case Western Reserve University. Carisma&#8217;s board of directors believes Dr.&#160;Scadden is qualified to serve as a member of Carisma&#8217;s board of directors due to his extensive executive leadership experience, medical background and training, and extensive service on the boards of other public and private biopharmaceutical companies and institutes.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">242</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Marella Thorell</span>, age 58, has served as a member of Carisma&#8217;s board of directors since June&#160;2024. Ms.&#160;Thorell is currently the Executive Vice President, Chief Financial Officer of Seres Therapeutics,&#160;Inc. (Nasdaq: MCRB), a public clinical stage biotechnology company, since March&#160;2024. Previously, she served as the Chief Financial Officer and Treasurer of Evelo Biosciences,&#160;Inc., a biotechnology company, from September&#160;2022 to December&#160;2023. From January&#160;2021 to July&#160;2022, Ms.&#160;Thorell served as Chief Accounting Officer and previously as Head of Finance at Centessa Pharmaceuticals PLC (Nasdaq: CNTA) (&#8220;Centessa&#8221;), a public pharmaceutical company. Prior to her role at Centessa, from October&#160;2019 to December&#160;2020, Ms.&#160;Thorell served as Chief Financial Officer at Palladio Biosciences, a biotechnology company, prior to its acquisition by Centessa. Before that, Ms.&#160;Thorell spent over 10&#160;years at Realm Therapeutics PLC, a biopharmaceutical company, serving in various roles of increasing responsibility, including Chief Financial Officer and Chief Operating Officer. Ms.&#160;Thorell has served on the boards of directors and as the Audit Committee Chair of Essa since July&#160;2019 and previously served on the board of directors of Vallon Pharmaceuticals,&#160;Inc., a pharmaceutical company, from February&#160;2021 until its reverse-merger with GRI Bio,&#160;Inc. in April&#160;2023. Ms.&#160;Thorell holds a B.S. in Business from Lehigh University. Carisma&#8217;s board of directors believes Ms.&#160;Thorell is qualified to serve as a member of Carisma&#8217;s board of directors due to her extensive executive leadership experience, medical background and training, and extensive service on the boards of other public and private biopharmaceutical companies.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">243</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_bdaecdbf_ffa0_406b_8467_cd84ec464f2e"></a><a id="PROPOSALNO4THEAUDITORRATIFICATIONPROPOSA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;4&#160;- THE AUDITOR RATIFICATION PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s stockholders are being asked to ratify the appointment by the audit committee of the board of directors of KPMG LLP as Carisma&#8217;s independent registered public accounting firm for the fiscal&#160;year ending December&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The audit committee is solely responsible for selecting Carisma&#8217;s independent registered public accounting firm for the fiscal&#160;year ending December&#160;31, 2025. Stockholder approval is not required to appoint KPMG LLP as Carisma&#8217;s independent registered public accounting firm. However, Carisma&#8217;s board of directors believes that submitting the appointment of KPMG LLP to the stockholders for ratification is good corporate governance. If the stockholders do not ratify this appointment, the audit committee will reconsider whether to retain KPMG&#160;LLP. If the selection of KPMG LLP is ratified, the audit committee, in its discretion, may direct the appointment of a different independent registered public accounting firm at any time it decides that such a change would be in the best interest of Carisma&#8217;s company and its stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is <b style="font-weight:bold;">not</b> conditioned upon the approval of this Auditor Ratification Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A representative of KPMG LLP is expected to virtually attend the Carisma Special Meeting and will have an opportunity to make a statement if such representative desires to do so and to respond to appropriate questions from Carisma&#8217;s stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma incurred the following fees from KPMG LLP for the audits of the consolidated financial statements and for other services provided during the&#160;years ended December&#160;31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:80.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.55%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.45%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Fee Category</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Audit fees<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">525,000</p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.45%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">570,740</p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Audit-related fees</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.55%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.45%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tax fees<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.55%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">92,457</p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.45%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">105,000</p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All other fees</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total fees</p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">617,457</p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">675,740</p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Audit fees&#8221; consists of fees incurred for the audit of Carisma&#8217;s consolidated financial statements, including the review of Carisma&#8217;s interim financial statements, fees related to comfort letters and review of SEC filings, and fees related to the review of Carisma&#8217;s Registration Statement on Form&#160;S-4 in 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Tax fees&#8221; consist of fees for tax compliance services and tax consulting.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As disclosed in a Current Report on Form&#160;8-K filed with the SEC on March&#160;8, 2023, on March&#160;6, 2023, the audit committee dismissed Ernst&#160;&amp; Young LLP as Carisma&#8217;s independent registered public accounting firm, effective as of the effective time of the Sesen Bio Merger and on March&#160;7, 2023, the audit committee approved the engagement of KPMG LLP as Carisma&#8217;s independent registered public accounting firm for the&#160;year ended December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma incurred the following fees from Ernst&#160;&amp; Young LLP for the audit of the consolidated financial statements and for other services provided during the&#160;year ended December&#160;31, 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Fee Category</b></p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Audit fees<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:3.12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">91,500</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Audit-related fees</p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tax fees<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:3.12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.8%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">63,398</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All other fees</p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total fees</p></td><td style="vertical-align:bottom;width:3.12%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">154,898</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Audit fees&#8221; for fiscal&#160;year 2023 consist of a) fees incurred in connection with Carisma&#8217;s registration statement on Form&#160;S-8 filed with the SEC April&#160;4, 2023, b) fees incurred in connection with Carisma&#8217;s registration statements on Form&#160;S-3 filed with the SEC on April&#160;17, 2023, and c) related comfort letter procedures.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Tax fees&#8221; for services performed in fiscal&#160;years 2023 consist of fees for tax compliance services relating primarily to the preparation of Sesen Bio&#8217;s U.S. and various state tax returns. In addition, &#8220;tax fees&#8221; for fiscal&#160;years 2023 relate to services </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">244</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rendered related to our recovery of German VAT taxes paid for the shipment of Carisma&#8217;s drug substance from the United States to Carisma&#8217;s contract manufacturer in Germany, and tax advisory transfer pricing services.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The reports of Ernst&#160;&amp; Young LLP on Sesen Bio&#8217;s condensed financial statements for the interim period from January&#160;1, 2023 through March&#160;7, 2023 did not contain an adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the audits of Sesen Bio&#8217;s condensed financial statements for the interim period from January&#160;1, 2023 through March&#160;7, 2023, there were no: (i)&#160;disagreements with Ernst&#160;&amp; Young LLP on any matters of accounting principles or practices, financial statement disclosure, or auditing scope and procedures, which disagreements if not resolved to the satisfaction of Ernst&#160;&amp; Young LLP, would have caused Ernst&#160;&amp; Young LLP to make reference to the matter in its report or (ii)&#160;reportable events as that term is described in Item&#160;304(a)(1)(v)&#160;of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ernst &amp; Young LLP&#8217;s letter, dated March 7, 2023, was originally filed as Exhibit 16.1 to Carisma&#8217;s Current Report on Form 8-K filed on March 8, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024 and 2023, neither Carisma, Legacy Carisma, nor anyone on Carisma or Legacy Carisma&#8217;s behalf, consulted with KPMG LLP, regarding either (i)&#160;the application of accounting principles to a specific transaction, completed or proposed, or the type of audit opinion that might be rendered on Legacy Carisma&#8217;s financial statements, and neither a written report nor oral advice was provided to Legacy Carisma that KPMG LLP concluded was an important factor considered by Legacy Carisma in reaching a decision as to any accounting, auditing or financial reporting issue or (ii)&#160;any matter that was either the subject of a disagreement (as defined in Item&#160;304(a)(1)(iv)&#160;of Regulation S-K and the related instructions) or a reportable event (as described in Item&#160;304(a)(1)(v)&#160;of Regulation S-K).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Audit Committee Pre-Approval Policy and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s audit committee has adopted policies and procedures relating to the approval of all audit and non-audit services that are to be performed by Carisma&#8217;s independent registered public accounting firm. This policy provides that Carisma will not engage its independent registered public accounting firm to render audit or non-audit services unless the service is specifically approved in advance by Carisma&#8217;s audit committee or the engagement to render the service is entered into pursuant to the audit committee&#8217;s pre-approval procedure described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, Carisma&#8217;s audit committee may pre-approve specified types of services that are expected to be provided to Carisma by its independent registered public accounting firm during the next 12&#160;months. At the time such pre-approval is granted, the audit committee must identify the particular pre-approved services in a sufficient level of detail so that Carisma&#8217;s management will not be called upon to make a judgment as to whether a proposed service fits within the pre-approved services and, at each regularly scheduled meeting of the audit committee following such pre-approval, management or the independent registered public accounting firm shall report to the audit committee regarding each service actually provided to Carisma pursuant to such pre-approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Carisma&#8217;s board of directors unanimously recommends the stockholders vote &#8220;FOR&#8221; the ratification of the appointment of the independent registered public accounting firm for the fiscal&#160;year ending December&#160;31, 2025.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">245</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF CARISMA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s audit committee has reviewed its audited consolidated financial statements for the fiscal&#160;year ended December&#160;31, 2024 and discussed them with Carisma&#8217;s management and KPMG LLP, Carisma&#8217;s independent registered public accounting firm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s audit committee has also received from, and discussed with, KPMG LLP various communications that KPMG LLP is required to provide to the audit committee, including the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board and the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, KPMG LLP provided Carisma&#8217;s audit committee with the written disclosures and the letter required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent registered public accounting firm&#8217;s communications with the audit committee concerning independence, and the audit committee has discussed with Carisma&#8217;s independent registered public accounting firm their independence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the review and discussions referred to above, Carisma&#8217;s audit committee recommended to Carisma&#8217;s board of directors that its financial statements audited by KPMG LLP be included in Carisma&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This report of the audit committee is not &#8220;soliciting material,&#8221; shall not be deemed &#8220;filed&#8221; with the SEC and shall not be incorporated by reference into any of Carisma&#8217;s filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent that Carisma specifically incorporates this information by reference, and shall not otherwise be deemed filed under such acts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The foregoing report has been furnished by the audit committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">BY THE AUDIT COMMITTEE OF THE<br/>BOARD OF DIRECTORS OF CARISMA<br/>THERAPEUTICS&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Marella Thorell<br/>Sohanya Cheng<br/>Sanford Zweifach</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">July&#160;21, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">246</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5bb19e4e_2b99_4d1b_bc60_d6f317ba819c"></a><a id="PROPOSALNO5THESAYONPAYPROPOSAL_214682"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;5&#160;- THE SAY ON PAY PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s compensation committee oversees Carisma&#8217;s executive compensation program and compensation awarded. The &#8220;Carisma Executive Compensation&#8221; section of this proxy statement/prospectus describes in detail Carisma&#8217;s executive compensation program and the decisions made by Carisma&#8217;s compensation committee and board of directors with respect to executive compensation matters. As described in the &#8220;Carisma Executive Compensation&#8221; section, Carisma&#8217;s executive compensation program embodies a pay-for-performance philosophy that supports Carisma&#8217;s business strategy and seeks to align the interests of Carisma&#8217;s executives with Carisma&#8217;s stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma is providing its stockholders the opportunity to vote to approve, on an advisory, non-binding basis, the compensation of Carisma&#8217;s named executive officers as disclosed in this proxy statement/prospectus in accordance with the SEC&#8217;s rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This proposal, which is commonly referred to as &#8220;say-on-pay,&#8221; is required by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, which added Section&#160;14A to the Exchange Act. Section&#160;14A of the Exchange Act also requires that stockholders have the opportunity to cast an advisory &#8220;say-on-frequency&#8221; vote with respect to whether future executive compensation advisory votes will be held every one, two or three&#160;years. Carisma last held a say-on-frequency vote in 2020, when Carisma&#8217;s stockholders voted in support of Carisma&#8217;s proposal to hold a &#8220;say-on-pay&#8221; advisory vote on the compensation of Carisma&#8217;s named executive officers each&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors is asking stockholders to approve a non-binding advisory vote on the following resolution:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">RESOLVED, that the compensation paid to Carisma&#8217;s named executive officers, as disclosed pursuant to the compensation disclosure rules&#160;of the SEC, including the compensation tables and any related material disclosed in this proxy statement/prospectus, is hereby approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA&#8217;S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE &#8220;FOR&#8221; THE ADVISORY VOTE ON CARISMA&#8217;S NAMED EXECUTIVE OFFICER COMPENSATION</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stockholders of Carisma should note the Merger is <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</b> conditioned on the approval of the Say on Pay Proposal, and as an advisory vote, this proposal is not binding. The outcome of this advisory vote does not overrule&#160;any decision by Carisma or its board of directors (or any committee thereof), create or imply any change to the fiduciary duties of Carisma or its board of directors (or any committee thereof), or create or imply any additional fiduciary duties for Carisma or its board of directors (or any committee thereof). However, Carisma&#8217;s compensation committee and board of directors value the opinions expressed by Carisma&#8217;s stockholders in their vote on this proposal and will consider the outcome of the vote when making future compensation decisions for Carisma&#8217;s named executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">247</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4cfc261b_1a8a_4da5_93b3_a3af5d86c651"></a><a id="PROPOSALNO6THEMERGERCOMPENSATIONPROPOSAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO. 6 - THE MERGER COMPENSATION PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section&#160;14A of the Exchange Act and Rule&#160;14a-21(c)&#160;thereunder, Carisma is seeking non-binding, advisory stockholder approval of certain compensation arrangements for Carisma named executive officers that are based on or otherwise relate to the Merger, as disclosed pursuant to Item&#160;402(t)&#160;of Regulation&#160;S-K in the section titled &#8220;<i style="font-style:italic;">The Merger&#8201;&#8212;&#8201;Interests of Carisma&#8217;s Directors and Executive Officers in the Merger&#8201;&#8212;&#8201; Golden Parachute Compensation</i>&#8221; beginning on page&#160;169&#160;of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors is asking stockholders to approve a non-binding advisory vote on the following resolution:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">RESOLVED, that certain compensation arrangements for Carisma&#8217;s named executive officers that are based on or otherwise relate to the Merger, as disclosed pursuant to Item&#160;402(t)&#160;of Regulation&#160;S-K in the section titled &#8220;<i style="font-style:italic;">The Merger&#8201;&#8212;&#8201;Interests of Carisma&#8217;s Directors and Executive Officers in the Merger&#8201;&#8212;&#8201; Golden Parachute Compensation</i>&#8221; in the proxy statement/prospectus, are hereby approved on a non-binding, advisory basis.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the vote is advisory in nature only, it will not be binding on Carisma. Accordingly, to the extent Carisma is contractually obligated to pay the compensation, the compensation will be payable to the named executive officers, subject only to the conditions applicable thereto, if the Merger is completed, regardless of the outcome of the advisory vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</b>&#160;conditioned upon the approval of the Merger Compensation Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the approval of the Merger Compensation Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA&#8217;S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT CARISMA&#8217;S STOCKHOLDERS VOTE &#8220;FOR&#8221; THE MERGER COMPENSATION PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">248</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_feafac61_f1b1_469d_8353_1fd8a17bfef2"></a><a id="PROPOSALNO7THEADJOURNMENTPROPOSAL_760612"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;7&#160;- THE ADJOURNMENT PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Carisma fails to receive a sufficient number of votes to approve Proposal No.&#160;1, Carisma may propose to adjourn the Carisma Special Meeting to a later date or dates, if necessary or appropriate, for the purpose of soliciting additional proxies to approve Proposal No. 1. Carisma currently does not intend to propose adjournment at the Carisma Special Meeting if there are sufficient votes to approve Proposal No.&#160;1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a quorum is not present at the Carisma Special Meeting, under Carisma&#8217;s by-laws, the chair of Carisma&#8217;s Special Meeting will have the power to adjourn the Carisma Special Meeting until a quorum is present or represented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</b><b style="font-weight:bold;">&#160;</b>conditioned upon the approval of the Adjournment Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the approval of the Adjournment Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Carisma&#8217;s board of directors unanimously recommends that the stockholders vote &#8220;FOR&#8221; the Adjournment Proposal, if necessary.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">249</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ffccb545_815a_4fff_8d33_365005f103df"></a><a id="CARISMASBUSINESS_106114"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA&#8217;S BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As used in this section, references to &#8220;the Company,&#8221; &#8220;Carisma,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Carisma Therapeutics&#160;Inc. (formerly Sesen Bio,&#160;Inc.) and its consolidated subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a biotechnology company that was previously focused on applying our industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. We have created a comprehensive set of platform technologies to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. We seek to apply our ability to engineer macrophages and monocytes, either<i style="font-style:italic;"> in vivo</i> or <i style="font-style:italic;">ex vivo</i>, using approaches and delivery systems most appropriate to each specific indication, to meaningfully alter the course of the disease. Our proprietary CAR-M platform uses chimeric antigen receptors (&#8220;CARs&#8221;) to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted anti-tumor immunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;7, 2023, we completed a business combination in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of September&#160;20, 2022 (the &#8220;Sesen Bio Merger Agreement&#8221;), pursuant to which Seahawk Merger Sub,&#160;Inc., our wholly-owned subsidiary merged with and into CTx Operations,&#160;Inc. (formerly CARISMA Therapeutics&#160;Inc.) (&#8220;Legacy Carisma&#8221;), with Legacy Carisma continuing as our wholly owned subsidiary and the surviving corporation of the merger (the &#8220;Sesen Bio Merger&#8221;) was consummated. Pursuant to the Sesen Bio Merger Agreement, we changed our name from &#8220;Sesen Bio,&#160;Inc.&#8221; to &#8220;Carisma Therapeutics&#160;Inc.&#8221; Following the completion of the Sesen Bio Merger, our business became primarily the business conducted by Legacy Carisma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2024 Revised Operating Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2024, following a strategic review of our operating plan for 2024 and future periods, we approved a revised operating plan intended to balance value creation and expense management with our available cash resources. The objective of our revised operating plan was to focus our clinical development efforts on high potential value programs with meaningful near-term milestones and eliminate non-essential expenses and headcount to extend our cash runway. Under that plan, we intended to focus our <i style="font-style:italic;">ex vivo </i>oncology clinical development efforts on our follow-on product candidate CT-0525, a CAR-Monocyte intended to treat solid tumors that over-express HER2 and cease development of CT-0508, our macrophage-based product candidate, and initial lead product candidate. In addition, at that time, we decided to continue to focus on our <i style="font-style:italic;">in vivo</i> mRNA/LNP, CAR-M programs in partnership with Moderna and paused development of CT-1119, amesothelin-targeted CAR-Monocyte, pending additional financing, reduce our workforce and decrease spending on other non-essential activities. All clinical activities of CT-0508 have ceased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2024, following a strategic review of our operating plan for 2025 and our future pipeline, we approved another revised operating plan intended to reduce&#160;monthly operating expenses, conserve cash, and refocus our efforts on strategic priorities. First, we decided to cease development of our HER2 directed autologous cell therapy platform including CT-0525. Our decision was based on an assessment of the competitive landscape in anti-HER2 treatments, including the impact of recently approved anti-HER2 therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product. We dosed the last patient in our Phase 1 clinical trial of CT-0525 in November&#160;2024 and all clinical activity ended in January&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further pursuant to the December&#160;2024 revised operating plan, we pivoted our focus to developing product candidates targeting two indications&#160;&#8212; liver fibrosis and solid tumor oncology, while retaining the potential to receive milestones and royalties from our collaboration with Moderna.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2025 Cash Preservation Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of a further revised plan approved by our board of directors on March&#160;25, 2025 to preserve our existing cash resources following our reduction in workforce, or our cash preservation plan, we reduced our operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down our business. We currently have no intention of resuming our historical research and development activities. As part of our cash preservation plan, our board of directors determined to terminate all of our employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">250</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nasdaq Deficiencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are not in compliance with the listing criteria for the Nasdaq Capital Market. Following a timely request for a hearing, we presented our plan to achieve compliance with applicable Nasdaq listing criteria and requested an extension of time to do so. On June&#160;10, 2025, Nasdaq notified us that the Panel determined to grant our request for an exception to, and an extension of time to comply with, Nasdaq listing standards. The extension of time is subject to our demonstrating compliance with Nasdaq Listing Rule&#160;5550(a)(2)&#160;by evidencing a closing bid price of $1.00 or more per share for a minimum of 10 consecutive trading sessions, completing a strategic transaction and otherwise demonstrating compliance with all initial listing requirements for the Nasdaq Capital Market, in each case on or before the Nasdaq Compliance Date. The extension of time is further subject to our meeting an interim milestone for a strategic transaction in connection with our ongoing strategic process. The Panel has the right to reconsider its determination based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make continued listing of our securities inadvisable or unwarranted. The Panel does not have discretion to grant continued listing for noncompliance with Nasdaq listing standards beyond the Nasdaq Compliance Date. There can be no assurance that we will be able to satisfy the requirements or conditions for continued listing within the period of time granted by the Panel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Current Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Merger</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the assistance of a financial advisor, we commenced an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic acquisition or other transaction as described in the section entitled &#8220;<i style="font-style:italic;">The Merger&#8201;&#8212;&#8201;Background of the Transaction</i>&#8221; beginning on page&#160;143 of this proxy statement/prospectus. After a comprehensive review of strategic alternatives, on June&#160;22, 2025, we entered into the Merger Agreement with Merger Sub, Ocugen and OrthoCellix, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into OrthoCellix, with OrthoCellix continuing as our wholly owned subsidiary and the surviving company of the merger. We refer to this as a &#8220;Merger&#8221;. The Merger was approved by our board of directors, and our board of directors resolved to recommend approval of the Merger Agreement to Carisma&#8217;s stockholders. If the Merger is completed, the business of OrthoCellix will continue as the business of the Combined Company. Prior to the completion of the Merger, we will seek to enter into a series of transactions with certain third parties to monetize certain legacy assets in accordance with the limitations and requirements set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we have entered into the Merger Agreement and intend to consummate the Merger, there is no assurance that we will be able to successfully consummate the Merger on a timely basis, or at all. If, for any reason, the Merger does not close, our board of directors may elect to, among other things, attempt to complete another strategic transaction like the Merger, attempt to sell or otherwise dispose of our remaining assets or dissolve and liquidate our assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger does not close, we might not have enough time or resources remaining to identify, evaluate and complete another strategic transaction before the Nasdaq Compliance Date. If the Merger is not completed, our board of directors may decide that it is in the best interests of our stockholders to commence bankruptcy or liquidation and dissolution proceedings. In that event, the amount of cash available for distribution to our stockholders would depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of our cash resources continues to decrease as we continue our wind down activities and incur fees and expenses related to the Merger. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution of the company, we would be required under Delaware law to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations. In addition, we may be subject to litigation or other claims related to a liquidation and dissolution of the company. If a liquidation and dissolution were pursued, our board of directors, in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, our stockholders could lose all or a significant portion of their investment in the event of a liquidation and dissolution of the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Historical Product Candidates and Pipeline</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our liver fibrosis program is based upon the discovery of a key efferocytosis defect in the macrophages that reside within the livers of patients with fibrosis. Using a novel mRNA/LNP approach, our product candidate aims to reverse fibrotic disease and improve the outcomes of patients with advanced liver fibrosis. In the second quarter of 2024, we achieved pre-clinical proof of concept in our liver fibrosis program, demonstrating the anti-fibrotic potential of engineered macrophages in two liver fibrosis models. </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">251</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:144pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Prior to pausing our research and development activities, we planned to continue to conduct pre-clinical development of our product candidate, CT-2401, sufficient to enable a regulatory submission to initiate a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our oncology program leverages our considerable expertise and experience in <i style="font-style:italic;">ex vivo</i> cell therapy. CT-1119 is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. Prior to pausing our research and development activities, we planned to initiate a Phase 1 clinical trial of CT-1119, a mesothelin-targeted CAR-Monocyte, in combination with tislelizumab, an anti-PD-1 antibody, in adult patients with mesothelin-positive solid tumors in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our collaboration with Moderna utilizes Moderna&#8217;s mRNA/LNP technology, together with our CAR-M platform technology, to create novel <i style="font-style:italic;">in vivo</i> oncology off-the-shelf gene therapy product candidates. In June&#160;2024, we announced that Moderna nominated the first development candidate under the collaboration and paid us a $2.0 million milestone. This development candidate targets GPC3, and is designed to treat solid tumors, including hepatocellular carcinoma. In November&#160;2024, we announced new pre-clinical data on our anti-GPC3 <i style="font-style:italic;">in vivo</i> CAR-M therapy for treating hepatocellular carcinoma. These pre-clinical data demonstrated robust anti-tumor activity. In February&#160;2025, Moderna nominated 10 additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February&#160;2025, Moderna has nominated all 12 oncology research targets under the collaboration for which we have the potential to receive future milestones and royalty payments. We will not conduct any additional research activities under the collaboration agreement and we will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the in-vivo oncology field exclusivity, which would allow us to pursue<i style="font-style:italic;"> in vivo </i>CAR-M programs, outside of the 12 nominated oncology targets and product polypeptides.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Historical Product Candidates and Discovery Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Using our industry leading expertise and proprietary technology in macrophage and monocyte engineering, we have developed a pipeline of product candidates, with a focus on liver fibrosis and solid tumor oncology. Our fibrosis and <i style="font-style:italic;">ex vivo </i>oncology programs are wholly owned while the <i style="font-style:italic;">in vivo </i>CAR-M therapies are being developed by Moderna under our collaboration agreement. Our historical pipeline is summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"><img src="tmb-20250331xs4023.jpg" alt="Graphic" style="display:inline-block;height:144pt;width:494pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liver Fibrosis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidate for liver fibrosis, CT-2401, is based upon the discovery of a key defect in the macrophages that reside within the livers of patients with fibrosis. Working in collaboration with researchers at Columbia University, we have identified that the macrophages that normally reside in the liver (Kupfer cells) become defective in patients with metabolic associated liver disease (&#8220;MASH&#8221;). Specifically, they lose the ability to perform a normal, maintenance function called efferocytosis. Efferocytosis is the clearance of dead and dying cells by macrophages and is a critical normal function in the body, including within the liver. In MASH, the accumulation of fat in liver cells (hepatocytes) leads to a fatty liver (steatohepatitis). This accumulation of fat in hepatocytes ultimately leads to dead and dying cells. Efferocytosis should clear these cells in a manner that does not cause inflammation or additional disease. However, as efferocytosis is defective in MASH, these dead and dying cells accumulate and cause inflammation and ultimately liver fibrosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">This defect in efferocytosis can be ascribed to the loss of a single receptor on the cell surfaces of Kupffer cells called TIM4. Although multiple factors are involved in efferocytosis, pre-clinical studies suggest that TIM4 is the major efferocytosis receptor that </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">252</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">is lost in MASH and is responsible for the defective efferocytosis seen in the disease. Samples of liver tissue from patients with MASH demonstrated a loss of TIM4. In pre-clinical studies conducted in the laboratory of Dr.&#160;Ira Tabas at Columbia University (published in Biorxiv), deleting TIM4 in Kupffer cells was observed to cause liver fibrosis. Restoring TIM4 expression caused a significant reduction of the fibrosis seen in these models.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pre-clinical data have consistently demonstrated that TIM4 replacement with TIM4 engineered macrophage cell therapy or with TIM4 mRNA/LNP lead to robust anti-fibrotic activity as evaluated by liver biopsy. TIM4 replacement therapy has demonstrated significant reduction of multiple independent biomarkers of MASH liver fibrosis, including overall liver collagen content, hepatic Collagen-1a1, hepatic osteopontin (a liver-specific fibrotic biomarker), and hepatic alpha-smooth muscle actin (a hepatic stellate cell activation marker associated with MASH) in mild and advanced MASH animal models.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CT-2401 is intended to be developed as an off-the-shelf, <i style="font-style:italic;">in vivo </i>mRNA/LNP<i style="font-style:italic;">, </i>approach designed to deliver mRNA encoding for TIM4 via LNPs that efficiently transfect Kupffer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The proposed indication for CT-2401 is patients with MASH and later stage liver fibrosis (F3 and F4 compensated cirrhosis on a 4-point scale). By directly targeting a key driver of liver fibrosis in these later stage patients, we aim to show more robust benefit on fibrosis than the current types of metabolic directed agents on the market or in development. These agents generally show efficacy on steatosis, but only a small fraction of patients achieve reduction or reversal of fibrosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to pausing research and development activities, we planned to continue to conduct pre-clinical development of CT-2401 sufficient to enable a regulatory submission to initiate a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Ex Vivo Oncology</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. CT-1119 incorporates two key enhancements as compared to CT-0508 and CT-0525: (1)&#160;a next-generation CAR that, in pre-clinical studies, led to a significant increase in tumor killing and cytokine release when compared to our first generation construct, and (2)&#160;the incorporation of a signal-regulatory protein alpha (&#8220;SIRP&#945;&#8221;), knockdown to overcome the cluster of differentiation, or CD47 immune checkpoint.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to pausing our research and development activities, we planned to initiate a Phase 1 clinical trial of CT-1119, a mesothelin-targeted CAR-Monocyte, in combination with tislelizumab, an anti-PD-1 antibody, in adult patients with mesothelin-positive solid tumors, in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to utilizing an enhanced CAR construct and SIRP&#945; knockdown technology, the Phase 1 clinical trial design built on observations from our prior Phase 1 clinical trials. For example, the dosing schedule was based on the previously presented data from our HER2 program, in which we observed reductions in circulating tumor (ct) DNA. ctDNA is a marker of overall tumor burden and decreases can be viewed as evidence of reductions in tumor. The reductions observed in some patients after receiving CT-0508 had a nadir approximately three weeks after infusion and then rebounded. Based on this observation, repeat dosing is intended to keep therapeutic pressure on tumors and potentially provide meaningful clinical benefit. Additionally, pre-clinical data suggests a potential for synergy between CAR-M approaches and check point inhibitors, particularly PD-1. Data from the clinical trials of CT-0508 showed markers of T-cell exhaustion as having correlation with limited efficacy from HER2 CAR-M therapy. Based on the initial data from Phase 1 clinical trial of CT-0508, co-administration of a PD-1 checkpoint inhibitor and CT-0508 was generally well-tolerated in cancer patients. Therefore, the CT-1119 trial was designed to incorporate the addition of the PD-1 checkpoint inhibitor tislelizumab to the repeat administration of CT-1119.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">In Vivo Oncology</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">To advance our <i style="font-style:italic;">in vivo</i> CAR-M therapeutics, we established a strategic collaboration with Moderna, which utilizes Moderna&#8217;s mRNA/LNP technology, together with our CAR-M platform technology, to create novel <i style="font-style:italic;">in vivo</i> oncology off-the-shelf gene therapy product candidates. Since entering into the agreement, we have made significant progress advancing this program. In the fourth quarter of 2023, we presented pre-clinical data from this collaboration demonstrating that CAR-M can be directly produced <i style="font-style:italic;">in vivo</i>, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP. Additionally, the pre-clinical data demonstrated feasibility, tolerability, and early efficacy of <i style="font-style:italic;">in vivo</i> CAR-M against metastatic solid tumors. In December&#160;2023, we announced the nomination of the collaboration&#8217;s first lead candidate. In June&#160;2024, we announced the achievement of the first development candidate under the collaboration with Moderna, triggering a $2.0 million milestone payment from Moderna. This </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">253</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">development candidate targets GPC3 and is designed to treat solid tumors, including hepatocellular carcinoma. In November&#160;2024, we presented pre-clinical data characterizing the efficacy of the development candidate targeting GPC3 for hepatocellular carcinoma. These pre-clinical data demonstrated robust anti-tumor activity. In February&#160;2025, Moderna nominated 10 additional oncology targets, four of which replaced two oncology research targets and two autoimmune targets, which Moderna concurrently ceased developing. As of February&#160;2025, all 12 oncology targets under the collaboration agreement were nominated by Moderna for which we have the potential to receive future milestones and royalty payments. We will not conduct any additional research activities under the collaboration agreement and we will not be receiving any further payments from Moderna for research and development services under the collaboration agreement. Moderna also agreed to terminate the <i style="font-style:italic;">in vivo</i> oncology field exclusivity, which would allow us to pursue <i style="font-style:italic;">in vivo</i> CAR-M programs, outside of the 12 nominated oncology targets, and to product polypeptides.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Background</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Limitations of Current CAR-T or CAR-NK Therapies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cellular immunotherapy is a type of immuno-oncology approach whereby human immune cells are utilized to recognize and destroy cancer cells in a targeted manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite the incredible promise shown by cell therapies for hematologic malignancies, the success has not been replicated in the solid tumor setting. There are numerous challenges impacting T and NK cell immunotherapy in patients with solid tumors, such as the inability of cells to appropriately access the tumor microenvironment (&#8220;TME&#8221;), overcome immunosuppression in the TME, and overcome target antigen heterogeneity. Importantly, there have been challenges in targeting solid tumors with CAR-T cells without inducing toxicities against normal tissues or inducing severe systemic cytokine release syndrome. To date, no CAR therapies for the treatment of solid tumors have received marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Opportunity for Engineered Macrophages in Treating Cancer and Liver Fibrosis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that macrophage and monocyte cell therapies hold promise in addressing the limitations of other cell types and transforming the cell therapy treatment paradigm for solid tumors and fibrotic diseases. The inherent biology of macrophages and monocytes offers several potential advantages that directly apply to current barriers for cell therapy efficacy in the solid tumor context. Macrophages and monocytes are actively recruited into solid tumors, while other immune cells, such as T cells, are often actively excluded. Macrophages are professional phagocytic cells capable of directly killing tumor cells through this unique mechanism. In addition to direct killing, macrophages can secrete pro-inflammatory factors that convert the immunosuppressive TME into an environment that promotes immunity. Importantly, macrophages and monocytes are professional antigen presenting cells, meaning they can directly present tumor-derived antigens to T cells leading to anti-tumor T cell responses, a phenomenon known as epitope spreading. Epitope spreading enables activity against tumor cells which either lack or lose expression of the initial antigen targeted by the CAR&#8201;&#8212;&#8201;a key challenge for cell therapies&#8201;&#8212;&#8201;and ultimately enables macrophages and monocytes to overcome target antigen heterogeneity within the patient&#8217;s cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to acting as a first line of defense in the innate immune system, macrophages and monocytes are found in all tissues in the body where they serve key regulatory functions such as wound healing, termination of immune responses and tissue regeneration. The prevalence and diversity of function of macrophages and monocytes make them an attractive potential therapeutic delivery cell.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, our liver fibrosis product candidate is designed with the goal of correcting acquired macrophage deficiencies, such as the loss of efferocytosis in MASH via the downregulation of the receptor TIM4. By aiming to restore TIM4 expression in hepatic macrophages (Kupffer cells), liver fibrosis as a result of MASH or other chronic liver injury may be significantly reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">CAR-M Pre-clinical data</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">CAR-M have the potential to address the key challenges involved in treating solid tumors. Pre-clinical studies with CAR-M have demonstrated the ability to infiltrate solid tumors, phagocytose and destroy tumor cells directly, and present tumor-derived antigens leading to activation of the adaptive immune system. CAR-M mount anti-tumor immunity in numerous ways. First, CAR-M leverage the natural tumor-homing ability of macrophages and monocytes, the naturally most abundant immune cells in the TME, to traffic to both primary tumors and metastases, enabling engineered macrophages to act as a &#8220;Trojan horse,&#8221; tricking the tumor into recruiting engineered, anti-tumor CAR-M as if they were normal monocytes or macrophages. Once within the tumor, CAR-M directly kill antigen-expressing tumor cells through phagocytosis and secretion of cytotoxic factors. CAR-M secrete inflammatory cytokines and chemokines that promote a pro-inflammatory environment and lead to the recruitment of T cells and other leukocytes. Finally, CAR-</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">254</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">M serve as professional antigen presenting cells for T cells, inducing epitope spreading, systemic anti-tumor immunity, and immune memory against tumor antigens, expanding anti-tumor immunity to target negative tumor cells and potentially preventing antigen negative relapse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pipeline of Product Candidates and Discovery Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Using our industry leading expertise and proprietary technology in macrophage and monocyte engineering, we have developed a broad pipeline of product candidates, with a focus on liver fibrosis and solid tumor oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lead oncology product candidate CT-1119 (Next generation Anti-Mesothelin CAR-Monocyte)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CT-1119 is a mesothelin-targeted CAR-Monocyte developed for study in patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. CT-1119 incorporates two key enhancements: (i)&#160;a next-generation CAR that, as demonstrated in pre-clinical studies, lead to a significant increase in tumor killing and cytokine release, and (ii)&#160;the incorporation of SIRP&#945; knockdown to overcome the CD47 immune checkpoint.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mesothelin is a well validated tumor associated antigen. Mesothelin has been shown to be aberrantly expressed on the surface of tumor cells and plays an important role in promoting cancer invasion and proliferation. Mesothelin has been demonstrated to be expressed at high levels in mesothelioma, lung cancer, ovarian cancer, pancreatic cancer, and other solid tumors with limited expression in normal tissue. Mesothelin positive solid tumors represent a significant unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CT-1119 Next-Gen CAR Design</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We developed additional next generation CAR-M improvements utilizing enhanced CAR constructs to increase potency and functionality of the engineered cells. This includes optimization of each element of the CAR itself&#8201;&#8212;&#8201;the binder (which gives the CAR specificity to a target antigen), the hinge (which connects the binder to the transmembrane domain and gives the CAR length and flexibility), the transmembrane domain (which spans the cell membrane), and the intracellular signaling domains (which are responsible for activation of immune cell function). These changes can lead to increased proinflammatory cytokine release and more potent <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i> killing relative to the first-generation CAR construct. A next generation CAR incorporating an optimized hinge, transmembrane, and signaling domain is incorporated into CT-1119.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CT-1</i><i style="font-style:italic;">119 SIRP&#945; Knockdown</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have also developed gene editing technologies for enhancing anti-tumor CAR-M functions. Macrophages naturally express the inhibitory receptor SIRP<span style="font-family:'Cambria Math';">&#9082;</span>, which suppresses phagocytosis after stimulation with CD47. Solid tumors can over-express CD47 to evade phagocytosis by macrophages. We have previously demonstrated using CRISPR/Cas9 that SIRP<span style="font-family:'Cambria Math';">&#9082;</span> knockout, can enhance CAR-M killing and phagocytosis of tumor cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have now developed a proprietary single-vector system to simultaneously deliver CAR and targeted gene knockdown. A novel vector was designed to introduce custom shRNA into a synthetic CAR intron under a shared promoter. Expression of this vector concomitantly produces CAR mRNA and SIRP<span style="font-family:'Cambria Math';">&#9082;</span>-targeting shRNA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We demonstrated that the intronic shRNA vector could deliver HER2-targeting CAR, reduce SIRP<span style="font-family:'Cambria Math';">&#9082;</span> expression, and enhance anti-tumor functions of primary human CAR-M. Importantly, the one-step vector design was as proficient as transduction followed by CRISPR/Cas9 editing. We also demonstrated that the intronic shRNA vector improved tumor clearance <i style="font-style:italic;">in vivo</i>, as compared to unedited CAR-M.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The intronic shRNA design is a generalizable technology that is valuable for additional CAR designs, target tumor antigens, and gene knockdown targets. The modular adenoviral vector introduces gene editing capabilities while remaining compatible with pre-existing manufacturing strategies. We have incorporated our proprietary intronic shRNA vector into the CT-1119 platform to enhance anti-tumor functions and overcome the CD47 checkpoint. SIRP<span style="font-family:'Cambria Math';">&#9082;</span> knockdown is incorporated into CT-1119 utilizing intronic shRNA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Synergistic Potential of CAR-M Therapy with T Cell Checkpoint Inhibitors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Blocking the immune checkpoint molecule PD-1 checkpoint inhibitor, has revolutionized cancer treatment for patients with a multitude of solid tumor indications. Pembrolizumab is a potent humanized immunoglobulin G4, monoclonal antibody (&#8220;mAb&#8221;), with </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">255</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">high specificity of binding to the PD-1 checkpoint inhibitor receptor, inhibiting its interaction with programmed cell death ligand 1, and programmed cell death ligand 2. While pembrolizumab is currently indicated for the treatment of patients across several solid tumor indications, the majority of patients have either primary or secondary resistance to immune checkpoint blockade and may benefit from combinatorial therapy that could overcome immune cell exclusion, poor antigen presentation, low T cell infiltration, high tumor-associated macrophages, infiltration, a lack of productive co-stimulation, low mutational burden, intra-tumoral (&#8220;IT&#8221;), immunosuppression, and a low frequency of tumor reactive T cell clones. Multiple additional PD-1 checkpoints, including tislelizumab, have also been approved for multiple oncology indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the data generated during pre-clinical development, CT-0508 was able to specifically recognize cancer cells through the binding of the CAR to HER2 expressed on the surface of the cancer cells. This interaction triggered activation of the CAR-M and resulted in direct anti-tumor effect by killing and phagocytosis of the tumor cells. In addition, CT-0508 recruited T cells, activated the TME, and as professional antigen presenting cells, processed and presented tumor associated antigen and/or neoantigens expressed by the tumor cells, leading to T cell immunity against these specific antigens. However, this indirect anti-tumor effect involves the engagement of T cells that may be actively suppressed, or exhausted, within the TME by a variety of factors including secreted immune-modulatory factors and inhibitory ligands expressed on both immune and tumor cells. Additionally, several studies have demonstrated that patients with low mutational burden, low major histocompatibility complex expression, defective antigen presentation, low CD8+ T cell infiltration, or minimal Type 1 T helper, cytokine signatures tend to be unresponsive to PD-1 checkpoint inhibitor blockade. Therefore, based on the mechanism of action of CAR-M and the limitations of PD-1 checkpoint inhibitor blockade, the combination of CAR-M therapy with PD-1 checkpoint inhibitor blockade therapy may be beneficial as CAR-M will drive TME remodeling and enhance antigen presentation (innate immunity) to initiate an anti-tumor T cell response (adaptive immunity) which will be strengthened by inhibiting the PD-1 checkpoint inhibitor pathway. Pre-clinical data demonstrating the synergy between CAR-M and PD-1 checkpoint blockade were published in Nature Communications in 2025 (Pierini S, et al. Nature Communications. 2025). These data lay the groundwork for exploration of combination therapies consisting of CAR-M therapies (such as CT-1119) and T cell checkpoint inhibitors (such as anti-PD1).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">mRNA/LNP Platform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In collaboration with Moderna, we have developed a mRNA based <i style="font-style:italic;">in vivo</i> CAR-M platform for oncology. This approach is highly differentiated in the cell therapy space&#8201;not only because it relies on myeloid cells as the engineered effectors, but also because it utilizes direct <i style="font-style:italic;">in vivo</i> reprogramming of patients&#8217; own cells with a well-validated mRNA/LNP platform. By engineering patients&#8217; own cells directly within their body, <i style="font-style:italic;">ex vivo</i> autologous or allogeneic cell manufacturing is entirely bypassed. Importantly, while this approach enables an off-the-shelf therapy, the engineered cells are autologous, as it is the patients&#8217; own cells being engineered into CAR-M <i style="font-style:italic;">in vivo</i>, or directly within their body.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Studies with the LNP have shown mRNA delivery leads to CAR expression on myeloid cells (monocytes, macrophages, and dendritic cells). Preliminary data have demonstrated that the LNP is efficient in transfecting myeloid cells <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i>. In addition, preliminary data confirms high CAR expression, viability, and CAR-M function. In the fourth quarter of 2023, we presented pre-clinical data from this collaboration demonstrating that CAR-M can be directly produced <i style="font-style:italic;">in vivo</i>, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP. Additionally, the data demonstrated feasibility and early efficacy of <i style="font-style:italic;">in vivo</i> CAR-M against metastatic solid tumors. In 2024, we announced nomination of the collaboration&#8217;s first development candidate, which will target the GPC3 antigen present on hepatocellular carcinoma, an indication with significant unmet medical need. In November&#160;2024, we announced new pre-clinical data on our anti-GPC3 <i style="font-style:italic;">in vivo</i> CAR-M therapy for treating hepatocellular carcinoma. These pre-clinical data demonstrated robust anti-tumor activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2025, Moderna nominated 10 additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February&#160;2025, Moderna has nominated all 12 oncology research targets under the collaboration for which we have the potential to receive future milestones and royalty payments. We will not conduct any additional research activities under the collaboration agreement and we will not be receiving any further research funding from Moderna under the collaboration agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liver Fibrosis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have a research program designed for liver fibrosis caused by advanced MASH. CT-2401 is designed to address defective efferocytosis, a novel pathway believed to drive the accumulation of dead hepatocytes in the liver of MASH patients leading to collagen deposition and chronic inflammation, resulting in liver fibrosis and MASH progression. Pre-clinical data identified TIM4 as a </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">256</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">key downregulated/lost efferocytosis receptor in MASH. CT-2401, aims to restore TIM4 expression using mRNA/LNP technology. Pre-clinical proof of concept has been established.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ex Vivo</span><b style="font-weight:bold;"> Oncology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Past Product Candidate: CT-0508 (anti-HER2 CAR-Macrophage)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CT-0508 is a cell product comprised of autologous, peripheral blood monocyte-derived, pro inflammatory macrophages, transduced with a chimeric adenoviral vector, Ad5f35, containing an anti-HER2 CAR. HER2 is a protein on the cell surface that promotes the growth of cancer cells. The anti-HER2 CAR is a first-generation CAR composed of a fully human single-chain variable fragment derived from mAb, trastuzumab, which is specific for human HER2. The anti-HER2 scFv is fused to a CAR backbone containing a CD8 hinge, CD8 transmembrane domain, and a CD3&#950; intracellular domain. The CAR is cloned into an adenoviral vector backbone and transduced into monocyte-derived macrophages. Based on the pre-clinical data generated to date, CT-0508 CAR-Macrophages are able to specifically recognize HER2 over-expressing tumor cells, which triggers both direct killing of tumor cells and phagocytosis. Additionally, CAR engagement to HER2 on tumor cells results in the secretion of a broad array of pro-inflammatory cytokines and chemokines, which contribute to the recruitment and activation of additional immune cells to the TME, including effector T cells and other antigen presenting cells. CT-0508 CAR-Macrophages are antigen presenting cells, and after phagocytosing tumor cells they process tumor-derived antigens and present them to T cells, leading to T cell immunity against tumor antigens. This additional activation of the adaptive immune system amplifies anti-tumor immune response and can lead to long term immune memory not only against HER2, the primary target, but other tumor specific neoantigens as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CT-0508 was studied in a multi-center open label Phase 1 clinical trial in the United States. A total of 20 patients received infusions of CT-0508 during either the primary portion of the trial (n=14) or during the expansion cohort in combination with pembrolizumab (n=6). The primary endpoints of safety and feasibility were met while the best overall response observed in any subject was stable disease (SD). The trial was closed to enrollment in April&#160;2024 and closed in its entirety in August&#160;2024. The final presentation of data from this trial was made in the third quarter of 2024 and results from the monotherapy portion of the trial were published in Nature Medicine in 2025 (Reiss KA, et al. Nature Medicine, 2025).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Past Product Candidate: CT-0525</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CT-0525 is a cell product comprised of autologous, peripheral blood derived CD14+ monocytes transduced with a chimeric adenoviral vector, Ad5f35, containing an anti-HER2 CAR. Unlike CT-0508, CT-0525 is a non-differentiated monocyte that is not fully matured during an <i style="font-style:italic;">ex vivo</i> cell culture process. Based on pre-clinical studies, CT-0525 is expected to differentiate into a CAR-Macrophage directly <i style="font-style:italic;">in vivo</i>, subsequently carrying out the same mechanism of action as described above for CT-0508. CT-0525 enables potentially higher dosing, improved trafficking, and enhanced persistence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CT-0525 was evaluated in a multi-center open label Phase 1 clinical trial in the United States. The Phase 1 clinical trial for CT-0525 was a single-arm, open-label study of systemic intravenous administration of CT-0525 intended to evaluate safety, tolerability, and the manufacturing feasibility of CT-0525. Secondary endpoints included cellular kinetics, overall response rate and duration of response. This trial enrolled participants with locally advanced (unresectable) or metastatic solid tumors over-expressing HER2 whose disease has progressed on standard approved therapies. The study consisted of two cohorts: Cohort 1 received IV administration of 3.0 billion CAR-positive cells, while Cohort 2 received IV administration of up to 10.0 billion CAR-positive cells. The first patient was dosed in May&#160;2024. Three subjects were treated in Cohort 1 and two were treated in Cohort 2. The last patient was dosed in November&#160;2024 and all clinical activity ended in January&#160;2025 due to the decision to cease development of CT-0525.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing and Delivery</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not own or operate, and currently have no plans to establish, our own manufacturing facilities. We have relied on third-party CMOs for manufacturing of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We had established arrangements with contract manufacturers to supply clinical materials and manufacturing capabilities for our clinical trials.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">257</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We strive to protect and enhance our proprietary technology, inventions and improvements that we believe are commercially important to the development of our business, including through seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also intend to rely on trade secrets related to our proprietary technology platform and our know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the fields of cancer and other indications including those related to fibrosis and other immunologic and inflammatory diseases, which may be important for the development of our business. We also may rely on regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions, where available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success may depend, in part, on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend, and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable licenses, patents or trade secrets that cover these activities. With respect to both our owned and licensed intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we file in the future, nor can we be sure that any of our existing patents or any patents that may be granted us in the future will be commercially useful in protecting our commercial products and methods of manufacturing such products, as well as being held valid if challenged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently control over 40 granted patents, which are expected to expire at various times between 2033 and 2045, and over 100 patent applications pending in several jurisdictions, including the United States, Europe, Australia, Brazil, Canada, China, Israel, Japan, Korea, Mexico, New Zealand, and Singapore. Intellectual property is a critical component of our business plan for maximizing return on our investments. We are actively developing intellectual property and will continue to maintain and defend United States and international patent rights for our products, technology, and development and improvement of our discovery platforms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To maintain our competitive position in the market, we have spent considerable effort and resources securing intellectual property rights, including several patent rights related to our proprietary CAR technology and myeloid cell engineering technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exclusively Licensed Intellectual Property&#8201;&#8212; Penn</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have exclusive rights to four patent families, and non-exclusive rights to related know-how by virtue of a license agreement with the Trustees of Penn. These patent families are directed to, among other things, methods of efficiently expressing CARs in myeloid cells, including monocytes, macrophages, and dendritic cells and enhancing effector activity, as well as the modified cells and compositions including such modified cells for use in several indications including various oncology targets. The applications will have an expiration date of no earlier than 2034. This licensed patent portfolio includes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes nine issued U.S. patents and three pending U.S. patent applications relating to modified macrophages, monocytes and dendritic cells comprising CARs. These U.S. patents are expected to expire in 2036, absent any term adjustments or extensions. Corresponding foreign patents and pending applications include one issued patent in Australia, one issued patent in Brazil, one issued patent in China, two issued patents in Israel, two issued patents in Japan, one issued patent in Mexico, one issued patent in Russia, one issued patent in Singapore, and pending applications in Australia, Brazil, Canada, China, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Russia, Singapore, Thailand and South Africa.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one pending U.S. patent application relating to modified macrophages, monocytes and dendric cells in protein aggregate-associated disorders. Patent applications in this family are expected to expire in 2039, absent any term adjustments or extensions. Corresponding foreign patents and pending applications include one issued patent in Australia, one issued patent in Japan, and pending applications in Canada, China, Europe, Israel, Korea, New Zealand, and Singapore.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one pending U.S. patent application relating to activation of antigen presenting cells. Patent applications in this family are expected to expire in 2040, absent any term adjustments or extensions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one issued U.S. patent and one pending U.S. patent application relating to CARs comprising human anti-mesothelin binding domains. Patent applications in this family are expected to expire in 2034, absent any </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">258</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adjustments or extensions. Corresponding foreign patents and pending applications include three issued patents in Australia, one issued patent in China, one issued patent in Colombia, one issued patent in Germany, two issued patents in Europe, one issued patent in Spain, one issued patent in France, one issued patent in the United Kingdom, one issued patent in Italy, two issued patents in Japan, one issued patent in Russia, and pending applications in Australia, Canada, China, Europe, and Japan.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exclusively Licensed Intellectual Property&#8201;&#8212;&#8201;NYU</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have exclusive rights to one patent family, and non-exclusive rights to related know-how by virtue of a license agreement with New York University (&#8220;NYU&#8221;). The rights granted under the NYU license are to all indications for human use. This licensed patent portfolio includes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one U.S. patent relating to a chimeric human immunodeficiency virus type 1,vector with a simian immunodeficiency virus, minimal Vpx packaging domain and method of making virions with enhanced infectivity for macrophages and dendritic cells. The U.S. patent is expected to expire in 2033, absent any term adjustments or extensions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Carisma Owned Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently own 11 U.S. patent families. This owned patent portfolio includes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes two issued U.S. patent and one pending U.S. patent applications relating to macrophages, monocytes and dendritic cells comprising novel CAR constructs. Patent applications in this family are expected to expire in 2041, absent any term adjustments or extensions. Corresponding foreign patent applications have been filed and are pending in Australia, Brazil, Canada, China, Europe, Israel, Japan, Korea, Mexico, New Zealand, Singapore, and South Africa.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one pending U.S. application relating to mRNA transfection of macrophages, monocytes and dendritic cells comprising CARs. Patent applications in this family are expected to expire in 2041, absent any term adjustments or extensions. Corresponding foreign patent applications have been filed and are pending in Australia, China, Eurasia, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore, and South Africa.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one pending U.S. application relating to modified immune cells for fibrosis and inflammation. Patent applications in this family are expected to expire in 2041, absent any term adjustments or extensions. Corresponding foreign patent applications have been filed and are pending in Australia, China, Eurasia, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore, and South Africa.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one pending U.S. application relating to self-polarizing immune cells. Patent applications in this family are expected to expire in 2042, absent any term adjustments or extensions. Corresponding foreign patent applications have been filed and are pending in Australia, Brazil, Canada, China, Eurasia, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore, and South Africa.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one pending U.S. application relating to </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> delivery of, among other things, CARs to macrophages, monocytes, and dendritic cells. Patent applications in this family are expected to expire in 2042, absent any term adjustments or extensions. Corresponding foreign patent applications have been filed and are pending in Australia, Europe, and Japan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one pending U.S. application relating to methods and constructs for modifying the response of certain cells to environmental and other stimuli. Patent applications in this family are expected to expire in 2043, absent any term adjustments or extensions. Corresponding foreign patent applications have been filed and are pending in Australia, Europe, and Japan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one pending PCT application relating to modified macrophages, monocytes, and dendritic cells including anti-mesothelin CARs. Patent applications in this family are expected to expire in 2043, absent any term adjustments or extensions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one pending PCT application relating to modified constructs including JAK/STAT binding domains. Patent applications in this family are expected to expire in 2043, absent any term adjustments or extensions.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">259</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one pending PCT application relating to modified constructs including DAP10 and/or DAP12 domains. Patent applications in this family are expected to expire in 2044, absent any term adjustments or extensions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one pending PCT application relating to modified constructs including cassettes engineered to produce one or more inhibitory RNAs and a CAR. Patent applications in this family are expected to expire in 2044, absent any term adjustments or extensions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A patent family that includes one pending PCT application relating to modified constructs including cassettes engineered to produce one or more chimeric signaling molecules capable of redirecting the response of cells to one or more stimuli. Patent applications in this family are expected to expire in 2044, absent any term adjustments or extensions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will also seek to generate additional intellectual property that covers enhancements to all aspects of the platform, including novel CARs, combinations, gene editing and manufacturing improvements. Where appropriate, we will also look to in-license relevant technology from third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent Term and Patent Term Extensions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20&#160;years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO, in examining and granting a patent or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug, biological product or medical device approved pursuant to a pre- market approval may also be eligible for patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. The length of the patent term extension is related to the length of time the drug is under regulatory review while the patent is in force. The Hatch-Waxman Act permits a patent term extension of up to five&#160;years beyond the expiration date set for the patent. Patent extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent applicable to each regulatory review period may be granted an extension and only those claims regarding the approved drug are extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trademarks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our trademark portfolio currently includes registered U.S. trademarks for Carisma in the United States, Europe, Great Britain and Japan. All of our trademarks are renewed on an ongoing basis. In order to supplement the protection of our brand, we also have a registered internet domain name. Going forward, we will consider additional trademarks to enhance our brand and support our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trade Secrets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely, in some circumstances, on trade secrets to protect our unpatented technology. However, trade secrets can be difficult to protect in certain circumstances. We seek to protect our trade secrets and proprietary technology and processes, including through confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached. We may not have adequate remedies for any breach and could lose our trade secrets through such a breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting trade secrets, know-how and inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Moderna Collaboration and License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In collaboration with Moderna, we have established an approach that uses Moderna&#8217;s mRNA/LNP technology, together with our CAR-M platform technology, to create novel <i style="font-style:italic;">in vivo</i> oncology gene therapies. We believe this approach has the potential to enable a series of off-the-shelf product candidates to target a patient&#8217;s own myeloid cells against cancer cells directly within their body.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In January&#160;2022, Legacy Carisma and Moderna established this collaboration by entering into a Collaboration and License Agreement (the &#8220;Moderna License Agreement&#8221;), which provides for a broad strategic collaboration to discover, develop and </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">260</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">commercialize <i style="font-style:italic;">in vivo</i> engineered CAR-M therapeutics. Under the Moderna License Agreement, the parties initiate research programs during a research term, focused on the discovery and research of products directed to biological targets. Moderna&#8217;s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. In February&#160;2025, Moderna nominated 10 additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February&#160;2025, Moderna has nominated all 12 oncology research targets under the Moderna License Agreement for which we have the potential to receive future milestones and royalty payments. We will not conduct any additional research activities under the Moderna License Agreement and we will not be receiving any further research funding from Moderna under the Moderna License Agreement. We received the final research and development payment of $2.9 million from Moderna in January&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moderna has the right to designate up to 12 research targets as development targets during a specified development target nomination period upon payment of a development target designation milestone payment. To date, Moderna has designated one research target as a development target. This development candidate targets GPC3 and is designed to treat solid tumors, including hepatocellular carcinoma. Moderna can replace development targets with research targets during a specified period of time. If Moderna exercises its right to designate a development target, Moderna will have a worldwide, exclusive license under patents and know-how controlled by us to develop and commercialize products directed to the applicable development target, subject to certain diligence obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Commencing a specified time after the effective date of the Moderna License Agreement, Moderna will have the right to nominate targets relating to diseases outside the field of oncology for inclusion in research programs in specified circumstances. Such right is subject to the same exclusions as Moderna&#8217;s right to nominate other targets for inclusion in research programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the term of the Moderna License Agreement, we and our affiliates are subject to various exclusivity obligations under which we are not permitted to research, develop or commercialize particular products outside of the collaboration, including products directed to any target included in the collaboration, or products containing a polypeptide provided by us to Moderna in connection with a research program that are directed to any development target. Moderna agreed to terminate the <i style="font-style:italic;">in vivo</i> oncology field exclusivity, which would allow us to pursue <i style="font-style:italic;">in vivo</i> CAR-M programs, outside of the 12 nominated oncology targets and product polypeptides.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Moderna License Agreement, we received a $45.0 million up-front cash payment. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, we are also eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. In addition, we are eligible to receive tiered mid-to-high single digit royalties on net product sales, subject to adjustment. Moderna has also agreed to cover the cost of certain milestone payments and royalties we owe as a licensor under one of our intellectual property in-license agreements with Penn that we are sublicensing to Moderna under the Moderna License Agreement, which royalties Moderna may deduct in part from any royalties owed to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless earlier terminated, the Moderna License Agreement will expire upon the expiration of all royalty obligations thereunder. The royalty period for each product developed under the Moderna License Agreement will expire on a country-by-country basis upon the later of (i)&#160;the expiration of the last-to-expire valid patent claim of specified patents, (ii)&#160;the expiration of regulatory-based exclusivity for such product in such country or (iii)&#160;10&#160;years after the first commercial sale with respect to such product in such country. Moderna has the right to terminate the Moderna License Agreement for convenience in its entirety or with respect to a specific product or target on 90&#160;days&#8217; prior notice. Either we or Moderna may terminate the Moderna License Agreement in its entirety if the other party is in material breach and such breach is not cured within the specified cure period, except in the case of Moderna&#8217;s breach of its diligence obligations, termination by us is limited to the applicable target and product. In addition, either we or Moderna may terminate the Moderna License Agreement in the event of specified insolvency events involving the other party. As an alternative to termination in the event of our uncured material breach of certain sections of the agreement, Moderna has the option to continue the collaboration under the agreement with reduced payment obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Penn License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November&#160;2017, Legacy Carisma entered into a license agreement (the &#8220;Penn License Agreement&#8221;), with Penn, which was amended in February&#160;2018, January&#160;2019, March&#160;2020 and June&#160;2021. Pursuant to the Penn License Agreement, Penn granted us (i)&#160;an exclusive, worldwide license, with specified rights to sublicense, under Penn&#8217;s interest in specified patents related to CAR macrophages, monocytes or dendritic cells, (ii)&#160;an exclusive, worldwide license, with specified rights to sublicense, under Penn&#8217;s </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">261</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">interest in specified patents related to CAR-M directed to mesothelin, and (iii)&#160;a nonexclusive, worldwide license under Penn&#8217;s interest in specified know-how related to CAR-M, with limited rights to sublicense only in combination with specified products or patents. These licensed patents and know-how arose primarily from research conducted by Dr.&#160;Saar Gill and Dr.&#160;Michael Klichinsky at Penn, co-founders of Carisma. The foregoing licenses are subject to rights retained by Penn for specified non-commercial uses and rights retained by the U.S. government. Under the Penn License Agreement, we are obligated to use commercially reasonable efforts to pursue development and commercialization of at least one CAR-M product in oncology and non-oncology fields.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are responsible for paying Penn an annual license maintenance fee in the low tens of thousands of dollars, payable until our first payment of a royalty. We are required to pay Penn up to $10.9 million per product in development and regulatory milestone payments, up to $30.0 million per product in commercial milestone payments, and up to an additional $1.7 million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. While the agreement remains in effect, we are required to pay Penn low to mid-single digit&#160;percentage tiered royalties on annual net sales of licensed products, which may be subject to reductions. Penn is guaranteed a minimum royalty payment amount in the low hundreds of thousands of dollars for each&#160;year after the first commercial sale of a licensed product. We must also pay Penn a&#160;percentage in the mid-single digits to low double digits of certain types of income we receive from sublicensees. In addition, we are required to pay Penn an annual alliance management fee in the low tens of thousands of dollars, ending after several&#160;years, unless we provide funding to Penn for research and development activities that extend beyond a specified date, in which case we will continue to owe the alliance management fee for each&#160;year in which we continue to fund such activities. We also paid Penn an upfront fee in the low hundreds of thousands of dollars for the license to the patents related to the mesothelin binder that is incorporated into the CAR design for our mesothelin product candidate. We are responsible for a pro rata share of costs relating to the prosecution and maintenance of the licensed patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The royalty period for each licensed product will expire on a product-by-product basis upon the later of (i)&#160;the expiration of the last-to-expire valid patent claim of the licensed patents covering such product in the country of sale or in the country of manufacture, or (ii)&#160;the expiration of regulatory-based exclusivity for such product in the country of sale. The license agreement remains in effect until the later of (i)&#160;expiration or abandonment of the last licensed patent or (ii)&#160;loss of regulatory exclusivity. We may terminate the agreement for convenience upon thirty&#160;days&#8217; prior notice. Penn may terminate the agreement for our material breach, subject to a specified cure period, except for certain breaches for which Penn may terminate immediately. Penn may also terminate if we become the subject of a specified insolvency event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NYU License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2020, Legacy Carisma entered into a license agreement with NYU (the &#8220;NYU License Agreement&#8221;). Pursuant to the NYU License Agreement, NYU granted us (i)&#160;an exclusive, worldwide license, with specified rights to sublicense, under NYU&#8217;s interest in specified patents related to the Vpx-LV and (ii)&#160;a nonexclusive, worldwide license, with specified rights to sublicense, under NYU&#8217;s interest in specified know-how related to the Vpx-LV, in each case to develop, manufacture, use and sell products developed using the Vpx-LV (the &#8220;Licensed Products&#8221;). The foregoing licenses are subject to rights retained by NYU to use, and to permit other non-commercial entities to use, the licensed patents and licensed know-how for educational and research purposes, as well as rights retained by the U.S. government. Under the NYU License Agreement, we are obligated to use reasonable diligence to carry out a specified development plan and to obtain regulatory approval for Licensed Products in the United States and each of the other countries in which we or our sublicensees intend to produce, use, and/or sell Licensed Products, as well as to begin the regular commercial production, use, and sale of the Licensed Products in good faith in accordance with the development plan and to continue diligently thereafter to commercialize the Licensed Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are required to pay NYU an annual license maintenance fee in the mid tens of thousands of dollars; up to $1,685,000 per Licensed Product in development and regulatory milestone payments; and low single digit&#160;percentage tiered royalties on annual net sales of Licensed Products on a country-by-country basis until the later of (i)&#160;12&#160;years after first commercial sale of a Licensed Product in such country or (ii)&#160;expiration of the last to expire licensed patent. We must also pay NYU a&#160;percentage in the low single digits to low double digits of certain types of income we receive from sublicensees or assignees of the agreement. We are also responsible for all costs relating to the prosecution, maintenance, and defense of the licensed patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NYU License Agreement remains in effect until the expiration of all royalty terms in all countries. Either party may terminate the NYU License Agreement for the other party&#8217;s uncured material breach or insolvency or bankruptcy.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">262</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biopharmaceutical industry, and in particular the cell therapy field and liver fibrosis field, is characterized by intense investment and competition aimed at rapidly advancing new technologies, intense competition, and a strong emphasis on intellectual property and proprietary products. Our platform and therapeutic product candidates are expected to face substantial competition from multiple technologies, marketed products, and numerous other therapies being developed by other biopharmaceutical companies, academic research institutions, governmental agencies, and public and private research institutions. Many of our potential competitors have substantially greater financial, technical, and other resources, such as larger research and development staff, established manufacturing capabilities and facilities, and experienced marketing organizations with well-established sales forces, and any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. In addition, there is substantial patent infringement litigation in the biopharmaceutical industry, and, in the future, we may bring or defend such litigation against our competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The key competitive factors affecting the success of our product candidates, if approved, are likely to be their efficacy, safety, convenience and price, the level of competition, and the availability of coverage and adequate reimbursement from third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unlike other cell therapy approaches, our CAR-M platform is based on engineering macrophages and monocytes with proprietary vectors, constructs, and processes, enabling a differentiated platform from other cell therapy competitors that primarily focus on T or natural killer cells (&#8220;NK cells&#8221;). While we believe that our scientific expertise, novel technology, and intellectual property position offer competitive advantages, we face competition from multiple other cell therapy technologies and companies. Other companies developing engineered myeloid cell therapies include, among others, Myeloid Therapeutics, Shoreline Biosciences, Inceptor Bio, Thunder Bio, Resolution Therapeutics, CellOrigin, Deverra, BobcatBio, and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the broad promise of cell therapies, and the potential of myeloid cell-based approaches to expand cell therapy efficacy into solid tumors and liver fibrosis, we expect increasing competition from new and existing companies across several fronts, which include, among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Myeloid cell therapies: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CellOrigin, Deverra, Inceptor Bio, Myeloid Therapeutics, Resolution Therapeutics, Shoreline Biosciences, Thunder Bio, among others</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Autologous </span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">T cell</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"> therapies: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2seventy</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">, </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Adaptimmune, Autolus, Bristol Myers Squibb, Cabaletta, Gracell, Kite/Gilead, Novartis, Poseida, TScan, Vor, among others</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Allogeneic </span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">T cell</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"> therapies: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allogene, Atara, Caribou, Century, Cellectis, Celyad, CRISPR, Fate, Gracell, Kite/ Gilead, Legend, Poseida, Precision Bio, Sana, TScan, Vor, among others</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">NK and other cell therapies: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Adicet, Artiva, Celularity, Century, Editas, Fate, Fortress, Gamida Cell, ImmunityBio, Nkarta, NKGen, Takeda, among others</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Direct in vivo reprogrammed cell therapies: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BioNTech, Ensoma, Interius, Sanofi, Umoja, Orna Therapeutics, Myeloid Therapeutics, Capstan, Abbvie, Alaya.bio, Liberate Bio, Generation Bio, EsoBiotec, among others</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Liver fibrosis therapies: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Madrigal, Akero, 89Bio, Boston Pharma, Resolution Therapeutics, among others and major pharmaceutical companies developing incretin therapies such as Eli Lilly, NovoNordisk, and others.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to competition from other cell therapy companies, any products that we develop may also face competition from other types of therapies. Other companies developing non-cell therapies, including gene therapies, in relevant therapeutic areas include Gilead, ALX Oncology, Five-Prime, Immune-Onc, Pionyr, Infinity, NextCure, OncoResponse, Curis, Faron, Apexigen, Pfizer, Dren, and multiple biotechnology and pharmaceutical companies developing other directly competitive technologies such as small molecules, immune agonists, antibodies, bi/tri specific antibodies, antibody drug conjugates, and other solid tumor therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We also have competed, and if we resume our historical research and development activities will continue to compete with third parties for retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. If we were to resume our historical research and development activities, we may pursue the in-license or acquisition of rights to complementary technologies and product candidates on an opportunistic basis. The acquisition and licensing of technologies and product candidates is a </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">263</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">competitive area, and a number of more established companies also have similar strategies to in-license or acquire technologies and product candidates that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to in-license or acquire the relevant technology or product candidate on terms that would allow it to make an appropriate return on our investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, including as result of our decision to pause research and development activities, which could result in our competitors establishing a strong market position before it is able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union (&#8220;EU&#8221;), extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products, including biological products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources and may have a substantial impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Licensure and Regulation of Biologics in the United States</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, our product candidates are regulated as biological products, or biologics, under the Public Health Service Act (&#8220;PHSA&#8221;) and the FDCA, and its implementing regulations and guidance. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products, and for their regulatory approval, is typically referred to as a sponsor. The failure of a sponsor to comply with the applicable U.S. requirements at any time during the product development process, including pre-clinical testing, clinical testing, the approval process, or post-approval process, may subject a sponsor to delays in the conduct of the study, regulatory review, and approval, and/or administrative or judicial sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A sponsor seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pre-clinical laboratory tests, animal studies, and formulation studies all performed in accordance with the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;), regulations and standards and other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of the manufacture, under cGMP, conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">design of a clinical protocol and submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent IRB representing each clinical site before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials to establish the safety, potency, and purity of the product candidate for each proposed indication, in accordance with current IND and GCP;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation and submission to the FDA of a BLA, for a biologic product requesting marketing for one or more proposed indications, including submission of detailed information on the CMC, for the product in clinical development and proposed labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">review of the product by an FDA advisory committee, where appropriate or if applicable;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">264</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the product&#8217;s identity, strength, quality, and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of any FDA audits of the pre-clinical studies and clinical trial sites to assure compliance with GLP, as applicable, and GCP, and the integrity of clinical data in support of the BLA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of substantial application and program fees under the PDUFA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the BLA authorizing the licensure and marketing of the new biologic product for particular indications in the United States; and</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">compliance with any post-approval requirements, including the potential requirement to implement a REMS and any post-approval studies or other post-marketing commitments required by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pre-clinical Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before testing any biologic product candidate in humans, the product candidate must undergo pre-clinical testing. Pre-clinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies. These studies are often referred to as IND-enabling studies. The conduct of the pre-clinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the U.S. Department of Agriculture&#8217;s Animal Welfare Act, if applicable. The results of the pre-clinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application. With passage of the FDA&#8217;s Modernization Act 2.0 in December&#160;2022, Congress eliminated provisions in both the FDCA and PHSA, that required animal testing in support of a BLA. While animal testing may still be conducted, the FDA was authorized to rely on alternative non-clinical tests, including cell-based assays, micro-physiological systems or bio-printed or computer models.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investigational New Drug Application</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks or any issues surrounding CMC for the proposed product. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trials can begin or recommence. As a result, submission of the IND may result in the FDA not allowing the trials to commence or allowing the trial to commence on the terms originally specified by the sponsor in the IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the FDA raises concerns or questions either during this initial 30-day period, or at any time following allowance of an IND, it may choose to impose a partial or complete clinical hold. Clinical holds are imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments in preclinical and/or clinical trials, and/or CMC. This order issued by the FDA would delay either a proposed clinical trial or cause suspension of an ongoing trial, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigations may proceed. This could cause significant delays or difficulties in completing a planned clinical trial or future clinical trials in a timely manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the issuance of a clinical hold or partial clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed or recommence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expanded Access to an Investigational Drug for Treatment Use</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules&#160;and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">265</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s)&#160;have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by the 21st Century Cures Act (the &#8220;Cures Act&#8221;) passed in 2016, if a sponsor has a policy regarding how it evaluates and responds to expanded access requests, sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 clinical trial, or 15&#160;days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product, or RMAT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to and separate from expanded access, the Right to Try Act, among other things, provides a federal framework for certain patients to access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Human Clinical Trials in Support of a BLA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under the supervision of a qualified principal investigator in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules&#160;and the requirements for informed consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data monitoring committee (&#8220;DMC&#8221;). A DMC may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on access that only the group maintains to available data from the study. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk on the basis of data and information to which only the DMC has access.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 1 </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or, on occasion, in patients, such as cancer patients.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 2 </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the potency and purity of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">266</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 3 </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy, and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a biologic; such Phase 3 studies are referred to as &#8220;pivotal.&#8221;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some cases, the FDA may approve a BLA for a product but require the sponsor to conduct additional clinical trials to further assess the product&#8217;s safety, potency and purity after approval. Such trials are typically referred to as post approval or post marketing clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any post marketing clinical trial requirement or to request a change in the product labeling. The failure to exercise due diligence with regard to conducting post approval clinical trials could result in withdrawal of approval for products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2022, with the passage of the FDORA, Congress required sponsors to develop and submit a diversity action plan for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, action plans must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans. In June&#160;2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for diversity action plans. Unlike most guidance documents issued by the FDA, the diversity action plan guidance when finalized will have the force of law because FDORA specifically dictates that the form and manner for submission of diversity action plans are specified in FDA guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2023, the FDA issued draft guidance with updated recommendations for GCPs aimed at modernizing the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products. The draft guidance is adopted from the International Council for Harmonisation&#8217;s recently updated E6(R3) draft guideline that was developed to enable the incorporation of rapidly developing technological and methodological innovations into the clinical trial enterprise. That guideline was finalized by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use on January&#160;6, 2025. In addition, the FDA issued draft guidance outlining recommendations for the implementation of decentralized clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finally, sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry, clinicaltrials.gov, maintained by the NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Although sponsors are also obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two&#160;years after the date of completion of the trial. The NIH&#8217;s final rule&#160;on registration and reporting requirements for clinical trials became effective in 2017. The PHSA grants the Secretary of the HHS, the authority to issue a notice of noncompliance to a responsible party to failure to submit clinical trial information as required. The responsible party, however, is allowed 30&#160;days to correct the noncompliance and submit the required information. As of December&#160;19, 2024, the FDA has issued six notices of non-compliance, signaling the government&#8217;s willingness to enforce these requirements against non-compliant clinical trial sponsors. While these notices of non-compliance did not result in civil monetary penalties, the failure to submit clinical trial information to clinicaltrials.gov, as required, is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">267</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical Studies Outside the United States in Support of FDA Approval</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with a clinical development program, a sponsor may conduct trials at sites outside the United States. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The acceptance by the FDA of study data from clinical trials conducted outside the United States in support of U.S. approval may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States., the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the U.S. population and U.S. medical practice; (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii)&#160;the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interactions with FDA During the Clinical Development Program</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the clearance of an IND and the commencement of clinical trials, the sponsor will continue to have interactions with the FDA. A development safety update report detailing the results of clinical trials must be submitted annually within 60&#160;days of the anniversary dates that the IND went into effect. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other trials or animal or <i style="font-style:italic;">in vitro</i> testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, sponsors are given opportunities to meet with the FDA at certain points in the clinical development program. Specifically, there are five types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important safety issue. Type B meetings include pre-IND and pre-BLA meetings, as well as end of phase meetings such as End of Phase 2 meetings. A Type C meeting is any meeting other than a Type A or Type B meeting regarding the development and review of a product. A Type D meeting is focused on a narrow set of issues, which should be limited to no more than two focused topics, and should not require input from more than three disciplines or divisions. Finally, INitial Targeted Engagement for Regulatory Advice on CBER/CDER ProducTs meetings are intended for novel products and development programs that present unique challenges in the early development of an investigational product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These meetings provide an opportunity for the sponsor to share information about the data gathered to date with the FDA and for the FDA to provide advice on the next phase of development. At the conclusion of these meetings, the FDA will typically provide its responses to questions posed by the sponsor regarding the clinical development program. The FDA will not indicate whether a BLA will be approved, but it will provide guidance to the sponsor on various questions, including whether an application should be submitted in the first place on the basis of the studies and data proposed by the sponsor. The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design of a clinical program may put the program at significant risk of failure.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">268</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Special Regulations and Guidance Governing Gene Therapy Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has defined a gene therapy product as one that mediates its effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome and which is administered as nucleic acids, viruses, or genetically engineered microorganisms. The products may be used to modify cells <i style="font-style:italic;">in vivo</i> or transferred to cells <i style="font-style:italic;">ex vivo</i> prior to administration to the recipient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Within the FDA, the CBER regulates gene therapy products. Within CBER, the FDA has established the OTAT to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review. In September&#160;2022, the FDA announced renaming of the OTAT to the OTP, and elevation of the OTP to a &#8220;Super Office&#8221; to meet its growing cell and gene therapy workload and new commitments under the PDUFA for fiscal&#160;years 2023 to 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has issued various guidance documents regarding gene therapies, including a November&#160;2024 draft guidance to address frequently asked questions surrounding the development of cellular and gene therapy products and final guidance documents released in January&#160;2020 relating to CMC information for gene therapy INDs, gene therapies for rare diseases and gene therapies for retinal disorders, as well as draft guidance in January&#160;2021 for Human Gene Therapy for Neurodegenerative Diseases. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, we believes that our compliance with them is likely necessary to gain approval for any gene therapy product candidate we may develop. The guidance documents provide additional factors that the FDA will consider at each of the above stages of development and relate to, among other things, the proper pre-clinical assessment of gene therapies; the CMC information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five&#160;years of annual examinations followed by 10&#160;years of annual queries, either in person or by questionnaire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finally, for a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with GTP. These standards are found in FDA regulations and guidance that govern the methods used in, and the facilities and controls used for, the manufacture of HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that T cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety, potency and purity of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The sponsor, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time. In May&#160;2023, the FDA issued new draft guidance that further describes the pediatric study requirements under PREA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are completed. The FDA is required to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although the FDA has recently taken steps to limit what it considers abuse of this statutory exemption in PREA. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although the FDA has taken steps to limit what it considers abuse of this statutory exemption in PREA. Further, Section&#160;505B of the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">269</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FDCA, as amended by the FDARA requires that any original NDA or BLA submitted on or after August&#160;18, 2020, for a new active ingredient, must contain reports on the molecularly targeted pediatric cancer investigation, unless the requirement is waived or deferred, if the drug that is the subject of the application is: (i)&#160;intended for the treatment of an adult cancer, and (ii)&#160;directed at a molecular target that the Secretary determines to be substantially relevant to the growth or progression of a pediatric cancer in accordance with FDA guidance. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Compliance with cGMP Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing commercial quantities of the product candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, and purity of the finished product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Specifically, the FDA&#8217;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and some state agencies, and they are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. The Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act, which was enacted in December&#160;2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Submission and Review of a BLA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The results of product candidate development, pre-clinical testing, and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a BLA requesting license to market the product. The BLA must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee. Under federal law, the submission of most BLAs is subject to an application user fee, which for federal fiscal&#160;year 2025 is $4,310,002 for an application requiring clinical data. The sponsor of a licensed BLA is also subject to an annual program fee, which for federal fiscal&#160;year 2025 is $403,889. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following submission of a BLA, the FDA has 60&#160;days to conduct a preliminary review of the application and it must inform the sponsor within that period of time whether the BLA is sufficiently complete to permit substantive review. In the event that the FDA determines that an application does not satisfy this standard, it will issue a Refuse to File determination to the sponsor. The FDA may request additional information and studies, and the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under the PDUFA, the FDA has 10&#160;months in which to complete its initial review of a standard application and respond to the sponsor, and six&#160;months for a priority review of the application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review process may often be significantly extended by the FDA requests for </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">270</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">additional information or clarification. The review process and the PDUFA goal date may be extended by three&#160;months if the FDA requests or if the sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three&#160;months before the PDUFA goal date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA seeks to meet these timelines for review of an application but its ability to do so may be affected by a variety of factors. While the costs associated with review of an application are typically covered by the PDUFA user fee program, other activities, including government budget and funding levels, the ability to hire and retain key personnel and statutory, regulatory and policy changes, may impact the FDA&#8217;s review and approval of marketing applications. Average review times at the FDA have fluctuated in recent&#160;years as a result. For example, during the past decade, the U.S. government has shut down several times and certain regulatory agencies, including the FDA, has had to furlough critical employees and stop critical activities. Further, there is substantial uncertainty as to how measures being implemented by the new Trump administration across the government will impact the FDA and other federal agencies with jurisdiction over biologics. For example, the potential loss of FDA personnel could lead to further disruptions and delays in the FDA&#8217;s operations and activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with its review of a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with IND and GCP requirements and the integrity of the clinical data submitted to the FDA. With passage of the FDORA, Congress clarified the FDA&#8217;s authority to conduct inspections by expressly permitting inspections of facilities involved in the preparation, conduct, or analysis of clinical and non-clinical studies submitted to the FDA as well as other persons holding study records or involved in the study process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may also refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. In particular, the FDA may refer applications for novel biologic products or biologic products that present difficult questions of safety, potency or purity to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions on approval. Data from clinical trials are not always conclusive, and the FDA or its advisory committee may interpret data differently than the sponsor interprets the same data. The FDA may also re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the sponsor during the review process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the FDA will review a sponsor&#8217;s financial relationship with the principal investigators who conducted the clinical trials in support of the BLA. That is because, under certain circumstances, principal investigators at a clinical trial site may also serve as scientific advisors or consultants to a sponsor and receive compensation in connection with such services. Depending on the level of that compensation and any other financial interest a principal investigator may have in a sponsor, the sponsor may be required to report these relationships to the FDA. The FDA will then evaluate that financial relationship and determine whether it creates a conflict of interest or otherwise affects the interpretation of the trial or the integrity of the data generated at the principal investigator&#8217;s clinical trial site. If so, the FDA may exclude data from the clinical trial site in connection with its determination of safety, potency and purity of the investigational product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA also may require submission of a REMS if it determines that a REMS is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the product. The REMS could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use (&#8220;ETASU&#8221;), such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS and the FDA will not approve the application without a REMS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The FDA&#8217;s Decision on a BLA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the PHSA the FDA may approve a BLA if it determines that the product is safe, pure, and potent, and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure, and potent. Specifically, the FDA must determine that the expected benefits of the proposed product outweigh its potential risks to patients. This &#8220;benefit- risk&#8221; assessment is informed by the extensive body of evidence about the proposed product in the BLA. On the basis of the FDA&#8217;s </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">271</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of pre-clinical and clinical trial sites to assure compliance with GCPs, the FDA may issue a complete response letter (&#8220;CRL&#8221;) or an approval letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the application is not approved, the FDA will issue a CRL, which will contain the conditions that must be met in order to secure final approval of the application and will outline recommended actions the sponsor might take to obtain approval of the application. Sponsors that receive a CRL may submit to the FDA information that represents a complete response to the issues identified by the FDA, withdraw the application or request a hearing. The FDA will not approve an application until issues identified in the CRL have been addressed. If a CRL is issued, the sponsor will have one&#160;year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional six-month extension to respond.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. The FDA may limit the approved indication(s)&#160;for use of the product. It may also require that contraindications, warnings, or precautions be included in the product labeling. In addition, the FDA may call for post&#160;-approval studies, including Phase 4 clinical trials, to further assess the product&#8217;s efficacy and/or safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expedited Review Programs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA is authorized to expedite the review of applications in several ways. None of these expedited programs changes the standards for approval but each may help expedite the development or approval process governing product candidates.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Fast Track designation</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Breakthrough therapy designation</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Priority review</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety, potency and purity in a new subpopulation. The FDA aims to complete its review of priority review applications within six&#160;months as opposed to 10&#160;months for standard review.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Accelerated approval</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Drug or biologic products studied for their safety, potency and purity in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">272</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">With the passage of FDORA in December&#160;2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded and require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to the FDA every six&#160;months (until the study is completed). Moreover, FDORA established expedited procedures authorizing the FDA to withdraw an accelerated approval if certain conditions are met, including where a required confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product is not shown to be safe or effective under the conditions of use. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence, including with respect to &#8220;conditions specified by the Secretary.&#8221; The new procedures include the provision of due notice and an explanation for a proposed withdrawal, and opportunities for a meeting with the FDA Commissioner or the Commissioner&#8217;s designee and a written appeal, among other things.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In March&#160;2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval. The agency indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to support accelerated approvals of oncology therapeutics. Subsequently, in December&#160;2024 and January&#160;2025, the FDA issued additional draft guidance relating to accelerated approval. This guidance describes the FDA&#8217;s latest thinking on what it means to conduct a confirmatory trial with due diligence and how the agency plans to interpret whether such a study needs to be underway at the time of approval. While this guidance is currently only in draft form and will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to ensure that their investigational products qualify for accelerated approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Regenerative advanced therapy</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. With passage of the Cures Act, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-Approval Regulation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA have imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety, potency and purity information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">273</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency, and effectiveness of pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. In September&#160;2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a biologic product. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the HHS as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in non-promotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information. Moreover, with passage of the Pre-Approval Information Exchange Act, in December&#160;2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patient access upon product approval. Previously, such communications were permitted under FDA guidance but the new legislation explicitly provides protection to sponsors who convey certain information about products in development to payors, including unapproved uses of approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in January&#160;2025, the FDA published final guidance outlining its policies governing the distribution of scientific information to healthcare providers about unapproved uses of approved products. The final guidance calls for such communications to be truthful, non-misleading and scientifically sound and to include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use of the approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;) and its implementing regulations, as well as the Drug Supply Chain Security Act (&#8220;DSCSA&#8221;), which regulate the distribution and tracing of prescription drug samples at the federal level, and set minimum standards for the regulation of distributors by the states. The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove counterfeit and other illegitimate products from the market. Manufacturers were required by November&#160;2023 to have such systems and processes in place to comply </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">274</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with the DSCSA, but, so as not to disrupt supply chains, the FDA has granted certain exemptions from enhanced drug distribution security requirements for eligible trading partners for particular periods of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Drug Designation and Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven&#160;years following the date of the product&#8217;s marketing approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process like any other product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same product for the same indication for seven&#160;years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The period of exclusivity begins on the date that the marketing application is approved by the FDA. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Under Omnibus legislation enacted in December&#160;2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by the FDA. In addition, the FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Circuit in September&#160;2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; On January&#160;23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. However, on February&#160;14, 2025, a federal district court in Washington, D.C. fully embraced the reasoning of the court decision in another decision challenging the scope of orphan drug exclusivity. The implications of this decision, and its impact on the FDA&#8217;s implementation of the Orphan Drug Act, are unclear at this point.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pediatric exclusivity is another type of non-patent exclusivity in the United States and for biologics, if granted, provides for the attachment of an additional six&#160;months of regulatory exclusivity to the term of any existing regulatory exclusivity, including orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">275</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity that cover the product are extended by six&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Biosimilars and Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ACA, which was signed into law in March&#160;2010, included a subtitle called the BPCIA. The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. A biosimilar is a biological product that is highly similar to an existing FDA-licensed &#8220;reference product.&#8221; The FDA has approved a number of biosimilar products and interchangeable biosimilar products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12&#160;years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The BPCIA also includes provisions to protect reference products that have patent protection. The biosimilar product sponsor and reference product sponsor may exchange certain patent and product information for the purpose of determining whether there should be a legal patent challenge. Based on the outcome of negotiations surrounding the exchanged information, the reference product sponsor may bring a patent infringement suit and injunction proceedings against the biosimilar product sponsor. The biosimilar applicant may also be able to bring an action for declaratory judgment concerning the patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA maintains a publicly-available online database of licensed biological products, which is commonly referred to as the &#8220;Purple Book.&#8221; The Purple Book lists product names, dates of licensure, and applicable periods of exclusivity. Further, the reference product sponsor must provide patent information and patent expiry dates to FDA following the exchange of patent information between biosimilar and reference product sponsors. This information is then published in the Purple Book.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In an effort to increase competition in the drug and biologic product marketplace, Congress, the executive branch, and the FDA have taken certain legislative and regulatory steps. For example, the 2020 Further Consolidated Appropriations Act included provisions requiring that sponsors of approved drug and biologic products, including those subject to REMS, provide samples of the approved products to persons developing biosimilar products within specified timeframes, in sufficient quantities, and on commercially reasonable market-based terms. Failure to do so can subject the approved product sponsor to civil actions, penalties, and responsibility for attorney&#8217;s fees and costs of the civil action. There have been recent government proposals to reduce the 12-year reference product exclusivity period, but none has been enacted to date. At the same time, since passage of the BPCIA, many states have passed laws or amendments to laws, which address pharmacy practices involving biosimilar products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Federal and State Data Privacy and Security Laws</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There are multiple privacy and data security laws that may impact our business activities, in the United States and in other countries where we conduct trials or where we may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the health care industry generally, under HIPAA, the HHS, has issued regulations to protect the privacy and security of protected health information, used or disclosed by covered entities including certain healthcare providers, health plans, and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our relationships with them. Our clinical trials are regulated by the Common Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">276</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">that may be applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. State attorneys general also have authority to enforce state privacy and security laws. New laws and regulations governing privacy and security may be adopted in the future as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">States are also active in creating specific rules&#160;relating to the processing of personal information. In 2018 California passed into law the CCPA, which took effect on January&#160;1, 2020, and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November&#160;2020, California voters passed a ballot initiative for the California Privacy Rights Act (the &#8220;CPRA&#8221;), which went into effect on January&#160;1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency&#160;- the California Privacy Protection Agency&#160;- whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to California, a number of other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime over the next several&#160;years. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering or have already passed comprehensive privacy laws that will go into effect in 2025 and beyond. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Health My Data Act in 2023 which specifically regulates the collecting and sharing of health information that is not otherwise regulated by the HIPAA rules, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation in 2025. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Patent Term Restoration and Extension</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent extension of up to five&#160;years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the time between the effective date of the IND clearing clinical studies and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14&#160;years from the product&#8217;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">277</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">FDA Approval of Companion Diagnostics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and <i style="font-style:italic;">in vitro</i> companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. In July&#160;2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and <i style="font-style:italic;">in vitro</i> companion diagnostic device on issues related to co-development of the products. The 2014 guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a biologic product candidate generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption (&#8220;IDE&#8221;) regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a product are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, the FDA issued additional guidance which describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple biological oncology products, when appropriate. The 2020 guidance expands on the policy statement in the 2014 guidance by recommending that companion diagnostic developers consider a number of factors when determining whether their test could be developed, or the labeling for approved companion diagnostics could be revised through a supplement, to support a broader labeling claim such as use with a specific group of oncology therapeutic products (rather than listing an individual therapeutic product(s)).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the FDCA, <i style="font-style:italic;">in vitro</i> diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, pre-clinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA previously has required <i style="font-style:italic;">in vitro</i> companion diagnostics intended to select the patients who will respond to the product candidate to obtain PMA, simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and pre-clinical data and the submission to and review by the FDA, can take several&#160;years or longer. It involves a rigorous premarket review during which the sponsor must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety, potency and purity and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. For federal fiscal&#160;year 2025, the standard fee is $540,783 and the small business fee is $135,196.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is possible that an <i style="font-style:italic;">in vitro</i> companion diagnostic device could be subject to FDA enforcement discretion from compliance with the FDCA if it meets the definition of a LDT. However, FDA issued a final rule&#160;in April&#160;2024 to end enforcement discretion for LDTs and actively regulate such products as medical devices. Under this final rule, LDTs are required to come into compliance with the FDA&#8217;s medical device regulatory requirements in a staged approach over the course of four&#160;years. The implementation of this LDT final rule&#160;could potentially be affected by the Executive Order, <i style="font-style:italic;">Regulatory Freeze Pending Review</i>, issued by President Trump on January&#160;20, 2025 and/or the anticipated change in leadership at the FDA under the new administration. Further, while the final regulation is set to take effect on May&#160;6, 2025, a number of parties have challenged the legality of the LDT regulation in a federal district court. That court held a hearing on this matter on February&#160;19, 2025, and is expected to issue a ruling shortly thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Coverage, Pricing, and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may seek regulatory approval by the FDA or other government authorities. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any product candidates a sponsor may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. Even if any product candidates a sponsor may develop are approved, sales of such product candidates would depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">278</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">health insurers, and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such product candidates. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover any product candidates a sponsor may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on a sponsor&#8217;s sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage may not be available to enable a sponsor to maintain price levels sufficient to realize an appropriate return on a sponsor&#8217;s investment in product development. In addition, any companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to any companion diagnostics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outside the United States, ensuring adequate coverage and payment for any product candidates a sponsor may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require a sponsor to conduct a clinical trial that compares the cost effectiveness of any product candidates a sponsor may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in a sponsor&#8217;s commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states may approve a specific price for a product or they may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of a sponsor&#8217;s products, if approved in those countries.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">279</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare Law and Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Arrangements with providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to physicians and teaching physicians and patient privacy laws and regulations and other healthcare laws and regulations that may constrain a sponsor&#8217;s business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal civil and criminal false claims laws, including the civil FCA, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal transparency requirements under the ACA, which require certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the CMS, within the HHS, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. In addition, certain state and local laws require drug manufacturers to register pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a sponsor&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to a sponsor, a sponsor may be subject to significant civil, criminal, and administrative penalties, damages, fines, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring of a sponsor&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare Reform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few&#160;years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2010, the U.S. Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government healthcare programs. Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August&#160;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to two&#160;percent per fiscal&#160;year, which will remain in effect through 2031 pursuant to the CARES Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The American Taxpayer Relief Act of 2012, which was enacted in January&#160;2013, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">280</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">limitations period for the government to recover overpayments to providers from three to five&#160;years. Further, with passage of the IRA, Congress extended the expansion of ACA premium tax credits through 2025. Those subsidies were originally extended through 2022 under the American Rescue Plan Act of 2021. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices a sponsor may obtain for any of a sponsor&#8217;s product candidates for which a sponsor may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Act, which was signed by President Trump on December&#160;22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019 Further, on June&#160;17, 2021, the U.S. Supreme Court dismissed a lawsuit after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Shortly after taking office in January&#160;2025, President Trump revoked numerous executive orders issued by President Biden, including at least two executive orders (e.g., EO 14009, Strengthening Medicaid and the ACA, and EO 14070, Continuing to Strengthen Americans&#8217; Access to Affordable, Quality Health Coverage) which were designed to further implement the ACA. We anticipate similar efforts to undermine the ACA, and litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pharmaceutical Prices</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in October&#160;2020, the HHS and the FDA published a final rule&#160;allowing states and other entities to develop a SIP to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the PhRMA, but the case was dismissed by a federal district court in February&#160;2023 after the court found that PhRMA did not have standing to sue the HHS. Several states have passed legislation establishing workgroups to examine the impact of a state importation program. Several states have also passed laws allowing for the importation of drugs from Canada. Certain of these states have submitted SIP proposals and are awaiting FDA approval. On January&#160;5, 2024, the FDA approved Florida&#8217;s plan for Canadian drug importation. Florida now has authority to import certain products from Canada for a period of two&#160;years once certain conditions are met. Florida will first need to submit a pre-import request for each product selected for importation, which must be approved by the FDA. Florida will also need to relabel the products and perform quality testing of the products to meet FDA standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, on November&#160;20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule&#160;also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed, and recent legislation imposed a moratorium on implementation of the rule&#160;until January&#160;1, 2026. The IRA, further delayed implementation of this rule&#160;to January&#160;1, 2032.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The IRA has implications for Medicare Part&#160;D, which is a program available to individuals who are entitled to Medicare Part&#160;A or enrolled in Medicare Part&#160;B to give them the option of paying a&#160;monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare beginning in 2026, with prices that can be negotiated subject to a cap; and it replaces the Part&#160;D coverage gap discount program with a new discounting program beginning in 2025. In addition, the IRA established inflation rebate programs under Medicare Part&#160;B and Part&#160;D. These programs require manufacturers to pay rebates to Medicare if they raise their prices for certain Part&#160;B and Part&#160;D drugs faster than the rate of inflation. On December&#160;9, 2024, with issuance of its 2025 Physician Fee Schedule final regulation, CMS finalized its rules&#160;governing the IRA inflation rebate programs. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part&#160;B and Part&#160;D. The CMS may negotiate prices for 10 high-cost drugs paid for by Medicare Part&#160;D starting in 2026, followed by 15 additional </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">281</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Part&#160;D drugs in 2027, 15 additional Part&#160;B or Part&#160;D drugs in 2028, and 20 additional Part&#160;B or Part&#160;D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least nine&#160;years and biologics that have been licensed for 13&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The IRA includes a provision exempting orphan drugs from Medicare price negotiations but this exclusion has been interpreted by CMS in final guidance issued in July&#160;2023 to apply only to those orphan drugs with an approved indication (or indications) for a single rare disease or condition. Thus, a biologic that is designated for more than one rare disease or condition will not qualify for the orphan drug exclusion, even if it is not approved for any indications for the additional diseases or conditions. The final guidance clarifies that CMS will consider only active designations/approvals when evaluating a drug for the exclusion, such that designations/indications withdrawn before the selected drug publication date will not be considered. CMS also clarified that, if a drug loses its orphan drug exclusion status, the agency will use the earliest date of approval/licensure to determine whether the product is a qualifying single source drug subject to price negotiations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023. On August&#160;15, 2024, the HHS published the results of the first Medicare drug price negotiations for 10 selected drugs that treat a range of conditions, including diabetes, chronic kidney disease, and rheumatoid arthritis. The prices of these 10 drugs will become effective January&#160;1, 2026. On January&#160;17, 2025, shortly before the new administration took office, CMS announced its selection of 15 additional drugs covered by Part&#160;D for the second cycle of negotiations. There has been uncertainty about the extent to which the new administration would support the price negotiation program. Following the change in administrations, CMS issued a public statement on January&#160;29, 2025, declaring that lowering the cost of prescription drugs is a top priority of the new administration and CMS is committed to considering opportunities to bring greater transparency in the negotiation program. The second cycle of negotiations with participating drug companies will occur during 2025, and any negotiated prices for this second set of drugs will be effective starting January&#160;1, 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;6, 2023, Merck&#160;&amp; Co. filed a lawsuit against the HHS and the CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce and pharmaceutical companies, also filed lawsuits in various courts with similar constitutional claims against the HHS and the CMS.&#160;HHS has generally won the substantive disputes in these cases, and various federal district court judges have expressed skepticism regarding the merits of the legal arguments being pursued by the pharmaceutical industry. Certain of these cases are now on appeal and, on October&#160;30, 2024, the Court of Appeals for the Third Circuit heard oral argument in three of these cases. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require pharmaceutical manufacturers and other entities in the supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for a sponsor&#8217;s products, once approved, or put pressure on a sponsor&#8217;s product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. This is increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Human Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June&#160;30, 2025, we had 2 full-time employees, all of whom are located in the United States. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our existing employees to be good.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">282</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our human capital objectives are focused on retaining and incentivizing our management team and other employees to complete the Merger, and if not completed, to evaluate our other strategic alternatives and prepare for the potential wind down, liquidation or dissolution of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cost Reduction Measures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2024, our board of directors approved a reduction in force of 39 full-time employees (representing approximately 37.0% of our total workforce), including certain employees engaged in research and development activities and certain finance and corporate employees. In December&#160;2024, our board of directors approved a further reduction in force of 23 full-time employees (representing approximately 34.0% of our total workforce) including certain employees engaged in research and development and manufacturing activities and certain finance and corporate employees. In March&#160;2025, in connection with approving our cash preservation plan, our board of directors approved a further reduction in force of 42 full-time employees (representing approximately 95.0% of our total workforce at that time including certain employees engaged in research and development and manufacturing activities and certain finance and corporate employees).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our principal executive offices are located at 3675 Market Street, Suite&#160;401, Philadelphia, PA, and our telephone number is (267) 491-6422. Our website address is <i style="font-style:italic;">httpp://www.carismatx.com</i>. The information contained on, or that can be accessed through, our website is not a part of this proxy statement/prospectus. We have included our website address in this proxy statement/prospectus solely as an inactive textual reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We own or have rights to, or have applied for, trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. Other trademarks, service marks and trade names appearing in this proxy statement/prospectus are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this proxy statement/prospectus are listed without the &#174; and &#8482; symbols.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We make available, through our website <i style="font-style:italic;">httpp://www.carismatx.com</i>, our Annual Report on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K, and amendments to those reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange Act, as soon as reasonably practicable after we electronically file such material with the SEC. We have included our website address in this proxy statement/prospectus solely as an inactive textual reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Properties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our principal facilities consist of office in Philadelphia, Pennsylvania. We occupy approximately 4,369 square feet of office space under a lease that is expected to expire in October&#160;2029. We believe that our facilities are sufficient to meet our current needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are currently not a party to any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">283</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c56cbe88_f94d_430f_b946_d180479e692e"></a><a id="ORTHOCELLIXSBUSINESS_195125"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ORTHOCELLIX&#8217;S BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix is a biotechnology company focused on discovering, developing, and commercializing new regenerative cell therapies that improve health and offer hope for patients across the globe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s initial product candidate is a Phase 3-ready regenerative cell therapy platform technology, NeoCart (autologous chondrocyte-derived neocartilage), which combines breakthroughs in bioengineering and cell processing to enhance the autologous cartilage repair process and is being developed for the repair of knee cartilage injuries in adults. Knee injury increases the risk of developing OA. Approximately 27.0 million people in the United States are diagnosed each&#160;year with knee OA&#160;&#8211; a large portion due to cartilage damage. It is estimated that more than 50.0% of patients with knee OA ultimately undergo total joint replacement. The average medical cost of knee OA management in the United States is $140,300 per person. Based on recent market research statistics and the current reimbursed cost of ACI, OrthoCellix believes the addressable market for NeoCart is approximately $3.0 billion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is one autologous chondrocyte implant product, approved product in the U.S. for the treatment of articular cartilage defects in the knee, MACI, made by Vericel corporation. The product was approved in 2017 with the indication: Autologous cellularized scaffold product indicated for the repair of symptomatic, single, or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Since launch Vericel has generated $905 million in sales of MACI (2017 &#8211; 2024) and the product is growing at an annualized rate of 24% per year. Approximately 85% of Vericel revenues derive from MACI and Vericel has a market capitalization of $1.87 billion as of July 16, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NeoCart is a three-dimensional tissue-engineered disc of new cartilage that is manufactured by growing the patient&#8217;s own chondrocytes, the cells responsible for maintaining cartilage health. Current surgical and nonsurgical treatment options for knee cartilage injuries in adults are limited in their efficacy and durability. In prior clinical studies, Phase 2 and Phase 3, NeoCart has shown potential to accelerate healing, reduce pain, and provide regenerative native-like cartilage strength with durable benefits post transplantation. NeoCart was shown to be generally well-tolerated and demonstrated greater clinical efficacy than microfracture surgery at two years after treatment. Based on this demonstrated clinical benefit, the FDA granted a RMAT designation to NeoCart for the repair of full- thickness lesions of knee cartilage injuries in adults. Additionally, OrthoCellix, vis-&#224;-vis Ocugen, has aligned with the FDA on the confirmatory Phase 3 trial design where chondroplasty will be used as a control group. Ocugen has completed renovating an existing facility into a GMP facility in accordance with the FDA&#8217;s regulations in support of NeoCart manufacturing for personalized Phase 3 trial material, and OrthoCellix plans to engage Ocugen for the manufacture of the substances for NeoCart and the final product of NeoCart for clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ORTHOCELLIX&#8217;S STRATEGY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix is developing novel solutions to medical challenges and approaching healthcare innovation with purpose and agility to deliver new regenerative cell therapies. To accomplish this mission, OrthoCellix plans to advance the clinical development of its regenerative medicine platform towards market authorization. OrthoCellix intends to initiate the Phase 3 trial contingent on adequate availability of funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMPETITIVE STRENGTHS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s key competitive strengths include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Platform Technologies. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s 3D tissue engineering platform technology utilizes state-of-the-art bioreactor which can be used to produce native cartilage-like tissues for implantation. Its first product candidate based on this platform technology, NeoCart, is an autologous cartilage tissue-engineered implant designed for use in repair of articular cartilage injuries in the knee. In contrast to the approved cell-matrix based product, NeoCart showed rapid healing and durable benefit in clinical studies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Product Designations. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeoCart was granted RMAT designation from the FDA for the repair of knee cartilage injuries in adults. The RMAT designation was created to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure a serious condition.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">284</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Licensing and Development Arrangements and Intellectual Property Portfolio.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> OrthoCellix has a license agreement with Purpose relating to NeoCart (the &#8220;Purpose Agreement&#8221;). As of July&#160;21, 2025, its global intellectual property portfolio contains 37 patents and 12 pending patent applications related to composition of matter, and methods of use for its product candidate, and other proprietary technology including those under the Purpose Agreement. It will leverage these domestic and global partnerships and its intellectual property portfolio to advance its near- and long-term product pipeline opportunities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NEOCART (AUTOLOGOUS CHONDROCYTE-DERIVED NEOCARTILAGE) CELL THERAPY PLATFORM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ocugen incorporated NeoCart as part of its development pipeline in 2019 through a reverse merger with Histogenics Corporation (&#8220;Histogenics&#8221;). Subsequently Ocugen created a dedicated regenerative cell therapy company called OrthoCellix to maximize the potential for NeoCart and the related pipeline opportunities related to this technology. In May&#160;2022, the FDA granted a RMAT designation to NeoCart for the repair of full-thickness lesions of knee cartilage injuries in adults.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NeoCart is based on OrthoCellix&#8217;s RCT platform, which OrthoCellix believes has the potential to be used for a broad range of additional therapeutic indications and combines expertise in the following areas:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cell therapy and processing: the handling of tissue biopsies and the extraction, isolation and expansion of the cells;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Biomaterials and Scaffold: three-dimensional biomaterials and structures that enable the proper delivery, distribution and organization of cells in their natural environment to support tissue formation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tissue engineering: the use of a combination of cells, engineering and biomaterials to improve or restore biological functions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bioadhesives: natural, biocompatible materials that act as adhesives for biological tissue and allow for natural cell and tissue infiltration and integration with native cells.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to 2019, Phase 1 and Phase 2 clinical trials were conducted to evaluate the safety and efficacy of NeoCart. These clinical trials reported a decrease in pain and improved function of the knee. Additionally, per the results of the Phase 2 clinical trial, more patients responded to NeoCart than microfracture surgery. No SAEs were reported. A Phase 3 clinical trial was conducted to assess the safety and effectiveness of NeoCart as compared to microfracture surgery to treat cartilage defects in the knee. This clinical trial enrolled 249 subjects between the ages of 18 and 59. The Phase 3 clinical trial of NeoCart missed the primary endpoint of a statistically significant improvement in pain and function in a dual threshold responder analysis one&#160;year after the treatment as compared to microfracture surgery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix, vis-&#224;-vis Ocugen, has aligned with the FDA on the confirmatory Phase 3 clinical trial design. This study will be a randomized, controlled clinical trial designed to evaluate the efficacy and safety of NeoCart in comparison to the current standard of care, chondroplasty, in subjects with articular cartilage defects. OrthoCellix intends to initiate the Phase 3 trial contingent on adequate availability of funding. The revised Phase 3 clinical trial will use chondroplasty as the control instead of microfracture, which was used in the Phase 3 clinical trial conducted by Histogenics. Additionally, OrthoCellix believes several additional improvements to the original trial design have been made based on the post hoc assessment of outcomes of the original Phase 3 trial conducted by Histogenics:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Phase 3 clinical trial conducted by Histogenics used a responder analysis for the co-primary endpoint (as opposed to microfracture) that included an improvement of at least 12 points in outcome compared to baseline at one&#160;year on the knee injury and OA outcome score pain assessment test and an improvement of at least 20 points in outcome compared to baseline on the International Knee Documentation Committee subjective test. In contrast, OrthoCellix&#8217;s Phase 3 clinical trial will use a co-primary efficacy endpoint defined as the mean change from baseline (as opposed to chondroplasty) to two&#160;years for the patients&#8217; Knee Injury and OA Outcome Score Pain and Function (Activities of Daily Living) subscale scales. OrthoCellix believes this is a more reasonable, predictable and accurate primary assessment measure.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Phase 3 clinical trial conducted by Histogenics enrolled patients with a total lesion size of less than six cm</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">2</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, while OrthoCellix&#8217;s Phase 3 clinical trial will enroll patients with total lesion sizes between one to three cm</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">2</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. OrthoCellix believes this will address the wider variability in individual patient outcomes seen in the original Phase 3 trial.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">285</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix&#8217;s Phase 3 trial is limited to 55&#160;years old and younger&#160;to minimize age-related confounders and maximize treatment effect.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cartilage is a complex tissue which protects the various joints and bones in the human body. It acts as a shock absorber throughout the body withstanding significant pressure and allows for joints to glide smoothly with minimal friction. Cartilage damage can be caused by acute trauma, such as a bad fall or a sports- related injury, or by repetitive trauma, such as general wear over time. Unlike other tissues in the body, cartilage in the joints has no innate ability to repair itself, making any injury permanent. If left untreated, even a small defect can expand in size and progress to debilitating OA, ultimately requiring a joint replacement procedure. A Global Burden of Disease Study published in 2023 by the Lancet Rheumatology estimated that approximately 595.0 million individuals worldwide were living with OA in 2020. This number is expected to increase as the population of aging yet active individuals and the rates of obesity increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix believes the current therapies available to treat cartilage damage in the knee are suboptimal with varying outcomes due to variable cellular responses. Chondroplasty is often recommended in patients with small cartilage lesions (between one and three cm<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>). This procedure is performed through small incisions on the sides of the knee with the aid of an arthroscope. During this procedure, the damaged cartilage is trimmed, and the remaining surface is smoothed. Microfracture surgery is a frequently used procedure for severe cartilage damage which yields varying outcomes from patient to patient. This surgery consists of the creation of tiny holes or &#8220;fractures&#8221; in the bone underneath the injured cartilage, leading to the formation of a blood clot in the affected area. The blood and bone marrow that form the blood clot contain stem cells, which are expected to grow into cartilage-building cells, as well as growth factors to support cell function and development of replacement cartilage matrix. Approximately 30.0% of patients that have undergone microfracture surgery continue to have pain and reduced knee function and 23.0% to 31.0% require revision surgery within two to five&#160;years of the original microfracture procedure. Additionally, current therapies require extensive recovery time. They are often ineffective in the long term as they do not adequately address cartilage damage, which leads to additional corrective surgeries. By contrast, NeoCart provides a patient&#8217;s own autologous cultured chondrocytes grown throughout a 3D bovine collagen membrane for the repair of symptomatic, single, or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults less than 55&#160;years of age. NeoCart comes in a three-by-five-centimeter cellular sheet with a density of 500,000 cells per cm<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> which can be cut and shaped to the exact size and shape of the articular cartilage defect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The other options for cartilage repair include osteochondral autograft transplantation (&#8220;OAT&#8221;), osteochondral allograft resurfacing (&#8220;OCA&#8221;), and ACI. During OAT, damaged cartilage is removed and replaced with healthy cartilage from a non-weight-bearing area of the joint. OAT is recommended for small to medium sized lesions (between 1.5 and four cm<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>) and is limited by the amount of donor tissue available, the need for open surgery, and donor site morbidity. OCA is a similar process to OAT except that the tissue is sourced from cadaveric donor bone and cartilage. OCA is recommended for large lesions (between four and 10 cm<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>) and can be performed in a single procedure but is limited by the availability of cadaveric tissue. ACI is a process where cartilage cells are harvested from a non-weight bearing part of the knee and are cultured in a laboratory. They are subsequently implanted into the injured area on a 2D porcine scaffold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Over one million knee arthroscopies are performed annually as a procedure to diagnose and treat issues of the joint. Patients and physicians need treatment options that offer more rapid and durable recovery compared to the current treatment options. The attributes of an optimal treatment for a damaged knee cartilage involve the reduction in pain, repair of the knee cartilage, rapid return to daily activities, durable response, and a non-opioid approach. OrthoCellix believes NeoCart would represent a better solution to treat cartilage damage in the knee as it has the potential to solve for the limitations of the current therapies and has the potential to provide improved efficacy, long-term patient benefits, accelerated patient recovery, and predictable patient outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">NeoCart is designed to treat pain at the source, improve function, and potentially prevent a patient&#8217;s progression to OA. NeoCart is a three-dimensional tissue-engineered disc of new cartilage that is manufactured by growing chondrocytes, the cells responsible for maintaining cartilage health. The chondrocytes are derived from the patient on a unique scaffold. In this therapy, the patient&#8217;s cells are separated from a tissue biopsy specimen and multiplied in a manufacturing facility. The cells are then infused into the scaffold, which is a three-dimensional structure that enables the proper delivery, distribution, and organization of cells in their natural environment to support tissue formation. Before NeoCart is implanted in a patient, the patient&#8217;s cells and the scaffold undergo a bioengineering process in a Tissue Engineering Processor (&#8220;TEP&#8221;). The TEP is designed to mimic the conditions inside a functional joint so that the tissue is prepared to begin functioning like normal healthy cartilage prior to implantation. Once NeoCart is ready to be implanted, a bioadhesive is used to anchor NeoCart at the site of cartilage injury and seal the implant to the surrounding native cartilage. The bioadhesive is a natural, biocompatible material which acts as adhesives for biological tissue, thereby eliminating the need for complicated suturing (<b style="font-weight:bold;">Figure 1</b>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">286</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:99.55pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 1: Mechanism of the regenerative medicine cell therapy technology, NeoCart.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"><img src="tmb-20250331xs4024.jpg" alt="Graphic" style="display:inline-block;height:99.55pt;width:463.95pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Figure 1</span><i style="font-style:italic;"> demonstrates the mechanism of OrthoCellix&#8217;s regenerative medicine cell therapy technology, NeoCart. OrthoCellix believes NeoCart has the potential to accelerate healing and reduce pain by reconstructing a patient&#8217;s previously damaged knee cartilage. In this therapy, healthy cartilage tissue is grown and implanted in the patient.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NeoCart Clinical Development Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NeoCart Phase 3 Clinical Trial</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NeoCart Phase 3 clinical trial was the largest and first prospectively designed, randomized clinical trial in North America evaluating the safety and efficacy of a restorative cell therapy to treat knee cartilage damage. Although it was unsuccessful, it was also believed to be the only trial with a dual threshold responder analysis endpoint.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of the prospective data analysis, Histogenics collected a variety of patient reported outcome endpoints, including all measures of the Knee Injury and Osteoarthritis Outcomes Score (&#8220;KOOS&#8221;) and the International Knee Documentation Committee (&#8220;IKDC&#8221;) score, which are validated, patient-centered assessments of pain and function that are commonly used in current clinical trials of cartilage therapies. On almost all of these measures, two of which are being utilized as primary endpoints in ongoing clinical trials by third parties in the U.S. for other therapies, NeoCart demonstrated statistically significant improvements versus microfracture at one and two&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Phase 3 clinical trial was the first study prospectively enrolled consistent with current FDA guidance, which provides for the use of microfracture as a comparator treatment in trials to repair knee cartilage damage. The published FDA guidance also specifically calls for a study population that, given the clinical limitations and variable results of microfracture, OrthoCellix believes provides more favorable results than what is typically seen in microfracture in both the literature and a real-world setting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The primary endpoint for the Phase 3 clinical trial was a dual-threshold responder analysis measuring the improvement in KOOS pain and IKDC function scores for each patient treated with NeoCart compared to those treated with microfracture one&#160;year after the time of treatment. Dual-threshold responders were defined as patients who, relative to their baseline measurements, had at least a&#160;12-point&#160;improvement in the KOOS pain&#160;sub-score&#160;assessment and a&#160;20-point&#160;improvement in the IKDC subjective assessment. The trial also evaluated additional pain, quality of life, and function outcomes using all five measures of KOOS subscales, including Sports and Recreation. The change from baseline and the relative change between the NeoCart and microfracture arms was also measured at one&#160;year which contrasts with clinical trials of other products, either on the market or in development, that measured these changes at two&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Demographics for both study arms were similar and represent a patient population that was intended to ensure that microfracture would respond favorably, including patients with an average age of approximately 39&#160;years old and a Body Mass Index of approximately 27. Furthermore, the mean lesion size was 2.1 cm in the NeoCart arm and 1.8 cm in the microfracture arm. There were no other significant differences between the treatment arms.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">287</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The results with respect to the primary endpoint (dual threshold responder analysis one&#160;year after treatment) are summarized below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">NeoCart</b></p></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:20.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Microfracture</b></p></td><td style="vertical-align:bottom;width:3.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Positive</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Responders</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Responder</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Rate</b></p></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:8.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Positive</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Responders</b></p></td><td style="vertical-align:bottom;width:1.91%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Responder</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Rate</b></p></td><td style="vertical-align:bottom;width:3.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Difference</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">ITT</b></p></td><td style="vertical-align:bottom;width:1.9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">121/170</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">71.2</p></td><td style="vertical-align:bottom;width:3.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">49/79</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">62.0</p></td><td style="vertical-align:bottom;width:3.38%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">9.2</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">p=0.1877</p></td></tr><tr><td style="vertical-align:bottom;width:27.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">mITT</b></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">121/163</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">74.2</p></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">49/79</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">62.0</p></td><td style="vertical-align:bottom;width:3.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">12.2</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">P=0.0714</p></td></tr><tr><td style="vertical-align:bottom;width:27.9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">As Treated</b></p></td><td style="vertical-align:bottom;width:1.9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">120/162</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">74.1</p></td><td style="vertical-align:bottom;width:3.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.94%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">50/80</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">62.5</p></td><td style="vertical-align:bottom;width:3.38%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">11.6</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">p=0.0735</p></td></tr><tr><td style="vertical-align:bottom;width:27.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Per Protocol</b></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">118/155</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">76.1</p></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">43/65</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 2.9pt 0pt 0pt;">66.2</p></td><td style="vertical-align:bottom;width:3.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">10.0</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">p=0.1362</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Key additional findings from the clinical trial include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">NeoCart demonstrated statistically significant improvements in pain and function at both one and two&#160;years after treatment as measured by changes in the KOOS and IKDC scores.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">KOOS pain score (mITT Population)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Change from Baseline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(NeoCart Baseline = 54.0; Microfracture Baseline = 52.4)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">NeoCart</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Microfracture</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Visit</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">N</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Mean</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">N</b></p></td><td style="vertical-align:bottom;width:1.91%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Mean</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">P-</b>&#160;<b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">3-months</b></p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">160</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">24.1</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">75</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">22.4</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">0.0487</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">6-months</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">157</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">28.6</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">75</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">27.0</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">0.0819</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">1-year</b></p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">158</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">31.4</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">72</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">28.7</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">0.0239</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">2-years</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">87</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">32.2</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">34</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">28.9</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">0.0080</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">3-years</b></p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">39</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">34.3</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">16</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">30.7</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">0.1071</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>Statistically significant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">IKDC subjective knee exam score (mITT Population)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Change from Baseline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(NeoCart Baseline = 40.3; Microfracture Baseline = 40.0)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">NeoCart</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Microfracture</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Visit</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">N</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Mean</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">N</b></p></td><td style="vertical-align:bottom;width:1.91%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Mean</b></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">P-</b>&#160;<b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3-months</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">159</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">13.7</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">76</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">14.5</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">0.9686</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6-months</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">156</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">24.4</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">74</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">22.4</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">0.1572</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1-year</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">158</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">33.1</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">71</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">28.3</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">0.0126</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2-years</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">87</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">35.3</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">34</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">30.2</p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">0.0366</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3-years</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">38</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">39.9</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">16</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">32.6</p></td><td style="vertical-align:bottom;width:1.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 3pt 0pt 0pt;">0.2691</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>Statistically significant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 2 Clinical Trial</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NeoCart Phase 2 clinical trial was initiated in 2007 to evaluate further the positive safety and early efficacy signals demonstrated in Histogenics&#8217; Phase 1 clinical trial of NeoCart for articular cartilage damage in the knee. Histogenics also sought to identify clinically meaningful endpoints and identify appropriate patient populations to be studied in the design of future clinical studies. The trial was a five-year prospective, controlled, randomized, clinical study of 30 patients conducted at six U.S. centers and completed its enrollment in 2008. 21 patients were randomized to receive a NeoCart implant and nine patients were randomized to undergo a microfracture procedure. The trial was completed in 2013 and final data collection was completed in 2014.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the Phase 2 clinical trial, baseline (preoperative) pain and function assessments were obtained and included, among other measurement instruments, the KOOS pain and symptoms subscales, the IKDC Subjective assessment and a visual analog pain scale. At every measurement interval between three&#160;months and three&#160;years, the same pain and function assessments were measured. The data were analyzed using descriptive statistics (mean and standard deviation), paired t testing and analysis of covariance with </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">288</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">significance levels (p-values) set at less than 0.05 (two-sided). According to the results of the analysis, those patients receiving a NeoCart implant achieved statistically significant improvement (all p-values &lt;0.05) compared to their baseline assessments on the KOOS pain and symptoms subscales, the IKDC Subjective assessment and a visual analog pain scale, meaning that sufficient data exist to indicate the improvement on each measure is unlikely to have occurred by chance. Furthermore, when this improvement from baseline was compared to the improvement of microfracture from baseline, NeoCart&#8217;s improvement was statistically significantly better (all p-values &lt;0.05) than microfracture&#8217;s improvement on over half of the measurements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional comparison of the two groups was performed with the previously described dual-threshold responder analysis OrthoCellix is utilizing in the Phase 3 clinical trial. To be considered a responder in the Phase 2 clinical trial, a patient must have achieved a minimum improvement on the KOOS pain subscale and the IKDC Subjective assessment compared to his or her baseline scores. The minimum required improvement for pain was 12 points and the minimum required improvement for function was 20 points.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The selected thresholds have been validated in the literature as clinically meaningful to patients. In some cases, patients entered the Phase 2 clinical trial with pain scores at a level such that they could not have improved a great deal (for example, a baseline of 91 points on a scale of 100). In those cases, patients were considered responders if their function scores improved a minimum of 20 points even if their pain scores did not improve the required 12 points. Compared to the microfracture group, significantly more NeoCart-treated patients responded to treatment at six&#160;months, one&#160;year and two&#160;years. In addition, most of the&#160;Year 1 responders with a NeoCart implant remained responders at&#160;Year&#160;3 compared to none of the microfracture responders at&#160;Year 1. The difference in responder rates between the groups favored NeoCart as early as three&#160;months post-surgery.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">289</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:199.7pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">RESPONDER RATE ANALYSIS AT&#160;YEAR 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"><img src="tmb-20250331xs4027.jpg" alt="Graphic" style="display:inline-block;height:199.7pt;width:336.2pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As shown in the graphic above, at&#160;Year 1, the number of NeoCart patients (represented by an &#8220;O&#8221;) who achieved responder status was greater than the number of microfracture patients (represented by an &#8220;X&#8221;) who achieved responder status. Many patients far exceeded the minimum dual thresholds required to be considered a responder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As explained more fully above, some patients entered the Phase 2 clinical trial with minimal pain indicated by a high baseline KOOS pain score. A score of 100 on the KOOS pain scale indicates the patient is reporting no pain. In those few cases, only the change in IKDC Subjective score was used to determine if the patients responded to therapy. In those cases, patients were deemed responders if their function scores improved a minimum of 20 points even if their pain scores did not improve the required 12 points.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RESPONDER RATE ANALYSIS AT&#160;YEAR 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"><img src="tmb-20250331xs4028.jpg" alt="Graphic" style="display:inline-block;height:199.7pt;width:336.2pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As shown in the graphic above, at&#160;Year 2, the number of NeoCart patients (represented by an &#8220;O&#8221;) who achieved responder status was greater than the number of microfracture patients (represented by an &#8220;X&#8221;) who achieved responder status. Many patients far exceeded the minimum dual thresholds required to be considered a responder. Some NeoCart patients continued to improve compared to their&#160;Year 1 results, indicative of durability of response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As explained more fully above, some patients entered the Phase 2 clinical trial with minimal pain indicated by a high baseline KOOS pain score. A score of 100 on the KOOS pain scale indicates the patient is reporting no pain. In those few cases, only the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">290</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:201.6pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">change in IKDC Subjective score was used to determine if the patients responded to therapy. In those cases, patients were deemed responders if their function scores improved a minimum of 20&#160;points even if their pain scores did not improve the required 12 points.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RESPONDER RATE ANALYSIS AT&#160;YEAR 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"><img src="tmb-20250331xs4029.jpg" alt="Graphic" style="display:inline-block;height:201.6pt;width:336.2pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As shown in the graphic above, at&#160;Year 3, the number of NeoCart patients (represented by an &#8220;O&#8221;) who achieved responder status was greater than the number of microfracture patients (represented by an &#8220;X&#8221;) who achieved responder status. Many patients far exceeded the minimum dual thresholds required to be considered a responder. Some NeoCart patients continued to improve compared to their&#160;Year 1 and&#160;Year 2 results, indicative of durability of response. A microfracture patient also far exceeded the minimum dual thresholds to be considered a responder. This patient had not been in the responder group prior to&#160;Year 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As explained more fully above, some patients entered the Phase 2 clinical trial with minimal pain indicated by a high baseline KOOS pain score. A score of 100 on the KOOS pain scale indicates the patient is reporting no pain. In those few cases, only the change in IKDC Subjective score was used to determine if the patients responded to therapy. In those cases, patients were deemed responders if their function scores improved a minimum of 20&#160;points even if their pain scores did not improve the required 12 points.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RESPONDER RATE ANALYSIS AT&#160;YEARS 1, 2 AND 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"><img src="tmb-20250331xs4030.jpg" alt="Graphic" style="display:inline-block;height:170.9pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:340.6pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2013, the five-year observation period for Phase 2 trial concluded. During the course of the trial, no serious adverse events (expected or unexpected) were product- or implant-related. Two-year results of this trial were published in the<i style="font-style:italic;"> Journal of Bone and Joint Surgery</i> in 2012.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">291</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 1 Clinical Trial</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A Phase 1 clinical trial was conducted to demonstrate the safety of NeoCart for use when implanted into cartilage defects in the knee with the intention of repairing the articular cartilage defects. The two-year results of the Phase 1 clinical trial were published in the<i style="font-style:italic;"> American Journal of Sports Medicine</i> in 2009. Among the eight patients studied, all of whom enrolled in 2005 and completed five&#160;years of observation, a highly favorable safety profile of NeoCart was documented. The trial was completed in 2010, and final data collection was completed in 2011. Specifically, few reported complications occurred, and no serious adverse events (expected or unexpected) were deemed treatment related. No cases of infection, implant rejection or immune reaction were documented. Additionally, joint stiffness and implant overgrowth did not occur in any patient. Efficacy signals in the form of significant improvement in pain and function, measured with patient-reported outcome surveys such as the visual analog pain scale and the IKDC Subjective score, compared to each patient&#8217;s baseline scores were also noted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMPETITION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biotechnology industry is characterized by rapidly advancing technologies as well as a strong emphasis on intellectual property leading to a highly competitive environment for the development and commercialization of therapeutic products and regenerative medicines. OrthoCellix faces competition with respect to NeoCart and will face competition with respect to any product candidates that it may seek to develop or commercialize in the future. OrthoCellix faces competition from many different sources, including from academic and other institutions, pharmaceutical companies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization of competitive technologies. OrthoCellix plans to compete in the segments of related markets with therapeutics and regenerative cell medicines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regenerative medicine sector is characterized by innovative science, rapidly advancing technologies, and a strong emphasis on proprietary products. The competitive landscape in the field of articular cartilage repair in the United States is emerging and has stimulated a substantial amount of interest from companies developing tissue repair solutions. Companies that may compete with OrthoCellix&#8217;s NeoCart product candidate include Vericel Corporation&#8217;s MACI, the only FDA-approved ACI product in the United States, and Aesculap Biologics, LLC&#8217;s NOVOCART 3D, which is currently enrolling subjects in its Phase 3 clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of OrthoCellix&#8217;s competitors, either alone or with strategic partners, may have greater financial resources to support research and development, manufacturing, preclinical studies, and clinical trials, as well as regulatory, commercialization, and marketing efforts. These organizations also compete with OrthoCellix in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, patient registration for clinical trials, licensing or acquiring technologies necessary for its programs, and in its commercialization efforts if its product candidates are approved. Early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Mergers and acquisitions in the biotechnology industries may result in even more resources being concentrated among a smaller number of its competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MANUFACTURING AND SUPPLY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix does not own or operate manufacturing facilities for the production of NeoCart and currently has no plans to build its own clinical or commercial scale manufacturing capabilities. Ocugen has completed renovating an existing facility into a cGMP facility in accordance with the FDA&#8217;s regulations in support of NeoCart manufacturing for Phase 3 clinical trial material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ocugen and OrthoCellix will enter into the OrthoCellix Manufacturing Agreement pursuant to which Ocugen will continue to manufacture and supply NeoCart to OrthoCellix until completion or cessation of the Phase 3 clinical trial, unless extended by the parties. OrthoCellix will obtain its supplies from Ocugen on a purchase order basis and do not have long-term supply arrangements in place. Should supply from Ocugen be unavailable to OrthoCellix for any reason, OrthoCellix believes there are a number of potential contract cell therapy manufacturers capable of supplying OrthoCellix needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LICENSE AND DEVELOPMENT AGREEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix is party to license and development agreements under which it licenses or co-owns patents, patent applications, technical information, and other intellectual property for its product candidate. Certain diligence and financial obligations are tied to these agreements. OrthoCellix considers the following agreements to be material to its business.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">292</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with Purpose</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix is party to the Purpose Agreement, pursuant to which OrthoCellix sublicenses certain technology from Purpose. Purpose entered into the original license agreement (&#8220;BWH-Purpose Agreement&#8221;) with Brigham and Women&#8217;s Hospital, Inc. (&#8220;BWH&#8221;) in August 2001. The BWH-Purpose Agreement granted Purpose an exclusive, royalty-bearing, worldwide, sublicensable license, under its rights in licensed patents and patent applications co-owned by BWH and Purpose to make, use, and sell (1) an apparatus for cultivating a cell or tissue, (2) cell or tissue products made using such apparatus, (3) cell or tissue products made using processes for cultivating a cell or tissue as disclosed in the licensed patents and patent applications, and (4) any apparatus that cultivates cells or tissues using such processes, in each case, whose manufacture, use, or sale is covered by a valid claim of the licensed patents and patent applications, only for therapeutic use. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Purpose Agreement, as amended, to date, provides OrthoCellix with the ability, worldwide, to (i) use, make, have made, sell, offer for sale, import or otherwise exploit products or services covered by claims of Purpose&#8217;s patents and (ii) use, reproduce, modify, create derivative works of and otherwise exploit Purpose&#8217;s technology for the design, development, manufacture, testing, support, and commercialization of any product or service that incorporates or builds upon Purpose&#8217;s technology, in each case, only in connection with articular cartilage, ligaments, tendons, and meniscus. Purpose retains the right to sell its single unit exogenous tissue processer machines to research institutes for general but noncommercial use anywhere in the world .</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Purpose Agreement, OrthoCellix is obligated to pay Purpose up to $10.0 million upon the achievement of certain regulatory and commercial milestones as well as a royalty payment in the low single digits on the net sales in Japan of NeoCart. Such royalty payment shall be reduced to the extent NeoCart does not rely on an outstanding Purpose patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MEDINET License and Commercialization Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix is party to a License and Commercialization Agreement (the &#8220;MEDINET Agreement&#8221;), dated December 21, 2017, with MEDINET Co.,&#160;Ltd. (&#8220;MEDINET&#8221;) with regards to the commercialization of NeoCart in Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the MEDINET Agreement, MEDINET agrees to pay up to an aggregate of approximately $86.9 million in milestone payments plus royalties, consisting of (i)&#160;a non-refundable upfront payment of $10.0 million which Histogenics received in January&#160;2018, (ii)&#160;potential regulatory and development milestone payments of up to an aggregate of $10.5 million, (iii)&#160;overall sales-dependent milestones of up to an aggregate of $66.4 million and (iv)&#160;tiered royalties on net sales of NeoCart in Japan. In return for such consideration, MEDINET received exclusive commercialization rights to NeoCart in Japan for the replacement or repair of damaged, worn or defective cartilage in humans and non-human animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The MEDINET Agreement will remain in effect until the later of (i)&#160;expiration of the last-to-expire valid and enforceable patent covering NeoCart in Japan and (ii)&#160;10&#160;years from the first commercial sale of NeoCart in Japan. MEDINET has an option to extend the term for five&#160;years upon written notice to OrthoCellix prior to the end of the initial term. MEDINET has the right to terminate the MEDINET Agreement for any or no reason at any time, and OrthoCellix may terminate the MEDINET Agreement in the event MEDINET or one of its affiliates or sublicensees challenges a patent covering NeoCart in Japan. Additionally, either party may terminate the MEDINET Agreement for an uncured material breach by the other party or upon certain insolvency or bankruptcy proceedings involving the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The parties also agreed to enter into supply, quality and pharmacovigilance agreements, pursuant to which MEDINET will purchase its requirements of NeoCart and the related biopsy kit from OrthoCellix. No amounts have been received or recorded pursuant to the MEDINET Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Angiotech License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2005, Histogenics entered into a worldwide license agreement with Angiotech Pharmaceuticals (US),&#160;Inc. and Angiodevice International GmbH (collectively, &#8220;Angiotech&#8221;), which Ocugen assumed as a result of the Histogenics merger. The license is for the exclusive right, under Angiotech&#8217;s licensed patents and patent applications and technical information, to make, use and sell any product that includes both Histogenics&#8217; intellectual property and CT3, the bio adhesive used in NeoCart, for the repair of articular cartilage, ligament, meniscus or tendon damage, including related osteochrondal defects. The license excludes any product in which one nonliving ingredient is included in CT3 for the primary purpose of producing a physiological, metabolic or biological effect in mammals. OrthoCellix has obligations to supply CT3 to Angiotech under certain terms and conditions, and Angiotech is entitled to use any data and results obtained from any clinical studies conducted by OrthoCellix with respect to CT3.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">293</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix will be obligated to pay a fee of $3.0 million within 30&#160;days after OrthoCellix receives regulatory approval from the FDA for a licensed product. As further consideration for the license, OrthoCellix will be required to pay royalties at&#160;percentage rates of single digits of net sales of NeoCart and certain other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The agreement terminates on the earlier of May&#160;12, 2035 and expiration of all royalty payment obligations under the agreement. Either party has the right to terminate the agreement if the other party materially breaches the agreement and fails to cure such breach within 30&#160;days from the date of notice of such breach (ten&#160;days in the case of non-payment). OrthoCellix may also terminate the agreement by giving at least one&#160;year&#8217;s notice. Angiotech may also terminate the agreement if OrthoCellix or any of OrthoCellix&#8217;s affiliates or sublicensees challenge the validity of Angiotech&#8217;s patents rights or rights to improvements (or directly or indirectly support any such challenge), or if OrthoCellix is acquired by or merges with a third party that has developed or is marketing, or has an affiliate that has developed or is marketing, a competitive product prior to such acquisition or merger and the resulting or surviving entity post-acquisition or merger fails to either continue to develop or sell licensed product at a level reasonably similar to the development or sale that was occurring prior to the acquisition or merger, during the six-month period following the acquisition or merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intrexon Mutual Termination Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Histogenics was party to an Exclusive Channel Collaboration (&#8220;ECC&#8221;) with Intrexon Corporation (&#8220;Intrexon&#8221;) governing a &#8220;channel collaboration&#8221; arrangement in which Histogenics intended to use Intrexon&#8217;s proprietary technology towards the design, identification, culturing and/or production of genetically modified cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2018, Histogenics and Intrexon entered into a mutual termination and release agreement (the &#8220;Mutual Termination Agreement&#8221;) pursuant to which Histogenics and Intrexon mutually agreed to terminate ECC. In lieu of the approximately $3.0&#160;million of research and development expenses under the ECC due from Histogenics to Intrexon, $0.375&#160;million was paid to Intrexon at the time of entering into the Mutual Termination Agreement and $1.125&#160;million will be payable by OrthoCellix within one&#160;year following any submission of a BLA to the FDA for NeoCart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INTELLECTUAL PROPERTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s success depends in part upon its ability to protect its core technologies and intellectual products. It has applied, obtained, and licensed patent protection for its product candidate. OrthoCellix intends to maintain and defend its intellectual property rights to protect its technology, inventions, processes, and improvements that are commercially important to the development of its business. There is no guarantee that any of its current or future intellectual property will advance the commercial success of its product candidate. There is also no guarantee patents will be issued or registered for any pending patent applications or patent applications that it may file in the future. Its commercial success also depends in part on the patents and proprietary rights of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of July 21, 2025, OrthoCellix&#8217;s patent portfolio for its product candidate included a total of 17 issued patents in the United States, 20 issued or registered patents in foreign countries, four pending patent applications in the United States, and eight pending patent applications in foreign countries. Its issued or registered patents and pending patent applications include those licensed from Purpose. Its intellectual property includes compositions of matter, methods of use, product candidate, and other proprietary technology. OrthoCellix&#8217;s current portfolio of issued patents in the United States and issued or registered patents in foreign countries related to its product candidate expire between 2026 and 2039.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some instances, OrthoCellix may need to license additional patents and trade secrets to commercialize its product candidate in certain territories. In addition to patents, it may rely, in some circumstances, on trade secrets to protect its technology. It seeks to protect its proprietary technology and processes, and obtain and maintain ownership of certain technologies, in part, by confidentiality and invention assignment agreements with its employees, consultants, scientific advisors, and contractors. It also seeks to preserve the integrity and confidentiality of its data and trade secrets by maintaining physical security of its premises and physical and electronic security of its information technology systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GOVERNMENT REGULATION AND PRODUCT APPROVAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Government authorities in the United States, at the federal, state, and local level, and in other countries including Canada, extensively regulate, among other things, the research, development, testing, approval, manufacture, packaging, storage, recordkeeping, monitoring and reporting, labeling, advertising, promotion, distribution, marketing, sales, import, and export of biotechnological and drug products such as those OrthoCellix is developing. In addition, labelers of marketed biotechnology and drug </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">294</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">products (the entity owning the National Drug Code listed for a marketed product) participating in Medicaid and Medicare are required to comply with mandatory price reporting, discounts, rebates, and other requirements. The processes for obtaining regulatory approvals in the United States and in other countries including Canada, along with compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted, introduced, passed in Congress and signed into law that could significantly change the statutory provisions governing the approval, manufacturing, and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations, guidances, and policies are often revised or reinterpreted by the agency in ways that may significantly affect the manner in which OrthoCellix&#8217;s products are regulated and marketed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FDA Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates biologics and drug products under the FDCA&#8221; and its implementing regulations. In addition, biological products are regulated under the PHSA and its implementing regulations. The process required by the FDA before product candidates may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&#8217;s GLP regulations, applicable requirements for the human use of laboratory animals, such as the Animal Welfare Act (&#8220;AWA&#8221;), or other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND application, which must become effective before human clinical trials may begin at United States clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an IRB for each clinical site, or centrally, before a clinical trial may be initiated at that site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adequate and well-controlled human clinical trials to establish the safety and efficacy, in the case of a drug product candidate, or safety, purity, and potency, in the case of a biological product candidate, for its intended use, performed in accordance with GCP and additional requirements for the protection of human research subjects and their health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development of manufacturing processes to ensure the product candidate&#8217;s identity, strength, quality, purity, and potency in compliance with cGMP;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of a BLA, including results of preclinical testing, detailed information about the CMC, and proposed labeling and packaging for the product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the products are produced to assess compliance with cGMP, and to assure that the facilities, methods, and controls are adequate to preserve the therapeutics&#8217; identity, strength, quality, purity, and potency as well as satisfactory completion of an FDA inspection of selected clinical sites, selected clinical investigators to determine GCP compliance, and payment of user fees; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and licensure of a BLA, to permit commercial marketing for particular indications for use, including agreement on post-marketing commitments, if applicable.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Studies and IND Submission</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The testing and approval process of product candidates requires substantial time, effort, and financial resources. Satisfaction of FDA pre-market approval requirements typically takes many&#160;years, and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. Preclinical studies include laboratory evaluation of chemistry, pharmacology, toxicity, and product formulation, as well as animal studies to assess potential safety and efficacy. Such studies must generally be conducted in accordance with GLP, the AWA, and other applicable regulations and requirements. Prior to commencing the first clinical trial at a United States investigational site with a product candidate, an IND sponsor must submit the results of the preclinical tests and preclinical literature, together with manufacturing information, analytical data, any available clinical data or literature, and </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">295</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">proposed clinical study protocols, among other things, to the FDA as part of an IND submission. Some preclinical studies may continue even after the IND is in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An IND application becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day time period, notifies the applicant of safety concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial may begin. A separate submission to an existing IND application must also be made for each successive clinical trial conducted during product development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects (healthy volunteers or patients) under the supervision of qualified investigators. Clinical trials must be conducted in accordance with federal regulations and GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, as well as the review and approval of the study by an IRB. Investigators must also provide certain information to the clinical trial sponsors to allow the sponsors to make certain financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety, the effectiveness criteria to be evaluated, and a statistical analysis plan. A protocol for each clinical trial, and any subsequent protocol amendments, must be submitted to the FDA as part of the IND submission. If a product candidate is being investigated for multiple intended indications, separate IND applications may also be required. In addition, an IRB at each study site participating in the clinical trial and/or a central IRB must review and approve the plan for any clinical trial, informed consent forms, and communications to study subjects before a study commences at that site. An IRB is charged with protecting the welfare and rights of trial participants, and considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits, and whether the planned human subject protections are adequate. The IRB must continue to oversee the clinical trial while it is being conducted. Progress reports detailing the results of the clinical trials must also be submitted at least annually to the FDA and the IRB and more frequently if SAEs or other significant safety information is found.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Sponsors are required to submit periodic progress reports and safety reports to FDA throughout the clinical development program. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. If the FDA issues a clinical hold halting a clinical trial, the agency must notify the IND sponsor of the grounds for the hold. Any identified deficiencies must be resolved before the FDA will lift the hold and allow the clinical trial to begin or resume. There is no guarantee the FDA will ever lift a clinical hold once put in place. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or if the trial poses an unexpected serious harm to subjects. The FDA or an IRB may also impose conditions on the conduct of a clinical trial. Clinical trial sponsors may also choose to discontinue clinical trials as a result of risks to subjects, a lack of favorable results, or changing business priorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The manufacture of investigational products for the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs, active ingredients, and therapeutic substances imported into the United States are also subject to regulation by the FDA. Further, the export of investigational products outside of the United States is subject to regulatory requirements of the receiving country, as well as the United States export requirements under the FDCA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, for purposes of BLA approval, human clinical trials are typically conducted in three sequential phases, which may overlap or be combined.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 1&#160;-</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Studies are initially conducted in a small group of healthy human volunteers or subjects to test the product candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution, and excretion. If possible, Phase 1 trials may also be used to gain an initial indication of product effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 2&#160;-</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Controlled studies are conducted in larger but still limited subject populations with a specified disease or condition to evaluate preliminary efficacy, identify optimal dosages, dosage tolerance and schedule, possible adverse effects and safety risks, and expanded evidence of safety.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">296</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 3&#160;- </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These adequate and well-controlled clinical trials are undertaken in expanded subject populations, generally at geographically dispersed clinical trial sites, to generate enough data to provide statistically significant evidence of clinical efficacy and safety of the product candidate for approval, to establish the overall risk-benefit profile of the product candidate, and to provide adequate information for the labeling of the product candidate. Typically, two Phase 3 trials are required by the FDA for product approval. Under some limited circumstances, however, the FDA may approve a BLA based upon a single Phase 3 clinical study.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may also require, or companies may conduct, additional clinical trials for the same indication after a product is approved. These are referred to as Phase 4 studies and may be made a condition to be satisfied after approval. The results of Phase 4 studies can confirm or refute the effectiveness of a product candidate and can provide important long-term safety information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, manufacturers must develop methods for testing the identity, strength, quality, potency, and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Marketing Application Submission, Review by the FDA, and Marketing Approval</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of the required clinical and preclinical testing, the results of product development, including CMC, non-clinical studies, and clinical trial results, including negative or ambiguous results, as well as positive findings, are all submitted to the FDA, along with the proposed labeling, requesting approval to market the product for one or more indications. In most cases, the submission of a marketing application is subject to a substantial application user fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, under the PREA, a BLA or supplement to a BLA for a new active ingredient, indication, dosage form, dosage regimen, or route of administration, must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after the approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Orphan products are also exempt from the PREA requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA also may require submission of a REMS to ensure that the benefits of the product candidate outweigh the risks. Following product approval, a REMS may also be required by the FDA if new safety information is discovered and the FDA determines that a REMS is necessary to ensure that the benefits of the product continue to outweigh the risks. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription, or dispensing of products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once the FDA receives an application, it generally takes 60&#160;days to review the marketing application to determine if it is substantially complete to permit a substantive review, before it accepts the application for filing. The FDA may refuse to review any application that it deems incomplete or not properly reviewable at the time of submission and may request additional information. If the submission is accepted for filing, the FDA begins an in-depth review of the marketing application. Under the goals and policies agreed to by the FDA under the PDUFA, the FDA aims to complete its initial review of a marketing application and respond to the applicant within 10&#160;months from the filing date for a standard marketing application, and within six&#160;months from the filing date for a priority marketing application. The FDA does not always meet its PDUFA goal dates for standard and priority marketing applications, and the review process is often significantly extended by FDA requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may also refer certain applications to an advisory committee. Before approving a product candidate for which no active ingredient has previously been approved by the FDA, the FDA must either refer that product candidate to an external advisory committee or provide in an action letter a summary of the reasons why the FDA did not refer the product candidate to an advisory committee. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The FDA reviews applications to determine, among other things, whether a product candidate meets the agency&#8217;s approval standards and whether the manufacturing methods and controls are adequate to assure and preserve the product&#8217;s identity, strength, quality, potency, and purity. Before approving a marketing application, the FDA typically will inspect the facility or facilities where </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">297</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the product is manufactured, referred to as a Pre-Approval Inspection. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontractors, are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Additionally, before approving a marketing application, the FDA will inspect one or more clinical trial sites to assure compliance with GCP. To assure cGMP and GCP compliance, an applicant will incur significant expenditure of time, money, and effort in the areas of training, recordkeeping, production, and quality control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After evaluating the marketing application and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a CRL. A CRL indicates that the review cycle for the application is complete and the application is not ready for approval. It also describes all of the specific deficiencies that the FDA identified. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the marketing application and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. If a CRL is issued, the applicant may either: resubmit the marketing application addressing all of the deficiencies identified in the letter; withdraw the application; or request an opportunity for a hearing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if the FDA approves a product, it may limit the approved indications or populations for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, including a boxed warning, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety and efficacy after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Patent Term Restoration and Regulatory Data Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States and elsewhere, certain regulatory exclusivities and patent rights can provide an approved drug product with protection from certain competitors&#8217; products for a period of time and within a certain scope. If approved, drug and biologic products may also be eligible for periods of the United States patent term restoration. If granted, patent term restoration extends the patent life of a single unexpired patent, that has not previously been extended, for a maximum of five&#160;years. The total patent life of the product with the extension also cannot exceed 14&#160;years from the product&#8217;s approval date. Subject to prior limitations, the period of extension is calculated by adding half of the time from the effective date of an IND application to the initial submission of a marketing application, and all of the time between the submission of the marketing application and its approval. This period may also be reduced by any time that the applicant did not act with due diligence. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60&#160;days of approval. The USPTO, in consultation with the FDA, reviews and approves the application for patent term restoration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, under the PHSA, innovator biological products, or reference products, are entitled to 12&#160;years of exclusivity. The FDA must wait four&#160;years after licensure of a biologic product under a BLA before accepting a filing for a biosimilar version of the reference product, and the FDA cannot approve a biosimilar version of the reference product until 12&#160;years after the reference product was approved under a BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Special FDA Expedited Review and Approval Programs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has various programs that are intended to expedite or simplify the process for the development and FDA review of certain product candidates that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs or present a significant improvement over existing therapy. The purpose of these programs is to provide important new therapeutics to patients earlier than under standard FDA review procedures. These expedited programs include fast track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation. Each of these programs has its own features and qualifying criteria. A sponsor must submit a request for fast track designation, breakthrough therapy designation, or priority review, which may or may not be granted by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product candidate is intended to treat a serious or life threatening disease or condition and demonstrates the potential to address an unmet medical need. If fast track designation is obtained, sponsors may be eligible for more frequent development meetings and correspondence with the FDA. In addition, the FDA may initiate review of sections of an application before the application is complete. This &#8220;rolling review&#8221; is available if the applicant provides and the FDA approves a schedule for the remaining information.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">298</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To be eligible for breakthrough therapy designation, the FDA must determine, based on the request of the sponsor, that a product candidate is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Products designated as breakthrough therapies are eligible for intensive guidance on an efficient development program beginning as early as Phase 1 trials, a commitment from the FDA to involve senior managers and experienced review staff in a proactive collaborative and cross-disciplinary review, rolling review, and the facilitation of cross-disciplinary review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Established under the 21st Century Cures Act, RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising regenerative medicine products, including genetic therapies. A regenerative medicine advanced therapy is eligible for RMAT designation if it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or therapy has the potential to address unmet medical needs for such disease or condition. Similar to breakthrough therapy designation, RMAT designation provides the benefits of intensive FDA guidance on efficient drug development, including the ability for early interactions with FDA to discuss surrogate or intermediate endpoints, potential ways to support accelerated approval and satisfy post-approval requirements, potential priority review of a BLA, and other opportunities to expedite development and review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may give a priority review designation to product candidates that are intended to treat serious conditions and, if approved, would provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of the serious condition. A priority review means that the goal for the FDA is to review an application within six&#160;months from the filing date, rather than the standard review of 10&#160;months under current PDUFA guidelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be developed and approved under the accelerated approval pathway, which means the FDA may approve the product candidate based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. A product candidate approved under the accelerated approval pathway is generally subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect of the product. Under the FDORA, the FDA is permitted to require, as appropriate, that confirmatory trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Further, under FDORA, the FDA has increased authority for expedited procedures to withdraw the accelerated approval of a product if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that such product no longer meets the qualification criteria, and therefore, that the sponsor is no longer eligible for the program benefits, including the benefit of a shortened time period for FDA review or approval. Additionally, fast track designation, priority review, accelerated approval, breakthrough therapy designation, and RMAT designation do not change the standards for approval and do not necessarily shorten the overall time it takes a sponsor to obtain FDA approval or the costs of obtaining it.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-Approval Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any products manufactured or distributed pursuant to FDA approvals are subject to extensive and continuing regulation by the FDA, including, among other things, requirements related to manufacturing, recordkeeping, and reporting, including adverse experience reporting, deviation reporting, shortage reporting, and periodic reporting, product sampling and distribution, advertising, marketing, promotion, certain electronic records and signatures, and post-approval obligations imposed as a condition of approval, such as Phase 4 clinical trials, REMS, and surveillance to assess safety and effectiveness after commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future FDA inspections may identify cGMP compliance issues at manufacturing facilities or at the facilities of third-party suppliers that may disrupt production or distribution or require substantial resources to correct and prevent recurrence of any deficiencies and could result in fines or penalties by regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to FDA review and approval. There also are continuing annual program user fee requirements for approved products, excluding orphan products. In addition, manufacturers and other entities involved in the manufacture and distribution of approved therapeutics are required to register their establishments with the FDA and certain state agencies, list their products, and are subject to periodic </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">299</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">announced and unannounced inspections by the FDA and these state agencies for compliance with cGMP and other requirements. Regulatory authorities may undertake regulatory enforcement action, withdraw product approvals, require label modifications, or request product recalls, among other actions, if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes to the manufacturing process are strictly regulated and often require FDA approval or notification before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and specifications, and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA also strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Physicians, in their independent professional medical judgment, may prescribe legally available products for unapproved indications that are not described in the product&#8217;s labeling and that differ from those tested and approved by the FDA. Drug and biological product companies, however, are required to promote their products only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including, but not limited to, criminal and civil penalties under the FDCA and FCA, exclusion from participation in federal healthcare programs, mandatory compliance programs under corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts. In addition, newly discovered or developed safety or efficacy data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the distribution of prescription drug and biological products is subject to the PDMA, which regulates the distribution of samples at the federal level. Both the PDMA and state laws limit the distribution of prescription drug and biological product samples and impose requirements to ensure accountability in distribution. Free trial or starter prescriptions provided through pharmacies are also subject to regulations under the MDR Program (&#8220;MDRP&#8221;) and potential liability under anti-kickback and false claims laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the Drug Supply Chain Security Act imposes obligations on sponsors of drug and biological products related to product tracking and tracing. Among the requirements of this legislation, sponsors are required to provide certain information regarding the products to individuals and entities to which product ownership is transferred, are required to label products with a product identifier, and are required to keep certain records regarding the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in significant regulatory actions. Such actions may include refusal to approve pending applications, license or approval suspension or revocation, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, Form&#160;FDA 483s, cyber letters, modification of promotional materials or labeling, provision of corrective information, imposition of post-market requirements including the need for additional testing, imposition of distribution or other restrictions under a REMS, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate integrity agreements, suspension and debarment from government contracts, refusal of orders under existing government contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement, civil or criminal penalties including fines and imprisonment, and adverse publicity, among other adverse consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Additional controls for biologics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To help reduce the increased risk of the introduction of adventitious agents through biological products, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits to FDA a release protocol showing the results of all of the manufacturer&#8217;s tests performed on the lot, and if required, samples of each lot of the product.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">300</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="FraudandAbuseDataPrivacyandSecurityandTr"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix&#8217;s business activities, including but not limited to, research, marketing, sales, promotion, distribution, medical education, and other activities following product approval are subject to laws and regulations by numerous federal and state regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Department of Justice, the HHS and its various divisions, including the CMS and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of Defense, and state and local governments. OrthoCellix&#8217;s business activities must comply with numerous healthcare laws, including but not limited to, the federal civil FCA, the federal Anti-Kickback Statute, other similar fraud and abuse laws and regulations as well as data privacy and security laws and regulations, which are described below, as well as state and federal consumer protection and unfair competition laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The federal Anti-Kickback Statute, prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting, or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order, or the referral to another for the furnishing or arranging of any item or service reimbursable under Medicare, Medicaid, or other federal healthcare programs, in whole or in part. The term &#8220;remuneration&#8221; has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between biotechnological industry members on one hand and prescribers, purchasers, formulary managers, and beneficiaries on the other. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of a federal healthcare covered business, including purchases of products paid by federal healthcare programs, the statute has been violated. A violation of the Anti-Kickback Statute may be established without proving actual knowledge of the statute or specific intent to violate it. The government or a whistleblower may assert that a claim for payment of items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil FCA. Although there are a number of statutory exemptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exemptions and safe harbors are drawn narrowly. Practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical and biological products, including certain discounts, or engaging such individuals as consultants, advisors, or speakers, may be subject to scrutiny if they do not fit within an exemption or safe harbor. OrthoCellix&#8217;s practices may not in all cases meet all of the criteria for exemption or safe harbor protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants, charitable donations, product support and patient assistance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The federal civil FCA prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of federal funds, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or avoiding, decreasing, or concealing an obligation to pay money to the federal government. Actions under the FCA may be brought by the federal government or as a whistleblower or qui tam action by a private individual in the name of the government. Many pharmaceutical manufacturers have been investigated and have reached substantial financial settlements with the federal government under the civil FCA for a variety of alleged improper activities. The government may deem companies to have &#8220;caused&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. The civil FCA provides for treble damages and a civil penalty for each false claim, such as an invoice or pharmacy claim for reimbursement, which can aggregate into millions of dollars, and potential exclusion from federal health care programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The civil monetary penalties statute is another statute under which biotechnological companies may be subject to enforcement. Among other things, the civil monetary penalties statue imposes fines against any person who is determined to have knowingly presented, or caused to be presented, claims to a federal healthcare program that the person knows, or should know, is for an item or service that was not provided as claimed or is false or fraudulent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The federal HIPAA prohibits, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statements or representations in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. The government need not establish actual knowledge of the statute, or the specific intent in order to prove a violation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The federal Physician Payments Sunshine Act requires manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value to physicians, teaching hospitals and </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">301</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">certain other healthcare professionals (such as physicians assistants and nurse practitioners), and ownership and investment interests held by physicians and their immediate family members, with the reported information made public on a searchable website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payment or reimbursement of prescription therapeutics by Medicaid or Medicare requires the product&#8217;s labeler to submit certified pricing information to CMS.&#160;The MDR statute requires labelers, as a condition of payment by Medicaid, to calculate and report price points, which are used to determine Medicaid rebate payments shared between the states and the federal government and Medicaid payment rates for certain therapeutics, to pay quarterly rebates on prescriptions paid by Medicaid, and to provide a discount based on the Medicaid rebate&#160;percentage to certain hospitals and clinics under the 340B program. For most therapeutics paid under Medicare Part&#160;B, labelers must also calculate and report their Average Sales Price, which is used to determine the Medicare Part&#160;B payment rate. In addition, therapeutics covered by Medicaid are subject to an additional inflation penalty which can substantially increase rebate payments. For products approved under a BLA (including biosimilars) or a NDA, the Veterans Health Care Act (&#8220;VHCA&#8221;) requires labelers, as a condition of payment by Medicaid, to enter a federal supply schedule contract with the Department of Veterans Affairs, which includes requirements to calculate and report to the VA a price called the Non-Federal Average Manufacturer Price, which is used to determine the maximum price that can be charged to certain federal agencies, referred to as the Federal Ceiling Price (&#8220;FCP&#8221;). Like MDRP, the FCP includes an inflation penalty for drugs whose prices increase faster than the rate of inflation. All of these price reporting requirements create risk of submitting false information to the government, and potential FCA liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This necessitates compliance with applicable federal procurement laws and regulations, including submission of commercial sales and pricing information, and subjects OrthoCellix to contractual remedies as well as administrative, civil, and criminal sanctions. In addition, labelers participating in Medicaid to agree to provide different mandatory discounts to certain Public Health Service grantees and other safety net hospitals and clinics under the 340B program based on the labelers&#8217; reported Medicaid pricing information. The 340B program has its own regulatory authority to impose sanctions for non-compliance and adjudicate overcharge claims against labelers by the purchasing entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, OrthoCellix may be subject to data privacy and security regulation by both the federal government and the states in which it conduct its business. HIPAA, as amended by HITECH and its respective implementing regulations imposes certain requirements on covered entities and their business associates&#160;&#8211; certain persons or entities that create, receive, maintain, or transmit protected health information in connection with providing a specified service or performing a function on behalf of a covered entity. In addition, other federal and state laws may govern the privacy and security of health and other information in certain circumstances. For example, state data breach notification laws, state health information and/or genetic privacy laws, and federal and state consumer protection and consumer privacy laws (such as Section&#160;5 of the FTC Act) and the CCPA and other similar states laws differ from each other in significant ways, thus complicating compliance efforts. Any failure by OrthoCellix or any of its third-party service providers to follow such laws could result in significant liability or reputational harm under such state and federal privacy and other laws. The landscape of federal and state laws regulating personal data is constantly evolving, and compliance with these laws requires a flexible privacy framework and substantial resources, and compliance efforts will likely be an increasing and substantial cost in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outside the United States, OrthoCellix&#8217;s operations may implicate international data protection laws, including the GDPR. The GDPR imposes strict obligations and restrictions on the ability to collect, analyze, and transfer personal data, including health data and samples from clinical trials and adverse event reporting. For example, these obligations and restrictions may concern obtaining explicit consent of the individuals to whom the personal data relate, providing transparency notices to individuals, sharing personal data with third parties, transferring personal data out of the EU, reporting personal data breaches with data protection authorities and affected individuals, and ensuring the security and confidentiality of personal data. Violations of EU data protection laws may result in significant financial penalties (including possible fines of up to four&#160;percent of global annual turnover for the preceding financial&#160;year or &#8364;20.0 million (or &#8364;17.5 million in the UK) whichever is higher). The EU GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with data protection authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the EU GDPR. These privacy and data protection laws and regulations increase OrthoCellix&#8217;s responsibility and liability in relation to personal data that it processes, and compliance has been and is expected to continue to be difficult, constantly evolving, costly and time consuming.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, as a result of the broad scale release and availability of Artificial Intelligence (&#8220;AI&#8221;) technologies such as generative AI, there is a global trend towards more regulation (e.g., the EU AI Act and AI laws passed in states of the United States) to ensure the ethical use, privacy, and security of AI and the data that it processes. Compliance with such laws will likely be an increasing and substantial cost in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Many states have also adopted laws similar to certain of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party payor, including commercial insurers. Certain state laws also regulate sponsors&#8217; use of </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">302</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">prescriber-identifiable data. Certain states also require implementation of commercial compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments or the provision of other items of value that may be made to healthcare providers and other potential referral sources; impose restrictions on marketing practices; or require drug companies to track and report information related to payments, gifts, and other items of value to physicians and other healthcare providers. Other state laws and local ordinances require identification or licensing of sales representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">States have also enacted or are considering legislation intended to make drug prices more transparent and deter significant price increases, typically as consumer protection laws. These laws may affect OrthoCellix&#8217;s future sales, marketing, and other promotional activities by imposing administrative and compliance burdens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If OrthoCellix&#8217;s operations are found to be in violation of any of the laws or regulations described above or any other applicable laws, it may be subject to penalties or other enforcement actions, including significant criminal, civil, and/or administrative monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of its operations, any of which could adversely affect its ability to operate its business and its results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that any of OrthoCellix&#8217;s products are sold in a foreign country, it may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</p><a id="CoverageandReimbursement_301127"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Coverage and Reimbursement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any drug candidates for which OrthoCellix obtains regulatory approval. In the United States and markets in other countries, sales of any products for which OrthoCellix receives regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, third-party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers, and other organizations. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. OrthoCellix may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of OrthoCellix&#8217;s products, in addition to the costs required to obtain the FDA approvals. Nonetheless, OrthoCellix&#8217;s product candidates may not be considered medically necessary or cost-effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the process for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party reimbursement may not be available to enable OrthoCellix to maintain price levels sufficient to realize an appropriate return on OrthoCellix&#8217;s investment in product development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If OrthoCellix elects to participate in certain governmental programs, OrthoCellix may be required to participate in discount and rebate programs, which may result in prices for OrthoCellix&#8217;s future products that will likely be lower than the prices OrthoCellix might otherwise obtain. For example, drug manufacturers participating under the MDRP must pay rebates on prescription drugs to state Medicaid programs. Under the Veterans Health Care Act (VHCA) drug companies are required to offer certain drugs at a reduced price to a number of federal agencies, including the U.S. Department of Veterans Affairs and Department of Defense, the Public Health Service and certain private Public Health Service designated entities in order to participate in other federal funding programs, including Medicare and Medicaid. Discounted prices must also be offered for certain U.S. Department of Defense purchases for its TRICARE program via a rebate system. Participation under the VHCA also requires submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas, as well as the entry into government procurement </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">303</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">contracts governed by the Federal Acquisition Regulations. If OrthoCellix&#8217;s products are approved and made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Different pricing and reimbursement schemes exist in other countries. In the European Union, governments influence the price of pharmaceutical products through their pricing and reimbursement rules&#160;and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular drug candidate to currently available therapies. Other Member States allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The marketability of any drug candidates for which OrthoCellix receives regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and OrthoCellix expects will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which OrthoCellix receives regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><a id="HealthcareReformMeasures_314273"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Healthcare Reform Measures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other healthcare funding and applying new payment methodologies. For example, in 2010, the ACA was enacted, which affected existing government healthcare programs and resulted in the development of new programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Among the ACA&#8217;s provisions of importance to the pharmaceutical industry, in addition to those otherwise described above, are the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">An annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">An increase in the statutory minimum rebates a manufacturer must pay under the MDRP to 23.1% and 13.0% of the average manufacturer price for most branded and generic drugs, respectively, and a cap on the total rebate amount for innovator drugs at 100.0% of the Average Manufacturer Price  (which was later removed effective January&#160;1, 2024 as a result of the American Rescue Plan Act of 2021);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 70.0% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part&#160;D (later replaced under the Inflation Reduction Act of 2022 by the Medicare Part&#160;D Manufacturer Discount Program);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals, including individuals with income at or below 133.0% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></td></tr></table><div style="margin-top:10pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">304</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA. In June&#160;2021, for example, in a case involving individual mandate, the U.S. Supreme Court ruled that certain challengers to the ACA lacked standing and upheld the ACA. It is unclear how any future litigation, and the healthcare reform measures of the current executive administration, will impact the ACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Other legislative changes have also been proposed and adopted in the United States since the ACA was enacted. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Budget Control Act of 2011 and subsequent legislation, among other things, created measures for spending reductions by Congress that include aggregate reductions of Medicare payments to providers of on average two&#160;percent per fiscal&#160;year, which remain in effect through fiscal&#160;year 2032, absent additional action from Congress.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation. Because the One Big Beautiful Bill Act of 2025 is expected to add to the federal deficit over the next decade, it is unclear whether this will trigger automatic spending cuts as part of the statutory Pay-As-You-Go Act&#8217;s requirements.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The U.S. American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The One Big Beautiful Bill Act of 2025 also added work requirements and more frequent eligibility enrollment reverifications for Medicaid enrollees, which is expected to have the effect of reducing the number of Medicaid enrollees.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices OrthoCellix may obtain for any of its product candidates for which the company may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For example, the Inflation Reduction Act of 2022 (IRA), for example, includes several provisions that may impact OrthoCellix&#8217;s business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part&#160;D beneficiaries from $7,050 to $2,000 starting in 2025, thereby eliminating the so-called coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part&#160;D; allow the U.S. government to negotiate Medicare Part&#160;B and Part&#160;D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January&#160;2032 the implementation of the U.S. Department of Health&#160;&amp; Human Services (HHS) rebate rule&#160;that would have limited the fees that pharmacy benefit managers can charge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, under the IRA, orphan drugs were previously exempted from the Medicare drug price negotiation program, but only if they had one orphan designation and the only approved indication(s)&#160;related to disease or condition. If a product were to have received multiple orphan designations or have multiple approved indications, it would not qualify for the orphan drug exemption. The One Big Beautiful Bill Act of 2025 eliminated this restriction and now all orphan drugs, regardless of the number of orphan designations or indications, are eligible for exemption from the Medicare drug price negotiation program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the IRA on OrthoCellix&#8217;s business and the healthcare industry in general is not yet known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Multiple executive orders have also been issued that have sought to reduce prescription drug costs. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On May&#160;12, 2025, President Trump signed the executive order, &#8220;Delivering Most-Favor-ed-Nation Prescription Drug Pricing,&#8221; which directs the Secretary of HHS to set and communicate most-favored-nation price targets to manufacturers and propose a rulemaking plan to impose most-favored-nation pricing if &#8220;significant progress&#8221; is not made towards achieving such pricing. It also directs the federal government to support regulatory paths to allow direct-to-patient sales for companies that meet these targets. It also states that the Trump Administration will take additional aggressive action (for example, </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">305</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">examining whether marketing approvals should be modified or rescinded or opening the door for individual drug importation waivers) should manufacturers fail to offer American consumers the most-favored-nation lowest price. Notably, a rule&#160;enacted under the first Trump Administration, also known as the &#8220;Most Favored Nations&#8221; rule, would have set Medicare Part&#160;B reimbursement at an amount no higher than the lowest price that a drug manufacturer receives on a particular product in an index of foreign countries. This rule&#160;was the subject of litigation and was formally rescinded by the former Biden Administration in August&#160;2021. FDA Commissioner Makary also announced in July&#160;2025 that FDA is contemplating a fast-track priority review voucher for drugs whose manufacturers commit to setting a price in line with drug pricing offered in economically similarly situated countries around the world. The effects of these proposals and how these proposals will be implemented are not yet known.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On April&#160;15, 2025, President Trump signed the executive order, &#8220;Lowering Drug Prices by Once Again Putting Americans First,&#8221; which included a multitude of directives to the federal government to lower drug prices. This includes directing HHS to issue updated IRA drug price negotiation guidance, including eliminating the so-called &#8220;pill penalty&#8221; under the IRA that creates a distinction between small molecule and large molecule products for purposes of determining when a drug may be eligible for drug price negotiation. Among other provisions, the executive order also directs the government to evaluate the role of pharmacy benefit managers.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the current administration may reverse or otherwise change these measures, both the current administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">OrthoCellix cannot predict the healthcare reform initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The demand for product candidates, if regulatory approval is obtained;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The ability to set a price that is fair for approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The ability to generate revenue and achieve or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The level of taxes that OrthoCellix is required to pay; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The availability of capital.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect OrthoCellix&#8217;s future profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix expects that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. Federal Government will pay for healthcare drugs and services, which could result in reduced demand for drug candidates or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm OrthoCellix&#8217;s business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for OrthoCellix&#8217;s future drugs or put pressure on OrthoCellix&#8217;s future drug pricing, which could negatively affect OrthoCellix;s business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">The Foreign Corrupt Practices Act</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The FCPA prohibits any United States individual or business from paying, offering, or authorizing payment or offering anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">306</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and suspension and debarment from government contracts, and refusal of orders under existing government contracts. Enforcement actions may be brought by the Department of Justice or the SEC, and legislation has expanded the SEC&#8217;s power to seek disgorgement in all FCPA cases filed in federal court and extended the statute of limitations in the SEC enforcement actions in intent-based claims such as those under FCPA from five&#160;years to 10&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Compliance with the FCPA may require significant technical and legal expertise and capital investment, which may be costly and cannot be predicted with certainty. Criminal and/or civil violations or alleged violations of the FCPA can result in significant criminal and/or civil penalties, fines, disgorgement, exclusion from government contracts, imprisonment of current or former employees, or other sanctions. It may also result in litigation with affected parties. Any of these factors may have an adverse effect on its operations and/or reputation, which could have a material adverse effect on its business, financial condition, competitive position, and other results of operations. OrthoCellix is subject to other international anti-corruption laws which may entail similar risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Regulation Outside of the United States</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to regulations in the United States, it may be subject to a variety of regulations in foreign jurisdictions that govern, among other things, clinical trials and any commercial sales and distribution of its product candidates, if approved, either directly or through its distribution partners. Whether or not it obtains FDA approval for a product candidate, it must obtain the requisite approvals from regulatory authorities in foreign jurisdictions prior to the commencement of clinical trials or marketing and sale of the product in those countries. The foreign regulatory approval process includes all of the risks associated with the FDA approval process described above, and the time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Requirements governing the conduct of clinical trials, product approval, pricing, and reimbursement vary from country to country. For instance, for conducting clinical trials in the EU, the EU-CTR has applied since 31 January&#160;2022. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in other countries. Moreover, some nations may not accept clinical studies performed for the United States approval to support approval in their countries or require that additional studies be performed on natives of their countries. In addition, in certain foreign markets, the pricing of drug products is subject to government control and reimbursement may in some cases be unavailable or insufficient. Resulting prices could be insufficient to generate an acceptable return to OrthoCellix or any future partner of ours. If OrthoCellix fails to comply with applicable foreign regulatory requirements, it may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution<span style="font-size:11pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">European Union Drug Development and Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Clinical Trial Approval</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In April&#160;2014, the EU adopted the EU-CTR which repealed and replaced the previous Clinical Trials Directive (2001/20/EC) on January&#160;31, 2022. The transitory provisions of the EU-CTR provide that all ongoing clinical trials must have transitioned to the EU-CTR by January&#160;31, 2025. The CTR overhauls the previous system of approvals for clinical trials in the EU. Specifically, the EU-CTR, which is directly applicable in all EU Member States (meaning no national implementing legislation in each Member State is required), aims at simplifying and streamlining the approval of clinical trials in the EU, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. The main characteristics of the EU-CTR include: a streamlined application procedure via a single-entry point through the Clinical Trials Information System; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials. The role of the relevant ethics committees in the assessment procedure continues to be governed by the national law of the applicable Member State, however overall related timelines are defined by the EU-CTR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Marketing Authorization</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To obtain a marketing authorization for a product in the EU, an applicant must submit a MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the EU or the additional Member States of the EEA (Norway, Iceland and Liechtenstein).</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">307</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The centralized procedure provides for the grant of a single marketing authorization by the EC that is valid for all EU Member States, as well as the additional Member States of the EEA. Pursuant to Regulation (EC) No.&#160;726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of cancer, HIV, AIDS, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions or viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the centralized procedure, the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;), established at the EMA is responsible for conducting an initial assessment of a product. The maximum timeframe for the evaluation of a MAA is 210&#160;days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Clock stops may extend the timeframe of evaluation of an application considerably beyond 210&#160;days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the EC, who makes the final decision to grant a marketing authorization, which is issued within 67&#160;days of receipt of the EMA&#8217;s recommendation. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the viewpoint of public health and, in particular, therapeutic innovation. If the CHMP accepts such a request, the time limit of 210&#160;days will be reduced to 150&#160;days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">National marketing authorizations, which are issued by the competent authorities of the Member States of the EU and only cover their respective territory, are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in a Member State of the EU, this national authorization can be recognized in other Member States through the mutual recognition procedure. If the product has not received a national authorization in any Member State at the time of application, it can be approved simultaneously in various Member States through the decentralized procedure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Data and Market Exclusivity in the European Union</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the EU, new chemical entities (including both small molecules and biological medicinal products) approved on the basis of a complete and independent data package qualify for eight&#160;years of data exclusivity upon marketing authorization and an additional two&#160;years of market exclusivity. Data exclusivity, if granted, prevents generic or biosimilar applicants from referencing the innovator&#8217;s pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization, for a period of eight&#160;years from the date on which the reference product was first authorized in the EU. During the additional two-year period of market exclusivity, a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced, but no medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of 11&#160;years if, during the first eight&#160;years of those 10&#160;years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with currently approved therapies. There is no guarantee that a product will be considered by the EMA to be a new chemical entity, and products may not qualify for data exclusivity. Even if a product is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company could nevertheless also market another version of the product if such company obtained marketing authorization based on a marketing authorization application with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Orphan Designation and Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Regulation (EC) No 141/2000 and Regulation (EC) No.&#160;847/2000 provide that a product can be designated as an orphan medicinal product by the EC if its sponsor can establish that: (1)&#160;the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition, (2)&#160;either (i)&#160;such condition affects no more than five in 10 thousand persons in the EU when the application is made, or (ii)&#160;without the benefits derived from orphan status, it is unlikely that the marketing of the product in the EU would generate sufficient return to justify the necessary investment in its development; (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the product would be of significant benefit to those affected by that condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">An orphan designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized EU marketing authorization. Marketing authorization for an orphan medicinal product leads to a ten-year period of market exclusivity being granted following marketing approval of the orphan product. During this market exclusivity period, the EMA, the EC or the competent authorities of the EU Member States may only grant marketing authorization to a &#8220;similar medicinal product&#8221; for the same therapeutic indication if: (i)&#160;a second applicant can establish that its product, although similar to the authorized </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">308</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">product, is safer, more effective or otherwise clinically superior; (ii)&#160;the marketing authorization holder for the authorized product consents to a second orphan medicinal product application; or (iii)&#160;the marketing authorization holder for the authorized product cannot supply enough orphan medicinal product. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six&#160;years if, at the end of the fifth&#160;year, it is established that the product no longer meets the criteria for orphan designation because, for example, the product is sufficiently profitable not to justify market exclusivity. Orphan designation must be requested before submitting an application for marketing approval. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:11pt;">The </span>aforementioned EU rules&#160;are generally applicable in the EEA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Reform of the Regulatory Framework in the European Union</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The EC introduced legislative proposals in April&#160;2023 that, if implemented, will replace the current regulatory framework in the EU for all medicines (including those for rare diseases and for children). The EC has provided the legislative proposals to the European Parliament and the European Council for their review and approval, and, in April&#160;2024, the European Parliament proposed amendments to the legislative proposals. Once the EC&#8217;s legislative proposals are approved (with or without amendment), they will be adopted into EU law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">HUMAN CAPITAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of June&#160;30, 2025, OrthoCellix did not have any employees. As a result of not having any employees, OrthoCellix does not have any affiliation with a labor union or a collective bargaining agreement. Following the Merger, OrthoCellix anticipates that it will have a full time, experienced executive management team and may initially engage consultants for certain technical roles and subsequently employees for its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Talent Management</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">OrthoCellix expects that its human capital will be critical to the success of its mission to deliver new regenerative cell therapies. It considers the performance, skills, and intellectual capital of its employees to be an essential driver of this mission and a key to its future prospects. As such, it plans to emphasize a number of measures and objectives in attracting, retaining, and developing its human capital, including, among others, employee safety, wellness, engagement, and compensation and pay equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compensation and Benefits</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">OrthoCellix plans to adopt compensation programs that will be designed to align its employees&#8217; interests with its achievement of its primary business goals. The salaries, bonuses, and opportunities for equity ownership that OrthoCellix expects to be provided to its employees will be competitive within its industry and it plans to engage outside compensation and benefits consulting firms to independently evaluate the effectiveness of its compensation and benefit programs and to provide benchmarking against its peers within the industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">309</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_dd679a40_ca64_4808_be8a_656fa6a1c484"></a><a id="CARISMAMANAGEMENTSDISCUSSIONANDANALYSISO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">RESULTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes included elsewhere in this proxy statement/prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the section titled &#8220;Risk Factors&#8221; in this proxy statement/prospectus, our actual results may differ materially from those anticipated by these forward-looking statements. As used in this section, references to &#8220;the Company,&#8221; &#8220;Carisma,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Carisma Therapeutics&#160;Inc. (formerly Sesen Bio,&#160;Inc.) and its consolidated subsidiaries. The following information and all other information contained in this proxy statement/prospectus does not give effect to the contemplated reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a biotechnology company that was previously focused on applying our industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2024 Revised Operating Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In late March&#160;2024, following a strategic review of our operating plan for 2024 and future periods, we approved a revised operating plan intended to balance value creation and expense management with our available cash resources. The objective of our revised operating plan was to focus our clinical development efforts on high potential value programs with meaningful near-term milestones and eliminate non-essential expenses and headcount to extend our cash runway. Under that plan, we intended to focus our&#160;<i style="font-style:italic;">ex vivo&#160;</i>oncology clinical development efforts on our follow-on product candidate CT-0525, a CAR-Monocyte intended to treat solid tumors that over-express HER2 and cease development of CT-0508, our macrophage-based product candidate, and initial lead product candidate. In addition, at that time, we decided to continue to focus on our&#160;<i style="font-style:italic;">in vivo</i>&#160;mRNA/LNP CAR-M programs in partnership with Moderna and paused development of CT-1119, a mesothelin-targeted CAR-Monocyte, pending additional financing, reduce our workforce and decrease spending on other non-essential activities. All clinical activities of CT-0508 have ceased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2024, following another strategic review of our operating plan for 2025 and our future pipeline, we approved another revised operating plan intended to reduce&#160;monthly operating expenses, conserve cash, and refocus our efforts on strategic priorities. First, we decided to cease development of our HER2 directed autologous cell therapy platform including CT-0525. Our decision was based on an assessment of the competitive landscape in anti-HER2 treatments, including the impact of recently approved anti-HER2 therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product. We dosed the last patient in our Phase 1 clinical trial of CT-0525, in November&#160;2024 and all clinical activity ended in January&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, pursuant to the December&#160;2024 revised operating plan, we pivoted our focus to developing product candidates targeting two indications&#160;&#8211; liver fibrosis and solid tumor oncology, while retaining the potential to receive milestones and royalties from our collaboration with Moderna.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of our cost-reduction initiatives in 2024, we implemented workforce reductions resulting in the termination of 62 full-time employees (representing approximately 58.0% of our total workforce), across research and development and general and administrative functions. The workforce reductions resulted in $4.1 million of severance related costs.&#160;As of&#160;December&#160;31, 2024, we accrued $2.7 million in severance costs from our workforce reduction, $2.3 million of which was paid in January&#160;2025.&#160;We may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the 2024 reduction in workforce.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On June&#160;26, 2024, we notified Novartis Pharmaceuticals Corporation (&#8220;Novartis&#8221;) of our termination of the Manufacturing and Supply Agreement, dated March&#160;1, 2023, relating to the manufacture of our first product candidate to enter clinical development, CT-0508 (the &#8220;Manufacturing Agreement&#8221;). The termination was effective July&#160;31, 2024. As a result of the termination of the Manufacturing Agreement, we incurred a termination fee of $4.0 million (the &#8220;Termination Fee&#8221;) which we paid in the third quarter of 2024. We separately agreed with Novartis that if we enter into an agreement for the tech transfer of another product (a &#8220;Substitute Product&#8221;) to Novartis on or before December&#160;31, 2024, then the Termination Fee shall be credited in full or in part against any amounts due to Novartis under such agreement relating to the Substitute Product. We did not enter into an agreement relating to the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">310</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Substitute Product with Novartis&#160;and we expensed the $4.0 million prepaid asset in the fourth quarter of 2024 to research and development in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2025 Cash Preservation Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of a further revised plan approved by our board of directors on March&#160;25, 2025 to preserve our existing cash resources following our reduction in workforce, or our cash preservation plan, we have reduced our operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down our business. We currently have no intention of resuming historical research and development activities. As part of our cash preservation plan, our board of directors determined to terminate all of our employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nasdaq Deficiencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are not in compliance with the listing criteria for the Nasdaq Capital Market. Following a timely request for a hearing, we presented our plan to achieve compliance with applicable Nasdaq listing criteria and requested an extension of time to do so. On June&#160;10, 2025, Nasdaq notified us that the Panel determined to grant our request for an exception to, and an extension of time to comply with, the Nasdaq listing standards. The extension of time is subject to our demonstrating compliance with Nasdaq Listing Rule&#160;5550(a)(2)&#160;by evidencing a closing bid price of $1.00 or more per share for a minimum of 10 consecutive trading sessions, completing a strategic transaction and otherwise demonstrating compliance with all initial listing requirements for the Nasdaq Capital Market, in each case on or before October&#160;7, 2025, which is the Nasdaq Compliance Date. The extension of time is further subject to our meeting an interim milestone for a strategic transaction in connection with our ongoing strategic process. The Panel has the right to reconsider its determination based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make continued listing of our securities inadvisable or unwarranted. The Panel does not have discretion to grant continued listing for noncompliance with Nasdaq listing standards beyond the Nasdaq Compliance Date. There can be no assurance that we will be able to satisfy the requirements or conditions for continued listing within the period of time granted by the Panel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Current Strategy&#160;- The Merger</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the assistance of a financial advisor, we commenced an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic acquisition or other transaction as described in the section entitled &#8220;<i style="font-style:italic;">The Merger&#8201;&#8212;&#8201;Background of the Transaction</i>&#8221; beginning on page&#160;143 of this proxy statement/prospectus. After a comprehensive review of strategic alternatives, on June&#160;22, 2025, we entered into the Merger Agreement with Merger Sub, Ocugen and OrthoCellix, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into OrthoCellix, with OrthoCellix continuing as our wholly owned subsidiary and the surviving company of the merger. We refer to this as the &#8220;Merger&#8221;. The Merger was approved by our board of directors, and our board of directors resolved to recommend approval of the Merger Agreement to Carisma&#8217;s stockholders. If the Merger is completed, the business of OrthoCellix will continue as the business of the Combined Company. Prior to the completion of the Merger, we will seek to enter into a series of transactions with certain third parties to monetize certain legacy assets, in accordance with the limitations and requirements set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we have entered into the Merger Agreement and intend to consummate the Merger, there is no assurance that we will be able to successfully consummate the Merger on a timely basis, or at all. If, for any reason, the Merger does not close, our board of directors may elect to, among other things, attempt to complete another strategic transaction like the Merger, attempt to sell or otherwise dispose of our remaining assets or dissolve and liquidate our assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the Merger does not close, we might not have enough time or resources remaining to identify, evaluate and complete another strategic transaction before the Nasdaq Compliance Date. If the Merger is not completed, our board of directors may decide that it is in the best interests of our stockholders to commence bankruptcy or liquidation and dissolution proceedings. In that event, the amount of cash available for distribution to our stockholders would depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of our cash resources continues to decrease as we continue our wind down activities and incur fees and expenses related to the Merger. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution of the company, we would be required under Delaware law to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations. In addition, we may be subject to litigation or other claims related to a liquidation and dissolution of the company. If a </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">311</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">liquidation and dissolution were pursued, our board of directors, in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, our stockholders could lose all or a significant portion of their investment in the event of a liquidation and dissolution of the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Historical Product Candidates and Pipeline</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our liver fibrosis program is based upon the discovery of a key efferocytosis defect in the macrophages that reside within the livers of patients with fibrosis. Using a novel mRNA/LNP approach, our product candidate aims to reverse fibrotic disease and improve the outcomes of patients with advanced liver fibrosis. In the second quarter of 2024, we achieved pre-clinical proof of concept in our liver fibrosis program, demonstrating the anti-fibrotic potential of engineered macrophages in two liver fibrosis models. Prior to pausing our research and development activities, we planned to continue to conduct pre-clinical development of our product candidate, CT-2401, sufficient to enable a regulatory submission to initiate a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our oncology program leverages our considerable expertise and experience in <i style="font-style:italic;">ex vivo</i> cell therapy. CT-1119 is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. Prior to pausing our research and development activities, we planned to initiate a Phase 1 clinical trial of CT-1119, a mesothelin-targeted CAR-Monocyte, in combination with tislelizumab, an anti-PD-1 antibody, in adult patients with mesothelin-positive solid tumors, in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our collaboration with Moderna utilizes Moderna&#8217;s mRNA/LNP technology, together with our CAR-M platform technology, to create novel <i style="font-style:italic;">in vivo</i> oncology off-the-shelf gene therapy product candidates. In June&#160;2024, we announced that Moderna nominated the first development candidate under the collaboration and paid us a $2.0 million milestone. This development candidate targets GPC3, and is designed to treat solid tumors, including hepatocellular carcinoma. In November&#160;2024, we announced new pre-clinical data on our anti-GPC3 <i style="font-style:italic;">in vivo</i> CAR-M therapy for treating hepatocellular carcinoma. These pre-clinical data demonstrated robust anti-tumor activity. In February&#160;2025, Moderna nominated 10 additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February&#160;2025, Moderna has nominated all 12 oncology research targets under the collaboration for which we have the potential to receive future milestones and royalty payments. As such, we will not be conducting any additional research activities under the collaboration agreement and we will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the <i style="font-style:italic;">in-vivo</i> oncology field exclusivity, which would allow us to pursue<i style="font-style:italic;"> in vivo </i>CAR-M programs outside of the 12 nominated targets and product polypeptides.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, we have not yet commercialized any products or generated any revenue from product sales and have financed our operations primarily with proceeds from sales of our preferred stock, proceeds from our collaboration with Moderna, research tax credits, convertible debt financing, and completion of the Sesen Bio Merger and related financing. Our operations have historically been limited to organizing and staffing the Company, business planning, capital raising, establishing and maintaining our intellectual property portfolio, building our pipeline of product candidates, conducting drug discovery activities, undertaking pre-clinical studies, manufacturing process development studies, conducting early-stage clinical trials, and providing general and administrative support for these operations. We have historically devoted substantially all of our financial resources and efforts to pursuing discovery, research and development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial Operations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our net losses were $60.5 million and $86.9 million for the&#160;years ended December&#160;31, 2024 and 2023, respectively, and $9.3 million and $19.0 million for the three&#160;months ended March&#160;31, 2025 and 2024, respectively. As of December&#160;31, 2024 and March&#160;31, 2025, we had $17.9 million and $7.7 million in cash and cash equivalents, respectively. We had an accumulated deficit of $314.8 million as of March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we have reduced operations in connection with our cash preservation plan, we have incurred expenses in connection with our evaluation of strategic alternatives. We expect to continue to incur significant expenses and operating losses in connection with consummating the Merger and the ongoing process of exploring transactions with certain third parties to monetize certain legacy assets. A considerable portion of these expenses, such as legal, accounting and advisory fees and other related charges, will be incurred regardless of whether we consummate the Merger or enter into a monetization transaction for legacy assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Although we believe our current cash and cash equivalents are sufficient to sustain our operating expenses and capital expenditure requirements into the fall of 2025, we do not expect that our cash and cash equivalents will support our operations for more than </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">312</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">one&#160;year following the date of our consolidated financial statements included in this proxy statement/prospectus. As a result of these conditions, substantial doubt exists about our ability to continue as a going concern. We have based this estimate on assumptions that may prove to be wrong. In addition, changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. As a result, we could deplete our capital resources sooner than we currently expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s future operations are highly dependent on the success of the Merger. Although we have entered into the Merger Agreement and intend to consummate the Merger, there is no assurance that we will be able to successfully consummate the Merger on a timely basis, or at all. If the Merger does not close, we might not have enough time or resources remaining to identify, evaluate and complete another strategic transaction before the Nasdaq Compliance Date. If the Merger is not completed, our board of directors may decide that it is in the best interests of our stockholders to commence bankruptcy or liquidation and dissolution proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financial Operations Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Collaboration Revenues</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future. Our revenues to date have been generated from the Moderna collaboration agreement. Moderna reimbursed us for all costs incurred by it in connection with its research and development activities under the Moderna collaboration agreement plus a reasonable margin for the respective services performed. As of February&#160;2025, Moderna has nominated all 12 oncology research targets under collaboration agreement with Moderna. As such, we will not be conducting any additional research activities under the collaboration agreement and we will not be receiving any further research funding from Moderna under the collaboration agreement. We are eligible to receive potential milestone and royalty payments from Moderna in the future. To date, we have received $2.0 million in milestone payments and we have not received any royalties under the Moderna collaboration agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our research activities, including discovery efforts and the development of product candidates, and include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred to conduct the necessary pre-clinical studies and clinical trials required to obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of funding research performed by third parties, including pursuant to agreements with =CROs as well as investigative sites and consultants that conduct our pre-clinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with CMOs, including manufacturing scale-up expenses and the cost of acquiring and manufacturing pre-clinical study and clinical trial materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of laboratory supplies and acquiring materials for pre-clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facility-related expenses, which include direct depreciation costs of equipment and expenses for rent and maintenance of facilities and other operating costs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party licensing fees.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development activities have historically been central to our historical business model. Product candidates in later stages of clinical development will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to continue to significantly decrease in 2025 as a result of our decision to pause our research and development activities as part of our cash preservation plan. We currently have no intention of resuming our historical research and development activities. If the Merger is completed, the business of OrthoCellix will continue as the business of the Combined Company.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">313</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger is not completed and we are able to resume historical research and development activities, our research and development expenses would increase; however, any future resumption of research and development activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we were to resume historical research and development activities, the success of any of our product candidates will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully completing pre-clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely filing and receiving clearance of IND applications to commence clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully initiating, enrolling patients in and completing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scaling up manufacturing processes and capabilities to support clinical trials of any of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">applying for and receiving marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining intellectual property protection and regulatory exclusivity for any product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making arrangements with third-party manufacturers, or establishing commercial manufacturing capabilities, for both clinical and commercial supplies of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of any of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, enforcing, defending and protecting our rights in our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not infringing, misappropriating or otherwise violating others&#8217; intellectual property or proprietary rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of our products following receipt of any marketing approvals.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development, manufacture or commercialization activities of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, if there are safety concerns or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we could be required to expend significant additional financial resources and time on the completion of clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel expenses, including salaries, benefits and stock-based compensation expense for employees in executive, finance, accounting, business development and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation and maintenance, and costs not otherwise included in research and development expenses, legal fees related to intellectual property and corporate matters as well as fees for accounting and consulting services.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">314</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that our general and administrative expenses will continue to decrease in 2025, as we have terminated all of our employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. However, we do expect to incur significant costs related to the Merger, including legal, accounting and advisory expenses and other related charges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Income, Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interest income, net consists of interest earned on our excess cash, net of interest expense. Interest expense consists of interest on our finance leases and our convertible promissory note that was converted into common stock upon the closing of the Sesen Bio Merger in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Change in Fair Value of Derivative Liability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Change in fair value of the derivative liability for the redemption feature of our convertible promissory note reflected the non-cash charge for changes in the fair value of the derivative liability that was subject to re-measurement at each balance sheet date through the settlement of the convertible promissory note upon the closing of the Sesen Bio Merger at which time the redemption feature was derecognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have incurred significant net losses. As of December&#160;31, 2024, we had NOLs for federal income tax purposes of $374.7 million. We have provided a valuation allowance against the full amount of our deferred tax assets since, in our opinion, based upon our historical and anticipated future losses, it is more likely than not that the benefits will not be realized. As of December&#160;31, 2024 and March&#160;31, 2025, we remained in a full valuation allowance position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The utilization of our NOLs may be subject to a substantial annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50.0%, as defined under Sections 382 and 383 of the Code, respectively, as well as similar state provisions. We have recorded a valuation allowance on all of our deferred tax assets, including deferred tax assets related to NOLs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the Three&#160;Months Ended March&#160;31, 2025 and 2024 (in thousands)</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,729</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,397</p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Research and development</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,156</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,462</p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">General and administrative</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,907</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,445</p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 14.4pt;">Total operating expenses</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,063</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,907</p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 14.4pt;">Operating loss</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,334)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(19,510)</p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest income, net</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">68</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">532</p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pre-tax loss</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,266)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(18,978)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Collaboration Revenues</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Collaboration revenues were $3.7 million and $3.4 million for the three&#160;months ended March&#160;31, 2025 and 2024, respectively, related to the research and development activities completed under the Moderna collaboration agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We track outsourced development, outsourced personnel costs and other external research and development costs of our CT-0508, CT-0525, and CT-1119 programs. We do not track internal research and development costs on a program-by-program basis. The following table summarizes our research and development expenses for the three&#160;months ended March&#160;31, 2025 and 2024 (in </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">315</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">thousands). Certain amounts related to prior period results were reclassified to conform to current period presentation. These reclassifications have not changed total research and development expenses.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">CT-0508<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,150</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,150)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">CT-0525<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">770</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,416</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,646)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">CT-1119<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">406</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(406)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel costs, including stock-based compensation<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,051</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,305</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">746</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other clinical and pre-clinical development expenses</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,291</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,444</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,153)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Facilities and other expenses</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,044</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,741</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3,697)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,156</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,462</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8,306)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our 2024 revised operating plans adjusted our research and development focus. For the Phase 1 clinical trial of CT-0525, the last patient was dosed in November&#160;2024 and all clinical activity ended in January&#160;2025. All clinical activities related to CT-0508 also ceased in 2024. In connection with our 2024 revised operating plans, we had also elected to pause further development of CT-1119, a mesothelin-targeted CAR-Monocyte, pending additional financing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our cash preservation plan and the 2024 revised operating plans included reductions in workforce which resulted in severance costs during the three&#160;months ended March&#160;31, 2025 and 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The decrease in research and development expenses was primarily attributable to a decrease in our program expenses, personnel costs and other clinical and pre-clinical development expenses in connection with the 2024 revised operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our general and administrative expenses for the three&#160;months ended March&#160;31, 2025 and 2024 (in thousands). Certain amounts related to prior period results were reclassified to conform to current period presentation. These reclassifications have not changed total general and administrative expenses.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel costs, including stock-based compensation<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,828</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,420</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(592)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,593</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,307</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(714)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Facilities and supplies</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">142</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">212</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(70)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Insurance, taxes, and fees</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">167</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">203</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(36)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other expenses</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">177</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">303</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(126)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Total general and administrative expenses</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,907</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,445</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,538)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our cash preservation plan and 2024 revised operating plans included reductions in workforce which resulted in severance costs during the three&#160;months ended March&#160;31, 2025 and 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The decrease in general and administrative expenses was primarily attributable to a decrease in our professional fees and personnel costs in connection with the cash preservation plan and continuation of the 2024 revised operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Income, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognized $0.1 million and $0.5 million in interest income, net for the three&#160;months ended March&#160;31, 2025 and 2024, which was attributable to interest earned on excess cash.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">316</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the&#160;Years Ended December&#160;31, 2024 and 2023 (in thousands)</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:99.53%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.23%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.45%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;Ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:2.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,632</p></td><td style="vertical-align:bottom;width:2.24%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,919</p></td></tr><tr><td style="vertical-align:bottom;width:76.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.5%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.23%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.45%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Research and development</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">59,673</p></td><td style="vertical-align:bottom;width:2.24%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.23%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.45%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">74,125</p></td></tr><tr><td style="vertical-align:bottom;width:76.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">General and administrative</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,138</p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">29,525</p></td></tr><tr><td style="vertical-align:bottom;width:76.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 14.4pt;">Total operating expenses</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">81,811</p></td><td style="vertical-align:bottom;width:2.24%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">103,650</p></td></tr><tr><td style="vertical-align:bottom;width:76.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 14.4pt;">Operating loss</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.5%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(62,179)</p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.23%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.45%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(88,731)</p></td></tr><tr><td style="vertical-align:bottom;width:76.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in fair value of derivative liability</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.24%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.23%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.45%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(84)</p></td></tr><tr><td style="vertical-align:bottom;width:76.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest income, net</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,702</p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,936</p></td></tr><tr><td style="vertical-align:bottom;width:76.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:8.5%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(60,477)</p></td><td style="vertical-align:bottom;width:2.24%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:8.45%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(86,879)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Collaboration Revenues</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Collaboration revenues were $19.6 million and $14.9 million for the&#160;years ended December&#160;31, 2024 and 2023, respectively. The increase was primarily related to Moderna&#8217;s development candidate nomination which resulted in $5.8 million of collaboration revenue consisting of $3.8 million of deferred option rights revenue recognition and $2.0 million of milestone revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our research and development expenses (in thousands). Certain amounts related to prior period results were reclassified to conform to current period presentation. These reclassifications have not changed total research and development expenses.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;Ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">CT-0508<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,652</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,354</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,702)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">CT-0525<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,757</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,440</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">317</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">CT-1119<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">575</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">928</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(353)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel costs, including stock-based compensation<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,724</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,249</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(525)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other clinical and pre-clinical development expenses</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,635</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,308</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(6,673)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Facilities and other expenses</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,330</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,846</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(4,516)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">59,673</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">74,125</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(14,452)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The revised operating plans that were implemented in 2024 adjusted our research and development focus. For the Phase 1 clinical trial of CT-0525, the last patient was dosed in November&#160;2024 and all clinical activity ended in January&#160;2025. All clinical activities related to CT-0508 also ceased in 2024. In connection with our 2024 revised operating plans, we had also elected to pause further development of CT-1119, a mesothelin-targeted CAR-Monocyte, pending additional financing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our revised operating plans, which were implemented in 2024, included reductions in workforce which resulted in severance costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The decrease in research and development expenses was primarily attributable to a decrease in our clinical and pre-clinical development expenses and facility costs due to less laboratory supplies and laboratory space needs in connection with our revised operating plans.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">317</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our general and administrative expenses (in thousands). Certain amounts related to prior period results were reclassified to conform to current period presentation. These reclassifications have not changed total general and administrative expenses.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;Ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:2%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel costs, including stock-based compensation<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,748</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,671</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(923)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,058</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,821</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(4,763)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Facilities and supplies</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,684</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,406</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">278</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Insurance, taxes, and fees</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,351</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,890</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,539)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other expenses</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,297</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,737</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(440)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Total general and administrative expenses</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,138</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">29,525</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(7,387)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our revised operating plans, which were implemented in 2024, included reductions in workforce which resulted in severance costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The decrease in general and administrative expenses was primarily attributable to a decrease in our professional fees as a result of non-recurring legal costs associated with the Sesen Bio Merger and a decrease in director and officer insurance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Income, net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognized $1.7 million in interest income, net for the&#160;year ended December&#160;31, 2024, which was primarily attributable to interest earned on excess cash, partially offset by interest on our finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognized $1.9 million in interest income, net for the&#160;year ended December&#160;31, 2023, which was primarily attributable to interest earned on excess cash, partially offset by interest expense on the convertible promissory note issued to Moderna, including non-cash interest expense associated with the amortization of the debt discount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Change in Fair Value of Derivative Liability</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognized a $0.1 million non-cash charge for the&#160;year ended December&#160;31, 2023, for the increase in fair value of the derivative liability associated with the redemption feature of the convertible promissory note with Moderna, which was attributable to the timing in which we expected the accrued settlement event to occur. There was no change in fair value of derivative liability during the&#160;year ended December&#160;31, 2024 because the derivative was redeemed in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sources of Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024 and March&#160;31, 2025, we had $17.9 million and $7.7 million, respectively, in cash and cash equivalents. As of March&#160;31, 2025, we had an accumulated deficit of $314.8 million. To date, we have not yet commercialized any products or generated any revenue from product sales and have financed operations primarily with proceeds from sales of preferred stock, proceeds from our collaboration with Moderna, research tax credits, convertible debt financing, and completion of the Sesen Bio Merger and related financing. Through December&#160;31, 2024 and March&#160;31, 2025, we have generated $44.4 and $46.2 million, respectively, of collaboration revenues related to research and development services, option rights, and milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After a comprehensive review of strategic alternatives, on June&#160;22, 2025, we entered into the Merger Agreement for the contemplated Merger. If the Merger is completed, the business of OrthoCellix will continue as the business of the Combined Company. Although we intend to consummate the Merger, there is no assurance that we will be able to successfully consummate the Merger on a timely basis, or at all. Carisma&#8217;s future operations are highly dependent on the success of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We and OrthoCellix has certain termination rights under the Merger Agreement. Upon termination of the Merger Agreement under specified circumstances, we may be required to pay OrthoCellix a termination fee of $500,000. Upon termination of the Merger </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">318</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Agreement upon specified circumstances, OrthoCellix may be required to pay us a termination fee of $750,000 and reimburse up to $500,000 of our fees and expenses incurred in connection with the transactions contemplated by the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of February&#160;2025, Moderna has nominated all 12 oncology research targets under the collaboration. As such, we will not be conducting any additional research activities under the collaboration agreement and we will not be receiving any further research funding from Moderna under the collaboration agreement. We received the final research and development payment of $2.9 million from Moderna in January&#160;2025. Under the terms of the Moderna Collaboration Agreement, assuming Moderna develops and commercializes 12 products, each directed to a different development target, we are eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. We are also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">On April&#160;17, 2023, we filed a universal shelf registration statement on Form&#160;S-3, which was declared effective on May&#160;2, 2023 (the &#8220;Registration Statement&#8221;). Under the Registration Statement, we may offer and sell up to $300.0 million of a variety of securities, including debt securities, common stock, preferred stock, depository shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May&#160;12, 2023, we entered into an Amended and Restated Open Market Sale Agreement</span><sup style="font-size:4.87pt;line-height:100%;top:0pt;vertical-align:top;">SM </sup><span style="font-size:10pt;">(the &#8220;Sale Agreement&#8221;) with Jefferies LLC, as sales agent, pursuant to which we may offer and sell shares of our common stock with an aggregate offering price of up to $100.0 million under the ATM program. As of December&#160;31, 2024 and March&#160;31, 2025, we have sold 1,362,917 shares of our common stock for net proceeds of $3.0 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three&#160;Months Ended March&#160;31, 2025 and 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table shows a summary of our cash flows for the three&#160;months ended March&#160;31, 2025 and 2024 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:2%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash (used in) provided by</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Operating activities</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(10,067)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(22,425)</p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Investing activities</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">524</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(17)</p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Financing activities</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(626)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,352</p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net change in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(10,169)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(21,090)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows from Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2025, we used $10.1 million of net cash in operating activities. Cash used in operating activities reflected our net loss of $9.3 million and a $3.0 million net change in our operating assets and liabilities attributable to the timing in which we pay our vendors for research and development activities, partially offset by $2.2 million of non-cash charges related to depreciation and amortization expense, stock-based compensation, reductions in the operating right of use (&#8220;ROU assets&#8221;) the write-off of deferred financing costs and gains on the sale of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2024, we used $22.4 million of net cash in operating activities. Cash used in operating activities reflected our net loss of $19.0 million and $4.4 million of non-cash charges related to depreciation and amortization expense, stock-based compensation, reductions in the ROU assets, and non-cash interest on the finance lease liability and a $7.9 million net change in our operating assets and liabilities attributable to the timing in which we pay our vendors for research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows from Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2025, we received $0.5 million of cash from investing activities related to the sale of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2024, we used a nominal amount of cash from investing activities which reflected purchases of property and equipment.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">319</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows from Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2025, we used $0.6 million of net cash from financing activities, attributable to $0.3 million in payments of finance liability for failed-sale leaseback arrangements and $0.3 million in payments of principal related to finance lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2024, we received $1.4 million of net cash from financing activities, primarily attributable to $2.3 million from the sale of common stock in connection with the Sale Agreement and $0.7 million in proceeds from failed-sale leaseback arrangements, partially offset by $0.3 million in payments of finance liability from failed-sale leaseback arrangements, and $1.3 million in payments of principal related to finance lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Years Ended December&#160;31, 2024 and 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table shows a summary of our cash flows for the&#160;years ended December&#160;31, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;Ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:2%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash (used in) provided by:</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Operating activities</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(59,917)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(81,177)</p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Investing activities</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(123)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">72,408</p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Financing activities</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">344</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,180</p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net change in cash and cash equivalents</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(59,696)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">53,411</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows from Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2024, we used $59.9 million of net cash in operating activities. Cash used in operating activities reflected our net loss of $60.5 million and a $12.0 million net change in our operating assets and liabilities attributable to the timing in which we pay our vendors for research and development activities that was offset by $12.5 million of non-cash charges primarily related to depreciation and amortization expense, stock-based compensation and reductions in the operating ROU assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2023, we used $81.2 million of net cash in operating activities. Cash used in operating activities reflected our net loss of $86.9 million and a $5.4 million net change in our operating assets and liabilities attributable to the timing in which we pay our vendors for research and development activities that was offset by $11.1 million of non-cash charges related to depreciation and amortization expense, stock-based compensation, reductions in the operating ROU assets, amortization of the debt discount on the convertible promissory note, change in fair value of the derivative liability, accretion on marketable securities, and non-cash interest on the finance lease liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows from Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2024, we used $0.1 million of net cash in investing activities which reflected purchases of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2023, we received $72.4 million of net cash from investing activities. Cash provided by investing activities reflected $108.0 million of proceeds from the sale of marketable securities, partially offset by purchases of marketable securities of $34.5 million and the purchase of property and equipment of $1.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows from Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2024, we received $0.3 million of net cash from financing activities, primarily attributable to $2.4 million from the sale of common stock in connection with the Sale Agreement, net of issuance costs, and $0.7 million in proceeds from failed-sale leaseback arrangements, partially offset by $1.4 million in payments of principal related to finance lease liabilities, and $1.3 million in payments to our finance liability from failed-sale leaseback arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">During the&#160;year ended December&#160;31, 2023, we received $62.2 million of net cash from financing activities, primarily attributable to the $37.9 million in the cash and cash equivalents acquired in connection with the Sesen Bio Merger, $30.6 million in proceeds </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">320</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">from the issuance of common stock in pre-closing financing, $1.2 million in proceeds from failed-sale leaseback arrangements, $0.6 million from the sale of common stock in connection with the Sale Agreement, partially offset by $5.8 million in payments of financing costs, $1.3 million in payments of principal related to finance lease liabilities, and $1.1 million in payments to our finance liability from failed sale-leaseback arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;31, 2025, we had cash and cash equivalents of $7.7 million. Our funding requirements will depend on the outcome of the planned Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we have reduced operations in connection with our cash preservation plan, we have incurred expenses in connection with our evaluation of strategic alternatives. We expect to continue to incur significant expenses and operating losses in connection with consummating the Merger and the ongoing process of exploring transactions with certain third parties to monetize certain legacy assets. A considerable portion of these expenses, such as legal, accounting and advisory fees and other related charges, will be incurred regardless of whether we consummate the Merger or enter into a monetization transaction for legacy assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we believe our current cash and cash equivalents are sufficient to sustain our operating expenses and capital expenditure requirements into the fall of 2025, we do not expect that our cash and cash equivalents will support our operations for more than one&#160;year following the date of our consolidated financial statements included in this proxy statement/prospectus. As a result of these conditions, substantial doubt exists about our ability to continue as a going concern. We have based this estimate on assumptions that may prove to be wrong. In addition, changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. As a result, we could deplete our capital resources sooner than we currently expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s future operations are highly dependent on the success of the Merger. Although we have entered into the Merger Agreement and intend to consummate the Merger, there is no assurance that we will be able to successfully consummate the Merger on a timely basis, or at all. If, for any reason, the Merger does not close, our board of directors may elect to, among other things, attempt to complete another strategic transaction like the Merger, attempt to sell or otherwise dispose of our remaining assets or dissolve and liquidate our assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger does not close, we might not have enough time or resources remaining to identify, evaluate and complete another strategic transaction before the Nasdaq Compliance Date. If the Merger is not completed, our board of directors may decide that it is in the best interests of our stockholders to commence bankruptcy or liquidation and dissolution proceedings. In that event, the amount of cash available for distribution to our stockholders would depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of our cash resources continues to decrease as we continue our wind down activities and incur fees and expenses related to the Merger. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution of the company, we would be required under Delaware law to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations. In addition, we may be subject to litigation or other claims related to a liquidation and dissolution of the company. If a liquidation and dissolution were pursued, our board of directors, in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, our stockholders could lose all or a significant portion of their investment in the event of a liquidation and dissolution of the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that our board of directors determines that a liquidation and dissolution of our business approved by stockholders is desirable or the best method to maximize value, we would prepare proxy materials and schedule a special meeting of our stockholders to seek approval of such a plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently have no intention of resuming historical research and development activities. Any future resumption of research and development activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding. Significant additional financing may not be available to us on acceptable terms, or at all, and may be impacted by the economic climate and market conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">To the extent that we are able to raise additional capital through the public or private sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing and preferred equity financing, if available, would increase our </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">321</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">fixed payment obligations and may involve agreements that include covenants limiting or restricting our operations and ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments, declaring dividends or other operating restrictions that could adversely impact our ability to conduct business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are able to raise funds through a strategic collaboration or partnership with one or more parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, discovery programs or product candidates, grant licenses on terms that may not be favorable to us or grant rights to develop and market product candidates that we would otherwise prefer to develop and market on our own, any of which may have a material adverse effect on our business, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we were to resume historical research and development activities, our expenses would increase and our future capital requirements would depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, costs and results of pre-clinical testing of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, costs and results of clinical trials of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of and development requirements for additional indications for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our collaborations with Moderna or others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to scale up our manufacturing processes and capabilities to support clinical trials of the product candidates we are developing and may develop in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential changes in the regulatory environment and enforcement rules;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the payment of license fees and other costs of our technology license arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for the product candidates we are developing and may develop in the future for which we may receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain acceptance of any approved products by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount and timing of revenue, if any, received from commercial sales of the product candidates we are developing or develop in the future for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential changes in pharmaceutical pricing and reimbursement infrastructure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of raw materials for use in production of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we in-license or acquire additional technologies or product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Identifying potential product candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">322</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Contractual Obligations and Commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our contractual obligations and commitments at March&#160;31, 2025 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less</b>&#160;<b style="font-weight:bold;">than 1</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;to&#160;3</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">4&#160;to&#160;5</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More</b>&#160;<b style="font-weight:bold;">than</b>&#160;<b style="font-weight:bold;">5</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Contractual obligations:</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease commitments<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,925</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,098</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">462</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">365</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:35%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Finance lease commitments</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">659</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">659</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total contractual obligations</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,584</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,757</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">462</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">365</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects obligations pursuant to our office and laboratory leases in Philadelphia, Pennsylvania.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. Our contracts with CMOs, CROs and other third parties for the manufacture of our product candidates and to support pre-clinical research studies and clinical testing are generally cancelable by us upon prior notice and do not contain any minimum purchase commitments. Payments due upon cancellation consisting only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation are not included in the table above as the amount and timing of such payments are not known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table above does not include any potential milestone or royalty payments that we may be required to make under our license agreement with Penn and under licensing agreements with other third parties not considered material. We excluded these milestone and royalty payments given that the timing and likelihood of any such payments cannot be reasonably estimated at this time. For further information about our lease arrangements, our license agreement with Penn and our other licensing agreements, see Note&#160;8 to our audited consolidated financial statements included elsewhere in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the cash preservation plan, we incurred $3.4 million during the three&#160;months ended March&#160;31, 2025 and incurred an additional $0.4 million in the second quarter of 2025 related to further potential terminations, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. We expect to pay the majority of related reduction in workforce amounts by the end of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described above, upon termination of the Merger Agreement under specified circumstances, we may be required to pay OrthoCellix a termination fee of $500,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on our limited historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in Note&#160;3 to our audited consolidated financial statements included elsewhere in this proxy statement/prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. During the three&#160;months ended March&#160;31, 2025, there were no material changes to our critical accounting policies from those described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenues from Contracts</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We account for our revenue in accordance with Accounting Standards Codification 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">323</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps at inception of the agreement or upon material modification of the agreement: (i)&#160;identifies the contract(s)&#160;with a customer; (ii)&#160;identifies the performance obligations in the contract; (iii)&#160;determines the transaction price, including variable consideration, if any; (iv)&#160;allocates the transaction price to the performance obligations in the contract; and (v)&#160;recognizes revenue when (or as) the entity satisfies a performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We consider the pattern of satisfaction of the performance obligations under step (v)&#160;above to be a critical accounting estimate. More specifically, the determination of the level of achievement of research and development service performance obligations, whose pattern of satisfaction is measured using costs incurred to date as compared to total costs incurred and expected to be incurred in the future is driven by a critical accounting estimate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In estimating the costs expected to be incurred in the future, we use our most recent budget and long-range plan, adjusted for any pertinent information. While this is our best estimate as of the reporting period, costs expected to be incurred in the future require managements judgment as the scope and timing of research and development activities may change significantly over time. We may adjust the scope of our research and development activities based on several factors, such as additional work needed to support advancement of product candidate or change in the number of patients in trials. Further, research and development services may no longer be within the scope of a collaboration agreement, as has been the case with certain of our programs. The timing of when research and development costs are expected to be incurred may change as a result of external factors, such as delays caused by manufacturing or supply chain, or difficulty in enrolling patients; or internal factors, such as prioritization of programs. Our estimate of the scope and timing of research and development services performed relative to the actual scope and timing may have a significant impact on revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Accruals</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We accrue expenses for pre-clinical studies and activities performed by third parties based upon estimates of the proportion of work completed over the term of the individual trial and patient enrollment rates in accordance with agreements with third parties. We determine the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with our internal clinical personnel and external service providers as to the progress or stage of completion of activities or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including our clinical development plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Non-refundable advance payments for goods and services, including fees for process development or manufacturing and distribution of pre-clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Milestone payments within our licensing and collaboration arrangements are recognized when achievement of the milestone is deemed probable to occur. To the extent products are commercialized and future economic benefit has been established, commercial milestones that become probable are capitalized and amortized over the estimated remaining useful life of the intellectual property. In addition, we accrue royalty expense and sublicense non-royalty payments, as applicable, for the amount we are obligated to pay, with adjustments as sales are made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We measure compensation expense for all stock-based awards based on the estimated fair value of the award on the grant date. We use the Black-Scholes option pricing model to value our stock option awards. We recognize compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. We have not issued awards where vesting is subject to a market or performance condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Black-Scholes option pricing model requires the use of subjective assumptions that include the expected stock price volatility and prior to the Sesen Bio Merger, the fair value of the underlying common stock on the date of grant. See Note&#160;9 to our audited consolidated financial statements included elsewhere in this proxy statement/prospectus for information concerning certain of the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">324</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted during the&#160;years ended December&#160;31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See Note&#160;3&#160;&#8212; <i style="font-style:italic;">Recently issued accounting pronouncements</i> to our unaudited interim consolidated financial statements found in this proxy statement/prospectus for a description of recent accounting pronouncements applicable to our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not have any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. We do not engage in off-balance sheet financing arrangements. In addition, we do not engage in trading activities involving non-exchange traded contracts. We therefore believe that we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.</p><a id="_e2363579_d1d6_4b0f_88a0_9c1808281b36"></a><a id="QUANTITATIVEANDQUALITATIVEDISCLOSURESABO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT THE MARKET RISK OF CARISMA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma is a smaller reporting company as defined by Rule&#160;12b-2 of the Exchange Act and is not required to provide the information otherwise required under this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">325</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0a40e0e1_0357_4f39_b358_8f448b985183"></a><a id="ORTHOCELLIXMANAGEMENTSDISCUSSIONANDANALY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ORTHOCELLIX MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">AND RESULTS OF</b><b style="font-weight:bold;"> OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion of our financial condition and results of operations should be read in conjunction with &#8220;Unaudited Pro Forma Combined Financial Statements,&#8221; the audited financial statements for the years ended December 31, 2024 and 2023, financial statements for the three months ended March 31, 2025 and 2024 and corresponding notes included elsewhere in this proxy statement/prospectus. This discussion includes forward-looking statements. Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;OrthoCellix,&#8221; &#8220;the NeoCart Business of Ocugen,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to OrthoCellix. All statements other than statements of historical facts contained in this proxy statement/prospectus, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;design,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would&#8221; or the negative version of these words and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements include, but are not limited to, statements concerning the following:</i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding expenses, future revenues, and capital requirements, as well as the timing, availability of, and the need for, additional financing to continue to advance our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the uncertainties associated with the clinical development and regulatory approval of NeoCart, and any other product candidates including potential delays in the initiation, enrollment, and completion of future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to realize any value from our product candidate and preclinical program being developed and anticipated to be developed, in light of inherent risks and difficulties involved in successfully commercializing products and the risk that our products, if approved, may not achieve broad market acceptance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to comply with regulatory schemes and other regulatory developments applicable to our business in the United States and other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the performance of third-parties upon which we depend, including contract development and manufacturing organizations, suppliers, manufacturers, group purchasing organizations, distributors, and logistics providers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the pricing and reimbursement of our product candidates, if commercialized;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patent protection, or obtain licenses to intellectual property and defend our intellectual property rights against third-parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain our relationships and contracts with our key collaborators and commercial partners and our ability to establish additional collaborations and partnerships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit and retain key scientific, technical, commercial, and management personnel and to retain our executive officers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to comply with stringent United States and applicable foreign government regulations with respect to the manufacturing of pharmaceutical products, including compliance with current Good Manufacturing Practice (&#8220;GMP&#8221;) regulations, and other relevant regulatory authorities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">326</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this proxy statement/prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this proxy statement/prospectus to conform these statements to actual results or to changes in our expectations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should read this proxy statement/prospectus and the documents that we reference in this proxy statement/prospectus and have filed with the SEC as exhibits to the registration statement of which this information is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a biotechnology company focused on discovering, developing, and commercializing biologics that improve health and offer hope for patients across the globe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">Our technology pipeline includes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Regenerative Medicine Cell Therapy Platform &#8212; Our Phase 3-ready regenerative cell therapy platform technology, which includes NeoCart (autologous chondrocyte-derived neocartilage), is being developed for the repair of knee cartilage injuries in adults. We received concurrence from the FDA on the confirmatory Phase 3 trial design. All of the assets associated with NeoCart (including but not limited to IP and contracts noted below) transferred to the Company from Ocugen as a part of the Contribution Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regenerative Medicine Cell Therapy Platform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NeoCart is a Phase 3-ready, regenerative cell therapy technology that combines breakthroughs in bioengineering and cell processing to enhance the autologous cartilage repair process. NeoCart is a three-dimensional tissue-engineered disc of new cartilage that is manufactured by growing the patient&#8217;s own chondrocytes, the cells responsible for maintaining cartilage health. Current surgical and nonsurgical treatment options for knee cartilage injuries in adults are limited in their efficacy and durability. In prior clinical studies, Phase 2 and Phase 3, NeoCart has shown potential to accelerate healing, reduce pain, and provide regenerative native-like cartilage strength with durable benefits post transplantation. On May 19, 2022, the FDA granted a RMAT designation to NeoCart for the repair of full-thickness lesions of knee cartilage injuries in adults. Additionally, we received concurrence from the FDA on the confirmatory Phase 3 trial design where chondroplasty will be used as a control group. All of the assets associated with NeoCart (including but not limited to IP and contracts noted below) transferred to the Company from Ocugen as a part of the Contribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Formation of the Company and Asset Contribution from Ocugen</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 19, 2025, Ocugen, Inc., a Delaware corporation (&#8220;Ocugen&#8221; or the &#8220;Parent&#8221;) contributed the NeoCart Assets to OrthoCellix, Inc., a Delaware corporation (the &#8220;Company&#8221;), which was established as a legal entity on February 28, 2025, pursuant to an Asset Contribution Agreement, by and between the Parent and the Company (the &#8220;Contribution Agreement&#8221;) in exchange for shares of Common Stock in the Company (such transactions, the &#8220;Contribution&#8221;). Per the Contribution Agreement, the Parent contributed NeoCart assets in exchange for 1,000 Shares of Common stock with the contemplation of the Agreement and Plan of Merger with Carisma Therapeutics, Inc. OrthoCellix will seek to continue development and commercialization of NeoCart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our historical financial statements have been prepared on a stand-alone basis and are derived from Ocugen&#8217;s financial statements and accounting records and are presented in conformity with U.S. GAAP. These historical financial statements may not be indicative of our future performance and do not necessarily reflect what our results of operations, financial condition and cash flows would have been had we operated as a separate, publicly traded company during the periods presented. We expect that changes will occur in our operating structure and capitalization as a result of the separation from Ocugen.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">327</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Capital Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have incurred significant operating losses. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of NeoCart. Our net loss was $270 and $310 for the three months ended March 31, 2025 and 2024, respectively, and $1,026 and $2,081 for the years ended December 31, 2024 and 2023, respectively. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for NeoCart. We expect to continue to incur significant expenses for at least the next several years as we advance NeoCart from discovery through preclinical development and clinical trials and seek regulatory approval and pursue commercialization. In addition, if we obtain marketing approval, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. In addition, we may incur expenses in connection with the in-license or acquisition of additional product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result, we will need additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the public or private sale of equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our product candidate or delay our pursuit of potential in-licenses or acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2025 and December 31, 2024, we had no cash. The future viability of the Company is dependent on our ability to raise additional capital to finance our operations, which cannot be assured. We have concluded that this circumstance raises substantial doubt about our ability to continue as a going concern within one year after the issuance date of our combined financial statements. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;&#8212;Liquidity and Capital Resources.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impact of General Economic Risk Factors on OrthoCellix&#8217;s Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Uncertainty in the global economy presents significant risks to OrthoCellix&#8217;s business. OrthoCellix is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including increases in inflation, fluctuating interest rates, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), recent bank failures, geopolitical factors, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the responses thereto, and supply chain disruptions. While OrthoCellix is closely monitoring the impact of the current macroeconomic and geopolitical conditions on all aspects of OrthoCellix&#8217;s business, including the impacts on participants in any future clinical trials and its employees, suppliers, vendors and business partners and OrthoCellix&#8217;s future access to capital, the ultimate extent of the impact on OrthoCellix&#8217;s business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside OrthoCellix&#8217;s control and could exist for an extended period of time. OrthoCellix will continue to evaluate the nature and extent of the potential impacts to its business, results of operations, liquidity and capital resources. For additional information see the section titled &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to OrthoCellix&#8217;s Business and Operations.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Components of Our Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our product candidates are successful and result in regulatory approval or additional license agreements with third parties, we may generate revenue in the future from product sales.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">328</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. These costs consist of internal and external expenses, as well as depreciation expense on assets used within our research and development activities. Internal expenses include the cost of salaries, benefits, and other related costs, including stock-based compensation, for personnel serving in our research and development functions, as well as allocated rent and utilities expenses. External expenses include development, clinical trials, and regulatory compliance costs incurred with research organizations, contract manufacturers, and other third-party vendors. License fees paid to acquire access to proprietary technology are expensed to research and development, unless it is determined that the technology is expected to have an alternative future use. We record costs for certain development activities, such as preclinical studies and clinical trials, based on our evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the combined financial statements as prepaid or accrued research and development expense, as applicable. Our recording of costs for certain development activities requires us to use estimates. We believe our estimates and assumptions are reasonable under the current conditions; however, actual results may differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses account for a significant portion of our operating expenses. We plan to incur research and development expenses for the foreseeable future as we expect to continue the development of our product candidate. We anticipate that our research and development expenses will be higher in fiscal year 2025 as compared to fiscal year 2024 due to an increase in clinical activities with respect to our product candidate as well as an increase in headcount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At this time, due to the inherently unpredictable nature of preclinical and clinical developments as well as regulatory approval, we are unable to estimate with any certainty the costs we will incur and the timelines we will require in our continued development and commercialization efforts. As a result of these uncertainties, the successful development and completion of clinical trials as well as the regulatory approval process are uncertain and may not result in approved and commercialized products. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We will continue to make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to our ability to enter into partnerships with respect to each product candidate and the scientific and clinical success of each product candidate as well as ongoing assessments as to the commercial potential of each product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expense consists primarily of personnel expenses, including salaries, benefits, insurance, and stock-based compensation expense, for employees in executive, accounting, commercialization, human resources, and other administrative functions. General and administrative expense also includes expenses related to pre-commercial activities, corporate facility costs, such as allocated rent and utilities, insurance premiums, legal fees related to corporate matters, and fees for auditing, accounting, and other consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We anticipate that our general and administrative expenses will increase in fiscal year 2025 as compared to fiscal year 2024 due to an increase in headcount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did not historically file separate income tax returns since the Company was not a separate entity. As such, the provision was calculated on a stand-alone basis for the purpose of these combined financial statements. The Company uses the asset and liability method in accounting for income taxes. Deferred tax assets and liabilities are recorded for temporary differences between the tax basis of assets and liabilities and their reported amounts in the combined financial statements, using statutory tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the combined statements of operations and comprehensive loss in the period that includes the enactment date. Accordingly, the reported provision for income taxes and the related balance sheet account balances may not equal the amounts that would have been allocable to the Company under applicable consolidated US federal and state tax laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company evaluates its deferred tax assets each period to ensure that the estimated future taxable income will be sufficient in character, amount, and timing, to result in its realizability. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets, unless it is more likely than not that those assets will be realized. Management utilizes considerable judgment </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">329</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">when establishing deferred tax valuation allowances. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences and carryforward deferred tax assets become deductible or utilized. The Company considers the scheduled reversal of taxable temporary differences, projected future taxable income, and tax planning strategies in making this assessment. As events and circumstances change, valuation allowances are adjusted within the combined statement of operations and comprehensive loss when applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes net tax benefits under the recognition and measurement criteria of FASB ASC Topic 740, Income Taxes, which prescribes requirements and other guidance for financial statement recognition and measurement of positions taken or expected to be taken on tax returns. The Company recognizes a tax benefit for positions taken for tax return purposes when it will be more likely than not that the positions will be sustained upon tax examination, based solely on the technical merits of the tax positions. Otherwise, no tax benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense in the combined statement of operations and comprehensive loss. Tax examinations are often complex, as tax authorities may disagree with the treatment of items reported by the Company and may require several years to resolve. As a result, the Company&#8217;s provision for income taxes is recorded on the basis of available information, but amounts recorded may be impacted as a result of future examinations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the Three Months Ended March 31, 2025 and 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our results of operations for the three months ended March 31, 2025 and 2024 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 17.35pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;months&#160;ended&#160;March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 17.35pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:9.5pt;">Operating expenses:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 17.34pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(43)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 17.34pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(40)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(310)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">40</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our research and development expenses between NeoCart and unallocated expenses for the three months ended March 31, 2025 and 2024 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.9pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;months&#160;ended&#160;March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.9pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 16.9pt;">NeoCart direct expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(90)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 16.55pt;">Unallocated costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 16.55pt;">Research and development personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 16.9pt;">Facilities and other support costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 16.9pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(43)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(40)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Segment and net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(310)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">40</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $139 for the three months ended March 31, 2025, compared to $182 for the three months ended March 31, 2024. The decrease of $43 was primarily due to a decrease of $62 in consulting fees and $29 for preclinical lab supplies offset by an increase of $46 for shared costs allocated based on assets contributed to the business as a part of the Asset Contribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $131 for the three months ended March 31, 2025, compared to $128 for the three months ended March 31, 2024. The increase of $3 was primarily due to an increase of $5 for employee related costs and $3 for professional services offset by a decrease of $4 for corporate fees and business taxes.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">330</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the Years Ended December 31, 2024 and 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our results of operations for the years ended December 31, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 15.7pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 15.7pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 15.7pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(930)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 15.7pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(125)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,055)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,026)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,081)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,055</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our research and development expenses between NeoCart and unallocated costs for the years ended December 31, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.9pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.9pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 16.9pt;">NeoCart direct expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(917)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 16.9pt;">Unallocated costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 16.9pt;">Research and development personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(16)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 16.9pt;">Facilities and other support costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(16)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 16.9pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(930)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(125)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,055)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Segment and net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,026)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,081)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,055</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $511 for the year ended December 31, 2024, compared to $1,441 for the year ended December 31, 2023. The decrease of $930 was primarily due to a decrease of $439 in chemistry, manufacturing, and control (&#8220;CMC&#8221;) costs to ensure the quality, safety, and efficacy of the product, $295 in preclinical costs, and $178 in consulting fees, and $12 for shared costs allocated based on assets contributed to the business as a part of the Asset Contribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $515 for the year ended December 31, 2024, compared to $640 for the year ended December 31, 2023. The decrease of $125 was primarily due to a decrease of $73 for professional services, $46 for employee related costs, $10 for insurance costs, and $5 for commercial fees offset by an increase of $6 for IT and software costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since our inception as a business, we have not generated any revenue and have incurred significant operating losses and negative cash flows from our operations. Historically, we have funded our operations primarily with proceeds allocated to our business from Ocugen. As of March 31, 2025 and December 31, 2024, we had no cash.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">331</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows for the Three Months Ended March 31, 2025 and 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows for the three months ended March 31, 2025 and 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1.85pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;months&#160;ended&#160;March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1.85pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash used on operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(230)</p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash (used in) provded by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">230</p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net increase (decrease) in cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2025, net cash used for operating activities primarily consisted of $122 for shared costs allocated based on assets contributed to the business as a part of the Asset Contribution Agreement, $66 for employee related costs, $47 for professional services, $16 for preclinical costs, $6 for insurance costs, and $5 for facilities costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2024, net cash used for operating activities primarily consisted of $76 for shared costs allocated based on assets contributed to the business as a part of the Asset Contribution Agreement, $62 for consulting fees, $61 for employee related costs, $45 for professional services, $44 for preclinical lab supplies, $7 for insurance costs, and $5 for facilities costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2025 and 2024, there were no investing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2025 and 2024, net cash provided by financing activities consisted of net transfers from the Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows for the Years Ended December 31, 2024 and 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows for the years ended December 31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash used on operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,050)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,057)</p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash (used in) provded by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,057</p></td></tr><tr><td style="vertical-align:bottom;width:74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net increase (decrease) in cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2024, net cash used for operating activities primarily consisted of $377 for shared costs allocated based on the assets contributed to the business as a part of the Asset Contribution Agreement, $260 for employee related costs, $159 for professional services, $126 for consulting fees, $26 for insurance costs, and $9 for preclinical costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2023, net cash used for operating activities primarily consisted of $439 for CMC costs, $389 for shared costs allocated based on assets contributed to the business as a part of the Asset Contribution Agreement, $307 for employee related costs, $304 for consulting fees, $304 for preclinical costs, $232 for professional services, and $36 for insurance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2024 and 2023, there were no investing activities.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">332</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2024 and 2023, net cash provided by financing activities consisted of net transfers from the Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant expenses in connection with our ongoing activities, particularly as we continue research and development, including preclinical and clinical development of our product candidate, prepare to manufacture our product candidates, prepare for the potential commercialization of our product candidate, add operational, financial, and information systems to execute our business plan, maintain, expand, and protect our patent portfolio, explore strategic licensing, acquisition, and collaboration opportunities to expand our product candidate pipeline to support our future growth; expand headcount to support our development, commercialization, and business efforts, and operate as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Factors impacting our future funding requirements include, without limitation, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, progress, timing, costs, and results of trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the preparation and submission of Investigational New Drug applications, or INDs, with the FDA for current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome, timing, and cost of the regulatory approval process for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of manufacturing and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs related to doing business internationally with respect to the development and commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of filing, prosecuting, defending, and enforcing our patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the acquisition of or in-licensing of additional product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of expanding infrastructure to support our development, commercialization, and business efforts, including the costs related to the development of a laboratory and manufacturing facility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in recruiting and retaining skilled personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we in-license or acquire other products, product candidates, or technologies and out-license our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with being a public company, including costs of audit, legal, regulatory and tax- related services associated with maintaining compliance with an exchange listing and SEC requirements, director and officer insurance premiums and investor and public relations costs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of geopolitical turmoil, macroeconomic conditions, social unrest, political instability, terrorism, or other acts of war.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2025 and December 31, 2024, we had no cash. This amount will not meet our capital requirements over the next 12 months. Due to the inherent uncertainty involved in making estimates and the risks associated with the research, development, and commercialization of biotechnology products, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">333</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to risks and uncertainties frequently encountered by companies in the biotech industry, and while we intend to continue research, development, and commercialization efforts for our product candidates, we will require significant additional funding. If we are unable to obtain additional funding in the future and/or our research, development, and commercialization efforts require higher than anticipated capital, there will be a negative impact on our financial viability. We will continue to explore options to fund our operations through public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sales of assets, licensing and/or collaboration arrangements with pharmaceutical companies or other institutions, funding from the government, particularly for the development of our novel inhaled mucosal vaccine platform, or funding from other third parties. Such financing and funding may not be available at all, or on terms that are favorable to us. While management believes that we have a plan to fund operations, our plan may not be successfully implemented. If we cannot obtain the necessary funding, we will need to delay, scale back, or eliminate some or all of our research and development programs and commercialization efforts; consider other various strategic alternatives, including a merger or sale&#894; or cease operations. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of these factors, together with the anticipated continued spending that will be necessary to continue to research, develop, and commercialize our product candidates, there is substantial doubt about our ability to continue as a going concern within one year after the date that these combined financial statements are issued. The combined financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our combined financial statements are prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). The preparation of our combined financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the combined financial statements, and the reported amounts of expenses during the reported period. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in the notes to the combined financial statements included elsewhere in this filing for the three months ended March 31, 2025 and for the year ended December 31, 2024, we believe that the following accounting policies and estimates are those most critical to the preparation of our combined financial statements:</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">334</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transition from Ocugen and Costs to Operate as an Independent Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined financial statements reflect our operating results and financial position as it was operated by Ocugen, rather than as an independent company. We will incur additional ongoing operating expenses to operate as an independent company. These costs will include the cost of various corporate headquarters functions, incremental information technology-related costs and incremental costs to operate stand-alone accounting, legal and other administrative functions. We will also incur non-recurring expenses and non-recurring capital expenditures. As an independent company, our information technology operating costs may be higher than the costs allocated in the historical combined financial statements. In addition, we will incur expenses and capital expenditures to establish independent information technology systems. We are currently building our accounting and other administrative infrastructure. We expect to enter into a manufacturing agreement and a transition services agreement with Ocugen that will provide us with certain services and resources related to corporate functions. These agreements will allow us to operate our business independently prior to establishing a stand-alone infrastructure. During the transition from Ocugen, we will incur expenses to expand our infrastructure. The financial statements reflect an estimate of these expenses based on an allocation of Ocugen expenses that best represents the costs to function as an independent business. Actual costs that would have been incurred if we operated as a stand-alone company during these periods would have depended on various factors, including organizational design, outsourcing and other strategic decisions related to corporate functions, information technology and back office infrastructure. The terms of these agreements, including information on the business purpose of such agreements, transaction prices, related ongoing contractual commitments and any related special risks or contingencies, are discussed in greater detail under &#8220;Related Party Transactions&#8221; appearing elsewhere in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not have any off-balance sheet arrangements during the periods presented, and we do not currently have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Issued Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our combined financial statements appearing at the end of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">335</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_84d2a0d0_a417_44f3_8536_50159d0614ae"></a><a id="MANAGEMENTFOLLOWINGTHEMERGER_235287"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MANAGEMENT FOLLOWING THE MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Executive Officers and Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the completion of the Merger, the business and affairs of the Combined Company will be managed under the direction of the Combined Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s board of directors will initially be fixed at six members, consisting of five members designated by OrthoCellix, who shall initially be Karthik Musunuri, Michael Shine, David Anderson,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and one member designated by Carisma, who shall initially be Steven Kelly. The staggered structure of the current Carisma board of directors will remain in place for the Combined Company following the completion of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each executive officer of the Combined Company will serve at the discretion of the Combined Company&#8217;s board of directors and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of the proposed Combined Company&#8217;s directors or executive officers. Although Karthik Musunuri, who is expected to serve on the board of directors of the Combined Company, is the son of Shankar Musunuri, a current member of the board of directors of OrthoCellix, Shankar Musunuri is expected to resign from his position as a director of OrthoCellix effective as of the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of Carisma&#8217;s current directors are expected to resign from their positions as directors of Carisma effective as of the closing of the Merger, except for Steven Kelly, who is expected to continue on the board of directors of the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the name, age as of July&#160;21, 2025 and position of each of the individuals who are expected to serve as executives and directors of the Combined Company following completion of the Merger:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:56%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td></tr><tr><td style="vertical-align:top;width:30%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">Executive Officers:</i></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Kelly</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">60</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Natalie McAndrew</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">51</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vice President of Finance (principal financial officer and principal officer)</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">Non-Employee Directors:</i></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Karthik Musunuri</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">31</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Shine, MBA</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">61</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">David Anderson</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">72</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:30%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Executive Officers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please see Proposal No. 3 on page 240 for the biographical information about Steven Kelly. Please also see &#8220;<i style="font-style:italic;">Carisma Executive Officers, Directors and Corporate Governance</i>&#8221; on page 203 for biographical information about Natalie McAndrew.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Non-employee Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Karthik Musunuri</span> is the son on Shankar Musunuri and is the Founder and Chief Executive Officer of Avstera Therapeutics Corp. (&#8220;Avstera&#8221;), a biotechnology company headquartered in Malvern, Pennsylvania. He has served in this role since January 2022. Prior to his role at Avstera, he served as the Founder and Chief Executive Officer Advaite Inc., which focused on developing novel therapeutics and diagnostics to help patients suffering from a variety of debilitating diseases, primarily within the oncology space, from December 2019 through January 2022. Mr. Musunuri currently serves on the boards of The Ark Institute in Philadelphia and the Musunuri Family Foundation, and participates in multiple advisory committees within BIO, the leading biotechnology trade organization based in Washington, D.C. In addition to his executive and advisory roles, Mr. Musunuri is a co-author on several peer-reviewed publications in high-impact scientific journals and a named inventor on multiple patents covering therapeutic and biological innovations. Mr. Musunuri received his Bachelor of Science in pharmaceutical and healthcare marketing from St. Joseph&#8217;s University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix believes Mr. Musunuri&#8217;s extensive experience in the biotech industry provides him with the qualifications and skills to serve on the Combined Company&#8217;s board of directors.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">336</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Michael Shine, MBA </span>was most recently the SVP, Commercial at Ocugen from June&#160;2021 to June&#160;2025. He has extensive pharmaceutical and biotechnology executive experience with 40&#160;years of diverse leadership roles in biotech, pharmaceuticals and healthcare products. Over the course of his career, Mr.&#160;Shine has held commercial and operational leadership positions within pharmaceutical companies, including Colgate Oral Pharmaceuticals and Pfizer Vaccines (formerly Wyeth). He also served as Chief Marketing Officer at Thomson Reuters and spent more than eight&#160;years in the start-up pharmaceutical space as the founder and former Chief Executive Officer of Novapharm Therapeutics from September&#160;2012 to June&#160;2021. Mr.&#160;Shine holds a Master of Business Administration from Villanova University, and a Bachelor of Science in business administration from the University of Scranton.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix believes Mr.&#160;Shine&#8217;s operational and commercial expertise provide him with the qualifications and skills to serve on the Combined Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">David Anderson </span>is the Chief Executive Officer of Cambridge Orthopaedic Labs. He has served in this role since January&#160;2021. Prior to his role at Cambridge Orthopaedic Labs, he served as the Chief Executive Officer of Braintemp,&#160;Inc. from October&#160;2017 through December&#160;2020. He currently serves on the board of directors and is a member of the compensation committee of Fesarius Technologies. He also serves as a director of ZSX Medical. He previously served on the board of directors and was chair of the audit committee of Longevity Health Holdings&#160;Inc. (Nasdaq: XAGE) from 2022 through 2024 and KORU Medical Systems&#160;Inc. (Nasdaq: KRMD) from 2016 through 2021. Mr.&#160;Anderson holds a Bachelor of Science in chemical engineering from Cornell University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix believes Mr.&#160;Anderson&#8217;s extensive experience as an executive officer in the orthopaedic&#8217;s space provides him with the qualifications and skills to serve on the Combined Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Composition of the Board of Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s board of directors currently consists of seven members, divided into three staggered classes, with one class to be elected at each annual meeting to serve for a three-year term. The Combined Company&#8217;s board of directors will initially be fixed at six members, consisting of five members designated by OrthoCellix: Michael Shine, Karthik Musunuri, David Anderson, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and one member designated by Carisma: Steven Kelly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The staggered structure of the board of directors will remain in place for the Combined Company following the completion of the Merger, with Class&#160;I directors holding terms expiring at the 2027 annual meeting of stockholders, Class&#160;II directors holding terms expiring at the 2028 annual meeting of stockholders and Class&#160;III directors holding terms expiring at the 2026 annual meeting of stockholders. It is anticipated that the incoming directors will be appointed to classes of the Combined Company board of directors following the completion of the Merger as follows: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are expected to be Class&#160;I directors; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are expected to be Class&#160;II directors; and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are expected to be Class&#160;III directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company will be a &#8220;controlled company&#8221; within the meaning of the Nasdaq Listing Rules&#160;and may elect not to comply with certain corporate governance standards. While the Combined Company does not presently intend to rely on these exemptions, the Combined Company may opt to utilize these exemptions in the future as long as it remains a controlled company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Director Independence</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nasdaq listing rules&#160;have objective tests and a subjective test for determining who is an &#8220;independent director.&#8221; The subjective test states that an independent director must be a person who lacks a relationship that, in the opinion of the board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating committees must be independent, and audit and compensation committee members must satisfy additional independence criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Based on information provided by each proposed director concerning her or his background, employment and affiliations, Carisma and OrthoCellix expect that the Combined Company&#8217;s board of directors will determine that Michael Shine, David Anderson, Karthik Musunari,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;qualify as &#8220;independent directors&#8221; as defined under Nasdaq listing rules. Steven Kelly, Carisma&#8217;s current President and Chief Executive Officer, and the expected President and Chief Executive Officer of the Combined Company, will not qualify as an independent director of the Combined Company. In making these determinations, the Combined Company&#8217;s board of directors will consider the current and prior relationships that each director has with Carisma and OrthoCellix and all other facts and circumstances that the Combined Company&#8217;s board of directors deems relevant in determining the independence of each proposed director, including the interests of each Combined Company director in the Merger, any relevant </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">337</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">related party transactions and the beneficial ownership of securities of Carisma, OrthoCellix or the Combined Company by each Combined Company director. See also the sections titled &#8220;</span><i style="font-style:italic;">The Merger&#8201;&#8212;&#8201;Interests of OrthoCellix&#8217;s Directors and Executive Officers in the Merger</i>,&#8221; &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions of the Combined Company</i>&#8221; and &#8220;<i style="font-style:italic;">Principal Stockholder of OrthoCellix</i>&#8221; beginning on pages&#160;170,&#160;340&#160;and&#160;367, respectively, of this proxy statement/prospectus for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Board Leadership Structure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following the completion of the Merger, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;is expected to serve as Chair of the Combined Company&#8217;s board of directors (&#8220;Chair&#8221;). Although the Combined Company&#8217;s governance documents will not require that the Combined Company separate the Chief Executive Officer and Chair positions, Carisma and OrthoCellix believe that having the positions be separate is the appropriate leadership structure for the Combined Company at this time as it helps facilitate independent board oversight of management and allows the Chief Executive Officer to focus on strategy execution and managing the business while the Chair focuses on corporate governance and managing the Combined Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Carisma's board of directors and OrthoCellix&#8217;s board of directors recognize that, depending on future circumstances, other leadership models, such as combining the roles of Chief Executive Officer and Chair, might be appropriate. Accordingly, the Combined Company&#8217;s board may periodically review its leadership structure. At any time when a non-independent director is serving as Chair, it is anticipated that the independent directors of the Combined Company will designate a lead independent director to preside at all meetings of the board of directors of the Combined Company at which the Chair is not present, preside over executive sessions of the independent directors, which will occur regularly throughout each&#160;year, serve as a liaison between the Chair and independent directors, and perform such additional duties as the Combined Company&#8217;s board of directors may otherwise determine and delegate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Board Committees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following the completion of the Merger, Carisma and OrthoCellix anticipate that the Combined Company&#8217;s board of directors will establish an audit committee, a compensation committee and a nominating and governance committee (&#8220;governance committee&#8221;), each of which will operate pursuant to a charter adopted by the board of directors of the Combined Company. Carisma and OrthoCellix believe that following the completion of the Merger the functioning and composition of these committees of the Combined Company will comply with the requirements of Nasdaq listing rules&#160;and SEC rules&#160;and regulations. The board of directors of the Combined Company may also establish other committees from time to time to assist the Combined Company and its board of directors. Each of the audit committee, compensation committee and the governance committee is expected to have the responsibilities described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Audit Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following the completion of the Merger, the members of the Combined Company&#8217;s audit committee are expected to be&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, each of whom is expected to qualify as an independent director for audit committee purposes as defined under the rules&#160;of the SEC and the applicable Nasdaq listing rules&#160;and has sufficient knowledge in financial and auditing matters to serve on the Combined Company&#8217;s audit committee. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;is expected to chair the audit committee. In addition, the Combined Company&#8217;s board of directors is expected to determine that&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;is an &#8220;audit committee financial expert&#8221; as defined under the rules&#160;of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The primary responsibilities of the Combined Company&#8217;s audit committee will be to oversee the Combined Company&#8217;s accounting and financial reporting processes, including the audits of the financial statements, and the internal and external audit processes. The audit committee will oversee the system of internal controls established by management and the Combined Company&#8217;s compliance with legal and regulatory requirements. The audit committee will also be responsible for the review, consideration and approval or ratification of related party transactions. The audit committee will oversee the independent auditors, including their independence and objectivity. The audit committee will be empowered to retain outside legal counsel and other advisors as it deems necessary or appropriate to assist it in fulfilling its responsibilities and to approve the fees and other retention terms of the advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compensation Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the consummation of the Merger, the members of the Combined Company&#8217;s compensation committee are expected to be&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, each of whom is expected to qualify as an independent director for compensation committee purposes as defined under the rules&#160;of the SEC and the applicable Nasdaq listing rules. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; is expected to chair the compensation committee.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">338</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The primary responsibilities of the Combined Company&#8217;s compensation committee will be to periodically review and approve the compensation and other benefits for the Combined Company&#8217;s senior officers and directors. This will include reviewing and approving corporate goals and objectives relevant to the compensation of the Combined Company&#8217;s executive officers, evaluating the performance of these officers in light of the goals and objectives and setting the officers&#8217; compensation. The compensation committee will also administer and make recommendations to the Combined Company&#8217;s board of directors regarding equity incentive plans that are subject to the board of directors&#8217; approval and approve the grant of equity awards under the plans to executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governance Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the consummation of the Merger, the members of the Combined Company&#8217;s governance committee are expected to be&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, each of whom is expected to qualify as an independent director as defined under applicable Nasdaq listing rules. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; is expected to chair the governance committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s governance committee will be responsible for engaging in succession planning for the Combined Company&#8217;s board of directors, developing and recommending to the Combined Company&#8217;s board of directors criteria for identifying and evaluating qualified director candidates and making recommendations to the Combined Company&#8217;s board of directors regarding candidates for election or reelection to the Combined Company&#8217;s board of directors at each annual stockholders&#8217; meeting. In addition, the governance committee will be responsible for overseeing corporate governance matters. The governance committee will also be responsible for overseeing the structure, composition and functioning of the Combined Company&#8217;s board of directors and its committees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Compensation Committee Interlocks and Insider Participation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None of the expected members of the Combined Company&#8217;s compensation committee has at any time been one of the officers or employees of the Combined Company. None of the Combined Company&#8217;s expected executive officers currently serves, or in the past fiscal&#160;year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers that is or are expected to serve on the Combined Company&#8217;s board of directors or compensation committee following the completion of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Conduct and Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the completion of the Merger, the Combined Company will adopt a Code of Conduct and Ethics that establishes the standards of ethical conduct applicable to all of the Combined Company&#8217;s directors, officers and employees. The full text of the Combined Company&#8217;s Code of Conduct and Ethics will be posted on the Combined Company&#8217;s website at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. It is expected to address, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting, external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. The Combined Company intends to disclose any amendments to the Code of Conduct and Ethics, or any waivers of its requirements, on its website to the extent required by applicable rules. The Combined Company&#8217;s audit committee will be responsible for applying and interpreting the Code of Conduct and Ethics in situations where questions are presented to it. Information contained on, or that can be accessed through, the Combined Company&#8217;s website is not incorporated by reference into this proxy statement/prospectus, and you should not consider information on the Combined Company&#8217;s website to be part of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">339</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_cd229337_9dfa_4394_93aa_bdc6b1bac39b"></a><a id="CERTAINRELATIONSHIPSANDRELATEDPARTYTRANS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following information and all other information contained in this proxy statement/prospectus does not give effect to the contemplated reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with Carisma&#8217;s and OrthoCellix&#8217;s directors and executive officers, including those discussed in the sections titled &#8220;<i style="font-style:italic;">Management Following the Merger</i>&#8221;, &#8220;<i style="font-style:italic;">Carisma Executive Compensation</i>&#8221; and &#8220;<i style="font-style:italic;">OrthoCellix Executive Compensation</i>&#8221; beginning on pages&#160;336, 211 and 229, respectively, of this proxy statement/prospectus, the following is a description of each transaction involving Carisma since January&#160;1, 2023, each transaction involving OrthoCellix since February&#160;28, 2025 (inception) and each currently proposed transaction in which:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amounts involved exceeded or will exceed the lesser of $120,000 and 1.0% of the average of Carisma&#8217;s or OrthoCellix&#8217;s total assets at&#160;year-end for the last two completed fiscal&#160;years, as applicable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any of Carisma&#8217;s or OrthoCellix&#8217;s directors, executive officers or holders of more than 5.0% of Carisma&#8217;s or OrthoCellix&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OrthoCellix&#8217;s Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Asset Contribution Agreement between OrthoCellix and Ocugen</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2025, OrthoCellix entered into an asset contribution agreement with Ocugen pursuant to which Ocugen agreed to contribute to OrthoCellix, and OrthoCellix agreed to acquire from Ocugen, all of its rights, title and interest in and to, and obligations and liabilities associated with, NeoCart. As consideration, OrthoCellix granted Ocugen 1,000 shares of OrthoCellix&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">OrthoCellix Transition Services Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ocugen and OrthoCellix will enter into the&#160;TSA pursuant to which Ocugen will provide, or cause its affiliates to provide, OrthoCellix with certain services to help facilitate an orderly transition of the NeoCart program, including the provision of assistance with respect to clinical operations, regulatory affairs, research and development, finance and accounting, information technology and human resources. The&#160;TSA&#160;will specify the fees payable for these services, which will be provided&#160;at varied hourly rates, which OrthoCellix anticipates will be in excess of $120,000 per annum.&#160;The&#160;TSA&#160;terminates on the end date of the last service provided under it, unless otherwise terminated earlier by either party under certain circumstances, including in the event of an uncured material breach by the other party or in the event of insolvency of the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">OrthoCellix Manufacturing Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ocugen and OrthoCellix will enter into the OrthoCellix Manufacturing Agreement pursuant to which Ocugen will continue to manufacture and supply NeoCart to OrthoCellix until completion or cessation of the Phase 3 clinical trial, unless extended by the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fee that Ocugen charges OrthoCellix for the provision of such manufacturing and supply services is based on its fully loaded cost of performance determined in accordance with Ocugen&#8217;s then current accounting standards included, plus a reasonable arm&#8217;s length mark-up. In the event the parties mutually agree to modify the work plan under the OrthoCellix Manufacturing Agreement to increase Ocugen&#8217;s performance thereunder, the parties will negotiate in good faith, including to reflect any adjustments necessary to account for such increased costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Carisma&#8217;s Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Legacy Carisma Pre-Closing Financing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Immediately prior to the effective time of Sesen Bio Merger on March&#160;7, 2023, Legacy Carisma (known prior to the Legacy Carisma Merger as Sesen Bio,&#160;Inc.) issued an aggregate of 1,964,101 shares of Legacy Carisma common stock at a price per share of $15.60 in cash, for an aggregate purchase price of approximately $30.6&#160;million pursuant to an Amended and Restated Subscription </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">340</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Agreement, dated as of December&#160;29, 2022 (the &#8220;Legacy Carisma Subscription Agreement&#8221;), between Legacy Carisma and certain investors named therein (the &#8220;Legacy Carisma Pre-Closing Financing&#8221;). All of the shares of Legacy Carisma common stock issued in the Legacy Carisma Pre-Closing Financing were exchanged into shares of our common stock at the effective time of the Legacy Carisma Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the aggregate number of shares of the Legacy Carisma common stock that were issued and sold to our directors, executive officers and then holders of more than 5.0% of our voting securities and their affiliates in the Legacy Carisma Pre-Closing Financing and the aggregate amount of consideration for such shares:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Purchaser</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Purchase&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">AbbVie Biotechnology Ltd</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">243,590</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,800,004.00</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">HealthCap VII L.P.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">303,205</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,729,998.00</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">SymBiosis II, LLC</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">205,128</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,199,996.80</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Wellington Life Sciences V GmbH &amp; Co. KG</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">211,538</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,299,992.80</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">See the &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Principal Stockholders of Carisma</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; section on page&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">365</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus for additional information about securities held by certain of these entities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Legacy Carisma Registration Rights Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;7, 2023, in connection with the consummation of the Legacy Carisma Pre-Closing Financing, Legacy Carisma and the investors party to the Legacy Carisma Subscription Agreement entered into a Registration Rights Agreement, pursuant to which Legacy Carisma (i)&#160;agreed to register for resale the shares issued in the Legacy Carisma Pre-Closing Financing, and (ii)&#160;provided the investors party to the Legacy Carisma Subscription Agreement (a)&#160;the right to require the company to register additional shares held by such investors under specified circumstances and (b)&#160;the right to participate in future registrations of securities by the company under specified circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Moderna Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2022, Carisma entered into a Collaboration and License Agreement (the &#8220;Moderna Collaboration Agreement&#8221;), with Moderna providing for a broad strategic partnership to discover, develop and commercialize <i style="font-style:italic;">in vivo</i> engineered CAR-M therapeutics for up to 12 oncology programs. Moderna is a holder of 5.0% or more of our voting securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Moderna Collaboration Agreement, Carisma received a $45.0&#160;million up-front cash payment. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, Carisma is also eligible to receive up to between $247.0&#160;million and $253.0&#160;million per product in development target designation, development, regulatory and commercial milestone payments. In addition, Carisma is eligible to receive mid to-high-single digit tiered royalties on net sales of any products that are commercialized under the agreement, which may be subject to reductions. Moderna has also agreed to cover the cost of certain milestone payments and royalties Carisma owes to a licensor under one of its intellectual property in-license agreements that Carisma is sublicensing to Moderna under the Moderna Collaboration Agreement, which royalties Moderna may deduct in part from any royalties owed to Carisma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of February&#160;2025, Moderna has nominated all 12 oncology research targets under the Moderna Collaboration Agreement. To date, Moderna has designated one research target as a development target. Carisma will not conduct any additional research activities under the Moderna License Agreement and Carisma will not be receiving any further research funding from Moderna under the Moderna License Agreement. Carisma received the final research and development payment of $2.9 million from Moderna in January&#160;2025. Carisma received total research and development payments of $29.0 million from Moderna from January&#160;1, 2023 through January&#160;2025. In June&#160;2024, we announced that Moderna nominated the first development candidate under the collaboration and paid us a $2.0 million milestone.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">341</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Former Director Affiliations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some of our former directors are or were affiliated or associated with entities which beneficially own or owned 5.0% or more of our voting securities as indicated in the table below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:99.53%;"><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Directors</b></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:48.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Principal&#160;Stockholder</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Regina Hodits, Ph.D.</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wellington Life Sciences V GmbH &amp; Co. KG</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Bj&#246;rn Odlander, M.D., Ph.D.</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HealthCap VII L.P.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Indemnification Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our certificate of incorporation limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the DGCL, and provides that no director will have personal liability to us or to our stockholders for monetary damages for breach of fiduciary duty as a director. In addition, we have entered into indemnification agreements with each of our directors and executive officers. Each indemnification agreement provides for indemnification and advancements by the company of certain expenses and costs relating to claims, suits or proceedings arising from each individual&#8217;s service to the company as an officer or director, as applicable, to the maximum extent permitted by applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Carisma&#8217;s Policies and Procedures for Related Person Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has adopted written policies and procedures for the review of any transaction, arrangement or relationship in which our company is a participant, the amount involved exceeds $120,000 and one of our executive officers, directors, director nominees or 5.0% stockholders, or their immediate family members, each of whom we refer to as a &#8220;related person,&#8221; has a direct or indirect material interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a related person proposes to enter into such a transaction, arrangement or relationship, which we refer to as a &#8220;related person transaction,&#8221; the related person must report the proposed related person transaction to our principal financial officer or general counsel, if any. The policy calls for the proposed related person transaction to be reviewed and, if deemed appropriate, approved by our audit committee. Whenever practicable, the reporting, review and approval will occur prior to entry into the transaction. If advance review and approval is not practicable, the audit committee will review, and, in its discretion, may ratify the related person transaction. The policy also permits the chair of the audit committee to review and, if deemed appropriate, determine whether to approve proposed related person transactions that arise between committee meetings, subject to ratification by the committee at its next meeting. Any related person transactions that are ongoing in nature will be reviewed annually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A related person transaction reviewed under the policy will be considered approved or ratified if it is authorized by the audit committee after full disclosure of the related person&#8217;s interest in the transaction. As appropriate for the circumstances, the audit committee will review and consider:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the related person&#8217;s interest in the related person transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approximate dollar value of the amount involved in the related person transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approximate dollar value of the amount of the related person&#8217;s interest in the transaction without regard to the amount of any profit or loss;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether the transaction was undertaken in the ordinary course of our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether the terms of the transaction are no less favorable to us than terms that could have been reached with an unrelated third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the purpose of, and the potential benefits to us of, the transaction; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any other information regarding the related person transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular transaction.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">342</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our audit committee may approve or ratify the transaction only if it determines that, under all of the circumstances, the transaction is in, or is not inconsistent with, our best interests. Our audit committee may impose any conditions on the related person transaction that it deems appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the transactions that are excluded by the instructions to the SEC&#8217;s related person transaction disclosure rule, our board of directors has determined that the following transactions do not create a material direct or indirect interest on behalf of related persons and, therefore, are not related person transactions for purposes of this policy:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interests arising solely from the related person&#8217;s position as an executive officer of another entity, whether or not the person is also a director of the entity, that is a participant in the transaction where the related person and all other related persons own in the aggregate less than a 10.0% equity interest in such entity, the related person and such person&#8217;s immediate family members are not involved in the negotiation of the terms of the transaction and do not receive any special benefits as a result of the transaction and the amount involved in the transaction is less than the greater of $200,000 or 5.0% of the annual gross revenues of the company receiving payment under the transaction; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a transaction that is specifically contemplated by provisions of our certificate of incorporation or by-laws.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The policy provides that transactions involving compensation of executive officers shall be reviewed and approved by our compensation committee in the manner specified in the compensation committee&#8217;s charter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">343</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4bb7d097_5d7b_4167_a99f_5b284a3ab921"></a><a id="UNAUDITEDPROFORMACONDENSEDCOMBINEDFINANC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Defined terms included below shall have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On June 22, 2025, Carisma Therapeutics Inc., a Delaware corporation, (&#8220;Carisma&#8221; or the &#8220;Parent&#8221;), its wholly owned subsidiary, Azalea Merger Sub, Inc., a Delaware corporation, (&#8220;Merger Sub&#8221;),  Ocugen, Inc., a Delaware corporation (&#8220;Ocugen&#8221;)  and its wholly owned subsidiary OrthoCellix, Inc., a Delaware corporation, (&#8220;OrthoCellix&#8221;), entered into an Agreement and Plan of Merger, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Agreement, Merger Sub will merge with and into OrthoCellix (the &#8220;Merger&#8221;), with OrthoCellix surviving as a wholly owned subsidiary of Carisma. The Merger is expected to close early in the fourth quarter of 2025 following the effectiveness of this registration statement and receipt of approval by the stockholders of each of OrthoCellix and Carisma. In connection with the Merger, the sole stockholder of OrthoCellix will receive shares of common stock of Carisma. Carisma following the Merger is referred to herein as the &#8220;Combined Company.&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the effective time of the Merger (the &#8220;Effective Time&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement, each share of common stock of OrthoCellix shall be converted into the right to receive a number of shares of common stock of Carisma equal to the Exchange Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Exchange Ratio is currently estimated to be approximately 327,677.6433 shares of Carisma common stock for each share of OrthoCellix common stock on the Closing Date. Under the Exchange Ratio formula, immediately after the Merger and the anticipated Concurrent Financing, Carisma securityholders as of immediately prior to the Merger are expected to own approximately 10% of the outstanding shares of the Combined Company on a fully-diluted basis and Ocugen, the sole stockholder of OrthoCellix, along with the other investors in the anticipated Concurrent Financing are expected to own approximately 90% of the outstanding shares of the Combined Company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Carisma&#8217;s Net Cash (as defined in the Merger Agreement) as of closing of the Merger being approximately $0 and the anticipated Concurrent Financing Amount of $25.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The following unaudited pro forma condensed combined financial information gives effect to the Merger, which, is expected to be accounted for as a reverse recapitalization under GAAP, as well as the Concurrent Financing. For further details related to the accounting for the Merger, please see Notes 1 and 3 below. All share amounts have been adjusted to reflect the estimated Exchange Ratio of 327,677.6433  shares of Carisma common stock for each share of OrthoCellix common stock, unless otherwise stated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined balance sheet combines the historical balance sheets of Carisma and OrthoCellix as of March 31, 2025. The pro forma condensed combined balance sheet depicts the accounting of the transactions prepared pursuant to Article 11 of Regulation S-X (the &#8220;pro forma balance sheet transaction accounting adjustments&#8221;). All transaction accounting adjustments and financing accounting adjustments on the pro forma balance sheet and pro forma statements of operations are collectively referred to as the &#8220;transaction accounting adjustments&#8221; or &#8220;pro forma adjustments.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These unaudited pro forma condensed combined financial information and related notes have been derived from and should be read in conjunction with:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical audited combined financial statements of the NeoCart Business of Ocugen (the &#8220;NeoCart Business&#8221; or &#8220;OrthoCellix, Inc.&#8221;) for the year ended December 31, 2024, and the related notes included elsewhere in this proxy statement/prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical audited consolidated financial statements of Carisma for the year ended December 31, 2024, and the related notes included elsewhere in this proxy statement/prospectus&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical unaudited combined financial statements of the NeoCart Business as of and for the three months ended March 31, 2025, and the related notes included elsewhere in this proxy statement/prospectus;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">344</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical unaudited consolidated financial statements of Carisma as of and for the three months ended March 31, 2025, and the related notes included elsewhere in this proxy statement/prospectus; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sections titled &#8220;Carisma&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; &#8220;OrthoCellix&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation,&#8221; and other financial information relating to Carisma and OrthoCellix included elsewhere in this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and pro forma adjustments that are described in the accompanying notes. The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed including but not limited to additional financing, additional direct and incremental offering costs and a contemplated reverse stock split. Adjustments have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting, expected to be completed after the closing of the Merger, may occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial information is not necessarily indicative of the financial position or results of operations in the future periods or the result that actually would have been realized had Carisma and OrthoCellix been a combined organization during the specified periods. The actual results reported in periods following the Merger may differ significantly from those reflected in the unaudited condensed combined pro forma financial information presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this unaudited pro forma condensed combined financial information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">345</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS OF MARCH 31, 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Historical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carisma</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Therapeutics</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Inc.&#160;(1A)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OrthoCellix,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Inc.&#160;(1B)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Accounting</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financing</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Accounting</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro&#160;Forma</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Cash and cash equivalents</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">(8,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(1D, 1E)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(1F)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Asset held for sale</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Total current assets</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">(8,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Right of use assets - operating leases</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred financing costs</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Total assets</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">(8,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">32,603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; (Deficit) Equity</b></p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Accounts payable</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Accrued expenses</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Deferred revenue</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Operating lease liabilities</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Finance lease liabilities</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Other current liabilities</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">853</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">853</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Total current liabilities</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred revenue</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease liabilities</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Finance lease liabilities</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other long-term liabilities</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Total liabilities</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">52,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">52,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stockholders&#8217; (deficit) equity:</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Carisma&#8217;s preferred stock, $0.001 par value</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Carisma&#8217;s common stock, $0.001 par value</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(1C)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(1F)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Additional paid-in capital</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">278,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">(323,523)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(1C, 1E)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(1F)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">(20,455)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Accumulated deficit</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">(314,845)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">314,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(1C, 1D)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total stockholders&#8217; (deficit) equity</p></td><td style="vertical-align:top;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">(36,662)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">(8,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">(20,012)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total liabilities and Stockholders&#8217; (deficit) equity</p></td><td style="vertical-align:top;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">(8,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">32,603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to the unaudited pro forma condensed combined financial information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">346</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR THE YEAR ENDED DECEMBER 31, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Historical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carisma</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Therapeutics</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Inc.&#160;(2A)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OrthoCellix,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Inc.&#160;(2B)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Accounting</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro&#160;Forma</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">59,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">60,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(2C)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">81,811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">85,480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(62,179)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,026)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,643)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(65,848)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(60,477)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,026)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,643)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(64,146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41,456,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(2D)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">443,606,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1.46)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to the unaudited pro forma condensed combined financial information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">347</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR THE THREE MONTHS ENDED MARCH 31, 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.018520355%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.92%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Historical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carisma</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Therapeutics</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Inc.&#160;(3A)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OrthoCellix,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Inc.&#160;(3B)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Accounting</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro&#160;Forma</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;background:#cceeff;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,334)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,604)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,266)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,536)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41,771,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(3C)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">443,921,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.3%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.02)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">See accompanying notes to the unaudited pro forma condensed combined financial information<br/><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">348</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="NOTESTOUNAUDITEDPROFORMACONDENSEDCOMBINE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Description of the Merger</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2025, Carisma Therapeutics Inc., a Delaware corporation, (&#8220;Carisma&#8221; or the &#8220;Parent&#8221;), its wholly owned subsidiary, Azalea Merger Sub, Inc., a Delaware corporation, (&#8220;Merger Sub&#8221;), OrthoCellix, Inc., a Delaware corporation, (&#8220;OrthoCellix&#8221;), and Ocugen, Inc., a Delaware corporation, (&#8220;Ocugen&#8221;) entered into an Agreement and Plan of Merger (&#8220;Merger Agreement&#8221;), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Agreement, Merger Sub will merge with and into OrthoCellix (the &#8220;Merger&#8221;), with OrthoCellix surviving as a wholly owned subsidiary of Carisma. The Merger is expected to close early in the fourth quarter of 2025 following the effectiveness of this registration statement and receipt of approval by the stockholders of each of OrthoCellix and Carisma. In connection with the Merger, the sole stockholder of OrthoCellix will receive shares of common stock of Carisma. Subject to the terms and conditions of the Merger Agreement, at closing of the Merger (the &#8220;Closing&#8221;), each share of common stock of OrthoCellix shall be converted into the right to receive number of shares of common stock of Carisma equal to the Exchange Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each share of OrthoCellix common stock issued and outstanding immediately prior to the Effective Time shall be converted into and become exchangeable for the right to receive a number of shares of Carisma common stock equal to the Exchange Ratio (the &#8220;Merger Consideration&#8221;). As of the Effective Time, all such shares of OrthoCellix common stock shall no longer be outstanding and shall automatically be cancelled and shall cease to exist and shall thereafter only represent the right to receive the Merger Consideration. Immediately following the Merger, and after giving effect to the anticipated $25.0 million Concurrent Financing: (a) Carisma securityholders as of immediately prior to the Merger are expected to own approximately 10% of the outstanding capital stock of the Combined Company on a fully diluted basis (excluding certain Carisma options), (b) the OrthoCellix sole stockholder, Ocugen, as of immediately prior to the Merger (but excluding for this purpose any shares purchased by Ocugen in the Concurrent Financing) is expected to own approximately 73.3% of the outstanding capital stock of the Combined Company on a fully diluted basis (excluding certain Carisma options), and (c) the investors in the Concurrent Financing (including for this purpose shares purchased in the Concurrent Financing by Ocugen) are expected to own approximately 16.7% of the outstanding capital stock of the Combined Company on a fully diluted basis, in each case, subject to certain assumptions, including, but not limited to, Carisma&#8217;s Net Cash as of the closing of the Merger being approximately $0.0 and the anticipated Concurrent Financing Amount of $25.0 million. Carisma is also scheduled to hold a separate special meeting of Carisma stockholders on August 5, 2025 to approve an amendment to Carisma&#8217;s certificate of incorporation to effect a reverse stock split of Carisma&#8217;s issued and outstanding common stock at a ratio of not less than 1-for-10 and not greater than 1-for-50, with the exact ratio within such range to be determined at the discretion of Carisma&#8217;s board of directors, without further approval or authorization of Carisma&#8217;s stockholders (the &#8220;reverse stock split&#8221;). No adjustment has been made to the pro forma financial information herein for the contemplated reverse stock split but certain notes include pro forma ranges of shares based on the range of potential outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Value Rights Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At or prior to the closing of the Merger, Carisma is expected to enter into a Contingent Value Rights Agreement (&#8220;CVR Agreement&#8221;) with a designated rights agent (the &#8220;Rights Agent&#8221;), pursuant to which each holder of record of shares of Carisma&#8217;s common stock before the Merger will receive the right to one contingent value right (each, a &#8220;CVR&#8221;) for each outstanding share of Carisma&#8217;s common stock held by such stockholder on such date. Each CVR will represent the contractual right to receive a contingent cash payment equal to (i) the Net Proceeds (as defined in the CVR Agreement) received by Carisma to the extent such payment related to the disposition of any Carisma Legacy Assets (as defined in the CVR Agreement) during the period beginning on the execution date of the Merger Agreement and ending on the second anniversary of the Closing, if any, plus (ii) the Net Proceeds received by Carisma to the extent such payment related to any royalties, milestones or other payments received by Carisma following the Closing under certain of Carisma&#8217;s existing agreements, including its collaboration and license agreement with ModernaTX, Inc., in each case subject to adjustment based on the terms and conditions set forth in the CVR Agreement. Consideration received by Carisma for the sale of assets prior to the Merger, would not results in a cash payment under the CVR. The CVR would apply to sales of assets subsequent to the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Management preliminarily concluded that these CVRs represent financial instruments that are to be accounted for under the fair value option election in <i style="font-style:italic;">ASC 825, Financial Instruments</i>. Under the fair value option election, the CVRs are initially measured at the aggregate estimated fair value of the CVRs and will be subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the CVR liability was determined using the discounted cash flow method to estimate future cash flows associated with Carisma&#8217;s legacy assets, including the expected milestone and royalty payments associated with Carisma&#8217;s legacy assets. Changes in fair value of the CVR liability, if any, are presented in the consolidated statements of operations </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">349</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and comprehensive income (loss). The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, and risk-adjustment discount rates, which represent a Level 3 measurement within the fair value hierarchy. Management has concluded that there is no value associated with the CVRs as the likelihood of any payments received in connection with Carisma&#8217;s legacy assets following the Closing is remote. Prior to the Closing, Carisma will seek to enter into a series of transactions with certain third parties to monetize certain legacy assets in accordance with the limitations and requirements set forth in the Merger Agreement, which would not result in a CVR payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anticipated Concurrent Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Subject to the terms of the Merger Agreement, Carisma and OrthoCellix will use commercially reasonable efforts to obtain investors (&#8220;Concurrent Investors&#8221;) to enter into a subscription agreement with Carisma (the &#8220;Subscription Agreement&#8221;), pursuant to which such investors will agree to subscribe for and purchase and Carisma will agree to issue and sell to investors concurrently with the Closing, an aggregate of up to 74,472,192 shares of Carisma common stock estimated at a price per share equal to $0.34, subject to adjustment as set forth in the Subscription Agreement. The price per share shall equal The Aggregate Valuation divided by the Post-Closing Carisma Shares, immediately following the Merger. Ocugen has agreed to purchase no less than $5.0 million of shares of Carisma common stock as a part of the Concurrent Financing.  The gross proceeds from the Concurrent Financing are anticipated to be approximately $25.0 million, before paying estimated expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The sole OrthoCellix stockholder is expected to receive approximately 342,572,082 shares of the Combined Company on a fully diluted basis in connection with the Concurrent Financing and the Merger (327,677,643 from the Merger, and 14,894,439 through the Concurrent Financing), based on the number of shares of Carisma common stock outstanding immediately prior to the Merger. These estimates are subject to certain inputs, which include, but are not limited to, Carisma&#8217;s Net Cash as of Closing being approximately $0 and the anticipated Concurrent Financing Amount of $25.0 million. The following table summarizes the pro forma number of shares of common stock of the Combined Company outstanding immediately following the consummation of the transactions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro&#160;Forma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Equity Capitalization Summary (fully diluted basis)</b><br/><b style="font-weight:bold;">Upon Consummation of the Merger and Concurrent Financing</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Shares&#160;Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;Ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Carisma stockholders<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">44,683,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">OrthoCellix stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">327,677,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">73.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Concurrent Investors<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(b)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">74,472,192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total common stock of the Combined Company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">446,833,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a) includes certain options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(b) includes OrthoCellix stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1) approval by Carisma stockholders of the issuance of Carisma common stock, (2) adoption of the Merger Agreement by the OrthoCellix stockholder, (3) Nasdaq&#8217;s approval of the listing of the shares of Carisma common stock to be issued in connection with the Merger, (4) Carisma&#8217;s Net Cash at the Closing being at least negative $1.0 million, and (5) the effectiveness of the registration statement of which this proxy statement/prospectus forms a part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The employment agreements for Carisma employees include entitlement to change in control payments for certain executives, which will be treated as pre-Merger compensation expense of Carisma and will be reflected as a reduction in Cash of Carisma, which will be assumed by the Combined Company at Closing to the extent they are not yet settled in cash beforehand by Carisma. Prior to the Closing, Carisma also has or expects to (i) discontinue its research and development activities, (ii) close out of all contracts related to Carisma&#8217;s clinical trial, and (iii) terminate its office space leases.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Basis of Presentation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X. The adjustments presented in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an understanding of the Combined Company upon consummation of the Merger.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">350</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and adjustments that are described in the accompanying notes. Accordingly, the pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary accounting conclusions and estimates and the final accounting conclusions and amounts may occur as a result of, among other reasons: (i) changes in initial assumptions in the determination of the accounting acquirer and related accounting, (ii) changes in the amount of Carisma&#8217;s Net Cash to be assumed at the Closing Date, and (iii) other changes in Carisma&#8217;s assets and liabilities, and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information and the Combined Company&#8217;s future results of operations and financial position.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Accounting for the Merger</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information gives effect to the Merger, which will be accounted for under GAAP as a reverse recapitalization of Carisma by OrthoCellix, as the transaction is, in essence, the issuance of equity for Carisma&#8217;s net assets, which will primarily consist of nominal assets and liabilities at the time of close. Under this method of accounting, OrthoCellix will be considered the accounting acquirer for financial reporting purposes. This determination is based on the expectations that, immediately following the Merger:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The OrthoCellix stockholder (Ocugen) will own a substantial majority of the voting rights in the Combined Company&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The OrthoCellix stockholder (Ocugen) will retain a controlling interest in the Combined Company (73.3%)&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix will designate a majority of the initial members of the board of directors of the Combined Company&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OrthoCellix, Inc. will be the name used by the Combined Company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Merger is expected to be accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, OrthoCellix will be considered the accounting acquirer for financial reporting purposes. This determination was primarily based on the expectations that, immediately following the Merger: (i) OrthoCellix&#8217;s sole stockholder will own a substantial majority of the voting rights of the Combined Company and (ii) OrthoCellix will designate a majority of the initial members of the board of directors of the Combined Company. For accounting purposes, the Merger will be treated as the equivalent of OrthoCellix issuing stock to acquire the net assets of Carisma, which are expected to primarily consist of nominal non-operating assets and liabilities. Following the closing of the Merger, the net assets of Carisma will be recorded at their fair value, which is expected to approximate their carrying value, with no goodwill or other intangible assets recorded in the financial statements of OrthoCellix and the reported operating results prior to the Merger will be those of OrthoCellix.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Shares of Carisma Common Stock Issued to be Issued upon Closing of the Merger and the Concurrent Financing</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At Closing, all outstanding shares of OrthoCellix common stock, on a fully-diluted basis, will be exchanged for shares of Carisma common stock based on the preliminary estimated Exchange Ratio of 327,677.6433 shares of Carisma common stock for each share of OrthoCellix common stock, determined in accordance with the terms of the Merger Agreement. The estimated number of shares of Carisma common stock that Carisma expects to issue upon closing of the Merger and the Concurrent Financing is determined as follows:</p><a id="_Hlk203812135"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Orthocellix shares of common stock outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exchange Ratio</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 327,677.6433</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated shares of Carisma common stock to be issued to Ocugen in connection with the Merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">327,677,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated shares of Carisma common stock to be issued to Concurrent Investors (Including OrthoCellix Stockholders)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">74,472,192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Carisma common shares outstanding<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44,683,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated shares of Carisma common stock outstanding upon completion of the Merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">446,833,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Includes 2,895,219 Carisma options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The Exchange Ratio is subject to change based on Carisma&#8217;s Net Cash at closing, which is targeted at $0.  If Net Cash exceeds $0 at closing the Exchange Ratio would decrease, and if Net Cash is less than $0 at closing, the Exchange Ratio would increase. By way of </span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">351</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">example, if Net Cash is $1 million at closing, the ratio would decrease by 20,480 shares and if net cash is negative $1 million, the ratio would increase by 23,405 shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Below represents the above determination calculated in three scenarios with respect to the contemplated reverse stock split:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:10</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:50</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Orthocellix shares of common stock outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exchange Ratio</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">32,767.7643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,922.5881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,553.5529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated shares of Carisma common stock to be issued to Ocugen in connection with the Merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">32,767,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,922,588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,553,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated shares of Carisma common stock to be issued to Concurrent Investors (including OrthoCellix Stockholders)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,447,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,482,406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,489,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Carisma common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,468,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,489,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">893,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated shares of Carisma common stock outstanding upon completion of the Merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44,683,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,894,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,936,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of March 31, 2025</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(1A)&#160;&#160;Derived from the unaudited consolidated balance sheet of Carisma as of March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(1B)&#160;&#160;Derived from the unaudited balance sheet of OrthoCellix as of March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma Balance Sheet Transaction Accounting Adjustments:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:23.75pt;text-indent:-23.75pt;margin:0pt 0pt 12pt 18pt;">(1C)&#160;&#160;To reflect the recapitalization of OrthoCellix and the derecognition of the accumulated deficit of Carisma, which is reversed to additional paid-in capital, as well as the par value for the additional shares issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The derecognition of accumulated deficit of Carisma of $319.0 million is determined as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:26.26%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.78%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carisma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OrthoCellix</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.56%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.62%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Transaction Accounting Adjustments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(1C) (1E)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(1C) (1D)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">OrthoCellix transaction costs and severance payments (1D) (1E)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(4,531)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3,819)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Elimination of Carisma&#8217;s historical equity carrying value (1C)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(318,992)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">318,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total Adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.76%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(323,523)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">314,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:23.75pt;text-indent:-23.75pt;margin:0pt 0pt 12pt 18pt;">(1D)&#160;&#160;To reflect preliminary estimated incremental compensation expense related to severance and change in control payments recorded in general and administrative expenses of $3.8 million, resulting from pre-existing employment agreements or from approval from Carisma&#8217;s board of directors that will be incurred upon Closing as well as D&amp;O Tail policy expenses and auditor fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:23.75pt;text-indent:-23.75pt;margin:0pt 0pt 12pt 18pt;">(1E)&#160;&#160;To reflect preliminary estimated transaction costs of $4.5 million, not yet reflected in the historical financial statements, which are expected to be incurred by Carisma and OrthoCellix in connection with the Merger, such as advisory and legal expenses.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">352</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Pro forma Balance Sheet Financing Accounting Adjustments:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.35pt;text-indent:-27.35pt;margin:0pt 0pt 12pt 17.99pt;">(1F)&#160;&#160;&#160;To reflect the anticipated investment of $25.0 million that investors will agree to subscribe for and purchase a number of shares of Carisma common stock at the time of Closing, inclusive of par value. This amount is inclusive of the planned $5.0 million investment from Ocugen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 54pt;">See table below for all changes to Stockholders&#8217; Equity associated with the Financing Accounting Adjustments (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:25.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.29%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carisma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OrthoCellix</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.42%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.58%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:top;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Financing Accounting Adjustments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(1F)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(1F)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Concurrent Financing Transaction (1F)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">24,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.29%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.64%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">24,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.47%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 2.9pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations for the year ended December 31, 2024:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.8pt;text-indent:-28.8pt;margin:0pt 0pt 10pt 18pt;">(2A)&#160;&#160;&#160;Derived from the audited consolidated statement of operations and comprehensive loss of Carisma for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.8pt;text-indent:-28.8pt;margin:0pt 0pt 10pt 18pt;">(2B)&#160;&#160;&#160;Derived from the audited statement of operations and comprehensive loss of OrthoCellix for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">OrthoCellix and Carisma did not record any provision or benefit for income taxes during the year ended December 31, 2024 because each company incurred a pre-tax loss in 2024 and each company maintains a full valuation allowance on its deferred tax assets. Accordingly, no pro forma adjustments have an impact on associated income tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma Statements of Operations Transaction Accounting Adjustments:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.8pt;text-indent:-28.8pt;margin:0pt 0pt 10pt 18pt;">(2C)&#160;&#160;&#160;To reflect preliminary estimated incremental compensation expense related to severance and change in control payments recorded in general and administrative expenses of $2.6 million, resulting from pre-existing employment agreements or from approval from Carisma&#8217;s board of directors that will be incurred upon Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.8pt;text-indent:-28.8pt;margin:0pt 0pt 10pt 18pt;">(2D)&#160;&#160;The pro forma combined basic and diluted earnings per share of Carisma have been adjusted to reflect the pro forma net loss for the year ended December 31, 2024. In addition, the number of shares used to calculate the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the Combined Company that would be outstanding as of the date of the Merger Closing, including the shares to be issued in the Concurrent Financing, as if they have been outstanding for the entirety of the periods presented. For the year ended December 31, 2024, the pro forma weighted average shares outstanding has been calculated as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Carisma weighted average common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">41,456,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Shares issued in Merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">327,677,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Concurrent Investors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">74,472,192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">443,606,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">353</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table represents the pro forma weighted average shares outstanding calculated for three potential scenarios in the contemplated reverse stock split:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:10</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:50</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Carisma weighted average common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,145,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,381,874</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">829,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Shares issued in Merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">32,767,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,922,588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,553,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Concurrent Investors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,447,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,482,406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,489,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44,360,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,786,868</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,872,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table represents the pro forma net loss per share attributable to common stockholders calculated for three potential scenarios in the contemplated reverse stock split:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:10</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:50</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(64,146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(64,146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(64,146)</p></td></tr><tr><td style="vertical-align:bottom;width:64.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44,360,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,786,868</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,872,121</p></td></tr><tr><td style="vertical-align:bottom;width:64.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1.45)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(4.34)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(7.23)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations for the three months ended March 31, 2025:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.8pt;text-indent:-28.8pt;margin:0pt 0pt 10pt 18pt;">(3A)&#160;&#160;&#160;Derived from the unaudited consolidated statement of operations and comprehensive loss of Carisma for the three months ended March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.8pt;text-indent:-28.8pt;margin:0pt 0pt 10pt 18pt;">(3B)&#160;&#160;&#160;Derived from the unaudited statement of operations and comprehensive loss of OrthoCellix for the three months ended March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Pro forma Statements of Operations Transaction Accounting Adjustments:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.8pt;text-indent:-28.8pt;margin:0pt 0pt 10pt 18pt;">(3C)&#160;&#160;The pro forma combined basic and diluted earnings per share have been adjusted to reflect the pro forma net loss for the three months ended March 31, 2025. In addition, the number of shares used to calculate the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the Combined Company that would be outstanding as of the date of the Closing, including the shares to be issued in the Concurrent Financing, as if they have been outstanding for the entirety of the periods presented. For the three months ended March 31, 2025, the pro forma weighted average shares outstanding has been calculated as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:4pt;"><td style="vertical-align:bottom;width:83.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Carisma weighted average common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41,771,213</p></td></tr><tr><td style="vertical-align:bottom;width:83.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Shares issued in Merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">327,677,643</p></td></tr><tr><td style="vertical-align:bottom;width:83.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Concurrent Investors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">74,472,192</p></td></tr><tr><td style="vertical-align:bottom;width:83.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">443,921,048</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table represents the pro forma weighted average shares outstanding calculated for three potential scenarios in the contemplated reverse stock split:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:10</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:50</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Carisma weighted average common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,177,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,392,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">835,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Shares issued in Merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">32,767,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,922,588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,553,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Concurrent Investors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,447,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,482,406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,489,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44,392,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,797,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,878,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">354</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table represents the pro forma net loss per share attributable to Carisma&#8217;s common stockholders calculated for three potential scenarios in the contemplated reverse stock split:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.1111145%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:10</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1:50</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,536)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,536)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;width:9.73%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,536)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44,392,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,797,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,878,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.64)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1.07)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Aptos';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">355</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_87881b19_2afc_4989_bac8_3cad469220d0"></a><a id="DESCRIPTIONOFCARISMACAPITALSTOCK_276019"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DESCRIPTION OF CARISMA CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following description of the securities of Carisma&#8217;s capital stock is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, Carisma&#8217;s certificate of incorporation, its by-laws, and applicable provisions of the DGCL. You should read Carisma&#8217;s certificate of incorporation and by-laws, which are filed as exhibits to the registration statement of which this proxy statement/prospectus forms a part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Authorized Capital Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s authorized capital stock consists of 350,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share, all of which is undesignated. Carisma&#8217;s common stock is registered under Section&#160;12(b)&#160;of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights</i>. Each holder of common stock is entitled to one vote for each share held of record on all matters to be voted upon by stockholders, including the election of directors. Carisma&#8217;s certificate of incorporation and by-laws do not provide for cumulative voting rights. Except as otherwise provided by law, Carisma&#8217;s certificate of incorporation and by-laws, all matters other than the election of directors, shall be decided by the vote of the holders of shares of stock having a majority in voting power of the votes cast by the holders of all of the shares of stock present or represented by proxy at the meeting at which a quorum is present and voting affirmatively or negatively on such matter.&#160;Directors shall be elected by a plurality of the shares present in person or represented by proxy at a meeting at which a quorum is present and entitled to vote on the election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends</i>. Subject to the rights, powers and preferences of any outstanding preferred stock, and except as provided by law or in Carisma&#8217;s certificate of incorporation, dividends may be declared and paid or set aside for payment on the common stock out of legally available assets or funds when and as declared by the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation or Dissolution</i>. Subject to the rights, powers and preferences of any outstanding preferred stock, in the event of Carisma&#8217;s liquidation or dissolution, Carisma&#8217;s net assets will be distributed pro rata to the holders of Carisma&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Rights</i>. Holders of the common stock have no right to convert the stock into any other security, have the stock redeemed, purchase additional stock, or&#160;maintain their proportionate ownership interest. Holders of shares of the common stock are not required to make additional capital contributions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma is authorized to issue &#8220;blank check&#8221; preferred stock, which may be issued in one or more series upon authorization of Carisma&#8217;s board of directors. Carisma&#8217;s board of directors is authorized to fix the designations, powers, preferences and the relative, participating, optional or other special rights and any qualifications, limitations and restrictions of the shares of each series of preferred stock. The authorized shares of Carisma&#8217;s preferred stock are available for issuance without further action by Carisma&#8217;s stockholders, unless such action is required by applicable law or the rules&#160;of any stock exchange on which Carisma&#8217;s securities may be listed. If the approval of Carisma&#8217;s stockholders is not required for the issuance of shares of Carisma&#8217;s preferred stock, Carisma&#8217;s board of directors may determine not to seek stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Provisions of Carisma&#8217;s Certificate of Incorporation and By-Laws and Delaware Law That May&#160;Have Anti-Takeover Effects</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain provisions of Carisma&#8217;s certificate of incorporation and by-laws may have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, control of Carisma. Such provisions could limit the price that certain investors might be willing to pay in the future for shares of Carisma&#8217;s common stock and may limit the ability of stockholders to remove management or directors or approve transactions that stockholders may deem to be in their best interest and, therefore, could adversely affect the price of Carisma&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">No Cumulative Voting.</i>&#160;The DGCL provides that stockholders are not entitled to the right to accumulate votes in the election of directors unless <span style="color:#231f20;">Carisma&#8217;s </span>certificate of incorporation provides otherwise. Carisma&#8217;s certificate of incorporation does not provide for cumulative voting.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">356</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Board of Directors</i>. Carisma&#8217;s certificate of incorporation and by-laws provide for a board of directors divided as nearly equally as possible into three classes. Each class is elected to a term expiring at the annual meeting of stockholders held in the third&#160;year following the&#160;year of such election. The number of directors comprising <span style="color:#231f20;">Carisma&#8217;s </span>board of directors is fixed from time to time by the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Removal of Directors by Stockholders</i>. Carisma&#8217;s certificate of incorporation provides that members of Carisma&#8217;s board of directors may only be removed for cause by the affirmative vote of the holders of at least 75.0% of the outstanding shares entitled to vote on the election of the directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Board Vacancies Filled Only by Majority of Directors Then in Office</i>. Vacancies and newly created seats on <span style="color:#231f20;">Carisma&#8217;s </span>board may be filled only by a vote of a majority of <span style="color:#231f20;">Carisma&#8217;s </span>board of directors. Further, only Carisma&#8217;s board of directors may determine the number of directors on Carisma&#8217;s board. The inability of stockholders to determine the number of directors or to fill vacancies or newly created seats on the board makes it more difficult to change the composition of Carisma&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stockholder Nomination of Directors</i>. Carisma&#8217;s by-laws provide that a stockholder must notify us in writing of any stockholder nomination of a director not earlier than the 120th day and not later than on the 90th day prior to the first anniversary of the preceding&#160;year&#8217;s annual meeting; provided, that if the date of the annual meeting is advanced by more than 30&#160;days or delayed by more than 60&#160;days from such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the 120th day prior to the date of such annual meeting and not later than on the later of (x)&#160;the 90th day prior to the date of such annual meeting and (y)&#160;the 10th day following the day on which notice of the date of such annual meeting was given or public disclosure of the date of such annual meeting was made, whichever occurs first.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">No Action By Written Consent</i>. Carisma&#8217;s certificate of incorporation provides that its stockholders may not act by written consent and may only act at duly called meetings of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Super-Majority Voting.</i>&#160;Delaware law provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or by-laws unless a corporation&#8217;s certificate of incorporation or by-laws, as the case may be, requires a greater&#160;percentage. Carisma&#8217;s by-laws may be amended or repealed by a majority vote of Carisma&#8217;s board of directors or the affirmative vote of the holders of at least 75.0% of the votes that all Carisma stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75.0% of the votes that all Carisma&#8217;s stockholders would be entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of <span style="color:#231f20;">Carisma&#8217;s </span>certificate of incorporation described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Delaware Business Combination Statute.</i>&#160;Carisma is subject to Section&#160;203 of the DGCL (&#8220;Section&#160;203&#8221;), which prohibits a Delaware corporation from engaging in business combinations with an interested stockholder. An interested stockholder is generally defined as an entity or person beneficially owning 15.0% or more of the outstanding voting stock of the corporation or any entity or person affiliated with or controlling or controlled by such entity or person, or interested stockholder. Section&#160;203 provides that an interested stockholder may not engage in business combinations with the corporation for a period of three&#160;years after the date that such stockholder became an interested stockholder, with the following exceptions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85.0% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i)&#160;by persons who are directors and also officers and (ii)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">357</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, Section&#160;203 defines business combinations to include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any merger or consolidation involving the corporation and the interested stockholder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any sale, lease, transfer, pledge or other disposition of 10.0% or more of the assets of the corporation to or with the interested stockholder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">358</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c47c7aae_3ce4_4645_94d8_522e1824437e"></a><a id="COMPARISONOFRIGHTSOFHOLDERSOFCARISMACAPI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">COMPARISON OF RIGHTS OF HOLDERS OF CARISMA CAPITAL STOCK AND ORTHOCELLIX CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">If the Merger is completed, OrthoCellix&#8217;s sole stockholder will receive shares of Carisma common stock, pursuant to the terms of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Carisma is scheduled to hold a separate special meeting of Carisma stockholders on August&#160;5, 2025 to approve an amendment to Carisma&#8217;s certificate of incorporation to effect a reverse stock split of Carisma&#8217;s issued and outstanding common stock at a ratio of not less than 1-for-10 and not greater than 1-for-50, with the exact ratio within such range to be determined at the discretion of Carisma&#8217;s board of directors, without further approval or authorization of Carisma&#8217;s stockholders. No such amendment or any reverse stock split will occur until the amendment to Carisma&#8217;s certificate of incorporation to effect the reverse stock split is filed with the Secretary of State of the State of Delaware and becomes effective. In addition, after the completion of the Merger, Carisma&#8217;s certificate of incorporation then in effect will be amended to change its corporate name to &#8220;OrthoCellix,&#160;Inc.&#8221; Carisma and OrthoCellix are both incorporated under the laws of the State of Delaware. The rights of Carisma&#8217;s stockholders and OrthoCellix&#8217;s sole stockholder are generally governed by the DGCL. Upon completion of the Merger, OrthoCellix&#8217;s sole stockholder will become a stockholder of Carisma, and its rights will be governed by the DGCL, the by-laws of Carisma and the certificate of incorporation of Carisma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The material differences between the current rights of OrthoCellix&#8217;s sole stockholder under the OrthoCellix certificate of incorporation and by-laws and its rights as a stockholder of Carisma after the Merger, under Carisma&#8217;s certificate of incorporation and Carisma&#8217;s by-laws, both as will be in effect immediately following the completion of the Merger, are summarized below. The summary below does not purport to be complete and is subject to, and qualified in its entirety by reference to, the DGCL and the governing corporate instruments that are subject to amendment in accordance with their terms. You should carefully read this entire document and the other referenced documents, including the governing corporate instruments, for a more complete understanding of the differences between being a stockholder of Carisma or OrthoCellix before the Merger and being a stockholder of the Combined Company following the completion of the Merger. For more information on how to obtain these documents, see the section titled &#8220;<i style="font-style:italic;">Where You Can Find More Information</i>&#8221; beginning on page&#160;372 of this proxy statement/prospectus.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Carisma</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">OrthoCellix</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Organizational Documents</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">The rights of Carisma&#8217;s stockholders are governed by Carisma&#8217;s certificate of incorporation, Carisma&#8217;s by-laws and the DGCL.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">The rights of OrthoCellix&#8217;s sole stockholder is governed by OrthoCellix&#8217;s certificate of incorporation, OrthoCellix&#8217;s by-laws and the DGCL.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Authorized Capital Stock</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Carisma is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that Carisma is authorized to issue is 355,000,000, of which 350,000,000 shares are common stock, par value $0.001 per share, and 5,000,000 shares are preferred stock, par value $0.001 per share. The number of authorized shares of Carisma preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the capital stock of Carisma entitled to vote thereon, voting as a single class, irrespective of the provisions of Section 242(b)(2) of the DGCL. The number of authorized shares of common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of Carisma entitled to vote, irrespective of the provisions of Section 242(b)(2) of the DGCL.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">OrthoCellix is authorized to issue one class of capital stock which is designated, as &#8220;common stock.&#8221; OrthoCellix is authorized to issue 1,000 shares of common stock, par value $0.00001 per share.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Common Stock</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Carisma&#8217;s authorized common stock consists of 350,000,000 shares of common stock. Each holder of a share of Carisma common stock is entitled to one vote for each such share held of record on all matters to be voted upon by stockholders, including the election of directors. There shall be no cumulative voting.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">OrthoCellix&#8217;s authorized common stock consists of 1,000 shares of common stock. Each holder of a share of OrthoCellix common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">359</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Carisma</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">OrthoCellix</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Preferred Stock</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Carisma&#8217;s authorized preferred stock consists of 5,000,000 shares of preferred stock. No shares of Carisma preferred stock are currently outstanding.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">OrthoCellix does not have any authorized preferred stock.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Number and Qualification of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Subject to the rights of holders of any series of Carisma&#8217;s preferred stock to elect a director, the number of directors of Carisma is established by Carisma&#8217;s board of directors. Carisma&#8217;s board of directors currently consists of seven members. No decrease in the authorized number of directors constituting Carisma&#8217;s board of directors will shorten the term of any incumbent director. Directors of Carisma need not be stockholders of Carisma.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">The number of OrthoCellix directors is fixed from time to time by resolution of the OrthoCellix board of directors. The OrthoCellix board of directors currently consists of two members. No decrease in the authorized number of directors constituting the OrthoCellix board of directors will shorten the term of any incumbent director. Directors of OrthoCellix need not be stockholders of OrthoCellix.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Structure of Board of Directors; Term of Directors; Election of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Subject to the rights of holders of any series of Carisma&#8217;s preferred stock to elect directors, Carisma&#8217;s board of directors is divided into three classes. Each class consists, as nearly as may be possible, of one-third of the total number of Carisma directors constituting Carisma&#8217;s entire board of directors. Each Carisma director shall serve for a term ending on the date of the third annual meeting of Carisma stockholders following the annual meeting of Carisma stockholders at which such Carisma director was elected.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">The holders of record of a majority of all of the shares of stock entitled to vote, are entitled to elect the directors of OrthoCellix. Each director shall hold office until the next election of directors and until his or her successor is elected and qualified, or until his or her earlier death, resignation, retirement, disqualification, or removal.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Removal of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Subject to the rights of the holders of any series of Carisma preferred stock, Carisma&#8217;s directors may be removed only for cause and only by the affirmative vote of the holders of at least 75.0% of the votes which all the Carisma stockholders would be entitled to cast in any annual election of directors or class of directors.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Except as otherwise provided by the DGCL or the OrthoCellix certificate of incorporation, the OrthoCellix board of directors or any individual director may be removed from office at any time, with or without cause by vote of the holders of a majority of the shares of stock entitled to vote at an election of directors.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Vacancies on the Board of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Subject to the rights of the holders of any series of Carisma preferred stock, any vacancy or newly created directorship in Carisma&#8217;s board of directors, however occurring, shall be filled only by a vote of a majority of Carisma&#8217;s directors then in office, although less than a quorum, or by a sole remaining director and shall not be filled by the stockholders. A director elected to fill a vacancy shall hold office until the next election of the class for which such director shall have been chosen, subject to the election and qualification of a successor and to such director&#8217;s earlier death, resignation or removal.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Any director may resign at any time upon notice given in writing or by electronic transmission to OrthoCellix. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. A vacancy in any directorship may filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next election of directors and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, retirement, disqualification, or removal. If there are no directors in office, then an election of directors may be held in the manner provided by Section 223(a) of the DGCL.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Stockholder Action by Written Consent</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Carisma stockholders may not take any action by written consent in lieu of a meeting of Carisma stockholders.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Action may be taken by written consent of OrthoCellix&#8217;s sole stockholder, signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">360</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Carisma</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">OrthoCellix</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Quorum</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Unless otherwise provided by law, Carisma&#8217;s certificate of incorporation, or Carisma&#8217;s by-laws, at each meeting of stockholders, the holders of a majority in voting power of the shares of the capital stock of Carisma issued and outstanding and entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by Carisma&#8217;s board of directors in its sole discretion, or represented by proxy, shall constitute a quorum for the transaction of business; <i style="font-style:italic;">provided, however</i>, that where a separate vote by a class or classes or series of Carisma capital stock is required by law or the Carisma&#8217;s certificate of incorporation, the holders of a majority in voting power of the shares of such class or classes or series of Carisma capital stock issued and outstanding and entitled to vote on such matter, present in person, present by means of remote communication in a manner, if any, authorized by Carisma&#8217;s board of directors in its sole discretion, or represented by proxy, shall constitute a quorum entitled to take action with respect to the vote on such matter. A quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">The holders of a majority of the voting power of all of the shares of stock entitled to vote at a meeting, present in person or represented by proxy, shall constitute a quorum. Where a separate vote by a class or classes or series is required, a majority of the voting power of the outstanding shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. Any meeting may be adjourned from time to time by the chairman of the meeting or a majority of the votes properly cast upon the question, whether or not a quorum is present. The stockholders present at a duly constituted meeting may continue to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Special Meetings of Stockholders</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Special meetings of Carisma stockholders for any purpose or purposes may be called at any time only by Carisma&#8217;s board of directors, and may not be called by any other person or persons. Business transacted at any special meeting of Carisma stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of meeting. Carisma may postpone, reschedule or cancel any previously scheduled special meeting of Carisma stockholders.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Special meetings of stockholders may be called by the board of directors or the chief executive officer, if one is elected, or a president and shall be held at place, on such date, and at such time as they or he or she shall fix.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Notice of Stockholder Meetings</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Unless otherwise provided by law, Carisma&#8217;s certificate of incorporation, or Carisma&#8217;s by-laws, notice of each meeting of Carisma stockholders, whether annual or special, shall be given not less than 10 nor more than 60 days before the date of the meeting to each Carisma stockholder entitled to vote at such meeting as of the record date for determining the Carisma stockholders entitled to notice of the meeting. Without limiting the manner by which notice otherwise may be given to Carisma stockholders, any notice shall be effective if given in accordance with Section 232 of the DGCL. The notices of all meetings shall state the place, if any, date and hour of the meeting, the means of remote communications, if any, by which Carisma stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining Carisma stockholders entitled to vote at the meeting, if such date is different from the record date for determining Carisma stockholders entitled to notice of the meeting. The notice of a Carisma special meeting shall state, in addition, the purpose or purposes for which the meeting is called.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Notice of all meetings of OrthoCellix&#8217;s stockholders shall state the place, if any, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, and, if such meeting is to be held solely by means of remote communication, the information required to access the stock list contemplated by OrthoCellix&#8217;s by-laws, shall be given not less than 10 nor more than 60 days before the meeting to each stockholder entitled to vote at the meeting as of the record date for determining the stockholders entitled to notice of the meeting. If mailed, notice is given when deposited in the mail, postage prepaid, directed to such stockholder at such stockholder&#8217;s address as it appears in OrthoCellix&#8217;s records. Without limiting the manner by which notice otherwise may be effectively given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the DGCL.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">361</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Carisma</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">OrthoCellix</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Advance Notice Requirements for Stockholder Proposals</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">If a Carisma stockholder wishes to propose a nomination of persons for election to Carisma&#8217;s board of directors or present a proposal at an annual meeting but does not wish to have the proposal considered for inclusion in Carisma&#8217;s proxy statement or proxy card, Carisma&#8217;s by-laws establish an advance notice procedure for such nominations and proposals. Carisma stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of Carisma&#8217;s board of directors or by a Carisma stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to Carisma&#8217;s corporate secretary of the stockholder&#8217;s intention to bring such business before the meeting. The required notice must be in writing and must otherwise meet the requirements set forth in Carisma&#8217;s by-laws (including providing the information required by Rule 14a-19 under the Exchange Act). For the avoidance of doubt, the foregoing clause (ii) is the exclusive means for a stockholder to make director nominations and submit other business (other than matters properly included in the corporation&#8217;s notice of meeting of stockholders and proxy statement under Rule 14a-8 under the Exchange Act) before an annual meeting of stockholders.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">OrthoCellix&#8217;s by-laws do not contain advance notice requirements for stockholder proposals.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Amendment of Certificate of Incorporation</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">The affirmative vote of the holders of at least 75.0% of the votes which all Carisma&#8217;s stockholders would be entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with, Articles SIXTH, NINTH, TENTH or ELEVENTH of Carisma&#8217;s certificate of incorporation.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">OrthoCellix reserves the right to amend, alter, change or repeal any provision contained in OrthoCellix&#8217;s Certificate of Incorporation. Notwithstanding any other provisions of OrthoCellix&#8217;s certificate of incorporation, OrthoCellix&#8217;s by-laws, or any provision of law which might otherwise permit a lesser vote or no vote, stockholders may vote to amend OrthoCellix&#8217;s certificate of incorporation pursuant to Section 242 of the DGCL.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Notwithstanding any other provisions of Carisma&#8217;s certificate of incorporation, Carisma&#8217;s by-laws, or any provision of law which might otherwise permit a lesser vote or no vote, stockholders may vote to amend Carisma&#8217;s certificate of incorporation pursuant to Section 242 of the DGCL.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Amendment of By-Laws</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Except as provided by law, Carisma&#8217;s board of directors shall have the power to adopt, amend, alter or repeal Carisma&#8217;s by-laws by the affirmative vote of a majority of the directors present at any regular or special meeting of Carisma&#8217;s board of directors at which a quorum is present. Carisma stockholders may not adopt, amend, alter or repeal the Carisma&#8217;s by-laws, or adopt any provision inconsistent therewith, unless such action is approved, in addition to any other vote required by Carisma&#8217;s certificate of incorporation, by the affirmative vote of the holders of at least 75.0% of the votes that all the Carisma stockholders would be entitled to cast in any annual election of directors or class of directors.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">OrthoCellix&#8217;s by-laws may be amended or repealed by the board of directors at any meeting or by the stockholders at any meeting.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">362</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Carisma</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">OrthoCellix</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Limitation on Director Liability</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty, no director of Carisma shall be personally liable to Carisma or Carisma stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability. If the DGCL is amended to permit further elimination or limitation of the personal liability of directors, then the liability of a director of Carisma will be eliminated or limited to the fullest extent permitted by the DGCL as so amended.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">The liability of the OrthoCellix directors to OrthoCellix or its stockholders for monetary damages for breach of fiduciary duty as a director of officer is and will be eliminated to the fullest extent under applicable law. If applicable law is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of OrthoCellix will be eliminated or limited to the fullest extent permitted by applicable law as so amended.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Indemnification</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Carisma&#8217;s certificate of incorporation provides that Carisma shall indemnify its directors and officers if such person acted in good faith and in a manner which such indemnitee reasonably believed to be in, or not opposed to, the best interests of Carisma, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful. Carisma&#8217;s certificate of incorporation also provides that Carisma will pay the expenses incurred by or on behalf of an indemnitee in defending an action, suit, proceeding or investigation or any appeal therefrom in advance of its final disposition, <i style="font-style:italic;">provided, however</i>, that such payment of expenses in advance of the final disposition of the proceeding will be made only upon receipt of an undertaking by or on behalf of the indemnitee to repay all amounts so advanced in the event that it shall ultimately be determined by final judicial decision from which there is no further right to appeal that the indemnitee is not entitled to be indemnified.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">To the fullest extent permitted by applicable law, OrthoCellix is authorized to provide indemnification of (and advancement of expenses to) directors and officers through provisions of OrthoCellix&#8217;s by-laws and certificate of incorporation. Any amendment, repeal or modification of applicable law shall not adversely affect any right or protection of any director, officer or other agent of OrthoCellix existing at the time of such amendment, repeal or modification.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Conversion Rights</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Holders of Carisma&#8217;s common stock have no right to convert the stock into any other security. Carisma does not have any outstanding shares of preferred stock.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">OrthoCellix&#8217;s sole stockholder does not have any conversion rights.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Right of First Refusal</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Carisma does not have a right of first refusal in place.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">OrthoCellix does not have a right of first refusal in place.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Right of Co-Sale</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Carisma does not have a right of co-sale in place.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">OrthoCellix does not have a right of co-sale in place.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Preemptive Rights</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Carisma stockholders do not have any preemptive rights.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">OrthoCellix&#8217;s sole stockholder does not have preemptive rights.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">363</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Carisma</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">OrthoCellix</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.33%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Distributions to Stockholders</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Carisma&#8217;s certificate of incorporation provides that dividends may be declared and paid on Carisma&#8217;s common stock from funds lawfully available therefor as and when determined by Carisma&#8217;s board of directors and subject to any preferential dividend or other rights of any then outstanding Carisma preferred stock. Carisma&#8217;s board of directors may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall not be more than 60 days prior to such action, to determine the Carisma stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights, entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action. If no such record date is fixed, the record date for determining Carisma stockholders for any such purpose shall be at the close of business on the day on which Carisma&#8217;s board of directors adopts the resolution relating thereto.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Dividends upon OrthoCellix capital stock, if any, may be declared by the OrthoCellix. The OrthoCellix board of directors may fix a record date for the determination of holders of OrthoCellix common stock entitled to receive payment of a dividend or distribution declared thereon, which record date is to be not to precede the date upon which the resolution fixing the record date is adopted, and which record date may not be more than 60 days prior to the date fixed for the payment thereof. If no record date is fixed, the record date shall be at the close of business on the day on which the OrthoCellix board of directors adopts the resolution relating thereto.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Exclusive Forum</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Carisma&#8217;s certificate of incorporation and Carisma&#8217;s by-laws do not contain an exclusive forum provision.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Unless OrthoCellix consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any claims, including claims in the right of OrthoCellix, brought by a current or former stockholder (a) that are based upon ; (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of OrthoCellix to OrthoCellix or OrthoCellix&#8217;s sole stockholder; (iii) any action asserting a claim against OrthoCellix arising pursuant to any provision of the DGCL, OrthoCellix&#8217;s second amended and restated certificate of incorporation or OrthoCellix&#8217;s by-laws; or (iv) any action asserting a claim against OrthoCellix governed by the internal affairs doctrine, except for, as to each of (i) through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within 10 days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction..</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Registration Rights</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Carisma stockholders do not currently have registration rights.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">OrthoCellix&#8217;s sole stockholder does not have registration rights.</p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Stock Transfer Restrictions Applicable to Stockholders</i></p></td></tr><tr><td style="vertical-align:top;width:48.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Shares of stock of Carisma are transferable in the manner prescribed by law and Carisma&#8217;s by-laws.</p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Shares of OrthoCellix are transferable in the manner prescribed by the DGCL.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">364</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_47d87320_1683_46cf_baa4_63a7f23bcb3f"></a><a id="PRINCIPALSTOCKHOLDERSOFCARISMA_390058"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PRINCIPAL STOCKHOLDERS OF CARISMA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The following information and all other information contained in this proxy statement/prospectus does not give effect to the contemplated reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unless otherwise provided below, the following table sets forth information with respect to the beneficial ownership of Carisma&#8217;s common stock as of June&#160;30, 2025 by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of Carisma&#8217;s directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of Carisma&#8217;s named executive officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of Carisma&#8217;s directors and executive officers as a group; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person, or group of affiliated persons, who is known to Carisma to be the beneficial owner of five&#160;percent or more of the outstanding shares of Carisma&#8217;s common stock.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The column entitled &#8220;Percentage of Shares Beneficially Owned&#8221; is based on a total of 41,788,096 shares of Carisma&#8217;s common stock outstanding as of June&#160;30, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Beneficial ownership is determined in accordance with the rules&#160;and regulations of the SEC and includes voting or investment power with respect to Carisma&#8217;s common stock. Shares of Carisma&#8217;s common stock subject to options that are currently exercisable or exercisable within 60&#160;days after June&#160;30, 2025 are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the&#160;percentage ownership of that person but not for the purpose of calculating the&#160;percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of the shares of Carisma&#8217;s common stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise set forth below, the address of the beneficial owner is c/o Carisma Therapeutics&#160;Inc., 3675 Market Street, Suite&#160;401, Philadelphia, Pennsylvania 19104.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.82%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of Beneficial Owner</b></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Beneficially&#160;Owned</b></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;Shares</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Beneficially&#160;Owned&#160;(%)</b></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5.0% Stockholders</b></p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">ModernaTX, Inc.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,059,338</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">12.11</p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">HealthCap VII L.P.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,398,248</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">8.13</p></td><td style="vertical-align:bottom;width:1.61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Entities affiliated with IPG<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,713,232</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">6.49</p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Wellington Life Sciences V GmbH &amp; Co. KG<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,297,546</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5.50</p></td><td style="vertical-align:bottom;width:1.61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">SymBiosis II, LLC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,215,877</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5.30</p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Named Executive Officers and Directors</b></p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sohanya Cheng<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,675</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">John Hohneker, M.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">36,550</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;width:1.61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Steven Kelly<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,666,432</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3.83</p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Klichinsky, Pharm.D., Ph.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup></p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">996,947</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2.36</p></td><td style="vertical-align:bottom;width:1.61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Richard Morris<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(10)</sup></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">460,539</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1.09</p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Briggs Morrison, M.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(11)</sup></p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">156,974</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;width:1.61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">David Scadden, M.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(12)</sup></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,975</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Marella Thorell<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(13)</sup></p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,975</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;width:1.61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sanford Zweifach<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(14)</sup></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">220,786</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">All current executive officers and directors as a group (9 persons)</i><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(15)</sup></p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.82%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,115,314</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.47%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7.02</p></td><td style="vertical-align:bottom;width:1.61%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Less than one&#160;percent</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based solely on a Schedule 13G filed by Moderna. on March&#160;13, 2023. Moderna is wholly owned by Moderna,&#160;Inc., a publicly-traded company. The business address of Moderna is c/o Moderna,&#160;Inc., 200 Technology Square, Cambridge, MA 02139.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based solely on a Schedule 13D/A filed by HealthCap VII,&#160;L.P. on May&#160;28, 2024. HealthCap VII GP LLC, a Delaware limited liability company, is the sole general partner of HealthCap VII,&#160;L.P. HealthCap VII GP LLC has delegated voting and dispositive power over the shares to HealthCap VI GP S.A., a corporation organized under the laws of Switzerland and disclaims beneficial ownership of all shares held by HealthCap VII&#160;L.P., except to the extent of their pecuniary interest therein. Vanessa Malier and </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">365</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Thomas Ramdahl are each directors of HealthCap VII GP&#160;LLC. Fabrice Bernhard serves as general manager of HealthCap VI GP S.A., and each of Dag Richter, Fran&#231;ois Kaiser and Daniel Schafer serves as a director of HealthCap VI GP S.A. Each of Messrs.&#160;Bernhard, Kaiser and Schafer may be deemed to share voting and investment power with respect to the shares held by HealthCap VII&#160;L.P. and disclaim beneficial ownership of all shares held by HealthCap VII&#160;L.P., except to the extent of their pecuniary interest therein. Bj&#246;rn Odlander is a Managing Partner of HealthCap VII Advisor AB, an affiliate of HealthCap VII&#160;L.P., and was a member of the Carisma board of directors until his resignation in June&#160;2024. The business address of HealthCap VII&#160;L.P. is c/o HealthCap VII GP S.A., 23 Avenue Villamont, Lausanne, CH 1005, Switzerland.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based solely on a Schedule 13G/A filed by the IPG entities (as defined below) on February&#160;2, 2024. Consists of (i)&#160;2,067,924 shares of common stock of the company held by IPG Cayman LP, (ii)&#160;267,864 shares of common stock of the company held by IPG USA SCO LP and (iii)&#160;377,444 shares of common stock of the company held by CT SPV Investment LP (collectively, the &#8220;IPG entities&#8221;). Longview Innovation Corp., formerly known as IP Group,&#160;Inc., has shared voting and investment control over the shares held by the IPG entities. The business address of the IPG entities is c/o Longview Innovation Corp., 3411 Silverside Road, Baynard Building, Suite&#160;252, Wilmington, Delaware 19810.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 2,297,546 shares held by Wellington Life Sciences V GmbH&#160;&amp; Co. KG (the &#8220;Wellington Fund&#8221;). The Wellington Fund is represented by Wellington Life Sciences Venture Capital Consulting GmbH (the &#8220;Wellington General Partner&#8221;). The Wellington General Partner holds voting and investment control over the shares. Dr.&#160;Regina Hodits and Dr.&#160;Rainer Strohmenger, in their functions as managing directors of the Wellington General Partner, have individual signatory power as well as voting and/or investment control over the shares. Dr.&#160;Hodits was a member of the Carisma board of directors until her resignation in June&#160;2024. The business address of the Wellington Fund and the Wellington General Partner is Tuerkenstrasse 5, 80333 Munich, Germany.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 2,215,877 shares held by Symbiosis II, LLC, which exercises voting and investment control of the shares. Chidozie Ugwumba is the Managing Partner of Symbiosis II, LLC and as such has sole voting and investment control over the shares. Mr.&#160;Ugwumba was also a member of the Carisma board of directors until his resignation in April&#160;2024. The business address of Symbiosis II, LLC is 609 S.W. 8th Street, Suite&#160;365, Bentonville, Arkansas 72712.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 9,675 shares of common stock underlying options held by Ms.&#160;Cheng that are exercisable as of June&#160;30, 2025 or will become exercisable within 60&#160;days of such date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 36,550 shares of common stock underlying options held by Dr.&#160;Hohneker that are exercisable as of June&#160;30, 2025 or will become exercisable within 60&#160;days of such date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 1,666,432 shares of common stock underlying options held by Mr.&#160;Kelly that are exercisable as of June&#160;30, 2025 or will become exercisable within 60&#160;days of such date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(9)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;484,347 shares of common stock held by Dr.&#160;Klichinsky and (ii)&#160;512,600 shares of common stock underlying options held by Dr.&#160;Klichinsky that are exercisable as of June&#160;30, 2025 or will become exercisable within 60&#160;days of such date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(10)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 460,539 shares of common stock underlying options held by Mr.&#160;Morris that are exercisable as of June&#160;30, 2025 or will become exercisable within 60&#160;days of such date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(11)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;12,175 shares of common stock held by Dr.&#160;Morrison and (ii)&#160;144,799 shares of common stock underlying options held by Dr.&#160;Morrison that are exercisable as of June&#160;30, 2025 or will become exercisable within 60&#160;days of such date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(12)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 13,975 shares of common stock underlying options held by Dr.&#160;Scadden that are exercisable as of June&#160;30, 2025 or will become exercisable within 60&#160;days of such date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(13)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 13,975 shares of common stock underlying options held by Ms.&#160;Thorell that are exercisable as of June&#160;30, 2025 or will become exercisable within 60&#160;days of such date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(14)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;413 shares of common stock held by Mr.&#160;Zweifach and (ii)&#160;220,373 shares of common stock underlying options held by Mr.&#160;Zweifach that are exercisable as of June&#160;30, 2025 or will become exercisable within 60&#160;days of such date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(15)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;496,935 shares of common stock held and (ii)&#160;2,618,379 shares of common stock underlying options that are exercisable as of June&#160;30, 2025 or will become exercisable within 60&#160;days of such date.</span></td></tr></table><div style="margin-top:10pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">366</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f16c01f5_2e0c_419e_930e_8632281a695d"></a><a id="PRINCIPALSTOCKHOLDERSOFORTHOCELLIX_13066"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PRINCIPAL STOCKHOLDER OF ORTHOCELLIX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the contemplated reverse stock split by Carisma.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information known to OrthoCellix regarding beneficial ownership of OrthoCellix capital stock on an as-converted to OrthoCellix common stock basis as of June&#160;30, 2025 for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of OrthoCellix&#8217;s directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of OrthoCellix&#8217;s named executive officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of OrthoCellix&#8217;s directors and executive officers as a group; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person, or group of affiliated persons, who is known by OrthoCellix to beneficially own greater than five&#160;percent of OrthoCellix&#8217;s common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beneficial ownership is determined in accordance with the rules&#160;of the SEC and thus represents voting or investment power with respect to OrthoCellix&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of June&#160;30, 2025. Shares of OrthoCellix common stock that an individual has the right to acquire within 60&#160;days of June&#160;30, 2025 are deemed to be outstanding and beneficially owned by the individual for the purpose of computing the&#160;percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the&#160;percentage ownership of any other person. To OrthoCellix&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned. The&#160;percentage of beneficial ownership shown prior to the Merger and anticipated Concurrent Financing in the table below is based on 1,000 shares of common stock outstanding as of June&#160;30, 2025. The following table does not reflect any shares of Carisma common stock that such holders have agreed to purchase in the anticipated Concurrent Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise noted below, the street address of each beneficial owner is c/o Ocugen,&#160;Inc., 11 Great Valley Parkway, Malvern, PA 19355.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.013893127%;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">NAME OF BENEFICIAL OWNER</b></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER&#160;OF</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">SHARES</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">BENEFICIALLY</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">OWNED</b></p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PERCENTAGE</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">OF&#160;SHARES</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">OUTSTANDING</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">BENEFICIALLY</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">OWNED</b></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">5.0% or Greater Stockholders</span></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Ocugen, Inc.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,000</p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Directors and Named Executive Officers</span></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.25%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.37%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Shankar Musunuri, Ph.D., MBA</p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Michael Shine, MBA</p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.25%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.44%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.37%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.81%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">All executive officers and directors as a group (2 persons)</p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Less than one&#160;percent</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 1,000 shares of OrthoCellix common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">367</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d9fbff86_7791_4000_841f_c8e13fb252bf"></a><a id="PRINCIPALSTOCKHOLDERSOFTHECOMBINEDCOMPAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the contemplated reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth certain information regarding beneficial ownership of the Combined Company&#8217;s common stock immediately after consummation of the Merger, assuming the consummation of the Merger occurred on June&#160;30, 2025 for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person or group of affiliated persons who is expected by Carisma and OrthoCellix to be the beneficial owner or more than five&#160;percent of the Combined Company&#8217;s common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person expected to be a director of the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person expected to be a named executive officer of the Combined Company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of the Combined Company&#8217;s expected directors and executive officers as a group.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beneficial ownership is determined in accordance with the rules&#160;of the SEC and thus represents voting or investment power with respect to the Combined Company&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual or entity has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of June&#160;30, 2025. Shares of the Combined Company&#8217;s common stock that an individual or entity has the right to acquire within 60&#160;days of June&#160;30, 2025 are deemed to be outstanding and beneficially owned by the individual or entity for the purpose of computing the&#160;percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the&#160;percentage ownership of any other person. To Carisma&#8217;s and OrthoCellix&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table lists applicable&#160;percentage ownership based on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock expected to be outstanding upon consummation of the Merger, after giving effect to the anticipated Concurrent Financing and prior to giving effect to the contemplated Carisma reverse stock split. The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60&#160;days, including upon the exercise of stock options. These stock options shall be deemed to be outstanding for the purpose of computing the&#160;percentage of outstanding shares of the Combined Company&#8217;s common stock expected to be owned by such person but shall not be deemed to be outstanding for the purpose of computing the&#160;percentage of outstanding shares of the Combined Company&#8217;s common stock expected to be owned by any other person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately after the Merger and the anticipated Concurrent Financing, Carisma securityholders as of immediately prior to the Merger are expected to own approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), and Ocugen, the sole stockholder of OrthoCellix, along with the other investors in the anticipated Concurrent Financing are expected to own approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the outstanding shares of the Combined Company (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, Carisma&#8217;s Net Cash as of the closing of the Merger being approximately $0 and the anticipated Concurrent Financing Amount of $25.0 million. Carisma management currently anticipates Carisma&#8217;s Net Cash as of the closing of the Merger will be approximately $0, and the currently estimated ownership&#160;<span style="white-space:pre-wrap;">percentages reflect this projection. There can be no assurances any of these assumptions will be accurate at Closing when the final Exchange Ratio is determined. The table below assumes that, based on Carisma&#8217;s and OrthoCellix&#8217;s capitalization as of June 22, 2025, the Exchange Ratio is estimated to be equal to approximately               shares of Carisma common stock for each share of OrthoCellix common stock, prior to giving effect to the contemplated Carisma reverse stock split. The estimated Exchange Ratio was derived on a fully-diluted basis as of June&#160;22, 2025, using a stipulated value of OrthoCellix of approximately $135.0 million and of Carisma of approximately $15.0 million, assuming Net Cash of $0 as of the closing of the Merger. The final Exchange Ratio is subject to adjustment prior to Closing based upon Carisma&#8217;s Net Cash at the closing of the Merger and the aggregate proceeds from the anticipated Concurrent Financing.</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">368</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Ocugen,&#160;Inc., 11 Great Valley Parkway, Malvern, PA 19355.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:99.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.56%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">NAME OF BENEFICIAL OWNER</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER&#160;OF</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">SHARES</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">BENEFICIALLY</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">OWNED</b></p></td><td style="vertical-align:bottom;width:2.36%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PERCENTAGE</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">OF&#160;SHARES</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">OUTSTANDING</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">BENEFICIALLY</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">OWNED</b></p></td><td style="vertical-align:bottom;width:1.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">5.0% or Greater Stockholders</span></p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.31%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10pt;">Ocugen, Inc.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.56%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Directors and Named Executive Officers</span></p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.56%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10pt;">Steven Kelly<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.56%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10pt;">Natalie McAndrew<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.56%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10pt;">Karthik Musunuri<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.56%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10pt;">Michael Shine, MBA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.56%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10pt;">David Anderson<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.56%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 10pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.56%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 10pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.56%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All executive officers and directors as a group ( persons)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.56%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.31%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Less than one&#160;percent</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the Combined Company&#8217;s common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of the Combined Company&#8217;s common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of the Combined Company&#8217;s common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of the Combined Company&#8217;s common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of the Combined Company&#8217;s common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of the Combined Company&#8217;s common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(7)</span></span>See Notes&#160;(2), (3), (4), (5)&#160;and (6)&#160;above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">369</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_939b7298_2bb7_48df_b8c1_580a8f34248a"></a><a id="LEGALMATTERS_608613"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LEGAL MATTERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Wilmer Cutler Pickering Hale and Dorr LLP will pass upon the validity of Carisma&#8217;s common stock offered by this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">370</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9a939d58_9c41_4798_8ed5_bbf301405f23"></a><a id="EXPERTS_777361"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXPERTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of Carisma Therapeutics&#160;Inc. as of December&#160;31, 2024 and 2023, and for the&#160;years then ended, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December&#160;31, 2024 consolidated financial statements contains an explanatory paragraph that states that Carisma Therapeutics&#160;Inc.&#8217;s losses and negative cash flows from operations since inception raise substantial doubt about the entity&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined financial statements of the NeoCart Business of Ocugen as of December&#160;31, 2024 and 2023 and for the&#160;years then ended included in this proxy statement/prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the NeoCart Business of Ocugen&#8217;s ability to continue as a going concern as described in Note&#160;1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">371</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6e4c7422_796e_4fe8_9d35_4275efb57bf1"></a><a id="WHEREYOUCANFINDMOREINFORMATION_997838"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma is subject to the informational requirements of the Exchange Act and in accordance therewith, files annual, quarterly and current reports, proxy statements and other information with the SEC electronically, and the SEC maintains a website that contains Carisma&#8217;s filings as well as reports, proxy and information statements, and other information issuers file electronically with the SEC at <i style="font-style:italic;">www.sec.gov</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma also makes available free of charge on or through its website at https://carismatx.com under the &#8220;For Investors&#8221; menu, its Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange Act as soon as reasonably practicable after Carisma electronically files such material with or otherwise furnishes it to the SEC. The website addresses for the SEC and Carisma are inactive textual references. Information included on these websites is not incorporated by reference into and does not constitute a part of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma has filed with the SEC a registration statement on Form&#160;S-4, of which this proxy statement/prospectus is a part, under the Securities Act to register the shares of Carisma&#8217;s common stock to be issued in the Merger. The registration statement, including the attached annexes, exhibits and schedules, contains additional relevant information about Carisma and Carisma&#8217;s common stock. This proxy statement/prospectus does not contain all of the information set forth in the registration statement because certain parts of the registration statement are omitted in accordance with the rules&#160;and regulations of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma has supplied all the information contained in this proxy statement/prospectus relating to Carisma, and OrthoCellix has supplied all information contained in this proxy statement/prospectus relating to OrthoCellix and to Ocugen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you are a Carisma<b style="font-weight:bold;">&#160;</b>stockholder and would like additional copies, without charge, of this proxy statement/prospectus or if you have questions about the Merger or the Proposals, including the procedures for voting your shares, you should contact Carisma&#8217;s proxy solicitor,<b style="font-weight:bold;">&#160;</b>MacKenzie Partners,&#160;Inc., at the following address and telephone number:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MacKenzie Partners,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7 Penn Plaza</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">New York, New York 10001</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">800-322-2885</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">proxy@mackenziepartners.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">372</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d05f784e_d38d_469a_aba2_e8d2ee4de783"></a><a id="OTHERMATTERS_595745"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OTHER MATTERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stockholder Proposals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have not yet determined the date of the Carisma Special Meeting, which will be a special meeting in lieu of Carisma&#8217;s 2025 annual meeting of stockholders. The date of the Carisma Special Meeting will be changed by more than 30&#160;days from the anniversary date of the 2024 annual meeting of stockholders. Prior to the Carisma Special Meeting, we will announce the date of such meeting and any dates specified below to the extent required by Rule&#160;14a-5 under the Exchange Act. A stockholder who would like to have a proposal considered for inclusion in the proxy statement for the Carisma Special Meeting must submit the proposal in accordance with the procedures outlined in Rule&#160;14a-8 of the Exchange Act so that it is received by us no later than a reasonable time before we begin to print and send our proxy statement for the Carisma Special Meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">A stockholder who would like to have a proposal considered for inclusion in our proxy statement for our 2026 annual meeting of stockholders must submit the proposal in accordance with the procedures outlined in Rule&#160;14a-8 of the Exchange Act so that it is received by us no later than&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. However, if the date of the 2026 annual meeting of stockholders is changed by more than 30&#160;days from the date of Carisma&#8217;s Special Meeting, then the deadline is a reasonable time before we begin to print and send our proxy statement for the 2026 annual meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">SEC rules set standards for eligibility and specify the types of stockholder proposals that may be excluded from a proxy statement.&#160;Stockholder proposals should be addressed to Carisma Therapeutics Inc., 3675 Market Street, Suite 401, Philadelphia, Pennsylvania 19104, Attention: Secretary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">If a stockholder wishes to propose a nomination of persons for election to our Board or present a proposal at the Carisma Special Meeting but does not wish to have the proposal considered for inclusion in our proxy statement and proxy card, our bylaws establish an advance notice procedure for such nominations and proposals. Stockholders at the Carisma Special Meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the Board or by a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to our corporate secretary of the stockholder&#8217;s intention to bring such business before the meeting. The required notice must be in writing and must otherwise meet the requirements set forth in our bylaws (including providing the information required by Rule&#160;14a-19 under the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The required notice for the Carisma Special Meeting must be in writing and received by our corporate secretary at our principal executive offices not earlier than the 120th day prior to such special meeting and not later than the close of business on the later of (x) the 90th day prior to such special meeting and (y) the tenth day following the day on which notice of the date of such special meeting was given or public disclosure of the date of such special meeting was made, whichever first occurs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">For proposals to be presented at our 2026 annual meeting of stockholders, the required notice must be in writing and received by our corporate secretary at our principal executive offices not less than 90&#160;days nor more than 120&#160;days prior to the first anniversary of the Carisma Special Meeting. However, in the event that the date of the 2026 annual meeting of stockholders is advanced by more than 30&#160;days, or delayed by more than 60&#160;days, from the first anniversary of the Carisma Special Meeting, a stockholder&#8217;s notice must instead be so received no earlier than the 120th day prior to such annual meeting and not later than the close of business on the later of (A)&#160;the 90th day prior to such annual meeting and (B)&#160;the tenth day following the day on which notice of the date of such annual meeting was given or public disclosure of the date of such annual meeting was made, whichever first occurs. For stockholder proposals to be brought before the 2026 annual meeting of stockholders, the required notice must be received by our corporate secretary at our principal executive offices no earlier than&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and no later than&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Any proposals, notices or information about proposed director candidates should be sent to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Carisma Therapeutics Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3675 Market Street, Suite 401</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Philadelphia, Pennsylvania 19104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Attention: Corporate Secretary</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">373</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Householding of Proxy Statement/Prospectus</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SEC has adopted rules&#160;that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for special meeting materials with respect to two or more stockholders sharing the same address by delivering a single set of special meeting materials addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Carisma Special Meeting, some banks, brokers and other nominee record holders will be participating in the practice of &#8220;householding&#8221; proxy statements. This means that only one copy of this proxy statement/prospectus may have been sent to multiple stockholders in your household. We will promptly deliver a separate copy of the proxy statement to you if you contact us at the following address or telephone number: Carisma Therapeutics&#160;Inc., 3675 Market Street, Suite&#160;401, Philadelphia, Pennsylvania 19104, Attention: Corporate Secretary, telephone: (267) 491-6422. If you want to receive separate copies of the proxy statement in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should contact your bank, broker or other nominee record holder, or you may contact us at the above address or telephone number.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">374</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_458f4a65_61b6_47d5_b641_a841e83271c5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carisma Therapeutics Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="INDEXTOCONSOLIDATEDFINANCIALSTATEMENTS_7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:91.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Audited Financial Statements for the Years Ended December 31, 2024 and 2023</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AccountingFirm_FS1"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm (KPMG LLP, Philadelphia, PA, Audit Firm ID: 185)</span></a></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBS1"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofOperations1"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Equity1"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CashFlow1"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Notes1"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:91.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Unaudited Consolidated Financial Statements for the Three Months Ended March 31, 2025 and 2024</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#UnauditedConsolidatedBalanceSheets_64748"><span style="font-style:normal;font-weight:normal;">Unaudited Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-24</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Statofoperation2"><span style="font-style:normal;font-weight:normal;">Unaudited Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-25</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#UnauditedConsolidatedStatementsofStockho"><span style="font-style:normal;font-weight:normal;">Unaudited Consolidated Statements of Stockholders&#8217; (Deficit) Equity</span></a></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-26</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Cashflow2"><span style="font-style:normal;font-weight:normal;">Unaudited Consolidated Statement of Cash Flows</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-27</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Notes2"><span style="font-style:normal;font-weight:normal;">Notes to the Interim Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-28</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeoCart Business of Ocugen, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:91.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Audited Financial Statements for the Years Ended December 31, 2024 and 2023</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ACCOUNTINGFIRM_FS3"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-39</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#COMBINEDBALANCESHEETS_286683"><span style="font-style:normal;font-weight:normal;">Combined Balance Sheets</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-41</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#COMBINEDSTATEMENTSOFOPERATIONSANDCOMPREH"><span style="font-style:normal;font-weight:normal;">Combined Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-42</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#COMBINEDSTATEMENTSOFCHANGESINEQUITY_1640"><span style="font-style:normal;font-weight:normal;">Combined Statements of Changes in Equity</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-43</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#COMBINEDSTATEMENTSOFCASHFLOWS_746300"><span style="font-style:normal;font-weight:normal;">Combined Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-44</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NatureoftheBusiness_986162"><span style="font-style:normal;font-weight:normal;">Notes to the Combined Financial Statements</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-45</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:91.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Unaudited Financial Statements for the Three Months Ended March 31, 2025 and 2024</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BALANCESHEETS4"><span style="font-style:normal;font-weight:normal;">Combined Balance Sheets</span></a></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-55</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#comprehensiveliss4"><span style="font-style:normal;font-weight:normal;">Combined Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-56</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#equity4"><span style="font-style:normal;font-weight:normal;">Combined Statements of Changes in Equity</span></a></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-57</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#cashflow4"><span style="font-style:normal;font-weight:normal;">Combined Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-58</p></td></tr><tr><td style="vertical-align:bottom;width:91.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NatureoftheBusiness_209432"><span style="font-style:normal;font-weight:normal;">Notes&#160;to the Combined Financial Statements</span></a></p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-59</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2d9785fe_b4a3_44fb_8968_b1405dfad2fa"></a><a id="AccountingFirm_FS1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Carisma Therapeutics&#160;Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Opinion on the Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have audited the accompanying consolidated balance sheets of Carisma Therapeutics&#160;Inc. and subsidiaries (the Company) as of December&#160;31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; (deficit) equity, and cash flows for the&#160;years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2024, and 2023, and the results of its operations and its cash flows for the&#160;years then ended, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note&#160;2 of the consolidated financial statements, the Company has incurred losses and negative cash flows from operations since inception that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note&#160;2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Critical Audit Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1)&#160;relate to accounts or disclosures that are material to the consolidated financial statements and (2)&#160;involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">/s/ KPMG LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have served as the Company&#8217;s auditor since 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">March&#160;31, 2025</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_bf20f2ba_bb9b_4551_af4b_8b17ba2987bf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><a id="ConsolidatedBS1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED BALANCE SHEET</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_fc7460c7_4420_46c5_8106_540459ab0f94"></a><a id="Tc_NAnNuyPyxUWAHWIxNFtjiQ_1_2"></a><a id="Tc_0zTOmZly-0Szm7ld-Nmlgw_2_2"></a><a id="Tc_Rj39PMhICUCzy3cM6K2DgQ_2_5"></a><a id="Tc_UdbhUOx7B0ycwdH78VKGNQ_3_0"></a><a id="Tc_eh_2fXBwNUiy3Q-Bzqn9vg_4_0"></a><a id="Tc_ylpegWYysUWytGtdkYjRjA_5_0"></a><a id="Tc_J9oE9Neb4kCBuiIGk80Yrw_5_2"></a><a id="Tc_xG00rk47W0Osd4IYp8vgcg_5_5"></a><a id="Tc_WUBma-pciEKIeqJN-Egd6Q_6_0"></a><a id="Tc_HfjdKPU0FU-mkFqEqowMsA_7_0"></a><a id="Tc_EnJLampBkk-GLotZDqCLCg_8_0"></a><a id="Tc_0vzjComh9ECiSOMAI9ZxWw_9_0"></a><a id="Tc_S5qaawR1AU6MGNhe5mbKNQ_10_0"></a><a id="Tc_5G7HadNvzECxLVDdDFe_XQ_11_0"></a><a id="Tc_kNoEDNHRnUyWm-MOsw2TFw_11_2"></a><a id="Tc_vcTJjCdNX0W7S_5UKxBWAQ_11_5"></a><a id="Tc_2DGMty1ukkGJTQCUVXYwZA_13_0"></a><a id="Tc_BmlIlMzLg0iTD-nH8w7YbA_14_0"></a><a id="Tc_qv1veeYzrkG7kQzfrRXk_Q_15_0"></a><a id="Tc_QNvFL4Fg0EWLRtdAMx2PIw_15_2"></a><a id="Tc_Yu0asedk90OL7lGk23Hs2w_15_5"></a><a id="Tc_R-di_Kcd2UWWNzRs6I9kxg_16_0"></a><a id="Tc_pI3zfhuCRkuynt0HWwDjmg_17_0"></a><a id="Tc_VGV05HmUnEa2PMGI5zx1Rw_18_0"></a><a id="Tc_Vsfa06R6gkWAHNKalnEqDA_19_0"></a><a id="Tc_HbEKsCAmPEyhLTGjA2yfwA_20_0"></a><a id="Tc_jHuleN3JxU6Xel1NxUaaew_21_0"></a><a id="Tc_JdMLNPE6ykK3PqcCxe3w3A_22_0"></a><a id="Tc_fTbMw_c79ECIyjpHtNsrDw_23_0"></a><a id="Tc_0gh5A8Eyi0uAluqSRoRTiQ_24_0"></a><a id="Tc_YfkCRJMse0uG87B161rj1A_25_0"></a><a id="Tc_NeMQS2DNd0ipvo3Xsz4HDg_26_0"></a><a id="Tc_8hAKvfE5PkKtFuAHe2CD6g_27_0"></a><a id="Tc_TShMWkwAokatR_XpI9KdDQ_29_0"></a><a id="Tc_z_T-AqnuikeLIAgXKawghQ_30_0"></a><a id="Tc_u9zSc_ZeM06kDYC4B8jWkw_31_0"></a><a id="Tc_8A2yXwzSiUW-ecLm7T43mA_32_0"></a><a id="Tc_Y8WkX2fKo0yQ8xXhTqSYZA_33_0"></a><a id="Tc_CQx24qNrr02epKCGs34egw_35_0"></a><a id="Tc_1-uRx31TAk-E2QP6YPleCg_36_0"></a><a id="Tc_j4Z2VrrquE2teQj9e-oSvw_36_2"></a><a id="Tc_8fJSxLg5Mk2mdyctYtU6pw_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_ScfF6enpZ0acuQwL87kVPA_5_3">17,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_iuqvWqikn0iEOn9F1GvEXw_5_6">77,605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_9b6jRnXY5kKNMALahGVP1w_6_3">5,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_rAZZHNWz0UCWG9Fy1vjr4w_6_6">2,866</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_xXHPfCBMjkiK-2sw39i8aQ_7_3">23,825</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_vPMWG_zHtkmePIQAmjIP7Q_7_6">80,471</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_pYH9FqbFHUq9DI4Er7QYmA_8_3">4,385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_Jt5iCieQNkqp05Gs6Muhdw_8_6">6,764</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Right of use assets &#8211; operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_zfD8tEOtukWw6ATn87WcpQ_9_3">2,040</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_TuDizU05DUe3Uwue5Iyc9w_9_6">2,173</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredFinancingCostsNoncurrent" scale="3" id="Tc_RllwiyQ98EiYGa-Y3ftrSA_10_3">208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredFinancingCostsNoncurrent" scale="3" id="Tc_TK_OlQn78kOlNOabwisgeQ_10_6">146</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_u4HBRRiqnkCeyr1nEtl2tg_11_3">30,458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_9jheHjh67kyExqSeSAXjCQ_11_6">89,554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Liabilities and Stockholders&#8217; (Deficit) Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_N8nNbvb9R0yh_AlhVQPclg_15_3">2,081</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_KP4EmMadk0m5OmeMpuvgZQ_15_6">3,933</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_pySY471fwUCe5Kn8o0rSbw_16_3">7,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_t823Uv_u906ueJS7RRdGGQ_16_6">7,662</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="Tc_4GlfYRutQ0qjXzLAbAcGRg_17_3">3,729</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="Tc_XTgWQqE2f0ugx8rhkdn6vQ_17_6">1,413</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_QTKbbkuYY0uIsSvMTBohuA_18_3">832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_2rAaNnhlkU24minmWP9NYQ_18_6">1,391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_-KgIRFzd8U-MzCl7rgTNhA_19_3">905</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_dzwbnBpFgEmnu8nBBrR9xw_19_6">544</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_kHjsnLPsGUS3SIHk3LzCpQ_20_3">1,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_vYlew8B480iZOvEhSVwAPg_20_6">965</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_F7O55URalE-_IxdrQ0fWQA_21_3">16,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_EHFyFs3ph0Sc1PbWkU9-Xg_21_6">15,908</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="Tc_ugyfEbI9J0it2DjHYcawrA_22_3">41,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="Tc_7RsfF5bfLUmtebqAWQ8spQ_22_6">45,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_JiVq-sqDo0WkWYZ63ZOwYw_23_3">724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_6YvAeeho-0CJ8c3ClcQz2A_23_6">860</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_ODd2FA7kkUS8mB631DQ0vA_24_3">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_BvGVY-41pESkeTD2TfswJw_24_6">328</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_GYRrzysAf0-8_v048qIbTw_25_3">318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_3yoGcVfPJE6IdlLUoJKmJQ_25_6">926</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_T8V3yYDg-kWWVNUZcy0HyQ_26_3">58,367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_e4AOBpNEiU-9VULkA8izPA_26_6">63,022</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Commitments and contingencies (Note 8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stockholders&#8217; (deficit) equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Preferred stock $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Yk4n7XcVekWjA_CM_9zveQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Ykf9TQ5D3kaSHVWbo0mzlQ">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_CQJIx3J280q2j19WX-FgRQ"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_bMsph9IzrUmlIwSRFSzY9g">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_8ExmDBW1Z0OGKxEydUpwVA"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_nXq37bjw_Uml8JS8zR3ljA"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_Pysm5OpygEC2k0l1PyNuZw"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_TrD5hqw7sUKp7o1oqnPwsg">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued or outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="Tc_9hxDwC96FkS6_LJBy6BUGQ_30_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="Tc_tlUs3c6LikWLamSx8R78YA_30_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Common stock $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_WXIiEDDZU0abkqGCnpFQOQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ECeJIXf_ckqiypN0UPnrng">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_aODT60ck2ECaN8yY3G6UHw"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_LkYJc7OHB0OFpDrLgLhjRg">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_7_Xp5yzf7UGCZwX5KMTscQ">41,750,109</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_FVmtYENuWkekuyboUliO-g">40,609,915</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_EC4pGizMUEmwsFpD3vArGA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_1t_Gb32An0ig-gvOCgjziA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December 31, 2024 and 2023, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_AaTmkQZ6KUCeCKHSP2SM8w_31_3">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_EFHSLmHe20algbJwYqXN4A_31_6">40</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_49i78GI3Rkeb-qe-Ia5Wbg_32_3">277,629</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_FdRS6GSzbESKDPTQYrtLLw_32_6">271,594</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_XD9ELp-Plk214pUnxsALhg_33_3">305,579</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_yaGDLZ7q3E6BOQ82Ya5KBg_33_6">245,102</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_9vyJDTxo-UqwbR0D4wG3ZA_35_3">27,909</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_9q5eSXfZS0Ku4OSgZp98kQ_35_6">26,532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total liabilities and stockholders&#8217; (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Aj7cLBsOHk-y7230ChkLlw_36_3">30,458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_h4W6Y_0Gc06uWw2MrCZs9g_36_6">89,554</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9387b4e8_bf9e_4130_b8fa_e4b4dc4568ab"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><a id="ConsolidatedStatementsofOperations1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><a id="_4100820e_0c3f_4953_8b80_4fcd7b2f334b"></a><a id="_14ab9a6f_2093_41d8_8650_068f2f714349"></a><a id="Tc_SI8Zceq-nkW1w1YC45F3Fg_1_2"></a><a id="Tc_hkGyyBppokug1cZt4lBZyg_2_2"></a><a id="Tc_WucuUCk1ykKTcuM_UHTdwA_3_2"></a><a id="Tc_dYR1VUHAjEmOS6BKYPTSQQ_3_5"></a><a id="Tc_HaUOvMe8sUmEo0JO2drRIQ_4_0"></a><a id="Tc_BZYsx5oPEkCBKVC7xVrR5g_4_2"></a><a id="Tc_rS4QzKlVMkOkKcJeFc68fw_4_5"></a><a id="Tc_ynzjdA570062Jm8t41YuBA_5_0"></a><a id="Tc_rsv49H0cD0WFoXkjgwb27w_6_0"></a><a id="Tc_myKN95uvhUqLxXqjZv6SfA_7_0"></a><a id="Tc_IEuBEEois0i1QNmRG0BfzA_8_0"></a><a id="Tc_tLAcHX1vM0-WG1DWFNfKCQ_9_0"></a><a id="Tc_OmUoNNw970iBwvFkJBrVgg_10_0"></a><a id="Tc_ImNq2X51akaze7HXTVXuEA_10_3"></a><a id="Tc_tV7hUk_ZYk6KS0IKpHPO0A_11_0"></a><a id="Tc_DPgibGjWu0OoF3epErRd3Q_12_0"></a><a id="Tc_LQ3FYYwuHUuxCiMeDLE6yA_12_2"></a><a id="Tc_qb4I1wF_oE-bivWldDlhGA_12_5"></a><a id="Tc_Jey0y823DUOBWU7FBSCFHg_14_0"></a><a id="Tc_APF-lqclpUatNZbZQN5R0A_15_0"></a><a id="Tc_3kM-DlQSY0-wpo2FV7ZRIQ_15_2"></a><a id="Tc_H3NDB6HjtUWICSQ0AmLUOg_15_5"></a><a id="Tc_gcYoX4zvu0iGa5sA0JwMRQ_16_0"></a><a id="Tc_qpiL9gxZ0Ei3p2_BW25xtQ_17_0"></a><a id="Tc_J8RgI7kEwUe81Tdm0ItSjQ_18_0"></a><a id="Tc_iXVYvEBORkWnQ76JHDjJsg_18_2"></a><a id="Tc_0W88dcK2fUqGnTtjbPBbBA_18_5"></a><a id="Tc_Cp64meraIE2mOjnOl0xFAQ_19_0"></a><a id="Tc_brd7vyjDEU-SW9steYK14w_19_3"></a><a id="Tc_jNdrShJtfkW8gd2kDxolKw_20_0"></a><a id="Tc_7uFFyBxi80iXELNFyT9T9A_20_3"></a><a id="Tc_F351cEGZj0Gpu79ygbHGPg_21_0"></a><a id="Tc_jfNUIrJmNUy42yUI-tsKgw_21_2"></a><a id="Tc_YRP3zibIbUKEY4yVanWEPg_21_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="Tc_hWJetWoeTUeWUSHsIntuKw_4_3">19,632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="Tc_up_zlNLeEkOgTT6Yca5dbg_4_6">14,919</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_VYumP-JhpkqS-wA1-Yj3Wg_6_3">59,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_rNTQTZmWs0SkFc0iBVtEtQ_6_6">74,125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_f4_AKSf2EEmG4c1gJx0M-w_7_3">22,138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_DPCLhzAD3kGVC6dTaumAXQ_7_6">29,525</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_fy6sIUPCTEm5rl-O3OpB1w_8_3">81,811</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_tFna7hTA7EmuTeTxmFB0wQ_8_6">103,650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_jxMMjz1YVU-IlJPBEtUxoQ_9_3">62,179</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_YH_TPL9ij0KwOwQ2lC11mw_9_6">88,731</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" sign="-" scale="3" id="Tc_WZs-skAUHEKOU2RJsKMNUg_10_6">84</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="Tc_6jeRPdCc8ECDUkmn740-VA_11_3">1,702</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="Tc_d9qCscXml0aLRvH9ER3LcA_11_6">1,936</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ZyRFUgJF1U2difHXvbNh8A_12_3">60,477</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_m5mCEItwAk6F1w4fSKhCXA_12_6">86,879</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share of common stock, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_aJ29XDNl8EuWp8rsfo69-g_15_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_aJ29XDNl8EuWp8rsfo69-g_15_3_2">1.46</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Lo9UTD6E7UW4XxYFh2e_XA_15_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Lo9UTD6E7UW4XxYFh2e_XA_15_6_2">2.59</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average shares of common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc__Hb_KBrooUCJAHBxEw3LFg_16_3"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc__Hb_KBrooUCJAHBxEw3LFg_16_3_2">41,456,210</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_e2zvsN8jC0a1w9g54q6AMQ_16_6"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_e2zvsN8jC0a1w9g54q6AMQ_16_6_2">33,524,197</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_KB5OuVAzOEO-2n-FziYedA_18_3">60,477</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HvNrqH5oaEC_En6qCBejHg_18_6">86,879</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_aVqu3lKffUKMGa6rN9m-1g_19_6">440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: reclassification to net loss of previous unrealized gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="Tc_YIn8XF6_8kqJD_7H9HG5mw_20_6">399</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_fgcVmbWZFESJd3OBxZqhxw_21_3">60,477</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_Y1j-VEWraU6DMonLLH-5ZQ_21_6">86,838</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_56cf6465_db92_4e91_b462_417567e651c8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><a id="Equity1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; (DEFICIT)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EQUITY (in thousands, except share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7eb119cb_b25c_4182_9b69_07bd881f8e4e"></a><a id="Tc_7gZLfouq0kOkaXqkSOrymA_1_2"></a><a id="Tc_9woAqIIFg0SvHRrLD0nmVA_1_8"></a><a id="Tc_sjnwnSlUsE2Ac9if9DTk0A_2_16"></a><a id="Tc_Zo1gETWSnEaxSQ-DI9fJug_3_13"></a><a id="Tc_P_gmKRCdVUKCoGn6ib0DTQ_3_16"></a><a id="Tc_ciiBiMULHEaaAuX25mCatQ_4_8"></a><a id="Tc_rfi7ylv56US4R7PAS4SCxg_4_13"></a><a id="Tc_GqETig_bVEWqRisdhAVoHA_4_16"></a><a id="Tc_moSGPd_9XkO0ZW0CXwMrvA_4_19"></a><a id="Tc_ktTqDBMxkEOChECvKakdjg_4_22"></a><a id="Tc_O9G10Tr6iEyU83qOUdqjhg_5_2"></a><a id="Tc_EkqzyAozlEWfwZd92Ep6WQ_5_4"></a><a id="Tc_l5apmpHJaUy9vu9sU5Ud7A_5_8"></a><a id="Tc_FUzR1gLG5kOc-tn0f1SfAw_5_10"></a><a id="Tc_tUWL8dY090ylVZFdbdfAHg_5_13"></a><a id="Tc_mwLi_5vfnk-70_D2Kq1SEQ_5_16"></a><a id="Tc_dBQBvYqjPkuURrahd9nxSQ_5_19"></a><a id="Tc_otsOu40Zvkms4Zq2PfpF-Q_5_22"></a><a id="Tc_z3gr0HqjvE-70gN2lEgcxQ_5_25"></a><a id="Tc_BeoG03qjN0eZV2ty44F-kA_6_0"></a><a id="Tc_YOeQ15ss-EeaBt6lNZOtSA_6_4"></a><a id="Tc_XkAPmcC2LUKpEn3UKXqUqg_6_10"></a><a id="Tc_Kqs8Idokdku3DPy48D7x_A_6_13"></a><a id="Tc_vsNBURPiSUmpeZvE3iUneA_6_16"></a><a id="Tc_saqjhHHn-ker_4BOXUS2AQ_6_19"></a><a id="Tc_UnzMXmRllkWeDLc-dV5WNg_6_22"></a><a id="Tc_PiUwtczDEESNdfZRAgAD8A_6_25"></a><a id="Tc__Z1Mpc5kxES0ENr1d-f9fA_7_0"></a><a id="Tc__eYJtMBA1EmUYPQtsRye1g_7_2"></a><a id="Tc_PqkX5_XeBEm_b5wlGIf2PQ_7_5"></a><a id="Tc_qeOK0cubFkShAEtI4qOpLg_7_11"></a><a id="Tc_bYd12XZcOEyXT9AEPCs67A_7_17"></a><a id="Tc_9tj5B5ibFEWq_fphWnN8Ow_7_20"></a><a id="Tc_vyb7PTJWc0WGZcD4HnyRkg_7_23"></a><a id="Tc_S1OxuD0qikeBagfX3r9z6A_8_0"></a><a id="Tc_kTkYnIQ3W0yw7cdQKZArgw_8_2"></a><a id="Tc_QTcW7Uz8-EOh69ysIDlVqw_8_5"></a><a id="Tc__SK_nhYb_UWLYXCxmQBCkQ_8_8"></a><a id="Tc_b_GMd52di0SYXYYStruVOg_8_11"></a><a id="Tc_0rAlfrUO1UC6NmTc5sjpcg_8_17"></a><a id="Tc_JbdJ_4PXQEaGh8hslnfWyw_8_20"></a><a id="Tc_Xl9UEanaz0Gc_ibNrHjjhw_8_23"></a><a id="Tc_JQHD8_03fk2RuGvgdVy22Q_9_0"></a><a id="Tc_wJOUSAgjV0CM5CcmI3YxIQ_9_2"></a><a id="Tc_mO3ydVSUVEWViYBxnnHyjw_9_5"></a><a id="Tc_mzGqHYhCYU6x9aMlIxQNZQ_9_8"></a><a id="Tc_4EBkr0k6bUirf8iCro5g9Q_9_11"></a><a id="Tc_-A1b32XodUS6TXgJLuOkRQ_9_14"></a><a id="Tc_cY6m9p2bwE6wOBg8WKt3tA_9_20"></a><a id="Tc_VPFr24iV9US31JeSKW57dA_9_23"></a><a id="Tc_e6W3bESxc0yWDMyfMbGk3w_10_0"></a><a id="Tc_PytPQtrTFkuaEQE418CM8w_10_2"></a><a id="Tc_P6W_rV6uI0mxTNoXMsBPng_10_5"></a><a id="Tc_Gp0sjpQ6wUajY7iQvt6lTA_10_8"></a><a id="Tc_M4DCj0VN1EOWENNKIsW8tA_10_11"></a><a id="Tc_ExCFaMK850uI2-JqVg1q5Q_10_14"></a><a id="Tc_F55NSDg4vUep6dnEfUBSaQ_10_20"></a><a id="Tc_P2QOchs9tkOxzoKye0n4qg_10_23"></a><a id="Tc_7mxqbQeAHUqYXXaMAxOLMA_11_0"></a><a id="Tc_SVbRgd21qE-8ihVG2sdp2w_11_2"></a><a id="Tc_o3QanoXbQEKt7EB6t-PyYQ_11_5"></a><a id="Tc_JeZCBqZ9SkmeiZbJ22g_7g_11_17"></a><a id="Tc_AOBGudz8Ok-Tlme7NodbxQ_11_20"></a><a id="Tc_fklLP7izCkq7MZ7VRMEQjg_11_23"></a><a id="Tc_huc-J9vs30-8jnGUMk898w_12_0"></a><a id="Tc_Qfikj8PWC0arna9e-d1_mA_12_2"></a><a id="Tc_RvQ5l6MWWUS_Baeq82xQgw_12_5"></a><a id="Tc_ZpBpCD0kbUK7kYNPgjobog_12_17"></a><a id="Tc_YwwYK0FE5EKJ0k2WBHw1vw_12_20"></a><a id="Tc_cPniOrB7lEiuNrkb0CgjuA_12_23"></a><a id="Tc_fZ28Rk7XfEGhsLSblYDG6g_13_0"></a><a id="Tc_kpU2osJzBU6gMQUa1ay5IQ_13_2"></a><a id="Tc_HCyO7xlttkSFOdTUwVUp5g_13_5"></a><a id="Tc_qo3UcU29oECrVUW3CBhZ6Q_13_17"></a><a id="Tc_CWNxnfHEV0yxeOUiNhfcSQ_13_20"></a><a id="Tc_vmT_B53yjU6pbBCZOjoZxQ_13_23"></a><a id="Tc_-s7d4ScbWUemSQYCHil6xg_14_0"></a><a id="Tc_3oYUTovZ7kuRyhTSq20Dqg_14_17"></a><a id="Tc_lmRawJlmu0yhAM76i4MolA_14_20"></a><a id="Tc_4Uyeh9xOHEK0n4BEixqeVw_15_0"></a><a id="Tc_txT1yu9F8UmZWanVJ7yt9w_15_2"></a><a id="Tc_DCl0d1uioUGBXT54iystpw_15_5"></a><a id="Tc_OkQna9R5QkKZ-H7FiSgebQ_15_11"></a><a id="Tc_aM_2LOgZv0KCgrAu6VcaJw_15_17"></a><a id="Tc_Tqz7yvnq8kuRo3VMZL7KNg_15_20"></a><a id="Tc_xaYbr63veEudehzxkj9AXw_15_23"></a><a id="Tc_edxrPyVtVE-67CYA3wnB-Q_16_0"></a><a id="Tc_hLauYQGMZ0ae472EOZybzw_16_2"></a><a id="Tc_dkmM39Yk0Eqwkk5BJYKhkA_16_5"></a><a id="Tc__0YD01YcnE25whTbzqH4pg_16_8"></a><a id="Tc_ZSzqSNNMskq_GLyXTSVHmw_16_11"></a><a id="Tc_dnJZ5vqA90KUfMAF8DYtsQ_16_14"></a><a id="Tc_UpbqgNUNPkytpuqA_5Etmg_16_17"></a><a id="Tc_MYQtrtyrGEy6J_EBQiPC_Q_16_23"></a><a id="Tc_6aaDr5gglEy61pByaEbT2w_17_0"></a><a id="Tc_WKnwwmyL4Uu5obvgxgLdVw_17_2"></a><a id="Tc_sJ9UEzw85U-S8-ncAy_PNQ_17_5"></a><a id="Tc_Xu5KMnQ4C0qVOZg9dcvlqw_17_17"></a><a id="Tc_7ze9TqJ4H0aog9MNeh39lg_17_23"></a><a id="Tc_2IeNKMEuFE-tODQkaI516Q_18_0"></a><a id="Tc_M3g_bP2BX0ir_tJQzvgpDA_18_2"></a><a id="Tc_upg5ew57dUe9Ijjtwu9kMA_18_5"></a><a id="Tc_BmM9j5dfwkuC4ikFir4Sjg_18_11"></a><a id="Tc_Ec8bt2SohkeraMFS_4h6Vg_18_17"></a><a id="Tc_2LDXkEQGt0qx9flWgBz2tw_18_20"></a><a id="Tc_UTvwvAaw80Gn47Eyz7DtNQ_18_23"></a><a id="Tc_2xi26v9KVUGNmBO3hTPr7A_19_0"></a><a id="Tc_GLmZCutS0U6UdWnWrDIP1w_19_2"></a><a id="Tc_iIt1hy_7GEOb00BKri4O0A_19_5"></a><a id="Tc_axK6FqKimkOLvhGHbWW4ug_19_8"></a><a id="Tc_D7Hekxa1dE6G6TQ_Bp-lMA_19_11"></a><a id="Tc_YAXRRJiWP0CIRy4eUaG64w_19_17"></a><a id="Tc_eJBcm5oGQEaK7KpzcHLsrQ_19_20"></a><a id="Tc_rH6FWN8QLkylZYqoco4NeA_19_23"></a><a id="Tc_ve5mmK7LPE6hV8DxCpqV4A_20_0"></a><a id="Tc_cpb6m42Y2UegYFGAKp8SYQ_20_2"></a><a id="Tc_whXbPJGkR06quKZXgYvbKQ_20_5"></a><a id="Tc_HQVZSuu4b02s6Ix9qaUXhw_20_17"></a><a id="Tc_ONVoWo7DvUqbHf-B6w8TJA_20_20"></a><a id="Tc_jtROtTlF80OusndfZt7cqw_20_23"></a><a id="Tc_NeCDcloKv0-oeaNP7wz4Tw_21_0"></a><a id="Tc_1UabDzeDtkSH-H4yTzrDOQ_21_2"></a><a id="Tc_zr-bo3l620KBgom5E6qYjw_21_5"></a><a id="Tc_KKsC47KuUEiXSRvhgBW3-A_21_8"></a><a id="Tc_gtIlu5wHckuy7sN9yYblOw_21_11"></a><a id="Tc_qGKQjO8HiEKmgOWKDBUemw_21_14"></a><a id="Tc_0FnpVQKT-0GFwokJ60Fpnw_21_17"></a><a id="Tc_hyk0CYAjrk6xRjzqZM0vfw_21_23"></a><a id="Tc_svXEVVMvsES46i402tfypA_22_0"></a><a id="Tc_MX5MLcqHAUWKSfLEWWsMAQ_22_2"></a><a id="Tc_EB4se5tJcUOe0lbHyinWjQ_22_4"></a><a id="Tc_Jh8KggCSq0WU_V9t2Kf1yg_22_5"></a><a id="Tc_QA5j6Krmj0We9eukFz0Ckg_22_10"></a><a id="Tc_hr4ctj1uzE-4u4ArRrEXBA_22_13"></a><a id="Tc_tcRpiXWKQUCQVp3zH9xD7w_22_16"></a><a id="Tc_7sSNSDWrckCeXydDbReUsg_22_17"></a><a id="Tc_ecD4SpKnLkuWQTyTVaFerA_22_19"></a><a id="Tc_FQM4sJj5JEuSTFlgm8Qt3w_22_22"></a><a id="Tc_ePYDF1bVxkGGr7r7vOpqkw_22_23"></a><a id="Tc_J2qjw7ULdUuZbC_VlHoVkQ_22_25"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible preferred stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="19" style="vertical-align:bottom;white-space:nowrap;width:55.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; (Deficit) Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Noncontrolling</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">interests</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance, December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_p8XQyH9BF0aYRMr4XoxG_Q_6_2">8,700,885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="Tc_ENGYyLNejk-H2En1wsTpDQ_6_5">107,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rddcZYrYF0aGvo9ie5UZTQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_c0iPWTNTYkizOzRvqZ0jKw_6_8">2,217,737</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rddcZYrYF0aGvo9ie5UZTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_UbzwsLjYJUO-FNAoDEysPg_6_11">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_W2GgALqdeUG9d8eSxLoY-A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_nOVT6EUfFkCrXpXBUuaUJQ_6_14">1,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Gi-5K4vpZ0SQCZsnJh6q1w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_pPfQlYnCRUCmAOyCJyGBEQ_6_17">41</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mWoZC8JK0EyoFq85L59bzA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_JWIGVHmM10ulHxbh_Xb8ww_6_20">158,223</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_4dq94_1obkuQkmJaNiEQBQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_eklVUV3Tk0G9StNjnRjE_A_6_23">14,395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_aq1PeZ7OQ0OLnK-Td6OVBg_6_26">142,670</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_bKL8fo_fHE6p010QTczf1A_7_8">128,716</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_WDU4c0mgUkaBi8m_NU_2Qg_7_14">187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_jbTgDoXy7UyQdJuEKXDuVQ_7_26">187</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_gu6tszI5Dk-2SgNNCrOcdg_8_14">2,316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Ys6Nn_KSp0ipkS8ZIPZgeA_8_26">2,316</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Unrealized gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qPQeNLve40WJSXsRyUdx0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_3hBntpiaXUyTvgfTFpq5gw_9_17">440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_wPxLjCRYMEebjWRw41QRZA_9_26">440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Reclassification to net loss of previous unrealized gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qPQeNLve40WJSXsRyUdx0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="Tc_iLdijBLhIUqQe41yIO5rtA_10_17">399</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="Tc_wmwyIdXCSUOM1x5PiCKQGg_10_26">399</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock for cash in pre-closing financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ" decimals="INF" format="ixt:num-dot-decimal" name="carm:StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" scale="0" id="Tc_631xhzqymUqlEyAdC8W2vw_11_8">3,730,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" scale="3" id="Tc_cBrt6_nL5ki1kLfFsiUfRQ_11_11">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w" decimals="-3" format="ixt:num-dot-decimal" name="carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" scale="3" id="Tc_AqByaNI6H0mN1t0ecbt7oA_11_14">30,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" scale="3" id="Tc_DJCa9THa1EOzmTPvSjX9PA_11_26">30,640</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_9q_2fgqNNUyVTnpIO2OGRA_12_8">5,059,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_Q693_hfPfUyR6TF3sm0DPw_12_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_hCRl3Zs7PESZ3FpRvHDvhg_12_14">42,442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_Mun6Wvlho0WAER8oO_g_Ag_12_26">42,447</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock to Sesen Bio shareholders in reverse capitalization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Tc_WAyz77n3ok-BDUi6tpYLnA_13_8">10,374,272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="Tc_hGhEyMXBzU2Zc8TS1SbgSg_13_11">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="Tc_DkEtVA56okezX9u5M2ItNg_13_14">72,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="Tc_XCX6xXEqO02O0kCJkO4JjQ_13_26">72,044</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Conversion of convertible preferred stock and non-controlling interests to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="INF" format="ixt:num-dot-decimal" name="carm:ReclassificationsOfTemporaryToPermanentEquityShares" sign="-" scale="0" id="Tc_xtJ8yGRJmUSIkX22sKmunw_14_2">8,700,885</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" sign="-" scale="3" id="Tc_EdQotmM7D0yakwIazDFEbg_14_5">107,808</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ" decimals="INF" format="ixt:num-dot-decimal" name="carm:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" scale="0" id="Tc_7IKZwR5BGEapTR5X5ld8xg_14_8">18,872,711</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" scale="3" id="Tc_VsMvmhl1FUq6I0E_4o96kA_14_11">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w" decimals="-3" format="ixt:num-dot-decimal" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" scale="3" id="Tc_4JpExyX2GE-vXzscwun6fQ_14_14">122,185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_pDUA6rIWwk-29qcuwaw0qg" decimals="-3" format="ixt:num-dot-decimal" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" sign="-" scale="3" id="Tc__sNvPTcUe0-dPehn66ddmg_14_23">14,395</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" scale="3" id="Tc_PFO2gvIMik2djkdhYVMDbw_14_26">107,809</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sale of common stock under Open Market Sales Agreement, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_qBofQcmgFkqWDWxUreYOdA_15_8">226,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc__djNd1YoBUi9ypMwi3g4Jw_15_14">597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_ZQLMmsMvH0eIqT8ht3zA6w_15_26">597</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dkWHVbHbIEmBDtxSTvwOZA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_RA1PattwDEKLCOu_eSDfDg_16_20">86,879</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ryqgrnM5WUGisA6yT7kkWQ_16_26">86,879</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance, December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sizU-8d-HkiGAXLhA7EliQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_Fdyb7_vx-kuvuJmLWHeJZQ_17_8">40,609,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sizU-8d-HkiGAXLhA7EliQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_Djc7VGoSD061xuTT-Rd_6Q_17_11">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CiZKxNIbvEyRs27cGTE1kw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_Jt8s8q1Q60yM7iFLYe5ahg_17_14">271,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p0MZ0Mf-7Uu7LB1ZZP5Iyg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_oVdMUnYltkeMDHZq2IW7Ew_17_20">245,102</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_eceFI1LNxky5NK75P8QxVA_17_26">26,532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yJlKgp-b0a9kywLP5wfMA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_DqHYuOj7aEO24zUeM58viQ_18_8">3,810</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giltrRhLwk2uYDDpgJGllg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_WPLCq8msS0iUAbeWH70daA_18_14">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Lc6hxokluUaEt3EbJn5Eeg_18_26">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giltrRhLwk2uYDDpgJGllg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_kA9DN3z01USnb79VXvD40A_19_14">3,649</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_4D3L3KxAnUa321yy9gOusg_19_26">3,649</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sale of common stock under Open Market Sales Agreement, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yJlKgp-b0a9kywLP5wfMA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_qtl8_XFIMUOuUzkKfbScag_20_8">1,136,384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yJlKgp-b0a9kywLP5wfMA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_C8xEfKyJ4kelmOYNZn-SqA_20_11">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giltrRhLwk2uYDDpgJGllg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_j5FnCm6h3E6qt5tOBu009Q_20_14">2,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Ng3LhRHoIEirCsukIgODqA_20_26">2,383</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-EXk6InjekuA8cdEMBjBkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XstGPXYV00W52ViZzbiJNg_21_20">60,477</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_doylNCyCEESVwJV42zjziw_21_26">60,477</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance, December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVEm6mt950Ss-dIhOM6psw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_8tQAuwAWzEGWBmZ-qyoY7A_22_8">41,750,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVEm6mt950Ss-dIhOM6psw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_bdzlEGHEm0anFnKQBBZbLg_22_11">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JA8S9njYW0u1srOBy-b4Fg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_qSrLUTajkk-rdMHnpOPjkg_22_14">277,629</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lu-cSSufUEqWCNoTK34t1Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_q-eqKcU83kKow5Jy8ZalKQ_22_20">305,579</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_gQOSzc4BE0CjaCrwjtGTQw_22_26">27,909</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0adfd1bd_8298_486c_85d2_6957fa6ec123"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><a id="CashFlow1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_67347d9a_2b90_4999_a0da_cf5a25065c4e"></a><a id="Tc_EHh0PlcfW0SyjhI23bj2jg_1_2"></a><a id="Tc_297XO5j6XkeHTDMgvU-d_g_2_2"></a><a id="Tc_HfuRt6FPOkK317eCBYF_xQ_3_2"></a><a id="Tc_pn9XBWJn8kmFjnK9jsBCUA_3_5"></a><a id="Tc_YRJN8dj3zEapoKcN616lDg_4_0"></a><a id="Tc_njjayrvYKkSwRKsht6bF6w_5_0"></a><a id="Tc_4oyhhzjWLE6fqZqTzYaVKQ_5_2"></a><a id="Tc_JJEKcNnLJEyp4sFfLCY8Kw_5_5"></a><a id="Tc_aoOHEwnA-EyHDv7bCOmZpA_6_0"></a><a id="Tc_vk3v0sxdVU62uSozrJl9Rw_7_0"></a><a id="Tc_LwMmsGTPcEGDwydNNcEYeA_8_0"></a><a id="Tc_Ez5hC3ChzUmmoA2yEB5e5A_8_3"></a><a id="Tc_GslfYWCCuUa2Mmfe24N83w_9_0"></a><a id="Tc_Bo_qIjKqt0-yImFlKfJAtw_10_0"></a><a id="Tc_jHk6P66plkCqmLkXvCp2Qw_11_0"></a><a id="Tc_4K-qyb0NLk6nWIGwbz6g5Q_11_3"></a><a id="Tc_9UO-x5Pd7U2jKegafqjXeg_12_0"></a><a id="Tc_vIV_WpQxn0inr78Zvf7gyQ_12_3"></a><a id="Tc_cPZKxZ7Ig0mIJBvdzJhAjA_13_0"></a><a id="Tc_uZkxWYGCtEWP7VEQ6Cyg-Q_13_3"></a><a id="Tc_Sk99z_55702T2_7JqUD43Q_14_0"></a><a id="Tc_2SOYpL-iNEGhvDXys9-f7g_14_6"></a><a id="Tc_E8zjGbjqPk21fU8-fG9CEA_15_0"></a><a id="Tc_EUTGZYGfR0-OPMiqQkZzyA_15_3"></a><a id="Tc_ebkclpyHjkmuXug6i0s7ww_16_0"></a><a id="Tc_d4DX4xNvt0-eSQNHbUPJvg_17_0"></a><a id="Tc_Ccf2XzvdWEu3GNlahbtDGw_17_6"></a><a id="Tc_1YAp-YSJ10iN5ziav2TQyA_18_0"></a><a id="Tc_qNc6J8juQU-pg4-6AUnSdw_18_6"></a><a id="Tc_F95q7yGpV0WJ_E3FtZasOA_19_0"></a><a id="Tc_Oi_RuMe_tEekMFyk59JTlw_20_0"></a><a id="Tc_SIchav1wa0CRK332nDRTHA_21_0"></a><a id="Tc_mVibh5vfwUG-__ahNrUD5Q_22_0"></a><a id="Tc_bDTtamOJQUSKfwuwAjMHWA_23_0"></a><a id="Tc_2hLQa-CTwkaT5-pSlEmZwg_24_0"></a><a id="Tc_rDN8cl8ZDEug7oi9OSzWyQ_25_0"></a><a id="Tc_wOlS6aGB3ki0OOMnoKgmWw_26_0"></a><a id="Tc_vDF509jLk0OAcFuMszxWiA_27_0"></a><a id="Tc_rzZWZYSAvUSWxjVq1m2JQA_28_0"></a><a id="Tc_F-2K5FivpECDl7L_VSPcqQ_28_3"></a><a id="Tc_jBP-DRPcG0aPn9k2-4H-cw_29_0"></a><a id="Tc_btwGIm9ytkKwUwRz53B4FQ_29_3"></a><a id="Tc_m5WBpLbMEE-Mh9-dw3Cp4A_30_0"></a><a id="Tc_TIaMXo6Z1EKweWD_A9JdUQ_31_0"></a><a id="Tc_t4K9LWLPgEedvDaz6A8tyg_32_0"></a><a id="Tc_CPuUzx_a20qEr5pczUQqng_33_0"></a><a id="Tc_AXRrbUdgp0WXMQiCPUEgBw_33_3"></a><a id="Tc_thUjVDJqpUSIzuj6D30dqg_34_0"></a><a id="Tc_qKRyMuURYEGVWsUX9wG7uw_34_3"></a><a id="Tc_DXspx5REtki8I7onOrIWGQ_35_0"></a><a id="Tc_7P47_f9tnUeVnsrE9ayLPQ_35_3"></a><a id="Tc_azHYIAywykShyNUuQcwfEw_36_0"></a><a id="Tc_XO6_B7HFFUizYXQF3fE2Wg_37_0"></a><a id="Tc_xFp2sYXMI0GJ3Sa3vBFXMQ_38_0"></a><a id="Tc_LwtzK2PNqkmw7xm8rber6w_39_0"></a><a id="Tc__x39xn0Dwkar3hMeZOEcag_39_3"></a><a id="Tc_M1Deu_34CEa9a25txf3XxQ_40_0"></a><a id="Tc_c4QbfgQElEePObvDvjjKUg_41_0"></a><a id="Tc_L-RaRGoVx0G4b829BRvO6g_42_0"></a><a id="Tc_KrmAAWw2bE6v-SkpHkPwqQ_43_0"></a><a id="Tc_55AlFVD9NEqls67BD2R9HA_44_0"></a><a id="Tc_MEvau84LlUarE82ScnSbGw_45_0"></a><a id="Tc_6_GDZGaMG0eozoZtGSjrXA_45_2"></a><a id="Tc_suF0-lPyoEutdAa5YLbKdA_45_5"></a><a id="Tc_PfcS2DatHkeVSYnwzF5iIA_46_0"></a><a id="Tc_7Rv0RsrHNEmgzKDOfuxsmg_47_0"></a><a id="Tc_nVePIliQ2020rFCmi-rukQ_47_2"></a><a id="Tc_IcM5ql_Yl0SsDtVa2Un9Mw_47_5"></a><a id="Tc_zAPVNxvqaEC-Zg4G1RsK1w_48_0"></a><a id="Tc_W8p8BSkqV0aHHSfWMYTf8A_49_0"></a><a id="Tc_m04d25UuhkiOLtzZS7pO7w_49_2"></a><a id="Tc_FexOTozdk0uwC_OghTyJRg_49_3"></a><a id="Tc_FYJjYPvdbEKZzOLIUpp2GQ_49_5"></a><a id="Tc_BExltBdj_UKZzvtAaaZLpg_50_0"></a><a id="Tc_ttBfeQtrZEChjWuD9e-8Tw_50_2"></a><a id="Tc_UR7MtgCGKUexsks5VmzdbA_50_3"></a><a id="Tc_SLL8U8KjAU-nU5Io4-rU2Q_50_5"></a><a id="Tc_QnVRCeam_0mm1ayTnnaxqw_51_0"></a><a id="Tc_T6mP1HX64USUqUfKy1RWug_51_2"></a><a id="Tc_XEqkAzPSs0ynHuNEElpxZw_51_3"></a><a id="Tc_DqJOeYBrc0uxP3Cs1zu-WQ_51_5"></a><a id="Tc_oAIXh01gDEK7kEKKX6hiow_52_0"></a><a id="Tc_9x6yOW8jy0WSZVAqLsLdfA_52_2"></a><a id="Tc_pdH860WhF0SWV0a_1sn-CQ_52_5"></a><a id="Tc_q8XrJ-uH2EiCp-0ebEWywA_52_6"></a><a id="Tc_mpY-4Wwzu0mKPiHF3xgkfQ_53_0"></a><a id="Tc_HLsAufE3iUeWYvE1o8pN5Q_53_2"></a><a id="Tc_Bl6OE7zOzUu2TiulpbCpOg_53_5"></a><a id="Tc_Assbln_kcE6RL96udL64hw_53_6"></a><a id="Tc_l2cYSuyFX0mLTr0R9F5vCA_54_0"></a><a id="Tc_uClfprG8-06HP-rrycL4Gg_54_2"></a><a id="Tc_LnoJjkF4WEOVxdectr9kzw_54_5"></a><a id="Tc_zvbx99vi-0CaP8lzqetF4g_55_0"></a><a id="Tc_aQ1sAlXezk2D3MmNuidrWg_55_2"></a><a id="Tc_g-1V_u1xfkaUi7eepqLXoA_55_5"></a><a id="Tc_UK4wiTPSCUmNHq7wBkH4Lw_55_6"></a><a id="Tc_zItchAZgsUODMamYzERbJg_56_0"></a><a id="Tc_BGCqq-8__UaW-h_Oc4lIXg_56_2"></a><a id="Tc_zgCa73xI6U6XH2Zzlxc0Cg_56_5"></a><a id="Tc_LglCbgcEhU2iv2_6cAUlWg_56_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_2PzkEeP5SEelAuFmHIVnEQ_5_3">60,477</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_8SrbnBJccEGMtSFQvN6sgw_5_6">86,879</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Adjustment to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_eTIzKyODD0y--o8U8PfowQ_7_3">3,354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_pJDaFwjYLU-A_blW4Qaasw_7_6">2,837</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Loss on disposal of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_Q5x-RX3x90-5DZR0VlIsVg_8_6">159</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_CNmmAUB6dUy02LnrzukVJA_9_3">3,649</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_GB6Ao6h3RkejvjUisiFD0Q_9_6">2,316</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Reduction in the operating right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_Z0Gjpvu1O0qJWR8ClxqbGw_10_3">4,963</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_tx67IpQLCUiPYOFQudCFHA_10_6">5,428</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Amortization of debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_SE6G5BXpdE-ekhM_EdeTFQ_11_6">1,283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" sign="-" scale="3" id="Tc_2XBpXWThLUSch-mMTWwKNw_12_6">84</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accretion on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:AccretionOnMarketableSecurities" scale="3" id="Tc_wrsjt67Fk0m0YTEkMBd-lg_13_6">709</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Write-off of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:WriteOffOfPropertyAndEquipment" scale="3" id="Tc_AVylJFC6oUWub_lX3JQPkw_14_3">362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Realized gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" scale="3" id="Tc_TZzDqkhsY0a5FVCpmkXC_w_15_6">399</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Non-cash interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:NoncashInterestExpense" scale="3" id="Tc_xyGL4bsmqkSZqyhsIhbPxQ_16_3">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:NoncashInterestExpense" scale="3" id="Tc_UsJiC6uL8EKwowxs1Qb9Fg_16_6">139</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Loss on sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:GainLossOnSaleOfEquipment" sign="-" scale="3" id="Tc_AJTpK2XvHEChFUg4KJ3Ydg_17_3">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Gain on sale of sale-leaseback</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" scale="3" id="Tc_mb3rLd7lH06mAon8EJwWHg_18_3">82</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_39Zt8lEVrEmoJJDmT_tzlA_20_3">3,120</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_S0SIOj9gj0C1JTmyhHstKQ_20_6">1,046</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_1ymrKhFFOEe8gA_EQbl2RA_21_3">1,852</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_BGIKFmpdx0yCP2slCNp2EA_21_6">2,191</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_BwL7QEdRrkKaMwxs4NRtrg_22_3">213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_b70pbFWKoEiq8klK0p6exA_22_6">2,899</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_yY5REgpMTk-zs_jK52_Qag_23_3">1,434</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_f3FtsqVYCkOHnDcVmbfUJA_23_6">1,046</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_fG5PNS0LOUiiLqVTJPo36Q_24_3">5,525</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_PumQDiKwGEupCnfy3BZtkg_24_6">4,941</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_YGZp2lHQpkeowaGj0PaKDw_25_3">192</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_i519MiD50E-6BxlaSucIIA_25_6">213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_bVNvZC2xXEiFjuWVNvjgIQ_26_3">59,917</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_bCMsgak7qEOaJzQuaegkLA_26_6">81,177</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Purchase of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_o42MLdPfSEedXUpwyikgcQ_28_6">34,460</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Proceeds from the sale of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:PaymentsForProceedsFromMarketableSecurities" sign="-" scale="3" id="Tc_KbU370ssmkaiUgthtAx3yg_29_6">108,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_h2dr_VgHLUG0zWZ591569g_30_3">123</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_m7I-IlpwfEG_U5x2x4XlEg_30_6">1,132</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash (used in) provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Zlb_RAH49UawUnC4wXKJdA_31_3">123</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_eP3BGxX6r0CUTjLoE8P9vA_31_6">72,408</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" scale="3" id="Tc_CgfiMrkSOEyTGTP3sEml0g_33_6">37,903</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Payment of reverse recapitalization finance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" scale="3" id="Tc_jHPokpxBD0q0VFR1REDbWQ_34_6">5,814</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Proceeds from the issuance of common stock in pre-closing financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing" scale="3" id="Tc_lM2d2S0WGkqDdt4dvduvrQ_35_6">30,640</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Payment of principal related to finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_ts4WOdJH-0ifEZi1CqjZ_A_36_3">1,429</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_qgQ7olwDoUK0WCKqb-b1jQ_36_6">1,301</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Proceeds from failed sale-leaseback arrangement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:ProceedsFromFailedSaleLeasebackTransaction" scale="3" id="Tc_4S4bo7scN0y2BUdKvG0YOQ_37_3">686</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:ProceedsFromFailedSaleLeasebackTransaction" scale="3" id="Tc_ASXWvdnobU-q5-4hZnUA9A_37_6">1,183</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Payment of finance liability from failed sale-leaseback arrangements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" scale="3" id="Tc_NQasSKnBbUmzbVeaC0Mbkw_38_3">1,309</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" scale="3" id="Tc_fOMQrx6dhkGPLBJUBfr5iQ_38_6">1,069</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Payment of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="Tc_Xu7tjOgRTUeK76jLWt0C5A_39_6">146</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Proceeds from the exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_PSw50UdE20Wp_FfIND541Q_40_3">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_KopKyvoXtUavdrRpBAIYyg_40_6">187</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Sale of common stock under Open Market Sales Agreement, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_2MKHfECWaEOLJzc4CLskjA_41_3">2,392</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_S1qNcdJ2gEqQxZDCOXTa4A_41_6">597</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Mx9FhPGWmEyKPocaU2-ohg_42_3">344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_sblf370ey0eBr5BvPlMOPQ_42_6">62,180</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_8hUBBWZSt0GxhdqS66fRKQ_43_3">59,696</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_YVt0DFND4EiBm3bILOgw8Q_43_6">53,411</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash and cash equivalents at beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Os6R0bb7YES_WafB5TIodA_44_3">77,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_D_8kuBKHxUSXirwbCahvMw_44_6">24,194</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash and cash equivalents at end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_u8p0gbo_B06YwvcLdst5Tg_45_3">17,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_2-GU0BFUsEm06dpRXU_4sw_45_6">77,605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Supplemental disclosures of cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_oghPBhTilUKnNGvf3xxVow_47_3">192</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc__hIc5wNwS06HBa0js0I3yw_47_6">352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Supplemental disclosure of non-cash financing and investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Conversion of convertible preferred stock and non-controlling interests upon Merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:NoncashOrPartNoncashAcquisitionEquityAssumed" scale="3" id="Tc_Xa_ZQyU-KEeOIUgDLi17qg_49_6">122,204</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Conversion of convertible promissory note, accrued interest and derivative liability upon Merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesReduction" scale="3" id="Tc_PS8lHraJ60O7ChnDtHoLtA_50_6">42,447</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Unrealized gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" scale="3" id="Tc_SOSfZuRMFkOJpQeCTmZjVQ_51_6">41</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Reclassification of deferred financing costs to additional paid-in-capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" scale="3" id="Tc_z2pOg6eitkiMeIQyOSBXzg_52_3">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Right-of-use assets obtained in exchange for new financing lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability" scale="3" id="Tc_MiVCyqLtf0GrRJpxiMn3bw_53_3">1,660</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Right-of-use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_OH5a7lq8JUWaciLuuk4tBg_54_3">6,411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_DnPlzIB2zUWF1MRVIRDgIw_54_6">2,779</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Modification of operating lease right-of-use asset and operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" sign="-" scale="3" id="Tc_fbvZ_MK9BE63NdLUM02fIQ_55_3">1,581</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Disposal of property and equipment in exchange for reduction in financing lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" scale="3" id="Tc_CZMgClRQEkyIKe4zVP2IAg_56_3">396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Notes1"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_H9FouxHpLkmjQFyGUXat9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-weight:bold;">Background</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma Therapeutics&#160;Inc., a Delaware corporation (collectively with its subsidiaries, the Company), biotechnology company focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;and December&#160;2024, the Company and its board of directors approved revised operating plans to reduce&#160;monthly operating expenses, conserve cash, and refocus its efforts on strategic priorities. As part of these plans, in March&#160;2024 the Company elected to cease further development of its first lead product candidate, CT-0508. In December&#160;2024 as part of the plan, the Company elected to cease further development of its then lead product candidate, CT-0525, following an assessment of the competitive landscape in anti-HER2 treatments and the impact of recently approved therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of its cost-reduction initiatives in 2024, the Company implemented workforce reductions during 2024, resulting in the termination of <ix:nonFraction unitRef="Unit_Standard_employee_8zftLesBXkivzIcTQ6E96w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ATt2SkLHckWBYPbLkkt-Gw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="Narr_coJ0WbHKPEqtew9IhmaUYg">62</ix:nonFraction> full-time employees (representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ATt2SkLHckWBYPbLkkt-Gw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_qIWV4lhHIkWbDpk2I7erng">58.0</ix:nonFraction>% of the Company&#8217;s total workforce), across research and development and general and administrative functions. The workforce reduction resulted in $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ATt2SkLHckWBYPbLkkt-Gw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="Narr_mJBhEtsL8kGMKRMfTfOVqw">4.1</ix:nonFraction>&#160;million of severance related costs, of which $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_c0xoT3reKkCaOeL1zPSHLQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="Narr_rjqOgoMUsUSIT2zw6swBpA">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_IC7n65_vc0OYd91beSu5RA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="Narr_6pyASvdGbUaDqSMWzbTJpg">2.1</ix:nonFraction>&#160;million are included within <span style="-sec-ix-hidden:Hidden_fhlu0P8GC0OSYzMKRGa6pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general and administrative</span></span> and <span style="-sec-ix-hidden:Hidden_qKYmVxKGPEGEDMmZP0kvsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research and development</span></span> expense, respectively, in the accompanying consolidated statement of operations and comprehensive loss. As of December&#160;31, 2024, $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_oh2OTmiJvkKgA0D-o9Y6Fw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserve" scale="6" id="Narr_Jr1NJm6BBECrF0bGZwumWg">2.7</ix:nonFraction>&#160;million in severance costs were accrued in the accompanying consolidated balance sheets. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the 2024 reduction in workforce.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;10, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that our common stock was not in compliance with Nasdaq Listing Rule&#160;5450(b)(2)(A), or the MVLS Requirement, which requires the Company to maintain a minimum market value of listed securities of $50,000,000. The Company has 180 calendar&#160;days, or until April&#160;8, 2025, to regain compliance with the MVLS Requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On January&#160;6, 2025, the Company received a separate written notice from Nasdaq notifying the Company that, based upon the closing bid price of its common stock for the last 38 consecutive business&#160;days, the Company was not in compliance with Nasdaq Listing Rule&#160;5450(a)(1)&#160;(the Bid Price Rule), which requires the Company to maintain a minimum bid price of $1.00 per share. The Company has 180 calendar&#160;days, or until July&#160;7, 2025, to regain compliance with the Bid Price Rule.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="carm:DevelopmentStageRisksAndLiquidityTextBlock" id="Tb_IIVISC03PUK_YVS7JyPtlg" continuedAt="Tb_IIVISC03PUK_YVS7JyPtlg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span><b style="font-weight:bold;">Development-Stage Risks and Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_Q6G2p4tMqkq1PvctdCxH-w">305.6</ix:nonFraction> million as of December&#160;31, 2024. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of December&#160;31, 2024, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_NJqzj3yb-0K91buWyVukGQ">17.9</ix:nonFraction> million. Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one&#160;year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company&#8217;s ability to continue as a going concern. In addition, changing circumstances could cause the Company to consume capital significantly faster than currently anticipated, and the Company may need to spend more than currently expected because of circumstances beyond its control. The Company&#8217;s cash forecast contains estimates and assumptions, and management cannot predict the timing of all cash receipts and expenditures with certainty. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liability that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Management is currently evaluating different strategies to maximize value and prepare to wind down the Company&#8217;s business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_IIVISC03PUK_YVS7JyPtlg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">divestiture of one or more of the Company&#8217;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. There is no assurance regarding when or if this strategic review process will result in any type of transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_-hdaUaWV3EKbKfIbsMiJ2g" continuedAt="Tb_-hdaUaWV3EKbKfIbsMiJ2g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(3)</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_0B29rIV8I06ok93LP2fsdQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:UseOfEstimates" id="Tb_UMFT8Zv_-UO4-ndbsfKP6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant areas that require management&#8217;s estimates include estimated research and development revenue, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_b1E-vdPYsUazD6plbkgg9g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_udeUxS8fiU6fSDkahdVkQw" continuedAt="Tb_udeUxS8fiU6fSDkahdVkQw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a01222cc_46b8_4398_b534_3b0b52fa0cba"></a><a id="Tc_IFZba40q2kufLEKEquNApw_1_2"></a><a id="Tc_7tUNgrHh80Wqz3I5GMFVEg_2_0"></a><a id="Tc_0xfgF-m3FUSkkQ1UCZl4SQ_2_2"></a><a id="Tc_9KIvzlNPKkenr7JQC2F8xg_2_5"></a><a id="Tc_SmqFzNLJhkCQJ8j4g5P1_Q_2_8"></a><a id="Tc_AH2kB8jUOUicqsVL7IIVtA_3_0"></a><a id="Tc_WHAFPoN5TkWWo7lwfpq4CA_4_0"></a><a id="Tc_mXXP7xnorE6FR_8gOuxk2A_5_0"></a><a id="Tc_6pnvwY0Ik0CeRHKls7U-yw_5_2"></a><a id="Tc_wmOX3mxn-0a4UUoHnUBIVw_5_5"></a><a id="Tc_jP1Yf-KiMUauG3_XBBaoWg_5_6"></a><a id="Tc_gWnwfgzyfUaLc2xouVxRFA_5_8"></a><a id="Tc_qm2Je1jGrEGC4ka3EO_BWg_5_9"></a><a id="Tc__Y1Cc1DxlEuzVqudg8MV3A_6_0"></a><a id="Tc_AO-f_buY2EuHKjt7r9WJ0g_7_0"></a><a id="Tc_S1FKrTxxcU-didE0XiWFYQ_8_0"></a><a id="Tc_HHiDPG3VQE6_gC8xSmzQxA_8_2"></a><a id="Tc_ZCpUZTwxgUus3ggjj63BUQ_8_5"></a><a id="Tc_AM2oKSX0uEaHL7BsNlhPlw_8_6"></a><a id="Tc_Ly-6RLvG3EatS42F6SFPIw_8_8"></a><a id="Tc_BUOT4Wb3aEG_BMjdaj4QPA_8_9"></a><ix:continuation id="Tb_-hdaUaWV3EKbKfIbsMiJ2g_cont1" continuedAt="Tb_-hdaUaWV3EKbKfIbsMiJ2g_cont2"><ix:continuation id="Tb_udeUxS8fiU6fSDkahdVkQw_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr></table><div style="margin-top:12pt;"></div><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_4gRnamplLk-mqYexy3okNQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_FPiLpPUNo06fNsnw6eJy3A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_MqQdEYQTbEyD9E2iC3zoxA_5_3">14,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_i3-WcXRxi0W0jzEpmZkO4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_pEuUi67Ot02_t9K1VYgFTQ_8_3">62,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_QI87H7O8CEiThqzp3QYihg" continuedAt="Tb_QI87H7O8CEiThqzp3QYihg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1)&#160;non-refundable, upfront license fees (2)&#160;reimbursement of certain costs; (3)&#160;customer option fees for additional goods or services; (4)&#160;development milestone payments, (5)&#160;regulatory and commercial milestone payments; and (6)&#160;royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&#160;the number of performance obligations based on the determination under step (i)&#160;above; (b)&#160;the transaction price under step (iii)&#160;above; (c)&#160;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&#160;above; and (d)&#160;the contract term and pattern of satisfaction of the performance obligations under step (v)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Upfront license fees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_-hdaUaWV3EKbKfIbsMiJ2g_cont2" continuedAt="Tb_-hdaUaWV3EKbKfIbsMiJ2g_cont3"><ix:continuation id="Tb_QI87H7O8CEiThqzp3QYihg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Customer options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and development services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The promises under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company&#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_qlNBx3BGkkGYgCiiFxThMA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_UCFBz0YBcUiCvkth7czORA" continuedAt="Tb_UCFBz0YBcUiCvkth7czORA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Segment information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4f59c362_e077_4cb1_8f24_c5c6b8b98014"></a><a id="Tc_9gYWIQ6AT02kvSBvd_Y06A_1_2"></a><a id="Tc_29fjgScfA0OPJd1ZBtuW8w_2_2"></a><a id="Tc_WqRpX5u4vkuSmFoIyeRG-g_3_2"></a><a id="Tc_U7dOL0dp5ECZLnlomFi_WQ_3_5"></a><a id="Tc_hcsihfL9KkaoBWdb37RNsA_4_0"></a><a id="Tc_OtuP4OjMn0ySpSuTKhko7g_4_2"></a><a id="Tc_2GinAWJ9zkm5Pr0aSQ6yyg_4_5"></a><a id="Tc_mrDU96nhXkytS5kOuj1B-w_5_0"></a><a id="Tc_4xFNdkzruUOiCIYi6MP9BQ_6_0"></a><a id="Tc__EWsxY91KESVBSmh6OpgVw_7_0"></a><a id="Tc_uo7b9TqiqU-XMLTA92P_tA_8_0"></a><a id="Tc_Mf7htXa7zUGv9MMraZkRFg_9_0"></a><a id="Tc_Y69v9e1njE2t9yXd52N83w_10_0"></a><a id="Tc_H3losy8Zk0idH-U-Zlr0vw_11_0"></a><a id="Tc_Qo3j6WRwlE6MTprH_AkoYA_12_0"></a><a id="Tc_XYbEUw3UnEuPuQtI3hDfdA_12_2"></a><a id="Tc_Brei5nceg0CEnjj3H2ELdg_12_5"></a><ix:continuation id="Tb_-hdaUaWV3EKbKfIbsMiJ2g_cont3" continuedAt="Tb_-hdaUaWV3EKbKfIbsMiJ2g_cont4"><ix:continuation id="Tb_UCFBz0YBcUiCvkth7czORA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">assessing performance. The Company has <ix:nonFraction unitRef="Unit_Standard_segment_ieOgHbuNO0uMDAyeDWsL6Q" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_3MGxWNEGXkS5c7Zi2csOag">one</ix:nonFraction> operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_nC-uDXv-i0KK1B7d3O3MXA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the&#160;years ended December&#160;31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="Tc_xW6HG0TajE62p-cH9H2pLg_4_3">19,632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="Tc_4doJu1VtykmD88WkD_Bg1A_4_6">14,919</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw" decimals="-3" format="ixt:num-dot-decimal" name="carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" scale="3" id="Tc_VD6CxjV_dE-qHazsd1TKlQ_6_3">33,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w" decimals="-3" format="ixt:num-dot-decimal" name="carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" scale="3" id="Tc_uAbdYWGi10W9IVCWn9kvsw_6_6">45,905</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw" decimals="-3" format="ixt:num-dot-decimal" name="carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" scale="3" id="Tc_eAepAi1CL0yrwTxjE6K2Vw_7_3">14,829</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w" decimals="-3" format="ixt:num-dot-decimal" name="carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" scale="3" id="Tc_31ufIBD7ak6bSeciyPBk8A_7_6">19,118</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw" decimals="-3" format="ixt:num-dot-decimal" name="carm:FacilitiesExpense" scale="3" id="Tc_p9005RqH20i4C_ybMmAQLA_8_3">5,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w" decimals="-3" format="ixt:num-dot-decimal" name="carm:FacilitiesExpense" scale="3" id="Tc_Ym3NwN2GAkeZuMvn1eH6OQ_8_6">7,671</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_Tau95sDw8E2gNnTAf1jM0g_9_3">24,564</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_TXeEjW6jzE2YWOWm_7arYg_9_6">27,324</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw" decimals="-3" format="ixt:num-dot-decimal" name="carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" scale="3" id="Tc_Kj3ZxRnunU27PQ9taiomHg_10_3">3,894</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w" decimals="-3" format="ixt:num-dot-decimal" name="carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" scale="3" id="Tc_gx5oP0c4E0uQ2WWDLT6C4A_10_6">3,984</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other segment items(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" sign="-" scale="3" id="Tc_w97pLue7N0-_TqZfVjsVsQ_11_3">2,242</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" sign="-" scale="3" id="Tc_7LT2qrz0KEG8hWpEIEFBvQ_11_6">2,204</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_bYK2moBqQkKfalCkIqUcLQ_12_3">60,477</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jT0dQsbSx0uXlUAyX_B3DA_12_6">86,879</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other segment items include changes in warrant liability and interest income.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_KDiS5ae5VUKOsHK_MIz5Qw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. As of December&#160;31, 2024 and 2023, cash equivalents consisted of investments in a money market account.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_Wko7YCepx0O_WreYZv5F_A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_w59cdNVWLU6d09CxPojcvA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to <ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_M2tlaUEGPU-AJlzF8cCTTw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_0i6ru0Np4keIOmfBj7QYag">five&#160;years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_Hu0oOxJF90CXzgAgUZiQOw" continuedAt="Tb_Hu0oOxJF90CXzgAgUZiQOw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="Narr_KOyJbYQSu0aEULjehtWe5Q"><ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="Narr_PmWbFpNxUk60L0TLCuiWTA">no</ix:nonFraction></ix:nonFraction>t recognize any impairment of long-lived assets during the&#160;years ended December&#160;31, 2024 or 2023.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_-hdaUaWV3EKbKfIbsMiJ2g_cont4" continuedAt="Tb_-hdaUaWV3EKbKfIbsMiJ2g_cont5"><ix:continuation id="Tb_Hu0oOxJF90CXzgAgUZiQOw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="carm:DeferredFinancingCostsPolicyPolicyTextBlock" id="Tb_7TQF5sfIIk-gburJFx3ZJQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Deferred Financing Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_duVRVEjfp0CN5ouiBYMq5g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one&#160;year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_WrcianDfcUW02npb6mrBkg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_R5jZf2OSJ0yjOF7Akhb5ng" continuedAt="Tb_R5jZf2OSJ0yjOF7Akhb5ng_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company&#8217;s common stock prior to the Merger (as defined in Note&#160;4), and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Merger (as defined in Note&#160;4), the fair value of the Company&#8217;s common stock was estimated by the Company&#8217;s board of directors, with input by management considering the Company&#8217;s most recently available third-party valuation of the Company&#8217;s common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f14a8949_b6c5_4943_99a2_2d78f5c599c5"></a><a id="Tc_fKlFc1VzPEK_w-bIlPxZeg_1_2"></a><a id="Tc_Sn0YlOg2mE6Tw7OxWGIHkg_2_2"></a><a id="Tc_wYjbux91skaODh1mqvjBtw_2_4"></a><a id="Tc_jxf4y0IvwUGUx8dBzlDhgQ_3_0"></a><ix:continuation id="Tb_-hdaUaWV3EKbKfIbsMiJ2g_cont5" continuedAt="Tb_-hdaUaWV3EKbKfIbsMiJ2g_cont6"><ix:continuation id="Tb_R5jZf2OSJ0yjOF7Akhb5ng_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_qbEpBwE-q0K3AbpVPD55fw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company&#8217;s consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#8217;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_Rql6D7rIZ0GRaLUrnvMRTw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_RfOjXOR880u186EN9hddPA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_0bTbe1UO4Eu2oXU8xcRc4A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_DOmHNv5D-kWjUEbt2HWjsg_3_2">7,746,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_4gn5Hkv1tkSIJa1ZsZNSzQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_t9Kmb2bP70yQPGY7yDdlsA_3_4">6,023,370</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_vRceG_uiF0uc-OeN6eiOYw" continuedAt="Tb_vRceG_uiF0uc-OeN6eiOYw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </i>(ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024 on a retrospective basis. The Company incorporated the improved segment disclosures in the summary of significant accounting policies, herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently issued but not yet adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </i>(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In November&#160;2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_-hdaUaWV3EKbKfIbsMiJ2g_cont6"><ix:continuation id="Tb_vRceG_uiF0uc-OeN6eiOYw_cont1"></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5a59af7e_110e_4af8_8590_0bf08eea96d3"></a><a id="Tc_s6Cd2Cnjg0CYc7QuihMQSg_1_2"></a><a id="Tc_NzrFtoC9z0GEri6aRNypig_2_0"></a><a id="Tc_msIzxwVaTU2RtHydPu7TYA_2_2"></a><a id="Tc_r_29kq48TEWXQVIJAJ6IPQ_3_0"></a><a id="Tc_JA2h3m_ce0mfraHbWKnFIw_4_0"></a><a id="Tc_109Hqk8LTU2wIafdtIl6IA_5_0"></a><a id="Tc_1mnrshFqaki--DemqS3VKw_6_0"></a><a id="Tc_pkYArmEo3Ua7Yd83K45g2A_7_0"></a><a id="Tc_EVqzWk3Rwk-2d3Hacn1IDA_8_0"></a><a id="Tc_Mv_qRZuL60qcEHBaaOBTdg_9_0"></a><a id="Tc_kYZOSz14IEqQDVJz8ckU-w_9_2"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="Tb_k9xuFLY8M0GQitht34-Sgg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(4)</b></span><b style="font-weight:bold;">Merger with Sesen Bio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;7, 2023, the Company (formerly publicly-held Sesen Bio,&#160;Inc.) consummated a merger with CTx Operations,&#160;Inc. (formerly privately-held CARISMA Therapeutics&#160;Inc.) (Legacy Carisma) pursuant to an Agreement and Plan of Merger and Reorganization, as amended (the Merger Agreement), by and among the Company, Legacy Carisma and Seahawk Merger Sub,&#160;Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company. The Merger Agreement provided for the merger of Merger Sub with and into Legacy Carisma, with Legacy Carisma continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the Merger). The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Sesen Bio were cash, cash equivalents and marketable securities. For financial reporting purposes Legacy Carisma was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i)&#160;Legacy Carisma stockholders own approximately <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="As_Of_3_7_2023_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_us-gaap_BusinessAcquisitionAxis_carm_CarismaTherapeuticsIncLegacyStockholdersMember_pAj3UmfAuUCFRdiN77L70Q" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="Narr_61esBNG_ekiIqsczyFtENg">74.2</ix:nonFraction>% of the Combined Company, (ii)&#160;Legacy Carisma holds the majority (<ix:nonFraction unitRef="Unit_Standard_stockholder_xwrsA79JVk6r5Olbumrfaw" contextRef="As_Of_12_31_2024_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_C2cp3L2L3EiZlfTKfZNEqg" decimals="INF" format="ixt-sec:numwordsen" name="carm:NumberOfBoardMembers" scale="0" id="Narr_wyt1KAm1hE-xfkFK6GoUxw">six</ix:nonFraction> of <ix:nonFraction unitRef="Unit_Standard_stockholder_xwrsA79JVk6r5Olbumrfaw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt-sec:numwordsen" name="carm:NumberOfBoardMembers" scale="0" id="Narr_ss0irSdqW0GvEw7Kmwu-Qg">seven</ix:nonFraction>) of board seats of the Combined Company and (iii)&#160;Legacy Carisma management holds all key positions of management. Accordingly, the Merger was treated as the equivalent of Legacy Carisma issuing stock to acquire the net assets of Sesen Bio. As a result of the Merger, the net assets of Sesen Bio were recorded at their acquisition-date fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Legacy Carisma. Immediately after the Merger, there were <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_7_2023_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_us-gaap_BusinessAcquisitionAxis_carm_CarismaTherapeuticsIncLegacyStockholdersMember_pAj3UmfAuUCFRdiN77L70Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_e5nohxq9X0KFDldcXUMYbA">40,254,666</ix:nonFraction> shares of the Company&#8217;s common stock outstanding.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="Tb_d4CrGAg0CkK0uwS7VqGFzQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table shows the net assets acquired in the Merger (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 7, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="Tc_xFAluFqt9UCIKdKswz9UAw_2_3">37,873</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" scale="3" id="Tc_88P3es2JuEKw9TBDo_ng4Q_3_3">44,588</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="Tc_dMO9hKC_ZECh-5E83u_dng_4_3">1,316</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA" decimals="-3" format="ixt:num-dot-decimal" name="carm:Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" scale="3" id="Tc_jwkSiXnUK0OFKx5n7SQNaw_5_3">30</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="3" id="Tc_PJfrCvRqC0W95DZjiAEPLw_6_3">3,499</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" id="Tc__p6PBuZeUEqCq8Ru2luT1g_7_3">80,308</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="3" id="Tc_tHDmuZUPYEmuUHWggnsusw_8_3">8,264</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total net assets acquired less transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="Tc_D2mUsFeGkkaSfmD_9u0YKw_9_3">72,044</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subsequent to March&#160;7, 2023, the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_3_1_2023_To_12_31_2023_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_61_8Uvl5hUOnb8pf--nrlg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="6" id="Narr_WWkxfb9W9EaKYDNephE1dg">4.6</ix:nonFraction> million of severance and personnel costs related to Sesen Bio.</p></ix:nonNumeric><a id="_f398dcb7_b1b8_4119_9854_6a33285d84b6"></a><a id="Tc_rxlFmez5dEGjc0JX_22FNw_1_2"></a><a id="Tc_zF-x42mT2kCJdWo9DHU0BA_2_2"></a><a id="Tc_qbWbP158i0mn-x9N5U1bZQ_2_5"></a><a id="Tc_6ZLn0uxU4UelCzFNQfiz3A_3_0"></a><a id="Tc_YBfEMiLck0mv2LUcF92wRg_3_2"></a><a id="Tc_l5Rea4geBUOjGxKXbLwZIw_3_5"></a><a id="Tc_HW38gkGKHEOcbKJKzEt0sQ_4_0"></a><a id="Tc_XQJP2TcNoUunUBFrV_YSAg_4_6"></a><a id="Tc_DpYMo0jiz0-4-b4hDAMKAA_5_0"></a><a id="Tc_ZhmyKaRsXki9Ne61VBSE2w_6_0"></a><a id="Tc_BNAbdn85hke3dYqD6HcQfQ_7_0"></a><a id="Tc_3ytpFXjk_0uEIYLpdVKShQ_8_2"></a><a id="Tc_S7ct7kDzq0ynA_iGafhusw_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:OtherAssetsDisclosureTextBlock" id="Tb_3iRnzq6pXUu3cT7aPXFakw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(5)</b></span><b style="font-weight:bold;">Prepaid Expenses and Other Assets</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_tzlg1HxfXkmVuN2p6-kIfA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prepaid expenses and other assets consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:PrepaidResearchAndDevelopmentCurrent" scale="3" id="Tc_FtXHt-vDiUSziJHoIyRdVQ_3_3">1,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:PrepaidResearchAndDevelopmentCurrent" scale="3" id="Tc_qRK7a79egUiNeI8Mk1ob6A_3_6">278</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Collaboration receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:ReceivableDueFromCollaborativeArrangementCurrent" scale="3" id="Tc_JFNl4VPjREOUQf2YEcUnjA_4_3">2,864</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_jFmrFFgLWEKDBxRc_-M2Nw_5_3">340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_BMQrSjOIcUOmNfq8z5rkeA_5_6">402</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" id="Tc_SzqJkexQ2k2WUl9r8nO3Og_6_3">925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" id="Tc_h7-bhCKrq02zdylfw2IQxA_6_6">891</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_CAifDpKeLkCCJdFYDomnJA_7_3">72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_YCIAJcaQFU-BzZmqpvTt3A_7_6">1,295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_ZGU_bVr9jEy2uDkO605wWQ_8_3">5,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_igXjBJVtOUufiH9G2C4-Jw_8_6">2,866</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1e05b7f9_5ecc_4354_abfe_46fe3f6e2435"></a><a id="Tc_ESEwXMT54EKbCcQAtJXFaQ_1_2"></a><a id="Tc_TrKEAL8fs0WY7WkLVcwsPA_2_2"></a><a id="Tc_u3ZcznCx_0G5h8MF09IjnQ_2_5"></a><a id="Tc_ZVxMVw_sYkGyVey3S-h03w_3_0"></a><a id="Tc_M1cIOXVUYUmKNOhCiOvEyw_3_2"></a><a id="Tc_OWRf7ro0pkWkCsaIqMf5gg_3_5"></a><a id="Tc_G7YErs66cEGUSZVPFMCbUQ_4_0"></a><a id="Tc_Vlxu6R55dkyM8Au7qHSQ3A_5_0"></a><a id="Tc_1xJGbf200UKGslul_jrlAA_6_0"></a><a id="Tc_2JceO-EI3U6LkAhGi0cvmA_7_0"></a><a id="Tc_UmnPfdeaSEqatJTLrehPnQ_7_3"></a><a id="Tc_xu1AFpv2YUy6G0C7PKi3Xg_9_0"></a><a id="Tc_VdA-T289g0uBP-fRx9iy4A_10_2"></a><a id="Tc_BN45tD6_F0eFRekNJ_IKhA_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_u7WxQGlVNUyQ7i1P9gD2DA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(6)</b></span><b style="font-weight:bold;">Property and Equipment, net</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_PVpiN2_ojUKQiaUmON-p7A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember_6a9BvHfS2069NVgEd9BlgQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_jed4e_tga0u06rTAO_TiRw_3_3">508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember_IuSFljhV5ECw_6wtTyDvMA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc__cf5HXVHwUCGeboDlTrPIA_3_6">903</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QKEF25OlKUyFEjDTw-T6ZQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_Jo3uH1Y-HUWDKv3VtHvuKA_4_3">11,157</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_V1MVYY5yOk6TrVp02Gj08A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_d9qAza6tfkqsWIbpGwWplg_4_6">11,392</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_SbAUMjqBzk-GzWMJw0e0Qw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_msK9wH_8xUmNDDJfcmINyA_5_3">267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_MqoxSix-Y02bOPp5O0niiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_vPvzpke-90ujC67qnffi-g_5_6">267</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_q6mQUCRJFESSS-dSvTvrAg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_Y9zRRZgsU0Swh7CatgWoew_6_3">340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_QBP2ErMrOUK4Ayldn4JM8Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_6LvW1MbxqU-S_43TgrJ33Q_6_6">340</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_GuIsy6UvbEOGPaKsDXeA4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_-Euj2zDHi0iQNYii3yY1eg_7_6">13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_CceeYxgMqkSpEuPL100UzQ_8_3">12,272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_WRJmrEDhN0KeyNrANZ4VGg_8_6">12,915</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="Tc_gVUEkTjOaUeRDSEF3g0yWw_9_3">7,887</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="Tc_rIZcPN_FTEqZ17eNCVYtFg_9_6">6,151</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_75FmhL-2xEaipD8HJ80nAg_10_3">4,385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_mzylf6mKx0ax90o30J8WUQ_10_6">6,764</ix:nonFraction></p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lab equipment includes failed sale lease-back assets of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleLeasebackTransactionNetBookValue" scale="6" id="Narr_IvsQkFaJ-UCaziO1HSQi-g">3.4</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million as of December</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31, 2024 and 2023. Lab equipment includes finance lease ROU assets of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="Narr_gSYCvAJzv0Sce9KemfKm0Q">3.2</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="Narr_tbcQ2onZnEqPnSuYZ9FpgQ">2.9</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million, respectively, as of December</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31, 2024 and 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The accumulated amortization balance includes </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleLeasebackTransactionAccumulatedDepreciation" scale="6" id="Narr_8aqxTFaNi0ChTD2aWFCoMw">1.5</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleLeasebackTransactionAccumulatedDepreciation" scale="6" id="Narr_X_SEsefpnkiHvm6_MRAHCQ">0.9</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million, respectively, related to failed sale-leaseback assets as of December</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31, 2024 and 2023. The accumulated amortization balance includes </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="Narr_a7ByPDYN-06xndVuI1CZGw">2.3</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="Narr_MpoMfF7HWES6MtUQ7_X2PA">1.7</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million, respectively, related to finance lease ROU assets as of December</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31, 2024 and 2023.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Depreciation and amortization expense was $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr_80ATnk1RD0mVifbI01nkRQ">3.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr_mfx2w9_0KkimDJxNG4FmlQ">2.8</ix:nonFraction>&#160;million for the&#160;years ended December&#160;31, 2024 and 2023, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c406459a_f55d_4f8f_a3f7_fb53b18dc7c5"></a><a id="Tc_UdHkr1e8y0yB_w1V3VhtXw_1_2"></a><a id="Tc_R1qvTHkxu0KAteLgp22maw_2_2"></a><a id="Tc_7ZoVpcX-DE2KbHt5J9TQfA_2_5"></a><a id="Tc_ioD1c77JmEGGp6XMw0j8hQ_3_0"></a><a id="Tc_BnIKDmqa5kmQcRaRnZpY5Q_3_2"></a><a id="Tc_0rhUdMcdDEebZicOfL7btw_3_5"></a><a id="Tc_1Mudkbfn3UGqkRtxABOXBQ_4_0"></a><a id="Tc_wNEDhL8Hz0iqS7VTU94l5w_5_0"></a><a id="Tc_p2zUsXPgEUuXVFLBO_yH4A_6_0"></a><a id="Tc_sxgb0kbXb069pwqVVt5yGw_7_2"></a><a id="Tc_41Vs8rByQ0yPvCh-S58O6w_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_GgPOyM-uYESCp3An-Z2kJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(7)</b></span><b style="font-weight:bold;">Accrued Expenses</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_Pi5wDf7zy0SNixDxeBdrlQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:AccruedResearchAndDevelopmentExpenseCurrent" scale="3" id="Tc_GkHNcP51dEqvVBlQ5XtS2w_3_3">1,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:AccruedResearchAndDevelopmentExpenseCurrent" scale="3" id="Tc_B7qb6hck7k2t4gJZfmko6Q_3_6">3,131</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_LDz5T59W9ESxgdjZ7gBQQQ_4_3">537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_pCr2hea62E21_RXKIJ5z3A_4_6">1,366</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_Wso9eg_dEEG4g2EgbfBiwg_5_3">4,879</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_UpxVm0fp8kiMOs3hA8wJDw_5_6">3,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_msBoaFMsD0G0Sq2MB7GnVg_6_3">187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_cdsSrsVR-UiuiFj34_X9tw_6_6">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_WyPIOIruCES3X3B-K7HA8g_7_3">7,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_VdLuvEMFP0mbgPHxOIhCeA_7_6">7,662</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_rLwjywlw2U2trrdcpaAEjA" continuedAt="Tb_rLwjywlw2U2trrdcpaAEjA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(8)</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#8217;s operating leases have term end dates ranging from 2025 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2025 to 2026. Effective February&#160;2024, the Company renewed an existing operating lease with an end date through 2026. In April&#160;2024, in connection with the revised operating plan, the Company notified the lessor that it would terminate the lease effective August&#160;2024. In July&#160;2024, the Company entered into an amendment extending the termination date of the lease to June&#160;2025 with an option to extend to December&#160;2025. The Company did not incur any penalties or fees in connection with the termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In September&#160;2024, the Company modified existing finance leases and failed sale-leaseback arrangements by assigning the rights and obligations of certain underlying assets to an unrelated third party. The modifications resulted in a reduction of its finance lease </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e07aa593_bb4e_432f_b525_61bad5251558"></a><a id="Tc_iAPDIHR6806xc6t7xAqjIQ_1_2"></a><a id="Tc_5lMAHxnNFEi1IUxqicqxxA_2_2"></a><a id="Tc_7PaFbHmCREO_lQX5JFJTBw_2_5"></a><a id="Tc_aRAKAKL5_Em0z8WFrLl76w_3_0"></a><a id="Tc_xR9z0wovdkWlqUd5oLWtZw_3_2"></a><a id="Tc_grpYWjRzUU-sUuAW7JWPYA_3_5"></a><a id="Tc_raqDcULi-0ic7koEPJN3ww_4_0"></a><a id="Tc_KFI9drsmuUq_3ORG42-B-A_5_0"></a><a id="Tc_Z4JgqdfxzEmW5baeiZ_6bg_6_0"></a><a id="Tc_qGlDRg8tR0iKzi9BbllJVQ_7_0"></a><a id="Tc_L2D3JxExkkykRZC5Dft7Qg_8_0"></a><a id="Tc_UHK2Loo9X06wcm29ifgGHA_9_0"></a><a id="Tc_HoLClqb3P0CYSzJKK82d2A_9_6"></a><a id="Tc_bWioeUmGfUuIHfUF14H45w_10_0"></a><a id="Tc_k55i60pIa0ueKUL2pZfvOA_10_2"></a><a id="Tc_nWTzg_N4HU63gexpjLCnBQ_10_5"></a><a id="_42346801_5538_4b13_95cb_d30453a4823f"></a><a id="Tc_Ncb8Yy384k6IhD5-yAxjWA_1_2"></a><a id="Tc_7Ig-JFahIUihxAPtrm5lRA_2_2"></a><a id="Tc_vY4MTWWRyUqq_GTroRXkjw_2_4"></a><a id="Tc_61BmU3_GxkG4Jira4yCcHw_3_0"></a><a id="Tc_D22L-pAytEWu06CTT4JUkQ_4_0"></a><a id="Tc_zDftGQQdL0GRWopEpzEuFA_5_0"></a><a id="Tc_pDZ3PGnzZUiKQ9D8inI1Ow_6_0"></a><a id="Tc_LEchUkHhKEeeSR2cKh7CAg_7_0"></a><a id="Tc_qB-kchaE3kiiD8AG8IrIUA_7_3"></a><a id="Tc_pIGND_-CnUS3du4TFQT2uQ_7_5"></a><a id="Tc_cZMzBUN7EEGSqvoveU50Nw_8_0"></a><a id="Tc_UxiKu87HtkSSeXo1tECGnw_8_3"></a><a id="Tc_9wPqAM45B06HokHBeprjxA_8_5"></a><a id="_3b87e072_5dc6_44ad_8ad1_0d0aa6b3316d"></a><a id="Tc_nLwugEvvOkytMOXmddsXpA_1_2"></a><a id="Tc_bq6pK5Hx30O8byNXitcrpg_2_2"></a><a id="Tc_29g4KWrZYk6RUiw4TnDNKA_3_2"></a><a id="Tc_DVXL8SxoCEOWHogg1BanyA_3_5"></a><a id="Tc_uPsDjpNY60m36ckdNonHTg_4_0"></a><a id="Tc_TFQlkA1XAECVfvCyVimvJg_5_0"></a><a id="Tc_vFTjN2BJzEys7GGJIBZO3Q_5_2"></a><a id="Tc_1a19z-O-zUyY1alHf7FIrA_5_5"></a><a id="Tc_NjYO0VQAs0-hBrIuOj9q_A_6_0"></a><a id="Tc_8T_FwmAgZ0CzHsSCjpQjlg_6_2"></a><a id="Tc_gs7Qt6fij0C7UMWHuMKKcQ_6_5"></a><a id="Tc_cINhth5vU0qBDyvgmPXGmQ_7_0"></a><a id="Tc_xWC6pZgG9EytCVDWyWXT4Q_7_2"></a><a id="Tc_6OBWnbajZUySfL5vv51sDw_7_5"></a><ix:continuation id="Tb_rLwjywlw2U2trrdcpaAEjA_cont1" continuedAt="Tb_rLwjywlw2U2trrdcpaAEjA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ROU assets and related lease liability of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_9_30_2024_CsDzke0V0UKpQy6JppgEbw" decimals="-5" format="ixt:num-dot-decimal" name="carm:IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" sign="-" scale="6" id="Narr_NdPdj6lXbEue-k5SeuDBlg">0.4</ix:nonFraction>&#160;million. In addition, the Company recorded a reduction of its failed sale-leaseback liability and gain on the sale of the corresponding assets of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_9_1_2024_To_9_30_2024_Zs5TM9E90UOa54MlGv6RJw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" scale="6" id="Narr_dnhR3qNnWkyuwnd09drcYg">0.1</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operating and finance lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company carries laboratory equipment from failed sale-leasebacks, as property and equipment, net on the accompanying consolidated balance sheets. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of December&#160;31, 2024, the Company had a $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QKEF25OlKUyFEjDTw-T6ZQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="6" id="Narr_EZYqumww0EqOKAEDC3Cn9w">1.4</ix:nonFraction> million financing liability recorded in other current liabilities and other long-term liabilities on the consolidated balance sheets.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:LeaseCostTableTextBlock" id="Tb_6DJQtyQT2E6dhu86cvPzuQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The elements of the lease costs were as follows (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_-0FuZHYwckm9vcUVUuHNEg_3_3">5,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_5oJtV6vd9kSxCuSF5boYww_3_6">5,774</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_tNLgD7-M00a9VoJqSPJqZg_5_3">1,584</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_RTV5r72xgk-edJCfCiykJA_5_6">1,187</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:FinanceLeasesInterestExpense" scale="3" id="Tc__y9w8R_S2kC2STREg43Jig_6_3">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:FinanceLeasesInterestExpense" scale="3" id="Tc_kWHPUIJEAUm8WcrOZtS-yQ_6_6">139</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:FinanceLeaseCost" scale="3" id="Tc_Fd7vd7CLkESS_yWXZwpOjg_7_3">1,801</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:FinanceLeaseCost" scale="3" id="Tc_Y0k2NnOuRkCtqgiKu3pmXw_7_6">1,326</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_9XQEGKB2HkKTZGwDQEwbpQ_8_3">1,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_DEVevxVakkWlWmFtCG7TLA_8_6">1,733</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Short term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" id="Tc_42dabL9UN0WmxMtC2azerQ_9_3">671</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="Tc_octQvlcgQ0OCM5PABlp1DQ_10_3">8,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="Tc_D2fLn8bc1E6GVB1FxCDAxw_10_6">8,833</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" id="Tb_ZPz6Nz5flUGQVGUe1ivlhQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lease term and discount rate information related to leases was as follows:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_BPkCyxyUIkWxld0K369XAw_4_2"> 2.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_Uyk8SDAOOE2_Sza4oCzwJg_4_4"> 2.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_C-EM7X86dUWes0D4pQFU4A_5_2"> 0.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_QZD5H6HN10uXfQUhmoqWfw_5_4"> 1.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_j1uKSl4d9UygRhcxd2nFMg_7_2">9.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_EmJLfRAEMECCz7k3jgblhw_7_4">9.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_s-54FzvodEWEc4zSE8V1UA_8_2">9.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_NUFRJh2xj0GaUHSOrbTJ2Q_8_4">9.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" id="Tb_Pg17Hgjl5EGZ3ZSTVMt20A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information was as follows (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_TbYguIVeMUWvRUQGwXVwKg_5_3">5,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_XajKoC9zgUudOtN_JLD3fw_5_6">5,764</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:FinanceLeasesInterestPaymentOnLiability" scale="3" id="Tc_eFp-kWrpHEeID-ts13aGBA_6_3">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:FinanceLeasesInterestPaymentOnLiability" scale="3" id="Tc_dl2C5Mri00q79ORN_gny6Q_6_6">139</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:FinancingCashUsedInFinanceLeases" scale="3" id="Tc_xUKwUu_VcU2qyu1wr_p2kA_7_3">1,429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:FinancingCashUsedInFinanceLeases" scale="3" id="Tc_RLYa56_W3E2dksPnxVEj-A_7_6">1,301</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1e96a6d7_0f50_4072_b4d5_98957948b66a"></a><a id="Tc_VidVrsxgHkixBx3hM4EN5Q_1_2"></a><a id="Tc_dM0ni-xxSE-qtzqCR6nndw_1_5"></a><a id="Tc_n3il3df3MEup8VDDpyTh2w_2_2"></a><a id="Tc_ycvUOu-EREWY1Km5e5YzKQ_2_5"></a><a id="Tc_um2m03uSIUKmW0YMUcLDpQ_3_0"></a><a id="Tc_1G15RlYmjEObN8ExBwgr3g_4_0"></a><a id="Tc_oZvvZN4vc0iPULHxT0I9Sw_4_2"></a><a id="Tc_3yrHdnYG5kixXmVAWqIvbQ_4_5"></a><a id="Tc_1o1-f6HaeUqRG2HufSr3IA_5_0"></a><a id="Tc_nGXtQKms0EKz1T-CydyOOA_6_0"></a><a id="Tc_SjhSEnBTxki_vORaMkNxrQ_6_6"></a><a id="Tc_pFiUsccLXESmxdKU9JzQ7g_7_0"></a><a id="Tc_xLmCzsFasE2w0NBRDAsvjA_7_6"></a><a id="Tc_u5VFcMQJA0SS0T5OE0ecdg_8_0"></a><a id="Tc_XvOjwbvMq0enW1553dT_3Q_8_6"></a><a id="Tc_a9UVYS3HWUWwE1JLcO9nvw_9_0"></a><a id="Tc_9eAw-lXe3kWM3nCg9sqeKw_9_3"></a><a id="Tc_vplVV28fGEewqhHkPg9W_w_9_6"></a><a id="Tc_Vyky_dZhe062hHhu_1TuCQ_10_0"></a><a id="Tc_YXhhj4w-lES5n3YmVP_DJQ_11_0"></a><a id="Tc_L3MoyPKpH0SIWOwyGEE1zw_12_0"></a><a id="Tc_RrjNqh0WMECYoBQlk53ldw_12_2"></a><a id="Tc_ogob2uP760m9ZS_emTcJjA_12_5"></a><ix:continuation id="Tb_rLwjywlw2U2trrdcpaAEjA_cont2"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" id="Tb_NuQXw6o3akCiM4A3_GY3kg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future maturities of lease liabilities were as follows as of December&#160;31, 2024 (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fiscal year ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_ZDXHxegPvEaTITwgI2ZMLA_4_3">927</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_Ex-S5iATFkCqdEcum8XClQ_4_6">942</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_bw91P4w-10KJDbHwYuTdvQ_5_3">225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_7RD6TyWi6UCBRs8SooKTQA_5_6">21</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_KVwGutQW-U-u6hVi9Pt-Hg_6_3">233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_dJ49fnfTO0C20_Qv1kIL2w_7_3">240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_Dge4OD6H4U-_QSklxOv4Ig_8_3">184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_u-4k-tCFVke_ELN4WLvsXA_10_3">1,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_V_MAuiJ2wUaclB4Bzzz6Bg_10_6">963</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_kf1JO61hmUisa4rAs1ziNQ_11_3">253</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_cvScem926Eq3ZdOoKWSiMQ_11_6">38</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_owgz2wQaE06HHvOWt2UzyA_12_3">1,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_CuaHvmcis0ORXkBLZ1gdlA_12_6">925</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Licensing and Sponsored Research Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November&#160;2017 (Penn License Agreement), the Company is required to make annual payments of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_9VloD_2BKUaBco__8m0cCA" decimals="-3" format="ixt:num-dot-decimal" name="carm:CommitmentsAnnualPaymentsRequiredToBePaid" scale="3" id="Narr_3UooqYS3q0mmopdPbGmD0Q">25,000</ix:nonFraction>. Penn is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_Tu1FMTWJ-EKur2Ehg_NuIw" decimals="-5" format="ixt:num-dot-decimal" name="carm:AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" scale="6" id="Narr_2lPObfexX0GvQrxv-QXoHg">10.9</ix:nonFraction> million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_c-DL08jYk0mOjzSXLvRWJA" decimals="-5" format="ixt:num-dot-decimal" name="carm:AdditionalMilestonePaymentsRequiredToBePaid" scale="6" id="Narr_5YBFeo3OTUGFTpaSW_W8zw">30.0</ix:nonFraction> million per product in commercial milestones and up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_9VloD_2BKUaBco__8m0cCA" decimals="-5" format="ixt:num-dot-decimal" name="carm:AdditionalMilestonePaymentsForTheFirstCARMProduct" scale="6" id="Narr_s0xG_MyOUEGW-2Gi7Gge4w">1.7</ix:nonFraction> million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2023, the Company entered into a manufacturing and supply agreement with Novartis Pharmaceuticals Corporation (Novartis) for the manufacturing of the Company&#8217;s CT-0508 product candidate (Novartis Agreement). The Novartis Agreement had a <ix:nonNumeric contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_8sZcvCnSPkeitKoqY5sunw" format="ixt-sec:durwordsen" name="carm:AgreementTerm" id="Narr_9KWQO46cr0O5PDN3WQmTnw">five year</ix:nonNumeric> term. On June&#160;26, 2024, in furtherance of its revised operating plan approved in late March&#160;2024, the Company terminated the Novartis Agreement. Upon termination, the Company incurred a termination fee equal to $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_6_26_2024_To_6_26_2024_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_pGYfhVmGEUO0Q3irnyGzOg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossOnContractTermination" scale="6" id="Narr_HwinnIljd0yN318-LtDHmA">4.0</ix:nonFraction>&#160;million, which was paid in the third quarter of 2024. A prepaid asset was recorded as the Company separately agreed with Novartis that if Novartis and the Company re-negotiate the agreement for a substitute product on or before December&#160;31, 2024, then the $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_6_26_2024_To_6_26_2024_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_pGYfhVmGEUO0Q3irnyGzOg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossOnContractTermination" scale="6" id="Narr_GyLLnhfyRkegMTmoiIy9JQ">4.0</ix:nonFraction>&#160;million termination fee would be credited in full or in part against any amounts due from the Company to Novartis under such agreement relating to the substitute product. The Company did not re-negotiate the agreement and expensed the $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_6_26_2024_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_eohhy-W8CE6cTQBIagwUsA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="Narr_g7qsjoAVrEadTHVCRM-17g">4.0</ix:nonFraction>&#160;million prepaid asset in the fourth quarter of 2024 to research and development in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. As of December&#160;31, 2024, the Company was in negotiations with a vendor to determine the total costs owed for research and development services provided. While the negotiations are ongoing, the Company believes a liability is probable. The Company has estimated the amount to be owed to be $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="Narr_pdjD9jN0uEirmuMHxe1R-A">1.2</ix:nonFraction>&#160;million which is included within accrued expenses on the accompanying consolidated balance sheets. The final amount owed may differ from the estimate as negotiations progress. The Company will continue to evaluate the matter and will adjust the liability as necessary based on any new information or agreements reached with the vendor.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_Sj8yGmtHL0S5tUZvw5MgxQ" continuedAt="Tb_Sj8yGmtHL0S5tUZvw5MgxQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(9)</b></span><b style="font-weight:bold;">Stockholders</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#8217;</b><b style="font-weight:bold;"> (Deficit) Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March&#160;7, 2023, in connection with the closing of the Merger, the following is reflected on the consolidated statements of convertible preferred stock and stockholders&#8217; (deficit) equity for the&#160;year ended December&#160;31, 2023: (i)&#160;the sale of <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_qbJeIn5ggkOjXRQiVBDE_w">3,730,608</ix:nonFraction> shares of common stock in a pre-closing funding at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_QONazLVsT0iPqxKFUrZHmQ">8.21</ix:nonFraction> per share for total proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_8zV9Z-G7RE6hwCBKITVSvw">30.6</ix:nonFraction> million, (ii)&#160;the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_OQ6THXb7L0qwMjairnCFDg">5,059,338</ix:nonFraction> shares of common stock upon the settlement of the Company&#8217;s $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="Narr_JlM75FWkBkanYNN0M04rng">35.0</ix:nonFraction> million convertible promissory note, accrued interest and related derivative liability, (iii)&#160;the conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_Sj8yGmtHL0S5tUZvw5MgxQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">interests into <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw" decimals="INF" format="ixt:num-dot-decimal" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" scale="0" id="Narr_C1S1vPzli0S9xuuyvI_LVQ">18,872,711</ix:nonFraction> shares of common stock, (iv)&#160;the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Narr_AMG4lBTsnkyrCAcHglM75Q">10,374,272</ix:nonFraction> shares of common stock to Sesen Bio stockholders as consideration for the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;17, 2023, the Company filed a universal shelf registration statement on Form&#160;S-3, which was declared effective on May&#160;2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_4_17_2023_x6SGs_0tqUWE9Nmq-r1zlw" decimals="-5" format="ixt:num-dot-decimal" name="carm:SaleOfStockStockOfferingAmount" scale="6" id="Narr_VFsYq8_pJU29lo9Oir38sw">300.0</ix:nonFraction>&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May&#160;12, 2023, the Company entered into an Amended and Restated Open Market Sale AgreementSM (Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_5_12_2023_2Ua3tacy0kqoCl2kZhnnpw" decimals="-5" format="ixt:num-dot-decimal" name="carm:SaleOfStockMaximumOfferingAmount" scale="6" id="Narr_bkGViahNN0GpGHoznoq0YQ">100.0</ix:nonFraction>&#160;million under an &#8220;at-the-market&#8221; offering program. During the&#160;years ended December&#160;31, 2024 and 2023, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_PW5Xs3_AFk2m4nSwFHd7Pg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_j2pBvOedU0OZGe4SCfyfrw">1,136,384</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_6dVwitkd0UeHb10KsXjOdw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_j91-WbRQ-kWXjbLhzo_1dA">226,533</ix:nonFraction> shares of common stock, respectively, for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_PW5Xs3_AFk2m4nSwFHd7Pg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" id="Narr_9t9dNKEohEyoK2ujxJJ9_A">2.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_6dVwitkd0UeHb10KsXjOdw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" id="Narr_pMVtrlIxVU-3m33Do8t5sw">0.6</ix:nonFraction>&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On June&#160;6, 2023, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Restated Certificate of Incorporation to increase the number of authorized shares of the Company&#8217;s common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ZJgmSvbfsEmBFrlJz5emyA">0.001</ix:nonFraction> par value, from <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_6_5_2023_xtoCxfMB7kSash1MJ5CA_A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_ivF6ULv-DEmR1KzpXumwQQ">100,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_6_6_2023__sMm62IFwUO3DNhZ5LDZlg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_1WZWkDHI70i15l44f1hwPA">350,000,000</ix:nonFraction> shares and authorized <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_6_6_2023__sMm62IFwUO3DNhZ5LDZlg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_lFeUm3T-BE2jocx9qW_wCQ">5,000,000</ix:nonFraction> shares of preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_6_6_2023__sMm62IFwUO3DNhZ5LDZlg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_3ZcYJdWoLkCLlk_7PU8cbA">0.001</ix:nonFraction> par value.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_AuyiENpqAUKA-MUCHJas6Q" continuedAt="Tb_AuyiENpqAUKA-MUCHJas6Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(10)</b></span><b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2017 Stock Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the CARISMA Therapeutics&#160;Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_2mhPn7jIZ0e-ZbcpUrxB9g" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_yzVNskjRtUGPZ_zJv1MBXw">ten&#160;years</ix:nonNumeric>, and stock options typically vested over a <span style="-sec-ix-hidden:Hidden_sktIWaH1v0C3Alvvbznotw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four-year</span></span> period. The Company&#8217;s stock options vest based on the terms in the awards agreements and generally vest over <span style="-sec-ix-hidden:Hidden_wSmhQcT4p0uaTZTD8dNi8A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four&#160;years</span></span>. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Legacy Carisma Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2014 Stock Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Amended and Restated 2014 Stock Incentive Plan, as amended, provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Company&#8217;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#8217;s board of directors at the time of grant. Stock options outstanding under the 2014 Amended and Restated Stock Incentive Plan (the 2014 Plan) generally vest over a <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_h2U2al8QUkCz4difeEQiVQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_LTgjy944c0ufpCr0IKeXtA">four-year</ix:nonNumeric> period and are exercisable for a period of <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_h2U2al8QUkCz4difeEQiVQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_Y-IGUj24tUmyIsOdboWJtg">ten&#160;years</ix:nonNumeric> from the date of grant. As of December&#160;31, 2024, approximately <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_0LrR7jztQ0mtgFQjdW7yZw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="Narr_NDd9IKw1Q0GbkAaSi2RW0A">4.8</ix:nonFraction> million shares of common stock remained available for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2014 Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carisma Therapeutics&#160;Inc. 2014 Employee Stock Purchase Plan (the Carisma 2014 ESPP) provides employees with the opportunity to purchase shares of common stock at a <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_pc5coAuKZUS70I6GNo3axA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="Narr_9VTQyPn2SUS1Tp2dF1iLnA">15</ix:nonFraction>% discount to the market price through payroll deductions or lump sum cash investments. The purpose of the Carisma 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock. The Carisma 2014 ESPP had <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_bhT6DCaLkEussR-MSi5DIA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="Narr_myIYHEfnRUirn5d3NYo5Dg">0.2</ix:nonFraction> million shares of common stock available for issuance as of December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_78b1f964_a878_43e4_a97a_fcd292ee313f"></a><a id="Tc_i34oqYd4kEKpU74pCdz0oA_1_7"></a><a id="Tc_qS7ikY_IKkKuP5BvoCS0KA_2_4"></a><a id="Tc_t0KsoFawkEOkDXrU8Mkg6w_2_7"></a><a id="Tc_tDzUw0iZ7UqIogqtXAUeJw_2_9"></a><a id="Tc_f0PWs8vOMUmFHeSBkFhDnQ_3_4"></a><a id="Tc_Vx5LL1GnKE-g9v1BUTFc0w_3_7"></a><a id="Tc_WO6UCnZGyEmxo8brg6SAmw_3_9"></a><a id="Tc_qdp1xaMjQEioP_nI8RiNIw_4_4"></a><a id="Tc_rBd2yaew-EyAF9HEy6E47A_4_7"></a><a id="Tc_RC_o-2oFXki6pxd86v_GUw_4_9"></a><a id="Tc_hn31TXrFNky1_PWxVlO3YA_5_2"></a><a id="Tc_FFYVXRJlbUSNibZ1srNwBg_5_4"></a><a id="Tc_J71TnNpIpkeX3nUWl1uR5A_5_7"></a><a id="Tc_jVADqBXaUUirB833E6liZQ_5_9"></a><a id="Tc_8vIGqmSVNkqGG1Y9c13Q6A_6_0"></a><a id="Tc_iB3HSRUnx0uL6W4FXGfhZQ_6_4"></a><a id="Tc_YcLph2EnDk2oenlsrdTArA_7_0"></a><a id="Tc_qH5MpOeDt0mV8HvXdeXtDg_7_9"></a><a id="Tc_yDDvxIgrtU-cl7_w0kw_Ag_8_0"></a><a id="Tc_rT5YV26ew02z3m9lVKhUsA_9_0"></a><a id="Tc_6-T6sxML_k6CfGGQ08EiFw_10_0"></a><a id="Tc_EdGfLlTArkmE-G0cKtG1Rw_10_4"></a><a id="Tc_k_c5_NaShUeYt5h_oxM5Sg_10_9"></a><a id="Tc_8drg-qLViEmz6UzTBlCq6g_11_0"></a><a id="Tc_6oe_7sD3VUetH7CBZuccvg_11_4"></a><a id="Tc_7O1sI7ly_E-vsvswFaxrIg_11_9"></a><a id="_70cae66a_9c58_40d1_8b87_193d64c03f35"></a><a id="Tc_Fn7ptAYG00mg3Qgv0kKyjQ_1_2"></a><a id="Tc_6VdWIr4sW0meh9orO2424Q_2_2"></a><a id="Tc_1litsCRtBk2Bu0Nkg-Aj-g_2_4"></a><a id="Tc_Wxe30bzlj0GQwbj31sL6XA_3_0"></a><a id="Tc_IKcLJaoMt0qwaxJFvDduLg_3_2"></a><a id="Tc_QcLi2JtZGkiN_gD11WJzvA_3_4"></a><a id="Tc_-cdLIKu7GUmlhkoU7aDlwg_4_0"></a><a id="Tc_ZGXK3eclbU2JHZeXkMqEWw_4_2"></a><a id="Tc_0bXVrMj02kqwfWIbWHPQig_4_4"></a><a id="Tc_9n77_1tYWkueceTdtDfgZg_5_0"></a><a id="Tc_EaaFyyJvUUSdn2jB5PVwAg_5_2"></a><a id="Tc_Kz_584uMc06GPDov4yN3Pw_5_4"></a><a id="Tc_xWNyZPar8UasFoIXMIN4dA_6_0"></a><a id="Tc_TAQIqbWYPUK0ySJhPFXn8w_6_2"></a><a id="Tc__8UxD2HZ3UqHf0E_5jAtyQ_6_4"></a><a id="_a5096b49_af5b_4d2d_afc1_581277c2a889"></a><a id="Tc_Z41sML_zGUeyQ2CPlj4nyg_1_2"></a><a id="Tc_jl9NxeJSokqVLbUhBixPvA_2_2"></a><a id="Tc_q4dl6nka606mG6EEXIlQEw_2_5"></a><a id="Tc_jHg5ATA56Uua-zBMWvSDXg_3_0"></a><a id="Tc_m-cwmMMenE2qrYGm1F2bxw_3_2"></a><a id="Tc_V3YfSWP0Y0GIgDZyoz7ayg_3_5"></a><a id="Tc_4uJFfEu52kyJLhtbjHOOlQ_4_0"></a><a id="Tc_koi5VgJZkUanhvWhhVUQxA_5_2"></a><a id="Tc_gkl0KXDceU-zrExya4B5AA_5_5"></a><ix:continuation id="Tb_AuyiENpqAUKA-MUCHJas6Q_cont1"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_8cOi6AyAb0Wdtrs015-vgQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_5v3d7-8a80CRFCosr2TJxw_6_2">6,023,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_9a5QQ1cxm0OPLtrCg4dwiw_6_5">3.94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Tvk_JEIRgkKrIApvrm2VjA_7_2">3,810</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_ZhMQxi6hUU-OeITieXdK7Q_7_5">0.99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Tc_Ymok24VEa0GHgnyHyCNQrA_7_10">4</ix:nonFraction></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc__BV4lNk5MU6240V48M7JCg_8_2">3,805,465</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_oTATtIe6BUOQs7eBus5rFA_8_5">1.76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_3idsouHWBUW9RqXWC0i4jA_9_2">2,078,034</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_An9LNww1FUq0pKqlIM8-QQ_9_5">4.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_2nnSqcsaH0aKgR8Dl2rS4A_10_2">7,746,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_8tRFswAlQ0qY5kwepRPsqQ_10_5">2.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_NOJILGvlGUC6CIlutmWUbg_10_7"> 7.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_QR8AsnwwT06nlWhYu6IwJQ_10_10">59</ix:nonFraction></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_yKPv9aS2WkWKK9C7U9wjww_11_2">4,414,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_c0_C6DfWLkm_dh5fg9rjBA_11_5">2.44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_BqVLQPC3KEmCb13qdOkYlQ_11_7"> 6.4</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_R-Or5PVt50yOQeLOcNp4oA_11_10">59</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date per share fair values of options granted during the&#160;years ended December&#160;31, 2024 and 2023 were $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_6dtC6NXAhUuwkhWr1a0TEA">1.36</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_NarghcerTEGjqGXP7kizgw">4.29</ix:nonFraction>, respectively. The fair values in the&#160;years ended December&#160;31, 2024 and 2023 were estimated using the Black-Scholes option-pricing model based on the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_-POMA6FSVk2f4IZsVKoESg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:32.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_XarV9JooQUGFgqT3MKU-nQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_Jy3A35tFQEaRCO09oGAs6g">3.77</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0Ff2XJct5EKaCIPhtjMWRg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_bXWFIHRgU0eef2KumIMzsA">4.59</ix:nonFraction>%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pbvS30z8A0CePGJ6mxV3wA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_2QWM7ENoBkm3owBikeh-ww">2.92</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rXpt9Tr8wEWedRsbme4_rg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_RdH8Z_AZ3kqYTDOSubzRkg">4.76</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_EbpMHxZ2vk61tk33Oa6FYQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_Hm3rnN2el0umdGqPQwHrew">6</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__FKxuQApK0mFwWZqpuOrwQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_i2gVs5Rp7E2UEQQGF2n0Ew">6</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_XarV9JooQUGFgqT3MKU-nQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_keootmrEjkaMBe5C0Tgmjg">86.55</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0Ff2XJct5EKaCIPhtjMWRg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_JMf7J6ZF5ESy7dTzR168oA">112.12</ix:nonFraction>%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pbvS30z8A0CePGJ6mxV3wA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr__GBi_A8djEu3T4Ds6Vc0-w">57.77</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rXpt9Tr8wEWedRsbme4_rg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_oQUBrmcmf0mb0AFkZgD0Uw">103.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation Expense</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_jODpYrZ6HkCIERAO53iOcQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_GdlsibT2VkyP132eYkVPyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_gBCbD4FYXkujI9Cc56B01Q_3_3">1,116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Nd0oPvzMG06tOEVwN21Lsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_kZGJ_9ubHkedlGnZe2YWcA_3_6">1,242</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_s7tqgkjRX0S1t8FSmRyS6w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_dDAkgPMlIkK9oa36JHifEg_4_3">2,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R3R2qv2BVEOZuSzVu7JMsw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_sCkoxlBvdU67SWyphzZJig_4_6">1,074</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_m23xSHqmQku5Z-ABsW_AWQ_5_3">3,649</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_DyezEggHyEGA_KU974st0A_5_6">2,316</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the reductions in force, <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_RevisedOperatingPlanMember_8xDVoP31YEeXATz_aXlYog" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Narr_h0d_vQoPsUaMVTeSYEREiw">1,898,297</ix:nonFraction> options were forfeited during the&#160;year ended December&#160;31, 2024. The Company recognized stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_carm_SesenBioIncMember_wbOBDpL9fE2NWwfHImRktA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_zY0nAHBN60OYa84ejfsemw">0.2</ix:nonFraction> million related to the modification of Sesen Bio options assumed in connection with the Merger during the&#160;year ended December&#160;31, 2023. Compensation cost for awards not vested as of December&#160;31, 2024 was $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_y38l3sVKRkuiTa7JxvCyUA">7.2</ix:nonFraction> million and will be expensed over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_VXN6r9RRSUGzBgueZWWu2Q">2.5</ix:nonNumeric>&#160;years.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0b90db7a_5a77_46b3_b131_c84091aa35f2"></a><a id="Tc_goqbyPqnC0mTV2u7Hm83Tw_1_2"></a><a id="Tc_2r-0TxYnmk6VHztj8pE6eQ_2_2"></a><a id="Tc_NCeRFDJiXkuLA5yZeKQG6g_2_4"></a><a id="Tc_b1elDck7GE28zgW3HbhNsQ_3_0"></a><a id="Tc_NDZ00i5_v0Sk1oDM4dmWZQ_3_3"></a><a id="Tc_skn7XnDNFEK75UkEvlY-3Q_3_5"></a><a id="Tc_KwqOjRucx0ikKAXn-MAkwQ_4_0"></a><a id="Tc_DvvjLBFpcEeksfp5pwfXjA_5_0"></a><a id="Tc_qhXQgZ8NmkmWeWaAqPFfVg_6_0"></a><a id="Tc_XjKEi-FiDUqrbQlqfcKhzQ_7_0"></a><a id="Tc_T_YXiHm0nE2j6K8SL612gw_8_0"></a><a id="Tc_83PX_me_GEOloqqgLaCc7g_9_0"></a><a id="Tc_gPq-G9BLzESxuKVpGISQlw_10_0"></a><a id="Tc_AAHP1ggzXkaDWUVEsxWgJw_10_3"></a><a id="Tc_NI3DHQ9Gl0qcboeadTYpaw_10_5"></a><a id="_e33b15ca_d0d0_4895_a23c_4d928dad8037"></a><a id="Tc_9tNlafeA8EW68vt0PAaOCQ_1_2"></a><a id="Tc_SyqjuSJq-0eidwxGAHnKkw_2_2"></a><a id="Tc_VxY8shHjikC8W-CQuYimSA_2_5"></a><a id="Tc_qQPeOFzCe0ehT1fbl41Lcw_3_0"></a><a id="Tc_ecmdtB9Om0CQTbWGB-aJrg_4_0"></a><a id="Tc_W7ajH4LzvUWPTpG4wIUeyw_4_2"></a><a id="Tc_3lLHtEHVCE2DVoTTmRGRUw_4_5"></a><a id="Tc_nHof_1lQrECBSqLnvSvuvg_5_0"></a><a id="Tc_Yi2zfMl7nUukfEO8R1hCYw_6_0"></a><a id="Tc_c8xKbvwrE0uwAZGnt5DM5w_7_0"></a><a id="Tc_3-AD0yfue0a5USwhVxHA5g_8_0"></a><a id="Tc_PklN9RXzcUO0tGrXlhQ6rw_9_0"></a><a id="Tc_nFv_SY_7tkSS8YomWDF0wA_10_0"></a><a id="Tc_jSK8i4wu5Ear2dvi2pzElw_11_0"></a><a id="Tc_TVGuPKLk70WZ_deLx4yi1g_12_0"></a><a id="Tc_JuHEb7jJLUqG7IyCzIcfMQ_13_0"></a><a id="Tc_1UPxO9cgFUGJ0iasAkVmhA_14_0"></a><a id="Tc_QsAluFTjLUKsVCZZC4JhKg_15_0"></a><a id="Tc_6i7-Ggfg2k6KJDxoSzKPcA_16_0"></a><a id="Tc_paeszQXpykuyH2v4fonZ6w_17_0"></a><a id="Tc_g-YzpJipJ06gIqOMRmcsLw_18_0"></a><a id="Tc_DYS08zaqjkuTwoUpj-lZRw_19_0"></a><a id="Tc_MS8twKLGfEijWxjVavlTkQ_20_0"></a><a id="Tc_w41KmstE9UyOEMs_BgklcA_20_2"></a><a id="Tc_k5OPF_gjjEKrqQ6RlLZflQ_20_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb__7BkDK_UMUO4naUWC3ByqA" continuedAt="Tb__7BkDK_UMUO4naUWC3ByqA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(11)</b></span><b style="font-weight:bold;">Income Taxes</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb__a53-otRS0mfJ0Wole9e4Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_PJWIVlyvmkqSFrpiSEIslg_3_2">21.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_CmWI4D9F0U-733TpaECEiA_3_4">21.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_5scoIBSUuE-beD8OWI_GSw_4_2">8.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_kRrBpdwNakqXAxgSTqrO1A_4_4">8.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" sign="-" scale="-2" id="Tc_g_oOW4lvKUuMt2MKgRE57g_5_2">3.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" sign="-" scale="-2" id="Tc_gZtmoWpMek6US4LVdDuJwA_5_4">1.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="3" format="ixt:num-dot-decimal" name="carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences" sign="-" scale="-2" id="Tc_QeMe6gXVzUmIkA5vIgTMjQ_6_2">0.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="3" format="ixt:num-dot-decimal" name="carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences" sign="-" scale="-2" id="Tc_8lNKVzof7ECWJw5MY2HsGg_6_4">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" sign="-" scale="-2" id="Tc_fKywLtth5E-G8hMnWXOMPw_7_2">5.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" sign="-" scale="-2" id="Tc_l0YHVCk4akaXxAZKRabhYA_7_4">0.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" sign="-" scale="-2" id="Tc_WZLlrC499USSS_mXeaUDew_8_2">33.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" sign="-" scale="-2" id="Tc_sLWFJj96CEa3_ZfkLqRHkA_8_4">28.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="Tc_KzQZoYc7zUqwBDjeAR0pgA_9_2">1.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="3" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="Tc_l5hb3HXSokCQ0BRvufOvHg_9_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="3" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_GLs2pDJ0vUu8N_wF2aieew_10_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="3" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_f7aM7QqPYEudNcNxtDhCyw_10_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for&#160;years in which differences are expected to reverse.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_jUsWgt8orE2jxBPBdPqT0Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets for federal income taxes consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_ElsyitPXm02oCte_ahjE5w_4_3">87,742</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_9uLfqI-NO0-g15VEFpqnEQ_4_6">72,689</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Capitalized research and development costs, net of amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" scale="3" id="Tc_gsT_Y7_UXk-BnDUNq00KFA_5_3">35,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" scale="3" id="Tc_uGtMjG7_n0Kdd1Qyse1epg_5_6">33,778</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_jBDZPD8ZHk6wj8LiOTv-0A_6_3">13,269</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_wbHG4JT8i0qUq4WqbQZzzw_6_6">9,746</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Start-up costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredTaxAssetsStartUpCosts" scale="3" id="Tc_j1E30Act602ilWME2ZrggQ_7_3">4,051</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredTaxAssetsStartUpCosts" scale="3" id="Tc_UmmfnEzYB0-35NhKAh9jFQ_7_6">4,407</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="Tc_ThSyv2T1qk-CD7Awfv5cQQ_8_3">12,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="Tc_KW5ECMY3AkK1XM0GVjvfWg_8_6">13,353</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredTaxAssetsLeaseLiability" scale="3" id="Tc_B4okYQa7DEuZdJJLyWY1iA_9_3">733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredTaxAssetsLeaseLiability" scale="3" id="Tc__GatYy3weES6xAr5msb-9w_9_6">668</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" scale="3" id="Tc_musarYxIiUSz88eqtEkekg_10_3">405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" scale="3" id="Tc_yRYCjf4gNEK0_RDdUlVqIg_10_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortizable assets and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredTaxAssetsAmortizableAssetsAndOther" scale="3" id="Tc_s8CcRBN6FE2godL19ZjcHg_11_3">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredTaxAssetsAmortizableAssetsAndOther" scale="3" id="Tc_NeKwA2E-80S6wc2WxZCioQ_11_6">21</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Equity compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredTaxAssetsEquityCompensation" scale="3" id="Tc_9ZepxX8OiE2UBGLC4QsxQQ_12_3">1,115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredTaxAssetsEquityCompensation" scale="3" id="Tc_ElsEDAMF4kuOWm6hbuwoLg_12_6">87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_SY8H5W1L0EKtLJNSa4rCtQ_13_3">155,132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_aC8D__eKB0Sl9xezJZxy6A_13_6">134,749</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_MKcuQjcURUm7AMHyl5llnQ_14_3">153,855</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_YowC-KxH502e0muFEL1LHg_14_6">133,580</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax assets, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_q03yMiby20WWQ_FEEj3jrw_15_3">1,277</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_NOD7J-s2GkKS4V5bMfEDMA_15_6">1,169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Right of use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_WVqY03WAk0ajTiG6ZUt33w_17_3">848</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_V4_b7jnEjkOJhVlgeGpxcQ_17_6">645</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_LmKinhvcEUanRSefjlVMlA_18_3">429</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_nnHz13E6zkWFy9LJ_CmToA_18_6">524</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_5NsSk3c_30e2mq7JqRJx8Q_19_3">1,277</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_sQisCJhUN0OIkoDOpJXbdg_19_6">1,169</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net deferred tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_eROSWIerskuXd2zPJEy2Qw_20_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_25xRhjAq0UCN-s4C4WuEAQ_20_6">&#8212;</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, the Company has net operating loss carryforwards (NOLs) for federal income tax purposes of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_f1OJ6DnIk0WtNUSppxvYrg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_ho6pKkp3z0utRGdHY_nSAA">374.7</ix:nonFraction>&#160;million, which are available to offset future federal taxable income. The pre-2018 federal NOLs of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_carm_Pre2018Member_dstQjZ_6a0e4qC0YXpJpZw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_k9JLDSQGjE2lNhQnzAQQnw">120.0</ix:nonFraction>&#160;million will begin to expire in 2031, if not utilized. The post-2017 federal NOLs of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_carm_Post2017Member_f3GDnlkCKkiBu7MDgLhD9Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_rHc7cYUhXU-_AfcsLzuKOQ">254.7</ix:nonFraction>&#160;million carry forward indefinitely. The Company also has NOLs for state and local income tax purposes of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_carm_StateJurisdictionMember_efJJVuhcvkquKiB45VCQ1A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_UqDV0DV7oEq5rBGrmthjPw">280.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_carm_LocalJurisdictionMember_3b4Lne7Dpk26SoUxioVhCg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_SBsuhHUE-kSiFjAOsGBDJA">65.1</ix:nonFraction>&#160;million, respectively that are available to offset future taxable income. The state NOLs will begin to expire in 2031 while the city of Philadelphia NOLs begin to expire in 2042. As of December&#160;31, 2024, the Company also had federal and state research and development tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_94R-tIsNFka2JCxWnjX7Fg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_pWzNGvvl-U2VOa5jjiz09g">12.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_carm_StateJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_F3DomWzyU0mk1y1R2qHVZQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_imHaCg40IEaNZy_00Wus0Q">0.8</ix:nonFraction>&#160;million that will begin to expire in 2029 and 2032, respectively, unless previously utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb__7BkDK_UMUO4naUWC3ByqA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of December&#160;31, 2024. The valuation allowance increased by $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_kVjE7JOpjUGYVLja_1DKdA">20.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_2WZKptYDKUKYC4Y0mZa3Nw">84.5</ix:nonFraction>&#160;million during the&#160;years ended December&#160;31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50&#160;percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits net operating loss utilization as a&#160;percentage of apportioned taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense/(benefit). As of December&#160;31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s financial statements. Tax&#160;years from 2021 and after remain subject to examination by all of the taxing jurisdictions. The NOLs and research credit carryforwards remain subject to review until utilized.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_S81WDWg1PkKTO1vAVItJuQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(12)</b></span><b style="font-weight:bold;">Related-Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company has a collaboration and license agreement with Moderna, a significant shareholder (Note&#160;13).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_NrYkvkfbXUm9cWfKnkpDww" continuedAt="Tb_NrYkvkfbXUm9cWfKnkpDww_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(13)</b></span><b style="font-weight:bold;">Moderna Collaboration and License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In January&#160;2022, the Company entered into the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize <i style="font-style:italic;">in vivo </i>engineered CAR-M therapeutics in oncology. Moderna has the right to designate up to <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_S3eeHUCF80-ErdmPj3uyZQ" decimals="INF" format="ixt-sec:numwordsen" name="carm:MaximumNumberOfResearchTargets" scale="0" id="Narr_mY4PKEUJLkqOK3V0d4pzjA">twelve</ix:nonFraction> research targets as development targets under this collaboration. While the collaboration was initially limited to oncology, in September&#160;2024, the companies agreed to expand the collaboration to discover, develop and commercialize <i style="font-style:italic;">in vivo </i>engineered CAR-M therapeutics in specific autoimmune diseases. As a result, Moderna nominated <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_CC5mai144UKxgWO0ed8BXg" decimals="INF" format="ixt-sec:numwordsen" name="carm:NumberOfResearchTargetsNominatedAutoimmune" scale="0" id="Narr_iSmwWLN2t0KvvA8MInBCEw">two</ix:nonFraction> autoimmune research targets. As of February&#160;2025, in connection with Moderna&#8217;s nomination of all <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_CVCA_jIaNUSvPGLAL1iRDw" decimals="INF" format="ixt:num-dot-decimal" name="carm:NumberOfResearchTargetsGrossOncology" scale="0" id="Narr_n3Lk4Aqd6EWazVkk-PCO5Q">12</ix:nonFraction> oncology research targets (Note&#160;14), the Company will not be conducting any additional research activities under the collaboration agreement and will not be receiving any further payments from Moderna for research and development services under the collaboration agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Subsequent to the nomination of a research target, Moderna may designate the research target as a development target. Upon Moderna&#8217;s designation of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA" decimals="-5" format="ixt:num-dot-decimal" name="carm:UpfrontNonRefundablePaymentReceived" scale="6" id="Narr_CLESUzWbHU-yqnoXTI9jXw">45.0</ix:nonFraction> million to the Company. Assuming Moderna develops and commercializes <ix:nonFraction unitRef="Unit_Standard_product_3mVjd4sUPUK6dqSqJB3SiQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA" decimals="INF" format="ixt:num-dot-decimal" name="carm:NumberOfPotentialProductsToDevelopAndCommercialize" scale="0" id="Narr__TqGxiqLWEykETuxzhB0yA">12</ix:nonFraction> products, each directed to a different development target, the Company is eligible to receive up to between $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_H-d_HedKTkqWEw-yuQFN0g" decimals="-5" format="ixt:num-dot-decimal" name="carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" scale="6" id="Narr_sfC5J2Z6Xk6VlJdHaxUtBA">247.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_BvRnm7gZx0yPcQ6vufXWdQ" decimals="-5" format="ixt:num-dot-decimal" name="carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" scale="6" id="Narr_FDW5YuMRBkqwQowOgB3DOw">253.0</ix:nonFraction> million per product in development target designation, development, regulatory and commercial milestone payments. Moderna also reimbursed the Company for all costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_8qNgXN0bH0eJkf5RqlBsfg" decimals="-5" format="ixt:num-dot-decimal" name="carm:MinimumCommitmentToReimburseResearchAndDevelopmentCosts" scale="6" id="Narr_QF4nlGkLa0SKk1inlk4Nvw">10.0</ix:nonFraction> million in research and development costs over the first <ix:nonNumeric contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA" format="ixt-sec:durwordsen" name="carm:PeriodOfReimbursementOfResearchAndDevelopmentCosts" id="Narr_ZHWJ6pLGakiMxg8n4m_1vA">three&#160;years</ix:nonNumeric> from execution of the Moderna License Agreement). The Company is also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments and royalties that the Company owes as a licensor under one of its intellectual property in-license agreements with Penn, which is sublicensed to Moderna under the Moderna License Agreement. Moderna may deduct these royalties in part from any royalties owed to the Company. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_8vyx9nS3T0OXsI3UU2fK0g_1_2"></a><a id="Tc_aJm4C4_rMUOMWUo4aUeB1Q_2_2"></a><a id="Tc_FpSdjm27fkSbolp4a5vGMA_3_0"></a><a id="Tc_xnv5oh8iWkmY58hNY8XtQA_4_0"></a><a id="Tc_GhTowCekO0y3LZehcXMP-w_4_2"></a><a id="Tc_6PzMI68TP0SH8PulmkWehg_5_0"></a><a id="Tc_JNszGP6I00a_p3XavCOCFg_6_0"></a><a id="Tc_vKTsctMLeEqZXlRMDW3Oeg_6_2"></a><ix:continuation id="Tb_NrYkvkfbXUm9cWfKnkpDww_cont1" continuedAt="Tb_NrYkvkfbXUm9cWfKnkpDww_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities and participation on the joint steering committee (JSC). The Company determined that there were 2 performance obligations comprised of (i)&#160;research and development services and (ii)&#160;option rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA" decimals="-5" format="ixt:num-dot-decimal" name="carm:UpfrontNonRefundablePaymentReceived" scale="6" id="Narr_CHUS6NAG40CpbL0cfWwTbw">45.0</ix:nonFraction>&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna exercises or determines not to exercise its option right to license and commercialize the designated development target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In June&#160;2024, the Company received notice from Moderna that Moderna had designated the first development candidate, an <i style="font-style:italic;">in vivo </i>CAR-macrophage targeting GPC3 that is designed to treat solid tumors, including hepatocellular carcinoma. Pursuant to the terms of the Moderna License Agreement, the designation triggered a $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_6_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_R70NvuCqk0WTJXiSPZpa9w" decimals="-5" format="ixt:num-dot-decimal" name="carm:CollaborativeArrangementRightsAndObligationsMilestonePayments" scale="6" id="Narr_-wD4QjrmNkCfs4mp4rOE0w">2.0</ix:nonFraction>&#160;million milestone payment from Moderna to the Company. As a result, the Company recognized collaboration revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_vCHDp2Flj0-8HoO2F7_1lQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_vx-d4dZDNk-0WHTGoDCnuw">2.0</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Company reduced its $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_AtWenqGmtUa8z3-Kd3hvvw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_OIbTavo0_0Sn7NEbh-_Gew">45.0</ix:nonFraction>&#160;million deferred revenue liability associated with the option rights by recognizing $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_Xj-_M61yuk6R7alr9CUi3Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="Narr_cmEeBBkCy0eeBgll5MJpCg">3.8</ix:nonFraction>&#160;million in collaboration revenue, which represents a proportional reduction based on the <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_xyxFVBcDT0CVZTmDOmX-AQ" decimals="INF" format="ixt:num-dot-decimal" name="carm:NumberOfPotentialResearchTargetDesignations" scale="0" id="Narr_S7FJM5EL_06npRqk6QY2kA">12</ix:nonFraction> potential early-stage research targets. As of December&#160;31, 2024, the Company recorded a collaboration receivable of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_vJj0iOym_06oJXQKAC1aOA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="Narr_pG2aAOAa00iA_ya91JK7ug">2.9</ix:nonFraction>&#160;million related to the reimbursement of costs incurred in connection with the Company&#8217;s research and development activities. The Company received the $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_1_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QZ72PuDG7USaQrTyk9GuVw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollectionOfOtherReceivables" scale="6" id="Narr_u6O1QRIAKk6h-SNFG_ujhw">2.9</ix:nonFraction>&#160;million in January&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company included the $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_5_pFMaKe_E6No8FPBreF8w" decimals="-5" format="ixt:num-dot-decimal" name="carm:UpfrontNonRefundablePaymentReceived" scale="6" id="Narr_fJRtQw74f0ejttkcPC5X3A">45.0</ix:nonFraction> million up-front and nonrefundable payment and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_ECKpLj9RxkeJ2fOMI7xCfQ" decimals="-5" format="ixt:num-dot-decimal" name="carm:VariableConsideration" scale="6" id="Narr_QdPQ77QveUK1pkjmuE3LwQ">73.9</ix:nonFraction> million of variable consideration for expected research and development services to be performed during the <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_ECKpLj9RxkeJ2fOMI7xCfQ" format="ixt-sec:durwordsen" name="carm:ContractTerm" id="Narr_Xw-5v_FCq0miBYYDZ4YXoA">five-year</ix:nonNumeric> contract term, inclusive of passthrough costs, in the transaction price as of the outset of the arrangement. During the&#160;years ended December&#160;31, 2024 and 2023, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_bfw3Sy3tpE67AkJxxSCfoQ">19.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_6lQ0gabG80ut61PU-iMmCA">14.9</ix:nonFraction> million, respectively, of collaboration revenues. Collaboration revenues for the&#160;year ended December&#160;31, 2024 include $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_OptionRightCollaborationRevenuesMember_SRYjOrMSy0aaO5SPhrCxDA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_w1G43hqe00mNwE7CUCvMrA">3.8</ix:nonFraction>&#160;million of deferred option rights revenue recognition and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_MilestonesMember_FUdbCZoQDk2Dag7HM2RG6A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_AY2tjKDENUSN5KLhZW-6Ng">2.0</ix:nonFraction>&#160;million of milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_gNQIWKQL-kC9gvHVRwSeLg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="Narr_APiiti0lf061tY2LqioTiA">38.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_OptionRightCollaborationRevenuesMember_SRYjOrMSy0aaO5SPhrCxDA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_MNKg5bqALEGSBE3VFM21mw">3.8</ix:nonFraction>&#160;million, respectively, of research and development services and option right collaboration revenues since inception of the Moderna License Agreement through December&#160;31, 2024. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="Group_PpG6IXWZZUmmbPbW4NXJDA" continuedAt="Group_PpG6IXWZZUmmbPbW4NXJDA_2" escape="true">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2024 (in thousands):</ix:nonNumeric></p><ix:continuation id="Group_PpG6IXWZZUmmbPbW4NXJDA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price unsatisfied</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" scale="3" id="Tc_T6-ejDEzaEOsUf1jPeQQQA_4_3">35,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:RevenueRemainingPerformanceObligationOptionRightsAmount" scale="3" id="Tc_N_kuLiuiM0SY1GSDLPxFfg_5_3">41,250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total performance obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="Tc_bgJim9b9iE6m5GlKUVgXKw_6_3">76,551</ix:nonFraction></p></td></tr></table></div></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_28957474_33b3_4f73_875b_a600d593321f"></a><a id="Tc_G5OBRKwWDk25_RG-S2Nwcg_1_2"></a><a id="Tc_OYuObHMwJ0qsJSi4lk64OA_2_2"></a><a id="Tc_AzpsDwdM0kuBEpL_AYrAgg_2_5"></a><a id="Tc_pvYEsjMHCk-bnMKj3QGjrA_3_0"></a><a id="Tc_WT58Q07m70qnnRL5uja3oA_3_2"></a><a id="Tc_RuykpaJUSUCUTmtQEdOVdQ_3_5"></a><a id="Tc_AExdKwNcMEWMYbtciAYKiw_4_0"></a><a id="Tc_wPWt2ON2VEyvCt2Oj7nwZw_5_0"></a><a id="Tc_YGKJ3CH1hky62TEIbN4ojg_6_0"></a><a id="Tc_GWOEHf0QrUehZY08iP6U5Q_6_2"></a><a id="Tc_H38zKsoLcU2CcEBzWdt0TQ_6_5"></a><ix:continuation id="Tb_NrYkvkfbXUm9cWfKnkpDww_cont2"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="carm:ScheduleOfChangesInDeferredRevenueTableTextBlock" id="Tb_dfPy4X3VI0-cY9xE1UVFyg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the changes in deferred revenue (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_d8KDTxlH10iFzaIJzA6hqg_3_3">46,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_dR3sD2ebZE-Jma-EnSOq1w_3_6">47,459</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferral of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:ContractWithCustomerLiabilityDeferralOfRevenue" scale="3" id="Tc_fl3z-RZjLkqH2fPCqU6U5A_4_3">16,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="carm:ContractWithCustomerLiabilityDeferralOfRevenue" scale="3" id="Tc_3AiibwghOEeAfxvLOqgFng_4_6">13,873</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recognition of unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" sign="-" scale="3" id="Tc_zoOlxWGGqEGt0FZpVrEVLA_5_3">17,632</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" sign="-" scale="3" id="Tc__AwFzF31tEiugbksLG_KGg_5_6">14,919</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_wZzpyl8veUKsdbzFxGYXbw_6_3">44,979</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_6elf04ekPkS9QEsrDb0rBA_6_6">46,413</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The current portion of deferred revenue represents advanced payments received from Moderna for costs expected to be incurred by the Company within the next twelve&#160;months. The noncurrent portion of deferred revenue represents the $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_oADG9dBYzE6u3XG_uLzZiA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="Narr_pTHlhBJbPU-BwJgR3VaIJw">41.3</ix:nonFraction> million upfront, non-refundable and non-creditable payment allocated to customer option right which is not expected to be recognized within the next 12&#160;months.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ" name="us-gaap:SubsequentEventsTextBlock" id="Tb_Yhd8rn4UwkebxMgLw8e3hA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(14)</b></span><b style="font-weight:bold;">Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company has evaluated subsequent events from the balance sheet date through March&#160;31, 2025, the issuance date of these consolidated financial statements, and has identified the following matter requiring disclosure. <i style="font-style:italic;">Moderna Collaboration and License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In February&#160;2025, Moderna nominated <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_9oZWrGbwu0CzsSwa4YaYUw" decimals="INF" format="ixt-sec:numwordsen" name="carm:NumberOfResearchTargetsNominatedOncology" scale="0" id="Narr_B2G03DImIEq9gUKghJqzUA">ten</ix:nonFraction> additional oncology research targets, <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_9oZWrGbwu0CzsSwa4YaYUw" decimals="INF" format="ixt-sec:numwordsen" name="carm:NumberOfResearchTargetsNominatedReplacements" scale="0" id="Narr_RjJ1hPjlXEWbzcLxtUM-ug">four</ix:nonFraction> of which replaced <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_9oZWrGbwu0CzsSwa4YaYUw" decimals="INF" format="ixt-sec:numwordsen" name="carm:NumberOfResearchTargetsTerminatedOncology" scale="0" id="Narr_W9V3JunqJEO-8IhLIH2hOQ">two</ix:nonFraction> oncology research targets and <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_9oZWrGbwu0CzsSwa4YaYUw" decimals="INF" format="ixt-sec:numwordsen" name="carm:NumberOfResearchTargetsTerminatedAutoimmune" scale="0" id="Narr_-dAxkVtO8k2rZEQJ1hOrYQ">two</ix:nonFraction> autoimmune research targets, which Moderna concurrently ceased developing. As of February&#160;2025, Moderna has nominated all <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_CVCA_jIaNUSvPGLAL1iRDw" decimals="INF" format="ixt:num-dot-decimal" name="carm:NumberOfResearchTargetsGrossOncology" scale="0" id="Narr_x2G9gmOY50KeNS__1im_7Q">12</ix:nonFraction> oncology research targets under the collaboration for which the Company has the potential to receive future milestones and royalty payments. The Company will not conduct any additional research activities under the collaboration agreement and the Company will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the <i style="font-style:italic;">in vivo </i>oncology field exclusivity, which would allow the Company to pursue <i style="font-style:italic;">in vivo </i>CAR-M programs outside of the <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_CVCA_jIaNUSvPGLAL1iRDw" decimals="INF" format="ixt:num-dot-decimal" name="carm:NumberOfResearchTargetsGrossOncology" scale="0" id="Narr_udg4-bFBa0y0GYZdVNHgyw">12</ix:nonFraction> nominated oncology targets and product polypeptides. The final research and development payment of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_1_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QZ72PuDG7USaQrTyk9GuVw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollectionOfOtherReceivables" scale="6" id="Narr_Y4cv-_2duUabPZoIweTblg">2.9</ix:nonFraction>&#160;million was received in January&#160;2025 which will be recognized as collaboration revenue for research and development services in the first quarter of 2025. The Company does not expect to recognize any additional unsatisfied research and development performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">2025 Cash Preservation Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of a further revised plan approved by the Company&#8217;s board of directors, on March&#160;25, 2025, to preserve the Company&#8217;s existing cash resources following its reduction in workforce (the &#8220;cash preservation plan&#8221;), the Company reduced its operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down its business. The cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help to evaluate our strategic alternatives. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company&#8217;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. Any future resumption of research and development activities would depend on completing a strategic transaction that would support the Company&#8217;s prior operating plans or otherwise obtaining significant additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of the cash preservation plan, the board of directors determined to terminate all of its employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. Affected employees were informed of the reduction in workforce on March&#160;25, 2025. The reduction in workforce was effective on March&#160;31, 2025. The reduction in workforce includes <ix:nonFraction unitRef="Unit_Standard_employee_8zftLesBXkivzIcTQ6E96w" contextRef="Duration_3_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QPK_k69qc0WEZlJvXGRPPA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="Narr_6PIRZAkihEKeP8xFLGqCRA">37</ix:nonFraction> of the Company&#8217;s full-time employees representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_3_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QPK_k69qc0WEZlJvXGRPPA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_9UATW1Zh8E6z6RjbBy8lNQ">84</ix:nonFraction>% of our total workforce, including certain employees engaged in research and development, manufacturing and corporate activities. The Company expects to incur approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_TTkLQHgTUUWOQaI1eLingg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="Narr_FjdE9j8xG0-UvmHgnVXHQg">3.8</ix:nonFraction>&#160;million in connection with the reduction in workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. The Company also expects to pay the majority of related reduction in workforce amounts by the end of 2025. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the reduction in workforce, including (but not limited to) impairment charges relating to the balances of property and equipment, net, prepaid research and development costs and right of use assets&#160;&#8211; operating lease.</p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Item1FinancialStatements_34786"></a><a id="_c38e04f3_e66a_4fc5_9053_695cdfbd93ff"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><a id="UnauditedConsolidatedBalanceSheets_64748"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED CONSOLIDATED BALANCE SHEETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and par value)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_75287d3e_738b_4351_9639_cd42dc29d19e"></a><a id="Tc_VQT2x20WYkmARkH1zvOqng_1_2"></a><a id="Tc_Z9odPADO1UOzq4KulSCqKQ_1_5"></a><a id="Tc_3ROKiomIVkK4btwOjKSR7w_2_2"></a><a id="Tc_pedM4VeS8U-zO2f6-DYOVA_2_5"></a><a id="Tc_US6Pcogdf0SoAitklM8trg_3_0"></a><a id="Tc_bcbx1fOjdkO15A64tKRzyQ_4_0"></a><a id="Tc_FM62cKsNT0WU3lcmefIPRw_5_0"></a><a id="Tc_WlHS_Hf9WEGI-mUg3X0MUQ_5_2"></a><a id="Tc_RaKQbk-lFEKy0xdc8qgGJA_5_5"></a><a id="Tc_eMfT1t5mfESYmhHijfr75w_6_0"></a><a id="Tc_3QBkI2Fe0E6qb3FgmJgvfA_7_0"></a><a id="Tc_SePS9wS0C06jKMSs8Svw-w_8_0"></a><a id="Tc_KJa3FkHhgUCQdqW3DyWlCA_9_0"></a><a id="Tc_kRuru5F2IE2TvtT3PEf_4Q_10_0"></a><a id="Tc_tIkm_b7y4kKq48ZZVT-_qw_11_0"></a><a id="Tc_45w6g_2Nk0-I8IdEnNlCUA_12_0"></a><a id="Tc_0HkFejc6JU65Kof33tkoAg_12_2"></a><a id="Tc_egvro_V_TEiqs3B3GF3vSg_12_5"></a><a id="Tc_IWrCLlmpv0asxdUka5kVsA_14_0"></a><a id="Tc_X3ilAz3aPkSDSxHVm4B8xg_15_0"></a><a id="Tc_7feK3VaY50SkNu1eaJxBTg_16_0"></a><a id="Tc_Sz4Oh-IF6EGBdATiFu1RoQ_16_2"></a><a id="Tc_A38omxOkzUO4olVwO1uLeg_16_5"></a><a id="Tc_P4jrANzCG0q-Ko6JPihFvA_17_0"></a><a id="Tc_OUV3Im_e4EClUjcota6V6g_18_0"></a><a id="Tc_Y2inzLngXU2x8V6TJhGMjA_19_0"></a><a id="Tc_DsR037gIQ0WL75-n3pHqWg_20_0"></a><a id="Tc_p4zSXer9-kWQyry6QtUDjA_21_0"></a><a id="Tc_v7Mcg8nbiEi45U8HhOkKiA_22_0"></a><a id="Tc_sikHG5vJKkyDxIR4TuvAjw_23_0"></a><a id="Tc_HUa0qyYlI0aAuyjUAB_OJQ_24_0"></a><a id="Tc_zZYfKRT6bUCmAE48q_URaA_25_0"></a><a id="Tc_EFLKMnMrlk6v_-bCVBJPSQ_26_0"></a><a id="Tc_O3UJMABwX02-WGtWPwObFA_27_0"></a><a id="Tc_xh1uTphaN0yOygW-lyZ_zQ_28_0"></a><a id="Tc_YUQd9DPVdEeQJpJJBl_W-g_29_0"></a><a id="Tc_-6cpGpxfzEi898WcivoJnQ_30_0"></a><a id="_8949d7e5_8ca6_4056_95fa_62dd7613786d"></a><a id="_8949d7e5_8ca6_4056_95fa_62dd7613786d_2"></a><a id="_8949d7e5_8ca6_4056_95fa_62dd7613786d_3"></a><a id="Tc_cbtcHHZuV021Ee2wS-2fPA_31_0"></a><a id="Tc_1KGKyVdtPE-HZHpeGaWbuA_32_0"></a><a id="Tc_1EgysdtmqUCYPczZUXdP3w_33_0"></a><a id="Tc_7QPs1b5pDkSKZBVsMBP28Q_34_0"></a><a id="Tc_wazA3lYNb0u7iceN4bLj0w_35_0"></a><a id="Tc_MBr4WqftnUW0PCbkJFGYLg_35_2"></a><a id="Tc_BaSQNbo_WkahGuS_zYQOVQ_35_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_hikf65ouskeBOU6I6shVyQ_5_3">7,740</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_NCD5xQCfuUmAzvAg7pDLkA_5_6">17,909</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_MEXZ3IjFa0qUWrOfrTT6cw_6_3">2,901</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_2FwH1VGp-U--zcGAFrXTXA_6_6">5,916</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_l1dt4TA66k--2c1wy27mKg_7_3">3,313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_Cdus7JJ-8k-ys-8Wkkiqwg_7_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_uI6HN9CuoES8NA_I9qom4A_8_3">13,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_RSiIdkrqskOq3EAZ_PT4Zg_8_6">23,825</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_cOyYhreVgUeyALfK6Bj2qg_9_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_K7m5xQq28EGtji8igmEHgw_9_6">4,385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_frZhWGCF2ESKufPY-qdyKA_10_3">1,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_RGjaru5BXEm8h9AKQhNE6A_10_6">2,040</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:fixed-zero" name="carm:DeferredFinancingCostsNoncurrent" scale="3" id="Tc_vTcHSXbTPEqT0SjtX5E8-w_11_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:DeferredFinancingCostsNoncurrent" scale="3" id="Tc_33rQhWCPbEKKndbm0w9eMQ_11_6">208</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_A5aKN8gLMky2hjjuOyI2Rg_12_3">15,953</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_2UlUOiPYb0GdZGKz33T8SQ_12_6">30,458</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities and Stockholders&#8217; Deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_Ec1mXNnlnUaIKfdNMo3h0w_16_3">3,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_kdfLweFUBkGWlRFIaxXzhw_16_6">2,081</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_LieRlSAHUkmc3SixJQG1Bg_17_3">4,705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_6V-l5zRXlUKFU2KTwf5uGA_17_6">7,448</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredRevenueCurrent" scale="3" id="Tc_V2MYLfbfFkaj1W8vtfGu2g_18_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="Tc_cXnGHGBrbkqKy0phdUKv5Q_18_6">3,729</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_fZNqTJXG-0O7k5HQpwD09w_19_3">998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_TIsGBCC0S0uMGmPAcHTAyA_19_6">832</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_J2oo-pqa7kGkvUzQpDkuRw_20_3">640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_8BM-utqrWkePaxAmcbDAJQ_20_6">905</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_2IHFbZmH-0WXUBSvv5_cXw_21_3">853</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_itguzrfVTUmg4z3jA1YoWg_21_6">1,060</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_Qm771NCrKEaOSUS56aq7mg_22_3">10,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_BvrDySrlNEylzKXfRVMzaA_22_6">16,055</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="Tc_c8IXs05nWU2Ekj1D9FCYfw_23_3">41,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="Tc_Q4BIEUVQh0qZKZs11YkuHw_23_6">41,250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_M3ZwlDGyE0OwhnE0nNXfFA_24_3">687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_6COrAjC33kiWH-X1Ty8C5Q_24_6">724</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_GLdZ-ZSLL0GUWdJwCaORiQ_25_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_3UPDeNreL0CJLY2WAX9ACg_25_6">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_vJPdI6wvdU28J3qViAK4rA_26_3">231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_p2XAoRPZDkeHVXiHdthpBg_26_6">318</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_Ks0yXsZTAEGL9xQG9dZcRw_27_3">52,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_a-JeyorOZEaw4R0VQA6mwQ_27_6">58,367</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; deficit:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_hI7qDL3e8kCnqIi8WEJMdA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_pITVLrciyEuLzrfnoIjwWw">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_7_WSi2_Mm0eL9sSS0DLnig"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_UWi2WLf5KU2NMp4LKnqxCA">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_KCEx7ZBCAUGAmtcwCc5PgA"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_tPQCWdBZxUiXAlZqooyrjA">none</ix:nonFraction></ix:nonFraction> issued or outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="Tc_usBJm8qUakmkjkixMQl9dg_30_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="Tc_jXmKKNUQDEGZg5VR6Hyxgw_30_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Common stock $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_stpbmber_0uGhPz8uUsrkg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_7o3jXEV0hEWpnrlU0n8DBw">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_4BXXXmBFAk2_Y6tGlAutbQ"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_rHC632bNDEODa2G23F4ePQ">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_3BH8PEQlTUCpncFInBUqDA">41,788,096</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Y_KHH4v8FkSWFVdo0dT-uA">41,750,109</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_UuJUKdscKU2BamT-vknOlA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_YsbYHRwR2UyuINXyqElSpg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at March<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span>31, 2025 and December<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span>31, 2024, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_bxvWCab-GkWoZHMPGvjpwQ_31_3">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_qIFn44woZkGUZaK7qKHrjg_31_6">41</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_syjcjMXIm0-Bno0Iiz2BYg_32_3">278,142</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_V3y1rKEuXUe8sSC4pJwVQw_32_6">277,629</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_A-lt1FHPa0mIkBwiSjwMzg_33_3">314,845</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_P80HED4a2UaDlUp-BvK98g_33_6">305,579</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_dgxN-w1CB0mEg1GRd4Vnag_34_3">36,662</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_qnxYZpESd0uPz4K8O95bFw_34_6">27,909</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities and stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_maw8L1LkYEaL9KfhHTeIWQ_35_3">15,953</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_QXgilkRSZkmLbFFG7TvM6w_35_6">30,458</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to unaudited interim consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:28pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_453df416_f316_4af3_8048_816d52ea505d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><a id="Statofoperation2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_85fc8233_ec32_4bc6_9d1c_00b3ccf49d4d"></a><a id="_71b8896b_84a1_43d5_a889_af290285adb2"></a><a id="Tc_-L9ViaAU90qCCD5cYHtchQ_1_2"></a><a id="Tc_eXcg65FJLkGEpoU-TNoESw_2_2"></a><a id="Tc_pv7t8KFUJEm21USijmrlNQ_3_2"></a><a id="Tc_EUSxF-NFj0eBze2RO_Qm7w_3_5"></a><a id="Tc_4Pt5IGTBXEif9YCyv0DS4w_4_0"></a><a id="Tc_2w_tSUj4vEmLTJslM-oNdw_4_2"></a><a id="Tc_AYzZwlTV00CfFd9CU7TWGw_4_5"></a><a id="Tc_bxmlsdwWA0mwhUTQdAdR8Q_5_0"></a><a id="Tc_OSxqCjkI3kSkXmKkiWRFKw_6_0"></a><a id="Tc_JRI_hWaJjkWtioEtVompPQ_7_0"></a><a id="Tc_T8Ze1BUPzEWpUn-RlbjEgw_8_0"></a><a id="Tc_R4dHrrae6k6ASSXQPLKx5A_9_0"></a><a id="Tc__PCINfX-n0qoj1Gs8b2SHg_10_0"></a><a id="Tc_JT4CQCQanUGM3--pxcNzaw_11_0"></a><a id="Tc_yp01E4cs7Ue4waQVcgiiNA_12_0"></a><a id="Tc_5YjgABYYb0WJ29qWm8ewEw_13_0"></a><a id="Tc_4A9Ii3wMkUyaf-ddFQXKHA_13_2"></a><a id="Tc_-sdBAzkoRE2EyfAlfOL5cA_13_5"></a><a id="Tc_nz5aQEJ0vkOjtfLvTX1DjQ_14_0"></a><a id="Tc_hNnJx7W-EkqshNUBEDAmMg_15_0"></a><a id="Tc_d-IW5NTzOUWX2KNCFkyScw_15_2"></a><a id="Tc_3e-CW7D_iEqMif2-2Z_s0A_15_5"></a><a id="Tc_qgM-hiAtzkCmOSZjaAF30g_16_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="Tc_hmsAByr0RU2sceMBx6q6fg_4_3">3,729</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="Tc_-n_WS5CgW0a-IDuu1uYjMA_4_6">3,397</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_5K0WzC2A5Uazo6hYHqgkSQ_6_3">9,156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_ZNPU9oZWUkqVhVmNtOnNPw_6_6">17,462</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_cvILskxFAkK6OTxJ8xnRQw_7_3">3,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_KADa7b8_kECjTtr10mDVQg_7_6">5,445</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_s4YfvQ8v_Umvl6Oh3vd2TQ_8_3">13,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_Tql4tU7nC0CLGfT5HYmf8w_8_6">22,907</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_VL_nYhMccEWkyEH_VtwvsQ_9_3">9,334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_DXiX2WbwgEatex2gsB3nIQ_9_6">19,510</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="Tc_YcuS3wp-s0qCGlvk88K2Fg_10_3">68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="Tc_906mp-bReUGQCwqYVI8VRw_10_6">532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pre-tax loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" sign="-" scale="3" id="Tc_lkJbNz7y4E-4u9lgJb-DlA_11_3">9,266</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" sign="-" scale="3" id="Tc_qlex_LyAdEKONJW0uHwUVg_11_6">18,978</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_fdLxP72Dp0mf0FfkB_qAsw_12_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_76aj-TKLiUeKdeuzHOifgA_12_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_OMxZDxDM5EqwH-6t4sl97Q_13_3">9,266</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_B-UsM1QtiEqjlApmVQ7aIg_13_6">18,978</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share of common stock, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_imzeJrgwX0eb63DHiIc4uw_15_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_imzeJrgwX0eb63DHiIc4uw_15_3_2">0.22</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_-TpCIHfWvkWJWbSPdkQbvA_15_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_-TpCIHfWvkWJWbSPdkQbvA_15_6_2">0.46</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average shares of common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_f5zgvzVEIEONwQeMDD1K4Q_16_3"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_f5zgvzVEIEONwQeMDD1K4Q_16_3_2">41,771,213</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_dJhAXrE0PEqo_TqeyCf5CA_16_6"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_dJhAXrE0PEqo_TqeyCf5CA_16_6_2">40,938,464</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to unaudited interim consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:28pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_7eff67de_4a7f_4640_8392_fb67b074c6c9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><a id="UnauditedConsolidatedStatementsofStockho"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; (DEFICIT) EQUITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_994fe065_8b9a_4e83_9961_af9fe57c31fa"></a><a id="Tc_opLxBE-aKESZMmL5Nkpi9g_1_2"></a><a id="Tc_28hkn9DMaUeVL-CNEDT7HQ_2_7"></a><a id="Tc_dgVomHJ_Y0WBMLPRUWY6wQ_3_2"></a><a id="Tc_34sJPByrik6QLggHhBioqA_3_7"></a><a id="Tc_V6bc9TjStUy-FslqHcC_Kg_3_10"></a><a id="Tc_WfXo0b7PD0ivNoP3AE2VeA_4_2"></a><a id="Tc_ZL9L6_r5HEebO0icFBhBEA_4_4"></a><a id="Tc_NuYlkQLWmk6CMb12-AVadQ_4_7"></a><a id="Tc_hvgZl5p3aUipezujPWYq1A_4_10"></a><a id="Tc_t3eZzdbmGk6SPb_Tb_SM4g_4_13"></a><a id="Tc_fg8OzRhtL0WA8nauTUJdVQ_5_0"></a><a id="Tc_FhtS6iak8k6V-45EJQfaog_5_4"></a><a id="Tc_n1e1efSloUCDNfRaM9kY9g_5_7"></a><a id="Tc_oQX38BmrlESbk2zH9hsi-g_5_10"></a><a id="Tc_13_J9H2_GES11UCBnrvzLg_5_13"></a><a id="Tc_W1svHIqV-kmjH0O4uaI10A_6_0"></a><a id="Tc_Oxk9_kWexkCV_1WjO37Zhw_6_5"></a><a id="Tc_rKKaDJwpbEOCc6ARaCVUAg_6_11"></a><a id="Tc_sQNcbXiIpEqhFNwPSL0Hfg_7_0"></a><a id="Tc_veviWcwlTUSIYnuWe-Z7qg_7_2"></a><a id="Tc_L-JIgskf9kmWLFZgHND9XQ_7_5"></a><a id="Tc_BXg8maz_j0-OdZgtHdYSvA_7_11"></a><a id="Tc_cwrCUDE6pk6rlTR75jEnYg_8_0"></a><a id="Tc_n93bFwvwcEWg-ZA5detghw_8_2"></a><a id="Tc_u7kjF3X4ekSuu0gNh2H-hQ_8_5"></a><a id="Tc_XjCbqK2DoEuZ3Qc1AOlm3Q_8_8"></a><a id="Tc_jRNzvNC9GkacH1J-4k4c7g_9_0"></a><a id="Tc_VzoSPJ9cuE24Emy6Mfed9g_9_4"></a><a id="Tc_gHsWknNoeUyJktIpebMgnw_10_0"></a><a id="Tc_YpgiiBX7Nk-LIcUl5nwx4g_10_4"></a><a id="Tc_hgLznrc85E6bzdHxHrSdOg_10_7"></a><a id="Tc_Gdx6PSNYoUStcEPokq7p2A_10_10"></a><a id="Tc_TrfftBaKAkObG91284aH7g_10_13"></a><a id="Tc_-6FQ360knU-il3PfIIA4OA_11_0"></a><a id="Tc_ilp9fjbrXkSCxwxcWbJGvg_11_5"></a><a id="Tc_ePAQqr3i8kmGXr5KG3f9Gg_11_11"></a><a id="Tc_t80bimx7bEivvpsSx6Jy_Q_12_0"></a><a id="Tc_ct8ZLXBxtUuea0YLCvCofA_12_2"></a><a id="Tc_KreYsbTuVUyC8trGnV3-wQ_12_5"></a><a id="Tc_40Tezo8OC0OWUFswUU9VJw_12_11"></a><a id="Tc_bTzu5l_EAkW8X-xbVZL_Fw_13_0"></a><a id="Tc_QjgU_gGWD0OrlT044ToGAw_13_11"></a><a id="Tc_dQPAUlkrpkakGMZ1TvlvlQ_14_0"></a><a id="Tc_jeYzh9F-3EiNsgMSlzEdFg_14_2"></a><a id="Tc_u2TFnSieYEKOQ_pSrW16Zg_14_5"></a><a id="Tc_kaA0Q1nX30-gZozML5W7lQ_14_8"></a><a id="Tc_5m5taaHQ3EOr3cmfBEbOow_15_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:46.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; (Deficit) Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVEm6mt950Ss-dIhOM6psw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_wASbobCoJkilZ6aoGSy28w_5_2">41,750,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVEm6mt950Ss-dIhOM6psw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_-pyxyNGzTkGDjI991ravLw_5_5">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JA8S9njYW0u1srOBy-b4Fg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_Lds1BeSBgkuPiGX9-KubUg_5_8">277,629</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lu-cSSufUEqWCNoTK34t1Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_XFb5EWWsx0yNgoA4VlV8aA_5_11">305,579</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_OQFmK0tAAEekYHeB7ae0LA_5_14">27,909</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wF0j2cynSUuqz6R2wHJFsQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_UtKJMxXhMUuJwWMZh5IoZA_6_2">37,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CtxCArF56kS82xK5cMVGuA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_JDpww9eOFU2tjqfTGH-YkQ_6_8">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_L0lkTqD2dkOm6GB4KPSYJg_6_14">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CtxCArF56kS82xK5cMVGuA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_AATflTq1jEiHNmt2yHv1_A_7_8">508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_CnMY6vQ-YEyKOLguK-V_HQ_7_14">508</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_o52ygJ2qtUW_8MtdyoucDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_2sYQz_N5vEyOaIJL3DEBpQ_8_11">9,266</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Pj2ZNO6CDUmfI-k014pnjw_8_14">9,266</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance at March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcPCJIcIO0eFOPtvCF5mqA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_kxNUtd9E4EyzSea7YmggUw_9_2">41,788,096</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcPCJIcIO0eFOPtvCF5mqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_rGRm1548PkeWhdCjshlc4A_9_5">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KyGaWAjqJkmBWbexZMF-jA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_vY4y27j0jEG0QRPGexN-Dg_9_8">278,142</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KOBMN_pRd0CpuuBgDONMeQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_EOnhoZyrZ0qrWSYGRvQPWw_9_11">314,845</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_Q2exaofhXEC-IYBtFa4JFw_9_14">36,662</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sizU-8d-HkiGAXLhA7EliQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_nVKQ0Ws9p0GdDPZptQa0_w_10_2">40,609,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sizU-8d-HkiGAXLhA7EliQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_wqEMrV6txUGHHlbAc-T-rA_10_5">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CiZKxNIbvEyRs27cGTE1kw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_UXSnjSdkwEOA7G-lGfJP0Q_10_8">271,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p0MZ0Mf-7Uu7LB1ZZP5Iyg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_EOc-iVJpNkqkg5kxSrE1jg_10_11">245,102</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_l2sSWlvDfk-tn82IDfQUyg_10_14">26,532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NBJH3utECkSeITbgKbOBjQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Hkj-DfIzk0-Mem0lhMhlKw_11_2">1,579</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3bekv5USnUGc01h2wLoVyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_UZvyk4_VqkucDZbvBaV_1Q_11_8">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_w5XvJep1OESv4jGl4nYlPQ_11_14">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3bekv5USnUGc01h2wLoVyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_3JEv7eeeOEqLsJdCmXWnAw_12_8">1,057</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_iG_qAiSHw0Ol9hAlSudYOA_12_14">1,057</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sale of common stock under Open Market Sales Agreement, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NBJH3utECkSeITbgKbOBjQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Tc_JhHXREyQl0iY8f5JPIRzIA_13_2">931,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NBJH3utECkSeITbgKbOBjQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_AsnqZpm8dEaufGzlLK-0LQ_13_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3bekv5USnUGc01h2wLoVyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Ax4s56LIXUyr4R74B9C2Ag_13_8">2,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Xv7c5mG8rU-yC-0n6gMeTg_13_14">2,282</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_V0Pkqzz_AEyhjqolIkoUug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-YYoQzy1z06x_vJlbVX8fA_14_11">18,978</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rionZWQ7T0yfU-ebyGkyBA_14_14">18,978</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance at March 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fkuPLbunBkio3h13YwQKEA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_5AHQ3a_PuEmPCFaiWUfTxg_15_2">41,542,744</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fkuPLbunBkio3h13YwQKEA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_mJcliWXffk2ddA4HoTgNaQ_15_5">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9V4P9b_imUeKWRIMprh3ug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_bzzwLJHN7k6j_nEXjIvj8g_15_8">274,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_djTn0QuJAUyMxSDTnffWJQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_c0B3zrTkBkqWgzYQAU4Iyg_15_11">264,080</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_S2vdfv8TkkqwipsZCv0Ymw_15_14">10,895</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to unaudited interim consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:28pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_65fa7a59_4c45_4b7c_b278_f0e54796f596"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS&#160;INC.</b></p><a id="Cashflow2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_42f9f2bd_bfbe_42c5_99bf_8712890a715e"></a><a id="Tc_xGLPsiJ51U6qRem1HlnUDg_1_2"></a><a id="Tc_7dYUl3_mBEGyHEYBg3wUDw_2_2"></a><a id="Tc_RIRf81vz50aVWq26JHmkzg_3_2"></a><a id="Tc_NKamhZDwtUiqpzbA4dOxxg_3_5"></a><a id="Tc_qQjkypvLB06PVJHxOOjvtg_4_0"></a><a id="Tc_lv4AEYBC60eHqYgVto42sA_5_0"></a><a id="Tc_DGDqvsuoL0yLAmtTcrUhIA_5_2"></a><a id="Tc_71xYGI608EaPr2DsxwGEgw_5_5"></a><a id="Tc_eHmbYBarF06nuVFzj8HtSw_6_0"></a><a id="Tc_yz9Lj0iz0UWaXsYhBWZ2bg_7_0"></a><a id="Tc_X-HTv_6sHESwKUX-zYeh3Q_8_0"></a><a id="Tc_6mI5Zrx_G0-cuqOGcZeeTQ_9_0"></a><a id="Tc_1g0rZJjMh0Ov1plNCwcCxA_10_0"></a><a id="Tc_2Yxt3hoz90y2fGrbG6Fa4A_11_0"></a><a id="Tc_w0dLSNQBHUi6x9IvebApYg_12_0"></a><a id="Tc_3KrR0xQDkESbgkupeFB7Og_13_0"></a><a id="Tc_5zpsVPgKSUq69sT8mCUwDQ_14_0"></a><a id="Tc_DRfezhiwU0SuOn1sGfLqQA_15_0"></a><a id="Tc_zXypGrXUJUSSne7qH1Shcw_16_0"></a><a id="Tc_XzrhKgxFrUilRL4CIcd4Zg_17_0"></a><a id="Tc_aoC7ZNtBJU-uqP3ZCMFwRw_18_0"></a><a id="Tc_0pB1jAeJ8U-NEjW1V0lF2Q_19_0"></a><a id="Tc_qTzSIRWnYkKLg331PnAI7w_20_0"></a><a id="Tc_IUvql_jQ7kWg2rXvd7LXSA_21_0"></a><a id="Tc_Gzrgd-0yb0y3b12zZnyzcA_22_0"></a><a id="Tc_cd1TWB6E5U-0vTyw6xC0iA_23_0"></a><a id="Tc_kfJLqVdvGEe2T9XdwUSRmw_24_0"></a><a id="Tc_FXsPNm6MqkuO-AVDPcfT8A_25_0"></a><a id="Tc_ujykTpNU-ESfKBwJqsA0lQ_26_0"></a><a id="Tc_r9nSVMwTW0qdM-DNDYyjLw_27_0"></a><a id="Tc_4psuhkBTSkqw9HkmpnHONA_28_0"></a><a id="Tc_awWVlEx5Q0GcR5Fszu9ypA_29_0"></a><a id="Tc_Ai_bS5lekEmhujQWcuAQwg_30_0"></a><a id="Tc_awUR4lRENEiKv7_4-f3IAw_31_0"></a><a id="Tc_F5t2ul3-y0GwS031yA9YCA_32_0"></a><a id="Tc_ikD0g1Yol0Wiz1YKm7DuFQ_33_0"></a><a id="Tc_u_7TxpvFgUmEAAjmi1Gx_w_34_0"></a><a id="Tc_9X2WQ2WxLEepYCIJ_FNtKw_34_2"></a><a id="Tc_tmhTpfCbO0GXF0CnMhMKgA_34_5"></a><a id="Tc_SX1KOVxWm0yKouA-d_Pbfw_35_0"></a><a id="Tc_KU1T0cqkL0Keo2zHB2lv_g_36_0"></a><a id="Tc_fXicdxNtmkaHoMWyVVNbww_36_2"></a><a id="Tc_aYemNU5g_k6aif81RMPLLA_36_5"></a><a id="Tc_gDhvtye_gU2LCqVD-fMRdQ_37_0"></a><a id="Tc_5p8roSN2XEqCa034MtSw2A_38_0"></a><a id="Tc_bfBn-4iv20W7hj0NkxsyYQ_38_2"></a><a id="Tc_mg2icotASUunT7FwNWZLSA_38_5"></a><a id="Tc_iCbTmvu7AEixGtam1aEg1w_39_0"></a><a id="Tc_YSc6H65o10uLMbXaBXgUIA_39_2"></a><a id="Tc_4Dg8MWZ9F0ibVcpkOBvK8A_39_5"></a><a id="Tc__9nl_rG8BEiNy4CKe5GYsQ_40_0"></a><a id="Tc_jo3ZjwGTlkuA8Eam-HIMNw_40_2"></a><a id="Tc_RY6hgsKylE2w45Y-RlB9RA_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_c1Ji8nnTPk6WFBvbbPzE4w_5_3">9,266</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zTImA9A_w021ayd_hLZsLQ_5_6">18,978</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Adjustment to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_hoOd16rlIUWlKLCDRcrGTQ_7_3">661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_YoRnLCx4Q02K8kNuGUekQg_7_6">1,693</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_6ijP5Evx1EqpoO7Gy8CYKg_8_3">508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc__JaevbG0vE-k0JZyX3vAVw_8_6">1,057</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reduction in the operating right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_IXNbFBEm1kaNGshpu3CmOw_9_3">877</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_KBDMHUqLvU6EkLZlB5kibA_9_6">1,360</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Write-off of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" scale="3" id="Tc_9p69a36xw0m1oQelb0FguQ_10_3">208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" scale="3" id="Tc_O2ZtvAU6M02o6X3sLfzcPg_10_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">(Gain) loss on sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_rvVQ2xx7OECPbTwEZrlMIA_11_3">113</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_a8ds-CX7UEyPwhHomGXnpA_11_6">67</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="carm:NoncashInterestExpense" scale="3" id="Tc_xCvDX-B_YEyDoC-xaUYW9g_12_3">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:NoncashInterestExpense" scale="3" id="Tc_M8p_ZsrWtUm3GINsphr0Dg_12_6">236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_6dOYxGk8-EazeMywADyy4w_14_3">3,015</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_d6ZTD_C8z0qpkJDS0M_v-Q_14_6">1,572</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_9pDeIBHY2Eedl8qw6U3Q6g_15_3">1,170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_URD26tGOUEGIXWhvqIZ9Ag_15_6">1,826</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_ZZlt0r-VLk6jfhJ8yfiPfg_16_3">2,743</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_aeSdeU41fUW6oPcIuHLoEA_16_6">2,933</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_8f8QaVn1ukGo99AG2X24Jg_17_3">3,729</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_LiX0EeE08k-wzXZ1192i2g_17_6">224</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_9a-4lYWDtkOW5BuPB6ILwA_18_3">707</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_R7BgGzH5wU-mUZiXZGh7ng_18_6">1,355</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_Cgxv3CipxkeWAmcX-AwKMQ_19_3">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_t4K9rdGumESUoDvmXxVSVg_19_6">50</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_5ucNpMu0lkSW_V8AROhLuA_20_3">10,067</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_pljkN2Nu6E-qNyJDF6n21Q_20_6">22,425</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from the sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_ra8ZCKQHx0KQvbRjjv_06A_22_3">524</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_SVRUB-_fgk2sFZuYnDrgFQ_22_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_z281pyCzb0yjGtu0SztOWw_23_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_ZhLNcd3B9ESUUZ7eTliY4w_23_6">17</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_uh04PcfHbk-7nzwXT5wgIw_24_3">524</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_zt3l1lzZwUOK8-mpJ7GUnQ_24_6">17</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Payment of principal related to finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_azx2a9YiHUWqss2k5J74tA_26_3">304</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_9aqPuLPng0e1zKuaXvqaoA_26_6">1,319</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from failed sale-leaseback arrangement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:fixed-zero" name="carm:ProceedsFromFailedSaleLeasebackTransaction" scale="3" id="Tc_TvOVJxo4_keLacqsbqWjtw_27_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:ProceedsFromFailedSaleLeasebackTransaction" scale="3" id="Tc_lvOFKv2Zy0qP-ilwM1Sx4w_27_6">686</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Payment of finance liability from failed sale-leaseback arrangements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" scale="3" id="Tc_SX630ivPlUCoGt_vL_SLOw_28_3">327</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" scale="3" id="Tc_yFGZGurVrkCh-JpXBYp5Gw_28_6">303</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from the exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_yjdqBCWCnEufGWBglC-qmA_29_3">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_i9ufkq0EsE-Vvr0NVCVC7A_29_6">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sale of common stock under Open Market Sales Agreement, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_dUvXrefTEUm-Zj9ZW_FItg_30_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_-armPOGTUUCSrDRa9Q7cYw_30_6">2,286</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30pt;">Net cash (used in) provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_tpeyFAtGgkGZv-l_L8Kcig_31_3">626</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_REjP3apJzUiIGWsAydrzOg_31_6">1,352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_mBklbqM5pEGkDJs85SlGWw_32_3">10,169</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_5MMp1tgWm0Gp8h_cOvj74A_32_6">21,090</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents, and restricted cash at beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_hLpEmsaNUEikD-hvRs0QlA_33_3">17,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_kyMAZhnaCky0RcHi2kEWoA_33_6">77,605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash at end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ovPolZk30U-HkxJ8FMZtcg_34_3">7,740</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_JAp1Byf6w0m7Fx5bdy0DpA_34_6">56,515</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supplemental disclosures of cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_1je46taVY06b61u9Vart2Q_36_3">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_rpUByuddIkG5cniPRapZpA_36_6">50</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supplemental disclosure of non-cash financing and investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Right-of-use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_ysLxNZ43pUulwi_xSgRymg_38_3">836</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_meXz7Vr9JUe8sP-HP0sNAA_38_6">4,337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Right-of-use assets obtained in exchange for new financing lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_wiA_7Net8U28WRrdfZJPDQ_39_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_USutB37Ny0KAWguhBbyoGA_39_6">2,470</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Property and equipment in accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_P0_cdtay-0uMYY3ZfLarMQ_40_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_MT8YmTOwvEGsKRR3nAevqQ_40_6">59</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to unaudited interim consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:28pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Notes2"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_UQKf56whEEC_NRJNyibhhg" continuedAt="Tb_UQKf56whEEC_NRJNyibhhg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-weight:bold;">Background</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma Therapeutics&#160;Inc., a Delaware corporation (collectively with its subsidiaries, the Company), is a biotechnology company focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;and December&#160;2024, the Company&#8217;s board of directors approved revised operating plans to reduce&#160;monthly operating expenses, conserve cash, and refocus the Company&#8217;s efforts on strategic priorities. As part of these plans, in March&#160;2024 the Company elected to cease further development of its first lead product candidate, CT-0508. In December&#160;2024 as part of the plan, the Company elected to cease further development of its then lead product candidate, CT-0525, following an assessment of the competitive landscape in anti-HER2 treatments and the impact of recently approved therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of a further revised plan approved by the Company&#8217;s board of directors on March&#160;25, 2025 to preserve the Company&#8217;s existing cash resources following its reduction in workforce, as further discussed below (the cash preservation plan), the Company reduced its operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down its business. The cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help to evaluate our strategic alternatives. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company&#8217;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. Any future resumption of research and development activities would depend on completing a strategic transaction that would support the Company&#8217;s prior operating plans or otherwise obtaining significant additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of the cash preservation plan, the board of directors determined to terminate all of its employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. Affected employees were informed of the reduction in workforce on March&#160;25, 2025, which became effective on March&#160;31, 2025. The reduction in workforce included <ix:nonFraction unitRef="Unit_Standard_employee_8zftLesBXkivzIcTQ6E96w" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_lGhVgDEdm0KquD87r_9DVA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="Narr_44aLA09Yfki_Jf0crlL-fw">37</ix:nonFraction> of the Company&#8217;s full-time employees representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_lGhVgDEdm0KquD87r_9DVA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_h-RR987w7EqV94u2TVgSQA">84</ix:nonFraction>% of the Company&#8217;s total workforce, including certain employees engaged in research and development, manufacturing and corporate activities. The Company incurred approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_lGhVgDEdm0KquD87r_9DVA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="Narr_8TqIXiFRvkaz0Vmpu8-9DQ">3.4</ix:nonFraction>&#160;million in connection with the reduction in workforce during the three&#160;months ended March&#160;31, 2025 and expects to incur an additional $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_e9iO1ErRnUC87OlaTyfKaA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" scale="6" id="Narr_aOPIs5lHGUmLDKtM7t4INA">0.4</ix:nonFraction>&#160;million in the second quarter of 2025 related to further potential terminations, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. The Company expects to pay the majority of related reduction in workforce amounts by the end of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">NASDAQ Compliance</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;10, 2024, the Company received written notice from The Nasdaq Stock Market LLC (Nasdaq) indicating that the Company no longer satisfied Nasdaq Listing Rule&#160;5450(b)(2)(A), which requires the Company to maintain a minimum market value of listed securities (MVLS) of $50.0 million (the MVLS Rule) for continued listing on The Nasdaq Global Market. In accordance with Nasdaq Listing Rule&#160;5810(c)(3)&#160;(the Grace Period Rule), the Company had 180 calendar&#160;days, or until April&#160;8, 2025 (the Compliance Date), to regain compliance with the MVLS Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;10, 2025, Nasdaq notified the Company that, based upon the Company&#8217;s continued non-compliance with the MVLS Rule, as of the Compliance Date, the Company&#8217;s securities were subject to delisting from Nasdaq unless the Company requested a hearing before the Nasdaq Hearings Panel (the Panel). The Company has requested a hearing before the Panel, which is scheduled to be held on May&#160;22, 2025. The request has stayed any further suspension or delisting action by Nasdaq at least until the hearing is held and any extension that the Panel may grant to the Company following the hearing has expired. There can be no assurance that the Panel will grant the Company&#8217;s request for continued listing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on April&#160;10, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule&#160;5450(b)(2)(C), which requires the Company to maintain a minimum market value of publicly held shares (MVPHS) of $15.0&#160;million (the MVPHS Rule) for continued listing on The Nasdaq Global Market. In accordance with the Grace Period Rule, the Company has 180 calendar&#160;days, or until October&#160;7, 2025, to regain compliance with the MVPHS Rule.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_UQKf56whEEC_NRJNyibhhg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, and as previously disclosed, on January&#160;6, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule&#160;5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share (the Bid Price Rule&#160;together with the MVLS Rule&#160;and the MVPHS Rule, the Price-based Rules) for continued listing on The Nasdaq Global Market. In accordance with the Grace Period Rule, the Company has 180 calendar&#160;days, or until July&#160;7, 2025, to regain compliance with the Bid Price Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To evidence compliance with the Price-based Rules, an issuer must evidence compliance with the applicable minimum threshold for at least ten, but generally not more than 20, consecutive business&#160;days. Although the Company is considering all available options to regain compliance with the applicable listing criteria, there can be no assurance that the Company will be able to do so.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="carm:DevelopmentStageRisksAndLiquidityTableTextBlock" id="Tb_m1UwAHc2eUCFcC0ZPkCFww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(2)</b></span><b style="font-size:10pt;font-weight:bold;">Development-Stage Risks and Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_qKw9dZ7REUaG_Z0flFAcOA">314.8</ix:nonFraction> million as of March&#160;31, 2025. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of March&#160;31, 2025, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_IRogPoIV20KtkECtqyxL4A">7.7</ix:nonFraction> million. Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one&#160;year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company&#8217;s ability to continue as a going concern. In addition, changing circumstances could cause the Company to consume capital significantly faster than currently anticipated, and the Company may need to spend more than currently expected because of circumstances beyond its control. The Company&#8217;s cash forecast contains estimates and assumptions, and management cannot predict the timing of all cash receipts and expenditures with certainty. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liability that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management is currently evaluating different strategies to maximize value and prepare to wind down the Company&#8217;s business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company&#8217;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. There is no assurance regarding when or if this strategic review process will result in any type of transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_j4jnChmJwEOUEO6ZPhhIZw" continuedAt="Tb_j4jnChmJwEOUEO6ZPhhIZw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(3)</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb__G4OzvDNXEKRV1Kb4jhE5Q" continuedAt="Tb__G4OzvDNXEKRV1Kb4jhE5Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interim Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summary of significant accounting policies is included in the Company&#8217;s audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (SEC) on March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance are meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The accompanying unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. In the opinion of management, the accompanying unaudited interim consolidated financial statements include all </p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_j4jnChmJwEOUEO6ZPhhIZw_cont1" continuedAt="Tb_j4jnChmJwEOUEO6ZPhhIZw_cont2"><ix:continuation id="Tb__G4OzvDNXEKRV1Kb4jhE5Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2025 and its results of operations for the three&#160;months ended March&#160;31, 2025 and 2024. Operating results for the three&#160;months ended March&#160;31, 2025 are not necessarily indicative of the results that may be expected for the&#160;year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain all of the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Company&#8217;s Annual Report on Form&#160;10-K filed with the SEC on March&#160;31, 2025.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:UseOfEstimates" id="Tb_OXGweKX_T0aJXNQKD6OshA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant areas that require management&#8217;s estimates include stock-based compensation assumptions and accrued research and development.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="carm:AssetsHeldForSalePolicyPolicyTextBlock" id="Tb_P3t3U3EOj0KN17NX2bT8-Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Assets Held for Sale</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2025, the Company committed to a plan to sell its remaining equipment and therefore has classified the amount as assets held for sale on the consolidated balance sheet as of March&#160;31, 2025. The assets held for sale were reported at the lower of the carrying amount or fair value, less costs to sell.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_4A2SX7hxEEetnyCla4HYpA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value of Financial Instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_rld2R-QQGES96YUkFqt5WA" continuedAt="Tb_rld2R-QQGES96YUkFqt5WA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value Measurements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ebcd0eb1_4f36_466e_ba50_9ce9de3d83ae"></a><a id="Tc_20Phv1B8O0yLMexiLM2vNw_1_2"></a><a id="Tc_q8gHtupXGESI2u0679IlSQ_2_0"></a><a id="Tc_vrsOsonxO0eORjtXuNG7kA_2_2"></a><a id="Tc_pmEzF5_M-0W_V5kWudUhRA_2_5"></a><a id="Tc_aPu1KYdH-UKRPmjD5nfFWQ_2_8"></a><a id="Tc_ixPTBuwNs0G-aqmB2KQ4sg_3_0"></a><a id="Tc_s2cgFvP9eEid96PG4YMc1g_4_0"></a><a id="Tc_OCWPe5r5MUqBYRZZzrsBLQ_5_0"></a><a id="Tc_FU-X9x_LOkG4xe6042zn2g_5_2"></a><a id="Tc_YFyhP2J1YEePxEAULEAikA_5_5"></a><a id="Tc_bWdahi_k9UaJ0AKi16I6gw_5_8"></a><a id="Tc_AlmsbXqqX0i2gI5Q2krJOg_6_0"></a><a id="Tc_c15J1UCIt0COLsCn0LEQxA_7_0"></a><a id="Tc_L38cCSYWDUGQAQ4RgGSWLA_8_0"></a><a id="Tc_LVT-Nfof4UmEK1EQ5dwgXg_8_2"></a><a id="Tc_3NxOSsgrjEKOfqMvD8UN4g_8_5"></a><a id="Tc_ZDpLzWfMh0Co18MwFMxBpw_8_8"></a><a id="_64988938_89b3_4914_a5c8_e18116a0e190"></a><a id="Tc_wmD_gOMmwEOjmfHUj5qWCw_1_2"></a><a id="Tc_uPqsgphdx06qRGbZFlW7Yg_2_2"></a><a id="Tc_z8z3FWuNpkGSNPipt7Re8Q_3_2"></a><a id="Tc_2e1J4fWmi06er4hEbVoDDw_3_5"></a><a id="Tc_M8yMISDCvUmDUFMStdtGVw_4_0"></a><a id="Tc_M57vDLjNU0K1fPz0kXC7gg_4_2"></a><a id="Tc_CTVcU1pGt0aDy4ZgBkFMnA_4_5"></a><a id="Tc_62iowj6UoECzbGBhD9n8wA_5_0"></a><a id="Tc_1j9v8_tndUeQf1Y0U2fEfA_6_0"></a><a id="Tc_zX9vKKcsiUq02YADIUUvdw_7_0"></a><a id="Tc_EntFY6jGCky4NZyiutRaNQ_8_0"></a><a id="Tc_SV4c-Ejxe0SAxgHD25YSiw_9_0"></a><a id="Tc_b-b7Nn_AH0C7DGfReX1tBQ_10_0"></a><a id="Tc_R_C4kChrekGJr1B3z5iB5w_11_0"></a><a id="Tc_I3H90KMIq0-GWl7WkQKWMw_12_0"></a><a id="Tc_5AGhO1mGzkWIwPZJVjNFKg_12_2"></a><a id="Tc_l_x6vPwezU2kAo6DeezC6A_12_5"></a><ix:continuation id="Tb_j4jnChmJwEOUEO6ZPhhIZw_cont2" continuedAt="Tb_j4jnChmJwEOUEO6ZPhhIZw_cont3"><ix:continuation id="Tb_rld2R-QQGES96YUkFqt5WA_cont1"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_pzCxxBEOtE-SsG3IDDp_Eg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C2na3yFo8kSa8lpEjLIVYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_kuroyCZP606FoPmL-lLc5Q_5_3">6,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qni1eLtrpEqVTUS5DP3Q5g" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_G3KwHH4vOUugBf7UBNbA3g_5_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NHpG9u0K8kSnQJhkduVBWQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_P-G8d6k6OEOwC0fBDECZsg_5_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_FPiLpPUNo06fNsnw6eJy3A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_NQMgm0x_QEKckYwLfkalFA_8_3">14,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RNeFS6gXN0O81arpfa3vew" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_0oXm2vhDaUetSv1VdKjKDA_8_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_P-hP9vpSB0SObx9s8SRr_w" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_DT3dlKWKpkCejpnhFRuWFg_8_9">&#8212;</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2025 and 2024, there were no transfers between Level 1, Level 2 and Level 3.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_SnvkQ_ciyECqY_RFEHWvRg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Concentration of credit risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_L5scubQROUKvvfAvoW4RGA" continuedAt="Tb_L5scubQROUKvvfAvoW4RGA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Segment information</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has <ix:nonFraction unitRef="Unit_Standard_segment_ieOgHbuNO0uMDAyeDWsL6Q" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_cXbnyVeEI0yCeHefFJ7Qww">one</ix:nonFraction> operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_2K0t-f_AgkWpcKIQUf0k9Q" continuedAt="Tb_2K0t-f_AgkWpcKIQUf0k9Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the three&#160;months ended March&#160;31, 2025 and 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="Tc_B0V0NNzsr0WrQgXdTi824A_4_3">3,729</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="Tc_RLNCNP2Rq0KRSoL2pqM2DA_4_6">3,397</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA" decimals="-3" format="ixt:num-dot-decimal" name="carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" scale="3" id="Tc_ltx3AXLilUCV_TF_hh1CKQ_6_3">1,528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag" decimals="-3" format="ixt:num-dot-decimal" name="carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" scale="3" id="Tc_Hw5KRHbHCkSipfVtvbFMeA_6_6">10,191</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA" decimals="-3" format="ixt:num-dot-decimal" name="carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" scale="3" id="Tc_eGl06d9M10SO0dnrbuGRzg_7_3">2,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag" decimals="-3" format="ixt:num-dot-decimal" name="carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" scale="3" id="Tc_Tyb4nJa-C0uFwxiN3mYxJQ_7_6">3,656</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA" decimals="-3" format="ixt:num-dot-decimal" name="carm:FacilitiesExpense" scale="3" id="Tc_lN6Ywu6eYESwC3mWcUk6Gw_8_3">1,099</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag" decimals="-3" format="ixt:num-dot-decimal" name="carm:FacilitiesExpense" scale="3" id="Tc_gSlpk0ACgkC9KpIr6QPsHQ_8_6">1,632</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_IX2PzxzKjUGKa--T7NMMfw_9_3">7,354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_tdhHrticaE2OzXcqCg_Cfw_9_6">6,529</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA" decimals="-3" format="ixt:num-dot-decimal" name="carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" scale="3" id="Tc_wvyqRgg2WEe3Na5SRF9IXw_10_3">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag" decimals="-3" format="ixt:num-dot-decimal" name="carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" scale="3" id="Tc_hlFjZglnFU-FilsfkTOGHQ_10_6">1,185</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" sign="-" scale="3" id="Tc_iRWbTd62RkWWpGPwPC0EsQ_11_3">119</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" sign="-" scale="3" id="Tc_sxvu6JImj0eLkkCxalAb3A_11_6">818</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_tvat5RJLF0OK7gJp_jdVfA_12_3">9,266</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_y-0VQiibjUq-b82nvgTPgQ_12_6">18,978</ix:nonFraction>)</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">&#8220;Other segment items&#8221; includes</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> interest income.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_67e3f044_5e8d_4e57_b17f_36e30f93a5a6"></a><a id="Tc_ovZGcC1ayEipa1ThjZ9ypg_1_2"></a><a id="Tc_iDX7v5Lmk06rtgHptNNIPQ_2_2"></a><a id="Tc_zs1g_zt-HUGUaHuC1M2epQ_2_4"></a><a id="Tc_1dkWJbnA40qnh54buWjvoQ_3_0"></a><ix:continuation id="Tb_j4jnChmJwEOUEO6ZPhhIZw_cont3"><ix:continuation id="Tb_L5scubQROUKvvfAvoW4RGA_cont1"><ix:continuation id="Tb_2K0t-f_AgkWpcKIQUf0k9Q_cont1"></ix:continuation></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_cFZSn9RJpUKpbdH67k56xw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net loss per share</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_D4gjTY6R2UKY71FywNWm-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_o9XCCXxBxk-Bcr0qGS2Bcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_oeH5owJ_70GRGiah0QytSg_3_2">6,895,824</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_zK5vgRHDUkuO_I7i5iruOQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_4MEKsf35sUmnAkfpYMdysQ_3_4">8,210,547</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_xmiZ_gFw90GH4vDCRJlbag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recently issued accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes </i>(Topic 740)<i style="font-style:italic;">: Improvements to Income Tax Disclosures </i>(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November&#160;2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures </i>(Subtopic 220-40): <i style="font-style:italic;">Disaggregation of Income Statement Expenses</i>, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1caeb015_d9dc_4fc7_934f_f7fa7ac660f9"></a><a id="Tc_572mOZvA20SnDUt87CIavg_1_2"></a><a id="Tc_31ddZqaH5kmOD6IbTQPYNg_1_5"></a><a id="Tc_A19g1GF6xEaeQgwtXNQ9kw_2_0"></a><a id="Tc_FYrmRb1WDU2qjmQoIrhw-g_2_2"></a><a id="Tc_rHYYhYXMTUCLEbxJ4t3c4g_2_5"></a><a id="Tc_PPstmHp71UKxYwuxPRvOJg_3_0"></a><a id="Tc_IGg2lMl8U0C2seJlKGWMNg_4_0"></a><a id="Tc_NdB5M14ZfUSKBDl5Saci0g_5_0"></a><a id="Tc_FOiLnuxNxkOZVgdwHL3r0Q_6_0"></a><a id="Tc_lao7YMLC5kKGy2F8_d9d6g_7_0"></a><a id="Tc_sGE7H-apo0iFcbeucSPpog_8_2"></a><a id="Tc_w0lCxelzpEuI2AkFagjvzQ_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:OtherAssetsDisclosureTextBlock" id="Tb_3IxskU3xnkiAdgrL87234Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(4)</b></span><b style="font-weight:bold;">Prepaid Expenses and other assets</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_3Cx3HPo_cU-bnbVgF57MuA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:fixed-zero" name="carm:PrepaidResearchAndDevelopmentCurrent" scale="3" id="Tc_sexeyGNlVUiwveWnAYIJbg_2_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:PrepaidResearchAndDevelopmentCurrent" scale="3" id="Tc_8_5sIT4h5ECXFh0odBJ5ww_2_6">1,715</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration receivable (Note 10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:fixed-zero" name="carm:ReceivableDueFromCollaborativeArrangementCurrent" scale="3" id="Tc_nTh44uM290aCHCkXJ_N6iA_3_3">&#8212;</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:ReceivableDueFromCollaborativeArrangementCurrent" scale="3" id="Tc_MKA1aHEmJkq5hSfMLe3Z0A_3_6">2,864</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables (a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesGrossCurrent" scale="3" id="Tc_kWck_JEI_UyqWI3kmZVO-Q_4_3">1,209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherReceivablesGrossCurrent" scale="3" id="Tc_FoMqtfCxbUS8YHXQTMkhRg_4_6">&#8212;</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" id="Tc_I63GGhiul0W_w65dvBjLCQ_5_3">845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" id="Tc_DfmxQsjW_kKIZ0Tz4NgKdw_5_6">925</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_eJ5TN3_eikS3VHB3yvBamA_6_3">717</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_BF4ywYAkH0Chsi5B7skPWw_6_6">340</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_mylie4p-OUOefPEZiy7guA_7_3">130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_uKkx0T9h6E-mhM_U-6teag_7_6">72</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_c4sjIchY70yJrCou5fbF5w_8_3">2,901</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_6taRs6gktEyTPoJAv0Krsw_8_6">5,916</ix:nonFraction></p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">&#8220;Other receivables&#8221; primarily</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> consisted of equipment sales, sales and use tax refunds, and research and development tax refunds.</span></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_bc2b5a42_bab5_4086_beb1_80bcd9e96241"></a><a id="Tc_MA05KVLbXEGlPpSK6QsivQ_1_2"></a><a id="Tc_18KLXE6VlUuRQEDX9_b5Hw_1_5"></a><a id="Tc_8z20GJgFu0etxxb_ftoMHA_2_0"></a><a id="Tc_YZFEW4T7e0e7Mhlb1jkAyw_2_2"></a><a id="Tc_9z69Zj9X5Ee3Vu5Ly5e6hg_2_5"></a><a id="Tc_uq1HRoJzpUKoSvnPDUrHOA_3_0"></a><a id="Tc_GxZuwVRZz0eurEFK1MXNOg_4_0"></a><a id="Tc_1093B24oEEOhVTiUr9SWiw_5_0"></a><a id="Tc_MFqhu6ipi0-pg8owdGoeNA_6_2"></a><a id="Tc_-e2d_LDcqkaxK8rMM_Bzsw_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_Y-rPrbGFU0-uMbnP1cs4WQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(5)</b></span><b style="font-weight:bold;">Accrued Expenses</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_KmwYmLYODUqPXObPGePEnA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="carm:AccruedResearchAndDevelopmentExpenseCurrent" scale="3" id="Tc_EqOi6S6TEEuGc_i2UQqPEA_2_3">525</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="carm:AccruedResearchAndDevelopmentExpenseCurrent" scale="3" id="Tc_K_uZS75jiEyFkTb73dh4-A_2_6">1,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_tbA5R1Cflku925ZjThcGZw_3_3">465</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_o3rB46Ko9UGREBZTEm9QeQ_3_6">537</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_X92bsqvoakyoQpVzK_0BAw_4_3">3,554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_esz8P2ygskCgRHQzoIhDJg_4_6">4,879</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_Sju_SbxDwEGqxkpVIO1LcA_5_3">161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_7CBICA65HUOTxC4foF9T0w_5_6">187</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_4Gn9eGjbeU2oyNa5pWrY5A_6_3">4,705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_3NEATdQO4USkjZdYP0YwNg_6_6">7,448</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_35dc0650_2da4_41cb_9a3e_79b9320b696e"></a><a id="Tc_-1T4MFlx2EyM8KQ2Bp4Mxg_1_2"></a><a id="Tc__RoZThseSE-ccY0bTxdlyg_2_2"></a><a id="Tc_JRaidQWY5UmIzg9JgbGbQQ_2_5"></a><a id="Tc_nwQWZ0JJCUmY30rBMluSAw_3_0"></a><a id="Tc__pNNoWPwT0G7gDHSNmJjMg_3_2"></a><a id="Tc_vWWbDR--_kK7HEWW5JZ5Vg_3_5"></a><a id="Tc_e2tOdAC_bEiZG3IO4-LLgA_4_0"></a><a id="Tc_aY4T0qXQf0O2-vlizWMHBQ_5_0"></a><a id="Tc_g6iF86O24U2Z5ZmaX-E7Gw_6_0"></a><a id="Tc_RXdOO0mcikKLXmvJW0pAUQ_7_0"></a><a id="Tc_mLsKwBz4806AWcUDadtoGg_8_0"></a><a id="Tc_ha3CgB8ql0WImVfLYqgU9w_9_0"></a><a id="Tc_NyYrnyrohkK2b3vE8QG36Q_9_2"></a><a id="Tc_5JfrHU7zH0S3qlD670166A_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_K8dWLq9OWEy2-hOUvYLgDA" continuedAt="Tb_K8dWLq9OWEy2-hOUvYLgDA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(6)</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#8217;s operating leases have term end dates ranging from 2025 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2025 to 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operating and finance lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company carries laboratory equipment from failed sale-leasebacks, as assets held for sale on the accompanying unaudited interim consolidated balance sheets. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of March&#160;31, 2025, the Company had a $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_mVjyQyWkQ0ysng36Cpz6dQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="6" id="Narr_x9SgLPB1LkirmkwGyNkNRw">1.7</ix:nonFraction> million financing liability recorded in other current liabilities and other long-term liabilities on the unaudited interim consolidated balance sheets.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:LeaseCostTableTextBlock" id="Tb_9cshu3lf3kieu_aAmPrADg" continuedAt="Tb_9cshu3lf3kieu_aAmPrADg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The elements of the lease costs were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_s4XrmSsj-0agbTO2szY5Mw_3_3">929</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_EcGLzwkQhEqHBwOOAGa_qQ_3_6">1,469</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_gc2X3v0sSUSYNydV0zZbXg_5_3">263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_8rda4gTKyECu6ijs1wKrdg_5_6">1,298</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_wsXVFw4uG0mQ7ayZliPflw_6_3">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_4DOD-YmpZ0yao71FpfrFyg_6_6">236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="carm:FinanceLeaseCost" scale="3" id="Tc_OmhPskGGpEuqmg6ARkFcBw_7_3">282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:FinanceLeaseCost" scale="3" id="Tc_CWbk3Ng_vkCEu7sksnIcsw_7_6">1,534</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_PcRy9rRY5UelgGpGWpFFGA_8_3">115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_EjCJCE5DT06cIEivW8zE2w_8_6">472</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="Tc_35oQV-1cxEKPdZyJb1h3rA_9_3">1,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="Tc_alxJ1iXhG02CALMmFH9HFA_9_6">3,475</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4191ea1c_effb_4063_9fb3_1f939daa91f5"></a><a id="Tc_NaYAYC7G_kquyiZfvSs0rA_1_2"></a><a id="Tc_vsOY42cA4EuXJoRVIxZoCQ_2_2"></a><a id="Tc_kB6c_FPE0ke8jqwwd3PM4A_2_4"></a><a id="Tc_EjtPbJKoo0ua4bL593E_Hw_3_0"></a><a id="Tc_dcWaMf4xg0u5nLZtR_0aEQ_4_0"></a><a id="Tc_upCq6ZqXvEGDZAOa47lgvA_5_0"></a><a id="Tc_67M9ADp_akWmQR_UcV4QuQ_7_0"></a><a id="Tc_K0nFFi088kaK6ksf0znkqg_8_0"></a><a id="Tc_nSHy1mDrE0qPDNBvm9v4fg_8_3"></a><a id="Tc_TNDnrp1UdEuCcnO5RTy_Ww_8_5"></a><a id="Tc_0sh9Vo5yL0KrOIh_3fuXUQ_9_0"></a><a id="Tc_iJXew_mFFU2iPkMCHTrCEw_9_3"></a><a id="Tc_EwK8ymfUU0-ucQtt8surTA_9_5"></a><a id="_60a1fe37_ed61_4ddd_82e1_26bb9b1ea191"></a><a id="Tc_hyKFOUX-skWyOq3fU3URCQ_1_2"></a><a id="Tc_hPQwsQ9-v0ah4URMxZOtWA_2_2"></a><a id="Tc_c0UaZL1rLUKBdXiWdV6AEA_3_2"></a><a id="Tc_moFy0PDac020BYqUwGgabQ_3_5"></a><a id="Tc_VKSq0uBmLUSBJVOxG58zaA_4_0"></a><a id="Tc_A0n4FLe25E6ehSJKzC2vaw_5_0"></a><a id="Tc_93_x5lkx0E27NizX5S7ITA_5_2"></a><a id="Tc_ytAxftn7sU6bpxIZ4Iss6w_5_5"></a><a id="Tc_iLN4ogBvBEe7GSuoNf1JAw_6_0"></a><a id="Tc_KZPkPGGx0k-y-58pPYDkDQ_6_2"></a><a id="Tc_bHSGl72LbUCn9uJa-oZJoA_6_5"></a><a id="Tc_2yuL1DtSNUezB6i0JAd-nw_7_0"></a><a id="Tc_yg2T-n1f5kq0oObIkoF9_A_7_2"></a><a id="Tc_ZMBo-wgGfU22pzgL-I6-9A_7_5"></a><a id="_5f7765fc_f0da_4e03_a8cb_ff384ddda4aa"></a><a id="Tc_jiQGVnitc0y-IUDUUSeAjw_1_2"></a><a id="Tc_Yi3qWZUeZE6nauesOTrW0w_1_5"></a><a id="Tc_TL6DWdbE9kig_xgERB0fOw_2_2"></a><a id="Tc_TeAsvchyTU-1EhN37zZXsQ_2_5"></a><a id="Tc_Mf2Q96e2KkqSzPdQOrEWZg_3_0"></a><a id="Tc_4AU9BTgi00S2xGd21xuQow_4_0"></a><a id="Tc_ViK0wLFGYEuu_iYKcUVWZw_4_2"></a><a id="Tc_5c_qCxf-vUCZa4gXZFwQ9A_4_5"></a><a id="Tc_qj6HHnbIUU-iH7BJ0RXpWg_5_0"></a><a id="Tc_aJfKF8ONeU-53TbiXTqsaA_6_0"></a><a id="Tc_pvIzTZnZMky7CxPcKTrGXg_7_0"></a><a id="Tc_n_-1tv6krE284IIPwDRbQw_8_0"></a><a id="Tc_urSBlaVDa0OxZaNTNdzZmg_9_0"></a><a id="Tc_eyqR6JKUiUOI_9IlGxAQhw_10_0"></a><a id="Tc_2cwxELl9pEWdt2-0DICUSg_11_0"></a><a id="Tc_K62Yx2wVN0uWUJyFbAr7AQ_12_0"></a><a id="Tc_2ediwqJDRkW_7pzWIFSQ6A_12_2"></a><a id="Tc_BkjQ6wU7e0Gi9L7ilvYRsw_12_5"></a><ix:continuation id="Tb_K8dWLq9OWEy2-hOUvYLgDA_cont1" continuedAt="Tb_K8dWLq9OWEy2-hOUvYLgDA_cont2"><ix:continuation id="Tb_9cshu3lf3kieu_aAmPrADg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" id="Tb_pDoYSFM3CU2vAa3Js1V_vQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Lease term and discount rate information related to leases was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_gvfFSlwJdESGWLjX-Tskpg_4_2"> 2.4</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_zlpHjq21Ykiv5sIYgi778g_4_4"> 2.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_Q3OeZkrJR0ulAiXidl_RMg_5_2"> 0.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_jbqpgttHdU61tCxbeZ0f4w_5_4"> 1.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_Y0436C88RUyR8yTDeQ8VdA_8_2">9.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_nvR41GGPIUSI69mm2TTCaw_8_4">9.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_HVM9F2OhFEal8caNhuwrWg_9_2">9.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_Ili_Znw5mEaXbjL4B9pt2g_9_4">9.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" id="Tb_pIyxeK7VV0inIDIZYbF3kg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Supplemental cash flow information was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_aem5JOyuNEO9ptv31UHu3g_5_3">707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_ZPgTIRLeQEK3o6Ygxhf7UA_5_6">1,463</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="Tc_Tm42VjuhYk-s2nNGcX94ug_6_3">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="Tc_BWujX_8ZiEWtT4ZqLrPfpA_6_6">236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="carm:FinancingCashUsedInFinanceLeases" scale="3" id="Tc_bTtnGckieEuHExI_DWosLw_7_3">304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:FinancingCashUsedInFinanceLeases" scale="3" id="Tc_VY42ZCInL0Wmo_zyJKM4Hw_7_6">1,319</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" id="Tb_VMpWYJVk-0KCSiXm0EFSPA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Future maturities of lease liabilities were as follows as of March&#160;31, 2025 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiscal year ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 (remaining nine months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_mOgMvMQvQk27iEFFsnR-7A_4_3">1,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_ORrMMNTvQ0yuA5t_RsXKag_4_6">639</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_FAASrDJ64E6CAQRbgSz8-A_5_3">226</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_K4YXM4mJqkOr6YOnFVSFjw_5_6">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_hFyydiC-9EGtOiGIMzqF4w_6_3">233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_f1VV3Bf_h0eKvLjsQSZHpQ_6_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_xy8PmIaBekSgea-G2m7NSw_7_3">240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_VUsNmePEqU2vTcmJlaO5bw_7_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_tCBihNPjPEWdLb3UHEtWwg_8_3">184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_AMl25d2RbUq5siTdG_oYHg_8_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:fixed-zero" name="carm:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="Tc_s1Oe5IDmBkCn2rEW5dBG0w_9_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:fixed-zero" name="carm:FinanceLeaseLiabilityToBePaidAfterYearFour" scale="3" id="Tc_NkiwD4wHzkC74jltz5ANKQ_9_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_wPyX6IY7tUuhF9UGl2O1lQ_10_3">1,925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_FkYQr85e4E6njyTT8n48WA_10_6">659</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_fzCuCFdlTkGu9kbW0sWlyA_11_3">240</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_fuqc_CEE_U-t9ZNhRy3DFA_11_6">19</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_aGttnn2CqE6ZxcvemEvgCg_12_3">1,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_yJt-7iVDSkiHvQXT3_WGXA_12_6">640</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licensing and Sponsored Research Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November&#160;2017, the Company is required to make annual payments of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_3NLofzzltkKOh4rmrr_2tg" decimals="-3" format="ixt:num-dot-decimal" name="carm:CommitmentsAnnualPaymentsRequiredToBePaid" scale="0" id="Narr_dOeQ8v2HoUuEYQfzInpLrQ">25,000</ix:nonFraction>. Penn is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_baLeGNcD3EigtjEBIXS6dg" decimals="-5" format="ixt:num-dot-decimal" name="carm:AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" scale="6" id="Narr_3StMc3JVCU2MzPKzKgR9hA">10.9</ix:nonFraction>&#160;million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_TrTvMEg3XUmfyU3iMfTZ3Q" decimals="-5" format="ixt:num-dot-decimal" name="carm:AdditionalMilestonePaymentsRequiredToBePaid" scale="6" id="Narr_P4ImWL6pK0q0nCCrJH4qOw">30.0</ix:nonFraction>&#160;million per product in commercial milestones and up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_3NLofzzltkKOh4rmrr_2tg" decimals="-5" format="ixt:num-dot-decimal" name="carm:AdditionalMilestonePaymentsForTheFirstCARMProduct" scale="6" id="Narr_czIRyji7YEmccR35rKymrQ">1.7</ix:nonFraction>&#160;million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Contingencies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. As of March&#160;31, 2025, the Company was in negotiations with a vendor to determine the total costs owed for research and development services provided. While the negotiations are ongoing, the Company believes a liability is probable. The Company has estimated the amount to be owed to be $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="Narr_bfcmhVSC9E-0QQeoVGLMGQ">1.5</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableMember_2St9M_1mr0e3gTe3DEn6vw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="Narr_2QylkQw8R0KbF0M3Ubm8tQ">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_mc__W33L60eUsMJuatMfaQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="Narr_oNef_WsnuEK7UMlLnWpqaQ">0.5</ix:nonFraction>&#160;million are included within accounts payable and accrued </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_K8dWLq9OWEy2-hOUvYLgDA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">expenses, respectively, on the accompanying consolidated balance sheets. The final amount owed may differ from the estimate as negotiations progress. The Company will continue to evaluate the matter and will adjust the liability as necessary based on any new information or agreements reached with the vendor.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_KzVnah18a0CPw89rbNNdwg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(7)</b></span><b style="font-size:10pt;font-weight:bold;">Stockholders&#8217; E</b><b style="font-size:10pt;font-weight:bold;">quity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Open Market Sales Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">On April&#160;17, 2023, the Company filed a universal shelf registration statement on Form&#160;S-3, which was declared effective on May&#160;2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_4_17_2023_x6SGs_0tqUWE9Nmq-r1zlw" decimals="-5" format="ixt:num-dot-decimal" name="carm:SaleOfStockStockOfferingAmount" scale="6" id="Narr_ZUhy9JWBtEOgO0avSvjtQQ">300.0</ix:nonFraction></span><span style="font-size:10pt;">&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May&#160;12, 2023, the Company entered into an Amended and Restated Open Market Sale Agreement</span>SM <span style="font-size:10pt;">(Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_5_12_2023_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_D_fnvKHBKEejhcN9RD39EQ" decimals="-5" format="ixt:num-dot-decimal" name="carm:SaleOfStockMaximumOfferingAmount" scale="6" id="Narr_i3-cKATUZkCyG1Tl9TVI0A">100.0</ix:nonFraction></span><span style="font-size:10pt;">&#160;million under an &#8220;at-the-market&#8221; offering program. During the three&#160;months ended March&#160;31, 2024, the Company sold </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_KzPkm9W5EE24UqG-d_OiTg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_1rbSikakzU-3o_1K9rl6Pw">931,250</ix:nonFraction></span><span style="font-size:10pt;"> shares of common stock for gross proceeds of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_KzPkm9W5EE24UqG-d_OiTg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" id="Narr_E9Hd26fL-0yKtkEjQQ8LqQ">2.3</ix:nonFraction></span><span style="font-size:10pt;">&#160;million. The Company did </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_OiQ4pvFuv0SzT93oHU7Tbw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_b86jHfqwkk652NsVJOIIGQ">no</ix:nonFraction></span><span style="font-size:10pt;">t sell any shares of common stock under the Sale Agreement during the three&#160;months ended March&#160;31, 2025.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_NLk95qX3WkW_-gUBJBcAMg" continuedAt="Tb_NLk95qX3WkW_-gUBJBcAMg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(8)</b></span><b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2017 Stock Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the CARISMA Therapeutics&#160;Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_O60app-ziUOiQI-0SFDxHQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_tlvQFsCm4UqnXLno3iAucw">ten&#160;years</ix:nonNumeric>, and stock options typically vested over a <span style="-sec-ix-hidden:Hidden_Y6YvLEfyKUG_kk0uMc5sKQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four-year</span></span> period. The Company&#8217;s stock options vest based on the terms in the awards agreements and generally vest over <span style="-sec-ix-hidden:Hidden_DGF8BxLO20aH0nuzKXhnJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four&#160;years</span></span>. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder and ceased granting awards under the Legacy Carisma Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2014 Stock Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Amended and Restated Stock Incentive Plan, as amended (the 2014 Plan), provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Company&#8217;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#8217;s board of directors at the time of grant. Stock options outstanding under the 2014 Plan generally vest over a <span style="-sec-ix-hidden:Hidden_RR1pBUqe5UemOm2ln3QA2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four-year</span></span> period and are exercisable for a period of <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_BqAFVKxD_0eZh52zf-_cHA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_K4YGYC6wpEKHgPgwTfg2uA">ten&#160;years</ix:nonNumeric> from the date of grant. As of March&#160;31, 2025, approximately <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_b0EJK8W8H06cy_5zpLWtsQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="Narr_8WkzYUJqhEyP9B28BbY_KQ">5.6</ix:nonFraction>&#160;million shares of common stock remained available for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2014 Employee Stock Purchase Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carisma Therapeutics&#160;Inc. 2014 Employee Stock Purchase Plan (the 2014 ESPP) provides employees with the opportunities to purchase shares of common stock at a <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_nnJFjCrHlUqpNk-U5M1Zug" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="Narr_VuqKHDhUVU2S5me25MsSMg">15</ix:nonFraction>% discount to the market price through payroll deductions or lump sum cash investments. The 2014 ESPP had <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_KcFLfiniXEG_gOlYI1LmVA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="Narr_T7Xu30A6XUu-lTHImhVjew">0.2</ix:nonFraction> million shares of common stock available for issuance as of March&#160;31, 2025.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_a07NgnqYVkGIZ48P3RqcRQ" continuedAt="Tb_a07NgnqYVkGIZ48P3RqcRQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_736499a4_560e_4e74_8e0f_e33cfe95ac39"></a><a id="Tc_irMMnlbBgkuj70AL1VjZPA_1_7"></a><a id="Tc_fXiknXJdSUK2WAIF7BaNKg_2_4"></a><a id="Tc_3BSionz8A0yaUBe2xMt32Q_2_7"></a><a id="Tc_krv_xaj31Uyqg2IBpzD-Mw_2_9"></a><a id="Tc_JTYKoDHMB0mlkKDtzKdOrA_3_4"></a><a id="Tc_vLc3c1pXF0-rf5ntfu4KaA_3_7"></a><a id="Tc_ZLTMVPOZXUWG8QnXWbIflw_3_9"></a><a id="Tc_fWK_RnCznEqPOunYJBwhOg_4_4"></a><a id="Tc_uQ95mpJBbUa8xx0WJ5Y3LA_4_7"></a><a id="Tc_R7hGGB05LU2do-AjpAGngw_4_9"></a><a id="Tc_CxcZ8GmPn0yPJgE4xCV8hg_5_2"></a><a id="Tc_iOvpt82qZ0mO5CXPWDUuYA_5_4"></a><a id="Tc_b5EtILGUokWup6B63cVBZg_5_7"></a><a id="Tc_xUX4hCHrq0aM-3wB-KYX7w_5_9"></a><a id="Tc_QtBxbL0YrEiaTjascMO0Og_6_0"></a><a id="Tc_6SqZDHBLN0S77lPGcI5mpw_6_4"></a><a id="Tc_FEfYEj9aOkmuA66oGSkSOw_7_0"></a><a id="Tc_hBQvTzXjFU2i-qbmwvgE8A_7_9"></a><a id="Tc_zyL8SrlL1ESuGXAoeUaekQ_8_0"></a><a id="Tc_otKR607QA0GwJpF31-bFXA_9_0"></a><a id="Tc_tjCjWRzGNEOr5K9V76XxSA_10_0"></a><a id="Tc_8p-pqPj7CUSMYrwrZHhDOQ_10_4"></a><a id="Tc_1iiVF1EDzUGEkmSOPfjjqg_10_9"></a><a id="Tc_Ium11TprKkq0ARI1JF9FaQ_11_0"></a><a id="Tc_HmGwIVJ3M0qfvak34f8R4Q_11_4"></a><a id="Tc_XZYMWuKhN0uOP6JOYGNtBw_11_9"></a><a id="_5125de6d_dda9_474e_8120_ec514658865f"></a><a id="Tc_ZzqGzJ7fcUCTINGh7zE5Qw_1_2"></a><a id="Tc_03SSgzT62kSnkBSIKfPhFQ_2_2"></a><a id="Tc_TBuFEZGmdEuRXuj5Zg2EHQ_2_4"></a><a id="Tc_q472yfAxpUCiXP8XTxmWNg_3_0"></a><a id="Tc_F1Q-5VxtgEqPffnPksBoSA_3_2"></a><a id="Tc_aCvuYbe-skKds1bqED1uZg_3_4"></a><a id="Tc_L895QJmBqUS4mBCfJ5vG4w_4_0"></a><a id="Tc_XJJjD6kCk0OH9YuAXcXTnA_4_2"></a><a id="Tc_QhQeD_ARvki-aCFgfXN4tQ_4_4"></a><a id="Tc_TrKI7EJotkmrOrpdrps0nQ_5_0"></a><a id="Tc_oNx6KkFH_kebFHeaiCVpfw_5_2"></a><a id="Tc_TaQ8v2OBHkC8KxAdLzzjiA_5_4"></a><a id="Tc_ce5i3Ez1DkGRlj5_39Zw7w_6_0"></a><a id="_6047dd3d_e04d_47c6_a93d_641bd8f24d38"></a><a id="Tc_l12y-qYwx0qZ2dUI0kMBUQ_1_2"></a><a id="Tc_SY_hvOlbfECduCBaKw7z7g_2_2"></a><a id="Tc_Vmit3M4xnUKfsZb3h3pfWQ_2_5"></a><a id="Tc_2J-ZwDW6CkKjYIJoatUsKg_3_0"></a><a id="Tc_b6rsAONGzEy_dJT6uorMIA_3_2"></a><a id="Tc_E37H607l10aFsJ-KMnCiXA_3_5"></a><a id="Tc_mspcD3HbPUudDj3qr_ThdQ_4_0"></a><a id="Tc_g8XeS7dFCkqGDqt-j6cVMQ_5_2"></a><a id="Tc_LHiDifXNV0qiIYDefVPemg_5_5"></a><ix:continuation id="Tb_NLk95qX3WkW_-gUBJBcAMg_cont1"><ix:continuation id="Tb_a07NgnqYVkGIZ48P3RqcRQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes stock option activity for the three&#160;months ended March&#160;31, 2025:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_2G_dnCPiHESQHXjxkxvoOQ_6_2">7,746,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_qJo9iMwr9ESqTjnumYatFA_6_5">2.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_OC0WVSIw5k2un9Uk91QPAQ_7_2">37,987</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_f_QK_zqCEkCKz37VUiR-CQ_7_5">0.11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Tc__pKlG1-HVkOSoN_Q9aXeOg_7_10">14</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_9oRDoIuYaUq1BFulczuw6A_8_2">1,749,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_wBMJyoRe40u-OtDYNxaezA_8_5">0.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_xO5proWhF0-g2338YEv7Xw_9_2">2,562,180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_DZ_6ygrlsUyEYpH-QfMOSg_9_5">1.99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_HKfocvkQmEuohMbAev-w6w_10_2">6,895,824</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_droeSGhIJkeUAWUm49H89g_10_5">2.54</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_BV7yeKN0mUqSb9CoH0X3Qg_10_7"> 7.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_1foJndhXHEickLyJCuWc9A_10_10">31</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_G8G9RwdqRkW8qcML3NYXNw_11_2">4,693,361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_pskQWTRm8UWVX4ce9uD3hQ_11_5">2.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_caaDxgQK_0iJWrhuQv92Dg_11_7"> 6.4</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_PKWAXcbI802TWWNB36BSTg_11_10">31</ix:nonFraction></p></td></tr></table></div></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The weighted-average grant-date per share fair values of options granted during the three&#160;months ended March&#160;31, 2025 and 2024 were $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_x2rLbQ7DJE-eKYWkVIec5Q">0.42</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_zmpB9w6GUUieQFhls6R9sg">1.72</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Group_XMzTf_JIsUyOdW4Y5guccg" continuedAt="Group_XMzTf_JIsUyOdW4Y5guccg_2" escape="true">The fair values in the three&#160;months ended March&#160;31, 2025 and 2024 were estimated using the Black-Scholes option-pricing model based on the following assumptions:</ix:nonNumeric></p><ix:continuation id="Group_XMzTf_JIsUyOdW4Y5guccg_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_mdBMAohFrEKCQsHlRmhX0g">4.32</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_9UXD9U5ONE-TZrbFYwnYAg">4.35</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_7_38DP6aq0K6BN-V9ESnIA">3.77</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_la5AnRxgukKLcYY7867XHg">3.89</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_DqhrVr02ZU-oUPRyCAWiAw">6</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_dLpkDchBI0-65ITg45gjHw">6</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_5_yel8VgcEOQLOFOwnUivQ">108.30</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_HEJyp0d_ZUmFCwfn40GA6g">110.68</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_1TXHphmqxEOyww_-Z0LQ0g">103.39</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_ndlAGzxo3UeewYgVaEHKwA">105.96</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_MrM77mS_Rk-aFF9ar7clJw_6_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_ilbyDmpEAEyp9ldzqZBvfA_6_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock-Based Compensation Expense</i></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_FJ6DC4XkGUKODm8poFaLPQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company recorded stock-based compensation expense in the following expense categories in its accompanying unaudited interim consolidated statements of operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SxDIMm3BHU201oGx7GMaZg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_nXwDPTxlkEyYhzdqL8ZiGw_3_3">107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_jY5QK3zjDki_xjht9LRM1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_O1cWLWiF7UC1gSc8Oyj7aQ_3_6">436</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_-bxZ8-y2T0-7QhFzHLqqMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_43kqgqyzTUOYH8r4rNcSwQ_4_3">401</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_weRP70dN20KmCCCCJPZOwg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ZvIdWsPJD0K_A-fm4P3PJQ_4_6">621</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Xhae2TaMBkmgyyqHP3alQQ_5_3">508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_hB5wc__EfUa9M7OiUUmceg_5_6">1,057</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the cash preservation plan, <ix:nonFraction unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_CashPreservationPlan2025Member_feBnUr3Dfkm1-xoc5Tr1Xg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" id="Narr_od01j0gu5kqicWrNrVjwPg">2.6</ix:nonFraction>&#160;million options were forfeited during the three&#160;months ended March&#160;31, 2025, resulting in a reduction in stock-based compensation expense related to research and development and, general and administrative employees. Compensation cost for awards not vested as of March&#160;31, 2025 was $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_OIoxGw7lhUilnwR-Hk_mdQ">3.7</ix:nonFraction>&#160;million and will be expensed over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_YsN9gtPcrEaGfque-WtYNw">2.3</ix:nonNumeric>&#160;years.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_CCBrQVOVr0uFMY8n2BRlPA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(9)</b></span><b style="font-weight:bold;">Related-Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has a collaboration and license agreement with Moderna, a significant stockholder (See Note&#160;10&#160;&#8211; Moderna Collaboration and License Agreement).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_HrRaNkqc0E2sMEHKIdOXrQ" continuedAt="Tb_HrRaNkqc0E2sMEHKIdOXrQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(10)</b></span><b style="font-weight:bold;">Moderna Collaboration and License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In January&#160;2022, the Company entered into a collaboration agreement with Moderna (the Moderna License Agreement), which provides for a broad strategic collaboration to discover, develop and commercialize <i style="font-style:italic;">in vivo </i>engineered chimeric antigen receptor macrophage and monocyte (CAR-M) therapeutics in oncology. Moderna has the right to designate up to <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_S3eeHUCF80-ErdmPj3uyZQ" decimals="INF" format="ixt-sec:numwordsen" name="carm:MaximumNumberOfResearchTargets" scale="0" id="Narr_CDjWJJJM2Ue8kDwOXLJyyQ">twelve</ix:nonFraction> research targets as development targets under this collaboration. While the collaboration was initially limited to oncology, in September&#160;2024, the companies agreed to expand the collaboration to discover, develop and commercialize <i style="font-style:italic;">in vivo </i>engineered CAR-M therapeutics in </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_HrRaNkqc0E2sMEHKIdOXrQ_cont1" continuedAt="Tb_HrRaNkqc0E2sMEHKIdOXrQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">specific autoimmune diseases. As of February&#160;2025, in connection with Moderna&#8217;s nomination of all <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_XRurAXNE0EKR2OlnCsvD0w" decimals="INF" format="ixt:num-dot-decimal" name="carm:NumberOfResearchTargetsGrossOncology" scale="0" id="Narr_H1wN8-4KSU2CdAjn86iM-w">12</ix:nonFraction> oncology research targets, the Company will not be conducting any additional research activities under the collaboration agreement and will not be receiving any further payments from Moderna for research and development services under the collaboration agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subsequent to the nomination of a research target, Moderna may designate the research target as a development target. Upon Moderna&#8217;s designation of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA" decimals="-5" format="ixt:num-dot-decimal" name="carm:UpfrontNonRefundablePaymentReceived" scale="6" id="Narr_iBacYlkjEEGLagJfPDqW4Q">45.0</ix:nonFraction> million to the Company. Assuming Moderna develops and commercializes <ix:nonFraction unitRef="Unit_Standard_product_3mVjd4sUPUK6dqSqJB3SiQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA" decimals="INF" format="ixt:num-dot-decimal" name="carm:NumberOfPotentialProductsToDevelopAndCommercialize" scale="0" id="Narr_KuIR15WJWEermk_8VEPtMg">12</ix:nonFraction> products, each directed to a different development target, the Company is eligible to receive up to between $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_H-d_HedKTkqWEw-yuQFN0g" decimals="-5" format="ixt:num-dot-decimal" name="carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" scale="6" id="Narr_80FhZLtjZEmmJcJkp6cAnw">247.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_BvRnm7gZx0yPcQ6vufXWdQ" decimals="-5" format="ixt:num-dot-decimal" name="carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" scale="6" id="Narr_AronO2VRbUKj0HvZETRneQ">253.0</ix:nonFraction> million per product in development target designation, development, regulatory and commercial milestone payments. Moderna reimbursed the Company for costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed into the first quarter of 2025; however, as discussed below, Moderna will no longer reimburse the Company for research and development services. The Company is eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments and royalties that the Company owes as a licensor under one of its intellectual property in-license agreements with Penn, which is sublicensed to Moderna under the Moderna License Agreement. Moderna may deduct these royalties in part from any royalties owed to the Company. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities and participation on the joint steering committee. The Company determined that there were <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_nQIYGPxOV02W0fAFKZQdvA" decimals="INF" format="ixt:num-dot-decimal" name="carm:NumberOfPerformanceObligations" scale="0" id="Narr_fhuZbsn05EGsNeEZjs0ipA">2</ix:nonFraction> performance obligations comprised of (i)&#160;research and development services and (ii)&#160;option rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA" decimals="-5" format="ixt:num-dot-decimal" name="carm:UpfrontNonRefundablePaymentReceived" scale="6" id="Narr_2k3f6G6MWkaMG5SolGXFmA">45.0</ix:nonFraction>&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna exercises or determines not to exercise its option right to license and commercialize the designated development target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company included the $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_nQIYGPxOV02W0fAFKZQdvA" decimals="-5" format="ixt:num-dot-decimal" name="carm:UpfrontNonRefundablePaymentReceived" scale="6" id="Narr_cVf775d3Ik6F974GZoo95Q">45.0</ix:nonFraction> million up-front and nonrefundable payment in the transaction price as of the outset of the arrangement. During the three&#160;months ended March&#160;31, 2025 and 2024, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_nZuzCa8jXEOmzNTuj_jKdQ">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_jpavFBFnE0eok-twRPIKyg">3.4</ix:nonFraction> million, respectively, of collaboration revenues. As discussed below, Moderna will no longer be reimbursing the Company for research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_Ffe941lEKUCa5q4ysfJI4A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_y7Mu5JzasEGzZ5RXxBNNZw">42.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_OptionRightCollaborationRevenuesMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_NbiVSknF-U-gNgbz4Ymr5w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_LHeOQG5FYkmm9amld7RdCg">3.8</ix:nonFraction>&#160;million, respectively, of research and development services and option right collaboration revenues since inception of the Moderna License Agreement through March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In February&#160;2025, Moderna nominated <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_UFBhEQ0DHUmjWP1OKnrZfg" decimals="INF" format="ixt-sec:numwordsen" name="carm:NumberOfResearchTargetsNominatedOncology" scale="0" id="Narr_D_9PFKTTG0-3r83qzKYsAw">ten</ix:nonFraction> additional oncology research targets, <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_UFBhEQ0DHUmjWP1OKnrZfg" decimals="INF" format="ixt-sec:numwordsen" name="carm:NumberOfResearchTargetsNominatedReplacements" scale="0" id="Narr_KEX3tHp3_EKcAFkHomIzHQ">four</ix:nonFraction> of which replaced <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_UFBhEQ0DHUmjWP1OKnrZfg" decimals="INF" format="ixt-sec:numwordsen" name="carm:NumberOfResearchTargetsTerminatedOncology" scale="0" id="Narr_clwuNWfSwU6SjgnHkKyORA">two</ix:nonFraction> oncology research targets and <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_UFBhEQ0DHUmjWP1OKnrZfg" decimals="INF" format="ixt-sec:numwordsen" name="carm:NumberOfResearchTargetsTerminatedAutoimmune" scale="0" id="Narr_zLcVP88hbUmtHbcYzQ_NQw">two</ix:nonFraction> autoimmune research targets, which Moderna concurrently ceased developing. As of February 2025, Moderna has nominated all <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_XRurAXNE0EKR2OlnCsvD0w" decimals="INF" format="ixt:num-dot-decimal" name="carm:NumberOfResearchTargetsGrossOncology" scale="0" id="Narr_TjoJgapD60ed43aZz5Pw1g">12</ix:nonFraction> oncology research targets under the collaboration for which the Company has the potential to receive future milestones and royalty payments. The Company will not conduct any additional research activities under the collaboration agreement </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f258ba4e_907e_490f_9770_ee5837838f86"></a><a id="Tc__ngNV23nN0iIc8OJBxFTNQ_1_2"></a><a id="Tc_kYKBTtmwqkyxwUjZRKUDhA_2_2"></a><a id="Tc_BsdHWxDxvECxaGjXHcIzrw_3_0"></a><a id="Tc_OZNOFd6iO0-OQ2JDyp2a2g_4_0"></a><a id="Tc_i5E33LgArUyUSuzmQLBSrQ_4_2"></a><a id="_57e4769c_52bc_4510_b8fb_278ef82ff401"></a><a id="Tc_oiptw1aeMkaNKfr_90Ul5g_1_2"></a><a id="Tc_jLZ0KvKnH02LKqxm31DnbA_2_2"></a><a id="Tc_BwkbJRd750ycUXFOZTYuAw_2_5"></a><a id="Tc_6lV3AynSF0mcxcwVbYK7cQ_3_0"></a><a id="Tc_YPAuSNV_UUmhD4-vURpwKA_3_2"></a><a id="Tc_PbcIOxKV0EGoFxds8Kg61g_3_5"></a><a id="Tc_1SXBLRz93UqwpvcsE2LEcw_4_0"></a><a id="Tc_RXKaR-azcEOq580zVH0xKg_5_0"></a><a id="Tc_cjX_7vir2EOhAUBecOJdGg_6_0"></a><a id="Tc_ee59iEVOFESwEnGnS3hwbw_6_2"></a><a id="Tc_uhLdx53kp0S-Zy8S5sudWw_6_5"></a><ix:continuation id="Tb_HrRaNkqc0E2sMEHKIdOXrQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">and the Company will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the <i style="font-style:italic;">in vivo </i>oncology field exclusivity, which would allow the Company to pursue <i style="font-style:italic;">in vivo </i>CAR-M programs outside of the <ix:nonFraction unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ" contextRef="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_XRurAXNE0EKR2OlnCsvD0w" decimals="INF" format="ixt:num-dot-decimal" name="carm:NumberOfResearchTargetsGrossOncology" scale="0" id="Narr_Wfdg6Qy9WECLh2m-vBXkcg">12</ix:nonFraction> nominated oncology targets and product polypeptides. The Company does not expect to recognize any additional unsatisfied research and development performance obligations.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="Tb_zVoruox3dkyI6KrPsijfnA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price unsatisfied</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="carm:RevenueRemainingPerformanceObligationOptionRightsAmount" scale="3" id="Tc_srByM8pktEa6XDHOYyX6OA_4_3">41,250</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s unaudited interim consolidated balance sheets. Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s unaudited interim consolidated balance sheets.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="carm:ScheduleOfChangesInDeferredRevenueTableTextBlock" id="Tb_E-3LoLpuJ0S0mYWVIyqHlg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the changes in deferred revenue (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_RjoX2sYThUay92XIjLXdfw_3_3">44,979</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_haI4e1_Jf0m00b8t2_5Nng_3_6">46,413</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferral of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';"><ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:fixed-zero" name="carm:ContractWithCustomerLiabilityDeferralOfRevenue" scale="3" id="Tc_VS3ls_IFNU2T_iz9Kl0JDQ_4_3">&#8212;</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="carm:ContractWithCustomerLiabilityDeferralOfRevenue" scale="3" id="Tc_EZ0XRP2a0kGoRWm-J0abrw_4_6">3,173</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Recognition of unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" sign="-" scale="3" id="Tc_fP_AO3tkfUW1ms59Gyy4IQ_5_3">3,729</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" sign="-" scale="3" id="Tc_n3pU5DfmVEyZZ4YV99Td4g_5_6">3,397</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_hv38DKxitUa7jrC8crA5fw_6_3">41,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_FSFHWdMDkEq0s9bG11052g_6_6">46,189</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The deferred revenue represents the unearned portion of the upfront, non-refundable and non-creditable payment allocated to Moderna&#8217;s option rights of $<ix:nonFraction unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw" contextRef="As_Of_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_Zc2Vn1pdQEyg-izKUAgkWw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="Narr_ySPGqOomKkGp4ER0p8FBZg">41.3</ix:nonFraction> million, which is not expected to be recognized within the next 12&#160;months.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_CyXIuuBxG062xfGf_qzAcw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(11)</b></span><b style="font-size:10pt;font-weight:bold;">Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has evaluated subsequent events from the balance sheet date through May&#160;13, 2025, the issuance date of these unaudited interim consolidated financial statements, and has not identified any additional items that have not previously been mentioned elsewhere requiring disclosure.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6.09pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt 0pt 6.1pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a17a437e_d897_4ff7_b6a6_5a61d7bc3f1a"></a><a id="ACCOUNTINGFIRM_FS3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the Board of Directors of Ocugen, Inc. and Stockholder of OrthoCellix, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying combined balance sheets of the NeoCart business of Ocugen, Inc. (the &#8220;Company&#8221;) as of December&#160;31,&#160;2024 and 2023, and the related combined statements of operations and comprehensive loss, of changes in equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;combined financial statements&#8221;). In our opinion, the combined financial statements present fairly, in all material respects, the financial position of the Company as of December<span style="font-family:'Georgia';">&#160;</span>31,<span style="font-family:'Georgia';">&#160;</span>2024 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Substantial Doubt </i><i style="font-style:italic;">About the Company&#8217;s Ability to C</i><i style="font-style:italic;">ontinue as a Going Concern</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying combined financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the combined financial statements, the Company has incurred recurring net losses since inception that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The combined financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These combined financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s combined financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits of these combined financial statements in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the combined financial statements are free of material misstatement, whether due to error or fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the combined financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the combined financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the combined financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Critical Audit Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the combined financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the combined financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the combined financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Corporate Expenses Allocated to the NeoCart Business Combined Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described in Notes 1 and 2 to the combined financial statements, on June 19, 2025, Ocugen, Inc., (&#8220;Ocugen&#8221;) contributed certain assets (the &#8220;NeoCart Assets&#8221;) to OrthoCellix, Inc.. The NeoCart Assets comprise Ocugen&#8217;s rights, title and interest in and to NeoCart, an internally developed, in-process product candidate, as well as associated contracts and licensing agreements. The combined financial statements include allocations of costs from Ocugen that were incurred by the NeoCart business of Ocugen for functions such as research and development, human resources, information technology, facilities, accounting, finance and legal, including the costs of salaries, benefits and other related costs. The costs allocated for these functions totaled approximately $1,026 thousand for the year ended December 31, 2024. These expenses have been allocated by management based on direct usage or benefit where identifiable, with the remainder allocated on the basis of the costs associated with research and development expenses, or proportional cost allocation based on the relative size of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The principal consideration for our determination that performing procedures relating to corporate expenses allocated to the NeoCart business combined financial statements is a critical audit matter is a high degree of auditor effort in performing procedures related to management<span style="font-family:'Georgia';">&#8217;</span>s determination and classification of the corporate expenses allocated to the NeoCart business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the combined financial statements. These procedures included, among others i) evaluating management&#8217;s process for determining the allocation methodologies; (ii) testing the completeness and accuracy of the data used by management in the allocation; and (iii) testing the allocation and classification of corporate expenses between Ocugen and the NeoCart business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ PricewaterhouseCoopers LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">July<span style="font-family:'Georgia';">&#160;</span>21,<span style="font-family:'Georgia';">&#160;</span>2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">We have served as the Company&#8217;s auditor since 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6.09pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6.09pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt 0pt 6.1pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d1da6efb_8b5f_4358_b1e2_7633ad508936"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN,&#160;INC.</b></p><a id="COMBINEDBALANCESHEETS_286683"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMBINED BALANCE SHEETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;">&#8199;&#8199;&#8199;&#8199;&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Commitments and Contingencies (Note 5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Parent Company Net Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(24)</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(24)</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities and Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these combined financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e955af2d_062f_4ea0_8b25_fad308ebe657"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMBINED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><a id="COMBINEDSTATEMENTSOFOPERATIONSANDCOMPREH"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,441</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">640</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,081</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,026)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,081)</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total comprehensive income/(loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,026)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,081)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these combined financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_244acdcc_47f7_47df_aac3_8b1a996871aa"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN,&#160;INC.</b></p><a id="COMBINEDSTATEMENTSOFCHANGESINEQUITY_1640"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMBINED STATEMENTS OF CHANGES IN EQUITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parent&#160;Company</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Net&#160;Investment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,081)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,081)</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Net Transfers from Parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,057</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(24)</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,026)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,026)</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Net Transfers from Parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,050</p></td></tr><tr><td style="vertical-align:bottom;width:73.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these combined financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_17af6c85_b676_45a3_97c7_bb7aee98f5b8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN,&#160;INC.</b></p><a id="COMBINEDSTATEMENTSOFCASHFLOWS_746300"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMBINED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,026)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,081)</p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Changes in liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.5pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24</p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net cash used on operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,050)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,057)</p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net cash (used in) provided by investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Net transfers from Parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,057</p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,057</p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash at beginning of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash at end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these combined financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_03c22c88_41ed_4be5_ba45_d74c265e67ae"></a><a id="NatureoftheBusiness_986162"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span><b style="font-weight:bold;">Nature of the Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix,&#160;Inc., a Delaware corporation, (the &#8220;Company&#8221;) was incorporated as a legal entity on February&#160;28, 2025. On June&#160;19, 2025, Ocugen,&#160;Inc., a Delaware corporation (&#8220;Ocugen&#8221; or the &#8220;Parent&#8221;) contributed certain assets (&#8220;the NeoCart Assets&#8221;) to the Company pursuant to an Asset Contribution Agreement, by and between the Parent and the Company (the &#8220;Contribution Agreement&#8221;) in exchange for shares of Common Stock in the Company (such transactions, the &#8220;Contribution&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Per the Contribution Agreement, the Parent contributed the NeoCart Assets in exchange for 1,000 Shares of Common stock in contemplation of the Agreement and Plan of Merger (&#8220;Merger Agreement&#8221;) with Carisma Therapeutics,&#160;Inc. The NeoCart Assets comprise Ocugen&#8217;s rights, title and interest in and to NeoCart, an internally developed, in-process product candidate, as well as associated contracts and licensing agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement, OrthoCellix will become a wholly owned subsidiary of Carisma and stockholders of the Company will receive shares of common stock of Carisma, which is contingent on Carisma concurrently receiving gross proceeds of $25.0 million from investors, including Ocugen, among other things. The Company&#8217;s commercial purpose is to seek to continue development and commercialization of NeoCart, a Phase 3-ready, regenerative cell therapy technology that combines breakthroughs in bioengineering and cell processing to enhance the autologous cartilage repair process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined financial statements represent the historical combined financial position, statement of operations, and cash flows of the NeoCart business of Ocugen (the &#8220;NeoCart business&#8221;), which have been carved out from the Parent&#8217;s operations. Historically, the NeoCart business was not a separate entity nor was financial information previously prepared for the NeoCart business on a stand-alone basis. The combined financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include the accounts of the NeoCart business. Transactions between the NeoCart business and the Parent are reflected in equity in the balance sheet as &#8220;Parent Company Net Investment&#8221; and in the combined statement of cash flows as a financing activity in &#8220;Net transfers from the Parent.&#8221; See Note&#160;7,&#8212;Related Party Transactions for additional information regarding related party transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts may require additional capital, additional personnel and infrastructure, and further regulatory and other capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2014-15,<i style="font-style:italic;">&#160;Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40)</i>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one&#160;year after the date that the combined financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred recurring net losses since inception. The Company incurred net losses of approximately $1,026 and $2,081 for the&#160;years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, the Company had no cash. The Company&#8217;s operations will not be sufficient to fund the Company over the next 12&#160;months after the date that the combined financial statements are issued.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company is subject to risks and uncertainties frequently encountered by companies in its industry, the Company will require significant additional funding. If the Company is unable to obtain additional funding in the future, there may be a negative impact on the financial viability of the Company. The Company will continue to explore options to fund its operations through the contemplation of a merger agreement and concurrent financing, public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sales of assets, licensing and/or collaboration arrangements with pharmaceutical companies or other institutions, funding from the government, or funding from other third parties. Such financing and funding may not be available at all, or on terms that are favorable to the Company. While the Company believes that it has a plan to fund operations, its plan may not be successfully implemented. If the Company cannot obtain the necessary funding, they will need to delay, scale back, or eliminate some or all of the Company&#8217;s research and development programs and commercialization efforts; consider other various strategic alternatives, including a merger or sale&#894; or cease operations. If the Company cannot expand their operations or otherwise capitalize on business opportunities because they lack sufficient capital, business, financial condition, and results of operations could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of these factors, together with the anticipated continued spending that will be necessary to continue to research, develop, and commercialize the Company&#8217;s product candidate, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one&#160;year after the date that these combined financial statements are issued. The combined financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</p><a id="_2974cd6c_206f_42ce_8c45_dcafd410007a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation and Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying combined financial statements included herein have been prepared in conformity with GAAP. The combined financial statements have been derived from the financial statements and accounting records of the Parent using the historical results of operations and historical basis of assets and liabilities of the NeoCart business of Ocugen to reflect the Parent&#8217;s net investment in the Company. Historically, stand-alone financial statements have not been prepared for the NeoCart business. The Company believes the assumptions underlying the allocations included in the combined financial statements are reasonable. However, the combined financial statements may not necessarily reflect the NeoCart business&#8217; results of operations, financial position and cash flows in the future, or what NeoCart&#8217;s results of operations, financial position and cash flows would have been had NeoCart been a stand-alone company during the periods presented herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined financial statements include allocations of costs from the Parent that were incurred by the NeoCart business of Ocugen for functions such as research&#160;&amp; development, human resources, information technology, facilities, accounting, finance and legal, including the costs of salaries, benefits and other related costs. No Ocugen employees will be employed by OrthoCellix and Ocugen will have certain transition agreements with OrthoCellix. The total costs allocated to the combined financial statements for these functions totaled approximately $1,026 and $2,081 for the&#160;years ended December&#160;31, 2024 and 2023, respectively, and are included in research and development and general and administrative expenses within the combined statement of operations and comprehensive loss. These expenses have been allocated to NeoCart based on direct usage or benefit where identifiable, with the remainder allocated on the basis of the costs associated with research and development expenses, or proportional cost allocation based on the relative size of the Company. As a stand-alone public company, the NeoCart business&#8217; total costs related to such support functions may differ materially from the costs that historically remained after allocation to the Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of these combined financial statements, all intercompany transactions between the NeoCart business and the Parent has been included within Parent Company Net Investment on the balance sheet. Intercompany transactions presumed to be subject to cash settlement at a future date are recorded as accounts receivables and payables on the balance sheets. See Note&#160;7&#8212;Related Party Transactions for additional information regarding related party transactions.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In preparing the financial statements in conformity with GAAP, the Company is required to make estimates and assumptions that affect the reported amounts and disclosures at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for allocation of research and development costs and general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. These costs consist of internal and external expenses, as well as depreciation expense on assets owned by the Parent used within the Company&#8217;s research and development activities. Internal expenses include the cost of salaries, benefits, and other related costs, including amounts owed to the Parent for stock-based compensation, for personnel serving in the Company&#8217;s research and development functions, as well as allocated rent and utilities expenses. External expenses include development, clinical trials, and regulatory compliance costs incurred with research organizations, contract manufacturers, and other third-party vendors. License fees paid to acquire access to proprietary technology are expensed to research and development, unless it is determined that the technology is expected to have an alternative future use. The Company recorded costs for certain development activities, such as preclinical studies and clinical trials, based on the Company&#8217;s evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the combined financial statements as prepaid or accrued research and development expense, as applicable. The recording of costs for certain development activities requires the Company to use estimates. The Company believes the estimates and assumptions are reasonable under the current conditions; however, actual results may differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expense consists primarily of personnel expenses, including salaries, benefits, insurance, and stock-based compensation expense, for employees in executive, accounting, commercialization, human resources, and other administrative functions. General and administrative expense also includes expenses related to pre-commercial activities, corporate facility costs, such as allocated rent and utilities, insurance premiums, legal fees related to corporate matters, and fees for auditing, accounting, and other consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Parent Company Net Investment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Parent Company Net Investment on the combined balance sheets represents the Parent&#8217;s net investment in the Company and is presented as &#8220;Parent Company Net Investment&#8221;. Parent Company Net Investment includes assets and liabilities that have historically been held by the Parent but specifically identifiable or otherwise attributable to the Company, and other assets and liabilities recorded by the Parent, whose related income and expenses have been pushed down to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Contractual Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates contractual agreements to determine the appropriate accounting treatment in accordance with GAAP. Depending on the specific terms and nature of each arrangement, such agreements may be accounted for under ASC 606&#160;&#8211; Revenue from Contracts with Customers, ASC 808&#160;&#8211; Collaborative Arrangements, or ASC 730&#160;&#8211; Research and Development. The assessment includes identifying performance obligations, determining whether the contractual obligation is distinct, and evaluating the timing and pattern of revenue recognition or expense treatment.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did not historically file separate income tax returns since the Company was not a separate entity. As such, the provision was calculated on a stand-alone basis for the purpose of these combined financial statements. The Company uses the asset and liability method in accounting for income taxes. Deferred tax assets and liabilities are recorded for temporary differences between the tax basis of assets and liabilities and their reported amounts in the combined financial statements, using statutory tax rates in effect for the&#160;year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the combined statements of operations and comprehensive loss in the period that includes the enactment date. Accordingly, the reported provision for income taxes and the related balance sheet account balances may not equal the amounts that would have been allocable to the Company under applicable consolidated US federal and state tax laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its deferred tax assets each period to ensure that the estimated future taxable income will be sufficient in character, amount, and timing, to result in its realizability. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets, unless it is more likely than not that those assets will be realized. Management utilizes considerable judgment when establishing deferred tax valuation allowances. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences and carryforward deferred tax assets become deductible or utilized. The Company considers the scheduled reversal of taxable temporary differences, projected future taxable income, and tax planning strategies in making this assessment. As events and circumstances change, valuation allowances are adjusted within the combined statement of operations and comprehensive loss when applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes net tax benefits under the recognition and measurement criteria of FASB ASC Topic 740, Income Taxes, which prescribes requirements and other guidance for financial statement recognition and measurement of positions taken or expected to be taken on tax returns. The Company recognizes a tax benefit for positions taken for tax return purposes when it will be more likely than not that the positions will be sustained upon tax examination, based solely on the technical merits of the tax positions. Otherwise, no tax benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense in the combined statement of operations and comprehensive loss. Tax examinations are often complex, as tax authorities may disagree with the treatment of items reported by the Company and may require several&#160;years to resolve. As a result, the Company&#8217;s provision for income taxes is recorded on the basis of available information, but amounts recorded may be impacted as a result of future examinations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures&#8221;. This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The guidance is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s combined financial statements. The Company adopted the guidance in the fiscal&#160;year beginning January&#160;1, 2024. There was no impact on the Company&#8217;s reportable segments identified and required disclosures have been included in Note&#160;6.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASU 2025-03, &#8220;Business Combination and Consolidation: Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity&#8221; (&#8220;ASU 2025-03&#8221;) provides clarifying guidance on determining the accounting acquirer in certain transactions involving VIEs. The update aims to improve consistency and comparability in financial reporting, especially when companies merge with a special-purpose acquisition company (&#8220;SPAC&#8221;). ASU 2025-03 requires entities to apply the same factors used for determining the accounting acquirer in other acquisition transactions. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 including interim periods within those annual periods, with early adoption permitted. The Company intends to adopt ASU 2025-03 for transactions occurring after its issuance, including the transaction with Carisma contemplated in the Merger Agreement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#8221;. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal&#160;years beginning after December&#160;15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company has not yet adopted this new ASU however the Company expects it to only impact its income tax disclosures upon adoption with no impact to its operations, cash flows, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2024, the FASB issued ASU No.&#160;2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03). The new guidance requires disaggregated information about certain income statement expense line items on an annual and interim basis. This guidance will be effective for annual periods beginning the&#160;year ended December&#160;31, 2027 and for interim periods thereafter. The new standard permits early adoption and can be applied prospectively or retrospectively. The Company is evaluating the effect that this guidance will have on their combined financial statements and related disclosures.</p><a id="_ea831cf6_926e_4b42_91a7_a901d0a8d1f6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span><b style="font-weight:bold;">Contractual Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The below contractual agreements were contributed to the Company from the Parent as a part of the Contribution Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">MEDINET License and Commercialization Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2017, Histogenics Corporation (&#8220;Histogenics&#8221;) entered into a License and Commercialization Agreement (the &#8220;MEDINET Agreement&#8221;) with MEDINET Co.,&#160;Ltd. (&#8220;MEDINET&#8221;) with regards to the commercialization of NeoCart in Japan, which Ocugen assumed as a result of a reverse merger with Histogenics subsequently, that took place in 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the MEDINET Agreement, Histogenics was eligible to receive up to an aggregate of approximately $86.9 million in milestone payments plus royalties, consisting of (i)&#160;a non-refundable upfront payment of $10.0 million which Histogenics received in January&#160;2018, (ii)&#160;potential regulatory and development milestone payments of up to an aggregate of $10.5 million, (iii)&#160;overall sales-dependent milestones of up to an aggregate of $66.4 million and (iv)&#160;tiered royalties at&#160;percentages ranging from 5% to 10% on net sales of NeoCart in Japan. In return for such consideration, Histogenics granted to MEDINET exclusive commercialization rights to NeoCart in Japan for the replacement or repair of damaged, worn or defective cartilage in humans and non-human animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The MEDINET Agreement will remain in effect until the later of (i)&#160;expiration of the last-to-expire valid and enforceable patent covering NeoCart in Japan and (ii)&#160;ten&#160;years from the first commercial sale of NeoCart in Japan. MEDINET has an option to extend the term for five&#160;years upon written notice to us prior to the end of the initial term. MEDINET has the right to terminate the MEDINET Agreement for any or no reason at any time, and the Company may terminate the MEDINET Agreement in the event MEDINET or one of its affiliates or sublicensees challenges a patent covering NeoCart in Japan. Additionally, either party may terminate the MEDINET Agreement for an uncured material breach by the other party or upon certain insolvency or bankruptcy proceedings involving the other party. Histogenics and MEDINET agreed to indemnify each other for third-party claims arising out of either the Company or the Company affiliates&#8217; willful misconduct or negligence, breaches of representations, warranties, covenants, obligations or agreements contained in the MEDINET Agreement, or MEDINET&#8217;s exploitation of NeoCart in its respective territory, subject to specified exclusions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Histogenics and MEDINET agreed to enter into supply, quality and pharmacovigilance agreements (the &#8220;MEDINET Supply Agreements&#8221;), pursuant to which MEDINET will purchase its requirements of NeoCart and the related biopsy kit from the Company. Pursuant to the terms of the MEDINET Agreement, the MEDINET Supply Agreements will contain terms and conditions customary for agreements of its type within the biotechnology industry, including those set forth in the MEDINET Agreement. No amounts have been received or recorded pursuant to the MEDINET Agreement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with Purpose</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2005, Histogenics entered into an exclusive agreement (the &#8220;Purpose Agreement&#8221;) to sublicense certain technology from Purpose Co.,&#160;Ltd. (&#8220;Purpose&#8221;), which Ocugen assumed as a result of the reverse merger with Histogenics, that took place in 2019. The Purpose Agreement granted Purpose an exclusive, royalty-bearing, worldwide, sublicensable license, under its rights in licensed patents and patent applications co-owned by Brigham and Women&#8217;s Hospital, Inc. and Purpose to make, use, and sell (1)&#160;an apparatus for cultivating a cell or tissue, (2)&#160;cell or tissue products made using such apparatus, (3)&#160;cell or tissue products made using processes for cultivating a cell or tissue as disclosed in the licensed patents and patent applications, and (4)&#160;any apparatus that cultivates cells or tissues using such processes, in each case, whose manufacture, use, or sale is covered by a valid claim of the licensed patents and patent applications, only for therapeutic use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Purpose Agreement was amended and restated in June&#160;2012, pursuant to which Purpose granted to Histogenics outside of Japan: (a)&#160;exclusive rights to all of Purpose&#8217;s technology (owned or licensed) related to the exogenous tissue processors, which is used in the development of NeoCart, (b)&#160;continued supply of exogenous tissue processors, and (c)&#160;rights to manufacture the exogenous tissue processors at any location Histogenics chooses. In exchange for such consideration, Purpose was granted an exclusive license in Japan for the use of all of NeoCart technology and was reimbursed for development costs on a multi-unit exogenous tissue processor. In May&#160;2016, the Purpose Agreement was amended, whereby Histogenics reacquired the development and commercialization rights to NeoCart in Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Purpose Agreement, as amended, provides the Company with the ability, worldwide, to (i)&#160;use, make, have made, sell, offer for sale, import or otherwise exploit products or services covered by claims of Purpose&#8217;s patents and (ii)&#160;use, reproduce, modify, create derivative works of and otherwise exploit Purpose&#8217;s technology for the design, development, manufacture, testing, support, and commercialization of any product or service that incorporates or builds upon Purpose&#8217;s technology, in each case, only in connection with articular cartilage, ligaments, tendons, and meniscus. Purpose retains the right to sell its single unit exogenous tissue processer machines to research institutes for general but noncommercial use anywhere in the world. The Purpose Agreement remains in effect for the life of the patents unless earlier terminated by providing written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Purpose Agreement (as amended), the NeoCart business of Ocugen is obligated to pay Purpose payments of up to $10.0 million in the event certain milestones are satisfied as well as a royalty payments in the low single digits on the net sales in Japan for NeoCart products that rely on a Purpose patent or incorporate or necessarily rely upon any Purpose technology. Such royalty payment shall be reduced if the applicable NeoCart products do not rely on an outstanding Purpose patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with Angiotech</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2005, Histogenics Corporation (&#8220;Histogenics&#8221;) entered into a license agreement with Angiotech Pharmaceuticals (US),&#160;Inc. and Angiodevice International GmbH (together, &#8220;Angiotech&#8221;), which was subsequently assumed by Ocugen following its merger with Histogenics in 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the agreement, Histogenics received exclusive worldwide rights to develop and commercialize products incorporating CT3 and the Company&#8217;s proprietary technology for the treatment of articular cartilage, ligament, meniscus, and tendon damage, subject to certain field limitations. The exclusivity of the license was formalized through a fifth amendment in August&#160;2010.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As consideration for the license, Histogenics paid a $1.0 million exclusivity fee and four annual patent maintenance payments of $50,000 each as of December&#160;31, 2018. The Company may be obligated to make an additional $3.0 million milestone payment upon regulatory approval of a licensed product by the U.S. Food and Drug Administration. Histogenics also agreed to pay Angiotech single-digit&#160;percentage royalties on net sales of NeoCart and other licensed products. This rate reflects a reduction from prior double-digit royalty obligations, achieved via $2.0 million in revenue share reduction payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The agreement includes customary supply and data-sharing provisions with respect to CT3 and clinical study results, and remains in effect until the earlier of May&#160;12, 2035 or expiration of all royalty payment obligations. Either party may terminate the agreement for uncured material breach, and Angiotech may also terminate under certain conditions, including competitive activity or patent challenges by the Company or its affiliates.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No amounts were paid or accrued under the Angiotech agreement during the&#160;years ended December&#160;31, 2023 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intrexon Collaboration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2014, Histogenics entered into an Exclusive Channel Collaboration (&#8220;ECC&#8221;) with Intrexon Corporation (&#8220;Intrexon&#8221;) governing a &#8220;channel collaboration&#8221; arrangement in which Histogenics intended to use Intrexon&#8217;s proprietary technology towards the design, identification, culturing and/or production of genetically modified cells (&#8220;Technology&#8221;). The ECC granted Histogenics an exclusive worldwide license to utilize Intrexon&#8217;s Technology to develop and commercialize allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2018, Histogenics and Intrexon entered into a mutual termination and release agreement (the &#8220;Mutual Termination Agreement&#8221;) pursuant to which Histogenics and Intrexon mutually agreed to terminate ECC. In connection with the Mutual Termination Agreement, Histogenics agreed to pay Intrexon an aggregate of up to $1.5 million, with $0.375 million paid at the time of entering into the Mutual Termination Agreement and $1.125 million payable within one year following any submission of a Biologics License Application (&#8220;BLA&#8221;) to the Food and Drug Administration for NeoCart. Ocugen assumed the ECC and Mutual Termination Agreement as a result of the Histogenics merger. The NeoCart business has not recorded the $1.125 million payable as the filing of the BLA does not meet the definition of probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Sponsored Collaborative Research Agreement with a Hospital</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2022, Ocugen entered into a sponsored collaborative research agreement (the &#8220;Research Agreement&#8221;) with a hospital to support NeoCart development.&#160;The research to be performed under the Research Agreement by the hospital is related to technology development and other regenerative therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Research Agreement, for the periods ending December 31, 2024 and 2023, Ocugen paid $80 and $422, respectively, which was recorded and is presented in research and development expenses. The Research Agreement was amended and restated in June&#160;2024, to extend the agreement through December&#160;30, 2024, at which time it expired. There were no incremental costs or payments during this period.</p><a id="_5a8e8ef4_099e_4981_8766_2b401bfd9c98"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The significant components of the net deferred income tax asset shown on the balance sheets as of December&#160;31, 2024, and 2023 are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Net operating loss carryforward</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">153</p></td></tr><tr><td style="vertical-align:bottom;width:74.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Tax credits</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">97</p></td></tr><tr><td style="vertical-align:bottom;width:74.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Research &amp; development costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">319</p></td></tr><tr><td style="vertical-align:bottom;width:74.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">569</p></td></tr><tr><td style="vertical-align:bottom;width:74.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">(835)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">(569)</p></td></tr><tr><td style="vertical-align:bottom;width:74.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Net deferred tax assets (liability)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, the Company had US federal net operating loss carryforwards of $1.3 million. As of December&#160;31, 2024, the Company had state NOL carryforwards of $1.3 million that begins to expire in 2043.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, the Company had US federal research and development tax credits of $0.1 million which begin to expire in 2043.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December&#160;31, 2024, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding&#160;years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company has recorded a full valuation allowance of $0.8 million as of December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2024 and 2023 related primarily to the increase in net operating loss carryforwards and tax credit carryforwards. Changes to the valuation allowance were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.018520355%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.45%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Valuation allowance as of the beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.45%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Increases to Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Valuation allowance at the end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.45%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Internal Revenue Code Section&#160;382, if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income may be limited. We have not completed a study to assess whether an &#8220;ownership change&#8221; has occurred or whether there have been multiple ownership changes since we became a &#8220;loss corporation&#8221; as defined in Section&#160;382. Future changes in our stock ownership, which may be outside of our control, may trigger an &#8220;ownership change.&#8221; In addition, future equity offerings or acquisitions that have equity as a component of the purchase price could result in an &#8220;ownership change.&#8221; If an &#8220;ownership change&#8221; has occurred or does occur in the future, utilization of the NOL carryforwards or other tax attributes may be limited, which could potentially result in increased future tax liability to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;4, 2025, President Trump signed H.R. 1, the &#8220;One Big Beautiful Bill Act,&#8221; into law. The legislation introduced significant changes to the US federal corporate tax system, including retroactive relief for certain small business taxpayers, including the Company, such as the reinstatement of immediate expensing for domestic research and experimental expenditures and modifications to the business interest expense limitation. However, since the legislation was enacted after the December&#160;31, 2024 balance sheet reporting date but before the issuance of the Company&#8217;s combined financial statements, it is considered a nonrecognized subsequent event. Accordingly, the effects of the legislation are not reflected in the Company&#8217;s income tax provision or deferred tax balances as of December&#160;31, 2024. The Company is currently evaluating the impact and will reflect the effects, as appropriate, in future reporting periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2017 Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) resulted in significant changes to the treatment of research and developmental (&#8220;R&amp;D&#8221;) expenditures under Section&#160;174 of the IRC. For tax&#160;years beginning after December&#160;31, 2021, taxpayers are required to capitalize and amortize all R&amp;D expenditures that are paid or incurred in connection with their trade or business. Specifically, costs for U.S.-based R&amp;D activities must be amortized over five&#160;years and costs for foreign R&amp;D activities must be amortized over 15&#160;years&#8212;both using a midyear convention. As of December&#160;31, 2024, the Company capitalized a substantial amount of R&amp;D expenditures primarily related to research and development activities performed in the US.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which we operate or do business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December&#160;31, 2024 and 2023, the Company did not record any uncertain tax positions in the combined financial statements.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company elected to recognize any interest and penalties related to unrecognized tax benefits on the income tax expense line in the combined statement of operations. As of December&#160;31, 2024 and 2023, no accrued interest or penalties have been recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did not file separate income tax returns for the periods presented, as its operations were historically included in the Parent&#8217;s consolidated US federal and state income tax returns. The Parent is subject to examination by taxing authorities of the jurisdictions in which it files income tax returns. There are currently no income tax examinations in progress.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Tax Rate</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s current and deferred income tax consequences that result from operations during the current and preceding&#160;years were allocated based on the separate return method, as if the Company were a standalone taxpaying entity historically filing separate income tax returns. Due to losses, there is no tax provision for the&#160;years ended December&#160;31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the Company&#8217;s statutory income tax rate to the Company&#8217;s effective income tax rate is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:7.2pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Income tax (benefit) at US statutory rate</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">State taxes, net of federal benefit</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">3.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Tax credits</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">4.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Change in valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">(25.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">(27.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Permanent differences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">(3.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">(1.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dea738c3_0782_480a_976d_bdda3f4e445a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Contractual Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ocugen entered into, or has assumed in connection with its merger with Histogenics in 2019, contractual agreements with various parties that are wholly attributed to Ocugen. These agreements entered into by Ocugen and related to the NeoCart noted above have been transferred subject to the Contribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Indemnification Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. To date, the Company has not incurred any costs as a result of such indemnification provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of December&#160;31, 2024, there were no matters.</p><a id="_b0ff3bb1_2654_4b47_9abb_917c39ac746c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></span><b style="font-weight:bold;">Segment Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has one operating and reportable segment related to the development of NeoCart. The Company has not generated any product revenue. The Company&#8217;s Chief Operating Decision Maker (the &#8220;CODM&#8221;) is the Company&#8217;s Chief Executive Officer. The CODM assesses the performance for the Company and its reportable segment based on net loss, which is reported on the combined statement of operations and comprehensive loss. The CODM uses net loss to evaluate performance, forecast future period financial results, allocate resources, and budget to actual results. The measure of segment assets is reported on the balance sheet as total assets.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS OF OCUGEN, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Operating expenses:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0pt 5.75pt;"><span style="letter-spacing:0.2pt;">NeoCart direct expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">1,052</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0pt 5.75pt;"><span style="letter-spacing:0.2pt;">Unallocated costs:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0pt 5.75pt;"><span style="letter-spacing:0.2pt;">Research and development personnel costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">276</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0pt 5.75pt;"><span style="letter-spacing:0.2pt;">Facilities and other support costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">75</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><span style="letter-spacing:0.2pt;">Other</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">38</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Total research and development costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">1,441</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">General and administrative</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">640</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Total operating expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">2,081</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Segment and net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">(1,026)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">(2,081)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212; Other expenses includes travel for research and development and a clinical and regulatory data repository system.</span></td></tr></table><div style="margin-top:12pt;"><a id="_de302b24_6df5_4e68_bca2_af2e592cdf4f"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></span><b style="font-weight:bold;">Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Historically, the NeoCart business has been managed and operated in the normal course with other businesses of Parent. Accordingly, certain shared costs have been allocated to the NeoCart business and reflected as expenses in the stand-alone Combined Financial Statements. Management of Parent and the NeoCart business considers the allocation methodologies used to be reasonable and appropriate reflections of the historical expenses attributable to the NeoCart business for purposes of the stand-alone financial statements. The expenses reflected in the Combined Financial Statements may not be indicative of expenses that would be incurred by the NeoCart business in the future. All related party transactions approximate prices at cost.</p><a id="_dd42a01e_4735_46ce_9d56_8a4530d48d4c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></span><b style="font-weight:bold;">Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Combined Financial Statements are derived from the Consolidated Financial Statements of Parent, which issued its annual financial statements for the fiscal&#160;year ended December&#160;31, 2024 on March&#160;5, 2025. Accordingly, the Company has evaluated recognizable subsequent events through the date of March&#160;5, 2025 and&#160;non-recognizable&#160;subsequent events through July&#160;21, 2025, the date these financial statements were available for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b4da4e49_64d3_42bb_a48b_d680b581ac22"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6.09pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">combined financial statements of the neocart business of ocugen,&#160;Inc.</b></p><a id="BALANCESHEETS4"></a><a id="COMBINEDBALANCESHEETS_320546"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">combined Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b>&#160;<br/><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b>&#160;<br/><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:76.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:76.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and Contingencies (Note 5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Parent Company Net Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:76.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:76.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities and Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these combined financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_419114f1_f5d7_47a4_952d_275cb1edfe82"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">combined financial statements of the neocart business of ocugen, inc.</b></p><a id="comprehensiveliss4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">combined Statements of Operations and Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.48%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;months&#160;ended&#160;March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:77.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">182</p></td></tr><tr><td style="vertical-align:bottom;width:77.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">128</p></td></tr><tr><td style="vertical-align:bottom;width:77.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">310</p></td></tr><tr><td style="vertical-align:bottom;width:77.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(310)</p></td></tr><tr><td style="vertical-align:bottom;width:77.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total comprehensive income/(loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(310)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these combined financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ba267e2b_226d_438d_a39c_ba6a0b83bf3d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">combined financial STATEMENTS of the neocart business of ocugen, inc.</b></p><a id="equity4"></a><a id="COMBINEDSTATEMENTSOFCHANGESINEQUITY_7947"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">combined Statements of Changes in Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parent&#160;Company</b><br/><b style="font-weight:bold;">Net&#160;Investment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(270)</p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Net Transfers from Parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">270</p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at March&#160;31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net&#160;Parent</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Investment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(24)</p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(310)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(310)</p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Net Transfers from Parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">230</p></td></tr><tr><td style="vertical-align:bottom;width:73.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance at March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(104)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(104)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these combined financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b7ff7b97_9e3c_40f8_93c5_9e906b9c9799"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">combined financial statements of the neocart business of ocugen, inc.</b></p><a id="cashflow4"></a><a id="COMBINEDSTATEMENTSOFCASHFLOWS_766837"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">combined Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;months&#160;ended&#160;March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(310)</p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Changes in liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">80</p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net cash used on operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(230)</p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net cash (used in) provided by investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Net transfers from Parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">230</p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">230</p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash at beginning of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash at end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these combined financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d02278ff_dcdc_4a0d_a8aa_bdadffb9d83d"></a><a id="NatureoftheBusiness_209432"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span><b style="font-weight:bold;">Nature of the Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OrthoCellix,&#160;Inc., a Delaware corporation, (the &#8220;Company&#8221; was incorporated as a legal entity on February&#160;28, 2025. On June&#160;19, 2025, Ocugen,&#160;Inc., a Delaware corporation (&#8220;Ocugen&#8221; or the &#8220;Parent&#8221;) contributed certain assets (&#8220;the NeoCart Assets&#8221;) to the Company pursuant to an Asset Contribution Agreement, by and between the Parent and the Company (the &#8220;Contribution Agreement&#8221;) in exchange for shares of Common Stock in the Company (such transactions, the &#8220;Contribution&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Per the Contribution Agreement, the Parent contributed the NeoCart Assets in exchange for 1,000 Shares of Common stock in contemplation of the Agreement and Plan of Merger (&#8220;Merger Agreement&#8221;) with Carisma Therapeutics,&#160;Inc. The NeoCart Assets comprise Ocugen&#8217;s rights, title and interest in and to NeoCart, an internally developed, in-process product candidate, as well as associated contracts and licensing agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement, OrthoCellix will become a wholly owned subsidiary of Carisma and stockholders of the Company will receive shares of common stock of Carisma, which is contingent on Carisma concurrently receiving gross proceeds of $25.0 million from investors, including Ocugen, among other things. The Company&#8217;s commercial purpose is to seek to continue development and commercialization of NeoCart, a Phase 3-ready, regenerative cell therapy technology that combines breakthroughs in bioengineering and cell processing to enhance the autologous cartilage repair process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined financial statements represent the historical combined financial position, statement of operations, and cash flows of the NeoCart business of Ocugen (the &#8220;NeoCart business&#8221;), which have been carved out from the Parent&#8217;s operations. Historically, the NeoCart business was not a separate entity nor was financial information previously prepared for the NeoCart business on a stand-alone basis. The combined financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include the accounts of the NeoCart business. Transactions between the NeoCart business and the Parent are reflected in equity in the balance sheet as &#8220;Parent Company Net Investment&#8221; and in the combined statement of cash flows as a financing activity in &#8220;Net transfers from the Parent.&#8221; See Note&#160;6,&#8212;Related Party Transactions for additional information regarding related party transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts may require additional capital, additional personnel and infrastructure, and further regulatory and other capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2014-15,<i style="font-style:italic;">&#160;Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40)</i>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one&#160;year after the date that the combined financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred recurring net losses since inception. The Company incurred net losses of approximately $270 and $310 for the three&#160;months ended March&#160;31, 2025 and 2024, respectively. As of March&#160;31, 2025, the Company had no cash. The Company&#8217;s operations will not be sufficient to fund the Company over the next 12&#160;months after the date that the combined financial statements are issued.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company is subject to risks and uncertainties frequently encountered by companies in its industry, the Company will require significant additional funding. If the Company is unable to obtain additional funding in the future, there may be a negative impact on the financial viability of the Company. The Company will continue to explore options to fund its operations through the contemplation of a merger agreement and concurrent financing, public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sales of assets, licensing and/or collaboration arrangements with pharmaceutical companies or other institutions, funding from the government, or funding from other third parties. Such financing and funding may not be available at all, or on terms that are favorable to the Company. While the Company believes that it has a plan to fund operations, its plan may not be successfully implemented. If the Company cannot obtain the necessary funding, they will need to delay, scale back, or eliminate some or all of the Company&#8217;s research and development programs and commercialization efforts; consider other various strategic alternatives, including a merger or sale&#894; or cease operations. If the Company cannot expand their operations or otherwise capitalize on business opportunities because they lack sufficient capital, business, financial condition, and results of operations could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of these factors, together with the anticipated continued spending that will be necessary to continue to research, develop, and commercialize the Company&#8217;s product candidate, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one&#160;year after the date that these combined financial statements are issued. The combined financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</p><a id="_b885acdc_c230_4f09_8d50_62d42abfcaa8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation and Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying combined financial statements included herein have been prepared in conformity with GAAP. The combined financial statements have been derived from the financial statements and accounting records of the Parent using the historical results of operations and historical basis of assets and liabilities of the NeoCart business of Ocugen to reflect the Parent&#8217;s net investment in the Company. Historically, stand-alone financial statements have not been prepared for the NeoCart business. The Company believes the assumptions underlying the allocations included in the combined financial statements are reasonable. However, the combined financial statements may not necessarily reflect the NeoCart business&#8217; results of operations, financial position and cash flows in the future, or what NeoCart&#8217;s results of operations, financial position and cash flows would have been had NeoCart been a stand-alone company during the periods presented herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined financial statements include allocations of costs from the Parent that were incurred by the NeoCart business of Ocugen for functions such as research&#160;&amp; development, human resources, information technology, facilities, accounting, finance and legal, including the costs of salaries, benefits and other related costs. No Ocugen employees will be employed by OrthoCellix and Ocugen will have certain transition agreements with OrthoCellix. The total costs allocated to the combined financial statements for these functions totaled approximately $270 and $310 for the three&#160;months ended March&#160;31, 2025 and 2024, respectively, and are included in research and development and general and administrative expenses within the combined statement of operations and comprehensive loss. These expenses have been allocated to NeoCart based on direct usage or benefit where identifiable, with the remainder allocated on the basis of the costs associated with research and development expenses, or proportional cost allocation based on the relative size of the Company. As a stand-alone public company, the NeoCart business&#8217; total costs related to such support functions may differ materially from the costs that historically remained after allocation to the Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of these combined financial statements, all intercompany transactions between the NeoCart business and the Parent has been included within Parent Company Net Investment on the balance sheet. Intercompany transactions presumed to be subject to cash settlement at a future date are recorded as accounts receivables and payables on the balance sheets. See Note&#160;6&#8212;Related Party Transactions for additional information regarding related party transactions.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In preparing the financial statements in conformity with GAAP, the Company is required to make estimates and assumptions that affect the reported amounts and disclosures at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for allocation of research and development costs and general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. These costs consist of internal and external expenses, as well as depreciation expense on assets owned by the Parent used within the Company&#8217;s research and development activities. Internal expenses include the cost of salaries, benefits, and other related costs, including amounts owed to the Parent for stock-based compensation, for personnel serving in the Company&#8217;s research and development functions, as well as allocated rent and utilities expenses. External expenses include development, clinical trials, and regulatory compliance costs incurred with research organizations, contract manufacturers, and other third-party vendors. License fees paid to acquire access to proprietary technology are expensed to research and development, unless it is determined that the technology is expected to have an alternative future use. The Company recorded costs for certain development activities, such as preclinical studies and clinical trials, based on the Company&#8217;s evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the combined financial statements as prepaid or accrued research and development expense, as applicable. The recording of costs for certain development activities requires the Company to use estimates. The Company believes the estimates and assumptions are reasonable under the current conditions; however, actual results may differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expense consists primarily of personnel expenses, including salaries, benefits, insurance, and stock-based compensation expense, for employees in executive, accounting, commercialization, human resources, and other administrative functions. General and administrative expense also includes expenses related to pre-commercial activities, corporate facility costs, such as allocated rent and utilities, insurance premiums, legal fees related to corporate matters, and fees for auditing, accounting, and other consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Parent Company Net Investment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Parent Company Net Investment on the combined balance sheets represents the Parent&#8217;s net investment in the Company and is presented as &#8220;Parent Company Net Investment&#8221;. Parent Company Net Investment includes assets and liabilities that have historically been held by the Parent but specifically identifiable or otherwise attributable to the Company, and other assets and liabilities recorded by the Parent, whose related income and expenses have been pushed down to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Contractual Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates contractual agreements to determine the appropriate accounting treatment in accordance with GAAP. Depending on the specific terms and nature of each arrangement, such agreements may be accounted for under ASC 606&#160;&#8211; Revenue from Contracts with Customers, ASC 808&#160;&#8211; Collaborative Arrangements, or ASC 730&#160;&#8211; Research and Development. The assessment includes identifying performance obligations, determining whether the contractual obligation is distinct, and evaluating the timing and pattern of revenue recognition or expense treatment.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did not historically file separate income tax returns since the Company was not a separate entity. As such, the provision was calculated on a stand-alone basis for the purpose of these combined financial statements. The Company uses the asset and liability method in accounting for income taxes. Deferred tax assets and liabilities are recorded for temporary differences between the tax basis of assets and liabilities and their reported amounts in the combined financial statements, using statutory tax rates in effect for the&#160;year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the combined statements of operations and comprehensive loss in the period that includes the enactment date. Accordingly, the reported provision for income taxes and the related balance sheet account balances may not equal the amounts that would have been allocable to the Company under applicable consolidated US federal and state tax laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its deferred tax assets each period to ensure that the estimated future taxable income will be sufficient in character, amount, and timing, to result in its realizability. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets, unless it is more likely than not that those assets will be realized. Management utilizes considerable judgment when establishing deferred tax valuation allowances. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences and carryforward deferred tax assets become deductible or utilized. The Company considers the scheduled reversal of taxable temporary differences, projected future taxable income, and tax planning strategies in making this assessment. As events and circumstances change, valuation allowances are adjusted within the combined statement of operations and comprehensive loss when applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes net tax benefits under the recognition and measurement criteria of FASB ASC Topic 740, Income Taxes, which prescribes requirements and other guidance for financial statement recognition and measurement of positions taken or expected to be taken on tax returns. The Company recognizes a tax benefit for positions taken for tax return purposes when it will be more likely than not that the positions will be sustained upon tax examination, based solely on the technical merits of the tax positions. Otherwise, no tax benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense in the combined statement of operations and comprehensive loss. Tax examinations are often complex, as tax authorities may disagree with the treatment of items reported by the Company and may require several&#160;years to resolve. As a result, the Company&#8217;s provision for income taxes is recorded on the basis of available information, but amounts recorded may be impacted as a result of future examinations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures&#8221;. This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The guidance is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s combined financial statements. The Company adopted the guidance in the fiscal&#160;year beginning January&#160;1, 2024. There was no impact on the Company&#8217;s reportable segments identified and required disclosures have been included in Note&#160;5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASU 2025-03, &#8220;Business Combination and Consolidation: Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity&#8221; (&#8220;ASU 2025-03&#8221;) provides clarifying guidance on determining the accounting acquirer in certain transactions involving VIEs. The update aims to improve consistency and comparability in financial reporting, especially when companies merge with a special-purpose acquisition company (&#8220;SPAC&#8221;). ASU 2025-03 requires entities to apply the same factors used for determining the accounting acquirer in other acquisition transactions. Essentially, it aims to make financial reporting more comparable and decision-useful for investors by ensuring that the accounting acquirer is appropriately identified in acquisitions of VIEs, particularly in SPAC transactions. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 including interim periods within those annual periods, with early adoption permitted. The Company intends to adopt ASU 2025-03 for transactions occurring after its issuance, including the transaction with Carisma contemplated in the Merger Agreement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#8221;. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal&#160;years beginning after December&#160;15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company has not yet adopted this new ASU however the Company expects it to only impact its income tax disclosures upon adoption with no impact to its operations, cash flows, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2024, the FASB issued ASU No.&#160;2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03). The new guidance requires disaggregated information about certain income statement expense line items on an annual and interim basis. This guidance will be effective for annual periods beginning the&#160;year ended December&#160;31, 2027 and for interim periods thereafter. The new standard permits early adoption and can be applied prospectively or retrospectively. The Company is evaluating the effect that this guidance will have on their combined financial statements and related disclosures.</p><a id="_3631dfb5_6d6f_4879_863a_bda2b8ba7f1f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span><b style="font-weight:bold;">Contractual Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The below contractual agreements were contributed to the Company from the Parent as a part of the Contribution Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">MEDINET License and Commercialization Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2017, Histogenics Corporation (&#8220;Histogenics&#8221;) entered into a License and Commercialization Agreement (the &#8220;MEDINET Agreement&#8221;) with MEDINET Co.,&#160;Ltd. (&#8220;MEDINET&#8221;) with regards to the commercialization of NeoCart in Japan, which Ocugen assumed as a result of a reverse merger with Histogenics subsequently, that took place in 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the MEDINET Agreement, Histogenics was eligible to receive up to an aggregate of approximately $86.9 million in milestone payments plus royalties, consisting of (i)&#160;a non-refundable upfront payment of $10.0 million which Histogenics received in January&#160;2018, (ii)&#160;potential regulatory and development milestone payments of up to an aggregate of $10.5 million, (iii)&#160;overall sales-dependent milestones of up to an aggregate of $66.4 million and (iv)&#160;tiered royalties at&#160;percentages ranging from 5% to 10% on net sales of NeoCart in Japan. In return for such consideration, Histogenics granted to MEDINET exclusive commercialization rights to NeoCart in Japan for the replacement or repair of damaged, worn or defective cartilage in humans and non-human animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The MEDINET Agreement will remain in effect until the later of (i)&#160;expiration of the last-to-expire valid and enforceable patent covering NeoCart in Japan and (ii)&#160;ten&#160;years from the first commercial sale of NeoCart in Japan. MEDINET has an option to extend the term for five&#160;years upon written notice to us prior to the end of the initial term. MEDINET has the right to terminate the MEDINET Agreement for any or no reason at any time, and the Company may terminate the MEDINET Agreement in the event MEDINET or one of its affiliates or sublicensees challenges a patent covering NeoCart in Japan. Additionally, either party may terminate the MEDINET Agreement for an uncured material breach by the other party or upon certain insolvency or bankruptcy proceedings involving the other party. Histogenics and MEDINET agreed to indemnify each other for third-party claims arising out of either the Company or the Company affiliates&#8217; willful misconduct or negligence, breaches of representations, warranties, covenants, obligations or agreements contained in the MEDINET Agreement, or MEDINET&#8217;s exploitation of NeoCart in its respective territory, subject to specified exclusions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Histogenics and MEDINET agreed to enter into supply, quality and pharmacovigilance agreements (the &#8220;MEDINET Supply Agreements&#8221;), pursuant to which MEDINET will purchase its requirements of NeoCart and the related biopsy kit from the Company. Pursuant to the terms of the MEDINET Agreement, the MEDINET Supply Agreements will contain terms and conditions customary for agreements of its type within the biotechnology industry, including those set forth in the MEDINET Agreement. No amounts have been received or recorded pursuant to the MEDINET Agreement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with Purpose</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2005, Histogenics entered into an exclusive agreement (the &#8220;Purpose Agreement&#8221;) to sublicense certain technology from Purpose Co.,&#160;Ltd. (&#8220;Purpose&#8221;), which Ocugen assumed as a result of the reverse merger with Histogenics, that took place in 2019. The Purpose Agreement granted Purpose an exclusive, royalty-bearing, worldwide, sublicensable license, under its rights in licensed patents and patent applications co-owned by Brigham and Women&#8217;s Hospital, Inc. and Purpose to make, use, and sell (1)&#160;an apparatus for cultivating a cell or tissue, (2)&#160;cell or tissue products made using such apparatus, (3)&#160;cell or tissue products made using processes for cultivating a cell or tissue as disclosed in the licensed patents and patent applications, and (4)&#160;any apparatus that cultivates cells or tissues using such processes, in each case, whose manufacture, use, or sale is covered by a valid claim of the licensed patents and patent applications, only for therapeutic use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Purpose Agreement was amended and restated in June&#160;2012, pursuant to which Purpose granted to Histogenics outside of Japan: (a)&#160;exclusive rights to all of Purpose&#8217;s technology (owned or licensed) related to the exogenous tissue processors, which is used in the development of NeoCart, (b)&#160;continued supply of exogenous tissue processors, and (c)&#160;rights to manufacture the exogenous tissue processors at any location Histogenics chooses. In exchange for such consideration, Purpose was granted an exclusive license in Japan for the use of all of NeoCart technology and was reimbursed for development costs on a multi-unit exogenous tissue processor. In May&#160;2016, the Purpose Agreement was amended, whereby Histogenics reacquired the development and commercialization rights to NeoCart in Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Purpose Agreement, as amended, provides the Company with the ability, worldwide, to (i)&#160;use, make, have made, sell, offer for sale, import or otherwise exploit products or services covered by claims of Purpose&#8217;s patents and (ii)&#160;use, reproduce, modify, create derivative works of and otherwise exploit Purpose&#8217;s technology for the design, development, manufacture, testing, support, and commercialization of any product or service that incorporates or builds upon Purpose&#8217;s technology, in each case, only in connection with articular cartilage, ligaments, tendons, and meniscus. Purpose retains the right to sell its single unit exogenous tissue processer machines to research institutes for general but noncommercial use anywhere in the world. The Purpose Agreement remains in effect for the life of the patents unless earlier terminated by providing written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Purpose Agreement (as amended), the NeoCart business of Ocugen is obligated to pay Purpose payments of up to $10.0 million in the event certain milestones are satisfied as well as a royalty payments in the low single digits on the net sales in Japan for NeoCart products that rely on a Purpose patent or incorporate or necessarily rely upon any Purpose technology. Such royalty payment shall be reduced if the applicable NeoCart products do not rely on an outstanding Purpose patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with Angiotech</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2005, Histogenics Corporation (&#8220;Histogenics&#8221;) entered into a license agreement with Angiotech Pharmaceuticals (US),&#160;Inc. and Angiodevice International GmbH (together, &#8220;Angiotech&#8221;), which was subsequently assumed by Ocugen following its merger with Histogenics in 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the agreement, Histogenics received exclusive worldwide rights to develop and commercialize products incorporating CT3 and the Company&#8217;s proprietary technology for the treatment of articular cartilage, ligament, meniscus, and tendon damage, subject to certain field limitations. The exclusivity of the license was formalized through a fifth amendment in August&#160;2010.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As consideration for the license, Histogenics paid a $1.0 million exclusivity fee and four annual patent maintenance payments of $50,000 each as of December&#160;31, 2018. The Company may be obligated to make an additional $3.0 million milestone payment upon regulatory approval of a licensed product by the U.S. Food and Drug Administration. Histogenics also agreed to pay Angiotech single-digit&#160;percentage royalties on net sales of NeoCart and other licensed products. This rate reflects a reduction from prior double-digit royalty obligations, achieved via $2.0 million in revenue share reduction payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The agreement includes customary supply and data-sharing provisions with respect to CT3 and clinical study results, and remains in effect until the earlier of May&#160;12, 2035 or expiration of all royalty payment obligations. Either party may terminate the agreement for uncured material breach, and Angiotech may also terminate under certain conditions, including competitive activity or patent challenges by the Company or its affiliates.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No amounts were paid or accrued under the Angiotech agreement during the three&#160;months ended March&#160;31, 2024 and 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intrexon Collaboration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2014, Histogenics entered into an Exclusive Channel Collaboration (&#8220;ECC&#8221;) with Intrexon Corporation (&#8220;Intrexon&#8221;) governing a &#8220;channel collaboration&#8221; arrangement in which Histogenics intended to use Intrexon&#8217;s proprietary technology towards the design, identification, culturing and/or production of genetically modified cells (&#8220;Technology&#8221;). The ECC granted Histogenics an exclusive worldwide license to utilize Intrexon&#8217;s Technology to develop and commercialize allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2018, Histogenics and Intrexon entered into a mutual termination and release agreement (the &#8220;Mutual Termination Agreement&#8221;) pursuant to which Histogenics and Intrexon mutually agreed to terminate ECC. In connection with the Mutual Termination Agreement, Histogenics agreed to pay Intrexon an aggregate of up to $1.5 million, with $0.375 million paid at the time of entering into the Mutual Termination Agreement and $1.125 million payable within one year following any submission of a Biologics License Application (&#8220;BLA&#8221;) to the Food and Drug Administration for NeoCart. Ocugen assumed the ECC and Mutual Termination Agreement as a result of the Histogenics merger. The NeoCart business has not recorded the $1.125 million payable as the filing of the BLA does not meet the definition of probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Sponsored Collaborative Research Agreement with a Hospital</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2022, Ocugen entered into a sponsored collaborative research agreement (the &#8220;Research Agreement&#8221;) with a hospital to support NeoCart development.&#160;The research to be performed under the Research Agreement by the hospital is related to technology development and other regenerative therapy. The Research Agreement was amended and restated in June&#160;2024, to extend the agreement through December&#160;30, 2024, at which time it expired. There were no incremental costs or payments during this period.</p><a id="_8c2db678_3fac_4b5b_a884_809eae268cc2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Contractual Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ocugen entered into, or has assumed in connection with its merger with Histogenics in 2019, contractual agreements with various parties that are wholly attributed to Ocugen. These agreements entered into by Ocugen and related to the NeoCart business noted above have been transferred subject to the Contribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Indemnification Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. To date, the Company has not incurred any costs as a result of such indemnification provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of March&#160;31, 2025, there were no matters.</p><a id="_a51a3665_f75b_490c_8dd0_c0d0cb190a22"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></span><b style="font-weight:bold;">Segment Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has one operating and reportable segment related to the development of NeoCart. The Company has not generated any product revenue. The Company&#8217;s Chief Operating Decision Maker (the &#8220;CODM&#8221;) is the Company&#8217;s Chief Executive Officer. The CODM assesses the performance for the Company and its reportable segment based on net loss, which is reported on the combined statement of operations and comprehensive loss. The CODM uses net loss to evaluate performance, forecast future period financial results, allocate resources, and budget to actual results. The measure of segment assets is reported on the balance sheet as total assets.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMBINED FINANCIAL STATEMENTS OF THE NEOCART BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">NeoCart</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">106</p></td></tr><tr><td style="vertical-align:bottom;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Unallocated costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Research and development personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">53</p></td></tr><tr><td style="vertical-align:bottom;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Facilities and other support costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">9</p></td></tr><tr><td style="vertical-align:bottom;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Other<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">14</p></td></tr><tr><td style="vertical-align:bottom;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">182</p></td></tr><tr><td style="vertical-align:bottom;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">128</p></td></tr><tr><td style="vertical-align:bottom;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">310</p></td></tr><tr><td style="vertical-align:bottom;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Segment and net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(310)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212; Other expenses includes travel for research and development and a clinical and regulatory data repository system.</span></td></tr></table><div style="margin-top:12pt;"><a id="_e0a33175_35bd_4ddd_ba87_9dd9bb75be00"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></span><b style="font-weight:bold;">Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Historically, the NeoCart business has been managed and operated in the normal course with other businesses of Parent. Accordingly, certain shared costs have been allocated to the NeoCart business and reflected as expenses in the stand-alone Combined Financial Statements. Management of Parent and the NeoCart business considers the allocation methodologies used to be reasonable and appropriate reflections of the historical expenses attributable to the NeoCart business for purposes of the stand-alone interim financial statements. The expenses reflected in the interim Combined Financial Statements may not be indicative of expenses that would be incurred by the NeoCart business in the future. All related party transactions approximate prices at cost.</p><a id="_2949e1f1_1686_46d2_905c_43d78b1b8973"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></span><b style="font-weight:bold;">Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These interim Combined Financial Statements are derived from the interim Consolidated Financial Statements of Parent, which issued its interim financial statements for the three&#160;months ended March&#160;31, 2025 on May&#160;9, 2025. Accordingly, the Company has evaluated recognizable subsequent events through the date of May&#160;9, 2025 and non-recognizable subsequent events through July&#160;21, 2025, the date these financial statements were available for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_cb98c49c_2c0d_41e4_8ddb_0b0dc9412a71"></a><a id="AnnexA_512168"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Annex A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Execution</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="AGREEMENTANDPLANOFMERGER_276206"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGREEMENT AND PLAN OF MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">by and among</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AZALEA MERGER SUB,&#160;INC.,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ORTHOCELLIX,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OCUGEN,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dated as of June&#160;22, 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d7301b50_221d_46ef_9d2e_be46e7ed522f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><td colspan="4" style="vertical-align:top;width:90.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ARTICLEI_641964"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;I DEFINITIONS&#160;&amp; INTERPRETATIONS</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-2</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section11_796897"><span style="font-style:normal;font-weight:normal;">Section&#160;1.1</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section11_796897"><span style="font-style:normal;font-weight:normal;">Certain Definitions</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-2</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section12_173360"><span style="font-style:normal;font-weight:normal;">Section&#160;1.2</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section12_173360"><span style="font-style:normal;font-weight:normal;">Interpretation</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-7</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section13_926082"><span style="font-style:normal;font-weight:normal;">Section&#160;1.3</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section13_926082"><span style="font-style:normal;font-weight:normal;">Currency</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-7</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:90.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ARTICLEII_431724"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;II THE MERGER</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-7</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section21_659566"><span style="font-style:normal;font-weight:normal;">Section&#160;2.1</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section21_659566"><span style="font-style:normal;font-weight:normal;">Formation of Merger Sub</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-7</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section22_187189"><span style="font-style:normal;font-weight:normal;">Section&#160;2.2</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section22_187189"><span style="font-style:normal;font-weight:normal;">The Merger</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-7</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section23_358929"><span style="font-style:normal;font-weight:normal;">Section&#160;2.3</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section23_358929"><span style="font-style:normal;font-weight:normal;">Closing</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-7</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section24_590246"><span style="font-style:normal;font-weight:normal;">Section&#160;2.4</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section24_590246"><span style="font-style:normal;font-weight:normal;">Effective Time</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-7</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section25_232200"><span style="font-style:normal;font-weight:normal;">Section&#160;2.5</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section25_232200"><span style="font-style:normal;font-weight:normal;">Effects of the Merger</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-8</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section26_743991"><span style="font-style:normal;font-weight:normal;">Section&#160;2.6</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section26_743991"><span style="font-style:normal;font-weight:normal;">Parent Governance</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-8</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section27_384720"><span style="font-style:normal;font-weight:normal;">Section&#160;2.7</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section27_384720"><span style="font-style:normal;font-weight:normal;">Surviving Company and Surviving Company Governance</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-8</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:90.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ARTICLEIII_257623"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;III EFFECT ON THE CAPITAL STOCK OF THE CONSTITUENT COMPANIES; EXCHANGE OF CERTIFICATES</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-9</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section31_103102"><span style="font-style:normal;font-weight:normal;">Section&#160;3.1</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section31_103102"><span style="font-style:normal;font-weight:normal;">Conversion of Capital Stock</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-9</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section32_339264"><span style="font-style:normal;font-weight:normal;">Section&#160;3.2</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section32_339264"><span style="font-style:normal;font-weight:normal;">[RESERVED.]</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-10</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section33_126427"><span style="font-style:normal;font-weight:normal;">Section&#160;3.3</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section33_126427"><span style="font-style:normal;font-weight:normal;">Exchange and Payment</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-10</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section34_640595"><span style="font-style:normal;font-weight:normal;">Section&#160;3.4</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section34_640595"><span style="font-style:normal;font-weight:normal;">Withholding Rights</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-12</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section35_759987"><span style="font-style:normal;font-weight:normal;">Section&#160;3.5</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section35_759987"><span style="font-style:normal;font-weight:normal;">Dissenters Rights</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-12</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section36_474184"><span style="font-style:normal;font-weight:normal;">Section&#160;3.6</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section36_474184"><span style="font-style:normal;font-weight:normal;">Calculation of Net Cash</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-12</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section37_309514"><span style="font-style:normal;font-weight:normal;">Section&#160;3.7</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section37_309514"><span style="font-style:normal;font-weight:normal;">Contingent Value Right</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-13</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:90.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ARTICLEIV_2834"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-14</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section41_417212"><span style="font-style:normal;font-weight:normal;">Section&#160;4.1</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section41_417212"><span style="font-style:normal;font-weight:normal;">Organization, Standing and Power</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-14</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section42_118110"><span style="font-style:normal;font-weight:normal;">Section&#160;4.2</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section42_118110"><span style="font-style:normal;font-weight:normal;">Capital Stock</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-14</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section43_862523"><span style="font-style:normal;font-weight:normal;">Section&#160;4.3</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section43_862523"><span style="font-style:normal;font-weight:normal;">Subsidiaries</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-15</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section44_367274"><span style="font-style:normal;font-weight:normal;">Section&#160;4.4</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section44_367274"><span style="font-style:normal;font-weight:normal;">Authority</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-15</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section45_544366"><span style="font-style:normal;font-weight:normal;">Section&#160;4.5</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section45_544366"><span style="font-style:normal;font-weight:normal;">No Conflict; Consents and Approvals</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-15</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section46_740677"><span style="font-style:normal;font-weight:normal;">Section&#160;4.6</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section46_740677"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-16</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section47_677331"><span style="font-style:normal;font-weight:normal;">Section&#160;4.7</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section47_677331"><span style="font-style:normal;font-weight:normal;">No Undisclosed Liabilities</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-16</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section48_40785"><span style="font-style:normal;font-weight:normal;">Section&#160;4.8</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section48_40785"><span style="font-style:normal;font-weight:normal;">Absence of Certain Changes or Events</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-16</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section49_568602"><span style="font-style:normal;font-weight:normal;">Section&#160;4.9</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section49_568602"><span style="font-style:normal;font-weight:normal;">Litigation</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-17</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section410_869871"><span style="font-style:normal;font-weight:normal;">Section&#160;4.10</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section410_869871"><span style="font-style:normal;font-weight:normal;">Compliance with Laws</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-17</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section411_198228"><span style="font-style:normal;font-weight:normal;">Section&#160;4.11</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section411_198228"><span style="font-style:normal;font-weight:normal;">Health Care Regulatory Matters</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-17</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section412_541143"><span style="font-style:normal;font-weight:normal;">Section&#160;4.12</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section412_541143"><span style="font-style:normal;font-weight:normal;">Benefit Plans</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-19</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section413_127420"><span style="font-style:normal;font-weight:normal;">Section&#160;4.13</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section413_127420"><span style="font-style:normal;font-weight:normal;">Labor and Employment Matters</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-20</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section414_626021"><span style="font-style:normal;font-weight:normal;">Section&#160;4.14</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section414_626021"><span style="font-style:normal;font-weight:normal;">Environmental Matters</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-21</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section415_361250"><span style="font-style:normal;font-weight:normal;">Section&#160;4.15</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section415_361250"><span style="font-style:normal;font-weight:normal;">Taxes</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-22</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section416_269654"><span style="font-style:normal;font-weight:normal;">Section&#160;4.16</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section416_269654"><span style="font-style:normal;font-weight:normal;">Contracts</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-23</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section417_476508"><span style="font-style:normal;font-weight:normal;">Section&#160;4.17</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section417_476508"><span style="font-style:normal;font-weight:normal;">Insurance</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-24</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section418_848423"><span style="font-style:normal;font-weight:normal;">Section&#160;4.18</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section418_848423"><span style="font-style:normal;font-weight:normal;">Properties; Assets</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-24</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section419_786375"><span style="font-style:normal;font-weight:normal;">Section&#160;4.19</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section419_786375"><span style="font-style:normal;font-weight:normal;">Intellectual Property</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-25</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section420_750885"><span style="font-style:normal;font-weight:normal;">Section&#160;4.20</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section420_750885"><span style="font-style:normal;font-weight:normal;">State Takeover Statutes</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-26</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section421_594003"><span style="font-style:normal;font-weight:normal;">Section&#160;4.21</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section421_594003"><span style="font-style:normal;font-weight:normal;">No Rights Plan</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-26</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section422_697171"><span style="font-style:normal;font-weight:normal;">Section&#160;4.22</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section422_697171"><span style="font-style:normal;font-weight:normal;">Related Party Transactions</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-26</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section423_37600"><span style="font-style:normal;font-weight:normal;">Section&#160;4.23</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section423_37600"><span style="font-style:normal;font-weight:normal;">Certain Payments</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-26</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section424_103351"><span style="font-style:normal;font-weight:normal;">Section&#160;4.24</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section424_103351"><span style="font-style:normal;font-weight:normal;">Trade Control Laws</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-27</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section425_717254"><span style="font-style:normal;font-weight:normal;">Section&#160;4.25</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section425_717254"><span style="font-style:normal;font-weight:normal;">Brokers</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-27</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section426_843592"><span style="font-style:normal;font-weight:normal;">Section&#160;4.26</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section426_843592"><span style="font-style:normal;font-weight:normal;">No Other Representations and Warranties</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-27</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ARTICLEV_87718"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;V REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-27</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section51_481410"><span style="font-style:normal;font-weight:normal;">Section&#160;5.1</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section51_481410"><span style="font-style:normal;font-weight:normal;">Organization, Standing and Power</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-27</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section52_882578"><span style="font-style:normal;font-weight:normal;">Section&#160;5.2</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section52_882578"><span style="font-style:normal;font-weight:normal;">Capital Stock</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-28</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section53_516598"><span style="font-style:normal;font-weight:normal;">Section&#160;5.3</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section53_516598"><span style="font-style:normal;font-weight:normal;">Subsidiaries</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-28</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section54_992636"><span style="font-style:normal;font-weight:normal;">Section&#160;5.4</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section54_992636"><span style="font-style:normal;font-weight:normal;">Authority</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-29</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section55_918402"><span style="font-style:normal;font-weight:normal;">Section&#160;5.5</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section55_918402"><span style="font-style:normal;font-weight:normal;">No Conflict; Consents and Approvals</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-30</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section56_816384"><span style="font-style:normal;font-weight:normal;">Section&#160;5.6</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section56_816384"><span style="font-style:normal;font-weight:normal;">SEC Reports; Financial Statements</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-30</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section57_418580"><span style="font-style:normal;font-weight:normal;">Section&#160;5.7</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section57_418580"><span style="font-style:normal;font-weight:normal;">No Undisclosed Liabilities</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-31</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section58_26206"><span style="font-style:normal;font-weight:normal;">Section&#160;5.8</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section58_26206"><span style="font-style:normal;font-weight:normal;">Absence of Certain Changes or Events</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-31</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section59_84371"><span style="font-style:normal;font-weight:normal;">Section&#160;5.9</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section59_84371"><span style="font-style:normal;font-weight:normal;">Litigation</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-32</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section510_522563"><span style="font-style:normal;font-weight:normal;">Section&#160;5.10</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section510_522563"><span style="font-style:normal;font-weight:normal;">Compliance with Law</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-32</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section511_582682"><span style="font-style:normal;font-weight:normal;">Section&#160;5.11</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section511_582682"><span style="font-style:normal;font-weight:normal;">Health Care Regulatory Matters</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-32</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section512_641872"><span style="font-style:normal;font-weight:normal;">Section&#160;5.12</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section512_641872"><span style="font-style:normal;font-weight:normal;">Benefit Plans</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-34</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section513_619194"><span style="font-style:normal;font-weight:normal;">Section&#160;5.13</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section513_619194"><span style="font-style:normal;font-weight:normal;">Labor and Employment Matters</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-35</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section514_269151"><span style="font-style:normal;font-weight:normal;">Section&#160;5.14</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section514_269151"><span style="font-style:normal;font-weight:normal;">Environmental Matters</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-36</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section515_547416"><span style="font-style:normal;font-weight:normal;">Section&#160;5.15</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section515_547416"><span style="font-style:normal;font-weight:normal;">Taxes</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-36</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section516_355503"><span style="font-style:normal;font-weight:normal;">Section&#160;5.16</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section516_355503"><span style="font-style:normal;font-weight:normal;">Contracts</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-38</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section517_83603"><span style="font-style:normal;font-weight:normal;">Section&#160;5.17</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section517_83603"><span style="font-style:normal;font-weight:normal;">Insurance</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-39</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section518_284419"><span style="font-style:normal;font-weight:normal;">Section&#160;5.18</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section518_284419"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-39</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section519_315560"><span style="font-style:normal;font-weight:normal;">Section&#160;5.19</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section519_315560"><span style="font-style:normal;font-weight:normal;">Intellectual Property</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-39</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section520_964554"><span style="font-style:normal;font-weight:normal;">Section&#160;5.20</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section520_964554"><span style="font-style:normal;font-weight:normal;">Related Party Transactions</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-40</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section521_919475"><span style="font-style:normal;font-weight:normal;">Section&#160;5.21</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section521_919475"><span style="font-style:normal;font-weight:normal;">Certain Payments</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-40</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section522_991525"><span style="font-style:normal;font-weight:normal;">Section&#160;5.22</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section522_991525"><span style="font-style:normal;font-weight:normal;">Trade Control Laws</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-41</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section523_939375"><span style="font-style:normal;font-weight:normal;">Section&#160;5.23</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section523_939375"><span style="font-style:normal;font-weight:normal;">Brokers</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-41</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section524_729691"><span style="font-style:normal;font-weight:normal;">Section&#160;5.24</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section524_729691"><span style="font-style:normal;font-weight:normal;">Opinion of Financial Advisor</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-41</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section525_794962"><span style="font-style:normal;font-weight:normal;">Section&#160;5.25</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section525_794962"><span style="font-style:normal;font-weight:normal;">State Takeover Statutes</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-41</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section526_594722"><span style="font-style:normal;font-weight:normal;">Section&#160;5.26</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section526_594722"><span style="font-style:normal;font-weight:normal;">No Other Representations or Warranties</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-41</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:90.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ARTICLEVI_44914"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;VI COVENANTS</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-41</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section61_670277"><span style="font-style:normal;font-weight:normal;">Section&#160;6.1</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section61_670277"><span style="font-style:normal;font-weight:normal;">Operation of Parent&#8217;s Business</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-41</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section62_142042"><span style="font-style:normal;font-weight:normal;">Section&#160;6.2</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section62_142042"><span style="font-style:normal;font-weight:normal;">Operation of Company&#8217;s Business</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-43</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section63_595445"><span style="font-style:normal;font-weight:normal;">Section&#160;6.3</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section63_595445"><span style="font-style:normal;font-weight:normal;">Access and Investigation</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-45</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section64_236943"><span style="font-style:normal;font-weight:normal;">Section&#160;6.4</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section64_236943"><span style="font-style:normal;font-weight:normal;">No Solicitation</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-45</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section65_724438"><span style="font-style:normal;font-weight:normal;">Section&#160;6.5</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section65_724438"><span style="font-style:normal;font-weight:normal;">Notification of Certain Matters</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-46</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section66_54265"><span style="font-style:normal;font-weight:normal;">Section&#160;6.6</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section66_54265"><span style="font-style:normal;font-weight:normal;">[RESERVED]</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-46</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section67_877834"><span style="font-style:normal;font-weight:normal;">Section&#160;6.7</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section67_877834"><span style="font-style:normal;font-weight:normal;">[RESERVED]</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-46</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section68_781194"><span style="font-style:normal;font-weight:normal;">Section&#160;6.8</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section68_781194"><span style="font-style:normal;font-weight:normal;">Parent ESPP</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-46</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section69_228371"><span style="font-style:normal;font-weight:normal;">Section&#160;6.9</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section69_228371"><span style="font-style:normal;font-weight:normal;">Parent 401(K)&#160;Plan</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-46</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:90.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ARTICLEVII_796982"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;VII ADDITIONAL AGREEMENTS</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-47</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section71_165354"><span style="font-style:normal;font-weight:normal;">Section&#160;7.1</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section71_165354"><span style="font-style:normal;font-weight:normal;">Registration Statement; Proxy Statement</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-47</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section72_549754"><span style="font-style:normal;font-weight:normal;">Section&#160;7.2</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section72_549754"><span style="font-style:normal;font-weight:normal;">Company Stockholder Approval</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-48</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section73_635842"><span style="font-style:normal;font-weight:normal;">Section&#160;7.3</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section73_635842"><span style="font-style:normal;font-weight:normal;">Parent Stockholders&#8217; Meeting</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-49</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section74_201965"><span style="font-style:normal;font-weight:normal;">Section&#160;7.4</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section74_201965"><span style="font-style:normal;font-weight:normal;">Efforts; Transaction Litigation</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-50</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section75_568219"><span style="font-style:normal;font-weight:normal;">Section&#160;7.5</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section75_568219"><span style="font-style:normal;font-weight:normal;">Indemnification, Exculpation and Insurance</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-51</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section76_973255"><span style="font-style:normal;font-weight:normal;">Section&#160;7.6</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section76_973255"><span style="font-style:normal;font-weight:normal;">Section&#160;16 Matters</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-52</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section77_100583"><span style="font-style:normal;font-weight:normal;">Section&#160;7.7</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section77_100583"><span style="font-style:normal;font-weight:normal;">Disclosure</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-52</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section78_665636"><span style="font-style:normal;font-weight:normal;">Section&#160;7.8</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section78_665636"><span style="font-style:normal;font-weight:normal;">Listing</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-52</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section79_359500"><span style="font-style:normal;font-weight:normal;">Section&#160;7.9</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section79_359500"><span style="font-style:normal;font-weight:normal;">Tax Matters</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-53</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section710_169755"><span style="font-style:normal;font-weight:normal;">Section&#160;7.10</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section710_169755"><span style="font-style:normal;font-weight:normal;">Directors and Officers</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-53</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section711_397314"><span style="font-style:normal;font-weight:normal;">Section&#160;7.11</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section711_397314"><span style="font-style:normal;font-weight:normal;">Obligations of Merger Sub</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-53</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section712_304407"><span style="font-style:normal;font-weight:normal;">Section&#160;7.12</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section712_304407"><span style="font-style:normal;font-weight:normal;">Allocation Certificate</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-53</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section713_163861"><span style="font-style:normal;font-weight:normal;">Section&#160;7.13</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section713_163861"><span style="font-style:normal;font-weight:normal;">[RESERVED]</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-54</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section714_186496"><span style="font-style:normal;font-weight:normal;">Section&#160;7.14</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section714_186496"><span style="font-style:normal;font-weight:normal;">Concurrent Investment</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-54</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section715_969743"><span style="font-style:normal;font-weight:normal;">Section&#160;7.15</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section715_969743"><span style="font-style:normal;font-weight:normal;">Parent Equity Plans</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-54</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section716_431477"><span style="font-style:normal;font-weight:normal;">Section&#160;7.16</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section716_431477"><span style="font-style:normal;font-weight:normal;">Parent SEC Documents</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-54</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section717_570155"><span style="font-style:normal;font-weight:normal;">Section&#160;7.17</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section717_570155"><span style="font-style:normal;font-weight:normal;">Parent Legacy Assets</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-54</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section718_882484"><span style="font-style:normal;font-weight:normal;">Section&#160;7.18</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section718_882484"><span style="font-style:normal;font-weight:normal;">Arrangements Between Company and Company Guarantor</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-55</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ARTICLEVIII_68041"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;VIII CLOSING CONDITIONS</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-55</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section81_141667"><span style="font-style:normal;font-weight:normal;">Section&#160;8.1</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section81_141667"><span style="font-style:normal;font-weight:normal;">Conditions Precedent of each Party</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-55</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section82_329862"><span style="font-style:normal;font-weight:normal;">Section&#160;8.2</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section82_329862"><span style="font-style:normal;font-weight:normal;">Conditions Precedent to Obligation of the Company</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-55</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section83_748811"><span style="font-style:normal;font-weight:normal;">Section&#160;8.3</span></a></p></td><td colspan="2" style="vertical-align:top;width:77.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section83_748811"><span style="font-style:normal;font-weight:normal;">Conditions Precedent of Parent and Merger Sub</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-56</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ARTICLEIX_583502"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;IX TERMINATION</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-57</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section91_252464"><span style="font-style:normal;font-weight:normal;">Section&#160;9.1</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section91_252464"><span style="font-style:normal;font-weight:normal;">Termination</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-57</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section92_133533"><span style="font-style:normal;font-weight:normal;">Section&#160;9.2</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section92_133533"><span style="font-style:normal;font-weight:normal;">Effect of Termination</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-58</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section93_567854"><span style="font-style:normal;font-weight:normal;">Section&#160;9.3</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section93_567854"><span style="font-style:normal;font-weight:normal;">Expenses; Termination Fees</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-58</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ARTICLEX_187148"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;X GENERAL PROVISIONS</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-60</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section101_22200"><span style="font-style:normal;font-weight:normal;">Section&#160;10.1</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section101_22200"><span style="font-style:normal;font-weight:normal;">Non-survival of Representations and Warranties</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-60</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section102_992811"><span style="font-style:normal;font-weight:normal;">Section&#160;10.2</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section102_992811"><span style="font-style:normal;font-weight:normal;">Amendment or Supplement</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-60</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section103_194259"><span style="font-style:normal;font-weight:normal;">Section&#160;10.3</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section103_194259"><span style="font-style:normal;font-weight:normal;">Waiver</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-60</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section104_649791"><span style="font-style:normal;font-weight:normal;">Section&#160;10.4</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section104_649791"><span style="font-style:normal;font-weight:normal;">Fees and Expenses</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-60</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section105_490351"><span style="font-style:normal;font-weight:normal;">Section&#160;10.5</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section105_490351"><span style="font-style:normal;font-weight:normal;">Notices</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-60</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section106_455883"><span style="font-style:normal;font-weight:normal;">Section&#160;10.6</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section106_455883"><span style="font-style:normal;font-weight:normal;">Entire Agreement</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-61</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section107_917211"><span style="font-style:normal;font-weight:normal;">Section&#160;10.7</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section107_917211"><span style="font-style:normal;font-weight:normal;">No Third Party Beneficiaries</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-61</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section108_616450"><span style="font-style:normal;font-weight:normal;">Section&#160;10.8</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section108_616450"><span style="font-style:normal;font-weight:normal;">Guaranty</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-62</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section109_975228"><span style="font-style:normal;font-weight:normal;">Section&#160;10.9</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section109_975228"><span style="font-style:normal;font-weight:normal;">Governing Law</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-62</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section1010_639968"><span style="font-style:normal;font-weight:normal;">Section&#160;10.10</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section1010_639968"><span style="font-style:normal;font-weight:normal;">Submission to Jurisdiction</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-62</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section1011_81190"><span style="font-style:normal;font-weight:normal;">Section&#160;10.11</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section1011_81190"><span style="font-style:normal;font-weight:normal;">Assignment; Successors</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-62</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section1012_156371"><span style="font-style:normal;font-weight:normal;">Section&#160;10.12</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section1012_156371"><span style="font-style:normal;font-weight:normal;">Specific Performance</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-62</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section1013_760388"><span style="font-style:normal;font-weight:normal;">Section&#160;10.13</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section1013_760388"><span style="font-style:normal;font-weight:normal;">Severability</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-62</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section1014_210561"><span style="font-style:normal;font-weight:normal;">Section&#160;10.14</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section1014_210561"><span style="font-style:normal;font-weight:normal;">Waiver of Jury Trial</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section1015_734615"><span style="font-style:normal;font-weight:normal;">Section&#160;10.15</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section1015_734615"><span style="font-style:normal;font-weight:normal;">Counterparts</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section1016_258827"><span style="font-style:normal;font-weight:normal;">Section&#160;10.16</span></a></p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section1016_258827"><span style="font-style:normal;font-weight:normal;">Facsimile or .pdf Signature</span></a></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#Section1017_983127"><span style="font-style:normal;font-weight:normal;">Section&#160;10.17</span></a></p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section1017_983127"><span style="font-style:normal;font-weight:normal;">No Presumption Against Drafting Party</span></a></p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit&#160;A</p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form&#160;of Parent Support Agreement</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit&#160;B</p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form&#160;of Company Support Agreement</p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit&#160;C</p></td><td style="vertical-align:top;width:76.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form&#160;of Lock-Up Agreement</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit&#160;D</p></td><td style="vertical-align:top;width:76.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form&#160;of CVR Agreement</p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:90.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Schedule 1.1(a) Parent Net Cash Schedule</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:90.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Schedule 2.6(c) Board of Directors</p></td><td style="vertical-align:top;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-iv</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INDEX OF DEFINED TERMS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Definition</b></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:48.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Location</b></p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2014 Stock Incentive Plan</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2017 Stock Incentive Plan</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025 Equity Incentive Plan</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025 ESPP</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025 Plans</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AAA &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.6(e)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acceptable Confidentiality Agreement</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounting Firm</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.6(e)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition Inquiry</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition Proposal</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition Transaction</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Action &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.9</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Affiliate &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aggregate Valuation</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(i)(A)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agreement &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Allocation Certificate</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.13</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Anticipated Meeting Date</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.6(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Book-Entry Shares</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.3(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Business Day</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash Determination Time</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.6(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certificate of Merger</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;2.4</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certificates &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.3(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Closing &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;2.3</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Code &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble, Preamble</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Allocation Percentage</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(i)(B)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Audited Financial Statements</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.1(g)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Board</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Board Adverse Recommendation Change</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.2(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Board Recommendation</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.2(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Bylaws</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.1(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Charter</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.1(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Common Stock</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Disclosure Letter</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Article&#160;IV</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Employee</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.13</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Fundamental Representations</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Interim Financial Statements</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.1(g)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Merger Shares</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(i)(C)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Notice Period</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.2(c)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Outstanding Shares</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(i)(D)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Owned IP</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Plan</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Products</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.11(c)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Registered IP</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.19(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Service Providers</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.12(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Stockholder Approval</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Support Agreements</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Termination Fee</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.3(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Triggering Event</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Valuation</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(i)(E)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Concurrent Investment</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Concurrent Investment Amount</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-v</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Definition</b></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:48.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Location</b></p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Concurrent Investment Shares</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(i)(F)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Confidentiality Agreement</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contemplated Transactions</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.5(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">control &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current Offering Period</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;6.8</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current Premium</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.5(d)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CVR &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.7(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CVR Agreement</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.7(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">D&amp;O Indemnified Parties</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.5(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Data Processors</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.19(h)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware Secretary of State</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;2.4</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delivery Date</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.6(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DGCL &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dispute Notice</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.6(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dissenting Shares</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.5</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective Time</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;2.4</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee Plan</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">End Date</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;9.1(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Environmental Law</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.14(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ERISA &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exchange Act</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.5(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exchange Agent</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.3(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exchange Fund</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.3(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exchange Ratio</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(a)(i)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Excluded Shares</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(a)(iii)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDA &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.11(c)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDA Ethics Policy</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.11(i)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDCA &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.11(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Final Parent Net Cash</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.6(c)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form&#160;S-4</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.1(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GAAP&#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.1(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Guarantor Investment Amount</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Guarantor Securities Purchase Agremeent</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hazardous Substance</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.14(c)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Care Laws</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.11(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intellectual Property</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IT Systems</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.19(g)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">knowledge &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Law &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.5(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lock-Up Agreement</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Material Contracts</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.16(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Measurement Date</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;5.2(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Merger &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Merger Consideration</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(a)(i)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Merger Sub</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Multiemployer Plan</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nasdaq &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nasdaq Fees</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nasdaq Issuance Proposal</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nasdaq Listing Application</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.8</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nasdaq Reverse Stock Split</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net Cash</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-vi</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Definition</b></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:48.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Location</b></p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ordinary Course</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ordinary Course Agreement</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.15(g)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent 401(k)&#160;Plan</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;6.9</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Allocation Percentage</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(i)(G)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Board</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Board Adverse Recommendation Change</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.3(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Board Recommendation</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.3(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Capital Stock</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Charter Amendment</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;2.6(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Common Stock</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Common Stock Issuance</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;5.4(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Disclosure Letter</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Article&#160;V</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Equity Plans</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent ESPP</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Fundamental Representations</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Intervening Event</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.3(c)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent IT Systems</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;5.19(d)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Legacy Assets</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Legacy Business</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1 (ii)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Legacy Transaction</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;6.1(c)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Material Adverse Effect</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;5.1(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Material Contracts</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;5.16(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Net Cash Calculation</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.6(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Net Cash Schedule</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.6(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Notice Period</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.3(c)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Options</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent OTM Options</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Outstanding Shares</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(i)(H)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Owned IP</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Plan</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Preferred Stock</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Products</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;5.11(c)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Registered IP</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;5.19(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Restricted Stock Unit Awards</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent SEC Documents</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;5.6(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Stockholder Approval</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;5.4(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Stockholder Meeting</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.3(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Stockholder Proposals</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.3(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Support Agreements</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Termination Fee</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.3(d)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Triggering Event</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Valuation</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(i)(I)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Value Per Share</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(i)(G)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Warrant</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permits &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.10</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permitted Alternative Agreement</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;9.1(j)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permitted Liens</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.18(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Person &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personal Information</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.19(h)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Post-Closing Parent Shares</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.1(i)(J)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-Closing Distribution</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.7(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-Closing Period</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;6.1(a)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-vii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Definition</b></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:48.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Location</b></p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Privacy Laws</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.19(h)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proxy Statement</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.1(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Registration Statement</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.1(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Representative &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Response Date</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.6(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rights Agent</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.7(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Safety Notices</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.11(g)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sarbanes-Oxley Act</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;5.6(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SEC &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities Act</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.5(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities Purchase Agreement</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subsequent Transaction</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subsidiary &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Superior Offer</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Surviving Company</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;2.2</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Takeover laws</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.20</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Action</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.15(d)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Opinion</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.9(b)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Return</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxes &#160;</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade Approvals</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.24</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade Laws</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4.24</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction Expenses</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.1</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction Litigation</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.4(c)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Tax Treatment</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;7.9(a)</p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Withholding Agent</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3.4</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-viii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_926ac046_d863_436f_b1a3_42e2df73a7aa"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT AND PLAN OF MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">THIS AGREEMENT AND PLAN OF MERGER (this &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221;), dated as of June&#160;22, 2025, by and among Carisma Therapeutics Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</span>&#8221;), Azalea Merger Sub,&#160;Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Sub</span>&#8221;) and wholly owned subsidiary of Parent, OrthoCellix,&#160;Inc., a Delaware corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221;) and Ocugen,&#160;Inc., a Delaware corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Guarantor</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Parent and the Company intend to effect a merger of Merger Sub with and into the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger</span>&#8221;) in accordance with this Agreement and the General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DGCL</span>&#8221;). Upon consummation of the Merger, Merger Sub will cease to exist and the Company will become a wholly owned subsidiary of Parent;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Board of Directors of the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Board</span>&#8221;) has (i)&#160;determined that the Contemplated Transactions (as defined below) are fair to, advisable and in the best interests of the Company and its sole stockholder, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole stockholder of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Company Board has unanimously approved this Agreement and the Merger, with the Company continuing as the Surviving Company (as defined below), after the Effective Time (as defined below), pursuant to which, among other things, each share of common stock, par value $0.00001 per share, of the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Common Stock</span>&#8221;) (other than any Excluded Shares or Dissenting Shares) shall be converted into the right to receive a number of shares of common stock, par value $0.001 per share, of Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Common Stock</span>&#8221;) equal to the Exchange Ratio;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Board of Directors of Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Board</span>&#8221;) has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to this Agreement and the Parent Support Agreements and the constructive issuance by the Company of the shares of Company Common Stock to stockholders of Parent (as reflected in Rule&#160;145(a)&#160;of the Securities Act) (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Constructive Issuance</span>&#8221;), (iii)&#160;determined that the Reverse Stock Split Proposal (as defined below), among other things, is advisable and in the best interests of Parent and its stockholders and (iv)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to authorize the issuance of the Parent Common Stock in accordance with Nasdaq Listing Rule&#160;5635 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq Issuance Proposal</span>&#8221;), the Reverse Stock Split Proposal and the other Parent Stockholder Proposals;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Merger Sub is a newly incorporated Delaware corporation that is wholly owned by Parent, and has been formed for the sole purpose of effecting the Merger;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, on June&#160;19, 2025, the Guarantor contributed the NeoCart Assets to the Company pursuant to an Asset Contribution Agreement, by and between the Guarantor and the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contribution Agreement</span>&#8221;) in exchange for shares of Common Stock in the Company (such transactions, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contribution</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the board of directors of Merger Sub has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Merger Sub and its sole stockholder, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Parent, Merger Sub and the Company each desire to make certain representations, warranties, covenants and agreements in connection with the Merger and also to prescribe certain conditions to the Merger as specified herein;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement, the officers, directors and stockholders of Parent listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;A</span> of the Parent Disclosure Letter have entered into Parent Support Agreements, dated as of the date of this Agreement, in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span> (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Support Agreements</span>&#8221;), pursuant to which such officers, directors and stockholders have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Parent Common Stock in favor of the approval of this Agreement and thereby approve the Contemplated Transactions, including, but not limited to the Parent Stockholder Proposals.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, concurrently with the execution and delivery of this Agreement and as a condition and inducement of Parent&#8217;s willingness to enter into this Agreement, the officers, directors and stockholders of the Company listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;A</span> of the Company Disclosure Letter have entered into Company Support Agreements, dated as of the date of this Agreement, in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;B</span> (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Support Agreements</span>&#8221;), pursuant to which such officers, directors and stockholders have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Company Common Stock in favor of the adoption of this Agreement and thereby approve the Contemplated Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement, certain members of the Company Board that are continuing in such role following the Merger, certain members of the Parent Board that are continuing in such role following the Merger and stockholders of the Company listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;B</span> of the Company Disclosure Letter are executing lock-up agreements in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;C</span> (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lock-Up Agreement</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, for United States federal income Tax purposes, it is intended that (i)&#160;the Merger shall qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</span>&#8221;), shall also qualify as a non-taxable exchange of shares of Company Common Stock for shares of Parent Common Stock within the meaning of Section&#160;351(a)&#160;of the Code and (ii)&#160;this Agreement shall constitute a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Sections 1.368-2(g)&#160;and 1.368-3(a); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, it is expected that within twenty-four (24) hours after the Registration Statement is declared effective under the Securities Act, the stockholders of the Company will execute an action by written consent by all holders sufficient to authorize the Contemplated Transactions of outstanding shares of Company Common Stock (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Stockholder Approval</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, as an inducement by Guarantor for Parent to enter into this Agreement, Guarantor will execute a Securities Purchase Agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Guarantor Securities Purchase Agreement</span>&#8221;) committing to purchase not less than $5,000,000 of shares of Parent Common Stock, substantially contemporaneously with the Closing (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Guarantor Investment Amount</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the premises, and of the representations, warranties, covenants and agreements contained herein, and intending to be legally bound hereby, Parent, Merger Sub and the Company hereby agree as follows:</p><a id="ARTICLEI_641964"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DEFINITIONS&#160;&amp; INTERPRETATIONS</b></p><a id="Section11_796897"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">Section&#160;1.1&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Definitions</span>. For purposes of this Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2014 Stock Incentive Plan</span>&#8221; means Parent&#8217;s Amended and Restated 2014 Stock Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2017 Stock Incentive Plan</span>&#8221; means Parent&#8217;s 2017 Stock Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2025 Equity Incentive Plan</span>&#8221; shall mean an equity incentive plan of Parent in form and substance as designated by the Company and reasonably acceptable to Parent, reserving for issuance a number of shares of Parent Common Stock to designated by the Company and consented to by Parent (such consent not to be unreasonably withheld, conditioned or delayed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2025 ESPP</span>&#8221; shall mean an &#8220;employee stock purchase plan&#8221; of Parent in form and substance as designated by the Company and reasonably acceptable to Parent, reserving for issuance a number of shares of Parent Common Stock to designated by the Company and consented to by Parent (such consent not to be unreasonably withheld, conditioned or delayed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2025 Plans</span>&#8221; shall mean both the 2025 Equity Incentive Plan and 2025 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceptable Confidentiality Agreement</span>&#8221; means a confidentiality agreement containing terms not materially less restrictive in the aggregate to the counterparty thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any standstill, non-solicitation or no hire provisions. Notwithstanding the foregoing, a Person who has previously entered into a confidentiality agreement with Parent or the Company, as applicable, relating to a potential Acquisition Proposal on terms that are not materially less restrictive than the Confidentiality Agreement with respect to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">the scope of coverage and restrictions on disclosure and use shall not be required to enter into a new or revised confidentiality agreement, and such existing confidentiality agreement shall be deemed to be an Acceptable Confidentiality Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acquisition Inquiry</span>&#8221; means, with respect to a party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to the other party) that would reasonably be expected to lead to an Acquisition Proposal, other than the Concurrent Investment, or (subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.13</span>) a Parent Legacy Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acquisition Proposal</span>&#8221; means, with respect to either party hereto, any proposal or offer (whether written or oral) from any Person (other than the other party or any of its Representatives) contemplating or otherwise relating to an Acquisition Transaction (other than in connection with the Concurrent Investment, or (subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.13</span>) a Parent Legacy Transaction).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acquisition Transaction</span>&#8221; means any transaction or series of related transactions (other than the Concurrent Investment or any Parent Legacy Transaction) involving:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i)&#160;in which a party is a constituent entity, (ii)&#160;in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules&#160;promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a party or any of its Subsidiaries or (iii)&#160;in which a party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such party or any of its Subsidiaries; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>&#8239;any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value of the fair market value of the assets of a party and its Subsidiaries taken as a whole.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</span>&#8221; of any Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Day</span>&#8221; means any day other than a Saturday, a Sunday or a day on which banks in New York, New York are authorized or required by applicable Law to be closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concurrent Investment</span>&#8221; means an aggregate commitment of not less than the Concurrent Investment Amount pursuant to which certain investors will agree, subject to the terms and conditions of the applicable Securities Purchase Agreement, to subscribe for and purchase a number of shares of Parent Common Stock substantially contemporaneously with the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(m)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concurrent Investment Amount</span>&#8221; means $25,000,000. For the avoidance of doubt, the Concurrent Investment Amount shall be inclusive of the Guarantor Investment Amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(n)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Fundamental Representations</span>&#8221; means each of the representations and warranties of the Company set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.1</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.4</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.25</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(o)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Owned IP</span>&#8221; means all Intellectual Property owned by the Company in whole or in part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(p)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Plan</span>&#8221; means each Employee Plan that is sponsored, maintained, or contributed (or required to be contributed) to by the Company or Guarantor for the benefit of current or former employees, officers, directors or other service providers of Guarantor or any of its Subsidiaries providing services to the Company or with respect to which the Company has any liability, contingent or otherwise, other than any plan, program, arrangement, agreement or policy mandated by applicable Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(q)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Triggering Event</span>&#8221; shall be deemed to have occurred if: (a)&#160;the Company Board shall have publicly approved, endorsed or recommended any Acquisition Proposal, (b)&#160;the Company shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement) permitted pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span> or (c)&#160;the Company shall have materially and willfully breached its obligations under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4(a)</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(r)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality Agreement</span>&#8221; means that certain Mutual Non-Disclosure Agreement, dated as of April&#160;7, 2025, between the Company and Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(s)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contemplated Transactions</span>&#8221; means the Merger, the Constructive Issuance and the other transactions contemplated by this Agreement (other than the Parent Legacy Transaction and Parent Charter Amendment) including the CVR Agreement, the Concurrent Investment and the Nasdaq Reverse Stock Split (to the extent applicable and deemed necessary by Parent and the Company).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(t)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">control</span>&#8221; (including the terms &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">controlled</span>,&#8221; &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">controlled by</span>&#8221; and &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">under common control with</span>&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(u)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee Plan</span>&#8221; means each &#8220;employee benefit plan&#8221; (within the meaning of section&#160;3(3)&#160;of ERISA, whether or not subject to ERISA), Multiemployer Plans, and all stock purchase, stock option, phantom stock or other equity-based plan, severance, employment, change-in-control, fringe benefit, bonus, incentive, deferred compensation, compensation, supplemental retirement, health, life, or disability insurance, dependent care, vacation and all other employee benefit and compensation plans, agreements, programs, policies or other arrangements, whether or not subject to ERISA (including any funding mechanism therefor now in effect or required in the future as a result of the Contemplated Transactions or otherwise), whether formal or informal, written or oral.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ERISA</span>&#8221; means the U.S. Employee Retirement Income Security Act of 1974, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(w)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</span>&#8221; means all intellectual property rights of any kind, including all of the following: (i)&#160;trademarks or service marks (whether registered or unregistered), trade names, domain names, social media user names, social media addresses, logos, slogans, and trade dress, including applications to register any of the foregoing, together with the goodwill symbolized by any of the foregoing; (ii)&#160;patents, utility models and any similar or equivalent statutory rights with respect to the protection of inventions, and all applications for any of the foregoing, together with all re-issuances, continuations, continuations-in-part, divisionals, revisions, extensions and reexaminations thereof; (iii)&#160;copyrights (registered and unregistered) and applications for registration; (iv)&#160;trade secrets and customer lists, in each case to the extent any of the foregoing derives economic value (actual or potential) from not being generally known to other Persons who can obtain economic value from its disclosure or use, and other confidential information (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trade Secrets</span>&#8221;); and (v)&#160;any other proprietary or intellectual property rights of any kind or nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">knowledge</span>&#8221; of any party means (i)&#160;the actual knowledge of any executive officer of such party or other officer having primary responsibility for the relevant matter or any employee consultant or interim officer serving similar roles and (ii)&#160;any fact or matter which any such Person would be expected to discover or otherwise become aware of in the course of conducting due inquiry, consistent with such Person&#8217;s title and responsibilities, concerning the existence of the relevant matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(y)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing and Supply Agreement</span>&#8221; means a manufacturing and supply agreement to be negotiated (in a form and substance subject to Parent&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed) pursuant to Section&#160;7.18, the material terms of which will be substantially final on or prior to July&#160;11, 2025, and to be entered into between the Guarantor and the Company on or prior to the Closing Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(z)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Multiemployer Plan</span>&#8221; shall have the meaning set forth in Section&#160;3(37) of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(aa)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq</span>&#8221; means The Nasdaq Stock Market LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(bb)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq Fees</span>&#8221; means all Nasdaq fees associated with any action contemplated by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.8</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(cc)&#160;&#8239;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq Reverse Stock Split</span>&#8221; means a reverse stock split of all outstanding shares of Parent Common Stock at a reverse stock split ratio as mutually agreed to by Parent and the Company that is effectuated by Parent for the purpose of maintaining or achieving compliance with Nasdaq listing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(dd)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NeoCart Assets</span>&#8221; has the meaning set forth in the Contribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">(ee)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net Cash</span>&#8221; means, without duplication, (i)&#160;the sum of Parent&#8217;s unrestricted cash, cash equivalents and short-term marketable securities and the cash consideration attributable to the sale of Legacy Assets, solely to the extent not received by </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Parent as of the Effective Time and solely to the extent Parent and the Company mutually agree will be received within ninety (90) days following the Closing, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">plus</span> (ii), solely to the extent Parent and the Company mutually agree such funds will be available to and usable by Parent within ninety (90) days of the Closing Date, all prepaid expenses and deposits, credits and refunds set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1(a)(ii)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</span> (iii)&#160;the sum of Parent&#8217;s short-term and long-term liabilities (including any outstanding liabilities with respect to Parent&#8217;s obligations with respect to the items set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1(a)(iii)</span>) (including all accounts payable and indebtedness), including lease termination costs, all actual costs and expenses (and reasonably projected costs and expenses as mutually agreed between Parent and the Company, acting in good faith) relating to the winding down of the Parent Legacy Business and any related prepayment penalties and premiums and any unpaid Transaction Expenses (including any costs, fees or other liabilities, including Taxes, related to the premiums, commissions and other fees payable in connection with obtaining Parent&#8217;s D&amp;O tail policy as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5(d)</span>), <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</span> (iv)&#160;any and all change in control payments and severance payments, in each case, payable to Parent&#8217;s employees, and any employer-side payroll or similar Taxes owed in connection with the foregoing or in connection with the exercise of Parent Options and vesting and settlement of Parent Restricted Stock Unit Awards, in each case to the extent payable in connection with the consummation of the Contemplated Transactions, and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</span> (v)&#160;50% of the mutually agreed estimated settlement amounts for any Transaction Litigation existing as of the Closing. Set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1(a)</span>&#160;of the Parent Disclosure Letter is an illustrative example of the calculation of Net Cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(ff)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ordinary Course</span>&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its business and consistent with its past practice or, with respect to the Company, the customary practices of a recently formed company at a similar stage of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(gg)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Capital Stock</span>&#8221; means the Parent Common Stock and the Parent Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(hh)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Equity Plans</span>&#8221; means each of Parent&#8217;s 2014 Stock Incentive Plan, 2017 Stock Incentive Plan and Parent ESPP in each case, as amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(ii)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent ESPP</span>&#8221; means Parent&#8217;s Amended and Restated 2014 Employee Stock Purchase Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(jj)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Fundamental Representations</span>&#8221; means each of the representations and warranties of Parent and Merger Sub set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.1</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.3</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.4</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.25</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(kk)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Legacy Assets</span>&#8221; means all assets, technology and Intellectual Property of Parent, as they existed at any time prior to the date of this Agreement, relating to the Company&#8217;s research and development programs, as conducted and proposed to be conducted, including its CT-0525, CT-0508, CT-1119 and its engineered macrophage, and <i style="font-style:italic;">in vivo</i> mRNA/lipid nanopartical CAR-M programs and its partnership with ModernaTX,&#160;Inc., including, for purposes of clarity, the tangible and intangible assets of Parent relating thereto (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Legacy Business</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(ll)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Options</span>&#8221; means options to purchase shares of Parent Common Stock issued pursuant to a Parent Equity Plan, but excluding, for the avoidance of doubt, the Parent ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(mm)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent OTM Option</span>&#8221; means Parent Options with an exercise price greater than $2.00 per share (before giving effect to the Nasdaq Reverse Stock Split).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(nn)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Owned IP</span>&#8221; means all Intellectual Property owned by Parent in whole or in part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(oo)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Plan</span>&#8221; means each Employee Plan that is sponsored, maintained, or contributed (or required to be contributed) to by Parent or any of its Subsidiaries for the benefit of current or former employees, officers, directors or other service providers of Parent or any of its Subsidiaries or with respect to which Parent or any of its Subsidiaries has any liability, contingent or otherwise, other than any plan, program, arrangement, agreement or policy mandated by applicable Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(pp)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Preferred Stock</span>&#8221; means the shares of Parent&#8217;s capital stock designated as preferred stock, par value $0.001 per share of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(qq)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Restricted Stock Unit Awards</span>&#8221; means each award of restricted stock unit awards with respect to shares of Parent Common Stock issued pursuant to a Parent Equity Plan or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(rr)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Warrant</span>&#8221; means warrants to purchase shares of Parent Capital Stock issued by Parent.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(ss)&#160;&#8239;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Triggering Event</span>&#8221; shall be deemed to have occurred if: (i)&#160;Parent shall have failed to include in the Proxy Statement the Parent Board Recommendation (as defined below), (ii)&#160;the Parent Board or any committee thereof shall have made a Parent Board Adverse Recommendation Change or approved, endorsed or recommended any Acquisition Proposal, (iii)&#160;Parent shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement permitted pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span>), (iv)&#160;a tender offer or exchange offer for outstanding shares of Parent Common Stock is commenced, and the Parent Board (or any committee thereof) recommends that the stockholders of Parent tender their shares in such tender or exchange offer or, within ten (10)&#160;Business Days after the commencement of such tender offer or exchange offer, the Parent Board fails to recommend against acceptance of such offer, (v)&#160;Parent shall have failed to issue a press release confirming the Parent Board Recommendation within ten (10)&#160;Business Days following the Company&#8217;s written request to Parent to issue such press release in response to any other publicly announced Acquisition Proposal with respect to Parent or (vi)&#160;Parent shall have materially and willfully breached its obligations under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(tt)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Person</span>&#8221; means an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, including any Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(uu)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representative</span>&#8221; means a party&#8217;s directors, officers, employees, investment bankers, financial advisors, attorneys, accountants or other advisors, agents or representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(vv)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC</span>&#8221; means the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(ww)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Purchase Agreement</span>&#8221; means each Contract, in form and substance as agreed to in writing between Parent and the Company, entered into on or following the date hereof and prior to the Closing pursuant to which the signatory thereto has agreed to purchase for cash shares of Parent Common Stock immediately following the Closing pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.14</span> or as otherwise agreed in writing between Parent and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(xx)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsequent Transaction</span>&#8221; means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(yy)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiary</span>&#8221; means, with respect to any Person, any other Person of which stock or other equity interests having ordinary voting power to elect more than 50% of the board of directors or other governing body are owned, directly or indirectly, by such first Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(zz)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Superior Offer</span>&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that: (i)&#160;was not obtained or made as a direct or indirect result of a breach of (or in violation of) the Agreement, and (ii)&#160;is on terms and conditions that the Parent Board or the Company Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other party to the Agreement to amend the terms of the Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to the Parent&#8217;s stockholders or the Company&#8217;s stockholders, as applicable, than the terms of the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(aaa)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Return</span>&#8221; means any return, declaration, report, certificate, bill, election, claim for refund, information return, statement or other written information and any other document filed or supplied or required to be filed or supplied to any Governmental Entity with respect to Taxes, including any schedule, attachment or supplement thereto, and including any amendment thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(bbb)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</span>&#8221; means all U.S. federal, state and local and non-U.S. net income, gross income, gross receipts, sales, use, stock, ad valorem, transfer, transaction, franchise, profits, gains, registration, license, wages, lease, service, service use, employee and other withholding, imputed underpayment, social security, unemployment, welfare, disability, payroll, employment, excise, severance, stamp, occupation, workers&#8217; compensation, premium, real property, personal property, windfall profits, net worth, capital, value-added, alternative or add-on minimum, customs duties, estimated and other taxes, fees, assessments, charges or levies in the nature of a tax (whether imposed, assessed, determined, administered, enforced or collected directly or through withholding and including any amounts resulting from the failure to file any Tax Return), whether disputed or not, together with any interest and any penalties, or additions to tax with respect thereto (or attributable to the nonpayment thereof).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(ccc)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Expenses</span>&#8221; means the aggregate amount (without duplication) of all costs, fees, Taxes and expenses incurred by Parent and Merger Sub, or for which Parent or Merger Sub are or may become liable in connection with the Contemplated Transactions and the negotiation, preparation and execution of this Agreement or any other agreement, document, instrument, filing, certificate, schedule, exhibit, letter or other document prepared or executed in connection with the Contemplated Transactions, including (i)&#160;the amount of fees and expenses payable to financial advisors, investment bankers, legal counsel, accountants, brokers, consultants, Tax advisors, transfer agents, proxy solicitor and other advisors of Parent, including the employer portion of any payroll or similar Taxes incurred or to be incurred by Parent or Merger Sub with respect to the payment of any item listed in this definition of Transaction Expenses; (ii)&#160;50% of the fees paid to the SEC in connection with filing the Registration Statement, the Proxy Statement, and any amendments and supplements thereto, with the SEC; (iii)&#160;50% of the fees and expenses incurred in connection with the printing, mailing and distribution of the Registration Statement and any amendments and supplements thereto; (iv)&#160;50% of the fees and expenses incurred in connection with the Exchange Agent; (v)&#160;50% of the Nasdaq Fees and (vi)&#160;100% of the fees of the Rights Agent under the CVR Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(ddd)&#160;&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Services Agreement</span>&#8221; means a transition services agreement to be negotiated in a form and substance subject to Parent&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed) pursuant to Section&#160;7.18, the material terms of which will be substantially final on or prior to July&#160;11, 2025, and to be entered into between the Guarantor and the Company on or prior to the Closing Date.</p><a id="Section12_173360"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;1.2&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</span>. When a reference is made in this Agreement to a Section, Article, Exhibit&#160;or Schedule such reference shall be to a Section, Article, Exhibit&#160;or Schedule of this Agreement unless otherwise indicated. The table of contents and headings contained in this Agreement or in any Exhibit&#160;or Schedule are for convenience of reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Any capitalized terms used in any Exhibit&#160;or Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement. All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth herein. The word &#8220;including&#8221; and words of similar import when used in this Agreement will mean &#8220;including, without limitation,&#8221; unless otherwise specified. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement shall refer to the Agreement as a whole and not to any particular provision in this Agreement. The term &#8220;or&#8221; is not exclusive. The word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall.&#8221; References to days mean calendar days unless otherwise specified.</p><a id="Section13_926082"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;1.3&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Currency</span>. All references to &#8220;dollars&#8221; or &#8220;$&#8221; or &#8220;US$&#8221; in this Agreement refer to United States dollars, which is the currency used for all purposes in this Agreement.</p><a id="ARTICLEII_431724"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE MERGER</b></p><a id="Section21_659566"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;2.1&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Formation of Merger Sub</span>. Parent has caused Merger Sub to be organized under the laws of the State of Delaware.</p><a id="Section22_187189"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;2.2&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Merger</span>. Upon the terms and subject to the conditions set forth in this Agreement and in accordance with the DGCL, at the Effective Time, Merger Sub shall be merged with and into the Company, the separate corporate existence of Merger Sub shall cease, and the Company shall continue as the surviving company of the Merger and a wholly owned subsidiary of Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surviving Company</span>&#8221;).</p><a id="Section23_358929"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;2.3&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</span>. Unless this Agreement is earlier terminated pursuant to the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span>, and subject to the satisfaction or waiver of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VIII</span>, the consummation of the Merger (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</span>&#8221;) shall take place remotely by the electronic exchange of documents, as promptly as practicable (but in no event later than the second Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VIII</span>, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions), unless another time, date and place is mutually agreed upon by Parent and the Company in writing. The date on which the Closing actually takes place is referred to as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Date</span>.&#8221;</p><a id="Section24_590246"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section&#160;2.4&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Time</span>. Upon the terms and subject to the provisions of this Agreement, at the Closing, the parties shall cause the Merger to be consummated by executing and filing a certificate of merger in a form to be mutually agreed by the parties hereto (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificate of Merger</span>&#8221;) with the Secretary of State of the State of Delaware (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware Secretary of State</span>&#8221; ), in such form as is required by, and executed in accordance with the relevant provisions of the DGCL. The Merger shall become effective at </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the time of the filing of such Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Certificate of Merger (the time as of which the Merger becomes effective being the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Time</span>&#8221;).</p><a id="Section25_232200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;2.5&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effects of the Merger</span>. At and after the Effective Time, the Merger shall have the effects set forth in this Agreement and in the relevant provisions of the DGCL. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, all the property, rights, privileges, powers and franchises of the Company and Merger Sub shall vest in the Surviving Company, and all debts, liabilities and duties of the Company and Merger Sub shall become the debts, liabilities and duties of the Surviving Company.</p><a id="Section26_743991"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;2.6&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Governance</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Certificate of Incorporation</span>. At the Effective Time, or at such other time as Parent and the Company shall agree in writing, Parent shall file an amendment to the certificate of incorporation to (i)&#160;change the name of Parent to &#8220;OrthoCellix,&#160;Inc.&#8221; or such other name as determined by the Company, (ii)&#160;increase the number of shares of Parent Capital Stock that Parent is authorized to issue to a number mutually agreed between Parent and the Company, such amount to be sufficient to allow for consummation of the Contemplated Transactions and (iii)&#160;make such other changes as mutually agreeable to Parent and the Company (such amendment, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Charter Amendment</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Bylaws</span>. At the Effective Time, the bylaws of Parent shall be identical to the bylaws of Parent immediately prior to the Effective Time, until thereafter amended in accordance with their terms and as provided by applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board of Directors</span>. The parties shall take all action necessary (including, to the extent necessary, procuring the resignation of any directors on the Parent Board immediately prior to the Effective Time) so that, as of the Effective Time, the Board of Directors shall upon the Effective Time initially include the Persons set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 2.6(c)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Officers</span>. The parties shall take all action necessary (including, to the extent necessary, procuring the resignation or removal of any officers of Parent immediately prior to the Effective Time) so that, as of the Effective Time, the Parent officers shall initially consist of the Persons designated by the Company as of the Effective Time.</p><a id="Section27_384720"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;2.7&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surviving Company and Surviving Company Governance</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>At the Effective Time:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(i)&#160;&#160;&#160;&#160;&#160;The Certificate of Incorporation of the Surviving Company shall, by virtue of the Merger and without any further action, be amended and restated to read in its entirety as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span> to the Certificate of Merger, and, as so amended and restated, shall be the Certificate of Incorporation of the Surviving Company until thereafter amended in accordance with applicable Law;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(ii)&#160;&#160;&#160;&#160;The bylaws of the Surviving Company shall be amended and restated to read in their entirety as the bylaws of Merger Sub as in effect immediately prior to the Effective Time (except that references to the name of Merger Sub shall be replaced with references to the name of the Surviving Company), and, as so amended and restated, shall be the bylaws of the Surviving Company until thereafter amended in accordance with applicable Law;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iii)&#160;&#160;&#160;The directors of the Surviving Company shall be such persons as are designated by the Company prior to the Effective Time, each to hold office in accordance with the certificate of incorporation and bylaws of the Surviving Company until the earlier of their resignation or removal or until their respective successors are duly elected and qualified; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iv)&#160;&#160;&#160;The officers of the Surviving Company shall be such persons as are designated by the Company prior to the Effective Time, each to hold office in accordance with the certificate of incorporation and bylaws of the Surviving Company until the earlier of their resignation or removal or until their respective successors are duly elected and qualified.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="ARTICLEIII_257623"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EFFECT ON THE CAPITAL STOCK OF THE CONSTITUENT COMPANIES; EXCHANGE OF CERTIFICATES</b></p><a id="Section31_103102"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;3.1&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conversion of Capital Stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>At the Effective Time, by virtue of the Merger and without any action on the part of Parent, Merger Sub, the Company or the holders of any shares of capital stock of the Parent, Merger Sub or the Company:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(f)</span>, each share of Company Common Stock issued and outstanding immediately prior to the Effective Time (other than any Excluded Shares or Dissenting Shares) shall be converted into and become exchangeable for the right to receive, a number of shares of Parent Common Stock equal to the Exchange Ratio (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Consideration</span>&#8221; ). As of the Effective Time, all such shares of Company Common Stock shall no longer be outstanding and shall automatically be cancelled and shall cease to exist, and shall thereafter only represent the right to receive the Merger Consideration. For purposes of this Agreement, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Ratio</span>&#8221; shall mean the ratio (rounded to four decimal places) equal to (A)&#160;the Company Merger Shares divided by (B)&#160;the Company Outstanding Shares, in which:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(A)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Aggregate Valuation</span>&#8221; means the <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">sum</span> of (i)&#160;the Company Valuation and (ii)&#160;the Parent Valuation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(B)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Allocation Percentage</span>&#8221; means the quotient (rounded to two decimal places) determined by dividing (i)&#160;the Company Valuation by (ii)&#160;the Aggregate Valuation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(C)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Merger Shares</span>&#8221; means (i)&#160;the product determined by multiplying (x)&#160;the Post-Closing Parent Shares by (y)&#160;the Company Allocation Percentage minus (ii)&#160;the Concurrent Investment Shares<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(D)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Outstanding Shares</span>&#8221; means the total number of shares of Company Common Stock outstanding immediately prior to the Effective Time, expressed on a fully diluted and as-converted-to-Company Common Stock basis assuming, without limitation or duplication the rights or commitments to receive shares of Company Common Stock (or securities convertible or exercisable into shares of Company Common Stock), whether conditional or unconditional, that are outstanding as of immediately prior to the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(E)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Valuation</span>&#8221; means (i)&#160;$135,000,000 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</span> (ii)&#160;the amount, if any, by which the Concurrent Investment Amount is less than $25,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(F)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concurrent Investment Shares</span>&#8221; means the number of shares of Parent Common Stock issued to investors in respect of the first $25,000,000 of Parent Common Stock purchased pursuant to the Concurrent Investment (or, if the aggregate amount of the Concurrent Investment is less than $25,000,000, such number of shares of Parent Common Stock issued to investors pursuant to the Concurrent Investment).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(G)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Allocation Percentage</span>&#8221; means the quotient (rounded to two decimal places) determined by dividing (i)&#160;the Parent Valuation by (ii)&#160;the Aggregate Valuation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(H)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Outstanding Shares</span>&#8221; means (i)&#160;the total number of shares of Parent Capital Stock outstanding immediately prior to the Effective Time (after giving effect to the Nasdaq Reverse Stock Split), assuming the exercise, conversion or exchange of all options, warrants, conversion rights, exchange rights or any other rights to receive shares of Parent Capital Stock which exist immediately prior to the Effective Time, (ii)&#160;without duplication of any amounts set forth in the foregoing <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clause (i)</span>, the exercise of Parent Options outstanding as of immediately prior to the Effective Time and (iii)&#160;without duplication of any amounts set forth in the foregoing <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clauses (i)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(ii)</span>, the settlement in shares of Parent Common Stock of Parent Restricted Stock Unit Awards outstanding as of immediately prior to the Effective Time. For the avoidance of doubt, Parent OTM Options and Parent Warrants, shall not be included in the total number of shares of Parent Capital Stock for purposes of determining the Parent Outstanding Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(I)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Valuation</span>&#8221; means (i)&#160;$15,000,000, minus (ii)&#160;the amount by which Net Cash is less than $0 (if any) and plus (iii)&#160;the amount by which Net Cash is more than $0 (if any).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(J)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Value Per Share</span>&#8221; equals the Parent Valuation divided by the number of Parent Outstanding Shares (rounded to four decimal places).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(K)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Post-Closing Parent Shares</span>&#8221; means the quotient determined by dividing (i)&#160;the Parent Outstanding Shares by (ii)&#160;the Parent Allocation Percentage. For the avoidance of doubt, the Post-Closing Parent Shares shall include the Concurrent Investment Shares but shall exclude any shares issued pursuant to the Concurrent Investment in excess of the Concurrent Investment Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt and for illustrative purposes only, sample &#8220;Exchange Ratio&#8221;, &#8220;Company Valuation&#8221; and &#8220;Parent Valuation&#8221; calculations are set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)(F)</span>&#160;of the Parent Disclosure Letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(ii)&#160;&#160;&#160;&#160;At the Effective Time, each share of Parent Capital Stock issued and outstanding immediately prior to the Effective Time shall remain outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iii)&#160;&#160;&#160;Each share of Company Common Stock held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Shares</span>&#8221;) shall automatically be cancelled and shall cease to exist, and no consideration shall be delivered in exchange therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iv)&#160;&#160;&#160;Each share of common stock, par value $0.001 per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into and become one validly issued, fully paid and non-assessable share of common stock, par value $0.001 per share, of the Surviving Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If, between the date of this Agreement and the Effective Time, the outstanding Company Common Stock or Parent Capital Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization (including the Nasdaq Reverse Stock Split to the extent such split has not previously been taken into account in calculating the Exchange Ratio), split, combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of Company Common Stock, and Parent Capital Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares or other like change; provided, however, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Common Stock or Parent Capital Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement.</p><a id="Section32_339264"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;3.2&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[RESERVED.]</span></p><a id="Section33_126427"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;3.3&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange and Payment</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent shall issue and deposit (or cause to be deposited) with a bank or trust company mutually agreed upon by the Company and Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Agent</span>&#8221;), in trust for the benefit of holders of shares of Company Common Stock immediately prior to the Effective Time (other than holders to the extent they hold Excluded Shares or Dissenting Shares), book-entry shares (or certificates if requested) representing the shares of Parent Capital Stock issuable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)</span>. In addition, Parent shall make available by depositing with the Exchange Agent, as necessary from time to time after the Effective Time any dividends or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>. All certificates representing shares of Parent Capital Stock, and any dividends, distributions and cash deposited with the Exchange Agent are hereinafter referred to as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Fund</span>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>As soon as reasonably practicable after the Effective Time and in any event not later than the third (3<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">rd</sup>) Business Day following the Closing Date, the parties shall cause the Exchange Agent to mail to each holder of record of a certificate that immediately prior to the Effective Time represented outstanding shares of Company Common Stock (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificates</span>&#8221;) and to each holder of record of uncertificated shares of Company Common Stock represented by book entry (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Book-Entry Shares</span>&#8221;) that were converted into the right to receive the Merger Consideration (together with any dividends or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>), (i)&#160;a form of letter of transmittal (which shall specify that delivery shall be effected, and risk of loss and title to any Certificates held by such Person shall pass, only upon proper delivery of such Certificates, if any, and identification of the Book-Entry Shares, if any, to the Exchange Agent, and which letter shall be in customary form and contain such other provisions as Parent or the Exchange Agent may reasonably specify) and (ii)&#160;instructions for use in effecting the surrender of any such Certificates and identifying such Book-Entry Shares in exchange for the Merger Consideration (together with any dividends or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>). Upon surrender of a Certificate and identification of the Book-Entry Shares, as applicable, to the Exchange Agent, together with such letter of transmittal, duly completed and validly executed in accordance with the instructions thereto, and such other documents as the Exchange Agent may reasonably require, the holder of such Certificate or Book-Entry Share shall be entitled to receive in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">exchange for the shares of Company Common Stock formerly represented by such Certificate or Book-Entry Share (other than Excluded Shares or Dissenting Shares) (A)&#160;that number of whole shares of Parent Capital Stock (after taking into account all shares of Company Common Stock then held by such holder under all Certificates so surrendered and Book-Entry Shares so identified) to which such holder of Company Common Stock shall have become entitled pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)</span>&#160;(which shall be in uncertificated book-entry form unless a physical certificate is requested), and (B)&#160;any dividends or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>, and any Certificate so surrendered, together with any Book-Entry Shares, shall forthwith be cancelled. No interest will be paid or accrued on any unpaid dividends and distributions, if any, payable to holders of Certificates or Book-Entry Shares. Until surrendered as contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span>, each Certificate or Book-Entry Share shall be deemed after the Effective Time to represent only the right to receive the Merger Consideration payable in respect thereof (together with any dividends or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>If payment of the Merger Consideration is to be made to a Person other than the Person in whose name the surrendered Certificate or Book-Entry Share is registered, it shall be a condition of payment that such Certificate so surrendered shall be properly endorsed or shall be otherwise in proper form for transfer or such Book-Entry Share shall be properly transferred and that the Person requesting such payment shall have paid any transfer and other Taxes required by reason of the payment of the Merger Consideration to a Person other than the registered holder of such Certificate or Book-Entry Share or shall have established to the satisfaction of Parent that such Tax is not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>(i)<span style="display:inline-block;width:8.56pt;"></span>No dividends or other distributions with respect to Parent Capital Stock with a record date after the Effective Time shall be paid to the holder of any unsurrendered Certificate with respect to the shares of Parent Capital Stock that the holder thereof has the right to receive upon the surrender thereof until the holder thereof shall surrender such Certificate in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span>. Following the surrender of a Certificate in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span>, there shall be paid to the record holder thereof, without interest, (A)&#160;promptly after such surrender, the amount of any dividends or other distributions with a record date after the Effective Time theretofore paid with respect to such whole shares of Parent Capital Stock, and (B)&#160;at the appropriate payment date, the amount of dividends or other distributions with a record date after the Effective Time but prior to such surrender and a payment date subsequent to such surrender payable with respect to such whole shares of Parent Capital Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Holders of Book-Entry Shares who are entitled to receive shares of Parent Capital Stock under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span> shall be paid (A)&#160;at the time of payment of such Parent Capital Stock by the Exchange Agent under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span>, the amount of dividends or other distributions with a record date after the Effective Time theretofore paid with respect to such whole shares of Parent Capital Stock, and (B)&#160;at the appropriate payment date, the amount of dividends or other distributions with a record date after the Effective Time but prior to the time of such payment by the Exchange Agent under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span> and a payment date subsequent to the time of such payment by the Exchange Agent under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span> payable with respect to such whole shares of Parent Capital Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>The Merger Consideration (together with any dividends or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>) shall be deemed to have been issued and paid in full satisfaction of all rights pertaining to the shares of Company Common Stock formerly represented by such Certificates or Book-Entry Shares. At the Effective Time, the stock transfer books of the Company shall be closed and there shall be no further registration of transfers of the shares of Company Common Stock that were outstanding immediately prior to the Effective Time. If, after the Effective Time, Certificates are presented to the Surviving Company or the Exchange Agent for transfer or transfer is sought for Book-Entry Shares, such Certificates or Book-Entry Shares shall be cancelled and exchanged as provided in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>No fractional shares of Parent Capital Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. For purposes of calculating the Merger Consideration issuable to each holder of Company Common Stock, the number of shares of Company Common Stock to be issued shall be rounded down to the nearest whole number (without any consideration payable for such fractional shares).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>Any portion of the Exchange Fund that remains undistributed to the holders of Certificates or Book-Entry Shares six months after the Effective Time shall be delivered to the Surviving Company, upon demand, and any remaining holders of Certificates or Book-Entry Shares (except to the extent representing Excluded Shares or Dissenting Shares) shall thereafter look only to the Surviving Company, as general creditors thereof, for payment of the Merger Consideration (together with any dividends or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>) (subject to abandoned property, escheat or other similar laws), without interest.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>None of Parent, the Surviving Company, the Exchange Agent or any other Person shall be liable to any Person in respect of shares of Parent Capital Stock, dividends or other distributions with respect thereto properly delivered to a public official pursuant to any applicable abandoned property, escheat or similar Law. If any Certificates or Book-Entry Shares shall not have been exchanged prior to two years after the Effective Time (or immediately prior to such earlier date on which the related Merger Consideration (and all dividends or other distributions with respect to shares of Parent Capital Stock) would otherwise escheat to or become the property of any Governmental Entity), any such Merger Consideration (and such dividends, distributions and cash) in respect thereof shall, to the extent permitted by applicable Law, become the property of the Surviving Company, free and clear of all claims or interest of any Person previously entitled thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit, in form and substance reasonably acceptable to Parent, of that fact by the Person claiming such Certificate to be lost, stolen or destroyed and, if required by Parent or the Exchange Agent, the posting by such Person of a bond in such amount as Parent or the Exchange Agent may determine is reasonably necessary as indemnity against any claim that may be made against it or the Surviving Company with respect to such Certificate, then the Exchange Agent will deliver in exchange for such lost, stolen or destroyed Certificate the Merger Consideration payable in respect thereof (together with any dividends or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>).</p><a id="Section34_640595"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;3.4&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding Rights</span>. Parent, the Surviving Company and the Exchange Agent (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agent</span>&#8221;) shall each be entitled to deduct and withhold, or cause to be deducted and withheld, from the consideration otherwise payable pursuant to this Agreement such amounts as any Withholding Agent is required to deduct and withhold under applicable Law. To the extent that amounts are so deducted and withheld by a Withholding Agent and remitted to the appropriate Governmental Entity, such amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of whom such deduction and withholding was made. The Withholding Agent shall use commercially reasonable efforts to (i)&#160;notify each holder of Company Common Stock at least five (5)&#160;Business Days prior to deducting or withholding any amounts of its intent to deduct and withhold and (ii)&#160;cooperate with such holder to minimize any such deductions and withholding.</p><a id="Section35_759987"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;3.5&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dissenters Rights</span>. Notwithstanding anything in this Agreement to the contrary, each share of the Company Common Stock (other than Excluded Shares) outstanding immediately prior to the Effective Time and held by a holder who is entitled to demand and has properly demanded appraisal for such shares of the Company Common Stock in accordance with Section&#160;262 of the DGCL and, as of the Effective Time, have neither effectively withdrawn nor lost their rights to such appraisal and payment under the DGCL (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dissenting Shares</span>&#8221;), shall not be converted into or be exchangeable for the right to receive a portion of the Merger Consideration but shall be entitled only to such rights as are granted by Section&#160;262 of the DGCL, unless and until such holder fails to perfect or withdraws or otherwise loses such holder&#8217;s right to appraisal and payment under the DGCL. If, after the Effective Time, any such holder fails to perfect or withdraws or loses such holder&#8217;s right to appraisal, such Dissenting Shares shall thereupon be treated as if they had been converted as of the Effective Time into the right to receive the portion of the Merger Consideration, if any, to which such holder is entitled pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)</span>, without interest. The Company shall give Parent (a)&#160;prompt notice of any demands received by the Company for appraisal of any shares of the Company Common Stock issued and outstanding immediately prior to the Effective Time, attempted written withdrawals of such demands, and any other instruments served pursuant to the DGCL and received by the Company relating to stockholders&#8217; rights to appraisal with respect to the Merger and (b)&#160;the opportunity to participate in all negotiations and proceedings with respect to any exercise of such appraisal rights under the DGCL. The Company shall not, except with the prior written consent of Parent, which shall not be unreasonably withheld, conditioned or delayed, voluntarily make any payment with respect to any demands for payment of fair value for capital stock of the Company, offer to settle or settle any such demands or approve any withdrawal of any such demands.</p><a id="Section36_474184"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;3.6&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Calculation of Net Cash</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Not less than five (5)&#160;Business Days prior to the anticipated date for the Parent Stockholder Meeting as mutually agreed in good faith by Parent and the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Anticipated Meeting Date</span>&#8221;), Parent will deliver to the Company a certificate signed by an officer of Parent in the form reasonably acceptable to the Company setting forth a schedule (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Net Cash Schedule</span>&#8221;, and the date of delivery of the Parent Net Cash Schedule, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery Date</span>&#8221;) setting forth, in reasonable detail, Parent&#8217;s good faith, estimated calculation of Net Cash (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Net Cash Calculation</span>&#8221;) as of the close of business on the Closing Date (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash Determination Time</span>&#8221;) prepared and certified by Parent&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for Parent). Parent shall make available to the Company (electronically to the greatest extent possible), as reasonably requested by the Company, the work papers and back-up materials (including all relevant invoices and similar evidence of outstanding obligations) used or useful in preparing the Parent </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Net Cash Schedule and, if reasonably requested by the Company, Parent&#8217;s internal finance personnel, accountants and counsel at reasonable times and upon reasonable notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Within three (3)&#160;Business Days after the Delivery Date (the last day of such period, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Response Date</span>&#8221;), the Company shall have the right to dispute any part of the Parent Net Cash Calculation by delivering a written notice to that effect to Parent (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute Notice</span>&#8221;). Any Dispute Notice shall identify in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to the Parent Net Cash Calculation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>If, on or prior to the Response Date, the Company notifies Parent in writing that it has no objections to the Parent Net Cash Calculation or, if prior to 11:59 p.m.&#160;(Eastern time) on the Response Date, the Company fails to deliver a Dispute Notice as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(b)</span>, then the Parent Net Cash Calculation as set forth in the Parent Net Cash Schedule shall be deemed to have been finally determined for purposes of this Agreement and to represent the Net Cash at the Cash Determination Time (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Final Parent Net Cash</span>&#8221;) for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>If the Company delivers a Dispute Notice on or prior to 11:59 p.m.&#160;(Eastern time) on the Response Date, then Representatives of Parent and the Company shall promptly, and in no event later than one calendar day after the Response Date, communicate and attempt in good faith to resolve the disputed item(s)&#160;and negotiate an agreed-upon determination of Net Cash, which agreed upon Net Cash amount (if so resolved) shall be deemed to have been finally determined for purposes of this Agreement and to represent the Final Parent Net Cash for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>If Representatives of Parent and the Company are unable to resolve the disputed items pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(d)</span>&#160;within three calendar days after delivery of the Dispute Notice (or such other period as Parent and the Company may mutually agree upon), then any remaining disagreements as to the calculation of Net Cash shall be referred to an independent auditor of recognized national standing jointly selected by Parent and the Company (provided that if the parties are unable to select an independent auditor within five (5)&#160;days, then either Parent or the Company may thereafter request that the Philadelphia, Pennsylvania Office of the American Arbitration Association (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AAA</span>&#8221;) make such selection (either the independent auditor jointly selected by both parties or such independent auditor selected by the AAA, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounting Firm</span>&#8221;)). Parent shall promptly deliver to the Accounting Firm all work papers and back-up materials used in preparing the Parent Net Cash Schedule, and Parent and the Company shall use commercially reasonable efforts to cause the Accounting Firm to make its determination within five calendar days of accepting its selection. Parent and the Company shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; provided, however, that no such presentation or discussion shall occur without the presence of a Representative of each of Parent and the Company. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination of the amount of Net Cash made by the Accounting Firm shall be made in writing delivered to each of Parent and the Company, shall be final and binding on Parent and the Company and shall (absent manifest error) be deemed to have been finally determined for purposes of this Agreement and to represent the Final Parent Net Cash for purposes of this Agreement. The parties shall delay the Closing until the resolution of the matters described in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(e)</span>. The fees and expenses of the Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount of the Net Cash that was unsuccessfully disputed amount by such party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Net Cash amount and such portion of the costs and expenses of the Accounting Firm borne by the Company and any other fees, costs or expenses incurred by the Company following the Anticipated Meeting Date in connection with the procedures set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(e)</span>&#160;shall be deducted from the final determination of the amount of Net Cash, to the extent of available amounts. If this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(e)</span>&#160;applies as to the determination of the Final Parent Net Cash described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(a)</span>, upon resolution of the matter in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(e)</span>, the parties shall not be required to determine the Net Cash again even though the Closing Date may occur later than the Anticipated Meeting Date. Notwithstanding anything else in this Agreement, Parent shall redetermine the Final Parent Net Cash if the Closing Date is more than ten calendar days after the Anticipated Meeting Date.</p><a id="Section37_309514"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section&#160;3.7&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contingent Value Right</span>. Prior to the Effective Time, Parent shall declare a distribution (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pre-</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Distribution</span>&#8221;) to holders of Parent Common Stock of record the right to receive one contingent value right (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CVR</span>&#8221;) for each outstanding share of Parent Common Stock held by such stockholder as of such date, each representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, the Contingent Value Rights Agreement in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;D</span>, to be entered into between Parent and Computershare (or such other nationally recognized rights agent agreed to between Parent and the Company) (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rights Agent</span>&#8221;), with such revisions thereto requested by the Rights Agent that are not, individually or in the aggregate, materially detrimental to the holders of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">CVRs and reasonably acceptable to Parent and the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CVR Agreement</span>&#8221;). The record date for the Pre-Closing Distribution shall be the close of business on the last Business Day prior to the day on which the Effective Time occurs.</p><a id="ARTICLEIV_2834"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as set forth in the corresponding section or subsection of the disclosure letter delivered by the Company to Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Disclosure Letter</span>&#8221;) (it being agreed that the disclosure of any information in a particular section or subsection of the Company Disclosure Letter shall be deemed disclosure of such information with respect to any other section or subsection of this Agreement to which the relevance of such information is readily apparent on its face), each of the Company and Guarantor represents and warrants to Parent and Merger Sub as follows:</p><a id="Section41_417212"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.1&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization, Standing and Power</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Company (i)&#160;is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation, (ii)&#160;has all requisite corporate or similar power and authority to own, lease and operate its properties and to carry on its business as now being conducted and as currently contemplated to be conducted and (iii)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, except in the case of clause&#160;(iii), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Adverse Effect</span>&#8221; means any event, change, circumstance, occurrence, effect or state of facts that (A)&#160;is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial condition, or results of operations of the Company, taken as a whole, or (B)&#160;materially impairs the ability of the Company to consummate the Merger or any of the other Contemplated Transactions; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that in the case of clause&#160;(A)&#160;only, Material Adverse Effect shall not include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (1)&#160;changes or conditions generally affecting the industries in which the Company operates, or the economy or the financial, debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (2)&#160;the outbreak or escalation of war or acts of terrorism or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak or any worsening of the foregoing, or any declaration of martial law, quarantine or similar directive, policy or guidance or Law or other action by any Governmental Entity in response thereto, (3)&#160;changes in Law or generally accepted accounting principles in the United States (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GAAP</span>&#8221;), or the interpretation or enforcement thereof or (4)&#160;the public announcement or pendency of this Agreement; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that, with respect to clauses&#160;(1), (2)&#160;and (3), the impact of such event, change, circumstance, occurrence, effect or state of facts is not disproportionately adverse to the Company as compared to other participants in the industries in which the Company operates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Company has previously made available to Parent true and complete copies of the Company&#8217;s Certificate of Incorporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Charter</span>&#8221;) and bylaws (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Bylaws</span>&#8221;), in each case as amended to the date of this Agreement, and each as so delivered is in full force and effect. The Company is not in violation of any provision of its Certificate of Incorporation or bylaws.</p><a id="Section42_118110"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.2&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capital Stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The authorized capital stock of the Company consists of 1,000 shares of Company Common Stock. (i)&#160;1,000 shares of Company Common Stock (excluding treasury shares) are issued and outstanding, all of which are owned by Guarantor, and (ii)&#160;no shares of Company Common Stock are held by the Company in its treasury. All outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable and not subject to any preemptive rights. The Company does not have any outstanding bonds, debentures, notes or other obligations having the right to vote (or convertible into, or exchangeable or exercisable for, securities having the right to vote) with the stockholders of the Company on any matter. Except as set forth above in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2(a)</span>, the Company does not have any outstanding (A)&#160;shares of capital stock or other voting securities or equity interests of the Company, (B)&#160;securities of the Company convertible into or exchangeable or exercisable for shares of capital stock of the Company or other voting securities or equity interests of the Company, (C)&#160;stock appreciation rights, &#8220;phantom&#8221; stock rights, performance units, interests in or rights to the ownership or earnings of the Company or other equity equivalent or equity-based awards or rights, (D)&#160;subscriptions, options, warrants, calls, commitments, Contracts or other rights to acquire from the Company, or obligations of the Company to issue, any shares of capital stock of the Company, voting securities, equity interests or securities convertible into or exchangeable or exercisable for capital stock or other voting </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">securities or equity interests of the Company or rights or interests described in the preceding clause&#160;(C), or (E)&#160;obligations of the Company to repurchase, redeem or otherwise acquire any such securities or to issue, grant, deliver or sell, or cause to be issued, granted, delivered or sold, any such securities. There are no stockholder agreements, voting trusts or other agreements or understandings to which the Company or Guarantor is a party or of which the Company or Guarantor has knowledge with respect to the holding, voting, registration, redemption, repurchase or disposition of, or that restricts the transfer of, any capital stock or other voting securities or equity interests of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>As of the date hereof, there are no outstanding options or other similar rights to purchase or receive shares of Company Common Stock or similar rights with respect to any Company Common Stock.</p><a id="Section43_862523"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.3&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiaries</span>. &#8206;The Company has no Subsidiaries and the Company does not own any capital stock or membership interests of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other entity. The Company is not and has never otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. The Company has not agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other entity. The Company has not, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other entity.</p><a id="Section44_367274"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.4&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Company has all necessary corporate power and authority to execute, deliver and perform its obligations under this Agreement and to consummate the Contemplated Transactions. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the Contemplated Transactions have been duly authorized by all necessary corporate action on the part of the Company and no other corporate proceedings on the part of the Company are necessary to approve this Agreement or to consummate the Merger and the other Contemplated Transactions, subject, in the case of the consummation of the Merger, to receipt of the Company Stockholder Approval. This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by Parent and Merger Sub, constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms (except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&#8217; rights generally or by general principles of equity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Company Board has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its sole stockholder, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions, (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole stockholder of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The Company Stockholder Approval is the only vote of the holders of any class or series of the Company Common Stock or other securities required in connection with the consummation of the Merger. Other than the Company Stockholder Approval (and except with respect to the Concurrent Investment), no vote of the holders of any class or series of the Company&#8217;s capital stock or other securities is required in connection with the consummation of any of the Contemplated Transactions to be consummated by the Company.</p><a id="Section45_544366"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.5&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflict; Consents and Approvals</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.5(a)</span>&#160;of the Company Disclosure Letter, the execution, delivery and performance of this Agreement by the Company does not, and the consummation of the Merger and the other Contemplated Transactions (including the Contribution) and compliance by the Company with the provisions hereof will not, conflict with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration of any obligation or to the loss of a benefit under, or result in the creation of any pledge, claim, lien, charge, option, right of first refusal, encumbrance or security interest of any kind or nature whatsoever (including any limitation on voting, sale, transfer or other disposition or exercise of any other attribute of ownership) (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liens</span>&#8221;) in or upon any of the properties, assets or rights of the Company under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under, or require any consent, waiver or approval of any Person pursuant to, any provision of (i)&#160;the Company Charter or Company Bylaws, (ii)&#160;any material bond, debenture, note, mortgage, indenture, guarantee, license, lease, purchase or sale order or other contract, commitment, agreement, instrument, obligation, arrangement, understanding, undertaking, permit, concession or franchise, whether oral or written (each, including all amendments thereto, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contract</span>&#8221;) to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">which the Company is a party or by which the Company or any of its properties or assets may be bound or (iii)&#160;subject to the governmental filings and other matters referred to in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.5(b)</span>, any federal, state, local or foreign law (including common law), statute, ordinance, rule, code, regulation, order, judgment, injunction, decree or other legally enforceable requirement (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Law</span>&#8221;) applicable to the Company or by which the Company or any of its properties or assets may be bound, except as, in the case of clause&#160;(iii), as individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any federal, state, local or foreign government or subdivision thereof or any other governmental, administrative, judicial, arbitral, legislative, executive, regulatory or self-regulatory authority, instrumentality, agency, commission or body (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Entity</span>&#8221;) is required by or with respect to the Company in connection with the execution, delivery and performance of this Agreement by the Company or the consummation by the Company of the Merger and the other Contemplated Transactions or compliance with the provisions hereof, except for (i)&#160;the filing with the SEC of such reports under Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</span>&#8221;), as may be required in connection with this Agreement and the Contemplated Transactions, (ii)&#160;such other filings and reports as may be required pursuant to the applicable requirements of the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Act</span>&#8221;), the Exchange Act and any other applicable state or federal securities, takeover and &#8220;blue sky&#8221; laws, (iii)&#160;the filing of the Certificate of Merger with the Delaware Secretary of State as required by the DGCL, and (iv)&#160;such other consents, approvals, orders, authorizations, registrations, declarations, filings or notices the failure of which to be obtained or made, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect.</p><a id="Section46_740677"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.6&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>As of the Closing, the Company will have made available to the Parent true and correct copies of the Company Audited Financial Statements and the Company Interim Financial Statements. Each of the Company Audited Financial Statements and the Company Interim Financial Statements (i)&#160;will be, as of the Closing, correct and complete in all material respects and have been prepared in accordance with the books and records of the Company; (ii)&#160;will have been prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto); and (iii)&#160;will fairly present, in all material respects, the financial position, results of operations and cash flows of the Company as at the respective dates thereof and for the respective periods indicated therein, except as otherwise noted therein and subject, in the case of the Company Interim Financial Statements, to normal and recurring year-end adjustments that will not, individually or in the aggregate, be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except as and to the extent adequately accrued or reserved against in the balance sheet set forth in the Company Audited Financial Statements, the Company does not have any liability or obligation of any nature, whether accrued, absolute, contingent or otherwise, whether known or unknown and whether or not required by GAAP to be reflected in a balance sheet of the Company or disclosed in the notes thereto, except for liabilities and obligations, incurred in the ordinary course of business consistent with past practice since the date of the Company Audited Financial Statements, that are not, individually or in the aggregate, material to the Company.</p><a id="Section47_677331"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.7&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Undisclosed Liabilities</span>. The Company does not have any liabilities or obligations of any nature, whether accrued, absolute, contingent or otherwise, known or unknown, whether due or to become due and whether or not required to be recorded or reflected on a balance sheet under GAAP, except for liabilities and obligations incurred in the ordinary course of business consistent with past practice (none of which is a liability for a breach or default under any contract, breach of warranty, tort, infringement, misappropriation or violation of law) that are not individually or in the aggregate material to the Company.</p><a id="Section48_40785"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.8&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Certain Changes or Events</span>. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.8</span> of the Company Disclosure Letter, since June&#160;19, 2025: (i)&#160;except in connection with the execution of this Agreement and the consummation of the Contemplated Transactions, the Company has conducted their business only in the ordinary course consistent with past practice and consistent with the business of the Company as currently contemplated to be conducted; (ii)&#160;there has not been any change, event or development or prospective change, event or development that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect; and (iii)&#160;the Company has not:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>(i)&#160;declared, set aside or paid any dividends on, or made any other distributions (whether in cash, stock or property) in respect of, any of its capital stock or other equity interests, (ii)&#160;purchased, redeemed or otherwise acquired shares of capital stock or other equity interests of the Company or any options, warrants, or rights to acquire any such shares or other equity interests, or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">(iii)&#160;split, combined, reclassified or otherwise amended the terms of any of its capital stock or other equity interests or issued or authorized the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>amended or otherwise changed, or authorized or proposed to amend or otherwise change, its certificate of incorporation or by-laws (or similar organizational documents);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>issued, granted, promised or otherwise committed to issue, any Company Common Stock or other securities of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>sold, leased, licensed or otherwise disposed of any of its assets or properties, or grant any Lien with respect to such assets or properties, including with respect to any Company Intellectual Property;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>adopted or entered into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or reorganization; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>changed its financial or Tax accounting methods, principles or practices, except insofar as may have been required by a change in GAAP or applicable Law, or revalued any of its material assets.</p><a id="Section49_568602"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.9&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Litigation</span>. There is no action, suit, claim, arbitration, investigation, inquiry, grievance or other proceeding (each, an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Action</span>&#8221;) (or basis therefor) pending or, to the knowledge of the Company, threatened against or affecting the Company, its properties or assets, or any present or former officer, director or employee of the Company in such individual&#8217;s capacity as such, other than any Action that (a)&#160;does not involve an amount in controversy in excess of $100,000 and (b)&#160;does not seek injunctive or other non-monetary relief. The Company&#8217;s properties and assets are not subject to any outstanding judgment, order, injunction, rule&#160;or decree of any Governmental Entity. There is no Action pending or, to the knowledge of the Company, threatened seeking to prevent, hinder, modify, delay or challenge the Merger or any of the other Contemplated Transactions.</p><a id="Section410_869871"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.10&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Laws</span>. The Company has been in compliance in all material respects with all Laws applicable to their businesses, operations, properties or assets. Neither Guarantor nor the Company has received, since January&#160;1, 2022 a notice or other written communication alleging or relating to a possible material violation of any Law applicable to their businesses, operations, properties, assets or Company Products (as defined below). The Company has in effect all material permits, licenses, variances, exemptions, applications, approvals, clearances, authorizations, registrations, formulary listings, consents, operating certificates, franchises, orders and approvals (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permits</span>&#8221;) of all Governmental Entities necessary or advisable for them to own, lease or operate its properties and assets and to carry on its businesses and operations as now conducted and as currently contemplated to be conducted, and there has occurred no violation of, default (with or without notice or lapse of time or both) under or event giving to others any right of revocation, non-renewal, adverse modification or cancellation of, with or without notice or lapse of time or both, any such Permit, nor would any such revocation, non-renewal, adverse modification or cancellation result from the consummation of the Contemplated Transactions.</p><a id="Section411_198228"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.11&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Health Care Regulatory Matters</span>. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.11</span> of the Company Disclosure Letter:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Company and Guarantor, and to the knowledge of the Company, each of its directors, officers, management employees, agents (while acting in such capacity), contract manufacturers, suppliers, and distributors are, and since January&#160;1, 2022 has been, in material compliance with all health care laws to the extent applicable to the Company or any of its products or activities, including, but not limited to the following: the Federal Food, Drug&#160;&amp; Cosmetic Act (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDCA</span>&#8221;); the Public Health Service Act (42 U.S.C. &#167; 201 et seq.), including the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. &#167; 263a); the Federal Trade Commission Act (15 U.S.C. &#167; 41 et seq.); the Controlled Substances Act (21 U.S.C. &#167; 801 et seq.); the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)); the civil monetary penalties law (42 U.S.C. &#167; 1320a-7a); the civil False Claims Act (31 U.S.C. &#167; 3729 et seq.); the administrative False Claims Law (42 U.S.C. &#167;&#160;1320a-7b(a)); the Stark law (42 U.S.C. &#167; 1395nn); the Criminal Health Care Fraud Statute (18 U.S.C. &#167; 1347); the exclusion laws (42 U.S.C. &#167; 1320a-7); Medicare (Title XVIII of the Social Security Act); Medicaid (Title XIX of the Social Security Act); any regulations promulgated pursuant to such laws; and any other state, federal or ex-U.S. laws or regulations governing the manufacturing, development, testing, labeling, advertising, marketing or distribution of drug, biologic and medical device products, kickbacks, patient or program charges, recordkeeping, claims process, documentation requirements, medical necessity, referrals, the hiring of employees or acquisition of services or supplies from those who have been excluded from government health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health care, clinical laboratory or diagnostic products or services, to the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">extent applicable to the Company (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Health Care Laws</span>&#8221;). To the knowledge of the Company, there are no facts or circumstances that reasonably would be expected to give rise to any material liability under any Health Care Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Company is not party to any material corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>All applications, notifications, submissions, information, claims, reports and statistical analyses, and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a Permit from the U.S. Food and Drug Administration (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA</span>&#8221;) or other Governmental Entity relating to products that are regulated as drugs, medical devices, or other healthcare products under Health Care Laws, including drugs or medical devices, compounds or products being researched, tested, stored, developed, labeled, manufactured, packed, imported, exported and/or distributed by the Company (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Products</span>&#8221;), including, without limitation, investigational new drug applications and investigational device exemptions, when submitted to the FDA or other Governmental Entity were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes, corrections or modification to such applications, submissions, information and data have been submitted to the FDA or other Governmental Entity. The Company does not have knowledge of any facts or circumstances that would be reasonably likely to lead to the revocation, suspension, limitation, or cancellation of a Permit required under Health Care Laws or of any application for marketing approval currently pending before the FA or such other Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>All preclinical studies and clinical trials conducted by or, to the knowledge of the Company, on behalf of the Company have been, and if still pending are being, conducted in compliance with research protocols and all applicable Health Care Laws, including, but not limited to, the FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, 312, 314, 320 and 812. No clinical trial conducted by or on behalf of the Company has been conducted using any clinical investigators who have been disqualified. No clinical trial conducted by or on behalf of the Company has been terminated or suspended prior to completion, and no clinical investigator that has participated or is participating in, or institutional review board that has or has had jurisdiction over, a clinical trial conducted by or on behalf of the Company has placed a clinical hold order on, or otherwise terminated, delayed or suspended, such a Company clinical trial at a clinical research site based on an actual or alleged lack of safety or efficacy of any Company Product or a failure to conduct such clinical trial in compliance with applicable Health Care Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>All manufacturing operations conducted by or, to the knowledge of the Company, for the benefit of the Company have been and are being conducted in material compliance with all Permits under applicable Health Care Laws, all applicable provisions of the FDA&#8217;s current good manufacturing practice (cGMP) regulations for drug products at 21 C.F.R. Parts 210 and 211, the Quality System (QS) regulations at 21 C.F.R. Part&#160;820 and all comparable foreign regulatory requirements of any Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>The Company has not received any written communication that relates to an alleged violation or non-compliance with any Health Care Laws, including any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import detention or refusal, FDA Warning Letter or Untitled Letter, or any action by a Governmental Entity relating to any Health Care Laws. All Warning Letters, Form-483 observations, or comparable findings from other Governmental Entities listed in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.11(f)</span>&#160;of the Company Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>There have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the Company Products required or requested by a Governmental Entity, or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company Products, or any adverse experiences relating to the Company Products that have been reported to FDA or other Governmental Entity (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Safety Notices</span>&#8221;). All Safety Notices listed in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.11(g)</span>&#160;of the Company Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.11(h)</span>&#160;of the Company Disclosure Letter, there are no unresolved Safety Notices, and to the knowledge the Company, there are no facts or circumstances that would be reasonably likely to result in a Safety Notice with respect to the Company Products or a termination or suspension of developing and testing of any of the Company Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Neither the Company, nor, to the knowledge of the Company, any officer, employee, agent, or distributor of the Company has made an untrue statement of a material fact or fraudulent or misleading statement to a Governmental Entity, failed to disclose a material fact required to be disclosed to a Governmental Entity, or committed an act, made a statement, or failed to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">make a statement that would reasonably be expected to provide a basis for the FDA to invoke its policy respecting &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September&#160;10, 1991) and any amendments thereto (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA Ethics Policy</span>&#8221;). None of the aforementioned is or has been under investigation resulting from any allegedly untrue, fraudulent, misleading, or false statement or omission, including data fraud, or had any action pending or threatened relating to the FDA Ethics Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>All reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Entity by the Company have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims, Permits or notices have not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. All such reports, documents, claims, Permits and notices were true and complete in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span>Neither the Company nor, to the knowledge of the Company, any officer, employee, agent, or distributor of the Company has been convicted of any crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law, including, without limitation, 21 U.S.C. &#167; 335a, or exclusion under 42 U.S.C. &#167; 1320a-7, or any other statutory provision or similar law applicable in other jurisdictions in which the Company Products are sold or intended to be sold. Neither the Company nor, to the knowledge of the Company, any officer, employee, agent or distributor of the Company, has been excluded from participation in any federal health care program or convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in any federal health care program under Section&#160;1128 of the Social Security Act of 1935, as amended, or any similar Health Care Law or program.</p><a id="Section412_541143"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.12&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Benefit Plans</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>As of the date hereof, the Company does not have any Employee Plans or employees, independent contractors, consultants, temporary employees, leased employees or other agents employed or used by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.12(a)&#160;</span>of the Company Disclosure Letter contains a true, correct, and complete list of each material Company Plan, specifying thereon the Company Plans that cover employees of and individual independent contractors (including those who work through substantially owned entities) that provide services to the Company or that will be or are reasonably likely to be assigned to the Company (together, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Service Providers</span>). Neither Guarantor, its Subsidiaries or any member of their Controlled Group has ever sponsored, maintained, contributed to, or been required to contribute to or incurred any liability (contingent or otherwise) with respect to: (i)&#160;a Multiemployer Plan, (ii)&#160;an &#8220;employee pension benefit plan&#8221; (within the meaning of Section&#160;3(2)&#160;of ERISA) that is subject to Title IV of ERISA or Section&#160;412 of the Code or Section&#160;302 of ERISA, (iii)&#160;any &#8220;multiple employer plan&#8221; as defined in Section&#160;413 of the Code or Section&#160;210 of ERISA, (iv)&#160;a &#8220;funded welfare benefit plan&#8221; within the meaning of Section&#160;419 of the Code or (v)&#160;any &#8220;multiple employer welfare arrangement&#8221; (as such term is defined in Section&#160;3(40) of ERISA).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>With respect to the Company Plans:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;each Company Plan is and has been established, operated and administered in all material respects with its terms and materially complies in form and in operation with the applicable provisions of ERISA and the Code and all other applicable legal requirements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(ii)&#160;&#160;&#160;&#160;&#160;no Company Plan is, or within the past six years has been, the subject of an application or filing under a government sponsored amnesty, voluntary compliance, or similar program, or been the subject of any self-correction under any such program;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iii)&#160;&#160;&#160;&#160;each Company Plan intended to be qualified under Section&#160;401(a)&#160;of the Code has received a favorable determination, advisory and/or opinion letter, as applicable, from the IRS that it is so qualified and nothing has occurred to the knowledge of Guarantor or the Company since the date of such letter that would reasonably be expected to cause the loss of the sponsor&#8217;s ability to rely upon such letter, and nothing has occurred to the knowledge of Guarantor or the Company that would reasonably be expected to result in the loss of the qualified status of such Company Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">(iv)&#160;&#160;&#160;&#160;&#160;there is no material Action (including any investigation, audit or other administrative proceeding) by the Department of Labor, the PBGC, the IRS or any other Governmental Entity or by any plan participant or beneficiary pending, or to the knowledge of Guarantor or the Company, threatened, relating to the Company Plans, any fiduciaries thereof with </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">respect to their duties to Company Plans or the assets of any of the trusts under any of the Company Plans (other than routine claims for benefits);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(v)&#160;&#160;&#160;&#160;&#160;none of the Company Plans currently provides, or reflects or represents any liability to provide post-termination or retiree welfare benefits to any person for any reason, except as may be required by COBRA, and neither Company nor any members of its Controlled Group has any liability to provide post-termination or retiree welfare benefits to any person or ever represented, promised or contracted to any employee or former employee of Guarantor or the Company (either individually or to such employees as a group) or any other person that such employee(s)&#160;or other person would be provided with post-termination or retiree welfare benefits, except to the extent required by statute or except with respect to a contractual obligation to reimburse any premiums such person may pay in order to obtain health coverage under COBRA;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(vi)&#160;&#160;&#160;&#160;all payments and/or contributions required to have been timely made with respect to all Company Plans either have been made or have been accrued in accordance with the terms of the applicable Company Plan and applicable law;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(vii)&#160;&#160;&#160;each Company Plan that includes Company Service Providers is subject exclusively to United States Law; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(viii)&#160;&#160;&#160;the execution and delivery of this Agreement, the Company Stockholder Approval, and the consummation of the Merger will not, either alone or in combination with any other event, (A)&#160;entitle any Company Service Providers to severance pay, unemployment compensation or any other similar termination payment, or (B)&#160;accelerate the time of payment or vesting, or increase the amount of or otherwise enhance any benefit due any such Company Service Providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>There is no agreement, plan or other arrangement to which Guarantor, the Company, or any of their Subsidiaries is a party or by which Guarantor, the Company, or any of their Subsidiaries is otherwise bound to compensate any Company Service Providers in respect of Taxes or other liabilities incurred with respect to Section&#160;409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Each Company Plan that relates to Company Service Providers is a &#8220;nonqualified deferred compensation plan&#8221; within the meaning of Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law) complies in both form and operation in all material respects with the requirements of Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law) and all applicable IRS guidance issued with respect thereto (and has so complied for the entire period during which Section&#160;409A of the Code has applied to such Company Plan) so that no amount paid or payable pursuant to any such Company Plan is subject to any additional Tax or interest under Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>No Company Plan provides major medical health or long-term disability benefits that are not fully insured through an insurance contract.</p><a id="Section413_127420"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.13&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Labor and Employment Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Solely with respect to Company Service Providers, Guarantor and each of its Subsidiaries are and, since January&#160;1, 2022, have been, in compliance in all material respects with all applicable Laws relating to labor or employment matters, including those relating to employment practices, terms and conditions of employment, collective bargaining, disability, immigration, health and safety, wages, hours and benefits, non-discrimination in employment, workers&#8217; compensation, the collection and payment of withholding and/or payroll Taxes and similar Taxes, unemployment compensation, equal employment opportunity, discrimination, harassment, employee and contractor classification, restrictive covenants, pay equity, information privacy and security, and continuation coverage with respect to group health plans, in each case to the extent applicable to Company Service Providers. Since January&#160;1, 2022, there has not been, and as of the date of this Agreement there is not pending or, to the knowledge of Guarantor or the Company, threatened, any labor dispute, work stoppage, labor strike or lockout with respect to the Company and involving any employee of Guarantor or its Subsidiaries that provides services primarily or exclusively to the Company or who will be or is reasonably likely to be assigned to the Company (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Employee</span>&#8221; ).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>None of Guarantor nor its Subsidiaries is, or since January&#160;1, 2022 has been, party to, or bound by, a collective bargaining agreement or similar labor agreement with respect to the Company Employees, and no such agreement is being negotiated. To the knowledge of Guarantor or the Company, there has not been any activity on behalf of any labor union, labor organization or similar employee group to organize any Company Employees. Solely with respect to Company Employees, there are no, and since January&#160;1, 2022, there has not been any: (i)&#160;unfair labor practice charges or complaints against Guarantor, the Company, or any of their Subsidiaries pending before the National Labor Relations Board or any other labor relations tribunal or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">authority in respect of any Company Employees, and to the knowledge of Guarantor and the Company no such charges or complaints are threatened, or (ii)&#160;&#160;grievances or pending arbitration proceedings against Guarantor or any of its Subsidiaries in respect of any Company Employees that arose out of or under any collective bargaining agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Since January&#160;1, 2022, solely with respect to Company Employees, (i)&#160;neither Guarantor nor any of its Subsidiaries has effectuated a &#8220;plant closing&#8221; (as defined in the WARN Act) affecting any site of employment or one or more facilities or operating units within any site of employment or facility, and, in each case, impacting Company Employees, and (ii)&#160;there has not occurred a &#8220;mass layoff&#8221; (as defined in the WARN Act) with respect to Guarantor or any of its Subsidiaries affecting any site of employment or one or more facilities or operating units within any site of employment or facility and, in each case, impacting Company Employees. Except as would not result in liability to the Company, Guarantor and its Subsidiaries properly classify and for the two (2)&#160;years immediately preceding the date hereof have properly classified, solely with respect to Company Service Providers, its and their (i)&#160;Company Employees as exempt or non-exempt in accordance with applicable overtime laws, and (ii)&#160;Company Service Providers employees or non-employees (e.g., consultants, independent contractors), in accordance with applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Except as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.13(d)</span>&#160;of the Company Disclosure Letter, with respect to any Company Service Provider, there are no Actions against Guarantor or any of its Subsidiaries pending, or to the knowledge of Guarantor or the Company, threatened to be brought or filed, in connection with the employment or engagement of any current or former Company Service Provider, including, without limitation, any claim relating to employment discrimination, harassment, retaliation, equal pay, employment classification, contractor classification, wages, hours, and benefits or any other employment related matter arising under applicable Laws, except where such action would not, individually or in the aggregate, result in the Company incurring a material liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Since January&#160;1, 2022, (i)&#160;no allegations of harassment or unlawful discrimination (with respect to any category protected by applicable law, including, without limitation, sexual harassment), retaliation on the basis of protected activity (including as a whistleblower) or protected class status in accordance with applicable law, or other material misconduct relating to the workplace, have been made, initiated, filed or, to the knowledge of Guarantor or the Company, threatened against or involving any current or former directors, officers or senior level Company Employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>No Company Service Provider is subject to any service relationship with the Guarantor or its applicable Subsidiaries that either (i)&#160;with respect to employees, is not &#8220;at-will&#8221;, or (ii)&#160;cannot be terminated on thirty (30) days&#8217; or less notice without penalty.</p><a id="Section414_626021"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.14&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect, (i)&#160;the Company has conducted its businesses in compliance with all, and have not violated any, applicable Environmental Laws; (ii)&#160;the Company has obtained all Permits of all Governmental Entities and any other Person that are required under any Environmental Law; (iii)&#160;there has been no release of any Hazardous Substance by the Company or any other Person in any manner that has given or would reasonably be expected to give rise to any remedial or investigative obligation, corrective action requirement or liability of the Company under applicable Environmental Laws; (iv)&#160;the Company has not received any claims, notices, demand letters or requests for information (except for such claims, notices, demand letters or requests for information the subject matter of which has been resolved prior to the date of this Agreement) from any federal, state, local, foreign or provincial Governmental Entity or any other Person asserting that the Company is in violation of, or liable under, any Environmental Law; (v)&#160;no Hazardous Substance has been disposed of, arranged to be disposed of, released or transported in violation of any applicable Environmental Law, or in a manner that has given rise to, or that would reasonably be expected to give rise to, any liability under any Environmental Law, in each case, on, at, under or from any current or former properties or facilities owned or operated by the Company or as a result of any operations or activities of the Company at any location and, to the knowledge of the Company, Hazardous Substances are not otherwise present at or about any such properties or facilities in amount or condition that has resulted in or would reasonably be expected to result in liability to the Company under any Environmental Law; and (vi)&#160;neither the Company nor any of its properties or facilities are subject to, or are threatened to become subject to, any liabilities relating to any suit, settlement, court order, administrative order, regulatory requirement, judgment or claim asserted or arising under any Environmental Law or any agreement relating to environmental liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>As used herein, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Law</span>&#8221; means any Law relating to (i)&#160;the protection, preservation or restoration of the environment (including air, surface water, groundwater, drinking water supply, surface and subsurface soils and strata, wetlands, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">plant and animal life or any other natural resource) or (ii)&#160;the exposure to, or the use, storage, recycling, treatment, generation, transportation, processing, handling, labeling, production, release or disposal of Hazardous Substances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>As used herein, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hazardous Substance</span>&#8221; means any substance listed, defined, designated, classified or regulated as a waste, pollutant or contaminant or as hazardous, toxic, radioactive or dangerous or any other term of similar import under any Environmental Law, including but not limited to petroleum.</p><a id="Section415_361250"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.15&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Company has (i)&#160;filed all income and other material Tax Returns required to be filed by or on behalf of it (taking into account any applicable extensions) and all such Tax Returns are true, accurate and complete in all material respects; and (ii)&#160;timely paid in full (or caused to be timely paid in full) all material Taxes that are required to be paid by or with respect to it, whether or not such Taxes were shown as due on such Tax Returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Company has not incurred, any liability for Taxes outside the ordinary course of business consistent with past practice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The Company has not executed any waiver of any statute of limitations on, or extended the period for the assessment or collection of, any amount of Tax, in each case that has not since expired (other than in connection with automatic extensions to file Tax Returns obtained in the ordinary course of business).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>No material audits or other investigations, proceedings, claims, assessments or examinations by any Governmental Entity (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Action</span>&#8221;) with respect to Taxes or any Tax Return of the Company are presently in progress or have been asserted, threatened or proposed in writing and to the knowledge of the Company, no such Tax Action is being contemplated. No deficiencies or claims for a material amount of Taxes have been claimed, proposed, assessed or asserted in writing against the Company by a Governmental Entity, other than any such claim, proposal, assessment or assertion that has been satisfied by payment in full, settled or withdrawn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Subject to exceptions as would not be material, the Company has timely withheld all Taxes required to have been withheld from payments made (or deemed made) to its employees, independent contractors, creditors, shareholders and other third parties and, to the extent required, such Taxes have been timely paid to the relevant Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>The Company has not engaged in a &#8220;listed transaction&#8221; as set forth in Treasury Regulations &#167;&#160;1.6011-4(b)(2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>The Company (i)&#160;is not a party to or bound by, and has no liability pursuant to, any Tax sharing, allocation, indemnification or similar agreement or obligation, other than any such agreement or obligation which is a customary commercial agreement obligation entered into in the ordinary course of business with vendors, lessors, lenders or the like the primary purpose of which is unrelated to Taxes (each, an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ordinary Course Agreement</span>&#8221;); (ii)&#160;is not and has not been a member of a group (other than a group the common parent of which is Guarantor.) filing a consolidated, combined, affiliated, unitary or similar income Tax Return; (iii)&#160;does not have any liability for the Taxes of any Person (other than the Guarantor or the Company) pursuant to Treasury Regulations &#167;&#160;1.1502-6 (or any similar provision of state, local or non-United States Law), as a transferee or successor, by Contract or otherwise by operation of Law; and (iv)&#160;is not and has not been treated as a resident for any income Tax purpose, or as subject to Tax by virtue of having a permanent establishment, an office or fixed place of business, in any country other than the country in which it was or is organized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>No private letter rulings, technical advice memoranda, or similar material agreements or rulings have been requested, entered into or issued by any Governmental Entity with respect to the Company which rulings remain in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>The Company will not be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i)&#160;a change in, or use of improper, method of accounting requested or initiated on or prior to the Closing Date, (ii)&#160;a &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar provision of Law) executed on or prior to the Closing Date, (iii)&#160;an installment sale or open transaction disposition made on or prior to the Closing Date, (iv)&#160;any prepaid amount received or deferred revenue accrued on or prior to the Closing Date, other than in respect of such amounts received in the ordinary course of business or (v)&#160;to the knowledge of the Company, an intercompany transaction or excess loss amount described in Treasury Regulations under Section&#160;1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>There are no liens for Taxes upon any of the assets of the Company other than Liens described in clause (i)&#160;of the definition of Permitted Liens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span>The Company has not distributed stock of another Person nor had its stock distributed by another Person, in a transaction (or series of transactions) that was purported or intended to be governed in whole or in part by Sections 355 or 361 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span>The Company has not been a United States real property holding corporation, as defined in Section&#160;897(c)(2)&#160;of the Code during the applicable period specified in Section&#160;897(c)(1)(A)(ii)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(m)</span></span>No material claim has been made in writing by any Governmental Entity in a jurisdiction where the Company does not currently file a Tax Return of a certain type or pay Taxes of a certain type that the Company is or may be subject to taxation of such type by such jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(n)</span></span>There are no outstanding shares of Company stock issued in connection with the performance of services (within the meaning of Section&#160;83 of the Code) that immediately prior to the Effective Time are subject to a substantial risk of forfeiture (as such terms are defined in Section&#160;83 of the Code) for which a valid election under Section&#160;83(b)&#160;of the Code has not been made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(o)</span></span>To the knowledge of the Company, the Company has not been, is not, and immediately prior to the Effective Time will not be, treated as an &#8220;investment company&#8221; within the meaning of Section&#160;368(a)(2)(F)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(p)</span></span>The Company has not taken any action, has not omitted to take any action, and has no knowledge of any fact or circumstance, the taking, omission, or existence of which, as the case may be, would reasonably be expected to prevent (i)&#160;the Merger from constituting a reorganization within the meaning of Section&#160;368(a)&#160;of the Code, or (ii)&#160;the Merger, from qualifying as a non-taxable exchange of shares of Company Common Stock for shares of Parent Common Stock within the meaning of Section&#160;351(a)&#160;of the Code.</p><a id="Section416_269654"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.16&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contracts</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.16(a)</span>&#160;of the Company Disclosure Letter sets forth each contract that, as of the date of this Agreement, that would constitute a &#8220;material contract&#8221; (as such term is defined in Item 601(b)(10)&#160;of Regulation&#160;S-K under the Securities Act), with respect to the Company (assuming the Company were subject to the requirements of the Exchange Act) (all such contracts, in addition to those set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.16(b)</span>&#160;of the Company Disclosure Letter, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Contracts</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.16(b)</span>&#160;of the Company Disclosure Letter lists the following contracts, in effect as of the date of this Agreement, which for the purposes of this Agreement shall be considered Material Contracts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;each Contract relating to any agreement for indemnification or guaranty not entered into in the ordinary course of business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(ii)&#160;&#160;&#160;&#160;&#160;each Contract containing (A)&#160;any covenant prohibiting the Company or the Surviving Company from engaging in any line of business or competing with any Person, or limiting the development, manufacture or distribution of the Surviving Company&#8217;s products or services, (B)&#160;any most-favored pricing arrangement, (C)&#160;any exclusivity provision in favor of a third party, or (D)&#160;any non-solicitation provision applicable to the Company, in the case of the foregoing clause (D), which are material to the Company, taken as a whole;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iii)&#160;&#160;&#160;&#160;each Contract relating to capital expenditures and requiring payments in excess of $250,000 after the date of this Agreement pursuant to its express terms and not cancelable without penalty;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iv)&#160;&#160;&#160;&#160;each Contract pursuant to which Guarantor has retained any right or interest that is used in or otherwise required for the operation of the Company&#8217;s business, as currently contemplated to be conducted by the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(v)&#160;&#160;&#160;&#160;&#160;each contract to which the Company is a party or by which any of its assets and properties is currently bound, which involves annual obligations of or payment by, or annual payments to, the Company in excess of $100,000;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(vi)&#160;&#160;&#160;&#160;each Contract relating to the disposition or acquisition of assets or any ownership interest in any Person;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(vii)&#160;&#160;&#160;&#160;each employment or independent contractor Contract or retention, severance, change in control, or deal-based bonus Employee Plan, arrangement, or Contract that covers any Company Service Provider;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(viii)&#160;&#160;each Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit or creating any material Liens with respect to any assets of the Company or any loans or debt obligations with officers or directors of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(ix)&#160;&#160;&#160;&#160;each Contract requiring payment by or to the Company after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A) any Contract involving supply or distribution (identifying any that contain exclusivity provisions), (B) any Contract involving provision of services or products with respect to any pre-clinical or clinical development activities of the Company, (C) any Contract involving a dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other Contract currently in force under which the Company has continuing obligations to develop or market any product, technology or service, or any Contract pursuant to which the Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by the Company or (D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of the Company or any Contract to sell, distribute or commercialize any products or service of the Company, in each case, except for Contracts entered into in the ordinary course of business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(x)&#160;&#160;&#160;&#160;&#160;each Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Company in connection with the Contemplated Transactions; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(xi) &#160;&#160;&#160;each Contract relating to leases of real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>(i)&#160;Each Material Contract is valid and binding on the Company, and to the knowledge of the Company, each other party thereto, and is in full force and effect and enforceable in accordance with its terms; and (ii)&#160;as of the date of this Agreement,&#160;the Company has not receive any written notice of any material default under any Material Contract by the Company or of any event or condition that has occurred that constitutes, or, after notice or lapse of time or both, would constitute, a material default on the part of the Company. The Company has made available to Parent true and complete copies of all Material Contracts, including all amendments thereto. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.16(c)</span>&#160;of the Company Disclosure Letter, there are no Material Contracts that are not in written form.</p><a id="Section417_476508"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.17&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</span>. The Company is covered by valid and currently effective insurance policies issued in favor of the Company that are customary and adequate for companies of similar size in the industries and locations in which the Company operates. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.17</span> of the Company Disclosure Letter sets forth, as of the date hereof, a true and complete list of all material insurance policies issued in favor of the Company, or pursuant to which the Company is a named insured or otherwise a beneficiary, as well as any historic incurrence-based policies still in force. With respect to each such insurance policy, (a)&#160;such policy is in full force and effect and all premiums due thereon have been paid, (b)&#160;the Company is not in breach or default, and has not taken any action or failed to take any action which (with or without notice or lapse of time, or both) would constitute such a breach or default, or would permit termination or modification of, any such policy and (c)&#160;to the knowledge of the Company, no insurer issuing any such policy has been declared insolvent or placed in receivership, conservatorship or liquidation. No notice of cancellation or termination has been received with respect to any such policy, nor will any such cancellation or termination result from the consummation of the Contemplated Transactions.</p><a id="Section418_848423"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.18&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Properties; Assets</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Company has, and will have after giving effect to the Contemplated Transactions (including the Contribution), good and valid title to, or in the case of leased property and leased tangible assets, a valid leasehold interest in, all of its real properties and tangible and other assets that are necessary for the Company to conduct the business and operate as operated by Guarantor and as currently contemplated to be conducted by the Company, after taking into account the services to be provided by the Transition Services Agreement and the Manufacturing and Supply Agreement, free and clear of all Liens other than (i)&#160;Liens for Taxes and assessments not yet due and payable or the amount or validity of which is being contested in good faith by appropriate proceedings, (ii)&#160;mechanics&#8217;, workmen&#8217;s, repairmen&#8217;s, warehousemen&#8217;s and carriers&#8217; Liens arising in the ordinary course of business of the Company consistent with past practice and (iii)&#160;any such matters of record, Liens and other imperfections of title that do not, individually or in the aggregate, materially impair the continued ownership, use and operation of the assets to which </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">they relate in the business of the Company as currently conducted (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Liens</span>&#8221;). Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, the tangible personal property currently used in the operation of the business of the Company is in good working order (reasonable wear and tear excepted).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Company has complied with the terms of all leases to which it is a party, and all such leases are in full force and effect, except for any such noncompliance or failure to be in full force and effect that, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect. The Company enjoys peaceful and undisturbed possession under all such leases, except for any such failure to do so that, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.18(c)</span>&#160;of the Company Disclosure Letter sets forth a true and complete list of (i)&#160;all real property owned by the Company and (ii)&#160;all real property leased for the benefit of the Company.</p><a id="Section419_786375"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.19&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.19(a)</span>&#160;of the Company Disclosure Letter sets forth a true and complete list of all (i)&#160;patents and patent applications; (ii)&#160;trademark registrations and applications; and (iii)&#160;material copyright registrations and applications, in each case owned or licensed by the Company (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Registered IP</span>&#8221;) and a true and complete list of all domain names owned or exclusively licensed by the Company. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect (A)&#160;all of the Company Registered IP is subsisting and, solely in the case of any Company Registered IP that is registered or issued, to the knowledge of the Company, valid and enforceable, (B)&#160;no Company Registered IP is involved in any interference, reissue, derivation, reexamination, opposition, cancellation or similar proceeding and, to the knowledge of the Company, no such action is threatened with respect to any of the Company Registered IP and (C)&#160;the Company owns exclusively, free and clear of any and all Liens (other than Permitted Liens), all Company Owned IP, including all Intellectual Property created on behalf of the Company by employees or independent contractors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.19(b)</span>&#160;of the Company Disclosure Letter accurately identifies (i)&#160;all contracts pursuant to which any Intellectual Property is licensed to the Company (other than (A)&#160;any non-customized software that (1)&#160;is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2)&#160;is not incorporated into, or material to the development, manufacturing, or distribution of, any of the products and services of the Company, (B)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials, (C)&#160;any confidential information provided under confidentiality agreements and (D)&#160;agreements between the Company and its employees in the Company&#8217;s standard form thereof), (ii)&#160;whether such contract involves the Company Registered IP licensed to the Company and (iii)&#160;whether the license or licenses granted to the Company are exclusive or nonexclusive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.19(c)</span>&#160;of the Company Disclosure Letter accurately identifies each of the Company&#8217;s contracts pursuant to which any Person has been granted any license or covenant not sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Company Registered IP (other than (i)&#160;any confidential information provided under confidentiality agreements and (ii)&#160;any Company Registered IP nonexclusively licensed to academic collaborators, suppliers, manufacturers or service providers for the sole purpose of enabling such academic collaborator, supplier, manufacturer or service provider to provide services for the Company&#8217;s benefit).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>The Company Registered IP constitutes all Intellectual Property owned by the Guarantor prior to the Contribution and necessary for the Company to conduct its business as currently proposed to be conducted (after giving effect to the Contribution).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>The Company has taken commercially reasonable measures to maintain the confidentiality of all information that constitutes or constituted a material Trade Secret of the Company, including requiring all Persons having access thereto to execute written non-disclosure agreements or other binding obligations to maintain confidentiality of such information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#8239;Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect, (i)&#160;to the knowledge of the Company, the conduct of the businesses of the Company, including the manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Company or currently contemplated to be sold or developed by the Company, has not infringed, misappropriated or diluted, and does not infringe, misappropriate or dilute, any Intellectual Property of any Person, (ii)&#160;the Company has not received any written notice or claim asserting or suggesting that any such infringement, misappropriation, or dilution is or may be </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">occurring or has or may have occurred and (iii)&#160;to the knowledge of the Company, no Person is infringing, misappropriating, or diluting in any material respect any Company Registered IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect, (i)&#160;the Company has taken commercially reasonable steps to protect the confidentiality and security of the computer and information technology systems used by the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IT Systems</span>&#8221;) and the information and transactions stored or contained therein or transmitted thereby, (ii)&#160;to the knowledge of the Company, since January&#160;1, 2022, there has been no unauthorized or improper use, loss, access, transmittal, modification or corruption of any such information or data and (iii)&#160;since January&#160;1, 2022, there have been no material failures, crashes, viruses, security breaches (including any unauthorized access to any personally identifiable information), affecting the IT Systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>The Company has at all times complied in all material respects with all: (i)&#160;applicable Laws, published privacy policies and contractual obligations relating to privacy, data protection, and the collection, retention, protection, and use of information that alone or in combination with other information can be used to identify an individual, household or device (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Personal Information</span>&#8221;) collected, used, or held for use by the Company (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Privacy Laws</span>&#8221;), (ii)&#160;since January&#160;1, 2022, no claims have been asserted or, to the knowledge of the Company, threatened in writing against the Company alleging a violation of any Person&#8217;s privacy or Personal Information, (iii)&#160;neither this Agreement nor the consummation of the Contemplated Transactions will breach or otherwise violate any Privacy Laws and (iv)&#160;the Company has taken commercially reasonable steps to protect the Personal Information collected, used or held for use by the Company against loss and unauthorized access, use, modification or disclosure, or other misuse. The Company has contractually obligated all vendors, processors, service providers and other Persons collecting, using or otherwise processing Personal Information by or for the Company (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Processors</span>&#8221;) to comply with applicable Privacy Laws and to take reasonable measures to protect Personal Information from unauthorized, access, use or disclosure. To the knowledge of the Company, no Data Processors have failed to comply with Privacy Laws with respect to the Personal Information processed on behalf of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>To the knowledge of the Company, no government funding, facilities or resources of a university, college, other educational institution or research center or funding from third parties was used in the development of Company Owned IP or any Intellectual Property exclusively licensed to the Company, and no Governmental Entity, university, college, other educational institution or research center has, to the knowledge of the Company, any claim or right in or to such Intellectual Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>Except as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.19(j)</span>&#160;of the Company Disclosure Letter, the execution, delivery and performance by the Company of this Agreement, and the consummation of the Contemplated Transactions, will not result in the loss of, or give rise to any right of any third party to terminate or modify any of the rights or obligations of the Company under any agreement under which the Company grants to any Person, or any Person grants to the Company, a license or right under or with respect to any Intellectual Property that is material to any of the businesses of the Company.</p><a id="Section420_750885"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.20&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">State Takeover Statutes</span>. As of the date hereof and at all times on or prior to the Effective Time, the Company Board has taken all actions so that the restrictions applicable to business combinations contained in Section&#160;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and the timely consummation of the Merger and the other Contemplated Transactions and will not restrict, impair or delay the ability of Parent or Merger Sub, after the Effective Time, to vote or otherwise exercise all rights as a stockholder of the Company. No other &#8220;moratorium,&#8221; &#8220;fair price,&#8221; &#8220;business combination,&#8221; &#8220;control share acquisition&#8221; or similar provision of any state anti-takeover Law (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Takeover Laws</span>&#8221;) or any similar anti-takeover provision in the Company Charter or Company Bylaws is, or at the Effective Time will be, applicable to this Agreement, the Merger or any of the other Contemplated Transactions.</p><a id="Section421_594003"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.21&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Rights Plan</span>. There is no stockholder rights plan, &#8220;poison pill&#8221; anti-takeover plan or other similar device in effect to which the Company is a party or is otherwise bound.</p><a id="Section422_697171"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.22&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Related Party Transactions</span>. Except as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.22</span> of the Company Disclosure Letter, there have been no transactions, agreements, arrangements or understandings between the Company, on the one hand, and the Affiliates of the Company (including Guarantor), on the other hand that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act (assuming the Company was subject to the requirements of the Exchange Act).</p><a id="Section423_37600"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section&#160;4.23&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Payments</span>. Since January&#160;1, 2022, the Company has not, nor, to the knowledge of the Company, any of their respective directors, executives, representatives, agents or employees (a)&#160;has used or is using any corporate funds for any illegal contributions, gifts, entertainment or other unlawful expenses relating to political activity, (b)&#160;has used or is using any corporate funds </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">for any direct or indirect unlawful payments to any foreign or domestic governmental officials or employees, (c)&#160;has violated or is violating any provision of the Foreign Corrupt Practices Act of 1977, as amended, (d)&#160;has established or maintained, or is maintaining, any unlawful fund of corporate monies or other properties, or (e)&#160;has made any bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment of any nature.</p><a id="Section424_103351"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.24&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trade Control Laws</span>. Since January&#160;1, 2022, the Company has been in material compliance with all applicable import, export control, and economic and trade sanctions laws, regulations, statutes, and orders, including the Export Administration Regulations, the International Traffic in Arms Regulations, and the regulations administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trade Laws</span>&#8221;) and have obtained, or are otherwise qualified to rely upon, all material import and export licenses, consents, notices, waivers, approvals, orders, authorizations, registrations, declarations or other authorizations from, and made any filings with, any governmental authority required for (i)&#160;the import, export, and reexport of products, services, software and technologies and (ii)&#160;releases of technologies and software to foreign nationals (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trade Approvals</span>&#8221;). There are no pending or threatened claims against the Company, nor any actions, conditions, facts, or circumstances that would reasonably be expected to give rise to any material future claims with respect to the Trade Laws or Trade Approvals.</p><a id="Section425_717254"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.25&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers</span>. No broker, investment banker, financial advisor or other Person, other than as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.25</span> of the Company Disclosure Letter, the fees and expenses of which will be paid by the Company, or following the Effective Time, Parent is entitled to any broker&#8217;s, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company or any of its Affiliates.</p><a id="Section426_843592"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.26&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Representations and Warranties</span>. Except for the representations and warranties contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span>, the Company acknowledges and agrees that none of Parent, Merger Sub or any other Person on behalf of Parent or Merger Sub makes any other express or implied representation or warranty whatsoever, and specifically (but without limiting the generality of the foregoing) that none of Parent, its Subsidiaries or any other Person on behalf of Parent or Merger Sub makes any representation or warranty with respect to any projections or forecasts delivered or made available to the Company or any of its Representatives of future revenues, results of operations (or any component thereof), cash flows or financial condition (or any component thereof) of Parent (including any such projections or forecasts made available to the Company and Representatives in certain &#8220;data rooms&#8221; or management presentations in expectation of the Contemplated Transactions), and the Company has not relied on any such information or any representation or warranty not set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span>.</p><a id="ARTICLEV_87718"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except (a)&#160;as disclosed in the Parent SEC Documents at least three (3)&#160;Business Days prior to the date of this Agreement and that is reasonably apparent on the face of such disclosure to be applicable to the representation and warranty set forth herein (other than any disclosures contained or referenced therein under the captions &#8220;Risk Factors,&#8221; &#8220;Forward-Looking Statements,&#8221; &#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; and any other disclosures contained or referenced therein of information, factors, or risks that are predictive, cautionary, or forward-looking in nature); or (b)&#160;as set forth in the corresponding section or subsection of the disclosure letter delivered by Parent to the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Disclosure Letter</span>&#8221;) (it being agreed that the disclosure of any information in a particular section or subsection of the Parent Disclosure Letter shall be deemed disclosure of such information with respect to any other section or subsection of this Agreement to which the relevance of such information is readily apparent on its face), each of Parent and Merger Sub represent and warrant to the Company as follows:</p><a id="Section51_481410"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.1&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization, Standing and Power</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Each of Parent and Merger Sub is a corporation duly organized or other entity duly formed, validly existing and in good standing under the Laws of the jurisdiction of its incorporation. Each of Parent and Merger Sub (x)&#160;has all requisite corporate or similar power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (y)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, except in the case of clause (y), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. For purposes of this Agreement, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Material Adverse Effect</span>&#8221; means any event, change, circumstance, occurrence, effect or state of facts that (A)&#160;is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial condition, or results of operations of Parent and its Subsidiaries, taken as a whole, or (B)&#160;materially impairs the ability of Parent or Merger Sub to consummate the Merger or any of the other Contemplated Transactions; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that in the case of clause&#160;(A)&#160;only, Parent Material Adverse Effect shall not </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (1)&#160;changes or conditions generally affecting the industries in which Parent and its Subsidiaries operate, or the economy or the financial, debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (2)&#160;the outbreak or escalation of war or acts of terrorism or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak (including the COVID-19 virus) or any worsening of the foregoing, or any declaration of martial law, quarantine or similar directive, policy or guidance or Law or other action by any Governmental Entity in response thereto, (3)&#160;changes in Law or GAAP, or the interpretation or enforcement thereof, (4)&#160;the public announcement or pendency of this Agreement, or (5)&#160;any specific action taken (or omitted to be taken) by Parent at or with the express written consent of the Company; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that, with respect to clauses&#160;(1), (2)&#160;and (3), the impact of such event, change, circumstance, occurrence, effect or state of facts is not disproportionately adverse to Parent and its Subsidiaries, as compared to other participants in the industries in which Parent and its Subsidiaries operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Parent has previously made available to the Company true and complete copies of the Certificate of Incorporation and bylaws of each of Parent, each of its Subsidiaries, and Merger Sub, in each case, as amended to the date of this Agreement, and each as so delivered is in full force and effect. None of Parent, its Subsidiaries, or Merger Sub is in violation of any provision of their respective Certificate of Incorporation or bylaws or equivalent governing documents.</p><a id="Section52_882578"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.2&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capital Stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The authorized capital stock of Parent consists of 350,000,000 shares of Parent Common Stock and 5,000,000 shares of Parent Preferred Stock. As of the close of business on June&#160;20, 2025 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Measurement Date</span>&#8221;), (i)&#160;41,788,096 shares of Parent Common Stock (excluding treasury shares) were issued and outstanding, all of which were validly issued, fully paid and nonassessable (which term means that no further sums are required to be paid by the holders thereof in connection with the issue of such shares) and were free of preemptive rights, (ii)&#160;zero (0) shares of Parent Common Stock were held in treasury, (iii)&#160;an aggregate of 6,424,376 shares of Parent Common Stock were subject to the exercise of outstanding Parent Options, (iv)&#160;zero (0) shares of Parent Common Stock were subject to outstanding Parent Restricted Stock Unit Awards in accordance with their respective terms, as in effect as of the date hereof, (v)&#160;zero (0) shares of Parent Common Stock were subject to the exercise of outstanding Parent Warrants and (vi)&#160;no shares of Parent Preferred Stock were issued and outstanding or held in treasury. Except as set forth above in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2(a)</span>, Parent does not have any outstanding bonds, debentures, notes or other obligations having the right to vote (or convertible into, or exchangeable or exercisable for, securities having the right to vote) with the stockholders of Parent or any of its Subsidiaries on any matter. Except as set forth above in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2(a)</span>&#160;and except for changes since the close of business on the Measurement Date resulting from the exercise of any options or vesting and settlement of outstanding Parent Restricted Stock Unit Awards as described above, as of the Measurement Date, there are no outstanding (A)&#160;shares of capital stock or other voting securities or equity interests of Parent or any of its Subsidiaries, (B)&#160;securities of Parent or any of its Subsidiaries convertible into or exchangeable or exercisable for shares of capital stock of Parent or any of its Subsidiaries or other voting securities or equity interests of Parent or any of its Subsidiaries, (C)&#160;stock appreciation rights, &#8220;phantom&#8221; stock rights, performance units, interests in or rights to the ownership or earnings of Parent or any of its Subsidiaries or other equity equivalent or equity-based awards or rights, (D)&#160;subscriptions, options, warrants, calls, commitments, Contracts or other rights to acquire from Parent or any of its Subsidiaries, or obligations of Parent or any of its Subsidiaries to issue, any shares of capital stock of Parent or any of its Subsidiaries, voting securities, equity interests or securities convertible into or exchangeable or exercisable for capital stock or other voting securities or equity interests of Parent or any of its Subsidiaries or rights or interests described in the preceding clause&#160;(C), or (E)&#160;obligations of Parent or any of its Subsidiaries to repurchase, redeem or otherwise acquire any such securities or to issue, grant, deliver or sell, or cause to be issued, granted, delivered or sold, any such securities. There are no stockholder agreements, voting trusts or other agreements or understandings to which Parent or any of its Subsidiaries is a party or of which Parent has knowledge with respect to the holding, voting, registration, redemption, repurchase or disposition of, or that restricts the transfer of, any capital stock or other voting securities or equity interests of Parent or any of its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The authorized capital stock of Merger Sub consists of 1,000 shares of common stock, par value $0.001 per share, of which 1,000 shares are issued and outstanding, all of which shares are beneficially owned by Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The shares of Parent Common Stock to be issued pursuant to the Merger will be duly authorized, validly issued, fully paid and nonassessable and not subject to any preemptive rights.</p><a id="Section53_516598"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section&#160;5.3&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiaries</span>. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.3</span> of the Parent Disclosure Letter sets forth a true and complete list of each Subsidiary of Parent, including its jurisdiction of incorporation or formation. Each of Parent&#8217;s Subsidiaries (i)&#160;is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization, (ii)&#160;has all requisite corporate or similar power and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">authority to own, lease and operate its properties and to carry on its business as now being conducted and (iii)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operations of its properties makes such qualification or licensing necessary, except in the case of clause (iii), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. All outstanding shares of capital stock and other voting securities or equity interests of each such Subsidiary are owned directly by Parent, free and clear of all Liens. Except for the capital stock of, or other equity or voting interests in, its Subsidiaries, Parent does not own, directly or indirectly, any equity, membership interest, partnership interest, joint venture interest, or other equity or voting interest in, or any interest convertible into, exercisable or exchangeable for any of the foregoing, nor is it under any current or prospective obligation to form or participate in, provide funds to, make any loan, capital contribution, guarantee, credit enhancement or other investment in, or assume any liability or obligation of, any Person. Merger Sub was formed solely for the purpose of engaging in the Merger and the other Contemplated Transactions and has engaged in no business other than in connection with the Contemplated Transactions.</p><a id="Section54_992636"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.4&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Each of Parent and Merger Sub has all necessary corporate power and authority to execute, deliver and perform its obligations under this Agreement and to consummate the Merger and the other Contemplated Transactions, including the issuance of the shares of Parent Common Stock to the holders of Company Common Stock as Merger Consideration (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Common Stock Issuance</span>&#8221;). The execution, delivery and performance of this Agreement by Parent and Merger Sub and the consummation by Parent and Merger Sub of the Merger and the other Contemplated Transactions have been duly authorized by all necessary corporate action on the part of Parent and Merger Sub and no other corporate proceedings on the part of Parent or Merger Sub are necessary to approve this Agreement or to consummate the Merger and the other Contemplated Transactions, subject to (i)&#160;assuming the Parent Common Stock is listed on Nasdaq immediately before the amendment to the Parent certificate of incorporation to effect the Reverse Stock Split is effective (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reverse Stock Split Proposal</span>&#8221;), obtaining the approval of the Nasdaq Issuance Proposal and the Reverse Stock Split Proposal by the holders of a majority of the votes cast for such proposal (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Stockholder Approval</span>&#8221;) and (ii)&#160;the approval of this Agreement by Parent as the sole stockholder of Merger Sub. This Agreement has been duly executed and delivered by Parent and Merger Sub and, assuming the due authorization, execution and delivery by the Company, constitutes a valid and binding obligation of each of Parent and Merger Sub, enforceable against each of Parent and Merger Sub in accordance with its terms (except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&#8217; rights generally or by general principles of equity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Parent Board, at a meeting duly called and held at which all directors of Parent were present, unanimously adopted resolutions (i)&#160;determining that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii)&#160;approving and declaring advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to this Agreement and the Parent Support Agreements and the Constructive Issuance, (iii)&#160;determining that the Reverse Stock Split Proposal, among other things, is advisable and in the best interests of Parent and its stockholders, and (iv)&#160;determining to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to authorize the Nasdaq Issuance Proposal, the Reverse Stock Split Proposal and the other Parent Stockholder Proposals. The board of directors of Merger Sub (by unanimous written consent) has: (x)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub and its sole stockholder, (y)&#160;approved and deemed advisable this Agreement and the Contemplated Transactions and (z)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of Merger Sub vote to adopt this Agreement and thereby the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The Parent Stockholder Approval is the only vote of the holders of any class or series of the Parent Common Stock or other securities required in connection with the consummation of the Merger and the other Contemplated Transactions, including the Parent Common Stock Issuance. Other than the Parent Stockholder Approval, no vote of the holders of any class or series of the Parent Common Stock or other securities is required in connection with the consummation of any of the Contemplated Transactions to be consummated by Parent.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Section55_918402"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.5&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflict; Consents and Approvals</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.5(a)</span>&#160;of the Parent Disclosure Letter, the execution, delivery and performance of this Agreement by each of Parent and Merger Sub does not, and the consummation of the Merger and the other Contemplated Transactions (including the Contribution) and compliance by each of Parent and Merger Sub with the provisions hereof will not, conflict with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration of any obligation or to the loss of a benefit under, or result in the creation of any Lien in or upon any of the properties, assets or rights of Parent or Merger Sub under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under, or require any consent, waiver or approval of any Person pursuant to, any provision of (i)&#160;the Certificate of Incorporation or bylaws of Parent or Merger Sub, (ii)&#160;any Parent Material Contract to which Parent or Merger Sub is a party by which Parent, Merger Sub or any of their respective properties or assets may be bound, or (iii)&#160;subject to the governmental filings and other matters referred to in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.5(b)</span>, any material Law or any rule&#160;or regulation of Nasdaq applicable to Parent or Merger Sub or by which Parent, Merger Sub or any of their respective properties or assets may be bound, except as, in the case of clauses&#160;(ii)&#160;and (iii), as individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any Governmental Entity is required by or with respect to Parent or Merger Sub in connection with the execution, delivery and performance of this Agreement by Parent or Merger Sub or the consummation by Parent or Merger Sub of the Merger and the other Contemplated Transactions or compliance with the provisions hereof, except for (i)&#160;the filing with the SEC of such reports under Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange Act, as may be required in connection with this Agreement and the Contemplated Transactions, (ii)&#160;such other filings and reports as may be required pursuant to the applicable requirements of the Securities Act, the Exchange Act and any other applicable state or federal securities, takeover and &#8220;blue sky&#8221; laws, (iii)&#160;the filing of the Certificate of Merger with the Delaware Secretary of State as required by the DGCL, (iv)&#160;any filings required under the rules&#160;and regulations of Nasdaq and (v)&#160;such consents, approvals, orders, authorizations, registrations, declarations, filings or notices the failure of which to be obtained or made, individually or in the aggregate, have not had and would not reasonably be expected to have a Parent Material Adverse Effect.</p><a id="Section56_816384"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.6&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC Reports; Financial Statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent has filed with or furnished to the SEC on a timely basis true and complete copies of all forms, reports, schedules, statements and other documents required to be filed with or furnished to the SEC by Parent since January&#160;1, 2022 (all such documents, together with all exhibits and schedules to the foregoing materials and all information incorporated therein by reference, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent SEC Documents</span>&#8221;). As of their respective filing dates (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act of 2002 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sarbanes-Oxley Act</span>&#8221;), as the case may be, including, in each case, the rules&#160;and regulations promulgated thereunder, and none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents (i)&#160;have been prepared in a manner consistent with the books and records of Parent, (ii)&#160;have been prepared in accordance with GAAP (except, in the case of unaudited statements, as permitted by Form&#160;10-Q of the SEC) applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto), (iii)&#160;comply as to form in all material respects with applicable accounting requirements and the published rules&#160;and regulations of the SEC with respect thereto and (iv)&#160;fairly present in all material respects the consolidated financial position of Parent as of the dates thereof and their respective consolidated results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal and recurring year-end audit adjustments that were not, or are not expected to be, material in amount), all in accordance with GAAP and the applicable rules&#160;and regulations promulgated by the SEC. Since January&#160;1, 2022, Parent has not made any change in the accounting practices or policies applied in the preparation of its financial statements, except as required by GAAP, SEC rule&#160;or policy or applicable Law. The books and records of Parent have been, and are being, maintained in all material respects in accordance with GAAP (to the extent applicable) and any other applicable legal and accounting requirements and reflect only actual transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Parent has established and maintains disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act). Such disclosure controls and procedures are designed to ensure that information relating to Parent </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">required to be disclosed in Parent&#8217;s periodic and current reports under the Exchange Act, is made known to Parent&#8217;s principal executive officer and principal financial officer by others within those entities to allow timely decisions regarding required disclosures as required under the Exchange Act. The chief executive officer and chief financial officer of Parent have evaluated the effectiveness of Parent&#8217;s disclosure controls and procedures and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form&#160;10-K or Form&#160;10-Q, or any amendment thereto, its conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by such report or amendment based on such evaluation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Parent has established and maintains a system of internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) which is effective in providing reasonable assurance regarding the reliability of Parent&#8217;s financial reporting and the preparation of Parent&#8217;s financial statements for external purposes in accordance with GAAP. Parent has disclosed, based on its most recent evaluation of Parent&#8217;s internal control over financial reporting prior to the date hereof, to Parent&#8217;s auditors and audit committee (i)&#160;any significant deficiencies and material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting which are reasonably likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (ii)&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in Parent&#8217;s internal control over financial reporting. A true, correct and complete summary of any such disclosures made by management to Parent&#8217;s auditors and audit committee is set forth as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.6(d)</span>&#160;of Parent Disclosure Letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Since January&#160;1, 2022, (i)&#160;neither Parent nor, to the knowledge of Parent, any of its directors, officers, employees, auditors, accountants or representatives has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, regarding the accounting or auditing practices, procedures, methodologies or methods of Parent or its internal accounting controls, including any material complaint, allegation, assertion or claim that Parent has engaged in questionable accounting or auditing practices and (ii)&#160;no attorney representing Parent, whether or not employed by Parent, has reported evidence of a material violation of securities Laws, breach of fiduciary duty or similar violation by Parent or any of its officers, directors, employees or agents to the Parent Board or any committee thereof or to any director or officer of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#8239;As of the date of this Agreement, there are no outstanding or unresolved comments in the comment letters received from the SEC staff with respect to the Parent SEC Documents. To the knowledge of Parent, none of the Parent SEC Documents is subject to ongoing review or outstanding SEC comment or investigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>Parent is not a party to, or has any commitment to become a party to, any joint venture, off balance sheet partnership or any similar Contract (including any Contract or arrangement relating to any transaction or relationship between or among Parent, on the one hand, and any unconsolidated Affiliate, including any structured finance, special purpose or limited purpose entity or Person, on the other hand, or any &#8220;off balance sheet arrangements&#8221; (as defined in Item 303(a)&#160;of Regulation S K under the Exchange Act)), where the result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, Parent in Parent&#8217;s published financial statements or other Parent SEC Documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>Parent is in compliance in all material respects with the provisions of the Sarbanes-Oxley Act.</p><a id="Section57_418580"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.7&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Undisclosed Liabilities</span>. Neither Parent nor any of its Subsidiaries has any liabilities or obligations of any nature, whether accrued, absolute, contingent or otherwise, known or unknown, whether due or to become due and whether or not required to be recorded or reflected on a balance sheet under GAAP, except (a)&#160;to the extent specifically and adequately accrued or reserved against in the audited balance sheet of Parent as at December&#160;31, 2024 included in the Annual Report on Form&#160;10-K filed by Parent with the SEC on March&#160;31, 2025 (without giving effect to any amendment thereto filed on or after the date hereof) and (b)&#160;for liabilities and obligations incurred in the ordinary course of business consistent with past practice (none of which is a liability for a breach or default under any contract, breach of warranty, tort, infringement, misappropriation or violation of law) since December&#160;31, 2024 that are not individually or in the aggregate material to Parent.</p><a id="Section58_26206"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.8&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Certain Changes or Events</span>. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.8</span> of the Parent Disclosure Letter, since December&#160;31, 2024, (i)&#160;except in connection with the execution of this Agreement and the consummation of the Contemplated Transactions, Parent and its Subsidiaries have conducted their business only in the ordinary course consistent with past practice; (ii)&#160;there has not been any change, event or development or prospective change, event or development that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect; and (iii)&#160;neither Parent nor any of its Subsidiaries has:</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>(i)&#160;declared, set aside or paid any dividends on, or made any other distributions (whether in cash, stock or property) in respect of, any of its capital stock or other equity interests, (ii)&#160;purchased, redeemed or otherwise acquired shares of capital stock or other equity interests of Parent or any of its Subsidiaries or any options, warrants, or rights to acquire any such shares or other equity interests, or (iii)&#160;split, combined, reclassified or otherwise amended the terms of any of its capital stock or other equity interests or issued or authorized the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>amended or otherwise changed, or authorized or proposed to amend or otherwise change, its certificate of incorporation or by-laws (or similar organizational documents);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>adopted or entered into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or reorganization; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>changed its financial or Tax accounting methods, principles or practices, except insofar as may have been required by a change in GAAP or applicable Law, or revalued any of its material assets.</p><a id="Section59_84371"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.9&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Litigation</span>. There is no Action (or basis therefor) pending or, to the knowledge of Parent, threatened against or affecting Parent or any of its Subsidiaries, any of its properties or assets, or any present or former officer, director or employee of Parent or any of its Subsidiaries in such individual&#8217;s capacity as such, other than any Action that (a) does not involve an amount in controversy in excess of $100,000 and (b) does not seek injunctive or other non-monetary relief. Neither Parent nor any of its Subsidiaries nor any of their respective properties or assets is subject to any outstanding judgment, order, injunction, rule or decree of any Governmental Entity. There is no Action pending or, to the knowledge of Parent, threatened seeking to prevent, hinder, modify, delay or challenge the Merger or any of the other Contemplated Transactions.</p><a id="Section510_522563"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.10&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Law</span>. Parent and each of its Subsidiaries are and have been in compliance in all material respects with all Laws applicable to its businesses, operations, properties or assets. Neither Parent nor any of its Subsidiaries has received, since January&#160;1, 2022, a notice or other written communication alleging or relating to a possible material violation of any Law applicable to its business, operations, properties, assets or Parent Products (as defined below). Parent and each of its Subsidiaries have in effect all material Permits of all Governmental Entities necessary or advisable for it to own, lease or operate its properties and assets and to carry on its business and operations as now conducted, and there has occurred no violation of, default (with or without notice or lapse of time or both) under or event giving to others any right of revocation, non-renewal, adverse modification or cancellation of, with or without notice or lapse of time or both, any such Permit, nor would any such revocation, non-renewal, adverse modification or cancellation result from the consummation of the Contemplated Transactions.</p><a id="Section511_582682"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.11&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Health Care Regulatory Matters</span>. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.11</span> of the Parent Disclosure Letter:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent, and to the knowledge of Parent, each of its directors, officers, management employees, agents (while acting in such capacity), contract manufacturers, suppliers, and distributors are, and at all times prior hereto were, in material compliance with all health care laws to the extent applicable to Parent or any of its products or activities, including, but not limited to the Health Care Laws, to the extent applicable to Parent. To the knowledge of Parent, there are no facts or circumstances that reasonably would be expected to give rise to any material liability under any Health Care Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Neither Parent nor any of its Subsidiaries is not party to any material corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>All applications, notifications, submissions, information, claims, reports and statistical analyses, and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a Permit from the FDA or other Governmental Entity relating to products that are regulated as biologics under Health Care Laws, including biological candidates, compounds or products being researched, tested, stored, developed, labeled, manufactured, packed, imported, exported and/or distributed by Parent or any of its Subsidiaries (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Products</span>&#8221;), including, without limitation, investigational new drug applications, when submitted to the FDA or other Governmental Entity were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes, corrections or modification to such applications, submissions, information and data have been submitted to the FDA or other Governmental Entity. Parent does not have knowledge of any facts or circumstances that would be reasonably likely to lead the revocation, suspension, limitation, or cancellation of a Permit required under Health Care Laws.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>All preclinical studies and clinical trials conducted by or, to the knowledge of Parent, on behalf of Parent in respect of a Parent Product for submission to the FDA or other Governmental Entity have been since January&#160;1, 2022, and if still pending are being, conducted in compliance with research protocols and all applicable Health Care Laws, including, but not limited to, the FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, 312, 314 and 812. No clinical trial conducted by or on behalf of Parent has been conducted using any clinical investigators who have been disqualified. Except as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.11(d)</span>&#160;of the Parent Disclosure Letter, no clinical trial conducted by or on behalf of the Company has been terminated or suspended prior to completion, and no clinical investigator that has participated or is participating in, or institutional review board that has or has had jurisdiction over, a clinical trial conducted by or on behalf of Parent has placed a clinical hold order on, or otherwise terminated, delayed or suspended, such a clinical trial at a clinical research site based on an actual or alleged lack of safety or efficacy of any Parent Product or a failure to conduct such clinical trial in compliance with applicable Health Care Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>All manufacturing operations conducted by or, to the knowledge of Parent, for the benefit of Parent have been and are being conducted in material compliance with all Permits under applicable Health Care Laws, all applicable provisions of the FDA&#8217;s current good manufacturing practice (cGMP) regulations at 21 C.F.R. Parts 210-211 and Parts 600 and 610 and FDA&#8217;s Quality System (QS) regulations at 21 C.F.R. Part&#160;820, and all comparable foreign regulatory requirements of any Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#8239;Parent has not received any written communication that relates to an alleged violation or non-compliance with any Health Care Laws, including any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import detention or refusal, FDA Warning Letter or Untitled Letter, or any action by a Governmental Entity relating to any Health Care Laws. All Warning Letters, Form-483 observations, or comparable findings from other Governmental Entities listed in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.11(f)</span>&#160;of the Parent Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>There have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the Parent Products required or requested by a Governmental Entity, or other Safety Notices. All Safety Notices listed in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.11(g)</span>&#160;of the Parent Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.11(h)</span>&#160;of the Parent Disclosure Letter, there are no unresolved Safety Notices, and to the knowledge Parent, there are no facts or circumstances that would be reasonably likely to result in a Safety Notice with respect to the Parent Products or a termination or suspension of developing and testing of any of the Parent Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Neither Parent, nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has made an untrue statement of a material fact or fraudulent or misleading statement to a Governmental Entity, failed to disclose a material fact required to be disclosed to a Governmental Entity, or committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide a basis for the FDA to invoke its FDA Ethics Policy. None of the aforementioned is or has been under investigation resulting from any allegedly untrue, fraudulent, misleading, or false statement or omission, including data fraud, or had any action pending or threatened relating to the FDA Ethics Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>&#8239;All reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Entity by Parent have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims, Permits or notices have not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. All such reports, documents, claims, Permits and notices were true and complete in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span>Neither Parent nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has committed any act, made any statement or failed to make any statement that violates the Federal Anti-Kickback Statute, 28 U.S.C. &#167; 1320a-7b, the Federal False Claims Act, 31 U.S.C. &#167; 3729, other Health Care Laws, or any other similar federal, state, or ex-U.S. law applicable in the jurisdictions in which the Parent Products are sold or intended to be sold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span>&#8239;Neither Parent nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has been convicted of any crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law, including, without limitation, 21 U.S.C. &#167; 335a, or exclusion under 42 U.S.C. &#167; 1320a-7, or any other statutory provision or similar law applicable in other jurisdictions in which the Parent Products are sold or intended to be sold. Neither Parent nor, to the knowledge of Parent, any officer, employee, agent or distributor of Parent, has been excluded from participation in any federal health care program or convicted of any crime or engaged in any conduct for which such Person could be excluded </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">from participating in any federal health care program under Section&#160;1128 of the Social Security Act of 1935, as amended, or any similar Health Care Law or program.]</p><a id="Section512_641872"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.12&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Benefit Plans</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.12(a)</span>&#160;of the Parent Disclosure Letter contains a true, correct, and complete list of each material Parent Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Parent has provided or made available to the Company a current, accurate and complete copy of each material Parent Plan, or if such Parent Plan is not in written form, a written summary of all of the material terms of such Parent Plan. With respect to each Parent Plan, Parent has furnished or made available to the Company a current, accurate and complete copy of, to the extent applicable: (i)&#160;all documents embodying or governing such Parent Plan and any related trust agreement or other funding instrument, (ii)&#160;the most recent determination letter of the IRS, (iii)&#160;any summary plan description, summary of material modifications, and other similar material written communications (or a written description of any material oral communications) to the employees of Parent or any of its Subsidiaries concerning the extent of the benefits provided under a Parent Plan, (iv)&#160;all non-routine correspondence to and from any governmental agency, and (v)&#160;for the three most recent years and as applicable (A)&#160;the Form&#160;5500 and attached schedules, (B)&#160;audited financial statements, (C)&#160;nondiscrimination testing results and (D)&#160;actuarial valuation reports.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Neither Parent, its Subsidiaries or any member of their Controlled Group has ever sponsored, maintained, contributed to, or been required to contribute to or incurred any liability (contingent or otherwise) with respect to: (i)&#160;a Multiemployer Plan, (ii)&#160;an &#8220;employee pension benefit plan&#8221; (within the meaning of Section&#160;3(2)&#160;of ERISA) that is subject to Title IV of ERISA or Section&#160;412 of the Code or Section&#160;302 of ERISA, (iii)&#160;any &#8220;multiple employer plan&#8221; as defined in Section&#160;413 of the Code or Section&#160;210 of ERISA, (iv)&#160;a &#8220;funded welfare benefit plan&#8221; within the meaning of Section&#160;419 of the Code or (v)&#160;any &#8220;multiple employer welfare arrangement&#8221; (as such term is defined in Section&#160;3(40) of ERISA).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>With respect to the Parent Plans:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;each Parent Plan is and has been established, operated and administered in all material respects with its terms and materially complies in form and in operation with the applicable provisions of ERISA and the Code and all other applicable legal requirements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(ii)&#160;&#160;&#160;&#160;&#160;no Parent Plan is, or within the past six years has been, the subject of an application or filing under a government sponsored amnesty, voluntary compliance, or similar program, or been the subject of any self-correction under any such program;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iii)&#160;&#160;&#160;&#160;each Parent Plan intended to be qualified under Section&#160;401(a)&#160;of the Code has received a favorable determination, advisory and/or opinion letter, as applicable, from the IRS that it is so qualified and nothing has occurred to the knowledge of Parent since the date of such letter that would reasonably be expected to cause the loss of the sponsor&#8217;s ability to rely upon such letter, and nothing has occurred to the knowledge of Parent that would reasonably be expected to result in the loss of the qualified status of such Parent Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iv)&#160;&#160;&#160;&#160;&#160;there is no material Action (including any investigation, audit or other administrative proceeding) by the Department of Labor, the PBGC, the IRS or any other Governmental Entity or by any plan participant or beneficiary pending, or to the knowledge of Parent, threatened, relating to the Parent Plans, any fiduciaries thereof with respect to their duties to Parent Plans or the assets of any of the trusts under any of the Parent Plans (other than routine claims for benefits);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(v)&#160;&#160;&#160;&#160;&#160;none of the Parent Plans currently provides, or reflects or represents any liability to provide post-termination or retiree welfare benefits to any person for any reason, except as may be required by COBRA, and neither Parent nor any members of its Controlled Group has any liability to provide post-termination or retiree welfare benefits to any person or ever represented, promised or contracted to any employee or former employee of Parent (either individually or to Parent employees as a group) or any other person that such employee(s)&#160;or other person would be provided with post-termination or retiree welfare benefits, except to the extent required by statute or except with respect to a contractual obligation to reimburse any premiums such person may pay in order to obtain health coverage under COBRA;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(vi)&#160;&#160;&#160;&#160;all payments and/or contributions required to have been timely made with respect to all Parent Plans either have been made or have been accrued in accordance with the terms of the applicable Parent Plan and applicable law;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(vii)&#160;&#160;&#160;each Parent Plan is subject exclusively to United States Law; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(viii)&#160;&#160;&#160;the execution and delivery of this Agreement, the Parent Stockholder Approval, and the consummation of the Merger will not, either alone or in combination with any other event, (A)&#160;entitle any current or former employee, officer, director or consultant of Parent or any of its Subsidiaries to severance pay, unemployment compensation or any other similar termination payment, or (B)&#160;accelerate the time of payment or vesting, or increase the amount of or otherwise enhance any benefit due any such employee, officer, director or consultant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Neither Parent nor any of its Subsidiaries is a party to any agreement, contract, arrangement or plan (including any Parent Plan) that may reasonably be expected to result, separately or in the aggregate, in connection with the Contemplated Transactions (either alone or in combination with any other events), in the payment of any &#8220;parachute payments&#8221; within the meaning of Section&#160;280G of the Code. There is no agreement, plan or other arrangement to which Parent or any of its Subsidiaries is a party or by which Parent or any of its Subsidiaries is otherwise bound to compensate any person in respect of Taxes or other liabilities incurred with respect to Section&#160;409A or 4999 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#8239;Each Parent Plan that is a &#8220;nonqualified deferred compensation plan&#8221; within the meaning of Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law) complies in both form and operation in all material respects with the requirements of Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law) and all applicable IRS guidance issued with respect thereto (and has so complied for the entire period during which Section&#160;409A of the Code has applied to such Parent Plan) so that no amount paid or payable pursuant to any such Parent Plan is subject to any additional Tax or interest under Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>No Parent Plan provides major medical health or long-term disability benefits that are not fully insured through an insurance contract.</p><a id="Section513_619194"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.13&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Labor and Employment Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent and each of its Subsidiaries are and, since January&#160;1, 2022, have been in compliance in all material respects with all applicable Laws relating to labor or employment matters, including those relating to employment practices, terms and conditions of employment, collective bargaining, disability, immigration, health and safety, wages, hours and benefits, non-discrimination in employment, workers&#8217; compensation, the collection and payment of withholding and/or payroll Taxes and similar Taxes, unemployment compensation, equal employment opportunity, discrimination, harassment, employee and contractor classification, restrictive covenants, pay equity, information privacy and security, and continuation coverage with respect to group health plans. Since January&#160;1, 2022, there has not been, and as of the date of this Agreement there is not pending or, to the knowledge of Parent, threatened, any labor dispute, work stoppage, labor strike or lockout against Parent or any of its Subsidiaries by employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>No employee of Parent or any of its Subsidiaries is, or since January&#160;1, 2022 has been, covered by an effective or pending collective bargaining agreement or similar labor agreement. To the knowledge of Parent, there has not been any activity on behalf of any labor union, labor organization or similar employee group to organize any employees of Parent or any of its Subsidiaries. There are no and since January&#160;1, 2022 there has not been any: (i)&#160;unfair labor practice charges or complaints against Parent or any of its Subsidiaries pending before the National Labor Relations Board or any other labor relations tribunal or authority and to the knowledge of Parent no such representations, claims or petitions are threatened, (ii)&#160;representations, claims or petitions pending before the National Labor Relations Board or any other labor relations tribunal or authority or (iii)&#160;grievances or pending arbitration proceedings against Parent or any of its Subsidiaries that arose out of or under any collective bargaining agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Since January&#160;1, 2022, (i)&#160;neither Parent nor any of its Subsidiaries has not effectuated a &#8220;plant closing&#8221; (as defined in the WARN Act) affecting any site of employment or one or more facilities or operating units within any site of employment or facility, (ii)&#160;there has not occurred a &#8220;mass layoff&#8221; (as defined in the WARN Act) in connection with Parent or any of its Subsidiaries affecting any site of employment or one or more facilities or operating units within any site of employment or facility and (iii)&#160;neither Parent nor any of its Subsidiaries has not engaged in layoffs or employment terminations sufficient in number to trigger application of any similar state, local or foreign law. Parent and its Subsidiaries properly classify and for the two (2)&#160;years immediately preceding the date hereof have properly classified its and their (i)&#160;employees as exempt or non-exempt in accordance </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">with applicable overtime laws, (ii)&#160;contingent workers in accordance with applicable law and (iii)&#160;workers as employees or non-employees (e.g., consultants, independent contractors), in accordance with applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Except as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.13(d)</span>&#160;of the Parent Disclosure Letter, with respect to any current or former employee, officer, consultant or other service provider of Parent, there are no Actions against Parent or any of its Subsidiaries pending, or to the knowledge of Parent, threatened to be brought or filed, in connection with the employment or engagement of any current or former employee, officer, consultant or other service provider of Parent, including, without limitation, any claim relating to employment discrimination, harassment, retaliation, equal pay, employment classification, contractor classification, wages, hours, and benefits or any other employment related matter arising under applicable Laws, except where such action would not, individually or in the aggregate, result in Parent incurring a material liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Except as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.13(e)</span>&#160;of the Parent Disclosure Letter or with respect to any Parent Plan (which subject is addressed in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.12</span> above), the execution of this Agreement and the consummation of the transactions set forth in or contemplated by this Agreement will not result in any breach or violation of, or cause any payment to be made under, any applicable Laws respecting labor and employment or any collective bargaining agreement to which Parent or any of its Subsidiaries is a party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#8239;Since January&#160;1, 2022, no allegations of harassment or unlawful discrimination (with respect to any category protected by applicable law, including, without limitation, sexual harassment), retaliation on the basis of protected activity (including as a whistleblower) or protected class status in accordance with applicable law, or other material misconduct relating to the workplace have been made, initiated, filed or, to the knowledge of Parent, threatened against or involving Parent or any of its Subsidiaries or any of their respective current or former directors, officers or senior level management employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>No employee or other worker of Parent is subject to any service relationship that is not &#8220;at-will&#8221; or that is terminable on more than 30 days&#8217; notice.</p><a id="Section514_269151"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.14&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&#160;Parent and its Subsidiaries have conducted its businesses in compliance with all, and have not violated any, applicable Environmental Laws; (ii)&#160;Parent and its Subsidiaries have obtained all Permits of all Governmental Entities and any other Person that are required under any Environmental Law; (iii)&#160;there has been no release of any Hazardous Substance by Parent or any of its Subsidiaries or any other Person in any manner that has given or would reasonably be expected to give rise to any remedial or investigative obligation, corrective action requirement or liability of Parent or any of its Subsidiaries under applicable Environmental Laws; (iv)&#160;Parent and its Subsidiaries have not received any claims, notices, demand letters or requests for information (except for such claims, notices, demand letters or requests for information the subject matter of which has been resolved prior to the date of this Agreement) from any federal, state, local, foreign or provincial Governmental Entity or any other Person asserting that Parent or any of its Subsidiaries is in violation of, or liable under, any Environmental Law; (v)&#160;no Hazardous Substance has been disposed of, arranged to be disposed of, released or transported in violation of any applicable Environmental Law, or in a manner that has given rise to, or that would reasonably be expected to give rise to, any liability under any Environmental Law, in each case, on, at, under or from any current or former properties or facilities owned or operated by Parent or any of its Subsidiaries or as a result of any operations or activities of Parent or any of its Subsidiaries at any location and, to the knowledge of Parent, Hazardous Substances are not otherwise present at or about any such properties or facilities in amount or condition that has resulted in or would reasonably be expected to result in liability to Parent or any of its Subsidiaries under any Environmental Law; and (vi)&#160;neither Parent or any of its Subsidiaries nor any of their properties or facilities are subject to, or are threatened to become subject to, any liabilities relating to any suit, settlement, court order, administrative order, regulatory requirement, judgment or claim asserted or arising under any Environmental Law or any agreement relating to environmental liabilities.</p><a id="Section515_547416"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.15&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent and its Subsidiaries have (i)&#160;filed all income and other material Tax Returns required to be filed by or on behalf of them (taking into account any applicable extensions) and all such Tax Returns are true, accurate and complete in all material respects; and (ii)&#160;timely paid in full (or caused to be timely paid in full) all material Taxes that are required to be paid by or with respect to them, whether or not such Taxes were shown as due on such Tax Returns.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>All material Taxes not yet due and payable by Parent as of the date of the balance sheet included in the financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents have been, in all respects, properly accrued in accordance with GAAP on the financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents, and such financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents reflect an adequate reserve (in accordance with GAAP) for all material Taxes accrued but unpaid by Parent through the date of such financial statements. Since the date of financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents, neither Parent nor any of its Subsidiaries has incurred, individually or in the aggregate, any liability for Taxes outside the ordinary course of business consistent with past practice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Neither Parent nor any of its Subsidiaries has executed any waiver of any statute of limitations on, or extended the period for the assessment or collection of, any amount of Tax, in each case that has not since expired (other than in connection with automatic extensions to file Tax Returns obtained in the ordinary course of business).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>No material Tax Action with respect to Taxes or any Tax Return of Parent or any of its Subsidiaries are presently in progress or have been asserted, threatened or proposed in writing and to the knowledge of Parent, no such Tax Action is being contemplated. No deficiencies or claims for a material amount of Taxes have been claimed, proposed, assessed or asserted in writing against Parent or any of its Subsidiaries by a Governmental Entity, other than any such claim, proposal, assessment or assertion that has been satisfied by payment in full, settled or withdrawn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Subject to exceptions as would not be material, Parent and its Subsidiaries have timely withheld all Taxes required to have been withheld from payments made (or deemed made) to its employees, independent contractors, creditors, shareholders and other third parties and, to the extent required, such Taxes have been timely paid to the relevant Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Neither Parent nor any of its Subsidiaries has engaged in a &#8220;listed transaction&#8221; as set forth in Treasury Regulations &#167; 1.6011-4(b)(2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>Neither Parent nor any of its Subsidiaries (i)&#160;is a party to or bound by, or has any liability pursuant to, any Tax sharing, allocation, indemnification or similar agreement or obligation other than any Ordinary Course Agreement; (ii)&#160;is or has been a member of a group (other than a group the common parent of which is Parent) filing a consolidated, combined, affiliated, unitary or similar income Tax Return; (iii)&#160;has liability for the Taxes of any Person (other than Parent or its Subsidiaries) pursuant to Treasury Regulations &#167; 1.1502-6 (or any similar provision of state, local or non-United States Law) as a transferee or successor, by Contract, or otherwise by operation of Law; or (iv)&#160;is or has been treated as a resident for any income Tax purpose, or as subject to Tax by virtue of having a permanent establishment, an office or fixed place of business, in any country other than the country in which it was or is organized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>No private letter rulings, technical advice memoranda, or similar material agreements or rulings have been requested, entered into or issued by any Governmental Entity with respect to Parent or any of its Subsidiaries which rulings remain in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Neither Parent nor any of its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i)&#160;a change in, or use of improper, method of accounting requested or initiated on or prior to the Closing Date, (ii)&#160;a &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar provision of Law) executed on or prior to the Closing Date, (iii)&#160;an installment sale or open transaction disposition made on or prior to the Closing Date, (iv)&#160;any prepaid amount received or deferred revenue accrued on or prior to the Closing Date, other than in respect of such amounts received in the ordinary course of business, or (v)&#160;to the knowledge of Parent, an intercompany transaction or excess loss amount described in Treasury Regulations under Section&#160;1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>There are no liens for Taxes upon any of the assets of Parent or any of its Subsidiaries other than Liens described in clause (i)&#160;of the definition of Permitted Liens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span>Neither Parent nor any of its Subsidiaries has distributed stock of another Person or has had its stock distributed by another Person, in a transaction (or series of transactions) that was purported or intended to be governed in whole or in part by Sections 355 or 361 of the Code.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span>&#8239;Neither Parent nor any of its Subsidiaries has been a United States real property holding corporation, as defined in Section&#160;897(c)(2)&#160;of the Code during the applicable period specified in Section&#160;897(c)(1)(A)(ii)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(m)</span></span>No material claim has been made in writing by any Governmental Entity in a jurisdiction where Parent or any of its Subsidiaries does not currently file a Tax Return of a certain type or pay Taxes of a certain type that Parent is or may be subject to taxation of such type by such jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(n)</span></span>There are no outstanding shares of Parent stock issued in connection with the performance of services (within the meaning of Section&#160;83 of the Code) that immediately prior to the Effective Time are subject to a substantial risk of forfeiture (as such terms are defined in Section&#160;83 of the Code) for which a valid election under Section&#160;83(b)&#160;of the Code has not been made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(o)</span></span>To the knowledge of Parent, neither Parent nor any of its Subsidiaries has been, is, or immediately prior to the Effective Time will be, treated as an &#8220;investment company&#8221; within the meaning of Section&#160;368(a)(2)(F)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(p)</span></span>Neither Parent nor any of its Subsidiaries has taken any action, has omitted to take any action, or has knowledge of any fact or circumstance, the taking, omission, or existence of which, as the case may be, would reasonably be expected to prevent (i)&#160;the Merger from constituting a reorganization within the meaning of Section&#160;368(a)&#160;of the Code, or (ii)&#160;the Merger, from qualifying as a non-taxable exchange of shares of Company Common Stock for shares of Parent Common Stock within the meaning of Section&#160;351(a)&#160;of the Code.</p><a id="Section516_355503"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.16&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contracts</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except for any Parent Plans (which are the subject of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.12</span>), except as set forth in the Parent SEC Documents publicly available prior to the date of this Agreement, and except for any agreement or contract, the expenses and obligations under which are included in the calculation of Net Cash, Parent is not a party to or bound by any &#8220;material contract&#8221; (as such term is defined in Item 601(b)(10)&#160;of Regulation S-K under the Securities Act) (all such contracts including those set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.16(b)</span>&#160;of the Parent Disclosure Letter, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Material Contracts</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.16(b)</span>&#160;of the Parent Disclosure Letter lists the following contracts, which for the purposes of this Agreement shall be considered Parent Material Contracts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;each Contract relating to any agreement of indemnification or guaranty not entered into in the ordinary course of business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(ii)&#160;&#160;&#160;&#160;&#160;each Contract containing any covenant prohibiting Parent, its Subsidiaries or the Surviving Company from engaging in any line of business or competing with any Person;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iii)&#160;&#160;&#160;&#160;each Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iv)&#160;&#160;&#160;&#160;each Contract relating to the disposition or acquisition of material assets or any ownership interest in any Person;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(v)&#160;&#160;&#160;&#160;&#160;each Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Liens with respect to any assets of the Parent or any of its Subsidiaries or any loans or debt obligations with officers or directors of the Parent;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(vi)&#160;&#160;&#160;&#160;each Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Parent in connection with the Contemplated Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(vii)&#160;&#160;&#160;each Contract to which the Parent is a party or by which any of its assets and properties is currently bound, which involves annual obligations of payment by, or annual payments to, the Parent in excess of $250,000 or pursuant to which the Company has outstanding unpaid obligations in excess of $250,000; and</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(viii)&#160;&#160;each Contract relating to leases of real properties with respect to which the Parent directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Parent or any of its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>&#8239;Each Parent Material Contract is valid and binding on Parent, and to the knowledge of Parent, each other party thereto, and is in full force and effect and enforceable in accordance with its terms; (ii)&#160;Parent, and, to the knowledge of Parent, each other party thereto, has performed all material obligations required to be performed by it under each Parent Material Contract; and (iii)&#160;there is no material default under any Parent Material Contract by Parent or, to the knowledge of Parent, any other party thereto, and no event or condition has occurred that constitutes, or, after notice or lapse of time or both, would constitute, a material default on the part of Parent or, to the knowledge of Parent, any other party thereto under any such Parent Material Contract, nor has Parent received any notice of any such material default, event or condition. Parent has made available to the Company true and complete copies of all Parent Material Contracts, including all amendments thereto. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.16(c)</span>&#160;of the Parent Disclosure Letter, there are no Parent Material Contracts that are not in written form. No Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to the Parent under any Parent Material Contract or any other material term or provision of any Parent Material Contract.</p><a id="Section517_83603"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.17&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</span>. Each of Parent and its Subsidiaries is covered by valid and currently effective insurance policies issued in favor of Parent or its Subsidiaries that are customary and adequate for companies of similar size in the industries and locations in which Parent and its Subsidiaries operate. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.17</span> of the Parent Disclosure Letter sets forth, as of the date hereof, a true and complete list of all material insurance policies issued in favor of Parent or any of its Subsidiaries, or pursuant to which Parent or any of its Subsidiaries is a named insured or otherwise a beneficiary, as well as any historic incurrence-based policies still in force. With respect to each such insurance policy, (a)&#160;such policy is in full force and effect and all premiums due thereon have been paid, (b)&#160;neither Parent nor any of its Subsidiaries is in breach or default, and has not taken any action or failed to take any action which (with or without notice or lapse of time, or both) would constitute such a breach or default, or would permit termination or modification of, any such policy and (c)&#160;to the knowledge of Parent, no insurer issuing any such policy has been declared insolvent or placed in receivership, conservatorship or liquidation. No notice of cancellation or termination has been received with respect to any such policy, nor will any such cancellation or termination result from the consummation of the Contemplated Transactions.</p><a id="Section518_284419"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.18&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Properties</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent and its Subsidiaries has good and valid title to, or in the case of leased property and leased tangible assets, a valid leasehold interest in, all of its real properties and tangible assets that are necessary for Parent and its Subsidiaries to conduct its businesses as currently conducted, free and clear of all Liens other than Permitted Liens. Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, the tangible personal property currently used in the operation of the business of Parent and its Subsidiaries is in good working order (reasonable wear and tear excepted).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Each of Parent and its Subsidiaries has complied with the terms of all leases to which it is a party, and all such leases are in full force and effect, except for any such noncompliance or failure to be in full force and effect that, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. Each of Parent and its Subsidiaries enjoys peaceful and undisturbed possession under all such leases, except for any such failure to do so that, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.18(c)</span>&#160;of the Parent Disclosure Letter sets forth a true and complete list of (i)&#160;all real property owned by Parent or any of its Subsidiaries and (ii)&#160;all real property leased for the benefit of Parent or any of its Subsidiaries.</p><a id="Section519_315560"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.19&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.19(a)</span>&#160;of the Parent Disclosure Letter sets forth a true and complete list of all (i)&#160;patents and patent applications; (ii)&#160;trademark registrations and applications; and (iii)&#160;material copyright registrations and applications, in each case owned or licensed by Parent and its Subsidiaries (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Registered IP</span>&#8221;) and a true and complete list of all domain names owned or exclusively licensed by Parent and its Subsidiaries. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect (i)&#160;all of the Parent Registered IP is subsisting and, solely in the case of any Parent Registered IP that is registered or issued and to the knowledge of Parent, valid and enforceable, (ii)&#160;no Parent Registered IP, is involved in any interference, reissue, derivation, reexamination, opposition, cancellation or similar proceeding and, to the knowledge of Parent, no such action is threatened with respect to any of the Parent Registered IP and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">(iii)&#160;Parent and its Subsidiaries own exclusively, free and clear of any and all Liens (other than Permitted Liens), all Parent Owned IP, including all Intellectual Property created on behalf of Parent or its Subsidiaries by employees or independent contractors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Parent and its Subsidiaries have taken commercially reasonable measures to maintain the confidentiality of all information that constitutes or constituted a material Trade Secret of Parent and its Subsidiaries, including requiring all Persons having access thereto to execute written non-disclosure agreements or other binding obligations to maintain confidentiality of such information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&#160;to the knowledge of Parent, the conduct of the businesses of Parent and its Subsidiaries, including the manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Parent or any of its Subsidiaries, has not infringed, misappropriated or diluted, and does not infringe, misappropriate or dilute, any Intellectual Property of any Person, (ii)&#160;neither Parent nor any of its Subsidiaries have received any written notice or claim asserting or suggesting that any such infringement, misappropriation, or dilution is or may be occurring or has or may have occurred and (iii)&#160;to the knowledge of Parent, no Person is infringing, misappropriating, or diluting in any material respect any Parent Registered IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&#160;Parent and its Subsidiaries have taken commercially reasonable steps to protect the confidentiality and security of the computer and information technology systems used by Parent or any of its Subsidiaries (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent IT Systems</span>&#8221;) and the information and transactions stored or contained therein or transmitted thereby, (ii)&#160;to the knowledge of Parent, during the past two (2)&#160;years, there has been no unauthorized or improper use, loss, access, transmittal, modification or corruption of any such information or data, and (iii)&#160;during the past two (2)&#160;years, there have been no material failures, crashes, viruses, security breaches (including any unauthorized access to any personally identifiable information), affecting the Parent IT Systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&#160;to the knowledge of Parent, Parent and its Subsidiaries have at all times complied in all material respects with all applicable Privacy Laws, (ii)&#160;during the past two (2)&#160;years since the Effective Time, no claims have been asserted or, to the knowledge of Parent, threatened in writing against Parent or any of its Subsidiaries alleging a violation of any Person&#8217;s privacy or Personal Information, (iii)&#160;neither this Agreement nor the consummation of the Contemplated Transactions will breach or otherwise violate any Privacy Laws and (iv)&#160;Parent and its Subsidiaries have taken commercially reasonable steps to protect the Personal Information collected, used or held for use by Parent or any of its Subsidiaries against loss and unauthorized access, use, modification or disclosure, or other misuse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>To the knowledge of Parent, no government funding, facilities or resources of a university, college, other educational institution or research center or funding from third parties was used in the development of the Parent Owned IP or any Intellectual Property exclusively licensed to Parent or any of its Subsidiaries, and no Governmental Entity, university, college, other educational institution or research center has, to the knowledge of Parent, any claim or right in or to such Intellectual Property. Except as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.19(f)</span>&#160;of the Parent Disclosure Letter, the execution, delivery and performance by Parent of this Agreement, and the consummation of the Contemplated Transactions, will not result in the loss of, or give rise to any right of any third party to terminate or modify any of the rights or obligations of Parent or any of its Subsidiaries under any agreement under which Parent or any of its Subsidiaries grants to any Person, or any Person grants to Parent or any of its Subsidiaries, a license or right under or with respect to any Intellectual Property that is material to any of the businesses of Parent or any of its Subsidiaries.</p><a id="Section520_964554"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.20&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Related Party Transactions</span>. Since January&#160;1, 2022 through the date of this Agreement, there have been no transactions, agreements, arrangements or understandings between Parent or any of its Subsidiaries, on the one hand, and the Affiliates of Parent or any of its Subsidiaries, on the other hand that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act and that have not been so disclosed in the Parent SEC Documents.</p><a id="Section521_919475"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section&#160;5.21&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Payments</span>. For the five (5)&#160;years immediately preceding the date hereof, neither Parent nor any of its Subsidiaries nor, to the knowledge of Parent, any of their directors, executives, representatives, agents or employees (a)&#160;has used or is using any corporate funds for any illegal contributions, gifts, entertainment or other unlawful expenses relating to political activity, (b)&#160;has used or is using any corporate funds for any direct or indirect unlawful payments to any foreign or domestic governmental officials or employees, (c)&#160;has violated or is violating any provision of the Foreign Corrupt Practices Act of 1977, as amended, (d)&#160;has </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">established or maintained, or is maintaining, any unlawful fund of corporate monies or other properties, or (e)&#160;has made any bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment of any nature.</p><a id="Section522_991525"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.22&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trade Control Laws</span>. Since January&#160;1, 2022, Parent and its Subsidiaries have been in material compliance with all applicable Trade Laws and have obtained, or are otherwise qualified to rely upon, all material Trade Approvals. There are no pending or threatened claims against the Parent or its Subsidiaries, nor any actions, conditions, facts or circumstances that would reasonably be expected to give rise to any material future claims with respect to the Trade Laws or Trade Approvals.</p><a id="Section523_939375"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.23&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers</span>. No broker, investment banker, financial advisor or other Person, other than Lucid Capital Markets, LLC, the fees and expenses of which will be paid by Parent or any of its Subsidiaries, is entitled to any broker&#8217;s, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent, any of its Subsidiaries or any of its Affiliates. Parent has furnished to Company a true and complete copy of any Contract between Parent and Lucid Capital Markets, LLC pursuant to which Lucid Capital Markets, LLC, could be entitled to any payment from Parent relating to the Contemplated Transactions.</p><a id="Section524_729691"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.24&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Opinion of Financial Advisor</span>. Parent Board has received the opinion of Lucid Capital Markets, LLC, dated the date of this Agreement, to the effect that, as of such date and based upon and subject to the qualifications, limitations, assumptions and other matters set forth therein, the Exchange Ratio is fair, from a financial point of view, to the stockholders of Parent, a signed true and complete copy of which opinion has been or will promptly be provided on a non-reliance basis to the Company.</p><a id="Section525_794962"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.25&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">State Takeover Statutes</span>. No Takeover Laws or any similar anti-takeover provision in the Certificate of Incorporation or bylaws of Parent applicable to Parent is, or at the Effective Time will be, applicable to this Agreement, the Merger, the Parent Common Stock Issuance, or any of the other Contemplated Transactions. The Parent Board and the Merger Sub board have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&#160;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement, and to the consummation of the Contemplated Transactions.</p><a id="Section526_594722"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.26&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Representations or Warranties</span>. Except for the representations and warranties contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IV</span>, each of Parent and Merger Sub acknowledges and agrees that none of the Company or any other Person on behalf of the Company makes any other express or implied representation or warranty whatsoever, and specifically (but without limiting the generality of the foregoing) that none of the Company, or any other Person on behalf of the Company makes any representation or warranty with respect to any projections or forecasts delivered or made available to Parent, Merger Sub or any of their respective Representatives of future revenues, results of operations (or any component thereof), cash flows or financial condition (or any component thereof) of the Company (including any such projections or forecasts made available to Parent, Merger Sub or any of their respective Representatives in certain &#8220;data rooms&#8221; or management presentations in expectation of the Contemplated Transactions), and none of Parent or Merger Sub has relied on any such information or any representation or warranty not set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IV</span>.</p><a id="ARTICLEVI_44914"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COVENANTS</b></p><a id="Section61_670277"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;6.1&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operation of Parent&#8217;s Business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except (i)&#160;as expressly contemplated or permitted by this Agreement, (ii)&#160;as expressly required by applicable Law, (iii)&#160;in connection with the winding down of Parent&#8217;s prior research and development activities (including the termination of employees, independent contractors, service providers, and ongoing contractual obligations related to Parent&#8217;s current products or product candidates, as well as any Parent Legacy Transaction) (but in all cases of this clause (iii), in consultation with the Company and subject to the Company&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed) or (iv)&#160;unless the Company shall otherwise consent in writing (email being sufficient), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> and the Effective Time (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pre-Closing Period</span>&#8221;), Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to (x)&#160;conduct its business and operations in material compliance with the applicable Law and the requirements of all Contracts that constitute Parent Material Contracts and (y)&#160;continue to pay material outstanding accounts payable and other material current liabilities (including payroll) when due and payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except (i)&#160;as expressly contemplated or permitted by this Agreement or the Securities Purchase Agreement, a Permitted Stock Purchase Agreement or any Parent Legacy Transaction, (ii)&#160;as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1(b)</span>&#160;of the Parent Disclosure Letter, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">(iii)&#160;as required by applicable Law, (iv)&#160;in connection the winding down of Parent&#8217;s prior research and development activities (including the termination of employees, independent contractors, service providers, and ongoing contractual obligations related to Parent&#8217;s current products or product candidates) (but in all cases of this clause (iv), in consultation with the Company and subject to the Company&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed) or (v)&#160;with the prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except for any CVR, or shares of Parent Common Stock from terminated employees, directors or consultants of Parent in accordance with agreements in effect on the date of this Agreement providing for the repurchase of shares at no more than the purchase price thereof in connection with any termination of services to Parent or any of its Subsidiaries);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(ii)&#160;&#160;&#160;&#160;&#160;sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A)&#160;any capital stock or other security (except for Parent Common Stock issued upon the valid exercise or settlement of outstanding Parent Options, Parent Warrants or Parent Restricted Stock Unit Awards, as applicable), (B)&#160;any option, warrant or right to acquire any capital stock or any other security or (C)&#160;any instrument convertible into or exchangeable for any capital stock or other security;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iii)&#160;&#160;&#160;&#160;except as required to give effect to anything in contemplation of the Closing, amend any of its organizational documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iv)&#160;&#160;&#160;&#160;form any Subsidiary (other than Merger Sub) or acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;(A)&#160;lend money to any Person, (B)&#160;incur or guarantee any indebtedness for borrowed money, (C)&#160;guarantee any debt securities or others or (D)&#160;other than the incurrence or payment of Transaction Expenses, make any capital expenditure or commitment;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(vi)&#160;&#160;&#160;&#160;other than as expressly required by applicable Law or the terms of any Parent Plan in effect as of the date of this Agreement: (A)&#160;adopt, establish or enter into any Parent Plan, including, for the avoidance of doubt, any equity award plans, (B)&#160;cause or permit any Parent Plan to be amended other than as required by Law or in order to make amendments for the purposes of Section&#160;409A of the Code, (C)&#160;pay any bonus or make any profit-sharing or similar payment to (except with respect to obligations in place on the date of this Agreement pursuant to any Parent Plan), or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its employees, directors or consultants, (D)&#160;increase the severance or change of control benefits offered to any current or new employees, directors or consultants, or (E)&#160;hire or terminate (other than for cause, or absent such a definition of cause, for conduct that the Parent or such Subsidiary determines in good faith constitutes material misconduct) any officer, employee or consultant;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(vii)&#160;&#160;&#160;enter into any transaction outside the Ordinary Course;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(viii)&#160;&#160;acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its material assets or properties, or grant any Lien with respect to such assets or properties (other than the disposition of Parent Legacy Assets, subject to and in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.17</span>);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(ix)&#160;&#160;&#160;make, change or revoke any material Tax election; file any amended income or other material Tax Return; settle or compromise any material Tax claim; waive or extend any statute of limitations in respect of a period within which an assessment or reassessment of material Taxes may be issued (other than any extension pursuant to an extension to file any Tax Return); enter into any &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar Law) with any Governmental Entity; surrender any material claim for refund; or adopt or change any material accounting method in respect of Taxes;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">(x)&#160;&#160;&#160;&#160;waive, settle or compromise any pending or threatened Action against Parent or any of its Subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of Parent or its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Parent or any of its Subsidiaries;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(xi) &#160;&#160;&#160;delay or fail to repay when due, any obligation, including accounts payable and accrued expenses;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(xii) &#160;&#160;forgive any loans to any Person, including its employees, officers, directors or Affiliate;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(xiii) &#160;sell, assign, transfer, license, sublicense or otherwise dispose of any Intellectual Property of the Parent;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(xiv) &#160;terminate or modify in any respect, or fail to exercise renewal rights with respect to, any material insurance policy;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(xv) &#160;&#160;enter into, amend, terminate, or waive any option or right under, any Parent Material Contract or Contract that would be deemed to be a Parent Material Contract if entered into on or prior to the date hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(xvi) &#160;&#160;other than the incurrence or payment of any Transaction Expenses, make any expenditures, incur any liabilities or discharge or satisfy any obligations;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(xvii)&#160;enter into any agreement to purchase or sell any interest in real property, grant any security interest in any real property, enter into any lease, sublease, license or other occupancy agreement with respect to any real property or alter, amend, modify, exercise any extension or expansion right under or violate or terminate any of the terms of any real property leases of Parent;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(xviii)&#160;other than as expressly required by Law or GAAP, take any action to change accounting policies or procedures;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(xix) &#160;&#160;(A)&#160;change pricing or royalties or other payments set or charged by Parent or any of Subsidiaries to its customers or licensees or (B)&#160;agree to change pricing or royalties or other payments set or charged by Persons who have licensed Intellectual Property to Parent or any of its Subsidiaries; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(xx) &#160;&#160;agree, resolve or commit to do any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the Effective Time. Prior to the Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Notwithstanding any provision herein to the contrary (including the foregoing provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1</span>), Parent may engage in the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) and/or winding down of, and/or the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or other disposition of any Parent Legacy Assets (each, an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Legacy Transaction</span>&#8221;); provided, however, that to the extent any Parent Legacy Transaction results in any monetary or other material obligations of Parent or otherwise or which could cause Parent to incur any material liability that could extend beyond Closing or contemplates that any consideration paid in respect thereof is in anything other than immediately available cash, or otherwise interferes with or delays in any manner the ability of Parent to perform its obligations under this Agreement or timely consummate the transactions contemplated hereby, Parent shall procure prior written consent of the Company prior to entering into any Parent Legacy Transaction. Notwithstanding anything to the contrary herein, Parent (i)&#160;shall permit the Company and its counsel to review and comment on the transaction documents related to the Parent Legacy Transaction; (ii)&#160;shall consider any such comments in good faith and shall accept all reasonable additions, deletions or changes suggested by the Company and its counsel in connection therewith; and (iii)&#160;shall not sign any agreements, contracts or other definitive documents (not including term sheets or letters of intent) related to Parent Legacy Transaction without first providing the Company and its counsel the opportunity to exercise their rights under clauses (i)&#160;and (ii)&#160;above.</p><a id="Section62_142042"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;6.2&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operation of Company&#8217;s Business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except (i)&#160;as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in Section&#160;6.2(a)&#160;of the Company Disclosure Letter, (iii)&#160;as expressly required by applicable Law or (iv)&#160;unless Parent shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the Pre-Closing Period, the Company shall, and shall </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">cause its Subsidiaries to, use commercially reasonable efforts to conduct its business and operations in the Ordinary Course and in material compliance with the applicable Law and the requirements of all Contracts that constitute Material Contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except (i)&#160;as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.2(b)</span>&#160;of the Company Disclosure Letter, (ii)&#160;as expressly required by applicable Law or (iii)&#160;with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except for shares of Company Common Stock from terminated employees, directors or consultants of the Company);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(ii)&#160;&#160;&#160;&#160;&#160;sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of any of the foregoing actions: (A)&#160;any capital stock or other security, (B)&#160;any option, warrant or right to acquire any capital stock or any other security or (C)&#160;any instrument convertible into or exchangeable for any capital stock or other security;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iii)&#160;&#160;&#160;&#160;amend any of its organizational documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(iv)&#160;&#160;&#160;&#160;&#160;form any Subsidiary or acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;(A)&#160;lend money to any Person, (B)&#160;incur or guarantee any indebtedness for borrowed money, or (C)&#160;guarantee any debt securities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(vi)&#160;&#160;&#160;&#160;sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Lien with respect to such assets or properties;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(vii)&#160;&#160;&#160;waive, settle or compromise any pending or threatened Action against the Company or any of its Subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of the Company or its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by the Company or any of its Subsidiaries;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(viii)&#160;&#160;delay or fail to repay when due any material obligation, including accounts payable and accrued expenses, other than in the Ordinary Course;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(ix)&#160;&#160;&#160;make, change or revoke any material Tax election; file any amended income or other material Tax Return; settle or compromise any material Tax claim; waive or extend any statute of limitations in respect of a period within which an assessment or reassessment of material Taxes may be issued (other than any extension pursuant to an extension to file any Tax Return); enter into any &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar Law) with any Governmental Entity; surrender any material claim for refund; or adopt or change any material accounting method in respect of Taxes;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(x)&#160;&#160;&#160;&#160;&#160;sell, assign, transfer, license, sublicense or otherwise dispose of any Intellectual Property of the Company; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(xi)&#160;&#160;&#160;&#160;agree, resolve or commit to do any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the Effective Time. Prior to the Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Section63_595445"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;6.3&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Access and Investigation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Subject to the terms of the Confidentiality Agreement, which the parties agree will continue in full force following the date of this Agreement, during the Pre-Closing Period, upon reasonable advance written notice and during normal business hours, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such party&#8217;s Representatives to: (a)&#160;provide the other party and such other party&#8217;s Representatives with reasonable access during normal business hours to such party&#8217;s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such party and its Subsidiaries, (b)&#160;provide the other party and such other party&#8217;s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data and other documents and information relating to such party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such party and its Subsidiaries as the other party may reasonably request, (c)&#160;permit the other party&#8217;s officers and other employees to meet with the chief financial officer and other officers and managers of such party responsible for such party&#8217;s financial statements and the internal controls of such party to discuss such matters as the other party may deem necessary and (d)&#160;make available to the other party copies of any material notice, report or other document filed with or sent to or received from any Governmental Entity in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3(a)</span>&#160;shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Notwithstanding anything herein to the contrary in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3(b)</span>, no access or examination contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3(b)</span>&#160;shall be permitted to the extent that it would require any party or its Subsidiaries (i)&#160;to waive the attorney-client privilege or attorney work product privilege, (ii)&#160;violate any applicable Law or (iii)&#160;breach such party&#8217;s confidentiality obligations to a third party; provided, that such party or its Subsidiary (A)&#160;shall be entitled to withhold only such information that may not be provided without causing such violation or waiver, (B)&#160;shall provide to the other party all related information that may be provided without causing such violation or waiver (including, to the extent permitted, redacted versions of any such information), (C)&#160;shall enter into such effective and appropriate joint-defense agreements or other protective arrangements as may be reasonably requested by the other party in order that all such information may be provide to the other party without causing such violation or waiver, and (D)&#160;in the case of subsection (iii)&#160;above, upon the other party&#8217;s reasonable request, such party shall use its reasonable efforts to obtain such third party&#8217;s consent to permit such other party access to such information, subject to appropriate confidentiality protections. In addition, no access or examination contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3</span> shall be permitted to the extent that it would require any party or its Subsidiaries, except as otherwise expressly required by this Agreement, to provide (A)&#160;information to the other party that relates to the negotiation of this Agreement, (B)&#160;information to the other party that relates to any process a party has conducted with any financial advisor or other communications with any Persons in connection therewith, or (C)&#160;minutes of the meetings of the board of directors of a party or any committee thereof discussing the transactions contemplated hereby.</p><a id="Section64_236943"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;6.4&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Solicitation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Each of Parent (except as it relates to the Concurrent Investment and any Parent Legacy Transaction) and the Company agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize any of its Representatives to, directly or indirectly: (i)&#160;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry, (ii)&#160;furnish any nonpublic information regarding such party to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry, (iii)&#160;engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry, (iv)&#160;approve, endorse or recommend any Acquisition Proposal (subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3</span>), (v)&#160;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction, (vi)&#160;take any action that would reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry or (vii)&#160;publicly propose to do any of the following; provided, however, that, notwithstanding anything contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span> and subject to compliance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span>, prior to obtaining the Parent Stockholder Approval, Parent may furnish nonpublic information regarding Parent and its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal by such Person which the Parent Board determines in good faith, after consultation with its financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A)&#160;such Acquisition Proposal was not obtained or made as a direct or indirect result of any breach of this Agreement, (B)&#160;the Parent Board concludes in good faith, after consulting with outside counsel, that the failure to take such action would reasonably be expected to be inconsistent with the Parent Board&#8217;s fiduciary duties under applicable Law, (C)&#160;at least two (2)&#160;Business Days prior to initially furnishing any such nonpublic information to, or enter into discussions with, such Person, Parent provides the Company written </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">notice of the identity of such Person and of Parent&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such Person, (D)&#160;Parent receives from such Person an executed Acceptable Confidentiality Agreement and (E)&#160;at least two (2)&#160;Business Days prior to furnishing any such nonpublic information to such Person, Parent furnishes such nonpublic information to the Company (to the extent such information has not been previously furnished by Parent to the Company). Without limiting the generality of the foregoing, each party acknowledges and agrees that, in the event any Representative of such party takes any action that, if taken by such party, would constitute a breach of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span> by such party, the taking of such action by such Representative shall be deemed to constitute a breach of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span> by such party for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If any party or any Representative of such party receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then such party shall promptly (and in no event later than one (1)&#160;Business Day after such party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other party orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such party shall keep the other party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Each party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any nonpublic information provided to such Person as soon as reasonably practicable after the date of this Agreement.</p><a id="Section65_724438"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;6.5&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notification of Certain Matters</span>. During the Pre-Closing Period, each of the Company, on the one hand, and Parent, on the other hand, shall promptly notify the other (and, if in writing, furnish copies of) if any of the following occurs: (a)&#160;any notice or other communication is received from any Person alleging that the consent of such Person is or may be required in connection with any of the Contemplated Transactions, (b)&#160;any Action against or involving or otherwise affecting such party or its Subsidiaries is commenced, or, to the knowledge of such party, threatened against such party or, to the knowledge of such party, any director, officer or employee of such party, (c)&#160;such party becomes aware of any inaccuracy in any representation or warranty made by such party in this Agreement or (d)&#160;the failure of such party to comply with any covenant or obligation of such party; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VII</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VIII</span>, as applicable, impossible or materially less likely. No such notice shall be deemed to supplement or amend the Company Disclosure Letter or the Parent Disclosure Letter for the purpose of (x)&#160;determining the accuracy of any of the representations and warranties made by the Company or Parent in this Agreement or (y)&#160;determining whether any condition set forth in Article&#160;VII or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VIII</span> has been satisfied. Any failure by either party to provide notice pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.5</span> shall not be deemed to be a breach for purposes of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.2(b)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.3(b)</span>, as applicable, unless such failure to provide such notice was knowing and intentional.</p><a id="Section66_54265"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;6.6&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[RESERVED]</span>.</p><a id="Section67_877834"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;6.7&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[RESERVED]</span>.</p><a id="Section68_781194"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;6.8&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent ESPP</span>. As soon as reasonably practicable following the date of this Agreement, the Parent Board shall adopt appropriate resolutions to provide that (a)&#160;no offering periods or purchase periods shall be commenced following or in addition to the offering period underway as of the date hereof under the Parent ESPP (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Current Offering Period</span>&#8221;), (b)&#160;no payroll deductions or other contributions shall be made or effected after the Current Offering Period with respect to the Parent ESPP after the date of such resolutions, and (c)&#160;the Current Offering Period shall be terminated and each Parent ESPP participant&#8217;s accumulated contributions under the Parent ESPP shall be returned to the participant in accordance with the terms of the Parent ESPP.</p><a id="Section69_228371"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;6.9&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent 401(K)&#160;Plan</span>. If requested by the Company in writing at least ten (10)&#160;Business Days prior to the Closing Date, the Parent Board or an authorized committee thereof shall take (or cause to be taken) all actions to adopt such resolutions as may be necessary or appropriate to terminate, effective no later than the day prior to the Closing Date but subject to the Closing, any Parent Plan that contains a cash or deferred arrangement intended to qualify under Section&#160;401(k)&#160;of the Code (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent 401(k)&#160;Plan</span>&#8221;). If Parent is required to terminate any Parent 401(k)&#160;Plan, then Parent shall provide to the Company prior to the Closing Date written evidence of the adoption by the Parent Board or an authorized committee thereof of resolutions authorizing the termination of such Parent 401(k)&#160;Plan (the form and substance of which shall be subject to the reasonable prior review and approval of the Company, not to be unreasonably withheld, conditioned or delayed).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="ARTICLEVII_796982"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ADDITIONAL AGREEMENTS</b></p><a id="Section71_165354"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.1&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Statement; Proxy Statement</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>As promptly as practicable (but in any event, no later than July&#160;18, 2025), (i)&#160;Parent shall prepare, and file with the SEC a proxy statement relating to the Parent Stockholders Meeting to be held in connection with the Merger (together with any amendments thereof or supplements thereto, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proxy Statement</span>&#8221;) and (ii)&#160;Parent, in cooperation with the Company, shall prepare and file with the SEC a registration statement on Form&#160;S-4 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Form&#160;S-4</span>&#8221;), in which the Proxy Statement shall be included as a part (the Proxy Statement and the Form&#160;S-4, collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Statement</span>&#8221;), in connection with the registration under the Securities Act of the shares of Parent Common Stock to be issued by virtue of the Contemplated Transactions, other than any shares of Parent Capital Stock which are not permitted to be registered on Form&#160;S-4 pursuant to applicable Law. Parent shall use its reasonable best efforts to (i)&#160;cause the Registration Statement to comply with the applicable rules&#160;and regulations promulgated by the SEC, (ii)&#160;cause the Registration Statement to become effective as promptly as practicable, and (iii)&#160;respond promptly to any comments or requests (written or oral) of the SEC or its staff relating to the Registration Statement. Parent shall promptly notify the Company upon the receipt of any comments or requests (written or oral) from the SEC or its staff or any request from the SEC or its staff for amendments or supplements to the Registration Statement. Parent shall take all or any action required under any applicable federal, state, securities and other Laws in connection with the issuance of shares of Parent Capital Stock pursuant to the Contemplated Transactions. Each of the parties shall reasonably cooperate with the other party and furnish all information concerning itself and their Affiliates, as applicable, to the other parties that is required by law to be included in the Registration Statement as the other parties may reasonably request in connection with such actions and the preparation of the Registration Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Parent covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will (i)&#160;comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL, and (ii)&#160;will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company covenants and agrees that the information supplied by or on behalf of the Company, concerning itself, to Parent for inclusion in the Registration Statement will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make such information, in light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, neither party makes any covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), if any, based on information provided by the other party or any of their Representatives regarding such other party or its Affiliates for inclusion therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#8217;s stockholders as promptly as practicable (but in any event no later than two (2)&#160;Business Days) after the Registration Statement is declared effective under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>If at any time before the Effective Time (i)&#160;any party (A)&#160;becomes aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement, (B)&#160;receives notice of any SEC request for an amendment or supplement to the Registration Statement or for additional information related thereto, or (C)&#160;receives SEC comments on the Registration Statement, or (ii)&#160;the information provided in the Registration Statement has become &#8220;stale&#8221; and new information should be disclosed in an amendment or supplement to the Registration Statement; then, in each case such party, as the case may be, shall promptly inform the other parties thereof and shall cooperate with such other parties in filing such amendment or supplement with the SEC (and, if appropriate, in mailing such amendment or supplement to the Parent stockholders) or otherwise addressing such SEC request or comments and each party shall use their commercially reasonable efforts to cause any such amendment to become effective, if required. Parent shall promptly notify the Company if it becomes aware (1)&#160;that the Registration Statement has become effective, (2)&#160;of the issuance of any stop order or suspension of the qualification or registration of the Parent Capital Stock issuance in connection with the Contemplated Transactions for offering or sale in any jurisdiction, or (3)&#160;any order of the SEC related to the Registration Statement, and shall promptly provide to the Company copies of all written correspondence between it or any of its Representatives, on the one hand, and the SEC or staff of the SEC, on the other hand, with respect to the Registration Statement and all orders of the SEC relating to the Registration Statement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>The Company shall reasonably cooperate with Parent and provide, and cause its Representatives to provide, Parent and its Representatives, with all true, correct and complete information regarding the Company that is required by law to be included in the Registration Statement or reasonably requested by Parent to be included in the Registration Statement. Without limiting the Company&#8217;s obligations in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.1(a)</span>, the Company will use commercially reasonable efforts to cause to be delivered to Parent a letter of the Company&#8217;s independent accounting firm, dated no more than two (2)&#160;Business Days before the date on which the Registration Statement becomes effective (and reasonably satisfactory in form and substance to Parent), that is customary in scope and substance for letters delivered by independent public accountants in connection with registration statements similar to the Registration Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#8239;The Company and its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration Statement, prior to the filing thereof with the SEC. No filing of, or amendment or supplement to, the Registration Statement will be made by Parent, and no filing of, or amendment or supplement to, the Registration Statement will be made by Parent, in each case, without the prior consent of the Company, which shall not be unreasonably withheld, conditioned or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>As promptly as reasonably practicable (and in no event by July&#160;9, 2025), the Company shall furnish to Parent (i)&#160;audited financial statements for each of its fiscal years required to be included in the Registration Statement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Audited Financial Statements</span>&#8221;) and (ii)&#160;unaudited interim financial statements for each interim period completed prior to Closing that would be required to be included in the Registration Statement or any periodic report due prior to the Closing if the Company were subject to the periodic reporting requirements under the Securities Act or the Exchange Act (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Interim Financial Statements</span>&#8221;). Each of the Company Audited Financial Statements and the Company Interim Financial Statements will be prepared in accordance with GAAP as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto and except, in the case of any unaudited financial statements, to normal year-end audit adjustments) and on that basis will present fairly, in all material respects, the financial position and the results of operations, changes in stockholders&#8217; equity, and cash flows of the Company as of the dates of and for the periods referred to in the Company Audited Financial Statements or the Company Interim Financial Statements, as the case may be.</p><a id="Section72_549754"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.2&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Stockholder Approval</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Promptly after the Registration Statement has been declared effective under the Securities Act, and in any event no later than one (1)&#160;Business Day thereafter, the Company shall solicit for approval the Company Stockholder Approval. Under no circumstances shall the Company assert that any other approval or consent (including with respect to any approval by Guarantor) is necessary to approve this Agreement and the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Company agrees that subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2(c)</span>: (i)&#160;the Company Board shall recommend that the Company&#8217;s sole stockholders vote to adopt and approve this Agreement and the Contemplated Transactions and shall use commercially reasonable efforts to solicit such approval within the time set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2(a)</span>&#160;(the recommendation of the Company Board that the Company&#8217;s sole stockholder vote to adopt and approve this Agreement being referred to as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Board Recommendation</span>&#8221;) and (ii)&#160;the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (ii), collectively, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Board Adverse Recommendation Change</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Notwithstanding anything to the contrary contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2(b)</span>, and subject to compliance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2</span>, if at any time prior to approval and adoption of this Agreement by the Company Stockholder Approval, the Company receives a bona fide written Superior Offer, the Company Board may make a Company Board Adverse Recommendation Change if, but only if, in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (1)&#160;the Company Board determines in good faith, after consulting with outside legal counsel, that the failure to withhold, amend, withdraw or modify such recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (2)&#160;the Company has, and has caused its financial advisors and outside legal counsel to, during the Company Notice Period, negotiate with Parent in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer (to the extent Parent desires to negotiate) and (3)&#160;if after Parent shall have delivered to the Company an irrevocable written offer to alter the terms or conditions of this Agreement during the Company </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Notice Period, the Company Board shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); provided that (x)&#160;Parent receives written notice from the Company confirming that the Company Board has determined to change its recommendation at least four (4)&#160;Business Days in advance of the Company Board Adverse Recommendation Change (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Notice Period</span>&#8221;), which notice shall include a description in reasonable detail of the reasons for such Company Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (y)&#160;during any Company Notice Period, Parent shall be entitled to deliver to the Company one or more counterproposals to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with Parent in good faith (to the extent Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (z)&#160;in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration or percentage of the combined company that the Company&#8217;s stockholders would receive as a result of such potential Superior Offer), the Company shall be required to provide Parent with notice of such material amendment and the Company Notice Period shall be extended, if applicable, to ensure that at least two (2)&#160;Business Days remain in the Company Notice Period following such notification during which the parties shall comply again with the requirements of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2(c)</span>&#160;and the Company Board shall not make a Company Board Adverse Recommendation Change prior to the end of such Company Notice Period as so extended (it being understood that there may be multiple extensions).</p><a id="Section73_635842"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.3&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Stockholders&#8217; Meeting</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Stockholder Meeting</span>&#8221;) to consider and obtain the Parent Stockholder Approval and thereby approve the Contemplated Transactions and the Parent Charter Amendment and, if deemed necessary by Parent, any Parent Legacy Transaction (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Stockholder Proposals</span>&#8221;). The Parent Stockholder Meeting shall be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act, and in any event no later than forty-five (45) days after the effective date of the Registration Statement. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholder Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Stockholder Meeting, or a date preceding the date on which the Parent Stockholder Meeting is scheduled, Parent reasonably determines in good faith that (i)&#160;it will not receive proxies sufficient to obtain the Parent Stockholder Approval, whether or not a quorum would be present or (ii)&#160;it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholder Meeting, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholder Meeting as long as the date of the Parent Stockholder Meeting is not postponed or adjourned by more than an aggregate of thirty (30) days in connection with any postponements or adjournments. Except as required by applicable Law, in no event shall the record date of the Parent Stockholders&#8217; Meeting be changed without Company&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Parent agrees that, subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(c)</span>, (i)&#160;the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder Proposals and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(a)</span>&#160;above and (ii)&#160;the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent&#8217;s stockholders vote to approve the Parent Stockholder Proposal (the recommendation of the Parent Board being referred to as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Board Recommendation</span>&#8221;) and (iii)&#160;the Parent Board Recommendation shall not be withheld, amended, withdrawn or modified (and the Parent Board shall not publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company, and no resolution by the Parent Board or any committee thereof to withdraw or modify the Parent Board Recommendation in a manner adverse to the Company or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (iii), collectively, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Board Adverse Recommendation Change</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Notwithstanding anything to the contrary contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(b)</span>, and subject to compliance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3</span>, at any time prior to the approval of the Parent Stockholder Proposal by the Parent Stockholder Approval, (i)&#160;if Parent receives a bona fide written Superior Offer or (ii)&#160;as a result of a material development or change in circumstances that was not known to, or reasonably foreseeable by, the Parent Board prior to the date hereof (other than any such event, development or change to the extent related to (A)&#160;any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof or (B)&#160;the fact, in and of itself, that Parent meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of Parent that occurs or arises </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">after the date of this Agreement (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Intervening Event</span>&#8221;), the Parent Board may make a Parent Board Adverse Recommendation Change if, but only if in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (1)&#160;the Parent Board determines in good faith, after consulting with outside legal counsel, that the failure to withhold, amend, withdraw or modify such recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (2)&#160;Parent has, and has caused its financial advisors and outside legal counsel to, during the Parent Notice Period, negotiate with the Company in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer (to the extent the Company desires to negotiate) and (3)&#160;if after the Company shall have delivered to Parent an irrevocable written offer to alter the terms or conditions of this Agreement during the Parent Notice Period, the Parent Board shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); provided that (x)&#160;the Company receives written notice from Parent confirming that the Parent Board has determined to change its recommendation at least four (4)&#160;Business Days in advance of the Parent Board Adverse Recommendation Change (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Notice Period</span>&#8221; ), which notice shall include a description in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (y)&#160;during any Parent Notice Period, the Company shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and cause its Representatives to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (z)&#160;in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration or percentage of the combined company that Parent&#8217;s stockholders would receive as a result of such potential Superior Offer), Parent shall be required to provide the Company with notice of such material amendment and the Parent Notice Period shall be extended, if applicable, to ensure that at least two (2)&#160;Business Days remain in the Parent Notice Period following such notification during which the parties shall comply again with the requirements of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(c)</span>&#160;and the Parent Board shall not make a Parent Board Adverse Recommendation Change prior to the end of such Parent Notice Period as so extended (it being understood that there may be multiple extensions) or (ii)&#160;in the case of a Parent Intervening Event, Parent promptly notifies the Company, in writing, within the Parent Notice Period before making a Parent Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Parent Intervening Event and that the Parent Board intends to make a Parent Board Adverse Recommendation Change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Unless this Agreement is validly terminated pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(j)</span>, Parent&#8217;s obligation to call, give notice of and hold the Parent Stockholder Meeting in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(a)</span>&#160;shall not be limited to or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or Acquisition Proposal, or by any withdrawal or modification of the Parent Board Recommendation or any Parent Board Adverse Recommendation Change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Nothing contained in this Agreement shall prohibit Parent or the Parent Board from complying with Rules&#160;14d-9 and 14e-2(a)&#160;promulgated under the Exchange Act; provided however, that any disclosure made by Parent or the Parent Board pursuant to Rules&#160;14d-9 and 14e-2(a)&#160;shall be limited to a statement that Parent is unable to take a position with respect to the bidder&#8217;s tender offer unless the Parent Board determines in good faith, after consultation with its outside legal counsel, that such statement would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law.</p><a id="Section74_201965"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.4&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Efforts; Transaction Litigation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The parties shall use commercially reasonable efforts to consummate the Contemplated Transactions. Without limiting the generality of the foregoing, each party: (i)&#160;shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such party in connection with the Contemplated Transactions, (ii)&#160;shall use commercially reasonable efforts to obtain each consent (if any) reasonably required to be obtained (pursuant to any applicable law or Contract, or otherwise) by such party in connection with the Contemplated Transactions or for such Contract to remain in full force and effect, (iii)&#160;shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (iv)&#160;shall use commercially reasonable efforts to satisfy the conditions precedent to the consummations of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Notwithstanding the generality of the foregoing, each party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted by such party to any Governmental Entity with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental Entity.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Without limiting the generality of the foregoing, Parent shall give the Company prompt (but not later than within two (2)&#160;Business Days) written notice of any &#8220;demand letter&#8221; or any litigation initiated, or threatened or in writing against Parent and/or its directors relating to this Agreement or the Contemplated Transactions (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Litigation</span>&#8221;) (including by providing copies of all pleadings with respect thereto) and keep the Company reasonably informed with respect to the status thereof. Subject to the penultimate sentence of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.4(c)</span>, Parent shall, on behalf of the parties hereto, control and lead all communications and strategy relating to any Transaction Litigation, subject to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.4(c)</span>. Parent will (i)&#160;give the Company the opportunity to participate in the defense, settlement or prosecution of any Transaction Litigation, (ii)&#160;consult with the Company with respect to the defense, settlement and prosecution of any Transaction Litigation, (iii)&#160;consider in good faith the Company&#8217;s advice with respect to such Transaction Litigation and (iv)&#160;will not settle or consent or agree to settle or compromise any Transaction Litigation without the Company&#8217;s prior written consent (which such consent shall not be unreasonably withheld or delayed). Without otherwise limiting the rights of current or former directors and officers of Parent with regard to the right to counsel, following the Effective Time, current or former directors and officers of Parent with rights to indemnification as described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span> shall be entitled to retain any counsel selected by such indemnified parties to defend any Transaction Litigation as it relates to such indemnified parties in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span>.</p><a id="Section75_568219"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.5&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification, Exculpation and Insurance</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>From the Effective Time through the sixth (6th) anniversary of the date on which the Effective Time occurs, each of Parent and the Surviving Company shall indemnify and hold harmless each Person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a director or officer of Parent or the Company, respectively (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">D&amp;O Indemnified Parties</span>&#8221;), against all demands, claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, Action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Parent or of the Company, whether asserted or claimed prior to, at or after the Effective Time, in each case, to the fullest extent permitted under the DGCL. Each D&amp;O Indemnified Party will be entitled to advancement of fees, costs and expenses incurred in the defense of any such demand, claim, Action, suit, proceeding or investigation from each of Parent and the Surviving Company, jointly and severally, upon receipt by Parent or the Surviving Company from the D&amp;O Indemnified Party of a request therefor; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that any such D&amp;O Indemnified Party to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such D&amp;O Indemnified Party is not entitled to indemnification. Such undertaking, if required, shall be unsecured and made without reference to the D&amp;O Indemnified Party&#8217;s ability to repay such advances or, except as may be limited by applicable Law, ultimate entitlement to indemnification. No other form of undertaking shall be required. All rights to indemnification, exculpation and advancement of expenses or other protection in respect of any claim asserted or made, and for which a D&amp;O Indemnified Party delivers a written notice to Parent or the Surviving Company prior to the sixth (6<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) anniversary of the Effective Time asserting a claim for such protections pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span>, shall continue until the final disposition of such claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The provisions of the certificate of incorporation and bylaws of Parent with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Parent that are presently set forth in the certificate of incorporation and bylaws of Parent shall not be amended, modified or repealed for a period of six (6)&#160;years from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of Parent, unless such modification is required by applicable Law. The certificate of incorporation and bylaws of the Surviving Company shall contain, and Parent shall cause the certificate of incorporation and bylaws of the Surviving Company to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>From and after the Effective Time, (i)&#160;the Surviving Company shall fulfill and honor in all respects the obligations of the Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&#8217;s organizational documents and pursuant to any indemnification agreements between the Company and such D&amp;O Indemnified Parties, with respect to demands, claims, Actions, suits, proceedings or investigations whether asserted or claimed prior to, at or after the Effective Time, arising out of matters occurring at or prior to the Effective Time and (ii)&#160;Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent&#8217;s organizational documents and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified Parties, with respect to demands, claims, Actions, suits, proceedings or investigations whether asserted or claimed prior to, at or after the Effective Time, arising out of matters occurring at or prior to the Effective Time.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>From and after the Effective Time, Parent shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent. In addition, Parent shall purchase, prior to the Effective Time, a six-year prepaid &#8220;D&amp;O tail policy&#8221; for the non-cancellable extension of the directors&#8217; and officers&#8217; liability coverage of Parent&#8217;s existing directors&#8217; and officers&#8217; insurance policies for a claims reporting or discovery period of at least six years from and after the Effective Time with respect to any claim related to any period of time at or prior to the Effective Time with terms, conditions, exclusions, retentions and limits of liability that are no less favorable than the coverage provided under Parent&#8217;s existing policies as of the date of this Agreement with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter claimed against a director or officer of Parent by reason of him or her serving in such capacity that existed or occurred at or prior to the Effective Time (including in connection with this Agreement or the Contemplated Transactions or in connection with Parent&#8217;s initial public offering of shares of Parent Common Stock); provided, that, in satisfying its obligation under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5(d)</span>, neither Parent nor the Surviving Company shall be obligated to pay annual premiums in excess of 300% of the annual premium most recently paid by Parent prior to the date of this Agreement for such insurance (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Current Premium</span>&#8221;) and if such premiums for such insurance would at any time exceed 300% of the Current Premium, then Parent shall, and shall cause the Surviving Company to, maintain policies of insurance that, in Parent&#8217;s and the Surviving Company&#8217;s good faith judgment, provide the maximum coverage available at an annual premium equal to 300% of the Current Premium.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>The provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their Representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#8239;In the event Parent or the Surviving Company or any of their respective successors or assigns (i)&#160;consolidates with or merges into any other Person and shall not be the continuing or surviving company or entity of such consolidation or merger or (ii)&#160;transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Company, as the case may be, shall succeed to the obligations set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span>. Parent shall cause the Surviving Company to perform all of the obligations of the Surviving Company under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span>.</p><a id="Section76_973255"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.6&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;16 Matters</span>. Prior to the Effective Time, each of Parent and the Company shall take all such steps as may be necessary or appropriate to cause the acquisitions of Parent Capital Stock (including derivative securities with respect to such Parent Common Stock) resulting from the Contemplated Transactions by each individual who will become subject to the reporting requirements of Section&#160;16(a)&#160;of the Exchange Act with respect to Parent to be exempt under Rule&#160;16b promulgated under the Exchange Act.</p><a id="Section77_100583"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.7&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure</span>. The parties shall use their commercially reasonable efforts to agree to the text of any initial press release and Parent&#8217;s Form&#160;8-K announcing the execution and delivery of this Agreement. Without limiting any party&#8217;s obligations under the Confidentiality Agreement, no party shall, and no party shall permit any of its Subsidiaries or any of its Representatives to, issue any press release or make any disclosure (to any customers or employees of such party, to the public or otherwise) regarding the Contemplated Transactions unless (a)&#160;the other party shall have approved such press release or disclosure in writing, such approval not to be unreasonably conditioned, withheld or delayed; or (b)&#160;such party shall have determined in good faith, upon the advice of outside legal counsel, that such disclosure is requited by applicable Law and, to the extent practicable, before such press release or disclosure is issued or made, such party advises the other party of, and consults with the other party regarding, the text of such press release or disclosure; provided, however, that each of the Company and Parent may make any public statement in response to specific questions by the press, analysts, investors or those attending industry conferences or financial analyst conference calls, so long as any such statements made by the Company or Parent in compliance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.7</span>. Notwithstanding the foregoing, a party need not consult with any other parties in connection with such portion of any press release, public statement or filing to be issued or made pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(d)</span>&#160;or with respect to any Acquisition Proposal, Company Board Adverse Recommendation Change, Parent Board Adverse Recommendation Change, or pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(e)</span>.</p><a id="Section78_665636"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section&#160;7.8&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Listing</span>. From the date hereof until the Effective Time, Parent shall use commercially reasonable efforts to maintain its existing listing on Nasdaq until the Effective Time. At or prior to the Effective Time, (a)&#160;Parent and the Company shall reasonably cooperate to seek approval of the listing of the combined corporation on Nasdaq, (b)&#160;in accordance with the rules&#160;and regulations of Nasdaq, prepare and submit (with the prior approval of the Company) to Nasdaq a notification form for the listing of shares of Parent Common Stock to be issued in connection with the Contemplated Transactions, and (c)&#160;prepare and timely submit to Nasdaq a notification form for the Nasdaq Reverse Stock Split (if required) and submit a copy of the amendment to Parent&#8217;s certificate of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">incorporation effecting the Nasdaq Reverse Stock Split, certified by the Secretary of State of the State of Delaware to Nasdaq on the Closing Date. In accordance with Nasdaq Marketplace Rule&#160;5110, the Company shall prepare and file an initial listing application for the Parent Common Stock on Nasdaq (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq Listing Application</span>&#8221;), and from the date hereof until the Effective Time, Parent shall assist the Company in preparing and filing such Nasdaq Listing Application and to seek to cause such Nasdaq Listing Application to be conditionally approved prior to the Effective Time. Each party will reasonably promptly inform the other party of all verbal or written communications between Nasdaq and such party or its Representatives. Parent will cooperate with the Company as reasonably requested by the Company with respect to the Nasdaq Listing Application and use commercially reasonable efforts to reasonably promptly furnish to the Company all information concerning Parent that may be required or reasonably requested in connection with any action contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.8</span>.</p><a id="Section79_359500"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.9&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The parties intend that (i)&#160;the Merger shall be treated as a transaction that qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code, and (ii)&#160;the Merger shall qualify as a non-taxable exchange of shares of Company Common Stock for shares of Parent Common Stock within the meaning of Section&#160;351(a)&#160;of the Code. Each of Parent, Merger Sub and the Company shall use reasonable best efforts to cause the Merger to qualify, and agree not to, and not to permit or cause any of their Affiliates to, take any action or cause any action to be taken which to its knowledge would reasonably be expected to (A)&#160;prevent or impede the Merger from qualifying, as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code or (B)&#160;prevent or impede the Merger from qualifying as a non-taxable exchange of shares of Company Common Stock for shares of Parent Common Stock within the meaning of Section&#160;351(a)&#160;of the Code (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">U.S. Tax Treatment</span>&#8221;). This Agreement is intended to constitute, and the parties hereto hereby adopt this Agreement as, a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulation Sections 1.368-2(g)&#160;and 1.368-3(a). Each of Parent, Merger Sub and the Company shall report the Merger as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code unless otherwise required pursuant to a &#8220;determination&#8221; within the meaning of Section&#160;1313(a)&#160;of the Code, including attaching the statement described in Treasury Regulations Section&#160;1.368-3(a)&#160;on or with its Tax Return for the taxable year of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If, in connection with the preparation and filing of the Registration Statement or any other filing required by applicable Law or the SEC&#8217;s review thereof, the SEC requests or requires that a tax opinion with respect to the U.S. federal income tax consequences of the Merger and the intended U.S. Tax Treatment be prepared and submitted (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Opinion</span>&#8221;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8221;</span>), (i)&#160;Parent and the Company shall each use their respective reasonable best efforts to deliver to Wilmer Cutler Pickering Hale and Dorr LLP, counsel to Parent, and to Goodwin Procter LLP, counsel to the Company, customary Tax representation letters satisfactory to each such counsel, dated and executed as of the date such relevant filing shall have been declared effective by the SEC and such other date(s)&#160;as determined to be reasonably necessary by each such counsel in connection with the preparation and filing of such Registration Statement or any other filing required by applicable Law, (ii)&#160;Parent shall use its reasonable best efforts to cause Wilmer Cutler Pickering Hale and Dorr LLP to furnish a Tax Opinion addressed to Parent, subject to customary assumptions and limitations, satisfactory to the SEC, and (iii)&#160;the Company shall use its reasonable best efforts to cause Goodwin Procter LLP to furnish a Tax Opinion addressed to the Company, subject to customary assumptions and limitations, satisfactory to the SEC.</p><a id="Section710_169755"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.10&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Directors and Officers</span>. Until successors are duly elected or appointed and qualified in accordance with applicable Law, the parties shall use commercially reasonable efforts to take all necessary actions so that the Persons listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 2.6(c)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.6(d)</span>&#160;of the Company Disclosure Letter are elected or appointed, as applicable, to the positions of officers and directors of Parent and the Surviving Company, as set forth therein, to serve in such positions effective as of the Effective Time. If any Person listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.6(c)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.6(d)</span>&#160;of the Company Disclosure Letter is unable or unwilling to serve as officer or director of Parent or the Surviving Company, as set forth therein, the party appointing such Person (as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 2.6(c)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.6(d)</span>&#160;of the Company Disclosure Letter) shall designate a successor. The parties shall use reasonable best efforts to have each of the Persons that will serve as directors and officers of the Parent following the Closing to execute and deliver a Lock-Up Agreement prior to Closing.</p><a id="Section711_397314"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.11&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligations of Merger Sub</span>. Parent will take all action necessary to cause Merger Sub to perform its obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement.</p><a id="Section712_304407"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.12&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation Certificate</span>. The Company will prepare and deliver to Parent at least five (5)&#160;Business Days prior to the Closing Date a spreadsheet setting forth (as of immediately prior to the Effective Time) (a)&#160;each holder of the Company Common Stock, (b)&#160;such holder&#8217;s name and physical address, (c)&#160;the number or percentage of the Company Common Stock held as of the Closing Date for each such holder and (d)&#160;the number of shares of Parent Capital Stock to be issued to such holder pursuant to this Agreement in respect of the Company Common Stock held by such holder as of immediately prior to the Effective Time (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation Certificate</span>&#8221;).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Section713_163861"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.13&#160;&#160;&#160;[<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RESERVED</span>].</p><a id="Section714_186496"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.14&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concurrent Investment</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Subject to the terms and conditions of this Agreement, the parties shall use commercially reasonable efforts to enter into Securities Purchase Agreements with one or more investors designated by the Company to subscribe for and purchase a number of shares of Parent Common Stock representing an aggregate commitment (inclusive of the Guarantor Investment Amount) at least equal to the Concurrent Investment Amount and to satisfy the conditions to the Concurrent Investment as set forth in the applicable Securities Purchase Agreement; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the form, terms and conditions of each Securities Purchase Agreement shall be in a form reasonably acceptable to each of the Company and Parent. The Company shall provide Parent at least five (5)&#160;Business Days&#8217; written notice prior to the execution of each Securities Purchase Agreement, which such execution shall be subject to the prior consent of Parent (such consent not to be unreasonably withheld, conditioned or delayed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>On or before August&#160;1, 2025, Guarantor shall enter into a Securities Purchase Agreement committing to purchase not less than the Guarantor Investment Amount, with terms (other than the Guarantor Investment Amount) and conditions of such Securities Purchase Agreement to be substantially similar to the terms of the Securities Purchase Agreement entered into by other investors of the Concurrent Investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Prior to the earlier of (i)&#160;the Closing and (ii)&#160;the termination of this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1</span>, Parent agrees, and shall cause its officers and employees, to use commercially reasonable efforts to cooperate in connection with the Concurrent Investment as may be reasonably requested by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>At or immediately following the Closing, in accordance with the terms and conditions of the Securities Purchase Agreement(s), Parent shall consummate the Concurrent Investment, and issue the equity contemplated thereunder.</p><a id="Section715_969743"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.15&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Equity Plans</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Prior to the Effective Time, the Parent Board will adopt the 2025 Equity Incentive Plan, subject to the Closing and effective as of the Effective Time, and will include provisions in the Proxy Statement for the stockholders of Parent to approve the 2025 Equity Incentive Plan. Subject to the approval of the 2025 Equity Incentive Plan by the stockholders of Parent prior to the Effective Time, Parent shall file with the SEC, promptly after the Effective Time and at the Company&#8217;s expense, a registration statement on Form&#160;S-8 (or any successor form), if available for use by Parent, relating to the shares of Parent Common Stock issuable with respect to the 2025 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Prior to the Effective Time, the Parent Board will adopt the 2025 ESPP, subject to the Closing and effective as of the Effective Time, and will include provisions in the Proxy Statement for the stockholders of Parent to approve the 2025 ESPP. Subject to the approval of the 2025 ESPP by the stockholders of Parent prior to the Effective Time, Parent shall file with the SEC, promptly after the Effective Time and the Company&#8217;s expense, a registration statement on Form&#160;S-8 (or any successor form), if available for use by Parent, relating to the shares of Parent Common Stock issuable with respect to the 2025 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>For the avoidance of doubt, approval of the 2025 Plans by the stockholders of Parent shall not be a condition to Closing.</p><a id="Section716_431477"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.16&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent SEC Documents</span>. From the date of this Agreement to the Effective Time, Parent shall timely file with the SEC all Parent SEC Documents. As of its filing date, or if amended after the date of this Agreement, as of the date of the last such amendment, each Parent SEC Document filed by Parent with the SEC (a)&#160;shall comply in all material respects with the applicable requirements of the Exchange Act and the Securities Act, and (b)&#160;shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</p><a id="Section717_570155"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section&#160;7.17&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Legacy Assets</span>. Prior to the Closing Date, but subject to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.17</span>, Parent shall be entitled, but under no obligation, to sell, transfer, license, assign or otherwise divest the Parent Legacy Assets to one or more third parties in one or a series of transactions prior to or substantially, concurrently with the Closing (each an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Asset Disposition</span>&#8221; and collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Asset Dispositions</span>&#8221;). Notwithstanding the foregoing, Parent may not enter into any agreement with respect to any Asset Disposition that would result in a continuing obligation or liability without the prior written consent of the Company (such consent shall not be unreasonably withheld, conditioned or delayed); <i style="font-style:italic;">provided</i>, that Parent shall provide the Company with a copy of any agreement with respect to an Asset Disposition that would be reasonably likely to result in such continuing obligation or liability of either Parent or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the Company on or after the Effective Time at least five (5)&#160;Business Days prior to entry into such agreement. Parent shall (i)&#160;permit the Company and its counsel to review and comment on the transaction documents related to any Asset Dispositions (ii)&#160;consider any such comments in good faith and shall accept all reasonable additions, deletions or changes suggested by the Company and its counsel in connection therewith; and (iii)&#160;not sign any agreements, contracts or other definitive documents (not including term sheets or letters of intent) related to without first providing the Company and its counsel the opportunity to exercise their rights under clauses (i)&#160;and (ii)&#160;above. For the avoidance of doubt, any sale, transfer, license, assignment or other divestiture of Parent Legacy Assets on or after the Closing Date shall be governed by the terms and conditions of the CVR Agreement. Parent shall deliver an executed copy of the CVR Agreement to the Company prior to the Closing.</p><a id="Section718_882484"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.18&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arrangements Between Company and Company Guarantor</span>. Prior to the Closing, the Company and the Company Guarantor shall enter into the Transition Services Agreement and the Manufacturing and Supply Agreement, the material terms of which will be substantially final on or prior to July&#160;11, 2025, in each case, by and between the Guarantor and the Company, each in form and substance reasonably satisfactory to the Company and the Guarantor (subject to Parent&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed. At least five (5)&#160;Business Days prior to July&#160;11, 2025, the Company shall provide Parent with a reasonable opportunity to review and comment on draft versions of the Transition Services Agreement and the Manufacturing and Supply Agreement and the Company will consider in good faith any reasonable comments provided by Parent thereto.</p><a id="ARTICLEVIII_68041"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CLOSING CONDITIONS</b></p><a id="Section81_141667"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;8.1&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions Precedent of each Party</span>. The obligations of each party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable Law, the written waiver by each of the parties, at or prior to the Closing, of each of the following conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or proceeding seeking a stop order with respect to the Registration Statement and has not been withdrawn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>No temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Contemplated Transactions shall have been issued by any court of competent jurisdiction or other Governmental Entity of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>(i)&#160;Parent shall have obtained the Parent Stockholder Approval and (ii)&#160;the Company shall have obtained the Company Stockholder Approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>The Lock-Up Agreements will continue to be in full force and effect as of immediately following the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>The Parent Charter Amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments as are necessary to consummate the transactions contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Parent shall have obtained approval of the listing of the combined corporation on Nasdaq.</p><a id="Section82_329862"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;8.2&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions Precedent to Obligation of the Company</span>. The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accuracy of Representations</span>. The representations and warranties of Parent and Merger Sub made in this Agreement (other than the Parent Fundamental Representations) shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of the Closing Date except (a)&#160;in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications) or (b)&#160;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">and warranties, any update of or modification to the Parent Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded). The Parent Fundamental Representations shall have been true and correct except in de minimis respects as of the date of this Agreement and shall be true and correct except in de minimis respects on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;in respect of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2</span> for such inaccuracies which are de minimis, individually or in the aggregate or (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance of Covenants</span>. Parent shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Parent Material Adverse Effect</span>. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net Cash</span>. The Company shall have Net Cash of at least (-$1,000,000) (negative one million dollars).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Documents</span>. The Company shall have received the following documents, each of which shall be in full force and effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>a certificate executed by an officer of Parent certifying that the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.2(a)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b), (c)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(d)</span>&#160;have been duly satisfied; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>written resignations in forms reasonably satisfactory to the Company, dated as of the Closing Date and effective as of the Closing executed by the officers and directors of Parent who are not to continue as officers or directors of Parent pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.10</span>.</p><a id="Section83_748811"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Section&#160;8.3&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions Precedent of Parent and Merger Sub</span>. The obligations of Parent and Merger Sub to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accuracy of Representations</span>. The representations and warranties of the Company made in this Agreement (other than the Company Fundamental Representations) shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of the Closing Date except (a)&#160;in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Material Adverse Effect (without giving effect to any references therein to any Material Adverse Effect or other materiality qualifications) or (b)&#160;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded). The Company Fundamental Representations shall have been true and correct except in de minimis respects as of the date of this Agreement and shall be true and correct except in de minimis respects on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;in respect of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2</span> for such inaccuracies which are de minimis, individually or in the aggregate, (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date), or (z)&#160;variances arising solely due to the transactions contemplated under the Securities Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance of Covenants</span>. The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Material Adverse Effect</span>. Since the date of this Agreement, there shall not have occurred any Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Certificate</span>. Parent shall have received a certificate executed by an officer of the Company certifying (i)&#160;that the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.3(a)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b)</span>, and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(c)</span>&#160;have been duly satisfied, (ii)&#160;that the information set forth in the Allocation Certificate delivered by the Company in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.12</span> is true and accurate in all respects as of the Closing Date, and (iii)&#160;the Contribution has been completed.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="ARTICLEIX_583502"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;IX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TERMINATION</b></p><a id="Section91_252464"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;9.1&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</span>. This Agreement may be terminated prior to the Effective Time (whether before or after the adoption of this Agreement by the Company&#8217;s stockholders and whether before or after approval of the Parent Stockholder Proposal by Parent&#8217;s stockholders, unless otherwise specified below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>by mutual consent of Parent and the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>by either Parent or the Company if the Merger shall not have been consummated by December&#160;23, 2025 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">End Date</span>&#8221;); provided, however, that the right to terminate this Agreement under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(b)</span>&#160;shall not be available to the Company or Parent if such party&#8217;s (or in the case of Parent, Merger Sub&#8217;s) breach of this Agreement has been a principal cause of the failure of the Merger to occur on or before the End Date;;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>by either Parent or the Company if a court of competent jurisdiction or other Governmental Entity shall have issued a final and nonappealable order, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions, provided, however, that the right to terminate this Agreement under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(c)&#160;</span>shall not be available to a party if such party&#8217;s (or in the case of Parent, Merger Sub&#8217;s) breach of this Agreement is a principal cause of any such Governmental Entity issuing any such order or taking any such other action;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>by either Parent or the Company if the Company Stockholder Approval shall not have been obtained by written consent of the Company&#8217;s sole stockholder in lieu of a meeting within two (2)&#160;Business Days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act]; provided, however, that once the Company Stockholder Approval has been obtained, neither party may terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(d)</span>&#160;and (ii)&#160;the right to terminate this Agreement under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(d)</span>&#160;shall not be available to a party if such party&#8217;s (or in the case of Parent or Merger Sub&#8217;s) breach of this Agreement is a principal cause of the failure of the Company Stockholder Approval to have been obtained on or before such second (2nd) Business Day;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>by either Parent or the Company if (i)&#160;the Parent Stockholder Meeting (including any adjournments and postponements thereof) shall have been held and completed and Parent&#8217;s stockholders shall have taken a final vote on the Parent Stockholder Proposal and (ii)&#160;the Parent Stockholder Approval shall not have been obtained at the Parent Stockholder Meeting (or any adjournment or postponement thereof); provided, however, that the right to terminate this Agreement under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(e)</span>&#160;shall not be available to a party if such party&#8217;s (or in the case of Parent, Merger Sub&#8217;s) breach of this Agreement is a principal cause of the failure of the Parent Stockholder Approval to have been obtained at the Parent Stockholder Meeting;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#8239;by the Company (at any time prior to obtaining the Parent Stockholder Approval) if any Parent Triggering Event shall have occurred;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>by Parent (at any time prior to obtaining the Company Stockholder Approval) if any Company Triggering Event shall have occurred;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>by the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Sub or if any representation or warranty of Parent or Merger Sub shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.2(a)</span>&#160;or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.2(b)</span>&#160;would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; provided that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; provided, further that if such inaccuracy in Parent&#8217;s or Merger Sub&#8217;s representations and warranties or breach by Parent or Merger Sub is curable by Parent or Merger Sub, then this Agreement shall not terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(h)</span>&#160;as a result of such particular breach or inaccuracy until the earlier of (i)&#160;the expiration of a 30-day period commencing upon delivery of written notice from the Company to Parent or Merger Sub of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(h)</span>&#160;and (ii)&#160;Parent or Merger Sub (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from the Company to Parent or Merger Sub of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(h)</span>&#160;(it being understood that this Agreement shall not terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(h)</span>&#160;as a result of such particular breach or inaccuracy if such breach by Parent or Merger Sub is cured prior to such termination becoming effective);</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>by the Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of Parent or Merger Sub shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.3(a)</span>&#160;or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.3(b)</span>&#160;would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; provided that Parent is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; provided, further that if such inaccuracy in the Company&#8217;s representations and warranties or breach by the Company is curable by the Company, then this Agreement shall not terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(i)</span>&#160;as a result of such particular breach or inaccuracy until the earlier of (i)&#160;the expiration of a 30-day period commencing upon delivery of written notice from the Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(i)</span>&#160;and (ii)&#160;the Company ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(i)</span>&#160;(it being understood that this Agreement shall not terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(i)</span>&#160;as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective); or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>by Parent (at any time prior to obtaining the Parent Stockholder Approval) and following compliance with all of the requirements set forth in the proviso to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(j)</span>, concurrently with Parent&#8217;s entering into a definitive agreement for a Superior Offer (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Alternative Agreement</span>&#8221;) and after having paid to the Company the Company Termination Fee pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3(c)</span>; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i>, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</i>, that Parent shall not enter into any Permitted Alternative Agreement unless: (i)&#160;the Company shall have received written notice from Parent of Parent&#8217;s intention to enter into such Permitted Alternative Agreement at least four (4)&#160;Business Days in advance, with such notice describing in reasonable detail the reasons for such intention as well as the material terms and conditions of such Permitted Alternative Agreement, including the identity of the counterparty together with copies of the then current draft of such Permitted Alternative Agreement and any other related principal transaction documents, (ii)&#160;Parent shall have complied in all material respects with its obligations under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3</span>, and (iii)&#160;the Parent Board shall have determined in good faith, after consultation with its outside legal counsel, that the failure to enter into such Permitted Alternative Agreement would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span>By Parent, if the Company otherwise fails to secure the Concurrent Investment Amount such that as of September&#160;15, 2025, Parent has not received, or at any time ceases to have, aggregate commitments equal to or in excess of the Concurrent Investment Amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The party desiring to terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1</span> (other than pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(a)</span>) shall give a notice of such termination to the other party specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail.</p><a id="Section92_133533"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;9.2&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination</span>. In the event of the termination of this Agreement as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1</span>, this Agreement shall be of no further force or effect; provided, however, that (a)&#160;this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.2</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;X</span> (and the related definitions of the defined terms in such section) shall survive the termination of this Agreement and shall remain in full force and effect and (b)&#160;the termination of this Agreement and the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span> shall not relieve any party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement.</p><a id="Section93_567854"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;9.3&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses; Termination Fees</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.9</span> all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the party incurring such expenses, whether or not the Merger is consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If (i)&#160;this Agreement is terminated by Parent or the Company pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(e)</span>&#160;(<i style="font-style:italic;">Termination for Failure to Obtain Parent Stockholder Approval)</i> or by the Company pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(h)</span>&#160;(<i style="font-style:italic;">Termination for Parent Breach</i>)<i style="font-style:italic;">,</i> (ii)&#160;at any time after the date of this Agreement and prior to the Parent Stockholder Meeting an Acquisition Proposal with respect to Parent shall have been publicly announced, disclosed or otherwise communicated to the Parent Board (and shall not have been withdrawn) and (iii)&#160;within twelve (12) months after the date of such termination, Parent enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then Parent shall pay the Company, within two (2)&#160;Business Days after termination (or, if applicable, upon such entry into a definitive agreement and/or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $500,000 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Termination Fee</span>&#8221;).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>If this Agreement is terminated (i)&#160;by the Company or by Parent pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(b)</span>&#160;(<i style="font-style:italic;">Termination at End Date</i>) (at a time when the Company has the right to terminate this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(f)</span>&#160;(<i style="font-style:italic;">Termination for Parent Triggering Event</i>)) or pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(f)</span>&#160;(<i style="font-style:italic;">Termination for Parent Triggering Event</i>) or (ii)&#160;by Parent pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(j)</span>&#160;(<i style="font-style:italic;">Termination for Parent Superior Offer</i>), then Parent shall pay to the Company the Company Termination Fee, by wire transfer of same day funds to an account designated by the Company, (x)&#160;in the case of a termination by Parent referred to in the foregoing clause (i)&#160;or (ii), prior (and as a condition) to such termination or (y)&#160;in the case of a termination by the Company described in the foregoing clause (i), within two (2)&#160;Business Days after such termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>If (i)&#160;this Agreement is terminated by Parent or the Company pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(d)</span>&#160;(<i style="font-style:italic;">Termination for Failure to Obtain Company Stockholder Approval</i>) or by Parent pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(i)</span>&#160;(<i style="font-style:italic;">Termination for Company Breach</i>)<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">,</span> (ii)&#160;at any time after the date of this Agreement and prior to obtaining the Company Stockholder Approval, an Acquisition Proposal with respect to the Company shall have been publicly announced, disclosed or otherwise communicated to the Company Board (and shall not have been withdrawn) and (iii)&#160;within six (6)&#160;months after the date of such termination, the Company enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then the Company shall pay to Parent, within two (2)&#160;Business Days after termination (or, if applicable, upon the earlier of such entry into a definitive agreement and/or the consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $750,000 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Termination Fee</span>&#8221;), by wire transfer of same-day funds to an account designated by Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>If this Agreement is terminated by Parent or by the Company pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(b)</span>&#160;(<i style="font-style:italic;">Termination at End Date</i>) (at a time when Parent has the right to terminate this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(g)</span>&#160;(<i style="font-style:italic;">Termination for Company Triggering Event</i>) or by Parent pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(g)</span>&#160;(<i style="font-style:italic;">Termination for Company Triggering Event</i>)) or by Parent pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(k)</span>&#160;(<i style="font-style:italic;">Termination for Failure to Obtain Financing</i>), then the Company shall pay to Parent the Parent Termination Fee, by wire transfer of same day funds to an account designated by Parent, (x)&#160;in the case of a termination by the Company referred to in the foregoing clause, prior (and as a condition) to such termination or (y)&#160;in the case of a termination by Parent described in the foregoing clause, within two (2)&#160;Business Days after such termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#8239;If this Agreement is terminated by Parent or the Company pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(d)</span>&#160;(<i style="font-style:italic;">Termination for Failure to Obtain Company Stockholder Approval</i>) or by Parent pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(g)</span>&#160;(<i style="font-style:italic;">Termination for Company Triggering Event</i>) or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(k)</span>&#160;(<i style="font-style:italic;">Termination for Failure to Obtain Financing</i>), the Company shall reimburse Parent for all reasonable out-of-pocket expenses incurred by Parent in connection with this Agreement and the transactions contemplated hereby, up to a maximum of $500,000, by wire transfer of same-day funds to an account designated by Parent, within two (2)&#160;Business Days following the date on which Parent submits to the Company true and correct copies of reasonable documentation supporting such expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>If either party fails to pay when due any amount payable by it under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span>, then (i)&#160;such party shall reimburse the other party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other party of its rights under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span> and (ii)&#160;such party shall pay to the other party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other party in full) at a rate per annum equal to the &#8220;prime rate&#8221; (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three percent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>The parties agree that, subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.2</span>, the payment of fees and expenses set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span> shall be the sole and exclusive remedy of each party following a termination of this Agreement under the circumstances described in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span>, it being understood that in no event shall either Parent or the Company be required to pay the individual fees, damages payable pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span> on more than one occasion. Subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.2</span>, following the payment of the fees and expenses set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span> by a party, (i)&#160;such party shall have no further liability to the other party in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the other party giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (ii)&#160;no other party or their respective Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such party or seek to obtain any recovery, judgment or damages of any kind against such party (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such party) in connection with or arising out of this Agreement or the termination thereof, any breach by such party giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (iii)&#160;all other parties and their respective Affiliates shall be precluded from any other remedy against such party and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such party giving rise to such termination or the failure of the Contemplated Transactions to be </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">consummated. Each of the parties acknowledges that (x)&#160;the agreements contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span> are an integral part of the Contemplated Transactions, (y)&#160;without these agreements, the parties would not enter into this Agreement and (z)&#160;any amount payable pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the parties in the circumstances in which such amount is payable; provided, however, that nothing in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3(g)</span>&#160;shall limit the rights of the parties under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10.3</span>.</p><a id="ARTICLEX_187148"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;X</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GENERAL PROVISIONS</b></p><a id="Section101_22200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.1&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-survival of Representations and Warranties</span>. None of the representations, warranties, covenants or agreements in this Agreement or in any instrument delivered pursuant to this Agreement shall survive the Effective Time, other than this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;X</span> and those covenants or agreements of the parties which by their terms apply, or are to be performed in whole or in part, after the Effective Time.</p><a id="Section102_992811"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.2&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment or Supplement</span>. This Agreement may be amended, modified or supplemented by the parties by action taken or authorized by their respective Boards of Directors at any time, whether before or after Company Stockholder Approval or the Parent Stockholder Approval has been obtained; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that after the Company Stockholder Approval or the Parent Stockholder Approval has been obtained, no amendment shall be made that pursuant to applicable Law requires further approval or adoption by the stockholders of the Company or Parent, as applicable, without such further approval or adoption. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each of the parties in interest at the time of the amendment.</p><a id="Section103_194259"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.3&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</span>. The parties may, by action taken or authorized by their respective Boards of Directors, to the extent permitted by applicable Law, waive compliance with any of the agreements or conditions of the other parties contained herein; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that after the Company Stockholder Approval or the Parent Stockholder Approval has been obtained, no waiver may be made that pursuant to applicable Law requires further approval or adoption by the stockholders of the Company or Parent, as applicable, without such further approval or adoption. Any agreement on the part of a party to any such waiver shall be valid only if set forth in a written instrument executed and delivered by a duly authorized officer on behalf of such party. No failure or delay of any party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. No party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. The rights and remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies which they would otherwise have hereunder.</p><a id="Section104_649791"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.4&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Expenses</span>. Except as otherwise set forth in this Agreement, all fees and expenses incurred in connection with this Agreement, the Merger and the other Contemplated Transactions shall be paid by the party incurring such fees or expenses.</p><a id="Section105_490351"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.5&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices and other communications hereunder shall be in writing and shall be deemed duly given (a)&#160;one (1)&#160;Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand or (c)&#160;on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m.&#160;New York City time, otherwise on the next succeeding Business Day. All notices hereunder shall be delivered to the addresses set forth below, or pursuant to such other instructions as may be designated in writing by the party to receive such notice:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>if to Parent, Merger Sub, to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Carisma Therapeutics Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">3675 Market Street, Suite&#160;401</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Philadelphia, PA 19104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Attention: Steven Kelly, President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Email: [**]</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">with a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Wilmer Cutler Pickering Hale and Dorr LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">7 World Trade Center</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">250 Greenwich Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">New York, New York 10007</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Attention:</span></span>Christopher D. Barnstable-Brown,&#160;Esq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 90pt;">Mark Nylen,&#160;Esq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 90pt;">Brian A. Johnson,&#160;Esq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">E-mail:&#160;&#160;&#160;</span></span>cbb@wilmerhale.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 90pt;">mark.nylen@wilmerhale.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 90pt;">brian.johnson@wilmerhale.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>if to Company, to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">OrthoCellix,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">11 Great Valley Parkway</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Malvern, Pennsylvania 19355</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">Attention:&#160;&#160;Shankar Musunuri</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">E-mail:</span></span>[**]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">with a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Goodwin Procter LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">3025 John F Kennedy Blvd</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Philadelphia, Pennsylvania 19104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Attention:</span></span>Rachael M. Bushey</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 90pt;">Jennifer L. Porter</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 90pt;">Laura U. Gulick</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Email:&#160;&#160;&#160;&#160;</span></span>RBushey@goodwinlaw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 90pt;">JPorter@goodwinlaw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 90pt;">LGulick@goodwinlaw.com</p><a id="Section106_455883"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.6&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</span>. This Agreement (including the Exhibits hereto), the Company Disclosure Letter, the Parent Disclosure Letter, the Securities Purchase Agreements, the CVR Agreement and the Confidentiality Agreement constitute the entire agreement, and supersede all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings among the parties with respect to the subject matter hereof and thereof; provided, however, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms; provided, further, that only the Certificate of Merger is incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL.</p><a id="Section107_917211"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.7&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third Party Beneficiaries</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person other than the parties and their respective successors and permitted assigns any legal or equitable right, benefit or remedy of any nature under or by reason of this Agreement, except as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except as set forth in the Securities Purchase Agreement, the representations and warranties in this Agreement are the product of negotiations among the parties hereto and are for the sole benefit of the parties hereto. Any inaccuracies in such representations and warranties are subject to waiver by the parties hereto in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10.3</span> without notice or liability to any other Person. In some instances, the representations and warranties in this Agreement may represent an allocation among the parties hereto of risks associated with particular matters regardless of the knowledge of any of the parties hereto. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Consequently, except as set forth in the Securities Purchase Agreement, Persons other than the parties hereto may not rely upon the representations and warranties in this Agreement as characterizations of actual facts or circumstances as of the date of this Agreement or as of any other date.</p><a id="Section108_616450"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.8&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Guaranty</span>. Guarantor hereby unconditionally guarantees the complete, due and punctual performance of the Company&#8217;s obligations set forth in this Agreement, including all representations, warranties, covenants and other obligations. This guaranty is an irrevocable guaranty of performance and shall continue in effect notwithstanding any extension or modification of the terms of this Agreement or any other act or event which might otherwise operate as a legal or equitable discharge of such guarantor.</p><a id="Section109_975228"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.9&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</span>. This Agreement and all disputes or controversies arising out of or relating to this Agreement or the Contemplated Transactions shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware.</p><a id="Section1010_639968"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.10&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Submission to Jurisdiction</span>. Each of the parties irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement brought by any party or its Affiliates against any other party or its Affiliates shall be brought and determined in the Court of Chancery of the State of Delaware; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then any such legal action or proceeding may be brought in any federal court located in the State of Delaware or any other Delaware state court. Each of the parties hereby irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally, with regard to any such action or proceeding arising out of or relating to this Agreement and the Contemplated Transactions. Each of the parties agrees not to commence any action, suit or proceeding relating thereto except in the courts described above in Delaware, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in Delaware as described herein. Each of the parties further agrees that notice as provided herein shall constitute sufficient service of process and the parties further waive any argument that such service is insufficient. Each of the parties hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out of or relating to this Agreement or the Contemplated Transactions, (a)&#160;any claim that it is not personally subject to the jurisdiction of the courts in Delaware as described herein for any reason, (b)&#160;that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c)&#160;that (i)&#160;the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii)&#160;the venue of such suit, action or proceeding is improper or (iii)&#160;this Agreement, or the subject matter hereof, may not be enforced in or by such courts.</p><a id="Section1011_81190"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.11&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment; Successors</span>. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated, in whole or in part, by operation of law or otherwise, by any party without the prior written consent of the other parties, and any such assignment without such prior written consent shall be null and void. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns.</p><a id="Section1012_156371"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.12&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</span>. The parties agree that irreparable damage would occur in the event that the parties hereto do not perform the provisions of this Agreement in accordance with its terms or otherwise breach such provisions. Accordingly, the parties acknowledge and agree that each party shall be entitled to seek an injunction, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of Delaware, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then in any federal court located in the State of Delaware or any other Delaware state court, this being in addition to any other remedy to which such party is entitled at law or in equity. Each of the parties hereby further waives and&#160;will not oppose the granting of an injunction, specific performance or other equitable relief on the basis of (a)&#160;any defense in any action for specific performance that a remedy at law would be adequate and (b)&#160;any requirement under any law to post any bond, surety or other security as a prerequisite to obtaining equitable relief.</p><a id="Section1013_760388"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.13&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable Law or rule&#160;in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or portion of any provision in such jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Section1014_210561"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.14&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Jury Trial</span>. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE CONTEMPLATED TRANSACTIONS.</p><a id="Section1015_734615"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.15&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party.</p><a id="Section1016_258827"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.16&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Facsimile or .pdf Signature</span>. This Agreement may be executed by facsimile or .pdf signature and a facsimile or .pdf signature shall constitute an original for all purposes.</p><a id="Section1017_983127"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;10.17&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Presumption Against Drafting Party</span>. Each of Parent, Merger Sub and the Company acknowledges that each party to this Agreement has been represented by counsel in connection with this Agreement and the Contemplated Transactions. Accordingly, any rule&#160;of law or any legal decision that would require interpretation of any claimed ambiguities in this Agreement against the drafting party has no application and is expressly waived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">The remainder of this page&#160;is intentionally left blank</i>.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f5fada1c_7a0e_436f_be54_69919fef5978"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:46.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven Kelly</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:41.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Kelly</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AZALEA MERGER SUB,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:46.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven Kelly&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:41.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Kelly</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[<i style="font-style:italic;">Signature Page&#160;to Agreement and Plan of Merger</i>]</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OCUGEN,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:46.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Shankar Musunuri</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shankar Musunuri</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman, Chief Executive Officer &amp; Co-Founder</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ORTHOCELLIX,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:46.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Shankar Musunuri</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shankar Musunuri</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:right;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[<i style="font-style:italic;">Signature Page&#160;to Agreement and Plan of Merger</i>]</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:36.04pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6fd2ae54_8724_4911_b783_faaca5cbbf49"></a><a id="AnnexB_435155"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20250331xs4048.jpg" alt="Graphic" style="display:inline-block;height:35.89pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:180pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Strictly Confidential</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">June 22, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Carisma Therapeutics Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3675 Market Street, Suite 401</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Philadelphia, PA 19104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Attention: Sanford Zweifach</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Chairman of the Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Members of the Board of Directors:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have been advised that Carisma Therapeutics Inc., a Delaware corporation (<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>Carisma<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span> or <span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>Parent<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span>), proposes to enter into an Agreement and Plan of Merger (the <span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>Agreement<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span>), by and among Parent, Azalea Merge Sub, a Delaware corporation (<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>Merger Sub<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span>) and wholly owned subsidiary of Parent, OrthoCellix, Inc., a Delaware corporation (<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>OrthoCellix<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span> or the <span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>Company<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span>) and Ocugen, Inc., a Delaware corporation and the sole stockholder of the Company (<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>Ocugen<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span> or the <span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>Guarantor<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span>). Upon the terms and subject to the conditions set forth in the Agreement, at the Effective Time, Merger Sub will be merged with and into the Company (the <span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>Merger<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span>), the separate corporate existence of Merger Sub will cease and the Company will continue as the surviving company of the Merger and a wholly owned subsidiary of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Effective Time, by virtue of the Merger and without any action on the part of Parent, Merger Sub, the Company or the holders of any shares of capital stock of any of them, each share of Company Common Stock (other than any Excluded Shares or Dissenting Shares) will be converted into and become exchangeable for the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Exchange Ratio is determined pursuant to the Agreement with reference to the respective assumed valuations of $135 million for the Company (including the Concurrent Investment Amount) and $15 million for Parent. The assumed valuation of the Company is subject to reduction by the amount, if any, by which the Concurrent Investment Amount is less than $25 million. The assumed value of Parent is subject to adjustment by the amount by which Net Cash is above or below $0. The terms and conditions of the Merger are more fully set forth in the Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Agreement provides that the parties will use commercially reasonable efforts to enter into Securities Purchase Agreements with one or more investors designated by the Company to subscribe for and purchase a number of shares of Parent Common Stock representing an aggregate commitment (inclusive of the Guarantor Amount) at least equal to $25 million (the <span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>Concurrent Investment Amount<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span>). Prior to the Closing, the Guarantor will enter into a Securities Purchase Agreement committing to purchase a number of shares of Parent Common Stock equal to not less than $5 million (the <span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>Guarantor Investment Amount<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although consummation of the Concurrent Investment is not a condition to the closing of the Merger, for purposes of rendering our Opinion we have, with your consent, assumed that (i) the Concurrent Investment Amount will be $25 million and will occur simultaneously with the closing of the Merger, (ii) Net Cash will be $0, (iii) the Exchange Ratio will be 327,677.6433, and (iv) immediately upon closing of the Merger and including the shares of Parent Common Stock issuable in the Concurrent Investment, the holders of Company Common Stock will in the aggregate hold approximately 73.3% of the fully-diluted shares of Parent Common Stock (excluding certain Parent Options) and the holders of Parent Common Stock will in the aggregate hold approximately 10.0% of the fully-diluted shares of Parent Common Stock (excluding certain Parent Options).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20250331xs4049.jpg" alt="Graphic" style="display:inline-block;height:28.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:170.49pt;"/></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">B-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In your capacity as members of the Board of Directors of Carisma (the &#8220;Board of Directors&#8221;), you have requested our opinion (our &#8220;Opinion&#8221;) as to the fairness, from a financial point of view and as of the date hereof, of the Exchange Ratio as set forth in the Agreement to the existing holders of Parent Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with our Opinion, we took into account an assessment of general economic, market and financial conditions as well as our experience in connection with similar transactions and securities valuations generally and, among other things:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Reviewed a draft of the Merger Agreement;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Reviewed and analyzed certain publicly available financial and other information for each of Carisma and OrthoCellix;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Discussed with certain members of the management of Carisma the historical and current business operations, financial condition and prospects of Carisma and OrthoCellix;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Reviewed and analyzed certain operating results of OrthoCellix as compared to operating results and the reported price and trading histories of certain publicly traded companies that Lucid deemed relevant;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Reviewed and analyzed financial projection relating to the Company initially prepared by management of the Company and adjusted by Parent management;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Reviewed and analyzed certain financial terms of the Agreement as compared to the publicly available financial terms of certain selected business combinations that Lucid deemed relevant;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Reviewed and analyzed certain financial terms of completed initial public offerings for certain companies that Lucid deemed relevant;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as Lucid deemed relevant for purposes of this Opinion.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Agreement provides that Parent may engage in a Parent Legacy Transaction or Asset Dispositions with respect to the Parent Legacy Assets. Any net proceeds from such transactions would increase Net Cash. We have, with your consent, assumed that no Asset Dispositions or Parent Legacy Transaction will occur prior to the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Agreement also provides that prior to the Effective Time, Parent will distribute to holders of Parent Common Stock the right to receive a contingent value right (&#8220;CVR&#8221;) representing the right to receive contingent payments upon the occurrence of certain events set forth in and subject to and in accordance with the terms and conditions of, a Contingent Value Rights Agreement. With your consent, we have not assigned any value to the CVRs due to the speculative nature of any assumptions that would be necessary for us to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have, with your consent, relied upon the assumption that all information provided to us by Carisma and OrthoCellix is accurate and complete in all material respects. We expressly disclaim any undertaking or obligation to advise any person of any change in any fact or matter affecting our Opinion of which we become aware after the date hereof. To the extent that the information reviewed by us includes estimates and forecasts of future performance prepared by or reviewed with management of the Company and Parent, we have assumed, with your consent, that such estimates and forecasts have been reasonably prepared in good faith on a basis reflecting the best currently available estimates and judgments of the management of the Company and Parent. We express no opinion with respect to such estimates and forecasts. We have assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of Carisma or OrthoCellix since the date of the last financial statements made available to us. We have not obtained any independent evaluations, valuations or appraisals of the assets or liabilities of Carisma or OrthoCellix, nor have we been furnished with such materials. In addition, we have not evaluated the solvency or fair value of Carisma or OrthoCellix under any state or federal laws relating to bankruptcy, insolvency or similar matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">B-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Opinion does not address any legal, regulatory, tax or accounting matters related to the Merger, as to which we have assumed that Carisma and the Board of Directors have received such advice from legal, tax and accounting advisors as each has determined appropriate. Our Opinion addresses only the fairness from a financial point of view of the Exchange Ratio as set forth in the Agreement to the existing holders of Parent Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We express no view as to any other aspect or implication of the Merger or any other agreement or arrangement entered into in connection with the Merger. Our Opinion is necessarily based upon economic and market conditions and other circumstances as they exist and can be evaluated by us on the date hereof. It should be understood that although subsequent developments may affect our Opinion, we do not have any obligation to update, revise or reaffirm our Opinion and we expressly disclaim any responsibility to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not considered any potential legislative or regulatory changes currently being considered or recently enacted by the United States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the Securities and Exchange Commission (the <span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>SEC<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span>), the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of rendering our Opinion we have assumed, with your consent, that except as would not be in any way meaningful to our analysis: (i) the final form of the Agreement will not differ from the draft Agreement that we have reviewed; (ii) the representations and warranties of each party contained in the Agreement are true and correct in all respects; (iii) each party will perform all of the covenants and agreements required to be performed by such party under the Agreement; and (iv) the transactions contemplated by the Agreement will be consummated in accordance with the terms of the Agreement, without any waiver or amendment of any term or condition thereof. We have also assumed that all governmental, regulatory and other consents and approvals contemplated by the Agreement or otherwise required for the transactions contemplated by the Agreement will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed, or waivers made that would have an adverse effect on Carisma, OrthoCellix, or the contemplated benefits of the Merger. We have assumed that the Merger will be consummated in a manner that complies with the applicable provisions of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and all other applicable federal and state statutes and the rules and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is understood that this letter is intended for the benefit and use of the Board of Directors (in its capacity as such) in its consideration of the financial terms of the Merger and, except as set forth in our engagement letter with Carisma, dated as of June 13, 2025 (the <span style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</span>Engagement Letter<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</span>), may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without our prior written consent, except that this Opinion may be included in its entirety in any filing related to the Merger required to be filed with the SEC and any proxy statement to be mailed to holders of Parent Common Stock. This letter does not constitute a recommendation to the Board of Directors of whether to approve the Merger or to any stockholder of Carisma or any other person as to how to vote or act with respect to the transactions contemplated by the Agreement (including the Merger) or any other matter. Our Opinion does not address Carisma<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8217;</span>s underlying business decision to proceed with the Merger or the relative merits of the Merger compared to other alternatives available to Carisma. We express no opinion as to the prices or ranges of prices at which shares or the securities of any person, including Carisma, will trade at any time, including following the announcement or consummation of the Merger, or as to the potential effects of volatility in the credit, financial, and stock markets on Carisma, OrthoCellix or the transactions contemplated by the Agreement. We have not been requested to opine as to, and our Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the Merger, or any class of such persons, relative to the compensation to be paid to the existing holders of Parent Common Stock in connection with the Merger or with respect to the fairness of any such compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid is an investment bank providing investment banking, brokerage, equity research, institutional sales and trading services. As part of our investment banking services, we are regularly engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. Lucid will receive a fee for rendering our Opinion set forth below pursuant to the Engagement Letter, which is not contingent upon consummation of the Merger. In addition, Carisma has agreed to reimburse our expenses and indemnify us for certain liabilities that may arise out of our engagement. In the two years preceding the date hereof, Lucid has not had a relationship with Carisma or its affiliates and has not received any fees from Carisma or any of its affiliates. In the two years preceding the date hereof, Lucid has not had a relationship with OrthoCellix or any of its affiliates, including Ocugen, and has not received any fees from OrthoCellix or any of its affiliates, including Ocugen. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to Carisma, OrthoCellix, Ocugen and/or their respective affiliates and expect to receive fees for the rendering of these services.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">B-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:21.6pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, Lucid or certain of our affiliates, as well as investment funds in which we or our affiliates may have financial interests, may acquire, hold or sell long or short positions, or trade or otherwise effect transactions in debt, equity, and other securities and financial instruments (including bank loans and other obligations) of, or investments in, Carisma, OrthoCellix, Ocugen or any other party that may be involved in the Merger and/or their respective affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consistent with applicable legal and regulatory requirements, Lucid has adopted policies and procedures to establish and maintain the independence of our research department and personnel. As a result, our research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to Carisma and the proposed Merger that may differ from the views of Lucid<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8217;</span>s investment banking personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Opinion set forth below was reviewed and approved by a fairness opinion committee of Lucid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based upon and subject to the foregoing, including the various assumptions and limitations set forth herein and such other factors that we deem relevant, it is our opinion that, as of the date hereof, the Exchange Ratio is fair, from a financial point of view, to the existing holders of Parent Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Very truly yours,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20250331xs4050.jpg" alt="Graphic" style="display:inline-block;height:21.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:178.2pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Lucid Capital Markets, LLC</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">B-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_aba0a15d_5d93_4f9c_87c9_e3025fff8f31"></a><a id="AnnexC_214320"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SUPPORT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This <b style="font-variant:small-caps;font-weight:bold;">SUPPORT AGREEMENT</b> (this &#8220;<span style="font-style:italic;font-weight:bold;">Agreement</span>&#8221;), is made as of [&#9679;], 2025, by and among <b style="font-variant:small-caps;font-weight:bold;">ORTHOCELLIX,&#160;INC.</b>, a Delaware corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span>&#8221;), <b style="font-variant:small-caps;font-weight:bold;">OCUGEN INC.</b>, a Delaware corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Guarantor</span>&#8221;), <b style="font-variant:small-caps;font-weight:bold;">CARISMA THERAPEUTICS,&#160;INC.</b>, a Delaware corporation (&#8220;<span style="font-style:italic;font-weight:bold;">Parent</span>&#8221;), and the Person set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule&#160;A</span> hereto (the &#8220;<span style="font-style:italic;font-weight:bold;">Stockholder</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, as of the date hereof, the Stockholder is the holder of the number of shares of common stock, par value $0.001 per share (&#8220;<span style="font-style:italic;font-weight:bold;">Common Stock</span>&#8221;), of Parent set forth opposite the Stockholder&#8217;s name on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule&#160;A</span> (all Common Stock owned by the Stockholder, or hereafter issued to or otherwise acquired, whether beneficially or of record, or owned by the Stockholder prior to the termination of this Agreement, as well as shares set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule&#160;A</span>, being referred to herein as the &#8220;<span style="font-style:italic;font-weight:bold;">Subject Shares</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, concurrently herewith, the Company, the Guarantor, Parent and Azalea Merger Sub,&#160;Inc., a Delaware corporation and wholly owned subsidiary of Parent (&#8220;<span style="font-style:italic;font-weight:bold;">Merger Sub</span>&#8221;), have entered into an Agreement and Plan of Merger, dated as of the date hereof (as such agreement may be amended, restated, amended and restated or otherwise modified from time to time, the &#8220;<span style="font-style:italic;font-weight:bold;">Merger Agreement</span>&#8221;), which provides, among other things, for the merger of Merger Sub with and into the Company, with the Company continuing as the surviving company (the &#8220;<span style="font-style:italic;font-weight:bold;">Merger</span>&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement (capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, as a condition to its willingness to enter into the Merger Agreement, the Company has required that the Stockholder, and as an inducement and in consideration therefor, the Stockholder (in the Stockholder&#8217;s capacity as a holder of the Subject Shares) has agreed to, enter into this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">VOTING AGREEMENT; GRANT OF PROXY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Stockholder hereby covenants and agrees that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.1.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting of Subject Shares</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="white-space:pre-wrap;">&#8239;&#8239;(a)&#160;&#160;&#160;From and after the date hereof and prior to the Expiration Time (as defined below), at every meeting of the holders of Common Stock (the &#8220;</span><span style="font-style:italic;font-weight:bold;">Parent Stockholders</span>&#8221;), however called, and at every adjournment or postponement thereof (or pursuant to a written consent if the Parent Stockholders act by written consent in lieu of a meeting), the Stockholder shall, or shall cause the holder of record on any applicable record date to, be present (in person or by proxy) and to vote or cause to be voted the Subject Shares: (i)&#160;in favor of adopting the Merger Agreement and approving the Merger and the other Contemplated Transactions, (ii)&#160;against approval of any proposal made in opposition to, or in competition with, the Merger Agreement or the consummation of the Merger, and (iii)&#160;against any Acquisition Proposal or any agreement, transaction or other matter that is intended to, or would reasonably be expected to impede, interfere with, delay, postpone or materially and adversely affect the consummation of the Merger and the transactions contemplated in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="white-space:pre-wrap;">&#8239;&#8239;(b)&#160;&#160;&#160;Except as permitted under clauses (A)&#160;through (J)&#160;of </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.2</span> below, the Stockholder shall retain at all times the right to vote the Subject Shares in the Stockholder&#8217;s sole discretion and without any other limitation on those matters other than those set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1</span> that are at any time or from time to time presented for consideration to the Parent Stockholders. In the event of a stock split, stock dividend or distribution, or any change in the Common Stock by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Subject Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">1.2.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Inconsistent Arrangements</b>. Except as provided hereunder or under the Merger Agreement, prior to the Expiration Time, the Stockholder shall not, directly or indirectly,&#160;(a)&#160;create any Lien other than restrictions imposed by Law or pursuant to this </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Agreement on any Subject Shares; (b)&#160;transfer, sell, assign, gift or otherwise dispose of (collectively, &#8220;<span style="font-style:italic;font-weight:bold;">Transfer</span>&#8221;), or enter into any contract with respect to any Transfer of, the Subject Shares or any interest therein; (c)&#160;grant or permit the grant of any proxy, power of attorney or other authorization in or with respect to the Subject Shares; (d)&#160;deposit or permit the deposit of the Subject Shares into a voting trust or enter into a voting agreement or arrangement with respect to the Subject Shares; or (e)&#160;take any action that, to the knowledge of the Stockholder, would make any representation or warranty of the Stockholder herein untrue or incorrect in any material respect or have the effect of preventing the Stockholder from performing the Stockholder&#8217;s obligations hereunder. Any action taken in violation of the foregoing sentence shall be null and void <i style="font-style:italic;">ab initio</i>. Notwithstanding the foregoing, the Stockholder may (A)&#160;Transfer Subject Shares as a <i style="font-style:italic;">bona fide</i> charitable contribution, gift or donation; (B)&#160;Transfer the Subject Shares to any trust for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder; (C)&#160;Transfer the Subject Shares by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the Stockholder; (D)&#160;Transfer the Subject Shares to stockholders, direct or indirect affiliates (within the meaning set forth in Rule&#160;405 under the Securities Act), current or former partners (general or limited), members or managers of the Stockholder, as applicable, or to the estates of any such stockholders, affiliates, partners, members or managers, or to another corporation, partnership, limited liability company or other business entity that controls, is controlled by or is under common control with the Stockholder; (E)&#160;make Transfers that occur by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement; (F)&#160;make Transfers not involving a change in beneficial ownership; (G)&#160;if the Stockholder is a trust, Transfer the Subject Shares to any beneficiary of the Stockholder or the estate of any such beneficiary; (H)&#160;exercise an option or warrant to purchase Common Stock or settle a restricted stock unit or other equity award (including a net or cashless exercise of such option or warrant); (I)&#160;Transfer Common Stock to Parent to cover tax withholding obligations of the Stockholder in connection with the vesting, settlement or exercise of any options, warrants, restricted stock units or other equity awards, as applicable; (J)&#160;Transfer Common Stock with the prior written consent of Parent; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i> that, with respect to clauses (A)&#160;through (J)&#160;above, the transferee agrees in writing to be bound by the terms and conditions of this Agreement and either the Stockholder or the transferee provides Parent with a copy of such agreement promptly upon consummation of any such Transfer; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</i><i style="font-style:italic;">,</i> that in each case, the underlying shares of Common Stock shall continue to be subject to the restrictions on Transfer set forth in this Agreement notwithstanding that such transferee has not executed a counterpart hereof or joinder hereto; or (K)&#160;Transfer Common Stock to another holder of capital stock of Parent that has signed a support agreement in the same form as this Agreement. The Stockholder agrees that any shares of capital stock or other equity voting securities of Parent that such Stockholder acquires or with respect to which such Stockholder otherwise acquires sole or shared voting power (including any proxy) after the execution of this Agreement and prior to the Expiration Time (as defined below), including, without limitation, by gift, succession, in the event of a stock split or as a dividend or distribution of any Shares (&#8220;<span style="font-style:italic;font-weight:bold;">New Shares</span>&#8221;), shall be subject to the terms and conditions of this Agreement to the same extent as if they constituted the Subject Shares. For purposes of this Agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.3.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Documentation and Information</b>. The Stockholder shall permit and hereby authorizes the Company and Parent to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that the Company or Parent reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, the Stockholder&#8217;s identity and ownership of the Subject Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement. The Company is an intended third-party beneficiary of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.3</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">1.4.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Irrevocable Proxy</b><b style="font-weight:bold;">.</b> The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to the Subject Shares. In the event and to the extent that the Stockholder fails to vote the Subject Shares in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1</span> at any applicable meeting of the Parent Stockholders or pursuant to any applicable written consent of the stockholders of Parent, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Parent and any of its designees with full power of substitution and resubstitution, as attorney-in-fact and proxy for and on behalf of the Stockholder, for and in the name, place and stead of the Stockholder, to: (a)&#160;attend any and all meetings of the Parent Stockholders, (b)&#160;vote, express consent or dissent or issue instructions to the record holder to vote the Subject Shares in accordance with the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1</span> at any and all meetings of the Parent Stockholders or in connection with any action sought to be taken by written consent of the Parent Stockholders without a meeting and (c)&#160;grant or withhold, or issue instructions to the record holder to grant or withhold, consistent with the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1</span>, all written consents with respect to the Subject Shares at any and all meetings of the Parent Stockholders or in connection with any action sought to be taken by written consent of the Parent Stockholders without a meeting. Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. The foregoing proxy shall be deemed to be a proxy coupled with an interest, is irrevocable (and as such shall survive and not be affected by the death, incapacity, mental illness or insanity of the Stockholder, as applicable) until the termination of this Agreement and shall not be terminated by operation of law or upon the occurrence of any other event other than the termination of this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</span>. The Stockholder authorizes such attorney and proxy to substitute any other Person to act hereunder, to revoke any substitution and to file this proxy and any substitution or revocation with the Secretary of Parent. The Stockholder hereby affirms that the proxy set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.4</span> is given in connection with and granted in consideration of and as an inducement to Parent, Merger Sub and the Company to enter into the Merger Agreement and that such proxy is given to secure the obligations of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Stockholder under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1</span>. The proxy set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.4</span> is executed and intended to be irrevocable, subject, however, to its automatic termination upon the termination of this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</span>. With respect to any Subject Shares that are owned beneficially by the Stockholder but are not held of record by the Stockholder (other than shares beneficially owned by the Stockholder that are held in the name of a bank, broker or nominee), the Stockholder shall take all action necessary to cause the record holder of such Subject Shares to grant the irrevocable proxy and take all other actions provided for in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.4</span> with respect to such Subject Shares. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate upon the termination of this Agreement in accordance with the terms set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.5.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Ownership Interest</b>. Nothing contained in this Agreement will be deemed to vest in Parent any direct or indirect ownership or incidents of ownership of or with respect to the Subject Shares. All rights, ownership and economic benefits of and relating to the Subject Shares will remain and belong to the Stockholder, and Parent will have no authority to manage, direct, superintend, restrict, regulate, govern or administer any of the policies or operations of Parent or exercise any power or authority to direct the Stockholder in the voting of any of the Subject Shares, except as otherwise expressly provided herein with respect to the Subject Shares and except as otherwise expressly provided in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.6.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Exercise of Appraisal Rights; Waivers</b>. In connection with the Contemplated Transactions, the Stockholder hereby irrevocably and unconditionally (a)&#160;waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters&#8217; rights and any similar rights (including any notice requirements related thereto) to the extent permitted under applicable Law, relating to the Merger that Stockholder may have by virtue of, or with respect to any Subject Shares (including all rights under Section&#160;262 of the Delaware General Corporation Law, a copy of which is attached hereto as Appendix I) and (b)&#160;agrees that the Stockholder will not, under any circumstances in connection with the Contemplated Transactions, exercise any dissenters&#8217; or appraisal rights in respect of any Subject Shares, and (c)&#160;agrees that the Stockholder will not bring, commence, institute, maintain, prosecute, participate in or voluntarily aid any action, claim, suit or cause of action, in law or in equity, in any court or before any Governmental Entity, which (i)&#160;challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii)&#160;alleges that the execution and delivery of this Agreement by the Stockholder, or the approval of the Merger Agreement by the board of directors of Parent (the &#8220;<span style="font-style:italic;font-weight:bold;">Parent Board</span>&#8221;), breaches any fiduciary duty of the Parent Board or any member thereof; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i> that the Stockholder may defend against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.7.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Solicitation of Transactions</b>. The Stockholder hereby agrees that, prior to the Expiration Time (as defined below), the Stockholder shall not, directly or indirectly, including through any of its officers, directors or agents: (a)&#160;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (b)&#160;furnish any non-public information regarding Parent to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (c)&#160;engage in discussions (other than to inform any Person of the existence of the provisions in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.7</span>) or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (d)&#160;approve, endorse or recommend any Acquisition Proposal; (e)&#160;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction (other than an Acceptable Confidentiality Agreement (as defined in the Merger Agreement) permitted under the Merger Agreement); or (f)&#160;publicly propose to do any of the foregoing<i style="font-style:italic;">.</i> The Stockholder hereby represents and warrants that the Stockholder has read Section&#160;6.4 (No Solicitation) of the Merger Agreement and agrees not to engage in any actions prohibited thereby. Notwithstanding the foregoing, the Stockholder will not be responsible for the breaches by its officers, directors or agents that have otherwise entered into a separate support agreement with Parent (in a form reasonably acceptable to the Company), unless the Stockholder knowingly and intentionally caused such breach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Stockholder represents and warrants to Parent that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">2.1.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization; Authorization; Binding Agreement</b>. The Stockholder, if not a natural person, is duly incorporated or organized, as applicable, validly existing and in good standing under the laws of its jurisdiction of incorporation or organization. The Stockholder has full legal capacity and power, right and authority to (a)&#160;execute and deliver this Agreement and to perform the Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby and (b)&#160;vote all of the Subject Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Entity). This Agreement has been duly and validly executed and delivered by the Stockholder, and constitutes a legal, valid and binding obligation of the Stockholder enforceable against the Stockholder in accordance with its terms </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&#8217; rights generally or by general principles of equity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.2.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership of Subject Shares; Total Shares</b>. The Stockholder is the record or beneficial owner of the Subject Shares and has good and marketable title to the Subject Shares free and clear of any Liens (including any restriction on the right to vote or otherwise transfer the Subject Shares), except (a)&#160;as provided hereunder, (b)&#160;pursuant to any applicable restrictions on transfer under the Securities Act and (c)&#160;as provided in the certificate of incorporation or bylaws of Parent. The Subject Shares listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule&#160;A</span> opposite the Stockholder&#8217;s name constitute all of the Common Stock owned by the Stockholder as of the date hereof. Except pursuant to Parent&#8217;s certificate of incorporation and bylaws, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of the Subject Shares. For purposes of this Agreement &#8220;<span style="font-style:italic;font-weight:bold;">Beneficial Ownership</span>&#8221; shall be interpreted as defined in Rule&#160;13d-3 under the Exchange Act; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i> that for purposes of determining Beneficial Ownership, a Person shall be deemed to be the Beneficial Owner of any securities that may be acquired by such Person pursuant to any Contract or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise (irrespective of whether the right to acquire such securities is exercisable immediately or only after the passage of time, including the passage of time in excess of 60&#160;days, the satisfaction of any conditions, the occurrence of any event or any combination of the foregoing).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.3.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting Power</b>. The Stockholder has full voting power, with respect to the Subject Shares, and full power of disposition, full power to issue instructions with respect to the matters set forth herein and full power to agree to all of the matters set forth in this Agreement, in each case, with respect to all of the Subject Shares. None of the Subject Shares are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of the Subject Shares, except as provided hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.4.</span></span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reliance</b>. The Stockholder has had the opportunity to review the Merger Agreement, including the provisions relating to the payment and allocation of the consideration to be paid to the Parent Stockholders, and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the transactions contemplated by the Merger Agreement. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company, Guarantor or any of their respective agents or representatives. The Stockholder understands that such Stockholder (and not Parent, the Company, Guarantor or the Surviving Company) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the transactions contemplated by the Merger Agreement. The Stockholder understands and acknowledges that the Company, Guarantor, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.5.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Litigation</b>. With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Subject Shares) that could reasonably be expected to prevent, delay or impair the ability of the Stockholder to perform the Stockholder&#8217;s obligations hereunder or to consummate the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.6.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Contravention</b>. The execution and delivery of this Agreement by the Stockholder and the performance of the transactions contemplated by this Agreement by the Stockholder does not and will not violate, conflict with, or result in a breach of: (a)&#160;the organizational documents of such Stockholder, (b)&#160;any applicable Law or any injunction, judgment, order, decree, ruling, charge, or other restriction of any Governmental Entity to which the Stockholder is subject, or (c)&#160;any Contract to which the Stockholder is a party or is bound or to which the Subject Shares are subject, such that it could reasonably be expected to prevent, delay or impair the ability of the Stockholder to perform the Stockholder&#8217;s obligations hereunder or to consummate the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</b>. All notices, requests and other communications to either party hereunder shall be in writing (including electronic mail) and shall be given, (a)&#160;if to Parent, in accordance with the provisions of the Merger Agreement and (b)&#160;if to the Stockholder, to the Stockholder&#8217;s address or electronic mail address set forth on a signature page&#160;hereto, or to such other address or electronic mail address as the Stockholder may hereafter specify in writing to Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">3.2.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</b>. This Agreement shall terminate automatically, without any notice or other action by any Person, upon the earlier of (a)&#160;the termination of the Merger Agreement in accordance with its terms and (b)&#160;the Effective Time (the &#8220;<span style="font-style:italic;font-weight:bold;">Expiration Time</span>&#8221;). Upon termination of this Agreement, neither party shall have any further obligations or liabilities under this Agreement; </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i><i style="font-style:italic;">, </i><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</i><i style="font-style:italic;">,</i> that (i)&#160;nothing set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</span> shall relieve either party from liability for any breach of this Agreement prior to termination hereof, and (ii)&#160;the provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span> shall survive any termination of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.3.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</b>. Except to the extent required by applicable Law, the Stockholder shall hold any&#160;non-public&#160;information regarding this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until Parent has publicly disclosed its entry into the Merger Agreement and this Agreement;&#160;<i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i>,&#160;<i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</i>, that the Stockholder may disclose such information (a)&#160;to its attorneys, accountants, consultants, trustees, beneficiaries and other representatives (<i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i>&#160;such representatives are subject to confidentiality obligations at least as restrictive as those contained herein), and (b)&#160;to any Affiliate, partner, member, stockholder, parent or subsidiary of the Stockholder,&#160;<i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i>&#160;in each case that the Stockholder informs the Person receiving the information that such information is confidential and such Person agrees in writing to abide by the terms of this&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span>. Neither the Stockholder nor any of its Affiliates (other than Parent, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.4.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments and Waivers</b>. Any provision of this Agreement may be amended or waived if such amendment or waiver is in writing and is signed, in the case of an amendment, by each party to this Agreement, or in the case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.5.</span></span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect; Benefit; Assignment</b>. The provisions of this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.3</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span>, no provision of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon any Person other than the parties hereto and their respective successors and assigns. Neither party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the consent of the other party hereto, except that Parent may transfer or assign its rights and obligations under this Agreement, in whole or from time to time in part, to one or more of its Affiliates at any time; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i> that such transfer or assignment shall not relieve Parent of any of its obligations hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.6.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Jurisdiction</b>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties hereto arising out of or relating to this Agreement, each party hereto: (a)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware (the &#8220;<span style="font-style:italic;font-weight:bold;">Delaware Courts</span>&#8221;); (b)&#160;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&#160;of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6</span>; (c)&#160;waives any objection to laying venue in any such action or proceeding in such courts; (d)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party hereto; (e)&#160;agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1</span> of this Agreement; and (f)&#160;irrevocably and unconditionally waives the right to trial by jury.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.7.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</b>. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile or electronic transmission in .PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.8.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</b>. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">3.9.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</b>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination will have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.10.&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</b>. Any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any Delaware Court, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties hereto waives any bond, surety or other security that might be required of any other party with respect thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.11.&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The parties hereto agree that any rule&#160;of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Except as otherwise indicated, all references in this Agreement to &#8220;Sections,&#8221; &#8220;Articles,&#8221; and &#8220;Schedules&#8221; are intended to refer to Sections or Articles of this Agreement and Schedules to this Agreement, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.12.&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</b>. Each of the parties hereto will execute and deliver, or cause to be executed and delivered, all further documents and instruments and use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary under applicable Law to perform their respective obligations as expressly set forth under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.13.&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capacity as Stockholder</b>. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as a holder of Common Stock, and not in the Stockholder&#8217;s capacity as a director, officer or employee of Parent or in the Stockholder&#8217;s capacity as a trustee or fiduciary of any employee benefit plan or trust. Notwithstanding anything herein to the contrary, nothing herein shall in any way restrict a director or officer of Parent in the exercise of his or her fiduciary duties as a director or officer of Parent or in his or her capacity as a trustee or fiduciary of any employee benefit plan or trust or prevent or be construed to create any obligation on the part of any director or officer of Parent or any trustee or fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such director, officer, trustee or fiduciary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.14.&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Agreement Until Executed</b>. Irrespective of negotiations among the parties or the exchanging of drafts of this Agreement, this Agreement shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and until (a)&#160;the Parent Board has approved, for purposes of any applicable anti-takeover laws and regulations, and any applicable provision of Parent&#8217;s organizational documents, the Merger, (b)&#160;the Merger Agreement is executed by all parties thereto, and (c)&#160;this Agreement is executed by all parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(SIGNATURE PAGE FOLLOWS)</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_acd7ca4b_ce98_4647_afa0_401dc5971434"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:51.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:51.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page&#160;to Support Agreement]</i></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ORTHOCELLIX,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:bottom;width:49.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page&#160;to Support Agreement]</i></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OCUGEN INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page&#160;to Support Agreement]</i></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">STOCKHOLDER</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Print Name of Stockholder)</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Signature)</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Name and Title of Signatory, if Signing on Behalf of an Entity)</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email:</p></td><td style="vertical-align:bottom;width:44.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page&#160;to Support Agreement]</i></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_09729053_a415_45a7_a148_6f62426446d3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule&#160;A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name of Stockholder</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:49.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No. Shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.9pt;">[&#9679;]</p></td><td style="vertical-align:top;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[&#9679;]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#167; 262. Appraisal rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&#160;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, who has otherwise complied with subsection (d)&#160;of this section and who has neither voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b)&#160;and (c)&#160;of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Appraisal rights shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation in a merger, consolidation, conversion, transfer, domestication or continuance to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g)&#160;of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264, &#167; 266 or &#167; 390 of this title (other than, in each case and solely with respect to a converted or domesticated corporation, a merger, consolidation, conversion, transfer, domestication or continuance authorized pursuant to and in accordance with the provisions of &#167; 265 or &#167; 388 of this title):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Provided, however, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at the record date fixed to determine the stockholders entitled to consent pursuant to &#167; 228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for the conversion, transfer, domestication or continuance (or, in the case of a merger pursuant to &#167; 251(h)&#160;of this title, as of immediately prior to the execution of the agreement of merger), were either: (i)&#160;listed on a national securities exchange or (ii)&#160;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f)&#160;of this title.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span>Notwithstanding paragraph (b)(1)&#160;of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, transfer, domestication or continuance, pursuant to &#167; 251, &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264, &#167; 266 or &#167; 390 of this title to accept for such stock anything except:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</span></span>Shares of stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity or the entity resulting from a transfer, domestication or continuance if such entity is a corporation as a result of the conversion, transfer, domestication or continuance, or depository receipts in respect thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</span></span>Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger, consolidation, conversion, transfer, domestication or continuance will be either listed on a national securities exchange or held of record by more than 2,000 holders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</span></span>Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d.</span></span>Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</span></span>In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(4)</span></span>[Repealed.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167; 266 of this title or a transfer, domestication or continuance effected pursuant to &#167; 390 of this title. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&#160;of this section, shall apply as nearly as is practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Appraisal rights shall be perfected as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>If a proposed merger, consolidation, conversion, transfer, domestication or continuance for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c)&#160;of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&#160;or (c)&#160;of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and, &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger, consolidation, conversion, transfer, domestication or continuance, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation, conversion, transfer, domestication or continuance shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10 days after the effective date of such merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity shall notify each stockholder of each constituent or converting, transferring, domesticating or continuing corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation, conversion, transfer, domestication or continuance, and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section, of the date that the merger, consolidation or conversion has become effective; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span>If the merger, consolidation, conversion, transfer, domestication or continuance was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then either a constituent, converting, transferring, domesticating or continuing corporation before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, or the surviving, resulting or converted entity within 10 days after such effective date, shall notify each stockholder of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation who is entitled to appraisal rights of the approval of the merger, consolidation, conversion, transfer, domestication or continuance and that appraisal rights are available for any or all shares of such class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting, transferring, domesticating or continuing corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, shall, also notify such stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance. Any stockholder entitled to appraisal rights may, within 20 days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, within the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20 days after the date of giving such notice, demand in writing from the surviving, resulting or converted entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, either (i)&#160;each such constituent corporation or the converting, transferring, domesticating or continuing corporation shall send a second notice before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance notifying each of the holders of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation that are entitled to appraisal rights of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance or (ii)&#160;the surviving, resulting or converted entity shall send such a second notice to all such holders on or within 10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20 days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting, transferring, domesticating or continuing corporation may fix, in advance, a record date that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</span></span>Notwithstanding subsection (a)&#160;of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s name, demand in writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1)&#160;or (2)&#160;of this section, as applicable; provided that (i)&#160;such beneficial owner continuously owns such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a)&#160;of this section and (ii)&#160;the demand made by such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by subsection (f)&#160;of this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Within 120 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity, or any person who has complied with subsections (a)&#160;and (d)&#160;of this section and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance. Within 120 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person who has complied with the requirements of subsections (a)&#160;and (d)&#160;of this section, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance (or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2)&#160;of this title)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3)&#160;of this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to the person within 10 days after such person&#8217;s request for such a statement is received by the surviving, resulting or converted entity or within 10 days after expiration of the period for delivery of demands for appraisal under subsection (d)&#160;of this section, whichever is later.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Upon the filing of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>At the hearing on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation, conversion, transfer, domestication or continuance the shares of the class or series of stock of the constituent, converting, transferring, domesticating or continuing corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&#160;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&#160;the value of the consideration provided in the merger, consolidation, conversion, transfer, domestication or continuance for such total number of shares exceeds $1 million, or (3)&#160;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules&#160;of the Court of Chancery, including any rules&#160;specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger, consolidation, conversion, transfer, domestication or continuance, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation, conversion, transfer, domestication or continuance through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&#160;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2)&#160;interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section may participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section who participated in the proceeding and incurred expenses in connection therewith, the Court may order all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal not dismissed pursuant to subsection (k)&#160;of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k)&#160;of this section.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span>Subject to the remainder of this subsection, from and after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, no person who has demanded appraisal rights with respect to some or all of such person&#8217;s shares as provided in subsection (d)&#160;of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation, conversion, transfer, domestication or continuance). If a person who has made a demand for an appraisal in accordance with this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in respect of some or all of such person&#8217;s shares in accordance with subsection (e)&#160;of this section, either within 60 days after such effective date or thereafter with the written approval of the corporation, then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, an appraisal proceeding in the Court of Chancery shall not be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just, including without limitation, a reservation of jurisdiction for any application to the Court made under subsection (j)&#160;of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance within 60 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, as set forth in subsection (e)&#160;of this section. If a petition for an appraisal is not filed within the time provided in subsection (e)&#160;of this section, the right to appraisal with respect to all shares shall cease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span>The shares or other equity interests of the surviving, resulting or converted entity to which the shares of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity interests of the surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no longer entitled to appraisal pursuant to this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8131d4af_e754_4c74_8023_4c70ec3ba693"></a><a id="AnnexD_774422"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SUPPORT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This <b style="font-variant:small-caps;font-weight:bold;">SUPPORT AGREEMENT</b> (this &#8220;<span style="font-style:italic;font-weight:bold;">Agreement</span>&#8221;), is made as of [&#9679;], 2025, by and among <b style="font-variant:small-caps;font-weight:bold;">ORTHOCELLIX,&#160;INC.</b>, a Delaware corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span>&#8221;), <b style="font-variant:small-caps;font-weight:bold;">Ocugen, inc.</b>, a Delaware corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Guarantor</span>&#8221;), <b style="font-variant:small-caps;font-weight:bold;">CARISMA THERAPEUTICS INC.</b>, a Delaware corporation (&#8220;<span style="font-style:italic;font-weight:bold;">Parent</span>&#8221;), and the Person set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule&#160;A</span> hereto (the &#8220;<span style="font-style:italic;font-weight:bold;">Stockholder</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, as of the date hereof, the Stockholder is the holder of the number of shares of common stock, par value $0.00001 per share (&#8220;<span style="font-style:italic;font-weight:bold;">Common Stock</span>&#8221;), of the Company set forth opposite the Stockholder&#8217;s name on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule&#160;A</span> (all Company Common Stock owned by the Stockholder, or hereafter issued to or otherwise acquired, whether beneficially or of record, or owned by the Stockholder prior to the termination of this Agreement, as well as shares set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule&#160;A</span>, being referred to herein as the &#8220;<span style="font-style:italic;font-weight:bold;">Subject Shares</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, concurrently herewith, the Company, the Guarantor, Parent and <b style="font-variant:small-caps;font-weight:bold;">AZALEA MERGER SUB,&#160;INC.</b>, a Delaware corporation and wholly owned subsidiary of Parent (&#8220;<span style="font-style:italic;font-weight:bold;">Merger Sub</span>&#8221;), have entered into an Agreement and Plan of Merger, dated as of the date hereof (as such agreement may be amended, restated, amended and restated or otherwise modified from time to time, the &#8220;<span style="font-style:italic;font-weight:bold;">Merger Agreement</span>&#8221;), which provides, among other things, for the merger of Merger Sub with and into the Company, with the Company continuing as the surviving company (the &#8220;<span style="font-style:italic;font-weight:bold;">Merger</span>&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement (capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, as a condition to its willingness to enter into the Merger Agreement, Parent has required that the Stockholder, and as an inducement and in consideration therefor, the Stockholder (in the Stockholder&#8217;s capacity as a holder of the Subject Shares) has agreed to, enter into this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">VOTING AGREEMENT; GRANT OF PROXY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Stockholder hereby covenants and agrees that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.1.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting of Subject Shares</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(a)&#160;&#160;&#160;From and after the date hereof and prior to the Expiration Time (as defined below), at every meeting of the holders of Company Common Stock (the &#8220;<span style="font-style:italic;font-weight:bold;">Company Stockholders</span>&#8221;), however called, and at every adjournment or postponement thereof (or pursuant to a written consent if the Company Stockholders act by written consent in lieu of a meeting), the Stockholder shall, or shall cause the holder of record on any applicable record date to, be present (in person or by proxy) and to vote or cause to be voted the Subject Shares: (i)&#160;in favor of adopting the Merger Agreement and approving the Merger and the other Contemplated Transactions, (ii)&#160;against approval of any proposal made in opposition to, or in competition with, the Merger Agreement or the consummation of the Merger, and (iii)&#160;against any Acquisition Proposal or any agreement, transaction or other matter that is intended to, or would reasonably be expected to impede, interfere with, delay, postpone or materially and adversely affect the consummation of the Merger and the transactions contemplated in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="white-space:pre-wrap;">&#8239;(b)&#160;&#160;&#160;In furtherance of subsection (a), promptly following the declaration of effectiveness of the Registration Statement, but in any case within twenty-four (24) hours thereafter, take any action reasonably necessary to cause the Subject Shares held by such Stockholder to be voted in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="white-space:pre-wrap;">&#8239;(c)&#160;&#160;&#160;Except as permitted under clauses (A)&#160;through (J)&#160;of </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.2</span> below, the Stockholder shall retain at all times the right to vote the Subject Shares in the Stockholder&#8217;s sole discretion and without any other limitation on those matters other than those set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1</span> that are at any time or from time to time presented for consideration to the Company Stockholders. In the event of a stock split, stock dividend or distribution, or any change in the Common Stock by reason of any split-up, reverse </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Subject Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.2.&#160;&#160;&#160;&#8239;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Inconsistent Arrangements</b>. Except as provided hereunder or under the Merger Agreement, prior to the Expiration Time, the Stockholder shall not, directly or indirectly,&#160;(a)&#160;create any Lien other than restrictions imposed by Law or pursuant to this Agreement on any Subject Shares; (b)&#160;transfer, sell, assign, gift or otherwise dispose of (collectively, &#8220;<span style="font-style:italic;font-weight:bold;">Transfer</span>&#8221;), or enter into any contract with respect to any Transfer of, the Subject Shares or any interest therein; (c)&#160;grant or permit the grant of any proxy, power of attorney or other authorization in or with respect to the Subject Shares; (d)&#160;deposit or permit the deposit of the Subject Shares into a voting trust or enter into a voting agreement or arrangement with respect to the Subject Shares; or (e)&#160;take any action that, to the knowledge of the Stockholder, would make any representation or warranty of the Stockholder herein untrue or incorrect in any material respect or have the effect of preventing the Stockholder from performing the Stockholder&#8217;s obligations hereunder. Any action taken in violation of the foregoing sentence shall be null and void <i style="font-style:italic;">ab initio</i>. Notwithstanding the foregoing, the Stockholder may (A)&#160;Transfer Subject Shares as a <i style="font-style:italic;">bona fide</i> charitable contribution, gift or donation; (B)&#160;Transfer the Subject Shares to any trust for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder; (C)&#160;Transfer the Subject Shares by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the Stockholder; (D)&#160;Transfer the Subject Shares to stockholders, direct or indirect affiliates (within the meaning set forth in Rule&#160;405 under the Securities Act), current or former partners (general or limited), members or managers of the Stockholder, as applicable, or to the estates of any such stockholders, affiliates, partners, members or managers, or to another corporation, partnership, limited liability company or other business entity that controls, is controlled by or is under common control with the Stockholder; (E)&#160;make Transfers that occur by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement; (F)&#160;make Transfers not involving a change in beneficial ownership; (G)&#160;if the Stockholder is a trust, Transfer the Subject Shares to any beneficiary of the Stockholder or the estate of any such beneficiary; (H)&#160;exercise an option or warrant to purchase Company Common Stock or settle a restricted stock unit or other equity award (including a net or cashless exercise of such option or warrant); (I)&#160;Transfer Company Common Stock to the Company to cover tax withholding obligations of the Stockholder in connection with the vesting, settlement or exercise of any options, warrants, restricted stock units or other equity awards, as applicable; (J)&#160;Transfer Company Common Stock with the prior written consent of Parent; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i> that, with respect to clauses (A)&#160;through (J)&#160;above, the transferee agrees in writing to be bound by the terms and conditions of this Agreement and either the Stockholder or the transferee provides Parent with a copy of such agreement promptly upon consummation of any such Transfer; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</i><i style="font-style:italic;">,</i> that in each case, the underlying shares of Company Common Stock shall continue to be subject to the restrictions on Transfer set forth in this Agreement notwithstanding that such transferee has not executed a counterpart hereof or joinder hereto; or (K)&#160;Transfer Company Common Stock to another holder of capital stock of the Company that has signed a support agreement in the same form as this Agreement. The Stockholder agrees that any shares of capital stock or other equity voting securities of the Company that such Stockholder acquires or with respect to which such Stockholder otherwise acquires sole or shared voting power (including any proxy) after the execution of this Agreement and prior to the Expiration Time (as defined below), including, without limitation, by gift, succession, in the event of a stock split or as a dividend or distribution of any Shares (&#8220;<span style="font-style:italic;font-weight:bold;">New Shares</span>&#8221;), shall be subject to the terms and conditions of this Agreement to the same extent as if they constituted the Subject Shares. For purposes of this Agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.3.&#160;&#160;&#160;&#8239;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Documentation and Information</b>. The Stockholder shall permit and hereby authorizes the Company and Parent to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that the Company or Parent reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, the Stockholder&#8217;s identity and ownership of the Subject Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement. The Company is an intended third-party beneficiary of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.3</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">1.4.&#160;&#160;&#160;&#8239;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Irrevocable Proxy</b><b style="font-weight:bold;">.</b> The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to the Subject Shares. In the event and to the extent that the Stockholder fails to vote the Subject Shares in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1</span> at any applicable meeting of the Company Stockholders or pursuant to any applicable written consent of the stockholders of the Company, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Parent and any of its designees with full power of substitution and resubstitution, as attorney-in-fact and proxy for and on behalf of the Stockholder, for and in the name, place and stead of the Stockholder, to: (a)&#160;attend any and all meetings of the Company Stockholders, (b)&#160;vote, express consent or dissent or issue instructions to the record holder to vote the Subject Shares in accordance with the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1</span> at any and all meetings of the Company Stockholders or in connection with any action sought to be taken by written consent of the Company Stockholders without a meeting and (c)&#160;grant or withhold, or issue instructions to the record holder to grant or withhold, consistent with the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1</span>, all written consents with respect to the Subject Shares at any and all meetings of the Company Stockholders or in connection with any action sought to be taken by written consent of the Company Stockholders without a meeting. Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">described in this Agreement. The foregoing proxy shall be deemed to be a proxy coupled with an interest, is irrevocable (and as such shall survive and not be affected by the death, incapacity, mental illness or insanity of the Stockholder, as applicable) until the termination of this Agreement and shall not be terminated by operation of law or upon the occurrence of any other event other than the termination of this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</span>. The Stockholder authorizes such attorney and proxy to substitute any other Person to act hereunder, to revoke any substitution and to file this proxy and any substitution or revocation with the Secretary of the Company. The Stockholder hereby affirms that the proxy set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.4</span> is given in connection with and granted in consideration of and as an inducement to Parent, Merger Sub and the Company to enter into the Merger Agreement and that such proxy is given to secure the obligations of the Stockholder under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1</span>. The proxy set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.4</span> is executed and intended to be irrevocable, subject, however, to its automatic termination upon the termination of this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</span>. With respect to any Subject Shares that are owned beneficially by the Stockholder but are not held of record by the Stockholder (other than shares beneficially owned by the Stockholder that are held in the name of a bank, broker or nominee), the Stockholder shall take all action necessary to cause the record holder of such Subject Shares to grant the irrevocable proxy and take all other actions provided for in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.4</span> with respect to such Subject Shares. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate upon the termination of this Agreement in accordance with the terms set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.5.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Ownership Interest</b>. Nothing contained in this Agreement will be deemed to vest in Parent any direct or indirect ownership or incidents of ownership of or with respect to the Subject Shares. All rights, ownership and economic benefits of and relating to the Subject Shares will remain and belong to the Stockholder, and Parent will have no authority to manage, direct, superintend, restrict, regulate, govern or administer any of the policies or operations of the Company or exercise any power or authority to direct the Stockholder in the voting of any of the Subject Shares, except as otherwise expressly provided herein with respect to the Subject Shares and except as otherwise expressly provided in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.6.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Exercise of Appraisal Rights; Waivers</b>. In connection with the Contemplated Transactions, the Stockholder hereby irrevocably and unconditionally (a)&#160;waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters&#8217; rights and any similar rights (including any notice requirements related thereto) to the extent permitted under applicable Law, relating to the Merger that Stockholder may have by virtue of, or with respect to any Subject Shares (including all rights under Section&#160;262 of the Delaware General Corporation Law, a copy of which is attached hereto as Appendix I) and (b)&#160;agrees that the Stockholder will not, under any circumstances in connection with the Contemplated Transactions, exercise any dissenters&#8217; or appraisal rights in respect of any Subject Shares, and (c)&#160;agrees that the Stockholder will not bring, commence, institute, maintain, prosecute, participate in or voluntarily aid any action, claim, suit or cause of action, in law or in equity, in any court or before any Governmental Entity, which (i)&#160;challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii)&#160;alleges that the execution and delivery of this Agreement by the Stockholder, or the approval of the Merger Agreement by the board of directors of the Company (the &#8220;<span style="font-style:italic;font-weight:bold;">Company Board</span>&#8221;), breaches any fiduciary duty of the Company Board or any member thereof; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i> that the Stockholder may defend against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.7.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Solicitation of Transactions</b>. The Stockholder hereby agrees that, prior to the Expiration Time (as defined below), the Stockholder shall not, directly or indirectly, including through any of its officers, directors or agents: (a)&#160;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (b)&#160;furnish any non-public information regarding the Company to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (c)&#160;engage in discussions (other than to inform any Person of the existence of the provisions in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.7</span>) or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (d)&#160;approve, endorse or recommend any Acquisition Proposal; (e)&#160;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction (other than an Acceptable Confidentiality Agreement (as defined in the Merger Agreement) permitted under the Merger Agreement); or (f)&#160;publicly propose to do any of the foregoing<i style="font-style:italic;">.</i> The Stockholder hereby represents and warrants that the Stockholder has read Section&#160;6.4 (No Solicitation) of the Merger Agreement and agrees not to engage in any actions prohibited thereby. Notwithstanding the foregoing, the Stockholder will not be responsible for the breaches by its officers, directors or agents that have otherwise entered into a separate support agreement with the Company (in a form reasonably acceptable to Parent), unless the Stockholder knowingly and intentionally caused such breach.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Stockholder represents and warrants to Parent that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.1.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization; Authorization; Binding Agreement</b>. The Stockholder, if not a natural person, is duly incorporated or organized, as applicable, validly existing and in good standing under the laws of its jurisdiction of incorporation or organization. The Stockholder has full legal capacity and power, right and authority to (a)&#160;execute and deliver this Agreement and to perform the Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby and (b)&#160;vote all of the Subject Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Entity). This Agreement has been duly and validly executed and delivered by the Stockholder, and constitutes a legal, valid and binding obligation of the Stockholder enforceable against the Stockholder in accordance with its terms (except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&#8217; rights generally or by general principles of equity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.2.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership of Subject Shares; Total Shares</b>. The Stockholder is the record or beneficial owner of the Subject Shares and has good and marketable title to the Subject Shares free and clear of any Liens (including any restriction on the right to vote or otherwise transfer the Subject Shares), except (a)&#160;as provided hereunder, (b)&#160;pursuant to any applicable restrictions on transfer under the Securities Act and (c)&#160;as provided in the certificate of incorporation or bylaws of the Company. The Subject Shares listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule&#160;A</span> opposite the Stockholder&#8217;s name constitute all of the Company Common Stock owned by the Stockholder as of the date hereof. Except pursuant to the Company&#8217;s certificate of incorporation and bylaws, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of the Subject Shares. For purposes of this Agreement &#8220;<span style="font-style:italic;font-weight:bold;">Beneficial Ownership</span>&#8221; shall be interpreted as defined in Rule&#160;13d-3 under the Exchange Act; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i> that for purposes of determining Beneficial Ownership, a Person shall be deemed to be the Beneficial Owner of any securities that may be acquired by such Person pursuant to any Contract or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise (irrespective of whether the right to acquire such securities is exercisable immediately or only after the passage of time, including the passage of time in excess of 60&#160;days, the satisfaction of any conditions, the occurrence of any event or any combination of the foregoing).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.3.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting Power</b>. The Stockholder has full voting power, with respect to the Subject Shares, and full power of disposition, full power to issue instructions with respect to the matters set forth herein and full power to agree to all of the matters set forth in this Agreement, in each case, with respect to all of the Subject Shares. None of the Subject Shares are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of the Subject Shares, except as provided hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.4.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reliance</b>. The Stockholder has had the opportunity to review the Merger Agreement, including the provisions relating to the payment and allocation of the consideration to be paid to the Company Stockholders, and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the transactions contemplated by the Merger Agreement. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company, Guarantor or any of their respective agents or representatives. The Stockholder understands that such Stockholder (and not Parent, the Company, Guarantor or the Surviving Company) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the transactions contemplated by the Merger Agreement. The Stockholder understands and acknowledges that the Company, Guarantor, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.5.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Litigation</b>. With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Subject Shares) that could reasonably be expected to prevent, delay or impair the ability of the Stockholder to perform the Stockholder&#8217;s obligations hereunder or to consummate the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.6.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Contravention</b>. The execution and delivery of this Agreement by the Stockholder and the performance of the transactions contemplated by this Agreement by the Stockholder does not and will not violate, conflict with, or result in a breach of: (a)&#160;the organizational documents of such Stockholder, (b)&#160;any applicable Law or any injunction, judgment, order, decree, ruling, charge, or other restriction of any Governmental Entity to which the Stockholder is subject, or (c)&#160;any Contract to which the Stockholder is a party or is bound or to which the Subject Shares are subject, such that it could reasonably be expected to prevent, delay or impair the ability of the Stockholder to perform the Stockholder&#8217;s obligations hereunder or to consummate the transactions contemplated hereby.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</b>. All notices, requests and other communications to either party hereunder shall be in writing (including electronic mail) and shall be given, (a)&#160;if to Parent, in accordance with the provisions of the Merger Agreement and (b)&#160;if to the Stockholder, to the Stockholder&#8217;s address or electronic mail address set forth on a signature page&#160;hereto, or to such other address or electronic mail address as the Stockholder may hereafter specify in writing to Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.2.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</b>. This Agreement shall terminate automatically, without any notice or other action by any Person, upon the earlier of (a)&#160;the termination of the Merger Agreement in accordance with its terms and (b)&#160;the Effective Time (the &#8220;<span style="font-style:italic;font-weight:bold;">Expiration Time</span>&#8221;). Upon termination of this Agreement, neither party shall have any further obligations or liabilities under this Agreement; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i><i style="font-style:italic;">, </i><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</i><i style="font-style:italic;">,</i> that (i)&#160;nothing set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</span> shall relieve either party from liability for any breach of this Agreement prior to termination hereof, and (ii)&#160;the provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span> shall survive any termination of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.3.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</b>. Except to the extent required by applicable Law, the Stockholder shall hold any&#160;non-public&#160;information regarding this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until Parent has publicly disclosed its entry into the Merger Agreement and this Agreement;&#160;<i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i>,&#160;<i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</i>, that the Stockholder may disclose such information (a)&#160;to its attorneys, accountants, consultants, trustees, beneficiaries and other representatives (<i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i>&#160;such representatives are subject to confidentiality obligations at least as restrictive as those contained herein), and (b)&#160;to any Affiliate, partner, member, stockholder, parent or subsidiary of the Stockholder,&#160;<i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i>&#160;in each case that the Stockholder informs the Person receiving the information that such information is confidential and such Person agrees in writing to abide by the terms of this&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span>. Neither the Stockholder nor any of its Affiliates (other than the Company, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.4.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments and Waivers</b>. Any provision of this Agreement may be amended or waived if such amendment or waiver is in writing and is signed, in the case of an amendment, by each party to this Agreement, or in the case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.5.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect; Benefit; Assignment</b>. The provisions of this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.3</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span>, no provision of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon any Person other than the parties hereto and their respective successors and assigns. Neither party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the consent of the other party hereto, except that Parent may transfer or assign its rights and obligations under this Agreement, in whole or from time to time in part, to one or more of its Affiliates at any time; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i> that such transfer or assignment shall not relieve Parent of any of its obligations hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.6.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Jurisdiction</b>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties hereto arising out of or relating to this Agreement, each party hereto: (a)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware (the &#8220;<span style="font-style:italic;font-weight:bold;">Delaware Courts</span>&#8221;); (b)&#160;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&#160;of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6</span>; (c)&#160;waives any objection to laying venue in any such action or proceeding in such courts; (d)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party hereto; (e)&#160;agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1</span> of this Agreement; and (f)&#160;irrevocably and unconditionally waives the right to trial by jury.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">3.7.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</b>. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">all parties by facsimile or electronic transmission in .PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.8.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</b>. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.9.&#160;&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</b>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination will have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.10.&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</b>. Any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any Delaware Court, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties hereto waives any bond, surety or other security that might be required of any other party with respect thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.11.&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The parties hereto agree that any rule&#160;of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Except as otherwise indicated, all references in this Agreement to &#8220;Sections,&#8221; &#8220;Articles,&#8221; and &#8220;Schedules&#8221; are intended to refer to Sections or Articles of this Agreement and Schedules to this Agreement, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.12.&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</b>. Each of the parties hereto will execute and deliver, or cause to be executed and delivered, all further documents and instruments and use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary under applicable Law to perform their respective obligations as expressly set forth under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.13.&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capacity as Stockholder</b>. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as a holder of Company Common Stock, and not in the Stockholder&#8217;s capacity as a director, officer or employee of the Company or in the Stockholder&#8217;s capacity as a trustee or fiduciary of any employee benefit plan or trust. Notwithstanding anything herein to the contrary, nothing herein shall in any way restrict a director or officer of the Company in the exercise of his or her fiduciary duties as a director or officer of the Company or in his or her capacity as a trustee or fiduciary of any employee benefit plan or trust or prevent or be construed to create any obligation on the part of any director or officer of the Company or any trustee or fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such director, officer, trustee or fiduciary.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.14.&#160;&#160;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Agreement Until Executed</b>. Irrespective of negotiations among the parties or the exchanging of drafts of this Agreement, this Agreement shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and until (a)&#160;the Company Board has approved, for purposes of any applicable anti-takeover laws and regulations, and any applicable provision of the Company&#8217;s organizational documents, the Merger, (b)&#160;the Merger Agreement is executed by all parties thereto, and (c)&#160;this Agreement is executed by all parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(SIGNATURE PAGE FOLLOWS)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_fd8472ba_b48c_493c_a58a_33abb4575791"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">[Signature Page to Support Agreement]</i></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ORTHOCELLIX,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:bottom;width:49.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">[Signature Page to Support Agreement]</i></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OCUGEN,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">[Signature Page to Support Agreement]</i></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">STOCKHOLDER</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Print Name of Stockholder)</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Signature)</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Name and Title of Signatory, if Signing on Behalf of an Entity)</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email:</p></td><td style="vertical-align:bottom;width:44.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">[Signature Page to Support Agreement]</i></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c5be8c7b_f13c_4b63_b72f_6a049a55ff73"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule&#160;A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of Stockholder</b></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:43.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No. Shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[&#9679;]</p></td><td style="vertical-align:top;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[&#9679;]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#167; 262. Appraisal rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&#160;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, who has otherwise complied with subsection (d)&#160;of this section and who has neither voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b)&#160;and (c)&#160;of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;Appraisal rights shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation in a merger, consolidation, conversion, transfer, domestication or continuance to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g)&#160;of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264, &#167; 266 or &#167; 390 of this title (other than, in each case and solely with respect to a converted or domesticated corporation, a merger, consolidation, conversion, transfer, domestication or continuance authorized pursuant to and in accordance with the provisions of &#167; 265 or &#167; 388 of this title):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">(1)&#160;&#160;&#160;Provided, however, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at the record date fixed to determine the stockholders entitled to consent pursuant to &#167; 228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for the conversion, transfer, domestication or continuance (or, in the case of a merger pursuant to &#167; 251(h)&#160;of this title, as of immediately prior to the execution of the agreement of merger), were either: (i)&#160;listed on a national securities exchange or (ii)&#160;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f)&#160;of this title.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">(2)&#160;&#160;&#160;Notwithstanding paragraph (b)(1)&#160;of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, transfer, domestication or continuance, pursuant to &#167; 251, &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264, &#167; 266 or &#167; 390 of this title to accept for such stock anything except:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">a.&#160;&#160;&#160;Shares of stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity or the entity resulting from a transfer, domestication or continuance if such entity is a corporation as a result of the conversion, transfer, domestication or continuance, or depository receipts in respect thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">b.&#160;&#160;&#160;Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger, consolidation, conversion, transfer, domestication or continuance will be either listed on a national securities exchange or held of record by more than 2,000 holders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">c.&#160;&#160;&#160;Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">d.&#160;&#160;&#160;Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">(3)&#160;&#160;&#160;In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">(4)&#160;&#160;&#160;[Repealed.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167; 266 of this title or a transfer, domestication or continuance effected pursuant to &#167; 390 of this title. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&#160;of this section, shall apply as nearly as is practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;&#160;&#160;Appraisal rights shall be perfected as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">(1)&#160;&#160;&#160;If a proposed merger, consolidation, conversion, transfer, domestication or continuance for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c)&#160;of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&#160;or (c)&#160;of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and, &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger, consolidation, conversion, transfer, domestication or continuance, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation, conversion, transfer, domestication or continuance shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10 days after the effective date of such merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity shall notify each stockholder of each constituent or converting, transferring, domesticating or continuing corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation, conversion, transfer, domestication or continuance, and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section, of the date that the merger, consolidation or conversion has become effective; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">(2)&#160;&#160;&#160;If the merger, consolidation, conversion, transfer, domestication or continuance was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then either a constituent, converting, transferring, domesticating or continuing corporation before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, or the surviving, resulting or converted entity within 10 days after such effective date, shall notify each stockholder of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation who is entitled to appraisal rights of the approval of the merger, consolidation, conversion, transfer, domestication or continuance and that appraisal rights are available for any or all shares of such class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting, transferring, domesticating or continuing corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, shall, also notify such stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance. Any stockholder entitled to appraisal rights may, within 20 days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, within the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20 days after the date of giving such notice, demand in writing from the surviving, resulting or converted entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, either (i)&#160;each such constituent corporation or the converting, transferring, domesticating or continuing corporation shall send a second notice before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance notifying each of the holders of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation that are entitled to appraisal rights of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance or (ii)&#160;the surviving, resulting or converted entity shall send such a second notice to all such holders on or within 10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20 days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting, transferring, domesticating or continuing corporation may fix, in advance, a record date that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">(3)&#160;&#160;&#160;Notwithstanding subsection (a)&#160;of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s name, demand in writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1)&#160;or (2)&#160;of this section, as applicable; provided that (i)&#160;such beneficial owner continuously owns such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a)&#160;of this section and (ii)&#160;the demand made by such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by subsection (f)&#160;of this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(e)&#160;&#160;&#160;Within 120 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity, or any person who has complied with subsections (a)&#160;and (d)&#160;of this section and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance. Within 120 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person who has complied with the requirements of subsections (a)&#160;and (d)&#160;of this section, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance (or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2)&#160;of this title)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3)&#160;of this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to the person within 10 days after such person&#8217;s request for such a statement is received by the surviving, resulting or converted entity or within 10 days after expiration of the period for delivery of demands for appraisal under subsection (d)&#160;of this section, whichever is later.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(f)&#160;&#160;&#160;Upon the filing of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(g)&#160;&#160;&#160;At the hearing on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation, conversion, transfer, domestication or continuance the shares of the class or series of stock of the constituent, converting, transferring, domesticating or continuing corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&#160;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&#160;the value of the consideration provided in the merger, consolidation, conversion, transfer, domestication or continuance for such total number of shares exceeds $1 million, or (3)&#160;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(h)&#160;&#160;&#160;After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules&#160;of the Court of Chancery, including any rules&#160;specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger, consolidation, conversion, transfer, domestication or continuance, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation, conversion, transfer, domestication or continuance through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&#160;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2)&#160;interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section may participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(i)&#160;&#160;&#160;The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(j)&#160;&#160;&#160;The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section who participated in the proceeding and incurred expenses in connection therewith, the Court may order all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal not dismissed pursuant to subsection (k)&#160;of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k)&#160;of this section.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(k)&#160;&#160;&#160;Subject to the remainder of this subsection, from and after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, no person who has demanded appraisal rights with respect to some or all of such person&#8217;s shares as provided in subsection (d)&#160;of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation, conversion, transfer, domestication or continuance). If a person who has made a demand for an appraisal in accordance with this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in respect of some or all of such person&#8217;s shares in accordance with subsection (e)&#160;of this section, either within 60 days after such effective date or thereafter with the written approval of the corporation, then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, an appraisal proceeding in the Court of Chancery shall not be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just, including without limitation, a reservation of jurisdiction for any application to the Court made under subsection (j)&#160;of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance within 60 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, as set forth in subsection (e)&#160;of this section. If a petition for an appraisal is not filed within the time provided in subsection (e)&#160;of this section, the right to appraisal with respect to all shares shall cease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(l)&#160;&#160;&#160;The shares or other equity interests of the surviving, resulting or converted entity to which the shares of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity interests of the surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no longer entitled to appraisal pursuant to this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_daff3d89_757d_40e5_adc6_27370ee62085"></a><a id="AnnexE_617142"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex E</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Lock-Up Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[</b><b style="font-family:'Times New Roman';font-weight:bold;">&#9679;</b><b style="font-weight:bold;">], 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Ladies and Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The undersigned (the &#8220;<span style="font-style:italic;font-weight:bold;">Stockholder</span>&#8221;) understands that: (i)&#160;<b style="font-variant:small-caps;font-weight:bold;">CARISMA THERAPEUTICS INC.</b>, a Delaware corporation (&#8220;<span style="font-style:italic;font-weight:bold;">Parent</span>&#8221;), has entered into an Agreement and Plan of Merger, dated as of [&#8226;], 2025 (as such agreement may be amended, restated, amended and restated or otherwise modified from time to time, the &#8220;<span style="font-style:italic;font-weight:bold;">Merger Agreement</span>&#8221;), with <b style="font-variant:small-caps;font-weight:bold;">ORTHOCELLIX,&#160;INC.</b>, a Delaware corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span>&#8221;), <b style="font-variant:small-caps;font-weight:bold;">OCUGEN,&#160;INC.</b>, a Delaware corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Guarantor</span>&#8221;), and <b style="font-variant:small-caps;font-weight:bold;">AZALEA MERGER SUB,&#160;INC.</b>, a Delaware corporation and wholly owned subsidiary of Parent (&#8220;<span style="font-style:italic;font-weight:bold;">Merger Sub</span>&#8221;), pursuant to which, at the effective time (the &#8220;<span style="font-style:italic;font-weight:bold;">Effective Time</span>&#8221;), Merger Sub will be merged with and into the Company (the &#8220;<span style="font-style:italic;font-weight:bold;">Merger</span>&#8221;) and the separate corporate existence of Merger Sub will cease and the Company will continue as the surviving corporation; and (ii)&#160;in connection with the Merger, the stockholders of the Company will receive shares of common stock, par value $0.001 per share, of Parent (&#8220;<span style="font-style:italic;font-weight:bold;">Parent Common Stock</span>&#8221;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a condition and inducement to the willingness of each of the parties to enter into the Merger Agreement and to consummate the Contemplated Transactions, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Stockholder hereby agrees that the Stockholder will not, subject to the exceptions set forth in this letter agreement, during the period commencing upon the date hereof and ending on the date that is 180 days after the Effective Time (the &#8220;<span style="font-style:italic;font-weight:bold;">Restricted Period</span>&#8221;), (a)&#160;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock received by the Stockholder in connection with the Contemplated Transactions or any securities of Parent received by the Stockholder in connection with the Contemplated Transactions that are convertible into or exercisable or exchangeable for Parent Common Stock, including without limitation, Parent Common Stock or such other securities which may be deemed to be beneficially owned by the Stockholder in accordance with the rules&#160;and regulations of the U.S. Securities and Exchange Commission and securities of Parent which may be issued upon exercise of a stock option or warrant or settlement of a restricted stock unit or other equity award (collectively, &#8220;<span style="font-style:italic;font-weight:bold;">Shares</span>&#8221;), (b)&#160;enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Shares, regardless of whether any such transaction described in clause (a)&#160;or (b)&#160;above is to be settled by delivery of Parent Common Stock or such other securities, in cash or otherwise, or (c)&#160;make any demand for or exercise any right with respect to the registration of any Shares, in each case other than:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(i)&#160;&#160;&#160;transfers of Shares as <i style="font-style:italic;">bona fide</i> charitable contributions, gifts or donations as such term is described in Section&#160;501(c)(3)&#160;of the Internal Revenue Code of 1986, as amended;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(ii)&#160;&#160;&#160;if the Stockholder is a natural person, transfers or dispositions of Shares to (A)&#160;any person related to the Stockholder by blood or adoption who is an immediate family member of the Stockholder, or by marriage or domestic partnership, or to a trust formed for the benefit of the Stockholder or any of the Stockholder&#8217;s immediate family, (B)&#160;to the Stockholder&#8217;s estate, following the death of the Stockholder, by will, intestacy or other operation of Law, (C)&#160;by operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement, or (D)&#160;to any corporation, partnership or other entity, in each case, all of the beneficial ownership interests of which are held by the Stockholder or an immediate family member of the Stockholder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(iii)&#160;&#160;&#160;if the Stockholder is a corporation, partnership or other entity, (A)&#160;to another corporation, partnership, or other entity that is a direct or indirect affiliate (as defined under Rule&#160;12b-2 of the Exchange Act) of the Stockholder, including investment funds or other entities under common control or management with the Stockholder (including, for the avoidance of doubt, where the Stockholder is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), (B)&#160;as a distribution or dividend to equity holders, current or former partners, members, stockholders or managers (or to the estates of any of the foregoing), as applicable, of the Stockholder (including upon the liquidation and dissolution of the Stockholder pursuant to a plan of liquidation approved by the Stockholder&#8217;s equity holders), (C)&#160;transfers or dispositions not involving a change in beneficial ownership or (D)&#160;with prior written consent of Parent (as constituted following the Closing);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(iv)&#160;&#160;&#160;transfers or dispositions of Shares by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the Stockholder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(v)&#160;&#160;&#160;transfers of Shares to stockholders, direct or indirect affiliates (within the meaning set forth in Rule&#160;405 under the Securities Act), current or former partners (general or limited), members or managers of the Stockholder, as applicable, or to the estates of any such stockholders, affiliates, partners, members or managers, or to another corporation, partnership, limited liability company or other business entity that controls, is controlled by or is under common control with the Stockholder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(vi)&#160;&#160;&#160;transfers that occur by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(vii)&#160;&#160;&#160;transfers or dispositions not involving a change in beneficial ownership;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(viii)&#160;&#160;&#160;if the Stockholder is a trust, transfers or dispositions to any beneficiary of the Stockholder or the estate of any such beneficiary; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i> that, in the case of any transfer or distribution of this clause (viii)&#160;such transfer is not for value and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Parent a lock up agreement in the form of this letter agreement with respect to the shares of Parent Common Stock or such other securities that have been transferred or distributed;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(ix)&#160;transfers pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Parent&#8217;s capital stock involving a change of control of the Parent, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Shares shall remain subject to the restrictions contained in this letter agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(x)&#160;&#160;&#160;any sales in open market transactions (including, without limitation, the establishment of a 10b5-1 Plan (as defined below) and any sales pursuant to such 10b5-1 Plan) during the Restricted Period to generate such amount of net proceeds to the Stockholder from such sales (after deducting commissions) in an aggregate amount up to the total amount of taxes or estimated taxes (as applicable) that become due as a result of the vesting and/or settlement of restricted stock units held by the Stockholder that are scheduled to vest and/or settle immediately prior to or during the Restricted Period;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(xi)&#160;&#160;&#160;transfers pursuant to an order of a court or regulatory agency;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(xii)&#160;&#160;transfers, distributions, sales or other transactions with the prior written consent of Parent (as constituted following the Closing); or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(xiii)&#160;&#160;transfers, distributions, sales or other transactions of Parent Common Stock, if any, issued in connection with the Concurrent Investment;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or (d)&#160;publicly disclose the intention to do any of the foregoing described in clauses (a), (b)&#160;and (c)&#160;above; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i>, that in each case of clauses (i)-(viii), (1)&#160;other than with respect to clause (v), no filing by any party (including any donor, donee, transferor or transferee, distributor or distributee) under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than filings made in respect of involuntary transfers or dispositions or a filing on a Form&#160;5 made after the expiration of the Restricted Period), (2)&#160;other than with respect to clause (v), any such transfer or distribution shall not involve a disposition for value, and (3)&#160;the transferee or donee agrees in writing to be bound by the terms and conditions of this letter agreement and either the Stockholder or the transferee or donee provides Parent with a copy of such agreement promptly upon consummation of any such transfer; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</i>, that in the case of clause (x), filings under Section&#160;16(a)&#160;of the Exchange Act shall only be permissible if such filing clearly indicates in the footnotes thereto that the filing relates to securities being sold to generate net proceeds up to the total amount of taxes or estimated taxes (as applicable) that become due as a result of the vesting and/or settlement of Parent equity awards. For purposes of this letter agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the restrictions imposed by this letter agreement, the Stockholder may (a)&#160;exercise an option or warrant to purchase Shares or settle a restricted stock unit or other equity award (including a net or cashless exercise of such option or warrant <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i> the Shares are transferred to Parent and not sold on the open market) and <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</i>, that the underlying Shares shall continue to be subject to the restrictions on transfer set forth in this letter agreement, (b)&#160;transfer Shares to Parent to cover tax withholding obligations of the Stockholder in connection with the vesting, settlement or exercise of such options, warrants, restricted stock units or other equity awards, as applicable, (c)&#160;establish a trading plan pursuant to Rule&#160;10b5-1 under the Exchange Act (&#8220;<span style="font-style:italic;font-weight:bold;">10b5-1 Plan</span>&#8221;) for the transfer of Shares, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i> that such plan does not provide for any transfers of Shares during the Restricted Period (except as provided in clause (ix)&#160;above) and, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further,</i> that, no filing under the Exchange Act or other public announcement shall be made voluntarily in connection with the establishment of such a plan (except if the Stockholder is a director or officer of Parent, for disclosure required under Item 408 to Regulation S-K), (d)&#160;transfer Shares to Parent pursuant to arrangements under which Parent has the option to repurchase such Shares, or (e)&#160;transfer or dispose of Shares acquired on the open market following the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any attempted transfer in violation of this letter agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this letter agreement, and will not be recorded on the stock transfer books of Parent. In order to ensure compliance with the restrictions referred to herein, the Stockholder agrees that Parent may issue appropriate &#8220;stop transfer&#8221; certificates or instructions. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s)&#160;or other documents or instruments evidencing ownership of the Shares:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY&#160;ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Stockholder hereby represents and warrants that the Stockholder has full power and authority to enter into this letter agreement. All authority conferred or agreed to be conferred and any obligations of the Stockholder under this letter agreement will be binding upon the successors, assigns, heirs or personal representatives of the Stockholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that during the Restricted Period any holder of Parent&#8217;s securities that is subject to a substantially similar agreement entered into by such holder, other than the Stockholder, is permitted by Parent to sell or otherwise transfer or dispose of shares of Parent Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder, the same percentage of shares of Parent Common Stock held by the Stockholder shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the &#8220;<span style="font-style:italic;font-weight:bold;">Pro-Rata Release</span>&#8221;); <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i>, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</i>, that such Pro-Rata Release shall not be applied unless and until permission has been granted by Parent to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holders&#8217; shares of Parent Common Stock in an aggregate amount in excess of 1% of the number of shares of Parent Common Stock originally subject to a substantially similar agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the release of any Shares from this letter agreement, Parent will cooperate with the Stockholder to facilitate the timely preparation and delivery of certificates or the establishment of book entry positions at the Parent&#8217;s transfer agent representing the Shares without the restrictive legend above and the withdrawal of any stop transfer instructions at the Parent&#8217;s transfer agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Stockholder understands that each of Parent and the Company is relying upon this letter agreement in proceeding toward consummation of the Merger. The Stockholder further understands that this letter agreement is irrevocable and is binding upon the Stockholder&#8217;s heirs, legal representatives, successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This letter agreement and any claim, controversy or dispute arising under or related to this letter agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Stockholder understands that if the Merger Agreement is terminated in accordance with its terms, or the board of directors of Parent makes a Parent Board Adverse Recommendation Change, the Stockholder will be released from all obligations under this letter agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This letter agreement may be executed by electronic (i.e., PDF) transmission, which is deemed an original.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Signature Page&#160;Follows</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Very truly yours,</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print Name of Stockholder:</p></td><td colspan="3" style="vertical-align:bottom;width:31.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:31.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Signature (for individuals):</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:31.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:31.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Signature (for entities):</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:28.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[<span style="font-variant:small-caps;">SIGNATURE PAGE&#160;TO LOCK-UP AGREEMENT</span>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_58265dec_77bd_4c5a_a568_b06b61d910df"></a><a id="AnnexF_507394"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex F</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">CONTINGENT VALUE RIGHTS AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS CONTINGENT VALUE RIGHTS AGREEMENT</b> (this &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), dated as of [&#9679;], 2025, is entered into by and between <b style="font-variant:small-caps;font-weight:bold;">Carisma Therapeutics Inc.</b>, a Delaware corporation (&#8220;<b style="font-weight:bold;">Parent</b>&#8221;), and Computershare Inc. a Delaware corporation (&#8220;<b style="font-weight:bold;">Computershare</b>&#8221;), and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company (collectively, as &#8220;<b style="font-weight:bold;">Rights Agent</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">A.</b></span>Parent, <b style="font-variant:small-caps;font-weight:bold;">Azalea Merger Sub, Inc.</b>, a Delaware corporation and wholly owned subsidiary of Parent (&#8220;<b style="font-weight:bold;">Merger Sub</b>&#8221;) and OrthoCellix, Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;) have entered into an Agreement and Plan of Merger, dated as of [&#9679;], 2025 (the &#8220;<b style="font-weight:bold;">Merger Agreement</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">B.</b></span>Pursuant to the Merger Agreement, and in accordance with the terms and conditions thereof, Parent has agreed to provide to the Holders (as defined herein) contingent value rights as hereinafter described.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">C.</b></span>The parties have done all things reasonably necessary to make the contingent value rights, when issued pursuant to the Merger Agreement and hereunder, the valid obligations of Parent and to make this Agreement a valid and binding agreement of Parent, in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, in consideration of the premises and the consummation of the transactions referred to above, it is mutually covenanted and agreed, for the proportionate benefit of all Holders, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 1.1 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Capitalized terms used but not otherwise defined herein have the meanings ascribed thereto in the Merger Agreement. The following terms have the meanings ascribed to them as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Acting Holders</b>&#8221; means, at the time of determination, the Holders of at least 40% of the outstanding CVRs, as reflected on the CVR Register.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Assignee</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Change of Control</b>&#8221; means (a) the acquisition in one transaction or a series of related transactions, by any Person or group (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934) of the securities of Parent possessing more than 50% of the total combined voting power of all outstanding securities of Parent (<i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that a Change of Control will not result upon such acquisition of ownership if such acquisition occurs as a result of: (i) a public offering of Parent&#8217;s securities or any financing transaction or series of financing transactions, in each case for <i style="font-style:italic;">bona fide</i> financing purposes or (ii) a merger or consolidation involving Parent where the holders of the outstanding voting securities of Parent immediately prior to such merger or consolidation (taken in the aggregate) possess beneficial ownership of 50% or more of the total combined voting power of all outstanding voting securities of Parent, the surviving entity, the acquiring entity or a parent or holding company of the acquiring entity, immediately after such merger or consolidation); or (b) the sale, transfer, exclusive license or other disposition (in one transaction or a series of related transactions) of all or substantially all of the assets of Parent (on a consolidated basis).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Closing Date</b>&#8221; has the meaning set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Common Stock</b>&#8221; means the common stock, $0.001 par value, of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">CVR</b>&#8221; means a contingent contractual right of Holders to receive CVR Payments pursuant to the Merger Agreement and this Agreement.&#8239;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">CVR Payment</b>&#8221; means a cash payment equal to (i) the Net Proceeds received by Parent to the extent such payment relates to a Parent Legacy Transaction entered into during the Disposition Period, if any plus (ii) the Net Proceeds received by Parent to the extent such payment relates to any royalties, milestones or other payments received by Parent following the Closing Date under Parent&#8217;s existing agreements as set forth on Schedule 1.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup>; <i style="font-style:italic;">provided</i>, that Parent, in its reasonable discretion as determined by the Board of Directors, may withhold up to 10% of any CVR Payment solely to the extent (a) that express contractual indemnity obligations under any Disposition Agreement are in excess of any escrow fund established therein, in each case to the extent not already deducted as Permitted Deductions and (b) of any Loss arising out of any third-party claims, demands, actions, or other proceedings relating to or in connection with any Parent Legacy Assets during the CVR Period that have been finally determined; <i style="font-style:italic;">provided, further</i>, that any such withheld Gross Proceeds shall be distributed (net of any Permitted Deductions actually applied against such Gross Proceeds within the (1) year period following such withholding) to the Holders no later than the date that is sixty (60) days following the first (1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup>) anniversary of the date such Gross Proceeds would have otherwise been distributed to the Holders in the CVR Payment from which such Gross Proceeds were otherwise deducted; <i style="font-style:italic;">provided, further</i>, that such withholding shall not be permitted if (x) the applicable indemnification period under the applicable Disposition Agreement related to such CVR Payment has expired by its terms when the CVR Payment is received or (y) the maximum aggregate liability in respect of the applicable indemnification obligations has been held back or setoff (including any amounts deposited in escrow) by the purchaser or acquiror under the applicable Disposition Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">CVR Payment Amount</b>&#8221; means with respect to each CVR Payment and each Holder, an amount equal to such CVR Payment divided by the total number of CVRs and then multiplied by the total number of CVRs held by such Holder as reflected on the CVR Register.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">CVR Payment Statement</b>&#8221; means, for a given CVR Payment, a written statement of Parent, signed on behalf of Parent, setting forth in reasonable detail and certifying the calculation of the applicable CVR Payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">&#8220;CVR Register</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3(b)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">CVR Term</b>&#8221; means the period beginning on the Closing and ending upon the [fifth (5<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) anniversary of this Agreement]<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Disposition Agreement</b>&#8221; means a definitive written agreement providing for a Parent Legacy Transaction that is entered into during the Disposition Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Disposition Period</b>&#8221; means the period beginning on the execution date of the Merger Agreement and ending on the second (2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">nd</sup>) anniversary of the Closing Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Gross Proceeds</b>&#8221; means, without duplication, the sum of all cash consideration and all cash proceeds from the sale of non-cash consideration of any kind that is actually paid to Parent or any of its Affiliates, or is actually received by Parent or any of its Affiliates, solely as such consideration relates to a Parent Legacy Asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Holder</b>&#8221; means, at the relevant time, a Person in whose name CVRs are registered in the CVR Register.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Liability</b>&#8221; means any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Loss</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.2(g)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Net Proceeds</b>&#8221; means, for any CVR Payment, Gross Proceeds minus Permitted Deductions, all as calculated, to the extent in accordance with GAAP, in a manner consistent with Parent&#8217;s accounting practices and the most recently filed annual audited financial statements with the SEC, except as otherwise set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Notice</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1</span>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> &#160;&#160;Schedule 1.1 to be updated as of the closing date, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> &#160;&#160;Date to be agreed pending asset sale status prior to the Closing.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Officer&#8217;s Certificate</b>&#8221; means a certificate signed by the chief executive officer or the chief financial officer of Parent, in their respective official capacities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Legacy Assets</b>&#8221; means all assets, technology and Intellectual Property of Parent, as they existed at any time prior to the date of this Agreement, relating to the Company&#8217;s research and development programs, as conducted and proposed to be conducted, including its CT-0525, CT-0508, CT-1119 and its engineered macrophage, and in vivo mRNA/lipid nanopartical CAR-M programs and its partnership with ModernaTX, Inc., including, for purposes of clarity, the tangible and intangible assets of Parent relating thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Legacy Transaction</b>&#8221; means the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) and/or winding down of, and/or the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or other disposition of any Parent Legacy Assets, in each cased entered into during the Disposition Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Party</b>&#8221; means Parent or the Rights Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Permitted Deductions</b>&#8221; means the sum of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>any applicable Tax (including any applicable value added or sales taxes) imposed on Gross Proceeds and payable by Parent (regardless of whether the due date for such Taxes arises during or after the Disposition Period) and, without duplication, any income or other similar Taxes payable by Parent or any of its Affiliates that would not have been incurred by Parent or any of its Affiliates but for the Gross Proceeds; <i style="font-style:italic;">provided</i> that, for purposes of calculating income Taxes incurred by Parent in respect of the Gross Proceeds, any such income Taxes shall be computed assuming the only items of income are the Gross Proceeds attributable to the gain recognized by Parent from the Parent Legacy Transaction and after reduction for any net operating loss carryforwards or other Tax attributes of Parent as of the Closing Date that are available to offset such gain after taking into account any limits of the usability of such attributes, including under Section 382 of the Code, as reasonably determined by Parent&#8217;s tax advisers (and for the sake of clarity such income taxes shall be calculated without taking into account any net operating losses or other tax attributes generated by Parent or its Affiliates after the Closing Date);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;(b)</span></span>any reasonable and documented out-of-pocket costs and expenses incurred by Parent to preserve the Parent Legacy Assets for sale or in respect of its performance of this Agreement following the Closing Date, including any damages, liabilities arising under any Disposition Agreement, including any incurred in litigation or other dispute resolution therefor, and including (i) any costs related to the prosecution, maintenance or enforcement by Parent or any of its Subsidiaries of intellectual property rights (but excluding any costs related to a breach of this Agreement, including costs incurred in litigation or dispute resolution in respect of the same), or (ii) any costs related to monetary liabilities of or relating to the Parent Legacy Assets that remain with the Parent following the consummation of any Parent Legacy Transaction;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;(c)</span></span>any reasonable and documented out-of-pocket costs or expenses incurred by Parent in connection with the negotiation, entry into and closing of any Parent Legacy Transaction, including any brokerage fee, finder&#8217;s fee, or other transaction fee, or other fee, commission or expense owed to any broker, finder, investment bank, auditor, accountant, counsel, advisor or other third party in relation thereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;(d)</span></span>any losses incurred by Parent arising out of any third-party claims, demands, actions, or other proceedings relating to or in connection with any Parent Legacy Transaction, including indemnification obligations of Parent set forth in any Disposition Agreement; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;(e)</span></span>any liabilities incurred during the CVR Term that would have been required to be included in the calculation of Net Cash (as defined in the Merger Agreement) arising solely out of a Disposition Agreement to the extent not taken into account in the calculation of Net Cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Permitted Transfer</b>&#8221; means a transfer of CVRs (a) upon death of a Holder by will or intestacy or by instrument to an inter vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (b)&#8239;pursuant to a court order; (c) by operation of law (including by consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; (d) in the case of CVRs held in book-entry or other similar nominee form, from a nominee to a beneficial owner and, if applicable, through an intermediary, to the extent allowable by DTC; (e) if the Holder is a partnership or limited liability company, a distribution by the transferring partnership or limited liability company to its partners or members, as applicable or (f) as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8220;</span><b style="font-weight:bold;">Rights Agent</b>&#8221; means the Rights Agent named in the first paragraph of this Agreement, until a successor Rights Agent will have become the Rights Agent pursuant to the applicable provisions of this Agreement, and thereafter &#8220;Rights Agent&#8221; will mean such successor Rights Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONTINGENT VALUE RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 2.1 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Holders of CVRs; Appointment of Rights Agent</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(a)&#160;&#160;&#160;The CVRs represent the rights of Holders to receive contingent CVR Payments pursuant to this Agreement. The CVRs shall be issued and distributed by Parent in the form a dividend in connection with the Merger, and the initial Holders will be the holders of Common Stock as of immediately prior to the Effective Time. One CVR will be issued with respect to each share of Common Stock that is outstanding as of immediately prior to the Effective Time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(b)&#160;&#160;&#160;Parent hereby appoints the Rights Agent to act as Rights Agent for Parent in accordance with the express terms and conditions set forth in this Agreement, and the Rights Agent hereby accepts such appointment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">Section 2.2 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-transferable</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer. Any attempted sale, assignment, transfer, pledge, encumbrance or disposal that is not a Permitted Transfer shall be void ab initio and of no effect. The CVRs will not be listed on any quotation system or traded on any securities exchange.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">Section 2.3 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Certificate; Registration; Registration of Transfer; Change of Address</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;&#8239;(a)&#160;&#160;The CVRs will be issued in book-entry form only and will not be evidenced by a certificate or other instrument. Holders&#8217; rights and obligations in respect of CVRs derive solely from this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(b)&#160;&#160;&#160;Subject to the receipt by the Rights Agent of the information and instructions described in </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.1</span>, the Rights Agent shall create and maintain a register (the &#8220;<b style="font-weight:bold;">CVR Register</b>&#8221;) for the purpose of registering CVRs and Permitted Transfers. The CVR Register will be created, and CVRs will be distributed, pursuant to written instructions to the Rights Agent from Parent. The CVR Register will initially show one position for Cede &amp; Co. representing shares of Common Stock held by DTC on behalf of the street holders of the shares of Common Stock held by such Holders as of immediately prior to the Effective Time. With respect to any payments or issuances to be made under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4</span> below, the Rights Agent will accomplish the payment to any former street name holders of shares Common Stock by sending one lump-sum payment or issuance to DTC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(c)&#160;&#160;Subject to the restrictions on transferability set forth in </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</span>, every request made to transfer a CVR must be in writing and accompanied by a written instrument of transfer in form reasonably satisfactory to the Rights Agent pursuant to its guidelines or procedures, including a guaranty of signature by an &#8220;eligible guarantor institution&#8221; that is a member or participant in the Securities Transfer Agents Medallion Program, duly executed and properly completed by the Holder thereof, the Holder&#8217;s attorney duly authorized in writing, the Holder&#8217;s personal representative or the Holder&#8217;s survivor, and setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the Rights Agent shall, subject to its reasonable determination that the transfer instrument is in proper form and the transfer otherwise complies with the other terms and conditions of this Agreement (including the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</span>), register the transfer of the CVRs in the CVR Register. Parent and the Rights Agent shall not be responsible for, and may require evidence of payment of a sum sufficient to cover (or evidence that such Taxes and charges are not applicable), any stamp, documentary, registration, or other Tax or governmental charge that is imposed in connection with any such registration of transfer. All duly transferred CVRs registered in the CVR Register will be the valid obligations of Parent and will entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer by the transferor. No transfer of a CVR will be valid until registered in the CVR Register and any transfer not duly registered in the CVR Register shall be void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">&#8239;(d)&#160;&#160;A Holder may make a written request to the Rights Agent to change such Holder&#8217;s address of record in the CVR Register. The written request must be duly executed by the Holder. Upon receipt of such written notice, the Rights Agent shall, subject to its reasonable determination that the transfer instrument is in proper form, promptly record the change of address in the CVR Register. The Acting Holders may, without duplication, make a written request to the Rights Agent for a list containing the names, addresses </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">and number of CVRs of the Holders that are registered in the CVR Register. Upon receipt of such written request from the Acting Holders, the Rights Agent shall promptly deliver a copy of such list to the Acting Holders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(e)&#160;&#160;Parent will provide written instructions to the Rights Agent for the distribution of CVRs to holders of Common Stock as of immediately prior to the Effective Time (the &#8220;</span><b style="font-weight:bold;">Record Time</b>&#8221;). Subject to the terms and conditions of this Agreement and Parent&#8217;s prompt confirmation of the Effective Time, the Rights Agent shall effect the distribution of the CVRs, less any applicable tax withholding, to each holder of Common Stock as of the Record Time by the mailing of a statement of holding reflecting such CVRs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">Section 2.4 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Procedures</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(a)&#160;&#160;&#160;No later than forty-five (45) days following the end of each calendar quarter during which Parent receives a CVR Payment during the CVR Term, Parent shall deliver to the Rights Agent a CVR Payment Statement. Concurrent with the delivery of each CVR Payment Statement, on the terms and conditions of this Agreement, Parent shall pay the Rights Agent in U.S. dollars an amount equal to one-hundred percent&#8239;(100%) of the applicable Net Proceeds (if any) for the applicable CVR Payment. Such amount of Net Proceeds will be transferred by wire transfer of immediately available funds to an account designated in writing by the Rights Agent not less than ten (10) Business Days prior to the date of the applicable payment. Upon receipt of the wire transfer referred to in the foregoing sentence, the Rights Agent shall promptly (and in any event, within ten&#8239;(10) Rights Agent, an amount equal to such Holder&#8217;s CVR Payment Amount. The Rights Agent shall, upon any Holder&#8217;s request in writing and as soon as practicable after receipt of a CVR Payment Statement under this </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4(a)</span>, send such Holder at its registered address a copy of such statement. For the avoidance of doubt Parent shall have no further liability in respect of the relevant CVR Payment upon delivery of such CVR Payment in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4(a)</span> and the satisfaction of each of Parent&#8217;s obligations set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4(a)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(b)&#160;&#160;&#160;The Rights Agent shall solicit from each Holder an IRS Form W-9 or applicable IRS Form&#8239;W-8 at such time or times as is necessary to permit any payment under this Agreement to be made without U.S. federal backup withholding. That notwithstanding, Parent shall be entitled to deduct and withhold and hereby authorizes the Rights Agent to deduct and withhold, any tax or similar governmental charge or levy, that is required to be deducted or withheld under applicable law from any amounts payable pursuant to this Agreement (&#8220;</span><b style="font-weight:bold;">Withholding Taxes</b>&#8221;). To the extent the amounts are so withheld by Parent or the Rights Agent, as the case may be, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the person in respect of whom such deduction and withholding was made. In the event Parent becomes aware that a payment under this Agreement is subject to Withholding Taxes (other than U.S. federal backup withholding), Parent shall use commercially reasonable efforts to provide written notice to the Rights Agent and the Rights Agent shall use commercially reasonable efforts to provide written notice of such Withholding Taxes to the applicable Holders and a reasonable opportunity for the Holder to provide any necessary Tax forms, including an IRS Form W-9 or appropriate IRS Form W-8, as applicable, in order to reduce such withholding amounts; <i style="font-style:italic;">provided</i> that the time period for payment of a CVR Payment by the Rights Agent set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4(a)</span> will be extended by a period equal to any delay caused by the Holder providing such forms. For the avoidance of doubt, in the event that notice has been provided to an applicable Holder pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4(b)</span>, no further notice shall be required to be given for any future payments of such Withholding Tax. Parent will use commercially reasonable efforts to provide withholding and reporting instructions in writing (email being sufficient) to the Rights Agent from time to time as relevant, and upon reasonable request of the Rights Agent. The Rights Agent shall have no responsibilities with respect to tax withholding, reporting or payment except specifically instructed by Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(c)&#160;&#160;&#160;Any portion of a CVR Payment that remains undistributed to the Holders six (6) months after the delivery of a CVR Payment Statement (including by means of uncashed checks or invalid addresses on the CVR Register) will be delivered by the Rights Agent to Parent or a person nominated in writing by Parent (with written notice thereof from Parent to the Rights Agent), and any Holder will thereafter look only to Parent for payment of such CVR Payment (which shall be without interest).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(d)&#160;&#160;&#160;If any CVR Payment (or portion thereof) remains unclaimed by a Holder two (2) years after the delivery of a CVR Payment Statement (or immediately prior to such earlier date on which such CVR Payment would otherwise escheat to or become the property of any Governmental Entity), such CVR Payment (or portion thereof) will, to the extent permitted by applicable Law, become the property of Parent and will be transferred to Parent or a person nominated in writing by Parent (with written notice thereof from Parent to the Rights Agent), free and clear of all claims or interest of any Person previously entitled thereto, and no consideration or compensation shall be payable therefor. Neither Parent nor the Rights Agent will be liable to any Person in respect of a CVR Payment delivered to a public official pursuant to any applicable abandoned property, escheat or similar legal requirement under applicable Law. In addition to and not in limitation of any other indemnity obligation herein, Parent agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or be subject to in connection with transferring such property to Parent, a public office or a person nominated in writing by Parent.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(e)&#160;&#160;&#160;For U.S. federal income and other applicable Tax purposes, the parties hereto agree to treat (i) the issuance of the CVRs as a distribution of property (and not debt or equity of Parent) by Parent to the stockholders of Parent governed by Section 301 of the Code, and (ii) the amount of any CVR Payment as a contractual payment pursuant to the rights afforded by this Agreement to the Holder and not as a distribution by Parent in respect of Parent stock (collectively, the &#8220;</span><b style="font-weight:bold;">Intended Tax Treatment</b>&#8221;). Consistent with the Intended Tax Treatment, Parent will send, or cause to be sent, IRS Forms 1099-DIV to all Holders notifying them of the portion of the CVR value that is a non-dividend distribution (or a dividend to the extent of Parent&#8217;s current or accumulated earnings and profits) for U.S. federal income Tax purposes. The parties hereto will not take any position contrary to the Intended Tax Treatment on any Tax Return or for other Tax purposes, except as may be required by a change in applicable Law or pursuant to a final &#8220;determination&#8221; within the meaning of Section 1313(a) of the Code, in each case, after the date hereof. Parent will independently retain and pay for the services of a third-party valuation firm to determine the fair market value of the CVRs and Parent will utilize such fair market value for purposes of all Tax reporting (including on IRS Forms 1099-DIV) with respect to the CVRs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">&#8239;<b style="font-weight:bold;">Section 2.5 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Voting, Dividends or Interest; No Equity or Ownership Interest</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(a)&#160;&#160;&#160;The CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of CVRs to any Holder.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(b)&#160;&#160;&#160;The sole right of the Holders to receive property hereunder is the right to receive CVR Payments, if any, in accordance with the terms hereof. It is hereby acknowledged and agreed that a CVR shall not constitute a security of Parent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(c)&#160;&#160;&#160;Nothing contained in this Agreement shall be construed as conferring upon any Holder, by virtue of the CVRs, any rights or obligations of any kind or nature whatsoever as a stockholder or member of Parent or any of its subsidiaries either at law or in equity. The rights of any Holder and the obligations of Parent and its Affiliates and their respective officers, directors and controlling Persons are contract rights limited to those expressly set forth in this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(d)&#160;&#160;&#160;By voting in favor of the adoption of the Merger Agreement, the approval of the principal terms of the Merger, and the consummation of the Merger and receiving the benefits thereof, including the receipt of CVRs in connection therewith and any consideration payable in connection with the CVRs, each Holder hereby acknowledges and agrees that the CVRs and the possibility of any payment hereunder with respect thereto are highly speculative and subject to numerous factors outside of Parent&#8217;s control, and there is no assurance that Holders will receive any payments under this Agreement or in connection with the CVRs. Each Holder acknowledges that it is highly possible that no Parent Legacy Transaction will occur prior to the expiration of the Disposition Period and that there will not be any Gross Proceeds that may be the subject of a CVR Payment Amount. It is further acknowledged and agreed that neither Parent nor its Affiliates owe, by virtue of their obligations under this Agreement, a fiduciary duty or any implied duties to the Holders and the parties hereto intend solely the express provisions of this Agreement to govern their contractual relationship with respect to the CVRs. It is acknowledged and agreed that this </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.5(d)</span> is an essential and material term of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">&#8239;<b style="font-weight:bold;">Section 2.6 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ability to Abandon CVR</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;A Holder may at any time, at such Holder&#8217;s option, abandon all of such Holder&#8217;s remaining rights represented by CVRs by transferring such CVR to Parent or a Person nominated in writing by Parent (with written notice thereof from Parent to the Rights Agent) without consideration in compensation therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by Parent of such transfer and cancellation. Nothing in this Agreement is intended to prohibit Parent or its Affiliates from offering to acquire or acquiring CVRs, in private transactions or otherwise, for consideration in its sole discretion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">THE RIGHTS AGENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Section 3.1 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Duties and Responsibilities</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(a)&#160;&#160;&#160;The Rights Agent will not have any liability for any actions taken or not taken in connection with this Agreement, except to the extent such liability arises as a result of the willful misconduct, intentional breach, bad faith, fraud or gross negligence of the Rights Agent (in each case as determined by a final non-appealable judgment of court of competent jurisdiction).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">&#8239;(b)&#160;&#160;&#160;The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect to any action or default by any person or entity, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Parent. The Rights Agent may (but shall not be required to) enforce all rights of action under this Agreement and any related claim, action, suit, audit, </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">investigation or proceeding instituted by the Rights Agent may be brought in its name as the Rights Agent and any recovery in connection therewith will be for the proportionate benefit of all the Holders, as their respective rights or interests may appear on the CVR Register.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">Section 3.2 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Rights of Rights Agent</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(a)&#160;&#160;&#160;The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied covenants or obligations will be read into this Agreement against the Rights Agent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(b)&#160;&#160;&#160;The Rights Agent may rely and will be protected by Parent in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document reasonably believed by it to be genuine and to have been signed or presented by or on behalf of Parent or, with respect to </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3(d)</span>, the Acting Holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(c)&#160;&#160;&#160;Whenever the Rights Agent deems it desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder, the Rights Agent may rely upon an Officer&#8217;s Certificate, which certificate shall be full authorization and protection to the Rights Agent, and the Rights Agent shall, in the absence of bad faith, fraud, gross negligence or willful misconduct (each as determined by a final non-appealable judgment of a court of competent jurisdiction) on its part, not incur any liability and shall be held harmless by Parent for or in respect of any action taken, suffered or omitted to be taken by it under the provisions of this Agreement in reliance upon such Officer&#8217;s Certificate; provided, that, Parent shall not be authorized to deliver an Officer&#8217;s Certificate inconsistent with the provisions set forth in this Agreement without the prior written consent of the Acting Holders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(d)&#160;&#160;&#160;The Rights Agent may engage and consult with counsel of its selection, and the advice or opinion of such counsel will, in the absence of bad faith, fraud, gross negligence or willful misconduct (in each case, as determined by a final, non-appealable judgment of a court of competent jurisdiction) on the part of the Rights Agent, be full and complete authorization and protection in respect of any action taken, suffered or not taken by the Rights Agent in reliance thereon.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(e)&#160;&#160;&#160;Any permissive rights of the Rights Agent hereunder will not be construed as a duty.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(f)&#160;&#160;&#160;The Rights Agent will not be required to give any note or surety in respect of the execution of its powers or otherwise under this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(g)&#160;&#160;&#160;Parent agrees to indemnify the Rights Agent for, and to hold the Rights Agent harmless from and against, any loss, liability, damage, judgment, fine, penalty, claim, demand, settlement, cost or expense (including the reasonable and documented fees and expenses of legal counsel) (each, a &#8220;</span><b style="font-weight:bold;">Loss</b>&#8221;) which may be paid, incurred or suffered by or to which it may become subject, arising from or out of, directly or indirectly, any claims or liability resulting from any action taken, suffered or omitted by the Rights Agent in connection the execution, acceptance, administration, exercise and performance of its duties under this Agreement, including the costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder, except to the extent such Loss has been determined by a final non-appealable decision of a court of competent jurisdiction to have resulted from the Rights Agent&#8217;s willful misconduct, bad faith, fraud or gross negligence; provided that this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.2(g)</span> shall not apply with respect to income, receipt, franchise or similar Taxes levied against the Rights Agent by a Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(h)&#160;&#160;&#160;Parent agrees (i) to pay the fees of the Rights Agent in connection with the Rights Agent&#8217;s performance of its obligations hereunder as set forth in a fee schedule agreed upon in writing by the Rights Agent and Parent on or prior to the date of this Agreement (the &#8220;</span><b style="font-weight:bold;">Fee Schedule</b>&#8221;), and (ii) to reimburse the Rights Agent for all reasonable and documented out-of-pocket expenses and other disbursements incurred in the preparation, delivery, negotiation, amendment, administration and execution of this Agreement and the exercise and performance of its duties hereunder, including all stamp and transfer Taxes (and excluding for the avoidance of doubt, any income, receipt, franchise or similar Taxes levied against the Rights Agent by a Governmental Entity) and governmental charges, incurred by the Rights Agent in the performance of its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(i)&#160;&#160;&#160;No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(j)&#160;&#160;&#160;The Rights Agent shall have no responsibility to Parent, any holders of CVRs, any holders of shares of Common Stock or any other Person for interest or earnings on any moneys held by the Rights Agent pursuant to this Agreement.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(k)&#160;&#160;&#160;The Rights Agent shall not be subject to, nor be required to comply with, or determine if any Person has complied with, the Merger Agreement or any other agreement between or among any of Parent, the Company or Holders, even though reference thereto may be made in this Agreement, or to comply with any notice, instruction, direction, request or other communication, paper or document other than as expressly set forth in this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(l)&#160;&#160;&#160;The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to Parent or the Company resulting from any such act, default, neglect or misconduct, absent willful misconduct, bad faith, fraud or gross negligence (each as determined by a final non-appealable judgment of a court of competent jurisdiction) in the selection and continued employment thereof.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(m)&#160;The Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement (except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been made by Parent only.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(n)&#160;&#160;The Rights Agent shall act hereunder solely as agent for Parent and shall not assume any obligations or relationship of agency or trust with any of the owners or holders of the CVRs. The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holders with respect to any action or default by Parent, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Parent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(o)&#160;&#160;The Rights Agent may rely on and be fully authorized and protected in acting or failing to act upon (a) any guaranty of signature by an &#8220;eligible guarantor institution&#8221; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#8220;signature guarantee program&#8221; or insurance program in addition to, or in substitution for, the foregoing; or (b) any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(p)&#160;&#160;The Rights Agent shall not be liable or responsible for any failure of Parent to comply with any of its obligations relating to any registration statement filed with the Securities and Exchange Commission or this Agreement, including without limitation obligations under applicable regulation or law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;(q)</span></span>The obligations of Parent and the rights of the Rights Agent under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.2</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1</span>. and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4</span> shall survive the expiration of the CVRs and the termination of this Agreement and the resignation, replacement or removal of the Rights Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(r)&#160;&#160;The Rights Agent will not be deemed to have knowledge of any event of which it was supposed to receive notice hereunder but has not received written notice of such event, and the Rights Agent will not incur any liability for failing to take action in connection therewith, in each case, unless and until it has received such notice in writing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">&#8239;<b style="font-weight:bold;">Section 3.3 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Resignation and Removal; Appointment of Successor</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(a)&#160;&#160;The Rights Agent may resign at any time by written notice to Parent. Any such resignation notice shall specify the date on which such resignation will take effect (which shall be at least thirty (30) days following the date that such resignation notice is delivered), and such resignation will be effective on the earlier of (x) the date so specified and (y) the appointment of a successor Rights Agent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(b)&#160;&#160;Parent will have the right to remove the Rights Agent at any time by written notice to the Rights Agent, specifying the date on which such removal will take effect. Such notice will be given at least thirty&#8239;(30) days prior to the date so specified (or, if earlier, the appointment of the successor Rights Agent).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(c)&#160;&#160;If the Rights Agent resigns, is removed or becomes incapable of acting, Parent will promptly appoint a qualified successor Rights Agent. Notwithstanding the foregoing, if Parent fails to make such appointment within a period of thirty (30) days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent, then the any Holder may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed will, upon its acceptance of such appointment in accordance with this </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.3(c)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.4</span>, become the Rights Agent for all purposes hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">&#8239;(d)&#160;&#160;Parent will give notice to the Holders of each resignation or removal of the Rights Agent and each appointment of a successor Rights Agent in accordance with </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</span>. Each notice will include the name and address of the successor Rights Agent. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If Parent fails to send such notice within ten (10) Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(e)&#160;&#160;Notwithstanding anything to the contrary in this </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.3</span>, unless consented to in writing by the Acting Holders, Parent will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust department of a commercial bank.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(f)&#160;&#160;The Rights Agent will reasonably cooperate with Parent and any successor Rights Agent in connection with the transition of the duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register, to the successor Rights Agent, but such predecessor Rights Agent shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">&#8239;<b style="font-weight:bold;">Section 3.4 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceptance of Appointment by Successor</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge and deliver to Parent and to the resigning or removed Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers, trusts and duties of the Rights Agent; </span><i style="font-style:italic;">provided</i> that upon the request of Parent or the successor Rights Agent, such resigning or removed Rights Agent will execute and deliver an instrument transferring to such successor Rights Agent all the rights, powers and trusts of such resigning or removed Rights Agent, except such rights which survive its resignation or removal under the terms hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">COVENANTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Section 4.1 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">List of Holders</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Parent will furnish or cause to be furnished to the Rights Agent, in such form as Parent receives from Parent&#8217;s transfer agent (or other agent performing similar services for Parent), the names and addresses of the Holders within fifteen (15) Business Days following the Closing Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">&#8239;<b style="font-weight:bold;">Section 4.2 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Obligations of Public Company</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;(a)&#160;&#160;[Notwithstanding anything herein to the contrary, (a) Parent and its Affiliates shall have the power and right to control all aspects of their businesses and operations (and all of their assets and products) with respect to any Parent Legacy Assets), and subject to Parent&#8217;s compliance with the terms of this Agreement, Parent and its Affiliates may exercise or refrain from exercising such power and right as it may deem appropriate and in the best overall interests of Parent and its Affiliates and its and their stockholders, rather than the interest of the Holders, (b) none of Parent or any of its Affiliates (or any directors, officer, employee, or other representative of the foregoing) owes any fiduciary duty or similar duty or any other implied duties (including the implied covenant of good faith and fair dealing) to any Holder in respect of the CVRs or the Parent Legacy Assets and (c) following the Disposition Period, Parent shall be permitted to take any action in respect of the Parent Legacy Assets in order to satisfy any wind-down and termination Liabilities of the Parent Legacy Assets. For clarity and without limitation of the foregoing, following the Disposition Period without a Parent Legacy Transaction, Parent may take any action in respect of the Parent Legacy Assets in its sole and absolute discretion. Notwithstanding anything else herein, none of Parent or any of its Affiliates may amend, modify, restate, amend and restate, terminate, rescind, sell, dispose of, waive any third-party&#8217;s obligations under or otherwise modify or transfer any of the agreements listed on </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1</span>.]<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">&#8239;<b style="font-weight:bold;">Section 4.3 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Books and Records</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">&#8239;Until the end of the CVR Term, Parent shall, and shall cause its Affiliates to, keep true, complete and accurate records in sufficient detail to support the applicable CVR Payments, if any, payable hereunder in accordance with the terms specified in this Agreement.</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup> &#160;&#160;Discussion of duties/obligations of Parent to be discussed pending outcome of legacy asset transaction structures and timing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 4.4 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audits</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Until the Termination Date and for a period of one (1) year thereafter, Parent shall keep complete and accurate records in sufficient detail to support the accuracy of the payments due hereunder. The Acting Holders shall have the right to cause an independent accounting firm reasonably acceptable to Parent to audit such records for the sole purpose of confirming CVR Payments received by Parent or its Affiliates. Parent may require such accounting firm to execute a reasonable confidentiality agreement with Parent prior to commencing the audit. The accounting firm shall disclose to Rights Agent or the Acting Holders, as applicable, only whether the reports are correct or not and the specific details concerning any discrepancies. No other information shall be shared, and in no event shall Parent be required to provide any Tax returns or any other Tax information it deems confidential to the Acting Holders or any other party. Such audits may be conducted during normal business hours upon reasonable prior written notice to Parent, but no more than frequently than once per year. No accounting period of Parent shall be subject to audit more than one time by the Acting Holders, as applicable. Adjustments (including remittances of underpayments or overpayments disclosed by such audit) shall be made by Parent to reflect the results of such audit, which adjustments shall be paid promptly following receipt of an invoice therefor. Whenever such an adjustment is made, Parent shall promptly prepare a certificate setting forth such adjustment, and a brief, reasonably detailed statement of the facts, computation and methodology accounting for such adjustment to the extent not already reflected in the audit report and promptly file with the Rights Agent a copy of such report and promptly deliver to the Rights Agent a revised CVR Payment Statement for the relevant CVR Payment. The Rights Agent shall be fully protected in relying on any such report and on any adjustment or statement therein contained and shall have no duty or liability with respect to, and shall not be deemed to have knowledge of any such adjustment or any such event unless and until it shall have received such report. The Acting Holders, as applicable, shall bear the full cost and expense of such audit unless such audit discloses an underpayment by Parent of the CVR Payment due under this Agreement, in which case Parent shall bear the full cost and expense of such audit. The Rights Agent shall be entitled to rely on any audit report delivered by the independent accounting firm pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8239;<b style="font-weight:bold;">ARTICLE 5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 5.1 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments Without Consent of Holders or Rights Agent</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent, at any time and from time to time, may (without the consent of any Person, including the Holders, other than the Rights Agent, with such consent not to be unreasonably withheld, conditioned or delayed) enter into one or more amendments to this Agreement for any of the following purposes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(i)&#160;&#160;&#160;&#160;to evidence the appointment of another Person as a successor Rights Agent and the assumption by any successor Rights Agent of the covenants and obligations of the Rights Agent herein in accordance with the provisions hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(ii)&#160;&#160;&#160;&#160;subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</span>, to evidence the succession of another person to Parent and the assumption of any such successor of the covenants of Parent outlined herein in a transaction contemplated by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</span>;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(iii)&#160;&#160;&#160;to cure any ambiguity, to correct or supplement any provision in this Agreement that may be defective or inconsistent with any other provision in this Agreement, or to make any other provisions with respect to matters or questions arising under this Agreement; <i style="font-style:italic;">provided</i> that, in each case, such provisions do not adversely affect the interests of the Holders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(iv)&#160;&#160;&#160;as may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act or the Exchange Act and the rules and regulations promulgated thereunder, or any applicable state securities or &#8220;blue sky&#8221; laws;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(v)&#160;&#160;&#160;as may be necessary or appropriate to ensure that Parent is not required to produce a prospectus or an admission document in order to comply with applicable Law;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(vi)&#160;&#160;as Parent may reasonably determine to facilitate the administration or performance of obligations under this Agreement and does not adversely affect the Holders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(vii)&#160;&#160;to cancel the CVRs (i) in the event that any Holder has abandoned its rights in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6</span>, or (ii) following a transfer of such CVRs to Parent or its Affiliates in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</span>;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(viii)&#160;as may be necessary or appropriate to ensure that Parent complies with applicable Law; or</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Promptly after the execution by Parent of any amendment pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</span>, Parent will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 5.2 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments with Consent of Holders</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)&#8239;</span></span>In addition to any amendments to this Agreement that may be made by Parent without the consent of any Holder pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</span>, with the consent of the Acting Holders (whether evidenced in a writing or taken at a meeting of the Holders), Parent and the Rights Agent may enter into one or more amendments to this Agreement for the purpose of adding, eliminating or amending any provisions of this Agreement, even if such addition, elimination or amendment is adverse to the interests of the Holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Promptly after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2</span>, Parent will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">Section 5.3 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Amendments</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;Upon the execution of any amendment under this </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 5</span>, this Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. Upon the delivery of a certificate from an appropriate officer of Parent which states that the proposed supplement or amendment is in compliance with the terms of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 5</span>, the Rights Agent shall execute such supplement or amendment. Notwithstanding anything in this Agreement to the contrary, the Rights Agent shall not be required to execute any supplement or amendment to this Agreement that it has determined would adversely affect its own rights, duties, obligations or immunities under this Agreement. No supplement or amendment to this Agreement shall be effective unless duly executed by the Rights Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSOLIDATION, MERGER, SALE OR CONVEYANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 6.1 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change of Control</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Termination Date, Parent shall not consummate a Change of Control without the consent of the Acting Holders (such consent not to be unreasonably withheld, conditioned or delayed), unless:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;(a)&#8239;</span></span>the Person that is the relevant transferee, assignee, acquiror, delegate or other successor (including by operation of law) in such Change of Control (the &#8220;<b style="font-weight:bold;">Surviving Person</b>&#8221;) shall assume or succeed to the obligations on all CVRs (when and as due hereunder); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;(b)</span></span>Parent has delivered to the Rights Agent an Officer&#8217;s Certificate stating that such Change of Control complies with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 6</span> and that all conditions precedent herein provided for relating to such Change of Control have been complied with.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">Section 6.2 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successor Substituted</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8239;Upon the consummation of any Change of Control in accordance with </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</span>, the Surviving Person shall succeed to, and be substituted for, and may exercise every right and power of, and shall assume all of the obligations of Parent under this Agreement with the same effect as if the Surviving Person had been named as Parent herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.1 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices to Rights Agent and to Parent</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All notices, requests and other communications (each, a &#8220;<b style="font-weight:bold;">Notice</b>&#8221;) to any party hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder when sent (a) fees prepaid, via a reputable international overnight courier service in the case of delivery in person, by FedEx or other internationally recognized overnight courier service or (b) on the date sent in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:96.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">if to the Rights Agent, to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[&#9679;]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attention: [&#9679;]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Email: [&#9679;]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">if to Parent, to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Carisma Therapeutics Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3675 Market Street, Suite 401</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, PA 19104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Attention: Steven Kelly, President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: [&#9679;]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with a copy, which shall not constitute notice, to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wilmer Cutler Pickering Hale and Dorr LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7 World Trade Center</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">250 Greenwich Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, New York 10007</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attention:</p></td><td style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Christopher D. Barnstable-Brown, Esq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Mark Nylen, Esq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Brian A. Johnson, Esq.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">E-mail:</p></td><td style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">cbb@wilmerhale.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">mark.nylen@wilmerhale.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">brian.johnson@wilmerhale.com</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or to such other address as such party may hereafter specify for the purpose by notice to the other parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.2 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice to Holders</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All Notices required to be given to the Holders will be given (unless otherwise herein expressly provided) in writing and mailed, first-class postage prepaid, to each Holder at such Holder&#8217;s address as set forth in the CVR Register, not later than the latest date, and not earlier than the earliest date, prescribed for the sending of such Notice, if any, and will be deemed given on the date of mailing. In any case where notice to the Holders is given by mail, neither the failure to mail such Notice, nor any defect in any Notice so mailed, to any particular Holder will affect the sufficiency of such Notice with respect to other Holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.3 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As between Parent and the Rights Agent, this Agreement constitutes the entire agreement between the parties with respect to the subject matter of this Agreement, notwithstanding the reference to any other agreement herein, and supersedes all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.4 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger or Consolidation or Change of Name of Rights Agent</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or Person resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, provided that such Person would be eligible for appointment as a successor Rights Agent under the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.3</span>. The purchase of all or substantially all of the Rights Agent&#8217;s assets employed in the performance of transfer agent activities shall be deemed a merger or consolidation for purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.5 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Agreement will be binding upon, and will be enforceable by and inure solely to the benefit of, the Holders, Parent and the Rights Agent and their respective successors and assigns. Except for assignments pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4</span>, the Rights Agent may not assign this Agreement without Parent&#8217;s prior written consent. Subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)(ii</span>) and Article 6 hereof, Parent may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder to one or more of its Affiliates or to any Person with whom Parent is merged or consolidated, or any entity resulting from any merger or consolidation to which Parent shall be a party (each, an &#8220;<b style="font-weight:bold;">Assignee</b>&#8221;); <i style="font-style:italic;">provided</i>, that in connection with any assignment to an Assignee, Parent shall agree to remain liable for the performance by Parent of its obligations hereunder (to the extent Parent exists following such assignment). Parent or an Assignee may not otherwise assign this Agreement without the prior consent of the Acting Holders (such consent not to be unreasonably withheld, conditioned or delayed). Any attempted assignment of this Agreement in violation of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5</span> will be void <i style="font-style:italic;">ab initio</i> and of no effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.6 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Benefits of Agreement; Action by Acting Holders</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nothing in this Agreement, express or implied, will give to any Person (other than Parent, the Rights Agent, the Holders and their respective permitted successors and assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of Parent, the Rights Agent, the Holders and their permitted successors and assigns. The Holders will have no rights hereunder except as are expressly set forth herein. Except for the rights of the Rights Agent set forth herein, the Acting Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or proceeding at law or in equity with respect to this Agreement, and no individual Holder or other group of Holders will be entitled to exercise such rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.7 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Agreement and the CVRs will be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any provision of law or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.8 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In any action or proceeding between any of the parties hereto arising out of or relating to this Agreement or any of the transactions contemplated hereby, each of the parties hereto: (a)&#8239;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, and appellate courts thereof; (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a) of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.8</span>; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party; and (e) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</span> of this Agreement; provided that nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.9 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WAIVER OF JURY TRIAL</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER, (III) EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 7.9</b><b style="font-weight:bold;">.</b></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.10 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability Clause</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that any provision of this Agreement, or the application of any such provision to any Person or set of circumstances, is for any reason determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent permitted by applicable Law. Upon such a determination, the parties hereto will negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that if an excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written Notice to Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.11 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts; Effectiveness</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Agreement may be signed in any number of counterparts, each of which will be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement or any counterpart may be executed and delivered by facsimile copies or delivered by electronic communications by portable document format (.pdf), each of which shall be deemed an original. This Agreement will become effective when each party hereto will have received a counterpart hereof signed by the other party hereto. Until and unless each party has received a counterpart hereof signed by the other party hereto, this Agreement will have no effect and no party will have any right or obligation hereunder (whether by virtue of any oral or written agreement or any other communication).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.12 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Agreement will automatically terminate and be of no further force or effect and, except the rights, protections and immunities of the Rights Agent under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 3</span>, the parties hereto will have no further liability hereunder, and the CVRs will expire without any consideration or compensation therefor, upon the earliest to occur of (a) the expiration of the CVR Term, (b) the expiration of all payment obligations under the Disposition Agreements or any of the agreements listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1</span> or (c) the delivery of a written notice of termination duly executed by Parent and the Acting Holders (such date, the &#8220;<b style="font-weight:bold;">Termination Date</b>&#8221;). The termination of this Agreement will not affect or limit the right of Holders to receive the CVR Payments under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4</span> to the extent earned prior to the termination of this Agreement, and the provisions applicable thereto will survive the expiration or termination of this Agreement until such CVR Payments, if any, have been made, if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.13 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Funds</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All funds received by Computershare under this Agreement that are to be distributed or applied by Computershare in the performance of services hereunder (the &#8220;<b style="font-weight:bold;">Funds</b>&#8221;) shall be held by Computershare, as agent for Parent, and deposited in one or more bank accounts to be maintained by Computershare in its name as agent for Parent. Until paid pursuant to the terms of this Agreement, Computershare may hold or invest the Funds through such accounts in: (a) funds backed by obligations of, or guaranteed by, the United States of America; (b) debt or commercial paper obligations rated A-1 or P-1 or better by S&amp;P Global Inc. (&#8220;<b style="font-weight:bold;">S&amp;P</b>&#8221;) or Moody&#8217;s Investors Service, Inc. (&#8220;<b style="font-weight:bold;">Moody&#8217;s</b>&#8221;), respectively; (c) Government and Treasury backed AAA-rated Fixed NAV money market funds that comply with Rule 2a-7 of the Investment Company Act of 1940, as amended; or (d) short term certificates of deposit, bank repurchase agreements, and bank accounts with commercial banks with Tier 1 capital exceeding $1 billion, or with an investment grade rating by S&amp;P (LT Local Issuer Credit Rating), Moody&#8217;s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). Computershare shall have no responsibility or liability for any diminution of the Funds that may result from any deposit or investment made by Computershare in accordance with this paragraph, including any losses resulting from a default by any bank, financial institution or other third party. Computershare may from time to time receive interest, dividends or other earnings in connection with such deposits or investments. Computershare shall not be obligated to pay such interest, dividends or earnings to Parent, any holder or any other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.14 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurance by Parent</b><b style="font-weight:bold;">.</b> Parent agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required or requested by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.15 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Rights Agent and Parent agree that all books, records, information and data pertaining to the business of the other party, including inter alia, personal, non-public CVR holder information, which are exchanged or received pursuant to the negotiation or the carrying out of this Agreement including the Fee Schedule shall remain confidential, and shall not be voluntarily disclosed to any other person other than representatives of the Rights Agent or Parent, except as may be required by Law, including, without limitation, pursuant to subpoenas from state or federal government authorities (e.g., in divorce and criminal actions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.16 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding anything to the contrary contained herein, the Rights Agent will not be liable for any delays or failures in performance resulting from acts beyond its reasonable control including, without limitation, acts of God, epidemic, pandemic, terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions or malfunction of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war, or civil unrest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 7.17 </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)&#8239;</span></span>For purposes of this Agreement, whenever the context requires: singular terms will include the plural, and vice versa; the masculine gender will include the feminine and neuter genders; the feminine gender will include the masculine and neuter genders; and the neuter gender will include the masculine and feminine genders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words &#8220;without limitation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)&#8239;</span></span>The headings contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement and will not be referred to in connection with the construction or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Unless stated otherwise, &#8220;Article&#8221; and &#8220;Section&#8221; followed by a number or letter mean and refer to the specified Article or Section of this Agreement. The term &#8220;Agreement&#8221; and any reference in this Agreement to this Agreement or any other agreement or document includes, and is a reference to, this Agreement or such other agreement or document as it may have been, or may from time to time be, amended, restated, replaced, supplemented or novated and includes all schedules to it.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)&#8239;</span></span>A period of time is to be computed as beginning on the day following the event that began the period and ending at 4:30 p.m. on the last day of the period, if the last day of the period is a Business Day, or at 4:30 p.m. on the next Business Day if the last day of the period is not a Business Day.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)&#8239;</span></span>Any reference in this Agreement to a date or time shall be deemed to be such date or time in New York City, United States, unless otherwise specified. The parties hereto and Parent have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and Parent and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of any provision of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>All references herein to &#8220;$&#8221; are to United States Dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[<i style="font-style:italic;">Remainder of page intentionally left blank</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_abb6f6bc_0934_41d9_a11f_5de934a4e910"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, each of the parties has caused this Agreement to be executed as of the day and year first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:49.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:44.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CARISMA THERAPEUTICS INC.</p></td></tr><tr><td style="vertical-align:top;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature Page to Contingent Value Rights Agreement</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, each of the parties has caused this Agreement to be executed as of the day and year first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:50.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COMPUTERSHARE TRUST<br/>COMPANY, N.A. and<br/>COMPUTERSHARE INC.,</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">On behalf of both entities</i></p></td></tr><tr><td style="vertical-align:middle;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:middle;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature Page to Contingent Value Rights Agreement</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8239;<span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:14.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</span></span>Collaboration and License Agreement, dated as of January 7, 2022, by and between Carisma Therapeutics Inc. and ModernaTX, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_fb0febd6_be5b_45e5_8768_8f4cd34414bf"></a><a id="ANNEXG_45134"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX G</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DELAWARE APPRAISAL RIGHTS FOR ORTHOCELLIX COMMON STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#167; 262. Appraisal rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(a)&#160;&#160; Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d) of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, who has otherwise complied with subsection (d) of this section and who has neither voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b) and (c) of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;&#160; Appraisal rights shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation in a merger, consolidation, conversion, transfer, domestication or continuance to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g) of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264, &#167; 266 or &#167; 390 of this title (other than, in each case and solely with respect to a converted or domesticated corporation, a merger, consolidation, conversion, transfer, domestication or continuance authorized pursuant to and in accordance with the provisions of &#167; 265 or &#167; 388 of this title):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">(1)&#160;&#160; Provided, however, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at the record date fixed to determine the stockholders entitled to consent pursuant to &#167; 228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for the conversion, transfer, domestication or continuance (or, in the case of a merger pursuant to &#167; 251(h) of this title, as of immediately prior to the execution of the agreement of merger), were either: (i) listed on a national securities exchange or (ii) held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f) of this title.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">(2)&#160;&#160; Notwithstanding paragraph (b)(1) of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, transfer, domestication or continuance, pursuant to &#167; 251, &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264, &#167; 266 or &#167; 390 of this title to accept for such stock anything except:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160; Shares of stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity or the entity resulting from a transfer, domestication or continuance if such entity is a corporation as a result of the conversion, transfer, domestication or continuance, or depository receipts in respect thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160; Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger, consolidation, conversion, transfer, domestication or continuance will be either listed on a national securities exchange or held of record by more than 2,000 holders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160; Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160; Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">(3)&#160;&#160; In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">(4)&#160;&#160; [Repealed.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(c)&#160;&#160; Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167; 266 of this title or a transfer, domestication or continuance effected pursuant to &#167; 390 of this title. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g) of this section, shall apply as nearly as is practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(d)&#160;&#160; Appraisal rights shall be perfected as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">(1)&#160;&#160; If a proposed merger, consolidation, conversion, transfer, domestication or continuance for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c) of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b) or (c) of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and, &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger, consolidation, conversion, transfer, domestication or continuance, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation, conversion, transfer, domestication or continuance shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10 days after the effective date of such merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity shall notify each stockholder of each constituent or converting, transferring, domesticating or continuing corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation, conversion, transfer, domestication or continuance, and any beneficial owner who has demanded appraisal under paragraph (d)(3) of this section, of the date that the merger, consolidation or conversion has become effective; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">(2)&#160;&#160; If the merger, consolidation, conversion, transfer, domestication or continuance was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then either a constituent, converting, transferring, domesticating or continuing corporation before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, or the surviving, resulting or converted entity within 10 days after such effective date, shall notify each stockholder of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation who is entitled to appraisal rights of the approval of the merger, consolidation, conversion, transfer, domestication or continuance and that appraisal rights are available for any or all shares of such class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting, transferring, domesticating or continuing corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, shall, also notify such stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance. Any stockholder entitled to appraisal rights may, within 20 days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title, within the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days after the date of giving such notice, demand in writing from the surviving, resulting or converted entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="white-space:pre-wrap;">stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, either (i) each such constituent corporation or the converting, transferring, domesticating or continuing corporation shall send a second notice before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance notifying each of the holders of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation that are entitled to appraisal rights of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance or (ii) the surviving, resulting or converted entity shall send such a second notice to all such holders on or within 10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3) of this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting, transferring, domesticating or continuing corporation may fix, in advance, a record date that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">(3)&#160;&#160; Notwithstanding subsection (a) of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s name, demand in writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1) or (2) of this section, as applicable; provided that (i) such beneficial owner continuously owns such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a) of this section and (ii) the demand made by such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by subsection (f) of this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(e)&#160;&#160; Within 120 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity, or any person who has complied with subsections (a) and (d) of this section and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance. Within 120 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person who has complied with the requirements of subsections (a) and (d) of this section, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance (or, in the case of a merger approved pursuant to &#167; 251(h) of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2) of this title)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3) of this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to the person within 10 days after such person&#8217;s request for such a statement is received by the surviving, resulting or converted entity or within 10 days after expiration of the period for delivery of demands for appraisal under subsection (d) of this section, whichever is later.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(f)&#160;&#160; Upon the filing of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">surviving, resulting or converted entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(g)&#160;&#160; At the hearing on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation, conversion, transfer, domestication or continuance the shares of the class or series of stock of the constituent, converting, transferring, domesticating or continuing corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1) the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2) the value of the consideration provided in the merger, consolidation, conversion, transfer, domestication or continuance for such total number of shares exceeds $1 million, or (3) the merger was approved pursuant to &#167; 253 or &#167; 267 of this title.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(h)&#160;&#160; After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger, consolidation, conversion, transfer, domestication or continuance, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation, conversion, transfer, domestication or continuance through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1) the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2) interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f) of this section may participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160; The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(j)&#160;&#160; The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f) of this section who participated in the proceeding and incurred expenses in connection therewith, the Court may order all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal not dismissed pursuant to subsection (k) of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k) of this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(k)&#160;&#160; Subject to the remainder of this subsection, from and after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, no person who has demanded appraisal rights with respect to some or all of such person&#8217;s shares as provided in subsection (d) of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation, conversion, transfer, domestication or continuance). If a person who has made a demand for an appraisal in accordance with this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in respect of some or all of such person&#8217;s shares in accordance with subsection (e) of this section, either within 60 days after such effective date or thereafter with the written approval of the corporation, then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, an appraisal proceeding in the Court of Chancery shall not be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just, including without limitation, a reservation of jurisdiction for any application </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">to the Court made under subsection (j) of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance within 60 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, as set forth in subsection (e) of this section. If a petition for an appraisal is not filed within the time provided in subsection (e) of this section, the right to appraisal with respect to all shares shall cease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(l)&#160;&#160; The shares or other equity interests of the surviving, resulting or converted entity to which the shares of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity interests of the surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no longer entitled to appraisal pursuant to this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_da41215f_69cf_4cf9_98e8_6732a6085147"></a><a id="ANNEXH_560042"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX H</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FORM OF 2025 STOCK OPTION AND INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">H-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_26af774b_624d_45fa_90ed_e80b82658c3b"></a><a id="ANNEXI_835065"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FORM OF SUBSCRIPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">I-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_560dc0a2_2dc4_45b3_9484_54ff7d43d69d"></a><a id="ANNEXJ_764894"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX J</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FORM OF REGISTRATION RIGHTS AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:612pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b2af2498_3e32_4483_93b6_4aff810a4aea"></a><a id="ANNEXK_360403"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">ANNEX K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">FORM OF PROXY CARD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"><img src="tmb-20250331xs4053.jpg" alt="Graphic" style="display:inline-block;height:612pt;width:472.92pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"><span style="color:#ffffff;">Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas.Special Meeting Proxy CardYour vote matters &#8211; here&#8217;s how to vote!Votes submitted electronically must be received by [TBD], Eastern Time, on [TBD], 2025.OnlineGo to www.investorvote.com/CARM or scan the QR code &#8212; login details are located in the shaded bar below.PhoneCall toll free 1-800-652-VOTE (8683) within the USA, US territories and CanadaMailMark, sign and date this card and return in the postagepaid envelope provided. Must be received no later than [TBD], 2025.T IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.TA Proposals &#8212; The Board of Directors recommend a vote FOR Proposals 1, 2, 4, 5, 6 and 7 and FOR each nominee listed in Proposal 3.1. To approve, pursuant to Nasdaq Listing Rules 5635(a), 5635(b), and 5635(d), the issuance of shares of common stock of Carisma Therapeutics Inc. (&#8220;Carisma&#8221;) to (i) stockholders of OrthoCellix, Inc. (&#8220;OrthoCellix&#8221;) pursuant to the terms of the Agreement and Plan of Merger among Ocugen, Inc. (&#8220;Ocugen&#8221;), Carisma, OrthoCellix and Azalea Merger Sub, Inc. (&#8220;Merger Sub&#8221;), dated as of June 22, 2025, a copy of which is attached as Annex A to the proxy statement/prospectus, pursuant to which Merger Sub will merge with and into OrthoCellix, with OrthoCellix continuing as a wholly owned subsidiary of Carisma and the surviving corporation of the merger (such transaction,the &#8220;Merger&#8221;) and (ii) investors in a concurrent financing, pursuant to the terms of the subscription agreements, the form of which is filed as Annex I to the registration statement, which will (a) represent more than 20.0% of the shares of Carisma common stock outstanding immediately prior to the Merger and (b) result in a change of control in Carisma (&#8220;Proposal No. 1&#8221;).For Against Abstain2. To approve the OrthoCellix, Inc. 2025 Stock Option and Incentive Plan, which will become effective as of and contingent on the completion of the Merger.For Against Abstain3. To elect three Class II directors, Steven Kelly, Briggs Morrison, M.D. and Sanford Zweifach, to Carisma&#8217;s board of directors and to hold office until Carisma&#8217;s 2028 annual meeting of stockholders and until their respective successor has been duly elected and qualified, or until their earlier death, resignation or removal provided that if the Merger is consummated, the election of these directors will only have an effect until the completion of the Merger because the composition of Carisma&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement:For Withhold For Withhold For Withhold01 - Steven Kelly 02 - Briggs Morrison, M.D. 03 - Sanford ZweifachFor Against Abstain For Against Abstain4. To ratify the appointment of KPMG LLP as Carisma&#8217;s independent registered public accounting firm for the fiscal year ending December 31, 2025.6. To approve, on an advisory basis, certain compensation arrangements for Carisma&#8217;s named executive officers that are based on or otherwise relate to the Merger.5. To approve, on an advisory basis, named executive officer compensation.7. To approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1.NOTE: The proxies are authorized to vote, in their discretion, upon such other business as may properly come before the stockholders at the Special Meeting or any adjournment or postponement thereof.1 U P X 046C9D</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:612pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><img src="tmb-20250331xs4054.jpg" alt="Graphic" style="display:inline-block;height:612pt;width:472.92pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"><span style="color:#ffffff;">The Special Meeting of Stockholders of Carisma Therapeutics Inc. will be held on[TBD], 2025 at [TBD] Eastern Time, virtually via the internet at https://meetnow.global/MMLQXXY.To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form.Important Notice Regarding the Availability of Proxy Materials for the Special Meeting of Stockholders to be Held on [TBD], 2025: Our proxy materials are available at: www.investorvote.com/CARM.Small steps make an impact.Help the environment by consenting to receive electronic delivery, sign up at www.investorvote.com/CARMT IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.TProxy - Carisma Therapeutics Inc.Carisma Therapeutics Inc. Special Meeting of Stockholders [TBD], 2025 at [TBD] Eastern TimeThis proxy is being solicited on behalf of the Board of DirectorsThe stockholder(s) hereby appoint(s) Steven Kelly and Natalie McAndrew, or either of them, as proxies, each with the power to appoint his or her substitute, and hereby authorize(s) each of them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of common stock of CARISMA THERAPEUTICS INC. that the stockholder(s) is/are entitled to vote at the Special Meeting of Stockholders to be held at [TBD] Eastern Time on [TBD], 2025, virtually at https://meetnow.global/MMLQXXY, and any adjournment or postponement thereof.This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors&#8217; recommendations.In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof.(Items to be voted appear on reverse side)B Authorized Signatures &#8212; This section must be completed for your vote to count. Please date and sign below.Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title.Date (mm/dd/yyyy) &#8212; Please print date below. Signature 1 &#8212; Please keep signature within the box. Signature 2 &#8212; Please keep signature within the box.C Non-Voting ItemsChange of Address &#8212; Please print new address below. Comments &#8212; Please print your comments below.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_22c8a007_f9c1_4644_8700_81c15284e116"></a><a id="PARTII_364617"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 20. Indemnification of Directors and Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall deem proper.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s certificate of incorporation provides that Carisma will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of Carisma), by reason of the fact that he or she is or was, or has agreed to become, Carisma&#8217;s director or officer, or is or was serving, or has agreed to serve, at Carisma&#8217;s request, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an Indemnitee), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees), liabilities, losses, judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, Carisma&#8217;s best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma&#8217;s certificate of incorporation also provides that Carisma will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of Carisma to procure a judgment in Carisma&#8217;s favor by reason of the fact that the Indemnitee is or was, or has agreed to become, Carisma&#8217;s director or officer, or is or was serving, or has agreed to serve, at Carisma&#8217;s request, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, Carisma&#8217;s best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to Carisma, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by Carisma against all expenses (including attorneys&#8217; fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If Carisma does not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">In addition, Carisma has entered into indemnification agreements with all of Carisma&#8217;s executive officers and directors. In general, these agreements provide that Carisma will indemnify the executive officer or director to the fullest extent permitted by law for claims arising in his or her capacity as an executive officer or director of Carisma or in connection with his or her service at Carisma&#8217;s request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that an executive officer or director makes a claim for indemnification and establish certain presumptions that are favorable to the executive officer or director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section&#160;102 of the DGCL permits a corporation to eliminate the personal liability of its directors or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached such director&#8217;s duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Carisma&#8217;s certificate of incorporation provides that no director shall be personally liable to Carisma or Carisma&#8217;s stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the elimination or limitation of liability of directors for breaches of fiduciary duty. These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Carisma also maintains general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Under the Merger Agreement, from the Effective Time of the Merger through the sixth (6th) anniversary of the date of the Effective Time, Carisma and the surviving corporation agree to indemnify and hold harmless each person who was, as of June 22, 2025, the signing date of the merger agreement, or had been at any time prior, or who becomes prior to the Effective Time of the Merger, a director or officer of Carisma or OrthoCellix, against all demands, claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with claims, actions, suits, proceedings or investigations arising out of or pertaining to the fact that such person is or was a director or officer of Carisma or OrthoCellix, whether asserted or claimed prior to, at or after the Effective Time of the Merger, in each case, to the fullest extent permitted under the DGCL. In addition, each such director and officer, or former director and officer, is entitled to advancement of fees, costs and expenses incurred in the defense of any such demand, claim, action, suit, proceeding or investigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Under the Merger Agreement, the certificate of incorporation and by-laws of the surviving corporation in the Merger shall contain provisions with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers that are no less favorable than those set forth in the certificate of incorporation and by-laws of Carisma in effect as of June 22, 2025, the date of the Merger Agreement. The provisions of the certificate of incorporation and by-laws of Carisma with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Carisma that were set forth in the certificate of incorporation and by-laws of Carisma in effect as of June 22, 2025, the date of the Merger Agreement, shall not be amended, modified or repealed for a period of six years from the Effective time of the Merger in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, of the Merger were officers or directors of Carisma, unless such modification is required by applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Merger Agreement also provides that Carisma shall maintain directors&#8217; and officers&#8217; liability insurance policies commencing at the closing of the Merger, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Carisma. The Merger Agreement also provides that Carisma shall purchase, prior to the Effective Time of the Merger, an insurance policy in effect for six years from the Effective Time of the Merger, providing no less favorable coverage as the directors&#8217; and officers&#8217; liability insurance policies maintained by Carisma in effect as of June 22, 2025, the date of the Merger Agreement, with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter claimed against a director or officer of Carisma by reason of him or her serving in such capacity that existed or occurred at or prior to the Effective Time of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_9516a707_f3e9_48f2_8749_e6e6e08995ef"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 21. Exhibits and Financial Statement Schedules</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><i style="color:#231f20;font-style:italic;">Exhibit Index</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A list of exhibits filed with this registration statement on Form S-4 is set forth on the Exhibit Index and is incorporated herein by reference.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:19pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><i style="color:#231f20;font-style:italic;">Financial Statements</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statements filed with this registration statement on Form S-4 are set forth on the Financial Statement Index and is incorporated herein by reference.</p><a id="_e98835e3_9f14_4303_a545_281e06e9aa0f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 22. Undertakings</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The registrant hereby undertakes:</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, </p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 90pt;">any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20.0% change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; table in the effective registration statement; and</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Provided, however</i>, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act (15&#160;U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or Section&#160;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To respond to requests for information that is incorporated by reference into the prospectus pursuant to Items 4, 10(b), 11, or 13 of this form, within one business day of receipt of such request, and to send the incorporated documents by first-class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a295faff_daff_4bdc_a3ef_3d6970042443"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">2.1+</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#AnnexA_512168"><span style="font-style:normal;font-weight:normal;">Agreement and Plan of Merger, dated as of June 22, 2025, by and among Carisma Therapeutics Inc., OrthoCellix, Inc., Azalea Merger Sub, Inc. and Ocugen, Inc. (incorporated by reference as Annex A to the proxy statement/prospectus).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000162828025020724/exhibit31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restated Certificate of Incorporation of Carisma Therapeutics Inc., dated March 7, 2023, as amended (incorporated by reference to Exhibit 3.1 to Carisma Therapeutics Inc.&#8217;s Annual Report on Form 10-K/A (File No. 001-36296) filed on April 29, 2025).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated By-Laws of Carisma Therapeutics Inc., dated March 7, 2023 (incorporated by reference to Exhibit 3.2 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">3.3*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex3d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of OrthoCellix, Inc., as currently in effect.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">3.4*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex3d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">By-Laws of OrthoCellix, Inc., as currently in effect.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">3.5**</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Form of Restated Certificate of Incorporation of Carisma Therapeutics Inc., to be renamed OrthoCellix, Inc., to be in effect immediately prior to the completion of the Merger.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">3.6**</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Form of Amended and Restated By-Laws of Carisma Therapeutics Inc., to be renamed OrthoCellix, Inc., to be in effect immediately prior to the completion of the Merger.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000162828025015673/carm-exx41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of the Carisma Therapeutics Inc.&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.1 to Carisma Therapeutics Inc.&#8217;s Annual Report on Form 10-K (File No. 001-36296) filed on March 31, 2025).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">5.1**</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to Carisma Therapeutics Inc.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.1#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923069917/tm2318211d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment and Restatement of Carisma Therapeutics Inc. Amended and Restated 2014 Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on June 9, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/tm2315501d2_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Open Market Sale Agreement</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, dated May 12, 2023 (incorporated by reference to Exhibit 1.1 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on May 12, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.3&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex10d32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and License Agreement, dated January 7, 2022, by and between Carisma Therapeutics Inc. and ModernaTX, Inc. (incorporated by reference to Exhibit 10.32 to Carisma Therapeutics Inc.&#8217;s Registration Statement on Form S-4/A (File No. 333-267891), filed on January 18, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.4&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex10d33.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated as of November 10, 2017, by and between Carisma Therapeutics Inc. and the Trustees of the University of Pennsylvania, as amended (incorporated by reference to Exhibit 10.33 to Carisma Therapeutics Inc.&#8217;s Registration Statement on Form S-4 (File No. 333-267891), filed on October 14, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.5&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex10d34.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated as of July 24, 2020, by and between Carisma Therapeutics Inc. and New York University (incorporated by reference to Exhibit 10.34 to Carisma Therapeutics Inc.&#8217;s Registration Statement on Form S-4 (File No. 333-267891), filed on October 14, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated March 7, 2023 (incorporated by reference to Exhibit 10.4 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Contingent Value Rights Agreement, dated March 7, 2023 (incorporated by reference to Exhibit 10.5 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.8#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement for Directors and Officers of Carisma Therapeutics Inc. (incorporated by reference to Exhibit 10.6 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.9#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated March 7, 2023, by and between Carisma Therapeutics Inc. and Steven Kelly (incorporated by reference to Exhibit 10.7 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.10#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated March 7, 2023, by and between Carisma Therapeutics Inc. and Richard Morris (incorporated by reference to Exhibit 10.8 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.11#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated March 7, 2023, by and between Carisma Therapeutics Inc. and Michael Klichinsky (incorporated by reference to Exhibit 10.9 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.12#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">CARISMA Therapeutics Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.10 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.13#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Nonstatutory Stock Option Agreement under the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.11 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.14#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement under the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.12 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.15#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Carisma Therapeutics Inc. Amended and Restated 2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.13 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.16#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2023 Form of Stock Option Agreement under the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan (incorporated by reference to Exhibit 10.14 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.17#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500324000005/carm-20231231xexx1017.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2024 Form of Stock Option Agreement under Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan (incorporated by reference to Exhibit 10.17 to the Carisma Therapeutics Inc.&#8217;s Annual Report on Form 10-K (File No. 001-36296) filed on April 1, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.18#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Agreement under Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan (incorporated by reference to Exhibit 10.15 to the Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.19#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Carisma Therapeutics Inc. 2014 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.16 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.20</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923058778/carm-20230331xex10d18.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease, dated April 22, 2019, by and between Wexford-SCEC 3675 Market Street, LLC and CARISMA Therapeutics Inc. (incorporated by reference to Exhibit 10.18 to Carisma Therapeutics Inc.&#8217;s Quarterly Report on Form 10-Q (File No. 001-36296) filed on May 11, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.21#</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465924131705/tm2432018d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Master Services Agreement, dated December 24, 2024, by and between Carisma Therapeutics Inc. and Danforth Global, Inc. and Danforth Advisors, LLC (incorporated by reference to Exhibit 10.1 to Carisma Therapeutics Inc.&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on December 26, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.22</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#AnnexC_214320"><span style="font-style:normal;font-weight:normal;">Form of Support Agreement, by and among Carisma Therapeutics Inc., OrthoCellix, Inc. and certain stockholders of Carisma Therapeutics Inc. (incorporated by reference to Annex C to this proxy statement/prospectus).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.23</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#AnnexD_774422"><span style="font-style:normal;font-weight:normal;">Form of Support Agreement, by and among Carisma Therapeutics Inc., OrthoCellix, Inc. and certain stockholders of OrthoCellix, Inc. (incorporated by reference to Annex D to this proxy statement/prospectus).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.24</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#AnnexE_617142"><span style="font-style:normal;font-weight:normal;">Form of Lock-Up Agreement, by and among Carisma Therapeutics Inc., OrthoCellix, Inc. and certain stockholders of Carisma Therapeutics Inc. (incorporated by reference to Annex E to this proxy statement/prospectus).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.25</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#AnnexF_507394"><span style="font-style:normal;font-weight:normal;">Form of Contingent Value Rights Agreement (incorporated by reference to Annex F to this proxy statement/prospectus).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.26#**</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Proposed OrthoCellix, Inc. 2025 Stock Incentive Plan (incorporated by reference to Annex H to this proxy statement/prospectus).</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.27**</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Form of Subscription Agreement (incorporated by reference to Annex I to this proxy statement/prospectus).</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.28**</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Form of Registration Rights Agreement (incorporated by reference to Annex J to this proxy statement/prospectus).</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.29*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d29.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated May 12, 2005, among Ocugen, Inc. and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.30*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d30.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to License Agreement, dated August 31, 2007 among Ocugen, Inc. and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.31*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to License Agreement, dated January 1, 2008 among Ocugen, Inc. and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.32*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to License Agreement, dated April 15, 2008 among Ocugen and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.33*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d33.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to License Agreement, dated November 1, 2008 among Ocugen, Inc. and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.34*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d34.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to License Agreement, dated August 6, 2010 among Ocugen, Inc. and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.35*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d35.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Reinstatement Agreement and Sixth Amendment to License Agreement, dated February 8, 2011 among Ocugen, Inc. and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH.</span></a></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.36*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d36.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Seventh Amendment to License Agreement, dated March 31, 2011 among Ocugen, Inc. and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.37*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d37.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Eighth Amendment to License Agreement, dated June 29, 2012 among Ocugen, Inc. and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.38*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d38.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agreement, dated June 22, 2012 between Ocugen, Inc. and Purpose Co., Ltd. f/k/a Takagi Sangyo Co. Ltd. and f/k/a Takagi Industrial Co., Ltd.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.39*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d39.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to License Agreement, dated May 9, 2016, between Ocugen, Inc. and Purpose Co., Ltd., f/k/a Takagi Sangyo Co. Ltd.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.40*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d40.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License and Commercialization Agreement, dated December 21, 2017 between Ocugen, Inc. and MEDINET Co., Ltd.</span></a> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.41**</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Form of Transition Services Agreements by and between Ocugen, Inc. and OrthoCellix, Inc.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.42**</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Form of Manufacturing and Supply Agreement by and between Ocugen, Inc. and OrthoCellix, Inc.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.43*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d43.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Contribution Agreement, dated June 19, 2025, by and between Ocugen, Inc. and OrthoCellix, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.44*&#8224;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d44.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive Channel Collaboration Agreement dated as of September 30, 2014 between Ocugen, Inc. and Intrexon Corporation</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.45*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex10d45.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Mutual Termination and Release Agreement dated December 21, 2018, between Histogenics Corporation and Intrexon Corporation.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">21.1*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Carisma Therapeutics Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">23.1*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of KPMG LLP, independent registered public accounting firm of Carisma Therapeutics Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">23.2*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex23d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of OrthoCellix, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">23.3**</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1).</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">23.4*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex23d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Lucid Capital Markets, LLC</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">24.1</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#SIGNATURES_605007"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on signature page).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">99.1*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Karthik Musunuri to serve as a director of Carisma Therapeutics Inc., to be renamed OrthoCellix, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">99.2*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Michael Shine to serve as a director of Carisma Therapeutics Inc., to be renamed OrthoCellix, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">99.3*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xex99d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of David Anderson to serve as a director of Carisma Therapeutics Inc., to be renamed OrthoCellix, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">101.INS*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">101.SCH*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">101.CAL*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">101.DEF*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">101.LAB*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">101.PRE*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">107*</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250331xexfees.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Filing Fee Table</span></a></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Filed herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To be filed by amendment.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Indicates a management contract or any compensatory plan, contract or arrangement.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b16a9c68_0a46_4894_92c7_ffa20e20f2d7"></a><a id="SIGNATURES_605007"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized on this 21st day of July, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven Kelly</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:44.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Steven Kelly</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:44.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President and Chief Executive Officer</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven Kelly and Natalie McAndrew, and each of them singly, as his or her true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:31.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven Kelly</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">President, Chief Executive Officer and Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July 21, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Kelly</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">Principal Executive Officer</i>)</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Natalie McAndrew</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Vice President of Finance</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Natalie McAndrew</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">Principal Financial Officer</i>&#160;<i style="font-style:italic;">and</i></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July 21, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Principal Accounting Officer</i>)</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Sanford Zweifach</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July 21, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sanford Zweifach</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Sohanya Cheng</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July 21, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sohanya Cheng</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John Hohneker, M.D.</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July 21, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John Hohneker, M.D.</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Briggs Morrison, M.D.</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July 21, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Briggs Morrison, M.D.</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Scadden, M.D.</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July 21, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Scadden, M.D.</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Marella Thorell</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July 21, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:28.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marella Thorell</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>2
<FILENAME>tmb-20250331xex3d3.htm
<DESCRIPTION>EX-3.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 03:59:38 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 3.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATE OF INCORPORATION OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ORTHOCELLIX, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The name of this corporation is OrthoCellix, Inc. (the &#8220;<b style="font-weight:bold;">Corporation</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The address of the Corporation&#8217;s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801, and its registered agent at such address is The Corporation Trust Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware, as the same exists or as may hereafter be amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Corporation is authorized to issue one class of shares to be designated Common Stock. &#160;The total number of shares of Common Stock the Corporation has authority to issue is 1,000 with a par value of $0.00001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The name and mailing address of the incorporator are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Laura Umbrecht Gulick<br>c/o Goodwin Procter LLP<br>3025 John F. Kennedy Blvd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Philadelphia, PA 19104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In furtherance and not in limitation of the powers conferred by statute, the Board of Directors of the Corporation (the &#8220;<b style="font-weight:bold;">Board</b>&#8221;) is expressly authorized to make, alter, amend or repeal the bylaws of the Corporation (the &#8220;<b style="font-weight:bold;">Bylaws</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Elections of directors need not be by written ballot unless otherwise provided in the Bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide. &#160;The books of the Corporation may be kept (subject to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">any provision contained in the statutes) outside the State of Delaware at such place or places as may be designated from time to time by the Board or in the Bylaws of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article IX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the fullest extent permitted by the General Corporation Law of the State of Delaware, as the same exists or as may hereafter be amended from time to time, a director or officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer.&#160; If the General Corporation Law of the State of Delaware is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware, as so amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation shall indemnify, to the fullest extent permitted by applicable law, any director or officer of the Corporation who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#8220;<b style="font-weight:bold;">Proceeding</b>&#8221;) by reason of the fact that he or she is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding. &#160;The Corporation shall be required to indemnify a person in connection with a Proceeding initiated by such person only if the Proceeding was authorized by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation shall have the power to indemnify, to the extent permitted by the General Corporation Law of the State of Delaware, as it presently exists or may hereafter be amended from time to time, any employee or agent of the Corporation who was or is a party or is threatened to be made a party to any Proceeding by reason of the fact that he or she is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Neither any amendment nor repeal of This Article IX, nor the adoption of any provision of this Certificate of Incorporation inconsistent with This Article IX, shall eliminate or reduce the effect of This Article IX in respect of any matter occurring, or any cause of action, suit or claim accruing or arising or that, but for This Article IX, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article X</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article IX</u> above, the Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or hereafter prescribed by statute, and all rights conferred upon stockholders herein are granted subject to this reservation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article XI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&#160;any derivative action or proceeding brought on behalf of the Corporation, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#8217;s stockholders, (iii)&#160;any action asserting a claim against the Corporation, its directors, officers or employees arising pursuant to any provision of the Delaware General Corporation Law or the Corporation&#8217;s certificate of incorporation or bylaws or (iv)&#160;any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i) through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. &#160;If any provision or provisions of This <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article XI</u> shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of This <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article XI</u> (including, without limitation, each portion of any sentence of This <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article XI</u> containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">I, the undersigned, as the sole incorporator of the Corporation, have signed this Certificate of Incorporation on February 28, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">/s/ Laura Umbrecht Gulick  </font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laura Umbrecht Gulick, Incorporator</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>3
<FILENAME>tmb-20250331xex3d4.htm
<DESCRIPTION>EX-3.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 03:59:38 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 3.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ORTHOCELLIX, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BYLAWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Adopted: </b>June 19, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE I</b><br><b style="font-weight:bold;">STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Meeting</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, if any, on such date, and at such time as the Board of Directors (or its designee)<sup style="font-size:7.5pt;vertical-align:top;">1</sup> shall each year fix.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Meetings</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Special meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by the Board of Directors or the Chief Executive Officer, if one is elected, or the President, and shall be held at such place, on such date, and at such time as they or he or she shall fix.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Meetings</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notice of the place, if any, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, and, if such meeting is to be held solely by means of remote communication, the information required to access the stock list contemplated by Section 8 of this Article I, shall be given, not less than 10 nor more than 60 days before the date on which the meeting is to be held, to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting, except as otherwise provided herein or required by law (meaning, here and hereinafter, as required from time to time by the Delaware General Corporation Law or the Certificate of Incorporation of the Corporation).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When a meeting is adjourned to another time or place (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), notice need not be given of the adjourned meeting if the time, place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting are (a) announced at the meeting at which the adjournment is taken, (b) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or (c) set forth in the notice of meeting given in accordance with</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;vertical-align:top;">1</sup><font style="display:inline-block;width:32.75pt;"></font>To the extent a company wishes to hold a meeting solely by means of remote communication, that determination must be made by the Board, and cannot be delegated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;">(Signature Page of Bylaws)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Section 222(a) of the Delaware General Corporate Law; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that if the adjournment is for more than 30 days, notice of the place, if any, date, and time of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting, shall be given to each stockholder in conformity herewith. &#160;If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for notice of such adjourned meeting, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and, except as otherwise required by law, shall not be more than 60 nor less than 10 days before the date of such adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting. &#160;At any adjourned meeting, any business may be transacted which might have been transacted at the original meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quorum</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At any meeting of the stockholders, the holders of a majority of the voting power of all of the shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be required by law. &#160;Where a separate vote by a class or classes or series is required, a majority of the voting power of the outstanding shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. &#160;The stockholders present at a duly constituted meeting may continue to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a quorum shall fail to attend any meeting, the chairman of the meeting or the stockholders by a majority of the votes cast affirmatively or negatively, may adjourn the meeting to another place, if any, date, or time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Such person as the Board of Directors may have designated or, in the absence of such a person, the Chief Executive Officer of the Corporation, if one is elected, or, if there is no Chief Executive Officer, the President, or, in his or her absence, such person as may be chosen by the holders of a majority of the voting power of the shares of stock entitled to vote who are present, in person or by proxy, shall call to order any meeting of the stockholders and act as chairman of the meeting. &#160;In the absence of the Secretary of the Corporation, the secretary of the meeting shall be such person as the chairman of the meeting appoints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of Business</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The chairman of any meeting of stockholders shall determine the order of business and the procedure at the meeting. &#160;Each of the chairman of the meeting and the Board of Directors shall have the authority to adopt and enforce rules providing for the orderly conduct of the meeting and the safety of those in attendance, including without limitation the authority to: (a) determine when the polls will open and close on items submitted for stockholder action; (b) fix the time allotted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for consideration of each agenda item and for questions and comments, if any, by persons in attendance; (c) adopt rules for determining who may pose questions and comments during the meeting; (d) adopt rules for determining who may attend the meeting; and (e) adopt procedures, if any, requiring attendees to provide the Corporation advance notice of their intent to attend the meeting. &#160;The chairman of the meeting shall have the power to adjourn or recess any meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proxies and Voting</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At any meeting of the stockholders, every stockholder entitled to vote may vote in person or by proxy given in accordance with Section 212 of the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation may, and to the extent required by law, shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. &#160;The Corporation may designate one or more alternate inspectors to replace any inspector who fails to act. &#160;If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting may, and to the extent required by law, shall, appoint one or more inspectors to act at the meeting. &#160;Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All elections shall be determined by a plurality of the votes cast, and except as otherwise required by law, all other matters shall be determined by a majority of the votes cast affirmatively or negatively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock List</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation shall prepare, no later than the tenth day before each meeting of stockholders, a complete list of stockholders entitled to vote at any meeting of stockholders, <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, if the record date for determining the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders entitled to vote as of the 10th day before the meeting date, arranged in alphabetical order and showing the address of each such stockholder and the number of shares registered in his or her name. &#160;Nothing contained in this Section 8 shall require the Corporation to include electronic mail addresses or other electronic contact information on such list. &#160;Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of 10 days ending on the day before the meeting date in the manner provided by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation&#8217;s stock ledger (as that term is used in Section 219(c) of the Delaware General Corporation Law) shall be the only evidence as to who are the stockholders entitled by this Section 8 to examine the aforementioned stock list or to vote in person or by proxy at any meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consent of Stockholders in Lieu of Meeting</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any action required to be taken at any annual or special meeting of stockholders of the Corporation, or any action which may be taken at any annual or special meeting of the stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or consents, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation in accordance with Section 228(d)(1) of the Delaware General Corporation Law; <i style="font-style:italic;">provided that</i> the Corporation shall not be required to designate an information processing system for the receipt of consents from stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No consent shall be effective to take the corporate action referred to therein unless consents signed by a sufficient number of holders to take action are delivered to the Corporation in the manner prescribed in the first paragraph of this Section within 60 days of the first date on which a consent is so delivered to the Corporation. &#160;Any person executing a consent may provide, whether through instruction to an agent or otherwise, that such consent will be effective at a future time, including a time determined upon the happening of an event, occurring no later than 60 days after such instruction is given or such provision is made, if evidence of the instruction or provision is provided to the Corporation. If the person is not a stockholder of record when the consent is executed, the consent shall not be valid unless the person is a stockholder of record as of the record date for determining stockholders entitled to consent to the action. Unless otherwise provided, any such consent shall be revocable prior to its becoming effective. &#160;Any such consent shall be delivered in accordance with Section&#160;228(d)(1) of the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used, <i style="font-style:italic;">provided that</i> such copy, facsimile or other reproduction shall be a complete reproduction of the entire original writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery to the Corporation</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Whenever one or more persons (including a stockholder of record) is required by this Article I to deliver a document or information to the Corporation or any of its officers, employees or agents, the Corporation shall not be required to accept delivery of such document or information unless the document or information is in writing (and not in an electronic transmission) and delivered by hand or by certified or registered mail, return receipt requested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BOARD OF DIRECTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number and Term of Office</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The number of directors who shall constitute the Board of Directors shall be such number as the Board of Directors shall from time to time have designated. &#160;Each director shall hold office until the next election of directors and until his or her successor is elected and qualified, or until his or her earlier death, resignation, retirement, disqualification, or removal. &#160;No decrease in the authorized number of directors shall shorten the term of any incumbent director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal of Directors; Resignation</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise provided by the Certificate of Incorporation or these Bylaws, any director or the entire Board of Directors may be removed, with or without cause, by the holders of a majority of the voting power of the outstanding shares entitled to vote at an election of directors. &#160;Any director may resign at</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">any time upon notice given in writing or by electronic transmission to the Corporation. &#160;Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vacancies and Newly Created Directorships</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise provided in the Corporation&#8217;s Certificate of Incorporation, as it may be amended, newly created directorships resulting from any increase in the authorized number of directors and any vacancies in the Board of Directors by reason of death, resignation, retirement, disqualification, removal or other cause may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next election of directors and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, retirement, disqualification, or removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If there are no directors in office, then an election of directors may be held in the manner provided by Section 223(a) of the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regular Meetings</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Regular meetings of the Board of Directors shall be held at such place or places, on such date or dates, and at such time or times as shall have been established by the Board of Directors and publicized among all directors. &#160;A notice of each regular meeting shall not be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Meetings</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Special meetings of the Board of Directors may be called by the Secretary of the Corporation upon the request of one-third of the directors then in office (rounded up to the nearest whole number) or by the Chief Executive Officer, if one is elected, or, if there is no Chief Executive Officer, the President, and shall be held at such place, if any, on such date, and at such time as they or he or she shall fix. &#160;Notice of the place, if any, date, and time of each such special meeting shall be given to each director by whom it is not waived by mailing written notice not less than five days before the meeting or by facsimile or electronic transmission of the same not less than 24 hours before the meeting. &#160;Unless otherwise indicated in the notice thereof, any and all business may be transacted at a special meeting. &#160;A meeting may be held at any time without notice if all the directors are present (except as otherwise provided by law) or if those not present waive notice of the meeting in writing, either before or after such meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quorum</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At any meeting of the Board of Directors, the greater of (a) a majority of the directors then in office at the time quorum is to be determined and (b) one-third of the total number of directors fixed pursuant to Section 1 of Article II of these Bylaws shall constitute a quorum for the transaction of business. &#160;If less than a quorum of directors attends any meeting, a majority of the directors present at such meeting may adjourn the meeting from time to time to another place, if any, date or time without further notice or waiver thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Participation in Meetings By Conference Telephone</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Members of the Board of Directors, or of any committee thereof, may participate in a meeting of such Board of Directors or committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation shall constitute presence in person at such meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of Business</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At any meeting of the Board of Directors, business shall be transacted in such order and manner as the Board of Directors may from time to time determine, and all matters shall be determined by the vote of a majority of the directors present, except as otherwise provided herein or required by law. &#160;Action may be taken by the Board of Directors without a meeting if all members thereof consent thereto in writing or by electronic transmission. &#160;After an action is taken, the consent or consents relating thereto shall be filed with the minutes of the proceedings of the Board of Directors in the same paper or electronic form as the minutes are maintained. &#160; Any person (whether or not then a director) may provide, whether through instruction to an agent or otherwise, that a consent to action will be effective at a future time (including a time determined upon the happening of an event), no later than 60 days after such instruction is given or such provision is made and such consent shall be deemed to have been given for purposes of this Section 8 at such effective time so long as such person is then a director and did not revoke the consent prior to such time. &#160;Any consent shall be revocable prior to its becoming effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation of Directors</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Directors, as such, may receive, pursuant to resolution of the Board of Directors, fixed fees and other compensation for their services as directors, including, without limitation, their services as members of committees of the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Emergency Bylaws</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The provisions of this Section 10 shall be operative during any emergency condition as contemplated by Section 110 of the Delaware General Corporation Law, notwithstanding any different or conflicting provisions in these Bylaws, the Certificate of Incorporation or the Delaware General Corporation Law. In the event of any such emergency condition, the director or directors in attendance at a meeting of the Board of Directors or a standing committee thereof shall constitute a quorum. Such director or directors in attendance may further take action to appoint one or more of themselves or other directors to membership on any standing or temporary committees of the Board of Directors as they shall deem necessary and appropriate. Except as the Board of Directors may otherwise determine, during any such emergency condition, the Corporation and its directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and officers, may exercise any authority and take any action or measure that is contemplated by Section 110 of the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMMITTEES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committees of the Board of Directors</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors may from time to time designate committees of the Board of Directors, with such lawfully delegable powers and duties as it thereby confers, to serve at the pleasure of the Board of Directors and shall, for those committees and any others provided for herein, elect a director or directors to serve as the member or members, designating, if it desires, other directors as alternate members who may replace any absent or disqualified member at any meeting of the committee. &#160;In the absence or disqualification of any member of any committee and any alternate member in his or her place, the member or members of the committee present at the meeting and not disqualified from voting, whether or not he or she or they constitute a quorum, may by unanimous vote appoint another member of the Board of Directors to act at the meeting in the place of the absent or disqualified member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of Business</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each committee may determine the procedural rules for meeting and conducting its business and shall act in accordance therewith, except as otherwise provided herein, determined by the Board of Directors or required by law. &#160;Adequate provision shall be made for notice to members of all meetings; one-third of the members shall constitute a quorum unless the committee shall consist of one or two members, in which event one member shall constitute a quorum; and all matters shall be determined by a majority vote of the members present. &#160;Action may be taken by any committee without a meeting if all members thereof consent thereto in writing or by electronic transmission. &#160;After an action is taken, the consent or consents relating thereto shall be filed with the minutes of the proceedings of such committee in the same paper or electronic form as the minutes are maintained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OFFICERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Generally</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The officers of the Corporation will be chosen by the Board of Directors and will consist of a President, a Secretary, a Treasurer and such other officers, including, without limitation, a Chief Executive Officer and one or more Vice Presidents, as may from time to time be appointed by the Board of Directors (or its designee). &#160;Officers shall be elected by the Board of Directors (or its designee), which shall consider that subject at its first meeting after every annual meeting of stockholders. &#160;Each officer shall hold office until his or her successor is elected and qualified or until his or her earlier resignation or removal. &#160;Any number of offices may be held by the same person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to any limitations which may be set forth in a resolution of the Board of Directors, all deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Corporation in the ordinary course of its business may be executed on behalf of the Corporation by a President or by any other officer, employee or agent of the Corporation as the Board of Directors (or the President) may authorize.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chief Executive Officer.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Chief Executive Officer, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">President</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the provisions of these Bylaws and to the direction of the Board of Directors, the President shall have the responsibility for the general management and control of the business and affairs of the Corporation and shall perform all duties and have all powers which are commonly incident to the office of President or which are delegated to him or her by the Board of Directors. &#160;He or she shall perform the duties and exercise the powers of the Chief Executive Officer and of the Treasurer in the event of a vacancy in the office of Chief Executive Officer or Treasurer, or in the event of either such person&#8217;s absence or disability. &#160;He or she shall have power to sign all contracts and other instruments of the Corporation which are authorized and shall have general supervision and direction of all of the other officers, employees and agents of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vice President</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Vice President shall have such powers and duties as may be delegated to him or her by the Board of Directors. &#160;One Vice President may be designated by the Board of Directors (or its designee) to perform the duties and exercise the powers of the President in the event of the President&#8217;s absence or disability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treasurer</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Treasurer shall have the responsibility for maintaining the financial records of the Corporation. &#160;He or she shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions and of the financial condition of the Corporation. &#160;The Treasurer shall also perform such other duties as the Board of Directors may from time to time prescribe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Secretary</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Secretary shall issue all authorized notices for, and shall keep minutes of, all meetings of the stockholders and the Board of Directors. &#160;He or she shall have charge of the corporate books and shall perform such other duties as the Board of Directors (or its designee) may from time to time prescribe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chairman of the Board</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise provided by the Board of Directors, the Chairman of the Board of Directors, if one is elected, shall preside, when present, at all meetings of the stockholders and the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Board of Directors. &#160;The Chairman of the Board shall have such other powers and shall perform such duties as the Board of Directors may from time to time designate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delegation of Authority</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors (or its designee) may from time to time delegate the powers or duties of any officer to any other officers or agents, notwithstanding any provision hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any officer of the Corporation may be removed at any time, with or without cause, by the Board of Directors (or its designee).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Action with Respect to Securities of Other Entities</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise directed by the Board of Directors, the Chief Executive Officer, if one is elected, or, if there is no Chief Executive Officer, the President or any officer of the Corporation authorized by the Chief Executive Officer or President shall have power to vote and otherwise act on behalf of the Corporation, in person or by proxy, at any meeting of equity holders of or with respect to any action of equity holders of any other entity in which this Corporation may hold securities and otherwise to exercise any and all rights and powers which this Corporation may possess by reason of its ownership of securities in such other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificates of Stock</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The shares of the Corporation shall be represented by certificates, <i style="font-style:italic;">provided that</i> the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares. &#160;Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. &#160;Each holder of stock represented by certificates shall be entitled to a certificate signed by, or in the name of the Corporation, by any two of the President, a Vice President, the Secretary, an Assistant Secretary, the Treasurer, an Assistant Treasurer or any other authorized officers of the Corporation, certifying the number of shares owned by him or her. &#160;Any or all of the signatures on the certificate may be by facsimile. &#160;In case any officer who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfers of Stock</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Transfers of stock shall be made only upon the transfer books of the Corporation kept at an office of the Corporation or by transfer agents designated to transfer shares of the stock of the Corporation. &#160;Except where a certificate is issued in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</u> of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</u> of these Bylaws, an outstanding certificate, if one has been issued, for the number of shares involved shall be surrendered for cancellation before a new certificate, if any, is issued therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Record Date</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the Board of Directors may, except as otherwise required by law, fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. &#160;If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. &#160;If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. &#160;A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that the Board of Directors may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance with the foregoing provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3</u> at the adjourned meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. &#160;If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order that the Corporation may determine the stockholders entitled to consent to corporate action without a meeting in accordance with Section 228 of the Delaware General Corporation Law, the Board of Directors may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall be not more than ten days after the date upon which the resolution fixing the record date is adopted. &#160;If no record date has been fixed by the Board of Directors and no prior action by the Board of Directors is required by the Delaware General Corporation Law, the record date shall be the first date on which a signed consent setting forth the action taken or proposed to be taken is delivered to the Corporation in accordance with Section 228(d)(1) of the Delaware General Corporation Law. &#160;If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by the Delaware General Corporation Law with respect to the proposed action by consent of the stockholders without a meeting, the record date for determining stockholders entitled to consent to corporate action without a meeting shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lost, Stolen or Destroyed Certificates</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of the loss, theft or destruction of any certificate of stock, another may be issued in its place pursuant to such regulations as the Board of Directors (or its designee) may establish concerning proof of such loss, theft or destruction and concerning the giving of a satisfactory bond or bonds of indemnity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulations</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The issue, transfer, conversion and registration of certificates of stock shall be governed by such other regulations as the Board of Directors (or its designee) may establish.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notice shall be deemed given:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">(a) if mailed, when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#8217;s address as it appears on the records of the Corporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">(b) if delivered by courier service, the earlier of when received or left at such stockholder&#8217;s address; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">(c) if given by electronic mail (as defined in Section 232(d)(2) of the Delaware General Corporation Law) to such stockholder&#8217;s electronic mail address (as defined in Section 232(d)(2) of the Delaware General Corporation Law) unless the stockholder has notified the Corporation in writing or by electronic transmission of an objection to receiving notice by electronic mail or such notice is prohibited by Section 232(e) of the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders may be given by another form of electronic transmission in the manner provided in Section&#160;232(b) of the Delaware General Corporation Law, and such notice shall be deemed given as provided in Section 232(c) of the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waivers</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A written waiver of any notice, signed by the person entitled to notice, or a waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person. &#160;Neither the business nor the purpose of any meeting need be specified in such a waiver. &#160;Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Facsimile Signatures</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the provisions for use of facsimile signatures elsewhere specifically authorized in these Bylaws, facsimile signatures of any officer or officers of the Corporation may be used whenever and as authorized by the Board of Directors (or its designee) or a committee thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Seal</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors may provide a suitable seal, containing the name of the Corporation, which seal shall be in the charge of the Secretary. &#160;If and when so directed by the Board of Directors (or its designee) or a committee thereof, duplicates of the seal may be kept and used by the Treasurer or by an Assistant Secretary or Assistant Treasurer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reliance upon Books, Reports and Records</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each director, each member of any committee designated by the Board of Directors, and each officer of the Corporation shall, in the performance of his or her duties, be fully protected in relying in good faith upon the books of account or other records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of its officers or employees, or committees of the Board of Directors so designated, or by any other person as to matters which such director, committee member or officer reasonably believes are within such other person&#8217;s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fiscal Year</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fiscal year of the Corporation shall be as fixed by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Offices</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the Corporation may require.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Records and Reports</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The application and requirements of Section&#160;1501 of the California General Corporation Law are hereby expressly waived to the fullest extent permitted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time Periods</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In applying any provision of these Bylaws which requires that an act be done or not be done a specified number of days prior to an event or that an act be done during a period of a</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">specified number of days prior to an event, calendar days shall be used, the day of the doing of the act shall be excluded, and the day of the event shall be included.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEMNIFICATION OF DIRECTORS AND OFFICERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Indemnification</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each person who was or is made a party to or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a &#8220;<b style="font-weight:bold;">proceeding</b>&#8221;), by reason of the fact that he or she is or was a director or an officer of the Corporation designated by the Board of Directors, or, while serving in either such capacity, is or was serving at the request of the Corporation as a director, officer, or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan (hereinafter an &#8220;<b style="font-weight:bold;">indemnitee</b>&#8221;), whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee, or in any other capacity while serving as a director, officer or trustee, shall be indemnified and held harmless by the Corporation to the fullest extent permitted by Delaware law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment) against all expense, liability and loss (including attorneys&#8217; fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such indemnitee in connection therewith; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that, except as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3</u> of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</u> with respect to proceedings to enforce rights to advancement and indemnification, the Corporation shall indemnify, and shall advance expenses to, any such indemnitee in connection with a proceeding (or part thereof) initiated by such indemnitee only if such proceeding (or part thereof) was authorized by the Board of Directors of the Corporation; <i style="font-style:italic;">provided, further</i>, that, to the fullest extent permitted by Delaware law, the Corporation may modify the extent of such indemnification by individual contracts with its directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Advancement of Expenses</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the right to indemnification conferred in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1</u> of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</u>, an indemnitee shall also have the right to be paid by the Corporation the expenses (including attorney&#8217;s fees) incurred in defending any such proceeding in advance of its final disposition (hereinafter an &#8220;<b style="font-weight:bold;">advancement of expenses</b>&#8221;); <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that, if the Delaware General Corporation Law requires, an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the Corporation of an undertaking (hereinafter an &#8220;<b style="font-weight:bold;">undertaking</b>&#8221;), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a &#8220;<b style="font-weight:bold;">final adjudication</b>&#8221;) that such indemnitee is not entitled to be indemnified for such expenses under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2</u> or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of Indemnitee to Bring Suit</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a claim under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2</u> of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</u> is not paid in full by the Corporation within 60 days after a written claim has been received by the Corporation, except in the case of a claim for an advancement of expenses, in which case the applicable period shall be 20 days, the indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. &#160;To the fullest extent permitted by law, if successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the indemnitee shall be entitled to be paid also the expense of prosecuting or defending such suit. &#160;In (a) any suit brought by the indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the indemnitee to enforce a right to an advancement of expenses) it shall be a defense that, and (b)&#160;in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that, the indemnitee has not met any applicable standard for indemnification set forth in the Delaware General Corporation Law. &#160;Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the indemnitee is proper in the circumstances because the indemnitee has met the applicable standard of conduct set forth in the Delaware General Corporation Law, nor an actual determination by the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) that the indemnitee has not met such applicable standard of conduct, shall create a presumption that the indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the indemnitee, be a defense to such suit. &#160;In any suit brought by the indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</u> or otherwise, shall be on the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successful Defense of a Proceeding</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent an indemnitee has been successful on the merits or otherwise in defense of any proceeding (or in defense of any claim, issue or matter therein), such indemnitee shall be indemnified under this Section 4 against expenses (including attorneys&#8217; fees) actually and reasonably incurred in connection with such defense. Indemnification under this Section 4 shall not require indemnitee to satisfy any standard of conduct, and the Corporation may not assert a failure to satisfy any standard of conduct as a basis to deny indemnification or recover amounts advanced, including in a suit brought pursuant to Section 3 of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</u> (notwithstanding anything to the contrary contained therein); provided, however, that, any indemnitee who is not a current or former director or &#8220;officer&#8221; (as such term is defined in the final sentence of Section 145(c)(1) of the Delaware General Corporation Law) shall be indemnified under Section 1 of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</u> and this Section 4 only if such indemnitee has satisfied the standard of conduct</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">required for indemnification under Section 145(a) or Section 145(b) of the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Exclusivity of Rights</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The rights to indemnification and to the advancement of expenses conferred in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</u> shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, the Corporation&#8217;s Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification of Employees and Agents of the Corporation</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification and to the advancement of expenses to any employee or agent of the Corporation to the fullest extent of the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</u> with respect to the indemnification and advancement of expenses of directors and officers of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:54pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nature of Rights</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The rights conferred upon indemnitees in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</u> shall be contract rights and such rights shall continue as to an indemnitee who has ceased to be a director, officer or trustee and shall inure to the benefit of the indemnitee&#8217;s heirs, executors and administrators. &#160;Any amendment, alteration or repeal of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</u> that adversely affects any right of an indemnitee or its successors shall be prospective only and shall not limit, eliminate, or impair any such right with respect to any proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment, alteration or repeal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;IX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These Bylaws may be amended or repealed by the Board of Directors at any meeting or by the stockholders at any meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;X</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FORUM SELECTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless the Corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, all Internal Corporate Claims shall be brought solely and exclusively in the Court of Chancery of the State of Delaware (or, if such court does not have jurisdiction, the Superior Court of the State of Delaware, or, if such other court does not have</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">jurisdiction, the United States District Court for the District of Delaware). &#160;&#8220;Internal Corporate Claims&#8221; means claims, including claims in the right of the Corporation, brought by a current or former stockholder (including a current or former beneficial owner) (a) that are based upon a violation of a duty by a current or former director, officer, employee or stockholder in such capacity or (b) as to which the Delaware General Corporation Law confers jurisdiction upon the Court of Chancery of the State of Delaware.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>4
<FILENAME>tmb-20250331xex10d29.htm
<DESCRIPTION>EX-10.29
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 03:59:39 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.29</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This License Agreement, effective as of May 12, 2005 (the &#8220;Effective Date&#8221;), is by and among:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiotech Biomaterials Corp.</b>, a corporation organized and existing under the laws of Delaware, with principal offices at 2500 Faber Place, Palo Alto, CA, 94303 (&#8220;Biomaterials&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiodevice International GmbH</b>, a corporation organized and existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (&#8220;Angiodevice&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">and,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Histogenics Corporation</b>, a corporation organized and existing under the laws of Massachusetts, with principal offices at 100 Hospital Road, Malden, MA 02148 (&#8220;Histogenics&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WITNESSETH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b> Angiodevice and Biomaterials (collectively, &#8220;Angiotech&#8221;) are under the indirect control of Angiotech Pharmaceuticals, Inc., (&#8220;Angiotech Parent&#8221;) and as such both are Affiliates (as defined below) of each other;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AND WHEREAS</b> Angiotech owns certain domestic and foreign patents and patent applications, and has developed know-how, relating to the manufacture and use of CT3;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AND WHEREAS</b> Histogenics desires to receive a license for the use of certain of such patents, patent applications and know-how, and Angiotech is willing, and has the right, to grant such a license to Histogenics;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW THEREFORE</b>, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice and Biomaterials and Histogenics (Angiotech and Histogenics shall be individually referred to as &#8220;Party&#8221; and collectively as &#8220;Parties&#8221;) hereby agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Capitalized terms used in this Agreement and not otherwise defined herein shall have the meaning as set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Action</u>&#8221; means any legal action or proceeding, or the filing of any counterclaim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</u>&#8221; means any entity, natural or otherwise, that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with a Party. For purposes of this definition, &#8220;control&#8221; means (a) the direct or indirect ownership of at least fifty percent (50%) (or such maximum lesser percentage allowed to be owned by a foreign owner in a particular jurisdiction) of the outstanding voting securities of such entity, or (b) the ability to affect management control or possessing the decision making authority of such entity through whatever means.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221; means this License Agreement, together with all exhibits annexed hereto, as the same shall be modified and in effect from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiotech Indemnitees</u>&#8221; has the meaning ascribed to it in Section 7.3(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 1 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Calendar Quarter</u>&#8221; means each three (3) month period during the Term commencing on January 1, April 1, July 1 or October 1; provided that the first Calendar Quarter of the Term shall be deemed to have commenced on the Effective Date and may be shorter than a full Calendar Quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Calendar Year</u>&#8221; means each twelve (12) month period during the Term commencing on January 1 and ending on December 31 of each year; provided that the first Calendar Year of the Term shall be deemed to have commenced on the Effective Date and may be shorter than a full Calendar Year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinical Data</u>&#8221; means the results and analysis of data arising from the testing of a drug, device or a combination thereof <i style="font-style:italic;">in vitro</i>, <i style="font-style:italic;">in vivo</i> in non-human subjects and <i style="font-style:italic;">in vivo</i> in human subjects, including safety and toxicity testing, or other pre-clinical testing, patient screening, patient enrollment, patient status, any communications with Regulatory Authorities, actions taken or modification in study design/conduct and summary of data collected on CRFs (Case Report Forms) either paper or electronic, interactions with a DSMB (data safety monitoring board) if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Competitive Product</u>&#8221; means, in a given country, (i) a drug or biologic approved for marketing or in Phase 3 clinical development, (ii) a 510(k), or foreign equivalent, device approved for marketing, or (iii) a PMA, or foreign equivalent, device approved for marketing or in pivotal study clinical development, other than an Eligible Product, that acts (or is being developed to act) for one or more target label indications substantially similar to one or more approved or target label indications for an Eligible Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u>&#8221; means all information and data provided by the Parties to each other hereunder in written or other tangible medium whether or not marked as confidential or, if disclosed orally or displayed, identified as confidential at the time of disclosure, except any portion thereof which:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>is known to the receiving Party, as evidenced by the receiving Party&#8217;s written records, before receipt thereof under this Agreement or any other agreement between the Parties providing for confidentiality;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>is disclosed to the receiving Party by a third person who is under no obligation of confidentiality to the disclosing Party hereunder with respect to such information and who otherwise has a right to make such disclosure;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>is or becomes generally known in the trade through no fault of the receiving Party;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>is independently developed by the receiving Party without reference to or reliance upon the Disclosing Party&#8217;s Confidential Information and by persons having no access thereto, as evidenced by the receiving Party&#8217;s written records; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>is required to be disclosed by applicable statute, rule or regulation of any court or Regulatory Authority with competent jurisdiction; provided that the Party whose information is to be disclosed shall be notified as soon as possible and the Party that is being required to disclose such information shall, if requested by the Party whose information is to be disclosed, use reasonable good faith efforts, at the expense of the requesting Party, to assist in seeking a protective order (or equivalent) with respect to such disclosure or otherwise take reasonable steps to avoid making such disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Confidential Information of Angiotech includes, without limitation, Licensed Patent Rights that are not publicly available and the Technical Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Control</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Controlled</u>&#8221; shall mean the legal authority or right of a Party hereto to grant a license or sublicense of intellectual property rights to another Party hereto, without breaching the terms of any agreement with a third party, infringing upon the intellectual property rights of a third party, or misappropriating or unlawfully disclosing the confidential, proprietary or trade secret information of a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CT3</u>&#8221; means a [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 2 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Diligence Date(s)</u>&#8221; means one or more of the date(s) set out in Section 4.1 as the context requires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute</u>&#8221; shall have the meaning ascribed to it in Section 9.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dollars</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">$</u>&#8221; means the lawful currency of the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Drug-Loaded Product</u>&#8221; means the inclusion in CT3 of at least one nonliving ingredient for the primary purpose of producing a physiological, metabolic or biological effect in mammals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Eligible Product</u>&#8221; means a product that is made up of Histogenics Technology and CT3, but excluding any Drug-Loaded Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA</u>&#8221; means the United States Food and Drug Administration or any successor agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Field</u>&#8221; means repair of articular cartilage, ligament, meniscus and/or tendon damage, including related osteochrondal defects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Commercial Sale</u>&#8221; means the date of the first sale of an Eligible Product made by or on behalf of Histogenics in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics Indemnitees</u>&#8221; has the meaning ascribed to it in Section 7.3(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics License</u>&#8221; has the meaning ascribed to it in Section 2.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics Technology</u>&#8221; means Histogenics&#8217; intellectual property and know how as it currently exists and as that intellectual property and know how may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Improvements</u>&#8221; means all improvements, variations, updates, modifications, and enhancements made to the Licensed Technology (including but not limited to the Manufacturing Technology and CT3) (i) by or on behalf of Histogenics prior to or during the Term or (ii) by or on behalf of Angiotech prior to or during the Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u>&#8221; has the meaning ascribed to it in Section 7.3(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</u>&#8221; has the meaning ascribed to it in Section 7.3(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Patent Rights</u>&#8221; means the patents and patent applications list on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>, together with all patent applications filed during the Term and Controlled by Angiotech that are related to the existing patents and patent applications set out in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> by way of any continuations, continuations-in-part, divisions or any substitute applications, any patent issued with respect to any such patent applications, any reissue, re-examination, renewal or extension (including any supplemental patent certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing, in each case only to the extent, however, that claims in any patent application filed during the Term are entirely supported in the specification and entitled to the priority date of the parent patent application in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Technology</u>&#8221; means Licensed Patent Rights and Technical Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Loss</u>&#8221; has the meaning ascribed to it in Section 7.3(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing Technology</u>&#8221; means all know-how, information, formulations, trade secrets, data and other proprietary information Controlled by Angiotech that are in existence as of the Effective Date and are necessary for the manufacture of CT3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net Sales</u>&#8221; means, with respect to any Eligible Product, gross sales from the sale, rent, lease or otherwise making available of [***] that contains an Eligible Product to end-user third parties by or on behalf of Histogenics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 3 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and its Affiliates and their permitted sublicensees, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">less</u> the following, to the extent they are separately invoiced and credited against, or deducted from, the invoiced amount:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>discounts, credits, rebates, allowances, adjustments, rejections, recalls and returns (in the amount of the credit provided to the customer), all as usual and customary in the business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>freight, postage, transit insurance, and other transportation charges; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>sales and use taxes, customs duties, and any other governmental tax or charge (except income taxes or taxes imposed on the right to do business) imposed on or at the time of the production, importation, use, or sale of such Eligible Products (if separately invoiced), including any value added taxes (VAT), as adjusted for reasonable and customary rebates and refunds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Person</u>&#8221; means an individual, partnership, association, corporation, or personal representative.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Authority</u>&#8221; means, with respect to any particular country, territory or union, the governmental authority, body, commission, agency or other instrumentality of such country, territory or union with the primary responsibility for the evaluation or approval of medical products before such medical product can be tested, marketed, promoted, distributed or sold in such country, territory or union including such governmental bodies that have jurisdiction over the pricing of such medical product. The term &#8220;Regulatory Authority&#8221; includes, but is not limited to the FDA, the European Agency for the Evaluation of Medicinal Products (EMEA), European Member State Competent Authorities and the Ministry of Health, Labour and Welfare (MHLW).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Approval</u>&#8221; means any approvals, licenses, registrations or authorizations of any federal, state, provincial or local regulatory agency, department, bureau or other governmental entity necessary for the manufacture and sale of a product in a regulatory jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Share</u>&#8221; has the meaning ascribed to it in Section 3.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Senior Staff at Angiotech</u>&#8221; means individuals employed by Angiotech who are at or above the level of Senior Vice President.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technical Information</u>&#8221; means all know-how, information, formulations, trade secrets, data and other proprietary information Controlled by Angiotech that are in existence as of the Effective Date and are necessary to for the use, sale or distribution of CT3 pursuant to this Agreement, plus the Manufacturing Technology, but excluding the Licensed Patent Rights; provided, however that any know-how, information, materials, formulations, trade secrets, data and other proprietary information (including Manufacturing Technology) disclosed by Angiotech to Histogenics pursuant to this Agreement shall continue to be Confidential Information of Angiotech.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u>&#8221; has the meaning ascribed to it in Section 8.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Territory</u>&#8221; means worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warrants</u>&#8221; has the meaning ascribed to it in Section 3.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warrant Agreement</u>&#8221; means the Warrant Agreement between Angiodevice and Histogenics of even date herewith and attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Grant.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant</u>. Subject to terms and conditions of this Agreement, Angiotech hereby grants to Histogenics, a non-exclusive right and license under the Licensed Technology solely to make, have Made, use, offer to sell, sell and import Eligible Products in the Field in the Territory (the &#8220;Histogenics License&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 4 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicensing</u>. Histogenics shall not have any rights to sublicense the Histogenics License, except as consented to in writing by Angiotech in advance, with such consent not to be unreasonably withheld, conditioned or delayed. No granting of any sublicense by Histogenics shall relieve Histogenics from or diminish any obligation of Histogenics under this Agreement and Histogenics shall be responsible for the performance by its permitted sublicensees under such sublicense. Any sublicense granted by Histogenics under this Agreement shall be subject to the terms and conditions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics Improvements</u>. [***] Histogenics shall notify Angiotech in writing of any such Improvements as soon as reasonably possible and will provide Angiotech with a description of the Improvements. [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing of CT3</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Supply</u>. Angiotech hereby agrees to supply Histogenics with 1000 kits containing CT3 to be used by Histogenics for pre-clinical and clinical studies. These kits shall be supplied to Histogenics at [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing Transfer</u>. The Parties agree that commencing upon the Effective Date of this Agreement, Angiotech shall facilitate the transfer of manufacturing of CT3 to Histogenics. The Parties shall cooperate to expedite transfer of the CT3 Manufacturing Technology from Angiotech to Histogenics and Angiotech agrees to make employees of appropriate skill and experience reasonably available to Histogenics to facilitate such transfer of Manufacturing Technology. Part of the transfer of CT3 manufacturing by Angiotech will be the transferring of knowledge concerning suppliers of CT3 raw materials, and assisting Histogenics with the negotiation of supply contracts as required. Angiotech and Histogenics will cooperate to minimize .the expenses associated with such transfer and to ensure that the transfer of the manufacturing is effectively coordinated. In no event will the transfer of manufacturing rights to Histogenics be deemed to prohibit Angiotech from manufacturing CT3, or from having CT3 manufactured, for its own purposes or for the purposes of other potential partners or customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing</u>. Histogenics agrees that this License Agreement shall only permit Histogenics to manufacture CT3 for use by Histogenics in Eligible Products in the Field during the Term and to manufacture CT3 for Angiotech as provided for in Section 2.4(e). [***] Technical Information, including Manufacturing Technology, is and shall remain the Confidential Information of Angiotech, and as such, shall be protected by Histogenics as provided for in Section 10.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Costs</u>. Except for costs to be borne by Angiotech as specifically set forth in this Agreement, Histogenics shall be solely responsible for any and all costs associated with the transfer of Manufacturing Technology to Histogenics. To facilitate the transfer, Histogenics shall pay to Angiotech [***] per personnel work hour, plus reimbursement to Angiotech of all related and reasonable out-of-pocket expenses, for any personnel work hours of assistance required to facilitate the transfer of manufacturing. Angiotech shall be responsible for costs associated with the termination by Angiotech of the manufacture, storage and packaging of CT3 (including but not limited to any related severance payments to Angiotech employees). Histogenics may, at its election, hire Angiotech&#8217;s employees that are involved in the manufacture of CT3, provided that Histogenics has obtained the prior consent of Angiotech to contact specific employee(s), which consent shall not be unreasonably withheld.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supply Back</u>. After the Manufacturing Technology has been successfully transferred to Histogenics, and in the event that Angiotech wishes to purchase CT3 at any time thereafter during the Term, the Parties agree that they will enter into a supply agreement, which will contain, in addition to the usual and customary turns contained in such agreements, the following;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>Histogenics agrees to supply CT3 to Angiotech [***]; and,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>Histogenics agrees to supply CT3 to Angiotech for use in commercial products [***]; and,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 5 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font>As provided for in Section 2.4(c) above, Histogenics shall be required to [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Responsibility and Compliance</u>. Histogenics will be responsible for obtaining and maintaining any establishment licenses or permits that are required by the FDA or any non-U.S. regulatory authority as manufacturer of CT3. At such time as any manufacturing transfer to Histogenics has been completed, Histogenics will be granted access to all current regulatory filings and approvals applicable to the manufacture of CT3 and Histogenics will be given the right to reference any establishment licenses or permits as required by the FDA or any non-U.S. regulatory agency, as applicable or allowable, for the purpose of obtaining and maintaining regulatory approval to manufacture CT3 or use it with any Eligible Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinical Studies</u>. To the extent permitted by applicable law and regulations, the data and results obtained from any clinical studies conducted by Histogenics with respect to CT3 will be promptly shared with Angiotech and Angiotech shall be entitled to use such data for research and development purposes and to generate Improvements.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics License Fees &amp; Revenue Share</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Fee</u>. In consideration for the Histogenics License, Histogenics shall surrender to Angiodevice warrants to purchase from Histogenics, for an exercise price of [***] per warrant, a number of common shares equivalent to [***] of the common shares of Histogenics outstanding as of the Effective Date under the terms and conditions of the Warrant Agreement (the &#8220;Warrants&#8221;). The Warrant Agreement shall contain appropriate anti-dilution provisions to ensure that such Warrants are not diluted to less than [***] by the next [***] of equity investment. Thereafter, such Warrants shall be subject to dilution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Share</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Sharing</u>. As further consideration for the Histogenics License, within thirty (30) days after the end of each Calendar Quarter during the Term, Histogenics shall pay to Angiotech [***] for so long as Histogenic&#8217;s rights under this License are nonexclusive (&#8220;Revenue Share&#8221;). At any time prior to December 31, 2007, or, provided Angiotech has not granted any other party rights to the Licensed Technology within the Field, at any time thereafter, Histogenics can elect to convert this License to one of exclusivity within the Field or any portion thereof by giving notice to Angiotech, and in such event Histogenics shall thereafter pay [***] of all Net Sales on those Eligible Products within the Field or portion thereof for which Histogenics elects to have exclusive rights to the Licensed Technology with respect thereto</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligation to Pay Revenue Share</u>. The obligation on Histogenics to pay a Revenue Share to Angiodevice for Net Sales in a country as provided for in this Article 3 begins at the end of the Calendar Quarter within which the First Commercial Sale occurred in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Arm&#8217;s-Length Sales</u>. On sales made in other than an arm&#8217;s-length transaction, the value of the Net Sales attributed under this Article 3 to such a transaction shall be that which would have been received in an arm&#8217;s-length transaction. Sales between and among Histogenics and its Affiliates and permitted sublicensees that are intended for resale shall not be included in Net Sales until those Eligible Products are sold to a third party by Histogenics or its Affiliate or permitted sublicensee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reporting of Histogenics Revenue Share</u>. Histogenics shall deliver to Angiotech together with each Revenue Share payment under Section 3.2 a written Revenue Share report setting forth for the applicable Calendar Quarter at least the following information:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The date of the First Commercial Sale in each country in the Territory;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>The number of Eligible Products sold, rented, leased or otherwise made available to third parties by or on behalf of Histogenics and its Affiliates and permitted sublicensees, reported on a country-by-country basis;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 6 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Total gross sales amounts received for such Eligible Products by jurisdiction, including separate items for the value of any goods or services received in exchange for Eligible Products, and any additional amounts to be added to Net Sales pursuant to Section 3.3;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Deductions applicable to determine Net Sales for such period by country;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>The amount of the Revenue Share due or, if no Revenue Share is due, a statement that no Revenue Share is due; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>Such other information as may reasonably be requested by Angiotech.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each Revenue Share report shall be certified as correct by the CFO of Histogenics and shall include a detailed listing of all deductions made to determine Net Sales and to calculate the Revenue Share payable hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Revenue Share</u>. All Revenue Share for each Calendar Quarter due under this Article 3 are to be paid in Dollars and are due within thirty (30) days after the end of each Calendar Quarter. For conversion of foreign currency to Dollars, the conversion rate shall be the New York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due. All payments shall be made by wire transfer to Angiotech&#8217;s account in accordance with such instructions as Angiotech may direct from time to time. Any loss of exchange, value, taxes, or other expenses incurred in the transfer or conversion to Dollars shall be paid entirely by Histogenics. The Revenue Share report required by Section 3.4 shall accompany each such payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.6</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Late Payments</u>. Interest will be assessed by Angiotech on any overdue payments at a rate of one percent (1%) per month, compounded monthly beginning on the due date of the applicable payment (an effective annual rate of 12.68 % per annum), or at such lower maximum rate permitted by law. The payment of such interest will not prevent Angiotech from exercising any other rights it may have as a consequence of the lateness of any payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.7</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Filings</u>. Except for taxes based on Angiotech&#8217;s income, Histogenics will be solely responsible for determining if any tax on Net Sales and Revenue Share payments is owed to any governmental authority and shall pay any such tax and be responsible for all filings with appropriate governmental authorities related thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.8</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit Rights</u>. Histogenics shall maintain complete and accurate records of all of its operations, and shall cause its Affiliates and permitted sublicensees to maintain complete and accurate records of all of their respective operations, within the scope of this Agreement. Such records shall be retained by Histogenics and any permitted sublicensees for five (5) years following each reporting period (as described in Section 3.4), and Angiotech, at its expense, shall have the right to have a certified public accountant inspect such records at the offices of Histogenics and its Affiliates and permitted sublicensees, as applicable, at any time during such retention period upon one (1) week prior notice by Angiotech. In the event the examination shows an underpayment for any Calendar Quarter, Histogenics shall pay to Angiotech the amounts underpaid, together with interest charges pursuant to Section 3.6. Where the amount of any such underpayment is more than three percent (3%) for any Contract Quarter, Histogenics shall also reimburse Angiotech for the reasonable cost of conducting such examination.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics Diligence Obligations</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Diligence Obligations</u>. It is understood and acknowledged that part of the consideration for this License is Histogenics&#8217;s intention to bring one or more Eligible Products to market through a program for exploitation of the Licensed Technology and, once commercialized, thereafter to continue active, diligent marketing and sales efforts for Eligible Products throughout the life of this Agreement. Histogenics further agrees that it shall be obligated to [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Failure to Meet Diligence Obligations</u>. In the event that Histogenics has not fulfilled the required obligation of Section 4.1, then Angiotech shall be entitled, at its discretion, to treat any such failure as a material breach in accordance with Section 8.2(a) of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 7 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Progress Reports</u>. Histogenics agrees to provide information reasonably required by Angiotech to evaluate Histogenics&#8217; performance under this Agreement and to allow Angiotech to fulfill its obligations under any third party licenses. Angiotech and Histogenics shall be required to meet to discuss Histogenic&#8217;s progress on or before March 1 of each Calendar Year. This meeting shall take place at Angiotech&#8217;s office in Vancouver at a time to be determined by the Parties, but not later then March 1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4</font></font>[***]</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Obligations of Histogenics and Angiotech</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Approvals</u>. Histogenics shall be responsible for obtaining all Regulatory Approvals for its Eligible Products in all geographical areas which it, in its sole discretion, deems necessary or advisable, including funding all pre-clinical and clinical studies deemed by Histogenics to be necessary or advisable for obtaining Regulatory Approvals. Angiotech agrees to provide reasonable assistance upon request by Histogenics in the pursuit of Regulatory Approvals for Eligible Products, and Histogenics shall reimburse Angiotech for its reasonable expenses of providing such assistance. Histogenics agrees that it shall provide to Angiotech copies of all correspondence, including but not limited to submissions, between Histogenics (and its permitted sublicensees) and all Regulatory Authorities within [***] after receipt or submission (as applicable) to the extent they relate to CT3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Applications and Foreign Filing</u>. Angiotech shall file, prosecute and maintain in force any and all patents and patent applications included in the Licensed Patent Rights and any patent and patent applications related to any Improvements. The filing, prosecution and maintenance of patents and patent applications pursuant to this Section 5.2 shall be done through patent counsel selected by Angiotech. To the extent Angiotech has the right to do so, Angiotech will keep Histogenics reasonably informed of all significant patent matters relating to the Licensed Patent Rights and the Improvements within the Field as they relate to Eligible Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Press Releases</u>. The Parties agree that the public announcement of the execution of this Agreement shall be in the form of a press release to be agreed upon by the Parties. Thereafter, Angiotech and Histogenics shall be free to use the information set forth in such press release in future public announcements. With respect to other public statements that reference the other Party hereto, including submissions to the Securities and Exchange Commission, Canadian Securities Administrators or stock exchange or market system on which its securities are listed, such statements shall be submitted to the referenced Party for review and approval, which approval shall not be unreasonably withheld or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publications</u>. The Parties agree that neither Party will publish or present the results of studies carried out that relate to CT3 without the opportunity for prior review and approval by the other, with such approval not to be unreasonably withheld, conditioned or delayed. The publishing Party shall provide the other Party with the opportunity to review any proposed abstracts, manuscripts or presentations (including information to be presented orally) covering information arising from the use of the Licensed Technology under this Agreement, and not previously disclosed, at least [***] prior to the intended submission for publication or (if not to be submitted first for publication) presentation. Each Party agrees, upon written request from the other, that it will not submit any such abstract or manuscript for publication or to make such presentation until, (a) the publishing Party has removed any Confidential Information as requested by the other Party, or (b) the other Party is given a reasonable period of time to secure patent protection for any material in such publication or presentation which it believes is patentable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinical Data</u>. To the extent permitted by applicable law and regulations, Histogenics shall provide to Angiotech in a timely manner any and all Clinical Data related to CT3 generated by or on behalf of Histogenics or its permitted sublicensees within [***] of the generation of any such Clinical Data.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Representations and Covenants.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties</u>. Angiotech and Histogenics each represent and warrant to the other that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 8 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization &amp; Power</u>. It is a corporation duly organized and validly existing under the laws of its place of incorporation and has all requisite corporate power and authority to enter into this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization</u>. It is duly authorized by all requisite action to execute, deliver and perform this Agreement and to consummate the transactions contemplated hereby, and that the same do not conflict or cause a default with respect to its obligations under any other agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Execution &amp; Delivery</u>. It has duly executed and delivered this Agreement, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Laws, Rules &amp; Regulations</u>. It shall and shall cause its Affiliates and permitted sublicensees to, comply with all laws, rules and regulations applicable to the performance of its obligations hereunder, including, to the extent applicable to such Party, the discovery, development, pre-clinical and clinical testing, manufacture, distribution, import, export and sale of the Eligible Product(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiotech Representations and Warranties</u>. Subject to Section 6.3, Angiotech represents and warrants to Histogenics that as of the Effective Date, except as otherwise set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> hereto:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Angiotech Controls the Licensed Patent Rights free of any liens or encumbrances and such Licensed Patent Rights include all of the rights Controlled by Angiotech and all of its Affiliates related to CT3;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>As of the Effective Date, Angiotech warrants that it has no actual knowledge of (a) prior art or inequitable conduct that would invalidate the patents listed in Exhibit A or other rights granted hereunder, or (b) any patents or patent applications, claiming inventions by the inventors of the Licensed Technology, which are controlled by Angiotech or any of its Affiliates, that are not included on Exhibit A attached hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>To the knowledge of the Senior Staff at Angiotech Parent, Angiotech and/or Angiotech Parent have not received any notice from any Person claiming to have any right, title or interest in or to the Licensed Patent Rights in the Field; and,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Angiotech has not entered into, and is not aware of, any outstanding options, licenses or agreements relating to the Licensed Patent Rights for use in Eligible Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclaimer</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>ANGIOTECH DOES NOT WARRANT THE VALIDITY OF THE LICENSED PATENTS AND MAKES NO REPRESENTATIONS WHATSOEVER WITH REGARD TO THE SCOPE OF THE LICENSED TECHNOLOGY OR THAT THE LICENSED TECHNOLOGY MAY BE EXPLOITED BY HISTOGENICS AND ITS AFFILIATES AND PERMITTED SUBLICENSEES WITHOUT INFRINGING THE INTELLECTUAL PROPERTY RIGHTS OF OTHERS. ANGIOTECH EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED OR EXPRESS WARRANTIES AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE LICENSED TECHNOLOGY. IN NO EVENT SHALL A PARTY BE LIABLE TO THE OTHER FOR INDIRECT, PUNITIVE, SPECIAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES OF ANY KIND, INCLUDING LOSS OF PROFITS AND LOSS OR INTERRUPTION OF BUSINESS, PROVIDED HOWEVER THAT THE FOREGOING PROVISION SHALL NOT BE CONSTRUED TO LIMIT A PARTY&#8217;S INDEMNIFICATION OBLIGATIONS UNDER SECTION 7.3 OF THIS AGREEMENT FOR THIRD PARTY CLAIMS WHICH MAY INCLUDE INDIRECT, SPECIAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY AND OTHER TYPES OF DAMAGES.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringement, Indemnity and Insurance</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notification</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">By Histogenics</u>. With respect to any Licensed Patent Rights, Histogenics shall notify Angiotech in writing of any alleged or threatened infringement of such Licensed Patent Rights of which it becomes aware, and shall provide to Angiotech available evidence thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 9 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">By Angiotech</u>. With respect to any Licensed Patent Rights in the Field, Angiotech shall notify Histogenics in writing of any alleged or threatened infringement of such Licensed Patent Rights of which it becomes aware, and shall provide to Histogenics available evidence thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defense and Enforcement of Licensed Patent Rights</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defense of Declaratory Judgment Action</u>. Angiotech shall be solely responsible, at its own expense, for defending any assertion of invalidity or unenforceability of the Licensed Patent Rights worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Litigation Actions</u>. [***] but not the obligation, to take actions to terminate alleged infringement identified pursuant to Section 7.1 without litigation (including the sole right to grant a license to the alleged infringer outside of the Field) with respect to Licensed Patent Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Litigation Actions</u>. [***] but not the obligation, to commence and control any Action, at its own expense. If Angiotech, in its sole discretion, elects to not take any Action against any alleged infringement of the Licensed Patent Rights, [***] shall have the right to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recoveries</u>. Any damages or other recovery related to the Licensed Patent Rights, including compensatory and other non-compensatory damages or recovery actually received from a third party, shall belong [***] unless the matter is pursued by [***] pursuant to Section 7.2(c), above, in which event all damages and other recovery shall belong [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics Indemnity</u>. Histogenics and each of its Affiliates and permitted sublicensees shall indemnify and hold Angiotech, its Affiliates, and their respective current and former officers, inventors, directors, employees, medical and professional staff, consultants, contractors and agents, and their respective successors, heirs and assigns, (&#8220;Angiotech Indemnitees&#8221;) harmless from and against any and all liability, damage, loss, cost (including reasonable attorneys&#8217; fees and expenses of litigation) and expense incurred, (a &#8220;Loss&#8221;) resulting from or imposed upon the Angiotech Indemnitees or any of them by any third party in connection with any claims, suits, actions, demands or judgments, including claims for bodily injury or property damage, (i) relating to the use of the Licensed Technology and/or the development, manufacture, use, storage, handling, distribution or sale of any Eligible Product by or on behalf of Histogenics or its Affiliates or permitted sublicensees, or their respective employees, consultants, contractors and agents, (ii) due to a breach of this Agreement by Histogenics, its Affiliates or permitted sublicensees, or (iii) due to the negligence or willful misconduct of Histogenics, its Affiliates or permitted sublicensees or their respective employees, consultants, contractors and agents; provided, however, that the foregoing indemnity shall not apply to any Loss to the extent that such Loss was caused by negligent or willful misconduct, or a breach of this Agreement, by Angiotech or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiotech Indemnity</u>. Angiotech shall indemnify and hold Histogenics and its Affiliates, and their respective current and former officers, inventors, directors, employees, medical and professional staff, consultants, contractors and agents, and their respective successors, heirs and assigns, (&#8220;Histogenics Indemnitees&#8221;) harmless from and against any and all Losses, resulting from or imposed upon the Histogenics Indemnitees or any of them by any third party in connection with any claims, suits, actions, demands or judgments, including any claim of bodily injury or property damage, (i) relating to the development, manufacture, use, storage, handling, distribution or sale of any product (other than Eligible Products) by Angiotech or its licensees or sublicensees (other than Histogenics and its Affiliates), (ii) due to a breach of this Agreement by Angiotech or its Affiliates, or (iii) due to the negligence or willful misconduct of Angiotech, its Affiliates or their respective employees, consultants, contractors and agents; provided, however, that the foregoing indemnity shall not apply to any Loss to the extent that such Loss was caused by negligent or willful misconduct, or a breach of this Agreement, by Histogenics or its Affiliates or permitted sublicensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Claims Procedures</u>. A Party entitled to be indemnified by the other Party (an &#8220;Indemnified Party&#8221;) pursuant to Section 7.3(a) or (b) hereof shall give written notice to the other Party (the &#8220;Indemnifying Party&#8221;) promptly after such Indemnified Party has actual knowledge of any threatened or asserted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 10 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom, provided:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting there from, shall be approved by the Indemnified Party (which approval shall not be unreasonably withheld or delayed), and the Indemnified Party may participate in such defense at such Indemnified Party&#8217;s expense (unless (A) the employment of counsel by such Indemnified Party has been authorized by the Indemnifying Party; or (B) the Indemnified Party shall have reasonably concluded that there may be a conflict of interest between the Indemnifying Party and the Indemnified Party in the defense of such action, in each of which cases the Indemnifying Party shall pay the reasonable fees and expenses of one law film serving as counsel for the Indemnified Party, which law film shall be subject to approval, not to be unreasonably withheld or delayed, by the Indemnifying Party);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Agreement to the extent that such failure to give notice did not result in prejudice to the Indemnifying Party or the Indemnifying Party&#8217;s insurer;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font>the Indemnifying Party, in the defense of any such claim or litigation, shall not, except with the approval of the Indemnified Party (which approval shall not be unreasonably withheld or delayed), consent to entry of any judgment or enter into any settlement which, (A) would result in injunctive or other relief being imposed against the Indemnified Party; or (B) does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation; and (iv) the Indemnified Party shall furnish such information regarding itself or the claim in question as the Indemnifying Party may reasonably request in writing, and shall be reasonably required in connection with the defense of such claim or litigation resulting there from.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</u>. Histogenics shall, at all times during the Term and until five (5) years after expiration of the last batch of Eligible Products sold or manufactured hereunder by or for Histogenics or its Affiliates, obtain and maintain at its own cost and expense, comprehensive commercial liability insurance, including, but not limited to, product liability and contractual liability insurance, and errors and omissions coverage, with respect to its activities hereunder from a reputable and financially secure insurance carrier. Such insurance shall be in such amounts and subject to such deductibles as the Parties may agree based upon standards prevailing in the industry at the time, but under no circumstances shall be less than, (a) prior to regulatory approval, the statutorily required minimum insurance level provided for in the jurisdiction in which the clinical trial or other research is being completed, and (b) after the First Commercial Sale in a country, the minimum that is customary in that country for similar products being sold in similar markets. Upon the written request of Angiotech, Histogenics shall provide copies of its Certificates of Insurance. Each policy will be endorsed to provide that the insurers will use reasonable efforts to give Angiotech, or its designee; not less than thirty (30) days prior written notice of any cancellation or material change in coverage. If Histogenics fails to place or maintain insurance as required under this Agreement, Angiotech or its designee may place and maintain such policy and all premium and other costs incurred by Angiotech or its designee shall be paid by Histogenics to Angiotech or its designee on demand.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term and Termination</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.1</font></font>The term of this Agreement shall, subject to the early termination provisions specifically provided for herein, begin on the Effective Date and end upon the expiration date of the last to expire United States or foreign patent included in the Licensed Patent Rights, including any United States or foreign patents which become part of the Licensed Patent Rights after the date of this Agreement as provided for herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Early Termination by Angiotech</u>. Notwithstanding the foregoing, and subject to the limitations set forth below, Angiotech shall be entitled in the following circumstances to terminate this Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Breach</u>. In the event that Histogenics materially breaches this Agreement, Angiotech shall have the right, at its sole election, to terminate this Agreement upon thirty (30) days, or ten (10) days in the case of breach for non-payment, prior written notice to Histogenics; provided, however, that if</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 11 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Histogenics shall cure the breach or default within the thirty (30) or the ten (10) day period, as applicable, all such licenses and agreements shall continue in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insolvency, Bankruptcy</u>. In the event that Histogenics files a petition in bankruptcy or if an involuntary petition shall be filed against it and such petition shall not be dismissed within sixty (60) days, or if it shall become insolvent or admit its inability to pay its debts when due, or if a receiver or guardian shall be appointed for it, then all licenses granted to such Party under this Agreement shall immediately terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Challenge of Licensed Patent Rights</u>. During the Term, should Histogenics or any of its Affiliates or permitted sublicensees (or any of successor or assign thereof) challenge the validity of any Licensed Patent Rights, or support, directly or indirectly, any such challenge to any Licensed Patent Rights, Angiotech shall be entitled to terminate this Agreement upon thirty (30) days prior written notice to Histogenics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics Merger or Acquisition</u>. Angiotech may, upon thirty (30) days written notice to Histogenics, terminate this Agreement throughout the Territory or on a country by country basis (to be determined at Angiotech&#8217;s sole discretion) if, (a) Histogenics is acquired or merges with a third party, and (b) the acquiring or merged-with third party or its Affiliate has developed or is marketing a Competitive Product prior to the acquisition of or merger with Histogenics, and (c) such acquisition or merger&#8217;s resulting or surviving entity fails to either continue to develop or to sell Eligible Product, at a level reasonably similar to the development or sale that was occurring prior to the acquisition or merger, during the six (6) month period following the acquisition or merger. If the acquiring or merged-with entity, or any of its Affiliates, has developed or is marketing a Competitive Product prior to the acquisition or merger, Histogenics shall notify Angiotech of its acquisition by or merger with such third party no later than twenty (20) days after the expiration of the six (6) month period following the acquisition or merger, and shall furnish information to Angiotech reasonably necessary for Angiotech to determine whether Eligible Products have been developed, made, used, sold, offered for sale, marketed, distributed, or imported by the surviving entity or Histogenics during the six (6) month period following the acquisition or merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="white-space:pre-wrap;">Notwithstanding Section 8.1(d), Angiotech shall not have the right to terminate this Agreement in the event that, (i) Histogenics states in the notice of acquisition or merger required herein that the resulting or surviving entity or its Affiliate(s), as applicable, has made a binding commitment to discontinue the development or marketing of the Competitive Product, as the case may be, or to divest itself of such Competitive Product, and (ii) the resulting  or surviving entity, or its Affiliate(s), in fact discontinues development or marketing, as the case may be, or divests itself of such Competitive Product within twelve (12) months after the consummation of the acquisition or merger. Angiotech&#8217;s rights hereunder to give notice terminating this Agreement pursuant to this Section 8.1(d) shall lapse: (x) nine (9) months after the date of consummation of the acquisition or merger, or (y) three (3) months after Angiotech&#8217;s receipt of the aforementioned notice of acquisition or merger.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Early Termination by Histogenics</u>. Notwithstanding the foregoing, and subject to the limitations set forth below, Histogenics shall be entitled in the following circumstances to terminate this Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Breach</u>. In the event that Angiotech materially breaches this Agreement, Histogenics shall have the right, at its sole election, to terminate this Agreement upon thirty (30) days, or ten (10) days in the case of breach for non-payment, prior written notice to Angiotech; provided, however, that if Angiotech shall cure the breach or default within the thirty (30) or the ten (10) day period, as applicable, all such licenses and agreements shall continue in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insolvency, Bankruptcy</u>. In the event that Angiotech files a petition in bankruptcy or if an involuntary petition shall be filed against it and such petition shall not be dismissed within sixty (60) days, or if it shall become insolvent or admit its inability to pay its debts when due, or if a receiver or guardian shall be appointed for it, then all licenses granted to such Party under this Agreement shall immediately terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Upon Notice</u>. At Histogenics&#8217; election at any time upon at least one (1) year&#8217;s prior notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 12 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u>. Upon termination of this Agreement for any reason, each of Angiotech and Histogenics shall remain liable for those obligations that accrued with respect to such license prior to the effective date of the termination. Histogenics may, for a period of no longer than twelve (12) months after the effective date of the termination of the Histogenics License, complete and sell any or all Eligible Products that it can demonstrate were in the process of manufacture or in inventory on the effective date of the termination; provided, however, that Histogenics shall remain obligated to pay any applicable Revenue Share thereon as provided in this Agreement. Within thirty (30) days after receipt of notice of termination, Histogenics shall provide Angiotech with an accounting of Eligible Products then on hand and in process and its best estimate of when within the twelve (12) month period sales of such products will conclude. Angiotech shall then have the right, but not the obligation, to purchase the inventory of CT3 at the cost of such material to Histogenics.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute Resolution</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Negotiation of Parties</u>. In the event of any dispute, claim or controversy arising out of or relating to the interpretation of any provision of this Agreement, to the performance of either Party under this Agreement or to any other matter under this Agreement, including any action in tort, contract or otherwise, at equity or law (a &#8220;Dispute&#8221;), either Party may at any time provide the other Party written notice specifying the terms of such Dispute in reasonable detail. As soon as practicable after receipt of such notice, the Chief Executive Officers of both Angiotech and Histogenics shall meet at a mutually agreed upon time and location for the purpose of resolving such Dispute. They shall engage in good faith discussions and/or negotiations for a period of up to thirty (30) days to resolve the Dispute or negotiate an interpretation or revision of the applicable portion of this Agreement which is mutually agreeable to both Parties, without the necessity of formal procedures relating thereto. During the course of such discussion and/or negotiation, the Parties shall reasonably cooperate and provide information that is not materially confidential in order so that each of the Parties may be fully informed with respect to the issues in the Dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration</u>. In the event any Dispute is not resolved pursuant to Section 9.1, then the same shall be submitted by the Parties to binding arbitration by a single arbitrator in Seattle, Washington in accordance with the AAA rules. The judgment rendered by the arbitrator shall include costs of arbitration, reasonable attorneys&#8217; fees and reasonable costs for expert and other witnesses. Nothing in this Agreement shall be deemed as preventing either Party from seeking injunctive relief (or any other provisional remedy). Any arbitrator chosen hereunder shall have educational training and industry experience sufficient to demonstrate a reasonable level of relevant scientific, medical and industry knowledge.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">10.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Provisions</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies</u>. The Parties acknowledge and agree that, in the event of a breach or a threatened breach by either Party of this Agreement for which it will have no adequate remedy at law, the other Party may suffer irreparable damage and, accordingly, shall be entitled to injunctive and other equitable remedies to prevent or restrain such breach or threatened breach, without the necessity of posting any bond or surety, in addition to any other remedy they might have at law or at equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement shall be governed by and construed in accordance with the laws of the State of Washington in force therein without regard to its conflict of law rules. Subject to Article 9, each Party hereby irrevocably consents to the exclusive jurisdiction and venue of the courts of Washington in connection with any action or proceeding brought by either Party against the other Party arising out of or relating to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u>. It is contemplated that in the course of the performance of this Agreement each Party may, from time to time, disclose Confidential Information to the other. Each Party agrees that for the Term and for a period of five (5) years thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose, and will not use any Confidential Information except for the limited purposes set forth in this Agreement; provided, however, that no provision of this Agreement shall be construed to preclude such disclosure of Confidential Information as may be necessary or appropriate (a) to obtain from any governmental agency any necessary approval (subject to Section 5.6), (b) to file patent applications or obtain patents that are included in the Licensed Technology; provided, further, however, that the Party whose information is to be disclosed shall be notified as soon as possible and the Party that is being required to disclose such information shall, if requested by the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 13 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Party whose information is to be disclosed, use reasonable good faith efforts, at the expense of the requesting Party, to assist in seeking a protective order (or equivalent) with respect to such disclosure or otherwise avoid making such disclosure. The receiving Party will take all precautions as are reasonably necessary to prevent unauthorized access to, reproduction, duplication, disclosure or use of the other Party&#8217;s Confidential Information and shall only disclose the Confidential Information of the other Party to those of its officers, directors and employees, or to officers, directors and employees of its Affiliates, on a &#8220;need to know basis&#8221; provided each such officer, director or employees agrees in favor of the disclosing Party to be bound by the same obligations of secrecy and confidentiality that the receiving Party is bound to under this Agreement and provides further that the receiving Party shall be directly responsible to the disclosing Party for any losses or damages suffered as a result of the breach of such obligations by the receiving Party&#8217;s directors, officers or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment and Waiver</u>. No provision of or right under this Agreement shall be deemed to have been waived by any act or acquiescence on the part of any Party, its agents or employees, but only by an instrument in writing signed by an authorized officer of such Party. No waiver by either Party of any breach of this Agreement by the other Party shall be effective as to any other breach, whether of the same or any other term or condition and whether occurring before or after the date of such waiver.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trademarks</u>. During the Term, Histogenics shall have the right to market and advertise Eligible Products under their respective names, trademarks, trade names, labels, or other designations, provided however, that all packaging of CT3 included in the Eligible Products shall be marked with the trademark &#8220;[***]TM&#8221; (in a form to be provided by Angiotech, and as such trademark may be modified or substituted by Angiotech from time to time upon written notice to Histogenics). All respective names, trademarks, trade names, labels, or other designations used shall are, and the same shall remain, the property of their respective owners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patents</u>. Histogenics agrees to mark the CT3 or its packaging sold in the United States with all applicable U.S. patent numbers and similarly, when applicable, to indicate &#8220;Patent Pending&#8221; status. All CT3 manufactured in, shipped to, or sold in other countries shall be marked in such a manner as to protect and preserve the Licensed Patent Rights in such countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.6</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Contractors</u>. Each Party represents that it is acting on its own behalf as an independent contractor and is not acting as an agent for or on behalf of any third party. This Agreement and the relations hereby established by and between Angiotech and Histogenics do not constitute a partnership, joint venture, agency or contract of employment between them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.7</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u>. Without limitation to the rights set forth in Section 8.2(d) and (e), this Agreement and Histogenics&#8217; rights and obligations hereunder [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.8</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u>. This Agreement shall bind and inure to the benefit of the Parties and their respective successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.9</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. All communications hereunder shall be in writing and shall be deemed to have been duly given upon receipt by the addressee at the addresses set forth below, or such other address as either Party May specify by notice sent in accordance with this section:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:108pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">If to Histogenics:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Histogenics Corporation<br>100 Hospital Road<br>Malden, MA 02148<br>Attention: President<br>Fax: (781) 321-9763</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:108pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">With a copy to:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Brown Rudnick Berlack Israels LLP<br>One Financial Center<br>Boston, MA 02111</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 14 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 144pt;">Attention: [***]<br>Fax: (617) 856-8201</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:108pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">If to Angiotech:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Angiotech Biomaterials Corp.<br>1618 Station Street<br>Vancouver, BC, Canada V6A 1B6<br>Attention: Chief Business Officer<br>Fax: (604) 221-6915</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:108pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">With a copy to:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Angiotech Biomaterials Corp.<br>1618 Station Street<br>Vancouver, BC, Canada V6A 1B6<br>Attention: General Counsel<br>Fax: (604) 221-6915</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.10</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. In the event any provision of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof. The Parties agree that they will negotiate in good faith or will permit a court or arbitrator to replace any provision hereof so held invalid, illegal or unenforceable with a valid provision which is as similar as possible in substance to the invalid, illegal or unenforceable provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.11</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Captions</u>. Captions of the Sections and subsections of this Agreement are for reference purposes only and do not constitute teens or conditions of this Agreement and shall not limit or affect the tennis and conditions hereof,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.12</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Word Meanings</u>. Words such as <i style="font-style:italic;">herein</i>, <i style="font-style:italic;">hereinafter</i>, <i style="font-style:italic;">hereof</i> and <i style="font-style:italic;">hereunder</i> refer to this Agreement as a whole and not merely to a Section or paragraph in which such words appear, unless the context otherwise requires. The singular shall include the plural, and each masculine, feminine and neuter reference shall include and refer also to the others, unless the context otherwise requires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.13</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Agreement and the Warrant Agreement including all exhibits to both contain the entire understanding of the Parties with respect to the transactions and matters contemplated hereby, including without limitation any licensing of the Licensed Technology, supersedes all prior agreements and understandings relating to the subject matter hereof, and no representations, inducements, promises or agreements, whether oral or otherwise, between the Parties not contained herein or incorporated herein by reference shall be of any force or affect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.14</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rules of Construction</u>. The Parties agree that they have participated equally in the formation of this Agreement and that the language and terms of this Agreement shall not be presumptively construed against any of them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.15</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures of the Parties will have the same effect as original signatures. In making proof of this Agreement, it shall not be necessary to produce or account for more than one such counterpart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.16</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u>. The following provisions shall survive the termination of this Agreement: Section 3.8, Article 7, Article 9, Section 8.4 and Section 10.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.17</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance</u>. The Parties shall comply fully with all applicable laws and regulations in connection with their respective activities under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed and delivered by their respective duly authorized officers as of the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 15 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANGIOTECH BIOMATERIALS CORP.</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANGIODEVICE INTERNATIONAL GmbH</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Thomas Bailey</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Hans Peter Weber</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ J&#252;rg Dannecker</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Thomas Bailey</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Hans Peter Weber</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">J&#252;rg Dannecker</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: VP BD</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Managing Director</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: 06/08/05</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: 24 June 2005</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24 June 2005</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Laurence J Berlowitz Tarrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Laurence J Berlowitz Tarrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: 15 July 2005</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 16 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">EXHIBIT A</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Patent Rights</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 1 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="11" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANGIOTECH PATENT SCHEDULE</p></td></tr><tr><td colspan="11" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">PATENT FAMILY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANPI<br>REF.&#160;#</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PATENT<br>NUMBER</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TITLE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DATES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERNATIONAL<br>PATENTS&#160;AND<br>APPLICATIONS&#160;(PER<br>PATENT&#160;FAMILY)</p></td></tr><tr><td style="vertical-align:top;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:14.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">[***]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">EXHIBIT B</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warrant Agreement</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WARRANT </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">to purchase shares of common stock of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:14.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:85.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warrant No. CS-1</u></p></td><td style="vertical-align:bottom;width:85.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:85.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective Date:</p></td><td style="vertical-align:bottom;width:85.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 12, 2005</p></td></tr><tr><td style="vertical-align:bottom;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:85.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expiration Date:</p></td><td style="vertical-align:bottom;width:85.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 11, 2010</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This certifies that ANGIODEVICE INTERNATIONAL GmbH, a corporation organized and existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland, or their transferees or assigns (collectively, the &#8220;Holder&#8221;) for the agreed upon value of and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, shall be entitled to purchase from HISTOGENICS CORPORATION, a corporation organized and existing under the laws of Massachusetts, with principal offices at 100 Hospital Road, Malden, MA 02148 (the &#8220;Company&#8221;), [***] fully paid and nonassessable shares of the Company&#8217;s Common Stock (the &#8220;Common Stock&#8221;) which represent [***] of the fully diluted equity securities (inclusive of but not limited to all classes of common stock, preferred stock and any outstanding stock options or restricted stock) issued and outstanding as of the Effective Date as defined in the License Agreement (as defined below) for cash at a price of [***] per share (the &#8220;Exercise Price&#8221;) at any time, or from time to time, up to and including 5:00 p.m. Pacific time on the Expiration Date, upon the surrender to the Company at its principal place of business (or at such other location as the Company may advise the Holder in writing) of this Warrant properly endorsed, a Subscription Form in substantially the form attached hereto as <b style="font-weight:bold;">Exhibit A</b> duly filled in and signed and, as applicable, upon payment in cash or by check of the aggregate Exercise Price for the number of shares for which this Warrant is being exercised determined in accordance with the provisions hereof, or the surrender of the right to acquire the number of shares of Common Stock determined in accordance with Section 1.2. The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to adjustment as provided in Section 3 of this Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Warrant is being issued pursuant to the License Agreement between the Company and the Holder dated as of May 12, 2005 (the &#8220;License Agreement&#8221;). This Warrant is referred to as the &#8220;Warrant&#8221; in the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The number of shares of Common Stock shall be subject to increase based on the sale of the next [***] of equity securities by the Company as provided for in the License Agreement. Upon the occurrence of such event, this Warrant shall be cancelled and replaced with a new warrant of like tenor reflecting the additional shares of Common Stock which this Warrant entitles the Holder to purchase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Warrant is subject to the following terms and conditions:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">EXERCISE; ISSUANCE OF CERTIFICATES; PAYMENT FOR SHARES</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.1</b></font><b style="font-weight:bold;">General</b>. This Warrant is exercisable at the option of the holder of record hereof at any time, or from time to time, up to the Expiration Date for all or any part of the shares of Common Stock (but not for a fraction of a share), which may be purchased hereunder. The Company agrees that the shares of Common Stock purchased under this Warrant shall be and are deemed to be issued to the Holder hereof as the record owner of such shares as of the close of business on the date on which this Warrant, properly endorsed, the completed and executed Form of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subscription and appropriate payment for such shares shall have each been delivered to the Company at its principal place of business. Certificates for the shares of Common Stock so purchased, together with any other securities or property to which the Holder is entitled upon such exercise, shall be delivered to the Holder by the Company at the Company&#8217;s expense within a reasonable time after the rights represented by this Warrant have been so exercised, and in any event, within five (5) business days of such exercise. In case of a purchase of less than all the shares which may be purchased under this .Warrant, the Company shall cancel this Warrant and execute and deliver a new Warrant or Warrants of like tenor for the balance of the shares purchasable under the Warrant surrendered upon such purchase to the Holder hereof within a reasonable time. Each stock certificate so delivered shall be in such denominations of Common Stock as may be requested by the Holder hereof</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">SHARES TO BE FULLY PAID; RESERVATION OF SHARES</b>. The Company covenants and agrees that all shares of Common Stock which may be issued upon the proper exercise of the rights represented by this Warrant and payment of the Exercise Price will, upon issuance, be duly authorized, validly issued, fully paid and nonassessable and free from all preemptive rights of any shareholder and free of all taxes, liens and charges with respect to the issue thereof. The Company further covenants and agrees that, during the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved, for the purpose of issue or transfer upon exercise of the subscription rights evidenced by this Warrant, a sufficient number of shares of authorized but unissued Common Stock, or other securities and property, when and as required to provide for the exercise of the rights represented by this Warrant. The Company will take all such action as may be necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any domestic securities exchange upon which the Common Stock may be listed; provided, however, that the Company shall not be required to effect a registration under Federal or State securities laws with respect to such exercise. The Company will not take any action which would result in any adjustment of the Exercise Price (as set forth in Section 3 hereof) if the total number of shares of Common Stock issuable after such action upon exercise of all outstanding warrants, together with all shares of Common Stock then outstanding and all shares of Common Stock then issuable upon exercise of Common Stock Warrant all options and upon the conversion of all convertible securities and other equity purchase rights then outstanding, would exceed the total number of shares of Common Stock then authorized by the Company&#8217;s Articles/Certificate of Incorporation (the &#8220;Company Charter&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF SHARES</b>. The Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time upon the occurrence of certain events described in this Section 3. Upon each adjustment of the Exercise Price, the Holder of this Warrant shall thereafter be entitled to purchase, at the Exercise Price resulting from such adjustment, the number of shares obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of shares purchasable pursuant hereto immediately prior to such adjustment, and dividing the product thereof by the Exercise Price resulting from such adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.1</b></font><b style="font-weight:bold;">Subdivision or Combination of Stock</b>. In case the Company shall at any time subdivide its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision shall be proportionately reduced, and conversely, in case the outstanding shares of Common Stock of the Company shall be combined into a smaller number of shares (by reverse stock split or otherwise), the Exercise Price in effect immediately prior to such combination shall be proportionately increased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.2</b></font><b style="font-weight:bold;">Dividends in Common Stock, Other Stock, Property, Reclassification</b>. If at any time or from time to time the Holders of Common Stock (or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received or become entitled to receive, without payment therefor,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Common Stock or any shares of stock or other securities which are at any time directly or indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>any cash paid or payable otherwise than as a cash dividend, or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Common Stock or additional stock or other securities or property (including cash) by way of spinoff, split-up, reclassification, combination of shares or similar corporate rearrangement, (other than shares of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Common Stock issued as a stock split or adjustments in respect of which shall be covered by the terms of Section 3.1 above), then, and in each such case, the Holder hereof shall, upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common Stock receivable thereupon, and without payment of any additional consideration therefor, the amount of stock and other securities and property (including cash in the cases referred to in clause (b) above and this clause (c)) which such Holder would hold on the date of such exercise had he been the holder of record of such Common Stock as of the date on which holders of Common Stock received or became entitled to receive such shares or all other additional stock and other securities and property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.3</b></font><b style="font-weight:bold;">Reorganization, Consolidation, Merger or Sale</b>. If any recapitalization or reorganization of the capital stock of the Company, or any consolidation or merger of the Company with another corporation, or the sale of all or substantially all of its assets or other transaction shall be effected in such a way that holders of Common Stock shall be entitled to receive stock, securities, or other assets or property (an &#8220;Organic Change&#8221;), then, as a condition of such Organic Change, lawful and adequate provisions shall be made by the Company whereby the Holder hereof shall thereafter have the right to purchase and receive (in lieu of the shares of the Common Stock of the Company immediately theretofore purchasable and receivable upon the exercise of the rights represented by this Warrant) such shares of stock, securities or other assets or property as may be issued or payable with respect to or in exchange for a number of outstanding shares of such Common Stock equal to the number of shares of such stock immediately theretofore purchasable and receivable upon the exercise of the rights represented by this Warrant. In the event of any Organic Change, appropriate provision shall be made by the Company with respect to the rights and interests of the Holder of this Warrant to the end that the provisions hereof (including, without limitation, provisions for adjustments of the Exercise Price and of the number of shares purchasable and receivable upon the exercise of this Warrant) shall thereafter be applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.4</b></font><b style="font-weight:bold;">Certain Events</b>. If any change in the outstanding Common Stock of the Company or any other event occurs as to which the other provisions of this Section 3 are not strictly applicable or if strictly applicable would not fairly protect the purchase rights of the Holder of the Warrant in accordance with such provisions, then the Board of Directors of the Company shall make an adjustment in the number and class of shares available under the Warrant, the Exercise Price or the application of such provisions, so as to protect such purchase rights as aforesaid. The adjustment shall be such as will give the Holder of the Warrant upon exercise for the same aggregate Exercise Price the total number, class and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.5</b></font><b style="font-weight:bold;">Notices of Change</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Upon any adjustment in the number or class of shares subject to this Warrant and/or of the Exercise Price, the Company shall give reasonable written notice thereof to the Holder, setting forth in reasonable detail and certifying the calculation of such adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>The Company shall give written notice to the Holder at least 10 business days prior to the date on which the Company closes its books or takes a record for determining rights to receive any dividends or distributions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>The Company shall also give written notice to the Holder at least 10 business days prior to the date on which an Organic Change shall take place.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">ISSUE TAX</b>. The issuance of certificates for shares of Common Stock upon the exercise of the Warrant shall be made without charge to the Holder of the Warrant for any issue tax (other than any applicable income taxes) in respect thereof; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than that of the Holder of the Warrant being exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-weight:bold;">CLOSING OF BOOKS</b>. The Company will not unreasonably close its transfer books in any manner which interferes with the timely exercise of this Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;">NO VOTING OR DIVIDEND RIGHTS; LIMITATION OF LIABILITY</b>. Nothing contained in this Warrant shall be construed as conferring upon the Holder hereof the right to vote or to consent or to receive notice as a shareholder of the Company or any other matters or any rights whatsoever as a shareholder of the Company. No dividends or interest shall be payable or accrued in respect of this Warrant or the interest represented hereby or the shares purchasable hereunder until, and only to the extent that this Warrant shall have been exercised. No provisions hereof, in the absence of affirmative action by the holder to purchase shares of Common Stock, and no mere enumeration herein of the rights or privileges of the holder hereof, shall give rise to any liability of such Holder for the Exercise Price or as a shareholder of the Company, whether such liability is asserted by the Company or by its creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-weight:bold;">WARRANTS NOT TRANSFERABLE</b>. This Warrant is not transferable, in whole or in part without the prior written consent of the Company, except as otherwise specifically provided for herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-weight:bold;">REGISTRATION RIGHTS</b>. The Holder has the right to cause the Company to register the Common Stock issued upon exercise hereof, under the Securities Act and any blue sky or securities laws of any jurisdictions within the United States at the time and in the manner specified in this Section 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.1</b></font><b style="font-weight:bold;">Registrable Securities</b>. As used herein the term &#8220;Registrable Security&#8221; means the shares of Common Stock, and any shares issued upon any stock split or stock dividend in respect of such shares of Common Stock; provided, however, that with respect to any particular Registrable Security, such security shall cease to be a Registrable Security when, as of the date of determination, (i) it has been effectively registered under the Securities Act and disposed of pursuant thereto, (ii) registration under the Securities Act is no longer required for subsequent public distribution of such security under Rule 144(k) promulgated under the Securities Act or otherwise, or (iii) it is no longer held by the Holder. The term &#8220;Registrable Securities&#8221; means any and/or all of the securities falling within the foregoing definition of a &#8220;Registrable Security.&#8221; In the event of any merger, reorganization, consolidation, recapitalization or other change in corporate structure affecting the Common Stock, such adjustment shall be made in the definition of &#8220;Registrable Security&#8221; as is appropriate in order to prevent any dilution or enlargement of the rights granted pursuant to this Section 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.2</b></font><b style="font-weight:bold;">Piggyback Registration</b>. In the event that the Company proposes to prepare and file any new registration statement or post-effective amendments with the intent of issuing a public offering (including, but not limited to, registration statements relating to secondary offerings of securities of the Company, but excluding registration statements relating to any employee benefit plan or a corporate reorganization) (for purposes of this Section 7, collectively, the &#8220;Registration Statement&#8221;), it will give written notice of its intention to do so by certified mail, return receipt requested (&#8220;Notice&#8221;), at least thirty (30) business days prior to the filing of each such Registration Statement, to the Holder. Upon the written request of the Holder, made within twenty (20) business days after receipt by the Holder of the Notice, that the Company include any of the Holder&#8217;s Registrable Securities in the proposed Registration Statement, the Company shall use its best efforts to effect the registration under the Securities Act of the Registrable Securities which it has been so requested to register (&#8220;Piggyback Registration&#8221;); at the Company&#8217;s sole cost and expense and at no cost or expense to (except as provided in Section 8.3(a) hereof). If the Holder decides not to include all of its Registrable Securities in any Registration Statement thereafter filed by the Company, the Holder shall nevertheless continue to have the right to include any Common Stock in any subsequent Registration Statement or Registration Statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a Registration Statement under which the Company gives notice under this Section 8.2 is for an underwritten offering, then the Company shall so advise the Holder. In such event, the right of the Holder&#8217;s Common Stock to be included in a registration pursuant to this Section 8.2 shall be conditioned upon Holder&#8217;s participation in such underwriting and the inclusion of Holder&#8217;s Common Stock in the underwriting. If Holder proposes to distribute any Common Stock through such underwriting, Holder shall enter into an underwriting agreement in customary form with the managing underwriter or underwriter(s) selected for such underwriting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the provisions of this Section 8.2, the Company shall have the right at any time after it shall have given written notice pursuant to this Section 8.2 (irrespective of whether any written request for inclusion of Registrable Securities shall have already been made) to elect not to file any such proposed Registration Statement, or to withdraw the same after the filing but prior to the effective date thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.3</b></font><b style="font-weight:bold;">Covenants of the Company With Respect to Registration</b>. The Company covenants and agrees as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The Company shall pay all costs, fees and expenses (other than underwriting fees, discounts and nonaccountable expense allowance applicable to the Registrable Securities and fees and expenses of counsel retained by the Holder) in connection with all Registration Statements including, without limitation, the Company&#8217;s legal and accounting fees, printing expenses, and blue sky fees and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>The Company will use its reasonable best efforts to take all necessary action which may be required in qualifying or registering the Registrable Securities included in the Registration Statement for offering and sale under the securities or blue sky laws of such states as are reasonably requested by the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>To the fullest extent permitted by law, the Company will indemnify and hold the Holder harmless against any losses, claims, damages, or liabilities to which it may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a &#8220;Violation&#8221;) by the Company: (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection with the offering covered by the Registration Statement; and the Company will reimburse the Holder for any legal or other expenses reasonably incurred by it in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this Section shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished to it expressly for use in connection with such registration by the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Promptly after receipt by an indemnified party under this Section of notice of the commencement of any action (including any governmental action), such indemnified party shall, if a claim in respect thereof is to be made against any indemnifying party under this Section, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying party; and provided further, that if there is more than one indemnified party, the indemnifying party shall pay for the fees and expenses of one counsel for any and all indemnified parties to be mutually agreed upon by such indemnified parties, unless representation of an indemnified party by the counsel retained by the other indemnified parties would be inappropriate due to actual or potential differing interests between such indemnified parties. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if materially prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(e) In the event that the indemnification provided for in this Section 8 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted by applicable law, contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the Violation(s) that resulted in such loss, claim, damage or liability, as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to,&#8217; among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">relates to information supplied by the indemnifying party or by the indemnified party and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. No person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11 of the Securities Act) shall be entitled to contribution from any person or entity that is not found to have been guilty of such fraudulent misrepresentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-weight:bold;">FURTHER REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Articles and Bylaws</u>. The Company has made available to Holder true, complete and correct copies of the Company Charter and Bylaws, as amended, through the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Due Authority</u>. The execution and delivery by the Company of this Warrant and the performance of all obligations of the Company hereunder, including the issuance to Holder of the right to acquire the shares of Common Stock, have been duly authorized by all necessary corporate action on the part of the Company, and the Warrant is not inconsistent with the Company Charter or Bylaws and constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consents and Approvals</u>. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Warrant, except for any filing required by applicable federal and state securities laws, which filing will be effective by the time required thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-weight:bold;">REPRESENTATIONS AND COVENANTS OF THE HOLDER</b>. This Warrant has been entered into by the Company in reliance upon the following representations and covenants of the Holder:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Purpose</u>. The Warrant and the Common Stock issuable upon exercise of the Warrant will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Holder has no present intention of selling or engaging in any public distribution of the same except pursuant to a registration or exemption pursuant to the 1933 Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Private Issue</u>. The Holder understands (i) that the Warrant and the Common Stock issuable upon exercise of this Warrant is not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant will be exempt from the registration and qualifications requirements thereof pursuant to Section 4(2) of the 1933 Act and any applicable state securities laws, and (ii) that the Company&#8217;s reliance on such exemption is predicated on the representations set forth in this Section 10.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disposition of Holders Rights</u>.: In no event will the Holder make a disposition of the Warrant or the Common Stock issuable upon exercise of the Warrant unless and until (i) the Company shall have approved of the proposed disposition, and (ii) if requested by the Company, it shall have furnished the Company with an opinion of counsel (which counsel may either be inside or outside counsel to the Holder) satisfactory to the Company and its counsel to the effect that (A) appropriate action necessary for compliance with the 1933 Act has been taken, or (B) an exemption from the registration requirements of the 1933 Act is available. Notwithstanding the foregoing, the restrictions imposed upon the transferability of any of its rights to acquire Common Stock or the Common Stock issuable on the exercise of such rights do not apply to transfers from the beneficial owner of any of the aforementioned securities to its nominee or from such nominee to its beneficial owner, and shall terminate as to any particular share of Common Stock when (1) such security shall have been effectively registered under the 1933 Act and sold by the holder thereof in accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the 1933 Act, or (3) a letter shall have been issued to the Holder at its request by the staff of the Securities and Exchange Commission or a ruling shall have been issued to the Holder at its request by such Commission stating that no action shall be recommended by such staff or taken by such Commission, as the case may be, if such security is transferred without registration under the 1933 Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required. Whenever the restrictions imposed hereunder shall terminate, as hereinabove provided, the Holder or holder of a share of Common Stock then outstanding as to which such restrictions have</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">terminated shall be entitled to receive from the Company, without expense to such holder, one or more new certificates for the Warrant or for such shares of Common Stock not bearing any restrictive legend.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Risk</u>. The Holder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Risk of No Registration</u>. The Holder understands that if the Company does not register with the Securities and Exchange Commission pursuant to Section 12 of the 1933 Act, or file reports pursuant to Section 15(d), of the Securities Exchange Act of 1934 (the &#8220;1934 Act&#8221;), or if a registration statement covering the securities under the 1933 Act is not in effect when it desires to sell (i) the Warrant, or (ii) the Common Stock issuable upon exercise of the Warrant, it may be required to hold such securities for an indefinite period. The Holder also understands that any sale of the Warrant or the Common Stock issuable upon exercise of the Warrant which might be made by it in reliance upon Rule 144 under the 1933 Act may be made only in accordance with the terms and conditions of that Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accredited Investor</u>. Holder is an &#8220;accredited investor&#8221; within the meaning of Rule 501 of Regulation D under the 1933 Act, as presently in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-weight:bold;">MODIFICATION AND WAIVER</b>. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-weight:bold;">NOTICES</b>. Any notice, request or other document required or permitted to be given or delivered to the holder hereof or the Company shall be delivered or shall be sent by an established overnight service provider (e.g., Federal Express), or registered or certified mail, postage prepaid, to each such holder at its address as shown on the books of the Company or to the Company at the address indicated therefor in the first paragraph of this Warrant or such other address as either may from time to time provide to the other in accordance with this Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-weight:bold;">BINDING EFFECT ON SUCCESSORS</b>. This Warrant shall be binding upon any corporation succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company&#8217;s assets. All of the obligations of the Company relating to the Common Stock issuable upon the exercise of this Warrant shall survive the exercise and termination of this Warrant. All of the covenants and agreements of the Company shall inure to the benefit of the successors and assigns of the holder hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></font><b style="font-weight:bold;">DESCRIPTIVE HEADINGS AND GOVERNING LAW</b>. The description headings of the several sections and paragraphs of this Warrant are inserted for convenience only and do not constitute a part of this Warrant. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of Delaware, without giving effect to principles of conflicts of laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15.</b></font><b style="font-weight:bold;">LOST WARRANTS</b>. The Company represents and warrants to the Holder hereof that upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction, or mutilation of this Warrant and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to the Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant, the Company, at its expense, will make and deliver a new Warrant, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16.</b></font><b style="font-weight:bold;">FRACTIONAL SHARES</b>. No fractional shares shall be issued upon exercise of this Warrant. The Company shall, in lieu of issuing any fractional share, pay the holder entitled to such fraction a sum in cash equal to such fraction multiplied by the then effective Exercise Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its officers, thereunto duly authorized.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: May 12, 2005</p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Corporate Seal)</p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Laurence Berlowitz</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laurence Berlowitz Tarrant, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President</p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attest:</p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Laurence J B Tarrant</p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Secretary</p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subscription Form</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To:</p></td><td style="vertical-align:bottom;width:45.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:4.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The undersigned hereby subscribes for shares of Common Stock covered by this Warrant. The certificate(s) for such shares shall be issued in the name of the undersigned or as otherwise indicated below:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature</p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:41.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td style="vertical-align:bottom;width:41.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[OR]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net Issue Election Notice</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To:</p></td><td style="vertical-align:bottom;width:45.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:4.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The undersigned hereby elects under Section 4 to surrender the right to purchase shares of Common Stock pursuant to this Warrant. The certificate(s) for the shares issuable upon such net issue election shall be issued in the name of the undersigned or as otherwise indicated below.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature</p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:41.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td style="vertical-align:bottom;width:41.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>5
<FILENAME>tmb-20250331xex10d30.htm
<DESCRIPTION>EX-10.30
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 03:59:38 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.30</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential.  Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDMENT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(1st Amendment)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Amendment to License Agreement, effective August 31, 2007, is by and among:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiotech Pharmaceuticals</b> (US), Inc., a corporation organized and existing under the laws of Washington, with principal offices at North Bend, WA (&#8220;Angiotech US&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiodevice International GmbH</b>, a corporation organized and existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (&#8220;Angiodevice&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Histogenics Corporation</b>, a corporation organized and existing under the laws of Delaware (formerly under the laws of Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (&#8220;Histogenics&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WITNESSETH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech Biomaterials Corp (&#8220;Biomaterials&#8221;), Angiodevice and Histogenics entered into that certain License Agreement effective as of May 12, 2005 pursuant to which Angiotech licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3 (the &#8220;Agreement&#8221;), a copy of which is attached hereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, effective as of November 4, 2005, all of the assets of Biomaterials were sold to Angiotech US and Biomaterials was wound up (&#8220;Angiodevice&#8221; and &#8220;Angiotech US&#8221; shall be collectively referred to as &#8220;Angiotech&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, in connection with such sale of assets, Biomaterials assigned the Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials under the Agreement as if it were the original party thereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US represents and warrants to Histogenics that Angiotech US has assumed all rights and obligations of Biomaterials under the Agreement; and,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics have determined that it is in their best interests to amend certain provisions of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW</b>, <b style="font-weight:bold;">THEREFORE</b>, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics (Angiotech US, Angiodevice and Histogenics shall be individually referred to as &#8220;Party&#8221; and collectively as &#8220;Parties&#8221;) hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. Capitalized terms shall have the meanings set forth in the Agreement. The following defined terms shall be added to Section 1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u> of the Agreement in the correct alphabetical order:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conversion to Exclusivity</u>&#8221; shall have the meaning ascribed to it in Section 3.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusivity Deadline</u>&#8221; shall have the meaning ascribed to it in Section 3.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusivity Payment</u>&#8221; shall have the meaning ascribed to it in Section 3.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Share Reduction Payment</u>&#8221; shall have the meaning ascribed to it in Section 3.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Grant</u>. Section 2.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant</u> of the Agreement is hereby amended to include the following additional sentence:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Prior to the Exclusivity Deadline as defined in Section 3.2(a) below, and after the Exclusivity Deadline if Histogenics pays Angiotech the Exclusivity Payment, also as defined in Section 3.2(a) below, Angiotech shall not grant to any other Person any rights to or license under the Licensed Technology to make, have made, use, offer to sell, sell or import any products containing CT3 for use in the Field in the Territory.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Manufacture</u>. The second sentence of Section 2.4(c) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing</u> of the Agreement is hereby changed and replaced with the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;In the event that Histogenics intends to have a third party manufacture CT3, Histogenics shall [***].&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supply Back</u>. Section 2.4(e)(iv) is hereby added to the Agreement as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(iv) Notwithstanding anything to the contrary in Section 2.4, Angiotech hereby acknowledges and confirms that Histogenics may sublicense to [***] (currently a subsidiary of [***]) the right to manufacture CT3 or any components of CT3, including methylated collagen. Further, Angiotech acknowledges that [***] is using certain equipment (as more fully described and listed in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u> (the &#8220;[***]&#8221;)) owned by Angiotech in connection therewith, and Angiotech confirms that [***] may continue to use such equipment in connection with the manufacture of CT3 or any of its components. Histogenics hereby agrees to purchase the [***] at the agreed to purchase price of [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supply Back</u>. Section 2.4(e)(i) of the Agreement is hereby deleted in its entirety and replaced with the following new Section 2.4(e)(i):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;(i) Histogenics shall use commercially reasonable efforts to supply CT3 to Angiotech at [***], for use only for research and in preclinical and clinical studies by Angiotech. Histogenics shall not be required to produce any quantities of CT3 for use in commercial products by Angiotech except, (i) where Angiotech has provided Histogenics with at least [***] lead time for delivery of CT3 and, (ii) where the amount of CT3 ordered by Angiotech does not exceed [***] of the amount to be produced by Histogenics during that [***] period. In the event that [***] of the amount of CT3 being produced by Histogenics is not sufficient to fill an order by Angiotech, Histogenics shall deliver the remaining portions of the order from subsequent production runs. For further clarification, Angiotech shall never be entitled to more than [***] of a production run, except at the sole discretion of Histogenics.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment Purchase</u>. A new section, Section 2.4(h) is hereby added to the Agreement as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(h) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment Purchase</u>. Histogenics hereby agrees to purchase for [***] from Angiotech the equipment used in the making of CT3 located at [***], that is the property of Angiotech. A list of such equipment is provided in Exhibit C. Histogenics shall be required to pay to Angiotech the [***] by September 28, 2007, and upon receipt of such payment in full, all right, title and interest in and to the [***] Equipment shall automatically and without any further action on the part of either Party be sold, assigned, conveyed and transferred to Histogenics, free and clear of all liens and encumbrances of any kind. Histogenics acknowledges and agrees that Angiotech makes no representations or warranties regarding the [***] Equipment, or the accuracy or completeness of Exhibit C, and that Histogenics is purchasing the [***] Equipment on an &#8220;as is and where is&#8221; basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Sharing</u>. Section 3.2(a) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Sharing</u> of the Agreement is hereby deleted in its entirety and replaced with the following new Section 3.2(a):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;(a) Revenue Sharing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 2 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(i) As further consideration for the Histogenics License, within [***] after the end of each Calendar Quarter during the Term, Histogenics shall pay to Angiotech [***] of the first [***] of Net Sales of Eligible Products and, thereafter, [***] of Net Sales of Eligible Products until such time as Histogenics makes the Revenue Share Reduction Payment, as defined below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(ii) At any time prior to the first to occur of, (A) [***], or (B) [***] (the &#8220;Exclusivity Deadline&#8221;), Histogenics may elect to convert this License to one of exclusivity within the Field by giving notice to Angiotech and paying one million dollars ($1,000,000) to Angiotech (the &#8220;Exclusivity Payment&#8221;) within fifteen (15) days of such notice (the &#8220;Conversion to Exclusivity&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(iii) If Histogenics exercises the Conversion to Exclusivity and at such time as Histogenics pays to Angiotech prior to [***] an additional two million dollars ($2,000,000) (the &#8220;Revenue Share Reduction Payment&#8221;), Histogenics shall thereafter be required to pay to Angiotech [***] of Net Sales of those Eligible Products that contain living human cartilage cells and [***] of Net Sales of those Eligible Products that do not contain living human cartilage cells. The payments of a percentage of Net Sales of Eligible Products as determined in this Section 3.2(a) shall be referred to herein as the &#8220;Revenue Share&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligation to Pay Revenue Share</u>. Section 3.2(b) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligation to Pay Revenue Share</u> of the Agreement is hereby amended to change the reference to Angiodevice to Angiotech.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Diligence Obligations</u>. The last sentence of Section 4.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Diligence Obligations</u> of the Agreement shall be deleted in its entirety and replaced with the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">[***] Any such failure to [***] will be considered a material breach of this Agreement as that term is used in Section 8.2(a).&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font>[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publications</u>. Section 5.4 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publications</u> of the Agreement is hereby deleted in its entirety and replaced with the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;5.4 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publications</u>. Neither Party will publish or present the results of studies carried out that relate to the performance of CT3 or that contain any Confidential Information of the other Party without (a) such other Party&#8217;s prior consent, or (b) providing such other Party with the opportunity to remove any Confidential Information contained therein.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u>. The second sentence of Section 8.4 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u> of the Agreement is hereby amended by adding the following phrase to the end of the sentence:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;&#8230;during such [***] period.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u>. The reference in Section 10.3 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u> of the Agreement to Section 5.6 is hereby changed to Section 5.1 and Section 5.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. The address for notice to Histogenics in Section 10.9 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u> of the Agreement is hereby changed to:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:108pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">If to Histogenics:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Histogenics Corporation<br>830 Winter Street, 3rd Floor<br>Waltham, MA 02451<br>Attention: Richard C. Vaillant</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:108pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">With a copy to:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Pepper Hamilton LLP<br>101 Federal Street, Suite 1010</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 3 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 144pt;">Boston, MA 02110<br>Attention: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Agreement</u>. Except as specifically otherwise amended as set forth herein, the Agreement shall continue in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Amendment may be executed in multiple counterparts, each of which shall be deemed and original, but all of which together shall constitute one and the same instrument. Facsimile signatures of the Parties will have the same effect as original signatures. In making proof of this Amendment, it shall not be necessary to produce or account for more than one such counterpart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed and delivered by the respective duly authorized officers as of the date set forth above.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANGIOTECH PHARMACEUTICALS (US), INC.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANGIODEVICE INTERNATIONAL GmbH:</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Hall</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Hans Peter Weber</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: David Hall</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Hans Peter Weber</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: CFO</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Managing Director</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October 4, 2007</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: 26th Sept. 2007</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ J&#252;rg Dannecker</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: J&#252;rg Dannecker</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Managing Director</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: 26/09/2007</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HISTOGENICS CORPORATION</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven Berrota</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Steven Berrota</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President &amp; CEO</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: 9/11/07</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 4 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>6
<FILENAME>tmb-20250331xex10d31.htm
<DESCRIPTION>EX-10.31
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 03:59:47 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.31</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECOND AMENDMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS SECOND AMENDMENT TO LICENSE AGREEMENT</b> (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Amendment</u>&#8221;), effective January 1, 2008, is by and among:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiotech Pharmaceuticals (US), Inc.</b>, a corporation organized and existing under the laws of the State of Washington, with principal offices at North Bend, WA (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiotech US</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiodevice International GmbH</b>, a corporation organized and existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiodevice</u>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Histogenics Corporation</b>, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WITNESSETH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech Biomaterials Corp. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biomaterials</u>&#8221;), Angiodevice and Histogenics entered into that certain License Agreement, effective as of May 12, 2005, pursuant to which Biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Original License Agreement</u>&#8221;), a copy of which is attached hereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, effective as of November 4, 2005, all of the assets of Biomaterials were sold to Angiotech US and Biomaterials was wound up;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, in connection with such sale of assets, Biomaterials assigned the Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials under the Original License Agreement as if it were the original party thereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics entered into that certain Amendment to License Agreement, dated as of August 31, 2007 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Amendment</u>&#8221;), a copy of which is attached hereto (the Original License Agreement, as amended by the First Amendment, shall be referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics have determined that it is in their best interests to amend certain provisions of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u><font style="white-space:pre-wrap;">.  Sub-clause (A) of Section 3.2(a)(ii) of the Agreement is hereby amended by striking the word &#8220;January&#8221; and inserting the word &#8220;March&#8221; in place thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-1-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Confirmation of Agreement</u><font style="white-space:pre-wrap;">.  Except as specifically otherwise amended as set forth herein, the Agreement shall continue in full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="white-space:pre-wrap;">.  This Second Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Facsimile signatures of the parties hereto will have the same effect as original signatures.  In making proof of this Second Amendment, it shall not be necessary to produce or account for more than one such counterpart.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">[Signature Page Follows]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-2-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties have caused this Second Amendment to be executed and delivered by the respective duly authorized officers as of the date set forth above.</p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANGIOTECH PHARMACEUTICALS (US), INC.</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANGIODEVICE INTERNATIONAL GmbH</b></p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Hall</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Hans Peter Weber</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Hans Peter Weber</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Title:  Chief Compliance Officer &amp; Senior Vice President Government &amp; Community Relations</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Managing Director</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: Jan 10, 2008</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ J&#252;rg Dannecker</p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: J&#252;rg Dannecker</p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Managing Director</p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-3-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.  THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RESTATED WARRANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">to purchase shares of common stock of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warrant No. CS-1</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Effective Date:<font style="display:inline-block;width:47.2pt;"></font>July 19, 2006</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Expiration Date:<font style="display:inline-block;width:41.63pt;"></font>May 11, 2010</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, On May 12, 2005, HISTOGENICS CORPORATION, a corporation organized and existing under the laws of Massachusetts, with principal offices at 100 Hospital Road, Malden, MA 02148 (the &#8220;Massachusetts Corporation&#8221;) issued to ANGIODEVICE INTERNATIONAL GmbH, a corporation organized and existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (&#8220;Angiotech International&#8221;), a warrant to purchase [***] shares of the Company&#8217;s Common Stock (the &#8220;Original Warrant&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Original Warrant was issued pursuant to the License Agreement between the Massachusetts Corporation and the Holder dated as of May 12, 2005 (the &#8220;License Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the License Agreement and the Original Warrant provide that upon the sale of [***] of equity securities by the Massachusetts Corporation (the &#8220;Financing&#8221;), the Original Warrant would be cancelled and replaced with a new warrant of like tenor the right to purchase such additional number of shares of Common Stock, calculated pursuant to the Original Warrant and the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, in connection with the Financing, the Massachusetts Corporation reincorporated as a Delaware corporation by merging (the &#8220;Merger&#8221;) the Massachusetts Corporation into a wholly owned Delaware subsidiary, with such subsidiary surviving the Merger (the &#8220;Company&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, pursuant to the Merger the Company is the successor of the Massachusetts Corporation under the License Agreement and is therefore issuing this new restated Warrant contemplated by the Original Warrant and the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Financing has occurred and therefore this Warrant amends and restates the Original Warrant in its entirety.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This certifies that Angiotech International, or its transferees or assigns (collectively, the &#8220;Holder&#8221;) for the agreed upon value of and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, shall be entitled to purchase from the Company, [***] fully paid and nonassessable shares of the Company&#8217;s Common Stock (the &#8220;Common Stock&#8221;) for cash at a price of [***] per share (the &#8220;Exercise Price&#8221;) at any time, or from time to time, up to and including 5:00 p.m. Pacific time on the Expiration Date, upon the surrender to the Company at its principal place of business (or at such other location as the Company may advise the Holder in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-4-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">writing) of this Warrant properly endorsed, a Subscription Form in substantially the form attached hereto as <b style="font-weight:bold;">Exhibit&#160;A</b><font style="white-space:pre-wrap;"> duly filled in and signed and, as applicable, upon payment in cash or by check of the aggregate Exercise Price for the number of shares for which this Warrant is being exercised determined in accordance with the provisions hereof, or the surrender of the right to acquire the number of shares of Common Stock determined in accordance with Section 1.2.  The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to adjustment as provided in Section 3 of this Warrant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Warrant is subject to the following terms and conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">EXERCISE; ISSUANCE OF CERTIFICATES; PAYMENT FOR SHARES.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.1</b></font><b style="font-weight:bold;">General</b><font style="white-space:pre-wrap;">.  This Warrant is exercisable at the option of the holder of record hereof at any time, or from time to time, up to the Expiration Date for all or any part of the shares of Common Stock (but not for a fraction of a share), which may be purchased hereunder.  The Company agrees that the shares of Common Stock purchased under this Warrant shall be and are deemed to be issued to the Holder hereof as the record owner of such shares as of the close of business on the date on which this Warrant, properly endorsed, the completed and executed Form of Subscription and appropriate payment for such shares shall have each been delivered to the Company at its principal place of business.  Certificates for the shares of Common Stock so purchased, together with any other securities or property to which the Holder is entitled upon such exercise, shall be delivered to the Holder by the Company at the Company&#8217;s expense within a reasonable time after the rights represented by this Warrant have been so exercised, and in any event, within five (5) business days of such exercise.  In case of a purchase of less than all the shares which may be purchased under this Warrant, the Company shall cancel this Warrant and execute and deliver a new Warrant or Warrants of like tenor for the balance of the shares purchasable under the Warrant surrendered upon such purchase to the Holder hereof within a reasonable time.  Each stock certificate so delivered shall be in such denominations of Common Stock as may be requested by the Holder hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.2</b></font><b style="font-weight:bold;">Net Issue Election</b><font style="white-space:pre-wrap;">.  The Holder may elect to receive, without the payment by the Holder of any additional consideration, shares of Common Stock equal to the value of this Warrant or any portion hereof by the surrender of this Warrant or such portion to the Company, with the net issue election notice annexed hereto duly executed, at the office of the Company.  Thereupon, the Company shall issue to the Holder such number of fully paid and nonassessable shares of Common Stock as is computed using the following formula:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X = <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Y (A-B)</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;"> A</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">where</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">X</font></font>=<font style="display:inline-block;width:30.36pt;"></font>the number of shares of Common Stock to be issued to the Holder pursuant to this Section 1.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Y</font></font>=<font style="display:inline-block;width:30.36pt;"></font>the number of shares of Common Stock covered by this Warrant in respect of which the net issue election is made pursuant to this Section 1.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A</font></font>=<font style="display:inline-block;width:30.36pt;"></font>the fair market value of one share of Common Stock, as determined in good faith by the Company&#8217;s Board of Directors, as at the time the net issue election is made pursuant to this Section 1.2, which determination shall be final and binding on the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">B</font></font>=<font style="display:inline-block;width:30.36pt;"></font>the Exercise Price in effect under this Warrant at the time the net issue election is made pursuant to this Section 1.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors shall promptly respond in writing to an inquiry by the Holder as to the fair market value of one share of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">SHARES TO BE FULLY PAID; RESERVATION OF SHARES</b><font style="white-space:pre-wrap;">.  The Company covenants and agrees that all shares of Common Stock which may be issued upon the proper exercise of the rights represented by this</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:18pt 0pt 0pt 0pt;">5</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">Warrant and payment of the Exercise Price will, upon issuance, be duly authorized, validly issued, fully paid and nonassessable and free from all preemptive rights of any shareholder and free of all taxes, liens and charges with respect to the issue thereof.  The Company further covenants and agrees that, during the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved, for the purpose of issue or transfer upon exercise of the subscription rights evidenced by this Warrant, a sufficient number of shares of authorized but unissued Common Stock, or other securities and property, when and as required to provide for the exercise of the rights represented by this Warrant.  The Company will take all such action as may be necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any domestic securities exchange upon which the Common Stock may be listed; provided, however, that the Company shall not be required to effect a registration under Federal or State securities laws with respect to such exercise.  The Company will not take any action which would result in any adjustment of the Exercise Price (as set forth in Section 3 hereof) if the total number of shares of Common Stock issuable after such action upon exercise of all outstanding warrants, together with all shares of Common Stock then outstanding and all shares of Common Stock then issuable upon exercise of all options and upon the conversion of all convertible securities and other equity purchase rights then outstanding, would exceed the total number of shares of Common Stock then authorized by the Company&#8217;s Articles/Certificate of Incorporation (the &#8220;Company Charter&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF SHARES</b><font style="white-space:pre-wrap;">.  The Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time upon the occurrence of certain events described in this Section 3.  Upon each adjustment of the Exercise Price, the Holder of this Warrant shall thereafter be entitled to purchase, at the Exercise Price resulting from such adjustment, the number of shares obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of shares purchasable pursuant hereto immediately prior to such adjustment, and dividing the product thereof by the Exercise Price resulting from such adjustment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.1</b></font><b style="font-weight:bold;">Subdivision or Combination of Stock</b><font style="white-space:pre-wrap;">.  In case the Company shall at any time subdivide its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision shall be proportionately reduced, and conversely, in case the outstanding shares of Common Stock of the Company shall be combined into a smaller number of shares (by reverse stock split or otherwise), the Exercise Price in effect immediately prior to such combination shall be proportionately increased.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.2</b></font><b style="font-weight:bold;">Dividends in Common Stock, Other Stock, Property, Reclassification</b><font style="white-space:pre-wrap;">.  If at any time or from time to time the Holders of Common Stock (or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received or become entitled to receive, without payment therefor,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Common Stock or any shares of stock or other securities which are at any time directly or indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>any cash paid or payable otherwise than as a cash dividend, or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Common Stock or additional stock or other securities or property (including cash) by way of spinoff, split-up, reclassification, combination of shares or similar corporate rearrangement, (other than shares of Common Stock issued as a stock split or adjustments in respect of which shall be covered by the terms of Section&#160;3.1 above), then, and in each such case, the Holder hereof shall, upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common Stock receivable thereupon, and without payment of any additional consideration therefor, the amount of stock and other securities and property (including cash in the cases referred to in clause (b) above and this clause (c)) which such Holder would hold on the date of such exercise had he been the holder of record of such Common Stock as of the date on which holders of Common Stock received or became entitled to receive such shares or all other additional stock and other securities and property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.3</b></font><b style="font-weight:bold;">Reorganization, Consolidation, Merger or Sale</b><font style="white-space:pre-wrap;">.  If any recapitalization or reorganization of the capital stock of the Company, or any consolidation or merger of the Company with another corporation, or the sale of all or substantially all of its assets or other Common Stock Warrant transaction shall be effected in such a way that holders of Common Stock shall be entitled to receive stock, securities, or other assets or property (an &#8220;Organic</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:18pt 0pt 0pt 0pt;">6</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">Change&#8221;), then, as a condition of such Organic Change, lawful and adequate provisions shall be made by the Company whereby the Holder hereof shall thereafter have the right to purchase and receive (in lieu of the shares of the Common Stock of the Company immediately theretofore purchasable and receivable upon the exercise of the rights represented by this Warrant) such shares of stock, securities or other assets or property as may be issued or payable with respect to or in exchange for a number of outstanding shares of such Common Stock equal to the number of shares of such stock immediately theretofore purchasable and receivable upon the exercise of the rights represented by this Warrant.  In the event of any Organic Change, appropriate provision shall be made by the Company with respect to the rights and interests of the Holder of this Warrant to the end that the provisions hereof (including, without limitation, provisions for adjustments of the Exercise Price and of the number of shares purchasable and receivable upon the exercise of this Warrant) shall thereafter be applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.4</b></font><b style="font-weight:bold;">Certain Events</b><font style="white-space:pre-wrap;">.  If any change in the outstanding Common Stock of the Company or any other event occurs as to which the other provisions of this Section 3 are not strictly applicable or if strictly applicable would not fairly protect the purchase rights of the Holder of the Warrant in accordance with such provisions, then the Board of Directors of the Company shall make an adjustment in the number and class of shares available under the Warrant, the Exercise Price or the application of such provisions, so as to protect such purchase rights as aforesaid.  The adjustment shall be such as will give the Holder of the Warrant upon exercise for the same aggregate Exercise Price the total number, class and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.5</b></font><b style="font-weight:bold;">Notices of Change.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Upon any adjustment in the number or class of shares subject to this Warrant and/or of the Exercise Price, the Company shall give reasonable written notice thereof to the Holder, setting forth in reasonable detail and certifying the calculation of such adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>The Company shall give written notice to the Holder at least 10 business days prior to the date on which the Company closes its books or takes a record for determining rights to receive any dividends or distributions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>The Company shall also give written notice to the Holder at least 10 business days prior to the date on which an Organic Change shall take place.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">ISSUE TAX</b><font style="white-space:pre-wrap;">.  The issuance of certificates for shares of Common Stock upon the exercise of the Warrant shall be made without charge to the Holder of the Warrant for any issue tax (other than any applicable income taxes) in respect thereof; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than that of the Holder of the Warrant being exercised.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-weight:bold;">CLOSING OF BOOKS</b><font style="white-space:pre-wrap;">.  The Company will not unreasonably close its transfer books in any manner which interferes with the timely exercise of this Warrant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;">NO VOTING OR DIVIDEND RIGHTS; LIMITATION OF LIABILITY</b><font style="white-space:pre-wrap;">.  Nothing contained in this Warrant shall be construed as conferring upon the Holder hereof the right to vote or to consent or to receive notice as a shareholder of the Company or any other matters or any rights whatsoever as a shareholder of the Company.  No dividends or interest shall be payable or accrued in respect of this Warrant or the interest represented hereby or the shares purchasable hereunder until, and only to the extent that this Warrant shall have been exercised.  No provisions hereof, in the absence of affirmative action by the holder to purchase shares of Common Stock, and no mere enumeration herein of the rights or privileges of the holder hereof, shall give rise to any liability of such Holder for the Exercise Price or as a shareholder of the Company, whether such liability is asserted by the Company or by its creditors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:18pt 0pt 0pt 0pt;">7</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-weight:bold;">WARRANTS NOT TRANSFERABLE</b><font style="white-space:pre-wrap;">.  This Warrant is not transferable, in whole or in part without the prior written consent of the Company, except as otherwise specifically provided for herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-weight:bold;">REGISTRATION RIGHTS</b><font style="white-space:pre-wrap;">.  The Holder has the right to cause the Company to register the Common Stock issued upon exercise hereof, under the Securities Act and any blue sky or securities laws of any jurisdictions within the United States at the time and in the manner specified in this Section 8.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.1</b></font><b style="font-weight:bold;">Registrable Securities</b><font style="white-space:pre-wrap;">.  As used herein the term &#8220;Registrable Security&#8221; means the shares of Common Stock, and any shares issued upon any stock split or stock dividend in respect of such shares of Common Stock; provided, however, that with respect to any particular Registrable Security, such security shall cease to be a Registrable Security when, as of the date of determination, (i) it has been effectively registered under the Securities Act and disposed of pursuant thereto, (ii) registration under the Securities Act is no longer required for subsequent public distribution of such security under Rule 144(k) promulgated under the Securities Act or otherwise, or (iii) it is no longer held by the Holder.  The term &#8220;Registrable Securities&#8221; means any and/or all of the securities falling within the foregoing definition of a &#8220;Registrable Security.&#8221; In the event of any merger, reorganization, consolidation, recapitalization or other change in corporate structure affecting the Common Stock, such adjustment shall be made in the definition of &#8220;Registrable Security&#8221; as is appropriate in order to prevent any dilution or enlargement of the rights granted pursuant to this Section 8.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.2</b></font><b style="font-weight:bold;">Piggyback Registration</b><font style="white-space:pre-wrap;">.  In the event that the Company proposes to prepare and file any new registration statement or post-effective amendments with the intent of issuing a public offering (including, but not limited to, registration statements relating to secondary offerings of securities of the Company, but excluding registration statements relating to any employee benefit plan or a corporate reorganization) (for purposes of this Section 8, collectively, the &#8220;Registration Statement&#8221;), it will give written notice of its intention to do so by certified mail, return receipt requested (&#8220;Notice&#8221;), at least thirty (30) business days prior to the filing of each such Registration Statement, to the Holder.  Upon the written request of the Holder, made within twenty (20) business days after receipt by the Holder of the Notice, that the Company include any of the Holder&#8217;s Registrable Securities in the proposed Registration Statement, the Company shall use its best efforts to effect the registration under the Securities Act of the Registrable Securities which it has been so requested to register (&#8220;Piggyback Registration&#8221;), at the Company&#8217;s sole cost and expense and at no cost or expense to (except as provided in Section 8.3(a) hereof).  If the Holder decides not to include all of its Registrable Securities in any Registration Statement thereafter filed by the Company, the Holder shall nevertheless continue to have the right to include any Common Stock in any subsequent Registration Statement or Registration Statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">If a Registration Statement under which the Company gives notice under this Section 8.2 is for an underwritten offering, then the Company shall so advise the Holder.  In such event, the right of the Holder&#8217;s Common Stock to be included in a registration pursuant to this Section 8.2 shall be conditioned upon Holder&#8217;s participation in such underwriting and the inclusion of Holder&#8217;s Common Stock in the underwriting.  If Holder proposes to distribute any Common Stock through such underwriting, Holder shall enter into an underwriting agreement in customary form with the managing underwriter or underwriter(s) selected for such underwriting.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the provisions of this Section 8.2, the Company shall have the right at any time after it shall have given written notice pursuant to this Section 8.2 (irrespective of whether any written request for inclusion of Registrable Securities shall have already been made) to elect not to file any such proposed Registration Statement, or to withdraw the same after the filing but prior to the effective date thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.3</b></font><b style="font-weight:bold;">Covenants of the Company With Respect to Registration</b><font style="white-space:pre-wrap;">.  The Company covenants and agrees as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The Company shall pay all costs, fees and expenses (other than underwriting fees, discounts and nonaccountable expense allowance applicable to the Registrable Securities and fees and expenses of counsel retained by the Holder) in connection with all Registration Statements including, without limitation, the Company&#8217;s legal and accounting fees, printing expenses, and blue sky fees and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:18pt 0pt 0pt 0pt;">8</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>The Company will use its reasonable best efforts to take all necessary action which may be required in qualifying or registering the Registrable Securities included in the Registration Statement for offering and sale under the securities or blue sky laws of such states as are reasonably requested by the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>To the fullest extent permitted by law, the Company will indemnify and hold the Holder harmless against any losses, claims, damages, or liabilities to which it may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a &#8220;Violation&#8221;) by the Company: (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection with the offering covered by the Registration Statement; and the Company will reimburse the Holder for any legal or other expenses reasonably incurred by it in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this Section shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished to it expressly for use in connection with such registration by the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="white-space:pre-wrap;">Promptly after receipt by an indemnified party under this Section of notice of the commencement of any action (including any governmental action), such indemnified party shall, if a claim in respect thereof is to be made against any indemnifying party under this Section, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying party; and provided further, that if there is more than one indemnified party, the indemnifying party shall pay for the fees and expenses of one counsel for any and all indemnified parties to be mutually agreed upon by such indemnified parties, unless representation of an indemnified party by the counsel retained by the other indemnified parties would be inappropriate due to actual or potential differing interests between such indemnified parties.  The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if materially prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 8.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="white-space:pre-wrap;">In the event that the indemnification provided for in this Section 8 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted by applicable law, contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the Violation(s) that resulted in such loss, claim, damage or liability, as well as any other relevant equitable considerations.  The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.  No person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11 of the Securities Act) shall be entitled to contribution from any person or entity that is not found to have been guilty of such fraudulent misrepresentation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:18pt 0pt 0pt 0pt;">9</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-weight:bold;">FURTHER REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Articles and Bylaws</u><font style="white-space:pre-wrap;">.  The Company has made available to Holder true, complete and correct copies of the Company Charter and Bylaws, as amended, through the date hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Due Authority</u><font style="white-space:pre-wrap;">.  The execution and delivery by the Company of this Warrant and the performance of all obligations of the Company hereunder, including the issuance to Holder of the right to acquire the shares of Common Stock, have been duly authorized by all necessary corporate action on the part of the Company, and the Warrant is not inconsistent with the Company Charter or Bylaws and constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consents and Approvals</u><font style="white-space:pre-wrap;">.  No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Warrant, except for any filing required by applicable federal and state securities laws, which filing will be effective by the time required thereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-weight:bold;">REPRESENTATIONS AND COVENANTS OF THE HOLDER.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Warrant has been entered into by the Company in reliance upon the following representations and covenants of the Holder:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Purpose</u><font style="white-space:pre-wrap;">.  The Warrant and the Common Stock issuable upon exercise of the Warrant will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Holder has no present intention of selling or engaging in any public distribution of the same except pursuant to a registration or exemption pursuant to the 1933 Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Private Issue</u><font style="white-space:pre-wrap;">.  The Holder understands (i) that the Warrant and the Common Stock issuable upon exercise of this Warrant is not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant will be exempt from the registration and qualifications requirements thereof pursuant to Section 4(2) of the 1933 Act and any applicable state securities laws, and (ii) that the Company&#8217;s reliance on such exemption is predicated on the representations set forth in this Section 10.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disposition of Holders Rights</u><font style="white-space:pre-wrap;">.  In no event will the Holder make a disposition of the Warrant or the Common Stock issuable upon exercise of the Warrant unless and until (i) the Company shall have approved of the proposed disposition, and (ii) if requested by the Company, it shall have furnished the Company with an opinion of counsel (which counsel may either be inside or outside counsel to the Holder) satisfactory to the Company and its counsel to the effect that (A) appropriate action necessary for compliance with the 1933 Act has been taken, or (B)&#160;</font><font style="white-space:pre-wrap;">an exemption from the registration requirements of the 1933 Act is available.  Notwithstanding the foregoing, the restrictions imposed upon the transferability of any of its rights to acquire Common Stock or the Common Stock issuable on the exercise of such rights do not apply to transfers from the beneficial owner of any of the aforementioned securities to its nominee or from such nominee to its beneficial owner, and shall terminate as to any particular share of Common Stock when (1) such security shall have been effectively registered under the 1933 Act and sold by the holder thereof in accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the 1933 Act, or (3) a letter shall have been issued to the Holder at its request by the staff of the Securities and Exchange Commission or a ruling shall have been issued to the Holder at its request by such Commission stating that no action shall be recommended by such staff or taken by such Commission, as the case may be, if such security is transferred without registration under the 1933 Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required.  Whenever the restrictions imposed hereunder shall terminate, as hereinabove provided, the Holder or holder of a share of Common Stock then outstanding as to which such restrictions have terminated shall be entitled to receive from the Company, without expense to such holder, one or more new certificates for the Warrant or for such shares of Common Stock not bearing any restrictive legend.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:18pt 0pt 0pt 0pt;">10</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Risk</u><font style="white-space:pre-wrap;">.  The Holder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Risk of No Registration</u><font style="white-space:pre-wrap;">.  The Holder understands that if the Company does not register with the Securities and Exchange Commission pursuant to Section 12 of the 1933 Act, or file reports pursuant to Section&#160;</font><font style="white-space:pre-wrap;">15(d), of the Securities Exchange Act of 1934 (the &#8220;1934 Act&#8221;), or if a registration statement covering the securities under the 1933 Act is not in effect when it desires to sell (i) the Warrant, or (ii) the Common Stock issuable upon exercise of the Warrant, it may be required to hold such securities for an indefinite period.  The Holder also understands that any sale of the Warrant or the Common Stock issuable upon exercise of the Warrant which might be made by it in reliance upon Rule 144 under the 1933 Act may be made only in accordance with the terms and conditions of that Rule.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accredited Investor</u><font style="white-space:pre-wrap;">.  Holder is an &#8220;accredited investor&#8221; within the meaning of Rule 501 of Regulation D under the 1933 Act, as presently in effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-weight:bold;">MODIFICATION AND WAIVER</b><font style="white-space:pre-wrap;">.  This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-weight:bold;">NOTICES</b><font style="white-space:pre-wrap;">.  Any notice, request or other document required or permitted to be given or delivered to the holder hereof or the Company shall be delivered or shall be sent by an established overnight service provider (e.g., Federal Express), or registered or certified mail, postage prepaid, to each such holder at its address as shown on the books of the Company or to the Company at the address indicated therefor in the first paragraph of this Warrant or such other address as either may from time to time provide to the other in accordance with this Section.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-weight:bold;">BINDING EFFECT ON SUCCESSORS</b><font style="white-space:pre-wrap;">.  This Warrant shall be binding upon any corporation succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company&#8217;s assets.  All of the obligations of the Company relating to the Common Stock issuable upon the exercise of this Warrant shall survive the exercise and termination of this Warrant.  All of the covenants and agreements of the Company shall inure to the benefit of the successors and assigns of the holder hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></font><b style="font-weight:bold;">DESCRIPTIVE HEADINGS AND GOVERNING LAW</b><font style="white-space:pre-wrap;">.  The description headings of the several sections and paragraphs of this Warrant are inserted for convenience only and do not constitute a part of this Warrant.  This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of Delaware, without giving effect to principles of conflicts of laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15.</b></font><b style="font-weight:bold;">LOST WARRANTS</b><font style="white-space:pre-wrap;">.  The Company represents and warrants to the Holder hereof that upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction, or mutilation of this Warrant and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to the Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant, the Company, at its expense, will make and deliver a new Warrant, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16.</b></font><b style="font-weight:bold;">FRACTIONAL SHARES</b><font style="white-space:pre-wrap;">.  No fractional shares shall be issued upon exercise of this Warrant.  The Company shall, in lieu of issuing any fractional share, pay the holder entitled to such fraction a sum in cash equal to such fraction multiplied by the then effective Exercise Price.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">17.</b></font><b style="font-weight:bold;">ORIGINAL WARRANT CANCELLED</b><font style="white-space:pre-wrap;">.  The Original Warrant is hereby replaced in its entirety by this Warrant, and the Original Warrant shall be null and of no force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:18pt 0pt 0pt 0pt;">11</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the Company and the Holder have caused this Warrant to be duly executed by its officers, thereunto duly authorized.</p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: January 4, 2008</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Corporate Seal)</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven Bernitz</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Bernitz</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President &amp; CEO</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: January 16, 2008</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANGIODEVICE INTERNATIONAL GmbH</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Corporate Seal)</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Hans Peter Weber</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hans Peter Weber</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ J&#252;rg Dannecker</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">J&#252;rg Dannecker</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:18pt 0pt 0pt 0pt;">12</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subscription Form</b></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;">Date:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">The undersigned hereby subscribes for shares of Common Stock covered by this Warrant.  The certificate(s) for such shares shall be issued in the name of the undersigned or as otherwise indicated below:</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:70.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature</p></td></tr><tr><td style="vertical-align:top;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td></tr><tr><td style="vertical-align:top;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td></tr><tr><td style="vertical-align:top;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[OR]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net Issue Election Notice</b></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;">Date:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">The undersigned hereby elects under Section 4 to surrender the right to purchase shares of Common Stock pursuant to this Warrant.  The certificate(s) for the shares issuable upon such net issue election shall be issued in the name of the undersigned or as otherwise indicated below.</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:70.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature</p></td></tr><tr><td style="vertical-align:top;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td></tr><tr><td style="vertical-align:top;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td></tr><tr><td style="vertical-align:top;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;">Common Stock Warrant</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:18pt 0pt 0pt 0pt;">13</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>7
<FILENAME>tmb-20250331xex10d32.htm
<DESCRIPTION>EX-10.32
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 03:59:47 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.32</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential.  Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THIRD AMENDMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS THIRD AMENDMENT TO LICENSE AGREEMENT</b> (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Amendment</u>&#8221;), effective April 15, 2008, is by and among:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiotech Pharmaceuticals (US), Inc.</b>, a corporation organized and existing under the laws of the State of Washington, with principal offices at North Bend, WA (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiotech US</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiodevice International GmbH</b>, a corporation organized and existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiodevice</u>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Histogenics Corporation</b>, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WITNESSETH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech Biomaterials Corp. (&#8220;Biomaterials&#8221;), Angiodevice and Histogenics entered into that certain License Agreement, effective as of May 12, 2005, pursuant to which Biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3 (the &#8220;Original License Agreement&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, effective as of November 4, 2005, all of the assets of Biomaterials were sold to Angiotech US and Biomaterials was wound up;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, in connection with such sale of assets, Biomaterials assigned the Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials under the Original License Agreement as if it were the original party thereto:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics entered into that certain Amendment to License Agreement, dated as of August 31, 2007 (the &#8220;First Amendment&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics entered into that certain Second Amendment to License Agreement, dated as of January 1, 2008 (the &#8220;Second Amendment&#8221;), (the Original License Agreement, as amended by the First Amendment and the Second Amendment, shall be referred to herein as the &#8220;Agreement&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics have determined that it is in their best interests to further amend certain provisions of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW</b>, <b style="font-weight:bold;">THEREFORE</b>, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby, acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Section 1 of the Second Amendment is hereby deleted in its entirety.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Section 3.2(a)(ii) of the First Amendment is amended by deleting it in its entirety and replacing it with the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At any time prior to the first to occur of, (A) [***], or (B) [***] (the &#8220;Exclusivity Deadline&#8221;), Histogenics may elect to convert this License to one of exclusivity within the Field by giving notice to Angiotech and paying one million dollars ($1,000,000) to Angiotech (the &#8220;Exclusivity Payment&#8221;). Such Exclusivity Payment shall be made in accordance with the schedule set out below, unless and until Histogenics closes an equity financing with proceeds to Histogenics in an amount not less than [***], whereby the Exclusivity Payment shall become due and payable in full within fifteen (15) days of such closing:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Payable by [***];</p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Payable by [***];</p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Payable by [***];</p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Payable by [***].</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement: Confirmation of Agreement</u><font style="white-space:pre-wrap;">.  Except as specifically otherwise amended as set forth herein, the Agreement shall continue in full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="white-space:pre-wrap;">.  This Third Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Facsimile signatures of the parties hereto will have the same effect as original signatures.  In making proof of this Third Amendment, it shall not be necessary to produce or account for more than one such counterpart.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">[Signature Page Follows]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties have caused this Third Amendment to be executed and delivered by the respective duly authorized officers as of the date set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANGIOTECH PHARMACEUTICALS (US), INC.</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANGIODEVICE INTERNATIONAL GmbH</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ / Thomas Bailey</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Harald Beck</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Name:  </font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thomas Bailey</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Harald Beck</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Title:  </font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">04/29/08</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: </p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12 May 2008</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">By:</u></p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ J&#252;rg Dannecker</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">J&#252;rg Dannecker</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: </p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">06 May 2008</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>8
<FILENAME>tmb-20250331xex10d33.htm
<DESCRIPTION>EX-10.33
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 03:59:48 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.33</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential.  Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOURTH AMENDMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS FOURTH AMENDMENT TO LICENSE AGREEMENT</b> (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fourth Amendment</u>&#8221;), effective November 1, 2008, is by and among:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiotech Pharmaceuticals (US), Inc.</b>, a corporation organized and existing under the laws of the State of Washington, with principal offices at North Bend, WA (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiotech US</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiodevice International GmbH</b>, a corporation organized and existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiodevice</u>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Histogenics Corporation</b>, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WITNESSETH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech Biomaterials Corp, (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biomaterials</u>&#8221;), Angiodevice and Histogenics entered into that certain License Agreement, effective as of May 12, 2005, pursuant to which Biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Original License Agreement</u>&#8221;), a copy of which is attached hereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, effective as of November 4, 2005, all of the assets of Biomaterials were sold to Angiotech US and Biomaterials was wound up;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, in connection with such sale of assets, Biomaterials assigned the Original License Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials under the Original License Agreement as if it were the original party thereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics entered into that certain Amendment to License Agreement, dated as of August 31, 2007 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Amendment</u>&#8221;), that certain Second Amendment to License Agreement, dated as of January 1, 2008 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Amendment</u>&#8221;), and that certain Third Amendment to License Agreement, dated as of April 15, 2008 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Amendment</u>&#8221; and together with the First Amendment and the Second Amendment, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prior Amendments</u>&#8221;), copies of each are attached hereto (the Original License Agreement, as amended by the Prior Amendments, shall be referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, pursuant to Section 3.2(a)(ii) of the Agreement, Histogenics has elected to convert the License (as defined in the Agreement) to one of exclusivity and has made two installment payments of the Exclusivity Payment (also as defined in the Agreement) of [***] on or prior to [***] and [***] on or prior to [***]; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics have determined that it is in their best interests to amend certain provisions of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW</b>, <b style="font-weight:bold;">THEREFORE</b>, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u><font style="white-space:pre-wrap;">.  Section 3.2(a)(ii) of the Agreement is hereby amended and restated in its entirety to state as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At any time prior to [***] (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusivity Deadline</u>&#8221;), Histogenics may elect to convert this License to one of exclusivity within the Field by giving notice to Angiotech (such election, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conversion to Exclusivity</u>&#8221;) and by paying Angiotech an aggregate of $1,045,000 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusivity Payment</u>&#8221;) in four (4) installments in accordance with the following schedule:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:42.29%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:53.84%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due and payable on [***];</p></td></tr><tr><td style="vertical-align:top;width:42.29%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:53.84%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due and payable on [***];</p></td></tr><tr><td style="vertical-align:top;width:42.29%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:53.84%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due and payable on [***]; and</p></td></tr><tr><td style="vertical-align:top;width:42.29%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:53.84%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due and payable on [***].</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding anything to the contrary herein, including Section 3.6, any Exclusivity Payment, or portion thereof, that is due and payable and remains unpaid and outstanding shall accrue interest, compounded quarterly, at a rate equal to [***] per annum or at such lower maximum rate of interest allowed by applicable law.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effects of Amendment on Payment Due [***]</u><font style="white-space:pre-wrap;">.  For the avoidance of doubt, the payment of [***] due by [***] under Section 3.2(a)(ii) of the Agreement as it existed prior to this Fourth Amendment shall not be considered to have been overdue by virtue of this Fourth Amendment being effective after such date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Confirmation of Agreement</u><font style="white-space:pre-wrap;">.  Except as specifically otherwise amended as set forth herein, the Agreement shall continue in full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="white-space:pre-wrap;">.  This Fourth Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Facsimile signatures of the parties hereto will have the same effect as original signatures.  In making proof of this Fourth Amendment, it shall not be necessary to produce or account for more than one such counterpart.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">[Signature Page Follows</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties have caused this Fourth Amendment to be executed and delivered by the respective duly authorized officers as of the date set forth above.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANGIOTECH PHARMACEUTICALS (US), INC.</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANGIODEVICE INTERNATIONAL GmbH</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David D. McMasters</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David D. McMasters</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Name:  </font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David D. McMasters</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David D. McMasters</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. VP, Legal &amp; General Counsel</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 4, 2008</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: </p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 4, 2008</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ F. Ken Andrews</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">F. Ken Andrews</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CEO &amp; President</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11-5-08</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>9
<FILENAME>tmb-20250331xex10d34.htm
<DESCRIPTION>EX-10.34
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 03:59:49 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.34</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. &#160;Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FIFTH AMENDMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS FIFTH AMENDMENT TO LICENSE AGREEMENT</b> (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fifth Amendment</u>&#8221;), effective August 6, 2010, is by and among:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiotech Pharmaceuticals (US), Inc.</b>, a corporation organized and existing under the laws of the State of Washington, with principal offices at North Bend, WA (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiotech US</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiodevice International GmbH</b>, a corporation organized and existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiodevice</u>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Histogenics Corporation</b>, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WITNESSETH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech Biomaterials Corp. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biomaterials</u>&#8221;), Angiodevice and Histogenics entered into that certain License Agreement, effective as of May 12, 2005, pursuant to which Biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Original License Agreement</u>&#8221;), a copy of which is attached hereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, effective as of November 4, 2005, all of the assets of Biomaterials were sold to Angiotech US and Biomaterials was wound up;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, in connection with such sale of assets, Biomaterials assigned the Original License Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials under the Original License Agreement as if it were the original party thereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics entered into that certain Amendment to License Agreement, dated as of August 31, 2007, that certain Second Amendment to License Agreement, dated as of January 1, 2008, that certain Third Amendment to License Agreement, dated as of April 15, 2008, and that certain Fourth Amendment to License Agreement, dated as of November 1, 2008 (the Original License Agreement, as amended by the foregoing amendments, shall be referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, pursuant to Section 3.2 of the Agreement, Histogenics elected to convert the Histogenics License (as defined in the Agreement) to one of exclusivity by making full payment of the Exclusivity Payment (as defined in the Agreement) pursuant to Section 3.2(a)(ii) of the Agreement, but failed to make the Revenue Share Reduction Payment (as defined in the Agreement) prior to [***] pursuant to Section 3.2(a)(iii) of the Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Histogenics desires to extend the deadline specified in Section 4.1 of the Agreement for [***] and to amend certain other provisions of the Agreement; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics have determined that it is in their best interests to amend certain provisions of the Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW</b>, <b style="font-weight:bold;">THEREFORE</b>, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1</font></font>The definition of &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics Technology</u>&#8221; in Section 1 of the Agreement is hereby amended and restated in its entirety to state as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics Technology</u>&#8221; means the intellectual property and know how of Histogenics and its permitted sublicensees, as such intellectual property and know how currently exist and as that intellectual property and know how may develop.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.2</font></font>The definition of &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net Sales</u>&#8221; in Section 1 of the Agreement is hereby amended by adding the following as a new paragraph at the end of such definition:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;Notwithstanding the foregoing, with respect to sales by the World Class Sublicensee or any of its affiliates or sublicensees, Net Sales shall be as defined in Exhibit D.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.3</font></font>Section 1 of the Agreement is hereby amended by adding the following new definition of &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Existing Angiotech Licensee</u>&#8221;:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Existing Angiotech Licensee</u>&#8221; means any third party who has received from Angiotech a license under the Licensed Patent Rights or Improvements as of the date of this Fifth Amendment.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.4</font></font>Section 2.1 of the Agreement is hereby amended to read as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;2.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant</u><font style="white-space:pre-wrap;">.  Subject to the terms and conditions of this Agreement, Angiotech hereby grants to Histogenics an exclusive (even as to Angiotech) right and license under the Licensed Technology and Angiotech&#8217;s interest in Improvements solely to make, have made, use, offer to sell, sell and import Eligible Products in the Field in the Territory (the &#8220;Histogenics License&#8221;).  For the avoidance of doubt, with the exception of Drug-Loaded Products, Angiotech shall not grant to any other Person any rights to or license under the Licensed Technology or Angiotech&#8217;s interest in Improvements to make, have made, use, offer to sell, sell or import any products containing CT3 for use in the Field in the Territory.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.5</font></font>Section 2.2 of the Agreement is hereby amended by adding the following clause to the end of the first sentence immediately before the period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;; provided that Angiotech hereby consents to Histogenics sublicensing any of its rights [***] (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">World Class Sublicensee</u><font style="white-space:pre-wrap;">&#8221;)&#8221;.  Expanding the sublicense in favor of the World Class Sublicensee to include countries beyond those sublicensed to the World Class Sublicensee on the effective date of such sublicense shall not require the consent of Angiotech.  Within [***] after entering into a sublicense with the World Class Sublicensee, Histogenics shall deliver written notice of such event, which notice shall set forth the identity of the World Class Sublicensee and the field of use, products and territory granted to the World Class Sublicensee, and Histogenics shall promptly inform Angiotech in writing of any change to the territory granted to the World Class Sublicensee&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.6</font></font>Section 2.2 of the Agreement is hereby amended by adding the following sentence to the end of such Section:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;For the avoidance of doubt, the distribution or sale of a given clinical or commercial quantity of CT3 under this Agreement by or on behalf of Histogenics or its Affiliate or their respective permitted sublicensees for use with an Eligible Product, or as part of a kit including an Eligible Product, shall effect an exhaustion in the Field in the Territory of all patent rights with respect to such clinical or commercial quantity of CT3; provided that the distribution or sale of the Eligible Products (or kits including Eligible Products) utilizing such clinical or commercial quantity of CT3 is accounted for in the determination of Net Sales.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.7</font></font>Section 2.4(g) of the Agreement is hereby amended by adding the following clause to the end of such section immediately before the period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;; provided, however, that with respect to data and results generated by the World Class Sublicensee, Histogenics shall only be required to provide Angiotech with the data and results received by Histogenics from the World Class Sublicensee and only to the extent Histogenics has the right to do so&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.8</font></font>Section 3.1 of the Agreement is hereby amended by adding the following sentence to the end of such section:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8220;As further consideration for the Histogenics License, Histogenics shall pay to Angiotech (a) three million dollars ($3,000,000) within thirty (30) days after Histogenics receives Regulatory Approval from the FDA for an Eligible Product, and (b) fifty thousand dollars ($50,000) on each December 31 starting on December 31, 2010 and ending on December 31, 2014 (for an aggregate payment of two hundred fifty thousand dollars ($250,000) pursuant to this Section 3.1(b)).  For the avoidance of doubt, receipt of such Regulatory Approval by the World Class Sublicensee shall trigger Histogenics obligation to make the payment described in Section 3.1(a).&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.9</font></font>Section 3.2(a)(iii) of the Agreement is hereby amended and restated in its entirety to state as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;(iii) The &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Share Reduction Payment</u><font style="white-space:pre-wrap;">&#8221; means (A) if paid after such date and prior to or on [***], [***]; or (B) if paid after such date and prior to or on [***], [***].  If Histogenics pays to Angiotech the Revenue Share Reduction Payment on or before [***], Histogenics shall thereafter be required to pay to Angiotech [***] of Net Sales of those Eligible Products that contain living human cartilage cells and [***] of Net Sales of those Eligible Products that do not contain living human cartilage cells.  The payments of a percentage of Net Sales of Eligible Products as determined in this Section 3.2(a) shall be referred to herein as the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Share</u>&#8221;.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.10</font></font>A new section numbered Section 3.2(a)(iv) is hereby added to the Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;(iv) Notwithstanding Sections 3.2(a) and 3.5, Histogenics shall pay to Angiotech the Revenue Share attributable to the Net Sales of the World Class Sublicensee (and its affiliates and sublicensees) for a particular Calendar Quarter within [***] after the end of such Calendar Quarter.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.11</font></font><font style="white-space:pre-wrap;">Section 3.4 of the Agreement is hereby amended by placing &#8220;(a)&#8221; before the phrase that reads &#8220;Histogenics shall deliver to Angiotech .  .  .&#8221; and re-numbering the paragraphs numbered (a) through (f) as (i) through (vi), respectively.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.12</font></font>Section 3.4 of the Agreement is further hereby amended by adding a new subsection (b) after the final paragraph of subsection (a) as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8220;(b) With respect to Net Sales attributable to the World Class Sublicensee (and its affiliates and sublicensees), Histogenics may satisfy its obligation to provide a written Revenue Share report for a particular Calendar Quarter by delivering to Angiotech a copy of the royalty report Histogenics receives from the World Class Sublicensee which covers the sale of Eligible Products for such Calendar Quarter, which copy shall be certified by Histogenics&#8217; CFO (or his designee) as a true and complete copy of the report received from the World Class Sublicensee.  Notwithstanding Section 3.4(a), Histogenics shall have until [***] after the end of a particular Calendar Quarter to provide such report to Angiotech.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.13</font></font>The following language is added to the end of the second sentence of Section 3.5 and before the period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;; provided that with respect to determinations pursuant to this Agreement in respect of Net Sales of the World Class Sublicensee (or its affiliate or sublicensee) made in a currency other than U.S. Dollars, such amounts shall be converted into U.S. Dollars using the actual average daily buying rate for the applicable currency of the country from which the royalties are payable certified by the United States Federal Reserve Bank of New York, as</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">published from time to time by the United States Federal Reserve Board, in respect of the Calendar Quarter to which the Net Sales relate&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.14</font></font>Section 4.1 of the Agreement is hereby amended and restated in its entirety to state as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;4.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Diligence Obligations</u><font style="white-space:pre-wrap;">.  In the event that Histogenics does not make the Revenue Share Reduction Payment as described in Section 3.2(a)(iii), then Histogenics shall be obligated to [***] in order to maintain its rights under the Histogenics License.  In the event that Histogenics does make the Revenue Share Reduction Payment as described in Section 3.2(a)(iii), then Histogenics shall be obligated to [***] in order to maintain its rights under the Histogenics License.  Any failure to [***] specified in this Section 4.1 will be considered a material breach of this Agreement as that term is used in Section 8.2(a).&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.15</font></font>Section 5.2 of the Agreement is hereby amended and restated in its entirety to state as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;5.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Applications and Foreign Filing</u><font style="white-space:pre-wrap;">.  [***] shall file, prosecute and maintain in force any and all patents and patent applications included in the Licensed Patent Rights, and any patent and patent applications related to any Improvements.  The filing, prosecution and maintenance of patents and patent applications pursuant to this Section 5.2 shall be done through patent counsel selected by [***].  [***] will keep [***] reasonably informed of all significant patent matters relating to the Licensed Patent Rights within the Field as they relate to Eligible Products (including providing [***] with copies of all documents filed with the applicable patent office and all correspondence between [***] and the applicable patent office) and, to the extent [***] has the right to do so, relating to the Improvements within the Field as they relate to Eligible Products, and, to the extent [***] has the right to do so, will give [***] a reasonable opportunity to review and provide input on the prosecution of such applications, to the extent such prosecution is pertinent to Eligible Products within the Field.  If [***] decides to finally abandon or allow to lapse the subject matter of any patents or patent applications described in this Section 5.2, then to the extent such subject matter is pertinent to Eligible Products in the Field, [***] shall promptly inform [***] and, to the extent compatible with [***] obligations to Existing Angiotech Licensees, [***] shall have the right to assume filing, prosecution and maintenance of such patents and patent applications at [***] sole expense.  If [***] exercises such right to continue the filing, prosecution and maintenance of any such patent or patent application, (a) [***] shall continue to own such patent or patent application (as applicable) but shall give power of attorney to [***] and/or its legal representative to continue the filing, prosecution and maintenance of such patent or patent application; provided, however, that all terms and conditions of this Agreement shall continue to apply (including, without limitation, Sections 2.1, 2.2 and 2.3); and (b) [***] shall be entitled to set off one-half of the costs and expenses it incurs in connection with such filing, prosecution and maintenance against [***] under this Agreement after the date that [***] exercises such right with respect to the applicable patent or patent application.  [***] may cease any such activities for any reason, in which case it shall promptly notify [***] of its decision, with such notice leaving [***] or its designee a reasonable period of time to commence such activities in advance of any upcoming due dates should [***] or its designee choose to do so.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.16</font></font>Section 5.5 of the Agreement is hereby amended by adding the following clause to the end of such section immediately before the period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;; provided, however, that with respect to Clinical Data generated by the World Class Sublicensee, Histogenics shall only be required to provide Angiotech with the Clinical Data received by Histogenics from the World Class Sublicensee and only to the extent Histogenics has the right to do so&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.17</font></font>Section 7.2 of the Agreement is hereby amended and restated in its entirety to state as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>&#8220;(a) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defense of Declaratory Judgment Action</u><font style="white-space:pre-wrap;">.  In the event of an assertion of invalidity or unenforceability of Licensed Patent Rights, [***], subject to the rights of Existing Angiotech Licensees, shall have the right to defend such assertion, but to the extent such assertion relates to Eligible Products in the Field, and to the extent [***] has the right to control such defense, [***] shall reasonably consider [***] views with respect to such defense.  If [***] does not defend any such assertion that relates to Eligible Products in the Field, then [***] shall have the right, but not the obligation, to present such issue to [***] [***].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Litigation Actions</u><font style="white-space:pre-wrap;">.  Subject to the rights of Existing Angiotech Licensees, [***] shall have the right, in its sole discretion, to take actions to terminate any alleged infringement identified pursuant to Section 7.1 without litigation (including the sole right to grant a license to the alleged infringer outside the Field) with respect to Licensed Patent Rights; provided, however, where such alleged infringement involves the Licensed Patent Rights within the Field, (i) [***] shall reasonably consider the interests of [***] and shall not settle or make any agreement that would have a material adverse effect on [***] rights in the Field under this Agreement, without the prior written consent of [***], which shall not be unreasonably delayed or denied; and (ii) if [***] declines or otherwise fails to take action to terminate any such alleged infringement without litigation, then [***] shall have the right, but not the obligation, to present such issue to [***].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Litigation Actions</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;">(i)<font style="display:inline-block;width:26.56pt;"></font><font style="white-space:pre-wrap;">[***] shall have the first right, but not the obligation, to commence and control any Action related to any alleged infringement of the Licensed Patent Rights within the Field.  In the event that [***] elects, in its sole discretion, to undertake such an Action, [***] agrees to reasonably cooperate with [***], including providing access to all necessary documents in [***] control, executing all papers and performing such other acts as may be reasonably required for such Action, including, but not limited to, consenting to be joined as a Party plaintiff in such Action.  [***] shall control such Action, and [***] may enter into settlements, stipulated judgments or other arrangements respecting such infringement; provided, however, [***] shall reasonably consider the interests of [***] and shall not settle or make any agreement that would have a material adverse effect on [***]&#8217;s rights under this Agreement, without the prior written consent of Histogenics, which shall not be unreasonably delayed or denied.  [***] shall keep [***] reasonably apprised of the progress of any such Action.  [***] may, at its option and sole expense, be represented by counsel of its choice, but all other costs associated with any such Action shall be at the sole expense of [***].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>If, within [***] after discovering or being notified by [***] in writing of an alleged infringement that would be the basis of a potential Action for any alleged infringement of the Licensed Patent Rights in &#8220;Patent Family 2&#8221; and/or &#8220;Patent Family 5&#8221; (as described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>) solely within the Field (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Declined Action</u><font style="white-space:pre-wrap;">&#8221;), [***] declines to commence such Action, then [***] shall have the right, but not the obligation, to commence such Declined Action; provided that prior to commencing any such Declined Action, [***] shall reasonably consider [***]&#8217;s reasons for declining to commence the Action.  In the event that [***] elects, in its sole discretion, to commence such Declined Action, (A) [***] shall reasonably consider [***]&#8217;s input with respect to such Declined Action, including the interests of Existing Angiotech Licensees; (B) [***] shall not enter into any settlement without the prior written consent of [***]; and (C) [***] agrees to reasonably cooperate with [***], including providing access to all necessary documents in [***]&#8217;s control, executing all papers and performing such other acts as may be reasonably required for such Declined Action, such as consenting to be joined as a party plaintiff in such Declined Action, at [***] sole expense.  [***] shall keep [***] reasonably apprised of the progress of any such Declined Action.  [***] may, at its option and sole expense, be represented by counsel of its choice, but all other costs associated with any such Declined Action shall be at the sole expense of [***].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;">(iii)<font style="display:inline-block;width:21pt;"></font>If, within [***] after discovering or being notified by [***] in writing of an alleged infringement that would be the basis of a potential Action for any alleged infringement of the Licensed Patent Rights in &#8220;Patent Family 1&#8221;, &#8220;Patent Family 3&#8221; and/or &#8220;Patent Family 4&#8221; (as described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>) solely within the Field (an &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Action</u><font style="white-space:pre-wrap;">&#8221;), [***] declines to commence such Action, then [***] shall have the right, but not the obligation, to present such issue to [***], [***] may commence such Other Action; provided that (X) [***] shall reasonably consider [***]&#8217;s input with respect to such Other Action, including the interest of Existing Angiotech Licensees; (Y) [***] shall not enter into any settlement without the prior written consent of [***]; and (Z) [***] agrees to reasonably cooperate with [***], including providing access to all necessary documents in [***]&#8217;s control, executing all papers and performing such other acts as may be reasonably required for such Other Action, such as consenting to be joined as a party plaintiff in such Other Action, at [***] sole expense.  [***] shall keep [***] reasonably apprised of the progress of any such Other Action.  [***] may, at its option and sole expense, be</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">represented by counsel of its choice, but all other costs associated with any such Other Action shall be at the sole expense of [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recoveries</u><font style="white-space:pre-wrap;">.  Any damages or other recovery related to the Licensed Patent Rights, including compensatory and other non-compensatory damages or recovery actually received from a third party, shall be allocated first to reimburse the costs and expenses, including reasonable attorneys&#8217; fees and expert witness fees, of the Party controlling the matter that led to the damages or other recovery and then to reimburse the other Party for such costs and expenses, if any.  Such reimbursement shall be made first from any compensatory damages, including attorneys&#8217; fees and costs recovered.  Any remaining balance of damages or other recovery, if any, shall be considered Net Sales with [***] receiving the applicable Revenue Share of such Net Sales and [***] receiving the remaining balance.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.18</font></font>Section 7.3(a)(i) of the Agreement is hereby amended by inserting the phrase &#8220;and/or Improvements&#8221; after the phrase &#8220;relating to the use of the Licensed Technology&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.19</font></font>Section 8.2(c) of the Agreement is hereby amended by inserting the phrase &#8220;and/or patent rights to Improvements&#8221; after both instances of the phrase &#8220;any Licensed Patent Rights&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.20</font></font>A new Section 8.5 is added to the Agreement as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;8.5 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicenses</u><font style="white-space:pre-wrap;">.  If this Agreement terminates for any reason other than its natural expiration, then [***]; provided that (a) the World Class Sublicensee is not in breach of its agreement with Histogenics and (b) the World Class Sublicensee was not the cause of this Agreement being terminated.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.21</font></font>Section 10.5 of the Agreement is hereby amended by inserting the following phrase after the phrase &#8220;provided however, that&#8221; in the first sentence:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;, to the extent feasible and to the extent permitted by applicable Regulatory Authorities,&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.22</font></font>Section 10.7 of the Agreement is hereby amended and restated in its entirety to state as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;10.7 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u><font style="white-space:pre-wrap;">.  &#8220;Without limitation to the rights set forth in Section 8.2(d) and (e), this Agreement and Histogenics&#8217; rights and obligations hereunder may not be sold, assigned or transferred, in whole or in part, to any third party without the consent of Angiotech, which consent shall not be unreasonably withheld, conditioned or delayed; provided, however, Angiotech&#8217;s consent shall not be required for any such sale, assignment or transfer to the World Class Sublicensee on the condition that prior to such sale, assignment or transfer Histogenics has delivered to Angiotech a written undertaking in which the World Class Sublicensee agrees to be bound by the terms and conditions of this Agreement in the capacity of Histogenics.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Confirmation of Agreement</u><font style="white-space:pre-wrap;">.  Except as specifically otherwise amended as set forth herein, the Agreement shall continue in full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="white-space:pre-wrap;">.  This Fifth Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Facsimile signatures of the parties hereto will have the same effect as original signatures.  In making proof of this Fifth Amendment, it shall not be necessary to produce or account for more than one such counterpart.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[<font style="font-style:italic;font-weight:bold;">Signature Page Follows</font>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties have caused this Fifth Amendment to be executed and delivered by the respective duly authorized officers as of the date set forth above.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANGIOTECH PHARMACEUTICALS (US), INC.</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANGIODEVICE INTERNATIONAL GmbH</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:44.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jonathan Chen</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David D. McMasters</p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:bottom;width:44.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jonathan Chen</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David D. McMasters</p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:bottom;width:44.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. VP, Legal &amp; General Counsel</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:44.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ F. Ken Andrews</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:bottom;width:44.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">F. Ken Andrews</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:bottom;width:44.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CEO &amp; President</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: </p></td><td style="vertical-align:bottom;width:44.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8-6-10</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DEFINITION OF NET SALES FOR WORLD CLASS SUBLICENSEE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net Sales</u><font style="white-space:pre-wrap;">&#8221; shall mean, for any period, the gross amount invoiced by the World Class Sublicensee or any of its affiliates or sublicensees for the sale of Eligible Products in the territory licensed to the World Class Sublicensee, less deductions for: (a) normal and customary trade, quantity and cash discounts and sales returns and allowances, including those granted on account of price adjustments, billing errors, rejected goods, damaged goods and returns, administration fees and chargebacks; (b) freight, postage, shipping and insurance expenses to the extent that such items are included in the gross amount invoiced and relate to outbound shipping from the place of manufacture to the purchaser; (c) customs and excise duties and other duties related to the sales, to the extent that such items are included in the gross amount invoiced; and (d) rebates and similar payments made with respect to sales paid for by any governmental or regulatory authority such as, by way of illustration and not in limitation of the Parties&#8217; rights hereunder, Federal or state Medicaid, Medicare or similar state program or equivalent foreign governmental program.  Any of the deductions listed above that involves a payment by or on behalf of the World Class Sublicensee or any of its affiliates or sublicensees shall be taken as a deduction in the Calendar Quarter in which the payment is accrued by the World Class Sublicensee, its affiliate or sublicensee, as the case may be.  For purposes of determining Net Sales, an Eligible Product shall be deemed to be sold when invoiced.  The transfer by the World Class Sublicensee or any of its affiliates or any of its sublicensees of Eligible Product to the World Class Sublicensee, any of its affiliates or any of its sublicensees shall not result in any Net Sales nor shall transfers or dispositions of Eligible Product for pre clinical or clinical purposes or as samples, in each case without charge, result in any Net Sales.  Net Sales shall be calculated using International Financial Reporting Standards, consistently applied.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>10
<FILENAME>tmb-20250331xex10d35.htm
<DESCRIPTION>EX-10.35
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 03:59:56 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.35</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REINSTATEMENT AGREEMENT AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIXTH AMENDMENT TO LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS REINSTATEMENT AGREEMENT AND SIXTH AMENDMENT TO LICENSE AGREEMENT</b> (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reinstatement and Sixth Amendment</u>&#8221;), effective February 8, 2011, is by and among:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiotech Pharmaceuticals (US), Inc.</b>, a corporation organized and existing under the laws of the State of Washington, with principal offices at North Bend, WA (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiotech US</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiodevice International GmbH</b>, a corporation organized and existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiodevice</u>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Histogenics Corporation</b>, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WITNESSETH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech Biomaterials Corp. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biomaterials</u>&#8221;), Angiodevice and Histogenics entered into that certain License Agreement, effective as of May 12, 2005, pursuant to which Biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Original License Agreement</u>&#8221;), copy of which is attached hereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, effective as of November 4, 2005, all of the assets of Biomaterials were sold to Angiotech US and Biomaterials was wound up;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, in connection with such sale of assets, Biomaterials assigned the Original License Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials under the Original License Agreement as if it were the original party thereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics entered into an Amendment to License Agreement, dated as of August 31, 2007, a Second Amendment to License Agreement, dated as of January 1, 2008, a Third Amendment to License Agreement dated as of April 15, 2008, a Fourth Amendment to License Agreement, dated as of November 1, 2008, and a Fifth Amendment to License Agreement, dated as of August 6, 2010 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fifth Amendment</u>&#8221;; and the Original License Agreement, as amended by the foregoing amendments, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, pursuant to Section 3.2 of the Agreement, Histogenics elected to convert the Histogenics License to one of exclusivity by making full payment of the Exclusivity Payment pursuant to Section 3.2(a)(ii) of the Agreement, but failed to make the Revenue Share Reduction Payment prior to [***] pursuant to Section 3.2(a)(iii) of the Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiodevice, Angiotech US and Histogenics entered into the Fifth Amendment to extend the deadline for Histogenics to make the Revenue Share Reduction Payment to [***], to extend the deadline specified in Section 4.1 of the Agreement for [***], and to amend certain other provisions of the Agreement, including adding provisions relating to a potential sublicensing transaction between Histogenics and a certain sublicensee;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, because the potential sublicensing transaction with such sublicensee was not completed, Histogenics was not able to make the Revenue Share Reduction Payment by the extended deadline and, therefore, the deadline for [***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:34pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, because Histogenics did not [***], Angiotech issued to Histogenics on January 19, 2011 a notice of termination of the Agreement for material breach pursuant to Section 8.2(a) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Notice</u>&#8221;), which notice specified a termination date of February 18, 2011 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Date</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics have determined that it is in their best interests to enter into this Reinstatement and Sixth Amendment to provide for reinstatement of the Agreement under certain conditions and, in the event such conditions are met, to amend certain provisions of the reinstated Agreement; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US has [***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW</b>, <b style="font-weight:bold;">THEREFORE</b>, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="white-space:pre-wrap;">.  Capitalized terms used in this Reinstatement and Sixth Amendment shall have the meaning given to them in the Agreement unless they are otherwise defined herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reinstatement of the Agreement</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><font style="white-space:pre-wrap;">Angiodevice, Angiotech US and Histogenics acknowledge that the Agreement shall terminate as of the Termination Date.  However, if no later than [***], Histogenics has fulfilled all of the following: (a) closed a bona fide financing of Histogenics with net proceeds to Histogenics of at least [***] (the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Qualified Financing</u>&#8221;); (b)&#160;paid to Angiotech one million dollars ($1,000,000) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reinstatement Fee</u>&#8221;); and (c) paid to Angiotech fifty thousand dollars ($50,000) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Patent Fee</u>&#8221;); then on the date that Histogenics fulfills the requirements of the last of (a), (b) and (c) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reinstatement Date</u>&#8221;), the Termination Notice shall be treated as if it were never given, the Agreement shall be deemed to have continuously been in full force and effect from the Termination Date to the Reinstatement Date, and the Agreement shall continue thereafter in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font><font style="white-space:pre-wrap;">If the Agreement is reinstated pursuant to Section 2.1 of this Reinstatement and Sixth Amendment, Angiotech hereby agrees not to [***].  Angiotech hereby acknowledges that in the event that the Agreement were rejected pursuant to section 365 of the Bankruptcy Code, Histogenics would be entitled to the benefit of section 365(n) of the Bankruptcy Code and elect to either retain its rights under the Agreement or treat such contract as terminated pursuant and subject to such provision of the Bankruptcy Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment to the Reinstated Agreement</u><font style="white-space:pre-wrap;">.  The following amendments shall become effective as of the Reinstatement Date:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</font></font><font style="white-space:pre-wrap;">Sections 1.2, 1.5, 1.7, 1.10, 1.11, 1.12, 1.13, 1.16, 1.20, and 1.22 of the Fifth Amendment are hereby deleted in their entirety.  Any sections of the Agreement amended by such sections of the Fifth Amendment shall revert to the language as it existed prior to the Fifth Amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</font></font>Section 1 of the Agreement is hereby amended by adding the following new definition of &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Term</u>&#8221;:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Term</u>&#8221; means, on a country by country and product by product basis, for each Eligible Product for a particular country in the Territory, the period commencing on the First Commercial Sale of such Eligible Product in such country and ending upon the date that is the last to occur of the following: [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</font></font>The new language added to Section 3.1 of the Agreement by Section 1.8 of the Fifth Amendment is hereby amended and restated in its entirety as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;As further consideration for the Histogenics License, Histogenics shall pay to Angiotech (a) three million dollars ($3,000,000) within thirty (30) days after Histogenics receives Regulatory Approval from the FDA for an Eligible Product, and (b) the Annual Patent Fee described in Section 2.1(c) of the Reinstatement and Sixth Amendment plus an additional fifty thousand dollars ($50,000) on each of the three following anniversaries of the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:34pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Qualified Financing (for an aggregate payment of two hundred thousand dollars ($200,000) pursuant to this Section&#160;<font style="white-space:pre-wrap;">3.1(b)).  For the avoidance of doubt, receipt of such Regulatory Approval by a permitted sublicensee shall trigger Histogenics&#8217; obligation to make the payment described in Section 3.1(a).&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.4</font></font>Section 3.2(a)(iii) of the Agreement is hereby amended and restated in its entirety to state as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;(iii) The &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Share Reduction Payment</u><font style="white-space:pre-wrap;">&#8221; means an aggregate payment of [***] as follows: (A) the [***] [***] Reinstatement Fee described in Section 2.1(b) of the Reinstatement and Sixth Amendment, plus (B) [***] paid to Angiotech in six (6) equal quarterly installments of [***], with the first such quarterly payment to be made to Angiotech within [***].  If Histogenics pays to Angiotech the full Revenue Share Reduction Payment according to the payment schedule described above, Histogenics shall thereafter be required to pay to Angiotech [***] of Net Sales of those Eligible Products that contain living human cartilage cells and [***] of Net Sales of those Eligible Products that do not contain living human cartilage cells.  The payments of a percentage of Net Sales of Eligible Products as determined in this Section 3.2(a) shall be referred to herein as the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Share</u><font style="white-space:pre-wrap;">&#8221;.  Any failure to make a payment describe in (B) above on or before the applicable deadline will be considered a material breach of this Agreement as that term is used in Section 8.2(a).&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.5</font></font>Section 3.2(b) of the Agreement is hereby amended and restated in its entirety to state as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;(b) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligation to pay Revenue Share</u><font style="white-space:pre-wrap;">.  The obligation on Histogenics to pay a Revenue Share to Angiotech for a given Eligible Product in a given country as provided for in this Article 3 begins upon the First Commercial Sale for such Eligible Product in such country and ends at the end of the Royalty Term for such Eligible Product in such country.  Histogenics shall make the first payment of Revenue Share to Angiotech after the end of the Calendar Quarter in which the First Commercial Sale of an Eligible Product in any country in the Territory occurs with the timing of such payment as described in Section 3.5.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.6</font></font>Section 4.1 of the Agreement is hereby amended and restated in its entirety to state as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.7</font></font>Section 8.1 of the Agreement is hereby amended and restated in its entirety to state as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;8.1 The term of this Agreement shall, subject to the early termination provisions specifically provided for herein, begin on the Effective Date and end upon the earlier of (a) thirty (30) years, and (b) the expiration of all royalty payment obligations&#8217; hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Certification of Agreement</u><font style="white-space:pre-wrap;">.  Except as specifically otherwise amended, as set forth herein, the Agreement shall continue in full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="white-space:pre-wrap;">.  This Reinstatement and Sixth Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Facsimile signatures of the parties hereto will have the same effect as original signatures.  In making proof of this Reinstatement and Sixth Amendment, it shall not be necessary to produce or account for more than one such counterpart.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">[Signature Page Follows]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:34pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties have caused this Reinstatement and Sixth Amendment to be executed and delivered by the respective duly authorized officers as of the date first set forth above.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="3" style="vertical-align:top;width:50.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">ANGIOTECH PHARMACEUTICALS (US), INC.</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">&#160;&#160;&#160;&#160;</font></p></td><td colspan="3" style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">ANGIODEVICE INTERNATIONAL GmbH</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:50.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:46.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">/s/ K. Thomas Bailey</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">/s/ David D. McMasters</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:46.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">Name:</font></p></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">K. Thomas Bailey</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">Name:</font></p></td><td style="vertical-align:top;width:38.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">David D. McMasters</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:38.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">Title:</font></p></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">President</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">Title:</font></p></td><td style="vertical-align:top;width:38.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:38.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">Date:</font></p></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">February 8, 2011</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">Date:</font></p></td><td style="vertical-align:top;width:38.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">February 8, 2011</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:50.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">HISTOGENICS CORPORATION</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:46.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">/s/ F. Ken Andrews</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:46.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">Name:</font></p></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">F. Ken Andrews</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">Title:</font></p></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">President &amp; CFO</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">Date:</font></p></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;">February 10, 2011</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:34pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>11
<FILENAME>tmb-20250331xex10d36.htm
<DESCRIPTION>EX-10.36
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 03:59:56 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.36</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SEVENTH AMENDMENT TO LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS SEVENTH AMENDMENT TO LICENSE AGREEMENT</b> (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seventh Amendment</u>&#8221;), effective March 31, 2011, is by and among:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiotech Pharmaceuticals (US), Inc.</b>, a corporation organized and existing under the laws of the State of Washington, with principal offices at North Bend, WA (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiotech US</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiodevice International GmbH</b>, a corporation organized and existing under the laws of the Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiodevice</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:10pt;font-weight:bold;">Histogenics Corporation</b><font style="font-size:10pt;">, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of Massachusetts), with principal offices at 830 Winter Street, 3</font><font style="font-size:8.5pt;">rd</font><font style="font-size:10pt;"> floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (&#8220;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics</u><font style="font-size:10pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WITNESSETH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech Biomaterials Corp. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biomaterials</u>&#8221;), Angiodevice and Histogenics entered into that certain License Agreement, effective as of May 12, 2005, pursuant to which biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacturer and use of CT3 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Original License Agreement</u>&#8221;), a copy of which is attached hereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b> effective as of November 4, 2005, all of the assets of Biomaterials were sold to Angiotech US and Biomaterials was wound up;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, in connection with such sale of assets, Biomaterials assigned the Original License Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials under the Original License Agreement as if it were the original party thereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics entered into an Amendment to License Agreement, dated as of August 31, 2007, a Second Amendment to License Agreement, dated as of January 1, 2008, a Third Amendment to License Agreement, dated as of April 15, 2008, a Fourth Amendment to License Agreement, dated as of November 1, 2008, a Fifth Amendment to License Agreement, dated as of August 6, 2010, and a Reinstatement Agreement and Sixth Amendment to License Agreement, dated as of February 8, 2011 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reinstatement</u>&#8221;); and the Original License Agreement, as amended by the foregoing amendments (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiodevice, Angiotech US and Histogenics entered into the Reinstatement for the purpose of reinstating the Agreement and setting forth the conditions for doing so;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice and Histogenics have determined that it is in their best interests to enter into this Seventh Amendment to amend the date by which Histogenics must have closed a Qualified Financing as set forth in Section 2.1 of the Reinstatement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW</b>, <b style="font-weight:bold;">THEREFORE</b>, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. Capitalized terms used in this Seventh Amendment shall have the meaning given to them in the Agreement unless they are otherwise defined herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment of Section 2.1</u>. Section 2.1 of the Reinstatement is hereby amended to read as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2.1 Angiodevice, Angiotech US and Histogenics acknowledge that the Agreement shall terminate as of the Termination Date. However, if no later than [***] (except as to clause (a), below, for which the date shall be no later than [***]), Histogenics has fulfilled all of the following: (a) closed a bona fide financing of Histogenics with net proceeds to Histogenics of at least [***] (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Qualified Financing</u>&#8221;); (b) paid to Angiotech one million dollars ($1,000,000) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reinstatement Fee</u>&#8221;); and (c) paid to Angiotech fifty thousand dollars ($50,000) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Patent Fee</u>&#8221;); then on the date that Histogenics fulfills the requirements of the last of (a), (b) and (c) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reinstatement Date</u>&#8221;), the Termination Notice shall be treated as if it were never given, the Agreement shall be deemed to have continuously been in full force and effect from the Termination Date to the Reinstatement Date, and the Agreement shall continue thereafter in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Confirmation of Agreement</u>. Except as specifically otherwise amended as set forth herein, the Agreement shall continue in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Seventh Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures of the parties hereto will have the same effect as original signatures. In making proof of this Seventh Amendment, it shall not be necessary to produce or account for more than one such counterpart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties have caused this Seventh Amendment to be executed and delivered by the respective duly authorized officers as of the date first set forth above.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANGIOTECH PHARMACEUTICALS (US), INC.</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:50.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANGIODEVICE INTERNATIONAL GmbH</p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">K. Thomas Bailey</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:45.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David D. McMasters</p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HISTOGENICS CORPORATION</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard C. Vaillant</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard C. Vaillant</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CFO</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3-24-11</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>12
<FILENAME>tmb-20250331xex10d37.htm
<DESCRIPTION>EX-10.37
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 03:59:56 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.37</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential.  Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EIGHTH AMENDMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS EIGHTH AMENDMENT TO LICENSE AGREEMENT</b> (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Eighth Amendment</u>&#8221;), effective June 29, 2012, is by and among:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiotech Pharmaceuticals (US), Inc.</b>, a corporation organized and existing under the laws of the State of Washington, with principal offices at North Bend, WA (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiotech US</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Angiodevice International GmbH</b>, a corporation organized and existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Angiodevice</u>&#8221; and, together with Angiotech US, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensor</u>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Histogenics Corporation</b>, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WITNESSETH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech Biomaterials Corp. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biomaterials</u>&#8221;), Angiodevice and Histogenics entered into that certain License Agreement, effective as of May 12, 2005, pursuant to which Biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Original License Agreement</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, effective as of November 4, 2005, all of the assets of Biomaterials were sold to Angiotech US and Biomaterials was wound up and in connection with such sale of assets, Biomaterials assigned the Original License Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials under the Original License Agreement as if it were the original party thereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Licensor and Histogenics entered into that certain Amendment to License Agreement, dated as of August 31, 2007, that certain Second Amendment to License Agreement, dated as of January 1, 2008, that certain Third Amendment to License Agreement, dated as of April 15, 2008, that certain Fourth Amendment to. License Agreement, dated as of November 1, 2008, that certain Fifth Amendment to License Agreement, dated as of August 6, 2010, that certain Reinstatement Agreement and Sixth Amendment to License Agreement, dated as of February 8, 2011, and that certain Seventh Amendment, effective as of March 31, 2011 (the Original License Agreement, as amended by the foregoing amendments, shall be referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Section 4.1 of the Original License Agreement contained a diligence obligation requiring Histogenics to [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Histogenics desires to amend the Agreement to remove the provision requiring [***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Angiotech US, Angiodevice, and Histogenics have determined that it is in their best interests to amend the provisions regarding diligence obligations in Section 4.1 of the Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW</b>, <b style="font-weight:bold;">THEREFORE</b>, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0.25pt;"><font style="display:inline-block;text-indent:0pt;width:35.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1 </font></font>Section 4.1 of the Agreement is hereby amended and restated in its entirety to state as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;4.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Diligence Obligations</u>. It is understood and acknowledged that part of the consideration for this License is Histogenics&#8217;s intention to bring one or more Eligible Products to market through a program for exploitation of the Licensed Technology and, once commercialized, thereafter to continue active, diligent marketing and sales efforts for Eligible Products throughout the life of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0.25pt;"><font style="display:inline-block;text-indent:0pt;width:35.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1 </font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Confirmation of Agreement</u>. Except as specifically otherwise amended as set forth herein, the Agreement shall continue in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2 </font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Eighth Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures of the parties hereto will have the same effect as original signatures. In making proof of this Eighth Amendment, it shall not be necessary to produce or account for more than one such counterpart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">[Signature Page Follows]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties have caused this Eighth Amendment to be executed and delivered by the respective duly authorized officers as of the date set forth above.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANGIOTECH PHARMACEUTICALS (US), INC.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANGIODEVICE INTERNATIONAL GmbH</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tammy Neske</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ K. Thomas Bailey</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Name:  </font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tammy Neske</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">K. Thomas Bailey</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Authorized Signatory</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 29, 2012</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: </p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 29, 2012</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HISTOGENICS CORPORATION</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Patrick O&#8217;Donnell</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patrick O&#8217;Donnell</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President &amp; CEO</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 29, 2012</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>13
<FILENAME>tmb-20250331xex10d38.htm
<DESCRIPTION>EX-10.38
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 03:59:58 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.38</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Agreement made and entered into as of the 22nd day of June, 2012, by and between Purpose Co., Ltd., f/k/a Takagi Sangyo Co. Ltd., and also f/k/a Takagi Industrial Co., Ltd., a Japanese corporation (&#8220;Takagi&#8221;), and Histogenics Corporation, a Delaware corporation (&#8220;Histogenics&#8221;) (the &#8220;Agreement&#8221;). The parties agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Introduction</u>. Takagi and Histogenics are parties to the following agreements and no others (the &#8220;Existing Agreements&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subscription and Business Agreement dated July 6, 2000 <br>Amendment to Subscription and Business Agreement dated September 23, 2005 <br>Supplemental Agreement dated May 11, 2006.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The purpose of this Agreement is to amend, restate and otherwise terminate the Existing Agreements and replace them with this Agreement. The parties further acknowledge that Histogenics is party to a term sheet dated February 24, 2012 with [***] (the &#8220;[***] Term Sheet&#8221;), a copy of which is attached hereto as Exhibit A. This Agreement is being entered into in contemplation of the Initial Closing under the [***] Term Sheet (the &#8220;Effective Date&#8221;), and this Agreement shall be in full force and effect as of the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Existing Agreements</u>. Upon the Effective Date, the Existing Agreements shall be of no further force and effect and this Agreement and any other agreements attached as or contemplated by Exhibits to this Agreement shall represent the entire understanding of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License of Technology</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License to Histogenics</u>. Takagi hereby grants to Histogenics outside of Japan the perpetual (with respect to patent rights, for the full term of each patent licensed hereunder), paid-up, worldwide, sublicensable, exclusive right under all patent rights (&#8220;Takagi Patents&#8221;) and technology (including, but not limited to, all know-how, trade secrets, copyrightable works, design and technical information and all improvements, modifications, updates or derivatives thereof) (the &#8220;Takagi Technology&#8221;) relating to Takagi&#8217;s exogenous tissue processor as used for producing the Histogenics Product Line (as such term is defined in Section 3(b) below), whether owned by Takagi or based upon rights held by Takagi, and whether now owned or held by Takagi or at any time following the date of this Agreement , in the Field of Use (as defined below) to (i) use, make, have made, sell, offer for sale, and import products or services that would, but for the license granted under the Takagi Patents, infringe a valid claim of any Takagi Patent, and (ii) use, reproduce, modify and create derivative works of the Takagi Technology for the design, development, manufacture, testing, support and commercialization of any product or service that incorporates or builds upon the Takagi Technology. The Takagi Patents hereby include, without limitation, the patent rights owned by Takagi that are listed on Exhibit B-1 to this Agreement. The &#8220;Field of Use&#8221; consists of any applications of the Takagi Technology and Histogenics Technology (as defined below) in connection with articular cartilage, ligaments, tendons and meniscus. Takagi retains its rights to the Takagi Technology and Takagi Patents for any applications outside the Field of Use. Takagi shall also have the right to sell its TEPs (as such term is defined below) in Section 4 to research institutes for general but noncommercial use anywhere in the world. Takagi acknowledges that the license granted hereby gives Histogenics the right but not the obligation, to use the Takagi Technology or practice the Takagi Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(b) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License to Takagi</u>. Histogenics hereby grants to Takagi the perpetual (with respect to patent rights, for the full term of each patent licensed hereunder), paid-up, subslicensable, exclusive right solely in Japan under all patent rights (&#8220;Histogenics Patents&#8221;) and technology (including, but not limited to, all know-how, trade secrets, copyrightable works, design and technical information and all improvements, modifications, updates or derivatives thereof) (the &#8220;Histogenics Technology&#8221;) relating to Histogenics&#8217; biotechnology and biomaterials, whether owned by Histogenics or based upon rights held by Histogenics, and whether now owned or held by Histogenics or at any time following the date of this Agreement in the Field of Use to (i) use, make, have made, sell, offer for sale, and import</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">products and services that would, but for the license granted under the Histogenics Patents, infringe a valid claim of any Histogenics Patent, and (ii) use, reproduce, modify and create derivative works of the Histogenics Technology for the design, development, manufacture, testing, support and commercialization of any product or service that incorporates or builds upon the Histogenics Technology. The Histogenics Patents hereby include, without limitation, the patent rights owned by Histogenics that are listed on Exhibit B-2 to this Agreement. Histogenics retains its rights to the Histogenics Technology and Histogenics Patents for any applications outside the Field of Use and for inside the Field of Use anywhere in the world other than Japan. Histogenics acknowledges that the license granted hereby gives Takagi the right, but not the obligation, to use the Histogenics Technology or practice the Histogenics Patents in Japan. Notwithstanding anything to the contrary contained in the foregoing, the license rights granted to Takagi under this Section 3(b) are limited to the following Histogenics&#8217; products: Neocart[***] (both individually and collectively, the &#8220;Histogenics Product Line&#8221;). Histogenics represents to Takagi that as of the date of this Agreement the Histogenics Product Line represents all of the products it has currently under development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sale of Machines</u>. Takagi shall continue to manufacture and sell single unit exogenous tissue processor machines (so-called &#8220;TEPs&#8221;) to Histogenics to the extent desired by Histogenics. Prior to the commercialization of Histogenics&#8217; first product (&#8220;Neocart&#8221;), Takagi shall sell TEPs to Histogenics at [***]. Thereafter, Takagi shall sell TEPs to Histogenics at [***]. Within 60 days of the execution of this Agreement, the parties shall enter into a service agreement, the form of which shall be attached to this Agreement as Exhibit C, which service agreement shall cover the maintenance and servicing of both the existing TEPs owned by Histogenics and any additional TEPs that Histogenics may purchase from Takagi in the future. The parties agree that the service agreement shall be &#8220;industry standard&#8221; as to its form and terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reimbursement of Development Costs</u>. The parties acknowledge that Takagi has incurred 19,572,000 YEN in costs prior to the date of this Agreement in developing a multi-unit TEP on Histogenics behalf. On the Effective Date Histogenics shall pay that amount to Takagi. Takagi acknowledges that Histogenics intends to continue the development of a multi-unit TEP with an alternative supplier and that Histogenics shall not be liable for any future costs incurred by Takagi in developing a multi-unit TEP absent a separate written agreement between the parties for that purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Territories</u>. The parties acknowledge that pursuant to the Existing Agreements various portions of the world were not allocated between the parties as exclusive Territories for exploiting the Takagi Technology and Histogenics&#8217; Technology. The parties hereby acknowledge and agree that Histogenics shall have worldwide rights to its products and technology and, within the Field of Use, the Takagi Technology with the sole exception that Takagi shall retain the exclusive rights to commercialize, manufacture, and sell the Histogenics Product Line in the Field of Use in Japan. Histogenics shall cooperate with Takagi, and provide such Histogenics Technology, data and technical information, support, and assistance to Takagi, at Takagi&#8217;s sole cost and expense, in order to commercialize all or any portion of the Histogenics Product Line in the Field of Use and to obtain the requisite governmental approvals to manufacture and sell the Histogenics Product Line in Japan from the Ministry of Health, Labour and Welfare. Prior to commercialization of the Histogenics Product Line in Japan, Histogenics shall supply Takagi with its clinical requirements of collagen scaffolds and CT3 at [***]. Upon commercialization of the Histogenics Product Line, Histogenics shall supply Takagi with such components at [***]. Takagi shall be responsible for [***]. Prior to commercialization of any of the products included in the Histogenics Product Line in Japan, the parties shall enter into an agreement that will address supply of components, sales and royally reporting and payments due to third parties, audit rights of sales records, and other commercially reasonable requirements. To the extent that Takagi is assisted in the commercialization, manufacture, sale or governmental approval process of the Histogenics Product Line or other Histogenics products in the Field of Use by third parties, Takagi agrees that it shall cause such parties to enter into appropriate nondisclosure and confidentiality agreements in such form as Histogenics shall reasonably require.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">7. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brigham and Women&#8217;s License</u>. Reference is made to the existing license between Takagi and the Brigham and Women&#8217;s Hospital, Inc. dated August 1, 2001 as amended by agreements dated December 30, 2005 and May 4, 2010 (the &#8220;B&amp;W License&#8221;). Pursuant to the Existing Agreements, Histogenics has undertaken to pay any royalties due under the B&amp;W License to the extent that such royalties are measured by Histogenics&#8217; revenue. Histogenics has also agreed to pay any minimum royalties or milestone payments required by Sections 4.4 and 4.5 of the B&amp;W License. Histogenics shall continue to honor these obligations until such time as Histogenics is no longer using the technology licensed by the B&amp;W License. Upon written notice from Histogenics of its intent to cease using the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">technology licensed by the B&amp;W License, Takagi shall reassume all responsibility under the B&amp;W License or, at Takagi&#8217;s option, allow the B&amp;W License to lapse. Histogenics shall defend, indemnify and hold Takagi harmless from any claim by or liability to [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consideration</u>. At such time as when Histogenics enters into a transaction that would constitute an &#8220;Event of Liquidation&#8221; as defined in the [***] Term Sheet (a &#8220;Liquidity Event&#8221;), then, upon the closing of such Liquidity Event, Takagi shall be paid from the proceeds, as, if; when and &#8220;in-kind&#8221; received by Histogenics or its stockholders, the Consideration (as such term defined below). The term &#8220;Consideration&#8221; shall mean 7.8125% of the net proceeds of any Liquidity Event. In the event that Histogenics requires financing exceeding the $48 million contemplated by the [***] Term Sheet prior to a Liquidity Event, and one or more the investors (including their successors and assigns) participating in the financing contemplated by the [***] Term Sheet (the &#8220;[***] Investors&#8221;) also participate in such additional financing, then the Consideration will be subject to dilution pursuant to the following formula:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:49.71%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$48M</p></td><td rowspan="2" style="vertical-align:middle;width:85.82%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x 7.8125% = New Consideration Percentage</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:14.17%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">($48M +$x)</p></td><td style="display:none;vertical-align:top;width:85.82%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">where $x is the additional amount of equity investment beyond the $48 million contemplated by the [***] Term Sheet. The Consideration shall be paid from the net proceeds to be received by the Histogenics&#8217; stockholders after the payment of; (a) transaction costs to unaffiliated third parties, (b) repayment of debt incurred after the Effective Date, if any, and (c) the payment of all rights and preferences due to the [***] Investors. To the extent that the stockholders of Histogenics receive payment of the purchase price from a Liquidity Event over time, such as an escrow, installment sale or earnout, then the Consideration shall be paid as funds (whether in cash or in-kind) are actually received by the stockholders of Histogenics. At the Effective Date, the stockholders (which term in this Agreement includes the [***] Investors) shall enter into a Stockholders Agreement whereby they agree on behalf of themselves and their successors and assigns to irrevocably authorize Histogenics to pay the Consideration upon the occurrence of a Liquidity Event from the proceeds thereof directly to Takagi in accordance with the terms hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If, in lieu of a Liquidity Event, Histogenics shall undertake an initial public offering of its common stock (an &#8220;IPO&#8221;) then immediately prior to the IPO Histogenics and/or its stockholders shall pay the Consideration in shares of its common stock valued at the IPO price, as determined by the Histogenics IPO pricing committee (the &#8220;Shares&#8221;). For purposes of determining the aggregate number of Shares to be issued to Takagi in such case, Histogenics shall take its pre-IPO value as determined by the Histogenics IPO pricing committee, subtract from that amount the transaction costs of the IPO, the amount of post-Effective Date indebtedness, if any, of Histogenics at the time and the amount of all rights and preferences of the [***] Investors, and then multiply the result by the Consideration percentage. [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subject to execution of any applicable confidentiality or nondisclosure agreement, Takagi shall have the right to receive and review copies of the closing documentation and agreements relating to any Liquidity Event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation with [***] Closing</u>. Takagi agrees to cooperate with Histogenics to assist it in closing the transactions contemplated by the [***] Term Sheet including without limitation executing such documents, votes, and certificates as Histogenics or the investors in the transactions contemplated thereby may reasonably request; provided, however, that none of such documents, votes or certificates shall be inconsistent with the provisions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>. Each party shall indemnify, defend and hold each other and their respective directors, officers, employees and agents, and their respective heirs, successors and assigns (the &#8220;Indemnitees&#8221;) harmless from and against any liability, damage, loss or expense (including reasonable attorney&#8217;s fees) incurred by or imposed upon the Indemnitees or any one of them in connection with any third-party claims, suits, actions, demands or judgments arising out of [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">11. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u>. Except as specified in Section 6, above, each party shall keep confidential any non-public information disclosed by or on behalf of, and belonging to, the other party in connection with this Agreement, whether marked as proprietary or confidential, or which, by the circumstances of the disclosure, would reasonably</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">be understood as the proprietary information of such other party, including, but not limited to all know-how, trade secrets and proprietary technical information. The receiving party shall not disclose the other party&#8217;s confidential information to any third party and shall protect such information with the same degree of care as it uses to protect its own confidential information of similar importance, but in no case using less than a reasonable degree of care, and may only disclose the confidential information to its affiliates, employees, agents or independent contractors on a need-to-know basis and who are bound by written confidentiality obligations consistent with the receiving party&#8217;s obligations hereunder. The receiving party shall only use the other party&#8217;s confidential information to perform its obligations or exercise its rights under this Agreement. If the receiving party receives a request pursuant to a court order, governmental body request or other legal process to disclose the other party&#8217;s confidential information, the receiving party will promptly notify the other party and provide reasonable assistance to limit the scope of the required disclosure or seek a protective order. The receiving party shall not be subject to confidentiality obligations for confidential information that (a) at the time of receipt was already known to it without confidentiality obligation; (b) becomes publicly known through no wrongful act of the receiving party; (c) was received from a third party without confidentiality restrictions; (d) is independently developed by the receiving party without use of the confidential information of the other party; or (e) is approved for release by prior written authorization by the other party or its authorized agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">12. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Prosecution</u>. Each party will have the sole right to make all decisions regarding the filing, prosecution and maintenance of its respective patents. Without limiting the foregoing, if a party does not make any filing or payment related to the prosecution or maintenance of any patent or patent application which it owns and is licensed under this Agreement (the Takagi Patents or Histogenics Patents, as applicable) or intends not to make such payment or filing or to abandon or allow any right to any such patent or patent application to lapse, it will promptly inform the other party, and such other Party will have the right, exercisable in its sole discretion and expense, to file or continue the prosecution or maintenance of such patent or patent application in its own name.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">13. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Enforcement</u>. Each party shall promptly notify the other party of any suspected infringement by a third party of which it is aware concerning the Takagi Patents or Histogenics Patents. [***] will have the first right, but not the obligation to initiate and prosecute legal proceedings with respect to any patent [***] under this Agreement ([***], as applicable), at its own expense, and to control the defense of any such action. If [***] does not intend to pursue any legal proceeding, [***] will promptly inform [***], and [***] will have the right, but not the obligation, to initiate an action at its own cost and expense only to the extent the potential infringement pertains to [***]&#8217;s products or services covered by a patent [***]. [***] will reasonably cooperate with [***] in any such effort, including being joined as a party to such action if necessary, at the expense of [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">14. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u>. The interpretation and application of this Agreement shall be governed by the laws of the Commonwealth of Massachusetts, which shall also serve as the exclusive venue for the resolution of any disputes. The failure of any party to enforce at any time any provision of this Agreement or any right with respect thereto, or to exercise any election as herein provided, shall in no way be considered to be a waiver of such provision, right or election, or in any way affect the validity of this Agreement. The exercise by any party of any right or election under the terms of this Agreement shall not preclude or prejudice any party from exercising the same or any other right it may have under this Agreement. Neither this Agreement nor the rights or obligations under it may be assigned by either party to a third party without the prior written consent of the other party, except that either party may assign this Agreement, or the rights or obligations under it, in connection with any merger, consolidation, sale of all or substantially all of its assets, equity or the business to which this Agreement relates, or similar business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. Written notices under this Agreement shall be addressed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">If to Takagi:</p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">Purpose Co., Ltd.</p></td></tr><tr><td style="vertical-align:bottom;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">Medical Technology and Business Development Department </p></td></tr><tr><td style="vertical-align:bottom;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">201 Nishi-Kashiwabara Shinden</p></td></tr><tr><td style="vertical-align:bottom;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">Fuji-shi Shizuoka 417-8505</p></td></tr><tr><td style="vertical-align:bottom;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">Japan</p></td></tr><tr><td style="vertical-align:bottom;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">Attn: [***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">With a copy to:</p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 16.55pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:80.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">If to Histogenics:</p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">Histogenics Corporation</p></td></tr><tr><td style="vertical-align:bottom;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">830 Winter Street</p></td></tr><tr><td style="vertical-align:bottom;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">3rd Floor</p></td></tr><tr><td style="vertical-align:bottom;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">Waltham, MA 02451</p></td></tr><tr><td style="vertical-align:bottom;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">Attn: Patrick O&#8217;Donnell, President and CEO</p></td></tr><tr><td style="vertical-align:bottom;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">With a copy to:</p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">Brown Rudnick LLP</p></td></tr><tr><td style="vertical-align:bottom;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">One Financial Center</p></td></tr><tr><td style="vertical-align:bottom;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">Boston, MA 02111</p></td></tr><tr><td style="vertical-align:bottom;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16.55pt;">Attn: [***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or to such other address as either party may request in writing. Notices sent by mail, facsimile, overnight delivery or email shall be effective if actually received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">16. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Agreement and the Exhibits hereto constitute the entire agreement and understanding between the parties and neither party shall be obligated by any condition or representation other than those expressly stated herein or as may be subsequently agreed by the parties hereto in writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">17. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Agreement may be executed in one or more counterpart signature pages, and executed signature pages may be delivered via facsimile or via email with PDF scan attachment, each of which shall be deemed an original but all of which together will constitute one and the same instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as an instrument under seal by their duly authorized representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;" align="center"><tr style="height:43.2pt;"><td colspan="2" style="vertical-align:top;width:46.39%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">PURPOSE CO., LTD.,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">F/K/A TAKAGI SANGYO CO., LTD. AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">F/K/A TAKAGI INDUSTRIAL CO., LTD.</b></p></td><td colspan="2" style="vertical-align:top;width:53.6%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HISTOGENICS</b> CORPORATION</p></td></tr><tr><td style="vertical-align:top;width:9.53%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:36.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Chiharu Ishikawa</p></td><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Patrick O&#8217;Donnell</p></td></tr><tr><td style="vertical-align:top;width:9.53%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:36.86%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chiharu Ishikawa</p></td><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:45.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patrick O&#8217;Donnell</p></td></tr><tr><td style="vertical-align:top;width:9.53%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:36.86%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Executive Director</p></td><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:45.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President &amp; CEO</p></td></tr><tr><td style="vertical-align:top;width:9.53%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:36.86%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 25, 2012</p></td><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:45.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 25, 2012</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">[***] TERM SHEET</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONFIDENTIAL TERM SHEET</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR PROPOSED INVESTMENT IN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">This Term Sheet summarizes the terms and conditions of a proposed investment by [***] through its affiliates in Histogenics Corporation It is for discussion purposes only and, except to the extent set forth herein, is not binding upon any party. Specific provision(s) may be made binding upon the parties by explicitly so stating within this Term Sheet. Neither party is obligated to consummate an investment unless and until a definitive investment agreement has been mutually agreed to and executed by the parties [***] will serve as the lead investor for this financing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Signature Page Follows]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><b style="font-weight:bold;">Accepted by Histogenics Corporation:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Accepted by [***]:</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">/s/ Patrick O&#8217;Donnell 2-28-12</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ [***] 2/14/12</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Signature Date</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature Date</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Patrick O&#8217;Donnell</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Printed Name</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Printed Name</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">President &amp; CEO</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Position</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Position</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT B-1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TAKAGI PATENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT B-1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TAKAGI PATENTS*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT B-2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">HISTOGENICS PATENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT B-2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">HISTOGENICS PATENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SERVICE AND MAINTENANCE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PURPOSE CO., LTD. EQUIPMENT MAINTENANCE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement No. PM12001</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Agreement, effective this day of July, 2012, made and entered into by and between</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purpose Co., Ltd.</b> Hereinafter called &#8220;Provider&#8221; and <br><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics Corporation</b> Hereinafter called &#8220;Customer&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PROVIDER:</b></p></td><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:57.6pt;"><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3508 Aza-mikaeshi Kamiide,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fujinomiya, Shizuoka. 418-0103</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">JAPAN</p></td><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phone:[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fax:[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contact:[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email:[***]</p></td></tr><tr><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CUSTOMER:</b></p></td><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">830 Winter St.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3rd Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waltham, MA 02145</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USA</p></td><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phone: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fax: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contact: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: [***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">This Agreement supersedes and replaces all prior service and maintenance agreements between the parties.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Customer, for the full, complete and faithful performance of this Agreement, agrees to pay Provider in accordance with the rates and prices as stated herein, and Provider, for the rates and prices stated herein, agrees to perform the services set forth herein.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment Covered by this Agreement</u> (the &#8220;Equipment&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Refer to EXHIBIT A. As Customer purchases new Equipment from Provider, such Equipment shall automatically be deemed included on Exhibit A.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Place of Servicing</u>. The Equipment is to be serviced at 830 Winter Street, 3rd Floor, Waltham, MA 02145. (&#8220;Permanent Installation Location&#8221;) or such other location as Customer may elect by notice to Provider.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u>. Unless earlier terminated in accordance with the terms hereof, this Agreement shall be in effect from the date hereof, and shall automatically and continually renew for additional one year periods (the &#8220;Term&#8221;) until such date as Customer elects to terminate by giving thirty (30) days prior notice to Provider.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Type of Service</u>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preventive Maintenance Service</u>. During the Term, Customer shall receive from Provider preventive maintenance service for the Equipment at regular intervals, twice every twelve month period (&#8220;PM Service&#8221;). Customer will provide written notice to Provider requesting PM Service, and following such request, the Customer and Provider will agree upon a mutually convenient date(s) and time(s) for the performance of the PM Service, provided that in no event shall such PM Service be performed by Provider later than sixty (60) days after Customer&#8217;s request. The services to be performed during the PM Service are set forth in Section 7 below.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Service</u>. In addition to the PM Service, upon request from Customer, Provider shall provide Customer with such additional services for the Equipment, including emergency repair services (&#8220;Additional Service&#8221;), as set forth in Section 8 below.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technical Assistance</u>. Provider shall provide Customer, at no additional cost, any information and technical specifications and assistance concerning the Equipment that Customer may require in connection with pursuing any governmental approvals for Customer&#8217;s products, including without limitation the U.S. Food and Drug Administration.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rates for Maintenance</u>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preventive Maintenance Service</u>. [***] per year for each TEP and up to two (2) TCUs. In addition, Provider shall be reimbursed its reasonable travel expenses, including airfare, ground transportation, hotel, and meals, and any related taxes, for each PM Service visit (&#8220;PM Service Rate&#8221;).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rate for Additional Service</u>. [***] per hour at Provider&#8217;s location or [***] per hour at any Permanent Installation Location, plus associated travel expenses and any taxes (&#8220;Additional Rate&#8221;).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PM Service to be Performed by Provider</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provider agrees to provide the inspection and PM Service according to the check list and protocol developed by Provider. Price quote of replacement parts will be provided to the Customer prior to each PM Service or Additional Service. A CHARGE WILL BE MADE FOR ANY PARTS REPLACED AT AN AMOUNT EQUAL TO THE PROVIDER&#8217;S STANDARD PRICING. Labor involved in repairing damage due to Customer mishandling, or improper operation of the Equipment will be charged at Additional Rate as provided in paragraph 6(b) of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There is no warranty to PM by Provider. Provider warrants the replacement parts within the range of Additional Service.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Service to be Performed by Provider</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provider agrees to provide the following Additional Services upon receipt of a request from Customer:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the inspection, testing and diagnostic evaluation (either on site or remotely) by the Provider;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">any fault reporting and resolving in an item of the Equipment;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the repair or replacement of parts;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">reinstallation of the Equipment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provider will promptly evaluate each Additional Service request received from Customer to determine if servicing can be addressed remotely. If on-site service is required the Provider will send a technician to the Customer within fourteen (14) days of requesting the on-site service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A price quote for replacement parts will be provided to the Customer prior to this service. A CHARGE WILL BE MADE FOR ANY PARTS REPLACED AT AN AMOUNT EQUAL TO THE PROVIDER&#8217;S STANDARD PRICING.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provider warrants that the repairs will remain in good working order and repair for a period of twelve (12) months following the repair.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">10.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Terms</u>. Provider shall invoice Customer for each PM Service and Additional Service separately. Customer&#8217;s payment shall be due net thirty (30) days from the invoice date. Upon request of Customer, Provider shall provide reasonable supporting documentation with respect to any invoice issued to Customer.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">11.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Renewal</u>. Unless terminated by either party as set forth below, Provider shall be entitled to increase its rates for maintenance no more often than every 12 months and in any event no more than [***] per annum. Provider</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">shall give Customer no less than sixty (60) days prior notice of any rate increase and will forward to Customer the rates that will take effect in the new term.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">12.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u>. Customer may terminate this Agreement at any time following thirty (30) days written notice. Provider shall have no right to terminate this Agreement except in the case of (i) Customer&#8217;s breach of its obligations hereunder to Provider after thirty (30) days&#8217; notice to Customer and Customer&#8217;s failure to cure such breach within such time period, (ii) Customer&#8217;s bankruptcy, insolvency, or assignment for the benefit of creditors, or (iii) Customer&#8217;s sale or cessation of business operations.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">13.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warranty</u>. Provider warrants that it shall have and maintain sufficient resources, facilities, capacity and manpower to assure that the services under this Agreement are diligently performed in accordance with the terms and conditions of this Agreement in a timely, skillful, professional, workmanlike and competent manner, by qualified persons familiar with the Equipment and fully trained to service the Equipment, and that the services provided shall conform to or exceed the standards generally observed in the industry for similar services. Notwithstanding the foregoing, Provider does not guaranty that damaged or worn Equipment will be successfully repaired or that all unique replacement parts for the Equipment will be readily available.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">14.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. All notices or other communications which are required or permitted hereunder shall be in writing and sufficient if delivered by hand, by facsimile transmission, by electronic mail, by registered or certified mail, postage pre-paid, or by courier or overnight carrier, to the applicable party at the addresses set forth above (or at such other address as may be provided hereunder), and shall be deemed to have been delivered (a) on the date of delivery if delivered personally, or by telecopy, facsimile or electronic mail, upon confirmation of receipt of delivery, (b) on the second business day following the date of dispatch if delivered by a nationally recognized next-day courier service, or (c) on the fifth business day following the date of mailing if delivered by registered or certified mail return receipt requested, postage prepaid.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">15.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement shall be governed by and construed in accordance with the Laws of the Commonwealth of Massachusetts, without regard to principles of conflicts of law.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u>. No amendment of any provision of this Agreement shall be effective unless the same shall be in writing and signed by the Customer and the Provider.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">17.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Waiver</u>. The waiver or failure of either party to exercise any right provided for herein shall not be deemed a waiver of any further right hereunder.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">18.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Relationship of Parties</u>. The performance by Provider of its duties and obligations under this Agreement shall be that of an independent contractor, and nothing herein shall create or imply an agency relationship between Provider and Customer, nor shall this Agreement be deemed to constitute a joint venture or partnership between the parties. Personnel supplied by Provider shall not be considered employees or agents of Customer for any purpose. Provider assumes full responsibility for the acts of such personnel while performing the Services and shall be solely responsible for such personnel&#8217;s supervision, direction and control, compensation, benefits and taxes.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">19.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. The invalidity or unenforceability of any one or more phrases, sentences, clauses, paragraphs, or sections contained in this Agreement shall not affect the validity or enforceability of the remaining portions of this Agreement hereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">20.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u>. This Agreement shall apply in all respects to successors and permitted assigns of Provider and inure to the Customer and its successors and permitted assigns. This Agreement shall not be assignable either in whole or in part by either of the parties without a prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:17.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">21.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Agreement contains the entire agreement of the Customer and Provider with respect to the matters set forth herein.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">22.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Agreement may be executed in counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party. Facsimile transmission of any signed original document shall be deemed the same as delivery of an original.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized representatives:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Authorized Representative for <b style="font-weight:bold;">Provider</b></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Authorized Representative for <b style="font-weight:bold;">Customer</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PURPOSE CO., LTD.</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">HISTOGENICS CORPORATION</p></td></tr><tr><td style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">By:</p></td><td style="vertical-align:top;width:40.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">By:</p></td><td style="vertical-align:top;width:39.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Name:</p></td><td style="vertical-align:top;width:40.41%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Name:</p></td><td style="vertical-align:top;width:39.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Title:</p></td><td style="vertical-align:top;width:40.41%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Title:</p></td><td style="vertical-align:top;width:39.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">EXHIBIT A</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment List</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:26.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Equipment Description</p></td><td style="vertical-align:bottom;width:21.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Serial Number</p></td><td style="vertical-align:bottom;width:47.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Histogenics Equipment Number</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1</p></td><td style="vertical-align:bottom;width:26.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02</p></td><td style="vertical-align:bottom;width:21.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02-07</p></td><td style="vertical-align:bottom;width:47.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EQ-115</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02</p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02-08</p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EQ-116</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02</p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02-09</p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EQ-117</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02</p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02-10</p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EQ-118</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02</p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02-11</p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EQ-290</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02</p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02-12</p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EQ-194</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02</p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TEP-P02-13</p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EQ-195</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">14</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">17</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">19</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">26</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">27</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">28</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">29</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">30</p></td><td style="vertical-align:bottom;width:26.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>14
<FILENAME>tmb-20250331xex10d39.htm
<DESCRIPTION>EX-10.39
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:06 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.39</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FIRST AMENDMENT TO AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This First Amendment to the Agreement (this &#8220;First Amendment&#8221;) effective as of May 9, 2016 (the &#8220;First Amendment Effective Date&#8221;) is made by and between <b style="font-weight:bold;">Purpose Co., Ltd.</b>, f/k/a Takagi Sangyo Co. Ltd., and also f/k/a Takagi Industrial Co., Ltd., a Japanese corporation (&#8220;Purpose&#8221; or &#8220;Takagi&#8221;), and <b style="font-weight:bold;">Histogenics Corporation</b>, a Delaware corporation (&#8220;Histogenics&#8221;). All capitalized terms used, but not otherwise defined in this First Amendment, shall have the same meanings ascribed thereto in the Agreement made and entered into by and between Purpose and Histogenics as of June 22, 2012 (the &#8220;Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Purpose has exclusively licensed to Histogenics perpetual use of all of Purpose&#8217;s patent rights relating to Purpose&#8217;s exogenous tissue processor as used for producing the Histogenics Product Line pursuant to the Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Purpose and Histogenics desire to amend the Agreement in the manner and on the terms and conditions set forth in this First Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">NOW THEREFORE, in consideration of the mutual promises and covenants in this First Amendment and other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Purpose and Histogenics hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TERMS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. Except as set forth below, capitalized terms used but not defined herein shall have the meanings given them in the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2. Revised Section 3. Section 3 of the Agreement is hereby deleted and replaced with the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;(a) License to Histogenics. Purpose hereby grants to Histogenics the perpetual (with respect to patent rights, for the full term of each patent licensed hereunder), paid-up, worldwide, sublicensable, exclusive right under all patent rights (&#8220;Purpose Patents&#8221;) and technology (including, but not limited to, all know-how, trade secrets, copyrightable works, design and technical information and all improvements, modifications, updates or derivatives thereof) (the &#8220;Purpose Technology&#8221;) relating to Purpose&#8217;s exogenous tissue processor as used for producing NeoCart [***] (collectively, the &#8220;Histogenics Product Line&#8221;), whether owned by Purpose or based upon rights held by Purpose, and whether now owned or held by Purpose or at any time following the date of this Agreement, in the Field of Use (as defined below) to (i) use, make, have made, sell, offer for sale, import and otherwise exploit products or services that would, but for the license granted under the Purpose Patents, infringe a valid claim of any Purpose Patent, and (ii) use, reproduce, modify, create derivative works of and otherwise exploit the Purpose Technology for the design, development, manufacture, testing, support and commercialization of any product or service that incorporates or builds upon the Purpose Technology. The Purpose Patents hereby include, without limitation, the patent rights owned by Purpose that are listed on Exhibit 3 to the Agreement, as well as [***]. The &#8220;Field of Use&#8221; consists of any applications in connection with articular cartilage, ligaments, tendons and meniscus. Purpose retains its rights to the Purpose Technology and Purpose Patents for any applications outside the Field of Use. Purpose shall also have the right to sell its TEPs (as such term is defined below) in Section 4 to research institutes for general but noncommercial use anywhere in the world. Purpose acknowledges that the license granted hereby gives Histogenics the right, but not the obligation, to use the Purpose Technology or Purpose Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(b) Termination of License to Purpose. The license under the Histogenics Patents and the Histogenics Technology (both as respectively defined in former Section 3(b) of the Agreement) previously granted by Histogenics to Purpose in the Agreement is hereby terminated. Histogenics shall assume sole responsibility for the development of and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">commercialization of all or any portion of the Histogenics Product Line in Japan, and Histogenics shall be the sole bearer of any accompanying expenses.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revised Section 6</u>. Section 6 is hereby deleted and replaced with the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6 (a) Obligations of Histogenics in Japan</u>. Histogenics shall, at its sole expense, use Commercially Reasonable Efforts (as defined below) to obtain the requisite government approvals to manufacture and sell the Histogenics Product Line, in Japan from the Ministry of Health, Labour and Welfare (&#8220;MHLW&#8221;) in Japan. Where reasonable, these activities shall include establishing NeoCart&#8217;s related manufacturing processes and facilities to Japan, conducting any requisite additional preclinical and clinical trials, and the engagement of clinical research organizations (&#8220;CROs&#8221;) to translate and assist in the submission of documents to the PMDA. Histogenics shall bear all responsibilities for any and all third party royalty obligations related to sales of the Histogenics Product Line in the Field of Use in Japan, the responsibilities of which were previously Purpose&#8217;s under the Agreement. For the purposes of this Section, &#8220;Commercially Reasonable Efforts&#8221; shall mean the fulfilling of obligations diligently and in good-faith, in each case, in a manner consistent with the efforts a party would be expected to devote to a product of similar market potential, profit potential, strategic value and potential for receiving all required regulatory approvals required for marketing, sale and distribution, resulting from its own research efforts, based on conditions then prevailing, taking into account, without limitation, issues of safety and efficacy, product profile, intellectual property situation, regulatory environment and other relevant scientific and commercial factors. Without limiting the foregoing, Commercially Reasonable Efforts in all cases shall require at least that (i) such party promptly assign responsibility for such obligations to specific employee(s) who monitor progress; (ii) such party set and seek to achieve specific and meaningful objectives for fulfilling such obligations; and (iii) such party makes and implements decisions and allocates resources designed to advance progress with respect to such obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(b) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligations of Purpose in Japan</u>. Purpose shall have no further obligations to develop or commercialize the Histogenics&#8217; Product Line in Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(c) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Books and Records</u>. For a period of [***] after the period to which the records relate, Histogenics shall keep complete and accurate records pertaining to the sale or other disposition of the Histogenics Product Line commercialized by it (the &#8220;Histogenics Sales Records&#8221;), in sufficient detail to permit Purpose to confirm the accuracy of all payments due under this First Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit Rights of Histogenics Sales Records</u>. The Histogenics Sales Records shall be kept at the Histogenics&#8217; address provided herein. Purpose&#8217;s duly authorized representative(s) shall have access to the Histogenics Sales Records for the period being audited at reasonable times during normal business hours of Histogenics, and shall be entitled to make reasonable photocopies thereof. Purpose shall have the right to remove and retain such copies. Upon Purpose&#8217;s reasonable request, Histogenics shall further provide Purpose with its quarterly and/or annual financial statements, audited or unaudited, consisting of a balance sheet, an income statement, and a cash flow statement, to the extent that such materials have been made publicly available by Histogenics. Purpose shall have the right to cause an independent certified public accountant reasonably acceptable to Histogenics to audit the Histogenics Sales Records to confirm the Net Sales and royalty payments; provided, however, that the auditor shall not disclose the audited Histogenics confidential information to Purpose, except to the extent that disclosure is necessary to verify the amount of royalties and other payments due under this First Amendment. Such audit right may be exercised [***], within [***] after the royalty or other payment period to which such records relate, on a mutually acceptable date or dates and on not less than [***] advance notice, and shall be conducted during normal business hours of Histogenics and without undue interruption to Histogenics. No period may be audited more than [***]. Any amounts validly shown to be owing by such audits shall be paid promptly with interest in the amount of [***] per month (or the maximum amount permitted by law, if less) from the date first owed until paid. Purpose shall bear the full cost of the audit unless the audit discloses that royalties actually paid by Histogenics are more than [***] less than the amount of royalties or other payments actually owed. In such case, Histogenics shall bear the full cost of the audit to the extent such cost is reasonable. The terms of this section shall survive any termination or expiration of the Agreement for a period of [***]. Histogenics represents and warrants that it will use commercially reasonable efforts that ensure any and all records and information provided to Purpose pursuant to this Section 6 (d) is complete and accurate.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revised Section 7</u>. Section 7 is hereby deleted and replaced with the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brigham and Women&#8217;s License</u>. Reference is made to the existing license between Purpose and the Brigham and Women&#8217;s Hospital, Inc. (&#8220;B&amp;W&#8221;) dated August 1, 2001 as amended by agreements dated December 30, 2005, May 4, 2010 and November 30, 2015 (the &#8220;B&amp;W License&#8221;). Histogenics has undertaken to pay any royalties due under the B&amp;W License to the extent that such royalties are measured by Histogenics&#8217; NET SALES (as defined in the B&amp;W License). Histogenics has also agreed to pay any minimum royalties or milestone payments required by Sections 4.4 and 4.5 of the B&amp;W License. In addition to fulfilling any such remaining obligations Histogenics has undertaken under the B&amp;W License, Histogenics has executed a third amendment to the B&amp;W License, effective as of November 30, 2015 and attached hereto as Exhibit 1, and Histogenics agrees to pay the amounts set forth in the newly added Section 4.8 of such amendment. Histogenics shall continue to honor these obligations with respect to the B&amp;W License, until such time as Histogenics is no longer using the technology licensed by the B&amp;W License. Upon written notice from Histogenics of its intent to cease using the technology licensed by the B&amp;W License, Purpose shall reassume all responsibility under the B&amp;W License or, at Purpose&#8217;s option, allow the B&amp;W License to lapse. Histogenics shall defend, indemnify and hold Purpose harmless from any claim by or liability to [***].&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revised Sections 8 and 9</u>. Sections 8 and 9 are hereby deleted and replaced with the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;8. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consideration</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Milestone Payments</u>. Histogenics agrees to pay to Purpose milestone payments if the milestones described below are met:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(i) Upon receipt of the first conditional governmental approval of one of the products of the Histogenics Product Line, from the MHLW in Japan, Histogenics shall pay to Purpose [***], within 90 days of obtaining such conditional approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(ii) Upon receipt of full marketing governmental approval (including, without limitation, reimbursement approval) of one of the products of the Histogenics Product Line, from the MHLW in Japan, Histogenics shall pay to Purpose [***], within 90 days of obtaining such full governmental approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(iii) Once the Annual Net Sales of the Histogenics Product Line in Japan to Histogenics reach [***], Histogenics shall pay to Purpose [***], within 90 days of reaching such milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If the conditional approval described in Section 8(a)(i) above is not received by Histogenics, but Histogenics receives full marketing approval as described in Section 8(a)(ii) above, then Histogenics shall pay to Purpose a milestone payment of [***], within 90 days of receiving such full marketing approval, instead of the [***] milestone payment described in Section 8(a)(i) and the [***] milestone payment described in Section 8(a)(ii) above. Notwithstanding anything to the contrary in this Agreement, each milestone described in Sections 8(a)(i), (ii) and (iii) directly above and in the foregoing sentence shall only be payable [***] during the term of this Agreement. Histogenics&#8217; payment obligations under this Section 8(a) shall terminate upon termination of this Agreement. For the purposes of Section 8(a)(iii) above, &#8220;Annual Net Sales&#8221; shall mean total Net Sales received by Histogenics or its affiliate or sublicensee for sale or other disposition of the Histogenics Product Line in Japan during a calendar year.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(b) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Payments</u>. Upon the earlier of (1) full marketing governmental approval or (2) conditional governmental approval with full coverage by the National Health Insurance, of the Licensed Products in Japan, and commercialization of the Licensed Products in Japan, Histogenics shall pay to Purpose, in cash, royalty payments in accordance with the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(i) Subject to subsection (vi) directly below, a [***] base royalty payment amounting to [***] of the Net Sales of the Licensed Products in Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(ii) &#8220;Net Sales&#8221; means the total revenue received by Histogenics or its affiliate or sublicensee for sale or other disposition of Licensed Products in Japan to a third party, less the following to the extent actually incurred or allowed with respect to such sale or disposition: [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(iii) &#8220;Licensed Products&#8221; shall mean any product for which the use, manufacture, or sale falls within the scope of a Valid Claim of a Purpose Patent in Japan or which incorporates or necessarily relies upon any Know-how. This term shall also refer to the product of the Histogenics Product Line known as [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(iv) &#8220;Valid Claim(s)&#8221; shall mean any valid claim(s) that has issued and is unexpired, and which has not been held unenforceable, unpatentable, or invalid by an administrative body or court of competent jurisdiction, in a decision that is unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or re-examination proceedings or disclaimer. Claims regarding the Japanese Patents listed in Exhibit 3 attached hereto, unless otherwise held or admitted to be unenforceable, unpatentable, or invalid, shall be considered Valid Claims until the Patents expire 20 years from the Filing Date of each respective Patent as listed in Exhibit 3. Claims regarding any new patents that are issued in Japan after the date of this Agreement and are owned or held by Purpose, insofar as such patents are licensed to Histogenics pursuant to Section 3(a), and are otherwise not held or admitted to be unenforceable, unpatentable, or invalid, shall be considered Valid Claims until the natural expiration of such new patents. However, in the event any of the aforementioned patents qualify for and actually receive an extension of the respective patent period as permitted by the Japan Patent Office (&#8220;JPO&#8221;) for products undergoing clinical trials and/or awaiting either conditional or full governmental approval, claims under such extended patents shall be considered Valid Claims until the expiration of the new extended patent period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(v) &#8220;Know-how&#8221; shall mean Purpose Technology, but only to the extent that it was first received by Histogenics from Purpose, remains confidential and does not fall into one of the exclusions set forth in Section 11(a), (b), (c), (d) or (e) of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(vi) Notwithstanding anything to the contrary in the Agreement, only one royalty payment shall be due with respect to each unit sold of the Licensed Product. The royalty payment owed on Net Sales of any Licensed Products sold in Japan during the term of this Agreement by Histogenics or its affiliate or sublicensee for which the use, manufacture or sale is not covered by a Valid Claim of at least one Purpose Patent shall be reduced to [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the event any third parties bring or allege a claim for patent infringement or trade secret misappropriation against Histogenics with respect to a Licensed Product, Purpose shall defend, indemnify and hold Histogenics harmless from any such claim by such third parties and liabilities, damages, costs and expenses with respect to such claims, to the extent such Licensed Products incorporates Purpose Patents or Know-how. Should, as a result of such claim(s), Histogenics be made to owe royalty payments to one or more third party(ies) (&#8220;Third Party Royalties&#8221;), and the total of such Third Party Royalties exceed [***] of the Net Sales of the Licensed Products, then Histogenics shall be entitled to deduct from the royalties owed by Histogenics to Purpose pursuant to this Section [***] of all such payments that are in excess of [***], but in no event shall the royalties paid by Histogenics to Purpose be less than (a) [***] of Net Sales in Japan where a Valid Claim of the Purpose Patent exists, or (b) [***] of Net Sales in Japan where a Valid Claim of the Purpose Patent does not exist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(vii) Histogenics shall make all royalty payments owed under this Agreement within [***] following the end of each calendar quarter for Net Sales of the Licensed Products in Japan from the previous calendar quarter, and together with such payment, shall submit to Purpose a written report setting forth (i) the Net Sales in Japan for such calendar quarter on a product-by-product basis (if applicable) upon which such royalty payments are based and (ii) reasonable information supporting the calculation of such Net Sales. All sums due under this Agreement shall be payable in United States dollars by bank wire transfer in immediately available funds to such bank account(s) as Purpose shall designate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(viii) When Licensed Products are sold for monies other than United States dollars, the earned royalties will first be determined in the foreign currency of the country in which such products of the Licensed Products were sold and then converted into equivalent United States funds. The exchange rate will be the rate published by the <i style="font-style:italic;">Wall Street Journal</i> on the last business day of each calendar quarter in which such royalties accrued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(ix) If applicable law requires Histogenics to withhold any taxes from payments made to Purpose under this Agreement, then such taxes shall be deducted by Histogenics as required by law and shall be paid by Histogenics to the proper tax authorities. Official receipts of payment of any withholding tax shall be secured and sent to Purpose whose payments were subject to withholding as evidence of such payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(x) The licenses granted in Section 3 shall be considered fully paid-up with respect to Histogenics&#8217; payment obligations for a Licensed Product upon expiration of the applicable term of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Side Letter Agreement</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The parties shall enter into the agreement contemplated in the side letter attached hereto as Exhibit 2 concurrently with entering into this First Amendment. In such side letter, Histogenics agrees to the retroactive annual increases requested by Purpose for the preventive maintenance service fees for each TEP for the years 2012 to 2015, which will increase the preventive maintenance service fee for each TEP to [***] in 2016.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Renumbered Sections 14, 15, 16, and 17</u>. Sections 14, 15, 16, and 17 are renumbered to be Sections 16, 17, 18, and 19, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">7. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">New Section 14</u>. The Agreement is amended to insert a new Section 14 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14</u>. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of First Offer</u>. If Histogenics desires to enter into any agreement with a third party to develop and/or manufacture a [***] and Purpose has the technology, experiences and resources necessary to assist with such development and manufacturing, then Histogenics shall in good faith provide a written offer for Purpose to potentially negotiate for such development and/or subsequent manufacturing work (the &#8220;Offer Notice&#8221;) to Purpose. Purpose shall have [***] from receipt of the Offer Notice to begin negotiating an agreement for such development and subsequent manufacturing work with Histogenics. If Purpose rejects the offer, is unable to develop or manufacture such [***], or if after [***] of negotiating the parties are unable to come to an agreement regarding such offer or to agree on a reasonable timeframe for concluding the negotiations , then Histogenics may enter into and have discussions with any third party regarding such offer and/or such development and manufacturing work, and Histogenics shall have no other obligations under this Section 14. For the sake of clarity, if the parties agree to extend the timeframe for concluding the negotiations as described in the foregoing sentence, then if by the end of such extension, the parties are unable to come to an agreement regarding such offer, then Histogenics may enter into and have discussions with any third party regarding such offer and/or such development and manufacturing work, and Histogenics shall have no other obligations under this Section 14. If the parties are able to come to an agreement on the terms of such projects, Histogenics and Purpose shall enter into a co-development agreement based on a specific project, working on design requirements, quality systems and testing of such [***]. If the parties then choose to develop commercial manufacturing capabilities based on such design, the parties will further negotiate reasonable terms and conditions for a manufacturing agreement for such [***] mentioned in this provision.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">8. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">New Section 15</u>. The Agreement is amended to insert a new Section 15 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15</u>. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation on Liability</u>. EXCEPT AS SPECIFICALLY STATED IN THIS AGREEMENT AND UNLESS PROHIBITED BY A RELEVANT LAW, EACH PARTY HEREBY DISCLAIMS ALL STATUTORILY IMPOSED GUARANTEES AND ALL WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, ORAL OR WRITTEN, WITH RESPECT TO THIS AGREEMENT. NEITHER PARTY EXCLUDES OR LIMITS ITS LIABILITY TO THE EXTENT THAT ANY EXCLUSION OR LIMITATION OF ITS LIABILITY IS VOID, PROHIBITED OR UNENFORCEABLE BY APPLICABLE LAW. SUBJECT TO THE FOREGOING EXCEPTIONS, IN NO EVENT SHALL EITHER PARTY BE LIABLE CONCERNING THE SUBJECT MATTER OF THIS AGREEMENT, REGARDLESS OF THE FORMA OF ANY CLAIM OR ACTION (WHETHER IN CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE), FOR ANY (I) FAILURE OR DELAY DUE TO A WAR, RIOTS, SABOTAGE, OR OTHER CIVIL DISORDERS, ACTS OF GOD, LAWS, REGULATIONS, RULES OR ORDERS OF ANY GOVERNMENT OR GOVERNMENTAL AGENCY, OR OTHER CIRCUMSTANCE BEYOND THE REASONABLE CONTROL OF A PARTY (&#8220;FORCE MAJEURE EVENT&#8221;), (II) LOSS OF USE OF PRODUCT OR COST OF PROCURING SUBSTITUTE GOODS OR SERVICES, OR (III) EXCEPT IN CONNECTION WITH ANY BREACHES OF CONFIDENTIALITY UNDER SECTION 11 (CONFIDENTIALITY), INDIRECT, PUNITIVE, INCIDENTAL, RELIANCE, SPECIAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES OR INJURY TO OR LOSS OF BUSINESS, REVENUES, PROFITS OR GOODWILL, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THESE LIMITATIONS ARE INDEPENDENT FROM ALL OTHER PROVISIONS OF THIS AGREEMENT AND SHALL APPLY NOTWITHSTANDING THE FAILURE OF ANY REMEDY PROVIDED HEREIN.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release of Claims and Acknowledgment Receipt</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">a. Acknowledgment of Receipt. Purpose hereby acknowledges that all payments owed by Histogenics to Purpose prior to the First Amendment Effective Date, including, without limitation, any equity consideration due under the Agreement and payments due under the Equipment Maintenance Agreement, by and between Purpose and Histogenics, dated July, 2012 (the &#8220;Service Agreement&#8221;) and the B&amp;W License, have been satisfied in full as of the First Amendment Effective Date, and Histogenics&#8217; only payment obligations to Purpose going forward are as expressly set forth in this First Amendment and the Service Agreement, unless otherwise agreed upon by the parties in a separate writing after the First Amendment Effective Date, including, without limitation, the letter set forth in Exhibit 2 attached hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">b. Release of Claims. Purpose hereby releases Histogenics from any liability in connection with Purpose&#8217;s right to the payments referenced in paragraph 9(a) of this First Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure</u>. The parties acknowledge that Histogenics will be permitted, and may be required pursuant to the rules and regulations promulgated under the Securities Exchange Act of 1934, as amended, to file a Current Report on Form 8-K disclosing the entry into this First Amendment by Histogenics and a brief description of the terms and conditions hereof that are material to Histogenics. To the extent that Histogenics reasonably determines that it is required to make a filing or any other public disclosure (other than as set forth in the preceding sentence) with respect to this First Amendment or the terms or existence hereof to comply with the requirements, rules, laws or regulations of any applicable stock exchange, Nasdaq or any governmental or regulatory authority or body, including without limitation the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) (collectively, the &#8220;Disclosure Obligations&#8221;), Histogenics shall promptly inform Purpose thereof and shall use reasonable efforts to maintain the confidentiality of Purpose&#8217;s confidential information in any such filing or disclosure. Prior to making any such filing of a copy of this First Amendment, the parties shall mutually agree on the provisions of this First Amendment for which the parties shall seek confidential treatment, it being understood that if one party determines to seek confidential treatment for a provision for which the other party does not, then the parties will use reasonable efforts in connection with such filing to seek the confidential treatment of any such provision. The parties shall cooperate, each at its own expense, in such filing, including without limitation such confidential treatment request, and shall execute all documents reasonably required in connection therewith. In furtherance of the foregoing, the parties will agree as promptly as practicable after the First Amendment Effective Date on the confidential treatment request to be filed with the SEC and the redacted form of this First Amendment related thereto. In furtherance thereof, any redaction reasonably requested by either party shall be included in such filing. The parties will reasonably cooperate in responding promptly to any comments received from the SEC with respect to such filing in an effort to achieve confidential treatment of such redacted form; provided, however, that a party shall be relieved of such obligation to seek confidential treatment for a provision requested by the other party if such treatment is not achieved after the [***] round of responses to comments from the SEC. Notwithstanding anything to the contrary in the Agreement, Histogenics may make reference to the existence of this First Amendment and the Agreement and describe in general terms the relationship between the parties in connection with any required securities filings without seeking Purpose&#8217;s prior consent. This paragraph shall apply with respect to the filing of a copy of this First Amendment or any public disclosure relating to this First Amendment to comply with the Disclosure Obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">11. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Changes</u>. Except as expressly set forth in this First Amendment, the Agreement remains in full force and effect and is hereby ratified and confirmed. In the event of any conflict between the terms of this First Amendment and the terms of the Agreement, the terms of the First Amendment shall control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">12. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Execution in Counterparts</u>. This First Amendment may be executed in any number of counterparts which together shall constitute one and the same instrument, and signatures may be exchanged by facsimile or pdf. For the purposes of this First Amendment, a signed copy shall have the same force and effect as an original signed First Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">13. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. The Agreement, as modified by this First Amendment, represents the entire agreement between Histogenics and Purpose relating to the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every nature relating to the subject matter of the Agreement. This First Amendment shall be deemed incorporated into, and part of, the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[<font style="font-style:italic;font-weight:bold;">Signature Page Follows</font>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties hereto have executed this First Amendment by their duly authorized representatives as of the date set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PURPOSE CO., LTD.,</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HISTOGENICS CORPORATION</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">f/k/a Takagi Sangyo Co., Ltd., and</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">f/k/a Takagi Industrial Co., Ltd.</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Hiromi Takagi</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Adam Gridley</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President &amp; CEO</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:42.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 9, 2016</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 9, 2016</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purpose Co., Ltd.</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Histogenics Corporation</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">201 Nishikashiwabara-shinden</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">830 Winter Street, 3rd Floor</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fuji City, Shizuoka 417-8505</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waltham, MA 02451</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">JAPAN</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USA</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[Remainder of page intentionally left blank]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Third Amendment to B&amp;W License</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Please see the attached.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Third AMENDMENT TO LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Side Letter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;">May 9, 2016</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Mr. Chiharu Ishikawa <br>Managing Director <br>Purpose Co., Ltd. <br>201 Nishikashiwabara-shinden <br>Fuji City, Shizuoka 417-8505 <br>JAPAN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Re:</b></font><b style="font-weight:bold;">Increase in Preventative Maintenance Service Fees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Dear Mr. Ishikawa:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Thank you for all of your assistance and cooperation (and the assistance and cooperation of your colleagues and legal counsel) in finalizing the First Amendment (the &#8220;First Amendment&#8221;) to the Agreement, by and between Purpose Co., Ltd., f/k/a Takagi Sangyo Co. Ltd., and also f/k/a Takagi industrial Co., Ltd. (&#8220;Purpose&#8221;), and Histogenics Corporation (&#8220;Histogenics&#8221;), dated June 22, 2012 (&#8220;Agreement&#8221;). The purpose of this letter is simply to clarify and confirm the parties&#8217; mutual understanding as to the increase in the preventive maintenance service fee to be charged by Purpose to Histogenics for each Purpose single unit exogenous tissue processor machine (each, a &#8220;TEP&#8221;) for 2016, as required in Section 9 of the Agreement, as amended by the First Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the First Amendment, the parties agree that Purpose may retroactively increase its preventive maintenance service fee for each TEP by [***] for each of 2013, 2014 and 2015 pursuant to Section 11 of the Equipment Maintenance Agreement, by and between Purpose and Histogenics, dated July, 2012 (the &#8220;Maintenance Agreement&#8221;), so that the preventive maintenance service fee for 2016 is [***] for each TEP. For the avoidance of doubt, notwithstanding the foregoing retroactive increase, such increase does not affect any amounts previously paid by Histogenics to Purpose prior to January 1, 2016 for preventive maintenance services, and in no event does Histogenics owe Purpose any additional amounts for any prevent maintenance services performed on any TEP prior to January 1, 2016.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">* * *</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If the foregoing is consistent with your understanding of the parties&#8217; mutual agreement regarding the increase in preventative maintenance service fees, please have an authorized representative of Purpose countersign below. This letter is effective as of the date signed by Purpose below. Except as expressly clarified herein, the Maintenance Agreement is hereby ratified and confirmed in all respects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Respectfully,</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Adam Gridley</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adam Gridley</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Histogenics Corporation</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acknowledged and Agreed:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:47.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purpose Co., Ltd.</p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Chiharu Ishikawa</p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:47.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mr. Chiharu Ishikawa</p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:47.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:47.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 9, 2016</p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT B-1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TAKAGI PATENTS*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">*Takagi Patents includes the patents and patent applications set forth in Exhibit B-1, all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations and renewals thereof, and any other related applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">TAKAGI PATENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Application </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Country</b></p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Filing Date</b></p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Status</b></p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Priority</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***].</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***].</p></td><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>15
<FILENAME>tmb-20250331xex10d40.htm
<DESCRIPTION>EX-10.40
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:06 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:47.05pt;margin:0pt 0pt 12pt 22.55pt;"><b style="font-weight:bold;">EXHIBIT 10.40</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. &#160;Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LICENSE AND COMMERCIALIZATION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS LICENSE AND COMMERCIALIZATION AGREEMENT</b>&#160;(this &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is effective as of 21<sup style="font-size:7.5pt;vertical-align:top;">st</sup>&#160;December, 2017 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;) by and between Histogenics Corporation., a corporation organized and existing under the laws of the State of Delaware, with offices at 830 Winter Street, 3<sup style="font-size:7.5pt;vertical-align:top;">rd</sup>&#160;Floor, Waltham, MA, 02451 (&#8220;<b style="font-weight:bold;">Histogenics</b>&#8221;), and MEDINET Co., Ltd., a corporation organized and existing under the laws of Japan, with offices at 2-3-12 Shinyokohama, Kohoku-ku, Yokohama-shi, Kanagawa-ken, Japan (&#8220;<b style="font-weight:bold;">MEDINET</b>&#8221;) (each, a &#8220;<b style="font-weight:bold;">Party</b>&#8221; and together, the &#8220;<b style="font-weight:bold;">Parties</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Histogenics is a regenerative medicine company focused on developing and commercializing products in various human indications;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, MEDINET is a regenerative medicine company focused on developing and commercializing products in various human therapeutic areas;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, subject to the terms and conditions herein, Histogenics desires to grant to MEDINET a license under certain patents, patent applications, know-how, and technology to develop and commercialize certain therapeutic products to replace or repair damaged, worn, or defective cartilage, and MEDINET desires to obtain such license, on the terms and conditions set forth in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article I.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;white-space:pre-wrap;"> DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As used in this Agreement, the following terms shall have the meanings set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.01&#8220;<b style="font-weight:bold;">Affiliate</b>&#8221;&#160;shall mean with respect to either one of the Parties, any person, firm, trust, partnership, corporation or other entity or combination thereof which directly or indirectly: (a) controls said Party; (b) is controlled by said Party; or (c) is under common control with said Party; the terms &quot;<b style="font-weight:bold;">control</b>&quot; and &quot;<b style="font-weight:bold;">controlled</b>&quot; as used in this definition, meaning ownership of fifty percent (50%) or more, including ownership by one or more trusts with substantially the same beneficial interests, of the voting and equity rights of such person, firm, trust, partnership, corporation or other entity or combination thereof or the power to direct the management of such person, firm, trust, partnership, corporation or other entity or combination thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.02&#8220;<b style="font-weight:bold;">Applicable</b>&#160;<b style="font-weight:bold;">Law</b>&#8221; shall mean all laws, statutes, ordinances, rules, regulations, writs, judgments, decrees, injunctions (whether preliminary or final), orders and other pronouncements having the effect of law of any&#160;Governmental Authority&#160;that may be in effect from time to time.&#160;&#160;For clarity, Applicable Law includes GCP, GLP, and GMP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.03&#8220;<b style="font-weight:bold;">Arising IP</b>&#8221;&#160;shall have the meaning set forth in&#160;Section 8.01(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.04&#8220;<b style="font-weight:bold;">BLA</b>&#8221; shall mean a Biologics License Application filed with or submitted to the FDA pursuant to 21 C.F.R.&#160;&#160;Parts 600-680 (or the foreign equivalent filed with or submitted to the PMDA or other relevant&#160;Regulatory Authority pursuant to Applicable Laws).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.05&#8220;<b style="font-weight:bold;">Biopsy Kit</b>&#8221; shall mean [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.06&#8220;<b style="font-weight:bold;">Business Day</b>&#8221; shall mean any Monday, Tuesday, Wednesday, Thursday or Friday that is not a public holiday in the&#160;USA or Japan in which MEDINET is actively carrying out Development or Commercialization activities with respect to Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.07&#8220;<b style="font-weight:bold;">Calendar Quarter</b>&#8221; shall mean a period of three (3) consecutive months corresponding to the calendar quarters commencing on the first day of January, April, July or October, except that the first&#160;Calendar Quarter&#160;of the&#160;Term&#160;shall commence on the&#160;Effective Date&#160;and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the&#160;Effective Date&#160;and the last&#160;Calendar Quarter&#160;shall end on the last day of the&#160;Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.08&#8220;<b style="font-weight:bold;">Calendar Year</b>&#8221; shall mean a period of twelve (12) consecutive months corresponding to the calendar year commencing on the first day of January, except that the first&#160;Calendar Year&#160;of the&#160;Term&#160;shall commence on the&#160;Effective Date&#160;and end on December 31 of the year in which the&#160;Effective Date&#160;occurs and the last&#160;Calendar Year&#160;of the&#160;Term&#160;shall commence on January 1 of the year in which the&#160;Term&#160;ends and end on the last day of the&#160;Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.09&#8220;<b style="font-weight:bold;">Cellular and Tissue-based Product</b>&#8221; shall mean a product that falls within the definition of Article 2, Paragraph 9 of the Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices of Japan (Act No. 145 of 1960, as amended).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.10&#8220;<b style="font-weight:bold;">Challenge</b>&#8221; shall mean, with respect to any&#160;Patents, to&#160;contest&#160;the validity or enforceability of any such&#160;Patents, in whole or in part, in any court, arbitration proceeding or other tribunal,&#160;including&#160;without limitation the United States Patent and Trademark Office and the United States International Trade Commission.&#160;&#160;For the avoidance of doubt, the&#160;term&#160;&#8220;contest&#8221;&#160;includes&#160;(a) filing an action under 28 U.S.C.&#160;&#167;&#167; 2201-2202 seeking a declaration of invalidity or unenforceability of any such&#160;Patents; (b) filing, or joining in, a petition under 35 U.S.C. &#167; 311 to institute inter partes review of any such&#160;patents&#160;or any portion thereof; (c) any foreign equivalent of subsection (a)&#160;or (b) in the&#160;Territory; or (d) filing or commencing any opposition, nullity or similar proceedings challenging the validity of any such&#160;Patents&#160;in any country outside the United States; but excludes&#160;(v)&#160;filing a request under 35 U.S.C. &#167; 302 for re-examination of any such&#160;Patents;&#160;(w)&#160;filing a request under 35 U.S.C. &#167; 251 for a reissue of any such&#160;Patents;&#160;(x)&#160;filing, or joining in, a petition under 35 U.S.C. &#167; 321 to institute post-grant review of any such&#160;Patents&#160;or any portion thereof;&#160;(y)&#160;provoking or becoming a party to an interference</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">with an application for any of the&#160;Patents&#160;pursuant to 35 U.S.C. &#167; 135; or (z) any foreign equivalents of subsection&#160;(v) through (y)&#160;applicable in the&#160;Territory&#160;outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.11&#160;&#8220;<b style="font-weight:bold;">Clinical Development</b>&#8221; shall mean the conduct of Clinical Trials for a Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.12&#8220;<b style="font-weight:bold;">Clinical Trial</b>&#8221; shall mean any of a&#160;Phase 1 Clinical Trial,&#160;Phase 2 Clinical Trial, or&#160;Phase 3 Clinical Trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.13&#8220;<b style="font-weight:bold;">Commercialize</b>&#8221; shall mean any and all activities directed to the promotion, marketing, distribution or sale (and offer for sale) for a product.&#160;&#160;&#8220;<b style="font-weight:bold;">Commercializing</b>&#8221; and &#8220;<b style="font-weight:bold;">Commercialization</b>&#8221; shall have corresponding meanings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.14&#8220;<b style="font-weight:bold;">Commercially Reasonable Efforts</b>&#8221; shall mean efforts and resources typically used by biotechnology companies similar in size and scope to perform the obligation at issue, which efforts shall not be less than those efforts made with respect to other products at a similar stage of development or in a similar stage of product life, with similar developmental risk profiles, of similar market and commercial potential, taking into account the competitiveness of the market place, the proprietary position of the products, the regulatory structure involved, the profitability of the applicable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.15&#8220;<b style="font-weight:bold;">Confidential Information</b>&#8221; shall mean all secret, confidential or proprietary&#160;information,&#160;Know-How&#160;or data, whether provided in written, oral, graphic, video, computer or other form, that (a) is provided by one Party (the &#8220;<b style="font-weight:bold;">Disclosing Party</b>&#8221;) to the other Party (the &#8220;<b style="font-weight:bold;">Receiving Party</b>&#8221;) that is marked or otherwise identified as confidential or that by its nature a reasonable&#160;person&#160;would understand to be confidential in connection with this&#160;Agreement,&#160;including&#160;all scientific, pre-clinical, clinical, regulatory, process, formulation,&#160;manufacturing, marketing, financial and commercial&#160;information&#160;or data.&#160;&#160;Notwithstanding the foregoing sentences,&#160;Confidential Information&#160;shall not&#160;include&#160;any&#160;information&#160;that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)was already known to the&#160;Receiving Party&#160;(other than under an obligation of confidentiality) at the time of disclosure by the&#160;Disclosing Party&#160;to the extent such&#160;Receiving Party&#160;has contemporaneous documentation or other competent evidence to that effect;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)was generally available to the public or otherwise part of the public domain at the time of its disclosure to the&#160;Receiving Party;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(c)became generally available to the public or otherwise part of the public domain after its disclosure, other than through any act or omission of a&#160;Party&#160;in breach of such&#160;Party&#8217;s confidentiality obligations under this&#160;Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(d)were subsequently lawfully disclosed to the&#160;Receiving Party&#160;by a&#160;Third Party&#160;who had no obligation to the&#160;Disclosing Party&#160;not to disclose such&#160;information&#160;to others; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(e)were independently discovered or developed by or on behalf of the&#160;Receiving Party&#160;without the use of, reliance on or reference to the&#160;Confidential Information&#160;belonging to the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other&#160;Party&#160;and the&#160;Receiving Party&#160;has contemporaneous documentation or other competent evidence to that effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.16&#8220;<b style="font-weight:bold;">Control</b>&#8221; and its correlative terms, &#8220;<b style="font-weight:bold;">Controlled</b>&#8221; or &#8220;<b style="font-weight:bold;">Controls</b>&#8221;, shall mean, with respect to any intellectual property right or&#160;information&#160;(including&#160;tangible embodiments thereof), that a&#160;Party&#160;owns or has a license or sublicense to such item or right, and has the ability to grant access, license or sublicense in or to such right without violating the terms of any agreement or other arrangement with any Third Party and without causing such Party to incur payment obligations to a Third Party by reason of the granting of a license thereunder (unless the other Party agrees to bear such payment obligations to the extent arising from the grant of a right or license thereunder to such other Party).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.17&#160;[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.18&#8220;<b style="font-weight:bold;">Develop</b>&#8221; shall mean the conduct of&#160;Development&#160;activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.19&#8220;<b style="font-weight:bold;">Development</b>&#8221; shall mean all activities relating to obtaining&#160;Regulatory Approval&#160;of a&#160;Product, including without limitation Clinical Development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.20&#8220;<b style="font-weight:bold;">Directly Competing Product</b>&#8221; shall mean any&#160;Cellular and Tissue-based Product&#160;(other than a Product that is the subject of the licenses and sublicenses from Histogenics to MEDINET in this Agreement) for use in the Field.&#160;&#160;For clarity, [***], would not be considered to be Directly Competing Products under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.21&#8220;<b style="font-weight:bold;">FDA</b>&#8221; shall mean the US Food and Drug Administration, and any successor or replacement agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.22&#8220;<b style="font-weight:bold;">Field</b>&#8221; shall mean [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.23&#8220;<b style="font-weight:bold;">First Commercial Sale</b>&#8221; shall mean, with respect to any&#160;Product, the first arm&#8217;s length sale for monetary value by&#160;MEDINET, its&#160;Affiliate, or its&#160;Sublicensees&#160;to a&#160;Third Party&#160;for end use or consumption by the general public of such&#160;Product&#160;in the&#160;Territory; provided, however, that in no event shall any sale or distribution of a&#160;Product&#160;for use in a&#160;Clinical Trial&#160;or otherwise any sales prior to receipt of all&#160;Regulatory Approvals&#160;necessary to commence regular commercial sales be deemed a&#160;First Commercial Sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.24&#8220;<b style="font-weight:bold;">GCP</b>&#8221; or &#8220;<b style="font-weight:bold;">Good Clinical Practice</b>&#8221; shall mean the then-current good clinical practice applicable to the Clinical&#160;Development&#160;of a&#160;Product&#160;under&#160;Applicable Law&#160;in an applicable country or&#160;territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.25&#8220;<b style="font-weight:bold;">GCTP</b>&#8221; or &#8220;<b style="font-weight:bold;">Good Gene, Cellular, and Tissue-based Products Manufacturing Practice</b>&#8221; shall mean good gene, cellular, and tissue-based products manufacturing practice required under the GCTP Ordinance&#160;of Japan&#160;(Ordinance issued by the MHLW No. 93 of 2014) and the requirements&#160;thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.26&#8220;<b style="font-weight:bold;">GLP</b>&#8221; or &#8220;<b style="font-weight:bold;">Good Laboratory Practices</b>&#8221; shall mean good laboratory practices required under the regulations set forth in&#160;21 C.F.R. Part 58, as in effect during the&#160;Term,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and the requirements thereunder imposed by the&#160;FDA, the PMDA and the equivalent thereof in any jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.27&#8220;<b style="font-weight:bold;">GMP</b>&#8221; or &#8220;<b style="font-weight:bold;">Good Manufacturing Practices</b>&#8221; shall mean the current good manufacturing practices required under the applicable regulations set forth in&#160;21 C.F.R.&#160;Subchapter C&#160;(Drugs) and Subchapter H&#160;(Medical Devices),&#160;including&#160;without limitation Parts 210&#8211;211, 808, 812, and 820, and the requirements thereunder imposed by the&#160;FDA, the PMDA and the equivalent thereof in any jurisdiction, and the laws, regulations, guidelines, guidance, pharmaceutical industry standards and requirements in force from time to time that apply to the&#160;manufacture&#160;of each&#160;Product&#160;in any jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.28&#8220;<b style="font-weight:bold;">Governmental Authority</b>&#8221; shall mean (a) any court, tribunal, arbitrator, agency, department, administration, legislative body, commission, official or other instrumentality of any government of any country or jurisdiction,&#160;(b)&#160;a federal, state, province, county, city or other political subdivision thereof, or (c) any supranational body.&#160;&#160;For clarity, all&#160;Regulatory Authorities&#160;are considered&#160;Governmental Authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.29&#8220;<b style="font-weight:bold;">IFRS</b>&#8221; shall mean the International Financial Reporting Standards, developed and maintained by the International Accounting Standards Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.30&#8220;<b style="font-weight:bold;">Indirect Taxes</b>&#8221; shall mean&#160;Value Added Taxes,&#160;sales taxes, consumption taxes and other similar taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.31&#8220;<b style="font-weight:bold;">Initiation</b>&#8221; of a Clinical Trial shall mean use in the first human subject in the relevant&#160;Clinical Trial&#160;of a&#160;Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.32&#8220;<b style="font-weight:bold;">Know-How</b>&#8221; shall mean all technical, scientific and other know-how and&#160;information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions, skills, techniques, procedures, ideas, concepts, designs, drawings, specifications, data, results and other material (together with all improvements to any of the foregoing), in each case that is secret and substantial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.33&#8220;<b style="font-weight:bold;">Licensed Know-How</b>&#8221; shall mean all Know-How Controlled by Histogenics as of the Effective Date or that comes into Control of Histogenics during the Term that is necessary to make, have made, use, offer for sale, sell, import, export, and otherwise Develop and Commercialize any Product pursuant to the terms and conditions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.34&#8220;<b style="font-weight:bold;">Licensed Patents</b>&#8221; shall mean all Patents Controlled by Histogenics as of the Effective Date or that comes into Control of Histogenics during the Term necessary to make, have made, use, offer for sale, sell, import, export, and otherwise&#160;Develop and&#160;Commercialize any Product pursuant to the terms and conditions of this Agreement.&#160;&#160; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>&#160;sets forth the Licensed Patents existing as of the Effective&#160;Date&#160;and shall be amended as necessary thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.35&#8220;<b style="font-weight:bold;">Licensed Technology</b>&#8221; shall mean the Licensed Patents and Licensed Know-How.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.36&#8220;<b style="font-weight:bold;">Licensed Trademarks</b>&#8221; shall mean all Trademarks that are (a) Controlled by Histogenics as of the Effective Date or that comes into Control of Histogenics during the Term</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and (b) used by Histogenics in connection with Histogenics&#8217; Commercialization of Products in the Field and outside of the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.37&#8220;<b style="font-weight:bold;">Master Quality, Supply and Pharmacovigilance Agreement</b>&#8221; shall mean the agreement first described in Section 6.01.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.38&#8220;<b style="font-weight:bold;">MEDINET IP</b>&#8221; shall mean all&#160;Patents,&#160;Know-How, or other intellectual property rights based on this Agreement that are&#160;Controlled by MEDINET&#160;or its&#160;Affiliates&#160;(a) prior the&#160;Effective Date&#160;or (b) that comes in&#160;Control&#160;of&#160;MEDINET&#160;or its&#160;Affiliates&#160;after the&#160;Effective Date based on this Agreement&#160;that is neither (i)&#160;Licensed Technology, nor (ii) Arising IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.39&#8220;<b style="font-weight:bold;">MHLW</b>&#8221; shall mean the Ministry of Health, Labor and Welfare of Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.40&#8220;<b style="font-weight:bold;">NDA</b>&#8221; shall mean a New Drug Application filed with or submitted to the FDA pursuant to 21 C.F.R. Part 314 (or the foreign equivalent filed with or submitted to the PMDA or other relevant&#160;Regulatory Authority pursuant to Applicable Laws).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.41&#8220;<b style="font-weight:bold;">Net Sales</b>&#8221; shall mean [***] by MEDINET or its Sublicensees to Third Parties, less the following deductions, accounted for in accordance with IFRS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:96.15pt;margin:0pt 0pt 12pt 0pt;">(a)[***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:96.15pt;margin:0pt 0pt 12pt 0pt;">(b)[***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:96.15pt;margin:0pt 0pt 12pt 0pt;">(c)[***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:96.15pt;margin:0pt 0pt 12pt 0pt;">(d)[***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:96.15pt;margin:0pt 0pt 12pt 0pt;">(e)[***]; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:96.15pt;margin:0pt 0pt 12pt 0pt;">(f)[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net Sales shall not be imputed to [***].&#160;&#160;For the avoidance of doubt, in the case of any transfer of any Product between or among MEDINET and its Sublicensees for resale, Net Sales shall be determined based on the sale made by such Sublicensee to a Third Party.&#160;&#160;In the case of any sale for value, such as barter or counter-trade, of a Product, or part thereof, other than in an arm&#8217;s length transaction exclusively for cash, Net Sales shall be deemed to be the Net Sales at which substantially similar quantities of such Product are sold for cash in an arm&#8217;s length transaction in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.42&#160;&#8220;<b style="font-weight:bold;">Patents</b>&#8221; shall mean (a) all patents or patent applications,&#160;including&#160;any continuations, continuations-in-part (to the extent relating to existing patents or patent applications and not to any new subject matter), divisions, provisional, converted provisional, continued prosecution or substitute applications, (b) any patent issued with respect to any of the foregoing patent applications,&#160;including&#160;utility models, petty patents, innovation patents and design patents and certificates of invention, (c) any reissue, reexamination, renewal, restoration or extension (including&#160;any supplementary protection certificate and the like) of any of the foregoing patents or patent applications, (d) any confirmation patent or registration patent or patent of addition based</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">on any such patent, (e) any similar rights,&#160;including&#160;so-called pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such foregoing patent applications and patents, and (f) all foreign counterparts of any of the foregoing, or as applicable portions thereof or individual claims therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.43&#8220;<b style="font-weight:bold;">PMDA</b>&#8221; shall mean the Pharmaceuticals and Medical Devices Agency of Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.44&#8220;<b style="font-weight:bold;">Phase 1 Clinical Trial</b>&#8221; shall mean any clinical study conducted on human subjects with primary endpoints to establish that a pharmaceutical product is reasonably safe for continued testing and to support its continued testing in&#160;Phase 2 Clinical Trials.&#160;&#160;Phase 1 Clinical Trials&#160;shall&#160;include&#160;without limitation those trials designated as &#8220;Phase 1a Clinical Trials&#8221; or &#8220;Phase 1b Clinical Trials.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.45&#8220;<b style="font-weight:bold;">Phase 2 Clinical Trial</b>&#8221; shall mean any clinical study that is not intended to be used as a pivotal study for purposes of seeking&#160;Regulatory Approval&#160;and that is conducted on human subjects who have the relevant disease or condition with primary endpoints to establish the efficacy of a&#160;Product&#160;for its intended use and to define warnings, precautions, and adverse reactions that may be associated with the pharmaceutical product in the dosage range to be prescribed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.46&#8220;<b style="font-weight:bold;">Phase 3 Clinical Trial</b>&#8221; shall mean any clinical study intended or used as a pivotal study for purposes of seeking&#160;Regulatory Approval, which study is conducted on sufficient numbers of human patients to establish that a pharmaceutical product is safe and efficacious for its intended use, to define warnings, precautions, and adverse reactions that are associated with the pharmaceutical product in the dosage range to be prescribed, and at a standard suitable to obtain&#160;Regulatory Approval&#160;or label expansion of such pharmaceutical product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.47&#8220;<b style="font-weight:bold;">Product</b>&#8221; shall mean (a) [***] and (b)&#160;&#160;[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.48&#8220;<b style="font-weight:bold;">Regulatory Approval</b>&#8221; shall mean any and all approvals (including&#160;applicable pricing and reimbursement approvals), licenses, registrations, permits or authorizations issued, granted and/or approved by any&#160;Regulatory Authority, necessary to commercially distribute, sell or market a product in a country or&#160;territory,&#160;including&#160;any: (a) any conditional or accelerated approval or adaptive licensing approval; (b) approval for a product (including&#160;any supplements and amendments thereto); (c) pre- and post-approval marketing approvals or authorizations (including&#160;any&#160;manufacturing&#160;approval or authorization related thereto); (d) labeling approval; and (e) technical, medical and scientific licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.49&#8220;<b style="font-weight:bold;">Regulatory Authority</b>&#8221; shall mean any national, supranational, regional, state or local regulatory agency, administration, department, bureau, commission, council or other governmental entity involved in the granting or receipt of&#160;Regulatory Approvals.&#160;&#160;For clarity, all&#160;Regulatory Authorities&#160;are considered&#160;Governmental Authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.50&#8220;<b style="font-weight:bold;">Regulatory Documentation</b>&#8221; shall mean all (a) applications, registrations, licenses, authorizations and&#160;Regulatory Approvals; (b) correspondence and/or reports submitted to or received from&#160;Regulatory Authorities&#160;(including&#160;minutes and official contact reports relating to any communications with any&#160;Regulatory Authority) and all supporting documents with respect</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">thereto,&#160;including&#160;all adverse event files and complaint files; and (c) clinical, chemistry,&#160;manufacturing&#160;and&#160;controls&#160;and other data contained or relied upon in any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.51&#160;&#8220;<b style="font-weight:bold;">Senior Officer</b>&#8221; shall mean the&#160;Chief Executive Officer&#160;of&#160;Histogenics&#160;and the&#160;Chief Executive Officer&#160;of&#160;MEDINET&#160;or the functional successor in their respective organizations, or their respective designees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.52&#8220;<b style="font-weight:bold;">Sublicensee</b>&#8221; shall mean a&#160;Third Party&#160;or&#160;Affiliate&#160;to whom&#160;MEDINET&#160;has granted a sublicense in accordance with the terms and conditions of this&#160;Agreement&#160;under the licenses or sublicenses&#160;granted by&#160;Histogenics&#160;to&#160;MEDINET&#160;in&#160;Section 2.01&#160;herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.53&#8220;<b style="font-weight:bold;">Territory</b>&#8221; shall mean Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.54&#8220;<b style="font-weight:bold;">Third Party</b>&#8221; shall mean any&#160;Person&#160;who is not a&#160;Party&#160;or an&#160;Affiliate&#160;of a&#160;Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.55&#8220;<b style="font-weight:bold;">Trademark</b>&#8221; shall mean any word, name, symbol, color, shape, designation or any combination thereof,&#160;including&#160;any trademark, service mark, trade name, brand name, sub-brand name, trade dress, product configuration, program name, delivery form name, certification mark, collective mark, logo, tagline, slogan, design or business symbol, that functions as an identifier of source or origin, whether or not registered and all statutory and common law rights therein and all registrations and applications therefor, together with all goodwill associated with, or symbolized by, any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.35pt;margin:0pt 0pt 12pt 0pt;">Section 1.56&#8220;<b style="font-weight:bold;">Transfer Price</b>&#8221; shall mean, with respect to a unit of a particular Product and Biopsy Kit, the per unit price (including&#160;[***]) as set forth on Exhibit B hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.57&#8220;<b style="font-weight:bold;">US</b>&#8221; and &#8220;<b style="font-weight:bold;">USA</b>&#8221; shall mean the United States of America,&#160;including&#160;all of its territories and possessions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.58&#8220;<b style="font-weight:bold;">USD</b>&#8221; shall mean United States Dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.59&#8220;<b style="font-weight:bold;">Value Added Tax</b>&#8221; shall mean any value added, goods and services or similar tax chargeable on the supply or deemed supply of goods or services under applicable legislation; in each event, including any interest, penalties or other additions to tax thereon; but, in each event, excluding any US sales tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 1.60<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</u>.&#160;&#160;Unless the context of this Agreement otherwise requires: (a) words of one gender include the other gender; (b) words using the singular or plural number also include the plural or singular number, respectively; (c) the terms &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby,&#8221; and other similar words refer to this entire Agreement; (d) the words &#8220;include&#8221;, &#8220;includes&#8221;, and &#8220;including&#8221; when used in this Agreement shall be deemed to be followed by the words &#8220;without limitation&#8221;, unless otherwise specified; (e) the terms &#8220;Article&#8221; and &#8220;Section&#8221; refer to the specified Article and Section of this Agreement (unless clear from the context that it&#160;refers to an Article or Section of some other document); (f) &#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;and/or&#8221;; (g) the words &#8220;will&#8221; and &#8220;shall&#8221; shall have the same meaning; and (h) references to an</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Applicable&#160;Law include any amendment or modification to such Applicable Law and any rules or regulations issued thereunder, whether such amendment or modification is made, or issuance of such rules or regulations occurs, before or, only with respect to events or developments occurring or actions taken or conditions existing after the date of such amendment, modification or issuance, after the date of this Agreement, but only to the extent such amendment or modification, to the extent it occurs after the date hereof, does not have a retroactive effect.&#160;&#160;Whenever this&#160;Agreement&#160;refers to a number of days, unless otherwise specified, such number shall refer to calendar days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article II.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;white-space:pre-wrap;"> LICENSE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 2.01<b style="font-weight:bold;">Licenses and Sublicenses Granted by&#160;Histogenics</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License and Sublicenses</u>.&#160;&#160;Subject to the terms of this Agreement, Histogenics hereby grants to MEDINET, and MEDINET hereby accepts, an exclusive (including with regard to Histogenics and its Affiliates, except with respect to the retained rights set forth in Section 2.01(d)), royalty-bearing, sublicensable (through multiple tiers, but only to the extent permitted pursuant to Section 2.01(b)) license (or sublicense, in the case of Patents Histogenics Controls as a licensee) under Histogenics&#8217; right, title and interest in, to and under (i) the Licensed Technology, and (ii) the Arising IP to conduct Clinical Development for, make, have made, use, offer for sale, sell, import, export, and otherwise Commercialize (collectively, &#8220;<b style="font-weight:bold;">Exploit</b>&#8221; or, as applicable, &#8220;<b style="font-weight:bold;">Exploitation</b>&#8221;) the Products in the Field in the Territory.&#160;&#160;For the avoidance of doubt, MEDINET shall have the right to conduct or have conducted Clinical Development and make or have made Commercialization of the Product by Third Parties, including but not limited to&#160;contract research organizations (&quot;<b style="font-weight:bold;">CROs</b>&quot;) and/or contract sales organizations (&quot;<b style="font-weight:bold;">CSOs</b>&quot;).&#160;&#160;Histogenics shall make available to MEDINET the documents set forth in Exhibit A within 30 days after the Effective Date and shall, as soon as reasonably practicable but in no event later than 45 days following a reasonable request from MEDINET, update such documents and provide new data, materials, information and documents relating to the Licensed Technology and the Arising IP (including, without limitation, nonclinical data, clinical data, communication with the Regulatory Authority, IND, NDA, safety).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicensing</u>.&#160;&#160;MEDINET&#160;shall have the right to grant sublicenses, through multiple tiers, under the licenses and sublicenses granted to&#160;MEDINET&#160;under Section 2.01(a), to its&#160;Affiliates without the prior consent of, but with written notice to, Histogenics.&#160;&#160;MEDINET&#160;shall have the right to grant sublicenses, through multiple tiers, under the licenses and sublicenses granted to&#160;MEDINET&#160;under&#160;Section 2.01(a), to Third Parties only with the prior written consent of Histogenics, which consent shall not be unreasonably withheld. &#160;For clarity, reasonable bases for Histogenics to withhold consent for such a sublicense may include but not be limited to (i) not wanting a sublicense to be granted to one of Histogenics&#8217; competitors, or (ii) reasonable questions about a potential Sublicensee&#8217;s ethics, reputation or track record of compliance with Applicable Laws.&#160;MEDINET&#160;shall ensure that all Sublicensees comply with all terms and conditions of this&#160;Agreement.&#160;&#160;MEDINET&#160;shall remain liable for any action or failure to act by any&#160;Sublicensee&#160;that would constitute a breach of this&#160;Agreement&#160;if such action or failure were committed by&#160;MEDINET.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(c)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Implied Rights or License</u>.&#160;&#160;Except as otherwise expressly provided&#160;herein, (i)&#160;Histogenics&#160;grants no other right or license to&#160;MEDINET,&#160;including&#160;any rights or licenses under the&#160;Licensed Technology, Arising IP,&#160;or any other&#160;Patents,&#160;Know-How, or intellectual property rights&#160;Controlled&#160;by&#160;Histogenics&#160;and (ii)&#160;MEDINET&#160;grants no other right or license to&#160;Histogenics,&#160;including&#160;any rights or licenses under the&#160;MEDINET&#160;IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(d)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rights Retained by&#160;Histogenics</u>.&#160;&#160;Notwithstanding the foregoing, Histogenics retains the right under (a) the&#160;Licensed Technology&#160;and&#160;(b) Histogenics&#8217; rights in the&#160;Arising IP&#160;to (i)&#160;research, Develop, use, sell, offer for sale, have sold, distribute, import, export, and otherwise Commercialize Products&#160;outside the&#160;Field&#160;and in the&#160;Territory&#160;and/or outside the&#160;Territory, (ii) to conduct Clinical Development of the Products within the Territory for the sole purpose of supporting Regulatory Approvals of the Products outside the Field and in the Territory and/or outside the Territory&#160;and (iii) to conduct any other activities expressly assigned to&#160;Histogenics&#160;under this&#160;Agreement and the Master Quality, Supply and Pharmacovigilance Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 2.02<b style="font-weight:bold;">Trademark License.</b>&#160;&#160;Histogenics hereby grants to MEDINET an exclusive, royalty-free, license for MEDINET to use the Licensed Trademarks in connection with MEDINET&#8217;s Commercialization of Products in the Field and the Territory during the Term. Such license shall only be sub-licensable to Third Parties with the prior written consent of Histogenics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 2.03<b style="font-weight:bold;">Non-Compete</b>.<b style="font-weight:bold;">&#160;&#160;</b>During the Term, MEDINET shall not (and shall ensure that its Affiliates and Sublicensees shall not) Commercialize any Directly Competing Product.&#160;&#160;For the avoidance of doubt, CROs and CSOs and other subcontractors engaged pursuant to Section 2.01 shall not be subject to this non-compete provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article III.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">GOVERNANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 3.01<b style="font-weight:bold;">Establishment of&#160;JOC</b>.&#160;&#160;Within sixty (60) days of the&#160;Effective Date, the&#160;Parties&#160;shall establish a Joint Operating Committee (the &#8220;<b style="font-weight:bold;">Joint Operating Committee</b>&#8221; or &#8220;<b style="font-weight:bold;">JOC</b>&#8221;) consisting of&#160;four&#160;members, with two&#160;representatives to be&#160;designated by each&#160;Party.&#160;&#160;The initial members of the&#160;JOC&#160;will be nominated by the&#160;Parties&#160;promptly following the&#160;Effective Date.&#160;&#160;Such representatives shall be individuals suitable in seniority and scientific experience and having delegated authority to make decisions of the&#160;JOC&#160;with respect to matters within the scope of the&#160;JOC&#8217;s responsibilities.&#160;&#160;The&#160;JOC&#160;shall operate in accordance with the provisions of this&#160;Article III, and shall have no authority to alter, amend or waive the terms and conditions of this&#160;Agreement,&#160;including&#160;any payment conditions or terms, periods for performance, or obligations of the&#160;Parties.&#160;&#160;A&#160;Party&#160;may change one or more of its representatives serving on the&#160;JOC&#160;at any time upon written notice to the other&#160;Party.&#160;&#160;At its meetings, the&#160;JOC&#160;shall discuss the matters described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 3.02<b style="font-weight:bold;">Responsibilities of&#160;JOC.&#160;&#160;</b>The JOC shall perform the following functions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)consult regarding&#160;a mutually agreed-upon clinical development plan outlining the Clinical Development activities to be conducted by&#160;MEDINET&#160;for the Products in the Territory (the &#8220;<b style="font-weight:bold;">Clinical Development Plan</b>&#8221;)&#160;within ninety (90) days&#160;after the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)consult regarding a mutually agreed-upon commercialization plan outlining the Commercialization activities to be conducted by MEDINET for the Products in the Territory (the &#8220;<b style="font-weight:bold;">Commercialization Plan</b>&#8221;) by at least one Calendar Quarter prior to the anticipated First Commercial Sale of a Product in any country within the Territory;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(c)consult regarding the activities to be conducted by&#160;MEDINET&#160;pursuant to the Clinical&#160;Development Plan and Commercialization Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(d)review and update the Clinical&#160;Development Plan and Commercialization Plan&#160;as the&#160;JOC&#160;agrees to do so from time to time, but in any event at least once per year; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(e)share information regarding research and development of Product, including, without limitation, new technology, additional indications of Product and new product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;"> </font>Section 3.03<b style="font-weight:bold;">Clinical Development Plan</b>.&#160;&#160;The Clinical&#160;Development Plan&#160;shall specify, among other things, the specific&#160;Clinical Trials&#160;to be performed by or on behalf of&#160;MEDINET&#160;in connection with the activities conducted under the Clinical Development Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 3.04<b style="font-weight:bold;">Commercialization Plan</b>.&#160;&#160;The Commercialization Plan shall specify details typical of other commercialization plans in the pharmaceutical/biotechnology industry, including without limitation [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 3.05<b style="font-weight:bold;">Co-Chairs</b>.&#160;&#160;Each Party shall designate one of its representatives on the JOC to co-chair the meetings for the JOC (each, a &#8220;<b style="font-weight:bold;">Co-Chair</b>&#8221;).&#160;&#160;The Co-Chairs shall coordinate and prepare the agenda for, and ensure the orderly conduct of, the meetings of the JOC.&#160;&#160;The Co-Chairs shall solicit agenda items from the JOC members and provide an agenda, along with appropriate information for such agenda, reasonably in advance of any meeting.&#160;&#160;Such agenda shall include all items requested by either Co-Chair for inclusion therein.&#160;&#160;In the event the Co-Chairs or another JOC member from either Party is unable to attend or participate in a meeting of the JOC, the Party whose Co-Chair or member is unable to attend may designate a substitute co-chair or other representative for the meeting&#160;upon written notice to the other&#160;Party.&#160;&#160;In addition to the Co-Chairs, MEDINET may designate one or more persons who will act as a member of the office of the JOC.&#160;&#160;The members of the office may work within MEDINET&#39;s business premises and support Co-Chairs of the JOC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 3.06<b style="font-weight:bold;">Meetings</b>. The JOC shall meet at least quarterly each year of the Term. JOC meetings may be conducted by telephone, videoconference or in person; provided, that in each year of the Term, the JOC shall meet in person at least once.&#160;&#160;Each Party shall be responsible for the cost of such Party&#8217;s own personnel and for its own expenses in attending such meetings and carrying out the other activities contemplated under this&#160;Article III.&#160;&#160;As appropriate, the JOC may invite a reasonable number of non-voting employees, consultants and scientific advisors to attend its meetings as non-voting observers; provided that such invitees are bound by confidentiality obligations at least as stringent as the provisions set forth herein.&#160;&#160;Each Party may also call for special meetings of the JOC to discuss particular matters requested by such Party.&#160;&#160;The Co-Chairs shall provide the members of the JOC with no less than ten (10) Business Days&#8217; notice of each regularly scheduled meeting and, to the extent reasonably practicable under the circumstances, no less than five (5) Business Days&#8217; notice of any special meetings called by either Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 3.07<b style="font-weight:bold;">Minutes</b>.&#160;&#160;Minutes will be kept in English of all JOC meetings by one of the Co-Chairs of the JOC (or his or her designees) on a rotating basis and sent to all members of the JOC by e-mail for review and approval within thirty (30) days after each such meeting.&#160;&#160;The JOC shall formally accept the minutes of the previous meeting at or before the next meeting of the JOC.&#160;&#160;Minutes will be deemed approved unless any member of the JOC objects to the accuracy of such minutes by providing written notice to the other members of the JOC prior to the next meeting of the JOC.&#160;&#160;Minutes shall list action items and shall designate any issues that need to be resolved by the JOC or applicable resolution process.&#160;&#160;In the event of any objection to the minutes that is not resolved by mutual agreement of the Parties, such minutes will be amended to reflect such unresolved dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 3.08<b style="font-weight:bold;">Decision Making within JOC</b>.&#160;&#160;Decisions of the JOC shall be made by unanimous vote, with each Party&#8217;s representatives collectively having one (1) vote.&#160;&#160;In order to make any decision, the JOC must have present (in person or via telephone or videoconference) and voting at least one (1) representative of each Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 3.09<b style="font-weight:bold;">Referral to Senior Officers</b>.&#160;&#160;If the JOC cannot resolve a matter within its jurisdiction within thirty (30) days, after it begins discussing any such delegated matter (a &#8220;<b style="font-weight:bold;">Committee Deadlock</b>&#8221;), then the JOC shall escalate such Committee Deadlock to the Senior Officers for resolution.&#160;&#160;If following consideration by the Senior Officers there is still no consensus, then within thirty (30) days (or such longer period as the Senior Officers may agree upon), [***].&#160;&#160;Notwithstanding the foregoing, in no event shall [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 3.10<b style="font-weight:bold;">Limitation of Powers</b>.&#160;&#160;The JOC will have only the powers as are specifically delegated to it under this Agreement.&#160;&#160;The JOC is not a substitute for the rights of the Parties under this Agreement and is intended to coordinate and facilitate the activities of the Parties during the Term.&#160;&#160;The JOC will have no power to amend this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article IV.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">DEVELOPMENT, COMMERCIALIZATION &amp; DILIGENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 4.01<b style="font-weight:bold;">Development&#160;and Commercialization</b>.&#160;&#160;Without limiting and subject to Histogenics&#8217; obligations under this Agreement, MEDINET&#160;shall be solely responsible for the Clinical&#160;Development&#160;(in accordance with the Clinical&#160;Development Plan) and Commercialization (including without limitation booking sales of Product and pricing and reimbursement activities) of the Products in the Field and in the Territory&#160;at is sole cost and expense.&#160;&#160;During the&#160;Term,&#160;MEDINET,&#160;through the&#160;JOC, shall provide a reasonably detailed summary report of the activities it has conducted under the Clinical&#160;Development Plan&#160;to&#160;Histogenics&#160;every&#160;six (6) months&#160;setting out progress made by&#160;MEDINET&#160;regarding the Clinical&#160;Development and/or Commercialization (as applicable)&#160;of the&#160;Products&#160;and&#160;MEDINET&#8217;s future plans and objectives relating thereto.&#160;&#160;MEDINET shall have the right to contract with Third Parties, including but not limited to contract CROs and/or CSOs, or designate a clinical trial administrator to conduct the Clinical Development (including, without limitation, clinical trials) and Commercialization (including, without limitation, promotion).&#160;&#160;Where MEDINET contracts with a CRO, CSO or other Third Party, or designates a clinical trial administrator to conduct the Clinical Development or Commercialization, MEDINET shall notify Histogenics of such fact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 4.02<b style="font-weight:bold;">[***].&#160;&#160;</b>At all times, all sales of Product by MEDINET must be [***].&#160;&#160;[***].&#160;&#160;If, at any time, Histogenics believes that MEDINET may be selling Product in a manner involving product bundling, multi-product tenders, or other circumstances in which [***], Histogenics may bring this concern to MEDINET&#39;s attention and the Parties will discuss the issue in good faith.&#160;&#160;If, following such discussions, Histogenics still has concerns, Histogenics may commence arbitration provisions under Section 12.03 of this Agreement, focused on the narrow question of whether or not [***].&#160;&#160;In the event that through such arbitration it is reasonably determined that MEDINET&#39;s [***], Histogenics may terminate this Agreement pursuant to Section 9.04. For the avoidance of doubt, where the Product is on the National Health Insurance Drug Price List, the [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 4.03<b style="font-weight:bold;">Regulatory Affairs</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Generally</u>.&#160;&#160;Except for and subject to responsibilities of Histogenics described in 4.03(b) below,&#160;MEDINET&#160;shall own, and be responsible for preparing, seeking, submitting and maintaining, all regulatory filings and&#160;Regulatory Approvals&#160;for&#160;Products&#160;in the&#160;Field&#160;and in the Territory,&#160;including&#160;preparing all reports necessary as part of a regulatory filing or&#160;Regulatory Approval&#160;or application therefore.&#160;&#160;Except to the extent prohibited by Applicable Law, all&#160;Regulatory Documentation&#160;(including&#160;all&#160;Regulatory Approvals)&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">relating</u>&#160;to the&#160;Products&#160;in the&#160;Field&#160;and in the&#160;Territory&#160;shall be owned by and shall be the sole property and held in the name of&#160;MEDINET, its&#160;Affiliates,&#160;or&#160;Sublicensees.&#160;&#160;MEDINET&#160;shall have the sole right to conduct and&#160;control&#160;all interactions and communications with any&#160;Governmental Authority&#160;relating to any&#160;Product, or the&#160;Exploitation&#160;thereof, in the&#160;Field&#160;and in the&#160;Territory, at&#160;MEDINET&#8217;s sole cost and expense&#160;except for the activities listed in the Section 4.03(b) which should be undertaken by Histogenics&#160;at its sole cost and expense.&#160;&#160;Except as expressly set forth in this&#160;Section 4.03, no rights to any regulatory filings,&#160;Regulatory Approvals, or&#160;Regulatory Documentation Controlled by&#160;Histogenics&#160;both (i) outside of the&#160;Field&#160;and in the&#160;Territory&#160;and (ii) outside of the&#160;Territory&#160;in any&#160;field of use&#160;with respect to&#160;Products&#160;are granted by&#160;Histogenics&#160;to&#160;MEDINET.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Responsibility of Histogenics,</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(i)Upon MEDINET&#8217;s reasonable request and as reasonably detailed and agreed upon in the Parties&#8217; agreed Clinical Development Plan to be developed by the JOC, and at Histogenics&#8217; sole cost and expense, Histogenics shall provide MEDINET with reasonable assistance in connection with the preparation and review for filing of Regulatory Documentation for the Product in the Field and in the Territory.&#160;&#160;In addition, Histogenics shall provide MEDINET, at MEDINET&#8217;s cost and expense, with additional reasonable assistance beyond that agreed by the JOC as set forth in the Clinical Development Plan.&#160;&#160;It is anticipated that the Clinical Development Plan shall detail an agreed level of support Histogenics shall provide in connection with:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(1)</p></td><td style="vertical-align:top;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***];</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(2)</p></td><td style="vertical-align:top;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]; and</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(3)</p></td><td style="vertical-align:top;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">[***].</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(ii)Histogenics shall use Commercially Reasonable Efforts to prepare the data and information as described in item&#160;(3) above by the following deadline:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(1) if the data and information requested by MEDINET or PMDA are (i) necessary or appropriate for the filing of a notification of clinical trial plan for Product in the Territory, (ii) necessary or appropriate for the BLA for Product in the Territory, or (iii) necessary with respect to inquiries, questions or requests from the PMDA or other relevant Regulatory Authority in the Territory, as soon as practicable but in any case within thre e (3) months following a written request from MEDINET or PMDA for such data and information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(c)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PMDA&#160;</u>Issues.&#160;&#160;Both Parties confirm that there are&#160;pending inquiries, questions and requests [***] and such pending inquiries, questions, requests and issues are set forth in Exhibit E.&#160;&#160;Each Party shall use Commercially Reasonable Efforts to respond to, and address such inquiries, questions, and requests within the time period set forth in Exhibit E.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(d)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of Reference</u>.&#160;&#160;Histogenics hereby&#160;grants to&#160;MEDINET&#160;a right of reference, under and to the&#160;Regulatory Documentation&#160;that&#160;Histogenics Controls, as and to the extent necessary for&#160;MEDINET&#160;to&#160;Exploit&#160;the&#160;Products&#160;in the&#160;Field&#160;in the&#160;Territory, and shall provide copies of&#160;such documents&#160;to&#160;MEDINET&#160;as soon as practicable&#160;upon&#160;MEDINET&#39;s&#160;request&#160;but in no event later than&#160;30&#160;days after such request.&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;</u>A lists documents MEDINET requests Histogenics provide within&#160;30&#160;days after the Effective Date.&#160;&#160;MEDINET&#160;hereby&#160;grants to&#160;Histogenics&#160;a right of reference, under and to the&#160;Regulatory Documentation&#160;that&#160;MEDINET&#160;or its&#160;Affiliates Control, as and to the extent necessary for&#160;Histogenics&#160;to research&#160;and/or Exploit&#160;the&#160;Products&#160;in (i) all&#160;fields of use&#160;except the&#160;Field&#160;in the&#160;Territory&#160;and (ii) in all fields of use outside of the&#160;Territory.&#160;&#160;Each&#160;Party&#160;shall promptly upon request of the other&#160;Party&#160;file with the applicable&#160;Regulatory Authorities&#160;such letter of access or cross reference as may be necessary to accomplish the intent of this&#160;Section 4.03.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(e)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Audits/Inspections</u>.&#160;&#160;If any&#160;Governmental Authority&#160;conducts, or gives notice to&#160;either Party&#160;of its intent to conduct, an inspection or audit at any investigational site or&#160;such Party&#8217;s office or facility or to take any other regulatory action, or otherwise makes an inquiry, in each case with respect to or involving or that would otherwise reasonably be expected to affect the&#160;Products in the Territory, such Party (the &#8220;<b style="font-weight:bold;">Notifying Party</b>&#8221;) shall, unless prohibited from doing so by Applicable Law, notify the other Party within three (3) Business Days after the Notifying Party first learns of the applicable Governmental Authority&#8217;s inspection or audit.&#160;&#160;Where reasonably practicable, the Notifying Party shall consult with the other Party&#160;in advance and permit the other Party&#160;to comment on any proposed plan of action for responding to or complying with any associated demand or request of such Governmental Authority.&#160;&#160;Wherever possible, and to the extent permitted under Applicable Law, the Notifying Party&#160;shall provide the other Party with the opportunity (i) [***]&#160;and (ii) to review in advance and comment on any communications or submissions proposed to be made by the Notifying Party to any Governmental Authority in relation to any such inquiry, inspection or audit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">Section 4.04<b style="font-weight:bold;">Diligence Obligations</b>.&#160;&#160;MEDINET&#160;shall use&#160;Commercially Reasonable Efforts&#160;to&#160;Develop&#160;and&#160;Commercialize Product&#160;in the Territory; provided, however, that in the case where&#160;[***].&#160;&#160;Histogenics shall use Commercially Reasonable Efforts&#160;to itself, or with or through a Third Party, complete the ongoing Clinical Trial in the USA, file a BLA (or NDA or equivalent) for Product in the USA and obtain approval for a BLA (or NDA or equivalent) for Product from the Regulatory Authority in the USA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 4.05<b style="font-weight:bold;">Reports of Clinical Development Activities</b>.&#160;&#160;MEDINET shall report on the Clinical Development activities of the Product undertaken by it in accordance with the Clinical Development Plan at each meeting of the JOC or at such other intervals as may be set forth in the Clinical Development Plan.&#160;&#160;The Development reports shall include a reasonably detailed summary of all results, data and material inventions, if any, obtained from such Clinical Development activities.&#160;&#160;In addition, MEDINET shall, at its own expense, make appropriate scientific and regulatory personnel available to Histogenics, either by telephone or in person as the Parties may mutually agree, as reasonably required to keep Histogenics informed of Clinical Development activities conducted by MEDINET.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 4.06<b style="font-weight:bold;">Adverse Event Reporting and Product Recall</b>.<b style="font-weight:bold;">&#160;&#160;</b>Each Party agrees to provide the other Party with the necessary safety information required by Regulatory Authorities to comply with Applicable Laws.&#160;&#160;Histogenics&#160;will hold the safety database for the Products and&#160;MEDINET&#160;will provide safety information as required by Applicable Laws, in a timely manner.&#160;&#160;Additional details regarding&#160;product recall and&#160;the Parties&#39; respective pharmacovigilance activities and responsibilities will be set forth in the Parties&#39; Master Quality,&#160;Supply&#160;and Pharmacovigilance&#160;Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 4.07<b style="font-weight:bold;">Compliance with Laws</b>. MEDINET shall implement appropriate processes and controls with respect to technology and work flow methodologies in connection with its activities under or in connection with its Clinical Development activities so as to protect the security and privacy of personally identifiable information in accordance with Applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Corrupt Practices Act Compliance</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(i)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with&#160;FCPA</u>.&#160;&#160;The&#160;US&#160;government imposes and enforces prohibitions on the payment or transfer of anything of value to foreign government officials, political&#160;parties, political party officials (or relatives or associates of such officials), whether directly or indirectly, to obtain or retain business.&#160;&#160;This&#160;US&#160;law is referred to as the Foreign Corrupt Practices Act (&#8220;<b style="font-weight:bold;">FCPA</b>&#8221;), and it can have application to conduct of a&#160;US&#160;corporation&#8217;s foreign subsidiaries, employees, agents and distributors.&#160;&#160;A summary of the law and related&#160;information&#160;can be found at http://www.justice.gov/criminal/fraud/fcpa.&#160;&#160;By signing this&#160;Agreement, each&#160;Party&#160;warrants that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(ii)It is familiar with the provisions and restrictions contained in the&#160;FCPA&#160;as well as each other&#8217;s&#160;FCPA&#160;policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(iii)It shall comply with the&#160;FCPA&#160;and the equivalent other countries&#39; anti-bribery laws as if such laws are applicable to each&#160;Party&#160;in&#160;Exploiting&#160;the&#160;Products&#160;in accordance with the terms of this&#160;Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(iv)It shall not, in the course of its duties under the&#160;Agreement, offer, promise, give, demand, seek or accept, directly or indirectly, any gift or payment, consideration or benefit in kind that would or could be construed as an illegal or corrupt practice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(v)It is not a foreign official (as the&#160;term&#160;is defined in the&#160;FCPA) or affiliated with any foreign official.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(vi)It shall immediately notify the other&#160;Party&#160;of any attempt by a foreign official to directly or indirectly solicit, ask for, or attempt to extort anything of value from such&#160;Party, and shall refuse any such solicitation, request or extortionate demand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(vii)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance Certificate</u>.&#160;&#160;From time to time upon request from the other&#160;Party, each&#160;Party&#160;shall submit to the other&#160;Party&#160;a compliance certificate stating that (x) it fully understands its obligations under this Section 4.07&#160;and any other&#160;Applicable Laws&#160;or as may come into existence from time to time after the&#160;Effective Date; (y) it has been complying with this Section 4.07&#160;and any other&#160;Applicable Laws&#160;or as may come into existence from time to time after the&#160;Effective Date; and (z) it will continue to comply with this Section 4.07&#160;and any other Applicable Laws and regulations mentioned&#160;herein&#160;or as may come into existence from time to time after the&#160;Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(viii)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Action</u>.&#160;&#160;In no event shall either&#160;Party&#160;be obligated under the&#160;Agreement&#160;to take any action or omit to take any action that such&#160;Party&#160;believes, in good faith, would cause it to be in violation of any&#160;Applicable Laws,&#160;including&#160;without limitation the anti-bribery laws referenced in this Section 4.07.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(ix)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Due Diligence</u>.&#160;&#160;Each&#160;Party&#160;shall have the right to visit the offices of the other&#160;Party&#160;from time to time during the&#160;term&#160;of the&#160;Agreement&#160;on an &#8220;as needed&#8221; basis and conduct due diligence in relation to such other&#160;Party&#8217;s business related to performance of its obligations under this Section 4.07&#160;and may do so in the way it deems necessary, appropriate or desirable so as to ensure that such other&#160;Party&#160;complies with this Section 4.07 and any other Applicable Laws and regulations in its business operations.&#160;&#160;Each&#160;Party&#160;shall make every effort to cooperate fully with the other&#160;Party&#160;in any such due diligence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(x)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit</u>.&#160;&#160;In the event that a&#160;Party&#160;has reason to believe that a breach of any obligation under this Section 4.07&#160;by the other&#160;Party&#160;has occurred or may occur, such&#160;Party&#160;shall have the right to conduct an audit, at such&#160;Party&#8217;s cost, of the other&#160;Party&#160;and review relevant books and records of the other&#160;Party, to satisfy itself that no breach has occurred.&#160;&#160;Unless otherwise required under&#160;Applicable Laws&#160;or by order of a&#160;Governmental Authority, the auditing&#160;Party&#160;shall keep confidential all audited matters and the results of the audit in accordance with&#160;Article VII; provided, however, the auditing&#160;Party&#160;reserves the right to disclose to the applicable&#160;Governmental Authority,&#160;including&#160;without limitation, the U.S. or foreign government, its agencies and/or any other government or non-government party, as applicable,&#160;information&#160;relating to a possible violation by the audited&#160;Party&#160;of any&#160;Applicable Law,&#160;including&#160;a violation of the&#160;FCPA&#160;or any other applicable anti-bribery law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(xi)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Breach</u>.&#160;&#160;Each&#160;Party&#160;acknowledges that any violation of this&#160;Section 4.07&#160;by such&#160;Party&#160;or any of its&#160;Affiliates, sublicensees or subcontractors shall be deemed a material breach of this&#160;Agreement&#160;by such&#160;Party&#160;and shall give rise to the right for the other&#160;Party&#160;to terminate this&#160;Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Consideration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 5.01<b style="font-weight:bold;">Upfront Fee</b>.&#160;&#160;MEDINET will pay Histogenics a non-refundable, upfront fee in the amount of ten million (10,000,000) USD&#160;within ten (10) Business Days&#160;of the Effective Date of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 5.02<b style="font-weight:bold;">Royalties</b>.&#160;&#160;During the Term, in consideration in part for the licenses and sublicenses granted hereunder, for the assistance of Histogenics in continued Development of the Product, and in partial consideration for the Supply of clinical and commercial quantities of the Product contemplated hereunder, MEDINET shall pay to Histogenics a running royalty, [***], on the Net Sales of Products sold by MEDINET, its Affiliates, or any of its Sublicensees in the Territory as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)For that portion of Net Sales of Product in the Territory up to and including [***] in a given Calendar Year, [***] of such Net Sales; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)For that portion of Net Sales of Product in the Territory greater than [***] in a given Calendar Year, [***] of such Net Sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 5.03<b style="font-weight:bold;">Royalty&#160;Payment&#160;Frequency, Reporting</b>&#160;<b style="font-weight:bold;">and Retrospective Adjustment</b>.&#160;&#160;MEDINET shall, on and from the date of First Commercial Sale, deliver to Histogenics, within [***] after the end of each Calendar Quarter a report setting forth for such Calendar Quarter the following information for Products: (a) Net Sales of Product on a Product-by-Product basis, (b) the royalties due to Histogenics on account of sales of Products, (c) the exchange rates used in calculating any of the foregoing, and (d) any deductions provided for under this Agreement.&#160;&#160;If no royalties were payable for any Calendar Quarter, MEDINET&#8217;s report shall so state.&#160;&#160;MEDINET&#160;shall pay such royalty payments within simultaneously with the delivery of each such report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 5.04<b style="font-weight:bold;">Development Milestone&#160;Payments</b>.&#160;&#160;MEDINET shall pay to Histogenics the following clinical milestone funding payments upon the first achievement of the following development milestone events by MEDINET, its Affiliates, or its Sublicensees:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:28.8pt;"><td style="vertical-align:middle;width:59.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Milestone Event</b></p></td><td style="vertical-align:middle;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Milestone Payment</b></p></td></tr><tr><td style="vertical-align:middle;width:59.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 2.85pt;">Filing of a BLA (or NDA or equivalent) for Product in the USA</p></td><td style="vertical-align:middle;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:59.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 2.85pt;">Filing of a BLA (or NDA or equivalent) for Product in the Territory</p></td><td style="vertical-align:middle;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:59.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 2.85pt;">Receipt of Regulatory Approval for Product in the Territory</p></td><td style="vertical-align:middle;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:59.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 2.85pt;">Filing in the Territory for Regulatory Approval (or a label expansion) to use Product to repair or replace cartilage in a second type of joint within the human body (beyond that first joint for which initial Regulatory Approval was earlier obtained), and for which MEDINET has agreed to Develop</p></td><td style="vertical-align:middle;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:58.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 2.85pt;">First Commercial Sale of Product in the Territory for use to repair or replace cartilage in a second type of joint within the human body (beyond that first joint for which initial Regulatory Approval was earlier obtained)</p></td><td style="vertical-align:middle;width:41.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt;">MEDINET shall notify Histogenics in writing promptly, but in any event within five (5) Business Days following the occurrence of each of the above-referenced development milestone events and shall pay Histogenics&#160;the applicable milestone payment&#160;within ten (10) days after achievement of the applicable milestone.&#160;&#160;For clarity, each of the above-referenced development milestone payments shall be paid only once with respect to the first Product to achieve such clinical milestone event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 5.05<b style="font-weight:bold;">Sales Milestone&#160;Payments</b>.&#160;&#160;MEDINET&#160;shall pay to&#160;Histogenics&#160;the following sales milestone&#160;payments&#160;upon the achievement of the following sales milestone events:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:33.35pt;"><td style="vertical-align:middle;width:59.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sales Milestone Event</b></p></td><td style="vertical-align:middle;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sales Milestone Payment [***]</b></p></td></tr><tr><td style="vertical-align:middle;width:59.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 2.85pt;">Net Sales of Products in the Territory by MEDINET, its Affiliate and its Sublicensees totaling [***] in any Calendar Year</p></td><td style="vertical-align:middle;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:59.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 2.85pt;">Net Sales of Products in the Territory by MEDINET, its Affiliate and its Sublicensees totaling [***] in any Calendar Year</p></td><td style="vertical-align:middle;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:59.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 2.85pt;">Net Sales of Products in the Territory by MEDINET, its Affiliate and its Sublicensees totaling [***] in any Calendar Year</p></td><td style="vertical-align:middle;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:59.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 2.85pt;">Net Sales of Products in the Territory by</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 2.85pt;">MEDINET, its Affiliate&#160;and its Sublicensees totaling&#160;[***]&#160;in any Calendar Year</p></td><td style="vertical-align:middle;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:59.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 2.85pt;">Net Sales of Products in the Territory by MEDINET, its Affiliate and its Sublicensees totaling [***] in any Calendar Year</p></td><td style="vertical-align:middle;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt;">MEDINET shall notify Histogenics in writing promptly, but in any event within [***] following the occurrence of each of the above-referenced sales milestone events and shall pay the applicable milestone payment within [***] after achievement of the applicable milestone.&#160;&#160;For clarity, each of the above-referenced sales milestone payments shall be paid only once, and are additive in that multiple sales milestone payments shall be paid if multiple sales milestones are achieved in the same Calendar Year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 5.06<b style="font-weight:bold;">Payment Currency</b>.&#160;&#160;[***], payments by MEDINET under this Agreement shall be paid to Histogenics in USD.&#160;&#160;[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 5.07<b style="font-weight:bold;">Payment Method</b>.&#160;&#160;All payments due to a Party hereunder shall be made via wire transfer of immediately available USD funds to an account designated in writing by that Party to the other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 5.08<b style="font-weight:bold;">Records Retention; Audit; Consolidation Reporting</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Record Retention</u>.&#160;&#160;MEDINET shall maintain complete and accurate books, records and accounts for the calculation of milestone and royalty payments due hereunder, in sufficient detail to confirm whether any milestone payments are payable and the accuracy of any royalty payments required under this Agreement, which books, records and accounts shall be retained by MEDINET for [***] after the end of the period to which such books, records and accounts pertain, or longer as is required by Applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit</u>.&#160;&#160;Histogenics shall have the right to engage an independent certified public accounting firm of internationally recognized standing reasonably acceptable to MEDINET&#160;have access during normal business hours, upon no less than thirty (30) days prior written notice, to such of the records of MEDINET and its Affiliates.&#160;&#160;Such audits may not be conducted more than once in any six (6) month period or be repeated for any period unless a subsequent verification uncovers a material error that is reasonable for Histogenics to assume existed in previously audited records.&#160;&#160;The independent certified public accounting firm shall review all books and records necessary to confirm MEDINET, its Affiliates&#8217; and any Sublicensee&#8217;s compliance with its obligations under this Agreement.&#160;&#160;Any and all records of MEDINET and its Affiliates examined by such independent certified public accounting firm shall be deemed MEDINET&#8217;s Confidential Information, which may not be disclosed by said independent certified public accounting firm to any Third Party or (except for the information expressly sought to be confirmed by Histogenics as set forth in this&#160;Section 5.08(b)) to Histogenics.&#160;&#160;For any audit initiated by Histogenics, Histogenics shall bear all costs of such audit, unless the audit reveals an underpayment of more than five (5%), in which case&#160;MEDINET&#160;shall bear the cost of the audit.&#160;&#160;The result of the audit shall, in the absence of manifest error, be final and binding on the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(c)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment&#160;of Additional Amounts</u>.&#160;&#160;If, based on the results of any audit conducted under Section 5.08(b), additional payments are owed to Histogenics under this Agreement, then MEDINET&#160;shall make such additional payments as soon as practicable, but in any event&#160;within [***], after the accounting firm&#8217;s written report is delivered to the Parties, with interest calculated thereon in accordance with Section 5.08(b).&#160;&#160;If the report is contested by either, the Parties shall follow the dispute resolution procedures described in Section 12.03. The responsible Party shall pay any amount ultimately found due as soon as practicable, but in any event&#160;within [***],&#160;after resolution of the dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 5.09<b style="font-weight:bold;">Interest on Late Payments</b>.&#160;&#160;Any failure by MEDINET to make a payment of any undisputed amount when due shall obligate MEDINET to pay interest to the other Party on the amount unpaid [***]&#160;(or, if lower, the maximum rate permitted by Applicable Law) calculated on a daily basis and payable for the period from the date payment is due until the date payment is actually made, without prejudice to recipient&#8217;s right to receive payment on the due date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 5.10<b style="font-weight:bold;">Taxes</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)The royalties, milestones and other amounts payable by&#160;MEDINET&#160;to&#160;Histogenics&#160;pursuant to this&#160;Agreement&#160;(&#8220;<b style="font-weight:bold;">Payments</b>&#8221;) shall not be reduced on account of taxes&#160;unless required by Applicable Laws.&#160;&#160;MEDINET shall deduct or withhold from the Payments any taxes&#160;that it is required by Applicable Laws to deduct or withhold.&#160;&#160;Notwithstanding the foregoing, if Histogenics is entitled (whether under any applicable tax treaty or otherwise under Applicable Laws) to a reduction in the rate of, or the elimination of, withholding tax, it may deliver to MEDINET or the appropriate Governmental Authority (with the assistance of MEDINET to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve MEDINET of its obligation to withhold tax, and MEDINET shall apply the reduced rate of withholding, or dispense with withholding, as the case may be, provided that MEDINET has received evidence, in a form reasonably satisfactory to MEDINET, of Histogenics&#8217; delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least five (5) Business Days prior to the time that the Payments are due; provided, however, that if Histogenics determines that it needs additional time to obtain such forms or authorization, Histogenics may elect, by written notice to MEDINET, to delay the payment date for any applicable Payment in order to obtain such forms or governmental authorization.&#160;&#160;Any such delay in accordance with such notice shall not be considered a breach of this Agreement by MEDINET.&#160;&#160;If, in accordance&#160;with the foregoing, MEDINET withholds any tax, it shall make timely payment to the proper tax authority&#160;of the withheld tax, in accordance with Applicable Laws, and send to Histogenics proof of such payment as soon as reasonably practicable following that payment.&#160;&#160;MEDINET agrees to take reasonable and lawful efforts to minimize such taxes&#160;to Histogenics.&#160;&#160;MEDINET shall cooperate with Histogenics as reasonably requested in any claim for refund or application to any tax authority.&#160;&#160;If MEDINET intends to withhold tax from any Payment, MEDINET shall inform Histogenics reasonably in advance of making such Payment to permit Histogenics an opportunity to provide any forms or information or obtain any&#160;tax authority&#160;approval as may be available to reduce or eliminate such withholding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Gross-up</u>.&#160;&#160;Notwithstanding anything to the contrary herein, if (i) MEDINET redomiciles or assigns its rights or obligations under this Agreement outside of Japan, (ii) as a result of such redomiciliation or assignment, MEDINET (or its assignee) is required by Applicable Law to withhold taxes, or such redomiciliation or assignment results in the imposition of Indirect Taxes that were not otherwise applicable, from or in respect of any amount payable under this Agreement, and (iii) such withholding taxes or Indirect Taxes exceed the amount of withholding taxes or Indirect Taxes that would have been applicable but for such redomiciliation or assignment, then any such amount payable to Histogenics pursuant to this Agreement shall be increased to take into account such withholding taxes or Indirect Taxes as may be necessary so that, after making all required withholdings (including withholdings on the additional amounts payable) and/or paying such Indirect Taxes, as the case may be, Histogenics receives an amount equal to the sum it would have received had no such increased withholding been made and no such Indirect Taxes had been imposed.&#160;&#160;The obligation to pay additional amounts pursuant to the preceding sentence shall not apply, however, to the extent such increased withholding tax or Indirect Taxes would not have been imposed but for the assignment by Histogenics of its rights or obligations under this Agreement or the redomiciliation of Histogenics outside of the United States, to the extent such assignment or redomiciliation occurs after the redomiciliation or assignment by MEDINET described in the first sentence of this Section 5.10(b).&#160;&#160;To the extent Histogenics receives additional amounts and its Affiliates, taken as a whole, actually realize an overall reduction in cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">taxes otherwise due (determined on a with and without basis and taking into account only the taxes required to be withheld under Applicable Law from any Payments made to Histogenics&#8217; Affiliates) as a result of a foreign tax credit or a tax refund attributable to withholding taxes in respect of which Histogenics received additional amounts pursuant to this Section 5.10(b) (such reduction, a &#8220;<b style="font-weight:bold;">Tax Benefit</b>&#8221;), Histogenics shall [***].&#160;&#160;The foregoing sentence shall not be construed to require Histogenics to make available its tax returns to MEDINET.&#160;&#160;Furthermore, Histogenics and its Affiliates agree not to take any action [***].&#160;&#160;Solely for purposes of this Section 5.10(b), a Party&#8217;s &#8220;<b style="font-weight:bold;">domicile</b>&#8221; shall include its jurisdiction of incorporation or tax residence and a &#8220;<b style="font-weight:bold;">redomiciliation</b>&#8221; shall include a reincorporation or other action resulting in a change in tax residence of the applicable Party or its assignee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(c)Notwithstanding anything to the contrary contained in this&#160;Section 5.10&#160;or elsewhere in this Agreement, the following shall apply with respect to Indirect Taxes.&#160;&#160;All Payments are exclusive of Indirect Taxes.&#160;&#160;If any Indirect Taxes are chargeable in respect of any Payments,&#160;MEDINET&#160;shall pay such Indirect Taxes at the applicable rate in respect of any such Payments following the receipt, where applicable, of an Indirect Taxes invoice issued by&#160;Histogenics&#160;in respect of those Payments, such Indirect Taxes to be payable on the due date of the payment of the Payments to which such Indirect Taxes relate or at the time such Indirect Taxes are required to be collected by&#160;Histogenics, in the case of payment of Indirect Taxes to&#160;Histogenics.&#160;&#160;The Parties shall issue invoices for all goods and services supplied under this Agreement consistent with Indirect Tax requirements, and to the extent any invoice is not initially issued in an appropriate form,&#160;MEDINET&#160;shall promptly inform&#160;Histogenics&#160;and shall cooperate with&#160;Histogenics&#160;to provide such information or assistance as may be necessary to enable the issuance of such invoice consistent with Indirect Tax requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(d)The Parties shall bear their own taxes (including but not limited to custom tax) based on their own income and any other applicable taxes (including but not limited to customs duties) in jurisdictions in which each Party operates that arise in connection with the performance of obligations under this Agreement by the Parties and for which each Party has a responsibility to pay and file tax returns or otherwise report to governmental authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Supply</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 6.01<b style="font-weight:bold;">Exclusive Supply Arrangement.&#160;&#160;</b>MEDINET&#160;shall, in accordance with and subject to the terms of a Master Quality, Supply and Pharmacovigilance Agreement (the &quot;<b style="font-weight:bold;">Master Quality, Supply and Pharmacovigilance Agreement</b>&quot;) purchase its requirements&#160;of Product and Biopsy Kits during the Term from Histogenics, and Histogenics shall supply such Product and Biopsy Kits in accordance with terms thereof and in accordance with Applicable Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)Clinical Supply Agreement.&#160;&#160;As soon as practicable after the Effective Date, the Parties shall negotiate in good faith the terms and conditions of the Clinical Supply Agreement. &#160;Such agreement shall apply to MEDINET&#39;s purchases of clinical supply requirements in respect of the Product.&#160;&#160;The price of Product for use in Clinical Development to be supplied to MEDINET under the Clinical Supply Agreement shall be the Transfer Price stipulated in Exhibit B.&#160;&#160;For the avoidance of doubt, the price at which Histogenics supplies Biopsy Kits to MEDINET shall be included in the Transfer Price.&#160;&#160;Histogenics shall manufacture in the USA such Products for use in Clinical Development in Japan and shall supply Products which have the same level of quality and stability as clinical trial products used for clinical trials in the USA to medical institutions designated by MEDINET.&#160;&#160;The Parties&#8217; Clinical Supply Agreement shall address the handling of pharmacovigilance responsibilities related to Product used in clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Master Quality,&#160;Supply&#160;and Pharmacovigilance&#160;Agreement</u>.&#160;&#160;As soon as practicable after the Effective Date of this Agreement, the Parties shall negotiate in good faith the terms and conditions of the Master Quality,&#160;Supply&#160;and Pharmacovigilance&#160;Agreement consistent with the high level terms set forth therefore on Exhibit C hereto.&#160;&#160;Such agreement shall apply to MEDINET&#39;s purchases of commercial supply requirements once Regulatory Approval for the sale of Product has been obtained in one or more countries within the Territory.&#160;&#160;[***].&#160;&#160;The price for Product to be supplied to MEDINET under the Master Quality,&#160;Supply&#160;and Pharmacovigilance&#160;Agreement shall&#160;be&#160;the Transfer Price&#160;stipulated in Exhibit B.&#160;&#160;For the avoidance of doubt, the price&#160;at which&#160;Histogenics&#160;supplies&#160;Biopsy&#160;Kits to MEDINET shall be&#160;included&#160;in the price for&#160;the&#160;Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 6.02<b style="font-weight:bold;">Preparation of Manufacturing Product</b>.&#160;&#160;Following the Effective Date, the Parties shall establish a joint manufacturing committee (&#8220;JMC&#8221;) to facilitate their discussion of manufacturing-related issues.&#160;&#160;Such JMC will report to the JOC and any disputes between the Parties at the JMC shall be referred to the JOC for resolution. &#160;Histogenics&#160;shall (i) determine the manufacturing site of the Product and Biopsy Kit [***] in respect of which a license has been obtained for the manufacturing of Cellular and Tissue-based Product [***] prior to the filing of a BLA (or NDA or the equivalent thereof) for the Product and Biopsy Kit in the Territory; (ii) complete preparation of the commercial production system in respect of the Product and Biopsy Kit in accordance with the GCTP Ordinance of Japan (Ordinance issued by the MHLW No. 93 of 2014), the GMP Ordinance of Japan (Ordinance issued by the MHLW No. 179 of 2008), the QMS Ordinance of Japan (Ordinance issued by the MHLW No. 169 of 2008), the Applicable Law and the description of the BLA in Japan within [***] after the filing of a BLA (or NDA or the equivalent thereof) for the Product and Biopsy Kit in the Territory; and (iii) comply with all audits and inspections by PMDA with respect to GCTP, GMP and QMS prior to approval. &#160;Histogenics shall start to supply the commercial Product to MEDINET as soon as MEDINET obtains the BLA for Product in Japan and continue to supply the commercial Products during the Term in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">accordance with the GCTP Ordinance of Japan, the GMP Ordinance of Japan, the QMS Ordinance of Japan, the Applicable Law and the description of the BLA in Japan.&#160;&#160;Histogenics&#160;shall change its manufacturing process only in accordance with the GCTP Ordinance of Japan, the GMP Ordinance of Japan, the QMS Ordinance of Japan and/or the Applicable Law and if Histogenics intends to change manufacturing process,&#160;Histogenics&#160;shall notify MEDINET necessary period for MEDINET to obtain the approval for a partial change of BLA in Japan in advance of such change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 6.03<b style="font-weight:bold;">Contract Manufacturing Organization.&#160;&#160;</b>Histogenics may contract with &#8220;contract manufacturing organizations&#8221; (&#8220;<b style="font-weight:bold;">CMOs</b>&#8221;) which may be a Third Party for the manufacturing of the Product and Biopsy Kit under the Clinical Supply Agreement and the Master Quality, Supply and Pharmacovigilance Agreement; provided that if Histogenics wishes to contract out the clinical or commercial manufacturing of the Products and Biopsy Kit to a Third Party, [***].&#160;&#160;Histogenics shall notify MEDINET of the fact that Histogenics may wish to contract out manufacturing well in advance in order to enable MEDINET to secure a reasonable period for technology transfer to manufacture the Products and Biopsy Kit at MEDINET&#39;s manufacturing site and fully cooperate with MEDINET and comply with all audits and inspections by PMDA with respect to GCTP, GMP and QMS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 6.04<b style="font-weight:bold;">Quality Audit</b>.&#160;&#160;MEDINET&#160;shall have the right, at its sole cost and expense, to conduct a reasonable quality audit of&#160;Histogenics&#8217; manufacturing sites for the Product.&#160;&#160;Histogenics&#160;shall cooperate with good faith with&#160;MEDINET&#160;in arranging for such quality audit to be conducted by&#160;MEDINET at such manufacturing sites, and relevant contractors.&#160;&#160;Where&#160;Histogenics&#160;contracts with&#160;Third Party CMOs to manufacture the Products under the&#160;Master Quality,&#160;Supply&#160;and Pharmacovigilance&#160;Agreement,&#160;MEDINET&#160;may be required to agree to certain terms and conditions required by such CMOs in order to conduct such quality audit.&#160;&#160;If, in connection with such quality audit by&#160;MEDINET,&#160;MEDINET&#160;reasonably requests a corrective and preventative action plan (&#8220;<b style="font-weight:bold;">CAPA</b>&#8221;) to be implemented to address bona fide issues arising out of such quality audit, the Parties shall negotiate in good faith and implement such CAPA to&#160;MEDINET&#8217;s reasonable satisfaction prior to the supply of Products to&#160;MEDINET&#160;under such Clinical Supply Agreement or Commercial Supply Agreement, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article VII.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;white-space:pre-wrap;"> CONFIDENTIALITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 7.01<b style="font-weight:bold;">Protection of&#160;Confidential Information</b>.&#160;&#160;The&#160;Receiving Party&#160;shall not, and shall cause its&#160;Affiliates&#160;and its and their officers, directors, employees and agents not to, disclose or disseminate&#160;Confidential Information&#160;of the&#160;Disclosing Party&#160;to any&#160;Third Party&#160;unless expressly permitted hereunder, and shall not use such&#160;Confidential Information&#160;for any purpose other than in performing the&#160;Receiving Party&#8217;s obligations or exercising the&#160;Receiving Party&#8217;s rights hereunder.&#160;&#160;In addition, the&#160;Receiving Party&#160;shall take, and shall cause its&#160;Affiliates&#160;to take, reasonable steps to protect the&#160;Confidential Information&#160;of the&#160;Disclosing Party&#160;from unauthorized use or disclosure, which steps shall be no less than those the&#160;Receiving Party&#160;takes to protect its own confidential and/or proprietary material of a similar nature.&#160;&#160;The foregoing obligations shall apply equally to all copies, extracts and summaries of the&#160;Disclosing Party&#8217;s&#160;Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">Section 7.02<b style="font-weight:bold;">Certain Permitted Disclosures</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">(a)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure Required by Law</u>.&#160;Notwithstanding the foregoing, each of Histogenics and MEDINET may disclose Confidential Information of the other Party to a Third Party to the extent such disclosure is reasonably necessary to exercise the rights granted to or retained by it under this Agreement, including in preparing, filing, maintaining or prosecuting Patents in accordance with Article VIII, complying with Applicable Law, or submitting information to Governmental Authorities in connection with seeking Regulatory Approval of the Product or as required by Applicable Law or Governmental Authorities; provided, however, that if a Party is&#160;required by Applicable Law or Governmental Authorities to make any such disclosure of the Disclosing Party&#8217;s Confidential Information, to the extent it may legally do so it shall: (i) give reasonable advance notice to the Disclosing Party of such disclosure to permit the Disclosing Party to use its reasonable efforts to secure confidential treatment of such Confidential Information prior to disclosure to the extent such treatment is applicable (whether through protective orders or otherwise), (ii) cooperates with the Disclosing Party in the exercise of its right to protect the confidentiality of the Confidential Information and (iii) discloses only that Confidential Information that is required to be disclosed.&#160;&#160;Each Party shall be responsible for any breach of its confidentiality obligations by its respective&#160;Affiliates and their employees and agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">(b)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure to Certain Third&#160;Parties</u>.&#160;&#160;The Receiving Party may disclose such of the Disclosing Party&#8217;s Confidential Information to its Affiliates, employees, directors, consultants and permitted sublicensees who have a need to know such Confidential Information and to existing or potential sublicensees, collaboration partners (including without limitation the CRO or CSO with whom MEDINET contracts for the Clinical Development and/or Commercialization), in each case who are bound by obligations of confidentiality and non-use substantially at least as stringent as those by which the Receiving Party is bound hereunder prior to such disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">Section 7.03<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Return of&#160;Confidential Information</u>.&#160;&#160;Upon termination of this Agreement, the Receiving Party shall promptly return all of the Disclosing Party&#8217;s Confidential Information, including all information relating to the Products, unless, and solely for so long as, the Receiving Party has continuing rights to use the foregoing pursuant to Article IX, received hereunder and copies thereof in any medium, except that the Receiving Party may retain one copy for its legal files.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">Section 7.04<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Unauthorized Use</u>.&#160;&#160;If either Party becomes aware or has knowledge of any unauthorized use or disclosure of the Disclosing Party&#8217;s Confidential Information, it shall promptly notify the Disclosing Party of such unauthorized use or disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">Section 7.05<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Public Disclosure</u>.&#160;&#160;Except as otherwise expressly permitted hereunder, neither Party shall mention or otherwise use the name, logo or Trademark of the other Party or any of its Affiliates or any of its or their sublicensees or any abbreviation or adaptation thereof in any advertising, marketing, promotional or sales literature or other form of publicity or in any document employed to obtain funds or financing without the prior written approval of the Party whose name is to be used save as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">(a)MEDINET, its&#160;Affiliates&#160;and&#160;Sublicensees&#160;may state that they are licensed under the&#160;Licensed Patents and Licensed&#160;Know-How,&#160;and Histogenics and its Affiliates may state that</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">they have licensed the Licensed Patents and Licensed Know-How&#160;to&#160;MEDINET,&#160;its&#160;Affiliates&#160;and&#160;Sublicensees.&#160;&#160;For this purpose, each&#160;Party&#160;may use the name and logo of the other&#160;Party, and may make a high level non-confidential statement about the existence, scope and key terms of this contractual relationship&#160;that is consistent with and limited to the information that is included within the press releases set out in Exhibit D&#160;or any other communication content that the&#160;Parties&#160;agree in writing is acceptable for general public use.&#160;&#160;Each Party may also make such disclosures related to this Agreement as may be necessary for it to comply with Applicable Law, and MEDINET acknowledges and agrees that as a publicly-traded company Histogenics must and shall be permitted to make appropriate disclosures related to this Agreement and its terms in order to comply with applicable securities laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">(b)The Parties have agreed upon the content of a press release which shall be issued substantially in the form(s) attached hereto as Exhibit D, the release of which the Parties shall coordinate in order to accomplish such release promptly upon execution of this Agreement.&#160;&#160;Neither Party shall issue any other public announcement or&#160;press release&#160;(subject to&#160;Section 7.05(a))&#160;or other public disclosure regarding this Agreement or its subject matter without the other Party&#8217;s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article VIII.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;white-space:pre-wrap;"> INTELLECTUAL PROPERTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">Section 8.01<b style="font-weight:bold;">Ownership of Inventions</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">(a)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inventions in the Territory</u>.&#160;&#160;All inventions, discoveries, or improvements conceived or reduced to practice by or on behalf of a Party (whether solely or jointly by or on behalf of the other Party) pursuant to any activities conducted in accordance with this Agreement (including all activities conducted under the Clinical Development Plan) and that are related to the Product or the Licensed Technology in the Territory (the &#8220;<b style="font-weight:bold;">Arising Inventions</b>&#8221;), and all Patents (&#8220;<b style="font-weight:bold;">Arising Patents</b>&#8221;) and Know-How (&#8220;<b style="font-weight:bold;">Arising Know-How</b>&#8221;) therein shall be owned solely by Histogenics (together, the &#8220;<b style="font-weight:bold;">Arising IP</b>&#8221;).&#160;&#160;MEDINET hereby assigns to Histogenics all of its right, title, and interest in, to, and under, all Arising Inventions and Arising IP and shall execute all documents and do all reasonable things to bring effect to the foregoing assignment.&#160;&#160;MEDINET shall ensure that all of its and its Affiliates&#8217; employees, personnel, independent contractors, agents, and other representatives performing activities in connection with this Agreement have signed invention assignment agreements that effectuate the assignment in the immediately preceding sentence (and shall require its Sublicensees to do the same).&#160;&#160;Upon the reasonable request and at the expense of Histogenics, MEDINET shall assist Histogenics in securing Patents or other intellectual property protection for the Arising Inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">(b)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure of&#160;Arising Inventions</u>.&#160;&#160;Each&#160;Party&#160;agrees to promptly disclose to the other&#160;Party&#160;all Arising Inventions&#160;in writing within thirty (30) days of discovery or&#160;development&#160;of each such Arising Inventions or&#160;Arising Invention (as applicable), and each&#160;Party&#160;shall make available to the other&#160;Party&#160;all Arising Know-How thereto in connection with such notification and from time to time as the other&#160;Party&#160;may reasonably request.&#160;&#160;MEDINET shall have the right to request that Histogenics file a patent application for an Arising Invention in the Territory, and Histogenics shall consider such request in good faith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 8.02<b style="font-weight:bold;">Maintenance and Prosecution of&#160;Patents</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preparation, Filing, Prosecution and Maintenance of&#160;Licensed Patents and Arising Patents</u>.&#160;&#160;Histogenics shall have the right, subject only to subparts (a) and (b) below,&#160;to prepare, file, prosecute and maintain the Licensed Patents and Arising Patents, and control any related interference, re-issuance, re-examination and opposition proceedings, at its sole discretion and expense and using counsel of its choice; provided, MEDINET shall have the opportunity to review and comment on all filing, prosecution matters, and maintenance matters related to the Licensed Patents and Arising Patents in the Territory reasonably in advance of any relevant deadlines in connection therewith, and Histogenics&#160;shall consider such comments in good faith. &#160;Notwithstanding the foregoing, in the event that Histogenics decides (a) not to continue the prosecution or maintenance of a patent or patent application within the Licensed Patents or Arising Patents in the Territory or (b) not to file a new patent application that would be deemed within the Arising Patents in the Territory and that is requested by MEDINET to be filed pursuant to Section 8.01(b) herein, Histogenics shall provide MEDINET with notice of such decision at least thirty (30) days prior to any pending lapse, abandonment, or publication or other event which would prejudice the ability to secure or maintain the relevant Licensed Patent or Arising Patent in the Territory.&#160;&#160;In such case, MEDINET shall, upon written notice to Histogenics, have the right, but not the obligation, to assume control and management of the preparation, filing, prosecution, and maintenance of such Licensed Patent or Arising Patent, at its sole cost and expense and using counsel of its choice; provided, Histogenics shall have the opportunity to review and comment on all filing, prosecution matters, and maintenance matters related to such Licensed Patent or Arising Patent in the Territory to the extent such Licensed Patents or Arising Patent claims or covers subject matter relevant to Products outside of the Field reasonably in advance of any relevant deadlines in connection therewith, and MEDINET shall consider such comments in good faith.&#160;&#160;Upon MEDINET&#8217;s exercise of such right, Histogenics shall provide to MEDINET all reasonable information and documents to allow MEDINET to assume control and management of such prosecution activities and shall provide reasonable assistance to MEDINET, at MEDINET&#39;s sole cost and expense, in connection with such transfer of such prosecution activities to MEDINET.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 8.03<b style="font-weight:bold;">Enforcement Against Third Party Infringers</b>.&#160;&#160;In the event that either&#160;Party&#160;learns of or suspects any&#160;Third Party&#160;infringement of any&#160;Licensed Patent or Arising Patent, such Party shall promptly inform the other Party and shall provide the other Party with reasonable evidence of such Third Party infringement of which it is aware or suspects has occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)Histogenics&#160;shall have the first right, but not the obligation, to initiate and litigate at its sole cost and expense any infringement action against such Third Party believed to be infringing the applicable Licensed Patents or Arising Patents, using counsel of its choice.&#160;&#160;If Histogenics (a) fails to institute and prosecute an action or proceeding to abate such infringement in the Territory within a period of ninety (90) days after receiving written notice from MEDINET or otherwise obtaining knowledge of such infringement or suspected infringement in the Territory, or (b) otherwise waives its rights under this Section 8.03(a), then MEDINET shall have the right, but not the obligation, after discussion with Histogenics and taking into consideration in good faith Histogenics&#8217; reasons for not initiating and prosecuting an action or Arising Patents in the Territory, at its sole cost and expense; provided, however, that in such event&#160;Histogenics&#160;has the right, to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">participate in such action and to be represented in any such action by counsel of its choice, at its sole expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)Each Party shall reasonably assist the Party pursuing such enforcement action as set forth in this Section 8.03&#160;and cooperate in any such litigation at the request and expense of the other Party, including by&#160;providing access to relevant documents (including laboratory notebooks) and other evidence and making its employees available at reasonable business hours; provided that the enforcing Party shall reimburse the assisting Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(c)Any damages awarded to the enforcing Party after deduction of reimbursement of the enforcing Party&#8217;s legal costs incurred in connection with pursuing such action to enforce the Licensed Patents or Arising Patents in accordance with this Section 8.03 shall be allocated to the enforcing Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(d) In addition to the foregoing, in the event that either Party learns of or suspects any Third Party infringement of any Licensed Patent or Arising Patent, which may be materially adverse to either Party&#39;s business, plans or activities, including without limitation, Clinical Development, Commercialization or Exploitation of the Products in the Territory, such Party shall promptly inform the other Party and both Parties shall discuss in good faith how to cope with such Third Party infringement and shall use its respective best efforts to take actions against such Third Party infringement, including, without limitation, by requesting licensor(s) of the Licensed Patent to take actions against such Third Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 8.04<b style="font-weight:bold;">Defense of Claims Brought by&#160;Third Parties</b>.&#160;&#160;If a Third Party initiates a proceeding, including an action before an administrative body, claiming that any Patent owned by or licensed to such Third Party is infringed by the Exploitation of the Products under this Agreement, or that the Licensed Patents or Arising Patents are invalid or unenforceable (a &#8220;<b style="font-weight:bold;">Third Party Infringement Claim</b>&#8221;), the Party who is the subject of the Third Party Infringement Claim (&#8220;<b style="font-weight:bold;">Affected Party</b>&#8221;) shall promptly notify the other Party thereof.&#160;&#160;Such other Party shall reasonably assist the Affected Party pursuing such defending against such Third Party Infringement Claim as set forth in this Section 8.04 and cooperate in any such litigation at the request and expense of the Affected Party, including by providing access to relevant documents (including laboratory notebooks) and other evidence and making its employees available at reasonable business hours; provided that the Affected Party shall reimburse the assisting Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">MEDINET&#160;Trademarks for Product&#160;<b style="font-weight:bold;">in the Territory</b>. &#160;The Parties agree that, MEDINET shall be entitled to register certain Trademarks that are designated for the Product for the Commercialization in the Territory (the &#8220;<b style="font-weight:bold;">MEDINET Trademarks</b>&#8221;) as the owner of such MEDINET Trademarks in the Territory.&#160;&#160;Histogenics agrees that it will not, during the Term, attack MEDINET&#8217;s title or rights in and to the designated MEDINET Trademarks in the Territory or the validity of such Trademarks.&#160;&#160;The nature and quality of the Product, and all advertising and promotional uses of the&#160;MEDINET&#160;Trademarks or the Licensed Trademarks by&#160;MEDINET&#160;in the Territory shall conform to Applicable Laws, including the requirements regarding proper use of the Trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article IX.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;white-space:pre-wrap;"> TERM AND TERMINATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 9.01<b style="font-weight:bold;">Term</b>.&#160;&#160;The term of this Agreement shall commence on the Effective Date and continue until the later of (a) ten (10) years after the First Commercial Sale of Product in the Territory or (b)&#160;expiration of the last-to-expire&#160;Licensed Patent or Arising Patent covering Product in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 9.02<b style="font-weight:bold;">Extension at MEDINET&#39;s option.</b>&#160;&#160;MEDINET shall have the right to extend the Term by five (5) years at its sole discretion by giving a written notice to Histogenics before the termination of this Agreement pursuant to Section 9.01 above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 9.03<b style="font-weight:bold;">Termination at Will by&#160;MEDINET</b>.&#160;&#160;MEDINET shall have the right to terminate this Agreement for any reason or no reason in its entirety at any time on one hundred twenty (120) days&#8217; prior written notice to Histogenics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 9.04<b style="font-weight:bold;">Material Breach</b>.&#160;&#160;In the event of a material breach of this Agreement by a Party, the non-breaching Party shall have the right to terminate this Agreement in its entirety in each case by written notice to the breaching Party specifying the nature of such breach in reasonable detail.&#160;&#160;Such termination shall become effective ninety (90) days from receipt of such notice by the breaching Party, except that such period shall be sixty (60) days in the event the basis of the alleged material breach is a failure to make payment(s) under this Agreement, unless the breaching Party has cured such breach within such ninety (90) or sixty (60) day period (as applicable), provided the breaching Party takes reasonable efforts to cure such breach as soon as practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 9.05<b style="font-weight:bold;">Insolvency</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)Either&#160;Party&#160;may terminate this&#160;Agreement&#160;in its entirety effective immediately upon written notice to the other&#160;Party&#160;if, at any time such other&#160;Party&#160;(i) files in any court or agency pursuant to any statute or regulation of any state or country a petition in bankruptcy or insolvency or for reorganization (save for solvent reorganization or solvent reconstruction) or for an arrangement or for the appointment of a receiver or trustee of the&#160;Party&#160;or of substantially all of its assets, (ii) proposes a written&#160;agreement&#160;of composition or extension of substantially all of its debts, (iii) is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not be dismissed within sixty (60) days after the filing thereof, (iv) proposes to be a party to any dissolution or liquidation, (v) admits in writing its inability generally to meet its obligations as they fall due in the general course, or&#160;(vi)&#160;makes an assignment of substantially all of its assets for the benefit of creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)All rights and licenses granted under or pursuant to any&#160;section&#160;of this&#160;Agreement&#160;are for purposes of&#160;Section&#160;365(n) of Title 11,&#160;United States Code&#160;or any analogous provisions in any other country or jurisdiction (the &#8220;<b style="font-weight:bold;">Bankruptcy Code</b>&#8221;) licenses of rights to &#8220;intellectual property&#8221; as defined in&#160;Section&#160;101(56) of the&#160;Bankruptcy Code (and any equivalent provisions under the bankruptcy or insolvency laws of any other relevant jurisdiction).&#160;&#160;The&#160;Parties&#160;shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. The non-bankrupt&#160;Party&#160;shall further be entitled to a complete duplicate of, or complete access to, any such</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">intellectual property and all embodiments of such intellectual property, which, if not already in its possession, shall be promptly delivered to the non-bankrupt&#160;Party (i)&#160;upon the commencement of a bankruptcy proceeding upon the non-bankrupt&#160;Party&#8217;s written request therefor, unless the&#160;Party&#160;subject to such proceeding elects to continue to perform all of its obligations under this&#160;Agreement&#160;or (ii) if not delivered under clause&#160;(i)&#160;above, following the rejection of this&#160;Agreement&#160;by or on behalf of the&#160;Party&#160;subject to such proceeding upon written request therefor by the non- bankrupt&#160;Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 9.06<b style="font-weight:bold;">Patent&#160;Challenge</b>.&#160;&#160;Prior to its expiration,&#160;Histogenics&#160;may terminate this&#160;Agreement&#160;in its entirety by written notice to&#160;MEDINET&#160;if&#160;(a) MEDINET,&#160;its&#160;Affiliate(s) or&#160;Sublicensee(s) Challenges the validity, scope or enforceability of or otherwise opposes any&#160;Patent&#160;included in the&#160;Licensed Patents or Arising Patents&#160;and&#160;(b) MEDINET&#160;does not cause such measures to cease within&#160;thirty (30)&#160;days after having received written notice thereof from&#160;Histogenics, requesting such measures to cease and stating&#160;Histogenics&#8217; intention to terminate this&#160;Agreement&#160;if such measures are not ceased within the prescribed time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 9.07<b style="font-weight:bold;">Effect of Termination of this&#160;Agreement</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MEDINET&#160;Triggered&#160;Termination</u>.<b style="font-weight:bold;">&#160;&#160;</b>In the event (i) Histogenics terminates this Agreement pursuant to Section 9.04 for MEDINET&#8217;s material breach; (ii) Histogenics terminates this Agreement pursuant to Section 9.06 for patent challenge by MEDINET; (iii) Histogenics terminates this Agreement pursuant to Section 9.05 for MEDINET&#8217;s insolvency; or (iv) MEDINET terminates this Agreement pursuant to Section 9.03 without cause, the following shall apply:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(i)All licenses and sublicenses and rights to the&#160;Licensed Technology and Arising IP&#160;granted by to&#160;MEDINET<b style="font-weight:bold;">&#160;</b>hereunder shall terminate as of the&#160;effective date&#160;of such termination, except to the extent to perform any responsibilities in connection with any then ongoing&#160;Clinical Trial&#160;or other activity being conducted by or on behalf of MEDINET that cannot be terminated as of such date under&#160;Applicable Laws,&#160;including GCP, it being agreed that all such activities and responsibilities shall be discontinued and ceased (unless otherwise agreed or required under&#160;Applicable Laws)&#160;by transitioning such activities and responsibilities to&#160;Histogenics&#160;as promptly as possible, subject to&#160;Applicable Laws,&#160;including GCP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(ii)MEDINET hereby grants to Histogenics a non-exclusive, worldwide, royalty free license, with the right to grant sublicenses under the MEDINET IP and the MEDINET Trademarks to research, Develop, make, have made, use, have used, sell, have sole, import, have imported, export, have exported, or otherwise Commercialize the Product;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>&#160;that Histogenics shall indemnify, defend and hold harmless MEDINET, its Affiliates and each of its and their respective employees, officers, directors, agents and Sublicensees from and against any Losses arising out of or resulting from Third Party claims (&#8220;<b style="font-weight:bold;">Third Party Claim</b>&#8221;) that arise or result from&#160;Histogenics&#8217; activities performed under the foregoing license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(iii)MEDINET<b style="font-weight:bold;">&#160;</b>shall, where permitted under&#160;Applicable Laws, as promptly as reasonably practical transfer to&#160;Histogenics&#160;all Regulatory Documentation and&#160;Regulatory Approvals&#160;with respect to&#160;the&#160;Products&#160;(but not with respect to any other products), and shall take</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">such other actions and execute such other instruments, assignments, and documents as may be necessary to effect the transfer of rights hereunder to&#160;Histogenics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Histogenics Triggered Termination</u>.&#160;&#160;In the event (i) MEDINET terminates this Agreement pursuant to Section 9.04 for Histogenics&#8217; material breach or (ii) MEDINET terminates this Agreement pursuant to Section 9.05 for Histogenics&#8217; insolvency, the licenses and sublicenses granted to MEDINET pursuant to Section 2.01(a) shall terminate immediately, except that MEDINET shall have the right to, for up to sixty (60) days after the effective date of termination, sell any then-existing inventory of Product in its possession.&#160;&#160;All other inventory of Products that MEDINET fails to sell after the 60-day period shall be destroyed or returned to MEDINET, at MEDINET&#8217;s sole cost and expense, in accordance with Applicable Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 9.08<b style="font-weight:bold;">Accrued Rights</b>.&#160;&#160;Termination, relinquishment, or expiration of the Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of either Party prior to such termination, relinquishment, or expiration, including without limitation damages arising from any breach hereunder.&#160;&#160;Such termination, relinquishment, or expiration shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 9.09<b style="font-weight:bold;">Survival</b>. The provisions of Articles I, VII, IX, XI and XII, as well as Sect. 8.01 hereof shall survive the expiration or termination of this Agreement for any reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 9.10<b style="font-weight:bold;">Termination Not Sole Remedy</b>.&#160;&#160;Termination is not the sole remedy under this Agreement and, whether or not termination is effected, all other remedies at equity or law shall remain available to the Parties except as agreed to otherwise herein; provided that in assessing the remedies available to Histogenics, the rights transferred to Histogenics following a termination of this Agreement shall be taken into account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article X.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;white-space:pre-wrap;"> REPRESENTATIONS AND WARRANTIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 10.01<b style="font-weight:bold;">Mutual Representations and Warranties and Covenants</b>.&#160;&#160;Each of Histogenics and MEDINET represents and warrants to the other Party, as of the Effective Date, and covenants, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)such&#160;Party&#160;is an entity duly organized, validly existing and in good standing under the laws of the state or country (as applicable) of its organization, is qualified to do business and is in good standing as a foreign entity in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to have such would prevent it from performing its obligations under this&#160;Agreement, and has full power and authority to enter into this&#160;Agreement&#160;and to carry out the provisions&#160;hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)such&#160;Party&#160;is duly authorized, by all requisite action, to execute and deliver this&#160;Agreement&#160;and the execution, delivery and performance of this&#160;Agreement&#160;by such&#160;Party&#160;does not require any shareholder action or approval, and the&#160;Person&#160;executing this&#160;Agreement&#160;on behalf of such&#160;Party&#160;is duly authorized to do so by all requisite action;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(c)no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any&#160;Governmental Authority&#160;is required on the part of such&#160;Party&#160;in connection with the valid execution, delivery and performance of this&#160;Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(d)such&#160;Party&#160;has not employed (and, to the best of its knowledge, has not used a contractor or consultant that has employed) and in the future shall not employ (or, to the best of its knowledge, use any contractor or consultant that employs, provided that, such&#160;Party&#160;may reasonably rely on a representation made by such contractor or consultant) any&#160;Person&#160;debarred pursuant to&#160;Section&#160;306 of the&#160;United States Federal Food, Drug,&#160;and Cosmetic Act (or subject to a similar sanction of a foreign Governmental Authority), or any&#160;Person&#160;that is the subject of an&#160;FDA&#160;debarment investigation or proceeding (or similar proceeding of a foreign Governmental Authority), in the conduct of its activities under this&#160;Agreement&#160;and such&#160;Party&#160;agrees to inform the other&#160;Party&#160;in writing promptly if it or any such&#160;Person&#160;who is performing services hereunder is debarred or is the subject of a conviction described in&#160;Section&#160;306 or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of its or its&#160;Affiliates&#8217; knowledge, is threatened, relating to the debarment or conviction of it or any such&#160;Person&#160;performing services hereunder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(e)this&#160;Agreement&#160;is a legal and valid obligation binding upon such&#160;Party&#160;and enforceable in accordance with its terms except as enforceability may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors&#8217; rights; and&#160;(ii)&#160;equitable principles of general applicability;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(f)&#160;the execution, delivery and performance by it of this&#160;Agreement&#160;and its compliance with the terms and provisions of this&#160;Agreement&#160;does not and shall not conflict with or result in a breach of any of the terms or provisions of (i) any other contractual or other obligations of such&#160;Party, (ii) the provisions of its operating documents or bylaws, or (iii) any order, writ, injunction or decree of any&#160;Governmental Authority&#160;entered against it or by which it or any of its property is bound.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 10.02<b style="font-weight:bold;">Histogenics&#8217; Additional Representations and Warranties and Covenants</b>.<b style="font-weight:bold;">&#160;&#160;</b>Histogenics represents and warrants to MEDINET as of the Effective Date:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)it has full right and authority to grant the licenses and sublicenses and other rights granted under this&#160;Agreement&#160;and no rights or licenses are required from&#160;Histogenics&#160;or, to its knowledge, any other&#160;Person, for&#160;MEDINET&#160;to&#160;Exploit Products&#160;as contemplated under this&#160;Agreement&#160;other than those granted under&#160;Article II.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)to Company&#8217;s knowledge, Company and its Affiliates, and its subcontractors, and their respective consultants and agents, have conducted all research and Development of the Product prior to the Effective Date in compliance with Applicable Laws;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(c)there are no&#160;Third Party Patents&#160;that, to&#160;Company&#8217;s knowledge and belief, would be infringed by&#160;Exploiting&#160;the&#160;Product,&#160;and no claim or litigation has been brought or asserted (and&#160;Company&#160;has no knowledge of any claim, whether or not brought or asserted, or of any facts or circumstances that exist that would reasonably be expected to give rise to any such claim or litigation) by any&#160;Person&#160;alleging that (a) the&#160;Licensed Patents existing as of the Effective Date&#160;are</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">invalid or unenforceable or (b) the conception,&#160;Development, reduction to practice, disclosing, copying, making, assigning or licensing of the&#160;Licensed Patents&#160;or the&#160;Licensed Know- How&#160;existing as of the&#160;Effective Date&#160;or the&#160;Exploitation&#160;of the&#160;Products&#160;as contemplated&#160;herein, violates, infringes, constitutes misappropriation of or otherwise conflicts or interferes with or would violate, infringe or otherwise conflict or interfere with, any intellectual property or proprietary right of any&#160;Person; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(d)to the knowledge of&#160;Company, no&#160;Person&#160;is infringing or threatening to infringe or misappropriating or threatening to misappropriate the&#160;Licensed Patents&#160;existing as of the&#160;Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article XI.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;white-space:pre-wrap;"> INDEMNIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 11.01<b style="font-weight:bold;">Histogenics</b>.&#160;&#160;Histogenics&#160;shall defend, indemnify and hold&#160;MEDINET, its&#160;Affiliates, Sublicensees&#160;and their respective directors, officers, employees and agents, at Histogenics&#8217; cost and expense, harmless from and against any and all&#160;losses, costs, damages, fees or expenses (including&#160;reasonable attorney&#8217;s fees and expenses) (&#8220;<b style="font-weight:bold;">Losses</b>&#8221;) incurred in connection with any Third Party Claim arising out of any:&#160;(i) any&#160;willful misconduct or negligence by Histogenics or any of its Affiliates, (ii) any breach by Histogenics of any of its representations, warranties, covenants, obligations or agreements hereunder, or (iii) any Exploitation of the Products outside the Territory or outside the Field within the Territory by or on behalf of Histogenics; except to the extent such Losses are attributable to 11.02(i)-(iii).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 11.02<b style="font-weight:bold;">MEDINET</b>.&#160;&#160;MEDINET&#160;shall defend, indemnify and hold&#160;Histogenics, its&#160;Affiliates&#160;and their respective directors, officers, employees and agents, at&#160;MEDINET&#8217;s cost and expense, harmless from and against any and all Losses incurred in connection with&#160;any Third Party Claim&#160;arising out of any: (i) any willful misconduct or negligence by&#160;MEDINET&#160;or any of its&#160;Affiliates, (ii) any breach by&#160;MEDINET&#160;of any of its representations, warranties, covenants, obligations or agreements hereunder, or (iii) any Exploitation of the Products in the Field and in the Territory by or on behalf of&#160;MEDINET; except to the extent such Losses are attributable to 11.01(i)-(iii).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 11.03<b style="font-weight:bold;">Notice of Claim</b>.&#160;&#160;All indemnification claims in respect of any person seeking indemnification under Section 11.01 or Section 11.02 (collectively, the &#8220;<b style="font-weight:bold;">Indemnitees</b>&#8221; and each an &#8220;<b style="font-weight:bold;">Indemnitee</b>&#8221;) shall be made by the corresponding Party (the &#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221;).&#160;&#160;The Indemnified Party shall give the indemnifying Party (the &#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221;) prompt written notice (an &#8220;<b style="font-weight:bold;">Indemnification Claim Notice</b>&#8221;) of any Losses or the discovery of any fact upon which such Indemnified Party intends to base a request for indemnification under Section 11.01 or Section 11.02 but in no event shall the Indemnifying Party be liable for any Losses that result from any delay by the Indemnified Party in providing such notice that materially prejudices the defense of such Third Party Claim.&#160;&#160;Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Losses (to the extent that the nature and amount of such Losses are known at such time).&#160;&#160;Together with the Indemnification Claim Notice, the Indemnified Party shall furnish promptly to the Indemnifying Party copies of all notices and documents (including court papers) received by any Indemnitee in connection with the Third Party Claim.&#160;&#160;The Indemnifying Party shall not be obligated to indemnify the Indemnified Party</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to the extent any admission or statement made by the Indemnified Party materially prejudices the defense of such Third Party Claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 11.04<b style="font-weight:bold;">Indemnification Procedure</b>.&#160;&#160;Except with respect to any Third Party Claim that is a Third Party Infringement Claim, the process for the defense of which shall be governed by Section 8.04, the obligations of an Indemnifying Party under this Section 11.04 shall be governed by and contingent upon the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)at its option, the&#160;Indemnifying Party&#160;may assume&#160;control&#160;of the defense&#160;of any Third Party Claim (which, for the avoidance of doubt, shall include the conduct of all dealings with such Third Party) by giving written notice to the Indemnified Party within thirty (30) days after the Indemnifying Party&#8217;s receipt of an Indemnification Claim Notice.&#160;&#160;The assumption of control of the defense&#160;of a Third Party Claim by the Indemnifying Party shall not be construed as an acknowledgement that the Indemnifying Party is liable to indemnify any Indemnitee in respect of the Third Party Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party&#8217;s claim for indemnification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)upon the assumption of the control of the&#160;defense&#160;of a Third Party Claim by the Indemnifying Party:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(i)subject to the provisions of Section 11.04(c), it shall have the right to and shall assume sole control and responsibility for dealing with the Third Party and the Third Party Claim, including the right to settle the claim on any terms the Indemnifying Party chooses, but at all times in accordance with the provisions of Section 11.04(c) and Section 11.04(d);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(ii)if it chooses, the Indemnifying Party may appoint as counsel in the defense of the Third Party Claim any law firm or counsel selected by the Indemnifying Party; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:94.15pt;margin:0pt 0pt 12pt 0pt;">(iii)except as expressly provided in Section 11.04, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party or any Indemnitee in connection with the analysis, defense, or settlement of the Third Party Claim.&#160;&#160;In the event that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold harmless an Indemnitee from and against the Third Party Claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all costs and expenses (including lawyers&#8217; fees and costs of suit) and any Losses incurred by the Indemnifying Party in its defense of the Third Party Claim with respect to such Indemnified Party or Indemnitee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(c)without limiting the remainder of this Section 11.04,&#160;any Indemnitee shall be entitled to participate in, but not control, the defense&#160;of a Third Party Claim and to retain counsel of its choice for such purpose; provided that such retention shall be at the Indemnitee&#8217;s own cost and expense unless (i) the Indemnifying Party has failed to assume the defense and retain counsel in accordance with Section 11.04(a)&#160;(in which case the Indemnified Party shall control the defense), or (ii) the interests of the Indemnitee and the Indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the representation by the same counsel of both Parties under any legal requirement, ethical rules or equitable principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(d)with respect to any Losses relating solely to the payment of money to the Third Party to settle the Third Party Claim and that will not result in the Indemnified Party or the Indemnitee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">becoming subject to injunctive relief, and as to which the Indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnitee under&#160;Section 11.04(c)<u style="color:#0000ff;text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">,</u>&#160;the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Losses.&#160;&#160;With respect to all other Losses or where the Indemnified Party will be subject to injunctive relief, where the Indemnifying Party has assumed the defense of a Third Party Claim in accordance with Section 11.04(a) the Indemnifying Party must not consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Losses, unless it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(e)if the Indemnifying Party chooses not to take control of the&#160;defense&#160;or prosecute any Third Party Claim, the Indemnified Party shall retain control of the&#160;defense&#160;thereof, but no Indemnified Party or Indemnitee shall admit any liability with respect to, or settle, compromise or discharge, any such Third Party Claim without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld, conditioned or delayed.&#160;&#160;The Indemnifying Party shall not be liable for any settlement or other disposition of Losses by an Indemnified Party or an Indemnitee under such a Third Party Claim that is reached without the written consent of the Indemnifying Party, which consent will not be unreasonably withheld, conditioned or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(f)if the Indemnifying Party chooses to control the defense&#160;of any Third Party Claim, the Indemnified Party shall, and shall cause each other Indemnitee to, reasonably cooperate in the defense thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith.&#160;&#160;Such cooperation shall include access during normal business hours by the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making the Indemnified Party, the Indemnitees and its and their employees and agents available on a mutually convenient basis to provide additional information and explanation of any records or information, to the extent the Third Party Claim is subject to indemnification hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 11.05<b style="font-weight:bold;">Expenses</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Except as expressly provided above, [***],&#160;incurred by the Indemnified Party where it participates in the defense under Section 11.04 or cooperates pursuant to Section 11.04(f) shall be reimbursed on a quarterly basis by the Indemnifying Party, without prejudice to the Indemnifying Party&#8217;s right to contest the Indemnified Party&#8217;s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 11.06<b style="font-weight:bold;">Insurance</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)MEDINET&#160;shall at all times comply, by obtaining a policy of insurance, with all statutory workers&#8217; compensation and employers&#8217; liability requirements covering any and all employees with respect to activities performed under this&#160;Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)MEDINET&#160;shall obtain at the appropriate time product liability and other insurance coverage appropriate to the risk involved in marketing&#160;Products, including coverage for Clinical</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Trials, will name the Histogenics as additional insureds, and shall maintain such insurance coverage for the Term plus an additional six (6)&#160;years of tail coverage.&#160;&#160;Within ninety (90)&#160;days after the&#160;Effective Date&#160;and thereafter annually between January&#160;1 and January&#160;31 of each&#160;Calendar Year,&#160;MEDINET&#160;shall present evidence to&#160;Histogenics&#160;that the coverage is being maintained in accordance with the terms&#160;herein.&#160;&#160;In addition,&#160;MEDINET&#160;will provide Histogenics&#160;with at least thirty (30)&#160;days&#8217; prior written notice of any change in or cancellation of the insurance coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 11.07<b style="font-weight:bold;">Consequential Damages</b>.&#160;&#160;EXCEPT IN THE EVENT OF THE GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR FRAUD OF A PARTY, IN NO EVENT SHALL EITHER PARTY OR THEIR AFFILIATES BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, TREBLE OR CONSEQUENTIAL DAMAGES OR INDIRECT LOST PROFITS, WHETHER BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY; PROVIDED, HOWEVER, THAT THIS LIMITATION SHALL NOT LIMIT (A) BREACHES OF CONFIDENTIALITY OBLIGATIONS UNDER Article VII OR (B) THE INDEMNIFICATION OBLIGATION OF SUCH PARTY IN RESPECT OF AMOUNTS ACTUALLY AWARDED AGAINST AN INDEMNIFIED PARTY AS A PART OF A THIRD PARTY CLAIM UNDER THE PROVISIONS OF THIS Article XI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 11.08Nothing in this&#160;Agreement&#160;shall limit a&#160;Party&#8217;s liability for death or personal injury caused by its negligence or for fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article XII.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;white-space:pre-wrap;"> MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 12.01<b style="font-weight:bold;">Assignment</b>.&#160;&#160;This Agreement may not be assigned or otherwise transferred by either Party without the prior written consent of the other Party; provided<i style="font-style:italic;">,&#160;</i>however, that either Party may assign this Agreement, without the consent of the other Party (a) to any of its Affiliates, if the assigning Party guarantees the full performance of its Affiliates&#8217; obligations hereunder, or (b) to a successor in interest in connection with a sale of all or substantially all of a Party&#8217;s assets to which this Agreement relates, whether by merger, consolidation, acquisition, stock sale, asset purchase, or otherwise.&#160;&#160;In all cases, the assigning Party shall provide the other Party with prompt written notice of any such assignment and the permitted assignee shall assume the obligations of the assigning Party hereunder in writing.&#160;&#160;No assignment of this Agreement shall act as a novation or release of either Party from responsibility for the performance of any accrued obligations hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 12.02<b style="font-weight:bold;">Governing Law</b>.&#160;&#160;This Agreement and any dispute or claim arising out of or in connection with it (whether contractual or non-contractual in nature such as claims in tort, from breach of statute or regulation or otherwise) shall be governed by and construed in accordance with the laws of New York without reference to any conflicts of laws principles and any dispute with respect to infringement, validity, or enforceability of any Patent, which shall be governed by and construed and enforced in accordance with the laws of the jurisdiction in which such Patent is issued or published.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 12.03<b style="font-weight:bold;">Dispute Resolution</b>.&#160;&#160;If any dispute or disagreement arises between the Parties regarding this Agreement, the Parties will follow the following procedures in an attempt to resolve the dispute or disagreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(a)The Party claiming that a dispute exists will give notice in writing (&#8220;<b style="font-weight:bold;">Notice of Dispute</b>&#8221;) to the other Party of the nature of the dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(b)Within [***] of receipt of a Notice of Dispute, unless the Parties agree to extend this period, the Chief Executive Officers of the Parties, or their designees (any such designee to be a senior member of the designating Chief Executive Officer&#8217;s management team), will meet at a mutually agreed-upon time and location for the purpose of resolving such dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(c)Except with respect to Section 12.03(e), if the dispute has not been resolved within a further period of [***], unless the Parties agree to extend this period, then the Parties agree that either Party may initiate binding arbitration to resolve the dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">(d)Except where&#160;Section 12.03(e)&#160;applies, disputes will be finally resolved by binding arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association (&#8220;<b style="font-weight:bold;">AAA</b>&#8221;) in effect on the date of filing of the arbitration (the &#8220;<b style="font-weight:bold;">Rules</b>&#8221;), except as modified in this Section, and the arbitrator(s) will be engaged on terms consistent with those set forth in this Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(i)<b style="font-weight:bold;">Selection of Arbitrator(s)</b>.&#160;&#160;If the amount in controversy, including claims and counterclaims, in terms of a monetary amount is less than [***] and does not relate to an allegation of material breach or termination of this Agreement there will be one (1) neutral and impartial arbitrator, who the Parties will jointly select within [***] of the respondent&#8217;s receipt of a copy of the demand for arbitration (&#8220;<b style="font-weight:bold;">Demand Date</b>&#8221;).&#160;&#160;If the amount in controversy is [***] or more, or if the dispute involves an allegation of material breach or termination of this Agreement, there will be three (3) neutral and impartial arbitrators, which will be appointed as follows: (i) Histogenics will appoint one (1) arbitrator within [***] of the Demand Date, (ii) MEDINET will appoint one (1) arbitrator within [***] of the Demand Date, and (3) the Party-appointed arbitrators will jointly select a third arbitrator, who will serve as chair of the arbitral tribunal, within thirty (30) days of the appointment of the second arbitrator.&#160;&#160;The AAA will appoint any arbitrator that is not timely appointed pursuant to this Section&#160;&#160;from the AAA&#8217;s large, complex case panel, using the listing, ranking, and striking procedure in the Rules, with each Party having no more than [***] peremptory strikes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(ii)<b style="font-weight:bold;">Qualifications of Arbitrators</b>.&#160;&#160;Whether appointed by a Party or the AAA, each arbitrator will satisfy the criteria set forth in this Section to the maximum extent possible.&#160;&#160;In all cases, each arbitrator should be a person with no less than ten (10) years of biotechnology industry experience and expertise having occupied at least one senior position within a biotechnology company relating to drug discovery,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 116.5pt;">product development, commercialization, or licensing, but under no circumstances will an appointed arbitrator be a current or former employee or consultant of either Party or its Affiliates, or anyone who has provider professional services to either Party or its Affiliates. &#160;If the dispute relates primarily to scientific matters, then each arbitrator should also have relevant scientific expertise. &#160;If the dispute relates primarily to Patent Rights or other intellectual property, then each arbitrator should also have at least ten (10) years of relevant expertise regarding Patent Rights or other intellectual property. &#160;In all cases, each&#160;arbitrator&#160;will be fluent in English.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(iii)<b style="font-weight:bold;">Conduct of Arbitrations Proceedings</b>.&#160;&#160;The following provisions will apply to the conduct of any arbitration proceedings under this Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(a)Within [***] after an arbitrator or arbitration tribunal, as applicable, is appointed, each Party will provide the arbitrator(s) with its one proposed resolution and a written memorandum in support of its position regarding the dispute and its proposed resolution (&#8220;<b style="font-weight:bold;">Opening Brief</b>&#8221;), which will not exceed [***] pages in total.&#160;&#160;In connection with the submission of an Opening Brief, a Party may also submit documentary evidence in support of its position and its proposed resolution, which evidence had both (A) existed prior to commencement of such arbitration and (B) been previously shared with the other Party as part of the Parties&#8217; attempts to resolve the dispute.&#160;&#160;The arbitrator(s) will provide each Party&#8217;s Opening Brief and supporting documentation, if any, to the other Party after receiving an Opening Brief from both Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(b)Within [***] after a Party receives the other Party&#8217;s Opening Brief from the arbitrator(s), the receiving Party will have the right to submit to the arbitrator(s) a response to the other Party&#8217;s Opening Brief (&#8220;<b style="font-weight:bold;">Response Brief</b>&#8221;), which will not exceed twenty (20) pages in total.&#160;&#160;In connection with the submission of a Response Brief, a Party may also submit documentary evidence in support thereof which had both (A) existed prior to commencement of such arbitration and (B) been previously shared with the other Party as part of the Parties&#8217; attempts to resolve the dispute. &#160;The arbitrator(s) will provide each Party&#8217;s Response Brief and supporting documentation, if any, to the other Party after receiving a Response Brief from both Parties (or at the expiration of such ten (10) day period if any Party fails to submit a Response Brief).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(c)Within [***] of the receipt by the arbitrator(s) of each Party&#8217;s Response Brief (or expiration of such [***] period if any Party fails to submit a Response Brief), the arbitrator(s) will conduct a single three (3) hour hearing during which each Party will have one (1) hour to present its position.&#160;&#160;At the hearing, each Party will have the right to call up to two (2) witnesses, one (1) of whom may be an employee, consultant or other</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 116.5pt;">advisor to the other Party.&#160;&#160;Each Party will notify the other Party and the arbitrator(s) of the identity of the witnesses it intends to call at least [***] in advance of the hearing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(d)There will be no discovery in the arbitration (e.g., document requests, interrogatories, depositions, etc.).&#160;&#160;The arbitrator(s) will, however, have the right to perform independent research and analysis and to request any Party provide additional documentary evidence based on specific requests for documents that are reasonably necessary for the arbitrator(s) to reach a decision, which documents each Party will provide to the arbitrator(s) to the extent the requested documents are reasonably related to the subject matter of the dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(e)Within [***] of such hearing, or within some other time to which the Parties and the arbitrator(s) agree, the arbitrator(s) will deliver his or her decision regarding the dispute in writing and will briefly state the findings of fact and conclusions of law on which it is based.&#160;&#160;The arbitrator(s)&#160;may only select the resolution proposed by one of the Parties.&#160;&#160;As part of any such decision, the arbitrator(s)&#160;will&#160;mandate that the Party whose resolution is not selected pay the reasonable attorneys&#8217; fees and expenses that the Party whose resolution is selected incurred in connection with the arbitration, as well as the costs and expenses of such arbitration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(f)The arbitration proceeding will be conducted in English.&#160;&#160;The arbitration proceeding will be held and the award/decision will be issued in New York, New York, although the Parties may agree in writing to conduct individual hearings in other locations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(g)The arbitration will be confidential.&#160;&#160;No Party will use or disclose any documents, including the other Party&#8217;s Opening Brief, Reply Brief, any supporting evidence, and the arbitration decision, obtained in the arbitration for any purpose except in the course of the conduct of the arbitration and (as far as applicable) proceedings before any court, and then only to the extent necessary for the implementation and enforcement of any award of the arbitrator(s) and subject to appropriate confidentiality protections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(h)In addition to damages, the arbitrator(s) may award any remedy provided under Law and the terms of this Agreement, including, without limitation, specific performance but not injunctive relief.&#160;&#160;The arbitrator(s) is/are not empowered to award damages in excess of compensatory damages, and each Party hereby irrevocably waives any right to recover punitive, treble, or similar damages with respect to any dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(i)The arbitration decision may be entered and enforced in any court having competent jurisdiction.&#160;&#160;The arbitration award will be final and binding on the Parties and will not be appealable to any court in any jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(j)Notwithstanding the arbitration provisions set forth above, the following disputes will be determined by courts of competent jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(i)Any dispute concerning the ownership or inventorship of any Patent Rights arising hereunder in a given jurisdiction will be determined by the courts of the jurisdiction in question.&#160;&#160;In all cases, the Parties agree that inventorship will be determined in accordance with the patent laws of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 116.5pt;">(ii)In the event of a threatened or actual breach of the provisions of&#160;Article VII,&#160;either Party may bring an action in&#160;any court of competent jurisdiction to obtain equitable relief, including, without limitation, an injunction relief or specific performance, to prevent the disclosure or dissemination of&#160;a&#160;Disclosing Party&#8217;s Confidential Information.&#160;&#160;Each Party acknowledges and agrees that any threatened or actual breach of the provisions of this Agreement protecting the confidentiality of the Disclosing Party&#8217;s Confidential Information would cause substantial and irreparable harm to the Disclosing Party, entitling the Disclosing&#160;Party&#160;to seek and obtain the equitable relief provided&#160;under&#160;this Section.&#160;&#160;Any equitable relief granted pursuant to this Section, will be in addition to, and not exclusive of, any other legal or equitable remedies available to the Disclosing Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 12.04<b style="font-weight:bold;">Force Majeure</b>.&#160;&#160;Neither Party shall be liable to the other for any failure or delay in the fulfillment of its obligations under this Agreement (other than the payment of monies due and owing to a Party under this Agreement), when any such failure or delay is caused by fire, flood, earthquakes, explosions, sabotage, terrorism, civil commotions, riots, invasions, wars, peril of the sea or requirements of Governmental Authorities (each, a &#8220;<b style="font-weight:bold;">Force Majeure Event</b>&#8221;).&#160;&#160;In the event that either Party is prevented from discharging its obligations under this Agreement on account of a Force Majeure Event, the Party so prevented by such Force Majeure Event shall (i)&#160;promptly notify the other Party and (ii) use good faith efforts to discharge its obligations, even if in a partial or compromised manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 12.05<b style="font-weight:bold;">Expenses</b>.&#160;&#160;Except as otherwise expressly provided herein or mutually agreed, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be borne by the Party incurring such costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 12.06<b style="font-weight:bold;">No Agency</b>.&#160;&#160;Nothing herein contained shall be deemed to create an agency, joint venture, amalgamation, partnership or similar relationship between Histogenics and MEDINET.&#160;&#160;Notwithstanding any of the provisions of this Agreement, neither Party shall at any time enter into, incur, or hold itself out to Third Parties as having authority to enter into or incur,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">on behalf of the other Party, any commitment, expense, or liability whatsoever, and all contracts, expenses and liabilities undertaken or incurred by one Party in connection with or relating to the Development, manufacture or Commercialization of Product shall be undertaken, incurred or paid exclusively by that Party, and not as an agent or representative of the other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">Section 12.07<b style="font-weight:bold;">No&#160;Third Party&#160;Beneficiaries</b>.&#160;&#160;The warranties and agreements contained in this Agreement are for the sole benefit of the Parties, and in MEDINET&#8217;s case, MEDINET&#8217;s Affiliates, and their respective successors and permitted assigns, and they shall not be construed as conferring any rights to any other Persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">Section 12.08<b style="font-weight:bold;">Entire Agreement; Amendment</b>.&#160;&#160;This Agreement (including all schedules and exhibits hereto), along with the Master Quality, Supply and Pharmacovigilance Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements or understandings, oral or written, with respect to such matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">For clarity, the&#160;Confidentiality Agreement&#160;dated&#160;December 6, 2017&#160;shall be superseded by this Agreement as of the Effective Date, and all information exchanged thereunder shall be considered Confidential Information exchanged between the Parties under this Agreement.&#160;&#160;The Parties acknowledge that this Agreement has not been entered into wholly or partly in reliance on, nor has either Party been given, any warranty, statement, promise or representation by the other or on its behalf other than as expressly set out in this Agreement.&#160;&#160;All warranties, conditions, terms and representations not set out in this Agreement whether implied by statute or otherwise are excluded to the extent permitted by law.&#160;&#160;This Agreement may be amended or modified only by a writing signed by both Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">Section 12.09<b style="font-weight:bold;">Severability</b>.&#160;&#160;If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future law and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully severable, (b) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom, and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties.&#160;&#160;To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision hereof illegal, invalid or unenforceable in any respect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:46.8pt;margin:0pt 0pt 12pt 0pt;">Section 12.10<b style="font-weight:bold;">Extension; Waiver</b>.&#160;&#160;At any time, either Histogenics or MEDINET may (a) with respect to obligations owed to it or the performance of other acts for its benefit, extend the time for the performance of such obligations or such other acts to be performed hereunder by the other, (b) waive any inaccuracies in the representations and warranties of the other contained herein or in any document delivered pursuant hereto and (c) waive compliance with any of the conditions to the obligations of the other contained herein.&#160;&#160;Any agreement on the part of either Party to any such extension or waiver shall be valid only if set forth in an instrument executed by such Party.&#160;&#160;No such waiver shall be operative as a waiver of any other subsequent requirement of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">this Agreement.&#160;&#160;The failure of any Party to assert any of its rights under this Agreement or otherwise shall not constitute a waiver of such rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 12.11<b style="font-weight:bold;">Notices</b>.&#160;&#160;All communications required to be made under this Agreement shall be effective upon receipt, and shall be sent to the addresses set out below, or to such other addresses as may be designated by one Party to the other by notice pursuant hereto, by (a) internationally recognized overnight courier; (b) prepaid registered or certified US mail, return receipt requested; or (c) facsimile transmission or other electronic means of communication with confirmation by letter sent by the close of business on or before the next following Business Day at the address set forth below, or such other address as may be designated in writing hereafter, in the same manner, by such Party as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">If to Histogenics:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">President and CEO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">830 Winter Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">Waltham, MA 02451</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">USA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">FAX: +[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">E-mail: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">If to MEDINET:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">President and CEO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">2-3-12 Shinyokohama,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">Kohoku-ku, Yokohama-shi,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">Kanagawa-ken 222-0033</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">FAX: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;">E-mail:&#160;[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 0pt 116.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 12.12<b style="font-weight:bold;">No Strict Construction</b>.&#160;&#160;This Agreement shall be construed as if it were drafted jointly by the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 12.13<b style="font-weight:bold;">English Language Only</b>.&#160;&#160;All written communications, notices, reports, and other documentation to be exchanged between the Parties or to be provided by one Party to the other Party in as required by or in connection with this Agreement shall be in the English language only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 12.14<b style="font-weight:bold;">Headings</b>.&#160;&#160;The headings herein are for convenience purposes only and shall not be used to interpret any of the provisions hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 12.15<b style="font-weight:bold;">Counterparts</b>.&#160;&#160;This Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together shall be deemed to constitute one and the same instrument.&#160;&#160;An executed signature page of this Agreement delivered by facsimile transmission or by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) shall be as effective as an original executed signature page.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:47.05pt;margin:0pt 0pt 12pt 0pt;">Section 12.16<b style="font-weight:bold;">Non-Exclusive Remedies</b>.&#160;&#160;The remedies set forth in this Agreement shall be in addition to, and shall not be to the exclusion of, any other remedies available to the Parties at law, in equity or under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 18pt 0pt;">[Remainder of the page intentionally left blank; signature page follows]</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Histogenics Corporation</b></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">MEDINET Co., Ltd.</b></p></td></tr><tr><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/Adam Gridley</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/Yoshiji Kimura</p></td></tr><tr style="height:3pt;"><td style="vertical-align:top;width:34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:top;width:33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: ADAM GRIDLEY</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: YOSHIJI KIMURA</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Function: PRESIDENT &amp; CEO</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Function: CEO</p></td></tr><tr style="height:3.5pt;"><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: DECEMBER 20, 2017</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: DECEMBER 21, 2017</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT A &#8211; LICENSED PATENTS and Documents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.&#160;<b style="font-weight:bold;">LICENSED</b>&#160;<b style="font-weight:bold;">PATENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.<b style="font-weight:bold;">&#160;Documents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT B &#8211; TRANSFER PRICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Press release(s)]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION AND MEDINET CO., LTD ENTER INTO LICENSING AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NEOCART FOR THE JAPANESE MARKET</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 233pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">&#8210; Transaction Terms Include a $10 Million Up-front Payment&#160;with a&#160;Potential of $87 Million in Total Milestones, and Tiered Royalties on Sales &#8210;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">&#8210;&#160;Japanese Cartilage Repair Market is Large and Growing with Established Reimbursement, and Physicians and Patients Seeking Improved Treatments for Cartilage Defects that may Prevent the Progression to Knee Osteoarthritis&#160;&#8210;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">&#8210; Plans to Initiate Phase 3 Clinical Trial in Japan in the Second Half of 2018 with Potential Commercialization in Japan in 2021 &#8210;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">WALTHAM, Mass., December 21, 2017 /GLOBE NEWSWIRE/</b>&#160;&#8211; Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that it has entered into an agreement with MEDINET Co., Ltd. (MEDINET), a pioneering leader in the development and commercialization of cancer immuno-cell therapy technologies,<font style="font-family:'Yu Mincho';">&#160;</font>for the development and commercialization of NeoCart<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup>&#160;for the Japanese market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;This transformative collaboration for Histogenics is a clear validation of the value NeoCart potentially provides to the physicians and patients who suffer from painful cartilage defects and related loss of function.&#160;&#160;MEDINET is one of the leaders of the burgeoning regenerative medicine sector in Japan, with strong capabilities in development and manufacturing of cell therapy products.&#160;&#160;We believe their recent initiatives to further develop their therapeutic capabilities with the addition of innovative products such as NeoCart will provide a rapid entry into the Japanese market,&#8221; stated Adam Gridley, President and Chief Executive Officer of Histogenics.&#160;&#160;&#8220;Our ability to leverage our long clinical and translational medicine history in the U.S. in markets such as Japan was a first step in bringing NeoCart to other regions, and we look forward to expanding our global presence more broadly in 2018 into other potential territories in Asia and Europe.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Histogenics&#8217; formal consultations with the Office of Cellular and Tissue-based Products of the Japan Pharmaceuticals and Medical Devices Agency (the PMDA) concluded in the second quarter of 2017 and the positive conclusion of those consultations played an integral role in enabling this collaboration. Formal feedback from the PMDA regarding the development and approval pathway for NeoCart in Japan included:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">A 30-patient, one-year confirmatory clinical trial in Japanese patients, comparing NeoCart to microfracture, would be sufficient for applying for full Marketing and Manufacturing Authorization in Japan in conjunction with data from Histogenics&#8217; fully enrolled U.S. Phase 3 clinical trial.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">NeoCart would be regulated as a Regenerative Medical Product, as covered by the recently enacted laws in Japan, and Histogenics can supply the confirmatory clinical trial from the U.S. using the current good manufacturing process (cGMP) for NeoCart.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;I am excited about the potential to bring this exciting therapy to Japanese patients and physicians through this new partnership,&#8221; stated Dr. Shuichi Mizuno, Ph.D., a scientific founder of NeoCart, Assistant Professor, Orthopedic Surgery, Brigham and Women&#8217;s Hospital, and Harvard Medical School, in whose laboratory the underlying technology for NeoCart was discovered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Japanese Cartilage Repair Market</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Japanese cartilage repair market is estimated to be the second largest market in the world after the U.S. and it is estimated that there may be at least 10,000 NeoCart treatments per year.&#160;&#160;If left untreated, cartilage defects may result in&#160;<font style="font-size:11pt;">Osteoarthritis</font>&#160;(OA) and ultimately, total knee replacements.&#160;&#160;Market forecasts predict that the number of OA patients in Japan aged 40 and older amounts to more than 25 million and is expected to accelerate as the population ages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the first half of 2017, Histogenics conducted market research in Japan with approximately 80 leading surgeons with the findings summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Approximately 60% of patients with knee cartilage defects are either not treated, or treated solely for temporary pain relief.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Approximately 60-70% of patients with knee cartilage defects that are left untreated will likely progress to OA in the knee.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Cartilage defects are believed to have caused OA in 15-20% of patients suffering from knee OA.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">More than 85% of orthopedic surgeons are not satisfied with the current options to treat knee cartilage defects.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Approximately 80% of orthopedic surgeons consider early improvement in pain and function to be important and more than half of the surgeons feel they would prescribe NeoCart based on published data.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;This licensing deal has been realized based on our longtime close relationship with Histogenics.&#160;&#160;I am excited about and proud of, the big challenge to enter into the regenerative medical product<font style="font-size:11pt;">&#160;</font>market with NeoCart in collaboration with the excellent team of Histogenics,&#8221; stated Yoshiji Kimura, Chief Executive Officer of&#160;MEDINET.&#160;&#160;&#8220;We believe this restorative cell therapy<font style="font-size:11pt;">&#160;</font>will contribute to better treatment by the physicians and quality life, of the patients&#160;with knee cartilage defects in Japan.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Locust Walk served as transaction advisor to Histogenics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Conference Call and Webcast Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Histogenics&#8217; management will host a conference call on Thursday, December 21, 2017 at 9:00 a.m. ET.&#160;&#160;A question-and-answer session will follow Histogenics&#8217; remarks.&#160;&#160;To participate on the live call, please dial 877-930-8064 (domestic) or 253-336-8040 (international) and provide the conference ID: 5982636 five to ten minutes before the start of the call.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A live audio webcast of the presentation will be available via the &#8220;Investor Relations&#8221; page of the Histogenics website,&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.histogenics.com</u>, or by&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clicking here</u>. &#160;A replay of the webcast will be archived on Histogenics&#8217; website for approximately 45 days following the presentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">About Histogenics Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Histogenics (Nasdaq: HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. &#160;Histogenics&#8217; lead investigational product, NeoCart, is designed to rebuild a patient&#8217;s own knee cartilage to treat pain at the source and potentially prevent a patient&#8217;s progression to osteoarthritis. &#160;NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. &#160;Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. &#160;Histogenics&#8217; technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. &#160;For more information on Histogenics and NeoCart, please visit&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.histogenics.com</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">About&#160;MEDINET&#160;Co.,&#160;Ltd.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">MEDINET is a pioneering leader in the development and commercialization of cancer immuno-cell therapies.&#160;&#160;MEDINET is also rigorously preparing to enter into the&#160;<font style="font-size:11pt;">regenerative medical product&#160;</font>market to leverage its long clinical and translational medicine history responding to the expected aging of the population.&#160;&#160;MEDINET went public in October, 2003 on the MOTHERS, Tokyo Stock Exchange. &#160;For more information, visit&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">http://www.medinet-inc.co.jp/english/</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Histogenics Corporation&#160;Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Various statements in this release are &#8220;forward-looking statements&#8221; under the securities laws.&#160;&#160;Words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;design,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and &#8220;would,&#8221; or the negative of these terms and similar expressions or words, identify forward-looking statements.&#160;&#160;Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Important factors that could cause actual results to differ materially from those reflected in Histogenics&#8217; forward-looking statements include, among others:&#160;&#160;the timing and success of Histogenics&#8217; NeoCart Phase 3 clinical trial, including, without limitation, possible delays in generating the data from the clinical trial; the ability to obtain and maintain regulatory approval of NeoCart or any product candidates, and the labeling for any approved products; NeoCart&#8217;s regulation as a Regenerative Medical Product; the market size and potential patient population in Japan; the scope, progress, expansion, and costs of developing and commercializing Histogenics&#8217; product candidates; the ability to obtain and maintain regulatory approval regarding the comparability of critical NeoCart raw materials following our technology transfer and manufacturing location transition; the size and growth of the potential markets for Histogenics&#8217; product candidates and the ability to serve those markets; Histogenics&#8217; expectations regarding its expenses and revenue; and other factors that are described in the &#8220;Risk Factors&#8221; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of Histogenics&#8217; Annual Report on Form 10-K for the year ended December 31, 2016 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC&#8217;s website at&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.sec.gov</u>.&#160;&#160;In addition to the risks described above and in Histogenics&#8217; annual report on Form 10-K and quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Histogenics&#8217; results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There can be no assurance that the actual results or developments anticipated by Histogenics will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Histogenics.&#160;&#160;Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All written and verbal forward-looking statements attributable to Histogenics or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.&#160;&#160;Histogenics cautions investors not to rely too heavily on the forward-looking statements Histogenics makes or that are made on its behalf.&#160;&#160;The information in this release is provided only as of the date of this release, and Histogenics undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* * * *</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Contact:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investor Relations<br>Tel: +1 (781) 547-7909</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">InvestorRelations@histogenics.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SOURCE: Histogenics Corporation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:10.5pt;">2017</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#24180;</font><font style="font-size:10.5pt;">12</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#26376;</font><font style="font-size:10.5pt;">21</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#26085;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.05%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'MS Mincho';">&#21508;</font> <font style="font-family:'MS Mincho';">&#20301;</font></p></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'MS Mincho';">&#20250;&#31038;&#21517;</font> <font style="font-family:'MS Mincho';">&#26666;&#24335;&#20250;&#31038;&#12513;&#12487;&#12451;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'MS Mincho';">&#12493;&#12483;&#12488;</font></p></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'MS Mincho';">&#20195;&#34920;&#32773;&#21517;</font> <font style="font-family:'MS Mincho';">&#20195;&#34920;&#21462;&#32224;&#24441;&#20250;&#38263;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'MS Mincho';">&#20860;&#31038;&#38263;</font> <font style="font-family:'MS Mincho';">&#26408;&#26449;</font> <font style="font-family:'MS Mincho';">&#20339;&#21496;</font></p></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'MS Mincho';">&#65288;&#12467;&#12540;&#12489;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'MS Mincho';">&#30058;&#21495;&#65306;</font>2370<font style="font-family:'MS Mincho';">&#26481;&#35388;&#12510;&#12470;&#12540;&#12474;&#65289;</font></p></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'MS Mincho';">&#21839;&#21512;&#12379;&#20808;</font> <font style="font-family:'MS Mincho';">&#21462;&#32224;&#24441;&#31649;&#29702;&#26412;&#37096;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'MS Mincho';">&#38263;</font> <font style="font-family:'MS Mincho';">&#23470;&#26412;</font> <font style="font-family:'MS Mincho';">&#23447;</font></p></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'MS Mincho';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'MS Mincho';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'MS Mincho';">&#65288;&#65332;&#65317;&#65324;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">045 &#8211; 478 - 0041<font style="font-family:'MS Mincho';">&#65289;</font></p></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'MS Mincho';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'MS Mincho';visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'MS Mincho';font-weight:bold;">&#12498;&#12473;&#12488;&#12472;&#12455;&#12491;&#12483;&#12463;&#12473;&#31038;&#12392;&#33258;&#24049;&#22521;&#39178;&#36575;&#39592;&#12300;</b><b style="font-weight:bold;">NeoCart&#174; </b><b style="font-family:'MS Mincho';font-weight:bold;">&#12301;&#12398;&#12521;&#12452;&#12475;&#12531;&#12473;&#22865;&#32004;&#12434;&#32224;&#32080;</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:13.7pt;margin:0pt;"><font style="font-family:'MS Gothic';font-size:10.5pt;">&#21462;&#32224;&#24441;&#20250;&#12391;&#27770;&#35696;&#12434;&#34892;&#12356;&#12289;</font><font style="font-family:'MS Gothic';">&#24403;&#35442;&#22865;&#32004;&#12434;&#32224;&#32080;</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#12375;&#12414;&#12375;&#12383;&#12398;&#12391;&#12362;&#30693;&#12425;&#12379;&#12375;&#12414;&#12377;&#12290;&#24403;&#31038;&#12399;&#20170;&#24460;&#12289;&#26412;&#22865;&#32004;&#12395;&#22522;&#12389;&#12365;&#12289;&#21516;&#31038;&#12363;&#12425;&#25552;&#20379;&#12373;&#12428;&#12427;&#21697;&#36074;&#12539;&#21069;&#33256;&#24202;&#12539;&#33256;&#24202;&#35430;&#39443;&#12487;&#12540;&#12479;&#12362;&#12424;&#12403;&#27835;&#39443;&#35069;&#21697;&#12434;&#20351;&#29992;&#12377;&#12427;&#12371;&#12392;&#12395;&#12424;&#12426;</font><font style="font-size:10.5pt;">2018</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#24180;&#24460;&#21322;&#12363;&#12425;&#33181;&#38306;&#31680;&#36575;&#39592;&#25613;&#20663;&#12434;&#23550;&#35937;&#12392;&#12377;&#12427;&#31532;</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#8546;</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#30456;&#33256;&#24202;&#35430;&#39443;&#12434;&#38283;&#22987;&#12375;&#12289;</font><font style="font-size:10.5pt;">2021</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#24180;&#12395;&#20877;&#29983;&#21307;&#30274;&#31561;&#35069;&#21697;&#12392;&#12375;&#12390;&#12398;&#35069;&#36896;&#36009;&#22770;&#25215;&#35469;&#12434;&#21462;&#24471;&#12377;&#12427;&#20104;&#23450;&#12391;&#12377;&#12290;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.7pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:13.7pt;margin:0pt;"><font style="font-family:'MS Gothic';font-size:10.5pt;">&#12498;&#12473;&#12488;&#12472;&#12455;&#12491;&#12483;&#12463;&#12473;&#31038;&#12399;&#12289;&#31859;&#22269;&#12395;&#12362;&#12356;&#12390;</font><font style="font-size:10.5pt;">NeoCart</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#12398;&#31532;</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#8546;</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#30456;&#33256;&#24202;&#35430;&#39443;&#12398;&#24739;&#32773;&#30331;&#37682;&#12434;&#12377;&#12391;&#12395;&#23436;&#20102;&#12375;&#12390;&#12362;&#12426;&#12289;</font><font style="font-size:10.5pt;">2018</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#24180;&#31532;</font><font style="font-size:10.5pt;">3</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#22235;&#21322;&#26399;&#12395;&#21028;&#26126;&#12377;&#12427;&#35430;&#39443;&#32080;&#26524;&#12395;&#22522;&#12389;&#12365;&#12289;</font><font style="font-size:10.5pt;">FDA</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#12395;&#29983;&#29289;&#23398;&#30340;&#35069;&#21092;&#25215;&#35469;&#30003;&#35531;&#12434;&#34892;&#12358;&#20104;&#23450;&#12391;&#12377;&#12290;&#21516;&#31038;&#12399;&#12289;&#12431;&#12364;&#22269;&#12395;&#12362;&#12356;&#12390;</font><font style="font-size:10.5pt;">2017</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#24180;&#31532;</font><font style="font-size:10.5pt;">2</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#22235;&#21322;&#26399;&#12414;&#12391;&#12395;&#29420;&#31435;&#34892;&#25919;&#27861;&#20154;&#21307;&#34220;&#21697;&#21307;&#30274;&#27231;&#22120;&#32207;&#21512;&#27231;&#27083;&#12392;&#12398;&#23550;&#38754;&#21161;&#35328;&#12434;&#23455;&#26045;&#12375;&#12390;&#12362;&#12426;&#12289;&#33256;&#24202;&#35430;&#39443;&#12487;&#12540;&#12479;&#12395;&#12388;&#12356;&#12390;&#12399;&#12289;&#21069;&#35352;&#12398;&#31859;&#22269;&#31532;</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#8546;</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#30456;&#33256;&#24202;&#35430;&#39443;&#12487;&#12540;&#12479;&#65288;</font><font style="font-size:10.5pt;">249</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#30151;&#20363;&#65289;&#12364;&#20351;&#29992;&#12391;&#12365;&#12427;&#12383;&#12417;&#12289;&#26085;&#26412;&#12395;&#12362;&#12356;&#12390;&#12399;&#31859;&#22269;&#12392;&#21516;&#27096;&#12398;&#12510;&#12452;&#12463;&#12525;&#12501;&#12521;&#12463;&#12481;&#12515;&#12540;&#25163;&#34899;&#12434;&#23550;&#29031;&#12392;&#12375;&#12383;&#31532;</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#8546;</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#30456;&#33256;&#24202;&#35430;&#39443;&#12434;</font><font style="font-size:10.5pt;">30</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#20154;&#35215;&#27169;&#12391;&#34892;&#12358;&#12371;&#12392;&#12395;&#12424;&#12426;&#35069;&#36896;&#36009;&#22770;&#25215;&#35469;&#30003;&#35531;&#12364;&#21487;&#33021;&#12392;&#12398;&#35211;&#35299;&#12434;&#24471;&#12390;&#12356;&#12414;&#12377;&#12290;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:13.7pt;margin:0pt;"><font style="font-size:10.5pt;">NeoCart</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#12364;&#36969;&#24540;&#21487;&#33021;&#12394;&#33181;&#38306;&#31680;&#36575;&#39592;&#25613;&#20663;&#24739;&#32773;&#12399;&#12289;&#12431;&#12364;&#22269;&#12391;&#12399;&#23569;&#12394;&#12367;&#12392;&#12418;&#24180;&#38291;</font><font style="font-size:10.5pt;">1</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#19975;&#20154;&#12392;&#25512;&#23450;&#12373;&#12428;&#12289;&#25918;&#32622;&#12377;&#12428;&#12400;&#22793;&#24418;&#24615;&#33181;&#38306;&#31680;&#30151;&#12420;&#12289;&#22580;&#21512;&#12395;&#12424;&#12387;&#12390;&#12399;&#33181;&#38306;&#31680;&#12398;&#20840;&#32622;&#25563;&#25163;&#34899;&#12364;&#24517;&#35201;&#12395;&#12394;&#12426;&#12414;&#12377;&#12290;&#12375;&#12363;&#12375;&#12289;&#12498;&#12473;&#12488;&#12472;&#12455;&#12491;&#12483;&#12463;&#12473;&#31038;&#12398;&#35519;&#26619;&#12395;&#12424;&#12427;&#12392;&#12289;&#12381;&#12398;&#32004;</font><font style="font-size:10.5pt;">60</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#65285;&#12364;&#22806;&#31185;&#30340;&#27835;&#30274;&#12394;&#12375;&#12414;&#12383;&#12399;&#20445;&#23384;&#27835;&#30274;&#12375;&#12363;&#26045;&#12373;&#12428;&#12390;&#12356;&#12414;&#12379;&#12435;&#12290;&#31309;&#26997;&#30340;&#12394;&#22806;&#31185;&#27835;&#30274;&#12434;&#21463;&#12369;&#12390;&#12356;&#12394;&#12356;&#22580;&#21512;&#12395;&#12399;&#12381;&#12398;</font><font style="font-size:10.5pt;">60</font><font style="font-family:'MS Mincho';font-size:10.5pt;">&#65374;</font><font style="font-size:10.5pt;">70</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#65285;&#12364;&#23558;&#26469;&#30340;&#12395;&#22793;&#24418;&#24615;&#33181;&#38306;&#31680;&#30151;&#12395;&#31227;&#34892;&#12377;&#12427;&#12392;&#32771;&#12360;&#12425;&#12428;&#12390;&#12356;&#12414;&#12377;&#12290;&#12371;&#12358;&#12375;&#12383;&#24739;&#32773;&#12395;&#12289;&#24739;&#32773;&#33258;&#36523;&#12363;&#12425;&#25505;&#21462;&#12375;&#12383;&#36575;&#39592;&#32048;&#32990;&#12434;&#36575;&#39592;&#27096;&#24418;&#29366;&#12395;&#22521;&#39178;&#12373;&#12428;&#12383;</font><font style="font-size:10.5pt;">NeoCart</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#12399;&#12289;&#25613;&#20663;&#37096;&#12395;&#20302;&#20405;&#35186;&#12391;&#31227;&#26893;&#12377;&#12427;&#12371;&#12392;&#12364;&#12391;&#12365;&#12289;&#26032;&#12383;&#12394;&#27835;&#30274;&#12398;&#36984;&#25246;&#32930;&#12398;&#19968;&#12388;&#12395;&#12394;&#12427;&#12371;&#12392;&#12364;&#26399;&#24453;&#12373;&#12428;&#12414;&#12377;&#12290;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:13.7pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:13.7pt;margin:0pt;"><font style="font-family:'MS Gothic';font-size:10.5pt;">&#24403;&#31038;&#12399;&#12289;&#12371;&#12358;&#12375;&#12383;&#29366;&#27841;&#12395;&#37969;&#12415;&#12289;</font><font style="font-size:10.5pt;">NeoCart</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#12364;&#26089;&#26399;&#12395;&#12431;&#12364;&#22269;&#12398;&#33181;&#38306;&#31680;&#36575;&#39592;&#25613;&#20663;&#24739;&#32773;&#12395;&#24681;&#24693;&#12434;&#12418;&#12383;&#12425;&#12375;&#24471;&#12427;&#28508;&#22312;&#21147;&#12395;&#30528;&#30446;&#12539;&#35413;&#20385;&#12375;&#12289;&#12381;&#12398;&#23566;&#20837;&#12434;&#27770;&#23450;&#12375;&#12383;&#12418;&#12398;&#12391;&#12377;&#12290;&#12381;&#12398;&#12383;&#12417;&#12398;&#23550;&#20385;&#12392;&#12375;&#12390;&#22865;&#32004;&#19968;&#26178;&#37329;</font><font style="font-size:10.5pt;">10</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#30334;&#19975;&#12489;&#12523;&#65288;&#32004;</font><font style="font-size:10.5pt;">11.3</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#20740;&#20870;&#65289;&#12395;&#21152;&#12360;&#12289;&#38283;&#30330;&#12539;&#36969;&#24540;&#25313;&#22823;&#12398;&#21508;&#27573;&#38542;&#12395;&#24540;&#12376;&#12383;&#19968;&#26178;&#37329;&#65288;&#32207;&#38989;&#32004;</font><font style="font-size:10.5pt;">11.6</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#20740;&#20870;&#65289;&#12394;&#12425;&#12403;&#12395;&#36009;&#22770;&#38283;&#22987;&#24460;&#12398;&#22770;&#19978;&#39640;&#12395;&#24540;&#12376;&#12383;&#25104;&#21151;&#22577;&#37228;&#65288;&#26368;&#22823;</font><font style="font-size:10.5pt;">73</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#20740;&#20870;&#65289;&#12362;&#12424;&#12403;&#12525;&#12452;&#12516;&#12523;&#12486;&#12451;&#12434;&#25903;&#25173;&#12358;&#12371;&#12392;&#12395;&#12394;&#12387;&#12390;&#12356;&#12414;&#12377;&#12290;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:13.7pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:13.7pt;margin:0pt;"><font style="font-family:'MS Gothic';font-size:10.5pt;">&#12498;&#12473;&#12488;&#12472;&#12455;&#12491;&#12483;&#12463;&#12473;&#31038;&#12398;&#33521;&#25991;&#21517;&#31216;&#12399;</font><font style="font-size:10.5pt;">Histogenics Corporation</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#65288;</font><font style="font-size:10.5pt;">Nasdaq:HSGX</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#65289;&#12391;&#12377;&#12290;&#21516;&#31038;&#12399;&#12289;&#20877;&#29983;&#32048;&#32990;&#27835;&#30274;&#12398;&#26368;&#26377;&#21147;&#20225;&#26989;&#12398;&#19968;&#12388;&#12391;&#12354;&#12426;&#12289;&#35443;&#32048;&#12399;&#12381;&#12398;</font><font style="font-size:10.5pt;">Web</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#12506;&#12540;&#12472;&#65288;</font><u style="font-size:10.5pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.histogenics.com</u><font style="font-family:'MS Gothic';font-size:10.5pt;">&#65289;&#12434;&#12372;&#21442;&#29031;&#12367;&#12384;&#12373;&#12356;&#12290;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'MS Gothic';font-size:10.5pt;">&#12304;&#20170;&#24460;&#12398;&#24433;&#38911;&#12305;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'MS Gothic';font-size:10.5pt;white-space:pre-wrap;">&#12288;</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#26412;&#20214;&#12398;&#26989;&#32318;&#65288;</font><font style="font-size:10.5pt;">2018</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#24180;</font><font style="font-size:10.5pt;">9</font><font style="font-family:'MS Gothic';font-size:10.5pt;">&#26376;&#26399;&#65289;&#12395;&#19982;&#12360;&#12427;&#24433;&#38911;&#12399;&#29694;&#22312;&#31934;&#26619;&#20013;&#12391;&#12354;&#12426;&#12289;&#20170;&#24460;&#12289;&#36969;&#26178;&#38283;&#31034;&#12398;&#24517;&#35201;&#24615;&#12364;&#29983;&#12376;&#12383;&#22580;&#21512;&#12395;&#12399;&#36895;&#12420;&#12363;&#12395;&#38283;&#31034;&#12356;&#12383;&#12375;&#12414;&#12377;&#12290;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;E</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PMDA Requests &amp; Necessary Actions by Histogenics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:5.9pt;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:19.99%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;background:#f2f2f2;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;background:#f2f2f2;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;background:#f2f2f2;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;background:#f2f2f2;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td rowspan="4" style="vertical-align:top;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td rowspan="4" style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="display:none;vertical-align:middle;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="display:none;vertical-align:middle;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="display:none;vertical-align:middle;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="display:none;vertical-align:middle;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="display:none;vertical-align:middle;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="display:none;vertical-align:middle;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td rowspan="4" style="vertical-align:top;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td rowspan="4" style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="display:none;vertical-align:middle;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="display:none;vertical-align:middle;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="display:none;vertical-align:middle;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="display:none;vertical-align:middle;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="display:none;vertical-align:middle;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="display:none;vertical-align:middle;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td rowspan="2" style="vertical-align:top;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td rowspan="2" style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="display:none;vertical-align:middle;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="display:none;vertical-align:middle;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:39.99%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td colspan="3" style="vertical-align:middle;width:60%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:28.5pt;"><td style="vertical-align:top;white-space:nowrap;width:20%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;"> [***]</font></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:middle;width:60%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Other PMDA Requests &amp; Necessary Actions by Histogenics</b></p></td><td style="vertical-align:middle;width:20%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:20%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:20%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td colspan="2" style="vertical-align:top;width:40%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:middle;width:20%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td colspan="2" style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:middle;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td colspan="2" style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td><td style="vertical-align:middle;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.43
<SEQUENCE>16
<FILENAME>tmb-20250331xex10d43.htm
<DESCRIPTION>EX-10.43
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:06 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.43</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ASSET CONTRIBUTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Asset Contribution Agreement (this &#8220;<b style="font-weight:bold;">Asset Contribution Agreement</b>&#8221;), dated as of June 19, 2025, is by and between Ocugen, Inc., a Delaware corporation (&#8220;<b style="font-weight:bold;">Ocugen</b>&#8221;), and OrthoCellix, Inc., a Delaware corporation (&#8220;<b style="font-weight:bold;">OrthoCellix</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, pursuant to this Asset Contribution Agreement, Ocugen desires to contribute, assign and convey to OrthoCellix, and OrthoCellix desires to accept from Ocugen, all of the NeoCart Assets (as defined below), and OrthoCellix agrees to assume and agree to pay, perform, discharge and fulfill all of the NeoCart Liabilities (as defined below) (such assignment and assumption, the &#8220;<b style="font-weight:bold;">Asset Contribution</b>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, as consideration for the Asset Contribution, OrthoCellix desires to issue to Ocugen, and Ocugen desires to accept from OrthoCellix, the OrthoCellix Shares (as defined below) (the &#8220;<b style="font-weight:bold;">Share Issuance</b>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Asset Contribution and the Share Issuance shall each be effective as of 11:59 p.m. (Eastern time) as of the date hereof (the &#8220;<b style="font-weight:bold;">Asset Contribution Time</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW</b>, <b style="font-weight:bold;">THEREFORE</b>, in consideration of the mutual covenants and promises contained in this Asset Contribution Agreement and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties to this Asset Contribution Agreement hereby agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-transform:uppercase;">DEFINITIONS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Affiliate</b>&#8221; of any Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person. &#8220;Control,&#8221; including the terms &#8220;controlled by&#8221; and &#8220;under common control with,&#8221; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, as trustee or executor, as general partner or managing member, by contract or otherwise, including the ownership, directly or indirectly, of securities having the power to elect a majority of the board of directors or similar body governing the affairs of such Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Contract</b>&#8221; means any written or oral contract, agreement, license, sublicense, lease, sublease, note, bond, indenture, deed of trust, mortgage, loan agreement or other legally binding commitment or arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Governmental Authority</b>&#8221; means any United States federal, state or local, or any supra national or non U.S., government, political subdivision, governmental, regulatory or administrative authority, instrumentality, agency body or commission, court, tribunal or judicial or arbitral body.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Intellectual Property Rights</b>&#8221; means any and all of the following in any jurisdiction throughout the world: (i) patents and patent applications and industrial designs and other</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">governmental grants for the protection of inventions or industrial designs, including patent rights, inventions, discoveries and invention disclosures (whether or not patented) (&#8220;<b style="font-weight:bold;">Patents</b>&#8221;), (H) copyrights in published and unpublished works, copyright registrations and applications for copyright registration, rights of publicity and privacy, and mask work rights, and all derivatives, translations, adaptations and combinations of the foregoing, (iii) rights in know-how, trade secrets and confidential or proprietary information, including research in progress, algorithms, data, databases, data collections, designs, processes, formulae, models, strategies, prototypes, techniques, source code, source code documentation, beta testing procedures and beta testing results, (iv) rights in registered and unregistered trademarks, trade names, logos, service marks, designs, emblems, signs, insignia, slogans, other similar designations of source or origin and general intangibles of like nature, and registrations and applications for registration for any of the foregoing, together with the goodwill of Ocugen or Ocugen&#8217;s business symbolized by any of the foregoing, and (v) domain names, registrations for domain names and web addresses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Liability</b>&#8221; means, with respect to any Person, any debt, loss, damage, liability or obligation (of any kind, character or description, whether direct or indirect, known or unknown, asserted or unasserted, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, secured or unsecured, joint or several, vested or unvested, executory or due or to become due, and whether in contract, tort, strict liability or otherwise), including all costs and expenses relating thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">NeoCart Assets</b>&#8221; means the assets specifically described on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> attached hereto and all goodwill relating to any of the foregoing assets (except that in no event will the NeoCart Assets include any of the Retained Assets (as defined below)).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">NeoCart Program</b>&#8221; means the research, development, manufacturing, regulatory approval and commercialization of Ocugen&#8217;s regenerative medicine cell therapy technology known as NeoCart (autologous chondrocyte-derived neocartilage).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Permits</b>&#8221; means permits, licenses, franchises, approvals, certificates, consents, waivers, concessions, exemptions, orders, registrations, notices or other authorizations of any Governmental Authority necessary for Ocugen to own, lease and operate its properties and to carry on the NeoCart Program or the Retained Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Person</b>&#8221; means an individual, corporation, partnership, limited liability Ocugen, joint venture, association, trust, unincorporated organization or other entity or group (as defined in Section 13(d) of the Securities Exchange Act of 1934, as amended). References to a Person are also to its permitted successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Representatives</b>&#8221; means, when used with respect to any Person, the directors, officers, employees, consultants, accountants, legal counsel, investment bankers or other financial advisors, agents and other representatives of such Person and its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Retained Assets</b>&#8221; means any and all assets, properties and rights not specifically described as an OrthoCellix Asset as described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Retained Business</b>&#8221; means any and all businesses, operations, assets, and activities of Ocugen and its Affiliates, other than those exclusively related to the NeoCart Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Subsidiary</b>&#8221; means any corporation more than 50% of whose outstanding voting securities, or any partnership, joint venture or other entity more than 50% of whose total equity interest, is directly or indirectly owned by Ocugen or OrthoCellix, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Taxes</b>&#8221; means any and all taxes, charges, fees, levies or other assessments in the nature of a tax, imposed by the Internal Revenue Service or any other taxing authority, and such term shall include any interest whether paid or received, fines, penalties or additional amounts attributable to, or imposed upon, or with respect to, any such taxes, charges, fees, levies or other assessments.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-transform:uppercase;">ASSET CONTRIBUTION</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer of Assets by Ocugen to OrthoCellix</u>. Upon the terms and subject to the conditions and other provisions set forth in this Asset Contribution Agreement, effective as of the Asset Contribution Time, Ocugen hereby contributes, assigns, conveys and transfers to OrthoCellix, and OrthoCellix hereby accepts from Ocugen, all of Ocugen&#8217;s right, title and interest in and to the NeoCart Assets (as defined herein).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assumption of NeoCart Liabilities</u>. Effective as of the Asset Contribution Time, Ocugen hereby assigns to OrthoCellix and OrthoCellix hereby assumes from Ocugen, and agrees to pay, perform, discharge and fulfill (i) any and all obligations of Ocugen under the Contributed Contracts (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>), whether relating to periods arising before, as of or after the Asset Contribution Time and (ii) any and all Liabilities of any kind, character or nature whatsoever to the extent related to the operation, ownership, use, sale, license or lease of the NeoCart Assets, whether arising before, as of or after the Asset Contribution Time, including all Liabilities arising out of facts, events and circumstances to the extent related to the past, present or future operation, ownership or use of the NeoCart Assets (the Liabilities described in the foregoing clauses (i) and (ii) referred to herein as the &#8220;<b style="font-weight:bold;">NeoCart Liabilities</b>&#8221;), except that in no event will the NeoCart Liabilities include any of the Retained Liabilities (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances; Limitations on Remedies</u>. Following the Closing, Ocugen agrees to execute further documentation as reasonably requested by OrthoCellix to record the transfer to OrthoCellix of the Intellectual Property Rights included in the NeoCart Assets, as is reasonably necessary to secure OrthoCellix&#8217;s rights under this Asset Contribution Agreement in the NeoCart Assets and any such Intellectual Property Rights in any and all countries. Ocugen and OrthoCellix hereby agree that at any time, and from time to time, upon the reasonable request of each other party, perform, execute, acknowledge and deliver all other further acts, deeds, assignments, conveyances, instruments, agreements or powers of attorney as may be necessary or appropriate to carry out the provisions of this Asset Contribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Representations or Warranties</u>. This Asset Contribution Agreement shall not be construed as containing, expressly or by implication, any representations or warranties by either party regarding (i) the nature, condition, amount or value of any NeoCart Assets, NeoCart Liabilities, the Retained Assets or the Retained Liabilities, (ii) any consents, waivers or approvals from any Governmental Authorities and other third parties that are required to be obtained in connection with the transactions contemplated by this Asset Contribution Agreement, or (iii) the absence of security interests, liens, claims and other encumbrances with respect to the NeoCart</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Assets or the Retained Assets. Ocugen is transferring all of the NeoCart Assets to OrthoCellix on an &#8220;as is, where is&#8221; basis. OrthoCellix agrees and acknowledges that Ocugen is not providing (i) any warranty, express or implied, with respect to the NeoCart Assets, including any implied warranty of merchantability, non-infringement or fitness for a particular purpose or (ii) any assurance as to the amount, nature or scope of any and all of the NeoCart Liabilities. OrthoCellix further understands and agrees that if the disclaimer of express or implied representations and warranties contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(d)</u> is held unenforceable or is unavailable for any reason under the laws of any jurisdiction, then, the parties intend that, notwithstanding any provision to the contrary under such laws, the provisions of this Asset Contribution Agreement shall prevail for any and all purposes among the parties and their respective Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bulk Sales</u>. Each party hereby waives compliance by itself and each of its Subsidiaries and Affiliates with the requirements and provisions of any &#8220;bulk-sale&#8221; or &#8220;bulk transfer&#8221; laws of any jurisdiction that may otherwise be applicable with respect to the transfer or sale of any or all of the NeoCart Assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Taxes</u>. Notwithstanding any provision herein to the contrary, OrthoCellix shall be responsible for and shall pay all transfer Taxes and other similar Taxes or charges of a Governmental Authority, if any, incurred by reason of the transactions contemplated by this Asset Contribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Retransfer of Assets and Liabilities; Omitted Assets</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>If, following the Closing, the parties jointly determine, which determination shall be reasonably made by each party, that (A) any asset transferred to OrthoCellix pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(a)</u> is not or should not have been a NeoCart Asset, then OrthoCellix shall transfer, assign and convey, or shall cause any such asset to be transferred, assigned and conveyed, to Ocugen without the payment of any additional consideration therefor and (B) any Liability assumed by OrthoCellix pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(b)</u> is not or should not be a NeoCart Liability, such Liability shall be promptly assumed by Ocugen or its designees without the payment of any additional consideration therefor, pursuant to an instrument of assumption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>If, following the Closing, the parties jointly determine, which determination shall be reasonably made by each party, that (A) any asset retained by Ocugen pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(a)</u> is or should have been a NeoCart Asset, then Ocugen shall transfer, assign and convey, or shall cause any such asset to be transferred, assigned and conveyed, to OrthoCellix without the payment of any additional consideration therefor, and (B) any Liability that constitutes a NeoCart Liability that should have been assumed by OrthoCellix at Closing pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(b)</u> but was not assumed, such Liability shall be promptly assumed by OrthoCellix, without the payment of any additional consideration therefor, pursuant to an instrument of assumption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>The parties agree that the foregoing determinations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(g)</u> will be made in good faith in light of the parties&#8217; intentions relating to the allocation of ownership of assets as set forth in this Asset Contribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non Assignable Assets</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>Notwithstanding anything contained herein to the contrary, this Asset Contribution Agreement shall not constitute an agreement to assign, license, sublicense, lease, sublease, convey or transfer any NeoCart Asset or any claim or right or any benefit arising thereunder or resulting therefrom as to which consent or approval from any Person (including consents and approvals of Governmental Authorities but excluding consents and approvals from the parties hereto and any of their Affiliates) to assignment, license, sublicense, lease, sublease, conveyance or transfer thereof or amendment thereof is required but has not been obtained as of the Asset Contribution Time ( the &#8220;<b style="font-weight:bold;">Non-Assignable Assets</b>&#8221;) unless and until such consent, approval or amendment is no longer required or has been obtained; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that for Tax purposes, to the extent not inconsistent with the terms thereof, the parties shall treat OrthoCellix as the owner of such Non-Assignable Assets to the extent that the benefits and burdens thereof are transferred to OrthoCellix.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>Following the Closing, the parties shall use commercially reasonable efforts to obtain any such consent, approval or amendment; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, that neither Ocugen nor any of its Affiliates shall be required to commence any litigation or offer, pay any money or otherwise grant any accommodation (financial or otherwise) to any Person. Upon obtaining the applicable consents, approvals or amendments required to effect the transfer and assignment thereof, such Non-Assignable Assets shall be transferred and assigned to OrthoCellix without additional consideration therefor. Notwithstanding anything else set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(h)(ii)</u>, neither of the parties shall be required to take any action that would reasonably be expected to (i) result in a violation of any obligation which such party has to any Person or (ii) otherwise violate applicable law. In the event any Liability arises with respect to a Non-Assignable Asset following the consummation of the Asset Contribution, OrthoCellix shall assume, agree to pay, discharge and satisfy such Liability as though such Liability was a NeoCart Liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>From and after the Asset Contribution Time, each of OrthoCellix and Ocugen shall, and shall cause their respective Affiliates to, hold, and shall use its reasonable best efforts to cause its or their respective Representatives to hold, in confidence any and all Confidential Information (as defined below) of the other party, except to the extent that either party can show that such information (A) is generally available to and known by the public through no act of such party, any of its Affiliates or their respective Representatives; or (B) is lawfully acquired by such party, any of its Affiliates or their respective Representatives from and after the Asset Contribution from sources which are not prohibited from disclosing such information by a legal, contractual or fiduciary obligation. If OrthoCellix, Ocugen or any of their respective Affiliates or their respective Representatives are compelled to disclose any information by judicial or administrative process or by other requirements of law, such party shall to the extent legally permissible promptly notify the other party in writing and shall disclose only that portion of such information which such party is advised by its counsel in writing is legally required to be disclosed, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, that such party shall use reasonable best efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>The term &#8220;<b style="font-weight:bold;">Confidential Information</b>&#8221; as used in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(i)</u> means (A) as to Ocugen, all information relating to business, the Retained Assets or the Retained Liabilities, and (B) as to OrthoCellix, all information relating to OrthoCellix business, the NeoCart Assets and the NeoCart Liabilities, in the case of each of clauses (A) and (B), whether disclosed prior to or after the Asset Contribution Time. For purposes of clarification, up to and as of the Asset Contribution Time, all information relating to the NeoCart Assets and NeoCart Liabilities shall be deemed the Confidential Information of Ocugen, and immediately following the Asset Contribution Time shall be deemed the Confidential Information of OrthoCellix and shall no longer be Confidential Information of Ocugen. All information concerning the Asset Contribution will be the Confidential Information of both parties.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-transform:uppercase;">RETAINED ASSETS AND RETAINED LIABILITIES.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Notwithstanding the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2</u>, Ocugen is not transferring any of Ocugen&#8217;s right, title and interest in and to any and all of the Retained Assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>From and after the Asset Contribution Time, (i) Ocugen shall retain all Liabilities of Ocugen that are not NeoCart Liabilities, including all Liabilities arising out of facts, events and circumstances to the extent related to the past, present or future operation, ownership or use of the Retained Assets (collectively, the &#8220;<b style="font-weight:bold;">Retained Liabilities</b>&#8221;); and (iii) OrthoCellix shall have no obligation to pay, perform, discharge or fulfill any of the Retained Liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>After the Asset Contribution Time, each party may receive from third parties payments, mail, packages or other communications properly belonging to the other party. The receiving party shall promptly deliver such mail, packages or other communications at its expense to the proper party.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-transform:uppercase;">ISSUANCE OF ORTHOCELLIX SHARES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>In partial consideration for the Asset Contribution and the commitments of Ocugen contained in this Asset Contribution Agreement, and such other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, effective as of the Asset Contribution Time, OrthoCellix hereby agrees to issue to Ocugen, and Ocugen hereby agrees to acquire from OrthoCellix, an aggregate total of 1,000 shares of the common stock of OrthoCellix, par value $0.00001 per share (the &#8220;<b style="font-weight:bold;">OrthoCellix Shares</b>&#8221;) .</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Ocugen and OrthoCellix acknowledge and agree that (i) the OrthoCellix Shares are not being registered with the U.S. Securities and Exchange Commission (the &#8220;<b style="font-weight:bold;">SEC</b>&#8221;) under the Securities Act of 1933, as amended, or state securities laws, but instead are being issued under exemptions from the registration and qualification requirements of such securities laws which impose certain restrictions on the subsequent sale, transfer or other disposition of OrthoCellix Shares by Ocugen and stockholders of Ocugen following the Asset Contribution, and (ii) the OrthoCellix Shares will not be certificated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-transform:uppercase;">REPRESENTATIONS AND WARRANTIES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of Ocugen</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>Ocugen is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware. Ocugen has the corporate power and authority to own and hold its properties and to carry on its business as proposed to be conducted, to execute, deliver and perform this Asset Contribution Agreement and each other document, agreement, certificate and instrument contemplated hereby to which it is a party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>The execution and delivery by Ocugen of this Asset Contribution Agreement and each other document, agreement, certificate and instrument contemplated hereby to which it is a party, the performance by Ocugen of its obligations hereunder and thereunder have been duly authorized by all requisite corporate action on the part of Ocugen and will not violate any provision of law, any order of any court or other agency of government, the certificate of incorporation of Ocugen or the bylaws of Ocugen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>This Asset Contribution Agreement has been duly executed and delivered by Ocugen and constitutes the legal, valid and binding obligation of Ocugen, enforceable against Ocugen in accordance with its terms, except to the extent such enforceability may be subject to applicable bankruptcy, reorganization, insolvency, moratorium and similar laws affecting the enforcement of creditors&#8217; rights generally and by general principles of equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of OrthoCellix</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>OrthoCellix is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. OrthoCellix has the power and authority to own and hold its properties and to carry on its business as proposed to be conducted, to execute, deliver and perform this Asset Contribution Agreement and each other document, agreement, certificate and instrument contemplated hereby to which it is a party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>The execution and delivery by OrthoCellix of this Asset Contribution Agreement and each other document, agreement, certificate and instrument contemplated hereby to which it is a party, the performance by OrthoCellix of its obligations hereunder and thereunder have been duly authorized by all requisite action on the part of OrthoCellix and will not violate any provision of law, any order of any court or other agency of government or the organizational documents of OrthoCellix.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>Except for consents which have been obtained prior to the Asset Contribution Time and subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(h)</u>, no consent, approval, license, order, authorization or registration with or of any Governmental Authority or any other Person is required to be made or obtained in order for the Asset Contribution to be effected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</font></font>This Asset Contribution Agreement has been duly executed and delivered by OrthoCellix and constitutes the legal, valid and binding obligation of OrthoCellix, enforceable against OrthoCellix in accordance with its terms, except to the extent such enforceability may be subject to applicable bankruptcy, reorganization, insolvency, moratorium and similar laws affecting the enforcement of creditors&#8217; rights generally and by general principles of equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</font></font>Except for this Agreement, OrthoCellix does not, and at the Asset Contribution Time, will not have any Contracts with Ocugen in effect.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-transform:uppercase;">MISCELLANEOUS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Asset Contribution Agreement, together with any schedules and exhibits hereto and any documents executed by the parties simultaneously herewith, pursuant thereto, or referenced herein, comprises the entire agreement of the parties, and all promises, representations, understandings, warranties and agreements with reference to the subject matter hereof, and all inducements to the making of this Asset Contribution Agreement relied upon by all the parties hereto, have been expressed herein and this Asset Contribution Agreement, supersedes any prior understandings, negotiations, agreements or representations by or among the parties, written or oral, to the extent they related in any way to the subject matter hereof or thereof. Neither this Asset Contribution Agreement nor any of the terms or provisions hereof are binding upon or enforceable against any party hereto unless and until the same is executed and delivered by all of the parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u>. Except as expressly permitted by the terms hereof, neither this Asset Contribution Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties hereto without the prior written consent of the other parties; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, that either party may, without obtaining the prior written consent of the other party, assign any of its rights, or delegate any of its obligations under this Asset Contribution Agreement to any Affiliate of such party so long as the assigning party also remains obligated for the performance of its obligations under this Agreement, and such Affiliate of the assigning party, as applicable, agrees to be bound by the provisions of this Asset Contribution Agreement and to assume all obligations of the assigning party under this Asset Contribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. If any term or other provision of this Asset Contribution Agreement is invalid, illegal or incapable of being enforced as a result of any rule of law or public policy, all other terms and other provisions of this Asset Contribution Agreement will nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto will negotiate in good faith to modify this Asset Contribution Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the greatest extent possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</u>. In this Asset Contribution Agreement, except to the extent otherwise provided or that the context otherwise requires: (i) references made in this Asset Contribution Agreement to a Section, Exhibit or Schedule are references to a Section, Exhibit, or Schedule of this Asset Contribution Agreement; (ii) all Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Asset Contribution Agreement as if set forth herein; (iii) the headings in this Asset Contribution Agreement are for reference purposes only and do not affect in any way the meaning or interpretation of this Asset Contribution Agreement; (iv) whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they are deemed to be followed by the words &#8220;without limitation&#8221;; (v) the words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import, when used in this Asset</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Contribution Agreement, refer to this Asset Contribution Agreement as a whole and not to any particular provision of this Asset Contribution Agreement; (vi) all terms defined in this Asset Contribution Agreement have the defined meanings when used in any certificate or other document made or delivered pursuant hereto, unless otherwise defined therein; (vii) the following general rules apply: the singular number will include the plural, and vice versa; the masculine gender will include the feminine and neuter genders; the feminine gender will include the masculine and neuter genders; and the neuter gender will include the masculine and feminine genders; (viii) any law defined or referred to herein or in any agreement or instrument that is referred to herein shall include any modification, amendment or re-enactment thereof, and any law substituted therefore, in each case as of the time of inquiry, representation or covenant and all rules, regulations and statutory instruments issued or related to such law; (ix) any reference to a Governmental Authority shall be deemed also to refer to any successor thereto unless the context requires otherwise; (x) a reference to any agreement (including this Asset Contribution Agreement), Contract or law is, unless otherwise specified, to the agreement, contract or law as amended, modified, supplemented or replaced at the time of inquiry, representation or covenant; (xii) no prior draft of this Asset Contribution Agreement nor any course of performance or course of dealing will be used in the interpretation or construction of this Asset Contribution Agreement; (xiii) although the same or similar subject matters may be addressed in different provisions of this Asset Contribution Agreement, the parties intend that, except as reasonably apparent on the face of the Asset Contribution Agreement or as expressly provided in this Asset Contribution Agreement, each such provision will be read separately, be given independent significance and not be construed as limiting any other provision of this Asset Contribution Agreement (whether or not more general or more specific in scope, substance or content); (xiv) references to a Person are also to its successors and permitted assigns; (xv) the use of &#8220;or&#8221; is not intended to be exclusive unless expressly indicated otherwise; and (xvi) all references to monetary amounts in this Agreement refer to U.S. dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Asset Contribution Agreement (and any claim or controversy arising out of or relating to this Asset Contribution Agreement) will be governed by the laws of the State of Delaware without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would cause application of the laws of any jurisdiction other than the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute Resolution</u>. Subject to the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(h)</u>, each of the parties hereby irrevocably and unconditionally consents to submit to the sole and exclusive jurisdiction of the state courts of the State of Delaware and of the United States District Court for the District of Delaware (the &#8220;<b style="font-weight:bold;">Chosen Courts</b>&#8221;) for any litigation arising out of or relating to this Asset Contribution Agreement, or the negotiation, validity or performance of this Agreement (and agrees not to commence any litigation relating thereto except in such courts), waives any objection to the laying of venue of any such litigation in the Chosen Courts and agrees not to plead or claim in any Chosen Court that such litigation brought therein has been brought in any inconvenient forum. Each of the parties hereto agrees, (a) to the extent such party is not otherwise subject to service of process in the State of Delaware, to appoint and maintain an agent in the State of Delaware as such party&#8217;s agent for acceptance of legal process and (b) that service of process may also be made on such party by prepaid certified mail with a proof of mailing receipt validated by the United States Postal Service constituting evidence of valid service. Service made pursuant to clauses (a) or (b)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">above shall have the same legal force and effect as if served upon such party personally within the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WAIVER OF JURY TRIAL</u>. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS ASSET CONTRIBUTION AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY DISPUTE DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS ASSET CONTRIBUTION AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF A DISPUTE, SEEK TO ENFORCE EITHER OF SUCH WAIVERS, (II) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (III) IT MAKES SUCH WAIVERS VOLUNTARILY, AND (IV) IT HAS BEEN INDUCED TO ENTER INTO THIS ASSET CONTRIBUTION AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 6(g)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</u>. Each of the parties hereto acknowledges and agrees that the other parties would be damaged irreparably, and in a manner for which monetary damages would not be an adequate remedy, in the event any of the provisions of this Asset Contribution Agreement are not performed in accordance with its specific terms or otherwise are breached. Accordingly, each of the parties hereto agrees that the other parties will be entitled to an injunction or injunctions to prevent breaches of the provisions of this Asset Contribution Agreement and to enforce specifically this Asset Contribution Agreement and the terms and provisions hereof in any action, litigation, suit, claim, hearing or proceeding instituted in any court of the United States or any state thereof having jurisdiction over the parties and the matter, in addition to any other remedy to which they may be entitled, at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u>. All covenants and agreements and other provisions set forth in this Asset Contribution Agreement and made by or on behalf of any of the parties hereto will bind, and inure to the benefit of, the successors (including any successor by merger, consolidation or division), heirs and permitted assigns of such party. This Asset Contribution Agreement may be executed in two or more counterparts, each of which when executed will be deemed an original and all of which together will constitute one and the same instrument. The parties agree that this Asset Contribution Agreement will be legally binding upon the electronic transmission, including by facsimile or email, by each party of a signed signature page to this Asset Contribution Agreement to the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver and Amendment</u>. No provision of this Asset Contribution Agreement may be waived or amended except in a written instrument signed by the party against whom enforcement of any such amendment or waiver is sought. No waiver of any of the provisions of this Asset Contribution Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar), nor shall such waiver constitute a continuing waiver unless otherwise expressly provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of Page Intentionally Left Blank</i>.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Asset Contribution Agreement to be signed by their respective officers thereunto duly authorized as of the date first written above.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OCUGEN, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Shankar Musunuri</p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shankar Musunuri, Ph.D., MBA</p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman, Chief Executive Officer &amp; Co-Founder</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Asset Contribution Agreement to be signed by their respective officers thereunto duly authorized as of the date first written above.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ORTHOCELLIX, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:54.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Shankar Musunuri</p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:54.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shankar Musunuri</p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Secretary</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.44
<SEQUENCE>17
<FILENAME>tmb-20250331xex10d44.htm
<DESCRIPTION>EX-10.44
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:08 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.44</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:10pt;font-weight:bold;">E</b><b style="font-size:8.5pt;font-weight:bold;">XCLUSIVE</b><b style="font-size:10pt;font-weight:bold;"> C</b><b style="font-size:8.5pt;font-weight:bold;">HANNEL</b><b style="font-size:10pt;font-weight:bold;"> C</b><b style="font-size:8.5pt;font-weight:bold;">OLLABORATION</b><b style="font-size:10pt;font-weight:bold;"> A</b><b style="font-size:8.5pt;font-weight:bold;">GREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:10pt;font-weight:bold;">T</b><b style="font-size:8.5pt;font-weight:bold;">HIS</b><b style="font-size:10pt;font-weight:bold;"> E</b><b style="font-size:8.5pt;font-weight:bold;">XCLUSIVE</b><b style="font-size:10pt;font-weight:bold;"> C</b><b style="font-size:8.5pt;font-weight:bold;">HANNEL</b><b style="font-size:10pt;font-weight:bold;"> C</b><b style="font-size:8.5pt;font-weight:bold;">OLLABORATION</b><b style="font-size:10pt;font-weight:bold;"> A</b><b style="font-size:8.5pt;font-weight:bold;">GREEMENT </b><font style="font-size:10pt;">(the &#8220;</font><b style="font-size:10pt;font-weight:bold;">Agreement</b><font style="font-size:10pt;">&#8221;) is made and entered into effective as of September 30, 2014 (the &#8220;</font><b style="font-size:10pt;font-weight:bold;">Effective Date</b><font style="font-size:10pt;">&#8221;) by and between </font><b style="font-size:10pt;font-weight:bold;">I</b><b style="font-size:8.5pt;font-weight:bold;">NTREXON</b><b style="font-size:10pt;font-weight:bold;"> C</b><b style="font-size:8.5pt;font-weight:bold;">ORPORATION</b><font style="font-size:10pt;">, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (&#8220;</font><b style="font-size:10pt;font-weight:bold;">Intrexon</b><font style="font-size:10pt;">&#8221;), and </font><b style="font-size:10pt;font-weight:bold;">H</b><b style="font-size:8.5pt;font-weight:bold;">ISTOGENICS</b><b style="font-size:10pt;font-weight:bold;"> C</b><b style="font-size:8.5pt;font-weight:bold;">ORPORATION</b><font style="font-size:10pt;">, a Delaware corporation having a place of business at 830 Winter Street, Waltham, MA 02451 (&#8220;</font><b style="font-size:10pt;font-weight:bold;">Histogenics</b><font style="font-size:10pt;">&#8221;). Intrexon and Histogenics may be referred to herein individually as a &#8220;</font><b style="font-size:10pt;font-weight:bold;">Party</b><font style="font-size:10pt;">&#8221;, and collectively as the &#8220;</font><b style="font-size:10pt;font-weight:bold;">Parties</b><font style="font-size:10pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:10pt;font-weight:bold;">R</b><b style="font-size:8.5pt;font-weight:bold;">ECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:10pt;font-weight:bold;">W</b><b style="font-size:8.5pt;font-weight:bold;">HEREAS</b><font style="font-size:10pt;">, Intrexon has expertise in and owns or controls proprietary technology relating to the identification, design and production of genetically modified cells and DNA vectors, and the control of peptide expression; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:10pt;font-weight:bold;">W</b><b style="font-size:8.5pt;font-weight:bold;">HEREAS</b><font style="font-size:10pt;">, Histogenics desires to become Intrexon&#8217;s exclusive channel collaborator in the Field with respect to such technology for the purpose of developing Collaboration Products for use in the Field, and Intrexon is willing to appoint Histogenics as an exclusive channel collaborator in the Field (as defined herein, and subject to amendments to the definition as permitted herein) under the terms and conditions of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:10pt;font-weight:bold;">N</b><b style="font-size:8.5pt;font-weight:bold;">OW</b><b style="font-size:10pt;font-weight:bold;"> T</b><b style="font-size:8.5pt;font-weight:bold;">HEREFORE</b><font style="font-size:10pt;">, in consideration of the foregoing and the covenants and promises contained herein, the Parties agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As used in this Agreement, the following capitalized terms shall have the following meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.1</b></font>&#8220;<b style="font-weight:bold;">Affiliate</b>&#8221; means, with respect to a particular Party, any other person or entity that directly or indirectly controls, is controlled by, or is in common control with such Party only for so long as such control continues to exist. As used in this Section 1.1, the term &#8220;controls&#8221; (with correlative meanings for the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) means the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities or other ownership interest of an entity, or the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether through the ownership of voting securities, by contract, or otherwise. Notwithstanding the foregoing, (i) Third Security shall be deemed not to be an Affiliate of Intrexon, (ii) neither Party shall be deemed to be an Affiliate of one another, and (iii) any other person, corporation, partnership, or other entity that would be an Affiliate of Intrexon solely because it and Intrexon are under common control by Randal J. Kirk or by investment funds managed by Third Security or an affiliate of Third Security shall also be deemed not to be an Affiliate of Intrexon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.2</b></font>&#8220;<b style="font-weight:bold;">Applicable Laws</b>&#8221; has the meaning set forth in Section 8.2(d)(xii).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.3</b></font>&#8220;<b style="font-weight:bold;">Approval Milestone Event</b>&#8221; means the first to occur of (i) the first Commercial Sale of a Collaboration Product anywhere in the Territory, (ii) the approval of a New Drug Application and/or Biologics License Application for a Collaboration Product by the FDA in the United States or (iii) equivalent regulatory action in a foreign jurisdiction in addition to any required pricing approval in such foreign jurisdiction but in no event later than 3 months from such action in the foreign jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.4</b></font>&#8220;<b style="font-weight:bold;">Amended Approval Milestone Event</b>&#8221; means after the occurrence of the Approval Milestone Event, the approval of a any new, amended or supplemental New Drug Application and/or Biologics License Application for a Collaboration Product by the FDA in the United States, or equivalent regulatory action in a foreign</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">jurisdiction, to expand the approved clinical indication for such Collaboration Product beyond the indication approved at the time of the Approval Milestone Event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.5</b></font>&#8220;<b style="font-weight:bold;">Authorizations</b>&#8221; has the meaning set forth in Section 8.2(d)(xii).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.6</b></font>&#8220;<b style="font-weight:bold;">CC</b>&#8221; has the meaning set forth in Section 2.2(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.7</b></font>&#8220;<b style="font-weight:bold;">Channel-Related Program IP</b>&#8221; has the meaning set forth in Section 6.1(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.8</b></font>&#8220;<b style="font-weight:bold;">Claims</b>&#8221; has the meaning set forth in Section 9.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.9</b></font>&#8220;<b style="font-weight:bold;">CMCC</b>&#8221; has the meaning set forth in Section 2.2(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.10</b></font>&#8220;<b style="font-weight:bold;">Collaboration Product</b>&#8221; means any product in the Field that is created, produced, or developed, in whole or in part by or on behalf of Histogenics during the Term through the use or practice of Intrexon Channel Technology, Intrexon IP, or the Intrexon Materials that are licensed or provided to Histogenics pursuant to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.11</b></font>&#8220;<b style="font-weight:bold;">Committees</b>&#8221; has the meaning set forth in Section 2.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.12</b></font>&#8220;<b style="font-weight:bold;">Commercialize</b>&#8221; or &#8220;<b style="font-weight:bold;">Commercialization</b>&#8221; (including derivative forms, such as &#8220;Commercializing&#8221;) means any activities directed to the marketing (including detailing to medical professions in efforts to increase prescribing preferences), manufacturing, promoting, distributing, importing for sale, offering to sell and/or selling of Collaboration Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.13</b></font>&#8220;<b style="font-weight:bold;">Commercialization Milestone Events</b>&#8221; means the IND Filing Milestone Event, the IND Acceptance Milestone Event, the Phase III Milestone Event, the Approval Milestone Event, and the Approval Amendment Milestone Event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.14</b></font>&#8220;<b style="font-weight:bold;">Commercial Sale</b>&#8221; means for a given product and country in the Territory, the sale for value of that product by Histogenics (or, as the case may be, by an Affiliate or permitted Sublicensee of Histogenics), to a Third Party after regulatory approval (if necessary) has been obtained for such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.15</b></font>&#8220;<b style="font-weight:bold;">Company Sale</b>&#8221; means the sale of Histogenics, whether in a single transaction or in a series of related transactions that are consummated contemporaneously (or consummated pursuant to contemporaneous agreements), to one or more Third Parties on an arm&#8217;s length basis, pursuant to which such Third Party or Third Parties acquires (i) (whether by merger, consolidation, sale or transfer of capital stock, recapitalization, or otherwise) more than fifty percent (50%) of Histogenics&#8217; common stock or (ii) all or substantially all of the assets of Histogenics determined on a consolidated basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.16</b></font>&#8220;<b style="font-weight:bold;">Complementary In-Licensed Third Party IP</b>&#8221; has the meaning set forth in Section 3.9(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.17</b></font>&#8220;<b style="font-weight:bold;">Confidential Information</b>&#8221; means any information belonging to a Party that is disclosed pursuant to this Agreement or any other confidentiality agreement between the Parties, regardless of whether in oral, written, graphic or electronic form, which is either marked &#8220;Confidential&#8221;, &#8220;Proprietary&#8221;, or the like, or is of such a nature or disclosed in such a manner that the discloser of the information would understand that information is confidential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.18</b></font>&#8220;<b style="font-weight:bold;">Control</b>&#8221; means, with respect to any Information, Patent or other intellectual property right, that a Party owns or has a license from a Third Party to such right and has the ability to grant a license or Sublicense as provided for in this Agreement under such right without violating the terms of any agreement or other arrangement with any Third Part</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.19</b></font>&#8220;<b style="font-weight:bold;">COGS</b>&#8221; means all costs of goods sold or costs of revenue that are directly and reasonably attributable to a Collaboration Product, as determined in accordance with US GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.20</b></font>&#8220;<b style="font-weight:bold;">Diligent Efforts</b>&#8221; means, with respect to a Party&#8217;s obligation under this Agreement, the level of efforts and resources reasonably required to diligently develop, manufacture, and/or Commercialize (as applicable) each Collaboration Product in a sustained manner, consistent with the efforts and resources a similarly situated company working in the Field would typically devote to a product of similar market potential, profit potential, strategic value and/or proprietary protection, based on market conditions then prevailing. With respect to a particular task or obligation, Diligent Efforts requires that the applicable Party promptly assign responsibility for such task and consistently make and implement decisions and allocate resources designed to advance progress with respect to such task or obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.21</b></font>&#8220;<b style="font-weight:bold;">Excess Product Liability Costs</b>&#8221; has the meaning set forth in Section 9.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.22</b></font>&#8220;<b style="font-weight:bold;">Executive Officer</b>&#8221; means : (a) the Chief Executive Officer of the applicable Party, or (b) another senior executive officer of such Party who has been duly appointed by the Chief Executive Officer to act as the representative of the Party to resolve, as the case may be, (i) a Committee dispute, provided that such appointed officer is not a member of the applicable Committee and occupies a position senior to the positions occupied by the applicable Party&#8217;s members of the applicable Committee, or (ii) a dispute described in Section 11.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.23</b></font>&#8220;<b style="font-weight:bold;">Existing Product</b>&#8221; means Histogenics&#8217; product candidate for autologous knee cartilage repair described more fully on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> attached hereto and incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.24</b></font>&#8220;<b style="font-weight:bold;">Fair Market Value</b>&#8221; means (a) in the event Histogenics&#8217; common stock is listed on a national exchange or trading system, the value of the issued shares of Histogenics&#8217; common stock using published market data of the share price for Histogenics&#8217; common stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the milestone event in question or (b) in the event Histogenics&#8217; common stock is not listed on a national exchange or trading system, the value determined in good faith by Histogenics&#8217; board of directors at the time of attainment of the milestone event in question based on an independent 409(a) valuation of Histogenics&#8217; common stock performed by a valuation firm of regionally recognized standing or Histogenics&#8217; auditors. Intrexon shall have the right to review the independent 409(a) valuation prior to final determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.25</b></font>&#8220;<b style="font-weight:bold;">FDA</b>&#8221; has the meaning set forth in Section 8.2(d)(xii).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.26</b></font>&#8220;<b style="font-weight:bold;">Field</b>&#8221; means the use of genetically modified cells, DNA or viral vectors, one or more human proteins and/or bioactive RNA species for the development and Commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment and/or repair of damaged articular hyaline cartilage in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.27</b></font>&#8220;<b style="font-weight:bold;">Field Infringement</b>&#8221; has the meaning set forth in Section 6.3(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.28</b></font>&#8220;<b style="font-weight:bold;">Form of Equity Terms</b>&#8221; means the terms attached hereto as exhibit C.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.29</b></font>&#8220;<b style="font-weight:bold;">Fully Loaded Cost</b>&#8221; means the direct cost of the applicable good, product or service plus indirect charges and overheads reasonably allocable to the provision of such good, product or service in accordance with US GAAP. Subject to the approval of a project and its associated budget by the JSC and the terms of Section 4.6, Intrexon will bill for its internal direct costs incurred through the use of annualized standard full-time equivalents; such rate shall be based upon the actual fully loaded costs of those personnel directly involved in the provision of such good, product or service. Intrexon may, from time to time, adjust such full-time equivalent rate based on changes to its actual fully loaded costs and will review the accuracy of its full-time equivalent rate at least quarterly. Intrexon shall provide Histogenics with reasonable documentation indicating the basis for any direct and indirect charges, any allocable overhead, and any such adjustment in full-time equivalent rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.30</b></font>&#8220;<b style="font-weight:bold;">Gross Proft</b>&#8221; means, with respect to a specific Collaboration Product, the Net Sales attributable to the Collaboration Product less COGS attributable to the Collaboration Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.31</b></font>&#8220;<b style="font-weight:bold;">Histogenics Platform Technology</b>&#8221; means the technology Controlled by Histogenics as of the Effective Date (i) relating to production of autologous artificial cartilage implants and/or implantation thereof to treat or repair damaged articular hyaline cartilage, and/or (ii) that covers or relates to the development, manufacture, use or sale of the Existing Product. For the avoidance of doubt, Histogenics Platform Technology includes, without limitation, the proprietary technology Controlled by Histogenics as of the Effective Date relating to its collagen scaffold, its Tissue Engineering Processor (TEP) and its CT3 bioadhesive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.32</b></font>&#8220;<b style="font-weight:bold;">Histogenics Indemnitees</b>&#8221; has the meaning set forth in Section 9.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.33</b></font>&#8220;<b style="font-weight:bold;">Histogenics Independent IP</b>&#8221; has the meaning set forth in Section 6.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.34</b></font>&#8220;<b style="font-weight:bold;">Histogenics Patents</b>&#8221; means all Patents that (i) are Controlled by Histogenics as of the Effective Date and (ii) contain one or more claims that cover Histogenics Platform Technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.35</b></font>&#8220;<b style="font-weight:bold;">Histogenics Platform Inventions</b>&#8221; has the meaning set forth in Section 6.1(e).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.36</b></font>&#8220;<b style="font-weight:bold;">Histogenics Program Patent</b>&#8221; has the meaning set forth in Section 6.2(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.37</b></font>&#8220;<b style="font-weight:bold;">Histogenics Termination IP</b>&#8221; means all Patents or other intellectual property that Histogenics or any of its Affiliates that are wholly-owned subsidiaries Controls as of the Effective Date or during the Term that cover, or is otherwise necessary for, the development, manufacture or Commercialization of a Reverted Product in the Field, but in any event excluding (i) any Histogenics Independent IP and (ii) any such Patent or other intellectual property for which Histogenics or its Affiliate does not have the ability to grant a license or sublicense as provided for in this Agreement without owing additional fees under the terms of any agreement or other arrangement with any Third Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.38</b></font>&#8220;<b style="font-weight:bold;">IND</b>&#8221; means an investigational new drug application filed with the FDA, or alternatively an equivalent regulatory filing filed with a regulatory agency in an applicable jurisdiction, for a Collaboration Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.39</b></font>&#8220;<b style="font-weight:bold;">IND Filing Milestone Event</b>&#8221; means the filing of an IND for a Collaboration Product with the FDA, or the filing of an equivalent regulatory filing in an applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.40</b></font>&#8220;<b style="font-weight:bold;">IND Acceptance Milestone Event</b>&#8221; means the acceptance of an IND that was filed for a Collaboration Product by the FDA, or the acceptance of an equivalent regulatory filing in the applicable jurisdiction, sufficient to permit clinical programs to proceed for such Collaboration Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.41</b></font>&#8220;<b style="font-weight:bold;">In-Licensed Program IP</b>&#8221; has the meaning set forth in Section 3.9(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.42</b></font>&#8220;<b style="font-weight:bold;">Information</b>&#8221; means information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including without limitation, databases, inventions, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, biological, chemical, biochemical, toxicological and clinical and pre-clinical test data, analytical and quality control data, stability data, studies and procedures, and patent and other legal information or descriptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.43</b></font>&#8220;<b style="font-weight:bold;">Infringement</b>&#8221; has the meaning set forth in Section 6.3(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.44</b></font>&#8220;<b style="font-weight:bold;">Intrexon Channel Technology</b>&#8221; means Intrexon&#8217;s current and future technology directed towards the design, identification, culturing, and/or production of genetically modified cells, including without limitation the technology embodied in the Intrexon Materials and the Intrexon IP, and specifically including without limitation the following of Intrexon&#8217;s platform areas and capabilities: (1) UltraVector<font style="font-size:8.5pt;">&#174;</font>, (2) LEAP<font style="font-size:8.5pt;">&#174;</font>, (3) DNA and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">RNA MOD engineering, (4) protein engineering, (5) transcription control chemistry, (6) genome engineering, (7) cell system engineering, and (8) endometrial regenerative cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.45</b></font>&#8220;<b style="font-weight:bold;">Intrexon Indemnitees</b>&#8221; has the meaning set forth in Section 9.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.46</b></font>&#8220;<b style="font-weight:bold;">Intrexon IP</b>&#8221; means the Intrexon Patents and Intrexon Know-How. For clarity, the Intrexon IP includes Intrexon&#8217;s rights under any of the Joint Program Inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.47</b></font>&#8220;<b style="font-weight:bold;">Intrexon Know-How</b>&#8221; means all Information (other than Intrexon Patents) that (a) is Controlled by Intrexon as of the Effective Date or during the Term and (b) is reasonably required for Histogenics to conduct the Program. For the avoidance of doubt, the Intrexon Know-How shall include any Information (other than Intrexon Patents) in the Channel-Related Program IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.48</b></font>&#8220;<b style="font-weight:bold;">Intrexon Materials</b>&#8221; means the cells, genetic code and associated amino acids and gene constructs, in each case that are Controlled by Intrexon, used alone or in combination and such other proprietary reagents and biological materials Controlled by Intrexon including but not limited to plasmid vectors, virus stocks, cells and cell lines, antibodies, and ligand-related chemistry, in each case that are reasonably required or provided to Histogenics by or on behalf of Intrexon to conduct the Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.49</b></font>&#8220;<b style="font-weight:bold;">Intrexon Patents</b>&#8221; means all Patents that (a) are Controlled by Intrexon as of the Effective Date or during the Term, and (b) are reasonably required for Histogenics to conduct the Program. For the avoidance of doubt, the Intrexon Patents shall include any Patent in the Channel-Related Program IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.50</b></font>&#8220;<b style="font-weight:bold;">Intrexon Trademarks</b>&#8221; means those trademarks related to the Intrexon Channel Technology that are established from time to time by Intrexon for use across its channel partnerships or collaborations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.51</b></font>&#8220;<b style="font-weight:bold;">Inventions</b>&#8221; has the meaning set forth in Section 6.1(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.52</b></font>&#8220;<b style="font-weight:bold;">IPC</b>&#8221; has the meaning set forth in Section 2.2(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.53</b></font>&#8220;<b style="font-weight:bold;">Joint Program Inventions</b>&#8221; has the meaning set forth in Section 6.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.54</b></font>&#8220;<b style="font-weight:bold;">JSC</b>&#8221; has the meaning set forth in Section 2.2(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.55</b></font>&#8220;<b style="font-weight:bold;">Losses</b>&#8221; has the meaning set forth in Section 9.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.56</b></font>Intentionally omitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.57</b></font>&#8220;<b style="font-weight:bold;">Net Sales</b>&#8221; means, with respect to any Collaboration Product, the net sales of such Collaboration Product by Histogenics or an Affiliate of Histogenics (including without limitation net sales of Collaboration Product to a non-Affiliate Sublicensee but not including net sales by such non-Affiliate Sublicensee), as determined in accordance with US GAAP. In the case of any sale for value, such as barter or counter-trade other than in an arm&#8217;s length transaction exclusively for cash, Net Sales shall be deemed to be the net sales at which substantially similar quantities of the product are sold for cash in an arm&#8217;s length transaction in the relevant country. If Collaboration Product is sold to any Third Party together with other products or services, the price of such product, solely for purposes of the calculation of Net Sales, shall be deemed to be no less than the price at which such product would be sold in a similar transaction to a Third Party not also purchasing the other products or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.58</b></font>&#8220;<b style="font-weight:bold;">Note</b>&#8221; means the convertible promissory note of the form set forth in the attached <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u> executed by Histogenics on the Effective Date and delivered by Histogenics contemporaneously with the execution by the Parties of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.59</b></font>&#8220;<b style="font-weight:bold;">Patents</b>&#8221; means (a) all patents and patent applications (including provisional applications), (b) any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, requests for</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">continued examination, confirmations, re-examinations, extensions, supplementary protection certificates and the like of the foregoing, and (c) any foreign or international equivalents of any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.60</b></font>&#8220;<b style="font-weight:bold;">Phase III Milestone Event</b>&#8221; means the meeting of the primary endpoint by or on behalf of Histogenics, or an Affiliate or permitted sublicensee of Histogenics, in a phase III clinical trial, whether such occurs in the United States of America under the jurisdiction of the FDA or elsewhere under the jurisdiction of a foreign regulatory agency, for a Collaboration Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.61</b></font>&#8220;<b style="font-weight:bold;">Product-Specific Program Patent</b>&#8221; means any issued Intrexon Patent where all the claims are directed to Inventions that solely and specifically cover Collaboration Products. In the event of a disagreement between the Parties as to whether a particular Intrexon Patent is or is not a Product-Specific Program Patent, the Parties shall seek to resolve the issue through discussions at the IPC, provided that if the Parties are unable to resolve the disagreement, the issue shall be submitted to arbitration pursuant to Section 11.2. Any Intrexon Patent that is subject to such a dispute shall be deemed not to be a Product-Specific Program Patent unless and until (a) Intrexon agrees in writing that such Patent is a Product-Specific Program Patent or (b) an arbitrator or arbitration panel determines, pursuant to Article 11, that such Intrexon Patent is a Product-Specific Program Patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.62</b></font>&#8220;<b style="font-weight:bold;">Product Sublicense</b>&#8221; has the meaning set forth in Section 3.2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.63</b></font>&#8220;<b style="font-weight:bold;">Product Sublicensee</b>&#8221; has the meaning set forth in Section 3.2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.64</b></font>&#8220;<b style="font-weight:bold;">Program</b>&#8221; means the channel collaboration between the Parties during the Term as established and governed by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.65</b></font>&#8220;<b style="font-weight:bold;">Proposed Terms</b>&#8221; has the meaning set forth in Section 11.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.66</b></font>&#8220;<b style="font-weight:bold;">Prosecuting Party</b>&#8221; has the meaning set forth in Section 6.2(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.67</b></font>&#8220;<b style="font-weight:bold;">RAC</b>&#8221; has the meaning set forth in Section 2.2(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.68</b></font>&#8220;<b style="font-weight:bold;">Recovery</b>&#8221; has the meaning set forth in Section 6.3(f).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.69</b></font>&#8220;<b style="font-weight:bold;">Retained Product</b>&#8221; has the meaning set forth in Section 10.4(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.70</b></font>&#8220;<b style="font-weight:bold;">Reverted Product</b>&#8221; has the meaning set forth in Section 10.4(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.71</b></font>&#8220;<b style="font-weight:bold;">SEC</b>&#8221; means the United States Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.72</b></font>&#8220;<b style="font-weight:bold;">Sublicensing Revenue</b>&#8221; means any cash consideration, or the cash equivalent value of non-cash consideration, regardless of whether in the form of upfront payments, milestones, or royalties, actually received by Histogenics or its Affiliate from a Third Party in consideration for a grant of a sublicense under the Intrexon IP for any rights to develop or Commercialize Collaboration Products, but excluding: (a) any amounts paid as bona fide reimbursement for research and development costs to the extent incurred following such grant; (b) bona fide loans or any payments in consideration for a grant of equity of Histogenics to the extent that such consideration is equal to or less than fair market value (i.e. any amounts in excess of fair market value shall be Sublicensing Revenue); (c) any amounts paid by Histogenics to a Third Party for the right to operate under or utilize Third Party owned intellectual property that is used to make or use a Collaboration Product underlying the Sublicensing Revenue, (d) subject to the waiver provisions of Section 5.3(c), any payments received by Histogenics from permitted sublicensees for the achievement of a Commercialization Milestone Event that is the same as (or substantially similar to) a Commercialization Milestone Event for which Intrexon is entitled to receive a milestone payment under Section 5.3(a), and (e) amounts received from sublicensees in respect of any Histogenics Product sales that are included in Net Sales and for which Intrexon receives revenue sharing payments under Section 5.2(a). For clarity, Sublicensing Revenue includes milestone payments for Histogenics Products received by Histogenics from a sublicensee of Histogenics (including a Product Sublicensee) for (i) the achievement by the Histogenics sublicensee of any milestone event that is not the same as, or substantially similar to, a Commercialization Milestone Event, (ii) the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">achievement by the Histogenics sublicensee of the second or subsequent occurrence of the same (or substantially similar) Commercialization Milestone Event, irrespective of whether the first occurrence of the Commercialization Milestone Event in question was achieved by Histogenics, or its Affiliate or a sublicensee, and (iii) the achievement by a permitted sublicensee of Histogenics of the first occurrence of the same (or substantially similar) Commercialization Milestone Event where Intrexon elects to share such milestone payment as Sublicensing Revenue in accord with Section 5.3(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.73</b></font>&#8220;<b style="font-weight:bold;">Superior Therapy</b>&#8221; means a therapy in the Field that, based on the data then available, (a) demonstrably appears to offer either superior efficacy or safety or significantly lower cost of therapy, as compared with both (i) those therapies that are marketed (either by Histogenics or others) at such time for the indication and (ii) those therapies that are being actively developed by Histogenics for such indication; (b) demonstrably appears to represent a substantial improvement over such existing therapies; and (c) has intellectual property protection and a regulatory approval pathway that, in each case, would not present a significant barrier to commercial development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.74</b></font>&#8220;<b style="font-weight:bold;">Supplemental In-Licensed Third Party IP</b>&#8221; has the meaning set forth in Section 3.9(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.75</b></font>&#8220;<b style="font-weight:bold;">Support Memorandum</b>&#8221; has the meaning set forth in Section 11.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.76</b></font>&#8220;<b style="font-weight:bold;">Technology Access Fee</b>&#8221; for the purposes of this Agreement has the meaning as set forth in Section 5.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.77</b></font>&#8220;<b style="font-weight:bold;">Term</b>&#8221; has the meaning set forth in Section 10.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.78</b></font>&#8220;<b style="font-weight:bold;">Territory</b>&#8221; means the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.79</b></font>&#8220;<b style="font-weight:bold;">Third Party</b>&#8221; means any individual or entity other than the Parties or their respective Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.80</b></font>&#8220;<b style="font-weight:bold;">Third Security</b>&#8221; means Third Security, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.81</b></font>&#8220;<b style="font-weight:bold;">Universal Cell Line</b>&#8221; means an allogeneic human chondrocyte cell line for use in Collaboration Products intended by the Parties to be developed under the Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.82</b></font>&#8220;<b style="font-weight:bold;">US GAAP</b>&#8221; means generally accepted accounting principles in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.83</b></font>&#8220;<b style="font-weight:bold;">Work Plan</b>&#8221; has the meaning set forth in Section 2.1(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">SCOPE OF CHANNEL COLLABORATION; MANAGEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.1</b></font><b style="font-weight:bold;">Scope</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Generally</b>. The general purpose of the Program described in this Agreement will be to use the Intrexon Channel Technology to research, develop and Commercialize Collaboration Products. As provided below, the JSC shall establish, monitor, and govern projects for Collaboration Products. Either Party may propose other potential projects in the Field for review and consideration by the JSC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Initial Work Plan</b>. The Parties shall mutually draft and finalize, within forty-five (45) days after the Effective Date, an initial work plan describing the development of a Universal Cell Line, which shall be based on the draft work plan provided by Intrexon to Histogenics from Scott Patterson to Stephen Kennedy on July 8, 2014 (&#8220;<b style="font-weight:bold;">Work Plan</b>&#8221;). The Work Plan shall serve as a basis for the operation of the Program following the Effective Date, but may be amended and revised by the JSC and the Parties as set forth in this Article 2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.2</b></font><b style="font-weight:bold;">Governance and Committees</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Generally</b>. The Parties desire to establish several committees (collectively, &#8220;<b style="font-weight:bold;">Committees</b>&#8221;) to oversee the Program and to facilitate communications between the Parties with respect thereto. Each of such Committees shall have the responsibilities and authority allocated to it in this Article 2. Each of the Committees shall have the obligation to exercise its authority consistent with the respective purpose for such Committee as stated herein and any such decisions shall be made in good faith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Formation and Purpose</b>. Promptly following the Effective Date, the Parties shall confer and then create the JSC and the IPC, and, optionally, create one or more of the other Committees listed in the chart below. Each Committee shall have the purpose indicated in the chart. To the extent that after conferring both Parties agree to not create a Committee (other than the JSC and the IPC), the creation of such Committee shall be deferred until one Party informs the other Party of its then desire to create the so-deferred Committee, at which point the Parties will thereafter promptly create the so-deferred Committee.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Committee</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Purpose</b></p></th></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joint Steering Committee (&#8220;<b style="font-weight:bold;">JSC</b>&#8221;)</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Establish projects for the Program and establish the priorities, as well as approve budgets for such projects. Approve all Subcommittee projects and plans. The JSC shall establish budgets not less than on a quarterly basis.</p></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chemistry, Manufacturing and Controls Committee (&#8220;<b style="font-weight:bold;">CMCC</b>&#8221;)</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Establish project plans and review and approve activities and budgets for chemistry, manufacturing, and controls under the Program.</p></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulatory Approval Committee (&#8220;<b style="font-weight:bold;">RAC</b>&#8221;)</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Review and approve all research and development plans and projects, including clinical projects, associated with any necessary regulatory approvals, all associated publications, and all regulatory filings and correspondence relating to gaining regulatory approval under the Program; and review and approve itemized budgets with respect to the foregoing.</p></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercialization Committee (&#8220;<b style="font-weight:bold;">CC</b>&#8221;)</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Establish project plans and review and approve activities and budgets for Commercialization activities under the Program.</p></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intellectual Property Committee (&#8220;<b style="font-weight:bold;">IPC</b>&#8221;)</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.34%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Evaluate intellectual property issues in connection with the Program; review and approve itemized budgets with respect to the foregoing.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.3</b></font><b style="font-weight:bold;">General Committee Membership and Procedure</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Membership</b>. For each Committee, each Party shall designate an equal number of representatives (not to exceed three (3) for each Party) with appropriate expertise to serve as members of such Committee. For the Committees each representative must either be an employee of such designating Party or an Affiliate of such Party, or be a person who is not an employee but where (i) such non-employee is authorized by such designating Party to act as its representative, (ii) such non-employee representative is bound by written agreement with terms that are consistent with the applicable terms of this Agreement for the treatment and ownership of Confidential Information and Inventions of the Parties, and (iii) the other Party consents to the designation of such non-employee representative, which consent shall not be unreasonably withheld. Each Party is responsible for any breaches of this Agreement by such non-employee representative. Each representative as qualified above may serve on more than one (1) Committee as appropriate in view of the individual&#8217;s expertise. Each Party may replace its Committee representatives at any time upon written notice to the other Party. Each Committee shall have a chairperson; the chairperson of each committee shall serve for a two-year term and the right to designate which representative to the Committee will act as chairperson shall alternate between the Parties, with</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Histogenics selecting the chairperson first for the JSC, RAC and CC, and Intrexon selecting the chairperson first for the CMCC and IPC. The chairperson of each Committee shall be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting of such Committee, and preparing and issuing minutes of each meeting within fifteen (15) days thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Meetings</b>. Each Committee shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held less frequently than once every six (6) months, with the caveat that both Parties may agree to suspend activities of a given Committee other than the JSC until such time as one Party informs the other Party of its then desire to reactivate the so-suspended Committee, at which point the Parties will thereafter schedule and hold the next meeting for the reactivated Committee within one (1) month. Meetings of any Committee may be held in person or by means of telecommunication (telephone, video, or web conferences). To the extent that a Committee holds any meetings in person, the Parties will alternate in designating the location for such in-person meetings, with Histogenics selecting the first meeting location for each Committee. A reasonable number of additional representatives of a Party may attend meetings of a Committee in a non-voting capacity. Each Party shall be responsible for all of its own expenses of participating in any Committee excepting that an Intrexon employee or agent serving on a Committee shall not prevent Intrexon from recouping the Fully Loaded Costs otherwise derived from the labor of that employee or agent in the course of providing manufacturing or support services as set forth in Sections 4.5 and 4.6 below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Meeting Agendas</b>. Each Party will disclose to the other proposed agenda items along with appropriate information at least three (3) business days in advance of each meeting of the applicable Committee; provided, that a Party may provide its agenda items to the other Party within a lesser period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence of a specific agenda for such Committee meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">Limitations of Committee Powers</b>. Each Committee shall have only such powers as are specifically delegated to it hereunder or from time to time as agreed to in writing by the mutual consent of the Parties and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, no Committee shall have any power to amend this Agreement. Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 12.7 below. Additionally, no member of any Committee shall be able to vote in such Committee and thereby bind its respective Party on any material matter accept as otherwise properly authorized, approved, or delegated by such Party in accord with Section 2.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.4</b></font><b style="font-weight:bold;">Committee Decision-Making</b>. If a Committee is unable to reach unanimous consent on a particular matter within thirty (30) days of its initial consideration of such matter, then either Party may provide written notice of such dispute to the Executive Officer of the other Party. The Executive Officers of each of the Parties will meet at least once in person or by means of telecommunication (telephone, video, or web conferences) to discuss the dispute and use their good faith efforts to resolve the dispute within thirty (30) days after submission of such dispute to the Executive Officers. If any such dispute is not resolved by the Executive Officers within thirty (30) days after submission of such dispute to such Executive Officers, then the Executive Officer of the Party specified in the applicable subsection below shall have the authority to finally resolve such dispute acting in good faith (but, in any event, not contrary to any provision in the Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Casting Vote at JSC</b>. If a dispute at the JSC is not resolved pursuant to Section 2.4 above, then the Executive Officer of Histogenics shall have the authority to finally resolve such dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Casting Vote at CMCC</b>. If a dispute at the CMCC is not resolved pursuant to Section 2.4 above, then (i) in the case of any disputes relating to the Intrexon Materials, the manufacture of the portion of the Collaboration Product using Intrexon Channel Technology or Intrexon IP, or the manufacturing of other components of Collaboration Products contracted for or manufactured by Intrexon (if any) or reasonable controls regarding the dissemination of Intrexon Technology, Intrexon IP or Intrexon Materials, the Executive Officer of Intrexon shall have the authority to finally resolve such dispute; and (ii) in the case of any other disputes, the Executive Officer of Histogenics shall have the authority to finally resolve such dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Casting Vote at RAC</b>. If a dispute at the RAC is not resolved pursuant to Section 2.4 above, then the Executive Officer of Histogenics shall have the authority to finally resolve such dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">Casting Vote at CC</b>. If a dispute at the CC is not resolved pursuant to Section 2.4 above, then the Executive Officer of Histogenics shall have the authority to finally resolve such dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font><b style="font-weight:bold;">Casting Vote at IPC</b>. If a dispute at the IPC is not resolved pursuant to Section 2.4 above, then the Executive Officer of Intrexon shall have the authority to finally resolve such dispute, provided that such authority shall be shared by the Parties with respect to Product-Specific Program Patents (i.e., neither Party shall have the casting vote on such matters, and any such disputes shall be resolved pursuant to Article 11).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font><b style="font-weight:bold;">Other Committees</b>. If any additional Committee or Subcommittee other than those set forth in Section 2.2(b) is formed, then the Parties shall, at the time of such formation, agree on which Party shall have the authority to finally resolve a dispute that is not resolved pursuant to Section 2.4 above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(g)</b></font><b style="font-weight:bold;">Restrictions</b>. Neither Party shall exercise its right to finally resolve a dispute at a Committee in accordance with this Section 2.4 in a manner that (i) excuses such Party from any of its obligations specifically enumerated under this Agreement; (ii) expands the obligations of the other Party under this Agreement; (iii) negates any consent rights or other rights specifically allocated to the other Party under this Agreement; (iv) purports to resolve any dispute involving the breach or alleged breach of this Agreement; (v) resolves a matter if the provisions of this Agreement specify that mutual agreement is required for such matter; or (vi) would require the other Party to perform any act that is inconsistent with applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.5</b></font><b style="font-weight:bold;">Authorization of Committee Representatives</b>. Each representative serving on a Committee shall be responsible for ensuring that he or she acts only as duly authorized by his or her respective Party and obtains any advance approvals, delegations, or other authorizations from his or her respective Party in advance of making any Committee votes. Any Committee representative shall only be able to bind his or her respective appointing Party via any Committee vote or other material Committee activity to the extent such vote or other activity has been previously approved by the Party, is within the authority duly delegated to the representative by the respective Party, or is otherwise authorized by its respective Party as may be required by that Party&#8217;s corporate charter or bylaws, or by its board of directors. Any action or vote taken without valid authority shall be considered null and void and shall be without effect unless subsequently approved by a vote in accord with this Section 2.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.6</b></font><b style="font-weight:bold;">Expansion of the Field</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Intrexon recognizes that Histogenics may during the Program wish to expand the Field beyond the treatment and/or repair of damaged articular hyaline cartilage to the treatment and/or repair of other types of damaged cartilage in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>During the Term up to and including the fifth (5<font style="font-size:8.5pt;">th</font>) anniversary of the Effective Date, Intrexon agrees that it shall first provide Histogenics with the ability to negotiate with Intrexon (who shall act in good faith) for 90 days regarding amendment to this Agreement so as to expand the Field to include the treatment and/or repair of any and all types of damaged cartilage excluding the spine in humans before Intrexon grants any conflicting rights under the Intrexon IP to any Third Party. If after such good faith negotiations the Parties are unable to come to mutually agreeable terms regarding an expansion of the Field under the prior sentence with respect to the applicable type of damaged cartilage in humans (other than articular hyaline cartilage), Intrexon&#8217;s obligations under this Section 2.6(b) will be deemed fulfilled with respect to such type of damaged cartilage and Intrexon shall thereafter have no further obligation to first negotiate with Histogenics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>Additionally at any time during the Term, Intrexon shall, upon reasonable request from Histogenics, engage in good faith negotiations with respect to expansion of the Field to the treatment and/or repair of any type of damaged cartilage in humans other than articular hyaline cartilage. For clarity, the right of Histogenics to request such negotiations under this Section 2.6(c) does not obligate Intrexon to reserve any area of collaboration outside the Field available to Histogenics, and does not, for example, prevent Intrexon from, either by</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">itself or in connection with Third Parties, engaging in activities outside of the Field or granting exclusive or non-exclusive rights under the Intrexon IP for Third Parties to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">LICENSE GRANTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.1</b></font><b style="font-weight:bold;">Licenses to Histogenics</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Subject to the terms and conditions of this Agreement, Intrexon hereby grants to Histogenics a license under the Intrexon IP to obtain regulatory approval for, research, develop, use, import, export, make, have made, manufacture, sell, and offer for sale and otherwise Commercialize and exploit Collaboration Products in the Field in the Territory. Such license shall be exclusive (even as to Intrexon) with respect to any development, selling, offering for sale and other Commercialization and exploitation of Collaboration Products in the Field, and shall be otherwise non-exclusive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Subject to the terms and conditions of this Agreement, Intrexon hereby grants to Histogenics a non-exclusive, royalty-free license to use and display the Intrexon Trademarks, solely in connection with the Commercialization of Collaboration Products in the promotional materials, packaging, and labeling for Collaboration Products, as provided under and in accordance with Section 4.8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.2</b></font><b style="font-weight:bold;">Sublicensing</b>. Except as provided in this Section 3.2, Histogenics shall not sublicense the rights granted under Section 3.1 to any Third Party, or transfer the Intrexon Materials to any Third Party, or otherwise grant any Third Party the right to research, develop, use, or Commercialize Collaboration Products or use or display the Intrexon Trademarks, in each case except with Intrexon&#8217;s written consent, which written consent may be withheld in Intrexon&#8217;s sole discretion. Notwithstanding the foregoing, Histogenics (and its Product Sublicensees only to the extent explicitly set forth in Section 3.2(a) below) shall have a limited right to sublicense under the circumstances described in Sections 3.2(a) through 3.2(c). Any breach of any such obligations by any Affiliate or subcontractor under Section 3.2 shall be deemed a breach by Histogenics of its obligations under this Agreement, and Histogenics shall be responsible and liable for any breach of any such obligations by any of its Affiliates or subcontractors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Histogenics may transfer, without Intrexon&#8217;s written consent, to the extent reasonably necessary and after providing Intrexon with reasonable advance notice thereof, Intrexon Materials that are or express ingredients for Collaboration Products to a Third Party contractor performing contract manufacturing responsibilities or manufacturing-related activities on behalf of Histogenics for Collaboration Products, and may in connection therewith grant limited sublicenses necessary to enable such Third Party to perform such activities. If Histogenics transfers any Intrexon Materials under this Section 3.2(a), Histogenics will remain obligated to ensure that the rights of Intrexon in and to the Intrexon Materials and Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are not violated by any such Third Party contractor. A Product Sublicensee of Histogenics may transfer, to the extent reasonably necessary and upon the consent of Intrexon, which consent shall not be unreasonably withheld, conditioned or delayed, Intrexon Materials that are or express ingredients for the Collaboration Product sublicensed by the Product Sublicensee to a Third Party contractor performing on behalf of that Product Sublicensee contract manufacturing responsibilities for Collaboration Products, and may in connection therewith grant limited sublicenses to the extent necessary to enable such Third Party to perform such activities. Histogenics will require and ensure that if any Product Sublicensee transfers any Intrexon Materials under this Section 3.2(a), that such Product Sublicensee will take commercially reasonable steps, including contractually obligating any such Third Party contractors, to ensure that the rights of Intrexon in and to the Intrexon Materials and Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are not violated by any Third Party contractors of such Product Sublicensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Histogenics may, (i) without Intrexon&#8217;s written consent, sublicense the rights granted under Section 3.1 to an Affiliate that is a wholly-owned subsidiary of Histogenics, transfer the Intrexon Materials to such Affiliate, and/or grant such Affiliate the right to display the Intrexon Trademarks and (ii) with Intrexon&#8217;s written consent, which consent shall not be unreasonably withheld, conditioned or delayed, sublicense the rights granted under Section 3.1 to an Affiliate that is not a wholly-owned subsidiary of Histogenics, transfer the Intrexon Materials to such Affiliate, and/or grant such Affiliate the right to display the Intrexon Trademarks. In the event of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">any such grant or transfer to an Affiliate, Histogenics shall remain responsible for, and be guarantor of, the performance by any such Affiliate and shall cause such Affiliate to comply with the provisions of this Agreement in connection with such performance (as though such Affiliate were Histogenics), including any payment obligations owed to Intrexon hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>Histogenics may grant a sublicense of the rights granted under Section 3.1 (and not including a right to sublicense under this Section 3.1(c)) without Intrexon&#8217;s written consent to a Third Party licensee of any Collaboration Product that would qualify as a Retained Product under any of the criteria set forth in Section 10.4 (a) (a &#8220;<b style="font-weight:bold;">Product Sublicensee</b>&#8221;), to the extent necessary to permit such Third Party to obtain regulatory approval for, research, develop, use, import, export, make, have made, sell, offer for sale, and otherwise Commercialize and exploit that Collaboration Product (a &#8220;<b style="font-weight:bold;">Product Sublicense</b>&#8221;), provided, that (i) such Product Sublicense is expressly limited to the appropriate Collaboration Product, (ii) such Product Sublicense does not grant the Product Sublicensee any rights to Intrexon IP other than as incorporated into the Collaboration Product at the time of the Product Sublicense, (iii) such Product Sublicense does not purport to relieve Histogenics of any of its obligations under this Agreement, (iv) the Product Sublicensee agrees in writing, to which Intrexon is an express third party beneficiary, to abide by provisions consistent with the following provisions of this Agreement: Sections 3.1, 3.3, 3.4, 3.6, 3.8, 3.10, and 3.11 and Articles 6, 7, and 10, (v) the Product Sublicense is summarized to the JSC by Histogenics before execution by Histogenics and the prospective Product Sublicensee and as soon as is reasonably practical for the purpose of allowing the JSC to review and comment upon the terms and scope of the Product Sublicense agreement before execution and (vi) the Product Sublicense does not include any &#8220;Bundling&#8221;. For the purposes of this Section, &#8220;<b style="font-weight:bold;">Bundling</b>&#8221; is a situation in which all three of the following exist: (A) the offering by Histogenics or its Affiliates to a Third Party, or by a Third Party to Histogenics or its Affiliates, of any rights, goods or services with respect to a Collaboration Product (including sale of Collaboration Product itself); (B) the offering by Histogenics or its Affiliates to a Third Party, or by a Third Party to Histogenics or its Affiliates, of any other rights, goods or services (including any rights, goods or services relating to other products Histogenics or any of its Affiliates Controls, sells or otherwise disposes of); and (C) the consideration for the rights, goods or services in such offering is less than would have been customarily accepted by Histogenics, or more than would have been customarily provided by Histogenics, if such rights, goods or services were offered individually (i.e., separate from the bundle).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, Histogenics may grant a sublicense of the rights granted under Section 3.1 (and not including a right to sublicense under this Section 3.1(c)), without Intrexon&#8217;s written consent, but only with respect to [***], to [***], of any Collaboration Product that would qualify as a Retained Product under any of the criteria set forth in Section 10.4 (a), to the extent necessary to permit such Third Party to obtain regulatory approval for, research, develop, use, import, export, make, have made, sell, offer for sale, and otherwise Commercialize and exploit that Collaboration Product in [***], provided, that Histogenics meets the requirements of (i) through (v) in the paragraph immediately above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.3</b></font><b style="font-weight:bold;">Limitation on Sublicensees</b>. None of the enforcement rights under the Intrexon Patents that are granted to Histogenics pursuant to Section 6.3 shall be transferred to, or exercised by, a Sublicensee except with Intrexon&#8217;s prior written consent, which may be withheld in Intrexon&#8217;s sole discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.4</b></font><b style="font-weight:bold;">No Non-Permitted Use</b>. Histogenics hereby covenants that it shall not, nor shall it permit any Affiliate or, if applicable, (sub)licensee, to use or practice, directly or indirectly, any Intrexon IP, Intrexon Channel Technology, or Intrexon Materials for any purposes other than those expressly permitted by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.5</b></font><b style="font-weight:bold;">Exclusivity</b>. Neither Intrexon nor its Affiliates shall make the Intrexon Channel Technology, Intrexon IP or Intrexon Materials available to any Third Party for the purpose of developing or Commercializing products in the Field (except as set forth in a JSC approved work plan), and neither Intrexon nor any Affiliate shall pursue (either by itself or with a Third Party or Affiliate) the research, development or Commercialization of any product for purpose of commercial use or sale in the Field, outside of the Program. Further, neither Histogenics nor its Affiliates who are wholly-owned subsidiaries of Histogenics shall pursue (either by itself or with a Third Party or Affiliate) outside of the Program the utilization of any synthetic biology platform in conjunction with a Universal Cell Line for the research, development or Commercialization of any product for purpose of commercial use or sale in the Field where such products would compete with Collaboration Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.6</b></font><b style="font-weight:bold;">Off Label Use</b>. For purposes of clarity, (a) the use by direct or indirect purchasers or other users of Collaboration Products outside the Field (commonly referred to as &#8220;off label use&#8221;) shall not constitute a breach by Histogenics of the terms of Article 3, provided that neither Histogenics nor its Affiliate (nor any Third Party under contract with either of them) marketed or promoted Collaboration Products for such off-label use; and (b) an &#8220;off-label use by any direct or indirect purchasers or other users of products sold by Intrexon, an Intrexon Affiliate, or a Third Party sublicensee, collaborator, or partner of Intrexon shall not constitute a breach by Intrexon of the terms of Article 3, provided that neither Intrexon nor its Affiliate (nor any Third Party under contract with either of them) marketed or promoted such products for such off-label use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.7</b></font><b style="font-weight:bold;">No Prohibition on Intrexon</b>. Except as explicitly set forth in Sections 3.1 and 3.5, nothing in this Agreement shall prevent Intrexon from practicing or using the Intrexon Materials, Intrexon Channel Technology, and Intrexon IP for any purpose, and to grant to Third Parties the right to do the same. Without limiting the generality of the foregoing, Histogenics acknowledges that subject to Section 2.6, Intrexon has all rights, in Intrexon&#8217;s sole discretion, to make the Intrexon Materials, Intrexon Channel Technology (including any genetic materials used in a Collaboration Product), and Intrexon IP available to Third Party channel partners or collaborators for use in fields outside of the Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.8</b></font><b style="font-weight:bold;">Rights to Regulatory Data</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Histogenics shall own and control all regulatory data and regulatory filings relating to Commercialization of Collaboration Products. Histogenics shall provide (or shall cause an applicable Product Sublicensee to provide) to Intrexon following receipt of Intrexon&#8217;s written request full copies of all regulatory data and reports, regulatory filings, and communications from regulatory authorities to the extent that they relate specifically to Intrexon Materials that are or express ingredients for Collaboration Products. To the extent that there exist any regulatory data and reports, regulatory filings, and communications from regulatory authorities owned by Histogenics (or a Product Sublicensee) that relate both to Collaboration Products and other products produced by Histogenics (or a Product Sublicensee) inside or outside the Field, following receipt of Intrexon&#8217;s written request Histogenics shall provide (or shall cause an applicable Product Sublicensee to provide) to Intrexon copies of the portions of such data, reports, filings, and communications that relate specifically to Intrexon Materials that are or express ingredients for Collaboration Products. Subject to its ongoing obligations of exclusivity under Section 3.5 and subject to Section 2.6, Intrexon shall be permitted, directly or in conjunction with or through partners or other channel collaborators, to reference this data, reports, filings, and communications relating specifically to Intrexon Materials that are or express ingredients for Collaboration Products in regulatory filings made to obtain regulatory approval for products for use in fields outside the Field. Intrexon shall have the right to use any such information in developing and Commercializing products outside the Field and to license any Third Parties to do so. Notwithstanding the provisions of this Section 3.8, Intrexon shall not, outside of the Program, utilize any Histogenics data, reports, filings or communications in support of obtaining regulatory approval for a product indicated for use in the Field. To the extent that any Histogenics data, reports, filings or communications in this 3.8(a) contain Confidential Information such information shall be subject to the provisions of Article 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Intrexon shall provide (or shall cause an applicable Affiliate or sublicensee to provide) to Histogenics following receipt of Histogenics&#8217; written request copies of all regulatory data and reports, regulatory filings, and communications from regulatory authorities to the extent that they relate specifically to Intrexon&#8217;s cell line(s) other than the Universal Cell Line and may be reasonably useful to Histogenics or its Affiliates or sublicensees in seeking regulatory approval for one or more Collaboration Products. Histogenics shall be permitted, directly or in conjunction with or through Affiliates or other sublicensees, to reference such data, reports, filings, and communications in regulatory filings made to obtain regulatory approval for Collaboration Products in the Field subject to Section 3.2. Histogenics shall have the right to use any such information in developing and Commercializing Collaboration Products for the Field and to license any of its Affiliates and sublicensees to do so subject to Section 3.2. Intrexon shall reasonably cooperate with Histogenics to provide Histogenics with such waivers, cross reference letters, assignments, and/or other reasonable documentation as may be necessary or useful for Histogenics&#8217; full exercise of its right of access under this paragraph. To the extent that any such data, reports, filings or communications in this 3.8(b) contain Confidential Information such information shall be subject to the provisions of Article 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.9</b></font><b style="font-weight:bold;">Third Party Licenses</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>[***] shall obtain, [***], any licenses from Third Parties that are required in order to practice the Intrexon Channel Technology in the Field where the licensed intellectual property is reasonably necessary for [***] to conduct genetic and cell engineering and related analytic activities under JSC established plans for the Program (but specifically excluding intellectual property directed to any specific target genes selected by the JSC for inclusion into the Universal Cell Line) (&#8220;<b style="font-weight:bold;">Supplemental In-Licensed Third Party IP</b>&#8221;). Other than with respect to Supplemental In-Licensed Third Party IP, [***] shall be solely responsible for obtaining, [***], any licenses from Third Parties that [***] determines, in its sole discretion, are required in order to lawfully make, use, sell, offer for sale, or import Collaboration Products (&#8220;<b style="font-weight:bold;">Complementary In-Licensed Third Party IP</b>&#8221;). Supplemental In-Licensed Third Party IP and Complementary In-Licensed Third Party IP are collectively referred to as &#8220;<b style="font-weight:bold;">In-Licensed Program IP</b>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>In the event that either Party desires to license from a Third Party any Supplemental In-Licensed Third Party IP or Complementary In-Licensed Third Party IP, such Party shall so notify the other Party, and the IPC shall discuss such In-Licensed Program IP and its applicability to the Collaboration Products and to the Field. As provided above in Section 3.8(a), [***] shall have the sole right and responsibility to pursue a license under Supplemental In-Licensed Third Party IP, and [***] hereby covenants that it shall not itself directly license such Supplemental In-Licensed Third Party IP at any time, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided that</u> [***] may (but shall not be obligated to) obtain such a license directly if the Third Party owner or licensee of such Supplemental In-Licensed Third Party IP brings an infringement action against [***] or its Affiliates or threatens to bring such action (including, without limitation, if such threats would reasonably be considered to subject the Third Party owner or licensee to declaratory judgment jurisdiction) and, after written notice to [***] of such action, [***] fails to obtain a license to such Supplemental In-Licensed Third Party IP using Diligent Efforts within ninety (90) days after such notice. Following the IPC&#8217;s discussion of any Complementary In-Licensed Third Party IP, subject to Section 3.8(c), [***] shall have the right to pursue a license under Complementary In-Licensed Third Party IP, at [***] sole expense. For the avoidance of doubt, [***] may at any time obtain a license under Complementary In-Licensed Third Party IP outside the Field, at [***] sole expense, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided that</u> if [***] decides to seek to obtain such a license, it shall use reasonable efforts to coordinate its licensing activities in this regard with [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>[***] shall provide the proposed terms of any license under Complementary In-Licensed Third Party IP and the final version of the definitive license agreement for any Complementary In-Licensed Third Party IP to the IPC for review and discussion prior to signing, and shall consider [***] comments thereto in good faith. To the extent that [***] obtains a license under Supplemental In-Licensed Third Party IP, [***] shall provide the final version of the definitive license agreement for such Supplemental In-Licensed Third Party IP to the IPC. If [***] acquires rights under any Supplemental In-Licensed Third Party Program IP outside the Field, it will do so on a non-exclusive basis unless it obtains the prior written consent of Intrexon for such license outside the Field to be exclusive. Any Party that is pursuing a license to any In-Licensed Program IP with respect to the Field under this Section 3.8 shall keep the other Party reasonably informed of the status of any negotiations relating thereto. For purposes of clarity, (i) any costs incurred by [***] in obtaining and maintaining licenses to Supplemental In-Licensed Third Party IP shall be borne solely by [***], and (ii) any costs incurred by [***] in obtaining and maintaining licenses to Complementary In-Licensed Third Party IP (and, to the limited extent provided in subsection (b), Supplemental In-Licensed Third Party IP) shall be borne solely by [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>For any Third Party license under which [***] or its Affiliates who are wholly-owned subsidiaries of [***] obtain a license under Patents claiming inventions or know-how specific to or used or incorporated into the development, manufacture, and/or Commercialization of Collaboration Products, [***] shall use commercially reasonable efforts to ensure that [***] will have the ability, to the extent required by [***], to assign such agreement to [***] or grant a sublicense to [***] thereunder (having the scope set forth in [***]).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>The licenses granted to Histogenics under Section 3.1 may include sublicenses under Intrexon IP that has been licensed to Intrexon by one or more Third Parties. Any such sublicenses are subject to the terms and conditions set forth in the applicable upstream license agreement, subject to the cost allocation set forth in Section 3.9(c), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided that</u> Intrexon shall either provide unredacted copies of such upstream license agreements to Histogenics or shall disclose in writing to Histogenics all of such terms and conditions that are applicable to Histogenics, in each case prior to or on the date on which the sublicense takes effect. Histogenics shall not be</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">responsible for complying with any provisions of such upstream license agreements unless, and to the extent that, such provisions have been disclosed to Histogenics as provided in the preceding sentence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font>If either Party receives written notice from a Third Party concerning activities of a Party taken in conjunction with performance of obligations under this Agreement, which notice alleges infringement by a Party of, or offers license under, Patents or other intellectual property rights owned or controlled by that Third Party, the receiving Party shall inform the other Party thereof within five (5) business days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.10</b></font><b style="font-weight:bold;">Licenses to Intrexon</b>. Subject to the terms and conditions of this Agreement, Histogenics hereby grants to Intrexon a non-exclusive, worldwide, fully-paid, royalty-free license, under any applicable Patents or other intellectual property Controlled by Histogenics or its Affiliates who are wholly-owned subsidiaries of Histogenics, solely to the extent necessary for Intrexon to conduct those responsibilities assigned to it under this Agreement, which license shall be sublicensable solely to Intrexon&#8217;s Affiliates or to any Intrexon subcontractors as permitted in accord with Section 4.5 or as otherwise permitted to be used by Intrexon in conjunction with support services under Section 4.6 (Subject to JSC research plan approval). Intrexon shall ensure that each of its Affiliates and subcontractors complies with all obligations imposed on Intrexon under this Agreement. Any breach of any such obligations by any Affiliate or subcontractor shall be deemed a breach by Intrexon of its obligations under this Agreement, and Intrexon shall be responsible and liable for any breach of any such obligations by any of its Affiliates or subcontractors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.11</b></font><b style="font-weight:bold;">Restrictions Relating to Intrexon Materials</b>. Histogenics and its permitted sublicensees shall use the Intrexon Materials solely for purposes of the Program and not for any other purpose without the prior written consent of Intrexon. With respect to the Intrexon Materials comprising Intrexon&#8217;s vector assembly technology, Histogenics shall not, and shall ensure that Histogenics personnel and permitted sublicensees do not, except as otherwise permitted in this Agreement (a) distribute, sell, lend or otherwise transfer such Intrexon Materials to any Third Party; (b) co-mingle such Intrexon Materials with any other proprietary biological or chemical materials without Intrexon&#8217;s written consent; or (c) analyze such Intrexon Materials or in any way attempt to reverse engineer or sequence such Intrexon Materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">OTHER RIGHTS AND OBLIGATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.1</b></font><b style="font-weight:bold;">Development and Commercialization</b>. Subject to Sections 4.5 and 4.6, Histogenics shall be solely responsible for the development and Commercialization of Collaboration Products. Histogenics shall be responsible for all costs incurred in connection with the Program except that Intrexon shall be responsible for the following: (a) if applicable, costs of establishing manufacturing capabilities and facilities in connection with Intrexon&#8217;s manufacturing obligation under Section 4.5 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing the applicable portion of a Collaboration Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (<i style="font-style:italic;">i</i>.<i style="font-style:italic;">e</i>., platform improvements) but, for clarity, excluding research described in Section 4.6 or research requested by the JSC for the development of a Collaboration Product (which research costs shall be reimbursed by Histogenics); (c) [***]; (d) costs of filing, prosecution and maintenance of Intrexon Patents; and (e) any other costs mutually agreed upon by the Parties in writing as being Intrexon&#8217;s responsibility. The costs encompassed within clause (a) of the previous sentence shall include, if applicable, the scale-up of Intrexon Materials for generating data for regulatory approval submissions and Commercialization of Collaboration Products undertaken pursuant to Section 4.5, which shall be at Intrexon&#8217;s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Histogenics (with Intrexon&#8217;s consent).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.2</b></font><b style="font-weight:bold;">Information and Reporting</b>. Histogenics will keep Intrexon informed about Histogenics&#8217; efforts to develop and Commercialize Collaboration Products, including reasonable and accurate summaries of Histogenics&#8217; (and its Affiliates&#8217; and, if applicable, (sub)licensees&#8217;) development plans (as updated) for Collaboration Products, including regulatory plans, marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, significant developments in the development and/or Commercialization of the Collaboration Products, including initiation or completion of a regulatory trial, submission</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, product safety event, receipt of regulatory approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Histogenics shall also provide to Intrexon copies of all final regulatory documents and reports, and regulatory correspondence and filings generated by Histogenics, to the extent that they relate specifically to Intrexon Materials that are or express ingredients for Collaboration Products, as soon as practical following receipt of Intrexon&#8217;s written request for such materials. Intrexon will keep Histogenics informed about Intrexon&#8217;s efforts to undertake discovery-stage research for the Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC, such disclosures by Histogenics and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Collaboration Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.3</b></font><b style="font-weight:bold;">Regulatory Matters</b>. At such time as the JSC authorizes the initiation of active regulatory activities for Collaboration Products, the RAC shall be formed and constituted to actively manage such regulatory activities. Histogenics shall thereafter own and maintain, at its own cost, all regulatory filings and regulatory approvals for Collaboration Products that Histogenics is developing or Commercializing pursuant to this Agreement. As such, Histogenics shall be responsible for reporting all adverse events related to such Collaboration Products to the appropriate regulatory authorities in the relevant countries, in accordance with the applicable laws and regulations of such countries. To the extent that Intrexon will itself develop, or in collaboration with other third parties develop, Intrexon Materials outside of the Field, Intrexon may request that Histogenics and Intrexon establish and execute a separate safety data exchange agreement, which agreement will address and govern the timely exchange of safety information generated by Histogenics, Intrexon, and relevant third parties with respect to specific Intrexon Materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.4</b></font><b style="font-weight:bold;">Diligence</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Histogenics shall use, and shall require its sublicensees to use, Diligent Efforts to develop and Commercialize Collaboration Products in accordance with plans for projects mutually agreed upon by the parties through the JSC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Without limiting the generality of the foregoing, Intrexon may, from time to time, notify Histogenics via the JSC that it believes it has identified a Superior Therapy, and in such case Intrexon shall provide to Histogenics its then-available information about such product and reasonable written support for its conclusion that the product constitutes a Superior Therapy. Promptly thereafter, Histogenics and Intrexon shall discuss and come to a mutual agreement regarding one or more tests that will be conducted to try to validate Intrexon&#8217;s conclusion that the product constitutes a Superior Therapy. If the parties mutually agree that Intrexon&#8217;s conclusion is validated by such test(s), then Histogenics shall have the following obligations with respect to such proposed Superior Therapy: (i) within sixty (60) days after such notification, Histogenics shall prepare and deliver to the JSC for review and approval a development plan detailing how Histogenics will pursue the Superior Therapy (including a proposed budget); (ii) Histogenics shall revise the development plan as directed by the JSC; and (iii) following approval of the development plan by the JSC, Histogenics shall use Diligent Efforts to pursue the development of the Superior Therapy under the Program in accordance with such development plan. If Histogenics fails to comply with the foregoing obligations, or if Histogenics unreasonably exercises its casting vote at the JSC to either (x) prevent the approval of a development plan for a Superior Therapy; (y) delay such approval more than sixty (60) days after delivery of the development plan to the JSC; or (z) approve a development plan that is insufficient in view of the nature and magnitude of the opportunity presented by the Superior Therapy, then Intrexon shall have the termination right set forth in Section 10.2(c) (Subject to the limitation set forth therein). For clarity, any dispute arising under this 4.4, including any dispute as to whether a proposed project constitutes a Superior Therapy (as with any other dispute under this Agreement) shall be Subject to dispute resolution in accordance with Article 11, and (ii) Intrexon shall have no right to terminate this Agreement pursuant to Section 10.2(c), and the cure period provided in Section 10.2(c) shall be stayed, during the period any such dispute is Subject to such dispute resolution process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>The activities of Histogenics&#8217; Affiliates and any permitted sublicensees shall be attributed to Histogenics for the purposes of evaluating Histogenics&#8217; fulfillment of the obligations set forth in this Section 4.4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.5</b></font><b style="font-weight:bold;">Manufacturing</b>. The JSC will determine the strategy for manufacturing of the Collaboration Product giving due consideration to the concerns of either Party regarding the protection of its proprietary Information (including know-how, trade secrets, and Confidential Information) and other intellectual property rights (including Patents, trademarks, and biomaterials). Intrexon shall have the option to propose to the JSC that Intrexon should perform (or have its preferred contract manufacturer perform) relevant manufacturing activities in connection with a Collaboration Product to the extent that such activities may be reasonably expected to materially impact Intrexon&#8217;s rights in and to Intrexon Channel Technology, Intrexon IP, and Intrexon Materials. To the extent that Intrexon so proposes under this Section 4.5, Histogenics, if it consents to such proposal, such consent not to be unreasonably withheld, may request that the Parties establish and execute a separate manufacturing and supply agreement, which agreement will establish and govern the production, quality assurance, and regulatory activities associated with manufacture of the relevant materials of the Parties. Any manufacturing Information or Intrexon Materials transferred hereunder to Histogenics or its contract manufacturer shall not be further transferred to any Third Party, including any sublicensee (including a Product Sublicensee), or any Histogenics Affiliate without the prior written consent of Intrexon, except as otherwise permitted under Section 3.2 and provided, however, that Intrexon shall not unreasonably withhold such consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.6</b></font><b style="font-weight:bold;">Support Services</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>The JSC will meet promptly following the Effective Date and prepare and approve the initial Work Plan under which Intrexon will provide support services to Histogenics for the research and development of Collaboration Products under the Program, which initial Work Plan may be amended from time to time by the JSC. The Work Plan shall set forth activities to be undertaken by Intrexon in support of development of Collaboration Products, deliverables, timelines, and estimated costs (including a detailed budget that shall include all estimated Fully Loaded Costs). Additionally, from time to time, on an ongoing basis, Histogenics may request, or Intrexon may propose, that Intrexon perform certain additional support services with respect to researching and developing new Collaboration Products or improving the manufacturing or processing methods for any existing Collaboration Products. To the extent that Intrexon perform such support services under this Section 4.6(a) that are requested by Histogenics and/or approved by the JSC, it is understood that Intrexon would be compensated for such services in cash payments from Histogenics based upon Intrexon&#8217;s Fully Loaded Cost in connection with such services as set forth in Section 4.6(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Prior to achievement of the IND Acceptance Milestone Event, Histogenics will compensate Intrexon for such support services under this Section 4.6 with cash equal to fifty percent (50%) of Intrexon&#8217;s invoiced Fully Loaded Cost in connection with such services. Within ninety (90) days of achievement of the first instance of the IND Acceptance Milestone Event, Histogenics shall pay Intrexon an additional (i.e., a second) fifty percent (50%) of Intrexon&#8217;s prior invoiced Fully Loaded Cost in connection with such services (i.e., such that Intrexon will have in total been compensated for one hundred percent (100%) of the Fully Loaded Costs that were invoiced prior to the first occurrence of the IND Acceptance Milestone Event), with cash. Following the first achievement of the IND Acceptance Milestone Event, unless otherwise agreed upon by the parties, Histogenics will thereafter compensate Intrexon for such support services under this Section 4.6 with cash payments equal to one hundred percent (100%) of Intrexon&#8217;s invoiced Fully Loaded Cost in connection with such services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>Under this Section 4.6, Intrexon shall keep the JSC reasonably apprised of any expected material deviations from budgeted costs under JSC-approved research projects and Work Plans as such deviations arise and/or as Intrexon becomes aware of the threat of such deviation, provided that in no event will Intrexon provide Histogenics with a report of budgeted costs to actual costs on such projects and Work Plans less frequently than once per calendar year. In the event that, in performance under a JSC-approved project or Work Plan is projected to exceed more than [***] of the amount budgeted or Intrexon reasonably determines that the JSC-established budget is insufficient to complete performance of the tasks under the project, it will notify the JSC such that the JSC can appropriately amend the respective project or Work Plan and Intrexon may discontinue performance under such project plan until the JSC has so amended the project or Work Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.7</b></font><b style="font-weight:bold;">Compliance with Law</b>. Each Party shall comply, and shall ensure that its Affiliates, (sub)licensees and Third Party contractors comply, with all applicable laws, regulations, and guidelines applicable to the Program, including without limitation those relating to the transport, storage, and handling of Intrexon Materials and Collaboration Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.8</b></font><b style="font-weight:bold;">Trademarks and Patent Marking</b>. To the extent Histogenics elects to use Intrexon Trademarks in connection with Collaboration Products and to the extent permitted by applicable law and regulations, Histogenics shall ensure that the packaging, promotional materials, and labeling for Collaboration Products, as appropriate, shall carry, in a conspicuous location, the applicable Intrexon Trademark(s), subject to Histogenics&#8217; reasonable approval of the size, position, and location thereof. Consistent with the U.S. patent laws, Histogenics shall ensure that Collaboration Products, or their respective packaging or accompanying literature as appropriate, bear applicable and appropriate patent markings for Intrexon Patent numbers. Histogenics shall provide Intrexon with copies of any materials containing the Intrexon Trademarks or such patent markings prior to using or disseminating such materials, in order to obtain Intrexon&#8217;s approval thereof, which approval shall not be unreasonably withheld, conditioned or delayed. Histogenics&#8217; use of the Intrexon Trademarks and patent markings shall be subject to prior review and approval of the IPC. Histogenics acknowledges Intrexon&#8217;s sole ownership of the Intrexon Trademarks and agrees not to take any action inconsistent with such ownership. Histogenics covenants that it shall not use any trademark confusingly similar to any Intrexon Trademarks in connection with any products (including any Collaboration Product). From time to time during the Term, Intrexon shall have the right to obtain from Histogenics samples of Collaboration Product sold by Histogenics or its Affiliates or Sublicensees, or other items which reflect public uses of the Intrexon Trademarks or patent markings, solely for the purpose of inspecting the quality of such Collaboration Products, the use of the Intrexon Trademarks, or the accuracy of the patent markings. In the event that Intrexon inspects under this Section 4.8, Intrexon shall notify the result of such inspection to Histogenics in writing promptly thereafter. Histogenics shall comply with reasonable policies provided by Intrexon in writing from time-to-time at least thirty (30) days prior to the due date of the obligation to comply to maintain the goodwill and value of the Intrexon Trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.9</b></font><b style="font-weight:bold;">Equity Purchase Commitment</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Subject to Section 4.9(b), if requested by Histogenics, Intrexon will participate in a Qualified Financing (as hereinafter defined) conducted by Histogenics and will purchase as part of, or in connection with, such Qualified Financing, $15,000,000 worth of Common Stock or other securities issued and sold by Histogenics in the Qualified Financing (the &#8220;<b style="font-weight:bold;">Equity Purchase Commitment</b>&#8221;), provided, however, that in no event shall Intrexon have any obligation to purchase more than that number of shares that, together with any other shares of Common Stock held by Intrexon, results in Intrexon&#8217;s aggregate ownership of Histogenix&#8217;s Common Stock following the Qualified Financing equaling or exceeding 25% of the outstanding Common Stock of Histogenics. For the purposes of this Section 4.9, a &#8220;<b style="font-weight:bold;">Qualified Financing</b>&#8221; shall mean a sale by Histogenics of Common Stock or equity securities convertible into Common Stock in an underwritten public offering raising gross proceeds of at least $50,000,000, including the Equity Purchase Commitment. The price per share paid by Intrexon in any such Qualified Financing shall be the same as that paid by the other investors in such Qualified Financing, and Intrexon shall receive securities of the same type and with the same rights, preferences and privileges as the other investors in such Qualified Financing, including, for example, any warrant coverage, subject to the execution by Intrexon of the investment documents entered into by the other investors in the Qualified Financing. Notwithstanding the foregoing, in the event that counsel to Histogenics or counsel to any underwriter in the Qualified Financing advises Histogenics that such participation is not permissible under and in compliance with applicable securities laws (including without limitation Section 5 of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(i)</b><font style="display:inline-block;width:26.56pt;"></font>Intrexon shall be under no obligation to participate in such public offering but may, upon receipt of the prospectus and other offering documents prepared by Histogenics in connection with such public offering, at its election, do so in an amount equal to the Equity Purchase Commitment. Upon such election, Histogenics shall permit Intrexon to participate in such public offering in the amount of the Equity Purchase Commitment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(ii)</b><font style="display:inline-block;width:23.78pt;"></font>In the event that Intrexon elects, in accordance with Section 4.9(a)(i), not to participate in a public offering, Intrexon shall be obligated to purchase an amount equal to the Equity Purchase Commitment in a private placement and not in such public offering. In any such private placement: (A) the offer of the securities in such private placement shall be made on the same terms and conditions as the offer of the securities in the public offering, (B) the closing of the private placement shall occur concurrently with the closing of the public offering, and (C) Histogenics shall provide registration rights in a form similar to those set forth in the Form of Equity Terms under the heading &#8220;Registration Rights&#8221; with respect to the securities purchased in the private placement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Notwithstanding the foregoing, Intrexon shall not be obligated to purchase shares of the Company&#8217;s Common Stock pursuant to this Section 4.9 unless:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(i)</b><font style="display:inline-block;width:26.56pt;"></font>the Company shall then be in substantial compliance with its obligations under this Agreement, and such Agreement shall not have been terminated, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(ii)</b><font style="display:inline-block;width:23.78pt;"></font>the Qualified Financing shall have closed within twelve (12) months following the date of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.1</b></font><b style="font-weight:bold;">Technology Access Fee</b>. In partial consideration for Histogenics&#8217; appointment as an exclusive channel collaborator in the Field and the other rights granted to Histogenics hereunder and as an access fee for commercial license rights to the Intrexon IP granted under Section 3.1, Histogenics shall pay to Intrexon a one time payment valued at ten million United States dollars ($10,000,000) (the &#8220;<b style="font-weight:bold;">Technology Access Fee</b>&#8221;). The Technology Access Fee shall be paid in the form of the Note executed and delivered by Histogenics on the Effective Date. The receipt by Intrexon of the executed Note for the Technology Access Fee on the Effective Date and compliance by Histogenics with regard to the maturity and payment provisions set forth in the Note are both conditions subsequent to the effectiveness of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.2</b></font><b style="font-weight:bold;">Royalty Payments for Collaboration Products</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>No later than thirty (30) days after each calendar quarter in which there is positive aggregate Gross Profit arising from the sale in the Field and Territory of Collaboration Products, Histogenics shall pay to Intrexon [***] of the aggregate Gross Profit for such Collaboration Products during such calendar quarter. For purposes of clarity, in the event that there is negative Gross Product for a particular Collaboration Product in any calendar quarter, (i) neither Histogenics nor Intrexon shall owe any payments hereunder with respect to such Collaboration Product and (ii) any such negative Gross Profit that results from Excess Product Liability Costs may be carried forward to future calendar quarters and offset against positive Gross Profit in such future calendar quarters for the same Collaboration Product; provided, that, except as set forth in the preceding sentence, Histogenics shall not be permitted to carry forward any negative Gross Profit to subsequent quarters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>No later than thirty (30) days after each calendar quarter in which Histogenics or any Histogenics Affiliate receives Sublicensing Revenue, Histogenics shall pay to Intrexon [***] of such Sublicensing Revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.3</b></font><b style="font-weight:bold;">Milestones</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Histogenics Commercialization Milestones</b>. Upon certain instances of attainment of certain Commercialization Milestone Events by a Collaboration Product (whether such attainment is achieved by Histogenics or by a permitted sublicensee), Histogenics has agreed to pay Intrexon milestone payments as set forth in this Section 5.3. The milestone payments are each payable, at Histogenics&#8217; election subject to 5.3(b), either in cash or in shares of Histogenics&#8217; common stock (using Fair Market Value to calculate the number of shares to be issued to Intrexon in lieu of cash). The specific milestone payments due to Intrexon upon achievement of the various Commercialization Milestone Events are set forth in Sections 5.3(a)(i) through 5.3(a)(v) below. Each of the Commercialization Milestone Events under Sections 5.3(a)(i) through 5.3(a)(iv) below will trigger payment by Histogenics only once (i.e., only the first time each such Commercialization Milestone Event in question is achieved), and Histogenics will not be obligated to make any milestone payment for any given Collaboration Product if that same milestone payment had been previously paid to Intrexon for any previous Collaboration Product having achieved previously the same Commercialization Milestone Event. The Commercialization Milestone Event under Section 5.3(a)(v) below, however, will trigger payment by Histogenics each time it is achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(i)</b><font style="display:inline-block;width:26.56pt;"></font>Histogenics shall pay Intrexon a milestone payment of five hundred thousand United States dollars ($500,000) within thirty (30) days of the first instance of the achievement of the IND Filing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Milestone Event, said payment being made, at Histogenics&#8217; option subject to Sections 5.3(b) and 5.3(c), either in cash or in shares of Histogenics&#8217; common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(ii)</b><font style="display:inline-block;width:23.78pt;"></font>Histogenics shall pay Intrexon a milestone payment of two million five hundred thousand United States dollars ($2,500,000) within thirty (30) days of the first instance of the achievement of the IND Acceptance Milestone Event, said payment being made, at Histogenics&#8217; option subject to Section 5.3(b) and 5.3(c), either in cash or in shares of Histogenics&#8217; common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(iii)</b><font style="display:inline-block;width:21pt;"></font>Histogenics shall pay Intrexon a milestone payment of three million United States dollars ($3,000,000) within thirty (30) days of the first instance of the achievement of the Phase III Milestone Event, said payment being made, at Histogenics&#8217; option subject to Section 5.3(b) and 5.3(c), either in cash or in shares of Histogenics&#8217; common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(iv)</b><font style="display:inline-block;width:21.56pt;"></font>Histogenics shall pay Intrexon a milestone payment of five million United States dollars ($5,000,000) within thirty (30) days of the first instance of the achievement of the Approval Milestone Event, said payment being made, at Histogenics&#8217; option subject to Section 5.3(b) and 5.3(c), either in cash or in shares of Histogenics&#8217; common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(v)</b><font style="display:inline-block;width:24.34pt;"></font>Histogenics shall pay Intrexon a milestone payment of one million United States dollars ($1,000,000) within thirty (30) days of each instance of the achievement of the Amended Approval Milestone Event, said payment being made, at Histogenics&#8217; option subject to Section 5.3(b) and 5.3(c), either in cash or in shares of Histogenics&#8217; common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Commercialization Milestones After Company Sale</b>. In the event that Histogenics consummates a Company Sale prior to paying to Intrexon any one or more of the respective milestone payments set forth in Sections 5.3(a)(i) through 5.3(a)(v) and this Agreement is transferred or assigned to the buyer in connection with such Company Sale, then all subsequent payments for Commercialization Milestone Events shall thereafter each be payable only in cash to Intrexon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Product Sublicense Milestones</b>. If (A) a Commercialization Milestone Event occurs that gives rise to a right for Intrexon to receive a payment from Histogenics under Section 5.3(a), (B) that Commercialization Milestone Event is achieved by a Collaboration Product licensed to a Product Sublicensee under a respective Product Sublicense, and (C) Histogenics is due to receive a milestone payment from the Product Sublicensee for achievement of that same (or substantially similar) Commercialization Milestone Event by the sublicensed Collaboration Product under the respective Product Sublicense, then Intrexon may elect at its own discretion to waive that particular milestone payment from Histogenics for that particular Commercialization Milestone Event and instead designate the amount of the payment due to Histogenics from the Product Sublicensee for achievement of that same (or substantially similar) Commercializaton Milestone Event as Sublicensing Revenue for which Intrexon will be entitled to receive revenue sharing under Section 5.2(b). If it so elects under this Section 5.3(b), Intrexon must notify Histogenics in writing of its waiver of the specific milestone under the above Section 5.3(a) and its concurrent election to share the milestone payment due from the Product Sublicensee as Sublicensing Revenue at least five (5) business days prior to the deadline for Histogenics to make a payment for the waived milestone payment. The actual receipt by Intrexon of its full share of the Product Sublicensee milestone payment as Sublicensing Revenue will be a condition subsequent to making final any waiver of Intrexon&#8217;s rights to receive the respective milestone payment otherwise due from Histogenics under Section 5.3(a). Histogenics will pay Intrexon any amount due under this Section 5.3(b) within the later of (i) thirty (30) days from underlying Commercialization Milestone Event, or (ii) ten (10) days following the date stipulated in the underlying Product Sublicense for Histogenics to receive the milestone payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">Histogenics Sales Milestones</b>. The Parties additionally agree that the sales based milestones set forth below in Sections 5.3(d)(i) through 5.3(d)(iii) shall be paid by Histogenics to Intrexon. Each milestone shall be payable only once upon the first instance of achievement thereof, and the respective payment for such will be due to be paid to Intrexon within thirty (30) days following the completion of the calendar quarter in which the respective sales milestone was achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(i)</b><font style="display:inline-block;width:26.56pt;"></font>Upon the first instance that cumulative annual Net Sales for Collaboration Products reaches three hundred million United States dollars ($300,000,000), Histogenics shall pay Intrexon a milestone payment of five million United States dollars ($5,000,000) within the time frames set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(ii)</b><font style="display:inline-block;width:23.78pt;"></font>Upon the first instance that cumulative annual Net Sales for Collaboration Products reaches six hundred and fifty million United States dollars ($650,000,000), Histogenics shall pay Intrexon a milestone payment of seven million five hundred thousand United States dollars ($7,500,000) within the time frames set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(iii)</b><font style="display:inline-block;width:21pt;"></font>Upon the first instance that cumulative annual Net Sales for Collaboration Products reaches one billion United States dollars ($1,000,000,000), Histogenics shall pay Intrexon a milestone payment of ten million United States dollars ($10,000,000) within the time frames set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.4</b></font><b style="font-weight:bold;">Equity Agreement Controls</b>. All issuances of equity interests to Intrexon in accordance with this Agreement shall be in accordance with the terms and conditions of the Note, with regard to the Technology Access Fee, and definitive stock issuance agreements on Histogenics&#8217; standard forms (including standard representations and warranties of Histogenics and Intrexon), as well as, the Equity Agreement Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.5</b></font><b style="font-weight:bold;">Method of Payment</b>. Payments due to Intrexon under this Agreement shall be paid in United States dollars by wire transfer to a bank in the United States designated in writing by Intrexon. All references to &#8220;dollars&#8221; or &#8220;$&#8221; herein shall refer to United States dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.6</b></font><b style="font-weight:bold;">Payment Reports and Records Retention</b>. Within thirty (30) days after the end of each calendar quarter during which, with respect to Collaboration Products, a positive Gross Profit or Sublicensing Revenue have been generated or received, a Commercialization Milestone Event has been achieved, a sales milestone under Section 5.3(d) has been met, or a negative Gross Profit has occurred, Histogenics shall deliver to Intrexon a written report that shall contain at a minimum for the applicable calendar quarter:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>gross sales of each Collaboration Product on a country-by-country basis;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>itemized calculation of Net Sales and Gross Profit, showing all applicable deductions and underlying calculations of COGS;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>itemized calculation of Sublicensing Revenue;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>the amount of any negative Gross Profit for the applicable calendar quarter, and any negative Gross Profit amount carried forward from a prior quarter and applied during the present quarter (as per Section 5.2(a));</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>the amount of the payment (if any) due pursuant to each of Sections 5.2(a) and 5.2(b);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font>the amount of the payment (if any) made by Histogenics, or that has become due by the achievement of milestones during the preceding calendar quarter under Section 5.3;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(g)</b></font>the amount of taxes, if any, withheld to comply with any applicable law; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(h)</b></font>the exchange rates used in any of the foregoing calculations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For three (3) years after each sale or other commercial use of Collaboration Product, or after incurring any component item Histogenics incorporated into its calculations above, Histogenics shall keep (and shall ensure that its Affiliates and, if applicable, (sub)licensees shall keep) complete and accurate records of such sales, commercial use, or component item in sufficient detail to confirm the accuracy of the payment calculations hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.7</b></font><b style="font-weight:bold;">Audits</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Upon the written request of Intrexon, Histogenics shall permit an independent certified public accounting firm of internationally recognized standing selected by Intrexon, and reasonably acceptable to Histogenics, to have access to and to review, during normal business hours and upon no less than thirty (30) days prior written notice, the applicable records of Histogenics and its Affiliates to verify the accuracy and timeliness of the reports and payments made by Histogenics under this Agreement. Such review may cover the records for sales made in any calendar year ending not more than three (3) years prior to the date of such request. The accounting firm shall disclose to both Parties whether the royalty reports and/or know-how reports conform to the provisions of this Agreement and/or US GAAP, as applicable, and the specific details concerning any discrepancies. Such audit may not be conducted more than once in any calendar year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>If such accounting firm concludes that additional amounts were owed during such period, Histogenics shall pay additional amounts, with interest from the date originally due as set forth in Section 5.9, within thirty (30) days of receipt of the accounting firm&#8217;s written report. If the amount of the underpayment is greater than five percent (5%) of the total amount actually owed for the period audited, then Histogenics shall in addition reimburse Intrexon for all costs related to such audit; otherwise, Intrexon shall pay all costs of the audit. In the event of overpayment, any amount of such overpayment shall be fully creditable against amounts payable for the immediately succeeding calendar quarter(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>Intrexon shall (i) treat all information that it receives under this Section 5 in accordance with the confidentiality provisions of Article 7 and (ii) cause its accounting firm to enter into an acceptable confidentiality agreement with Histogenics obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement, in each case except to the extent necessary for Intrexon to enforce its rights under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.8</b></font><b style="font-weight:bold;">Taxes</b>. The Parties will cooperate in good faith to obtain the benefit of any relevant tax treaties to minimize as far as reasonably possible any taxes which may be levied on any amounts payable hereunder. Histogenics shall deduct or withhold from any payments any taxes that it is required by applicable law to deduct or withhold. Notwithstanding the foregoing, if Intrexon is entitled under any applicable tax treaty to a reduction of the rate of, or the elimination of, applicable withholding tax, it may deliver to Histogenics or the appropriate governmental authority (with the reasonable assistance of Histogenics to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Histogenics of its obligation to withhold tax, and Histogenics shall apply the reduced rate of withholding tax, or dispense with withholding tax, as the case may be, provided that Histogenics has received evidence of Intrexon&#8217;s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least fifteen (15) days prior to the time that the payment is due. If, in accordance with the foregoing, Histogenics withholds any amount, it shall make timely payment to the proper taxing authority of the withheld amount, and send to Intrexon proof of such payment within forty-five (45) days following that latter payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.9</b></font><b style="font-weight:bold;">Late Payments</b>. Any undisputed amount owed by Histogenics to Intrexon under this Agreement that is not paid within the applicable time period set forth herein shall accrue interest at the lower of (a) two percent (2%) per month, compounded, or (b) the highest rate permitted under applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">INTELLECTUAL PROPERTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.1</b></font><b style="font-weight:bold;">Ownership</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Subject to the license granted under Section 3.1, all rights, technology, and intellectual property, including the Intrexon IP, (A) Controlled by Intrexon as of the Effective Date, or (B) thereafter developed by Intrexon independent of the Program and independent of Histogenics Platform Technology, shall be owned by and remain the sole property of Intrexon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>All rights, technology, and intellectual property (A) Controlled by Histogenics or any of its Affiliates that are wholly-owned subsidiaries as of the Effective Date (but excluding any Intrexon IP licensed hereunder), or (B) thereafter developed by Histogenics or any of its Affiliates that are wholly-owned subsidiaries independent of the Program, Intrexon Channel Technology, Intrexon IP or Intrexon Materials, shall be owned by</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and remain the sole property of Histogenics and such Affiliates (the &#8220;<b style="font-weight:bold;">Histogenics Independent IP</b>&#8221;). For clarity, the Histogenics Independent IP includes (i) the Histogenics Platform Technology and Histogenics Patents and (ii) any and all improvements and modifications to, and any and all derivatives of, Histogenics Platform Technology conceived, reduced to practice or made by or on behalf of Histogenics or any of its Affiliates that are wholly-owned subsidiaries, provided, that such improvements or modifications are not based upon, do not incorporate, and do not require the use of, Intrexon IP, the Intrexon Channel Technology or Intrexon Materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>Histogenics and/or Intrexon may solely or jointly conceive, and/or reduce to practice, inventions, processes, techniques, and other technology, whether or not patentable, in the course of performing the Program (collectively &#8220;<b style="font-weight:bold;">Inventions</b>&#8221;). Each Party shall promptly provide the IPC with a detailed written description of any such Inventions to enable the IPC to reasonably identify those Inventions that relate to the Field. Inventorship shall be determined in accordance with United States patent laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>As between the Parties, and excluding Joint Program Inventions, Intrexon shall solely own all right, title and interest in all Inventions (together with all Patent rights and other intellectual property rights therein) that (A) (i) solely relate to use of the Intrexon Channel Technology, Intrexon IP, or Intrexon Materials, and/or (ii) relate generally to the discovery, design and development of markers, cell processing techniques and lines, complex transgenes and vectors, and production processes, and (B) in any case, that are not based upon and do not incorporate or require the use of the Histogenics Independent IP or Histogenics Patents (collectively, the &#8220;<b style="font-weight:bold;">Channel-Related Program IP</b>&#8221;). For clarity and notwithstanding the foregoing, the Universal Cell Line and any other cell lines delivered to Histogenics under the Program, and all intellectual property rights therein, shall constitute Channel-Related Program IP and shall therefore be owned by Intrexon. In addition, notwithstanding the first sentence of this Section, all Inventions (together with all Patent rights and other intellectual property rights therein) that (a) relate generally to cell processing techniques and lines, (b) that are not based upon, do not incorporate, or do not require the use of, Intrexon IP, the Intrexon Channel Technology or Intrexon Materials and (c) were invented solely by Histogenics shall be deemed Histogenics Platform Inventions. Histogenics hereby assigns and agrees to assign to Intrexon all of Histogenics&#8217;s interests in and to any and all Channel-Related Program IP, and shall perform or have performed any and all acts reasonably necessary to assist Intrexon in perfecting its rights in and to any and all of the Channel-Related Program IP (not including any Histogenics Independent IP that may be included therein), including executing or having executed any documents affecting the appropriate assignment to Intrexon to the extent reasonably requested by Intrexon at Intrexon&#8217;s request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>Subject to the foregoing, and excluding Joint Program Inventions, Histogenics shall solely own all right, title and interest in all Inventions (together with all Patent rights and other intellectual property rights therein) that (A) (i) solely relate to use of the Histogenics Independent IP or Histogenics Patents, and (ii) that are not based upon, do not incorporate, or do not require the use of, Intrexon IP, the Intrexon Channel Technology or Intrexon Materials, and/or (B) were invented solely by Histogenics (collectively, &#8220;<b style="font-weight:bold;">Histogenics Platform Inventions</b>&#8221;). Intrexon hereby assigns and agrees to assign to Histogenics all of Intrexon&#8217;s interests in and to any and all Histogenics Platform Inventions, and shall perform or have performed any and all acts reasonably necessary to assist Histogenics in perfecting its rights to any and all Histogenics Platform Inventions, including executing or having executed any documents affecting the appropriate assignment to Histogenics to the extent reasonably requested by Histogenics at Histogenics request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font>Notwithstanding anything to the contrary in this Agreement, any discovery, invention, process, technique, or other technology, whether or not patentable, that is conceived, and/or reduced to practice by Histogenics solely or jointly through the use of the Intrexon Channel Technology, Intrexon IP, or Intrexon Materials in breach of the terms and conditions of this Agreement, together with all patent rights and other intellectual property rights therein, shall be solely owned by Intrexon and shall be included in the Channel-Related Program IP. Notwithstanding anything to the contrary in this Agreement, any discovery, invention, process, technique, or other technology, whether or not patentable, that is conceived, and/or reduced to practice by Intrexon solely or jointly through the use of the Histogenics Independent IP and/or Histogenics Platform Inventions, in breach of the terms and conditions of this Agreement, together with all patent rights and other intellectual property rights therein, shall be solely owned by Histogenics and shall be included in the Histogenics Platform Inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(g)</b></font>All Information regarding Channel-Related Program IP shall be Confidential Information of Intrexon. Histogenics shall be under appropriate written agreements with each of its employees, contractors, or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">agents working on the Program, pursuant to which such person shall grant all rights in the Channel-Related Program IP to Histogenics (so that Histogenics may convey such rights to Intrexon, as provided herein) and agree to protect all Confidential Information relating to the Program. All Information regarding Histogenics Platform Inventions shall be Confidential Information of Histogenics. Intrexon shall be under appropriate written agreements with each of its employees, contractors, or agents working on the Program, pursuant to which such person shall grant all rights in the Histogenics Platform Inventions to Intrexon (so that Intrexon may convey such rights to Histogenics, as provided herein) and agree to protect all Confidential Information relating to the Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(h)</b></font>Subject to the foregoing clauses of this Section 6.1, all Inventions conceived and/or reduced to practice during the performance of the Program (together with all Patent rights and other intellectual property rights therein) that (i) are neither Channel-Related Program IP nor Histogenics Platform Inventions, and (ii) disclose and/or claim a combination of Intrexon Channel Technology and Histogenics Independent IP (collectively the &#8220;<b style="font-weight:bold;">Joint Program Inventions</b>&#8221;) shall be owned jointly by Intrexon and Histogenics in undivided one-half interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>For clarity, the Parties&#8217; joint ownership of the Joint Program Inventions does not by itself grant either Party rights in any other intellectual property of the other Party, and, except for the explicit licenses set forth in this Agreement (i) Intrexon is not permitted to use any Histogenics intellectual property (except as may be otherwise expressly granted by Histogenics) in the practice of Joint Program Inventions, and (ii) Histogenics is not permitted to use any Intrexon IP (except as may be otherwise expressly granted by Intrexon) in the practice of Joint Program Inventions. Neither Party shall claim priority to a patent application of the other Party without such other Party&#8217;s written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.2</b></font><b style="font-weight:bold;">Patent Prosecution</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Intrexon shall have the sole right, but not the obligation, to conduct and control the filing, prosecution and maintenance of the Intrexon Patents. At the reasonable request of Intrexon, Histogenics shall cooperate with Intrexon in connection with such filing, prosecution, and maintenance, at Intrexon&#8217;s expense. Under no circumstances shall Histogenics (i) file, attempt to file, or assist anyone else in filing, or attempting to file, any Patent application, either in the United States or elsewhere, that claims or purports to claim an Invention owned by Intrexon, or (ii) use, attempt to use, or assist anyone else in using or attempting to use, the Intrexon Know-How, Intrexon Materials, or any Confidential Information of Intrexon to support the filing of a Patent application, either in the United States or elsewhere, that contains claims directed to the Intrexon IP, Intrexon Materials, or the Intrexon Channel Technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Histogenics shall have the sole right, but not the obligation, to conduct and control the filing, prosecution and maintenance of any Patents claiming Histogenics Platform Inventions (&#8220;<b style="font-weight:bold;">Histogenics Program Patents</b>&#8221;) and any Histogenics Patents. At the reasonable request of Histogenics, Intrexon shall cooperate with Histogenics in connection with such filing, prosecution, and maintenance, at Histogenics&#8217;s expense. Under no circumstances shall Intrexon (i) file, attempt to file, or assist anyone else in filing, or attempting to file, any Patent application, either in the United States or elsewhere, that claims or purports to claim an Invention owned by Histogenics, or (ii) use, attempt to use, or assist anyone else in using or attempting to use, Histogenics Independent IP, Histogenics Platform Inventions, or any Confidential Information of Histogenics to support the filing of a Patent application, either in the United States or elsewhere, that contains claims directed to Histogenics Independent IP or Histogenics Platform Inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>The Parties through the IPC shall reasonably cooperate, to the extent such cooperation can be done without substantially compromising any Patents of either Party, to develop a portfolio of Product-Specific Program Patents and Patents for Joint Program Inventions covering relevant Collaboration Products. The Parties shall also reasonably cooperate to conduct and control the filing, prosecution, and maintenance of any applications for patent term extension and/or supplementary protection certificates that may be available as a result of the regulatory approval of any Collaboration Product. Notwithstanding the foregoing, this Agreement does not require either Party to develop Product-Specific Program Patents and Patents for Joint Program Inventions. During the Term, Intrexon shall have, the first right, but not the obligation, to conduct and direct the filing, prosecution and maintenance of any Patents for Joint Program Inventions consistent with any relevant strategies and determinations set forth by the IPC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>As used in this Section 6.2(d), &#8220;<b style="font-weight:bold;">Prosecuting Party</b>&#8221; means Intrexon in the case of Intrexon Patents, and Histogenics in the case of Histogenics Program Patents. The Prosecuting Party shall be entitled to use patent counsel selected by it (including in-house patent counsel as well as outside patent counsel) for the prosecution of the Intrexon Patents and Histogenics Program Patents, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.3</b></font><b style="font-weight:bold;">Infringement of Patents by Third Parties</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Except as expressly provided in the remainder of this Section 6.3, Intrexon shall have the sole right to take appropriate action against any person or entity directly or indirectly infringing any Intrexon Patent (or asserting that an Intrexon Patent is invalid or unenforceable) (collectively, &#8220;<b style="font-weight:bold;">Infringement</b>&#8221;), either by settlement or lawsuit or other appropriate action. Intrexon shall have no right to enforce any Patent owned or Controlled by Histogenics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Notwithstanding the foregoing, Histogenics shall have the first right, but not the obligation, to take appropriate action to enforce Product-Specific Program Patents against any Infringement that involves a commercially material amount of allegedly infringing activities in the Field (&#8220;<b style="font-weight:bold;">Field Infringement</b>&#8221;), either by settlement or lawsuit or other appropriate action. If Histogenics exercises the foregoing right, Intrexon agrees to be named in any such action if required and to reasonably cooperate with Histogenics with respect to any such action. If Histogenics fails to take the appropriate steps to enforce Product-Specific Program Patents against any Field Infringement within one hundred eighty (180) days of the date one Party has provided notice to the other Party pursuant to Section 6.3(g) of such Field Infringement, then Intrexon shall have the right (but not the obligation), at its own expense, to enforce Product-Specific Program Patents against such Field Infringement, either by settlement or lawsuit or other appropriate action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>With respect to any Field Infringement that cannot reasonably be abated through the enforcement of Product-Specific Program Patents pursuant to Section 6.3(b) but can reasonably be abated through the enforcement of Intrexon Patent(s) (other than the Product-Specific Program Patents), Intrexon shall be obligated to choose one of the following courses of action: (i) enforce one or more of the applicable Intrexon Patent(s) in a commercially reasonable manner against such Field Infringement, or (ii) [***]. To the extent Histogenics shall be entitled to a share of the Recovery as set forth in Section 6.3(f), Intrexon and Histogenics shall bear the costs and expenses of such enforcement equally. The determination of which Intrexon Patent(s) to assert shall be made by Intrexon in its sole discretion; provided, however, that Intrexon shall consult in good faith with Histogenics on such determination. For the avoidance of doubt, Intrexon has no obligation under this Agreement to enforce any Intrexon Patents against, or otherwise abate, any Infringement that is not a Field Infringement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>In the event a Party pursues an action under this Section 6.3, the other Party shall reasonably cooperate with the enforcing Party with respect to the investigation and prosecution of any alleged, threatened, or actual Infringement, at the enforcing Party&#8217;s expense (except with respect to an action under Section 6.3(c), where all costs and expenses will be shared equally in accordance with terms thereof).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>Histogenics shall not settle or otherwise compromise any action under this Section 6.3 in a way that diminishes the rights or interests of Intrexon outside the Field or adversely affects any Intrexon Patent without Intrexon&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. Intrexon shall not settle or otherwise compromise any action under this Section 6.3 in a way that diminishes the rights or interests of Histogenics in the Field or adversely affects any Intrexon Patent with respect to the Field without Histogenics&#8217; prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font>Except as otherwise agreed to by the Parties in writing, any settlements, damages or other monetary awards recovered pursuant to a suit, proceeding, or action brought pursuant to Section 6.3 will be allocated first to the costs and expenses of the Party controlling such action, and second, to the costs and expenses (if any) of the other Party (to the extent not otherwise reimbursed), and any remaining amounts (the &#8220;<b style="font-weight:bold;">Recovery</b>&#8221;) will be shared by the Parties as follows: In any action initiated by Intrexon pursuant to Section 6.3(a) that does not involve Field Infringement, Intrexon shall retain one hundred percent (100%) of any Recovery. In any action initiated by Intrexon pursuant to Section 6.3(b), Intrexon shall retain one hundred percent (100%) of any Recovery, but shall share such Recovery with Histogenics as follows: [***]. In any action initiated by Histogenics pursuant to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Section 6.3(b), Histogenics shall retain one hundred percent (100%) of any Recovery, but shall share such Recovery as follows: [***]. No Recovery that is the result of a settlement agreement between Histogenics and a Third Party shall qualify as a Recovery based upon lost profits under the prior sentence unless Histogenics can establish to Intrexon&#8217;s reasonable satisfaction that (i) the Recovery is in compensation for an Infringement by such Third Party, (ii) there is a Collaboration Product that is available for Commercial Sale in the relevant jurisdiction(s), (iii) the balance of facts concerning such Infringement and such Collaboration Product are such that they would have more likely than not qualified Histogenics under United States patent laws to have secured a monetary damages award calculated using a lost profits methodology, and (iv) the size of the Recovery in question is consistent with the size of an damages award that, applying the facts concerning the Subject Infringement and corresponding Collaboration Product, more likely than not would have been awarded using a lost profits methodology under United States patent laws. In any action initiated by Intrexon or Histogenics pursuant to Section 6.3(c), the Parties shall [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(g)</b></font>Histogenics shall promptly notify Intrexon of any suspected, alleged, threatened, or actual Field Infringement of which it becomes aware, and Intrexon shall promptly notify Histogenics of any suspected, alleged, threatened, or actual Field Infringement of which it becomes aware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">CONFIDENTIALITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.1</b></font><b style="font-weight:bold;">Confidentiality</b>. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement any Confidential Information disclosed to it by the other Party pursuant to this Agreement, except to the extent that the receiving Party can demonstrate by competent evidence that specific Confidential Information:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>was already rightfully known to the receiving Party and can be demonstrated by written records, other than under an obligation of confidentiality, at the time of disclosure by the other Party;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party or any of its Affiliates or sublicensees or any of its or their employees or independent contractors in breach of this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>was disclosed to the receiving Party, other than under an obligation of confidentiality to a Third Party, by a Third Party who had no obligation to the disclosing Party not to disclose such information to others; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>was independently discovered or developed by the receiving Party without the use of Confidential Information belonging to the disclosing Party, as documented by the receiving Party&#8217;s written records.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The foregoing non-use and non-disclosure obligation shall continue (i) indefinitely, for all Confidential Information that qualifies as a trade secret under applicable law; or (ii) for the Term of this Agreement and for seven (7) years thereafter, in all other cases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.2</b></font><b style="font-weight:bold;">Authorized Disclosure</b>. Notwithstanding the limitations in this Article 7, either Party may disclose the Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>complying with applicable laws or regulations or valid court orders, <i style="font-style:italic;">provided that</i> the Party making such disclosure provides the other Party with reasonable prior written notice of such request or demand for disclosure and makes a reasonable effort to obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the disclosure and/or requiring that the terms and conditions of this Agreement be used only for the purposes for which the law or regulation required, or for which the order was issued;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>to regulatory authorities in order to seek or obtain approval to conduct regulatory trials, or to gain regulatory approval, of Collaboration Products or any products being developed by Intrexon or its other licensees and/or channel partners or collaborators outside the Field, provided that the Party making such disclosure (i) provides the other Party with reasonable opportunity to review any such disclosure in advance and to suggest redactions or other means of limiting the disclosure of such other Party&#8217;s Confidential Information and (ii) does not unreasonably reject any such suggestions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>disclosure to investors and potential investors, acquirers, or merger candidates who agree to maintain the confidentiality of such information, <i style="font-style:italic;">provided that</i> such disclosure is used solely for the purpose of evaluating such investment, acquisition, or merger (as the case may be);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>disclosure on a need-to-know basis to Affiliates, licensees, sublicensees, employees, consultants or agents (such as CROs and clinical investigators) who agree to be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7; each Party shall be responsible and liable for any breaches of confidentiality by any such Affiliates, licensees, sublicensees, employees, consultants or agents and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>disclosure of the terms of this Agreement by Intrexon to collaborators and other channel partners or collaborators who agree to be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.3</b></font><b style="font-weight:bold;">Publicity; Publications</b>. The Parties agree that the public announcement of the execution of this Agreement shall be substantially in the form of a press release (the form of which shall be mutually agreed to by the Parties) and/or the filing of a Form 8-K by one or both of the Parties (to the extent required by relevant laws or regulations relating to required disclosure of material information to public markets and/or the SEC). The Parties agree each Party will provide the other Party with the opportunity to review and comment, prior to submission or presentation, of external reports, securities filings, publications and presentations (e.g., press releases, reports to government agencies, abstracts, posters, manuscripts and oral presentations) that refer specifically to this Agreement or, Collaboration Products, or the Program. For such reports, publications, and presentations, the disclosing Party will provide the other Party at least fifteen (15) calendar days for review of the proposed submission or presentation. In the case of any Form 8-K or other securities filing, such shall be provided to the non-filing Party by the filing party as soon as practicable prior to filing for review and comment and the Parties shall reasonably cooperate to seek and obtain confidential treatment (to the extent appropriate and permissible) of sensitive business information. For reports and manuscripts, the disclosing Party will provide the other Party at least thirty (30) days for review of the report or manuscript. The presenting Party will act in good faith to incorporate the comments of the other Party and shall, in any event, redact any Confidential Information of the other Party and cooperate with the other Party to postpone such submissions or presentations if necessary to provide the other Party with sufficient time to prepare and file any related Patent applications before the submission or presentation occurs, as appropriate. Notwithstanding anything to the contrary in this Agreement, in no event will either Party be obligated to provide the other Party with the opportunity to review and comment, prior to submission or presentation, of external reports, securities filings, publications and presentations (e.g., press releases, reports to government agencies, abstracts, posters, manuscripts and oral presentations) that are specifically related to this Agreement, Collaboration Product or the Program if the information disclosed in such reports, publications and presentations that refer specifically to this Agreement, Collaboration Product or the Program is the same as or substantially and materially similar to information previously presented by a Party to the other Party for review and comment pursuant to this Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.4</b></font><b style="font-weight:bold;">Terms of the Agreement</b>. Each Party shall treat the terms of this Agreement as the Confidential Information of other Party, Subject to the exceptions set forth in Section 7.2. Notwithstanding the foregoing, each Party acknowledges that the other Party may be obligated to file a copy of this Agreement with the SEC, either as of the Effective Date or at some point during the Term. Each Party shall be entitled to make such a required filing, provided that it requests confidential treatment of certain commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably available to it. In the event of any such filing, the filing Party shall provide the other Party with a copy of the Agreement marked to show provisions for which the filing Party intends to seek confidential treatment and shall reasonably consider and incorporate the other Party&#8217;s comments thereon to the extent consistent with the legal requirements governing redaction of information from material agreements that must be publicly filed. The other Party shall promptly provide any such comments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.5</b></font><b style="font-weight:bold;">Proprietary Information and Operational Audits</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>For the purpose of confirming compliance with the Field-limited licenses granted in Article 3, the diligence obligations of Article 4, the intellectual property provisions of Article 6, and the confidentiality obligations under Article 7, Histogenics acknowledges that Intrexon&#8217;s authorized representative(s), during regular business hours may (i) examine and inspect Histogenics&#8217; facilities and (ii) inspect all data and work products relating to this Agreement, subject to restrictions imposed by applicable laws. Any examination or inspection hereunder shall require five (5) business days written notice from Intrexon to Histogenics. Histogenics will make itself and the pertinent employees and/or agents available, on a reasonable basis, to Intrexon for the aforementioned compliance review, provided that such inspection may occur no more than once per calendar year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>For the purpose of confirming compliance with the diligence obligations of Section 4.6, and the confidentiality obligations under Article 7, Intrexon acknowledges that Histogenics authorized representative(s), during regular business hours may (i) examine and inspect Intrexon&#8217;s facilities and (ii) inspect all data and work products relating to this Agreement. Any examination or inspection hereunder shall require five (5) business days written notice from Histogenics to Intrexon. Intrexon will make itself and the pertinent employees and/or agents available, on a reasonable basis, to Histogenics for the aforementioned compliance review, provided that such inspection may occur no more than once per calendar year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>In view of the Intrexon Confidential Information, Intrexon Know-How, and Intrexon Materials transferred to Histogenics hereunder, Intrexon from time-to-time, but no more than quarterly, may request that Histogenics confirm the status of the Intrexon Materials at Histogenics (i.e. how much used, how much shipped, to whom and any unused amounts destroyed (by whom, when) as well as any amounts returned to Intrexon or destroyed). Within ten (10) business days of Histogenics&#8217; receipt of any such written request, Histogenics shall provide the written report to Intrexon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.6</b></font><b style="font-weight:bold;">Intrexon Commitment</b>. Intrexon shall use reasonable efforts to obtain an agreement with its other licensees and channel partners or collaborators to enable Histogenics to disclose confidential information of such licensees and channel partners or collaborators to regulatory authorities in order to seek or obtain approval to conduct regulatory trials, or to gain regulatory approval of, Collaboration Products, in a manner consistent with the provisions of Section 7.2(b). Intrexon must notify Histogenics in writing if Histogenics does not have any such disclosure rights with respect to any such Confidential Information, prior to any such disclosures by Histogenics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">REPRESENTATIONS AND WARRANTIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.1</b></font><b style="font-weight:bold;">Representations and Warranties of Histogenics</b>. Histogenics hereby represents and warrants to Intrexon that, as of the Effective Date:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Corporate Power</b>. Histogenics is duly organized and validly existing under the laws of Delaware and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Due Authorization</b>. Histogenics is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on Histogenics&#8217; behalf has been duly authorized to do so by all requisite corporate action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Binding Agreement</b>. This Agreement is a legal and valid obligation binding upon Histogenics and enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors&#8217; rights, and subject to general equity principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Histogenics does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound. Histogenics is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.2</b></font><b style="font-weight:bold;">Representations and Warranties of Intrexon</b>. Intrexon hereby represents and warrants to Histogenics that, as of the Effective Date:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Corporate Power</b>. Intrexon is duly organized and validly existing under the laws of Virginia and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Due Authorization</b>. Intrexon is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on Intrexon&#8217;s behalf has been duly authorized to do so by all requisite corporate action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Binding Agreement</b>. This Agreement is a legal and valid obligation binding upon Intrexon and enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors&#8217; rights, and subject to general equity principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Intrexon does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound. Intrexon is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">Additional Intellectual Property Representations</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(i)</b><font style="display:inline-block;width:26.56pt;"></font>Intrexon possesses sufficient rights to enable Intrexon to grant all rights and licenses it purports to grant to Histogenics with respect to the Intrexon IP under this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(ii)</b><font style="display:inline-block;width:23.78pt;"></font>The Intrexon Patents existing as of the Effective Date constitute all of the Patents Controlled by Intrexon as of such date that are necessary for the development, manufacture and Commercialization of Collaboration Products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(iii)</b><font style="display:inline-block;width:21pt;"></font>Intrexon has not granted, and during the Term Intrexon will not grant, any right or license, to any Third Party under the Intrexon IP that conflicts with the rights or licenses granted or to be granted to Histogenics hereunder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(iv)</b><font style="display:inline-block;width:21.56pt;"></font>There is no threatened or pending litigation, Intrexon has not received any notice of any such threatened or actual claims or litigation, seeking to invalidate or otherwise bearing on the Intrexon Patents or Intrexon&#8217;s rights therein;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(v)</b><font style="display:inline-block;width:24.34pt;"></font>None of the Intrexon Patents is subject to any threatened or pending <i style="font-style:italic;">inter partes</i> review, post grant review, re-examination, opposition, interference, litigation or other dispute resolution proceedings;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(vi)</b><font style="display:inline-block;width:21.56pt;"></font>All of the Intrexon Patents have been filed and prosecuted in accordance with all Applicable Laws and have been maintained, with all applicable fees with respect thereto (to the extent such fees have come due) having been paid;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(vii)</b><font style="display:inline-block;width:18.78pt;"></font>Intrexon has entered into agreements with each of its current and former officers, employees and consultants involved in research and development work, including development of Intrexon IP, providing Intrexon, to the extent permitted by law, with title and ownership to patents, patent applications, trade secrets and inventions conceived, developed, reduced to practice by such person, solely or jointly with other of such persons, during the period of employment or contract by Intrexon (except where the failure to have entered into such an agreement would not have a material adverse effect on the rights granted to Histogenics herein), and Intrexon is not aware that any of its employees or consultants is in material violation thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(viii)</b><font style="display:inline-block;width:16pt;"></font>To Intrexon&#8217;s knowledge, there is no infringement, misappropriation or violation by Third Parties of any Intrexon Channel Technology or Intrexon IP in the Field;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(ix)</b><font style="display:inline-block;width:21.56pt;"></font>There is no pending or, to Intrexon&#8217;s knowledge, threatened action, suit, proceeding or claim by others against Intrexon, that Intrexon infringes, misappropriates or otherwise violates any intellectual property or other proprietary rights of others in connection with the use of the Intrexon Channel Technology or Intrexon IP, and Intrexon has not received any notice of such claim;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(x)</b><font style="display:inline-block;width:24.34pt;"></font>To Intrexon&#8217;s knowledge, no employee of Intrexon is the Subject of any claim or proceeding involving a violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, non-disclosure agreement or any restrictive covenant to or with a former employer (A) where the basis of such violation relates to such employee&#8217;s employment with Intrexon or actions undertaken by the employee while employed with Intrexon and (B) where such violation is relevant to the use of the Intrexon Channel Technology in the Field;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(xi)</b><font style="display:inline-block;width:21.56pt;"></font>None of the Intrexon Patents owned by Intrexon or its Affiliates, and, to Intrexon&#8217;s knowledge, none of the Intrexon Patents licensed to Intrexon or its Affiliates, have been adjudged invalid or unenforceable by a court of competent jurisdiction or applicable government agency, in whole or in part, and there is no pending or, to Intrexon&#8217;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intrexon Patents; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(xii)</b><font style="display:inline-block;width:18.78pt;"></font>Except as otherwise disclosed in writing to Histogenics, Intrexon: (A) is in material compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product that is under development, manufactured or distributed by Intrexon in the Field (&#8220;<b style="font-weight:bold;">Applicable Laws</b>&#8221;); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the United States Food and Drug Administration (the &#8220;<b style="font-weight:bold;">FDA</b>&#8221;) or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#8220;<b style="font-weight:bold;">Authorizations</b>&#8221;), which would, individually or in the aggregate, result in a material adverse effect; (C) possesses all material Authorizations necessary for the operation of its business as described in the Field and such Authorizations are valid and in full force and effect and Intrexon is not in material violation of any term of any such Authorizations; and (D) since January 1, 2011, (1) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit investigation or proceeding; (2) has not received notice that the FDA or any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority is considering such action; (3) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (4) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post sale warning, letters to customers, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to Intrexon&#8217;s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(xiii)</b><font style="display:inline-block;width:16pt;"></font>Intrexon has no knowledge of any claims that the Universal Cell Line, infringes, misappropriates or otherwise violates any intellectual property or other proprietary rights of others in connection with the use of the Intrexon Channel Technology or Intrexon IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">except, in each of (ix) through (xiii), for any instances which would not, individually or in the aggregate, result in a material adverse effect on the rights granted to Histogenics hereunder or Intrexon&#8217;s ability to perform its obligations hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.3</b></font><b style="font-weight:bold;">Warranty Disclaimer</b>. EXCEPT FOR THE EXPRESS WARRANTIES PROVIDED IN THIS ARTICLE 8 OR IN THE NOTE, EACH PARTY HEREBY DISCLAIMS ANY AND ALL OTHER WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">INDEMNIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.1</b></font><b style="font-weight:bold;">Indemnification by Intrexon</b>. Intrexon agrees to indemnify, hold harmless, and defend Histogenics and its Affiliates and its and their respective directors, officers, employees, and agents (collectively, the &#8220;<b style="font-weight:bold;">Histogenics Indemnitees</b>&#8221;) from and against any and all third party liabilities, damages, costs, expenses, or losses (including reasonable legal expenses and attorneys&#8217; fees) (collectively, &#8220;<b style="font-weight:bold;">Losses</b>&#8221;) resulting from any claims, suits, actions, demands, or other proceedings brought by a Third Party (collectively, &#8220;<b style="font-weight:bold;">Claims</b>&#8221;) to the extent arising from (a) the gross negligence or willful misconduct of Intrexon or any of its Affiliates, or their respective employees or agents, (b) the use, handling, storage or transport of Intrexon Materials by or on behalf of Intrexon or its Affiliates, licensees (other than Histogenics) or sublicensees; or any of its or their employees and independent contractors or (c) breach by Intrexon of any representation, warranty or covenant in this Agreement. Notwithstanding the foregoing, Intrexon shall not have any obligation to indemnify the Histogenics Indemnitees to the extent that a Claim arises from (i) the negligence, gross negligence or willful misconduct of Histogenics or any of its Affiliates, licensees, or sublicensees, or its or their respective employees or agents; or (ii) a breach by Histogenics or any of its Affiliates, licensees, or sublicensees, or its or their respective employees or agents of a representation, warranty, or covenant or other provision of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.2</b></font><b style="font-weight:bold;">Indemnification by Histogenics</b>. Histogenics agrees to indemnify, hold harmless, and defend Intrexon, its Affiliates and Third Security, and its and their respective directors, officers, employees, and agents (and any Third Parties which have licensed to Intrexon intellectual property rights within Intrexon IP on or prior to the Effective Date, to the extent required by the relevant upstream license agreement) (collectively, the &#8220;<b style="font-weight:bold;">Intrexon Indemnitees</b>&#8221;) from and against any third party Losses resulting from Claims, to the extent arising from any of the following: (a) the gross negligence or willful misconduct of Histogenics or any of its Affiliates or their respective employees or agents; (b) the use, handling, storage, or transport of Intrexon Materials by or on behalf of Histogenics or its Affiliates, licensees, or sublicensees or any of its or their employees and independent contractors; (c) breach by Histogenics of any material representation, warranty or covenant in this Agreement; or (d) the design, development, manufacture, regulatory approval, handling, storage, transport, distribution, sale or other disposition of any Collaboration Product by or on behalf of Histogenics or its Affiliates, licensees, or ublicensees. Notwithstanding the foregoing, Histogenics shall not have any obligation to indemnify the Intrexon Indemnitees to the extent that a Claim arises from (i) the negligence, gross negligence or willful misconduct of Intrexon or any of its Affiliates, licensees or sublicensees or its or their respective employees or agents; or (ii) a breach by Intrexon or any of its Affiliates, licensees, or sublicensees, or its or their respective employees or agents of a representation, warranty, or covenant or other provision of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.3</b></font><b style="font-weight:bold;">Product Liability Claims</b>. Notwithstanding the provisions of Section 9.2, any Losses arising out of any Third Party claim, suit, action, proceeding, liability or obligation involving any actual or alleged death or bodily injury arising out of or resulting from the development, manufacture or Commercialization of any Collaboration Products for use or sale in the Field, to the extent that such Losses exceed the amount (if any) covered by the applicable Party&#8217;s product liability insurance (&#8220;<b style="font-weight:bold;">Excess Product Liability Costs</b>&#8221;), shall be paid by [***], except to the extent such Losses arise out of any Third-Party Claim based on the gross negligence or willful misconduct of, its Affiliates, or its Affiliates&#8217; sublicensees, or any of the respective officers, directors, employees and agents of each of the foregoing entities, in the performance of obligations or exercise of rights under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.4</b></font><b style="font-weight:bold;">Control of Defense</b>. As a condition precedent to any indemnification obligations hereunder, any entity entitled to indemnification under this Article 9 shall give written notice to the indemnifying Party of any Claims that may be subject to indemnification, promptly after learning of such Claim. If such Claim falls within the scope of the indemnification obligations of this Article 9, then the indemnifying Party shall assume the defense of such Claim and control such defense. The indemnified Party shall cooperate with the indemnifying Party in such</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">defense. Without limiting the indemnifying Party&#8217;s right to control the defense of a Claim, the indemnified Party may, at its option and expense, be represented by counsel of its choice in any action or proceeding with respect to such Claim. The indemnifying Party shall not be liable for any litigation costs or expenses incurred by the indemnified Party without the indemnifying Party&#8217;s written consent, such consent to be provided in the indemnifying Party&#8217;s sole discretion. The indemnifying Party shall not settle any such Claim if such settlement (a) does not fully and unconditionally release the indemnified Party from all liability relating thereto or (b) adversely impacts the exercise of the rights granted to the indemnified Party under this Agreement, unless the indemnified Party otherwise agrees in writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.5</b></font><b style="font-weight:bold;">Insurance</b>. Immediately prior to, and during marketing of Collaboration Products, Histogenics shall maintain in effect and good standing a product liability insurance policy issued by a reputable insurance company in amounts considered standard for the industry. Immediately prior to, and during the conduct of any regulatory trials, Histogenics shall maintain in effect and good standing a regulatory trials liability insurance policy issued by a reputable insurance company in amounts considered standard for the industry. At Intrexon&#8217;s reasonable request, Histogenics shall provide Intrexon with reasonable details regarding such policies, including without limitation copies of the applicable liability insurance contracts. Histogenics shall use reasonable efforts to include Intrexon as an additional insured on any such policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 10</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">TERM; TERMINATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.1</b></font><b style="font-weight:bold;">Term</b>. The term of this Agreement shall commence upon the Effective Date and shall continue until terminated pursuant to Section 10.2 or 10.3 (the &#8220;<b style="font-weight:bold;">Term</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.2</b></font><b style="font-weight:bold;">Termination for Material Breach; Termination under Section 4</b>.<b style="font-weight:bold;">4(b)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Either Party shall have the right to terminate this Agreement upon written notice to the other Party if the other Party commits any material breach of this Agreement that such breaching Party fails to cure within sixty (60) days following written notice from the nonbreaching Party specifying such breach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Intrexon shall have the right to terminate this Agreement, at its sole discretion, if (i) the Note for the Technology Access Fee has not been duly executed and delivered in accord with Section 5.1, or (ii) upon maturity of the Note, Intrexon has not received payment of the Technology Access Fee in accord with the terms and conditions of the Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>Intrexon shall have the right to terminate this Agreement under the circumstances set forth in Section 4.4(b) upon written notice to Histogenics, such termination to become effective sixty (60) days following such written notice unless Histogenics remedies the circumstances giving rise to such termination within such sixty (60) day period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>Intrexon shall have the right to terminate this Agreement should Histogenics execute any purported assignment of this Agreement contrary to the prohibitions in Section 12.8, such termination occurring upon Intrexon providing written notice to Histogenics and becoming effective immediately upon such written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.3</b></font><b style="font-weight:bold;">Termination by Histogenics</b>. Histogenics shall have the right to voluntarily terminate this Agreement in its entirety upon ninety (90) days written notice to Intrexon at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.4</b></font><b style="font-weight:bold;">Effect of Termination</b>. In the event of termination of this Agreement pursuant to Section 10.2 or Section 10.3, the following shall apply:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Retained Products</b>. Histogenics shall be permitted to continue the development and Commercialization in the Field of any product resulting from the Program that, at the time of such termination, satisfies at least one of the following criteria (a &#8220;<b style="font-weight:bold;">Retained Product</b>&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(i)</b><font style="display:inline-block;width:26.56pt;"></font>the particular product is used in a Collaboration Product that is being sold by Histogenics (or, as may be permitted under this Agreement, its Affiliates and, if applicable, (sub)licensees) triggering profit sharing payments therefor under Section 5.2(a) or (b) of this Agreement,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(ii)</b><font style="display:inline-block;width:23.78pt;"></font>the particular product is used in a Collaboration Product that has received regulatory approval,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(iii)</b><font style="display:inline-block;width:21pt;"></font>the particular product is used in a Collaboration Product that is the subject of an application for regulatory approval in the Field that is pending before the applicable regulatory authority, or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(iv)</b><font style="display:inline-block;width:21.56pt;"></font>the particular product is used in a Collaboration Product that is the subject of any ongoing or completed human clinical trial wherein the Collaboration Product was implanted into at least one patient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Such right to continue development and Commercialization shall be subject to Histogenics&#8217; full compliance with the payment provisions in Article 5, a continuing obligation for Histogenics to use in accord with Sections 4.4(a) and 4.4(c) Diligent Efforts to develop and Commercialize any Retained Products, and all other provisions of this Agreement that survive termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Termination of Licenses</b>. Except as necessary for Histogenics to continue to obtain regulatory approval for, development, use, manufacture, Commercialization of and exploitation of the Retained Products in the Field as permitted by Section 10.4(a), all rights and licenses granted by Intrexon to Histogenics under this Agreement shall terminate and shall revert to Intrexon without further action by either Intrexon or Histogenics. Histogenics&#8217; license with respect to Retained Products shall be exclusive or non-exclusive, as the case may be, on the same terms as set forth in Section 3.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Reverted Products</b>. Any products (e.g., a cell line) resulting from the Program that are not Retained Products shall be referred to herein as the &#8220;<b style="font-weight:bold;">Reverted Products</b>.&#8221; Histogenics shall immediately cease, and shall cause its Affiliates and, if applicable, (sub)licensees to immediately cease, all development and Commercialization of the Reverted Products, and Histogenics shall not use or practice, nor shall it cause or permit any of its Affiliates or, if applicable, (sub)licensees to use or practice, directly or indirectly, any Intrexon IP with respect to the Reverted Products. Histogenics shall immediately discontinue making any representation regarding its status as a licensee or channel collaborator of Intrexon with respect to the Reverted Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">Intrexon Materials</b>. Histogenics shall promptly return, or at Intrexon&#8217;s request, destroy, any Intrexon Materials in Histogenics&#8217; possession or control at the time of termination other than any Intrexon Materials necessary for the continued research, development, regulatory approval, use, import, export, manufacture, Commercialization and exploitation of the Retained Products in the Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font><b style="font-weight:bold;">Licenses to Intrexon</b>. Histogenics is automatically deemed to grant to Intrexon, subject to the terms and conditions of this Agreement, a worldwide, fully paid, royalty-free, exclusive (even as to Histogenics and its Affiliates), irrevocable, license (with full rights to Sublicense) under the Histogenics Termination IP, solely to make, have made, import, use, offer for sale and sell Reverted Products in the Field, subject to any exclusive rights held by Histogenics in Reverted Products pursuant to Section 10.4(c). The Parties shall also take such actions and execute such other instruments and documents as may be reasonably necessary to document such license to Intrexon. All other licenses granted by Histogenics to Intrexon under this Agreement shall terminate and shall revert to Histogenics without further action by either Histogenics or Intrexon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font><b style="font-weight:bold;">Regulatory Filings</b>. Histogenics shall promptly assign to Intrexon, and will provide full copies of, all regulatory approvals and regulatory filings to the extent that they relate specifically and solely to Reverted Products (if any). Histogenics shall also take such actions and execute such other instruments, assignments and documents as may be reasonably necessary to effect the transfer of rights thereunder to Intrexon. To the extent that there exist any regulatory approvals and regulatory filings that relate both to Reverted Products and other products, Histogenics shall provide copies of the portions of such regulatory filings that relate specifically to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Reverted Products and shall reasonably cooperate to assist Intrexon in obtaining the benefits of such regulatory approvals with respect to the Reverted Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(g)</b></font><b style="font-weight:bold;">Data Disclosure</b>. Histogenics shall provide to Intrexon copies of the relevant portions of all material reports and data, including regulatory trial data and reports, obtained or generated by or on behalf of Histogenics or its Affiliates to the extent that they relate specifically to Reverted Products, within sixty (60) days of such termination unless otherwise agreed, and Intrexon shall have the right to use any such Information in developing and Commercializing Reverted Products and to license any Third Parties to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(h)</b></font><b style="font-weight:bold;">Third Party Licenses</b>. At Intrexon&#8217;s request, Histogenics shall promptly provide to Intrexon copies of all Third Party agreements under which Histogenics or its Affiliates obtained a license under Patents claiming inventions or know-how specific to or incorporated into the development, manufacture and/or Commercialization of the Reverted Products. At Intrexon&#8217;s request such that Intrexon may Commercialize the Reverted Products, Histogenics shall promptly work with Intrexon to either, as appropriate (i) with respect to such Third Party agreements relating solely to the applicable Reverted Products and permitting assignment, immediately assign (or cause to be assigned), such agreements to Intrexon, and (ii) with respect to all other such Third Party agreements, Histogenics shall reasonably cooperate to assist Intrexon in obtaining the benefits of such agreements. Thereafter Intrexon shall be fully responsible for all obligations due for its actions under such sublicensed or assigned Third Party agreements. Notwithstanding the above, if Intrexon does not wish to assume any financial or other obligations associated with a particular Third Party agreement identified to Intrexon under this Section 10.4(h), then Intrexon shall so notify Histogenics and Histogenics shall not make such assignment or grant such sublicense (or cause it to be made or granted).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font><b style="font-weight:bold;">Remaining Materials</b>. At the request of Intrexon, Histogenics shall transfer to Intrexon all quantities of Reverted Product (including final products or work-in-process) in the possession of Histogenics or its Affiliates. Histogenics shall transfer to Intrexon all such quantities of Reverted Products without charge, except that Intrexon shall pay the reasonable costs of processing and shipping.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(j)</b></font><b style="font-weight:bold;">Third Party Vendors</b>. At Intrexon&#8217;s request, Histogenics shall promptly provide to Intrexon copies of all agreements between Histogenics or its Affiliates that are wholly-owned subsidiaries of Histogenics and Third Party suppliers, vendors, or distributors that relate specifically to the supply, sale, or distribution of Reverted Products in the Territory. At Intrexon&#8217;s request, Histogenics shall promptly: (i) with respect to such Third Party agreements relating solely to the applicable Reverted Products and permitting assignment, immediately assign (or cause to be assigned), such agreements to Intrexon, and (ii) with respect to all other such Third Party agreements, Histogenics shall reasonably cooperate to assist Intrexon in obtaining the benefits of such agreements. Histogenics shall be liable for any costs associated with assigning a Third Party agreement to Intrexon or otherwise obtaining the benefits of such agreement for Intrexon, to the extent such costs are directly related to Histogenics&#8217; breach. For the avoidance of doubt, Intrexon shall have no obligation to assume any of Histogenics&#8217; obligations under any Third Party agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(k)</b></font><b style="font-weight:bold;">Commercialization</b>. Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Histogenics, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(l)</b></font><b style="font-weight:bold;">Confidential Information</b>. Each Party shall promptly return, or at the other Party&#8217;s request destroy, any Confidential Information of the other Party in such Party&#8217;s possession or control at the time of termination; provided, however, that each Party shall be permitted to retain (i) a single copy of each item of Confidential Information of the other Party in its confidential legal files for the sole purpose of monitoring and enforcing its compliance with Article 7, (ii) Confidential Information of the other Party that is maintained as archive copies on the recipient Party&#8217;s disaster recovery and/or information technology backup systems in the ordinary course of business, or (iii) Confidential Information of the other Party necessary to exercise such Party&#8217;s rights in Retained Products (in the case of Histogenics) or Reverted Products (in the case of Intrexon). The recipient of Confidential Information shall continue to be bound by the terms and conditions of this Agreement with respect to any such Confidential Information retained in accordance with this Section 10.4(l).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(m)</b></font><b style="font-weight:bold;">Cost Reimbursement</b>. In the event of termination of this Agreement prior to achievement of the IND Acceptance Milestone Event either (i) by Intrexon pursuant to Section 10.2, or (ii) by Histogenics pursuant to Section 10.3, Histogenics shall pay to Intrexon fifty percent (50%) of Intrexon&#8217;s Fully Loaded Cost invoiced in connection with services under Section 4.6 (i.e., such that Intrexon will have in total been compensated for one hundred percent (100%) of the Fully Loaded Costs that were invoiced prior to the termination of this Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.5</b></font><b style="font-weight:bold;">Surviving Obligations</b>. Termination or expiration of this Agreement shall not affect any rights of either Party arising out of any event or occurrence prior to termination, including, without limitation, any obligation of Histogenics to pay any amount which became due and payable under the terms and conditions of this Agreement prior to expiration or such termination. The following portions of this Agreement shall survive termination or expiration of this Agreement: Sections 3.1 through 3.4 and 3.8(b) (each as applicable with respect to 10.4(b)), 5.2 through 5.9, 6.1, 6.2 (with subsection (c) surviving only to the extent relating to Intrexon Patents that are relevant to Retained Products that, to Intrexon&#8217;s knowledge, are being developed or Commercialized at such time, if any), 7.1, 7.2, 7.4, 7.5, 10.4, and 10.5; Articles 9, 11, and 12; and any relevant definitions in Article 1. Further, Article 7 and Sections 4.4(a), 4.4(c), 6.3, and 9.5 will survive termination of this Agreement to the extent there are applicable Retained Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 11</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">DISPUTE RESOLUTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.1</b></font><b style="font-weight:bold;">Disputes</b>. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation. In the event of any disputes, controversies or differences which may arise between the Parties out of or in relation to or in connection with this Agreement (other than disputes arising from a Committee), including, without limitation, any alleged failure to perform, or breach, of this Agreement, or any issue relating to the interpretation or application of this Agreement, then upon the request of either Party by written notice, the Parties agree to meet and discuss in good faith a possible resolution thereof, which good faith efforts shall include at least one in-person meeting between the Executive Officers of each Party. If the matter is not resolved within thirty (30) days following the written request for discussions, either Party may then invoke the provisions of Section 11.2. For the avoidance of doubt, any disputes, controversies or differences arising from a Committee pursuant to Article 2 shall be resolved solely in accordance with Section 2.4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.2</b></font><b style="font-weight:bold;">Arbitration</b>. Any dispute, controversy, difference or claim which may arise between the Parties and not from a Committee, out of or in relation to or in connection with this Agreement (including, without limitation, arising out of or relating to the validity, construction, interpretation, enforceability, breach, performance, application or termination of this Agreement) that is not resolved pursuant to Section 11.1 shall, subject to Section 11.10, be settled by binding &#8220;baseball arbitration&#8221; as follows. Either Party, following the end of the thirty (30) day period referenced in Section 11.1, may refer such issue to arbitration by submitting a written notice of such request to the other Party, with the arbitration to be held in the state where the other Party&#8217;s principal office is located (or some other place as may be mutually agreed by the Parties). Promptly following receipt of such notice, the Parties shall meet and discuss in good faith and seek to agree on an arbitrator to resolve the issue, which arbitrator shall be neutral and independent of both Parties and all of their respective Affiliates, shall have significant experience and expertise in licensing and partnering agreements in the pharmaceutical and biotechnology industries, and shall have some experience in mediating or arbitrating issues relating to such agreements. If the Parties cannot agree on a single arbitrator within fifteen (15) days of request by a Party for arbitration, then each Party shall select an arbitrator meeting the foregoing criteria and the two (2) arbitrators so selected shall select within ten (10) days of their appointment a third arbitrator meeting the foregoing criteria. Within fifteen (15) days after an arbitrator(s) is selected (in the case of the three-person panel, when the third arbitrator is selected), each Party will deliver to both the arbitrator(s) and the other Party a detailed written proposal setting forth its proposed terms for the resolution for the matter at issue (the &#8220;<b style="font-weight:bold;">Proposed Terms</b>&#8221; of the Party) and a memorandum (the &#8220;<b style="font-weight:bold;">Support Memorandum</b>&#8221;) in support thereof. The Parties will also provide the arbitrator(s) a copy of this Agreement, as it may be amended at such time. Within fifteen (15) days after receipt of the other Party&#8217;s Proposed Terms and Support Memorandum, each Party may submit to the arbitrator(s) (with a copy to the other Party) a response to the other Party&#8217;s Support Memorandum. Neither Party may have any other communications (either written or oral) with the arbitrator(s) other than for the sole purpose of engaging the arbitrator or as expressly permitted in this Section 11.2; provided that, the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">arbitrator(s) may convene a hearing if the arbitrator(s) so chooses to ask questions of the Parties and hear oral argument and discussion regarding each Party&#8217;s Proposed Terms. Within sixty (60) days after the arbitrator&#8217;s appointment, the arbitrator(s) will select one of the two Proposed Terms (without modification) provided by the Parties that he or she believes is most consistent with the intention underlying and agreed principles set forth in this Agreement. The decision of the arbitrator(s) shall be final, binding, and unappealable. For clarity, the arbitrator(s) must select as the only method to resolve the matter at issue one of the two sets of Proposed Terms, and may not combine elements of both Proposed Terms or award any other relief or take any other action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.3</b></font><b style="font-weight:bold;">Governing Law</b>. This Agreement shall be governed by and construed under the substantive laws of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.4</b></font><b style="font-weight:bold;">Award</b>. Any award to be paid by one Party to the other Party as determined by the arbitrator(s) as set forth above under Section 11.2 shall be promptly paid in United States dollars free of any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the losing Party. Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 11, and agrees that, subject to the United States Federal Arbitration Act, 9 U.S.C. &#167;&#167; 1-16, judgment may be entered upon the final award in any United States District Court located in New York and that other courts may award full faith and credit to such judgment in order to enforce such award. The award shall include interest from the date of any damages incurred for breach of the Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrator(s). With respect to money damages, except as otherwise expressly provided in Section 11.2, nothing contained herein shall be construed to permit the arbitrator(s) or any court or any other forum to award consequential, incidental, special, punitive or exemplary damages. By entering into this agreement to arbitrate, the Parties expressly waive any claim for consequential, incidental, special, punitive or exemplary damages, except as otherwise expressly provided in Section 11.2. The only damages recoverable under this Agreement are direct compensatory damages, except as otherwise expressly provided in Section 11.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.5</b></font><b style="font-weight:bold;">Costs</b>. Each Party shall bear its own legal fees. The arbitrator(s) shall assess his or her costs, fees and expenses against the Party losing the arbitration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.6</b></font><b style="font-weight:bold;">Injunctive Relief</b>. Nothing in this Article 11 will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending an arbitration proceeding. Specifically, the Parties agree that a material breach by either Party of its obligations in Section 3.5 or Article 7 of this Agreement may cause irreparable harm to the other Party, for which damages may not be an adequate remedy. Therefore, in addition to its rights and remedies otherwise available at law and equity, including, without limitation, the recovery of damages for breach of this Agreement, upon an adequate showing of material breach of such Section 3.5 or Article 7, and without further proof of irreparable harm other than this acknowledgement, such non-breaching Party shall be entitled to seek (a) immediate equitable relief, specifically including, but not limited to, both interim and permanent restraining orders and injunctions, without the requirement of proving actual damages or posting a surety or bond, and (b) such other and further equitable relief as the court may deem proper under the circumstances. For the avoidance of doubt, nothing in this Section 11.6 shall otherwise limit a breaching Party&#8217;s opportunity to cure a material breach as permitted in accordance with Section 10.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.7</b></font><b style="font-weight:bold;">Confidentiality</b>. The arbitration proceeding shall be confidential and the arbitrator(s) shall issue appropriate protective orders to safeguard each Party&#8217;s Confidential Information. Except as required by law, no Party shall make (or instruct the arbitrator(s) to make) any public announcement with respect to the proceedings or decision of the arbitrator(s) without prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrator(s), except as required in connection with the enforcement of such award or as otherwise required by applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.8</b></font><b style="font-weight:bold;">Survivability</b>. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after termination of this Agreement for any reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.9</b></font><b style="font-weight:bold;">Jurisdiction</b>. For the purposes of this Article 11, the Parties acknowledge their diversity and agree to accept the jurisdiction of any United States District Court located in New York for the purposes of enforcing or appealing any awards entered pursuant to this Article 11 and for enforcing the agreements reflected in this Article 11 and agree not to commence any action, suit or proceeding related thereto except in such courts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.10</b></font><b style="font-weight:bold;">Patent Disputes</b>. Notwithstanding any other provisions of this Article 11, and subject to the provisions of Section 6.2, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Party&#8217;s Patents shall be submitted to a court of competent jurisdiction in the country in which such Patent was filed or granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 12</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">GENERAL PROVISIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.1</b></font><b style="font-weight:bold;">Use of Name</b>. No right, express or implied, is granted by this Agreement to either Party to use in any manner the name of the other or any other trade name or trademark of the other in connection with the performance of this Agreement, except that (a) either Party may use the name of the other Party as required by law or regulation and in press releases accompanying quarterly and annual earnings reports approved by the issuer&#8217;s Board of Directors, and (b) Histogenics may use the Intrexon Trademarks in accord with licenses and restrictions set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.2</b></font><b style="font-weight:bold;">LIMITATION OF LIABILITY</b>. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 9, OR DAMAGES AVAILABLE FOR BREACHES OF THE OBLIGATIONS SET FORTH IN ARTICLE 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.3</b></font><b style="font-weight:bold;">Independent Parties</b>. The Parties are not employees or legal representatives of the other Party for any purpose. Neither Party shall have the authority to enter into any contracts in the name of or on behalf of the other Party. This Agreement shall not constitute, create, or in any way be interpreted as a joint venture, partnership, or business organization of any kind.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.4</b></font><b style="font-weight:bold;">Notice</b>. All notices, including notices of address change, required or permitted to be given under this Agreement shall be in writing and deemed to have been given when delivered if personally delivered or sent by facsimile (provided that the party providing such notice promptly confirms receipt of such transmission with the other party by telephone), on the business day after dispatch if sent by a nationally-recognized overnight courier and on the third business day following the date of mailing if sent by certified mail, postage prepaid, return receipt requested. All such communications shall be sent to the address or facsimile number set forth below (or any updated addresses or facsimile number communicated to the other Party in writing):</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:49.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If to Intrexon:</p></td><td style="vertical-align:top;width:50.05%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intrexon Corporation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20374 Seneca Meadows Parkway</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germantown, MD 20876</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attention: Senior Vice President,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Sector</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fax: (301) 556-9901</p></td></tr><tr><td style="vertical-align:top;width:49.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">with a copy to:</p></td><td style="vertical-align:top;width:50.05%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intrexon Corporation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20374 Seneca Meadows Parkway</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germantown, MD 20876</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attention: Legal Department</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fax: (301) 556-9902</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.05%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">rd Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.94%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If to Histogenics:</p></td><td style="vertical-align:top;width:50.05%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Histogenics Corporation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">830 Winter Street, 3rd Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waltham, MA 02451</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attention: Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fax: (781) 547-445</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.5</b></font><b style="font-weight:bold;">Severability</b>. In the event any provision of this Agreement is held to be invalid or unenforceable, the valid or enforceable portion thereof and the remaining provisions of this Agreement will remain in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.6</b></font><b style="font-weight:bold;">Waiver</b>. Any waiver (express or implied) by either Party of any breach of this Agreement shall not constitute a waiver of any other or subsequent breach. All waivers must be in writing signed by an authorized representative of the Party against whom such waiver is being enforced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.7</b></font><b style="font-weight:bold;">Entire Agreement; Amendment</b>. This Agreement, including any exhibits attached hereto, constitute the entire, final, complete and exclusive agreement between the Parties and supersede all previous agreements or representations, written or oral, with respect to the subject matter of this Agreement (including any prior confidentiality agreement between the Parties). All information of Intrexon or Histogenics to be kept confidential by the other Party under any prior confidentiality agreement, as of the Effective Date, shall be maintained as Confidential Information by such other Party under the obligations set forth in Article 7 of this Agreement. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.8</b></font><b style="font-weight:bold;">Non-assignability; Binding on Successors</b>. Any attempted assignment of the rights or delegation of the obligations under this Agreement shall be void without the prior written consent of the non-assigning or non-delegating Party; provided, however, that either Party may assign its rights or delegate its obligations under this Agreement without such consent (a) to an Affiliate of such Party or (b) to its successor in interest in connection with any merger, acquisition, consolidation, corporate reorganization, or similar transaction, or sale of all or substantially all of its assets to which this Agreement relates, provided that such assignee agrees in writing to assume and be bound by the assignor&#8217;s obligations under this Agreement. This Agreement shall be binding upon, and inure to the benefit of, the successors, executors, heirs, representatives, administrators and permitted assigns of the Parties. Notwithstanding the foregoing, in the event that either Party assigns this Agreement to its successor in interest by way of merger, acquisition, consolidation, corporate reorganization, or similar transaction, or sale of all or substantially all of its assets to which this Agreement relates (whether this Agreement is actually assigned or is assumed by such successor in interest or its affiliate by operation of law (e.g., in the context of a reverse triangular merger)), the intellectual property rights of such successor in interest or any of its Affiliates other than those expressly licensed in this Agreement shall be automatically excluded from the rights licensed to the other Party under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.9</b></font><b style="font-weight:bold;">Force Majeure</b>. Neither Party shall be liable to the other for its failure to perform any of its obligations under this Agreement, except for payment obligations, during any period in which such performance is delayed because rendered impracticable or impossible due to circumstances beyond its reasonable control, including without limitation earthquakes, governmental regulation, fire, flood, labor difficulties, civil disorder, acts of terrorism and acts of God, provided that the Party experiencing the delay promptly notifies the other Party of the delay and uses commercially reasonable efforts to overcome any such cause of delay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.10</b></font><b style="font-weight:bold;">No Other Licenses</b>. Neither Party grants to the other Party any rights or licenses in or to any intellectual property, whether by implication, estoppel, or otherwise, except to the extent expressly provided for under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.11</b></font><b style="font-weight:bold;">Non-Solicitation</b>. During the Term and for a period of one (1) year following the end of the Term, neither Histogenics nor Intrexon may directly or indirectly solicit in order to offer to employ, engage in any discussion regarding employment with, or hire any employee of the other Party or an individual who was employed by the other party within one (1) year prior to such solicitation, discussion, or hire, without the prior approval of such other Party. General employment solicitations or advertisements shall not be considered direct or indirect solicitations, and are not prohibited under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.12</b></font><b style="font-weight:bold;">Legal Compliance</b>. The Parties shall review in good faith and cooperate in taking such actions to ensure compliance of this Agreement with all applicable laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.13</b></font><b style="font-weight:bold;">Counterparts</b>. This Agreement may be executed in any number of counterparts (including by facsimile, PDF, or other means of electronic communication), each of which taken together will constitute one and the same instrument, and any of the Parties hereto may execute this Agreement by signing any such counterpart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[Remainder of page intentionally left blank.]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:10pt;font-weight:bold;">I</b><b style="font-size:8.5pt;font-weight:bold;">N</b><b style="font-size:10pt;font-weight:bold;"> W</b><b style="font-size:8.5pt;font-weight:bold;">ITNESS</b><b style="font-size:10pt;font-weight:bold;"> W</b><b style="font-size:8.5pt;font-weight:bold;">HEREOF</b><font style="font-size:10pt;">, the Parties hereto have duly executed this Exclusive Channel Collaboration Agreement.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">INTREXON CORPORATION</b></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:top;width:48.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Gregory Frost, PhD</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Adam Gridley</p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.15%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gregory Frost, PhD</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.5%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adam Gridley</p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Health Sector</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">SIGNATURE PAGE FOR EXCLUSIVE CHANNEL COLLABORATION AGREEMENT</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Existing Product</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">NeoCart&#174; is a cartilage-like implant created using patient&#8217;s own cartilage cells through a series of tissue engineering processes. First, the patient&#8217;s cells are separated from a tissue biopsy specimen extracted from the patient by a surgeon and multiplied in Histogenics&#8217; laboratory. The cells are then infused into Histogenics&#8217; proprietary scaffold that provides structure for the developing implant. Histogenics&#8217; three-dimensional honeycomb collagen scaffolds are designed to produce a cartilage-like implant. The term &#8220;honeycomb&#8221; describes the shape of the pores inside of the scaffold as they are shaped like a honeycomb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in our Tissue Engineering Processor (TEP). Histogenics&#8217; proprietary TEPs incubate the cell- and scaffold-based implants under conditions designed to mimic the conditions found in the knee and joints, including pressure changes and low oxygen levels, so that the implant is prepared to begin functioning like normal healthy cartilage prior to implantation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The NeoCart impant is shipped to physicians for implantation into the patient with Histogenics&#8217; proprietary bioadhesive, CT3. CT3 is comprised of three components provided in syringes: methylated collagen, activated polyethylene glycol (PEG) and a simple salt buffering solution that acts as a curing component. The syringes of collagen and PEG are mixed at the time of surgery. When the NeoCart implant is implanted, the bioadhesive is used to anchor the NeoCart implant in the cartilage injury and seal the implant to the surrounding native cartilage interface. The curing agent is applied prior to closure of the surgical site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Existing Product therefore includes the cartilage-like implant comprised of cells and scaffold, the adhesive and the curing agent, along with certain tools to facilitate the spreading of adhesive and fixation of the implant and is being evaluated in Phase III clinical trials.</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Please see the attached.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE BORROWER THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONVERTIBLE PROMISSORY NOTE</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">No. CPN-01</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Date of Issuance</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$10,000,000.00</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">September 30, 2014</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FOR VALUE RECEIVED, Histogenics Corporation, a Delaware corporation (the &#8220;Company&#8221;), as payment for the Technology Access Fee (as defined in that certain Exclusive Channel Collaboration Agreement dated September 30, 2014 by and between the Company and Intrexon Corporation (&#8220;Intrexon&#8221;) (the &#8220;ECC&#8221;)), hereby promises to pay Intrexon the principal sum of ten million dollars ($10,000,000.00), together with interest thereon from the date of this Note. Interest shall accrue at a rate of six percent (6%) per annum, compounded annually. As set forth below, the principal and accrued interest under this Note shall be due and payable and converted into shares of the Company&#8217;s common stock, par value $0.001 (the &#8220;Common Stock&#8221;) or payable in cash pursuant to the terms of this Note, upon the earliest to occur of: (i) September 30, 2015, (ii) the Initial Public Offering (as defined below) and (iii) the closing of a Corporate Transaction (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</u>. All payments shall be made in cash or Common Stock pursuant to the terms of this Note at the principal office of the Company, or at such other place as the holder hereof may from time to time designate in writing to the Company. Payment shall be credited first to Costs (as defined below), if any, then to accrued interest due and payable and the remainder applied to principal. Prepayment of principal, together with accrued interest, may not be made by the Company. The Company hereby waives demand, notice, presentment, protest and notice of dishonor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security</u>. This Note is a general unsecured obligation of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Priority</u>. This Note is subordinated in right of payment to all indebtedness of the Company arising under that certain Loan and Security Agreement (as amended and restated or modified from time to time (the &#8220;Senior Agreement&#8221;) between the Company and Silicon Valley Bank, whether existing on the date hereof or hereafter arising (the &#8220;Senior Debt&#8221;). The Company hereby agrees, and by accepting this Note Intrexon hereby acknowledges and agrees, that so long as any Senior Debt remains outstanding, (i) upon notice by Silicon Valley Bank to the Company and Intrexon that an event of default, or any event which the giving of notice or the passage of time or both would constitute an event of default, has occurred under the terms of the Senior Agreement (a &#8220;Default Notice&#8221;), the Company shall not make, and Intrexon shall not receive or retain, any cash payment made under this Note unless and until Silicon Valley Bank provides notice to the Company that the circumstances giving rise to the Default Notice have been resolved, and (ii) if any payment is made in violation of this Section, Intrexon shall promptly deliver the same to Silicon Valley Bank in the form received, with any endorsement or assignment necessary for the transfer of such payment from Intrexon to Silicon Valley Bank, to be either (in Silicon Valley Bank&#8217; sole discretion) held as cash collateral securing the Senior Debt or applied in reduction of the Senior Debt and, until so delivered, Intrexon shall hold such payment in trust as the property of Silicon Valley Bank. Nothing in this Section shall preclude or prohibit Intrexon from receiving and retaining any payment hereunder unless and until Intrexon has received a Default Notice (which shall be effective until waived in writing by the Silicon Valley Bank) or from converting this Note or any amounts due hereunder into shares of Common Stock. This Note shall be senior in all respects (including right of payment) to all other indebtedness of the Company, now existing or hereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of the Company</u>. In connection with the transactions provided for herein, the Company hereby represents and warrants to Intrexon that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization, Good Standing and Qualification</u>. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect on its business or properties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization</u>. Except for the authorization and issuance of the shares issuable in connection with the Initial Public Offering or a Corporate Transaction, all corporate action has been taken on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution and delivery of this Note. The Company has taken all corporate action required to make all the obligations of the Company reflected herein the valid and enforceable obligations they purport to be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Other Instruments</u>. The authorization, execution and delivery of this Note will not constitute or result in a material default or violation of any law or regulation applicable to the Company or any material term or provision of the Company&#8217;s current Certificate of Incorporation or bylaws, or any material agreement or instrument by which it is bound or to which its properties or assets are subject.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Valid Issuance of Capital Stock</u>. The capital stock, when issued, sold and delivered upon conversion of this Note, will be duly authorized, validly issued, fully paid and nonassessable and, based in part upon the representations of Intrexon herein, will be issued in compliance with all applicable federal and state securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of Intrexon</u>. In connection with the transactions provided for herein, Intrexon hereby represents and warrants to the Company that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization</u>. This Note constitutes Intrexon&#8217;s valid and legally binding obligation, enforceable in accordance with its terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or similar laws relating to or affecting the enforcement of creditors&#8217; rights and (ii) laws relating to availability of specific performance, injunctive relief or other equitable remedies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Entirely for Own Account</u>. Intrexon acknowledges that this Note is issued to Intrexon in reliance upon Intrexon&#8217;s representation to the Company that the Note will be acquired for investment for Intrexon&#8217;s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that Intrexon has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Note, Intrexon further represents that Intrexon does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to this Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure of Information</u>. Intrexon acknowledges that it has received all the information it considers necessary or appropriate for deciding whether to acquire this Note. Intrexon further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Experience</u>. Intrexon is an investor in securities of companies in the development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in this Note. Intrexon also represents it has not been organized solely for the purpose of acquiring this Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accredited Investor</u>. Intrexon is an &#8220;accredited investor&#8221; within the meaning of Rule 501 of Regulation D, as presently in effect, as promulgated by the Securities and Exchange Commission (the &#8220;SEC&#8221;) under the Securities Act of 1933, as amended (the &#8220;Act&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Securities</u>. Intrexon understands that this Note is characterized as a &#8220;restricted security&#8221; under the federal securities laws inasmuch as it is being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Act, only in certain limited circumstances. In this connection, Intrexon represents that it is familiar with Rule 144 as promulgated by the SEC under the Act, as presently in effect (&#8220;Rule 144&#8221;), and understands the resale limitations imposed thereby and by the Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Limitations on Disposition</u>. Without in any way limiting the representations and warranties set forth above, Intrexon further agrees not to make any disposition of all or any portion of this Note unless and until the transferee has agreed in writing for the benefit of the Company to be bound by this Section 5, Section 8.8 and Section 8.9 and:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>(i) Intrexon shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, (ii) Intrexon shall not make any disposition to any of the Company&#8217;s competitors as such is in good faith determined by the Company&#8217;s Board of Directors, and (iii) if reasonably requested by the Company, Intrexon shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144 except in extraordinary circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Agreements</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conversion of the Note</u>. The Note shall be convertible according to the following terms:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>The following terms shall have the meanings assigned below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Transaction</u>&#8221; means (A) the closing of the sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets, (B) the consummation of the merger or consolidation of the Company with or into another entity (except a merger or consolidation in which the holders of capital stock of the Company immediately prior to such merger or consolidation continue to hold at least 50% of the voting power of the capital stock of the Company or the surviving or acquiring entity), (C) the closing of the transfer (whether by merger, consolidation or otherwise), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an underwriter of the Company&#8217;s securities), of the Company&#8217;s securities if, after such closing, such person or group of affiliated persons would hold 50% or more of the outstanding voting stock of the Company (or the surviving or acquiring entity), or (D) the liquidation, dissolution or winding up of the Company; provided, however, that a transaction shall not constitute a Corporate Transaction if its sole purpose is to change the state of the Company&#8217;s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately prior to such transaction. Notwithstanding the prior sentence, the sale of shares of the Company&#8217;s preferred stock, par value $0.001 (the &#8220;Preferred Stock&#8221;) in a bona fide financing transaction that would not otherwise qualify as a &#8220;Corporate Transaction&#8221; under the foregoing definition shall not be deemed a &#8220;Corporate Transaction.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Securities</u>&#8221; means the Company&#8217;s Common Stock or Preferred Stock or any securities conferring the right to purchase the Company&#8217;s Common Stock or Preferred Stock or securities convertible into, or exchangeable for (with or without additional consideration), the Company&#8217;s Common Stock or Preferred Stock, except any security granted, issued and/or sold by the Company to any director, officer, employee or consultant of the Company in such capacity for the primary purpose of soliciting or retaining their services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Public Offering</u>&#8221; means the closing of the issuance and sale of shares of Common Stock of the Company in the Company&#8217;s first underwritten public offering pursuant to an effective registration statement under the Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>In the event of an Initial Public Offering of the Company prior to September 30, 2015 or prior to the time when the Note may be otherwise converted as provided herein, all outstanding principal and unpaid accrued interest due on such Note shall be converted into Common Stock at a price equal to the offering price of the Common Stock at the time of the Initial Public Offering, as determined by the Company&#8217;s Pricing Committee of the Company&#8217;s Board of Directors at the time of such Initial Public Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>In the event of a Corporate Transaction prior to September 30, 2015 or prior to the time when the Note may be otherwise converted as provided herein, all outstanding principal and unpaid accrued interest due on such Note shall be converted into Common Stock of Company at the price of the Common Stock offered in such Corporate Transaction, as determined by the definitive agreements governing such Corporate Transaction, or, if not determined in such definitive agreements, as determined in good faith by the Board of Directors at the time of conversion based on an independent 409(a) valuation of the Company&#8217;s Common Stock performed by a valuation firm of regionally recognized standing or the Company&#8217;s auditors. Intrexon shall have the right to review the independent 409(a) valuation prior to final determination by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(d)<font style="display:inline-block;width:24.34pt;"></font>If this Note has not otherwise been converted pursuant to Sections 6.1(b) or (c) hereof by September 30, 2015, the principal and unpaid accrued interest of this Note shall be converted into shares of Common Stock or payable in cash at the Company&#8217;s election. If the Company elects to convert into Common Stock, the number of such shares to be issued upon such conversion shall be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note on the date of conversion by the fair market value of the Common Stock as determined in good faith by the Board of Directors at the time of conversion based on an independent 409(a) valuation of the Company&#8217;s Common Stock performed by a valuation firm of regionally recognized standing or the Company&#8217;s auditors. Intrexon shall have the right to review the independent 409(a) valuation and supporting documents prior to final determination by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(e)<font style="display:inline-block;width:24.9pt;"></font>Upon the conversion of this Note, in lieu of any fractional shares to which Intrexon would otherwise be entitled, the Company shall pay the holder cash equal to such fraction multiplied by the fair market value of such Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(f)<font style="display:inline-block;width:26.01pt;"></font>As promptly as practicable after the conversion of this Note, and in any event within fifteen (15) days following surrender by Intrexon, the Company at its expense will issue and deliver to Intrexon, upon surrender of the Note, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion. Contemporaneously with issuance of any shares under this Note the Parties shall execute an agreement incorporating the Form of Equity Terms attached as Exhibit C of the ECC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defaults and Remedies</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Events of Default</u>. The following events shall be considered Events of Default with respect to this Note:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>The Company shall default in the payment of any part of the principal or unpaid accrued interest on the Note for more than thirty (30) days after the same shall become due and payable, whether at maturity or at a date fixed for prepayment or by acceleration or otherwise;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>The Company shall make an assignment for the benefit of creditors, or shall admit in writing its inability to pay its debts as they become due, or shall file a voluntary petition for bankruptcy, or shall file any petition or answer seeking for itself any reorganization, arrangement, composition, readjustment, dissolution or similar relief under any present or future statute, law or regulation, or shall file any answer admitting the material allegations of a petition filed against the Company in any such proceeding, or shall seek or consent to or acquiesce in the appointment of any trustee, receiver or liquidator of the Company, or of all of any substantial part of the properties of the Company, or the Company or its respective directors or majority stockholders shall take any action looking to the dissolution or liquidation of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>Within thirty (30) days after the commencement of any proceeding against the Company seeking any bankruptcy reorganization, arrangement, composition, readjustment, liquidation, dissolution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or similar relief under any present or future statute, law or regulation, such proceeding shall not have been dismissed or, within thirty (30) days after the appointment without the consent or acquiescence of the Company of any trustee, receiver or liquidator of the Company or of all or any substantial part of the properties of the Company, such appointment shall not have been vacated;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(d)<font style="display:inline-block;width:24.34pt;"></font>Any default or defined event of default shall occur under any agreement to which the Company or any of its subsidiaries is a party that evidences indebtedness of Five Hundred Thousand Dollars ($500,000) or more; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(e)<font style="display:inline-block;width:24.9pt;"></font>The Company shall fail to observe or perform any other obligation to be observed or performed by it under this Note, or any other agreement with Intrexon, within thirty (30) days after written notice from Intrexon to perform or observe the obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">7.2.<font style="display:inline-block;width:21pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies</u>. Upon the occurrence of an Event of Default under Section 7.1 hereof, at the option and upon the declaration of Intrexon, the entire unpaid principal and accrued and unpaid interest on this Note shall, without presentment, demand, protest or notice of any kind, all of which are hereby expressly waived, be forthwith due and payable, and Intrexon may, immediately and without expiration of any period of grace, enforce payment of all amounts due and owing under this Note and exercise any and all other remedies granted to it at law, in equity or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u>. Except as otherwise provided herein, the terms and conditions of this Note shall inure to the benefit of and be binding upon the respective successors and assigns of the parties; provided, however that the Company may not assign its obligations under this Note without the written consent of the Holder. Nothing in this Note, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Note, except as expressly provided in this Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Note shall be governed by and construed under the laws of the Commonwealth of Massachusetts as applied to agreements among Massachusetts residents, made and to be performed entirely within the Commonwealth of Massachusetts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Titles and Subtitles</u>. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Finder&#8217;s Fee</u>. Each party represents that it neither is nor will be obligated for any finder&#8217;s fee or commission in connection with this transaction. Intrexon agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder&#8217;s fee (and the costs and expenses of defending against such liability or asserted liability) for which Intrexon or any of its officers, partners, employees or representatives is responsible. The Company agrees to indemnify and hold harmless Intrexon from any liability for any commission or compensation in the nature of a finder&#8217;s fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</u>. If any action at law or in equity is necessary to enforce or interpret the terms of this Note, the prevailing party shall be entitled to reasonable attorneys&#8217; fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. If one or more provisions of this Note are held to be unenforceable under applicable law, such provision shall be excluded from this Note and the balance of the Note shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.8.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Market Stand-Off&#8221; Agreement</u>. Intrexon hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the Initial Public Offering and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days) (a) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of the Company&#8217;s Equity Securities (whether such Equity Securities are then owned by Intrexon or thereafter acquired), or (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Company&#8217;s Equity Securities acquired through the conversion of the Note contemplated by this Agreement, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of securities, in cash or otherwise. The underwriters in connection with the Company&#8217;s initial public offering are intended third-party beneficiaries of this Section 8.8 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Intrexon further agrees to execute such agreements as may be reasonably requested by the underwriters in the Initial Public Offering that are consistent with this Section 8.8 that are necessary to give further effect thereto, including without limitation the form of lock-up agreement attached as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Standstill Provision</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>Intrexon hereby agrees that, unless specifically invited in writing by the Company&#8217;s Board of Directors to do so, neither Intrexon nor any of its Affiliates (as defined below) will, or will cause or knowingly permit any of its or their directors, officers, employees, investment bankers, attorneys, accountants or other advisors or representatives on Intrexon or its Affiliate&#8217;s behalf to, in any manner, directly or indirectly:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>acquire, offer to acquire, or agree to acquire, directly or indirectly, by purchase or otherwise, any voting securities or direct or indirect rights to acquire any securities of the Company or any subsidiary thereof, or of any successor to or person in control of the Company if after such acquisition Intrexon, together with its Affiliates, would own more than thirty percent (30%), of the outstanding shares of capital stock of the Company or any material assets of the Company or any subsidiary or division thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>effect or seek, initiate, offer or propose (whether publicly or otherwise) to effect, or cause or participate in or in any way advise or, assist any other person to effect or seek, initiate, offer or propose (whether publicly or otherwise) to effect or cause or participate in, any acquisition of any securities (or beneficial ownership thereof) or assets of the Company; any tender or exchange offer, merger, consolidation or other business combination involving the Company; any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect to the Company; or any &#8220;solicitation&#8221; of &#8220;proxies&#8221; (as such terms are used in the proxy rules of the SEC) or consents to vote any voting securities of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font>form, join or in any way participate in a &#8220;group&#8221; (as defined under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), hereafter a &#8220;Group&#8221;) with respect to any securities of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(iv)<font style="display:inline-block;width:21.56pt;"></font>otherwise act, alone or in concert with others, to seek to control or influence the management, Board of Directors, or policies of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(v)<font style="display:inline-block;width:24.34pt;"></font>enter into any voting agreements, trusts or similar arrangements with respect to voting securities of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(vi)<font style="display:inline-block;width:21.56pt;"></font>take any action which could reasonably be expected to force the Company to make a public announcement regarding any of the types of matters set forth in this Section 8.9; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(vii)<font style="display:inline-block;width:18.78pt;"></font>enter into any agreements, discussions or arrangements with any third party with respect to any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>Notwithstanding the foregoing, the Company hereby agrees that the provisions of this Section 8.9 shall not apply to the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>the exercise by Intrexon and/or its Affiliates, if applicable, of any voting rights available to Company stockholders generally pursuant to any transaction described Sections 8.9(a)(i) or (ii) above, provided that Intrexon has not then either directly, indirectly, or as a member of a Group made, effected, initiated or caused such transaction to occur or otherwise violated this Section 8.9;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>the exercise by Intrexon and/or its Affiliates, if applicable, of any voting rights generally available to it or them as non-Affiliate security holders of a third party that is a participant in an action or transaction described in Sections 8.9(a)(i) or (ii) above, provided that Intrexon has not then either directly, indirectly, or as a member of a Group made, effected, initiated or caused such action or transaction to occur or otherwise violated this Section 8.9;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font>any activity by Intrexon after the Company or a third party has made any public announcement of its intent to solicit or engage in any transaction which would result in a Corporate Transaction;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(iv)<font style="display:inline-block;width:21.56pt;"></font>any activity authorized pursuant to the terms of the ECC; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(v)<font style="display:inline-block;width:24.34pt;"></font>making any communication to Company executive management on a confidential basis solely that Intrexon would be interested in engaging in discussions with the Company that could result in a negotiated transaction described in Sections 8.9(a)(i) or (ii) so long as Intrexon does not propose any such transaction or discuss or refer to potential terms thereof without the Company&#8217;s prior consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>Intrexon&#8217;s obligations under this Section 8.9 shall terminate upon the earlier of (i) three (3) years from the date hereof and (ii) the first anniversary of termination of the ECC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(d)<font style="display:inline-block;width:24.34pt;"></font>For purposes of this Section 8.9, &#8220;Affiliate&#8221; shall have the definition set forth in Rule 12b-2 promulgated under the Exchange Act, provided, that Affiliate shall not include any other person, corporation, partnership, or other entity that would be an Affiliate of Intrexon solely because it and Intrexon are under common control by Randal J. Kirk or by investment funds managed by Third Security, LLC or an affiliate of Third Security, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intrexon Proposals</u>. Notwithstanding any of the foregoing provisions of Section 8.9, the Company further agrees that nothing herein shall limit the ability of Intrexon to confidentially propose to the executive management of the Company and its Board of Directors, and/or advocate for, any transaction between the Company and any third party unaffiliated with Intrexon or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.11.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement</u>. Intrexon understands and agrees that the conversion of the Note into Common Stock may require Intrexon&#8217;s execution of certain agreements relating to the purchase and sale of such securities as well as registration, co-sale, rights of first refusal, rights of first offer and voting rights, if any, relating to such securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.12.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exculpation of Intrexon</u>. Intrexon acknowledges that it is not relying upon any person, firm or corporation, other than the Company and its officers and directors, in making its investment or decision to invest in the Company. Intrexon agrees that neither Intrexon nor the respective controlling persons, officers, directors, partners, agents or employees of any Intrexon shall be liable for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with this Note and any Company securities issued upon conversion thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.13.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgement</u>. In order to avoid doubt, it is acknowledged that Intrexon shall be entitled to the benefit of all adjustments in the number of shares of Common Stock issuable upon conversion of the Preferred Stock which occur prior to the conversion of the Note, including without limitation, any increase in the number of shares of Common Stock issuable upon conversion as a result of a dilutive issuance of capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.14.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnity; Costs, Expenses and Attorneys&#8217; Fees</u>. The Company shall indemnify and hold Intrexon harmless from any loss, cost, liability and legal or other expense, including attorneys&#8217; fees of Intrexon&#8217;s counsel, which Intrexon may directly or indirectly suffer or incur by reason of the failure of the Company to perform any of its obligations under this Note, any agreement executed in connection herewith or therewith, any grant of or exercise of remedies with respect to any collateral at any time securing any obligations evidenced by this Note, or any agreement executed in connection herewith (collectively, &#8220;Costs&#8221;), provided, however, the indemnity agreement contained in this section shall not apply to liabilities which Intrexon may directly or indirectly suffer or incur by reason of Intrexon&#8217;s own gross negligence or willful misconduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.15.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurance</u>. From time to time, the Company shall execute and deliver to Intrexon such additional documents and shall provide such additional information to the Intrexon as Intrexon may reasonably require to carry out the terms of this Note, and any agreements executed in connection herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.16.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Jury Trial</u>. TO THE EXTENT EACH MAY LEGALLY DO SO, EACH PARTY HERETO HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, CAUSE OF ACTION OR PROCEEDING ARISING UNDER OR WITH RESPECT TO THIS NOTE, OR IN ANY WAY CONNECTED WITH, OR RELATED TO, OR INCIDENTAL TO, THE DEALING OF THE PARTIES HERETO WITH RESPECT TO THIS NOTE, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND IRRESPECTIVE OF WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. TO THE EXTENT EACH MAY LEGALLY DO SO, EACH PARTY HERETO HEREBY AGREES THAT ANY SUCH CLAIM, DEMAND, ACTION OR PROCEEDING SHALL BE DECIDED BY A COURT TRIAL WITHOUT A JURY AND THAT EITHER PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF ANY OTHER PARTY HERETO TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.17.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Amendments and Waivers</u>. This Note and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. Any term of this Note may be amended and the observance of any term may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the Intrexon. Any waiver or amendment effected in accordance with this Section shall be binding upon each future holder of all such securities, and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.18.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Officers and Directors not Liable</u>. In no event shall any officer or director of the Company be liable for any amounts due and payable pursuant to this Note.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HISTOGENICS CORPORATION</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adam Gridley</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ACKNOWLEDGED AND AGREED:</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTREXON CORPORATION</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:41.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:41.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:41.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A. INFORMATION RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Information Rights</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If, at any time, Intrexon determines that it is required by any law, regulation or any regulatory body applicable to Intrexon, to include information concerning the Company (including, but not limited to, financial information) in any reports or filings, then the Company shall use commercially reasonable best efforts to provide all such reports and information concerning the business and affairs of the Company as Intrexon may reasonably request, in each case within a reasonable time following such request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">B. REGISTRATION RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Piggyback Registration Rights</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If, at any time, the Company proposes to file a registration statement under the Securities Act, other than a registration relating solely to employee benefit plans or Rule 145 transactions, with respect to an underwritten offering for its own account of any class of securities of the Company (a &#8220;<b style="font-weight:bold;">Registration Statement</b>&#8221;), then each such time, the Company shall give written notice of such intention to file a Registration Statement (a &#8220;<b style="font-weight:bold;">Piggyback Notice</b>&#8221;) to Intrexon at least five (5) days before the anticipated filing date. The Piggyback Notice shall describe the number of shares to be registered and the intended method of distribution and offer Intrexon the opportunity to register pursuant to such Registration Statement such shares held by Intrexon (the &#8220;<b style="font-weight:bold;">Registrable Shares</b>&#8221;) as Intrexon may request in writing to the Company within five (5) days after the date Intrexon first received the Piggyback Notice (a &#8220;<b style="font-weight:bold;">Piggyback Registration</b>&#8221;). The Piggyback Registration rights shall be subject ratably to potential underwriter&#8217;s limitations set forth herein. The Company shall take all reasonable steps to include in the Registration Statement the Registrable Shares which the Company has been so requested to register by Intrexon. The Company shall be entitled to suspend or withdraw a Registration Statement prior to its becoming effective. If the managing underwriter with respect to such an offering advises the Company in writing that the inclusion of all or any portion of the Registrable Shares which Intrexon has requested to be included in the Registration Statement would materially jeopardize the success of the offering, then the Company shall be required to include in the underwriting only that number of Registrable Shares which the underwriter advises the Company in writing may be sold without materially jeopardizing the offering. If Intrexon disapproves of the terms of any such underwriting may elect to withdraw its Registrable Shares from it by written notice to the Company and the underwriter. Intrexon also agrees to be subject to any lock-up agreements reasonably requested by a managing underwriter so long as the Company shares held by the Company&#8217;s largest shareholder are also subject to a similar lock-up agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Expenses</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All reasonable fees and expenses incident to the performance of or compliance with the Registration Rights contained in this Agreement by the Company, except as and to the extent specified in this section, shall be borne by the Company whether or not the Registration Statement is filed or becomes effective and whether or not any shares are sold pursuant to the Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses (A) with respect to filings required to be made with each securities exchange or market on which shares are listed, (B) with respect to filings required to be made with the Financial Industry Regulatory Authority and (C) in compliance with state securities or Blue Sky laws, (ii) messenger, telephone and delivery expenses, (iii) fees and disbursements of counsel for the Company, (iv) Securities Act liability insurance, if the Company so desires such insurance, and (v) fees and expenses of all other persons or entities retained by the Company in connection with the consummation of the transactions contemplated by this section, including, without limitation, the Company&#8217;s independent public accountants. Notwithstanding the foregoing, any costs that are incurred by Intrexon or that relate specifically and solely to the inclusion of Intrexon&#8217;s securities in a registration that are in excess of $20,000 per Registration Statement shall be borne by Intrexon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification by the Company</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless Intrexon, its permitted assignees, officers, directors, agents, Affiliates and employees, to the fullest extent permitted by applicable law, from and against any and all claims, losses, damages, liabilities, penalties, judgments, costs and expenses (including, without limitation, reasonable attorneys&#8217; fees and expenses) (collectively, &#8220;<b style="font-weight:bold;">Losses</b>&#8221;), arising out of or relating to any untrue or alleged untrue statement of a material fact contained in a Registration Statement or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, except (i) to the extent that such untrue statements or omissions are based upon information furnished to the Company by Intrexon expressly for use in the Registration Statement; (ii) as a result of the failure of such indemnitee to deliver a prospectus, as amended or supplemented, to a purchaser in connection with an offer or sale; or (iii) the use by the indemnitee of an outdated or defective prospectus after the Company has notified Intrexon in writing that the prospectus is outdated or defective, but only if and to the extent that following such receipt the misstatement or omission giving rise to such Loss would have been corrected; provided, however, that the indemnity agreement contained in this section shall not apply to amounts paid in settlement of any Losses if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification by Intrexon</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Intrexon shall indemnify and hold harmless the Company, its directors, officers, agents and employees to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising out of or relating to any untrue or alleged untrue statement of a material fact contained in a Registration Statement or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, to the extent that such untrue statement or omission is contained in or omitted from any information regarding Intrexon furnished in writing to the Company by Intrexon expressly for use in therein, and that such information was reasonably relied upon by the Company for use therein, or to the extent that such information relates to Intrexon or Intrexon&#8217;s proposed method of distribution of shares and was furnished in writing by Intrexon expressly for use therein. Notwithstanding anything to the contrary contained herein, in no event shall the liability of Intrexon under this section exceed the net proceeds to Intrexon as a result of the sale of shares pursuant to a Registration Statement in connection with which the untrue or alleged untrue statement or material omission was provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">C. PRE-EMPTIVE RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intrexon Election</u>. Until the 5<font style="font-size:8.5pt;">th</font> anniversary of the Effective Date of the ECC, Intrexon shall be entitled to, at its election, participate in each Qualified Financing (as hereinafter defined) conducted by the Company and may purchase as part of, or in connection with, such Qualified Financing an amount of Common Stock or other the Company securities issued and sold by the Company in the Qualified Financing (excluding the securities sold pursuant to this Section 1.1) equal to a pro-rata portion of the aggregate securities offered in the Qualified Financing based on Intrexon&#8217;s percentage ownership of the issued and outstanding securities of the Company (on a fully-diluted basis) as of the time of such Qualified Offering (collectively, the &#8220;<b style="font-weight:bold;">Equity Purchase Participation Right</b>&#8221;). For the purposes of Article C of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u>, a &#8220;<b style="font-weight:bold;">Qualified Financing</b>&#8221; shall mean a sale by the Company of Common Stock, or equity securities convertible into Common Stock, in a public or private offering for primarily equity financing purposes. The price per share paid by Intrexon in any such Qualified Financing shall be the same as that paid by the other investors in such Qualified Financing, and Intrexon shall receive securities of the same type and with the same rights, preferences and privileges as the other investors in such Qualified Financing, including, for example, any warrant coverage, subject to the execution by Intrexon of the investment documents entered into by the other investors in the Qualified Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.2</font></font>In the event that the Qualified Financing is a public offering made pursuant to a registration statement filed with the SEC pursuant to the Securities Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Upon receipt of the prospectus and other offering documents prepared by the Company in connection with such public offering, Intrexon shall, within ten (10) days of receipt of such documents, notify the Company as to whether Intrexon wishes to participate in the Qualified Financing. Upon such election, and subject to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Section 1.2(b), the Company shall permit Intrexon to participate in such public offering in the amount elected by Intrexon in accordance with the preceding sentence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>If counsel to the Company or counsel to any underwriter in such public offering advises the Company that Intrexon&#8217;s inclusion is not permissible under and in compliance with applicable securities laws (including without limitation Section 5 of the Securities Act), the offering and sale of securities to Intrexon pursuant to Article C of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u> shall be made by the Company in a concurrent private placement and not in such public offering. In any such private placement: (i) the offer of the securities in such private placement shall be made on the same terms and conditions as the offer of the securities in the public offering, (ii) the closing of the private placement shall occur concurrently with the closing of the Qualified Financing, and (iii) the Company shall provide registration rights similar to those provided in Article B of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u> with respect to the securities purchased in the private placement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>18
<FILENAME>tmb-20250331xex10d45.htm
<DESCRIPTION>EX-10.45
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:15 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.45</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MUTUAL TERMINATION AND RELEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">THIS MUTUAL TERMINATION AND RELEASE AGREEMENT (the &#8220;<font style="font-style:italic;font-weight:bold;">Agreement</font>&#8221;) is made as of December 21, 2018 (the &#8220;<font style="font-style:italic;font-weight:bold;">Effective Date</font>&#8221;) by and between Histogenics Corporation, a Delaware corporation (&#8220;<font style="font-style:italic;font-weight:bold;">Histogenics</font>&#8221;), and Intrexon Corporation, a Virginia corporation (&#8220;<font style="font-style:italic;font-weight:bold;">Intrexon</font>&#8221;). Histogenics and Intrexon are from time to time referred to herein individually as a &#8220;<font style="font-style:italic;font-weight:bold;">Party</font>&#8221; and collectively as the &#8220;<font style="font-style:italic;font-weight:bold;">Parties</font>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Histogenics and Intrexon are parties to that certain Exclusive Channel Collaboration Agreement dated as of September 30, 2014, as amended (the &#8220;<font style="font-style:italic;font-weight:bold;">Collaboration Agreement</font>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, both of the Parties desires to mutually terminate the Collaboration Agreement and release the other Party from liability in connection therewith in accordance with the terms of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</u>. As consideration for the Parties entering into this Agreement, and in full satisfaction of all of Histogenics&#8217; obligations with regard to the payment of Fully Loaded Costs (as defined in the Collaboration Agreement) in accordance with Section 10.4(m), Histogenics agrees to pay Intrexon up to $1,500,000.00, payable as set forth below in this Section 1. The payments set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1</u> shall be in lieu of any and all other cost reimbursement required to be paid pursuant to Section 10.4(m) of the Collaboration Agreement or otherwise that were or may have been due and owed to Intrexon under the Collaboration Agreement as of the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>$375,000.00 cash shall be paid by Histogenics to Intrexon on the date hereof (the &#8220;<font style="font-style:italic;font-weight:bold;">Effective Date Payment</font>&#8221;). For clarity, if the Effective Date Payment is not paid on the Effective Date, this Agreement shall have no force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Histogenics shall make to Intrexon a second cash payment in the amount of $1,125,000.00 at any time within 12 months following the acceptance by the U.S. Food and Drug Administration of a Biologics License Application for an autologous cartilage implant product</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mutual Release of Claims</u>. Histogenics and Intrexon (each a &#8220;<font style="font-style:italic;font-weight:bold;">Releasing Party</font>&#8221;), on behalf of themselves and their respective officers, directors, managers, members, stockholders, partners, partnerships, employees, representatives, administrators, affiliates, divisions, subsidiaries, predecessors, successors and assigns, hereby fully and forever release each other and their respective officers, directors, managers, members, stockholders, partners, partnerships, employees, representatives, administrators, affiliates, divisions, subsidiaries, predecessors, successors and assigns from, and agree not to sue concerning, any and all claims, suits, charges, demands, losses, costs, expenses (including reasonable attorneys&#8217; fees), duties, obligations, liabilities, commitments and/or damages, acts, causes, occurrences, facts or causes of action relating to or arising out of the Collaboration Agreement, the transactions contemplated by the Collaboration Agreement, any performance or nonperformance under the Collaboration Agreement or any other contract between the Parties or any other prior dealings between Intrexon and Histogenics whether now existing, presently known or unknown, direct or indirect, absolute, accrued, contingent or otherwise, suspected or unsuspected that have occurred prior to or on the Effective Date, including, without limitation, rights arising from any alleged violations of any contracts, express or implied, any covenant of good faith and fair dealing, express or implied, any claim in tort that either Releasing Party may have or any other relationship between Intrexon and Histogenics existing on or prior to the Effective Date. Histogenics and Intrexon agree that the release set forth herein shall be and remain in effect in all respects as a complete general release as to the matters released.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u>. Subject to the surviving obligations set forth in Section 10.5 of the Collaboration Agreement and the obligations of this Agreement set forth above, which are hereby acknowledged by both Parties, the Collaboration Agreement and all other contracts, agreements, undertakings and understandings between the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Parties, and all rights and obligations thereunder, are hereby terminated and without further force or effect as of the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Modifications</u>. This Agreement contains the entire understanding of the Parties relating to the subject matter hereof and supersedes all prior agreements and understandings, written or oral, among or between the Parties relating to the subject matter hereof. The recitals to this Agreement are hereby incorporated by reference into and made a part of this Agreement for all purposes. This Agreement may not be amended, modified, altered or supplemented other than by means of a written instrument duly executed and delivered on behalf of all of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns; No Third Party Rights</u>. This Agreement will be binding upon, inure to the benefit of and be enforceable by the respective successors and assigns of the Parties to this Agreement. Nothing expressed or referred to in this Agreement will be construed to give any person other than the Parties to this Agreement any legal or equitable right, remedy or claim under or with respect to this Agreement or any provision of this Agreement. This Agreement and all of its provisions and conditions are for the sole and exclusive benefit of the Parties to this Agreement, and their respective successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. In the event that any provision of this Agreement, or the application of any such provision to any Party to this Agreement or any set of circumstances, shall be determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to the Parties to this Agreement or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, shall not be impaired or otherwise affected and shall continue to be valid and enforceable to the fullest extent permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Waiver</u>. Neither the failure nor any delay by any Party to this Agreement in exercising any right, power or privilege under this Agreement will operate as a waiver thereof, and no single or partial exercise by a Party to this Agreement of its rights hereunder shall preclude any other or future exercise thereof or the exercise of any other right, power or privilege. Observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with written consent of the Parties to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to any choice of law or conflict of law principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts; Construction</u>. This Agreement may be executed by facsimile or electronic signature and in counterparts, each of which shall constitute an original and all of which, when taken together, shall constitute one agreement. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 30pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</u>. Each of the Parties agrees that money damages would not be a sufficient remedy for any breach of this Agreement by the other Party. The Parties therefore agree that, in the event of any breach or threatened breach by any Party to this Agreement of any covenant, obligation or other provision set forth in this Agreement for the benefit of any other Party to this Agreement, such other Party shall be entitled to (a) a decree or order of specific performance or mandamus to enforce the observance and performance of such covenant, obligation or other provision and (b) an injunction restraining such breach or threatened breach. Such remedy shall not be deemed to be the exclusive remedy for breach of this Agreement but shall be in addition to all other remedies available at law or equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[Remainder of Page Intentionally Left Blank.]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 30pt 0pt;">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered as of the date first written above.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HISTOGENICS CORPORATION</b>,</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Delaware corporation</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:43.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Adam Gridley</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adam Gridley</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">830 Winter Street, 3rd Floor</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waltham, MA 02451</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">INTREXON CORPORATION</b>,</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Virginia corporation</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:43.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Donald P. Lehr</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Donald P. Lehr</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Legal Officer</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20374 Seneca Meadows Parkway</p></td></tr><tr><td style="vertical-align:bottom;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germantown, MD 20876</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>19
<FILENAME>tmb-20250331xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:15 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUBSIDIARIES OF CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;white-space:nowrap;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Legal Name</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Jurisdiction of Incorporation</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Azalea Merger Sub, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware, U.S.</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CTx Operations, Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware, U.S.</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CARISMA Therapeutics S.&#224; r.l.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Luxembourg</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>20
<FILENAME>tmb-20250331xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:16 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We consent to the use of our report dated March 31, 2025, with respect to the consolidated financial statements of Carisma Therapeutics Inc., included herein, and to the reference to our firm under the heading &#8220;Experts&#8221; in the prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">/s/ KPMG LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Philadelphia, Pennsylvania<br>July 18, 2025</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>21
<FILENAME>tmb-20250331xex23d2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:19 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.2</b></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:center;margin:0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">We hereby consent to the use in this Registration Statement on Form S-4 of Carisma Therapeutics Inc. of our report dated July<font style="font-family:'Georgia';">&#160;</font>21,<font style="font-family:'Georgia';">&#160;</font>2025 relating to the financial statements of the NeoCart Business of Ocugen, Inc. which appears in this Registration Statement. We also consent to the reference to us under the heading <font style="font-family:'Georgia';">&#8220;</font>Experts<font style="font-family:'Georgia';">&#8221;</font> in such Registration Statement.</p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">/s/ PricewaterhouseCoopers LLP<br>Philadelphia, Pennsylvania<br>July 21, 2025</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.4
<SEQUENCE>22
<FILENAME>tmb-20250331xex23d4.htm
<DESCRIPTION>EX-23.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:23 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;23.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consent of Lucid Capital Markets, LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 21, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Carisma Therapeutics Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3675 Market Street, Suite 401</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, PA 19104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Re: Registration Statement on&#160;Form&#160;S-4&#160;of&#160;Carisma Therapeutics Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Members of the Board:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We hereby consent to the inclusion of our opinion letter, dated June 22, 2025, to the Board of Directors of Carisma Therapeutics Inc. (&#8220;CARM&#8221;) as Annex B to, and to the reference thereto under the headings &#8220;Prospectus Summary &#8212; Opinion of Lucid for Carisma&#8217;s Board of Directors,&#8221; &#8220;The Merger &#8212; Background of the Merger,&#8221; &#8220;The Merger &#8212; Carisma&#8217;s Reasons for the Merger,&#8221; and &#8220;The Merger &#8212; Opinion of Carisma&#8217;s Financial Advisor&#8221; in the proxy statement/prospectus relating to the proposed merger involving CARM and OrthoCellix, Inc. (&#8220;OrthoCellix&#8221;), which such proxy statement/prospectus forms a part of CARM&#8217;s and OrthoCellix&#8217;s Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) to be filed on the date hereof, which this consent is filed as an exhibit thereto. In giving the foregoing consent, we do not admit (1) that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the rules and regulations of the Securities and Exchange Commission (the &#8220;Commission&#8221;) promulgated thereunder, or (2) that we are experts with respect to any part of the Registration Statement within the meaning of the term &#8220;experts&#8221; as used in the Securities Act and the rules and regulations of the Commission promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Very truly yours,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="tmb-20250331xex23d4001.jpg" alt="Graphic" style="display:inline-block;height:32.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LUCID CAPITAL MARKETS, LLC</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LUCID CAPITAL MARKETS, LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">570 Lexington Ave, 40th Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">New York NY 10022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>23
<FILENAME>tmb-20250331xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:24 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Carisma Therapeutics Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Karthik Musunuri</p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Karthik Musunuri</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: July 17, 2025</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>24
<FILENAME>tmb-20250331xex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:24 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Carisma Therapeutics Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Shine, MBA</p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Michael Shine, MBA</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: July&#160;15, 2025</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>25
<FILENAME>tmb-20250331xex99d3.htm
<DESCRIPTION>EX-99.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:28 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.7pt;text-align:right;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.7pt;text-align:justify;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;">Carisma Therapeutics Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sincerely,</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ David Anderson</p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Name: David Anderson</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: July&#160;15, 2025</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>26
<FILENAME>tmb-20250331xexfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/21/2025 04:00:32 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;107</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Calculation of Filing Fee Tables</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form&#160;S-4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(Form Type)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CARISMA THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(Exact Name of Registrant as Specified in its Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Table&#160;1 - Newly Registered and Carry Forward Securities</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:-0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Security</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Security</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Class&#160;Title</b></p></td><td style="vertical-align:bottom;width:7.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fee</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Calculation</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">or&#160;Carry</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Forward</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Rule</b></p></td><td style="vertical-align:bottom;width:9.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b><br><b style="font-weight:bold;">Registered</b></p></td><td style="vertical-align:bottom;width:6.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Proposed</b><br><b style="font-weight:bold;">Maximum</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Offering</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Price&#160;Per</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Unit</b></p></td><td style="vertical-align:bottom;width:9.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum</b><br><b style="font-weight:bold;">Aggregate</b><br><b style="font-weight:bold;">Offering&#160;Price</b></p></td><td style="vertical-align:bottom;width:7.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fee&#160;Rate</b></p></td><td style="vertical-align:bottom;width:7.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount&#160;of</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Registration</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Fee</b></p></td><td style="vertical-align:bottom;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carry</b><br><b style="font-weight:bold;">Forward</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Form</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carry</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Forward</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">File</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carry</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Forward</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Initial</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">effective</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">date</b></p></td><td style="vertical-align:bottom;width:7.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Fee</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Previously</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Paid&#160;In</b><br><b style="font-weight:bold;">Connection</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">with&#160;Unsold</b><br><b style="font-weight:bold;">Securities&#160;to</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">be&#160;Carried</b><br><b style="font-weight:bold;">Forward</b></p></td></tr><tr><td colspan="13" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Newly Registered Securities</b></p></td></tr><tr><td style="vertical-align:middle;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees&#160;to&#160;Be</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Paid</b></p></td><td style="vertical-align:middle;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Equity</p></td><td style="vertical-align:middle;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Common<br>Stock,<br>$0.001<br>par&#160;value<br>per&#160;share</p></td><td style="vertical-align:middle;width:7.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Other</p></td><td style="vertical-align:middle;width:9.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">327,677,643&#160;(1)</p></td><td style="vertical-align:middle;width:6.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(2)</p></td><td style="vertical-align:middle;width:9.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$1,092.26&#160;(2)</p></td><td style="vertical-align:middle;width:7.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$0.00015310</p></td><td style="vertical-align:middle;width:7.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$0.17</p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Previously</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Paid</b></p></td><td style="vertical-align:middle;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:9.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:6.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:9.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="13" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carry Forward Securities</b></p></td></tr><tr><td style="vertical-align:middle;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carry</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Forward</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Securities</b></p></td><td style="vertical-align:middle;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:9.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:6.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:middle;width:31.37%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Total&#160;Offering&#160;Amounts&#160;</b></p></td><td style="vertical-align:middle;width:6.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$1,092.26&#160;(2)</p></td><td style="vertical-align:middle;width:7.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$0.17</p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:middle;width:31.37%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Total&#160;Fees&#160;Previously&#160;Paid&#160;</b></p></td><td style="vertical-align:middle;width:6.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:middle;width:31.37%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Total&#160;Fee&#160;Offsets&#160;</b></p></td><td style="vertical-align:middle;width:6.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:middle;width:31.37%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Net&#160;Fee&#160;Due&#160;</b></p></td><td style="vertical-align:middle;width:6.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$0.17</p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Relates to common stock, $0.001 par value per share, of Carisma Therapeutics Inc., a Delaware corporation (&#8220;Carisma&#8221;), issuable to holders of common stock, $0.00001 par value per share, of OrthoCellix, Inc., a Delaware corporation (&#8220;OrthoCellix&#8221;), in the proposed merger of Azalea Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Carisma, with and into OrthoCellix, with OrthoCellix surviving as a wholly owned subsidiary of Carisma and the surviving company of the merger.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 39.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 39.75pt;">The amount of common stock of Carisma to be registered includes the estimated maximum number of shares of common stock of Carisma that are expected to be issued pursuant to the proposed merger, without taking into account the effect of a contemplated reverse stock split of common stock of Carisma and assuming an estimated pre-split exchange ratio (which is subject to adjustment prior to the closing of the merger) of approximately 327,677.6433 shares of common stock of Carisma for each outstanding share of common stock of OrthoCellix.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 39.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.75pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the Securities Act of 1933, as amended. OrthoCellix is a private company, no market exists for its securities, and it has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price for the shares of common stock expected to be issued in the proposed merger is one-third of the aggregate par value of the OrthoCellix securities expected to be exchanged in the proposed merger.</font></td></tr></table><div style="margin-top:12pt;"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>tmb-20250331xs4015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &  [0# 2(  A$! Q$!_\0
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MBAG?IYL)Z;6Z[>JGCT- F>V4444""BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***8TJKUX[9-
M#Z*;O% 8&@!U%-WBD,@% #Z*89 #T-/H **** "BBB@ HHHH **** "BBB@
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M/O*BBB@04F!2T4 )BC%+10 FT4$9I:* $Q2T44 %%%% !1110 4444 %%%%
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M=#3_ !MH%UH]TIPT\,;8'NT;?,/PS5+,H0?+B8NF_/;[]AJJEI-6/H3R(O\
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M* (_L\7_ #S7\J/L\7_/-?RJ2B@"/[/%_P \U_*C[/%_SS7\JDHH C^SQ?\
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M'@ ]F;/9>>^U[]CQ?%6NM%K7C35-3\(.@$FDW"(T[A;O[4D1N/O>4K@87&[
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M#_OV* +?VB+_ )Z)_P!]"C[1%_ST3_OH54_L+3_^?*#_ +]BC^PM/_Y\H/\
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M]$_[Z%'VB+_GHG_?0JI_86G_ //E!_W[%']A:?\ \^4'_?L4 6_M$7_/1/\
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M#/FSXW_"JP^*7C&_\0_#[]FWQKJ6D7\S3+K>E>*VT:WU#+9,\=MY<JA7.2&
M4G.XC)->_P#[$VB>&OASJ\V@WOPAUWX7>-=1MGECN_$&IMJKZE!&5,B1738(
MV%D+1A$&"I&XYQX[\2O"'P3OO#7C#XF7'C;QY\,O"5K>2&QL]"U^(G5CYC*6
MM;([VB61U)16V JP8A%Y'HO[!6M> H=64G1?&>E>+=:LFGTK4O'6IQWTM_8A
ME)6!D;$;#*L\>Q205.7 ^4 ^Z*3:*6B@D;L'I08U+;BHW 8SWIU% ";1Z48&
M:6B@!-HI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH *_)W_@H[_P G)7?_ &#[;_T6*_6*OR=_X*._\G)7?_8/MO\
MT6*^AR+_ 'SY/]#Y[/O]QEZK\SY;HHHK]$/RT*7-)10 5T7ASQ]KWA=U.GZC
M+''G_4R'<G_?)XKG:4=:YZ^&HXJ#I5X*47T:NOQ-:=6=)W@[,^GM(\9Q:WI5
MI)J]BDC2Q*[21+GDCGY>OY5;/AW3]47?IEX$/=&.X#VQU%<7X?\ ^0#I_P#U
M[I_*KXRK;@2K#^('!_.OY)Q5&-/$5(T]$I/TW/[3P62>SPU*ME]>5&3C%M7Y
MH-M*]XR_1HT;CP]J5M,L9MC+N.%>([E_'TJ^O@J\,>3<0JY&=F#Q[$U/X3UF
M>:\:UN;@R(R9BW]<@\C/T/Z5UF1ZUYTZDX.Q\MG7$><Y976$GR*22=XIM23V
M^+;SMUV9YE=6LUC<O!/&8Y5Z@_S!J*NR\5Z+<:E]GEMHA)+&K!@6PQ!P>*XV
M5'@F,<J-%*.J.,&NBG-35^I^@9'G%/-\)"KS+VGVHI[-.VVZ3WU[VN/M/^/^
MT_Z^(_\ T,5^O0[?6OR%M.+^T_Z^(_\ T,5^O61D<]Z^SR#:I\OU/D.-=\/_
M -O?^VCZ***^O/S(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH 3%+110 4F*6B@!,4M%% !3)7$<;,Q"J!DD] *?6!\0-!N/%7@/Q'
MHMK(L-SJ.G7%I%(QP%:2-E!)[#)H ^//VCOA5X=_:7^*L.M7?C:R\1^!;'P=
M=SZ?I6E:_#%%#?*\F+J?#@-"W"B3.%:,AL BNX_X)\>&M:T/X77UQ=PVFEZ#
M>31'3M'M/$":VMLR1A9W^T(S(HD<;A$K$)CDY)KP#1OV2_$_CSQA\<=;_P"%
M=Z/X0N+MM$_X1_P[K,\/E3QVJL+B%OL[?);SLG## 9D!.=IKWC]AKX?^*OAS
MJ7Q#LO%/@_0_ C7$]C<0:3X<N_.LN86#. 6)5S@*W !V#&>M!1](_$"6.W\!
M^)));#^U(DTVY9K .$^T@1-F/<>!N^[D],U^7FCZ9+%X?MO&UQJ7[.;Z0;=-
M1_X0K=$MPL9 ;[()\%O. ^3))&\8)QS7ZD^-+_3M,\':[>ZNADTFWL)YKQ%7
M>6A6-C( ._R@\=Z_+/PKHGA:2RT7Q/J7[)WANP^&-]92:G;7U]KJQ:I+IL90
M&YV22J';9(CA< N#\O4&@2/L"V\2?LL^&X4MXT\&6LDBK-+;V,*72Q.0,JSP
M!TW# R,^AZ$$E=EX9_9#^!VGZ3$^D?#W2H+*Z N5"QRC=N488@MD' '%% SS
M;_@H#\(_%?Q/MOA]>>%O!F@^,#HES?7%Y'XDN?*LH(7@5<N-RYSC.?X=F>*X
M']B'X2>,O#7QB'B35?AQX'\*Z ^CW5JNK^"KL3B>8R0$0RD.PVX5FZ=5%>M?
MMU^![CQEX0\/M?>#-;^(G@RRN99=9\,Z!J)M)[AMJ_9Y6 (,J1L')3<.65N=
MN*\Q_89\!VVA?$6XU?P5\-/$WP@\&SV$L.H:;XFU)I?[5N0R&)XK=V+*T8+Y
MDXX?;@[C@ ^[Z^5_VP?#R>,[C1]*U/P/K5\EKJ.G7&E>*O#<>Z_LW:XVSI%*
MI#P.%"$,?D.>>0,?5%-VY.3U]:"3Y"^,G@#XK>-O^"?\_A37["7Q%\3[RUMX
M[B"U:/S)&6[1U+G(3>(57>1QN#8[5]!>,OB>?!^O>#+!_#^IWUKXCNC:->P!
M=MC(5S'YRD[L,3C(! P<UWF*K2:?;RW45R\$3W$0(CF9 70'J <<9[XH ^:;
M[P+'\6/BAX.\4:1\/K_X?>*/#>NM-JFMW5M#;O=V>UUD@$D;'[0LP*GG[N3T
M/7S;6?@+XQD^'?COX*PZ'=/%XD\<G7K?Q&"#9Q:;+=PW,A=LY\U-CILQDDJ>
MF:^Y]I &*-M [GPYXO\ @9XUE\"_%?X06FA7,X\:^,FUZS\0C;]CBL[B6"2<
MRG.5>/RY %Q\V5QWQ]O6MLMG:PV\8(CB0(N3DX P*EQ^5.H$%4[S38[UE9WE
M0K_SSD*_RJY10!F_V#!_SVNO^_[4?V#!_P ]KK_O^U:5% &;_8,'_/:Z_P"_
M[4?V#!_SVNO^_P"U:5% &;_8,'_/:Z_[_M_C1_8,'_/:Y_[_ +?XUI44 9G]
M@0?\]KK_ +_M_C2_V#!_SVNO^_[5I44 9G]@0?\ /:Z_[_M_C1_8,/\ SVNO
M^_[?XUIT4 9G]@0?\]KK_O\ M_C2_P!@P?\ /:Z_[_M6E10!F_V#!_SVNO\
MO^U']@P?\]KK_O\ M6E10!F_V#!_SVNO^_[4?V#!_P ]KK_O^U:5% &;_8,'
M_/:Z_P"_[4?V#!_SVNO^_P"U:5% &;_8,'_/:Z_[_M1_8,'_ #VNO^_[5I44
M 9O]@P?\]KK_ +_M1_8,'_/:Z_[_ +5I44 9O]@P?\]KK_O^W^-']@P?\]KK
M_O\ M_C6E10!F_V#!_SVNO\ O^U']@P?\]KK_O\ M_C6E10!F_V#!_SVNO\
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M4'Z5SM%2X19PXS)L#C6IU*=IK:4?=DO1K]=#IH_#MG?2PW.EW@=4E21HV.<
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M$$\R(-^#_<+[L'^[S6_XS_98\,^,M8UJZ?4-3T^T\16MM9>(K&UE4)J\5O\
MZH2,5+(V,(S(5++P?6NIU;X-:3KUSJT6HZAJEYX=U/1_[%F\+R3J-,6'!!=(
MP@99"IQNW] , $9H ^5?%?B[7/V9/$D4/AS5-0U6+4_AIJ>O7L=[,UV)=4M$
M5DOFWDX+[\.%PK +QQ6Q\.+_ %+X8_%+]G>*SUB_U/\ X6/H%\WB1;Z\DN%N
MKN&VAN%O0&8[9"SNAVX7:P&/E&/</"'[,OAOP]?3WFJWVH>++DZ&?#-N^L,C
M?9]+R<VX"*NXMD;W;+-@9/%2_#C]FW0?AYK^CZL=4U/7IM!TYM'T)-3=&73+
M-B"R)M4;F.U5,C9;:BCL<@'K=(WW:6FORIH$?"O[:>H:'I7QGM6U3]HS4_@G
M-+HD!73=/M7D6^ FF'GL=X&1RF/1*V_V1?B#\*OASHWB'5F^-U[\2-0\0:Y9
M:;<:]K*M$DMXT.VWMXEY&[8IR<]ATQ7,?MM^)O$.B?&RU@T,_"<1OHL#R_\
M"QHD-QN\Z8?N"2&,> ,C)&[=C&374_L%ZW=?$FW\>67BRR^']U+HFKVDEM!X
M+LH_L44GD;UF#C.Y_FQG<2NTCB@9]6_$$Z>_@#Q(-5>6+2SIES]KD@QYBP^4
MV\KG(SMSCWK\F=!\#:=X_N8/B+X2_96LI_@IX;R)+2XW_P!L^($9/*6==S?,
M$)$A51@X)+'/'ZW>,A=#PAK?V'3XM5O?L,_D6$_^KN9/+;;$V?X6. ?K7YP6
M%S\=/AS8_#[Q=JOQ<\1W'B;Q1'/):>"-+\,&ZTR"YC,6--EA#+Y2D2-&9 %"
M%<J6QF@$,\'?LL:O\;M/N/$_@CX8VGP<\,23F"ST/4W=;FX"JNZZD4D[2S%D
M '&(@>]%?I?9R2W%G;R74'V:Y>-6E@5]XC8C)7<,9P>,]Z*!GS5^W)XJ\):'
MX?\ "]IX]T30-5\'/<S:CJ,^N3O') ELJ/LM%7!EN9-Y1(\C=SG@&O,?V./$
M<?C7X[7?Q"UKX7^'/!>O>/=+NM0TU]+NY7U2.P2:,&6^A;Y$$Q:/;*@!=EY4
M!@:[/_@H7\2=7\#^'O VFV&O^#?"]EK6HSQW.K>,;/[9# T<6Z+9%Y<G4D@O
MM^7*\C->;_L6?$+Q%XR_:'9=;^*W@7XDL=!N2R>$K%H;F';);JC32&%,Q@$J
M%W<%AQ0!^@M>0_%/]I#2?AMXTTWPE;Z+J?B;Q'=1V]W-8Z8(U-M:S7(MDF9I
M&526D)54!RQ!^Z.:]>KXW_;3C\'7GB_0+B]NM1\%>/=)N=/DTGQ9;PR%9+:2
MZQ(BE5*3>6RAC"_/S*RCF@1[7XL_:;\+>"_@@OQ4U&PUM?#>$\V!=/(O(&,O
MDE9(F(VE7^4DG'<$BO6E<E S#:<9(STKXG_:.\2>+?'7_!."\O/%^AR:9XSU
M:VMEFTRWM7#R.+U"K^4 60O&@E*D?+N(.,5].^*/C'X6\.:KX4T:^OY8KGQ<
MSV^D2I:RO#+(%!"M(JE8R=R@;R,D\=#0!S>E_M2>#]6\3VNF0Q:BNF7NLR>'
MK/Q"\"C3[G44!+6Z/NW9RK*&*[692H)(Y6__ &HO".G^)[O3FBU"32++5H]!
MO?$B0*=-M=1DV[;9Y-V[.712P4JK.H)!)Q\I^#?"6M3?"SX4?!5=-OX_&_A7
MXA_;=5)MW18K&&^FNSJ E(VF-XY$"G.69MH&>*=XI\'ZP?A7\3?@J=-O/^$[
M\2_$AM4TZ(6TC1S6$]]#=+>^:%V"-(TD#'/RM$5(!Q0.Q]5:Y^U'X0T#Q)J.
MGW$>HR:5I>H0:1J?B** '3K"]F*^7!+(6!S\\89E4JID0,1DX]@S7Y[>-/".
MLQ_#+XU_!D:;=R^.O%OCQ]5T>%;:0QW5E=36\@N1+MV!(ECDWDD;?+QW&?T"
MM83;6L,+.TIC0(7?JV!C)^M F6*3/M2U4N[22Y=2EU+;@=D Y_,4"+5+69_9
M5Q_T$;C\E_PH_LJX_P"@C<?DO^% &G169_95Q_T$;C\E_P */[*N/^@C<?DO
M^% 'S_\ MJ_M"^)?V>_"V@:CX;AL9IK^\:WE%]$SJ%"%N,,.<BOD7_AYG\5?
M^@?X?_\  23_ ..5['_P5 MI(/A[X/WW$D__ !-'^_C_ )Y-Z5^<F:^ZRG!8
M>OA5.I!-ZGP&<9AB</BG"E.RLCZX_P"'F?Q5_P"@?X?_ / 23_XY1_P\S^*O
M_0/\/_\ @))_\<KY'S1FO8_LS"?\^T>'_:^._P"?C/KC_AYG\5?^@?X?_P#
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M<?\ 01N/R7_"C^RKC_H(W'Y+_A0!IT5F?V5<?]!&X_)?\*/[*N/^@C<?DO\
MA0!IT5F?V5<?]!&X_)?\*/[*N/\ H(W'Y+_A0!IU^3O_  4=_P"3DKS_ +!]
MM_Z+%?J?_95Q_P!!&X_)?\*_*S_@HLAC_:.NU9VD(T^VRS=3^[%?0Y%_OGR?
MZ'SV??[C+U7YGR_1117Z(?EH4444 %*.M)2CK3 ]U\/_ /("T_\ ZX)_*M"L
M_P /_P#(!T__ *]T_E6A7\CXS_>JO^*7YL_T R[_ '*A_@C_ .DH****Y#T
MHHHH&26@_P!/M/\ KXC_ /0Q7ZT#Q'I>!G4;7U_UJ_XU^2L'-Q!GO(G_ *$*
M^FI5'F'BL9\0RR*RC3Y^?SM:WR\SX;B7 +&NC>5K<WXV/M'_ (272O\ H(VO
M_?Y?\:/^$ETK_H(VO_?Y?\:^*]H]*-H]*R_XB#5_Z!U_X$_\CXK^P8_\_']Q
M]J?\))I?_01M?^_J_P"-'_"2Z5_T$;7_ +_+_C7Q7M'I1M'I1_Q$&K_T#K_P
M)_Y!_8,?^?C^X^TSXCTH_P#,1M?^_P O^-0W-WH>N)]BGFLKU)?E\AV5]WMB
MOC+:/2NE^&L6_P ?:$JL8RURH#+U'O73A>.:F*KPH/#I<S2^+N[=C.KDD:<)
M2Y]EV/5/&?[+7A[697O-!N)O#FH [E,!+1$_[N01_P !(KC5\0?%WX*N%U*U
M'BG1(^/-!,H"_P"^!N3\017T=_9=Q_T$;C\E_P *1M*F(YU"XQ]%_P *_1ZF
M6T^;VE!NG+RV^:V9\8Z2WCHSSKP/^TIX1\8&.WN)WT/4&X^SW_"EO19!\I_2
MO4X;F.X19(I$DC89#H<@UYMXQ_9^\+>- TEW T%V1_Q\VH6-R?? P?QKS*X^
M$WQ,^$Y>X\':TVM:<G/V)S\X'^XWRG\"#[5'M\9A?X\.>/>._P U_D+FJ0^)
M7]/\CZ:S2U\W^&OVF4CNUT[QE;:AX?OD.UYHXB8P?5D(W+^ ->U:'J-EXELU
MN]*\0B_MVZ/;NC ?7C@^QKNH8RAB?X4KOMU^XTC.,_A9TU%9?]ESG_F)7&/H
MO^%+_95Q_P!!&X_)?\*[30TZ*S/[*N/^@C<?DO\ A1_95Q_T$;C\E_PH TZ*
MS/[*N/\ H(W'Y+_A1_95Q_T$;C\E_P * -.BLS^RKC_H(W'Y+_A1_95Q_P!!
M&X_)?\* -.BLS^RKC_H(W'Y+_A1_95Q_T$;C\E_PH TZ*S/[*N/^@C<?DO\
MA1_95Q_T$;C\E_PH TZ2LW^RKC_H(W'Y+_A1_95Q_P!!&X_)?\* -.BLS^RK
MC_H(W'Y+_A1_95Q_T$;C\E_PH TZ2LW^RKC_ *"-Q^2_X4?V5<?]!&X_)?\
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M  KY*MQ5E.'J2I5*MI1=GH]U\CU899BJD5*,='YH][Q1BO!/^&E;O_H!Q?\
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M'/P7X=\7CPU?:U%!J:O%%-\K&*VDEXA2:3[L;.>%#'GBN_S0 M%%% !1110
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M:_Y &F_]>Z?RK];X _C8CTC^;/E<^^"GZLU:***_:#XX**** "BBB@ HHHH
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M_H!EW^Y4/\$?_24%%%%<AZ 4444 .M_^/B#_ *Z)_.OIN7_6'VKYD@_U\/\
MUT3^=?3<O^M:OBN(MZ/_ &]_[:?.9MO#Y_H,HHHKXX\ **** "NF^&V\^/="
M$)42?:5VEQD?C7,UU'POX^(>@?\ 7TE>IE?^_4?\4?S1S8G^#/T9]5&+6<_Z
M^RQ_UR?_ .*I/*UG_GO9?]^F_P#BJU:*_J\_+3*\K6?^>]E_WZ;_ .*I?*UC
M_GM9?]^F_P#BJU** ,KRM9_Y[V7_ 'Z;_P"*I?*UC_GM9?\ ?IO_ (JM2B@#
M*\K6?^>]E_WZ;_XJCRM9_P">]E_WZ;_XJM6B@#+\K6/^>UE_WZ;_ .*I/*UG
M_GO9?]^F_P#BJU:* ,KRM9_Y[V7_ 'Z;_P"*H\K6?^>]E_WZ;_XJM6B@#+\K
M6/\ GM9?]^F_^*JO=Z;J-]"T-S_9UQ$W!22%B#^!-;E%)JZLP/#O%_[+VC^(
MG:ZL'B\/ZAG<)+%&\HGWC)X^H(KD"WQ?^"QP=OBK1(^[9F 7]'3]17T^1D4A
M7((ZUY-7+:3E[2BW3EWCI]ZV9C*DF[QT?D>(>$/VF-'\32);7L\/A[4"=IAO
MHF://M("/R(%>K6UQJ-[ DUO>:?/$XRKQHS _B&K \:?!;PIX[5VU'3(TN6'
M%U;?NY!^(Z_C7D-]\$_'_P +YVO/ NO2:E9*=QL9F"OCTVGY&_0UG[;&X7^+
M#VD>\='\U_D3S5(?$KKR/H/R]8/_ "WLO^_3?_%4>5K/_/>R_P"_3?\ Q5>&
M>&OVI)M(O%TWQWH5SI-TIVM=0Q-C/JT9Y'U4FO5+OXQ^#K/P]_;3:]:R:?T#
M1-N<G^Z$'S9]L5U4<?AJT7)32MNGHU\F:1J0ELSH/*UC_GM9?]^F_P#BJ/*U
MC_GM9?\ ?IO_ (JO.M!_:?\  VO:DED+F[L'D;:DM[;[(V/;Y@3C\<5ZK',D
MR*Z,&5AD$<@BNFCB*.(5Z4E+T*C*,OA=S.,6L8_U]E_WZ;_XJN4^)>O:_P"%
MO"5SJ%M<VD<T;J%982>I]"2*[\]*\\^.W'PYO?\ KHG\ZX,WJ3I9?7G3=FHR
ML^VAVX2*GB(1DKIM'CG_  O7QF/^8C#_ . L?^%'_"]O&?\ T$8?_ 6/_"N!
M)S25_-_]N9I_T$S_ / G_F?H?U+#?\^X_<CO_P#A>WC/_H(P_P#@+'_A1_PO
M;QG_ -!&'_P%C_PK@**/[<S3_H)G_P"!,/J6&_Y]Q^Y'?_\ "]O&?_01A_\
M 6/_  H/QU\9X/\ Q,H?_ 6/_"N H/2C^W,T_P"@F?\ X$_\P^I8;_GW'[D?
M0/P=\>^)O&MYJ4=Y>6TH@1&4/;A<9)_NX]*]0\K6?^>]E_WZ;_XJO%OV9_\
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M)/\ <X^K_,_+\_\ ]]?HOR"BBBO>/G HHHH *_2O_@EO_P DW\7_ /81B_\
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M#Y3)]XIGY<_A7-Z%^ROX.T?4ENYC=ZD$;<D-RX* ]L@=?QKV"&!((TCC4(B
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M^?*'_O\ ?_6H TZ*S/M.J?\ /E#_ -_O_K4?:=4_Y\H?^_W_ -:@#3K\G?\
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MA_[_ '_UJ/M.J?\ /E#_ -_O_K4 :=%9GVG5/^?*'_O]_P#6H^TZI_SY0_\
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MAIT5F?:M4_Y\H?\ O]_]:I;2>^DF GMXXX\?>63<<_E0!>I&&5-+2,,@XZT
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M_0,N?R7_ !H_M:?_ *!ES^2_XUJ44 9?]K3_ /0,N?R7_&C^UI_^@9<_DO\
MC6I10!E_VM/_ - RY_)?\:/[6G_Z!ES^2_XUJ44 9?\ :T__ $#+G\E_QH_M
M:?\ Z!ES^2_XUJ44 9?]K3_] RY_)?\ &C^UI_\ H&7/Y+_C6I10!E_VM/\
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M<&BNGL8%L;*WMUFDG6*-4$LS[G<  ;F;N3W-% %VBBB@04444 %-*Y(YIU%
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ML^G7=^OB'3?L=HXCN)S<*%A8G #9/&<C&>M7/#?C;0O%[7JZ)JUIJC64ODW
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M*-5NY8Q<,+RS^82::L<?W;Q7*A6&4=2#G*MN!GLEE^S]^TK=0 :K\:-+MFB
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MQ\.O$'A/X]>/-?N]#.F:!K&E:7!:R"2/#S00A)LHK$@Y[D<U]!A0!C%&T>E
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M^8Y=&P^1Q( &Z9Z=*^I\"J6L:)I_B'3Y;#5+&WU&QEQYEM=1"2-\$$94Y!Y
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M9JIJ5F;^PN+<'9YL93=Z9&*SGS<KY=QJUU<\R'[1_AT_\N>H?]^U_P#BJ/\
MAH_P[_SYZA_W[7_XJN?'[,\@&/[<'_?C_P"O2_\ #-,O_0<'_?C_ .O7Y?\
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M(<1R88 E&/ <94^M>6Z3^RE?6FG?%'0FUD6^@:X;C_A'8X<E],%PN9\_609
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M  'W!R2<]=OI0 _X'_&JU^+OPS3Q3=VG_".75M)/;:KI]Y( VGSPL5E20G&
M-I.3CCFLSQA^U9\./"'AK4M9?7X]173[BVM9K2S1WG#W#!83LQD(W)#XVD*<
M$GBO*=6_95\5'5OB_P"&]&OQ9>!/'EDDJW5S>-+=VVIA0'F*X^9)-JAANSP?
M6K_BOX/_ !4^)GPBU#2]?TGPII'BB&;3#;2:9<2,+U+2X27][,4#*"%.U<-M
M)]Z /:KSXY^!=-M-8N;WQ+96,>C&W&I_:&*&R,X7R?-!&5W;UP3ZBIA\;? S
M^*(O#B>)]/?6)9S:);K)D&<)O,.\#:)=OS>63NQSBOG;XM?LT_$3QC<?%5=+
MBT7RO'=GHY:2YNW4VDUIY(>/ 0[E819#>_2I-8_9U^)6K^.=.OYXM!?3]-\:
M0:_;R6\[6^ZS6)XV1HECPTPWDF1B2V!R.E &O%^U=XD71K&\DT73&>7XCMX(
MF5'DPL(>1/.7G);]WG!XYKW+1/C#X.\1Z*NKZ;X@MKW3GU#^RA/"&(^U;MOE
M8QG=N&/PKYR/[-7CMM M;7[/IJ2Q_$]O&K[KLX^QF25]@.W_ %F) ,=.#S76
M?!/2/#_C3XN>*_&/@77%U/P!>W*W\UK' Z0C6]K13R1LP&X% I;C&]F/7- '
M;_M#?%[6?A'!X'?2-/L;]_$?B2V\/M]MD=1"9DD99!MZX\H\>]8G@G]J+3+K
MQ-XT\-^+_L>C:KX9U*+3OM5A*US;:@\L7G(D  +M*J9\R( E-ISQ4_[3GPK\
M0?%B+X?6NC65I<6^A^*;37K[[7/Y8DAA256B4;3EF\W(S@<5)\2_A)JXF\#C
MP#I&B:;IFG:H]UJUH(UM9Y$>(KOBG5"4;=@N1AG4$;J -R;XSZ7JWB3X=1>'
M?$?AR]T?Q2UTR&6X<W%XD<)8?9 ORLRL/G#8P >]<_XD_:1L[7XV_#;P/X?E
ML-:MO$MUJ-M?72M)NMC;6YDS$P&Q_G&QL$XS7D_PX_99\>^%-/\ @G87QTQ4
M\%:AKDM]<65TV\Q7J2I&T.Y?O*9=Q!].]:GP_P#V>_B1H/B#X(6^J1:$VE?#
M:YU"!]0M[AQ+J%M-:F&*7RRGRR'.7!8\Y.:!GUM11102%%%% !1110 4444
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M6T85H)8U'RQN0>5.1GIQ0%D?0]C\:O!&I:3>ZC;>)+.6VLKK[#<KEA+%<?\
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' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>tmb-20250331xs4016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %_ [8# 2(  A$! Q$!_\0
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M**?M'>,=(^('P]^ OPYU.70/$7C::!;[6K639<6\$T_D1QQ.#E&9@[,PPP"
M*?F->\:5^PW\'=%\(+H=IX9>&\"@GQ)'=RIK+38_UYO%(EW[OFX.T'HH'%?+
M_P#P4L^"7BW0OC'\-OVA_!VC7&O1^%9;4:S:6,)DGB6WN?/BFVC)9"&=&/\
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M$]M;"2P@@9E+NK'[\Y0_+%@8W[F^[M;ZJ^'/C<?$+PG:ZTNA:[X;$Q=/[/\
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M[<[DE<'"$ @D$\9YKIOVX/$ND2_\%#/V9+M=3LY+:&6QFDE2=61(WOLHY;.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#_  ):@#4HK+_L!?\ G^O_ /P):C^P%_Y_K_\ \"6H U**R_[ 7_G^O_\
MP):C^P%_Y_K_ /\  EJ -2BLO^P%_P"?Z_\ _ EJ/[ 7_G^O_P#P):@#4HK+
M_L!?^?Z__P# EJ/[ 7_G^O\ _P "6H U**R_[ 7_ )_K_P#\"6H_L!?^?Z__
M / EJ -2BLO^P%_Y_K__ ,"6H_L!?^?Z_P#_  ):@#4HK+_L!?\ G^O_ /P)
M:C^P%_Y_K_\ \"6H U**R_[ 7_G^O_\ P):C^P%_Y_K_ /\  EJ -2BLO^P%
M_P"?Z_\ _ EJ/[ 7_G^O_P#P):@#4HK+_L!?^?Z__P# EJ/[ 7_G^O\ _P "
M6H U**R_[ 7_ )_K_P#\"6H_L!?^?Z__ / EJ -2BLO^P%_Y_K__ ,"6H_L!
M?^?Z_P#_  ):@#4HK+_L!?\ G^O_ /P):C^P%_Y_K_\ \"6H U**R_[ 7_G^
MO_\ P):C^P%_Y_K_ /\  EJ -2BLO^P%_P"?Z_\ _ EJ/[ 7_G^O_P#P):@#
M4HK+_L!?^?Z__P# EJ/[ 7_G^O\ _P "6H U**R_[ 7_ )_K_P#\"6H_L!?^
M?Z__ / EJ -2BLO^P%_Y_K__ ,"6H_L!?^?Z_P#_  ):@#4HK+_L!?\ G^O_
M /P):C^P%_Y_K_\ \"6H U**R_[ 7_G^O_\ P):C^P%_Y_K_ /\  EJ -2BL
MO^P%_P"?Z_\ _ EJ/[ 7_G^O_P#P):@#4HK+_L!?^?Z__P# EJ/[ 7_G^O\
M_P "6H U**R_[ 7_ )_K_P#\"6H_L!?^?Z__ / EJ -2BLO^P%_Y_K__ ,"6
MH_L!?^?Z_P#_  ):@#4HK+_L!?\ G^O_ /P):C^P%_Y_K_\ \"6H U**R_[
M7_G^O_\ P):C^P%_Y_K_ /\  EJ -2BLO^P%_P"?Z_\ _ EJ/[ 7_G^O_P#P
M):@#4HK+_L!?^?Z__P# EJ/[ 7_G^O\ _P "6H U**R_[ 7_ )_K_P#\"6H_
ML!?^?Z__ / EJ -2BLO^P%_Y_K__ ,"6H_L!?^?Z_P#_  ):@#4HK+_L!?\
MG^O_ /P):C^P%_Y_K_\ \"6H U**R_[ 7_G^O_\ P):C^P%_Y_K_ /\  EJ
M-2BLO^P%_P"?Z_\ _ EJ/[ 7_G^O_P#P):@#4HK+_L!?^?Z__P# EJ/[ 7_G
M^O\ _P "6H U**R_[ 7_ )_K_P#\"6H_L!?^?Z__ / EJ -2BLO^P%_Y_K__
M ,"6H_L!?^?Z_P#_  ):@#4HK+_L!?\ G^O_ /P):C^P%_Y_K_\ \"6H U**
MR_[ 7_G^O_\ P):C^P%_Y_K_ /\  EJ -2BLO^P%_P"?Z_\ _ EJ/[ 7_G^O
M_P#P):@#4HK+_L!?^?Z__P# EJ/[ 7_G^O\ _P "6H U**R_[ 7_ )_K_P#\
M"6H_L!?^?Z__ / EJ -2BLO^P%_Y_K__ ,"6H_L!?^?Z_P#_  ):@#4HK+_L
M!?\ G^O_ /P):C^P%_Y_K_\ \"6H U**R_[ 7_G^O_\ P):C^P%_Y_K_ /\
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M:G&,DGCU;X9>/M/^*GP]\.>,=)2>+3-=L(-1MX[E=LBI*@<*P!(W#.#C(]*
M.IHKP+X2_M)ZI\9/B!K$'A[PUHMW\-].FF@?QA;^*[>XFW1@@![%(]\.]E;&
M]Q\HW8YQ6=\//VL3XSU/P/J-YH']F^!_']Y=V'AC5?/+3F:#S"GVJ,J!&+A(
MI'BVEB-FUN6X!V/HZBOG'P?^UNGB;4/".L3Z#':_#GQGKMSX=\.Z^+O=-)=1
M-.L;S0[1LCN&MY!%@DC:-P&\8^CJ!!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!S?Q$Y^'WB;/3^R[K_ -%-7X/#M7[Q?$3_ ))]XF_[!EU_Z*:O
MP=]*^SX=5U4^7ZGQ/$C:C2L^X8'K1@>M)17V-D?"\\NXN!ZT8'K24460<\NX
MN!ZT=J2E7H*5D5&<KK4_;?\ 9E_Y-Y^&W_8!L_\ T2M>G5YC^S1_R;Q\-_\
ML 67_HE:].K\BK_Q9^K_ #/V?#_P8/R7Y!1116)N%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M91G%2B[IFJ:>J,K_ (1^/_G[O?\ P);_ !H_X1^/_G[O?_ EO\:U:*H9E?\
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MWB^(G_)/O$W_ &#+K_T4U?@[Z5]GP[M4^7ZGQ'$VL:7S_02BBBOLCX,****
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M[O?_  );_&C_ (1^+_G[O?\ P);_ !K5HH RO^$?B_Y^[W_P);_&C_A'X_\
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M^=^""_*KD9"C['L/M7V&W^V^3]L\M?.^SY\O?@;MN>=N>F><5;HHH)"BBB@
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M_"/P?\_%W_X$/_C0!JT5E_\ "/0?\]KO_P "'_QI/^$?@_Y^+O\ \"'_ ,:
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M7?\ X$/_ (TG_"/P?\_%W_X$/_C0!JT5E?\ "/P?\_%W_P"!#_XTO_"/0?\
M/:[_ / A_P#&@#4HK*_X1^#_ )^+O_P(?_&E_P"$>@_Y[7?_ ($/_C0!J45E
M?\(_!_S\7?\ X$/_ (T?\(_!_P _%W_X$/\ XT :M%97_"/P?\_%W_X$/_C1
M_P (_!_S\7?_ ($/_C0!JT5E?\(_!_S\7?\ X$/_ (T?\(_!_P _%W_X$/\
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O$_BY^SGI_C2276- *:-XB!\PLF4AN''=@.4;_ &U_'->V45S8C#4L
M5#V=577];$2@IJTCYG\"_M :UX$U?_A%?B7;SP30D(NI2+EU'0&3'$BGM(OX
MYKZ.L[ZWU*TBNK2>.YMI5#QS1,&1QV(8<$5SWCSX<Z%\2-)^PZU:B7;\T5S'
M\LT+>J-CCZ=#W%?/#P>.?V7=3\R(MKW@R67+#D1\GN.?)<^OW&KQ_:U\MTK7
MG2_FZK_%W7F87E1TEJNY]945Q_P\^)VA?$O2_M>DW694 \^SEPLT!/9E]/0C
M@UV%>[3J0JQ4Z;NF=*::N@HHHK084444 %%%% !1110!SGQ$_P"2?>)O^P9=
M?^BFK\'?2OWB^(G_ "3[Q-_V#+K_ -%-7X.^E?:<.[5/E^I\1Q+\-+Y_H)11
M17V)\&%%%% !1110![OX?_Y .F_]>L?_ * *OU0T+_D Z;_UZQ_^@BK]?R1C
M?]ZJ_P"*7YL_O_+?]QH?X(_^DH****Y#T0HHHH *_0/]B7_D@UE_U_7?_HPU
M^?E?H'^Q+_R0:R_Z_KO_ -&&OH,C_P!Z?H_T/B>+_P#D7+_&OR9[[1117WI^
M,!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)_X1V+_G[O?_  );_&C_ (1V'_GZOO\ P);_ !K6HH R?^$>A_Y^KW_P)?\
MQH_X1R'_ )^[[_P*?_&M:B@#)_X1^'_GZOO_  *;_&C_ (1Z'_G[O?\ P(?_
M !K6HH R?^$=A_Y^K[_P);_&C_A'(?\ G[OO_ I_\:UJ* ,G_A'8?^?J^_\
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M^E?9\.[5?E^I\1Q-\-+YB4445]D?!A1110 4444 >[^'_P#D Z;_ ->L?_H
MJ_6?H'_("TS_ *]HO_016A7\D8S_ 'JK_BE^;/[_ ,M_W&A_@C_Z2@HHHKD/
M1"BBB@ K[X_8RTN.]^!=@[37$9%_=<12L@_UA[ U\#U^@?[$O_)!K+_K^N__
M $8:^@R/_>GZ/]#XGB__ )%R_P :_)GL_P#PCD/_ #]WW_@4_P#C1_PC\/\
MS]7W_@4W^-:U%?>GXP9/_".0_P#/W??^!3_XT?\ ".P_\_5]_P"!+?XUK44
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M%_J,DK6C(US$/*992Q63*JRD$ CS..*]T_:^\2>+=$;PC%\/OA3I'Q-\:/\
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MP N[KP*]IU'4+?2K"YOKR9+>TMHFFFF<X6-%!+,3Z #-?(_Q^@\>:_\ LO\
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M_A'+?_GXO/\ P)?_ !H U:*RO^$<M_\ GXO/_ E_\:/^$<M_^?B\_P# E_\
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M)]145X;\)?C/H7Q',>G7\L^B^(3\OV4W+B*=AP?*8G.?]D_,/>O7?^$<M_\
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M .- &K165_PCEO\ \_%Y_P"!+_XT?\(Y;_\ /Q>?^!+_ .- &K165_PCEO\
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M_A'+?_GXO/\ P)?_ !H_X1RW_P"?B\_\"7_QH U:*RO^$<M_^?B\_P# E_\
M&C_A'+?_ )^+S_P)?_&@#5HK*_X1RW_Y^+S_ ,"7_P :/^$<M_\ GXO/_ E_
M\: -6BLK_A'+?_GXO/\ P)?_ !H_X1RW_P"?B\_\"7_QH U:*RO^$<M_^?B\
M_P# E_\ &C_A'+?_ )^+S_P)?_&@#5HK*_X1RW_Y^+S_ ,"7_P :/^$<M_\
MGXO/_ E_\: -6BH;> 6\*Q*6*J, N2Q_$GK4U !17B?[3/QTNO@MHWA^#38M
M/36?$=W/86.H:Y,8=.M98[6:X'FL.6=_*\N.,8+NX&1BH9?CQKW@7X=7FJ>.
M_#44?B)=1M-)TJTT>5Q#KUQ=+%]F6#SE5HR9)61U;<4\IVRPH'8]RHKQ'QO\
M<-6\,^)O#?P[TZSTG6/B;JED+^[62X:VTS3+8OY0N)6;,CAY2(XXD!>1L_=
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M*T**!&7_ ,(]:_WKG_P(?_&C_A'K7^]<_P#@0_\ C6I10!E_\(]:_P!ZY_\
M A_\:/\ A'K7^]<_^!#_ .-:E% 'QY_P4JTV&R_9[T]HS(2=?MA\\C./]3/V
M)/I7Y>5^IW_!3;_DWK3_ /L8+;_T3<5^6-?H>1?[I\V?FW$7^]+T"BBBOHCY
M4**** "O5OV5P'_:.^'0/0ZU;]./XJ\IKU;]E3_DX_X<?]AJW_\ 0JY<7_N]
M3T?Y'H9?_O=+U1^SA\/VI_CN?_ A_P#&C_A'K7^]<_\ @0_^-:E%?DA^QF7_
M ,(]:_WKG_P(?_&C_A'K7^]<_P#@0_\ C6I10!E_\(]:_P!ZY_\  A_\:/\
MA'K7^]<_^!#_ .-:E% &6/#]J/X[G_P(?_&OC&Y_X^9_^NC_ ,S7W%7P[<_\
M?<W_ %U;_P!"-?D/B%\&%]9_^VGUF0;U/E^I'1117XT?7A1110 4444P/JOX
M9:/!=?#_ $"1VFW-:)G;,P'?L#BNG_X1ZU_O7/\ X$/_ (UC?"K_ ))SX?\
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M^L^&7U?5](,YD%M)!/#!;W(4D^69$D>,@8#>2IQ\N:\1^/'_  34TWXC>/\
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M169_PCEE_=F_[_O_ (T?\(Y9?W9O^_[_ .- &G169_PCEE_=F_[_ +_XT?\
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M_P"_^- &G17'ZY\/AK%S%-#X@US1T1=IAT^Z54<YSN;>K'/;@UG_ /"II/\
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M^M_T$+_P%_YGT']O0_Y]O[SX^W#UHW#UK[!_X5SX:_Z MK_WQ1_PKGPU_P!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0@K)#44E9'W;1115@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M::/\._!E_9ZPPC< 3O9J1964:<DQJVQW+=HU4=3CW&@3"BBB@04444 %%%%
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MZ8^E:1-=O>R1RSO.SRLJJ6+.23\J*,9_AKT>B@ HHHH **** "BBB@ HHHH
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M@B6FT--2U'4S:)IZZKKVHRW]W':(Q9;:.20GRX0QSL0*I.,YP,>J44 %%%%
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M ,:/^$:T_P#YXR?]_P"3_P"*K5HH RO^$:T__GC)_P!_Y/\ XJC_ (1K3_\
MGC)_W_D_^*K5HH RO^$:T_\ YXR?]_Y/_BJ/^$:T_P#YXR?]_P"3_P"*K5HH
M RO^$:T__GC)_P!_Y/\ XJC_ (1K3_\ GC)_W_D_^*K5HH RO^$:T_\ YXR?
M]_Y/_BJ/^$:T_P#YXR?]_P"3_P"*K5HH RO^$:T__GC)_P!_Y/\ XJC_ (1K
M3_\ GC)_W_D_^*K5HH RO^$:T_\ YXR?]_Y/_BJ/^$:T_P#YXR?]_P"3_P"*
MK5HH RO^$:T__GC)_P!_Y/\ XJC_ (1K3_\ GC)_W_D_^*K5HH RO^$:T_\
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M3_XJM6B@#*_X1K3_ /GC)_W_ )/_ (JC_A&M/_YXR?\ ?^3_ .*K5HH RO\
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M_P!_W_\ BJU:* ,K_A&M/_YXR?\ ?^3_ .*H_P"$:T__ )XR?]_Y/_BJU:*
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M?BYXZD^&7PR\2^*XK-=0DTBRDNQ:O)Y8E*C.W=@XS]*^'_\ AZQJG_1.;/\
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MHWQSJNO_  3?XB:W>?#ZW\7^&-3U'6-.M[1$(GMIHTMI8]\3R1"6-_,*'IO
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MKTQEMZ!L;=AQC..M<V(Q%/#1YZKLCOP6!Q&85'2PT;R2ONEI\_4^FJ*^,/\
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M';RVUI#Y0CA=4&,KN/S9);KDT"/=Z*** "BBB@ HHHH **** "BBB@ HHHH
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MX@^$OP \/>"+F;2;_6]%TQ-.BN(1*MM/Y:!$9\C<,@<X_"N'^"/P6^*'P?\
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M.6/)9-WF#*@K7'?&'Q=XE\-_#KQ'J]GXV\30,GQ3LM)BG@OV9DTZ:2V#11@
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>tmb-20250331xs4023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $> ]P# 2(  A$! Q$!_\0
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MZ7XYUOPQJ"V-C9>"X=7L[::U1GL[[[1Y<RR;ER2IRNUN.^!FM5A*CMM_5O\
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M\'7EJ_Q!\1Z-'KE]<3PQF,V\-HLUP=I4JID=E5> .2 1UK0^+_QS\5:M\*/
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MF;XZ>-O&7B;5='\;O9/=ZQI4?BGPU#;A5Q82.R>4Y"C#*PCZY;Y\]*X3X/\
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MHBBCZQ56TA_5Z;>J/F75/V+K&WT+Q!H7A;Q3-X6T:]UBTUS3K&&Q6=-,N(E
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MOXO^(K>.8IU46\;:+;Z?]F(SN.8C\V<CKTQ7HE%3*M.:M*WW(J-&$'>/YO\
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M#G)_X*KO_P"-5^.5%']D4.[_  _R#^U*W9?C_F?L;_P\'^!7_0YR?^"J[_\
MC5'_  \'^!7_ $.<G_@JN_\ XU7XY44?V10[O\/\@_M2MV7X_P"9^QO_  \'
M^!7_ $.<G_@JN_\ XU1_P\'^!7_0YR?^"J[_ /C5?CE11_9%#N_P_P @_M2M
MV7X_YG[&_P##P?X%?]#G)_X*KO\ ^-4?\/!_@5_T.<G_ (*KO_XU7XY44?V1
M0[O\/\@_M2MV7X_YG[&_\/!_@5_T.<G_ (*KO_XU1_P\'^!7_0YR?^"J[_\
MC5?CE11_9%#N_P /\@_M2MV7X_YG[&_\/!_@5_T.<G_@JN__ (U1_P /!_@5
M_P!#G)_X*KO_ .-5^.5%']D4.[_#_(/[4K=E^/\ F?L;_P /!_@5_P!#G)_X
M*KO_ .-4?\/!_@5_T.<G_@JN_P#XU7XY44?V10[O\/\ (/[4K=E^/^9^QO\
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M^9^QO_#P?X%?]#G)_P""J[_^-4?\/!_@5_T.<G_@JN__ (U7XY44?V10[O\
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M_P"-4?\ #P?X%?\ 0YR?^"J[_P#C5?CE11_9%#N_P_R#^U*W9?C_ )G[&_\
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MP/LTLD/[N1XU5067/8'D5XI7ITI^T@I]SQ*U/V51P[!1116IB%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA<LO_!K;_P#Q='UK#_SK[T'U:O\ R/[F?,U%?3/_  [G^./_ $+EE_X-;?\
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MTS_P[G^./_0N67_@UM__ (NC_AW/\<?^A<LO_!K;_P#Q='UK#_SK[T'U:O\
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MZ%RR_P#!K;__ !='UK#_ ,Z^]!]6K_R/[F?,U%?3/_#N?XX_]"Y9?^#6W_\
MBZ/^'<_QQ_Z%RR_\&MO_ /%T?6L/_.OO0?5J_P#(_N9\S45],_\ #N?XX_\
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M?Y5^)_0?IVIVFL6,-[87<-[9SJ'BN+>021R*>A5AP15L<"OR6_X)_?M#:O\
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M_+_(QC0C%-=SY2OOAUXH\:?#.[U#7]!NE\1^.]5TG3[ZP7+MI&CQ3H3&^3@
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M%_\ CU'_  Z9TO\ Z*1>?^"A?_CU']I87^;\'_D']GXG^7\5_F?G'17Z.?\
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M'N;DC^\V  /15  ]*]1'2OF\=B5BJG-'9;'T."PSPU.TMV+1117G'H!1110
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M_P#DC[T_X;'^'7_/?4O_  "/^-'_  V/\.O^>^I?^ 1_QKX+HH_L'"=W]_\
MP _XB%G/:'_@+_\ DC[T_P"&Q_AU_P ]]2_\ C_C1_PV/\.O^>^I?^ 1_P :
M^"Z*/[!PG=_?_P  /^(A9SVA_P" O_Y(^]/^&Q_AU_SWU+_P"/\ C1_PV/\
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MW_\  #_B(6<]H?\ @+_^2/O3_AL?X=?\]]2_\ C_ (T?\-C_  Z_Y[ZE_P"
M1_QKX+HH_L'"=W]__ #_ (B%G/:'_@+_ /DC[T_X;'^'7_/?4O\ P"/^-'_#
M8_PZ_P">^I?^ 1_QKX+HH_L'"=W]_P#P _XB%G/:'_@+_P#DC[T_X;'^'7_/
M?4O_  "/^-'_  V/\.O^>^I?^ 1_QKX+HH_L'"=W]_\ P _XB%G/:'_@+_\
MDC[T_P"&Q_AU_P ]]2_\ C_C1_PV/\.O^>^I?^ 1_P :^"Z*/[!PG=_?_P
M/^(A9SVA_P" O_Y(^]/^&Q_AU_SWU+_P"/\ C1_PV/\ #K_GOJ7_ (!'_&O@
MNBC^P<)W?W_\ /\ B(6<]H?^ O\ ^2/O3_AL?X=?\]]2_P# (_XT?\-C_#K_
M )[ZE_X!'_&O@NBC^P<)W?W_ / #_B(6<]H?^ O_ .2/O3_AL?X=?\]]2_\
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M=?\ /?4O_ (_XT?\-C_#K_GOJ7_@$?\ &O@NBC^P<)W?W_\  #_B(6<]H?\
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M^]/^&Q_AU_SWU+_P"/\ C1_PV/\ #K_GOJ7_ (!'_&O@NBC^P<)W?W_\ /\
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M , /^(A9SVA_X"__ )(^]/\ AL?X=?\ /?4O_ (_XT?\-C_#K_GOJ7_@$?\
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MOJ7_ (!'_&O@NBC^P<)W?W_\ /\ B(6<]H?^ O\ ^2/O3_AL?X=?\]]2_P#
M(_XT?\-C_#K_ )[ZE_X!'_&O@NBC^P<)W?W_ / #_B(6<]H?^ O_ .2/O3_A
ML?X=?\]]2_\  (_XT?\ #8_PZ_Y[ZE_X!'_&O@NBC^P<)W?W_P# #_B(6<]H
M?^ O_P"2/O3_ (;'^'7_ #WU+_P"/^-'_#8_PZ_Y[ZE_X!'_ !KX+HH_L'"=
MW]__   _XB%G/:'_ ("__DC[T_X;'^'7_/?4O_ (_P"-'_#8_P .O^>^I?\
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M^>FC_P#@4W_Q%8PQ674VG&<4U^IVU\KXEQ,90K4:DE*S=UO;;[NAX)17O?\
MPQ?\0?\ GIH__@4W_P 11_PQ?\0?^>FC_P#@4W_Q%=/]I8/_ )^K[SS?]6<Z
M_P"@6?W'@E%>]_\ #%_Q!_YZ:/\ ^!3?_$4?\,7_ !!_YZ:/_P"!3?\ Q%']
MI8/_ )^K[P_U9SK_ *!9_<>"45[W_P ,7_$'_GIH_P#X%-_\11_PQ?\ $'_G
MIH__ (%-_P#$4?VE@_\ GZOO#_5G.O\ H%G]QX)17O?_  Q?\0?^>FC_ /@4
MW_Q%'_#%_P 0?^>FC_\ @4W_ ,11_:6#_P"?J^\/]6<Z_P"@6?W'@E%>]_\
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M7_$'_GIH_P#X%-_\11_PQ?\ $'_GIH__ (%-_P#$4?VE@_\ GZOO#_5G.O\
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M_<>"45[W_P ,7_$'_GIH_P#X%-_\11_PQ?\ $'_GIH__ (%-_P#$4?VE@_\
MGZOO#_5G.O\ H%G]QX)17O?_  Q?\0?^>FC_ /@4W_Q%'_#%_P 0?^>FC_\
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M]6<Z_P"@6?W'@E%>]_\ #%_Q!_YZ:/\ ^!3?_$4?\,7_ !!_YZ:/_P"!3?\
MQ%']I8/_ )^K[P_U9SK_ *!9_<>"45[W_P ,7_$'_GIH_P#X%-_\11_PQ?\
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M?^>FC_\ @4W_ ,11_:6#_P"?J^\/]6<Z_P"@6?W'@E%>]_\ #%_Q!_YZ:/\
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MW_Q%'_#%_P 0?^>FC_\ @4W_ ,11_:6#_P"?J^\/]6<Z_P"@6?W'@E%>]_\
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M7_$'_GIH_P#X%-_\11_PQ?\ $'_GIH__ (%-_P#$4?VE@_\ GZOO#_5G.O\
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MEL?J/_PG_A?_ *&31_\ P/B_^*H_X3_PO_T,FC_^!\7_ ,57Y<45T?ZN4_\
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MX3_PO_T,FC_^!\7_ ,57Y<44?ZN4_P#GX_N_X(?\1+Q'_0,O_ G_ )'ZC_\
M"?\ A?\ Z&31_P#P/B_^*H_X3_PO_P!#)H__ ('Q?_%5^7%%'^KE/_GX_N_X
M(?\ $2\1_P! R_\  G_D?J/_ ,)_X7_Z&31__ ^+_P"*H_X3_P +_P#0R:/_
M .!\7_Q5?EQ11_JY3_Y^/[O^"'_$2\1_T#+_ ,"?^1^HY\?^%_\ H9-'_P#
M^+_XJM+3-9L-8B,EA?VU]&#@O;2K(!^*DU^4U:OASQ1JWA'58M1T>_FTZ]B.
M4EB?'X$9PP]CP:SGPXK>Y4U]#>CXESYU[;#+EZVEK^*/U3HKSKX&_$Y?BMX$
MM-7=%BOXF-M>Q)]T2J 21[,"K>V<=LUZ+7Q]2G*C-TYJS1^U83%4L;0AB:+O
M&237S"BBBLSK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWTO]W0\<HKV+_ADGXG?] &+_ ,#X/_BZ/^&2?B=_T 8O_ ^#_P"+K?Z_A/\
MG['[T>=_8&;_ /0)4_\  )?Y'CM%>Q?\,D_$[_H Q?\ @?!_\71_PR3\3O\
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M ,7_ ('P?_%T?7\)_P _8_>@_L#-_P#H$J?^ 2_R/':*]B_X9)^)W_0!B_\
M ^#_ .+H_P"&2?B=_P! &+_P/@_^+H^OX3_G['[T']@9O_T"5/\ P"7^1X[1
M7L7_  R3\3O^@#%_X'P?_%T?\,D_$[_H Q?^!\'_ ,71]?PG_/V/WH/[ S?_
M *!*G_@$O\CQVBO8O^&2?B=_T 8O_ ^#_P"+H_X9)^)W_0!B_P# ^#_XNCZ_
MA/\ G['[T']@9O\ ] E3_P  E_D>.T5[%_PR3\3O^@#%_P"!\'_Q='_#)/Q.
M_P"@#%_X'P?_ !='U_"?\_8_>@_L#-_^@2I_X!+_ "/':*]B_P"&2?B=_P!
M&+_P/@_^+H_X9)^)W_0!B_\  ^#_ .+H^OX3_G['[T']@9O_ - E3_P"7^1X
M[17L7_#)/Q._Z ,7_@?!_P#%T?\ #)/Q._Z ,7_@?!_\71]?PG_/V/WH/[ S
M?_H$J?\ @$O\CQVBO8O^&2?B=_T HO\ P/@_^+KJ/!?[%_BO4]0B;Q%<6NB:
M>#F412">9AZ*%^4?4G\*B6982"YG47R=_P C>CPUG->:IQPLTWWBTOO=D>F?
ML0:7<6W@/6KV4%8+F_"Q*>A*H-Q'XMC\*^DJQO"WAO3_  AH=CHVEP+;6%G&
M(XHQZ=R3W).22>22<ULU^:8NO]9KSK);L_J3)< \KR^C@Y.[@M7Y[OY7V"BB
MBN0]H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** .9_P"%F>#_ /H:]$_\&,/_ ,51_P +-\'_ /0UZ)_X
M,8?_ (JE_P"%9^#_ /H5-$_\%T/_ ,30?AGX/_Z%31/_  70_P#Q- "?\+-\
M'_\ 0UZ)_P"#&'_XJC_A9O@__H:]$_\ !C#_ /%5RIN/@X-=&B%_ _\ ;)?R
MO[/)LQ<;_P"[Y?WL^V*ZO_A6?@__ *%31/\ P70__$TVFMT)-/9B?\+-\'_]
M#7HG_@QA_P#BJ/\ A9O@_P#Z&O1/_!C#_P#%4O\ PK/P?_T*FB?^"Z'_ .)I
MDWPX\&V\+RR>%]"CC12S.VGP@*!U).VD,=_PLWP?_P!#7HG_ (,8?_BJ/^%F
M^#_^AKT3_P &,/\ \54%G\/O!-_;Q7%KX:T"XMY%#)+%8P,C ]P0O(JQ_P *
MS\'_ /0J:)_X+H?_ (F@!/\ A9O@_P#Z&O1/_!C#_P#%4?\ "S?!_P#T->B?
M^#&'_P"*I?\ A6?@_P#Z%31/_!=#_P#$T?\ "L_!_P#T*FB?^"Z'_P")H 3_
M (6;X/\ ^AKT3_P8P_\ Q5'_  LWP?\ ]#7HG_@QA_\ BJ#\,_!X'_(J:)_X
M+X?_ (FHU^'7@LSF'_A%]"\T+N*?V?#G'KC;0!)_PLWP?_T->B?^#&'_ .*H
M_P"%F^#_ /H:]$_\&,/_ ,52_P#"L_!__0J:)_X+H?\ XFC_ (5GX/\ ^A4T
M3_P70_\ Q- "?\+-\'_]#7HG_@QA_P#BJ/\ A9O@_P#Z&O1/_!C#_P#%4O\
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MK/P?_P!"IHG_ (+H?_B: $_X6;X/_P"AKT3_ ,&,/_Q5'_"S?!__ $->B?\
M@QA_^*I?^%9^#_\ H5-$_P#!=#_\31_PK/P?_P!"IHG_ (+H?_B: (;GXA^"
MKVWD@G\3:#-#(NUXY+^!E8'L06YJGHWBWX>^&[%++2=:\-:99H25M[*[MXHU
M)ZX52!6E_P *S\'_ /0J:)_X+H?_ (FC_A6?@_\ Z%31/_!=#_\ $T>0K=1/
M^%F^#QU\6:(/^XC#_P#%57O/'W@C4(&ANO$F@7$).3%+?0,IP<\@MV-6?^%9
M^#_^A4T3_P %T/\ \31_PK/P?_T*FB?^"Z'_ .)H&-'Q,\'C_F:]$_#48?\
MXJE_X6;X/_Z&O1/_  8P_P#Q5+_PK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3
M_P %T/\ \30 G_"S?!__ $->B?\ @QA_^*H_X6;X/_Z&O1/_  8P_P#Q5+_P
MK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3_P %T/\ \30 G_"S?!__ $->B?\
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MO1/_  8P_P#Q5+_PK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3_P %T/\ \30
MG_"S?!__ $->B?\ @QA_^*H_X6;X/_Z&O1/_  8P_P#Q5+_PK/P?_P!"IHG_
M (+H?_B:/^%9^#_^A4T3_P %T/\ \30 G_"S?!__ $->B?\ @QA_^*H_X6;X
M/_Z&O1/_  8P_P#Q5+_PK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3_P %T/\
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MK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3_P %T/\ \30 G_"S?!__ $->B?\
M@QA_^*H_X6;X/_Z&O1/_  8P_P#Q5+_PK/P?_P!"IHG_ (+H?_B:/^%9^#_^
MA4T3_P %T/\ \30 G_"S?!__ $->B?\ @QA_^*H_X6;X/_Z&O1/_  8P_P#Q
M5+_PK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3_P %T/\ \30 G_"S?!__ $->
MB?\ @QA_^*H_X6;X/_Z&O1/_  8P_P#Q5+_PK/P?_P!"IHG_ (+H?_B:/^%9
M^#_^A4T3_P %T/\ \30 G_"S?!__ $->B?\ @QA_^*H_X6;X/_Z&O1/_  8P
M_P#Q5+_PK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3_P %T/\ \30 G_"S?!__
M $->B?\ @QA_^*H_X6;X/_Z&O1/_  8P_P#Q5+_PK/P?_P!"IHG_ (+H?_B:
M/^%9^#_^A4T3_P %T/\ \30 G_"S?!__ $->B?\ @QA_^*H_X6;X/_Z&O1/_
M  8P_P#Q5+_PK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3_P %T/\ \30 G_"S
M?!__ $->B?\ @QA_^*H_X6;X/_Z&O1/_  8P_P#Q5+_PK/P?_P!"IHG_ (+H
M?_B:/^%9^#_^A4T3_P %T/\ \30 G_"S?!__ $->B?\ @QA_^*H_X6;X/_Z&
MO1/_  8P_P#Q5+_PK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3_P %T/\ \30
MG_"S?!__ $->B?\ @QA_^*H_X6;X/_Z&O1/_  8P_P#Q5+_PK/P?_P!"IHG_
M (+H?_B:/^%9^#_^A4T3_P %T/\ \30 G_"S?!__ $->B?\ @QA_^*H_X6;X
M/_Z&O1/_  8P_P#Q5+_PK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3_P %T/\
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MK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3_P %T/\ \30 G_"S?!__ $->B?\
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MO1/_  8P_P#Q5+_PK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3_P %T/\ \30
MG_"S?!__ $->B?\ @QA_^*H_X6;X/_Z&O1/_  8P_P#Q5+_PK/P?_P!"IHG_
M (+H?_B:/^%9^#_^A4T3_P %T/\ \30 G_"S?!__ $->B?\ @QA_^*H_X6;X
M/_Z&O1/_  8P_P#Q5+_PK/P?_P!"IHG_ (+H?_B:/^%9^#_^A4T3_P %T/\
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M8E,JQ$@L@?KM) )&>U<__P (5X)T#7+G6FT30M.U;4=T,U\UK#%-<[A\RER
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M .*KG:*/94_Y5]P?6\1_S\?WO_,Z+_A8?BO_ *&?5_\ P82__%4?\+#\5_\
M0SZO_P"#"7_XJN=HH]E3_E7W!];Q'_/Q_>_\SHO^%A^*_P#H9]7_ /!A+_\
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MF"1T(X &<^^_ SPK9^"_BQ\4M+L[BZNU\^QN);B_N'N)Y9'ME9F=V)/)/08
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M/#?P*\+^%H]-2RCO +&SO;*$S732-Y=W+YLVYFR68OSDGBASHM\UM?\ A_\
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M+O@OX;\:ZW<ZIJ4-S]IN;>VM9UM[EXDE6WN1<PEE4X++(O!ZX)'0UK:M\/\
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MC^T#:H&<9^]QZ5U<WA/1+BY6XET:PEG7&)7MD+#'3!QGCC%*OA+1%O3>#1[
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MC/\ Z*7J'_@ILO\ XW7H-% 'GW_""^,_^BEZA_X*;+_XW1_P@OC/_HI>H?\
M@ILO_C=>@T4 >??\(+XS_P"BEZA_X*;+_P"-T?\ ""^,_P#HI>H?^"FR_P#C
M=>@T4 >??\(+XS_Z*7J'_@ILO_C='_""^,_^BEZA_P""FR_^-UZ#10!Y]_P@
MOC/_ **7J'_@ILO_ (W1_P (+XS_ .BEZA_X*;+_ .-UZ#10!Y]_P@OC/_HI
M>H?^"FR_^-T?\(+XS_Z*7J'_ (*;+_XW7H-% 'GW_""^,_\ HI>H?^"FR_\
MC='_  @OC/\ Z*7J'_@ILO\ XW7H-% 'GW_""^,_^BEZA_X*;+_XW1_P@OC/
M_HI>H?\ @ILO_C=>@'I29'K^= ' ?\(+XS_Z*7J'_@ILO_C='_""^,_^BEZA
M_P""FR_^-UW^1ZBC(]10*YP'_""^,_\ HI>H?^"FR_\ C='_  @OC/\ Z*7J
M'_@ILO\ XW7?Y'J*,CU% 7. _P"$%\9_]%+U#_P4V7_QNC_A!?&?_12]0_\
M!39?_&Z[_(]11D>HH"YP'_""^,_^BEZA_P""FR_^-T?\(+XS_P"BEZA_X*;+
M_P"-UW^1ZBC(]10%S@/^$%\9_P#12]0_\%-E_P#&Z/\ A!?&?_12]0_\%-E_
M\;KO\CU%&1ZB@+G ?\(+XS_Z*7J'_@ILO_C='_""^,_^BEZA_P""FR_^-UWX
M8=,BG4#//O\ A!?&?_12]0_\%-E_\;H_X07QG_T4O4/_  4V7_QNO0:* //O
M^$%\9_\ 12]0_P#!39?_ !NC_A!?&?\ T4O4/_!39?\ QNO0:* //O\ A!?&
M?_12]0_\%-E_\;H_X07QG_T4O4/_  4V7_QNO0:* //O^$%\9_\ 12]0_P#!
M39?_ !NC_A!?&?\ T4O4/_!39?\ QNO0:* //O\ A!?&?_12]0_\%-E_\;H_
MX07QG_T4O4/_  4V7_QNO0:* //O^$%\9_\ 12]0_P#!39?_ !NC_A!?&?\
MT4O4/_!39?\ QNO0:* //O\ A!?&?_12]0_\%-E_\;H_X07QG_T4O4/_  4V
M7_QNO0:* //O^$%\9_\ 12]0_P#!39?_ !NC_A!?&?\ T4O4/_!39?\ QNO0
M:* //O\ A!?&?_12]0_\%-E_\;H_X07QG_T4O4/_  4V7_QNO0:* //O^$%\
M9_\ 12]0_P#!39?_ !NC_A!?&?\ T4O4/_!39?\ QNO0:* //O\ A!?&?_12
M]0_\%-E_\;H_X07QG_T4O4/_  4V7_QNO0:* //O^$%\9_\ 12]0_P#!39?_
M !NC_A!?&?\ T4O4/_!39?\ QNO0:* //O\ A!?&?_12]0_\%-E_\;H_X07Q
MG_T4O4/_  4V7_QNO0:* //O^$%\9_\ 12]0_P#!39?_ !NC_A!?&?\ T4O4
M/_!39?\ QNO0:* //O\ A!?&?_12]0_\%-E_\;H_X07QG_T4O4/_  4V7_QN
MO0:* //O^$%\9_\ 12]0_P#!39?_ !NC_A!?&?\ T4O4/_!39?\ QNO0:* /
M/O\ A!?&?_12]0_\%-E_\;H_X07QG_T4O4/_  4V7_QNO0:* //O^$%\9_\
M12]0_P#!39?_ !NC_A!?&?\ T4O4/_!39?\ QNO0:* //O\ A!?&?_12]0_\
M%-E_\;H_X07QG_T4O4/_  4V7_QNO0:* //O^$%\9_\ 12]0_P#!39?_ !NC
M_A!?&?\ T4O4/_!39?\ QNO0:* //O\ A!?&?_12]0_\%-E_\;H_X07QG_T4
MO4/_  4V7_QNO0:* //O^$%\9_\ 12]0_P#!39?_ !NC_A!?&?\ T4O4/_!3
M9?\ QNO0:* //O\ A!?&?_12]0_\%-E_\;H_X07QG_T4O4/_  4V7_QNO0:*
M //O^$%\9_\ 12]0_P#!39?_ !NC_A!?&?\ T4O4/_!39?\ QNO0:* //O\
MA!?&?_12]0_\%-E_\;H_X07QG_T4O4/_  4V7_QNO0:* //O^$%\9_\ 12]0
M_P#!39?_ !NC_A!?&?\ T4O4/_!39?\ QNO0:* //O\ A!?&?_12]0_\%-E_
M\;H_X07QG_T4O4/_  4V7_QNO0:* //O^$%\9_\ 12]0_P#!39?_ !NC_A!?
M&?\ T4O4/_!39?\ QNO0:* //O\ A!?&?_12]0_\%-E_\;H_X07QG_T4O4/_
M  4V7_QNO0:* //O^$%\9_\ 12]0_P#!39?_ !NC_A!?&?\ T4O4/_!39?\
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MMNJM.SS-+Y2QKO4;MV6++@<\*V(7](J]#^KEO5_V;+#6?"WA/1&UV]@A\/\
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M8(]:N4T;3-<,^M+?VZV^K7&G:A GV2.'S+>[C \J0,IRI!5EQGD8-JG1MO\
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MQ))I=_<CQ'J#W$WVNWO(FN VY"722WC4<D\H!P#FNL@^ ,/@OQ]=7?@FTM-
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MZ*VL<5WW+'VV?_GM+_WV:/ML_P#SVE_[[-5Z*+!=]RQ]MG_Y[2_]]FC[;/\
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MBBOF?_AO'PA_T -;_P"^8?\ XY1_PWCX0_Z &M_]\P__ !RLK&Q],45\S_\
M#>/A#_H :W_WS#_\<H_X;Q\(?] #6_\ OF'_ ..46 ^F**^9_P#AO'PA_P!
M#6_^^8?_ (Y1_P -X^$/^@!K?_?,/_QRBP'TQ17S/_PWCX0_Z &M_P#?,/\
M\<H_X;Q\(?\ 0 UO_OF'_P".46 ^F**^9_\ AO'PA_T -;_[YA_^.4?\-X^$
M/^@!K?\ WS#_ /'*+ ?3%%?,_P#PWCX0_P"@!K?_ 'S#_P#'*/\ AO'PA_T
M-;_[YA_^.46 ^F**^9_^&\?"'_0 UO\ [YA_^.4?\-X^$/\ H :W_P!\P_\
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MO'PA_P! #6_^^8?_ (Y1_P -X^$/^@!K?_?,/_QRNB&(KTURPFTO)L\NME6
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M^!,__P <KSO_ (;Q\(?] #6_^^8?_CE'_#>/A#_H :W_ -\P_P#QRCZWB?\
MGY+[V']B97_T"T__  "/^1Z)_P ,Q_"__H58?_ F?_XY1_PS'\+_ /H58?\
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M<X.HZ5]J++Y3BSDV!?XMP\SDGC'/'O7A_P#PWCX0_P"@!K?_ 'S#_P#'*/\
MAO'PA_T -;_[YA_^.4^=]E]R(]C'N_O?^9[<]IXN-E&J:GI(NPYWN]E(4*8X
M 'F9!S[TEW9^,&BM_LVIZ1'*$Q.9;&1@S>JXE&!CMS]:\2_X;Q\(?] #6_\
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8*FA_;F\)3*6&@ZT!G'(A_P#BZSL;G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>tmb-20250331xs4024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4024.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #( Z # 2(  A$! Q$!_\0
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M_LR\[21'ZD_X4 :?V@4]90U8S6E^I/RQO_NM49FNX?OP./<#- &]N%+D'O6
MFK@'#':WH>*MQ:DK?Q"@#5HJLEVK8YJ99%;O2 ?1110 4444 %%%% !1110
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MB34G9/#6@VNF6Y^[-?DRR?7:, ?F::3>Q7*]S[(73(0,L6<^YJO>ZEHVC_\
M'Y=V=GQG_2)53_T(U^=>N_&;XB>,2QU'Q=J2QN,-!92?9H\>F(P,_CFN7&DM
M>2^9<-)<2'J\SF0G\3FJY&/E/T<O/B_X$TV3RY_%.DHP["Y1OY54/QY^':G!
M\5Z9G_KI_P#6K\_H-#11@* /H*LC0U8_,,CZ4U ?*??D?QO^'TQ 7Q7I1)Z
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M&VLT/0H#R_\ P(C/Y5E65SS7N82FJ:N]V<E5N6AU5O<DBK'VP D,WX5AI=C
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M!^G45GZ#JPG13NZCI7CW["?QXE^,'PMETK5[@3>)/#C)9W1<Y>:$K^ZE/KD
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M["MC3EQM8CYC6L42]C2AB54P1S4N 0!BF*^3BGH<N 3@>M;KS,7N0SVS,#@
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M8T=J\FI^<8/LZ8+;P<8XX_&@#Z+^ GQTDUV2W\,:_(7U$C99W>,F8 ?<?_:
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M1M2LR;>7M'<*0\+'V$BJ2.X!'>OR2MKZYTJ[FL[V,PW]O*T%Q"PP8Y%.UE_
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M<])?+WR_^/L]<UX0#7,GG/\ ?D8N?J<FNY^+.JBQ\-"PC.V2^<18'78.6_3
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MEKX)LY!N+@AM0<'_ %:?[ _B;\!SG'Z">+_$]EX!T"&ULHHTN-@@LK2)0JH
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M0 C#(K*U"U$BGBM:HY8]ZFF!Q<5Y/X>O3(@+VSG]Y&/YCWK)^-7P3\*_M&>
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M>:A,]S<-QN;HH] .@'L*['1/#(CP=M;NGZ"L0'R"M^UL%CQQCZ59SE6PTT1
M#;C%:\,(0<T^.(**DI#"BBBD 4444 %%%% !1110!%+%O6LB_P!-$J'(XK<I
MDD8<=*=P//+S1Y[&Y%S:2/!,O1T_K[5I:9XZ:!A#J\9C["Y1<K_P(=OKTKHK
MFR#Y&.U8&I:"DH/RYI[@<W\6?V>/AI^T)I__ !4^@V>IS[=L6IVW[NZB]-LJ
M_-^!R/:OA_XK?\$G-9T_SKWX=>*+?4T ++IFMCR9/HLJ@@D_[0'UK[A?2+O2
MIC+932VK]_+;@_AWJ_9^/]3TY@NH6BWD8X\R+Y'_ !'0_I4N-RE)QV/Q=\>?
MLT_%#X732KXI\#:KI\*-C[9'%]HMC])8MR_K7"I:9.#P0?ND8(K]^;3X@:)J
M"F.65K8L,&.Y3;G^E86O?!OX9?$!-VI>%=!U0G^,VL>[\P,U'*:*IW/PQ@TS
M=@L,KZ5J6NG*N BCZXK]=]5_8'^"^I^85\,/8NW\5I>2ICZ#=BN6E_X)K_"Q
MS^[O/$$ ]$OE./S0T[,OVB/S$@TE-X9EW'VK72UCC0?+MX[U^DD?_!-OX9QM
MDZIXCD'H;R,?RCK6TW_@GG\)+.3=<VNK:D/[MSJ#@?\ CN*7*+VI^75U/%'D
M>8N<T:7H^J>);Q+;2-,O=6N7(58;"W>9B?HH-?KQH'[(?P>\*'S8/!6FNXP?
M,O<S$8_WR:[RUOO!_@J%HK/^S-+0#!BLXT0X],**AT[EJNELC\P_AS^P5\6O
M'DL,U[I,/@^P(R9]9E E//.(5RV?][;7UK\*_P#@G1\//!4\5]XF>;QIJ"$-
MY=Z/+M0W_7(?>_X$37MVI_&.R3<NF6-Q>R= \G[N/]>?TKD]0\4^)?$>5DN3
M:0M_RQMAM&/KU-4J4492KSD>AZEXM\/>!+"*P@$$8@39#I]@@ 0#HH48"C\J
M\XUSQ7K7C)F@8FRL&_Y=XB<L/]INI_E1I?A+G++EB<ECU-==I?AE8P/E'Y5M
M8PW.:T+PIC;\G ]J[S2M%6$ ;:T++2EC  6M>WMA&.E%P([6T"8]JN 8H Q2
MU(PHHHH **** "BBB@ I,4M% %:XMQ(#QFL._P!)64'Y:Z0U')"&'3-.X'FM
MYHL]A<?:+21[>8?QQG&?8^OXUH:?\0;FQ98]5M3(G3SX.OU*_P"%=7=:<K@_
M+6%?Z"LH/RTP&>)/#/@?XQ:*^FZ_I6E>)K!P0;;4+=9"F>I 894^XP:^5_B7
M_P $H?A7XLDEN?#%]JG@RX?)6&VE\^V![?(^2![ U]"WWA7;)OCRCCHR\$?2
MF1:OXBT@@17K3(. DZ[Q_0_K2L";1^<OC7_@D;\4-$>:3PYXCT'Q/;KS''.[
MV<[>V"&0?]]5YI>_L._&+PA=>7J'PYU6Y9>3+IP2\0_C$S5^N]O\4;ZW^6]T
MI9!_?MY2/T(_K6G!\5M'? FBN[<]]\.0/R)K)T[FJJM'XS/\+/%.B3>5>>%M
M:LI%ZK-ILRX_\=JQ%X:U2%@LNE7H?H UJXY_*OV>B^)/AZ0#_B8*GLZ,#_*I
M3X[\.2$,VI6YQTW?_JJ/9>9:KM=#\9D\*ZW<$*F@ZG(W;R[&4Y_):WM-^ GQ
M(\01A]/^'_B*ZC;H_P#9[HOYM@5^O#_$;P[&.=3B/T!/]*IW'Q7\/0'Y)YKC
M_KE Q_G2]CYFBQ36R/S@\)_L!_%_7]C7FF:;X?A<;MVHWRLP'NL6\YKVSP;_
M ,$S;&,))XL\7SW;<%[?2X!$N>XWMDD>^!7TY>_&:$96QTFXG)Z-,XC'Y#)K
M!O?B+XGU3*P"#3T/_/%-S?FW^%6J,27BJCZE_P"'W[.'PQ^#RI=:1X=L(+R(
M?\A*_P 33CW\Q\[?PQ6UKWQ<TK3R8=.5M6N1QF+B)?JQZ_AFO/)=*U'6Y!)?
MW$UVW_35R0/PZ5LZ9X0P1E,CZ5LHI;'+*4I:LRM8UK6_&;[;R8QVA/\ QZPY
M5/Q]?QK2T;PKMVDIBNLTWPVD>/D%=%9Z4J#[M,5C(TO05B5?E_2NDL[((!QB
MIX+81XXJPHP*5QB*@6G444@"BBB@ HHHH **** "D(S2T4 02VX8=*HSZ>'!
MX!K5I" :8'+7>AI)G*BL2\\+)(#\@KT!H0U026@/&*+@>5S^$0C91=I[$<5
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M5 /E K46)5IX4"E<"M#:*O858"A>@IU%( HHHH **** "BBB@ HHHH ****
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M-U*FIW8LX?LD8<AR,C=EA@?G7D_P-_Y.5^,/_7:/^=1?MK?\@CP%_P!AZ/\
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M"ULQ91VJ;1!L (Z8S_%Z]JB\,?!31?"_B#QAJR7%U=OXG=VO8)V7RP'+%E7
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2BN<ZPHHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>tmb-20250331xs4027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4027.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &0 J$# 2(  A$! Q$!_\0
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M458?]#9XT_\ "BN/\:/^%%6'_0V>-/\ PHKC_&O3:* N>9?\**L/^AL\:?\
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M0KV4]J %'2B@=** "BBB@ HHHH **** "BBB@ I<4E% !1110 4444 %%%%
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MH7<$4AC^V%&"K$2.=O.2.]>R-TK@?B9\/?\ A*VT_4[*^FTG7--8O:7\ RR
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MHH ^6_#P_P",F_&?_7-?Y"O9#T7Z5XYX?Y_:;\9?]<U_D*]C8XQ]*8#AT%%
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MJAM[N&;?&)5V.#E#_%]/>H+KQ1I%E LT^I6L,+@LKO*H# '!(YYY.*^<+[Q
MG@OXG1^((] UV3PUJOA=;&QBL=/DD9)5))1T'W"<C&:YWX<_#B\\2:_\%4\2
M^'[XV=GH^M3SQ7L;*L$S7"-$LH_O8.0#0!]8-XITA-4BTUM2M5U"5=Z6QE7S
M&'J!G-:@.:^+/^$#OIO&6IV/B&?5].U1O$<5Y;SV6CM.S1!E\O9<#I'@88=
M.M?:$8(503D@<GUH DJ.:=((WDD8(B*69B<  =34E9^OZ6-;T:^T]I&C2[@D
MMV=>JAE*Y_#- ',R?&7PG#I;ZBVHL+19?)5_(?,C<\(,9;H>G:NJTO5K36]/
M@O;&=+FUG4/'+&<AA7A&F_ ?Q%HMOI\]G=VD=QI;11VMF9',$BHC(96)R0[
M@G''RUZ]X \(KX'\(Z=HJ2F86T>TN>Y)R?U- !II!\;:H0<@V\>/SKI*Y#PW
MI<.E>+M6CA,C!H48F1RQSFNO% "T444 %%%% !1110 4444 %%%% !24M)0!
M\M^'&5_VFO&94@CRUZ?05[*_)%>)># ?^&DO&A'(VU[:W! ]* '#H**!T%%
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MR!2F$,I[GW&:EHH A9"2IQBE,>W/4YJ6B@" 1@#@ >F!TIRQ@C'W1[#%2T4
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MH **** "BBB@ HHHH **** "BBB@ HHHH *:R!J=10 QHPW:EV@$GVIU(>E
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M[5D#!3_8DG0'_6?_ %J /?\ (]:,UX(/VJK<]=#D_P"_M'_#5-M_T Y?^_M
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M^LWP[I T'0=-TP32W"V5M';":8Y>0(@7<Q[DXR:TJ!!1110!S?Q%./!&L_\
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MSU2Y-E<Z=),TD9!!/FJ#T*D<D>M>J'KF@ HHHH **** "BBB@ HHHH ****
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MT:B1X)5C(X=T*C&.N377:;\)=7U;2;&_BN=/0WZ%[:VDN LTH!V\*??WJ_\
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M/"EWJT>G1ZS UTTOEH.0C/W4-TS6-XITS6/#WCEO$VEV*:Q#<VJVEW8-((W
M5B5=&/'?D4 :GA/QM?W^O3:!K]C!8:LL'VJ&2SD+P7$>=K%=W(*D@'/K77$U
MY[X;L]9\0^.%\2:K81:2EM:M9VEBL@E?#,&:1V'&25&!7H1^]^% #J*** "B
MBB@ HHHH **** "BBB@ HHHH 7TKSKQI_P EO^#'_7YJG_I(M>B^E>=>-/\
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M@C(]QFKE% 'RAX2_83\):9X7\2:=JJ3:W?:O(\D^HWQ#7!))VD-V(]>]>Q_
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M4 (5/I2T#BC- !12C![TAP.] !11FC- !28Y]J7(HR* &@$"@Y ]J=F@_=H
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M#7I__?9_PKR3X8?!70_$EMJ]AJ^G61UC1KPV5Q+#%A)> RN!V)5AGWS7;?\
M#-'A4?\ ,.M_^_8H Z7_ (7O\/Q_S->G_P#?9_PI#\>?A_\ ]#5I_P#WV?\
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M ,,LZ3Z6G_?FC_AEG2/2S_[\T 6/^%O>"/\ H9['_OH_X4?\+>\$?]#/8_\
M?1_PJO\ \,LZ1Z6?_?FC_AEG2/2S_P"_- %C_A;W@G_H9['_ +Z/^%+_ ,+>
M\$_]#-8_]]'_  JM_P ,LZ1Z6?\ WYH_X98TC^[9_P#?F@"S_P +>\$?]#/8
M?]]G_"D/Q?\ !'_0S6/_ 'V?\*K_ /#+.D>EG_WYH_X99TCTL_\ OS0!8'Q?
M\$?]#-8_]]G_  H_X6_X(_Z&>Q_[Z/\ A5?_ (99TCTL_P#OS1_PRSI/I:?]
M^: +'_"W_!'_ $,]C_WT?\*/^%O>"/\ H9['_OH_X57_ .&6=)]+3_OS1_PR
MSI'I9_\ ?F@"Q_PM[P1_T,]C_P!]'_"C_A;W@KMXFL?^^C_A5?\ X99TCTL_
M^_-'_#+.D>EG_P!^: +'_"WO!7_0S6/_ 'T?\*7_ (6]X)_Z&:Q_[Z/^%5O^
M&6=(]+/_ +\T?\,LZ3Z6G_?F@"S_ ,+?\$?]#-8?]]G_  I/^%P>"/\ H9K+
M_OH_X57_ .&6=)]+3_OS1_PRSI'I:?\ ?F@">7XN>!Y8RK>);$@_[9_PJ+_A
M:7@'R1#_ ,)#8!!SC<>OY4W_ (99TCTM/^_-'_#+.D^EI_WYH GC^+?@>) B
M^);!5'0;S_A2_P#"WO!'_0S6/_?9_P *K_\ #+.D?W;/_OS1_P ,LZ3Z6G_?
MF@"Q_P +>\$?]#/8_P#?1_PH_P"%O^"/^AGL?^^C_A5?_AEG2/2T_P"_-'_#
M+.D^EI_WYH L?\+>\$?]#/8_]]'_  H/Q>\$_P#0S6/_ 'T?\*K_ /#+.D>E
MG_WYH_X98TC^[9_]^: +'_"WO!/_ $,]C_WT?\*7_A;W@G_H9K'_ +Z/^%5O
M^&6-(_NV?_?FC_AEG2/2S_[\T 6?^%O^"!U\36/_ 'T?\*/^%O\ @C_H9K'\
M7/\ A5;_ (99TCTL_P#OS1_PRSI'I9_]^: +/_"WO!/_ $,UC^#'_"D_X6]X
M)_Z&>Q_[Z/\ A5?_ (99TCTL_P#OS1_PRSI/I:?]^: +'_"W_!'_ $,]C_WT
M?\*YC6?$VE>)_C/\&Y](OX=0@2^U17DA.0#]D7BM_P#X99TCTM/^_-<]J?PX
MM/AW\9O@[:VWE!);W5'(B7:"?L@ZB@:/I;!]/UHHW#U'YT4$7/%?!FI_V+\-
M/B1?/9+JB0:[K4C6;=)@)F^4^QKYQ^%'PDT+XI7^BS:IX6\!6>E:DI=H]+U>
M9KY5;)V!2>O8CTKZ(\,:A;Z5\*OB7>7E@-3MX==UEGLSTF'GM\IQV/>OFOX#
MW\&D_&S08+KP)X$T":6[\N$Z6+AKP*\7F+)&"^-F"06QC(/M04??>EZ?!I.G
M6ME:Q+!:VT2PQ1+T1%&% ^@ JW3$)89(P?2GT %%%% #7X4UXW\1OVE=#^%/
MQ/T/PIXCM+NPL=7CS#KDBXM5ESQ&3V->R.<+7QC^W!I7B[XM>(]"^&6A^&T7
M3KL+>77B.Y0,(E4\I&?X6'?N: /8/ ?[4_A[XG?&;4_ OAJTNM5L]-M_-N->
M@^:U64''EY_3/<U[>O3UKXC_ &*_#7B;X*>/]7^&FM>'A<:<T;:C9>)K:/:L
MBYQLF]3GH#R*^W%H 6BBB@ HHHH **** "BBB@ HHHH ***2@#S[X\V7A74/
MA9X@@\:2Q0^'&MV^U/*<!1C@CWSTK\J]$\27?B/_ (1?P[XSUG6XO@@FJR)8
MSSH0KC/R+(?[G_UZ_73QWX*TSX@>&+W0M8M8[S3KM=LL,PRK"N/U?]GWPGKO
M@1/"UWI5M+I2JJBU,0" +T ';I0!W/A"RLK#PUIEOIQB?3HK:-;4PMN3R@H"
M;3Z;<5L$#TK/\/Z/#X?T6RTVV01V]I$L,2*,!548 'T K0/2@#G-._Y';5?^
MO>/^==&*YO3O^1WU7_KWC_G72"@!:*** $Q1BEHH 3%&*6B@"*3@CWS]*\KD
M\!:_X9U/46\,:Z-/T^_E:=K2>V$HBE8Y9T)/&?2O6::5#=10!R/PY\%)X*TN
M6#SY;RYN)6N+F[F^_/(QY8_AP/85V%)BEH *2EHH ^>/V?2!\5?B)GG-X<?G
M7T!-:QSG+#GIFO /V?\ _DJOQ"_Z_#_.OH4=J (XH(X4V*HQ3N$^E.ICMM/2
M@#BO%GQ+_L364T72])N-=U<H)9(8'6-(8S_$[MP/I4W@GXBP^++N]TVXLI]'
MUJQ >XT^Y(+!#P)%8<,I((R.X-?+/QW^+WBW]F#X[W/BZ^MH];^'6N*D-Q:I
MA9X)57AE)^GTK3_9-\=^./C9\4M:^)6M)!IOAF\MOL.DZ3 H+)"KG#LPZG.2
M<\\^F* /L-2#D&F36T=PN&% 9E!)Y':DDN$MXS)+(D<?]]S@"@!T5O'#]U<>
M]2U#%()55UD#HW(*'(-34 %%123I$"SR*BCJ6. *;#.LZAXY%EC;HR$$4 3T
M4U&W*#3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\8^+O\ R7CX*?\ 7UJG_I**]GKQCXN_\EW^
M"G_7UJG_ *2B@#V>BBB@@^:Q\7_#OPJ^'7CB;6-2L+*]NO$&MBQMK]L+=2+,
MV5QWKS?]G;QM:^-_'7A;69_'W@:\U2>W\M=)LM),=]%%@GR%DSQC^E:'C_5H
M_#VC6^JZQ8VTWA6V\?:F-8O9M.CO&MK<W#=F5MJD]2!G%:6D?$7X?>)?CCX%
ML_A%!I%^P:9]9&EZ1&J16^T8D:78"C X PW<\4%GUPHP*=2#I2T %%%% #64
M,,$9%5+C2+6ZN$FEA5Y$Z$BKM% %)-)M4N_M(B F QNJ[110 4444 %%%% !
M32<4ZF.N[')&.>* /.?BY\>O"GP171'\5W,MG#JUT+6*98BR1G^\Y[+57Q[^
MTAX'^'GB#POHNH:F+C4?$4BK90V0\XE&QB1MO13D8/>O.?V[?&&B:)\(I-%U
M#P[+XFU377^R:=9)"S*)NSEA]TC]>E?(W[./A+4_V>/C5X=?XE^'+BZCUZ%+
M;2]6CW7)L),C$>.W8$8X[4 ?J8DF_!!&#4U008P,,6]R,5/0 4444 %)2TA.
M* %I#TIOF#)I0X8'D4 <YIW_ ".^J_\ 7O'_ #KI!7-Z=_R.^J_]>\?\ZZ04
M +1110 4444 %%%% !1110 4444 %%%% 'SQ^S__ ,E5^(/_ %^'^=?0PKYY
M_9__ .2J?$+_ *_#_.OH;O0 5&XPV>N>U2TTIDY- 'RM\7?V6]1^,_QPCUGQ
M-K+ZEX/M80+/12I$<<F,,6]:O_LU_L[ZU\ ?B!XF@L];EG\$WP$MKI,HW>1-
MGDAC[5],E.<TH3'U]2.M #"#MXY^M>.W^F)\2?BUXCTC6)W?3]$M[4VNEB0I
M'*)58M*ZC[^" /09]:]EX7K7#>-OASIGBW5;?4?,N+/5[5-L5Y8S^5.J'J.X
M(_W@: .=\$VC>#/BI>>&+&\EFTB6Q%X+.63S/LC[L84]E([5ZX>G%<;X&^'^
MF>#7N6ME9[RX;S+BXGF,LTI]78_R  KLATH \C\9VG_"9_%6S\-ZA<31Z7;V
M!NULXY#&MVY;!W8Y8+Z>]1:/I,?P]^+>F:3I4TB:;J]A+)<::TA>.)D8;94!
M^YUVGL2:['QU\.=-\:O:W%U',E[:,6MKNVE,4T)/7:P]?0Y%5/!?PPL?"NHW
M>HJ;FYU*Z4)->WLQEF=>N.P SC[H% '=*-J@4ZFJ" ,\FG4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5XQ\7?^2\?!3_ *^M4_\ 245[/7C'Q<_Y+Q\$_P#KZU3_ -)10![/1110
M0>5_!>P@U+P]XQMKN"*ZMY/%&JJ\,R!T8?:&X(/!KMM \$Z#X5:1M&T33]*:
M4Y=K.V2(M]2H%<G\"O\ D$>+/^QIU7_TH:O2J"PHHHH **** "BBB@ HHHH
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M:I_Z2BO9Z\8^+O\ R7CX*?\ 7UJG_I** /9Z***"#S3X%?\ ((\6?]C3JO\
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M_P#3O'72 B@!:*** "BBB@ HHHH **** "BBB@ HHHH ^;OV9^/B-\0_^O\
MD_\ 0S7TA7S?^S0/^+B_$0_]/[_^AFOI&@ HHHH **** "DI:* $I:** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KQCXN_P#)>/@I_P!?6J?^DHKV>O&/B[_R7?X*
M?]?6J?\ I** /9Z***"#S7X%?\@CQ9_V-.J_^E#5Z57FOP*_Y!'BS_L:=5_]
M*&KTJ@L**** "BBB@ HHHH **** "BBB@ JK>V27J,D@#(0001D$'J"*M44
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>,?%W_DO'P4_Z^M4_P#245[-7C/Q<_Y+
MQ\$_^OK5/_244 >ST444$'FGP*_Y!'BS_L:=5_\ 2AJ]+KS3X%?\@CQ9_P!C
M3JO_ *4-7I=!84UVVC^M.J*5B,<X'<T 8EYXQMK/4KFS6WNKF6 )YGDQ;@NX
M9 _*HQXWB_Z!NH?]^#6I"MK"\MVC1*UR5,DH88<CA>?TJXN2V"./6@#G_P#A
M-HO^@;J'_?@T?\)M%_T#=0_[\&NCP*,"@#G/^$VB_P"@;J'_ 'X-'_";1?\
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M?] W4/\ OP:Z/ HP* .<_P"$VB_Z!NH?]^#2'QM%_P! W4/^_!KI,"FMP.*
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M;J'_ 'X-'_";1?\ 0-U#_OP:Z/ HP* .<_X3:+_H&ZA_WX-'_";1?] W4/\
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MJ: .5^&%CJ.F^!M(MM69VOHXB'$C;F R2H)]0N!76TT(!VIU !1110 4444
M%%%% !4<O"\=>U24UTWC&<4 >(_#;0M5@\=O++:7EK<PRW?]J74KL8KK?)F+
M8"<>XQT%>WK35C [YIW2@!:*** "BBB@ HHHH **** *NI;/[/N/-#-%Y;;@
MN<D8YQCFOF:QT2^?X>Z-9RZ=J=UIUL;^'[(!()5F>1C;L23D@*1R3@5]1$9I
MIC]^: ,;P7:W=CX7TFWO0XN8K9%D$AW,&VC@GUK<IBIM/6GT %%%% !1110
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M Y- #J*J6>IVNHHSVES#<HK%&:&0.%8=5)!Z@]JG:5%!); '))Z"@"2BJO\
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M@0^*M-U'PMXLDF?Q)J5Q'):Z'/+')&\[,C(X&&4CD$5UP^.M@./^$3\:<?\
M4NW'^%!9Z917F?\ PO6P/_,I^-/_  G;C_"C_A>MC_T*?C3_ ,)VX_PH ],H
MKS/_ (7K8_\ 0I^-/_"=N/\ "C_A>MC_ -"GXT_\)VX_PH ],HKS/_A>MC_T
M*?C3_P )VX_PI1\=;#OX3\:?^$]<?X4 >ET5YG_PO6P_Z%/QG_X3MQ_A1_PO
M6Q_Z%/QI_P"$[<?X4 >F45YG_P +UL?^A3\:?^$[<?X4?\+UL?\ H4_&G_A.
MW'^% 'IE%>9_\+UL?^A3\:?^$[<?X4?\+UL?^A3\:?\ A.W'^% 'IE%>9_\
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MXL\T ?+7P UW4-0U"UE\22W*:QH7A.6[\$Z>7)@NV*/YLX)^_," -IZ"H9=
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M?63Z6INYTL+ZS$Z"2./<6()P21C!QQ7&67[2/Q-LO@__ ,)O>7FD3+K&M_\
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E?$EI9:7-J,E[=:EI$UM%$KVP5,NPQRW% T?0N:*9S[T4$V/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>tmb-20250331xs4028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &0 J$# 2(  A$! Q$!_\0
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M?^%#<?XUZ710!YF?@389_P"1L\:?^%%<?XTO_"BK#_H;/&G_ (45Q_C7I=%
MCS7_ (458?\ 0V>-/_"BN/\ &D_X458?]#9XT_\ "AN/\:]+HH \U_X458?]
M#9XT_P#"BN/\:/\ A15A_P!#9XT_\**X_P :]*HH \U_X458?]#9XT_\**X_
MQI#\"K#'_(V>-/\ PHKC_&O2Z* /,_\ A15@/^9L\:?^%%<?XU%<_!"PMXR_
M_"5>-GV MM7Q#<$G Z 9KU&HILXR,\>E 'S?&_A/?=P7/B#XCV5U;LJFUN-7
MNEEDR"<J,\\ GZ5WNE?!_2-9L;>]M?%_C.6VF0/&X\17&&!'^]5>[^#>HM''
M>6>MP1^('O9KJZO;BV+I*'4H%"[AC:H4=>Q]:]&\*Z!'X:T&STN-S(EM$$W'
MN>Y]J .,'P+L&(/_  E?C,<?]#%<?XTI^!-A_P!#9XT_\**X_P :WO#&GQZ-
MXGU6SMY)F@,:2[992^&)YQGI76B@#S,_ JP_Z&SQI_X45Q_C1_PHJP_Z&SQI
M_P"%%<?XUZ;10.YYE_PHJP_Z&SQI_P"%%<?XT?\ "BK#_H;/&G_A17'^->FT
M4!<\S_X458_]#9XT_P#"BN/\:/\ A1-A_P!#7XT_\**X_P :],HH$>:_\**L
M/^AL\:?^%%<?XT?\**L/^AL\9_\ A17'^->E44 >9_\ "B;#_H:_&G_A17'^
M-*?@58?]#9XS_P#"AN/\:]+HH \S/P*L?^AL\:?^%%<?XTG_  HJP/\ S-GC
M3\/$-Q_C7IM% 'S3'I.DWOQ*U?P@OB/QREQ81K(9O^$EG"N,9P!^-=(?A99\
M?\55XW/_ ',MQ7)Z2H/[4/C,]Q F/;Y17KS@9 ' % '&GX66??Q5XW'_ ',M
MQ2?\*LLO^AK\;_\ A2W%=H%XI=M '%?\*LLO^AK\;_\ A2W%'_"K++_H:_&_
M_A2W%=IM%&T>E '&?\*LL_\ H:O&Q_[F6XH_X599_P#0U>-O_"EN*[/:*-H]
M* .,_P"%66?_ $-7C;_PI;BC_A5EG_T-7C;_ ,*6XKL]H]*-H]* .,_X599_
M]#5XV_\ "EN*3_A5EE_T-?C?_P *6XKM-H]*-H]* .,_X599_P#0U>-O_"EN
M*3_A5EE_T-?C?_PI;BNTVBC:/2@#C/\ A5EG_P!#5XV_\*6XI/\ A5MG_P!#
M3XW_ /"EN*[3:/2C:/2@#B_^%6V?_0T^-_\ PI;BE/PMLR?^1J\;?^%+<5V>
MT>E&T>E '&?\*LL_^AJ\;?\ A2W%'_"K+/\ Z&OQL/\ N9;BNSVBC:/2@#B_
M^%667_0U^-__  I;BC_A5=E_T-7C<_\ <RW%=IM'I1M'I0!QG_"K+,?\S5XV
M_P#"EN*/^%66?_0U^-__  I;BNSVCTHVB@#B_P#A5EE_T-?C?_PI;BC_ (59
M9?\ 0U^-_P#PI;BNTVBC:/2@#C/^%66?_0U>-O\ PI;BC_A5EG_T-7C;_P *
M6XKL]H]*-H]* .,_X599_P#0U>-O_"EN*/\ A5EG_P!#5XV_\*6XKL]H]*-H
M]* .+_X599?]#7XW_P#"EN*4_"RS_P"AJ\;?^%+<5VF!2;1Z4 <7_P *MLO^
MAJ\;_P#A2W%'_"K;+_H:_&__ (4MQ7:;11M'I0!Q?_"K++_H:_&__A2W%+_P
MJRS_ .AK\;G_ +F6XKL]H]*-H]* .,_X599_]#5XV_\ "EN*/^%66?\ T-7C
M;_PI;BNSVCTHVCTH XS_ (599_\ 0U>-O_"EN*/^%66?_0U>-O\ PI;BNSVB
MC:* .,_X59:?]#5XV_\ "EN*3_A5EE_T-?C?_P *6XKL\#-+M'I0!QG_  JV
MR_Z&KQMQ_P!3+<5S=SIEWX(^-/POAT_Q-XFN;/59]1BN[34M8ENH91';!TRC
M'&0W.:]7VBO._&P_XOA\&1C_ )?-4Y]/]$% 'T!D^IHIVT>E% 'FOP*_Y!'B
MS_L:=5_]*&KTNO-/@5_R"/%G_8TZK_Z4-7I= !1110 4444 %%(QP,TPR +N
M/RCKS0!)152#4K>X+"*>.4KU$;AL?7%2RW4<,;RR2+%&@RS.< #U)- $U)FJ
MC:K:^3%,+B$PRD*DF\;7)Z 'H>G:IS*1_#[$^E $M%,\P <GFL_4_$FF:)&D
MFI7]MIZ.VU&N95C#'VR: -.BH8KJ.>-)(G65'P5=#D$>H-.,H!/(H DHIBR;
MB0.1ZBGT %%%% !1110 4A&1@TM% #/+7/2EQ@D]\4ZD/2@#G-._Y';5?^O>
M/^==&*YO3O\ D=]5_P"O>/\ G72"@!:*** "BBB@ HHHH **** "BBB@ HHH
MH ^8](7_ (R?\9G_ *8Q_P A7K;UY)H[ ?M/>,O^N,?_ *"*]<?I0 X=**!1
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(<
MT +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>>>-/^2X?!G_K\
MU3_TD%>B>E>=>,_^2X?!G_K\U3_TD% 'T%1110!YI\"O^01XL_[&G5?_ $H:
MO2Z\T^!3#^R/%G_8TZK_ .E#5Z09 #CO0 ^BD!S2T %%%% #7.%->7?$YKOQ
M!XHT'PI]NEL-,NHY+N]-O(8Y;A$P!"&Z@$G)QU%>HN,K7$?$3P/_ ,)8EE=6
M]Y+IVJ:?)YMG>VXRT9Z%6!^\I'44 >?>.?AGI/PT\,W_ (M\)V$/AK5=(3[6
M&T\F..Z"D%HIUSAPP[G^M=C\6KXZK\#?$5RT14W&D-(R9/&Y02*Q+CP3XG\8
M+!9^+?$,%_I22!Y+#3;0P+<8((64DDE<@' QFO2-0\-6FN^&[C1;^/S+&YA\
MB6,'!*$8QD=* /B6VN9O!'A?P+\-KF:=M/DUC2]7T*YF8EY8'#F:$L>IC=L_
M1EKTM_C%\1O$7CO5Y] EO9;#2]=.E#1(=&62UFA5E#R27/WT< L< @<"O;=>
M^"_A+Q-;^%X-1TU9U\,3+/I;;R'@=0 ,'N, 9!ZX%4]0^ OA2\\72>(42^L;
M^2=;J9+*^DAAEE!^^\:G#$XY/?% 'C_BOXM_$"7P]X[^(6E^(+33]$\(WT]J
MOAB:QC=;](F ;S)B/,1VR<!3CI6OX8\+:'\7_CG\1G\::7;:R=*@L(-*LK]0
MR06\MN))"JGKESRWX5Z'K7[.7@G7_%K>(;JQN#=23"XFM8[IUM9Y000TD(.U
MCP,Y%6O'_P !_"OQ'U:VU34X+NVU&"/R?M6FW;VLCQ]D8H1N'L: /'OC5X]O
M/A- VG> O$%QIMKH-F+AM#TO1H[VW5,\+<2MDQ*V"!M/%;&D^._'WQ+^+]_H
MNF>(+?PUH5GX?TW5W1+&.XF9YT9FC#.,;?4]>!CO7;ZY^S1X&UZ17NK*Z0?9
MEM)4@NY$6XC7.!( ?GZGDUU/A[X9:!X7\176MZ;:M#J-S86^FRR%RP,$ (C7
M!] 3SWH X7]FJ#Q"="U>XUGQ,^NPG4)HX8GMDC\K#G/S*,GZ&O::XSP=\*="
M\":WJ^IZ0ES!-JDAFN(GN7>(.>I1"<+GVKLZ "BBB@ HHHH **** "D/2@L!
M1G(- '-Z=_R.^J_]>\?\ZZ05S>G?\COJO_7O'_.ND% "T444 %%%% !1110
M4444 %%%% !112&@#YDT89_:?\:?]<8__017KC\XKR/1_P#DY[QI_P!<8_\
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MJ;PY\2+3Q1)H@M=,OQ;:I9/>I=RJBQPA3C8_S9W9] 1QUKYTT+PGX@F\4O\
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M<RMFGTU.E.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:++CM^\% 'OU%>!?\-4V_P#T!)?^_@I1^U1 ?^8+)_W\% 'OE%>!C]JBW/\
MS!9?^^Q0?VJ+<?\ ,%D_[[% 'OE%>!_\-4V__0%D_P"^Q1_PU3;_ /0%D_[[
M% 'OE%>!_P##5-O_ - 63_OL4?\ #5%O_P! 63_OL4 >^45X'_PU3;C_ )@L
MG_?P4?\ #5%O_P! 63_OL4 >^45X'_PU1;_] 63_ +[%'_#5%O\ ] 63_OL4
M >^4F17@G_#5%O\ ] 67_OX*Z3X=_'*+Q]XA_LM-.>V;89-[-F@#U>HIV6-#
M)(0J*,EB< #N3[5+574K&'4K*>UN8A-;SQM%)&20&5A@CCU!- 'ED?QZAOS=
MPZ=HMU=7,=Z]M;1N0GGHB[FEYZ+UQZ\5Z1X:UR#Q'HUKJ5N&6&ZC$BAQAAGL
M?>O-[;]FWPOH?F/H,E]H<K2A]]O<,Y"[-GEC>6PN*]*T/1K?0=)M].M%*6]L
M@C3/7CN?6@#)T2[@O?&6K26\\=Q&((QNB<, <],BNI%<IH5A;:?XQU6.UMX[
M9#!&2L:A03GKQ764 %%%% !1110 4444 %%%% !1110 4444 ?+/PW.?CY\0
MOJO_ *$:]F>O&/AM_P E]^(7U3_T(U[2_4_6@ '2B@=*0X)QWH 6C/-8'BGQ
MQHW@\1+J-Q(9Y1F.VM86FF8>NQ><>]6/#/BW2_&%I)<Z7<>:(B$EAD4I+$WH
MZ'E: ->BBB@ HHHH ***6@!**** %'6FO]VG4U_NT ,N)UM;>69SA(T+M] ,
MFO,=*U+QKXSL(]<LM7@TF"?+V5C]EWQ; ?E\PYR2>^.E>GSQ+<6[Q,-R2*5*
MGN"*\RTS0_&/@VTDT?1KVQET[<PM;B[0^9:H><8_CQGCI0!UO@#Q6_C'PS#?
MSPBUO4DEMKF '(26-RC$>Q*Y'M70_P =<_X#\,1^$/#L-@KM,^]Y)9GX:61V
M+.Y^I/X5T'\= #A1110 HIN.?QI:3'SCTS^5 'G^JZ[K_B7Q7J>DZ+=QZ18:
M6R1RW@B\R6>9@254?PA>_KQ5OP3XGU?_ (2"]\-Z_+%<:C!$+FWNX4V">$\'
M<O9@>#536?#VNZ!XNOM<\.W-NR:@JBZL+L'RRZ])%8?=)[C'-6O!7A;4K?6[
MW7M:N4N]4NP(PL2[8[>,=(U]?<]Z .T/0C[N2,#&3Q1RP[?B*=^.?>E_"@!J
M-SG/'3)Z5@R^"=,G\;VOBQTD.L6]HUC')GY?+8@GC\*Z#OTHH :"=P)QGUQQ
M09"S9Z\]#U-.I,=>!0 8YXP".GM]?6DY#9'/J.U+BCF@ 9BV"Q9C0Q8G+,&/
M0Y[T<T$4 -Z\8X]^IIXSUZ>G'/XT#I1S0 F"#2T44 %%%% !7GGC7_DN'P9_
MZ_-4_P#205Z)Z5YUXS_Y+A\&?^OS5/\ TD% 'T%1110!\S:[X1L?&7P+^)MI
MJ=QJ%I:0^(=6N6?39=DIV7#$ 'H0>X->:?"+PY\-_"_BOX47UEK&I^+=6U-&
M2WMY-5-P-/DV9+F(< #IGM7O7@C6)-%^'/Q%U""S%_+;:_K,@MF&1(1.W!'<
M5\U_LV>/=$M?B9;QZ?HGA2Z\57^MO:SW.B69C:*Q:)7+#/*[7.T^IH ^_%.1
M_C3J8AXQ3Z "BBB@#"\=<^#M9_Z]9/\ T$U\,*,"ON?QU_R)VL_]>LG_ *":
M^&1]T4 %'6BC/6@#M/ .@Z-?:#XGU;6K:XNH-)CA=(;:;RV8NQ4\]/3BK6K_
M  O6]ETF\\/SM_9&I6KW7F7Q"M;JAP^['4"LOP7XML?#VEZ]IFI:?+?VFK1P
MHZQ2^65",6Z_C6W9_%]K/6[:6#3OLNCV]FUC#9P2X>-"<E@Y_BS0!D)\+M5:
M_P#+^T6?V(6GVTZ@7/D"(G <=SSVQFI8/A)K$MW=Q&XLX8K6*.X-U++MB>-^
MC@_TZUIZ;\6_[.UB\E"ZG<V%Q:?9B9KO=<1G.=R-V^E4+[XCQSV>O6ZPWD\>
MIPQP))>7'F.FTYY/]* (M8^$VL:)8WUP]U87#62B26WM[@/)Y;$;7 ]"2/>H
M]3^%FKZ7:SL9+6XNK<Q"YLXY/WMOYF N[MW' SBI[OXE"X;5Y%LV5[NPBLU)
M8?(8RI#'U!*]/>M'Q+\7/^$@)N5BU"*^9XI)(3=G[*S(!G"#UQGGI0 W4_AF
MGAOP3KMW?7-I<ZE:RPQA;:8,8"?O*X[&N;\,>")?$Z@1:E86EP[&.*VN9=LL
MS?0?='IGK6[XI^(^GZSI6L6]EH[V=SJLL<]U*\V\%U]!V%)X)^)D'@_1X++^
MSY6EAN3<B:VD$9F!_AD/4@>@H X2Z@DLYY8)5"S1,5=1S@@X(!I!R/>IM3N_
M[0U&ZN@I3SY6E"_W<G.*@STSU]J %KT_]G 8^(X_Z]V_G7F!Z5ZA^SC_ ,E'
M7_KV/\Z /K(4M)WI: $H[4M(>E '.:<?^*VU7_KWC_G71BN;T[_D=]5_Z]X_
MYUT@H 6BBB@ HHHH **** "BBB@ HHHH **** /EGX;?\E]^(7U3_P!"->T/
M]YOK7C/PVCQ\=?B%+ZR*OZU[*[<F@ QFC!#YX/%-R:52<\G'O0!Y;=:OIGAK
MXKZQ-XBN%TZ._BC_ +/O[C*QA /FB#] V<FI?"&HV/B'XIZEJWAUOM&C+8+;
M7.HHNV.XGWL0JG^(J#RWOCM7H.H:3;ZBFV:..0>DB!A^&:?8:?!IZ!8D5 !@
M*B[0* +?&,#Y<4II@^_[4Z@ H)XQ0>AIJ4 . )P<8S^7%(. #P1][(/!%>>>
M,)+SQ-XYMO#::A=:=I\5G]KG%E(8I;EBV%7>.0HQSCUJOHEO>>!?B%8:,NH7
M5]I6K6LDJVU[,9GMI4(^9'/.T@X(]: /3,8HIKY]<^].'2@ IK#GI3J0GIZ@
MB@#RO]HKXJ^(OA#X/M?$&@>'U\06T-T/[24'$D5O_$R#N?:O.;K]M&Q\:^+_
M  IX?^&6CMXEN;]DFU26Y'E1V,)^\"3_ !#WKN?VI5\:WGP^32O!%M!)=:C.
M+6ZN9SDV\+<,RKW/.*^>_A_^S=XR_9^^('AO6O#$\6LZ;>LL&L6UV,#!Y9Q^
M/04 ?<J,K*&YY'(/\/I]:!WH!!1<<+Z4HH **** "D+8.*<>*3&: &GYQTS_
M "HR .!3\8I,"@  [T444 %%%% !1110 4444 %%%% !1110 4444 %%%% "
MUYUXTX^.'P9_Z_-4_P#205Z)7G?C?_DN'P8_Z_-5_P#204#/H'(HIM% 'SSX
M>MO$4.B>(]3TOQ-:>'-)L/$NMR:BUW:><)$\UMIZC 4\^]?/?P]\=ZMX@\4W
MD'@7XC>&T\5W:O)9";P<]@NJLOS;%F8X()P,_C7LNK>#O$WBSX>>,(]#\4P^
M&M-C\2:T=3$MF;DW$1G88 '(_"O,?@A<0:M\3_ &D:E\2F\31Z(9/[-TJXT*
M6W.0N-X<@#*CC- C[C\./J$F@Z:^K1Q1:JUM$UXD!S&LQ4;PI[C=G'M6G3(^
M5!P0/>GT %%%% &%XZ_Y$[6?^O63_P!!-?#&<+GK7W/XY_Y$[6?^O63_ -!-
M?# /R\=: .F\&^#(O%5GJ]Y<:FFD66FQK)+/)&7^\V!P*-:^'6L:9X@32K:$
MZB\T*W$,EOTDC(R&YZ?CBM+X<^,X/!VC>)W9T6_N;>-;9'C#AV#Y.0>.GK77
MV_Q#\/SZOJL[W$<9U>SBW"YC<I;RKC=&0I!V]QB@#RRV\):S>W%U;0:9</<V
MO^NCVY:/ZYI\/@W7KRR>[M]*NI;14,C3+%E0@."<_A7I>G^/]+O-:U==:U2T
MGTBX""2*.!T\W8N%:,@Y#=N>M:UOK>E:%X9\$:C<:Q<6<-M:W+)IX!/V@%F"
MJV#C(R.M 'CNG^$]:U/3YM1M-+NKBRASOGCC)4#O]:2+PEK5QIHOTTNY>S\L
M.)E0E2GK7J'A_P"(FA0#P[J4VIW%D^CV\T4FE1JQ^T,Q.&ZX/7'-5+3XF6"W
MGAG-_+%9VNDSP7-NI8(LKYP"._UH X_PC\.-2\3@SM;7%MIQAD<7ICRF54MM
MS[XK%M/#>K7VBMJD&G3OIR]9E3*CC]?KTKU/2_'^A"STNY?5Y[22VTN:P;30
MAV%V#8<XXYX]ZBL_B'I@\&:8L%Q::?J%GI[64EO<0/(YR.=I#!<'/<4 >8W_
M (;U32[&.ZO+">VM96V1S2+\KDC. ?I7667PLANM.T21_$5I:ZGK$)GM+&>-
MAO&<;=W(SFJ7Q-\50^)[_3A9W4DUA;V44/E$D(D@7#8'K[UTL.O>%KBP\%WU
MYJLD=UH-F$>QBB),C[]P ;H.E 'GLWAG5()A&]C-O,[6R8&0T@."F?6G6/A+
M6=3-X;73+BY^QL5GV+_JV'4?ACI7I.C_ ! T35HK6YU6]DT^XL]6;4/($>_S
M%)R!D<9%3:%\1M)327A^TVUC=VNJSWL4MW$[B178[67:1\V.S9% 'CC*5X.1
MSCFO4?V<?^2CC_KV/\Z\VO[HWFHW5PVPF65G.P;1R<Y KTG]G+CXBJ?^G=OY
MT ?67>EHHH *0]*6D/2@#F]._P"1WU7_ *]X_P"==(*YO3O^1WU7_KWC_G72
M ]J %HI,T;A0 M)G%-9PO)( ]ZB:]@CR7GB7'JX% $]+6)=^,M$L3BXU6SA_
MWIEK*N_BUX2L@3)KUH<==CAOY4 =3<W,=O$TDKB.-069VX4 =23V%>9ZE^T9
MX1TV\:!)+W4%7[T]G;%XQ^.17)?%/XC:;\2'T3PKH.IEX=1O!%?/&"I$?& #
MWY-?*'Q"^+GC/]BOQUXF\+6]Y:>+=)UI&GTW[85,NFNQP"X Z#.<'B@#]$/"
MGC32/&NG?;='O%NHL@,,$,A]"#T-;H^][=*^+OV?]+\0?#F+P1KNJ>(?[=N/
M$UQ(+J2 @Q[6 ; QP<$CZ<U]H)G..PH ?1110!\O_#8Y^-OQ /I,O\Z]!\:>
M+AX3L+9DLWU#4;R86]I9QG;YLAYY)Z #DFO/OAIQ\;/B"/\ ILO\ZZWXDZ+J
M5VND:KI*)<7^F7'G"VE;:LR$89<]C[T 5K;X@:SI6KZ?:>(])MK6VOY?(BOK
M.;S$BE(X1P0,9Z ^IKO9% + ]0<$>E>5ZA<ZW\1KC3+-]"N?#NG6EPES</>,
MI>9D.52,*2-NX#DXKU1B2O/Y=A[4 "@8%+BA>@HH 7C%)110 'I38QUIW:@#
M ZT <IXP\"Q^)+NSU"&[N=-U2TR(KRS?:X4]5Y!!'L15;PKX"_LG69]7O[Z[
MUC5I8_*-U?.&94R#M0  !<_C7: 8'7_"DQ@]?>@ ?IZTHZ48XH[4 %(1S3J0
MC- #)(TD # -2-%&X *\ < 4_:* H% "<87'44[&*-HI: $HHHH 3#9X(/MZ
M>]+L<*"1@$\9X!KEOB9X@O?#OA82:;)'!?W=U%8P7$G*PM(3^\/T"GKW(KC]
M<\/:QX!TD>(+3Q!J=[-;,C74>H3;X[L$@,"N.#SQB@#U@DX#>M*.GK45K<K>
M6<%PH*^;&LF#VR,XJ13D4 +1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 4444 %%%% !1110 4444 +2'FBB@ Z4444 %%%% !1110
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M7LZ_LG>%3TT>T [<N3_Z%0!Z\?B/X5(Q_P )'I7_ (%Q_P"-56\:>$&D#_\
M"0Z7G_K\3_&O+?\ ADOPL?\ F$6GXE__ (JE_P"&2_"W?2+/'^\__P 50!P/
MPQ\0Z5:_%OQS<S:E:06TMQF.22955^>JG/->Q_\ ";^'.O\ ;VG'_MZ3_&O
M?A9\#M)\6^/O%FF75E!+::;*8HE8D!>>@YS7K'_#)?A?_H#V8^K/_P#%4 =/
M_P )OX</_,=T[_P*3_&D_P"$X\.#_F.Z?_X%)_C7,C]DOPK_ - >T_[ZD_\
MBJ7_ (9,\+=M'M/SD_\ BJ .E_X3CP[_ -!W3_\ P*3_ !H/C?P[VU[3O_ I
M/\:YK_ADSPM_T![/\W_^*H_X9*\+'KI%G_WT_P#\50!TG_";>'>^NZ=_X%)_
MC2_\)MX<_P"@[IW_ (%)_C7,G]DKPN.FD6>/]Z3_ .*H_P"&2_"__0(L_P W
M_P#BJ .F_P"$V\.?]!W3O_ I/\:3_A./#?\ T'M._P# I/\ &N:_X9+\+_\
M0(L_^^G_ /BJ4?LF>%Q_S"+/_OJ3_P"*H Z7_A-_#G_0>TW_ ,"D_P :3_A.
M/#>/^0]IW7_GZ3_&OE']I7P*_P  ?$VA^(O^$9T[5?A^1Y&I11*_GPL3]_._
M\JR_@)I$?[0?Q-O]1TCPM8Z;\,K2)K>)KE7\^ZEZAP0WRD'KU&..: /L/_A-
MO#G_ $'M/_\  I/\:/\ A-O#G_0>T[_P*3_&N9_X9+\+/@C1[,?C)_\ %4?\
M,E^%_P#H$6?_ 'U)_P#%4 =+_P )OX<_Z#VG?^!*?XTO_";>'!_S']._\"4_
MQKFO^&3?"X_YA%G^<G_Q5(?V3/"Y'_((M/S?_P"*H U=?^*GA/PYIDM]<ZW:
M3(A $5O,KR.QZ!0#U-8>B?'CPYJ.KP:?J)_L9[A28)+F5&B8_P!TLI.&]C7+
M?$K]E_2="M--U33M COXK.??=V=N6WRPD8. 3R5SG\*YBZ^#W@[QM=:?I?A+
M0Y6E:=9+N^FMYH8[:)>H._&7/3C/>@#WW_A.?#N0/[>T_..GVE,_SH/C?PY_
MT'M._P# E/\ &N8B_9.\+-&O_$HM>G1F<G\\T_\ X9,\+#IH]G_WU)_\50!T
MG_";^'/^@]IW_@2G^-'_  F_AS_H.Z=_X%)_C7-?\,F^%_\ H#V?YR?_ !5'
M_#)OA;_H#V?YR?\ Q5 '2_\ ";>'/^@[IW_@4G^-)_PF_AP?\QW3_P#P)3_&
MN;_X9,\+'_F#V?YR?_%4?\,F>%_^@/9_F_\ \50!TG_"<>'/^@[I_P#X$I_C
M1_PF_AS_ *#VG?\ @2G^-<W_ ,,F>%O^@/9_G)_\51_PR9X7/_,(L_\ OJ3_
M .*H Z3_ (3?PY_T'M._\"4_QH_X3?PY_P!![3O_  )3_&N<_P"&3/"__0(L
M_P#OI_\ XJC_ (9-\+_] >S_ .^G_P#BJ .D/C?PY_T'=._\"4_QI/\ A./#
MG_0=T_\ \"4_QKG/^&2_"W_0'L_^^G_^*I/^&3?"W_0'L_SD_P#BJ .E_P"$
MW\.?]!W3O_ I/\:3_A-_#G_0>T[_ ,"4_P :YO\ X9,\+?\ 0'L_S?\ ^*I?
M^&3?"_\ T![/\W_^*H Z3_A-_#G_ $'=._\  I/\:/\ A-O#G_0=T[_P*3_&
MN:/[)GA;_H#V?YR?_%4G_#)GA;_H#VGYO_\ %4 =-_PF_AWMKNG?^!2?XT?\
M)MX>_P"@[IW_ ($I_C7-?\,F>%O^@/:?F_\ \50?V2_"I_Y@]G_WT_\ \50!
MTO\ PF_AT==>TX?]O*?XTG_";^'/^@]IW_@2G^-<U_PR5X6'32+/\W_^*I1^
MR7X7_P"@19_]]/\ _%4 =)_PG'AS_H.Z<?\ MY3_ !I1XW\.?]!W3_\ P*3_
M !KFO^&3/"X_YA%F?QD_^*H_X9-\+?\ 0'L_SD_^*H Z7_A-_#G_ $'=._\
M I/\:/\ A-_#G_0=T[_P*3_&N:_X9,\+'_F#V?YR?_%4G_#)?A?_ *!%G_WU
M)_\ %4 =+_PF_AW/_(=T[_P)3_&N-\2:M8ZM\:O@W+8W<-Y$M[J@9X'#@'[(
MO4BKO_#)7A?_ *!%G_WU)_\ %5B:C\.=-^&OQ?\ @WI^FVL=K#/?ZK(Z1Y()
M^R <Y)H ^E^?444[)]!^=% KGA?AJ*"X^%'Q-BO+QM/MGUW6EDNASY:^>WS<
M=A7R_P#".*S\$ZII?B?6_%7A32_ ,.NB\AN]%E=WFNC$L0B*X^12!N;/>OJ;
MPE;:=??"[XE0:I=&PTU]>UH7%P #Y:><V6QWQZ5\D>&_!%S\2-;@L?#'B\RW
M&H6LMK"U_P""Y+2P=&C,1?<HP#LSANN[% S]'[2YBO+:&>"19H95#I(IR&4C
M((_"K%8?@KP^/"?A#0]$64W"Z98P60F;K)Y<:IN/UVUN4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %)2T4 )@>E& !C Q2TAZ4 <WIW
M_([ZK_U[Q_SKI#T-<YI__(ZZK_U[Q_SKHQ0!A^+?"6G^,=(ETW4X?/MY/F]"
MK=B#ZUY>/V>[F."2QC\6W\>D-P;3:.GIFO;:0@'- '.>#?!6E^"-&6PTN';'
M]Z21_OR-ZL:Z,#CI05!Q2T %%%% &=KFCVGB#39M/OH%N+6=2LD;#J*^;M5T
M>UT76K_2/"NL>(Y[2R;%U'IT6^. ]T#'[S ?PCFOIZ;YD([X_*O#_"'BO3?A
MN-:T7Q-;3V5S%>S7$%Q'"SK>H[;@RE0<OV(H ZCX*>'/"]KH2ZSH,LE_)>96
M:]NP?.+ D%&!Y4@YR*]+P!VKS'X(V5ZL'B#5KJSDTR'6=0:\MK"3AH8]H4$C
ML6V[L'UKTYCA21S0 M(>E1+(6Y!5AG'':E64,V 0>>W;VH ^??V?EQ\5_B&?
M6\;^=?0PKYY_9_/_ !=7XA?]?A_G7T-0 M%%% !1110 4F*6B@ I&R <4M%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_$3_ *_G_P#0S7T?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7C'Q=_Y+Q\%/^OK5/\ TE%>SUXQ\7?^2\?!3_KZU3_TE% +<]GHHHH(
M/-/@5_R"/%G_ &-.J_\ I0U>EUYI\"O^01XL_P"QIU7_ -*&KTN@L***2@!:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/2BC.<
MT <WIW_([ZK_ ->\?\ZZ05S>G?\ ([ZK_P!>\?\ .ND% "T444 %%%% !111
M0 4444 %%%% !112&@#YR_9FY^(OQ$_Z_P!__0S7T=7SC^S.I'Q#^(C8X-^X
MS_P(U]'4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444G- "T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C
M'Q=_Y+Q\%/\ KZU3_P!)17L]>,?%W_DO'P4_Z^M4_P#244 MSV>BBB@@\T^!
M7_((\6?]C3JO_I0U>EUYI\"O^01XL_[&G5?_ $H:O2Z"PJ-R0>.:DICG% &%
MJ?CC1M%U"2SO+X17" %H]C' (R.@JO\ \+,\.?\ 01'_ 'Z?_P")K4ATNVAN
M[J[6,&:Z*F1GY^ZH48].!5J.WA<_<C;_ ( * ,'_ (69X<'741_WZ?\ ^)I/
M^%F^&_\ H(C_ +]/_P#$UT8M(1_RR3_OD4OV6'_GC'_WR* .;_X6;X;_ .@B
M/^_3_P#Q-'_"S?#?_01'_?I__B:Z3[+#_P \8_\ OD4?98?^>,?_ 'R* .<_
MX69X;_Z"(_[]/_A1_P +,\-C_F(C_OT_^%=']EA_YY)_WR*/LL/_ #QC_P"^
M10!S?_"S?#?_ $$1_P!^G_\ B:/^%F^&_P#H(C_OT_\ \372?98?^>,?_?(H
M^RP_\\8_^^10!S?_  LOPX3QJ0_[]/\ X4B?$OPV791J:EAU'EOG^5=$]O"O
M_+%/?Y1Q5--&M(;Z>\6-?.F14;C^[G&!^- &6?B9X<'_ #$1_P!^G_PI/^%F
M^&_^@B/^_3__ !-;RQ1%\&*/'LHQ4WV6'_GC'_WR* .;_P"%F^&_^@B/^_3_
M /Q-'_"S?#?_ $$1_P!^G_\ B:Z3[+#_ ,\8_P#OD4?98?\ GC'_ -\B@#F_
M^%F^&_\ H(C_ +]/_P#$T?\ "S?#?_01'_?I_P#XFND^RP_\\8_^^11]EA_Y
MXQ_]\B@#G!\3/#9_YB(_[]/_ (4A^)OAO_H(C_OT_P#A72?98?\ GC'_ -\B
MC[)!_P \8_\ OD4 >7^.OCA8:-]BMM&DBO+ZY9C^^1U1$49)/'?I^-;'AOXP
M^'->T:TU#[:83<1AVC>-\J>XZ>M:_B[X?:-XTAM8M2MF86SF2)X7,;*2,'E<
M9!!Q6K8:59:;9PVMM;1QP0J(TC"C@"@#BK#X@:"GBO4+DWX$,D$85O+?G]*W
M?^%F^'!_S$1_WZ?_  K5MM(M8[V6Z$2F:10K<#! Z8':KPM82.(D_P"^10!S
MG_"S?#?_ $$1_P!^G_\ B:4_$SPV/^8B/^_3_P"%=']EA_YY)_WR*/LL/_/*
M/_OD4 <W_P +-\-_]!$?]^G_ /B:/^%F^&_^@B/^_3__ !-=)]EA_P">,?\
MWR*/LL/_ #QC_P"^10!SG_"R_#G_ $$1_P!^G_\ B:3_ (6;X<_Z"(_[]/\
MX5T?V2'_ )Y)_P!\BE^RP_\ /)/^^10!S?\ PLWPW_T$1_WZ?_XFC_A9OAO_
M *"(_P"_3_\ Q-=)]EA_YXQ_]\BC[+#_ ,\D_P"^10!S@^)?AQNFHC_OT_\
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M_/*/_OD4?98?^>,?_?(H YS_ (67X=_Z" _[]/\ X4?\+-\-_P#01'_?I_\
MXFNB^R0?\\D_[Y%+]EA_YY)_WR* .<_X67X<_P"@B/\ OT_^%(?B;X;SC^T1
M_P!^G_PKI/LL/_/)/^^11]EA_P">2?\ ?(H YO\ X69X</\ S$1_WZ?_ .)I
M3\3/#@ZZB/\ OT__ ,371_98?^>2?]\BD%I"/^62?]\B@#G/^%F>&STU$?\
M?I_\*8/B;X<W@'5$#'D+Y;Y(^F*Z5[6';Q"G_?(J@^C6,VIPWYA4W$,;1JVW
MC:<9_E0!F#XF>&^?^)B/^_3_ .%'_"S?#?\ T$1_WZ?_ .)K?\B'(Q%'_P!\
MBI1:PX_U4?\ WR* .;_X6;X;_P"@B/\ OT__ ,32CXF>'#_S$1_WZ?\ ^)KH
M_LL/_/)/^^12?9(?^>2?]\B@#G?^%F^&Q_S$1_WZ?_XFD_X6;X;_ .@B/^_3
M_P#Q-=)]EA'_ "R3_OD4?98?^>,?_?(H YO_ (6;X;_Z"(_[]/\ _$T#XF^&
MS_S$1_WZ?_"ND^RP_P#/&/\ [Y%'V6'_ )XQ_P#?(H YP_$SPV/^8B/^_3_X
M4G_"S/#9X&HC/_7)_P#"ND^RP_\ /&/_ +Y%(;6''^J3/^Z* .:_X69X<C.'
MU-1S@9C?D_E3_P#A9GAO_H(C_OT_^%:MWI-K>2V[O$NZ!O,3"\9J<1Q$<PQC
M/3Y?\_G0!A?\+-\-_P#01'_?I_\ XFC_ (6;X;_Z"(_[]/\ _$UT8M8<#]TG
M_?(I?LL/_/&/_OD4 <Y_PLSPX>FH@_\ ;)_\*/\ A9?AW_H(#_OT_P#A71_9
M(?\ GBG_ 'R*3[)!_P \D_[Y% SG?^%E^'/^@@/^_3__ !-'_"S/#8ZZB/\
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M9O-&'^\=N[WV[:[&D"!1TIU !1110 4444 %%%% !37)",0,D#IZTZD(R"*
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MM4_])10![111100>:? K_D$>+/\ L:=5_P#2AJ]+KS3X%?\ ((\6?]C3JO\
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M94*+N)'("G&.E-O?!'PZNX(?*\)?$2SNH=3GU6&\M]'NDFBFE_UFUL<*W3%
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M 'H* .+U2V\1_!IOA'XIL/B#K7B*Z\2ZE;66K:=J-PLT%VDPW,\: #:5/IG
MJW\%]?USPK\;/[%^)NL>)K7Q7J=[=G3)7ND?2-3@W'9'&H&5*KCBMCP9X(^'
M?@KQ!8:I%X5^(NI2:8K#3;?4=)NYHK#/!,2D?*<=^M6_"7ASP/X4\96WB4>&
MOB-JM_9^8;%-2TFZGCL]YRQC4CY2:!GGW[4_BC6H?C[J&CV7B+Q3IAA\-&YT
MFR\-Y;S+_< GF*%/RDGDG'UKL/%7[2GCKX3>$/#ZZY9:)?Z[;:3;W.LVCW+B
M[\QL;OD52$XQ\S'!)KO8_$?A:/XFR^/%\'^.!X@EL!IID.A7/EB'<&QMQC.0
M.:Y#X@^%O 'Q'\3ZCK^H^$OB%;WNIVB6=\MIH]U$EU&F-@< <[<<4 <YKW[3
M%UX!UCQOK^EZ#/J5R=1TNT6VN[\B,_:8\Y48PFW ^M>S? _XP>(/B%K?C;P_
MXDT2STC7O#-U';R"RN#-#*LD0D4AB 1PP!KS75/ OPVUF+4$N/!OC\B^N;.[
MEVZ-=#Y[88BQQQ@=17:^%/$OA;P;XJ\3^(=/\(>.5U'Q'-%-?,^A7+*6CC$:
M[1CCY5'2@1X/HWQ,\6?##Q+\3?'NHZ-:ZWJA\00Z)#'_ &G)L3>5"HJ$;0,$
M'.,]:]3\0?M&_$&UUZ\\-:7X5TB;Q'H6A+KNO+<WK) BN<I#"<?,VWDL>,TN
MLZ)X UNPU:UNO!WCYHM3U:/6K@+HMT";A,;2..!\HXJ'XE>'/ ?Q-UXZUJ'A
M7XAZ?J+V0T^ZFTW1[J WEMG/E28'S+Q0!DWO[8OB?6XH9?"7A&TNXUT :_<_
M;[LQM&@8B2,8!W'@XKL_@]^T3XE\<>/]&T/Q!X7M-'LM?T0:[I<]K=>:PBR1
MLE&!AB!GBLN#1/AY:W4\EMX'\<6PFT?^PS%%H=RJ+;8Z 8X//7K6AX=F\%^&
M/$'AS5[+P=X[%[H.DC1K-GT.Z*BW'8\<GWH \0_:.\9^,-/^+_CV;1M1\41K
MH=E:W-K/I<ZBSL,M\[W"'ED(SD"O2/'O[6NL> K#3+VQBT/Q)IT5I8S7;PW#
MBZE\[:&;8%(CY)(W'FI_&WA'P'X\\6W^OZCX:^)$<VH1QPWUM;:5=QP72(>%
M= ,$52\2?#;X8>(M3NKM_!?Q LK>\A@@NK"RT>ZBMYQ ,0ED ZKU% '56O[3
M^H)\3M>T;5-+M-%TG38I)K=+R1UN[^)8]XEA&-K*>F,Y%>5>+?VJM=^)?PP\
M76<NB-INGZGX;OKVSU*P\T-9F,<)*Y  + \%3UKT"70/ MWXTC\2:CX7^(FJ
M3Q!Q;6EYH]U);V^]-K!$QQD<5GZ7X'\"Z1I.M:1'H7Q,ET34;*:P.ERZ7=&"
M"*7[PC7'RGT/:@=CD-$^/%W\,=,U#5H]/N-6O]'\ Z%=,MQ?,8YFD2,$;2#A
MOF)+<DUV%U^V-KOA'2O%DGBWPK:6VHZ986=_80V%V94F6Y(6-9#M&TC()QGC
M-/O? OPVU&QO[6;P9X^:&]TBTT27&C70)MK;'E ''7Y1DU?USP[\.O$$FK_V
MAX&\=7/]JZ;!IDX.AW.!%!S&5XX8$#F@1W'[/_QLU?XGZCKNF:UH8T^XTU()
M8[ZV206UTLB[B%WJ#E> ?7K7M .:^?OAGXAT7X8V]W%:Z3\2=4^T[,MJFD7,
MY14&%"Y7@ <5VW_"];'_ *%/QG_X3MQ_A0!Z917F?_"];'_H4_&G_A.W'^%*
M/CK8=_"?C3_PG;C_  H ]+HKS0_'6P_Z%/QI_P"$[<?X4G_"]+#_ *%/QI_X
M3MQ_A0!Z917F9^.U@?\ F4_&G_A.W'^% ^.UA_T*?C3_ ,)VX_PH ],HKS0?
M'6PQ_P BGXT_\)VX_P *7_A>MA_T*?C3_P )VX_PH ]*HKS0_'6Q_P"A3\9_
M^$[<?X4G_"];'_H4_&G_ (3MQ_A0!Z917F?_  O6Q_Z%/QI_X3MQ_A1_PO6Q
M_P"A3\9_^$[<?X4 >F45YK_PO6P_Z%/QI_X3MQ_A2?\ "]K#_H4_&G_A/7'^
M% 'I=%>9_P#"]K#_ *%3QI_X3MQ_A2CX[6&?^14\:?\ A.W'^% 'I=%>:_\
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$FQ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>tmb-20250331xs4029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4029.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &4 J$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[:\!> #X]
M;Q3J6H^*_%L4R>)-1MTBL]<GABCC2=@B*@.%4#@ <5UG_"B;$C/_  EWC8?]
MS%<?XTOP*7_B4>+/^QIU7_TH:O2P,"@#S+_A1-A_T-WC7_PHKC_&C_A1-A_T
M-WC7_P **X_QKTZB@=SS+_A1%C_T-OC7_P **X_QH/P(L/\ H;?&O_A17'^-
M>FT4"/,?^%$V'_0W>-?_  HKC_&E7X$V'_0W>-?_  HKC_&O3:*!W/-/^%$V
M'_0W>-?_  HKC_&FGX$V.?\ D;O&O_A17'^->FT4"/,?^%$V'_0W>-?_  HK
MC_&C_A1-A_T-WC7_ ,**X_QKTZB@=SS'_A1-A_T-WC7_ ,**X_QH_P"%$V'_
M $-WC7_PHKC_ !KTZB@+GF/_  HFP_Z&[QK_ .%%<?XT?\*)L/\ H;O&O_A1
M7'^->G44!<\Q_P"%$V'_ $-WC7_PHKC_ !H_X438?]#=XU_\**X_QKTZB@+G
MF/\ PHFP_P"AN\:_^%%<?XTH^!-AG_D;O&O_ (45Q_C7IM% 7/,S\";#'_(W
M>-?_  HKC_&D/P(L/^AM\:_^%%<?XUZ;10(\R'P)L/\ H;O&O_A17'^-0W?P
M4L+.WDF;Q9XV98D+G;XAN"< 9X&>:]3J.0@9XS0!\[Q0>"IK.XN&\:^/(FMI
MQ!)!)K=TLN\J7QMSDX56)] *[?3_ (,Z5J-G!>6_C+QG+;S1B2.1?$=QAE(R
M#UJG_P *FUBQL;*]L[JRE\0K?W=W=RSQDQS>>A3IV*@1C\&]:]$\'^'5\->%
M=/T@R&;[/#Y;N?XF/+8]LDX]J .-C^!NGN/E\7^,V^GB.X/]:=_PHBQ_Z&WQ
MK_X45Q_C71>&;*/3?$NO6MN66!3$X1F)"DIDXKJZ /,Q\";#'_(W>-?_  HK
MC_&E_P"%$V'_ $-WC7_PHKC_ !KTNB@#S$_ FPS_ ,C=XU_\**X_QH_X438?
M]#=XU_\ "BN/\:].HH'<\Q_X438?]#=XU_\ "BN/\:/^%$V'_0W>-?\ PHKC
M_&O3J* N>8_\*)L/^AN\:_\ A17'^-'_  HFP_Z&[QK_ .%%<?XUZ=10%SS'
M_A1-A_T-WC7_ ,**X_QH_P"%$V'_ $-WC7_PHKC_ !KTZB@+GF/_  HFP_Z&
M[QK_ .%%<?XT?\*)L/\ H;O&O_A17'^->G4AZ&@+GS!I6GZ9J_Q#USPJOB#Q
MU%+IJAOM'_"3SXDS[=JZYOA9:9_Y&OQO^'B6XKA?!V/^&D?&/^X/Z5[8V#B@
M1QG_  JRT_Z&OQQ_X4UQ0?A79G_F:_''_A37%=IMS1L% '%?\*LLQ_S-GCC_
M ,*6XH_X599_]#9XX_\ "EN*[4H*-@H XK_A5EG_ -#9XX_\*6XH_P"%66?_
M $-GCC_PI;BNT\L4>6OI0!Q?_"K+/_H;/''_ (4MQ1_PJRS_ .AL\<?^%+<5
MVNP4;!0!Q7_"K+/_ *&SQQ_X4MQ1_P *LL_^AL\<?^%+<5VNP4FQ: .+_P"%
M66?_ $-GCC_PI;BC_A5EG_T-GCC_ ,*6XKM-E(0!UH XS_A5EG_T-GCC_P *
M6XH_X599_P#0V>./_"EN*[, =P:4*": .,'PLL_^AL\<?^%-<4'X66?_ $-G
MCC_PIKBNTV"C8* .*_X599_]#9XX_P#"EN*/^%66?_0V>./_  I;BNT*@4!0
M: .+_P"%66?_ $-GCC_PI;BC_A5EG_T-GCC_ ,*6XKM=@I/+% '%_P#"K+/_
M *&SQQ_X4MQ2_P#"J[/_ *&SQQ_X4UQ7:;!1L% '%_\ "J[/_H;/''_A37%'
M_"J[/_H:_&__ (4UQ7:;!2>6/2@#B_\ A5EG_P!#9XX_\*6XH_X599_]#9XX
M_P#"EN*[3RQZ4NP4 <5_PJRS_P"AL\<?^%+<4?\ "K+/_H;/''_A2W%=KL%&
MP4 <5_PJRS_Z&SQQ_P"%+<4?\*LL_P#H;/''_A2W%=KL%)L% '%_\*LL_P#H
M;/''_A2W%'_"K+/_ *&SQQ_X4MQ7:[!1L% '%?\ "K+/_H;/''_A2W%'_"K+
M/_H;/''_ (4MQ7:[!1L% '%?\*LL_P#H;/''_A2W%'_"K+/_ *&SQQ_X4MQ7
M:[!2;!0!Q?\ PJRS_P"AL\<?^%+<4?\ "K+/_H;/''_A2W%=KL%&P4 <7_PJ
MNS_Z&SQO_P"%-<4?\*KL_P#H:_''_A37%=GY8]*/+7TH XO_ (599_\ 0V>.
M/_"EN*;X:T&7PC\4M M[3Q#XBO[:\@G$UOJ^KRW<>5 *D*_ -=MY8KGW&?BU
MX4_Z][G_ -!% 'KWX?I12\^U% 'FOP*_Y!'BS_L:=5_]*&KTNO-/@5_R"/%G
M_8TZK_Z4-7I= !1110 4444 %)2U&TZ1JS,0JJ,EF. !0!)15&QUFRU,N+2[
MANBGWA%(&Q^537-[!96\D]Q(L,$:[GDD.%4>I/:@"Q15(ZK:+#;2_:H?)N2H
MA?S!B0L,C:>^1Z59,F!TYH DHJ(3 ]0016=JWBG2=!>"/4=2M;&2<[8TN)0A
M<^@R>: -:BHDG5T##D'H1R#2^:,9/'% $E%,60-TI] !1110 4444 %-9<G-
M.HH 8J 9]^]."XI:* .<T?\ Y''Q!](/_1==$*YW1_\ D<-?^D'_ *+KHJ %
MHHHH **** "BBB@ HHHH **** "D/2EI#TH ^4_![8_:3\8CU4?TKVQSG! K
MQ?P9&#^T3XX8CYE5,?B:]I<8H =V%% Z44 %%%% !1110 4444 %&!110 AX
M(QTKG/&?C:+PFMC;Q64^K:OJ$C1VFG6PPTNT99V8_=4=S71GJ*X#X@VFH:?X
MIT#Q-:63ZI:V*2VUW9Q8\TQOT>//4@YR/2@"WX>^(MS=Z[%HVOZ$WA[4+B,R
M6SI<BYM[C'55D 'S#/0BNVP1G)Y],Y_.O+9+^X\?>*]#EL=)NM-TK2YC<27%
MX@1II,8"(HYQR<FO4>2<G\Z "BBB@!:2BB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N>/\ R5OPK_UPN?\ T$5T-<ZY
MQ\7/"7_7&Y_]!% 'L%%%% 'F?P,8)I/BP$\_\)3JO_I0U>E;Q@&O!="\>+\,
MOA-\2/%'V3[:=.\1:M*L ;&\_:2 ">PR>361\(OVF]8\9>)_"WAW6]/T<:AJ
MWVUK@Z5=F40>5L*$#'((;!)[B@#Z2!STI::F0/QIU !1110 U^E>6?$*-_%7
MC[2/"T\TL>E?9'U":&)RAN6#A5C)'\/.2!7J;C*D?RKB/B!X';Q')8ZA9WDF
MEZS8,6M;Z) Y3/5&4\.A]* .1\>^"X/!VCMXFT5%TO4M+VNK0L52= <&)UZ'
M([]:O_M"W1N_V>_%<S*5\[35+J"1PQ7(_(FH6\'^(_%ES;1>*=9BO-.MI%D3
M3["V\A)W4_*TC9)P/[HX]Z[_ %_PK8^*O#-WH>J0&?3[N/RIHE)&5SG /X"@
M#XY%W>>!;[X8_#/4+RYN4L?$FFZMHEY*3NGL)HY28B>YBDWKC^[LKT?0_BK\
M1O%_B(ZMHMK<7&G1ZX-.?2_LJB$6HD"22&4G.Y1ENGM7M6O_  G\+^)=3\+:
MAJ&EQW%YX:D$NE3DG?;L%V\'N" ,@^E4HO@QX9M/%,NNVR7=E-+<"[GM+>Y9
M+::<=)&C'&[]/:@#QN7XJ>/-3\.^)?']GJ]I;:1HVO2:;%H7V;<);=)51B[]
M?,;=GVQ6S\,?"FA?$[QG\1-2\46Z:IJ,=^MI';W39^QP>6"@1?X<YSD<UWTW
M[.W@BX\13ZP=-D!N;L:C/8K<.+26ZSGSVB!P7SC)Z' XJQXL^ GA#QCK<NK7
MEA+;W\Z>5<S64[0FY3^[)M/S#''K[T >/_%SXJ:E\-)-4@\*>(6N8?#"6L;:
M/'8;X+>(B-=D\Y/+%6##OS766'B+Q[XX^,'B+2--U^ST70M(MX98X?L8EDE>
M5#]YB>@/..]=)JG[-'@+4YI"^DR16LR0)/9Q7+K!.85587D7/S,BHJ@D]!S7
M::/X*TK0]=U+6;*T$6HZ@L:7$NX_.J#"C'M0!Y=^QY%KK_!71KO6=:_MA+A7
M, :/:T0$L@8%B26R?7H.*]SKD/ 'PPT'X807]OH$$MI:7DWGM;-*SQQMR2$4
M_=&2>!76[AG&>: '44A.*6@ HHHH ***3(S0 M%)F@$'I0!SND?\C?K_ -(/
M_1=='7.:/_R-^O\ T@_]%UT= !1110 4444 %%%% !1110 4444 %(>E+2&@
M#Y9\%#=^T+XZ/^RG\Z]F?FO&O!'_ "<)X[_W4_G7LS<=: '=A11V%% !1110
M 4444 %%%% !1110 A'-)+&LJA2 1ZFG44 10VT<395<9QS4N,=.E%% !110
M<]J "B@9[T4 %%%% !1110 4449YQWH **<4('(_#O\ E3: "BD# G%*3B@
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M=V\OBW3DN(U7/[EO,5\CMP>: .U^('QB\._#GX<CQG?W#3Z,T,<T!MAN><.
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M,=L5O6%I'I]G';1#$<8V@* !C'I4PX)Z_6E _*@!J_>IU&** "BBB@ HHHH
M**** "BBB@ HHHH **** "N=;_DK?A3_ *X7/_H(KHJYUO\ DK?A3_KA<_\
MH(H ]@HHHH ^;;[3;C6_@?\ $S2+/4X=)O\ 4/$>JV]O-<W8MPSFZ/R[\C!(
MR./6O./V>OA@WA?]HN6+1;/1X]*T:"5;R^M=:^U32^8B;86A))4HP;YJ=\0_
MACX@^(=AYFF>&HO%VFV'BS7FNM*FNS;*9&E812Y'4H>?K4O[./P.\8^"_B;X
M2O[WP-:^%;33+"[M]1U.&\\V346D*E/,&,D@@\G- S[/0Y6GTU1QQQ3J!!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <YI'
M_(WZ_P#2#_T771USFC_\CAK_ -(/_1=='0 4444 %%%% !1110 4444 %%%%
M !2'I2TAZ4 ?*?PW_P"2^>/,>J_^A5[<_6O$/AL<_'OQ[]5_]"KV]N<4 +11
M10 4444 %%%% !1110 4444 %%%% "TUJ6D/:@#C?B3KVI:>-#TC2+E;+4-:
MNVMA>$9,"*F]RH_O$<#WKC=3\1M\+_$6EB3QA)JEO<W,=K?:7J4Z,Z!SCSLK
MRC YR#UXQCFNZ^(WA5O$NB[X)I;;4;$FYM+B#[\<@4]/KT->*?#GX?V'BSPY
M;ZEXEU/3Y[>W=YKJ+R!&QN/XFN6;+,P[= .PH ^E00X5E(8$ @C&#0&R:XCX
M,7$TW@&U61G>*.XGCM6DZFW#D1'_ +YKM@/FH ?2444 <?\ %'0+[7?#T)TU
M8Y-1L;E+VWAE.U)63^!CV!&:Y7Q-XAU?X@:%_P (_8>$=6T:>\>-+N_U:%8[
M>! RLQC(8^:?E('3[V:]9/((/(/6H5LH%;<%&?>@#'U/P9I6O6%M;WVGVUZD
M"A$^U1+(5P,<9'!K0T?0[31+1+>SMXK6!1\L4"!$7Z 5>.","@#@#-  "#FG
M4@ %% !1110 4444 %%%% !1110 4444 %%%% !1110 5SDA_P"+N^$_^N-S
M_P"@BNCKFY/^2N>$O^N-S_Z"*!GL5%%% CP/1_%U[X"^$/Q,\0:98?VE?Z?X
M@UB:&V8D!F%PW7V'4U0^!7Q1\8^./$EC_;7C7P+JMC<VS3'2]#O%DO$. 1\N
M=W'?(IMWX8N_&OP&^+&B6*I)=7>MZQ'&LUS]GCS]H)PT@^ZOK7G'[).G(?'\
M!MO!WPVLO[/LWANM5\+ZB9[U6P!]S<1AB.30!]ICVI::O(XIU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5;4+^'3+.>ZN'$=O!&TLC
MGHJJ,D_D*LU0UNR.H:3?6WDQ7/GP/%Y,Q(1]RD;6(Y .<'% '*VOQF\,W?AI
M=>6XN4TYYVMXVDM9$>5@-Q*(1N9< G<!C -=?8ZA#J-I#<V\BRP3()$=3PRG
MD&O#].^$7B_1(K6YL5TF-[.XD6TT62\FDLK>!X&0LCE=^[<1P>  ?6O6_!WA
ML^&_"FGZ5)*99+> 1R.IX).2<>P)./;% $6C'/C#Q!["#_T771UR/A/2XM(\
M3>(8(6D="8&S*^XYV>M=?0 4444 %%%% !1110 4444 %%%% !2&EI#0!\I?
M#7_DO7CW /4?^A&O;V/%>*_#:+_B^?CQP3]\#'_ C7M,G':@!U% Z44 %%%%
M !1110 4444 %%%% !1110 4C=*6@C- "#D$9Q[UR.I?"_0=2U&2]ETV%I7(
M+X)4.0<@LHX)^M==M]*-OK0!#96D=E L48"JHP%48 ^@J4?>IP&*0+@YH 6B
MBB@!"N31M%+10  8I ,4M'<T %%'<T4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7..,_%OPG_ -<;G_T$5T=<ZW_)6_"G_7"Y_P#010![!1110!\W
M:EID6O? /XKV,FJ1:-'/KNL1F\G)5(_])/WB.<'I^-<A\ ?A7XHN?BIX<\3W
M/@72/ .D:+IDMHTVESASJV\*%8XXVC;D9YYK/^)GQ&G\'_#?QWI%[X6U?6O#
M.K:MK27.HZ3"[M;S?:B C%?N KSN/>M#]F+3_#]EXYTT:7_PL^,K9,$B\26,
MT>GJN!QO;C([4 ?7R@@<_I3J13D=*6@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I",BEHH :%P*7&*6B@#G-(_Y&_7_ *0?^BZZ.N<T
MC_D;]?\ I!_Z+KHZ "BBB@ HHHH **** "BBB@ HHHH *0]*6D/2@#Y<^&W'
MQM\>?]=1_.O9'KQOX9_/\;O'N?\ GJ/YU[(] #ATHH'2B@ HHHH **** "BB
MB@ HHHH **** "BBB@ I:2B@ HHHH **** "BBB@ H[T4$XH **,C':@_7CV
MH ** 1C)HZ=: "BC(HR* "BC<#1D#WH **-P ).,?6C(X/0'UH **"0.M)N!
M.* %HHR!G/%% !1110 &N<8_\7;\)_\ 7"Y_]!%=&>E<VW_)6_"?_7&Y_P#0
M10-'L5%%% CPKPMXQL/ 'PP^(>OZI;FZL;'Q'JTDD"("9/\ 26PH!X.21UI?
MAQ^TLOC35_#6D7_AN?0K_6?M2I%),D@A: *=K8_O!LC%0:1I<VJ_"+XF6=O9
MV-[--KVL*EMJ+[+=S]H;AV[#WKQ/]DV3P)HGQHET)]$OX_'"6TQCNTU+^T;&
M)>-X1QPI/ ]>* /N2/[H[^M/IJ_=%.H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#G-(_Y&_7_ *0?^BZZ.N<TC_D;]?\
MI!_Z+KHZ "BBB@ HHHH **** "BBB@ HHHH *0TM(: /ESX9'_B]OCS_ *Z#
M^=>RMUKQKX9_\EM\>?\ 70?SKV5J %'2B@=** "BBB@ HHHH **** "BBB@
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MF?\ PT-X._Y_9/\ OV:/^&AO!W_/Z_\ W[- 'IE%>9_\-#>#O^?V3_OV:/\
MAH;P=_S^R?\ ?LT >F45YH/VA?!W_/\ /_W[-'_#0O@[_G]?_OV: /2Z*\S_
M .&AO!W_ #^R?]^S1_PT-X._Y_9/^_9H ],HKS/_ (:&\&_\_K_]^S1_PT-X
M-_Y_7_[]F@#TRBO,_P#AH;P=_P _LG_?LT?\-#>#O^?V3_OV: /3**\S/[0W
M@[!_TV3_ +]FN@\'_$O0_'%S-!I5PTSQ+N8%<<4 =6>E-=MO3/'I3C6?K=C)
MJ>F7MG%<-:2SPM$LR=8R1C</<9H Y9OC+X.33K[4#KL3VEE?/ID[K'(VVX1=
MSQ@!<L0.21D>]==I]]#J5I#=VTHGMID$D<B]&4C(->%^'/@IXJ\%0-+:7MGJ
M]Q'JMS=0Q2?N5\J: 1ECC^+<H/Y^M>P^#O#Y\.>%+#1WD\YK>'8[=,DY)Q^)
M- $6C'/C'Q!T(Q!C_OBNC%<EX4TV+2?%/B&"#?Y9\ALR.6.2GJ:ZT4 +1110
M 4444 %%%% !1110 4444 %(>AI:1NE 'RY\,SGXU^/#_P!-!_.O9'Z5XO\
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M&OC72O#>L745Y)K&F&ZNO(&V(7"#+E!V';'>OI4=!F@!:*** "BBB@ HHHH
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M3^Q]-C-K!%?[C_I:&3GKQQDG(]:I^*_"/AO3;Z+38[&0217UM%!.EK(%>-B
MPDE/RMG/!% 'D&I:]J&M[/M]]->;68IYK[MN2,D?6M:_?Q7IFDB&[.I6VG&/
M:JR A"A[?2K?Q.^P6WC&]TW3M.AT^VTZX:WS&2S3G(^9L]_I7JEZ-9_X3'69
M+[SQX232\2O<\0Y\H;0F>^?2@#Y\+ $#Z'%.#<@9PQ[5[&W@"REFTR[CTPMI
MC>%WN99P,Q_:,#:2>QR.E-O_  IX=TGPG:K+:RS-/I@N5NK>VDD<3$9YD'RA
M1T(ZT >/^E>T_LO?\C1J'_7O_6O%%;('(Y'7UKVG]E]O^*HU'C@6_7MUH ^G
M**:6 J.:YBMT9Y9%C1?O,[8 _.@"1CMQQFF23)&A=V"*O5F. *\N\4?'K2K2
MZ?3/#=K/XIUC=M6&R4M&#[L...^*RE^'_C7XE2+<>+M3_L736Y_LJQ/S$>C-
M0!)K'QGTKP_XKUJ+3HI==U"X,4<,%DNX%@F#D^QJLOA7Q]\3G$FOWO\ PC>C
MMR+*T;]ZR^C&NN^'W@G2/!_B#6K/3K1(TB6':[?,_*Y)R:[]1N&30!\\_$[X
M1WW@;2;?6?A\'@U2UAEBE=OWCG>A EQW()KY'G^ &@R^"S?MXBOU^*(N?MIU
M5T?>T^[.W/\ =K].VC.>>1SQCFJ+:#ITLXG-C;>=_P ]#",T >(?L_\ ASQ5
MK-]9>+O&C"34+6Q%E"P3;YIP T@7L"*^@AT%1K"H4*.!V XQ4F0!U_.@!:*0
M-GVI: "BFEP,Y('UJ)[VW0?-<1+]7 H F)P:1G 4G(Q[UDWOBS1+%3]IU>SB
M Z[IU_QKS'XO?$_3[W0(-'\/:W:SZCJ-PELQMI@SQHQY;B@#K-6^-/A#1;YK
M2XU>-IDX81 N%/H2*Z;0O$6G>)K%;S3+R*]MFX$D39Y]#7BG@KPE/+I,@T>V
MTVTT]6:..:\MO/EOB."\A_A4G. .163X.U4>"_B'I[VT(TN'4[A[#4=*C;=%
M%<*<!X_]ENHH R?A%Q\8_'W_ %W/_H1KVN3M7BOPD0_\+?\ 'S_PFX(!_P"!
M&O:I.HH =V%!S1V%% "$&DVGVIU%  .E*>M)10 4444 %%%% !1110 4444
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M:XEFVYW%"0%&WH?6@9]2*-HQV%.IJ9QS3J!!24M(: .,^,'_ "3K6A_TP/\
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MI>!'NO\ 0?$B,[:C'MXW8V0'^[Q7D/Q:TVYM/'.L33VTL$4LS&)G0@,/4=J
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M^T793Y%AX>U:[.< >05S^=,'QL\172'[+\/M5D)Z,S "O7EMXUZ1(H]E%/
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M;J:".:.*5TCF79(BGAQZ&I+'4[W3#)]CNI;8R##^4Q&17JY_9OU<G_C\0_\
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MJ'2Y+?6([C^TY9PH$<85CP"N<GU% ]S[HSFEID? Q[T^@04444 (1D48I:*
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M.HH ;L7T'Y4>6IZJ#^%.HH 9Y2?W%_*E\M!_"/RIU% #=B^@_*C8OH/RIU%
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MQ(HY/* ',@.<J#G% 'TLF=HS3Z:O3VIU !1110 4444 %%%% !1110 4444
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M2_[3;PUJ\&K+I]P;6Y,)SY<@[?3WKL* "HKEUCMY'8$JJEB%Z\>E2TC#*D4
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M_P#I0U>EX'I0 BXQP:=110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5Y[XI_P"2N^#O^N%U_P"@BO0J\\\5'_B[
MO@W_ *X77_H(H ]#HHHH \T^!0_XE'BS_L:=5_\ 2AJ]+KS7X%?\@CQ9_P!C
M3JO_ *4-7I5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA4444 >:_ K_ )!'BS_L:=5_]*&KTJO-/@5_R"/%G_8TZK_Z4-7I= !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.
M:1_R-^O_ $@_]%UT=<YI'_(WZ_\ 2#_T771T %%%% !1110 4444 %%-8]L5
M1OM=T[3'C2\O[:TDD.$2>94+_0$\T :%%,1PYXZ4^@ J.<XA?UVG^525'/\
MZB3_ '3_ "H ^>OV76+>(_'A+$DZG(2?7FM[P?H>F^,/&_C.XUZ"VO\ 7;:[
M^SI#>('^SVVP;0@/\+=2?4FL']EXX\1>.O\ L)2?SKU/Q3\+]'\3:F+^>V/V
MW;L-Q!,T+NO]UBIY'UH YOX/);Z9XA\7Z1I$QDT"TN$\A%8M'#*1F2./L%!Q
MP.F:]87I6+X8\*V/A?3UM;"UCLX@<[(QU/<GU/O6VHP!GF@!:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O/?%/_ "5WP=_UPNO_ $$5Z%7GOBG_
M )*[X._ZX77_ *"* /0J*** /-/@5_R"/%G_ &-.J_\ I0U>EUYK\"O^01XL
M_P"QIU7_ -*&KTJ@ HHICG! SB@!]%<K_8VK:EJ5_++J=Q8V_F[;>.';C8!U
MY'K4O_"+7W;Q#??DG^% '2T5S/\ PBM__P!#!??DG^%'_"*W_P#T,%]^2?X4
M =-17,_\(K?_ /0P7WY)_A1_PBM__P!#!??DG^% '345S/\ PBM__P!#!??D
MG^%'_"*W_P#T,%]^2?X4 =-17,_\(K?_ /0P7WY)_A1_PBM__P!#!??DG^%
M'345S/\ PBU]C'_"07N?HG^%5K7PSJ[7%R)M=O%B#8B(V<KCZ4 =?17,CPK?
M'IXAO3_WQ_A1_P (K?\ _0P7WY)_A0!TU%<S_P (K?\ _0P7WY)_A1_PBM__
M -#!??DG^% '345S/_"*W_\ T,%]^2?X4?\ "*W_ /T,%]^2?X4 =-17,_\
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M_P"A@OOR3_"@#IJ*YG_A%;__ *&"^_)/\*/^$5O_ /H8+[\D_P * .FIN0W
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MP>)-%LM4M<B"ZB$BJ>H]C].E:U9GA[1[?P_H]IIMHI6VMHQ&@)R<#N?<UIT
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MUW)?7ES(H0RSN%#,%'"CY1P*PO%/_)6_!I_Z8777_=% 'H=%)FB@#S;X%?\
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M_P#&*** #_A4M]_T4?QK_P"!MO\ _&*/^%2WW_11_&O_ (&V_P#\8HHH /\
MA4M]_P!%'\:_^!MO_P#&*/\ A4M]_P!%'\:_^!MO_P#&*** #_A4M]_T4?QK
M_P"!MO\ _&*/^%2WW_11_&O_ (&V_P#\8HHH /\ A4M]_P!%'\:_^!MO_P#&
M*/\ A4M]_P!%'\:_^!MO_P#&*** #_A4M]_T4?QK_P"!MO\ _&*/^%2WW_11
M_&O_ (&V_P#\8HHH /\ A4M]_P!%'\:_^!MO_P#&*/\ A4M]_P!%'\:_^!MO
M_P#&*** #_A4M]_T4?QK_P"!MO\ _&*/^%2WW_11_&O_ (&V_P#\8HHH /\
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=]M&Z11:K<Q/$FX<D!8E.?QHHH ]#W'VHHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>tmb-20250331xs4030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4030.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %6 JH# 2(  A$! Q$!_\0
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M<?\ Q5)\"@/[)\7_ /8U:K_Z4-7I8&* /-_^%%Z=_P!#3XR_\*&X_P#BJ0_
MO3\?\C3XR_\ "AN/_BJ]*HH \T_X47I__0T^,O\ PH;C_P"*H_X47I__ $-/
MC+_PH;C_ .*KTNH;QI4M)F@57F"G8KG"D]@30.YYS_PHO3O^AI\9?^%#<?\
MQ5+_ ,*+T_\ Z&GQE_X4-Q_\56!8_&?5(?AE%K6H00RZK<ZQ_9:+; A%W2A
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MJF_\*+T__H:?&7_A0W'_ ,57I=% 'F@^!>GY_P"1I\9?^%#<?_%4I^!>G_\
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MBM/_ .AI\9?^%#<?_%5Z5D>M+0!YL/@7IV/^1I\9?^%#<?\ Q5'_  HO3O\
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M !5'_"B]._Z&GQE_X4-Q_P#%5Z310!YJ?@7IY_YFGQE_X4-Q_P#%4#X%Z?\
M]#3XR_\ "AN/_BJ]*HH \T/P+T_/_(T^,O\ PH;C_P"*I1\"]/Q_R-/C+_PH
M;C_XJO2J* /-3\"]._Z&GQE_X4-Q_P#%4G_"B]/_ .AI\9?^%#<?_%5Z710!
MYI_PHO3_ /H:?&7_ (4-Q_\ %4?\*+T__H:?&7_A0W'_ ,57I=% [GFG_"B]
M/_Z&GQE_X4-Q_P#%4?\ "B]/_P"AI\9?^%#<?_%5Z710%SS4? O3_P#H:O&7
M_A0W'_Q5)_PHK3_^AI\9?^%#<?\ Q5>ET4"/-/\ A16G_P#0T^,O_"AN/_BJ
M4? O3_\ H:?&7_A0W'_Q5>E44 >;'X%Z=C_D:?&7_A0W'_Q5-_X47I__ $-/
MC+_PH;C_ .*KTNB@#S3_ (47I_\ T-/C+_PH;C_XJC_A1>G_ /0T^,O_  H;
MC_XJO2Z*!W/-!\"]/S_R-/C+_P *&X_^*IW_  HO3O\ H:?&7_A0W'_Q5>DT
M4"/-3\"]/Q_R-/C+_P *&X_^*I/^%%Z?_P!#3XR_\*&X_P#BJ]+HH&>:?\*+
MT_\ Z&GQE_X4-Q_\51_PHO3_ /H:?&7_ (4-Q_\ %5Z710%SS3_A1>G_ /0T
M^,O_  H;C_XJE'P+T_\ Z&GQE_X4-Q_\57I5% 'FW_"B]._Z&GQE_P"%#<?_
M !5(?@5IQ/\ R-7C+_PH;C_XJO2J*!'@'QB^&:>"_AOKFM:;XM\8QWUFD<D;
M-K]PX!\Q!R-W(P>E>\PY,2<Y^4=:\[_:,X^"_BCM^XC_ /1J5Z)#_JD_W10,
M\Z^!/_()\7?]C5JO_I0U>EUYI\"?^03XN_[&K5?_ $H:O2Z!!1110 5%<[OL
M\FS&_:0N[IGWJ6D(R,&@#R2S^#4P^';>'[N]3[5'J1U.WGB4X5Q)YB@^V1@^
MU/G^$=Q>0W.I->Q+XEGU&'4WN%3$9:,;5B]0I7@GK7J_EKZ4;0.WX4 <AX3\
M'R^%K+5[@S)+K.J7#W5Q<8PN\\(H]E7 'TKC_$/P4O-;18QK3H)[;RKI\$$2
MEP[3)C^(GCGH*]>,:G@C/>D\E<8Y^M #;2#[-;10[B_EH%W'J<#&:IZY$GV%
MWV N&7YL<_>%:(&*H:Y_R#7_ -Y?_0A0!? Q2T@I: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3O44LI1&;!. 3@#-35!
M=*[0R+$P20J=KL,@''!H \2\-_M*P^(+RXE6PC;3HI;V"2**7==6YME+,TJ?
MPA@.*E\._M&1:CK'A-+JSB.F>+;&XO=(GM)-[J88Q(\,H[.588QWXKG/"_P"
MU32_B3IGBY[1+#6E^T1:W>P7 :+5X6^XK18Q^?2NF\#_  %T_2_'=EXIET:P
MT"/3!<#3-&TXYBCDFXEG<]"[!5  &%'OS0!3\(_M)OXDN[RSDT5X[IM.34+)
M(<MNWS-"L+CM)E<D>E>VZ9+</80&]6-+ORP94B)*AL<X]J\B^)7PW\0Z]%J[
M^%%L] NH@IM)84$;7$Q(,LC$<9VY4'J"2<UU/P>\/^(O#WAN6V\0W!ED-P[V
MT,DYGD@B)X5I3RY]Z ._HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI.E&: %HI,T9H 6BBDS
M0 M%%% !124M !1110!YK^T;_P D6\4?]<8__1J5Z)#_ *I/]T5YW^T;_P D
M6\4?]<8__1J5Z)#_ *I/]T4#/.O@3_R"?%W_ &-6J_\ I0U>EUYI\"?^03XN
M_P"QJU7_ -*#7I= @HHHH **** "BD)P*;Y@XH ?13/-!IP.10 M9^N?\@U_
M]Y?_ $(5H5GZY_R#7_WE_P#0A0!?%+2"EH **** "BBJ]W?V^GP//=3QVUO&
M,O-,X1%'J2>!0!8HK(TKQ;HNNR-'INK6.HNHRRVERDI ]PI-2MXBTU8[N0WL
M/EV@S.^\;8A[GIVZ4 :5%92>*-+DTZ&_2^A>SF(6.97RK$] />M0'- "T444
M %%%% !1110 4444 %%%% !1110 4444 )FN*U3XP^!=,U"XL;[Q9I-K>6SF
M.:WFNE#1L.H(SP:[4C)K\I/CM&O_  NWQV=BG_B<7';_ &J /T?_ .%X?#L=
M?&>BG_M\3_&C_A>/P\//_"9Z+G_K]3_&ORG*I_<7\J-B]D7\J!V/U8/QQ^'A
MSCQGHP^EXG^-.7XY_#SH/&6C?^!B?XU^4NU1_"OY4@C4\;1^ H$?L)H7B+3?
M$^G)?Z3>P:C9.2%GMW#H?7D5I5X;^QD /@/HX QB27_T*O<J "BBB@ HHHH
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M.N'.G/\ [R_^A"K-EYIMHO/VB<H/,V]-V.<?C6?X@M=]FTGG2* R?*&X^\*
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MTH KM80,P)B1B!@$J.!3Q:H"I"JI7@%1T'I3VD"_0<YI$G210R,K*>05.10
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M GDD#K7A_P"QG_R0?2/^NLO\Z]QS0 M)11F@ HQ1FEH **** "BBB@ HHHH
M**** $-?"?[?W_(^^'_^O)O_ $*ONPU\)_M^_P#(_>'O^O-O_0J /EAJ4?7-
M*O2@GG@9H&A!]ZE?M2'WI#0#/M7_ ()\?\@OQ?\ ]=XOY&OK^OD#_@GQ_P @
MKQ?_ -=XOY&OK[(H$+124M !129HS0 M%)FC- "T4F1ZT4 +129HH 6BBB@
MHHHH **** "BBB@ HHHH \U_:-_Y(MXH_P"N,?\ Z-2O1(?]4G^Z*\[_ &C?
M^2+>*/\ KC'_ .C4KT2'_5)_NB@9YU\"?^03XN_[&K5?_2AJ]+KS3X$_\@GQ
M=_V-6J_^E#5Z70(:_%?/W[3WA[3/%U[X<T._TO6KZVNI"+Z72KX6T4=KN7<)
M^#O!..!SUYKWZ5A$I<E5102S,< "OE3QY^T'\-_B#:ZA!XX\.>(="\-VCR"P
M\27-N\4-XZ-M*PNG.21P#U[4 >N?"B;PW'XN\4Z5HQ:*YTCR;%[9"IABB5?W
M87:!^.237J:C %>"?LE-;W7AS5;[2O!=YX0\/W4^^S?5"3>7X[SR9.X9[9[5
M[Y0 4444 %%%% !6?KG_ "#7_P!Y?_0A6A6?KG_(-?\ WE_]"% %\4M(*6@
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M* "BBB@#S7]HW_DBWBC_ *XQ_P#HU*]$A_U2?[HKSO\ :-_Y(MXH_P"N,?\
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MM5^ 0.)[W_P%->B>!_'.E>/]$75-(>1[0L4!E3:<CKQ7YV5]F_LHC_BUL?\
MU\24 >S@YI:0#%+0 4444 %%%% !1110 AKX3_;^_P"1^\/?]>3?^A5]V&OA
M/]OXX\?>'O\ KR;_ -"H ^62:3KU%!))-&#04@P*!C\J09W"GX /XT S[2_X
M)[\Z5XNS_P _$7\C7UVT ;D@$^XKY%_X)\<:5XO_ .N\7\C7UYYHQWH)'$9Z
MTUHP2.2,=A1Y@]#2>82P 7CU- "F,$#VH"8SSG/:E#@XZ\TZ@!FSYLY(^E!C
MR02:?10 P(!R!04W=>13Z* &[!Z"D\M1VYI]% " 8X'2EHHH **** "BBB@
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M JIK@_XESG_:3_T(5H5GZY_R#7_WE_\ 0A0!?%+2"EH **** ,+QW_R).O\
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ML?YUJ@T$@><4'(I<=*",T *.M?9W[*'_ "2U/^OEZ^,!G-?9_P"RA_R2U/\
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MA6&&/.<*.!D]S6MGMWH$+1110 4444 %%%% !1110 AK\I?CL?\ B]OCL?\
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MA_\ %4?\-9^ _74O_ 8?_%5\94=: /L[_AK+P'_>U+_P%'_Q5=9\/_C'X?\
MB;=W<&C&Z,EJH=_/B"#!Z8YYKX$V@U]$?L;#_BH=?_Z]T_\ 0C0!]6JH48IU
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!YK^T;_R1;Q1_P!<8_\
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M_8V_Y&'Q!_UP3_T(U\[U]$?L;?\ (P^(/^N"?^A&@#ZNHHHH **** "BBB@
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MCL?YUK=*"1/XJ6C-&:  $9ZU]G_LH?\ )+8_^OEZ^+\"OM']E+CX6Q?]?#T
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MT_P'HRZ7I-S>16BL7 >16.3UYVUU=% %'^S7_P"?VY_[Z7_XFE.G/_S^W/\
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MU[,'))XZ4\=* /%_^&2_ _\ >U+_ ,"1_P#$TG_#)/@;^]J7_@2/_B:]JHH
M\6_X9*\#_P![4O\ P)'_ ,374> O@IH7PXN;N?1IKV.2Z4)(990W /;Y:]!H
MH HC37QC[;<_]]+_ (4?V<__ #^W/_?2_P#Q-7J* */]G/\ \_MS_P!]+_\
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M'Q"\0'_E_'_?I?\ "@=CVK-&:\6_X6#K^1_IX_[]+_A3O^$_U_M?C_OTO^%
M6/:*2O&?^$^U_P#Y_O\ R&O^%*OC[7B2#??^0U_PH"Q[+FC->-_\)[KW_/\
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MC+]F.FO)YS0RP!@9!T8GKG%10>++^+4$O;:9+698C"JP(%4(>JX]* .A\/\
M@_3-9UT6GGW9MVE%MD)M*,?XF8_+U[#TK2.DA_ EEH\MPPB/B<VQD  (!0C.
M"<9KE-(\8ZIH5B+6TDB$"3BY0O$&*2#N#2W'C75+B(0--"J?;/MP"1*I6?\
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M5[2_!_C:75-)N=22&UB\L_;+>RU)R#.IRLN2GW6 P5[9H ] 7P%I!'^KD/\
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MYI  S YRIX'(Q3[KX*>'-0GTZ>];4+V>P$7DR7%](Q!C?>C'GKN[T 6O#OQ
MBG\$:?KNLLEH]R=A6,'&_<0 /K[U7O?C'X;TNWDFO+XQJ'*!!"Q88V@Y'L77
M\ZU3X TMO"B>'G5Y=-4%=CMDD$YP?6N1U'X)V\4U@FDW#6MG;F5L2DR.KLJA
M6^;(8+M'!Z\4 ;%Y\8] M[RXLC<R0741E4B:!@I,>PR 'N0'4_C532OBY9W_
M (FU.RG9[*VLKDVHDGA(CE(C#E@_3H>E/?X)Z)?F*>^FNKN^_?M)=>9MWO,L
M:RMM' W>4G Z5:G^#F@78NDN%EFAN9VN)8R^-SM'Y9(/;Y0.GI0!?O\ XC:1
MI\,$EU++;+<7$=O$9(2-Y=@B,/\ 9+,!GWJO8?%KPY?R21BZD@<1F1//B*><
MHD\L[,_>^<A?J15*7X(>&[F+34NSJ%X-/""#[1?RN5V2*Z').>&4?RIMY\#/
M#&I6:VMY%<3PI ]L@\XJ45IA/D$<AA(JL#VQ0!N6'Q!T>]U:/2UGDCU!SM^S
MR1,K*V,X/H<<UT8D/XYKD[7X8Z7937LD-SJ49O(EBG(OY=S[1@-G=G=CO750
M6XA14!)"@ %FR?\ /O0!-2TF:,T +129HS0 M%)FEH **2C- "T4F:,T +12
M9HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T
M4F:,T +129HS0!YM^T=_R1;Q3_UPC_\ 1J5Z)#_JD_W17G/[1Y_XLKXIQ_SP
MCZ?]=4KT:'_4I_NB@9Y5IGPI\:^';O6?[&\<6MG8:AJESJ2V\NC)*T1FD+E=
MQ<9QG&:T?^$/^)?_ $4&P_\ !"G_ ,<HHH /^$0^)G_10K#_ ,$*?_'*/^$1
M^)?_ $4&P_\ !"G_ ,<HHH$'_"(?$S_HH5A_X(4_^.4?\(C\2_\ HH-A_P""
M%/\ XY110 ?\(A\2_P#HH-A_X(4_^.4?\(A\3/\ HH5A_P""%/\ XY110 ?\
M(A\3/^BA6'_@A3_XY1_PB/Q+_P"B@V'_ ((4_P#CE%% !_PB/Q+_ .B@V'_@
MA3_XY1_PB'Q,_P"B@V'_ ((4_P#CE%% !_PB'Q+_ .BA6'_@A3_XY1_PB'Q+
M_P"B@V'_ ((4_P#CE%% !_PB'Q+_ .B@V'_@A3_XY1_PB'Q+_P"B@V'_ ((4
M_P#CE%% !_PB'Q+_ .B@V'_@A3_XY1_PB'Q+&?\ BX-A_P""%/\ XY110,3_
M (0_XEGK\0; _P#<!3_XY2_\(?\ $L=/B#8#_N I_P#'***!"?\ "'_$S/\
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:"K*(M$16*A@W!\SCI7KJ1%45<]!BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>tmb-20250331xs4048.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4048.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !& 5\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#T?_@J#^TA
M\2_@7XN^']IX"\53>';;4;.[DNXXK>*02LK(%)WJ2, GI7Q/_P /!/VB!_S4
MR[_\ ;;_ .-U]'_\%FO^1Z^%O_7A>_\ H<=?G=0!^H?CKX^?&4_\$V?A[\6-
M$\7WD?BM+X-K>I1VD+F6U:XGAW.I3:H5O)&0!7Q__P / _VB#_S4RZ_\ ;;_
M .-U^F'[!GA#2?'?_!/[P-X=UZRBU+1]4TN\M+NUE&5DB>YG##U!P>HY!Y%?
MGG^T]_P3S^(OP'UV\NO#>DW_ (X\"EFDM=1TV$SW5K'DD)<Q*-V5'_+105;V
M.10!S/\ P\%_:(_Z*9=_^ -M_P#&Z4_\%!/VB/\ HIEW_P" -M_\;KP)[&\C
M<H^G:@CCAE-G*"#]-M1_9KO_ *!]_P#^ DO_ ,30!] _\/!OVB/^BEW7_@#;
M?_&Z0?\ !0;]HA7##XF765(89T^U(SG/(,?(]17@'V>[_P"@???^ 4O_ ,31
M]ENO^@??_P#@'+_\30!^X'[$O[;&C_M2>&/[-U+R-'^(FF0@ZCI0.$N%Z?:;
M?)RT9/5>J'@]B?J2OYK_  OXI\0?#WQ+IOB;0;C4-!UK2YA/::A'!(AC8>I(
M"E2."IX8<&OVK_8B_;:T3]JGPI]@OFM]*^(6FPJ=0TQ'&RY7I]IM\G+1D]5Z
MH>#V) /J6BBB@ HHHH **** .'^+O@KQ)X]\)_V7X6\;WGP_U7[0DW]L6-G#
M=2;!G='LE&W!R.>O%?FW^VK\1OVC_P!CS6O#\8^-UYXHT;6X)GM[J72;6">.
M2':7C9 I!!#@A@?K7ZN5^77_  6T_P!3\*OIJ?\ Z!%0![W\)?@;^T!XR\">
M&O$NO_M*:K8W>J6<%_)I^G^'[)X8UD576,.PW$[2 3CKTK['12$ )W$#!/K7
M'?!3_DCG@3_L V'_ *3I7:4 %8'CK0M3\3^$M5TK1M>N/"^JW<#1V^L6L*32
M6KGHZHXVL1Z&M^B@#\V/VRT_:+_92\!Z7XOL/C_?>*-+N-033;F"\T2TMYHI
M)%8QNFU2K+\A!S@CC&:Z?]E?P;^T/^T3\&])\?ZO^T3J7AR#6#(UE8Z?H5G<
M,(DD:/=(SJ,,61CM X&.:Z#_ (*_?\FJZ;_V-5A_Z!/7I'_!-G_DR3X7_P#7
MI<_^E<] 'T3I%G/8:596MU>/J%S! D4EY*H5IW"@,Y X!8C) XKEOBYX+\2>
M/?"1TOPOXWO? &J^>DHUBPM(KJ38,[H]DH*X.>O7BNXHH _.?]H/P_\ M-?!
MWQU\-= T/]H"XU^W\:ZN-&CN=1T6U@>RF(W;V5%(=-@)XP<BOJGX0?!7XE^
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MPY_[ (_]+C7ZZ5^1G_!8[_DO_P ./^P"/_2Z@#]:[+_CS@_ZYK_(58JO9?\
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MNUA\%O@OXNU_59?W:ZMXJL_[*TJU8_QR.S%G '.T;2?6@=BQ\?KF/XC?MF?
M3P+8R;Y_#37OC'56C4,((EC,5N&Q]TO)N'-?6E>%?LT_L\7WPE;Q#XK\9ZX/
M%WQ2\52I/KFNA-L:JHQ':VZD I!&. ,#/H, #W6@#X=_X*M_ B\^)/P3T[QI
MHUH]UJW@N>2YGAB7+26$B@3G'5MA5'QZ!S3O^"4GQWL_'_P&3P#=7,?]O^#7
M-ND6X;I[!V+P2KS\P!+1D@8&Q?6OMFXMXKN"2&:-)89%*/&X!5@1R".A!%?G
M/\6_^"??CSX&?%-?BQ^S+J$=O=Q2R32^$[J0(JJW,D,+,0LD+<_NG(*G&UO0
M$?H_17QOX2_X*'1:-:Q:=\7OA9XW^'7B2- +@QZ+/>V+G'+QR1@MM)Z#!Q_>
M/6I_%_\ P43TB\LI;3X6_#GQO\1O$DJE;:"+0KBUM0^" 9))%#!0>N%Y]10,
MX+_@J9\7K?3)/A/\-K:1'U'5O$EEK%V@)#16T,P2,GMAY'./^N=??U?E!X$_
M8/\ CO\ M*_&=?B?\8[RW\'K->P7TL,K":\V1,&BMX85.V*-=H7YVSU;!-?J
M_0 5^1?_  6-_P"3@OAS_P!@$?\ I<:_2/XU?%[7_A7_ &5_8?PT\2_$1KWS
M/,'A\18M=NW'F&1U^]NXQ_=-?F5^VEX*^/?[5_Q1TSQ+:? KQ/X?T_2-/6QL
MH)_*EED(E,K/(0X RV %';O0(_7ZR_X\X/\ KFO\A5BOEGX<?M3_ !-U4Z!I
MGB?]G3QMH][</!;7E_;O;R6<#,55I>7#!!RQ&"0/6OJ:@".;_5/]#_*OR5_X
M(_\ _)R7Q0_[ TG_ *7U]K?%C]IOXD^%-3\1:-X3_9_\8^)[JS9X++52T"6%
MRP'RR [RY3/., GIQ7Q+^PSX+^,7[+'Q*\4>*/$?P/\ &FM)K.G?9!'ID, 9
M93/YK,0\H 7L.:!V/URJO=74-E;2W%Q*D,$2EY)9&"JB@9))/  '.37S3)^U
ME\1+I1'IW[,_Q"ENVX1;Z:RM8L_[4AE;:/?%>?\ CGX*_M'_ +7<?]D?$'5M
M*^#/PYF8?:O#WA^X-_J=Z@SA)IQA-I[@';ZHU CYD^,6H:E_P4U_;%LO"W@^
M:9OAGX73[++JZ*WDI;[P;FZYXW3%1'$."RJ&.!FOUG\/Z#8>%M!TW1M,MQ::
M;IUM':6T"](XD4*BCV  %<;\$?@1X+_9Y\$P>%_!&D+I>GH0\TS'?/=2XP9)
MI#R['\AT  XKT2@ HHHH ^+?VF/V9_%?PZ^(+_M _ &".V\>VR,WB#PNBYMO
M$=N>9/W8QF8XR0,%B RX<?,GPB_X*K?!WQSI,0\87-Y\.M;0;;BUU2!Y(/,!
M(98YHP<X(Y#!2.A%?:=?GC_P4&_X)]#QX-1^*'PQTY1XJ4&?6?#]L@"ZJ!RT
MT*]!< <D?\M/][[P!]#_ /#P3]G?_HJ^A_G+_P#$4?\ #P3]G?\ Z*OH?YR_
M_$5^#P4?-E2""597&&!!P00>00>"#0RCTH _>+_AX)^SM_T5?0O_ "+_ /$4
MG_#P3]G?_HJ^A_G+_P#$5^#Q ]%H91Z4 ?T"^"/VO_@M\1=4&G>'OB5X>O[]
MB MN;L0O(2< *)-NXY/09KV.OYE'ACEQOC5\'(XZ'U'H:_0S_@FM^VSKVD>.
M-*^$7CK59M6T'5C]F\/ZA>2&2:QN "5MF<DEHW VIGE6PO0\ ' ?\%9O^3L8
MO^Q=M/\ T.2OB[4/^0=<_P#7)_\ T$U]H_\ !6?_ ).RA_[%ZU_]#DKXNU#Y
M=.N?>)__ $$T ?T3_LV_\F]_#3_L6]/_ /2=*](KS?\ 9M_Y-[^&G_8MZ?\
M^DZ5Z10 4444 %%>2?M,?&#4O@M\.$U+0-*CUOQ3J^I6NA:)97+E()+ZY?9$
M92#D1KRS8Y(7&1U'*^$?#'[1/@GQ=X<N-<\:^'?B3X>OYA#KEE_9*Z3-I8*D
M^=:R(S><JL,%9!N(QC') !]"T51UG5[/P_I-[JFHW"6EA9027-S<2<+%$BEF
M=O8 $FOEO]D7]I'QQ\3?&VJZ/\0[.#31XBTM?&'@Z**#RC_8[SO$(I">6D4"
M!SWVS ],4 ?65%>._M<_$;7?A)^SEXW\7>&;B&UUW2[6.2UGGB$L:,TT:$LI
MX.%8]:\I^#7QN\:Z=^T-H_PVU_XA>&_B[I^NZ%/J_P#:>@V,5K/HTD+(-DRP
MR.C1R;R%8D-N'IU /KBBO#OVB_BCXB^'7C/X,:=H=U#;VOB?Q?%I&IK+ )#+
M;&&1V52?N'*#YAS7HWQ(T3Q-XD\)W-CX/\31>$===T,.K3:<M^D2A@6'DLRA
MLKD9SQ0!U=%?)W[).N?&7XDZQK>N^+?B;I^K>'] \0ZGX>GT6V\-0VS7AMSL
M2<3B0M'EB&*!3Z9KTW]J;XJZQ\+?AB@\*+!+XZ\1:C:^'O#D-R R&^N'"*[
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M/DBC0NY_):^<?V.?V@/'WQ'UG6_#WQ2L[73=>O=.M?&'A^&WC$9;1;O(2-P
M/GA=0K$\YD /(H ^J**\3_;%^)'B'X2_L^>(?$WA:_M],URVGLH8;VZ@6:.
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/P/L #Y0,GIU[T44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>tmb-20250331xs4049.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4049.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  R 2@# 2(  A$! Q$!_\0
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M11VD0"V.F$33 # ><C*+_P !!WGW*5T5 !1112 **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9&BHH55"@9P ,=Z?1
M10 4444 %%%% !1110 4444 ,2-(RQ554L=S8&,GU/Y"GT44 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>tmb-20250331xs4050.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4050.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  D 2D# 2(  A$! Q$!_\0
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MX#_&R7X=^%+"_P!?^).JV\FH^(_$<^Z_NX8P-XDO[MSF/>V-J# S@[1QGN?
M'[3'A_XI_$+Q/HGABRN=2\,>&HBNH^-1(B:6+L'+6T3DYE*KRSK\H]>AH ]F
MHKY \>?\%!=,DT_Q'=_##PY_PF>E:#N74?%FJWZ:7H4$@_Y9I.X+7$A[)$K,
MW;BKGA3]O"PTC]F/3_BO\4O#DW@J_P!3GD@TOPW!(9[O5>0(FMT8*Q#YZD8
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M?_\ A%=6L[G35\1>%IIKC3;3Q!9&]TJX:55!%Q ""<%%96!R"N,$$UY1I?\
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M^PB(L:!5 50, #@ 5EV?A/1-.UFZU>TT>PMM6NQBXOX;9$GF''WW W-T'4T
M?G_\2=:\3_!OQ_X/^*?[1OA/4OB->WBS-I.C>%X_/TKPE<IAHT$))$T[AO\
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5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>tmb-20250331xs4053.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4053.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 3( [(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN@Z'8PZ;I.G0);6MI N$BC48 '^/4DDGK6QN% 7N+12 Y]:,T"%HI,T9QZT
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M1H=LOELXVR+@G([C)Y%>VS6T4T#0.BM"RE&C(RI4C!&/3%?.7P1_8/\ AS\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.E67PRGNI);>_P#.U/3;&[^S37D)0JNUBRA@K')7<,^^*]'_ &3/"OCWP5\
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M7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK_<;Z4ZFO\
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MDBMYT,B6L(4',VQ78EN.!Q4WQ>_:H^(7@WP=9?$OP]X+T6_^%0TRPU.6\O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D(S2T4 )BC%+1
M0 @&*6BB@ HHHH :(U!R  ?6C8,8QQZ4ZB@!OEJ1C'%)Y8Z=O2G9%+0 P1(K
M$A0"0!D#G'I2[1W /UIU% #?+![4>6N<XR:=10 W8,YQS0% .:=10 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHT:SA?[\<1 ^16QR!UY]:^:G^,'B+Q'KVAZ/XWT+1Y=9T/XF6.@+-I%[=1P
MM8-.+A1E2Q^;'EOE?4'&:W?@S^T?XV\;>.?"MGXAT;0K?P]XK&LQZ;+IMQ,;
MJ"33Y]C&97&W#J>-IX(YZXH ]PTGX2^"= TG5],T[PEHEAINKNTFHVEO81)%
M=EOO&50N'S[T_2_A7X-T71M*TG3_  OI%GIFE7*WMA:064:16MP,XFC4#"N,
MGYASR>:^?/VP/BUXNM=*\=^#_"%O86\.E^#Y=:UC4[NZEAN$BE:2)$M?+'^L
M'ENQ+$#H.,YK*U;]L:[\&_$BU\,QP:++H6D7.DZ-?6\]U+_:UU)<Q0EKBWC
M*F.+SDW!CEMKD'@9 /HO6/@UX+UG19M,_P"$>L;.)EO%2:PA6":W:[5EN7B=
M0#&\@=MS+@G)S6EHGP^\.^'_  )I_@NWTNW?PU:6*:=%IUR@EC:!%"A'#9#<
M#G/6OF7X6?$?QMX)\'_'7Q#XCUCPM;6]AXNOH+*ZU.ZNO*CN=\:&-_E+>4$,
M81$!8MD8Y!J'PA^T!<?%JY^%]]JFEZ;>:BOC/5=$34M)N[J*VW0Z9-*+F*-M
MI;<N$*3 [3DCD"@#Z9TCX4^"]#TS2+#3O"NCV5CI%S]LT^W@LHT2UGP1YL8
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M$*)#+N9OE5"%!!X"+[UTDG[4W@+2/%MEX1U36W'B%WLK:=X=-N/LD<]U$LD
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG[.GQ5\9Q^((=<TC78=<O? ^LZ)>:OXAUY+VUNM4FEA:,V\8<^1 XC_A51C
M(!7)WM=^#WQ,^**_$;7[CP7J'AB[O(_"=QIVFR:K;QW-T^F37#W$<<R,PA<B
M3Y&;OM/?C[C"XHVBBXSXZTSX4>*/"]MX3\=Z+X'\2W.IV?BV?5=3T37=:@NM
M4NH9+%K-;A9-WEJ0-F8RV=H//:O3?@I\/?$OA_\ 9:G\,ZUI;:;XDG@U@MI[
M3I*4>XGN'C7>I*GB1>0<<]J]XVT;:!'PUH_PK^,FH>"6NK#PW?>#/$7A_P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M ",,C\:_/OX3Q?LU>+O"L^M?%O4?#&K_ ! OM4U"34Y_$-^6NE(NY5C3!8;$
M6-4"J!@"OT$-?/'['?A/0]4^ >C7%YHVG7=PU]J>Z6>TC=VQ?S@9)&30,\U_
MX1G]B+_GG\//_ P?_%TA\,?L1?\ //X>?^!8_P#BZ^M?^$"\,_\ 0NZ3_P"
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M%B .,XYH$>E45\U_"?\ ;0\+>)/AM#XT\:Z[X?\ "]AJ>I7-KI=O%=O)(5B
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M>X_LJ^&-5\*_"F[L-:TVXTV[;7]9N!;W4>UC%)?SO&V#V964CU!KIOAM\=_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(7:$"]-N.,>E 'SU\4/B+\-?#W@35I_"@CG\37FD:-IT;^&;J.SOQ:W4_DV
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MD'C)SUJ77?V?OAUXGU?3-4U;P9HU_J&FV\5I:7,UJ&>&*,@QH#Z*0,9Z=NM
M'S0/B5KFJ?M2>&M6T6XUZS\.W_C"^\-7'V_7TFMKK[/;2"6--/"YB021[E<G
M=W/#+7VPAW*#7"Q? OP#!XZD\9Q^$=(3Q3).+EM66V G\W:5W[NS$$@GOWS7
M=@8% A:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $9=PQ
M7*:[\)/ WBG4I-0UKP9X?UB_D #W=_I4$\K <#+LA)_.NLHH X/_ (4'\,?^
MB<^$O_!':_\ QN@_ /X9?]$Y\)_^".U_^-UWE% &9X?\,:1X3TY=/T32[+1[
M!"66UT^W2")2>I"( /TK3HHH ***0T +17SG_P -J^&(?"_QIU>ZTVZMG^&5
M_+8WEJTB%[P@[8WC] [@J,]"#7H_AOXY^%-5\->$=1U36M-\/7_B:Q@O;+2M
M1OXH[A_-4$(JDC><G''>@#T6BO!O&7[4#^!K_P 10:CX5E,6G^)=,\.6<L&H
MP2&[:\QB9U!+0JF3\K#)XQWQ[P#D4 +1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8#^Z2ZC\:W\_G0 M%%% !1110 4444 %%%% !1110 4444 %%%% !13)9DA
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MO"FIVUBL^@131P2K+:1SYQ*2V1YF/PH$>UT444 %%%% !1110 4444 %%%%
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M%T@;Y3A>H0XV\<'&*K>'_!FC>%KW5[O2K)+.;5KA+F[*$X=TB2%<#HH"1HH
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M#/\ \%-__P#':!GOD$WGVZ2;&CWJ&V.,,,CH1V->$_ +_DO'[1/_ &,6G?\
MIJMJ@.C?M-8_Y&7X9_\ @IO_ /X[6]^S]\*_%W@36_B!X@\:ZKH^IZUXKU*"
M^<:);RPP1"*VC@"A9"3R(P>O>@#V2BBB@04444 %%%% !1110 4444 %%%%
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M;_P%L_\ XJBP'Z745^:/_">?MV_] ^V_\!;/_P"*H_X3S]NW_H'VW_@+9_\
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MS_\ BJ+ ?I=17YH_\)Y^W;_T#[;_ ,!;/_XJC_A//V[?^@?;?^ MG_\ %46
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M $#[?_P$L_\ XJBP'Z6T5^:7_"=?MW?] ^W_ / 2S_\ BJ/^$Z_;N_Z!]O\
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MB@ HHHH *Y/QXH,-GQ_&_P#(5UE<IX\_U-G_ +[_ ,A0!QI5%#,=JJHW$G
M ZD^@]ZS]'\0Z-XB\\Z3JNGZJ+<[9OL-S'-Y9SC#;2<<\<UXK^W1I_B;4_V9
MO$T/A87+W(EMY+Z.SSYKV08^: %Y(SL+ ?P@]LUYU^ROX7^!5[.GC_X87-_I
M_B;1= F74/#ES?N&:019:29#_K%+*0"N4^8' ( JP/L#8O\ ='Y4;%_NC\J^
M+M$_;L\<S>"_#/C[6OA;;6'PZO\ 4ETN\U>WU!GD64MC="AP2% /WAABI (K
MN?B1^U3XNT[QGXZT_P"'O@&#QCX>\ QJ_B/59[PPG.-SK HZE5#'N?E)Q@4
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M=_X4*_\ QFC_ (9KC_Z*G\3O_"A7_P",U[%10!X[_P ,UQ_]%3^)W_A0K_\
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M$.HZ/XYT_P"%-SX;%B[6$C)JVEW)=Y!%.4'',GW>,CI]VOO]?&&B( %U_2P
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MEN@_]!W2O_ ^+_XJ@#5HK*_X2W0?^@[I7_@?%_\ %4?\);H/_0=TK_P/B_\
MBJ -6BLK_A+=!_Z#NE?^!\7_ ,51_P );H/_ $'=*_\  ^+_ .*H U:*RO\
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M);H/_0=TK_P/B_\ BJ -6BLK_A+=!_Z#NE?^!\7_ ,51_P );H/_ $'=*_\
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MW]M?%/\ Z'OX3?\ ?NX_^.T?VU\4_P#H>_A-_P!^[C_X[0![317BW]M?%/\
MZ'OX3?\ ?NX_^.T?VU\4_P#H>_A-_P!^[C_X[0![317BW]M?%/\ Z'OX3?\
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M!W2O_ ^+_P"*H U:*RO^$MT'_H.Z5_X'Q?\ Q5'_  EN@_\ 0=TK_P #XO\
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M_P!#_K7_ ( 6]'_#G;P=_P!#_K7_ ( 6]?H310%V?GM_PYV\'?\ 0_ZU_P"
M%O1_PYV\'?\ 0_ZU_P" %O7Z#/*L0+.0JCJ2<"H_MUO_ ,]H_P#OH4!=GY^_
M\.=O!W_0_P"M?^ %O1_PYV\'?]#_ *U_X 6]?H-Y@&,X&>E(DR2$[6#8]#0%
MV?GU_P .=O!W_0_ZU_X 6]'_  YV\'?]#_K7_@!;U^@HF0X^8<].:3[3'M#;
MUP>AS0%V?GW_ ,.=O!W_ $/^M?\ @!;T?\.=O!W_ $/^M?\ @!;U^@OGH<?,
M.W?UZ4-,BC)90,XR3WH"[/SZ_P"'.W@[_H?]:_\  "WH_P"'.W@[_H?]:_\
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M8@$$CK@TAF4-M##=Z9H"[/SZ_P"'.W@[_H?]:_\  "WH_P"'.W@[_H?]:_\
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MN[TS2F90FXL-OKGB@+L_/K_ASMX._P"A_P!:_P# "WH_X<[>#O\ H?\ 6O\
MP MZ_04SH& W#)Z#/6@3(6VA@6],T!=GY]?\.=O!W_0_ZU_X 6]'_#G;P=_T
M/^M?^ %O7Z!O=PQG:\B*P[%A3H[B.4X217/^RP- 79^?7_#G;P=_T/\ K7_@
M!;T?\.=O!W_0_P"M?^ %O7Z$T4!=GY[?\.=O!W_0_P"M?^ %O1_PYV\'?]#_
M *U_X 6]?H310%V?GM_PYV\'?]#_ *U_X 6]'_#G;P=_T/\ K7_@!;U^A-%
M79^>W_#G;P=_T/\ K7_@!;T?\.=O!W_0_P"M?^ %O7Z$T4!=GY[?\.=O!W_0
M_P"M?^ %O1_PYV\'?]#_ *U_X 6]?H310%V?GM_PYV\'?]#_ *U_X 6]'_#G
M;P=_T/\ K7_@!;U^A-% 79^>W_#G;P=_T/\ K7_@!;T?\.=O!W_0_P"M?^ %
MO7Z$T4!=GY[?\.=O!W_0_P"M?^ %O1_PYV\'?]#_ *U_X 6]?H310%V?GM_P
MYV\'?]#_ *U_X 6]'_#G;P=_T/\ K7_@!;U^A-% 79^>W_#G;P=_T/\ K7_@
M!;T?\.=O!W_0_P"M?^ %O7Z$T4!=GY[?\.=O!W_0_P"M?^ %O1_PYV\'?]#_
M *U_X 6]?H310%V?GM_PYV\'?]#_ *U_X 6]'_#G;P=_T/\ K7_@!;U^A-%
M79\4_!G_ ()A>&/@U\4?#OC:R\9ZKJ%UHMS]ICM9[.%$D.TK@E>1][M7VJ!@
M 4M% MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9P>!7Z'W7P^\-WVK2ZI<:)8S:C+<V]X]R\ ,C30 B&0G^\@)"GMDUE:Q\$_
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M1110 4444 %%%)D>HH 6BDR/449'J* %HI,TM !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q1_P4M^/GCSX$:%X
M!N/ ^N'1)=2O;N*[801R^8J1(RCYP<8)/3UK[7K\Z/\ @L8<>&/A=_V$;_\
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MTR.] 'W-_P )5JG_ #\G_O@?X5SUS\;-.M/'-EX,F\0P+XIO+<W<&EA,RM"
MQWG"X4$*V-Q&<'%?-O[2/C#7D\>^)=+L_'-]X'L_#/@&7Q38?89$C_M"^$S*
M!*6!\R-0H7RQ_>J+X,V-[XE_:P\0^*K_ %74H+NY\":#JMQIH=1;F2YC*F$K
MMSY<;9=%!&&8Y)'% 'T5XL_:'\.^ ]:LM(\2>,],T+4[V,36]M?RK$TB%BH8
M$C&,@C)/:M7_ (6Y;_\ "81>%?[=@/B*6P.J1Z< #(UKNV^<,#!7/O[]*^9O
MC.OA1OVE;T>-!IS:!_PJO4!-_:6S9G[4=NW=_'G&,?-GI7FWAGQ=XM\.?"[1
M$FU.]L+^T^!UWJ46&"RQRI>,+>7=C<&$6P#GICB@#[\_X2C5,X^TG_O@?X4G
M_"4ZI_S\G_O@?X5\1>/[_P <^#[+X6>&]-\5^-/$C^+],N==O;V+4[6UO?/2
MTB*0132A8TA0N963[S>]:MOXF\:^,]?\-Z%XR^(5Q\,[O3/ EMKUS>:;-;K'
M>WS7?E--*V2DL?EJOR*=N9,^M 'UO;?$W[;X@U#0H-8AEUC3X(KF[LD ,D$<
MN?*9QCC=M..^!FM'_A*=4_Y^3_WP/\*^-KVVO_ GQ]_:'\7:;XCU2[U/1O"]
MMJUII<\R-;W<LEI*R(\87+1PD;HU'3G.17':]\2O%_@OX>>.(=.^(VK>)WN?
MAII_BU=2GG1Y],U&6YC1UA= -B.&8!#TVF@#[[_X2C5,X^TG/^X/\*3_ (2G
M5/\ GZ)^B#_"OD+XX:5XO^&7A/PO=VOCWQ?J_ANVAN]4\0RV>IV\6N!6BB*3
M1!U"RV\)W9B ZN,UZ!^TYXQO]%_9>U_Q)X8UB[L+QK/3I[+5(#LG"2SP /TX
M9D<Y&/XB* /??^$IU3_GY/\ WP/\*/\ A*M4QG[5D>RC_"OB3XXW7Q"\">-M
M-^'_ (8\4^+];>/PU=^(H=2?5+2WN);UI@BFXDFVH]M"%QY*\_.378:7KWB3
MQY\8-3MO%'Q!NOAM)X9LO#;KIEI+ MK=SW:A[KS5?B4/(3"N#A>,9H ^JSXI
MU0#/VDX_W!_A2_\ "4:J#_Q\G_O@?X5\7>"/B=XLU+XB^%?$=SXKOY[K7OB'
MJ?A2]\%,Z?9+33XED",D6-RR1A%<N3SN_/SKP7K_ (]\0>%_"%S/\4_%Z/XA
M\'^)-<NO+NT^2;3Y6^SK&2F54\;CU8#&0* /T5_X2G5/^?D_]\"E_P"$HU3_
M )^3_P!\#_"OS[\=_$OQWJWAK5O%-GXYUS1;K2/AQX:\11VEA*BVTU[<3I',
M\B%3D,&)*C )ZY'%;?BOXB>./!$7CWPC:>(_$/B".W\>Z+HT>HO=01ZE':W5
MGY\T<4[@1Q&210BLW";L"@#[I_X2G5,X^TG/^X/\*@OO&UYIEE<WEWJ"6UI:
MQ////*%5(XU!9G8]@ "<U\76.J?$?7I_A#X4U_Q'XA\+G5/$7B"Q>\M-2MY;
M^ZL(;99;<3S1;HVD1M\98<_+GK7)0_$'Q1\5?A/X9LM>\<:EHT7_  K#6=>N
M;BWECB;5[N*YDMU2<L,.OEJ 5XSNSUH"Q]\Z1X_N=?TFRU/3]16ZL+V!+FVG
M1!MEB=0R,..A!!'UJW_PE.J#_EY/_? _PKY^O_&EM\/?V.=,U^[EU"".U\):
M?&LFDNJ7:22Q111F)W!56W./F8$ <X-9_P"RKXE\3WVL_%'0?$MW?79\/ZK8
MK:0ZGJ,>HSVZS6OF/&;F, 2*6 (XXW$>M 'TC_PE.J?\_)_[X'^%1W7C*^LK
M::XN+]8+>&-II9I0JI&B@EF8GH  23[5\CV_CWQ7:_':[^'0UK4KZ;1/$FJ>
M)I0TAW3:,NG+/:6KGJT1GDV8]L5Y_P"'?%WBCQ5X3TZ"]^(FK:ZOCWX=ZWKN
MKVRRQ_\ $JN;?+H+<!?W49YA9#U!/?H ?=^A_$27Q+HUAJ^EZFE]IE_ MS:W
M,2#9-$W*NO'0CFK-QXQO[2WFGFO1%##&TLCLHPB*"S,>.@ )_"OA"TUGQ-X3
M^"W[/GACP]K/B;4[?Q-83W]XVE:E;6UZCI9H\=E#/+A(XHR=^P_,0".<U])?
M#W4?$^J?LZVMUXR2-?%#^'[L7K1R1R+*RQ2JDNZ,E"70(Q*G&2: .E\)_M2>
M#/'=W<6WA_Q_H^K3V]J][,D$R_NH$P7E8D !5!&2>E6O#_[1_ACQ7X;U?Q!H
M_C;2]2T71P6U&]MY%*6B@9+2<9 QR#C![5\6Z;HOB>R_X)RZG>ZBFA/IMSX?
MT\V#Z19&._2R-THN1<RD9<E0.AQ@'-=#\8!X>'CGXM-X+%@NB?\ "G"=2.E;
M/)W^<OV3.SC=Y>??% 'U[X(^.VC?$JVN)_"GBW3O$$5L0)S82*YBSTW#&0#V
M)&#5/Q%^TAX7\(>*(O#FN>-])TC79%C=+"]F6*0J_P!P\C #=LFOFK]DBRO=
M;^*OB'6-9T[2?#&LZ!X6TK0?[&TA/^/VVEC6>*_E? #[@ HP,@YS[Y7QG\#>
M)?B9^T3\4O"GAW0= U4:QX,TNSN[_79@@TN-V<"XB7:2[@] "#D#Z4 ?;O\
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M3(W/3)7CM0!]G_\ "4ZI_P _)_[X'^%9UM\3?MGB'4-"@UB&;6-/@AN;NR0
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MSB(1PQ[CRV!PHR3B@#W;QG\9;'X=:(=7\4>)+/0=,#B,7-ZRHK.>BKQECWP
M35SPY\35\8:'::SH>MV^K:3=KO@O+1E>.09P<$>A&".HKR[]H#QUIGP_\+:3
M=77AVP\4:_=ZM#8^'],U)4$1U!PP61W?B-$7<6;TX[U6^!7A/1_@K\-=.T2\
M\2Z/=WNIZK<W,MQ:3)':37]P^][>U7/1> JCDXSCF@#VBX\87]I;S3SWRPP0
MQM+)(X4*B*"68GL  23[5G>%_BE'XVT&TUO0-;@U?2+L,;>]M<-'* 2IVG'.
M""/PKPS]JKQ!=IHGASP@NG:U-HGB6^V:_?:-8R74D&FPD-+ !&"0\YVQY[+N
M-4/V,/&&BR? +PII:R'3+@7M_9VEI>KY#7+"XDDVVX;F4*C*"5S@@@]* /;?
M'7Q[T3X8QV4GBSQ98>'DO2ZVS7S!/.*8W;>.<;AGZUMZ#\1W\4:+9:OI&K1:
MCI=[$)K:[@ :.9"2 RG'(X/Y5X9\?O FH^*/&'@C6M)\6^%O#E[H=MJ;B'Q1
M )TF22-0TJ1DX;9M )/3=GMBMK]GKXKP_$KX3^"M3U$:9I.OZM933#2;1EB$
MBPS/&TT$77RCLW<# R>: /4/%?Q:MO NC2ZOXC\0V>AZ9&=K75\Z1IN[*,]3
M[#)K5B\7:C-%'*EWNCD171@HPRL 0>G<$&OCW]H.UUKQ%^TA;0VVJ^&]-@\+
M>")M>T]/%5O]IM9)S*PE>.(D*9,(J%SG:O09KU$_&>.Y_91'Q1U>VO-'%QX9
M&IW$&F8%Q!(Z[!Y!<$ [B&4L" ",YQ0![G_PE.J9_P"/DC_@ _PI1XGU5F"B
MX)8G 4(,G]*_/B_^)?Q"TCP;\2M'D\2:]I5S8:OX5^Q3W.K1:A>VB7L@$RBY
M10K*ZD-L(X/%==#XO\5P^(#\.+CQUKL&F#XKW'AN3Q.]RBZC%8QV*W"1><5P
M"TAQG'3CIQ0!]A:/\58O$.C7.KZ9K<%]I=O)<12WD.#$K0$B8;L<["K D<<&
MN8\(?M2^#/B!KD.C>&O'VDZWJTT;RQ6=G(&D=%7<S 8Z <FO.?V.(PGP!LHV
MN#J &L:PAGD"DSC[8X+''!W=3CCGTJ/X5Z)8>*?VAOBEXN%A:0Q>&9X?"&C+
M;6Z1)"%B$MY* H'SN[*I/]T8H ^A_P#A*=4QG[2?^^!_A1_PE.J8)^TG _V!
M_A7QC^V+\5]?\,ZMX@3PCJ7B#3M4\):%9ZM=2VFJ06U@GGW'[HO;LI>Y9@"K
M*" !C SFHO%_B[Q;:?%;Q9KEOXSURUL](\?^'='@T*.=?[/-M>0H9T9"I)!W
M' S@=>IH ^PM4^)9T2\TFTO]8AM;K5[K[%80R ![J?:7*(,<D*I)] *R/'/Q
M[T3X9164OBSQ98>'H[YG6U:^8()BH!8+QS@,/SKX[T+6M4\9_''X9>)-8\3W
MU[>2?$_7=+3P])*GV73[>VAFCB\J/&Y&VC!.<'=SS7I7[3VFZYJ_Q9^!EIX;
M;1UUJ6\U86Y\06[3V6?LJD^8@Y(P#C'?% 'L^I_M0^#M&\/Z+KE]X^T>TT?6
MF9=.O)9E"76UMK%.,D!@03C />K?C#]HOPU\/KS3K7Q+XUTK0[C48?M-FEY,
MJ>?%G&]3C!7/?.*^>-:MO#]C^TAXOM_'\>BQ6:?"V$6*7$*16GWY/MQMT8 #
M+\\?-R*\ OM>\2^%?"'P=UC_ (1RQ\47=C\)=1FN;'75+JEE]KVB8(02[)&R
M$+Q\N>>* /TRMO&5]>VT5Q;WZ7%O,BRQ31;721&&592."".014O_  E.J?\
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MD:5;^?/DVQ*_NWD$:(7;)H ^YO\ A*=4_P"?D_\ ? _PI/\ A*=4_P"?D_\
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M 4444 %%%% !1110 5^=7_!8B)YO#/PO"(SD:C?9V@G_ )81U^BM4[_2+/5
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M47 ^>1\&_ P\%3^#T\(Z8GA6:=KEM)$1\KS2<^9G.[?GH^<C'I4&L_ WX?\
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ME\&Z4WARWG-U#I_E,$2<\&4,#NWD'!8G)''2OHSRHC_RS7_OD4&",#_5J?\
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M+^!/P\T30M9T73_!&CVFDZS@:C:1VWR704Y0,22<*>5 ("GD8KZ/\B/^XO\
MWR*/(C_N+_WR*+@?.47P.\ 6_A:_\-1>#-)CT&_E2XNM/6$B.69!M24\Y#@#
MA@0:T+;X6^$;*&QBM_#&FP16.G3:1:I%!M$-G-_KH% /W7R=V>223FO??(C_
M +B_]\BCR(_[B_\ ?(HN!XA<^"M"N_"!\*3Z/:R^&3:+8?V2R$P?9U VQ8SG
M:,#O5:[^&WA:_36DNO#NGW*:W;0V>I+-#N%W#"NV%) >H0 ;<8(XKWCR(_[B
M_P#?(H\B/^XO_?(HN!X!H_PJ\(:!I6BZ;IOAG3[*QT6]_M+3H(HB!;7>"/M
M.<F3D_,Q-/L_A=X2T]K VWAJP@-@;M[39&?W!NL_:2O/'FY.[USVKWSR(_[B
M_P#?(H\B/^XO_?(HN!\_1?"7P;!9"SC\+Z>EH-).A"$1':-/+%S:XS_J]QSC
MKD]:CU;X.^"->UG1]6U+PCI5]J6CQ1P6%U/;[F@CC_U2CG#!,#:&!V]J^A?(
MC_N+_P!\BCR(_P"XO_?(HN!X#/\ "OPA<>.D\:2>&--D\6I@KK+09N P7:'S
MTWA3C?C=CC-:VH>&],U;5-*U*]TZ&ZO])>22PN95)>U9TV.R<\%EX/M7M'D1
M_P!Q?^^11Y$?]Q?^^11<#YMU+X"?#G6+'1[*^\#Z1=V>CAET^&2 E;=6<R.J
M\\JSDL5.03VK=N_A]X<O_&-CXLN-!LIO$MC ;6VU-HOWL4)!&P8X(PS 9!P&
M(%>Z^1'_ '%_[Y%'D1_W%_[Y%%P/G70?@GX!\,6>MV>D^#-'L+36XVAU*&*U
M^2ZB.<QL"3\G).P8 /(YJ_X*^&7A7X<0W4/A;P[8^'X[H1BX6RC*^=L!"%R2
M<D GGKS75:5^T+X-UKXF7_@:SBU.?5["[DL;N==*F^QP3)%YK*]QL\M?D(/+
M=P.]>BG4=-6&*4W%L(Y1F-RZX?Z'OU%%P/$YOAUX9N;^>^E\/V4EY/J<6M2S
MLAW/?1+MBN2<_P"L5> >GM6EH/AS3?"L-Q%HVGPZ;'<7<E],ENI DN)#F24Y
M)^9B,DU[,((S_ O_ 'R*#!&!]Q?^^11<#Q7P[X5TCPCI/]F:)ID&E:=YDLOV
M6V0JF^4EI&P2>6))/UK.F^&7A2X\$+X-E\-V$GA1%V)H[1$P(-Y<;1G*D,20
M0<@FO3;_ .)WA?3?B=I?P_N+M$\4ZEITNJ6UGY1^>"-@K-NQ@').!U.T^E=%
M_:.FXF)N+8>3DR?.OR8X.?2BX'R]XR_9M\)^+QX TTZ7867A+PI<W=S_ &!'
M;'R;KSH?+VY!!7#9<ODL3BNFUSX->!O$^@:+H>K>$-*O](T4!=.LY;?$=HN
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M5X/#FCZY;ZA$EQ=S165Q<317$MQ&#OGEC\KS-D>"P)Q]WGJ=-^-OB)?C%?\
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MT=KNBKX*TBRT6*Z/B[Q#J^D6<VI:L\KP3VVK2I(9&903']G5W0+G#*D?0AJ
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MNFVESI(_M#4-1NM5#?8U=;5H+>,[#N\PO<-(F. 8LFOI@ =<#FC ]!0(_/\
M'PH\?^)?B=X0U[4_A]J:>)IK3P<R>(9A&(])ELI9FU,2,'! =2!@ [P0.,UG
MWG[/WB"_^'/Q6TI/A=?7VE+KFGZS8#5K2%-8U)UOI)+N(LLI6X58798Y&VDK
M*5/3C] ;S7-,T^?R;J^M;>7&[9+*JG'K@FH/^$JT3_H*67/_ $W3_&@9\/\
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MTVQ$MK.^I3R!&,B+G:S8/!/6OM+X2C'PL\'#_J#67_HA*\F_X*!_\F=?$_\
M[!R_^CHZ]:^$W_)+?!W_ &!K+_T0E '5T444""BBB@!"<"O@'X/_  <\<:+_
M ,%)_'/C2^\*ZI:>$[L:CY&L2VY6VEWI $VOT.=K8^E??U&T<4  Z4M%% !1
M110 4444 %%%% !1110 4444 <]X_P#%FE>!O!VK:[KC8TJR@,DZ[-YD!^41
MJO\ $S$A0O<L!WKA9OVAO!EAK$]A=B>QN+.\GM;MI8 %M)(=.2^G+L#P$A=5
M+#^(A:L_M*^&]1\3?":^32K1]0O=/O;#5UL47<UTMK=PW#Q*.[,L3!1W;:*T
M?B;X#MOBE\)/%>BV,<5G<>(]%N[6&ZD@V-&UQ 4#-QD'E<YYXP>E &3X#^/'
MA7Q#X;U#4[ZRN_!&GVDD08>)+=;%)$G7?%(A)VLL@R<9W Y# 'BM[Q1\0?#7
MAQ+KR#::MJR6\3-I=E+!]JD@9D4-AV7Y ) W)QCIU&?"O&^C_%OXB_"W2M)O
M_ O]D06MS%:W>F6EW8W-Y<(MG(AEC:<-#&@N#&,_?,>XX7I6!H'[-7BRU^'G
MBZVN?#]F/$=[:>%[2SN#)$\FRT@LUNE$A.0JO"_RDX;:.N10,^GY_&_@JVBO
M4GUK18TT5U@NE>XB LF/ 5AGY"<=#CI20_$#P1)8:IJ<6O:(UI9^7+?727,1
M2'> 4:1L\9&T@GKQ7S5I_P !?$UQXJUNQ'@Y+7P=+XNT[6?(U5K.::4B_GFN
MR)$):6WVNLBI+EU9RHX''*^'_P!FWX@^"?#M@FF^&(+<2Z+IUAK-O8?8WGN%
M35KN:<1K*#$TPAD@97<$  @'(% 'T[KWQO\ ">C>(['2OL\^HO,^FO;WEE L
ML&_4+AX+?:X/4E)&)'1 3FKD7QA\,6WPR\1>.]KVNFZ.MY)J<#Q*ES%-;%EE
MB=<_ZS*;0"><KC@BLG]F;X>ZA\/?@=X3T#Q!I\5IK=A R3Q%DE:,B>5D^=<J
M2 _\/ R<8%<;H?PXU?QE\#OC1 =,^RW7CF\UFZTO3[]/+*K+ (+=I%8?(7,2
MR<]-X/6@1Z]X?\?>$_$,>D&TU/33<Z];+?VMJ9HS-<H #N"@Y?;C!(SC'M6=
M\0/BEHOA+53ILVGW&LZM;:9-K8M+5(RT4,3*@8M(RJC.S[4R1DJW/!KYRTOX
M#>,9?'/AV\7P7!I<-Q<>'=034VFMU?P]%81[;JS"H<_O6#8$?RM]H<G&#75_
MM$?#3Q#XF\4_$.UTG2VU$^,O JZ382<!([NUN)9##(Y^5 Z7(922 2C]\9!G
MNOA/QAH_C:;7[2WMV@N]&O9--O[2ZA"NC%5<''=)$=7!Z,&^HK#U#XW^!-%U
MGPOIT.K:?<OKVH3:3:S6<\1CCFCC,CH[!N/NA<#G<RC'(KF_ASX7OKKQY\8?
M$<^GW"Z?K$EII5G:3Y@:Z%G:M%)*N<85Y)&16XR(PW0@UX_\//@9XKT$> 6N
M/ B)HWAKQ6S6-G=BQ:_M;"33C;^=,Z'9,89]A5\^8R1JQRP!H ^I%\5^#WL=
M6?\ M31S:Z/,6U ^=%LLY1R3+V1N_.#64OQ9\+ZIXAO]&,\<[6=I9W\4[;&A
MN?M'G-"(6S\[G[.Y 'MBOE30OV;O'6G:5!Y_@RUSH$&EV]_9"Z@(\6O;:F;J
M6<\X):/+#SL$M(RG@&NSNO@CXQO?C1X<\<V/AM-%T:UT^PL6\,+/!Y%D'BOH
MY9D"G'FV_G0[=O&V64+SF@#WGP;\9O!OBWP*GC"UUFPM-)>"*XNI+BXB0VID
M1659R&PCX9>":B'Q3\'/KGB71[B>UM+?2;6QU*]O;HQI9R+=F3R6#DX8DPGG
MW7FOF71_V;O%/A32=#G'@6QU2VTVV\,SZAH4+VZ+J,MK;WL5T,$A'D1[B*0%
M^'V]20*A\.?LV^//".G:1+J'A>W\2PZ8OA^6?11=0NEXD']I^;;KYAVG[/\
M;;?;NPK>5QT% 'U-X%^+7A3X@:-X>U.SO+>VFU^%[NPL[QT2YF1"REU3.3@
M\C/!J]'\1O!&R)T\1:)M>[6RC9;J+!N-N5B'/W]IX'7!KY+\ ?LP>+-/\5^
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MP[U'_+\E>5?\$X+ZWU/X=?$:[M)DN;6X\=:I-%-&<JZ,R%6!]""#7M!_9?\
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M(D+,< 8[DXKRKXE_LAZQHGA^RTGP'J$L]M>7,NF/8-;1BWM=,EU$7X5Y'DW
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M\=>)/A9KE_X0\.>(Y/$\^L1>'#87?B>Z>Z2TN[U;LW,KN,,49+4.L8(&YL#
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M@B\.Q13^(I7DU$->ZI-8W4=PPZR1&$J/]I>217OWB'POX5^,W@V"WU*&+6]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTCQ49?AUX/EUOQ=XQ@M[F['_  L"Y6>X2;3M1^QSM'#&0N85:X #(GR@K$.
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M3&) D<JI\WW HQBJOPR\2:OK.CZ3%XYUSQ*FJOX-MWT&R+3"+4I6@O/MOVE
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M^'UB\4:0[^(%W:2%O$)OA_TRY^?\* /@_0-6UWPQ\+O FG:+K/B>SDMO#O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'C?[65O=W/P@VV&FC5[P:[HCQ6!QB<KJ=LVTD@@#CD
MD8'4UY'HO[+/BS4;?QL+^#3M&F\1^&-:L[8QS++_ &9=7^HW-RL*E1G:D<R
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M?B)XBO\ Q-XOUW4[BUU.PU#Q;X*$.ER^<%M#<P6,C&)ED'"B7A<89^6!!*T
M>Z7'[,B:IXMT[6]2\7:C?!GT^YUNU-M"B:O=V+%[:9R!F/:Q7*IP1&@['..O
M['6G6F@6UE8^*=1MKZTTC3-+M;YK>*0QO8ZA)>Q3E#PQ+RE2IXP/6O.K']J/
MXAW^D6DZ2Z&MQXFBTN^TO_1)&&DQW6KQV+0W"[\R,$D# C;ETD&,"O1D^.?B
MBW_9PF\3S?V?)XHCUU_#?VLQLEIYHU8Z>+EDW$A<?O"F[KQGG- %_P 0?LJZ
M-KDOB S:]>Q2:W;:];/MC3Y/[4%OYK*#U*?9@5]=QSTK&UG]C73-7UW7KF3Q
M9J,>FZA%JBQ:<+>(K;3:A%$ES('^\V3"K!3P,D5R_@GQ'XG^)/[0W@*37=3T
M^Z3P]%XFLI8[2&18KJ>TN;>W%T@$F%=DF48;<%VR@9W CG?'&H>,O^$^^*,%
MMXG$2M\2?"]CI\927%J9$LB-P$@W1;7 :,8#-N)/S8H ]<\3_LB:%XH75EN]
M:U$1ZC<ZW=.L2HI5]1\DMM/_ $S:W1E]3UJ#X7? 36M0^"_Q$\,_$"\G2^\;
MZE?7=W+ \:W$4<T,4*[C$3&'Q"&(4E?FQD\UYKX<_:I^)GB36O"^G:=H4.KW
M,$,<FK+8Z>[I> ZI<V4C!_,'V?;':M*,A\L=O &:[[]HKXQ>.? ?C<:=X6N]
M'MK&TTW3[VX34;-YVF>ZU1+$ ,KKM51)OZ$DJ!Q0 2_L;I=>%;G0IO&4PM-0
MUD:SJ(M](M8EDD$4$:^0%'^C,HMP5>/D%V)S73_'7]F/3OC=JUAJ$VM7&DS0
M6,FFS;;6*Y$ENTJ2_)Y@/E/NC'[Q>2#CT(\=G_:>^*(U?2?#NF:3!KNMV%SJ
M2:@]CISO'J*VNK/8@#]X/LV8XV<L2^&*C&,UL:K\=/B2T;&SU?0;;^UM=UVT
MTZ6;39&2TMM,^U'9)^]'FRS>5&,@J%"N0#0![=\5_@9HGQ>UCPKJ&L2S*= F
MNI8XHP"LRSV[0LCY[#*O]46N+TS]D?1-'\-:7H]OK5]Y5CI6BZ6)6C0M)_9V
MH&]65O5I)"0WL<CFO-/#?[5'Q%\2^)8A:Z)%+HUGI=H^IRQV+&&)YM'6^:Y\
M[?A0LDD<8BVG*DG=FN\\1_$+QQH_['FK^-=3U>PE\3WNBIJ$%UI]HT$-DMPD
M6TA69B3&)&;<3SCIQ0 ]OV.])NI+Q9_$VI3V*2+_ &/:F*(#2X#J46H2PJP&
M9 \L$:Y;E4&!SS3[S]FQ;?XB_"ZY@62^TKPUJFM:W=7<TBH3)=2&:& Q@Y<"
M:3S%/\/D#/)KDO&OQA\8?!:_\7Z"DEM;:=H>BJ_AF"]MY+DZC#"+=9)WN_,Y
ME0O+YD3*&P48$C-;$/QJ\<>+/B3/X5T?4?#^D+!JVL-]MO[=Y%EM+)[)%A #
MCYV^U.6?/ 5?EYH [GXL_L[6'Q8\20ZK)KU_I,-Q9QZ7J]G:!"FHVD<XG2(L
M>8R'W#<O.UF'O69I7[)WAG3OB1!XSCO[N34(?$E_XD\M@NPRW-NL1C/?8A!D
M7_:8UR'[/GCWQ-;_ !,O_#FH7UOJ.@:Q?^)[VTC>-_M5H;751&%>1F(<,)B
M !M"*!7*^$O'7Q#T;6/$>F:;XBTZ2YU_XL7^A0SZA9RS_88%M)9FVKYHR/W*
M*JC 7YCSG@ [ZX_8LT.3P[IVGIKUV;G3-(TK3+&YN+2&=8GL)KF2.9HF&V0N
M+J1&5N,8(P>:T;K]E"";7M"U"'Q5=6<5J=+EU*SMM/MXXM1FL)FE@DPH AY=
M@5C !&/0Y\RO/VKO&5YJ_B2+0IK6XTRX>R_L34=0TEX(P)=7BT]V4"8M,@60
MMN(0[AP"#6UX:_:%\=MKGA#_ (2&YTVP\-G5M1T+4=8@T]Y4NKRVU&:U5& D
MS:B2.-61B'4N2I(P,@'K?Q-^!2?%#QUX:UO4-?N;;3=$E6XCTVWMH@[2@."1
M<8\Q%</M= <,% ]:\[T;]CG_ (1[3HUM?B!J::G8G24TR_>Q@)LX=/2XCMHR
MG1_DN7#,W)P#Q7(>'/VF_'OBNYN]+LKBRM/[8U'28]%UK5-(:VCBM;Q;V3S3
M%YS&12MFHC)9"3)R!TINO:]XJL/%_P 6)]8U;2]<M5_X1*#[#&DZ6ZS330H9
M8F$H(3+2-@=2RY) ((!Z#+^QWI\Z>';1_%-\=+T/2[BQMH?L< G,D]O-%-*T
MX <JYN'D:(_(6"],4L/['MG;:G:F'Q=J2:+# =^E_9H2KW9TDZ8USYF-P)AV
MMMZ;ESWK@[K]IWQ^;6_N[>;0%75H[R72H# [MIIM];@TW;/AQYN])MYQLVLI
M7FO>/@1X]U3QEX6O(_$5S93Z]I^L:GI3RVB&);E;6Z>'S5C+$KD!<C)P3UH
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M2++-&L@?).2!8^HK+X#?#K3-0U"]MO">EPW.HW"7-PZQ?ZR1)Q<*<9P,3*)
M  -PS5+Q+\-?A?X5E@\8:SH>E6+Z+<27<=_*A AFGG+L^,X+--*6&0?F?(P3
M7RAXE\0^+=73PT;6RUR,R^)KW4],U&:+4!/+&^O[?)1$(1%6U <F=2/+DPH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*0PZ5IWG[2_CNUM=8U9-6TLIJ<.KI;Z7):?-X>-IJT-C'-,P;+H4E,C;@OS
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*0'<,CI2*X;..QQ0 ZBBB@ HIH<$9'2FM,BLJD@%N #WH DHIC2JO4XI5<.
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M)]E;6GBG0[768;:0R0"X!#1L5VMM92" RD@C.".#D4 9GP<U>V\6_"#PI/\
MVK-K)N=$M&EO9AY4\^^!<R.N<HS<G\:^4]&\7ZW\)]5\5Z;X2O42^?5O$=Q]
ML\2WMQ>PI9Z4ENT=HH>3Y"YN/O\ 4*I.&XK[+T'P5H7A;4+^]TK2[?3[J_2"
M.X>!=OF)!'Y<*XZ (GR@ # K!U_X+> _%-E+:ZKX9T^^MI-0DU21)$/S74@
MDD)!S\P ##HPX((H \W^,?QY\1Z)X&^&UWX8TR1-5\8[90/L+WKVRBS:Y*"%
M64LQ(53\PVKO;G&#Y1-\=O'>B:]XBN8=.NK#Q%XAU30[1],DM7U Z2QT-KJ:
M-(%==S;XR,!APS,<XQ7U!\4M#\#:SX:L=/\ &UK8RZ1)?6UO:1W)* 7,CB*%
M8RI!5B7V#:1D,1T-&L_!3P+K]C?66H>&K&>WO9+>6<8969X(Q%"P8$%62,;
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M;2\MK:15D\P^>H:>0,0J8*C&:]^B\._#WX6ZAH5Q#8Z;H-W]GDT73?*78QB
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M?6_#>@Z/J5JL)TZ6W2.]T^UB9D2=I&,HWN0PP-JC[S$&O=F^&OPQ%_;>#9-
ML))SHLB1V4J.^;#[4DCJ6).09]C')R6YK6D^"G@.3Q1?^)7\,::^LW\<J7-V
M\>?-66/RY<J3M^=  W'S #.: /G'XT>._B5\-/$&F:V_B/1=4U;0?"6O:S<+
M;6TJV5]##/8$1&+S/DE.\J),L%!)QS7T)\;M6NV^!7C^ZTF^6RU&#0;UTN%R
MQ@D%NS=B"& Z<Y&0:DL_@+\.]/T9M'A\*Z>NGR6=S8- RLV^WN&1IXR222',
M4><G^!?2J=Z/ GPFT[Q':ZM>QQP:^^HZ]?PWA\PSQA$^TG:!DHD9C7'88'-
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MM_$-UX:T>77](EU+QOXFM]6D,MR8XDFL;PVDH9OE"Y>-PR\%L<[L5]1O\:_
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MNWNOVR=+TZ36[J\\,ZE%H-C8:C>VVJ++"R7ILKJ*TGC1=^Y3]HE"*6 !"DY
MJWX/_:OB\>:KX=TC0_"MWJ&K:A<WMO?1PWD#0V M'@6:0R[]LBXN8F4QYSG'
M4' !YYXA^!6K1?$'X9Z7<^2Z:CXGUV[UA(4\V.72O[0.J0*[$<$3QVRX_P"F
MC 9YKO?VBO@1X@^*>KZK<Z5]A,5SX5DT>,74FT^>VH6UQZ'"[(7Y]<5>^.7Q
MOU3X=?%?X::%IQM/[+U"\\S7_M!4.EI++':0%,D<_:)T8X!^6-JR]>_;'LM
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M\TOQ7JFNZ7INC:JVG>-+KQ)IMG>7ICBU""[L'MI$E^0^6\1;<O4-STKZCHH
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M7L8Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !17D/Q_P#CA??!V7PG:Z9X?B\0:AX@O);2**?48K&./RX6E+-)
M)\O12 /6I=%_:1\'27.H:3KFKV6C^*-'T][[6=)%P)OL7EQAYT\Q1M<QA@6V
MYP"#WH ]9HKF?AY\2/#WQ4\.KKOAC4!J>E/(T27*(RJY&,[=P&1R.1P:Z:@
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MK/B74=<^S:9.9H8$N9=ZQABJY(Y!X%>N4F!2T""BBB@ HHHH **** "BBB@
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M** "OD7X]Z?:ZK^WQ^SU:7MK#>6LFE:YO@N(UD1L09&58$'GFOKJODSXV?\
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M\(Z'H?P!LKC3M'T^PN/^$FTE?-MK2.-\&XY&5 -?8,/^J7Z#^5?*?_!2H_\
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M'A7_ *%K1_\ P7P__$U\P_%#0M-T']O[X"1Z;I]II\<FD:T76T@2(,1'P3M
MS7V!D>HKY.^,O/\ P4"^ '_8'UO_ -%T ?6(Z"@]#0.@H/0T ?('PXT/3M>_
MX*!?'*+4M/M-1B30](9$NX$E"G:.0&!Q7TZ/AQX5_P"A:T?_ ,%\/_Q-?.'P
MB_Y2#_'7_L!:/_Z"*^L<CU% 'Q[_ ,%(_"&@Z)^RIKESI^BZ=8W(U+35$UM:
M1QN ;N/.&"@C-?7EC_QY0?\ 7-?Y"OEG_@IN<_LE:[C_ *">F_\ I7'7U-8_
M\><'_7-?Y"@9/1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M I"H-+10 @ %&,TM% ";11M%+10 F!1@4M% "8%&!2T4 9[Z!ITFN1ZRUG$V
MJ1V[6B797,BQ,P9D![ LJD_05H444 %%%% !1110 4444 %%%% !1110 AKY
MW_:+_9F\1?%WXD^"_&WA;QPW@K6O#5K=VT%PEF+ACY^T,1DX^Z".G>OHFB@#
MY._X9K^/A_YN)NO_  2Q53UC]E;XY:[I-[IM_P#M!W-Q8WL#VUQ"=%B >-U*
MLN0>X)%?7M% '!? ?X8GX,?"#PMX):^&IG1+,6GVL1^7YN&)SMR<=:[VBB@#
MRG]ISX)/^T)\(M2\%QZJ-%:[GMYA>&'S=OE2J^-N1UVUY#%^S/\ 'J*-43]H
MBZ55 4#^Q8N@Z5]:44 ?)I_9J^/A'_)Q-U_X)8J[G]F']G/6/@7J?CS5=?\
M%I\7ZOXLO8+ZZNS:B B1$922 2.<]O2O>:* "BBB@ HHHH 3:,]*-HI:* "D
MVBEHH @O;*#4;.>TN8Q+;SQM%(AZ,K @C\036"?AKX6.CZ+I/]@6']EZ+*DV
MGV?D#R;=T!VLJ=,C)()[\]>:Z6B@!-HHVBEHH 3:!1@4M4M:UJQ\.:1>:IJ=
MU%8Z?9Q-/<7,[!4B11EF8GH * +FT48KE_ GQ2\)?$ZTNKKPGXAT_P 0V]K(
M(IY=/G658V(R 2.AQS73[Q0 V*WB@4K%&L:EBQ" #))R3]23FG[12TA.* #
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M#3%M9FCM;:.YN+EVDF*[0DH7;U)V@9+< 'U517E_BOXZ6&B>"/!WB/1M)O\
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M\>:C\9/BA;:<FNZ9:#0/%%H^GB6[F!,%DAL;C#CRD,A!>,1<\L&SFNX\ ?\
M"8P_'O0=5FU'Q*T$OB==*FM)YY38BQ_L&*4_N2-@_?Y._P#O<>M?;N5]?UI<
M"@+B)]T4ZBB@04444 %%%% !1110 5QGQ+^$7A;XLZ4MEXET>TU/R4E6VFN(
M@[VS2)M9D/8XQ]<5V=% ' _"OX6GX5:5#I%IK5U?:):Z?9:?9:?-$BI:B"+8
M[J5&293\S9/!Z<5QGBK]E^SUR?4[_3O$VHZ%K5YK-YJJZA;11NT2W5M';W$
M5A@JR1*03R& /.,5[>W:OB*;]I'XM#P)X$OK$6NLZ_XLM-2UFW@L=*W1Q):F
M-([0@RCB1Y 7ES\HZ*:!GT]=?![14T7X?Z7:RRV.F^";J"YL(E(;<L-M);HC
MD]MLA)/J*\KD_8J\/S#Q:A\1WWV#7-/U"QBB6"$/:+=W<5W(YEQNE*RQ KO/
M"G;7&^/_ (_>,;C5O%$,ATM- (UO1WT">W<SH]IHINR[RJX.&D8K@ ?* 0<F
MLKXD?%OQ8/!7C+P_<ZG#X=M+WP$;WPY#:6C,+@1V$$MPRW DW+*A:4&-@#LV
M,">: /=)?V;+"_\ %<7B2_U^^O-5.K:1K4TGEQHLT]C:O;KP!PKB0L0.AZ<5
M;^"OPE?P!XS^*7B&XM4M)/$VOFZMHUE$@6U2) IX^[OE:XD*^K\\UY;HWQI^
M(T?QET3P58V:ZWIFD1:3;:O=PV&R.X2Y@,DMSO,G[KR_D"H V[;)DCC')2_M
M&_%R+P5X!N+&.U\0>(/$^DWGB*.#3]+/E;83 D=G\THP&:4EILDKD86@#W2Q
M_9NTZQ\0-?G7KV2W'B>\\46UDT<86&>ZMIX9X]W5E)N'<9Y! '2L[P+^RAI'
MP^\3>%M4TO6)3%I&FV6GW$%S86TS7AM8/)BE\UE+Q-MV[@A )1>G.>&T3XB^
M)/'/[3?A)[V_AM-%L]9U[2(M#A1EEC>WLX\RRMNP^YG<@;0 -I!.:N>-?COX
MVT#XO:_I]K>Z6VA66NIX?ATU[4_:"9-$>_%QYF_G;(@7;MY4GG- '>_$3]FW
M3?'OQ,L/&$NM7%C(CZ<]Q:);Q2"=K*X:>#;(PWQ#<S!@A^88S[^4:1^R=XGT
M_P"%T5M<>(3_ ,)A-+IEM O[KR-(M8=66]<1''[QLJ2"W7:%]ZQ/$'QB\6_$
MV;P-:1:U9Z/<_P!K^%KF*^AC+1I+>:5>S3^8@<>8N]!A"0 <9SBJ/A'XMZOX
MPU_PYXEU2"WN[K6;KP:);8O(8('D?45DD@4,,%C$&&<CYAD' H ]AO?V.M)O
M;2PC/B?58IIH[B#Q!/&D8;6XI[PWDJ.,8BS,SX*=%=E]ZT=3_9.T+4[7Q% V
ML7Z)K2ZTLFU4_=_VE=0W$NW_ '&A4+GL3FM/]G;QUXC\;^ D\6>)]:TB\@U6
MTAU2"RTZ H^FQN'+12,6._ 4 -@'*OQTKQK0_P!ISQIXA_M6ULKVWAMM7O=!
M71-9U/2_LZP6VHSW*&81"5O,0);KL+%"6?D 8H ]IM/V=[.T\47>IC7;R2TE
M\4Q>+8K!HDV178@>&0!NI5]P;!Z;>*Y1OV,?#R^$['1X]9O#+IVD:5IME=3V
M\4PB>PFN)8IFC8%7+?:I%92,%>F#S5*X^,7C?2]<\6RS:OH=W9>!M&BN+ZRA
MMF5]>F>QEN3);MO/EKN1448;[LF3P*Q/!7[0OC1M;T/2=7U/1=4-WK&DI-?6
M4!C06]]I=W=F'!<@-');J V?F1ER 30!Z+=?LPZ9?P)]IUJY-Q_9NDZ?))!:
MPP*WV'43?I((T4*I>0E2 ,8]ZZ;P;\([#PSX6\4^&+G4Y=8T37KW4+E;.=$3
M[/#=,S30*5Y9=TDAW'GY@.U?./@_]I_XA^(=8\&W$UUI2:=?/X:L[RT6S;?)
M+JD%P7E5]_RB-HD(7!SR,BN3^'WQ.\4>!/@WX"U9KRRUS6X_!OBS5K;4+V.5
MI()()K?9&W[S#@LY+;AG 4#&#D ^BO"?[*NG^'KBPO+WQ-JFMZG9:GIUY'>W
M4<:L;>QBECM;8A0 0HFD)?[S,<^U=#\5O@)HGQ1U6[U#5M0NK4W/AZY\/ 0E
M5$8FN()UF4]1(DEO&5KP?QE^T/\ $CPWI>N:0FMZ)_;.AOX@N9-5EL&"7<=A
M86MU'"(?,^4NUWM+;C\L>0"37>?':;5?&.F?L_.;Z.UMM6\6Z;+J%KY;%+C_
M $*>X"G##Y0T9(!R-VP_PX(!Z?H'PDLM)T/QQ8C4[BZ/BZ[FO+RX*J&222UB
MMGV <8Q$&P>Y-<3H7['W@[1(X81-=7-L^G7&G7\+A0+Y9M/MK%V<@<'RK53Q
M_$S&O,?AY\:/&%SHMS-IDFE:5HVA^"KSQ1-8+:O(US<&[U&-4$C2910;=&/4
MDDXP#QJ_##XU_$B[^)'AW2O$&KZ/J>FW6JPZ3<QVNG/;NQN-&.I"16,C8V,/
M+ QRN23F@#U_X-_!6#X3WVM7MSXBO?$VNZM%:6\M]J"QQR?9;562WCVH &*B
M1\N>6+<] *XRS_91O++P9+X8C^(>K_V9;ZG;ZMI"FRM\Z;/%=M= J<?O 7;!
M#YX%</\ $GQ+XA\)?M&>.M9L=0M7F%AX8T'3#>0.\>F?VC>3123G#@%5\LLP
MQ\Q\L9 7GH?A=\7?'WC[XH:+X8GU;2H;33;;4YM5NH+$M_:9M-3:S5H3O_=J
MZ@,?O88$"@#UKP-\+F\(^*;WQ'J7B"ZU[6[S1[/2[NZN8HXO-%O).ZR[4P S
M>>00./E%<U\9_P!FG3/C'XIT_6[C6+C39(K6.QN8X[>*83P)<+<(JEQF)MZ\
MLG+ X[ CQ']IK4?$-CXZ^.KP>()(-/M_AWILMO9)O1HY&N[E0Z,'&TAD8L0,
ML&4<;0:G\3?M'_$_1YI/"NF0VVL^)++6=8M!>V>F%DNULX[62*)HC*!&'-T%
M9PQVJF0#G@ ]^\&_!F'P?\4_%'CR]U^XU/4=;B6S2-X(K>.& 2M(B-L \UE+
M;5=_F"@#FN2U']D_3=:M/%>EOXMUH>%-;CO/LV@PL@MK&:YF6::12!F0>:F5
M5^%#./XJB^/T6J>*-1^!4$LHTJ#4/%5O+J.F3(T@<K9S3"-BK+G:T9]1NVGG
M;@^=_#7XY>*=)MOA_-<6UII?A'4M*GDMK6RM&G^VWX>[=K5I&D+0,1%&8R0R
MN3(,@X% 'L'PP_9KT_X<:UIVKC6KG4M0M;O4[QV:WB@CDDO5MUDPB#"*OV9<
M ?WCFLFU_91L(;GP'#_PD]Z^E>#HV-K9?981(\[>=F0S8WA6$Q#1@[6V+TK@
M/$/Q\\;>'O@IHFM3^)],U'Q7XF@75M,M=%TCSO)A%D;J:!PTRC:OR_O"02N<
M*2>.O_9\\4:SX\\1_%/4_M*0:E?VVA75NCLTD%M+-HL$GRJ3PGF.3@8SSWH
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MHEKZ/H'=GP[X \&>(?@M^W#X1\&2?$3Q/XNT?4?"][J<L6MW>]1(K;%PHX.
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MGQ9^TE\4-%E3PSI$-KXB\16>H:S#]ML-/WIJ(LTM'ACV&4"(.;L([AFV^7D
MYXZ23XX_$A_B-JMC9OH\T$]UJVDZ;I-Q 8S#=VVE17D1EGWX(\US&W &WG-
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MB75+VRM[V2ZAN)5DE61)E9=VY(]KCE=N.02*^BJ* ([>%;>%(U4*B*%"J,
M=@.U2444 %?,?_!1;Q1K/A#]F34]1T'5;S1=0&J:=$MW8RF*55>Y56 8>H-?
M3E?*'_!3C_DU+5/^PQI?_I4E T-3]AG5V16'QW^(N",_\?RTI_87UC_HN_Q$
M_P# Y:^K(/\ 41_[H_E4E 79\D_L*2ZY8>)?CCX:U?Q-JOBF+PYXI&F6EUK$
MYEE$:1?IGJ<5]:CI7RC^QC_R5[]IS_L>G_\ 1=?5] C+\4R/#X:U62-VCD2T
MF974X*D(V"*^"?V5OV>/$WQY^!WA[QMJ?QJ\>Z=?:B;@26]K?YC7RYGC&">>
MB@U]Z>+?^16UC_KSF_\ 1;5\]?\ !-[_ )- \$_[][_Z5RT#,K_AA?6/^B\?
M$7_P.6N'\&>#/$?P2_;D\ >#9/B-XH\6Z-JWAO4=1G@UJ[WIYB91?E'!QC//
M>ONBODGXB_\ *2?X2_\ 8EZK_P"C&H#<^M1TH;H:!TH/0T"/A74_ 'B/X[?M
ME?%WPW_PLKQ5X3TK0K/3+BUMM%N]D>98@&&T\#D9X]37=_\ #"^L?]%X^(O_
M ('+2?!3_D_G]H#_ +!>C?\ HNOK&@=S\[OVK?@%XH_9]^#=_P",]+^-'CO4
M[RUO;.!;>[OL1L)9T1LXYZ,:_0?3"6T^V+$LQB0DGJ?E%?,'_!2[_DU#7/\
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M2^6T?/L<'@D5]94E+0!E^*(9+CPWJL42-)*]I,JHHR6)1@ *^"?V7_CKX^^
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M7W?[1_@2TM/$-T=4N)K?0;PV&H26]E-*L4P9U9 54[MIB?=C.W'.*FM?VA_
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MYCQN$W8WX^7- 'I]%>87'[2'P^MM)@U'_A($FMY[&TU& 01/))-#<O)';[$
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MGY@ .O%G2/VT]+UOQGX>TR'1633=2L[">YG>Y7[5;2W=F;J," #+1JFU7?.
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M4E5)KK/@EX)^(7PON=+\.WZ6-QX8N);^[D2&[EN4T>();I:V4$DN'=2_GO\
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MVGWXGNXG.W'SGS(#'UP!&&_BKK]?_;.N_"&E3VFJ^%8(?%5CJEYI]W8/JB"
MI;6L%R[QS;?G=TN8E5,#+Y&0!F@"CX6_8\U;P_KWA:XOI=,UJR@C@AU*&2]N
MK=8_(U&XNXI(HX\+,<3@;9!A70,#R:K7?['?BF3PQ=6::WI7VT^'KO3(F(DV
M&X?6_P"THR3C(3: C$<YY .*[T?M0W37'B34_P#A&DA\%Z%?Z;87.LW%Z$E4
MW0M',C0E<JL<=V&))ZH17-Z-^U:OQ*LM"DL].U'0W76M*M[J*WGCWB2XOKF$
M6\@93\K1VZRD##;94 (ZT!J=UHGPL\6VWQ\_X34W&F:+I%Q9E-3M=-N)G.J2
MF&-$\V)E"*T3JQ$R_,R[5(XKVM1@8KY<C_;,N!X$AUJ?PW86&I7VMG1K+3;O
M5UC,#"*25Q>L5S;R*L9!0@Y++@D'->_?#3QQ;_$KP!H'BFTMI[.WU>RCO%MK
MI-LL6]<E&'J#D?A0(Z:BBB@ KY*^/_Q$^+=U^T]X<^&7PW\0:/H4=_X;DU>2
M35;,S+OCE96Y'/(V\8KZUKY/\6#_ (V4^!_^Q#O/_1[4 ,_X5W^UK_T4OP1_
MX*Y*Y;XI1_M5?"KX<^)/%]_\0_!UU9Z)8RWTL$&F/OD5%R57/&3[U]MXKQK]
MLH8_96^*G_8O7?\ Z!0,Z_X(^);_ ,:?!WP/X@U61)=3U31+.]NGC7:K2R0J
MS$#L,D\5V]>:?LS_ /)NWPR_[%K3O_2=*]+H$?/'[</Q6\6?"'X4:-JG@R\M
M;'6=0\1V&DB:[A\V-4G+J<CZA3GV-<F?AW^UKG_DI?@G_P %<E/_ ."D7_)'
M/!O_ &/.B_\ HUZ^K@.: /D[_A7?[6O&?B7X)_\ !7)71_L4?%3QI\3O#7CF
M/QSJ%GJ6K^'_ !+<:,)[&#R8V6)5!('?+9/-?1S#I]17R?\ \$_^;;XT_P#9
M0=2_]EH ^LJQ/&VHW&C^$-<O[1@EU:V,\\3,,@.L;,I(^H%;=<W\2?\ DGWB
M7_L%W7_HEZ /C7X':K^U-\<OA5X>\<:9\0/"%C9:Q"TL=O=:8_F)M=D(;&1U
M4G\:[O\ X5W^UK_T4OP1_P""N2ND_P""=HS^QK\-/^O.;_THEKZ.Q0!\=_#;
MQ_\ &OPA^U;X=^&OQ%\3:%K]AJF@7>KC^R;(Q;3&=J@LW.<@FOL0=*^3_&O_
M "DE^'O_ &(M_P#^CC7UC0,*:W(]Z=28YH$>4?!7X>^*?A=X;\,>&Y[G2KK2
M;.TNWU&9#)Y\EY+<M*&3(QL/F/G/.:YOXG? ;7_%7Q"USQ=I&H:?%=F+0)M-
MMKO?L:XTZ[N9V64@'".L^T,,E2,XXKWF3A2?:OD_4?BCXMUKXS>&_#6BWU^F
MF2>/M4L=2\ZXA5C#:V,,ZQ1_NS^Y^=F*GYB01N&1@ [V/X'>)K']GK4_"%AK
ML5CXIU&_N-7GN[:22&#S9[\W<]NKK\ZQL&>'>!N ;=C->.7'[-GCRV>#P99K
MID=KK>D>)(-5U RW$MO8V^H:A;RB.*1ANEF5%?&_&[:23Q7MOCO]H"_\'?%B
MV\*Q>&EOM(2728;W5/MJH\+:A/+!#LB(R^'BRW(P#^%<+X6_;;@\86>LRZ=X
M8,\_^C#1(DOE(O&N+[['%'.<8@DWD.5.[$9SR>*!ZG-Z7^SQXR\<7?Q CG^R
M:+I*WWBJUTDW:R?:+EK]$@65AC B"HS J26R.!BO1_&7[/WB+7/B,-0L=2TY
M/#^J3:#=:L+A7-U%)I=P9D$/&UEE.U3N(V88C.:JZM^U==>&?B%H7A#6_#$5
MEJLJV U>%-121[1[R>2&'R% _?JNS>[#&U6'&<@9TW[7^J1^"+S7V\*65O+%
MX@71#;7.K!!8 B4F2_;9_HW,84 @@F5.<'- &3?_ +'VMC0]7$6LVU]?0>*X
MM9T:W>XFM$33X4N%ALVFB^>-A]LN#N3.#M[$UZ-XD^"6KQ_ SPYX,\*W%KH4
MVDSVDTUE;W=Q%;744<F^:V\\?OD1R3\P^;@ \$UA>,OVLU\&_$6Y\-2:18ZA
M'%I%UJ&^RU-99HYK>P:\>*2,+A 50J&W$\J<8.:??_M/:YX=L])CU[P6EIJ^
MM:=;WVEV-IJ*S"Y>6^BMA#NVCYE6XAE;&< MUVYH Y/0OV1/$FE^$+?29=7T
MPSKI6FV+F,RLF^WUV347(+#<5,<FP$\EAS75_M+_   \6?&+6["31]:MH=)6
MR%O)8WUS/%'!,MU'.+E4C^69BL9CVR< '([UT_[5WC7Q)\/O@AK&N>%"B:S#
M=6,4<CNJ[5DO(8V^\".0^WIQNSVK-TK]HR^N?B19>'[WPQ]FT>?5SX:?5H[Q
M7*ZLMG]K>(1XR8@H9/,[LO3'- CQSXQ_L_\ C;2_#?B2UMOLFL:=/'J^G:%;
M6*RR7DTNJZG;W>9QMV(D9CD!?., $XKKO%?[)?B#Q=J7B73Y];T^W\/3'7[O
M2YD1S=?:-5A,;K,,8V1EI"""2P*# V\]OXU_:0_X0CXE>(M OM$2/2="T.36
MI;R:[$=S>(L+2G[+"1^]4%0C,&^5B,C'-<%K7[2/B;5[S3M/N],E\(ZK8:A-
M'JUC;7"7'FV\FB7=[;%)2N V8AD8X9,<CJ#U.J^'/P.\7:9X_L_%OB2\T=+L
MZ]>:Q<6NF/(\:I+I5M9*BLZ@DAK<L<@##5S%M^R=XB@MK!#K.G%K>Q^RDC?]
M[_A(4U/(XZ>4FS_>]JU/#?[0&N>)/!%Q_9VAWMQI&D^$K>]U;Q%-?0K>PW,N
ME"[3;'MVNV&C#,  '<87:#C6_9]^)'BSQG\1O&&GZBAG\,V6EZ-/87-Q<(;@
M/-91RL'15'S.69F.< J !@T <OX@_9'UWQ#I6K6<NMV2&YM-9CB;,G$MUK4.
MHP[B,$*!#L8J<Y;(Z4V__9.UC4/!NJV-H=*T*^U;PYKFFW<4=[<WB&[OIK1E
MF::4;WPEJ Y/4]!6UKW[7R:'XT\:: FBVFJG1K1IK*73=264W,PN[>T6&4;0
M(F,MRG=L!6S@C%>9>*/VH/B)H_PR\>6D5A'_ ,)I _B*_:074?E:-964T, \
MMBN)V5YEV@@9 8GIB@#Z4^%GP_UCP+XI^(LMY/:7&D>(-<.MV31,WGHTD$4<
MD<@(P IA!!!.=W;%>&V_['_BQ_#%SHMQK>CB/3=-L]$T>6%) 9K:+5HK]I9^
M/E<K$L85=PW!FS\U;%I\7O%T_P >- \/:09[[1Y?%VLZ;J:7]S$H5(+*V<"(
M!,^6@E9PI.XMD$X(Q%\.OVJ;M] \+*-&OM9TM+;2Y-=UG4;R(7-H=1NY+>U.
MQ% E.5!;:!M4CJ<T >R?$OP'J_B7Q9\/-<TB>U1O#FM/>74%VS*);>6WE@DV
M%0?G59=P!X.,$BO#M2_8[UZ_\*6^F-K-B9K+2K6"$K)+&'N;?5WOT!=<,B,K
M!"R_,IY'05KZ#^V1<ZK8Z[->^&K/13#ICZGI<E]JJI#=(FH-8E97V_NF,J_*
MH#%@<=>*V/@C\=]2^,?Q%T.Y5#IVBW_A.YO6TP,)%6[AU1[5I!)@%E(C.WIP
M1D T =GX2^&^K^"?@Q/H&AVNBZ=XAF\^X:&YEGO;$SRREY/,>3]XX;<VYCU)
M)P>E?/&K?LV^/;.YTSPKI<6EV]OK6B>)[2\9!,VF:';7\MF!;P';EBH5W5"%
M4G>!M %>AZ]^U_>^&_\ A*KJ]\'8TK38M9.FW$5^K/?2Z;.D4T;)C]UN\P,I
M.?NG..,Z;_M,ZYIOC*UT+6/!L=K':W.G:?KEW;ZBLJV%W?LPM40;1YJ8\LNP
MQM\P8#8- '.7_P"Q[/?>(/'44MQ9R:5KMMJ'V'4Y;NY:YLIKNU$##[-GR2!A
MLOU96"]LUJ^,O@?\2OB+IVA7-]KNC>'=?TS2-9TR.YT=IB(S<PVT<+JQ4'.8
M'W$ %0XVY*YJBO[3E[XQM[5SHNI^&TTWQGI?AJ^:"ZB;?>M,ZW4!W*=T* 1Y
M9<%A)\I!!JIIG[<::SX3\0ZS8^%EG^QQVEW9!+X-%]EGN3!YMVZJ?LYCP'=<
M-M1P>>< &K\(_P!FOQ!X*\9Z'X@U&ZTV%+36-8U.6RM;F>YV+>6EK"D:RRC>
MY5K=B6;L1BLOXP?L:3?%'Q-XVUX:C9V^H:JT[6)8/CY[&""+SL=?+DBDD7&<
M;Z]1\:?$*XB\)?#?56>:SEUS7M+MY$TFZBFC/G$DH9"I#Q'N5P2,$$5Y?X/^
M)/C]?V.?B!X\OK@R>+ NLWUFTEQ')';K$[H@CP@ 5/+.%8$DKDGYN !^L?L?
MRZ[XH^( NYK-]*\11:G+9ZDUY<M=6,][;"%U%M_J<#+_ #CYF5@,9&:O>%?V
M;O$7AZ#P9J4*:/9Z[I'BF/6-04:C=W27L L7L6;S9@7$@CD)5<;0%5<]ZS]%
M_:#\9^'_ (HV6G:_H\=UI-];^'+&Z2*\0G3+N^:Y0,GRCS@Y1"QXV@< TW0O
MVWSXIT_4Y=)\)K=W+2V0TF%=07;<)<WWV-!.^,02!RKE#GY&!SUP!J)I?[)O
MB32_#@L/[7TV69;(6P;#[2PU]M2!/'3RFV?[WM6)X8\"?$;X?_%G75\/Z;:Z
MROAW2-2M-,O)(I(H99-2U>"\"RE@JLT<1<MY;,/DY()Q7HWA/]J?^W?C!#X$
MO="BM9OM#:7<36]Z)GAOTMEGE4Q[0?(&2BRG&6&, $&KOQ _:4A\"_%^P\&_
M8+'4(;F)@\L&H W4$PMIK@!X-ORH5AZEL_.#@CF@#W-.E.KY4U#]M6^\.Z7X
M6NM9\'P6<^M:;'K[6<>J+)*NFR/&D31C;^]G)=CY0Z+&><X%?5,;B1%<=&&1
M0(=7@/[</Q9\2?!7X!:AXG\*7$%KK,>H65M')<0^:@66=4;*_0U[]7RA_P %
M./\ DU+4_P#L,:7_ .E24#1$OP]_:U=0P^)7@D C/_(+DI3\._VM<?\ )2_!
M'_@KD_PKZO@ \B/_ '1_*GXH$?-'[&WQ/\?>.M3^*N@_$'4[#5M4\(Z^-(2X
MT^W\F-L1Y8@=3D^M?2XKY1_8Q_Y*]^TY_P!CT_\ Z+KZOH SO$=W+8:!J5S"
M0LT-M+(A(R P0D?J*^'O@3KW[4GQZ^&&D^-M)\?>$=/L=1,H2WN],?S%\N1H
MSG''537VWXN&?"VL?]><W_HMJ^>_^";P_P",0/!/^_>_^E<M S'_ .%=_M:_
M]%+\$?\ @KDK(^'WQ"^-O@O]K'PA\-OB)XFT+7M.UO1+[53_ &38F(KY654%
MFY^\,U]DX%?)7Q%_Y23_  E_[$O5?_1C4 ?6HZ4-]T_2@=*&^Z:!'QCXG\>?
M'3XA?M0?$?P'\/O%6@:#I7AFVL;A5U6P:1F$T8) 9>OS9/-;G_"N_P!K7_HI
M?@C_ ,%<E+\%?^3^?V@/^P7HW_HNOK'% SX*^/'B?]J']G_X=77C'6/'GA/4
MK&VN;:W>WL],<2-YLJQ@C=QQNK[NT^1IK*"1SEGC5B?<@5\O?\%+0!^RCKG_
M &$],_\ 2N.OI_2_^0=:_P#7%/\ T$4"+5%%% !1110 4444 %%%% !1110
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M9?,D9"%7)7 R:^Q/^$%\.?\ 0!TS_P  HO\ XFC_ (07PY_T =,_\ HO_B:
M.1_9GX_9W^&6>#_PC6G<'_KW2O2ZBMK:*T@CAAC2*&-0B1QJ%50.@ '05+0!
M\D_\%+KN+3_@?X6NYRRP6WC329Y652Q5$:1F.!Z $UO_ /#Q/X%@_P#(V2_^
M"^?_ .(KZ,U+2;/6(/(OK2"\@W!O+N(ED7(Z'!!&:S?^$%\.?] '3/\ P"B_
M^)H \%_X>)? LXSXLEZ_] ^?_P"(KF/^"<VKVOB#P[\6=6L7:6PU#QS?7=M(
MR%=\3JC*V#R,@BOJ'_A!?#G_ $ =,_\  *+_ .)K1TW1['1XFBL+.WLHF;<4
MMXEC!/J0H'- %RN:^)1Q\/O$Q_ZA=U_Z)>NEIDL2S(R.H=&&TJPR"/0T ? 7
M[&O[9_PH^%'[-/@7PKXD\0RV&MZ=:R)<V_V*9]A:9V R%P>&!_&O:?\ AXG\
M#/\ H;)?_!?/_P#$5[T/ GAP#']@:7_X!1?_ !-'_""^'/\ H Z9_P" 47_Q
M- 'QCX6^-?A+XY_\%!?!.M^#M0?4].M/!]_:32FW>+;+O+;?F SP0:^ZATK+
ML?"NC:7<BXL]*L;2< @2P6R(P!ZC( -:M !1110 C#*FO.=-^!7AG2_&$/B:
M$7G]IQ:Q>ZXI:?*?:+JV6WF^7'W=B+@=CS7HLGW&QUQ7Q-XQ^/OQ%\+>._&-
MW9:R=1LH+[Q-IUEHDEI&8XOL.F0W,$BL '9M[MD$X*Y'7F@#Z8\5?![PSXB\
M3R:WJ,ES%J%U/ICC9.$5I+&9Y[< 8_O.VX=QZ8K @_9C\+6WAO6= AO]:CT:
M]ECGM+-;T!-)>.<SQM:87*%9?F&2W "].*^>6\4ZYXN\<>"+.\^(LVKZ3H7C
MJW@M/%,$%NB7HGT=YVB; V95R8QCG$V/O &O:?C9\0-<\&_&3X?0)XA-AX6O
M)H;>\T^P\A[MYY;E(XVECD^=K=L["T7S(<DY'0&=''\"O#_AK5]-\3/XBURU
MNM-MHXKZ\GU!0-1BB>22,W;%?FVF63&-O#;>F*YN?]GCP1J<.NZ<_C+6YM2\
M0?9UOKHZI$UU<6WE3)%;-\F&C*2S$9!8]=WRBOF?QQ\7O%'Q=^#NJZ#JGB03
M ^'+&YU-8((BR71\0_9V5UQ@9B" J>#MZ<G/<VUM>>"?C)KEY;RIK-S<?$VR
MTP175C!O$47A^66-(G"Y0Y"H,<* <8W-D ]LNOV5/ ,&MFX-WJ=E!=QW$$6E
MI?!;?S9K#[%+(JE=QD-NH&23@KG'6MGQC\%(/$OCGX3Z@BP'2_ \UQ<+Y[$S
M,WV;R8%'&" Q#DGO&N*\,T3XF:Y>^#_AIXB;Q7:>/M:U&_-_-9&QAW:;.=%N
MY_LD>P%DS(@49^< $9.:Q_A[\6OBIXS\&^&UNO&"V7_"0Z]H]HFJ6OV*XNK<
M7%I<RW,/EIN5%#QQ;/,&\#<#DB@#Z3/P9L=;^#*?#7Q-KU_KS-;(+K4FGVWC
MR";S5F!.2I615*YR!M YQ1IW[/GAG3_B!#XN%QJ5Q?13B^%I/=;K4WOV86QO
M#'@?OC$-I(P.2<9.:\2_9@\2:QXY^,4/B?7/$4AU'5/ .D3RZ;Y<:1W3B:Z1
MI%&-PVE-QV\9E(/&VJ'Q&^.?Q!\+^)_B1HEIK+)-X2CO-0EE>P5HTM+R:S33
MV) Y$*27K?[7V?YN,T >^^,/@9X9\;>-X]:U^^U"_P!]O/!#H\UT!:)YELUO
M*\:8W F)V!PV,MG&<5E:-^RQX.TBSCB>XU?4+D7#W#W][>"2XFS8R6**[;1E
M4@E95&.#R2237SY9^,_$6L?%;P7J$WC&;7?^$>O?%&G:9<QPPH-<6&WM)41L
M+@NS.T1,8Y\K(P<U'X?^-'Q8U;X+ZEK\OBVRC5I-+O!=&ZT\7NV2.5[NTMU#
M&-'PJ-&LWS$+(IYP: /H6']FSP;H%Q +?4]7TZTN-)B\/S6"ZAM@OU2T:TB:
M12/GE$)(!& 2JD@[175>"?@[HGP_\37>L:1<Z@CW>FV>FS6LLX:!EMD$<4NW
M;GS-BA2<X('2O._B+XZ>_P# 'P7UW3Y5O8]6UO3I1<ZA9KYK(]E<2"381^[D
M)4'(Y&2!6=^R=X^\7>*[F_M/%'B"37_/\+^'O$$4LMM'"UM+?13F6-=@ * Q
M(1GGKZ\ &W!^R[\/]6N/$<<&IZK<6MU'=V!LH=0!BTTSW4=Y*(0%S&_GQI("
M22#QTJ/5OV-_!6M^'WTRZU/Q"S3F_%Y?IJ 6YO([QTDN8I6V8*,\<;8 &"O!
MKY>A^*^O_!;X.::GAW6[X:]/J>N^(;N>:"TCAN88]7:VV2LPWS,2"=J'?ASR
M JBO3M=^.'CZSO/&VE)K[VK^$KZ/1M3U"6Q0"'[?K*+;78R,?N-/;//RDMN;
MI0!] #X >&X_%5KXBMY]2M-4M]>N/$(DAN  \\\*0S1L"O,3)&@*]<C.:Q-,
M_9/\$Z3<^''M9=6BMM&BM(C:"\_<WPM9GGM?M*[?WACDD9EZ=@<@5Y]\+/'?
MC3Q[\0_"6C2>-)I-)LAKTTU[;6D.-<BLM2AMX&<XPH9)&#&/&2N1@5/\8/B_
MXJ\._&N?3K'7ETJWTR3P^ECX>:"-CX@%]>/#=$,WSCRD (V="I+9!H ZI?V7
MOAS?6 BL]0OUDTB);2.[@OE,EE+'?G4%DSM($B3,3\PQM."*ZOX7?!;PE\/[
MFQU+0+N[O9K6QN-.%Q<78GWI->/>2EB ,N9I&.?0XQ7B'@'0VT+]AOXL7$FH
M37UQ>6WBNXDNGA1)2RR7<>XE "Y.S.YB3SC. *R/ W@#QC\/;7P;::=JUGX#
MC\>:O9Q-:>&U%S%;P0Z7<2NX$R[1+,ZH6*K@!!U))H ]1T3]DC2+R+Q>WBK4
MK_4I=>GU9$MH+K%O96U[="9Q"I7Y9&$<89N>0<<$UVWB+]G[POXF^(,'B^X:
M_@OT>VGFMK>XV6UU/;;OLLTJ8^9XMY*\@<+D' KYFU7]H;QS#I7BF_3QC%!=
M3V&L3RZ?]DCSX<>TU>"T@/(R=\,CDB3[Q&5XH\0_'OQMIN@7UM%\08XH-(3Q
M)=6'B&2SA;^W)+%K;[-;' V$-Y\JL(\,WE_+C!H ^@-'_94\#>'Q:"R74D$-
M]I^IR*UV6%Q=VDDDD=Q)D?-(YE;S#_& O]T5/IW[/NB:!X?U'PUIOBCQ%IUE
M>.CVEO%J"9L8HV9O*@#(?W>9""K;LKM'0"O&=?\ V@=>\*^*/B(NO>(;P;M*
M^TZ+8Z2EK)%9Y:TB99"WS13Q2W&&\X["K;A]TBD_9V\;Z_X]^*OA&]\27AO]
M2M--\4::9V:-B\<&H6B)N:/$;L!P70 ''% 'T!:?"#PE8^#O!_A:W,D6E>%+
MVTFTZ,7.7$UODQJY_BZDD<9]JNV'PA\/:=\+[WP"D<\OAZ]@N[>9))<R%+EY
M'E&['K*V/3BOBXW.N:7^T.TB"ZOM U;XN3LL:L0EI?6=B^$'/2>*;I_>A/K7
ML/[-GQUU76]:2#Q3XOM=<LM4T'2M3%P\<<"V&IW<LZ-IR;<9($2E5;+\'/44
M >GVW[//A2*\L7NKW4[_ %&&32;@3W5TIEF?37D:W=L*,\RMNP.>.E+HO[-W
MAO1-,DTN*^UF71TU&TU*STZ>\#0V+V]S]HC2$;<A/,/())V@+G %<Q\0[G2O
M"?[5G@KQ#?W@T^V'@[7&OKJYN"L$<4,]B0Q!.U<>8^6&"<\]!7OL$Z7$2R1L
M'C<!E93D$$9!% '"Z3\']+T+XB:CXML+_5+674)&N+K2X[D"QEG:-8VG,>W.
M\JBYPV,C.,UBZ]^S=X8\0^.[CQ3<W.JQW%Q<B]EL8;H+:/<_9'M//*;2=_DN
M5ZXX!Q7K%% CRR[_ &>_#\C>$7LK[6-(G\-Z=%I%O/I]V(WN;./84AG)4[US
M&IR #DM@C<:]2 P*6B@ KY1_X*;@G]E+52%+;=7TQB "3@729Z5]755U'3+3
M5K8V][;0W<!()BN(Q(I(Z'!R* /G"/\ X*(_ Q(U4^+)<@ ?\@^?_P"(IQ_X
M*)_ S_H;)?\ P7S_ /Q%>]?\(+X<_P"@#IG_ (!1?_$T?\(+X<_Z .F?^ 47
M_P 30!\L?L#>)]/\;>-?VA?$6DRM<:3JOC'[9:3,C)YD3Q95L$9%?8E4=-T3
M3]&1TT^RMK%7.YEMX5C#'U.T#-71Q0!D^+O^15UG_KRG_P#1;5\'?L5_MC_"
MSX0_LX^%_"WBC7Y=.UNR:Z,]O]BF?:'N)'7D*0?E85^@TB"1"K ,I&"",@BL
M0>!?#G_0 TO_ , HO_B: /!?^'B?P,_Z&R7_ ,%\_P#\17DNA_&OPE\=O^"A
M'PTUGP;J#ZGI]CX4U2TGE:W>+9(27"_,!V(-?:G_  @OAS_H Z9_X!1?_$U8
ML?"NC:7<K<6>DV-I<*"!+!;(C 'J,@ T :@.10WW3]* ,4'D4 ?!MO\ 'CP;
M\!OVZ/C=?^,]3?2[;4K#28;5UMY)=[)$"P^4'& 17KG_  \3^!G_ $-DO_@O
MG_\ B*^@;WPGHNI7+W-WI%A=7#XW2S6L;LV..21DU!_P@OAS_H Z9_X!1?\
MQ- 'P7^VU^U[\+_C)\ =3\,>%->EU+6KC4+"6.W^QRIN5+E'<Y90. #7Z#:4
M<Z;:_P#7%/\ T$5F_P#""^'/^@#IG_@%%_\ $UMJNT8& .V* '4444 %%%%
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M;T^_CC=U]ZJ0>!_#MMO\G0=,BWW0OFV6<:[K@=)CA>9!V?K[UL[QZU&;N ,
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MX( '>O+XOC-XQ^#^J?$>]T^\BU>PN=2\8W5OID\!+0W%D]N4D$F[+*3*Q*8
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M)IM*MI=R$MD(-Q7&.3DGG->_^*? ?AWQO806.OZ)8:S9P2"6*"]MUE1' (!
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MH7!IU @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#@KA_^)KO:* ,_0] TWPSID&G:38V^F:? "(K6TB$<29.3A1P.236A110
M4444 %%%% !1110 444F1ZT +129Q1D>M "T4F:6@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>tmb-20250331xs4054.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xs4054.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 3( [(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9+I3&K9DW8# 8P:^N/V6]2GUC]I+XEWUY.;B\NO"'A2>:5CDN[6;LS'ZDDT
M>]:?\<?".H^-_&?A--1,6L^$;6*]U:*:)D6*&1"X=6/#@*.2.F1GK6E\+OBA
MH/Q@\!:3XQ\-W$EQH>J*[VTL\+0NP61D.4;!'S(>M? OQF\'Z[K?[4OQ0D\,
M7$T5QXAU;3/ NLF/D0Z;?6$;M, /XD-O)_WW7 75[>0_!GX&:!/J%AIW@=](
M\1M#-K.N3Z19B]BOYEBD:>%6+2QQ_.B$8)S0%C]8S(%(!(!-<1)\9/#H\7^*
M?#,+W5UK'AK38M4U&""U=]D4@=D5,#YW(0G:N3T[FOSO^,NI^-M2\3^&M,\2
M>-]!L]7M/ &DW6B>)=1\2W&G68OS*WFWMJ40BZD8B(,K@?*1QAC7J.G>&?#O
MA_\ :[^+]WJU\++QG)X0AU'3XTU*5!<74MC/]L:%"P\Q0%) P0G4 &@+'VQX
M&\:V?C[P?I'B.R@O+.SU.W6YB@U&V:WN$5N@>-N5/L:WC*%."0#Z&ORBU:S/
MC#X<Z%=:IJFJS3Z3\ 7UZU>+5)XS]NCN9/+G?:X\QE."-V>0*T/CAXFLM;O?
M&=_XI\3WUMXOM=-\'?\ "*V_]JS0&>WG2-[MHXU8"7<Y<N2#C:N<4!8_4W?@
M9.,5P/Q@^-N@?!31M+OM:AU&_EU6_33;"PTFT:YN;J=U9@J(.O"L>O:O,OVY
M-4DL/AEX7@NM0N-*\)W_ (LTVS\37MM.T!BTQW?S \J\QHSB)68$<,>>:^2U
M\+Z1X^MOAUITM[J&L^"K;XQWFA>&KUM2FS)I#0ARL<H8,Z+*K!) <@ @'% '
MZ$_%/XR^&?@UX2B\0^*+N6TLYIH[:W@AMWFN+F>3[D,<2 LSG!X [&N=T3]J
M'P'XAT#PGJUC?7;P^)M:/A^QAEL98IA>@.7BD1P#'L$;DD\<=ZY7]L?2_ U]
M\.O#Z^,?%\_@"X@UJVET/Q+ I8Z?J"AC$[G!4)@$$L0.G(-?)'B[Q;9_&[P;
M\)/$?Q-U"SN;31_B-<^&;KQ7IES+8Z?J=@L$KF\0J5";W51O&#D$ _,10!^G
M/F#."0#Z55U75K;1=-O+^\E$-K:0O<328)V1JI9FP.> #7YQ^/?$2Q?';7[U
M?$>I0_$_3_B!H.F^%M)BOY0)="D6#<$@W;9(7B:9W<@\C).:Z7X>:AX2UCQ?
M\1M2\5^+=6A^,QU/Q39+HAOYO+>QB@?R8Y+?E%A6 *Z$[06)P2>* /KN?]H'
MPA:_! _%B:ZN8?!XTX:H)VMG\XP$X4B(?-DG&![CI7H%I>I>6D5PF0DB!P&Z
M@$9Y]Z_)3P?JM\G[*7Q9M/%;*-??X=Z/>>'C%<,T*:)YNP*B?=#B9"9&Y)9N
MO&*]%\71M\-E^+O@_2]9UC3? 4/B3P<-8?\ M&:62TL+N%C?2><2717*IN8'
MI0%C] ?''Q/T/X?77AFVU>:5+CQ'JL6C:='#$7,MPZLP!QPH"HQ)/&!3O$7Q
M,T3POXQ\*^%[V:0:SXFDN(]/ACB+!O(B\R4LW10%(Z]21BO@CPKJ,,U]X$L=
M'U.?5O!.F?'06?A:YGN6N$:S&GS,R12L27C68NJG)XZ&N6^%.L6M]\4/ASK>
MGZS<:I\8;B3QM+K5C<7SS2PW4<<ZV8,#'$?"HJX RH'X 6/U($H()R..OM1Y
MJXSN&,XZU^3?P]U;6I?@3\4=9M_%NE,MS\-;FXUC3K/Q)<WNIR:EYJ[+VXBD
M4?9I0?-C95;^Z.PKU3]HKX?>%_A9\)_AU=6FOVWV/[/<>(=2\)^(/$]U:3:^
M[6L"R3076\L)XOE*)]W+Y S0%C]$MV!7(?%/XIZ'\'O FI^+?$,LJ:58!-XM
MHC+*[.X1$11U8LP ^M>0?M&^+]8'[$FK>(O"*ZII%Q<:%97"?,QOK.TD,/G$
MGEO,2%GRW4$$YR*^0OB5IOAC4OA1\;-'\):S=Z[\,-%U;PQ=:)<_VG+<0Q7T
MV$O$CE+'<-KJQ7)"NQ. 1P C](A\2-)M/AW_ ,)IK!G\.:-'8_VA<_VQ$;>6
MTB"[F$J'E6'0KZ\5S'P7_:3\#_'H:HGA6_N6O--$;W-EJ%G):7"Q2#,4HCD
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M?X@^+=7TKQ_8>,;:P\*Z7!?S1B;3S9JT48@7*O!(QE9V(QE1EAGD ^W1(&)
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M<M_%;H)Y%'0-(!N(]B:^!-;_ &>_B:?@W\%M)UOP?K'C>+3=5U2[O_#L6O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!XA\1OA%XQU;]HCP7\1_#%[HB6ND:3<:/>VFK";>\4\\;N\6P8W!8\#
M=QD\UU^E_!W2]*^,'B'XB17=XVK:WI=OI,]NS+Y"10LS*RC&=QW'/.*] HH
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MUXKOJ* /G3X??L4>&? EW=2R>)O$NOP2^')_"<5MJEU&R6VG2-D11%4!4J.
M<G/6O3O@O\*D^#/P_P!.\)P:]JOB&UL ([>YU>17ECA4!8X5V@ (BJ !BN]H
MH \!_9^^!7BSX;>"/&'@SQ/?Z-=Z#JEW?W%E/I/FBY47<LKRB3S!M^4.H7&>
M0<]JM:W^R;H&K_!+P3\-(=?UW2[#PC<6MUIVJ64T:7BRP*XC8L5(R/,)X Y
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MMG>^);,ZI)<M8^9?+'=WGED'R9D5I5 !&U4!V]Z L?I9YB[=V1M]:"ZJ 2<
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M_/+P1\3Y_%?[2^EZQILZ:-9^)9_%-I?Z-_PD5Q>WCI;Q2!?M=M(=D #INC"
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M/K7HE @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=)X]Z_=;:P(R/6M>B@#"N? OAV\DNWN-!TR=[N:*XN&DLXV,TL7^J=\CYF3
MVD\CM2CP1H"^)6\1+HFG+K[1^4VJ"T3[24QC;YF-V/QK<HH SM8\/:;XBM4M
M=5T^UU*V219EANX5E02*<JP# @$'D'M5;4_!>@:U->3:AHFG7TM[ MK=/<VJ
M2-/"K;EC<D?,H/(4\ \UM44 8^O^#]$\5:?%8:UI%AJUE%(LL=M?6R31HR_=
M8*P(!'8U4O?ASX5U+6_[9N_#>D76K_N_]/FL8GG_ '9RGSE<_*>G/%='10!S
M<'PX\*6NLS:O%X:T>/5II'EEOTL(A.[LNUF+A<DE203GD&M*U\.:78:(NC6V
MFVEOI"PFW6PB@58!&1@IL V[2">,8YK2HH YZ7X>^&)K9[=_#NE/ ]FFG-$U
ME&5-LIW+ 1C!C!Y"= >U/NO ?AR]URRUFXT'3)]7LD\NVOY+.-IX%_NHY&5'
MT-;U% &''X(\/P^)9/$*:'IJ:])'Y3ZHMH@N67&-IDQN(QQUJL/AMX44ZB1X
M9TC.HW"7=Y_H,?\ I,R'*22<?,ZGD,>0>:Z6D;[I^E &(/!GAYIS)_8FF^<+
MW^TB_P!E3=]JQCS\X_UF,C?U]Z\PNOV6] U/XQ:AX]OKZ1FEL[FUL],LK2"T
MCMFN8A%<S-)&H>:5U!PSD[<G [UX1:_&/Q'\.O'WQFCT**'5O$OB#XE:=X7T
M<:O<2&UM7EL5?<^#D1HD<AVKC)(]:Z&R_:M^(_B6VT/P7H^A>'X?BC=>)]5\
M-W<]W-*=*C_L^ 7$LZ ?.0Z/&%4G@DY)Q0,^H_!/@O2_A[X0T7PUHT1M]*TB
MTBLK:-FW$1HH49/<G&2>Y)-<K\*?@WIOPU\(ZQH4]W_PD+ZSJE[JVIW%] @%
MU+=2EWW1\C: 0N.>!7@'[0_[77C7X':/HCWW_"(VOB:#14U76_#'^F7DQ;S=
MC+'-$GEPH1G:\IY88]ZS_"?Q'\::#^U5\;?$VI2:9<>$M'\,6.JW%F)9C/'9
MBWGFMU@4_(LC$-YO0$X(H"Q]9#X;>%/^$7'AS_A&M(_X1X$,-*^PQ_90<YSY
M>W;G/.<=:T-#\/Z5X;M6L]'TZSTNV+M*T%E D2;SU8JH R<=?:OB+P?_ ,%#
M==N_!/CC5M1T[P_K%[IOAF+Q'8)HCSK#;R23I!]ANFD S(C31$LG##=C&*]-
M_9<U+QE>_'WXXQ^.9K"37[=="C>/2996LXU:S+#REDY3.[+#^]N/- 6/H:W\
M >&K6&VBA\/Z7%';1300(EG&HBCE.944 <*Y^\!PW?-5=0^%G@[5ELEOO"FB
M7BV5O]CM5N-.B<00?\\TRORKQT'%?.6K_M:^,;'XD7]Y!H>CO\,--\;6_@2Z
MD>63^TVN9%3=<H!\GEJ\BKM/)&3FJ/PP_:R^(?B/XJ^&-.U[2O#L?A37_%&N
M>%K<V)F^VQRV(D82ON)3:?+VX'7.>.E 6/J)/ GAF'Q&OB :!I2:\(_)74UL
MXQ<[,8V^9C=C''7IQ5G2O">B:-JFI:EIVD6%CJ.HL'OKJVMDCEN6&<&1@,L1
MD]?6OF;]JN^\?1_M&? 2U\*W6D0VT]Y?M##J4LZQR7"VY,AF6/AE$1.SJ0Y/
M:N \%?&3QO\ #CXZ^.)%33-2\':S\5T\-737L\SW\+36P,9A'W%CC$8^7ON/
M ZT ?:MQX&\.W<UQ+-H6F32W-S'>3/):1L99X_\ 5RL2.77'#'D=JA@^'GA>
MVU]]=B\.:3%K3RF=M12QC%PTA4J7,@&[.TD9ST)KY6^"O[<VH_$WXW:9X<N(
M-$.@Z]>ZC8V5I8&=M1TTVQ?RI+LLOEE9UC8@(?E)4'O7I/Q@^+/Q'T_X]>%O
MAOX MO#9?5M#N-8GO/$'G8B6&>-&"B/J2'&!Z\YXH ]MM?"NCV-OJ$%MI5C;
MPZC(\U['';(JW+N,.T@ PY8<$G.:;X;\):+X-TX:?H.DV.BV 8O]EL+9(8]Q
MZG:H S[U\<>"OV[O$/C[XH2^'M*MO#\MMJ\^K:;H]FHG:^LKBUBD:WFO/X#%
M.T3#:A!7*C)R:EOOV\=>M_ =UXJAT33'M;'P;H^I7<4K2*(M9U"Y:&.!F!.(
MHQ%,S#!;Y1ZT!8^N;OX?^&K_ %'4=0NO#^EW%_J5M]CO;F6SC:2Y@X_=2,1E
MTX'RGC@>E3+X+T%6NV&BZ<#=VZ6=R?LD?[Z!!A(GX^9 "0%/ ':OCK3?VVO&
MVO>"K:/1+7PMK/BD>.++PH-2C^TII-[#=6\DL<\>[]XA!3:P.[!4XSFNQU7]
MH?XD^%?CKX-^'/B1O!VAR7EE:2W.H7RW<=OK$\DC">+3Y,%5:-0N$DY9CC@8
MH ^F?#OA;2/"&F)INA:99:/IZ$LMK8VZPQ*3U(50!D^M01>"/#UM<0W$6A:;
M'/#=27L4J6D8:.>08DE4XX=@2"W4CK7R=\//VZK_ ,9_'^R\+O;Z*?#>J:[?
M:!;65L9SJMF8-XCNI\CR_+E:-@%7E=RYSS7H'[5?[07BCX,:[X+T_1DT+2=-
MUIYUN?$OBA9_[.MY4"^5;NT()C:3<<.W V]^< 6/;]/\&^'=*EL39:)IEK+I
MRR+:&WM8T-LLI)D$>!\@<Y)QC/.:99> _#-E>ZM=6N@:7;W>JJ4U":*SC5[M
M2,$2D#+@\\'K7R5XV^-=Q\*/B;\<M<T?0]/N_$JVWA2RMIWOKA[>[N;TF&,L
MA;:L:$YS& 6'7GFN-TW]HGQ=\$3\5;O7[C0SXOU;X@VN@_;;J>X?2; ?85=I
M\<R")47(C'\3]< F@+'WB?".BM:Z7;'2+ VVENDEA$;9-EHRC"M$,80@< KC
M%06W@GP]826DEOH6FV\EF\TEL\5I&IA:;_7,F!\I?^+'WN^:\V_9O^/;_&3X
M-R^+M3MX+:[T^ZO+*]:P#FWF-NQ_?0;P&\N1 KJ&Y&[!KPG2/VK_ (F^--%M
M#=:-X>TJQ\?>&=9U7PE-;SS&:S:T7.R[/<M&P<,F,-@4!8^M="^'GA'P^;E]
M&\-Z+IYGC>"=K&QBC\Q&;<Z,5494GD@\5+I/@7PQH4.G)IV@:581Z89/L0MK
M..,6AD_UGEX'R%N^.O>O!?V$?#VKZ+^R+X;N;>'3(]7U>R;4[67S9Y%G>2,>
M7+<ER6\QB 9-GR]=M?,NB:_\1#^QK:7E]?Z?/-<_$JUAL)([NX$D\QU=UFCN
MG)R83*%  S^['(S0!^B-I\/O"FG)JL5OX=TBVCU@G^T$CLHD%Z3G/F@+^\SS
MUSU-:.G^%](TB]:]LM+LK.Z:WCM6G@MU1S"GW(RP&=J]EZ#M7QI)\9=9\?>)
MOAO;>,]#TJ?Q)H/Q7N?"\MQI=W=0VRO%:^8+B- PW<.%V29'RDXYQ7I7[+O[
M17BKXT^,/%FG^(U\.Z)+I;2H?#$?VB/6-/99BBF=9 $DC9 #YB<9.* />+[P
MGX>U#78=6O-'TZXUA('M8KV:WC:<0L/FC#D9VD$Y&<<GUHM_ ?ANV2)8= TN
M)(K,Z=&J6<8"6I.3 !CB,]TZ>U?'7QCUK5O#W[;][XJUF+3]1\,^!O 4WB2&
MU,\XGBA0R!VB0'8;AI3M^8%?+/J!5B__ &R/B9X,\%>++CQ/X?\ #@U]/!,'
MCG1/[.DF>W%N\\<+6]QN()=?-3YE(!YXXH"Q]9Z=\,/".D:9>:=8^%]%L]/O
M8E@N;2WT^)(IXQD!74+A@,G@^M:MGX:TK3]"31;;3;.WT=(/LRZ?% JP"+&-
MFP#&W!/&,<U\M^-?CI\;O"4O@'0WLO [^)_%J:K>HZ_:FM+:UMK1+B,9X9I/
M]8#T!^7IR:N_LS?M/^-_BMXZT72_%FDZ%86'B/PBGBK3!I,DKRPJ+CR&CF+\
M$D_,-HXSC)ZT ?0DGPS\)RW^E7S^&=':]TI%BL+AK"(R6B*,*L3;<H .@'3M
M6)\7_@SI?QE@\+VVL3R)9:)K=OK9MDC1UNFA#;8I P(V'=\PQR..]>@#I2T"
M,.S\#^'M.ATF*TT/3;:/2-_]G+#:1J+/<,-Y0 ^3(Z[<9HN_!'A[4);N6ZT/
M3;B6[EBGN'EM$8S21?ZIW)'S,F/E)Y':MRB@#G[_ .'_ (:U6PU*QO?#^EW5
MEJ4WVB]MIK.-X[J7C]Y(I&';Y1R<G@47?@#PUJ&IZ;J-SX?TNXU#35$=E=2V
M<;2VRCHL;$94#L!TKH** .>E^'GAB;Q ==D\.Z3)K1=)3J+649N-Z#"-YF-V
M0#@'/%:-]H.G:G>65W>6%K=7=DS/:SS0J[P,PVL4)&5)'!QU%:%% &)IW@K0
M-(EL)+'1-.LI-/B>"T>WM40V\;G+I&0/E5CR0.":DU;PEHNO7VFWNIZ18ZA>
M:;+Y]E<75LDDEK)_>C8@E#P.1CH*UZ* ,*U\#>';&6UEM]"TR"2TGENK=X[2
M-3#-)_K)$('RLV3N8<GO2Z-X(T#PYJ5_J.E:)IVFW]^V^[NK2TCBEN&]790"
MQ^M;E% &!J'@+PYJ_B"TUV^T'3+S6K3'V?49[.-[B''3;(1N'YT]?!'A]94D
M&AZ:)%O3J0?[)'D71&#.#C_6$<;^OO6Y10!S>F_#CPKH^J2ZG8^&M(L]2E,C
M27EO8Q1RN7QYA+A<G=@9]<4:)\-O"GAI9UTCPUI&E+<1-!,+.PBB\R-B24;:
MHRI))P>.:Z2B@#F+;X8^$K/PY<>'X/#&C0Z#<-NFTR.PB%O(<YRT>W:3D Y(
M["M70_#>E>&;5[;2--L]*MGD,K0V4"PHSG +%5 &>!S[5I44 <YH_P .?"WA
M[4Y=1TOPWI&FZA+&T4EU:6,44KH6+%2RJ"0222.]5K7X3>"K&&\AMO".A017
MD;17*1:;"JSHSAV5P%^92P#8/< UUE% #(8D@B2.-%2- %55&  .@ I]%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,,J
M12T4 >!^)/V0M!\1'QE<?V]JUAJFO>([;Q5:ZA:F-9=*OX(A'&\.1@C 8$-G
M(8BLZ7]BS1(?!^CV>F^+?$.E^+M-U>[UY?&,$L9OYKVZ79=.ZE=A61,+MP,!
M5QTY^C:* /F/Q_\ L*Z'XXLOLR>-_%>EK=>'HO#>K2K<QW$NJV\3%XFG>122
MX9FR1C(P.,5VG_#,6DCXHZEXM&N:I]CUC0XM#UG028S::C''"\,;2';N&U)&
MX4@$G/M7M%% 'SQHW['5A:_#3Q)X"UGQSXH\3>&=4TV/2+.SU">(+IEO&=T7
ME;4!:12%^=LY"@$5U/P0_9[3X-:UXIUF;Q9K/B_6?$8M/MU]K/E;R;>,QIMV
M*N!M(&#G&.IKUZB@#Y_U/]CKPYJ7Q6;Q:==UJ+1YM;B\37/A1)4_L^?58U"I
M<G*[QP%)4'!(!J?PQ^R/H/A?5_">H0ZWJ4\WA[Q+JOB>$2B/$L]\KK)&^!]U
M?,.,<^M>\T4 >6?&CX$P_%W4_!^K1>(]4\+:UX7O9+NRU#2O++[9(_+EC(=2
M,,O&<<5SES^R7H=SJ]Y?G6]2$ESXZ@\=LNV/:+F*,H(!Q_JR#GU]Z]VHH \8
M^&'[-</PH\;W>J:-XR\0_P#",O/=W5MX1DDB.GVTMR_F2D'9O8;RS*I;Y2QZ
MUU6I?"*QU+XU:+\2'OKE-2TO1KG1HK10ODO'-*DC.W&=P,8 P<<FN]HH \6^
M''[-,'PN\?7FLZ+XQ\01^&Y;FZO8?")DB_L^">X;=*P^3>R[LLJEL*36#HO[
M$?@?1O 7Q#\*+=:D]CXQU+^TY)_,59K!U;?"(& X$;Y9<YZGUKZ'HH&>'+^S
M&VH^'_#=EXB\>>(O%%_HOB>W\4)J.H^3O>6%&180JH%2+#9P.<\YYJ;XI_LS
M0_%KQWIVL:QXRU__ (1ZVN[._?PK&T1LGN+9M\3JQ3?'\P!;:WS8ZBO:Z*!'
MC/@C]FZ+X??$O4?$>C^,O$-OH%Y?W>K-X262+^SQ=W))F?[F\J6)<)G"L<^U
M6/CU^S_+\=;"+3I?&VN^&](EMI;'4=-TWR6@OX)"-P=9$;#X& X.1DXKUZB@
M#Y^\3?L:^%O$=KXVM_[4U2SB\26.CV<?D.F[3VTP?Z++$Q&2P(!.[(.*SH/V
M*-+3PWK-K/XV\1WGB*^U^#Q/!XFE:$7EIJ$47E"1 $"%2NX%",8..V:^DJ*
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M=(\2:!\4+?PUJL=CJ=PEM=2H4DMU5]H8PNSD29&0$! .<#UV']B![ZQ\0_\
M"0?$/4=>U76[[0KZXOWTZ"#:=+?=$BHAP%8 *>XQGG-:_BG]CFUU_0?&-I:>
M+K[2M1USQE'XUM=0CM(Y#I]V@0*H0G$BC:>N.OMR!H:?[6VKZUI/[('CS4);
MG^R->BT,/-/IMPZB"?*;_+DX;:"6P>#BOF?X5_M-ZQX8\5:MKOB^XOKW4_ 7
MPQGMM?T83MB34;;4/+1\$X+2QM"?,QR'STK[.^*/PC_X6M\$M9^'NJ:W<*=5
MTP:?<:N(4,K-A=TNSA<L020,#FO/]8_8P\)Z_P#$'QUXEO;VZDB\9^&5\.:K
M8HBH&VA!]I5QR),1Q]L94&@#Q#XQ?M(?$[5O@E\6?#.LZ/I?A?QIIGA^SUQ;
MK1]3F,?]EW3%7,;[0PN(R"N.%.[@UTM[\3M1\!^-/A)K'C?2U75K+P'KFJW?
M]CZO.ULL-O&CJ!$P"RN\87YGY5CQG -=QHW[%5H?"'CW3?%/C75O%FM>+-(A
MT&36[B"*&2TLH0?)CCC7Y20QW,Q/S'TK9C_91CU>X\'W'BSQ;>^*)M#\/ZGX
M=NFDM([?^T(+P;6+!#\A1 %&,YP"3F@#@;_]K'XD>!?@K<>//&W@O0=+M]63
M3&\-2VVKLT#M>M\J79*;H_*CQ([ $$<#FO4?V7/C[)\>?"6MW-Y'IRZMH6K2
MZ3>3:+<-/87)55=)[=V 8QLKCJ 0017(6?[%LD_PVU+PAKWQ+\0^(($2QCT&
M>XAA7^Q!9OOMGC0 K)(#\KLWWU^4@=:]A^$GP\U'X<>%FT[5O$L_BS4I;A[F
M;4KBSAM=Q;&$6.)0JHH' .3R>>U 'Y[_  W\=ZS<_'[[%X=\4^,;GQZ?B1J"
M7NFSW$DFB_\ "/13G[0S!_ERBGHIW [1@'%>U_#K_@H2/$_BJ^_M'3=(/AZX
MTW6-2T^#2[]IM2MDT]7D(O(V4+&9HXV=-I/H:]*TG]CBPT/7M#URS\47T6K:
M3XPU'Q3%<?9TP\5]@7-BRYYC8 ?-UR <4_P#^Q_;>!WUS23XQU'4? =]:7]E
M:^&)+.W06L=V6,H-P%,DFW>X3)&T,>HH#0XGP-^UMX]O3JH\8:+X1\-Q_P#"
M"IXUT^[;59OLRQRRA(8[ES'F/ /S%0W.,9SBN<TK]O'Q5JW@C5YM/T/PWKGB
M/3_%FE>'HYK"]G33KM+U&*.K21B1&4J5.Y?>L[X?_L=>(_%^O^//#WB[5/$)
M\'1>%H/!^DZOJT-O#=-Y%UYT3P11E@84V)\TAS(2>G;U.U_8H>YGU2_UWX@Z
MCKNLZGXCTCQ'=WTFG00[Y;!658PB':J.&^HQWYH#0\J_:;^/OQ5F\!^.O!O]
ME:+IFI^'?#UG>^*M2TO5)XWMY+JY*Q)9'8"X$:@N6VYW,!TYUO$'QTU3X0^-
M?B]>^'-$CU/61X@\*:,(]4U><VTQO+55#*A!6#;N'W 0W4]*]/\ CI^QQ%\8
M_%GB#6;3QMJ?A6'Q)IEOINMV-G:Q3)?+;R;X&+/RFW."!]X=Q5KQ9^Q_IWBK
M6_%.I2>)+RW?7==T+7'1+9"(7TQ%1(P<\B3;DD],\4 <+8_M<?$#4M,TWPW;
M^%_#[?$RZ\;7_A%H6OYAI8%I")Y9Q)L\S!5E4#;U.?:O7_@%\6O$7QG^!$'B
M^32]/T_Q'<-?P16"W#M;":">6&-6DQG:3&,D#N<"O-?B7^RO_P (]H>N>*=
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M^.GP>\/^-4M1ISZA%(MQ:B3>L,T<C1R!6XW+N0E3CE2#7QO\)_VC?%UCX_\
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M)WX1Q^[D(8KY@R<8&* /'O'_ .U_XK\ :OX@C\,:3I/BOP-X/T31-7O=:O\
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MT16:.WU>XCEMXO[/>2U6WP/D\U26D(P58\9JK>_M>>-/AGX)TRW\,^%M(O\
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M,Q&3\Q[8&!CFU:?L7W#_  D\5> =6^(^J:QINK6%OI=E))IEK$VGV\,@=?N
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M<ZGYH'F%-HW*L0.&XY/2M3XN_LR:M\1?BSIWC_1/B-JG@S5K'26TB%;*P@N
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MH>(;.SU#3H(=.N)#-;W+%89#M0[02.=V,<9Q72_%OX]>#/@?%I+^,-3DT_\
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MS(2 :\P^+7[>/A+0/@O=>,_!<YU>X&J6FF1)?Z==0IF5E9G(**2/)W.I!PV
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M*!Q2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_#4OP>_Z*?X2_P#!S!_\50!ZE17EO_#4OP>_Z*?X2_\ !S!_\51_PU+\'O\
MHI_A+_P<P?\ Q5 'J5%>6_\ #4OP>_Z*?X2_\','_P 51_PU+\'O^BG^$O\
MP<P?_%4 >I45Y;_PU+\'O^BG^$O_  <P?_%4?\-2_![_ **?X2_\','_ ,50
M!ZE17EO_  U+\'O^BG^$O_!S!_\ %4?\-2_![_HI_A+_ ,','_Q5 'J5%>6_
M\-2_![_HI_A+_P ','_Q5'_#4OP>_P"BG^$O_!S!_P#%4 >I45Y;_P -2_![
M_HI_A+_P<P?_ !5'_#4OP>_Z*?X2_P#!S!_\50!ZE17EO_#4OP>_Z*?X2_\
M!S!_\51_PU+\'O\ HI_A+_P<P?\ Q5 'J5%>6_\ #4OP>_Z*?X2_\','_P 5
M1_PU+\'O^BG^$O\ P<P?_%4 >I45Y;_PU+\'O^BG^$O_  <P?_%4?\-2_![_
M **?X2_\','_ ,50!ZE17EO_  U+\'O^BG^$O_!S!_\ %4?\-2_![_HI_A+_
M ,','_Q5 'J5%>6_\-2_![_HI_A+_P ','_Q5'_#4OP>_P"BG^$O_!S!_P#%
M4 >I45Y;_P -2_![_HI_A+_P<P?_ !5'_#4OP>_Z*?X2_P#!S!_\50!ZE17E
MO_#4OP>_Z*?X2_\ !S!_\51_PU+\'O\ HI_A+_P<P?\ Q5 'J5%>6_\ #4OP
M>_Z*?X2_\','_P 51_PU+\'O^BG^$O\ P<P?_%4 >I45Y;_PU+\'O^BG^$O_
M  <P?_%4?\-2_![_ **?X2_\','_ ,50!ZE17EO_  U+\'O^BG^$O_!S!_\
M%4?\-2_![_HI_A+_ ,','_Q5 'J5%>6_\-2_![_HI_A+_P ','_Q5'_#4OP>
M_P"BG^$O_!S!_P#%4 >I45Y;_P -2_![_HI_A+_P<P?_ !5'_#4OP>_Z*?X2
M_P#!S!_\50!ZE17EO_#4OP>_Z*?X2_\ !S!_\51_PU+\'O\ HI_A+_P<P?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#$UU%% '+_ /"K?!G_ $*.A?\ @L@_^)H_X5;X,_Z%'0O_  60?_$UU%%
M'+_\*M\&?]"CH7_@L@_^)H_X5;X,_P"A1T+_ ,%D'_Q-=110!R__  JWP9_T
M*.A?^"R#_P")H_X5;X,_Z%'0O_!9!_\ $UU%% '+_P#"K?!G_0HZ%_X+(/\
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M<2#>.5LT8%>#\Y![=/I_PSX6TCP=H=KH^AZ9::3I5J@CAL[.%8HD ]%'%4_
M/@C2_AOX+T3PMHD"VVDZ1:1V=O$HQA$7&3[DY)/<DUYE\9?VE8? ?B:V\"^#
MM"N/'GQ*O8A+#H%BX5+6,])KJ8_+#'WYY/8=Z /:I;B."-GD=8T49+,< #WK
MP7XC?MM_!OX?WKZ5?>)X-9ORZPS66CQ&],8=@G[TH"JC+#.XUS,G[,_BOXKP
M2:Q\>?'TUWIP!G;PAX:F:PTBW0#<5FE!\R<#G)8@<5S?[0.@?#6']@KQCJOP
MMTK2+3PU<V<$]M<Z3;",3K'>Q L6(W-RC<DDG% SHOB7\(=7_9ZU>\^*/P;L
MV6T5S<^)_ 5OQ::K .9)[9.D5RHRPVX#XQCU^A/A[X^T;XH>"]'\4^'KM;W1
M]5MEN;:8=2I[$=F!R".Q!%:>B2?;-&L9R<F2WC?/U4&OGK]GZT_X5)^T#\4O
MA5"#'H%P(?&6@P=%@BNF:.ZB0=E6="P Z;_>@1]*'H:\ _9D_P"2E_M#_P#8
M]_\ N,L:]_/0UX!^S)_R4O\ :'_['O\ ]QEC0!] 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!YI^TY_R;;\5_^Q3U7_TCEK9^#'_)
M'_ W_8"L/_2>.L;]IS_DVWXK_P#8IZK_ .D<M;/P8_Y(_P"!O^P%8?\ I/'0
M!Y/^V* 9O@H)O^/$_$C2?M&>F-L^S/MNQ7T01\IKQC]K_P ":EX\^!&NIH49
MD\1Z-)!KVE*.K75I*LZJ/]X(R?\  J[OX4?$?2OBY\.O#_B_1I-]AJ]HETB_
MQ1L1\Z-Z,K;E(]5- 'C_ ,)I!IO[9WQXL'X-_IGA_48A_>413Q,?S %>'/\
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MB'K0U.PL+A=LL6G11B*T+CLSJ&?'HPH ?\2]O_#;OP5\G_7_ /"/>(?M&/\
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M0?V<O%&H?#WX)S0Z-'XBU?P3I9T[4="CUN333/YMK'$S17<9&"CQJ<'AAD4
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M#XI_%C2?A/I5A<ZA;7^I7>I7:V.GZ7I-L;B[NYBK.5CC'7"HS$G  ')KR_\
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MB*GPD^$GBWQE+$)_[$TR>]6$])'1"44^Q;:*\*^"\VC?LT_#KP7KWC1+J_\
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MM![[/:@1]*'H:\ _9D_Y*7^T/_V/?_N,L:]_/0UX!^S)_P E+_:'_P"Q[_\
M<98T ?0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2T")DT_3HMGF2G,L\A.Z2:1OXG=B68^IKL:**!!1110 4444 %%%% !1110
MF,TFT>E.HH 3 J.*"*UB$<4:11C.%10 .YX%2UP'Q^&L'X(^/?\ A'S,-<_L
M*]^P_9_]9YWD/LVX_BST]Z +>F?%+1M7^(NJ>#K4R2W^G:9#JD]R-OD".21X
MU4-GELQL3Q@<<TOC'XGZ-X._X1AIS)=KXBU>'1;-[,"1?.E#L"QS@*!&V3S7
MYXS1^&9?!_Q-;X3+"FEMX)\-C4CIJS,,"\/VX2[?G+>5GS0OS8WYYS7H'@;0
M[;3]/\$WFC>(?#VN>'+_ .+&G365IX4CF&GZ>PLI5F2+S"<!F <A3M#,WO0.
MQ]N^"O%Y\5Z%'?W.E7OAZX>2=3I^J;%N%2.5HQ(0K,-K;0P.>C#.#Q6P-3LV
MFAC%U"TDR[XD$@S(/51W'TK\W]375_!OP"\">*-&M)Y;_67\6^ W$6[>9-0U
M&Y-H3Z 31YW=LBM3Q%\/FTK]HZ;PL_B/0?"^KZ7J'AZW\*W6L1W+:B]E;PPC
M98E#Y920I.DHP?FD8MCB@+'Z%?VO8B4Q&\@\Q>J>:N1SMYY]>/K5F.:.21XE
MD5I(\;D!Y7/3([5\5>'_ ((Z7X[^$'[0>H:=I,$/C6^\3:^EIJ6UO.+VUZ+B
MU3.>%$L4? ]/>NX_93^(NDZG9OXTUIY=.U[XN:Y<WNDV<T;-(UM:VZQ(AP"$
M"I"S\D#+GUH ^F+J_MK)HEGGB@:5MD8D<*6;T&>IK#T7Q>-2NO$$=YI=YHMO
MI5Y]E%WJ.Q(KM=BMYL1#'Y,MM^;!R#Q7RK^W+)X:T'QYX4\3ZI/I'B/4=/T]
MXD\"ZV)0=2A>YC)EL73[MVK( .#E<CCK7(>.Y-+B\3^*)?%:[/ 9^+\+:^+K
M(MA =*3ROM'_ $R\[9G/R[MN>U 'WA)K%A;Q"62]MTB.<.TJ@'!P><^I _&K
M,D\<$!EED6.(<EV.% ^M?FGX+\&^&/&WAOX>Z=<:9;ZKX;BLOB)<6-O(':)5
M2^'V=@#SPN-N>1]:^@?%7]H:W_P37M)'^TWU^_@2QGE8AGE?;#"SL>Y.%)/?
M@T!8^IY+^UA+^9<1(4(#;G VD] ?J*DMKB&\@2:&5)H7&Y9(V#*P]017YS_$
M_P 9^#?'>K^.M=.HVFK>!Y_&O@9+N\+,;62W6/;-DCJ@&X-CW]#7TC^QY+#9
M?#+QK/H,,EQX13Q7JTWAB&$GRI-/#*46WS_RS,GFA>W/'% 'MGB?QMI'A3PY
MKVMW=RDMIHMI+>7B0,KR(D:%R,9^\0. >N:9X:U_2?&_A;0O%,448MKJTCU"
MWDN%4O;K)$&.3SM8*Q!P?45^<?@.33_B+KGC:>*P\-C^W/AAKEYJ.@>';2=#
M;7@N(I$AO?,<^;<H[-@@*0=W&"M?8_P(\-^$_&7[)&B:'X86Q.BZMX>-G-]C
M'[HW$L&RX)_VO-9]WOF@#V]KZV4MF>(;0I;+CC=]W\^WK2+?VI"E;B(@JS [
MQ@J.I^@K\S_A%!XK\5^,?AQ/J,=X8?'6J6&F7T,J?+"GAIXF+M[3%)_SJIX[
MTOQ)X>UOQ78:=8WCV7AG4M0^'5O '.VX37IKB9)_^V?GVH'_ -84!8_3R._M
M9 I2XB;<_EJ0X.6QG'UQS6-XP\6MX9\-2:M9Z3>^(RDT40L]*"/*V^58RPW,
MHPFXLW/13C)XKX*^-VF:S\+/C!XF@T6UN?[$\!+8_$RVBA!*W7EV]OI[VY_V
MBL5RWY5VOB[4]&T3]C6'X<PZ@USXLT.'PSJ.K6AC<21-=ZI;3;F;&"2S/G!/
M3F@#[7.IV8N##]KA\X;B8_,&X!>O&<\9&:<+VV?R\3QGS$\Q,./F4?Q#U'/6
MO@V3P=I7_"X-0\1_V:BZ]/\ &LZ1)J(W"5[&735$D!.<>6P=LC'?-<3%H'BB
M]^%7Q2L[:._&H?#+PY'X#5XU?]Y'_:;37+1A?F*BQ2W4E>2I;% 6/TD_M>Q-
MB;T7EO\ 8P#FX\P>6!_O9Q7*ZC\1] F^(]I\/+F/[3J&I:/-JN)%1K=[=94B
M*')Y+%^%P<@-7P^GA'PS-\'/$%ZOQ'\!VGAF7Q98W^EZ?:PW/_"."[BM'$EI
M<!FR(Y5Q(=IPLB@\GBNF^&[>#]>^,OP8\0S>$].\)WVI?#V>/0+&[W,([^&Z
M184A=^6*QF1ESSL?.* L?<=O>6$,<D$$UNB6:A'CC90(5 X! ^Z /I3X-3L[
MIRL-U#*RYR$D!(QUZ>F1^=?F7X3723X(E_X1H7(\61_#?Q*/B&6\PS?;2%\H
M7F[_ );^=YI3/S;=V.*]0^-/A:U^!'P=^&/B[P/HBZ=--I=WH4T-@C?/<ZK8
M(L,SC.6(NH8,D] S&@#[C.J69:!?M<.ZX!,*B09EQ_=YY_"N8\#_ !4T7Q[J
M'BRTT]GC;PWJDFDWC3[5#2HB.S+SG8-X&3CD&OA/XO\ A'1_A]J/BGPK/',O
MQ TC2?"]A\-1'O,_[D(DAL\<;O/$AE/]TC=QBG^--!T30_"W[15AH%G8Z=XD
M3QQ;2:O$L4@E709+BU>5I5C^<VS9F9MG)4R8H"Q^BUK<P7T"3V\J3PN,K)&P
M92/8BHX]0MIY9HX[B*22 XE17!,??##M^-?*_P"S+XIT#X<^$KRTC\9^'=0L
M_%OB2:V\-6?AN&X^P077V=6>WA+YVJ67?UV LV.M>*^'_P#A$9/V4_%R^&Q=
MM\8AH\0\:" S_P!H>3_::&_%QC_EIY?GX_CV'Y>* /T035;*6U6Y2[@:W<[1
M*) 4)] <X[46^K65W*L<-W!+(T8E5$D#$H>C  ]/>OSUU'1?"/BF?5M.\&VL
M-[\'[_XD^$+>PM[7>=/EE(VWXB_V#F(/MXW;N^:L_"7P_P"'?AE\2?!GB&UL
MDT>*T\6>,;.\NTW_ "Z;;02.D+9)_=($!5>@QQWH"Q]*^(OVI]/\+>,?%VEW
M&BWNHVND:A8Z%IZ:4GVB[U75)X&GDMX8^%_=Q[2S%@!\V<8&=/5_VJ_!6A?
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MA)0N?PJ-_P!E'Q'X_8#XJ_%?7O%NG'[^A:1&ND6$G^S((OWDB^Q84 9WQ/\
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MB_X<_P![Q+_X4M[_ /'*/^&+_AS_ 'O$O_A2WO\ \<H ]T^T1_WQ^='VB/\
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M"2,H+*#UP>HKQ+_AB_X<_P![Q+_X4M[_ /'*/^&+_AS_ 'O$O_A2WO\ \<H
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M[@ V5'('3/TKQ'_AB_X<_P![Q+_X4M[_ /'*/^&+_AS_ 'O$O_A2WO\ \<H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH Y+XJ?#O3OBO\ #_7?">JF1+/5+9H&EA8K)"W5)$(.0RL
MP^E?EG^R;^R;XP\1_M2ZOX<\:3ZB=#\!W0FU8O<R^5>29S;1KSRLN!)_N ^M
M?KS5:WT^WMKJXN8K>**>X*F:5$ >4J,*6/4X' SVH \6_:!O+BU^)/P)CAN)
MH8Y_%TB2I%(R"1?[.NCM8 _,,@'!XR!7G/\ P3I\*WD'P5TOQ7JFFR07VKV,
M'EZI)KD]\^HP@LWFO%(=L#[B1M7/'?M7U-JOAS3-;N]-NK^PM[RXTV<W-G+-
M&&:WEVLF]">C;689'8FD\/>'-,\):)9Z/HNGV^EZ79QB*WL[2,1Q1)_=51P!
MR: /SK\4:]XET&Q^)FA6>JZK!)\+]/U:Q>[6>0&.#4]5B,,N\G)>&P\PJYSM
MY(J_XZ\':$FF_$+2-%U/4KWPIX;\6^'[;19X-;N'%O\ ;OLPOH%E5\NI&QL$
MG:9#C&:^_!X)T$7>MW/]C6!GUM$CU.0VZDWJJA15ER/G 4E<'L367I7PB\&:
M'X7B\-Z?X7TFST&*X6[33H;5%A$RN'63:!RP9003SP/2@9\6_&[1]=T[QAXR
M\+>"]7N]*N[#Q+X-M-',M[*ZQ%+69T1F+$D.R*K9SG/.:Y"R\=P?$OPOH5UK
MS:T/#.H?\)AKT6CIK)T^>>_BNHQ';^<S*JM#'),ZAB "F<'@5^A]U\/O#=]J
MTNJ7&B6,VHRW-O>/<O #(TT (AD)_O("0I[9-96L?!/P'K^A+HVH^#]%O=*6
M\DU!;*>R1HEN'8L\H!'#,6))[Y.: /GGX^Z_-XM_94^%M]IHN]NL:MH(6'6=
M3>UDGCD/W+JYBP5W#&]U'<G%>+>']+\3>)/#GP\TZP\17D2>+M9U+X?:\QU&
M69;:WM[Z2Z7[)-NS,$AAGMUF.&=)%SC''Z"^)_ 'ASQKH*:)KVAV&K:.C(RV
M-W KPJ4^X0A&!CMZ4EI\//#.GV>AVEKX?TVVM=#D\[3((+5$2R?:R[HE PAV
MNPR/[Q]:!'SC^VKXDUGX>ZO\(=>T!K@Q^'=2O=8O+""9E-W96MFSSPXSAB81
M)C=GD ]:^:?$OQ%\5V/[..I:!J.N:G;>+]9^(FJWTLUB)KB>);:!+T0($RP4
M2FWB('R@,V>,U^E^L^%-(\17%G/JFF6FH2V?F?9VN8@YB\Q"DFW/3<A*GU!Q
M5*R^'/AG3M7&JVN@Z?;ZB)KB<74<"K())]@G?/K((TW'OM&>E SX>^,'Q-N_
M%EYXG\366IW%E9ZEX=^'NHQK#=,L<0GUUO-Q@@#(RK'N%P>*^[=/\5Z-JMW'
M:66JV=W=2PFY2"&='=H@^PN #RH;Y<],\5@3?!/P%<:-)I,G@_1I-,DL[?3V
MM&LT,36\$AE@B*XQL1V9E7H"213/"?P6\(>!?$QUS0-%M](NETM-'CALU$<$
M5LL\D^U(QPI,DK,2.O'I0!\6^/[L> _$_P <8[W5)M<U?Q!X?\5W6C^)=*U^
M1UA6*#>]C<V@?$,EM\JQR*/7H2:LKXIM;?XR0ZMK[Z_J>IZ5K_A+1]%CTW6A
M:FTL[FQMF\UH';%Q%-<2S)(%5F(4\C;D?9P^"_@1=6US5!X/T4:CKEO):ZG<
MBRC#WD4@Q(DAQ\P?^+^]WS5F?X4>#;KQ)I7B&?POI,NN:5"L%CJ#VB&:VC48
M54;&0 ,X],G&* /A/]FKQQX@T[XW^#M)\1:K</HOVWQ?K]G?7%T_DBT\Z2"6
M%RQQ^YEMW89X59!C%?0G[9-SI^N^$OA3#+J3IX>U?QSI<-W<VE\UNDUI)#<%
MOWJ,"%(P<YP<"O6=<^"7@O7O#TVC2^'K*VM)+2^LD:TB6*2&*\W?:A&P&5\P
MLQ;'4DFM'7OA=X4\5>%K'PWK?A[3M7T*Q\K[/I]] LL,9C38A"D8X7@?6@#\
M_P#PC<7OCWQE\(=/U?43X@T"&WU^*.[UCQ'/IYGTVWU=(K6[$D?^OE$6-JM@
M.,Y-=UX[M](^$GQ._:-\464NI"[T+PYIESI"MJ5Q+'#>ZD+R)W6(N0Q9_*(&
M.-ORXKZW\1_ _P  >+XM-BUKP7H6IQ:9#]GLH[BQC9;:+(.R,8PJ\#@5IWWP
MW\,:G=75S=^'].N+BZ:U:XDDMU+2FV8M;[CW\LLQ7/3)H ^#? _B>T\<^#/@
M[\//%GB34QX-TW5O$&CZOJ=U<3:;->26=N); S,Q61"8Y2X5SDF,$YQ4?Q/\
M3Z_8>)_%]KX3U"7Q#X*)\!!_$-UK3_:EB:ZB$<D:@8E,W1V!7(.2#TK[K\0?
M!_P5XLM=3MM9\*:3JEOJ5U'>WD=U:)(+B=$")*V1RX0!=W7''2K%Q\,/"=V;
MSS_#FF2?:_LOG@VJXD^S,&MLC'_+,@%?[N.* /F?_@HM\0]1\->$O".B:-?W
MNGZG<7\^MB33DEDD9+"$S)&RQ@L(Y)C"C,?E ;)XKQ?XX?%'7;SXL>*-=TC4
M;N7PEXEM?!UEY=O<NJVLUQ*EW;SK@X576*:)L==XSFOT1O\ PCHVJ:O%JMWI
MEK<ZC%:RV*74L0:18)2IDB!_NL44D=]H]*QH_A!X+AL7LT\*Z2+5TM(VA^RI
MM*VI_P!%&,=(OX/[O:@$?'7P7U:;3_VDK";3-=U"XU;6O'/BZPUG2FU"26%M
M.@=V@D:%F*Q^6^Q58 <.1S47Q@N]5E_;9DM;*34+":76O#-M:ZZNK20VEAE)
M)I[9[<-B4W,4,D:Y7&[&2#BOM+P]\,/"?A/7M4US1O#6E:9K6J,SWNHVMHB3
MW!9MS;W R<L23SUYJ34?AQX8U?4+F_OM T^[O;F:UN)KB6W5I));9MUNY;KN
MC/*GMVH ^*_V?O!6F^-OA)\5-1UV,&[GDUAK6YM_%%U)>21P7UPZ^9;[@+?R
MWBB52I.Y1S@'!IZ,UM\/O"'P8O5U6\TZTUGX:^(+^\N+W4I66>_DL[)]Q9W/
MS?*[*!TPV.]?9VB?!/P%X:U74M3TGP?HVG:AJ4<L-Y<VUFB27"2MND5R!R&/
M)!ZU8U[X1^#/%'AW2] U;PMI&I:+I>PV-A=6B20VVQ=J;%(PN!Q@=N* /SM\
M+ZCK]Q\9/AO:>=J]KJ,FE> [>+79M6ECM].E:SDEN(9X=Q$S721/& PP7 !(
M)&>J_96\6>)KCX[^ M"U:_OKG3;B?Q9K>FR27$C(]M)<&W:!\GYC#-;.0#T$
MHQ7WA>?#/PMJ%]/>W/A[39KR>6TGDG:V7>TEJ2;9B<=8BQV'^')Q3],^''AC
M1KG3+BQT#3K.?3!<"RDAMU5K<7#[Y]A ^7>Q+-CJ3F@#YP\=_#W2(?VQ5O$?
M4(Y&\%:AXB,:ZG<"'[=%<00QR^5OVX".PVXQSDC-?+5MXM\:WGP7OVUEFT](
M_A+9OITUOK$LCW49U6,">4\&*0Y*G!8@=^U?J%<^%M(O-:&KSZ;:RZH+1[ 7
MCQ@RBW=@SQ;NNTLJDCID"L*;X-^![C2QILGA/29+ :>ND_9FM4,?V-7\P08Q
M_JP_S;>F>: N>.3:1#X._8N\>C3T@TJ^&@:I<W*:3K<VJ);W'D/_ *NYD(<G
M 0XXP3QZU\P^"=4O%LT\%ZWJLVF>&]2\4>&H]9L]/UZ>[LX;.XLIW %VY#HU
MQ/"BRQ# 7Y<$[\G]"]"^%WA+PQX7O?#>D^'-,TW0+WS/M.FVMLJ03;QM?<@&
M#N'!]:H6GP1\ V'A*^\+VW@W0X/#M\V^ZTR*PC6"=QC#.H'S,,#!/(P,=* /
MB?PKX,T_QI=_"(:A>ZMJ6G3>-=9\.6MXNL7*_;-)M1=O;*660!PK+@/U(0 D
MU-\2?"=M\/\ 6/VD+_0[W5K!]';0K6&Y&K7#G3[2_$1U"1 SD*=C2,&Q\O;&
M*^Z;;X?^'+*VT*WM]"T^"WT$[M+BBMU5;(["F8@!\AVLPX]34LO@K09YM<ED
MT:QD?7(TBU,O K?;45/+59<CYP$)4 ]J N?GOXWUC5? 6ISZ?\/M2OM1\.>%
M/B-%?:9 -0DG62"'1C>7UFLA8[UPCD*20&D->U?LL:[XBUGX5?&_4O$,UPFK
MW.NW]^(9)68VL<^GP7,,2\_+L25!@8 (-?1>C?"/P9X>TG3=,TWPMI-EI^FS
M27%G;06J*D$CHR.ZC'WF5V4GN&(K7L?"6C:;'J:6NEVMNFJ2&6^6.(*+EC&L
M9+X^\=B*OT4"@#\XOA?HOBO2_@/X2UC6'UKPQX#\8/X2TS4'N_$#7#WPDE)N
M[X,')M8KA6BC*[@<,20,5A_%+7[S3_#FFV5N=:\2^%]!U[QG9Z4MGK4L$@T^
MWBMS#/YX?=(EO(\ASECM0@ [:_3";P#X=N?!R^$Y=#T^7PRMLMD-)>W5K80*
M %C"$8VC P.V!5&+X2>#(--TS3X_"VDQV.F6T]G96ZVB!+>&9=LT:#& '4D,
M/XLG- 7/EK1/A?;:;\>=&EU/5KS6M9A^'0U^YU"WU2X-M=:FCK";I8P^PAE!
MP,;3G.,UXG?:]/=_#*'4]2\2:E8Z[X8^&VAZKX25-2DC,M_+<2"20+N_>NTB
M1PD-N^4X[U^D%EX!\/:=/;36VC64$MMIXTF%TB ,=F""(!Z1\#Y>E9=S\&?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !29I:^:_VS=>^-^@:7X5;X*V:7=U+<W U,-!%+B,(OE_ZQ
MACYMW2@#Z3S1FOS*_P"%A?MV_P#0&A_\ ;3_ ..4?\+"_;M_Z T/_@#:?_'*
M=@L?IKFC-?F5_P +"_;M_P"@-#_X VG_ ,<H_P"%A?MV_P#0&A_\ ;3_ ..4
M6'8_37-&:_,K_A87[=O_ $!H?_ &T_\ CE'_  L+]NW_ * T/_@#:?\ QRBP
M6/TUS1FOS*_X6%^W;_T!H?\ P!M/_CE'_"POV[?^@-#_ . -I_\ '*+!8_37
M-&:_,K_A87[=O_0&A_\  &T_^.4?\+"_;M_Z T/_ ( VG_QRBPK'Z:YHS7YE
M?\+"_;M_Z T/_@#:?_'*/^%A?MV_] :'_P  ;3_XY18=C]-<T9K\RO\ A87[
M=O\ T!H?_ &T_P#CE'_"POV[?^@-#_X VG_QRBPK'Z:YHS7YE?\ "POV[?\
MH#0_^ -I_P#'*/\ A87[=O\ T!H?_ &T_P#CE%AV/TUS1FOS*_X6%^W;_P!
M:'_P!M/_ (Y1_P +"_;M_P"@-#_X VG_ ,<HL*Q^FN:,U^97_"POV[?^@-#_
M . -I_\ '*/^%A?MV_\ 0&A_\ ;3_P".46"Q^FN:,U^97_"POV[?^@-#_P"
M-I_\<H_X6%^W;_T!H?\ P!M/_CE%AV/TUS1FOS*_X6%^W;_T!H?_  !M/_CE
M'_"POV[?^@-#_P" -I_\<HL%C]-<T9K\RO\ A87[=O\ T!H?_ &T_P#CE'_"
MPOV[?^@-#_X VG_QRBP6/TUS1FOS*_X6%^W;_P! :'_P!M/_ (Y1_P +"_;M
M_P"@-#_X VG_ ,<HL*Q^FN:,U^97_"POV[?^@-#_ . -I_\ '*/^%A?MV_\
M0&A_\ ;3_P".46"Q^FN:,U^97_"POV[?^@-#_P" -I_\<H_X6%^W;_T!H?\
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M ;3_ ..4?\+"_;M_Z T/_@#:?_'*+!8_37-&:_,K_A87[=O_ $!H?_ &T_\
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MH?\ P!M/_CE'_"POV[?^@-#_ . -I_\ '*+!8_37-&:_,K_A87[=O_0&A_\
M &T_^.4?\+"_;M_Z T/_ ( VG_QRBP6/TUS1FOS*_P"%A?MV_P#0&A_\ ;3_
M ..4?\+"_;M_Z T/_@#:?_'*+!8_37-&:_,K_A87[=O_ $!H?_ &T_\ CE'_
M  L+]NW_ * T/_@#:?\ QRBP6/TUS1FOS*_X6%^W;_T!H?\ P!M/_CE'_"PO
MV[?^@-#_ . -I_\ '*+!8_37-&:_,K_A87[=O_0&A_\  &T_^.4?\+"_;M_Z
M T/_ ( VG_QRBP6/TUS1FOS*_P"%A?MV_P#0&A_\ ;3_ ..4?\+"_;M_Z T/
M_@#:?_'*+!8_37-&:_,K_A87[=O_ $!H?_ &T_\ CE'_  L+]NW_ * T/_@#
M:?\ QRBP6/TUS1FOS*_X6%^W;_T!H?\ P!M/_CE'_"POV[?^@-#_ . -I_\
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MB%_V'?$6A?$VXM8-?T3169M3MI_/21K1E>UG+#G>=JH1USSWKW[_ (2'2/\
MH,:=_P"!L?\ \569XEC\)^,= O-$URXTC5=(O5"7-E<7D9CE4$, P#@D9 /7
MM0!YS^QOX1N/"7[.OA9[\LVK:YYNOWTDAR[RW+;@6]]@3\Z]J5F7.UF&?0UD
MVVM:':6T-O!J>F0P01K%%&EY$%1% 55'S=  !^%2_P#"0Z1_T&-._P# V/\
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M2FHZ,O!D.?O$LVXX (P<<U](_P#"0Z1_T&-._P# V/\ ^*H_X2'2/^@OIO\
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MY+0N S8^3<8W'/3(S7U1_P )#I'_ $%]-_\  R/_ .*H_P"$ATC_ *"^F_\
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MZ!#+XIU;^RM:M+FXE1[><6_FO!;97]Y(N5ZX!_'@"[/%O^'/WA3_ **'K/\
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M&NE6GA;6_$MK/<:S:O<FX.FM]RV161=K^:^><_*!R*]7TO\ :"^'^M?$JZ\
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MQE8/X>TJXBM;V[.\"!Y6"Q;E(W .6&UL8(Y!Q0%V?*__  Y^\*?]%#UG_P
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MUG_P"B_^*H_X<_>%/^BAZS_X!1?_ !5?H+10%V?GU_PY^\*?]%#UG_P"B_\
MBJ/^'/WA3_HH>L_^ 47_ ,57Z"T4!=GY]?\ #G[PI_T4/6?_  "B_P#BJ/\
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M]9_\ HO_ (JC_AS]X4_Z*'K/_@%%_P#%5^@M% 79^?7_  Y^\*?]%#UG_P
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MU&06XYZ?7EJ)/(C\X*)=HWA>F<<X_&I-HI0,4"%HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4M=03$&6,Y?"JQ4$A<=*]'HH IV6DVFGZ;!I]O!'%8P1+!% %^5(U4*J@>@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_I]IJ>BM<^'],CTCQ*^I(T$-W<076G_9 K1%9#'(O[]B,-ALCD8KTG0/VF=
MU7XG1^"!9WV]KR32(]9D$8MIM0A@$TUN%#[PP0GDKM)5@"<4#/:,"C ]!7Q]
M\;?VP-:^%'C3XTZ"(+:>;0]!LKWPR&A),UW*BB2)N?GVF2.3 QA<_6O6_AU\
M?3XQUNPT1/#VJ7JP65M_:_B.WB1=/M+N2S2Z,39?>/D=3D @%U!.30(]FP*,
M"OECX7?M<ZA?>!O$6L^)]$GO;\>(K6UT?3=)1//GL=18'36.YP,L&P22.A.*
MB^*G[9$UK\+9[[PIX>U2#Q+)837<ZWD$;1Z,(K_[%(;D>8 W[U9  A;(&[I0
M!]68%&!7@^J?M66.G2ZX%\):W*EGKS>&+"4M;HNJZ@KR!XX2T@VJJQ.Y>3:,
M#UXJ/3_VR/!M^- ;['J=O%K5YIME;23I&H5KP3@,WS\+&]K+&Y[,!C(.: /?
M,"C %<GX(^(5EXV^'>F^,%M[C2]-OK/[>L=\H62.'!8,P!(^Z-W7H:\AMOVS
M]#N-%:^_X1+Q$D]R--GTBP:.$3:M:W\Y@M9X1YF K. "'*LNY<CF@#Z*P*,"
MO-?'_P 9XOAUX1\.ZGJ.A7[ZUKMQ%96F@QR0BX-RT32M&SLXC&Q(W)8MCY>"
M<BO$_B'^U7J/]CMK_@9;_5X;V'PS/#IKV4*_9XKW49H)?G:0$ROY+0[3PCE#
MD@D@ ^ML"BOF?PI^U3-I?Q#\;:)XPTR\@TJTUZ^LM/U>"%/LT"6VEPWLEO+A
MRYE""=BP7:?E4'-7[/\ ;*TC4=&WVOA#7[C7WU"SL(= C^SFYD^UP23VLN[S
M?+"ND,F<ME2I! H ^BJ2O,?BE\;H/AA;:!$_AW5==UW68YYH-%TQ8VN!%!$)
M;AR695Q&&48!R690,YKD/@[\9-7^+7QN\5K:&Y'@.QT73+K2W$$0AN3=1+.)
MF?<9 Y4D!=H4!6SSB@#WW-+7R!I_[3WC^:#3+A_"U]<32^/]1T+^SK>*#SKV
MTACNF6.$F7:K(84#LY&><9%>@V?[8_A'4=6\,V]II^I3V6KV^F2W&H;8UCTY
MK]BMI',I<,2S @E P7(R0#0![]17R[%^WCH$@6X;P7XFATSR5O6OGC@V)9?;
M#9-<D"0MM$XV[<;B.<8KZ4U;4AI.DWMZ89+C[-"\ODQ8#R;5)VKN(&3C R0/
M>@"]17SG:?MG:/?:?IXMO"FLW6N7FKRZ.ND036KL)([=+DD3";RCF*1=H#[B
M05 R#7>?&'XWP?":3P_:_P#".ZMXCU+6S="VLM+$6\"W@,\I8NZCA%;OR1CO
M0!ZA17@$W[7^@E-5O;7P[KE[H6GZ98:B^JQQQB.1[Z*)[.W1"^\RR&9$QMPI
MZD#FF:C^V%H.AZ-;W6J^&]?L+M[VZT>2P,$;RQ:I%Y92Q.URIDF64-&02K -
MR,4 ?0-+7SIJG[45CX"DU^*_@U7Q)J":_?V<&G6]O#"]O!:6T$]QM8R!72-9
M1AB0SEL!379>!_V@]+^(GQ"G\-Z%H^H7EE;V=M>2ZUF);=!/;)<0@H7\S#(X
MPVS;N!&<@T >LT5YY\8/C)8?"6TT<2Z?=ZUJFKW+VUCIMDT:23%(FFE;=(RH
MH6-&/)&> ,DBN/F_:Q\-)JO@2./3KZ71O%\5L]GJWF0A(VG#>6CQ&3S>"I#$
M(0I(R>M 'N=%?,?B3]J;6]6\.^$M<\,>#=<AT[5?$5A;6INX(=VMV,\<[!K8
MF0!2WE*Q\PJ0K XYKTFT^/VAW7PJ\->/3:7L.DZS>6EB8W11+:23W MOWHS@
M!)3M8@GID9H ]3HKYPC_ &L=!\?:+I\WAV?4]+9[JP>2=K..4A)=7^P"%E+C
M!D9'.1T0[ASQ7#Z/^U7XZ32?!NJW_A>^N/MWB3Q#97>EVT<'GW-K:1W#Q^4Q
MEVJ(_+"L6(+&,X'(H ^QZ*\%^,7QZU+1?AK\-O%W@O3KC6+3Q5K6CQK&D:>8
MUG=$/M =U"NZD(#G@MSQS7-^#?VLVTWQ9XYTOQII]W#8Z=K&NKI^KVT"_9OL
MVGQ)*\! <N950L22H#'@&@#Z>HKRSX6_'S2_B=I'B*Y33+W1[_00CWNFWAC:
M5$DA$\3AHV9"'C/KD$$'!%<1HW[9FAZMH?VIO"FOV6J7<6G3Z/H]PD/VC58[
MYWCMFB(D*J"\4@.]EVA"30!]%45\^-^V=X.M[.UFOM/U6PEF>T@DMYXD$D$T
MM_+8R1. W#0S0MO[!2",YI8OVQ_"L^LZ5:1Z5JAMKF:&.[O6$2I8K/>RVEJ\
MBE]S++)"S H&VH59L9H ^@J*\R^&/QE/Q5T;7=7TWPKJ]IIEA-<VUI/=F%?[
M1E@EEAE$(#D@"2$KE]N<UX]\-_VQ;S_A3OA+6_$_A;6-1\0WVE76M:A%ID,6
M(M/MW437NWS/]6#(JJF2YVM\O&: /JZBO._BE\8;/X;> X/%46FSZ]8S[706
M=Q!%^[9"XDW2NBD$#@ DDD "N&L/VO\ PYJ?B72K"WT'6CI%_P#V:@UUXXUM
MHI;^V$]I$PW[]S@A3\N Q&3S0![[29KYWT+]LS0M;T.6_;PIX@L;BXM]/NM'
ML+B.(S:NEY.;>W,.V0@9E&#O*[003Q5/4?VL=+TVY;7)[;6X;.RT#4+F^\,_
M8HC/'=6VHP6<B-)YG$BO+@*,JRMNW=,@'TI2U\U1?M-:SXE^*7P\T/2?"^IV
MEM>ZIJVE>(+&Y$!FM)[:*)E!828PJRK*2F[*D <\5?\ BG^T9>_";XZ?V1J.
MG75_X.3P_8WMU-8Q(S64UQJ+VHFE+,"4_P!6-J GEC0!]#45\^^&_P!I".#Q
M)I7A1K#6/%&M:GJ>J)YJ6]O:BVM[:_:U8D&0!PC=DRY1=Q45U/Q>_:%TGX1:
MK#87&C:KK<T>G2ZSJ!TR-6%AI\;K&]Q)N89 9ONKEB%8@<4 >LT5YO\ #OXQ
MQ?$CQ?XITC3O#^I0:=X?O)-.EUNX,0M;BX382D0#ES\LBMDJ![UY#X"_;#33
M=#UY_'6EZA;S6LFM7=C?0P1B#4(+34OL@AA <G>IEMTRX4,6)SB@#ZFHKP+3
MOVLK#69M%TS3?!VNW_B6_P!1N],GT:%K<R6,MLL3RF63S=A3RYXW#*S9!]>*
M['Q=\:K7PO\ %3PYX#AT34=6U75X/MC2VIB2.VMQ,L+2MO=2^UFR50,P4$XH
M ]+I:^8?B9^UU"OPVGOO"=A>PZU/ILFJVIN($=?*AU:&PE3&[F1C(2@Z="2.
ME=%9_M9Z9?ZKHFBV_A/7&\1WVI7FFW.D,8$EL7M6B$Q=C($<A9XI J,S%"2!
MP: /?**^7_"W[0'B?6-2U"/5;2^TQK?Q]?Z#8Q16L#IJ$,4%PZ6^[S,H1Y S
M(>I=0.,D6/A=^U:\OP;T+7O&>D:A%K,WAC4O$MP(HX@LMO9E-[(%<@;Q*-@)
M_A.<<9!V/IBBOF+3?VJM1TKQ1\0H=:\.:A<6=KXALM%\.6\'V>-KMY[*.<1;
MFD #%?,F+/M 0@?>XKW3X:_$'3/BGX'TKQ1H_FK8:A&66.X7;)$RL4>-P,@,
MKJRG!(R.,T".IHKP'Q+^U[H?A'7?%FE:EX=U9;G0H/M,:026TK7R"YBMCL59
M24.^>(@2;20V>U8?C_\ ; ?3_AKK5UHOA+6D\8P6VM@Z7-'"S:<^GHOFSS'S
M-K1JTT!PC$L'X'!H ^FJ*\#^*'QC\3>"=/\ A#=:9ILVOS>(+O9J&GV$<?GW
M2#39K@B,NRJGSH&))Z CO3;+]L;P?J>K>%X+.RU*;3-:ATR1]6*QI#9/J _T
M.*52X<LYP#L5@N]<D9H ]^I*^<6_;-TP>%K#7?\ A"O$"0ZH]PVF02-;++>6
MUNA>YN5!EPJ(%P Q#,64*#5'1/VLRGQ$U^VN]+O]4\)WEQI\6@ZI9PQK%NN=
M,6[AA?<X<R3'(7Y=H+("1F@#Z=HKSCX7_&W1_BS>31:-9WJ0Q:1INKM<7$85
M M[&TL477/F*B@L.VY?6N-@_:UT%/$NJZ'?Z%JEA?66HZ?8(IDMYO.%W>BSC
ME_=R-L"R$%E?#!2#@T >\4M?,.M_M-ZW?_$^UTSP]HUQ_8']A>(II[BXCCQ%
M=Z?=+;^:_P ^?)5E8$*"Q\Y/0X?\.OVO?[0^'.F3:YX6UMO&#P:-#'IR1PAM
M5GOX&DBDA(D*(C>3.WSLNT)SVH ^FZ*^?[?]JO3O%<EOIVB:#K@GN=!N-:NK
MYH(@NCQQR7$#^<C2 M(DUNZ[5SDXYQS3]*_:8MM%'@ZRUO1=:DM-7\/C6?\
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MW\017EDCW%I)9"+?;,-^%&)E=I%W?*R%<Y. 1T/BC]EVU\0^$[[3?[6A-_\
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M4D;\*%))XK,NOVI-"T_7]+TN]T#7[%IUL!J,]Q9A8]&EO9#%:PW?S91W< 8
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M@YX('!KT&N-\=?%71?AWJ.CVNLF>%=32\>*X2(M$GV:W:XD#M_"?+1R/7::
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MN9@HV@X?:3A14,_[67B:(7D@\,7;BW^))\*"W2Q;S;BS\F5P(1NPTVZ(9)P
MK@UWL?[8'@2YB\-3P_VE+8:S:6EY)?+:,(=.2YG-O!]I8_ZLO,KICG!4DX'-
M &'X$_9CU>U\0>%?%OB/Q%!=>(K#58-2NDM;'RH7BATN6QBMU&\X*^<TC/DY
M/  &*D\*_LJ3>"+CQ4-&O?#:P7Z7G]FW%]X=2XO(C<S^=*EQ*7'G1X+Q[<#*
ML,_= .M\</BMXJ\(?$3P;X:T.XT/0[768IG75?$22FVNKE'0+8JZ?ZN1D9V!
M;.=H !.:MQ?M7>#D\7:QH5Y#JFGQ:7+J%O+JUS9LMD\UC%YMU&DG=ECR_3D
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MP[K"^(=+U32K>:QO;#+O:7=YY'GHH;D'9(B@D'>4!'->A?%?Q]K^@WGPYL-
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M@;OEC*R.3D9RT?K79VW[2OA[5-"EU'2M-UC5G71M*UQ;2VM?WKV^H"0V^-Q
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M**!'A_C?]GBY\6R_%%TUF*V_X3*;1Y8PT!;[-]B,98'GYM_E\8QC/>N?U_\
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MKF&1Y]*^T"&:Y*JQ,;1KF1HGPVW& 3Q3O%7[;.C^&/#VBZTWA^[DL]1LKK7
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M<ZHK1"+2X#<+"DK*Y_>$MOPJ@G"$U[7X"\)P^!/ _A_PW!,]S!H^GP6$<\H
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M+;*UFLK?5;83BVN,>9"V2K(V.,AE89'I7#7G[-.EWOCE/$S:Q>)<+K^FZ_\
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M C&3G//[&]C'X=TO3H?%-W%<Z5H]KIMG=BU4E)[?41?PW!7/.)%"E.A&>>:
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M,'BD65EXIU%;Z_AGTN*Y"XLX;9?*+$&.1/)\Q)!RK-T.* T/?XI/-C5BI0D
M[3U'M3ZYCP3X8U/PNNI0WWB"XURUEN UBES"JM9P"-$$.\<R<J6+MR2QKIZ!
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP9XFU^7P[;1QVUG:7VE)#J0=72YO!:1QW;; +>569)'4;L(V02>* /LO(HW
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MZA!VD>6Z#&",CJ#FO=,4M 'B\'[*/@BTU%;FU6^M8XYM!FCMHY@8HQI 86B
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M2,S2%S&K'I&N<*O85T]%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_:)\<_$OX,>)O%=U8R:.=)TBT\9:+J5M9W-I;I(KEFL)6D^6Y!CP"Z?*XD.
M"H-?2K_LZ>!'\;6'BK^RI5U:R-N\92\F$)DAB,,4KQ!MCN(CLW$$[<#M66?V
M8/!MMH-UH-@NH66A7M[;7-WIAOI9[>2"&0R+:(DC,L4!?&4C R/EZ= #UBQN
M?MEG!/L:/S8U?8_#+D X/YU8I,4M @HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXK_:;^&W@CQ9J'AO7/$1L-6T^:.WNHVM)FCA>1-\8:0*5&X'CGD\46 ^BO\
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MKVDZK#%_9LTMVTBPW*,<36[J0S8],=Z_0$^!K8=;F3_OD4O_  @MM_S\R?\
M?(HN!\UZ'X;\7Z!^TOJNOW.C#4=#\1>&=-T^ZUBUF58;.YM=[2AD/S$.Y 4
M=#[5SGQ]\*>-Y_BEI_B/PMX0D\5V3>"]5\.SK%<Q1&*:Z?"$AR-P P3CMFOK
M;_A![;K]JD_[Y%+_ ,(-;'_EYD_[Y%%P/SZ\2_LK^*+?4=+TVXTS6O$^AZCX
M4T?0;]= UN*PBAGM5VRBY\Q3OBP=Z$=P?6OH/]H7P)J_C#X?Z7!X;@&IZGH&
MMZ;K4&GS2!/MZVCY,19N-S*<C/5A[U[]#X.L;I-\5Z95#%=R8(!!P1^!!'X5
M)_P@UM_S]2?]\BBX'R1XJLOB-J/BWP%\48?AVCZGI/\ ;=G<^$H+V+[0(+T
M0W#L<(9,C]XN2<-G->?VG[-/CC0?"=OI"6"7TZ?"?5O#KO#.I0:G=7;SI;*2
M1P X ;I\O6OO'_A$=/*3M_:'R0$B4_+A"!DY]..:E3P3:RHLBW;LC#(8 $$4
M7 _/;XX_#[Q+X0\#^.M8OM-\NRN=!\$Z7:DRKB:\M9T6:+@\88@9(Q7:S_"G
MQWXG\32>+;[PQ)HMWJ?Q2TKQ)/H\ES')):6%I;M"\SE3M)+'( YQBOLV_P#A
MKI>J0""]5+V!9$E$5Q"LB;T.Y&VG(RI (/8C-23>#K*#9YM\8][A%WX&YCT
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M_P AJS_ZZ#^5>E#I7/6/A&"QO(KA;AV:-MP4@8-=%28!1112 **** "BBB@
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M:QB$67DKY(0=%"8V[?;&*JZEX-T#683%?Z'IM]$UR+PQW-I'(IGP )<$'Y\
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M+55(Y'DLPVR9;=$S9P:^S;7P#X8LK&*RM_#FDV]E%.EU';Q6,2QI,OW9 H7
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M/G8*X\S/\?7WJ6?P?H-SJ[ZK-HNG2ZI)'Y+WKVL;3M'M*["Y&XKAB,9Q@D4
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MOK9Y2_EA%E4DMC.,9ZX[4!<J>%=?N/$5G=3W&D7VBM#>36JPWZ*KRK&Y43*
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MG[.;B$7&"WE&0;L 9)QU[UD_\)K8'7X=+022B2VEN3>QKNMHQ&R*4:3H'/F
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M HHHH **** "BBL?QAXMTOP'X8U/Q!K=TMEI6G0-<7$[ G:@Z\#DGL .I(H
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MML:)&@+,2>.!0!UU%>=^"/CSX0^(-_;V>CWTCS2Z=+J;">!X?)BCN#;R+)O
MV.LJLI0X(VFNW;6;)5MV-W;A+@XA)E'[P_[/K^% %VBJ3:Q9*;@&[@!M_P#7
M R#]U_O>GXUD>,_'VD>!/"DWB+59RNEQ201&6!3(2TTR0QX"]<O(HS[YH Z2
MBJ?]K6F^)/M,(:5F2,>8,NPSD#U(P:/[6L]\ZFZAW08$H\P9CSTW>GXT 7**
MK17\%Q;"XBFCD@(+"5'!7'KFLD^,K(ZW:Z?&LLT=Q9RWJW\:[K54C=%*M(.
MQWY [A3Z4 ;]%4/[=T_RHY?MUMY<AVH_FKACP, YYZC\ZS?%?CO1?!?A_7-8
MU2^CBM-&LI+^\"'?)'"BEF.P<G@<#O0!T-%9VFZ_9:KI]M>V]Q&8+B..5"6
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M6@#I:*IMJUFKQHUU"&E.U%,@RQR1@#OT/Y4Z#4;>ZMS/!-'/",Y>)@PXZ]*
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M"XF\/-I6LV\:O'HZVVH-+?!B6'EET9&R =P&.W':_P##>'P)_P"BA:9_X_\
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MY2:\0K*_G?/*NZ4X+X4\U[U_PWA\"<Y_X6%IG_C_ /A1_P -X? G_HH6F?\
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M **%IO\ X_\ X4!8]^HKP'_AO'X%?]%"TW_Q_P#PH_X;Q^!7_10M-_\ '_\
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MES^S_P"#O#FGI?ZYJ>G:CX<>5[O;]I>.WOK9Y9),$C<J(S-@G[IY-0_\-X?
MG_HH6F?^/_X4?\-X_ G_ **%IO\ X_\ X4 >B^//A5;>/[^VNYO$/B+1F@C,
M0BT;43;1N"V=S *<GW]*X3X^_"[5?$7P]\$>&]$GU:Z>R\3Z/+-J23*][!;Q
M3@R7.]A@LJ\Y(/T-5?\ AO'X%?\ 10M-_P#'_P#"C_AO'X$_]%"TW_Q__"@#
MR[XL_LWZ]I-UK&G^#['4]1TT^&81<7D[+<7&HSG6A=WD;Y*"226/>=IVJP^7
M@&N,\9?!KQU)X(\$Z/I'A[5[NP5KC4;-YM&ACNM/NGU%)# P\P_8X!&N]=A+
M<[>,;:^A/^&\/@3_ -%"TW_Q_P#PH_X;P^!/_10M,_\ 'O\ "@-3Q/Q5\(/%
M=Y)\5+/0?">JQ:/<ZO:ZK-<ZAI\3WU^!J#2W%K&?,Q>0;"945BI Q$<Y 'I&
MJ?"CQ%_PQE_PB6BKJ[ZY/<6TUK'?6L<-U9!M3CFXA#,JK"N65-QPJ >U=)_P
MWA\"?^BA:9_X]_A1_P -X? G_HH6F_\ C_\ A0!X,OP%\:W'B'X<VVK:7K%C
M;Z9;Q:6;_1[)+EH;VWU.266]+O(#"MRGERF4 E@SKV .#XI^$WB/PEX0^,&I
M^)[#5Y+YXYX)R+)$L]52?689HBMP)-T[B/"KN5=@9DR*^E_^&\/@3_T4+3/_
M !__  JO>?MQ? +48'@NO'>D7,#$%HYD9U.#D9!7'! /U% :F9X$^'-\G[.G
MQ(TC4= UO2M*UR_U6XTSP]IY6+4+2QFP$BC7=A')$CA,X^?'?%>4:A\*?B#K
M/@/3/)\(RZ<EIX<U6T>SM;9;$W<']L6,^Q[<.1%-<VT,^8PV,DC@'%>XC]N_
MX%#_ )J%IF/^!_X4R;]NGX#7$;1R>/\ 2I(G4JR.K$,#U!&WI0!\WZ9\)[GX
MI> -8O/#G@V8Z7!!XY_L>S,87[%>2W-H;(1@-A9,QR["#A2IQBMSQM\&_B!X
MZ^(WQ"EO/",Q^W>'/$&FHZ64<5M=%[:$:<3.&W3R,T2L=_$;KQCO[9I?[;7[
M/NB6%O8Z=XVT6PL;=0D-K:Q&.*-?[JJJ@ >PJY_PWA\"?^BA:9_X_P#X4!J>
M377@'Q./$_AZ+2O >L6.D:I'X-FB5(%CBTQ=.O)I+J.==W[M@LBD 9SD^AKF
MO%/[-?B"W^%GPVMU\,WT2-;7ZZ]::5IT=W=KJ$Y4173(\B#>J+(!+N)C+ C
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M:6D45Q86,=R^F7,6IW$\[O(TB_9Q(CPDNH;>NY2. #[W_P -X_ G_HH6F_\
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M_P#"@-3YNU_X6:J=5\(^$]-\/ZUJGB;_ (1>*32]0O;5()M#D?6VF\R51(1
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M[?2;&7PKINIVFK1KY<J6-I?I<R8#'=$))(L'^+(.,5[M_P -X? G_HH6F?\
MCW^%'_#>'P)'_-0M,_\ 'O\ "@#BO@-\'?$?A?\ :'\2:OK<.JVLD4^INMY'
M81I8W]K/,C6R&X$A:0QQK&%0H/+\MAP,9Y3XH_ 7XA:Q\8?$DVDV5P?#=UJ\
M-K"X(\M[#51$=7D(S_RR:TBQ_P!=&KV#_AO#X$_]%"TW_P ?_P */^&\/@3_
M -%"TS_Q_P#PH \RM?@[KEM\2=#UB\\&W-TPU3QM%%>B%7-F+JY$UA*Q)RJ,
M@F"D=#)CC=69\-/@/XH\&WW@N"S\+7&EZ?;2^%KR[CB&U%N(M,O8[V1AGEA(
M\*L>Y*]<5[!_PWA\"?\ HH6F?^/_ .%'_#>'P)_Z*%IG_C_^% :G._LA_"36
M?A?<QI?:!)H5M<^"M BO$(PLNIQFZ^U%^3F7#1;F[C'->7G]G+4=1\ 6F@?\
M*]>W.EWGC%I(7MU6.:XFB;[!<1X/S JT:(W8ICC%>Y?\-X_ G_HH6F_^/_X4
M?\-X? G_ **%IG_C_P#A0&IYK\-O@_XOM_VDK+7_ !!#K=OL:WO[:^CLHY(#
M;C2XK=[6>Z,FY<2B4F$(1NVODY)%SXB?"[Q#K'[3T^J:;X5O1=3ZCHEU9^+%
M0""TM;>&87<329R-V\+MP=V[VX[[_AO#X$_]%"TS_P ?_P */^&\/@3G_DH6
MF?\ C_\ A0&IX#H?P-\=3> =2TC3/".H^'->ETO1='DOYY-H?7H+J22;6@X8
MEDC4[O-ZR;@N.,#ZG^ ]Q=Z+X1\->%)O!FH^&4T[0;9Y&GVM D^]XY( ^<LX
M*>83CD2*<Y-<M_PWA\"?^BA:9_X]_A1_PWA\"?\ HH6F_P#C_P#A0![]17@/
M_#>/P*_Z*%IO_C_^%'_#>/P*_P"BA:;_ ./_ .% 6/?J*\!_X;Q^!7_10M-_
M\?\ \*/^&\?@5_T4+3?_ !__  H$>_45PWPM^-G@OXTV%]>^#-=M]=M;&407
M$EOG$;E=P!R/3FNYH **** "BBB@ HHHH *^6_VJ=*LM:_:%_9LLM0M(+ZSF
MUW4UDM[F,21N/L.<%2"#R!7U)7S+^TO_ ,G)_LS_ /8>U/\ ](: /:%^#G@(
MJ/\ BBO#W_@KA_\ B:7_ (4WX"_Z$KP]_P""N#_XFNO3[HIU ''?\*;\!?\
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M<'_Q-=C10!QW_"F_ 7_0E>'O_!7!_P#$T?\ "F_ 7_0E>'O_  5P?_$UV-%
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MX"_Z$KP]_P""N#_XFC_A3?@+_H2O#W_@K@_^)KL:* .._P"%-^ O^A*\/?\
M@K@_^)H_X4WX"_Z$KP]_X*X/_B:[&B@#CO\ A3?@+_H2O#W_ (*X/_B:/^%-
M^ O^A*\/?^"N#_XFNQHH X[_ (4WX"_Z$KP]_P""N'_XFOFCXH>%-$\*?M[?
ML\1:+H]AI$<UAKC2K8VR0B0BW."VT#.,GKZFOLBODSXW_P#)_G[.7_8.UW_T
MGH&CZR P*^:_^"B_R_L=_$(_],K;_P!*8J^E!TKYK_X*,_\ )G7Q"_ZY6W_I
M3%0(])\$?"'P-<^#="EE\&Z!)(]A;LSOID)))B7))VUM_P#"F_ 7_0E>'O\
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M%_T)7A[_ ,%<'_Q-=C10!QW_  IOP%_T)7A[_P %<'_Q-'_"F_ 7_0E>'O\
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M@_\ B:[&B@#CO^%-^ O^A*\/?^"N#_XFC_A3?@+_ *$KP]_X*X/_ (FNQHH
MX[_A3?@+_H2O#W_@K@_^)H_X4WX"_P"A*\/?^"N#_P")KL:* .._X4WX"_Z$
MKP]_X*X/_B:/^%-^ O\ H2O#W_@K@_\ B:[&B@#CO^%-^ O^A*\/?^"N#_XF
MC_A3?@+_ *$KP]_X*X/_ (FNQHH X[_A3?@+_H2O#W_@K@_^)H_X4WX"_P"A
M*\/?^"N#_P")KL:* .._X4WX"_Z$KP]_X*X/_B:/^%-^ O\ H2O#W_@K@_\
MB:[&B@#CO^%-^ O^A*\/?^"N#_XFC_A3?@+_ *$KP]_X*X/_ (FNQHH X[_A
M3?@+_H2O#W_@K@_^)I#\&_ 0_P"9*\/?^"N'_P")KLJ0]* /DC]A>SM].\<_
MM$6MK!%;6L/CJ9(H(4")&HCP JC@#V%?7%?)O[$7_)1/VC_^Q\G_ /0*^LJ
M"BBB@ HHHH **** "OF7]I?_ ).3_9G_ .P]J?\ Z0U]-5\R_M+_ /)R?[,_
M_8>U/_TAH ^F$^Z*=34^Z*=0 4444 %%%% !1110 5PGQP^)UO\ !WX7>(/%
MD\?VB6PM_P#1;4<M<W+D)!"H[EY&1?QKNB<"OG;X@D?&?]IGPOX)7]]X;\"1
MIXHUP#E)+]]R:?;M[K^\G(]D]: .Y_9O^&%U\*?A/I6F:K*+GQ)>M)JNN77>
M?4+AO-G8GOAFVCV45ZC2 8 I: "BBB@ HHHH **** "D;H:6L?Q?XHT_P3X6
MU;Q!JTZVNF:9:RWES,QP$CC4LQ_(4 >&?%DCXR_M!^#?AM&!/H'AC9XN\2#J
MCNK%=/MF['=(&E*GJ(AVKZ*7H*\-_9,\+ZB/!6I^/O$5NUOXI\?WIU^\BD'S
M6UNPVV=M[". (,?WF;OFO<Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KY,^-__)_G[.7_ &#M=_\ 2>OK.ODSXW_\G^?LY?\ 8.UW_P!)Z!H^LATK
MYK_X*,_\F=?$+_KE;?\ I3%7TH.E?-?_  49_P"3.OB%_P!<K;_TIBH$>[^
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M-?35?,O[3!"_M)?LSD\ :]J?/_;C0!],)]T4ZH$NHMH_>+^=.^U1?\]%_,4
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M+^8H EKQ']MG_DTWXL?]B[=?^@5[3]JB_P">B_F*\3_;6GCD_9.^+"JP8_\
M".W?0_[% '5?LW?\F]_#3_L6]._])DKT5^@^HKSK]F[_ )-[^&G_ &+>G?\
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M3_P?/_A7T#_PGB_\^C?]]BC_ (3Q?^?1O^^Q18#Y^_X=[^'/^BC?$3_P?/\
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M)_X/G_PH_P"'>_AS_HHWQ$_\'S_X5] _\)XO_/HW_?8H_P"$\7_GT;_OL46
M^?O^'>_AS_HHWQ$_\'S_ .%'_#O?PY_T4;XB?^#Y_P#"OH'_ (3Q?^?1O^^Q
M1_PGB_\ /HW_ 'V*+ ?/W_#O?PY_T4;XB?\ @^?_  H_X=[^'/\ HHWQ$_\
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M^#Y_\*^@?^$\7_GT;_OL4?\ ">+_ ,^C?]]BBP'S]_P[W\.?]%&^(G_@^?\
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M^$\7_GT;_OL4?\)XO_/HW_?8HL!\_?\ #O?PY_T4;XB?^#Y_\*/^'>_AP?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_"':=_<D_[[K=HH PO^$.T[^Y)_WW1_PAVG?W)/^^ZW:* ,+_A#M._N2?\
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MZ.6/^TKZ74;CS9WES-)C<5W$[5X&%7 '85M5\G_\+!_:T_Z);X3_ /!V*/\
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M=B@#ZPHKY/\ ^%@_M:?]$M\)_P#@[%1W7Q*_:PL[6:XE^%_A-8HD9V/]M#@
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M'8H_X6#^UI_T2WPG_P"#L4 ?3WA[PYIOA30=/T72+.*PTK3[=+6UM81A(HD
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M6R6L[=>-T,2+QTQD<UX9_P +!_:T_P"B6^$__!V*/^%@_M:?]$M\)_\ @[%
M'T#X9^%/AOP?XAO-:TBSDM+V\LK:PGQ<2&-XX$"1$H3MW!0%W8R0 ":Y>T^
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M 3%&*6B@!,5F>*!_Q36K?]>DW_H!K4K+\4_\BSJW_7I-_P"@&@#YT_X)J?\
M)FO@3_>OO_2R:OI74_\ D'7/_7)__037S5_P34_Y,T\"?[U]_P"EDU?2NI_\
M@ZY_ZY/_ .@F@?4^7_\ @F@/^,4M%_["FI_^E<E?5.*^5_\ @FA_R:EHO_84
MU/\ ]*Y*^J:!"8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8
MHQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
MF*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
M )BC%+10 F*,4M% "8HQ2T4 )BC%+10!\@?M3?\ )XW[,/\ U_ZC_P"BTKZ^
M7[H^E?(/[4W_ ">-^S#_ -?^H_\ HM*^OE^Z/I0/H+1110(**** "BBB@ KY
ME_:7_P"3D_V9_P#L/:G_ .D-?35?,O[2_P#R<G^S/_V'M3_](: /IA/NBG4U
M/NBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !67XI_P"19U;_ *])O_0#6I67XI_Y%G5O^O2;_P!
M- 'SI_P34_Y,T\"?[U]_Z635]*ZG_P @ZY_ZY/\ ^@FOFK_@FI_R9IX$_P!Z
M^_\ 2R:OI74_^0=<_P#7)_\ T$T#ZGS!_P $T/\ DU+1?^PIJ?\ Z5R5]4U\
MK?\ !-#_ )-2T7_L*:G_ .E<E?5- @HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_GOKO_@EN/\ XFC_ (>.?"'_ )[Z[_X);C_XF@+'U+17RU_P\<^$/_/?7?\
MP2W'_P 31_P\<^$/_/?7?_!+<?\ Q- 6/J6BOEK_ (>.?"'_ )[Z[_X);C_X
MFC_AXY\(?^>^N_\ @EN/_B: L?4M%?+7_#QSX0_\]]=_\$MQ_P#$T?\ #QSX
M0_\ /?7?_!+<?_$T!8^I:*^6O^'CGPA_Y[Z[_P""6X_^)H_X>.?"'_GOKO\
MX);C_P")H"Q]2T5\M?\ #QSX0_\ /?7?_!+<?_$T?\/'/A#_ ,]]=_\ !+<?
M_$T!8^I:*^6O^'CGPA_Y[Z[_ ."6X_\ B:/^'CGPA_Y[Z[_X);C_ .)H"Q]2
MT5\M?\/'/A#_ ,]]=_\ !+<?_$T?\/'/A#_SWUW_ ,$MQ_\ $T!8^I:*^6O^
M'CGPA_Y[Z[_X);C_ .)H_P"'CGPA_P">^N_^"6X_^)H"Q]2T5\M?\/'/A#_S
MWUW_ ,$MQ_\ $T?\/'/A#_SWUW_P2W'_ ,30%CZEK+\4_P#(LZM_UZ3?^@&O
MF[_AXY\(?^>^N_\ @EN/_B:IZU_P41^$E_H]];1S:[YDT$D:_P#$FN.I4@?P
M^] 6-+_@FI_R9IX$_P!Z^_\ 2R:OI74_^0=<_P#7)_\ T$U\W?\ !-VWEL_V
M._ T,\3PS(U\&212I'^F3=C7TCJ?_(/N?^N3_P#H)H#J?,'_  30_P"34M%_
M["FI_P#I7)7U37YS?L8?M@> O@?\"M.\)^*/[8M]8MK^^EDCATJ:50LEP[KA
ME7!X(KW3_AXY\(?^>^N_^"6X_P#B: L?4M%?+7_#QSX0_P#/?7?_  2W'_Q-
M'_#QSX0_\]]=_P#!+<?_ !- 6/J6BOEK_AXY\(?^>^N_^"6X_P#B:/\ AXY\
M(?\ GOKO_@EN/_B: L?4M%?+7_#QSX0_\]]=_P#!+<?_ !-'_#QSX0_\]]=_
M\$MQ_P#$T!8^I:*^6O\ AXY\(?\ GOKO_@EN/_B:/^'CGPA_Y[Z[_P""6X_^
M)H"Q]2T5\M?\/'/A#_SWUW_P2W'_ ,31_P /'/A#_P ]]=_\$MQ_\30%CZEH
MKY:_X>.?"'_GOKO_ ();C_XFC_AXY\(?^>^N_P#@EN/_ (F@+'U+17RU_P /
M'/A#_P ]]=_\$MQ_\31_P\<^$/\ SWUW_P $MQ_\30%CZEHKY:_X>.?"'_GO
MKO\ X);C_P")H_X>.?"'_GOKO_@EN/\ XF@+'U+17RU_P\<^$/\ SWUW_P $
MMQ_\31_P\<^$/_/?7?\ P2W'_P 30%CZEHKY:_X>.?"'_GOKO_@EN/\ XFC_
M (>.?"'_ )[Z[_X);C_XF@+'U+17RU_P\<^$/_/?7?\ P2W'_P 31_P\<^$/
M_/?7?_!+<?\ Q- 6/J6BOEK_ (>.?"'_ )[Z[_X);C_XFC_AXY\(?^>^N_\
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M_?E?\*NT4 4O[%L/^?*V_P"_*_X4?V+8?\^5M_WY7_"KM% %+^Q;#_GRMO\
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M\*/[%L/^?*V_[\K_ (5=HH I?V+8?\^5M_WY7_"C^Q;#_GRMO^_*_P"%7:*
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MBAK'QH^ /A/QEKZVZ:MJ<<KSK:(5C!69T& 2>RBO7Z"0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $)Q1N%#=*^.?A;^U/XT\8?MS>,_A1?+IP\+Z0MXT!C@(G/EB$I
MELX_Y:'/'I0!]CT444 %%%% !1110 4444 %%%% !1110 5^8O\ P6+_ .1C
M^%O_ %Z:C_Z';U^G5?F)_P %B_\ D8_A;_UZ:C_Z';T#6Y^=5 ZBDI5ZB@T/
MW#_X)Y?\F??#S_KWN/\ TIEKZ-KYQ_X)Y'_C#[X>?]<+C_TIEKZ.H,@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!*YZQ^'?AC3/$]SXCM- TZVUZYW";4HK95N)-V-VYP,G.!GZ5T5%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>tmb-20250331xex23d4001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250331xex23d4001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  L ,H# 2(  A$! Q$!_\0
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M@BIJ "BBB@ HJ..>*9Y%CD1VC.UU5@2IZX/I46H:E::3:M<WUU#9VZ_>FN)
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MR&.\#YO7/V;?@3X_NO!UE:>/(6\&Z!)MNM1T2&[2XU;Q#>,H$DVI74?RQP\
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MU=N/,6-FDDF'S.R87Y0-WB]E^R^/AEX@M?@QX;T9/%S^%?"2^.M8L;F01?\
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8SSBI:* "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>41
<FILENAME>tmb-20250331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/21/2025 4:00:26 AM-->
<!--Modified on: 7/21/2025 4:00:26 AM-->
<xsd:schema targetNamespace="http://carismatx.com/20250331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:attributeFormDefault="unqualified" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:carm="http://carismatx.com/20250331">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails" id="DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails">
        <link:definition>140401 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>140601 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails">
        <link:definition>140802 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>140805 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>141101 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails">
        <link:definition>141102 - Disclosure - Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails" id="DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails">
        <link:definition>141302 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetailss" id="DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetailss">
        <link:definition>1599555275 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailsss" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailsss">
        <link:definition>1599555365 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets" id="StatementUnauditedConsolidatedBalanceSheets">
        <link:definition>200100 - Statement - UNAUDITED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>200200 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows" id="StatementUnauditedConsolidatedStatementOfCashFlows">
        <link:definition>200400 - Statement - UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss">
        <link:definition>240303 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss" id="DisclosurePrepaidExpensesAndOtherAssetsDetailss">
        <link:definition>240401 - Disclosure - Prepaid Expenses and other assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss" id="DisclosureAccruedExpensesDetailss">
        <link:definition>240501 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss" id="DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss">
        <link:definition>240602 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss">
        <link:definition>240605 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity">
        <link:definition>100300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureBackgroundDetails" id="DisclosureBackgroundDetails">
        <link:definition>140101 - Disclosure - Background (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails">
        <link:definition>140301 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>140302 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails">
        <link:definition>140303 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails">
        <link:definition>140304 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>140801 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails" id="DisclosureStockholdersDeficitEquityDetails">
        <link:definition>140901 - Disclosure - Stockholders' (Deficit) Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails" id="DisclosureStockBasedCompensationNarrativeDetails">
        <link:definition>141001 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails" id="DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails">
        <link:definition>141003 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
        <link:definition>141004 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>141103 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails" id="DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails">
        <link:definition>141301 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>141401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity" id="StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity">
        <link:definition>200300 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureBackgroundDetailss" id="DisclosureBackgroundDetailss">
        <link:definition>240101 - Disclosure - Background (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss">
        <link:definition>240301 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss">
        <link:definition>240304 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss" id="DisclosureCommitmentsAndContingenciesNarrativeDetailss">
        <link:definition>240601 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>240701 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss" id="DisclosureStockBasedCompensationNarrativeDetailss">
        <link:definition>240801 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss" id="DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss">
        <link:definition>240803 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss" id="DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss">
        <link:definition>240804 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss" id="DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss">
        <link:definition>241001 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DocumentCoverPage" id="DocumentCoverPage">
        <link:definition>100090 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureBackground" id="DisclosureBackground">
        <link:definition>110101 - Disclosure - Background</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidity" id="DisclosureDevelopmentStageRisksAndLiquidity">
        <link:definition>110201 - Disclosure - Development-Stage Risks and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>110301 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBio" id="DisclosureMergerWithSesenBio">
        <link:definition>110401 - Disclosure - Merger with Sesen Bio</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssets" id="DisclosurePrepaidExpensesAndOtherAssets">
        <link:definition>110501 - Disclosure - Prepaid Expenses and Other Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>110601 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>110701 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>110801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquity" id="DisclosureStockholdersDeficitEquity">
        <link:definition>110901 - Disclosure - Stockholders' (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>111001 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>111101 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>111201 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreement" id="DisclosureModernaCollaborationAndLicenseAgreement">
        <link:definition>111301 - Disclosure - Moderna Collaboration and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>111401 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>120302 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>130303 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioTables" id="DisclosureMergerWithSesenBioTables">
        <link:definition>130403 - Disclosure - Merger with Sesen Bio (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTables" id="DisclosurePrepaidExpensesAndOtherAssetsTables">
        <link:definition>130503 - Disclosure - Prepaid Expenses and Other Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>130603 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>130703 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>130803 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>131003 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>131103 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTables" id="DisclosureModernaCollaborationAndLicenseAgreementTables">
        <link:definition>131303 - Disclosure - Moderna Collaboration and License Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetails" id="DisclosureDevelopmentStageRisksAndLiquidityDetails">
        <link:definition>140201 - Disclosure - Development-Stage Risks and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" id="DisclosurePrepaidExpensesAndOtherAssetsDetails">
        <link:definition>140501 - Disclosure - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetNarrativeDetails" id="DisclosurePropertyAndEquipmentNetNarrativeDetails">
        <link:definition>140602 - Disclosure - Property and Equipment, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>140701 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails">
        <link:definition>140803 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetails">
        <link:definition>140804 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" id="DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails">
        <link:definition>141002 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetails" id="DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetails">
        <link:definition>141303 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical" id="StatementUnauditedConsolidatedBalanceSheetsParenthetical">
        <link:definition>200105 - Statement - UNAUDITED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureBackgrounds" id="DisclosureBackgrounds">
        <link:definition>210101 - Disclosure - Background</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquiditys" id="DisclosureDevelopmentStageRisksAndLiquiditys">
        <link:definition>210201 - Disclosure - Development-Stage Risks and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciess" id="DisclosureSummaryOfSignificantAccountingPoliciess">
        <link:definition>210301 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetss" id="DisclosurePrepaidExpensesAndOtherAssetss">
        <link:definition>210401 - Disclosure - Prepaid Expenses and other assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpensess" id="DisclosureAccruedExpensess">
        <link:definition>210501 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciess" id="DisclosureCommitmentsAndContingenciess">
        <link:definition>210601 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>210701 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensations" id="DisclosureStockBasedCompensations">
        <link:definition>210801 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureRelatedPartyTransactionss" id="DisclosureRelatedPartyTransactionss">
        <link:definition>210901 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreements" id="DisclosureModernaCollaborationAndLicenseAgreements">
        <link:definition>211001 - Disclosure - Moderna Collaboration and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSubsequentEventss" id="DisclosureSubsequentEventss">
        <link:definition>211101 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" id="DisclosureSummaryOfSignificantAccountingPoliciesPoliciess">
        <link:definition>220302 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless" id="DisclosureSummaryOfSignificantAccountingPoliciesTabless">
        <link:definition>230303 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTabless" id="DisclosurePrepaidExpensesAndOtherAssetsTabless">
        <link:definition>230403 - Disclosure - Prepaid Expenses and other assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpensesTabless" id="DisclosureAccruedExpensesTabless">
        <link:definition>230503 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTabless" id="DisclosureCommitmentsAndContingenciesTabless">
        <link:definition>230603 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTabless" id="DisclosureStockBasedCompensationTabless">
        <link:definition>230803 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTabless" id="DisclosureModernaCollaborationAndLicenseAgreementTabless">
        <link:definition>231003 - Disclosure - Moderna Collaboration and License Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetailss" id="DisclosureDevelopmentStageRisksAndLiquidityDetailss">
        <link:definition>240201 - Disclosure - Development-Stage Risks and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetailss" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetailss">
        <link:definition>240302 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss" id="DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss">
        <link:definition>240603 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetailss" id="DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetailss">
        <link:definition>240604 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss" id="DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss">
        <link:definition>240802 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetailss" id="DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetailss">
        <link:definition>241002 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetailss" id="DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetailss">
        <link:definition>241003 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://carismatx.com/20241231/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:element name="DeferredFinancingCostsNoncurrent" id="carm_DeferredFinancingCostsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ReclassificationsOfTemporaryToPermanentEquityShares" id="carm_ReclassificationsOfTemporaryToPermanentEquityShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" id="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" id="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" id="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" id="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AccretionOnMarketableSecurities" id="carm_AccretionOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="WriteOffOfPropertyAndEquipment" id="carm_WriteOffOfPropertyAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NoncashInterestExpense" id="carm_NoncashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="GainLossOnSaleOfEquipment" id="carm_GainLossOnSaleOfEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PaymentsForProceedsFromMarketableSecurities" id="carm_PaymentsForProceedsFromMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" id="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" id="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockPreClosingFinancing" id="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromFailedSaleLeasebackTransaction" id="carm_ProceedsFromFailedSaleLeasebackTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" id="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NoncashOrPartNoncashAcquisitionEquityAssumed" id="carm_NoncashOrPartNoncashAcquisitionEquityAssumed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" id="carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" id="carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" id="carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" id="carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DevelopmentStageRisksAndLiquidityAbstract" id="carm_DevelopmentStageRisksAndLiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DevelopmentStageRisksAndLiquidityTextBlock" id="carm_DevelopmentStageRisksAndLiquidityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredFinancingCostsPolicyPolicyTextBlock" id="carm_DeferredFinancingCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" id="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" id="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" id="carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfChangesInDeferredRevenueTableTextBlock" id="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReportingSegmentMember" id="carm_ReportingSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" id="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" id="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="FacilitiesExpense" id="carm_FacilitiesExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" id="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CarismaTherapeuticsIncLegacyStockholdersMember" id="carm_CarismaTherapeuticsIncLegacyStockholdersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CarismaTherapeuticsInc.Member" id="carm_CarismaTherapeuticsInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfBoardMembers" id="carm_NumberOfBoardMembers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" id="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="PrepaidResearchAndDevelopmentCurrent" id="carm_PrepaidResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ReceivableDueFromCollaborativeArrangementCurrent" id="carm_ReceivableDueFromCollaborativeArrangementCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AccruedResearchAndDevelopmentExpenseCurrent" id="carm_AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PennLicenseAgreementMember" id="carm_PennLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" id="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TrusteesOfUniversityOfPennsylvaniaMember" id="carm_TrusteesOfUniversityOfPennsylvaniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" id="carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CommitmentsAnnualPaymentsRequiredToBePaid" id="carm_CommitmentsAnnualPaymentsRequiredToBePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" id="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AdditionalMilestonePaymentsRequiredToBePaid" id="carm_AdditionalMilestonePaymentsRequiredToBePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AgreementTerm" id="carm_AgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinanceLeaseCostAbstract" id="carm_FinanceLeaseCostAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinanceLeaseCost" id="carm_FinanceLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LeasesWeightedAverageRemainingLeaseTermAbstract" id="carm_LeasesWeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LeasesWeightedAverageDiscountRateAbstract" id="carm_LeasesWeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" id="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinancingCashUsedInFinanceLeases" id="carm_FinancingCashUsedInFinanceLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AtTheMarketMember" id="carm_AtTheMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" id="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SaleOfStockStockOfferingAmount" id="carm_SaleOfStockStockOfferingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="SaleOfStockMaximumOfferingAmount" id="carm_SaleOfStockMaximumOfferingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="TwoThousandSeventeenStockIncentivePlanMember" id="carm_TwoThousandSeventeenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandFourteenStockIncentivePlanMember" id="carm_TwoThousandFourteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandFourteenEmployeeStockPurchasePlanMember" id="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" id="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SesenBioIncMember" id="carm_SesenBioIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RevisedOperatingPlanMember" id="carm_RevisedOperatingPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" id="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" id="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsStartUpCosts" id="carm_DeferredTaxAssetsStartUpCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsLeaseLiability" id="carm_DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsAmortizableAssetsAndOther" id="carm_DeferredTaxAssetsAmortizableAssetsAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsEquityCompensation" id="carm_DeferredTaxAssetsEquityCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxLiabilitiesRightOfUseAsset" id="carm_DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="Pre2018Member" id="carm_Pre2018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Post2017Member" id="carm_Post2017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StateJurisdictionMember" id="carm_StateJurisdictionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LocalJurisdictionMember" id="carm_LocalJurisdictionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAndLicenseAgreementMember" id="carm_CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ModernaLicenseAgreementMember" id="carm_ModernaLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ModernaMember" id="carm_ModernaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndDevelopmentServicesMember" id="carm_ResearchAndDevelopmentServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OptionRightCollaborationRevenuesMember" id="carm_OptionRightCollaborationRevenuesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonesMember" id="carm_MilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumNumberOfResearchTargets" id="carm_MaximumNumberOfResearchTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfResearchTargetsNominatedAutoimmune" id="carm_NumberOfResearchTargetsNominatedAutoimmune" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfResearchTargetsGrossOncology" id="carm_NumberOfResearchTargetsGrossOncology" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="UpfrontNonRefundablePaymentReceived" id="carm_UpfrontNonRefundablePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPotentialProductsToDevelopAndCommercialize" id="carm_NumberOfPotentialProductsToDevelopAndCommercialize" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" id="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="MinimumCommitmentToReimburseResearchAndDevelopmentCosts" id="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="PeriodOfReimbursementOfResearchAndDevelopmentCosts" id="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPerformanceObligations" id="carm_NumberOfPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementRightsAndObligationsMilestonePayments" id="carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfPotentialResearchTargetDesignations" id="carm_NumberOfPotentialResearchTargetDesignations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VariableConsideration" id="carm_VariableConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ContractTerm" id="carm_ContractTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" id="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="RevenueRemainingPerformanceObligationOptionRightsAmount" id="carm_RevenueRemainingPerformanceObligationOptionRightsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ContractWithCustomerLiabilityDeferralOfRevenue" id="carm_ContractWithCustomerLiabilityDeferralOfRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CashPreservationPlan2025Member" id="carm_CashPreservationPlan2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfResearchTargetsNominatedOncology" id="carm_NumberOfResearchTargetsNominatedOncology" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfResearchTargetsNominatedReplacements" id="carm_NumberOfResearchTargetsNominatedReplacements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfResearchTargetsTerminatedOncology" id="carm_NumberOfResearchTargetsTerminatedOncology" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfResearchTargetsTerminatedAutoimmune" id="carm_NumberOfResearchTargetsTerminatedAutoimmune" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DevelopmentStageRisksAndLiquidityTableTextBlock" id="carm_DevelopmentStageRisksAndLiquidityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AssetsHeldForSalePolicyPolicyTextBlock" id="carm_AssetsHeldForSalePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdditionalMilestonePaymentsForTheFirstCARMProduct" id="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" id="carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="FinanceLeaseLiabilityToBePaidAfterYearFour" id="carm_FinanceLeaseLiabilityToBePaidAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="FinanceLeasesInterestPaymentOnLiability" id="carm_FinanceLeasesInterestPaymentOnLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FinanceLeasesInterestExpense" id="carm_FinanceLeasesInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability" id="carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>42
<FILENAME>tmb-20250331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/21/2025 4:00:26 AM-->
<!--Modified on: 7/21/2025 4:00:26 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails" roleURI="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails" roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailsss" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailsss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementUnauditedConsolidatedBalanceSheets" roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementUnauditedConsolidatedStatementOfCashFlows" roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePrepaidExpensesAndOtherAssetsDetailss" roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureAccruedExpensesDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638886672225003438" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638886672225003438" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_638886672225003438" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_638886672225003438" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638886672225003438" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638886672225003438" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638886672225003438" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638886672225003438" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638886672225003438" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_638886672225013696" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638886672225003438" xlink:to="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_638886672225013696" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638886672225013696" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638886672225003438" xlink:to="us-gaap_OperatingIncomeLoss_638886672225013696" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:label="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_638886672225013696" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_638886672225013696" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638886672225013696" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638886672225013696" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:label="carm_ProceedsFromFailedSaleLeasebackTransaction_638886672225013696" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="carm_ProceedsFromFailedSaleLeasebackTransaction_638886672225013696" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:label="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_638886672225013696" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_638886672225013696" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638886672225023620" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638886672225023620" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638886672225023620" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638886672225023620" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:label="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_638886672225023620" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_638886672225023620" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:label="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_638886672225023620" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_638886672225023620" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638886672225023620" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="us-gaap_PaymentsOfFinancingCosts_638886672225023620" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PaymentsForProceedsFromMarketableSecurities" xlink:label="carm_PaymentsForProceedsFromMarketableSecurities_638886672225023620" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xlink:to="carm_PaymentsForProceedsFromMarketableSecurities_638886672225023620" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638886672225033520" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638886672225033520" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638886672225033520" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638886672225033520" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638886672225033520" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_NetIncomeLoss_638886672225033520" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638886672225033520" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_DepreciationAndAmortization_638886672225033520" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638886672225033520" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638886672225033520" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638886672225043523" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_ShareBasedCompensation_638886672225043523" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638886672225043523" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638886672225043523" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NoncashInterestExpense" xlink:label="carm_NoncashInterestExpense_638886672225043523" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="carm_NoncashInterestExpense_638886672225043523" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet_638886672225043523" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_SaleAndLeasebackTransactionGainLossNet_638886672225043523" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_GainLossOnSaleOfEquipment" xlink:label="carm_GainLossOnSaleOfEquipment_638886672225043523" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="carm_GainLossOnSaleOfEquipment_638886672225043523" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_638886672225053522" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_638886672225053522" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_WriteOffOfPropertyAndEquipment" xlink:label="carm_WriteOffOfPropertyAndEquipment_638886672225053522" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="carm_WriteOffOfPropertyAndEquipment_638886672225053522" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AccretionOnMarketableSecurities" xlink:label="carm_AccretionOnMarketableSecurities_638886672225053522" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="carm_AccretionOnMarketableSecurities_638886672225053522" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_638886672225053522" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_638886672225053522" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638886672225053522" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638886672225053522" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638886672225053522" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638886672225053522" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638886672225063698" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638886672225063698" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638886672225063698" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638886672225063698" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638886672225063698" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638886672225063698" order="17" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638886672225063698" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638886672225063698" order="18" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638886672225073469" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638886672225073469" order="19" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails" xlink:type="extended" xlink:title="140401 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_638886672225073469" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_638886672225073469" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_638886672225073469" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_638886672225073469" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="140601 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638886672225083482" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638886672225083482" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638886672225083482" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638886672225083482" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" xlink:type="extended" xlink:title="140802 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638886672225083482" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_VariableLeaseCost_638886672225083482" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeaseCost" xlink:label="carm_FinanceLeaseCost_638886672225083482" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="carm_FinanceLeaseCost_638886672225083482" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638886672225093174" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638886672225093174" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_638886672225093174" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_638886672225093174" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="140805 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638886672225093174" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638886672225093174" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638886672225093174" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638886672225093174" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638886672225093174" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638886672225093174" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638886672225103194" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638886672225103194" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="141101 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638886672225103194" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638886672225103194" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638886672225103194" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638886672225103194" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638886672225103194" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638886672225103194" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_638886672225103194" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_638886672225103194" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638886672225103194" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638886672225103194" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_638886672225113444" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_638886672225113444" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638886672225113444" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638886672225113444" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails" xlink:type="extended" xlink:title="141102 - Disclosure - Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638886672225113444" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638886672225113444" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638886672225113444" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638886672225113444" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638886672225113444" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="carm_DeferredTaxLiabilitiesRightOfUseAsset_638886672225113444" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638886672225113444" xlink:to="carm_DeferredTaxLiabilitiesRightOfUseAsset_638886672225113444" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638886672225113444" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638886672225113444" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638886672225123435" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638886672225113444" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638886672225123435" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638886672225123435" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638886672225113444" xlink:to="us-gaap_DeferredTaxAssetsGross_638886672225123435" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsEquityCompensation" xlink:label="carm_DeferredTaxAssetsEquityCompensation_638886672225133526" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638886672225123435" xlink:to="carm_DeferredTaxAssetsEquityCompensation_638886672225133526" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:label="carm_DeferredTaxAssetsAmortizableAssetsAndOther_638886672225133526" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638886672225123435" xlink:to="carm_DeferredTaxAssetsAmortizableAssetsAndOther_638886672225133526" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_638886672225133526" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638886672225123435" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_638886672225133526" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_638886672225133526" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638886672225123435" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_638886672225133526" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsLeaseLiability" xlink:label="carm_DeferredTaxAssetsLeaseLiability_638886672225133526" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638886672225123435" xlink:to="carm_DeferredTaxAssetsLeaseLiability_638886672225133526" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsStartUpCosts" xlink:label="carm_DeferredTaxAssetsStartUpCosts_638886672225133526" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638886672225123435" xlink:to="carm_DeferredTaxAssetsStartUpCosts_638886672225133526" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638886672225133526" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638886672225123435" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638886672225133526" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:label="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_638886672225143437" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638886672225123435" xlink:to="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_638886672225143437" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638886672225143437" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638886672225123435" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638886672225143437" order="9" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails" xlink:type="extended" xlink:title="141302 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="RevenueRemainingPerformanceObligation" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:label="carm_RevenueRemainingPerformanceObligationOptionRightsAmount_638886672225143437" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="RevenueRemainingPerformanceObligation" xlink:to="carm_RevenueRemainingPerformanceObligationOptionRightsAmount_638886672225143437" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:label="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_638886672225143437" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="RevenueRemainingPerformanceObligation" xlink:to="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_638886672225143437" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetailss" xlink:type="extended" xlink:title="1599555275 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:label="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_638886672225153589" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_638886672225153589" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_638886672225153589" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_638886672225153589" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_638886672225153589" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_638886672225153589" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_638886672225153589" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_638886672225153589" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_638886672225153589" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_638886672225153589" order="5" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailsss" xlink:type="extended" xlink:title="1599555365 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638886672225163446" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638886672225163446" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638886672225163446" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638886672225163446" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638886672225163446" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638886672225163446" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638886672225163446" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638886672225163446" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638886672225163446" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638886672225163446" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="200100 - Statement - UNAUDITED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638886672225173490" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638886672225173490" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredFinancingCostsNoncurrent" xlink:label="carm_DeferredFinancingCostsNoncurrent_638886672225173490" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="carm_DeferredFinancingCostsNoncurrent_638886672225173490" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638886672225173490" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638886672225173490" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638886672225173490" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638886672225173490" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638886672225173490" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638886672225173490" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638886672225173490" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638886672225173490" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638886672225173490" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638886672225173490" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_638886672225173490" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638886672225173490" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_638886672225173490" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638886672225183529" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638886672225183529" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638886672225183529" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638886672225183529" xlink:to="us-gaap_LiabilitiesCurrent_638886672225183529" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638886672225183529" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638886672225183529" xlink:to="us-gaap_OtherLiabilitiesCurrent_638886672225183529" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638886672225183529" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638886672225183529" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638886672225183529" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638886672225193550" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638886672225183529" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638886672225193550" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638886672225193550" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638886672225183529" xlink:to="us-gaap_DeferredRevenueCurrent_638886672225193550" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638886672225193550" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638886672225183529" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638886672225193550" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638886672225193550" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638886672225183529" xlink:to="us-gaap_AccountsPayableCurrent_638886672225193550" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent_638886672225193550" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638886672225183529" xlink:to="us-gaap_DeferredRevenueNoncurrent_638886672225193550" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638886672225203542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638886672225183529" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638886672225203542" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638886672225203542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638886672225183529" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638886672225203542" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638886672225203542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638886672225183529" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638886672225203542" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672225203542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672225203542" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638886672225203542" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672225203542" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638886672225203542" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638886672225213541" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672225203542" xlink:to="us-gaap_AdditionalPaidInCapital_638886672225213541" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638886672225213541" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672225203542" xlink:to="us-gaap_CommonStockValue_638886672225213541" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638886672225213541" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672225203542" xlink:to="us-gaap_PreferredStockValue_638886672225213541" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638886672225213541" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638886672225213541" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="200200 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638886672225223478" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638886672225223478" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="us-gaap_IncomeLossAttributableToParent_638886672225223478" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeLossAttributableToParent_638886672225223478" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638886672225223478" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossAttributableToParent_638886672225223478" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638886672225223478" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638886672225223478" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossAttributableToParent_638886672225223478" xlink:to="us-gaap_OperatingIncomeLoss_638886672225223478" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638886672225223478" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638886672225223478" xlink:to="us-gaap_OperatingExpenses_638886672225223478" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638886672225233508" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638886672225223478" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638886672225233508" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638886672225233508" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638886672225223478" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638886672225233508" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672225233508" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638886672225223478" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672225233508" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows" xlink:type="extended" xlink:title="200400 - Statement - UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638886672225233508" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638886672225233508" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638886672225243445" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638886672225233508" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638886672225243445" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638886672225243445" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638886672225233508" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638886672225243445" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:label="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_638886672225243445" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638886672225233508" xlink:to="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_638886672225243445" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:label="carm_ProceedsFromFailedSaleLeasebackTransaction_638886672225243445" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638886672225233508" xlink:to="carm_ProceedsFromFailedSaleLeasebackTransaction_638886672225243445" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638886672225243445" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638886672225233508" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638886672225243445" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638886672225243445" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638886672225243445" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638886672225243445" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638886672225243445" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638886672225243445" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638886672225253438" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638886672225243445" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638886672225253438" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638886672225253438" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638886672225253438" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638886672225253438" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638886672225253438" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638886672225253438" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638886672225253438" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638886672225253438" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638886672225253438" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638886672225263544" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638886672225263544" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638886672225263544" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638886672225263544" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638886672225263544" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="us-gaap_DepreciationAndAmortization_638886672225263544" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638886672225263544" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="us-gaap_ShareBasedCompensation_638886672225263544" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638886672225263544" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638886672225263544" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_638886672225273442" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost_638886672225273442" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638886672225273442" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638886672225273442" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NoncashInterestExpense" xlink:label="carm_NoncashInterestExpense_638886672225273442" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="carm_NoncashInterestExpense_638886672225273442" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638886672225273442" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672225253438" xlink:to="us-gaap_NetIncomeLoss_638886672225273442" order="13" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss" xlink:type="extended" xlink:title="240303 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638886672225283450" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_LaborAndRelatedExpense_638886672225283450" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638886672225283450" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638886672225283450" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FacilitiesExpense" xlink:label="carm_FacilitiesExpense_638886672225283450" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="carm_FacilitiesExpense_638886672225283450" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:label="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_638886672225283450" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_638886672225283450" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:label="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_638886672225283450" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_638886672225283450" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672225283450" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672225283450" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:label="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_638886672225293155" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_638886672225293155" order="7" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss" xlink:type="extended" xlink:title="240401 - Disclosure - Prepaid Expenses and other assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_638886672225293155" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_638886672225293155" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PrepaidResearchAndDevelopmentCurrent" xlink:label="carm_PrepaidResearchAndDevelopmentCurrent_638886672225293155" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="carm_PrepaidResearchAndDevelopmentCurrent_638886672225293155" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="us-gaap_OtherReceivablesGrossCurrent_638886672225293155" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_638886672225293155" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638886672225343458" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_638886672225343458" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ReceivableDueFromCollaborativeArrangementCurrent" xlink:label="carm_ReceivableDueFromCollaborativeArrangementCurrent_638886672225353434" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="carm_ReceivableDueFromCollaborativeArrangementCurrent_638886672225353434" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638886672225353434" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638886672225353434" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss" xlink:type="extended" xlink:title="240501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638886672225353434" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638886672225353434" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638886672225353434" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638886672225353434" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="carm_AccruedResearchAndDevelopmentExpenseCurrent_638886672225363418" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="carm_AccruedResearchAndDevelopmentExpenseCurrent_638886672225363418" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638886672225363418" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638886672225363418" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss" xlink:type="extended" xlink:title="240602 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeaseCost" xlink:label="FinanceLeaseCost_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638886672225363418" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseCost_2" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638886672225363418" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638886672225363418" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseCost_2" xlink:to="us-gaap_FinanceLeaseInterestExpense_638886672225363418" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss" xlink:type="extended" xlink:title="240605 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638886672225363418" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638886672225363418" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638886672225373419" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability_638886672225373419" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638886672225373419" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638886672225373419" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638886672225373419" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638886672225373419" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638886672225373419" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638886672225373419" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_638886672225373419" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_638886672225373419" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638886672225383132" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638886672225383132" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638886672225383132" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638886672225383132" order="6" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>43
<FILENAME>tmb-20250331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/21/2025 4:00:26 AM-->
<!--Modified on: 7/21/2025 4:00:26 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" roleURI="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureBackgroundDetails" roleURI="http://carismatx.com/20241231/role/DisclosureBackgroundDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails" roleURI="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockholdersDeficitEquityDetails" roleURI="http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationNarrativeDetails" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity" roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureBackgroundDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureBackgroundDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockholdersEquityDetails" roleURI="http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationNarrativeDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://carismatx.com/20241231/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: IncomeStatementAbstract to ResearchAndDevelopmentExpense" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://carismatx.com/20241231/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="RestructuringPlanAxis" xlink:title="RestructuringPlanAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="RestructuringPlanDomain" xlink:title="RestructuringPlanDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringPlanAxis" xlink:to="RestructuringPlanDomain" xlink:title="definition: RestructuringPlanAxis to RestructuringPlanDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain" xlink:title="definition: TaxPeriodAxis to TaxPeriodDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="extended" xlink:title="100300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:label="carm_ReclassificationsOfTemporaryToPermanentEquityShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="carm_ReclassificationsOfTemporaryToPermanentEquityShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:label="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:label="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:label="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:label="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureBackgroundDetails" xlink:type="extended" xlink:title="140101 - Disclosure - Background (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="us-gaap_BusinessCombinationSegmentAllocationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="us-gaap_RestructuringCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="us-gaap_RestructuringReserve" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="140301 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="140302 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails" xlink:type="extended" xlink:title="140303 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ReportingSegmentMember" xlink:label="carm_ReportingSegmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="carm_ReportingSegmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:label="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:label="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FacilitiesExpense" xlink:label="carm_FacilitiesExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="carm_FacilitiesExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:label="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="140304 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails" xlink:type="extended" xlink:title="140401 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:label="carm_CarismaTherapeuticsIncLegacyStockholdersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="carm_CarismaTherapeuticsIncLegacyStockholdersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CarismaTherapeuticsInc.Member" xlink:label="carm_CarismaTherapeuticsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="carm_CarismaTherapeuticsInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfBoardMembers" xlink:label="carm_NumberOfBoardMembers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="carm_NumberOfBoardMembers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:label="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="140601 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionNetBookValue" xlink:label="us-gaap_SaleLeasebackTransactionNetBookValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SaleLeasebackTransactionNetBookValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:label="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="140801 - Disclosure - Commitments and Contingencies - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PennLicenseAgreementMember" xlink:label="carm_PennLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="carm_PennLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:label="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:label="carm_TrusteesOfUniversityOfPennsylvaniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="carm_TrusteesOfUniversityOfPennsylvaniaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" xlink:label="carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SaleAndLeasebackTransactionGainLossNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:label="carm_CommitmentsAnnualPaymentsRequiredToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="carm_CommitmentsAnnualPaymentsRequiredToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:label="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:label="carm_AdditionalMilestonePaymentsRequiredToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="carm_AdditionalMilestonePaymentsRequiredToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AdditionalMilestonePaymentsForTheFirstCARMProduct" xlink:label="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AgreementTerm" xlink:label="carm_AgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="carm_AgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTermination" xlink:label="us-gaap_LossOnContractTermination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossOnContractTermination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails" xlink:type="extended" xlink:title="140901 - Disclosure - Stockholders' (Deficit) Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AtTheMarketMember" xlink:label="carm_AtTheMarketMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="carm_AtTheMarketMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:label="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SaleOfStockStockOfferingAmount" xlink:label="carm_SaleOfStockStockOfferingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="carm_SaleOfStockStockOfferingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SaleOfStockMaximumOfferingAmount" xlink:label="carm_SaleOfStockMaximumOfferingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="carm_SaleOfStockMaximumOfferingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="141001 - Disclosure - Stock-based Compensation - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:label="carm_TwoThousandSeventeenStockIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="carm_TwoThousandSeventeenStockIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandFourteenStockIncentivePlanMember" xlink:label="carm_TwoThousandFourteenStockIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="carm_TwoThousandFourteenStockIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended" xlink:title="141003 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="141004 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SesenBioIncMember" xlink:label="carm_SesenBioIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="carm_SesenBioIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_RevisedOperatingPlanMember" xlink:label="carm_RevisedOperatingPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="carm_RevisedOperatingPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="141103 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_Pre2018Member" xlink:label="carm_Pre2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="carm_Pre2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_Post2017Member" xlink:label="carm_Post2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="carm_Post2017Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StateJurisdictionMember" xlink:label="carm_StateJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="carm_StateJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LocalJurisdictionMember" xlink:label="carm_LocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="carm_LocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails" xlink:type="extended" xlink:title="141301 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CollaborationAndLicenseAgreementMember" xlink:label="carm_CollaborationAndLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="carm_CollaborationAndLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ModernaLicenseAgreementMember" xlink:label="carm_ModernaLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="carm_ModernaLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ModernaMember" xlink:label="carm_ModernaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="carm_ModernaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ResearchAndDevelopmentServicesMember" xlink:label="carm_ResearchAndDevelopmentServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="carm_ResearchAndDevelopmentServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_OptionRightCollaborationRevenuesMember" xlink:label="carm_OptionRightCollaborationRevenuesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="carm_OptionRightCollaborationRevenuesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_MilestonesMember" xlink:label="carm_MilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="carm_MilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_MaximumNumberOfResearchTargets" xlink:label="carm_MaximumNumberOfResearchTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_MaximumNumberOfResearchTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedAutoimmune" xlink:label="carm_NumberOfResearchTargetsNominatedAutoimmune" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_NumberOfResearchTargetsNominatedAutoimmune" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsGrossOncology" xlink:label="carm_NumberOfResearchTargetsGrossOncology" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_NumberOfResearchTargetsGrossOncology" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_UpfrontNonRefundablePaymentReceived" xlink:label="carm_UpfrontNonRefundablePaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_UpfrontNonRefundablePaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPotentialProductsToDevelopAndCommercialize" xlink:label="carm_NumberOfPotentialProductsToDevelopAndCommercialize" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_NumberOfPotentialProductsToDevelopAndCommercialize" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:label="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:label="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:label="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPerformanceObligations" xlink:label="carm_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:label="carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPotentialResearchTargetDesignations" xlink:label="carm_NumberOfPotentialResearchTargetDesignations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_NumberOfPotentialResearchTargetDesignations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfOtherReceivables" xlink:label="us-gaap_ProceedsFromCollectionOfOtherReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollectionOfOtherReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_VariableConsideration" xlink:label="carm_VariableConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_VariableConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ContractTerm" xlink:label="carm_ContractTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_ContractTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="141401 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ModernaMember" xlink:label="carm_ModernaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="carm_ModernaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CollaborationAndLicenseAgreementMember" xlink:label="carm_CollaborationAndLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="carm_CollaborationAndLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RestructuringPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashPreservationPlan2025Member" xlink:label="carm_CashPreservationPlan2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="carm_CashPreservationPlan2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedOncology" xlink:label="carm_NumberOfResearchTargetsNominatedOncology" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="carm_NumberOfResearchTargetsNominatedOncology" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedReplacements" xlink:label="carm_NumberOfResearchTargetsNominatedReplacements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="carm_NumberOfResearchTargetsNominatedReplacements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsTerminatedOncology" xlink:label="carm_NumberOfResearchTargetsTerminatedOncology" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="carm_NumberOfResearchTargetsTerminatedOncology" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsTerminatedAutoimmune" xlink:label="carm_NumberOfResearchTargetsTerminatedAutoimmune" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="carm_NumberOfResearchTargetsTerminatedAutoimmune" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsGrossOncology" xlink:label="carm_NumberOfResearchTargetsGrossOncology" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="carm_NumberOfResearchTargetsGrossOncology" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfOtherReceivables" xlink:label="us-gaap_ProceedsFromCollectionOfOtherReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromCollectionOfOtherReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="extended" xlink:title="200300 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureBackgroundDetailss" xlink:type="extended" xlink:title="240101 - Disclosure - Background (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RestructuringPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashPreservationPlan2025Member" xlink:label="carm_CashPreservationPlan2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="carm_CashPreservationPlan2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="us-gaap_BusinessCombinationSegmentAllocationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="us-gaap_RestructuringCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss" xlink:type="extended" xlink:title="240301 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss" xlink:type="extended" xlink:title="240303 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ReportingSegmentMember" xlink:label="carm_ReportingSegmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="carm_ReportingSegmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:label="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:label="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FacilitiesExpense" xlink:label="carm_FacilitiesExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="carm_FacilitiesExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:label="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss" xlink:type="extended" xlink:title="240304 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss" xlink:type="extended" xlink:title="240601 - Disclosure - Commitments and Contingencies - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:label="carm_TrusteesOfUniversityOfPennsylvaniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="carm_TrusteesOfUniversityOfPennsylvaniaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PennLicenseAgreementMember" xlink:label="carm_PennLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="carm_PennLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:label="carm_CommitmentsAnnualPaymentsRequiredToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="carm_CommitmentsAnnualPaymentsRequiredToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:label="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:label="carm_AdditionalMilestonePaymentsRequiredToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="carm_AdditionalMilestonePaymentsRequiredToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AdditionalMilestonePaymentsForTheFirstCARMProduct" xlink:label="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="240701 - Disclosure - Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AtTheMarketMember" xlink:label="carm_AtTheMarketMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="carm_AtTheMarketMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SaleOfStockStockOfferingAmount" xlink:label="carm_SaleOfStockStockOfferingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="carm_SaleOfStockStockOfferingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SaleOfStockMaximumOfferingAmount" xlink:label="carm_SaleOfStockMaximumOfferingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="carm_SaleOfStockMaximumOfferingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss" xlink:type="extended" xlink:title="240801 - Disclosure - Stock-based Compensation - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:label="carm_TwoThousandSeventeenStockIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="carm_TwoThousandSeventeenStockIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandFourteenStockIncentivePlanMember" xlink:label="carm_TwoThousandFourteenStockIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="carm_TwoThousandFourteenStockIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashPreservationPlan2025Member" xlink:label="carm_CashPreservationPlan2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="carm_CashPreservationPlan2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss" xlink:type="extended" xlink:title="240803 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss" xlink:type="extended" xlink:title="240804 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss" xlink:type="extended" xlink:title="241001 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ModernaMember" xlink:label="carm_ModernaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="carm_ModernaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CollaborationAndLicenseAgreementMember" xlink:label="carm_CollaborationAndLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="carm_CollaborationAndLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ModernaLicenseAgreementMember" xlink:label="carm_ModernaLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="carm_ModernaLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ResearchAndDevelopmentServicesMember" xlink:label="carm_ResearchAndDevelopmentServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="carm_ResearchAndDevelopmentServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_OptionRightCollaborationRevenuesMember" xlink:label="carm_OptionRightCollaborationRevenuesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="carm_OptionRightCollaborationRevenuesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_MaximumNumberOfResearchTargets" xlink:label="carm_MaximumNumberOfResearchTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_MaximumNumberOfResearchTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsGrossOncology" xlink:label="carm_NumberOfResearchTargetsGrossOncology" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_NumberOfResearchTargetsGrossOncology" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_UpfrontNonRefundablePaymentReceived" xlink:label="carm_UpfrontNonRefundablePaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_UpfrontNonRefundablePaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPotentialProductsToDevelopAndCommercialize" xlink:label="carm_NumberOfPotentialProductsToDevelopAndCommercialize" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_NumberOfPotentialProductsToDevelopAndCommercialize" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:label="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPerformanceObligations" xlink:label="carm_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedOncology" xlink:label="carm_NumberOfResearchTargetsNominatedOncology" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_NumberOfResearchTargetsNominatedOncology" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedReplacements" xlink:label="carm_NumberOfResearchTargetsNominatedReplacements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_NumberOfResearchTargetsNominatedReplacements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsTerminatedOncology" xlink:label="carm_NumberOfResearchTargetsTerminatedOncology" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_NumberOfResearchTargetsTerminatedOncology" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsTerminatedAutoimmune" xlink:label="carm_NumberOfResearchTargetsTerminatedAutoimmune" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="carm_NumberOfResearchTargetsTerminatedAutoimmune" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>44
<FILENAME>tmb-20250331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/21/2025 4:00:26 AM-->
<!--Modified on: 7/21/2025 4:00:26 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Financial Position [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use assets - operating leases</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredFinancingCostsNoncurrent" xlink:label="carm_DeferredFinancingCostsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DeferredFinancingCostsNoncurrent" xlink:to="carm_DeferredFinancingCostsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DeferredFinancingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Financing Costs, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DeferredFinancingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Financing Costs, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_DeferredFinancingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' (Deficit) Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 6)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 8)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' deficit:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' (deficit) equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock $0.001 par value, 350,000,000 shares authorized, 41,788,096 and 41,750,109 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock $0.001 par value, 350,000,000 shares authorized, 41,750,109 and 40,609,915 shares issued and outstanding at December 31, 2024 and 2023, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity common stock, shares outstanding immediately after merger (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Comprehensive Income [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of derivative liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Nonoperating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share of common stock, basic (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share of common stock, diluted (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares of common stock outstanding, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares of common stock outstanding, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain on marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification to net loss of previous unrealized gain on marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: reclassification to net loss of previous unrealized gain on marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling interests</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:label="carm_ReclassificationsOfTemporaryToPermanentEquityShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:to="carm_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock classified as temporary equity reclassified or converted to permanent equity during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications of Temporary to Permanent Equity, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications of Temporary to Permanent Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock and non-controlling interests to common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' (Deficit) Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:label="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:to="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of stock issued during the period pursuant to pre-closing financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Pre-closing, Financing Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for cash in pre-closing financing (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:label="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:to="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued pursuant to preclosing financing during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Values, Pre-closing Financing Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for cash in pre-closing financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to Sesen Bio shareholders in reverse capitalization</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:label="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:to="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Preferred Stock and Non-controlling Interests Upon Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:label="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:to="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock and Non-controlling Interests Upon Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock and non-controlling interests to common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued in a pre-closing funding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock under Open Market Sales Agreement, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization, Nonproduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Gain) loss on sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in the operating right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt discount</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AccretionOnMarketableSecurities" xlink:label="carm_AccretionOnMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_AccretionOnMarketableSecurities" xlink:to="carm_AccretionOnMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_AccretionOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accretion on marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_AccretionOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion on Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="carm_AccretionOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion on marketable securities</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_WriteOffOfPropertyAndEquipment" xlink:label="carm_WriteOffOfPropertyAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_WriteOffOfPropertyAndEquipment" xlink:to="carm_WriteOffOfPropertyAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_WriteOffOfPropertyAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write-off of Property and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_WriteOffOfPropertyAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write-off of Property and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_WriteOffOfPropertyAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write-off of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Security, Realized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized gain on marketable securities</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NoncashInterestExpense" xlink:label="carm_NoncashInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NoncashInterestExpense" xlink:to="carm_NoncashInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NoncashInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to the increase (decrease) in interest expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NoncashInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NoncashInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest expense</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_GainLossOnSaleOfEquipment" xlink:label="carm_GainLossOnSaleOfEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_GainLossOnSaleOfEquipment" xlink:to="carm_GainLossOnSaleOfEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_GainLossOnSaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Sale of Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_GainLossOnSaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Sale of Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="carm_GainLossOnSaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on sale of equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:to="us-gaap_SaleAndLeasebackTransactionGainLossNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale and Leaseback Transaction, Gain (Loss), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on sale of sale-leaseback</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on sale of sale-leaseback</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of marketable securities</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PaymentsForProceedsFromMarketableSecurities" xlink:label="carm_PaymentsForProceedsFromMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_PaymentsForProceedsFromMarketableSecurities" xlink:to="carm_PaymentsForProceedsFromMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_PaymentsForProceedsFromMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The net cash paid (received) associated with the acquisition or disposal of all investments, including marketable securities and other assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_PaymentsForProceedsFromMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for (Proceeds from) Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="carm_PaymentsForProceedsFromMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the sale of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:label="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:to="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash, cash equivalents and restricted cash acquired associated with the reverse capitalization during the period .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Restricted Cash Acquired in Reverse Recapitalization, Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:label="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:to="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash outflow for payment of reverse recapitalization finance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Finance Costs, Reverse Recapitalization, Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of reverse recapitalization finance costs</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:label="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:to="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock, Pre-Closing Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock, Pre-Closing Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of common stock in pre-closing financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of principal related to finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:label="carm_ProceedsFromFailedSaleLeasebackTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:to="carm_ProceedsFromFailedSaleLeasebackTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ProceedsFromFailedSaleLeasebackTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash inflow received by a seller-lessee in a failed sale-leaseback recognized in financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ProceedsFromFailedSaleLeasebackTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Failed Sale Leaseback Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ProceedsFromFailedSaleLeasebackTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from failed sale-leaseback arrangement</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:label="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:to="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash outflow in a failed sale-leaseback recognized in financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Finance Liability, Failed Sale Leaseback Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of finance liability from failed sale-leaseback arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock under Open Market Sales Agreement, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents, and restricted cash at beginning of the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of non-cash financing and investing activities:</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:label="carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:to="carm_NoncashOrPartNoncashAcquisitionEquityAssumed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NoncashOrPartNoncashAcquisitionEquityAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of equity that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NoncashOrPartNoncashAcquisitionEquityAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash or Part Noncash Acquisition, Equity Assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NoncashOrPartNoncashAcquisitionEquityAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock and non-controlling interests upon Merger</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReduction" xlink:label="us-gaap_NotesReduction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReduction" xlink:to="us-gaap_NotesReduction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Reduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesReduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible promissory note, accrued interest and derivative liability upon Merger</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:label="carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:to="carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of unrealized gain (loss) on marketable securities in a noncash (or part noncash) transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash or Part Noncash, Unrealized Gain (Loss) on Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain on marketable securities</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" xlink:label="carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" xlink:to="carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash or Part Noncash Transaction, Reclassification of Debt Finance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash or Part Noncash Transaction, Reclassification of Debt Finance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of deferred financing costs to additional paid-in-capital</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability" xlink:label="carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability" xlink:to="carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Finance Leases Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets obtained in exchange for new financing lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" xlink:label="carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" xlink:to="carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Cash Effect of Modification of Operating Lease Right-of-Use Assets Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Cash Effect of Modification of Operating Lease Right-of-Use Assets Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Modification of operating lease right-of-use asset and operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" xlink:label="carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" xlink:to="carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal of property and equipment in exchange for reduction in financing lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Background</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:label="carm_DevelopmentStageRisksAndLiquidityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:to="carm_DevelopmentStageRisksAndLiquidityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DevelopmentStageRisksAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DevelopmentStageRisksAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development-Stage Risks and Liquidity</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DevelopmentStageRisksAndLiquidityTextBlock" xlink:label="carm_DevelopmentStageRisksAndLiquidityTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DevelopmentStageRisksAndLiquidityTextBlock" xlink:to="carm_DevelopmentStageRisksAndLiquidityTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DevelopmentStageRisksAndLiquidityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development-Stage Risks and Liquidity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DevelopmentStageRisksAndLiquidityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development-Stage Risks and Liquidity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_DevelopmentStageRisksAndLiquidityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development-Stage Risks and Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger with Sesen Bio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payables and Accruals [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' (Deficit) Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related-Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Moderna Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Financial Statements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of credit risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-lived Assets</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:label="carm_DeferredFinancingCostsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:to="carm_DeferredFinancingCostsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DeferredFinancingCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Financing Costs, Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DeferredFinancingCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Financing Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_DeferredFinancingCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Financing Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently issued accounting pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently adopted accounting pronouncements and Recently issued but not yet adopted accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value Hierarchy of Assets and Liabilities Measured on Recurring Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Significant Expense Categories by Segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Dilutive Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Net Assets Acquired in the Merger</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Prepaid Expenses and Other Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Lease Costs</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:label="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:to="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of ease term and discount rate information relating to operating and finance leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating and Finance Lease, Lease term and Discount Rate Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Lease Term and Discount Rate Information</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:to="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of supplemental cash flow information relating to operating and finance leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating and Finance Lease, Supplemental Cash flow Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Supplemental Cash Flow Information</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" xlink:label="carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" xlink:to="carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of undiscounted cash flows of lessee's operating lease liability and finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating and Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Maturities of Lease Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Estimated Using The Black-Scholes Option-Pricing Model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock-Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock-based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets for Federal Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:label="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:to="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of changes in deferred revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Changes in Deferred Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Changes in Deferred Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Restructuring [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Restructuring [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Severance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Severance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="us-gaap_BusinessCombinationSegmentAllocationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="us-gaap_BusinessCombinationSegmentAllocationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSegmentAllocationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Segment Allocation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationSegmentAllocationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Background</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in workforce, number of employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in workforce (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value hierarchy</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents - money markets accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger with Sesen Bio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, estimated useful lives (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Long-Lived Asset, Held-for-Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ReportingSegmentMember" xlink:label="carm_ReportingSegmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ReportingSegmentMember" xlink:to="carm_ReportingSegmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ReportingSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reporting Segment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ReportingSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reporting Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ReportingSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reporting Segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information, Additional Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less:</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:label="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:to="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development, Excluding Facilities, Personnel, Depreciation and Amortization Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development, Excluding Facilities, Personnel, Depreciation and Amortization Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development, excluding facilities, personnel, depreciation and amortization expenses</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:label="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:to="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative, Excluding Facilities And Personnel Expenses, Depreciation And Amortization Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative, Excluding Facilities And Personnel Expenses, Depreciation And Amortization Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FacilitiesExpense" xlink:label="carm_FacilitiesExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_FacilitiesExpense" xlink:to="carm_FacilitiesExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_FacilitiesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facilities Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_FacilitiesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facilities Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_FacilitiesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facilities expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Labor and Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel expense</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:label="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:to="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Amortization And Interest On Finance And Sale-Leaseback Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Amortization And Interest On Finance And Sale-Leaseback Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Other Segment Item, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other segment items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other segment items(a)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive securities (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:label="carm_CarismaTherapeuticsIncLegacyStockholdersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:to="carm_CarismaTherapeuticsIncLegacyStockholdersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_CarismaTherapeuticsIncLegacyStockholdersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the stockholders of legacy CARISMA Therapeutics, prior to the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_CarismaTherapeuticsIncLegacyStockholdersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CARISMA Therapeutics Inc, Legacy, Stockholders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_CarismaTherapeuticsIncLegacyStockholdersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CARISMA Therapeutics Inc, Legacy, Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CarismaTherapeuticsInc.Member" xlink:label="carm_CarismaTherapeuticsInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_CarismaTherapeuticsInc.Member" xlink:to="carm_CarismaTherapeuticsInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_CarismaTherapeuticsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Carisma Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_CarismaTherapeuticsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carisma Therapeutics Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_CarismaTherapeuticsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carisma Therapeutics Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Percentage of Voting Interests Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business acquisition percentage of voting interests acquired (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfBoardMembers" xlink:label="carm_NumberOfBoardMembers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NumberOfBoardMembers" xlink:to="carm_NumberOfBoardMembers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NumberOfBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NumberOfBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NumberOfBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of board seats</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:label="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:to="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of restricted cash from business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BusinessCombinationRecognizedIdentifiableAssetsAcquiredRestrictedCash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total net assets acquired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Transaction costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total net assets acquired less transaction costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance and personnel costs paid</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PrepaidResearchAndDevelopmentCurrent" xlink:label="carm_PrepaidResearchAndDevelopmentCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_PrepaidResearchAndDevelopmentCurrent" xlink:to="carm_PrepaidResearchAndDevelopmentCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_PrepaidResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Research and Development, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_PrepaidResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Research and Development, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_PrepaidResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ReceivableDueFromCollaborativeArrangementCurrent" xlink:label="carm_ReceivableDueFromCollaborativeArrangementCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ReceivableDueFromCollaborativeArrangementCurrent" xlink:to="carm_ReceivableDueFromCollaborativeArrangementCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ReceivableDueFromCollaborativeArrangementCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable due from Collaborative Arrangement, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ReceivableDueFromCollaborativeArrangementCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable due from Collaborative Arrangement, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ReceivableDueFromCollaborativeArrangementCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration receivable (Note 10)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="carm_ReceivableDueFromCollaborativeArrangementCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office furniture</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionNetBookValue" xlink:label="us-gaap_SaleLeasebackTransactionNetBookValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionNetBookValue" xlink:to="us-gaap_SaleLeasebackTransactionNetBookValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleLeasebackTransactionNetBookValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Leaseback Transaction, Net Book Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleLeasebackTransactionNetBookValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale lease-back asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease, ROU assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:label="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:to="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Leaseback Transaction, Accumulated Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale leaseback transaction, accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease, accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="carm_AccruedResearchAndDevelopmentExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="carm_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and related expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PennLicenseAgreementMember" xlink:label="carm_PennLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_PennLicenseAgreementMember" xlink:to="carm_PennLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_PennLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Penn License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_PennLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Penn License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_PennLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Penn License Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:label="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:to="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to manufacturing and supply agreement with Novartis Pharmaceuticals Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing and Supply Agreement with Novartis Pharmaceuticals Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:label="carm_TrusteesOfUniversityOfPennsylvaniaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:to="carm_TrusteesOfUniversityOfPennsylvaniaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_TrusteesOfUniversityOfPennsylvaniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Trustees of the University of Pennsylvania .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_TrusteesOfUniversityOfPennsylvaniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trustees of the University of Pennsylvania [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_TrusteesOfUniversityOfPennsylvaniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Penn</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" xlink:label="carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" xlink:to="carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Finance Lease, Liability, Lease Modification</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Finance Lease, Liability, Lease Modification</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in finance lease, liability, lease modification</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:label="carm_CommitmentsAnnualPaymentsRequiredToBePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:to="carm_CommitmentsAnnualPaymentsRequiredToBePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_CommitmentsAnnualPaymentsRequiredToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments Annual Payments Required To Be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_CommitmentsAnnualPaymentsRequiredToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments Annual Payments Required To Be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_CommitmentsAnnualPaymentsRequiredToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual payments to be made</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:label="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:to="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Payable upon Achievement of Certain Clinical, Regulatory and Commercial Milestone Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Payable upon Achievement of Certain Clinical, Regulatory and Commercial Milestone Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:label="carm_AdditionalMilestonePaymentsRequiredToBePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:to="carm_AdditionalMilestonePaymentsRequiredToBePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_AdditionalMilestonePaymentsRequiredToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Milestone Payments Required to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_AdditionalMilestonePaymentsRequiredToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Milestone Payments Required to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_AdditionalMilestonePaymentsRequiredToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional milestone payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AdditionalMilestonePaymentsForTheFirstCARMProduct" xlink:label="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct" xlink:to="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Milestone Payments for the First CAR-M Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Milestone Payments for the First CAR-M Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional milestone payments for first CAR-M product</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AgreementTerm" xlink:label="carm_AgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_AgreementTerm" xlink:to="carm_AgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_AgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_AgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_AgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTermination" xlink:label="us-gaap_LossOnContractTermination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossOnContractTermination" xlink:to="us-gaap_LossOnContractTermination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossOnContractTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on Contract Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossOnContractTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract termination fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Estimate of Possible Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss contingency, estimate of possible loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeaseCostAbstract" xlink:label="carm_FinanceLeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_FinanceLeaseCostAbstract" xlink:to="carm_FinanceLeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_FinanceLeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_FinanceLeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_FinanceLeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease cost:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of lease assets</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeasesInterestExpense" xlink:label="carm_FinanceLeasesInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_FinanceLeasesInterestExpense" xlink:to="carm_FinanceLeasesInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_FinanceLeasesInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of interest expense on finance lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_FinanceLeasesInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Leases, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_FinanceLeasesInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeaseCost" xlink:label="carm_FinanceLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_FinanceLeaseCost" xlink:to="carm_FinanceLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_FinanceLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of finance lease cost expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_FinanceLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="carm_FinanceLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total finance lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short term lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease cost</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:label="carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:to="carm_LeasesWeightedAverageRemainingLeaseTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_LeasesWeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_LeasesWeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases, Weighted Average Remaining Lease Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_LeasesWeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance leases</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LeasesWeightedAverageDiscountRateAbstract" xlink:label="carm_LeasesWeightedAverageDiscountRateAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_LeasesWeightedAverageDiscountRateAbstract" xlink:to="carm_LeasesWeightedAverageDiscountRateAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_LeasesWeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_LeasesWeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases, Weighted Average Discount Rate [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_LeasesWeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance leases</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash used in operating leases</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeasesInterestPaymentOnLiability" xlink:label="carm_FinanceLeasesInterestPaymentOnLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_FinanceLeasesInterestPaymentOnLiability" xlink:to="carm_FinanceLeasesInterestPaymentOnLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_FinanceLeasesInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of interest paid on finance lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_FinanceLeasesInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Leases, Interest Payment on Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_FinanceLeasesInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash used in finance leases</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinancingCashUsedInFinanceLeases" xlink:label="carm_FinancingCashUsedInFinanceLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_FinancingCashUsedInFinanceLeases" xlink:to="carm_FinancingCashUsedInFinanceLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_FinancingCashUsedInFinanceLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash outflow for payment on finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_FinancingCashUsedInFinanceLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing cash used in finance leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_FinancingCashUsedInFinanceLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing cash used in finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2029</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2029</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future minimum payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2029</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future minimum payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock, Class of Stock [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock, Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AtTheMarketMember" xlink:label="carm_AtTheMarketMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_AtTheMarketMember" xlink:to="carm_AtTheMarketMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_AtTheMarketMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At-the-Market</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_AtTheMarketMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At-the-Market [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_AtTheMarketMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At-the-Market</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue price per share (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:label="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:to="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock and Non-Controlling Interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued upon conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SaleOfStockStockOfferingAmount" xlink:label="carm_SaleOfStockStockOfferingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_SaleOfStockStockOfferingAmount" xlink:to="carm_SaleOfStockStockOfferingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_SaleOfStockStockOfferingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Stock Offering, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_SaleOfStockStockOfferingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Stock Offering, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_SaleOfStockStockOfferingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock offering, amount</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SaleOfStockMaximumOfferingAmount" xlink:label="carm_SaleOfStockMaximumOfferingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_SaleOfStockMaximumOfferingAmount" xlink:to="carm_SaleOfStockMaximumOfferingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_SaleOfStockMaximumOfferingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Maximum Offering Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_SaleOfStockMaximumOfferingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Maximum Offering Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_SaleOfStockMaximumOfferingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of stock, maximum aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales of stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received Per Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:label="carm_TwoThousandSeventeenStockIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:to="carm_TwoThousandSeventeenStockIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_TwoThousandSeventeenStockIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Two Thousand Seventeen Stock Incentive, a Legacy Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_TwoThousandSeventeenStockIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Seventeen Stock Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_TwoThousandSeventeenStockIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Seventeen Stock Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="carm_TwoThousandSeventeenStockIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017 Stock Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandFourteenStockIncentivePlanMember" xlink:label="carm_TwoThousandFourteenStockIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_TwoThousandFourteenStockIncentivePlanMember" xlink:to="carm_TwoThousandFourteenStockIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_TwoThousandFourteenStockIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Two Thousand Fourteen Stock Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_TwoThousandFourteenStockIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Fourteen Stock Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_TwoThousandFourteenStockIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Fourteen Stock Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="carm_TwoThousandFourteenStockIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2014 Stock Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:to="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Two Thousand Fourteen Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Fourteen Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Fourteen Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2014 Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terms (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount to the market price (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of March 31, 2025 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of December 31, 2024 (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based options forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable as of March 31, 2025 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable as of December 31, 2024 (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of March 31, 2025 (in USD per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of December 31, 2024 (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable as of March 31, 2025 (in USD per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable as of December 31, 2024 (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value (in USD per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant-date per share fair values granted (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of March 31, 2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable as of March 31, 2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable as of December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value (in thousands)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of March 31, 2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable as of March 31, 2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable as of December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SesenBioIncMember" xlink:label="carm_SesenBioIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_SesenBioIncMember" xlink:to="carm_SesenBioIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_SesenBioIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the entity Sesen Bio, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_SesenBioIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sesen Bio, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_SesenBioIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sesen Bio, Inc.</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_RevisedOperatingPlanMember" xlink:label="carm_RevisedOperatingPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_RevisedOperatingPlanMember" xlink:to="carm_RevisedOperatingPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_RevisedOperatingPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revised Operating Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_RevisedOperatingPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revised Operating Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_RevisedOperatingPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revised Operating Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future compensation cost for awards not vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average period compensation cost of unvested awards to be expensed (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal tax benefit at statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local tax, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local tax rate change</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Permanent Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Permanent Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating losses</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:label="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:to="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development costs, net of amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsStartUpCosts" xlink:label="carm_DeferredTaxAssetsStartUpCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DeferredTaxAssetsStartUpCosts" xlink:to="carm_DeferredTaxAssetsStartUpCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Start Up Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Start Up Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Start-up costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsLeaseLiability" xlink:label="carm_DeferredTaxAssetsLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DeferredTaxAssetsLeaseLiability" xlink:to="carm_DeferredTaxAssetsLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:label="carm_DeferredTaxAssetsAmortizableAssetsAndOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:to="carm_DeferredTaxAssetsAmortizableAssetsAndOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DeferredTaxAssetsAmortizableAssetsAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Amortizable Assets And Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DeferredTaxAssetsAmortizableAssetsAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Amortizable Assets And Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_DeferredTaxAssetsAmortizableAssetsAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortizable assets and other</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsEquityCompensation" xlink:label="carm_DeferredTaxAssetsEquityCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DeferredTaxAssetsEquityCompensation" xlink:to="carm_DeferredTaxAssetsEquityCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DeferredTaxAssetsEquityCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Equity Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DeferredTaxAssetsEquityCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Equity Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_DeferredTaxAssetsEquityCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets, net of valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="carm_DeferredTaxLiabilitiesRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="carm_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="carm_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_Pre2018Member" xlink:label="carm_Pre2018Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_Pre2018Member" xlink:to="carm_Pre2018Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_Pre2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_Pre2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_Pre2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-2018</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_Post2017Member" xlink:label="carm_Post2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_Post2017Member" xlink:to="carm_Post2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_Post2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Post-2017</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_Post2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Post-2017 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_Post2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Post-2017</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StateJurisdictionMember" xlink:label="carm_StateJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_StateJurisdictionMember" xlink:to="carm_StateJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_StateJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State Jurisdiction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_StateJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_StateJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LocalJurisdictionMember" xlink:label="carm_LocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_LocalJurisdictionMember" xlink:to="carm_LocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_LocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Jurisdiction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_LocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_LocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CollaborationAndLicenseAgreementMember" xlink:label="carm_CollaborationAndLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_CollaborationAndLicenseAgreementMember" xlink:to="carm_CollaborationAndLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ModernaLicenseAgreementMember" xlink:label="carm_ModernaLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ModernaLicenseAgreementMember" xlink:to="carm_ModernaLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ModernaLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to moderna license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ModernaLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Moderna License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ModernaLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Moderna License Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ModernaMember" xlink:label="carm_ModernaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ModernaMember" xlink:to="carm_ModernaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ModernaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Moderna, a significant shareholder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ModernaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Moderna [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ModernaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Moderna</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ResearchAndDevelopmentServicesMember" xlink:label="carm_ResearchAndDevelopmentServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ResearchAndDevelopmentServicesMember" xlink:to="carm_ResearchAndDevelopmentServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to research and development services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Services</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_OptionRightCollaborationRevenuesMember" xlink:label="carm_OptionRightCollaborationRevenuesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_OptionRightCollaborationRevenuesMember" xlink:to="carm_OptionRightCollaborationRevenuesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_OptionRightCollaborationRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Right Collaboration Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_OptionRightCollaborationRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Right Collaboration Revenues [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_OptionRightCollaborationRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Right Collaboration Revenues</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_MilestonesMember" xlink:label="carm_MilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_MilestonesMember" xlink:to="carm_MilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_MilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_MilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_MilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Moderna Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_MaximumNumberOfResearchTargets" xlink:label="carm_MaximumNumberOfResearchTargets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_MaximumNumberOfResearchTargets" xlink:to="carm_MaximumNumberOfResearchTargets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_MaximumNumberOfResearchTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of research targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_MaximumNumberOfResearchTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Number of Research Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_MaximumNumberOfResearchTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum of research targets</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedAutoimmune" xlink:label="carm_NumberOfResearchTargetsNominatedAutoimmune" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NumberOfResearchTargetsNominatedAutoimmune" xlink:to="carm_NumberOfResearchTargetsNominatedAutoimmune_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NumberOfResearchTargetsNominatedAutoimmune_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Targets Nominated, Autoimmune</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NumberOfResearchTargetsNominatedAutoimmune_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Targets Nominated, Autoimmune</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NumberOfResearchTargetsNominatedAutoimmune_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of nominated autoimmune target</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsGrossOncology" xlink:label="carm_NumberOfResearchTargetsGrossOncology" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NumberOfResearchTargetsGrossOncology" xlink:to="carm_NumberOfResearchTargetsGrossOncology_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NumberOfResearchTargetsGrossOncology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Targets, Gross, Oncology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NumberOfResearchTargetsGrossOncology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Targets, Gross, Oncology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NumberOfResearchTargetsGrossOncology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of oncology research targets</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_UpfrontNonRefundablePaymentReceived" xlink:label="carm_UpfrontNonRefundablePaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_UpfrontNonRefundablePaymentReceived" xlink:to="carm_UpfrontNonRefundablePaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_UpfrontNonRefundablePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront non-refundable payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_UpfrontNonRefundablePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Non-Refundable Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_UpfrontNonRefundablePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront non-refundable payment received</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPotentialProductsToDevelopAndCommercialize" xlink:label="carm_NumberOfPotentialProductsToDevelopAndCommercialize" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NumberOfPotentialProductsToDevelopAndCommercialize" xlink:to="carm_NumberOfPotentialProductsToDevelopAndCommercialize_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NumberOfPotentialProductsToDevelopAndCommercialize_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of potential products to develop and commercialize</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NumberOfPotentialProductsToDevelopAndCommercialize_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Potential Products to Develop and Commercialize</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NumberOfPotentialProductsToDevelopAndCommercialize_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of potential products to develop and commercialize</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:label="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:to="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount receivable per product in development target designation, development, regulatory and commercial milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Receivable Per Product in Development Target Designation, Development, Regulatory and Commercial Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount receivable per product</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:label="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:to="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum commitment to reimburse research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Commitment to Reimburse Research and Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum commitment to reimburse research and development costs</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:label="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:to="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of reimbursement of research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of Reimbursement of Research and Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of reimbursement of research and development costs (in years)</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPerformanceObligations" xlink:label="carm_NumberOfPerformanceObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NumberOfPerformanceObligations" xlink:to="carm_NumberOfPerformanceObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of performance obligations</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:label="carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:to="carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Rights and Obligations, Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Rights and Obligations, Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in contract with customer, liability</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPotentialResearchTargetDesignations" xlink:label="carm_NumberOfPotentialResearchTargetDesignations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NumberOfPotentialResearchTargetDesignations" xlink:to="carm_NumberOfPotentialResearchTargetDesignations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NumberOfPotentialResearchTargetDesignations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Potential Research Target Designations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NumberOfPotentialResearchTargetDesignations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Potential Research Target Designations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NumberOfPotentialResearchTargetDesignations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of potential research target designations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfOtherReceivables" xlink:label="us-gaap_ProceedsFromCollectionOfOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollectionOfOtherReceivables" xlink:to="us-gaap_ProceedsFromCollectionOfOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCollectionOfOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Collection of Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromCollectionOfOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from collection of collaboration receivable</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_VariableConsideration" xlink:label="carm_VariableConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_VariableConsideration" xlink:to="carm_VariableConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_VariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of variable consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_VariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_VariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable consideration</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ContractTerm" xlink:label="carm_ContractTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ContractTerm" xlink:to="carm_ContractTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ContractTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ContractTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ContractTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of contract (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent portion of deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationAbstract" xlink:label="us-gaap_RevenuePerformanceObligationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePerformanceObligationAbstract" xlink:to="us-gaap_RevenuePerformanceObligationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuePerformanceObligationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Performance Obligation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuePerformanceObligationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance obligations:</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:label="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:to="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transaction price allocated to research and development performance obligation that has not been recognized as revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Remaining Performance Obligation, Research and Development, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:label="carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:to="carm_RevenueRemainingPerformanceObligationOptionRightsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_RevenueRemainingPerformanceObligationOptionRightsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_RevenueRemainingPerformanceObligationOptionRightsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Remaining Performance Obligation, Option Rights, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_RevenueRemainingPerformanceObligationOptionRightsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Remaining Performance Obligation, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total performance obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInDeferredRevenueRollForward" xlink:label="us-gaap_MovementInDeferredRevenueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MovementInDeferredRevenueRollForward" xlink:to="us-gaap_MovementInDeferredRevenueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MovementInDeferredRevenueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Movement in Deferred Revenue [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MovementInDeferredRevenueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Movement in Deferred Revenue [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:label="carm_ContractWithCustomerLiabilityDeferralOfRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:to="carm_ContractWithCustomerLiabilityDeferralOfRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_ContractWithCustomerLiabilityDeferralOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of revenue deferred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_ContractWithCustomerLiabilityDeferralOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract With Customer Liability, Deferral of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_ContractWithCustomerLiabilityDeferralOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferral of revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognition of unearned revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Plan [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Plan [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Plan [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Plan [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashPreservationPlan2025Member" xlink:label="carm_CashPreservationPlan2025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_CashPreservationPlan2025Member" xlink:to="carm_CashPreservationPlan2025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_CashPreservationPlan2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Preservation Plan, 2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_CashPreservationPlan2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Preservation Plan, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_CashPreservationPlan2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Preservation Plan, 2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="carm_CashPreservationPlan2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 Cash Preservation Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedOncology" xlink:label="carm_NumberOfResearchTargetsNominatedOncology" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NumberOfResearchTargetsNominatedOncology" xlink:to="carm_NumberOfResearchTargetsNominatedOncology_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NumberOfResearchTargetsNominatedOncology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Targets Nominated, Oncology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NumberOfResearchTargetsNominatedOncology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Targets Nominated, Oncology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NumberOfResearchTargetsNominatedOncology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of oncology research targets, nominated</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedReplacements" xlink:label="carm_NumberOfResearchTargetsNominatedReplacements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NumberOfResearchTargetsNominatedReplacements" xlink:to="carm_NumberOfResearchTargetsNominatedReplacements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NumberOfResearchTargetsNominatedReplacements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Targets Nominated, Replacements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NumberOfResearchTargetsNominatedReplacements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Targets Nominated, Replacements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NumberOfResearchTargetsNominatedReplacements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of research targets, replacement nominations</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsTerminatedOncology" xlink:label="carm_NumberOfResearchTargetsTerminatedOncology" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NumberOfResearchTargetsTerminatedOncology" xlink:to="carm_NumberOfResearchTargetsTerminatedOncology_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NumberOfResearchTargetsTerminatedOncology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Targets, Terminated, Oncology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NumberOfResearchTargetsTerminatedOncology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Targets, Terminated, Oncology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NumberOfResearchTargetsTerminatedOncology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of oncology research targets, ceased development</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsTerminatedAutoimmune" xlink:label="carm_NumberOfResearchTargetsTerminatedAutoimmune" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_NumberOfResearchTargetsTerminatedAutoimmune" xlink:to="carm_NumberOfResearchTargetsTerminatedAutoimmune_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_NumberOfResearchTargetsTerminatedAutoimmune_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Targets, Terminated, Autoimmune</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_NumberOfResearchTargetsTerminatedAutoimmune_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Targets, Terminated, Autoimmune</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_NumberOfResearchTargetsTerminatedAutoimmune_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of nominated autoimmune target</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="carm_NumberOfResearchTargetsTerminatedAutoimmune_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of autoimmune research targets, ceased development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Expected Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected cost with the reduction in workforce</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Group, Including Discontinued Operation, Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="us-gaap_IncomeLossAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) Attributable to Parent, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-tax loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Debt Issuance Cost, Writeoff</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write-off of deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets obtained in exchange for new financing lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment in accounts payable</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DevelopmentStageRisksAndLiquidityTableTextBlock" xlink:label="carm_DevelopmentStageRisksAndLiquidityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_DevelopmentStageRisksAndLiquidityTableTextBlock" xlink:to="carm_DevelopmentStageRisksAndLiquidityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_DevelopmentStageRisksAndLiquidityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on risks of development-stage and liquidity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_DevelopmentStageRisksAndLiquidityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development-Stage Risks and Liquidity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_DevelopmentStageRisksAndLiquidityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development-Stage Risks and Liquidity</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AssetsHeldForSalePolicyPolicyTextBlock" xlink:label="carm_AssetsHeldForSalePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_AssetsHeldForSalePolicyPolicyTextBlock" xlink:to="carm_AssetsHeldForSalePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_AssetsHeldForSalePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Held-for-Sale, Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_AssetsHeldForSalePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Held-for-Sale, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_AssetsHeldForSalePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Held for Sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Expected Cost Remaining</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected remaining restructuring costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables, Gross, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Financial Position Location, Balance [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Financial Position Location, Balance [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Financial Position Location, Balance [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Financial Position Location, Balance [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesMember" xlink:to="us-gaap_AccruedLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Payment on Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash used in finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 (remaining nine months)</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, after Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 (remaining nine months)</label>
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:label="carm_FinanceLeaseLiabilityToBePaidAfterYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="carm_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="carm_FinanceLeaseLiabilityToBePaidAfterYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="carm_FinanceLeaseLiabilityToBePaidAfterYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, after Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="carm_FinanceLeaseLiabilityToBePaidAfterYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, after Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="carm_FinanceLeaseLiabilityToBePaidAfterYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, maximum</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>45
<FILENAME>tmb-20250331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/21/2025 4:00:26 AM-->
<!--Modified on: 7/21/2025 4:00:26 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DocumentCoverPage" roleURI="http://carismatx.com/20241231/role/DocumentCoverPage" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementConsolidatedBalanceSheets" roleURI="http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" roleURI="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureBackground" roleURI="http://carismatx.com/20241231/role/DisclosureBackground" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureDevelopmentStageRisksAndLiquidity" roleURI="http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureMergerWithSesenBio" roleURI="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBio" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePrepaidExpensesAndOtherAssets" roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureAccruedExpenses" roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockholdersDeficitEquity" roleURI="http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensation" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureIncomeTaxes" roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureRelatedPartyTransactions" roleURI="http://carismatx.com/20241231/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreement" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSubsequentEvents" roleURI="http://carismatx.com/20241231/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureMergerWithSesenBioTables" roleURI="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePrepaidExpensesAndOtherAssetsTables" roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureAccruedExpensesTables" roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationTables" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureIncomeTaxesTables" roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreementTables" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureBackgroundDetails" roleURI="http://carismatx.com/20241231/role/DisclosureBackgroundDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureDevelopmentStageRisksAndLiquidityDetails" roleURI="http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails" roleURI="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePrepaidExpensesAndOtherAssetsDetails" roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePropertyAndEquipmentNetNarrativeDetails" roleURI="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureAccruedExpensesDetails" roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetails" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockholdersDeficitEquityDetails" roleURI="http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationNarrativeDetails" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails" roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetails" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementUnauditedConsolidatedBalanceSheets" roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementUnauditedConsolidatedBalanceSheetsParenthetical" roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity" roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#StatementUnauditedConsolidatedStatementOfCashFlows" roleURI="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureBackgrounds" roleURI="http://carismatx.com/20241231/role/DisclosureBackgrounds" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureDevelopmentStageRisksAndLiquiditys" roleURI="http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquiditys" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciess" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePrepaidExpensesAndOtherAssetss" roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureAccruedExpensess" roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpensess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciess" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockholdersEquity" roleURI="http://carismatx.com/20241231/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensations" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureRelatedPartyTransactionss" roleURI="http://carismatx.com/20241231/role/DisclosureRelatedPartyTransactionss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreements" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSubsequentEventss" roleURI="http://carismatx.com/20241231/role/DisclosureSubsequentEventss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTabless" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePrepaidExpensesAndOtherAssetsTabless" roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureAccruedExpensesTabless" roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpensesTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesTabless" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationTabless" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreementTabless" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureBackgroundDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureBackgroundDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureDevelopmentStageRisksAndLiquidityDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosurePrepaidExpensesAndOtherAssetsDetailss" roleURI="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureAccruedExpensesDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockholdersEquityDetails" roleURI="http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationNarrativeDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20250331.xsd#DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetailss" roleURI="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DocumentCoverPage" xlink:type="extended" xlink:title="100090 - Document - Cover Page" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638886672226513767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638886672226513767" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638886672226513767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638886672226513767" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638886672226513767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638886672226513767" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638886672226513767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638886672226513767" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638886672226513767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638886672226513767" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638886672226513767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638886672226513767" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638886672226513767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638886672226513767" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="100100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638886672226523541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638886672226523541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638886672226523541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638886672226523541" xlink:to="us-gaap_AssetsCurrentAbstract_638886672226523541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638886672226523541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638886672226523541" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638886672226523541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638886672226523541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638886672226523541" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638886672226523541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638886672226523541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638886672226523541" xlink:to="us-gaap_AssetsCurrent_638886672226523541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638886672226523541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638886672226523541" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638886672226523541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638886672226533475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638886672226523541" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638886672226533475" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredFinancingCostsNoncurrent" xlink:label="carm_DeferredFinancingCostsNoncurrent_638886672226533475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638886672226523541" xlink:to="carm_DeferredFinancingCostsNoncurrent_638886672226533475" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638886672226533475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638886672226523541" xlink:to="us-gaap_Assets_638886672226533475" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672226533475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672226533475" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638886672226533475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672226533475" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638886672226533475" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638886672226533475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672226533475" xlink:to="us-gaap_AccountsPayableCurrent_638886672226533475" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638886672226533475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672226533475" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638886672226533475" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638886672226533475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672226533475" xlink:to="us-gaap_DeferredRevenueCurrent_638886672226533475" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638886672226533475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672226533475" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638886672226533475" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638886672226543145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672226533475" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638886672226543145" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638886672226543145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672226533475" xlink:to="us-gaap_OtherLiabilitiesCurrent_638886672226543145" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638886672226543145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672226533475" xlink:to="us-gaap_LiabilitiesCurrent_638886672226543145" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent_638886672226543145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672226533475" xlink:to="us-gaap_DeferredRevenueNoncurrent_638886672226543145" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638886672226543145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672226533475" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638886672226543145" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638886672226543145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672226533475" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638886672226543145" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638886672226543145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672226533475" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638886672226543145" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638886672226553097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672226533475" xlink:to="us-gaap_Liabilities_638886672226553097" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638886672226553097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672226533475" xlink:to="us-gaap_CommitmentsAndContingencies_638886672226553097" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226553097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672226533475" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226553097" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638886672226553097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226553097" xlink:to="us-gaap_PreferredStockValue_638886672226553097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638886672226553097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226553097" xlink:to="us-gaap_CommonStockValue_638886672226553097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638886672226553097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226553097" xlink:to="us-gaap_AdditionalPaidInCapital_638886672226553097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638886672226553097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226553097" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638886672226553097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672226563531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226553097" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672226563531" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638886672226563531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672226533475" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638886672226563531" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="100105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638886672226563531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638886672226563531" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638886672226563531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638886672226563531" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638886672226563531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638886672226563531" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638886672226563531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638886672226563531" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638886672226573444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638886672226573444" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638886672226573444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638886672226573444" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638886672226573444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638886672226573444" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638886672226573444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638886672226573444" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672226573444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672226573444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638886672226573444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638886672226573444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638886672226573444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638886672226573444" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638886672226573444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638886672226573444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638886672226573444" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638886672226573444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638886672226573444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638886672226573444" xlink:to="us-gaap_OperatingExpenses_638886672226573444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638886672226583613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638886672226583613" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_638886672226583613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_638886672226583613" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638886672226583613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638886672226583613" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638886672226583613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_638886672226583613" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638886672226583613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638886672226583613" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638886672226583613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638886672226583613" xlink:to="us-gaap_EarningsPerShareBasic_638886672226583613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638886672226583613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638886672226583613" xlink:to="us-gaap_EarningsPerShareDiluted_638886672226583613" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638886672226583613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638886672226583613" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638886672226583613" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638886672226583613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638886672226583613" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638886672226583613" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226593516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226593516" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638886672226593516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226593516" xlink:to="us-gaap_NetIncomeLoss_638886672226593516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638886672226593516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226593516" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638886672226593516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_638886672226593516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226593516" xlink:to="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_638886672226593516" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638886672226593516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672226593516" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638886672226593516" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="extended" xlink:title="100300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638886672226593516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638886672226593516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638886672226593516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638886672226593516" xlink:to="us-gaap_StatementEquityComponentsAxis_638886672226593516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638886672226603514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638886672226593516" xlink:to="us-gaap_CommonStockMember_638886672226603514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638886672226603514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638886672226593516" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638886672226603514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638886672226603514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638886672226593516" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638886672226603514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638886672226603514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638886672226593516" xlink:to="us-gaap_RetainedEarningsMember_638886672226603514" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember_638886672226603514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638886672226593516" xlink:to="us-gaap_NoncontrollingInterestMember_638886672226603514" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638886672226603514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638886672226593516" xlink:to="us-gaap_EquityComponentDomain_638886672226603514" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638886672226603514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638886672226593516" xlink:to="us-gaap_StatementLineItems_638886672226603514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638886672226603514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638886672226603514" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638886672226603514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_638886672226613464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638886672226603514" xlink:to="us-gaap_TemporaryEquitySharesIssued_638886672226613464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_638886672226613464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638886672226603514" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_638886672226613464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:label="carm_ReclassificationsOfTemporaryToPermanentEquityShares_638886672226613464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638886672226603514" xlink:to="carm_ReclassificationsOfTemporaryToPermanentEquityShares_638886672226613464" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_638886672226613464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638886672226603514" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_638886672226613464" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_6388866722266134641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638886672226603514" xlink:to="us-gaap_TemporaryEquitySharesIssued_6388866722266134641" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_6388866722266134641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638886672226603514" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_6388866722266134641" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638886672226603514" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638886672226613464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_SharesIssued_638886672226613464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672226613464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672226613464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638886672226623506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638886672226623506" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638886672226623506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638886672226623506" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638886672226623506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638886672226623506" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638886672226623506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638886672226623506" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_638886672226623506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_638886672226623506" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:label="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_638886672226623506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_638886672226623506" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:label="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_638886672226623506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_638886672226623506" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638886672226633529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638886672226633529" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638886672226633529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638886672226633529" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638886672226633529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638886672226633529" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_638886672226633529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_638886672226633529" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:label="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_638886672226633529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_638886672226633529" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:label="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_638886672226633529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_638886672226633529" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638886672226643439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638886672226643439" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638886672226643439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638886672226643439" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638886672226643439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_NetIncomeLoss_638886672226643439" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638886672226643439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_SharesIssued_638886672226643439" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672226643439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672226613464" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672226643439" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638886672226653525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="us-gaap_NetIncomeLoss_638886672226653525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638886672226653525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="us-gaap_DepreciationAndAmortization_638886672226653525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638886672226653525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638886672226653525" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638886672226653525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="us-gaap_ShareBasedCompensation_638886672226653525" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638886672226653525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638886672226653525" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638886672226663513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638886672226663513" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_638886672226663513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_638886672226663513" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AccretionOnMarketableSecurities" xlink:label="carm_AccretionOnMarketableSecurities_638886672226663513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="carm_AccretionOnMarketableSecurities_638886672226663513" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_WriteOffOfPropertyAndEquipment" xlink:label="carm_WriteOffOfPropertyAndEquipment_638886672226663513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="carm_WriteOffOfPropertyAndEquipment_638886672226663513" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_638886672226663513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_638886672226663513" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NoncashInterestExpense" xlink:label="carm_NoncashInterestExpense_638886672226663513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="carm_NoncashInterestExpense_638886672226663513" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_GainLossOnSaleOfEquipment" xlink:label="carm_GainLossOnSaleOfEquipment_638886672226663513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="carm_GainLossOnSaleOfEquipment_638886672226663513" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet_638886672226663513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="us-gaap_SaleAndLeasebackTransactionGainLossNet_638886672226663513" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672226663513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672226663513" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638886672226663513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672226663513" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638886672226663513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638886672226673442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672226663513" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638886672226673442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638886672226673442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672226663513" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638886672226673442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638886672226673442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672226663513" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638886672226673442" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638886672226673442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672226663513" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638886672226673442" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638886672226673442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672226663513" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638886672226673442" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672226673442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638886672226653525" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672226673442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638886672226673442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638886672226673442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638886672226673442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638886672226673442" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638886672226673442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PaymentsForProceedsFromMarketableSecurities" xlink:label="carm_PaymentsForProceedsFromMarketableSecurities_638886672226683511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638886672226673442" xlink:to="carm_PaymentsForProceedsFromMarketableSecurities_638886672226683511" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638886672226683511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638886672226673442" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638886672226683511" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638886672226683511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638886672226673442" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638886672226683511" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672226683511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672226683511" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:label="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_638886672226683511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672226683511" xlink:to="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_638886672226683511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:label="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_638886672226683511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672226683511" xlink:to="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_638886672226683511" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:label="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_638886672226683511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672226683511" xlink:to="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_638886672226683511" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638886672226693435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672226683511" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638886672226693435" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:label="carm_ProceedsFromFailedSaleLeasebackTransaction_638886672226693435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672226683511" xlink:to="carm_ProceedsFromFailedSaleLeasebackTransaction_638886672226693435" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:label="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_638886672226693435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672226683511" xlink:to="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_638886672226693435" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638886672226693435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672226683511" xlink:to="us-gaap_PaymentsOfFinancingCosts_638886672226693435" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638886672226693435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672226683511" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638886672226693435" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638886672226693435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672226683511" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638886672226693435" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638886672226703487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672226683511" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638886672226703487" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638886672226703487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638886672226703487" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638886672226703487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638886672226703487" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6388866722267034871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6388866722267034871" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638886672226703487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638886672226703487" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638886672226713548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638886672226703487" xlink:to="us-gaap_InterestPaidNet_638886672226713548" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672226713548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672226713548" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:label="carm_NoncashOrPartNoncashAcquisitionEquityAssumed_638886672226713548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672226713548" xlink:to="carm_NoncashOrPartNoncashAcquisitionEquityAssumed_638886672226713548" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReduction" xlink:label="us-gaap_NotesReduction_638886672226713548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672226713548" xlink:to="us-gaap_NotesReduction_638886672226713548" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:label="carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_638886672226713548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672226713548" xlink:to="carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_638886672226713548" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" xlink:label="carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts_638886672226713548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672226713548" xlink:to="carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts_638886672226713548" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability" xlink:label="carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability_638886672226723434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672226713548" xlink:to="carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability_638886672226723434" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638886672226723434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672226713548" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638886672226723434" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" xlink:label="carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities_638886672226723434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672226713548" xlink:to="carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities_638886672226723434" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" xlink:label="carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability_638886672226723434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672226713548" xlink:to="carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability_638886672226723434" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureBackground" xlink:type="extended" xlink:title="110101 - Disclosure - Background" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638886672226733483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638886672226733483" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidity" xlink:type="extended" xlink:title="110201 - Disclosure - Development-Stage Risks and Liquidity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:label="DevelopmentStageRisksAndLiquidityAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DevelopmentStageRisksAndLiquidityTextBlock" xlink:label="carm_DevelopmentStageRisksAndLiquidityTextBlock_638886672226733483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DevelopmentStageRisksAndLiquidityAbstract" xlink:to="carm_DevelopmentStageRisksAndLiquidityTextBlock_638886672226733483" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="110301 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638886672226733483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638886672226733483" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBio" xlink:type="extended" xlink:title="110401 - Disclosure - Merger with Sesen Bio" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="BusinessCombinationAndAssetAcquisitionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_638886672226793410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_638886672226793410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssets" xlink:type="extended" xlink:title="110501 - Disclosure - Prepaid Expenses and Other Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_638886672226793410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_638886672226793410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="110601 - Disclosure - Property and Equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638886672226793410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638886672226793410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="110701 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638886672226823429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638886672226823429" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="110801 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638886672226823429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638886672226823429" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquity" xlink:type="extended" xlink:title="110901 - Disclosure - Stockholders' (Deficit) Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638886672226823429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638886672226823429" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="111001 - Disclosure - Stock-based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638886672226833587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638886672226833587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="111101 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638886672226833587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638886672226833587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="111201 - Disclosure - Related-Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638886672226833587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638886672226833587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreement" xlink:type="extended" xlink:title="111301 - Disclosure - Moderna Collaboration and License Agreement" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638886672226833587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638886672226833587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="111401 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638886672226843542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638886672226843542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="120302 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638886672226843542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638886672226843542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638886672226843542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638886672226843542" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638886672226843542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638886672226843542" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638886672226853569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638886672226853569" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638886672226853569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638886672226853569" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638886672226853569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638886672226853569" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638886672226853569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638886672226853569" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638886672226853569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638886672226853569" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638886672226853569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638886672226853569" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638886672226853569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638886672226853569" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:label="carm_DeferredFinancingCostsPolicyPolicyTextBlock_638886672226853569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="carm_DeferredFinancingCostsPolicyPolicyTextBlock_638886672226853569" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638886672226853569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638886672226853569" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638886672226863154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638886672226863154" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638886672226863154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638886672226863154" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638886672226863154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638886672226863154" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638886672226863154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638886672226863154" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638886672226863154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638886672226863154" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="130303 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638886672226873148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638886672226873148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638886672226873148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638886672226873148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638886672226873148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638886672226873148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioTables" xlink:type="extended" xlink:title="130403 - Disclosure - Merger with Sesen Bio (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="BusinessCombinationAndAssetAcquisitionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_638886672226873148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_638886672226873148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTables" xlink:type="extended" xlink:title="130503 - Disclosure - Prepaid Expenses and Other Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638886672226873148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638886672226873148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="130603 - Disclosure - Property and Equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638886672226883470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638886672226883470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="130703 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638886672226883470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638886672226883470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="130803 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638886672226883470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638886672226883470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:label="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_638886672226893418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_638886672226893418" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_638886672226893418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_638886672226893418" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" xlink:label="carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_638886672226893418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_638886672226893418" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="131003 - Disclosure - Stock-based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638886672226893418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638886672226893418" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638886672226893418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638886672226893418" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638886672226893418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638886672226893418" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="131103 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638886672226893418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638886672226893418" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638886672226903595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638886672226903595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTables" xlink:type="extended" xlink:title="131303 - Disclosure - Moderna Collaboration and License Agreement (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_638886672226903595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_638886672226903595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:label="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_638886672226903595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_638886672226903595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureBackgroundDetails" xlink:type="extended" xlink:title="140101 - Disclosure - Background (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226903595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226903595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_638886672226903595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226903595" xlink:to="us-gaap_RestructuringCostAndReserveAxis_638886672226903595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_638886672226913149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis_638886672226903595" xlink:to="us-gaap_TypeOfRestructuringDomain_638886672226913149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember_638886672226913149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_638886672226913149" xlink:to="us-gaap_EmployeeSeveranceMember_638886672226913149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638886672226913149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226903595" xlink:to="us-gaap_IncomeStatementLocationAxis_638886672226913149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638886672226913149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638886672226913149" xlink:to="us-gaap_IncomeStatementLocationDomain_638886672226913149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638886672226913149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638886672226913149" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638886672226913149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638886672226913149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638886672226913149" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638886672226913149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="us-gaap_BusinessCombinationSegmentAllocationLineItems_638886672226913149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226903595" xlink:to="us-gaap_BusinessCombinationSegmentAllocationLineItems_638886672226913149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638886672226913149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems_638886672226913149" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638886672226913149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638886672226913149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems_638886672226913149" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638886672226913149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638886672226923441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems_638886672226913149" xlink:to="us-gaap_RestructuringCharges_638886672226923441" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638886672226923441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCharges_638886672226923441" xlink:to="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638886672226923441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve_638886672226923441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems_638886672226913149" xlink:to="us-gaap_RestructuringReserve_638886672226923441" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetails" xlink:type="extended" xlink:title="140201 - Disclosure - Development-Stage Risks and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:label="DevelopmentStageRisksAndLiquidityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638886672226923441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DevelopmentStageRisksAndLiquidityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638886672226923441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638886672226923441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DevelopmentStageRisksAndLiquidityAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638886672226923441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="140301 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638886672226923441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638886672226923441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638886672226933423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638886672226923441" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638886672226933423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638886672226933423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638886672226933423" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638886672226933423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638886672226933423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638886672226933423" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638886672226933423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638886672226933423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638886672226923441" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638886672226933423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638886672226933423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638886672226933423" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638886672226933423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638886672226933423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638886672226933423" xlink:to="us-gaap_FairValueInputsLevel1Member_638886672226933423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638886672226933423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638886672226933423" xlink:to="us-gaap_FairValueInputsLevel2Member_638886672226933423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638886672226933423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638886672226933423" xlink:to="us-gaap_FairValueInputsLevel3Member_638886672226933423" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638886672226933423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638886672226923441" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638886672226933423" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_638886672226933423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638886672226933423" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_638886672226933423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638886672226933423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638886672226933423" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638886672226933423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="140302 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226943456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226943456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638886672226943456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226943456" xlink:to="srt_RangeAxis_638886672226943456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638886672226943456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638886672226943456" xlink:to="srt_RangeMember_638886672226943456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638886672226943456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638886672226943456" xlink:to="srt_MinimumMember_638886672226943456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638886672226943456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638886672226943456" xlink:to="srt_MaximumMember_638886672226943456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638886672226943456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226943456" xlink:to="us-gaap_BusinessAcquisitionLineItems_638886672226943456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638886672226943456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226943456" xlink:to="us-gaap_NumberOfOperatingSegments_638886672226943456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638886672226943456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226943456" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638886672226943456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638886672226943456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226943456" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638886672226943456" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails" xlink:type="extended" xlink:title="140303 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638886672226953438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638886672226953438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638886672226953438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638886672226953438" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638886672226953438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638886672226953438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638886672226953438" xlink:to="us-gaap_SegmentDomain_638886672226953438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ReportingSegmentMember" xlink:label="carm_ReportingSegmentMember_638886672226953438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638886672226953438" xlink:to="carm_ReportingSegmentMember_638886672226953438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638886672226953438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638886672226953438" xlink:to="us-gaap_SegmentReportingInformationLineItems_638886672226953438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672226953438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638886672226953438" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672226953438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672226953438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638886672226953438" xlink:to="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672226953438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:label="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_638886672226963568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672226953438" xlink:to="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_638886672226963568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:label="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_638886672226963568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672226953438" xlink:to="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_638886672226963568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FacilitiesExpense" xlink:label="carm_FacilitiesExpense_638886672226963568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672226953438" xlink:to="carm_FacilitiesExpense_638886672226963568" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638886672226963568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672226953438" xlink:to="us-gaap_LaborAndRelatedExpense_638886672226963568" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:label="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_638886672226963568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672226953438" xlink:to="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_638886672226963568" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638886672226963568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672226953438" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638886672226963568" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638886672226963568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638886672226953438" xlink:to="us-gaap_NetIncomeLoss_638886672226963568" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="140304 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638886672226973591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638886672226973591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638886672226973591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638886672226973591" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638886672226973591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638886672226973591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638886672226973591" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638886672226973591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638886672226973591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638886672226973591" xlink:to="us-gaap_EmployeeStockOptionMember_638886672226973591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638886672226973591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638886672226973591" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638886672226973591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638886672226973591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638886672226973591" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638886672226973591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails" xlink:type="extended" xlink:title="140401 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="BusinessCombinationAndAssetAcquisitionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226973591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226973591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638886672226983645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226973591" xlink:to="us-gaap_BusinessAcquisitionAxis_638886672226983645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638886672226983645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638886672226983645" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638886672226983645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:label="carm_CarismaTherapeuticsIncLegacyStockholdersMember_638886672226983645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638886672226983645" xlink:to="carm_CarismaTherapeuticsIncLegacyStockholdersMember_638886672226983645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638886672226983645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226973591" xlink:to="dei_LegalEntityAxis_638886672226983645" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638886672226983645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638886672226983645" xlink:to="dei_EntityDomain_638886672226983645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CarismaTherapeuticsInc.Member" xlink:label="carm_CarismaTherapeuticsInc.Member_638886672226983645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638886672226983645" xlink:to="carm_CarismaTherapeuticsInc.Member_638886672226983645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638886672226983645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672226973591" xlink:to="us-gaap_BusinessAcquisitionLineItems_638886672226983645" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_638886672226983645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226983645" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_638886672226983645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfBoardMembers" xlink:label="carm_NumberOfBoardMembers_638886672226983645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226983645" xlink:to="carm_NumberOfBoardMembers_638886672226983645" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638886672226983645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226983645" xlink:to="us-gaap_CommonStockSharesOutstanding_638886672226983645" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_638886672226983645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226983645" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_638886672226983645" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_638886672226993532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226983645" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_638886672226993532" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_638886672226993532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226983645" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_638886672226993532" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:label="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_638886672226993532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226983645" xlink:to="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_638886672226993532" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_638886672226993532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226983645" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_638886672226993532" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_638886672226993532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226983645" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_638886672226993532" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_638886672226993532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226983645" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_638886672226993532" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_638886672226993532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226983645" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_638886672226993532" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1_638886672226993532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638886672226983645" xlink:to="us-gaap_SeveranceCosts1_638886672226993532" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" xlink:type="extended" xlink:title="140501 - Disclosure - Prepaid Expenses and Other Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PrepaidResearchAndDevelopmentCurrent" xlink:label="carm_PrepaidResearchAndDevelopmentCurrent_638886672227003542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="carm_PrepaidResearchAndDevelopmentCurrent_638886672227003542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ReceivableDueFromCollaborativeArrangementCurrent" xlink:label="carm_ReceivableDueFromCollaborativeArrangementCurrent_638886672227003542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="carm_ReceivableDueFromCollaborativeArrangementCurrent_638886672227003542" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638886672227003542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance_638886672227003542" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_638886672227003542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DepositsAssetsCurrent_638886672227003542" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638886672227003542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638886672227003542" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638886672227003542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638886672227003542" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="140601 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638886672227014250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638886672227014250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638886672227014250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638886672227014250" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638886672227014250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227014250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638886672227014250" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227014250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember_638886672227014250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227014250" xlink:to="us-gaap_SoftwareDevelopmentMember_638886672227014250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638886672227014250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227014250" xlink:to="us-gaap_EquipmentMember_638886672227014250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638886672227014250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227014250" xlink:to="us-gaap_FurnitureAndFixturesMember_638886672227014250" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638886672227014250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227014250" xlink:to="us-gaap_LeaseholdImprovementsMember_638886672227014250" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638886672227014250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227014250" xlink:to="us-gaap_ConstructionInProgressMember_638886672227014250" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638886672227023273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638886672227014250" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638886672227023273" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638886672227023273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638886672227023273" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638886672227023273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638886672227023273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638886672227023273" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638886672227023273" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638886672227023273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638886672227023273" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638886672227023273" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionNetBookValue" xlink:label="us-gaap_SaleLeasebackTransactionNetBookValue_638886672227023273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638886672227023273" xlink:to="us-gaap_SaleLeasebackTransactionNetBookValue_638886672227023273" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_638886672227023273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638886672227023273" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_638886672227023273" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:label="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_638886672227023273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638886672227023273" xlink:to="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_638886672227023273" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638886672227023273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638886672227023273" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638886672227023273" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetNarrativeDetails" xlink:type="extended" xlink:title="140602 - Disclosure - Property and Equipment, net - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638886672227033150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization_638886672227033150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="140701 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="carm_AccruedResearchAndDevelopmentExpenseCurrent_638886672227033150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="carm_AccruedResearchAndDevelopmentExpenseCurrent_638886672227033150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638886672227033150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638886672227033150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638886672227033150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638886672227033150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638886672227033150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638886672227033150" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638886672227043193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638886672227043193" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="140801 - Disclosure - Commitments and Contingencies - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_638886672227043193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable_638886672227043193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638886672227043193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638886672227043193" xlink:to="us-gaap_TypeOfArrangementAxis_638886672227043193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227043193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638886672227043193" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227043193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PennLicenseAgreementMember" xlink:label="carm_PennLicenseAgreementMember_638886672227043193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227043193" xlink:to="carm_PennLicenseAgreementMember_638886672227043193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:label="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_638886672227043193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227043193" xlink:to="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_638886672227043193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638886672227043193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638886672227043193" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638886672227043193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227043193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638886672227043193" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227043193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638886672227053164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227043193" xlink:to="us-gaap_EquipmentMember_638886672227053164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638886672227053164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638886672227043193" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638886672227053164" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638886672227053164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638886672227053164" xlink:to="us-gaap_RelatedPartyDomain_638886672227053164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:label="carm_TrusteesOfUniversityOfPennsylvaniaMember_638886672227053164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638886672227053164" xlink:to="carm_TrusteesOfUniversityOfPennsylvaniaMember_638886672227053164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638886672227053164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638886672227043193" xlink:to="srt_RangeAxis_638886672227053164" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638886672227053164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638886672227053164" xlink:to="srt_RangeMember_638886672227053164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638886672227053164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638886672227053164" xlink:to="srt_MaximumMember_638886672227053164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_638886672227053164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638886672227043193" xlink:to="us-gaap_LossContingenciesLineItems_638886672227053164" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" xlink:label="carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_638886672227053164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227053164" xlink:to="carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_638886672227053164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:label="us-gaap_SaleAndLeasebackTransactionGainLossNet_638886672227053164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227053164" xlink:to="us-gaap_SaleAndLeasebackTransactionGainLossNet_638886672227053164" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638886672227063166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227053164" xlink:to="us-gaap_FinanceLeaseLiability_638886672227063166" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:label="carm_CommitmentsAnnualPaymentsRequiredToBePaid_638886672227063166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227053164" xlink:to="carm_CommitmentsAnnualPaymentsRequiredToBePaid_638886672227063166" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:label="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_638886672227063166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227053164" xlink:to="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_638886672227063166" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:label="carm_AdditionalMilestonePaymentsRequiredToBePaid_638886672227063166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227053164" xlink:to="carm_AdditionalMilestonePaymentsRequiredToBePaid_638886672227063166" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AdditionalMilestonePaymentsForTheFirstCARMProduct" xlink:label="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct_638886672227063166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227053164" xlink:to="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct_638886672227063166" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AgreementTerm" xlink:label="carm_AgreementTerm_638886672227063166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227053164" xlink:to="carm_AgreementTerm_638886672227063166" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTermination" xlink:label="us-gaap_LossOnContractTermination_638886672227063166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227053164" xlink:to="us-gaap_LossOnContractTermination_638886672227063166" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638886672227063166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227053164" xlink:to="us-gaap_PrepaidExpenseCurrent_638886672227063166" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss_638886672227073146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227053164" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss_638886672227073146" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" xlink:type="extended" xlink:title="140802 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638886672227073146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost_638886672227073146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeaseCostAbstract" xlink:label="carm_FinanceLeaseCostAbstract_638886672227073146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_FinanceLeaseCostAbstract_638886672227073146" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638886672227073146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_FinanceLeaseCostAbstract_638886672227073146" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638886672227073146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeasesInterestExpense" xlink:label="carm_FinanceLeasesInterestExpense_638886672227073146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_FinanceLeaseCostAbstract_638886672227073146" xlink:to="carm_FinanceLeasesInterestExpense_638886672227073146" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeaseCost" xlink:label="carm_FinanceLeaseCost_638886672227083156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_FinanceLeaseCostAbstract_638886672227073146" xlink:to="carm_FinanceLeaseCost_638886672227083156" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638886672227083156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_FinanceLeaseCostAbstract_638886672227073146" xlink:to="us-gaap_VariableLeaseCost_638886672227083156" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_638886672227083156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_FinanceLeaseCostAbstract_638886672227073146" xlink:to="us-gaap_ShortTermLeaseCost_638886672227083156" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638886672227083156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCost_638886672227083156" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails" xlink:type="extended" xlink:title="140803 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:label="carm_LeasesWeightedAverageRemainingLeaseTermAbstract_638886672227083156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_LeasesWeightedAverageRemainingLeaseTermAbstract_638886672227083156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638886672227083156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_LeasesWeightedAverageRemainingLeaseTermAbstract_638886672227083156" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638886672227083156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638886672227093353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_LeasesWeightedAverageRemainingLeaseTermAbstract_638886672227083156" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638886672227093353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LeasesWeightedAverageDiscountRateAbstract" xlink:label="carm_LeasesWeightedAverageDiscountRateAbstract_638886672227093353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_LeasesWeightedAverageDiscountRateAbstract_638886672227093353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638886672227093353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_LeasesWeightedAverageDiscountRateAbstract_638886672227093353" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638886672227093353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638886672227093353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_LeasesWeightedAverageDiscountRateAbstract_638886672227093353" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638886672227093353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetails" xlink:type="extended" xlink:title="140804 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638886672227093353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638886672227093353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638886672227093353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638886672227093353" xlink:to="us-gaap_OperatingLeasePayments_638886672227093353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeasesInterestPaymentOnLiability" xlink:label="carm_FinanceLeasesInterestPaymentOnLiability_638886672227093353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638886672227093353" xlink:to="carm_FinanceLeasesInterestPaymentOnLiability_638886672227093353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinancingCashUsedInFinanceLeases" xlink:label="carm_FinancingCashUsedInFinanceLeases_638886672227103446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638886672227093353" xlink:to="carm_FinancingCashUsedInFinanceLeases_638886672227103446" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="140805 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227103446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227103446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638886672227103446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227103446" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638886672227103446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638886672227103446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227103446" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638886672227103446" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638886672227103446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227103446" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638886672227103446" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638886672227103446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227103446" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638886672227103446" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638886672227103446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227103446" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638886672227103446" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638886672227103446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227103446" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638886672227103446" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638886672227113183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227103446" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638886672227113183" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638886672227113183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227103446" xlink:to="us-gaap_OperatingLeaseLiability_638886672227113183" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227113183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227113183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638886672227113183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227113183" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638886672227113183" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638886672227113183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227113183" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638886672227113183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638886672227113183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227113183" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638886672227113183" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638886672227113183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227113183" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638886672227113183" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638886672227113183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227113183" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638886672227113183" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638886672227113183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227113183" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638886672227113183" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638886672227123523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227113183" xlink:to="us-gaap_FinanceLeaseLiability_638886672227123523" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails" xlink:type="extended" xlink:title="140901 - Disclosure - Stockholders' (Deficit) Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638886672227123523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_638886672227123523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638886672227123523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638886672227123523" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638886672227123523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638886672227123523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638886672227123523" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638886672227123523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AtTheMarketMember" xlink:label="carm_AtTheMarketMember_638886672227123523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638886672227123523" xlink:to="carm_AtTheMarketMember_638886672227123523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638886672227123523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638886672227123523" xlink:to="us-gaap_ClassOfStockLineItems_638886672227123523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638886672227123523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638886672227123523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638886672227123523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="us-gaap_SharesIssuedPricePerShare_638886672227123523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638886672227133461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638886672227133461" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638886672227133461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638886672227133461" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638886672227133461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638886672227133461" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:label="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_638886672227133461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_638886672227133461" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638886672227133461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638886672227133461" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SaleOfStockStockOfferingAmount" xlink:label="carm_SaleOfStockStockOfferingAmount_638886672227133461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="carm_SaleOfStockStockOfferingAmount_638886672227133461" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SaleOfStockMaximumOfferingAmount" xlink:label="carm_SaleOfStockMaximumOfferingAmount_638886672227133461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="carm_SaleOfStockMaximumOfferingAmount_638886672227133461" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638886672227133461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638886672227133461" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_638886672227133461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_638886672227133461" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638886672227133461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638886672227133461" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638886672227143607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="us-gaap_CommonStockSharesAuthorized_638886672227143607" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638886672227143607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="us-gaap_PreferredStockSharesAuthorized_638886672227143607" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638886672227143607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638886672227123523" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638886672227143607" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="141001 - Disclosure - Stock-based Compensation - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227143607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227143607" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638886672227173597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227143607" xlink:to="us-gaap_PlanNameAxis_638886672227173597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638886672227173597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638886672227173597" xlink:to="us-gaap_PlanNameDomain_638886672227173597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:label="carm_TwoThousandSeventeenStockIncentivePlanMember_638886672227173597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638886672227173597" xlink:to="carm_TwoThousandSeventeenStockIncentivePlanMember_638886672227173597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandFourteenStockIncentivePlanMember" xlink:label="carm_TwoThousandFourteenStockIncentivePlanMember_638886672227173597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638886672227173597" xlink:to="carm_TwoThousandFourteenStockIncentivePlanMember_638886672227173597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_638886672227173597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638886672227173597" xlink:to="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_638886672227173597" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638886672227173597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227143607" xlink:to="us-gaap_AwardTypeAxis_638886672227173597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638886672227173597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638886672227173597" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638886672227173597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638886672227173597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638886672227173597" xlink:to="us-gaap_EmployeeStockOptionMember_638886672227173597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227183160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227143607" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227183160" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638886672227183160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227183160" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638886672227183160" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638886672227183160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227183160" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638886672227183160" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638886672227183160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227183160" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638886672227183160" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_638886672227183160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227183160" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_638886672227183160" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:type="extended" xlink:title="141002 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227193123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227193123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638886672227193123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227193123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638886672227193123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638886672227193123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227193123" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638886672227193123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638886672227193123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227193123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638886672227193123" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638886672227193123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227193123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638886672227193123" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6388866722271931231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227193123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6388866722271931231" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638886672227193123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227193123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638886672227193123" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227193123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227193123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638886672227193123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227193123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638886672227193123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638886672227193123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227193123" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638886672227193123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638886672227203118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227193123" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638886672227203118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638886672227203118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227193123" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638886672227203118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638886672227203118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227193123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638886672227203118" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638886672227203118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227193123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638886672227203118" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638886672227203118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227193123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638886672227203118" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638886672227203118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638886672227203118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638886672227203118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638886672227203118" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638886672227203118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638886672227203118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638886672227203118" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638886672227203118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638886672227213160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638886672227213160" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638886672227213160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638886672227213160" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638886672227213160" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638886672227213160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638886672227213160" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638886672227213160" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638886672227213160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638886672227213160" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638886672227213160" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended" xlink:title="141003 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227213160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227213160" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638886672227213160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227213160" xlink:to="us-gaap_AwardTypeAxis_638886672227213160" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638886672227223485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638886672227213160" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638886672227223485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638886672227223485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638886672227223485" xlink:to="us-gaap_EmployeeStockOptionMember_638886672227223485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638886672227223485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227213160" xlink:to="srt_RangeAxis_638886672227223485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638886672227223485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638886672227223485" xlink:to="srt_RangeMember_638886672227223485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638886672227223485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638886672227223485" xlink:to="srt_MinimumMember_638886672227223485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638886672227223485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638886672227223485" xlink:to="srt_MaximumMember_638886672227223485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227223485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227213160" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227223485" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638886672227223485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227223485" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638886672227223485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638886672227223485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227223485" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638886672227223485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638886672227233451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227223485" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638886672227233451" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638886672227233451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227223485" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638886672227233451" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="141004 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638886672227233451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638886672227233451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638886672227233451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638886672227233451" xlink:to="us-gaap_IncomeStatementLocationAxis_638886672227233451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638886672227233451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638886672227233451" xlink:to="us-gaap_IncomeStatementLocationDomain_638886672227233451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638886672227233451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638886672227233451" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638886672227233451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638886672227243456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638886672227233451" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638886672227243456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638886672227243456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638886672227233451" xlink:to="us-gaap_BusinessAcquisitionAxis_638886672227243456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638886672227243456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638886672227243456" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638886672227243456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SesenBioIncMember" xlink:label="carm_SesenBioIncMember_638886672227243456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638886672227243456" xlink:to="carm_SesenBioIncMember_638886672227243456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638886672227243456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638886672227233451" xlink:to="us-gaap_PlanNameAxis_638886672227243456" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638886672227243456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638886672227243456" xlink:to="us-gaap_PlanNameDomain_638886672227243456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_RevisedOperatingPlanMember" xlink:label="carm_RevisedOperatingPlanMember_638886672227243456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638886672227243456" xlink:to="carm_RevisedOperatingPlanMember_638886672227243456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638886672227243456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638886672227233451" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638886672227243456" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638886672227243456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638886672227243456" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638886672227243456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638886672227253705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638886672227243456" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638886672227253705" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638886672227253705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638886672227243456" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638886672227253705" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638886672227253705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638886672227243456" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638886672227253705" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="141101 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638886672227253705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638886672227253705" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638886672227253705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638886672227253705" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_638886672227263347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_638886672227263347" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_638886672227263347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_638886672227263347" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638886672227263347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638886672227263347" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638886672227263347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638886672227263347" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638886672227263347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638886672227263347" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638886672227263347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638886672227263347" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails" xlink:type="extended" xlink:title="141102 - Disclosure - Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638886672227263347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638886672227263347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:label="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_638886672227273117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" xlink:to="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_638886672227273117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638886672227273117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638886672227273117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsStartUpCosts" xlink:label="carm_DeferredTaxAssetsStartUpCosts_638886672227273117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" xlink:to="carm_DeferredTaxAssetsStartUpCosts_638886672227273117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_638886672227273117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_638886672227273117" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsLeaseLiability" xlink:label="carm_DeferredTaxAssetsLeaseLiability_638886672227273117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" xlink:to="carm_DeferredTaxAssetsLeaseLiability_638886672227273117" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_638886672227273117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_638886672227273117" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:label="carm_DeferredTaxAssetsAmortizableAssetsAndOther_638886672227273117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" xlink:to="carm_DeferredTaxAssetsAmortizableAssetsAndOther_638886672227273117" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxAssetsEquityCompensation" xlink:label="carm_DeferredTaxAssetsEquityCompensation_638886672227273117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" xlink:to="carm_DeferredTaxAssetsEquityCompensation_638886672227273117" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638886672227273117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" xlink:to="us-gaap_DeferredTaxAssetsGross_638886672227273117" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638886672227273117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638886672227273117" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638886672227273117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638886672227263347" xlink:to="us-gaap_DeferredTaxAssetsNet_638886672227273117" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_638886672227283110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_638886672227283110" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="carm_DeferredTaxLiabilitiesRightOfUseAsset_638886672227283110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638886672227283110" xlink:to="carm_DeferredTaxLiabilitiesRightOfUseAsset_638886672227283110" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638886672227283110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638886672227283110" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638886672227283110" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638886672227283110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638886672227283110" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638886672227283110" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638886672227283110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638886672227283110" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638886672227283110" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="141103 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638886672227293649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638886672227293649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_638886672227293649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638886672227293649" xlink:to="us-gaap_TaxPeriodAxis_638886672227293649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_638886672227293649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis_638886672227293649" xlink:to="us-gaap_TaxPeriodDomain_638886672227293649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_Pre2018Member" xlink:label="carm_Pre2018Member_638886672227293649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain_638886672227293649" xlink:to="carm_Pre2018Member_638886672227293649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_Post2017Member" xlink:label="carm_Post2017Member_638886672227293649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain_638886672227293649" xlink:to="carm_Post2017Member_638886672227293649" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638886672227293649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638886672227293649" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638886672227293649" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638886672227293649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638886672227293649" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638886672227293649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638886672227293649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638886672227293649" xlink:to="us-gaap_DomesticCountryMember_638886672227293649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_StateJurisdictionMember" xlink:label="carm_StateJurisdictionMember_638886672227293649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638886672227293649" xlink:to="carm_StateJurisdictionMember_638886672227293649" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LocalJurisdictionMember" xlink:label="carm_LocalJurisdictionMember_638886672227293649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638886672227293649" xlink:to="carm_LocalJurisdictionMember_638886672227293649" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638886672227303462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638886672227293649" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638886672227303462" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638886672227303462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638886672227303462" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638886672227303462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638886672227303462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638886672227303462" xlink:to="us-gaap_ResearchMember_638886672227303462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638886672227303462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638886672227293649" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638886672227303462" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638886672227303462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638886672227303462" xlink:to="us-gaap_OperatingLossCarryforwards_638886672227303462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638886672227313161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638886672227303462" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638886672227313161" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638886672227313161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638886672227303462" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638886672227313161" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails" xlink:type="extended" xlink:title="141301 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672227313161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672227313161" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638886672227313161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672227313161" xlink:to="us-gaap_TypeOfArrangementAxis_638886672227313161" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227323450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638886672227313161" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227323450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CollaborationAndLicenseAgreementMember" xlink:label="carm_CollaborationAndLicenseAgreementMember_638886672227323450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227323450" xlink:to="carm_CollaborationAndLicenseAgreementMember_638886672227323450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ModernaLicenseAgreementMember" xlink:label="carm_ModernaLicenseAgreementMember_638886672227323450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227323450" xlink:to="carm_ModernaLicenseAgreementMember_638886672227323450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638886672227323450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672227313161" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638886672227323450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638886672227323450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638886672227323450" xlink:to="us-gaap_RelatedPartyDomain_638886672227323450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ModernaMember" xlink:label="carm_ModernaMember_638886672227323450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638886672227323450" xlink:to="carm_ModernaMember_638886672227323450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638886672227323450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672227313161" xlink:to="srt_RangeAxis_638886672227323450" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638886672227323450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638886672227323450" xlink:to="srt_RangeMember_638886672227323450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638886672227323450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638886672227323450" xlink:to="srt_MinimumMember_638886672227323450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638886672227333479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638886672227323450" xlink:to="srt_MaximumMember_638886672227333479" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638886672227333479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672227313161" xlink:to="srt_ProductOrServiceAxis_638886672227333479" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638886672227333479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638886672227333479" xlink:to="srt_ProductsAndServicesDomain_638886672227333479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ResearchAndDevelopmentServicesMember" xlink:label="carm_ResearchAndDevelopmentServicesMember_638886672227333479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638886672227333479" xlink:to="carm_ResearchAndDevelopmentServicesMember_638886672227333479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_OptionRightCollaborationRevenuesMember" xlink:label="carm_OptionRightCollaborationRevenuesMember_638886672227333479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638886672227333479" xlink:to="carm_OptionRightCollaborationRevenuesMember_638886672227333479" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_MilestonesMember" xlink:label="carm_MilestonesMember_638886672227333479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638886672227333479" xlink:to="carm_MilestonesMember_638886672227333479" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638886672227333479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672227313161" xlink:to="us-gaap_SubsequentEventTypeAxis_638886672227333479" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638886672227333479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638886672227333479" xlink:to="us-gaap_SubsequentEventTypeDomain_638886672227333479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638886672227333479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638886672227333479" xlink:to="us-gaap_SubsequentEventMember_638886672227333479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672227313161" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_MaximumNumberOfResearchTargets" xlink:label="carm_MaximumNumberOfResearchTargets_638886672227343401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_MaximumNumberOfResearchTargets_638886672227343401" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedAutoimmune" xlink:label="carm_NumberOfResearchTargetsNominatedAutoimmune_638886672227343401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_NumberOfResearchTargetsNominatedAutoimmune_638886672227343401" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsGrossOncology" xlink:label="carm_NumberOfResearchTargetsGrossOncology_638886672227343401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_NumberOfResearchTargetsGrossOncology_638886672227343401" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_UpfrontNonRefundablePaymentReceived" xlink:label="carm_UpfrontNonRefundablePaymentReceived_638886672227343401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_UpfrontNonRefundablePaymentReceived_638886672227343401" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPotentialProductsToDevelopAndCommercialize" xlink:label="carm_NumberOfPotentialProductsToDevelopAndCommercialize_638886672227343401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_NumberOfPotentialProductsToDevelopAndCommercialize_638886672227343401" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:label="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_638886672227343401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_638886672227343401" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:label="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_638886672227353119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_638886672227353119" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:label="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_638886672227353119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_638886672227353119" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPerformanceObligations" xlink:label="carm_NumberOfPerformanceObligations_638886672227353119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_NumberOfPerformanceObligations_638886672227353119" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:label="carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_638886672227353119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_638886672227353119" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638886672227353119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638886672227353119" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638886672227353119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="us-gaap_ContractWithCustomerLiability_638886672227353119" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638886672227363116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638886672227363116" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPotentialResearchTargetDesignations" xlink:label="carm_NumberOfPotentialResearchTargetDesignations_638886672227363116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_NumberOfPotentialResearchTargetDesignations_638886672227363116" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638886672227363116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="us-gaap_OtherReceivablesNetCurrent_638886672227363116" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfOtherReceivables" xlink:label="us-gaap_ProceedsFromCollectionOfOtherReceivables_638886672227363116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="us-gaap_ProceedsFromCollectionOfOtherReceivables_638886672227363116" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_VariableConsideration" xlink:label="carm_VariableConsideration_638886672227363116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_VariableConsideration_638886672227363116" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ContractTerm" xlink:label="carm_ContractTerm_638886672227373543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="carm_ContractTerm_638886672227373543" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672227373543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672227373543" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_638886672227373543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672227343401" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_638886672227373543" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails" xlink:type="extended" xlink:title="141302 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationAbstract" xlink:label="us-gaap_RevenuePerformanceObligationAbstract_638886672227373543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenuePerformanceObligationAbstract_638886672227373543" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:label="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_638886672227373543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuePerformanceObligationAbstract_638886672227373543" xlink:to="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_638886672227373543" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:label="carm_RevenueRemainingPerformanceObligationOptionRightsAmount_638886672227383460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuePerformanceObligationAbstract_638886672227373543" xlink:to="carm_RevenueRemainingPerformanceObligationOptionRightsAmount_638886672227383460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_638886672227383460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuePerformanceObligationAbstract_638886672227373543" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_638886672227383460" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetails" xlink:type="extended" xlink:title="141303 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInDeferredRevenueRollForward" xlink:label="us-gaap_MovementInDeferredRevenueRollForward_638886672227383460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_MovementInDeferredRevenueRollForward_638886672227383460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638886672227383460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInDeferredRevenueRollForward_638886672227383460" xlink:to="us-gaap_ContractWithCustomerLiability_638886672227383460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:label="carm_ContractWithCustomerLiabilityDeferralOfRevenue_638886672227383460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInDeferredRevenueRollForward_638886672227383460" xlink:to="carm_ContractWithCustomerLiabilityDeferralOfRevenue_638886672227383460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638886672227393153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInDeferredRevenueRollForward_638886672227383460" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638886672227393153" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638886672227393153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInDeferredRevenueRollForward_638886672227383460" xlink:to="us-gaap_ContractWithCustomerLiability_638886672227393153" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="141401 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638886672227393153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638886672227393153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638886672227393153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638886672227393153" xlink:to="us-gaap_SubsequentEventTypeAxis_638886672227393153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638886672227393153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638886672227393153" xlink:to="us-gaap_SubsequentEventTypeDomain_638886672227393153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638886672227393153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638886672227393153" xlink:to="us-gaap_SubsequentEventMember_638886672227393153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638886672227393153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638886672227393153" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638886672227393153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638886672227393153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638886672227393153" xlink:to="us-gaap_RelatedPartyDomain_638886672227393153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ModernaMember" xlink:label="carm_ModernaMember_638886672227403559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638886672227393153" xlink:to="carm_ModernaMember_638886672227403559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638886672227403559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638886672227393153" xlink:to="us-gaap_TypeOfArrangementAxis_638886672227403559" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227403559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638886672227403559" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227403559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CollaborationAndLicenseAgreementMember" xlink:label="carm_CollaborationAndLicenseAgreementMember_638886672227403559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227403559" xlink:to="carm_CollaborationAndLicenseAgreementMember_638886672227403559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_638886672227403559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638886672227393153" xlink:to="us-gaap_RestructuringCostAndReserveAxis_638886672227403559" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_638886672227403559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis_638886672227403559" xlink:to="us-gaap_TypeOfRestructuringDomain_638886672227403559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember_638886672227403559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_638886672227403559" xlink:to="us-gaap_EmployeeSeveranceMember_638886672227403559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis_638886672227403559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638886672227393153" xlink:to="us-gaap_RestructuringPlanAxis_638886672227403559" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_638886672227403559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis_638886672227403559" xlink:to="us-gaap_RestructuringPlanDomain_638886672227403559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashPreservationPlan2025Member" xlink:label="carm_CashPreservationPlan2025Member_638886672227413556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain_638886672227403559" xlink:to="carm_CashPreservationPlan2025Member_638886672227413556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638886672227413556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638886672227393153" xlink:to="us-gaap_SubsequentEventLineItems_638886672227413556" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedOncology" xlink:label="carm_NumberOfResearchTargetsNominatedOncology_638886672227413556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638886672227413556" xlink:to="carm_NumberOfResearchTargetsNominatedOncology_638886672227413556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedReplacements" xlink:label="carm_NumberOfResearchTargetsNominatedReplacements_638886672227413556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638886672227413556" xlink:to="carm_NumberOfResearchTargetsNominatedReplacements_638886672227413556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsTerminatedOncology" xlink:label="carm_NumberOfResearchTargetsTerminatedOncology_638886672227413556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638886672227413556" xlink:to="carm_NumberOfResearchTargetsTerminatedOncology_638886672227413556" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsTerminatedAutoimmune" xlink:label="carm_NumberOfResearchTargetsTerminatedAutoimmune_638886672227413556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638886672227413556" xlink:to="carm_NumberOfResearchTargetsTerminatedAutoimmune_638886672227413556" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsGrossOncology" xlink:label="carm_NumberOfResearchTargetsGrossOncology_638886672227413556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638886672227413556" xlink:to="carm_NumberOfResearchTargetsGrossOncology_638886672227413556" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfOtherReceivables" xlink:label="us-gaap_ProceedsFromCollectionOfOtherReceivables_638886672227413556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638886672227413556" xlink:to="us-gaap_ProceedsFromCollectionOfOtherReceivables_638886672227413556" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638886672227473384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638886672227413556" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638886672227473384" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638886672227483589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638886672227413556" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638886672227483589" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_638886672227483589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638886672227413556" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1_638886672227483589" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="200100 - Statement - UNAUDITED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638886672227483589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638886672227483589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638886672227483589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638886672227483589" xlink:to="us-gaap_AssetsCurrentAbstract_638886672227483589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638886672227483589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638886672227483589" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638886672227483589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638886672227493436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638886672227483589" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638886672227493436" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_638886672227493436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638886672227483589" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_638886672227493436" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638886672227493436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638886672227483589" xlink:to="us-gaap_AssetsCurrent_638886672227493436" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638886672227493436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638886672227483589" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638886672227493436" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638886672227493436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638886672227483589" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638886672227493436" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DeferredFinancingCostsNoncurrent" xlink:label="carm_DeferredFinancingCostsNoncurrent_638886672227493436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638886672227483589" xlink:to="carm_DeferredFinancingCostsNoncurrent_638886672227493436" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638886672227493436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638886672227483589" xlink:to="us-gaap_Assets_638886672227493436" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672227493436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672227493436" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638886672227493436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672227493436" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638886672227493436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638886672227493436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672227493436" xlink:to="us-gaap_AccountsPayableCurrent_638886672227493436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638886672227503532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672227493436" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638886672227503532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638886672227503532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672227493436" xlink:to="us-gaap_DeferredRevenueCurrent_638886672227503532" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638886672227503532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672227493436" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638886672227503532" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638886672227503532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672227493436" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638886672227503532" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638886672227503532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672227493436" xlink:to="us-gaap_OtherLiabilitiesCurrent_638886672227503532" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638886672227503532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638886672227493436" xlink:to="us-gaap_LiabilitiesCurrent_638886672227503532" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent_638886672227503532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672227493436" xlink:to="us-gaap_DeferredRevenueNoncurrent_638886672227503532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638886672227503532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672227493436" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638886672227503532" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638886672227513809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672227493436" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638886672227513809" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638886672227513809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672227493436" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638886672227513809" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638886672227513809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672227493436" xlink:to="us-gaap_Liabilities_638886672227513809" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638886672227513809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672227493436" xlink:to="us-gaap_CommitmentsAndContingencies_638886672227513809" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672227513809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672227493436" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672227513809" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638886672227513809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672227513809" xlink:to="us-gaap_PreferredStockValue_638886672227513809" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638886672227523449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672227513809" xlink:to="us-gaap_CommonStockValue_638886672227523449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638886672227523449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672227513809" xlink:to="us-gaap_AdditionalPaidInCapital_638886672227523449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638886672227523449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672227513809" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638886672227523449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672227523449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638886672227513809" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672227523449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638886672227523449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638886672227493436" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638886672227523449" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="200105 - Statement - UNAUDITED CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638886672227533572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638886672227533572" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638886672227533572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638886672227533572" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638886672227533572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638886672227533572" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638886672227533572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638886672227533572" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638886672227533572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638886672227533572" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638886672227533572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638886672227533572" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638886672227533572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638886672227533572" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638886672227533572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638886672227533572" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="200200 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672227543442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672227543442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638886672227543442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638886672227543442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638886672227543442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638886672227543442" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638886672227543442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638886672227543442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638886672227543442" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638886672227543442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638886672227543442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638886672227543442" xlink:to="us-gaap_OperatingExpenses_638886672227543442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638886672227543442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638886672227543442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638886672227543442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638886672227543442" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="us-gaap_IncomeLossAttributableToParent_638886672227543442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossAttributableToParent_638886672227543442" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638886672227553444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638886672227553444" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638886672227553444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_638886672227553444" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638886672227553444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638886672227553444" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638886672227553444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638886672227553444" xlink:to="us-gaap_EarningsPerShareBasic_638886672227553444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638886672227553444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638886672227553444" xlink:to="us-gaap_EarningsPerShareDiluted_638886672227553444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638886672227553444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638886672227553444" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638886672227553444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638886672227553444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638886672227553444" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638886672227553444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="extended" xlink:title="200300 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638886672227563484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638886672227563484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638886672227563484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638886672227563484" xlink:to="us-gaap_StatementEquityComponentsAxis_638886672227563484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638886672227563484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638886672227563484" xlink:to="us-gaap_CommonStockMember_638886672227563484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638886672227563484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638886672227563484" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638886672227563484" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638886672227563484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638886672227563484" xlink:to="us-gaap_RetainedEarningsMember_638886672227563484" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638886672227563484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638886672227563484" xlink:to="us-gaap_EquityComponentDomain_638886672227563484" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638886672227563484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638886672227563484" xlink:to="us-gaap_StatementLineItems_638886672227563484" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672227563484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638886672227563484" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672227563484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638886672227563484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672227563484" xlink:to="us-gaap_CommonStockSharesIssued_638886672227563484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672227573461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672227563484" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638886672227573461" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638886672227573461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672227563484" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638886672227573461" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638886672227573461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672227563484" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638886672227573461" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638886672227573461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672227563484" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638886672227573461" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638886672227573461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672227563484" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638886672227573461" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638886672227573461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672227563484" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638886672227573461" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638886672227573461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672227563484" xlink:to="us-gaap_NetIncomeLoss_638886672227573461" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638886672227573461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672227563484" xlink:to="us-gaap_CommonStockSharesIssued_638886672227573461" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6388866722275734611" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638886672227563484" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6388866722275734611" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows" xlink:type="extended" xlink:title="200400 - Statement - UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638886672227583454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" xlink:to="us-gaap_NetIncomeLoss_638886672227583454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638886672227583454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" xlink:to="us-gaap_DepreciationAndAmortization_638886672227583454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638886672227583454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" xlink:to="us-gaap_ShareBasedCompensation_638886672227583454" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638886672227583454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638886672227583454" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_638886672227583454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost_638886672227583454" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638886672227583454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638886672227583454" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NoncashInterestExpense" xlink:label="carm_NoncashInterestExpense_638886672227593545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" xlink:to="carm_NoncashInterestExpense_638886672227593545" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672227593545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672227593545" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638886672227593545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672227593545" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638886672227593545" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638886672227593545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672227593545" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638886672227593545" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638886672227593545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672227593545" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638886672227593545" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638886672227593545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672227593545" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638886672227593545" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638886672227593545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672227593545" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638886672227593545" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638886672227593545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638886672227593545" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638886672227593545" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672227593545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638886672227583454" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638886672227593545" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638886672227603579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638886672227603579" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638886672227603579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638886672227603579" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638886672227603579" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638886672227603579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638886672227603579" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638886672227603579" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638886672227603579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638886672227603579" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638886672227603579" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672227603579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672227603579" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638886672227603579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672227603579" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638886672227603579" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:label="carm_ProceedsFromFailedSaleLeasebackTransaction_638886672227603579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672227603579" xlink:to="carm_ProceedsFromFailedSaleLeasebackTransaction_638886672227603579" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:label="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_638886672227603579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672227603579" xlink:to="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_638886672227603579" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638886672227613546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672227603579" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638886672227613546" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638886672227613546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672227603579" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638886672227613546" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638886672227613546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638886672227603579" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638886672227613546" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638886672227613546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638886672227613546" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638886672227613546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638886672227613546" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6388866722276135461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6388866722276135461" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638886672227623446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638886672227623446" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638886672227623446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638886672227623446" xlink:to="us-gaap_InterestPaidNet_638886672227623446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672227623446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672227623446" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638886672227623446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672227623446" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638886672227623446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638886672227623446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672227623446" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638886672227623446" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638886672227633490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638886672227623446" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638886672227633490" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureBackgrounds" xlink:type="extended" xlink:title="210101 - Disclosure - Background" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638886672227633490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638886672227633490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquiditys" xlink:type="extended" xlink:title="210201 - Disclosure - Development-Stage Risks and Liquidity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:label="DevelopmentStageRisksAndLiquidityAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DevelopmentStageRisksAndLiquidityTableTextBlock" xlink:label="carm_DevelopmentStageRisksAndLiquidityTableTextBlock_638886672227643461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DevelopmentStageRisksAndLiquidityAbstract" xlink:to="carm_DevelopmentStageRisksAndLiquidityTableTextBlock_638886672227643461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciess" xlink:type="extended" xlink:title="210301 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638886672227643461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638886672227643461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetss" xlink:type="extended" xlink:title="210401 - Disclosure - Prepaid Expenses and other assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_638886672227643461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_638886672227643461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureAccruedExpensess" xlink:type="extended" xlink:title="210501 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638886672227653464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638886672227653464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciess" xlink:type="extended" xlink:title="210601 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638886672227663463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638886672227663463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="210701 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638886672227663463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638886672227663463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensations" xlink:type="extended" xlink:title="210801 - Disclosure - Stock-based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638886672227673649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638886672227673649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureRelatedPartyTransactionss" xlink:type="extended" xlink:title="210901 - Disclosure - Related-Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638886672227673649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638886672227673649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreements" xlink:type="extended" xlink:title="211001 - Disclosure - Moderna Collaboration and License Agreement" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638886672227673649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638886672227673649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSubsequentEventss" xlink:type="extended" xlink:title="211101 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638886672227683477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638886672227683477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" xlink:type="extended" xlink:title="220302 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638886672227683477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638886672227683477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638886672227693549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638886672227693549" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AssetsHeldForSalePolicyPolicyTextBlock" xlink:label="carm_AssetsHeldForSalePolicyPolicyTextBlock_638886672227693549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="carm_AssetsHeldForSalePolicyPolicyTextBlock_638886672227693549" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638886672227693549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638886672227693549" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638886672227693549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638886672227693549" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638886672227693549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638886672227693549" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638886672227693549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638886672227693549" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638886672227693549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638886672227693549" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638886672227693549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638886672227693549" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless" xlink:type="extended" xlink:title="230303 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638886672227703456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638886672227703456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638886672227703456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638886672227703456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638886672227703456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638886672227703456" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTabless" xlink:type="extended" xlink:title="230403 - Disclosure - Prepaid Expenses and other assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638886672227703456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638886672227703456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureAccruedExpensesTabless" xlink:type="extended" xlink:title="230503 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638886672227713474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638886672227713474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTabless" xlink:type="extended" xlink:title="230603 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638886672227713474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638886672227713474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:label="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_638886672227723594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_638886672227723594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_638886672227723594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_638886672227723594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" xlink:label="carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_638886672227723594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_638886672227723594" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTabless" xlink:type="extended" xlink:title="230803 - Disclosure - Stock-based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638886672227723594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638886672227723594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638886672227723594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638886672227723594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638886672227723594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638886672227723594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTabless" xlink:type="extended" xlink:title="231003 - Disclosure - Moderna Collaboration and License Agreement (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_638886672227733461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_638886672227733461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:label="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_638886672227733461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_638886672227733461" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureBackgroundDetailss" xlink:type="extended" xlink:title="240101 - Disclosure - Background (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672227733461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672227733461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_638886672227733461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672227733461" xlink:to="us-gaap_RestructuringCostAndReserveAxis_638886672227733461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_638886672227733461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis_638886672227733461" xlink:to="us-gaap_TypeOfRestructuringDomain_638886672227733461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember_638886672227733461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_638886672227733461" xlink:to="us-gaap_EmployeeSeveranceMember_638886672227733461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis_638886672227743455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672227733461" xlink:to="us-gaap_RestructuringPlanAxis_638886672227743455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_638886672227743455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis_638886672227743455" xlink:to="us-gaap_RestructuringPlanDomain_638886672227743455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashPreservationPlan2025Member" xlink:label="carm_CashPreservationPlan2025Member_638886672227743455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain_638886672227743455" xlink:to="carm_CashPreservationPlan2025Member_638886672227743455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="us-gaap_BusinessCombinationSegmentAllocationLineItems_638886672227743455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638886672227733461" xlink:to="us-gaap_BusinessCombinationSegmentAllocationLineItems_638886672227743455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638886672227743455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems_638886672227743455" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638886672227743455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638886672227743455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems_638886672227743455" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638886672227743455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638886672227743455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems_638886672227743455" xlink:to="us-gaap_RestructuringCharges_638886672227743455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_638886672227743455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSegmentAllocationLineItems_638886672227743455" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_638886672227743455" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetailss" xlink:type="extended" xlink:title="240201 - Disclosure - Development-Stage Risks and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:label="DevelopmentStageRisksAndLiquidityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638886672227753435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DevelopmentStageRisksAndLiquidityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638886672227753435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638886672227753435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DevelopmentStageRisksAndLiquidityAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638886672227753435" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss" xlink:type="extended" xlink:title="240301 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638886672227753435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638886672227753435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638886672227753435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638886672227753435" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638886672227753435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638886672227753435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638886672227753435" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638886672227753435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638886672227763164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638886672227753435" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638886672227763164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638886672227763164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638886672227753435" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638886672227763164" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638886672227763164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638886672227763164" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638886672227763164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638886672227763164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638886672227763164" xlink:to="us-gaap_FairValueInputsLevel1Member_638886672227763164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638886672227763164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638886672227763164" xlink:to="us-gaap_FairValueInputsLevel2Member_638886672227763164" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638886672227763164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638886672227763164" xlink:to="us-gaap_FairValueInputsLevel3Member_638886672227763164" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638886672227763164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638886672227753435" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638886672227763164" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_638886672227763164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638886672227763164" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_638886672227763164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638886672227763164" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638886672227763164" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638886672227763164" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetailss" xlink:type="extended" xlink:title="240302 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638886672227773546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_638886672227773546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss" xlink:type="extended" xlink:title="240303 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638886672227773546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638886672227773546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638886672227773546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638886672227773546" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638886672227773546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638886672227773546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638886672227773546" xlink:to="us-gaap_SegmentDomain_638886672227773546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ReportingSegmentMember" xlink:label="carm_ReportingSegmentMember_638886672227783448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638886672227773546" xlink:to="carm_ReportingSegmentMember_638886672227783448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638886672227783448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638886672227773546" xlink:to="us-gaap_SegmentReportingInformationLineItems_638886672227783448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672227783448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638886672227783448" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672227783448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672227783448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638886672227783448" xlink:to="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672227783448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:label="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_638886672227783448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672227783448" xlink:to="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_638886672227783448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:label="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_638886672227783448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672227783448" xlink:to="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_638886672227783448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FacilitiesExpense" xlink:label="carm_FacilitiesExpense_638886672227783448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672227783448" xlink:to="carm_FacilitiesExpense_638886672227783448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638886672227783448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672227783448" xlink:to="us-gaap_LaborAndRelatedExpense_638886672227783448" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:label="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_638886672227793551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672227783448" xlink:to="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_638886672227793551" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638886672227793551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638886672227783448" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638886672227793551" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638886672227793551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638886672227783448" xlink:to="us-gaap_NetIncomeLoss_638886672227793551" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss" xlink:type="extended" xlink:title="240304 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638886672227793551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638886672227793551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638886672227793551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638886672227793551" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638886672227793551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638886672227793551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638886672227793551" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638886672227793551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638886672227793551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638886672227793551" xlink:to="us-gaap_EmployeeStockOptionMember_638886672227793551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638886672227803459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638886672227793551" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638886672227803459" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638886672227803459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638886672227803459" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638886672227803459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss" xlink:type="extended" xlink:title="240401 - Disclosure - Prepaid Expenses and other assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PrepaidResearchAndDevelopmentCurrent" xlink:label="carm_PrepaidResearchAndDevelopmentCurrent_638886672227803459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="carm_PrepaidResearchAndDevelopmentCurrent_638886672227803459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ReceivableDueFromCollaborativeArrangementCurrent" xlink:label="carm_ReceivableDueFromCollaborativeArrangementCurrent_638886672227803459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="carm_ReceivableDueFromCollaborativeArrangementCurrent_638886672227803459" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="us-gaap_OtherReceivablesGrossCurrent_638886672227803459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherReceivablesGrossCurrent_638886672227803459" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_638886672227803459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DepositsAssetsCurrent_638886672227803459" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638886672227803459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance_638886672227803459" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638886672227813165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638886672227813165" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638886672227813165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638886672227813165" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss" xlink:type="extended" xlink:title="240501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="carm_AccruedResearchAndDevelopmentExpenseCurrent_638886672227813165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="carm_AccruedResearchAndDevelopmentExpenseCurrent_638886672227813165" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638886672227813165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638886672227813165" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638886672227813165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638886672227813165" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638886672227813165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638886672227813165" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638886672227813165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638886672227813165" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss" xlink:type="extended" xlink:title="240601 - Disclosure - Commitments and Contingencies - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_638886672227823486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable_638886672227823486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638886672227823486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638886672227823486" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638886672227823486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227823486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638886672227823486" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227823486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638886672227823486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638886672227823486" xlink:to="us-gaap_EquipmentMember_638886672227823486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638886672227823486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638886672227823486" xlink:to="us-gaap_BalanceSheetLocationAxis_638886672227823486" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638886672227823486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638886672227823486" xlink:to="us-gaap_BalanceSheetLocationDomain_638886672227823486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember_638886672227823486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638886672227823486" xlink:to="us-gaap_AccountsPayableMember_638886672227823486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember_638886672227823486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638886672227823486" xlink:to="us-gaap_AccruedLiabilitiesMember_638886672227823486" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638886672227833444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638886672227823486" xlink:to="us-gaap_RelatedPartyTransactionAxis_638886672227833444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638886672227833444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638886672227833444" xlink:to="us-gaap_RelatedPartyTransactionDomain_638886672227833444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:label="carm_TrusteesOfUniversityOfPennsylvaniaMember_638886672227833444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638886672227833444" xlink:to="carm_TrusteesOfUniversityOfPennsylvaniaMember_638886672227833444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638886672227833444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638886672227823486" xlink:to="us-gaap_TypeOfArrangementAxis_638886672227833444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227833444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638886672227833444" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227833444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_PennLicenseAgreementMember" xlink:label="carm_PennLicenseAgreementMember_638886672227833444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672227833444" xlink:to="carm_PennLicenseAgreementMember_638886672227833444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638886672227833444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638886672227823486" xlink:to="srt_RangeAxis_638886672227833444" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638886672227833444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638886672227833444" xlink:to="srt_RangeMember_638886672227833444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638886672227833444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638886672227833444" xlink:to="srt_MaximumMember_638886672227833444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_638886672227843444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638886672227823486" xlink:to="us-gaap_LossContingenciesLineItems_638886672227843444" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638886672227843444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227843444" xlink:to="us-gaap_FinanceLeaseLiability_638886672227843444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:label="carm_CommitmentsAnnualPaymentsRequiredToBePaid_638886672227843444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227843444" xlink:to="carm_CommitmentsAnnualPaymentsRequiredToBePaid_638886672227843444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:label="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_638886672227843444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227843444" xlink:to="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_638886672227843444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:label="carm_AdditionalMilestonePaymentsRequiredToBePaid_638886672227843444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227843444" xlink:to="carm_AdditionalMilestonePaymentsRequiredToBePaid_638886672227843444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AdditionalMilestonePaymentsForTheFirstCARMProduct" xlink:label="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct_638886672227843444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227843444" xlink:to="carm_AdditionalMilestonePaymentsForTheFirstCARMProduct_638886672227843444" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss_638886672227843444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638886672227843444" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss_638886672227843444" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss" xlink:type="extended" xlink:title="240602 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638886672227853524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost_638886672227853524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeaseCostAbstract" xlink:label="carm_FinanceLeaseCostAbstract_638886672227853524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_FinanceLeaseCostAbstract_638886672227853524" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638886672227853524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_FinanceLeaseCostAbstract_638886672227853524" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638886672227853524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638886672227853524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_FinanceLeaseCostAbstract_638886672227853524" xlink:to="us-gaap_FinanceLeaseInterestExpense_638886672227853524" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeaseCost" xlink:label="carm_FinanceLeaseCost_638886672227853524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_FinanceLeaseCostAbstract_638886672227853524" xlink:to="carm_FinanceLeaseCost_638886672227853524" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638886672227853524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_FinanceLeaseCostAbstract_638886672227853524" xlink:to="us-gaap_VariableLeaseCost_638886672227853524" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638886672227853524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCost_638886672227853524" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss" xlink:type="extended" xlink:title="240603 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:label="carm_LeasesWeightedAverageRemainingLeaseTermAbstract_638886672227873581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_LeasesWeightedAverageRemainingLeaseTermAbstract_638886672227873581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638886672227873581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_LeasesWeightedAverageRemainingLeaseTermAbstract_638886672227873581" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638886672227873581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638886672227873581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_LeasesWeightedAverageRemainingLeaseTermAbstract_638886672227873581" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638886672227873581" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LeasesWeightedAverageDiscountRateAbstract" xlink:label="carm_LeasesWeightedAverageDiscountRateAbstract_638886672227873581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_LeasesWeightedAverageDiscountRateAbstract_638886672227873581" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638886672227883537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_LeasesWeightedAverageDiscountRateAbstract_638886672227873581" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638886672227883537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638886672227883537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_LeasesWeightedAverageDiscountRateAbstract_638886672227873581" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638886672227883537" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetailss" xlink:type="extended" xlink:title="240604 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638886672227883537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638886672227883537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638886672227883537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638886672227883537" xlink:to="us-gaap_OperatingLeasePayments_638886672227883537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_638886672227883537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638886672227883537" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_638886672227883537" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinancingCashUsedInFinanceLeases" xlink:label="carm_FinancingCashUsedInFinanceLeases_638886672227883537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638886672227883537" xlink:to="carm_FinancingCashUsedInFinanceLeases_638886672227883537" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss" xlink:type="extended" xlink:title="240605 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227893477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227893477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638886672227893477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227893477" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638886672227893477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638886672227893477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227893477" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638886672227893477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638886672227893477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227893477" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638886672227893477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638886672227893477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227893477" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638886672227893477" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638886672227893477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227893477" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638886672227893477" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_638886672227903166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227893477" xlink:to="carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_638886672227903166" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638886672227903166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227893477" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638886672227903166" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638886672227903166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227893477" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638886672227903166" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638886672227903166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638886672227893477" xlink:to="us-gaap_OperatingLeaseLiability_638886672227903166" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227903166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227903166" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_638886672227903166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227903166" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_638886672227903166" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638886672227903166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227903166" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638886672227903166" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638886672227903166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227903166" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638886672227903166" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638886672227903166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227903166" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638886672227903166" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638886672227903166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227903166" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638886672227903166" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:label="carm_FinanceLeaseLiabilityToBePaidAfterYearFour_638886672227913447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227903166" xlink:to="carm_FinanceLeaseLiabilityToBePaidAfterYearFour_638886672227913447" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638886672227913447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227903166" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638886672227913447" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638886672227913447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227903166" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638886672227913447" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638886672227913447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638886672227903166" xlink:to="us-gaap_FinanceLeaseLiability_638886672227913447" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="240701 - Disclosure - Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_638886672227913447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_638886672227913447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638886672227923476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_638886672227913447" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638886672227923476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638886672227923476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638886672227923476" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638886672227923476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AtTheMarketMember" xlink:label="carm_AtTheMarketMember_638886672227923476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638886672227923476" xlink:to="carm_AtTheMarketMember_638886672227923476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_638886672227923476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_638886672227913447" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_638886672227923476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SaleOfStockStockOfferingAmount" xlink:label="carm_SaleOfStockStockOfferingAmount_638886672227923476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_638886672227923476" xlink:to="carm_SaleOfStockStockOfferingAmount_638886672227923476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_SaleOfStockMaximumOfferingAmount" xlink:label="carm_SaleOfStockMaximumOfferingAmount_638886672227923476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_638886672227923476" xlink:to="carm_SaleOfStockMaximumOfferingAmount_638886672227923476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638886672227923476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_638886672227923476" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638886672227923476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_638886672227923476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_638886672227923476" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_638886672227923476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss" xlink:type="extended" xlink:title="240801 - Disclosure - Stock-based Compensation - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227933449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227933449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638886672227933449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227933449" xlink:to="us-gaap_AwardTypeAxis_638886672227933449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638886672227933449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638886672227933449" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638886672227933449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638886672227933449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638886672227933449" xlink:to="us-gaap_EmployeeStockOptionMember_638886672227933449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638886672227933449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227933449" xlink:to="us-gaap_PlanNameAxis_638886672227933449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638886672227933449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638886672227933449" xlink:to="us-gaap_PlanNameDomain_638886672227933449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:label="carm_TwoThousandSeventeenStockIncentivePlanMember_638886672227933449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638886672227933449" xlink:to="carm_TwoThousandSeventeenStockIncentivePlanMember_638886672227933449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandFourteenStockIncentivePlanMember" xlink:label="carm_TwoThousandFourteenStockIncentivePlanMember_638886672227933449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638886672227933449" xlink:to="carm_TwoThousandFourteenStockIncentivePlanMember_638886672227933449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_638886672227943442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638886672227933449" xlink:to="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_638886672227943442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CashPreservationPlan2025Member" xlink:label="carm_CashPreservationPlan2025Member_638886672227943442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638886672227933449" xlink:to="carm_CashPreservationPlan2025Member_638886672227943442" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227943442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227933449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227943442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638886672227943442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227943442" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638886672227943442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638886672227943442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227943442" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638886672227943442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638886672227943442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227943442" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638886672227943442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_638886672227943442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227943442" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_638886672227943442" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638886672227953473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227943442" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638886672227953473" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638886672227953473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227943442" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638886672227953473" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638886672227953473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227943442" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638886672227953473" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638886672227953473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227943442" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638886672227953473" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss" xlink:type="extended" xlink:title="240802 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227964020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227964020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638886672227964020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227964020" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638886672227964020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638886672227964020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227964020" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638886672227964020" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638886672227964020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227964020" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638886672227964020" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638886672227964020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227964020" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638886672227964020" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6388866722279640201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227964020" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6388866722279640201" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638886672227964020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638886672227964020" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638886672227964020" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227964020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227964020" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638886672227973460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227964020" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638886672227973460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638886672227973460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227964020" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638886672227973460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638886672227973460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227964020" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638886672227973460" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638886672227973460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227964020" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638886672227973460" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6388866722279734601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227964020" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6388866722279734601" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638886672227973460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638886672227964020" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638886672227973460" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638886672227973460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638886672227973460" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638886672227973460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638886672227973460" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638886672227973460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638886672227973460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638886672227973460" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638886672227973460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638886672227983469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638886672227983469" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638886672227983469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638886672227983469" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638886672227983469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638886672227983469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638886672227983469" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638886672227983469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638886672227983469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_638886672227983469" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638886672227983469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss" xlink:type="extended" xlink:title="240803 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227993466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227993466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638886672227993466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227993466" xlink:to="us-gaap_AwardTypeAxis_638886672227993466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638886672227993466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638886672227993466" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638886672227993466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638886672227993466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638886672227993466" xlink:to="us-gaap_EmployeeStockOptionMember_638886672227993466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227993466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638886672227993466" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227993466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638886672227993466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227993466" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638886672227993466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638886672227993466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227993466" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638886672227993466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638886672227993466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227993466" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638886672227993466" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638886672227993466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227993466" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638886672227993466" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638886672227993466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227993466" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638886672227993466" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638886672227993466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638886672227993466" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638886672227993466" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss" xlink:type="extended" xlink:title="240804 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638886672228003464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638886672228003464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638886672228003464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638886672228003464" xlink:to="us-gaap_IncomeStatementLocationAxis_638886672228003464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638886672228003464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638886672228003464" xlink:to="us-gaap_IncomeStatementLocationDomain_638886672228003464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638886672228003464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638886672228003464" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638886672228003464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638886672228003464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638886672228003464" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638886672228003464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638886672228003464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638886672228003464" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638886672228003464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638886672228003464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638886672228003464" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638886672228003464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss" xlink:type="extended" xlink:title="241001 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672228013461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672228013461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638886672228013461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672228013461" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638886672228013461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638886672228013461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638886672228013461" xlink:to="us-gaap_RelatedPartyDomain_638886672228013461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ModernaMember" xlink:label="carm_ModernaMember_638886672228013461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638886672228013461" xlink:to="carm_ModernaMember_638886672228013461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638886672228013461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672228013461" xlink:to="us-gaap_TypeOfArrangementAxis_638886672228013461" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672228013461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638886672228013461" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672228013461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_CollaborationAndLicenseAgreementMember" xlink:label="carm_CollaborationAndLicenseAgreementMember_638886672228013461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672228013461" xlink:to="carm_CollaborationAndLicenseAgreementMember_638886672228013461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ModernaLicenseAgreementMember" xlink:label="carm_ModernaLicenseAgreementMember_638886672228013461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638886672228013461" xlink:to="carm_ModernaLicenseAgreementMember_638886672228013461" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638886672228023166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672228013461" xlink:to="srt_ProductOrServiceAxis_638886672228023166" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638886672228023166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638886672228023166" xlink:to="srt_ProductsAndServicesDomain_638886672228023166" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ResearchAndDevelopmentServicesMember" xlink:label="carm_ResearchAndDevelopmentServicesMember_638886672228023166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638886672228023166" xlink:to="carm_ResearchAndDevelopmentServicesMember_638886672228023166" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_OptionRightCollaborationRevenuesMember" xlink:label="carm_OptionRightCollaborationRevenuesMember_638886672228023166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638886672228023166" xlink:to="carm_OptionRightCollaborationRevenuesMember_638886672228023166" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638886672228023166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672228013461" xlink:to="srt_RangeAxis_638886672228023166" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638886672228023166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638886672228023166" xlink:to="srt_RangeMember_638886672228023166" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638886672228023166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638886672228023166" xlink:to="srt_MinimumMember_638886672228023166" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638886672228023166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638886672228023166" xlink:to="srt_MaximumMember_638886672228023166" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638886672228013461" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_MaximumNumberOfResearchTargets" xlink:label="carm_MaximumNumberOfResearchTargets_638886672228033162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="carm_MaximumNumberOfResearchTargets_638886672228033162" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsGrossOncology" xlink:label="carm_NumberOfResearchTargetsGrossOncology_638886672228033162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="carm_NumberOfResearchTargetsGrossOncology_638886672228033162" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_UpfrontNonRefundablePaymentReceived" xlink:label="carm_UpfrontNonRefundablePaymentReceived_638886672228033162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="carm_UpfrontNonRefundablePaymentReceived_638886672228033162" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPotentialProductsToDevelopAndCommercialize" xlink:label="carm_NumberOfPotentialProductsToDevelopAndCommercialize_638886672228033162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="carm_NumberOfPotentialProductsToDevelopAndCommercialize_638886672228033162" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:label="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_638886672228033162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_638886672228033162" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfPerformanceObligations" xlink:label="carm_NumberOfPerformanceObligations_638886672228033162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="carm_NumberOfPerformanceObligations_638886672228033162" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638886672228033162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638886672228033162" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672228043465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_638886672228043465" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedOncology" xlink:label="carm_NumberOfResearchTargetsNominatedOncology_638886672228043465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="carm_NumberOfResearchTargetsNominatedOncology_638886672228043465" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsNominatedReplacements" xlink:label="carm_NumberOfResearchTargetsNominatedReplacements_638886672228043465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="carm_NumberOfResearchTargetsNominatedReplacements_638886672228043465" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsTerminatedOncology" xlink:label="carm_NumberOfResearchTargetsTerminatedOncology_638886672228043465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="carm_NumberOfResearchTargetsTerminatedOncology_638886672228043465" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_NumberOfResearchTargetsTerminatedAutoimmune" xlink:label="carm_NumberOfResearchTargetsTerminatedAutoimmune_638886672228043465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="carm_NumberOfResearchTargetsTerminatedAutoimmune_638886672228043465" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_638886672228043465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638886672228033162" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_638886672228043465" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetailss" xlink:type="extended" xlink:title="241002 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationAbstract" xlink:label="us-gaap_RevenuePerformanceObligationAbstract_638886672228053479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenuePerformanceObligationAbstract_638886672228053479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:label="carm_RevenueRemainingPerformanceObligationOptionRightsAmount_638886672228053479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuePerformanceObligationAbstract_638886672228053479" xlink:to="carm_RevenueRemainingPerformanceObligationOptionRightsAmount_638886672228053479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetailss" xlink:type="extended" xlink:title="241003 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInDeferredRevenueRollForward" xlink:label="us-gaap_MovementInDeferredRevenueRollForward_638886672228063436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_MovementInDeferredRevenueRollForward_638886672228063436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638886672228063436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInDeferredRevenueRollForward_638886672228063436" xlink:to="us-gaap_ContractWithCustomerLiability_638886672228063436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20250331.xsd#carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:label="carm_ContractWithCustomerLiabilityDeferralOfRevenue_638886672228063436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInDeferredRevenueRollForward_638886672228063436" xlink:to="carm_ContractWithCustomerLiabilityDeferralOfRevenue_638886672228063436" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638886672228063436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInDeferredRevenueRollForward_638886672228063436" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638886672228063436" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_6388866722280634361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInDeferredRevenueRollForward_638886672228063436" xlink:to="us-gaap_ContractWithCustomerLiability_6388866722280634361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CARISMA THERAPEUTICS&#160;INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001485003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,740<span></span>
</td>
<td class="nump">$ 17,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,901<span></span>
</td>
<td class="nump">5,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,954<span></span>
</td>
<td class="nump">23,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets - operating leases</a></td>
<td class="nump">1,999<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredFinancingCostsNoncurrent', window );">Deferred financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">15,953<span></span>
</td>
<td class="nump">30,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,251<span></span>
</td>
<td class="nump">2,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,705<span></span>
</td>
<td class="nump">7,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">998<span></span>
</td>
<td class="nump">832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">640<span></span>
</td>
<td class="nump">905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,447<span></span>
</td>
<td class="nump">16,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">41,250<span></span>
</td>
<td class="nump">41,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">52,615<span></span>
</td>
<td class="nump">58,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock $0.001 par value, 350,000,000 shares authorized, 41,750,109 and 40,609,915 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">278,142<span></span>
</td>
<td class="nump">277,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(314,845)<span></span>
</td>
<td class="num">(305,579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(245,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' deficit</a></td>
<td class="num">(36,662)<span></span>
</td>
<td class="num">(27,909)<span></span>
</td>
<td class="nump">$ 10,895<span></span>
</td>
<td class="nump">26,532<span></span>
</td>
<td class="num">$ (142,670)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 15,953<span></span>
</td>
<td class="nump">$ 30,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredFinancingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Financing Costs, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredFinancingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 06, 2023</div></th>
<th class="th"><div>Jun. 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">41,788,096<span></span>
</td>
<td class="nump">41,750,109<span></span>
</td>
<td class="nump">40,609,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">41,788,096<span></span>
</td>
<td class="nump">41,750,109<span></span>
</td>
<td class="nump">40,609,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="nump">$ 19,632<span></span>
</td>
<td class="nump">$ 14,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">59,673<span></span>
</td>
<td class="nump">74,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">22,138<span></span>
</td>
<td class="nump">29,525<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">81,811<span></span>
</td>
<td class="nump">103,650<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(62,179)<span></span>
</td>
<td class="num">(88,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">1,702<span></span>
</td>
<td class="nump">1,936<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (60,477)<span></span>
</td>
<td class="num">$ (86,879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in USD per share)</a></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in USD per share)</a></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding, basic (in shares)</a></td>
<td class="nump">41,456,210<span></span>
</td>
<td class="nump">33,524,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding, diluted (in shares)</a></td>
<td class="nump">41,456,210<span></span>
</td>
<td class="nump">33,524,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (60,477)<span></span>
</td>
<td class="num">$ (86,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Less: reclassification to net loss of previous unrealized gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(399)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (60,477)<span></span>
</td>
<td class="num">$ (86,838)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815-15/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,885<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ReclassificationsOfTemporaryToPermanentEquityShares', window );">Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,700,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of convertible preferred stock and non-controlling interests to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (107,808)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">2,217,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1,197<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (158,223)<span></span>
</td>
<td class="nump">$ 14,395<span></span>
</td>
<td class="num">(142,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">128,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification to net loss of previous unrealized gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(399)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction', window );">Issuance of common stock for cash in pre-closing financing (in shares)</a></td>
<td class="nump">3,730,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction', window );">Issuance of common stock for cash in pre-closing financing</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">30,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)</a></td>
<td class="nump">5,059,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">42,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)</a></td>
<td class="nump">10,374,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock to Sesen Bio shareholders in reverse capitalization</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">72,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger', window );">Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)</a></td>
<td class="nump">18,872,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger', window );">Conversion of convertible preferred stock and non-controlling interests to common stock</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">122,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,395)<span></span>
</td>
<td class="nump">107,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)</a></td>
<td class="nump">226,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,879)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">40,609,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">271,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(245,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)</a></td>
<td class="nump">931,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,978)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,978)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">274,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(264,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,895<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">40,609,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">271,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(245,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">3,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)</a></td>
<td class="nump">1,136,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,477)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">41,750,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">277,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(305,579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27,909)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">37,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 278,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (314,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (36,662)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ReclassificationsOfTemporaryToPermanentEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock classified as temporary equity reclassified or converted to permanent equity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ReclassificationsOfTemporaryToPermanentEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to pre-closing financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to preclosing financing during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (60,477)<span></span>
</td>
<td class="num">$ (86,879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">3,354<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,649<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the operating right of use assets</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AccretionOnMarketableSecurities', window );">Accretion on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(709)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_WriteOffOfPropertyAndEquipment', window );">Write-off of property and equipment</a></td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_GainLossOnSaleOfEquipment', window );">Loss on sale of equipment</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleAndLeasebackTransactionGainLossNet', window );">Gain on sale of sale-leaseback</a></td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(3,120)<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,852)<span></span>
</td>
<td class="nump">2,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,434)<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(5,525)<span></span>
</td>
<td class="num">(4,941)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long term liabilities</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(59,917)<span></span>
</td>
<td class="num">(81,177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PaymentsForProceedsFromMarketableSecurities', window );">Proceeds from the sale of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(1,132)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(123)<span></span>
</td>
<td class="nump">72,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities', window );">Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities', window );">Payment of reverse recapitalization finance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing', window );">Proceeds from the issuance of common stock in pre-closing financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of principal related to finance lease liabilities</a></td>
<td class="num">(1,429)<span></span>
</td>
<td class="num">(1,301)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ProceedsFromFailedSaleLeasebackTransaction', window );">Proceeds from failed sale-leaseback arrangement</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction', window );">Payment of finance liability from failed sale-leaseback arrangements</a></td>
<td class="num">(1,309)<span></span>
</td>
<td class="num">(1,069)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">2,392<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">62,180<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(59,696)<span></span>
</td>
<td class="nump">53,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of the year</a></td>
<td class="nump">77,605<span></span>
</td>
<td class="nump">24,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of the period</a></td>
<td class="nump">17,909<span></span>
</td>
<td class="nump">77,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NoncashOrPartNoncashAcquisitionEquityAssumed', window );">Conversion of convertible preferred stock and non-controlling interests upon Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReduction', window );">Conversion of convertible promissory note, accrued interest and derivative liability upon Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities', window );">Unrealized gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts', window );">Reclassification of deferred financing costs to additional paid-in-capital</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability', window );">Right-of-use assets obtained in exchange for new financing lease liabilities</a></td>
<td class="nump">1,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">6,411<span></span>
</td>
<td class="nump">$ 2,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities', window );">Modification of operating lease right-of-use asset and operating lease liabilities</a></td>
<td class="num">(1,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability', window );">Disposal of property and equipment in exchange for reduction in financing lease liability</a></td>
<td class="nump">$ 396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AccretionOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AccretionOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash, cash equivalents and restricted cash acquired associated with the reverse capitalization during the period .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_GainLossOnSaleOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Sale of Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_GainLossOnSaleOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Effect of Modification of Operating Lease Right-of-Use Assets Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in interest expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NoncashOrPartNoncashAcquisitionEquityAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NoncashOrPartNoncashAcquisitionEquityAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Transaction, Reclassification of Debt Finance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on marketable securities in a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of reverse recapitalization finance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in a failed sale-leaseback recognized in financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PaymentsForProceedsFromMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including marketable securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PaymentsForProceedsFromMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ProceedsFromFailedSaleLeasebackTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow received by a seller-lessee in a failed sale-leaseback recognized in financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ProceedsFromFailedSaleLeasebackTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock, Pre-Closing Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_WriteOffOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of Property and Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_WriteOffOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815-15/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleAndLeasebackTransactionGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleAndLeasebackTransactionGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Background</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-weight:bold;">Background</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma Therapeutics&#160;Inc., a Delaware corporation (collectively with its subsidiaries, the Company), is a biotechnology company focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;and December&#160;2024, the Company&#8217;s board of directors approved revised operating plans to reduce&#160;monthly operating expenses, conserve cash, and refocus the Company&#8217;s efforts on strategic priorities. As part of these plans, in March&#160;2024 the Company elected to cease further development of its first lead product candidate, CT-0508. In December&#160;2024 as part of the plan, the Company elected to cease further development of its then lead product candidate, CT-0525, following an assessment of the competitive landscape in anti-HER2 treatments and the impact of recently approved therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of a further revised plan approved by the Company&#8217;s board of directors on March&#160;25, 2025 to preserve the Company&#8217;s existing cash resources following its reduction in workforce, as further discussed below (the cash preservation plan), the Company reduced its operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down its business. The cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help to evaluate our strategic alternatives. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company&#8217;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. Any future resumption of research and development activities would depend on completing a strategic transaction that would support the Company&#8217;s prior operating plans or otherwise obtaining significant additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of the cash preservation plan, the board of directors determined to terminate all of its employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. Affected employees were informed of the reduction in workforce on March&#160;25, 2025, which became effective on March&#160;31, 2025. The reduction in workforce included 37 of the Company&#8217;s full-time employees representing approximately 84% of the Company&#8217;s total workforce, including certain employees engaged in research and development, manufacturing and corporate activities. The Company incurred approximately $3.4&#160;million in connection with the reduction in workforce during the three&#160;months ended March&#160;31, 2025 and expects to incur an additional $0.4&#160;million in the second quarter of 2025 related to further potential terminations, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. The Company expects to pay the majority of related reduction in workforce amounts by the end of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">NASDAQ Compliance</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;10, 2024, the Company received written notice from The Nasdaq Stock Market LLC (Nasdaq) indicating that the Company no longer satisfied Nasdaq Listing Rule&#160;5450(b)(2)(A), which requires the Company to maintain a minimum market value of listed securities (MVLS) of $50.0 million (the MVLS Rule) for continued listing on The Nasdaq Global Market. In accordance with Nasdaq Listing Rule&#160;5810(c)(3)&#160;(the Grace Period Rule), the Company had 180 calendar&#160;days, or until April&#160;8, 2025 (the Compliance Date), to regain compliance with the MVLS Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;10, 2025, Nasdaq notified the Company that, based upon the Company&#8217;s continued non-compliance with the MVLS Rule, as of the Compliance Date, the Company&#8217;s securities were subject to delisting from Nasdaq unless the Company requested a hearing before the Nasdaq Hearings Panel (the Panel). The Company has requested a hearing before the Panel, which is scheduled to be held on May&#160;22, 2025. The request has stayed any further suspension or delisting action by Nasdaq at least until the hearing is held and any extension that the Panel may grant to the Company following the hearing has expired. There can be no assurance that the Panel will grant the Company&#8217;s request for continued listing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on April&#160;10, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule&#160;5450(b)(2)(C), which requires the Company to maintain a minimum market value of publicly held shares (MVPHS) of $15.0&#160;million (the MVPHS Rule) for continued listing on The Nasdaq Global Market. In accordance with the Grace Period Rule, the Company has 180 calendar&#160;days, or until October&#160;7, 2025, to regain compliance with the MVPHS Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, and as previously disclosed, on January&#160;6, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule&#160;5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share (the Bid Price Rule&#160;together with the MVLS Rule&#160;and the MVPHS Rule, the Price-based Rules) for continued listing on The Nasdaq Global Market. In accordance with the Grace Period Rule, the Company has 180 calendar&#160;days, or until July&#160;7, 2025, to regain compliance with the Bid Price Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To evidence compliance with the Price-based Rules, an issuer must evidence compliance with the applicable minimum threshold for at least ten, but generally not more than 20, consecutive business&#160;days. Although the Company is considering all available options to regain compliance with the applicable listing criteria, there can be no assurance that the Company will be able to do so.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-weight:bold;">Background</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma Therapeutics&#160;Inc., a Delaware corporation (collectively with its subsidiaries, the Company), biotechnology company focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;and December&#160;2024, the Company and its board of directors approved revised operating plans to reduce&#160;monthly operating expenses, conserve cash, and refocus its efforts on strategic priorities. As part of these plans, in March&#160;2024 the Company elected to cease further development of its first lead product candidate, CT-0508. In December&#160;2024 as part of the plan, the Company elected to cease further development of its then lead product candidate, CT-0525, following an assessment of the competitive landscape in anti-HER2 treatments and the impact of recently approved therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of its cost-reduction initiatives in 2024, the Company implemented workforce reductions during 2024, resulting in the termination of 62 full-time employees (representing approximately 58.0% of the Company&#8217;s total workforce), across research and development and general and administrative functions. The workforce reduction resulted in $4.1&#160;million of severance related costs, of which $2.0&#160;million and $2.1&#160;million are included within <span style="-sec-ix-hidden:Hidden_fhlu0P8GC0OSYzMKRGa6pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general and administrative</span></span> and <span style="-sec-ix-hidden:Hidden_qKYmVxKGPEGEDMmZP0kvsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research and development</span></span> expense, respectively, in the accompanying consolidated statement of operations and comprehensive loss. As of December&#160;31, 2024, $2.7&#160;million in severance costs were accrued in the accompanying consolidated balance sheets. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the 2024 reduction in workforce.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;10, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that our common stock was not in compliance with Nasdaq Listing Rule&#160;5450(b)(2)(A), or the MVLS Requirement, which requires the Company to maintain a minimum market value of listed securities of $50,000,000. The Company has 180 calendar&#160;days, or until April&#160;8, 2025, to regain compliance with the MVLS Requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On January&#160;6, 2025, the Company received a separate written notice from Nasdaq notifying the Company that, based upon the closing bid price of its common stock for the last 38 consecutive business&#160;days, the Company was not in compliance with Nasdaq Listing Rule&#160;5450(a)(1)&#160;(the Bid Price Rule), which requires the Company to maintain a minimum bid price of $1.00 per share. The Company has 180 calendar&#160;days, or until July&#160;7, 2025, to regain compliance with the Bid Price Rule.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development-Stage Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DevelopmentStageRisksAndLiquidityAbstract', window );"><strong>Development-Stage Risks and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DevelopmentStageRisksAndLiquidityTextBlock', window );">Development-Stage Risks and Liquidity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span><b style="font-weight:bold;">Development-Stage Risks and Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $305.6 million as of December&#160;31, 2024. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of December&#160;31, 2024, the Company had cash and cash equivalents of $17.9 million. Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one&#160;year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company&#8217;s ability to continue as a going concern. In addition, changing circumstances could cause the Company to consume capital significantly faster than currently anticipated, and the Company may need to spend more than currently expected because of circumstances beyond its control. The Company&#8217;s cash forecast contains estimates and assumptions, and management cannot predict the timing of all cash receipts and expenditures with certainty. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liability that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Management is currently evaluating different strategies to maximize value and prepare to wind down the Company&#8217;s business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">divestiture of one or more of the Company&#8217;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. There is no assurance regarding when or if this strategic review process will result in any type of transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DevelopmentStageRisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DevelopmentStageRisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DevelopmentStageRisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development-Stage Risks and Liquidity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DevelopmentStageRisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(3)</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interim Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summary of significant accounting policies is included in the Company&#8217;s audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (SEC) on March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance are meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The accompanying unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. In the opinion of management, the accompanying unaudited interim consolidated financial statements include all </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2025 and its results of operations for the three&#160;months ended March&#160;31, 2025 and 2024. Operating results for the three&#160;months ended March&#160;31, 2025 are not necessarily indicative of the results that may be expected for the&#160;year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain all of the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Company&#8217;s Annual Report on Form&#160;10-K filed with the SEC on March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant areas that require management&#8217;s estimates include stock-based compensation assumptions and accrued research and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Assets Held for Sale</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2025, the Company committed to a plan to sell its remaining equipment and therefore has classified the amount as assets held for sale on the consolidated balance sheet as of March&#160;31, 2025. The assets held for sale were reported at the lower of the carrying amount or fair value, less costs to sell.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value of Financial Instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value Measurements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2025 and 2024, there were no transfers between Level 1, Level 2 and Level 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Concentration of credit risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Segment information</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the three&#160;months ended March&#160;31, 2025 and 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,397</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,191</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,656</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,632</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,529</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,185</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (818)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,266)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,978)</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">&#8220;Other segment items&#8221; includes</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> interest income.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net loss per share</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,895,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,210,547</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recently issued accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes </i>(Topic 740)<i style="font-style:italic;">: Improvements to Income Tax Disclosures </i>(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November&#160;2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures </i>(Subtopic 220-40): <i style="font-style:italic;">Disaggregation of Income Statement Expenses</i>, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(3)</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant areas that require management&#8217;s estimates include estimated research and development revenue, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1)&#160;non-refundable, upfront license fees (2)&#160;reimbursement of certain costs; (3)&#160;customer option fees for additional goods or services; (4)&#160;development milestone payments, (5)&#160;regulatory and commercial milestone payments; and (6)&#160;royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&#160;the number of performance obligations based on the determination under step (i)&#160;above; (b)&#160;the transaction price under step (iii)&#160;above; (c)&#160;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&#160;above; and (d)&#160;the contract term and pattern of satisfaction of the performance obligations under step (v)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Upfront license fees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Customer options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and development services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The promises under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company&#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Segment information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">assessing performance. The Company has one operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the&#160;years ended December&#160;31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,919</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,905</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,118</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,671</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,324</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,984</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other segment items(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,242)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,204)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (60,477)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,879)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other segment items include changes in warrant liability and interest income.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. As of December&#160;31, 2024 and 2023, cash equivalents consisted of investments in a money market account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_w59cdNVWLU6d09CxPojcvA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to five&#160;years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did not recognize any impairment of long-lived assets during the&#160;years ended December&#160;31, 2024 or 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Deferred Financing Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one&#160;year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company&#8217;s common stock prior to the Merger (as defined in Note&#160;4), and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Merger (as defined in Note&#160;4), the fair value of the Company&#8217;s common stock was estimated by the Company&#8217;s board of directors, with input by management considering the Company&#8217;s most recently available third-party valuation of the Company&#8217;s common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company&#8217;s consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#8217;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,023,370</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </i>(ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024 on a retrospective basis. The Company incorporated the improved segment disclosures in the summary of significant accounting policies, herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently issued but not yet adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </i>(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In November&#160;2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Sesen Bio<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Merger with Sesen Bio</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(4)</b></span><b style="font-weight:bold;">Merger with Sesen Bio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;7, 2023, the Company (formerly publicly-held Sesen Bio,&#160;Inc.) consummated a merger with CTx Operations,&#160;Inc. (formerly privately-held CARISMA Therapeutics&#160;Inc.) (Legacy Carisma) pursuant to an Agreement and Plan of Merger and Reorganization, as amended (the Merger Agreement), by and among the Company, Legacy Carisma and Seahawk Merger Sub,&#160;Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company. The Merger Agreement provided for the merger of Merger Sub with and into Legacy Carisma, with Legacy Carisma continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the Merger). The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Sesen Bio were cash, cash equivalents and marketable securities. For financial reporting purposes Legacy Carisma was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i)&#160;Legacy Carisma stockholders own approximately 74.2% of the Combined Company, (ii)&#160;Legacy Carisma holds the majority (six of seven) of board seats of the Combined Company and (iii)&#160;Legacy Carisma management holds all key positions of management. Accordingly, the Merger was treated as the equivalent of Legacy Carisma issuing stock to acquire the net assets of Sesen Bio. As a result of the Merger, the net assets of Sesen Bio were recorded at their acquisition-date fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Legacy Carisma. Immediately after the Merger, there were 40,254,666 shares of the Company&#8217;s common stock outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table shows the net assets acquired in the Merger (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 7, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,873</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,588</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,499)</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,308</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,264)</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total net assets acquired less transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,044</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subsequent to March&#160;7, 2023, the Company paid $4.6 million of severance and personnel costs related to Sesen Bio.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(4)</b></span><b style="font-weight:bold;">Prepaid Expenses and other assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,715</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration receivable (Note 10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,864</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables (a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 925</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,916</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">&#8220;Other receivables&#8221; primarily</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> consisted of equipment sales, sales and use tax refunds, and research and development tax refunds.</span></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(5)</b></span><b style="font-weight:bold;">Prepaid Expenses and Other Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prepaid expenses and other assets consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 278</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Collaboration receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 402</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 891</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,295</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,866</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(6)</b></span><b style="font-weight:bold;">Property and Equipment, net</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 903</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,392</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,915</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,887)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,151)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,764</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lab equipment includes failed sale lease-back assets of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.4</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million as of December</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31, 2024 and 2023. Lab equipment includes finance lease ROU assets of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.2</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.9</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million, respectively, as of December</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31, 2024 and 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The accumulated amortization balance includes </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.5</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.9</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million, respectively, related to failed sale-leaseback assets as of December</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31, 2024 and 2023. The accumulated amortization balance includes </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.3</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.7</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million, respectively, related to finance lease ROU assets as of December</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31, 2024 and 2023.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Depreciation and amortization expense was $3.4&#160;million and $2.8&#160;million for the&#160;years ended December&#160;31, 2024 and 2023, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(5)</b></span><b style="font-weight:bold;">Accrued Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,845</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 537</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,879</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,448</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(7)</b></span><b style="font-weight:bold;">Accrued Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,131</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,366</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,100</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,662</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(6)</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#8217;s operating leases have term end dates ranging from 2025 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2025 to 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operating and finance lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company carries laboratory equipment from failed sale-leasebacks, as assets held for sale on the accompanying unaudited interim consolidated balance sheets. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of March&#160;31, 2025, the Company had a $1.7 million financing liability recorded in other current liabilities and other long-term liabilities on the unaudited interim consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The elements of the lease costs were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,469</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,298</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,534</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 472</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,475</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Lease term and discount rate information related to leases was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Supplemental cash flow information was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,463</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,319</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Future maturities of lease liabilities were as follows as of March&#160;31, 2025 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiscal year ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 (remaining nine months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 659</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (240)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 640</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licensing and Sponsored Research Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November&#160;2017, the Company is required to make annual payments of $25,000. Penn is eligible to receive up to $10.9&#160;million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $30.0&#160;million per product in commercial milestones and up to an additional $1.7&#160;million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Contingencies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. As of March&#160;31, 2025, the Company was in negotiations with a vendor to determine the total costs owed for research and development services provided. While the negotiations are ongoing, the Company believes a liability is probable. The Company has estimated the amount to be owed to be $1.5&#160;million, of which $1.0&#160;million and $0.5&#160;million are included within accounts payable and accrued </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">expenses, respectively, on the accompanying consolidated balance sheets. The final amount owed may differ from the estimate as negotiations progress. The Company will continue to evaluate the matter and will adjust the liability as necessary based on any new information or agreements reached with the vendor.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(8)</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#8217;s operating leases have term end dates ranging from 2025 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2025 to 2026. Effective February&#160;2024, the Company renewed an existing operating lease with an end date through 2026. In April&#160;2024, in connection with the revised operating plan, the Company notified the lessor that it would terminate the lease effective August&#160;2024. In July&#160;2024, the Company entered into an amendment extending the termination date of the lease to June&#160;2025 with an option to extend to December&#160;2025. The Company did not incur any penalties or fees in connection with the termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In September&#160;2024, the Company modified existing finance leases and failed sale-leaseback arrangements by assigning the rights and obligations of certain underlying assets to an unrelated third party. The modifications resulted in a reduction of its finance lease </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ROU assets and related lease liability of $0.4&#160;million. In addition, the Company recorded a reduction of its failed sale-leaseback liability and gain on the sale of the corresponding assets of $0.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operating and finance lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company carries laboratory equipment from failed sale-leasebacks, as property and equipment, net on the accompanying consolidated balance sheets. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of December&#160;31, 2024, the Company had a $1.4 million financing liability recorded in other current liabilities and other long-term liabilities on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The elements of the lease costs were as follows (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,774</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,187</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,326</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,733</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Short term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,833</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lease term and discount rate information related to leases was as follows:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information was as follows (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,764</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,301</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future maturities of lease liabilities were as follows as of December&#160;31, 2024 (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fiscal year ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 942</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 963</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (253)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 925</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Licensing and Sponsored Research Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November&#160;2017 (Penn License Agreement), the Company is required to make annual payments of $25,000. Penn is eligible to receive up to $10.9 million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $30.0 million per product in commercial milestones and up to an additional $1.7 million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2023, the Company entered into a manufacturing and supply agreement with Novartis Pharmaceuticals Corporation (Novartis) for the manufacturing of the Company&#8217;s CT-0508 product candidate (Novartis Agreement). The Novartis Agreement had a five year term. On June&#160;26, 2024, in furtherance of its revised operating plan approved in late March&#160;2024, the Company terminated the Novartis Agreement. Upon termination, the Company incurred a termination fee equal to $4.0&#160;million, which was paid in the third quarter of 2024. A prepaid asset was recorded as the Company separately agreed with Novartis that if Novartis and the Company re-negotiate the agreement for a substitute product on or before December&#160;31, 2024, then the $4.0&#160;million termination fee would be credited in full or in part against any amounts due from the Company to Novartis under such agreement relating to the substitute product. The Company did not re-negotiate the agreement and expensed the $4.0&#160;million prepaid asset in the fourth quarter of 2024 to research and development in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. As of December&#160;31, 2024, the Company was in negotiations with a vendor to determine the total costs owed for research and development services provided. While the negotiations are ongoing, the Company believes a liability is probable. The Company has estimated the amount to be owed to be $1.2&#160;million which is included within accrued expenses on the accompanying consolidated balance sheets. The final amount owed may differ from the estimate as negotiations progress. The Company will continue to evaluate the matter and will adjust the liability as necessary based on any new information or agreements reached with the vendor.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' (Deficit) Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(7)</b></span><b style="font-size:10pt;font-weight:bold;">Stockholders&#8217; E</b><b style="font-size:10pt;font-weight:bold;">quity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Open Market Sales Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">On April&#160;17, 2023, the Company filed a universal shelf registration statement on Form&#160;S-3, which was declared effective on May&#160;2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to </span><span style="font-size:10pt;">$300.0</span><span style="font-size:10pt;">&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May&#160;12, 2023, the Company entered into an Amended and Restated Open Market Sale Agreement</span>SM <span style="font-size:10pt;">(Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to </span><span style="font-size:10pt;">$100.0</span><span style="font-size:10pt;">&#160;million under an &#8220;at-the-market&#8221; offering program. During the three&#160;months ended March&#160;31, 2024, the Company sold </span><span style="font-size:10pt;">931,250</span><span style="font-size:10pt;"> shares of common stock for gross proceeds of </span><span style="font-size:10pt;">$2.3</span><span style="font-size:10pt;">&#160;million. The Company did </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;">t sell any shares of common stock under the Sale Agreement during the three&#160;months ended March&#160;31, 2025.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(9)</b></span><b style="font-weight:bold;">Stockholders</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#8217;</b><b style="font-weight:bold;"> (Deficit) Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March&#160;7, 2023, in connection with the closing of the Merger, the following is reflected on the consolidated statements of convertible preferred stock and stockholders&#8217; (deficit) equity for the&#160;year ended December&#160;31, 2023: (i)&#160;the sale of 3,730,608 shares of common stock in a pre-closing funding at $8.21 per share for total proceeds of $30.6 million, (ii)&#160;the issuance of 5,059,338 shares of common stock upon the settlement of the Company&#8217;s $35.0 million convertible promissory note, accrued interest and related derivative liability, (iii)&#160;the conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">interests into 18,872,711 shares of common stock, (iv)&#160;the issuance of 10,374,272 shares of common stock to Sesen Bio stockholders as consideration for the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;17, 2023, the Company filed a universal shelf registration statement on Form&#160;S-3, which was declared effective on May&#160;2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to $300.0&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May&#160;12, 2023, the Company entered into an Amended and Restated Open Market Sale AgreementSM (Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to $100.0&#160;million under an &#8220;at-the-market&#8221; offering program. During the&#160;years ended December&#160;31, 2024 and 2023, the Company sold 1,136,384 and 226,533 shares of common stock, respectively, for gross proceeds of $2.4&#160;million and $0.6&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On June&#160;6, 2023, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Restated Certificate of Incorporation to increase the number of authorized shares of the Company&#8217;s common stock, $0.001 par value, from 100,000,000 shares to 350,000,000 shares and authorized 5,000,000 shares of preferred stock, $0.001 par value.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(8)</b></span><b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2017 Stock Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the CARISMA Therapeutics&#160;Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was ten&#160;years, and stock options typically vested over a <span style="-sec-ix-hidden:Hidden_Y6YvLEfyKUG_kk0uMc5sKQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four-year</span></span> period. The Company&#8217;s stock options vest based on the terms in the awards agreements and generally vest over <span style="-sec-ix-hidden:Hidden_DGF8BxLO20aH0nuzKXhnJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four&#160;years</span></span>. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder and ceased granting awards under the Legacy Carisma Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2014 Stock Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Amended and Restated Stock Incentive Plan, as amended (the 2014 Plan), provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Company&#8217;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#8217;s board of directors at the time of grant. Stock options outstanding under the 2014 Plan generally vest over a <span style="-sec-ix-hidden:Hidden_RR1pBUqe5UemOm2ln3QA2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four-year</span></span> period and are exercisable for a period of ten&#160;years from the date of grant. As of March&#160;31, 2025, approximately 5.6&#160;million shares of common stock remained available for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2014 Employee Stock Purchase Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carisma Therapeutics&#160;Inc. 2014 Employee Stock Purchase Plan (the 2014 ESPP) provides employees with the opportunities to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The 2014 ESPP had 0.2 million shares of common stock available for issuance as of March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes stock option activity for the three&#160;months ended March&#160;31, 2025:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,987)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,749,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,562,180)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,895,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,693,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The weighted-average grant-date per share fair values of options granted during the three&#160;months ended March&#160;31, 2025 and 2024 were $0.42 and $1.72, respectively. The fair values in the three&#160;months ended March&#160;31, 2025 and 2024 were estimated using the Black-Scholes option-pricing model based on the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">4.32% - 4.35%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">3.77% - 3.89%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">108.30% - 110.68%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">103.39% - 105.96%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock-Based Compensation Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company recorded stock-based compensation expense in the following expense categories in its accompanying unaudited interim consolidated statements of operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 436</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,057</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the cash preservation plan, 2.6&#160;million options were forfeited during the three&#160;months ended March&#160;31, 2025, resulting in a reduction in stock-based compensation expense related to research and development and, general and administrative employees. Compensation cost for awards not vested as of March&#160;31, 2025 was $3.7&#160;million and will be expensed over a weighted-average period of 2.3&#160;years.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(10)</b></span><b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2017 Stock Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the CARISMA Therapeutics&#160;Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was ten&#160;years, and stock options typically vested over a <span style="-sec-ix-hidden:Hidden_sktIWaH1v0C3Alvvbznotw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four-year</span></span> period. The Company&#8217;s stock options vest based on the terms in the awards agreements and generally vest over <span style="-sec-ix-hidden:Hidden_wSmhQcT4p0uaTZTD8dNi8A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four&#160;years</span></span>. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Legacy Carisma Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2014 Stock Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Amended and Restated 2014 Stock Incentive Plan, as amended, provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Company&#8217;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#8217;s board of directors at the time of grant. Stock options outstanding under the 2014 Amended and Restated Stock Incentive Plan (the 2014 Plan) generally vest over a four-year period and are exercisable for a period of ten&#160;years from the date of grant. As of December&#160;31, 2024, approximately 4.8 million shares of common stock remained available for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2014 Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carisma Therapeutics&#160;Inc. 2014 Employee Stock Purchase Plan (the Carisma 2014 ESPP) provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The purpose of the Carisma 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock. The Carisma 2014 ESPP had 0.2 million shares of common stock available for issuance as of December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,023,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,810)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,805,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,078,034)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,414,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date per share fair values of options granted during the&#160;years ended December&#160;31, 2024 and 2023 were $1.36 and $4.29, respectively. The fair values in the&#160;years ended December&#160;31, 2024 and 2023 were estimated using the Black-Scholes option-pricing model based on the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:32.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.77% - 4.59%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.92% - 4.76%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">86.55% - 112.12%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">57.77% - 103.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,242</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,074</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,316</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the reductions in force, 1,898,297 options were forfeited during the&#160;year ended December&#160;31, 2024. The Company recognized stock-based compensation expense of $0.2 million related to the modification of Sesen Bio options assumed in connection with the Merger during the&#160;year ended December&#160;31, 2023. Compensation cost for awards not vested as of December&#160;31, 2024 was $7.2 million and will be expensed over a weighted-average period of 2.5&#160;years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(11)</b></span><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for&#160;years in which differences are expected to reverse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets for federal income taxes consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,689</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Capitalized research and development costs, net of amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,778</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,746</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Start-up costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,407</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,353</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 668</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortizable assets and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Equity compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 134,749</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (153,855)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133,580)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax assets, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,169</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Right of use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (848)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (645)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (429)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (524)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,277)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,169)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net deferred tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, the Company has net operating loss carryforwards (NOLs) for federal income tax purposes of $374.7&#160;million, which are available to offset future federal taxable income. The pre-2018 federal NOLs of $120.0&#160;million will begin to expire in 2031, if not utilized. The post-2017 federal NOLs of $254.7&#160;million carry forward indefinitely. The Company also has NOLs for state and local income tax purposes of $280.3&#160;million and $65.1&#160;million, respectively that are available to offset future taxable income. The state NOLs will begin to expire in 2031 while the city of Philadelphia NOLs begin to expire in 2042. As of December&#160;31, 2024, the Company also had federal and state research and development tax credit carryforwards of $12.6&#160;million and $0.8&#160;million that will begin to expire in 2029 and 2032, respectively, unless previously utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of December&#160;31, 2024. The valuation allowance increased by $20.3&#160;million and $84.5&#160;million during the&#160;years ended December&#160;31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50&#160;percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits net operating loss utilization as a&#160;percentage of apportioned taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense/(benefit). As of December&#160;31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s financial statements. Tax&#160;years from 2021 and after remain subject to examination by all of the taxing jurisdictions. The NOLs and research credit carryforwards remain subject to review until utilized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(9)</b></span><b style="font-weight:bold;">Related-Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has a collaboration and license agreement with Moderna, a significant stockholder (See Note&#160;10&#160;&#8211; Moderna Collaboration and License Agreement).</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(12)</b></span><b style="font-weight:bold;">Related-Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company has a collaboration and license agreement with Moderna, a significant shareholder (Note&#160;13).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Moderna Collaboration and License Agreement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(10)</b></span><b style="font-weight:bold;">Moderna Collaboration and License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In January&#160;2022, the Company entered into a collaboration agreement with Moderna (the Moderna License Agreement), which provides for a broad strategic collaboration to discover, develop and commercialize <i style="font-style:italic;">in vivo </i>engineered chimeric antigen receptor macrophage and monocyte (CAR-M) therapeutics in oncology. Moderna has the right to designate up to twelve research targets as development targets under this collaboration. While the collaboration was initially limited to oncology, in September&#160;2024, the companies agreed to expand the collaboration to discover, develop and commercialize <i style="font-style:italic;">in vivo </i>engineered CAR-M therapeutics in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">specific autoimmune diseases. As of February&#160;2025, in connection with Moderna&#8217;s nomination of all 12 oncology research targets, the Company will not be conducting any additional research activities under the collaboration agreement and will not be receiving any further payments from Moderna for research and development services under the collaboration agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subsequent to the nomination of a research target, Moderna may designate the research target as a development target. Upon Moderna&#8217;s designation of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $45.0 million to the Company. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, the Company is eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. Moderna reimbursed the Company for costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed into the first quarter of 2025; however, as discussed below, Moderna will no longer reimburse the Company for research and development services. The Company is eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments and royalties that the Company owes as a licensor under one of its intellectual property in-license agreements with Penn, which is sublicensed to Moderna under the Moderna License Agreement. Moderna may deduct these royalties in part from any royalties owed to the Company. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities and participation on the joint steering committee. The Company determined that there were 2 performance obligations comprised of (i)&#160;research and development services and (ii)&#160;option rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The transaction price of $45.0&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna exercises or determines not to exercise its option right to license and commercialize the designated development target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company included the $45.0 million up-front and nonrefundable payment in the transaction price as of the outset of the arrangement. During the three&#160;months ended March&#160;31, 2025 and 2024, the Company recognized $3.7 million and $3.4 million, respectively, of collaboration revenues. As discussed below, Moderna will no longer be reimbursing the Company for research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $42.4&#160;million and $3.8&#160;million, respectively, of research and development services and option right collaboration revenues since inception of the Moderna License Agreement through March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In February&#160;2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February 2025, Moderna has nominated all 12 oncology research targets under the collaboration for which the Company has the potential to receive future milestones and royalty payments. The Company will not conduct any additional research activities under the collaboration agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">and the Company will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the <i style="font-style:italic;">in vivo </i>oncology field exclusivity, which would allow the Company to pursue <i style="font-style:italic;">in vivo </i>CAR-M programs outside of the 12 nominated oncology targets and product polypeptides. The Company does not expect to recognize any additional unsatisfied research and development performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price unsatisfied</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,250</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s unaudited interim consolidated balance sheets. Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s unaudited interim consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the changes in deferred revenue (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,413</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferral of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,173</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Recognition of unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,729)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,397)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,189</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The deferred revenue represents the unearned portion of the upfront, non-refundable and non-creditable payment allocated to Moderna&#8217;s option rights of $41.3 million, which is not expected to be recognized within the next 12&#160;months.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(13)</b></span><b style="font-weight:bold;">Moderna Collaboration and License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In January&#160;2022, the Company entered into the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize <i style="font-style:italic;">in vivo </i>engineered CAR-M therapeutics in oncology. Moderna has the right to designate up to twelve research targets as development targets under this collaboration. While the collaboration was initially limited to oncology, in September&#160;2024, the companies agreed to expand the collaboration to discover, develop and commercialize <i style="font-style:italic;">in vivo </i>engineered CAR-M therapeutics in specific autoimmune diseases. As a result, Moderna nominated two autoimmune research targets. As of February&#160;2025, in connection with Moderna&#8217;s nomination of all 12 oncology research targets (Note&#160;14), the Company will not be conducting any additional research activities under the collaboration agreement and will not be receiving any further payments from Moderna for research and development services under the collaboration agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Subsequent to the nomination of a research target, Moderna may designate the research target as a development target. Upon Moderna&#8217;s designation of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $45.0 million to the Company. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, the Company is eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. Moderna also reimbursed the Company for all costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $10.0 million in research and development costs over the first three&#160;years from execution of the Moderna License Agreement). The Company is also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments and royalties that the Company owes as a licensor under one of its intellectual property in-license agreements with Penn, which is sublicensed to Moderna under the Moderna License Agreement. Moderna may deduct these royalties in part from any royalties owed to the Company. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities and participation on the joint steering committee (JSC). The Company determined that there were 2 performance obligations comprised of (i)&#160;research and development services and (ii)&#160;option rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The transaction price of $45.0&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna exercises or determines not to exercise its option right to license and commercialize the designated development target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In June&#160;2024, the Company received notice from Moderna that Moderna had designated the first development candidate, an <i style="font-style:italic;">in vivo </i>CAR-macrophage targeting GPC3 that is designed to treat solid tumors, including hepatocellular carcinoma. Pursuant to the terms of the Moderna License Agreement, the designation triggered a $2.0&#160;million milestone payment from Moderna to the Company. As a result, the Company recognized collaboration revenue of $2.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Company reduced its $45.0&#160;million deferred revenue liability associated with the option rights by recognizing $3.8&#160;million in collaboration revenue, which represents a proportional reduction based on the 12 potential early-stage research targets. As of December&#160;31, 2024, the Company recorded a collaboration receivable of $2.9&#160;million related to the reimbursement of costs incurred in connection with the Company&#8217;s research and development activities. The Company received the $2.9&#160;million in January&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company included the $45.0 million up-front and nonrefundable payment and $73.9 million of variable consideration for expected research and development services to be performed during the five-year contract term, inclusive of passthrough costs, in the transaction price as of the outset of the arrangement. During the&#160;years ended December&#160;31, 2024 and 2023, the Company recognized $19.6 million and $14.9 million, respectively, of collaboration revenues. Collaboration revenues for the&#160;year ended December&#160;31, 2024 include $3.8&#160;million of deferred option rights revenue recognition and $2.0&#160;million of milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognized $38.7&#160;million and $3.8&#160;million, respectively, of research and development services and option right collaboration revenues since inception of the Moderna License Agreement through December&#160;31, 2024. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2024 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price unsatisfied</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,301</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,250</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total performance obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,551</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the changes in deferred revenue (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,459</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferral of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,873</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recognition of unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,632)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,919)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,413</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The current portion of deferred revenue represents advanced payments received from Moderna for costs expected to be incurred by the Company within the next twelve&#160;months. The noncurrent portion of deferred revenue represents the $41.3 million upfront, non-refundable and non-creditable payment allocated to customer option right which is not expected to be recognized within the next 12&#160;months.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(11)</b></span><b style="font-size:10pt;font-weight:bold;">Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has evaluated subsequent events from the balance sheet date through May&#160;13, 2025, the issuance date of these unaudited interim consolidated financial statements, and has not identified any additional items that have not previously been mentioned elsewhere requiring disclosure.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(14)</b></span><b style="font-weight:bold;">Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company has evaluated subsequent events from the balance sheet date through March&#160;31, 2025, the issuance date of these consolidated financial statements, and has identified the following matter requiring disclosure. <i style="font-style:italic;">Moderna Collaboration and License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In February&#160;2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February&#160;2025, Moderna has nominated all 12 oncology research targets under the collaboration for which the Company has the potential to receive future milestones and royalty payments. The Company will not conduct any additional research activities under the collaboration agreement and the Company will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the <i style="font-style:italic;">in vivo </i>oncology field exclusivity, which would allow the Company to pursue <i style="font-style:italic;">in vivo </i>CAR-M programs outside of the 12 nominated oncology targets and product polypeptides. The final research and development payment of $2.9&#160;million was received in January&#160;2025 which will be recognized as collaboration revenue for research and development services in the first quarter of 2025. The Company does not expect to recognize any additional unsatisfied research and development performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">2025 Cash Preservation Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of a further revised plan approved by the Company&#8217;s board of directors, on March&#160;25, 2025, to preserve the Company&#8217;s existing cash resources following its reduction in workforce (the &#8220;cash preservation plan&#8221;), the Company reduced its operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down its business. The cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help to evaluate our strategic alternatives. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company&#8217;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. Any future resumption of research and development activities would depend on completing a strategic transaction that would support the Company&#8217;s prior operating plans or otherwise obtaining significant additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of the cash preservation plan, the board of directors determined to terminate all of its employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. Affected employees were informed of the reduction in workforce on March&#160;25, 2025. The reduction in workforce was effective on March&#160;31, 2025. The reduction in workforce includes 37 of the Company&#8217;s full-time employees representing approximately 84% of our total workforce, including certain employees engaged in research and development, manufacturing and corporate activities. The Company expects to incur approximately $3.8&#160;million in connection with the reduction in workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. The Company also expects to pay the majority of related reduction in workforce amounts by the end of 2025. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the reduction in workforce, including (but not limited to) impairment charges relating to the balances of property and equipment, net, prepaid research and development costs and right of use assets&#160;&#8211; operating lease.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interim Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summary of significant accounting policies is included in the Company&#8217;s audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (SEC) on March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance are meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The accompanying unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. In the opinion of management, the accompanying unaudited interim consolidated financial statements include all </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2025 and its results of operations for the three&#160;months ended March&#160;31, 2025 and 2024. Operating results for the three&#160;months ended March&#160;31, 2025 are not necessarily indicative of the results that may be expected for the&#160;year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain all of the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Company&#8217;s Annual Report on Form&#160;10-K filed with the SEC on March&#160;31, 2025.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant areas that require management&#8217;s estimates include stock-based compensation assumptions and accrued research and development.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant areas that require management&#8217;s estimates include estimated research and development revenue, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value of Financial Instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value Measurements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2025 and 2024, there were no transfers between Level 1, Level 2 and Level 3.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1)&#160;non-refundable, upfront license fees (2)&#160;reimbursement of certain costs; (3)&#160;customer option fees for additional goods or services; (4)&#160;development milestone payments, (5)&#160;regulatory and commercial milestone payments; and (6)&#160;royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&#160;the number of performance obligations based on the determination under step (i)&#160;above; (b)&#160;the transaction price under step (iii)&#160;above; (c)&#160;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&#160;above; and (d)&#160;the contract term and pattern of satisfaction of the performance obligations under step (v)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Upfront license fees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Customer options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and development services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The promises under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company&#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Concentration of credit risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Segment information</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the three&#160;months ended March&#160;31, 2025 and 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,397</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,191</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,656</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,632</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,529</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,185</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (818)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,266)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,978)</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">&#8220;Other segment items&#8221; includes</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> interest income.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Segment information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">assessing performance. The Company has one operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the&#160;years ended December&#160;31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,919</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,905</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,118</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,671</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,324</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,984</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other segment items(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,242)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,204)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (60,477)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,879)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other segment items include changes in warrant liability and interest income.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. As of December&#160;31, 2024 and 2023, cash equivalents consisted of investments in a money market account.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_w59cdNVWLU6d09CxPojcvA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to five&#160;years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did not recognize any impairment of long-lived assets during the&#160;years ended December&#160;31, 2024 or 2023.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredFinancingCostsPolicyPolicyTextBlock', window );">Deferred Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Deferred Financing Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one&#160;year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company&#8217;s common stock prior to the Merger (as defined in Note&#160;4), and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Merger (as defined in Note&#160;4), the fair value of the Company&#8217;s common stock was estimated by the Company&#8217;s board of directors, with input by management considering the Company&#8217;s most recently available third-party valuation of the Company&#8217;s common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company&#8217;s consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#8217;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net loss per share</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,895,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,210,547</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,023,370</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements and Recently issued but not yet adopted accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recently issued accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes </i>(Topic 740)<i style="font-style:italic;">: Improvements to Income Tax Disclosures </i>(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November&#160;2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures </i>(Subtopic 220-40): <i style="font-style:italic;">Disaggregation of Income Statement Expenses</i>, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </i>(ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024 on a retrospective basis. The Company incorporated the improved segment disclosures in the summary of significant accounting policies, herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently issued but not yet adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </i>(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In November&#160;2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredFinancingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Financing Costs, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredFinancingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2025 and 2024, there were no transfers between Level 1, Level 2 and Level 3.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Significant Expense Categories by Segment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the three&#160;months ended March&#160;31, 2025 and 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,397</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,191</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,656</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,632</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,529</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,185</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (818)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,266)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,978)</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">&#8220;Other segment items&#8221; includes</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> interest income.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the&#160;years ended December&#160;31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,919</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,905</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,118</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,671</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,324</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,984</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other segment items(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,242)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,204)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (60,477)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,879)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,895,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,210,547</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,023,370</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Sesen Bio (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Net Assets Acquired in the Merger</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table shows the net assets acquired in the Merger (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 7, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,873</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,588</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,499)</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,308</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,264)</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total net assets acquired less transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,044</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,715</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration receivable (Note 10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,864</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables (a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 925</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,916</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">&#8220;Other receivables&#8221; primarily</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> consisted of equipment sales, sales and use tax refunds, and research and development tax refunds.</span></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prepaid expenses and other assets consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 278</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Collaboration receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 402</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 891</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,295</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,866</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 903</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,392</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,915</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,887)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,151)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,764</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lab equipment includes failed sale lease-back assets of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.4</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million as of December</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31, 2024 and 2023. Lab equipment includes finance lease ROU assets of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.2</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.9</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million, respectively, as of December</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31, 2024 and 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The accumulated amortization balance includes </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.5</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.9</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million, respectively, related to failed sale-leaseback assets as of December</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31, 2024 and 2023. The accumulated amortization balance includes </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.3</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.7</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million, respectively, related to finance lease ROU assets as of December</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31, 2024 and 2023.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,845</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 537</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,879</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,448</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,131</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,366</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,100</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,662</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The elements of the lease costs were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,469</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,298</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,534</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 472</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,475</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The elements of the lease costs were as follows (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,774</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,187</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,326</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,733</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Short term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,833</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock', window );">Schedule of Lease Term and Discount Rate Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Lease term and discount rate information related to leases was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lease term and discount rate information related to leases was as follows:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Supplemental cash flow information was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,463</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,319</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information was as follows (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,764</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,301</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock', window );">Schedule of Future Maturities of Lease Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Future maturities of lease liabilities were as follows as of March&#160;31, 2025 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiscal year ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 (remaining nine months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 659</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (240)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 640</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future maturities of lease liabilities were as follows as of December&#160;31, 2024 (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fiscal year ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 942</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 963</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (253)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 925</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of ease term and discount rate information relating to operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability and finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental cash flow information relating to operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes stock option activity for the three&#160;months ended March&#160;31, 2025:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,987)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,749,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,562,180)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,895,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,693,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr></table></div><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,023,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,810)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,805,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,078,034)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,414,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Using The Black-Scholes Option-Pricing Model</a></td>
<td class="text">The fair values in the three&#160;months ended March&#160;31, 2025 and 2024 were estimated using the Black-Scholes option-pricing model based on the following assumptions:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">4.32% - 4.35%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">3.77% - 3.89%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">108.30% - 110.68%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">103.39% - 105.96%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:32.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.77% - 4.59%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.92% - 4.76%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">86.55% - 112.12%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">57.77% - 103.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company recorded stock-based compensation expense in the following expense categories in its accompanying unaudited interim consolidated statements of operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 436</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,057</p></td></tr></table></div><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,242</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,074</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,316</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets for Federal Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets for federal income taxes consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,689</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Capitalized research and development costs, net of amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,778</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,746</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Start-up costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,407</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,353</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 668</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortizable assets and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Equity compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 134,749</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (153,855)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133,580)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax assets, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,169</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Right of use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (848)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (645)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (429)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (524)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,277)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,169)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net deferred tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price unsatisfied</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,250</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2024 (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price unsatisfied</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,301</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,250</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total performance obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,551</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock', window );">Schedule of Changes in Deferred Revenue</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the changes in deferred revenue (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,413</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferral of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,173</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Recognition of unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,729)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,397)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,189</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the changes in deferred revenue (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,459</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferral of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,873</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recognition of unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,632)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,919)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,413</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ScheduleOfChangesInDeferredRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background (Details) - Employee Severance<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>employee</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Background</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Reduction in workforce, number of employees | employee</a></td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in workforce (as a percent)</a></td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Background</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">General and administrative<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Background</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Research and development<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSegmentAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSegmentAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Development-Stage Risks and Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DevelopmentStageRisksAndLiquidityAbstract', window );"><strong>Development-Stage Risks and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 314,845<span></span>
</td>
<td class="nump">$ 305,579<span></span>
</td>
<td class="nump">$ 245,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DevelopmentStageRisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DevelopmentStageRisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents - money markets accounts</a></td>
<td class="nump">$ 6,965<span></span>
</td>
<td class="nump">$ 14,887<span></span>
</td>
<td class="nump">$ 62,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents - money markets accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents - money markets accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="nump">$ 3,729<span></span>
</td>
<td class="nump">$ 3,397<span></span>
</td>
<td class="nump">$ 19,632<span></span>
</td>
<td class="nump">$ 14,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,266)<span></span>
</td>
<td class="num">(18,978)<span></span>
</td>
<td class="num">(60,477)<span></span>
</td>
<td class="num">(86,879)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=carm_ReportingSegmentMember', window );">Reporting Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="nump">3,729<span></span>
</td>
<td class="nump">3,397<span></span>
</td>
<td class="nump">19,632<span></span>
</td>
<td class="nump">14,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses', window );">Research and development, excluding facilities, personnel, depreciation and amortization expenses</a></td>
<td class="nump">1,528<span></span>
</td>
<td class="nump">10,191<span></span>
</td>
<td class="nump">33,147<span></span>
</td>
<td class="nump">45,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses', window );">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</a></td>
<td class="nump">2,421<span></span>
</td>
<td class="nump">3,656<span></span>
</td>
<td class="nump">14,829<span></span>
</td>
<td class="nump">19,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FacilitiesExpense', window );">Facilities expense</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">1,632<span></span>
</td>
<td class="nump">5,917<span></span>
</td>
<td class="nump">7,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Personnel expense</a></td>
<td class="nump">7,354<span></span>
</td>
<td class="nump">6,529<span></span>
</td>
<td class="nump">24,564<span></span>
</td>
<td class="nump">27,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities', window );">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
<td class="nump">3,894<span></span>
</td>
<td class="nump">3,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items(a)</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(818)<span></span>
</td>
<td class="num">(2,242)<span></span>
</td>
<td class="num">(2,204)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,266)<span></span>
</td>
<td class="num">$ (18,978)<span></span>
</td>
<td class="num">$ (60,477)<span></span>
</td>
<td class="num">$ (86,879)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Amortization And Interest On Finance And Sale-Leaseback Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FacilitiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facilities Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FacilitiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative, Excluding Facilities And Personnel Expenses, Depreciation And Amortization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development, Excluding Facilities, Personnel, Depreciation and Amortization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationAdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=carm_ReportingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=carm_ReportingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">6,895,824<span></span>
</td>
<td class="nump">8,210,547<span></span>
</td>
<td class="nump">7,746,991<span></span>
</td>
<td class="nump">6,023,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>stockholder </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 07, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger with Sesen Bio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfBoardMembers', window );">Number of board seats | stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Entity common stock, shares outstanding immediately after merger (in shares) | shares</a></td>
<td class="nump">40,609,915<span></span>
</td>
<td class="nump">41,788,096<span></span>
</td>
<td class="nump">41,750,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,499)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Less: Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total net assets acquired less transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=carm_CarismaTherapeuticsInc.Member', window );">Carisma Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger with Sesen Bio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfBoardMembers', window );">Number of board seats | stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and personnel costs paid</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember', window );">CARISMA Therapeutics Inc, Legacy, Stockholders | Carisma Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger with Sesen Bio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Entity common stock, shares outstanding immediately after merger (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,254,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of restricted cash from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Board Members</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=carm_CarismaTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=carm_CarismaTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PrepaidResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,715<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ReceivableDueFromCollaborativeArrangementCurrent', window );">Collaboration receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="nump">891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">$ 2,901<span></span>
</td>
<td class="nump">$ 5,916<span></span>
</td>
<td class="nump">$ 2,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PrepaidResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research and Development, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PrepaidResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ReceivableDueFromCollaborativeArrangementCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable due from Collaborative Arrangement, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ReceivableDueFromCollaborativeArrangementCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,272<span></span>
</td>
<td class="nump">$ 12,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: accumulated depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,887)<span></span>
</td>
<td class="num">(6,151)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,385<span></span>
</td>
<td class="nump">6,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionNetBookValue', window );">Sale lease-back asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Finance lease, ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation', window );">Sale leaseback transaction, accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Finance lease, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,157<span></span>
</td>
<td class="nump">11,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The accumulated depreciation and amortization related to the asset(s) sold in connection with the property sold to another party and leased back to the seller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481266/840-40-55-50<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481266/840-40-55-52<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481266/840-40-55-51<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481192/840-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionNetBookValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481266/840-40-55-50<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481266/840-40-55-52<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481266/840-40-55-51<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionNetBookValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 661<span></span>
</td>
<td class="nump">$ 1,693<span></span>
</td>
<td class="nump">$ 3,354<span></span>
</td>
<td class="nump">$ 2,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development</a></td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 1,845<span></span>
</td>
<td class="nump">$ 3,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related expenses</a></td>
<td class="nump">3,554<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 4,705<span></span>
</td>
<td class="nump">$ 7,448<span></span>
</td>
<td class="nump">$ 7,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification', window );">Decrease in finance lease, liability, lease modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleAndLeasebackTransactionGainLossNet', window );">Gain on sale of sale-leaseback</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="nump">$ 640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember', window );">Penn License Agreement | Penn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CommitmentsAnnualPaymentsRequiredToBePaid', window );">Annual payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AdditionalMilestonePaymentsForTheFirstCARMProduct', window );">Additional milestone payments for first CAR-M product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember', window );">Penn License Agreement | Penn | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AdditionalMilestonePaymentsRequiredToBePaid', window );">Additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember', window );">Novartis Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AgreementTerm', window );">Agreement term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Contract termination fee</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid asset</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AdditionalMilestonePaymentsForTheFirstCARMProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Milestone Payments for the First CAR-M Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AdditionalMilestonePaymentsForTheFirstCARMProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AdditionalMilestonePaymentsRequiredToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Milestone Payments Required to be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AdditionalMilestonePaymentsRequiredToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Payable upon Achievement of Certain Clinical, Regulatory and Commercial Milestone Events</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CommitmentsAnnualPaymentsRequiredToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Annual Payments Required To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CommitmentsAnnualPaymentsRequiredToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Finance Lease, Liability, Lease Modification</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 275<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479072/912-275-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleAndLeasebackTransactionGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleAndLeasebackTransactionGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_TrusteesOfUniversityOfPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_TrusteesOfUniversityOfPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 929<span></span>
</td>
<td class="nump">$ 1,469<span></span>
</td>
<td class="nump">$ 5,245<span></span>
</td>
<td class="nump">$ 5,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinanceLeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease assets</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinanceLeasesInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
<td class="nump">1,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 1,326<span></span>
</td>
<td class="nump">$ 3,475<span></span>
</td>
<td class="nump">$ 8,788<span></span>
</td>
<td class="nump">$ 8,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance lease cost expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinanceLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinanceLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinanceLeasesInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinanceLeasesInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LeasesWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LeasesWeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LeasesWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LeasesWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LeasesWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LeasesWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash used in operating leases</a></td>
<td class="nump">$ 707<span></span>
</td>
<td class="nump">$ 1,463<span></span>
</td>
<td class="nump">$ 5,807<span></span>
</td>
<td class="nump">$ 5,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinanceLeasesInterestPaymentOnLiability', window );">Operating cash used in finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinancingCashUsedInFinanceLeases', window );">Financing cash used in finance leases</a></td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">$ 1,319<span></span>
</td>
<td class="nump">$ 1,429<span></span>
</td>
<td class="nump">$ 1,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinanceLeasesInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinanceLeasesInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinancingCashUsedInFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinancingCashUsedInFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum payments</a></td>
<td class="nump">1,925<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">1,685<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum payments</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 640<span></span>
</td>
<td class="nump">$ 925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 06, 2023</div></th>
<th class="th"><div>Jun. 05, 2023</div></th>
<th class="th"><div>May 12, 2023</div></th>
<th class="th"><div>Apr. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in a pre-closing funding (in shares)</a></td>
<td class="nump">3,730,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue price per share (in USD per share)</a></td>
<td class="nump">$ 8.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">$ 30,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,282<span></span>
</td>
<td class="nump">$ 2,383<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)</a></td>
<td class="nump">5,059,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests', window );">Shares issued upon conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests (in shares)</a></td>
<td class="nump">18,872,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)</a></td>
<td class="nump">10,374,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_SaleOfStockStockOfferingAmount', window );">Stock offering, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_SaleOfStockMaximumOfferingAmount', window );">Sale of stock, maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketMember', window );">At-the-Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_SaleOfStockMaximumOfferingAmount', window );">Sale of stock, maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">931,250<span></span>
</td>
<td class="nump">1,136,384<span></span>
</td>
<td class="nump">226,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_SaleOfStockMaximumOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Maximum Offering Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_SaleOfStockMaximumOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_SaleOfStockStockOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Stock Offering, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_SaleOfStockStockOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandSeventeenStockIncentivePlanMember', window );">2017 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember', window );">2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount to the market price (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_TwoThousandSeventeenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_TwoThousandSeventeenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_TwoThousandFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2024 (in shares)</a></td>
<td class="nump">7,746,991<span></span>
</td>
<td class="nump">6,023,370<span></span>
</td>
<td class="nump">6,023,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(37,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,810)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,749,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,805,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(2,562,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,078,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of March 31, 2025 (in shares)</a></td>
<td class="nump">6,895,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,746,991<span></span>
</td>
<td class="nump">6,023,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of December 31, 2024 (in shares)</a></td>
<td class="nump">4,693,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,414,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December 31, 2024 (in USD per share)</a></td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in USD per share)</a></td>
<td class="nump">1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of March 31, 2025 (in USD per share)</a></td>
<td class="nump">2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.81<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of December 31, 2024 (in USD per share)</a></td>
<td class="nump">2.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value (in USD per share)</a></td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="nump">$ 4.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding as of December 31, 2024</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable as of December 31, 2024</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding as of December 31, 2024</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable as of December 31, 2024</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.77%<span></span>
</td>
<td class="nump">2.92%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.55%<span></span>
</td>
<td class="nump">57.77%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.59%<span></span>
</td>
<td class="nump">4.76%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.12%<span></span>
</td>
<td class="nump">103.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="nump">$ 3,649<span></span>
</td>
<td class="nump">$ 2,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock-based options forfeited (in shares)</a></td>
<td class="nump">2,562,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,078,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Future compensation cost for awards not vested</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period compensation cost of unvested awards to be expensed (in years)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_RevisedOperatingPlanMember', window );">Revised Operating Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock-based options forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,898,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember', window );">Sesen Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="nump">$ 1,116<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">$ 621<span></span>
</td>
<td class="nump">$ 2,533<span></span>
</td>
<td class="nump">$ 1,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_RevisedOperatingPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_RevisedOperatingPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local tax, net of federal benefit</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="num">(8.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal', window );">State and local tax rate change</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development</a></td>
<td class="num">(5.80%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in valuation allowance</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">28.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 87,742<span></span>
</td>
<td class="nump">$ 72,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization', window );">Capitalized research and development costs, net of amortization</a></td>
<td class="nump">35,608<span></span>
</td>
<td class="nump">33,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">13,269<span></span>
</td>
<td class="nump">9,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsStartUpCosts', window );">Start-up costs</a></td>
<td class="nump">4,051<span></span>
</td>
<td class="nump">4,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">12,182<span></span>
</td>
<td class="nump">13,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">733<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Accrued compensation</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsAmortizableAssetsAndOther', window );">Amortizable assets and other</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsEquityCompensation', window );">Equity compensation</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">155,132<span></span>
</td>
<td class="nump">134,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(153,855)<span></span>
</td>
<td class="num">(133,580)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(848)<span></span>
</td>
<td class="num">(645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(429)<span></span>
</td>
<td class="num">(524)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(1,277)<span></span>
</td>
<td class="num">(1,169)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets and liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsAmortizableAssetsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Amortizable Assets And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsAmortizableAssetsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsEquityCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Equity Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsEquityCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Start Up Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="nump">$ 84.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">374.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">12.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=carm_StateJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">280.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=carm_StateJurisdictionMember', window );">State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=carm_LocalJurisdictionMember', window );">Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=carm_Pre2018Member', window );">Pre-2018 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=carm_Post2017Member', window );">Post-2017 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 254.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=carm_StateJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=carm_StateJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=carm_LocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=carm_LocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=carm_Pre2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=carm_Pre2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=carm_Post2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=carm_Post2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>product </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,250<span></span>
</td>
<td class="nump">46,189<span></span>
</td>
<td class="nump">44,979<span></span>
</td>
<td class="nump">46,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
<td class="nump">$ 3,397<span></span>
</td>
<td class="nump">19,632<span></span>
</td>
<td class="nump">$ 14,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=carm_OptionRightCollaborationRevenuesMember', window );">Option Right Collaboration Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=carm_MilestonesMember', window );">Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember', window );">Moderna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Collaboration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember', window );">Moderna | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfOtherReceivables', window );">Proceeds from collection of collaboration receivable</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfPotentialResearchTargetDesignations', window );">Number of potential research target designations | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_VariableConsideration', window );">Variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ContractTerm', window );">Term of contract (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Noncurrent portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_MaximumNumberOfResearchTargets', window );">Maximum of research targets | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsNominatedAutoimmune', window );">Number of nominated autoimmune target | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsGrossOncology', window );">Number of oncology research targets | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsGrossOncology', window );">Number of oncology research targets | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_UpfrontNonRefundablePaymentReceived', window );">Upfront non-refundable payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfPotentialProductsToDevelopAndCommercialize', window );">Number of potential products to develop and commercialize | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts', window );">Minimum commitment to reimburse research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts', window );">Period of reimbursement of research and development costs (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfPerformanceObligations', window );">Number of performance obligations | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna | Minimum | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments', window );">Amount receivable per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna | Maximum | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments', window );">Amount receivable per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember', window );">Moderna License Agreement | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember', window );">Moderna License Agreement | Option Right Collaboration Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember', window );">Moderna License Agreement | Moderna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount receivable per product in development target designation, development, regulatory and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CollaborativeArrangementRightsAndObligationsMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_MaximumNumberOfResearchTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of research targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_MaximumNumberOfResearchTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum commitment to reimburse research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfPotentialProductsToDevelopAndCommercialize">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of potential products to develop and commercialize</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfPotentialProductsToDevelopAndCommercialize</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfPotentialResearchTargetDesignations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Potential Research Target Designations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfPotentialResearchTargetDesignations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsGrossOncology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets, Gross, Oncology</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsGrossOncology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsNominatedAutoimmune">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets Nominated, Autoimmune</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsNominatedAutoimmune</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of reimbursement of research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_UpfrontNonRefundablePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront non-refundable payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_UpfrontNonRefundablePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_VariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_VariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the collection of receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=carm_OptionRightCollaborationRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=carm_OptionRightCollaborationRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=carm_MilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=carm_MilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=carm_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=carm_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationAbstract', window );"><strong>Performance obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_RevenueRemainingPerformanceObligationOptionRightsAmount', window );">Option rights</a></td>
<td class="nump">$ 41,250<span></span>
</td>
<td class="nump">41,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_RevenueRemainingPerformanceObligationOptionRightsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_RevenueRemainingPerformanceObligationOptionRightsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to research and development performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInDeferredRevenueRollForward', window );"><strong>Movement in Deferred Revenue [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 44,979<span></span>
</td>
<td class="nump">$ 46,413<span></span>
</td>
<td class="nump">$ 46,413<span></span>
</td>
<td class="nump">$ 47,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ContractWithCustomerLiabilityDeferralOfRevenue', window );">Deferral of revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,173<span></span>
</td>
<td class="nump">16,198<span></span>
</td>
<td class="nump">13,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of unearned revenue</a></td>
<td class="num">(3,729)<span></span>
</td>
<td class="num">(3,397)<span></span>
</td>
<td class="num">(17,632)<span></span>
</td>
<td class="num">(14,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at the end of the period</a></td>
<td class="nump">$ 41,250<span></span>
</td>
<td class="nump">$ 46,189<span></span>
</td>
<td class="nump">$ 44,979<span></span>
</td>
<td class="nump">$ 46,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ContractWithCustomerLiabilityDeferralOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue deferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ContractWithCustomerLiabilityDeferralOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInDeferredRevenueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInDeferredRevenueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>item</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>employee</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Reduction in workforce, number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in workforce (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance | 2025 Cash Preservation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Reduction in workforce, number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in workforce (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember', window );">Moderna | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsNominatedOncology', window );">Number of oncology research targets, nominated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsNominatedReplacements', window );">Number of research targets, replacement nominations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsTerminatedOncology', window );">Number of oncology research targets, ceased development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsTerminatedAutoimmune', window );">Number of autoimmune research targets, ceased development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsGrossOncology', window );">Number of oncology research targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Employee Severance | 2025 Cash Preservation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Reduction in workforce, number of employees | employee</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in workforce (as a percent)</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost with the reduction in workforce | $</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Moderna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfOtherReceivables', window );">Proceeds from collection of collaboration receivable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Moderna | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsNominatedOncology', window );">Number of oncology research targets, nominated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsNominatedReplacements', window );">Number of research targets, replacement nominations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsTerminatedOncology', window );">Number of oncology research targets, ceased development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsTerminatedAutoimmune', window );">Number of autoimmune research targets, ceased development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsGrossOncology', window );">Number of oncology research targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsGrossOncology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets, Gross, Oncology</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsGrossOncology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsNominatedOncology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets Nominated, Oncology</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsNominatedOncology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsNominatedReplacements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets Nominated, Replacements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsNominatedReplacements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsTerminatedAutoimmune">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets, Terminated, Autoimmune</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsTerminatedAutoimmune</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsTerminatedOncology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets, Terminated, Oncology</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsTerminatedOncology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the collection of receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=carm_CashPreservationPlan2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=carm_CashPreservationPlan2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,740<span></span>
</td>
<td class="nump">$ 17,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,901<span></span>
</td>
<td class="nump">5,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="nump">3,313<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,954<span></span>
</td>
<td class="nump">23,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets - operating leases</a></td>
<td class="nump">1,999<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredFinancingCostsNoncurrent', window );">Deferred financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">15,953<span></span>
</td>
<td class="nump">30,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,251<span></span>
</td>
<td class="nump">2,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,705<span></span>
</td>
<td class="nump">7,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">998<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">640<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,447<span></span>
</td>
<td class="nump">16,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">41,250<span></span>
</td>
<td class="nump">41,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">52,615<span></span>
</td>
<td class="nump">58,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock $0.001 par value, 350,000,000 shares authorized, 41,788,096 and 41,750,109 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">278,142<span></span>
</td>
<td class="nump">277,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(314,845)<span></span>
</td>
<td class="num">(305,579)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' deficit</a></td>
<td class="num">(36,662)<span></span>
</td>
<td class="num">(27,909)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 15,953<span></span>
</td>
<td class="nump">$ 30,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredFinancingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Financing Costs, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredFinancingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 06, 2023</div></th>
<th class="th"><div>Jun. 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">41,788,096<span></span>
</td>
<td class="nump">41,750,109<span></span>
</td>
<td class="nump">40,609,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">41,788,096<span></span>
</td>
<td class="nump">41,750,109<span></span>
</td>
<td class="nump">40,609,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="nump">$ 3,729<span></span>
</td>
<td class="nump">$ 3,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,156<span></span>
</td>
<td class="nump">17,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,907<span></span>
</td>
<td class="nump">5,445<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,063<span></span>
</td>
<td class="nump">22,907<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(9,334)<span></span>
</td>
<td class="num">(19,510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Pre-tax loss</a></td>
<td class="num">(9,266)<span></span>
</td>
<td class="num">(18,978)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,266)<span></span>
</td>
<td class="num">$ (18,978)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in USD per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in USD per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding, basic (in shares)</a></td>
<td class="nump">41,771,213<span></span>
</td>
<td class="nump">40,938,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding, diluted (in shares)</a></td>
<td class="nump">41,771,213<span></span>
</td>
<td class="nump">40,938,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1,197<span></span>
</td>
<td class="num">$ (158,223)<span></span>
</td>
<td class="num">$ (142,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">128,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)</a></td>
<td class="nump">226,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,879)<span></span>
</td>
<td class="num">$ (86,879)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">40,609,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,609,915<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">271,594<span></span>
</td>
<td class="num">(245,102)<span></span>
</td>
<td class="nump">$ 26,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)</a></td>
<td class="nump">931,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,978)<span></span>
</td>
<td class="num">(18,978)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">41,542,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">274,934<span></span>
</td>
<td class="num">(264,080)<span></span>
</td>
<td class="nump">$ 10,895<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">40,609,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,609,915<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">271,594<span></span>
</td>
<td class="num">(245,102)<span></span>
</td>
<td class="nump">$ 26,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">3,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)</a></td>
<td class="nump">1,136,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,477)<span></span>
</td>
<td class="num">$ (60,477)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">41,750,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,750,109<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">277,629<span></span>
</td>
<td class="num">(305,579)<span></span>
</td>
<td class="num">$ (27,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">37,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,266)<span></span>
</td>
<td class="num">$ (9,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="nump">41,788,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,788,096<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 278,142<span></span>
</td>
<td class="num">$ (314,845)<span></span>
</td>
<td class="num">$ (36,662)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,266)<span></span>
</td>
<td class="num">$ (18,978)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the operating right of use assets</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write-off of deferred financing costs</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on sale of property and equipment</a></td>
<td class="num">(113)<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">3,015<span></span>
</td>
<td class="num">(1,572)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,170<span></span>
</td>
<td class="num">(1,826)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(2,743)<span></span>
</td>
<td class="num">(2,933)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(3,729)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(707)<span></span>
</td>
<td class="num">(1,355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long term liabilities</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,067)<span></span>
</td>
<td class="num">(22,425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">524<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of principal related to finance lease liabilities</a></td>
<td class="num">(304)<span></span>
</td>
<td class="num">(1,319)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ProceedsFromFailedSaleLeasebackTransaction', window );">Proceeds from failed sale-leaseback arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction', window );">Payment of finance liability from failed sale-leaseback arrangements</a></td>
<td class="num">(327)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(626)<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(10,169)<span></span>
</td>
<td class="num">(21,090)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of the year</a></td>
<td class="nump">17,909<span></span>
</td>
<td class="nump">77,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of the period</a></td>
<td class="nump">7,740<span></span>
</td>
<td class="nump">56,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">4,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for new financing lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment in accounts payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in interest expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in a failed sale-leaseback recognized in financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ProceedsFromFailedSaleLeasebackTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow received by a seller-lessee in a failed sale-leaseback recognized in financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ProceedsFromFailedSaleLeasebackTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Background</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-weight:bold;">Background</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma Therapeutics&#160;Inc., a Delaware corporation (collectively with its subsidiaries, the Company), is a biotechnology company focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;and December&#160;2024, the Company&#8217;s board of directors approved revised operating plans to reduce&#160;monthly operating expenses, conserve cash, and refocus the Company&#8217;s efforts on strategic priorities. As part of these plans, in March&#160;2024 the Company elected to cease further development of its first lead product candidate, CT-0508. In December&#160;2024 as part of the plan, the Company elected to cease further development of its then lead product candidate, CT-0525, following an assessment of the competitive landscape in anti-HER2 treatments and the impact of recently approved therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of a further revised plan approved by the Company&#8217;s board of directors on March&#160;25, 2025 to preserve the Company&#8217;s existing cash resources following its reduction in workforce, as further discussed below (the cash preservation plan), the Company reduced its operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down its business. The cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help to evaluate our strategic alternatives. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company&#8217;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. Any future resumption of research and development activities would depend on completing a strategic transaction that would support the Company&#8217;s prior operating plans or otherwise obtaining significant additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of the cash preservation plan, the board of directors determined to terminate all of its employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. Affected employees were informed of the reduction in workforce on March&#160;25, 2025, which became effective on March&#160;31, 2025. The reduction in workforce included 37 of the Company&#8217;s full-time employees representing approximately 84% of the Company&#8217;s total workforce, including certain employees engaged in research and development, manufacturing and corporate activities. The Company incurred approximately $3.4&#160;million in connection with the reduction in workforce during the three&#160;months ended March&#160;31, 2025 and expects to incur an additional $0.4&#160;million in the second quarter of 2025 related to further potential terminations, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. The Company expects to pay the majority of related reduction in workforce amounts by the end of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">NASDAQ Compliance</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;10, 2024, the Company received written notice from The Nasdaq Stock Market LLC (Nasdaq) indicating that the Company no longer satisfied Nasdaq Listing Rule&#160;5450(b)(2)(A), which requires the Company to maintain a minimum market value of listed securities (MVLS) of $50.0 million (the MVLS Rule) for continued listing on The Nasdaq Global Market. In accordance with Nasdaq Listing Rule&#160;5810(c)(3)&#160;(the Grace Period Rule), the Company had 180 calendar&#160;days, or until April&#160;8, 2025 (the Compliance Date), to regain compliance with the MVLS Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;10, 2025, Nasdaq notified the Company that, based upon the Company&#8217;s continued non-compliance with the MVLS Rule, as of the Compliance Date, the Company&#8217;s securities were subject to delisting from Nasdaq unless the Company requested a hearing before the Nasdaq Hearings Panel (the Panel). The Company has requested a hearing before the Panel, which is scheduled to be held on May&#160;22, 2025. The request has stayed any further suspension or delisting action by Nasdaq at least until the hearing is held and any extension that the Panel may grant to the Company following the hearing has expired. There can be no assurance that the Panel will grant the Company&#8217;s request for continued listing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on April&#160;10, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule&#160;5450(b)(2)(C), which requires the Company to maintain a minimum market value of publicly held shares (MVPHS) of $15.0&#160;million (the MVPHS Rule) for continued listing on The Nasdaq Global Market. In accordance with the Grace Period Rule, the Company has 180 calendar&#160;days, or until October&#160;7, 2025, to regain compliance with the MVPHS Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, and as previously disclosed, on January&#160;6, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule&#160;5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share (the Bid Price Rule&#160;together with the MVLS Rule&#160;and the MVPHS Rule, the Price-based Rules) for continued listing on The Nasdaq Global Market. In accordance with the Grace Period Rule, the Company has 180 calendar&#160;days, or until July&#160;7, 2025, to regain compliance with the Bid Price Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To evidence compliance with the Price-based Rules, an issuer must evidence compliance with the applicable minimum threshold for at least ten, but generally not more than 20, consecutive business&#160;days. Although the Company is considering all available options to regain compliance with the applicable listing criteria, there can be no assurance that the Company will be able to do so.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-weight:bold;">Background</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Carisma Therapeutics&#160;Inc., a Delaware corporation (collectively with its subsidiaries, the Company), biotechnology company focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;and December&#160;2024, the Company and its board of directors approved revised operating plans to reduce&#160;monthly operating expenses, conserve cash, and refocus its efforts on strategic priorities. As part of these plans, in March&#160;2024 the Company elected to cease further development of its first lead product candidate, CT-0508. In December&#160;2024 as part of the plan, the Company elected to cease further development of its then lead product candidate, CT-0525, following an assessment of the competitive landscape in anti-HER2 treatments and the impact of recently approved therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of its cost-reduction initiatives in 2024, the Company implemented workforce reductions during 2024, resulting in the termination of 62 full-time employees (representing approximately 58.0% of the Company&#8217;s total workforce), across research and development and general and administrative functions. The workforce reduction resulted in $4.1&#160;million of severance related costs, of which $2.0&#160;million and $2.1&#160;million are included within <span style="-sec-ix-hidden:Hidden_fhlu0P8GC0OSYzMKRGa6pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general and administrative</span></span> and <span style="-sec-ix-hidden:Hidden_qKYmVxKGPEGEDMmZP0kvsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research and development</span></span> expense, respectively, in the accompanying consolidated statement of operations and comprehensive loss. As of December&#160;31, 2024, $2.7&#160;million in severance costs were accrued in the accompanying consolidated balance sheets. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the 2024 reduction in workforce.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;10, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that our common stock was not in compliance with Nasdaq Listing Rule&#160;5450(b)(2)(A), or the MVLS Requirement, which requires the Company to maintain a minimum market value of listed securities of $50,000,000. The Company has 180 calendar&#160;days, or until April&#160;8, 2025, to regain compliance with the MVLS Requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On January&#160;6, 2025, the Company received a separate written notice from Nasdaq notifying the Company that, based upon the closing bid price of its common stock for the last 38 consecutive business&#160;days, the Company was not in compliance with Nasdaq Listing Rule&#160;5450(a)(1)&#160;(the Bid Price Rule), which requires the Company to maintain a minimum bid price of $1.00 per share. The Company has 180 calendar&#160;days, or until July&#160;7, 2025, to regain compliance with the Bid Price Rule.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development-Stage Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DevelopmentStageRisksAndLiquidityAbstract', window );"><strong>Development-Stage Risks and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DevelopmentStageRisksAndLiquidityTableTextBlock', window );">Development-Stage Risks and Liquidity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(2)</b></span><b style="font-size:10pt;font-weight:bold;">Development-Stage Risks and Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $314.8 million as of March&#160;31, 2025. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of March&#160;31, 2025, the Company had cash and cash equivalents of $7.7 million. Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one&#160;year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company&#8217;s ability to continue as a going concern. In addition, changing circumstances could cause the Company to consume capital significantly faster than currently anticipated, and the Company may need to spend more than currently expected because of circumstances beyond its control. The Company&#8217;s cash forecast contains estimates and assumptions, and management cannot predict the timing of all cash receipts and expenditures with certainty. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liability that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management is currently evaluating different strategies to maximize value and prepare to wind down the Company&#8217;s business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company&#8217;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. There is no assurance regarding when or if this strategic review process will result in any type of transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DevelopmentStageRisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DevelopmentStageRisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DevelopmentStageRisksAndLiquidityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on risks of development-stage and liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DevelopmentStageRisksAndLiquidityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(3)</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interim Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summary of significant accounting policies is included in the Company&#8217;s audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (SEC) on March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance are meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The accompanying unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. In the opinion of management, the accompanying unaudited interim consolidated financial statements include all </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2025 and its results of operations for the three&#160;months ended March&#160;31, 2025 and 2024. Operating results for the three&#160;months ended March&#160;31, 2025 are not necessarily indicative of the results that may be expected for the&#160;year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain all of the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Company&#8217;s Annual Report on Form&#160;10-K filed with the SEC on March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant areas that require management&#8217;s estimates include stock-based compensation assumptions and accrued research and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Assets Held for Sale</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2025, the Company committed to a plan to sell its remaining equipment and therefore has classified the amount as assets held for sale on the consolidated balance sheet as of March&#160;31, 2025. The assets held for sale were reported at the lower of the carrying amount or fair value, less costs to sell.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value of Financial Instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value Measurements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2025 and 2024, there were no transfers between Level 1, Level 2 and Level 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Concentration of credit risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Segment information</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the three&#160;months ended March&#160;31, 2025 and 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,397</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,191</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,656</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,632</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,529</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,185</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (818)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,266)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,978)</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">&#8220;Other segment items&#8221; includes</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> interest income.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net loss per share</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,895,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,210,547</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recently issued accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes </i>(Topic 740)<i style="font-style:italic;">: Improvements to Income Tax Disclosures </i>(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November&#160;2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures </i>(Subtopic 220-40): <i style="font-style:italic;">Disaggregation of Income Statement Expenses</i>, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(3)</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant areas that require management&#8217;s estimates include estimated research and development revenue, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1)&#160;non-refundable, upfront license fees (2)&#160;reimbursement of certain costs; (3)&#160;customer option fees for additional goods or services; (4)&#160;development milestone payments, (5)&#160;regulatory and commercial milestone payments; and (6)&#160;royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&#160;the number of performance obligations based on the determination under step (i)&#160;above; (b)&#160;the transaction price under step (iii)&#160;above; (c)&#160;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&#160;above; and (d)&#160;the contract term and pattern of satisfaction of the performance obligations under step (v)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Upfront license fees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Customer options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and development services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The promises under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company&#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Segment information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">assessing performance. The Company has one operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the&#160;years ended December&#160;31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,919</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,905</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,118</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,671</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,324</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,984</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other segment items(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,242)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,204)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (60,477)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,879)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other segment items include changes in warrant liability and interest income.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. As of December&#160;31, 2024 and 2023, cash equivalents consisted of investments in a money market account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_w59cdNVWLU6d09CxPojcvA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to five&#160;years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did not recognize any impairment of long-lived assets during the&#160;years ended December&#160;31, 2024 or 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Deferred Financing Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one&#160;year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company&#8217;s common stock prior to the Merger (as defined in Note&#160;4), and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Merger (as defined in Note&#160;4), the fair value of the Company&#8217;s common stock was estimated by the Company&#8217;s board of directors, with input by management considering the Company&#8217;s most recently available third-party valuation of the Company&#8217;s common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company&#8217;s consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#8217;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,023,370</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </i>(ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024 on a retrospective basis. The Company incorporated the improved segment disclosures in the summary of significant accounting policies, herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently issued but not yet adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </i>(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In November&#160;2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and other assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and other assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(4)</b></span><b style="font-weight:bold;">Prepaid Expenses and other assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,715</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration receivable (Note 10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,864</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables (a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 925</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,916</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">&#8220;Other receivables&#8221; primarily</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> consisted of equipment sales, sales and use tax refunds, and research and development tax refunds.</span></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(5)</b></span><b style="font-weight:bold;">Prepaid Expenses and Other Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prepaid expenses and other assets consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 278</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Collaboration receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 402</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 891</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,295</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,866</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(5)</b></span><b style="font-weight:bold;">Accrued Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,845</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 537</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,879</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,448</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(7)</b></span><b style="font-weight:bold;">Accrued Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,131</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,366</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,100</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,662</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(6)</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#8217;s operating leases have term end dates ranging from 2025 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2025 to 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operating and finance lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company carries laboratory equipment from failed sale-leasebacks, as assets held for sale on the accompanying unaudited interim consolidated balance sheets. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of March&#160;31, 2025, the Company had a $1.7 million financing liability recorded in other current liabilities and other long-term liabilities on the unaudited interim consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The elements of the lease costs were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,469</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,298</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,534</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 472</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,475</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Lease term and discount rate information related to leases was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Supplemental cash flow information was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,463</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,319</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Future maturities of lease liabilities were as follows as of March&#160;31, 2025 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiscal year ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 (remaining nine months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 659</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (240)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 640</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licensing and Sponsored Research Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November&#160;2017, the Company is required to make annual payments of $25,000. Penn is eligible to receive up to $10.9&#160;million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $30.0&#160;million per product in commercial milestones and up to an additional $1.7&#160;million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Contingencies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. As of March&#160;31, 2025, the Company was in negotiations with a vendor to determine the total costs owed for research and development services provided. While the negotiations are ongoing, the Company believes a liability is probable. The Company has estimated the amount to be owed to be $1.5&#160;million, of which $1.0&#160;million and $0.5&#160;million are included within accounts payable and accrued </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">expenses, respectively, on the accompanying consolidated balance sheets. The final amount owed may differ from the estimate as negotiations progress. The Company will continue to evaluate the matter and will adjust the liability as necessary based on any new information or agreements reached with the vendor.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(8)</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#8217;s operating leases have term end dates ranging from 2025 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2025 to 2026. Effective February&#160;2024, the Company renewed an existing operating lease with an end date through 2026. In April&#160;2024, in connection with the revised operating plan, the Company notified the lessor that it would terminate the lease effective August&#160;2024. In July&#160;2024, the Company entered into an amendment extending the termination date of the lease to June&#160;2025 with an option to extend to December&#160;2025. The Company did not incur any penalties or fees in connection with the termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In September&#160;2024, the Company modified existing finance leases and failed sale-leaseback arrangements by assigning the rights and obligations of certain underlying assets to an unrelated third party. The modifications resulted in a reduction of its finance lease </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ROU assets and related lease liability of $0.4&#160;million. In addition, the Company recorded a reduction of its failed sale-leaseback liability and gain on the sale of the corresponding assets of $0.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operating and finance lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company carries laboratory equipment from failed sale-leasebacks, as property and equipment, net on the accompanying consolidated balance sheets. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of December&#160;31, 2024, the Company had a $1.4 million financing liability recorded in other current liabilities and other long-term liabilities on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The elements of the lease costs were as follows (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,774</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,187</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,326</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,733</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Short term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,833</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lease term and discount rate information related to leases was as follows:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information was as follows (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,764</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,301</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future maturities of lease liabilities were as follows as of December&#160;31, 2024 (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fiscal year ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 942</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 963</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (253)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 925</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Licensing and Sponsored Research Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November&#160;2017 (Penn License Agreement), the Company is required to make annual payments of $25,000. Penn is eligible to receive up to $10.9 million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $30.0 million per product in commercial milestones and up to an additional $1.7 million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2023, the Company entered into a manufacturing and supply agreement with Novartis Pharmaceuticals Corporation (Novartis) for the manufacturing of the Company&#8217;s CT-0508 product candidate (Novartis Agreement). The Novartis Agreement had a five year term. On June&#160;26, 2024, in furtherance of its revised operating plan approved in late March&#160;2024, the Company terminated the Novartis Agreement. Upon termination, the Company incurred a termination fee equal to $4.0&#160;million, which was paid in the third quarter of 2024. A prepaid asset was recorded as the Company separately agreed with Novartis that if Novartis and the Company re-negotiate the agreement for a substitute product on or before December&#160;31, 2024, then the $4.0&#160;million termination fee would be credited in full or in part against any amounts due from the Company to Novartis under such agreement relating to the substitute product. The Company did not re-negotiate the agreement and expensed the $4.0&#160;million prepaid asset in the fourth quarter of 2024 to research and development in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. As of December&#160;31, 2024, the Company was in negotiations with a vendor to determine the total costs owed for research and development services provided. While the negotiations are ongoing, the Company believes a liability is probable. The Company has estimated the amount to be owed to be $1.2&#160;million which is included within accrued expenses on the accompanying consolidated balance sheets. The final amount owed may differ from the estimate as negotiations progress. The Company will continue to evaluate the matter and will adjust the liability as necessary based on any new information or agreements reached with the vendor.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(7)</b></span><b style="font-size:10pt;font-weight:bold;">Stockholders&#8217; E</b><b style="font-size:10pt;font-weight:bold;">quity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Open Market Sales Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">On April&#160;17, 2023, the Company filed a universal shelf registration statement on Form&#160;S-3, which was declared effective on May&#160;2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to </span><span style="font-size:10pt;">$300.0</span><span style="font-size:10pt;">&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May&#160;12, 2023, the Company entered into an Amended and Restated Open Market Sale Agreement</span>SM <span style="font-size:10pt;">(Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to </span><span style="font-size:10pt;">$100.0</span><span style="font-size:10pt;">&#160;million under an &#8220;at-the-market&#8221; offering program. During the three&#160;months ended March&#160;31, 2024, the Company sold </span><span style="font-size:10pt;">931,250</span><span style="font-size:10pt;"> shares of common stock for gross proceeds of </span><span style="font-size:10pt;">$2.3</span><span style="font-size:10pt;">&#160;million. The Company did </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;">t sell any shares of common stock under the Sale Agreement during the three&#160;months ended March&#160;31, 2025.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(9)</b></span><b style="font-weight:bold;">Stockholders</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#8217;</b><b style="font-weight:bold;"> (Deficit) Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March&#160;7, 2023, in connection with the closing of the Merger, the following is reflected on the consolidated statements of convertible preferred stock and stockholders&#8217; (deficit) equity for the&#160;year ended December&#160;31, 2023: (i)&#160;the sale of 3,730,608 shares of common stock in a pre-closing funding at $8.21 per share for total proceeds of $30.6 million, (ii)&#160;the issuance of 5,059,338 shares of common stock upon the settlement of the Company&#8217;s $35.0 million convertible promissory note, accrued interest and related derivative liability, (iii)&#160;the conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">interests into 18,872,711 shares of common stock, (iv)&#160;the issuance of 10,374,272 shares of common stock to Sesen Bio stockholders as consideration for the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;17, 2023, the Company filed a universal shelf registration statement on Form&#160;S-3, which was declared effective on May&#160;2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to $300.0&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May&#160;12, 2023, the Company entered into an Amended and Restated Open Market Sale AgreementSM (Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to $100.0&#160;million under an &#8220;at-the-market&#8221; offering program. During the&#160;years ended December&#160;31, 2024 and 2023, the Company sold 1,136,384 and 226,533 shares of common stock, respectively, for gross proceeds of $2.4&#160;million and $0.6&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On June&#160;6, 2023, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Restated Certificate of Incorporation to increase the number of authorized shares of the Company&#8217;s common stock, $0.001 par value, from 100,000,000 shares to 350,000,000 shares and authorized 5,000,000 shares of preferred stock, $0.001 par value.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(8)</b></span><b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2017 Stock Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the CARISMA Therapeutics&#160;Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was ten&#160;years, and stock options typically vested over a <span style="-sec-ix-hidden:Hidden_Y6YvLEfyKUG_kk0uMc5sKQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four-year</span></span> period. The Company&#8217;s stock options vest based on the terms in the awards agreements and generally vest over <span style="-sec-ix-hidden:Hidden_DGF8BxLO20aH0nuzKXhnJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four&#160;years</span></span>. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder and ceased granting awards under the Legacy Carisma Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2014 Stock Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Amended and Restated Stock Incentive Plan, as amended (the 2014 Plan), provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Company&#8217;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#8217;s board of directors at the time of grant. Stock options outstanding under the 2014 Plan generally vest over a <span style="-sec-ix-hidden:Hidden_RR1pBUqe5UemOm2ln3QA2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four-year</span></span> period and are exercisable for a period of ten&#160;years from the date of grant. As of March&#160;31, 2025, approximately 5.6&#160;million shares of common stock remained available for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2014 Employee Stock Purchase Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carisma Therapeutics&#160;Inc. 2014 Employee Stock Purchase Plan (the 2014 ESPP) provides employees with the opportunities to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The 2014 ESPP had 0.2 million shares of common stock available for issuance as of March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes stock option activity for the three&#160;months ended March&#160;31, 2025:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,987)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,749,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,562,180)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,895,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,693,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The weighted-average grant-date per share fair values of options granted during the three&#160;months ended March&#160;31, 2025 and 2024 were $0.42 and $1.72, respectively. The fair values in the three&#160;months ended March&#160;31, 2025 and 2024 were estimated using the Black-Scholes option-pricing model based on the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">4.32% - 4.35%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">3.77% - 3.89%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">108.30% - 110.68%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">103.39% - 105.96%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock-Based Compensation Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company recorded stock-based compensation expense in the following expense categories in its accompanying unaudited interim consolidated statements of operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 436</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,057</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the cash preservation plan, 2.6&#160;million options were forfeited during the three&#160;months ended March&#160;31, 2025, resulting in a reduction in stock-based compensation expense related to research and development and, general and administrative employees. Compensation cost for awards not vested as of March&#160;31, 2025 was $3.7&#160;million and will be expensed over a weighted-average period of 2.3&#160;years.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(10)</b></span><b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2017 Stock Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the CARISMA Therapeutics&#160;Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was ten&#160;years, and stock options typically vested over a <span style="-sec-ix-hidden:Hidden_sktIWaH1v0C3Alvvbznotw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four-year</span></span> period. The Company&#8217;s stock options vest based on the terms in the awards agreements and generally vest over <span style="-sec-ix-hidden:Hidden_wSmhQcT4p0uaTZTD8dNi8A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four&#160;years</span></span>. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Legacy Carisma Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2014 Stock Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Amended and Restated 2014 Stock Incentive Plan, as amended, provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Company&#8217;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#8217;s board of directors at the time of grant. Stock options outstanding under the 2014 Amended and Restated Stock Incentive Plan (the 2014 Plan) generally vest over a four-year period and are exercisable for a period of ten&#160;years from the date of grant. As of December&#160;31, 2024, approximately 4.8 million shares of common stock remained available for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2014 Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carisma Therapeutics&#160;Inc. 2014 Employee Stock Purchase Plan (the Carisma 2014 ESPP) provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The purpose of the Carisma 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock. The Carisma 2014 ESPP had 0.2 million shares of common stock available for issuance as of December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,023,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,810)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,805,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,078,034)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,414,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date per share fair values of options granted during the&#160;years ended December&#160;31, 2024 and 2023 were $1.36 and $4.29, respectively. The fair values in the&#160;years ended December&#160;31, 2024 and 2023 were estimated using the Black-Scholes option-pricing model based on the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:32.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.77% - 4.59%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.92% - 4.76%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">86.55% - 112.12%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">57.77% - 103.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,242</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,074</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,316</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the reductions in force, 1,898,297 options were forfeited during the&#160;year ended December&#160;31, 2024. The Company recognized stock-based compensation expense of $0.2 million related to the modification of Sesen Bio options assumed in connection with the Merger during the&#160;year ended December&#160;31, 2023. Compensation cost for awards not vested as of December&#160;31, 2024 was $7.2 million and will be expensed over a weighted-average period of 2.5&#160;years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(9)</b></span><b style="font-weight:bold;">Related-Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has a collaboration and license agreement with Moderna, a significant stockholder (See Note&#160;10&#160;&#8211; Moderna Collaboration and License Agreement).</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(12)</b></span><b style="font-weight:bold;">Related-Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company has a collaboration and license agreement with Moderna, a significant shareholder (Note&#160;13).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Moderna Collaboration and License Agreement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(10)</b></span><b style="font-weight:bold;">Moderna Collaboration and License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In January&#160;2022, the Company entered into a collaboration agreement with Moderna (the Moderna License Agreement), which provides for a broad strategic collaboration to discover, develop and commercialize <i style="font-style:italic;">in vivo </i>engineered chimeric antigen receptor macrophage and monocyte (CAR-M) therapeutics in oncology. Moderna has the right to designate up to twelve research targets as development targets under this collaboration. While the collaboration was initially limited to oncology, in September&#160;2024, the companies agreed to expand the collaboration to discover, develop and commercialize <i style="font-style:italic;">in vivo </i>engineered CAR-M therapeutics in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">specific autoimmune diseases. As of February&#160;2025, in connection with Moderna&#8217;s nomination of all 12 oncology research targets, the Company will not be conducting any additional research activities under the collaboration agreement and will not be receiving any further payments from Moderna for research and development services under the collaboration agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subsequent to the nomination of a research target, Moderna may designate the research target as a development target. Upon Moderna&#8217;s designation of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $45.0 million to the Company. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, the Company is eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. Moderna reimbursed the Company for costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed into the first quarter of 2025; however, as discussed below, Moderna will no longer reimburse the Company for research and development services. The Company is eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments and royalties that the Company owes as a licensor under one of its intellectual property in-license agreements with Penn, which is sublicensed to Moderna under the Moderna License Agreement. Moderna may deduct these royalties in part from any royalties owed to the Company. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities and participation on the joint steering committee. The Company determined that there were 2 performance obligations comprised of (i)&#160;research and development services and (ii)&#160;option rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The transaction price of $45.0&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna exercises or determines not to exercise its option right to license and commercialize the designated development target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company included the $45.0 million up-front and nonrefundable payment in the transaction price as of the outset of the arrangement. During the three&#160;months ended March&#160;31, 2025 and 2024, the Company recognized $3.7 million and $3.4 million, respectively, of collaboration revenues. As discussed below, Moderna will no longer be reimbursing the Company for research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $42.4&#160;million and $3.8&#160;million, respectively, of research and development services and option right collaboration revenues since inception of the Moderna License Agreement through March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In February&#160;2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February 2025, Moderna has nominated all 12 oncology research targets under the collaboration for which the Company has the potential to receive future milestones and royalty payments. The Company will not conduct any additional research activities under the collaboration agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">and the Company will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the <i style="font-style:italic;">in vivo </i>oncology field exclusivity, which would allow the Company to pursue <i style="font-style:italic;">in vivo </i>CAR-M programs outside of the 12 nominated oncology targets and product polypeptides. The Company does not expect to recognize any additional unsatisfied research and development performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price unsatisfied</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,250</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s unaudited interim consolidated balance sheets. Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s unaudited interim consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the changes in deferred revenue (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,413</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferral of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,173</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Recognition of unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,729)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,397)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,189</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The deferred revenue represents the unearned portion of the upfront, non-refundable and non-creditable payment allocated to Moderna&#8217;s option rights of $41.3 million, which is not expected to be recognized within the next 12&#160;months.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(13)</b></span><b style="font-weight:bold;">Moderna Collaboration and License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In January&#160;2022, the Company entered into the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize <i style="font-style:italic;">in vivo </i>engineered CAR-M therapeutics in oncology. Moderna has the right to designate up to twelve research targets as development targets under this collaboration. While the collaboration was initially limited to oncology, in September&#160;2024, the companies agreed to expand the collaboration to discover, develop and commercialize <i style="font-style:italic;">in vivo </i>engineered CAR-M therapeutics in specific autoimmune diseases. As a result, Moderna nominated two autoimmune research targets. As of February&#160;2025, in connection with Moderna&#8217;s nomination of all 12 oncology research targets (Note&#160;14), the Company will not be conducting any additional research activities under the collaboration agreement and will not be receiving any further payments from Moderna for research and development services under the collaboration agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Subsequent to the nomination of a research target, Moderna may designate the research target as a development target. Upon Moderna&#8217;s designation of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $45.0 million to the Company. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, the Company is eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. Moderna also reimbursed the Company for all costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $10.0 million in research and development costs over the first three&#160;years from execution of the Moderna License Agreement). The Company is also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments and royalties that the Company owes as a licensor under one of its intellectual property in-license agreements with Penn, which is sublicensed to Moderna under the Moderna License Agreement. Moderna may deduct these royalties in part from any royalties owed to the Company. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities and participation on the joint steering committee (JSC). The Company determined that there were 2 performance obligations comprised of (i)&#160;research and development services and (ii)&#160;option rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The transaction price of $45.0&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna exercises or determines not to exercise its option right to license and commercialize the designated development target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In June&#160;2024, the Company received notice from Moderna that Moderna had designated the first development candidate, an <i style="font-style:italic;">in vivo </i>CAR-macrophage targeting GPC3 that is designed to treat solid tumors, including hepatocellular carcinoma. Pursuant to the terms of the Moderna License Agreement, the designation triggered a $2.0&#160;million milestone payment from Moderna to the Company. As a result, the Company recognized collaboration revenue of $2.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Company reduced its $45.0&#160;million deferred revenue liability associated with the option rights by recognizing $3.8&#160;million in collaboration revenue, which represents a proportional reduction based on the 12 potential early-stage research targets. As of December&#160;31, 2024, the Company recorded a collaboration receivable of $2.9&#160;million related to the reimbursement of costs incurred in connection with the Company&#8217;s research and development activities. The Company received the $2.9&#160;million in January&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company included the $45.0 million up-front and nonrefundable payment and $73.9 million of variable consideration for expected research and development services to be performed during the five-year contract term, inclusive of passthrough costs, in the transaction price as of the outset of the arrangement. During the&#160;years ended December&#160;31, 2024 and 2023, the Company recognized $19.6 million and $14.9 million, respectively, of collaboration revenues. Collaboration revenues for the&#160;year ended December&#160;31, 2024 include $3.8&#160;million of deferred option rights revenue recognition and $2.0&#160;million of milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognized $38.7&#160;million and $3.8&#160;million, respectively, of research and development services and option right collaboration revenues since inception of the Moderna License Agreement through December&#160;31, 2024. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2024 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price unsatisfied</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,301</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,250</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total performance obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,551</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the changes in deferred revenue (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,459</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferral of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,873</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recognition of unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,632)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,919)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,413</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The current portion of deferred revenue represents advanced payments received from Moderna for costs expected to be incurred by the Company within the next twelve&#160;months. The noncurrent portion of deferred revenue represents the $41.3 million upfront, non-refundable and non-creditable payment allocated to customer option right which is not expected to be recognized within the next 12&#160;months.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">(11)</b></span><b style="font-size:10pt;font-weight:bold;">Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has evaluated subsequent events from the balance sheet date through May&#160;13, 2025, the issuance date of these unaudited interim consolidated financial statements, and has not identified any additional items that have not previously been mentioned elsewhere requiring disclosure.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(14)</b></span><b style="font-weight:bold;">Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company has evaluated subsequent events from the balance sheet date through March&#160;31, 2025, the issuance date of these consolidated financial statements, and has identified the following matter requiring disclosure. <i style="font-style:italic;">Moderna Collaboration and License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In February&#160;2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February&#160;2025, Moderna has nominated all 12 oncology research targets under the collaboration for which the Company has the potential to receive future milestones and royalty payments. The Company will not conduct any additional research activities under the collaboration agreement and the Company will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the <i style="font-style:italic;">in vivo </i>oncology field exclusivity, which would allow the Company to pursue <i style="font-style:italic;">in vivo </i>CAR-M programs outside of the 12 nominated oncology targets and product polypeptides. The final research and development payment of $2.9&#160;million was received in January&#160;2025 which will be recognized as collaboration revenue for research and development services in the first quarter of 2025. The Company does not expect to recognize any additional unsatisfied research and development performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">2025 Cash Preservation Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of a further revised plan approved by the Company&#8217;s board of directors, on March&#160;25, 2025, to preserve the Company&#8217;s existing cash resources following its reduction in workforce (the &#8220;cash preservation plan&#8221;), the Company reduced its operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down its business. The cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help to evaluate our strategic alternatives. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company&#8217;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. Any future resumption of research and development activities would depend on completing a strategic transaction that would support the Company&#8217;s prior operating plans or otherwise obtaining significant additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of the cash preservation plan, the board of directors determined to terminate all of its employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. Affected employees were informed of the reduction in workforce on March&#160;25, 2025. The reduction in workforce was effective on March&#160;31, 2025. The reduction in workforce includes 37 of the Company&#8217;s full-time employees representing approximately 84% of our total workforce, including certain employees engaged in research and development, manufacturing and corporate activities. The Company expects to incur approximately $3.8&#160;million in connection with the reduction in workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. The Company also expects to pay the majority of related reduction in workforce amounts by the end of 2025. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the reduction in workforce, including (but not limited to) impairment charges relating to the balances of property and equipment, net, prepaid research and development costs and right of use assets&#160;&#8211; operating lease.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Interim Financial Statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interim Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summary of significant accounting policies is included in the Company&#8217;s audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (SEC) on March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance are meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The accompanying unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. In the opinion of management, the accompanying unaudited interim consolidated financial statements include all </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2025 and its results of operations for the three&#160;months ended March&#160;31, 2025 and 2024. Operating results for the three&#160;months ended March&#160;31, 2025 are not necessarily indicative of the results that may be expected for the&#160;year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain all of the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Company&#8217;s Annual Report on Form&#160;10-K filed with the SEC on March&#160;31, 2025.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant areas that require management&#8217;s estimates include stock-based compensation assumptions and accrued research and development.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant areas that require management&#8217;s estimates include estimated research and development revenue, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AssetsHeldForSalePolicyPolicyTextBlock', window );">Assets Held for Sale</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Assets Held for Sale</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2025, the Company committed to a plan to sell its remaining equipment and therefore has classified the amount as assets held for sale on the consolidated balance sheet as of March&#160;31, 2025. The assets held for sale were reported at the lower of the carrying amount or fair value, less costs to sell.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value of Financial Instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value Measurements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2025 and 2024, there were no transfers between Level 1, Level 2 and Level 3.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Concentration of credit risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Segment information</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the three&#160;months ended March&#160;31, 2025 and 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,397</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,191</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,656</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,632</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,529</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,185</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (818)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,266)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,978)</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">&#8220;Other segment items&#8221; includes</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> interest income.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Segment information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">assessing performance. The Company has one operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the&#160;years ended December&#160;31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,919</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,905</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,118</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,671</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,324</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,984</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other segment items(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,242)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,204)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (60,477)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,879)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other segment items include changes in warrant liability and interest income.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net loss per share</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,895,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,210,547</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,023,370</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recently issued accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes </i>(Topic 740)<i style="font-style:italic;">: Improvements to Income Tax Disclosures </i>(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November&#160;2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures </i>(Subtopic 220-40): <i style="font-style:italic;">Disaggregation of Income Statement Expenses</i>, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </i>(ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024 on a retrospective basis. The Company incorporated the improved segment disclosures in the summary of significant accounting policies, herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently issued but not yet adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </i>(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In November&#160;2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AssetsHeldForSalePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets Held-for-Sale, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AssetsHeldForSalePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy of Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents <span style="font-family:'Arial','Helvetica','sans-serif';">&#8211;</span> money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2025 and 2024, there were no transfers between Level 1, Level 2 and Level 3.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents &#8211; money markets accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Significant Expense Categories by Segment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the three&#160;months ended March&#160;31, 2025 and 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,397</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,191</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,656</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,632</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,529</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,185</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (818)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,266)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,978)</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">&#8220;Other segment items&#8221; includes</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> interest income.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the&#160;years ended December&#160;31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,919</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and development, excluding facilities, personnel, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,905</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,118</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Facilities expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,671</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Personnel expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,324</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,984</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other segment items(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,242)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,204)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (60,477)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,879)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,895,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,210,547</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,023,370</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and other assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,715</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration receivable (Note 10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,864</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables (a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 925</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,916</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">&#8220;Other receivables&#8221; primarily</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> consisted of equipment sales, sales and use tax refunds, and research and development tax refunds.</span></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prepaid expenses and other assets consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 278</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Collaboration receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 402</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 891</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,295</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,866</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,845</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 537</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,879</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,448</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,131</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,366</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,100</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,662</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The elements of the lease costs were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,469</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,298</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,534</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 472</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,475</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The elements of the lease costs were as follows (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,774</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,187</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,326</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,733</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Short term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,833</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock', window );">Schedule of Lease Term and Discount Rate Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Lease term and discount rate information related to leases was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lease term and discount rate information related to leases was as follows:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Supplemental cash flow information was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,463</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,319</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information was as follows (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,764</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash used in finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,301</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock', window );">Schedule of Future Maturities of Lease Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Future maturities of lease liabilities were as follows as of March&#160;31, 2025 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiscal year ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 (remaining nine months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 659</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (240)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 640</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future maturities of lease liabilities were as follows as of December&#160;31, 2024 (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fiscal year ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 942</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 963</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (253)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 925</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of ease term and discount rate information relating to operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability and finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental cash flow information relating to operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes stock option activity for the three&#160;months ended March&#160;31, 2025:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,987)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,749,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,562,180)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,895,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,693,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr></table></div><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,023,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,810)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,805,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,078,034)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,746,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,414,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Using The Black-Scholes Option-Pricing Model</a></td>
<td class="text">The fair values in the three&#160;months ended March&#160;31, 2025 and 2024 were estimated using the Black-Scholes option-pricing model based on the following assumptions:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">4.32% - 4.35%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">3.77% - 3.89%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">108.30% - 110.68%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">103.39% - 105.96%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:32.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.77% - 4.59%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.92% - 4.76%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">86.55% - 112.12%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">57.77% - 103.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company recorded stock-based compensation expense in the following expense categories in its accompanying unaudited interim consolidated statements of operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 436</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,057</p></td></tr></table></div><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,242</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,074</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,316</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price unsatisfied</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,250</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2024 (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price unsatisfied</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,301</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,250</p></td></tr><tr><td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total performance obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,551</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock', window );">Schedule of Changes in Deferred Revenue</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the changes in deferred revenue (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,413</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferral of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,173</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Recognition of unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,729)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,397)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,189</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the changes in deferred revenue (in thousands):</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,459</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferral of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,873</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recognition of unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,632)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,919)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,413</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ScheduleOfChangesInDeferredRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background (Details) - Employee Severance<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Background</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Reduction in workforce, number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in workforce (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Cash Preservation Plan, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Background</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Reduction in workforce, number of employees | employee</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in workforce (as a percent)</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Expected remaining restructuring costs</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSegmentAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSegmentAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected cost remaining for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=carm_CashPreservationPlan2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=carm_CashPreservationPlan2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Development-Stage Risks and Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DevelopmentStageRisksAndLiquidityAbstract', window );"><strong>Development-Stage Risks and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 314,845<span></span>
</td>
<td class="nump">$ 305,579<span></span>
</td>
<td class="nump">$ 245,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DevelopmentStageRisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DevelopmentStageRisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents - money markets accounts</a></td>
<td class="nump">$ 6,965<span></span>
</td>
<td class="nump">$ 14,887<span></span>
</td>
<td class="nump">$ 62,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents - money markets accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents - money markets accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - segment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="nump">$ 3,729<span></span>
</td>
<td class="nump">$ 3,397<span></span>
</td>
<td class="nump">$ 19,632<span></span>
</td>
<td class="nump">$ 14,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,266)<span></span>
</td>
<td class="num">(18,978)<span></span>
</td>
<td class="num">(60,477)<span></span>
</td>
<td class="num">(86,879)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=carm_ReportingSegmentMember', window );">Reporting Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="nump">3,729<span></span>
</td>
<td class="nump">3,397<span></span>
</td>
<td class="nump">19,632<span></span>
</td>
<td class="nump">14,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses', window );">Research and development, excluding facilities, personnel, depreciation and amortization expenses</a></td>
<td class="nump">1,528<span></span>
</td>
<td class="nump">10,191<span></span>
</td>
<td class="nump">33,147<span></span>
</td>
<td class="nump">45,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses', window );">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</a></td>
<td class="nump">2,421<span></span>
</td>
<td class="nump">3,656<span></span>
</td>
<td class="nump">14,829<span></span>
</td>
<td class="nump">19,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FacilitiesExpense', window );">Facilities expense</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">1,632<span></span>
</td>
<td class="nump">5,917<span></span>
</td>
<td class="nump">7,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Personnel expense</a></td>
<td class="nump">7,354<span></span>
</td>
<td class="nump">6,529<span></span>
</td>
<td class="nump">24,564<span></span>
</td>
<td class="nump">27,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities', window );">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
<td class="nump">3,894<span></span>
</td>
<td class="nump">3,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(818)<span></span>
</td>
<td class="num">(2,242)<span></span>
</td>
<td class="num">(2,204)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,266)<span></span>
</td>
<td class="num">$ (18,978)<span></span>
</td>
<td class="num">$ (60,477)<span></span>
</td>
<td class="num">$ (86,879)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Amortization And Interest On Finance And Sale-Leaseback Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FacilitiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facilities Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FacilitiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative, Excluding Facilities And Personnel Expenses, Depreciation And Amortization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development, Excluding Facilities, Personnel, Depreciation and Amortization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationAdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=carm_ReportingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=carm_ReportingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">6,895,824<span></span>
</td>
<td class="nump">8,210,547<span></span>
</td>
<td class="nump">7,746,991<span></span>
</td>
<td class="nump">6,023,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and other assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PrepaidResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,715<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ReceivableDueFromCollaborativeArrangementCurrent', window );">Collaboration receivable (Note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Other receivables</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="nump">891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">$ 2,901<span></span>
</td>
<td class="nump">$ 5,916<span></span>
</td>
<td class="nump">$ 2,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PrepaidResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research and Development, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PrepaidResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ReceivableDueFromCollaborativeArrangementCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable due from Collaborative Arrangement, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ReceivableDueFromCollaborativeArrangementCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development</a></td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 1,845<span></span>
</td>
<td class="nump">$ 3,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related expenses</a></td>
<td class="nump">3,554<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 4,705<span></span>
</td>
<td class="nump">$ 7,448<span></span>
</td>
<td class="nump">$ 7,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing liability</a></td>
<td class="nump">$ 640<span></span>
</td>
<td class="nump">$ 925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=carm_TrusteesOfUniversityOfPennsylvaniaMember', window );">Penn | Penn License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CommitmentsAnnualPaymentsRequiredToBePaid', window );">Annual payments to be made</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AdditionalMilestonePaymentsForTheFirstCARMProduct', window );">Additional milestone payments for first CAR-M product</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=carm_TrusteesOfUniversityOfPennsylvaniaMember', window );">Penn | Penn License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents', window );">Milestone payments</a></td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AdditionalMilestonePaymentsRequiredToBePaid', window );">Additional milestone payments</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing liability</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AdditionalMilestonePaymentsForTheFirstCARMProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Milestone Payments for the First CAR-M Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AdditionalMilestonePaymentsForTheFirstCARMProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AdditionalMilestonePaymentsRequiredToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Milestone Payments Required to be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AdditionalMilestonePaymentsRequiredToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Payable upon Achievement of Certain Clinical, Regulatory and Commercial Milestone Events</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CommitmentsAnnualPaymentsRequiredToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Annual Payments Required To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CommitmentsAnnualPaymentsRequiredToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=carm_TrusteesOfUniversityOfPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=carm_TrusteesOfUniversityOfPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 929<span></span>
</td>
<td class="nump">$ 1,469<span></span>
</td>
<td class="nump">$ 5,245<span></span>
</td>
<td class="nump">$ 5,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinanceLeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease assets</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
<td class="nump">1,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 1,326<span></span>
</td>
<td class="nump">$ 3,475<span></span>
</td>
<td class="nump">$ 8,788<span></span>
</td>
<td class="nump">$ 8,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance lease cost expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinanceLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinanceLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LeasesWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LeasesWeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LeasesWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LeasesWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LeasesWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LeasesWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash used in operating leases</a></td>
<td class="nump">$ 707<span></span>
</td>
<td class="nump">$ 1,463<span></span>
</td>
<td class="nump">$ 5,807<span></span>
</td>
<td class="nump">$ 5,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash used in finance leases</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinancingCashUsedInFinanceLeases', window );">Financing cash used in finance leases</a></td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">$ 1,319<span></span>
</td>
<td class="nump">$ 1,429<span></span>
</td>
<td class="nump">$ 1,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinancingCashUsedInFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinancingCashUsedInFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025 (remaining nine months)</a></td>
<td class="nump">$ 1,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">$ 927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum payments</a></td>
<td class="nump">1,925<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">1,685<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025 (remaining nine months)</a></td>
<td class="nump">639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum payments</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 640<span></span>
</td>
<td class="nump">$ 925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 12, 2023</div></th>
<th class="th"><div>Apr. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_SaleOfStockStockOfferingAmount', window );">Stock offering, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_SaleOfStockMaximumOfferingAmount', window );">Sale of stock, maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketMember', window );">At-the-Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_SaleOfStockMaximumOfferingAmount', window );">Sale of stock, maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sales of stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">931,250<span></span>
</td>
<td class="nump">1,136,384<span></span>
</td>
<td class="nump">226,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_SaleOfStockMaximumOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Maximum Offering Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_SaleOfStockMaximumOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_SaleOfStockStockOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Stock Offering, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_SaleOfStockStockOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date per share fair values granted (in USD per share)</a></td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="nump">$ 4.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock-based options forfeited (in shares)</a></td>
<td class="nump">2,562,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,078,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Future compensation cost for awards not vested</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period compensation cost of unvested awards to be expensed (in years)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember', window );">Two Thousand Fourteen Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenEmployeeStockPurchasePlanMember', window );">Two Thousand Fourteen Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount to the market price (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_CashPreservationPlan2025Member', window );">Cash Preservation Plan, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock-based options forfeited (in shares)</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Two Thousand Seventeen Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_TwoThousandFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_CashPreservationPlan2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_CashPreservationPlan2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_TwoThousandSeventeenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_TwoThousandSeventeenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2024 (in shares)</a></td>
<td class="nump">7,746,991<span></span>
</td>
<td class="nump">6,023,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(37,987)<span></span>
</td>
<td class="num">(3,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,749,000<span></span>
</td>
<td class="nump">3,805,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(2,562,180)<span></span>
</td>
<td class="num">(2,078,034)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of March 31, 2025 (in shares)</a></td>
<td class="nump">6,895,824<span></span>
</td>
<td class="nump">7,746,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of March 31, 2025 (in shares)</a></td>
<td class="nump">4,693,361<span></span>
</td>
<td class="nump">4,414,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December 31, 2024 (in USD per share)</a></td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">0.11<span></span>
</td>
<td class="nump">0.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in USD per share)</a></td>
<td class="nump">1.99<span></span>
</td>
<td class="nump">4.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of March 31, 2025 (in USD per share)</a></td>
<td class="nump">2.54<span></span>
</td>
<td class="nump">2.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of March 31, 2025 (in USD per share)</a></td>
<td class="nump">$ 2.51<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding as of March 31, 2025</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable as of March 31, 2025</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding as of March 31, 2025</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable as of March 31, 2025</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">4.32%<span></span>
</td>
<td class="nump">3.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.35%<span></span>
</td>
<td class="nump">3.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">108.30%<span></span>
</td>
<td class="nump">103.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">110.68%<span></span>
</td>
<td class="nump">105.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="nump">$ 3,649<span></span>
</td>
<td class="nump">$ 2,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">$ 621<span></span>
</td>
<td class="nump">$ 2,533<span></span>
</td>
<td class="nump">$ 1,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>product </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
<td class="nump">$ 3,397<span></span>
</td>
<td class="nump">19,632<span></span>
</td>
<td class="nump">$ 14,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=carm_OptionRightCollaborationRevenuesMember', window );">Option Right Collaboration Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Noncurrent portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember', window );">Moderna License Agreement | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember', window );">Moderna License Agreement | Option Right Collaboration Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember', window );">Moderna | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_MaximumNumberOfResearchTargets', window );">Maximum of research targets | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsGrossOncology', window );">Number of oncology research targets | item</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsNominatedOncology', window );">Number of oncology research targets, nominated | item</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsNominatedReplacements', window );">Number of research targets, replacement nominations | item</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsTerminatedOncology', window );">Number of oncology research targets, ceased development | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsTerminatedAutoimmune', window );">Number of nominated autoimmune target | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember', window );">Moderna | Collaboration and License Agreement | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_UpfrontNonRefundablePaymentReceived', window );">Upfront non-refundable payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfPotentialProductsToDevelopAndCommercialize', window );">Number of potential products to develop and commercialize | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfPerformanceObligations', window );">Number of performance obligations | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember', window );">Moderna | Collaboration and License Agreement | Research and Development Services | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments', window );">Amount receivable per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember', window );">Moderna | Collaboration and License Agreement | Research and Development Services | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments', window );">Amount receivable per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember', window );">Moderna | Moderna License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount receivable per product in development target designation, development, regulatory and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_MaximumNumberOfResearchTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of research targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_MaximumNumberOfResearchTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfPotentialProductsToDevelopAndCommercialize">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of potential products to develop and commercialize</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfPotentialProductsToDevelopAndCommercialize</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsGrossOncology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets, Gross, Oncology</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsGrossOncology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsNominatedOncology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets Nominated, Oncology</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsNominatedOncology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsNominatedReplacements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets Nominated, Replacements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsNominatedReplacements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsTerminatedAutoimmune">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets, Terminated, Autoimmune</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsTerminatedAutoimmune</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsTerminatedOncology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets, Terminated, Oncology</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsTerminatedOncology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_UpfrontNonRefundablePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront non-refundable payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_UpfrontNonRefundablePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=carm_OptionRightCollaborationRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=carm_OptionRightCollaborationRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=carm_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=carm_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationAbstract', window );"><strong>Performance obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_RevenueRemainingPerformanceObligationOptionRightsAmount', window );">Option rights</a></td>
<td class="nump">$ 41,250<span></span>
</td>
<td class="nump">$ 41,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_RevenueRemainingPerformanceObligationOptionRightsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_RevenueRemainingPerformanceObligationOptionRightsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInDeferredRevenueRollForward', window );"><strong>Movement in Deferred Revenue [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 44,979<span></span>
</td>
<td class="nump">$ 46,413<span></span>
</td>
<td class="nump">$ 46,413<span></span>
</td>
<td class="nump">$ 47,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ContractWithCustomerLiabilityDeferralOfRevenue', window );">Deferral of revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,173<span></span>
</td>
<td class="nump">16,198<span></span>
</td>
<td class="nump">13,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of unearned revenue</a></td>
<td class="num">(3,729)<span></span>
</td>
<td class="num">(3,397)<span></span>
</td>
<td class="num">(17,632)<span></span>
</td>
<td class="num">(14,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at the end of the period</a></td>
<td class="nump">$ 41,250<span></span>
</td>
<td class="nump">$ 46,189<span></span>
</td>
<td class="nump">$ 44,979<span></span>
</td>
<td class="nump">$ 46,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ContractWithCustomerLiabilityDeferralOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue deferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ContractWithCustomerLiabilityDeferralOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInDeferredRevenueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInDeferredRevenueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>165</ContextCount>
  <ElementCount>356</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100090 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DocumentCoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>110101 - Disclosure - Background</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureBackground</Role>
      <ShortName>Background</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>110201 - Disclosure - Development-Stage Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidity</Role>
      <ShortName>Development-Stage Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110301 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110401 - Disclosure - Merger with Sesen Bio</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureMergerWithSesenBio</Role>
      <ShortName>Merger with Sesen Bio</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>110501 - Disclosure - Prepaid Expenses and Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssets</Role>
      <ShortName>Prepaid Expenses and Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>110601 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>110701 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>110801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>110901 - Disclosure - Stockholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquity</Role>
      <ShortName>Stockholders' (Deficit) Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>111001 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>111101 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>111201 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>111301 - Disclosure - Moderna Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreement</Role>
      <ShortName>Moderna Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>111401 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>120302 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>130303 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>130403 - Disclosure - Merger with Sesen Bio (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioTables</Role>
      <ShortName>Merger with Sesen Bio (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureMergerWithSesenBio</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>130503 - Disclosure - Prepaid Expenses and Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>130603 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>130703 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureAccruedExpenses</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>130803 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>131003 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>131103 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131303 - Disclosure - Moderna Collaboration and License Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTables</Role>
      <ShortName>Moderna Collaboration and License Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreement</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>140101 - Disclosure - Background (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureBackgroundDetails</Role>
      <ShortName>Background (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureBackground</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>140201 - Disclosure - Development-Stage Risks and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetails</Role>
      <ShortName>Development-Stage Risks and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>140301 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>140302 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>140303 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>140304 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>140401 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails</Role>
      <ShortName>Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>140501 - Disclosure - Prepaid Expenses and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140601 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>140602 - Disclosure - Property and Equipment, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetNarrativeDetails</Role>
      <ShortName>Property and Equipment, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>140701 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>140801 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>140802 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>140803 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>140804 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>140805 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>140901 - Disclosure - Stockholders' (Deficit) Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails</Role>
      <ShortName>Stockholders' (Deficit) Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquity</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>141001 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>141002 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>141003 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>141004 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>141101 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>141102 - Disclosure - Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails</Role>
      <ShortName>Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>141103 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>141301 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails</Role>
      <ShortName>Moderna Collaboration and License Agreement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>141302 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails</Role>
      <ShortName>Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>141303 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetails</Role>
      <ShortName>Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>141401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureSubsequentEvents</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>200100 - Statement - UNAUDITED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets</Role>
      <ShortName>UNAUDITED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>200105 - Statement - UNAUDITED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>UNAUDITED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>200200 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>200300 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity</Role>
      <ShortName>UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>200400 - Statement - UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows</Role>
      <ShortName>UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>210101 - Disclosure - Background</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureBackgrounds</Role>
      <ShortName>Background</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>210201 - Disclosure - Development-Stage Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquiditys</Role>
      <ShortName>Development-Stage Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>210301 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciess</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>210401 - Disclosure - Prepaid Expenses and other assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetss</Role>
      <ShortName>Prepaid Expenses and other assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>210501 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureAccruedExpensess</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>210601 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciess</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>210701 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>210801 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockBasedCompensations</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>210901 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureRelatedPartyTransactionss</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>211001 - Disclosure - Moderna Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreements</Role>
      <ShortName>Moderna Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>211101 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSubsequentEventss</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>220302 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>230303 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>230403 - Disclosure - Prepaid Expenses and other assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTabless</Role>
      <ShortName>Prepaid Expenses and other assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetss</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>230503 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureAccruedExpensesTabless</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureAccruedExpenses</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>230603 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTabless</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>230803 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTabless</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>231003 - Disclosure - Moderna Collaboration and License Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTabless</Role>
      <ShortName>Moderna Collaboration and License Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreement</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240101 - Disclosure - Background (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureBackgroundDetailss</Role>
      <ShortName>Background (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureBackground</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240201 - Disclosure - Development-Stage Risks and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetailss</Role>
      <ShortName>Development-Stage Risks and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidity</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240301 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240302 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetailss</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240303 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240304 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240401 - Disclosure - Prepaid Expenses and other assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss</Role>
      <ShortName>Prepaid Expenses and other assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTabless</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240501 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240601 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240602 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240603 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240604 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetailss</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240605 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240701 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/20241231/role/DisclosureStockholdersEquity</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240801 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss</Role>
      <ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240802 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240803 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss</Role>
      <ShortName>Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240804 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>241001 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss</Role>
      <ShortName>Moderna Collaboration and License Agreement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>241002 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetailss</Role>
      <ShortName>Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="tmb-20250331xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>241003 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetailss</Role>
      <ShortName>Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tmb-20250331.xsd</File>
    <File>tmb-20250331_cal.xml</File>
    <File>tmb-20250331_def.xml</File>
    <File>tmb-20250331_lab.xml</File>
    <File>tmb-20250331_pre.xml</File>
    <File doctype="S-4" isDefinitelyFs="true" isUsgaap="true" original="tmb-20250331xs4.htm">tmb-20250331xs4.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tmb-20250331xs4015.jpg</File>
    <File>tmb-20250331xs4016.jpg</File>
    <File>tmb-20250331xs4023.jpg</File>
    <File>tmb-20250331xs4024.jpg</File>
    <File>tmb-20250331xs4027.jpg</File>
    <File>tmb-20250331xs4028.jpg</File>
    <File>tmb-20250331xs4029.jpg</File>
    <File>tmb-20250331xs4030.jpg</File>
    <File>tmb-20250331xs4048.jpg</File>
    <File>tmb-20250331xs4049.jpg</File>
    <File>tmb-20250331xs4050.jpg</File>
    <File>tmb-20250331xs4053.jpg</File>
    <File>tmb-20250331xs4054.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="845">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="7">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>155
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tmb-20250331xs4.htm": {
   "nsprefix": "carm",
   "nsuri": "http://carismatx.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "tmb-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "tmb-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20250331xs4.htm"
     ]
    }
   },
   "keyStandard": 275,
   "keyCustom": 81,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 25,
   "memberCustom": 23,
   "hidden": {
    "total": 20,
    "http://fasb.org/us-gaap/2024": 18,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 165,
   "entityCount": 1,
   "segmentCount": 51,
   "elementCount": 533,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 845,
    "http://xbrl.sec.gov/dei/2024": 7
   },
   "report": {
    "R1": {
     "role": "http://carismatx.com/20241231/role/DocumentCoverPage",
     "longName": "100090 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
     "longName": "100100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
     "longName": "100300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA",
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "unitRef": "Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA",
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "unitRef": "Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw",
      "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://carismatx.com/20241231/role/DisclosureBackground",
     "longName": "110101 - Disclosure - Background",
     "shortName": "Background",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidity",
     "longName": "110201 - Disclosure - Development-Stage Risks and Liquidity",
     "shortName": "Development-Stage Risks and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "carm:DevelopmentStageRisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "carm:DevelopmentStageRisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "110301 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBio",
     "longName": "110401 - Disclosure - Merger with Sesen Bio",
     "shortName": "Merger with Sesen Bio",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssets",
     "longName": "110501 - Disclosure - Prepaid Expenses and Other Assets",
     "shortName": "Prepaid Expenses and Other Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R12": {
     "role": "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNet",
     "longName": "110601 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://carismatx.com/20241231/role/DisclosureAccruedExpenses",
     "longName": "110701 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R14": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingencies",
     "longName": "110801 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R15": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquity",
     "longName": "110901 - Disclosure - Stockholders' (Deficit) Equity",
     "shortName": "Stockholders' (Deficit) Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R16": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockBasedCompensation",
     "longName": "111001 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R17": {
     "role": "http://carismatx.com/20241231/role/DisclosureIncomeTaxes",
     "longName": "111101 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://carismatx.com/20241231/role/DisclosureRelatedPartyTransactions",
     "longName": "111201 - Disclosure - Related-Party Transactions",
     "shortName": "Related-Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreement",
     "longName": "111301 - Disclosure - Moderna Collaboration and License Agreement",
     "shortName": "Moderna Collaboration and License Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://carismatx.com/20241231/role/DisclosureSubsequentEvents",
     "longName": "111401 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "120302 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R22": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "130303 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioTables",
     "longName": "130403 - Disclosure - Merger with Sesen Bio (Tables)",
     "shortName": "Merger with Sesen Bio (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTables",
     "longName": "130503 - Disclosure - Prepaid Expenses and Other Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "130603 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://carismatx.com/20241231/role/DisclosureAccruedExpensesTables",
     "longName": "130703 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "130803 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTables",
     "longName": "131003 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://carismatx.com/20241231/role/DisclosureIncomeTaxesTables",
     "longName": "131103 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTables",
     "longName": "131303 - Disclosure - Moderna Collaboration and License Agreement (Tables)",
     "shortName": "Moderna Collaboration and License Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
     "longName": "140101 - Disclosure - Background (Details)",
     "shortName": "Background (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ATt2SkLHckWBYPbLkkt-Gw",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Standard_employee_8zftLesBXkivzIcTQ6E96w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_oh2OTmiJvkKgA0D-o9Y6Fw",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetails",
     "longName": "140201 - Disclosure - Development-Stage Risks and Liquidity (Details)",
     "shortName": "Development-Stage Risks and Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
     "longName": "140301 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C2na3yFo8kSa8lpEjLIVYw",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "longName": "140302 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_ieOgHbuNO0uMDAyeDWsL6Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
     "longName": "140303 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails",
     "longName": "140304 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_o9XCCXxBxk-Bcr0qGS2Bcg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails",
     "longName": "140401 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)",
     "shortName": "Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "carm:NumberOfBoardMembers",
      "unitRef": "Unit_Standard_stockholder_xwrsA79JVk6r5Olbumrfaw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "carm:NumberOfBoardMembers",
      "unitRef": "Unit_Standard_stockholder_xwrsA79JVk6r5Olbumrfaw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetails",
     "longName": "140501 - Disclosure - Prepaid Expenses and Other Assets (Details)",
     "shortName": "Prepaid Expenses and Other Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "carm:PrepaidResearchAndDevelopmentCurrent",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "140601 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetNarrativeDetails",
     "longName": "140602 - Disclosure - Property and Equipment, net - Narrative (Details)",
     "shortName": "Property and Equipment, net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetails",
     "longName": "140701 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "carm:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "longName": "140801 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_CsDzke0V0UKpQy6JppgEbw",
      "name": "carm:IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_CsDzke0V0UKpQy6JppgEbw",
      "name": "carm:IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails",
     "longName": "140802 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "carm:FinanceLeasesInterestExpense",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails",
     "longName": "140803 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetails",
     "longName": "140804 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "carm:FinanceLeasesInterestPaymentOnLiability",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
     "longName": "140805 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
     "longName": "140901 - Disclosure - Stockholders' (Deficit) Equity (Details)",
     "shortName": "Stockholders' (Deficit) Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
     "longName": "141001 - Disclosure - Stock-based Compensation - Narrative (Details)",
     "shortName": "Stock-based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_O60app-ziUOiQI-0SFDxHQ",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
     "longName": "141002 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails",
     "longName": "141003 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)",
     "shortName": "Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_XarV9JooQUGFgqT3MKU-nQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails",
     "longName": "141004 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_RevisedOperatingPlanMember_8xDVoP31YEeXATz_aXlYog",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "141101 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails",
     "longName": "141102 - Disclosure - Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)",
     "shortName": "Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails",
     "longName": "141103 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
     "longName": "141301 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)",
     "shortName": "Moderna Collaboration and License Agreement - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_MilestonesMember_FUdbCZoQDk2Dag7HM2RG6A",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails",
     "longName": "141302 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)",
     "shortName": "Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetails",
     "longName": "141303 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)",
     "shortName": "Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:ScheduleOfChangesInDeferredRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails",
     "longName": "141401 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ATt2SkLHckWBYPbLkkt-Gw",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Standard_employee_8zftLesBXkivzIcTQ6E96w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QPK_k69qc0WEZlJvXGRPPA",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Standard_employee_8zftLesBXkivzIcTQ6E96w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets",
     "longName": "200100 - Statement - UNAUDITED CONSOLIDATED BALANCE SHEETS",
     "shortName": "UNAUDITED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical",
     "longName": "200105 - Statement - UNAUDITED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "UNAUDITED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Cover",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "200200 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity",
     "longName": "200300 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY",
     "shortName": "UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rddcZYrYF0aGvo9ie5UZTQ",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fkuPLbunBkio3h13YwQKEA",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows",
     "longName": "200400 - Statement - UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS",
     "shortName": "UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "63",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://carismatx.com/20241231/role/DisclosureBackgrounds",
     "longName": "210101 - Disclosure - Background",
     "shortName": "Background",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquiditys",
     "longName": "210201 - Disclosure - Development-Stage Risks and Liquidity",
     "shortName": "Development-Stage Risks and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "carm:DevelopmentStageRisksAndLiquidityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "carm:DevelopmentStageRisksAndLiquidityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciess",
     "longName": "210301 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetss",
     "longName": "210401 - Disclosure - Prepaid Expenses and other assets",
     "shortName": "Prepaid Expenses and other assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "67",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R68": {
     "role": "http://carismatx.com/20241231/role/DisclosureAccruedExpensess",
     "longName": "210501 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "68",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciess",
     "longName": "210601 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockholdersEquity",
     "longName": "210701 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "70",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockBasedCompensations",
     "longName": "210801 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "71",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R72": {
     "role": "http://carismatx.com/20241231/role/DisclosureRelatedPartyTransactionss",
     "longName": "210901 - Disclosure - Related-Party Transactions",
     "shortName": "Related-Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "72",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R73": {
     "role": "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreements",
     "longName": "211001 - Disclosure - Moderna Collaboration and License Agreement",
     "shortName": "Moderna Collaboration and License Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "73",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://carismatx.com/20241231/role/DisclosureSubsequentEventss",
     "longName": "211101 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "74",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R75": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
     "longName": "220302 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "75",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "carm:AssetsHeldForSalePolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless",
     "longName": "230303 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "76",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R77": {
     "role": "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTabless",
     "longName": "230403 - Disclosure - Prepaid Expenses and other assets (Tables)",
     "shortName": "Prepaid Expenses and other assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "77",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R78": {
     "role": "http://carismatx.com/20241231/role/DisclosureAccruedExpensesTabless",
     "longName": "230503 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "78",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R79": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTabless",
     "longName": "230603 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "79",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R80": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTabless",
     "longName": "230803 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "80",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R81": {
     "role": "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTabless",
     "longName": "231003 - Disclosure - Moderna Collaboration and License Agreement (Tables)",
     "shortName": "Moderna Collaboration and License Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "81",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R82": {
     "role": "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss",
     "longName": "240101 - Disclosure - Background (Details)",
     "shortName": "Background (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ATt2SkLHckWBYPbLkkt-Gw",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Standard_employee_8zftLesBXkivzIcTQ6E96w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_lGhVgDEdm0KquD87r_9DVA",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetailss",
     "longName": "240201 - Disclosure - Development-Stage Risks and Liquidity (Details)",
     "shortName": "Development-Stage Risks and Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R84": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss",
     "longName": "240301 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C2na3yFo8kSa8lpEjLIVYw",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R85": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetailss",
     "longName": "240302 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_ieOgHbuNO0uMDAyeDWsL6Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R86": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss",
     "longName": "240303 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R87": {
     "role": "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss",
     "longName": "240304 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_o9XCCXxBxk-Bcr0qGS2Bcg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R88": {
     "role": "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss",
     "longName": "240401 - Disclosure - Prepaid Expenses and other assets (Details)",
     "shortName": "Prepaid Expenses and other assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "carm:PrepaidResearchAndDevelopmentCurrent",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:OtherReceivablesGrossCurrent",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss",
     "longName": "240501 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "carm:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R90": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss",
     "longName": "240601 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:FinanceLeaseLiability",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_3NLofzzltkKOh4rmrr_2tg",
      "name": "carm:CommitmentsAnnualPaymentsRequiredToBePaid",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss",
     "longName": "240602 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss",
     "longName": "240603 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R93": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetailss",
     "longName": "240604 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss",
     "longName": "240605 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails",
     "longName": "240701 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "As_Of_4_17_2023_x6SGs_0tqUWE9Nmq-r1zlw",
      "name": "carm:SaleOfStockStockOfferingAmount",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R96": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
     "longName": "240801 - Disclosure - Stock-based Compensation - Narrative (Details)",
     "shortName": "Stock-based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_CashPreservationPlan2025Member_feBnUr3Dfkm1-xoc5Tr1Xg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss",
     "longName": "240802 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R98": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss",
     "longName": "240803 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)",
     "shortName": "Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss",
     "longName": "240804 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R100": {
     "role": "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
     "longName": "241001 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)",
     "shortName": "Moderna Collaboration and License Agreement - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R101": {
     "role": "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetailss",
     "longName": "241002 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)",
     "shortName": "Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw",
      "name": "carm:RevenueRemainingPerformanceObligationOptionRightsAmount",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R102": {
     "role": "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetailss",
     "longName": "241003 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)",
     "shortName": "Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "carm:ScheduleOfChangesInDeferredRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250331xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureAccruedExpenses",
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61",
      "r64",
      "r766"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r669"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts Payable",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "carm_AccretionOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "AccretionOnMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion on marketable securities.",
        "label": "Accretion on Marketable Securities",
        "negatedLabel": "Accretion on marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetails",
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss",
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Expenses",
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetails",
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "carm_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetails",
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development Expense, Current",
        "label": "Accrued Research and Development Expense, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r17",
      "r427",
      "r430",
      "r480",
      "r538",
      "r539",
      "r702",
      "r703",
      "r704",
      "r712",
      "r713",
      "r714",
      "r715"
     ]
    },
    "carm_AdditionalMilestonePaymentsForTheFirstCARMProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "AdditionalMilestonePaymentsForTheFirstCARMProduct",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Milestone Payments for the First CAR-M Product",
        "label": "Additional Milestone Payments for the First CAR-M Product",
        "terseLabel": "Additional milestone payments for first CAR-M product"
       }
      }
     },
     "auth_ref": []
    },
    "carm_AdditionalMilestonePaymentsRequiredToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "AdditionalMilestonePaymentsRequiredToBePaid",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Milestone Payments Required to be Paid",
        "label": "Additional Milestone Payments Required to be Paid",
        "terseLabel": "Additional milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r669",
      "r831"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r712",
      "r713",
      "r714",
      "r715",
      "r776",
      "r832"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r335"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "carm_AgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "AgreementTerm",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of agreement.",
        "label": "Agreement term",
        "terseLabel": "Agreement term (in years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r376"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://carismatx.com/20241231/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r79",
      "r283",
      "r784"
     ]
    },
    "carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Payable upon Achievement of Certain Clinical, Regulatory and Commercial Milestone Events",
        "label": "Amount Payable upon Achievement of Certain Clinical, Regulatory and Commercial Milestone Events",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount receivable per product in development target designation, development, regulatory and commercial milestone payments.",
        "label": "Amount Receivable Per Product in Development Target Designation, Development, Regulatory and Commercial Milestone Payments",
        "terseLabel": "Amount receivable per product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net loss per share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r115",
      "r141",
      "r166",
      "r192",
      "r196",
      "r220",
      "r223",
      "r231",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r422",
      "r424",
      "r448",
      "r501",
      "r582",
      "r641",
      "r642",
      "r669",
      "r686",
      "r736",
      "r737",
      "r789"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r147",
      "r166",
      "r231",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r422",
      "r424",
      "r448",
      "r669",
      "r736",
      "r737",
      "r789"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "carm_AssetsHeldForSalePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "AssetsHeldForSalePolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Held-for-Sale, Policy",
        "label": "Assets Held-for-Sale, Policy [Policy Text Block]",
        "terseLabel": "Assets Held for Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Assets held for sale",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r57",
      "r58",
      "r87",
      "r90",
      "r136",
      "r137"
     ]
    },
    "carm_AtTheMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "AtTheMarketMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-Market",
        "label": "At-the-Market [Member]",
        "terseLabel": "At-the-Market"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "terseLabel": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r799",
      "r800"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "terseLabel": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r254",
      "r799",
      "r800"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Interim Financial Statements",
        "verboseLabel": "Basis of Presentation and Principles of Consolidation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r417",
      "r655",
      "r656"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r417",
      "r655",
      "r656"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Transaction Costs",
        "negatedLabel": "Less: Transaction costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Merger with Sesen Bio",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business acquisition percentage of voting interests acquired (as a percent)",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBio"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Merger with Sesen Bio",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r418"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total net assets acquired",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedLabel": "Accounts payable and accrued expenses",
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Total net assets acquired less transaction costs",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_BusinessCombinationSegmentAllocationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationSegmentAllocationLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Segment Allocation [Line Items]",
        "verboseLabel": "Background",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of restricted cash from business combination.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredRestrictedCash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment in accounts payable",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "carm_CarismaTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "CarismaTherapeuticsInc.Member",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Carisma Therapeutics Inc.",
        "label": "Carisma Therapeutics Inc. [Member]",
        "terseLabel": "Carisma Therapeutics Inc."
       }
      }
     },
     "auth_ref": []
    },
    "carm_CarismaTherapeuticsIncLegacyStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "CarismaTherapeuticsIncLegacyStockholdersMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the stockholders of legacy CARISMA Therapeutics, prior to the merger.",
        "label": "CARISMA Therapeutics Inc, Legacy, Stockholders [Member]",
        "terseLabel": "CARISMA Therapeutics Inc, Legacy, Stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r140",
      "r633"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents - money markets accounts",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash, cash equivalents and restricted cash acquired associated with the reverse capitalization during the period .",
        "label": "Cash, Cash Equivalents and Restricted Cash Acquired in Reverse Recapitalization, Financing Activities",
        "terseLabel": "Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetails",
      "http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of the year",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r82",
      "r163"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r82"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing and investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "carm_CashPreservationPlan2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "CashPreservationPlan2025Member",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Preservation Plan, 2025",
        "label": "Cash Preservation Plan, 2025 [Member]",
        "terseLabel": "Cash Preservation Plan, 2025",
        "verboseLabel": "2025 Cash Preservation Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r194",
      "r285",
      "r286",
      "r287",
      "r289",
      "r292",
      "r297",
      "r299",
      "r548",
      "r549",
      "r550",
      "r551",
      "r650",
      "r688",
      "r709"
     ]
    },
    "carm_CollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "CollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to collaboration and license agreement.",
        "label": "Collaboration and License Agreement [Member]",
        "terseLabel": "Collaboration and License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "carm_CollaborativeArrangementRightsAndObligationsMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payments",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payments",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Moderna Collaboration and License Agreement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)",
        "verboseLabel": "Commitments and contingencies (Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r109",
      "r503",
      "r569"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingencies",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r263",
      "r264",
      "r626",
      "r728",
      "r731"
     ]
    },
    "carm_CommitmentsAnnualPaymentsRequiredToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "CommitmentsAnnualPaymentsRequiredToBePaid",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments Annual Payments Required To Be Paid",
        "label": "Commitments Annual Payments Required To Be Paid",
        "terseLabel": "Annual payments to be made"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r712",
      "r713",
      "r715",
      "r776",
      "r830",
      "r832"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r570"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "verboseLabel": "Entity common stock, shares outstanding immediately after merger (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r71",
      "r570",
      "r588",
      "r832",
      "r833"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock $0.001 par value, 350,000,000 shares authorized, 41,788,096 and 41,750,109 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively",
        "verboseLabel": "Common stock $0.001 par value, 350,000,000 shares authorized, 41,750,109 and 40,609,915 shares issued and outstanding at December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r505",
      "r669"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r149",
      "r151",
      "r156",
      "r499",
      "r512",
      "r513"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r124"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "carm_ContractTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ContractTerm",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of contract.",
        "label": "Contract Term",
        "terseLabel": "Term of contract (in years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Deferred revenue liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r321"
     ]
    },
    "carm_ContractWithCustomerLiabilityDeferralOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ContractWithCustomerLiabilityDeferralOfRevenue",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue deferred.",
        "label": "Contract With Customer Liability, Deferral of Revenue",
        "terseLabel": "Deferral of revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Noncurrent portion of deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r321"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Recognition of unearned revenue",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTables",
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "carm_DeferredFinancingCostsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DeferredFinancingCostsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Financing Costs, Noncurrent",
        "label": "Deferred Financing Costs, Noncurrent",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DeferredFinancingCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DeferredFinancingCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Financing Costs, Policy",
        "label": "Deferred Financing Costs, Policy [Policy Text Block]",
        "terseLabel": "Deferred Financing Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r108",
      "r396"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "carm_DeferredTaxAssetsAmortizableAssetsAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DeferredTaxAssetsAmortizableAssetsAndOther",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Amortizable Assets And Other",
        "label": "Deferred Tax Assets, Amortizable Assets And Other",
        "terseLabel": "Amortizable assets and other"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization",
        "label": "Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization",
        "terseLabel": "Capitalized research and development costs, net of amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "carm_DeferredTaxAssetsEquityCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DeferredTaxAssetsEquityCompensation",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Equity Compensation",
        "label": "Deferred Tax Assets, Equity Compensation",
        "terseLabel": "Equity compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets and liabilities",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "carm_DeferredTaxAssetsStartUpCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DeferredTaxAssetsStartUpCosts",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Start Up Costs",
        "label": "Deferred Tax Assets, Start Up Costs",
        "terseLabel": "Start-up costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences",
        "terseLabel": "Accrued compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days)."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Depreciation",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "carm_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsForFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right Of Use Asset",
        "label": "Deferred Tax Liabilities, Right Of Use Asset",
        "negatedTerseLabel": "Right of use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetails",
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits Assets, Current",
        "terseLabel": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation, Amortization And Interest On Finance And Sale-Leaseback Lease Liabilities",
        "label": "Depreciation, Amortization And Interest On Finance And Sale-Leaseback Lease Liabilities",
        "terseLabel": "Depreciation, amortization and interest on finance and sale-leaseback lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetNarrativeDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r35"
     ]
    },
    "carm_DevelopmentStageRisksAndLiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DevelopmentStageRisksAndLiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Development-Stage Risks and Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DevelopmentStageRisksAndLiquidityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DevelopmentStageRisksAndLiquidityTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquiditys"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on risks of development-stage and liquidity.",
        "label": "Development-Stage Risks and Liquidity [Table Text Block]",
        "terseLabel": "Development-Stage Risks and Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DevelopmentStageRisksAndLiquidityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DevelopmentStageRisksAndLiquidityTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development-Stage Risks and Liquidity",
        "label": "Development-Stage Risks and Liquidity [Text Block]",
        "terseLabel": "Development-Stage Risks and Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensation",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r337",
      "r368",
      "r369",
      "r371",
      "r658"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability",
        "label": "Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability",
        "terseLabel": "Disposal of property and equipment in exchange for reduction in financing lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://carismatx.com/20241231/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Share information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of common stock, basic (in USD per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r182",
      "r184",
      "r186",
      "r187",
      "r188",
      "r191",
      "r415",
      "r420",
      "r434",
      "r435",
      "r500",
      "r514",
      "r636"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share of common stock, diluted (in USD per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r184",
      "r186",
      "r187",
      "r188",
      "r191",
      "r415",
      "r420",
      "r434",
      "r435",
      "r500",
      "r514",
      "r636"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r190"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTotalLabel": "Total provision",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r660"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedTerseLabel": "Federal tax benefit at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r384",
      "r406",
      "r660"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "negatedTerseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r660",
      "r711",
      "r767"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "negatedTerseLabel": "Other",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "xbrltype": "percentItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "label": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "negatedTerseLabel": "Permanent differences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedTerseLabel": "State and local tax, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r660",
      "r711",
      "r767"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Percent",
        "negatedTerseLabel": "State and local tax rate change",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax contingency."
       }
      }
     },
     "auth_ref": [
      "r711",
      "r767"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r711",
      "r767",
      "r769"
     ]
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "negatedLabel": "Change in fair value of derivative liability",
        "terseLabel": "Change in fair value of derivative liability",
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetails",
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Future compensation cost for awards not vested",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period compensation cost of unvested awards to be expensed (in years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options",
        "terseLabel": "Stock options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://carismatx.com/20241231/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://carismatx.com/20241231/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://carismatx.com/20241231/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://carismatx.com/20241231/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://carismatx.com/20241231/role/DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment",
        "verboseLabel": "Lab equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r133",
      "r153",
      "r154",
      "r155",
      "r168",
      "r169",
      "r170",
      "r172",
      "r177",
      "r179",
      "r181",
      "r193",
      "r232",
      "r233",
      "r251",
      "r300",
      "r404",
      "r405",
      "r412",
      "r413",
      "r414",
      "r416",
      "r419",
      "r420",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r458",
      "r480",
      "r511",
      "r538",
      "r539",
      "r540",
      "r558",
      "r610"
     ]
    },
    "carm_FacilitiesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "FacilitiesExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities Expense",
        "label": "Facilities Expense",
        "terseLabel": "Facilities expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value hierarchy",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r445",
      "r661"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r445",
      "r661"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r447",
      "r490",
      "r491",
      "r492",
      "r648",
      "r649",
      "r652",
      "r653",
      "r654",
      "r661",
      "r664"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r439",
      "r441",
      "r661",
      "r780",
      "r782"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r325",
      "r330",
      "r438",
      "r445",
      "r490",
      "r652",
      "r653",
      "r654",
      "r661"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r325",
      "r330",
      "r438",
      "r439",
      "r445",
      "r491",
      "r648",
      "r649",
      "r652",
      "r653",
      "r654",
      "r661"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r438",
      "r439",
      "r440",
      "r441",
      "r445",
      "r492",
      "r648",
      "r649",
      "r652",
      "r653",
      "r654",
      "r661",
      "r664"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r439",
      "r441",
      "r661",
      "r780",
      "r782"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r447",
      "r490",
      "r491",
      "r492",
      "r648",
      "r649",
      "r652",
      "r653",
      "r654",
      "r661",
      "r664"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueHierarchyOfAssetsMeasuredOnRecurringBasisDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "carm_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of finance lease cost expense.",
        "label": "Finance Lease Cost",
        "totalLabel": "Total finance lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "carm_FinanceLeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "FinanceLeaseCostAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Finance Lease Cost [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss": {
       "parentTag": "carm_FinanceLeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r467",
      "r668"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash used in finance leases",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r472"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "terseLabel": "Financing liability",
        "verboseLabel": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r476"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2029",
        "verboseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2028",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2025 (remaining nine months)",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "carm_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, to be Paid, after Year Four",
        "label": "Finance Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of principal related to finance lease liabilities",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r472"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "terseLabel": "Finance lease, accumulated amortization",
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r694"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss": {
       "parentTag": "carm_FinanceLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of lease assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r467",
      "r668"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Finance lease, ROU assets",
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r668"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r668"
     ]
    },
    "carm_FinanceLeasesInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "FinanceLeasesInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Leases, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "carm_FinanceLeasesInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "FinanceLeasesInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Leases, Interest Payment on Liability",
        "terseLabel": "Operating cash used in finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "carm_FinancingCashUsedInFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "FinancingCashUsedInFinanceLeases",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment on finance lease.",
        "label": "Financing cash used in finance leases",
        "terseLabel": "Financing cash used in finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office furniture",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "carm_GainLossOnSaleOfEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "GainLossOnSaleOfEquipment",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Sale of Equipment",
        "label": "Gain (Loss) on Sale of Equipment",
        "negatedTerseLabel": "Loss on sale of equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment",
        "negatedTerseLabel": "(Gain) loss on sale of property and equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General And Administrative, Excluding Facilities And Personnel Expenses, Depreciation And Amortization Expenses",
        "label": "General And Administrative, Excluding Facilities And Personnel Expenses, Depreciation And Amortization Expenses",
        "terseLabel": "General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r592"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r34",
      "r89",
      "r662"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r91"
     ]
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Pre-tax loss",
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r155"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "verboseLabel": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r254",
      "r257",
      "r442",
      "r443",
      "r446",
      "r535",
      "r537",
      "r595",
      "r629",
      "r663",
      "r801"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r257",
      "r442",
      "r443",
      "r446",
      "r535",
      "r537",
      "r595",
      "r629",
      "r663",
      "r801"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r384",
      "r385",
      "r392",
      "r401",
      "r660",
      "r772"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r384",
      "r385",
      "r392",
      "r401",
      "r660",
      "r772"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r380",
      "r384",
      "r389",
      "r390",
      "r391",
      "r393",
      "r400",
      "r407",
      "r409",
      "r410",
      "r411",
      "r553",
      "r660"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r131",
      "r180",
      "r181",
      "r192",
      "r204",
      "r223",
      "r383",
      "r384",
      "r408",
      "r515",
      "r660"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r381",
      "r382",
      "r393",
      "r394",
      "r399",
      "r403",
      "r547"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Decrease in contract with customer, liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r707"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Finance Lease, Liability, Lease Modification",
        "label": "Increase (Decrease) in Finance Lease, Liability, Lease Modification",
        "negatedTerseLabel": "Decrease in finance lease, liability, lease modification"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r707"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long term liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Stockholders' (Deficit) Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Convertible preferred stock",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Nonoperating",
        "terseLabel": "Interest income, net",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r706",
      "r718"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r160",
      "r161"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "terseLabel": "Personnel expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r668"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTables",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r477"
     ]
    },
    "carm_LeasesWeightedAverageDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "LeasesWeightedAverageDiscountRateAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Leases, Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "carm_LeasesWeightedAverageRemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "LeasesWeightedAverageRemainingLeaseTermAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Leases, Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTables",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of ease term and discount rate information relating to operating and finance leases.",
        "label": "Lessee, Operating and Finance Lease, Lease term and Discount Rate Information [Table Text Block]",
        "terseLabel": "Schedule of Lease Term and Discount Rate Information"
       }
      }
     },
     "auth_ref": []
    },
    "carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTables",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability and finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating and Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Maturities of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTables",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of supplemental cash flow information relating to operating and finance leases.",
        "label": "Lessee, Operating and Finance Lease, Supplemental Cash flow Information [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailsss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailsss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      },
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailsss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailsss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2029",
        "verboseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailsss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2028",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailsss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      },
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2025 (remaining nine months)",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "carm_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r68",
      "r166",
      "r231",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r423",
      "r424",
      "r425",
      "r448",
      "r568",
      "r637",
      "r686",
      "r736",
      "r789",
      "r790"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r110",
      "r507",
      "r669",
      "r710",
      "r723",
      "r783"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Deficit",
        "verboseLabel": "Liabilities and Stockholders' (Deficit) Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r139",
      "r166",
      "r231",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r423",
      "r424",
      "r425",
      "r448",
      "r669",
      "r736",
      "r789",
      "r790"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "carm_LocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "LocalJurisdictionMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local Jurisdiction",
        "label": "Local Jurisdiction [Member]",
        "terseLabel": "Local"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r271",
      "r377",
      "r647",
      "r732",
      "r733"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r271",
      "r377",
      "r647",
      "r732",
      "r733"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss contingency, estimate of possible loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r270",
      "r271",
      "r377",
      "r647"
     ]
    },
    "us-gaap_LossOnContractTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossOnContractTermination",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on Contract Termination",
        "terseLabel": "Contract termination fee",
        "documentation": "The loss recognized on termination of a contract."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to manufacturing and supply agreement with Novartis Pharmaceuticals Corporation.",
        "label": "Manufacturing and Supply Agreement with Novartis Pharmaceuticals Corporation [Member]",
        "terseLabel": "Novartis Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Security, Realized Gain (Loss)",
        "negatedTerseLabel": "Realized gain on marketable securities",
        "documentation": "Amount of realized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r332",
      "r377",
      "r441",
      "r495",
      "r534",
      "r536",
      "r543",
      "r560",
      "r561",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r627",
      "r628",
      "r644",
      "r650",
      "r657",
      "r664",
      "r665",
      "r666",
      "r667",
      "r671",
      "r738",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ]
    },
    "carm_MaximumNumberOfResearchTargets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "MaximumNumberOfResearchTargets",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of research targets.",
        "label": "Maximum Number of Research Targets",
        "terseLabel": "Maximum of research targets"
       }
      }
     },
     "auth_ref": []
    },
    "carm_MilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "MilestonesMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones",
        "label": "Milestones [Member]",
        "terseLabel": "Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "MinimumCommitmentToReimburseResearchAndDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum commitment to reimburse research and development costs.",
        "label": "Minimum Commitment to Reimburse Research and Development Costs",
        "terseLabel": "Minimum commitment to reimburse research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r332",
      "r377",
      "r441",
      "r495",
      "r534",
      "r536",
      "r543",
      "r560",
      "r561",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r627",
      "r628",
      "r644",
      "r650",
      "r657",
      "r664",
      "r665",
      "r666",
      "r671",
      "r738",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ]
    },
    "carm_ModernaLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ModernaLicenseAgreementMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to moderna license agreement.",
        "label": "Moderna License Agreement [Member]",
        "terseLabel": "Moderna License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "carm_ModernaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ModernaMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Moderna, a significant shareholder.",
        "label": "Moderna [Member]",
        "terseLabel": "Moderna"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MovementInDeferredRevenueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MovementInDeferredRevenueRollForward",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfChangesInDeferredRevenueDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Movement in Deferred Revenue [Roll Forward]",
        "terseLabel": "Movement in Deferred Revenue [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      },
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      },
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r84",
      "r111",
      "r137",
      "r148",
      "r150",
      "r155",
      "r166",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r185",
      "r231",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r415",
      "r420",
      "r435",
      "r448",
      "r510",
      "r590",
      "r608",
      "r609",
      "r684",
      "r736"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements",
        "verboseLabel": "Recently adopted accounting pronouncements and Recently issued but not yet adopted accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Effect of Modification of Operating Lease Right-of-Use Assets Operating Lease Liabilities",
        "label": "Non-Cash Effect of Modification of Operating Lease Right-of-Use Assets Operating Lease Liabilities",
        "terseLabel": "Modification of operating lease right-of-use asset and operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NoncashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NoncashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to the increase (decrease) in interest expenses.",
        "label": "Noncash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NoncashOrPartNoncashAcquisitionEquityAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NoncashOrPartNoncashAcquisitionEquityAssumed",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of equity that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition.",
        "label": "Noncash or Part Noncash Acquisition, Equity Assumed",
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests upon Merger"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash or Part Noncash Transaction, Reclassification of Debt Finance Costs",
        "label": "Noncash or Part Noncash Transaction, Reclassification of Debt Finance Costs",
        "terseLabel": "Reclassification of deferred financing costs to additional paid-in-capital"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on marketable securities in a noncash (or part noncash) transaction.",
        "label": "Noncash or Part Noncash, Unrealized Gain (Loss) on Marketable Securities",
        "terseLabel": "Unrealized gain on marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interests",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r300",
      "r712",
      "r713",
      "r714",
      "r715",
      "r832"
     ]
    },
    "us-gaap_NotesReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesReduction",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Reduction",
        "terseLabel": "Conversion of convertible promissory note, accrued interest and derivative liability upon Merger",
        "documentation": "The value of notes retired (or transferred to another entity) in noncash investing or financing transactions."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "carm_NumberOfBoardMembers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NumberOfBoardMembers",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Board Members",
        "label": "Number of Board Members",
        "terseLabel": "Number of board seats"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r717"
     ]
    },
    "carm_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Performance Obligations",
        "label": "Number of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfPotentialProductsToDevelopAndCommercialize": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NumberOfPotentialProductsToDevelopAndCommercialize",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of potential products to develop and commercialize",
        "label": "Number of Potential Products to Develop and Commercialize",
        "terseLabel": "Number of potential products to develop and commercialize"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfPotentialResearchTargetDesignations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NumberOfPotentialResearchTargetDesignations",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Potential Research Target Designations",
        "label": "Number of Potential Research Target Designations",
        "terseLabel": "Number of potential research target designations"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsGrossOncology": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NumberOfResearchTargetsGrossOncology",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Research Targets, Gross, Oncology",
        "label": "Number of Research Targets, Gross, Oncology",
        "terseLabel": "Number of oncology research targets"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsNominatedAutoimmune": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NumberOfResearchTargetsNominatedAutoimmune",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Research Targets Nominated, Autoimmune",
        "label": "Number of Research Targets Nominated, Autoimmune",
        "terseLabel": "Number of nominated autoimmune target"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsNominatedOncology": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NumberOfResearchTargetsNominatedOncology",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Research Targets Nominated, Oncology",
        "label": "Number of Research Targets Nominated, Oncology",
        "terseLabel": "Number of oncology research targets, nominated"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsNominatedReplacements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NumberOfResearchTargetsNominatedReplacements",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Research Targets Nominated, Replacements",
        "label": "Number of Research Targets Nominated, Replacements",
        "terseLabel": "Number of research targets, replacement nominations"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsTerminatedAutoimmune": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NumberOfResearchTargetsTerminatedAutoimmune",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Research Targets, Terminated, Autoimmune",
        "label": "Number of Research Targets, Terminated, Autoimmune",
        "terseLabel": "Number of nominated autoimmune target",
        "verboseLabel": "Number of autoimmune research targets, ceased development"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsTerminatedOncology": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "NumberOfResearchTargetsTerminatedOncology",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Research Targets, Terminated, Oncology",
        "label": "Number of Research Targets, Terminated, Oncology",
        "terseLabel": "Number of oncology research targets, ceased development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r638",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r668"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMaturitiesOfLeaseLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash used in operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r472"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use assets - operating leases",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Reduction in the operating right of use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r668"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateInformationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r668"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "NOL carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "carm_OptionRightCollaborationRevenuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "OptionRightCollaborationRevenuesMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Right Collaboration Revenues",
        "label": "Option Right Collaboration Revenues [Member]",
        "terseLabel": "Option Right Collaboration Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackground",
      "http://carismatx.com/20241231/role/DisclosureBackgrounds"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Background",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r104",
      "r544",
      "r545"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetails",
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssets",
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid Expenses and other assets",
        "verboseLabel": "Prepaid Expenses and Other Assets",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain on marketable securities",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r10",
      "r105"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r669"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetails",
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r724"
     ]
    },
    "us-gaap_OtherReceivablesGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables, Gross, Current",
        "terseLabel": "Other receivables",
        "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Collaboration receivable",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of reverse recapitalization finance costs.",
        "label": "Payment of Finance Costs, Reverse Recapitalization, Financing Activities",
        "negatedLabel": "Payment of reverse recapitalization finance costs"
       }
      }
     },
     "auth_ref": []
    },
    "carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in a failed sale-leaseback recognized in financing activities.",
        "label": "Payment of Finance Liability, Failed Sale Leaseback Transaction",
        "negatedLabel": "Payment of finance liability from failed sale-leaseback arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "carm_PaymentsForProceedsFromMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "PaymentsForProceedsFromMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including marketable securities and other assets.",
        "label": "Payments for (Proceeds from) Marketable Securities",
        "negatedLabel": "Proceeds from the sale of marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Financing Costs",
        "negatedTerseLabel": "Payment of deferred financing costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "carm_PennLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "PennLicenseAgreementMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Penn License Agreement",
        "label": "Penn License Agreement [Member]",
        "terseLabel": "Penn License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts": {
     "xbrltype": "durationItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "PeriodOfReimbursementOfResearchAndDevelopmentCosts",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of reimbursement of research and development costs.",
        "label": "Period of Reimbursement of Research and Development Costs",
        "terseLabel": "Period of reimbursement of research and development costs (in years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ]
    },
    "carm_Post2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "Post2017Member",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post-2017",
        "label": "Post-2017 [Member]",
        "terseLabel": "Post-2017"
       }
      }
     },
     "auth_ref": []
    },
    "carm_Pre2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "Pre2018Member",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-2018",
        "label": "Pre-2018 [Member]",
        "terseLabel": "Pre-2018"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r285"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r570"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r285"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r570",
      "r588",
      "r832",
      "r833"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r504",
      "r669"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetails",
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss",
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other assets",
        "totalLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid asset",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r234",
      "r235",
      "r634"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetails",
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r645",
      "r724"
     ]
    },
    "carm_PrepaidResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "PrepaidResearchAndDevelopmentCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetails",
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Research and Development, Current",
        "label": "Prepaid Research and Development, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCollectionOfOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromCollectionOfOtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Collection of Other Receivables",
        "terseLabel": "Proceeds from collection of collaboration receivable",
        "documentation": "Amount of cash inflow from the collection of receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "carm_ProceedsFromFailedSaleLeasebackTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ProceedsFromFailedSaleLeasebackTransaction",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow received by a seller-lessee in a failed sale-leaseback recognized in financing activities.",
        "label": "Proceeds from Failed Sale Leaseback Transaction",
        "terseLabel": "Proceeds from failed sale-leaseback arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Sale of common stock under Open Market Sales Agreement, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ProceedsFromIssuanceOfCommonStockPreClosingFinancing",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Common Stock, Pre-Closing Financing",
        "label": "Proceeds from Issuance of Common Stock, Pre-Closing Financing",
        "terseLabel": "Proceeds from the issuance of common stock in pre-closing financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "verboseLabel": "Proceeds from the sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r14"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r227",
      "r498",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r632",
      "r651",
      "r670",
      "r671",
      "r672",
      "r674",
      "r675",
      "r734",
      "r735",
      "r739",
      "r798",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r227",
      "r498",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r632",
      "r651",
      "r670",
      "r671",
      "r672",
      "r674",
      "r675",
      "r734",
      "r735",
      "r739",
      "r798",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r694",
      "r727"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r725"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Property, plant and equipment, gross",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r696",
      "r726"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r477"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r125",
      "r129",
      "r130"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r125",
      "r129",
      "r509"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r477"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful lives (in years)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r324",
      "r332",
      "r363",
      "r364",
      "r365",
      "r377",
      "r441",
      "r493",
      "r494",
      "r495",
      "r534",
      "r536",
      "r543",
      "r560",
      "r561",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r627",
      "r628",
      "r644",
      "r650",
      "r657",
      "r664",
      "r665",
      "r666",
      "r667",
      "r671",
      "r678",
      "r729",
      "r738",
      "r780",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r324",
      "r332",
      "r363",
      "r364",
      "r365",
      "r377",
      "r441",
      "r493",
      "r494",
      "r495",
      "r534",
      "r536",
      "r543",
      "r560",
      "r561",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r627",
      "r628",
      "r644",
      "r650",
      "r657",
      "r664",
      "r665",
      "r666",
      "r667",
      "r671",
      "r678",
      "r729",
      "r738",
      "r780",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ]
    },
    "carm_ReceivableDueFromCollaborativeArrangementCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ReceivableDueFromCollaborativeArrangementCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetails",
      "http://carismatx.com/20241231/role/DisclosurePrepaidExpensesAndOtherAssetsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable due from Collaborative Arrangement, Current",
        "label": "Receivable due from Collaborative Arrangement, Current",
        "terseLabel": "Collaboration receivable (Note 10)",
        "verboseLabel": "Collaboration receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "negatedLabel": "Reclassification to net loss of previous unrealized gain on marketable securities",
        "negatedTerseLabel": "Less: reclassification to net loss of previous unrealized gain on marketable securities",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r17"
     ]
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassifications of Temporary to Permanent Equity",
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests to common stock",
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r106"
     ]
    },
    "carm_ReclassificationsOfTemporaryToPermanentEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ReclassificationsOfTemporaryToPermanentEquityShares",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock classified as temporary equity reclassified or converted to permanent equity during the period.",
        "label": "Reclassifications of Temporary to Permanent Equity, Shares",
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "terseLabel": "Related Party [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r331",
      "r484",
      "r485",
      "r502",
      "r508",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r587",
      "r589",
      "r617"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r485",
      "r788"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "terseLabel": "Related Party [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r331",
      "r484",
      "r485",
      "r502",
      "r508",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r587",
      "r589",
      "r617",
      "r788"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureRelatedPartyTransactions",
      "http://carismatx.com/20241231/role/DisclosureRelatedPartyTransactionss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r554",
      "r555",
      "r556",
      "r593",
      "r594",
      "r595",
      "r614",
      "r616"
     ]
    },
    "carm_ReportingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ReportingSegmentMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Segment",
        "label": "Reporting Segment [Member]",
        "terseLabel": "Reporting Segment"
       }
      }
     },
     "auth_ref": []
    },
    "carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development, Excluding Facilities, Personnel, Depreciation and Amortization Expenses",
        "label": "Research and Development, Excluding Facilities, Personnel, Depreciation and Amortization Expenses",
        "terseLabel": "Research and development, excluding facilities, personnel, depreciation and amortization expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r629",
      "r641",
      "r797"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "carm_ResearchAndDevelopmentServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ResearchAndDevelopmentServicesMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to research and development services.",
        "label": "Research and Development Services [Member]",
        "terseLabel": "Research and Development Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected cost with the reduction in workforce",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r258",
      "r260",
      "r262"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Expected Cost Remaining",
        "terseLabel": "Expected remaining restructuring costs",
        "documentation": "Amount of expected cost remaining for the specified restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Reduction in workforce, number of employees",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Reduction in workforce (as a percent)",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r259",
      "r260",
      "r730"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r260",
      "r261"
     ]
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r690"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve",
        "terseLabel": "Restructuring reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r261"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetails",
      "http://carismatx.com/20241231/role/DisclosureDevelopmentStageRisksAndLiquidityDetailss",
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r98",
      "r506",
      "r541",
      "r542",
      "r552",
      "r571",
      "r669"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r168",
      "r169",
      "r170",
      "r172",
      "r177",
      "r179",
      "r181",
      "r232",
      "r233",
      "r251",
      "r404",
      "r405",
      "r412",
      "r413",
      "r414",
      "r416",
      "r419",
      "r420",
      "r426",
      "r428",
      "r429",
      "r431",
      "r433",
      "r456",
      "r458",
      "r538",
      "r540",
      "r558",
      "r832"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Collaboration revenues",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r774"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenues",
        "verboseLabel": "Collaboration revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r192",
      "r197",
      "r198",
      "r218",
      "r223",
      "r227",
      "r228",
      "r229",
      "r319",
      "r320",
      "r498"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r631"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreement",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Moderna Collaboration and License Agreement",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r323"
     ]
    },
    "us-gaap_RevenuePerformanceObligationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuePerformanceObligationAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Performance Obligation [Abstract]",
        "terseLabel": "Performance obligations:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "totalLabel": "Total performance obligations",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTables",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "terseLabel": "Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations",
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "carm_RevenueRemainingPerformanceObligationOptionRightsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "RevenueRemainingPerformanceObligationOptionRightsAmount",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails": {
       "parentTag": "us-gaap_RevenueRemainingPerformanceObligation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Option Rights, Amount",
        "terseLabel": "Option rights"
       }
      }
     },
     "auth_ref": []
    },
    "carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails": {
       "parentTag": "us-gaap_RevenueRemainingPerformanceObligation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementScheduleOfEstimatedRevenueExpectedToBeRecognizedInFutureRelatedToPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to research and development performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Research and Development, Amount",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "carm_RevisedOperatingPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "RevisedOperatingPlanMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revised Operating Plan",
        "label": "Revised Operating Plan [Member]",
        "terseLabel": "Revised Operating Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new financing lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r668"
     ]
    },
    "carm_RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Leases Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new financing lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r668"
     ]
    },
    "us-gaap_SaleAndLeasebackTransactionGainLossNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleAndLeasebackTransactionGainLossNet",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale and Leaseback Transaction, Gain (Loss), Net",
        "negatedTerseLabel": "Gain on sale of sale-leaseback",
        "terseLabel": "Gain on sale of sale-leaseback",
        "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r479",
      "r668"
     ]
    },
    "us-gaap_SaleLeasebackTransactionAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleLeasebackTransactionAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Leaseback Transaction, Accumulated Depreciation",
        "terseLabel": "Sale leaseback transaction, accumulated depreciation",
        "documentation": "The accumulated depreciation and amortization related to the asset(s) sold in connection with the property sold to another party and leased back to the seller."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r478"
     ]
    },
    "us-gaap_SaleLeasebackTransactionNetBookValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleLeasebackTransactionNetBookValue",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Leaseback Transaction, Net Book Value",
        "terseLabel": "Sale lease-back asset",
        "documentation": "The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r787"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Gross proceeds",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "carm_SaleOfStockMaximumOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "SaleOfStockMaximumOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Maximum Offering Amount",
        "label": "Sale of Stock, Maximum Offering Amount",
        "terseLabel": "Sale of stock, maximum aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sales of stock (in shares)",
        "verboseLabel": "Sale of stock (in shares)",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "carm_SaleOfStockStockOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "SaleOfStockStockOfferingAmount",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Stock Offering, Amount",
        "label": "Sale of Stock, Stock Offering, Amount",
        "terseLabel": "Stock offering, amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesTables",
      "http://carismatx.com/20241231/role/DisclosureAccruedExpensesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "verboseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Dilutive Securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss",
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r417"
     ]
    },
    "carm_ScheduleOfChangesInDeferredRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ScheduleOfChangesInDeferredRevenueTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTables",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in deferred revenue.",
        "label": "Schedule of Changes in Deferred Revenue [Table Text Block]",
        "terseLabel": "Schedule of Changes in Deferred Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets for Federal Income Taxes",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r660",
      "r767"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTables",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "verboseLabel": "Schedule of Stock-based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Hierarchy of Assets and Liabilities Measured on Recurring Basis",
        "verboseLabel": "Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r477"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Net Assets Acquired in the Merger",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Significant Expense Categories by Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r336",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTables",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r99"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTables",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Estimated Using The Black-Scholes Option-Pricing Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "terseLabel": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r93",
      "r96",
      "r97",
      "r98",
      "r142",
      "r143",
      "r144",
      "r194",
      "r285",
      "r286",
      "r287",
      "r289",
      "r292",
      "r297",
      "r299",
      "r548",
      "r549",
      "r550",
      "r551",
      "r650",
      "r688",
      "r709"
     ]
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r192",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r229",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r250",
      "r258",
      "r262",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r640",
      "r641",
      "r642",
      "r646",
      "r673",
      "r798",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_SegmentReportingInformationAdditionalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationAdditionalInformationAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information, Additional Information [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment items",
        "verboseLabel": "Other segment items(a)",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r209",
      "r210",
      "r223",
      "r641"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r226",
      "r228",
      "r639",
      "r640",
      "r643"
     ]
    },
    "carm_SesenBioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "SesenBioIncMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the entity Sesen Bio, Inc.",
        "label": "Sesen Bio, Inc [Member]",
        "terseLabel": "Sesen Bio, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureMergerWithSesenBioScheduleOfNetAssetsAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Severance and personnel costs paid",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Discount to the market price (as a percent)",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock-based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r336",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for issuance (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual term (years)"
       }
      }
     },
     "auth_ref": []
    },
    "carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in thousands)",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable as of March 31, 2025 (in shares)",
        "verboseLabel": "Exercisable as of December 31, 2024 (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable as of March 31, 2025 (in USD per share)",
        "verboseLabel": "Exercisable as of December 31, 2024 (in USD per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)",
        "terseLabel": "Stock-based options forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value (in USD per share)",
        "verboseLabel": "Weighted-average grant-date per share fair values granted (in USD per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding as of March 31, 2025",
        "verboseLabel": "Outstanding as of December 31, 2024",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding as of March 31, 2025 (in shares)",
        "periodStartLabel": "Outstanding as of December 31, 2024 (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding as of March 31, 2025 (in USD per share)",
        "periodStartLabel": "Outstanding as of December 31, 2024 (in USD per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in USD per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r341",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r372",
      "r373",
      "r374",
      "r375"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Terms (in years)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfEstimatedUsingBlackScholesOptionPricingModelDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable as of March 31, 2025",
        "verboseLabel": "Exercisable as of December 31, 2024",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable as of March 31, 2025",
        "verboseLabel": "Exercisable as of December 31, 2024",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding as of March 31, 2025",
        "verboseLabel": "Outstanding as of December 31, 2024",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Issue price per share (in USD per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r668"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPolicies",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r164"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Development [Member]",
        "terseLabel": "Computer software",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "carm_StateJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "StateJurisdictionMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Jurisdiction",
        "label": "State Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetails",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantExpenseCategoriesBySegmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r135",
      "r192",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r229",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r250",
      "r253",
      "r258",
      "r262",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r640",
      "r641",
      "r642",
      "r646",
      "r673",
      "r798",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r71",
      "r74",
      "r75",
      "r133",
      "r153",
      "r154",
      "r155",
      "r168",
      "r169",
      "r170",
      "r172",
      "r177",
      "r179",
      "r181",
      "r193",
      "r232",
      "r233",
      "r251",
      "r300",
      "r404",
      "r405",
      "r412",
      "r413",
      "r414",
      "r416",
      "r419",
      "r420",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r458",
      "r480",
      "r511",
      "r538",
      "r539",
      "r540",
      "r558",
      "r610"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r193",
      "r458",
      "r498",
      "r546",
      "r559",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r591",
      "r592",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r610",
      "r679"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r193",
      "r230",
      "r458",
      "r498",
      "r546",
      "r559",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r591",
      "r592",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r610",
      "r679"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r98"
     ]
    },
    "carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock and Non-Controlling Interests",
        "terseLabel": "Shares issued upon conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock and Non-controlling Interests Upon Merger",
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests to common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r38",
      "r71",
      "r74",
      "r98",
      "r282"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued in a pre-closing funding (in shares)",
        "verboseLabel": "Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r70",
      "r71",
      "r98",
      "r548",
      "r610",
      "r623"
     ]
    },
    "carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesPreclosureFinancingTransaction",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to pre-closing financing.",
        "label": "Stock Issued During Period, Shares, Pre-closing, Financing Transaction",
        "terseLabel": "Issuance of common stock for cash in pre-closing financing (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetailss",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r70",
      "r71",
      "r98",
      "r347"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock to Sesen Bio shareholders in reverse capitalization",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r71",
      "r74",
      "r75",
      "r98"
     ]
    },
    "carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Preferred Stock and Non-controlling Interests Upon Merger",
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r71",
      "r74",
      "r75",
      "r98"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of common stock under Open Market Sales Agreement, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r70",
      "r71",
      "r98",
      "r558",
      "r610",
      "r623",
      "r685"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r71",
      "r74",
      "r75",
      "r98"
     ]
    },
    "carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "StockIssuedDuringPeriodValuesPreclosureFinancingTransaction",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to preclosing financing during the period.",
        "label": "Stock Issued During Period, Values, Pre-closing Financing Transaction",
        "terseLabel": "Issuance of common stock for cash in pre-closing financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' deficit",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r133",
      "r134",
      "r154",
      "r168",
      "r169",
      "r170",
      "r172",
      "r177",
      "r179",
      "r232",
      "r233",
      "r251",
      "r300",
      "r404",
      "r405",
      "r412",
      "r413",
      "r414",
      "r416",
      "r419",
      "r420",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r449",
      "r450",
      "r454",
      "r457",
      "r480",
      "r539",
      "r540",
      "r557",
      "r572",
      "r588",
      "r611",
      "r612",
      "r624",
      "r685",
      "r710",
      "r723",
      "r783",
      "r832"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedBalanceSheets",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' deficit:",
        "verboseLabel": "Stockholders' (deficit) equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquity",
      "http://carismatx.com/20241231/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "verboseLabel": "Stockholders' (Deficit) Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r165",
      "r284",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r300",
      "r432",
      "r613",
      "r615",
      "r625"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r488"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r488"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r488"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r488"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r488"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSubsequentEvents",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r489"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee [Line Items]",
        "terseLabel": "Subsidiary or Equity Method Investee [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockholdersDeficitEquityDetails",
      "http://carismatx.com/20241231/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r166",
      "r231",
      "r448"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "carm_TrusteesOfUniversityOfPennsylvaniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "TrusteesOfUniversityOfPennsylvaniaMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Trustees of the University of Pennsylvania .",
        "label": "Trustees of the University of Pennsylvania [Member]",
        "terseLabel": "Penn"
       }
      }
     },
     "auth_ref": []
    },
    "carm_TwoThousandFourteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "TwoThousandFourteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Two Thousand Fourteen Employee Stock Purchase Plan.",
        "label": "Two Thousand Fourteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "Two Thousand Fourteen Employee Stock Purchase Plan",
        "verboseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "carm_TwoThousandFourteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "TwoThousandFourteenStockIncentivePlanMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Two Thousand Fourteen Stock Incentive Plan.",
        "label": "Two Thousand Fourteen Stock Incentive Plan [Member]",
        "terseLabel": "Two Thousand Fourteen Stock Incentive Plan",
        "verboseLabel": "2014 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "carm_TwoThousandSeventeenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "TwoThousandSeventeenStockIncentivePlanMember",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureStockBasedCompensationNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Two Thousand Seventeen Stock Incentive, a Legacy Plan.",
        "label": "Two Thousand Seventeen Stock Incentive Plan [Member]",
        "terseLabel": "Two Thousand Seventeen Stock Incentive Plan",
        "verboseLabel": "2017 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetails",
      "http://carismatx.com/20241231/role/DisclosureBackgroundDetailss",
      "http://carismatx.com/20241231/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r260",
      "r261"
     ]
    },
    "carm_UpfrontNonRefundablePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "UpfrontNonRefundablePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails",
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront non-refundable payment received.",
        "label": "Upfront Non-Refundable Payment Received",
        "terseLabel": "Upfront non-refundable payment received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://carismatx.com/20241231/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r122",
      "r123",
      "r126",
      "r127"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "carm_VariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "VariableConsideration",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureModernaCollaborationAndLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable consideration.",
        "label": "Variable Consideration",
        "terseLabel": "Variable consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails",
      "http://carismatx.com/20241231/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r668"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares of common stock outstanding, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r188"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares of common stock outstanding, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r188"
     ]
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementUnauditedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Debt Issuance Cost, Writeoff",
        "terseLabel": "Write-off of deferred financing costs",
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "carm_WriteOffOfPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20250331",
     "localname": "WriteOffOfPropertyAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://carismatx.com/20241231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of Property and Equipment",
        "label": "Write-off of Property and Equipment",
        "terseLabel": "Write-off of property and equipment"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481192/840-30-45-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-50"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "51",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-51"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-52"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "275",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479072/912-275-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815-15/tableOfContent"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>156
<FILENAME>0001410578-25-001470-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001410578-25-001470-xbrl.zip
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MXDG=39KA5*4#VR!IX$!%G_Z+OM3UR_\#4$L#!!0    ( &TQ]5KVM\+:#1L
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MP0:2Q^?Z_O%Y0+\6 \!NN 80M V&W?L.(1 M0**%4#3/T9[]:P\^&IKG<KI
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MJS%PK3^?(Y.W,JJ:B(J-':QO*,TCXKQBT*Z;]^\N>X<H3'/0,V$0IMVJ$F]
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M9?@4;\X'THLTQ,7B+7X[\R41[/3\X_\!4$L#!!0    ( &TQ]5JD1CD7<3P
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M>(_I XI3JS/RV%K%K,YME((?R;'CQK3 I!G!&[:R;]E"SE?M#==YAN@>:P7
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M'W)8:^$J+>[RTA 2>W5ZU2 $$;>4)LB_%MFN,\2V+G[Z?LT#^BH^*=<7P\8
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MIC&0(R^!%/L!$,;J<\JJR+9=S7R]=LEVNGP,5E&P##R7T>IY_.UBD>@1!EZ
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M?$@K#)_YL1O)0]$&@-NK$XDHR(-S "L:^NP567%EAMY2FB!&;,'P&^P9ZKL
MX-PZSFHVHA:DH-GADM&/B$@6G",/!2_BH>!&HC;J!(#OJRMA&]$+X$Q^Q0[
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MNGK(8. 1)#U[F6E$AB&K+28=49#_CDM$'RO0\C''U4F;%+,MSKA>5 PSRJ>
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MF]HGHM"Y\%RM*5RZGNJ ]CJ<H(>S+=6$!%6^BR%X02**"YK OLMYA::PKHY
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M5?+O=84J_7U!44T:5-E/*)&BZB6?8%4^X9RF-Q"0=ZEJVL!Q*Y@]QT2OAY(
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M-+ B_DPO.E_>7MV]7R+1J@7:YG&6HS)C+3?L/J[OG":P.\:J#P5$%"X05[E
MHE*/-25!XW+J0(G,A[Y[S)Z_CW#,QTCDAW9H1/[Q3ZHUN223J'+?,S_I?P(F
M.PYX0]FOY\_PAC!#1NJ7&R/R$!?H8Y[AQR<+H<+5]4X6>OX,-TCZ_*@C1/P;
MS/#HM5#W.ZJ_(!\#=L?.F!Y_?S=UN/W=?$?7WTT:3'\WX['SH>T&ALJ5HJ,1
M#X3AKREWI3Z"&]A:]QC(VMX-)F"2S_\1K]:_9;R^*S^_650K%9'Z HJ:,)BT
M9@:CD:5!!4GP1A.&_#&[C-9JIDL*7'=SH+NH5]DB*$N+3H$*A(V$;0>G9XY3
MW. 45,K1JX#\HWY:9R>P?TQ4WPG]-@ORB%-J;^4.R7,PJ6+4LV;@T_<0\/'.
MH,G:V33-!=Y,+*KD.AW9S-VQX5&,9>\>F'<%#OQ<N5I3VWFV>8A3]NW>XC![
M3.,_<'05D>\Y7L?T9!R_?[:FU&4:"84OR-_(IQ^=!\53=7WU<Y#0H?<(C5M3
M"I/=W&+>-V"RHQ'^P,JRWR>/*P3[%JBU$(DF\NNIVP$8*_TBF(DJ.Q>(6MK<
M<5_9ZG6X!A3^!J>0_H"E8,V/B'=Y3AKP)]\'^>^XI"W;'#D7[TO!AJ^(IE7?
MB#76'C/@*R%Q91B@<3HWO&JP0*WM0O;N_$G>^NL1<"MDN,V;[V]RO WBNF8I
M>9X55^)_<_T*1VSY2OE?Y0TYZ0>&#/D*^P,E.(#W"Y4/=?5DUI!75^-/O*PN
MPNH;JZ&L;TE@6&8,RZ /2_VUW!J?L,4G;_")!7RXWGIIF2XTYW%8XHA.8/K6
MKDP)ADG4YK%KEI>-2 6^'FW61]THNW_"M-+MCG!8MD:M<#XI9Z?0'FKJ%"QU
MNW</ RI-&KUMK* +'NX7T&& =]O]LE[(D%]>MM^94IA]@UO,+8_6P53]=SPL
M-UE;W?+XVU81^Y\Y\"E^I!>1.!YDF\1_&8:TDR_0-M@SB-EM9&&8[W!TRD5D
MH%C9V2K+5[B$XF9]Y&M:_("]LF%QO2(K@\05E1H"^9[:C%)<5FL/37X9D&S7
M\ZPH5^L:"7X0X#X/4C*<K_\\H?2$HK1YD)\F2B,)KRJBX-.8KD-F4UX%-8CI
M\3R$<XW*-='Y2P>%L <%R*.Q7[,L^APG22\%?\"R2EWVM,V#FBRA;&!P-J8*
M/K79<MC+,&V!:OL6\A$;L7).VTO6$9>.V5!"WT,)@6_O\#/.Z4URK"=Y(T'X
M^"G8_";QJGOO6N<1N'PB,U3_7K5*GH6ACOK-:;9\HN2T;:[996&%Z"ZNL;W:
M:E?X%A>8?) T)?6"*$^R+=UKJ];-^G9!%-O!C*O)GC<;J2J-@.^33G+AU&2#
M6@O[D 4]S4JSTWW/E^_Z\-:E$_\[?D>M?&.4109#.'ZF Z"+'>9E49.$WG >
MT)*ERYPPYR,>H2\-&8"I3!>1AM:F"@!.<=KNZ'_SM4(4[7!=;%C0B02E?KCO
M*\9DF!2= R/()U.EO(7IU8>LQ.C-Z\-3U49 &+CR$!8,/J:-5<=XE18[-NZ6
MC/-['H/9*XSY)<X<#Y^!.W646GKJ4*V1Z&7V:-PMF3M.0ND";[,B+@N^.-4_
M!!M[%G90#7HH1E;O@W##:]A<W8^QEMJD]/OHZ-VXZ"/<V F![KF!X9@;;  [
M\,9]%:-/_C3<$%2P6?<CY:=F#L[3^(U&V]YZV8!HK@V_R;,MSLO]#7&AK([Z
MLX40=C.W;"59O3GL6)V*0V<O0[$MW#B>[('^"):+7R"FH"F3P51(+H%WM"<"
M&0)'DTJ)WV_W]T3MP.U%:BUA$\ $[[NST=%F<,-^BO':R4U9^GAV'3_C"-T3
M"7&3W>#SRB. COL-<>KUX"U(:BUG&N+'WBN%>-MLAB'>8[R%+]WG14@@77<S
MJ,_6Y><@Q\)NZ> M[D//PP[I44\[XW39PW##=]QD[9R=2K*XU>^G6+E]7_D]
MI/2^XTJ%CZ!LZ&<P%(^?@AV $J_$L#MX!&ZPR0S5OH^CG=7YC"O3;EWS7= L
MW[?S5L<[P!9=8X4H=1. 3B:)=[L\C<M=3HOIO(N_T)_ZKS54:@";.L9]%5E$
M_C1<0E&P6?=+;42S]:-:N%^BL>CN:KV.0XS6M08?L7F-B2GT7KZKS3;/GEER
MR7!P#K> '9T*WHKA.? XW/A4,5K_4%\E&XG"_0:H&W]C0;B/.#W/TJ+,=^QD
MSU5ZDV>/!,SA0!UI CM25?P50W7H>;BQJF2U_@2Q%8[B%-7B_8:K4Y>WE7A0
MR]+7<8JO2KR9O/$D-H0=O>J^*ZU)-ZW@1O($VRWML5)%B&D"MC(-  &_ <]F
M#BG-!67CB=OX\:E<K3\6_.SP6[S.R.PB#'>;74*K.5S06R;#F*5DDZ;+39:7
M\1]]YRS<:IXIY9A'7XFSS*F=(>E9<-X09RP.2(,O-#!3$;,5,6//LO49,9=O
M>RW0 [,8"28CT68F1;0:%@&#?!O;AL&;M<D%>LPS8(.U8>Q\L/;7S=?.F?HK
MY>@YL;,?6E8OP07[%?!"78& 872(82#'T$WJ1Y!PA!Z"\'>AI-@'TGMEV>^_
M!<E.FLNMUA0V5T[QOY,;HM .+G--LEX[8X0H08T6L5X=JSV%J";$5/E)'W&&
M 2V5C\\8"*RRE)>-X@FC5(4!U@GB8//!J3AUMJ U9<'EC9,]TMZ^%D<J"]6)
MI/=YHW>\D@JOU4?]2Y"LC3$DH[")?"V7 IMI-%%1&81(1,#E%5U'; Q-9%,>
M4(,4J\ D#3"E"(QL'@-L.&-L(/,"AS!F!B\O:=CB<< REY&*HS&*2"\GKHKT
MU]5;\MMK^JL##M:6T&@.DR)T<6@*Z4UH"[R&GHXGNE]ZI4M:,M-)N8H^@OPZ
MD1BNE^<2#H.U1$\>4E5^W^39&A<%B9H@>8?Q2(6KT48P>7":S^*P:+@%W"&0
MHMVGQK4H'U$%?BOP6/:ZX^T:^[D0[W*S3;(]QK>8C9V$NQ&&0U>E'>SH5?:\
M<[IPK!'<&%8W7?L$8J7A+.<JQ(M#_$:R?=_IH5_2M[=;LS4&/F^[9'6^*A93
MCNS11K##6LWGHU)XTA9P UK1[M-*XM5=,YA0=N&UE_-^&;W3*"WC]!&G(?%H
MJ!">]&'8L3GL8^> 7^^3<&-QQ%[]@B_L"B]!KM>J=;Z]=!*(M%[/:BV4=!\H
M12=[%G88#GHH1F'O@W"#<-A< Y7XN[<R\"Q&X=^\QRR?@O3@*@>/M>?FA8F;
MI:K6O&*91A_(_+O]C;!+.GR(=[H4V*2@B4IG=6N:"+A$HNN(SW#R6?ONY>!U
MPE6!.$VOXY#.]9>/.<;2VEOC3\,D"D4OV\L I8\"W]M3,%Q[R9>(1I5LU AW
M>\N?:^_\5#4 \2;UV>1]D.[6A#1W.9D3$4J]VVVWR;[1\X^X?/J0/0=Y&1<W
M3Z1!$.)=&8=!0N9G^;:Z-DI./V;% ^8K"S@V!&=0-G!&M.&I_J;WEOC(JAN1
MOAW%Z3HC"MFR.SW+1?IT8B,J,[01C68#@X*9C8*&F3X3PU%M.3HP'0FV?^>4
MHB'!_?X(16Z-P._**'KL"2!!VD!U2K=Q\BRXV@J[(:;LQ2'ZV[WXEX&UKTD"
M8'81^EB(TU[UUG!GO!H^Z!-XE:5)N(3,%.M]4JJ K?SZ6ROS  *3Z'$M3'1L
M\$:&W@?G$]7R^Q:.GYI'E!JZ4F L&GTN*UETMXH[TXM ]_FN*#$N5NN/:?Q,
M_(O+_6I-YXK%/GD.TCB0S\DFM(49=UH(-+,IU8; ITJ3W; ^#ZHM0MF:/=G:
M17\C6H;<3G.<034! 7\S%&=H4)$@$ERN1\IM#C: 28'JO@XFNUS#+ZNI8+/)
M=)!KSS4T+;I[GFTV<<GK==-16$>-L9')51KF]*3<!>;_O4K%,WMU(MV>_>M]
M%L7K.)3V<2?(@AFV1A!J1C*Z@H"/;$YV2S= :L7H5:WZ6UI"^N",;&/ HBI(
M)MK@=%SS)U"5;=U";/>#PQ]OH-4**5+K[IGBI$6*_09MY$@YKUO00"+IL63/
MPF1@)0]E!0::!^$.EX;--50FH!'LO0: :1?I5#:QZ9W"[5]V_+OADWCT3 O&
MT>DH9YJD/=E@; @H##27:;H+DIM@S_YU2PO]YH2AL[?X)HBC/GZ>TA@FQ>AA
MT(SJE%L"'\9-]\/$Q(:K0K4N5"M#]QEZBQ'5YW2,]E6A,+SPY Z*ROUM[7Z9
MH0<RJ HBG0O6)%5:-MDN+8D']/C(QRTM=?448WX]U&I]SA=&SXD8NK=_BQ]I
MQ9@LWR_3B,* \S .DO=Q@HLR2_'E,S6S#S,[:@#SID5<V^HPYG4 YV*;'FL'
M*;,)54:A';$*"6;1(4IE&*HM6Z#6MFH)J[8.->8A;I_;VC1_XFN__X (<HM*
MW=F8ZV&B*"Y9S8Y&R91Q]+3FD'N$Z3BT3*_>%CJ#:WBBS1R-+B'JC\>2?%3E
M?$3]U2$QPHI^X-AX(;YW67[_A-_%>5&>+V_?W^19M O[RR!J")DG"0YCHD*%
M_1+F2X@C_M@A@W66LYP/IA81O6?O4:49"CU^#;AHDZ5]<(XIDX&S%H#9]@)S
M I76B?_W.-_T G+P &0*[/.EI3?QK]"IJ]=6[:0S$EQ;G,=91*=TS9DCMREV
M9EUJC_R0<-YXH F+WJ!79,*]QT%>?.LK.6Z5TM2?/ B9?W$Z5'A^Z'F89*'L
MZ6%F7._#<'=ZQTT^*2\N2U$M&PG"O27%V7&U<;%LA=(2J7YN(,5;,DL;+/$^
M]BSLD!STL'M39\^#<$-QV-P3=NRI5+^UQMVXZ.V^N6ZZ[?ZR*.--4.+5^H;\
M(7Y(,'U@@)54VL*.R4D(R)/))0WAQNPT\PVEF.\7J%;$3H14JM#U\:77[GI6
M1RB$(@I80&%;HY!XNOI[1:9/ ;6-I5R=9X6T8G'?@[##6^Y;IS+QT5-P W?
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MLZ!")&\0X50(()V\FZ\PBLT;25>A(08FBYZ*BSPI9UP&W#&-MB?&$GJ4V 5
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M;OHKK_J8A%EP,J3ANRMXI&:GS\ FG#ZKO%FELKNO)C:%&8@Z_@\?3SMN!WS
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MDA>R"5+R2BYB\G1.W#T:6ITJ"R8?&4&HR=/3%00\B^]DMVQS#FJT(T&]TUS
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M7/TBC5CZH5(7,-0:)C%IHB ?JDF;SFW4-NZ(4;H0U%6_0T0AZDM]=3R:>^%
M3!SEV4-#=)QG2+$.(M-,?E8DO,O_VI'1I<CG2C#T-IL3Q<G]EG/;<9NYD=J
M!T:#F.L9NM3 ,8F],,<GDI8%[RM'3QR56<K&5AW8U@_#)"XU'\>SKF<TC>O:
M:S[+VDHLCIV/L.0E3QN/@"96_U8?-%W6YTQ5T>EM.;,(E7L_&*['S684NP/&
M&PWD1@]:2HXPG^;[Q-.1+G#X#<:I[2-7/V#E T_\T9F%L>#?8-R2YV84J**U
M1B/S T_0M!V@VOVN4<?;_K;)3 527$'PN]Z.BO&$$XK]C683N@,^2X*XI\4L
MPGG(;B.!+2B =TS1JO<TNI-6@8WU-\'^6WJ-Q6K]L>!KBB-S^L&&,,-TNN]]
MJW#R5O-9AU/PP7SH,DWTU G1Q7MK7ZMQ+]']*<4PW4#!':9WWA357@*<<<A-
M3@]\EGMZ\W>Y3".ZD,@R\B<Q_I 4F!1X(BKC0Q>IB+F-9<8=,4\1M<X%NY&^
M9#MOC5X@RPN.(-KF.(R]+^@WM60$KT<@DC29!QT,^=L7^WW/PP_T0:LM35E\
MED9RX_?IDQ7S2X."HQ-6"8]:S2-X1[P>7#OL-H$?PF.&FUY1A+%T:-A9NE+:
MLW/'[PCQ&\GR:B_W-#5) MAX*]B1K.BU&,DC3>!&LJKAVN4Z!RH:H4],AY_%
M0X"..PEIPF+\_MWEEU@VB#Y\!G:X]GHD!F?G ;BAV&^F=G5,TI%4ETE_H@+]
M1)E;G]P&T$6V">+#)5[Y4S,)HJY7O6'$'YE!(!T8:N*SXR(]!Y,SO_3WMFYR
M_,/K-W]_CS</_>=E#A^ &1YR7YH]J<Y?@>\]]=NJ^_T0:6=4G-/](SLNH$]<
MH-O =O=.3@CDK"B)P+\-1/+A$Y!#N=>;-I8[?X8>S/W&:G\Y1!S]=/[F-IPM
M.>$SH-V\%R>#W6:M>KDKG[(\+O<#TT;IPS )0<U'<03<_R3<@?"(O;I?I' -
MQ?_:Y7$1Q2%+=/0XSX3@J:> ')R&#CP^MZ"43TQES\XI, U-Z:0?K,]Y*Q1O
MW6Q^$HN*,@[/LUU:YOO>8?/8L[!#<]##SO9FWX-P@W+87.VMS$IJSU?J8X1J
MU]EW.,)YD!B;?-Z1V0\609//0N6/PHPF%?^:>:GD.> 3U#&K3RBD6N).+#F=
MLKISR^,DUJJ3QOCAFCR:J/&#_%' _##B7\,/DN> \\.8U=K5$JE<?_S@SBV/
M_&#524_;NL=7#PSG2$B?A\DHRIX>;/KV/PQW'#]N\BD;ICW7:'A.L(#@K+\0
M_1!L\%@FQDBK&8;KL=>C0=LVF5GH]AAN^)M>(*K#>W('/->=A'5]*\_@4MG1
M0["#MM\G,4:[3\ -28F=VJ=1ZRN8I-V+SU4Q6\X>7/\'*Y7_.D[Q58DWLI&N
M6DO8\3C!>[6T_J89W,B=8KR=+'>J!S%%T'+\_2/@.>@G(S;C$)\6V7,,:*M?
M,;#0/?V\W>H:A0,.>EQNVM#=N$DS_;H%[-A4\'9\T8D]#C<Z58PV/GGC\N%,
M6 WZR^]D[42JCT ]KN!Y>![X_(DXB:_2P>C5$ ,[I'5Q$>-\J@RXP:_MR>E5
M8!N-PD6,S;'Y!;V3,6>WA[VZP/RG;[W2AD>DO!;BO N?<+1+\&I]GB5$?4:'
M-\]XF>?46[HJ0&\/^4 "3_+G>_)3$;"]ML'3]U84P>8B>]B*;&5>"UP^L^BK
M;AQW#$&"*K:Z)OZ;7<&#2D(CJ-O(9[T!@(A>Q$7P^)C3\D64'K,UNN67VYY0
MGZ _3T=PF=T1=QV'].:X)5'.?).G[2BWA,E0&MXW23UJS8#G^$QT0G^E?4O,
MIT%$XAZC."4SA@W_K&EMO"!.Z=I&F:%0M*<JL<,L0D%MTG=.LX4< 71^Y'>E
M"#6:/&83P0'!&.6]SR*<IX$ZTXTU $QP2KXVO#;X-' Z4[/=.HMMN!F^N<LN
M&I5T4$3ER6/3K#3*0C-BG6&6F1.KN&:12NT"!:B(']-X'8>TW''Q%.3X*4O(
M'[W0B>%@\DX69OTQMG95Y*6P;D7^U:Y9D7_\\R;/HEU8KO([G#\3/NI)A1YX
M#"9MC/E%R4/V#+RUFE%+]6O(,*%L@%S)]9'B[-\_V\%%5WPJ XK>'.:Q9\&'
MF=S#@U@[?A!TP V8:_2K])&1#,9-_6%NG7A)S!?2+FM/Y*-?Q78PPVZRY\U8
M6:41\"'T)!>LCZQS,?$W:NU!1660VX&U(W#ZDYWK*"\\CL1A &",WE9;^LVQ
MBYTZ2YK5]LT P2FW!$QQT[QO2$ZM&7":F^B$?CHH(S5^=5AWU;S6Y)3 X+CM
MD<3@@&!N.3).<%%FZ1!E]3P#F)QD'K7KD@</ "<<J;G:RUB-0+=KB_;\\+G"
MZ.SMN,F1VST4^+]VY'N\?*89+T350 4&^=,P^4'1RT[*6?^C\)9&5 W6+AO4
MR$5,,**2?=9= ."HKY <K+8P]/SLPE)>84'Z\*Q"T]"2GN2;]5E- 8BS/D)T
ML(R"[-E9A::\J$+O@[,)25,E]@Z_4*\E%=SXZ"/N#.1Q7X^47C"L G:4V\!3
M) >3\N%RBA4O?9[9N/9<1 (4H'52D]-,YN!+O-EM/NPH<Z_6]3;'?9 _XO*0
MN=1:P"2B"=ZVRWF#CT-?W%,S7OMCY>)1RN33\T7-OFC)53C.+W3C[H?&7:'8
M%5/A88'0C<L]K]88_4AL_Y!MXC0H<;3<E5F\V>S2PP.QTUL#IJ7I*#04I=X4
M.%UI.*)=(T8:PZA1MT"M0J<\]I7A,,QP7L!(:^DH:,17Q&>;]W[-LZ)8T6%G
M]KB? ,AAN_EQ7:_G8RS7:31/?NMWP7Q$+Q#3M$"U+@BD]J*<UV(R6PADE4A[
M([>/6Q+4:?F!IJBL=VE$:PK<!'L: [<XQ&2^'/7AH-8,,']-\+NA+X4VP-EK
MB@>Z7V^E@_2_Z5G>:$%;KH9\R5R/VVFE2\>)DK-6"ZK4H%J/>]("]-:-C[QN
MLI+(CX.D/@UQGU5IO<LT.L\V&YR'Y*_Q'X,SSTE2 +.:/BI'8S1U$< Y[P2'
M3N_ M[52M*VTTJ,'U6D#MB8<BIJ]C.:\ -,H13<",!<",.>V@5$;Z<WPL]%G
M55[.CW<*K)? >>7V52J<EN"CW@M,3Z2SN!/^=HL?=PG5M^_@TR0M5AU/[YZ$
M6_6 >=S#>V@Z (>Z@?<</I#0Y0YN:S7.XD,O0B45>Z X[9QPXY-(\JO&Y(7X
M]P414YM]0#9H4UM>#^T<[P_-\)VTQB)B;=W?T7<B'D#C%J,+\9U<B._DMOM.
M6L-18WD]U_"PB37#]](?*P;/S:1TWXTZ$I?,]^P6QYN''8&Q_ZSC>59(]NJU
M10'NXT[$1SBLHR4'>-]SJE?ZATN87D;Y7#$_*UVIEI^:#JEZQ[D"GC$Z[V#4
MJ&[7K0\/&3/U/DX@S?%;,D;$I"N*LXBNV5>*J8YV"5^1@[6D *9??50:YITN
M CCIGN"0=JD5II(GYPA*.]DZ *C6*S*WA\A (]@Y?3?H%9EX[,D#Q;?F%^-Q
MSJJM$.99/?S?]JZL-W+<"+_G5_ MLX"<((\)@@7LF?'&@&=LC)T9+/RD5K/=
MPJBE7AT^\NO#(G6PNR6*HB2R9"^PV/7:8AU?=WWB4:R*0E&SO)5->T<@9DX]
M;T\WU%L?1\Z(FL9/L!_<*""2!C<;XF_(6<U-[KD]WDL>)YT>3]*\X"##GU?(
M@%L DEM:6]%C!2+FKTFP:NN ,%P:<O:;QK?)+^9XHO!+QE_PD@F>I9W 3@+]
M$R\##G8+VI?C_7PWW>5YS:)+QE$?DSA/_2#_$>;;CP6S;$?3SR]!5*S#^!%:
MC[%_H O9$9+C).$DZPG0.6QF/U@,WAN48YPQKQTH&B_!IT,JK>29J2657H_4
MFDFE&AK].;D4Z0*CPSN/Z8QUZ)YHNDH6"H"EJ^^G+E^'_BJ,POSX4H+N&-Q$
MJ>7QX6USQ0"\Y*=GMODWN)W9:@US1/.>;V=]CM>J>)[7[PL_XLM3/^>%@VG,
M=]?@1V'<?&[?Y7Z:HW%\11_#F!=)GMU]C7O]<SI>M^(M:9I$'5]Q*WQ=-0&N
M6@!?Q28,/EP*;DXW1$5F^8$B\/*^J2.F\='2EAJREIR\('JIPC8XE1Y )#A
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MK#>^C%XJ$;51R[WEZMKM V@BI2HW.V[(01A_LMYZC"",\",H:,6M4!TX:DO
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M1&8RTA2'N?^AT9K-(F&E>YM$8? J_JWD2NV1B"ERF/<U,^H-0TZ( YT8F2T
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M1IEV.Q/V#@:VXP61#VXL^]O2]R)W+CBUE[:@0( [L :.]XG!1*@NP0P&W_"
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MH.D.H;)=;7RWTG;IG*UK(WAFI./?3SZ)R])&G96D_YI?U!"@^R"$*QS7\#7
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M?H3 G8/Y]J<PQ V?GJ#NG0R^#-+JZ*^DA8'@DUI8!HR\9^<^Z^#GT#R_B%N
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M1]=VHCG)<>H358:A#]^C$)_DO'EX;D2XH'ZC7BP?732+@:#J,%3N1WI.P@[
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M-#Q7]&AS%?[Y#'TBPA@\#'DBZ\4B[,].AB=G]2/L!W]-__8W70>R@<'V-U8
M@\EBKT.;^,_*4%RNRKH,<[%@^P:R]2 CX]< 3!;W00C13$'-V)\O9*::.610
MG:RLL3(?+.C_9CD1R-SM?'01)A%QZ,:4INB8JZZ9JJ\OFNJ\8O(8\0PLO!!C
M@44F?N[Z>?C.A^<7:@Y@:S*CEGBJ\W^UO4?GHXA8(V;R1(*,JI\VE!#(Y=H
MRTY.#F'P[1;U&8;X;]2H+6H-,VD@*I#J[%C-/0!@B:?$&?CT?-$] U==,WE0
M7S35":BD9'#'L8A[S_EP,8*KKIF,J"^:ZC3K[5WIX2,%;W4S>=%(.N.?"GQ<
M?2(#FSQDX.^2ISUY[O()KD%\.9IS[JC3E)F4D2:IM%<!)6<[3+Z=?Z27Q[(0
MK6Z6_J5(E^K<W.<7G@ B>)(=F6]J8-0PBP%U!4J5;J[C<H8T@5#$)E0FQ55R
M:9/IMN2HF<?L8GAZKB95J:C+H9Y@*1G,]5GN(I&SL<KQJ]P(C4>R!T=+(;:I
MV#[M&BV92199@J;D,=>EN0V<Y30K*<7-I(&0-*FNS?5(WEN^BY#!CPF3 <"G
M\HI:9FJ^CE I <QU3[Z [QF8?,]%?[5!YE"/CQ&BS9A)$2E2IIQIZL!4<N&0
M*]3IC61QX MT&IZ@_S4)=(H_=@QSDF@\VA]@'CGXJ#\]VXT])B3:?)M:(SGO
MG4_PVT^1[Z.>DS@@HI#*DPV9W\@/L\OAJ:+GN 0-SM8AZ$%LU0ZD_0.CS$/!
M-YODE_RL$VK-='XU%];XL*X=&&,$X!PZ$=[+[9Y$O/]A.Q%:GN+PA-5GE";X
MW[<*^2DFZT.FLZ]5'-J*+E.0JUG,:AH5K:;2C,W:&T@]3MV\&P-HZ?:0'?LG
MF#_.L1MI =-3*-)-1-/\HI^\#BUH2DGYBB[33?-DT%T 8^RE%6;6:+&IZ+PX
M%57FCM9^6CKH)-(UNUN97*9AL[I,32TDHFX%&H,GI])$U6+3TD79M$1-5ZW]
MA-3?O-6UP]LH[+\:CB[[D*.:+9ZQ@WLO,[78H+XL#NK]_-3ZCV03$U5G]O.%
M),N"VY2J!K09S6+IJ!L*:.QX9F38%1O;5\6QS<Q#K?U [VU":A)7ATU5KI%/
M*:W+,&^<8EI$OK9&>;-XXCA:<OL._/;![SB DOSQ!OP5CJ-#B& O\,P*0>88
M@<F#-CZ1!Q<_UJ%F*UB;/)V!HOKHI@[C7J//3X?$55A.^BJ]1+8)-7\(3&L.
MB.I;_K7FM<0^VSP@_"SG7\#RGZT0GT]M&L]GO$T? KN:@=%6A@!%R=F%3.+3
MDY+8*$J*=NVMX0/.U9X)Q2B-,B<ZC4/-@[$=PG75%"2O85TF(/D9VUO"1K4%
MWPH9$SS'WRU_GL4%1Z7%VL<GHO'/:A.S_D<.BZ22<5*] 9!(V/O5I^-M '@%
M_AK:H'Q<CQW2#1),M#OXGP(?>K&&^+DK^7N'0.,N().TV5 10)]Y.4/,$CPM
M6H+9]S.TM_Z,?$@C0^O% F ;8:= [(G!W$5[) =6NR5D-*G+_"'X$(=TD7MD
M@J5Q'PB*LN!_04H)M9:#]OID>'Y];A:;FDO;EFFDRUL08DM,R44L@1<AM%^!
M^O@TQ RL+(C#Y9'M1-RUK@TF[PY<$D7AB @;&71O<(6*H"T&^FFPB-]+X9I9
M)']%EQFG^4,3K2*B>GDK]Z7OYMW;#\M=@N#132?@!)1JI[EH&P831IZ\QBY2
M-Y;];>E[$<Z^$EK0X5R(1B<E;P7NVL)O#I/6M%UH)O[20AM:@B"B2^ Y<)ZN
MT-,,NIE4VJ_H)X#E[Y;4IBHS-[W,D;FY$=QL,O\BXZ#2ON5K1I=90RH/RDW@
M!H"H7F5D)+P*_<C&!XEQCC<$*\[XY*_!^ >DO<-044L7[DA5=9D9(XZ"\81Y
M0VUC?V-&]#L/VW$4JE#+Y^%!.Z>1FI1X3;19Y(28N,:S8>>H7@,?V^_/8/4.
M? H7**5U8X*8#HL<$!'3> ;$CJ?MDON4'$DP%@]&#=V8T-+"(8J I,V+RA0D
M%)&92P>SCFY4$=4I-RO:7SY4\N(7X*(YTL&W0^8KZ,* /&JQ!LD]).9RPE77
M$)X(+3#U!3=^N6%FHV6RA:-F'[E25VSC UY*4E\D69IV@1-/J,0C I=FJ@BU
MH1M[6C)>FF/27N2)&K<)V2AN@WY>(CRF)HNIER!][^ 3#/QK'F\*=V.ZT:TY
M+RH\+,V0Z</*5P.+.!P,_8D3;TOE7Z[E(QGKPV3\2IOWG'U8_I+Z@&]9T3PH
M9\/1Z+3?W&')K?H*F%PR( ,V2A/R;,W8R2*V:R<^CF;UP0>R1+?1;/?X/#.
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M'.)H3#=V"=. BTEU@5 ]%Y6O+FFZM1O/\N?Q3%H:[5Q6KD?Z%I-1*PNOUN,
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M^1_=-0ADQ-<Q&LH!>G$R/+^\-CF^3E12XS=E"  ;@'F 7\4L\=V/W7G588E
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M=VBPZ]'NX"O3J:-]K$ED:D8GZ5)]%]'DJM-$?DQ>#T>7AMG(TH0VWMIY D$
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M$*K31HVP2VJO,E%HF,ZDI8#FEND&NFT;I-]_RS5&O/D__@=02P,$%     @
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M+@1H JWP"-"^55PA929QTK=J$%%0/GY4V/FQ4<*H20GER6VG!G:)P[ZE 5I
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MU2RHC:'52 J;,+U0B]2XIE:VAG@R%)5P'DQ!A?;.C):J2\@$7;437X0_M61
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MS*1D\,POLM9TSYE>1!1]*3P @YC.,94NV6T&4?^$@X,A!32Z%6MSDI*(K1>
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MIOQ"XK F.AN2)U<*=&K2F]';)"3(;_;L-]NITQ7WJPR3X])EB%4>L>!I!G?
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M"3NV88M46]CM:.16!E"SCR&YP8C_H$5!N'7^P;O&4YN,73[95DO<9":,16<
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M8QP3:0ZZ83N!-^S"OJY1,Z($7L?46,01UM?!$7(M*LK81R;/4" I[M#*]?>
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MM>V@A \8\CZ(X2\0G_[<==YY\9>TF.7^?!7I.@[)HPG4DX?:QS<R3R!'!KJ
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M3(M70\_*M=$"H+B VK+I3&',$]'!+:_5PH=0F&SI/O/BN$M:"=WM9I?36Z'
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M)8HS,)",SBB7%8KC,-.86/TD/B)N1X&K4N ZTF,_@W[H'"L/,V2%#/$K@<\
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MQ,R=#>NBD0*SD:G?][();K*'>^_3I'F]9D NM"N5!>]_5:D?PH//\&JSY/@
MF&8.7(E.)Q$L?L(5XV^+&:U>C$.$%:8)O7@#I#7;GFX[9YX/',GG>Q*>0TW>
MN'P\\9>L@#5F@DYL@L%QA'EFD?$L\GS9R0RFGL$&(Y\ MEP C?#)CA*?W^)E
ME8=-079XP17.%K]FUH$+?(VT$E]N\F[ D=9VURQ-8-F OF!P29KAP?:<BV*4
M^6E(^^V\3](I/B*#+V%;\]!#<B3"Q%^\/(<C"3N$3 *7*W.6>JKZ7R<@58"%
MHV_*"0IXUCB,(J8#8D+ #YF27'R8-YM%()[AQ,EJSKPY40=<3I0 BP.\"89
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M/T.@HL/E=KC<]>-R*[Y5TC!GJ-2E(6I]VK>)"K&M-;)*.O&NE*,\^'J$OJE
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ML2*_[5P.X1N9(F46QE&)"#._V'1"OC%/$*=S8U21>"5Q.M+;; IK'$CR1%M
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MD27C(F(L1*#^51!LN:QX8(8^A5_K.-UK*22S@.G;,59R*QL44J6T#..U>#&
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MAS*:=)/A_N[XGH<G2/NS;&B?\U1L>"<9VHO+?'ZK_N^Z6BW_Y_\!4$L#!!0
M   ( &TQ]5IAO/?V;!4  #F^   8    =&UB+3(P,C4P,S,Q>&5X,3!D,S N
M:'1M[3W]4QNYDO^*+GN["UO&V 828K)4.<8$KL+'@?>EZJ[N!WE&ME49C^9)
M,Q"_O_ZZ6YHO?Q G2["=-TD!MF=&ZF[U=[?D=_^QM]<+QSSTA,\N^E<?F:^\
M9"+"F'E:\!@^?93QF/55%/&070FM91"P]UKZ(\%8LUEOP/_F87-O[_0=C-5U
M#ZFPS=[LMYK[K4;KB#4.VD=OVP?'K'/%=O[J=W?Q[G$\">"WX/[INXF(.?/&
M7!L1__GJK_[YWO&KTW>QC -Q^FX__6OO'2A_>OK.EP_,Q-- _/EJPO5(AGNQ
MBMH'C2@^@2?WX?+,/5_V'J4?C]O-1N/7DXC[O@Q'>X$8QNVC^O%Q_I&6HW'V
MF3(REH"+%@&/Y8/ L0NC>H'@NCU0\?AD=H)%3T;I<T,5QGM#/I'!M/U[7TZ$
M8=?BD=VI"0]_K]E/X*\16@Y_/Z&[C?R7@*$!O5A\B?=X($<P.,)Z8O%OPS6&
M/\V6?8$S#DHS/@K";: "'R[VOHSE0,+]C?I!X]W^ *@6/1>,WP72XUC&8L]$
MW!/M2(N]1\TC>*(K=,QER*0/7"F'$KA+AD.E)QP)S,;<L($0(1-?O"#QX>I0
MJPF+Q]+ 1Q;%@?!X8@2#E_ IKA<+5<Q@!(">!XR'/EZ(QX+%TPA^C7E,[[08
M21-K#N(0(V<;!K-%6C[ DTQIYJEP:.'B09VQRP)<-,8CW*XF,D:1R "%J0D'
M"V,F;R1GG$4!X#\&>@A=1'DP)8" L)_9;[\<MUJ-D__]XX\__H]>-T_JS[R
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M>R?\,\34I%XFW(>7B8%?:C@41$8C@J!&OW%4.8D@O*'9(JU0:1D,]#%[@MR
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M8\P8"TD3]2">!M)A8D_;P/"C,@C?I-36LIFGXWDZ@25;Z+(]T21__%*"N@3
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MX\ .J!=RZV*K)8X5JKK#M1Q9_;'BIQC%K[5HQ6Z[6(Z%&O5&7%*NZJ4Z=:*
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MG?.-!!U60UF>"78-0&#! @.U+$@8?RX9]G#C$TSFBF-:3\Z?ME5RMW2Z&*A
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M+J"0ATATL!T?)K"RY1 V'C,7/1@Y%]<L& $L-1W2:C3V'0.F<X.>-!#AI%U
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M5;]S&K V(:404N7.7TR5C)J45SM*8Z7_MSA:V6]I:2F/DA49!H;XOO2"0^Q
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M04O)C+:0_])&R5YWNK/6UYW^Z+M-\>WX][W:='LDO#G\F>K /_P?4$L#!!0
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MO>T=]J]\X+FC/<-I:@A5#A.WOX('^@[.(QZ(2/J*G93']GCT=PJZ]AU/!=M
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MOR._QZ04]&-1*<,LZ)<\]DDRM[]75GLPC=5.!C87T)K\D&I/#&,Q-@ ](E/
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M    =&UB+3(P,C4P,S,Q>&5X,3!D,S4N:'1M[5W[5]M(LOY7^C)W9F".,7X
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M ID)3&KG726C #VJ(QR/X6$F!66YUMB0A97AZ2@+[?DZ]%>9;[0ETFXAH%R
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MP<JXC#<39Y1$/N@_ WLPF55YO# "@6%OR2\_G=;KU>:?KU^__LN\KC7+C^S
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M9,8J!KW&Z&M92K( 2,*\'TEQQ]6Z:7.IX7I;G*D*G0>98T9!.8]!^@BX3=O
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M4F!EMU ><YWK"\'TO:YYLR^_U,BZ9[Z4#C$#I^!/"FZ,#4S!--D;YMIT?E#
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M;IY? 79?X*(;NV=NG%0)0>QK'ID*?C6&0QB%@GM9J2^7ZSP$"2;.Y;*X0\;
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M=+P+V>::?+'8?0(:>$RR(M6190'&7*%FG]4>%$F19Z!ZDUJ(RAECA$K'*B^
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MM5$H1L#"X.0P)\S334Q\A#@(;]"$?0@ZC=+.AG)05T-02 O*>@1S)"<8>PV
MCA4G\)A#L&RT0/1MRDAPHF/6MOJ.F6E.P9@(XN,R#:V72=+A:I:+(V.UI:,%
M>0)V%L0VSI4>]8LT8^# 2;XK&:0X3#(;ZZO N!YVM@$4B>*1.&XH>F\Z.Z\W
M.Y@D\,^C$_:GH<]N[-/W;(/-\&F2JV)41+E>)[8$F(+JD8\F?05'.NB*TZ9@
M9.5)/ONQG!CY,P(#*2^ETBV.J$I@'<D@).PH.2HILB7D4!>M+YN=B&#E1X!'
M,2O*J-%&&ET6%/*LS<3K15VFCX*>? E626/D-T!U4"^]KG? 4/8IYHE<!8X5
M 7638DY:[)&*37;R^1)K[;!.DQ2Q&&IXM;C(-T A2;7Z'K0'$&2%9 R:%?*^
MEH#O($31;O']TZP-WZ!^C.<+YPRRBF+6#4"7F>?X\M9(IZ&^C:-$Y]8'<J?C
MV\K,NHUC)S/:M;];XM@E8YU&4?*=N""E9X5HHGC/HJTZE-AJ:O#/=&;LQ:3&
M*'+\(5#4N,RLK(AHMHJ,3*HX#0WEEIJ%JMF;3A^Z5?]L\BKI1JO&2M)DK)C2
M*'7:B]JAMP_A1@[X9MND@[Q2SO8=.N/8I!IF&"$A6>W86T<X&+EX)X$1>0BG
M7WP;HR%"P3YRQ$Q!BE5MYD &I9O,_#L!1?M(P#QSAY2J?Q4Z U-&7*'*$9L,
M,+!% 3@RRF8JK7?-S8YAD_^KQ"<=:Y+WJ$DJX,7#CO@H^TG!//B+B@82E0JG
MAS;JH-\U::<!"XCA.R9-F( T$@!SHB,E,*2&><!$:(1)&$%D@1R <1<R&1U>
M;GFZ)B7BW'N=W[D\0DH8'.8P"3=./?;IK:\H"H"A.2NFS&.W0Y*2>NJV6VRR
MMO6T:V8&I&_7G7VIQJXT+%< !33%S$2S:8*VW6:'G+XF.2^9D%$,%B>B/)GZ
M(:H1?$HA6U3 Q]+0K@%HK0#MUGE]!F:X%"5/:)S>[ LIH4)3R PT8H2@CPD
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M)LGC6SM/7@&R7U%,HR#O-CS#8Q@.3^EX8165.$@GL\:@'AT41^+5.BZ8MOO
MO5%-3HY9LA;?O4P:1. IJ6'[-YR=,C,IQ2; (%^OY>N@ ZD/P@5[AI22H<:G
MS4&Q&\6(V7+86^2%64N-+]EN$("$E":#T4".26?PT8*FBE!CIPMW>;A%M6FQ
MIFLEE=!+V^Y31+\:^TK2>H"LS"&LN&FFRP2M2.0N)=<:-A$D8UW"TOJ!;-,J
MKY2I#-CXE49-SI&% ._-PAQ_G.GA*D<9W4SCDFHG(1/X3.KI(37)Q!%>ZE46
M.XC7R"W[/G]+Z=N9KEBP2 4_$D>Q9PH4<IWDRA!*@"8.5:1Q;E+-&U?U)1FG
MT.QUYD;08[9G+>P*0^S;Y)BP(X;)C;K&7%SB.3'YKP;-"Z56(/XRO=XNIGS8
M]5<S$AOM#9>@5:FV6$Q3JXV%=;5B#[VI\&!T/)(FRCXQD')^_(YQ[9?^?*K>
M-'U8G.9E*D"14["R0VP5= $0H_@7'G<R449;PXR6O&2[U??Q<]:9I<OYHM5L
M!:12Z2JLAQEP,BR/X:)!%V; ?*H15W G&:&+27[RG9]>-H;,84>QFKAPR0 F
M?5%)O$259(1B/2Q51F^%-FW*H"WJKXU5YK%)DECGXZ @"8%#$\0"4P8*XTHT
M!F#4/XKPRC3#237[Y L2A'.,HTRA[Z*:LAU619M!7TH$1%Z$6&3[0;IBF5<
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MA@68Y#YCQA&3(A>1'NF<=X1+^]R]Z(KW"6B7N(5W:7$E#D*PX6$G#.?6*G\
MRK]^AA1X3E$^Q$?/NFIM\]8V?RS;G*\1!).+79:(:4J"CGIY=$;,JQB3'GR3
MB+7-%^+R\'-649*GU%ZPWU*E1_T"<RV$SM'4DQE( $1+X'[7*A+JVUC%F:IP
M4M!J!V#8=01K=?AHG(U!994\S3#)5<26]$B184_2(49>'Y%#.)??<$BW \]B
M1%4S;[#T!9+773')EJ):L]%GQX1AL^S'DIQ +TA1"_)+L4B/<)$S&&;Z<<3H
M.R)R'3&."DP4R9) ,^I7Z<J1!I%$DXVX.+S_2761W6>(_![?9$?=69,S\#;E
M9-[I'4X6><E/QC)!M5S':& XN\-W*5(DD2P+=OH$0Q5\!;4^RTV*59(G $H1
M@D2-DG%URV@.X2C_*D!(H:/5)!>2<8)I@AG[<M&WZ5RN2=7SR_$[^+8NNQJ9
M35<<B,,/!^>_'XDOQQ\_BM^.Q*>#=T?B_>FY.#CYIS@[.+^\$.='9Q\/#H_>
MB8-+^%8<?#K]?'*)E= ''\7EJ;C\<"1L.97A3A?BXO+@Y-W!^3OXY?CP^.3W
MKO@H@0< [*Z3Z)KCKNR$0FB%<B2OE @+0HG2!-.@#,0AX-15!S>@1[!OY'+X
MCV%^@YH19R$4#.%X.:6AQK#0D>7@!\L R,(YR_%0O%KKOYA.Q9M/2OUT+;-"
M0S-#<_=&IJ"VY!.*"7RJHXAUZ_-#&6?Q-6 *["(V*7[Q%>%3 P*T^4-W\<0W
MSY!%3R/*BK+J,EHVO:7,NN$#I6$\H _9[)/?>T0B^?GT]XHSOC+;Q6343Z(_
MDS^^MWOK?6M/MOJJ/.^(W(1=45J'6E[%"7P.A+J64<$29TUIREQ+,$B9DV!-
MU0C-RLD+SF%5CC+V6UOP&>$2FDH#6428/X N!XM'J0*^2NE6F&P6"P#]:$IQ
M:5'E.:&*T=DP!DO\H]3> "](@6OQX3GA Y;.>"Z:.G-X<NW*)BZ-QGDTL=)0
ML9'9H"Q:-<ID9(55?0J5M%!Q.BI(WX%)0T &&0![!#53<LFT"IUH[8KC@4 ]
M%46NS=W2F8W0A16QR\O-%+JO;%A0RWC*6#8VTB ITAS+\=9ZVR;=B(QOEX.%
M+]7F7HQ1>,!%6<8C,*BQBONZ!,BLS19N^2\$4DUFL<Q%R6<-H "?)!PY_-\5
MQE5ODO0KGC"Q4UO0B5R9<K%M;A^2(Z?\K?4V7W#>7^;9%N4LK3U]=WGOQC,T
MJ,_DA$@6\U:SQM0'=(PAJ3NR;0I (8(VL-M,H0^+V>1TOH&9VL75T,L6JWPZ
M]]_5,-BU8$YH5WSVD]6 %.Y,5?,B=5DQMIIPF 0%94B4.13 X]'P0M[$"1T\
MK<ZR@OF8G:J-+3R$T):LD'XQD36LI)%1I>K'J_8!^]R8[R@\)]6<1DIC;(I$
M8_ [CQ@E=1P@?BN.2;NT"C^U/$Y 1*3H<<VIQA\T#\X;[VU:V8&$3,;@Q&1*
MVW?HZ3*<)^.X&'4]3UN;8MFF6#YNL]PFG8I,N5]^90*XPL0/)Y8 49FHFK+T
M*]5CZ%#%O HT%!S5(.*3(@9$ ZI:A<M[_0A(>:/G<OE5V2([$\_ 6CFDZ5;9
MNEL&+%F'C(65?2*_I]ZP* <J.9UE&62MJM-D36#Q2T6WKVE)U;*=*3UN**])
M A#=5\LN:_.I;X$:.Z0.D#J 9-;TBVD=#GD5EDP/2.HD?4 _D]N*44."2Z5^
MB*MEZDLWPWD%1Y6"H:E9!U)'14H/!OA?*CHP2S&F,WU%$&-3J0/K;]R C+^F
MQ3@/)IBLA>Y0+$.@H"YFYE[%W![!%"_T08@/-"F;P#9 W4W2C)Z%P9M&SV1$
M?O@ &)-SH/2+#% %.)4+%K<]=A[$0IYC=Y(O)@)?,]6JS@6=^S3OVCU)HHO!
M0 =46(?>_R(-**<0, BT*(U_!Q+Q*9^8]^)Q<L-$#/10L"*85UOM&#*O,2UX
M-(1!K^!#-/%JWFZM:S?UYVQ(9M,I#_0VT36V3L^^@B >%!%5^@V I,CZ[)#S
M!%8>Z:_*C#@:*^P^C?N)T4 $=?M?!6#Z0,.*L&\6SD;(H65:+LJKO<0*QP)+
M$_,4X,@JMW7WU>J:*.=_"DK.#<9' [ODID4),@ADN<97B,4 (2@@F0#0 8/
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M.:%T7:\CCGD671.HKOJ>?0>N%WYKD;)%%*R"1%$?@QDEK-;D"V$JBJ@]2.(
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MU;7H)E,9_[7!W\#?F4K#T5_?TM-9^%\%3</T<O4EWY%1.(;&<:QO>?X'\)O
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MHFA/2:YC-AK-%*"_@<2>YS.@E%[2B8K<AUAC-TW VNAFX-W*D_B5Q T)K%)
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MD;V7):-?#\(0H\A/*<5@2^WRS\&RBCGB<\''-G9W=-5$($:YV;7V@[-AIQ0
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M4=%IUW(1OL4U9P-]8RC35X=5T&D3+[!.-+5)'4B.E1EAFNE)6FF$N-?;K0>
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M+M&GGXXT*\T.S3ZRSQCW73!N<!K^I1._)&Y8>IUFN:;JZZEPSK\FE 4LQP+
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M>)!WH]O_,ILWW AIQ4.'Z+4$FUZ8.;M./F9:\B=!0B(,+N/&YYJJ-3-.8$A
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M2=O^D'/OMDNNZK^-2)[SF2 0Y6!^'DV">XO5SB&#+^Q<-L8N#J&+!:5($?.
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M8+L>!64(>LX%N2F]D.X!LN)L#M;+C9+B(OV4+=H%H:"ATK? ^]-CR8S\"T)
M;3-8[<IK'>*CEWGV50A=I[N0L?V)5SCO_19(L"5-'ITT?%<1;!Y$_*_ WZ92
MYC3-EAD1I>*AJ2518>G[M==%F7>&NE[<;9^DVU#CR?%::GR??A*$U;U+>>]2
MWKN4-WCYWOM8D>,@'(=>(/9F+<2W(\QKLNI1E0<+6)9M52/>+_/B 5#_K3J1
M^W)%NY&[2#!;Z*#/">]U )<-L@0ICF&+8=@95:_Q/C*0)9I8R&FO$#K8,NXW
M5G4#N>6]D W\9KT'C(S\[NC!5%Z5#7YN'341X&86(3J#D8L0RSF\[D"]DJRA
MDI+C]9-./R4-8MF2[>BZQ?"/HWF..%A0*:*G&C45(ZZ2UX\\B#EU3!<59VQ7
M1!-//Z&;@-M5.2A6W6H%J_9Z5/4W7(%U*>9FB&SMZ0*,8=K8-D6DG?ONEI4[
M%?(3U)Z%+.TN@X %PZ+B+T3)1-,Z\HDP$<91>]FB8"O*BG_/O9'L#L2]O\C]
MJA1'VX=S#6DS)<QM5JWY#O2\D,X'52KTP+"N'GS+#9K)&*;CF9BQ@VRE#?0A
M-D1]F('.B^X.=-I1W31NB;_#W+^(>G^LO),>1RCDZBOR 51U9;*'O-D'U)H;
M"-YK:98U,A]&\O&IY]*GGI2IYY^TKR-L[02R!%N:]M>OLFM2"(D;S#$9^1>^
M(I5IH/L0WO[P:LX,]QG1ABQP%;#17.T;@MK+CHO!V4[DQ:,GQ5]#Z#3!0S.Y
M0:AV8#*A2S78>N(WN:2GJ/Y'ZJ7Z-KUMUX!B5DA3J*&9#6]UQPS@_FHTA1X+
MDKZ5:0<,7A'GJ6M,V"S&2T%PMD7'*1"\S-EI,3MUG1'X>EB^3JS+,^'QI'(;
MK5%20>K#?0+>FBJ_"CH<T+A&KW//#L3]*CFK"",SD=L!7@5CJF-,Y^%9JMY-
M](S6(.L)\<_YP5[I1U@ZM6W;Z?FJ<5)Y>C-O<VFX1[\"X@;V_T_Q;_C"<-A%
M&'(SU[./-B/R2$;<V_)H/*)IGF8+(F+N7$$7AO=26:F<I#N9V$&A<T$K4@+9
M/OMEH8^CR,6(VQ.PPS68M3=EG.CL.K4^P(]4CHL[]<81$1N9X<+A]BW1:](6
M&<?*A>'05.P=]+V]I<))N$Y=/229*@R%M-B%:^;"^4Z>(;2?B'4Y64]V[)2M
M>%<Q/# UDY^JLJX/VV7' QGK:[:_N; (;HA5<<X%!DQ!3!QD(TM*L.OE(IMF
M.;?00A7GLN 6UV0KU7RZZ^,D2=DVR"^1TOZ6+E-XS4$&+TFI88;U50M$N;PP
ML\3#+PU)_$ @LOD[8T;K5=OX\@C(]N8W6H^MJ)C90HT[G/&%])=/R-QG%D;P
M\"@GG!+K=<'C6TL7Q,(HJ#.874%JWO0[<@G1'GLU=VB?EX5#1[/".(R917UR
MMGF0ET/]C2G22HW"/8&,_L;Y5KLH#FC;T31::BQ+(E.M+ZLO*Z;(S,15C/*
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M!7[>\&0LTN C-([!+JB-Y*LXU<$F!RB8-P[Z8U8NZU7R7UECJ^P$NV?!KII
M*<4GNDZ(FN?(UL# V#W[S)O*.?YS:?^^*4=AIZCT(!V=*?ZYDE]_]5AO3K_G
MJ#^?SZ4C^3/0-_IJ$PIS65)%$VX2:NJ8Y"ZZ!V\D;B 6FV2L=8@A,SS!Q"]A
MC&)PDNGE563>_^%I;4F+1K?0[W+\/JDEL95F>SYU3!-0[*=!/PUMGP%#V,G[
M[:'9>K*6B9?6IXK6FE6[&"-1N2(-O*%)  TL);$>7G[^Z0HX?9/\V"DS(^,8
M]/:9:GNSLIV(FX"7@Z'5CBM1IEP']\*;OA_^1$>/#<:$T]Q0S N4WV(B7*NN
M#&IY&ES.>N,>P^<4RO=PAN24[1"\/ELZ3" Z.0Z!&_(;LR]^O$E%;07RMT33
M4('J4D>CKN]S@A?R?U#[2T"GI)G1EUD!9]6T3.D>ZL- 4I9GI*AG>1.%@-92
M:=W?%2Q#6U$N.TPXT,TSZQ4@RE2:MDWMP]7M%C>[HXR62,(I%\)3</9Y1]9%
M&=V=5)A;LMAN0M^79+I?9(D=GP"1(N@*<LUX JYRE@0I>O[1>%;F=4:I/TW9
M4[7^.2S?=4'J8_I4XC[4X)*91-@Z"8U;"L=K0R)*_RS(HT:UM!1NJO! O)Y(
M%E>P!^*I7[KX#3:W$1]?YOQH7_G#B=%,_9B;BS+ZI22/3$_$SX!'2P41_\72
MB/\]))+4]<IRR3IB&W^'[0KY'RKO=XG%>6;%O?55(-BXJ[(Y&R^M3$4I("OK
M5!X^#_S?FU4Z@Y(QSVJXB]+):Q&\!V\;)E>;1"M7_O;RS-:DP"G!3U'F(']B
M9QF6^K=UK; S_FB'*I7(M=J#8@%CPR6C? KU&>&4__;ZS#K>I% 2[VQS@]<V
M\&"Q!QR'\<!@@,Z]BE\<C--FM3A5M= NC=(8F*QH8]52)NEO49TY#WZ_Y>$P
M1#MAWC01G(@>/J0<*WP=/'IF\AQN:D6O>4^;><@N2WT_OS#(ZI\/=[(FC[CM
M9JW6T,A.8&!5,2M\RCF7%K)H&1(PA\4L\Q:U"[^L5\#J%L/Z>L^+.W8<_/JG
ML_=ODM?5+"N4,['^>. ^LX$=9K$_O_@E>54>)3_<QU_?.SYY,.)+\M/+SQSI
MY/L?>*CCQS+4WU^^^\RA'L5#15D,BJS$B5-+?Y_Q@*W^W .\>5<$X9))B2HD
M5DFBG@%KV.*F0R?E!3;AS4N81!S3Q+,=T['@$[BGEK@UK;OG&JO9T*3,3$1A
MB"C1D\JV$L!I<K9:B:YE;;<W:ICM3!6,^&8%X\VM?6'7V9$5>W?RWIW\1W$G
M;\X;NP677\>WUS'BW\-9A[P@OO:@>2^48^;+<8+RJ&O.8[N=1/O<M6HR^,"*
MX]):5Q4DB^A=P'CM\@6Y6IFHBTDK( 1,QZMCE2J>1@MCU7!#Q(R*<*9D*K"D
M0,:%Q4;<%I)^N:NZ__VUNO\9I0^!9 FU_M?595KT51JB'1#71TYU#"(GT=[M
MAY%2Z0U<:\;75K7J9R]?AW7J#OL+ZZL"S*Y!A7:-3K&-/U6OZ^?%+9Y&I;_1
M-;@!XX@3>.S>87(JB72=$?H,G7A?M[PZ7A_5F7N;-.[).NQJ--&UTJZ7.#E:
M0TP+N(C.$L)YWAA*[[/7R"^"E>P1[Z+69HK.W=0ODO2N=&.F5P4(_LN50]*E
M?$[G%UZW*:X 6SQ /187)1ZTF*@3%5'Z>'A?6NO<56[R8.T=E0N1"!;GYD:M
M(1CG.*'J;52)<\&&P^TPGZB\?BQTQ9?7IP?K@"<,LG+>(RC8#]X]W3HV-;82
MM2$=>+Y2EUD5+!:IG4*UA!RF=6;AM"UNH "H19@@N#7T5,\:Q@(GF9OKE%VI
M=/?**O1\_(+6U<#"])G:6X+/49'[KKU8EGW*K+^$4[$O]TWXO9]>R*G52!P,
ME=OOK?8K*FDC:4D^\U':ZAY.7]%[G!?5<Z31$?8MIUMYC1E0H*!5XD\CC*N*
M0-!2_H#?N<S1MM]*<)Z^.0T$)U-:ALX3W&791 D!36 V":)MBN^,$L%(O+2N
MLC58YFUB"<0/]<5R## ]F]89(W]ZE]R"7C \G>=P$MO7;\K3&0__$!QV>NF@
MB(=ASYR$C;^F&D:7C/>5N/0M>]&NR7@YQ29!L'G_N+@XLCUIOXUT'5#O&G-8
M+].I>0(7X/"F2I<P5'+V^M7SBV?GK]Y?G+ZX>/\_7V]5OT]6?K\IF0=HM3%:
M6,$$.H1SVY&D[Y7-OJ6"'?+3<P5(8!"-O8CV-&TY2T9XK(<HK.Q8%1;)1454
M=H.(TYR<6^(_#=S=<F4DAS.]I$@8%[6,+?:N8.+4AJ$-UJ_-YNE8T?&,AXD6
MQ3 3'<&D-YM J!S2D(,4]+#FW6;@C'$[D!=L,ST+3\VE.)*42]BW"!W-V;#B
M8!LX&&%H?JHL%F)\0D93;_6H%.3:!85"J; U6^,U0SGRP!*D6]"'%"V- X[<
MF&4ML!D-*;)77^BP*1>K+13P!E/R+5GASULLN))*!9J$#<)$P.AX6.MW U<5
M+(*0HFX*1G#6-6AQ.Z7FFP;]"A9WG/S:=0;\)JT2('B8W)H:-9\ _%@T%;IS
M3)I5S"7!QP'O8;6,\_06P'@R+04;W$(FF/5'L0=SW#N _W .X$"4/SIZO*TD
M7Q\_/Q.SXXT5.L\LF_KBP*F_=U5WU8?&;4'RUK.\7J0W7C;3!@A&!2.+2VO5
M)"; 0U4ZAAB=^JQ\Q.+8%]:'/N%$381O&)8[L0#WG!AU<@G:K%A5%/YW/6(\
M-V.8C>6J>;@5Q3*M: <X=#JV;7H$XQ#D$/K%&N;YC2:A=M*)G?9_,187E4*[
M1'YYP1":( 'S--P&HG^J#S RXXKRCB%L#!71]^5&12Y8JBA;AW4$/QAZ]5IX
M0&V_I56PG_<*5QEN\?4<4<A2AJ3OFJ85(;$)<&=N+DG^STH$[5%(O">4%'*9
M78<@<>(Y=3"$?3.QUKHW:0>$UOL$?-W:7'K[.@^(3KRQ@6Y$6*=:KLG6]=!5
MM&9[.*7XZKD1,]_:=KBKS56%S3949Z.J8I2S84'8:*QY(K:TS0:\.DN78)"]
MSSX*3J3C!LO/>*,I;C"T;)><H-RJ5E0)(-?!QUPKFZ"4UK8X";3,<U=%YV4D
M.61^-6$<Q",NK[,23SLE?E6KEQKV.+8,/&.QSR[<*:EW1^F^SP*Z5L6 )(TD
M"K*;K)/1BT9"9)^$XLUOW71KGH.3B7&'[)$%!CZFX;8YR&,Q.9PA7?M-JV^N
M2O;=IP2UBN-_+,J;#==?ZJ*IZY)*LK*1'_KCCZE>/)THY /&9 N\WA$^&?HD
MJ>Q5+PQ<PK>OR8?W[K7 \5Z5MIE2XKS<ZO7O+0@0:\_Y 17>EAR_='^H4AUW
M 6O=)]3/8A)>'\H@#F\7 X\5A^QZF*#:(R7@%C87\X$:E/V".<HF+$+/DK7;
M])!)5LL$7*])RV<C_K]+5])3K^_?46=$K!G>PMD67<T/V'"-LS(]A;*;31^?
M2U2ESR7+9-Q_ONK@R-_!HJ:"@H(FG<,%45>X]G027X^#E0$M ]L) I'U3Q_3
M1"7#C-K8L6XK&D*@J ?00*IS7OSWV$/GLY3)09DE*5=2"R<XLUCMTB[&B?3:
MLK#0?5R1=6I*GH?!>#W(WTB)HBKQG9(^'JD_N!-2_^"[SC[4IJ>;DW0&DDV=
M& 0= )9_0\V8*CI]Y.BYF7$2#'>/6>>1^SUDW<2W1?(.UNJUZZ>SHP3P\&X:
M?'%[.Z>.="C@G*]9ZJ.E;?"?%P')2 &>*0)0)NYT(!RB2!=F#%SFD@SA]U4Z
M,[!''_LL<M%.12WU=,SPBU+!-@)M1 '6)Q/LL^C 2F;ITFD&/J\! PH[ =9B
M6U<?34/_1/(K!?<,662*6,$@NM%Z:/EB\*0)CAH+Y&@:F<!(\>"S<MJ2&B$:
MULS+-^,^SO#;.67,^7J,E)=XC3O3V&JFG;HAC0"W%B4_FP14<5>3/J;(1/63
M':+_@W3D][,<#$%IFH [6Q?TKZ7T@\7"BA0O^=DLSCYXH9^K<P3%CGXHQ3_
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M,_K'Q:O3]Q>O7^UJRX<?-A6&HACJZ^5 )?K=JF[+:#%#9$J=SLGD"7N[!YU
M6_AO3K_"#!P2L!C*Q&CAP<GQ*%G!Y:N]UJS/*?#K-SR)FI8/)-OQU$&7R\*V
MNWE:P_F6A_1-/QA/7]H.E7@6EX-OW2E=T#ON]?G9YYB\I$EZ809+2:T>CU@S
MVKZH@]*A9E:E05-CCH1P\- >;7_V+?SPDH/'Z?I4.;7B&Z'*0<S#WMQ&O $(
M='*]6V$0;WKK,VC>>RN&G?P%=<E()QKJ:C9X9KJ+)MY 1>1E&RJAF+/^ 1>
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M1[;KR'8=V99EFH(*TR**74L$^6-]'6%1PI1@ADRFF&'QK,D)!8/&H)231R5
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M3)'#:^0ZMQ=0$6"HF!80BI/EA LH"CJ^JG44Q]M%,0@66KK7$0Q"$QWF,<]
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MIC@='<JI[8.QR:$XI&LA/5L*S;AJ'V$3>.$)C,VCD%=&47#E2/KM^^!G-@*
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MNS:-R:^[#P&%3DFC&WI=60HA6P6IWDM$6N9-5 R \@X$5G)'XJK@H/G238K
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M=(1::H'+FH'?-.%,./TR5:<70$SPM"L-!NHLQ=VS?ZGHLIS3XX#,BG5#3@3
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M2RR2&A6!WZRV7A9,PG,TCMB4:-0AT&!!4HU@"'HVCK[BO%@HQN?60';W$;J
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M/RO6BLC]99Q <TM5?BU>N$'@>H2J#&T]G\3*,'/UT7Z4\THHF4C<K)B>DJK
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MF3=>#--P ?],BFG\YG\!4$L#!!0    ( &TQ]5KB(:4G1PD! &^1!@ 8
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MTN.S"/$VM 7G")7"6G&LJ\DR'8E/*C"PJXZGIA#W1AL8)]1Y003^X$Q.^W;
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M4[N[VKQ^4L(X!'_-3"[YSGF9";QS9_#.PPF\,X%W_O5<6M_B\3 ZK_CNIZN
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M=\.=*S0P:>E42"*#.MB]0@Q>%9G4O>G?]:V*>*[-7-K+#9[,BH7&E''*Y9*
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M48H<%[D;EM.5DZV83^4ELKO3JOG(3D^GP,5AV5\-EOUWM4^.904?\Q,6R>
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MCQ4K;+)%>;!$:"9LN-KO[TP-)3YOLR*M^]#87D]E^>,CMKK"-SF)KJ@F6*;
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M[LQ$FLDG1;SA;'<20MPH]:I66[]-F*P.9];U:2\ R3W;JXI_8ZJBYS5L+X2
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ML>#J<@43@'728=;Z<1>E90!U'N&8/\9()Y *+&^Y T,.E)QUS]HD#/?C]9[
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M3AA!T9WN,@&\F,LRTP)!HY3 R\END??136EJIF,_011"!;=E.U] QC^?7)W
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M=5PJNB7&&B@#Y$U$-1[)5,1NX:,EEYLS:#T+I666@WLQ-CV3=HHKGAC<A*W
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M(D9!B.QR5YCKHCD%KQQK-":K5@RR.S4V\RZ\*4NJ)9 :3:^1U4*YD3"PZ'X
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M2,6:=I8.*O)9&.W:^V8G?'>N&AR%-9N;7V&7]TX1MJZUK>JC+F):(Q@4> J
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MM&2Q"'%P) ]@G\ V@6__YY30"V->G3E;AP(,(K\5SY-D.,W*3WO_]S_^7OP
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M<0#7O1F.<%*4<.9C% L#7)I;@>VZ0/$W QME<X[Y3I0&0S?!#&XGYBH.QVT
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MS+'''%6HD.[TM2X"P><""6&*S!&+7('GN')-[& 3-*F1?C\>6.8AV"3B"R(
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M?-@AP]MS0[/MJ>--#,&FSO?+@Z!_;H*@31"TJ?/]9A?F7@#36NXJU/IB0ON
M(F57RP+NKN5VO$GEFE379QB&B&(Z; *\3B+R,;P;MGA'4:;>A4:OKJJ>D]</
M*\?X>7:-<TC"8Z6.:[DW5_*PE05/8!I/_O5]IA",>$XI!#,M2C8,->^?ES'=
MJ)YWW4E[ 8SK,C[0YOH5B$"%YH2!6&%LW!#-Y$VNH0E]:/L(UI"*] GHD,,:
M6E:"BY(JN!]\$\F;2IT_3!W2DAX%6=&JL[7JL"2ERA&AW =?0E,P7D8!MI/)
M"H</;FN L,216@KD49#^YB'YSV[#V4T#L@4I+9P&6B/J?)SG*36S^!_\+E<(
M8\7JV@6:":A-$,9CJ2P3Y%C88!"9>-VPY\7<1(F-1TKUVG XN%I5CV;@[OT_
MPB\;F$#K8B:Q<WF_-31C=GD51D[5]] NR QC,W6LDD]&$E$TUN\WDH5ZR.+3
M I8$Y!HC2C"!C+S)M5BS;9G,BPK!HK>3!D+OSJ?B?C#TQ+':@EMMC=<:'WEO
M*&Z$FP7O9/AGC'[9$=E&"7PE%T&0GA 5T[)DNT)GV02U9PNL;)[;P"I7#QNK
MNO(E.BA#+AB%?)*M,9BUW8UZ9:Q2Y?JZ96,WPGQ78=X+9MJ'C#F59LEO6UC[
M$1:JR17>3T9O.TGGGZ-.;Y1T6NVWR;O6Q^2L<]HZ._N8G/2383_EOY^W!J./
MR=O.H ,OX3]>?X3WS@>=X1">_-#J_J,S3%J]C\F@>_IV1"T/NJVS!![[[?W@
M8])_0[^VSUK==VERTGG7ZIVD2:L]ZO9[:=)NO1]VZ!GZ0](?).>#?KO3.>GV
M3I/6H#O$?[[OG70&^-N'[NAM I\^[[3Y4V^[PZ37'W52_+7;HT]]@)&T^[T>
M/-,YH5?HUT'GK(5_&/7EX7;W!$8/7<6_X'2<=%IG^#GH#OXGCKP+@Y.QW_QM
M?&$T:/6&/)"A^QR_GF+O:$+;+1CQA[<=_ '>_P"SV1V.Z+L#^E;KS0A^D;'#
M5/5.DNY /@RSC=TSKP_[,#7X*C0.0X8.M$<PEOY@A(WU\9D/W6'GJQ>\=3KH
MP$R,WK9&-,7#]SB0V)(&*SA\"^TGKW%N<;I/4"Q:T-7WT$.6$YS6_GMHEL4%
M1TN?Z71IA%YOL,MONF<=> J^TSWM]J !:*P'$X8/XL>Q]?./O(:P0-3S=SAH
M6C\21?IZ:YA\&'1',!])YQ\H">V.67B8R2&^(:+;KW=$II.D?X#/=4?#'1N@
M.2/O>D;N!3FLPUQ(-@+U*FEAI9J[E_D0K4+"  ,^Q):*N\KEXM<)7X*H31CK
M!;+TL2VQ+4N!/!(V)A/K,EA(3M_5$5+#C"$*/I;6&(V@VHY_AQNZTHDMQG&<
MM*AXE*$]G"=:D$M,=9X=%3%[90O'V$2ORM/,RI0<B0??):9*1:'DDFZQJ J1
M7:D=&BJ_ -.Q7F8&-9R+<(W/O[P^3EWZU@Z@JA !RJ@_/,I/F:$2S,Q2VBS1
M&#J:EP-C/4(>/TN.$,I"M<BYM,8S%,3;4MLG$_UHMO\=M_]>")SZ.N+E0#G0
M@#RCV)#U,"Z60J(HU-YDZ-/+#DUA6:.LC,28 B(Q83$+\D,]S@7T8U.0XZ\_
MH/,>EF=#KYC@!0<!R+I?5?FOYE_T4N"R2H@"_=\$1+78^#$!CCKHB$#=O[]9
MP_\0 :ZL8'Q__>'Y#]8SCU#WDZR4< S'/^3M%W_Y'^W3EX\8__YCB1ELIC2V
M^'@VRY7)J7O@L?SO?SW[TT^OZO_O=?KV!7$#>/#5 #ULU#_M]+KM(>A6@_/^
MH(6JHAO CR16C6@]M&A]S5@>M<1]\< :23P\2;QM+#\_??;R@8?S6M"H[MK%
M%R^?_N+"^9([\&SU+RJJF29&U3F,)6GV4+.''OEP_/V&N2Q[WFRM:39/3M?%
MM,ROFYW4[*2#&8[LI <=S[EARB0#NGV))"D=6ZD@)GVSBPYY%S76Q=XE<>RU
M*0Z[\;*D-+SVWWO]#V>=D]/."85L*,QR DKON)')1B8?W2 ;23R @1V2)'9[
MHT'GG_U>W)_9B-L!#.R0Q*TY^/Y3)/$.TO?GIX_3G>EOD6?8R^_#H=ELH@,8
MV*/?1+ULGM_3-GH\?LQFCS5[;(][;(1%?,TF:S;9H6^R'RG#RQ0R/Y+NV6Z8
MA,+%<I'[Y>\W?N9+>X]-?9^8!+\TF 0-)L'#8Q+$I/.G2!+Q32$ P\W8MC[_
M1];!UM.DVWO3'[PCYQQ79PR_<6?O+P%[_$WZQ_^)#<6RKV6B$ %L;+.N=T_I
MO1:CN_+& :%;89?N!^TF7*GN+-7ET*F"<LT9^--'79*:RJE!_"%2^'5^L2TM
MXQ;S9]%?ENOK9+R<7FL:>544FC)L$B-<ZB)/YOE9!-1<R9$MA4^3\99 _QCU
M@: K4B+?7A"SF&KLV" QK_/5<LW@2 B4M[BH4D;@KA>S(OXE\7RO)XP,:*M*
M$1RCHHH*:@N+WZ5HU=9#F.\0KM3N05E*,JIVF<VR8EUCT+NEN#5'$(%""C0F
M"'6!)1U4A*(Z3)6[EHS ])'>_N;U&=_BZ'K]-!ET3KO#T: YNQ[]V75>7%Q<
MH[*6#!30W_Z/,;V+!-:3=BOL_)RVA^ILM<DV7&H6974CJ%Z%'1>\;?$'#73W
MTF*O62 =D"%F86& X!<O-01HE4;P*AQE-E: 63[QF6!](N2"$,^:&K5)F565
MSW(>'B='EE/NQ@WHK>303 XNIL.K8.H"/'<8W;LVZ7R0$AFW&04<U\7$X44R
M>+[4],NZQ#]]UXX[8>S1IW27/3 "$!50/^$<GV'_CEX>)U/0Y&&Y9DR9BL5)
MA@]P*K<%H68S_DOX'1FL 4Z/HPTQ7!Z+#I5(FEHYRP\_SS>72P*1G>(D%&/&
MY<3G& 730==BE>(*KYGM0MC?3<->*17-\XXYY=H][MME7DX]C@1-5'@G6<&+
M9DB->9->O\#HWM%DT3X!IKG!_(5QE T$7>YXZ@4[=))33>8FMC:?+3MZOO1@
MPK7WYE5@2VT!I52C)O S7=<>O+W=V_G:@J@X]"K-!L=PQC'4(6:O@W]1-SVL
M_ZKR=2J:DQT2H']RZR<P,1XM4H9[(T>(<+."#!9FA4[)3JRS <98M863;C%E
MC)C-Y72=?=J]]RT:&)Y[8[B'YB@U7-(*JPYVSLQ1/%+-JIO=VL'*R"+J0&4J
MW<H;KA9. [9+,VI0R'!(HNCB'E389#NGT^-^\>9PG)OEFMZR7@SA;DB70:A^
MSY<K)!?\=RX5T$0V;7F=98P[M5PZCD2=KPN-G4:<A^7"D%*X<^U&T=&+<,L<
M2UUUA<!9!LLM-DBC.)MQT<H[<Z6HP,@ 7=Q=>Q;FQ9)0>&/"[^:E"(:50Y2R
MR,@(OPMN<A#TX#H+SB]SJJL)T!BP)6PA P2[U >%H%2A@OEDN_(1F$.E7\RO
MN,@K6HY@R?5)'^/2*$&]PL.9'I5";T3]IT[K?EK2T%IO'T;;.R 5_?G^573O
M-#$P=P^GFK?\.XH@ZP@.P0#NP;G#^>P&89S1Y S^ J$X@T)=:,R"/&9N1)#1
M6@Y%PI/Y% G$<^ACQIVQB/_$YX3713$KZ@AKJ4)(0"2^H-7$T*A#GX7?:]=9
M#FVBRDMW(%UJ,!'V3J,N!6VI/8Q[DD[+D%4I_BV^D.OS;A$XZ>P/J!@0<()P
MW S&(=T-:11L$[EF6!-1G\=/B>),G]:^FU@C]?X=M>ILU^*X\>ZM<<Y<7?0L
MFR3. G(\\6MX:OU'3M1+?$^IZ2Q1C9G"4%Y_P3=QYMY8UU-W,=W"+%SC:A@?
M6(N9L 3H\:A]S)!BOE23&>I9;^OD=;F%*^@/\K-5*1/U@*C ZA#;_0;NK]4E
M\F,KV+5K.X7T KQAYQ;.RC'(C%PLB%G*.)%D5WK; UG  B-8P546"P&((QA^
M[YI9HAE4X+R*D6>?I*%?'4=6VJA4BM^&,<Q19RQ(5&5?!_LMBC-.F+'5=C[W
M*(NTP4T'!1KIV4;!.]H]?HNDQJY.O&I0I26%5?CBV#R'[5G5Z4^\S98*/B4R
M<I..A1))P(OB:-5,'_0 ^1QR<TY-F!<18?2L"Z*FL]90&S7L>LVIH;I!)R5K
ME?_]_*<4KB-<HIU69>U\M'9!HQKXJL'/^U<-! 9W9ECK_.UU?SK"O001'R2^
M_8W&T(2[FW#W_8>[=Q^3-1=-BDIFC:&K1OVG5>HTAGQM :]=C \MZA4V1*PA
M6545%XL\W\5EP@PFJ6*S8EW!T)FDEEY[6Y84BF.=W7UA[(4;*4 IZ-N(*I<A
M)EMB6;;@LIJ463&'=A&9&]N?9G/H1)5J[.04VE]D)?_K[]OIA9"L\Z7MJZVW
MJ _*%HKC>>O6CG>@1]_HRCRC@?C^^FP-@HN.G*T!SM:\23@=H*NLMZ0GPZ3D
M%T1;2']QX1'"OC>NF60&VI1O<NWTX1'__&T=6,Z+JC(Q9.F"^UO]TX$^3MT4
MR+^"&@&]$"0162SAB3GZ2\E+9GI5V6>/Q/RA$*KXBPPJWY8#QDO&#O3_6FU!
MSJPO%7$.4V-)E;@@1O><%.O)=LY0@ 8.W;K*P&J$5\F<."9+#X8,AP4+D%BI
MQ.;IF:BDH(E/RU^E2CAZA P6E;AQ5AE6'1V0GFW7BZ*Z=+P/%K=-J9P@B:#,
M5Z!5HHVPK6YQ*K\2_FN?,2& CQ?+@*'-<W*A&<CH3$UQ2LT(.*,WW429B8XH
MPT:VCID"QL]+[V9E_DJH:X7L=%M9^UWUA98?I71JR+2GN3'+U>K72:2%U)O]
M!G;Z8KYDU0R<I]%/<7X#>5V+6<1#06W58OJ3O%CQ)W#Y]>ZS^^BBN&(2-:8Y
MI!?QO!#G,C&<DJL?-,8U@4:^BF/36[_X5P+4&T3 55;0\U6^V93NN(&)Y>,,
MYT'@)NT#1>6@+35),(<,;H;/--0(YE?7M3$Z;Y73%5M&MRF>]@O&)#>K!<9%
M/FT,F^#^>?$H#1M'+_=@20D^T<Y-VI(GF*@P*8W(J4G"[N;I0]]&'8+NG8GZ
MDU76]]"H#5^I-MR_@G!7K<"[!(K 5:Y(_2Q/C584&&@9Y]Q%WJWNL#N4?Q<U
M B?2P :;ONM/?\J" %A9&%4F\ 6:=FVCCD.J-CO^X$JR,G1^R')=]Y=)%M'.
M- V7Z4'>>^AW=(YNGI2-"?A'^)*9X-C18L%^65^KA33C+FIPO2QO,0YD1<UC
M[FA4.2678I%C^'V)_^W/3T2]LU2P/ <Z-+%S?T=T-AU!OOU@6;N];84;9]YH
M+(\RO[']-#D?=)YTWIT3H<&]I#=J78 T@.\'+/O9TV?[Y#7OE"RN#(W]?K$I
M>'^]K$\$#>V7IR]IGC:7TEW8R@L"U<?=*YNG8R-_)^C7-W]MMU4^=BR3AI(>
M45W(2Q.\8/1YRERSJ<'_MP6Y);M$PE1PCAQEE9P8;,J Z8&GR'$B5$WU8 L>
M:Y@SX1B@*_H:=#<5\/M@-Z=\VL8^CWF4<Y.^Z+'P60(T+ZQ4XXB5<$<L)(3_
M&1TR'&W"I$8GEFLS$DU5J/@@<<<): UPRK#1N5X^P;RN,/DGN[C FS((XJ$%
MZE)[8OUB\QS:J=\Y^1K/F@SCEY^0X?>R6)FOJ7D Y<A>%#=D?^+!37KB]1,B
M,,0ESJJB(G/=A,DP6=R8Z*ZS?9,O%;BC[IHFV &="ZX>RWE^;J74AN_]5+LW
M$I"$1>'<7>A3"]^!6Z9M?9$/1%-M:WVV?X,==Z<!1]99#5 V\SRG=&*Z.@,Q
M#G8%;;"<)U&M,'-4;@K4[&N\[ZG047 XDH@FBBL^7E0V,?P1[@8XL$WS,RN7
M9NXY@0 >G%!R!E_Q;+!K;4;*+'9N>7N L;HPSSE%"4XPT]3&4HHPES:2$12+
MG2VRWA@<D)(,&MD'],G-]4K2*TRPF/YL2.57E!21DQI._ 0P905J'Y7)I_JL
M_BE7\(RX"C,PVX0 \5.V)AK#R1*6$'9XJE.L6&LE4$??>K6[W]&0._H54DOH
MK$';9N=\[CB'[HNLX[O3/Y[[^D>79Y05;NL8B^T I..U^]%L0LHC\=7E'=4)
MG#!D!7?8:=<R@/R,C5\/DW[E 5U51]FQ\E6]7Y$]R&Y4V6C:YXM7+>=DF<5S
M>P].#E"&[I2B0N=%( :AHI>:1'CT8!X]^TD2X8GDU/:/&K)=2-G]'"AM9+B9
M7#+[C4]HEW+YFJ\O[CH;$IH;^J#3-4D'LX=6DRG09 HTF0+?6Z: ,X*>'XV/
M8S5>[&I6Q4FU0R5VX)G#1JQ .E3RND)98RO#$QE.P*E.4CU0FK&'O.?&^I[K
MNL3/P&5+R=;V%_;ON]*"74L9*_ @1:AFT+J4Q()YQDAXJHHL&'9&<MET+3M6
MQ3"4:H]IL2KC(I)P8:WXE^9&]W4D$6DW%KS3C"_3/:F]GUKI>@PVJ;.L2)>L
M*R 9U9YC2(?KJ<@*!&F=L%Z)0\:UV+&\1 !G+;O:Z[]R=H*90VMM>>FE\5>#
MCDMA(]MI5+N#/;-!5V>"[?X.NPP"S>K(1/PGY9*#24:UB_=G.4'.<S=E$@..
M-;'3*G5I!L%A*6@!ZUCQH%35T)X$P]NZL7%D1M!>[U/0PM3X8 &,9]!ZNVHS
M_+31SCY3._M:5>QJ">MXBR;V(V)TP#\N-_/R;_\/4$L#!!0    ( &TQ]5K^
M8FM-DA$  /%]   8    =&UB+3(P,C4P,S,Q>&5X,3!D-#4N:'1M[5UK4]M(
MUOXKO=F='5)EC&U@8 Q+%4.<A"HN*7 V6[6U']I2R^Y%4FM;DHW?7_^>2TN6
MC$V8W PIS53 EEO=YWZ><[IECO^RO3V()S+VE"_>#R\OA&^\/%)Q)CRK9 97
M9SJ;B*%)$AF+2V6M#D/QA]7^6 G1[;8[\']WK[N]?7(,<YVYFTS<%P<[O>Y.
MK]/;%YV]?J?3[^Z+TTNQ]7%X]AI'3[(HA)]*^B?'D<JD\";2IBK[QZN/P[?;
MAZ].CC.=A>KD>*?XS6-'QI^?'/MZ*M)L'JI_O(JD'>MX.S-)?[>39$=PYPY\
MO#3F?GNF_6S2[W8ZOQPETO=U/-X.59#U]]N'AXM+5H\GY363ZDP#+U:%,M-3
MA7,_LG)E!1B8%,,"$V?;@8QT..__.M212L65FHD;$\GXUQ9?@=^ILCKX]8A&
MI_K_%$P$<_(:?<<8?EA,.]6I'NE09_/^1/N^BF' W_]ZV.OL'AWOX$"00[)"
M%EZHI.V/3#8Y6A;+*GZ_#1N9NL^V9:C',#E*N,*7P'_='K_ %4>U%6>*-#(R
MH0\?#NXGP#2,[[3W]H]W1LSC-Z?1 P]0]DN)O/PX_'AZ(8:#F\OSJ]/A^?65
M.+UZ(VX&%X/3VX$X?7<S&%P.KH;?@WX=@R5D_=W?DL=D/'Q_?BN>2J;8RB9*
MH&GU.D<U$V0"\'5?9R Y[VB%-$['5BD,*<XJ::+NT6NA4Q%)7PF9"A.(-\I3
MT4A9T>NV1*_3/?S*90=!H#PT8O$&0M+RVJ.YD+$O1BJ;*16+]SK-S%C%VDO%
MF;&)L1(=H24DT!7*F;1*>(OK8NN+R:JLM$13BR@ZCS.K[F&))3+^J5&76GXC
M,HIEEFAHUR11HP=%$%@3B0R,4&2&?UL50$Z B \7)LHJ'0NP0#W5?B[#<(ZZ
ME5^NPP_29O,ZB4249\*0E<M+?)6AX"):+6FCO1F__/1^< /.UWI<#0E33$J8
M2$C5RF82)#^X]\(\19,_@Y0>JQ",* SEJ#"7TA.%3UF:'>]6)1E[WFZ'/&^O
M16J#@3X,^CHO7$/ DMF15C<L<4R(* YDUYF$\%6J+0LZRC.V:,@+D8Y!?C1R
MG8!19Y!%E4QY'$P. B9[9B\*M>3D#?X"]@S:\F@*'*<(<\%UZ8&W^XC.&(;A
M3+A^RH1" "U7W)#!7EU_$D,4X=OKFT'+\9)J7SF).(&R]."SJ8IEG+%-RX+V
MU(4.&0!S C"@"(S-)AP0X:63WM@8GRY-99C+4:CJ:[5H)0MI1">L@#0/ NUI
M%7MS)&0VT=X$LPZNA@G NXO-+%0 9?U63>]$&3I! .HUL[2_&>'6W,W7:1+*
M>5_'H8[5]B@TWEUML@4"I6F7;O\JFBNN'AL;R;#FZN[2JY-NNP2>_"LO5B<Z
M?>4Y1]F& &YL_Z\=^N]H^5-DL)\#5Q9?/?B8"4E-J#E\SSFBY"=M<9HNV1]:
M3U6SA.L YX.E4O2LNA#;&YAPD$.-D\($:2"]PHS!^?%7)3!C].H>' DS LQ(
MRZ7LIE:-I?4Y/&.T)@+QYK<Y1I +(S&PGID4+']+8I@)@$]:^I&8\GI51+AU
M80/Q\%;T>BEQX*T4O8"&10K)$[STMVYKO]-I@?S;\ M'D$L!.:4# CP"ZV>R
M0%#E6FTQ7/!5'5^,_"&*+\E!U8MT@@H:*:0AU"HGE<6,\DAU%$(\D#FH1T>C
M'&I-4HM5_\NU0S CY$K[(H%/<XA3>&U)PD5$6Q?XBV@UTQ3Y(3O/(-K@Y0AT
M,)&0G$>(./U<$6UFQDLOM(/L/YY;TH*(.L;]7BG@H/=31:DM^;H>IOZV>[#O
M_$!X,ITL;(F, 3)%U:FJNN)\36B*D@JHY5L6+:*,;4L@_2V8DQ=*"_ !<NXJ
M6RANQ707FXPY<>361[:6HJ#CGBPU-NC8'IFOHKL:&WN:C8V6;*QJ02S@2-ZI
MFC%)"*20O'RVP2)KN)P@(Y-S#H&XW>V5]BHSBG)4BV%"@.'=GHA@R4F!7C#;
MT12>!TB?4@>8-%[YV+Y%6W*HZHW-Q^+4!W +M"[@FQ1_: C:8Z3\0GLJAKAV
MFB1@P(L,*X'Z/,-1)H<,C+DVE&.(Q1$H"LA.K/%S+VM0U%-LI[<)%'7) /W&
ME2R@][-0ZBAE6+6V&MU2$B#U5U3XO"":Z(I:'^ ,K#%2X"^!2WE1JL*I8BK@
MK;:0O]/$A3.#<%_9M"5\R.A>9O E: 9,D5Y1E0LO@!GO;@($T#NLIN/:JXE.
MX)T"XS5S % M6".!9< \J"L*%^3"36@1"2M#19<I6AL[LP &8:%\!%A40Z#&
M#V .D+]*4[HES3WWFC%*FNHQWN.*DX"@HBN U%39LIPDD3.<^5FE0"5R:U$D
M4@J#6)GF5/,!=S&83*L&\#RR5YQ19_ +=Q/&1(@"WGUX$9HTQ0N( 9&Q^P1C
M&2!P'7MACLU_X%"F)F8<G %/L9J7*#\ &8!!^GE&;%1 ?ZLLYC7/'T4Z8V@,
M*^] ?/1E)(D8*"=PA,R)$N-YN;50GN(;+#523+3\*85>1I[<C<<H;O!SD",Y
MC,FSSX!1+FI!/7'*4U%UE*%*J?_CTL#:NU&\B;(!1J:844!LXNJ5SX-5R@[S
M$GY#X !2RKYKM32KC4RL1KDIB!OQ."W'+Y(E:+T:E6831?=!00^:A0_(/IR]
M@B-AI1_C$GE,+POGP$O8L,37P/ (XF&.F B2I<VQ+8 DPUS+T![MC#P.-[MP
MUL5; OT$GYQ^?<<-JV\-""N-L$5Y')4;:K CU]J@39.TU#VUD,CZPU"-884I
MY&A7@KK"IY UFSH(@B2,&5DC7SR$VS%X"S57 HDU)04=J4OQ/S(!^AQ!%"C_
MF'&E20]+<7U1_-2TS)8-1$.L^;R."[VB"(U="'5%)?1(_Y3B"9'*[2(.JHL:
MUG6QRQJ .WF1I,ZV0\%4B</'+NJFW.8&QT]"!=@;UE56AN7D,BW(C""L0&@M
M/O$WU+5[:9!H=Q.0:.@:O1IW21 %W>:C_Z+RG2[3W$XAR:$]5AI M69(I7>P
M_[G&@<OEM<D>='DKT\,<4X@;W-3$78$574V,\-37=C&V]5D*JJV2,GXL&K4M
MCOB9O*.PC'?0A13J"K\6J6&.;VC;WWD7G+;QX75FHN^WD[]V>[FWYSRT4SIH
MMT(T_YS8@H@1:'ALH1STEZR]PE+]@PF[$Y;8Y.+N?6<5Y^Y2Y62$NU(]&+%\
M\"$!=+,] O1TMTT]_+X,9W*>.C$>'K9[>[\<@<6!I;CS!IT'1RF: QH;/:"Q
M/EF4L:.(#P46P>YE)5C1SA5%@U8U'I7[9=QE*,!-D%L*,TO]I1_>W/S),N7>
M)C+E " R*+S,)$?BTO@Z<!TBUT,8UA,9IA? 5+QWKWB"6BI9WHNM5D&<?CD;
M,Z0JVJ^\[0<E"H K;!. N3).K&PV/LQ:D$:MAFD(5P*/80L;;DB#75FJ/(D6
MWB6!P@*['PX!UD10<1) _^Y8!R=M.E:!A2'O4R'%?%2&JO,5N("Z<,AL#M-
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MTLP)$J-FA ""P X0U_C[D_S]8!/^#HG^DT0<Q\Y^Y3J\I%6I0\SBL7-# 'P
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M.W&/&#X7$;^L1W%W?^BCN%_[W"U^G]OG'KO=X;^8OD-_</W_ 5!+ P04
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MN7IPL+/WY+O#D;$PT1HK[Z^U ;XV%[:EN= XE.O]!X$K[ \=>3MD9UY"K]K
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MX-15WH2GRG)^=<*_)F/GUU_I;2MK7MYDX8*(ND*Z[MI5.97B;'FA/TLY?5T
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MLT]]_5=JH@TKQ'A ='N20*:(N3J7/8JE(-M'63I+:W8=M$=W3*YFMXJW&"5
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M@5!<"!R"]_Y!A)/S.M6-EV:\77+#*48.QIU\4Z0Y2L23,RZH(FB.#Z$%.H)
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M=Z!M:'KN[R 7**^\UHWS7'^<TUWM34EN0H258,_ &)3L//=J6-K D<)%[*O
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MUN*P'A#B+-"M]G;>$@PK)>U%E'F':@IB66M;B39.R[B9X5901+$'[-#:1-S
M%L>U&X@8C46>-'%]]WT;$0 '!XLUI.?YL^\AA:W:.5,T8.#$<]]+5\RX$&-R
MXI,U7U?-;&Y):EG[:VP(51@*KUM!+UG.]$8MUE7T<N?/QIEMS-40;[.LF].H
M[I55CAM0V7*YNFXX8[:[,2M- */(]V4."3GW;17H2(6^3<!S<(O=<Y?,]1"3
MN=X[T?.54#S)Y;]Y(3G;I"Y>!>$*H0W8)2NZ2<GAG<%0.&S"CX:R3$X")%J.
MT.X#)."/&,>88S!J0;I"4^/^J&,=[(T2\0C=X,I];_6.9>Z%((!A7R[.;"'9
M#]W8@QZGL13DHUD]:8?#]8_,E8T1&WV+R3/(.*>W]MYS)NRU[9W%)E558>JI
MLB+;Z@;9J,_Q0C7FV>:+OEO%W@5BBC9V:#_ZJ:L#^->#68*G&];6]V"A</-L
MG658&%3,KYUTB.[J<F&@'4P2"AS)D\AYV<4[8SPSRJT;[B1*47*3@;!$E9=K
M*<PUH\IASHDBMG3QI8A]G !"Z7CAE<JU92Q:* GEI#E0 K;XN<P"'W[_;"^^
M2S&9_66$95O=\+;QL0](*0B[:'$N/O4&^[3GW.^L]#LK_8:2)BS48I_&WJ(Z
MH&5%\"W^-^L#M.YDRP>3=OT6OCG'Y)<JO4&G.IP <DYL62C-U=2/[FN?;BD7
M3 KW@$H9Q-=L\,()JE]K6?A6)4W6PZ6,'(J\G&Y P<2*P_F=65S%+.\QA8LX
MANBE'4.B#7PY"XOJ7.2Q[P4P2&[JNM2:@Y"IK&S1K6@.])9BQ+JNT%CNC#U?
MRG&]XQ4;S3B_R*NF1.K:/M[0"2H%"1NE;*!V&3-5[4;]T@:D<QPQ B'A]SIC
M0#2NR=M)][!Q0&@/O?9J6)V%&1\]B2"C3\L <5'T^:(OBAY+)E#1*9.A(7G!
M'0=AT5"R@X30S4'!*'TF&N!%VTY]OT)/KU8+W0D+WU""?=L4@9&W!G>+B.?T
MV@ [M$[AUG,,&\QNK%8NG+Z+OK(D&^VZ1,/$GQ)5R-2^6(_C]$?@RX.;JO.^
M,GW#L\T'"S.T(IC^W1O:OP,QNR=V\WPCN@G!!W\%*HE3+L@![XQ&U59H&V-M
MDV7,B&V!%?EL2Q_4:=YH 3T,+?<&:C#6RM6H7IZ!Z2510;-L.":7G<12=US@
M5D69ZA2YJ?Z(H2B&ZKVL9L1^,Y4=,'#!)4RJ# 0HS\!,<<:;97^,N))@;1(,
MIE94HZ<B)E^:0,!PK8T_FWTD!%9I=A+C<^9<XX=-E6Z-J<0#1K+#PF64"EY+
M.NULKM+2!2B)@ME))UZ$Z0Z8B&Z2(8J8S<TQWT>2[.M_._'2U4F>-15)L&F3
M$EX7Q0=3H;4_>[1_![]FK(V+_]U6I(W3-^=O7\'_KCXWE,:?YJP.$$E HTWB
MM#T1RZO0UT&9&(9V99.]9\$(G_J:C]C6GK!?+]_]_B9Z?_[Z_ RQ7+;JF/WN
M2MSY(C76_R$MQBMG9PHX$L"NR^4A3I63T1^M[LULK918Q@L ?GV1T^M.8X:!
MH//:X_;&Y0EWBQ9>;XV&Y$66X3<EW2)G4Y2?2XM<U 6:W*.0(_%NQ?1>4FAV
M*9*-X(^F3*LDE9 L:J2AZ-W2==/;-"-QF*:-%:33P<Y#MO.0W9.'#+KIGN:P
M<NLK%"?A9SG;ID:7_=H[W_M&X!3/^B#U&E_[3 /?YG"4R@]HX&\,[5H)L!..
M[X71]3G[_;*<?AQ*SZ,L;U.F7G&;ZW*? K=9+"T)UL6H+BJZ28O,Y2LB=OQB
M: 0KS*3^  W4N4W>+##*>U\4#9LPN#H%E56M*F!3#JQ^?4;XY%Z)_L]2^$T!
MFL4* O]N7"0+^&=:S[*7_Q]02P,$%     @ ;3'U6A#5:]#: P  .@X  !<
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MUM1L@U%.YZO/$5M3!\W8G1:\V_W)9#@:W^]_.Y:$DU![7(K#:>M74$L#!!0
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M"#[3?LL-_)- _V.</] +!&*H@_Y_?OVK5<_!C\9$4$.OQ'_?J)H^%A3[L3.
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M>W!#\!X@J]=114YI!=0]@,QD&U)P[1+J5,7 *VCZV%81@@Z<RS0(9]TN$8>
M48$-.J\/MH_:GIU2'4(@T%@%=!?$/ES2PH4[?!I\//I2@4Z=".S[BT %NJ 0
M)>@FZ9;]X.(5(0Z!.'(>KD"?'SVOI\T)%\#O-#NZT.;!0 -$NT3PBS%D^7]C
M-LJDXO'(LE&IOXP&V>T[AMSAXHM 9AR"%81< *D0$1#:-KH0Q":6;EBHT!_>
MVH3ZRLE&).D_>G_:?_O$'6AF9D5S,P80-A6XB#4W;6(\%<>Z77X'@JZ@R2\^
M\VZX#>W&YE?<N&#OZ?J'DH! 0,EIQGR@0:"HD@TG3!V;<2U=</VEN'Z_I$M"
ME3Q0N"X<R(]1R&4V!%CU(##H?H\.QKT"'PY1+HI 0;-0(+H1TG645%K[+:%J
M:FSM#\88*CGX%MT]<=45TU=(%4)DH%T,B(&NS:!T=GZ[AL@'>&$2Z,NJHQ@A
MCI%- O>T:7GX9^HO][)W+]B\./="1)'.Q1O6ZEX)=97/!A3=B]$N47IS&B 9
M'U9C'R,OX\S02/;)/DB0_2Z5$9+=.,B(74'L];H"3668-".2<2KSRYZA8=_1
M$KNS43O^NJB1U"BF=RR^7UJ\R*G[+M4EEZ^LO/)6F2['<MPBV8D-JZD$:)9F
MJ!=O^<K%(!9;F!E*:]?I-B30^SI%JRPZP&CYRK>7<JT]7;1?1HL4,ZK$65U\
M':)GQI>O[+-BZ2Y?8";DZ[QS.QPW'X#X,.O2JV]OEY2GW/WBA1R!MX?'6?KM
M7C"*++QRY>W\K'MWWWNI-$86GWO*IHMOH#MG44>A<^4/Z-NRL[IN%C5^'<]$
M*"D32#FOYF=.E9=)'2,Q%D8#<YV.4F[LYZ#!#XO2U^EDA% 0O?3D%[!!_,(&
M44 #<YV)$BN<'1K>3];OIZ0/XLLLN:GH?]BE01F$M8;]#DFH_93>L0>CK47V
MQ[S(8RF; V,4+QZY0*O_?AB+'Y79A]\*>P!*_)C ^RZ4&'E!LV[H9D#2+(V&
ML4/*__DE0\ 90'0F/&.4H]#)0-,70/UUC DR!?2.G/..7ZX[6>.5F#FKE1ZY
MW%-7'Y;)VX$XNH>.)[E5;?SZI[8N$.-A;\VXF!\G5I/?0ZP>Q5SX5L*7WQ2=
MB[X07I[BN(YPMPN@GJ8I/;A_S>QI\Z,('@S>K&7(*C ,3_!8Z39E-!+/V79,
M?Y+G'9)],7,#*'CB'^*U9;&TS'F;!-&W5RN;>308N"./P[-?+I^_7DA=)/()
M)3*W/@5RD<>'D,<N<(L8MCD;M)Y<YICG1[K52#V.Y%Q',.JWR6GI909?<P"Y
M'-]1+O^05O^#9-3ACQL2AE>$O#XA*_>7<[%#P2"@)2\B0U[5<*K=,NS$*%PH
M@.N4"'2E';DB[#-B<&X;E[TLT,MQU0LJBU$A$#1D34& 8L= %511%A04;M$L
M%1M8AC,)!A5 :>AHBG">G[<K<6QW/O6'\.<?])]_9)UTOY/M#*?MOVE*_:/(
MGJ"3QA!S7!$311!1*P#QB%+"""*HL@$"3P(&%#T([>A+ 96O3709?=:]O#&&
M.A[DKP,%#<FT)O!ONPP*G>*"<(1K-4S_I+:;J (FF/<.YL89$(O_(3M4\T=.
MUPPCEL4)4:)D&!;\3PO@TI$ZJLOX\_PI:!.@XE*,\JIIPH!J#65=BN&C^<X&
M6@D?6MMJ:%N0>P(S95&A'Y2CN#S)V%J/B3Y8XM"IW=3Q?PU4[#D6%D0/0 $I
M0D\(#<3"W*K ;V736"[Z1))2P2P<6(0Q1*6<*-9""$3?TG%AC5\Q-1NB!A;#
M'GT+C2)E82\+K5<PMR[:?C(N9[3K4'L RO9@*:J,2W(@6?A%CB$YG89R>HN$
M1E4J:&KU%8($7C*0<&V.O]&M2UM93PC,@K'CR27P];9X"^H;0Y"EU<U<881)
M $)C#)U77$3=6[4=$(6M(9\#=B'L>J!(^/B0=>>#!(X/67>ZR(%;/+V-2[(!
MU=7";G+_&!04"'FW47]7:^XC7F\PL87^_:^=^OP#IQHY:Z,Q/@8@9F<%,0_=
M",I,6!B.-Y).7]-QK]_? S8^H D?($7X?_[E]?Z?X%2JX&B$^'5\)5^_FBL-
MY37?'Y_@W)6D$2UY<8KUY0)TYCJ5\99 I[&K]H;%^_R&3E#)1)J.DYM>0%['
M$Z%WA)D(.GZ)M4L/%RK MZXY26KGEWSZ#=X3$>:]4ZW6GH@5U'G8!W4>C^TW
MY&/>Z!H2J']0:?*:DL#@SZ4WSY#8A(L>:Q*X\9QJ7?DK-C9BH1_-'OKZ$-YR
M.NPLOUB&*?<70;K9WG78[V-FW*"[9=6OWY>=)@#4RK'P5<MO^!EI2],R4#TJ
M<GVP0P-,N\G64=BV$I&NT? >(]1M@"Y =\&+(,U*[^NRCY^T)0<L [2"G7;A
M%LMCY0:@]D1/ETWW9R3U18S2T)4]:X%6%=XB4OO0JWL)3BZ=X:X'M '[7JC%
M<>>+\_@)4I@F="9]';@B9P]\2,.::.G//?DN"7D<"\VE>JP#'GT'&#J1C$N9
MKA@'O6X\G4QU,VDJWDV2/3HAIOID@@%.0>KQCZJR ^,TPGGRHY*";V?ON%R+
M:-71X52-"H>.K+DB\BPZ=.NN77DZUA%W^^QJ74=BL]ZH\W#-5:Y9/.1I-@=>
MYU.]W20>ZBV.*/'$ ]=\(DK51KW98@]Y/)"_YBUN(%ZRDTYIV0UZO']Z+FX#
MV#ZT#0O5.O3!M!P4L?+\RO_IZJOWX8!^^X)1GX0[B9T(CM_]PVD]<&YW6@V@
M \2^0;$NN V"O-6[VN%I""P"U!$:\C^UF8KZ(JV>(4LR\GD#8'5?ZS_>?W-=
MM ;>I X,;?=J^Q?_RBVKV("<;;=L6;;]8G\=_L/=Q1"8-W!#(52G:,*+UU*)
MGMU0L+9UP?D'(KDP"+SKO2?B@S95)U)#T[84N@IYK]CKAYL::ZBE$8<$H-D#
M%V)<!3 'C0YH!Z!0,7!CM<XZ@U"R?PI\ V&@3^4I-A6,W=#J]:-Z=X9&/=O!
M@?$F&+@[OR9*Z[LR[<NNO-?A?3EV$XJCN"\#./.! +2*L  UN'TU[N/\3K%
M:RR.FT!+1[?;%>VN6#?HX#*/-N[)""I.2L5]\HE$ 6LNM1*;\MCK35Y#@9QW
M(5J#SUY 0"$E=.JTV_F,#5HH*"$5"CHQ%10+$/\-K1!TI#VR_>RK\;2_("&M
MX9O0X_Q7RB@Z*V$ZTBP3YPH0/O[0G#XRQ$7^G_:)V,MO"SZ9\")30P"-=(0V
M'9\1O7 WXO6-8KJ^(B19A\! =*[C+(K]Z0HE4EPZ@;\$F$L>CX&$@NSPGHDN
M:[K;\QT&*[KK#]%YEV!XW(O#]((,C6@"VV(&,12FJ$L9RAL4OP<Z?"Z8 UW$
M.94UH3A/H,'__&GS!/)<-!7Y<KY$DKPXFN-J8+/6[5+$[[;[<46 FS$#?8\^
MG+<2P3()./"Z(I#1:BFX6 R"$;,3ZJ%W >4NB,!R(M""#C<[UG34HF<*T+ER
MDAV&(Q9,V40>E4-;?\MKS'K9A):+Z'B%JX+6+AQ-TQ3]E_LKM/'1I-F 6O \
MLR;Z[N_?\C^NW.A!1T]5<3<YQ)4P<(/J:=)E-H0J+!%PV'&C[W;UOH@)K^+$
M @:*9[=;^\KG,)<]9.0E29C"L5*T"3#@5T(-!C<#?4W!187AB0BD5R#V)S;X
MO=\]I8@I7H2$+<C(MY\"2(I(VZUHQ;"20)ZP/:\4!XZ]&^U?W06AO"E.BV'F
MPHDQFS[!V%Y07]?&P9V$7'VAWT<!/DSC3D29B-L93&)M7#P8#P\)Y/!E 7L'
MKA\E;X@$F70&=".V0B_*(_(:6\H <QD.YN/FZ*L \[H0"0E(P42-V"Y&H "#
M._?8F "O%A1,#I^R X@/] +B 3*]8S_"+> .6K1O -7GGU""VFG='@XI$ W4
MY)U3H',)><!= F\O:O7NJY \#6OD98$:5F@8L8&DY560?4H.P@G[CY"=A:#J
M:P$\/Z,'^DCNL-; ,APY0;GVEV,+8L()T+>PG<)MPO4DXBJY!A^+$"3CWP*4
MN2-8UB#<F]X>0CR>K.!A=(!2?XB&1  @[WIX1T$=!1B&K7#_.W%-$E"^*!CU
M ?@6+0%EJ=8!V"9;4QO8O>">,;<&)5=AHTJ%\-3QS&"[D$ =^!:B9W$JAK9!
MX@AA]G2TZQ)&3!PN=*4!SI79(D% <5!Y@F#CZ!VX/^<;9.BM+LZ38:&3YIOV
M:U?->\&VTD2',UR-\<Y+WK7_S2&\RK AN6R7VEO#$,#$91=@^#9 <-V:6RKB
M#K9QA>X[\@2#$(D.;' Y,L"'L ]7M.E=(8OE+K9BD2C"S*\&ADGP,0IQ;? +
M!H=L/PI=>YR+,R?'K8W8/F '&\G.XP,C=AR1N?1^UX&!8F^&8[.&!];E(3WV
M^G=9,#:1^A;RS4*FTQI;:;N1Y) OZVOE)K"M-F<WOIL&+28VL#0^J+4#]V.%
MM0,W(*MJDSD%I>X'S:GK$YE%7,A?VLP=LK')SW%DPI*BPURK@S$V>3;<Z%HV
M#G>Z7H"E"OA9OCJV<7@J$&4%PQ[,M*R:EF(VOLH2)I@^WQP;"PN>=6$1K&2$
MD2U5D/2W2\Y6=:##0J)@# DWY+WLZVYT)V7O <@K,TP\' SS!P0V[NCQQAHY
M;I0_0PS>P="IJV0J=9V,,\R.>MI)_/CO"GL"A*0!._4R0*^S?7Y/^J"$Q7AB
M\[!+CSJ D@LE>O"&C(D"+8T_;!MDDS!Q##L<-C)0Z.?%>8D@H<P=UJ:]39CU
M5UX#"!T0[$&SS_9V-JE#Q[C#UZ_W"I'-[IXW8,M0?U'&U?GZC(?DX,V5%9=R
MCW,N]SAN^_E/3,4>+^W*4/VX1 /0!0R5ZL9!.M--IS*]+N@GXYF^E,DP GGX
MM.LVM>YCMA3P3?U1EJ[L=G("[WLVKH9R'.F%FXZSE?[&.*O['A2NF$]L8P?^
MI,W4L/9U)"W$U/^XLC9H0OGJ>*WKA"2[K1ACDHQJE"2D\F2H8M:9+8:F.!K6
MWH07-OBC9YDHX.EH+-OUDG'$ ,T1Q047SDI<WQ^;;L[M.SI,.)*^'1I$BKEF
M#@L(%].^M[>SY^SK\!6(K$##>>C:!WF0^I.8:19T0%?W326O4X?==\ @<KTY
M 9KI=LS0"!@H5P3"/@ZIR&/9QLS5BL'DF4F"MYCU5I$]R32\N_\F=V8X%#:P
M["FV_TUO"NRLO9'%-_K!F#:N#G?W+LJZ:(T16$5@7(5M-VQ)VL$)E&_1C:$\
M<?H2@([J"Z!B]:JE;4,.N^$S='8P*JB&=^&_/7,3/4J!)JVRSI#V0;G5NG0!
M!NTJ05D/*WO+ZQVT+W6F?*G+>I+6J5P+A&W<0$,XJH@Z<"P<0T%_ZYH"*7HL
MO&A(V+IW3C6[1EJ;P8>[D2'<(>0\WDZ):?I&3KE"J%VAS$TC.S[Z+_$)WEWK
M6$&Z90T<)#0LQ=P6,$.DZ/*# SCD1"Q-9T3A1$<TC8&@!L@,-=\87GT\<BMJ
M@B$)KW;1B7O(7J62\R*(]N^A"#7B"8P&MTW+[K\*)T3\!/@ #2Q2<1[#Z[BZ
M)CI#U#^P=J>>'SF! +']6SNL:GNSRL)A-B.0#]D49D1KU29V,YD)3?,WL'*G
M*\7[EFGIN(A?T>Q" ]ET8AT(.:O@/A&S\>]D45 ]B1<80 -F?>GD(#MG1S)<
M=/NC:PW<%N,)7+997:E,<"M4O3=@7(?'3F]^%5J./1K[U8+,BSUC/X(>")[;
MW27(RH 6*;S?O=%I/K-38(Y(6,,JVQ8!F0V+J\VB*I2OZZ'(,RKBD'8KX?"+
M7'VC9^@*_2"B-FEW_%83GUB#CJ.VM[ )1_5<Y=%[=<D9:.N%;@/18&@$C(75
MS=IK\\H)>J9-[4A<3@7%O=:%_A:#Q%ZG;5;@G!\A0O2A1B,-FR"Z+0!08-!]
MFK],%]!C2"+:TIKP;_;"[-N]Q>%0O/W>:Z+4W_1PAV*=9\O]I:<X/]MO0&47
M >#@=SNEU1X,D16@.HDH$'X/CL7;)=HNXOS?#8 G,9M#5^"L3+QWEA(TEN&+
M[8>Z05._^]).8 #(/[=00TX1X3H/1J?HFC[5O9<FP6]QHKGAI2%9@BNY,;"
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M/3D3A7 :<_4,G$U+=5:"YE'BBL#%FB?CV5>>*^12A"*C&EW#ZJ$3CUXM=%H
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M]VC=-8K\Y(_#/_YTLTU6F;-91/26&BYLM8M>D<GO%G<@$IUJ(V"_U%XS"M]
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MD=-"BBUO1KYCBR4QR$)2;K9H^R ZAU,%3_VF47CF\^O<;7E4'>WV)J2O"HT
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MS !(_(=? 3,=-G#PB^9,B/&XL1RCN3?>\(\,@=]5PGU-7IY'>A\J8?%C%)T
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ML[BKBS1.S$PKGG2)G3;ME4)AA24G8-C!H/67^4N6^#>"BW'.7T?WNA\%#ZW
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MG5HN,A<V8A _UJ( /(/!(7=298NNV?&+RX>)3IY6@7P1Q%,4?-%X1GA8P2"
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M6T\Q#E <5 NE-LA"T\FJF)KAE-#,(+UUD;I$@@2W$B[L@4#<FEOQWOGHE=[
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M6;QN1)A;V$AL2Z/^Y)@0!UD"@4W%@ZP(*SS4J!T":!X%4BXH!<VVT01G!&"
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M:Q%WB@#?LO/\-?D!-/O6/+L4C.@9L-MEH&(Z8)?OR58& PI 7>^;/0ZSZ[)
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MV!%.?.4!CX42"M"QK=U:Y4?I#^ F//U[7X7<1/*SW#F;LM@L3KPA7VO7"OR
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MN+6.R-2U44^H(SV*$\839A,.S&6Q"Z4ODKL,\?9= 24E\@K'=(*O7-<J4A1
M+08];"IR43;4Z(9Y>C;23>8.S&@6X2<\;I=%1<F! 0<?AUQ#YCD*D\\!1E.:
MS8*@][2ZS"M,6I1M1+U3Q92@S3F42J'\Q@?42Y$ABF13/I!J"DZH)U@/!Q@Y
M#;!F@KI:/!UQ"UR<5WJWJ1QV,9,?$A"*'D=U)&YW,^DJB<^9TM-71XB'*8IK
M1LSP54P*@1O!0G8#;;V-F:+J92<IZ7;"V_74&A.E$Z5[TC?#1&K(5#]39L!P
MG8@VS'O0PBA.@*>J*'=869 L'TIBC.S]*QO,UC*PE@^W=][OWN-/;J+OAUO
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M3/V(QD-%=0^ZXU)=8N%[35"O=Y 3M#IOHZ3CF9RX7AA&I1K6;@<7[#@E.^P
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MG[>=!TV&KYWXEKS<9X'^>XE;6H=Y4'NH_MP"SF+5;"L[&V^WQ4:KHZ9IX8:
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M!FO7BU(R17C-W-+7<.AEFF5Y05*;PS8ANB2^,:W]!GF.>\/!/2J;=:3==T7
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MP8AAXCG\P@J2ZIS\O1=5$]H8>1E)7I$LTRQUC8S/73^!<35:*68G"+;=>L5
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M1X?$N683&?0+-.-Z55!8A5YC;KCZ!#%6QDH2?B%"YMTC6-YL,W=I,VHH[JU
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MJ=%)T& S?)O#T:-O A[GJK#BP8DYBY-%AC\AAGQKI#H%^A[@ZF(P>0P_E&3
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MG9-/L H"?:)6=+N &I"'.:;_P\7$>Z* 8)I.8>;B+#K&<V(TV8FU3B44S_7
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MZIRL04M!_]O7P7'M7KRNZY,M@@$$[IAY%KV6L";/DS;_A0P"\9TJN "E870
MLDANWLK\%'.7>J=OLYS4 O8]TGD'1,U_*=V<;\'W&1P.9BRU@Z>]I; UN&>S
M[:Q.HH8=EM!H0F2R(NVC39\D'GY)AG065?;"_5H5,BMZ^?9LWQ-9HV\ ZA;N
M_7K,9)S,>5J7&1*"H3>#L)B: MA\EQV#X7/3Y^6O\ 0@"-X>,5ODL"_Y+! M
M\'L&&IOTH9]T4UAUK6>4\+Q2S0]W@O>P:ZAI.W*;\RFOO?S2$V9.<*(GP[E\
M;E+CZ_*>\F) Q;D*[^C"$&9)V^$J2#^:GI"+A9<UIW!R*L4/<E%>,'(]X%?T
MW$5I#C]?W!>J ?G!6MZ+TG+2*YYZ=D_^RW/O9P)CF-XC5MA1^&3O3'Z5[\F]
M/D?[2-%G,'Z;C<< \[4G8F=+&8(  V)Q N7+Y$(W:A.,A'/GJ42@\PL7WLGI
M]C*$UUX]&WZ" >T%AY)20OB7(%%7B/&.,F+&'-*NRV*2H$ZH2#K''EU%[0&E
M 4B&;>;6S/J=X?@.RT9]NM4X\+3#Q.\]BOK@BCM#9WDBBS"%CF6+@S[(69FK
MK%'^9D= :R4C.PADF\*.95*)L(-N',:O5XA-KIT-I='V)ZS36^GU?\*-E*;K
M_U:L)_G-]N*!W?:;W_SFERF:;Y(+3&"71!A00SL-#JWM.*/3A:5V#'>%P@K?
M-M1(5<&/B%Q*S,8A.#0W<D"47LDI0M(:;KJ!?<23D-]C,^UBN4O[*XPM4#IQ
MDX5= CC'YJ<L^;[AZA9[.)_Y=O]7TN[_Y>[W1XR9QW&#G!*: VCA*1;$A#!"
MH]4I'C1.*";PW-2'B(:>H?2EF)#]I&$JFX&1! 84I^Y#WU6[=0(IB'J!ONF1
M'DKEVQMLW(IN#@SL6Z9D(V:D.-ONAKM*JGV%ZSUN270@<3(HGS=*,@P'X2PL
M64<?7>@X*/=\?MBQK)&U.QJ>>=-^L%O-Z\;F3&(O<(32++R"$NZ#\7<';?-_
MWS5M%'@D'V*,Y-KH1]6-_VGMD#2$N811(K17A!&]E6_.I@NIU<$0GO9T/$](
M\+CI9TR5#QH# @=5<?*4Z_Y7M&1,,>6^05 E^T?( !49,7/7%;:/;PDGAJH@
MBUGE' ()H(#A2& -=(%HV@&%9#JUQ%X0KR]=S0=O0&%0#S@K@HW/^JHGO*.N
M$'*L,YQ=83@CRO$FDQGZ3#S6X6:(A=(0!W1_#(<;9W6LGRL-7I!G.<Y4JU?[
M;,EHF9Q>[QRC/5^^;F5\+#K1<+&_C\WV-7FVD<T)X7RXDU,U#)FM\'$-*:6C
M#L*/PZH.RZ8Q10GTE3FKU>==7U/!;>U/@\2:[VN>==IV+VB/.SX'K]<7J=&0
MA.]T#Y<W S,^\B;6NKYMYE\H1Q,,0[13)>7WC$8F,;.^0FZTOG)>!#=1K[WF
M0-1ZB!(/!GTZ'-R@%2+UH>'N1^G-D$OP*0"U?&1I#2Y@ "OT= "="J8P-+@]
M2?/>E<;QORZ-XZ5QO#2.48%7ORO"11HS2<^)#SHYE6;SR6X\GT;R5N2"P<Y(
MAU"W.F1-P_PD]Z<&U4AHYB214_*=AJD4BL[P,#\.]V5Q>$M(I:>UNF-J%$Z]
MWUHJ71/M''E,^-9XID&&34@>7*"A+C")29.S'1W-'DNTEN9#!&K&8P[AG7?.
M[BR0?N$.3TC_8\?!+IX'X%7%74O^(8\C)!KLQYF893C;#-T9%&Z#2,L1.DW?
MNK$!/D\BXH]6#3W"G5WC#XE@JF"'M\%::,!1:7K6L7.K!"FL0D1+M9>9L[^/
MU"2TND:%Z(.Y37Q'&%0HGK2(:(@H$([\]%,>E9@V%U+F\4QT.9HGI;%.,\2G
MD";K/=[2)/#Q E&6?\1Y1L.!A;> W<!<XOISQ2@+S5M*;ZMLJ///(V4#E>WN
M\"M&@C.X?:/9(BU1?;[M=GPMPJ)X4JW;,=C/:M/M+DPP@%FN[UY^\Q(_3&)%
M(<'*XG^4_@EDOY-F=[ZK3$#Q?H*M5I*@*T&K5@_X1Z&1WON:G/'!P9_RP$%8
M4A>W(D&)$Q[?CWTST-5E1L'?P_90-9&I*0N!<0$%"KBY>U_'(;_CD@&;;IL
M^>\KYF^@6/'11'5>T&M:$WR@8W3"@&$4FM1!AB928KO9WV ME'>-N,MPU6
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M=_?IN>X^YJRW(HI)G&D6GZRUOZ;3.';C_4,_S-=_II@L6GYI3TLUW*&XJN2
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MD3V%4'9W!J>SSLP*WX)Z (G<=HKN>>BHI2SZ%F2\2.H8E'D02#==,MPCV3;
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MEW 5&G6* P_'NC[KI+/(^:T(VC->E9!K@^L[$-4#M9*[#009N3K+3-OL4XA
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MN3Z>SGX6/<9>HYM*(-K/2N7M4,G^\@K'@%(>YM^"Z@-[Z;!+,/4?1^T?PXG
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M$,N/SD 140'-S?A;?]R "#6E7/$SSG4]X\C(]!R:V?L^R>*6;DR=9FK-)N[
M4_/_D^!OQ 64=FX9=R!OF[T.NIZ<6 T@8#K:U#T5A9GW.@9J2H1-[B3C%W84
MV6=RF=S2-IR"U.85"+7F%*1/?V:&MW<F7@%+@/U\'OF\7/U)&F6E-: #$^HF
M)#+KYZB(Z95B+ 5;J5RH38A>"2(=?.R@AZ$@ ;)H- )NGQ";1=>7]?]S2TO(
M5#/*"-Z=<2!IC&PN2=RH%Y,L5>(#X71Q8X@5T!\4U&RZNWS5)N>7-WXX ?7:
MCH(!04?)CTZ S-YSF'"SZT(32LQ\1;8W[NDV@6@-WU/$H5%'T9OUN0I7M?'
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M<;T29F%UD^Z#=O]MVE=+NUGM[EL^1@3I-1%"QDT(??OJ9@S_%QI+V!<D%_#
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M: JO7A1.RY=O EK N*JLC+6&LSGT]6QIS.GA532D/67B??.2V2_#X?LS%-.
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M/ZQ#0O/A;U^NODS^_H/W\?>_6Z>+^U75A]R"6;9VW8G92#RR0&E%L7[$/R4
M8ETZY#7&X<:UMNUK3*U_:U]%JLC+3HMZ1'D$SAW<,#MA4^#KY^_?WR)E2O%%
MCY0962BJ=\E;X&R:N.I[J_BJPJW0A?C?<=W_G[TW77+CNK)&7P71WW<[Y(ZL
M$DE-ENGHB%*1LFB;(B])M>/^3 ")JA2!3'0.582?_IZ]]G#VR0%5M&P5%<:/
M;E,H((<S[+.'M==BDA)8<Q7[B_9?OUE =2V,XM<:\^@[A3MFBVL]6\5X>:F5
M:+?PJ.G6"+:C;XD(=JA7H3L+#A=!1/Z99BNMS_Q^LH#H3=O9';;MO_[KOWZ=
M[,DRN<&("3I:+R4R@1IPW(_,G8.!#OX.Z4.NL+89,"_R@E$U(.(>8MBS"2%X
M?0NS&-8%.5!D9<H=\V=X13X^Y4KRC-*<D[NUOT-?@6LG:EN&M0AFD>4_,Z?R
M#X[N&[SHFV@5WT3C=J&G$[W<*X0<?T703PF8L(')M7E)"G)-^^N]S$<GV@:I
MC'CD\EFG9QNYLR5E-:JK[IJ2, DMDV1.R +)*>H8F7@11:;6?AM^S'PAD754
M:*RBS*(]B&)SIQ@X$].1^)UF^QZ(;?2=IA:FR'?UU5S0/*2Q8NJ*PYZV"PE?
MYN_A(%6')*JV3<G>R&Y'_K3J1:RV)5-+=>10"A49?."6<4K!"2Z:NF_5T1TF
MFSR0A(B'FB)2NQ<S3MR !>NW0F[X^Q,XY 0.^?3!(?]R<L-AP)4ED99D7()9
MXE@YHFO-UL#C3SCFKQ*3YV*\M:;TF*"O57F=H9V/1/=V$^^L"!/5#=TN/%"X
MXD#X^&]3FMPS!PWZ2X8/( ?81.]V)?D,\/-^*%N?G4D/JIE+M]K K6RTFA";
M:-\F5WO^G'R@^/[5=$Z#TVB@\4>Q@W.M,X,.%4%FA!^=07;$G6C _@T1">H=
MT0X)'@AB9VZU0M(!-3!45RA/ S9+K[\]<(!. *G3LDJ +DLO>[ N=J2+WD@/
M"OS?L)K:C6;Z8QRDC+=#LX>,=;[ALS&6QEP LQ>!F+64:4Y+\K0D>4DZJ,XP
M;M.BZZXHN+2T)1\!V5RR=RVGU&+N;>6"3A=APKV18_>T[D[K[IZF<,;6C9WR
MJ+RP+*IB0Z7R,'NX'^-,@F4$)5;[_G04G];?G1Z>TA@W^Z:(?AWB2Z!)PL=G
MMOC:KE]+G][)ZSLMM<FEAJ4C4$+EYAF>M4J,,HYHO<!N0FC2]H!::,94*[?(
M91!L19Q)6N3&PNZ_UQQ/?TLB(%$H.*WITYH>F\]-B00_+\V5B1,11ZOD811I
M2K^*BE>2LZ*4'5O0\#$5Y6%/1<;U3$'[3B:++V^*UJ:EM?%&6.3@M*6:-LLV
M7/C4=W):Q,DB'D-]@%QQN><8?R-?&J$&6\LH S\6'HP@;0VASXU(.,U/EY4S
MX3XN^JVUE+R[CC79<>DVI^SR=DO_2T/GZHNEJCDJ>W-R#%K?""NPJ11FST+I
M6N:?/;'0&@1:)4\U-J6?R*8#J>)T/D=]:O?K90%&A58(J=7-5"_E/!T/%HPG
M04["4)#6-''[$='3=8$C>^)%M>!L105#.<Z]<Z):&I&RQ>*7^28YBX'L *T2
MM41<\4ZG9:(4?;Y@T(/'7C+Y6]]M\9KYD@X1U#OX#!#Y;&3Z)Y%]*K<T\F0^
M!51B$:=$E78&A?KL&&)1#]6C$X^EL2EN"S0#[.I&Y%22;&#+.-S;0F%G6=18
M<2?W'ET^MRS94F'8@_UKKHHA5*+EWZ,I(LXTG=/$55)%<%;1@+J2,D>4?ZI;
MVH/[\#]G<=4/5F.F(@+V^A/Y4"9%6VSSL-0YDV!0>*4,1#Z+_L[W ']@+!]"
MNK<M&[@#"OAV2K]C1D\<$_D$N/I\<1'!Z 1N8Y!GNRJJO"EK+5DYP2,8(0-6
ML/]BMN8(+.53;:ESIL> K?1Z<;@G0VIX<,/)9P]R9!'5F )4+RINDUBAJ#^D
M]5N5W.JE682WH+]Z:RM@<MI9O+>!AM,1 QPEC[&O$O@1%G6YD58!^LZZ" X@
M4(GV/%G,KD[@IMHH,#H0ZDL(7#+C$%S*35@#U7\)]YH[.Q4XJ6<Y%=H)%<\2
M@&$D^\@GX]8TH3+IT1^V:W&F:*Q80\>[E+=MO>(>/BW[E<VH_C]:#X,J<ME(
MK=#H@#,?RF22F\RH:!.6^>I <[P*'O[[HMCCVVJBPE?#=.=7A FPPP%0_4X.
M7SJ':]$>)!)?$8 ,&V?9RWGS@8]>PA3L^)]-[ H1<;BFN!81Q.@$^VQ^S+;.
M'$U3>0/6+A>T\<M[7.283.+YXOO@#?;-/>![TV<#"#3333]8_M.-0RFB(\H:
M3G3A(88 ]N HXF/^V)X<1?07\ \Q>!YO\BLY- S\97'F*NQK=2;(ZC8ENFK"
M(V[86Q>A1EIJ.JB)F, 8KC,>*UX[='E>HZ9Y[K(#=DH8LKANKO)*]F0[$"'4
M'T4A:_I"6 YK]-S4T,-NL38P"V6KQ\OYXBUI-M/C34RJ6.=V(B&'-J:6R;;=
M29><</";!R,VH]/Z6P$W?GL"-Y[ C2=P8YKQ3/:TY.AO*!+HV[G3$#U*HO'<
MY'LTL[CP+64@F#RZK&HJQ5 !BL#G.%_,N$4NB#=02:956UC_7;V&YQ?^&6$G
M$I])W%CS84'M;1I/0::#8\B"$C#6STW^??VA7!GUI?13AX"(6NP:0 ZD+5)<
M=P[FQK[[A'T&E28?^V 8I,YF%V'U;3C@:;J!9 B.6]-?T66-)X:<)1ET]()M
MN7EL+^P4^WIO.4,\H7D*X4S8UWA7YCDPP"9/)Z)-?)G6Y[[]YZK;?B2GA^N^
M.#:88:9HQ\\[>_FRJ?-U-@C(T"Y&&H/#A@+BB8SL8Z,&@B8B2QRG)!6IVI@$
M([S =LL12IA#!N:F/1E,>H >A!R;KI!LY'0? N&-,XE9/RAQ=166];8[UEY>
M5C?U]H8Z0B^%VWK:0[6,LP,D^PB#&\LS8\@N*P5"H^54VRW<P!$NI^]&.6Q'
MH(VK.#,C#:9F8:)7JR_F/#:>0);MC0%JVGU,-_ZY,.A:ZAN?^S8F;^%83?SC
M$Z><*-[TK)%MK!B'Q"$7@[0N5IP*%,)=SLBW\TEY:<O&NDO)\:(/E\7%&HNL
MG, 8=*30<F3[[Z$%5E]@R@5+Z(Z !FDV1%I#.76$J<C$HCDK-V4#)X'NG**:
M2C0G35,6:^$ 4,^?:2)^-O><(LZ5^=U(YKD4X"[\R G)<['$S:];>,Q?,-)%
M>"#C^'W?T.1FP@R!MNMB7>;TMF%52]SQ/"R68!LBW=$71LSQ^LUS8^;(I$2/
ML=L+A!@K&!^CD*DRV1.L KN^!;4#OH"%PU$+[0K&C_I#GH_ERO7437'85,A?
M15Y>>[<PN?YHRSGQJWG\==UJI)>OJ8(!^):&P3 I,Y?"%R(;BR/3&4-9K5D3
M;\=D)1I@$Z_&FB@=&MZ#MWE)_0I&_(+*PD7\BBQ?9>R!Z)%T6$^T N2H;K-U
M%H(-?5*VQ>:/)6C<<*7U(34F]!^L=QY&"A4EZ76.X^...TN4*K6'M_(\O32^
MR>Q*"TRQ5CZ/6-=QU,NCVRV+L.2YA"56DYRTA*B@2OO$PW%/)^BVK6/0*[."
M6Q>E\."P0-;P.$>U-#Z&6Q+TEQ7EOU 2D"Q^W&8OJALR?%?\Y=?;A#/J,-B3
M8"<()YDED2CQE(!><ETKR/;+\K!UHT]OE'F:E\:=PAS;#9CYX>XRC"$6D'8K
MBO>TK*9:8.>2/^-)0-)72+VO^AQK>I[7>^*]G5 I<WWSJN/&&,DV^X2\9NWP
M)S;DN"*EVK<'J8%SVY&X8_S6?%+%FJ[+KS;%ON?#,+PZ:A^<!>$SI><5Q:)^
MUB7.^1 1"'$H^>0,BVY+N.#G5 <SKL+@D88WQR']"MS[3D08TX/%[<XU+4HF
M;WXL2VE)Y>&NP<<]FS)JTJ[6.<3=J/295"CP>)] F1)E&R$G$G(8BH9@>GCC
MJ?WT- S^-+BA4AL%5H3S83?,-NQ8DH:6!_%GP'_Z8SE?:OJ/__XK5>07WR'6
M7SQGQZJDF]P$3S,O=V$+UW_\O/SO3&@^<EK>F77^A<T='KSIM^%QCM_H\KJX
M:<+LT=->G&<<NKRH5N=TIQ^#TTVO'[R <-'@FRZ>!6M"!%U"G!&_3P]SKGN"
MGNG+1SX,LBV7RO$P-GK#[*=[0@I(+V!^552KPY1+:9% Y! JMQ+ZYKME>=53
MO@%Q$*5#RU7/)?=]N>*C8&)>R+/;[]W3X?81K=6"\Z??[3'C:Z-9 @<#Z73B
M6>25X,,4'\BY:Y5VQ\DJ+W[NUU?8[L!#8-$(.@(6B$P_OSRK'+:Q0+'2HDTI
M/(,8"A]Q')P3=Y&NT]<47*Q[II-<?-8YRL?7YKX%?\).8R*&+.]:IY=U0]"@
MU\$9'JR=[VH",(3Q^Q,MQ:IN(N!(!IE\RR8\V=M#VQ4[7LUQ <=QS<7IYJH\
MRYJ2^R*7<=4<]_*O+Q J+XT@* Y=6WX8<!EVCNROK'[N.6\/GV(+>[799(LP
MCM=*[&4_0-M^3SR0=$'20R-^GV"9UKS8:'J1*P]6&W>C>H!H4Z+LC7_K35JX
M#TWK0UYHNE)$DD^, I&Z0(X*!P,O&Q<>4_C#YYH^1W9\.J4,T.FA^/R#X, <
M@5*8VS_38=0>,IHS6)I@)JI!]59VD(I6N:HJE>C"SEB5-Z4[K]A]3)8LXN&"
MWHV!2&T<3P47A'&#2Y*$L?&@@06IA^0*XSC;#N]XD9&.+L)PF8/\?8':X6 -
M^A<?IERTQ'B)X@+[32\)/!9,&*^>_PQ&_*E\5H;3-FR.DFRNWZN7+]_&4$N]
M(:D<)6$Y#*IR2UF*).*)..0Y+AV<B7\8!ST=K4B5YM[?#SXCP)!.B2X6TQBA
MX Z_TKM1\116LB-/1X)K&%+MUZL+?E^*.1S  SSYI>#SB$F-\JLNI!4]+KQ/
M =860@*+JZ^#[5:)9;23W$;*P!GY+.E>C#_J)3'CB;P>/?DBB\[(LY)3&'+J
M*?;CQQH)@"K^/=SP7? I6B=5MTY35:YN3HQ_Y:8@_Z2K*RKC)R.@P4%.CGYY
MQ4,9HQNX1(\>80QO 8KSI7TPT.+\8+]*RPF[L.QZ"LZ4\$M9+0EHMW@>GK#/
MC;?O91QN(Y#3W,6;YW%#L<7FL0DO=4$6VT%DOB\WQ+9<-JN^)&F)%4/W*/IH
M]-@)/H7.F!^3&'O),B$JFA! L?0WHZOB&0#(W+9\3]L VFW%#:'-.78J&\9T
MB<LA^SI7UAHA?<N1E,]7FO%.)RCF)F"4V'?XNT[&XZ\Q:F'M/,[X6?)F68:!
M$W*Q50XBQ# -6&Y_[JO"5IM0PZ7>%27MFL@EON.'8_":'8\@W>U#%!-\V[[=
M'B:R$W&$:.A,1-K./TH-1$I;88L65FVJP;=&(XH'?[7J:D\"*,]^T77DTP23
M]2>@?[;L(% 35<OQ#]'J,S9"^+@17-+#:7R[UHVT4K>?MY/?[<E.5V(-&L^\
M"N'NP1[KJVSJDL)Y1V<23;T%\LIYRM3_4X_(Z!XV&%A>?=/2OVC,S/0'6U&H
ME+% &D-(N*IWA7G$T8BQL'$7S="LH?R-E/>_>70J[Y_*^Z?R_M"9&2$+G6*)
M=U:L#)QZ0D04S?D@,4*2>A&PIA0@=CA5T]H+\9TV[#Y%L_.I@H+OA>$K*Z/N
M3;B5I'?#RODS.5>(;!2Q@LUG-Q(&R>7DK&=ZW1"C97+]$7[U+N3KPZ);7R0:
M.=((LUZTU(KCT?ES^7SXYP8NG!QX9 ,5 IQF39'0D:ELBWV.<9G#\^&@/7"&
MW]@ Z0]:)4U*U#'E:F4*5PI&M@;%_%9XN%;$#M88ACROM"3O(U>IH?(5[V1,
MY#;QS89[:!VD0'Q6U#)'/X?CJ"U>N-$1[/ILKXHL,RQ#[EYH%6P.;YI3QP/
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MC,B+*JS2_^USMH5KK5.(@962P?-+-\Q<\V%0U$0]%6>6^TY[W7?K^I:F7&\
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M& D RT5WE@/C=S$\GCX5&)=H,!.U&%""<>1L&YTG$:U]-K$*IU9 .%/DEVA
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MT@%3.F#E_19W/:?%=":!CMMX<DHPMF(T;!R%Q&];// B?A:^'7:$,(?$)>Z
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M_(1:GV+B3L11%#JBWPI_VY<G]-P)/??IH^?^U7E HO-M)-4:C&X3#)^S"-G
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M2)P7KGS!AXT: G\,Q0=!6)T. 1W!QT9E5^25.]JN:I&ITMM&,;J\&J[7MOS
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M=A:#S449DZS_OA-7$W8IF_9\J<9F'ED(!*Y*$8\Q!Q\"/4C\ R_5M<>/"4E
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MJ]Q#Q"[$R:T4[H,-(:U6:!AUK81OP\+4IC_V".@=77NMSW7&8NT?3%\XB?,
M>2BY=+8I*6%0>[ 30W 0Q=]B9P.A,/G8M/4(&,EJV,-;)9*/HO<XZ[PP](#3
MVC28HJ@)DXEVSBEA4H' TML60'0/BM"+STA48"OEYWY]\,"*-?/&D \?W4E7
M'B0DJG#]S4Y:OOCNKQ?D[5K;=\RV0VBPZ/S*Y&1S'@."9 ;X"8G:!#>_H6UU
M$-?==2N+W:9?CZQV([<PP-H87Q/!=F1BVVM27A.,OLB]1PQ43.6DHIF0O1\A
MDV(T-#.(,Q%!N7&+QE[? J7J$,=KO RL\U1?#/MWW5.Y?EN2S2R2&9"&\[U
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M$1_DY4T;!!3 7%G)@+U-T 8Y\#\-N[]C-8LTHMDS2-5UL:4]<!VF5; C'4.
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M#7.Z4\F+["F,A<U5G*1_:B&3640B&$VP9<DC(VO/9XTS\>Z=AX<2(3SO X-
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MA)(XC53!PC@O_0%*Z35H-Q# =<1:)_HZ_#@"^-\F('OMA,U\#M!+HQ!H> S
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MZ;1%R0OQ>SADDT8NSZ8BJVUT:KA$][@3X$C3FX[%3,/;A(GA2!_0G!T6+C_
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MRTI+1V2?):GT= [DX;&5H8-Q^B!V0)X 9P0[%L)8R<<UAZ6".%'/:H0?_RV
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M<ZO_\?OJ_[ZFNWCYV=,P&'[3^N3-'ZS\+M5J*"K>&*$5(C"*EK1+E"2,,5$
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M2!N048I?NL@7,@41 M5:]H>(N/A%(%G]8-%U2XJ^R3,!G@6VQ4O8K*>2NYT
M; 'LJL<= VL[53S[B3 QKG5BGK[L\>N;H__LH8^RN>"2(?#-3@1.<DF<WR$W
MQ L1_7,D+PB4\L,!<V3R ZS[3,:S4;LA.8":U'K"4)7<9XH],WV].!VO1%%P
M];QQ#3O ONJ.4AMF^@I^X:+,(V\[=_.L>$=D'/(8#,:2YN 7;NN(E4>>X1/Z
MJ/^/CUGD#_ 1+L5!B.;6.\@#_A;]=!K[77B!^!UMJ?\U*.PIECV7/%]ZQP+,
MR;S=71@#N/@&[]G>P"KT##:#  \M#P409E/WY;='VS9*O*HX'F6F$A.A>=SJ
M#LL@+&%*144@7_]" ER,0,"SDAB'N^R>"%XNO"+:VQ4HON@^[OR/$/ Z T=+
M0-IW954K6+,:\F#,0$=QO7D-G%=ZI5U5CX/+[IJ^K9,9<F6M,!.8 K_OY]=5
MD+1UF0F&$ SWY^G+@#,F,A0&<,H=(JS(WJ&)[-16J\Y;Z]D?K%?^?Y(F41Q[
M*7?$]0KD(E/AVHF:Z\T/C!+39&8*[!/L;>[$$*-1VBPBY!5SH1$!BH_P:LAD
MHNA%P:.N&$OI^D-U8G8.##(KRHM?TZX(QR!/?0M<$.Y*&' GF 'O0KR=8GA4
M2[-#=447HR'>#KA4ME*F^9BN#-T7 QZ$,";:P[5W:];R)Q3-="P<M4I L_;X
M.&0__!>$IH<@@7 G;^&/RS./RAJ"' /^BZC[.)DMMWD)W#^#.,]?(/L!?7WC
MR1L3H,9\.W0/488N_*TE2M,HQ(*2$Q\@Y#$Z2T+O?.JL>/X7]"AUU:!]?J Y
M<]K+\@IHF^=:\+3-6<$M9-8I-X"RVIBJ*"Z6!P?.E'0RUB[^-9J,)32_94WD
M8[GM6J6SGS+7WQ&<A7Y'S&6+499APFEU%"D;^<P_&P(<OAX"\N"^[>J=SR?<
M M QNJM4%:B4KT=$^P*@72@E>"8^4+C+\RH.-DO")2'C?.+<>IPP<\Z[>\DL
M4MQ\0-Z1^$X_,MW!0TCZG.%, ;./ -:3.V/(>!KL_T*G?EJ?G>9_=_[,X 7^
MRZ':^2]0%OGI1R\^_NSG'P!8OHU'S)H\\D[?@Q[$']8>Q-J#>/X]B&?(O)49
MR.$9'"B;\X2OII R>TCO3>>_0A*.C+66;#^HZQJH=3I2Z_]1$T6KPV!83<KM
MH7)WSBCDX+385T'N("UV9 9[%^;/><A%YWE9XX8'><]A:IFB]^P!-044+* /
M@RI%^(%P;5(J)J2C/D_MGI9<[.O("N,7-3L<ELR\T9P8Y$%\D 46T)%MG<ES
MA_)-!#?[UU:G]1X-9C7HH:D<'YZ,G:Q<PF)#% X<+F:!;<Q_+((?5EDMI*P.
MT[#EEC*>,@FE^G+OAC._!%C$[<+@-JNJ\!N+$8A_=,PIUPLS;8_?0K^$_0=%
M'+X=4E-6,]1%5',<FUKFKGD'^W@W5BOK<YC=XSF]Z5R1;N+,^!SGXOD!.L2(
MDCDVLY^+$T/\FZ37.'OW^:E?NA:7RH38,\Z8D6*+JA. 9:)E@.4Y<02Z,):;
MVYBD7R<F[G<-Y];Q326OYW&#K'OFFAP6ZKTZ05AF3'\R717R[/ <YNKZKG,%
M 6RLX!]C\S-3N8JW'ZIVIO:LVLKS:OP3U=Y^N%B,-(X?!%BR3=L]A;\O/_O=
MR^+%1W\D&_W=1\6+3U_.ZZC^F\MEU$()DHGWB\G?+]R,<1NVQC^?O Q#C,L.
M)9]UQI)7N 1I<<=GQUN.5/(I7R&=A\(*C1O3__27B*.^_A_B']+M&9LDLJV2
MF=^4TCLE"*GVTA#U7WFJD;ZUJ_Z$G4[Q@3HFKO*?*,DL1F"A6MZY<# 1M:#^
MP40S"?:^12)2<5@"F@BBQ4E)Z[WST<FN%?JQ&BD;*5,%P&,KQ[6QF+F!KH:S
M&@X;CL*%^X)=S@[_03.AKM=9T< 8,02ZC#PT#2PY^[:N5NSZ:E_6,14A%[,(
M]30S2^4.PF0DQ9GY2OUJ9*N1+9Q^Q=)01**^L !*L,,YJXVM-L8V9J3"@FTY
M @ \R' (/H/2_WEDYL49+0TJ(+MNO(WUXORD(@G3+?([OOO4[VK<JW&S<6LM
MJD\;$+_87*T.\JX6N%H@6^"!1F%LTJIC!Z8\@DHC(5^9:<:44-(J2S3;.+RP
M6MIJ:5+/V_4_<3HF6%52NPL&&RECD\S%&.QJC:LUBC6N4X"K1?VL%F6SDX5C
M43C>MW_[YCMT>[EC7)F^19FPJ4D%!N3<*:&J_R_J-:^3@:O]!?OCH]7USW86
M\"<#9]\#..H?5SCJ"D?]K<!1WPEI:$0P+I)TIYB0:I^7,G]'DNZHI6MYNC,#
M!_W@DPHW)>NFH1;H:[A.)K&:0E2#9U-9,H%#$NH!^U+(#&S92=61Y3BH2$@H
M.R)N'?K<+;&V?01A"G3KPB %?\G\G TJM@<(;3>WO!2/)Y_U%[6/V9!H(H$O
MT:K<E$!1]@S7? 0#[1-!PW2<VS[));BB-Y-"E9A241%;2296QD<.N5S$C"X,
MMR^57Z8:XHJFI;="GY+$FF2L+P(35/X"M%;4CN81=X4'&NQ+4*2EJT;H8$8/
MX;)ZS;OIU4Q4:LS@W0,SE$ \DDK 1?(X X<C!\1CVB23C&U3Z,QU)U/E\C71
MZI3WG0#L)N-64Y3IT\\EY^;29OATF3C;.?''N>^S!BUG.B2PX$/.JILN0#+R
M%JFQ50$L;^ RYJ48B71:34QVF>\A"+3[GUF^<=*PQGU[?PO:!P@MB/)<#0\O
MRLHP@[S0[J\AK/Z3]0Z_2$\0@:3^POJ%/]=\2DH=49\WD45!]J6AB%2QB2>=
MK'B$X-GEAYKLGL'?6'VI"QF/J@>@]84N4,'8VF68O<*6EX1I\J!*46N40:"D
M$#)1A3$C\;D'\L]YQ.G@PZ/-O_Q7^EV0.K/GI%$VGDZ1Q-:PCHO>.!Q$R4D5
M6W!F#D@H)Q)*YNLIJA_# ][=1,EY.6B)HZ$]MD-$?LOO5L/%[ESDN4 @*Z4C
M\' 0QMM?P#_;0EB;G]CE023Y229'R&%]GA"G/]^W]ORE&6COIB%X0!%O5J,N
M#+W0@+*.K="YT+4U:XX?)63FV9",CHQ*6I4]QV36=J<AUX2EWEOCL>I[X3'8
MDO1(!!2#1:8<WC'85F6'^64BT<V%+P99!IWQ#[<]H1(W)..I0!-V$G6>PZ U
M1WV7^ 7:SI^Y2R1.(C%4]CV^1.?K-'.B%T\6:Z:A9E-TLU&6X,YTPD>CUMPD
M3A@5"H%\E M8&@&;A/KQ!U&?[2<#$Q2X\AS2CDAM^C:?\(8P1IDU '+I^"0X
ME-WQYZ6N^3E/9DJB,//CWX)NVL +_OTWKW[PP086I>1LWQMB+RJL?"SHX!6=
M.\#8^_T((J0TRTT2>!6"Z.*;4>TY8DX@'BV,T04(3J@@P$Z,/C!9W>1D8_=H
M@$3R&T\]G+GYIHR*O!\5X60@>@U=:[NR?C'UT71,",(U/ABGE*6NK_S+V+XA
ML_.;.RJXN(W_2T3GWEO44!>F^@>$DSB#FOW2/0B^X)'XY$/FLZM$+FSJ+J.*
MAW^CO)UIO:$6B^@<^9U/"QP[0YJO(K%1?W7OH=H=X0JQ_7V:QQJWK*.+%6['
M/M)<\+W2^SQ1E#N];>8@PDD@G#3:()X;9Z2/R9IG</3\<$5BFGQJ\V-D4FT(
M*U8[(O[:VZ_1%"VS\S028N%MTT_MPIAL..W$E2H^+F._IBQ&5&6Q J>6A*=%
MVH"'V_I[2K<'KX7JZ1Z=&^3]QN6*3"J4*S,::8M]AV560S7?Z",=UEW[YODZ
MN1\.6<48??$N;)P+H9HM.Z(4A[+;<#BSON;&Z&M2:ML<G!0.QT:DE'G,.'^*
MZ0')YQ<?1GM3]XLE1GO"2;UT$?$=SK:Y"' ZI9P5^$-&P44M98AZ@--G=KIG
M#D,N)Y"E_(K>.)@ 5R;\.W-]5HW%!S^@2<);#""['@\\B:]FZ%1@^G#0EULW
M4DO2T!8PT>6_9(2;",!(?E7>&^TC4_..9;*E[$#4>LW7N9RM>,/1Q\K"RT?_
MR:Z4[-3RUDG^F7$PC]D#- EM3)O$&X?S"0\/\6<(R%*D;E5D]SZ^;.]5SHG,
MKMDZK6-,ZN5\VQ-!J5G(4/7I;@NQ/U6?3C1Y,Y[\*VI&;^,X8C() U<=#!UB
MU?L#4=_L)$4PJX!;K.@>:$ZX$MWKD<5Z.B[92V%+2J*.+ ?1C/_V5U*M\P?*
MIH4P^D9($NAE[3BWIJ5*)_/EX:]S4;F\$Y*6[9B'*DDEB>)2XZ0'=7%?:8-C
M4G<SCBAM)N0JD:'2(<87W=3[T@K^T]H*7EO!OY56\'+HQ;5U<Y[/&C9,EGDI
M*J!#*H0F$F32=6.8CJ-TJ<@2@::Z&D]4\GI-3)O$4#D+UL75]7JR:$T)W)TA
M (@UJ7(HN4S#B%=6_HRP6:)OS#; >?GBG):L:V1;97H<XO%1#AVZFB:2LU01
MU5GMF7/.>)%$Q+V%:"HRN 61:H/CS23EFTN+2#V<"RMIEXBIBZ>/GQ:I@\)]
MJU$ZDWO0U:8ZYP++TWK;Y*D@0AFBMJ78X/O\.Z/*YD*T(71 V<(($Z'N23N\
M%0XD)7[1;BMUK4%O:S+ W"8BBZ/0R1#,) DL)_NS/H$A8X@# X6A'&;,!<=N
M"82CK_R.+!>A''S78,;D,H))725)<N1A*F93:AOO<X[MCGP+QLG"/W[@KF^O
MBP#^T!H Q^-<U(CJYN)R8$#$X3[NT.K>G=K*'Q@?%LL+J)='E".4[Z[<'B:7
MKU%E@*F"SQJD%UNR':TQ;IW@.\S#@M(,Q8.^XMB;*)U"+06U!GE6X%#:M_[5
M<5(0UGGKG2<84SOZ/6FNTVL#GZ_=S.2)8QR7V8'4_8#?9LHDR++;P1!OBD_?
M^F9X@D]4O=\"S5*(\RU0X8X5Z"7-@YT#5ZEO?S_G*Z55VTJ_'.&O68J'N&T7
M:Y!,V&QS[<=)X9I4967/^0VB@8/+G"6MFJP39__7?R?3_OK[OT:W)RXV-;6E
ME(W;KV#))E1.&S+TC85FE)/-4E#A$!8[_1?*9DE974BTS.G)N_"(QF#(:8?6
MVR[[,C[L^/B9-9>XCAPOD)6%F&7,?/5UQF/=53-%R.D9$NNM=*KKH:$<E?27
M160XF-![3TR/>M?E5@BN%\R21\KS6V6UV=5FC6*4#W# 5HB2LP\J*; )E;7]
MS,06E78SS2S)[H@:4Z1+%OC_P&_4>>M2NEG1RYG\LEROK]O[!Z\GJ#SZBT9%
M.KKVA *P4>1)?Z%@'EY@^ZBXSO7EJ_'$)P_8;5%')Z;-"[^^[J]U?RVK!">
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M!Y;._[Y0N)5&ZG@:,7'0@G6;TKOIU$B^UQ /XTE/)ID92-CO%-E)K76,KT1
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MY>ZDAD_#8U(1514/%L.14FR P">$EK1/:?P]D;!0)A>9ANJ%V4$F19E[AP6
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M/,#UF+#%!T:(QK=PCXMS3Q* \63^X#_@^"^8B0S1-ZEC%1OJ4ZB&IM"ZS+8
MGPH^U4?(J*T-H8,;'.F0+/]&X*Z%SI?V[OIY[+#NLW6?/8-]!KM4AIG>N3<V
MZ#F5;+URBO30#=VRP"Q*FO2O/K<*Y$D)YD;X*S"+'90']RI@Q[0N=BB2?HEW
MT&J<JW&*<0JC_0>&#$C^BEQTI)NC?'1*VG;CI@WK5-\HT'(&S_]AH8SM[.F)
M>]"5/5.ZBKP:R9#0?_%V8#KH&'KI-8Q&6Y1:^F#*NJOH7&=T3;]%!DXIYU=R
M-KWJ>U064!:$KHH5V?F"2&>5W9CY[^B6SQ\6B=27OQO_C%UR#ZHC5?LDJ:\C
M4]Y4E^XQB\?O1/$"_*,?%O;@]-<$QP(A]J)N@2[PN_W:>GZN+NH9N*@ D(8"
MUI2Y+'(Q"K.QR$(V49("]3,<F5M@74,H&J0P#-_(:O&KQ3\'BX]4<%*Q T_Q
M(HLIT=J5?OU)Q9BJ$OQ9@,#JZHY8=.B$NJ,QP4U)U#.KK:^V_@QL/90&2#9D
M>P[:#HF KDS_J=)H%'V*"B*D)-Z+/^=!P5W@4;)PBO;&KV'0"=V2T#;S:#)A
MIZH/ Z!I(Z+SNF/6'?,,=DSH'B)X2?2;J*MK-;!C*VRUW=5VGX'MWK?=&Y2:
M7809<(0>4]Q[(!$DH!D;Y+KH?XI^[?'(:E!-D)):"[ZKD3\S([?<&YJ$CBIX
MM_GJ\^]>J<C ?UYO_MI5-ZX[;UYM!PAWO-A\@']"[^6C%Y^9?Z2_>?G9AX4M
MU!Q]8DNVI0[?*(*OFV'=#,]A,S# 'Q6:_M!ZCX]^8Q0?)2 5@&!*UD6P'*KW
MEO=1LPF<X_5YKDN?LH8_@[QVG7)935\MPJ22WHR#*MG$^!-Q>.D*V KG?=DQ
M$--?HNVJ_D@G0%/Z'>"_L*OZ$IV-WG(_^8^[(] GX:CP[YJ0Y=HAI$[!B F*
M'GET 4&CX?#OL7Q#S//GTZ&EV]C74#CF['E?^3M_%G,Y[T9,VEO%Y'<$$#)U
MV[O!!ZW2VT#PS1R4LW;O@1[;X[0<6$B/M0GF.+W$1:,V^>[(1"9XK.L%Q.T4
M^Y@H-01&79TT"]3:<QG!)]4R"=S!6Q705>5"(RLQ$<58D/[(#Z/?5&T0%#]'
M0G5"8D>Q"R,RF$7K3I9[[ >1S<G#S%-)DLR-O3>S/I^NLS[KK,\ZZS-UY\2H
M5W8=J/\NN7+13)?)$?^K=]76S>6"@A>,QXMXCDM4&\E-624L']A4K,]7MXT3
M(#L%VC>MD+7EI'>RDG )5SY?)_I'G'E!@3[0QLZN$T5\PD$IT*\G(FY_'?6E
MK0B#037G_3Z.659+L\?3X,HCC24Q!-0'03E)C\Z=,*K5#&2_U&E132G#$S]C
M<!25[#Y;^HNA[@QK.M6Z\A:*6*+LEVV(Q-FA?8[!+(H890!+XL5DSD$-=0D^
M"X'F=[3AZ\WW;MN-50BEAL['CO0'65$NHOJ C-M>L"GZG+<+?P U_7BD7XG
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M*B^98\SA6GNUUABJ;2U8]-@QRP@'XBRNU<] 5$?BK'*?CCZ4MP%I,+G5$$Q
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M71#Z K6.)R,*9LN(5%(G)GV/H^S&<O'HPK!,M]L$_#TE[_1C20%;?B).-=Z
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ML18Y&E$3L$Q_IL^ /^U\6\:X;HY1C ,VOS:[6_?.$<>*@4)^W(4W;:9SY=&
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M+7Z [)[S8-"N:'98JHF^<]=(%XW@?T=<;4R9<+5X$ZQUM\8< R0< 0Z+@%Z
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M1'V)1]=*N"].1-08-ASV;%O\TQ<F$<IDXL(N[2B8)R\XT3?]O8NAH ;/8*;
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M;&18\#FV=A>ZAW^ 6/A-M<7#;J::A: *RZ0FC\;)[2/0'Y0<CIX/:8=*(D#
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M2_!AD&](3RS!<!@U V*<\5_&+]41<R R3=+W;(S7D,@+1^'G W*\G.)!>=K
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M$6ATSAJB-1&*"W@65$IX]O?T)6@F1N#-EED_]LG\M/#TL[AK'$#,P5R=B3$
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M3*F"_A $S/['>3DO]\1-VO7D$DU@G!M$HUM7I!OW*- &= D%QWM']#:,N;\
M92, 9LA$V+?&4;)N3:.!Q+*M7""%V:8VDK=?+G)IMQ:2&X-)C87$Q3YZ[,\=
MMBO1EL];&4.=(,X&=)6W9K $A\T?"WZ!%L0CG.U3GZF8<M%8[S4'78;H<?8*
MX76U-OH6*F/U0F"$C:"*%S.7&>#F0*H8MY'0PZKA-+]'P\$G !,9]B,R:XF:
M@N$3@CJ_TMMU%(#\?L/H(L!TY6T+\L]NH;RM>!J4SXE8FUX2EA[(MYSW'%R&
M$T=E6V *I90$S<ZV[Q8T.OC?YPXCCL0"?# 3"LVMEH6'D8<I"B8]#"43^](R
M.KD#, <Y+8XEVS4# LRK1<)VRD^A[TSGP*5WV"]23A"L9$_1]=*0S\7J35D9
M.)NH\O= :LO>A8#>)7.K8]W+RTDN04A)]3'[XOQ<@F5HX6\D2>4KYX6Q"[8*
M#_T2'6OX2(;MQKK:.J8NV#3@Z==X %(6U(P$MI<TY\*1<-Q2?Y=V*1A 0"D(
M*R9 '!IF'B2O2OL3/"/SU>BZL3UE> 3X3>!7V(SP=S0'6KK%.KJ'!Z%J'>U1
M53^PV0;"$,F7F@_H*R&[B'U&J!HF<BFC8^R#H,GZU4T?1@?H+MD_G;%GA%0H
M/<16BJIG]#$"3YELC<.4D.NZQE0_'->DR $GA TW6@TAC!^!KBG3TZRF]J9:
MW_]X]AP^S 0H(XKYO7)PM^XX0#I=O1"E_)3^ D\%4 2@H" A:3_<+2D#$EC<
MA&P-\A*9"B7Y/:<W-9NUF\IT5#R/-@\20YMUI=OY'6H%G' 7="F.'?MZ&]SN
M6%+G!L]*M/*,DR1(JG2-K'PBJQBG+SHB66@OC  .$D5O!%WQ'Q;(:-D;LM7N
MRWF7."H9?X2MD5C@?KLV7'5@TZ./LKNM^+EXWOB*\COU37B[RBJ!F?IR6M0?
M3J7NJ=0]E;JO[KK]ND9DMT[B>VQ9-I.YW6/,^4,C9%5*R>J:,CH(HK(:#S75
M3WE7Y/\D<R[U".?E4E:(5#A\F\!;])6;==WV[!+CR#+E T%YHLY7#N&O>XK)
M#+ZJ%\<.K.T)<-!H%FY0>FI' W<%\V&4?"*7N%2)M$:HY(4TD$-X@<"YW67K
MO?-. -F*C*9*>SC4@[]IZBI#:J.X5]JS!T1H+D?YU' K,=;)%PVEPYGER+P/
M\K9Z1Z2&%L/_PH04B1\.48IIC-QV@<^SFP(AE)#CV7<"12QKY(>DA@H'  V2
M]DZ:_#X(LK.3V%).C,B-KS8[J?GJX?$)(#GK<K6QIZHLF 9QQSN6=BW'2[2I
M*ZR()4F+K ]%Y'H4I@T:7HX]H9I=[N+<%)N*7A^$L] #(\T[F*2!5*,Q\J:2
M+6!VSYYOSC9=3R?H$8$P40KQG1/QGWV28L6N[@#A"5$!Q%@]0T]4"R%Z\825
M2#Y/"C'*<H*NE<*+!A*%#39X"ZQ;0B-PU]%Y.3VRTF!-%5[ _N4,X8>M_N.C
MD\SK5KH*=]!C(@L3.P2W]8U,A;Q(:)EMG<J*%S_T4.E6,'=,6N+\86JE,]07
M;^,+ABG!=[L3)+N^3'(M+Y6 /(/WX?N7RJ5\MLAV7'R&WMS8Y>B>'W-\;HC+
M(TB]$F-I6GX5'8;KRXKH9"4*$I*J4))ILSMJ<VL%3M8HT10=2^?_90*O?BA?
M'<>EK'!3IB23/W*@6R['G!2G,YWJ#QY+LY8D_(X;<SAR%?P61K8 G21:G-O+
ML*0ROK_PD#U (.W5SAS+WC\W39]+#W%>4T[&#^R2*DRFO0AE21T @<NQWFX"
M#_.1_>$(LUC!1?%.,T0HMDUM0_7YI@+G2L)CTT$<6G;G3"!B+1&]&576D$P^
MW.J7LGX_>WMN#"7*X5<_OWLQ^TZN^AU<U?<:H^<I?:)5^9XJ':0U6Z'"F)NH
MPH2*FPHHBF0XVI5#WL4SJ"%@B@.KID(P3 =*EPHO[#Y@Q6%%_1^MVO@,2R*M
M#5:19<COBTR9=#3#7,_@]J@MIU^](^+=#_L*K8G$%%J@&"CE19-E*).P-)>
MP6B;]SAO/:]$;?/X!<IBT.X$3+Y[-^=X]KSJ&HVE.RQ+,\!22*%E1.&DVS[X
ME'@] $S*OZMC0$7XD#<G@/\P!\Z@!=;9U *KT0[Y%I-4'WR@/>Z)")$<%W>"
M_#BYT;>TG/#S&.Y5B%2:&AN?9M;"V^/=JJ3CPA=//%32?T6R=MR<Y[.Z5EI7
M:TY'CB>@,9/J^,64I%VQ#D&J1E+_E.K<(Z%2-2%<"=5+F@$F5:2A33/LQKR5
MG@9[R'A]*PLEX0L@1RZ9Q.<CHRL1@I7BSP$Q#L+-2-6"1TV%]+'\_;*LU'R.
MMS^\R+AI,E.=E+B-W!HG@WR3O&D',>(GJ<GM!8'+%UK22)M8'[_B;#B*  4T
M9G8&UJ%&ASN,P!WM"R;Y.4$Q>I9<CB)GBPM!!IQ$Q?7[QD9VW%Y^?WYT?Z06
ME*$:##MB@17&7F]'"1K+^(B&[\'4 1C+'59RAM0.#"HYK8TZH:M#?4:7.?P<
M9)]U1Z1BW9%I1!V]LU6>K>D>X"R2G%D=X*8[$TI>7S-&4>SPDW>I/A0W'V)^
M=7IRHCHZ$:N#K;Y<8$<[ZXD?HAQ4G-S+-P6, H.*"'AHN$7QP7MKF"H'Y.'A
MR4,YC&_S=IY;V3[Z^4-EME0<_*-4?2]%R,.T_(XM"%T,YO0*.])#(?1&)BY!
MENQ6?4P-&,JA-EIJQ@$H[- $O #JC0:+'8X$T-#CW:#%A*YB9RWEX!SFC+'_
M1\CFJ$]J['@P;@),C4#N16H!J].34!2&"J*+TNP?BE,*91Y2H#05!C;!J!S/
MRI3WS#EB5M('[?VR2Y._)\CR6(T8SB'TH0TQ$YCVM->$0 4&*^@GR*Z^S[3!
MPH!##NF8<^TB/&5\._OL;J(5!2I.JW*UP-I(!0-26$5F&,.%DU&^9&>9<+]#
M/#0?,N7NN%ZS+Z=(^6@J4DY%RJE(^1FZ]5P%C."'!,%V!9E8?6-73@ 5)50B
M$,A8(PR^LU<[WCU+].4XQ0B-1^ PW&S@]$O; !XUW5[@"G,=6Z4XU7EXY'O5
MP"OM_;EX=AP;Y$O&E'5)7.2ZX9P3&2\G*D8021$_W880B/XE7_] ;V"L_6IC
MHQ\>%#?KMO8EK/QMK-MN_,@NW"'CRI<\E>M07T207LIJHA,!'Y"<D'MZ@JNG
M[]&-WZ2D;L;G%%.\<=?65)1'_\W]$^R*Y[UG/\(@U+G;UG&X2O3P/(EFU"5C
MF-Q'88VI Z^^:!8;ES;!Z657?'!K(O#J42_GX$94<=Q>9;.EQ8_=5J8/2#Y&
MLT:_[0KO<H>TILLU!P=*',$H5":03M%00?#DS/#\L%]KHQGWS&&T0^N$+CCQ
M-AVS0!$$2^H5V&V $'OL].5Z4)Y/+6,Z7PK0_0XL8R)(NCD2__3S@2+#UZSB
M#3ZHK&^$JF#H8JL7,*8$TRS//LI9E9VSFB*&*8.ZIYWM<$WG"G@"*<*228^5
M?.#8;=N&\<;PSV5K#Y95'NZZM"?(,+^"Q(8]V%9K8I:M,"!D4N$GH$F185%[
M3<;6'KY*N.V)CX^B;>2=,%F*:3N\KT_*NEXASV]OK);[SBSR3><BNK(^)_X1
M;(/Q8UWAT<(K=_A(RIQ@X9/?J7X$66V\6/TB.VGJQ=W$3C+81[_W6!'QE*)J
M-0B2D+,OPQZ@D]!?@-$+?B[2'U]%_P3IDRLEOQ"^X&@;%8#GJK[L:.8TZO 6
M)Y=5%Q_V<7^74TI0J>!NF'/@Q*K3R8:X,RQ*+9!^OTXF03NG!V04;FM1"U2=
M?<E@T@UJ4^S$S#%;!JD\A%K0._0O0Q=IP7<:0\9Q<U]Q4+H:FW<-:(\Z;[=J
M7L9HDR.U=OEE.4I@KQ6YXB7X&D;,D3&"-D4])]@-*4GM1_KAK_" -U^[.ORQ
M/O$[A0DWC)>P2G7C.$T]@WS-!Y^UFG3 E\"!41?(9G6Q/W<X$(@@Y9NF!5*=
MXS3PQ7$T7>DRI(]\T9L]8N3-@5^1*$.:%Z$0^&=WL KBR()/\&QTMVE[?!$9
M=*JJI:GC<)C\Y\&<[,]\&O"Y7#C^!E%:/.OY,-G"OSIU0=>#957Q55GAT^.Z
MIU+?C;^PZ;@O"_OL97:E/'I>_&XEF"W12R$J5MN0S=85ELZ[CYCZ^JO;]%_L
MG5_BG5\XE>SDX:5[#Z_\ @X@UG_P\.$7S+8]IIJ*AGPBATO>D6<AJ#\0DD$*
M"A &KFG:49P,:+IO7H=+$9\8;?G8=?N>DYO#,. A96=R1%-U6*_"](0PN<!5
MSMKFTCJ2>_E3'2@ H!LT8:#'<5A1$WHPN53@3P"-!7RUJRKC,JX"-!(7?8M#
MRI"H&&LO\(4S'!,@5QUG7K^M,OZ\)ER<Q_&Q9SL&-1NO5.* =>9TDWQ&<ORC
M<LIAFV@R<]F.X5,1J\0,WK35MX"]YQ?=$Z!R1:U!*XR&MW8%;[6G_B&U2A%A
MY<E$UW\K(WOH&?05ZQ[&(1T-@L9H)W>WO980(%6[E@)PQ#H]4 .2!U?!-:;1
M\6J>MY<:$(I:6E71ZZ/03)$]?2%UTJ^G.NE4)_V3UDF??(0I>TDN!_%6>J+[
M.22\73/F8*(6)1</P(J0/D'^!<SIW(#]>:+3=?ZA"/J^54.#QCQ74)N4>*-H
M%SO&D*)0.L#H$P'SW H2XOM9[A>)20FA^:/XD#!CCK@(@V.(89$?*QIRN#LT
MJ_*UC$P+VWBNXMP%>3K5J2B&]( Q"!D_V5F)X]@8=<Z^@4RX*Z+P+U.M#'N'
M,5#%.NS*W#OP GE5Z?KA8 JYT&976R]7/=C+23[:OMEE([G9:% &YC&";;:_
M[:E_%=O:/N#^5=N/GZ!!_SOB(I4K8,"E$6OAI)&Q+3J>_1SWU"X"@K;/N7P.
M2A8P#LDWL*"'F5<F?0!]E'[ZY(2N5EAG0"5NN+LU%H60B0C%&F8*N[)*91_W
M:+-6_.B.4'Q,%<D YAH<YIHJ3,+L<06-)I?!E#A>Z YA2JF/<R"WQ'R3U#V$
MVE:-1-#6<!?:<2J^_F#X>>*="P C=RI$!J&[61^CNE0?V;$&[>NH@LR%L$O[
M?G"$8%Y0M4XV2NU)EA2>SQC ?HS1?XZB.W9"]X!V4U0S:D8+*< :=K9*].<2
M.=RY"5F]N5;;1KUS9;VL<'@=E@:IS@H-!7-DP7$S] X+@+A[!SN3;]0-^57F
MJ(^_ -C%I/6(9_F.!,9:]E.-^)&J6D?T"ON/!L^-4Y\;S7)]&L%QYRL_.X,&
M#"B3Q].B/H_IV#]!:K^&F]UIJ)G/KO2(.$<+@@/>S7194W0YU-1=UX&C9X+A
M"CUW&JY*.@#9P ?ZR4 K>W?.GI>\<6:YTCLT^^KD\$E@S]&CA2M^=5^-^XKR
MAZ5C$@U>(->"%^<-H-"1 :1W@_90WVQ]_ZR>@?#'JH5,=TKMO$340V>M5%ZV
M7=1M,-P)V:#MZ%;0+ASPZ.A/J&$MX4G2?"98VF?% @S73:6X7(5@%[GE B06
M%)VJ478]7^5"/GTH\2"VM89<C?=Q+AIJ9FPNT>!0U%#E6SU; !-H 4]_ND<C
M8.DDCV&0*07LS6?-&W^,V7TE \4]*ZFT74MY!+V'[MQ_H)'V):I]RM\WM:9K
M3GPVGX.#DMK(+&(;;AF."/Y*IFAB*"I$_<!Q(K5R1\'?35K2=^<?F8$7#\\=
MJT+Z4-0;*EP#'DK>Z"N4=T-;7_:#L0O'LQ_&OHL(PXJM *'2"&;E/NKZ]J^4
M4E!!RDYG YLTJYQ"_N$]1X<#[4/T8'LBJBJF[:)\-WJ!(QOI[KH+1@I;1 WL
M#%)W6#\R9KRMC3Q[[0G5UV7-\#==$(>D.+]F*E=?H_,L1"]93:^GY>XX^9?U
M&1 >J+.'-0 8+4!J3I]VN*-]%BB-*WICK$0<=+L%,4CL$R<$ZTFKA-=*= YP
M' UCJ=IJFVFNB7%,%_:L2_,6;/JFK8-\8JQ[:$"75CU!(O$VJO@DO-8'/O.V
MR0O-L,1.K8)J8KG;==;#:[1FW.S()3H7#M&VIN@\CN*@;!<1O0."#AT 1$D'
ME[-KA.H'X1?I[6V;C2OH0_9"^IGQ<P&+=L!5<('#S.US8%&8;LHD2#=K1*[R
MRIR6N:&7=CS[7[O[LK^T_0Y:.JJHW%Q!/PU(K=^M0BZ[+2'_0GD?/*?VP>.7
MMF>P"+- $M$:#07HC&_!]/C42O+)8*+L+I2L"G2O%0U:@=\R_('YZ_U&#M&L
MJ8E%_%S1Z'!X0H5RJ+D)0I[4T[34:.MHK^@]A-8(LVIK4)*;6J9'.8\=+NK'
M.]J[ &*\1TC3'B.3DT>H>U>_",V7&GD!3_O3SS_:AVK;K348ETCSZ;O4^_P#
M%J1AG &/H<"^,PQX-5=Q(K_*&>8_5)M .JU3)1CK_5T8S\-X[J9&V+_QD'>&
M%((\V* )P,CC@%J/#Z#T/Z4R,8$MX]E]XAJI,1A$)*J=  S)6? 8N]NM^]XL
M<"@S%VA.L4#S4#\#4#<5,((^HZ(27AVF>%:)=QF7(&9?/7C\\/BQ9 RRV5?W
MGYP</W#T$G"MK[Y^='SJ/\',)Z@<CH-U1%<^O7_\=7BAD^,G>A0YKYN<7%QZ
MX-GK<4M6P1<E\HZKNV?>G,V-0Q\VRV4'P0;/V<H_X%OX8L 2CR>PQ 26^-.#
M)8#(=66.9[]B"4O\K"J_'.94?SU^>^Q4B=5XJ.2L\@E9<EC+@S+./_AV52CK
M ;;1;M7I$RHG<@-CB>!D^_N'#]#] #6_Z4O$I4?$/IOK+O+^(Z5[=R]2ZIR4
M-+"K?>P&>5D%7U*7 .AX)$I9 JLI:L@Y9YH*X$WJ2[;U ":!K,+00)2=2F#/
MK"TXH1P[JU%Y+Z^XR4F2XNB?X5<N,0_S 6/Z"[L+S:8CY<Y%)ABO#(W2 )OE
M_; [EMQ1[KWJ9@^>W,?+/WCRP#OM, PUWM:K>2YHJ34!G.-2\JUX8KZY#W'I
MR@"+S6I#)\,-]X!9;C)[#"&/C%CW \GHDX(QUZ6=H,\,GE<]Y^S,U/"$4$F!
M!J\NSE^$I,HP0ZG9K DR%*3ZSQLJQ0AEU]*NGNZX-NV"'S"7SNL(+J2CQ;)5
M4];F6UH%EH@?G007A"S&NBDQVN+8S'ZW:BXQI)5+#+["C,C6AVR8@-+J:',$
MAX$[/?;U=RBGE@XMNG17$)%13X*. "9 [#>JDFY5#OSAV F.I2"L'N4)/W5D
M0+RPETO?G!Z4?CQ[:^]>V6U2) R8(<0XCQ$!Z&OAZO/+':/. .O>1<_-\]9T
MKVK<.>P'0?'.\8[I[=J.%8(.:%]S8S&%W=!W(<9YT$_;??H)([)?5=;PK&KF
M,)7.OFL;8"]\UY0\V-5&OU]KR#N,++])MLC=*1_W;.G%[WC]H)Q8>^I]9:4>
M[+S0Z.J_^!VD9#JT9,PZB-H,5<D:9*<K_,N#C+%*GNI^>K"&AHRO=0[>=P=S
M1P:* B@ ##:_A1S"HU=)#';=WR'J#^DH"^\E\$[#""^"%\:SAG1C@]TT6+;,
M6N217KSK:I03)([V<;?Q0%BHUUH?M2OGV*T/N\ST)?@!Y$QH-VLF46\/0<5:
MY=M;/45X?*J$,M$RC[#L7!)=1H73<"\VU>!'GC5$M' 8;6M #IH&<UJ').S,
M4G5?S.A"9A?SOKWN<G*ZI,)P/&IPY,K0#D7#@]>#"MD?HDGGP?5#I?D&3\T;
M/P#N.YX.]H**3)7?N&_OS6]&?5T#Y7UUEI9<RFH5M9D[GE!AH#9YK9!$3*O_
M(\.KWP3T3)GV4QA71UR;@!KE$B1X$"W(!9RFF*[5><3[F6I!N8?.ZHCK(;EN
ME[GM<LJJ]>P-Y4 *4Y 8Q%=<A+S,>1O2$X#_,K;"F[1\SZ-NXVSV\V)CC9>+
MFW@2N4??,)4Y1W18Q=&8#OY=&@)U<.DT0A'M$4P.>8;RZ2<CC8EI4GX2TZ8D
M*T!I_]W?RGPX Q<@3:FC%8EOX[T3LYJ&\90*!%MC[\%%62!U-(9>V*15RW!?
MQ?*[=W?DL!'> ,<[A!PE5SAL =YI<$M[/+Y!,2>;+?E%S 4>X43B=6>^D1^>
M?0)U?S1O>FM@O_&'X*AOUIBGQS4<68MK9?4;'!NMTTV2H"0%V[?VOR)*%L(U
M_W)/_^&C%HQ#RQ=YQ6E;/,-VK<^L_/3FR*J(!60$+]M\_4PM@--HO-"__?7I
MUX^?/OOV7E_H=84?&IJ+ZR[YP%PE*$,:&>.)OGC:  WJD)DP("78F(PI :UG
M6(@U(6\PFY*YQ85.W'.'Q[-?P X]<QH7MND>O-Q[* V38$Z"R8*YT 3N"YFS
M.I14:/HB+V4Y2TKG##G^\)J7+5RDAEP,4/U#@-,"M9WOD*&[^#"*.%<8<]:M
MK?M32N8']?8DR),@[Q1D$<,9A&:U$&(!3@]2V0@8(P!9X7'2@$I/SG6;;P>L
MZ(&8@V?B;N3&1R9\AH\Y3YDD_?.B6?>)4X5$![1\P$A4&_+=P[.FMX,Y4X]O
MT6$ZF0[3S1VF_SF'*2W4T>)[+$=)6QP@@Z?Z(2J_-S4/&:VVW%YWR.P(<,-!
MJE4)(?ZF([QA6$>'PRIFR"(+Y/[64>^2P;J-J1;V-,+.$HSAP%@L)AX9"X^[
MCXB/58)I;Y"A@K+Q$QL !MPY>D("1:7Q6\,.R0A<ZDD\(%X+!(!&K^P?.9),
MR CXEE(M-#>A->LJ)S#HK-X #$APW&%'B?Z.1LVH<B4%H_XU'K6<1ELW5;F0
MR25KY!K!Q.8[&HU2$]*0OLY%)D<SM]4#@_$A2Q01?% :9QI6H0Z;CN6'L.0%
M#.QTO'=(,,PYJA6,$>JP69C&X&$%+AAGG"$UYA'TU6Q65&5#*]CU3-J&A3%(
M/,,V!TENSD2/#%K38X ZJ- !]HHH6L4__-)F63R98$<3[.CVPX[R65G\^U]^
M.WGPZ/3AH^+Q;T^?/GKPV\/'R]/?\J?+Y6]?+T\?/_SZ@<D?/US\A3:"OO'Z
M^9O__N'=+V]>O?CA^4_??__J'Z^^_^&G[U_]]/+G-Z^?OWOU\T^_/3IY_/7#
MI_RESWP"$P9I9^&#5C_#Y<_L^F?R #/U!']PR4.M?2?3!P04;BZZ'U&AS. +
M+BB^IJJ4SQ=UVY7= #'"+YZ_><UF]P;YV:5EU[4@[7QX^X-G5[GOV%7@X2H
MX!0Y9>X]V8MO!X?*'P"L%,K=MX5UW.^S9S.MK;0?_>KD^.'#4S!6E/^G.LPU
MGD0:MT^?\*3V*Z_CP=/[]_5" H+<Q/2'(>$/DZ-QD$V,#DP <6-<X\+HGNJZ
MVW<XE.>]K#9 2TLU:W4MUYK3!ZP"Z)DD&37 JU>;YFOG2/7HHP'GK"*_;F4X
M3%H88B;7:*/ >Z,Z/OY\0SO^O".7+FBF5N+W%C?BE3 R_ (#SCO[J3ONIY^:
M8Q;FNY LV3F]/C& _NW:8"G]-4^8X$9-\(N7FTJF!#I2Z'C*/'K(PH0>D_.
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M@=L2\6]\X<U8IU,SUM2,-35C36;D5IF1E)& SA JJ_)DNKS> /B:&?03W@H
M&@_7UI.(_>E%C$BX'-J%9W[T$2JGQ):!3+"T\)G:G#4]^":S97[1^&8.\)AI
M1#@*D'U_.<WWK4IKFSOF_B+H0-ZVD&)1#1;LH]<VP.VZW+HR."6Z*_GZC7@]
M67@66A590,P"#R \8)/\3_*_H\Q5U@=$PX(A]TQ"\"0@US##FIF'[.<$2 D_
M,S<2MS -=?4DEY-<IB#A5LY(W+ 7:[, 3;C<5 .*3;3U"1> @()A/<TK5\8J
M(",0I$PF*9RD<(=V5.TT-L9%VPHJD<K[F')+2.#<@.BRI08VK&B6 ,WN\7^W
M$E_!6D #ES5(IE6PG &IJ9L1.#SY=%PTU05]R1^.RGH-K;TIIC2&"T(?!G*-
MD[1/TCY,@SL#GRE7%UN6F>]J%].5/C&3D9\$;A29P-7DLM:96H:CKAS$_PQX
M+VMJ:*\AF5E>3%(T2=$ WS)- 9B$0H2B,F=E1SGD3"F7;+9NK'W#F %4B['1
M:;,J%R&'^=QL&^XH1;)TH@ Y??P,@]FVF5J7)SD+(H1449+P*U4J7LB(V<&&
MGR5%H'W^'HKP-?1OJ+ B*L@+2W02>1 U\?ER9LSQS^1)GE(2V^I<7Z$,JY@H
MS"8A'_1W8#"*P29[8S-0IF><S?8RUYG%IJ7I*HO*'HX9$Y+K3ZM.N**$O2-4
M38_%=P\-I/9785-7+4KIX4+G>;O:W>#I<(LY3AMR7$(JD0E9I++N-BTF*W$,
M![;@-O0SD%=P#@EC\7QE_]I]@8QL\*#FK,%CCWHL)&$#PH6^A1;X'.8KGN>;
MKB>(72&?1*JVO.!1'[]O:GK/J'-BHBA@J2$1L5>$C 9734S5F4OX]_$N'C=J
MEZP;(G/C+/(HGPZ3ESBZ>R'&.9Z]M.]VN6FQU@(S5C962WMI8QHGGQM<Y$#(
M-L99OE/00AJJ3%/W(M\Y<5>YQJ@1@BIDHR*5?="5K+FPG^N($ZM<K9%'CQ)#
MYSM8M= DX5"C:%?&#9RJ$8QW#C)HQNBW(FP=QC[PHG<'G3F/J*SK3JF_>G80
M)W=FE0_=K>/!,Z!/^LI^@IG=OBT32 NH5I0+>RS>@)Y[26+P[;WR/X3\;6X=
MRKIF'@A N/SMKZ=?GSR[_S6MO\3BVH>MW])[]M]H=#>@&M8W<,)?+16I?F?X
M5=IW%";71>+ XPAX^.U7X+"MUG2T #^%)[AI@9$_PTV6Q+O]1CCE\BI'9A]%
MVR[B2"*SVT$7A^BMG:\'-9-PQ30U= 0Z?PHR5H>\X5'5532H3C?VC;7HYN'^
MSBNV@Y@BV]A_+BI@.\#;[2:@0_\0F?)&.2P1=:667_/0$+AP0 ZXR@M#[S%L
M;0])%?QMX *U%=6R1OWC.]KG!F9"V#M?6&<7?4,&S9'JRF">GUEC;RBG=[#_
MK<HO/^'1\"<A=I(N2H&2?W->%O;LH*OUY/[) Q_)A?BW6XO4NS\A]2:DWNU'
MZN6SLOCWO_SV=)$_.3'YH]^>F"?%;P\?S!_^]O0T?_S;XO%C\_3AD\=?WS_-
M_T(;0=]X]Y\_O/[AS=]_>//;DR>/OG[Z@/_XF4]:PGA^.P]NR>]TWE0%O-'_
M_&%&R_SVWOP_;L:Z[W9CWH&]$@](?"7Y=^@/O4MP1^SQ>L Q&CL);@FG3TY$
MT'<N==2\SI2)+DRW:,LY^Y'L(5AS@G3#(VQP\4,=S_[G'"8+CIEJ)C66N**4
MNZYIF!:$?EUX?P%W'7+W3)(]3!9/J9RJDJ\/;*J]O_7?&^LUD-7?-IOCV?\V
M&XF],/!:6-^%BKVX8/!U6[-S)\G)1ZH$YYRC=P+>0S$D(1U['O<'PJT5C75
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MYCFQOQ*@./LCZ%212Z"E+E>/7!NR%)<0!H-V9!,#*K)5A;2@/".ZW"K"O>^
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M+[6I*].I_D^[41712IN.//%S:W+Q[1I@P,.C\DM>8\L2=?H!NK*XZ;#B]/0
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M=1NL(CSN;MW-IH?"%0W;%HE)1;^WG_+7Y:<??\%\3<D.^%ES :0#=F/Y+?J
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MET-9(ZO4D&Z]3Y8LX%[C)0M_4U\((?*53. !T7*S67>.WXDW>,=.*LP#'2$
M>0&1>S5L80GI:4$X<L8U8]53R*P7;BX+!6!0$;0G8H%HGEAA(@+!)_I&Q@@(
MO,D43@="=_B>VGKHUCJFNI!26]B^QFKV:1*< QVGF!THF$>P68LXPH=&3(S&
M.EE[\MX(>AX3G&[P 8+) SYQ47"ZXU:8E[R_MG:3R,F(=QZ/;I^U:ZI-%/SN
M)-;^#O= Y6YI3@2#.#55T%(;"T>Z$IA%\4G&-@:13NS-. 2+6C^]$/:";[Q7
MGB*#I\,I/"YIRVHT[?LXJ+.+< &W:!5'0ET'FI2@]1 ?N'R3?-,C&'!D#Y)Q
MX6W=DGS6B(@V'"R)\ER!15.O-U-)K/3C!(-$'*4<O'&@N),D-#6L<Q4!WB_5
M*$HFYH@=-TBP([<+\"$!SU_( D&CX_<\NW5L8& 4V&RJFI\; K5" XO]$G='
M?5LFBFF -2T74#ES0;;P>[S@U_=KG6^(?^@7SC. 0GKI5O+*K^3;>^5_</?5
M'P^QNG__>B&LBU=7GO?.=40F8EBN-8QT0HY&N IJZ*+<W=\/_/)E6=C[0B:E
MV& R@M7E%U--?S)5TZ=J^E1-WXVJ295_#X+5#"AO=]:\LBLE;+,(DF?#[!+1
M<7OT;")F"0D\TX[S8-Y6:G!*U#.Z>R'*$U>[A%T'@;4=G7.C_-+CU/ \SM!
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MIHWY_&>=J<'N*-X(=QK3 ^PR']$8F*+2M1NF,VGTY&7]AQ' AW3VJWY^GB:
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MZ;E+<<PW(PJUM8>BP_THVS7RTZ/>JO5T0S^0'&9UKE/^$OHM!,Y5M,EC458
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M2E_F$L_>'+6;^WDV8=;-WMY^LU.0@1M,@)-GGM(3/OJNI38$;?,6-UP+4K9
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M[+$HMGJ[UX9Y!N=60<D\9B ;G=:2#:?J#'6/=H\-U*TMU.T]@(:./160?#!
MJ.:(]Y2%(RS/KI?!,5N^!OYN"_P]>(8H]D;:\<YN>\_ WPV$OV>C?N!,GF:8
MMX>!%03!_W%'(Q[2J7H>JYID^MZ"93AJD'$5],^C.\!F"[B(BY?NS;R%#O,&
MXF)0UB'_KT'#=4?#%]_.SSX:_&OP[[;@WZ-MQ;][NWNKVNM:2W/5X>\I@^'^
MPIDG;/'7V#%X:=,0,'A3=[ NDZ>T<*XY"PWDK:2YW)_>"3:5L[-CUQ_=R :_
M!\M'GK)H:'W"VL8]661XW26R.6BB4;&DZ(*E1*T^PQ(ER3CP56'G"$MCI@5A
MM6N1*>W#]Y'^PD&,Y^'8@Y7X'@?IQRK&(>>6C50:4#E>K \Z#.Y]51OT4M0[
M%N5AM=*H:?%@K.%*!9S_*RL)J]K6^ -_&',_XJIJ,M7.+<X)JVTRU^=.V2O7
MPZDOOC7F(65;4SE<JFN=RE1*K;1PM2H:F\2P,I .ZFK@< R#1#[CDP9A,++:
MW>;!7[&$:_L0_DBKPV)9Y$A5/15\EERVV=A%\6 15FX%^;"IY'G@<"^MH)LQ
M62P%9 PPF-UBX>DHIF+H\C&R#FY685757+\)F8-+)MN(G=#SLV-!IVG-Z:RD
M;7L?9M&T/KO =5&_NL!#F 8\G(J^XUA#*DL.^J*KJ):KLHNEXET@JY1I()/#
MQ7>\,-%4Z/'K;SQ EPP%[39D(R'J]);F F_)D1LX/^8Q5=,%^'0?#Q6IHR@A
M>6 @CD 7%CKJ N2R& FLIESA85Q/(. #-QPA6R?TAE,L93YB%D@M,(BJQ<><
MC=8D[%G-YU0=%<07OBD*K:8)P#*J&N)3O,-O?1):H:@T13-#6VE7P/TIT^;4
M7\X*'\^OO?RFVSEHMBR]TO+^T5&SK;Y92Y%EO0Z75E[,]C@+T2$9OD@QL9D%
M5#I[F9^APNL'[>)(_R=7"2T-,V"-Y2 \42>LM3G("FP=<J1N^8XHM$9K](1Y
M]VP2R6D"/SI[JM[,27I*NXO#V<<.5E;V)Y)CBG!8OEFC6 ZDB[ORY9GE=X]4
M>WO9@FY$[&Y&\9^9!7ID\+>?_G)S<5KJ]N+?)SYVSO#>Z_Z/_ J+:/1%Q?/3
M@$I91ZEOQOZN<;-<XL3(!,UV4+C3T4JB95_FB3U%1?$C+N*W>(7U?Z"1\<YW
M!?KFV-36_&WY0O'5C,>_*%MTEW,&']"HNO;[$C]4Z?GO2E]4QD/N:1TWL@KK
M5^@31JFJVH+&,IX[ *_+=D6WCU#.OZR;#)@%T-KD>8%"_P?S$Z9*TV!3VR4[
MN<RA=-;#96:7#K"F(S<9"0,)YA*\$U=X\_ --=P0[3H:%O,"&/"]"V9(-!KY
M,V%^#!)+C;E'/ 9G\@F]/%BNE<?)^N5Z.5+7L6' L(PZTBYH9A]?7^R?D0_V
M+-5SV51;7:+:ZO 9V61*0V\"ERI57=VPR2RF3>92=]^P:0/89!;3)G#)]#78
M""X9_^$%V92E&STG>*I1S>SRS@AK,Q;5*ZS^W%BA1K)SG81W[AV,4!!-["!.
MC!B]N!CMUTJ,Q":UD:$%9:BDQ\-335J]VD!HG1D^JN@Y49%:.\R[<Q"$XCXA
MDN*F.=?+9A&/7/6=#UW;XXL-X1N/Q1""@5P1+!H^TT#>OAF-U&;\N[Q<O8R?
M]-HIA8])S6S_<HI:"V<=;JY^6LH!KP:!7CG3V C55@C54D%'(U0U%ZJ7\:^V
M1,"6;#5)P92UGF4[TC;IB\>]YISM.MAM'^#AKOWZGMX\6B+LMF3'P;5S/'_>
M*^01Y?-^<(/QD,'R;ECU/H#]0JS=7S<!IEC[V9O8P3E<3D7'WGYCD</^/+$^
M?_WWZ3O#W@T[=SW%W:6;2;4KH7R6*'^RU,'I=<+O%<WHWF[G:%4SNCTK[Y51
M[]0Z^P=S.!I'E4R[LGG<(I:]+J:<8EF/A\$=YO7FJFZF!K#W_>9L%0.X/0RL
MZ('H%YKLZRN8)>J'/,D&KM_<KV06V_L&7=8#7=[<L=!Q<WK8P,N:P,M3%K(9
M%O:T=]4S$'/3(.:ZYU\)];6X:>[4'9^V.[OM+EKB/>,L5QB@7C+OCGL>>QXK
MNT5\6S-*O73ADLBZI*"[36QCGF9$+[]<71N8:F#J)L#4)\9JUV_V5S&/K=WV
MX:KF<:L]O2H"U>27WZYZSQ+GW6[65@^G_NKZ\6RH^NN-@:H&JM8<JK;;=8>J
M+=$>PB#5*B/5?_&'*;AC8&K%8>IW-P2G:(;U_/[EZHO!J :C;@)&/=@^B'J\
MNW+\=JO]NPH"U(LP^?%,(=[M9FWU &KOZK27I5]K>4H?OEP8:&J@::VAZ=.L
M<O5-\-%NN[-K<&FE<>DG-^0#;P)W)Z')\]T<:/HO=L<_,F!6F!G-?_6^?S2(
MU"#234"D[;WM@Z1X<'0U>[C5;ET%$>D-CP/?M7.8U+!U\]'H]ZL+ )[Z<9DK
M T,-#*TW#&UW:XY#]W;;9H.TZD#TAMU'@XD_<9RG6M4MXMF:0>B%;P=^<#<K
MO^CBV\WO!H\:/+H1>/1I:4+KM_<KV,7N;N? [)'6 Y%>PQ6^V22M)RR]Y;_/
MJN?P>:5R#EO-88-/UTT LTU:,,/[!I]6'9_^L]O!1!6S,UIU4/I+,,+6]A/K
MG#NN[?I<,Y>?OOQN$*E!I!N!2)]88V']%GXU4[ARJ':K?;H*(M*O9]_^8_!H
M'?'H9V#IT(VI-*166_?J\A>#10T6K346;7=J#T;;>P:,5AV,?AF-$C^XY?[O
M#>OKUU/#JPKCT4]N&,46YNNBO;R4!UT^_>N#.3UJD.A&(-'V_O8A43RY0A6.
MNL:EW7@H>CJQO6!6O=9_WQC84@-0VAN//9<[UGG@<3OQ6&C=A,R/QD$8:]NE
MYS<K6=VM9K;!J.LFP)+FNN80%6OS'JUJFK=';->-4>E$*4!4;K9,JPY1OW$P
MFLD/UY_A(WW[:A)Y#5C=$+"ZA0=+VVU9K=Z U1J 51;&/'*9;S9/ZXA3KSG@
MTYCIY98S0WOUK6?ZDQI\6G-\6O?SIF".5[;&VR.VZ\:GOP9A&* :-M6.*@]0
M/X7\SP1LY60&0/UT=?9/ U -0-T(@+J-NZFMW6[; -1Z -2OB7]KL&D=L6G/
M]7@8S(H"][Y>?3/@U(#3>H/3VG<V;>VV#PPZK3HZ_1;$K.]QZROK@WW]&CL&
MH%89H'YGD4@Z^N#BGC?:3>29UBWFP]<;@U -0MT$A+J-)T^/=]L&H-8$H'YT
MF1\/D\B U#J"U',&!C:>57/P_/.-Z6EJ0&J]0>H3#73UK?&1P:@;@%'/OEQ:
MZCSC*0_O@G/N&(Q399CZT1T,DL@-_*E>M*D!_?CITTI1WNUAH@&J5;&#3PS6
MKM_DK]9$YM@ U7H U1M ,%3*8>4S,MO-T>J!TP\L<=A#OC#2A]^O5CH]L]6\
M-9!TW018SA37/:<7S&['(-*J(]+K\23DSQ/VW2*FK1F4]OBMQ^E S*P:]U]7
M*G*_/1PTB+0J9K"SA<F]![MFY[0F@/3,<VTW,/NF=82F/?\6 []@9D=8&)]I
M!O;;9Y/8:P!JO0'J8<T!ZIX!J!L 4#]??3%'3C<"E7YGGC=OG_3[UPNS3VI0
MZ6:@TN/M0Z58@<' TGK TE/FV2ZU\V(&CM8$CGX.V:2?W%K?7<I'TMK(]/YM
MP*@!H[4&HT^L ;$)UG?EXOG;([7K!J.G+'2CT3,U#=\BMJT9F5[SB/OY%*/K
MLVL#1@T8W0@PNHWUCSJ['5.?MR9@],SWW#MNJO/6$I5^@4_:SNB7\RMSFM2
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MX!%W0.H@B>!5,0]'KD\W14A2R8M1$,46&X_#8!RZ&/AF/LJQQ^\8B-R(Q\/
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M2F#D113)9(5T @&Z52BW^0&F1,W8V) J&)5QS!YPSY:CAQ)BO  <(QX+ C>
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MDO=HJ,#%B_AI@. [LKY^O6QDZY.NS-(08Q6\PB,+E-^H$E.48P*0^('1CK2
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MX<%E+(L"C^LCMR(P8(+#(0=PA-2#\=R'+I!<.#Q$L:7'L2:I_H0K-@F!_E(
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M(D'P]H8M!KJ]ND+YG&17.2Q'XANBLBAL48DJ$K8B=RQ"S[JK2VDL4:I)36D
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M:1(1!GI"R:2F*)ER>1USQ7VLV9E"7]#F-VW[^7+7&YL;='*.JT:VX%J_6(U
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M59A*:1\:I;'IJ;(XU-:,,,C3HA$QEGY//.]A E9Y]?%=-LT=Q(^<.!!YHRE
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MSI*!^PZAE8R'S<A98>)A2H2X8W@[O<89HOHS8:41YG#!;H<R/]J^QA0'7^'
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M  9,_N0[#. >_,.X"_YX?'AX^.*%8"7?9=[ K='-V]X-.]W-H22?=QV88%@
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MHSQ"/6<B^A&V#XP59X(I[F62YS&*,IH0^CDYDRR5-AK<:0R6V]&'D%H$@MJ
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MZI')T!DZ8Z,;HZAT,CR=+=(\F6 ,S4A5.IR"I0'7%L^^OU#]A>(+9:T=8TT
M65'5G.[O2J8R BAJIY680HYVW!$:H]P8[8V@($-'@)02*.5]6.BFI'ARK@WU
MB8SH.0="%C/F!H16LQV2@2U/(2XI70=Y,WV2HG7N9M2RR KERI2@]<Y"PC!%
MK=GYD+P-'(9S'7$BKD+C+(KN<IBGE.;'>340H[#3D]=?ROY2\J5$1Z<D/ Y
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MA7(TR]")3)D"EGH*<NT7M;=+Z SUV_8@&M7FP@X-W9FV@0-Y[V&,H)DI0Q"
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M?HZ2$JX"_W .M\WO34DJ&/JHV4TUNTWP^S$F$7-^E!F9FK%KO]>JIZD;LW-
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MKGZYN/KC]/#EX>GQHZ9I= JR=<G6S#N0B0<W[P.8>L!S-]3,R[P&FLF+F2&
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MMC$E\QL.NMK!))-V.*PFQ-,0>S\C]S_Z8>_R).YRY?94VU,M4>VU3YVDS&?
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M7KI1KG'F'<(8<9% ^J4I*27Z560_&69 :=.(:OQ)HPAV.-<;_<@03Y;48J1
M(J8Z%.#R+2?D7 *))K9/(.?P.WUJBX[)P13C7;7GAI18.1+'O&&);EY7AO#(
M#'%Z/US-6=*.+.3B2D?!F[R8",;:_LN7NZ\O_XFB)!G-A3=/3!8B\"A_SG*#
MM=J_XM1WR/'4?><:D+TM9[!B'"0X2Q&P;7SK\UL%RL%$<A-:N-"H%C]B]BS@
MRBW;Y2BC[D:''</#3AEMW7@]5G7(-8>3+V!%RF,7]W ,MZ"3(T!FTVG62AG#
M%AX/-X(8O$#MV8W&"C)<036%76EUZ+CN,!)[<!X+60IIEE);9-@+3;SVH&M
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M&J:*T?/J$Y(PS OM4B#I4F(;LZ"L,*L@T2W^;#2)0X33@OKUF2#+AH+:UZZ
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MP124J2%9&^^B,H[^%115JDHV]H4QP'%/HC_S0O*]HB#%])I8)ZDN(A[-*2;
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M56QW#K@WZ9-VW 5O+7+<7Z5+5%+V!FN(+#_ WGRU,U)2-LJ@ZB_#3),@CN;
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MCA9K!(D\Q<AULM!A4ZQJ<04L";A3;8>2O&"88 HVXRXP. UL*RJ1F''8_13
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M2[$ $A@E,:-(/1F.W)0:E;(X!J<!A49*:A"?4LF^G-!1KA,"&\:]"XEZ]?#
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M>!'H"6F.&!9S9M#,A>N!%1X)Y$7Z3JH;T##S-'*GH&Z83'9IXP6^=,,96.$
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MLL]?PW#,O@+8 2UGI-N 8L= W(',Y"1KUWSND#\F5^$B[G!0]=GUE >WDH\
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M# I#T\.\V<!AVPFH ^E+ :+R$7.@+9DVS .&9!A@<!J$@SR<7C[N#@)]KF@
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M6 \D-OM-IS_L6R0>+Q);3K?3=8:M'9T2B\1Z(+'9&3KMRX%%XGZ[^AS>,SS
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MP5B)DQV7UV!_"^\QT.+(T<D 4E08BR3Q29Y2YA/4?SR5TV-:%%\(]2H:[$.
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M8!T<20<]S*C&F8HY+H=&:!UY<.1\F]SH?9!'XTT[A83D."]66!*@CG&(?S4
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M[\#6+5HI4)0"JV^F "+*.S^;O+]T)X"\03NW$THIS6>2"P?D_.UY>R?N/<&
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MB,+47!,O @"-0B L-A."5CH5/N 'A%%XC[^69T01!Z +$$;Z$QB-YIJ&/JP
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M!UL#>!:Z*! I%#=)%&167,BT!RJZ0G@HJ'EQG,J+IC94KNG69WDE9D!%J;F
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MZLM*P6P-;+5&296AG2ET.N1C.<A60P+X'"W.6\C?MI<FKZ#/J$<8]&^8;A#
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M F3:E:P'H.EG9,=TEIMZ%":R!>Y.XUEBUN\C2&%% %K9D*I&VI)@;9&;G,V
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M3Z]VHE?#T>'@]>#UP4^\$?R&YAQGY[O 4S2S.OX _SDY/]-__70H+WVK&_B
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M,@K\J#R"0;685Q+^P>V9A5EXDX6SL0#MG@$<86][ T?8P!'6'X[P38YE613
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M3I*H&[R@$H8HP4V)YX[]\TO..BYROU()%D:/AS&,_+0(_$<2!)9GP&( JR.
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MO<+%P<F</'<O#@]?<#=7UROCR)?H$.[# G,<D&8L>,=N<('1!;<DI8\4T/@
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MCI?31/1-70W4103#0T8OG]$@3F<YV.ZU>>E/CBGSP5E&ZT$9N8O[AT J'&:
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M$^<9ZK?E3'BV)'857#HCY5JN[<NW6RJS%Z(\2SF>?A&NW57SL)ZH8[:>,'E
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MV=\2ZRGSJH8%5.DQ0H:][2)(.M&XC.#O\3W/X&=:YN+VP ^U,RBZ<^G,B?,
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M>AB[_?H R0^3*?M Q;W3ACAMB%^_(=S9%-?[7R_^]MGKJXNK#XX$_E!K_F,
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MT315AO380>MJB%J^2XATV<^QZ3R\Z:IT4!_+H7A%9-NTT8][\/VDO.DT%-<
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MQPVVHD<!XL_%WVWH'TU%^N&I(GVJ2)\JTN]C:LY>)-%]I!#B*JISC-$@=,C
MW-WJ6>:\/Q:Q4>I8C5DH;D- #LRZ[OJ6+2;T+&.O N\] :!>)C]O"$<9W-\P
MN=1@B6C34FM2 .2<W)/FG.?E=9XWDV?HV N7LC^_" ==7JPF?PMW#'YJ^V8W
M"=$RGX*S^FQ18[;@(,FARX$<-3TPBEV&.DB0RJP$5QK-8C08'&<(=&P.J)O+
M12M;K42/_+I3O9=KRC-4G(Z(>:E]9ZA$_N)Q:0Q>N!AI187<O*T9SE8LP@@[
MG_'SR9Q^(BI&P-TD['A*>U1%S/QI@&7I/56J2A.0QTH)_*.0]@1T^[J>++#J
M848A:UI1PD57-D#/186V@$6AB.,))4JI#X=]Z7K;YM1N&/XQ)Q>9:G+ALICA
M$&:6*[CH'*TF94C)$#!N&V-#)Q=W..>RAC@[]Z=@-K^Y2P:NUQPVS$9E>L7/
M'^S/Z1W,R[$=XJODE2^\_^GA^==VR?<=F+5N\4REZVK<(BHV/(U"N)\+X2L7
MMVQCC$XP7F:-Y*%/&K+-"/-"7DYP/#3)F.029;E02A&I1'JOT9Y9RI9];.UR
M='8#F33F2<18J/,O.-GD!".5#,&I[;H/@R!JUFT,.>D)EL%XA<OM79*6?XJY
ME'>F4KQFG N;"12_#5]'2M2F,1],F(RN/[$P-S3D>;V=QC^Z4)6DN5KN[070
M/:;7V?S'HZ?8DR0>?=%Q>P<[6&)/!QL31LJ)G/?9WJK*B ELJ04E7[DD%?GL
M2$#>6M7(H")A1'8V[(5[.. *4KK27F?MB X! 52"-2XCI>):GB1ZKY%RQC;9
M\^@CR\,N>ELDEZ(GD?X%&V;L/=GDY=SF>[OAVD=O<N^T6/%EL<,2.XXX3%AA
MJ0PUUG0N3:BSNME0RD(C9_H^Q7-<HL"-R#J[2PR0W,X^IV<']?^&34PM,^T2
M!^\"Y8"TYBW-;=1M8O!F?ZYH%K;G!AWIF#R4N>Z;@F%26CZ@I+1^Y_=,2H_-
M&Y=F:.[[F=_8ZX_6(S9QS<@G$;M89)*+_G")[I%12+?V(*,S.,C$G1B?1S^N
ML#:G89TQ"["?TH'<9O)XJ[IMTX?RCV/M4&E&--^;"Y>77D)Y]7!&&P;C7=?&
M1DTSG&GM[AUI9XQ/SACI\6H=1'%D#.6:VKS"?ZUV;HRP<^Y+"[*0TI2%Y+<,
M">?G_C3P/<R&DH;K_>I(^NMV%=&,#]X_*\H"M^&Q?'IT]#&CS&T_93GZ]0Q_
M_KT3EB*_^W[Y2AKSWS=OSW[XNV8,[IHP^,!C&\LJQ,$Q.TBN7DN$Z&6I!:8(
M%G6G8K6*B017/FVUD"(/[5^U"4*_E!^F:L:_*K:G%\^1-8="Y&0"ZR25G%Z@
M3U4V=N7D-Z/'%EW(_F@3A[,WC#N7""MI P@Q^Z8&T#TG5Q,T2;\BF[!G>>]+
M)KC\02S-4:TH;^A(VW9[$;J;55[IA#&Q3H('4?H3>N;!:QLE*N#.8BETQ4K:
M"*$/E_7H /'! Y9MY1G%,GNKGZ%#.,SI8"C)= ,Y<RV#XZ?QN#9=KPA.;,%H
M=$6_&7W2ZYK\KISV(O$NS((7.X>SB.W9;Y[P\VJ.NKR;#@PA86]*L%?W0'>C
M0SAVBB8-WFA]WCDULR9@]('8[;$E5+*O_OQE]N#! ^0^^E/PWMF+Q[R!PY;]
M($F$X:IX!^CC@&/X\-$0/W$@X!^;BA%TQHC7Z=S,2'W7,W0CZ0.\WWW9@_Z,
M?MCL 3SE%O#Z8E@9M\ /0QU$?XBPWQ'M97Z=JF3 HA"ZP7L6]XT>! >CD/W(
M*(9.DO'"-(E!-N@*8TR&#O_X$#0=X( 2YGGLA3XTWN$FEH2\>M-L-]U,>J<_
MAO+IHU/Y]%0^_4\IGWZ@&/92Z$[">(\7N9(YG98$& G+8H:F5G"?SDG :)<)
M8XEO>4!>B)Q*[H-5N#Z'!3>%DW/%!QFE-V?A\B%*"H/]%WOZ.&I T')3,(I9
MJW@Z)1/F3LR#7<\WY9PH:]'M"P;5XC:V\0K#)5_/72 3XNF6V'RNB:]H"0\$
M%9\QS'*?,<E(M";$9F:=R#G3QVD+\!BA1I]<=T%=;.$XI\8?M)/ZY\19OR;B
MF U5B)+'8L;&I$2#8N4V>$/4Z**:=T(6$CQ\\'):Q*D<-R.OF(:05[A+/B-V
ML? H%K 1P4?9;966UJ(Q"NPHCBI55F@#'T6FKKQ)>LC]1<XG+PAYK>Q+UE?K
M*'^X1<O-4GCEU^!2:=!T6I'[E_$$T1-DCNXOW#-<=\80><KWM\&[:ZZ+ Y6+
M<)?%(DLX0%*V73 QA]@$WB_].GPD_^1;TQMND$"<RXNBGZ6L3@B#* 0[\S=B
M[QFLDW(MFIPQ9A:!R8>'(K:NQ1;,HGO[ Z680E,J$5CQMFR50%K6"!80;2#[
M"^["13\XH@FU(JIN:'GN5; 0K$G?FBULI=6L%C2'[!31G%TGD-!W&)PLO2\B
M? ROX0EFSU1*.^[JRDS#/%&12^IXEO5-$5FMX-<+657.O8R2#9*W&[G)^NL@
M \^LT%%F,"^K\DU!$3/(6SNP[11$(I?/PARV^:*@KBF?XY8M.M.T#BTBK@/U
M+"8B"UX!I3*NH51!P0[6:N06*]?3;=.*[VM$TF?L-(>0Z7BS_W-%,Z1Y%G]<
M*7\2V/R&;$YA07-])"PHY=D 17O$57)ES*"5V&C^X+@I\)8S1Q6?]4GWP-/$
MK7O6%%4B>V4CP82./("WF=BZ#G1$K!PT\BO:)B%8V39A<[T)9L&8FC[1U/+?
M^ \QS6CT=9%N2DC7'*<?C%Y74H*(&:X\^Q4["V-GJSIF1$95-,F>P+'>,5[U
MMN"S<O_Y.#(?_L@T+P)'6SBY)<\F?W!$$YY$Q1-<.;LHO9B)P&P8Y OY]I7C
M <DFKY=U0V798O)=60OK2$N"T531"2\C_#4+/^&,-/[Q*AQ:*RZUII>Z#,/X
M*7BUA*1[0C7[AI2JZ^DL[_!#._>.U[YKE6YFJ@KOF>@459D@SF$T*?',I\*E
MFW I1\9M*3D9O$G_GM6^<0W%4PN,.)]82^R#T7ND7# .]?["HI.0#W,Y*.-:
MH0T?K+*@)B8 "!A&9G1M?(O7<9+?^;>3%]G/7/MBU'1\:Y+<?[38R:CM2(W0
MN/W::XWV&+;$E/E-<(]D=TX;XW@;XV+;T9E,4:JNB.D?L!&44!H;$FF5/_:Q
M[X,->-0"MK'3^Y=_P./;S;,)\2S\\2)/\WS3,0-9-L':(P[?[YIPJM<K,GG!
M2WC]SVTYG0;_*I^& +SK<N*-SVFA9)._A=WVV;/@ .<AP/JQOJ%\5[C R[HM
M0@P6S-WK$(YED[_7S<G:G:S=T-JM@JTKJB)$2"=K]P?O?)GZL.U#])UG@%Q-
MZRW%454(@'<<4%&^A6.K'6WQRU?/7[]\E4V^!RPY-0,3M0,_%.'"<V<%7C;%
M#!HD[/:\SJN3:3B9AL-[Y,>_N43U?0D3+N;EC"AW+L*<W^38%E3< =>2;9NG
M\_!4K>Z1[^NF:XHV_/M9&-L\QZX*L06=N>%WV! _O@GG9KC<CW][5H0M<96_
M*6C;G';%:5?T=L43]$E-A)J+J!Z9DHMJ?O=EDX0E_>-50=CMIU4;+DR!--4P
MR;,,IK]>E-GDYW7]2_C@)Z*E2./F\3#[,BSBCHZ+B^GTIJ1#*ZRU_'Q*N^>'
M<LHJE-A+SUB3T@Z;IVT=_K\K9O=V/STX;:=C;:<?TLK[/=@\+_)Y4UY3F?;B
M3=&$]?OG;[",OZL)CSAYB?K?@;237^/2BO0+M<'NJ6+[S#[RO1W7$"65KU7A
MIZLR;+,5"3R%(*_^,2S LGW32ZE_5'JVKB8KH-DTP;VG@*2E_UAWCM5F+3!;
M"\EX34; !XIBM,D^6'4!Y+Q7(HCLF*GV22;Z.J)9ZS 7.>7S-0=O[OK%#__O
MY">C6/\^;(FSETV89W%2BK/P8?#APP/L&K+E"^*]IY409OL2A6;Z]2N160ZV
MFL0#R?UIJ#9ZL2G>$E Y7&$17E2XPI.FD)JIE:>FL-")T-8=%BS/I&FH^.I8
M4MS25=RN":QHHM'"+T^ T)IT3O%>NQ #S3&)TS*LXC)R>?G/Y+]W++PXJZM?
MMM<BS&H^JZNT^)?P1Q6?!&]MRGJ";YA+N7'!N-EVNV85JR5E?!K,]5VZ5@?]
MIPE\(M%%EDY8Y5S]YS888[0.>,DS5A30AM5-,"C$MRK28@H!09UI558L@  P
M:%MJFX H\(A^H'@ Z A+?I&B^P&^)S0ZJX.Z-4//P^J%4(&KT2A8%52'IC\L
M*&H5U $S A-#-C7F$KJ#^7!_W=0:;$,8&SI(NQDM) &3:<16%W8M/+TQ]^N[
M(T 9$7&$ N*6]D!X%R+E2#@,?Z?8OX*MM[C3]4EWZ>,A,_K\A,8]H7'_4]"X
M!^5U(LHD+&!%A%9;HK ##J%N4ITX5_VW Z<5 6*5XV*$PH@I:XH[V1)UL\@V
M1K'7#DJ&8:A*-S0^+/J1: Z,@FA8;)S$9PRC48:AA]G*F-C9H)(8G@(LWTVG
MX^&0/21@'!W#D:@W!GS-TG7FQAHUU+<5';W2C,*M+321.J?Q,-@ZS@;[K<I2
M[WD+:'%3OS'Z8_4(N X*1N@!X??B*,9+M >M\S>%Z0=N&M%)ZK8-,0@)!;*"
MF(^$Q_EIF[3RV3'8[43C$P(QS'9)?9I$DL44Y^6BCY:\B_R$$<03T+#)9!NI
M/D/&"W11W-(F"Z^T4!0-[:6Y?K-E("-^:T!%]/D#WPA:Y+<;.J89BE:-!RM,
M](PA,U#;/XLM&NGB)/5Z:J\4T/!X2R=O&;L1!J@8=(Q#[BK73'X;)C,):*C/
M%:J@IENK!03T#'*;ZEU<*29-P<N4"Y;5X-4E#J8AWQF;'"%XTX*:B6EUDU>C
M^NZ54NSPUT>47A4/ZIQDV8\,9V5&SC6]I1FT,X#S)\%:EF=5L'H?(0H58#$$
M10C MD":TE"V#"FCJ+")2/O[R,[ZS"#RDU>\K([:U>&&DV^[9=V4HO,V;$W.
MJ,4"8.MB3CBWC)#Q72%=HN3K RILG2#]SF7Z\R\4*,_+F?0+>$'I0B3:P[8)
MMPVK3_&G3W^.+*]@#:)]#M8W3%^*K*-54UVWF5CVGD*'"-H5 /#U>O()\HR_
M)F#E3 GU$<3!3$*')[/=3,QHLS?Y-7Y+84]8DW01:G!^4Q0;_'V5$U06LG%S
M9!9;_(/0D+5H"E (5TZMQ5*Z!#+:C<&A5],1GI1V,,MWT0XG VYZ=.4:PN[2
M<P"-]T4_KQ ;1.+L.Y6]V,MRQ7V?C$-FFS75D#9V,>C(#K2SEXA*"SJW#ZZ&
M?$6OD>D:MM.V^.<6U#@4XI6Q5=PQ8-/ZV^I=&MM-;=+O$4UW7-^9=F1KRR>Q
M7T&LC?AK7)<"*PM12X?VE?3<(N=E^=^%%Y'/.CWVI\3G$*;Q2.9H3Y!Q*$=,
MCA)-!SUB-%,T.]_)4AE_WQ:+'(E;9<1HC3=*2%L^6Y YG;XC>P 9$/U[FSF"
M\)?<S?27(E^%)?FZ:&["E$TNPBW4:KW\R^L+M5L&;?[^R>6%[%1B1=#<!>VC
M_O*]WI;@1SB?7(C;O,M\HQ3&YEN(Y.3O@A/:QLYN/HBUVUCD.R-GE^6?T"=O
M>:.$BD&T?OK,3Y+YBW[0B)>$EKYNMZ&+PF(')U!H$" 6@D'6HBZQR,N5;$'[
MQ'(\N\@3X0P *$!D*XLP"4LG8M_.HW943Z%"'VR&*K777"K.8O),CXGA7V08
M;)+M.A0T),;:/B$KH00LR;/-0[R[LZVDXH_21]]VV_DN$9AIBINRN)7HU.98
MJ#WR.7$K<B+P!E'.+^&IA JAFAU3M^W"GED].)LCQ$UP.^'5ZBE(!I40][K[
MQD\7^'M86N!?:,.3M]PY54IV?$7.I^=36=04L8%,K2LV)R#^OVL%]% *+=GF
M(@!1(W\L)9%R39LF;#]K3*$^*ST%Y0/P0&R*AC[BB&:,U28$DD;L  X<=[\-
M$CGAVWIH//OA9?1U^R<".1?SO)E[]\;90O?UQ_>HU']:Z<=<Z6("'9=-RD,&
MAV;V[,5+M"!R#$\G&7\7I3YQ:Z4Q%'_2TQ29%9Q48MV9?$IIP6A+++?AAOV"
ME/?TC1HI^"*K'8<HLMHUB\"G[FE1GQ8U+VHANDU=UK FNSJ\:]%SFJ[+5K-G
M8H;Q@VKR_,<G<%K[*U-].V&V)G]"NMRCGJPDQ,87-:>XPI(XK=332N65:E[N
ME" >Q%U04*J!HH_GK[X#EK%H)0!DVDA=4U3EU^66?L(H ,FG2D 7WN!IS9W6
M'#NW[)$J$;=Q,)!=!+^(4Q(?-V247=?Z !_OPA*!SNS93@E=&N%\\ %VK)9Y
M=4CB]"0/.82CIG,\\)9GVP:"KV2@Z0;/+E^>5O5I55O(MLF;F+K:?\)/OOOA
M(A,R>\L>Z/(D;Y,/>I?"1FJ[0L8$);R1!9MDB=R]B863<%XK?!O[CIUMSE9<
MOKC,+/GFQ4C&$FW**H5;:\'@M -..X!W .?^^O:6'0M:^_G\IFPIJT"E>!*I
M)SHD,"]Y/ (%:0N7-CBPOCX&_-H7)_S:";]V__%K)U/]'V6J71W"JA#B+7@_
M@ZQV64%$V\L8I^2"PB4(2)KG%?30B5JYEQT&'6@-*0G&\P)%*AI1&$?5B<)[
MO6" E1#&2WFN)5Q5O_A.J<)>P:W2[V^;(F8$_5#711CB7!+I$GUP =:"$]#5
MAU"XN2G\<*,8PQR2 \18UX4@X;I;&B+#1R,G;^FT!=^Y!:D^#(<I;)^NC0Z5
MJPE9A8<6[%C[15SQ_1WR[(>7Z+>(+E:FT6RD.*,\^;6&SS$8(-DM4--O%+M#
M7P[QS&E=G]:UQ,%1;=/CC62U67ALH T2 7"PE2<_?W^O%M.#TUHZWEHB(RA1
MI0>4.+NCF+E_*8YFE2##')<Q_R1!;&B(RIJTQ@KNDBJCH [(CMRWUMI]"+O/
MO]IH_TB"4:QV/2B0]YGZN-=(>.F^A9X%!8A-\LFKIR]>1P+HY-IZ6AER&A_'
ME\,)@;5H:DFY5424PAHX$BJQ'(D;!9+X7__/2W\:O^;G UO84>!+WW$=1DJ$
M> .#51X3WUKU%A#R\ NH+<(H7]>CD+/SR<O^7V,/L\./%.'M;W,+'NQ.RV)=
M,D>VAZTD5?6D)U07$"7^^9)%;V$BF:^LJNSRORUGY,!0(C_!RVA7DOE0@/2%
M"_7A?\]_?')FY,;^QWT<W&"*V@$D1[Z)R&9+" 0D7373NVV[!$4H /8!PF;?
M)@T^W3O0.)WJD3VA-'6G1_1%</*"U2.PA84R%SQ;_RA6"YJ:"PK*DI0<SP'W
M;HR[IX)3ZNKK OL=#Y6&C3X9S5;#T!7D9F:J"8=,X=SGT,.;H4=PU7+G7)Q/
M_@$.Z^#\HH5L,< XO:C#W!HFE1"QC\X?T"IY4LP*ZJ8SZ<-'&:6 KAOT[\1&
M(Z@+MWH\4-;'H+-X$@+69AQH.NP(YE1?>.I#HR*@I-6];P*8V5%G]]26'36,
MZV3<DB<O9R!/4T.M!S2IJRX\)T,M0570>SEQ]7CJXC!M.XJ(RUE3GVV6NS:"
MCMM=VQ7K5B#'9YNFA RCQ.M;:KI9A[E='0M%?M!>/T=CF]#KAX>A$3PAJ-!%
M7#O'L]\7O(ZIB8F$+(OU)G)3V-KB5C4"A^)KVTII]$<L.#<KMLMRLV'D'\0B
MN1U&.N&X "HH*-3^TQGJA97<;RKE*?R40U1>>KF2=BC&MQ L=O^JALRJY0QB
M8X)=O T.=]X)%)NA+:W#MGS^("K:BJ0:1,8VG?,53 9<H F<[RE%)18.95ZV
M(!,(SE!383ESR0V&<TIBBOY49'W=U-I+"2R=H61'Z<5Q>RYB6W.<X*R%L&&*
M]@Y<CT!IE9-Z7#)XORG;-ZR:%H[U,@3UH,]H4#:@FUV^N/0E/+Z6*<>CYR#O
MT,?&9H/F6O%P$?=_P:<0-8^LJ%ND@JXD#A&Z"7W!GLKFMAB4YL,2%'%&,$Q@
MK7&30(OE0V=&UBM0ZJ#(UL6.0!U65<NJ5V\T@@#TZA.6ANM])?T&7Y#;8VNP
M2F.91=5,64,1*:CC.A(D_?GB;DNV8'4WZR6 !'L)I^CS!V?S?&>2S#1+KOL@
M LTQ=X;'@"W*J*D2;=W+NF:E6.K=(EE8CI4H#&LB@MW6P;)>S<\GE_Z?[&+Q
MS[U?3]6_BIII.<L+=25^1 G)F#V$P1W6S(0F[-B)2A$=.PR+$DN5^QQ<W1K'
M='!/;(C2CC D(>&_A_U$1HGTE2B4YRV7CAO-JVB-T.G/]YD%S!*Z8]MMBQY@
M3?*%-<DRN&(^6.*/,-M^X]E+1Q/7M"@J2TI#2&I.[DDQ3W;R,C@%I/*-=:UN
M)]X[68+$)#,J$'T@Q5P>FWMS9=#E=45T,-1^+KT@-+LEN=K;E;9B:OX2O;HD
MC5J-S@.+X QL!IT_6)+4)D&_;8ZTY;ZOO1&A]VZ;(EW@$\T8^'.2/LC\-Y.)
MYC[K:K4S&AIH^.Y[8]:"H_6*X<7<2Y-EB?,$NL[TJWFA.H\"^/ N-YS8^=#L
MS>JF<7H^\R*\YY)ELF@/W93UMJ7.E5)</\3SMR28P0GMG?Z2!K1G\'1&R.![
MI\0]=!R?0KXCC/2"E8W(QPD6LN?6P)4DHW5%+!2(KGYNBS_.H?0#S6?<T]4&
M_ZG#+<BC"A](#P>, 0Y?\@9)(%E:.B9,MZ>]ZGM<MQ;FB<@/?&D@'LH=S8 :
M;Y$4HN>!R%M#_%[%O&3KM2H7Q5FW!'$'NG;G82&AWUZ\KE*DQ\(Y(6<$G205
MM]SE#1?JFTE22_%Q3V=OH]Z(>!M"5Z(:4^'XM#'7J:87Z83R(8;^ ?X\'&CD
M?NO'H/#8,V/N.*.G4?:/*NPN49OJ_]11T'$6U 7W8/2XPUTYK2XQLNQS/0G$
M7\0$H;&00KU9F?/1&^=-]<Y%"SF\' @ADY%A%>3P]6^1,@WF9,NR:?R8G["$
M\)D>XS2(CX9VZLL3;.<$V[G_L)W?FW;*)=;:GF$@:>IUT5Q#ZKDM.K(BHLA8
M5V?#CSY]S#D(L?ZXO;GXFWICK8%,U\&2E^[OEJV0@'%?8D&,GC=AVGB3C+^?
M-SR.Q_D/.MF4.8M3]_V1<6J[=Q:Q%[)O#JRW4ZPWYDPM?6ZS#@0RV;$-DO-B
MN+/$'T18,3@D^"2WNQ/S#9Q/=3DIV"FM/P['-^*:?H?SK"FA(([GW7VK8_BD
M%:5[):YX/_<A\1X,T\ !YGOX#JK)5X?KYM=53?D383?);"VQESQRW\>] H5.
MNI[ZOVQ;N/MMO\+&V9Y%/)X->SWV1?:'NC1Q%+OU:2DFPU*934S:_+%=UQ;8
M@2TV5R>7J6N0@BCF;I!8 S0:['12@N2E&%D=,DVF92Y[(!'Q>-PD.32.235I
M/F1WZ<..D]"$[B.R?ND<>G1[>H'C*:W:.JVG*XV8N%G T3* R8W 0;[=M75R
MMR-&XW&(4&\IW9(QEU=:9WWTL.U4+X'H@L,3@BV$/I/ P?YJM"$41W!^^=&#
MAU]QF<B&N02#QJ8.A@Q<2'F#A,:2Z>BTCJ>%+?K5O!WSNV6E443#5U9N%'D
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MJ[\(T]4PLP4?.#'CPQV'&\ST;<U[:%?DC>_X0$J5EM) QDX>\8I?J9DV6 +
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M]%)?((WV5;C>P;=OHGLF5M)^3$'/52TC9\>$<2R/.CB8?T:$AC/W8T&/*FU
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MZYFP9L1I*\DV?SC7%259KG<XI4T%CCU\SK*Q2$HOS18V,-5A"=0)P;K@IZL
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MS?G*(5?"A@&6)2<K"4\^T4YA'&DL>0$\88O!^_D\!'L"KARAYI8H&;CTD:G
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MO5:7%ND:X!N=U--4W3>"L^K*X) \)EYUGVS'X'.5+GUC$&0(KMO<Q-QEA"7
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M9LE93)0-O<,[9H2+3DA3OP@8S/+D'O(ZBFWZB#[&. ><2GZ3(>LGU2&@E8+
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M!3CM&9EUSI. 57%I4R2X$G7LGNE6S)2BK]'.DSSA6J64LOX:=%MS@9 0*FC
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ME>R ]ACCI7 #KO8S,P#1I#+0__W3\>.CXV=_^;Z:V'&%'VIKMOL.^1VO*XI
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M],25)G=P</0Z>,JD^Q[%.D)9<;@H)5XA*TD?EH[;]G0X$C?B6\L+<M27);<
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M7TSJ>Z]/??>I[S[UW38O^) ?#1H'VZJ=O.@P2_A[3]CYV=^]QW>/68T27Z*
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MX$P7.&D.Q])J$=:&8ICD&0B89\:V$]9<TP@8H7QV,K!42]Q2D9O7MXB6?-M
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M6&/5XL,(C/XR!U-U#$M=#KQZ)Q,LF=PB)2S8HB!Q>_"JB?D6@LT?7[&BA >
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M&1)$82HS!(?";>@&/H^XN(*J3JY-^.F]\CXO)Y]G.#9T@&8XT6%!*%6$%>G
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MV+A[WVF8=>J7&M2G6<6DY;P(ASMI[!C7UN9$1'1K+O%7XDH&CM!N&6TE?7S
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M&66@T_Z!#41:U =L!%XWY5+*ZI SL5$U8:-SP2TZJ 8SI.ZX,=#^AQ\3TF.
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MN&G:=ZKHQU2AH^?+WB )H;S\\X*M0DW6CQY'3,N:_5Z!3?5 >N/UMN^8XWL
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MX0;P9X[)^\(SW7"M:;BL-OJ2*V)/Z/S27TC32 EX2<J3]TFZB Y:%=X%BO^
M9L5;D!BNT1:SB5Y(Q#W-*!XZ!6TBZM<Y$YW>%>7?':=XG!R?"J+ZWB4N$3Y@
M7\Z2QVH/W1VCNV,T>8PX@8ORK.N";!)4'R+9PN3*L;,5\:C?487<':?1<0(9
M#0RU_+W:>MY:+-.NA<$(NV/[N#M"J43B+A'&Z;_(-T'85%^<XUOO(K(^&[7M
M *+)XN'6OS[M=L545 /@OC7R3IYNI3S<95X:G[&3X[OCC3JGW]X9+\KY Q%M
M3S4PX+!_]/\!L=38URV4 =:@<LKKG.PSS_UL>^-I=ZE\O%3[!SG:^*0OIQM,
M!+M&VG;_JKC#6A_F'(9A3PNRZ^+\(XB?6S<<*BQP%I-= GS8TZ4BXJ\0J4D:
MHN1,1(LCW:4E#Q):&9#=QPH7!]VW6,F :LJ#C2.=?L3L>UPXVAA%3'UZ?Q?<
M[+=$KWMCOIIYJ&0WA%X3#;8"Z6*2D:'0X0E5@[X;"%;YPH(8>&(<<IQD^'.S
M!2K<YQ4A 09]G'CBV^J=]@T$8N9%<8E,C+" +(?QB\;DBIU_I+-&+1!,?B73
M7TCV+]S!VX"%,P=;-QCM3"X$U_^C^9(%<,*N,1/*H%E*. N^+13'9P9='%Q"
M]BH\A33+1&/N+0[>O%QJB4"XCQJ%T_!Q$:YOA%N/NEPA)8C[36BCJO3%UA;1
MY_N!+EA#B.%D^55L[XD(ODH.JUB@]  5F'O9<8N 9YF$\'B?-'[YP&_B??$2
M3+MA3>J6_\Q^_T9R;0(\X\3:K7U1R&)Y+MGCTZ9MMQLBS95B*@)5_W[M470T
MI^?4&*6Y*N<ESN%N('_=%:#J"H7WLN&0[["OR-GR?[46@,==$'E -UZ^0Z]
M<11M'24SJ.$MTAW53D'>_*\9 ';USO+M#;HBH[=60^ETW" 2+'AOK-136+ND
M<5 _*$WG9 "D-S)T^Y8^U\J6*6^2/@B^ORNIEXZ5^9XEH6\C^(;)D733?^A7
M.%:-)8=&:^8580**SJ$$.8_>%8NMRJ&6.\;M(_717JE2QTC-$[:L[5RQ$KM1
M$2#.A9*^ ?6\:=[Q!?IBFJ5^>X<+O,,%?OZXP-^F66K<%N)H(*0S.SJ+(#B"
M7*BX@14%=@$P6E'7=93AP%K,(Z$2"X0@*17!Y>F&PT6P]IG$&5,NN591LJ1D
MWUR7DITU44*0+.U=QVTN603C89674&8[,OK-ORUJ]6-2C$'@]@:BO@XVN>;
M29K.LD*ZPB%7VM :D" E:[79]H3%& O.&2K<HB,5#"I"(K#5OPCOJ\CRD'Y9
M;=DUDD0,QO=ETUX6_"_PA])94%X=T).K\[$LYL'>,P_>^>O6X59K>%?;+J^X
M^ EU)XQQF.J#93\]SIZY>F[=4DF6SELN3!%$65I3^.=MUXO# O#_LU,>AG>>
MJ(P:7+Y+@:Z$;\7>5=SI7M+0?DD0=0C'#%INP2W'2^%C5Z][ ;9 5%D3-[R^
M8 ]!B6B]\/JD?CV/+ 3HG-D?S4%ULJCR<MTQVA\P/-*GO)H8$W9BP%-",WGX
M("4N.81/?$J*O$2&&LI<#WB"</ 5$'VQN*K-5ZW(0T/@H^WU5DI C @=@[?%
MAS8&>.:<IQ9I(=GY>:$)>N+AH'&(7]KOCK-3=TTHE\TWA6^D%NH1@(=2ZO[3
M59Q,>N_\=!:3#V?T#Z2.W,CT#A;O@\#JS)F=OF7^$B-0*&@,AMX2VI*@C\T.
M!=_FH78Y(XFX2@,A,>YZKZ-WL$XVO[2#'6"DA)XZJ7<1Q4+82'*!Z4D<V:@U
MR&:$(S78+E*OYBO8D\'Q4II*YTGQ<S+RY%H0A$X^[P/^E-5*7VO78F76-%=]
M[&\=#Z/UODX1/TME>MCB,AAC\'L /B;FD7@8J0PR;+=%+,ONW>?HQ,5VXT0N
M#>6BU=M>O_S>G2Y]9"WI#^B#7E,>!(J#11BX#<R)!Z$L.*P^>(;Z26G7:^AF
MOGU[6"$'+:.1,@S78] ]E_] .+ZVG&^U,':: @90",U:!U%0XH7>H50(&/T^
M>2;=T!H=O/\J6/[P;9)_1"4'1ZX#,CII])N/Q\#K1ZV&A'2&F3BX/WWAR@(@
MG3QLPT6;]BXJD-<*V<1"U:( )WIP-TD] MDC>>Q/[]#LK!03_'IT?J> )0AJ
M=0X%BH)N?B[N*?G'S8*[)D75Y5=/'S%N3REXNSZ<_R3?)\L9T2VCAO/X;;I>
M:[JJ8:-1"($51S"3:@&(A5AK \#=,7J5'_!Q]L:S3_&Y=B766,OQ'LQLG6.;
M8 N C=L!$]<(#U,:9+,_S[VR43(<CF'/J-F5, =L&7X[W'PY><]^G<G_/SI]
M^P9F')I7$4TC^'\?/QQ24CQZ1).=@!/5X#_0D877^[7.EDW!!9=%C5#@)"*)
M#.&&>1R(8"%'J<J6LUC,DI'$3?8\X[9AD.ART41'WNPK-NT #\_0<?8R''S:
MW1FWE53& 3RW@4M5!-EJR]WUP3LJ0)P'RR%RYZ6!&1N_JR'U<^JE-9B>9:AX
M-O&&.2M])5EF]M8P]5I0DGP3RV16PV[OFEO0:RZ-W&<B&[3Z0D.V$IA.E?K0
MM&JJB2.]YCWE[O)P .9D@$NF%C060&(BFH<^RF^,QE1X5A9:/^6_EZ!.R&["
MON");=%O6R@[;Y (?9CF)UG<PX+9DM0_6R7?IG,YCJ;%MF\3XM'3TTUKT6D]
M*%:L<Q:)QRR\;]GF-^P%3MP#)UJ"=@L"F!Y1E/_$95HY&BPQT'";8H)%6EFH
MA4UA<B#/FWHBD .SXR&LB9A*_]P,L6?;-DPU##W<.ZUT?^J:/]-\3V3Q?D-K
M[ ,S*"="9.21E0MR^%2HO(7I'D=;'LYV="4MCQX\_%JUB27"G7)1XNRP"Y7P
MIEFC018K3,R3I?/LLJ=:C9+=>_3@P<.O'CWXZMGI?1)IB6IZS$U%'[&!@LA5
MJ>+<]<YV(Q)B4I&@9*0(7\I06\)@8[)'?FS92)[4/6V^FQS/-SP>^@8)Q*M\
M6W7I?&/8RYE_I+[WZ>P))CT9A..I-+/6B24)MX3]>5F@8D*TS[UUN!DT\;K)
MS %+DN$^V$/5=GEXB7^&AU_=#]*#HBIA43MZ2+G:F8G9MT6^KDJSC2+1XMA
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MI>P>A4N.Y N(;J&_21#<E7X*T8\*_B,P2!90<C:1^PJIXP=R3 1EQX*\)5
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MD4U(N#'\SG'/-,JRQ=(HW9ROMO26LI&6<JWS+WN]@_UNZ/8K(&\,BRL7U)'
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M:N\E22$-R5C74. 8[E=%O=B-N)^2%QB]G+!K"[B0;OI"Z'B=I4,(7G%)QH!
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MJ]7X$P%ZLO)DU496L"HDD&K:CE-@BQFYG$<*6+4ZVDR.NDD/\X3G"8\)#V_
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M[+>EJC]D]MU#PL_\X@#*G]4!Y;<"@.:7Y8#WJR%H'+P$4XGD8"ZT(S7<!,5
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MF =E-9VF.G+G_HZ4&V1*#>GPVF35$@+I+.#^.F<6I[ QJ#>.'P6\>"D,6>_
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M?V-7^F^T[-PNX_1O7?L-C]-_+YS^=9"@;XO4/VV6AP0P0"2[B,CEP*I[A4(
M:#RK5%U&4B8,#Y9YG!"N-('L8RN3SP@,'?P]R8,/JKA4!<^U]M5A L/-<OY3
M/AHE,3R6Z"0%<U(/AL:]?']7XX:_QQ)R5<Z"]UF<3U089&JV.:#P/PAA.[_,
MX.5A\*K;.0[@FREV.$CP_\E<$SO78,1=:+C>?ZZB0CK$+, #"8,) ZXD(/,A
M&"Y#+LZ ]&)LTA!'Y3@,IA'(K2B%-^%D2YC$8&[?R9GDN$6+ EJ*#-;WYO?S
M]&'WL_\$^RE,CR\A[\5Y1M<&#@UL/4F /XLY(K #WY5EQ:CN'W*XL;+(+?)'
M%L?/+8[<QN+1)(>/_)M@ %! S$A*#6; V&6,<//;P+R,YX!'^2Y*BN!_HK2B
M/@QOX2M7+#)_32)6UK>%J:/@U7ZG:\C0G$H\A@'4K<E/GL=S-K)WA)MQI3>#
M3\YL2*HWI/78X=95DRD=^DA%LZHP0ZRB.WK=D)SEB"8?X#BS9(+4B'>ZJ )$
MA]PV"@DOC@LD8F"#&:L' =SO\+_P?A[##46M"&!>^($LE[8#B\MN7?*PHOMM
M?7D9#%1,C:P:NX@?Q[V""6KEI?]$'+$*X.37Y%]5,J3#A6OW/)HBJP2?5 D2
M.4:_Z> A>6#%))=T41'.;9GY9YXAGIQ9A&M./SG7GI4L25JI G?W S93JOU^
M:)JAO>H>.U<-/OWJV-[E(2I>2/) 2>D\I%9&* +P.?H/!1L A(RM9#H!3V35
MUV"K@6NJ2<7M/X8*M*V$U+I7_>Y!YT1_%S@G#X81]E2C-Z5QQQPN'+C_)JH
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M#XU+NR54NV$P1U-LR)6[-MQTYIB'FP)Q?&N0 V]3?D<UHY1;\JKKHCY*R;S
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MH*P)")+I4DV,KW35P%-8=YQ,"47.W%SM6M$#JQQ/<V'9>[R[1"-><4++6TN
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M.*.9@,5:T-4V1?>1<1V5RBPL#,H*?60E#9"2QP?]2:06HD-K>)60!VFD]"[
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MK0QPXT(H #\+9I@L >X$,$7U G3BK'RTQ7M>4O8M[)%^A42L?4/B*E:+AA?
M9$XC6AT0#KI-AE8G<#O:ZMTT3F%6WJWLYZNZQ0^-Z<!&.]V<EZGU7D9]IC17
ML:M0U8\(;^:HF.G[E:-S&6G1Y'.6,):Q$TF!)$,(SA))8$P:-7U<+D8Q>/&J
M3M%Y6,%9ZD3&T.J+0-H5MB<"T8YJ$B5'PY:30_ZRB"8E:PTY[7*,ICWZ]>!)
M^"/P$Y.0XK;!=.<;C[YH9Z/H*B]<[:R05^T\135UE:W%+UHO+1&&52KY-E\R
M3BX1HNLL)!\!Q=4P==?L8F2L#4UL@6(U0][5I!76R15,WU*T"8ZR;);VM&^'
M+ !U2QN";6?CF6IH/=J7)#1C Q-NQ+UA1DQPLT>1\1:@),5:L]NVQ+K??6 *
MR6W5,I7%T0Z[7;#HDG O)JW*\,U>K^.6Q_!4OOO1_<.]9MRH!"0"@+F^ 7*=
MJ3U0 V+4';#9PQMG DX-'U6LG1X=G[YI%AG6'UI43.XZY36U&K) 4)H0$]E^
MXYJ)*)D'DYK -$2"G4FJN*CSBZ+ EN0MU EZTO*D52<M2U;L4?)4Y:EJ#:K*
M*LP5)\]OX]JLW7L4W;5J.]S8L"4V[<-3FJ>TFRC-28%@[Y5C&$A.VX=\B,EX
MQG#R%.0I2"BH80^7,3IVJRF1$GRF0AV<:V(D?](FQ]F:8<IU84]^RW4IEVS3
M'A.#5T2C]JUR!@+;81)#8[O!DZPG62OT),%?\C?8PC0)VH6ZK-)HACFTA;I*
MX/M>:?-4=0-537.*I6($C&KV3=J30TTJNTJ*/#/Y@BH#)2WF_,&B2CTY>7):
M<J^J$K<^D?1OS 0D5_<2?RY(-L>WKKW=;L&0"93:S&X3,N7 @/.PITI/E8Z_
M0X>R1MK[WJPT83^(W)DS%8^S/,TOY^9Q3UN>ME:H92R;3&:M=OMC:FF!DDJ7
M&+GQ ^/A-SI:S?@(*>&$@HL8EM$ZGYNQR9GR#V-KT% &Z@@?DPI_]_N2'N89
MP#- ZY7/R6KU^U[RRJ0T&V-<)AM2J+8DX!E@$ Y_(TU.U) L:N2@*DL$1X;J
M$_<PL(O/SW/OU/&4Z(IBR7:NRV*)UW.:&N;H&^02*E2W,IKE[:V\-UB+<;,P
M]8+4D^^=3/'I.((_QZJB16,BJLG'+%0R&51%J23S?E1$H!=4L7<;>JIJ"$5.
MS>4[&N5A=.T4"Z"@P@I<AC\1F$CO._2D=5?3AZM2R'X9):E-'\\QGYV+'"+*
MS(<[,-6!W]"HB_H%=C/JI,G6C#P],(A%-8O0\2WI[11\'DE9&2J<K:_O&7 )
M*@][@^]M$77O>^+>+''K I+<*G*8*B[^(,QA8-@Y-Y?!.(X()[--@':6DU@M
MM]\<?)=;6TD:^]-G2DK5-C&NT5%:E&.NY:;,8G9IM&2GT3.-8&E2"AK 'J,%
MD.3@M,I$:G2K3*=):SP;RFO%'/'2XH+H2FPJ]VX 4@"E!I<JPU14KE_.%(Z#
M0@-F'TEN.J4_F:I=:\XNZNV<KAZ/"8Y%;P:9#XT:U?9;E&T1L8)#D_FK!W1-
M$DYTZ.Q,!4W/5]#X"IH'KJ !F; G5-'MZE8;NU93\].@]H$ZYASN?!&Q?G+1
M*+<Y!VF0S 2&;K A#+HOZ-JPN$NL#"&T2P&CE1:G1];0+!F*[1JPI+0%RR[X
MGAPH>57"\^4/MTYZYU4=P62%4I#>8B;H&I%&U2RO4RC]4J,A[N=2)R+^K::"
MT8MU*IH5>KJ:8$4=6ZM[3?_P-MWZ' YP/H:5*",X)]V31?][#_6PURQ,KV$K
M;Y1CCAYJ'HT&5.+^V+S3CMM(#Z+:N6;?).>V?*R&B?X('N,(;M6=WA_!HQS!
MOC^#39^!ET0;/P(OB39_!%X2;?P,O"3:^!%X2;3Y(_"2:.-GX"71QH_ 2Z+-
M'X&71!L_ R^)-GX$7A)M_@B\)'K$,Z#T@'HFQ\.%#YYN"TYNL06/)(#OO=@%
MF-&5\3R.;2W^KPG@Z77&>8J+_^MWO>_68K>NCG>;)+CIMX!ZG@0ZE/[$F[(T
M/6"-;?J2SZ)T84_\V;^$L_]5E13/ELU9]2AU;^G2_JUZ[*=!\>/?;GSJ?U54
M>))[D237Y5V9Y9)Z\( 457J2>I$D=5 GJ4-/4IZD[DE2'_)"W>)B7//11Z3,
M.U@I-@_T]5_B6*G1Z,D-EUK"UW&G-ZWGP^WQ3[5C<[/TG RWUW=@TBW8@.66
MV\/;:MW6%0O34I;[)CGVZ;=CW^^'9PA/ )XA/$-XAO ,X1G",X1G",\0GB$\
M0RSNQPY$0>_@3+@PC7%2ZACCE,C]5%;U:=&'CFG*:9(I4PR)P6P-#M LQL^G
M\)'ONS_ =E;3+?<C;D*6;'1YK^["[4\]8\>)2260;GEH7W^2/M@-3WN'GL2V
MBL2>X/K99H+</SWQ!.D)<EL(\N"HY\G1D^.VD&/_R%_7GARWAAQQ;=W>FY<6
M4C;@2?R'[_[VCAH;J!:+T'N'[N,=VH:TD"US$&W-EJPO)8X.3ST?>#[P?.#Y
MP/.!YX-%K='S@N<%SPN>%SPO>%ZXIS=AVUT';Z1X<AGJJO?N+7!]C9[[0,_#
MO$)X64W0VYLY<:=H\6ZM=WWN[H6')P>>O#UY[])Z;Q.Y/CX\]N3MR7N7UNOC
MX)ZX/7'[J+HG[EU;[RKB[G5.U["K6[I7W7U&;OL8!\U+?M&ISFX_F$[W5$UN
M;.ZR3@LB!Y%L<3CZ=.=(&;X][-B6:UF>*;-Q 78%"?:#??RNB^BUVQWD[C6O
MAV@41ZGL6]4D[I,:84_!LM;M9EH5915QWSCLBI./1DG,;<S2"#8XFN7%G!,\
MJ,7KQW&21D.53L=)% 8?59:5\_0JRI)HUSK%?1F[*2O2B[G4?9&9^F$'KKB)
M<E26>9Q0_\7K9#8V?BSI[8:/< M(Q2_B_JG+*$WGP2#1G1V'_' Y57$RF@?P
MUZ $ DM@R^D(5#'!7FM9G%;T!E$\-GL#"9),JDD B[Z"XZ'6<0.%C5"'(3\5
MFF?@\:NH2&@:V(&7&K[A54E]*WD2BKNY?4LFU&#.-,.DO\1,&2!Q5!%PVTQ9
M:R>X<!HGE;P3YQ\N8-SS3Q?<.BF'-PKN?!Y@YW/L+(A-6ZE+>I15HXAZ_BYO
MV<I3S(.RFD[S8E;OS%>H4F$S)B 6V"+=QF^A;Q^,S^WS</]CS%%*:3\&<]BS
MH)KFV)HO@5EE^4R3^S"GIG:X.NX)/S=;"DP2CQLI3IW@8S3G#E'#2O&8_*64
M6 L'*A.>3YZEU,IVJM_ #3%G2<<SY(/F1H+$:G%5%'BNEAQ ;CMK<;E8-E.&
MU",6<"[5%/<2-Q\W%Q^L31)W"E?-'X$YM)%_&2QM5EY6<!9F67JTKR <L\[F
M.G^YLQ_F\"5GB72PMC,DS >(!BY$ZJF8SZ-T-K<+(G:5KHP#5>NU.(F^*N$1
MW'K=9S.Z+!3WN";F0 $I/2'Q27Z*2%0_)US4QC9"CB4>)7Q4-T'N!']@MT\Y
M,'@//FN70<VVF^NX!)T@DRZ48\/P)*22KRI-QGD^Q./$O:D?*5 +3H,6'Y5Y
M!CL[#Y#-)B0+:<"DI(:8G> =[.&H*F@I"4K#B5#9 .YOWB;*%(R* GN&TQ?"
MM;:/KB8:MVT+0Z!\%?P&A\K(0B?Z-HN <:AE+NPBZJTTYQ%E+5*WRAG\P.LT
M#*#24EW#AQ2S0D+\^6UNG_T1>P-/L3EON2$2?T_")5/<^YHVBL1T5(Y16J(4
MX'V?IE$6<B-8EB;!JW[G (DEQ3\/JX*ZXR%%C&$O>?,F,*]Q";<9[L:'ELYW
M>!YFP"AS^\F^VG>&%U%2*FRS&ORK JI&9AGQ*+J;,9R4)AG+E7@3PBE)KV7N
M9PL"&[8$]A9>I57BL0'%[R'M!6HR3?,Y4('S*E!MID8)2FC@VG@&KS:O<9S@
M=5Y\I9L;!I:&XL)B>,HX0> &N;_^S O=EESF;][!]=JAM#HQX#=5-M0KWQ#1
MG,$NJ#(ND@&>&HK&D"\M=\-$!?B@BDLXCS/#C"R]6&])D)^2(JXFP!)PE93A
M$@F)NW8!)YN?PW63?,.VN<ZG1HINHU>'^_LAF#,/N2O+-V%U4TLX6E(CSN(8
M#P]YXR-(C5CK&3^+V-M@7TO4OV#(B(4G6;C';Y"^R[@J2Y*UV.D7>'$.R@=N
ML)5VR(;)3#^C^P>CZL"EO:A(P#L#D-! K)ENDKE:<&KN'$=PUPZ4RJ2A.JL2
M$>QD,:0<<6*WWSN?.XYF!G]64[I&[(X#F\,WIM2:&.]R'LZ0YUJ3D@4R@^+>
MI'D).J=IEERB%JCO<'V9\5L@(*K)E#>#-?O1B*3 &(D;%5*<KC WWIAEJ7 7
M4E"XT165(#\4"J[;2D8T*IU6O>V$2!W+:=UD@M!8<BV;X7 ?UUHU"2T\/7K<
M+DN.,H5+'U^%*PUL.B)TG%J1*#B>D'6V8%: I))Y7YFM1'LBARWC&Q@U^+RP
MRM$ % @E9I)1$I1K/]2E!6^EH3ZF'U06Z"^P@(059#@=)(@_J^&EG"JI$7S5
M%06U^+Z*4MQG<Q +FV>L,]1B8'9#O$# ^(&?8,='13Z1596P1['B350X+*G+
MM8ULT@=Q$OSO98Y3H8FSA23Y#7J1*!N'"=!1P1]DE<V.RSO%3P@=V&\4EF\W
MI6_\ 38_[X5KK;H\:Z0D;+2]9; 5>4Z_@$65XC^MBM9_(A4M="G4*,"V-?"R
M5<"UA6IU7H(*KN\%,:0<@D0VL<=86OOI+E*K$[R]DT)&' 53OE9$YL9.",!F
M!<%2ZITVZVA;LQ F+MH>(.Q;?OU$-_.21N#)+((9OFFYKC]I(4M3UUB7I>OY
M?W1.0>90>C]):.%&B_AONP =U>(SR,-A5("T/<^'Q%1$+4?[1V$@:VLL3?PM
M%<CO"1CWP?=X__?VWYQ]/L?7Z%_=-S]T@M])H,C/Z/,)4*^>H>8<Y\#!_Z:K
MD#\!C 2J*UIZ,FZ0#] !4K*?)T_)<0'S2)"\+\%0)*&DO1<AK3+3W@'BL$([
M&L5Y1 8LK\YPH$R(=6PB49B; C,5QP/CEDA7'$=(E L?!NT@1\E"*J4RRUEH
M3-'>!OXQNFLL!='M'=BXA Z]]?K-F?['6EY_9PT2 .B1Z_E2[7'GD6@$7WX=
MI=?1O)1EGIQT>@?67:ZGU<?I''9.3OXSL/]I';(UI^VW/6?':LE__%:]][C\
M=D/[DR?H9]^W._Y3%(!('?WUN[]\N3A?+F]6.="_L-]M1!S)98XB:Z*_.:?9
M3G'B^*8]VZM'CGC3[(_US5X2*@)!'G^/3P3_!;< OOE#8W]KQU3+VBP$CJ<U
M=/0$Q^+(?9%(;!(">[NN(5'>C/0RW,Y7-$I#[6.(P8;!DS$RSY$QH..B=EDV
M;OX1"IMRIJ8E>K% N5!3UP:VGBB8%1G*YEZ=N/*Z^?CKX/OD![Z@$[PRT& V
MDI#D^/>E_)W$>60$[QMX<\FKL@2Z1UR_KRQ?CTPCZ"&<W2*% O:U9-\^AP5<
MS[()&-2D-3Q!+D$<]DI&!;LMCTG=:1U4ZTAK3QA5J._UX,NNI^^1,,H?W$,M
M8<"2]B=:\K%-*<MV$WDGHAF< ]$)SUFV2^AFV4:)QP7(TVX/.[0Y]!.UJG-:
M&>T$B,JN'38Q&MO,$IHH:K2;PE[3-1_%8]23F>I'-MA"X1%\*)_2WTR<H7WR
MZ!/ .WO9TD%AGX"=6*&3H")7;@QZMHUYX!(I6A&A$C)A;P(2EF20UY[5)G8L
MSL2!X^T4:AM5%'&"SPX+<H0/YC?MW\8<NS(#;0;P8M=:'UDZE5C_9+B@1@6G
M-0![17'@)LU1^I-JQ;[A:/@G2!\T2)#%,A*6\'%\S7'@@U%,)B#96NA6@B\,
M8*9FO_"DA)C824*V!6Q'/@QOLP;MH'%\7*6QMW0@BH5]/0ZUE%21Y*[8%8!F
MN.B5CAV+D;DKY%6*8/S!GDS>EOK5PIK]S9\Q_K,2_EX ?8F_).3("BS"<9BC
MPSC(E!JJ6LPS&EXA4VE&7 B2DEN ER+[EU63 7O7@>L2I2/9>%^!JOR./>SA
MC2S-NP1&)%**PE-NO6:C@!) *#^ '(KZ]@MQ?6/X_^0*E*B$V#XQD!9&5FWD
M][*()N+FLT=)$G_I/)F8*-R^A*"<8\:]%B\,C@R,".*H[42&H/S,,=A%-CR(
M!QNIIED5=#(I#9P V^3LKDGB"L-L:+%D8"FE1/6R_6_PH21;]D4*/P,5_-M(
M8KL?%X[72;/5K8C>AI990"OQAB97YH(6%]7"L+A[Y,N-:LZ>!*0P$&">F8O9
M4=RVUT/@[,];9W_ "B]@]4_K*VBNY].RTS,.8\D@<")?Y"^N77])>RS0'6]I
MIH6)<F'D]2:.L]_<G&(5X;DINT%X:=720]RL$$<D6S:@<)P;8V=I3?J]XS$7
MW:S(Z2YC_B11C>I(JE#J\*4QYH"C?@,S?:Z2(7(6B5Z:B$@$D1&TIP5]IL4_
MU$P+J$V6SLNZ/$@;-G,>H'?G*E'7K$^)RR@,@%N'>+?;@6E..J.%? (F+ZC(
MJ\NQ$TW2R0F5(\K,9L.NEDAZJ>A@\O>%)!2ZMW.]HS"/DATY,[CAF:)I3V6;
MG6-SDV1,WA*N8[A'!X8A1!;^TRAA%8;$JW41_7=^C9=PJ,6=T')-BMKL(;HL
MZ6X9@Q@!=JLRN;-0;@_^E&APD91?>1#GJADJH$FRI6AJD7,A&]EO[2URQ^KO
MNLR&6MGF^*L1#Q/!P5SG!K+H3PJL!6"?E(BW'"M0,4DU63=<916E$3DW*9/+
MC11)2"H2KR(K:.]'[O55SURKF2,C2SN2?6;,'#4:H9*%1J_U?-N%DR)]G:2I
MJP9&?&4(P\)'TWDG^"W/]@HU EN-$XY8:ZNG>;'C$A?GNDQ-AI\R8BR/D3%J
M@KMHZ"$DFN%&*))!9=4&5_ZAEF+"7K0&21/$8S$Z]HU*;"B1G)$R-I:QS3$&
M9FX-'>X@5=]Z=W7L519?L$U<33C)S3)UH:QLWA#9?S"94^;81..U>4EZ[QM*
MK^NJXN"GV2)28AOF-&60F*^A-8H2>8A'/R#ZP3A-#'<LN;:)(K_-2"CPS:TW
M<C)1!?(2GP5,2\X5\VSR21+KM!>KA\,GX0,),"F98WH .QLAF $,,5%V0O2]
M:$H:EOY8-,$K\=_N#6C3P0HU 6E)4K $ODAA_T;*7HXSE6)@ /D([U:0K<!$
M[VT&$7&>7/(ZATU3&G%0-=")8AFR7B/-C8R/"#D@QNF')N]4@A/7O"+Q5)@D
ME5"N7F)V.<TR**-4*'02#1_4(?"0*N[G61Y_W?L[2=)SN$=A;X@X-ZK9XDW"
M_AVZV_6<S%&2KP%SGVGR? U$UQ0*,W="G:Y&45)PK-_X6_%Y_2#831G?/J0B
MH1,$?_Y[&L'XG^-QCD>93XV;D@R='(P^I  9%J/;.!_]'$^(QC-\W;X<NNY!
M*$=X,'L(>"])#(9!R*M1)C/E>L[(-\+)#_"L38K!%ZXDD5GDJKMFFA%9:)34
M6I:5W3T.BNN7851':XF CHNOBFX5]Z(TV05/)'\E17>-LS').KAV<FR-]((2
M2DMN9.KH!%^6G.(<X#-EW_15CC8PUHNQ#DP9X**9?L:$PN#O22[);^PN7:0[
M\LNF<U:R)Q-T\S#59+4D:Z+(#HSJIJ6>/E'. S&8FW\+WP%%EN2RXX3!^>Y,
MN/3 ATM]N-2'2W5$IR;]KJV*C]K/7 </UKO_VAT*S3NW>3^6+.(PO](D+;&4
MFV/'7<E6>JMBA69P+6'I@*0O_$=_"Y)^/W&,Q$WY+4"-KL3[OL%4W_K=T=<=
MJ*FF-?@I6:XFZD6!+J'5 S>]MKZZY&_Z4JHR?2V1JR>9K'$]C5#DKGLC19)9
M9L+L$I]:.CM'E]>3;,V;VSP578Q&H(2S*^0SN4+.'.-P<S2$_D(N:V.??C:7
M0 "<[#B9BGL/-MP]:8JPB__-[C?Z($%%I==<#X9YN@33<49+*;3? -7.$E7C
MBFK^-!%1^(HD&8Y;%5,,%IMQ)*VX4*[9:DPY_3C[U5"9XV!I#B=0=T;5S/-<
MEP\Y^&/ 'QD\E%_C7W5VM(POOE;>.Y5=1AQI6_R*;! 5'=KO+5JU"T/!++@J
MU/H[DPPTU"NI]-LS27#X)"N+N@KS#\4IGR,,\M>26\7$Q4_I=)64;.B\E/,
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M]*66'NR45(KY>[M*RG),2A,7SNL\C3]!U;:)&E*^\;LQO,#TQ!IZN&7/\\F
M+M%WYJ.?;<VE5'JP4UC>76*?L=;<9I,'"^9XN'H0*DD*%JN1@EIEN!DQSL$&
M**=Y)M@5G/%PERK[X L^X!R(#$-30\_W7IKG5"OH%E/]GJ64:6#T!4S.B,G"
MR2VN"1#/HDI!)9Q4C!>KTLQ0= M43N3DG.IF<R;R)QS_-Y6#UC0+_HY)KC27
M47 15Y<JJYV@O''.&E1SH&O5_*4JF[\ =>I?+ 1+"19-&A6,*L/KP:D[<^X$
M9VGMI#4(!=U%]M>16S/*P7I!25'K&/^NM>@,6ZC+J##9$#8VW<)+%.2TEJA<
M$B$%76;J4MSY8)9)(@N5;5($0 88Y>8+=E@.<J\BH2^,#C L]4:+K=7<_TFT
M>&Q)FC9_,PD&C=^Y!+A:^#V"G^-DVO(&T#Y<*\U?T6^3#1>^2ANQ^$V03LT?
M*2>X^9L&95CX UJ)BP.72GU=^&W<]K5K_%'_)BR9J4M.4[Q2A9:];%SR.5 4
M6 @;%H:Y1$PA!<>7,TFDE?J)^<KCU8$T#CKR9Y8_;TKB,0E.TO0,@7$\*?]3
M"7@2ERKKP+RMI);ZZF;I-.4<<Z'YDILF;&<-RP,AWCC%;,_F>5-BVL#(GCH[
MY3J.)BQC/XG9R$S[J[=#A' (G[ 5UMJ-,LM#]UDG %4KPGF-#DC2!9X<;:YK
M >H? &[.@8'[[L>MPJ'[/W\Y/3H^?;-E6'3UPGI[%>@<L]!>"%SERU0JR2CZ
MGK99']<*T[6D*(F2PN#GJPCD!!OHP#46^PPI'"D[=#/QK2,/Q(>6R.0QDZRN
M]AS:-\M1[SQ)ORB2YNP B:^3/[<-;*@UZY.MB,LJ9;1%PN:[BBA7473(4'!=
MYJ*CM<#F627+XBA)78-DZ268KB^5?38963BKEH0KS-=(C?6T[FG=BF\M6:ET
MGQ($B3XY8LS *FT24U0E9=/(N>X%="$RNYDM=+*AT8!UF8_Y.P$/I#@M)-@D
M&S-VBDW.-@4Z-K3"YDI9Q9AJ.ZH('-))IY0(I.1:RF5AHR#.<DHNC24^)>Q-
M*IJ:Z8S/8%#DT5!'5!CE".\0ST">@5H9B*3OG&\)YR(HX[&:*!=7U?FC<X&T
M1<J-XB_"__>,%'/R(KDC4NP=$^$]<7KBM)I,HY:"ZI#V=-$4E;APZNJU+GUQ
MO3PZ5+V@Y#3+*B^C3"H@J322BA>P4L8!"L9_8NQIJFN66MXT-1&Y+F5*\TO$
MWHU+6X;DZ=O3MT/?D@;'JG<R&51%:2HUVDT]NO/KY1>>ICQ-69HJ60<>HKRZ
MAIO<VF&Z^H<4PM( A;71F/9?.]H!%@T81#H>PA.>)SPFO)H:R&%S]F%Q$>9D
M"D8]P75JPDJR8077Y=R3D">A5F.$\?]$7TNX&P*:X%R)..,0!V%@R)-2DT=5
MWJU%?E)I.E*&!-L>HCP0H--+1!^<U55.3ZR>6%N)U5 HP_.XN<WLUJQA9^)#
M7]7<*>35DM&IBM69SFU7L4E)=D,'M;)@B04ZV=*>=CWM+G&;QD65:/<_43$2
M9QDG#/X7AP%(VS&Y2=VZ[5#;T@*1U4#BH)$-3ZAO*JXHI,ZMG< 0QJ>VB";W
M/4EN#4FZCDCTJ3 P_:+OT/$W8A$";$IPB>7.&</;L)?2 LA@(IC4(<]J?: $
MO6,ZCF ^L:IF.B2@O>R.3PEFEEBD')V&\0NVKOE0&_ C2GPL^-4 R;]\^*C!
MD=VYA37':JJN(CMWBL-58',55)NQ[<W-.'UQ=<(&YFC4"L(M1 U%3<)F^+(.
M=^\>1A,H'&2-;/4G#)>\8\2;CD[N03#*G'!XKG4"%J-C8YK/W%@I5-6-LC":
M)L-4H'6XQN@J*7*BK0[M%T=Y8%W%I<2:L/*(R(M18F:ZI&":EV4B9,K(B%9L
M4I4!)3$1'(%L0H85,,"$UU1BCAYTBIT* -J('M4M$"0ER";9%"YN!XR_,P4
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M?5R=LA=7K=(7$(V69*-4(/U&*?H)V8:F%D[ &=QI/*3 -S4%U'?7+()-'KE
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M#*TD#1]=&"<UF8H5S=*XN2IS@J>EJEB)OI,;^EQ0MC/ZV0W# 776;/N'J\%
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M@2FB9^3%6;G"'0$3?&)@@NM%P 0[#V0-0[PUZ?9ER.!TC %RE,:YJ#_/ &!
MP#NT:M(8?A._61NDF/=W"LN6K@F:LGVVE7/V+\)<YHU?^DW.8)VV5_$W>>,T
M#TA<@ YFS&/YC=/V7TR7O0 %O!$CE\[QK-D]F<>Q^,7L[+-=HYRS7_YVY V
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MQ-*Z0KLFP2XF55N?WS)ZA1F]O('3EM$MHU>)T=^5,3=ZGV):FQHE?<@>4^7
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MM68^?^DUO6OLF>;YR2+^W]D [&57?74GGYMS;D^>.^>V<TR7[AZ/NB4_A&<
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M+=FRU? 5=)MC?#[$H%6^E4M!9;'%RU@B+'Q9^8;^##F!4CMEP1*)6(*^&'U
MNO'& SBZQ%:W6:^9R83!<BQ5^J6Q8D"PR:2[I]@[%Q<SZ.UCJM1#^\\X$ [9
MF1)1I-G[S,M*9FKDN1R11X(H/I<&F"[2B5CSHG._*HRE'YZAHP6*LZ4Y*4\B
M6P8>20\>A5XBAJG8_1698E!DGJ'5%"&;")^39MJ$CIF"@)RO%B+@[5.,@.*:
M6CE3D,HDL11MPX&%G;'G&IM/E<N@;2J%J>-X6<@UC.[=0$9P">L$?134&PDQ
M5UY"L@CN0/2]F%RLQ;S7F">H5(R,X54N,YIYPAR&U\>7\:^Y ?/Y$NXP@S1)
M84$Q<4","0'S"<2/W/J!K$V^M=J+NL8(-<]59S<>>TD6?<(ST&59H!:0$3DC
MR,AW'-;H4\R#_#HO[J<QS\%Q8!T8^U6N';NP,I;S53[TBXM-+'?9,F,9X4$'
M'(Q(NBJF'#O0'-^?,HGX"1NS4&FE%8W_W0R'1[^X/@7$;D=8GW)II*-V%]G[
M%Y[8@.(>G,NAV.KPJ"?7&M-:<ZDS(Z2DY%&J#"%A=$"P5:Q7WTNK/AT4P4 ,
MZ9Z55W"4^OHFH))!#JMPC.SV^JJ:!_Y5]'GC'RD^GHO[1F$08LQZQV=_*8,P
M$W4K1&K-'-//1VC--1N%12I_R[D\5]KILRSRN8DB$&<9+>5#_PS/=#IT72^/
M.VL=(4,P@DHZMZDD7HY[O0=!FQ,;M+%!F^H';5S'&_SMU1_GQX..VQJT_G"/
MVV=_'!\/NW^<GW1/_SAIM4\N!JW3]K$K7C$A^!N?+C]?_N/ZT_7GNP\WO_UV
M\Z^/G_]Q]RO\^^L_KK_^T>F>=,[/Y.<W+'SK7C/9PAV]<@>6[O#:2[Y<GKG(
M:\+A0V?SAHOM^3I_+\OP=W@%_CX)E?N/A2CJ(L3??*(2C48!0QHMXN'0]2)M
M@5RI^TE&TW09 -?-#(P4%_<=&.\H?I=@\<_>@><6NA'=8ZI585=)G;OU5JE\
M7$^:!#WT7[^C*9$XL??=&5,6)6XH*%+9/SQ$WI!_D[Z9#ME%R2B\$K[O?0<G
M>A0B$GCQ%?\-+L3(^^9\2N,T .NTX7SR^B-7^&!JP\(;SGOW 8S<2SR(. P:
M\^:*;^*_9!%O\X7DQ@:*G 5J7KG8-N#.I>1M@CE=Y[^!WARE1.OI_IX*.[.&
M7)6?EMAC\J%SV2$2V+:#EAU5!^K\VI3D9.FS12*Y(TFX=L&S%EJ3J;:AA5H
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MIZ.B#82B6%P8=V-L:M9^QAZ2YF@$2N@(;QP?<4;O/5B31YP=A4^NS],, R>
M1>)5%JOY'(K8V;2YW(&88US=C!_X$AV[3PB\8HRG@_>E:G:U.FT:BT)S] R
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MWP0DS-%O4-8Q83"Z$_(]_H]?P&'F?UQ>?J%VYD<0 W61SCJ-IO,AC#1VXT
MG_E9HE&5*?/[%9*QN>8)F,RPC%@(YW.8(,@M,4*7_9VF<^E+"&X9C8^-^D!W
M@,Z7@B0?^D02O$VU%B[H/F"9G XN3PEC\IL2 :0?'K$7CJRO07.GY@4RWHKL
MUG-]:GV,1T(DZM=\[F!8@J[#"'+^4SG"D6(U[47Z*X'H.UT&KCR1S8RK+V,@
M)EY?]CH:3#2=LT%O5DQ<M/],+^,20_V@X-MM_,Y7QAE&+K\]^I^<796M*;^
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MKK1R('F5E=[2E58."Z^RVUX#+Z_3.&V5.$&BQG)1XPK2GWNY%S\*9!K8CC^
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MS>?;GW_J;5&]+MP(+-VY^_4:_O_K];7SZ>;SW:^WSC5LY+WSZ?+KU:].M]V
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M:<E/OM,05W?5OGM[3JKWJ7 6E.I^K7'V2QA/@GON>>XW^P!8]J/!LH.;;C7
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MH8"$$&]1PJGH.M[."[5%6/;;C?;)H(FX=^4(B+K 3^!=@"8K#F1=N?Y2."W
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M("LDS]:4Q3;E6)*;1LL6A[LL<RL*Y$.MHD((6)"28/#O!/@G)AMD@4/L-\=
MSTRBY1&\QG(\ROE5T]LE;I/Z7H\Q&>!QLFP"Z(+IL-I>*(A-H)51,?7[A0*]
MRK+86Q,GI]'<D%LQ &I^S.A.JMFR\(?T\KQ=!-U!^6/#^@G1(+L+!6I;S]LH
M"*T3>.':GIDG$Q7TC:.=B*NEN1?RB@6-I=9A02!]?G3=2IO1#_QKZ22B$;E%
M%B2>,->9L'C*TM*-:5D!2 JIE\X-M9;;:8_(/+UI31[E(PX+0_*EJ<>0J/S
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MUQ9Y+#C41BS>^N2GFJ!-7_<3^@:\G;8164DD7@>FD$-C6^9>N.)4Z5ZR4TU
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MYZYL[#O??[%C-SM=N]=J&ARX6!QHVNU!TQZ4U!?Y,G% *A&UQ8%!Z]9NMLK
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M7X2+=^F[P8N/6VH*ZI !]@+#6";5R:0FE5:18W>(G@LO0Q+U7#)+Z'1HM8M
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M4+9NAD\-ZR<5)W%];.$M68L/*MH+14:&JIU?Q'7015SV")0%%++,0HJ6U54
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M@Z7CD,Z$19X[#RSRR6V"[*M4BU5HGLO^+ _528_/AE/*/XA>ZKYX7O:G%B2
MU*'/ 2]L]WT6G,QX((T'<E_E1A6ZUJ%:]-94BYIJT>I7BYH$9I/ 7+?L6)/
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MR5877\06D;#.1,R&=7@4!=2?0.)HOO&IC5]=> Y9A(NCQCB+)U0W2X57U*@
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M'3$V>NI&D9REEO/2/=#<.0UO4L)/)Z&)UZDIO8E/="N&KM',/YHT))I-9,_
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MI\3 8XV=G)<9K$X[U4Z[I#V+J-J<)6!D1)3Y)'],\Z3AS)Y44%62OZJXV:2
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MX(:ZY=)5J#4O.[HJF4M*A;)LR++A"Q.I^@5U*X$.D?#.:2J>,DSM>;$/HI(
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M!GD7-.OFT3']B0;2</YZ<T+JS 7WKN3; 4P1& ],71]OF)^JUO]W' #?'_>
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M(7+\LQYRM=PJ0%)!6/I-EWMV+R;F;;\?7I!L6Y)!:+"M0 N$M2E:##%$]ZR
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M?,-$5C-PXR,D*# V3.2^9N9H%]$H6'NN3TOQT%@R3$LREQM#>.>*+\^K;JH
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M-^>X96A%BTN:-D>)=)>N64JB?#_)S ;R +<,K:C;R8VE^$16A>LRFEY5X\)
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M0 2V:!KC@"3/$&^:DCX@UU6$A?="9*.M;L.2NZH]S#L6WB9D[KIGV;U"=M=
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MYZ<JW"&59P^9N_8\!$PJSTCE&:D\(ZEPI/*,$/ C$3"I/",$?,<$3,J9+DS
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MF<-XKZFTMU;@2>B0%!O> AV2H-2+E<G)<]=VT*SLCO'.NW&"!C:A,D<65 O
M9=CPR-O 6BD2\,W3%I",J8Z?@BW5$T:IRJ6RM>B6HH6V/DZDNOU5-D9Q(SJ%
M8UC1,!L+=G B,H/4)!+==;]T>,\6*J'#QZ%#4A9'R/#J9$C*XNX4R9\]QG,%
M]!W+1BO1\H;3!3'*T)Z7FM9=>XK0-PH)_0Q]/W#Y7!MN%"J=DW F_*Z"#DX9
M6*$ZW/905;14X(30,#O$32V ;;EP2(<?PJ\IMNVBCJSP^[9#2NZ>NF*)E-P]
M9,;9\Q P*;DC)7>DY.[12^Z"UY>_E-DM'2TYZN>*5:'N"ENU/!FW)7$*EXG*
M[.@P'67#T22I-R"E=H]2:G?30:$_$15G3#<,"HH7>S*3W/"3LE>*J4!;U >U
MH1YI+SDD*%"O69I("%++2&H9'RYL_*?28A[/Z9D%.XOR[-*)._6T2U&I)I86
MJ",MQ!0?-6\B$H/4,)(:QF<FX ?S*!$"?C8")C6,A'[OEWY)#>-#FQQ?6L/X
MD9E0FT8KLU;!*/**E;%=M3BM9WVG F[R"LV$Z!/4+M: $](,^WS!Y+ODTEW@
M[6;OWR6UC.='^(]XL_3STC&IA7SV6LAGI/KG3&R-7_VP+QK!)'3\''2<O/YA
M7S3.1NCX&>AX%_!Y1#K>17\('3\''3^R57C3=/R?"]R)>-[,AW>N2(SP?94M
MZG.@NEQ2DOEJ>IY6/^/+K &GJ$O& E0,V_[HIL.^[>0;_4&7HGIQIJL,MV.E
M5)N.&!K?=,A2X5@B02XZ/&M [1$E@Q]=NUG!0!3<^>-JCTC&?I#M9LGX&OKM
M[&&V7U9-LN%IM8R7X?EV=UWJQICM?*NLL6IB?T4U/7#Y9UK44/EF.)0%$D80
MH2@=#J'SNM/L@2N4PKUF\RAD<]EPQQJX 3XGQ9Y72LV[-DV\VJ5_$>HGE:(W
MP"VD4O2^^.7\I:1O;N#^?$%8L<LOV(63BE-M.R(79_4J:]KK3]6.XM7XV5LG
M*D233I-SUUQOR^=[Z<4PLO2,08(;,0RJ$(W1X42<"M/4!5OY/;O*?;=$]-J,
M=7:5^V[YZ+57>KU4SBO(CS_)_9P9&CP@VY\+M%$U%YU!P[#0'G".8RECUQ'A
MB76,FJ&C!5J&IL$A1;A4*'V<$T;L6-YJ?+[ +RA1S^GE9CH]'%>F2/"@BM,8
M*3G]^I+3:_/AV27.N^6HUU[IW4J<CPM42URRG=+G@Q[ETK953WN1<2SWZ0+5
M2TB?9=NJ"!UQKJH12ZX6=+/>F*N^]$$5K(E$F&4(Z/GZ&M9K,^;91="[]:W7
M7BFIOR)>MJ_PLMT=]5\BEO1)K?M.<H3F1J1VVYT(_+*7J1F=<C3FT)\N]#J'
MNGTW=+6,@&59$I)1M6RLXR4O.12U<A/I7915$:7BX7@BJ'?/EU9!1,\[I<O7
M9L@+*-[3\9QK+Y3HW6OG9]P>35S \+W-A5Y;[79:28]>%H0I7QXM8ZV>0><Z
MTT_W6[NHQIPVZ^VM%$OS5&8N9JSUW,EWFFNL,5$1=2*<.N&=?YOL\6_\^LLS
M]2^R\=F#@Q) .WDL2M'_-'.0I6T 0J*$KHX5=0_N?$@W'/@RQT#T@L-S$(?)
MH8FBB[JDB!J<X Z8V=_/..5/[]R_966U_Q/^L?^VI '10E)AMGO%@<71JW8Z
M@*+^^R*1V=>;S\1>E-AN\W.1^-O)_Y_CV;\(JHAD:(;U8R^-CI8U S@$S6#!
M- 61L05$-2).X)M_B-I:].S=,I/)[\PA5^W'0:*AC0C%OR>3_QUZ^1%M1V O
M%^(F<K1CKY*0_&_M/_*CXKO/#!L[QGY80!,=9070LU\]%1^+8Y@_&/H[>Z%3
M><, T9<S^!\Q-+.03/RO3CUS4A6CGZ$0@:)/\Q^[]K=\]]&W?SI(AJ F^1DD
M8G74'G]'F.(Q<7Y(EG@7(S3U_66VNVU\^?#U]@?VU?\E%)/27VA$Z/^%&/S-
MO]_L^*N#HX\TVCZ; 7_TSN/WQR)B,3RB1'DBTV-YE&12R5$LR4JC9%QF1FPJ
MGIB(+)!H)OK-WX@ODFWLR\F.7[UQ=VICJ)/@+S-<J]BN<J%.@6]Q#5[H%#-M
M/R>@6,M R3;^*H'\TXG6:^UZI9CE.GPVU.[ OZI\K=,.U7.A#-<NA'*5>J]]
MF*]_+!G1GN4T8TU_V=;_;!5_*7K(F1FN#8&*_?>9M_?3RF-'S&PB&DO(*7'$
MC%/4*)9*I48B)8LC:1(7F3C%QJ48V.VHN$<A?&%&-31ITJ/:WGQ69*+C.3.?
MHL38MR.95*)?C\_9O@H*G6QUNA(B\F@Z8H(C"Q.WY;"Y1ETM1^D$R*0'N=&F
M.8H&1YIZJI_NE?2DNLC-]7)J;J<S @='QM^.'+1*M:0\CVYYT33*4HVE62T[
M'<5&U-N1^GPN>M9J4%;;ZU;9GCGL.,>N1_'@R)CAS6;;>:_"LY/E<-G9#L1N
MN0E'!N99*O'PG7JEQ'MFS,Y-*IE!LHR>&9BG:-0+_%KG(KQ7R*X2XTQ],32Y
M$1M\^TJ-KBA[(W<%EG';QM8J::G6>I0(CJRLJPL[WVE(?#Z[]N1:3>('@!LE
M@R/Y;7R6B69F6V&Q,#C&X]-Q$$<CHV]'YFUM,NAE,JX@,M7%!#"Q6C*Z'J6"
MSTP;HV5Q7EXZ5,0K+G):>5+BG/6(IH)#YP65;;"LJ:F9Y:*B]E<9DX&0EJ9/
M['TYLO3&5*VBLGJOF%^/M^PTWD1# U--"?7()MZ0$P(S+X.I.%G.^V"*T']P
M3XO=4<]L;G1*T:U$<KB:)*9>$QL*;X=*C6%Y,TP4I]2B6$JOY&UIQLVY$1T-
M/M4=JIO>()]Q^%XCT>6;;,:;1IIH:."I;365VH[B\03%=)A1HK04LK$H''J"
M3IEV?6!6(DJ-S\]6V;YGIR)PMF@H&SC6Y':>'\^7#96A)T(R,LFG,CR<ZPF:
MAIH@/QSD)RTJ4F]4E653'6X]/#0P5S!6)<WT"G-UX?;=*:M0=F(-3^L$K<JQ
M;#^VJ:T@#8!VLU88"XW2"L[U!+%FI G3WZ[D'N]&\S5-G(V=;'Z-A@:610\X
M,S)HEVA*J<6WBKAB.DTTUQ.$O:Q);"DY=YM"Q)S&(BPGZ&UYC88&GII+Q9<)
M+V]VJ5YIQ$=SSE"TZ_C^TL!3Z\JHY5;!R.&!6LUY:CQ5ZFAKU,<J,+1=E&;B
MBEZ+5*95CD89/=OJ%#B4FA\8NN@JXUE\-5D+^<AH),YJEI"-8U=H8.@XVW'$
M1;W4%-KER=I=<_-JH0>?>H((F5FE*48RG;4J=N(1LZWQB^$:BM\3E&5E:TE)
M2PZSO#M-&$H*VID]R 7,"7)9U[4V*^;3456AZO6J;I2GBQ[<@5/R*IN+4ZEY
M1:7JG)1SJ_9VTU/@7$_0@+4=]H:#-K<2VKW-O+ND%TRI"8>>.-A<A"G'<\K*
MY#-9+5$9==L-:=E$0P/T.D\W(ME60\I38D-/J4PD5HA(<*XG#G;LK//%1<IS
MU/):6+>V\6@ZEFNBH8&G+N*]M%D95WD^4IVE(O(ZFC%C4 6=H(%.4:SV#79(
M\^4UZ&5'7*HD"TWD@P@,=6+E5*57:4QY(*^RXI;EDHXW'45/T$"FX0K;S4AD
MJ"5OQ4UI*S27.AQZ@@:X?LL:"_+4I'K]:E/)- 1^FEZCH8%E.3-AWLV6EJ;0
M+F[=.9N-4O(2/O4$N2S++:_J"JT!G^_V;*&?6N<3[AH-#3PUV[?-3;S%.ZJ2
M+"8,O6X5>WFX R<H*]&()4:3E*,+H*O;%I\2O4H##PT\5=P6!D7.6WMJ>^;5
M!+<IK2<\G, )(NS7V5$Z4<CE!&4[Z#=ST0G/]."R3A#A)F<R]J!?+5+Y4K0M
M1E?I'-RT4?0$$5;6SK;,-&I+=;%.;!9):PPL"!FB)RAKM(FFH'K)0C:THK,J
M&-9Y=/%&] 1E5>DL<.$V9G@Q!?&7LYE$^Q &Q4Y0EA1KCB?3)J_QH%$?K[*K
M^;PL0'1S@K(JD9;8RAO=#96/C:'5DFZMZBP<>H*RRM:"XWIK9LRSJTA;-0MJ
M8PUY*W:"LN)Q3LMULZD:O]1L-I'.,JT4%&^Q$^12Y5>BFXQ5-$&T^"33EO3V
M& KXV D:8$?Y[# O5O,4,+;&T,FWYU:?0T,#",MV<U1$:W@&[SHR)\8'E7%9
MQD,#$*LQD=I,5G0**NBV!_IZFXLK13CT!+DD6BNJ95N%&K^8;LO9^L3=V NX
M62?(1>^"1E%3F@S%4%8NLU BEJLVT=# 7(M2-;[41@.-:MM9IRLR@IZJKM'0
MP%RW7*-;VZR6(I^)#*>Q/-VRRS0<>H((>TDSF6ZKRRXE%@KM2:\ZZ$R2<%DG
MB'!!Q60F+K@S5:E7G.VPG3#KB34:&IAK#FSJ'6,KJY2[SHSJTUG'*[6F:&B
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MO)(Q(Q08\SUOC9\:P%D+<Q")]=9;EUJ4&THA%]U,U0E\Z@GI4JC8G#OAHXH
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M79>@F%&H%->4K1#>5F(6 [,L7\_G0F^\*/$YF[ZO0>D!Q-LR3(Q.'C.W5Y6
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MS1XQ#UQX(LB^#KC+4=W&]VG4X;6D"M3%H!1-5&T)S3,6%%5&:T041JE J''
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MWMB:[$V2\L"F+_$C: !Y'WP*UNF"X4$,E!0)  &E6VU NAVUE#5!!?&"0O"
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M4KSSS[<NPGVKK4U8V?-E-8>OM^P( ?%EM6ZO-QX- ?%UU9\A1=P"($+6=".
M"%G3C0#BK0;/(2 N6P_]-<T8;[TJ\KH]WLY[![N"Z-BG"Z*9:.+RU8)_4A_W
MB$JJ"!X:K<J?E9*%Z!^B_POH?\?EHR_W PCIXP;IXT*UTSM*H#]+"10935QW
M5NA-5=#_9#2X=RQ@SL$'KYUF@"((Q$R"ESZR;$*:HK"40VBF;'A0$R*PKQT0
M4R YGHW=](0U.I[J_OO;S"LX8P;G+0Q0_/K&S[<X*?42V=(ALGX/9+VYL: O
M(NL=*-I/F=0XE.LYO@BQ+I%@_6.:Z'_I(<\WY.+^<H=N=H;%82)M0UHC1<PY
MT0^_,WQ4O6(75(7>HB4T\\M^=UE6Q1B:9Q%[2)*)<)[%CR/%<-CE.:=1O)L4
M^]*D;&52&U7PE+I;$TN5+(-K8N.(%!-Q]CM,O'R/\!^=/Q_\%G3O&QIL=X]<
MZ>9LQ.^B,^ ,TOU\4:>(7%O <0-F53<K@>-F?8)M@=PLHO?L68$'Q6S$=2A&
MRJ<Y,8XT")JZH/YP;;P.Z?E[F='?1?'X0WI6##H3J]H:2<X3J7JK)JKF.MZ$
M](P&;S.O%8C>@;O!OY:OTCA^!#NZ1]X3.AO.K#C ZT-Q(0'24]$\X#TG.,Q*
M*"\%3^S* CU?>]32%F>TSHD)I#%0#RQ]H2+TD")OF")#G\.91?^'*+)5>91B
M<;''\+2B.PUSU>4G$4212.8_,.1KX^;OIP0/;0N!13,]*3C$7N;J7D*N#/4
M&V'M.'CI;FXK>ODE,G)?3"R@V;UR^4"'B5#QYWFW_W603[Q3JU')FF7_WF9'
M[)TKR&.F,;&I(.*G*TLC^.K?DK&4UDYPSF0R2K/;Q(O?NPP+=!-$+)I,_D4\
M_8CNX^@R437<WI4=%,3YWSHLB0L^>R-G.H"+:\W0Z!Q4?#>%OVZSL]DH>R%
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MT:6-UJ\IS]@5_30Z&G%W="F$O+^[!T*R->RLQA0M&Y(V11]"X#D.OND' CU
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M\"$9%$Y_SYK>!!--OMK[*RP3^J)Z+3K*,"$@;@ 05)0-"^=N 1"I*!U2Q"T
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M;!O-6)%6:'P*<!T_>5N3\'8UU%71!A!376!/-1.N]&?C6'YWQ;W4,&((W"4
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MX8"5'Y*C?]W2FMUASCQH*\2Y6\:YZ]:%O(ASW]FR;:%+0&:LYP1E#:$.&X8
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M4=;54286+$4S\>_082P93.B"Y3^0&;/W&,WQB2)OE?-C_M\]"##_($A%WA#
M?XH3#(86+]#=47?/;6*)-MDFA.W"(M 2W9U7(=@9F$4L;5)IWB>NYNRGSXA'
MP7PP 04&6B.3\(.[92N;*%8T!0<\R%%].P-9>,8*<LE.OO93?RZ^8A,CL5VW
M"LU2%9T*MF7XN61;1Y#F;)(4P7-0Q-6N,,AV8\:>/ P@U%_? %IN$\!J,*H
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M=5OBUX_/\5#O0OAP/_ES6_3UH+C%&YVL_.)(NPQ#!_9$]Z>[EUWX1@MSF$
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M<^3!.KO,]5X'00HW#3 I?LE_&TKQ#Y7BL"##8UVA,HJAXK2BU_56LL$Y=F:
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M2,%4;'AX[?&68@[%H6\9O77R G4#V$RJ&"P/?2U9]A0J!LK>L7QHT_BF#-*
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M(JD<]\_J--KDDL2[/7W"-O4\L9[79N;9'F?])+":V$R-X&OK&5WRC%9Z5FJ
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M/*7?Q"<CK,DIHTJ>L)1D:$[]H%[U-]=5'G#U#P"8-U1O?)&NJ1G-F5I GG.
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M912_@<ZTGYO,S3S O 53,CQ(Q[IEPR6PKFMK \\5!X;2MF )-C _VS(,,*0
M9FHKSD6(E(?+*K8@TBE\P@V)7%.F.Z8((!*UMJ"8*,.<^HW"2ALA.CQ] <;O
MH!W='AYFYK+7GW(M&??J:[J4J"5C@^P"P@/R6$639\*>/JU /9G'ZJW2C2@@
MZ"MTK- X_9AQ2@$ DBT/B,)#@.W__CIGUAU6_@!._Z^IZ\B:\BD.GX'2B;A(
ME(FRWN/$<K*DCO)MI=!M"!3JUD'$HLD8%48%A1!Q"XCXB._J9T+$%U5Z_"A&
M-%Z'FJ$W6WU]4AYDL[EX>UYA%A CD,,J2L?>+93]'Z3K79\Y_U!JK\XID@+5
MUL.)M10E(DJ2-0&O7<'>J:;E@N>[%F 2$:C#\!91@S_3)I 'D!&"KA95U(Q%
M0[XP\ &J,/ERQ7D_"/D^/8W_R-I\\R?X8_-KR5!$&P+0*'C%%DS@JP+@Q?'_
MN0ED'#("F=C@YQ8QLACL]G<X^_]O?_H[3,0DR[#L?S; M[>ND9]80"(,'"K8
MP%9$'1-5\.I_1&,AKIQ@G8G$GD/LGRUX0DI$8M"LB>S^"NEQ0LR)N,3V2'9@
MD?B_VGR$P'+SF>6@X(-_;,4087( ?/;!4]&^N-;T'Y)X86ZT+4=G&+7;A/\K
M1D8VQ-O_U:ZESR6"O)_+T8: %K'42!K"-Y#0+6>*^]QYD2\1%3$"G"C;V09D
MW'UX2/X3NOI? L26_H(C(O\G0J)?_GU$\8.-.S N_1?Z'[WQ^,VVB.A$$.@8
M):LTP0@J!?Z@1942$CB=$!($(\=(18SA,?F73XC; RW:6F:WLX.#-P:[-@ G
M'$S799N%5H6-M/-<DZUS?+N0;OG.I4(U#1!VX.^<OTR8 &JIEM_LTS+)+UO1
M>ZO@JRR?*;2Y3"1=J[9JY4*&A?]HM<'_*ERUW8K4LI%:'2RQ70 #(FP5CJS4
MFUR>J[8*'2Y2KK5:V]7>?T%_:6;$'5F> Y0E)QI1EI("]A.EJ2%O!=B"X%_@
M?!3_OO+,/WT,!5*1B*E2@J0H09$H4J '$B,D94(2<'Q 29)*)V5Z(Q7!+^+$
M()%(,@,A08N$0%-R3!#!!X*HDDF<3,1$>4 >_ +H8E@YV=%$ED_BLW0Z$Y-Z
M>5<:-02@+1Z/5%ZE(1/+%LMZCIM:/-:N6EQK(9"G(Z?SN)LH97E@AY($W]+&
M$]NH AOP="3'MY99K)H=XTIJK9#-FM"8Q($F*,2.1])U-U;(M5.OG*8F>^G5
M',^TZ(5 "_CQ2'(AN"U^3,^Y2;E==(P*9E5E./+D[6QOW5\8[0Z.I]6LG$SS
M\78W!T>>O'VPG!B.O.BR^&0QXML-F96;B880.WU[K;6<I<=Z@=);^NNDI&O=
M9K:T$)C3D<5F01AUQ>)8[P(\X-P.4.SJ#2%^.K*=Z"M$BJ^ON>Z4-[&F,1AS
MPX60.!W9I.6\;8L*HS-LJ_7:J)=+RQ@K)$]'"O5TH:J^8B8^L\9$SDD,R%9^
M*!#XF8FVZ70CW1!-/E>A,&RZE*IK<2$0Q.G0U10G.%IRXKQ"+\1&1QIJ6I6%
M]L?)T%AO/&13O=X [Q;)Y*P[22@+#CR5.AU*L\F"1BTJ.K\254R6LXW74IZ%
M0T_9V9%3[%JWFAS)K5364&OEF(2&GNRIN8Z)#:Z(S_7:V%7+\_8KD1D#SC_#
M4J.J65S&NQBGSYQ1E4]Q&792 <0ZL_\R5NC&JNUUC>^^DJ5J.JNO6M("#CV9
M*Z5@Z6X\(VC<K**I)$;V!0=GX="3N<Z&%6RDL>Y:3T]JK?Y89+,4#B:P8RMD
M#VU5/M_F!>J>(4X=Y9_-7_:A"BI)@=H'E0+)USH.%;+38_U4XW7MS5N#IQ$^
M\'W8%QZ_>$.VIW+L/=\"SU0-:['!T<V_,>@1^,?77F%-L'<5QT"3/U!6Q $P
MG3SW6%GY8G_1WN_ EW]@P7S6H4;$PGUYO'TA7JB+L>SAOMQG7Y(O#!7NR^/M
M"\"Q>+@OC[<O(8X]YKZ$.';3??G]4)'+ZO'=B)"8NO\]<;U\R1WG>YKIITF2
M^(B'\)!&@[/O?*\(SAG7U7Z)_\-R_X-#V@&3#A+T__V*_?I3.M(OQ&/3\9 T
M[9&M*)$*^&+D1#A3AN6;]HD2BM;CB];'O._O$.FWQ.MJ%+V6P-TQ6O3* HD*
MC$4H(AK*X8^4P^N+%OFGHD7@+TGF.\D6C.<[.?-O8P&'S/0#F(F^!D8_6'AE
M&MYJ@%U"U^D16YDKIJ<X5X/?!UOM/8))J<=,![Y]+"GT@3S@PN\:2IKQ?$D3
M""&(-V];>\'GPWG?6"_5OJ,S=*&(Y3I<KE;^7%(T$NBL;4WV)'VNL+8MFD,4
MQ<@M@SR@@[&F"U?<U=Q1VG/ 1BGVF1C4T<1A4RL;;_*D(RF5U)*9,>I0\!,"
MH_&+%6H^>12'P!("RX,M_*& A=X'%EJ0O&XU#T2UQV.89,04M:)6THV'!1;,
M%+JM6'K8Q46LD/$\PNN-*ZR 4@FI*)6,7[7TU;U-YYH?SF@.(\IRJIB.XERG
MF_17V+\/"8H^$,! YL>"OROF3",,O.<Z[]M.^BNL\9"U0];^NG[2#^4;\"LK
M-A5'0>YI&.\M@T/<L*;P8 ^] S=7XK^3*/^P O1?;^+[4LJ:<F8GHYRO29[1
MK6,EO+M.DVR,%]<6,^KE9T.]U1 8:+0GHT3LM&M3:+2'\A[*^^-8WK\G[_UJ
MG4]:_2ZOSSJCSJ3JULQJ'2;3 %N:B$?I,U6[GM.8]I66G&(":]I .HLH3S13
M<US?-1':U)\W/![2JW@;VR/T(WZ%]A*(*P S]D!8W\8S:5XH._HRR^HEIM9>
M%A-+L]E8"''_TB&)7_(-AAZ'4/!#P7\(->;W!;_$9L3X("'H7'K<=FT"GV0Z
MC2$0?*#(Q*+TF:+NW\8?<U WT#JY+@@=,G>_5?TQCMDG(\U#8>JME:GM16(
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M82I$,DHRS T3(4(<>%H<\'T#(1+<TCOP82&NC\E^M<:D,_Q$+6 Z3M!3<[R
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M%@_3%3<"ASD1=F@K2$&)1DSP(?B9YC@>2NJ2+,<-HRG":(K'B*:XCE?/#Z8
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M_!;7KGH0B:SV^]5^QA7'#.K:T*L-VA>FC8-EM).36%(.QQ9S=LP9=:1UV>S
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M@:$KN)&ZN87JOYMZZ&)$8,*=\J+]U\Q$_X,R&U><J?YIHT:OW '+>M+\9W?
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MX9]>\T-\PC77!UQFG2O:PI-*::1&/U$^NE*[7NQ'8_.A**:E2N.NLE2[P^&
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M8YV@#YP\^,##D\ L_8>\@,4%24_=4C:M+2/2R.GJ1:>36W56E?J7Y0/^ [B
MEH;'_P75=\T2(=['$\-0HY%,Q.=Q<7J?C#A\ZW[0K L__DE$]GCBWR\QA6W
MY5V?>K8Q,+$I"6>%CUNP&8NM69(-_-)!AT]W67?ZLKM<:I:ZACGRG8(4CSQU
M3G4C4SLL^-\?&]3_3"P8BKZ?!]-#?/[Z&C[%?#R5:$T+#VJV,1O)*_9^/'$2
MH62FCG'F=I^I7-,;ZYWNB8+W6D>44D3!.G*H]2A[P A[:"*_&0]\!H?1@5/,
MT^")$0>:/? -L3DW"LRIF6:WTN?U< E*JE5.-!MZ.YV(5S6YM>P7Y9-QR392
MB633Z=\--*8Z)'>0A>1JK6!%M7RN/2YEBG8Y;D<*%0Q+[)^P$#$7$-[_'C-U
ML"8(2GB?TMZDLP&Z>P;D9&W!>,H>-3JH:H358:QI8I5U<\R!S8NV#T'_3[$V
MI:,^Z(E4J027@V49BDI>O.;I#1NON7L;SWPLBJT\:E'(SV#Y+:F50%?R@FQ@
M8XHD +J&O%OOF6AQ9XD,[WFSU0,1+T@F4!6(O@C-C% G2]54X&=,U LYAZLZ
M4\6:_]K]Q;$$)B*[O@(%J> 8F>/]Q_P"FC\V19F^:8P)U2JRU9.G#.D5#*@S
M0C93*J69G_2+7^#GQ7:230%+WK*]\,,8#=N^""Q%6[7Z*GZ1^\"2ZR9I.)J+
M;]%(E/W9_?63__53^.6QJ0GIGU!0TO]8XGQ0=7( RPSF3W7LC/%'9'+4&X%Y
M0L-OP._# N-0[R3SLWQ?:OZ"[_X[RMZRC"=:Q+4"WY'9_"*>A75(A3R']$G1
M_1N2TXPN%BVZ(\3;""D.9@^(3H7AY84F./:G\NMG^!?]-WE]#DL]8JAB0Z>Q
M3:BAW&.X!,L I !&TY_VY"66:#Q=+!.JQ@A8JC7Z3<(]%'YZ#Z'\R&2P<,&C
MP44\D%77PE8WT][:BPM9NIAW?4MQ.1=;=>Z6 H\27MIB"LQ\-TQ7!H^9,W&=
MF+L:W8:JI C+L:439YQ/,?3MWV%/O8_1B 5K.=UG#'0TIN$Q$9$K=QF.KF'+
M>D<<IPXB;"LS0ZQ#PD^ZJ ].&'O#>WGZC<749!UIE,3DSU_;2#N4K=>>2'[F
M"9N*%Z$,,>YJ]"3I(O"9]:C5O'1-;'[;9B9/)V^R;'E)'&'+]1%D.18$&CQ7
MUGH77.4#8[B[(IDX]/&#*!_#S+S)XDF121#W'SD^;/>1:[BAVP ^MX$)'AOB
MZ=QLP\;UZG\N3!D?11A<>F0M$"23X9 #U,('FT/TD=V7$$>B^Y8#/.#MQT$$
MN93;2+,,(.&[)(I1[7>C>/H4*#YQNOAHQ;H&80(+:^<4R&MY%\FYZ"V[K2FY
M<(Y'G!3/#Z+T+DA;KX/TUJD<]PCQ&B![JZ%,]+];&0R?(LLK<BC+*Q%D>059
M7I=/F@JRO#Y]EA<&1!?BJ;%Z-&/*S82ZQ&&\]L5H2QIZAXP$B%4;CH5/.;=2
M(.K=P/ET)^/EF*[F%3OOF2W_^LF]Y\#NJA#W!9N1G,:W+ N=E^A)38_B%!Y1
M(R,VK[2- 2(JXK[BO<F1V3[YZ%%+'A2B:CY\:EW;\7[G:,LWG>W;VW,A);$%
M87'(!5#0P4GN;3LP+];-+0?3<.Q@E??HSR$S3%7(J>#Q#7@VK2&&,T*_M0&
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M4VTX+#S-]Z^\'AX77'E]U3,1_N,KKTUG/ 8!P6SE(R*SH2+CD7'MCS@S+Z5
MO:KV=_AH2?^[STM2+E)=S3*5!['8N.>*W<CS4(S6]WGI\+A+\=+1A+."6S=E
M?9&<V=PDOUSN&9PYUH9;MF[3;+AEXG(+@-GZEH5Z6-_QZL2\KM;2*ZQ4=Z6%
M9J@'!#ZG5\;\5B3-IMV^*.JZ%B)XN*.O9R3HNH/?U$#$4,50F\4RY:53A(IX
M,IH_#;*YR0:"-WM5(&%A8VR#DCR%IIC^]=*5E,L1;LL0>D>%GD.FD;H?;VG?
M-F]]3G[\-9J0-"4?@YB8+=0)>(U^Y@2A]HM>+C,14:>5M2T$=QJ]DD(^%_W
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M0-YJI'3CKR[CXTU\;B,O!<B"I,,0'&.8;[P\#YI$X'OU93FWC \R/#.8R7%
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MO1P2.[GT:MX3W3U%J.("Z_:)+PD/'R+KR8A+D?[2U#TAK_*7(=KEF34>,&O
MK)^%62]#QO<PZ]7Y-=ZKYM $M]^?P6%Q;F7FZ\O7T;C-IT7^S\IRQ\-H7X7G
MCD;/ YX+>.X\>L0U\MR7=9>L+Z?&R"S2NQ6-7KY)_9K?CO('QWG\0=I:+=<5
M)[PR25_&/?/QXG(5?IS__J*>&2:\=6N;.7-W4_<BB[2^OI):KO_,>U<\B"M7
M6*C6_G!:>8 ,X,JDBN^A1_J*5V6A'"72E>7AY_G+7*WORK@/3O.Z'%YFC<2H
M*2>TB?A<*MP_;G=B#;^Y$ZN@]W::L:[GDEE78ETW8@W_\"Y%C1S36*:?:C$V
MEC5JXU)(*RE1N(X9_O%/["89B^XU8_TR?HM+(,XU.#A.!#E7YU_[O)##GQMR
MIKK*H9)M3L3I?:O=C&9JX7IT< QR2,&;T J9QBG1)A<NSO/YR*S:=@:I?KR=
MJG2%,%SICKGJ#O^? &\"O/D<+M+/BS?A<^--)3_))1VVB%4<O7XW'/6<^U2G
M_O%X4POE$KW8*%85J_,TVT]EQ/23!7B3_!.\^3*N;J\SA1?4CWQ.I_>%3,3/
MZ?$*G-Z?E>4^W%-Y2IX+G-X!SWTTSP5.[T\?/+^TC?)-O<\GUC:NRS[[JOE6
MW]6/<&(U)6#6@%D_![->G>?KBR<'?IV@_I<7]8]VSYPN7/_5'=<<[WJN(Y\J
M.)^MJ:5)K5TQV%B_8NGS&+I;AH4+!><K]?)@S"ZDNEA41H_S4G\D:UFH%QS^
M\0\7N4DDXN>+EGUYZ/APE\?IXNX!=EQEE+U10=EF;/!08:L)3C8G?3D\0T<3
M>\X3]6*-AS$_&V;D-K*;,^Z^5WPN9@ V/B+*'N#&E>+&9;VDGQ@WSAXMKX6&
MM>1LTDRQS6IWD;02S88I70 W,JUP3RMVBI-1&CU/]&&VX72RT$K@SZ/E7H,B
M6ESJ2B3^P]N+9C8MY>VAB1 UD[&M9P\M!NG0EJV\W\>95!$'YG7;3]'NS;K!
MV"8V(?O(W#2^= NEW#!>/SCXJ5NIX'";V_WN3V<N*9\V="BV0)_44*U1VD0]
M+./XKW6!^*8^&]4E15V*Z>FCU,B*^<ZL<:X"\2^3ZWCSVJV%0'LBA2R$,?%*
M+M?!-GNHN3)M<#8QH,8Z;<5G.=UGI&S5KB>-O#%$JWU\?N@V4'ZS/FMG@;3%
MJV5#6T$\&17:__5IXV9@N=T.SML-;*%+NHW_9V$D(X7R:!M8U,/P"Y/#WY B
M^=N-HE7;6?=80POHF0FOW/^5IH[5W3="WW7HY(86$[S!&(VA!#_^'$.>11MW
M6@YT@_5Z3,,:U@VN\9+5]<\-MZ><?Z?(AD#+!OS+E[?@$EVFFV@ #-#PJI(=
M[S!=BEJ*TZTWJNWB;-879D8GTL@=Z#!]>-Q5=IAV-\#?M>%RLEG%S">3XG 6
MG19M,=A#F-&!(3'W8'XU=.0V3\<'&BE+@V7,0FZS"=I=T$(3V80"<SU\;IO(
M1EMM*3"WKEL6DOZ":-/"NDO;<"I#%?498STA4"DL^'XLCY#)_$Q7,^5?-]".
MT/LFA+^!D>!MGD"W=O(-Z=<^-.8@$M 3$7HI,R:R#,?T.N*"A$$9/ :_C,P1
M2]^^=/ZAWN=NG*2BZB#?=2I5UBEGA"7*=*Q2K/[C%!*TT:X*E>R6>A6RD )N
M'2@&:B%]5]BP%&.MK=I?D]EE/FNM4K%4U"JR:4K*0U=?WB.QP"[3*(_ZV;MX
M?3[_\0\F_YXRY2.4NP%;&[CN.@)4 ^IO*(P66*<D+8F-/D8K9![Y(::,/$#6
MP7XF[@3(00#-2@#^H523#*UE2;^2=2/+B6,"2A(&IAP!\U[SQ.WE.KN[\$YX
M$2 0.K+@60)LN]M*Y!$686'*@D#:0UA*#V.:J79IUUSRM3/&KR)GGO\@./ "
M=[]A?ZDDX'?Z!(%VB/9-8-W&74<V.9Z\3N5XAVEQ2?HU(;&?"):-_V_L08>/
M7N0PPN0TT1#A,QNS CR6SLOKC KK\': =JXY\+JNK)$I6T,$#4RA6;V][FKM
M6Z<#:R3''UX<PG_8S-CH(<TZ!!JJCH]8P&>W(^LV?Y-MTV5MN7J!+[U=(JO$
MBK1J&Z ..[T!_@+;PI8#T1/;P?/$'.AHH L9+B4HM_IHX78D=M]!&?7#&BSM
M'M6%#:"GENZ7^T<V7V2Q^$C"8-29*,5"O=UG1\GZ_I%]>-Q9C^S7&R_1KD%8
MS\*L0"5*]>CLERI0VG0LA7"V# P3I-9$ T>33:SUF6BFHCF $#W8",MX4/0>
M(ROHN^0/C9ZE[U(\?)L("J;[=-8+MA (!_U^KH$0W&TDZ$1V#81(WO*!1%P#
M(0)HNA)"!-!T)83 T,0'A#@=(=Z8E/BJUOH]NIL<1^4OT]TD^M[*YGSX-GYM
M;2JV2Y>WP"IFRM0@%L$@_JL:YH%<!'+QYW+QB4O^E[WZ]X&X7+VX?-6^&1Q[
M&^<_M131WA'=@(LNS$6?G8DBIT#ASW&I.@V.?$PM&L$WT0SI#CK-9:#P%5PV
MOD2R;N3PC?H+BL1Y\GNI._,*5WJYE.!7XK9>AF[3BZ>GH(DCLBPOFX/D\2JR
M.9;6L5KW*S=M5RI'JXOGAJ2S8^4I9FNE1B_4^9NK0@TJ\5G3&/N@8(8$TY3U
M 9FDN% T!ZBT-1:R]Q2[H]K#M&-A.B/S0'9OBKUG*Y659;(=LSYXZ+74!!\1
MI A<)@K?Q/GD>>X$!,AS5?)X#N3AKW*EUX,\$3_R1$Z /+G)_3,?52M"NSB*
M%XI%+JT5Y:/E/"^*/(U2)5VI\8TI6VPTC1(_F9;Y#"!/#) GG#QVB_$ZK>YW
M*'<E3.#3U,OY" _45<#GYRS8\%ID^5.6$@EX[MIY[FC(\--4!/D\]OI.D9 &
MLA#Q&T-^80]N8AD3.#9OX X+/3B9OJP $ZO(NH%\5,O0=:3=P.48$Q_+U.J'
MG\MC./17] ,W*S)P YQ!&?^TPGX9,EZ/1GV]MCR\Y+<'!H+>RVR@8*U!9]<X
M4/-0(./# /PKP8< H@L !Q1KS5Z$A8>2JK73]U(K*PV'7+I8EV*D/LA-E$\$
M)GV (F^UV[\/BERO7?ZA*)*?1XN-?#>?'C752?_>GG6S921@%,'F.<?><$GN
MR]OG.\I<#NEPV9@J8[VQJJN631TBA]4Y,G"MT:U5M@]7[;X% G]:N+VL5R#0
MT/S8ZDHX@.26?!] 5SQF#; >BKX/:%%.8V.]9)ECFU6VIYM=)]=8#:0XJ&O\
M380_AK,!,GQA9+BL[R;0NBZ.#*UE-Z+?R:$TZV3G"[42'C\N[NH8&4B$)!:-
MG5P#^WP>MLV^>XI38,P&QFS@$OL<"M=&>ET8/.3.JL0>YTX,/8K->3H\[BCM
M42PW=\O=WK#)($,E0(# G?59%:L_08!!4YN,6"$]&*63Q4G!C-5K5KY.*]=R
M-[$P_]T\4;5=IU)@$7X+BS#P%5V%ZN+EQY4@(PZ;<PVX,HUZ+P-8X8&OK1:K
MXG,[5Y1#H5:\4B[WYU(25)CX33@:"5P\WU.@ Q?/56@B;Q9HNS?,$UJ+?'7U
MH$S3 RE-!!IK)+&;Z-&L^>_BF?'[O&ZV0UP0\U+ATA<4_\/_IJ5^$?G<PEN-
M7RE;");,D+\8396[KIH8&'>!<1>X=ZY>1R+&W9;;VP< &&(+KOA7=5JS'.'/
MFECT2Y[DDS]*&[D_@,+SV7+:& SXCHC"%3G:;&23A8>YQ+%$K^*.F84!=GQ[
M[ @<0]>JCGT$=@RU[//30-.S[5!6U:S^J%7-Y>N '<2IQ"6BW\VI5(7V(NM"
MT%ANQM;_6<[VU,C+XK=1_ ,-,T?(JS0&E;]L8T+6L[,3^&/\\)_R+XQ%SB0P
M;-^&M]=T+_34BMOUW@0%]/WY;56WE]J'$( HX-EA.'9T^P<ITXV?>@!=U4:G
MV^K%^,:HTYGD:O-:FA4MC*X<"=IQ^^;QKP 7 EQPE;+OC0O7JY:= !>LQ<R)
MW17&SRPJC4;IA:P)W;  N("UK@2W?S/EUS?PF^$W5]Q&%H&!>N[:&F&,)SW#
M@<8)G[FXQI^4];G 4@.=ZA7LQ()>T!5CC$I8VH\AI3V3[6CCKI1EJ\7XX&XB
M/??N^P+I9?KCG^0-']M/_CR=#A6@Q_6(U*5*\WP_]+A^S>N/T6,98N_KJMI]
M;D]#W02OSP:MVJ .Z '>K<1-,OZZJK7=M-=7"O[]-+[=,+3'9KY// ?2&/_M
M.99NN20:'RA.OUUQWE^G?LW7T K),'][S.LKBK__./+JVQCRE$<^>LMZE@AL
M$EJS(B,[ML&P# OO]1>5?T,SIK^#@B,[1^80TN2EX;C=H/T;Y2['%=EM3?J]
M\TH></B!%(/7[^5#AKWEHWL@0ER$V\BV@S)[=8S?.6'Z+W@.GA<6/FVK(*O[
M$3UD>/8_!_RBY!ON/XRJP^T/B$G3<^B#)[B)H:L$%6[7Y^&>$/LDQ,<ST"'1
MQ\<'FD,?;Q;MYW_?&Q0-R2:<0\,=E@T#(<_1+.+%:K)\Q.?GIFR4#86YW980
M__5'$.);EXLF/.'B 0K13AIR'[_ZMZS-Y:7EKC.1N.4C&]GSY@4[P41O$XE_
M,YL_-Z38(M<BY-NR+>.2_FJ[6YO[V2OM/'Q,P'.WL1W4C=Q&SD2HG>A#>$.6
M_Y.9H0G'\K]:U?3!HN6ORD.+0+#19Z "'9S0:WF0_SEUW]$72A?O]2<^5L<X
M+30*S;+ M/)B0ZB)[58AW60*E?3MNKCQE4VX4FV)3:95A1GCB;;$1J',I*N5
M9K54R @M,<-D"Q6ADBX():;9PA^4Q4JKN2G5_#I0$+8.;6L*E*\W'V[+PPNJ
M 3Z/E)\P@OD?AB>__+7%XAP)8OTXTF31[\HQW3#70>5A6TYDHH-)L3@*]]E(
M1(JB1$^*H&A<ZG+QOA2.H3#;3X;EJ!S[03E3]K0V8_:44]*<O!35B<RUAL]/
MR>5D ,KI[D@U\Q"?14OC$1LS[4%^8E<JA5I=XO='KBQN(*WL4+Z=:\MY)\V5
M>32!D9'=D5QOU+GKZD*$G>K#:*3K=)YG1ATKQ*P[<@?^O2:DSY%G/3T<W\W%
M:ENLQIYJPV'A:4Z:BV)3]:5?'>TB_N*OCC8R/7A"[7URYI:NHFSJF&.@^D9S
M*)OHI6[K2O:IJ2<;=Y-V<=+MY6/Q432VF%]9_W3/+0E5+!@+EG.Y]NDIV<+T
MTO=F!'B/E9^Q :<%WF'H70P-CQV;MH7%\DU;#J]_ZO:*I="&>B$9*[#X#&=T
MTL&;=$.&!UM[3\9:M05&)CRMYYCP?TA6AC 7U>C=,AE5(V_]DTFZFB.9"3:^
MD6+?,"HT?5_>,'W3&-/VQ 8<8ZH,]SR0J4 ?>,,$GH7>QB 6I'.S@J="R\=9
M#I2:L]P1M@K'X00?JL@T28]H>#/)L:3+F9 6T5Z+Z;GA:#VW3[+7Z5JU+,=K
MCHRG;!([&$_G\ ;=,EEH&?_B+MR\<]_=GN:D*S<T]^V^Q H]!S%N)^D^MFKQ
M'[*-5X>@9_EZ.,)FNPVU]KS-U99TSM <>[.;I!FX;M@>J=;=O^%D<30WD97,
M3#49=3R!%ZI0],560][S/KB+M(#?[;VZN5X)O:..>K0V+T@&>6>UOXM5^RB5
MB0R>6X^Q!M\N/L:Y[')>Z8Q#YT*IUUM&][$9;<Q5TF#]./&&F+F8+D*Z6YD'
MDV\M5<IF#X#5/'[=X\O74>#&98"E*SQ=M$W^H)OTOA*U,0%/TTTZ=LM%@KZ(
MVQE:%VK9&N$"0EP!(9*WT:!3Z#40(I"(*R$$EHB #J>CPULS<5X[HC][>\SS
MH,-GWY5UH[KPNYN&<K>1R$43 J^D:6@@0-]1@/Y&^_O$,G/2%J$!A[R@#7UN
M!OG+]I\43R^=Y=;T>V%/QNV77M4);P-$/U^>VCOO<%)7H]28/2V%8K+^Q*JA
M1C1N-N?6T'Y?SNM?NH)3R\,/(#EOWCO$\40SE@@11JX2/G8SWXSD0SK]L$@M
M1J&48K+37)-/*5N9;X5*]DVI;W^YGO75!)HIQZXSY0R4CQKS.RG.YAHY51ZR
M]:7='. -Y:&21R(9O4GP9RK/\]6D-1#65X7UA133RPKKJAB=#1KY3'OD5*5"
M7(VJIE.M7Z.P1LIBT>J'HU9[K NC_N2QW%M:D*(0^?%/XH;GV)MHY-6VD=MY
MK5<2G'DM]^[,(42\4D%18-<Q'6JFH>,_%1+LM6@"PTMI#(NQ^B0-LO,DF\M'
M9IETXT[K0HKS5:4Q-!#HF-J2A+-1CY'72V4F6VN]7'9#06<R>)8@CQ22,?'"
M-%Z>%9HI;^9"L\W -R$V><,<7S1-%&=:\@+/&1;VLV5,,._$(^ROX[_\S13&
M>%]F=$\@H+YY%I-1+44S+,?TGNJ;TB\OE0 M,&/W:-2^Y_N!B::."JD($,6G
M.:N,#1.\95I#U2++P_]'\R$@H@OC^BK@ -V5)9)-B^DBO(N & Q)N-S9.2YZ
M Q.*X,FH-IZ+;&+*RSVJ9T.RP%BU;=2#5R(&2X'>(XF]UG =PIU,-!5/$N+[
MP"#6Q)T-Y!U8L$1\?)G(]GU#?J*XJ4K6[DL [&1]23)3'-.DO(AFL@8Y27@5
MFQP0"#;;L!-;? DS43$E?%MY^S%L2CFS KS@Y\S(BYP9";'A/^3,];T*@$..
M_\_Z$@79+Q,-D6[!WM+A[B"W)!NPH3P8F&A ]WR/*YM.UR;LSO-L"'/\[U?F
MM/,\3(;=63+BNB^/^H_'Z)A2D(.M0WX!EA.0&K6'F+$!R2C(EC&G0-X(/3I)
MPDC7<#"O8;Y1^\!CF&?0P#!5FF?@M?YA?DX<4QG*%OU8U6=X H:YO&&0>XJ3
M) 8\UJVN=K2CT*^M%!8%ZW6RNFXSA&= #5!(%++ %">,3_,D=.(3@%)X>.^\
M?< 3,C"#DT=;E,$'#AX%:4(D1>;$@AR[V=2+4\=NLI5%A%O5W_O0^"TC;@/#
MOMBNL<%BQO+2CPQ()7<"?G*_Z$-](($?B1F!%K2#Q*WUOEF>I,!6>(N@,]S(
M/VP5[/<:!V C\?B?O/NF+=BA[Y(U#=-.]3UU0TGU "4/S>W/<<I-="*95?#O
M]?[A&?LP ),'3XMDX;C@]>H<:(_478A[_1+"E6AP;MXOI\BHRW)1J9?L886U
MK\2E9#C2E_KQOAR7E5B,[2=W,V^C<7Y<?9H)/-O4,VT[$4\7Y-G!O-\PU^L]
M3>5\=#2N9F*%;JM>>ZS R.CN2(%+#KA<-K80950?S.V'2CTYFDO\.IMW/3+[
M:(X;7:Z3:?/3YW'=*)C#>6AP*)?8S#\^#A\?RJUVNB1V%W<1.ZQ$8.3>VVLU
MRQ[G)W&N75P\SIU%K3&KW@U\N<3KD87<@-?*6J+-IGD+W6G%7*>,5Q39'UGI
MI:)E+O+4;S>+J8P6;<J*R@ZDZ($55=62[BPJBU'UZ7[0F^=+89.%!IA[(S79
MB#^62^GHJ)A;\MD$4"T&O9?V1EHY,9X/R1.#5;-*%SE*LS8Q!E)B?Y?FK)9>
M(&TU$9T"+XRR\N!YMH)JY=XNG5F7)_>5!,M"MK4Y%O<U]W!A88W:X84^4H7>
MP"PEXGPX4O]XS=TO:ECZ)YJ\_*WJI+I4%R:\I9YLDL>\K+7N2>9W_(*)ZW?^
M&?E%W<Y4Z(^YJ&LFFLAJ;ZTS$&PSR*$A$\JL_==G9H:,F_R;-BS;2LL3HO"L
M4,^=H*#W_I1=THMPOF9(2CO4U;OW@VPT7G:$<V:"4I_-LV/9:G_YBI+J[3=Z
M:;_)\:-:1+OITP3A=2[I3W)*&HX%-LNO4^9L;J5"\A%RY62K%(C[69#;>3!.
M$TO><D<K.GW=Q!WJEKQEHX>!\N*);5P\H,OUT86[#1^MAA_0Y4)TX<BEW( P
MUT88#&0!7:Z0+@&072E=,)#% L)<2V;UJPKRQ3;ADEFAQW73LZ>O'=BCPTX*
MP51E#;\AC[09@B7"VV3="OE?N>U7H$[@_?_NY4NNDZ_Y]R9?<^%;/G;5>8*O
M;O0+N=C,23-,CRL0E]^$S\-MUYWJ_T9N\Z).'L/]7<:J"_07S1;;WX &LA 1
M*A*Y03.D&1,(Y9P,Q:]LO9<H2QF^=->5_6TX11%*UR*^Q@8L6Q0_;<5)P9*J
M?9\/?QA[;LY+]\]WXK@X',?RDW$STIH?*Q!)BOJ%5L@TMIJEN/YO3R %O9?9
MB&.:QG(/E>-&"[3,5;3[MCJ?H8XN/!;NNA#0"U->YOC_G"?UE;L^K@Z$^Z3"
M';M^X3YU@R4JW5"AV<OU;226W#3?'HA%:1II= PNVQJ\NYG:.V4\(46M0BLR
MC(KIA^R0-7JIN^@<$@%(GZ,X=\(^1U=@CJ8AEH6U2)H)96(E3)V1V-?/BF$C
MAF-/4R3[S";FU8+5U:SY3:;-YIK#R7;C-8?^)725O]B?\T#A&12=QEJB,PZB
M%PG6 C]#@FG*^@ =!T2]-8Q$G#*?9.5T/CUZN),J,56 R1Y3>D[HGKHF.?HF
MV'&R:TZO.L #/>8U/>8$(EPN"IR<%\=WHVETV.R72RC\Q(((8YV&OTG$CEW8
M^Q*>%UJ3?*/>6 RIGAZX7;ZP9792#/L$OI?KTTE>N?5(A'*#;E;.-"SK91 ;
M=921="<6I/9RVBF$1^.G^VJH+D5(B\0;GMUODABX7KZT@%^;@?,)7#C79_/\
ME=JT;_2\$UNR1GEJ]].+;KN9>,P_U%OET; !MRIB;[!Q/I_W)X-(5LAIBJD$
M/I[/K^-<%5A].H7&$R=Z.^1EM"G$PKG<4'4TMB/-8]'>+/5<2M>E*&@RB<@Q
M!W/@1OF^XAFX4=[K1GFK?&;ZXT7=>NY(HV+AB6VM(I5!L3?'\HFU@21_^@#0
ME>G5!=UR3+B>'CA(OK3]%#A(KER?<"/8:WD\ %7H+MJJA"6DCIKA^WPJO)RE
MY+$@Q4"5B'/':CL%+I% I#^]/^/SZ2!_(-.I;&0Y?Q1&>38]M-1H*FZ-:ITY
MEFFL?H0C[)?*/R%^FL#]\#<(=+D4\(_7,"Z\UBO IG/'8UQ\<@MQO&PCC9>:
MBB*34+5=1?V:^*0NXP-'D.(D&A,^!E*!#R.0\6,J1R#CY]0_WB3D3G&T8%O)
M84P,C8=EJ1V*V4B&<D]8$XGS7]T/\O'2'GA+CIM6%R^.?;EK/A=?^A7@XOE=
M+2XB;I?Y>AD?E8CU7%"&CW%V>6>F#2?:[V:C<RD!2A!_DV2YP/\2@,0'7A>Z
M^-*O "0^P'GS1I2(V7+#B@U&MKALU8P[8<8630M0 FM1T9LD%WM;!7Y?>8_W
MT^IVPZ@>N_@^L8T)_2?^VRM+<LLET?A P9'M*B+^VB-K_H32>8;YVV-"7Z&3
M_<>15]_&D*<:\M%;UC,*8(_0FJ48V;$-AF58>*^_,L@;BO?]G8@?V3DRAY F
M+PW'35/R;Y2['%?TMO7D]\XKB1^V R1$&O&,CIPE["T?W0,#DAN]#5$[:/%B
M&MD;)TS_!<\Y5$?4_8@>'CS[G[TL;O(Y]Q\HYXSW'T_ .UX^>'[;U3*A:/^$
MULC'2&#=T/\CE_X=BQ3PQVOH8[FP:*5N\X6R /Z1M^N#<Q\57FF%<8;2G-RZ
M^(-7F'._Q.@+A6X(F[Z]VH\/5Q0-[Q8<DL,=,0S#B\]1U.C%,A=\Q#OCUX=:
M-A3F=V?_7W\$B[YUN0C)DWT?H!"M^$2*G_^6M;F\M-QU)A*^,B"_U^<[[ 03
M!5."V?RY@4G?;*!8J6_+MJA,?[5=L=3][)6R4SXPY+G;V,Y)$KF-G(E0.YI7
M>$.6_Y.9H0E*PK]:U?1!YGQ5R%OD6,'RG39(<5=KS:OR/Z?N+G&LIHJ_&/2Q
MBBIIH5%HE@6FE1<;0DULMPKI)E.HI&_7E56N;,*5:DML,JTJS!A/M"4V"F4F
M7:TTJZ5"1FB)&29;J B5=$$H,<T6_J L5EK-39V8UX&"L'5H6_NA?+WY<%L>
M7E!W\!FK_(01S/\P//GEKQT1V,9+/X+2%]*/7M&FW!KY787O1N4(+W7E;E2*
ML(F8U$5=3DJP7:671,D8'^%^_+-=5;TLL-'B?:G[(.:TVJ19C-4M=58_5".?
M2Q1+#V+L7FL[C;J8>4A*W6A^?JA&?F+%L[F[0=9AD;U8=*6^;93SPJ$:^8]/
M6;$3:<41B^+EH=;EGD?"<GZH1GYR%4L^/2<?HB(*WSO1TC**8L.#-?*=*9=O
M&'>K2;MH-&=Z+=,V\U7A4(W\W.+)F=\WGE8L<DPQ6^3*#Y7JP1KY')L,I_B(
M(8K5X7U+;9O)9D>='ZJ17\Y.ATY,G:AL:#)(&/->SD 52+386U$(\3VIE%&F
M(WE13)CELI1:61"^_:!Z]FYC*JLF+P&QL)6"/S$=U"NI,CEU572T<OECR*R9
MW5RVS8:<<E>O<8H5Z02%[H\5NH_^<:%[EQ2^YC@N>IV9*9K*$/4<#57[^\Q
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M1W ^A.WZB/+=]EWXZ% 9!IS5D!XA4! ,7PC31E5:)J'"\U@ (Q1^"&8\1#2
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MA*B]J) /7H#__5NV('$)*)8D"T S43,W2"1$<Z9KIFX D6A ,PD-42,2(P,
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M\Y0X:X@[E'-IQG_%_W;2K1RL7DK-<M$1P/@@O C9)6Q]=<'P&,IVGL UK="
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MH\2D[7Z/%/#>_-[Y3/MK#0/(ZM V4&:*5\(Z9KIIH8BO8!LH&CQ<'\K@TP
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MYR-%HV;*$TF[08?.Z_1)?-7$<7OXX7;B.U_':2*/Y=O,!+^W__#N"GD'KF>
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MO?S1Q:3/A3X7WBS]A@Q&J>_$A2C:> (GG\;N36/?C,28:PCT!\N\2+KQ?G>
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M[XSNLB"YHME-N"_Z4<MTU!S?='I]C/D%P*NAQEG(NFTJ:R@L@$:@!\+5\,=
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M7;A"ANW"B2_Q1*">D<IU:)V!FFS3M@C02A/$BYIDH<]!:[B3Z 'EO=!?"R
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MKC'A4'V/CK1:$=#\,+IG(DI5 55]+*LN[+: 9"?;8,0';1&]6A1A7M9V:>G
MYUT\Y'/M UI&U^+>SE5C!OOI>4D^CP8HZ^%]=8#2$,5NB:*SM E^G:%2!^MC
MZ81Z3"95N<Q;E7/UN+Z-R/K0/7X+1]Y&[V(EK@Y]KI6]B\O36NQC36-)WD*^
MZN[%Q=M%_^&Q;UN6;8L@F,8B3+#31I@V!%$/@NA4H6GY^A1A,/J(K3#=D]CT
M<*"^5D=EE>V'7I=J8(>FWVI::Y4F_@+("ODTG<T=7@WY-.2S?;ONA=!/-<W
M0D+=6;LW+=8:O>&/9O(%.Y2R?#:@C5RI9A5!+H(;"_$)*2BU.M%3,[KJ2[X-
M)K\X3%Z>J%1?5*Z-_?=DX=3MMEDX7>KF-U/QB%GJC3J['76V D-I*VD/5G)<
M[0IWT,ZB=G/ .')?9_6PXO#4LMS\JP&Y8)[4L9MP'.%S&T/NR9&-ZB1M583N
MJPZA \K+ERD<JXP,AR>7^9!BQ4"T3X%9 TO3",U=",O&MJP@ >PJLZ9F8&CL
MS(9R*D Y3S0K:T(ZQV=S8IR0&LOG/=^Q2P\L(4,7DW9>T5BDP>O&XERE0E>
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M2J\%G[Z9QI$+3 D37;S,Q:R7T/,]H.@64O0#, NB["2)P"@DTD%@ ^XD])K
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M?EK)^.G>U0X0UNG&]O<(;2JV$\'21768U#]E+!L;W*?8A[:Z2XR5I;8DBG6
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MS'MK9WC=9).)RA.XL=0HRTGY*0J0ZVP[ZZL,SAI2&SM\WV%$$\_PB</*2ED
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M(*G^%0L(0XY-D*53O B=")I0&'+A%1AC;>$=Y<4?6,&EIM?9I2 4K8T*Q@)
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M\>+$,NV#T*V+=74IIH#FG@BK60>'CK#M)5!J;I$4G&I45(/T6#Y<3$W=@FT
MQH7.WQFH89X_HZ[2Z;9EM/<Y26&:&\:Z.-:X)Y566E3+E;=KUJ9N.]=%7193
MO\O5V;'*KGC$2+(QE?V$!D[A457Y3;%*EX("%$W$9M@A-P5&8YA[;Y<A"CND
MS8[H7+D1C=92H5=UR^K(IDH5YEO5'L@4+G/O]<NI^T/4SG]"IK,BVQOMKC!-
M:G0)]U7!T<T_5S]2]4%([WK8#<+2(G][X$ZO\X88Q\RO@91G]V *CYQ7EC'V
MFC$%$<'P$6,G>OFB1+XYS7*K6FTS*V3(/?O:]X\-4)6;G4A4VV2V\\J,'+19
MF>FS5B"\HD5G45TQ]61)Q[(SQC)RP!=-1[1?)5%O#A%#>DQ7R:SUR('BT'9\
M30MN+V*%,U1;L#.3V:1HJ3L.4-AK#B3D.&)GE!^OJBTD[Q,;E#8SMWOH2G%^
MTG5'I[<7O5-YVQ_V>[<777%V*RXZ7:\CSKWNZ+3IH3NKEIRLW4-W41'&H::D
M(_(-)?#;1547U/*Q,'.ZF"\TVR>2V\QC:S+34:YLI/7/58TS_77]*]A+7TQ5
MMVH,/-,_WIRC:@IG]ZS%36KO9.B[Z*.='R-O?6^<IE*-U0 N"+K&NJ<O#,?5
MD%LP$%Q_?16UU1SP/U-02UX5GRX^PQI>8K6Y7#AK&76W?PBX"YTXH;IN4@7R
M?.A3Z#1#W<:?WF=##MNQZ\DC:K9<&D7?>.(%O@V ?5&1Z=^%.O:Y>RAB!,8Q
M)-C"ODK^TU.\LRFIF6$^4:]DCMOY:?O"C-_&-"(_0 4?VT/JROMID"5.'#UR
MWD!+^\%5'?HK_S5?O@ ]$,Q?B?,AN!Y\"JP$ WF\$$W[1K/8O(ZOU3Z*VKK'
M=V^%;N!JSEOP+OVR/,MA9IZF701?<A;80SE8<&<#O3-ZDWY51$D! 4\K>9,G
MJIG5EZUZ>MKNF_/B_E[Y]VI= "8-Z-. =42JS@84 2\0:!]A+9@92#+X+WQ'
MM_-?J!]@QI(9H#)+,MB11&?C4(\0+&\S&7Z<7V##_0[>HT2!1C;YW85[IZ'F
M<T1*+H?$;J.J7VS2L6-I!LFPCD2CR3$!4$S@9!X0=113:A*FWK$"F$\RQZ;G
M6.BM"O< K[CN6X2 N,$A\U+G:%%/(YJPFJS5.W1F!"H5".U%FU) =_;SS$;^
M39*^2:,W](W$?#R?8XL2-7)7$CWAB MJJG#/8^+G8,_XI=\"/[8-6*O)>YRD
MUJ42%I4CD3XL)2Z%ENV*77A4-C-R*F4SWQ>Z"I.A^!"CL4J)7KXKN>U$/H&7
M4ZN]O%^'3R2-2Q9?3AA%LR7P*8I6\:2+L@MA.X)4\S!2#2JH6RGVO?!-*J6E
M\F!6S:I5E8N!<BG-US351^H$!#$:D;-"TLB7A'(T4.ARIF402')YB)47V78N
M33-3%%72I] ;=ZE99Z\, >P41IEIN@>O@]$48 0J#2JR5L7,5KROW-ZCI"?T
M)6$O9!%^B[-IZE+FARLE^FCLV.G,<NT"<T%HZSV2'DI\!DEN$OJC1\X$X:>9
M>^0M>=R @K 80"-QDY$44?"P;S J_IG?A$Z-02H=90'PX@3]#CBR!?%#WH'@
ME!3%8^ P/S4U^MJ+\4#5PEK^ 6 $E^?FQ;/4W277LM68%"O2-R_$X0E+2>)6
M.3@!S$_+="'./32.);C2&,>*X]2"O$FO*GN6GN;?AQO,OAH%2$5E!15[2".J
M8ZV#&CBFAWM%]Z#:<*6$!=\R/?6&%K&L,*U[XJ"S7+]BM4,_1.P;O@8*Q53&
M="8KU[J#N?H-/YHFC\XWWQIU8[IM;ZK0V1_/G2.?%$?Y"Z:BW9JI[%*1.<WG
M*B*BXDWIXU3:6=PKI]NK$#O60^%DK?%"/*8V^CI1,4][,:H<27^5OCB=@<K\
M8K6.?U\T\>\F_MW$OYOX=Q/_;N+?ZWDGM5_.MB=!V'[B-,"J.2,[@Z+?H.AD
M#"VG@2CU**ICE7@420?4!E.>JIFK**1BZ><7N!S5U[G:MX[CD%6ZI:[#Q=Y"
MBO7,G<KX4_0W-FA:RN7S^&8HJ>DUN4("#U!5MG(@D,Q1\&BI<C323MGW AM0
M7WK*GM2S-<BV5'5V>MSG&]/Y]AT^+R;TVW]&$_01*-/CCRA1<T7?AVZ;?J"W
MKWII8Z&X[O&';6!?=;7KCPK[L*@_4RTIL6+IGF-> FX3Y[V"A481U9;SJJ>>
M*WZA9VEB98\G=5$Z-6;2B\.S)^L_2[8JED*NW!/U#N8 6FZQK0M?ALBKO@'&
MHP4-0AS]:G0$P'N3_,6)?4RSWY:C"R1<@1#G/F96$UMU$VI2+089R9G 5RR4
M_XB,9^-A6OLPE >@W'BQF-)L96HJ>SBGVSR!H<^;LE5,#CZ%1=EQG.GIJ$"B
MO3+;3Z]GN3UMKA9E*3I*$73DC_G9>26,ZTXSN-P'JJ896\R'Z,GB7:^8_+!X
M1%W#:[O\COQ*W_'M.*DX1VA$!AIZR[OVDT(#=-O3G5NI0"%#32&1&8;+!B6U
MG5_R&D)C5SV=G\_"NU5;U6XVTXO=!JL[CJ*$NV4C-^2F#HN\T_J*\*+U-14$
MC!85<Y[GC)N J%O1QKO=H!F.^4!3Z_S)$'##I,'/=BJG9)X)TNX;',R\Y.!T
MIK]$'JPX98M^*>*V>+884&PQ!**2[KVY6Q:EDZ\7.^.K1+'<T%@?W%1TV$Z[
M?*(S:Z<%N0C',_YSXGTLD,C?@"R_12()N!=W$E:<L86)23B;K-!L4CG9<IF!
MOU;=4&U&JKR/);1M,]'<XT[[0M<A+HM;C#Q_!,=PJ>*7QZURDS\XV#>N.=-%
MWX6-+6$E&LL!>*#]MXH-Q0L2(I4)5Z"H^6SS$ZV-EQ&AKP=9Y[ P?5!TSUD"
MU##S T]Y]Q?O<U:"<7(9S? (I54;@1$?;/ 3Y\&?EH,^5=69!L,,1L3"9R"C
MLZ1MT"N6J";.Q =(-T%5"24K]:5>0KLTHLX=8_U3H5D[K)KZ:98JY4%/B\"B
MW# *K>A)1NK=HQH3R*R9\':1;LBAHI+6.G#ND1DLHC%,-?S M"0??=[:\T\(
MRF1$S1H+<9:*!+'GS_XJ9P*ORP<.6K-&L3J:_>NJ ;-X-$O.!W2+H>5"M$9;
M$U;$%@L;L2MUPE5\UEP#K9WGK]#J8/2@,<KS[_S4C*_+([$%6:1/9K@,D5.L
M6A4(ZRBI"I):I,;!"7L2+_P?IUZ&.11R>FL[-RA$9_;N)!AVXMXOR)) =U"#
MU_-N0'/;5'/>S49#TH<P3XZRLPN[KFQQ^0*S^C*\8[_WH0UK2U>8M:F?F."C
M]2&QX,3.)PZGD#XOP 9Y]?7FM3*BC<%'OP:1@MQ?S311,Q5_GPS_ %,>-H'2
MRI2.FN5G;6[4<^R$&V-]XSA=/4L8F\U0D5^:+,S:.6Q>SE?3!D:4)]^8,$>N
MF1JMQ5+-E)B>$\&6X9I3/Z4/?SF9#5/;M>AE@T>T&"ETP%@J8%M&I*J8.$E;
ME:)1B"MJ%@KL,L .;1,5HU2% _KP&+HK&IR$")15S/U,= & @*5&J #HD@.J
M.,CNLB0U2G3G4#722=$:L02T<L?8&$!5" +DCR5^;'B,I%0IR5F>W\P\'Q6!
M5/)D:UNB_3CHM#J=CNI331^5Y3IWSXNYQJHY2$%HT@PT],_DXU%_/+%V.I<C
MQ5+&SJK"A+%[[F$E+#^"TA=5,L'7]DW;^0U[V%!'ZCB[*TS%B,*9G  <MY!'
M@E&TYYR*I>P;DK*S*5%6OM2B)*B\D=+L9G42NJHNH3DN[ RD%E]XT^AEY/P4
M+\J&>A=&L!:Z9:/>*)'V[WVX_UY1_=!=KD$$Q])Z@[[G QIGPDIJ44T.\_"Q
M\A50+IU(Q1O<OW*F<7.;Q,Q<FBKFH'E58530HY[PHH<YS6J]>8:45F[A#HU<
M1,=-KW,R4,VKK'PIU&AF]1SK6MK.]?)T&5%(DUF0(]/*Q2&A)"Y#.)NOQ2Y9
MS1CS4+P=0Z?Q)UB)?V_&%E&NBLX RK."9EH31?%,1E&M ^.#3A,8;P+C36"\
M"8PW@?$C#HQOH(98*6-4CS0['R]OOYG+X%QPYVU?[83C)46!K)]0\Z?#J%U/
M:08/=MQW4'FL\3!1>&B_Q8V<IMRK!\R/_O)D@&MC$5^-!0V4*QS%.#>NKZZ*
M14+6T>==(?I+\\@=.NRY,EM[)5SU/M=^G^XT9<W]R9L%%ST.>84]>G?M-RZS
MO]/H@6N;+/>\;A7FJK 61H(9>0$A?T)-D"T3I=NBFSE5/?8I>H#>20X9Z_-_
M,2_,6T"A4@]0-(&R8NIMJ6M"F^=X1FYI/'_.+_;9EK@PL&DP[MQW%QQ@#,IQ
M'+F/J>2XNQ593LK<%B7U(I8C8PRZ/U8=EY2+'*Z2W/2PXDJEV>1G@](S7KM)
M1N69VJK054+ IJ5(%F71_,4/?;$>FD^HF8]Z+]P3;P*-/F.0YV8.X!5%-V<C
M-Y2^NV0C,S HF/KFS;/U4MJ5;Y=BT=M^[+1/SLR'RN>BAN3"+5)HF\J]N658
MM')[! %X4;=GK_I("JU*DT:G"%6;YXY*-,V2;#CQD\1TMGOG(XG@(8W3.<^G
M,&3[[L]+.]>)F@PL\9;8$83V; )3JLB=LNJ7GG$^T\F^%':Y,ON8B\/HCA)Y
MQWKXU0* J0H=M%6Y*!#_@A,[7B1YE0F..&#&./)#TQ<0N-]PV\W MQI'N)EB
M"T0DV.*4-C-_;2; ($P:U:$EM9T%T^NU- [-\)_$G,\MG"^?3US*@>:/7Y3@
M8%HJ,#BJN .#\!K'K)BU:JOQ96R]DON,JAEU!5VP!.K*;V)>YQ<:6UO2>3:1
M0@]=UV,&[J422UN=][BM$N#YD[?RR3>JOX4:@&@DD=)]^UKW/3%(0.SSQ_,.
M,\$^HD=>681E.'D,QY#_W.A1\G$NGV*MH@-EQ+)F_A8U9"G4&^8(J4,),QI_
M1[>ZQ2$I/ D")03E &!UI6?ZO^+_A33UEZM]J"=-POD@QAUO; UNO@.0+K37
M&(AS>2Y'_=O.Q86\[5^<=V_/STY/;WO#?J<[''D7[L5YTUYCEJWVUVZO49R)
MM55?P58%A1G_A(V\+O-A1G_FPXP.*A',_@H=M)1NP.5K*V=1J?;;BP=165,$
MBJ,K3#_<?(J)FA'!',+N/VZF#1CFAU$>;W[_:EI7,L:1O::I?F'6\N+8&3$(
MQ1=YU$FB]#PPM0H>*FYLHEI *X<U.9??D,B<)O)G_0_[?M#%J]R[Z.MQV4-:
M<!")+(V*WB'ZI.#1F7?HS+OTTUAO3/N3&8E33W\.%C)99<HUQM$!M<I9OWUQ
M]E^VGTR]3_O,+&>3M3Y:W=C62[O*]-]O'D"&_LSN>3 WO96><16J*+BIQ#")
M@BR==5/9X8^?4F^-$X[]5+X!LG.1&^'.](KM_GD]SKQM7E?.W>B'\.5&+M!-
M+H+.U&E?].H!]2UB6J=]UG]QAVY?-.2U=_+JMD].ZP'U[6':>7MP4M,S_Y3&
M*+NW)J>W@\ID+FA0M4_.UL+M<ZWX/R6<ME-!?F"@; @#4"3QP__]8?##.BC1
M.VD/3*Z#SOGH3K\[-+7#T6D4.X3.>1EPGAX=#F0*/Z=[QEV^Z;2[ WKF7^B'
MO2X$^-"_82S"AJ!J0U"E*%. "=MI\_]?3BJ]M4BEVVV?GJXF%?4]IND<)1VA
MX5LDFF?J>(L FK<C3X\/F2[:YQ?U8KO.22$E[XFH<[(-?IMG^_W\_[FNE*/1
M_EEPP<5RUN[-^-+>\$>+&?4,D#KT\Q]^^2!3:P@>#8JSIPQOFTE7 9*+8;15
M:66Y#TI.?2BNO09(?MS&;;,+H?('MQ@0N2H7\Y^37F][$NB%40%;^95'AJU3
M 5OZE3_W^D30'9S4SG;9D>#$H)D;2\\O#ORIN"5S>%ZPRJ%>[R,^V:5^>-+N
M][<FWX[U=M=R6=?[B$]U6A\<?R_.&BMOH; RZ4S_+2;3M_-]@QHS;[=FWB$<
M+I5D(ROMPNI :@/3\/1BEZ;A@?V5AZ>N5>9C=7"F$D*Z#H#:@+BZ%XW)J4S.
M"/-]35JAR2=L#- GR.H"19P 17#SC(.'U?;LH*T7&-9G&^<G@QT%#"T@O30)
M7"]DV94[MUY06)]D!J?/EK15L/MV)'S_CR?B8@4HIMQCRGYC-1_(:K8HK(3^
MCA5FV[>I*P;'):P*WOH*1/KKQLZNHIU=,3RJJQ5>,3"N($=0%UXWEGF>155B
MESNO=*GAX^O&1F]L],9&+Q@<U+6G][:QTQL[O;'3GT$V)'M_HG+OW5<'KHFT
MA^B O:1NWFY4.Q:>\_7&&4F/YF.$RS.@N;LU7)%N(=1V-GL5=0EQ/GS\<_FR
M/&MA*.]H.$BD.G]P+_G^R>':BC\-J O;K*1YVAQ!H-/N&@APZQ,"P2((U+6;
M<+?I)LSWTG03;KH)KW^X5>?YT'03WG!C33?A:G03_BVCX83 Q.VI9M1$#23D
M4(9RI$2D_.[35+0%W8Y0P*Y487 @((X+"+"IW%2&GID$1:OC2OBJ)!N-?-=7
M<IIXF^I=I/I+XA/VRKJ]V 8J4=XD#]N\WINH"K5KY1Z>$J<,4J\[F@LZ&W:A
M3FRA!$W#*PX3T1-0<&T<C74O_( .(7%R7XCS[1!''4:&>ZE@=T<(8496\GP)
M3PW9I7D0>#8%7QPFH;O8N5D<Z]Y\4YRJ@UAGM7<N[LZ<SE-3ZKBE'+::A T!
MX062Q[F)) IAVX_.O[&WGC]Z=$:,+#-WPJK5W*)^XDRB&-OE?L/[AH]IQAI_
MKT9,JK:6<_ZJ!]#$Z,=#C9H(XTL7&^KAA)/'6:7/[K8'VX2GRRZ,%;USH^@M
MZW&U)TT7A2&-\S3#TLHVSD,VY^&4=_-VRAIYS_<Q-!T>IS$0(LU'4ST3J96?
MX*F@*^E8MR)C#;KX9=O1!U(KEY*.+/0-^WEOP'Z*#;F+!F9O0(9TSP<XIV4P
MH]O.BXYYX^'Y?<N6%+_\5'FG\+:;!FWD$;[8#>0NVA>#G=W)DCW7_T[@?#N"
MW'G[;$ETZ#DK Q[MH8YE%W?RA A;M0KMBKT@CJ,SS&';Y:S?>VD1@'J]]NF@
M7GU!5IG7V'>)54IJOL3_G-,UM]11AME)33K*-+RDTKQD[XV!EL2=+];HT78D
MC:>VW&&JOZ3-4L7XP3X0J3>7QU%[7#DY)MEQ0 7F:4*H"DG23\@B*TD?5VXP
MZ@&/,<_0FD2#7J4FK_Q9OH+*M]W9>MX+>S(J?^XG5J0\5R:_,")@YTSED6$'
MR5]GY85(U3KW,B+HM2]VE">I5(ZC(86:V+%/T!?>J[ 017-*:\^J;] >G@DJ
M3:!JW0]V)?FK=L[U)7WO]/18K._#8[T2_57#AEV)^JJ=<]_Z;2W]"(VC8!-'
M 0^BQ7F2C7]@]_Z!NI2,[-V!4!? [+]-S (/0U.1MLH-41>4VKN?HBZ .9"V
M\[)HK:GP@SU\I:'J[S%@%XK ^2SO99AA,K(GG1L<!!Z%*KWCO-=R_)$C'#>*
MIQ&G;?-,]KN(4N;U4/CH(91Q,O:GCDNYLRTU$Y[3N_.'R0-W]A8>9<"@4R;#
MG-V4QHN_X:=+BOSRL>W6SRB1.$UC?YBE[.")1B.<"TS+14FJ?Z@2O2?B$1.R
M W\"-.&UG7]*9RSN)25JX^CA0*:4?YVDF4=;PRSE),FSZ!>>5Q\7$[DCE_+9
M/1PEKI],:>HXO6R((Y4G6$@PQ9*GF842)_$YOQA^Z K,3M?OY#3F(BSQG?!*
M3XXH==T/YRZP[:@*"3?/THXRS+Z-W&_YZW76O@)1E*58 4#Y^O!C3 ".HZ!%
M7P.\[^Z60J.MM_8>E&]@#KBAEDZ^E__.\.(CK+P MD$3UX4+'W)A2<+Y]00J
M]5.<%Y^/AM::^S2+X6V .]/8=Q')LL#30ZWAC.OL;O2$&_40\>D#G>_.YVHY
M6>K/EJ"4%*O&"HUG<+>(FOHV^%#3"+.O?3!C'JT#ZGQWSZIJ,!.Y%6$=J-KU
M8^C\(PL>&0?[E,$_:#F?8.]8/I(Z7^)L,J7!W[#[/]J?VTZ7ZR'477P,I?/.
MOW/>20% '64!_!4$SJ6;&K[BAW# 0#QP:4@@[_PD8-#[B*I>YL+2A='BQ9Q^
MJ\16DQ1#,'E,4CEIJ?(5C"3'$A84+A6ZQ#+PY8C*&5P0MP+N(9E@+<@P [I%
M7@%K3,4CH)*]A%7KT7*2#,MY$U47XX=4USQ1F.U/)M+S<3/R^U2&"3Y-Q1/
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M)_QOFL7'__QKK@OQT\.A#:U5A];6P)S%C92WW*C[= TB.E1TX[D4MMU>W$L
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M%B:0 $MWAC)]D#*D=7AO]+&];!'@9:N9#<'NY7>7VJTZ(SAX,H8E><YR-)G
M(S<I4(WCA\47))D[9O\%9K)$8=)R%KQ3OVF;9LL&N/I)QFKGY4"UH&C?[/P5
MSD&JVP*5V;F9A5>BX46#D2?3@#%-$:]Y,]W9IT#0-W_)^ [VJ?%'_3E_60]^
M.G9@3WXR$0Y8EK&82CB1FUBXCI_/;AW-3WA(.CF>=\_>)@Y)!+PZ/PTD[0@-
M4CA/B@<@K(KT6BUMK\:A"()'QY/W,HBFTL.YY&^F<>3BM'+XKY>YF/H4>KX'
M%-U"BGX 7D&4G2016+-$.@ALP)V$7A/X(+<32HS2A]ZJG;L)PE@DB3<V>QG
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M!'J'(YE#V@[<8L9J88[]/.3@D26CB^:>A0*NF/HI_!>^'&48N;<8W*=9C0L
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M;>>2WE;RQ"RZP08CTIS*+<!<6#%W0T$]1#P: 6OS)5O:)-;L95%:T@<AP!X
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M8XD?], B],DF0S<*&$Y@]\M$J[>+TWAFY BEO\HQ.@U@&8RDF0P#O63.  I
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MY?5+1?RV0M^S@&T!)P]P*2YR\20FKY"KPV1EV]5;#%57.8;(ZR9".]E"\W1
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M_!#T8V3.K;Q)0XE RG$;L3:/"%%[$.EFN+=B5&HN#:TDTI7S\IE3&KG5=M:
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ML$ V&\!_8V$#1R4EY%8^;TD$"'<+HZB5-3=IL$UUH\#6EI0 A^$9%X&#Y0$
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M2^TW(OJ/2$\!.%(93J712X"5PK!'/'LSD$>"?PM:1-+ZC?$@A.*9U$;&"2[
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MLP8G(@)F/?.>-[) @;!'S4$!D"416!$1W\5AE"C1K;+JZ,.L-:((:.&.43$
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M2D<=JUDCF_W4MW5XHARDN:8S)R)N6"=DX1U -;Z4Z5%N&/7S+4O,47S,5S2
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MN<PF6=- .+RC@(.^W+']#/;)0 ,TAPDU\_ZKIA=%;L,<OYH>9,W5O#MJ*CS
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MVRWN2,%2?DH&U:[7SC2:U5[0+^!RCP_JU5#UN,+'@T'19454*H)K=ICW:5:
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MD?!.V"!CXCHNZ)I?FS>H8>*[Q?_>728IJ^4[E\M%!FO>+.UYFF.S.^9HZ5B
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M:\Z:&G6O,=5UKZ6-[>NACM_->TY;.[JF'9T%=O2#V3\U&8NT6.4INS(:V1Y
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M_'KQGGSAU%XSK!>C\U]F.0Y2)G\LR(><UNEM:6+X&KT^^'ZN-<O(SMFW((0
MY=$%Z\8/\=A<';W"08]:S--V"O@Z,$RWKJ\MD$4QU&E8XXEZO8[K7A_&4K7
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M06P*,(F!9/.S1KX=;I%O6^3;OR[R;0G>H^<?*%3!&D8KL.J8*"FM_<T@W]5
M2X,YP=D(IUBC0D;7S@2WQ0C1X?:\;_'5,,^WJ#Q/@)(I6US, RG/H12&GC%
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M+GZHI#WTVI[DG>JO8-PAH>DQUXW7]=CJH@.E!HG; 1I'G(%FKY;X;$(4N92
M]]T2T49U!&WEH+8JF#9!C7!3 SR[5 =C>TR'%!H1;,ZF%-(!(R862A_O0+K\
M?IV/\Y8LT!MW%E7<+H<1'+9<15QS<!$[B$98>-%+<DJR$/,5-H4HO7;4XDWE
M@_C%E0^ZNQ&;8J>LW^.?J!9F!2#@Z>M!D_25* :!\<)>&XAR;_(I97J1E8=\
MRRLS-%>X 20;0L%'G7/'>Y^G\EFC(8^V:,@M&G*+ANPW;IGCMN%.Q:5\3D^B
MO\8\K#OB>A"O+]=6+<GO+S+.6\R;4@0>R_H0$ 2H08,^R CA@9J<+N@G1N?
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M1H@IPVB(U,RH<0(8 G/*\)-/;)F=GAXN8BDZ+1>%G,PIN8"3 K .C-J$00%
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M8&=LIO"Q;LQ0'54M2Y>;!5E-0/65#.T]56BC)N;L9ZWH0&T%UA42"D!A>>=
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M)L GUEYYI)TW\FK=&-6I<2N:S27_D$H<)$.*HJ$F^[R=4VQ_@=H'DU;M:,4
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M:I9CE;8FP(JO6<SPE)RJ]RA05A4-E\$$P2$_)0H=2)BD:&Y25,/*#,\'>\(
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ML3$:*<HF B.!?P"0GC+[#JE IR[ZA]F4JQ)I P'JHBJ*KDVM;]ZFD%:E'U/
M]?!300SQ/9^8I9A.\RJ=L.=I(F(3#-;PV-Z>PNX]Z*ADZ#&+D*^(M>38'W<M
M!AY8F&&)L0R8>;(NKJAP\O7H].#PY,FT\9UL+FF+K4/;).V/)6F_!,DLZ]I2
ML0R2D6:U0EB'W>1^10Z:E#]EYDPIXR)9$.\C#DLA^7/C]K;I-Y(Q@2AP,L&
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MK+E#?A_*?RB6M&IS+&FOW />@R6-*X@Y4?(6L%@I^:'UC4,JO;[,E LH[N%
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MU?D8K_#(8PG1B1FW]Z2C&D1XS,39FW@WX=3=:L;FKO#E73=)\VDA;5P/M2(
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M','S3Z?\TZP>!\"8?.3^:)@QT0,R:4@E*7=KA1/1A-*>FV'Y2< W"SI/YG*
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M7D7*B\\WY;#DH>F@Y6Z*BU>GG54AW3=#J2 %^WG5I^'2:T'1F;(EC)65'.M
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M.T\-;$BA4F'D @?L5U_T=-R,B0(E6@J=EI_@T,%>(BQWJM!CYX%YJ7#;$_2
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MA%-3C!KZE-@[3<+E>BUNY@7\^5^+IFS')3?+WB&M^6.7D3.,(P@>_/=!GWC
M8DDT/ _ \G/$M=-HLC+V3>/10)SE?Z>[UIT:A2<Z@C(YL:-"M *E+O=[-[Q/
MZ$WGDX):;@M(*^8C9:")C!7&AZ*R@F\-)X*SBN&P$A9EA=G8928>2?)RA1&3
MA+%8O_3EM <=7D(-+>J,"5+@D!,X/#Y69GJE\LAIRU7'1W2^=#MAW=GH\2/,
MRWA=U^-H&GSOV^C7W]_NKSM.C@X/GAT='N(3TF_.&"YR=DC_;^_[WV#?W99Y
M3RQN>__]?LT-R-9>'!UD>HC"/.6-%%<+H.AJ?'THEJ?89?2^"9M(Q.JMG!\P
MW6F< *?PI\3.7J-E97L:B+=6>(Y'6R&1KX]I$VQB45Z\1^A8$ [3&;4+* HC
M%U%!;M>-.P'P'P4D*T;<D1DD=]PR;(:E:O)1RLL=.Q U*19TLFBAA@S.Z#_R
MIH(1D%, ?_X[R9V.U4_@-!@3%B 8<5VV,%F_&(!)"^_G)@G:>9^=7!P/ZB%T
M$TMNIFZ"?53B/+64O.SSGL'5GT)SW'BK%5:_)#=RQ +$)U/8L#EO(9L\$8*/
M24R$OS,;7X\0Y@-#4>15.#^U+<K_)0XPV./C)K]'83N 5T^G*%W'FXH+.)IY
M0[L>'%J4M1:6#]N7$VP;LTP4+Z3).<Y^8O:[=Q=ZUW/PGIR_-Z2C1[LO_-V3
MV"S7N\WRY#=+S'_RU# M?H";Z]G[DKZA#@OW1P^(X\&X@-5I?*,3']Y_%1G9
M6XN/L*KNH26"?<#U,:7G)4-DVLX2E]WMC UW1KD2:Y!M2KO)4'S!^3#,)SPL
MZB;*0G"WYZ92:\BBNYAR8=.KF)DO(BHV>:I ;H!,K=#MK%-J\[0\_5<E)X_K
M:I3)R/BQ_*CP8_[^J.R6VT'[+=9/+4"\UP5RXD@I7?*Q*!A_5W\BK"O\YM7\
M!DK9;U%M!_*-GLXOAY!N1N<^')V:8\(SB<+@P"'G_0T3C<XKNM(45TQ%)B\S
M+R<SKX8??=H&;Q=5\]J6"[L28F"]DIF2<4ACZ[6G XW8]^@^^\X.;&8'_NKA
MM)P*1S3XBUZ:5+ CDCZAS"@Y92F)U$"EJ4XHI7)=H4];W6,:3'VA7G-M[5 C
M4CR3'H3O^:^9+P5JXRN?N/8*SX^69-Z$?J273H0<XHW':]^0XAU"DN]>F(-5
M/R4J*>@:PZLP:(&<<#RZ;[E2(DX^]&*#VU_-13%UMRDWW)2?U@(!O]G9;(^U
MI3W7D#_3F/+X8 O^CD<;)9]8"?T75IZ_<OOZV7^5HT\ 8$#E;&2=.[H8_/WY
M^^<OGP_ $3Y_,3@\/CK(GYT/L^#;O^"1\A*7..G;'!]&7SP^/[J4IKUN9DN0
M440LP,C%"5V=-:#Q0\7G9W!9  $'Y4#:$+8D@]V$*KK:<7/AUBW56#P-)TO"
MNE_OU. VVQ'3]#'U'3>&5&#O2J(II"ADU'!GC"$U9WHZK$-I08^<*:9!6.?T
M"86KN]BX&.8-[JE.I0)[I]?@YXXZV^/X-.<5SCA.OO#)47H'QGL&=RS4 [0.
M8D' W?U"7_N*.R;1E/?XE][[SC/_TG&FQD*[;4JZR()+6#BV3[9_P,W/=9//
M*%9XX+(!+Y]F2/JLW$H!)C7!YO.(?FB V_$.X+8#N/WK MQ6.*RQH:%.J76&
MANQXD&,\/'2.E? UUTCX\9[8E)#( /YT>'E\BEK<3-ZC]EY,>N1$,<@=[OC\
M_Z8Z+8\^GIT<7IP_F4[+H^UU6O[$P(6WT[S2QLI=$/2X_L1M)>F/_$@VJ_1
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MF"%]EV$"TKY/ BL4#'= 1&"TL7.=..Q$5JE#.B/*V1"URYB(?%8N9AQR\6/
M&KK-EX2!0VE>%_@/$5LH%3JP>+FS3V0"<(5M;Q_W>S[@0KLGF?%&1 =$$QKH
M?MM4AP=C M7B=$G)Y,[D3J>A.>"UYK^-7ZOM;T2EL\1_NDGUO8ISJSP3A0F=
MO+&) _+[%S\T3N)DAY/8X23^=7$2#[1P*1.7RGQ(T,HXN#MN:OI[A:E_ *:Z
M4?[F; ?8D^T9[.3SS /A3R1]*Z;N$1KV+ZT*:&:]LO<@? 64'\X*7X$8[AU2
M<J_0"65QA/L2:SI _TLV/)^BS]<PJ\90#FSM*F=I+5)BT'),03W:!'9CJH2N
M?Z)LPJ'(!XYO.L\K2P6QHJH%Y'G@->$1X@ZWS!W"= N,6B#%452M.AI=8+#U
M1/AP) 4UK12-1L64Z.;Q=$)4WT0^"Q^],^VS+OYJD*4>#R_2""'I,L^Y4E0W
M.%P8C.2:24Y[&;I6:^=HE^9])(')PVAW\Y!T-_?[SDM4F^0]PJ? !$71N+%.
M7&8!WW(]1+B%*)P$SI-M)#VRP;WD^1H0/&2#MTCDR8G*I;;R^;H&C'%T ZZX
M^)@/J)T<71S\:HLGH62,F7 2(=,,AIET( !'..T&VD#^E5)FX@%?]-MX" Z9
MT$BAD2EL.!=2L'W(/UO11BO KB7$V+>.,H^76'8[N;P,RDP[$_!E7"RO8K]!
MZI]:':SJRB<,Q\6DP)<5G"P/K13BNS3IX[U:%.^5521,R L*?R+]*VZ&X5BG
M<Q5I?'X#:7M;@ &WTE=A? EF=6UG?E,,8AJ@[S3X!-$?9!>O05D0!8%(4S3<
M)LS]OR=5KK:621AK(RUX) "B=<];NU=(5$VTYU<_VHWDX\D@QSGB?;@;KA<P
M4G38HP N' #YDHI;BP8$3U5>*X4<BQ2XP MGYCC0[>,>"1!23)<DOM'[V%F6
M1]*UO DK?9(6=3ON+\#D%6-BY:/DD?N-.X6O,2,&;2J24_1)0N$T!WSA9 &Y
MN[("+"HX]$V]N(:CFGZ%NT1<DJ1$SO''L\/+P\N3IP+</MZBA")4,]#FO/+Q
M0B20L]L!C\-Q/T#^;;6.VN.UX<(FNC8H$DWQU=<2C.*;G^7,^>5]]OD-4$G8
M+YK/&ZU4#X6 WJYR+D@&_VD(%*93UF$<NA>?EQ5&C'[# QW:K+P6;C2V#JC;
M@+PK(!".5/(W]8+AD#Y+#DC,"*<(:FSF_O=U\\D]'M=E ^\EX\0 #9"3#<;'
MARF%? *3M/P['6Y0$F&O%@?)QPO^9D40GH$2MWMAYL_U+0 D%Q5.0O@4L ":
MO&WI&;2TP5.-9@[B898S%YIYE!PN:;(A-U^1K#HD\4D&/"34OVW*.V ?Q<?@
MSIE,[U%6C./4+'_LIE]358A>&'B"[?/!^Q5K>J["<F#1">+!Z-9(<"#,\@Q,
MX7?^"/U,*H72V@>C@DW9L"Y K>(6DL89_Q6F[Q.IPSEC _VF(@&[/D0:^JK4
M#O/ZV.Z&-_5#U6Y%IZ=OV1DX$2YD4>QAR486H95%E;16(2S?=P/C,2I_VD2M
MRBY]Y8&Y0YR Y33VJW51X;X6L^VUPNU =,)H/R(\%S]9!*72S=#RDG]@ BVR
M<+USFWXL ^U=5).\E+E2CMB1,V[7E!7 HPVPR.T#MIJ\K2$H.U/&\8V(J)!W
M\ZX0;MB?D'LZR(#2:!K]"-8!*R9K7KC#CT2D5DK%(14ATY10T5JZ(AC<@(MJ
MSF=BWA2!/?*@N8V^_EV>%U*_/B-_[2;ZCMC2S/8P+*8&-?.05\=./?@78%XI
M0^P1)&OVWXY1XG&M!*M.9=VK/:B0U%N4'4\V=$%06LV'3B'JA[Y!]^XLGMM
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M^_*[JQ*133%WIW^0ST3HD<UY1CG)%>E*F]?-@L1N&+^:JPM= B6MW;LO6],
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M+P<_JX"#%C8R.9?D.,H\SG,%D=>O5U=OI:;SE!Z,4G)X&CVE80E=(G3DY&.
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MG+2P?(&B7?-=:X#WPAQMIQ!PPX?TL'!6^A88XNI%Z\^+@+HXO/3^\\$_N$:
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M5HU&9I*\P__XVM7DGJ'%/MKJ<?[\\^L/K_]X<_7;X.K7=Z]>_?[JS8?W.MC
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M)^].Y/-\_MS>0!32-@W_^,0,A*)96C7!E8:F60'6P4"SF]9-?YS5J@U.P-B
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M-MOOE>?6(%ZC.12<S0;:,W"_IK@\#O;9^=;K:&?K(-2/_;G&@:_WH2PN:,M
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MYU2&>OT74T.2C'8/6=E\R@S#E0FXM?%&'9VI-&NS?-V@ E22MFJAE;4^Y1!
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M@5.&3!920<C+-;,A3S]U-(&">\+)RFZR(2HOE(L8U,HXN8*E4#;"JI3V:M&
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M$K/^O*'A@W-LWTH"^=<=/<3VN%)+5-SA)$-TI;@_NCT>,XP/*;HF]37^D*N
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M@.Q ^9HUF'XYO-/?M7P!6ZFF(!M#>I>%.1P,T@DU8S-?!.4%2@B<9 DHH,R
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M",ZC<3;V7JN#( HLO\/1Z:S#,!W0_4#<$0P \)UT=:6IT!<2?;4N,Q<AS-=
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M1'9?(?\P[T-BVNP&36$XEP-Q4O&[5H:54)B:>M!X9"KBL"7@-U)@!@$T2IG
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MW5=6?,% NPA.0^L+SWFG0LCM4X^L-*PVXF@!!>.<N4X=(L?9%B+KAS"@GV1
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MQ)8$$_#:B#1:X(1S#;]H"'/LF:>7:Y\WZ;2(<DP!(GE!J&!,:-4M&G*9G$
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M)IM-.[,Y;:2K;BAXVH,95KMLQMT,FV..X0-YT8Z;<L0K9Y>^M8TDO7Z0P4:
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M26NGHQY^K&3;FT/:C\G?R1V$GLVD_$*+D>47FJ!S,_B\FHHOP?O:*H_M&()
MOE4X.H?6/75TE:JHR,?N/X(08A;,9",*EXR8JO8^#R/GDGDUB,(9^97@06AS
M\.VTP].:->RH R\1D1N&(^P*E- 7\ 11?G*5,OQU[0+F@J&L$:O+(9_#*F87
M!9(-(#\V1APS^RRH$_ICJ$01*-?7Q10)4E_><A.1JJ^R6304XM&"Z341HV&Z
MYL(0O>,/=-M!NNP,UFRW3A@Q#)X8BSHZ+CV S#D'OWHPRCDZM)9MKH7/M).R
M:.5<TD6#0%9WKARA=6]Z2Z#&I@-E+"L%/5TO.P2>](Q,$WK*"[1MXJOH1G(H
M7&-&'F--<T!&%@KEO*MLZ74I1;K'F+;-JI)-J[P>$T<9WMWN?;A8Z,(_('N6
M]1TR=GSP'F6DL+FVHV^C\/N\Z7C'8$X853-Q=Z9LD\!8,Q?8'.<91#!;.C+2
M&M+$S0?%LZ5-[W&JJ$Z7&H2E?0&T$UA*Z)9@4)]!U8I6OT EADN.Y: >?8 K
M1"$_A5=&ML;.!JJ]"%2[HC;ZH>A[,326%1@FYP'#W:'.ZZ,I/"AVYG(R7D>.
M6;H<FXL\E)2,1'CMK&!UZ7R"XM=L?8S0D)PRE<MY,2\5NX]S[K-5LL;A3ZNE
M['EX?0I+!?+WDCM;27A;S]UB3.)5PH6<@SBI8[U__YOO[.5"A] PEQ+$B5<]
M'UQV>,MGF*7>NLY?J"@#C8=<BK#8L#S++MBTI-?A"'!)\B:[C%H?48B>:# A
MYB O3MA))I0>,=Q.MYA9>\!C>^TI[)D*WJV_Y,E,>=GP.4CNR;>,8^]M,!?,
M4*+ICK-,CB]13ZPH;*;67XDYM3?/U[D6 =R/<^&VD57.3D_A6.,V5QV"QFFE
MV:2) \ANUU9<R!?VE;&O:Z;E<3N"(!9?""Z1*^$%17 FI %\%JNSS8W]S=P6
MFS,,89-WEGC&>%_87R'^.;P:\ ^XE!CPI\-<5O-:D')TWD5 8)+C,UJ"QI)3
ME%):Q/&YIL!X! M$;VRA5R'#4SB! 43A,J<]1#_;;JR<VD [D8:C<(\I)C"9
MBM@Z>VF'IF^TDBTMX@J_,5EJW2#/[T%B$ES"J)/W!]J@,1KO)=&$3JC VO?N
M6"PX=L2!TY+WT,&UNEZ+3LQ]Q"2(8W'@.EBW3<DT.T=5M0#K+8EUJ-8<C&8'
MMXTJ/\/UY&H#"OS)AM[4^AX*J8/^*WT8-8RHK%G$)=]_Q>&\F*BQ0;\$)[GP
MU6!\'N=! >['3?NPM\ZHKS/JZXSZ=^ @3P('^3>UWL6?DQRPZ&OQ[+!8PIK%
MCHUR,Q\71GZA-B7'<N;"GV@N%(J D6GL@)0<_B_X5!1#)UD[?CY,Q9BQ-<*A
MC)_PH3A%ZBTBF#?NJ5=S;N:,('!\$-ZG>0<VLQ^ND7)K=4#1]>+TGL2<I)@>
MQLNKIJ[>11'+P4D9?MGHQ<R0+C"#X%LS2Q_9HJ,GUZWK--LOTAO8)B";*,/.
MF":F*#SU6E!N)FO6GV=\PPLW'7A8$%;4NIW>8FXE'P?VAJ"F;9W096 '1B$&
M=49.^Q3(Y/R3V37-QDIQK%0'9Z#3M( VE/)&QL",XE)OC^7!63G5=5_>N:ER
MWS1"DPVL0XW_D1P)_L9*C>08)>7(2\.PO=K-H+7$!(?#(G:Q*X$09\$.J)?B
M+YQ:R(CQ;?N'$.[>JKBI$*P#DE%]>QH6\\]](:Q\(4R=$)H6<[JTW#UE$JNW
MZG7&(1>)RXL6!*-8UOC=& 54&N;H>ZT2JZ[58]("29Q8T^&$Q=(AM6BE!'M6
MSN4IWA]-+D$.55292PFZ(HM0LAUK'\5B;$"NL1B;\&-SR$1OO F<LY;)SV?G
MVHF DQ<,[/<W#A</9!.#-?Q>^W31WXX[1,K8935RX&"WV%K"9H,4=+$ Y:5(
MG%L$>?&\ERK(IZC$LA29D0.S<.4I*FKQ;JXSC'**(UDN4@[N()$KF.PI73P@
M>=-^6"?^'.0R+L#+W/X/@W3JYC8)O7"WP%D]+4VECSXRM?G;7EA= P0F2FC(
MT&]7THPW/[06,NM_WTY \TY+88(U<1 [FNOK\!;3B*UOI.B-=!;>2":VSJ?(
M7#BMI_F'FI2E@ZK4&A0(INO&$JV-]4AI.CA+3BPEDD5R:8I0-3M?P4 AW1+(
M]'0*TM*071Y5[WC),=R =; =[>*+-])JS<CSM&O1!A77J9@:IG?^/-STK5?.
MPG8Q:+BSF=1?%U\PUNF%IFXS$UF?%N2ST7IK1[%4+KE4\M/G6>DD<[)9W56.
M,&@6VU\+N+PJ#_Q&BVK_WM?.5)./469:A4ZH!L%[+R[P<"/<KL8LWV^54-?H
MUX4)#4X8P@HI"6(%U:IL5#^G=8VDKQTB/-#@9H.7J>/#3A !@C*U#=?,=MTU
M)L7%O^@;SK,K%2+\]><N/_4CKRA!&'&#6?RKR\ .)X8M4V<)BTO@B7GR#&Z7
M"SG@/Q=X 4S!<D)7N:#%I#V@8/&&?\!:BOG#)#=QS6#X<#F#R*(G12N#/A9:
M8OC?O&OT"$E(=53,+]$#O>$"!H7QZJA<LRQ;R:&3]77Q]-6<([IF >6^<S3"
M#?D5B)TONS(0X(597B+'HQ6&]R(-<6JC#912,M+F;1O9K1S8<,55/$-"(IN#
MVG8SG*!GAN0EY6;I\.LA=S=$QM36?.AUE0=U'*6=C"+H^Y+&ZC#3F7-/3-H(
MGE2>JL7$[Q0($.X8G':<C4"NU!>_:<C?#U*Y^X$9\7)<GA-\LQJ\KP(3/NVK
MG%0_38+?8+;'*DSGB0X =%(RHW0$]7#=S<H%IC87W7*8"3\ WF/KA1&^*FXS
M2'TU@#D2V;>+.>FF5%;(<2['U@;I*J>(T"*T;$47LWN5&/"7S$X(7Z^QMT/"
MM+6!%S7PRL# ^W@6.DB-M$8(]>F0 KC>A+BIY 5Q,;OQK#>VDO<R,@O/KCDX
M;$HO'/&Q 6.&IC!F$/PH1F1DK7^R.9SHA#L<  R<]$)+@ N$58R979&#WOSW
M=ACJ%'R3$L3T378TEUV>$4&OW))<TU"Z-@P8%"%<GX'H&?@<.0,<[53E:PU_
M4_ =O>'X=LR^N$@GTH%%(%AY48#H8<QL3F$,18ZX/98C-QTE0U9)R6,8Q%'R
M>=]DTO;)'>$]T'>I6CX4\/+*4"/"249M$4;&Z/ I2R],O6YT'3A%(8]S_+W4
MD%1,RUDY%TO;P*'1S)UCR/K*G.-)(;%'TFKZ@QDIO O_W<Q;=7[8TB7T,!K#
MF<=G9C0B.3".ZS?4MQOO,@E#%<,MW/\8V  *H)C" LZ:P-,OLR;H.8H;#W:\
MD://8(6W><E/Z:,5!M[WN)$)S];(A#4R88U,^ ZN[#^"*_O$+:Y"*-PL*ZM<
M2X6#J VWEL/T^_TAA:LZ! I',ON*\PY)BC$99QF!8_ XZWN[\:HEX&=QD"ZQ
M=(;8/W*8!??+/JMB>1W/ "0?JW)RRC^('0SF2%...B'=JGR,I$3:KOT>O$,+
MK$(Z" $^,B\/,712S*1L%Y57WOH>;U)R+@NWF?R0S$/+N[?_8)VVMST!2>\-
M(--*5JI0_FQ0A!:,4&41O[FT+$9FYLIC,02'%'1OM!PC4G8K%<\: C-9 IUX
MR*\7MH(08G(J>? GU+/4_#A7ZZL<9X%YS\9@<A;75Z ,5&\,.HT>D-?:C9*P
M=&) 8@5KN,E= R<:QQ:C_EV\&^,.JQ_CNLM]-^9S1]Z]"0C'#/#%]J>J%]?7
MD7557P"A7CTK]7-<B"+<%Q) I,);[6[AK&5&,N6+0J2XX]8K;QY)D<U#%D>U
M0RU&!G6(4<2"U>JK--Y)=I$=?CO*" Q=H(,*RPJ-%XD,;W&'6]-5$'<2DGF,
M)MTT$H6Q'1?9)*" R94)*?;[N"\12K3PS;!%K*/10R"_'_2HNVG.R":;2[2O
MPF+_GLBY1=O+W?FF' ]#=QTC1#M0K VL++^$VIY%42 "SKFM93/9&)P"A^MM
M0):5W(!%2R<MF=;5Z2#EI1NEN/N ?2C:>!.,RBE,\M59F<-9@ ^@]GVZ>V#$
MT1V&GJ0*+L>#FXV)CIX$$!8/RHX>_[CD$!]K4&9_'919!V4>8U F2\K\KS]\
M>K&]NYWO99-/Q?-G>Y_VQL_W/KUXNK.+_WI:C'='V?[+W1]X(?@;AU55?/GI
MT_/G>WL[._*76S]Y-(]%$9^1]T;9SQ$XU?!'&F'RTW_]9?2W6U3"@WKAIL,[
M^>W]^W<?/B:'OWPX.OK[T=N/=S%0,8S('!H>YT>\L(+!7F1-"??9JQ:.QO3)
M.#MO#Y:=1+)!-R!J]YVG!T,'$9PJ\))B#SW4V@\Y?O2@[8/-5!E<*#LY2?[Q
MG__V<O_YRX-_IG! =IZEC(?($>L!%L!7S0?F\NN[UT=OWAS_;\J&\O';UULX
M*73^HAU@-]"(^.JYOJ9RD:O>3+]N]./NM"! U_@NQ_Q+EX';,\=F';<QZM>'
M'XY/_GZ8?/SUZ,/A^Z/?/AZ_/DFN7_:O'OY[:JO;&[OFSMZS/>AQUW@OH8.5
M8[2.1A+<Z.%?T5YZ1>8W_JOW9QXLN9=XG+!TJ9L6+'J',L:$$0+?N&LG-MX8
MS/TV;=0;:)V%VO%W$(:CPQ,1 6/KDWO.Q3OLLIZX++XA-13^U$-CP[\P^(%;
MC-]-,88A^<Y_AVL6_F\;?0+^^#>(V6M^"0VP)VPFA$6GWQ6V<[JPBW!R'EW:
M"HCD!CIW.GQWJGX+:V<&A'FW(<ZR;3MVHM3!(P<T&S,GE(616)Z!J?)J<J@\
M%<*"Z-O\H'D/B@:B8FX9DJ_+ K&(MJO<ZIQ^Q#&B1^NR30@L4J*87Z\2)%1P
M0I,.A/1@U;4"^/>$QZCF4Z8?<Z$7))C\@[FNTH15/ZGZK[JJ#O_?X9NCP^3O
M1Q]^.?J0G/SVX[)&@A2%39D,$-E-;.=U$$@9U]<KF[]S^0AL:$_54 2&+%4A
M.\&0CA%^&MG[:4;GXN\2\,PS:;#;U[I$R"*<&?H([:^"/;'QY&)T!I^0ZJ_H
M)?I;_[S/ZISK37L(Z_3;9%M69-B6Y B:<N>E8C5JI3?#I+6 5GMWZQ+A0G/(
MBW%!)LHO8F?R-ZHAG1(Q.;0F:I6,Y3/?=KWSP'JS-%%T"Q,,4CX.:M +4>/?
MPD5,-N!DT!@P>L>/[%HWD&<V5DE[M+8W(.?BB#)&W&=%5DFUVK@I1X7M/L+/
M'QC*)E4MKKJ.RJ2'.Z^P-HO'SB4P9>*[17!GQ26=LB'A3(W:PNBDI8;6/@;>
M%2NM'(D@*^_&]H@S4LTIAZ-LXZ1N^F;4AJQXS/J [<_&E)/%B?F6EG^;;-)P
M24G@CJ;^+-W[=Q7-S[?O?D_)(3GZ^=V'(][+WA(JA%CSH,:%<*3;E/YRMRY0
M#5F#MU&)*F=<7Q155@E+ND-Y8 _BJ)C6EXEFSU@[4;$/_@JM5@I9>>,R/$I%
M>3Z7$R\=<L;")4HEJ0WK='2:QW]4]>6TR$^9N]K"/=GS2*5!1LE-1D'73XM3
MLL=&&-/$Y)=Y%$[BCGJS+PJ]7!L,^@!NY9LCN:Y7-2;T?]Y]/'[[BXVF'"2_
M?#A\^S%Y]W/R_L.[__V_#QDB\I6$;'=$@JGY^OS6]WVY86YO;6_Q'KO_?\&:
MWZ$Y_W]J[5H?VMFCO]V[SI.$J&%J=/__SWTDF6OQ,<6PXTT=65(Q')G'T4?Z
M:I,X20OB%IL5A2Z#=<Y;#K)'O,=;B::YDAJZ-19+@<6S9*16N1UNEG^NNZ;2
M*E5PQN=@02F!LYC 3"'GH)(5IB.TRLK\'QL.-F9&?[7WE2J9ED6GC(NT:)O]
MRUEZ.]2-IM^IYM,/>R@C=N6B4?":\-H>U-((@FXGNO25[(@*RZC7]::B-+A5
M>J.OHSN R2C[-_\KRXWN,E5F>7UN^D'V#$O:! +P!!_1.Y6O/DK,:$N4CPB^
MX#[7<)E:>G$%LKN (8+!-#7L)P&$.'\MP1:VS%+N8$GFN&%$,AYE;\"V146O
M>XNZ44)ZWAL6#.40PQSRZO<Z+(4/6<-O;F=H\^#PLKE"@<I6KF8QLI 'D/+Z
M#G,ZHB*IV%J8*F%Z1(*.%Q5";626.?BMX+JHQ..C9DCCQX$7YGE"W L2=CA
MH^$%,%OGS*+UF]H,V/8/I1T]A0-6TKQX K\9%Z_@E#RY;+)SR5GOOCS8&$44
MZ3&(>]?@)F51;GPJIIR=8[S";\\#=\@TLU:E@2-Q1PR7R$L^=**LD2FY7B4?
M=:JO5230)?SUZLD$M%FRL;,'YCC\JW5 ABD7II/$\0@=F:D*9-3%Z 12P!@=
MXQ]TN""FEN;*U5*N@@C9:ED/2$PDQ/1%]<)B&9JS*;(5!3K<J>@\_3K)&4<D
MY\A6ZF.H<HX38\P."$:'!3P;AZ;:F6OG-_[;0KET[O<5J&21YM=O;^UH4)@N
M_X$[*\'.2"BG3'\PI[WP0&=TQT2D;($["@,J7'X$Y9!#W"8U@R:%:1&<7%N&
MT&]6HJW/[(=_"&(@F!A]F%7=UE4US>)<GG<X3WU. LLR-6'\D^OOUX,F"5%:
M$ SR0O#OF6+)P'1 UCGZ0<'M^&X7U6Z8_ U)LK[)FG5$-)>U4OR'&0]\\I/N
M'*.%=*L\XOZK/SW97J-_UNB?QXC^N9_VJZI'P/_0\+'!4L]&DIBC/R/G%[/?
MR6_*RBMU,$SL3CZ7#?%I^8>D##!LK"ZD?Y6(#VBKA1#YKX3^$[9;I- 7.>B]
M$A\G1^AWZ7"*?O"[?KV/=B=T:-PH LHA.%3BIE$1W5=^28J\6NL9:.:Y2TA/
M/]APGJ$/UU9;CM7T0%%6L XB 1DQA1XF+O.VAON.+L<6CWERB '94XZ\4FPF
M.>KS)MGV1K7;#:L?JU\4*1DRC:H:OL@<%9SCAK65GR3!:.(V8.F@]X["\J8L
M/&9B3+ UI9C(X.75+6?&WV2721"Q\ /P&BGP#\M!8GP<6^4 WM\TI8Z7IW :
M3\O)W$_G(;!8.OIMP)9-V8V!:7Q]3.>CO+R/H6C<G()FV1J,K_2J%N"/^IS$
M0$=\,U.,&)_/IZQ@&=1@/\7 /2TEV>CT$/F="3!\(1?ZD@,Q6J1O?7?%OK-,
ME*87KCO8_M@.;.%C7I!*#T9A?AO+Q,CZH'U-_F;3M?-P\?2/F1O?R.S!6&J0
MR&FH]26A;\F](^2+)MM@!NSFL#B ,=,'^!D46C!.H5Q%OJWIQJZB3FITE+25
MFCC)&M2P]8"-S4NRYTV\6PU9P^JAN^\@PQM6'SF*(W\WWDD] ON1\SY6?S#%
MD:X*3)+$X**LIP-))=-JS_8H[:9</G51EWGR7^7P<?KA;]D('H\FP'_]I?S;
MM75\X4SQYC&.ISE @7A1*G#Q*$9UE2434*0X"F*>$,80.K'&CU!]DM=L$H#<
M_QB^/"+?<L!9L#5E+Y0_CC(5)-$\)C;R)4-*F_#5&/DHC.GU$F/""&])D5I6
MT A^T)9_VOZ/!S=G7 1>V-3%R/IJE&3SY/\"KA!D"4XM*DIZ$">S0G%NRT_D
MI^46UZU43F,+B_V1IR4Q%F\XA6B2V?==Z@\&X+3W])ESDYY8"^EP/ ?U+M@>
M,9)FW,)S3@UK-DYA]@U'3,FY+W+X J] RX'+"IRHIHWJ%Z^M9YHXI=6T$:8I
M?*\16^I,-#6CB;Y8'YM5O/^>$:O?/"O!_97QPW\S+H\Q>!!S:9C>N%K^A0$!
M.CGUM"50M/P@7#DU02$E?,1>N'S  E-\03@202"EJ]+ B;RD'L-.T&//G<3W
M%(P*/P?RKPX..T%YM!0R8:>#ZN4;.64^8PY#:-""1NXHZH?%5*(PII_C8T*4
M25E=U-,+[JYG@PZQ;ISPG%\T%]$_]=IR$PM_EU PWID;U"%RG%TA<KX( _I5
M!E1\*9HQ81XQ$Q%<;D3BIRVHXCC+1M:+JY+)]#-ML[JJM):95LXQGX[+>9E4
MQ9S3.NT9E<:9,:D+TAO8)LS@.-0;T0$&$2?B$J<:YNP+;;QI.^5<DY%EC4@,
M?N0"10SO+"LT[!G9"= A.O=Q%VT:7ZQ^>2:M5MOK FS"KHLG;\;)_D"8[3.8
MOX.%-^<=>D'JV="-+)V] AOO^M!S-JHOU.N6Y4#TQZDRQFEO/\X'$%A$L;I1
MVKH>-I=)K$IQ<J+GS7FQ:80K@"E1+]I#-X MFEP,8>3"/)8YO+K/#[Y3FEO"
M'5ML;J5F4ZG17";4J[Q1_-HKO]0V*L.286;HHF9]VY"CQG$ZT<W54]&/H]M-
MK7I6J))C.INI3 5PHL<=X5$38NXM&KP_%9P@+ 5J^L]K=D/^9UD-I1>TS9Y+
MB,IO#6"4F%8)HP/,C>>Z<^1S<^1*K)\6@?IHN3#BTT.\)2&<QD'.L.396@5_
M.(&2$K?-"2_%!MS+SPG*OHVYGT[;:.^T&1_??)FR+[542N0Z%O9^ V9E11-8
MQ@7:U2@>_^L )]=0YX'60>\B=<QLT^DRGO8@L[IEZR2:]U M(4;"UX.W,? 6
MA> [S4>#8[>D]E2F'11%T#&TN*V@4ZY,OXLXC&,K^;GV6R6&91,RX=#7\*.L
MZ 2('R_&(#9)A^T83>LZQ^;+#7CCITS'(ZGAE [^K*:0YHS3@O 4;CT/2@#,
MX0<+9^ZN6CCS)VTF;S*@Q[8W+L<S0VW#.R/Q(_R&@C>5F:'U= B5"/"-2E8I
MD:)KL'L\E0ZZQ/ D8Q&@N=2SM Y'"0O:T>O4A,:I02_1X4NW5<.;A8_N0 :,
MOVPPSZ^MBR0#<[ +;C<'NK(LF&' EG3P*O145:&#6*.AB _J"=,(RS@A V$Y
MA394V1QGV3=]+>H:+JUR;A?6M9@=9H_@?M%%*@4/KC"AL[+)GS!Q3\^C>;AT
M]Z[HOGLZV'26]U;M+!\W37%1,UCO/5Z9!/A=A!BFLJ/> 9?SC _[@WHL6PNC
M]C!\_(E\TUS2I5HAO<!JIFAP8KBGN+>>Z85QX0!=X+2(DQLI^CK3?VH!*B2D
MGWEHH(;8;@[@,@"_1O&@(9C4?T+$<:0;/2 /=)X^E&3RTIT4\"Z-M%V9_32]
ML,&J1961>T5SHAVI10#U4T>1HK5'7GR;^$#8&UD6>B4A,8_]%3O5DAR! _H$
M>Z"(V0="+[Q#A& =%3#X232.IY_2[NT9)MBX_2'=/O,BRZ-?G->OG);UN+P\
M,YHAF2RT:SU;^L2+!9KL&$IHJIWF[4;1%:;_I&K7!.&?32?.DG&@W'[7-Q-X
MCB\(#QP-=U6.P U6<B@J:+,D+08=YMJ-AU(F$0#UHE<83)@YD83-[27V-"R5
MWG#/(@]P$LRKN5<I[5"PBGW:UICA\D@V><NH+K[[T*G <CL-$<J6?+':3[*'
M/9Y8%R186)_H,4/6=M:0M35D;0U9Z[OX8-A('7(O<&E:$TMJGI5'Q+S":GCY
MZ[CNSHWS*WZ8-))I'0L,@UI<NZO(+P*988TXFS/"E<N5%Y;R(B^R.;78TLI<
M3$=6&# LIU,N'T#-VV95&05,!/F-38<8<2%I1F(;K\G(]..2@PR3A0B;TEIT
M2BE2LRZ3IN&@)@?B?&V[>!BNZ?P@%^JN@;]'HKHVGL*Y!\4#65-7&F1P&,Y9
MBO>6O'D\M^B1E+&*Z+1)AB(PM.'/U M>.8*_7%D,HOM9V X6/3\2<H+=?N9.
M@E-NVO[<-&0TF908BC1.G)R)54'1[ZEE"D/ MNE5W S)C0D0J_*.5M7#2K-Y
MD;JD$!K4<;*>UY3WRU=,>S!:/S-:E \,[K.U<DVJE&-!#VQ7LJBLL!C8A!)S
M=VCU'"HQ1R&G&G,W%:.I\C? N:XQOCKVE)-'M?%(--;O$:!D"'[0\A.A6G+I
MF"*\2UB.AI_&6X'JPVQ!:N33&XZREYR7S_<T1.]D1D7O<$( G,<99=4?:3)J
M0$]2HKBJ,2!<#!742BD<M:.D;1NH?_,=/TTI]]$B[ \2$,NYX:TZ-J\35*BX
MES;3R^[22IR87A^/_I3[N$)[D?D^;YA"BB^1ZXX)73[W"M5S1[)A#(YE3]Y
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MR7-*P_;B,,Z+>MIA=0/6&G"#=8WLIX@C+6=XJ91SRR&#@Y>_(_4-1X@0K4C
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MY\?V_'3RI?U5\/@_W$*W1A*(N###Q6V$<V"E8>VVV (9S%QJ 7,4.N1(7V9
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M6HY129K]**;PC::NRC'%4[L&,XYS<SWVYCPT%EH-U,6L=#?)OD C8#R&0R?
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M!><TC3]2, I>%I/;6MZ=]<DF)XWGOBS0I>>;QM:Q*@A,.B6[L!6,0R\NL4R
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MS) XV(]L>0=!SOGP?,?I$X$[J0>MR;K^#_FF89O\F$3_^U:[;QZ&NK<U"CM
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M^W+5V87CY+V*Z $]/0="T/,:X3\+T?,G88A;H#6O/Y9F8_>]'M ?[@#\XAT
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M<UFD!/!;$&N%\)YZM#SF9K-3/&/PA <C4*#Q;JX7P0(11 MN<%37ING ]X:
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M H\4$3<<8@\*D'FF')E/6\4OH#M"IE\S,@Y _E#6I!9WE4]#MW42I71.XIW
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M.4L$#,5SE@A $VKP\#!P(_X#[459UTV/FM1DAP+0%N4D1VT53<,?5.8NG^'
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M/05S H1A*BA6'X#OJ7:,118Q>IQ@E%ZU7[Q/]#SVZOYVNL\*/DH-:AF61U7
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M7 )=!G\PUX02/V2VMB?=?>K-:EH+@ 4]1A-0<(7^<#^,L27U(]6#Q=I!A3Y
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M^7O);A9"#G%#_\B^5YWX85P=C0LVAM4+3),J:%B<E,$*R>39Z,&(0X$Q]K(
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MP*[9?1B$DP?GY#[A08Q%%<,Q%\A\O VD=W3XQ9+>YI#>$?.'J4\98E^\X/L
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M4"*[:(>,]IG6-NTA^+6AK *,ZQB7B3L S].^8+2SDY!^$,)?NI8BAI<0YQC
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M*SC6\K+ 9(') M/: =/:65YG+.*^SYSK<0C_8<%I$\#)6EV;A3I;:G59[-A
M[+"*S59"S LK-GLXR7MMS*65#$*D"Z=+S_+]2?;F"9.-C<G!0Y^S"!AF+!^A
M=-\V/$K*@A>=V#R345J=:>(TLO^)1YZ>[NX75_^_<H./V?#[;12F@0MS[,/H
M@Q*TQGO)@<LMO8LTMKY;[_<5+,BY];F/0("W"2YN^2X-8V8CL=X/["[T7+DW
M_7Z]I87^AP9LDUSK('0?Q+_&R<3_R_\'4$L#!!0    ( &XQ]5H#1<8I[JT
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M',<]7_3ZS(_JAJWUHB0MC5=;+TRUR6E$\\+^>\H[N0^?(5NI&HQYKYM,N'B
M +99U//N4P XSO$YQ<#PVC_>%5TW+-A?R=(&%$&)I]Q&3"@"%\R\E(H&-4Y3
MB1;FA?'63K.]EAUYN&&<%\;%MG0_1YL-&*I?K.92^K%?9*I!#QP63(</RQV+
MDM6MA$E/,!8JQP&B>?^H\ARC0:LMVV<W\9U!-L[D2T+<+WZTR?FP >MBC1UD
M+4JYU*:D"?W+8M6%J+'K>JHJOCA/"\FPYBE=;:7$\7\^&EA-=AF2.K6N,FM
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MK>:W_\]<.R1_SW7(7J$26=19L!X60Q?2D#$FU>F#RTG;@@WLPH_#'CHPK.4
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MDLM>I?;9=HO N0@/@WCLO>$RYBTOKH_#8HGAU\XFR#*0]9N)[^RV99_"RI=
MSU;$X0[\E8WJT&0! 9<^PA_ZO).3H'HO[')&.+9WM]-"#^H,M"*,"8*&](@P
M54/);RRSMN]>^0U=I7PG)FS*RO)A,4WXP>DEUDS\6W1G#)KVAK+='J+2JE--
MQ^-!"EMC7?JM0E5IAF:_DF+O?%=JO@0^$[G0?*@H-@"I'MU\IGP(RGJWP27F
M=LB'N;DKA<G4+\EZM@,O,E)[/U 3A6?M(:;;;,?>IAC*+@0EY%4_Q>?*<[6S
M.(NJ7BRA;PJ[LNF:ZS(A9ZI-&06QZD)$@YB:? /H0OD_#\BK43U^?<9;SH>I
M2_26 />A:NQ@BK"NF>*U'MGEA,L7/H_% 4?NBP?NV#2D5'0V#?;Q IP#Z[?1
MQL/?&+^$ ;_V%1NYYV:O47@N+5"C\%/Y3]539K<8'I>X@B^O*0J05^58H ]J
MY3(J8:TZZ5.W:]"EQ2CU2H7=Y2./*4V#[.RT+?^7N4&J-M-(AT2\5YF;#%Y_
MI$GMO=L<_Y@.O(">9LCU?N:UF7-N^*X[45H[K.=B^<*?0_H<#K1'Y!FQ>JKG
M!>KOY]"I7D7=P]B_=1[[&4"FGL4W-)7_<^)<\%VKV<0>[A<4+2"C08W;1S'M
MB(I+^:4@3H@E?>#W>61._/X>YD+)_8.? :=79UG[*"\Q]%^RC#IS?SE(@:R[
M:]@]3YZF)(H"H EA.RV6R--,>];II]B>"27,)9X0#%_6G401@6R/(_,7_^NK
M-**E!]E". KRPJXXL.-ET.,)2.=1__C'Z4)/-;V>AW ]M%<I#>T]SHCQYC5!
M@YY>DL.%=U<W^)$=L(@2[IQXK/6(]\/#VE @N45X0#YN\$UQIVW^BA)8&J^%
MO2=C"QEO732KL@=/LT3=5=-Z+SK_C/Y13&2H,E:D,_MVX"%F8K9&?=#GQ;6C
M/4HTC,(^7NUCD'350YV*3AT:)4I0:U-_IT-E4F33;7N+"F6+Z8>K$\_?'*>M
M>:1..#T@ BTYREN2A/WC5SLC2:W;ZX_<A5E$[S%79#^Y$VFT(_@;H59]#Z&7
ML<7HP@0"Z]@S1)&(NM.+1.S>Q"HU@5QWJ$I5'6=>\]I?C@CPNG+:J V]D4-W
M3@AL\4+;T'UFW]Y2]SZ-?X<_P!WP?$A/M00_^1-2TP,(8C638!&#S.''PCHM
M6T-X+6N:[3=X\1O[-[OQVCX_V3=T?#-7XAL4#-6B0[*ECE80::!_8K?QC)J;
M>Z?N/V$P_U.;OC;P5VJ62&Y:=7P'WL.(%5V@.$AN!.[ 7*8?_/*R8\KX+%+D
M_XP(?/UJ1P0FP--$0#ONF"[I9'>)"&BM5FX?<C^"?SLBV3CXH'&OYB]3]R*@
MH)#?]:)*_L'J@7>T I8,O?;"#/;)LUZ(\++TT9\EP^H-H2]GQX<(," V*>X1
M@3S+SQ<19^%XZT>(;R=E2>C\-82@>F7';S/+W\3 ^N7Q'ZZ+L][]5W6BY/]7
M];^LJNNWJK>.VIY/+,"Y)!M IC=37%@@)!@&/C5F:X6&;TG!WD'-,%3%R-=]
M9O=3VP1D/C4F;ZXD_HR\ZCT8P3$31<62\N (6:'S:'XJ:3%RSKV9I7H0:LKP
M*O\'6&E(0JJ@MNG6<C-,OGF@3-%92P!0>U4Y&;Q=O3V!@5J45=F,)\H;&K<R
MA.D7S C*_>38WM)GKL/-F=5QW?;^0A&H5%:+\MDL0A^BGO"8V;M:!K),N(\=
M-]ZVGFJON-UTPSA#[&*0T.H*_YHHVB?67F9<%59"&+394]XB/"<"])Z+8!Y;
M_3AAF2Z/@Z?G[X$DFA]"$9>%[@-P&VP.9M@:O;UI6XPW*Z^]);^"_F;S1#IM
MYERVLP8O_T'&;.0/FVSED_0]!VZ/['/UD6:-@U7];-.VUI#X&Y4TK"9Q9+&M
MM;>>:C#'G2QS'9;E6V.E'%$<HU5;NF:?Z]&A^7F)[$T2@;2BP\^=;UQ:6-;C
M[N=B.WV4VC$'QE!O]J.4%H:J'Y]X2QH@FXO@L]HP(3NJ44E3:V^"TT[,?'58
M*S[_F;@+<J6Q%*^(?8L#VY;5PS["V[-HCO :&8>2%_6#Z*L4:0/#4LN?!FE2
M<;KQ/1 ?;Q+!2;L>6^;+'\96JR X;].3-4EZ!@"Y6N^D55#G-&:V.U=5:P:'
M"K$>./D?S>08CJ@2>P_.YG,9;38>K@20P4"NVUAB[0,N"N@3P>*'WT<I1IXS
MWONUV_9KHT/7;N3LD+^AYO%2>\U8S8ZAV*N:7 LSH\7(\/"O'=!5E/&T?1<R
MYLM:J#!>%QUR&(D<L6/5'AC:$>\]T<\R$*6I,S\*=:I#,ZHN@$(PJP>N:/58
M6,W=X"K8YD9230=3;Y. ;7!X2,\J^U'2K[<()C=(DLK6Q(F:CX55:<\G0*\@
M*2W1A]%2JM+!WI*Q4TXXK8)KUS>J90(3.Z@@W6<'#Y*BU3V) %5?@29!<7@_
M*3IS-VS[+39N\ F2)J)"Z.P]U^]Z]"T]G\XR:T._EN$]L(P8J?9'S?4H1O[U
M9M7Z]$5GSL!'=&,#UJW,@;:"S:V:2^6>?*\8Y4QDMWWX\69H6!O]%1^\ RI$
MJ$TA*9FOH7HSL%632L]P4Y$OD%M>%[G:201BB !'B@[:)6'/F%7.HT&OJG=M
M)47ZS;WG_#VRZZ>@)YA(I&(K#("D]-XFY8R1SMC4D@V0>].HJF[9#>'XZ^6U
MIX=Z>K8JE)QVV2@3_0S(OLJOYI#[)T7 JA1*7()S\?R?L7=JDQZJ/VER**JK
MK/O,\:U$HCPV5BRQ+>:4K<257$OP\8R8>]EK#_G"J"I%Q0L[D'SS%.0+L;2P
MY5@^\D<82T63<R,W@QZ;I7>Y S9BC>]GOQ[D4IL:SFX9_8?VQJA0%=5$X,P/
M =%JA>.:+!\8IZ,RN>[ /BC*8_"F:*?[D)6F.RZ;%N4S:7S#(S4$Z66VJO'9
MWH1:(@S'%PW*N@-BA=[!ZA@?U&2KFA9H=TT)"GBS!9T/=<3&'=\9#G0I#9;M
M%>O814Z_P]?@:J3]S<:4!506YJ?B6\%"8@SY$IFG)I4ZYH_S0MX\4.>S*IMR
MF':8+CBH['I(D? Q6>F>XZ8N>R>V:Z'V29-GV?CQ#>E91?QG6]&X&\<IR@3Y
MI?&<RO%X/(6*/82V?2BV9?;@RO3];:=18]1%M3(5>KS>Q>1M?M L07.EF/'I
M[6.#0#>/E6GC*:&.;(HZ W4![%USD\"3"O8)WAE0 RE$J5W83IACP7R?V)NU
M.><_O_/C ;3^X1K9!O9^@^M]KD?;R=>'-O=@3WU+SKB%&,W%N4*?O<@=SW.7
M##4B!2RZL*6E,B*P"?(B>=:.T'*KI6T\6Q#!Z/HVH>5@_EC":M#983M'Y!BD
ME@.KZQT-=>GU-]4.C0VU83/5!MCR2\]+GM+U#YTE],'^A8MN&C_P5,<D_66=
M4%!UZ%4';.4^[!7.#H3L&@S5>O_NYT%^4/5=3^4X[VUWQ<<F%+]J"O_(=_X[
M"A\1:%?1@BV 6*9*.S[G&[Z[W7E)BD]8^OX%W@*G+Z9O4M?H0YU=$?35#K%@
MNJ%+\HQ3*LB$4+8Q><J!CI4L) Y2B+L;UCFG>*?0F<N,EJQ-W(E.]CA@L2,1
MSXAB?SEU^EG6 [YY(M!5YR!9N4($RD^V/<=7I*+!Y)"IUJ$A\:2G#A157J<G
MNCS\#DQL;]Q-I/"LUS#B66:>M73:1=9?",_?JVA#UD;)X>[%@1C<:)0K+^70
M;'O>*6_=1\5-#TGF50UYYD;K7SH71WDMW5+BYUL-NJYZ-?V\\)SL>?YJ'X'0
M,>60.A[%UC-X;O;)^F'/IIL?TT?.7;R^XG#IUC<C748.R)J?KL!;W*69F1\(
MSDU/J$,N%JS.D<3P.?K5>PCGK925H7&C*)2DY]CC2<G4"S(?<WW.1G:OMA 4
M\"#$R5NH1< BZ#3AVQS7J%SI=<ML?N_#]N&)V^X4OM]VKGK(N1<>9TUZ^\VL
M"ASA.-P.<LX$!*+!I6@/7:P52M)L=/ML_9"\U);4UNF\.]S.Z9K#EV:_1 6*
M]S)=%3:AGJC>Y=SBQFE"\K_ N)I$%M0$O13;'GB83O7YE&Y<EOLT?^,PGB[=
M][F%Q9CLBK3(>2-J^;TMZ"+.!"O5@6 6-*:OC9!0]5CH+?D,AHE^2S;D+>QT
MT5?T>V\BQO*6KDB.Q6>#!]XE:=O:H#?DJ2J&W H4=WEMGF,6[.V5:1%H$<=^
MXS+=!]!# 0JR2#NIS2.,Y<8BJ,6!'C)M.H0H]]X7#Q9X?!8WRG/%7L;TDZ*0
MYTQ1PR<X)Q%X0KUH]01\!B*"G'EDAWBV&-VIUW3U?2^*L=SX(C=7U_T4&5D9
M"<_DJC?2YHNG*M08C3!%24WR7@OT/$0 24B]QU'J>S[MY%E2L;<=RZ#F1XG(
M.]8:H,>\F@EDV0N;#P0$3C[NGQBUM8:JU@]780E\D*(.+V0\U_"#ICA9E>D.
MR$^CV5()%[&$J+-+0QLYU>F?BW[,B6(VE4-B\.(Y=-A/$,N#.8V58Z]*71_Y
M(87 *.M[7#?\A)R2,WO1_9N-J%GUMCEJK&, ?P[^[!P3)AS#Q]/]4BXCT,/W
M_(C"NTMYQC*:'^?]+RX%Y-N<9*C:P9#;W% I[6H?2FQ^)PS]0A_^JK77R_.0
M>:;?8VGQ/+Z[IQA7Z/RUQ5YC8!2CN.4$=PL4N((9?9=UEP@PJG*CM-%;^XTQ
MN(!!RZ>77!(KJZ]YR2#U5&H4A>3WK]V4&!1._N3_@-O:Z"KU9V@4*F?R<4<M
M 81]BA[JD.1M:5; F&#X&G:_4];X&@B;V6DX=EK'7]-D\GWJIS?=/_[I2_I
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MIZ:&7;YX.]1\G9+=:-?PV7Y:UK(F8O>[)J*GS%2#&S%Q&=;O <<11F!W6HB
M6AEB&V>9QD;V^B22&G_00 006[H'=*#=J0T"$:AV^TN(^<5_:EDEM=1BQTA
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M!#\A'J0YBP\DSVZ<3MSU?] @0QTRA^!\D@( .NH5V4D\2Y?9%MSN#\.FO/F
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M)=J2.]CTVJ;[ED331J<5(N^FVMOPWBL0?'Y"C&Y39UJQI=BA%<U)A-GC.:?
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MH1#\=AC8A9TO5HZKO<74CJZ$-8&/$?*FKT+@V@3W*60TOCVO]='^R9I\4EJ
MT+KWYAF3QJ.=B#?576_:9)2]@:75S0?K-)K36P,58 ["V9V=N0D?G%$$LFO
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MRO[>7OY'A#=&MC.Z87SGNW0*H:^3?'0$YS?7,6KAB>3,+M,N^I)BI5P@_$I
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M N_V/(LMKWED$S9UD\R2#2R>##1S3[!+8%E57WUVN=>L!MG%!*>=39X>;J4
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M#)4K8AI <X\X IQQBB!&^\03=*(C.A<WQKN3TK@CO1Y3V3UU?\ZTHH50QO1
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M%H=SO2>3(^2%GCX1Z3*99^U4SK3(5NJ$G&J)>:0+Y['\:$4V&N18XM%TN&F
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M04R-^\2"@]!4O0.M+!/S9YA:VZ^ ".[[DEO!A'A<Q/^NPE1\D H*63T"6,4
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M32=JH7RD! ?V+9B P^2,&\<FK#\H\[)4''I6E)LIVT)HU&TK^GJ$RA$@S$^
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MU%34M#_LHJ#T_C&!C9KFU-EC[)I&M'<].(05GM%Q7HY)+VZD%SEGC.6R?33
MP"VJB!;#_3#MIV7_-<,"_EN6_=6PO]DU#F"BHB O'A4;  0XNODN3 +P'QI4
MLTB\1,Z&X)R@"(:V>>8IBL7KPF-6-NBX$_>A97F<0VLM!WA>1^ &B]&;P%+Y
M9L#3,_N1?FWQA\P$P0'8R6K!G& ;_H8T)+N.MZ2KC#)H++E5V/JP_@%+OZ^$
M@%DW"8 U[@NPD>FO/TM0/DHG"&;<=AW FUH9%8R;-]FGBE5^VL8D.W7:GTHY
M00*PC(@'Z![T73\J@3.YJC-4X$RB6V3X5ML6E:#KZ57L+C2O9W5VM7JF[T&_
MEH*"J)10CD64+A!J^#&G:0&<:5EU_&*8'-^:^:>WE2ELGY),DG0\W[[^:O%"
M36"L#5'JOF&%445.;+96@R+N5 W"+N 4FL9)@*9^FRH*&4QD9&!0)YWC4U6%
M0*1\T)K-Q*$A[-Y'G'?S)CWL7*)5-!H5IBZA*W,ZQ"I!M'KP<5VA3$_<:4S8
M)I^/L,K=3XL3G:;M73-8(TB@D#S> $T"4!!,J_&Y.6M$26S647E]C"M+N&MF
M+]='_^4!.HA"P2/I.Z?E\T5259]&?T#,9B;)I"RM(^9ZC<W!NZEQU"K<*AZ?
M]-PR5>0#.KH#%%A8WZ]!Z*&C$YIX?Q* >A=O@A-I]CU:"E%7L)X^&4 "&(PZ
M1AW@_=]Y>3D]?QUS.8_]&BZ(M_G.$?C0%#Z0RH*?(*-F<3QACX]<P0%S+7S6
M)1^2'B3V1:W?UKA70?^R9Z!"LV%EVW\H:9H$"+B/!Z$_5Q[*$RZ-RBB"F5V$
M9#\&7/&!)7S40[C*C8LQUF'M(\/2VCQ>*DCP;D*889Z8UR!'!#.^M.U \*@]
M_%@@S6Y^YHII^K=4A,2YO,MG#YO'N@7Y%[C:8.)'%;44N'ST7D2M(]KO$GQ3
M"YMYSVI;)JQ="A"LS98>MWA*^X;'!N3RV*)<" G@.,,!4SVJ(_AA<S1"&[%%
M&'4D\(62242U-#>]1[WND#.%OL&BY>Q.V%S.->KH8CF0*XJA63RPH/"Q'*<+
M7 1G^NI@(3&X4''G8H2I)/UV=F2FX=.YH$GS'<:W8^DP87QN!LP)*Q,=KDA3
M&WVM-@%J9WWY:^$2,U,?T[.,![="(H-9E7#N&U^Q$PTD '>]LO-H E$52 <_
MBW?7J43UP_3\'[GMK*UY2K=<WOZ@]D+X\3U:U>+3E\\?5M2?($[RC36"OK*B
M9R+ADE!5D^'OT6QK[%^DQ[5B&_8\>&SE'*Y+S)SLI )TP3V>?DV3]M]:+CEE
MRA\?3'>)KJB#-5I=$/_L4!GFC@MI1P7%ZJJ=02-XU"/SH%ZB\1N%<ZZNCK:K
M>D)7>\^=$1&R6I^(3G1?:YK6EM;J*=R%UJ*4(F9.-T:D?#VL$O0<K'<^2E'3
MFW5_03R))P'0K2,[[NR6JS8RGZPBSSI:!+7FFUM>W:@$J=F'6#=+O?1)8UN*
MQ,R$0,IUVL!?<]H/+KTR2T@:]AV;*)Q_^4(D=;I7T.V;B143MN.1"M77Q(4[
MX$K8M:-B-7KL4&OU7HA8Y2A!*Q?J"2:.XF@)(KM EVCM\GV$SZ/65W)=$[NR
M2^.,;JTP+ZS<KODHR)X$P$MX!^\P^N5W]P57MW[(S<5[+;TL$47=FY"^?B[Z
MHN(I?;M%@Y!AN;?:J8+X2X<NA"?8]G9KQU9U=FQ[M'AU5?FP8NYBV,3-\E@+
M7N%7ER,&15K/Z6P=C9I>Z9SE_>Z^T7WX2*Z1!'A.Y$]L8+-9]0V)LGVQ ^&8
ML**7/OGLC7YU\>'V*Y"T^8F93_7?1@_RT7V1[2UR].-K^NFN]?P</.!U$H#M
M:[+^\'CK(URL+BTOK5J4Z[8<D8$+2VQO0)7R-)R J:*G'#6Q#\(+P14R$ 6P
M V?AHM9N8*>V1U606M&46H39*FV@FD,6E 1H-KU(##DWY<S3N3@^60L^D71N
MS]KDJ2K84'?>4^/-_IM#:ZBG02GY^7M+$.R7*8RL""_,3E;/S6F6RN2)55IH
MN!=# 8A]GX8+C/(;&P=RH^XC@F=*42U@5BAM:XS+@<%H+I-V$V;BAG.A6DF;
M$B!=IO&V&P/XAA0&,7[81A1$$AGBL#>-PVV&LH9V.G8ZW#\,KC IQ\IL?)Z/
M;VPZ3B?*T>;S(7EW%B<;(T?@/+=K7V-]X[.^DT-QDIZQE[WN]*'$0NG33('
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MYC2RV+/4J'[=\>##N\_JNMF2&4)/#44NAW43&R#[1!0)T)"0<4B!6#H@ 4@
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M;WX^+Q)5:^3A39.3N-0M8&,7.M3SL.;UCE%JYH$A39@D]:=@JQ>G+(RR(\Y
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M^BG\(1C;'OK8[[5ETZ;FRX9"!$/+^0 ]D4HJIWT$W-IU%1()H9.MEW1.F#/
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M W9/9S J&KO7N+=[L77X>;2L^?JKH]@V)='218UH$2'*]H@$W[UJBB!.(XV
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M7W,+IQR)-=Z<%0_*+E9.Y-/:S1?==E7A'WD77VA.01=T->T"!;*O7;(6ME\
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MC3'MMB<>:GE.J^$]TV&Z@_#F0LL73P@#M]NW>AE],^RB<ZY,FO6QTD8A'*;
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MC\ "9PO;PM];N4)8U!XJ]7H;)XP,MDH7+-8DC)LOGI1&.BM</2YK=71OML;
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M& W+[.0S)J]UQDX/CI].<GZ+MM.B+N58!O3"HG$'K$*N)$ )^9$/)5AE6MM
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M6-8OT_F(=+?B0X*4@J=FA,([ULCB_:L"F82;."P:QH#K<#J.L[K1#[F&?LN
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MNG,B2X?"J>][HQ<*!"E.GR?I]=HCDIC/'3HDZ!B$!:4">Y)LIG4EW"=E'7+
M4 =6 -TV<@WFNYL-N"L)F#FBFU)KYYK5:UZ"CMJ2U]*X2?&C["3_!DD>1V1*
M-1W9<%:O5PT-ZPXC>64L"&VCR8"DK(/0I,=2IL(2JA('*_"/J;_]MW!56TUM
ML9D,4-'?9O;$0KOO$YJYVFAL,M_T%M:["?8PWNNO;:+<0_)WZ@O9<PS!4>M2
MB_<&G1Q*NJZ,GHJ>G/Q6J,84D?NMZ3C/7'])K6&G1?\,HM^)%U&4*-_L9G^A
MG2O4.^<2+^QSP1%BJ2JW!ZP%RN!*M$=:WQ[()UP2&\H!!;DU&K;>?S/:11>H
M<LYX2)__SJB!*V>M1N@*#P@SE(5I;9SBQJC#LW%R8![(S?X:Z5D)ADGD'F>B
M\#7'/._33;2%)9AQ7E&X2.XWY+&O@#6?JBFQGCXZSP23_B'.@.E3@<M'.RI;
MYA61I_99^*?.]ZTG%R<YW.H3DGBJ[6W+GV@@&%G$>"8ZT,H_@.N341>X=+@>
M&N@TP^W2? 7VVK6;"=?BK0T]C7M!UUO)FV1]QO2:T[GK*:+%[+29[0?=_:_[
M?<\MY6%CFZ%T;CGW:S#PU[YGQVS';K*>5"ZU_>:W<"BK2"/-=I>=^IO<<Z^>
M<ZJ3VJNV^?.E6K/>F7J6FC?\EO(2TX/N_II?5. OJBJX&J^QEH57(%@C8G1Q
MM_*<2O(D#&L@)6,1<2[G2^,5%8DHY_D[-.VG7P=*N>PG E@P^^M@#'(O"/?V
M13]$%?>!OJ!QL2)2PG7ZQ-A)M^#4>YT*ZE)"%<\[>84OAHFU--IO<! 2< F8
MG#W?P3H1W!Z^&5KRO9CBUS%.X(+T8O W^FM&'A:]FU"U K2\N+J"]/.Z>_*0
M:L^2"*-@ .()I8,+K'4BV+A@@4QEQ[[Q%<FSI1]ET_Q4_%].)]A[4<L8O2(#
MD)<@O*6J/,,E\#%5,WRMM4[,K"Z80[?TR=>S:U+-[]BOQ2@#KD[(,^[K,)_"
M<^[U8$!-8LXU]&A84)TX!H%<1=!-6$Q:X.#-//>:[;D*12](]JG/T- ]+*(X
M_M]%J/9NE>&ZT P\76@P-\$<8]0,HQ&/54E,[/;OJA;+&]>F.K/.?.E32I(\
MEU7RBAO"T>FX.0YV#9.?YXWIV)]E?;/C'1;B!J*Q+=\R,V?G9GE0K=D?1T!,
M7;J3^GV"NL.YT;>1=+HTMG4L(XQP$0,RQ+&B+KFF6KN?*(0J:>5->&;W%(VU
M4<=\S4S81S0OKG-1704^UU-C9GKHT6TPL .B73F,>)M>5IDU9MJN4O8QZN34
M\J 6HP@/E9RD=(O7< L44&(!OD5,=^L^ [F"&0Z&R,Z857==![,LR;^DM[*J
M,#&332XOCS[B='N=-[I3B79+LV-Q(UZ(?:L4YB>F>H4 QK0VB7$V>.TCD2=@
M6<N^? GF?8BB35DVQX?&Z#*W=FFV24C]M)1X0VF$LSD0R1#@*S?@*C&ZB,K/
M027>T'(*Y)BHBJG.U:$QNV38)Q*<I]IYJ3ZA>SOR:TW*QJ2?I.]\RJM*C+L?
MB=JC"G@$PH>[" HJ57J*@\[N#F]"U)0Y7<??BH^MH%=H+B3P*T?3),,ZS8O*
M/YK9F.);?BD'6\LSM?7TP]B#5L!:W'OGM=,BUT./_5+YQ9ZX"O^MWL(J>-/\
MMVQ(.[VK[% ,S)0,\%K\H^: US!^&/1K>N3[N]2M<,R]/#E.B=%-79MO;Q)]
M1R!;TK!=Z3W^0Z/Y>=\,:(,.8FZJA S LXDA=G2:?8V'ESQ9\1E=\ 1G5GS?
MWT.L>NB8$JI'Y72I4S\,_5]A+#"^]J>H57$0<B\#MP']O1I 'K36Y=>4VJQ?
MHEG_1U,[88PA9I*4?NE;$$[!;@O0PR4RX-OPA %FO9O@TT4&6)A1'DKV@"$8
M?()U"(JWW8T[L:L*SN*FF/:W0,O?8FF2JCFX)ZD-;A@RX&KDF$.73=RX])'I
MKPKY\#\]D!5$F R(<J' CL.=6ZOVAYWB9,"+5!(;29-0S$BP/41\Z_S3$VH0
M^(804Y6_Y<$/I-12??KK!J^D?E2'*"7M=O]>G&&W8#__U[4K%4H^A?AI_62@
M?UNWO%M"5.'8C;#CB-?*VA>4\8&Q;J_Z%7^OQ_)/J[(:_%ZD9>$BN'<W89)*
M+Q1_IS*F8P54+:KCO\'PB.&Y70#+[O8;.[5&N^6E_D%I5.JE:]MJHTG[*1[[
M2#BKZ]*.+LMX\Y-LGQ'Q=V_NM59=QH?K8N#OAQ,AUW &V3A:ZP\--7V=#R7X
M[@$$4ZK( "K?H,)\D5*O6.3TVU@.?I$T7("90>^(I]D(#7^(EP,O]@*T"$H%
MIM87;9F3<MMZTJWMJ>>TZ3I. 6UN2Z0Y[\BFWI;6471)K!8T;OZ]40FN=:;Y
M2^D#V<UCMV)CHN;?OG>J\#YXO!TYR?!-Z6F-G>84C:4B8VHDC:$&&V_$2=Z=
M@B\=VQ!Q)YUN!C'#J# */$XK!\=:=36AA!\^L5WOW;&N7 +_CC"/&1QV_VF_
MD_2PA0RH-2 #F!%R4,\GB T94 .0>)&"#,V#4GZ)Z:Y/TX'F-/_8P$3+;@ I
M%]3_N+#MN8]/(0.8"'&S"XAZ2T3JE6R*#Z&B>O\7'R(#2B_W2J5\[T4_NJYD
MF(#D'>=7V)I[O%(P?,RHZ&<Q*> CQD%G^YO NT,,Q..K0[L()EM+KG)INZH/
M^8EGCON;?RN<8[B=!*4EO4>9",V]Y_2B8-SEVX1%V7YV_?F#\]!_QF,U!4UD
M0*FU7XF:6V',HOE[5[RHMU4W?O/UP=,*?^PV&MQ$;5/#C9(HJF\Z7FD3WJQ1
M73;2.F<_DA6/>G!@)6[[,A1!H$*Z)9?<(07UZB2/MM#)Q!ZYVBZ JJ?:S@=2
MQCZK? 3%>X\,:+K5_QI^86AY,7KYC2 P0J33:$:^:3J8231)$@L>61^)&NJ\
M]/'U6DC9Y8-A!Q1\5+?!]-QP7<2J^4<W_/UJOFY\"&P@OG-5@>*H-:1V5+>3
MPO1<!F*1G%Z?#(OQNLO;WQP@$JA:[?L5RGR3DYJ(@]-23:1'.=<R""]P?C,9
M"2A[5H6%&_8EWGZF^F#-7Y"J(B#H5K^#Z](KNK(Q%AC?-!6\I333F$O-:3]T
M8S)UHP!W?FV.I.@S!E3X 4V-HL,0++B83?U*0?&82G;0;I_.-^AYRT2*:GC-
M0XT9?;LN(V2)NF)N?N[#]FH,O^_UVA.A*ZFQ#VV4&FF)4P58<9G/W/>D05\=
MRHY-OSCCJO=\AB'Y^R70W^@RE,ZRS!'WWV@_\)_4QY]Z,Q^)_1-E_T[S O[/
MU.Z_<>.:U+V@KZ&MR"LF(5\Z+1]LQ"7@. ?B]ZJPFV.Z)+6W@B0$=$^]X"/:
MZ> L6@5TW\O3"3\/ O<<K+I ?1#2=R:FIT%Q7WK!WV)]NONH'Y,!/F2 M [E
MJM.W7C56G_J7"R0\Z6E"):)N.BXE5!S_>@AR"0Q""P1Q5J_;)BB\8)APG!D>
MF/YY.O;SW6_@6_=<&0[7I@^IC(9V\8@C<ELK\%GHX6W=H&X0#*@[^-<K;[1L
M_?V_6:)C<IC@\\;]+P?9.#\6$K06?E3=W0:'PT]\QI5GC!\;+@6=MHNY:]%@
M[YU15,52\:996(?N:/%Y-J4[I^^?J1].PA7OZ98#&69U&.[!];!$6'!NC=7I
MRCQ-X^F5F.S,,+F)9P')^HZ,@)-OZQ46ESJ$J%X/*3,X8%6A5/;QN[4;"1)!
MFW<*>$)$6GJ)7Z]CSW]\-4XHN#QZZYV\@^-S$3YTT!HQA7 '>V1H7']0AMYT
M5C,!.18P%7V!;]HVJFR_S*=C_/FHR(5UMRF\V8+L2LE=ZD"*0A>ODZG%V<_D
M@6[I %'3_A*YI2%'O](I%M\3S4VY'7570>,%<J,E6\IX=F*)XNT0ZG$?ON!*
M"+K8K!)BR Z0Q[2L&M+K$;,U^:8J*NYCR/BW4ZW0J38ESX.K+(>"6,%6/E1!
M@+CR#;GH3'L.GP21J=;TIJ<5?M.X!>.@+MX[Z49BY?Q4X4;=""H2+^0X)B,,
M IW-XYS]#L^%<8(O$O:N[(?D]8DP?0[6?/@N55WUA23RO $KSH9#61!9)XI#
MY.BFCW3BV7#V&J6]._O%A3&'7>*&;*="IVYZCA=J,^&ZS3^]T&'970C Z^'
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M4A()B-%%^HH,0I\\8MV#X5R20&BW7Y &Q=$1@@6!=BYX>%-F_)4,P,J*Q39
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MKIO&\U1_P27<*AO8\;G>;]#O&/W-;Z_%+9[]/1G ="6*S=L?S$>X@&/!;*)
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M*U8".D4 855*O.X$H?!&H6RR0@[7B?D$LZRQ=W'WLY]3B2_RTK"^!#4ZT:^
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MJ]S$OS*"-?JSPVMAF-F]N '7:D3P.=.8_*K'.BSIN5?2]O:PYQ2M&5OJG10
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M'PN=60QV*Z!;L3Q7@G-"<2:JXE;N'OCZYKAPG=$ZI4S:X]?DKIGO*)MKU8^
M[:GV;J0-URG@<OB7DBY@Y]>JS/S?5X0>TW9//(GZD!8RP#C<V>5#E[,L=[@0
MY_;P)7>>8ZK-4^.YQT_5V9Y,I$FVS?+ZJ\-21W#>MTKZ93HUG\G@-6/8Q/)Z
M+MP,E<S.5@#0'IT_[*[J%=T4E+X5\5CA6(B%QMQ)EA^5N!$HCGXR8#$<OD_2
M)0G#<.HE9,#!K""1#(@F T)_>Z]Y'HCDT4X&0.?( '0F&?#&7I<,2)*"3A^
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MON(>*[J!X%,UVNB*W.&[T9I%46NF-4G&[S._3XXH=/?5 <F H%P[^,Z=9V0
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MV-2\Y83]B#//6MV(F,1:-O?[GHA>8T>M?NN:?@APZ4RZ;.1[XC9/1O;%L!Q
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M\G2Q$;$-A"]SO<PK3U>U-68:TU8_?DE,25/6-H5G_['T5F\HIDXO\K9-_I7
M!G?JH?/MH>9* C,^-AU\D.8*'--[KF1]L8ZJ8W--(;3PV]%UW08S^.N4PW_2
MB1*M$TM?PYSIKL[;)3I0I/!_/+L44![?&P=A*-K?M2#-;0^W:ITB_UIHFL..
M(FN\.'X>2[1/\,B4A,X[E[Y_[_ZI^!X'[=W?TKP?6;;PK#N,9:>.)(.$8($H
MV1/SSK&55ZN>Z9"6CE</C5&!+U,W[]JD+%<..,]S(T@\!.D^""/L>1?95_[Z
M5C1/9QMQ(%Y^#5>MOM/^8-JRS:VY+9S_1JQ0]>IJ%PEA1KZYS"H(E?WF3AK
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M3.>XS[&?Y^3BXF)FX^'EYN3EX.3B_*<2&MH3S&FZLW1T9SE9F%@X_V\7ZA>
M_0R-$.T4+<UEX!0[#2T[#;4# )WX24?SWPKP[X7FU(F/] QGSC(RG1C4G@-.
MT=#2GCI-^X_7)U>#3ZX#I]GI."Y=UZ(_;_R8X;(7YXW0I-PSPK<^?^4R^440
MD7OR,NPL(S</+Q^_J)BXQ!5)>05%)645U=MWM'5T[^K=,S5[:&YA:67M\-3Q
MF9.SBZNWCZ^?/S0@,#SB=614=$QL<LK;U+3T=QF9>?D%A47%):5EU36HVKKZ
MAL:FMO:.SJ[N;]]_# X-CXR._1Z?F,/-+RPN+:^LKA&WMG=V]_9)!X?_Z*(!
M:&G^>_D_U<5^HNO4Z=.TIQG^T45SRO\? _;3=)>NTW-H&3,\]CI_^4;H&<Y;
M2;F?OYX5EC,A<#UY^8N16T1^3I3XC[3_INQ_3%C8_R-E_[NP_T/7!,!,2W/2
M>;3L !@X-LV+E:"EQ=&7^N:2V#HR$^+#I"8U%)=P#)*\5V/.W_@@Q';QA=N\
M;"@$!4F V<Q[1H[648'S;!U26<[7B: HW:B\.CM!];PN(Y0N__$H[T+6M%KL
MD4.G-3\IIYV_*WY;H=I5T=N:[\TI!XY+!E^$"IP4H@@U7\Z194E!N5!KIF(T
MXAY*_V$3M$T^5X?VG'*O[U#I&5/7>QM4P [S;:'<T+N4.RN9TDP%,@B84"K@
MRA8C)/S+1P_5'S,6(DR*"BCE3?]RN\V8*6#.)E*W<^).OG-TP.OP!0<&03?L
MQ3&T.,R%B$6,M:'5C4ZMV/,V\KM7HJP-6N=G#,][J_?>2"[/>4LG/*: =#RZ
MO#H!_TH%F$F*V [_3ZX4@>&GPSLY')V,E;T52+4?OVUG2V?,JEX$[IXJ(HJO
M_ZK0QP4[61+\.Q+TO[+A.+6J)JU="%/: 1?M(BT[/GQ9\(<0JTI'VK^C;:0/
M Y RDQY]=TV0G(U_]O"+^*FM7IYY_PYXW&%.>Y: /M&3?,D_,W:->Z)R.C'#
MTZ?&UAK=]JWFRD3E6+B)*P04<IGDI*=Y8=CW**B??04-'H)I^%=\?<S!HM,%
MR\F\S*BS\,+/@7>>#WEGF H\]1UR('B3Q+O2*:QHPDC+)^V /0G/[-D?WB+)
M9W68KJ]YF>?LZ0QZ: JN6;/TQ_C:Y+!C\>RD2 AG V+CMG%\6(HDS2?)T(2L
M:T8ASGL-;I5<K>K[1U'K^+6J3?PBY1FX$X&POT1R(7IW*_;<L'<.!+]*L:T;
M$HDY5;O:Y!PN_\KS*XT6GS"?AAODBQ WZ7=W>^!H/E&LW6:H5LU(R6RHRB=:
MNC,I24G8ND6O\0<'O8B(X@W7L4CP,RZE$*EA]$5H]2:.M1:G(>)LP6,RWOGX
M@OG-E,7N"[97KOIS]WD/<?&$8I[9F;93A G'2QBBN W1'C&7F\!V-_M,I?DD
M4^W]:NUPE8>S'MV#U2\+\GNXD:OH+/G-%>?\ASV9>L=';F/VW3RSID2W!\<?
MR5JSY9OQ2A9-D*B-J[MGSQ)VPQ0F?G3[&-3>"&?:?[N<>?B9H3?[=Q53._;L
MHX&0:Z3WW3VE^@I=]0Z>3_<,."*B[^@Q"Y2*:T@-N&6BAB>\UIML;%Q]?H6'
M^?\YQ%:%:G.:,]PTUGX)Y_9MQC*398E^-44_+@[+;PAM_9DPR6W3O\#ZK=.(
MX30K&^=@<_5Y6-DZ7@(96W$RQ'/X2&[=(*8_OJNX5H)A\6R"N"E1L#N%$_ZD
ML2459].F<\;HFDZA[@_:\_&S0XND7J)<IQ_Z_. .AJ\]#^*F*3^\HS-R>4BZ
MRF_RUKHP8[QBW?6QTEV%\=U[,6MCN_ M94H]DW/.KN>VYF >6IX([I:-@; ]
M;[&:$S3M4&RJCT%IZ!HXJVNQOK\@AAM<>E!H+V1L^_)&[=!M)-F:-(WSO( )
MA[D[S3;+,F(%9?HZ=[Y5I1LWWC%_UI#T]8K ^?H%/F#Y=*+3VJ!^1JT'%?!/
MS] _S[V>XEF/I>@.HRSZ0"BV#BH0/<-'Z Z%B<_%H)J-8K,O;XMEY)VRN9M7
M6R]GQWFC=.[=Y2N.%+DI<\\.9*RF+!&^/E9,MB&()UBT,[GDZY78N_04WH:F
M>TO0Y$G+7E_W]?UV8= R0('']]G&<>".0(>VG=6T%!6PSP0]^ 41!45CV,DT
M5( QT,Z[^W;' *EIQR@X2VCF=[>'.S/ZWOJ%62K PQ#;']Y%!?C(>@2,):F[
MF#33;C"T_G,_#<WJ+G9%NA 5DVBB'WXTL%YF:)&+*U\;Q&;8+*].?LNIJ&RT
MH]BWDOL_.R,1J)R);@@$X1=3THV(Y*]++:0!)W]TL4@?R)">T .F:\<%SSJ@
MN$V3XD$NQVEDKRJ8+DEP;O,<-'G18[<\O5D_)HTK^GKBFN78X@/@X &KAI3J
MNX AA'P+1H *)/G@VPH:'99)-N1^R[Q8J0^KC!)54O.RT;YL9V&21(_Z@F\7
MAU''BD%Q+HP,3)=S)?T^A/<_N=+I+9]TP_5*G1_*HBV'$>/")N!*N3Q0^9PB
M9DW6IPS\*FX=>9X[X%"K*EPAFAK_N<2\W:NV"8?..'X/<RHGWR9)SU7"[9ML
M>LVW.+;[/E]]G(C37'O%,&>G\&([#RF+#Z%$:5R]X]JL>TBI"DSEVHIJWYS0
M[YBY>)S+(:@39$%RP*GU;/"T%XD:X/V=.5'QLT[/&]X">LN PX7.,D3\FY"!
M4?M34?.7])DV%-T=G31YJZ49KT[> 1R2XF$'_9R42I$-L;1T_*%,V.%/ZQ;3
MP,GBM<,<:V,(^VK.A193G%%\]DDHV.^R03 *2+^PM')^ U7P3(-&SK!\BXZ0
M_G;P/GX,\A@G&P?AKR([(:&FW>8S+(/JX""%Q*S"DVC9[B-KS[ZMT8[YF1LM
MS#1P842?28)L((M!]FR)/LF7?:VT#\_8=><BP&.I@)OG.;P_G$U&G!0*:JL$
M60X\:QZ6F1L8,C,-N+!Q7K)<^-IMU)M 0 5O DW9BR1]=3P"KP;.9)5*SR#]
M<4N#.Y4O[2Y)&]87G;&;;SA2?Q5-;BL^3?,%E!!\KRC=#0+I&SV*.5S4>)Z=
MG;/L_>>'U#R6F3*D*4W$;IR?S9+3Q=1#:"&K>U3 /5)9^.58LDU&!NSG4W=>
M7A;(8PL%:Y-"1YFF+/FRKLJI0#I.8\OW=)QC1\7Q8S_MI<<T):#S>W%$HS"R
M.)$>S.#2I(EP@S,;Y=G,5&SI-7#Y>37JW%R!]KH9YJ#0=75%#R6#U%R"<HQ^
M02Y#07OQQ.4$7\CK'MZ:Q'GSVM&/P_(["7<L_-,"[EQ*M%9PLIT5HE'I?0([
M3]J8SS+"Z<05D8J[J<"SL2IKSXT<6M+[FY2?SE^8+8XT?6Z)2(6^VMA.#!R[
MW6:F5S>:0[!8\:XP$] 31Y+9MC5'\]!F!-9:8O&\X<E\A<G-!TO=&_)0.,O1
MWN:?^40A?T+WRJUG#< /D4<%Y!;:==<M4CC._V3&1J,5AUJNS$/5:0J@]^;D
M"4DN2?;?@WP>J,FA\J,/N@#ZW+D)=Q5I):S1E\)H [&\W4EW^/G5":D%SR@J
M@(J*WS7PG\NBM'IY"L553,^0'"SKZ^N-.0/?7ITQ6R--G6[VB_A.F[W[ XK=
M2R;BR:I17>;VDE0@ GZ+"$),Z@YZ7AQ\TNKF+B2?)B?9\2##KB"^3@4LPV!=
M&U$RC4'B;]G+G+7'CNWT-TH@8V!&Q,E.>UX2"P["L0KFVH29!K,6/W;-+,J=
MW1UBB7BI5W?K4\LC@U25%:_Z&13E',R8%$Z4ZSC<"Y^#QR3,]_*N&EV&5I*O
M9;X8D@T]GA*U.O6]^4/8V5-1$9EQ[UU[QGIZ?NKS\(ARUH;D+ 4CM&&UA/!Y
M<(=L?+;:H/QYYFR!N+:D)N@//6G38YD=CAA/]D=^N=WOK.XJ7_3*/(R]NJ&R
M6Q7X=EJ\1[HO]N'#A[WL.\8&(=I/GZO&DDE#&%=9D&:Q8&=])Y.=0X<[3G'(
M@015![,GNWFIW#\@5BT>T&]T(ZP_SQM-.'29ARB0$(]R>-BB?+- EMD]-PD1
M]ASZVZ5<M-\C[I?<=?)>W.WGVT/JKBG(NB&[R1A!A!I^>+ 5([M-!<*"J8 V
MS(!X>WX9(8^)IO -[,(%IF"RB9MMYDV5Z]Q"O':.H\=3%9\Y)]8_!NY-)N[N
M*(521%P.C=H-)/=MB1]"+@^+HY+7I)KQ=P:K/%/]06G#&Y+0KNN;,XW+41\N
M%QP>4H%4S'GH$V$5Y;T=*J!&82C]!9&&J;:0IHFZ=P;1PB[V2H/2%0I,_=?5
M+_D77439")(N3DG(!33K!-_P&CS9BX9BSBF<+!7035Q75H6]:&?5:V1PE%'"
M);.M)UNI=0N 3<I(8Z&JS)7F8G<J<#G?2J_0J0J;L3YL<;+RL6.<<V+Y54G3
MZBH!@GOYQ:0EK/;0<THW.];C5]HUG^]3-P]JFK//E*,EC\M:="M60U1&R==+
MI!,2TL/F1M8WBFIU@M0V40'>5]^GBY3^V/!0FWU6:WDO<1)N3@7DQ..*D' \
M?$NS)P]M54OT[]A,"+D^["/+!!UD.ST!A>O7I.%VY1L\%C$MF1<7;GR[EA3F
MM17_872L<S,:Q $[3TAOLV;VM[X#YR$;P+E3W+R?*ED+/VVI%W"$-%TV##%%
M-7Q1R!E9]!4HQWS!5.CTF?M!8G8<N;;2<H]T2 CSX^P66ERKXIJ&6H=%X'11
M0N6E,*7)&SV+MF*#9^PZ/'@7Z'F1Y:Z2)JG@N'Z"?+&Y@B9(MD,B+[;CMT1>
M$GKU(UT>1K,2[@H2H@+/>Z0Q'4=V1AU,.(NA2Z1 -"BF('O*H,8_.Y8OQ-[?
M*7%W$@^N$QV+J Q1/(FRE;X\,?+OF[^U*+]Q[E?W.WI$+^I_]X>7N.F5U>^X
MYAG&,C_K8TH61C"1+J%H-S 8NQ2<I0U+)2K-UW?P4KA@XM4$W\5RLA91*$&H
M,=A+_?J[WA;%.(6O$V9E&8*I%J]4+K*/HC1ER=Y$\TI"_A<A68+/_H11E,*G
M%#?5OKC"JE+OXERC=U>EDU#*DC8,O*M6%?+3=6,G RU2'OI.:K-XEPJP!NMK
MP[1PD GQSD//+],"5D-H"9?,<EO2:_DEHF)&WD'ZE>=?EONKH5WC4;X/ER]8
MU(7\I%P=5K=SJ;*U(^MA2.&<1OS"$*C92N3OV917QK O+U4V$('BD1\N+F'3
M(5OD-MYW??>NA$"6#X26M6&;.$@L^-QSC&O.*9()KF_R-D&Q]#@OB2Y9Y8_"
M;;I/*;WP]&MY-4 9ZWQMW(N;H%L?\9:&K&>51FQGN#@G]?,_'4KDU<@S2N2]
M8I1 7CTN;G&O(*N0N'!4@(,4LOA\-TMSY&E=%L[J(>^/N.3*-U#QDK)XVX6\
MIB05">WO.QJ&L:3P+SDHW?@_,+W*U0FCCF;/V*;GFEPM(QZURCZ\ZY%QOOSG
M&=.TSXHMG79_G@,)L@9O('QQ[FRS?>\+\/X<I'SSX0UI\JVA%22GJ<ZWF4>Z
MSA&PNAD'\+UUJ&HI%6@_V0U]^_P6NX/Y>60>>Z#;B47YQZ 0$[0]J,8:R.M#
M\US/N6.+G]K;(9.JBW:&2ERFJ!<WEY,L,2C9+K 05 Z77>SD.\^4$XGFBYSA
M'M@%DW1U<HNP/W3L/(H9-WBGM^9N3K &;%YOZS.0^H,\MK%)O6K&X5E3OQL2
M-<YIT0GF1H-)S8:DFEQG!IQ/"/.O/RV7W"I:]Z-:%!5^>U3-F.ML8?SZ%]E_
M?/YRH.L-T26Q/1BKA8>;^S=Y1@L3G[5ZN0A/K!W6?9APM;UK5<=W\>$T[P5F
M]^^T&GB5@53E4KU-/,5<AFO>Q/"*^RK%7T,H]J!YUC.A)5B\<\.[3>@2T3T=
M(8TZUE1+N+778ZCOC.H959\H_WA**[%W&[@1.#;(-&#N>Z7IY>*SMVN2L:N6
MUB=]J?#O?9F)<?.,/<2VM_I_4>2')^:2@@O7]I78U_@[)GPLPA3NMLOV7!1&
M7@@<1:TV52_$I%K'O@W(V*GD(M1E'9E!A_0)FED5:T+"!C:WHSJ35LMQ0<$\
M/RACU1/ZJ>$NP@SQ'[]OV.<0]O<^UA,Q72!0+;I</IMF "6A<&:^<<A^].X4
M_8WZ3?:G8/]7T)W*Q8ARSO$(+Y^%0<W,/#3D. .M"IWLLA<;\8$+M*9,X_G-
M0JX0AA7G++@YU,3?+DBT2YTY7$3#=JK.GVS8N\'1JND=&VSZQ"C$^=M$Z45\
M>RF)IR,;=,0L9/6,]DASU2SC DOS;:7^9A6-_K*^+0MKN%TX_@'*+KMXTL>B
M38B>=' RG'E(/6:U(YHW7#5!F6SL4ZL#*VEH>IMOV6>6)EY-7[4T:0]/28K/
M/$3.JY+J*>?&4MH"=S%18J$M^&E#?=H@=?.UL_#+P)D UFNTS&9FN9(OC5.P
M8V3,Y5(<U]U&[9/>@V>LO+5X0^G)!H^%B,+$/HW"M/W=2US% N:4S(D5TI(B
M\26#'071!1=9OO_>$V1 FLO%17R W(8:&$KJEQAK<]&]YC2^2<>UB$$M)^PB
MHB"G808X%GJBS['Y#X PU2(E$;_ O/%(BZP-C5H_(.([T)=(.4((I0Y]SY@9
M/G>N6D%]LSAM?;I!<5O0E>QK7-5*OCM5[QY\6&V*<SP99&1#E[%X24E/O^!P
M;5CAD2;EEZ8,$=G9W SB?"=,Z(Z]V( A)$?<@>:%/4O(>YE_]6?#&R=UMB_0
M87 M3P<3/L%['<R5T!_OOHM_+RCWA1VJ+7[DHZ?9:?RB--M"Y,U+H-*<-3\E
M,=.&>!#@YBT>7Y17Z%1Z**H-RR$:[L^SIA!MODYH9A'OK*39RZ3=O&H4M?X'
M7+VGPYOWK?W&=E):IT7Z7@2Q/I2B3 IOFSC^-MPBS?7!G'OB5VTL5[CI-1YS
M&.OI"*&S7]094R/?IN*&!H^#U;B)UPT'#=P\LEO[JR20$3#=(UWH\GH.DT,S
MZ;52Q*4Q>16DYZZ:+$MWF9X(_M+#4USQL^S3.O0:> N<4C?X/.GV%RK ].<Q
MJ=V;.P?'8D@YR2*YITE:PJF7$W0ZC\[K)M6&VH:F]04R(DN'FRRP8X7DEGA*
M(XM=W0[>$PR^O9$IM8P8OXTSBM.\!.*"N^*QA$R2?1\T18?X>!!< T;1F"Z%
MG@/.)6S] 7P4=B29I5\.AQ>+T_L.E91IZ[&>9'5R-PLTKKBPW0,.7G:?;!=X
M-17<A&1&R$RX#=FV)L/0DN_%+A/:,VGI4J7J<-C4_1#H5Q7:GH6'R G3>:4.
M(SJ7;+Z!%C[Z#S!_T82NYO);0";O^H;#M*3$XY0EE=_% $&7KQ+$0>F9V,8+
MB0B=(Z4$G\PE%FBF)\JUZ;XJS/N;B+J:39^EO%H40[CI-*5;\QQ1-T&V%LF_
MW,4=Y^!2[*+(4Z1-Z8_D:@\AZ&7P_4X3?87?M(_-HA,5=Y-)&RLZ@I0N*9LO
MNMAO5E(!F>XK1,Q>WAA,P840U$%AK*>,$DXV[+GOS891<XRHP7%=9F^]6H0D
M,??-&S7D[7@+\#QVPJEST!G,L2O+A*\K=W&J=$[+Y-K\G9_J4->L+=-IA%5Y
M3IZ*?](J_@5<'6]_>D3]PG><E:R/)R-D;<BER2?MW:1+$!^D1FY3Y,#QW:;P
M$DL\:VVO[/KUQP4D\:X0_H$64[$4ERJ\>5-GAKOZ??EYVG3+L R&=XWJ3KRT
MO!IN=_69N-,]93=#HC-T.?Z,0<"RVU+0<%Q4)UOXX0QFSH@=FF]$])WNCI2I
MG1:WB;JG+UX/57Z:?/%GA<KI$'2J;ON,!JF>Z-"M^BP\EW38W]9 *$RKE?N>
M>]M/1CPEDE?TWJE@-L'7_M<I/4U=K2>9.X0?=C.G4U-\6#[ 1U]#RZ>D8G9H
M-B5M_)3*E-Y7D7KE,I:CJ]#F6T3ZG HH&/>*T#G%SU47I:89RC6>>IFB@)4Y
ME])_&Q%XS\>]"5.4?A3:5KOGMSNV+7?YN)!L7$;INU)JT^[ T,E4Z=4"<N<
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MV8S73R=\19O0X#O%N5,GZ$1V=!*XLEPJ70X3>GMK"W=K>WL_3ZI?^U%%!.D
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M@!QD33"^2E.VC,(!7K. ?U=:=GB3B#:\">EMO(G!0$;"Z]<6;-Q@(AS )>T
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M-T6;:4"ZK66>UX@V.3S:TF!A^0Y7)T[?.1:/4**;>3'S HJ<2?,]'U#AS)^
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M_1BX>"I\S!Z!UTK/Q8.GTL"<&-LRG<(?_GZ/QE5^HK;U1L4*O 3B!7;$,*\
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MG6!'VM+I"N\DT6=R+?2]?ZOL8M&!:'N@M%PN=%>&4\4>=HZ%#@8Z.;;;%SW
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MX<D+Z6#OJ/WI2<BT"M?<[*CX7YO$E/K!4#PHN$,)7X1&"*'P[E\Z@-&,_#@
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M^U>'S;UO\^(T"#YUOO+G5S#T:=BE^&P\[Q^O;?V+W55V4*_AZZ282'>:3DE
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MOC4Q>1]9%"5BVF=9-9&Q(SGWO30XH\5(90#(QZHL !0F:+R^=?DVW<+=O>L
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M__]B]G\3^V^\%@&XJ"C_-@^5$" %>-3\%<$&^&\ "1M? @XYVE+?@,>T$M4
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M$E[;%,*@FPE7*2HI3:Q'&(+U?C/WC6:Y+J(Z><,M1GE^8Y,S'BEX>),L-0]
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MH1.*1V\=@B)XP8I]&?P:J$V6*7'H).H?_@MOZ/&MF7"*W, !P8<J@!STIF;
M.O4=BOJ@K7GOV.0_%:R WIE4J">_,I<5P;F]MLAYW6? SOWP;ITJY^9/3<2%
M_@></@A)J)17NT$.(G&276;DL[?0P+M%H1XH!N++:_ SP 84)07.7X@SET*(
M'%#>9_FB5$7Y,3]-T0HCBYCB1HH%P_.;Z6WN0&F][_(Z5QTG@:GYP-<WFH8K
M(\QCHZ/Z"I:F)XA#A6WX2DRF AW;9KV.[+ LLY&8TDO_5VR7+QH0KFW9K8-3
ME;KS#;+HCOIZU)=/E+"F_+\UJ?8%'/Z"FS"[RYHLP -(9[570HZ1-,_17!/5
M<2MBUD'1TEQ?#^\[AD3IU,$'7\GD5L<BY^QVG>TZK/2O[ST?0)\KNUNIZS.<
MGH@3U16*,*C,*2H;UI30G;0<3^1+YQ:=HM_G. Z5[=10#[Z]P^&W@Q!\T>%:
M#<(_P>!9;17Y9JZ9T3=#[3 P_5<^WTFT,"DBP4*5-OE3KQ_'&4'O3SG$*LW,
M27V) GJ0ZKE4':OL@XP[T+U"V)(1<&9X75)4%/?A?C8JQX9B#7S@&)3=*)@-
M=<9(W-IGG+*TXP"]9[_GHU-XG4@W%W\4<6=KP$E I-_O92/N@JW%#]0YIM"E
M#67\SGGNJ%OMYD6:1#JH:430;;(([9>JVVW&):QOF0MF3GT-$1_KLX6TX?IM
M>;L*#+,DUK+_<0&&WVE>1_YDV3N^^5 R,4)_7RE1!OG]((\R!EXC\&/T!&X5
M?<^=$Q?SRTCYP<.VI++P-<Y-CD9[,+=0D5M<"D+_L[%O\,9EZR\!%(*OV12C
MO*YY1*4R@U8J4F'NM%6!^Y^W7'_V\B59FUGC7:,(W^(7]2?3OQF,BSIS2K-8
MS_"* NO9'2NE9@<$?^'7BNSG'0&/&1GX.-T<=TQ$'S3.6CT;^\_U>EE<$0)1
MZL'B8O_N\NQMR:PK=: [2MUAHS']+,N,(Y-5AH/BWH[T G 2)6(ZB"@GY@D6
MFG]&C@ESR*N<'8?B7)+YR_$P78VI-?NV6:%IWQ9H'O5;CBL1-VD-P=\.MR;B
M*OF,&$I%9I#G>.UPQ/LKL%:X0Y(ZU$Q5)C$A9\^ B,;*.T.5]^(+@APG Y@5
M7E?;>:A_>BMMK)W.5:\/5C^KE>LB,">USKY).KZ5%-V":=;W%G_M9>R$U'2R
MHJU[]'N)K\3ZVN28J,P1Y5'3J_=K/F[@+H40J,GQ'X7#^2V/&HL%=,3\NYIQ
M4:A9O_C:&.^6E!%DO3=[LP!D1,VR+5SC-N3%1U<\.><6HG8[RHAF]'(@P97$
MIU'8UE2W&QZ6TX"'%S!=U$=AH +M047Y/@':KO:HQZ>APE0Q(#>S6]7& @_-
MX/@M4PZP?(&XYQ?4B)VKL.%E<+_;302AZE33HZW&TC0Y+<P%0FVKD(E?EYVY
MV7;4AT7E40%1:6?P[RWP@C?T;0<8:KA;'FGG'M+5["%4I8[/MF*/5UST+$\E
MJ^B5ZC&E3),RN7IB548QU2?4 ^_*JFQ.D;%R(=>_/V>HDV>L6H]_CI#U9"QF
M)*_J1E@'=JN!NZNFI) L4 31D_!I\-]>(ULP2]U&4PH(VUQ\63=E\?7RP+S)
MC9[OD2V?S7E=1KN$R)\KUE"8HX 6\7=AQLF]C&,$ZVI>QD:;JK6KU*N780/S
MW$\.HI@T4$G8Y/Y-H98Q9,ZYQU5+D]'^-_L5/8FZ#( 9V/+#-,M9LWDQ'_XO
M0^4OEX(;2^[4T.!J5^E=RVNNM#T=$H^5_U)7L5UN=F^+>+'=9OJOEFSG%6>&
M*_FNPU)(UE[,[$EG?6C_"%V0,2#ET#O>WL-GS:*!WKR$<=?'FV FXJ%F]H<F
M,GV3W2&GP<PVJ!^+8IY8Y!"2>#<7FK;I!:R-7 -?X>,/Z7";F/15N4CAW754
M[4Q/3.ZZZ4[WZ4^;&(V16&[7E[_>G??:""W96LJ8GA:0,%#ZLP?[)T3P)'<_
M,.O*BO=&?7TBW>=]FFA9J0KE=M,&L;4%762P-D<ITP]*L;@T#:K ]A)L"<R*
M>[VL'!JB,:@_-G]MZF;-N!T6X2)8>5_;JQ/5GEQ@CT!2($ ".>GFWV7B5<?+
MB]QMK&I:YUAU<^N57%?J:\U?_ ND#RBV;!5;O#D_PT9)+%=*A#4&,J?N*' ,
M*8>XGK*_>L]J=:C:+L<7.4O=M&Q6A"]/:B\N9&,#0GM7^-%1#6_ZNX)D$48[
M\<9@B,8S0.,U3K-N3<@ +^CUD*^<>LPXFG;<=W/P/+ &">Z=W(<P>/&B,;L0
M@/757!)=4@9WFPL%8,=_+<=6Y/1$[?V#9>&H"?AB0/K%L:ZXH<2.3?"(:^&A
M$+%R-L](_"!I+/>Z+*C496\A2Y;J)?D[*'A2_-T9D:_D9X-&9NPN=P%$!PW\
M%_SME*=[;:,3V(1SH2F3?)C)JL [M(>S_QXWY8>B.-Y1+_N^[<%PD5DD74C0
MFPG2DG^U?-6G;$CR3.F,6L)HQZQ]JLME1:;>>>9B>N,K"A& ::T E3J).>%<
MQ@$:?0/6X%3M52MX6\P,75;46:$P^N#WN5P"<G?\T(CL7$Q.M\C97U7X#MC;
MP0]KJ3O#&_5H5 6+)E[P"%-?5[7XR(\>WE(P3G5 S_[VO+27/G',==<+LR%Q
MH\]2]IQR_SDQ+VQ%JI)P+2!DE>!I>T4VZ=]MB59,DT9GB_!A+5^S276R37FM
ML6"R(,_<F$4(R_OJ.5A\O2^GO^/#DROCR%2X3_K3L!A@3H@$RC@Z,?SXK=F\
M%(RVKJ/][DPF&QRY_6,GI?'$+_'A!7+BVUEC=Z>-A3S,0(U^QAY3QD7XJU3+
M<CPR9A9RM_# 5^Z%R@(WR2*[/NE4?R*]W3@%;X[==-.%IU!V.5Y2A0@N1@&V
M%1SD69=<XLCI3,7F#E+:[0DB?/@;R53J+,AV%V7VE\V_WD?<&[:2G)%42(4[
M/EE=A)*8E['U%RDA->&21EOG!]NZ4U5!89+),*H3TCT_\EF?&94\B5C;D_)"
MW+R,J_2S@D5V="[Z_SSH4B+JZ?0GG!QV"6,PS^ALL\[MBU4+F#,JVEL5.-&9
M'"S-HG  NQU,R+N1C8E0_1-#B9GFB*FEMMC8;=%$$_:1"B/;NZB;FX3Z&P^"
M#CE35<G 27Q_34F.!WEHF+%(<VMT[+5]&16(7P('=>09T!4VL:.G Q2?:PXJ
M+"EK7QC6;K9VT[EABJBY[L+&70O^5C#?U3T(XURSIS\;\Q#A)&>KLW?CEQU>
M]BRN$C!PBW4V%;XO;+Z/5K)]0E3;QK>^QJ4U%2R6.!2)">NG?"T::<1Q!M.=
M16Y_E@$X1^R:-NNE__0,\BG3254#N!WH]\@S$[LM,5:BOV_2'O<ST1]^@M^*
M?I=,?GD(HN\>ET WJ?^XS6U\2%A*&(=]4ZEJD+X;%<3D[\509:*Z>UE^2Z,M
M3Y_1X](Q4*W@\$U5-)C<+%;EZ@<3T>^EV-\_G2#PQQFGJ*8H#*D"\Y517<+6
M F?%+\<J1Y]X=\X1XRBE"'KUX5_;<2JK,,6#B93W?K )]@RF86[@SO ^A+*[
M5?5]INN$0&'KKN$+)PE;V&Q--/E5>=58M02^G!9L_"*^L5""<[73C&#1W(?C
MC-+S75^C70?IS.X+^*:EF!TW^;KY=?0XW_Z@!'85X8P:.B, 2%$I%^2"H8!F
MVFP>H:"@EUUO_/Y/]&Q39Z/J91.F&*3% _-@1L<OL S[C\I)7H'GS3'KV:9)
M%-U+BRF8=X!0N+CPL)6KX<YN4-5)@60SH.3&!'*YHC*#!/<Y$F4:J-[/M]?-
M^&%>,N3RQ9>)T0:#WKMAE,,QDMV9I<<<\AP,)_M$(]CR461(AJFL<[ <6+ (
M8#)6*':CM\/W>9.0&7.JLG@Z;>KJ*H;',DG!QNZUT-$,$/L9;44+O-]3$D@G
MW@=A$X?6R_ 4>)A[WB!\[Y65KW]DASX1MO%4CT(:"E!="#P9&7.?SA"3P.$[
MMW" !<1[5EER9>5&<4"/.M6+>B>2.$'A1.&O$<M/FT&8#7$!MY9>->S B"8)
M8)I;XT]BC$D* V%/K- EZ_.U#Y?;SS$TOD5XH;F6-N@T<_;;+7Q0OYA;+/Y2
M![+)=+[5Z:_(68>*5CF@B R@VTK[8V"M''R<,<+^5J^FP)AMJ\HYD<8.8+LI
M@Y_6YQ!/+U9Q9Q-5KHM4IJ7)CQKXYJ&Y228K/K +S_,*CSDH$0Y(H\[#?1<=
MI-[3SE?0]AAD=N39]1#7[=BY32CN!<E:+!\D1EF1SJ_2$T3#4NRW(GB;MC-&
M]^4DN#(*FDT)III_.I"\')2^^ JT*>;1&A#&%*[4U-%T9A2<1#D6U8A7%[\Q
M:.3YBYN?0M,"3$.&^UE)^ L<KC)HQ+?R?0M]T=;9Q_-TT+5=T^]Y9=+FH4EW
M+^+C.O<,L.JD>P;8'SCRWRF/!)3:,-?0S.@=8DK3'Z\%;'::M+%O9A,\F)\R
MQS3_6JDX28:^2J%(#8UNQWHBT^S&;/?C&BO@8/U"[595*/5--79PPS$6V-TR
MBG@&8*V%66D%SS\TI-KWU$S(0%M\L36//C,OC[=+6HS'=MAQ[TX[6M0U;5K'
M$-Q_JGD 55>W$+&5J](<>%<PSN0:*CM /8'(Q,X=-4^H)O% V_:<[%Z6NZT'
MCIM.0ZHGJ64^FCBJ7F.4>;P9W8"S/I%34::.SZ>Q3M5K:7Z4@#.K_MZN-8(K
M"1E\[A=87%W/@*P8]Y('OM;3JJ0V\2Z&A*6T\U%(XB%H1@KT#'A%!5+%/W@S
M1#3,W.L/64>G]B83V+Q#OU5+LXORJ+ YT9B_PF/Y$N5L0.LL/0-D++1E*MXC
M+;\+/3G+3#1J),QE'J&MT#KA3M9*F-7QGN!^NY<QT-KQM@T?EIG!S6:DL8<@
M',Y$H,8)5Q$B2SQPGQA@C=MOU;\[@<<@=.&PM6I]^?NP\YE&S I/DINIPY;V
ML>UQC]]]Q6:3P,2(#%#2U:GS3:7](+W6XSP%->Z,RZ@VIG)O2>GWO1'.P'%>
MVY\[]]6FI7P'QB['W@I&*;2F)^1?L_\2JHV(W*:M7V_/LOTPEUD8OY:0:M42
M>-GESR'H8GNLK^ P4N'+,!Z1<^KE,#MIS3C1\H[7?WZ(%B84? F"'E]YF=XK
MC>9V>L\J''.V3+<1.KH4?D 0V_<$++;D8ER+MUQMMD\-I,-RM1D%;.V+VYRS
M?@5-,4^9]?[<(U]!:)T4CF.HS.X5N.L-RGH1E8PQ9!5XU MB3')&P;G/Q[WI
M%)=G_VI?!,8:9FRZ1?8T+WI6VB94RU#/A7%KI8H,5[[42\I"Z7<3G5FO QL:
ME[& QYR%/,"U.$/;5X$I HWW4CXZV>N#@W18R%J1MA_>WC/?+_="&N*"DNC4
M [.[@!*E(UF@:'B:J&AFU'=A4O75'<4QW:<0<2L[ <>7[?V=?RF9#=+2/% 3
M[RRKV[B*L4V_4&_C@U(>8Q\\LTFD+*I"(:.(%KUZZ^,3H0:]_-#W\BK>B112
MT8:G?=%68.:Z.,K7/%F^V*2'1:Z>L7)FL_9,RWD9L(S1Z7R,]PKD4@B<V'X/
M1]!&M+XURWE1#%PG>N:\_%6<W-8G5!,G?M@.'?H3O_[#A^I8U4Z+0., 25?6
M%TY2T;Z/<K97=A?R6-PFMEG.VI<[S,:?'N10]]EFS!>CO[2V&#%^RC@(T5G%
M3/KNW(5>(IC02JG<RKC^=]&!0I+_P67F<B]!CS\6_R,7G%]#VN]EMFI[M^1L
M:J&GGPG*)USWN/D@"R(OZ]8TUII]/*>6I]RRI2,@)&]-W",A-07LR$)=1]1G
MEDLA/B?FO?5HIJ7*(O=X%_4:D]PDIVK\T%2B0$[$S>HR&I?4^AO[MSRF$FGF
MP[O.'Z+0L)8(VV]95+KU2.*;2)(OBM\A6:!^<>G-2.\R@CKF7P+'7C)-T4/V
M[3>0O0)'50OH)M>YB=$XO<ZB*1.GO(1$!VS 1# Y/]WG>&7UY/?2TL^:3S']
MK?#)R-2V"0\\C6BL%BV$V]+E,R 0_*F'<N_:N 2W#'6B0? %0YNCQ$2!ZQTT
MC B^ZOL1H:C$1UB-VRQR@)RC*#J2<F@R93Y7JJ0D3XQU $U+DC](ML!9@PME
M?UC=50,#QCXW_Z@5SYP@E0U>7FT0?0:$W+W!9LGU;5LQ>OC-\U3AR]G8H>7<
M(&3'-LC2@L?7D[UP]NM+@6&,K*@.-\RRH58XMK'"\;6HN]SN6<551HPR]<IQ
M-\E.BS=<_,*1*H#U++\UQ<R+Y8'T *'5GS_J)SLT05Z14M2N@IWG_5'G(KX6
MY9*AW6.C_X&LI9B(ATB^]34-04X5Y^2W>'4/WY.K?=H7YR9]:OG^@K-< 4?S
M,[+&5[%B=*0<JD-WE']FX\Q]5K#*+$)IRA@&-,SP8E2-;=?3S)@NC);A<CW"
MH%P(3<&I5R$R9%ZN,+$UY$#)[C>-"E^\AF?)C,'GO/B&!AUGNWXA!.'6XK92
M>].#L['')E;@(+]*MW:W^K@8L.RHVBOH>'#GW^^7/&P<A[S-(H,"6S/1"S=>
MOGY ,I]<>[R3Z$VE5B;?TY.W'T2&G@%'.MMD(;K+/Y="5VS7D(G@O -(V\?/
MND7Q3D[O041<'PG>RE'$6@JKPYMV\F8>_;2S. E4RLU O\3*FB5_GP:KTL=X
MT#-1NX!-O)]Z.PECHY\(*M/!/"G/@-X;C.[(Q]U0E%^.0\G/ ']@U^NSEJZ^
M/#0)WW^[? _L\.N29!=5[:\PD>,E#=2<'L9:QCL3E-OZ/KN4,NMZIN *H6/L
M%V;;XH4DW&LAF,_73NWN-I_HCJ7(C T"&EBAHCS'R\\ \3G[O&6O^)(QETZB
MO'.!:-Y]LSV=L,P;-+HC_2>J;!]%E_=R%;X'#X=N9PG #">[C(C7:B+?;N>2
M?<R1V1ZG<WVTY"VACXPJV>-*K5_][J+3Z*^_)=A^W*N8$D(52-^8(-+UK))O
MG*E?@&].6?RNS0IM8JRA3<[EZ5'CDS3;6QXDEU!1G6K;NDX_ZT7R;20ONT][
M"2WF19*G^:Y7/%7'(O&AHI?>A+LF8E!GZ$^?]'L'SZB1K7?XUK_7N&!E*\*8
MK0U_!O\HVZB(3\FKF@W:L:@%.I[&\!FD *. "9SQ-3]VR<4Z8)WV[$M95\<R
M\WN@DM;KE9R$Y7M-F:>-[WXA-:N:C.B8NR6.3"\=7KS'G+D64-$G):\8WFDG
M<"(AZG+K5_!9M<C%^># R3W/AFHS+@K32ZI/8_S.X54>_3:\8S+E3RGG"\"V
MEK(?^9GV=EB"PB$'41LM)ZOZI4"4@YYHZ$0WR56[J9\=BIYCP!C#BGWI=>"V
M -XP^'R=#A)A4_W>2;6X_,('9:>T?3R_:?WB4W'<XP_F]DS<B)Z69A$['-^=
M4Y^-.CU-(S-&@3&.5,%HP: 4=Z[%NA.FO00\KMDY@62);DN!WWM@)3Y+BO?^
M+P#%[YA[Z#)J*ZX B>AF@R5%RT9>U5E!WII!=X3\YK;@;9AS2]M2<J@/[=7T
MH0?YQQ<7?PT="I=BZ5&N*B&)_^IZN;RG02@)W88J@G!C9*#I_0&D%6J^ENN8
MG/#IG$AJP:GHXJH*3A &]W.(ICF,@I6%.$CYGT(+_(AM4Q-T%1M?-2M\<V;@
MS;2W$$&CZ^D$MQ%6]I^]7M\-+67$H!R(QEUW.#D-?!BS4C[Y9BQH$W4Z>Y-.
MN;T]9V/#LD.ZXX??^C:\R=\[ZJ;J2W6<'5I\;'%%^J@U+1LF_QJ/_$; '>79
M1.@:U:^FLY"2C6AWM51V+PZ]E1H4<Z-!K-4@=XEG0 ;IA&5IHX8]VAY,;URZ
M?$SZ-!]RIHR;K1)K9_]FNWEBPR0=6G_3%^['ZF,++XPQ$5*<8K;G'6+_'1=*
M)'SL(>P@]Y7S4FQS,%QJ PL)W+3_9IB?HN]:086/Y1O$3G?*P'GNH?BE+R#<
M1GA$B'7M@I4_OD*@8FQ,DA:EWS7#!UU+1R4KT/81E%\=12O!J66[4/2-O(M\
MM]'^S8!(*1EAH(%./)F ]4#_B/Q9Q&+MP)]^JR69&$Z=Q;<H@?#08OV!X'+O
MF \4-'SZ*63RM7LB9HA^]<!7A2K8QYQF*H;VII)F^OU$U_RYX=KOY02X40"F
M:56)$1#J)K1U"/QHM/_DDT3=>V% Q%B+__$@5;!]W5?"5MKD='>Y465-:R5P
M=HO:PV8-=[B"]*5 )_B"&F6BP,)(/YT:UQ?$9Y"'JIZ<+_P2.2?BEZLJE5W@
M)@3O(9/X4/FI[Z9GE:;4+S\&%K5G)L_BM1=92, Y&-"-, :7[/Y5_VQRY?SX
M%W+4IE",=E$POK)<X7+GEIJ=KALWK@2,%AH]B=5A9S;-O,YFX1LJCVRU>9-L
M$3WJ(NO3[SSS2I9@!@AD;F+S]2UC.%].C**#0B;2_LC>T96MU0'["I##IW(?
MX)6Z2IZG/\36Y5G'8[=]'CT=D:\*IAKW[RK&@M)'B9+0;@Q/H6^!8W2G7YX!
MI,-X<S'BC$Q1?Y[VM ,4-A1&79S_AG5RW(4.$CZ&#A!^P2#;)&7*VJ;^-R-7
M>97M[' PP8'MA'_XYM=%QBPF0W,TCN^?DNO*%,9DTB]#=GLOM>SPCVY5?T'U
M6\$W!%-U]==+Q8H$%*J';/N8P]D-[GD[/C*3&Y9O&*='LW]</ 1[Z426!B^B
M;+5[F#2**8/./GWT>M]P;A/ZVVPE>?SO+F<_?[3ABXZKC.3T<M,,B2(%^"?H
MZZE&QIG 2_K-MCJEV<]V(D=&>!UE,+_3[IO*IO']%)@8157 %RM6@5@OGQ-!
M%FG6"O-G@&V-L&:VIOQ=##$3]15F@"9+1(229B(RT>\Z@TI0VL,^C:6MD.+S
MU_?;F2F5%X.:DL5GTM^[>.RN2?> ZFG4 \)?02,5?R4(//#,*ZT57#[K83)=
M9"M.I&QNTW0+7_4#^:1DA>GT,PWQ2HMNG0U+:$,E8'1$MQEFOQ<N1LS03M'-
MEFUJ5Y9+7P905M^.BWIKMT9N_,9;MQ+'9\^VETLV>YE.%8#0K_BRXK G7>3S
M,;*W@[ZF/@[%[!76>O3@I-"&\5[1H1-Y8%X(D"I TY@]W].=[:$ULLG,BX"J
M)C/BQ!7*VS-,&,) L90%6U \./2<1;""JSMF2<T8W55S*\TT9E%18GC4C6T!
M^*.#!6#1@?SY+C%5>'V9VLZ.C*^F&BYB@G3(MK$[N9D>_\KR&:#&D]A>O5*6
M. ,#;-0E7HH#T5;&MHA2"MS)"6?V1"J5M)N&A04*2M8(NX0K3>_VWYL-7PF$
MM[CSN"F,8ZUO=I0^9MJO9V_0QIU_HHXR=DR/(WZJ*=O&,[[R>+]]]PHR]P>*
M*LF+%.I>P^4?X].#3_U^(DL:?BG-:;_"2/B[A ;/=6-18V:OCV4C]U*<:8EE
M2"\W5F2!F-3$#UUL+)'IMM;\9A4ZT-!!@V0T1M9LO*0C0:HJ^YI\Z%B[!DT>
MO4HU2S(E_=T@Q$[!"#.,W8!&6#8EH$WI%41'\(;GK<=@W<\>&M&:&8U;J[Y_
M!J2</P/6>I_XL7?^Z;RI[++$AZ/&V'636$M 4:C%5^_'7^^>."*S SI$:V$I
MFUL?/'/#*>7 SH2+.42JJQ/2,I,Q0BHS#JZ1^XYO][Q!Q;KB+@-.6C%7UYC=
MJE%Q#PHUWIQ]KT --2?I)#X)W,[MOA*#%3XEZU48MGYB<]^F^8<:Y??>L=_'
ML[J;'3P<(>A"H?CUG:&B' NZ<BU6@&7#IML=1^@',9QT/,K%1)H@;R#CO32(
M" E=]XCZN\ZDC)\LV-,NS1GP<%0VZT(:XQRQXR>Y?XZ,_==]S#7_MNZ ^)A5
M&(T%/"A1EE7:+L*\\#--058XPB7EM]*%%#=+P\R[7W(&YZG$V8:-DK-2#V_X
M/$WD4]5:.NC)1N3+TFGKJOCM/T[-^@V"'5/5].5XB8H>L_Z5LA5;!,0'S@+U
MX582Q5\HIF3I[TG%Y_I[HK3<9QZS"NU*)Y*UZK\L_:5HGU:)>XC+3C)/./>3
MZ,39RKC[5#P0WV=Q8?*V[, P-=P'7&)H&VT=+T/5RE'VZ[QL@ 0:[4W74Q5:
M9_N"G>6M8?P%3T6I9C*;X5%9]K=<3%R.^M8?SP"\#EJJ1_GE>C%]-0P4)K:J
MR@?T#<]+*L]T4YQU?&?#N0!Q*HQXAS3I3%QJ8-%\E^DB]M\;&2O%S [V;,SH
M@1%BL;&5]#M$[V-1%'&,"H\A=RY*LR5K%@3H7&&XLXN"L3&9L?.=0O>$G+60
M4W3\7/2]\X[\.NPG(\=Q(&:!A8VH[^_AT&W+=LJ++T3FM,GZ$NRFXJ9URGDK
MP2 2+KL(ABB M_><ZNDY@@MVF_NU(.O])P_R\C]VN0-^;=?]("0OD[++>BWW
M%DZRWU:6#*%[? CSA49RK!6LY5L7_=DTJ=#B<**-H2^(; K1\0%EHN+U:V+E
M]SSN""-2CD6XI ;_NS(Q,04ODV\J<,,5VHT/7>4K+%[Z JN"<2)CQAD:O6A[
MIY498)?P7E$'WN9!D& N2N5+PSI+(EJ"7($#_7KOL'%\4&);S3O6<6E9B3+L
MLJP3_/R2^SE)2>1%43YE-&Q:T)*IA *QV ;'D_5,$DD,&Z)''>KWMD+(;,Q7
M3"VI?_R47^ >DU:5Q?PS15;DUGFJV5"4KG6G*:V-FGA6?[#TH(,GY>E&N<9&
M.L2[:8<]8,3<?*Z^FSPLKU"]Z_ZWO-1/G[P-(_?%WCY*N\;/;WF6&?DKLI.E
M]P),-)#$6HW(Y,I/OY"66K,P$<)\749F;&T*LQ3 OXMVGS=+T3G)?'9I\@$:
MXS1;JE.@$67XZ]?)E#T79+[#(BZ*PIQQLED*GCJ>F+TZ)!D#'6@9 VY@1KG*
MA*U95V%F*!9:A6W'J,H6+3[0GOT\P:6D&I(HC((*5N4WWU(,>5U )[R@?[>@
MT8Q#YP":A;-IYW'.-A/_+"G&)YEAJ5,6NB>.:A_M=3QHU^;,48:WKF^11W++
M9_LEY^P6U>*\#X(=I#XZ,Y(4M@/R-X8'B=7WRKGBA(\[E]_N;JIJ^:&O%CSS
M/M;/UA^TW5,U]<6+:&!CSM"&=)@CWYSRJI*+0^"M+^7R&%%)<-\[A%T_[5U4
ME3(%<R%2A/^810.T/Y/C8'[ +/BTG"^=GSGLXCMX514(M<-3A0XB%'E5N,HK
M- ^2N)X!=<!52I&^&Z4LEZ+;N:[L!EB9[@.T.3EDIG6ZHD #&HD2]PS8%ZB@
M8<(SO'@4W4_ X$/"MX'DU%87E6)?TA)"A2ON#2;:( '&$1!;\S^M]LX[(>#,
M;/W@2IKE%&'] NZ<ZMRWW;)\@;H7H/UC=_.(4*9H1C+77S=6.-(/MGWZ(;-[
ML0--L-G(3->[V30W.VJ>H<M*+VWY_6B6\>+5E(E1]I#]]7L=\EE3[8E/\@)?
M%;8)]>ZU;$OFX0FW&)ZEQ,;/ /<2)4@Y3[PV4YOVO@SM+!4;V4ZGR+=_2ENI
M=BQNOG0.^%O-K J<,=(T$T<DM%GKQNU0LCSMG?E"Z,7L3S<?)>I,G2\M#>NJ
M#,4CQ>$N+E#1'DW.A(&"_E/477$=G]2<2P?81X,N$58!F:ISWS))4_TZ@;9U
M0\LB)CDJG]L)V\'&5F"<3V^V?IV;Y)^; 8G2S;MT94Z*Q<QU#!%Q('.)H9/\
MD8%^]#!ZM1#.CIM2]TZR./&!.A<FB;?<\0BU!R4T;#2<.MB!86 'DXZ]RB5Z
ME02;NE8VLDO+!7#W=6XD&^7I+=*@2U#_SC-66YEG+TLHC%]#\@K'Q4];& 'O
M&#UM[.DD\USJU;<*XS>B5!JCTVQ0:A5+Y)#;[=OBN-<-H< 4IJ<%0>Q=,DFG
M-:VXF>)<$Z0OP4I[(\\ B1TZ!:H'4%X]TF(S\B+2EWE;9/!NYAE .1N[KAIK
M :@*-:>_N?]L\J - F=NHO=U;2MS^WX)>@;H6U[C4_.L9)Y,B%0^^J'X?&#-
MQA^20NS2/7$W8SV(%8]50LWD;,]M_9P#CP^^+W4/"&^=Y1#\>GKAXYIHE+#6
M2_D0?$4DJ+>RQ?(5<QEZ[8^9]6_-:]#U2,[5MX>C$*38J?'T1G] 6^N"6Y4A
M/=$XY@C6TR94<[752!X1KYI'L*=W1^9EA?@!L>NTZB0T8QRS-A6^B0==A"J%
M9=+I/[(\5O//S4I939"@:>R2Q$!S]$@237ZTJ"CBRW!22>^[IO"LOX.W2$BH
M@#!5Q:HY<ZN'2'^Y4Z<WFV(-B%1$"MC/)EIU58Q(_BH12P3KCRD,4FPV</TA
M1KNZ+!]A6>254_VD#T<I=$(RO$$H.[#+3]<U7C2TNAYWP$IP;?.<A"6SDM%T
M/Z/YRLC7.0]PNAZ;KXQ8[\C*C6D.=%W]U3)+2@0RVL4DVRR'B%H.#1UR! 7\
M5)$C=<O''MXL-52,GKS<+?Z1?MY%O,NZ*V$;/?DJ1#+ONXSUJ%9)W!YM2#,"
MI*&;Y]/HJ)\RA98>NDDU&TG_"HLZ6__<D>@PQ,M<[0'_>\N[U\A TVI<OHAS
M54+0BQ4#W"]3[E6<A&)VD)DW]J/MIAXSCO^$$9'3AZNRAI1"?NHM4L7?2U_1
M8XR>S/3/?*>P^KUNK$R5DUD^E,7LM9O:8ID-L[(T<&?C>JU3ZVA?>$7'P(0$
M(R3^/F'?N%P_ ^@*(IFXQI.%A?>=U.:6LTE1E%7EH&I'=Q'(NB?LLWP%Y[-6
MS394'OT#7KH;#]&JHT?.X[^11'NZ?[8PXV+Z?.5)#S20ZENFT+ Q*-Y("_,=
M\)O]#11G\X&;("E;$<$%;CRMT!L5=4XN#\L>GOW%M.4.O*A(QY#Y9EO\9_/S
M_9 '#N V] F':L,]M5>2Y(S?MDO/6"!I"C\LH5(62M)UP] A.>7V5OBV9HTV
M^0YZ5K2!Z!PP":)]<]I;+3M3/MR86N^!\ZEG<%Z^5/X$A>;H7''Q;D^Q-6/\
MF@_OL:T"O>_M>[-X%;A)5Z"NJAP8 BFC;2^R#9YCI0MVA8N&(),P '.)!XM_
M5R[[71?]&OH_T/V&:7QT]I! ,T0WZ4S<9Y><'&]>Z=[#A($);9L'^("I&GV^
MMC_3.+G(;=69?BQ@"F_/,99:_UE>ML "N"@[KARV:K>8D?:;')VD:GP(M!5"
M'Y[8T55D.X[Z,5\D^=UO4C43UZMPV?HXI]AYXB-8)_H2A+'2'PM67[9U_NW/
M%X>IN+<3JYFWJ"A&49$_.OAVC;7X2%\?(Q9-B,6DDP&<>A!A"E*7%=R+U=1M
M@7?B-9@'#*>2,XI3%I!SYXL,GT#@Z<ZXH[4A>F_4XPB^S"ZU2RO25$2<96,^
M?.1INZX-_DS7%KL&;PE_4"M/!^(2T,<D_R%K5K%9.;8_U ^$0F,5=]RXY(/M
MWH_;%N96W?HGS(X=4I9VJ*AP9C@<.ZNZ*Y>8M)Z/&8Y=YRQT,])>IK;DXGSX
MAISC*[;-E1N5K@0V3Q/>15]?),@9)X\<+L8F4>$"Q.V-KU2!9UC#\F'N$])Z
M/(/,O7^3(XG')=A)Z+F<^G\$SM$F+20HH,BK#?/Y% >VT@(>#K?H-?>5O4./
M54_=H=%2]5*AKA>$OIP*<;:+D0%Q\9^[BJ7^2LYVWY1&M"K@J S776VM$WS_
MA92ZE_#DZQW/4K*AI&;8 $^9O//I1-Y+@(U?X8%9,Y\!?K+<?D4LK=F1HL4U
MIY/548B$VSY=&G=\@\NN!]"/4]^4F2\QGE7?K&-)6^O^N*:=AE^645[_9*G(
M.213Y\UO%#S_6/Z(8L'(>I$_G;?XO3Z8A2\!"3X]4D:"<YF3$S";G"@WMV,S
M@%<313F5]5-_Y'%_J@O)]B[^).&Q77QI,"[4+ZZ,&WF(Q2&WHVE2N&U;D/M%
MPR#24N*F^,E5?Y_@=S:-P3)2R&!&7(+MQ5^5#'EFR_LF64;&-0#EQ4\#("P%
M#O0PX1)AS17XVWFJ8?]B:R.[SUN5J)>6OXJHO[[)&+W/%K5JIG)*,J0#_>Q=
M3%&[3F-84M35X'E5QC51U+*=;[*(;('P+,1P7YPU3WJ+(,QY/9;=?"5F&]7$
M 4DL&S( 1Y>?RWH\6J\*SGJCC-G? .2E?F,?I6HWMV:,.J-QN+JJUI5+K>.V
M-<+)UP"9T@C5G'.U#HC6NL/9KSBGP/"<8&FNX-X+YA#NJMC_2TCHG0 !\A<4
MQ+#UK^Z2M1W7C;Z&UW&-?Y X4C(6;HI/2L&+R;PNM[8Z'R;=4^XPVV?C["9C
M-;K22^7?:^TU$]?T@T<Y=^4O-;=]A0<1L6!)7@DF^C10!CG6"QZ74%P5%\:9
MK\.U+RNH[49^KM3,\;-3N8#O4VN.L,OT]=!X#;'B:QJ]NLWVT=UT; NT)\UB
M^.!M!MVBKL9OX&:S)R/C7]7B\SH^VXEMMKLOJ1GXX:1,:'YFVCFS]O+\35A@
M/>TABF4:5RPVX%NZ;*FR[2<0;5\VT$LE7X:IM5R@9O$(ZOBIF]>?3!EM9XY<
MTZ"EFV+I-)!MY<$-TUIOGD!=K*YS7;032EA"860#VU&)\?)]]\X"0<ZW5Q+Q
MCA7/:+'$=VNOQ"RJ&W0O#\C+H".8CJFG D%%HTO[D!F&)#-L+E5*Y-C&D2/%
MOD-EO[;+!C"P"=B?4=&ZI,I/Q%@>UD>(G%OV$VD-L$\SC*W[0C 6DWQN$@&;
M;Y.N-.Q).>TE&M(<9:5JM1(84\D#U]SYJ>J 7@XSYV[7&I%78G%#+@5NY!Z(
MG@$]YR!:D3/5<.-WE_:BPV^G5%;M*IIB[W<(=CG7U\@^7=,H)!!1[YU4B4@F
MW]/=X_LPI:[O'5_]6K(E#'.+!OX?=+UG5%-1NS4:!41 0) F7:E2I7>B(B @
MO7>E0P2DMT!$E!(Z""A= >E$>N^]&7H@=$*O"35 "-?W?O?<<>X9]_R8O_;8
M:ZPUGKG7,^?>:\SM6U[DQL![?*=6^[KH8;"7M=J7/+BN1N6QO/9W>452_Z ]
M!47S]KV1W38^RYO"'F1PKLRQC="+,UO\W3JP( 6'=<'')!?BGFR^MBF5MWI#
MKTWQ:^CV7#C**F-UWK52F*5T&]Z;.&D61^31IH"U!F&(>QAI9_+878&:)X\/
M.C8=;!H(SW7KLS>;3>X1:>J)\H/\#][',>C:0B5(B_+NO-@FDMSP_%U8M/'8
M#-#_!\)C9*_ ^3;$ C%@C=99)F]M*UP5IGX:LC.A06)W,>#-=D4;#"H2J6V,
M\\"1)Y]6\)]G8&UY>N%AC#,I=FT.Q30V5QV0$"?\NQ^W "=[R(JA![CJ[5O<
MW*1[_T!G:>"R+FGSP(("4<#?C)( Y=?0H8Z$@05:A?LX<N^9IJ1J=H(CX\#L
M+\?5KZYU0%%(51[W%XT[IEZ[[]C2-F@S2D%,=FD,NIDVE9Q359?D.2ZHS+_(
MC[(U4Y5_=VOOY:HQ2$OT<1<TQ/F7DA0G:#$5JJ.^_1WHG=V/*VCXI!7LX@0C
M>2P@8@$VRQF^B&@%7H/>]7E!,^*_[65C[F[)SX";$OJ7*GPU_1M0T J?%X$)
MV@6,Z2H"TRW3)(11'XEK[19<,IJ M&:@*1\.=B/O-)&X5N>%W:B?W+G:3+<
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MF[ZGY)!^ 9T;E*F@DC>L)][J5-A56FN8RMIH^U$:VTR9N?^UDV,CF>VKZN:
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M.,F'P@FG^BA^ZJ?_K@A^=,V-NU=[DZ%(-K=]H2)29D%9OT?/_OG!AHI*4 F
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M>=K?S3%LHA=B5/$7@Q7',]>=>-*OOZKQ(Q-C#QC*4*^E3[N@$5H;)3L?XD>
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M.FNR;JP3WOG):N6U+8V";=D7(>DY-GS%/*%6?A@E5,A7=(YN9=6T^*+9N<9
MNM.\9LU)R@OI)W&K819L^UNEV&PV!O]DE=9XZXRN+L[&23>P,IT0QX=/F-3M
M0,QIQ0DJOE=#^ N>,DT_G:MI:FN$,;CXL>B(*K-/QRY$Z*SK3\@PPY\)JXGS
M*BU$TV1>;5/VMTH\@D! +ZVJ]G =!E+P;FJ]\FL2D2>_UO+77R..$01+%.X@
MIQB_[8XHSCEPO"9MCK)M2>RO][!JN<\2,=/"L^+>'704@:>= ;NO^8"6'[LD
M# 9[6A_U,N@-TU>B$F0_RAE_V6F3QK1'M\A(1>]+4-(O8BMA\O-.']@7"P1>
M-GX)1<05HB]@KTPMF0V=RS@;WS-QS[>N']6G9N"NL@W$P"K47U@EF:=Y CA3
MTJ%UNT=+T\[+6A&+S3=?A7"GL&2<?C&VOY^-K::=PM0?>MW]?->*+3RH88WS
MNQ3_8\DGTA3:CP_T%DS],_J7&>*[E5 *&F_&<7+Y_9SUDF74F_@7163)<,X&
MG@K Q:@7Q*XF.<N@=<DOS]=:\&Q26[]RR\_U573(+>#I-/]P"$Q38NJJTEQ\
M]W+K'(1)BR2.E7=?L70T2NMYZ"0*F_-YAK;C;R@V<KNY<RY7NFTH0[MI@Y[H
M,O3./ZINVDUOPE%:$T3'R7XNIYDI%[\21T*@=%#>"K&6_VXZ_R?X,S%;\37Q
MX7CF1H3$<)C[>Q*R8Z&M1/BBLM7ZE;&J%?VUI;4SP6IK74:1DI=B'J1(F2ZU
M;H2F?&S0R,8?><]K+Z>O^:.!$<<CK6\PA[.Z\]V R_"G)A9<ZF.U:QG&R!O@
MHY_8@&LEK-\::YNW=+F$(+VQ4PNV7 +DSE48?SWPDCW&:*L7&,VHW27(B#"8
M*8<Y5#<TT'7NKU%_L"%AJNH&K""^^$L"'V[GU ##(WI6R9=:O7XSB#N?=A&U
MO/=SIQ:Z(SBX52BQ#ZR)_Z(:$T*&31_E6/8B:I]G/Z.DHNR?N@MD/ .M/J^I
MK'E_"Q#: LTMNB!]?><"R@_]&\!NHG5W6Y5Q)EYFN_#7Z9NQBQG'0::I(5Q@
M-_1RURBQQG3MUZ;T93W7NAW'ATDJEU))+]]W,!PMZ&&W4, (''&!?\C5.7]S
M#<(NCI]W/\_83^B.WLOWG_R$86:7GM/SYY\;T&W1CP-6QL L$CUY\F1U1#00
M5.4T_*ML-]@$8]R9Q><@>@OHDG#V\/!GRA07TA.X!2R+I)^V5Q;I?4XQ.J)P
M!&JH]4^<X[0%'6>AT\S.7,.*AL1N]="LZ_D,M.(D Y_B6S8E=</  V9$'^,M
M(*Y%&4/<ERWE.P4V?N1,3^Z8;^;O)KS0M:O%"K%(V3D$:?3ET.*<@U>/PJU8
MIZV-QF&U3O;))K(?I-N_*3]Y45F\;2*$PI]]A+R?;N'X6W%Q?!'0%BC<<MH^
MPRA?G<91-;=3NJESZ7($TP3'%^*"UV;!1"NCUCVBR-KU0)]F"W&J/T8?Y>[Z
MT\ C0L2CUXC#Q'.HE%QF=%T>1AF1,(BQPU^I3K191QMAY(&4BOS;",S>B?][
M[]\-$X=@);KY+S)W\@2786SJ>>BP'MGZ?VM982,4@OFLMI*I3N@=.J$2NH6*
MUI->44V+? (N>BW'+FG21F0VIJP=;L"ZAX.;EX8'-O&+:3,[W8E(ER%9ZXR<
MM) 9S>62$\6)12WBIVVB&*/V<J=E&HEJ#)L9QCKB@QE6*!Z2]X<1[$$LIQ3#
M_/FGUW(%:#_#6<]?[\VLO!L!/\47UC.4[7/1SCYJSTT]\_*F#U=',-NECDV1
M?O5\@P +EK*+W5KSTGFM[50H+^SY6=?_XG3^"Q2J:\!>0>)5*ZB$8.#&K]CE
MH?#[^N#)]@M=5?TK0[9P-KI]/&]_D41%?*G3D=T JX+9[*N_S")&%B(#EYK^
M$0=DK-6E^/$VP*3X<A59,F&L#1*:5A_G_OW'8]4E/IJ'<@G\55AZ#%NO\2V
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M\@]ZZKWGO>_]_M_W;9CGR=Y[ULPJ,VO]ULPDF G,-X!*4U5#%<#!!0 <[!^
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M=<BA*& 1 \!-3#B^OSF[X)>[@P-1O U>L[M00@K=!#.0Z8TU!\H@.>- ##6
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MQ9YXR=]B6F\:J#Y$?WD@&:#B3+WCV-M@ZY-G?C.&/LF=#EUY5)-;=2HLR$S
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M<M>'NAS9![9'$C3 A9E$%;4T.LP;88R2)W(^+7W2I8F&W/!MT7%-9#B,/%<
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MR!U>[6I3$S7V37AG1_-H,T0M#W(<UD0QC;JGW83(?R''O^AL M^UM7L\Z,G
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M)3_:KN7BA*8O&69"9#N2F\01R\GE-C!6!KT=8LXV_CXB\"URMW$H:$M"(*=
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MS>W+'I*K\3C X!G_2M4@P/&O3M/]_8;E(E=O \<)$WE;@<Z8C?-B0_-_6'2
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MIEG0X;_4&(!&;A%&PZ^XO?(G*?0#KC?+% _H<+2(-X\O&M,2  ?LR_AO>*.
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MM0_2744ND.W4MDU_&;R8WW1<&\'<_U5%HCG"3C <X9^*W;QL2HJHS0YKD=%
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MK+W[Q.EJZ^-CLOA.R:ZJFM#=ZA*H]T00!EHK&N[DN3C^K6JRO)SU\'&J3O[
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MN1L<>JUY&??CY4$%T6S![,5?G%'.:RS\MP#;B^(CPL0+;.T_O72<PW>.C4N
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M$[AUOH?_J_X?#J0))1L73P8+."*:.KRIO'N[J)+$U2HEIO& XPF'ZXL2:'!
M I6+BR]_BB0]#VQN"V, *G.,KW:,01M68F]B'LWZ/&-3,BLXWP=_T#L;DM_
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M*HG)_76[%UV^@'04+:'RZVF.$%O,R!"/%UVY8WMGT#[$\@4]O[_SWT9.NKA
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M]_>;G7U2(;%#;?&9QN<\LD;]61?$H:J4?7I;E8;ZLSLO':M_R&]D6N;SA>)
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M2E3,:\0;/.!,R%N7K3DQUPXULF>_I#-,0S?WJ%4[6'4RW^R(M6[,[6;0M';
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M347. ),T6R2D4X9J+'RGE=1Y<]##2D0\F7SP;"2)\)B":$A7NZ]L?.-9"'F
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M"-*^S1$+1DUW^JAOAE;X0UL5*XN*!+YEY[1L#&_[%P1&F6X0U6^HK%[9NSN
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MP[7 ZEJ":#??^YX%+;;J^SCTKLP*'D!UCS5!VXB//]M@[A_;\!V+R^,!^R+
MFV#J+'PMX6JC>:1U1Y9&>(!3MUP4\*<1Y3T]'WR'WTC:J/"3ISS/$?ON-,:>
M^M:B)P'7-&/VWL.A6&QC_C&Z/U"Y=M-Z2+*8M[JZL3H9UC3T:8N^:T?E+2YN
M3E='9QAL'*_1T'"^7D2\E?E[M2W?LG7P=%G,6TUL .T1,I8@(U,P>J^)D+K
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M);,]@W%%F^+"Q*]Z*5!!BF0:.?V,^/C:?()8UQ X:=".L#8MM@SR-/O+"SQ
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M4PGV#G%,7GYZ1@JOG5T3'+UU!W\[+W"'OZN/W+HSX ;LVT^=/L>U.T<66,J
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M0^+3E<"M)DAQ\WALIJ<]W^5+E?"'+7?HT?!K[@.'G$)%'D#UV&H&01EE#I=
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M7'! F[X?.>$1;QL.V!.WAQWJ#B^;6P3*3&/I35_@ "6=:!CB934.@!=0-S5
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MW[+N=!0TM=MGU)SR#YTV%V8)<'3=#[4-BGQ9#.T4QP%39I@3NL2(BYIJ_+;
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M<<,AR([9V1X9FVSJ7#@T1C) $BVS)&.=#9VQ@,8$Z*_KH04/]$\,(<L#"(+
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M *_7]LV:T1T15B]-X_X-D;/&<[DMYQT9F.]3/)'DDMDO>=L?P6F9YP-L@\?
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MIW .&^=N[9\O5+108E4BGO$\_.B+8P(UT2++^EBIN_.8IF&_'WBVR-*PXOV
M6Y'^EI=9*[&1\8T(U0WKL3S!!=\,P?NC>VY2 EURS_?.ITH5]>2YO[P6?B3E
M+'G9VPI0(]L/ZA :>V,'*3/H")>1?;W\Q&QLI9)QT%3M\/*KMXX?33BX3*S@
M<E$=W^0Y$F<VV;7RT:)1;:SU>HJ, YI=E,4:,FH4I+K>+7R=I"/U^^W3+&BG
M+"_C#U-G^\NEV1^.ZH7N"JDTBS\QP82#6I2V+3^?6-)X\M#U#C14#@^OF@41
M]^>:^LQDVX\$HV[E)264>K]\E]TX/ 'L,1@V!;",0M[7@\2'+AI#+98'[*K>
MF<RKGS&X555,<F'JYAK'9S["R_MSSVN+(V649\\X%"\EV%9)/;K918<I6(QV
M 9,29I#'IW4CH!U"2FTP"G<8VW):1E3A^!=C56^A'%JU,J-'Q!LOXS5M'AB8
M9V!<C3C *! XL-X=3DWCI:-K+.A_4^A3[D<*!>+V]<\KI/(8UM(<U!GWV7PY
M+@=&C\J4VKSH\]F#;#H#!HV]%%)/TV:"2> RS8NQD3X+@5(QSG.,N4YP+8)>
M[;[<ND%WOMGGDZ]2+=[SS+*6@"]+=O4"2'VO$'A[1:Z?RJ#8"3^YK>7!:V<3
MED'Q$PRDWUA 'AFWGB/O[(5D*><L^6@]"N+UI;!]>9L<!YS*TE?-TX )18MV
MT[^_&L=]^V(9WSG74=(*0#LPMGS%@J='^OK2_VE<A?P<5\67DQ>@_ZQ(.I']
MMFG4QWJR-J9;3(2U0*)+0-7H(&USSP65]W:YUK\([\>9Y;IMEX4:TI<OU"H:
M/C)5E?9Q'6G,=DFX)-H1$%QO"5^,E>-!Z72PZB)*@LV15\+31G1DYX?UA\I;
M8[(6+@L&#;(_].<C=)C9#Y*Y,[.Z;JK#Z)6*/16QX5=*.9WP;EU7;J%MQJ)!
MI1XVTQN!=H='5$3%L=CNL1)XAZSYN%>L3&J>LGS1\Z:&M(IA>6W\1F*?+G +
ME!8S+V,Y4A/WV%0ZI*F6:?Q<F/I"FG+P";CB5P\)XG<2>D-I")%0/)-W_7V;
MD%]Z"[L+3"91C7,Z-77Q:N/.]9GG3Y\DD"!R:P/\-6',/22^^IN]&@A?2;1>
MT?@JQ^F!XF)A"\1^A+EF1$ZB8RJK+R%7<]%$OGGV$Z]5([F3R--C-U)6X3$>
M$EF#%&\R1</O.0I4Y<LK;D!:^0C'Z.=]A]E=L0HEV"V\,!2+KZXLL5!]X^(,
M>1[Y>7330E/U<6+]>QQ AD5D4=[]GZ& T#]0P+DQ?I_K2J?UY_L(;(B0:;=@
M([Q'G]!+[7:6)AHAF%RL&^@0YEK2->L<RGLK#.0NE)(BS'C*8T.06:+;^V;0
MD;)74'%Y[[H6^8#Q'6-5UHJ<E'V"B^#][/C,H#4?PWQ[J?-8+I22<+)#V?J5
M6IVO<U-?V-)D3F:VX\',(PB1&Y3$BU!CH$*69V1./[)+2/CS>_&/$J029A>>
M"WLW9:F^0%]%31>@"C]LW3;^2LDN+.+DM"%<),Z\X!8ZO=#>\H0*Z&UPAY[8
M)1,3B8#0^$G2/_)RUG:X_1;=<<"9HBP-5_2A8BA=^;II&@II=CZAF3MEMSR[
M+C<VMDYPK;+OO'(@9^P-P@_ 2,!+A'2S45ZXL)MF.HOIQP6D.-G'B<Z$3U(
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MGZM3QUW][;',^A(5M?TX4C4TO8TR;_R3RS>[=]=X,R:$_;9@+MH^P!?G-Y%
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M+1;8>AYK'UL+A>,=V2;O\5%C5&X.??GQ7A,H]-?35!^PN5!RC!>R'XP(=3C
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MVC<?9NN.TKMU]*IHE#UE=)^==!*9$"EWB>\=J+!$E>9VS4F@+SLYGUJP?9W
M,G5>E3]J\\U^YZ%%(:RYHP(5D^^5=VV$HTW<*D)<DR=0C?<B3^?7T\_;%1%>
MDF^[K\P4M<5%B:U[F-&J>[K8" V*O+A/(>-ZTO'>Y+ O[0$Y,(YR1>KWPLWK
M4K4'=MD<^-A?,7GJ$<6JWA3X6+^EP# ^RH]8;7)!R_:Q:8:M3:J,7IK8M!IS
MY6+D*MAP*/S/Z[#5F9&55_8YV!IJ*D;OEU^MJ$Q1OFQ.FG '5M?5_H"9BM1D
M9M3)1*=5![0R)58]:-K2.KBD=ULRJ86RMK,,@DCMFJ?6 & S+]_:FU&7ZY7
MDHN[\YJ=3<^11412ME(%+LJXE? A4B-DS'  F4H98MJP(<7I_HA!0]7H*,7"
MES(K*RK"N+IHW]'W7H9*]7UNMDXB%;=WTY//FV[-RMMT=<ZX=>@TEW*B'#E1
MF2YS9_+IQ$8<K)S\7I9S2I)Z^/21N,/:,ZEP0/-M<!C<X5-A>;V40\\[496R
M-XP"O8-9JRO*DM@KMOWVM;&9YUZ@7<=NRQYNAG/X:3QH(S5M+&\$H_2NA,EH
M%D]]<1A\G5@XT045SN@KL"TV 3XG[%(T';@,N;^5!@?J?\A7]76%2PIO0,KN
M#5K'%\G;&8Q[;'ERJ&H #<[(5<V,YN8%+4&]]]A^QUL=[JPO:]D>>EC-9-Y_
MW7!9,B1+0D"M9W#(\!DJ<\:]*M*/^.ZL9H.J>W*Y(A=_%8D\J6KT(M_<47/#
MV9YNQZ*[07=>6,@'UG1),'?)E8,L_I/4\ATN=,D^ZF(8_"II<H#,NF?BVL0Y
M?/@929+N^6:YG8U=8>?3DZ55*<Z <&F-C*R=LX%X&X9$"%=\@M 9W5G57]G,
MLW__@7PRR_CI62QQ8M#SF2<Z$F]UF+SJ6G$ !?9<SI7$3T5>SO@?2[5&"([F
M[=-<EMC;SQ<]=95]S![YD3G-^F(LK]LU#A?:;ZD*K?=I!2M&&@"ZV@ 1UET)
MSM1R%;GW<G8\=8BU]XAUUSG[:ISGT[E2269Z4/@;/ZW!1D8EZU<.GE4^[55[
M=[U=]VS35&]]2IZ07[R_%I11YV"_"9]*MH'?X57U=6C!Y/$%L\$$:;U#/8FY
MMQ.H<Y7AX- !>PB-DXS9:P?JW)6SG^VJ\LUO9]=64O44!JN,G/RLY#J::V6*
MIJUN0,J^+N6-X'E6)'YU*$LSZL$W0.NU['@X.'Q1G@HZ1J$<J>5>+-:M,=:B
M\G3\SO0GJC/JGF]">WPW264OIFVB(<4EC\7RG2U#9V^3*#9*>7"&!%/K*C_T
M,"-GTAE Z]DQON*66I^M=Y5]W_E8^U(N60L_(3C&P4\2!;5#3#=[U#(DMY9]
M(!0-2UHDCE732PQE#_/*HLHY/3  "HK\]VG;_],DL+<INTH=Z>&%A_$__N^/
MM"T<$-QCB< !,>P2@G!_D^CMWHSA[7LOCY312B'Z=1$R"N_%G@T;KCU!@'"
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ME!,Q7?PKOB$8/Q>M\A-^=/1;R1=VU#.G=_= Y3H"5JQW3]78'80$S8 MK.$
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MXJ_2N;3VTX(CEX\U\5M5SGK#_6&OX6AT!IX%JP?R_K G[1V5DA&+3\RWPSY
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MY>A%GJVTBLJ:TQ-EQT7KJ3T^*UYK9HJI!R]O/_J*I;2@>[IR@U;O2WE<SM7
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MK\HF&F-=[3L:VYL>!EQ*WP@4-#'O7CW.DX,LP33NT,6'25I=L3<W?^)C'%A
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MG=BM +O9AN;PVUQ;8UVDEF17PPY'H /W(5N_W>(.<P,6=_KF'A@D?DF7 <$
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MG/JNQE?S+S:&<PW/G:635.>_DQV]0XR[L7+1F)HOF;$@T,9?\U3?_E'(3"H
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MS.JONBW.=%LN4YTF:&H\VKL 7NPZ7S&K;[O9GDN8/Z;O R=?F[UWYWURJ&9
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M$_I3WUQ&_?6+($K,##2P "Z3I8D@';M2<TK['T]:Q%@&Z6Z/RV-H*),@8,7
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M\'C'&ATXAM3N?59J""%SGM'Q5].VN:[7^\C)/QH<Q:K""9FWL<!-3D_QV L
M!/$_OF$. Z!Z&O]R2/U/QL(J<-W@08$]0.5;-J;Q-\4_F1@O8@!FH-_K96G#
M/W&NGJ\!!?3^V4 7L_\&4$L#!!0    ( &XQ]5ITQ[:0!!8  .\6   6
M=&UB+3(P,C4P,S,Q>',T,#4P+FIP9YV7>3C4;;C'?V-H[$/V)?-F2&49V;<,
M9??&2\GV,EFR),F6*=.,)62OA%264%EB"%DS&$M"U(@:VRR5(LRD^,D8QWNN
ML_QSSKG..=_GN?^Z[^=Y[L]U7\^V^V&7!H@YV-C; ! > (#L-6!W!C@)0'EX
M_NE[XMWK?/Q\?+R\?((PV#Y^84%A82%!(2$1T?UB(J+BHD)"8M)BXA*24E)2
MPG 966E)V?V24I+_3 *![HWAY1/@XQ.0%!$2D?P_:[<'$.<'5"!'H!!E@$<<
M A6'[/8#B+T\^2#_*N#?!.'9RW$?C%] 4&@OH$4,X(% H3R\T'^RWO->W_,#
MO.)\^P\>L]PGX>('4XZ4U$F\_8@?>:*Q5\KU+4M%US\J24!06D963E[UD-KA
M(T?U] T,C8Q-3EI9V]C:V3N</N-VUMW#TRL@\'Q0<$CHA>B8V"MQV*O7DF^D
MI*;=3,^XDW<WOZ#P7M']\HK*QT^>5E77/&]J;GG1VM;>T4?N'Q@<>C7\^AUE
M\OW4](>/5#J#^>GSE\6OWY;8/]9__MK8!+=^_\,% :"0?]=_R26^Q\7#RPOE
MA?W#!>&)^R= G)?OX+%]^RU=8'Z1$LHZB?R2)VX_:NP50.JZLJ3\H]X*2JOH
MT579_Z#]*]G_#BSI_T7V'V#_R44%A*&0O>)!Q0$TL'.Z/.,P0)3<J29<@(MR
M1[HA\F]J%98Z/G-*S[^-$3K](/L$,T'*@C>%-WLL.2M!IQ\ZA8L Q^FE"1B1
M7Q@YL/ZG5VB!.*<QR6RFR'DV51N_WDB#][-$</K;1S@(-G$EG2WDNE/9C5R8
M#5$W+ JEC?#[N7/'$Z1Y&) _CCXVYO_L';V6A[B28(Q([U8&B=77"RA#Y@9L
MZ:=LYL!7-%T>=*.-67_7P!DJ/AR*Q?L?S+0QOVAZ9:LHU8%;P#%]%UL'Z\$K
M47#6U;M >-A&@9@EH8J)""W^"Y97MCTJ\,:8R >ZA[,B:.C!8?P!T+5O%\"
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M>([*XIIP]ZHJOX:[3@2GEJU %_H,XP4U+BWQQ?/)>AFC1(^JJ^4^"Z;&IFV
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MC/88W,P8P_'I\.%-7O_#DD\$T+&1<];2I7#S8[[<Z71Z6Y>('R.L%.9A4:)
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M D/^VI@P_R*<V^'"D;_5>(5U^=)OUOIO&@= .IOM*)HQ:NP4H-[?)V*Z,T1
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ML!'>P8@K=6"L6Z53H2"2T%T@\]E#D:XQHU3U=9(T[G>=8,G/U@#%)X/?O5^
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MC8FV711U8D8T=@)]#ED-%033+DN'3)UK<'1#ID1MA\B*Q&WNA+]F_FO1CVJ
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MNWX9L;QHMKU8Y(-%L44>AQYKD:^@B5&O<(X95,@H%/MZMFIO0;[44Q^VMM2
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MJM5\=J09%JE?&I(WL*"K9-_#-YXY<K1@]%E1\BU;P8?:#AT:%G0;[^\N%*J
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M!Y4J>\&$!).'B2:#+&,J=70 X6<L09G<K0Q_]\!*%!=B27I%Z"R87AXMV+8
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MNKK,!0&7C,13IVS&0 U[_2M44!%J(,J%."U[$.+>%RI62YSY>,Q<#7[8^G[
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MLMKAKI_[X *T@@9&KSOT&U>*V5YO@J*?MR ^Z"BTAR_XREWY.@+QR&=MU[P
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MJ(YCQ&\A$G4XGC:S_D/JO<1CVOB=(8NV8FNR.2G?@AQSHF5*8G!PL'@U[AG
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M>@9=7$8VX!CG_.5PI%,9ZG/B&4;MM5>/SXK:E.V&[2^93@_5.!5@M"\PB-A
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M$/]N4PHC1@_CHA"?NM%:D%O T)XJ ,<,GY)'Y^#N'\.QJ]Y?#(CL(ZZ?%,*
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MO_C/<,*L+S$N:>6P"+,I4;%Y9Z V->NR:P7Y0UM1#ATF>5(@1PH4-"]RK5H
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M<(T3O5/+'UJJ>7'QRJR#^A=OPD<SN98KO1>]%]^_7CP&>)?";5?!((SI<*?
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M0*]]MK"EH7%V!]Q-BP=E28[:45$;#9*3K@S Y S!*97T,<M#.WX4ZL#7DT;
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MHY7OI]CVT/@F8!TPYCC]E[+)I3/<30WSG\WZ9.\F/*6Z\UM[I_]6>YY;K&>
M--L@=_IWNTM$_JWEG2/0/IP -)?^XP(^[J0IKXM.E]<-N_FKBO:F[LI[GA^_
M#P[Y[PX>G7!KA8HUS-]P4IRACD[3F&PHZ%\9BF[J_(IDJ:9\V"1]K%2#?,[>
MOV1>.C<+LX&XI1VW1(8/9ZA2U7;_6O%<.OD0GB'%. L!?>X?8X9D;_SZ*V_<
ML[Q#097:HAAWC[%!=F$][U_P(-N6' F(""&?P** KY02/\[EMHHDJ,[U+.U!
M?CCA*7ST_G'A5-SU\"YCG\A=ALG?IN,__DT^]M^0QP4P-C_<WAN]5 !\0B>[
MP>__"R)Q&[XICSE5VJ)Q\\SXJY,^G]J08NFQ,3C>OSD&L0:;16!/+:;]XP*A
M;8M1&G30#>4GNT2,8KKH^F^IEOX;J:(#;],*Q70+[5?$,[XXZX=$1;5#P!#T
MIT7R9%M" FS)'8$^[,_KD]-LI>=N=[_>T"Y3H:TZXQPSOEKSK[C^S$'L0O/#
MU2F-R5]KM+_B1Z<*&_XZA;,-!O7L W<,)ZM611C\A[?^,I1C0I/&A%.[IF=:
M=-<^1,;]5H@$_)5&5)ZQIAT;Z@\];.]IY]PNG?Y7 H;=I#.8(<)=X>(=>H9'
MF0KC9G\1,#7R57$BIS6'R^5?WRZ+&BH6R_KKM(QXJ8'=T"+'I.]3#A%!S=^I
MO_K?I+Y.B^X@C^GEY<GGN85Z@GM_:5VA GJO^?9.!4-7L_PDQJY6S&]K(?[2
M_0K%MU48"F,TW=G.>94\\KG^5ZGB$\S@YOD^L:_.V205HVK"JN-/'*'\R[R/
MG2"3%"[]F^1_E(2=P$,"HIU#7):1 R F/&ID,*RV)/#E_,DK=9M-]+7T+8EH
MJXS#=BM4\6T*(YU3\__JHUK^=Y^O7>)0]:DN"0($"16K>LXZ=JO)G=?:^DUZ
M\ZT,6E6&-Y3,Y9$VQ&%$O4^RAM[QS0TB/Z[L*&&<0!,@.I,T/_+-T>#%G&['
MS_IE ^(RN/%HUZ)F[SC<LSKI60TF,3SZE<<-(-0P^9++]+*O BI*P^[@44=+
M(SX+*WK96S1.E>!PWC!#_[V(T^:/TL8HB.Q[&IKD1X[^)(!J'5OS%70Z ,&Q
MD?<@W>G^@6QH6%G>U\.QU[WT*GDX_:#NXP0^*XW@+2?S^UW\4TKMG<H;Q-[%
MGRO&+^:_C"@ZYRTZO,D?+TQI?'8W2#2K;Y%_2N/"2YNU(^DBG_+U(+\G-9M;
MPBP#K+# 6[XTHE$0-<(->$BN=AW^>8G-1ML;5JC,U+XG5[O-5^K+2IJ6P@SM
MP\,A#S1Z:_V;,\5)0&J'0(EH/HY>?R)0T_"PMY /YQ._U6"S/+O-;W?2OME[
M=#K;2;KLP0/6H.=,<GG'V! Q;:ZPA;$#I4=%=M?2S-/G*E6J7M^PM$][<?J"
M;SB;39A5KPRU>R174E\8[/%>OB:UQ.-V8S6^6];7/J!GC8L?]CP]:ZK!;$@-
MM<.UZR$#=KA#1GH7Z6>V]ZK;F5GQRE-Z\HL??K 8V12P/*L343]?[:8ZIEI[
M963(%VJ$[7H<"%=NT%!X#>MUANN4OJH/^+6*2-R0$T"\^%A5P_#P^@9W%)T;
MS2.GDD,GY@Z5B&JC*GOW'(7[\O-SBYHCW0PIBL"3NV+'[\_0A=^=M:S#FG:'
M$6/;E$N73S@/#>V&E4[7%P[S7F@)DOP9I<<PD"#69>).N5J4UD98E#K)!G,N
M>;S<\:ZK=C_G/!NHTI@9\A7R<..[),>\7.=TL!@'9A$T23#&F#)!-:;>:.B$
MLH:TVTQW@3P_!O*XVGF&AZ]+YVYF>7_L.1<7'O@,72!BO\(?&8TOZA;DQ]5&
MYXEVEGR^CU*3E_^\T VG>WH<>XZ;>VO=P .[VZ<641COX8D^448AKV9]FA**
MGF&1+/*47GO*< ZU*0_IB'!GV4W;JL88NZ&WX=AXQW'>Y2'T@N&A=<?;:%?S
MX'N>KF,:ES]Q/[OV;*%02]/S>Q$K00?GD+:Y4NG.F]I:.1>"L,$G5"T9*3W)
MPX3DH*@ZSPI=?WOC4O.31S^C1@L5G,J/QAXKIK'8VXQ5>>3DQ39%NGU!?1?Z
M+B-'9]"LJ7)./$)[X&8]WA]=H&[%6U,;4S&W<=XS86#:5_R]2-'M@MT?0BDJ
M@L>Z868*Z)UD$)LWP284 V.SN1_,:1F6&Q\IN"'W1N5Z7;\8TFYTD)926'RH
MQ5Y08GL!,A"F7!TL4)Y3[18<*"GZ32@N(-@]9E,:T'CMDZNI,'#;F.P^*U[%
MO.N%S!-E4R+OFJ=0$V_&^V>Q^O>BS[<,]@>Y6JR=$3'7$,/:]0J>QLDA%1DY
ME_3;'*040]#O;O"SV$G^-&T4YK\D;_A1_\?O-U[9K1S7+4/8"'ZIA[?R[6<(
MVFCRH+S@3KPPV?A+P-FZ>/% 1?D1CB%G27SH?)IC;%Y]UZ7&9OPP4PV\"U&Y
M$69)GGI!.FG&LX\K&]ZUUC7Y*!4'#?2;VQO)ZW/8/#%_/Y=QX(N76=:9:1PU
M"X'HD$WO<Z&VXJ%D*7,H>PRK2#Q(%H8A'D)GGA/90Y1_].=9/7'#=F5)MY9?
M>6N]P>P>Y^D^[6S!QP,PK$R)<1<SQY( 5SA_2(P)?FEY2ZS?MJ9O#>&%BT2X
M1?@%$/4;=LNBK>WKAK;O-0?QH"VUDZW&BYJ,/Q75XHW0U^4W3 H%9PC^Y7W!
M_A[0V76ELO1YSI,-V7/Z/9]\?25F \>B'>F1'9K**3+Q;VIJ1!JZZG4;$NYD
M<L-5(E[K=M^#]GZT$S 0;0C<>;S(CK-Z_ :J4H,/-YG9DP!);!Y%[-%+RCV;
MNG.VS.7Q<H0[Y2X)Z%7AZM+$Y?8*0*RF39\HTGKMXTO;9S7TP(5N4U[[ 8FS
MFP:@HU_7K%$U42NJ2@LAVTOZ> .<^D$*3N=I6WK[>(?J*_MU.E1V?UU?>"7]
M^X+9\U_EW'X^X5[Q&4D\6NJ'41(H,/B&SXWPTVNV+VSO0MSJ4S&#RG;N]4SO
M!V6KNY<M"P[[8 SW@ZVL5")!4[72TGDSM2*9"T:&7L\:NU:61B0'_*=$H\",
M6$C"EH;_\E@,@EG#!F-\/43%>*9#NW3CJ&"F'_4 F6DSE_" X>/ W2LN3UNL
M5$5E3?QN$$QQ8(0S!L:%PIN:Y?:#Z<2ZM0E7 VL@J!S1MB=Z(O>I+R@$!)U^
MR*2O*;&-. L%8:V2I +5O=QZ\TPJ?2H=],)#!69>ZDN+7:/-;-*3/GMZ <D?
M4,T%8M 0"_+1(",NC\P(^&97B')U OAC3TT]><R0?'\:UIYZD?([#'^QN5]3
MK\^1%9N:4.JTN'Y4,$ X^IQE8G W([.735YWA%M2.-.%3@'TE'H8T^&T$C\@
M$+2+&4I46A"^T9[;ZWBA$1N8F^OS<*/IG;UA;M!N+1.'PYT\T2&'%57X!-_O
MBV&H5W#.ZN!7MO,;<K8C=W)O]O/J1-]\I?^(^(/]IEY$Z61=*5Y[N>6!XZB&
M1%F2E9$^"E3_:K*IXH3=1> \D7G[H)@%A^R)L/6"'&2^S;^.#*1/L;/%C26]
M42JXU'CFPN.&-0'4&5[..W6_?.HLHOA5^:>=N*7W;6!>SZ4>E$U+BN;:8D<;
M:]O:&M)1UO=$\L+=FAD3C#^:#?-^\VOG$<)T36(/^YC/X$T=9Y1&^?IL+9_7
MW$\>"W^-0ITW];5I5CZD%),TT-C_7C8=R1_B8C4M[?/[]Y';!]\][1)J+S1;
M9AIXY0>VY_QH4_A0N/":$H/X<MQCZY/2Q0J]-1WXN:>]T-BYQMN+<"/PPM>,
MG@C?']_MMD\MC82\M! W^<:_S,\;IF '!6/C>Y)F9GP4?Y#K+_R)S(ZT3. E
M&S=$YJ?A0\Y@B,J'S>* /I?.B(*74#8L5URC@Y'Y)!14ZH&**^=_NV@_9_/2
MP#>S:9WC/7^<1GK83$HX&A2C<0.](*,UTR%5=M]6.O?MY\\.MB+I<P\<*NOT
M>Y?]'LTE H0M;%<I?!YZ%^_CL7K_H"TYSRIJ"X-TG2E/73+)?O,U!\.#GK\V
M&I"A<5NVQY="**.P^L 2YY90"U;'TU^9@>_4!LPE$&QJUNL-_(2%YPQ\O5 T
MP[^2%>Q4@3W69*M%KB(&@M1K)]-P?_26LN?PMX9" ]27X(:<LGQ7,8$[DD$@
M]/  Y#K>#YW"NWJ]I6Y<\8?J7H^O9%G<@D7-0-].D3/EM\7^=RZ5JL7,+S2"
ML8?Z\0<#=OT15U3Y>FSCGR1[5L[31BYP])\=DLE&>)]29VP94A56^CG3G 3U
M#,4ZGC3F>&D*XXU<CP)FC_KK-:?=+)+/?-/@+E,5][5^M-0866*/M]/OF(V#
M@_,]I5]+"78[:MS^(+40HV'7MB59I;^>+D'G$Q-)TS(YF"\6N_=<DKJPS?1+
MW@P#S,5JEXI[Z.@M"5!>?/X]JG4ER^,L7OU &K<V-<DHCG?G+1_]X*$VCWII
M-Q_*3*S]?H7_!=7E%2K<#R=9O-BM#CM%K&-SU>BK$)^;.+VXTMD'>R=AX>V7
M'VQ+5OB>GDM?0[+U)DE>I8BT9T.([<E<P3N@91A"' _[PDSC%4=5M#IWP5.O
M4'/BVLJXQD,A;O5XFMG7ME 6+&-\++Q#QFMY@8F9:4GYN$9>@G;VS+P+PP;-
MQSY*JI^R<K\?;HJ%QRB2 %X'PGG>Q]LUE1Y3(4@;[+<:S \NB8-1T6F'SOH<
M&\#W30OS="R090XUP!8T]YVX'*0CQG<"/6DFYJXTQGV]CV0*.#;"L4R+:'VZ
M4I B3#TT,L<-;_/J N$??IB[TMP\WH"7VF-K-TJ4"+2H5Z=S%:)Y'_2.2=/8
M2":Z@><[\D*6;EW&_OM)J>L==$M>.J92OW$?U04MS=?T185$E5DE)XK[_K]_
M4-PHL:775\B.3^$X> Y,BQ3<C1;@7G2R>?,X=;]7E<Z HDQIRZE^L!TCY8:V
M&CPQZE>P%X7[URXM/;F;_0PU!"XZ_5%.!B+=GTU-#0@A)\)4>B'4(>$&4P&C
M*KTHXYRB5Z,7!@H:.%]74J4FIV[('3YW>%J(?E(3#CKCCGH0EF>['M2T7J5_
MK\L:0R=M/5B7B3\>NB-^PDX'$#!XIY=XN!&>&2WE8AWAV2=(B8O!&UV?%MSI
M9_0][#4P:.]BX,^WKN5XF5R[[-N?+F<-8V\\'H7TY7EEM\YV&*$C:!QQ!85/
MF\*FW^HK'H?4?%3XA3[4S_FI$:_JTD@+;,&GSG10HN>*:&1BOXWO_8+*-XW<
M5<QMMFPZ>Y'"A597.9F!Z3.'KDQL(4.,\90BGB!5-N3RRL[4[9YWTQ/619[<
M!Q/%@T"@B"Q1\L4X%]AV LPUYX$0#/ (U+3=M9UUQ@<H'1=<6;K5HHRTS5/K
M]<Z1/::]1T/)9^*?C$Q8\IQ:(,C'FT]W&%1:_^CBQGN5;'2QWIHN2QZ!2?5'
M&YS:/OG1D, OHKSS=*4S,MTFA*8/%7 P9><^:V;D59$BRJ4?)?<EFC8J3*_[
M5YBEPUA/$:6C2GP>C'9MJCD^RD%D^&[*P5E9K23A;T"4WP;%#RT0R]JB! [\
M_-C4=AV)>OP5!7H2>5&CR3VKU<@NR8[3J#J8!RW@FC 3YJJ,:9>94UXQ;\&E
M]0LH#UFW3=K"XF?/L&,_K37]'*X9 N6=RHBF?*AWF1M>F]:'8#BIE8!O"D"V
MY.[+5 _)-3L,APW7U5(,L7)<, H<8F_;Z1MC#,G;P*Q:CK]1XDM*NOLNS^@9
M!TJ?4UM\L'__AA #S>M1 'I\?,ZS+;?_&5CF*N9NF]'^[)3^=,W7 J(!YFT<
M?9ID-%UUFT)TR_$R\HDQ.A<+BFKT,NJ]<[#BD+9RNBO>X_1!XT.7O$7Z-WW>
MGS;GN$2B/XNDMJX[P=;!W),-?#6&JR93-6^\ R72&AU'J)QY,5XET"'A'65V
MAB+#8G+CABJ(,-*[JX5?"939BN%Y%'32'+33X$(,<Z,)MJ6*#-41;5R!L4$U
MISH,TPV1CN*X]9F&.02;O36J6WC:ZRI5:]KWK.'Y7B6A4PJ'.N&'6SU>?A>:
M>PK$C']Z2]42KGNA)G=L\HV;6Q,"CG/HI3Z&WG-Z*GM9]79I9SCB"9@*JH%S
M:--^$R)Q=1J=BOF^)=Q6;\#AVG+[D!706\R(D@S/&/7 -Z/38@FA95_6(\]C
MOS^O69^]+HB:/?IR+Y63SHR#RN]G)O@I QZT$@FO"J'!1")\2C=4BK"Q\S9X
M\[Z7B[-$F\=E<+51'U\1D1Q=%F,VY8=S2!&D=>9:6$X*+GX@#)&TSV>:2+TZ
MT/9 [<K&=K21];ET'>8ONU%U5^H^EFL)-6V^P'0-)*&YHC%33J9.]!X2=W"H
M_EG,A$9]SI#R2+(+2Z'55*/44*\IM4-(C"7R K8I_6BP^L&#G9W1EZ%(V8S&
MTJ!!?6'@*(IB70LDCE^QFB"$OHP<(PH@"3HB8,8.[+?YH^R!IM?C9P)I%==X
MV7-NW0Z^&'J/SO0"A>J GR %[C06Y]23QH<?,2OJKZ[T.*+.R="&&U"7E"[H
M_]1C_-C4$U7(]W:BXSG/+_]HB<V>8PVH@BGC"'H?"XI'7LM<]W$RY85&&A3H
M3HC.NP1-)!_Y339Z=[&&R!\.\/HDB&)K,T0[7PW6V6Q(W0,5G'K=2_7 K^&N
MS*'_X$7*W:7>O%#3+Z!!WOVO/ZB;0RM[W)&SQ NMA=\Q<\>>=^.L#4[-<=,J
MLV6O"E^&EX+I-C+[L+"5U.<5&X=Y\+@& 2O+^G&?;>D\S+5F.QU_UNO][]X\
M5*BJ$SD8X]C,67I7T2=Q.5#_-I8K'AU_RU3ZE_#;9/JGBR)S8B#914K_>=>V
M!;&>/,X8] "6F%]FO7[$VS\NG>]Y:@A(>==Z!:!F,HEX2,;MB.L3^W.0+S[H
M[*6X;>=)@O^;D'=7L^^]PPD,EAZ\S'EGQ%S40?Q6?GL-QP 7SDH5'\.!K#KP
M5U_BYTQ:9[;LALSQS;TY6,E)];GYI<7XNA7(I=B$IX+S3-F'8_%=IPE@;-YY
M]RZ&"<5&H]<^3VV_B(2T/)%-=*19U-JFV% !V4XGH8L>GYO:W!3&?G^68QD6
M?U#3V#8GI.]]F+L[XQ=U_#S?=]N=\JLI-3[4^>1UI(3DH&HQ=M[RX.C>Z- 3
M:>'6.(L)9[.,+ZMW7W>WYXJ=:^>_:S;>H>>Q8OIEY< 6N]V*.<,<'_C(@R9!
M-.VF^]=LI$FF]>U""Z\/@CK#5-&&%%M.3O90?JS.4K)IDBNV,$,F8<2'B R_
MIJ+ZD]#QZ]G8_(7(%Y9>\$T<=G*H[RCUL<\RA+FG=$.*S^&+GC-W8E :V$Y^
M);/ULJ:N.^6RA 2(GV!# F(I]<;Y;)&-@]C"&L&,JB&X4M'G3 &/DOKI5UXK
MG^CI7NERMWC'=:X<!,5-1(()#CC0$[=W*0$1X6:)2^9M.(81\=.)+.+YHN";
MO>SM"0H](K==E/:]\Y>]*/6F)>%O%.WX)-HE0)LC'E[+M]R]@JE_FE-^N_Y:
M78^'8\R><!H?&%IS/ZR#>&;\U8R28I[$W+"DV<C#^MHO5YOD>W)C"E]&@<D(
M([H$RM(^0[A40;B-+5@8]^0N;9[E'$3W&KL/':H EWH^VU$=6ID3E#:7L*8[
M45Q+U)%,=AN%Y\*?0^TP%JE'>PZ&GV;'5P[/0ON7J^I<28#'>TV)=9%QQ;V)
ME4F=E.8#6RVIG/[^5RQG*:X\T/ "*%*S2R:C?C]J0/L_+_3^?_L\%WSY^Z6@
M:3=T]5X7GWZ9I=CP/_\BW/\#'ZL!$/;F4EJA!IZE)(1ZI?L(/7%A&NZ-:7>F
M>O@K,4/XXJ^>P3.:FIY;880ULG,'R8,0.O@DUH<$[%T+8/2&EI/1&AV>&!:R
M-39EVDP",)<@:#0,A%B#^A"XYD@ CF,>UG-9@\\Y&+/$'=)G,Y[?S^N:Z^%1
M6O-2>]75[K@LH<B;>3Y9(>OS7>3'(O8.#DA?6D*D.+:F^[P#WZW6NF'B!0-N
MB0BZ+4C*Z?5P$-RI;FD0Q@V]?E*D"&+!YUJII=;Y^X=DSC^[H2)N:*'+3M%]
M4(M:.4C'=E:D./5R"5Z>]"*893[A,\P+,(B-/<5&Y>)'==OM!3(ALEL84I\;
M!_NQ8T8")KYW# V Z E&N*P5TR$$G0>O96R>Q6I"0"X")UTJ<^2:^ZV'/-"^
M+';X^)'])^T0S+9487L%DV(1-L^RKTUD+\(^W2C:_0G;>43DP%FV8A#<'H+<
M)R_!Y^9"YIS"$6<\#X]TL\J-Q;N*O-AHS:Y/9(\H7K$,7"7#(&LB&(=,[& I
MAE['=F7C0-;DH2!IB=[8#6-3ZQ(^8AXNQ"7[ZX-RMO!WNC#*_6+F=ACZTHQ"
M6L,+$M "Z<TELA:8$R--3["0WJX+3OSX5XRZ.^A5@IA:Z_@2)B_$A<C&U7(5
M)A!C0Q]SMLA[?- T7?DR#4=1)7X5P_0.ZV\\+8PSJ8LHQ7OVAVT753FNY6)M
M/=6:BA[<T@YFNSPGD]6:5)663Y\'')?AJV\!10TOF!!")(#NTR11%.:U=/_
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MW"M!LT.1"D[,!#O\M\ W4)GQ[UBN)QUN4L2"Y><$_:,71^6=20^,8F@SU^E
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M&&$FY#8FI&ASD8'N.#I4L?&<ZRK.K@%[K&,.8G:&N"TK7QJJVI#R&T\9ZP[
M%=3A^B0V62:N;]1?ZZ986@(8]W,/B=+51J84PLK2C52T@PR56\/IE.(72\-"
M=*8Y64@U_K[(V0CD#8\$U<BKF2O.'9S1<T)T5!9POW_O[V-EKHKFYG[@]<7V
M29=)K6R8'ZN)R2+(L-_+N,/CHY#+P^C2 ZHQ,7.Z2M"2H-!*:]*Y<&/0]/E[
M1'+?3$*/+>GN6S767BREOHV^*,N8'$N)=?)>U,LCE4E96S5&36\P_CCL1K$[
M+0[-XH+2'0E:&=!0)!5HQRQY]AP<GQ,\D(,S?P?XG^:?_FT^V?^:OLG_,7WO
MZ6-N*DLL'FXF_]9-\7C$&@I?>8$<#,OG)GP$S"O.(?B[&WIU!^!7_$M_1BM)
M0DO6*=6#'E*]Y0,S\-;V-K'[+^-%4F^<3#:5 [W^\^^E_^]ADFF"T O/<L1'
M\S^*WK 16X0\O@.DD,QO5VAW3/&<O0@ZGEK99W\3 =>%9C4.BN<0=9D\N)W(
M$D99(*HONMI);>.(5+S+V<$N%0O*K+J)^W%FG4KK(W2)DHF^W'CKNKV^*NLF
MO16&_:D0'DFUVY)-D=&VQ*:8 J59&KF6C/H)C3:_6_]NECS_B:<]=P ,ECL
MW.H>F8JO[P Y\F&W#^[G2N^$SGB,_T<J(UD+1[RR?,YKHSL OL =@'?4NS(=
M5B&D."OB^V9 /71:<W93^0SOY[>PYH1[I9VUP?^@+7)>K:XZ7-[1'I\$/SZA
MOQ3;"_%0;4/QIN^^RO)2B:#DXF!A*5I?FQ4"FC$I7P=K/C=Q5</$<WTRGABN
MC%">',P#8^]UQL6R;J\_/8_1>#G6*4"R*;XS0]XW^P:0RRR/A&?N[[$VHS!^
M?8+)^YK\^\0,K_V73*XWM+X /1FQT?C2Y++!T]V29J#WUI#-V@22X]8IERU+
MJ88_^7]8&)*Q:Q!_-Y?AK@2,KV=:*0N6=VC$38OU:Q^:U^$[PY[+]1#C/5 _
MO 3G^X3? 1H[+@;S!^.NH^XOVD@^G+%V%A3+&B/EKOM5;,/:*,O;MH:&V"GJ
MHH8NI?@X7L!;;$I,1S<ZW%03E,Q:-CED-^5J($3XX"6].LK&(\@**K3\=8&#
ME?C5P:6SP #Y*7\"XP7E[269)\D=P,G_*$&^$[E,^[H*<9YL6;CC_MP:8I_Q
MDM9;1>]<GI0P,O_7WN7L:/'$K<[NRK_2_7?ZE)A]K:]@]MQ]*9J+>P9VDIGE
M8@+&B@3#B27"EJ[.A(J_BQ/>N:V&^=$@Y<? +F7;%%[)_>#/:7ZY;+V?ZI:K
M14\C+JDUEP+WC(_^65"_#I3*VJANWQP#9QNBZ(<;7.IA#&^=Q,??59[F) D+
MW^BXB=^<BWCW Q\@+GIE!&6D>J_8*MM,R;IAO$>:U>4!Q'0?8[\HC;=Y9_\C
MV<OC/1A.D*,T519Q:K>!!OKI#D=:VAM#NT#6,9\^B!S1_!:.]-G/NKB@%4PD
M84S>#DUJL&O4*+_">S71T8,J^KQ?/5P Q>%E)0FL8T]PGO0_NQ6Z#<2:D.;W
M)3],R(-8-R3HR1<6G&^_XBU0:WZ&K;'T5AGSK/Q>;-,@Q(*EY=A;<E"**E,B
M/WP.YN?BOR619@P*93PT VY3G?;;;CL^E3WDOSE^=LQR"[^7/4^C M>,!5%&
M,,;PI)T34'Z/I'L;7U9?A?$Y_19=1CRAPKOXQ]H)6;-ECK *P?E>RN9]25<!
M6]T4I/[2ZE,SY8_16^+C]F5)@;'<D/\2]_@*-TIQK8-A]SRM.,*'HW /$E-@
MQNT=H[ Z*I!CUO6"@PHK:5 ZK:4"A-/3SM+<U#PK+"6U%Y4I4>M9D";T@^=[
MJ*U+$$Z*$@[#[&'6/[#2B=9%]'1G24[PU&H0HYP']*9XWM"JJ/P<,O2-)'$G
MEC/Y]G#M6%RB].H.T'6$B2HE("4P[+J2OVD/+TW[)&00DQ(N$#ZI@#V&L>#<
M1-WG^_@?F)'F\@]KIVU&9OCQI<M5I_;NV,RIE I[I@YRO>OW_QI3 &;)92G\
M9&V"B<;(W99<B2A&"2G73(FT$KP9>_8H]D!N./\D,^>8C!C'U$3AWVA1_!=Z
M/A!EMUHCLKM626(S5IXA^K/!HAFB$-J%**IWZ\\>L6Q**;S;H,.?Z^^ ^7+W
M>=%!^*J*#'<-7@]'L47O7!<]>L74.0 H3=@)-)[^9]AX_7< O%8V)*^=;I\?
MS33ZU3DEO_TY2H6J)J:36 [R1; X.%:>O0%1T\W .G^:Z:&#J/_QT^;J3:F>
MT;@='K3T.!+G)25*#HMS)_+BZ)]X<??'E^8P7?<&4T%1MNK!?;I<W?9&S#?7
MAU2?QU_\%N?!5MJUD9(-82":KB@_./ 1*(9V65B[%$,5Z3X]LJ\D='AJ[+?_
M%=USJ3O!\(^>_AGR(T;Q>>.E<TIS%XL4CF4[%HQBA!\DCF$38.%D-T9C:$'I
M;7PU8'$A(F7V?I [0(^7[V9'.(.$B-56^*\VT R/ _IF _"0!<NL[>3?0/PW
M,O/60(0QB(9N('W#1,X46JAX03ZG=6K'UO&Q2;5T6;VENM])=*AYHJW46]03
MQ(G>Y*D]^W67I,S*C_SRDF*(BH.J>QDSN[RQ2UW$$ Z+]/SD[3_'%P<B*\X#
MY@)K.DVW1@/MY2.FV>)<&2T!S^*L]P%4IYVE0#R4/<P_3/3B"\BPY]P+7_>S
M:*,AJ\5)Y(.?>HG*3*2"OIY@SW\7.^Y?Q6]DX"3Z6NOM3SX*#Z\MLT(KBI0N
M#)5R^=U4S 15I=QN,SG%=E>WBOU]N3'AC)OW#5YWLW&R9QDW&WIN#B643ZK_
M:..AF3)7(U:6O"_&/T>CHW\@(]$GA U(K96Z,)M@P'F^:J>(_7C*I2M!_6"X
M%R#.$BNIJV^>8PTQCJ*(L2B&+NX00V]BN?% Z,:W](4^=5J37Y0&FL"?_ADW
M;R'*4'G21P0GK-RUQ=;^ 9ZY)</WJJV' 1M4]72;ZAHX,K:8]_2-+4T TR#<
MH\&.@=$+J4VZ?='5J@XB)3U0ZE]\+,$=W#F&#?H_@['@>3^V3]W_%KQ7^ C+
M2E+A5W-=;)RM94G%5P.]EA#<H7,EY&;7_+</^)8)L772#)13!S[RWN">8CF&
M!F]'^L+1JY*3SZ%"WV)B/?$@;;FF$1V;:7_C3OT_HRM:#V6K.BWBJZM3.YW;
M,%/GR']PH=0A,Y_2HNT'DGH7+[YM.^ZC<2T)>KL'ZXA!\\+4&%41/BO<M:(-
MNG,I!>L\M&PN%XJC7['X--Y<%?_[O*_PS6_UP7\KPRB)\E@#!TGSPVCO  1Z
M(%W5.(692<JW=:*7*ELZ>,TOE$\',4,XHK4_HZ@1M^M=];=/4KN:M4'.*RYN
MA-F;SU]G("SP"0\VZ"@X6)VFVJ./\V2/1^_GBUS0<]G9>Y\9\)?DO2XZC\)6
MGM5,V8LX/K2ZF$M3J]%?D&.K)UW!G&/#51S)^N(RQ $6<=&ZI\9EXWGM^G9$
M?::;8PD4:F \P/,Z MY U:#PI\"_6^$1.(?B67J![=\D\ 4(?^;?/KCO+C?,
MY+'5+<XD[ZD_T<[[*]%4!_V\VEJUG^4#/$O'RM(IK$D?;LL0'CV2A5M1DCM#
M9LV.]RV$<3V',N%Y_/2TR_K4-*;!W#C Q;T-YGHJM/FW, *O9?^W%U&!, 81
ME!,L+H(BI3Z+"W&3&FY?\<DZ)_)6<(^V^N S%4NB>#DKZLG:-:</7;-Q'&&$
M*<S73,U]7/W7BU\RT&ZS%5@UB*#QX]F#]F\DK_T#[VOS(O*I4Y7+[7;>FN>G
MMVJ8G\42B$I)N2,UO@+IZN;1M"6+>C$RTNP-=X!%=]&]<!;O7UC5'S="KWL_
MKO-I%/H2FX6;/VN] U1S_M53?_X5Y,E%[-_W[\(]%NXSXT&T9\*Q:P;KO1<B
M0($2%N^QB MB=<6%4[+QA>UE!^H9N.N"]^<E_;[ZR%A8X"NEG,_U.PI_G\$O
MHWNX'I,_DW:%]U]&%DXLD PE"]?[^Q!)< ^-?SA-;Y+=_"2%5<T(0 ['>IW+
MF:C0T=@JA28TCB_)Q=01F"S,^"FQ7TDN)!?:,,(9;=^/+1/*O?!?1. HQ*33
M/RR-/=6I6 _$_Z:NJBEQ17]-*9VTE: 9QZ=>66&#IJ/"APWA&+[O9LBKW7WE
M>U99]I.OPI=LDI2/']"9&>O2@4E-M1[Y7^,N#O7A+ #Q*T8I30BWV-.J1*PH
M[>^O<Y(*U6]Q27TZ>6NU0C,M+7T5M9/F*DI08BQS PM4NI;O 3"\_Y,B3@VV
M_,<P891&C:S]";Q]:J-EP\"!2/E1N=*'4:]\Q,S3S?/'E"DZP)-Z3- I>G:D
M(S2+O"/Q2B6;2&_L8K[^*GE$VOY'90[MQQ]-UX, 7-N5UO\B59Q\&!"O&83]
M*15A,@+2FA?LR#J+KQ'HXT+5@#\8X1SB=$E)H_:K*),WLVZ^'#IMTQ^;9FI3
M$DZOF\A^\!K(0S8)04LYF/.%WAK_D(<(1EH?;D18;UT5 P^B/Q/.^$O"6]N7
M<)W"DXE8KJMS.(M04F?O"&O;(*N0(M\C3W_)1+YXJ&! J&]8?U" K9$>RTZ<
M.VZXK>>_U'@L K8LUI-&7AE19(U8M#K_E6[%8_[6+);/WYV\YG@M(3BKJ,F>
M?TVC9_3)RSE7(]DN&IFBI/(U&]$$J$^JG+JF &L&Y^8+)LX-L_:X?]9;0AXA
MU4EQ2]&!F#'&GS*?<-Q4B:J0,7TJ\5FNCDUZ0QPS%(MFHAYE"*-]9F?6@.A/
MQWHOZ0J1+Y7'GB3(6-W+T21:]LE<W$A4MUW]+^@+_X#B?MF""$047,F4MU.+
M1IG>) ZJ,EIJBO9%_['J/-*IO*4%&=R(%#0C#K.=TY9K1;T21PEA'OC<]63Q
M#+D 6J<@<3#HGY2#D8_F0H0&%EHU.Z3#,H'# _)MMU/3.9%/']:M/+I^(3&4
ME'0B('PM&[)".@WIA()LNC$_.JQ,?[*\P-Z3M>8>9W!0/_IP#O;Y9SUDY1&I
M7;_T\<31_,6%.5/J7YE)Z/,U>#Y UF5W+^C6*S4,XMZCI-9BO/4GS^Q5NB5U
MS@OS^^@H*+6AAU8L<3=O8[]T/1<-Q7&TN:+\+[W$OP/@HIF=U@N0!5E4TY^0
M-A\KJR<^KSTWRCV9!FG'H)9CA0P@8:&GHX;OINJXER5IRV[8-A*[MW38#O2G
MS:M=NBS6KG5K_ZDST]WX [()W:+H&8:O.Z_DE[-BJ5U1GP*2&]Z[L)2>#-<D
M]JG+R92Y'\$NPOC1YN;PD1CL84?2A4Y[^SK1J(NJEW*TV.(L^)V?Z+"9=)LO
M_W'Z3%?&(#\,1%]6@V4!2DCQ5^W<NI7;,[.Z2[X\B=]VCV4Y6/>I ,<29;>X
M* N821CQ\BN8(^$"RD\JEZK1\-GP)13CT8=$YQ<<6:WS.H5^$^T$<^WL)BB:
M,5YU7^/N0Q7:IODWZ?M?5!,\R\%.-2,F\<$C'IAM7IPSKK.AG&I]OV*UOB\U
MPV[#.K3N3:=$.SWH\]:M]XZ/K 7;QE6&P4Q--?VX+^E!Y$;&':!<9XTA:[8P
M!^6BAB@7([&"^$C:>5 ZFZBF[+Y(A+_ZP2;!L64FJ.;]/$@(C?<_1$<2^*\D
MR1%'(:YQCW9D%]/8?V G%WLFCIP;?N)*WV0KL"/U-%.6-1A+AZ6&\$D3MQ.D
M]KB3@K0HS:P.2)XSK7RPIQZ.[XV7&V1O$[T#P#U"3E<C("8]UU&U&F2[!J[-
MA779W_Q +!_+H54!SNHXVK57NO(W^45P,P?>L*0DCK$.=G&)T[PUG[9U_L6&
M;C]^!L"T>JJI!8P?]\/RTAW@HZ*=3SI8DI'?0>[AET7G2QYU[J)Y( &(MO<*
M.RIW=X5X"GP:0_9PNGRSH=<]*D!T(.B1=JPNJ]@7VP4VY%P<932OC\S&V/0'
MZ_&2PEWHD\]/]2D$\1<6Z%*H/FS$VMKM2EJ%2L3T-22SV"FN-'X^Q6DZOT>J
M A@1UF5P!XAP727>-7XR=232)F&NHK)H?VN5(GMF V!6TH!AT;>5)*#I$*^-
M!?TI!F"\ M+J\[)VDJ7=KV_]<']@C&$2JZM+['J"C1%QO?Q$H%4])%]ZP6\^
MOE89_YMT/WSOEQJ;!2$*?@B,^81^9RF:,'A8[Q$>F@'1@69EX&PQDE41T]2/
M\,G;&.'^*A<@-'.RC2'SLY&./1!FQ-(-(9/D2RB$6D.DY69YF.,NN.BCQ"$N
M\7W?X[TVYD5@1X$=1*VLS</;*[B3I[-S3-Y&+^3L^WKY+^ 2'(^\2]=TJW?N
M ,1HB1+4R7M$2%MW?4,A!&JTU&W>_;7Q1+JB'&3V6OV+4(#$GA;J!*X;ZD>'
M<O>UU6^)E!)WR*EQ9'L=S9XF'RO2N:WR?&_BTRG9!T*6EQ,\T@)Y"]M7\M$&
M#LFFN%#((K1R 1;CQ16G@13QMCX5V:9I"!<>9>\^WQP>FTL9=Y\['V;],?FN
M"A*<PDH(H-LPRT6,1]:"R;:;U0L="'[-5.0WA\X=R[+#=";$"6A]AA>D@\3S
MUKZT:.2"52?N !M$%G> #[J7.N"GP,'[\5+,%4(%P-A^UDB8%\D)T%)2Y\2*
M-*3^,Q5 _]\V>\HJQE+(:]UY81E'F.K5^SJ7(H@1J'NJ^W8*ZV5#_!!=L7D5
M5@"N)6:E9PZ1*0>]%8[('UE&^T.'>V]3?3BB.^-J.RJKVCCSL75JB^0-:RA'
M@ASK<X@2-=6&;JS/,]0J>/LJ-<R5-CS;  '?3<FB:9L3D5IG+[I*[L]*7?D\
M$8C/\EOO*D@H*R@ 6)K7B@EG/*#V6+L#Q'AI!.]__#6S7VQJZUWE@'^>)%)^
M\;BMU^\-^A=XT,23J!&?$-1&=%Z$"JQX!1NEO27I('H%!Q,#DV1^B)W0BE<X
MEE<>OAM<,3X2H!G]%O#< S,-QWQ/DGMC5.R\ PEL@Y6!R?1!CBI1"L%*DUO'
M?/RLUZ]6=WDW7U$^>O>Z.OO'268;I8B[":2G%Z*V9V40%U8[CZ1NR7X=*658
M@B]&DZ$[%V^OP$78'WHN4741ELK$$CV!,S.C.YY=<W0@X(\$]UW5Y5OQ6^9Z
MDB[O7$4[_2;C\>#%21:2Q!)\CL=TO!CZ&"=Y2R-6MI:] U$S@&=NFJ]G0T,?
MFH1=4ZHFTU,XD'@Q8O.6'/?=+Z*.+2:?QJ-.EM5M<+*;"62O5Q3R3M  Y:*>
M>.YM9*"48CB@AX8:^?'R/>]E9M:W.*%:BU< R-@<W1..M0F-CTP3L@\<+JQ&
M [GN:6?P58= QQJURY0B:*7K#\TA$]Q2+/B7X9JDC:8OQHNMP"E^/'[S!MD!
M=N@/YVGNZ;R'@17&!FS115O*CG8'%?:?$W6.\TT91YV)6^*CCC=./MP!^A@A
M+OW'.R8DPJ-2ZM.N+1;3/HK8226O/#@@:^GJ]9&ZR?.?)][\AG[1^!VI@1/
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M9&>U6C$<K>SY<]2Q$A3V?MZT#9&55-FRNU]NUIRF4I ZTETY"R7SYY 16IK
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M,YS-TS3:]<8":9\^<69^9F:?L%58S<3TP:D2*S M]>NNP<)T&(MA*-]<J(Y
MFR?ON\65?HOX(A?H7R?&M%]/26Z/9Z1_ZPU%X/DKDQ_O$'HY(O5CEG'Q]396
M(&^UK&VWL&+GMYW"X-1B\%JJGO?S\2+G<M<"*8PK:A6>ES.]/)+CHB,%+0UC
MV)SP$H&DSC2_\'RVK@YED+6?>1;V="PY'(AY,V .C:X0R ]#"':TZ6LKQ3B)
M+@Q.E]'P+YX!-<W:DK[)DJL,IBNYSRL[4;%A E_.BRK#Z=NZ&>4UXT5KRL>
M^#?6B%7CKHX"I@G8^?LL07+L<\.R?P$V5.&LV%<8]=J?.=L9NZ>*K_3?Z&:_
MS-5C3?01B&5[U]$=;W6OLGRQ!QG7MO 2 #F-"L?%7M\7'!62,0:A;WX9$O)7
M,OJA6T  AV7[8R>_>/P*WPG_FZT8$^3%R XEN/1UP: "<6MCTCD\'8U4?\3A
M7_>SY1)I$?#R([V"ST<YX@=0>^AM=H\S?US*66Q&E37(:,([*S@Q6_HYS.VY
M0:UJ8,?9 R?_9" .DQ^C6SWT<&.ESWF6;<L&_%]#G$@#T]L%H&IY_V\K30+Q
M[5/$(6F*0EPVZ6_,/G,_I_1C_!V@&6IQL(!LU:G=Q5/LR,4VJ![RD_$M^?6$
M_:.7N[=W +GQC37>JQ&_ EI4?<P>NX)I3_N[CZ[9J^;AQ>R;;BE>POKQ^,G]
M]:O$7<T%?Z;#9W&$/4BMP7S.H:[M# ]0];&'2.TBMQGAL=E6UN] 0;_AO\,<
MZMW.:3D(84F+O5TQ&/YPH+3O\0J4N] P9W0;_$-!E;*@;?#]IP? T9BUX/JA
M[4B.L4IPWZ#Y%<C?L>989@*8Y,(?"]ZG!;HYN%Q2\;]EW%ASF)<9OB#98*3%
MY.JD.#9LY/KOVS-BB*>!MU/B^5MR#*C*2!P%9EN$;1 GO1!*)%*'R/FAC94A
MG(88C5>J=#2&-*J3C!Z+\O+1,I<%\0*-[P Q$4Z*-MH8O88U$(XBY-81LD,)
M,X=F*E;UJ#L[NJ?_]>)>4S,@]1*9&=N8BU:9K?? .A9;:9 WGC**CXGWSW=9
M<E,*\*FISBJ,<X=Y^[Q5AKN U7^97!<B,UR5'1L+?ZWZAK4IINK-CA_)&N\B
M@W97)Z5WB'$"T%9X:17X%4RKQX!L.B*H<MJ+L*W@G\?6T(\D$KO$LC3IM>9.
ML63 C,RG>\GD/(%RM4%18K$,61[.0]?FWZVEXM+DVG+^U&_+%N&%IAUI&LJ*
M4P<)-C(J-2Q GX&=S3").++F)9Z.Y=@,HN98N=?IIOS.;]=C)Q\)[$4FU58"
M5WULGH1/11!@]9!CHQRLG:L]3\C="RA3='/?Z'"EU9[S0+LS?O"Q8UR</SWH
M9'[YR(/AC\>#AYB&L0CJ'AGD(NZA*F,3(M]S4G718*C\H^7.2UYU7NNFAZ3G
M:DUC15+H<A]K,8S8K@WG24TU)F/07*D[O$GXP2%NFC^5BR]F@AW/?JRSB%(+
MQT:V.W9+7TAY!]C]8)*(6^>$S [.LH9/<=) K.C&S#DJOV^[>K#WEO?">M+;
M_L@:RA=0A,QB)8@';?X)<K#<IUP'&[AVA./_+/A41GF&2LS>JO/>FPM@$\-_
M!^ #]1>B\9KN  M^]2LUKO_"H)F.7L[.Y $K6:A:PR':,^UY30:57P# ^]HY
MXO$^Y.LDS55M9.%@R.GZ FQF%4&4#?RMZ]TTVKW^7Z$*GD"O9?B:,A&1%E:X
MD/+/':!POT$=E?TQ5 %%9O!E:+A+)+G;D;[$K[TOTE'#FX0<[R)*,^PTY0X0
M:XO1NP.\V!M2Q@@G8!^S9$6X4T531-X!R 2'>K6P??Q!)EBZJ'\[;S#^*-;S
M!8?.U@[42K7D&\T/]8GC[R*ON**MY_[O$^)<9V,CD&9,&!/'W0L\< @<G2M0
M"*]C'%-K2G\C8;&FTL0K!V#D"NSGS'P@<YJ,&5?!:.V%W@'F*&_N #K;W:P-
M8?9$E<X^KOX/+<TW->?UR*.?_APB+PLDH'V,OV>SEHO.QECM1JQ;P*%Q]9C3
M%PM_0A2%M7R<?0.J^?0/Y8;PYW:_H.\ &'>Q:,XKHU"%.T#DA+DZVAJC782'
M/!J2?61_(ZZ,+/__'!G_J($$JX&<'=[!/!XIJ(-;?9BT7LSH%[?H'4DL>6%&
M.*.;K@"/Q(+.S!&A_$B3_H('RZ\JX;,D/V$"1?8NX8MV3FDZC7M"J?*/J'YT
MNP'^YUF'[F3GBJ1+JRR\HZ?% E-F^IK/[S?#/L'WQ$LR0G=*N$&Y&T?F9=R9
M%))NS%H*DXX31!II-IO_!$6XF?NEA+<["R50?]#Z\;Z[<^+X\J,^((0C%U4X
M$+P:CU6%G\K5'2U!RK_\L:.@OO$)\?'FV!&YF1(5WTH)?SI:B?(:A)E\VK%9
MFC)NKRMJZQ1(O:#//ESF$6_^9*R OI3E]YV[;L@[NLT"ZI1A(CE?S=4Y?KG/
MU1JQ*QB@GN!:W=63.D% 1N?;F9.'$8P(;TU]"14,U9X(W:#Y>;3_+IG5&Y-E
M(!O(T1[!Z^_5I]N1H,[HX4*J,/ [\^.3RS0)6K D^;^^(6M9Y,7GGF<X[L56
M!1;)HMB@<_MO#]748B.>1_8_E=]'?3F <EF"I:>%>[1$\N2W2^$QG2$42C_
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M8>(W[R1W8(M#.3VL+XV[B#]7K$B)F-P\D7QMJ[3*=IMG&<\>:*MI:R?PZXK
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M?3M,YOG=47/N#M!L+K+1\0-W'=C /"8%"U7"!.TIDPP56;B%*UE]F'SUV[X
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M 6Y>?-V6? =XM7+A<2[RJZ[ A<X@>5-^HU8\J$+#W^P1H_'K: B@QZ2D8<"
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M@>B=Z;9V"C#JQWH1Y<Z@DF(GRF!@6F@$!1-$QYS',-:AF0O!M(I].=0<>X*
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M(90B]R4CSJ1WM$-EN_><4<&J'W=;*E8XA3,T\Z/HR5,&+TF()56=W-CK?[0
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MG8/\F)=V5,49@ZQ$6AP(P1@ ;C1X#MS?&E^*-/7) <0^4_H'8O>FWWF/F5,
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M6(-T'-N7O@FU/R 6V;AA"&D/M=ZI(\E#UKM_M8C"_3>BNMZ='>?=1OJMB%&
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MR+&?[KSSM4P <Y] ",?5EWHS0"?I<J8C"R'VN\XZG1"Y.:DF!,]R!(5#JG?
M6V-C/O%YST*F#6NV_]QG@ X<[.NC]G9X8HVFI"0+7=$)<;@PY[)GOP]O\=A9
MR6"^J0L7I3W];$#^;?""'42WB<ZINGXT7?SZHY -C=:?ONIO&DS+[5'JSZ\V
MS5)$;2H&*A.*_KHJU>.F]B]E*UVYGK1- ]5*SH8#RUVS(-43G1':H?)Q&CQ?
M/@D1EQGM5=*-OUK]D#A(PW;YZCM.<M[F]Z:Q#&*1J7EJMYHGV:DK=]L@F74
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MZSHJK_<;/F/?4U_:?1LR93QP>+\-M9<*A;7VATL30_"/7Y2:;^.EF6_\4 ^
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MS:3'F$=JHR\9#E\HB$8'0QUCT%<CR]U4[1'E/VW17?LQ=@GV1 M"S$G_%3P
MJ)]IKBH"RJI=\J'+ ]DS #BV.9CVH#G+**TTIU&IEU,PC:DM^B;"=B2I8^;-
M '8 G3'8+8;I+JWX??2>-[\*S&6$'D1YRB5J^Y4I())%%MJT26M&GWI.^;4D
MJ#C4T1WZHGZL"7_;40NDJ7I/5G8IK"A<K/:>_RQ=9C4J/L?VCX82*2# =%@E
MX5*%6!C"OCOB4;&!+38-UZXW%_DJ+H.V'+7!#RD.P9\T?PU9/ V:"R9%+DA/
MJ7?:E1(+T^T*G>R=#:\X?!F/#?25:(RWIRHA>UF]10UYVM8VVTU]P/2LS^D]
M@E45KF7GMPI7<*XN:R%FILQXOR="./PY#[:31WN7WOG9339"HP0N1(DU/Q>6
M6(%/3XH>'WML[FEGXKQL-GE7P*<B[IGGC OWKH/'(3RB/!R:%B&@TM4-=:JW
MZ D!$V.'UXQL'59 UA=RBJ;&.QZQRK187\11H.>@Q6YZ1NEZ^VO2R=.$U'3F
M$,O D__H=NKY2L&O$X(=\VG <8/RJ LHW#GRYAV&=/V#.5!!% JN+L3?/>36
MV/C=W258B-GORZ?31@1'TC.1^)L4UX$U^H&,T#M5QT1XL(K>#5?]IW)F\JF$
M'HET%NH7B2U]*JS5BMZ8N*%[@H6B2& PF1G<<JI">-9.<KJC5[-W]]&WZ[.Q
MY[A=(!W,0%_^:J,E'!PV?#%(=Z9.(AEV>E>@Z=9[E3SPU,:JK$UO]6:[M@H=
M9;!,=W^X=+H4**FV@"H-29[^6*W>&3_^>IR8I&(,V9G?']PP$GTKOK-F924M
MR+=0U/US NA7[0O_F.(%;FBY-\O\0^SOSC#-SW@41'17IJB H7Z!=B\OV'"Y
M>@<R;5XR;6YT)61)E]!VO%( <%W5/@K\>8A+\:FL\N@! -L?Z.)T>P3V7M-&
M$1MTM]>W+7%\9Q JB<05(U\_ =BQ4'C.=RXM7[[!&*5AK05.O&Y (&8KJJ5#
MH%_VY$M0L8WYV[F$8K[)=M4N"1Q%KQK"(%R(*D8VXI:UW+69C76^'+V977%
MM"3KP;G!G:5FKBX9=&PG0>%S!E/8C\7SWYC ZB'VZHK6#[+<4UB4>1?+>]I^
M\G6H)]=#TPT_Q5]+?)#F(GIA)*1!0_D6ABW>)K@E1L[$_F6Y;$_X*O/V;V2I
MTU4MW4_65 D]2WRWGI.;9>DJ"-72B2(K.D[[]'QM3%' _O)O FRPNGY]7S-]
M<IC@W1O)49SGT_.Z$N(Z6&]T_K"_1Z\>(U8!F+<A(DT<L*9$-:X]W'$_ TM=
M>4U"9?F?X5/3337:4=7*+Z92@!G\H$7<01W$XXXYU =EKKQ^@NZ!2IZ9E,LX
M[>S<>0"./MU*Z,BDU@@@ZSCC,O9_YKT'0P7N>9NAV=A.9VA9<DVL$+B(^T-(
MCH$E1!/9&>FQ&CYXU<V_X+[;T1 VQ?R&>HQF:J^HK]AZ97Q<9CM?8I?H;XB_
M5W4P?M#DO33:)P;1]6Y->X$78Q/E+4@G;@UJ7%>K6 .NK%L\JIX++D;=:,OS
MDX80\)7B*JT-!+-*L;[>;H["\ &#L:^] G7'F:=:]%K[>6XJWNSSI<S#I.H2
MV B7%;5+?].Q<==W_;S0YED40MEF!&CC"CA\3A0SHF,=Q5O^[P'0_PTS''$C
M>RN+ULT(H/P)418J^HE"20L(F=P3['BG<K<9BX0':%P#J"@2)<VVGO0X;;'<
M2F)L!JX2O#;D%][.%2S<J@4Z!<V3FG\(>Y7(VR(>VBW'0O-=3 'W$=D+ %L'
MDCRA_774O2S8$P&]/&LNK3YH88JU"L,S(&AJECEIZW_3Z__J)VTY2@ ]?:6^
M> $*9G3Q=/G[<79M0[?)P<XOAE+TEJ0*)[%4\U!P&F)UHP"N&[1A=L(FD#4V
M+]/Y__GODLDYA]E/:H4#7$L24H80IS<->/'1SMTS3P(B?B.&+5?7(ZIN<HF7
MZ@@F&I)9U9OT.EK[44MP[3<^G1VHZZ^/W]R'F>DU-<UCA$4-R7],PZ9RR'QC
MFI;T^HIX<Z?Y3'(Q#)\3!A' \ U8RW[[,'L19Z4#GQ8\!BH?JW')<^6_A;K+
MW1_492K*WG"#T]Y@^*+<I<UJ8#IB(R"VPL?-#<)%:UUEY9X!>!VT!/EW_A0E
MM<MJ*WM=*I>>6'6D383_3-R?B]+Y#8CAE_:+L08^F99YA9B:M-#VQR^IN3[Y
M2G62S'+N-=SH./]E/[X->F9M-N51?KWYHBE5G;P#%;F6?K!(]Y?<XAB:%-]-
MLG1K"D)4B5*NK(-:3.("26/?*([$),LG*[VA6#F"[C/4B;5C*9$R=VGNW:PC
M/.'@>*FT00N3&X761=)YCL VG/\>\[%0HXR]>D(W18/CTOV[D"XR</);[OWA
M+^LC"DKP=>7,2][&X5FB2)ZOF;L 2WW)WYCY]*QB(H%%@O_5>_Z_C4[UX-E(
M_.AN!@AK]_*MJ&N+1:?IW\!V01H =TOR\ , ')I.IL\VU/>;U&\Z_\;HD(T<
MDY$HW.E28LD7=2RML.+FS>P8$]&RZE4A6@JSQP^H-Q0X$X>F NH\L37HPPED
M3Z@W.XDKO:^,S)6C -WA9$4ZXX=OO#'+G[B>80K[\%@\+95__+N AH.RLOM&
M'3V+=#<&G8LG[_TH39S:%TSUONG^Q!.(\27Q<O?__&((:W6C>9!/I4B,G(*X
MG#A]1I0Z=34E[@DFFQXC$3+:S#0?"P%GI_6V_J;,LJA<4,DZUF3+$ETZG2(#
M>]Q<*"1Q2#=YV6PJ*61RBB+/9(RC$Q]I^V:4MF+Z VN(8 EBQ?I5@=^<6"]*
MMTH3\#0'3%34[&1R@CMKJG8UXOK/4@FY4T&\P:M'VDDVZ+R&LB/YQ&^^A2Y+
M[:\B\<)>!KNX]Q4GVDC(#).=9,KD*)"<]^+G@O[YEH!#EV"01_%A^^,?J8S0
M#4?9YFQ4,JDUJ[(&9?HU;>[,9M_*%[DA]1U1>-1@5OKW-*SV@+U22V)UIQ1&
M+\!CW[*P-57 H%BX_8D=P\AW_ G.^I,H%_9&02T,[B!QP _KH6UG%#).$PKZ
M_BN=5_X___C8[_$?OVHS59@*#5*/ATC^=,UO_)/P ]3>71.(G'+4HSCT;3;U
M:0^5.1!N:,K=#S4P$6MT$YEH&Y"9)-G69Z*1?@# FZV(!X*$ENW1/Z+>S$EG
M>IFYB\("@.\#%44Y]79//B>4*>/L-O7V<GN:/ "@'M&W_W249H*V9B\?\5XE
M8CK-CV@-.G#SLN:,)J5A=&M?9D_%BV/D^8P?DGTU:N#O=#YK"=.?'V6NA#6N
M\L>^R0S6Q@$(SO5ANE<.*R8:@!W!85+EB4O@K-3U(R"("6IBK1'';/$DOC!#
M&YP%__AM&MGP3&R:@ _ YHR;VWK74/,^\5(=G5AV]-Q<BGU+506&O)]+TG.R
MR;XRRW*>9F=\37ID97Y7A"K$TE;=OLI_T1US7I4=QSS%8\6F6?NT0Z8Q;/OX
M=$E=R'[ZT:.-JF<#EV_0%>UY.S=.)AW-VM'YNJ%[\2-E@UGQOB=XW")O%#&\
MOE2J%?H:@K!&K)I;(1;?'#V<4'/H;[ (8Y[2/Q2[UE-\M[[1-1FJ5JB:G9M!
M4K[[_*J 7/Q_6(B=9AT"# #EDC$HBN3AZ5&.Y\-EJNNGG3)]_1"7C?4)1A0^
M29VZ@KCJ=[72P4S8'01FWLL[?.#JRU$R*-3C::[^ZHC[_<<O512_8V2.1;ES
MO VM(,$-=5\1\QSS"R8_TR>Q03;D5J]J*.@I81,;W%_Q^J&>FL>5!;QD\Z4:
M@FJO[M*] GD? %J+]ABRNN ?JZZF?R.&!I&/Z8M.&8I:(U]I]D>OJ+')A&AL
M=LXRL91'!KMEDS.Y]#I;TW4L>F=GKQ$(07_7U8QE"0[F;J?\VFJ4&>K,WOG
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M@'B&U,SY_MDB#SHOB:WDR3?O^DP+I.8FK5"E1'*HF.4I9%IK"/!EN0=V'^>
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MV]K:'@::\% 8S%#F_50;&C0G_5_ZQUSE;2VST&6E&Y/E 8\P)OS^-58+^'A
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M'0BJO"L(>HKM7GN+;4)8.0U.X'F"79%N^,=T#5!?@][T/:3:L[%NN5"G#6:
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ME_I#+.3OVU=1[_8T.3;7?*H_>*<8->#Z?%[JDM]!Y(>6+TIE7T-DB[KVXJB
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MC^CDX8?*# NW>JS3^1\YK22 /QPU&M^WGJQPO2,<^+3**MB*X1MBCVB'G3X
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MIV/*6%]P(GHCQ[WO :#N?.6.3UG_FS3P=X_8J!R[A57G/^B?K\RG\P,LN(/
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M!:VV7>1S12)?8?%?CH0Y-U\:OY9BQV-A_C[^C8&N[+VHO)Q2RQ6#;3W>;T:
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MN=I<.U YK)@'(:E,CICS]IZA.AU;8E9QNQWK<-5Y'1%+ISC;N$1 ]C"E>2P
MO!^XMKAL:SCI)C7HDZR@A<V*$779GBK-EN-NTX#)K+5#ZX2_DNDLF136..-4
M!L#1MY1)Z-,:IAUSY\7EH"2P\@95NK^ ,O(/M)SN#K#\(<"$KQ.V$AVR#F2
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MO_9][766&B(LU>EXN ^55F^ 9;!@/%+LIWG5\FROK.?2F!#>TS$)VS6X9OT
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M7[9WQ/!6RB1W@(B6=K$[ +G^%^G3B%\N>L,7G\69OUFP[FSFW@$.CJ=:G.X
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M5R5UQ@\TGF15!O1072P\_+2#6VO.9U%$]MWLDI8=R.N95FX](S'I3(IR,04
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M5,.T)4>:V_]TM4&TSO@DXU_Q6+@0P3Z3;\#L+*_SG']\\!^,O(&<J%#?+@:
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M[4FS2LND2*5;JWG9-JW:B\P]!K,UD0L;*6Y+O_N',SS,>519AE%4GD*)$D)
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M;HG#&CV";Q=1.JMPOM +;>^YY3D5*X7C >B=O1L #7WWJP.#0:2T59Q1=<B
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MX-+E.D^ 6YY3V2!?2C6SI1;=_3[-;CGET:#0E'W!S>-X^.WOE3L D-] RQO
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M?))/'*Q(!'$W:KLL<:OOH.OX)#6F835[$JCZ=[)/ JF8>"[NTL2OT\*N.91
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M*,4=%<A.0V55@]F[S%M]%?>D_M^B=L[:OC"7%N==<NE](+(#!!)'57$Y6],
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M<@-21.;_:??L&]4J5PSU1T+L7GW>J<&;;HH?]L2)!'QZT*^!_3>"4(R4GKD
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MF>\J*^+I^/TBQQ&%/<XL3A5Z8ELUHBZ70MM%ONL,_ ZTD#&C ?>9[=$0CZ+
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MOLN_=7C$Q5@Q4]^.P@&?H@TSM&?_/FO;:^^1UMUFA:&S) G)-[R091S C+?
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M.H8Q(Q2K-!71=R@SJP? QU!P"7A^84'85'1&V_LR_>?!J.CW8PTU\_@D5G:
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M3T7Q[ *?.DY/GX%%9A8_2Y(6953>+RS=NSZZDIMMDO \6E1CPO9\_<WQZP=
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M)IA$RY,<KG=KC>[8@A'?@J%:U0L9&HTS[,AK8[1_?D+2IZ=_MGN\E<3'98H
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M20-</%.WF$;E@C7,^ 6C\6DB2140 -D-1[EM85=NKW%UO]B*,QMT%@5ZN/J
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M.\37YUA8:2?GC?2Z@ IS7ME.08'MB>NT'-(UAR^K[;&(33SZ KEZ-N@@_0\
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MWE&@-O&^KZ!5GUOIBA+5[82';PSYQSQ5@'33/6LG0/TPMJ<.K;G92D0\H=*
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MUOI*7<\CPCOT1@MV8"YK9"PLILS=9*2MQD:YU[P2MMM!RK&"N=?^._#^N+!
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M>-2X'2.:Y(2T@[HUWSR8$5-2][XLO:X?X4ZE*ZL/\BGA?CY57V!:L&&HR.4
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M9A3S*=]WW=_S^WRA!V*%D\,VU)92XJXO(0A\UV">44'T_I3<;/'G_-T$\[<
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MEL-+\UAXJ?">$AH6]MVPS_JW^H\T6HENZ[>$2R@*-*8@4DX,-M6>4.G(XU=
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M]1:@U]KZ1?KSV>NK5R,R^%IB(TUS:@C0KXW+A9!UKJ@P)JP?ND8LKMVJ&HI
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MJCYM9/=;JY\\^(J@7I@UIO!@2/H6\*&0,HQU=^%\7ID1O7+^1;2"?! &/?0
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M/<X4+OU/JND+=>W <[2MX"6-+@\SPEN>$6\0?&S9WW:=&%67:\'HQP,X;'W
M5TW2J%BG<^1B9)@#_8Y4(=-YN\Z34D>+L2K)+16;H8)C(!W_$)&LJZHK-6;/
M$V_S?4OFV91>S*#4^M7AVH'H8'M% ":W\IQ]RM_(R(D)5G,.PE<:&$R*)NW\
M:6X28[;D"__!5"II[>%_GT\90Z1&&YKB&)-"I6Q)WH\0IAB=6-#=@NM'AK;>
M[M*MR.=TI0\L%':!;V[.@_4/+P#).;4]$$ZR)9[^U7@?-B?*CBCR!5:\Y:?@
M5_LD?0 F0N*LV\_TCJ1>X.NU(CIOAY7 RZV)1D6B<5(2BS93/A*>HQ+O8R%/
M'C]*Y-T7FOT ?D+4Y)5 ['@2*9^.RRW2SY(@J!VBS%;?U#F3B]6Y75&$Z_5L
MRYY,T&\V)V.%(^7C:@CI&A': ^$ZO_H _T^N30-,Y$-!NM@BYU2M;^1F6SB8
MI7)AGS@(,:Q=:9W"0[:K+[WL.*8*7J(Y!=(2C9<@0WR7#4'K:<:&OKR-TK&O
MD,G*%H)E$+R]=.+2,O6HAJ-&-/9O-V+F H!2YR/*!%C],?3V]67ZY.B"A<:)
M8'^WRE((T.EP#=VA7 YCA._A$Q>_4T640N90PI-3/:I*XE6W)TL.J@?<6 ((
M<TU<%N3.;_>-C+VH]8\&'8[Q1-$8LC#,KFPCE'.4[',N,=$JK=:75_HK0QSH
M8+QOY#2S>G,VA<UOS=LYP@:#.&6O2E_*PXD2%XK\<ZW@WQ9[L$X5:<9OG59>
M@'9@/WA_^+]?&1:DI*QRFKH V)\:/O;EV9'MXVC6B /V3BV(UTQ&)<HF*+8\
MX,6LBOX:X#)9I!;@GZ"**0H=[N# DS8(0:AS>0.3$O4\U@1/-Z&%FD'>)-X(
MZZ2!IANFR<_>0GC(HF<%P38.RQ> Q':1NHE<XM706V/R$":2\^.VEE?)U\8E
M%^;SL(6?R3^C"0 N&D;YX_.X);$V#EPLH91X;7*>-/ZG7N7/2)^HJXU%P,K-
M>Q[7ZL*I'Z0NM$([<VIB(LYY-L,8D&H4O<EEN(2 '5^>7J3-R:%7I_W[%P=]
M7M:"Q9Z:7(H7@ ;V(O\"TK!9#9C>!:N=4N(B8[G)?[LUX\ZKUHXX9WCF@([#
M=]$7]R)[?RAMO8!%=;@TDA:KR;231Q*22D>RRVH0K8##$#.<^)>E>C^6?+O@
M/[ZS4>_I'*>"\LZ[ W6B0QD?+PU*]39_:B]SQNN23>SP7!++:="@TG!=MGQ[
MLT>Z?9V%I\0Q)(CME-<:#C8A%.=Y+M.>V9YJ$6V+\.CL(-WW\W.V#QU2..]V
MAUO4"/CWW:%GI"&8[VCA@>\@WTLBCF*/<N@7H8'OFN?GNTF-)DT<YI$\3;H6
MCSR;[-^8>W]Z_D\GE*4WK'XMJ5XJ_ER0E(([DUQ\3M@&,M1+W5Q8QQ87"(4Y
M-F2X<IMXQ!=9.>2TOE%_,/S MEQTFP/FBD/0NV8H(H[4^ _TQXX,:?#GJM>%
MH0.T&PNN]G=FF&I<&7B]XYUC.U[&^G;!H(P]:M:&8T6$H2\X0[-?"[]8S@J<
M7/2Z[/62<M3,2]2\-5T"S'N'8V4-2LDO4K72GXY]):UUU?9[-1<.'W_VH)-\
MIHUFNFN&NOUF?DL#7YT$,G?'(3BD(I<5O$3[NHH7>':\5MK'%IM<GGF>_K#5
M1O65T'R3SGZ[?@%@#45S@^.D6NW>M NTU"%ZK(X3*C\[-&A;.Q2_8^IN I5?
MY1)-V3,D:FP'N%:3P'TJSQL3I.IG=_S['/HPV(]^M2T6-@@I^ZNBS +[I\O*
MQ[D,87CJ'=-EJ9C M7B01 BN[1Z8_6$[/S?KS;F?(Q"]4L,_1C<$I)GTJR@H
M4Q+Q;5K'D:2V\N"[A+\Q=B,^ S8.O:$BF,I#^GL+^][T-=G&OQT_A0O=+O1
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M,*R14!\8FG 64;;Y]X3]Z_O%%K<4\.LJLZ!8/W<+)Y=Y<SI=M!JT9DS#09B
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MIB>#8SMO.<E ,UM5S=!G17;NL=?H9[M7#V0?;<J\N*L:Z*SVV-NJ<5O/,X@
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ME^+9M.7^L(KY-6[=$-V-"=N1:[@ F,T6/KSE55C.^H)-J3-7#F0"LEN>'4X
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MX6)CL%3\T2?!4.T"@).:\+$)TS9T6\5P(6EO?;A:$[X*E)(IVVJAT9:!SE\
MW,_$^@(1$2!E3]RT_+P!*LWJ^QP\\PFAK;]Q8K?BBN+-&E1P9?2]$B&'<4%P
M=]AWJE2< BD %'JKHZ6#T- 8@N=I&8A]WUX9X)=8!_J,H_Y]GT.)AKK-/XQ+
MG6T+R'PX>-<'R =5OSKI,U"-?!!4].Z#LM[3(I$H4LI](PI!Z@P Z?@O&GLV
MN+@]P]@-8YF#=Z#\ ]M.=*02Y/4*FC,VE9RDH' VV0;._MDL=&"5%P-TJOBL
M"O0DAV5&D-#^WQJ: S$?3F5HNE-YEG>6.PU6>MP(>R^LJK*[E#&*.!9!C@5+
M++78,*)5&C[A-1B@C:&WPFXBZV4-@KQ]*AH?+[^^O6<FX* :LO7@ N#0I@Z)
M[R!\J$[P?4QH(C+#V\B"*SK'?I.CFAS\L,79']32A_-#GKT4>7T=.Q1$*7P,
M"A+'+S1.EG(H(H-4I&+MQXX&W(VKBMSEOWKU?>AGGV.4>63?<D.L410)_^]H
M#_4F(NVQ"-$12S\=HT\8+([([RU['" >F+2#@SKX.8I^C$V_PR/4\3O0?/1$
M=-MO 0AFVS +NWFT'LQ5/K.).0[E>H;8/I9QHVC]1QNR$5G'_OBUN]"^%U1F
MZYAU=+8[6X!PEA,ON2TN/RCX>'R/64R),+XQ5"09N4;QY]$SNYVOJ9HN]D#L
M'EKEU9<JDM=I=X9@L%XC,:KDG;A$)>R/"K3?FSK[0[^@P)O2B$8[+UW."IYA
MQ'_KQA">8!;N>GK</%B?N%J=1T(8C>_.[(ADC'4[SY5$$E-BC%&([C;3WH[:
MG9@X))#+K09>;C*&;(/V^-G>&3^B=1&4*+*U?GCKX3=XBO[NS]?.ZA-PYV/5
M<9":5,3N*E'BO*1L75V@@RB9%^1-0S6Y)W4+7NP*P,NC"!Q* )I+.I6#8&&]
MY_=(94L:L>U"XR_'0#=!=_&(FZY8C_12/?%T=LRO7)[87U',.P^?)2;J3;^U
M"I0BLXI9MY*"EN>-; 11YLV[";A3"/-T5Z';TQ?6L4X_=&TQ*_%W]? R(CM-
MIBUO>P,5(SOLU#2Z3]H^;/(K3+8^P"6IZD_6B]%3;6+O+#?6=EP K#D^=\@R
MI1[P3W-RKDZ6;$/>7 !N@)XO\5GCU<LJ7)N14>WI3D(93A6&);,H =_3<"Y'
MU6>R=73A2C]SY?X++8OU>[V0:!FXJ-[4(?#:.G8X]D_S%]@1O15>341I?&#?
M/71TA?>%7AOB]Y7@MH"JK6/\5*M!;N@O?M6)5E6063IQHV?.1L>+J'>5.LZ6
MW215@'J%UUD-:KJ\M[T61D0_KAN)288%:^"67V%4TKZPY\!\^;8=JX?HWDKK
M7\'9!#HNF=L0>99VOQ!9EH9J"0M!F0EJHL9C'=^C>IR#1P4TO\UHP)-R#S#A
M(!;;L_QV49*B+J$ZRJ>#!A[TC%C4\6Z5:%;'L_FT\JO?_8:?RU'''@&%E*1P
MP)%HI6\8__D]C<0+@!V"F72*:E0,!!\W1J4_17ZX\<2[4_C9:RK>2$JF%&-X
MXS%HHM6R"!YH1LJKF"95#3S^05@MPM-".2DW WT&F_*D0Z9_70;3*MU^49$V
MGCX@A5P8$QG00C*P\U9(RE-/SA!GZ<G7$XAB>V[$0*%D\F^$>OA^Z(RM,,EA
M28-]HUV<<)Q"'1>L <NC5]P^240XRUG%SM#.Z?_B"OZ>/':3D<8SNP1[*8V&
M$?O!@82&%OD_@6Z;)PSE(I_\%1+>C$_/VST?"_)_R5D@QL!YA0;IV;!8<Y:T
M%D6V<<8S\K@U_XV51X]S+T(^8#B+Q_NRM2RO)FGW3<](M.S]66U#X#A0@P8X
M=#00/$DVU$CPO5MEN^JN'W1'0O8K((Y7G\V8HE,H&ZP& )#/VTCS>.$/I]VQ
MV1('B+Y]CIY;BZ<@ZY":DNG6G7]#&BMI"OBVK8=GS3R6I//VFZ?\B>T\S43A
MX2CW'O\A;+T_$]6535V%'?:]VQ^?\KSY*>1M\_L"4+N0HQB]*X<@Z56S"5\R
M)5FT'3:3*J:8N1J2P]4W--M\:I;^[G+LXTLY"=PQ<8<(+H@UW.W4] >FF% ]
M+9$ATIH%_APZ\NRGH+A_;-_]Z2XT*U7,8 Y]APN0WW7Q"D@4%\;P@*$%'P(#
M$XU:PKY!K1)K00II4U-,JXH4<1]K*;SWDPIR-PZ!W</QTF39LUB0XO*\X]RF
M@S[AG<JGOG^TAEX#UU^SO\[Z/?WG9+4)<Q;U\CL!_>YPG@.-K8HK=?'#-F2)
ME,$NU>Q\6I[JH-PUGENZSK@^,)^:FK<^B:7 FDS10 *7@17*\HICY91+7@JF
M6;2V91)DV%J2?P@84P\W5^_D+%\ KL&ET!+X:FJ7A@7)T7H;J9Y 7^0G\@>K
M%S,+\T(\0EYY:;HSL4K7]/YXV@Z<JI-?$G5ZU*!XZAB00Z%K,S@V6+A,R_7^
MZ&XV'FNQVFBY?"OK>2-@%LSY$_^#\]+!76"M7/@=L1Y^C<E6K4KH,7?H^XSY
MP0K=8S]V[\*1[I0R;,_WX"$CBZ]$VW["90*^UA$>'$2D[2%LFMH:+-.V6#>Y
M%R8]=T]4V+K^7&#E.P=HA#J2+$(*8NS-B;M,$:^M,&UXW<G@1SY*U]+JY,2@
MKT>LC8(_4;]V;P5^IEM*66AET1V3IV<\YB(5+*^#K/$M"";U(N]"H4;NB;'K
MN+?/GFEQBJZ$%+B^#.@_JJX.I24K$-&HO20--AAL6RZ=@(A'IF$J8?CV5RTZ
M-U',?2/;G5<%^69_',H_[W"D!YT/90N2]-N%6ZW5G$U^3%@_8^]?[1F;#REP
M>;(4#N^7H]@W:EH&,KE< *@N "YJMZ<LB(@8\7KTB-/8H0;K8M.4'%'^MX'<
MPDNA6,?^YRC^!T-BDSXYC(L;MJ*D&4+@:6^V"*95NH#D-=YKI38_5"[0\3WE
MP\,1GH\H&=CCU_R+28':9:<WN_#@Z_#=X1YU=0QRCY74KLH#[6":G^WFIPVR
MQ+CDQ[-U7YMC"%B3#V6<&;8A.2]!^&U(0<9AL3G,(!MF["8W.MZC-Q?^4$Z_
M?*7@ZC,S(0'>[$+/<(:.XP>3,/GJF1A<U'F!O_S1T5 $5&Y*D9E+*.678YVT
MT(>0K5\='EF"3X+45+9)U7TF\*'],7?5[FQ60M'!PZGF9'_AKD=<+[_PS"2/
MM).J,I<4N\! ,JB#Y.14OO402 ^'= GJM8R_KJ;5\B[[EQL0I9#TJY8R>CEU
M#*DN>?X[H[$'DJ#BCS@$QV)+WLI#^83K8\U^==.&U]9'ZW%RJ;"K>D>,!H[P
M@7-:_8M)4WCS1#(8E\,*'[8:E0?'A-%M(WU"&,BS0MB!PFKAWU$:&( =[5NT
M>! &TNMN=8KW[QZ.SA8=)]LMWU67)U6CTF3@ERA_C1B/%2OJRCBQ^ BH^4J^
MI! I3OZ%,Z+@L4H._MI\<A&P)\G_T92DW#7"5"Q23!7NOY6F^2?&M,>+>?B@
M6K/'OAR:4YMUR _B%R* >P8=.J,E:(91#<<-9C=?7)>00/^,W_<><$)0"HU0
MQY*]5:K?A2J3<GHZF.7VXDSA(D/CCV8J2:;&4!N9B=CCN8';5#P1'ZL>)BXI
M!,:?:G4V_TU$(CC@2/E!%G -H4+&.H?132$]^W4CH3ZHT-4!?8D*#E/J,]52
MI)S3.UL0=E^]'61' O_MU"YS_(1;-H<!_*JYK>Z3;[^HUB=G%.]S]8MF'$E1
MDM4F@F_A%]G=TOG%)GRS9"T^S%?X6']\ "L4\MR6[M814KRZ-N+?+\#7QFJB
M&?E_L!WIJ@!__=/1_\<M*M=9::S^YX].]%,9__.9\0IIB]C1AV7L2:+&#:/4
MJ TPP39AQ7-0?YDM[U:SAN.4^YKJ1@8M604UFVZ0J$7DWCN0YQ*$;O.D%9$+
MY:Y*"*LP+&J%W8U4O4%GWJ%2=5W'-&(R^KY8-HF(@P'A4LO#,:'B)(YN]^7W
MS=>&8^3IN6E+=U8U]^/LOEC^O*9%=W^36A[/H5$'Z66,#F4G!3:'187A)"<1
M4<%Z!6XC&U.UCQK\,PK[WO06"LBY6!2;*XN-9U"%// ^A9 E&S'!RH47 -B@
M9!Z>1U5-RRB23P6O)=\VP!:MA608T5WSD^[SM)'J[4#8TI& [!_.[T_\&;\
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MZ@!UJCMYW_Z)6V;IJ>-<M_JW(0'&MF4@Y3YA.5[K6079P;3KV*FFR-;6;FE
MQ+-6YC=/O31"+>W;N>Z;0ZI[0]V0,(1B[:R.S&/8<@\IVSZ.:&O>/%TM6;>7
M0I+O:Z\YB;Y[_8=6"]^]X8Q]K3&+/!3UW#(6;X8 NNDHH)V2]ZV)[(=O%'"_
M'.MKDEY6?M'N.:^\WDD99_+%>2[H8_E?:4$^DCTMB9J8K:/0A;DG R<HKV&1
MK7!*)4ZI^*UXAIY4"KWJJ58@M9 =2RF@";@+9N;[$6/%OA%4M2K'5SGZ%>Z9
MI*N@"^GI[R5&V7X%*CWY-SA6HS-?Y9S0-V22$#)>(GTT(5=#\[91\^#.BE)J
MTVZ(U;F/<";R< E9PF3RXCC%0"%%K1H7I.@72O\DOM<I<^OYK#I7)T&,O;CV
MG7;0@_?W^+2/'Y[4_&$^S4S5##"67ISP"&N_QK5I[@?1F*"[=7>_DFXG?L+/
M?7O\[B\@[)P-_@\$@\+^<T)]M0N?F&3RJL5$?DM+BP5#@;HI0H'-W.KEH-*U
MGG,7T.%P.;(ID1];FD #..?>]V1ZLG7>-8_9DV5;UC.0)5<A,%/:]<4P_,NG
MI$,EGVNRJ62#8P786)]0\6Q*)=F]ORE03.@SNF!2M:R!+&S\K@J7?6.@HTH]
M.L-Q^+>$>^)[$N!0<^R4E/8MW6@D5"[WH<Z[9O%9Y4E.^>7,-^2P?LET^3U[
M*\XC ."H\U@0)".1)EL/P41V-RU=FVV7>%9F*AVO0E:4LI4MOXF?_%49KBQW
MO_7LZS(1O#0Z>T^5++L*(M]#UJF%^:D+-46IGG#LVS1P#>48/[7DOJ[Y><&7
M(IF^H+I&925+$./W5Q&1%>0Z(R)'H6_)$UB<XL'PB8=FDHY_2U,JE#VW<Z>W
M[<[%WF3OO'< ,>R*^ *X%T+X1!7>SM.:OC2I98##7_>_6.K:F/XCUL%5S?,B
M;[RAP*?=EV? O_!+VL3?283AWD/["VBG;':U^5312GQ1\^NZSX]81=R^]]?0
MAR]U\J-6 @? K' %LJ([UI/!/=NJ'P_L^^Q:V-_J40,5[2@/+?3+#"34<<IW
M,E*J?GN=#=4\?K0AIH6F<L_;DI6/#5?O)3RJ15G6CWL:9.#Q$37'M]7VKPN+
M=CX12:837 OCOW=22^7>1  GX&;>."L[1:O6YL\-\\^\IH3?\OM]KM=C+:P^
MM*;_<E"IJ8@IQ1;3 ,E^*<P#."F[P(?Q3$T1MJX6]"/G,V7LOD69O..X?5<_
MQ*G3F:Q^K V_-=YN0%@ZMB ,?G@&+:$8HE47BJ<;F*M^7ZAMKN7LD:R-UG'(
M_&LB*!D!KK2=1CI!>$!XZ2I1L"Y1K0X+=1\@+<DVS-1W!+/::4P]-]I_8EO[
M3LQE28N]*^A.8J(/W4%U/PV08"]*UON@5TY."_E8*?W>]G9CP .[+WN\3MW&
M&3F_3T%6Q+\J>)B41X9^G&O =\5=RAR'^8!YXV8%U=1RA-^DW0O8>S0XB8*)
ML%F)'MN2(4.=$BD]3+T!&%)I_L+6_<:.8IB[I9W:T9K:JXJS3G)=EXSUE7Z^
M",9U^K2?O-&Y_ 1^AJS_87XCR;FZ(A@5K67&_6-PTM8UL&G)=[A=3=@E45U0
M&GD'<#1[B@'E9.]B<DP?1G6M0;MXMDVTJ-$'7/I#DN%)&'1F[4J-X-ZU"KTQ
M!I;]NN.[Y.2Q_FS[-\MS0OE=Y!SU2!M3WN8'SNXB.A[S].&M*U[G(.EYRO86
MQ[?A;.2Z5?&$[#=JV6H=E>1GJDF,^WHA\FXW5'*$A8,NJ7,.NXRJ?Q,TI8_P
M4@("Q-*65XQ2N =)_$-]>ZPN5-5EV(=B98.H*?L9"X7K;1^>)76%)+^AVT$O
M-Z1$*( 352J!]]R[N#<T[$@%V:&_BDCE_B1'!^G,WV'&O&$,)=[OT;F;-$"3
M87H5=01QD8A(4DTN7%VD[PLX&OQ0:,(SKEO[C8<KJEOI=M7CP"L2LHG[V43D
M.0H=>>0C><5-Y^JXEA&RW!86TG\$)=5\<D^UP]@_^=%O4#V'77[K\*S!.TJ0
M_@)TA)Z$)->L@J*7+D8<=C_8T$C.(%2ANQLM?>T7OASE3OXP4#81M,1\Y-."
M]XLTRM!OUQV#84 #(CB&<K&2',$*X74+("5",P79+$PUZ'E\C.F,,?JY\3OG
M5D4-@W?C4+SM($)*W\2VCD3VEO!-:5N7@=PWZ/M:K[AX).^,3)B,7A^ >^*0
M\Y$#Z"YA58/I=G6<G7LO5;IMPI_;O]"=\'A^7KOB6A'*/:G'V27O_ 1^U)#1
M(*04[XE%B9/CAWK,L *JB_J&C3/O#O"*?38%FTV']P3>/;]RW;&WHOAQ-#9U
M6U>@4^NDN5TJG[R*%<U+#>4HQE8+2J*MA-X$9'&U!ZQH>?UU*S_,]I_KW@LW
MN>!?[46P&O!DA^O/M(-+7#1B.SL(LP5^E?=!5Z:^M-!+*74S'B4FRZXNQX 8
M$=+PZP3DSB:"RMPVTZ#(O-4ZN=7Z4/UST'CQVI_D^SL+CW6AW_7&FE0/FOHZ
MG/MM&IM6C56[F*2C=G8.G&+,.DQC?VG4TS$J&%N\D2X1SEO\2,]*%4K'?J[G
M!^*DDLP:RP-K\,56G)O?+?]D+* 67\.VYO[Z6OKM8DRQI++09XX<+;6_CQ_&
M&#9%N[LZ.+=F3ML9OKUZO95+6#K9^ST1<A%N<Y*D<P&6@%/O%S4UC'?\W$;D
MK0_6+)KX:*=\[^NL5Q&!_L87">GAOWHC?J#ZTIW*U6I.BBTQ*X["#55:Z,,>
M0ZWTSM^-Y8>\*JZ-8NMCVJE9E4Y!5;G0;Y1#,,/8T-%8?W^B@"F]H^-'N5J;
MNSGXW[^S9Y=T67Y&OWL<6I,>/@)U1_+[X8VP8RD'NVQN:BG>6"2>]6:5*G,Q
MW_B2S8=]/K-"WTO7^GA&O;Q'X//$0)+F+%S_(UQVTB_!,O1,7V_:1NNV_M7!
MN[.?ZS%!-R^DDAKEAWS3!]S)K#T0'LI- J-GC%!*A,W^/31%M,+-9K"#M!')
M[K-9[%G[=O^KPX6_^TU[^1Q4T"F36'_EAV1;@*'[29E+$M,J4,U'+=31VM80
M/=%)2KHLC^8E^;PG$72"VW;+%!7U\/:UV&VF40A7"O-;Q(@"#8!7:GMU,6!=
MV&>!^ION9G6JENVQ*L5XNIU[5588R68JOWC8B^* (99 ];?8LDB3O_/.!S[E
M%?E)*:U1W<B$U'4EVI)JFV8E:\_#Z' )_;6+<0_?S%J94\?F^&]^81I93.0"
MJ]#M4/E/RJ@"L+['1,9W);!/&-LDCJ60MA;)I-57/:S0;.LB1]:K$E[?7X6Y
M?]>11RSI<(WKL"["QGI\<^U7W#*S7Y@@2^UNO<O(>/=%IBA%VK>,B3V,[NM
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M=L+;>C1%WY_;#2,UW>FP28H-WQ50<69S^!$FAE(SLR8?'^M2] B! QVL/<O
M/YX<VZQ!V+9J3C.%)AAI98@A_$YAU<,7UWHDQ*."E@?%Y[=QAWC@JIG6=J"E
M/9>=9O<#UT.KS(#-0->@CTLB=K:]5<>IMPJ *GLW!MT3R>G'<O#;Y.U"&-LI
M_VH20M24P)5;)S&^P?'R#6]_I7PUFJ,!-+Y\[#YX M**!QQT,5)_N..6X\49
M_P2IP/RZ@)1;A)_9K[.#SF7/$NT-K)N\BL_%A=WX*N7>>I)V*JL64!BP/K&J
MEJ0V:X/(PFDF*9I?XY-7_53D*9+F3(Z%O_>VYR0:D;R(Z$%9;2Y3\+GJB&IY
MJJB>Z\O&/7VAS>!V];)+?7Q#FD99:WM*:HW*V7\4(Y?.$8=V#J035/Y9=ZY-
MG9PX2!$WX&UW#^4Y@S;F4QL_^?PBMUOEKIJ(FH\+_1;FRB>3;?-\O?^3A=UG
MGF?&RP *XF7HKLF(_"_>U?S?6<XE3H2YNN0S#%BTCN\H-LAJ'N<(NR<LR-,
MCLV9%R;UV@'' HE5NCU#%@.0@C!NGM,N I)='/+XXV];)4V7R[)% !F$2O,W
MA *C57+L%$UJFJ;\%AYR]KBZ"B3+O$&R?%QA&3^M=R81>,?F=%S:,@/R/("W
MA?23IW;N_G,MGZ'[3R%/_;TS#BI/3\=\+BS$(MS4 '"9J5A [,WIY>>)3O_S
MUNO_7/V/ZF^>!O]S9_BFP3^V>/ZC6O@_1T6\_0]#3X/_-PL,_U1UFC)G/?TH
M]3_-/?V/[W@L_A\NC^P>/*B?\%OHN$5=D]44-LX.^BWME3H@%/'X70H <$[R
MR"HG!9.S0J0!LE%818I(#PTP<(^IS,+>E@9@-R6$4..1K[H(ODPT *\1156Q
M9_?H"I6+!NCY+DYY! C.X/W519CN8NK:*"6;T@!,UY#$A\B^^Q0Q&J#@O\W]
MM[G_-O??YO[;W/^+YA[-P91QXM$Z$M;@$"P4:4[D?<_UE^N':Y:)AN1;]OK:
M-+H^^I1@P,;'_X)=7_?!&,^4^39<XPT0(6ZKZ\A(_B%9CS#5RP\YU\ZKLL0[
M(95IQC60NVS^*O/RXCE)_,^9+HPOU:P)UW42'UQ-31VV!3&"?J:0A:G=EN)'
M8%& #0T09;LR=L3CITCATZ,!^B=H ):F'M0?F0T(62Z2!HBK*G@G62:DK'SV
MD:#D>X ,??:_K5$M0U3$QV#KJA9AR&Z-RPU$TWZUD5]C3-'R_9FS(YORPYQ<
M5 :46XF.-'6"?\M#GLJZ,7M-S'+I>, BJ#]DYQ9=/M#AWS?"ET.J)$J'*=$
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M8\-M'B'WF):XW/GXB.=>=#09)WOAKX9Y>06-E=$3RY7 (N<%'5,=8GWLDGF
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MX4CIPV OQ;C;,N1U,[=N]__1]M$8,[F2KZR@$W83S#Y8OCQ =FQ</[R%7XF
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MT+2LLF67SVE+AM][I5$]B5%ZQCKCLJ0?,2I$[W<O3$@P&0^Q3<OPQCM]F$K
M?D6UJREN8!>Y].4M1(*?T#.?Z?VI)<0?&!(X3-49>#&6:%2(&)ML]-W+#5".
MPH%CF:0R13=-)G&372EK<]TP78O7OK8O$NK+^_<&ZL<WU>T)5(:5D]+5Z2CL
M;IBVND*C5/-[J&?/UY#\>R&SR8.G)=;S\%L=FM#8]4,JH\,;EG%KA$]N4UZV
M[Q]!0SP[(_1-YCR[I)OP/SILSS;6-_QZC:4.#C<M^37E*Z5?"N73ZY65&G?T
M*,C6%+3 $%*OY68!X2Q3W##P0CKER+=Z5$DB0!R9 BL5#EOJ%PI[NQF_6 X!
ME'!L, <BU:*4E0G^>4O]E#W0YI&+N1Q<9OW\:UW8NNQ,59-R5Y]0+8U(>:#9
MPH%1I&+9Z763AK'J=2C?J^M+&V;OV[AUZK.<[>1Z#P<B*,1'BS4[4/1]%%<P
MC-G#KPP.[W7?LT&[S37]\9?:%VUSDZ'@[%OZ9;"%S@4FGRW6?-::J=CF0%\W
MY:W.*4[E=]2[?,9MTO8_\[?]91/T0/%'([9'AX^MK/7=\$[Z8_"L."B:C<^O
MNFG2<<QM\X$-9#FLWUO0PFR9GI'1_-R6[1:.*13,I&[F_A0J2#N\JV)?W]"D
MMUF:HFU1SJW1&<*RGW^/3O"+MR5""K#':@JZ* ?:13>K%D(#?5.I:FM::RWL
M(\*>45[FA^<G%5! J("%DK5L,@!5,?/M(&&%*'R1$\&._U97@TZ_[R(Q6&4U
M2T,CEOSD]K6!E[6[?4J3HHV"!7GP^P3;"MR1SA@NM('@GL7XM+$I)V62^B'+
MU3WXHJ1QJ?=Y8VJI)G&5BLH'@/9B??74V%0[YOKG9K]*I?IJ(\F"RH'W2]R=
M3FD[&P:>^-2V#%NAB9H^N%0^I/+M#-^EPQ_.V;Z?1-V<YRI3J#] <D"!QE0?
M6U4F=I""SJBJ8U"4[S&(19\IW$-=U1]2X.GV5I'<Y@J#VND(L31N@8^"%E=2
M^[1N>EKKAL OP]7-\/;=)/EQ<<*%-4M$:$&^,73T<K'SOHEZ<H>WU+M[XI'?
M%3W.ZB"L%V,/91%#8/JQ#B\@&$Z%W1T1;;2:&NM&@5.<;E7KUW'/5=M#7OJ4
M654\R:9O(>ADX?2;)?+U*UPJ2TT#XRQT5[3>RH;R\;OQT!W-$F)!Q'U\8?;M
M/5U"9$N 6EO9O.MC2Z5==(R[4T-]+0DS+9S.JE7;3<[P9#F@=U#BVU!88_X[
M(AA8*G0Y:/E:@BVCNCM16LUW&%=8GRPU.6+=F2HGN<X?OU:JKU'5%216]WT5
M_W%0P(1;G1(+W)]@ZV_5^RY"OGPQ1KFOY]/%D-E]GO(Z?;QC1 [@"=<L7.54
M0T16*M(58CY4?A!YM&D<0A:>BK+.!!&WQA2#_8;VK  '?VS3<Q\T_[J@Y/"R
MQ2.BKF?Q47%!Z6C'RI9F@XNYFOI5B=XO2[%51-V)+0CSMU;EL7+?(%/".$D*
M7]!,IYBXMW]Q/_<[;.CC_3,.5'44!<$_L%NA2*;FL]&9,N&*AE(F:WS+G+7Z
M@M)GZ,]DA.X_O102F- S67,&<,+J^1Q>HB:J%HJE9><>E;BYU_:R\K4L$W>M
M[T&^.LY>.AG/V=I:!<V1KN#8?KE$9_6+'"VM+[P]<731F_?3?,SOB/H%3%^0
ME5[NZW7OX6%7E&'!P,;V8$?IS9?*86%7L7/W+"_C]//&,U7%?,?RT[G%TZR\
MHI*]+@NEA 2934V!J=19_)?8<-/-XOD&.*^98U#-_ C#(!PM W%4V*>Q*^+(
M@AZJPQ4K\:2\7"N J0/O?!"G,^5WZ[/.F5=Y0^F?ZK^4WV2ZE0D":#_V]&AR
M(K&@D9W3DS4;GLWB);KYKI7K TY[HE&6SH]JSF?!?H2UOTF.E.;+K8 =O<JM
MMDM"<\%U<3S?EVS MN-GZL8WFZ_*?PQ]\.1Z85_2LW<1TK@;>'UN[H%@JT*
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MR6<0=I=NW4W"J*FU.5GJ^X9P4,S7^YV>K],=(1_(D;0_T#2(410MT;<,\^V
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M$K9PFA'5FK2V"T) 61Z4R_;,9>Z:=Y&CF+EE"^YWC[\P/0-=G@W:G0$T#]6
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M_UI\ATAN&F")=3JJK"*4#/$IX!9/XH.E1 ?[^3L*]WD=C<OR&J^Z33WNW^%
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M/E6+?GD*ZNK3$T$L[/UZ'QU8?&BL/!UY"QN-ICT?R>2ZLEQJNG_4N(4+02A
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MB7PJ^E>GVGQ]6'[\R\1M^9O;<TWR$B74A$Q=:8V--\'^+#MZJGX)^CF*=W4
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MS:=-9@4_'CB)IB3._6P&ABJN/YT,^=! 8@'ZPB;+\LQ'GSKF>N/WM#=_RU]
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MXNPG@SX),86E_M(7H/O,_GP\K-2P><LBQDECC[^#K: >[-\"TQJ5/B@(M68
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MKW_I^'-NU5Z/_R7BT89@[Z+K7-FLYB1'KV?.M\;M7&Y\$HHE9+TWMI[^=NK
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MHIYP'A+F^VD9BGQ]\(Z=9,EWSZ%UPC7D4S9G!C6BX,PIZ U @?\;E4/S[!4
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M[S)QQ<[3%,%SU_%0QE5&+AM6:ZA$]>CUAC1(V?V/-259\FD<"AR49^XC(!;
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M14G.$@XDM@<[P+L11W'&29/7]KBZ:-7V@'XU)0';NYE35'+"KNV!GAX.\7
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MX%E;@H6F3VV)9,E[_.Z[W6UZ)8:_&Z2/\R[>?E],ZH]@S0#M)O(NE<H8QM\
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MS1? KKD 6V5=EOHA[JRYBY\9(S8,TUFZ3F\H %X7#NRIJ#HD>F2Y=R\@N.3
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M,1>W-O#A^'"&J-D\5,U[3V@\%U2VKZ22O>:*#]A=EG!* 5_^'-&#^1[$ZMA
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M](KU8./?\$#C$\5NT1]GY!%J4]1T'Z3%MKSIKJ?"Q+!U_TB+T^UB-17?'/T
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M?6+GCY?E\&M U K[-PO6QRV8A*D_U7%'[/#E5UR.0MYER8.E(XR<!3DQ\?$
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M[PU/A%!OJM@+X]0O>MW4*OEM+&GT!$C1X,%@>C=*IQ:IK>IJ9SUC1\85ELC
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MNE-%?=AKZ7<(K3@"1(X_+&K GF*D![I!Y#C5:BWD@8PZ1K\O,+""-Z(W/5U
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MA3<VLI3]JVT'YD:)(2[5)$[XIX/:H3IN.9-7.K/0BY(>" O9QYBZQ%]^JGG
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MJ.JFJU$6-O#JL6'>Z0^CPL3W'\G5Z/4!^;'W_G95CR5A!1UP<4#RCGWNH&M
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MQ_A16O*:^D9Z)]-Y=;U1=X"7I>+G*0D?%L$$TL6VEZF$M+-$95UG4K)HH<;
MS+_^QZ/GKL2/C4(_[F_9CL;Y5^PLF"ZEE$*TC2</>'->^? AOM@UA[(AC1G6
M&HD2[_\!=8NP[JZ(_H#:!7W.X0O20"5C? Y3'32"Q/O>+-QTX%S[)LT4,;35
M/HU'&,OB57#AW\$7MNAQE<:/QW03D!]RTJ-,)PF,5;X#M5G+ 1ZT1%8CP=R:
M$R7B^:A-7@^%4#&VWNI6PE#-.[V0[+79V"H<+;H]B+&;@^=',=KP"S3#%)Q>
M2Q30]\>\DRACR)W,@%O[&T0A69/-:)FD<V99![&^K&:HQ("@_R 73?3T+K?
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MF1N:"F_'!-)!82&T4'FT-K(]NP"K\1*.3?MBNJKA4NTD5R$68C\JM*A9LU3
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M"**.,/'CW8A@(.<4.S@;YJDM65O&,8D8"B[<@4Z+CG0)+<%56;^@ )FX3/D
MHF7PG@(3%^8*F3\H2SLY?-DE=3.BC,Y-CK2916@X%LWR;T3!U>W4B^D@_8?3
M52,^ BAW</7>'2")Z6GS2)>,MQLIW&0O0\HUTY<RS;Y>ARF6O?T7>VL*;IP:
MQSOCT>,DG!$=A0>!:7Z(<2Z]AI[&CIG]0^>C6%"G7\WT>AL[0#-.A2X2)^>$
M,1W_F@5.?,-_!V@0.8!;41*=J?UU&);WAAUBUC?OIV4,9;6NW97_Q"YSF%$P
M*9C(:B?K]"__OH<B46CC_(,$.GJ ^W3]<J>DQ)#_]@'=^C)A?_!CB&J9$SQ'
MRGNK[NNNAW'U0;T6JVD[#UWI/JG"KM^0[U^PO&);:&'FJ]F2R)1UH>YBN]=-
M%TG%3Z;:B%5]:/;T09;T,Q!U-X:>FE*3W8^JK#]2+/O2>#INYK!" 4FP&FPY
M8=314#+E'__M2!'%&H*"EMO!*?R(K=:7]DWYJF0ZD,'$C>+0W@5LRL?"X(HU
MP?@\,= = )LP,)!/Q,-E;9%&)$"#V@8:?"!MTC/-W+_YNI&-M1; FT#J804:
M1]2P;ALEO\W6:,PT2.*$:LQ#E:0&_0L@KH\"$I"I\H1_IBZ"+-/>YUE]TG=I
M).HQ?&6\GOA%.K@S3TAA$NLF0_ ((GK%:K)J:C6&3'S=/WP)KEGB1(O8O^1'
MA=<B5G.ZP=?RS>*#1%S]XP'6R#3DGQ_^+T8#*:H5K;M^N1P6F&ER#[-T7M&'
M,'WF)5VH:Q?I)M.>6DMED.I?U(E2-W5(FJ.(M521=&!1&",;E=5ZVX0*"B^#
M:X! 7X%S<S-+A.TL43,BJCG/K9_I/K=RQ_<U#W'$009C+.X 9! M1*Y0<FRM
M%QVL>\YK+SIJAM(A6WWZ6[[])IMSYK3V FR9FGK<&6RTOCK82PF^-9D[)@P4
MF-=*W&I\8::2^O*2=?GF*_?GBQ]W $>/L(+2(;O=ATSO[]V;:#&%WDVF7:2?
MK=Z9%Z)D,FL@J:X=RH0<G?#4O7^:KH#H)=T=8%]6^F!J\2:5MZY1=0N&)[3)
M:\,B-#P-:\'RW-02OU^PUWQ!CW896=#[EWGI2$)>WFYU?F2+66M')_B5]=JP
M5BU-$1Y?1P/?8"BL*&BZEU0T&8"!]D&%P"$[>;17NK0E):&A=27\,L_H"#:W
MC%6VC(Q[/+J-'7"-&L?7;O"VSK6[_FFWSEDCNX0C($WJ+X^$5[^_/_8Q-^C(
MC_(*=#T>/M*;J78[W&?_Z\+5T:K.#@T^4OGQ4.E02"$Y B*-EAYF(CP)M"1B
MLK I<RJRZC8NA2;.JMJB7YJ,?DA,J#<^M$N!I@H7%>"U0'2N5,&3_2MT:.RR
M!-;VUMD304I8"2A-D90V=SRG]?V$KD=+L9[(R%OPAPADS^][CV&E\GOT)LVF
MI2B#TJJ)\]'KQ1)]V++/Q6<OF]'1RB8,_H"XJ5U2KGBTUY?F*YQL#76^]XXU
M$P0_'(T>?I,%["E,1O3P@<<,ZE%N@ZLD,"09XD;0N V=?K/<]VK95[8[/3_=
MD0:CQY7+PN(^R#660'N)LYZ<+*.TIA-VBW4?W7NS,?-MU^S)8O9OVTC&.;Q6
M>PY+M^6B%ZS,#NM;IZS=,#V4571+?##K'>#EK&#!W_')=$\'^OAM&T9[ C8?
MB>5Y"C?]*:]QD$::YD^1*[,;J;<$9[[/JS]V)(4481.L^1PH,#&)P^H8E)%W
M@,A+K;.O4WMTS6#1D9KM9A#AM!]?):WHEKI)"OEAS+Y2GH[$J!L9R(I"C@$B
M_+.%B4GFEGD.8E>L)9O>3%J=Q_AE#B6BUC9Z%:GPZ>EC9[\)_(7$M7SB[LW(
M14<IZX[Z1.NFG 58SP+6B/$BC0()\V,L[5:43ZB=S.SBGRPO,JT/@G:IO&J_
MBMMHL V9;7NYMF2._0I("%!'@VXT8-B9P"S$"%AC#+P5[IQ!6E=8-BJ2J7$]
M@?(?LR=5OM6 %"ZK4R.[*L_7HQK<O2R4-.;L6I/UIT] A+G!NHU0JC./\5H=
MH.>+CK#HL8?-C#:C)"L]T]D#4K+#,9<B'6\3.I3*,N !BX50WIP#H777%Q-"
M)O#>$"]9U8%Y?QE_E]STKC,N'?T'Q58=\;F5E=^-'FFO%5-,.@$P+7+2$)7,
M 5K#&OS$O#5@EO>ODT@^Q+-*ZFNUN2<7$<3DBVN0SZ/?)NM^W[+':V#N"8_L
M3T=0H9L?T4'+5K)(O1J]\C.5V)\ITY_R5'657_2M/H0(K9'@[ZS0SYZ,.#0T
M1A8:=27:I2K,?,EI9\N=:?@ P/%8>_QHET^DDY]'DJVQ.6R</:74&YK #*3>
MS F1?._'55% \D,'WPH</Y1'A[98Z<8-6[TEM; :%GHAB2>9K4/[/.'OSYM4
MHTLUWGD9=;0#4B?"V1Z5F!Q;V@&2)VW-9^R4:&K^J-+!W[+AWJD1$_*WU/,&
MF9)._]<*)!CEY16)M. 9?0_6:E+AGP6]4N<4%OJ>JKXXRW[Y4RH_W(O(:2[
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M,]Z"(HGBJW[?"$5MI;G9D>]X,W09"O$!A6\6L"/[K!<ZXO*8'CKZU/FC_G1
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M)'1I5& V'"W9>F:;]Y+WVYL7W&Q:L@)8Y+I:A5T250]AJ6I/QC-&E@)YF)C
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M_44/W2F 5K3(E>R([ NTO?M+TP$(*@,B4HY/1S/?7JE+9'XQ^^#<)&S!2^H
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MEE\4RY<+3VYRR+#9YT[$&Y^9,$&M3E7DG6R0=E39>=?4=[CI8U;S/%C7IT>
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MPC >$Y'[B4J(?HDB;;L3R]C99:N'U3$+3T>]WRCPW#W'N7DO?%_^*?_'O--
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M@ACUU!UCWH5]U4@6QO4C)S6+1;TEANNV[N6[I!F)%WX8."W-^MSCZ(?=-),
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M^J1D,)$6-]#HCS[WSOWD?$F\19U0NT0.7Y%#T:/=%M;GNQXRMM\12<H%UU&
M(H<P92%5M$*XNBZLKF3%':[]?.13D^(#<V.]NVZB)FPGCD>E6L4YFF;=W:7T
MAG:NXW?_Z%04R(!]I=<O,%!;"L!F[7DTL1 ^8WR-VV4T(@Z^&3MPB0+<[7%(
MG#C0?][P9:P5FB[R>?"EO0;5H'4[_.<LB&U^WV*Q.#<?KW6SM;6TMJ!41O+4
M4K6?'Z^'S@=$54(G0^;O^2/R]]S1CSY[,/T_*Q7^TZ?W C,9?1I15[09[UPT
M1:C9WO[#GW>W6Z[>A%XMBIEXHY--'2>;Z) C^-H^V>J+^UW_ZQ]N"$;MNG.?
M]?0N=-18Q4=J@;.>A!^>= @@'\:[C"_1S'"[(G/="[;FV@[WYNXYAKAVQ#20
M/U7)BK98[U/3^,+)FCW*?"%C!\2="6=2 @VO1X@>;VMXY\O"<_1H=?.T3-PM
M@@CQ5(]PWYU2[*P>YD@BY-[R/=5KE29%&KTE@N?D@W:7'>S@C5\>QS&L%V&P
MI;46Y,G;D7@C*A\DL:(8*0!Z05\J"]]%$,!;3#@$6?1(?TCNS(R[4E%5B606
M;?X\^N%HY2Y:7YV(-RJ0)$$%VVYG27\$*W8C8A$"SAS4M<LQS6A^*?%EGP+[
MM=,'Y#SNG7^3A!AMHHW'(K]9XS(%8*)N@ *DF(R#B'PAP(:2-MK2OQ@:+(M0
MK.BZ F8=OG^G?,7T<!1[VL,BE07K_3=B3/T_,@*]ZZB=1!%+; DXZ(%UHN'C
MNT6Q#=FLE@<#SS<,^+@YE9>W>\#I*4# (X(QM$L<"R/O;1# YD%M];:.(M@H
M0,U@$LMM',/")^Q*?2!^U-WS3/B4@:-6OY.FO?JG@_&?GC>J#9S'!!XX<ULJ
MY&,Y*0K!:?II1C9G/*5D2TB-1SIBW85&N=-^!T)@PU=+.WRS1H3C"_B;Z5/)
MG"P8:PIPL;06BE=@I\'$P]\+T-GR[R_#CFQI9[R2?2M1Q%S=FZ_+,171OM)T
M(L]],,[G6L2!B,#DN'4WK!A9J%NFN:@R>,GYU9WB(C8;+A;V6X)67<2"SSHA
M$>\UU,;+5LREOE,>:/PFN1^VJ@T1H0"/\E7X-[ ]Z(T !*LQN&:\DE$\G)@E
MWKHA=V6D[?CU(;^TJ)<A[XCORM_SB18.IB8U=2,N_U!=ZMW&4+]5,TE]'#.F
M^$7$-/BE92_80]DK6W27DCMIZ 1NUC0WCJ"$%U#M*ZHD\$G8WI F[%KM#11M
MCF5,BI"-D(D_-"P\%/:1R?^!XZ!A*+5,JB'E@&9B\7H4@.%/GM>+@=Z%!O5S
M[TQ.,S&RD>TO;:.)2>G+C35[FAW,;C.AV\*=EIM,,_PHS/!""F0?%AH(N6H)
MM^9VKC ;34]SM:9/G^H:EG9LF&I" &,F!8T[=MZ\!*QRC$-_:*.Y%7)'/'\^
M[AUA8F]>QYL1#V//P4]<SB%CV@YGLG.32SY^>B5:QA?P\*Q,OA.6IX;+4S@\
MK24E:]":TS#>Y;FY$WF.Z4VK&V/"U.)Y-3W!8O<@HIC 4 \YV.$Q!<"Z'OM6
MO8"7]_1[Z$YS\P9WY]*017$ME($FNB)6SN3)3<Z93P8,_%<>BW8%Z=M>H):S
MC!#QR<K*5Z]M=;B>F1J%RZN=KECTO?3L,9H"=%PTZ#!7$GW_K>W5OUV9=H0+
M#7XT<!EWO3,/9AF<E(BZ6DBXC[K[_-(IJ5UN]]5]LC_2B"0LVX)K!?9 9- *
MF/,K%[HG\\J0@?U,<6HBK=I6CT_2/B,> ^")/UZG7WT!B9W2S,WO'(TS\K>U
MGI1[QAYR]MZ-D?.5^7OO719I#COYX=T&LB"RSNZ":L]J93CGA+;)68D[5UQX
MPI=)*:JQ+C$;7U0].$RS6.6.R7Q&_=!<B_%--2R[;'WXJ[LR>])"^N>O/KMQ
MVL1,>T_7F *G=6J,T6E934+: XT9F_2E!1*Z3?U&7N_BPI*]_?W[ >%YKZZ6
M.X=?%-_U]#C$(T7.9<6' K1Z=,A,_'C-)>6#>)EQ\&YW.4-L0\SC:&O/IM>D
MU/7*MQ+"E:>;/I='&]Y>T *JW0$:4TSI0CEVN:5.Y&)I=V[...$V6'S$.+QV
M3/U$P]1;$U_RS1UBC>RRLKP6')\%?@P=\A1@81,-93WWYNB7F..Q6]J:=RI"
MEJT6.;6MPO3EM7@>%C2V5OHU[W%*Z/4L71C'SAL7F&C#]PS+O)O!SHBR5KX+
M/99Y8S+T4:=6R*<YC:F!<.B/8H^A>XP'&_%J'(316YCY'$G0VC)3FVQ[_;FU
MV\+1K!YCOI/C <,MD^O+T!]Y]P[EO!2$WH_Q-_L8_!D%^*$_S>\6G:( /\X8
M6[4AFZ!O5?:M?+[_3^SEFAN8%6G+I' C]R@>/"X3(F1I02HZ U")>?_S%_ C
MI.?*IVT$!!#T>*\F^?3GW"Z+&0.',3E&13:"B1J-C--/?<DR<QO1K[QNW+T<
M_:259OU@$HN<0*%AG=-$&[3>83S4VH7O(5.HU[A@Y84C[<GVI_;;A73[TA;X
MFO#&AZJ17I#YK.3-8@)R'^L8%)J.B#TS:Q.#"ZU_&3+P.!AZ]B1,S%YD-W"@
M 3*+S5I_04I3EL8K2[*[7QU'!DJL6B^*^!^_UZ>C8WQ\M^SU\CEF%ZJ0WZC$
MLM@:53CMNYI5+?]E^(+1=,_B_44,K-VIP,1$O<BO7!'CKZX'F5JY!AI_X<,K
M&70IF-]O:C"425P>=&+N6O2!'+ZQX9:G)^^X#ZD?[@V<SO$0^3$P'YU>F$0S
MG^\U&9D)?_!(K["[1==-JM)D:-0[EUZL55,4U%&6\*QW(J6/ MSKV&%+6S^A
MJ[R.(K,JS*R)7UCP?-V&(#PV )]R/3-HI& _'/YIL]#\W(]3M8">NU==O$.
M-!](M5ML(J^[B.!<7%S\^-:18.#ZY06 '>-VO@ G'/QFEOLQR*IGC<E#7.*P
MD"^NXKG+AZD[K&?@<3]VF/VKJJ@Z\-ZQ61^>GHR>F 6B@J*<_'W5X7V*EZ4O
M)R)E]P_>G#[[I?P,\AZ4IF9\T]DH6W(RCW#'L&2F(J=__KC@GGTFI2]?7!,M
MP.@P9ZN=,E?_!\RC)<.G/9&N6P;,@C*9O4J;;"*>"[,[NKIDM_N=HLV8YL.
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M3FFK L+'&L39@1>I[$7Z.VZ'7>E2^=<>IEEFP% 5(1)..$D!!LBI5&_L1B#
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M+3(P,C4P,S,Q7V-A;"YX;6Q02P$"% ,4    " !M,?5:I$8Y%W$\  #:O ,
M%               @ $N-0  =&UB+3(P,C4P,S,Q7V1E9BYX;6Q02P$"% ,4
M    " !M,?5:4164 W^&  !-4 D %               @ '1<0  =&UB+3(P
M,C4P,S,Q7VQA8BYX;6Q02P$"% ,4    " !M,?5:*X=Z&S-^  "YBPD %
M            @ &"^   =&UB+3(P,C4P,S,Q7W!R92YX;6Q02P$"% ,4
M" !M,?5:<ZJ^\S.+  "EV@0 &               @ 'G=@$ =&UB+3(P,C4P
M,S,Q>&5X,3!D,CDN:'1M4$L! A0#%     @ ;3'U6F&\]_9L%0  .;X  !@
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M-"YH=&U02P$"% ,4    " !M,?5:T*"\9"H5   %RP  &
M@ %UF@( =&UB+3(P,C4P,S,Q>&5X,3!D,S4N:'1M4$L! A0#%     @ ;3'U
M6MD?-+7/#   YV,  !@              ( !U:\" '1M8BTR,#(U,#,S,7AE
M>#$P9#,V+FAT;5!+ 0(4 Q0    ( &TQ]5H&^YRBR@P  (Y[   8
M      "  =J\ @!T;6(M,C R-3 S,S%X97@Q,&0S-RYH=&U02P$"% ,4
M" !M,?5:J9RBE<$Z  #:*0( &               @ ':R0( =&UB+3(P,C4P
M,S,Q>&5X,3!D,S@N:'1M4$L! A0#%     @ ;3'U6M]IHX01-0  H5H" !@
M             ( !T00# '1M8BTR,#(U,#,S,7AE>#$P9#,Y+FAT;5!+ 0(4
M Q0    ( &TQ]5K\7YF$^LL  &P4!0 8              "  1@Z P!T;6(M
M,C R-3 S,S%X97@Q,&0T,"YH=&U02P$"% ,4    " !M,?5:WJQ_*-TP  ![
M,P$ &               @ %(!@0 =&UB+3(P,C4P,S,Q>&5X,3!D-#,N:'1M
M4$L! A0#%     @ ;3'U6N(AI2='"0$ ;Y$& !@              ( !6S<$
M '1M8BTR,#(U,#,S,7AE>#$P9#0T+FAT;5!+ 0(4 Q0    ( &TQ]5K^8FM-
MDA$  /%]   8              "  =A !0!T;6(M,C R-3 S,S%X97@Q,&0T
M-2YH=&U02P$"% ,4    " !M,?5:^HDW)$<#   1#P  %P
M@ &@4@4 =&UB+3(P,C4P,S,Q>&5X,C%D,2YH=&U02P$"% ,4    " !M,?5:
M-V?5#J8"   L!@  %P              @ $<5@4 =&UB+3(P,C4P,S,Q>&5X
M,C-D,2YH=&U02P$"% ,4    " !M,?5:(VM@=18#   O!P  %P
M    @ 'W6 4 =&UB+3(P,C4P,S,Q>&5X,C-D,BYH=&U02P$"% ,4    " !M
M,?5:FW?)V%@&  "@'P  %P              @ %"7 4 =&UB+3(P,C4P,S,Q
M>&5X,C-D-"YH=&U02P$"% ,4    " !M,?5:VCZE0$,-  "Q1   %@
M        @ '/8@4 =&UB+3(P,C4P,S,Q>&5X,V0S+FAT;5!+ 0(4 Q0    (
M &TQ]5HCOC:;138  #2  0 6              "  49P!0!T;6(M,C R-3 S
M,S%X97@S9#0N:'1M4$L! A0#%     @ ;3'U6A#5:]#: P  .@X  !<
M         ( !OZ8% '1M8BTR,#(U,#,S,7AE>#DY9#$N:'1M4$L! A0#%
M  @ ;3'U6GGDRR#H P  [@T  !<              ( !SJH% '1M8BTR,#(U
M,#,S,7AE>#DY9#(N:'1M4$L! A0#%     @ ;3'U6L"L,/H(!   W X  !<
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M,#(U,#,S,7AS-# R,RYJ<&=02P$"% ,4    " !N,?5:Q[JG:!B(   /B@
M%@              @ %H;18 =&UB+3(P,C4P,S,Q>',T,#(T+FIP9U!+ 0(4
M Q0    ( &XQ]5JDI1K#\&$  (-T   6              "  ;3U%@!T;6(M
M,C R-3 S,S%X<S0P,C<N:G!G4$L! A0#%     @ ;C'U6I/R?N!!:   7'H
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M;6(M,C R-3 S,S%X<S0P-3 N:G!G4$L! A0#%     @ ;C'U6AAB1Y[0* ,
M+V<# !8              ( !-]$8 '1M8BTR,#(U,#,S,7AS-# U,RYJ<&=0
M2P$"% ,4    " !N,?5:"<%4$8.% @ \ 0, %@              @ $[^AL
L=&UB+3(P,C4P,S,Q>',T,#4T+FIP9U!+!08     +  L ,4+  #R?QX    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>tmb-20250331xs4_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:carm="http://carismatx.com/20250331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tmb-20250331.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_94R-tIsNFka2JCxWnjX7Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_carm_StateJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_F3DomWzyU0mk1y1R2qHVZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:StateJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wF0j2cynSUuqz6R2wHJFsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yJlKgp-b0a9kywLP5wfMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NBJH3utECkSeITbgKbOBjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KOBMN_pRd0CpuuBgDONMeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KyGaWAjqJkmBWbexZMF-jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lu-cSSufUEqWCNoTK34t1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JA8S9njYW0u1srOBy-b4Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_djTn0QuJAUyMxSDTnffWJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9V4P9b_imUeKWRIMprh3ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p0MZ0Mf-7Uu7LB1ZZP5Iyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CiZKxNIbvEyRs27cGTE1kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mWoZC8JK0EyoFq85L59bzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_4dq94_1obkuQkmJaNiEQBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_W2GgALqdeUG9d8eSxLoY-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Gi-5K4vpZ0SQCZsnJh6q1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rddcZYrYF0aGvo9ie5UZTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_CashPreservationPlan2025Member_feBnUr3Dfkm1-xoc5Tr1Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_RevisedOperatingPlanMember_8xDVoP31YEeXATz_aXlYog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:RevisedOperatingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_b0EJK8W8H06cy_5zpLWtsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_KcFLfiniXEG_gOlYI1LmVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_0LrR7jztQ0mtgFQjdW7yZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_bhT6DCaLkEussR-MSi5DIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_XarV9JooQUGFgqT3MKU-nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0Ff2XJct5EKaCIPhtjMWRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pbvS30z8A0CePGJ6mxV3wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rXpt9Tr8wEWedRsbme4_rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_EbpMHxZ2vk61tk33Oa6FYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__FKxuQApK0mFwWZqpuOrwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_nnJFjCrHlUqpNk-U5M1Zug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_pc5coAuKZUS70I6GNo3axA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_O60app-ziUOiQI-0SFDxHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_BqAFVKxD_0eZh52zf-_cHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_2mhPn7jIZ0e-ZbcpUrxB9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_h2U2al8QUkCz4difeEQiVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_12_31_2023_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_61_8Uvl5hUOnb8pf--nrlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_OiQ4pvFuv0SzT93oHU7Tbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_PW5Xs3_AFk2m4nSwFHd7Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_KzPkm9W5EE24UqG-d_OiTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_6dVwitkd0UeHb10KsXjOdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2024_To_9_30_2024_Zs5TM9E90UOa54MlGv6RJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_Ffe941lEKUCa5q4ysfJI4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_OptionRightCollaborationRevenuesMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_NbiVSknF-U-gNgbz4Ymr5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:OptionRightCollaborationRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2024_To_6_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_vCHDp2Flj0-8HoO2F7_1lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_OptionRightCollaborationRevenuesMember_SRYjOrMSy0aaO5SPhrCxDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:OptionRightCollaborationRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_MilestonesMember_FUdbCZoQDk2Dag7HM2RG6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:MilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_gNQIWKQL-kC9gvHVRwSeLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_oh2OTmiJvkKgA0D-o9Y6Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_IC7n65_vc0OYd91beSu5RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_c0xoT3reKkCaOeL1zPSHLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QPK_k69qc0WEZlJvXGRPPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_lGhVgDEdm0KquD87r_9DVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ATt2SkLHckWBYPbLkkt-Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_e9iO1ErRnUC87OlaTyfKaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_TTkLQHgTUUWOQaI1eLingg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_m_pObOvhDEicQLnUh4byOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_M2tlaUEGPU-AJlzF8cCTTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember_6a9BvHfS2069NVgEd9BlgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_q6mQUCRJFESSS-dSvTvrAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_SbAUMjqBzk-GzWMJw0e0Qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember_IuSFljhV5ECw_6wtTyDvMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_QBP2ErMrOUK4Ayldn4JM8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_MqoxSix-Y02bOPp5O0niiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_V1MVYY5yOk6TrVp02Gj08A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_GuIsy6UvbEOGPaKsDXeA4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_1_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QZ72PuDG7USaQrTyk9GuVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_26_2024_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_eohhy-W8CE6cTQBIagwUsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_vJj0iOym_06oJXQKAC1aOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qPQeNLve40WJSXsRyUdx0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_carm_Pre2018Member_dstQjZ_6a0e4qC0YXpJpZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">carm:Pre2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_carm_Post2017Member_f3GDnlkCKkiBu7MDgLhD9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">carm:Post2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_f1OJ6DnIk0WtNUSppxvYrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_carm_StateJurisdictionMember_efJJVuhcvkquKiB45VCQ1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:StateJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_carm_LocalJurisdictionMember_3b4Lne7Dpk26SoUxioVhCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:LocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_o52ygJ2qtUW_8MtdyoucDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-EXk6InjekuA8cdEMBjBkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_V0Pkqzz_AEyhjqolIkoUug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dkWHVbHbIEmBDtxSTvwOZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_26_2024_To_6_26_2024_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_pGYfhVmGEUO0Q3irnyGzOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-26</startDate>
            <endDate>2024-06-26</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_mc__W33L60eUsMJuatMfaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableMember_2St9M_1mr0e3gTe3DEn6vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_Xj-_M61yuk6R7alr9CUi3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_mVjyQyWkQ0ysng36Cpz6dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QKEF25OlKUyFEjDTw-T6ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_Zc2Vn1pdQEyg-izKUAgkWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_oADG9dBYzE6u3XG_uLzZiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_AtWenqGmtUa8z3-Kd3hvvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcPCJIcIO0eFOPtvCF5mqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVEm6mt950Ss-dIhOM6psw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fkuPLbunBkio3h13YwQKEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sizU-8d-HkiGAXLhA7EliQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_6_2023__sMm62IFwUO3DNhZ5LDZlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="As_Of_6_5_2023_xtoCxfMB7kSash1MJ5CA_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-06-05</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NHpG9u0K8kSnQJhkduVBWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qni1eLtrpEqVTUS5DP3Q5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C2na3yFo8kSa8lpEjLIVYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_P-hP9vpSB0SObx9s8SRr_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RNeFS6gXN0O81arpfa3vew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_FPiLpPUNo06fNsnw6eJy3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_i3-WcXRxi0W0jzEpmZkO4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_7_2023_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_us-gaap_BusinessAcquisitionAxis_carm_CarismaTherapeuticsIncLegacyStockholdersMember_pAj3UmfAuUCFRdiN77L70Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:CarismaTherapeuticsIncLegacyStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_o9XCCXxBxk-Bcr0qGS2Bcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_0bTbe1UO4Eu2oXU8xcRc4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_zK5vgRHDUkuO_I7i5iruOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_4gn5Hkv1tkSIJa1ZsZNSzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SxDIMm3BHU201oGx7GMaZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_-bxZ8-y2T0-7QhFzHLqqMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_GdlsibT2VkyP132eYkVPyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_s7tqgkjRX0S1t8FSmRyS6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_jY5QK3zjDki_xjht9LRM1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_weRP70dN20KmCCCCJPZOwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Nd0oPvzMG06tOEVwN21Lsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R3R2qv2BVEOZuSzVu7JMsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_carm_SesenBioIncMember_wbOBDpL9fE2NWwfHImRktA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CtxCArF56kS82xK5cMVGuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giltrRhLwk2uYDDpgJGllg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3bekv5USnUGc01h2wLoVyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_5_pFMaKe_E6No8FPBreF8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_pDUA6rIWwk-29qcuwaw0qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="As_Of_4_17_2023_x6SGs_0tqUWE9Nmq-r1zlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-04-17</instant>
        </period>
    </context>
    <context id="As_Of_5_12_2023_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_D_fnvKHBKEejhcN9RD39EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-12</instant>
        </period>
    </context>
    <context id="As_Of_5_12_2023_2Ua3tacy0kqoCl2kZhnnpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-05-12</instant>
        </period>
    </context>
    <context id="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_9oZWrGbwu0CzsSwa4YaYUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_UFBhEQ0DHUmjWP1OKnrZfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2024_To_9_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_CC5mai144UKxgWO0ed8BXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_CVCA_jIaNUSvPGLAL1iRDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_XRurAXNE0EKR2OlnCsvD0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_xyxFVBcDT0CVZTmDOmX-AQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_nQIYGPxOV02W0fAFKZQdvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_C2cp3L2L3EiZlfTKfZNEqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_8qNgXN0bH0eJkf5RqlBsfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_S3eeHUCF80-ErdmPj3uyZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_CsDzke0V0UKpQy6JppgEbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">carm:ReportingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">carm:ReportingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">carm:ReportingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">carm:ReportingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_ECKpLj9RxkeJ2fOMI7xCfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_R70NvuCqk0WTJXiSPZpa9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_H-d_HedKTkqWEw-yuQFN0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_BvRnm7gZx0yPcQ6vufXWdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_baLeGNcD3EigtjEBIXS6dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_Tu1FMTWJ-EKur2Ehg_NuIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_8sZcvCnSPkeitKoqY5sunw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_TrTvMEg3XUmfyU3iMfTZ3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_c-DL08jYk0mOjzSXLvRWJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_3NLofzzltkKOh4rmrr_2tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_9VloD_2BKUaBco__8m0cCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">
        <measure>carm:item</measure>
    </unit>
    <unit id="Unit_Standard_stockholder_xwrsA79JVk6r5Olbumrfaw">
        <measure>carm:stockholder</measure>
    </unit>
    <unit id="Unit_Standard_product_3mVjd4sUPUK6dqSqJB3SiQ">
        <measure>carm:product</measure>
    </unit>
    <unit id="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_ieOgHbuNO0uMDAyeDWsL6Q">
        <measure>carm:segment</measure>
    </unit>
    <unit id="Unit_Standard_employee_8zftLesBXkivzIcTQ6E96w">
        <measure>carm:employee</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      id="Hidden_ltVNbYivXkekjiw03dKW4A"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      id="Hidden_M3CYe3Zv_E6bgld5te8Zvw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      id="Hidden_sU_Vuv9WSUmKRxDVcXLfLA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      id="Hidden_1E9j0k2uV0iCfG9MW9TNAw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="INF"
      id="Hidden_WPLQ41LZf0eyECdOSYT34w"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Hidden_XLxbnzFrpUm-24ijgeqr1g"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">0</us-gaap:PreferredStockSharesOutstanding>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tc_KLusxZL3ikSEZWZMgx-krw_1_1">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tc_J-aQsiQ57kCsHnQKoa7Xag_2_1">0001485003</dei:EntityCentralIndexKey>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Hidden_EC4pGizMUEmwsFpD3vArGA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41750109</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="INF"
      id="Hidden_1t_Gb32An0ig-gvOCgjziA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">40609915</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_c0xoT3reKkCaOeL1zPSHLQ"
      id="Hidden_fhlu0P8GC0OSYzMKRGa6pg">http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_IC7n65_vc0OYd91beSu5RA"
      id="Hidden_qKYmVxKGPEGEDMmZP0kvsg">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_m_pObOvhDEicQLnUh4byOw"
      id="Hidden_w59cdNVWLU6d09CxPojcvA">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_2mhPn7jIZ0e-ZbcpUrxB9g"
      id="Hidden_sktIWaH1v0C3Alvvbznotw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_2mhPn7jIZ0e-ZbcpUrxB9g"
      id="Hidden_wSmhQcT4p0uaTZTD8dNi8A">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="INF"
      id="Hidden_UuJUKdscKU2BamT-vknOlA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41788096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Hidden_YsbYHRwR2UyuINXyqElSpg"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41750109</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_O60app-ziUOiQI-0SFDxHQ"
      id="Hidden_Y6YvLEfyKUG_kk0uMc5sKQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_O60app-ziUOiQI-0SFDxHQ"
      id="Hidden_DGF8BxLO20aH0nuzKXhnJA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_BqAFVKxD_0eZh52zf-_cHA"
      id="Hidden_RR1pBUqe5UemOm2ln3QA2w">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Narr_XGoNSfJdwECecumJTYRVmA">S-4</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Narr_Cc9ftLfcw0-A7w-7Ea_dRA">CARISMA THERAPEUTICS&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tc_NSl-twNIXECY_rhK0HgckQ_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tc_u8U1sP5ZBU-rYixW0AjtCg_2_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tc_E3ZX2TP7XkiCWasOH6vIjw_3_4">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_ScfF6enpZ0acuQwL87kVPA_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">17909000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_iuqvWqikn0iEOn9F1GvEXw_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">77605000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_9b6jRnXY5kKNMALahGVP1w_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5916000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_rAZZHNWz0UCWG9Fy1vjr4w_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2866000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_xXHPfCBMjkiK-2sw39i8aQ_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">23825000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_vPMWG_zHtkmePIQAmjIP7Q_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">80471000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_pYH9FqbFHUq9DI4Er7QYmA_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4385000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_Jt5iCieQNkqp05Gs6Muhdw_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">6764000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_zfD8tEOtukWw6ATn87WcpQ_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2040000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_TuDizU05DUe3Uwue5Iyc9w_9_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2173000</us-gaap:OperatingLeaseRightOfUseAsset>
    <carm:DeferredFinancingCostsNoncurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_RllwiyQ98EiYGa-Y3ftrSA_10_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">208000</carm:DeferredFinancingCostsNoncurrent>
    <carm:DeferredFinancingCostsNoncurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_TK_OlQn78kOlNOabwisgeQ_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">146000</carm:DeferredFinancingCostsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_u4HBRRiqnkCeyr1nEtl2tg_11_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">30458000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_9jheHjh67kyExqSeSAXjCQ_11_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">89554000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_N8nNbvb9R0yh_AlhVQPclg_15_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2081000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_KP4EmMadk0m5OmeMpuvgZQ_15_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3933000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_pySY471fwUCe5Kn8o0rSbw_16_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7448000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_t823Uv_u906ueJS7RRdGGQ_16_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7662000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_4GlfYRutQ0qjXzLAbAcGRg_17_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3729000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_XTgWQqE2f0ugx8rhkdn6vQ_17_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1413000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_QTKbbkuYY0uIsSvMTBohuA_18_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">832000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_2rAaNnhlkU24minmWP9NYQ_18_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1391000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_-KgIRFzd8U-MzCl7rgTNhA_19_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">905000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_dzwbnBpFgEmnu8nBBrR9xw_19_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">544000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_kHjsnLPsGUS3SIHk3LzCpQ_20_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1060000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_vYlew8B480iZOvEhSVwAPg_20_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">965000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_F7O55URalE-_IxdrQ0fWQA_21_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">16055000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_EHFyFs3ph0Sc1PbWkU9-Xg_21_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">15908000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_ugyfEbI9J0it2DjHYcawrA_22_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41250000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_7RsfF5bfLUmtebqAWQ8spQ_22_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">45000000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_JiVq-sqDo0WkWYZ63ZOwYw_23_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">724000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_6YvAeeho-0CJ8c3ClcQz2A_23_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">860000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_ODd2FA7kkUS8mB631DQ0vA_24_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">20000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_BvGVY-41pESkeTD2TfswJw_24_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">328000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_GYRrzysAf0-8_v048qIbTw_25_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">318000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_3yoGcVfPJE6IdlLUoJKmJQ_25_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">926000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_T8V3yYDg-kWWVNUZcy0HyQ_26_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">58367000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_e4AOBpNEiU-9VULkA8izPA_26_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">63022000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="INF"
      id="Narr_Yk4n7XcVekWjA_CM_9zveQ"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_Ykf9TQ5D3kaSHVWbo0mzlQ"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="INF"
      id="Narr_CQJIx3J280q2j19WX-FgRQ"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_bMsph9IzrUmlIwSRFSzY9g"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="INF"
      id="Narr_8ExmDBW1Z0OGKxEydUpwVA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_nXq37bjw_Uml8JS8zR3ljA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="INF"
      id="Narr_Pysm5OpygEC2k0l1PyNuZw"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_TrD5hqw7sUKp7o1oqnPwsg"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_9hxDwC96FkS6_LJBy6BUGQ_30_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_tlUs3c6LikWLamSx8R78YA_30_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="INF"
      id="Narr_WXIiEDDZU0abkqGCnpFQOQ"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_ECeJIXf_ckqiypN0UPnrng"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="INF"
      id="Narr_aODT60ck2ECaN8yY3G6UHw"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_LkYJc7OHB0OFpDrLgLhjRg"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_7_Xp5yzf7UGCZwX5KMTscQ"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41750109</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="INF"
      id="Narr_FVmtYENuWkekuyboUliO-g"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">40609915</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_AaTmkQZ6KUCeCKHSP2SM8w_31_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_EFHSLmHe20algbJwYqXN4A_31_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">40000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_49i78GI3Rkeb-qe-Ia5Wbg_32_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">277629000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_FdRS6GSzbESKDPTQYrtLLw_32_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">271594000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_XD9ELp-Plk214pUnxsALhg_33_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-305579000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_yaGDLZ7q3E6BOQ82Ya5KBg_33_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-245102000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_9vyJDTxo-UqwbR0D4wG3ZA_35_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-27909000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_9q5eSXfZS0Ku4OSgZp98kQ_35_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">26532000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_Aj7cLBsOHk-y7230ChkLlw_36_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">30458000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_h4W6Y_0Gc06uWw2MrCZs9g_36_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">89554000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_hWJetWoeTUeWUSHsIntuKw_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">19632000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_up_zlNLeEkOgTT6Yca5dbg_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">14919000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_VYumP-JhpkqS-wA1-Yj3Wg_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">59673000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_rNTQTZmWs0SkFc0iBVtEtQ_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">74125000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_f4_AKSf2EEmG4c1gJx0M-w_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">22138000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_DPCLhzAD3kGVC6dTaumAXQ_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">29525000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_fy6sIUPCTEm5rl-O3OpB1w_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">81811000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_tFna7hTA7EmuTeTxmFB0wQ_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">103650000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_jxMMjz1YVU-IlJPBEtUxoQ_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-62179000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_YH_TPL9ij0KwOwQ2lC11mw_9_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-88731000</us-gaap:OperatingIncomeLoss>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_WZs-skAUHEKOU2RJsKMNUg_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-84000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_6jeRPdCc8ECDUkmn740-VA_11_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1702000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_d9qCscXml0aLRvH9ER3LcA_11_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1936000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_ZyRFUgJF1U2difHXvbNh8A_12_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-60477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_m5mCEItwAk6F1w4fSKhCXA_12_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="2"
      id="Tc_aJ29XDNl8EuWp8rsfo69-g_15_3"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">-1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="2"
      id="Tc_aJ29XDNl8EuWp8rsfo69-g_15_3_2"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">-1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="2"
      id="Tc_Lo9UTD6E7UW4XxYFh2e_XA_15_6"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">-2.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="2"
      id="Tc_Lo9UTD6E7UW4XxYFh2e_XA_15_6_2"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">-2.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="0"
      id="Tc__Hb_KBrooUCJAHBxEw3LFg_16_3"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41456210</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="0"
      id="Tc__Hb_KBrooUCJAHBxEw3LFg_16_3_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41456210</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="0"
      id="Tc_e2zvsN8jC0a1w9g54q6AMQ_16_6"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">33524197</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="0"
      id="Tc_e2zvsN8jC0a1w9g54q6AMQ_16_6_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">33524197</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_KB5OuVAzOEO-2n-FziYedA_18_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-60477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_HvNrqH5oaEC_En6qCBejHg_18_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_aVqu3lKffUKMGa6rN9m-1g_19_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">440000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_YIn8XF6_8kqJD_7H9HG5mw_20_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">399000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_fgcVmbWZFESJd3OBxZqhxw_21_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-60477000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_Y1j-VEWraU6DMonLLH-5ZQ_21_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-86838000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA"
      decimals="INF"
      id="Tc_p8XQyH9BF0aYRMr4XoxG_Q_6_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">8700885</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA"
      decimals="-3"
      id="Tc_ENGYyLNejk-H2En1wsTpDQ_6_5"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">107808000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rddcZYrYF0aGvo9ie5UZTQ"
      decimals="INF"
      id="Tc_c0iPWTNTYkizOzRvqZ0jKw_6_8"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">2217737</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rddcZYrYF0aGvo9ie5UZTQ"
      decimals="-3"
      id="Tc_UbzwsLjYJUO-FNAoDEysPg_6_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_W2GgALqdeUG9d8eSxLoY-A"
      decimals="-3"
      id="Tc_nOVT6EUfFkCrXpXBUuaUJQ_6_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Gi-5K4vpZ0SQCZsnJh6q1w"
      decimals="-3"
      id="Tc_pPfQlYnCRUCmAOyCJyGBEQ_6_17"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mWoZC8JK0EyoFq85L59bzA"
      decimals="-3"
      id="Tc_JWIGVHmM10ulHxbh_Xb8ww_6_20"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-158223000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_4dq94_1obkuQkmJaNiEQBQ"
      decimals="-3"
      id="Tc_eklVUV3Tk0G9StNjnRjE_A_6_23"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">14395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA"
      decimals="-3"
      id="Tc_aq1PeZ7OQ0OLnK-Td6OVBg_6_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-142670000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ"
      decimals="INF"
      id="Tc_bKL8fo_fHE6p010QTczf1A_7_8"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">128716</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w"
      decimals="-3"
      id="Tc_WDU4c0mgUkaBi8m_NU_2Qg_7_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">187000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_jbTgDoXy7UyQdJuEKXDuVQ_7_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">187000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w"
      decimals="-3"
      id="Tc_gu6tszI5Dk-2SgNNCrOcdg_8_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2316000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_Ys6Nn_KSp0ipkS8ZIPZgeA_8_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2316000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qPQeNLve40WJSXsRyUdx0g"
      decimals="-3"
      id="Tc_3hBntpiaXUyTvgfTFpq5gw_9_17"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">440000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_wPxLjCRYMEebjWRw41QRZA_9_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">440000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qPQeNLve40WJSXsRyUdx0g"
      decimals="-3"
      id="Tc_iLdijBLhIUqQe41yIO5rtA_10_17"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">399000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_wmwyIdXCSUOM1x5PiCKQGg_10_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">399000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <carm:StockIssuedDuringPeriodSharesPreclosureFinancingTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ"
      decimals="INF"
      id="Tc_631xhzqymUqlEyAdC8W2vw_11_8"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">3730608</carm:StockIssuedDuringPeriodSharesPreclosureFinancingTransaction>
    <carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ"
      decimals="-3"
      id="Tc_cBrt6_nL5ki1kLfFsiUfRQ_11_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4000</carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction>
    <carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w"
      decimals="-3"
      id="Tc_AqByaNI6H0mN1t0ecbt7oA_11_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">30636000</carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction>
    <carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_DJCa9THa1EOzmTPvSjX9PA_11_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">30640000</carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ"
      decimals="INF"
      id="Tc_9q_2fgqNNUyVTnpIO2OGRA_12_8"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">5059338</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ"
      decimals="-3"
      id="Tc_Q693_hfPfUyR6TF3sm0DPw_12_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w"
      decimals="-3"
      id="Tc_hCRl3Zs7PESZ3FpRvHDvhg_12_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">42442000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_Mun6Wvlho0WAER8oO_g_Ag_12_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">42447000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ"
      decimals="INF"
      id="Tc_WAyz77n3ok-BDUi6tpYLnA_13_8"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">10374272</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ"
      decimals="-3"
      id="Tc_hGhEyMXBzU2Zc8TS1SbgSg_13_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">10000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w"
      decimals="-3"
      id="Tc_DkEtVA56okezX9u5M2ItNg_13_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">72034000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_XCX6xXEqO02O0kCJkO4JjQ_13_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">72044000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <carm:ReclassificationsOfTemporaryToPermanentEquityShares
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="INF"
      id="Tc_xtJ8yGRJmUSIkX22sKmunw_14_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">-8700885</carm:ReclassificationsOfTemporaryToPermanentEquityShares>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_EdQotmM7D0yakwIazDFEbg_14_5"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-107808000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <carm:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ"
      decimals="INF"
      id="Tc_7IKZwR5BGEapTR5X5ld8xg_14_8"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">18872711</carm:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ"
      decimals="-3"
      id="Tc_VsMvmhl1FUq6I0E_4o96kA_14_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">19000</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w"
      decimals="-3"
      id="Tc_4JpExyX2GE-vXzscwun6fQ_14_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">122185000</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_pDUA6rIWwk-29qcuwaw0qg"
      decimals="-3"
      id="Tc__sNvPTcUe0-dPehn66ddmg_14_23"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-14395000</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_PFO2gvIMik2djkdhYVMDbw_14_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">107809000</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VG8llPHGyE6xXTspJOhumQ"
      decimals="INF"
      id="Tc_qBofQcmgFkqWDWxUreYOdA_15_8"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">226533</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Mr5VgsHnCUeBJ4dXFyGQ8w"
      decimals="-3"
      id="Tc__djNd1YoBUi9ypMwi3g4Jw_15_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">597000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_ZQLMmsMvH0eIqT8ht3zA6w_15_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">597000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dkWHVbHbIEmBDtxSTvwOZA"
      decimals="-3"
      id="Tc_RA1PattwDEKLCOu_eSDfDg_16_20"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_ryqgrnM5WUGisA6yT7kkWQ_16_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sizU-8d-HkiGAXLhA7EliQ"
      decimals="INF"
      id="Tc_Fdyb7_vx-kuvuJmLWHeJZQ_17_8"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">40609915</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sizU-8d-HkiGAXLhA7EliQ"
      decimals="-3"
      id="Tc_Djc7VGoSD061xuTT-Rd_6Q_17_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">40000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CiZKxNIbvEyRs27cGTE1kw"
      decimals="-3"
      id="Tc_Jt8s8q1Q60yM7iFLYe5ahg_17_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">271594000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p0MZ0Mf-7Uu7LB1ZZP5Iyg"
      decimals="-3"
      id="Tc_oVdMUnYltkeMDHZq2IW7Ew_17_20"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-245102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_eceFI1LNxky5NK75P8QxVA_17_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">26532000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yJlKgp-b0a9kywLP5wfMA"
      decimals="INF"
      id="Tc_DqHYuOj7aEO24zUeM58viQ_18_8"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">3810</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giltrRhLwk2uYDDpgJGllg"
      decimals="-3"
      id="Tc_WPLCq8msS0iUAbeWH70daA_18_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_Lc6hxokluUaEt3EbJn5Eeg_18_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giltrRhLwk2uYDDpgJGllg"
      decimals="-3"
      id="Tc_kA9DN3z01USnb79VXvD40A_19_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3649000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_4D3L3KxAnUa321yy9gOusg_19_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3649000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yJlKgp-b0a9kywLP5wfMA"
      decimals="INF"
      id="Tc_qtl8_XFIMUOuUzkKfbScag_20_8"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">1136384</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yJlKgp-b0a9kywLP5wfMA"
      decimals="-3"
      id="Tc_C8xEfKyJ4kelmOYNZn-SqA_20_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giltrRhLwk2uYDDpgJGllg"
      decimals="-3"
      id="Tc_j5FnCm6h3E6qt5tOBu009Q_20_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2382000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_Ng3LhRHoIEirCsukIgODqA_20_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2383000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-EXk6InjekuA8cdEMBjBkQ"
      decimals="-3"
      id="Tc_XstGPXYV00W52ViZzbiJNg_21_20"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-60477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_doylNCyCEESVwJV42zjziw_21_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-60477000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVEm6mt950Ss-dIhOM6psw"
      decimals="INF"
      id="Tc_8tQAuwAWzEGWBmZ-qyoY7A_22_8"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41750109</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVEm6mt950Ss-dIhOM6psw"
      decimals="-3"
      id="Tc_bdzlEGHEm0anFnKQBBZbLg_22_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JA8S9njYW0u1srOBy-b4Fg"
      decimals="-3"
      id="Tc_qSrLUTajkk-rdMHnpOPjkg_22_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">277629000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lu-cSSufUEqWCNoTK34t1Q"
      decimals="-3"
      id="Tc_q-eqKcU83kKow5Jy8ZalKQ_22_20"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-305579000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_gQOSzc4BE0CjaCrwjtGTQw_22_26"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-27909000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_2PzkEeP5SEelAuFmHIVnEQ_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-60477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_8SrbnBJccEGMtSFQvN6sgw_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_eTIzKyODD0y--o8U8PfowQ_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3354000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_pJDaFwjYLU-A_blW4Qaasw_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2837000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_Q5x-RX3x90-5DZR0VlIsVg_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-159000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_CNmmAUB6dUy02LnrzukVJA_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3649000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_GB6Ao6h3RkejvjUisiFD0Q_9_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2316000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_Z0Gjpvu1O0qJWR8ClxqbGw_10_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4963000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_tx67IpQLCUiPYOFQudCFHA_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5428000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_SE6G5BXpdE-ekhM_EdeTFQ_11_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1283000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_2XBpXWThLUSch-mMTWwKNw_12_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-84000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <carm:AccretionOnMarketableSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_wrsjt67Fk0m0YTEkMBd-lg_13_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">709000</carm:AccretionOnMarketableSecurities>
    <carm:WriteOffOfPropertyAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_AVylJFC6oUWub_lX3JQPkw_14_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">362000</carm:WriteOffOfPropertyAndEquipment>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_TZzDqkhsY0a5FVCpmkXC_w_15_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">399000</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <carm:NoncashInterestExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_xyGL4bsmqkSZqyhsIhbPxQ_16_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">217000</carm:NoncashInterestExpense>
    <carm:NoncashInterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_UsJiC6uL8EKwowxs1Qb9Fg_16_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">139000</carm:NoncashInterestExpense>
    <carm:GainLossOnSaleOfEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_AJTpK2XvHEChFUg4KJ3Ydg_17_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-49000</carm:GainLossOnSaleOfEquipment>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_mb3rLd7lH06mAon8EJwWHg_18_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">82000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_39Zt8lEVrEmoJJDmT_tzlA_20_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3120000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_S0SIOj9gj0C1JTmyhHstKQ_20_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-1046000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_1ymrKhFFOEe8gA_EQbl2RA_21_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-1852000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_BGIKFmpdx0yCP2slCNp2EA_21_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2191000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_BwL7QEdRrkKaMwxs4NRtrg_22_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-213000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_b70pbFWKoEiq8klK0p6exA_22_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-2899000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_yY5REgpMTk-zs_jK52_Qag_23_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-1434000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_f3FtsqVYCkOHnDcVmbfUJA_23_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-1046000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_fG5PNS0LOUiiLqVTJPo36Q_24_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-5525000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_PumQDiKwGEupCnfy3BZtkg_24_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-4941000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_YGZp2lHQpkeowaGj0PaKDw_25_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">192000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_i519MiD50E-6BxlaSucIIA_25_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">213000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_bVNvZC2xXEiFjuWVNvjgIQ_26_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-59917000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_bCMsgak7qEOaJzQuaegkLA_26_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-81177000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_o42MLdPfSEedXUpwyikgcQ_28_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">34460000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <carm:PaymentsForProceedsFromMarketableSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_KbU370ssmkaiUgthtAx3yg_29_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-108000000</carm:PaymentsForProceedsFromMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_h2dr_VgHLUG0zWZ591569g_30_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">123000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_m7I-IlpwfEG_U5x2x4XlEg_30_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1132000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_Zlb_RAH49UawUnC4wXKJdA_31_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-123000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_eP3BGxX6r0CUTjLoE8P9vA_31_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">72408000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_CgfiMrkSOEyTGTP3sEml0g_33_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">37903000</carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities>
    <carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_jHPokpxBD0q0VFR1REDbWQ_34_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5814000</carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities>
    <carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_lM2d2S0WGkqDdt4dvduvrQ_35_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">30640000</carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_ts4WOdJH-0ifEZi1CqjZ_A_36_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1429000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_qgQ7olwDoUK0WCKqb-b1jQ_36_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1301000</us-gaap:FinanceLeasePrincipalPayments>
    <carm:ProceedsFromFailedSaleLeasebackTransaction
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_4S4bo7scN0y2BUdKvG0YOQ_37_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">686000</carm:ProceedsFromFailedSaleLeasebackTransaction>
    <carm:ProceedsFromFailedSaleLeasebackTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_ASXWvdnobU-q5-4hZnUA9A_37_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1183000</carm:ProceedsFromFailedSaleLeasebackTransaction>
    <carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_NQasSKnBbUmzbVeaC0Mbkw_38_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1309000</carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction>
    <carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_fOMQrx6dhkGPLBJUBfr5iQ_38_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1069000</carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_Xu7tjOgRTUeK76jLWt0C5A_39_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">146000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_PSw50UdE20Wp_FfIND541Q_40_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_KopKyvoXtUavdrRpBAIYyg_40_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">187000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_2MKHfECWaEOLJzc4CLskjA_41_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2392000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_S1qNcdJ2gEqQxZDCOXTa4A_41_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">597000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_Mx9FhPGWmEyKPocaU2-ohg_42_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">344000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_sblf370ey0eBr5BvPlMOPQ_42_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">62180000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_8hUBBWZSt0GxhdqS66fRKQ_43_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-59696000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_YVt0DFND4EiBm3bILOgw8Q_43_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">53411000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_Os6R0bb7YES_WafB5TIodA_44_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">77605000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA"
      decimals="-3"
      id="Tc_D_8kuBKHxUSXirwbCahvMw_44_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">24194000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_u8p0gbo_B06YwvcLdst5Tg_45_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">17909000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_2-GU0BFUsEm06dpRXU_4sw_45_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">77605000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_oghPBhTilUKnNGvf3xxVow_47_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">192000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc__hIc5wNwS06HBa0js0I3yw_47_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">352000</us-gaap:InterestPaidNet>
    <carm:NoncashOrPartNoncashAcquisitionEquityAssumed
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_Xa_ZQyU-KEeOIUgDLi17qg_49_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">122204000</carm:NoncashOrPartNoncashAcquisitionEquityAssumed>
    <us-gaap:NotesReduction
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_PS8lHraJ60O7ChnDtHoLtA_50_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">42447000</us-gaap:NotesReduction>
    <carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_SOSfZuRMFkOJpQeCTmZjVQ_51_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41000</carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities>
    <carm:NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_z2pOg6eitkiMeIQyOSBXzg_52_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">9000</carm:NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts>
    <carm:RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_MiVCyqLtf0GrRJpxiMn3bw_53_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1660000</carm:RightOfUseAssetObtainedInExchangeForFinanceLeasesLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_OH5a7lq8JUWaciLuuk4tBg_54_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">6411000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_DnPlzIB2zUWF1MRVIRDgIw_54_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2779000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <carm:NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_fbvZ_MK9BE63NdLUM02fIQ_55_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-1581000</carm:NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities>
    <carm:DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_CZMgClRQEkyIKe4zVP2IAg_56_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">396000</carm:DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_H9FouxHpLkmjQFyGUXat9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(1)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Background&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Overview&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Carisma Therapeutics&#160;Inc., a Delaware corporation (collectively with its subsidiaries, the Company), biotechnology company focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March&#160;and December&#160;2024, the Company and its board of directors approved revised operating plans to reduce&#160;monthly operating expenses, conserve cash, and refocus its efforts on strategic priorities. As part of these plans, in March&#160;2024 the Company elected to cease further development of its first lead product candidate, CT-0508. In December&#160;2024 as part of the plan, the Company elected to cease further development of its then lead product candidate, CT-0525, following an assessment of the competitive landscape in anti-HER2 treatments and the impact of recently approved therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of its cost-reduction initiatives in 2024, the Company implemented workforce reductions during 2024, resulting in the termination of 62 full-time employees (representing approximately 58.0% of the Company&#x2019;s total workforce), across research and development and general and administrative functions. The workforce reduction resulted in $4.1&#160;million of severance related costs, of which $2.0&#160;million and $2.1&#160;million are included within &lt;span style="-sec-ix-hidden:Hidden_fhlu0P8GC0OSYzMKRGa6pg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;general and administrative&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_qKYmVxKGPEGEDMmZP0kvsg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;research and development&lt;/span&gt;&lt;/span&gt; expense, respectively, in the accompanying consolidated statement of operations and comprehensive loss. As of December&#160;31, 2024, $2.7&#160;million in severance costs were accrued in the accompanying consolidated balance sheets. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the 2024 reduction in workforce.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On October&#160;10, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that our common stock was not in compliance with Nasdaq Listing Rule&#160;5450(b)(2)(A), or the MVLS Requirement, which requires the Company to maintain a minimum market value of listed securities of $50,000,000. The Company has 180 calendar&#160;days, or until April&#160;8, 2025, to regain compliance with the MVLS Requirement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On January&#160;6, 2025, the Company received a separate written notice from Nasdaq notifying the Company that, based upon the closing bid price of its common stock for the last 38 consecutive business&#160;days, the Company was not in compliance with Nasdaq Listing Rule&#160;5450(a)(1)&#160;(the Bid Price Rule), which requires the Company to maintain a minimum bid price of $1.00 per share. The Company has 180 calendar&#160;days, or until July&#160;7, 2025, to regain compliance with the Bid Price Rule.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ATt2SkLHckWBYPbLkkt-Gw"
      decimals="INF"
      id="Narr_coJ0WbHKPEqtew9IhmaUYg"
      unitRef="Unit_Standard_employee_8zftLesBXkivzIcTQ6E96w">62</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ATt2SkLHckWBYPbLkkt-Gw"
      decimals="3"
      id="Narr_qIWV4lhHIkWbDpk2I7erng"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.58</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ATt2SkLHckWBYPbLkkt-Gw"
      decimals="-5"
      id="Narr_mJBhEtsL8kGMKRMfTfOVqw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_c0xoT3reKkCaOeL1zPSHLQ"
      decimals="-5"
      id="Narr_rjqOgoMUsUSIT2zw6swBpA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_IC7n65_vc0OYd91beSu5RA"
      decimals="-5"
      id="Narr_6pyASvdGbUaDqSMWzbTJpg"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringReserve
      contextRef="As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_oh2OTmiJvkKgA0D-o9Y6Fw"
      decimals="-5"
      id="Narr_Jr1NJm6BBECrF0bGZwumWg"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2700000</us-gaap:RestructuringReserve>
    <carm:DevelopmentStageRisksAndLiquidityTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_IIVISC03PUK_YVS7JyPtlg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Development-Stage Risks and Liquidity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $305.6 million as of December&#160;31, 2024. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of December&#160;31, 2024, the Company had cash and cash equivalents of $17.9 million. Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one&#160;year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. In addition, changing circumstances could cause the Company to consume capital significantly faster than currently anticipated, and the Company may need to spend more than currently expected because of circumstances beyond its control. The Company&#x2019;s cash forecast contains estimates and assumptions, and management cannot predict the timing of all cash receipts and expenditures with certainty. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liability that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Management is currently evaluating different strategies to maximize value and prepare to wind down the Company&#x2019;s business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;divestiture of one or more of the Company&#x2019;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. There is no assurance regarding when or if this strategic review process will result in any type of transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#x2019;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.&lt;/p&gt;</carm:DevelopmentStageRisksAndLiquidityTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-5"
      id="Narr_Q6G2p4tMqkq1PvctdCxH-w"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-305600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-5"
      id="Narr_NJqzj3yb-0K91buWyVukGQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">17900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_-hdaUaWV3EKbKfIbsMiJ2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(3)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation and Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant areas that require management&#x2019;s estimates include estimated research and development revenue, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets measured at fair value on a recurring basis:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurement at reporting date using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents &#x2013; money markets accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents &#x2013; money markets accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years ended December&#160;31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue in accordance with ASC Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/i&gt;(ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1)&#160;non-refundable, upfront license fees (2)&#160;reimbursement of certain costs; (3)&#160;customer option fees for additional goods or services; (4)&#160;development milestone payments, (5)&#160;regulatory and commercial milestone payments; and (6)&#160;royalties on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&#160;the number of performance obligations based on the determination under step (i)&#160;above; (b)&#160;the transaction price under step (iii)&#160;above; (c)&#160;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&#160;above; and (d)&#160;the contract term and pattern of satisfaction of the performance obligations under step (v)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Upfront license fees&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Customer options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Research and development services&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The promises under the Company&#x2019;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company&#x2019;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Milestone payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of credit risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Segment information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;assessing performance. The Company has one operating segment. The Company&#x2019;s CODM is the chief executive officer. The Company&#x2019;s CODM manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#x2019;s net loss and monitors budget versus actual results to assess the performance of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the&#160;years ended December&#160;31, 2024 and 2023:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collaboration revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,919&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development, excluding facilities, personnel, depreciation and amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,118&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Facilities expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,671&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Personnel expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,564&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,324&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Depreciation, amortization and interest on finance and sale-leaseback lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,894&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,984&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other segment items(a)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,242)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,204)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (60,477)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (86,879)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other segment items include changes in warrant liability and interest income.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly-liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. As of December&#160;31, 2024 and 2023, cash equivalents consisted of investments in a money market account.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:Hidden_w59cdNVWLU6d09CxPojcvA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; to five&#160;years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not recognize any impairment of long-lived assets during the&#160;years ended December&#160;31, 2024 or 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Deferred Financing Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one&#160;year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company&#x2019;s behalf are expensed as services are rendered.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company&#x2019;s common stock prior to the Merger (as defined in Note&#160;4), and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the Merger (as defined in Note&#160;4), the fair value of the Company&#x2019;s common stock was estimated by the Company&#x2019;s board of directors, with input by management considering the Company&#x2019;s most recently available third-party valuation of the Company&#x2019;s common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company&#x2019;s consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#x2019;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,746,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,023,370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Recently adopted accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In November&#160;2023, the FASB issued ASU 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/i&gt;(ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024 on a retrospective basis. The Company incorporated the improved segment disclosures in the summary of significant accounting policies, herein.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Recently issued but not yet adopted accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/i&gt;(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In November&#160;2024, the FASB issued ASU 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_0B29rIV8I06ok93LP2fsdQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation and Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_UMFT8Zv_-UO4-ndbsfKP6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant areas that require management&#x2019;s estimates include estimated research and development revenue, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_b1E-vdPYsUazD6plbkgg9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_udeUxS8fiU6fSDkahdVkQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets measured at fair value on a recurring basis:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurement at reporting date using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents &#x2013; money markets accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents &#x2013; money markets accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years ended December&#160;31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_4gRnamplLk-mqYexy3okNQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets measured at fair value on a recurring basis:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurement at reporting date using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents &#x2013; money markets accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents &#x2013; money markets accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_FPiLpPUNo06fNsnw6eJy3A"
      decimals="-3"
      id="Tc_MqQdEYQTbEyD9E2iC3zoxA_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">14887000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_i3-WcXRxi0W0jzEpmZkO4g"
      decimals="-3"
      id="Tc_pEuUi67Ot02_t9K1VYgFTQ_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">62999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_QI87H7O8CEiThqzp3QYihg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue in accordance with ASC Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/i&gt;(ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1)&#160;non-refundable, upfront license fees (2)&#160;reimbursement of certain costs; (3)&#160;customer option fees for additional goods or services; (4)&#160;development milestone payments, (5)&#160;regulatory and commercial milestone payments; and (6)&#160;royalties on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&#160;the number of performance obligations based on the determination under step (i)&#160;above; (b)&#160;the transaction price under step (iii)&#160;above; (c)&#160;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&#160;above; and (d)&#160;the contract term and pattern of satisfaction of the performance obligations under step (v)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Upfront license fees&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Customer options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Research and development services&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The promises under the Company&#x2019;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company&#x2019;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Milestone payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_qlNBx3BGkkGYgCiiFxThMA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of credit risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_UCFBz0YBcUiCvkth7czORA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Segment information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;assessing performance. The Company has one operating segment. The Company&#x2019;s CODM is the chief executive officer. The Company&#x2019;s CODM manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#x2019;s net loss and monitors budget versus actual results to assess the performance of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the&#160;years ended December&#160;31, 2024 and 2023:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collaboration revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,919&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development, excluding facilities, personnel, depreciation and amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,118&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Facilities expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,671&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Personnel expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,564&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,324&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Depreciation, amortization and interest on finance and sale-leaseback lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,894&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,984&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other segment items(a)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,242)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,204)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (60,477)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (86,879)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other segment items include changes in warrant liability and interest income.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="INF"
      id="Narr_3MGxWNEGXkS5c7Zi2csOag"
      unitRef="Unit_Standard_segment_ieOgHbuNO0uMDAyeDWsL6Q">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_nC-uDXv-i0KK1B7d3O3MXA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the&#160;years ended December&#160;31, 2024 and 2023:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collaboration revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,919&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development, excluding facilities, personnel, depreciation and amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,118&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Facilities expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,671&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Personnel expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,564&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,324&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Depreciation, amortization and interest on finance and sale-leaseback lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,894&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,984&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other segment items(a)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,242)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,204)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (60,477)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (86,879)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw"
      decimals="-3"
      id="Tc_xW6HG0TajE62p-cH9H2pLg_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">19632000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w"
      decimals="-3"
      id="Tc_4doJu1VtykmD88WkD_Bg1A_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">14919000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw"
      decimals="-3"
      id="Tc_VD6CxjV_dE-qHazsd1TKlQ_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">33147000</carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses>
    <carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w"
      decimals="-3"
      id="Tc_uAbdYWGi10W9IVCWn9kvsw_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">45905000</carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses>
    <carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw"
      decimals="-3"
      id="Tc_eAepAi1CL0yrwTxjE6K2Vw_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">14829000</carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses>
    <carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w"
      decimals="-3"
      id="Tc_31ufIBD7ak6bSeciyPBk8A_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">19118000</carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses>
    <carm:FacilitiesExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw"
      decimals="-3"
      id="Tc_p9005RqH20i4C_ybMmAQLA_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5917000</carm:FacilitiesExpense>
    <carm:FacilitiesExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w"
      decimals="-3"
      id="Tc_Ym3NwN2GAkeZuMvn1eH6OQ_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7671000</carm:FacilitiesExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw"
      decimals="-3"
      id="Tc_Tau95sDw8E2gNnTAf1jM0g_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">24564000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w"
      decimals="-3"
      id="Tc_TXeEjW6jzE2YWOWm_7arYg_9_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">27324000</us-gaap:LaborAndRelatedExpense>
    <carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw"
      decimals="-3"
      id="Tc_Kj3ZxRnunU27PQ9taiomHg_10_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3894000</carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities>
    <carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w"
      decimals="-3"
      id="Tc_gx5oP0c4E0uQ2WWDLT6C4A_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3984000</carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw"
      decimals="-3"
      id="Tc_w97pLue7N0-_TqZfVjsVsQ_11_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-2242000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w"
      decimals="-3"
      id="Tc_7LT2qrz0KEG8hWpEIEFBvQ_11_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-2204000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_nhaLnpq-eUuc-n1ajrjbEw"
      decimals="-3"
      id="Tc_bYK2moBqQkKfalCkIqUcLQ_12_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-60477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_dhZPzXNjQEeGATe17YLY2w"
      decimals="-3"
      id="Tc_jT0dQsbSx0uXlUAyX_B3DA_12_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_KDiS5ae5VUKOsHK_MIz5Qw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly-liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. As of December&#160;31, 2024 and 2023, cash equivalents consisted of investments in a money market account.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_Wko7YCepx0O_WreYZv5F_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:Hidden_w59cdNVWLU6d09CxPojcvA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; to five&#160;years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_M2tlaUEGPU-AJlzF8cCTTw"
      id="Narr_0i6ru0Np4keIOmfBj7QYag">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_Hu0oOxJF90CXzgAgUZiQOw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not recognize any impairment of long-lived assets during the&#160;years ended December&#160;31, 2024 or 2023.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="0"
      id="Narr_KOyJbYQSu0aEULjehtWe5Q"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="0"
      id="Narr_PmWbFpNxUk60L0TLCuiWTA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <carm:DeferredFinancingCostsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_7TQF5sfIIk-gburJFx3ZJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Deferred Financing Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately.&lt;/p&gt;</carm:DeferredFinancingCostsPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_duVRVEjfp0CN5ouiBYMq5g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one&#160;year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_WrcianDfcUW02npb6mrBkg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company&#x2019;s behalf are expensed as services are rendered.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_R5jZf2OSJ0yjOF7Akhb5ng">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company&#x2019;s common stock prior to the Merger (as defined in Note&#160;4), and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the Merger (as defined in Note&#160;4), the fair value of the Company&#x2019;s common stock was estimated by the Company&#x2019;s board of directors, with input by management considering the Company&#x2019;s most recently available third-party valuation of the Company&#x2019;s common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_qbEpBwE-q0K3AbpVPD55fw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company&#x2019;s consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#x2019;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_Rql6D7rIZ0GRaLUrnvMRTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,746,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,023,370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_RfOjXOR880u186EN9hddPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,746,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,023,370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_0bTbe1UO4Eu2oXU8xcRc4A"
      decimals="INF"
      id="Tc_DOmHNv5D-kWjUEbt2HWjsg_3_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">7746991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_4gn5Hkv1tkSIJa1ZsZNSzQ"
      decimals="INF"
      id="Tc_t9Kmb2bP70yQPGY7yDdlsA_3_4"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">6023370</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_vRceG_uiF0uc-OeN6eiOYw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Recently adopted accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In November&#160;2023, the FASB issued ASU 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/i&gt;(ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024 on a retrospective basis. The Company incorporated the improved segment disclosures in the summary of significant accounting policies, herein.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Recently issued but not yet adopted accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/i&gt;(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In November&#160;2024, the FASB issued ASU 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_k9xuFLY8M0GQitht34-Sgg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(4)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Merger with Sesen Bio&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March&#160;7, 2023, the Company (formerly publicly-held Sesen Bio,&#160;Inc.) consummated a merger with CTx Operations,&#160;Inc. (formerly privately-held CARISMA Therapeutics&#160;Inc.) (Legacy Carisma) pursuant to an Agreement and Plan of Merger and Reorganization, as amended (the Merger Agreement), by and among the Company, Legacy Carisma and Seahawk Merger Sub,&#160;Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company. The Merger Agreement provided for the merger of Merger Sub with and into Legacy Carisma, with Legacy Carisma continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the Merger). The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Sesen Bio were cash, cash equivalents and marketable securities. For financial reporting purposes Legacy Carisma was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i)&#160;Legacy Carisma stockholders own approximately 74.2% of the Combined Company, (ii)&#160;Legacy Carisma holds the majority (six of seven) of board seats of the Combined Company and (iii)&#160;Legacy Carisma management holds all key positions of management. Accordingly, the Merger was treated as the equivalent of Legacy Carisma issuing stock to acquire the net assets of Sesen Bio. As a result of the Merger, the net assets of Sesen Bio were recorded at their acquisition-date fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Legacy Carisma. Immediately after the Merger, there were 40,254,666 shares of the Company&#x2019;s common stock outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table shows the net assets acquired in the Merger (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 7, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses and other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accounts payable and accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,499)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total net assets acquired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80,308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Transaction costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,264)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total net assets acquired less transaction costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Subsequent to March&#160;7, 2023, the Company paid $4.6 million of severance and personnel costs related to Sesen Bio.&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="As_Of_3_7_2023_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_us-gaap_BusinessAcquisitionAxis_carm_CarismaTherapeuticsIncLegacyStockholdersMember_pAj3UmfAuUCFRdiN77L70Q"
      decimals="3"
      id="Narr_61esBNG_ekiIqsczyFtENg"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.742</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <carm:NumberOfBoardMembers
      contextRef="As_Of_12_31_2024_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_C2cp3L2L3EiZlfTKfZNEqg"
      decimals="INF"
      id="Narr_wyt1KAm1hE-xfkFK6GoUxw"
      unitRef="Unit_Standard_stockholder_xwrsA79JVk6r5Olbumrfaw">6</carm:NumberOfBoardMembers>
    <carm:NumberOfBoardMembers
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_ss0irSdqW0GvEw7Kmwu-Qg"
      unitRef="Unit_Standard_stockholder_xwrsA79JVk6r5Olbumrfaw">7</carm:NumberOfBoardMembers>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_7_2023_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_us-gaap_BusinessAcquisitionAxis_carm_CarismaTherapeuticsIncLegacyStockholdersMember_pAj3UmfAuUCFRdiN77L70Q"
      decimals="INF"
      id="Narr_e5nohxq9X0KFDldcXUMYbA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">40254666</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_d4CrGAg0CkK0uwS7VqGFzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table shows the net assets acquired in the Merger (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 7, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses and other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accounts payable and accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,499)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total net assets acquired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80,308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Transaction costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,264)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total net assets acquired less transaction costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA"
      decimals="-3"
      id="Tc_xFAluFqt9UCIKdKswz9UAw_2_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">37873000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA"
      decimals="-3"
      id="Tc_88P3es2JuEKw9TBDo_ng4Q_3_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">44588000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA"
      decimals="-3"
      id="Tc_dMO9hKC_ZECh-5E83u_dng_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1316000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <carm:Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash
      contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA"
      decimals="-3"
      id="Tc_jwkSiXnUK0OFKx5n7SQNaw_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">30000</carm:Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA"
      decimals="-3"
      id="Tc_PJfrCvRqC0W95DZjiAEPLw_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3499000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA"
      decimals="-3"
      id="Tc__p6PBuZeUEqCq8Ru2luT1g_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">80308000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA"
      decimals="-3"
      id="Tc_tHDmuZUPYEmuUHWggnsusw_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">8264000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA"
      decimals="-3"
      id="Tc_D2mUsFeGkkaSfmD_9u0YKw_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">72044000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:SeveranceCosts1
      contextRef="Duration_3_1_2023_To_12_31_2023_dei_LegalEntityAxis_carm_CarismaTherapeuticsIncMember_61_8Uvl5hUOnb8pf--nrlg"
      decimals="-5"
      id="Narr_WWkxfb9W9EaKYDNephE1dg"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_3iRnzq6pXUu3cT7aPXFakw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(5)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Prepaid Expenses and Other Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 278&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Collaboration receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,864&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 402&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 891&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,866&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_tzlg1HxfXkmVuN2p6-kIfA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 278&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Collaboration receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,864&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 402&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 891&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,866&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <carm:PrepaidResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_FtXHt-vDiUSziJHoIyRdVQ_3_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1715000</carm:PrepaidResearchAndDevelopmentCurrent>
    <carm:PrepaidResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_qRK7a79egUiNeI8Mk1ob6A_3_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">278000</carm:PrepaidResearchAndDevelopmentCurrent>
    <carm:ReceivableDueFromCollaborativeArrangementCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_JFNl4VPjREOUQf2YEcUnjA_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2864000</carm:ReceivableDueFromCollaborativeArrangementCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_jFmrFFgLWEKDBxRc_-M2Nw_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">340000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_BMQrSjOIcUOmNfq8z5rkeA_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">402000</us-gaap:PrepaidInsurance>
    <us-gaap:DepositsAssetsCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_SzqJkexQ2k2WUl9r8nO3Og_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">925000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_h7-bhCKrq02zdylfw2IQxA_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">891000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_CAifDpKeLkCCJdFYDomnJA_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">72000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_YCIAJcaQFU-BzZmqpvTt3A_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1295000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_ZGU_bVr9jEy2uDkO605wWQ_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5916000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_igXjBJVtOUufiH9G2C4-Jw_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2866000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_u7WxQGlVNUyQ7i1P9gD2DA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(6)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Property and Equipment, net&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 903&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment(1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,157&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,392&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 267&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,915&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation and amortization(2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,887)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,151)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,764&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Lab equipment includes failed sale lease-back assets of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3.4&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million as of December&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;31, 2024 and 2023. Lab equipment includes finance lease ROU assets of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3.2&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.9&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million, respectively, as of December&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;31, 2024 and 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The accumulated amortization balance includes &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.5&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.9&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million, respectively, related to failed sale-leaseback assets as of December&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;31, 2024 and 2023. The accumulated amortization balance includes &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.3&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.7&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million, respectively, related to finance lease ROU assets as of December&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;31, 2024 and 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Depreciation and amortization expense was $3.4&#160;million and $2.8&#160;million for the&#160;years ended December&#160;31, 2024 and 2023, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_PVpiN2_ojUKQiaUmON-p7A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 903&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment(1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,157&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,392&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 267&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,915&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation and amortization(2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,887)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,151)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,764&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Lab equipment includes failed sale lease-back assets of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3.4&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million as of December&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;31, 2024 and 2023. Lab equipment includes finance lease ROU assets of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3.2&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.9&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million, respectively, as of December&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;31, 2024 and 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The accumulated amortization balance includes &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.5&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.9&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million, respectively, related to failed sale-leaseback assets as of December&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;31, 2024 and 2023. The accumulated amortization balance includes &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.3&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.7&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million, respectively, related to finance lease ROU assets as of December&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;31, 2024 and 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember_6a9BvHfS2069NVgEd9BlgQ"
      decimals="-3"
      id="Tc_jed4e_tga0u06rTAO_TiRw_3_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">508000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember_IuSFljhV5ECw_6wtTyDvMA"
      decimals="-3"
      id="Tc__cf5HXVHwUCGeboDlTrPIA_3_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">903000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QKEF25OlKUyFEjDTw-T6ZQ"
      decimals="-3"
      id="Tc_Jo3uH1Y-HUWDKv3VtHvuKA_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">11157000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_V1MVYY5yOk6TrVp02Gj08A"
      decimals="-3"
      id="Tc_d9qAza6tfkqsWIbpGwWplg_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">11392000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_SbAUMjqBzk-GzWMJw0e0Qw"
      decimals="-3"
      id="Tc_msK9wH_8xUmNDDJfcmINyA_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">267000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_MqoxSix-Y02bOPp5O0niiA"
      decimals="-3"
      id="Tc_vPvzpke-90ujC67qnffi-g_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">267000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_q6mQUCRJFESSS-dSvTvrAg"
      decimals="-3"
      id="Tc_Y9zRRZgsU0Swh7CatgWoew_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">340000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_QBP2ErMrOUK4Ayldn4JM8Q"
      decimals="-3"
      id="Tc_6LvW1MbxqU-S_43TgrJ33Q_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">340000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_GuIsy6UvbEOGPaKsDXeA4g"
      decimals="-3"
      id="Tc_-Euj2zDHi0iQNYii3yY1eg_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">13000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_CceeYxgMqkSpEuPL100UzQ_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">12272000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_WRJmrEDhN0KeyNrANZ4VGg_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">12915000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_gVUEkTjOaUeRDSEF3g0yWw_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7887000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_rIZcPN_FTEqZ17eNCVYtFg_9_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">6151000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_75FmhL-2xEaipD8HJ80nAg_10_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4385000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_mzylf6mKx0ax90o30J8WUQ_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">6764000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:SaleLeasebackTransactionNetBookValue
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-5"
      id="Narr_IvsQkFaJ-UCaziO1HSQi-g"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3400000</us-gaap:SaleLeasebackTransactionNetBookValue>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-5"
      id="Narr_gSYCvAJzv0Sce9KemfKm0Q"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3200000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-5"
      id="Narr_tbcQ2onZnEqPnSuYZ9FpgQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2900000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:SaleLeasebackTransactionAccumulatedDepreciation
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-5"
      id="Narr_8aqxTFaNi0ChTD2aWFCoMw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1500000</us-gaap:SaleLeasebackTransactionAccumulatedDepreciation>
    <us-gaap:SaleLeasebackTransactionAccumulatedDepreciation
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-5"
      id="Narr_X_SEsefpnkiHvm6_MRAHCQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">900000</us-gaap:SaleLeasebackTransactionAccumulatedDepreciation>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-5"
      id="Narr_a7ByPDYN-06xndVuI1CZGw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2300000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-5"
      id="Narr_MpoMfF7HWES6MtUQ7_X2PA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1700000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-5"
      id="Narr_80ATnk1RD0mVifbI01nkRQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-5"
      id="Narr_mfx2w9_0KkimDJxNG4FmlQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_GgPOyM-uYESCp3An-Z2kJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(7)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,131&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Compensation and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 187&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,448&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,662&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_Pi5wDf7zy0SNixDxeBdrlQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,131&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Compensation and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 187&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,448&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,662&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <carm:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_GkHNcP51dEqvVBlQ5XtS2w_3_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1845000</carm:AccruedResearchAndDevelopmentExpenseCurrent>
    <carm:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_B7qb6hck7k2t4gJZfmko6Q_3_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3131000</carm:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_LDz5T59W9ESxgdjZ7gBQQQ_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">537000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_pCr2hea62E21_RXKIJ5z3A_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1366000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_Wso9eg_dEEG4g2EgbfBiwg_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4879000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_UpxVm0fp8kiMOs3hA8wJDw_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_msBoaFMsD0G0Sq2MB7GnVg_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">187000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_cdsSrsVR-UiuiFj34_X9tw_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">65000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_WyPIOIruCES3X3B-K7HA8g_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7448000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_VdLuvEMFP0mbgPHxOIhCeA_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7662000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_rLwjywlw2U2trrdcpaAEjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(8)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#x2019;s operating leases have term end dates ranging from 2025 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2025 to 2026. Effective February&#160;2024, the Company renewed an existing operating lease with an end date through 2026. In April&#160;2024, in connection with the revised operating plan, the Company notified the lessor that it would terminate the lease effective August&#160;2024. In July&#160;2024, the Company entered into an amendment extending the termination date of the lease to June&#160;2025 with an option to extend to December&#160;2025. The Company did not incur any penalties or fees in connection with the termination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In September&#160;2024, the Company modified existing finance leases and failed sale-leaseback arrangements by assigning the rights and obligations of certain underlying assets to an unrelated third party. The modifications resulted in a reduction of its finance lease &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;ROU assets and related lease liability of $0.4&#160;million. In addition, the Company recorded a reduction of its failed sale-leaseback liability and gain on the sale of the corresponding assets of $0.1&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s operating and finance lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company carries laboratory equipment from failed sale-leasebacks, as property and equipment, net on the accompanying consolidated balance sheets. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of December&#160;31, 2024, the Company had a $1.4 million financing liability recorded in other current liabilities and other long-term liabilities on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The elements of the lease costs were as follows (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,774&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Amortization of lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,584&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total finance lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,801&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,326&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,071&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Short term lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 671&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,833&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Lease term and discount rate information related to leases was as follows:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental cash flow information was as follows (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash used in operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,764&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash used in finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financing cash used in finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Future maturities of lease liabilities were as follows as of December&#160;31, 2024 (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Fiscal year ending:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 927&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total future minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (253)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (38)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 925&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Licensing and Sponsored Research Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November&#160;2017 (Penn License Agreement), the Company is required to make annual payments of $25,000. Penn is eligible to receive up to $10.9 million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $30.0 million per product in commercial milestones and up to an additional $1.7 million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March&#160;2023, the Company entered into a manufacturing and supply agreement with Novartis Pharmaceuticals Corporation (Novartis) for the manufacturing of the Company&#x2019;s CT-0508 product candidate (Novartis Agreement). The Novartis Agreement had a five year term. On June&#160;26, 2024, in furtherance of its revised operating plan approved in late March&#160;2024, the Company terminated the Novartis Agreement. Upon termination, the Company incurred a termination fee equal to $4.0&#160;million, which was paid in the third quarter of 2024. A prepaid asset was recorded as the Company separately agreed with Novartis that if Novartis and the Company re-negotiate the agreement for a substitute product on or before December&#160;31, 2024, then the $4.0&#160;million termination fee would be credited in full or in part against any amounts due from the Company to Novartis under such agreement relating to the substitute product. The Company did not re-negotiate the agreement and expensed the $4.0&#160;million prepaid asset in the fourth quarter of 2024 to research and development in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. As of December&#160;31, 2024, the Company was in negotiations with a vendor to determine the total costs owed for research and development services provided. While the negotiations are ongoing, the Company believes a liability is probable. The Company has estimated the amount to be owed to be $1.2&#160;million which is included within accrued expenses on the accompanying consolidated balance sheets. The final amount owed may differ from the estimate as negotiations progress. The Company will continue to evaluate the matter and will adjust the liability as necessary based on any new information or agreements reached with the vendor.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <carm:IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification
      contextRef="As_Of_9_30_2024_CsDzke0V0UKpQy6JppgEbw"
      decimals="-5"
      id="Narr_NdPdj6lXbEue-k5SeuDBlg"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-400000</carm:IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet
      contextRef="Duration_9_1_2024_To_9_30_2024_Zs5TM9E90UOa54MlGv6RJw"
      decimals="-5"
      id="Narr_dnhR3qNnWkyuwnd09drcYg"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">100000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QKEF25OlKUyFEjDTw-T6ZQ"
      decimals="-5"
      id="Narr_EZYqumww0EqOKAEDC3Cn9w"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1400000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_6DJQtyQT2E6dhu86cvPzuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The elements of the lease costs were as follows (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,774&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Amortization of lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,584&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total finance lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,801&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,326&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,071&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Short term lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 671&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,833&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_-0FuZHYwckm9vcUVUuHNEg_3_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5245000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_5oJtV6vd9kSxCuSF5boYww_3_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5774000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_tNLgD7-M00a9VoJqSPJqZg_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1584000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_RTV5r72xgk-edJCfCiykJA_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1187000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <carm:FinanceLeasesInterestExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc__y9w8R_S2kC2STREg43Jig_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">217000</carm:FinanceLeasesInterestExpense>
    <carm:FinanceLeasesInterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_kWHPUIJEAUm8WcrOZtS-yQ_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">139000</carm:FinanceLeasesInterestExpense>
    <carm:FinanceLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_Fd7vd7CLkESS_yWXZwpOjg_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1801000</carm:FinanceLeaseCost>
    <carm:FinanceLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_Y0k2NnOuRkCtqgiKu3pmXw_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1326000</carm:FinanceLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_9XQEGKB2HkKTZGwDQEwbpQ_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1071000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_DEVevxVakkWlWmFtCG7TLA_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1733000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_42dabL9UN0WmxMtC2azerQ_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">671000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_octQvlcgQ0OCM5PABlp1DQ_10_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">8788000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_D2fLn8bc1E6GVB1FxCDAxw_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">8833000</us-gaap:LeaseCost>
    <carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_ZPz6Nz5flUGQVGUe1ivlhQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Lease term and discount rate information related to leases was as follows:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      id="Tc_BPkCyxyUIkWxld0K369XAw_4_2">P2Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      id="Tc_Uyk8SDAOOE2_Sza4oCzwJg_4_4">P2Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      id="Tc_C-EM7X86dUWes0D4pQFU4A_5_2">P0Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      id="Tc_QZD5H6HN10uXfQUhmoqWfw_5_4">P1Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="3"
      id="Tc_j1uKSl4d9UygRhcxd2nFMg_7_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="3"
      id="Tc_EmJLfRAEMECCz7k3jgblhw_7_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.098</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="3"
      id="Tc_s-54FzvodEWEc4zSE8V1UA_8_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.09</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="3"
      id="Tc_NUFRJh2xj0GaUHSOrbTJ2Q_8_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.09</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_Pg17Hgjl5EGZ3ZSTVMt20A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental cash flow information was as follows (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash used in operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,764&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash used in finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financing cash used in finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_TbYguIVeMUWvRUQGwXVwKg_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5807000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_XajKoC9zgUudOtN_JLD3fw_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5764000</us-gaap:OperatingLeasePayments>
    <carm:FinanceLeasesInterestPaymentOnLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_eFp-kWrpHEeID-ts13aGBA_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">217000</carm:FinanceLeasesInterestPaymentOnLiability>
    <carm:FinanceLeasesInterestPaymentOnLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_dl2C5Mri00q79ORN_gny6Q_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">139000</carm:FinanceLeasesInterestPaymentOnLiability>
    <carm:FinancingCashUsedInFinanceLeases
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_xUKwUu_VcU2qyu1wr_p2kA_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1429000</carm:FinancingCashUsedInFinanceLeases>
    <carm:FinancingCashUsedInFinanceLeases
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_RLYa56_W3E2dksPnxVEj-A_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1301000</carm:FinancingCashUsedInFinanceLeases>
    <carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_NuQXw6o3akCiM4A3_GY3kg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Future maturities of lease liabilities were as follows as of December&#160;31, 2024 (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Fiscal year ending:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 927&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total future minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (253)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (38)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 925&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_ZDXHxegPvEaTITwgI2ZMLA_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">927000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_Ex-S5iATFkCqdEcum8XClQ_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">942000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_bw91P4w-10KJDbHwYuTdvQ_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">225000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_7RD6TyWi6UCBRs8SooKTQA_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">21000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_KVwGutQW-U-u6hVi9Pt-Hg_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">233000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_dJ49fnfTO0C20_Qv1kIL2w_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">240000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_Dge4OD6H4U-_QSklxOv4Ig_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">184000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_u-4k-tCFVke_ELN4WLvsXA_10_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1809000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_V_MAuiJ2wUaclB4Bzzz6Bg_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">963000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_kf1JO61hmUisa4rAs1ziNQ_11_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">253000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_cvScem926Eq3ZdOoKWSiMQ_11_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">38000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_owgz2wQaE06HHvOWt2UzyA_12_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1556000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_CuaHvmcis0ORXkBLZ1gdlA_12_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">925000</us-gaap:FinanceLeaseLiability>
    <carm:CommitmentsAnnualPaymentsRequiredToBePaid
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_9VloD_2BKUaBco__8m0cCA"
      decimals="-3"
      id="Narr_3UooqYS3q0mmopdPbGmD0Q"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">25000000</carm:CommitmentsAnnualPaymentsRequiredToBePaid>
    <carm:AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_Tu1FMTWJ-EKur2Ehg_NuIw"
      decimals="-5"
      id="Narr_2lPObfexX0GvQrxv-QXoHg"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">10900000</carm:AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents>
    <carm:AdditionalMilestonePaymentsRequiredToBePaid
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_c-DL08jYk0mOjzSXLvRWJA"
      decimals="-5"
      id="Narr_5YBFeo3OTUGFTpaSW_W8zw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">30000000</carm:AdditionalMilestonePaymentsRequiredToBePaid>
    <carm:AdditionalMilestonePaymentsForTheFirstCARMProduct
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_9VloD_2BKUaBco__8m0cCA"
      decimals="-5"
      id="Narr_s0xG_MyOUEGW-2Gi7Gge4w"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1700000</carm:AdditionalMilestonePaymentsForTheFirstCARMProduct>
    <carm:AgreementTerm
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_8sZcvCnSPkeitKoqY5sunw"
      id="Narr_9KWQO46cr0O5PDN3WQmTnw">P5Y</carm:AgreementTerm>
    <us-gaap:LossOnContractTermination
      contextRef="Duration_6_26_2024_To_6_26_2024_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_pGYfhVmGEUO0Q3irnyGzOg"
      decimals="-5"
      id="Narr_HwinnIljd0yN318-LtDHmA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4000000</us-gaap:LossOnContractTermination>
    <us-gaap:LossOnContractTermination
      contextRef="Duration_6_26_2024_To_6_26_2024_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_pGYfhVmGEUO0Q3irnyGzOg"
      decimals="-5"
      id="Narr_GyLLnhfyRkegMTmoiIy9JQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4000000</us-gaap:LossOnContractTermination>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_6_26_2024_us-gaap_TypeOfArrangementAxis_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_eohhy-W8CE6cTQBIagwUsA"
      decimals="-5"
      id="Narr_g7qsjoAVrEadTHVCRM-17g"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-5"
      id="Narr_pdjD9jN0uEirmuMHxe1R-A"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1200000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_Sj8yGmtHL0S5tUZvw5MgxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(9)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Stockholders&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#x2019;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt; (Deficit) Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March&#160;7, 2023, in connection with the closing of the Merger, the following is reflected on the consolidated statements of convertible preferred stock and stockholders&#x2019; (deficit) equity for the&#160;year ended December&#160;31, 2023: (i)&#160;the sale of 3,730,608 shares of common stock in a pre-closing funding at $8.21 per share for total proceeds of $30.6 million, (ii)&#160;the issuance of 5,059,338 shares of common stock upon the settlement of the Company&#x2019;s $35.0 million convertible promissory note, accrued interest and related derivative liability, (iii)&#160;the conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;interests into 18,872,711 shares of common stock, (iv)&#160;the issuance of 10,374,272 shares of common stock to Sesen Bio stockholders as consideration for the Merger.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April&#160;17, 2023, the Company filed a universal shelf registration statement on Form&#160;S-3, which was declared effective on May&#160;2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to $300.0&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May&#160;12, 2023, the Company entered into an Amended and Restated Open Market Sale AgreementSM (Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to $100.0&#160;million under an &#x201c;at-the-market&#x201d; offering program. During the&#160;years ended December&#160;31, 2024 and 2023, the Company sold 1,136,384 and 226,533 shares of common stock, respectively, for gross proceeds of $2.4&#160;million and $0.6&#160;million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On June&#160;6, 2023, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s Restated Certificate of Incorporation to increase the number of authorized shares of the Company&#x2019;s common stock, $0.001 par value, from 100,000,000 shares to 350,000,000 shares and authorized 5,000,000 shares of preferred stock, $0.001 par value.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw"
      decimals="INF"
      id="Narr_qbJeIn5ggkOjXRQiVBDE_w"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">3730608</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_7_2023_g1D7IEP1006Nq5SKGq7_CA"
      decimals="2"
      id="Narr_QONazLVsT0iPqxKFUrZHmQ"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">8.21</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw"
      decimals="-5"
      id="Narr_8zV9Z-G7RE6hwCBKITVSvw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">30600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw"
      decimals="INF"
      id="Narr_OQ6THXb7L0qwMjairnCFDg"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">5059338</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw"
      decimals="-5"
      id="Narr_JlM75FWkBkanYNN0M04rng"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">35000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests
      contextRef="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw"
      decimals="INF"
      id="Narr_C1S1vPzli0S9xuuyvI_LVQ"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">18872711</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_3_7_2023_To_3_7_2023_UJRGBMzkhkeDVlgoLRqNnw"
      decimals="INF"
      id="Narr_AMG4lBTsnkyrCAcHglM75Q"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">10374272</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <carm:SaleOfStockStockOfferingAmount
      contextRef="As_Of_4_17_2023_x6SGs_0tqUWE9Nmq-r1zlw"
      decimals="-5"
      id="Narr_VFsYq8_pJU29lo9Oir38sw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">300000000</carm:SaleOfStockStockOfferingAmount>
    <carm:SaleOfStockMaximumOfferingAmount
      contextRef="As_Of_5_12_2023_2Ua3tacy0kqoCl2kZhnnpw"
      decimals="-5"
      id="Narr_bkGViahNN0GpGHoznoq0YQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">100000000</carm:SaleOfStockMaximumOfferingAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_PW5Xs3_AFk2m4nSwFHd7Pg"
      decimals="INF"
      id="Narr_j2pBvOedU0OZGe4SCfyfrw"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">1136384</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_6dVwitkd0UeHb10KsXjOdw"
      decimals="INF"
      id="Narr_j91-WbRQ-kWXjbLhzo_1dA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">226533</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_PW5Xs3_AFk2m4nSwFHd7Pg"
      decimals="-5"
      id="Narr_9t9dNKEohEyoK2ujxJJ9_A"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2400000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_6dVwitkd0UeHb10KsXjOdw"
      decimals="-5"
      id="Narr_pMVtrlIxVU-3m33Do8t5sw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">600000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_ZJgmSvbfsEmBFrlJz5emyA"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_5_2023_xtoCxfMB7kSash1MJ5CA_A"
      decimals="INF"
      id="Narr_ivF6ULv-DEmR1KzpXumwQQ"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_6_2023__sMm62IFwUO3DNhZ5LDZlg"
      decimals="INF"
      id="Narr_1WZWkDHI70i15l44f1hwPA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_6_2023__sMm62IFwUO3DNhZ5LDZlg"
      decimals="INF"
      id="Narr_lFeUm3T-BE2jocx9qW_wCQ"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_6_2023__sMm62IFwUO3DNhZ5LDZlg"
      decimals="INF"
      id="Narr_3ZcYJdWoLkCLlk_7PU8cbA"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_AuyiENpqAUKA-MUCHJas6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(10)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;2017 Stock Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company adopted the CARISMA Therapeutics&#160;Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was ten&#160;years, and stock options typically vested over a &lt;span style="-sec-ix-hidden:Hidden_sktIWaH1v0C3Alvvbznotw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;four-year&lt;/span&gt;&lt;/span&gt; period. The Company&#x2019;s stock options vest based on the terms in the awards agreements and generally vest over &lt;span style="-sec-ix-hidden:Hidden_wSmhQcT4p0uaTZTD8dNi8A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;four&#160;years&lt;/span&gt;&lt;/span&gt;. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Legacy Carisma Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;2014 Stock Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Amended and Restated 2014 Stock Incentive Plan, as amended, provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Company&#x2019;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#x2019;s board of directors at the time of grant. Stock options outstanding under the 2014 Amended and Restated Stock Incentive Plan (the 2014 Plan) generally vest over a four-year period and are exercisable for a period of ten&#160;years from the date of grant. As of December&#160;31, 2024, approximately 4.8 million shares of common stock remained available for issuance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;2014 Employee Stock Purchase Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Carisma Therapeutics&#160;Inc. 2014 Employee Stock Purchase Plan (the Carisma 2014 ESPP) provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The purpose of the Carisma 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock. The Carisma 2014 ESPP had 0.2 million shares of common stock available for issuance as of December&#160;31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes stock option activity:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;term (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,023,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,810)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,805,465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,078,034)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,746,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,414,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant-date per share fair values of options granted during the&#160;years ended December&#160;31, 2024 and 2023 were $1.36 and $4.29, respectively. The fair values in the&#160;years ended December&#160;31, 2024 and 2023 were estimated using the Black-Scholes option-pricing model based on the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:32.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.77% - 4.59%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.92% - 4.76%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;86.55% - 112.12%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;57.77% - 103.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation Expense&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,649&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In connection with the reductions in force, 1,898,297 options were forfeited during the&#160;year ended December&#160;31, 2024. The Company recognized stock-based compensation expense of $0.2 million related to the modification of Sesen Bio options assumed in connection with the Merger during the&#160;year ended December&#160;31, 2023. Compensation cost for awards not vested as of December&#160;31, 2024 was $7.2 million and will be expensed over a weighted-average period of 2.5&#160;years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_2mhPn7jIZ0e-ZbcpUrxB9g"
      id="Narr_yzVNskjRtUGPZ_zJv1MBXw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_h2U2al8QUkCz4difeEQiVQ"
      id="Narr_LTgjy944c0ufpCr0IKeXtA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_h2U2al8QUkCz4difeEQiVQ"
      id="Narr_Y-IGUj24tUmyIsOdboWJtg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_0LrR7jztQ0mtgFQjdW7yZw"
      decimals="-5"
      id="Narr_NDd9IKw1Q0GbkAaSi2RW0A"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_pc5coAuKZUS70I6GNo3axA"
      decimals="2"
      id="Narr_9VTQyPn2SUS1Tp2dF1iLnA"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_bhT6DCaLkEussR-MSi5DIA"
      decimals="-5"
      id="Narr_myIYHEfnRUirn5d3NYo5Dg"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_8cOi6AyAb0Wdtrs015-vgQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes stock option activity:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;term (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,023,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,810)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,805,465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,078,034)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,746,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,414,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="INF"
      id="Tc_5v3d7-8a80CRFCosr2TJxw_6_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">6023370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="2"
      id="Tc_9a5QQ1cxm0OPLtrCg4dwiw_6_5"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">3.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="INF"
      id="Tc_Tvk_JEIRgkKrIApvrm2VjA_7_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">3810</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="2"
      id="Tc_ZhMQxi6hUU-OeITieXdK7Q_7_5"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_Ymok24VEa0GHgnyHyCNQrA_7_10"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="INF"
      id="Tc__BV4lNk5MU6240V48M7JCg_8_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">3805465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="2"
      id="Tc_oTATtIe6BUOQs7eBus5rFA_8_5"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">1.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="INF"
      id="Tc_3idsouHWBUW9RqXWC0i4jA_9_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">2078034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="2"
      id="Tc_An9LNww1FUq0pKqlIM8-QQ_9_5"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">4.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Tc_2nnSqcsaH0aKgR8Dl2rS4A_10_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">7746991</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="2"
      id="Tc_8tRFswAlQ0qY5kwepRPsqQ_10_5"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tc_NOJILGvlGUC6CIlutmWUbg_10_7">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_QR8AsnwwT06nlWhYu6IwJQ_10_10"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">59000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Tc_yKPv9aS2WkWKK9C7U9wjww_11_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">4414750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="2"
      id="Tc_c0_C6DfWLkm_dh5fg9rjBA_11_5"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tc_BqVLQPC3KEmCb13qdOkYlQ_11_7">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_R-Or5PVt50yOQeLOcNp4oA_11_10"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">59000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="2"
      id="Narr_6dtC6NXAhUuwkhWr1a0TEA"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">1.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="2"
      id="Narr_NarghcerTEGjqGXP7kizgw"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">4.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_-POMA6FSVk2f4IZsVKoESg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:32.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.77% - 4.59%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.92% - 4.76%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;86.55% - 112.12%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;57.77% - 103.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_XarV9JooQUGFgqT3MKU-nQ"
      decimals="4"
      id="Narr_Jy3A35tFQEaRCO09oGAs6g"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.0377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0Ff2XJct5EKaCIPhtjMWRg"
      decimals="4"
      id="Narr_bXWFIHRgU0eef2KumIMzsA"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.0459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pbvS30z8A0CePGJ6mxV3wA"
      decimals="4"
      id="Narr_2QWM7ENoBkm3owBikeh-ww"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.0292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rXpt9Tr8wEWedRsbme4_rg"
      decimals="4"
      id="Narr_RdH8Z_AZ3kqYTDOSubzRkg"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.0476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_EbpMHxZ2vk61tk33Oa6FYQ"
      id="Narr_Hm3rnN2el0umdGqPQwHrew">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__FKxuQApK0mFwWZqpuOrwQ"
      id="Narr_i2gVs5Rp7E2UEQQGF2n0Ew">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_XarV9JooQUGFgqT3MKU-nQ"
      decimals="4"
      id="Narr_keootmrEjkaMBe5C0Tgmjg"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.8655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0Ff2XJct5EKaCIPhtjMWRg"
      decimals="4"
      id="Narr_JMf7J6ZF5ESy7dTzR168oA"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">1.1212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pbvS30z8A0CePGJ6mxV3wA"
      decimals="4"
      id="Narr__GBi_A8djEu3T4Ds6Vc0-w"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.5777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rXpt9Tr8wEWedRsbme4_rg"
      decimals="4"
      id="Narr_oQUBrmcmf0mb0AFkZgD0Uw"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_jODpYrZ6HkCIERAO53iOcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,649&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_GdlsibT2VkyP132eYkVPyQ"
      decimals="-3"
      id="Tc_gBCbD4FYXkujI9Cc56B01Q_3_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Nd0oPvzMG06tOEVwN21Lsg"
      decimals="-3"
      id="Tc_kZGJ_9ubHkedlGnZe2YWcA_3_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1242000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_s7tqgkjRX0S1t8FSmRyS6w"
      decimals="-3"
      id="Tc_dDAkgPMlIkK9oa36JHifEg_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2533000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_R3R2qv2BVEOZuSzVu7JMsw"
      decimals="-3"
      id="Tc_sCkoxlBvdU67SWyphzZJig_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_m23xSHqmQku5Z-ABsW_AWQ_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3649000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_DyezEggHyEGA_KU974st0A_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2316000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_carm_RevisedOperatingPlanMember_8xDVoP31YEeXATz_aXlYog"
      decimals="INF"
      id="Narr_h0d_vQoPsUaMVTeSYEREiw"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">1898297</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_carm_SesenBioIncMember_wbOBDpL9fE2NWwfHImRktA"
      decimals="-5"
      id="Narr_zY0nAHBN60OYa84ejfsemw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-5"
      id="Narr_y38l3sVKRkuiTa7JxvCyUA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Narr_VXN6r9RRSUGzBgueZWWu2Q">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb__7BkDK_UMUO4naUWC3ByqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(11)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local tax rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for&#160;years in which differences are expected to reverse.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets for federal income taxes consisted of the following (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87,742&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,689&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Capitalized research and development costs, net of amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,608&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,778&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,269&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,746&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Start-up costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,051&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,407&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Amortizable assets and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Equity compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 155,132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 134,749&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (153,855)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133,580)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (848)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (645)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (429)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (524)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,277)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,169)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net deferred tax assets and liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2024, the Company has net operating loss carryforwards (NOLs) for federal income tax purposes of $374.7&#160;million, which are available to offset future federal taxable income. The pre-2018 federal NOLs of $120.0&#160;million will begin to expire in 2031, if not utilized. The post-2017 federal NOLs of $254.7&#160;million carry forward indefinitely. The Company also has NOLs for state and local income tax purposes of $280.3&#160;million and $65.1&#160;million, respectively that are available to offset future taxable income. The state NOLs will begin to expire in 2031 while the city of Philadelphia NOLs begin to expire in 2042. As of December&#160;31, 2024, the Company also had federal and state research and development tax credit carryforwards of $12.6&#160;million and $0.8&#160;million that will begin to expire in 2029 and 2032, respectively, unless previously utilized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#x2019;s net deferred tax assets as of December&#160;31, 2024. The valuation allowance increased by $20.3&#160;million and $84.5&#160;million during the&#160;years ended December&#160;31, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50&#160;percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits net operating loss utilization as a&#160;percentage of apportioned taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense/(benefit). As of December&#160;31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s financial statements. Tax&#160;years from 2021 and after remain subject to examination by all of the taxing jurisdictions. The NOLs and research credit carryforwards remain subject to review until utilized.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb__a53-otRS0mfJ0Wole9e4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local tax rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="3"
      id="Tc_PJWIVlyvmkqSFrpiSEIslg_3_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="3"
      id="Tc_CmWI4D9F0U-733TpaECEiA_3_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="3"
      id="Tc_5scoIBSUuE-beD8OWI_GSw_4_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.08</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="3"
      id="Tc_kRrBpdwNakqXAxgSTqrO1A_4_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.085</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="3"
      id="Tc_g_oOW4lvKUuMt2MKgRE57g_5_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">-0.031</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="3"
      id="Tc_gZtmoWpMek6US4LVdDuJwA_5_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal>
    <carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="3"
      id="Tc_QeMe6gXVzUmIkA5vIgTMjQ_6_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">-0.001</carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="3"
      id="Tc_8lNKVzof7ECWJw5MY2HsGg_6_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">-0.004</carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="3"
      id="Tc_fKywLtth5E-G8hMnWXOMPw_7_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">-0.058</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="3"
      id="Tc_l0YHVCk4akaXxAZKRabhYA_7_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="3"
      id="Tc_WZLlrC499USSS_mXeaUDew_8_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">-0.33</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="3"
      id="Tc_sLWFJj96CEa3_ZfkLqRHkA_8_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">-0.284</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="3"
      id="Tc_KzQZoYc7zUqwBDjeAR0pgA_9_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="3"
      id="Tc_l5hb3HXSokCQ0BRvufOvHg_9_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="3"
      id="Tc_GLs2pDJ0vUu8N_wF2aieew_10_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="3"
      id="Tc_f7aM7QqPYEudNcNxtDhCyw_10_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_jUsWgt8orE2jxBPBdPqT0Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets for federal income taxes consisted of the following (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87,742&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,689&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Capitalized research and development costs, net of amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,608&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,778&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,269&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,746&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Start-up costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,051&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,407&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Amortizable assets and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Equity compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 155,132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 134,749&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (153,855)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133,580)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (848)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (645)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (429)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (524)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,277)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,169)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net deferred tax assets and liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_ElsyitPXm02oCte_ahjE5w_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">87742000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_9uLfqI-NO0-g15VEFpqnEQ_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">72689000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_gsT_Y7_UXk-BnDUNq00KFA_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">35608000</carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization>
    <carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_uGtMjG7_n0Kdd1Qyse1epg_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">33778000</carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_jBDZPD8ZHk6wj8LiOTv-0A_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">13269000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_wbHG4JT8i0qUq4WqbQZzzw_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">9746000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <carm:DeferredTaxAssetsStartUpCosts
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_j1E30Act602ilWME2ZrggQ_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4051000</carm:DeferredTaxAssetsStartUpCosts>
    <carm:DeferredTaxAssetsStartUpCosts
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_UmmfnEzYB0-35NhKAh9jFQ_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4407000</carm:DeferredTaxAssetsStartUpCosts>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_ThSyv2T1qk-CD7Awfv5cQQ_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">12182000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_KW5ECMY3AkK1XM0GVjvfWg_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">13353000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <carm:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_B4okYQa7DEuZdJJLyWY1iA_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">733000</carm:DeferredTaxAssetsLeaseLiability>
    <carm:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc__GatYy3weES6xAr5msb-9w_9_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">668000</carm:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_musarYxIiUSz88eqtEkekg_10_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">405000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_yRYCjf4gNEK0_RDdUlVqIg_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <carm:DeferredTaxAssetsAmortizableAssetsAndOther
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_s8CcRBN6FE2godL19ZjcHg_11_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">27000</carm:DeferredTaxAssetsAmortizableAssetsAndOther>
    <carm:DeferredTaxAssetsAmortizableAssetsAndOther
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_NeKwA2E-80S6wc2WxZCioQ_11_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">21000</carm:DeferredTaxAssetsAmortizableAssetsAndOther>
    <carm:DeferredTaxAssetsEquityCompensation
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_9ZepxX8OiE2UBGLC4QsxQQ_12_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1115000</carm:DeferredTaxAssetsEquityCompensation>
    <carm:DeferredTaxAssetsEquityCompensation
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_ElsEDAMF4kuOWm6hbuwoLg_12_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">87000</carm:DeferredTaxAssetsEquityCompensation>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_SY8H5W1L0EKtLJNSa4rCtQ_13_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">155132000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_aC8D__eKB0Sl9xezJZxy6A_13_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">134749000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_MKcuQjcURUm7AMHyl5llnQ_14_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">153855000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_YowC-KxH502e0muFEL1LHg_14_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">133580000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_q03yMiby20WWQ_FEEj3jrw_15_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1277000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_NOD7J-s2GkKS4V5bMfEDMA_15_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1169000</us-gaap:DeferredTaxAssetsNet>
    <carm:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_WVqY03WAk0ajTiG6ZUt33w_17_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">848000</carm:DeferredTaxLiabilitiesRightOfUseAsset>
    <carm:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_V4_b7jnEjkOJhVlgeGpxcQ_17_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">645000</carm:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_LmKinhvcEUanRSefjlVMlA_18_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">429000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_nnHz13E6zkWFy9LJ_CmToA_18_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">524000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_5NsSk3c_30e2mq7JqRJx8Q_19_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1277000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_sQisCJhUN0OIkoDOpJXbdg_19_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1169000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_eROSWIerskuXd2zPJEy2Qw_20_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_25xRhjAq0UCN-s4C4WuEAQ_20_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_f1OJ6DnIk0WtNUSppxvYrg"
      decimals="-5"
      id="Narr_ho6pKkp3z0utRGdHY_nSAA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">374700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_carm_Pre2018Member_dstQjZ_6a0e4qC0YXpJpZw"
      decimals="-5"
      id="Narr_k9JLDSQGjE2lNhQnzAQQnw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">120000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_carm_Post2017Member_f3GDnlkCKkiBu7MDgLhD9Q"
      decimals="-5"
      id="Narr_rHc7cYUhXU-_AfcsLzuKOQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">254700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_carm_StateJurisdictionMember_efJJVuhcvkquKiB45VCQ1A"
      decimals="-5"
      id="Narr_UqDV0DV7oEq5rBGrmthjPw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">280300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_carm_LocalJurisdictionMember_3b4Lne7Dpk26SoUxioVhCg"
      decimals="-5"
      id="Narr_SBsuhHUE-kSiFjAOsGBDJA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">65100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_94R-tIsNFka2JCxWnjX7Fg"
      decimals="-5"
      id="Narr_pWzNGvvl-U2VOa5jjiz09g"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">12600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_carm_StateJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_F3DomWzyU0mk1y1R2qHVZQ"
      decimals="-5"
      id="Narr_imHaCg40IEaNZy_00Wus0Q"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-5"
      id="Narr_kVjE7JOpjUGYVLja_1DKdA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">20300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-5"
      id="Narr_2WZKptYDKUKYC4Y0mZa3Nw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">84500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_S81WDWg1PkKTO1vAVItJuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(12)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Related-Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company has a collaboration and license agreement with Moderna, a significant shareholder (Note&#160;13).&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_NrYkvkfbXUm9cWfKnkpDww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(13)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Moderna Collaboration and License Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In January&#160;2022, the Company entered into the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize &lt;i style="font-style:italic;"&gt;in vivo &lt;/i&gt;engineered CAR-M therapeutics in oncology. Moderna has the right to designate up to twelve research targets as development targets under this collaboration. While the collaboration was initially limited to oncology, in September&#160;2024, the companies agreed to expand the collaboration to discover, develop and commercialize &lt;i style="font-style:italic;"&gt;in vivo &lt;/i&gt;engineered CAR-M therapeutics in specific autoimmune diseases. As a result, Moderna nominated two autoimmune research targets. As of February&#160;2025, in connection with Moderna&#x2019;s nomination of all 12 oncology research targets (Note&#160;14), the Company will not be conducting any additional research activities under the collaboration agreement and will not be receiving any further payments from Moderna for research and development services under the collaboration agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Subsequent to the nomination of a research target, Moderna may designate the research target as a development target. Upon Moderna&#x2019;s designation of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $45.0 million to the Company. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, the Company is eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. Moderna also reimbursed the Company for all costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $10.0 million in research and development costs over the first three&#160;years from execution of the Moderna License Agreement). The Company is also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments and royalties that the Company owes as a licensor under one of its intellectual property in-license agreements with Penn, which is sublicensed to Moderna under the Moderna License Agreement. Moderna may deduct these royalties in part from any royalties owed to the Company. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#x2019;s intellectual property to conduct research and development activities and participation on the joint steering committee (JSC). The Company determined that there were 2 performance obligations comprised of (i)&#160;research and development services and (ii)&#160;option rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#x2019;s estimated probability of the options&#x2019; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The transaction price of $45.0&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna exercises or determines not to exercise its option right to license and commercialize the designated development target.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In June&#160;2024, the Company received notice from Moderna that Moderna had designated the first development candidate, an &lt;i style="font-style:italic;"&gt;in vivo &lt;/i&gt;CAR-macrophage targeting GPC3 that is designed to treat solid tumors, including hepatocellular carcinoma. Pursuant to the terms of the Moderna License Agreement, the designation triggered a $2.0&#160;million milestone payment from Moderna to the Company. As a result, the Company recognized collaboration revenue of $2.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In addition, the Company reduced its $45.0&#160;million deferred revenue liability associated with the option rights by recognizing $3.8&#160;million in collaboration revenue, which represents a proportional reduction based on the 12 potential early-stage research targets. As of December&#160;31, 2024, the Company recorded a collaboration receivable of $2.9&#160;million related to the reimbursement of costs incurred in connection with the Company&#x2019;s research and development activities. The Company received the $2.9&#160;million in January&#160;2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company included the $45.0 million up-front and nonrefundable payment and $73.9 million of variable consideration for expected research and development services to be performed during the five-year contract term, inclusive of passthrough costs, in the transaction price as of the outset of the arrangement. During the&#160;years ended December&#160;31, 2024 and 2023, the Company recognized $19.6 million and $14.9 million, respectively, of collaboration revenues. Collaboration revenues for the&#160;year ended December&#160;31, 2024 include $3.8&#160;million of deferred option rights revenue recognition and $2.0&#160;million of milestones.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company recognized $38.7&#160;million and $3.8&#160;million, respectively, of research and development services and option right collaboration revenues since inception of the Moderna License Agreement through December&#160;31, 2024. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2024 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price unsatisfied&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Performance obligations:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Option rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total performance obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,551&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table summarizes the changes in deferred revenue (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at the beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferral of revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Recognition of unearned revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,632)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,919)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at the end of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,413&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The current portion of deferred revenue represents advanced payments received from Moderna for costs expected to be incurred by the Company within the next twelve&#160;months. The noncurrent portion of deferred revenue represents the $41.3 million upfront, non-refundable and non-creditable payment allocated to customer option right which is not expected to be recognized within the next 12&#160;months.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <carm:MaximumNumberOfResearchTargets
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_S3eeHUCF80-ErdmPj3uyZQ"
      decimals="INF"
      id="Narr_mY4PKEUJLkqOK3V0d4pzjA"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">12</carm:MaximumNumberOfResearchTargets>
    <carm:NumberOfResearchTargetsNominatedAutoimmune
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_CC5mai144UKxgWO0ed8BXg"
      decimals="INF"
      id="Narr_iSmwWLN2t0KvvA8MInBCEw"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">2</carm:NumberOfResearchTargetsNominatedAutoimmune>
    <carm:NumberOfResearchTargetsGrossOncology
      contextRef="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_CVCA_jIaNUSvPGLAL1iRDw"
      decimals="INF"
      id="Narr_n3Lk4Aqd6EWazVkk-PCO5Q"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">12</carm:NumberOfResearchTargetsGrossOncology>
    <carm:UpfrontNonRefundablePaymentReceived
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA"
      decimals="-5"
      id="Narr_CLESUzWbHU-yqnoXTI9jXw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">45000000</carm:UpfrontNonRefundablePaymentReceived>
    <carm:NumberOfPotentialProductsToDevelopAndCommercialize
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA"
      decimals="INF"
      id="Narr__TqGxiqLWEykETuxzhB0yA"
      unitRef="Unit_Standard_product_3mVjd4sUPUK6dqSqJB3SiQ">12</carm:NumberOfPotentialProductsToDevelopAndCommercialize>
    <carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments
      contextRef="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_H-d_HedKTkqWEw-yuQFN0g"
      decimals="-5"
      id="Narr_sfC5J2Z6Xk6VlJdHaxUtBA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">247000000</carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments>
    <carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments
      contextRef="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_BvRnm7gZx0yPcQ6vufXWdQ"
      decimals="-5"
      id="Narr_FDW5YuMRBkqwQowOgB3DOw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">253000000</carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments>
    <carm:MinimumCommitmentToReimburseResearchAndDevelopmentCosts
      contextRef="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_8qNgXN0bH0eJkf5RqlBsfg"
      decimals="-5"
      id="Narr_QF4nlGkLa0SKk1inlk4Nvw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">10000000</carm:MinimumCommitmentToReimburseResearchAndDevelopmentCosts>
    <carm:PeriodOfReimbursementOfResearchAndDevelopmentCosts
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA"
      id="Narr_ZHWJ6pLGakiMxg8n4m_1vA">P3Y</carm:PeriodOfReimbursementOfResearchAndDevelopmentCosts>
    <carm:UpfrontNonRefundablePaymentReceived
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA"
      decimals="-5"
      id="Narr_CHUS6NAG40CpbL0cfWwTbw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">45000000</carm:UpfrontNonRefundablePaymentReceived>
    <carm:CollaborativeArrangementRightsAndObligationsMilestonePayments
      contextRef="As_Of_6_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_R70NvuCqk0WTJXiSPZpa9w"
      decimals="-5"
      id="Narr_-wD4QjrmNkCfs4mp4rOE0w"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2000000</carm:CollaborativeArrangementRightsAndObligationsMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_vCHDp2Flj0-8HoO2F7_1lQ"
      decimals="-5"
      id="Narr_vx-d4dZDNk-0WHTGoDCnuw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_AtWenqGmtUa8z3-Kd3hvvw"
      decimals="-5"
      id="Narr_OIbTavo0_0Sn7NEbh-_Gew"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">45000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_Xj-_M61yuk6R7alr9CUi3Q"
      decimals="-5"
      id="Narr_cmEeBBkCy0eeBgll5MJpCg"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3800000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <carm:NumberOfPotentialResearchTargetDesignations
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_xyxFVBcDT0CVZTmDOmX-AQ"
      decimals="INF"
      id="Narr_S7FJM5EL_06npRqk6QY2kA"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">12</carm:NumberOfPotentialResearchTargetDesignations>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_vJj0iOym_06oJXQKAC1aOA"
      decimals="-5"
      id="Narr_pG2aAOAa00iA_ya91JK7ug"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2900000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:ProceedsFromCollectionOfOtherReceivables
      contextRef="Duration_1_1_2025_To_1_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QZ72PuDG7USaQrTyk9GuVw"
      decimals="-5"
      id="Narr_u6O1QRIAKk6h-SNFG_ujhw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2900000</us-gaap:ProceedsFromCollectionOfOtherReceivables>
    <carm:UpfrontNonRefundablePaymentReceived
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_5_pFMaKe_E6No8FPBreF8w"
      decimals="-5"
      id="Narr_fJRtQw74f0ejttkcPC5X3A"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">45000000</carm:UpfrontNonRefundablePaymentReceived>
    <carm:VariableConsideration
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_ECKpLj9RxkeJ2fOMI7xCfQ"
      decimals="-5"
      id="Narr_QdPQ77QveUK1pkjmuE3LwQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">73900000</carm:VariableConsideration>
    <carm:ContractTerm
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_ECKpLj9RxkeJ2fOMI7xCfQ"
      id="Narr_Xw-5v_FCq0miBYYDZ4YXoA">P5Y</carm:ContractTerm>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-5"
      id="Narr_bfw3Sy3tpE67AkJxxSCfoQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">19600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-5"
      id="Narr_6lQ0gabG80ut61PU-iMmCA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">14900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_OptionRightCollaborationRevenuesMember_SRYjOrMSy0aaO5SPhrCxDA"
      decimals="-5"
      id="Narr_w1G43hqe00mNwE7CUCvMrA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_MilestonesMember_FUdbCZoQDk2Dag7HM2RG6A"
      decimals="-5"
      id="Narr_AY2tjKDENUSN5KLhZW-6Ng"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_gNQIWKQL-kC9gvHVRwSeLg"
      decimals="-5"
      id="Narr_APiiti0lf061tY2LqioTiA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">38700000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_carm_OptionRightCollaborationRevenuesMember_SRYjOrMSy0aaO5SPhrCxDA"
      decimals="-5"
      id="Narr_MNKg5bqALEGSBE3VFM21mw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Group_PpG6IXWZZUmmbPbW4NXJDA">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2024 (in thousands):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price unsatisfied&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Performance obligations:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Option rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total performance obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,551&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_T6-ejDEzaEOsUf1jPeQQQA_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">35301000</carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount>
    <carm:RevenueRemainingPerformanceObligationOptionRightsAmount
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_N_kuLiuiM0SY1GSDLPxFfg_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41250000</carm:RevenueRemainingPerformanceObligationOptionRightsAmount>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_bgJim9b9iE6m5GlKUVgXKw_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">76551000</us-gaap:RevenueRemainingPerformanceObligation>
    <carm:ScheduleOfChangesInDeferredRevenueTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_dfPy4X3VI0-cY9xE1UVFyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table summarizes the changes in deferred revenue (in thousands):&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at the beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferral of revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Recognition of unearned revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,632)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,919)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at the end of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,413&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</carm:ScheduleOfChangesInDeferredRevenueTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_d8KDTxlH10iFzaIJzA6hqg_3_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">46413000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_RxWEW6abfkejY7rH4iRxrA"
      decimals="-3"
      id="Tc_dR3sD2ebZE-Jma-EnSOq1w_3_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">47459000</us-gaap:ContractWithCustomerLiability>
    <carm:ContractWithCustomerLiabilityDeferralOfRevenue
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_fl3z-RZjLkqH2fPCqU6U5A_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">16198000</carm:ContractWithCustomerLiabilityDeferralOfRevenue>
    <carm:ContractWithCustomerLiabilityDeferralOfRevenue
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc_3AiibwghOEeAfxvLOqgFng_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">13873000</carm:ContractWithCustomerLiabilityDeferralOfRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      decimals="-3"
      id="Tc_zoOlxWGGqEGt0FZpVrEVLA_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-17632000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2023_To_12_31_2023_Mtr72XjygUa3N7S0mf9TFw"
      decimals="-3"
      id="Tc__AwFzF31tEiugbksLG_KGg_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-14919000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_wZzpyl8veUKsdbzFxGYXbw_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">44979000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_6elf04ekPkS9QEsrDb0rBA_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">46413000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_oADG9dBYzE6u3XG_uLzZiA"
      decimals="-5"
      id="Narr_pTHlhBJbPU-BwJgR3VaIJw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_G5WJy5JjKEeSNePS663WoQ"
      id="Tb_Yhd8rn4UwkebxMgLw8e3hA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(14)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company has evaluated subsequent events from the balance sheet date through March&#160;31, 2025, the issuance date of these consolidated financial statements, and has identified the following matter requiring disclosure. &lt;i style="font-style:italic;"&gt;Moderna Collaboration and License Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In February&#160;2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February&#160;2025, Moderna has nominated all 12 oncology research targets under the collaboration for which the Company has the potential to receive future milestones and royalty payments. The Company will not conduct any additional research activities under the collaboration agreement and the Company will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the &lt;i style="font-style:italic;"&gt;in vivo &lt;/i&gt;oncology field exclusivity, which would allow the Company to pursue &lt;i style="font-style:italic;"&gt;in vivo &lt;/i&gt;CAR-M programs outside of the 12 nominated oncology targets and product polypeptides. The final research and development payment of $2.9&#160;million was received in January&#160;2025 which will be recognized as collaboration revenue for research and development services in the first quarter of 2025. The Company does not expect to recognize any additional unsatisfied research and development performance obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;2025 Cash Preservation Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As part of a further revised plan approved by the Company&#x2019;s board of directors, on March&#160;25, 2025, to preserve the Company&#x2019;s existing cash resources following its reduction in workforce (the &#x201c;cash preservation plan&#x201d;), the Company reduced its operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down its business. The cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help to evaluate our strategic alternatives. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company&#x2019;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. Any future resumption of research and development activities would depend on completing a strategic transaction that would support the Company&#x2019;s prior operating plans or otherwise obtaining significant additional funding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As part of the cash preservation plan, the board of directors determined to terminate all of its employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. Affected employees were informed of the reduction in workforce on March&#160;25, 2025. The reduction in workforce was effective on March&#160;31, 2025. The reduction in workforce includes 37 of the Company&#x2019;s full-time employees representing approximately 84% of our total workforce, including certain employees engaged in research and development, manufacturing and corporate activities. The Company expects to incur approximately $3.8&#160;million in connection with the reduction in workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. The Company also expects to pay the majority of related reduction in workforce amounts by the end of 2025. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the reduction in workforce, including (but not limited to) impairment charges relating to the balances of property and equipment, net, prepaid research and development costs and right of use assets&#160;&#x2013; operating lease.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <carm:NumberOfResearchTargetsNominatedOncology
      contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_9oZWrGbwu0CzsSwa4YaYUw"
      decimals="INF"
      id="Narr_B2G03DImIEq9gUKghJqzUA"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">10</carm:NumberOfResearchTargetsNominatedOncology>
    <carm:NumberOfResearchTargetsNominatedReplacements
      contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_9oZWrGbwu0CzsSwa4YaYUw"
      decimals="INF"
      id="Narr_RjJ1hPjlXEWbzcLxtUM-ug"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">4</carm:NumberOfResearchTargetsNominatedReplacements>
    <carm:NumberOfResearchTargetsTerminatedOncology
      contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_9oZWrGbwu0CzsSwa4YaYUw"
      decimals="INF"
      id="Narr_W9V3JunqJEO-8IhLIH2hOQ"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">2</carm:NumberOfResearchTargetsTerminatedOncology>
    <carm:NumberOfResearchTargetsTerminatedAutoimmune
      contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_9oZWrGbwu0CzsSwa4YaYUw"
      decimals="INF"
      id="Narr_-dAxkVtO8k2rZEQJ1hOrYQ"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">2</carm:NumberOfResearchTargetsTerminatedAutoimmune>
    <carm:NumberOfResearchTargetsGrossOncology
      contextRef="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_CVCA_jIaNUSvPGLAL1iRDw"
      decimals="INF"
      id="Narr_x2G9gmOY50KeNS__1im_7Q"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">12</carm:NumberOfResearchTargetsGrossOncology>
    <carm:NumberOfResearchTargetsGrossOncology
      contextRef="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_CVCA_jIaNUSvPGLAL1iRDw"
      decimals="INF"
      id="Narr_udg4-bFBa0y0GYZdVNHgyw"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">12</carm:NumberOfResearchTargetsGrossOncology>
    <us-gaap:ProceedsFromCollectionOfOtherReceivables
      contextRef="Duration_1_1_2025_To_1_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QZ72PuDG7USaQrTyk9GuVw"
      decimals="-5"
      id="Narr_Y4cv-_2duUabPZoIweTblg"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2900000</us-gaap:ProceedsFromCollectionOfOtherReceivables>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="Duration_3_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QPK_k69qc0WEZlJvXGRPPA"
      decimals="INF"
      id="Narr_6PIRZAkihEKeP8xFLGqCRA"
      unitRef="Unit_Standard_employee_8zftLesBXkivzIcTQ6E96w">37</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_3_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QPK_k69qc0WEZlJvXGRPPA"
      decimals="2"
      id="Narr_9UATW1Zh8E6z6RjbBy8lNQ"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.84</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_TTkLQHgTUUWOQaI1eLingg"
      decimals="-5"
      id="Narr_FjdE9j8xG0-UvmHgnVXHQg"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3800000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_hikf65ouskeBOU6I6shVyQ_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7740000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_NCD5xQCfuUmAzvAg7pDLkA_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">17909000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_MEXZ3IjFa0qUWrOfrTT6cw_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2901000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_2FwH1VGp-U--zcGAFrXTXA_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5916000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_l1dt4TA66k--2c1wy27mKg_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3313000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_Cdus7JJ-8k-ys-8Wkkiqwg_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_uI6HN9CuoES8NA_I9qom4A_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">13954000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_RSiIdkrqskOq3EAZ_PT4Zg_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">23825000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_cOyYhreVgUeyALfK6Bj2qg_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_K7m5xQq28EGtji8igmEHgw_9_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4385000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_frZhWGCF2ESKufPY-qdyKA_10_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1999000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_RGjaru5BXEm8h9AKQhNE6A_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2040000</us-gaap:OperatingLeaseRightOfUseAsset>
    <carm:DeferredFinancingCostsNoncurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_vTcHSXbTPEqT0SjtX5E8-w_11_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</carm:DeferredFinancingCostsNoncurrent>
    <carm:DeferredFinancingCostsNoncurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_33rQhWCPbEKKndbm0w9eMQ_11_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">208000</carm:DeferredFinancingCostsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_A5aKN8gLMky2hjjuOyI2Rg_12_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">15953000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_2UlUOiPYb0GdZGKz33T8SQ_12_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">30458000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_Ec1mXNnlnUaIKfdNMo3h0w_16_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3251000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_kdfLweFUBkGWlRFIaxXzhw_16_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2081000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_LieRlSAHUkmc3SixJQG1Bg_17_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4705000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_6V-l5zRXlUKFU2KTwf5uGA_17_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7448000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_V2MYLfbfFkaj1W8vtfGu2g_18_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_cXnGHGBrbkqKy0phdUKv5Q_18_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3729000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_fZNqTJXG-0O7k5HQpwD09w_19_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">998000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_TIsGBCC0S0uMGmPAcHTAyA_19_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">832000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_J2oo-pqa7kGkvUzQpDkuRw_20_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">640000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_8BM-utqrWkePaxAmcbDAJQ_20_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">905000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_2IHFbZmH-0WXUBSvv5_cXw_21_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">853000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_itguzrfVTUmg4z3jA1YoWg_21_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1060000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_Qm771NCrKEaOSUS56aq7mg_22_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">10447000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_BvrDySrlNEylzKXfRVMzaA_22_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">16055000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_c8IXs05nWU2Ekj1D9FCYfw_23_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41250000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_Q4BIEUVQh0qZKZs11YkuHw_23_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41250000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_M3ZwlDGyE0OwhnE0nNXfFA_24_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">687000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_6COrAjC33kiWH-X1Ty8C5Q_24_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">724000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_GLdZ-ZSLL0GUWdJwCaORiQ_25_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_3UPDeNreL0CJLY2WAX9ACg_25_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">20000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_vJPdI6wvdU28J3qViAK4rA_26_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">231000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_p2XAoRPZDkeHVXiHdthpBg_26_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">318000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_Ks0yXsZTAEGL9xQG9dZcRw_27_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">52615000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_a-JeyorOZEaw4R0VQA6mwQ_27_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">58367000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="INF"
      id="Narr_hI7qDL3e8kCnqIi8WEJMdA"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_pITVLrciyEuLzrfnoIjwWw"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="INF"
      id="Narr_7_WSi2_Mm0eL9sSS0DLnig"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_UWi2WLf5KU2NMp4LKnqxCA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="INF"
      id="Narr_KCEx7ZBCAUGAmtcwCc5PgA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_tPQCWdBZxUiXAlZqooyrjA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_usBJm8qUakmkjkixMQl9dg_30_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_jXmKKNUQDEGZg5VR6Hyxgw_30_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="INF"
      id="Narr_stpbmber_0uGhPz8uUsrkg"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_7o3jXEV0hEWpnrlU0n8DBw"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="INF"
      id="Narr_4BXXXmBFAk2_Y6tGlAutbQ"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_rHC632bNDEODa2G23F4ePQ"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="INF"
      id="Narr_3BH8PEQlTUCpncFInBUqDA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41788096</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Narr_Y_KHH4v8FkSWFVdo0dT-uA"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41750109</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_bxvWCab-GkWoZHMPGvjpwQ_31_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_qIFn44woZkGUZaK7qKHrjg_31_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_syjcjMXIm0-Bno0Iiz2BYg_32_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">278142000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_V3y1rKEuXUe8sSC4pJwVQw_32_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">277629000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_A-lt1FHPa0mIkBwiSjwMzg_33_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-314845000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_P80HED4a2UaDlUp-BvK98g_33_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-305579000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_dgxN-w1CB0mEg1GRd4Vnag_34_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-36662000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_qnxYZpESd0uPz4K8O95bFw_34_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-27909000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_maw8L1LkYEaL9KfhHTeIWQ_35_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">15953000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_QXgilkRSZkmLbFFG7TvM6w_35_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">30458000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_hmsAByr0RU2sceMBx6q6fg_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3729000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_-n_WS5CgW0a-IDuu1uYjMA_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3397000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_5K0WzC2A5Uazo6hYHqgkSQ_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">9156000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_ZNPU9oZWUkqVhVmNtOnNPw_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">17462000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_cvILskxFAkK6OTxJ8xnRQw_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3907000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_KADa7b8_kECjTtr10mDVQg_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5445000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_s4YfvQ8v_Umvl6Oh3vd2TQ_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">13063000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_Tql4tU7nC0CLGfT5HYmf8w_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">22907000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_VL_nYhMccEWkyEH_VtwvsQ_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-9334000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_DXiX2WbwgEatex2gsB3nIQ_9_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-19510000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_YcuS3wp-s0qCGlvk88K2Fg_10_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">68000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_906mp-bReUGQCwqYVI8VRw_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">532000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_lkJbNz7y4E-4u9lgJb-DlA_11_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-9266000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_qlex_LyAdEKONJW0uHwUVg_11_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-18978000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_fdLxP72Dp0mf0FfkB_qAsw_12_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_76aj-TKLiUeKdeuzHOifgA_12_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_OMxZDxDM5EqwH-6t4sl97Q_13_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-9266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_B-UsM1QtiEqjlApmVQ7aIg_13_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-18978000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="2"
      id="Tc_imzeJrgwX0eb63DHiIc4uw_15_3"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="2"
      id="Tc_imzeJrgwX0eb63DHiIc4uw_15_3_2"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="2"
      id="Tc_-TpCIHfWvkWJWbSPdkQbvA_15_6"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">-0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="2"
      id="Tc_-TpCIHfWvkWJWbSPdkQbvA_15_6_2"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">-0.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="0"
      id="Tc_f5zgvzVEIEONwQeMDD1K4Q_16_3"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41771213</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="0"
      id="Tc_f5zgvzVEIEONwQeMDD1K4Q_16_3_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41771213</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="0"
      id="Tc_dJhAXrE0PEqo_TqeyCf5CA_16_6"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">40938464</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="0"
      id="Tc_dJhAXrE0PEqo_TqeyCf5CA_16_6_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">40938464</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVEm6mt950Ss-dIhOM6psw"
      decimals="INF"
      id="Tc_wASbobCoJkilZ6aoGSy28w_5_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41750109</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVEm6mt950Ss-dIhOM6psw"
      decimals="-3"
      id="Tc_-pyxyNGzTkGDjI991ravLw_5_5"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JA8S9njYW0u1srOBy-b4Fg"
      decimals="-3"
      id="Tc_Lds1BeSBgkuPiGX9-KubUg_5_8"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">277629000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lu-cSSufUEqWCNoTK34t1Q"
      decimals="-3"
      id="Tc_XFb5EWWsx0yNgoA4VlV8aA_5_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-305579000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_OQFmK0tAAEekYHeB7ae0LA_5_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-27909000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wF0j2cynSUuqz6R2wHJFsQ"
      decimals="INF"
      id="Tc_UtKJMxXhMUuJwWMZh5IoZA_6_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">37987</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CtxCArF56kS82xK5cMVGuA"
      decimals="-3"
      id="Tc_JDpww9eOFU2tjqfTGH-YkQ_6_8"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_L0lkTqD2dkOm6GB4KPSYJg_6_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CtxCArF56kS82xK5cMVGuA"
      decimals="-3"
      id="Tc_AATflTq1jEiHNmt2yHv1_A_7_8"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">508000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_CnMY6vQ-YEyKOLguK-V_HQ_7_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">508000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_o52ygJ2qtUW_8MtdyoucDg"
      decimals="-3"
      id="Tc_2sYQz_N5vEyOaIJL3DEBpQ_8_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-9266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_Pj2ZNO6CDUmfI-k014pnjw_8_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-9266000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcPCJIcIO0eFOPtvCF5mqA"
      decimals="INF"
      id="Tc_kxNUtd9E4EyzSea7YmggUw_9_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41788096</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcPCJIcIO0eFOPtvCF5mqA"
      decimals="-3"
      id="Tc_rGRm1548PkeWhdCjshlc4A_9_5"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KyGaWAjqJkmBWbexZMF-jA"
      decimals="-3"
      id="Tc_vY4y27j0jEG0QRPGexN-Dg_9_8"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">278142000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KOBMN_pRd0CpuuBgDONMeQ"
      decimals="-3"
      id="Tc_EOnhoZyrZ0qrWSYGRvQPWw_9_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-314845000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_Q2exaofhXEC-IYBtFa4JFw_9_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-36662000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sizU-8d-HkiGAXLhA7EliQ"
      decimals="INF"
      id="Tc_nVKQ0Ws9p0GdDPZptQa0_w_10_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">40609915</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sizU-8d-HkiGAXLhA7EliQ"
      decimals="-3"
      id="Tc_wqEMrV6txUGHHlbAc-T-rA_10_5"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">40000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CiZKxNIbvEyRs27cGTE1kw"
      decimals="-3"
      id="Tc_UXSnjSdkwEOA7G-lGfJP0Q_10_8"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">271594000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p0MZ0Mf-7Uu7LB1ZZP5Iyg"
      decimals="-3"
      id="Tc_EOc-iVJpNkqkg5kxSrE1jg_10_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-245102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_l2sSWlvDfk-tn82IDfQUyg_10_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">26532000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NBJH3utECkSeITbgKbOBjQ"
      decimals="INF"
      id="Tc_Hkj-DfIzk0-Mem0lhMhlKw_11_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">1579</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3bekv5USnUGc01h2wLoVyQ"
      decimals="-3"
      id="Tc_UZvyk4_VqkucDZbvBaV_1Q_11_8"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_w5XvJep1OESv4jGl4nYlPQ_11_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3bekv5USnUGc01h2wLoVyQ"
      decimals="-3"
      id="Tc_3JEv7eeeOEqLsJdCmXWnAw_12_8"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1057000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_iG_qAiSHw0Ol9hAlSudYOA_12_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1057000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NBJH3utECkSeITbgKbOBjQ"
      decimals="-3"
      id="Tc_JhHXREyQl0iY8f5JPIRzIA_13_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">931250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NBJH3utECkSeITbgKbOBjQ"
      decimals="-3"
      id="Tc_AsnqZpm8dEaufGzlLK-0LQ_13_5"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3bekv5USnUGc01h2wLoVyQ"
      decimals="-3"
      id="Tc_Ax4s56LIXUyr4R74B9C2Ag_13_8"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2281000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_Xv7c5mG8rU-yC-0n6gMeTg_13_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2282000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_V0Pkqzz_AEyhjqolIkoUug"
      decimals="-3"
      id="Tc_-YYoQzy1z06x_vJlbVX8fA_14_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-18978000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_rionZWQ7T0yfU-ebyGkyBA_14_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-18978000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fkuPLbunBkio3h13YwQKEA"
      decimals="INF"
      id="Tc_5AHQ3a_PuEmPCFaiWUfTxg_15_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">41542744</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fkuPLbunBkio3h13YwQKEA"
      decimals="-3"
      id="Tc_mJcliWXffk2ddA4HoTgNaQ_15_5"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9V4P9b_imUeKWRIMprh3ug"
      decimals="-3"
      id="Tc_bzzwLJHN7k6j_nEXjIvj8g_15_8"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">274934000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_djTn0QuJAUyMxSDTnffWJQ"
      decimals="-3"
      id="Tc_c0B3zrTkBkqWgzYQAU4Iyg_15_11"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-264080000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A"
      decimals="-3"
      id="Tc_S2vdfv8TkkqwipsZCv0Ymw_15_14"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">10895000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_c1Ji8nnTPk6WFBvbbPzE4w_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-9266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_zTImA9A_w021ayd_hLZsLQ_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-18978000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_hoOd16rlIUWlKLCDRcrGTQ_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">661000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_YoRnLCx4Q02K8kNuGUekQg_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1693000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_6ijP5Evx1EqpoO7Gy8CYKg_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">508000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc__JaevbG0vE-k0JZyX3vAVw_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1057000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_IXNbFBEm1kaNGshpu3CmOw_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">877000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_KBDMHUqLvU6EkLZlB5kibA_9_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1360000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_9p69a36xw0m1oQelb0FguQ_10_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">208000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_O2ZtvAU6M02o6X3sLfzcPg_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_rvVQ2xx7OECPbTwEZrlMIA_11_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">113000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_a8ds-CX7UEyPwhHomGXnpA_11_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-67000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <carm:NoncashInterestExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_xCvDX-B_YEyDoC-xaUYW9g_12_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">19000</carm:NoncashInterestExpense>
    <carm:NoncashInterestExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_M8p_ZsrWtUm3GINsphr0Dg_12_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">236000</carm:NoncashInterestExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_6dOYxGk8-EazeMywADyy4w_14_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-3015000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_d6ZTD_C8z0qpkJDS0M_v-Q_14_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1572000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_9pDeIBHY2Eedl8qw6U3Q6g_15_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1170000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_URD26tGOUEGIXWhvqIZ9Ag_15_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-1826000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_ZZlt0r-VLk6jfhJ8yfiPfg_16_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-2743000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_aeSdeU41fUW6oPcIuHLoEA_16_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-2933000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_8f8QaVn1ukGo99AG2X24Jg_17_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-3729000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_LiX0EeE08k-wzXZ1192i2g_17_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-224000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_9a-4lYWDtkOW5BuPB6ILwA_18_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-707000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_R7BgGzH5wU-mUZiXZGh7ng_18_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-1355000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_Cgxv3CipxkeWAmcX-AwKMQ_19_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">33000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_t4K9rdGumESUoDvmXxVSVg_19_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">50000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_5ucNpMu0lkSW_V8AROhLuA_20_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-10067000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_pljkN2Nu6E-qNyJDF6n21Q_20_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-22425000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_ra8ZCKQHx0KQvbRjjv_06A_22_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">524000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_SVRUB-_fgk2sFZuYnDrgFQ_22_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_z281pyCzb0yjGtu0SztOWw_23_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_ZhLNcd3B9ESUUZ7eTliY4w_23_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">17000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_uh04PcfHbk-7nzwXT5wgIw_24_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">524000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_zt3l1lzZwUOK8-mpJ7GUnQ_24_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-17000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_azx2a9YiHUWqss2k5J74tA_26_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">304000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_9aqPuLPng0e1zKuaXvqaoA_26_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1319000</us-gaap:FinanceLeasePrincipalPayments>
    <carm:ProceedsFromFailedSaleLeasebackTransaction
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_TvOVJxo4_keLacqsbqWjtw_27_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</carm:ProceedsFromFailedSaleLeasebackTransaction>
    <carm:ProceedsFromFailedSaleLeasebackTransaction
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_lvOFKv2Zy0qP-ilwM1Sx4w_27_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">686000</carm:ProceedsFromFailedSaleLeasebackTransaction>
    <carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_SX630ivPlUCoGt_vL_SLOw_28_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">327000</carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction>
    <carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_yFGZGurVrkCh-JpXBYp5Gw_28_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">303000</carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_yjdqBCWCnEufGWBglC-qmA_29_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_i9ufkq0EsE-Vvr0NVCVC7A_29_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_dUvXrefTEUm-Zj9ZW_FItg_30_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_-armPOGTUUCSrDRa9Q7cYw_30_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2286000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_tpeyFAtGgkGZv-l_L8Kcig_31_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-626000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_REjP3apJzUiIGWsAydrzOg_31_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1352000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_mBklbqM5pEGkDJs85SlGWw_32_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-10169000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_5MMp1tgWm0Gp8h_cOvj74A_32_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-21090000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_hLpEmsaNUEikD-hvRs0QlA_33_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">17909000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_kyMAZhnaCky0RcHi2kEWoA_33_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">77605000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_ovPolZk30U-HkxJ8FMZtcg_34_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7740000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A"
      decimals="-3"
      id="Tc_JAp1Byf6w0m7Fx5bdy0DpA_34_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">56515000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_1je46taVY06b61u9Vart2Q_36_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">33000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_rpUByuddIkG5cniPRapZpA_36_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">50000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_ysLxNZ43pUulwi_xSgRymg_38_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">836000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_meXz7Vr9JUe8sP-HP0sNAA_38_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4337000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_wiA_7Net8U28WRrdfZJPDQ_39_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_USutB37Ny0KAWguhBbyoGA_39_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2470000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_P0_cdtay-0uMYY3ZfLarMQ_40_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_MT8YmTOwvEGsKRR3nAevqQ_40_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">59000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_UQKf56whEEC_NRJNyibhhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(1)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Background&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Carisma Therapeutics&#160;Inc., a Delaware corporation (collectively with its subsidiaries, the Company), is a biotechnology company focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March&#160;and December&#160;2024, the Company&#x2019;s board of directors approved revised operating plans to reduce&#160;monthly operating expenses, conserve cash, and refocus the Company&#x2019;s efforts on strategic priorities. As part of these plans, in March&#160;2024 the Company elected to cease further development of its first lead product candidate, CT-0508. In December&#160;2024 as part of the plan, the Company elected to cease further development of its then lead product candidate, CT-0525, following an assessment of the competitive landscape in anti-HER2 treatments and the impact of recently approved therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of a further revised plan approved by the Company&#x2019;s board of directors on March&#160;25, 2025 to preserve the Company&#x2019;s existing cash resources following its reduction in workforce, as further discussed below (the cash preservation plan), the Company reduced its operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down its business. The cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help to evaluate our strategic alternatives. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company&#x2019;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. Any future resumption of research and development activities would depend on completing a strategic transaction that would support the Company&#x2019;s prior operating plans or otherwise obtaining significant additional funding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of the cash preservation plan, the board of directors determined to terminate all of its employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. Affected employees were informed of the reduction in workforce on March&#160;25, 2025, which became effective on March&#160;31, 2025. The reduction in workforce included 37 of the Company&#x2019;s full-time employees representing approximately 84% of the Company&#x2019;s total workforce, including certain employees engaged in research and development, manufacturing and corporate activities. The Company incurred approximately $3.4&#160;million in connection with the reduction in workforce during the three&#160;months ended March&#160;31, 2025 and expects to incur an additional $0.4&#160;million in the second quarter of 2025 related to further potential terminations, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. The Company expects to pay the majority of related reduction in workforce amounts by the end of 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;NASDAQ Compliance&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On October&#160;10, 2024, the Company received written notice from The Nasdaq Stock Market LLC (Nasdaq) indicating that the Company no longer satisfied Nasdaq Listing Rule&#160;5450(b)(2)(A), which requires the Company to maintain a minimum market value of listed securities (MVLS) of $50.0 million (the MVLS Rule) for continued listing on The Nasdaq Global Market. In accordance with Nasdaq Listing Rule&#160;5810(c)(3)&#160;(the Grace Period Rule), the Company had 180 calendar&#160;days, or until April&#160;8, 2025 (the Compliance Date), to regain compliance with the MVLS Rule.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April&#160;10, 2025, Nasdaq notified the Company that, based upon the Company&#x2019;s continued non-compliance with the MVLS Rule, as of the Compliance Date, the Company&#x2019;s securities were subject to delisting from Nasdaq unless the Company requested a hearing before the Nasdaq Hearings Panel (the Panel). The Company has requested a hearing before the Panel, which is scheduled to be held on May&#160;22, 2025. The request has stayed any further suspension or delisting action by Nasdaq at least until the hearing is held and any extension that the Panel may grant to the Company following the hearing has expired. There can be no assurance that the Panel will grant the Company&#x2019;s request for continued listing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Also on April&#160;10, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule&#160;5450(b)(2)(C), which requires the Company to maintain a minimum market value of publicly held shares (MVPHS) of $15.0&#160;million (the MVPHS Rule) for continued listing on The Nasdaq Global Market. In accordance with the Grace Period Rule, the Company has 180 calendar&#160;days, or until October&#160;7, 2025, to regain compliance with the MVPHS Rule.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Additionally, and as previously disclosed, on January&#160;6, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule&#160;5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share (the Bid Price Rule&#160;together with the MVLS Rule&#160;and the MVPHS Rule, the Price-based Rules) for continued listing on The Nasdaq Global Market. In accordance with the Grace Period Rule, the Company has 180 calendar&#160;days, or until July&#160;7, 2025, to regain compliance with the Bid Price Rule.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;To evidence compliance with the Price-based Rules, an issuer must evidence compliance with the applicable minimum threshold for at least ten, but generally not more than 20, consecutive business&#160;days. Although the Company is considering all available options to regain compliance with the applicable listing criteria, there can be no assurance that the Company will be able to do so.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_lGhVgDEdm0KquD87r_9DVA"
      decimals="INF"
      id="Narr_44aLA09Yfki_Jf0crlL-fw"
      unitRef="Unit_Standard_employee_8zftLesBXkivzIcTQ6E96w">37</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_lGhVgDEdm0KquD87r_9DVA"
      decimals="2"
      id="Narr_h-RR987w7EqV94u2TVgSQA"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.84</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_lGhVgDEdm0KquD87r_9DVA"
      decimals="-5"
      id="Narr_8TqIXiFRvkaz0Vmpu8-9DQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1
      contextRef="As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_carm_CashPreservationPlan2025Member_e9iO1ErRnUC87OlaTyfKaA"
      decimals="-5"
      id="Narr_aOPIs5lHGUmLDKtM7t4INA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">400000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <carm:DevelopmentStageRisksAndLiquidityTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_m1UwAHc2eUCFcC0ZPkCFww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;"&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Development-Stage Risks and Liquidity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $314.8 million as of March&#160;31, 2025. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of March&#160;31, 2025, the Company had cash and cash equivalents of $7.7 million. Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one&#160;year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. In addition, changing circumstances could cause the Company to consume capital significantly faster than currently anticipated, and the Company may need to spend more than currently expected because of circumstances beyond its control. The Company&#x2019;s cash forecast contains estimates and assumptions, and management cannot predict the timing of all cash receipts and expenditures with certainty. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liability that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management is currently evaluating different strategies to maximize value and prepare to wind down the Company&#x2019;s business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company&#x2019;s assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. There is no assurance regarding when or if this strategic review process will result in any type of transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#x2019;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.&lt;/p&gt;</carm:DevelopmentStageRisksAndLiquidityTableTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-5"
      id="Narr_qKw9dZ7REUaG_Z0flFAcOA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-314800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-5"
      id="Narr_IRogPoIV20KtkECtqyxL4A"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_j4jnChmJwEOUEO6ZPhhIZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(3)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Interim Financial Statements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The summary of significant accounting policies is included in the Company&#x2019;s audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (SEC) on March&#160;31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance are meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. In the opinion of management, the accompanying unaudited interim consolidated financial statements include all &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2025 and its results of operations for the three&#160;months ended March&#160;31, 2025 and 2024. Operating results for the three&#160;months ended March&#160;31, 2025 are not necessarily indicative of the results that may be expected for the&#160;year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain all of the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Company&#x2019;s Annual Report on Form&#160;10-K filed with the SEC on March&#160;31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant areas that require management&#x2019;s estimates include stock-based compensation assumptions and accrued research and development.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Assets Held for Sale&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March&#160;2025, the Company committed to a plan to sell its remaining equipment and therefore has classified the amount as assets held for sale on the consolidated balance sheet as of March&#160;31, 2025. The assets held for sale were reported at the lower of the carrying amount or fair value, less costs to sell.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair Value Measurements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurement at reporting date using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents &lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2013;&lt;/span&gt; money markets accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents &lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2013;&lt;/span&gt; money markets accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the three&#160;months ended March&#160;31, 2025 and 2024, there were no transfers between Level 1, Level 2 and Level 3.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Concentration of credit risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Segment information&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one operating segment. The Company&#x2019;s CODM is the chief executive officer. The Company&#x2019;s CODM manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#x2019;s net loss and monitors budget versus actual results to assess the performance of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the three&#160;months ended March&#160;31, 2025 and 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Collaboration revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development, excluding facilities, personnel, depreciation and amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,191&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,656&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Facilities expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,099&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,632&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Personnel expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation, amortization and interest on finance and sale-leaseback lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,185&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (818)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,266)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,978)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;&#x201c;Other segment items&#x201d; includes&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt; interest income.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Net loss per share&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,895,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,210,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently issued accounting pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes &lt;/i&gt;(Topic 740)&lt;i style="font-style:italic;"&gt;: Improvements to Income Tax Disclosures &lt;/i&gt;(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In November&#160;2024, the FASB issued ASU 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures &lt;/i&gt;(Subtopic 220-40): &lt;i style="font-style:italic;"&gt;Disaggregation of Income Statement Expenses&lt;/i&gt;, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb__G4OzvDNXEKRV1Kb4jhE5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Interim Financial Statements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The summary of significant accounting policies is included in the Company&#x2019;s audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (SEC) on March&#160;31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance are meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. In the opinion of management, the accompanying unaudited interim consolidated financial statements include all &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2025 and its results of operations for the three&#160;months ended March&#160;31, 2025 and 2024. Operating results for the three&#160;months ended March&#160;31, 2025 are not necessarily indicative of the results that may be expected for the&#160;year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain all of the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes as of and for the&#160;year ended December&#160;31, 2024 found in the Company&#x2019;s Annual Report on Form&#160;10-K filed with the SEC on March&#160;31, 2025.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_OXGweKX_T0aJXNQKD6OshA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant areas that require management&#x2019;s estimates include stock-based compensation assumptions and accrued research and development.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <carm:AssetsHeldForSalePolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_P3t3U3EOj0KN17NX2bT8-Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Assets Held for Sale&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March&#160;2025, the Company committed to a plan to sell its remaining equipment and therefore has classified the amount as assets held for sale on the consolidated balance sheet as of March&#160;31, 2025. The assets held for sale were reported at the lower of the carrying amount or fair value, less costs to sell.&lt;/p&gt;</carm:AssetsHeldForSalePolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_4A2SX7hxEEetnyCla4HYpA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_rld2R-QQGES96YUkFqt5WA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair Value Measurements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurement at reporting date using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents &lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2013;&lt;/span&gt; money markets accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents &lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2013;&lt;/span&gt; money markets accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the three&#160;months ended March&#160;31, 2025 and 2024, there were no transfers between Level 1, Level 2 and Level 3.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_pzCxxBEOtE-SsG3IDDp_Eg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurement at reporting date using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents &lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2013;&lt;/span&gt; money markets accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents &lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2013;&lt;/span&gt; money markets accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the three&#160;months ended March&#160;31, 2025 and 2024, there were no transfers between Level 1, Level 2 and Level 3.&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C2na3yFo8kSa8lpEjLIVYw"
      decimals="-3"
      id="Tc_kuroyCZP606FoPmL-lLc5Q_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">6965000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qni1eLtrpEqVTUS5DP3Q5g"
      decimals="-3"
      id="Tc_G3KwHH4vOUugBf7UBNbA3g_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NHpG9u0K8kSnQJhkduVBWQ"
      decimals="-3"
      id="Tc_P-G8d6k6OEOwC0fBDECZsg_5_9"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_FPiLpPUNo06fNsnw6eJy3A"
      decimals="-3"
      id="Tc_NQMgm0x_QEKckYwLfkalFA_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">14887000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RNeFS6gXN0O81arpfa3vew"
      decimals="-3"
      id="Tc_0oXm2vhDaUetSv1VdKjKDA_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_P-hP9vpSB0SObx9s8SRr_w"
      decimals="-3"
      id="Tc_DT3dlKWKpkCejpnhFRuWFg_8_9"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_SnvkQ_ciyECqY_RFEHWvRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Concentration of credit risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_L5scubQROUKvvfAvoW4RGA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Segment information&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one operating segment. The Company&#x2019;s CODM is the chief executive officer. The Company&#x2019;s CODM manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#x2019;s net loss and monitors budget versus actual results to assess the performance of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the three&#160;months ended March&#160;31, 2025 and 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Collaboration revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development, excluding facilities, personnel, depreciation and amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,191&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,656&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Facilities expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,099&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,632&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Personnel expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation, amortization and interest on finance and sale-leaseback lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,185&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (818)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,266)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,978)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;&#x201c;Other segment items&#x201d; includes&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt; interest income.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="INF"
      id="Narr_cXbnyVeEI0yCeHefFJ7Qww"
      unitRef="Unit_Standard_segment_ieOgHbuNO0uMDAyeDWsL6Q">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_2K0t-f_AgkWpcKIQUf0k9Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the three&#160;months ended March&#160;31, 2025 and 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Collaboration revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development, excluding facilities, personnel, depreciation and amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,191&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,656&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Facilities expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,099&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,632&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Personnel expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation, amortization and interest on finance and sale-leaseback lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,185&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (818)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,266)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,978)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;&#x201c;Other segment items&#x201d; includes&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt; interest income.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA"
      decimals="-3"
      id="Tc_B0V0NNzsr0WrQgXdTi824A_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3729000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag"
      decimals="-3"
      id="Tc_RLNCNP2Rq0KRSoL2pqM2DA_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3397000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA"
      decimals="-3"
      id="Tc_ltx3AXLilUCV_TF_hh1CKQ_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1528000</carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses>
    <carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag"
      decimals="-3"
      id="Tc_Hw5KRHbHCkSipfVtvbFMeA_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">10191000</carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses>
    <carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA"
      decimals="-3"
      id="Tc_eGl06d9M10SO0dnrbuGRzg_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2421000</carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses>
    <carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag"
      decimals="-3"
      id="Tc_Tyb4nJa-C0uFwxiN3mYxJQ_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3656000</carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses>
    <carm:FacilitiesExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA"
      decimals="-3"
      id="Tc_lN6Ywu6eYESwC3mWcUk6Gw_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1099000</carm:FacilitiesExpense>
    <carm:FacilitiesExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag"
      decimals="-3"
      id="Tc_gSlpk0ACgkC9KpIr6QPsHQ_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1632000</carm:FacilitiesExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA"
      decimals="-3"
      id="Tc_IX2PzxzKjUGKa--T7NMMfw_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7354000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag"
      decimals="-3"
      id="Tc_tdhHrticaE2OzXcqCg_Cfw_9_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">6529000</us-gaap:LaborAndRelatedExpense>
    <carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA"
      decimals="-3"
      id="Tc_wvyqRgg2WEe3Na5SRF9IXw_10_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">712000</carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities>
    <carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag"
      decimals="-3"
      id="Tc_hlFjZglnFU-FilsfkTOGHQ_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1185000</carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA"
      decimals="-3"
      id="Tc_iRWbTd62RkWWpGPwPC0EsQ_11_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-119000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag"
      decimals="-3"
      id="Tc_sxvu6JImj0eLkkCxalAb3A_11_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-818000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember__M5OxjR_n0mcZ6tlLRd-WA"
      decimals="-3"
      id="Tc_tvat5RJLF0OK7gJp_jdVfA_12_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-9266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_carm_ReportingSegmentMember_GpVj25iNAUKk7IKK1ClKag"
      decimals="-3"
      id="Tc_y-0VQiibjUq-b82nvgTPgQ_12_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-18978000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_cFZSn9RJpUKpbdH67k56xw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Net loss per share&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,895,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,210,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_D4gjTY6R2UKY71FywNWm-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,895,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,210,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_o9XCCXxBxk-Bcr0qGS2Bcg"
      decimals="INF"
      id="Tc_oeH5owJ_70GRGiah0QytSg_3_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">6895824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_zK5vgRHDUkuO_I7i5iruOQ"
      decimals="INF"
      id="Tc_4MEKsf35sUmnAkfpYMdysQ_3_4"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">8210547</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_xmiZ_gFw90GH4vDCRJlbag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently issued accounting pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes &lt;/i&gt;(Topic 740)&lt;i style="font-style:italic;"&gt;: Improvements to Income Tax Disclosures &lt;/i&gt;(ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In November&#160;2024, the FASB issued ASU 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures &lt;/i&gt;(Subtopic 220-40): &lt;i style="font-style:italic;"&gt;Disaggregation of Income Statement Expenses&lt;/i&gt;, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal&#160;years beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)&#160;prospectively to financial statements issued for periods after the effective date of this ASU or (2)&#160;retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_3IxskU3xnkiAdgrL87234Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(4)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Prepaid Expenses and other assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,715&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collaboration receivable (Note 10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other receivables (a)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,209&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 925&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 717&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,901&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,916&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;&#x201c;Other receivables&#x201d; primarily&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt; consisted of equipment sales, sales and use tax refunds, and research and development tax refunds.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_3Cx3HPo_cU-bnbVgF57MuA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,715&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collaboration receivable (Note 10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other receivables (a)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,209&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 925&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 717&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,901&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,916&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;&#x201c;Other receivables&#x201d; primarily&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt; consisted of equipment sales, sales and use tax refunds, and research and development tax refunds.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <carm:PrepaidResearchAndDevelopmentCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_sexeyGNlVUiwveWnAYIJbg_2_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</carm:PrepaidResearchAndDevelopmentCurrent>
    <carm:PrepaidResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_8_5sIT4h5ECXFh0odBJ5ww_2_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1715000</carm:PrepaidResearchAndDevelopmentCurrent>
    <carm:ReceivableDueFromCollaborativeArrangementCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_nTh44uM290aCHCkXJ_N6iA_3_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</carm:ReceivableDueFromCollaborativeArrangementCurrent>
    <carm:ReceivableDueFromCollaborativeArrangementCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_MKA1aHEmJkq5hSfMLe3Z0A_3_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2864000</carm:ReceivableDueFromCollaborativeArrangementCurrent>
    <us-gaap:OtherReceivablesGrossCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_kWck_JEI_UyqWI3kmZVO-Q_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1209000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_FoMqtfCxbUS8YHXQTMkhRg_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_I63GGhiul0W_w65dvBjLCQ_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">845000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_DfmxQsjW_kKIZ0Tz4NgKdw_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">925000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_eJ5TN3_eikS3VHB3yvBamA_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">717000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_BF4ywYAkH0Chsi5B7skPWw_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">340000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_mylie4p-OUOefPEZiy7guA_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">130000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_uKkx0T9h6E-mhM_U-6teag_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">72000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_c4sjIchY70yJrCou5fbF5w_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2901000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_6taRs6gktEyTPoJAv0Krsw_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">5916000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_Y-rPrbGFU0-uMbnP1cs4WQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(5)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 525&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 537&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,879&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 161&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,448&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_KmwYmLYODUqPXObPGePEnA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 525&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 537&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,879&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 161&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,448&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <carm:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_EqOi6S6TEEuGc_i2UQqPEA_2_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">525000</carm:AccruedResearchAndDevelopmentExpenseCurrent>
    <carm:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_K_uZS75jiEyFkTb73dh4-A_2_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1845000</carm:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_tbA5R1Cflku925ZjThcGZw_3_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">465000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_o3rB46Ko9UGREBZTEm9QeQ_3_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">537000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_X92bsqvoakyoQpVzK_0BAw_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3554000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_esz8P2ygskCgRHQzoIhDJg_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4879000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_Sju_SbxDwEGqxkpVIO1LcA_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">161000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_7CBICA65HUOTxC4foF9T0w_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">187000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_4Gn9eGjbeU2oyNa5pWrY5A_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">4705000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_3NEATdQO4USkjZdYP0YwNg_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">7448000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_K8dWLq9OWEy2-hOUvYLgDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(6)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#x2019;s operating leases have term end dates ranging from 2025 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2025 to 2026.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s operating and finance lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company carries laboratory equipment from failed sale-leasebacks, as assets held for sale on the accompanying unaudited interim consolidated balance sheets. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of March&#160;31, 2025, the Company had a $1.7 million financing liability recorded in other current liabilities and other long-term liabilities on the unaudited interim consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The elements of the lease costs were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,298&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total finance lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,534&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,475&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Lease term and discount rate information related to leases was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Supplemental cash flow information was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash used in operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 707&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash used in finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financing cash used in finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Future maturities of lease liabilities were as follows as of March&#160;31, 2025 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fiscal year ending:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2025 (remaining nine months)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 639&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 226&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total future minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (240)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 640&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licensing and Sponsored Research Agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November&#160;2017, the Company is required to make annual payments of $25,000. Penn is eligible to receive up to $10.9&#160;million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $30.0&#160;million per product in commercial milestones and up to an additional $1.7&#160;million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Contingencies&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. As of March&#160;31, 2025, the Company was in negotiations with a vendor to determine the total costs owed for research and development services provided. While the negotiations are ongoing, the Company believes a liability is probable. The Company has estimated the amount to be owed to be $1.5&#160;million, of which $1.0&#160;million and $0.5&#160;million are included within accounts payable and accrued &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;expenses, respectively, on the accompanying consolidated balance sheets. The final amount owed may differ from the estimate as negotiations progress. The Company will continue to evaluate the matter and will adjust the liability as necessary based on any new information or agreements reached with the vendor.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_mVjyQyWkQ0ysng36Cpz6dQ"
      decimals="-5"
      id="Narr_x9SgLPB1LkirmkwGyNkNRw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1700000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_9cshu3lf3kieu_aAmPrADg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The elements of the lease costs were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,298&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total finance lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,534&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,475&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_s4XrmSsj-0agbTO2szY5Mw_3_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">929000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_EcGLzwkQhEqHBwOOAGa_qQ_3_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1469000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_gc2X3v0sSUSYNydV0zZbXg_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">263000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_8rda4gTKyECu6ijs1wKrdg_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1298000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_wsXVFw4uG0mQ7ayZliPflw_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">19000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_4DOD-YmpZ0yao71FpfrFyg_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">236000</us-gaap:FinanceLeaseInterestExpense>
    <carm:FinanceLeaseCost
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_OmhPskGGpEuqmg6ARkFcBw_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">282000</carm:FinanceLeaseCost>
    <carm:FinanceLeaseCost
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_CWbk3Ng_vkCEu7sksnIcsw_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1534000</carm:FinanceLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_PcRy9rRY5UelgGpGWpFFGA_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">115000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_EjCJCE5DT06cIEivW8zE2w_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">472000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_35oQV-1cxEKPdZyJb1h3rA_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1326000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_alxJ1iXhG02CALMmFH9HFA_9_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3475000</us-gaap:LeaseCost>
    <carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_pDoYSFM3CU2vAa3Js1V_vQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Lease term and discount rate information related to leases was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      id="Tc_gvfFSlwJdESGWLjX-Tskpg_4_2">P2Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A"
      id="Tc_zlpHjq21Ykiv5sIYgi778g_4_4">P2Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      id="Tc_Q3OeZkrJR0ulAiXidl_RMg_5_2">P0Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A"
      id="Tc_jbqpgttHdU61tCxbeZ0f4w_5_4">P1Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="3"
      id="Tc_Y0436C88RUyR8yTDeQ8VdA_8_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.098</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A"
      decimals="3"
      id="Tc_nvR41GGPIUSI69mm2TTCaw_8_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.093</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="3"
      id="Tc_HVM9F2OhFEal8caNhuwrWg_9_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.09</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A"
      decimals="3"
      id="Tc_Ili_Znw5mEaXbjL4B9pt2g_9_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.09</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_pIyxeK7VV0inIDIZYbF3kg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Supplemental cash flow information was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash used in operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 707&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash used in finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financing cash used in finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_aem5JOyuNEO9ptv31UHu3g_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">707000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_ZPgTIRLeQEK3o6Ygxhf7UA_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1463000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_Tm42VjuhYk-s2nNGcX94ug_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">19000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_BWujX_8ZiEWtT4ZqLrPfpA_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">236000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <carm:FinancingCashUsedInFinanceLeases
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_bTtnGckieEuHExI_DWosLw_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">304000</carm:FinancingCashUsedInFinanceLeases>
    <carm:FinancingCashUsedInFinanceLeases
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_VY42ZCInL0Wmo_zyJKM4Hw_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1319000</carm:FinancingCashUsedInFinanceLeases>
    <carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_VMpWYJVk-0KCSiXm0EFSPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Future maturities of lease liabilities were as follows as of March&#160;31, 2025 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fiscal year ending:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2025 (remaining nine months)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 639&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 226&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total future minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (240)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 640&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_mOgMvMQvQk27iEFFsnR-7A_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1042000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_ORrMMNTvQ0yuA5t_RsXKag_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">639000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_FAASrDJ64E6CAQRbgSz8-A_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">226000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_K4YXM4mJqkOr6YOnFVSFjw_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">20000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_hFyydiC-9EGtOiGIMzqF4w_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">233000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_f1VV3Bf_h0eKvLjsQSZHpQ_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_xy8PmIaBekSgea-G2m7NSw_7_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">240000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_VUsNmePEqU2vTcmJlaO5bw_7_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_tCBihNPjPEWdLb3UHEtWwg_8_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">184000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_AMl25d2RbUq5siTdG_oYHg_8_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <carm:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_s1Oe5IDmBkCn2rEW5dBG0w_9_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</carm:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <carm:FinanceLeaseLiabilityToBePaidAfterYearFour
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_NkiwD4wHzkC74jltz5ANKQ_9_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</carm:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_wPyX6IY7tUuhF9UGl2O1lQ_10_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1925000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_FkYQr85e4E6njyTT8n48WA_10_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">659000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_fzCuCFdlTkGu9kbW0sWlyA_11_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">240000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_fuqc_CEE_U-t9ZNhRy3DFA_11_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">19000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_aGttnn2CqE6ZxcvemEvgCg_12_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1685000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_yJt-7iVDSkiHvQXT3_WGXA_12_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">640000</us-gaap:FinanceLeaseLiability>
    <carm:CommitmentsAnnualPaymentsRequiredToBePaid
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_3NLofzzltkKOh4rmrr_2tg"
      decimals="-3"
      id="Narr_dOeQ8v2HoUuEYQfzInpLrQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">25000</carm:CommitmentsAnnualPaymentsRequiredToBePaid>
    <carm:AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents
      contextRef="As_Of_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_baLeGNcD3EigtjEBIXS6dg"
      decimals="-5"
      id="Narr_3StMc3JVCU2MzPKzKgR9hA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">10900000</carm:AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents>
    <carm:AdditionalMilestonePaymentsRequiredToBePaid
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_TrTvMEg3XUmfyU3iMfTZ3Q"
      decimals="-5"
      id="Narr_P4ImWL6pK0q0nCCrJH4qOw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">30000000</carm:AdditionalMilestonePaymentsRequiredToBePaid>
    <carm:AdditionalMilestonePaymentsForTheFirstCARMProduct
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionAxis_carm_TrusteesOfUniversityOfPennsylvaniaMember_us-gaap_TypeOfArrangementAxis_carm_PennLicenseAgreementMember_3NLofzzltkKOh4rmrr_2tg"
      decimals="-5"
      id="Narr_czIRyji7YEmccR35rKymrQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1700000</carm:AdditionalMilestonePaymentsForTheFirstCARMProduct>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-5"
      id="Narr_bfcmhVSC9E-0QQeoVGLMGQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1500000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="As_Of_3_31_2025_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableMember_2St9M_1mr0e3gTe3DEn6vw"
      decimals="-5"
      id="Narr_2QylkQw8R0KbF0M3Ubm8tQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="As_Of_3_31_2025_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_mc__W33L60eUsMJuatMfaQ"
      decimals="-5"
      id="Narr_oNef_WsnuEK7UMlLnWpqaQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">500000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_KzVnah18a0CPw89rbNNdwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;"&gt;(7)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Stockholders&#x2019; E&lt;/b&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;quity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Open Market Sales Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;On April&#160;17, 2023, the Company filed a universal shelf registration statement on Form&#160;S-3, which was declared effective on May&#160;2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$300.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May&#160;12, 2023, the Company entered into an Amended and Restated Open Market Sale Agreement&lt;/span&gt;SM &lt;span style="font-size:10pt;"&gt;(Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$100.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million under an &#x201c;at-the-market&#x201d; offering program. During the three&#160;months ended March&#160;31, 2024, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;931,250&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares of common stock for gross proceeds of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2.3&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;t sell any shares of common stock under the Sale Agreement during the three&#160;months ended March&#160;31, 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <carm:SaleOfStockStockOfferingAmount
      contextRef="As_Of_4_17_2023_x6SGs_0tqUWE9Nmq-r1zlw"
      decimals="-5"
      id="Narr_ZUhy9JWBtEOgO0avSvjtQQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">300000000</carm:SaleOfStockStockOfferingAmount>
    <carm:SaleOfStockMaximumOfferingAmount
      contextRef="As_Of_5_12_2023_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_D_fnvKHBKEejhcN9RD39EQ"
      decimals="-5"
      id="Narr_i3-cKATUZkCyG1Tl9TVI0A"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">100000000</carm:SaleOfStockMaximumOfferingAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_KzPkm9W5EE24UqG-d_OiTg"
      decimals="INF"
      id="Narr_1rbSikakzU-3o_1K9rl6Pw"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">931250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_KzPkm9W5EE24UqG-d_OiTg"
      decimals="-5"
      id="Narr_E9Hd26fL-0yKtkEjQQ8LqQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">2300000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_carm_AtTheMarketMember_OiQ4pvFuv0SzT93oHU7Tbw"
      decimals="INF"
      id="Narr_b86jHfqwkk652NsVJOIIGQ"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_NLk95qX3WkW_-gUBJBcAMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(8)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;2017 Stock Incentive Plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company adopted the CARISMA Therapeutics&#160;Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was ten&#160;years, and stock options typically vested over a &lt;span style="-sec-ix-hidden:Hidden_Y6YvLEfyKUG_kk0uMc5sKQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;four-year&lt;/span&gt;&lt;/span&gt; period. The Company&#x2019;s stock options vest based on the terms in the awards agreements and generally vest over &lt;span style="-sec-ix-hidden:Hidden_DGF8BxLO20aH0nuzKXhnJA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;four&#160;years&lt;/span&gt;&lt;/span&gt;. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder and ceased granting awards under the Legacy Carisma Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;2014 Stock Incentive Plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Amended and Restated Stock Incentive Plan, as amended (the 2014 Plan), provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Company&#x2019;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#x2019;s board of directors at the time of grant. Stock options outstanding under the 2014 Plan generally vest over a &lt;span style="-sec-ix-hidden:Hidden_RR1pBUqe5UemOm2ln3QA2w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;four-year&lt;/span&gt;&lt;/span&gt; period and are exercisable for a period of ten&#160;years from the date of grant. As of March&#160;31, 2025, approximately 5.6&#160;million shares of common stock remained available for issuance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;2014 Employee Stock Purchase Plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Carisma Therapeutics&#160;Inc. 2014 Employee Stock Purchase Plan (the 2014 ESPP) provides employees with the opportunities to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The 2014 ESPP had 0.2 million shares of common stock available for issuance as of March&#160;31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table summarizes stock option activity for the three&#160;months ended March&#160;31, 2025:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;term (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,746,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,987)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,749,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,562,180)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,895,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,693,361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The weighted-average grant-date per share fair values of options granted during the three&#160;months ended March&#160;31, 2025 and 2024 were $0.42 and $1.72, respectively. The fair values in the three&#160;months ended March&#160;31, 2025 and 2024 were estimated using the Black-Scholes option-pricing model based on the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;4.32% - 4.35%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;3.77% - 3.89%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;108.30% - 110.68%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;103.39% - 105.96%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories in its accompanying unaudited interim consolidated statements of operations:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 436&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 401&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 621&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,057&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In connection with the cash preservation plan, 2.6&#160;million options were forfeited during the three&#160;months ended March&#160;31, 2025, resulting in a reduction in stock-based compensation expense related to research and development and, general and administrative employees. Compensation cost for awards not vested as of March&#160;31, 2025 was $3.7&#160;million and will be expensed over a weighted-average period of 2.3&#160;years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_carm_TwoThousandSeventeenStockIncentivePlanMember_O60app-ziUOiQI-0SFDxHQ"
      id="Narr_tlvQFsCm4UqnXLno3iAucw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_BqAFVKxD_0eZh52zf-_cHA"
      id="Narr_K4YGYC6wpEKHgPgwTfg2uA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenStockIncentivePlanMember_b0EJK8W8H06cy_5zpLWtsQ"
      decimals="-5"
      id="Narr_8WkzYUJqhEyP9B28BbY_KQ"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_nnJFjCrHlUqpNk-U5M1Zug"
      decimals="2"
      id="Narr_VuqKHDhUVU2S5me25MsSMg"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_3_31_2025_us-gaap_PlanNameAxis_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_KcFLfiniXEG_gOlYI1LmVA"
      decimals="-5"
      id="Narr_T7Xu30A6XUu-lTHImhVjew"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_a07NgnqYVkGIZ48P3RqcRQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table summarizes stock option activity for the three&#160;months ended March&#160;31, 2025:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;term (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,746,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,987)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,749,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,562,180)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,895,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,693,361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="INF"
      id="Tc_2G_dnCPiHESQHXjxkxvoOQ_6_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">7746991</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="2"
      id="Tc_qJo9iMwr9ESqTjnumYatFA_6_5"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="INF"
      id="Tc_OC0WVSIw5k2un9Uk91QPAQ_7_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">37987</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="2"
      id="Tc_f_QK_zqCEkCKz37VUiR-CQ_7_5"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc__pKlG1-HVkOSoN_Q9aXeOg_7_10"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="INF"
      id="Tc_9oRDoIuYaUq1BFulczuw6A_8_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">1749000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="2"
      id="Tc_wBMJyoRe40u-OtDYNxaezA_8_5"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="INF"
      id="Tc_xO5proWhF0-g2338YEv7Xw_9_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">2562180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="2"
      id="Tc_DZ_6ygrlsUyEYpH-QfMOSg_9_5"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">1.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="INF"
      id="Tc_HKfocvkQmEuohMbAev-w6w_10_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">6895824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="2"
      id="Tc_droeSGhIJkeUAWUm49H89g_10_5"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">2.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tc_BV7yeKN0mUqSb9CoH0X3Qg_10_7">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_1foJndhXHEickLyJCuWc9A_10_10"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">31000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="INF"
      id="Tc_G8G9RwdqRkW8qcML3NYXNw_11_2"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">4693361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="2"
      id="Tc_pskQWTRm8UWVX4ce9uD3hQ_11_5"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">2.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tc_caaDxgQK_0iJWrhuQv92Dg_11_7">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_PKWAXcbI802TWWNB36BSTg_11_10"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">31000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="2"
      id="Narr_x2rLbQ7DJE-eKYWkVIec5Q"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">0.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="2"
      id="Narr_zmpB9w6GUUieQFhls6R9sg"
      unitRef="Unit_Divide_USD_shares_vMkji1s3hkOcVqKtByqzMA">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Group_XMzTf_JIsUyOdW4Y5guccg">The fair values in the three&#160;months ended March&#160;31, 2025 and 2024 were estimated using the Black-Scholes option-pricing model based on the following assumptions:&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;4.32% - 4.35%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;3.77% - 3.89%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;108.30% - 110.68%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;103.39% - 105.96%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw"
      decimals="4"
      id="Narr_mdBMAohFrEKCQsHlRmhX0g"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.0432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw"
      decimals="4"
      id="Narr_9UXD9U5ONE-TZrbFYwnYAg"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.0435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg"
      decimals="4"
      id="Narr_7_38DP6aq0K6BN-V9ESnIA"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.0377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg"
      decimals="4"
      id="Narr_la5AnRxgukKLcYY7867XHg"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0.0389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw"
      id="Narr_DqhrVr02ZU-oUPRyCAWiAw">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg"
      id="Narr_dLpkDchBI0-65ITg45gjHw">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw"
      decimals="4"
      id="Narr_5_yel8VgcEOQLOFOwnUivQ"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">1.083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw"
      decimals="4"
      id="Narr_HEJyp0d_ZUmFCwfn40GA6g"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">1.1068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg"
      decimals="4"
      id="Narr_1TXHphmqxEOyww_-Z0LQ0g"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">1.0339</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg"
      decimals="4"
      id="Narr_ndlAGzxo3UeewYgVaEHKwA"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">1.0596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QUYaBjdQJUOYJHfz18ERbw"
      decimals="2"
      id="Tc_MrM77mS_Rk-aFF9ar7clJw_6_2"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OiUEKhCMvkKh4Ufs5e-fEg"
      decimals="2"
      id="Tc_ilbyDmpEAEyp9ldzqZBvfA_6_4"
      unitRef="Unit_Standard_pure_ZbLFCly4_kubnKuWGzWzNQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_FJ6DC4XkGUKODm8poFaLPQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories in its accompanying unaudited interim consolidated statements of operations:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 436&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 401&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 621&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,057&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SxDIMm3BHU201oGx7GMaZg"
      decimals="-3"
      id="Tc_nXwDPTxlkEyYhzdqL8ZiGw_3_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">107000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_jY5QK3zjDki_xjht9LRM1g"
      decimals="-3"
      id="Tc_O1cWLWiF7UC1gSc8Oyj7aQ_3_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">436000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_-bxZ8-y2T0-7QhFzHLqqMQ"
      decimals="-3"
      id="Tc_43kqgqyzTUOYH8r4rNcSwQ_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_weRP70dN20KmCCCCJPZOwg"
      decimals="-3"
      id="Tc_ZvIdWsPJD0K_A-fm4P3PJQ_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">621000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_Xhae2TaMBkmgyyqHP3alQQ_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_hB5wc__EfUa9M7OiUUmceg_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">1057000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_carm_CashPreservationPlan2025Member_feBnUr3Dfkm1-xoc5Tr1Xg"
      decimals="-5"
      id="Narr_od01j0gu5kqicWrNrVjwPg"
      unitRef="Unit_Standard_shares_RvZyAK9QZ0i-R57rSwshtw">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-5"
      id="Narr_OIoxGw7lhUilnwR-Hk_mdQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Narr_YsN9gtPcrEaGfque-WtYNw">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_CCBrQVOVr0uFMY8n2BRlPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;"&gt;(9)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Related-Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company has a collaboration and license agreement with Moderna, a significant stockholder (See Note&#160;10&#160;&#x2013; Moderna Collaboration and License Agreement).&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_HrRaNkqc0E2sMEHKIdOXrQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;"&gt;(10)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Moderna Collaboration and License Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In January&#160;2022, the Company entered into a collaboration agreement with Moderna (the Moderna License Agreement), which provides for a broad strategic collaboration to discover, develop and commercialize &lt;i style="font-style:italic;"&gt;in vivo &lt;/i&gt;engineered chimeric antigen receptor macrophage and monocyte (CAR-M) therapeutics in oncology. Moderna has the right to designate up to twelve research targets as development targets under this collaboration. While the collaboration was initially limited to oncology, in September&#160;2024, the companies agreed to expand the collaboration to discover, develop and commercialize &lt;i style="font-style:italic;"&gt;in vivo &lt;/i&gt;engineered CAR-M therapeutics in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;specific autoimmune diseases. As of February&#160;2025, in connection with Moderna&#x2019;s nomination of all 12 oncology research targets, the Company will not be conducting any additional research activities under the collaboration agreement and will not be receiving any further payments from Moderna for research and development services under the collaboration agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Subsequent to the nomination of a research target, Moderna may designate the research target as a development target. Upon Moderna&#x2019;s designation of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $45.0 million to the Company. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, the Company is eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. Moderna reimbursed the Company for costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed into the first quarter of 2025; however, as discussed below, Moderna will no longer reimburse the Company for research and development services. The Company is eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments and royalties that the Company owes as a licensor under one of its intellectual property in-license agreements with Penn, which is sublicensed to Moderna under the Moderna License Agreement. Moderna may deduct these royalties in part from any royalties owed to the Company. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#x2019;s intellectual property to conduct research and development activities and participation on the joint steering committee. The Company determined that there were 2 performance obligations comprised of (i)&#160;research and development services and (ii)&#160;option rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#x2019;s estimated probability of the options&#x2019; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The transaction price of $45.0&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna exercises or determines not to exercise its option right to license and commercialize the designated development target.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company included the $45.0 million up-front and nonrefundable payment in the transaction price as of the outset of the arrangement. During the three&#160;months ended March&#160;31, 2025 and 2024, the Company recognized $3.7 million and $3.4 million, respectively, of collaboration revenues. As discussed below, Moderna will no longer be reimbursing the Company for research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized $42.4&#160;million and $3.8&#160;million, respectively, of research and development services and option right collaboration revenues since inception of the Moderna License Agreement through March&#160;31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In February&#160;2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February 2025, Moderna has nominated all 12 oncology research targets under the collaboration for which the Company has the potential to receive future milestones and royalty payments. The Company will not conduct any additional research activities under the collaboration agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;and the Company will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the &lt;i style="font-style:italic;"&gt;in vivo &lt;/i&gt;oncology field exclusivity, which would allow the Company to pursue &lt;i style="font-style:italic;"&gt;in vivo &lt;/i&gt;CAR-M programs outside of the 12 nominated oncology targets and product polypeptides. The Company does not expect to recognize any additional unsatisfied research and development performance obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price unsatisfied&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Performance obligations:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Option rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#x2019;s unaudited interim consolidated balance sheets. Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#x2019;s unaudited interim consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table summarizes the changes in deferred revenue (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at the beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,413&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferral of revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,173&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Recognition of unearned revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,729)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,397)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at the end of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,189&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The deferred revenue represents the unearned portion of the upfront, non-refundable and non-creditable payment allocated to Moderna&#x2019;s option rights of $41.3 million, which is not expected to be recognized within the next 12&#160;months.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <carm:MaximumNumberOfResearchTargets
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_S3eeHUCF80-ErdmPj3uyZQ"
      decimals="INF"
      id="Narr_CDjWJJJM2Ue8kDwOXLJyyQ"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">12</carm:MaximumNumberOfResearchTargets>
    <carm:NumberOfResearchTargetsGrossOncology
      contextRef="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_XRurAXNE0EKR2OlnCsvD0w"
      decimals="INF"
      id="Narr_H1wN8-4KSU2CdAjn86iM-w"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">12</carm:NumberOfResearchTargetsGrossOncology>
    <carm:UpfrontNonRefundablePaymentReceived
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA"
      decimals="-5"
      id="Narr_iBacYlkjEEGLagJfPDqW4Q"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">45000000</carm:UpfrontNonRefundablePaymentReceived>
    <carm:NumberOfPotentialProductsToDevelopAndCommercialize
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA"
      decimals="INF"
      id="Narr_KuIR15WJWEermk_8VEPtMg"
      unitRef="Unit_Standard_product_3mVjd4sUPUK6dqSqJB3SiQ">12</carm:NumberOfPotentialProductsToDevelopAndCommercialize>
    <carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments
      contextRef="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_H-d_HedKTkqWEw-yuQFN0g"
      decimals="-5"
      id="Narr_80FhZLtjZEmmJcJkp6cAnw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">247000000</carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments>
    <carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments
      contextRef="As_Of_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_BvRnm7gZx0yPcQ6vufXWdQ"
      decimals="-5"
      id="Narr_AronO2VRbUKj0HvZETRneQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">253000000</carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments>
    <carm:NumberOfPerformanceObligations
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_nQIYGPxOV02W0fAFKZQdvA"
      decimals="INF"
      id="Narr_fhuZbsn05EGsNeEZjs0ipA"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">2</carm:NumberOfPerformanceObligations>
    <carm:UpfrontNonRefundablePaymentReceived
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_WNOjg8qD30meSNbg795cdA"
      decimals="-5"
      id="Narr_2k3f6G6MWkaMG5SolGXFmA"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">45000000</carm:UpfrontNonRefundablePaymentReceived>
    <carm:UpfrontNonRefundablePaymentReceived
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_nQIYGPxOV02W0fAFKZQdvA"
      decimals="-5"
      id="Narr_cVf775d3Ik6F974GZoo95Q"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">45000000</carm:UpfrontNonRefundablePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-5"
      id="Narr_nZuzCa8jXEOmzNTuj_jKdQ"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-5"
      id="Narr_jpavFBFnE0eok-twRPIKyg"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_Ffe941lEKUCa5q4ysfJI4A"
      decimals="-5"
      id="Narr_y7Mu5JzasEGzZ5RXxBNNZw"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">42400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_carm_OptionRightCollaborationRevenuesMember_us-gaap_TypeOfArrangementAxis_carm_ModernaLicenseAgreementMember_NbiVSknF-U-gNgbz4Ymr5w"
      decimals="-5"
      id="Narr_LHeOQG5FYkmm9amld7RdCg"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <carm:NumberOfResearchTargetsNominatedOncology
      contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_UFBhEQ0DHUmjWP1OKnrZfg"
      decimals="INF"
      id="Narr_D_9PFKTTG0-3r83qzKYsAw"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">10</carm:NumberOfResearchTargetsNominatedOncology>
    <carm:NumberOfResearchTargetsNominatedReplacements
      contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_UFBhEQ0DHUmjWP1OKnrZfg"
      decimals="INF"
      id="Narr_KEX3tHp3_EKcAFkHomIzHQ"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">4</carm:NumberOfResearchTargetsNominatedReplacements>
    <carm:NumberOfResearchTargetsTerminatedOncology
      contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_UFBhEQ0DHUmjWP1OKnrZfg"
      decimals="INF"
      id="Narr_clwuNWfSwU6SjgnHkKyORA"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">2</carm:NumberOfResearchTargetsTerminatedOncology>
    <carm:NumberOfResearchTargetsTerminatedAutoimmune
      contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_UFBhEQ0DHUmjWP1OKnrZfg"
      decimals="INF"
      id="Narr_zLcVP88hbUmtHbcYzQ_NQw"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">2</carm:NumberOfResearchTargetsTerminatedAutoimmune>
    <carm:NumberOfResearchTargetsGrossOncology
      contextRef="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_XRurAXNE0EKR2OlnCsvD0w"
      decimals="INF"
      id="Narr_TjoJgapD60ed43aZz5Pw1g"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">12</carm:NumberOfResearchTargetsGrossOncology>
    <carm:NumberOfResearchTargetsGrossOncology
      contextRef="As_Of_2_28_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_carm_ModernaMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_XRurAXNE0EKR2OlnCsvD0w"
      decimals="INF"
      id="Narr_Wfdg6Qy9WECLh2m-vBXkcg"
      unitRef="Unit_Standard_item_dzZdGrzEb0KR5OPCu_UJJQ">12</carm:NumberOfResearchTargetsGrossOncology>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_zVoruox3dkyI6KrPsijfnA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price unsatisfied&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Performance obligations:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Option rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <carm:RevenueRemainingPerformanceObligationOptionRightsAmount
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_srByM8pktEa6XDHOYyX6OA_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41250000</carm:RevenueRemainingPerformanceObligationOptionRightsAmount>
    <carm:ScheduleOfChangesInDeferredRevenueTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_E-3LoLpuJ0S0mYWVIyqHlg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table summarizes the changes in deferred revenue (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:18pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at the beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,413&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferral of revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,173&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Recognition of unearned revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,729)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,397)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at the end of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,189&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</carm:ScheduleOfChangesInDeferredRevenueTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_TR8y1qHUgEK_q4RWo1FTgA"
      decimals="-3"
      id="Tc_RjoX2sYThUay92XIjLXdfw_3_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">44979000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_eDqQ_Wxs5kuqQ3oPjDkljQ"
      decimals="-3"
      id="Tc_haI4e1_Jf0m00b8t2_5Nng_3_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">46413000</us-gaap:ContractWithCustomerLiability>
    <carm:ContractWithCustomerLiabilityDeferralOfRevenue
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_VS3ls_IFNU2T_iz9Kl0JDQ_4_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">0</carm:ContractWithCustomerLiabilityDeferralOfRevenue>
    <carm:ContractWithCustomerLiabilityDeferralOfRevenue
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_EZ0XRP2a0kGoRWm-J0abrw_4_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">3173000</carm:ContractWithCustomerLiabilityDeferralOfRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      decimals="-3"
      id="Tc_fP_AO3tkfUW1ms59Gyy4IQ_5_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-3729000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2024_To_3_31_2024_cuWNHByrYU--cl5efMfMCQ"
      decimals="-3"
      id="Tc_n3pU5DfmVEyZZ4YV99Td4g_5_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">-3397000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_3_31_2025_h6jSwLVjJEmKhm6HpmS4Tw"
      decimals="-3"
      id="Tc_hv38DKxitUa7jrC8crA5fw_6_3"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41250000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_3_31_2024_PEqk_MbOlkGXaMJ0WYG61A"
      decimals="-3"
      id="Tc_FSFHWdMDkEq0s9bG11052g_6_6"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">46189000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_3_31_2025_srt_ProductOrServiceAxis_carm_ResearchAndDevelopmentServicesMember_us-gaap_TypeOfArrangementAxis_carm_CollaborationAndLicenseAgreementMember_Zc2Vn1pdQEyg-izKUAgkWw"
      decimals="-5"
      id="Narr_ySPGqOomKkGp4ER0p8FBZg"
      unitRef="Unit_Standard_USD_WaaJMSTE9E6gBnszZXTXhw">41300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_gvZlzxfZsk64IJ-GVEGOLA"
      id="Tb_CyXIuuBxG062xfGf_qzAcw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;"&gt;(11)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company has evaluated subsequent events from the balance sheet date through May&#160;13, 2025, the issuance date of these unaudited interim consolidated financial statements, and has not identified any additional items that have not previously been mentioned elsewhere requiring disclosure.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
